From 84c2c91f7d85f95a1c5dc9c1e01d4739e08312ca Mon Sep 17 00:00:00 2001 From: cthunes Date: Wed, 17 Apr 2024 17:24:16 -0400 Subject: [PATCH 01/32] 231 add initial api data retrieval vignette with json api responses --- DESCRIPTION | 3 +- vignettes/Data_retrieval_via_API.Rmd | 283 + .../0/api-ccte.epa.gov/bioactivity/assay.json | 109160 +++++++++++++++ .../bioactivity/data/search/by-aeid/704.json | 9207 ++ .../data/search/by-dtxsid/DTXSID30944145.json | 1064 + .../data/search/by-m4id/1842443.json | 211 + .../data/search/by-spid/TP0000904H05.json | 1715 + 7 files changed, 121642 insertions(+), 1 deletion(-) create mode 100644 vignettes/Data_retrieval_via_API.Rmd create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json diff --git a/DESCRIPTION b/DESCRIPTION index a1a190f4..f3c22322 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -57,7 +57,8 @@ Suggests: kableExtra, colorspace, magrittr, - vdiffr + vdiffr, + httptest License: MIT + file LICENSE LazyData: true RoxygenNote: 7.2.3 diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd new file mode 100644 index 00000000..420badc7 --- /dev/null +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -0,0 +1,283 @@ +--- +title: Data Retrieval with tcpl via API +author: "Center for Computational Toxicology and Exposure, US EPA" +output: + prettydoc::html_pretty: + theme: architect + toc: yes + toc_depth: 4 +vignette: > + %\VignetteIndexEntry{Data Retrieval via API} + %\VignetteEngine{knitr::rmarkdown} + %\usepackage[utf8]{inputenc} +--- + + + + + + +```{css, echo=FALSE} +.scroll-300 { + max-height: 300px; + overflow-y: auto; +} + +.noticebox { + padding: 1em; + background: lightgray; + color: blue; + border: 2px solid black; + border-radius: 10px; +} +``` + +```{r setup, include = FALSE} +devtools::load_all() +library(httptest) +start_vignette("api") +``` + +# Introduction + +This vignette describes how the user can retrieve ToxCast data (invitrodb v4.1) from the CCTE Bioactivity API, using tcpl. The API documentation can be found at . tcpl interfaces to the CCTE API through the R package ccdR (), which wraps the API endpoints and provides helpful functions for storing meta-information related to your connection. + +::: {.noticebox data-latex=""} + +**NOTE:** Users must have a personal API key for full functionality of many of these functions and executing the examples in this vignette. To obtain an API key, send an email request to . + +::: + +## Setup API Connection + +After loading tcpl, use the function tcplConf to set options for connecting to the API. Where a regular database connection requires 5 different options to be filled, using an API connection requires just two: $TCPL_PASS and $TCPL_DRVR . These two can be set using tcplConf like the following: + +```{r setup-api} +tcplConf(pass = "", + drvr = "API") +``` + +## Overview of Key Functions + +To support different data retrieval needs within tcpl, there are a number of functions which query the API and return information to the local R session. + +## Overview of Data Nomenclature + +Throughout this vignette we will use abbreviated designations for data retrieved from the database or to refer to processing steps within tcpl. For data from single concentration assays we use 'SC.' 'MC' is used for assay data with multiple concentrations. A particular data or processing level is indicated by appending the level id/number to the end of the 'SC' or 'MC' designation. For example, if we are discussing single concentration data from level 2 processing, then we will use the abbreviation 'SC2.' + +### Assay Elements + +The tcplLoadAsid, tcplLoadAid, tcplLoadAcid, and tcplLoadAeid functions load relevant assay ids and names for the respective assay elements based on the user specified parameters. + +```{r tcplLoad, eval = FALSE} +# List all assay source IDs +tcplLoadAsid() +# Create table of all assay endpoint ids (aeids) per assay source +aeids <- tcplLoadAeid(fld="asid", # field to query on + val=14, # value for each field + # values should match their corresponding 'fld' + add.fld = c("aid", "anm", "acid", "acnm")) # additional fields to return +``` + +### Data + +tcplQueryAPI is a general querying function which is flexible enough to handle most kinds of queries users may have for the API. Unlike tcplQuery, tcplQueryAPI does not use accept a MySQL query but instead has a few arguments which can be set to mimic a request to the various API endpoints. tcplQueryAPI is used mostly as a helper function to other tcplLoad functions, but is available to users for more specific and/or personalized requests. + +```{r tcplQueryAPI, eval = FALSE} +# Request and load all assays+annotations for specified asid +data <- tcplQueryAPI(resource = "data", # resource to query from API, either 'data' or 'assay' + fld = "aeid", val = 891, # field and val to query on + return_fld = c("spid", "chnm", "hitcall")) # specify the return fields, leave NULL for all fields +``` + +The tcplLoadData function can be used to load data from the CCTE API into the R session. To add useful chemical and assay annotation information, mapped to the retrieved data, remove add.fld = FALSE or conversely set add.fld = TRUE. When connected to the API as the data source, only MC (multiple concentration) screening data is available. In addition, only levels 3, 4, 5, 6, and 'agg' are available. The output will look as similar as possible to regular tcplLoadData output, though some less common columns may be missing and the column order may differ. + +```{r tcplLoadData, eval=FALSE} +# Load multi concentration data from level 4 +mc4_dat <- tcplLoadData( + lvl = 4, # data level + fld = 'aeid', # field to query on + val = 891, # value for each field + # values should match their corresponding 'fld' + type = 'mc', # data type, default, not necessary + add.fld = FALSE # FALSE will only show fields/columns which are usually + # returned for this level, default TRUE will return all available + ) +# Print the first 6 rows of 'mc2_fmtd' +head(mc4_dat) +``` + +When loading data, the user must indicate the applicable fields and ids which are query-able via the CCTE API. These such fields include and are limited to "AEID", "m4id", "SPID", and "DTXSID". Any other fields will result in error. While supplying multiple ids (val) are valid, multiple fields are not, so combinations of fields are not compatible with tcplLoadData when connected to the API. If some or no data is found, tcplLoadData will return whatever it finds, and list in output which val(s) were not found. Examples of loading data are detailed in later sections. + +### Assay Annotations + +Assay source, assay, assay component, and assay endpoint are registered via tcpl scripting into a collection of tables, which in the CCTE APIs are joined into one. The annotations capture four types of information: + +i. Identification information +ii. Design information such as the technology, format, and objective aspects that decompress the assay’s innovations, +iii. Target information, such as the target of technological measurement, +biological intended target, and biological process, and +iv. Analysis information about how the data were processed and analyzed. + +```{r annotation_query_ex, eval = FALSE} +# load all assays and their annotations +assays <- tcplQueryAPI(resource = "assay") +``` + +# Retrieving Processed Multi-Concentration (MC) Data and Annotations + +The goal of MC processing is to estimate the hitcall, potency, efficacy, and other curve-fitting parameters for sample-assay endpoint pairs. API data is stored for levels 3 through 6, users can inspect the activity hitcalls, model parameters, concentration-response plots, and the applied methods for the multiple concentration data. + +## Load Data + +Load filtered data on a sample by endpoint level. Set add.fld = FALSE to limit fields to those which are defaults for each level when loading from invitrodb directly. Leaving add.fld = TRUE (default) will return all of the API's fields, which contain fields from levels 3 through 6. + +### By aeid +```{r data_by_aeid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="aeid", # fields to query on + val=704, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By spid +```{r data_by_spid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="spid", # fields to query on + val="TP0000904H05", # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By m4id +```{r data_by_m4id} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By DTXSID +```{r data_by_dtxsid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="dtxsid", # fields to query on + val="DTXSID30944145", # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By level + +In addition to level 5 data, levels 3, 4, 6, and 'agg' are available to pull from the API. +```{r data_levels} +mc3 <- tcplLoadData(lvl=3, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 3 parameters + +head(mc3) + +mc4 <- tcplLoadData(lvl=4, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 4 parameters + +head(mc5) + +mc6 <- tcplLoadData(lvl=6, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 6 parameters + +head(mc6) + +agg <- tcplLoadData(lvl="agg", # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just agg level parameters + +head(agg) + +all_fields <- tcplLoadData(lvl=5, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=TRUE) # include all fields + +head(all_fields) +``` + + +## Load Assay Annotations + +Load and filter mapped annotation data on an assay component endpoint level (aeid). + +### Load aeid + +To load aeid and aenm as well any other mapped annotations by request, use tcplLoadAeid. Any available field in the API annotations table can be subset using this function. + +```{r load_aeid} +# load aeid and aenm for given acid +aeid <- tcplLoadAeid(fld = "acid", val = 400) +head(aeid) +# subset all aeids by using multiple fields -- val must be same length in list form! +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), val = list("protein", "Colorimetric")) +head(aeids) +``` + +### Load acid (in development-tbd) +### Load aid (in development-tbd) +### Load asid (in development-tbd) +### Load unit (in development-tbd) +### Load concentration unit (in development-tbd) + +# Plotting (in development-tbd) + +tcplPlot is tcpl’s single flexible plotting function, allowing for interactive yet consistent visualization of concentration-response curves via customizable parameters. As a standalone plotting utility built with the R library plotly to display the additional curve-fitting models, tcplPlot implements the R library plumber to provide representational state transfer-application programming interface (REST API) functionality. The tcplPlot function requires the selection of a level (`lvl`), field (`fld`), and value (`val`) to load the necessary data and display the associated plots. Level 4, `lvl = 4`, plots the concentration-response series fit by all models. Level 5, `lvl = 5`, extends Level 4 plotting by highlighting the winning model with activity hit call presented. Level 6 multi-concentration plotting, including lists of flags, are not currently supported by tcplPlot. Moreover, only multi-concentration plotting is currently supported. + +Customization of output is possible by specifying parameters, including `output`, `verbose`, `multi`, `by`, `fileprefix`, `nrow`, `ncol`, and `dpi`. + +- The `output` parameter indicates how the plots will be presented. In addition to outputs viewable with the R console, tcplPlot supports a variety of publication-quality file type options, including raster graphics (PNG, JPG, and TIFF) to retain color quality when printing to photograph and vector graphics (SVG and PDF) to retain image resolution when scaled to large formats. + +- The `verbose` parameter results in a plot that includes a table containing potency and model performance metrics; `verbose = FALSE` is default and the only option in console outputs. When `verbose = TRUE` the model aic values are listed in descending order and generally the winning model will be listed first. + +- The `multi` parameter allows for single or multiple plots per page. `multi = TRUE` is the default option for PDF outputs, whereas `multi = FALSE` is the only option for other outputs. If using the parameter option `multi = TRUE`, the default number of plots per page is set by the `verbose` parameter. The default number of plots per page is either 6 plots per page (`verbose = FALSE`) or 4 plots per page (`verbose = TRUE`). + +- The `by` parameter indicates how files should be divided, typically by $aeid$ or $spid$. + +- The `fileprefix` parameter allows the user to set a custom filename prefix. The standard filename is tcplPlot_sysDate().output (example: tcplPlot_2023_08_02.jpg) or, if `by` parameter is set, tcplPlot_sysDate()_by.output (example: tcplPlot_2023_08_02_aeid_80.pdf). When a `fileprefix` is assigned the default _tcplPlot_ prefix is replaced with the new filename. (example: myplot_2023_08_02_aeid_80.pdf or myplot_2023_08_02.jpg). + +- The `nrow` parameter specifies the number of rows for the multiple plots per page; this is 2 by default. The `ncol` parameter specifies the number of columns for the multiple plots per page; this is 3 by default. If `verbose = FALSE`, `ncol` is 2. `nrow` and `ncol` can customize the number of plots included per page. Both `nrow` and `ncol` must be greater than 0. While there is no hard coded upper limit to the number of rows and columns, the underlying technology has a dimension limitation of `nrow = 9` and `ncol = 7`. + +- The `dpi` parameter specifies image print resolution for image file output types (PNG, JPG, TIFF, SVG); this is 600 by default. + +The following examples demonstrate tcplPlot functionality through available the variety of customization options: + +```{r, include=FALSE} +end_vignette() +``` \ No newline at end of file diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json new file mode 100644 index 00000000..39709efb --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json @@ -0,0 +1,109160 @@ +[ + { + "aeid": 2574, + "assayComponentEndpointName": "ERF_CR_ENZ_hELANE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hELANE was analyzed at the assay endpoint, ERF_CR_ENZ_hELANE, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ELANE. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine peptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3',4'dichloroisocoumarin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine peptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2527, + "assayComponentName": "ERF_CR_ENZ_hELANE", + "assayComponentDesc": "ERF_CR_ENZ_hELANE is an assay component calculated from the ERF_CR_ENZ_hELANE assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by absorbance with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in absorbance produced from the regulation of catalytic activity reaction involving the key substrate, MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide, are indicative of changes in enzyme function and kinetics related to the gene ELANE.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 729, + "assayName": "ERF_CR_ENZ_hELANE", + "assayDesc": "ERF_CR_ENZ_hELANE is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Neutrophil Elastase Human Chymotrypsin Serine Peptidase Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 111, + "geneName": "elastase, neutrophil expressed", + "description": null, + "geneSymbol": "ELANE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1991, + "officialSymbol": "ELANE", + "officialFullName": "elastase, neutrophil expressed", + "uniprotAccessionNumber": "P08246" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2575, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHA1 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2528, + "assayComponentName": "ERF_CR_ENZ_hEPHA1", + "assayComponentDesc": "ERF_CR_ENZ_hEPHA1 is an assay component calculated from the ERF_CR_ENZ_hEPHA1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl-beta Abeta Abeta AAEEEIYEEIEAKKK, are indicative of changes in receptor function and kinetics related to the gene EPHA1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl-beta Abeta Abeta AAEEEIYEEIEAKKK", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 731, + "assayName": "ERF_CR_ENZ_hEPHA1", + "assayDesc": "ERF_CR_ENZ_hEPHA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See EphA1 Human RTK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 113, + "geneName": "EPH receptor A1", + "description": null, + "geneSymbol": "EPHA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2041, + "officialSymbol": "EPHA1", + "officialFullName": "EPH receptor A1", + "uniprotAccessionNumber": "P21709" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2576, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHA2 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHA2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2529, + "assayComponentName": "ERF_CR_ENZ_hEPHA2", + "assayComponentDesc": "ERF_CR_ENZ_hEPHA2 is an assay component calculated from the ERF_CR_ENZ_hEPHA2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide , are indicative of changes in receptor function and kinetics related to the gene EPHA2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 790, + "assayName": "ERF_CR_ENZ_hEPHA2", + "assayDesc": "ERF_CR_ENZ_hEPHA2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See EphA2 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 110, + "geneName": "EPH receptor A2", + "description": null, + "geneSymbol": "EPHA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1969, + "officialSymbol": "EPHA2", + "officialFullName": "EPH receptor A2", + "uniprotAccessionNumber": "P29317" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2577, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHB2 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP2", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2530, + "assayComponentName": "ERF_CR_ENZ_hEPHB2", + "assayComponentDesc": "ERF_CR_ENZ_hEPHB2 is an assay component calculated from the ERF_CR_ENZ_hEPHB2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in receptor function and kinetics related to the gene EPHB2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 789, + "assayName": "ERF_CR_ENZ_hEPHB2", + "assayDesc": "ERF_CR_ENZ_hEPHB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See EphB2 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 115, + "geneName": "EPH receptor B2", + "description": null, + "geneSymbol": "EPHB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2048, + "officialSymbol": "EPHB2", + "officialFullName": "EPH receptor B2", + "uniprotAccessionNumber": "P29323" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2578, + "assayComponentEndpointName": "ERF_CR_ENZ_hFGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFGFR1 was analyzed at the assay endpoint, ERF_CR_ENZ_hFGFR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2531, + "assayComponentName": "ERF_CR_ENZ_hFGFR1", + "assayComponentDesc": "ERF_CR_ENZ_hFGFR1 is an assay component calculated from the ERF_CR_ENZ_hFGFR1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD , are indicative of changes in receptor function and kinetics related to the gene FGFR1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 770, + "assayName": "ERF_CR_ENZ_hFGFR1", + "assayDesc": "ERF_CR_ENZ_hFGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FGFR Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 126, + "geneName": "fibroblast growth factor receptor 1", + "description": null, + "geneSymbol": "FGFR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2260, + "officialSymbol": "FGFR1", + "officialFullName": "fibroblast growth factor receptor 1", + "uniprotAccessionNumber": "P11362" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2579, + "assayComponentEndpointName": "ERF_CR_ENZ_hFGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFGFR3 was analyzed at the assay endpoint, ERF_CR_ENZ_hFGFR3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2532, + "assayComponentName": "ERF_CR_ENZ_hFGFR3", + "assayComponentDesc": "ERF_CR_ENZ_hFGFR3 is an assay component calculated from the ERF_CR_ENZ_hFGFR3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene FGFR3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 775, + "assayName": "ERF_CR_ENZ_hFGFR3", + "assayDesc": "ERF_CR_ENZ_hFGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See FGFR3 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 127, + "geneName": "fibroblast growth factor receptor 3", + "description": null, + "geneSymbol": "FGFR3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2261, + "officialSymbol": "FGFR3", + "officialFullName": "fibroblast growth factor receptor 3", + "uniprotAccessionNumber": "P22607" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2580, + "assayComponentEndpointName": "ERF_CR_ENZ_hFLT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFLT1 was analyzed at the assay endpoint, ERF_CR_ENZ_hFLT1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2533, + "assayComponentName": "ERF_CR_ENZ_hFLT1", + "assayComponentDesc": "ERF_CR_ENZ_hFLT1 is an assay component calculated from the ERF_CR_ENZ_hFLT1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in enzyme function and kinetics related to the gene FLT1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 792, + "assayName": "ERF_CR_ENZ_hFLT1", + "assayDesc": "ERF_CR_ENZ_hFLT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Flt-1 (VEGFR1) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 131, + "geneName": "fms-related tyrosine kinase 1", + "description": null, + "geneSymbol": "FLT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2321, + "officialSymbol": "FLT1", + "officialFullName": "fms-related tyrosine kinase 1", + "uniprotAccessionNumber": "P17948" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2581, + "assayComponentEndpointName": "ERF_CR_ENZ_hFLT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFLT4 was analyzed at the assay endpoint, ERF_CR_ENZ_hFLT4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2534, + "assayComponentName": "ERF_CR_ENZ_hFLT4", + "assayComponentDesc": "ERF_CR_ENZ_hFLT4 is an assay component calculated from the ERF_CR_ENZ_hFLT4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene FLT4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 776, + "assayName": "ERF_CR_ENZ_hFLT4", + "assayDesc": "ERF_CR_ENZ_hFLT4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See FLT4 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 132, + "geneName": "fms-related tyrosine kinase 4", + "description": null, + "geneSymbol": "FLT4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2324, + "officialSymbol": "FLT4", + "officialFullName": "fms-related tyrosine kinase 4", + "uniprotAccessionNumber": "P35916" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2582, + "assayComponentEndpointName": "ERF_CR_ENZ_hFYN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFYN was analyzed at the assay endpoint, ERF_CR_ENZ_hFYN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2535, + "assayComponentName": "ERF_CR_ENZ_hFYN", + "assayComponentDesc": "ERF_CR_ENZ_hFYN is an assay component calculated from the ERF_CR_ENZ_hFYN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl-beta Abeta Abeta AYQAEENTYDEYEN, are indicative of changes in enzyme function and kinetics related to the gene FYN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl-beta Abeta Abeta AYQAEENTYDEYEN", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 747, + "assayName": "ERF_CR_ENZ_hFYN", + "assayDesc": "ERF_CR_ENZ_hFYN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Fyn Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 137, + "geneName": "FYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "FYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2534, + "officialSymbol": "FYN", + "officialFullName": "FYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06241" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2583, + "assayComponentEndpointName": "ERF_CR_ENZ_hGSK3b", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hGSK3b was analyzed at the assay endpoint, ERF_CR_ENZ_hGSK3b, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene GSK3B. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2536, + "assayComponentName": "ERF_CR_ENZ_hGSK3b", + "assayComponentDesc": "ERF_CR_ENZ_hGSK3b is an assay component calculated from the ERF_CR_ENZ_hGSK3b assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide , are indicative of changes in enzyme function and kinetics related to the gene GSK3B.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 773, + "assayName": "ERF_CR_ENZ_hGSK3b", + "assayDesc": "ERF_CR_ENZ_hGSK3b is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See GSK3beta Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 146, + "geneName": "glycogen synthase kinase 3 beta", + "description": null, + "geneSymbol": "GSK3B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2932, + "officialSymbol": "GSK3B", + "officialFullName": "glycogen synthase kinase 3 beta", + "uniprotAccessionNumber": "P49841" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2584, + "assayComponentEndpointName": "ERF_CR_ENZ_hHDAC6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hHDAC6 was analyzed at the assay endpoint, ERF_CR_ENZ_hHDAC6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene HDAC6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "epigenetic enzyme", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2537, + "assayComponentName": "ERF_CR_ENZ_hHDAC6", + "assayComponentDesc": "ERF_CR_ENZ_hHDAC6 is an assay component calculated from the ERF_CR_ENZ_hHDAC6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, fluorogenic HDAC substrate, are indicative of changes in enzyme function and kinetics related to the gene HDAC6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorogenic HDAC substrate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 756, + "assayName": "ERF_CR_ENZ_hHDAC6", + "assayDesc": "ERF_CR_ENZ_hHDAC6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See HDAC6 Human Histone Deacetylase (HDAC) Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 361, + "geneName": "histone deacetylase 6", + "description": null, + "geneSymbol": "HDAC6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10013, + "officialSymbol": "HDAC6", + "officialFullName": "histone deacetylase 6", + "uniprotAccessionNumber": "Q9UBN7" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2585, + "assayComponentEndpointName": "ERF_CR_ENZ_hIRAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hIRAK4 was analyzed at the assay endpoint, ERF_CR_ENZ_hIRAK4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene IRAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2538, + "assayComponentName": "ERF_CR_ENZ_hIRAK4", + "assayComponentDesc": "ERF_CR_ENZ_hIRAK4 is an assay component calculated from the ERF_CR_ENZ_hIRAK4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-FLGFTYVAP, are indicative of changes in enzyme function and kinetics related to the gene IRAK4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-FLGFTYVAP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 784, + "assayName": "ERF_CR_ENZ_hIRAK4", + "assayDesc": "ERF_CR_ENZ_hIRAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See IRAK4 Human TKL Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 425, + "geneName": "interleukin-1 receptor-associated kinase 4", + "description": null, + "geneSymbol": "IRAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51135, + "officialSymbol": "IRAK4", + "officialFullName": "interleukin-1 receptor-associated kinase 4", + "uniprotAccessionNumber": "Q9NWZ3" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2586, + "assayComponentEndpointName": "ERF_CR_ENZ_hJAK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hJAK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hJAK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene JAK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2539, + "assayComponentName": "ERF_CR_ENZ_hJAK2", + "assayComponentDesc": "ERF_CR_ENZ_hJAK2 is an assay component calculated from the ERF_CR_ENZ_hJAK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene JAK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 771, + "assayName": "ERF_CR_ENZ_hJAK2", + "assayDesc": "ERF_CR_ENZ_hJAK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See JAK2 Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 182, + "geneName": "Janus kinase 2", + "description": null, + "geneSymbol": "JAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3717, + "officialSymbol": "JAK2", + "officialFullName": "Janus kinase 2", + "uniprotAccessionNumber": "O60674" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2587, + "assayComponentEndpointName": "ERF_CR_ENZ_hKDR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hKDR was analyzed at the assay endpoint, ERF_CR_ENZ_hKDR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene KDR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2540, + "assayComponentName": "ERF_CR_ENZ_hKDR", + "assayComponentDesc": "ERF_CR_ENZ_hKDR is an assay component calculated from the ERF_CR_ENZ_hKDR assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene KDR.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 767, + "assayName": "ERF_CR_ENZ_hKDR", + "assayDesc": "ERF_CR_ENZ_hKDR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See KDR (VEGFR2) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2588, + "assayComponentEndpointName": "ERF_CR_ENZ_hLCK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hLCK was analyzed at the assay endpoint, ERF_CR_ENZ_hLCK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LCK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2541, + "assayComponentName": "ERF_CR_ENZ_hLCK", + "assayComponentDesc": "ERF_CR_ENZ_hLCK is an assay component calculated from the ERF_CR_ENZ_hLCK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene LCK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 778, + "assayName": "ERF_CR_ENZ_hLCK", + "assayDesc": "ERF_CR_ENZ_hLCK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Lck Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 188, + "geneName": "LCK proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LCK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3932, + "officialSymbol": "LCK", + "officialFullName": "LCK proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06239" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2589, + "assayComponentEndpointName": "ERF_CR_ENZ_hLYN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hLYN was analyzed at the assay endpoint, ERF_CR_ENZ_hLYN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2542, + "assayComponentName": "ERF_CR_ENZ_hLYN", + "assayComponentDesc": "ERF_CR_ENZ_hLYN is an assay component calculated from the ERF_CR_ENZ_hLYN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + His-tagged Rb truncated protein, are indicative of changes in enzyme function and kinetics related to the gene LYN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + His-tagged Rb truncated protein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 750, + "assayName": "ERF_CR_ENZ_hLYN", + "assayDesc": "ERF_CR_ENZ_hLYN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See LYN (B) Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2590, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAOA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAOA was analyzed at the assay endpoint, ERF_CR_ENZ_hMAOA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "clorgiline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2543, + "assayComponentName": "ERF_CR_ENZ_hMAOA", + "assayComponentDesc": "ERF_CR_ENZ_hMAOA is an assay component calculated from the ERF_CR_ENZ_hMAOA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, kynuramine, are indicative of changes in enzyme function and kinetics related to the gene MAOA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "kynuramine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 732, + "assayName": "ERF_CR_ENZ_hMAOA", + "assayDesc": "ERF_CR_ENZ_hMAOA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See Monoamine Oxidase A (MAO-A) Human Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4645, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "MAOA", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 4128, + "officialSymbol": "MAOA", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2591, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAOB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAOB was analyzed at the assay endpoint, ERF_CR_ENZ_hMAOB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "deprenyl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2544, + "assayComponentName": "ERF_CR_ENZ_hMAOB", + "assayComponentDesc": "ERF_CR_ENZ_hMAOB is an assay component calculated from the ERF_CR_ENZ_hMAOB assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by luminescent intensity with luminescence technology.", + "assayComponentTargetDesc": "Changes in luminescent intensity produced from the regulation of catalytic activity reaction involving the key substrate, D-Luciferin derivative, are indicative of changes in enzyme function and kinetics related to the gene MAOB.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "Luciferase", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "D-Luciferin derivative", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 800, + "assayName": "ERF_CR_ENZ_hMAOB", + "assayDesc": "ERF_CR_ENZ_hMAOB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Monoamine Oxidase B (MAO-B) Human Enzymatic Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4646, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "MAOB", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 4129, + "officialSymbol": "MAOB", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2592, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAPK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAPK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMAPK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2545, + "assayComponentName": "ERF_CR_ENZ_hMAPK1", + "assayComponentDesc": "ERF_CR_ENZ_hMAPK1 is an assay component calculated from the ERF_CR_ENZ_hMAPK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene MAPK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 772, + "assayName": "ERF_CR_ENZ_hMAPK1", + "assayDesc": "ERF_CR_ENZ_hMAPK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See ERK2 (MAPK1) Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 259, + "geneName": "mitogen-activated protein kinase 1", + "description": null, + "geneSymbol": "MAPK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5594, + "officialSymbol": "MAPK1", + "officialFullName": "mitogen-activated protein kinase 1", + "uniprotAccessionNumber": "P28482" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2593, + "assayComponentEndpointName": "ERF_KP_ENZ_hMAPK11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hMAPK11 was analyzed at the assay endpoint, ERF_KP_ENZ_hMAPK11, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP1 Analog II. 1NM-PP1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2546, + "assayComponentName": "ERF_KP_ENZ_hMAPK11", + "assayComponentDesc": "ERF_KP_ENZ_hMAPK11 is an assay component calculated from the ERF_KP_ENZ_hMAPK11 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, myelin basic protein, are indicative of changes in enzyme function and kinetics related to the gene MAPK11.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "myelin basic protein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 701, + "assayName": "ERF_KP_ENZ_hMAPK11", + "assayDesc": "ERF_KP_ENZ_hMAPK11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See SAPK2 (p38beta) Human CMGC Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 261, + "geneName": "mitogen-activated protein kinase 11", + "description": null, + "geneSymbol": "MAPK11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5600, + "officialSymbol": "MAPK11", + "officialFullName": "mitogen-activated protein kinase 11", + "uniprotAccessionNumber": "Q15759" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2594, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAPKAPK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAPKAPK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hMAPKAPK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2547, + "assayComponentName": "ERF_CR_ENZ_hMAPKAPK2", + "assayComponentDesc": "ERF_CR_ENZ_hMAPKAPK2 is an assay component calculated from the ERF_CR_ENZ_hMAPKAPK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + CREBtide, are indicative of changes in enzyme function and kinetics related to the gene MAPKAPK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + CREBtide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 799, + "assayName": "ERF_CR_ENZ_hMAPKAPK2", + "assayDesc": "ERF_CR_ENZ_hMAPKAPK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See MAPKAPK2 Human CAMK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 352, + "geneName": "mitogen-activated protein kinase-activated protein kinase 2", + "description": null, + "geneSymbol": "MAPKAPK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9261, + "officialSymbol": "MAPKAPK2", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 2", + "uniprotAccessionNumber": "P49137" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2595, + "assayComponentEndpointName": "ERF_PL_ENZ_hMAPKAPK5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hMAPKAPK5 was analyzed at the assay endpoint, ERF_PL_ENZ_hMAPKAPK5, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2548, + "assayComponentName": "ERF_PL_ENZ_hMAPKAPK5", + "assayComponentDesc": "ERF_PL_ENZ_hMAPKAPK5 is an assay component calculated from the ERF_PL_ENZ_hMAPKAPK5 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, PRAK substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene MAPKAPK5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "PRAK substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 725, + "assayName": "ERF_PL_ENZ_hMAPKAPK5", + "assayDesc": "ERF_PL_ENZ_hMAPKAPK5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PRAK Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 343, + "geneName": "mitogen-activated protein kinase-activated protein kinase 5", + "description": null, + "geneSymbol": "MAPKAPK5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8550, + "officialSymbol": "MAPKAPK5", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 5", + "uniprotAccessionNumber": "Q8IW41" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2596, + "assayComponentEndpointName": "ERF_CR_ENZ_hMARK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMARK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMARK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MARK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2549, + "assayComponentName": "ERF_CR_ENZ_hMARK1", + "assayComponentDesc": "ERF_CR_ENZ_hMARK1 is an assay component calculated from the ERF_CR_ENZ_hMARK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene MARK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 796, + "assayName": "ERF_CR_ENZ_hMARK1", + "assayDesc": "ERF_CR_ENZ_hMARK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See MARK1 Human CAMK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 198, + "geneName": "MAP/microtubule affinity-regulating kinase 1", + "description": null, + "geneSymbol": "MARK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4139, + "officialSymbol": "MARK1", + "officialFullName": "MAP/microtubule affinity-regulating kinase 1", + "uniprotAccessionNumber": "Q9P0L2" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2597, + "assayComponentEndpointName": "ERF_CR_ENZ_hMET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMET was analyzed at the assay endpoint, ERF_CR_ENZ_hMET, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MET. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2550, + "assayComponentName": "ERF_CR_ENZ_hMET", + "assayComponentDesc": "ERF_CR_ENZ_hMET is an assay component calculated from the ERF_CR_ENZ_hMET assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene MET.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 769, + "assayName": "ERF_CR_ENZ_hMET", + "assayDesc": "ERF_CR_ENZ_hMET is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Met Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 200, + "geneName": "MET proto-oncogene, receptor tyrosine kinase", + "description": null, + "geneSymbol": "MET", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4233, + "officialSymbol": "MET", + "officialFullName": "MET proto-oncogene, receptor tyrosine kinase", + "uniprotAccessionNumber": "P08581" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2598, + "assayComponentEndpointName": "ERF_CR_ENZ_hMMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMMP3 was analyzed at the assay endpoint, ERF_CR_ENZ_hMMP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ilomastat", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metallopeptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2551, + "assayComponentName": "ERF_CR_ENZ_hMMP3", + "assayComponentDesc": "ERF_CR_ENZ_hMMP3 is an assay component calculated from the ERF_CR_ENZ_hMMP3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, NFF-2 , are indicative of changes in enzyme function and kinetics related to the gene MMP3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NFF-2 ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 823, + "assayName": "ERF_CR_ENZ_hMMP3", + "assayDesc": "ERF_CR_ENZ_hMMP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See MMP3 Human Matrix Metallopeptidase Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2599, + "assayComponentEndpointName": "ERF_CR_ENZ_hMMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMMP9 was analyzed at the assay endpoint, ERF_CR_ENZ_hMMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ilomastat", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metallopeptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2552, + "assayComponentName": "ERF_CR_ENZ_hMMP9", + "assayComponentDesc": "ERF_CR_ENZ_hMMP9 is an assay component calculated from the ERF_CR_ENZ_hMMP9 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, NFF-2 , are indicative of changes in enzyme function and kinetics related to the gene MMP9.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NFF-2 ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 824, + "assayName": "ERF_CR_ENZ_hMMP9", + "assayDesc": "ERF_CR_ENZ_hMMP9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See MMP9 Human Matrix Metallopeptidase Enzymatic Assay, Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2600, + "assayComponentEndpointName": "ERF_CR_ENZ_hMSK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMSK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMSK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MSK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2553, + "assayComponentName": "ERF_CR_ENZ_hMSK1", + "assayComponentDesc": "ERF_CR_ENZ_hMSK1 is an assay component calculated from the ERF_CR_ENZ_hMSK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, Histone H3 full length, are indicative of changes in enzyme function and kinetics related to the gene RPS6KA5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Histone H3 full length", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 805, + "assayName": "ERF_CR_ENZ_hMSK1", + "assayDesc": "ERF_CR_ENZ_hMSK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See MSK1 Human AGC Kinase Enzymatic Radiometric Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 351, + "geneName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "description": null, + "geneSymbol": "RPS6KA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9252, + "officialSymbol": "RPS6KA5", + "officialFullName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "uniprotAccessionNumber": "O75582" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2601, + "assayComponentEndpointName": "ERF_CR_ENZ_hNEK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hNEK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hNEK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NEK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2554, + "assayComponentName": "ERF_CR_ENZ_hNEK2", + "assayComponentDesc": "ERF_CR_ENZ_hNEK2 is an assay component calculated from the ERF_CR_ENZ_hNEK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-FLGFTYVAP, are indicative of changes in enzyme function and kinetics related to the gene NEK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-FLGFTYVAP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 785, + "assayName": "ERF_CR_ENZ_hNEK2", + "assayDesc": "ERF_CR_ENZ_hNEK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NEK2 Human Other Protein Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 215, + "geneName": "NIMA-related kinase 2", + "description": null, + "geneSymbol": "NEK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4751, + "officialSymbol": "NEK2", + "officialFullName": "NIMA-related kinase 2", + "uniprotAccessionNumber": "P51955" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2602, + "assayComponentEndpointName": "ERF_CR_ENZ_hNTRK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hNTRK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hNTRK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NTRK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2555, + "assayComponentName": "ERF_CR_ENZ_hNTRK1", + "assayComponentDesc": "ERF_CR_ENZ_hNTRK1 is an assay component calculated from the ERF_CR_ENZ_hNTRK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene NTRK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 777, + "assayName": "ERF_CR_ENZ_hNTRK1", + "assayDesc": "ERF_CR_ENZ_hNTRK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See TRKA Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 222, + "geneName": "neurotrophic tyrosine kinase, receptor, type 1", + "description": null, + "geneSymbol": "NTRK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4914, + "officialSymbol": "NTRK1", + "officialFullName": "neurotrophic tyrosine kinase, receptor, type 1", + "uniprotAccessionNumber": "P04629" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2603, + "assayComponentEndpointName": "ERF_CR_ENZ_hPAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPAK4 was analyzed at the assay endpoint, ERF_CR_ENZ_hPAK4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2556, + "assayComponentName": "ERF_CR_ENZ_hPAK4", + "assayComponentDesc": "ERF_CR_ENZ_hPAK4 is an assay component calculated from the ERF_CR_ENZ_hPAK4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene PAK4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 797, + "assayName": "ERF_CR_ENZ_hPAK4", + "assayDesc": "ERF_CR_ENZ_hPAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PAK4 Human STE Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 364, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "description": null, + "geneSymbol": "PAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10298, + "officialSymbol": "PAK4", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "uniprotAccessionNumber": "O96013" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2604, + "assayComponentEndpointName": "ERF_CR_ENZ_hPDE10A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPDE10A was analyzed at the assay endpoint, ERF_CR_ENZ_hPDE10A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE10A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "papaverine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2557, + "assayComponentName": "ERF_CR_ENZ_hPDE10A", + "assayComponentDesc": "ERF_CR_ENZ_hPDE10A is an assay component calculated from the ERF_CR_ENZ_hPDE10A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE10A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 813, + "assayName": "ERF_CR_ENZ_hPDE10A", + "assayDesc": "ERF_CR_ENZ_hPDE10A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE10A2 Human Phosphodiesterase Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2605, + "assayComponentEndpointName": "ERF_CR_ENZ_hPDE4A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPDE4A was analyzed at the assay endpoint, ERF_CR_ENZ_hPDE4A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 20-1724", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2558, + "assayComponentName": "ERF_CR_ENZ_hPDE4A", + "assayComponentDesc": "ERF_CR_ENZ_hPDE4A is an assay component calculated from the ERF_CR_ENZ_hPDE4A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE4A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 811, + "assayName": "ERF_CR_ENZ_hPDE4A", + "assayDesc": "ERF_CR_ENZ_hPDE4A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE4A1A Human Phosphodiesterase Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 232, + "geneName": "phosphodiesterase 4A, cAMP-specific", + "description": null, + "geneSymbol": "PDE4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5141, + "officialSymbol": "PDE4A", + "officialFullName": "phosphodiesterase 4A, cAMP-specific", + "uniprotAccessionNumber": "P27815" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2606, + "assayComponentEndpointName": "ERF_PL_ENZ_hPDE4D2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPDE4D2 was analyzed at the assay endpoint, ERF_PL_ENZ_hPDE4D2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rolipram", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2559, + "assayComponentName": "ERF_PL_ENZ_hPDE4D2", + "assayComponentDesc": "ERF_PL_ENZ_hPDE4D2 is an assay component calculated from the ERF_PL_ENZ_hPDE4D2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, FAM-cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE4D.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "FAM-cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 712, + "assayName": "ERF_PL_ENZ_hPDE4D2", + "assayDesc": "ERF_PL_ENZ_hPDE4D2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PDE4D2 Human Phosphodiesterase Enzymatic Assay, Panlabs.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5360, + "geneName": "phosphodiesterase 4D", + "description": null, + "geneSymbol": "PDE4D", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5144, + "officialSymbol": "PDE4D", + "officialFullName": "phosphodiesterase 4D", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2607, + "assayComponentEndpointName": "ERF_KP_ENZ_hPKD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hPKD2 was analyzed at the assay endpoint, ERF_KP_ENZ_hPKD2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2560, + "assayComponentName": "ERF_KP_ENZ_hPKD2", + "assayComponentDesc": "ERF_KP_ENZ_hPKD2 is an assay component calculated from the ERF_KP_ENZ_hPKD2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, KKLNRTLSVA, are indicative of changes in enzyme function and kinetics related to the gene PRKD2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "KKLNRTLSVA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 702, + "assayName": "ERF_KP_ENZ_hPKD2", + "assayDesc": "ERF_KP_ENZ_hPKD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See PKD2 Human Protein Ser/Thr Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 416, + "geneName": "protein kinase D2", + "description": null, + "geneSymbol": "PRKD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25865, + "officialSymbol": "PRKD2", + "officialFullName": "protein kinase D2", + "uniprotAccessionNumber": "Q9BZL6" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2608, + "assayComponentEndpointName": "ERF_KP_ENZ_hPRKAA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hPRKAA1 was analyzed at the assay endpoint, ERF_KP_ENZ_hPRKAA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKAA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2561, + "assayComponentName": "ERF_KP_ENZ_hPRKAA1", + "assayComponentDesc": "ERF_KP_ENZ_hPRKAA1 is an assay component calculated from the ERF_KP_ENZ_hPRKAA1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, AMARAASAAALAR, are indicative of changes in enzyme function and kinetics related to the gene PRKAA1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "AMARAASAAALAR", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 705, + "assayName": "ERF_KP_ENZ_hPRKAA1", + "assayDesc": "ERF_KP_ENZ_hPRKAA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See AMPKalpha1 Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 255, + "geneName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "description": null, + "geneSymbol": "PRKAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5562, + "officialSymbol": "PRKAA1", + "officialFullName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "uniprotAccessionNumber": "Q13131" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2609, + "assayComponentEndpointName": "ERF_PL_ENZ_hPRKACA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPRKACA was analyzed at the assay endpoint, ERF_PL_ENZ_hPRKACA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKACA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1-(5-ISOQUINOLINESULFONYL)-2-M", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2562, + "assayComponentName": "ERF_PL_ENZ_hPRKACA", + "assayComponentDesc": "ERF_PL_ENZ_hPRKACA is an assay component calculated from the ERF_PL_ENZ_hPRKACA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, PKA substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene PRKACA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "PKA substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 727, + "assayName": "ERF_PL_ENZ_hPRKACA", + "assayDesc": "ERF_PL_ENZ_hPRKACA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PKA Human AGC Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 256, + "geneName": "protein kinase, cAMP-dependent, catalytic, alpha", + "description": null, + "geneSymbol": "PRKACA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5566, + "officialSymbol": "PRKACA", + "officialFullName": "protein kinase, cAMP-dependent, catalytic, alpha", + "uniprotAccessionNumber": "P17612" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2610, + "assayComponentEndpointName": "ERF_PL_ENZ_hPRKCZ", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPRKCZ was analyzed at the assay endpoint, ERF_PL_ENZ_hPRKCZ, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKCZ. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2563, + "assayComponentName": "ERF_PL_ENZ_hPRKCZ", + "assayComponentDesc": "ERF_PL_ENZ_hPRKCZ is an assay component calculated from the ERF_PL_ENZ_hPRKCZ assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, histone, are indicative of changes in enzyme function and kinetics related to the gene PRKCZ.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "histone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 730, + "assayName": "ERF_PL_ENZ_hPRKCZ", + "assayDesc": "ERF_PL_ENZ_hPRKCZ is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PKCzeta Human PKC Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 258, + "geneName": "protein kinase C, zeta", + "description": null, + "geneSymbol": "PRKCZ", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5590, + "officialSymbol": "PRKCZ", + "officialFullName": "protein kinase C, zeta", + "uniprotAccessionNumber": "Q05513" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2611, + "assayComponentEndpointName": "ERF_PL_ENZ_hPTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPTEN was analyzed at the assay endpoint, ERF_PL_ENZ_hPTEN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTEN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(NH4)6Mo7O24", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2564, + "assayComponentName": "ERF_PL_ENZ_hPTEN", + "assayComponentDesc": "ERF_PL_ENZ_hPTEN is an assay component calculated from the ERF_PL_ENZ_hPTEN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, DiFMUP, are indicative of changes in enzyme function and kinetics related to the gene PTEN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DiFMUP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 733, + "assayName": "ERF_PL_ENZ_hPTEN", + "assayDesc": "ERF_PL_ENZ_hPTEN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See PTEN Human Phosphatase Enzymatic Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2612, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTGS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTGS2 was analyzed at the assay endpoint, ERF_CR_ENZ_hPTGS2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTGS2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ns-398", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2565, + "assayComponentName": "ERF_CR_ENZ_hPTGS2", + "assayComponentDesc": "ERF_CR_ENZ_hPTGS2 is an assay component calculated from the ERF_CR_ENZ_hPTGS2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate;substrate, arachidonic acid; ADHP, are indicative of changes in enzyme function and kinetics related to the gene PTGS2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid; ADHP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 817, + "assayName": "ERF_CR_ENZ_hPTGS2", + "assayDesc": "ERF_CR_ENZ_hPTGS2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.083 hour after chemical dosing in a 96-well plate. See COX2 Human Cyclooxygenase Enzymatic Assay, Cerep.", + "timepointHr": 0.083, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5831, + "geneName": "prostaglandin-endoperoxide synthase 2", + "description": null, + "geneSymbol": "PTGS2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5743, + "officialSymbol": "PTGS2", + "officialFullName": "prostaglandin-endoperoxide synthase 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2613, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTPN11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTPN11 was analyzed at the assay endpoint, ERF_CR_ENZ_hPTPN11, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPN11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "protein tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2566, + "assayComponentName": "ERF_CR_ENZ_hPTPN11", + "assayComponentDesc": "ERF_CR_ENZ_hPTPN11 is an assay component calculated from the ERF_CR_ENZ_hPTPN11 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-4, are indicative of changes in enzyme function and kinetics related to the gene PTPN11.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 704, + "assayName": "ERF_CR_ENZ_hPTPN11", + "assayDesc": "ERF_PL_ENZ_hPTPN11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See SHP2 Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 270, + "geneName": "protein tyrosine phosphatase, non-receptor type 11", + "description": null, + "geneSymbol": "PTPN11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5781, + "officialSymbol": "PTPN11", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 11", + "uniprotAccessionNumber": "Q06124" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2614, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTPRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTPRB was analyzed at the assay endpoint, ERF_CR_ENZ_hPTPRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTPRB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "protein tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2567, + "assayComponentName": "ERF_CR_ENZ_hPTPRB", + "assayComponentDesc": "ERF_CR_ENZ_hPTPRB is an assay component calculated from the ERF_CR_ENZ_hPTPRB assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-5, are indicative of changes in enzyme function and kinetics related to the gene PTPRB.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-5", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 706, + "assayName": "ERF_CR_ENZ_hPTPRB", + "assayDesc": "ERF_PL_ENZ_hPTPRB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PTPbeta Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 274, + "geneName": "protein tyrosine phosphatase, receptor type, B", + "description": null, + "geneSymbol": "PTPRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5787, + "officialSymbol": "PTPRB", + "officialFullName": "protein tyrosine phosphatase, receptor type, B", + "uniprotAccessionNumber": "P23467" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2615, + "assayComponentEndpointName": "ERF_PL_ENZ_hPTPRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPTPRF was analyzed at the assay endpoint, ERF_PL_ENZ_hPTPRF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPRF. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(NH4)6Mo7O24", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2568, + "assayComponentName": "ERF_PL_ENZ_hPTPRF", + "assayComponentDesc": "ERF_PL_ENZ_hPTPRF is an assay component calculated from the ERF_PL_ENZ_hPTPRF assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, DiFMUP, are indicative of changes in enzyme function and kinetics related to the gene PTPRF.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DiFMUP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 734, + "assayName": "ERF_PL_ENZ_hPTPRF", + "assayDesc": "ERF_PL_ENZ_hPTPRF is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See LAR Human Phosphatase Enzymatic Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 276, + "geneName": "protein tyrosine phosphatase, receptor type, F", + "description": null, + "geneSymbol": "PTPRF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5792, + "officialSymbol": "PTPRF", + "officialFullName": "protein tyrosine phosphatase, receptor type, F", + "uniprotAccessionNumber": "P10586" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2617, + "assayComponentEndpointName": "ERF_CR_ENZ_hRAF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hRAF1 was analyzed at the assay endpoint, ERF_CR_ENZ_hRAF1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene RAF1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2570, + "assayComponentName": "ERF_CR_ENZ_hRAF1", + "assayComponentDesc": "ERF_CR_ENZ_hRAF1 is an assay component calculated from the ERF_CR_ENZ_hRAF1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + inactive MEK1, are indicative of changes in enzyme function and kinetics related to the gene RAF1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + inactive MEK1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 724, + "assayName": "ERF_CR_ENZ_hRAF1", + "assayDesc": "ERF_CR_ENZ_hRAF1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See c-Raf (Raf-1) Human TKL Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 278, + "geneName": "Raf-1 proto-oncogene, serine/threonine kinase", + "description": null, + "geneSymbol": "RAF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5894, + "officialSymbol": "RAF1", + "officialFullName": "Raf-1 proto-oncogene, serine/threonine kinase", + "uniprotAccessionNumber": "P04049" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2618, + "assayComponentEndpointName": "ERF_CR_ENZ_hROCK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hROCK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hROCK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ROCK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2571, + "assayComponentName": "ERF_CR_ENZ_hROCK1", + "assayComponentDesc": "ERF_CR_ENZ_hROCK1 is an assay component calculated from the ERF_CR_ENZ_hROCK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene ROCK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 798, + "assayName": "ERF_CR_ENZ_hROCK1", + "assayDesc": "ERF_CR_ENZ_hROCK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See ROCK1 Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 283, + "geneName": "Rho-associated, coiled-coil containing protein kinase 1", + "description": null, + "geneSymbol": "ROCK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6093, + "officialSymbol": "ROCK1", + "officialFullName": "Rho-associated, coiled-coil containing protein kinase 1", + "uniprotAccessionNumber": "Q13464" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2619, + "assayComponentEndpointName": "ERF_CR_ENZ_hSGK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSGK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hSGK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SGK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2572, + "assayComponentName": "ERF_CR_ENZ_hSGK1", + "assayComponentDesc": "ERF_CR_ENZ_hSGK1 is an assay component calculated from the ERF_CR_ENZ_hSGK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE , are indicative of changes in enzyme function and kinetics related to the gene SGK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 783, + "assayName": "ERF_CR_ENZ_hSGK1", + "assayDesc": "ERF_CR_ENZ_hSGK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See SGK1 Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 295, + "geneName": "serum/glucocorticoid regulated kinase 1", + "description": null, + "geneSymbol": "SGK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6446, + "officialSymbol": "SGK1", + "officialFullName": "serum/glucocorticoid regulated kinase 1", + "uniprotAccessionNumber": "O00141" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2620, + "assayComponentEndpointName": "ERF_CR_ENZ_hSIRT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSIRT3 was analyzed at the assay endpoint, ERF_CR_ENZ_hSIRT3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SIRT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nicotinamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "epigenetic enzyme", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2573, + "assayComponentName": "ERF_CR_ENZ_hSIRT3", + "assayComponentDesc": "ERF_CR_ENZ_hSIRT3 is an assay component calculated from the ERF_CR_ENZ_hSIRT3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, fluoro-lysine sirtuin 2 deacetylase substrate, are indicative of changes in enzyme function and kinetics related to the gene SIRT3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluoro-lysine sirtuin 2 deacetylase substrate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 761, + "assayName": "ERF_CR_ENZ_hSIRT3", + "assayDesc": "ERF_CR_ENZ_hSIRT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate. See Sirtuin 3 Human Histone Deacetylase (HDAC) Enzymatic Antagonist Assay, Cerep.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 376, + "geneName": "sirtuin 3", + "description": null, + "geneSymbol": "SIRT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23410, + "officialSymbol": "SIRT3", + "officialFullName": "sirtuin 3", + "uniprotAccessionNumber": "Q9NTG7" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2621, + "assayComponentEndpointName": "ERF_CR_ENZ_hSRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSRC was analyzed at the assay endpoint, ERF_CR_ENZ_hSRC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SRC. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2574, + "assayComponentName": "ERF_CR_ENZ_hSRC", + "assayComponentDesc": "ERF_CR_ENZ_hSRC is an assay component calculated from the ERF_CR_ENZ_hSRC assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene SRC.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 779, + "assayName": "ERF_CR_ENZ_hSRC", + "assayDesc": "ERF_CR_ENZ_hSRC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Src Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2622, + "assayComponentEndpointName": "ERF_CR_ENZ_hSYK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSYK was analyzed at the assay endpoint, ERF_CR_ENZ_hSYK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SYK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is spleen tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "spleen tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2575, + "assayComponentName": "ERF_CR_ENZ_hSYK", + "assayComponentDesc": "ERF_CR_ENZ_hSYK is an assay component calculated from the ERF_CR_ENZ_hSYK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene SYK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 765, + "assayName": "ERF_CR_ENZ_hSYK", + "assayDesc": "ERF_CR_ENZ_hSYK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Syk Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 308, + "geneName": "spleen tyrosine kinase", + "description": null, + "geneSymbol": "SYK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6850, + "officialSymbol": "SYK", + "officialFullName": "spleen tyrosine kinase", + "uniprotAccessionNumber": "P43405" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2623, + "assayComponentEndpointName": "ERF_CR_ENZ_hZAP70", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hZAP70 was analyzed at the assay endpoint, ERF_CR_ENZ_hZAP70, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ZAP70. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is protein tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "protein tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2576, + "assayComponentName": "ERF_CR_ENZ_hZAP70", + "assayComponentDesc": "ERF_CR_ENZ_hZAP70 is an assay component calculated from the ERF_CR_ENZ_hZAP70 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl- beta Abeta Abeta ADEEEYFIPP, are indicative of changes in enzyme function and kinetics related to the gene ZAP70.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl- beta Abeta Abeta ADEEEYFIPP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 832, + "assayName": "ERF_CR_ENZ_hZAP70", + "assayDesc": "ERF_CR_ENZ_hZAP70 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See ZAP70 Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 338, + "geneName": "zeta-chain (TCR) associated protein kinase 70kDa", + "description": null, + "geneSymbol": "ZAP70", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7535, + "officialSymbol": "ZAP70", + "officialFullName": "zeta-chain (TCR) associated protein kinase 70kDa", + "uniprotAccessionNumber": "P43403" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2624, + "assayComponentEndpointName": "ERF_CR_ENZ_rACFSK_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_rACFSK_Agonist was analyzed at the assay endpoint, ERF_CR_ENZ_rACFSK_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cAMP", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2577, + "assayComponentName": "ERF_CR_ENZ_rACFSK_Agonist", + "assayComponentDesc": "ERF_CR_ENZ_rACFSK_Agonist is an assay component calculated from the ERF_CR_ENZ_rACFSK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand, [3H]-forskolin, are indicative of changes in enzyme function and kinetics related to the gene ADCY5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 786, + "assayName": "ERF_CR_ENZ_rACFSK_Agonist", + "assayDesc": "ERF_CR_ENZ_rACFSK_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Adenylyl Cyclase Hamster Enzymatic Agonist Assay, Cerep.", + "timepointHr": 0.16, + "organismId": null, + "organism": "hamster", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2625, + "assayComponentEndpointName": "ERF_CR_ENZ_rACFSK_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_rACFSK_Antagonist was analyzed at the assay endpoint, ERF_CR_ENZ_rACFSK_Antagonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cAMP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2578, + "assayComponentName": "ERF_CR_ENZ_rACFSK_Antagonist", + "assayComponentDesc": "ERF_CR_ENZ_rACFSK_Antagonist is an assay component calculated from the ERF_CR_ENZ_rACFSK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand, [3H]-forskolin, are indicative of changes in enzyme function and kinetics related to the gene ADCY5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 787, + "assayName": "ERF_CR_ENZ_rACFSK_Antagonist", + "assayDesc": "ERF_CR_ENZ_rACFSK_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Adenylyl Cyclase Hamster Enzymatic Antagonist Assay, Cerep.", + "timepointHr": 0.16, + "organismId": null, + "organism": "hamster", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2626, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_g5HT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_g5HT4 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_g5HT4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR4 (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CHEMBL83954", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2579, + "assayComponentName": "ERF_PL_GPCR_binding_g5HT4", + "assayComponentDesc": "ERF_PL_GPCR_binding_g5HT4 is an assay component calculated from the ERF_PL_GPCR_binding_g5HT4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-GR-113808, are indicative of changes in receptor function and kinetics related to the gene HTR4 (homolog).", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR-113808", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 764, + "assayName": "ERF_PL_GPCR_g5HT4", + "assayDesc": "ERF_PL_GPCR_g5HT4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See 5-HT4 Guinea Pig Serotonin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 471, + "geneName": "5 hydroxytryptamine (serotonin) receptor 4", + "description": "provisional", + "geneSymbol": "Htr4", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135548, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70528" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2627, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_gANPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_gANPA was analyzed at the assay endpoint, ERF_PL_GPCR_binding_gANPA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ANPA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is guanylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ANF (rat)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "guanylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2580, + "assayComponentName": "ERF_PL_GPCR_binding_gANPA", + "assayComponentDesc": "ERF_PL_GPCR_binding_gANPA is an assay component calculated from the ERF_PL_GPCR_binding_gANPA assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]Atrial Natriuretic Factor (ANF) rat, are indicative of changes in receptor function and kinetics related to the gene ANPA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]Atrial Natriuretic Factor (ANF) rat", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 746, + "assayName": "ERF_PL_GPCR_gANPA", + "assayDesc": "ERF_PL_GPCR_gANPA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Atrial Natriuretic Factor (ANF, Non-Selective) Guinea Pig Binding Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "adrenal gland membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 472, + "geneName": "natriuretic peptide A", + "description": "model", + "geneSymbol": "Nppa", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135578, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P27596" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2628, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADORA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADORA1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADORA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CPA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenosine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2581, + "assayComponentName": "ERF_CR_GPCR_binding_hADORA1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADORA1 is an assay component calculated from the ERF_CR_GPCR_binding_hADORA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-8-Cyclopentyl-1,3-dipropylxanthine (CCPA), are indicative of changes in receptor function and kinetics related to the gene ADORA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-8-Cyclopentyl-1,3-dipropylxanthine (CCPA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 820, + "assayName": "ERF_CR_GPCR_hADORA1", + "assayDesc": "ERF_CR_GPCR_hADORA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See A1 Human Adenosine GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 10, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 134, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P30542" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2629, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADORA2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADORA2A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADORA2A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NECA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenosine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2582, + "assayComponentName": "ERF_CR_GPCR_binding_hADORA2A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADORA2A is an assay component calculated from the ERF_CR_GPCR_binding_hADORA2A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-CGS 21680, are indicative of changes in receptor function and kinetics related to the gene ADORA2A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGS 21680", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 810, + "assayName": "ERF_CR_GPCR_hADORA2A", + "assayDesc": "ERF_CR_GPCR_hADORA2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See A2A Human Adenosine GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2630, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADRA1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADRA1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADRA1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRA1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "WB-4101", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2583, + "assayComponentName": "ERF_CR_GPCR_binding_hADRA1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADRA1A is an assay component calculated from the ERF_CR_GPCR_binding_hADRA1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Prazosin, are indicative of changes in receptor function and kinetics related to the gene ADRA1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 753, + "assayName": "ERF_CR_GPCR_hADRA1A", + "assayDesc": "ERF_CR_GPCR_hADRA1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha1A Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 483, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "ADRA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 148, + "officialSymbol": "ADRA1A", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2631, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRA2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRA2A was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRA2A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "yohimbine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2584, + "assayComponentName": "ERF_PL_GPCR_binding_hADRA2A", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRA2A is an assay component calculated from the ERF_PL_GPCR_binding_hADRA2A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, rauwolscine, are indicative of changes in receptor function and kinetics related to the gene ADRA2A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "rauwolscine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 738, + "assayName": "ERF_PL_GPCR_hADRA2A", + "assayDesc": "ERF_PL_GPCR_hADRA2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha2A Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 13, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "ADRA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 150, + "officialSymbol": "ADRA2A", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P08913" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2632, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRA2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRA2C was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRA2C, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "yohimbine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2585, + "assayComponentName": "ERF_PL_GPCR_binding_hADRA2C", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRA2C is an assay component calculated from the ERF_PL_GPCR_binding_hADRA2C assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, rauwolscine, are indicative of changes in receptor function and kinetics related to the gene ADRA2C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "rauwolscine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 739, + "assayName": "ERF_PL_GPCR_hADRA2C", + "assayDesc": "ERF_PL_GPCR_hADRA2C is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha2C Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 14, + "geneName": "adrenoceptor alpha 2C", + "description": null, + "geneSymbol": "ADRA2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 152, + "officialSymbol": "ADRA2C", + "officialFullName": "adrenoceptor alpha 2C", + "uniprotAccessionNumber": "P18825" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2633, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRB1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRB1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "S(-)-Propranolol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2586, + "assayComponentName": "ERF_PL_GPCR_binding_hADRB1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRB1 is an assay component calculated from the ERF_PL_GPCR_binding_hADRB1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I] Cyanopindolol, are indicative of changes in receptor function and kinetics related to the gene ADRB1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I] Cyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 740, + "assayName": "ERF_PL_GPCR_hADRB1", + "assayDesc": "ERF_PL_GPCR_hADRB1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See beta1 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 15, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "ADRB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 153, + "officialSymbol": "ADRB1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P08588" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2634, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADRB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADRB2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADRB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ICI 118551", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2587, + "assayComponentName": "ERF_CR_GPCR_binding_hADRB2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADRB2 is an assay component calculated from the ERF_CR_GPCR_binding_hADRB2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H](-)CGP 12177, are indicative of changes in receptor function and kinetics related to the gene ADRB2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H](-)CGP 12177", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 736, + "assayName": "ERF_CR_GPCR_hADRB2", + "assayDesc": "ERF_CR_GPCR_hADRB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See beta2 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2635, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRB3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRB3 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRB3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "alprenolol ", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2588, + "assayComponentName": "ERF_PL_GPCR_binding_hADRB3", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRB3 is an assay component calculated from the ERF_PL_GPCR_binding_hADRB3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, cyanopindolol, are indicative of changes in receptor function and kinetics related to the gene ADRB3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "cyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 741, + "assayName": "ERF_PL_GPCR_hADRB3", + "assayDesc": "ERF_PL_GPCR_hADRB3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See beta3 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant HEK-293 cells", + "cellShortName": "HEK293", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2636, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hAGTR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hAGTR1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hAGTR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "saralasin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "angiotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2589, + "assayComponentName": "ERF_PL_GPCR_binding_hAGTR1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hAGTR1 is an assay component calculated from the ERF_PL_GPCR_binding_hAGTR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, angiotensin II, are indicative of changes in receptor function and kinetics related to the gene AGTR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 744, + "assayName": "ERF_PL_GPCR_hAGTR1", + "assayDesc": "ERF_PL_GPCR_hAGTR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 3 hour after chemical dosing in a 96-well plate. See AT1 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 19, + "geneName": "angiotensin II receptor, type 1", + "description": null, + "geneSymbol": "AGTR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 185, + "officialSymbol": "AGTR1", + "officialFullName": "angiotensin II receptor, type 1", + "uniprotAccessionNumber": "P30556" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2637, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hAGTR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hAGTR2 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hAGTR2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "saralasin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "angiotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2590, + "assayComponentName": "ERF_PL_GPCR_binding_hAGTR2", + "assayComponentDesc": "ERF_PL_GPCR_binding_hAGTR2 is an assay component calculated from the ERF_PL_GPCR_binding_hAGTR2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I] CGP-42112A, are indicative of changes in receptor function and kinetics related to the gene AGTR2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I] CGP-42112A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 745, + "assayName": "ERF_PL_GPCR_hAGTR2", + "assayDesc": "ERF_PL_GPCR_hAGTR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 3 hour after chemical dosing in a 96-well plate. See AT2 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1620, + "geneName": "angiotensin II receptor type 2", + "description": null, + "geneSymbol": "AGTR2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 186, + "officialSymbol": "AGTR2", + "officialFullName": "angiotensin II receptor type 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2638, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hAVPR1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hAVPR1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hAVPR1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene AVPR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "[d(CH2)51,Tyr(Me)2]-AVP", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "vasopressin and oxytocin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2591, + "assayComponentName": "ERF_CR_GPCR_binding_hAVPR1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hAVPR1A is an assay component calculated from the ERF_CR_GPCR_binding_hAVPR1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]AVP, are indicative of changes in receptor function and kinetics related to the gene AVPR1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]AVP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 714, + "assayName": "ERF_CR_GPCR_hAVPR1A", + "assayDesc": "ERF_CR_GPCR_hAVPR1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See V1A Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 29, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "AVPR1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 552, + "officialSymbol": "AVPR1A", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P37288" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2639, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hBDKRB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hBDKRB2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hBDKRB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene BDKRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is bradykinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Npc 567", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "bradykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2592, + "assayComponentName": "ERF_CR_GPCR_binding_hBDKRB2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hBDKRB2 is an assay component calculated from the ERF_CR_GPCR_binding_hBDKRB2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Bradykinin, are indicative of changes in receptor function and kinetics related to the gene BDKRB2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Bradykinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 795, + "assayName": "ERF_CR_GPCR_hBDKRB2", + "assayDesc": "ERF_CR_GPCR_hBDKRB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See B2 Human Bradykinin GPCR Binding (Agonist Radioligand) Assay, Cerep - ITEM 33.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1955, + "geneName": "bradykinin receptor B2", + "description": null, + "geneSymbol": "BDKRB2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 624, + "officialSymbol": "BDKRB2", + "officialFullName": "bradykinin receptor B2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2640, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hCCKAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hCCKAR was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hCCKAR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CCKAR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "devazepide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "cholecystokinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2593, + "assayComponentName": "ERF_PL_GPCR_binding_hCCKAR", + "assayComponentDesc": "ERF_PL_GPCR_binding_hCCKAR is an assay component calculated from the ERF_PL_GPCR_binding_hCCKAR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] L-364,718, are indicative of changes in receptor function and kinetics related to the gene CCKAR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] L-364,718", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 748, + "assayName": "ERF_PL_GPCR_hCCKAR", + "assayDesc": "ERF_PL_GPCR_hCCKAR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CCK1 (CCKA) Human Cholecystokinin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant astrocytoma cells", + "cellShortName": "1321-N1", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 2158, + "geneName": "cholecystokinin A receptor", + "description": null, + "geneSymbol": "CCKAR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 886, + "officialSymbol": "CCKAR", + "officialFullName": "cholecystokinin A receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2641, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCCKBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCCKBR was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCCKBR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CCKBR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CCK-8s", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "cholecystokinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2594, + "assayComponentName": "ERF_CR_GPCR_binding_hCCKBR", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCCKBR is an assay component calculated from the ERF_CR_GPCR_binding_hCCKBR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]CCK-8s, are indicative of changes in receptor function and kinetics related to the gene CCKBR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]CCK-8s", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 814, + "assayName": "ERF_CR_GPCR_hCCKBR", + "assayDesc": "ERF_CR_GPCR_hCCKBR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CCK2 (CCKB) Human Cholecystokinin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 2159, + "geneName": "cholecystokinin B receptor", + "description": null, + "geneSymbol": "CCKBR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 887, + "officialSymbol": "CCKBR", + "officialFullName": "cholecystokinin B receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2642, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "pirenzepine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2595, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM1 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]pirenzepine, are indicative of changes in receptor function and kinetics related to the gene CHRM1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]pirenzepine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 835, + "assayName": "ERF_CR_GPCR_hCHRM1", + "assayDesc": "ERF_CR_GPCR_hCHRM1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M1 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 61, + "geneName": "cholinergic receptor, muscarinic 1", + "description": null, + "geneSymbol": "CHRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1128, + "officialSymbol": "CHRM1", + "officialFullName": "cholinergic receptor, muscarinic 1", + "uniprotAccessionNumber": "P11229" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2643, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "methoctramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2596, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM2 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]AF-DX 384, are indicative of changes in receptor function and kinetics related to the gene CHRM2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]AF-DX 384", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 836, + "assayName": "ERF_CR_GPCR_hCHRM2", + "assayDesc": "ERF_CR_GPCR_hCHRM2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M2 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 62, + "geneName": "cholinergic receptor, muscarinic 2", + "description": null, + "geneSymbol": "CHRM2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1129, + "officialSymbol": "CHRM2", + "officialFullName": "cholinergic receptor, muscarinic 2", + "uniprotAccessionNumber": "P08172" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2644, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM3 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2597, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM3", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM3 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 837, + "assayName": "ERF_CR_GPCR_hCHRM3", + "assayDesc": "ERF_CR_GPCR_hCHRM3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M3 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2645, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM4 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2598, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM4", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM4 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 838, + "assayName": "ERF_CR_GPCR_hCHRM4", + "assayDesc": "ERF_CR_GPCR_hCHRM4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M4 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 64, + "geneName": "cholinergic receptor, muscarinic 4", + "description": null, + "geneSymbol": "CHRM4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1132, + "officialSymbol": "CHRM4", + "officialFullName": "cholinergic receptor, muscarinic 4", + "uniprotAccessionNumber": "P08173" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2646, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM5 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM5, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2599, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM5", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM5 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM5 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM5.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 839, + "assayName": "ERF_CR_GPCR_hCHRM5", + "assayDesc": "ERF_CR_GPCR_hCHRM5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M5 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 65, + "geneName": "cholinergic receptor, muscarinic 5", + "description": null, + "geneSymbol": "CHRM5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1133, + "officialSymbol": "CHRM5", + "officialFullName": "cholinergic receptor, muscarinic 5", + "uniprotAccessionNumber": "P08912" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2647, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCYSLTR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCYSLTR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCYSLTR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CYSLTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "leukotriene D4", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "leukotriene", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2600, + "assayComponentName": "ERF_CR_GPCR_binding_hCYSLTR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCYSLTR1 is an assay component calculated from the ERF_CR_GPCR_binding_hCYSLTR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]LTD4, are indicative of changes in receptor function and kinetics related to the gene CYSLTR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]LTD4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 833, + "assayName": "ERF_CR_GPCR_hCYSLTR1", + "assayDesc": "ERF_CR_GPCR_hCYSLTR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CysLT1 Human Leukotriene GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 9689, + "geneName": "cysteinyl leukotriene receptor 1", + "description": null, + "geneSymbol": "CYSLTR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 10800, + "officialSymbol": "CYSLTR1", + "officialFullName": "cysteinyl leukotriene receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2648, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hDRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hDRD1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hDRD1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SCH 23390", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2601, + "assayComponentName": "ERF_CR_GPCR_binding_hDRD1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hDRD1 is an assay component calculated from the ERF_CR_GPCR_binding_hDRD1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-SCH 23390, are indicative of changes in receptor function and kinetics related to the gene DRD1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SCH 23390", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 819, + "assayName": "ERF_CR_GPCR_hDRD1", + "assayDesc": "ERF_CR_GPCR_hDRD1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See D1 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2649, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hDRD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hDRD2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hDRD2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "butaclamol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2602, + "assayComponentName": "ERF_CR_GPCR_binding_hDRD2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hDRD2 is an assay component calculated from the ERF_CR_GPCR_binding_hDRD2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]methyl-spiperone, are indicative of changes in receptor function and kinetics related to the gene DRD2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]methyl-spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 708, + "assayName": "ERF_CR_GPCR_hDRD2", + "assayDesc": "ERF_CR_GPCR_hDRD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See D2L Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant HEK-293 cells", + "cellShortName": "HEK293", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 100, + "geneName": "dopamine receptor D2", + "description": null, + "geneSymbol": "DRD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1813, + "officialSymbol": "DRD2", + "officialFullName": "dopamine receptor D2", + "uniprotAccessionNumber": "P14416" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2650, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hDRD4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hDRD4 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hDRD4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "spiperone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2603, + "assayComponentName": "ERF_PL_GPCR_binding_hDRD4", + "assayComponentDesc": "ERF_PL_GPCR_binding_hDRD4 is an assay component calculated from the ERF_PL_GPCR_binding_hDRD4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] Spiperone, are indicative of changes in receptor function and kinetics related to the gene DRD4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 749, + "assayName": "ERF_PL_GPCR_hDRD4", + "assayDesc": "ERF_PL_GPCR_hDRD4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See D4.2 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 101, + "geneName": "dopamine receptor D4", + "description": null, + "geneSymbol": "DRD4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1815, + "officialSymbol": "DRD4", + "officialFullName": "dopamine receptor D4", + "uniprotAccessionNumber": "P21917" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2651, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hGALR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hGALR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hGALR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GALR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is galanin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "galanin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "galanin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2604, + "assayComponentName": "ERF_CR_GPCR_binding_hGALR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hGALR1 is an assay component calculated from the ERF_CR_GPCR_binding_hGALR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Galanin, are indicative of changes in receptor function and kinetics related to the gene GALR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Galanin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 826, + "assayName": "ERF_CR_GPCR_hGALR1", + "assayDesc": "ERF_CR_GPCR_hGALR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GAL1 Human Galanin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 3457, + "geneName": "galanin receptor 1", + "description": null, + "geneSymbol": "GALR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2587, + "officialSymbol": "GALR1", + "officialFullName": "galanin receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2652, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHRH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHRH1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHRH1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene HRH1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is histamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "pyrilamine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "histamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2605, + "assayComponentName": "ERF_CR_GPCR_binding_hHRH1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHRH1 is an assay component calculated from the ERF_CR_GPCR_binding_hHRH1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Pyrilamine, are indicative of changes in receptor function and kinetics related to the gene HRH1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 834, + "assayName": "ERF_CR_GPCR_hHRH1", + "assayDesc": "ERF_CR_GPCR_hHRH1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See H1 Human Histamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2653, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "8-OH-DPAT", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2606, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR1A is an assay component calculated from the ERF_CR_GPCR_binding_hHTR1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]8-OH-DPAT, are indicative of changes in receptor function and kinetics related to the gene HTR1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]8-OH-DPAT", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 700, + "assayName": "ERF_CR_GPCR_hHTR1A", + "assayDesc": "ERF_CR_GPCR_hHTR1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See 5-HT1A Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4067, + "geneName": "5-hydroxytryptamine receptor 1A", + "description": null, + "geneSymbol": "HTR1A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3350, + "officialSymbol": "HTR1A", + "officialFullName": "5-hydroxytryptamine receptor 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2654, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR5A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR5A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR5A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR5A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2607, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR5A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR5A is an assay component calculated from the ERF_CR_GPCR_binding_hHTR5A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR5A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 707, + "assayName": "ERF_CR_GPCR_hHTR5A", + "assayDesc": "ERF_CR_GPCR_hHTR5A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT5A Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 167, + "geneName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "description": null, + "geneSymbol": "HTR5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3361, + "officialSymbol": "HTR5A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "uniprotAccessionNumber": "P47898" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2655, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR6 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2608, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR6", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR6 is an assay component calculated from the ERF_CR_GPCR_binding_hHTR6 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR6.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 709, + "assayName": "ERF_CR_GPCR_hHTR6", + "assayDesc": "ERF_CR_GPCR_hHTR6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT6 Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2656, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR7 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR7, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR7. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2609, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR7", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR7 is an assay component calculated from the ERF_CR_GPCR_binding_hHTR7 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR7.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 710, + "assayName": "ERF_CR_GPCR_hHTR7", + "assayDesc": "ERF_CR_GPCR_hHTR7 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT7 Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2657, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hLTB4R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hLTB4R was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hLTB4R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene LTB4R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "LTB4", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "leukotriene", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2610, + "assayComponentName": "ERF_PL_GPCR_binding_hLTB4R", + "assayComponentDesc": "ERF_PL_GPCR_binding_hLTB4R is an assay component calculated from the ERF_PL_GPCR_binding_hLTB4R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Leukotriene B4, are indicative of changes in receptor function and kinetics related to the gene LTB4R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 757, + "assayName": "ERF_PL_GPCR_hLTB4R", + "assayDesc": "ERF_PL_GPCR_hLTB4R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See BLT1 (LTB4) Human Leukotriene GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human histiocytic lymphoma U-937 cells", + "cellShortName": "U-937", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 68, + "geneName": "leukotriene B4 receptor", + "description": null, + "geneSymbol": "LTB4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1241, + "officialSymbol": "LTB4R", + "officialFullName": "leukotriene B4 receptor", + "uniprotAccessionNumber": "Q15722" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2658, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNPY1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNPY1R was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNPY1R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NPY", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neuropeptide Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2611, + "assayComponentName": "ERF_CR_GPCR_binding_hNPY1R", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNPY1R is an assay component calculated from the ERF_CR_GPCR_binding_hNPY1R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Peptide YY, are indicative of changes in receptor function and kinetics related to the gene NPY1R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 693, + "assayName": "ERF_CR_GPCR_hNPY1R", + "assayDesc": "ERF_CR_GPCR_hNPY1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Y1 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 219, + "geneName": "neuropeptide Y receptor Y1", + "description": null, + "geneSymbol": "NPY1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4886, + "officialSymbol": "NPY1R", + "officialFullName": "neuropeptide Y receptor Y1", + "uniprotAccessionNumber": "P25929" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2659, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNPY2R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNPY2R was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNPY2R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY2R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NPY", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neuropeptide Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2612, + "assayComponentName": "ERF_CR_GPCR_binding_hNPY2R", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNPY2R is an assay component calculated from the ERF_CR_GPCR_binding_hNPY2R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Peptide YY, are indicative of changes in receptor function and kinetics related to the gene NPY2R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 694, + "assayName": "ERF_CR_GPCR_hNPY2R", + "assayDesc": "ERF_CR_GPCR_hNPY2R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Y2 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2660, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNTSR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNTSR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNTSR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NTSR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neurotensin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "neurotensin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neurotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2613, + "assayComponentName": "ERF_CR_GPCR_binding_hNTSR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNTSR1 is an assay component calculated from the ERF_CR_GPCR_binding_hNTSR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]Tyr3-neurotensin, are indicative of changes in receptor function and kinetics related to the gene NTSR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]Tyr3-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 695, + "assayName": "ERF_CR_GPCR_hNTSR1", + "assayDesc": "ERF_CR_GPCR_hNTSR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NT1 Human Neurotensin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 223, + "geneName": "neurotensin receptor 1 (high affinity)", + "description": null, + "geneSymbol": "NTSR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4923, + "officialSymbol": "NTSR1", + "officialFullName": "neurotensin receptor 1 (high affinity)", + "uniprotAccessionNumber": "P30989" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2661, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRD1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRD1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DPDPE", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2614, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRD1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRD1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRD1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]DADLE, are indicative of changes in receptor function and kinetics related to the gene OPRD1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]DADLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 696, + "assayName": "ERF_CR_GPCR_hOPRD1", + "assayDesc": "ERF_CR_GPCR_hOPRD1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See delta (DOP) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 225, + "geneName": "opioid receptor, delta 1", + "description": null, + "geneSymbol": "OPRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4985, + "officialSymbol": "OPRD1", + "officialFullName": "opioid receptor, delta 1", + "uniprotAccessionNumber": "P41143" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2662, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRL1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRL1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nociceptin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2615, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRL1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRL1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRL1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]nociceptin, are indicative of changes in receptor function and kinetics related to the gene OPRL1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]nociceptin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 803, + "assayName": "ERF_CR_GPCR_hOPRL1", + "assayDesc": "ERF_CR_GPCR_hOPRL1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NOP (ORL1) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 226, + "geneName": "opiate receptor-like 1", + "description": null, + "geneSymbol": "OPRL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4987, + "officialSymbol": "OPRL1", + "officialFullName": "opiate receptor-like 1", + "uniprotAccessionNumber": "P41146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2663, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRM1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DAMGO", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2616, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRM1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRM1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRM1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]DAMGO, are indicative of changes in receptor function and kinetics related to the gene OPRM1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]DAMGO", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 697, + "assayName": "ERF_CR_GPCR_hOPRM1", + "assayDesc": "ERF_CR_GPCR_hOPRM1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See mu (MOP) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 227, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "OPRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4988, + "officialSymbol": "OPRM1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P35372" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2664, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOXTR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOXTR was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOXTR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OXTR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "oxytocin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "vasopressin and oxytocin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2617, + "assayComponentName": "ERF_CR_GPCR_binding_hOXTR", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOXTR is an assay component calculated from the ERF_CR_GPCR_binding_hOXTR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Oxytocin, are indicative of changes in receptor function and kinetics related to the gene OXTR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Oxytocin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 807, + "assayName": "ERF_CR_GPCR_hOXTR", + "assayDesc": "ERF_CR_GPCR_hOXTR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See OT Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Chem-1 RBL cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5269, + "geneName": "oxytocin receptor", + "description": null, + "geneSymbol": "OXTR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5021, + "officialSymbol": "OXTR", + "officialFullName": "oxytocin receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2665, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hTACR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hTACR1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hTACR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-703606", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "tachykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2618, + "assayComponentName": "ERF_PL_GPCR_binding_hTACR1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hTACR1 is an assay component calculated from the ERF_PL_GPCR_binding_hTACR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Substance P, are indicative of changes in receptor function and kinetics related to the gene TACR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Substance P", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 759, + "assayName": "ERF_PL_GPCR_hTACR1", + "assayDesc": "ERF_PL_GPCR_hTACR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See NK1 Human Tachykinin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 6719, + "geneName": "tachykinin receptor 1", + "description": null, + "geneSymbol": "TACR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6869, + "officialSymbol": "TACR1", + "officialFullName": "tachykinin receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2666, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hTACR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hTACR2 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hTACR2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MEN-10376", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "tachykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2619, + "assayComponentName": "ERF_PL_GPCR_binding_hTACR2", + "assayComponentDesc": "ERF_PL_GPCR_binding_hTACR2 is an assay component calculated from the ERF_PL_GPCR_binding_hTACR2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] SR-48968, are indicative of changes in receptor function and kinetics related to the gene TACR2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] SR-48968", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 760, + "assayName": "ERF_PL_GPCR_hTACR2", + "assayDesc": "ERF_PL_GPCR_hTACR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See NK2 Human Tachykinin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 309, + "geneName": "tachykinin receptor 2", + "description": null, + "geneSymbol": "TACR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6865, + "officialSymbol": "TACR2", + "officialFullName": "tachykinin receptor 2", + "uniprotAccessionNumber": "P21452" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2667, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hVIPR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hVIPR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hVIPR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene VIPR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is VIP and PACAP.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "VIP ", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "VIP and PACAP", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2620, + "assayComponentName": "ERF_CR_GPCR_binding_hVIPR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hVIPR1 is an assay component calculated from the ERF_CR_GPCR_binding_hVIPR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Vasoactive intestinal peptide (VIP), are indicative of changes in receptor function and kinetics related to the gene VIPR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Vasoactive intestinal peptide (VIP)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 713, + "assayName": "ERF_CR_GPCR_hVIPR1", + "assayDesc": "ERF_CR_GPCR_hVIPR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See VIP1 (VPAC1) Human VIP and PACAP GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 7188, + "geneName": "vasoactive intestinal peptide receptor 1", + "description": null, + "geneSymbol": "VIPR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7433, + "officialSymbol": "VIPR1", + "officialFullName": "vasoactive intestinal peptide receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2668, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_rGHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_rGHB was analyzed at the assay endpoint, ERF_CR_GPCR_binding_rGHB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPAN17. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is ghb .", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NCS382", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "ghb ", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2621, + "assayComponentName": "ERF_CR_GPCR_binding_rGHB", + "assayComponentDesc": "ERF_CR_GPCR_binding_rGHB is an assay component calculated from the ERF_CR_GPCR_binding_rGHB assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-NCS-382, are indicative of changes in receptor function and kinetics related to the gene TSPAN17.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-NCS-382", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 806, + "assayName": "ERF_CR_GPCR_rGHB", + "assayDesc": "ERF_CR_GPCR_rGHB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GHB Rat Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat cerebral cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 454, + "geneName": "tetraspanin 17", + "description": null, + "geneSymbol": "Tspan17", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 306771, + "officialSymbol": "Tspan17", + "officialFullName": "tetraspanin 17", + "uniprotAccessionNumber": "Q4V8E0" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2669, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_rPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_rPY2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_rPY2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene P2RY1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is P2Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "datpalphas", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "P2Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2622, + "assayComponentName": "ERF_CR_GPCR_binding_rPY2", + "assayComponentDesc": "ERF_CR_GPCR_binding_rPY2 is an assay component calculated from the ERF_CR_GPCR_binding_rPY2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [35S]dATPalpha S, are indicative of changes in receptor function and kinetics related to the gene P2RY1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[35S]dATPalpha S", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 699, + "assayName": "ERF_CR_GPCR_rPY2", + "assayDesc": "ERF_CR_GPCR_rPY2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Non-Selective Rat P2Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2670, + "assayComponentEndpointName": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rCACNA1C_Dihydropyridine was analyzed at the assay endpoint, ERF_CR_IC_binding_rCACNA1C_Dihydropyridine, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nitrendipine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Calcium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2623, + "assayComponentName": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine", + "assayComponentDesc": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine is an assay component calculated from the ERF_CR_IC_binding_rCACNA1C_Dihydropyridine assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nitrendipine, are indicative of changes in transporter function and kinetics related to the gene CACNA1C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrendipine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 715, + "assayName": "ERF_CR_IC_rCACNA1C_Dihydropyridine", + "assayDesc": "ERF_CR_IC_rCACNA1C_Dihydropyridine is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Dihydropyridine Site) Assay, Cerep.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2671, + "assayComponentEndpointName": "ERF_CR_IC_binding_rCACNA1C_Diltiazem", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rCACNA1C_Diltiazem was analyzed at the assay endpoint, ERF_CR_IC_binding_rCACNA1C_Diltiazem, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "diltiazem", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Calcium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2624, + "assayComponentName": "ERF_CR_IC_binding_rCACNA1C_Diltiazem", + "assayComponentDesc": "ERF_CR_IC_binding_rCACNA1C_Diltiazem is an assay component calculated from the ERF_CR_IC_binding_rCACNA1C_Diltiazem assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Diltiazem, are indicative of changes in transporter function and kinetics related to the gene CACNA1C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diltiazem", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 716, + "assayName": "ERF_CR_IC_rCACNA1C_Diltiazem", + "assayDesc": "ERF_CR_IC_rCACNA1C_Diltiazem is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Diltiazem Site) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2672, + "assayComponentEndpointName": "ERF_CR_IC_binding_rKCNJ1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rKCNJ1 was analyzed at the assay endpoint, ERF_CR_IC_binding_rKCNJ1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene KCNJ1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "glyburide potassium salt", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Potassium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2625, + "assayComponentName": "ERF_CR_IC_binding_rKCNJ1", + "assayComponentDesc": "ERF_CR_IC_binding_rKCNJ1 is an assay component calculated from the ERF_CR_IC_binding_rKCNJ1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Glibenclamide, are indicative of changes in transporter function and kinetics related to the gene KCNJ1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Glibenclamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 717, + "assayName": "ERF_CR_IC_rKCNJ1", + "assayDesc": "ERF_CR_IC_rKCNJ1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See KATP Rat Potassium Ion Channel Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 391, + "geneName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "description": null, + "geneSymbol": "Kcnj1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24521, + "officialSymbol": "Kcnj1", + "officialFullName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "uniprotAccessionNumber": "P35560" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2673, + "assayComponentEndpointName": "ERF_CR_IC_binding_rKCNN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rKCNN1 was analyzed at the assay endpoint, ERF_CR_IC_binding_rKCNN1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene Kcnn1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "apamin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Potassium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2626, + "assayComponentName": "ERF_CR_IC_binding_rKCNN1", + "assayComponentDesc": "ERF_CR_IC_binding_rKCNN1 is an assay component calculated from the ERF_CR_IC_binding_rKCNN1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Apamin, are indicative of changes in transporter function and kinetics related to the gene Kcnn1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Apamin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 718, + "assayName": "ERF_CR_IC_rKCNN1", + "assayDesc": "ERF_CR_IC_rKCNN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See SKCa (Non-Selective) Rat Potassium Ion Channel [125I] Apamin Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 428, + "geneName": "potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1", + "description": "provisional", + "geneSymbol": "Kcnn1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54261, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P70606" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2674, + "assayComponentEndpointName": "ERF_CR_IC_binding_rSCN1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rSCN1A was analyzed at the assay endpoint, ERF_CR_IC_binding_rSCN1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SCN1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Sodium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "veratridine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Sodium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2627, + "assayComponentName": "ERF_CR_IC_binding_rSCN1A", + "assayComponentDesc": "ERF_CR_IC_binding_rSCN1A is an assay component calculated from the ERF_CR_IC_binding_rSCN1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Batrachotoxin, are indicative of changes in transporter function and kinetics related to the gene SCN1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Batrachotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 721, + "assayName": "ERF_CR_IC_rSCN1A", + "assayDesc": "ERF_CR_IC_rSCN1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Non-Selective Rat Sodium Ion Channel [3H] Batrachotoxinin Binding (Site 2) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 436, + "geneName": "sodium channel, voltage-gated, type I, alpha subunit", + "description": null, + "geneSymbol": "Scn1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81574, + "officialSymbol": "Scn1a", + "officialFullName": "sodium channel, voltage-gated, type I, alpha subunit", + "uniprotAccessionNumber": "P04774" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2675, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_hGABRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_hGABRA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_hGABRA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GABRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "muscimol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2628, + "assayComponentName": "ERF_CR_LGIC_binding_hGABRA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_hGABRA1 is an assay component calculated from the ERF_CR_LGIC_binding_hGABRA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]muscimol, are indicative of changes in transporter function and kinetics related to the gene GABRA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]muscimol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 788, + "assayName": "ERF_CR_LGIC_hGABRA1", + "assayDesc": "ERF_CR_LGIC_hGABRA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GABAA (alpha1/beta2/gamma2) Human GABAA Ion Channel Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 3427, + "geneName": "gamma-aminobutyric acid type A receptor alpha1 subunit", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2554, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid type A receptor alpha1 subunit", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2676, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGLRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGLRA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGLRA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GLRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glycine).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "strychnine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glycine)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2629, + "assayComponentName": "ERF_CR_LGIC_binding_rGLRA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGLRA1 is an assay component calculated from the ERF_CR_LGIC_binding_rGLRA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-strychnine, are indicative of changes in transporter function and kinetics related to the gene GLRA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-strychnine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 831, + "assayName": "ERF_CR_LGIC_rGLRA1", + "assayDesc": "ERF_CR_LGIC_rGLRA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Non-Selective Rat Glycine Ion Channel [3H] Strychnine Binding Assay, Cerep.", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "spinal cord", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat spinal cord membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 414, + "geneName": "glycine receptor, alpha 1", + "description": null, + "geneSymbol": "Glra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25674, + "officialSymbol": "Glra1", + "officialFullName": "glycine receptor, alpha 1", + "uniprotAccessionNumber": "P07727" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2677, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGRIA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGRIA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGRIA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-Glutamate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2630, + "assayComponentName": "ERF_CR_LGIC_binding_rGRIA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGRIA1 is an assay component calculated from the ERF_CR_LGIC_binding_rGRIA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-AMPA, are indicative of changes in transporter function and kinetics related to the gene GRIA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-AMPA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 827, + "assayName": "ERF_CR_LGIC_rGRIA1", + "assayDesc": "ERF_CR_LGIC_rGRIA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Glutamate (AMPA, Non-Selective) Rat Ion Channel [3H] AMPA Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 424, + "geneName": "glutamate receptor, ionotropic, AMPA 1", + "description": null, + "geneSymbol": "Gria1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50592, + "officialSymbol": "Gria1", + "officialFullName": "glutamate receptor, ionotropic, AMPA 1", + "uniprotAccessionNumber": "P19490" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2678, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGRIK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGRIK1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGRIK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "kainic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2631, + "assayComponentName": "ERF_CR_LGIC_binding_rGRIK1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGRIK1 is an assay component calculated from the ERF_CR_LGIC_binding_rGRIK1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Kainic acid, are indicative of changes in transporter function and kinetics related to the gene GRIK1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Kainic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 830, + "assayName": "ERF_CR_LGIC_rGRIK1", + "assayDesc": "ERF_CR_LGIC_rGRIK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Glutamate (Kianate, Non-Selective) Rat Ion Channel [3H] Kainic acid Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 420, + "geneName": "glutamate receptor, ionotropic, kainate 1", + "description": null, + "geneSymbol": "Grik1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29559, + "officialSymbol": "Grik1", + "officialFullName": "glutamate receptor, ionotropic, kainate 1", + "uniprotAccessionNumber": "P22756" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2679, + "assayComponentEndpointName": "ERF_PL_LGIC_binding_rGRIN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_LGIC_binding_rGRIN1 was analyzed at the assay endpoint, ERF_PL_LGIC_binding_rGRIN1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIN1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2632, + "assayComponentName": "ERF_PL_LGIC_binding_rGRIN1", + "assayComponentDesc": "ERF_PL_LGIC_binding_rGRIN1 is an assay component calculated from the ERF_PL_LGIC_binding_rGRIN1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-MK-801, are indicative of changes in transporter function and kinetics related to the gene GRIN1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-801", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 752, + "assayName": "ERF_PL_LGIC_rGRIN1", + "assayDesc": "ERF_PL_LGIC_rGRIN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Glutamate (Kainate, Non-Selective) Rat Ion Channel [3H] Kainic acid Binding Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat cortex membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2680, + "assayComponentEndpointName": "ERF_CR_MP_binding_hTSPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_MP_binding_hTSPO was analyzed at the assay endpoint, ERF_CR_MP_binding_hTSPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is mitochondrial associated translocator protein.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK 11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "membrane protein", + "intendedTargetFamilySub": "mitochondrial associated translocator protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2633, + "assayComponentName": "ERF_CR_MP_binding_hTSPO", + "assayComponentDesc": "ERF_CR_MP_binding_hTSPO is an assay component calculated from the ERF_CR_MP_hTSPO assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-PK11195, are indicative of changes in receptor function and kinetics related to the gene TSPO.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 804, + "assayName": "ERF_CR_MP_hTSPO", + "assayDesc": "ERF_CR_MP_hTSPO is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PBR Human Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous U-118-MG", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 37, + "geneName": "translocator protein (18kDa)", + "description": null, + "geneSymbol": "TSPO", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 706, + "officialSymbol": "TSPO", + "officialFullName": "translocator protein (18kDa)", + "uniprotAccessionNumber": "P30536" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2681, + "assayComponentEndpointName": "ERF_PL_NR_binding_hAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hAR was analyzed at the assay endpoint, ERF_PL_NR_binding_hAR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is androgens.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2634, + "assayComponentName": "ERF_PL_NR_binding_hAR", + "assayComponentDesc": "ERF_PL_NR_binding_hAR is an assay component calculated from the ERF_PL_NR_binding_hAR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-methyltrienolone, are indicative of changes in receptor function and kinetics related to the gene AR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 742, + "assayName": "ERF_PL_NR_hAR", + "assayDesc": "ERF_PL_NR_hAR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 20 hour after chemical dosing in a 96-well plate. See AR Human Androgen NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human LNCaP clone FGC cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2682, + "assayComponentEndpointName": "ERF_PL_NR_COA_hFXR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hFXR_Antagonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hFXR_Antagonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Z-Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "liver X receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2635, + "assayComponentName": "ERF_PL_NR_COA_hFXR_Antagonist", + "assayComponentDesc": "ERF_PL_NR_COA_hFXR_Antagonist is an assay component calculated from the ERF_PL_NR_COA_hFXR_Antagonist assay. It is designed to measure TR-FRET using a type of binding reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the receptor binding reaction involving the key ligand;antibody, Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody, are indicative of changes in receptor function and kinetics related to the gene NR1H4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 794, + "assayName": "ERF_PL_NR_COA_hFXR_Antagonist", + "assayDesc": "ERF_PL_NR_COA_hFXR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FXR Human Liver X Receptor-Like NHR Functional Antagonist Coactivator Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2683, + "assayComponentEndpointName": "ERF_CR_NR_binding_hGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hGR was analyzed at the assay endpoint, ERF_CR_NR_binding_hGR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NR3C1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "triamcinolone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2636, + "assayComponentName": "ERF_CR_NR_binding_hGR", + "assayComponentDesc": "ERF_CR_NR_binding_hGR is an assay component calculated from the ERF_CR_NR_binding_hGR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-dexamethasone, are indicative of changes in receptor function and kinetics related to the gene NR3C1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dexamethasone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 822, + "assayName": "ERF_CR_NR_hGR", + "assayDesc": "ERF_CR_NR_hGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 6 hour after chemical dosing in a 96-well plate. See GR Human Glucocorticoid NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous IM-9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2684, + "assayComponentEndpointName": "ERF_PL_NR_binding_hHTR2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hHTR2C was analyzed at the assay endpoint, ERF_PL_NR_binding_hHTR2C, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB 242084", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2637, + "assayComponentName": "ERF_PL_NR_binding_hHTR2C", + "assayComponentDesc": "ERF_PL_NR_binding_hHTR2C is an assay component calculated from the ERF_PL_NR_binding_hHTR2C assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Mesulergine, are indicative of changes in receptor function and kinetics related to the gene HTR2C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Mesulergine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 763, + "assayName": "ERF_PL_NR_hHTR2C", + "assayDesc": "ERF_PL_NR_hHTR2C is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See 5-HT2C Human Serotonin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 165, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "description": null, + "geneSymbol": "HTR2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3358, + "officialSymbol": "HTR2C", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "uniprotAccessionNumber": "P28335" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2685, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPGR was analyzed at the assay endpoint, ERF_CR_NR_binding_hPGR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PGR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2638, + "assayComponentName": "ERF_CR_NR_binding_hPGR", + "assayComponentDesc": "ERF_CR_NR_binding_hPGR is an assay component calculated from the ERF_CR_NR_binding_hPGR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]progesterone, are indicative of changes in receptor function and kinetics related to the gene PGR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]progesterone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 754, + "assayName": "ERF_CR_NR_hPGR", + "assayDesc": "ERF_CR_NR_hPGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 20 hour after chemical dosing in a 96-well plate. See PR Human Progesterone NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous T47D cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2686, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPPARA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPPARA was analyzed at the assay endpoint, ERF_CR_NR_binding_hPPARA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW 7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2639, + "assayComponentName": "ERF_CR_NR_binding_hPPARA", + "assayComponentDesc": "ERF_CR_NR_binding_hPPARA is an assay component calculated from the ERF_CR_NR_binding_hPPARA assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]WY 14643, are indicative of changes in receptor function and kinetics related to the gene PPARA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]WY 14643", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 828, + "assayName": "ERF_CR_NR_hPPARA", + "assayDesc": "ERF_CR_NR_hPPARA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See PPARalpha Human NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2687, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPPARG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPPARG was analyzed at the assay endpoint, ERF_CR_NR_binding_hPPARG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARG. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2640, + "assayComponentName": "ERF_CR_NR_binding_hPPARG", + "assayComponentDesc": "ERF_CR_NR_binding_hPPARG is an assay component calculated from the ERF_CR_NR_binding_hPPARG assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]rosiglitazone, are indicative of changes in receptor function and kinetics related to the gene PPARG.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]rosiglitazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 829, + "assayName": "ERF_CR_NR_hPPARG", + "assayDesc": "ERF_CR_NR_hPPARG is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See PPARgamma Human NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2688, + "assayComponentEndpointName": "ERF_PL_NR_binding_hRARa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hRARa was analyzed at the assay endpoint, ERF_PL_NR_binding_hRARa, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene RARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is retinoic acid receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "retinoic acid receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2641, + "assayComponentName": "ERF_PL_NR_binding_hRARa", + "assayComponentDesc": "ERF_PL_NR_binding_hRARa is an assay component calculated from the ERF_PL_NR_binding_hRARa assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] 9-cis-Retinoic acid, are indicative of changes in receptor function and kinetics related to the gene RARA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] 9-cis-Retinoic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 762, + "assayName": "ERF_PL_NR_hRARa", + "assayDesc": "ERF_PL_NR_hRARa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See RARalpha Human Retinoic Acid NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2689, + "assayComponentEndpointName": "ERF_PL_NR_COA_hTHRA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hTHRA_Agonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hTHRA_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of agonist, gain-of-signal activity can be used to understand changes in protein-protein interaction as they relate to gene THRA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2642, + "assayComponentName": "ERF_PL_NR_COA_hTHRA", + "assayComponentDesc": "ERF_PL_NR_COA_hTHRA is an assay component calculated from the ERF_PL_NR_COA_hTHRA assay. It is designed to measure TR-FRET using a type of inducible reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the regulation of transcription factor activity reaction involving the key ligand; antibody, liothyronine, are indicative of changes in receptor function and kinetics related to the gene THRA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "liothyronine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 802, + "assayName": "ERF_PL_NR_COA_hTHRA", + "assayDesc": "ERF_PL_NR_COA_hTHRA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See TRalpha Human Thyroid Hormone NHR Functional Agonist Coactivator Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2690, + "assayComponentEndpointName": "ERF_PL_NR_binding_rI2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_rI2 was analyzed at the assay endpoint, ERF_PL_NR_binding_rI2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene NISCH (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is imidazoline receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "idazoxan", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "imidazoline receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2643, + "assayComponentName": "ERF_PL_NR_binding_rI2", + "assayComponentDesc": "ERF_PL_NR_binding_rI2 is an assay component calculated from the ERF_PL_NR_binding_rI2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] Idazoxan, are indicative of changes in receptor function and kinetics related to the gene NISCH (homolog), gene id 100009085.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Idazoxan", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 755, + "assayName": "ERF_PL_NR_rI2", + "assayDesc": "ERF_PL_NR_rI2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Imidazoline I2, Central Rat Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 9986, + "organism": "rabbit", + "tissue": "cerebral cortex", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat cerebral cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 10019, + "geneName": "nischarin", + "description": null, + "geneSymbol": "NISCH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 11188, + "officialSymbol": "NISCH", + "officialFullName": "nischarin", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2691, + "assayComponentEndpointName": "ERF_PL_TR_binding_hSLC35B3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_hSLC35B3 was analyzed at the assay endpoint, ERF_PL_TR_binding_hSLC35B3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC29A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nitrobenzylthioinosine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2644, + "assayComponentName": "ERF_PL_TR_binding_hSLC35B3", + "assayComponentDesc": "ERF_PL_TR_binding_hSLC35B3 is an assay component calculated from the ERF_PL_TR_binding_hSLC35B3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nitrobenzylthioinosine, are indicative of changes in transporter function and kinetics related to the gene SLC29A1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 737, + "assayName": "ERF_PL_TR_hSLC35B3", + "assayDesc": "ERF_PL_TR_hSLC35B3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Adenosine Human Transporter Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human u937 cells CRL-1593", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 112, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "SLC29A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2030, + "officialSymbol": "SLC29A1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "Q99808" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2692, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A2 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "protriptyline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2645, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A2", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A2 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nisoxetine, are indicative of changes in transporter function and kinetics related to the gene SLC6A2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 801, + "assayName": "ERF_CR_TR_hSLC6A2", + "assayDesc": "ERF_CR_TR_hSLC6A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See NET Human Norepinephrine Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 296, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "SLC6A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6530, + "officialSymbol": "SLC6A2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": "P23975" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2693, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A3 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SLC6A3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "BTCP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2646, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A3", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A3 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]BTCP, are indicative of changes in transporter function and kinetics related to the gene SLC6A3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]BTCP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 825, + "assayName": "ERF_CR_TR_hSLC6A3", + "assayDesc": "ERF_CR_TR_hSLC6A3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See DAT Human Dopamine Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 297, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "description": null, + "geneSymbol": "SLC6A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6531, + "officialSymbol": "SLC6A3", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "uniprotAccessionNumber": "Q01959" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2694, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A4 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "imipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2647, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A4", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A4 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]imipramine, are indicative of changes in transporter function and kinetics related to the gene SLC6A4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]imipramine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 818, + "assayName": "ERF_CR_TR_hSLC6A4", + "assayDesc": "ERF_CR_TR_hSLC6A4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See SET Human Serotonin Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 298, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "SLC6A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6532, + "officialSymbol": "SLC6A4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31645" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2695, + "assayComponentEndpointName": "ERF_PL_TR_binding_rSLC18A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_rSLC18A2 was analyzed at the assay endpoint, ERF_PL_TR_binding_rSLC18A2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC18A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is vesicular transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrabenazine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "vesicular transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2648, + "assayComponentName": "ERF_PL_TR_binding_rSLC18A2", + "assayComponentDesc": "ERF_PL_TR_binding_rSLC18A2 is an assay component calculated from the ERF_PL_TR_binding_rSLC18A2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-dihydrotetrabenazine, are indicative of changes in transporter function and kinetics related to the gene SLC18A2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydrotetrabenazine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 758, + "assayName": "ERF_PL_TR_rSLC18A2", + "assayDesc": "ERF_PL_TR_rSLC18A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See VMAT2 Rat Vesicular Monoamine Transporter Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat brain minus cerebellum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 408, + "geneName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "description": null, + "geneSymbol": "Slc18a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25549, + "officialSymbol": "Slc18a2", + "officialFullName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "uniprotAccessionNumber": "Q01827" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2696, + "assayComponentEndpointName": "ERF_PL_TR_binding_rTSPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_rTSPO was analyzed at the assay endpoint, ERF_PL_TR_binding_rTSPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "diazepam", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2649, + "assayComponentName": "ERF_PL_TR_binding_rTSPO", + "assayComponentDesc": "ERF_PL_TR_binding_rTSPO is an assay component calculated from the ERF_PL_TR_binding_rTSPO assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-PK11195, are indicative of changes in transporter function and kinetics related to the gene TSPO.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 751, + "assayName": "ERF_PL_TR_rTSPO", + "assayDesc": "ERF_PL_TR_rTSPO is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PBR Rat Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "heart", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat heart", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 382, + "geneName": "translocator protein", + "description": null, + "geneSymbol": "Tspo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24230, + "officialSymbol": "Tspo", + "officialFullName": "translocator protein", + "uniprotAccessionNumber": "P16257" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2697, + "assayComponentEndpointName": "UKN2_HCS_IMR90_neural_migration", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN2_HCS_IMR90_neural_migration was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neural crest cell migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cytochalasin D", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural crest cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2650, + "assayComponentName": "UKN2_HCS_IMR90_neural_migration", + "assayComponentDesc": "UKN2_HCS_IMR90_neural_migration is an assay component measured from the UKN2_HCS_IMR90 assay. It is designed to make measurements of neural crest cell migration, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of migrated cells are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neural crest cell migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33341", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of migrated cells", + "aid": 840, + "assayName": "UKN2_HCS_IMR90", + "assayDesc": "UKN2_HCS_IMR90 is a cell-based, multiplexed-readout assay screening for neural crest cell migration and cell viability that uses IMR90 (neural crest cells differentiated from iPSC), a human embryo cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN2, also known as cMINC, is an assay that uses IMR90 cells (neural crest cells differentiated from iPSC) as a model of neural crest cell migration. 24 hr after cell seeding, cell migration was initiated and proceeded for 24 hr. Then, chemical was applied, and after 24 hr of exposure migration and viability were assessed using high-content imaging of cells stained with calcein-AM and Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "IMR90 (neural crest cells differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-1977-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/28477266/", + "pmid": 28477266, + "title": "Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library", + "author": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M", + "citation": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M. Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266.", + "otherId": "0", + "citationId": 280, + "otherSource": "" + } + }, + { + "aeid": 2699, + "assayComponentEndpointName": "UKN2_HCS_IMR90_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN2_HCS_IMR90_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2651, + "assayComponentName": "UKN2_HCS_IMR90_cell_viability", + "assayComponentDesc": "UKN2_HCS_IMR90_cell_viability is an assay component measured from the UKN2_HCS_IMR90 assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33342", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 840, + "assayName": "UKN2_HCS_IMR90", + "assayDesc": "UKN2_HCS_IMR90 is a cell-based, multiplexed-readout assay screening for neural crest cell migration and cell viability that uses IMR90 (neural crest cells differentiated from iPSC), a human embryo cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN2, also known as cMINC, is an assay that uses IMR90 cells (neural crest cells differentiated from iPSC) as a model of neural crest cell migration. 24 hr after cell seeding, cell migration was initiated and proceeded for 24 hr. Then, chemical was applied, and after 24 hr of exposure migration and viability were assessed using high-content imaging of cells stained with calcein-AM and Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "IMR90 (neural crest cells differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-1977-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/28477266/", + "pmid": 28477266, + "title": "Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library", + "author": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M", + "citation": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M. Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266.", + "otherId": "0", + "citationId": 280, + "otherSource": "" + } + }, + { + "aeid": 2701, + "assayComponentEndpointName": "UKN4_HCS_LUHMES_neurite_outgrowth", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN4_HCS_LUHMES_neurite_outgrowth was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Narciclasine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2652, + "assayComponentName": "UKN4_HCS_LUHMES_neurite_outgrowth", + "assayComponentDesc": "UKN4_HCS_LUHMES_neurite_outgrowth is an assay component measured from the UKN4_HCS_LHUMES assay. It is designed to make measurements of neurite outgrowth, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33343", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area", + "aid": 841, + "assayName": "UKN4_HCS_LUHMES", + "assayDesc": "UKN4_HCS_LUHMES is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses LUHMES, a human central nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN4, also referred to as NeuriTox, is an assay that uses LUHMES neuronal precursors as a model of dopaminergic neuronal differentiation. Following a 2-day differentiation period, cells are exposed to chemicals for 24 hr and neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "central nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "LUHMES", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2703, + "assayComponentEndpointName": "UKN4_HCS_LUHMES_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN4_HCS_LUHMES_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2653, + "assayComponentName": "UKN4_HCS_LUHMES_cell_viability", + "assayComponentDesc": "UKN4_HCS_LUHMES_cell_viability is an assay component measured from the UKN4_HCS_LHUMES assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33344", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 841, + "assayName": "UKN4_HCS_LUHMES", + "assayDesc": "UKN4_HCS_LUHMES is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses LUHMES, a human central nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN4, also referred to as NeuriTox, is an assay that uses LUHMES neuronal precursors as a model of dopaminergic neuronal differentiation. Following a 2-day differentiation period, cells are exposed to chemicals for 24 hr and neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "central nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "LUHMES", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2705, + "assayComponentEndpointName": "ERF_PL_NR_binding_hPPARG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hPPARG was analyzed at the assay endpoint, ERF_PL_NR_binding_hPPARG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding receptor, gain-of-signal activity can be used to understand changes in binding receptor as they relate to gene PPARG.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2654, + "assayComponentName": "ERF_PL_NR_binding_hPPARG", + "assayComponentDesc": "ERF_PL_NR_binding_hPPARG is an assay component calculated from the ERF_PL_NR_hPPARG assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in radiometry produced from the receptor binding reaction involving the ligand [3H] Rosiglitazone are indicative of changes in receptor function and kinetics related to the gene PPARG.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Rosiglitazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 842, + "assayName": "ERF_PL_NR_hPPARG", + "assayDesc": "ERF_PL_NR_hPPARG is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 24 hour after chemical dosing in a 96-well plate. See PPARgamma Human NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2731, + "assayComponentEndpointName": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_HCS_1.5hr_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, TAMU_HCS_1.5hr_Cytotoxicity, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2667, + "assayComponentName": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity", + "assayComponentDesc": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity is a phenotype derived from the Total.Cells parameter and uses an EC10 as its POD (10% decrease in total cell count, compared to controls). Total Cells measures the total number of nuclei (cell count) using HCS Fluorescent Imaging technology. There is no preprocessing performed on the data to model this phenotype.", + "assayComponentTargetDesc": "Changes in the total number of nuclei (cell count) is used to quantify changes in cell number, which can be an indication of cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye; MitoTracker Orange; Ca+2 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 843, + "assayName": "TAMU_HCS_1.5hr", + "assayDesc": "TAMU_HCS_1.5hr is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2760, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_QT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_QT was analyzed into 1 assay endpoints. This assay endpoint, TAMU_PeakParms_SingleDonor1434_QT_Prolongation, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is QT interval.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "QT interval", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2682, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_QT", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_QT is a phenotype derived from the decay.rise.ratio.avg parameter and uses an EC05 as its POD (5% increase in decay/rise ratio, compared to controls). Decay.Rise.Ratio.Average measures as the average ratio between the rise time and the decay time of the calcium flux, using Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. Before modeling, data is preprocessed to remove data points where there is a cessation of beating (where peak.freq.avg equals 0) and data points after they develop of a severe notch phenotype in order to avoid capturing non monotonic effects related to an advanced pathology.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in the QT interval, which can be an indication of an increased QT interval, a significant risk factor for severe arrhythmia. ", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "QT interval", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average ratio between the rise time and the decay time of the calcium flux", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2767, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_Chronotropy", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_Chronotropy was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Chronotropy_Negative, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is lowered beat rate.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "lowered beat rate", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2685, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_Chronotropy", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_Chronotopy is a phenotype derived from the peak.freq.avg parameter and uses an EC05 as its POD (5% increase in beat rate, compared to controls). Peak.Freq.Avg measures the average peak frequency, in beats per second, uisng Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. Before modeling, data is preprocessed to remove data points where there is a cessation of beating (where peak.freq.avg equals 0) to ensure the capture of the upwards response that isn't confounded by the drop in beat rate at higher concentrations and to ensure the drop in beat rate is captured before asystole, which is captured elsewhere.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in peak frequency, which can be an indication of elevated or lowered beat rate.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "beating", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average peak frequency, in beats per second", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2771, + "assayComponentEndpointName": "IUF_NPC1b_proliferation_BrdU_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1b_proliferation_BrdU component was analyzed at the endpoint IUF_NPC1b_proliferation_BrdU in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain or loss-of-signal activity can be used to understand cell proliferation effects.", + "assayFunctionType": "cell proliferation", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "media without growth factors", + "signalDirection": "bidirectional", + "intendedTargetType": "dna", + "intendedTargetTypeSub": "dna-unspecified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2687, + "assayComponentName": "IUF_NPC1b_proliferation_BrdU_72hr", + "assayComponentDesc": "IUF_NPC1b_proliferation_BrdU_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell proliferation as assessed by the incorporation of Bromodeoxyuridine (BrdU) in the last 16 h of a 72 h compound exposure using a luminescence-based cell proliferation ELISA.", + "assayComponentTargetDesc": "Changes to chemiluminescence signals based on BrdU incorporation during DNA synthesis in proliferating cells are correlated to proliferation of the system.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Chemiluminescence", + "detectionTechnologyTypeSub": "luminescence intensity", + "detectionTechnology": "Luminescence-based cell proliferation ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "BrdU antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "BrdU labeled DNA", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2773, + "assayComponentEndpointName": "IUF_NPC1a_proliferation_area_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1a_proliferation_area component was analyzed at the endpoint IUF_NPC1a_proliferation_area in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain or loss-of-signal activity can be used to understand cell proliferation effects.", + "assayFunctionType": "cell proliferation", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "media without growth factors", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "sphere size", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2688, + "assayComponentName": "IUF_NPC1a_proliferation_area_72hr", + "assayComponentDesc": "IUF_NPC1a_proliferation_area_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell proliferation as assessed by an increase in sphere area over 72 h using automated phase contrast imaging.", + "assayComponentTargetDesc": "Changes in sphere size based on microscopic measurements are correlated to the proliferation of the system. ", + "parameterReadoutType": "multiplexed", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Increases in sphere area", + "detectionTechnology": "Automated phase contrast imaging ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "sphere size", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2775, + "assayComponentEndpointName": "IUF_NPC1_viability_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1_viability component was analyzed at the endpoint IUF_NPC1_viability in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2689, + "assayComponentName": "IUF_NPC1_viability_72hr", + "assayComponentDesc": "IUF_NPC1_viability_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell viability assessed as mitochondria-dependent reduction of resazurin to resorufin using the alamar blue cell viability assay. Viability is measured as a fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in mitochondrial activity are correlated to cellular viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar blue viability assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2776, + "assayComponentEndpointName": "ERF_PL_NR_COA_hFXR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hFXR_Agonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hFXR_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2690, + "assayComponentName": "ERF_PL_NR_COA_binding_hFXR_Agonist", + "assayComponentDesc": "ERF_PL_NR_COA_hFXR_Agonist is an assay component calculated from the ERF_PL_NR_COA_hFXR_Agonist assay. It is designed to measure TR-FRET using a type of binding reporter as detected by fluorescence intensity with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand;antibody, Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody, are indicative of changes in receptor function and kinetics related to the gene NR1H4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide; Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 847, + "assayName": "ERF_PL_NR_COA_hFXR_Agonist", + "assayDesc": "ERF_PL_NR_COA_hFXR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FXR Human Liver X Receptor-Like NHR Functional Agonist Coactivator Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2777, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2699, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the number of branch points using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2778, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2698, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2779, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2697, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2780, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2696, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures cell viability related to the number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2781, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2707, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of branch points using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2782, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2702, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of cell body-associated synapses (synaptophysin puncta) per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of cell body-associated synapses (synaptophysin puncta) per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of cell body-associated synapses (synaptophysin puncta) per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2783, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2706, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2784, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2705, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2785, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2704, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2786, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2703, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurite-associated synapses (synaptophysin puncta) per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurite-associated synapses (synaptophysin puncta) per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurite-associated synapses (synaptophysin puncta) per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2787, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2701, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2788, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2708, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of synpases per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of synpases per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of synpases per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2789, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects. This assay component endpoint is considered less reliable by experts on the assay due to low occurrence of branch points in the hN2 cells. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2695, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the hN2 cells. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2790, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2694, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2791, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2693, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2792, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2692, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2793, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine (0.1 uM)", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2691, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_Casp3_7 is one component of the CCTE_Mundy_HCI_hNP1_Casp3_7 assay. It measures apoptosis related to caspase activation using Luminescent Reporter.", + "assayComponentTargetDesc": "Changes in the caspase activation are indicative of cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "apoptosis", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "Luminescent Reporter", + "keyAssayReagentType": "luciferase assay", + "keyAssayReagent": "Caspase-Glo 3/7 detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase activation", + "aid": 848, + "assayName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "assayDesc": "CCTE_Mundy_HCI_hNP1_Casp3_7 is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.5 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.5, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2794, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_CellTiter was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_CellTiter in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine (0.1 uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cell count", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2700, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_CellTiter is one component of the CCTE_Mundy_HCI_hNP1_CellTiter assay. It measures cell viability related to ATP content using Luminescent Reporter.", + "assayComponentTargetDesc": "Changes in the ATP content are indicative of cell viability.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "Luminescent Reporter", + "keyAssayReagentType": "luciferase assay", + "keyAssayReagent": "CellTiter-Glo assay buffer", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "ATP content", + "aid": 851, + "assayName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "assayDesc": "CCTE_Mundy_HCI_hNP1_CellTiter is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.5 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.5, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2797, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "aphidicolin (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2710, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten is one of three components of the CCTE_Mundy_HCI_hNP1_Pro assay. It measures proliferation related to percentage of BrdU positive cells using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the percentage of BrdU positive cells are indicative of cell proliferation.", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "proliferation", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Brdu antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "percentage of BrdU positive cells", + "aid": 853, + "assayName": "CCTE_Mundy_HCI_hNP1_Pro", + "assayDesc": "CCTE_Mundy_HCI_hNP1_Pro is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.25 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.25, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2808, + "assayComponentEndpointName": "UTOR_hL-FABP_binding_Kd", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UTOR_hL-FABP_binding was analyzed into 1 assay endpoint. This assay enddpoint, UTOR_hL-FABP_binding_Kd, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, measures of fluorescence for loss-of-signal activity can be used to understand competitive binding of L-FABP. Furthermore, this assay endpoint can be referred to as the primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is fatty acid binding protein.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1,8-ANS", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "fatty acid binding protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2717, + "assayComponentName": "UTOR_hL-FABP_binding_Kd", + "assayComponentDesc": "UTOR_hL-FABP_binding_Kd is the calculated from the UTOR_hL-FABP_binding assay. It is a measuremnt of hL-FABP binding affinity as detected with fluorescence intensity signals by size-exclusion chromatography-co-elution (SECC) and nontarget analysis (NTA) technology by mass spectroscopy. An IC50 was obtained from dose-response curves and converted into its corresponding dissociation constant (Kd) concentration for tcpl processing as a single concentration value.", + "assayComponentTargetDesc": "Liver fatty acid binding protein (L-FABP) is a primarily expressed in the liver where it is involved in the binding, transport and metabolism of long-chain fatty acids and other hydrophobic molecules including xenobiotics like PFAS. The binding of PFAS to hL-FABP with increasing concentrations displaces 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) resulting in the loss of fluorescence intensity of the latter.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescence displacement", + "biologicalProcessTarget": "L-FABP binding affinity", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "size-exclusion chromatography-co-elution (SECC) and mass spectrometry using an LC-Orbitrap for non-targeted analysis (NTA)", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "1-anilinonaphthalene-8-sulfonic acid (1,8-ANS)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "hL-FABP protein-bound 1,8-ANS", + "aid": 855, + "assayName": "UTOR_hL-FABP_binding", + "assayDesc": "UTOR_hL-FABP_binding is a cell-free, single-readout assay that uses extracted liver fatty acid binding proteins (hL-FABP) from E. coli lysates with measurements taken at 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "BL 21 (DE3) strain of E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "biochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "NA", + "dilutionSolventPercentMax": null, + "asid": 32, + "assaySourceName": "UTOR", + "assaySourceLongName": "University of Toronto, Peng Laboratory", + "assaySourceDesc": "The Peng Lab at the University of Toronto screened PFAS binding to hL-FABP through a Material Transfer Agreement for the PFAS screening library.", + "gene": { + "geneId": 124, + "geneName": "fatty acid binding protein 1, liver", + "description": null, + "geneSymbol": "FABP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2168, + "officialSymbol": "FABP1", + "officialFullName": "fatty acid binding protein 1, liver", + "uniprotAccessionNumber": "P07148" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.est.0c00049", + "url": "https://pubmed.ncbi.nlm.nih.gov/32249562/", + "pmid": 32249562, + "title": "Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty Acid Binding Protein", + "author": "Yang D, Han J, Hall DR, Sun J, Fu J, Kutarna S, Houck KA, LaLone CA, Doering JA, Ng CA, Peng H", + "citation": "Yang D, Han J, Hall DR, Sun J, Fu J, Kutarna S, Houck KA, LaLone CA, Doering JA, Ng CA, Peng H. Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty Acid Binding Protein. Environ Sci Technol. 2020 May 5;54(9):5676-5686. doi: 10.1021/acs.est.0c00049. Epub 2020 Apr 16. PMID: 32249562; PMCID: PMC7477755.", + "otherId": "0", + "citationId": 243, + "otherSource": "" + } + }, + { + "aeid": 2809, + "assayComponentEndpointName": "BSK_BT_Bcell_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_Bcell_Proliferation was analyzed at the endpoint, BSK_BT_Bcell_Proliferation, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1068, + "assayComponentName": "BSK_BT_Bcell_Proliferation", + "assayComponentDesc": "BSK_BT_Bcell_Proliferation is an assay component measured in the BSK_BT assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", + "assayComponentTargetDesc": "B cell proliferation is a critical event driving both adaptive immunity (antibody production) as well as auto-immune diseases where B cells are key disease players (Lupus, MS, RA etc). Inhibition of B cell proliferation is considered an immune supressive effect.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2811, + "assayComponentEndpointName": "BSK_BT_PBMCCytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_PBMCCytotoxicity was analyzed at the endpoint, BSK_BT_PBMCCytotoxicity, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1069, + "assayComponentName": "BSK_BT_PBMCCytotoxicity", + "assayComponentDesc": "BSK_BT_PBMCCytotoxicity is an assay component measured in the BSK_BT assay. It measures dehydrogenase activity, a form of viability reporter, as detected with fluorescence intensity signals by Alamar Blue Reduction technology.", + "assayComponentTargetDesc": "PBMC Cytotoxicity in the BT system is a measure of the cell death of PBMC. Cell viability of non-adherent cells is measured by alamarBlue® staining, a method based on a cell permeable compound that emitts fluorescence after entering cells. The number of living cells is proportional to the amount of fluorescence produced", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar Blue Reduction", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Alamar blue", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2813, + "assayComponentEndpointName": "BSK_BT_sIgG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_sIgG was analyzed at the endpoint, BSK_BT_sIgG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'immunoglobulin' intended target family, where the subfamily is 'IgG'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "immunoglobulin", + "intendedTargetFamilySub": "IgG", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1070, + "assayComponentName": "BSK_BT_sIgG", + "assayComponentDesc": "BSK_BT_sIgG is an assay component measured in the BSK_BT assay. It measures secreted IgG related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Secreted IgG (sIgG) is produced by B cells and is the main type of antibody found in blood and extracellular fluid that mediates the immune response against pathogens. sIgG is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IgG", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4172, + "geneName": "immunoglobulin heavy constant gamma 1 (G1m marker)", + "description": null, + "geneSymbol": "IGHG1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3500, + "officialSymbol": "IGHG1", + "officialFullName": "immunoglobulin heavy constant gamma 1 (G1m marker)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2815, + "assayComponentEndpointName": "BSK_BT_xIL17A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL17A was analyzed at the endpoint, BSK_BT_xIL17A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1071, + "assayComponentName": "BSK_BT_xIL17A", + "assayComponentDesc": "BSK_BT_xIL17A is an assay component measured in the BSK_BT assay. It measures secreted IL-17A related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 17A (IL-17A) is a proinflammatory cytokine produced by T cells that induces cytokine production and mediates monocyte and neutrophil recruitment to sites of inflammation. Secreted IL-17A (sIL-17A) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-17A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4248, + "geneName": "interleukin 17A", + "description": null, + "geneSymbol": "IL17A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3605, + "officialSymbol": "IL17A", + "officialFullName": "interleukin 17A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2817, + "assayComponentEndpointName": "BSK_BT_xIL17F", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL17F was analyzed at the endpoint, BSK_BT_xIL17F, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1072, + "assayComponentName": "BSK_BT_xIL17F", + "assayComponentDesc": "BSK_BT_xIL17F is an assay component measured in the BSK_BT assay. It measures secreted IL-17F related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 17F (IL-17F) is a proinflammatory cytokine produced by T cells that induces cytokine, chemokine and adhesion molecule production and mediates neutrophil recruitment to sites of inflammation. Secreted IL-17F (sIL-17F) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-17F", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 18205, + "geneName": "interleukin 17F", + "description": null, + "geneSymbol": "IL17F", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 112744, + "officialSymbol": "IL17F", + "officialFullName": "interleukin 17F", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2819, + "assayComponentEndpointName": "BSK_BT_xIL2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL2 was analyzed at the endpoint, BSK_BT_xIL2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1073, + "assayComponentName": "BSK_BT_xIL2", + "assayComponentDesc": "BSK_BT_xIL2 is an assay component measured in the BSK_BT assay. It measures secreted IL-2 related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 2 (IL-2) is a secreted proinflammatory cytokine produced by T cells that regulates lymphocyte proliferation and promotes T cell differentiation. Secreted IL-2 (IL-2) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4213, + "geneName": "interleukin 2", + "description": null, + "geneSymbol": "IL2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3558, + "officialSymbol": "IL2", + "officialFullName": "interleukin 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2821, + "assayComponentEndpointName": "BSK_BT_xIL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL6 was analyzed at the endpoint, BSK_BT_xIL6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1074, + "assayComponentName": "BSK_BT_xIL6", + "assayComponentDesc": "BSK_BT_xIL6 is an assay component measured in the BSK_BT assay. It measures secreted IL-6 related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 6 (IL-6) is a secreted proinflammatory cytokine and acute phase reactant. Secreted IL-6 (sIL-6) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-6", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2823, + "assayComponentEndpointName": "BSK_BT_xTNFa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xTNFa was analyzed at the endpoint, BSK_BT_xTNFa, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1075, + "assayComponentName": "BSK_BT_xTNFa", + "assayComponentDesc": "BSK_BT_xTNFa is an assay component of the BSK_BT assay. It measures secreted TNF-alpha related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Tumor necrosis factor alpha (TNF-alpha) is a secreted proinflammatory cytokine involved in Th1 inflammation. Secreted TNF-alpha is categorized as an inflammation-related activity in the BT system modeling T cell dependent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene protein expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted TNF-alpha", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 327, + "geneName": "tumor necrosis factor", + "description": null, + "geneSymbol": "TNF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7124, + "officialSymbol": "TNF", + "officialFullName": "tumor necrosis factor", + "uniprotAccessionNumber": "P01375" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2825, + "assayComponentEndpointName": "BSK_MyoF_ACTA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_ACTA1 was analyzed at the endpoint, BSK_MyoF_ACTA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'actin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "actin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1081, + "assayComponentName": "BSK_MyoF_ACTA1", + "assayComponentDesc": "BSK_MyoF_ACTA1 is an assay component measured in the BSK_MyoF assay. It measures a-SMA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "alpha-Smooth muscle actin (a-SMA) is a protein involved in muscle contraction, cell motility, structure and integrity and is a marker for activated myofibroblast phenotype. a-SMA is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "a-SMA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 1526, + "geneName": "actin, alpha 1, skeletal muscle", + "description": null, + "geneSymbol": "ACTA1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 58, + "officialSymbol": "ACTA1", + "officialFullName": "actin, alpha 1, skeletal muscle", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2827, + "assayComponentEndpointName": "BSK_MyoF_bFGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_bFGF was analyzed at the endpoint, BSK_MyoF_bFGF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'basic fibroblast growth factor '.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "basic fibroblast growth factor ", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1082, + "assayComponentName": "BSK_MyoF_bFGF", + "assayComponentDesc": "BSK_MyoF_bFGF is an assay component measured in the BSK_MyoF assay. It measures bFGF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Basic fibroblast growth factor (bFGF) is a pro-fibrotic growth factor that drives fibroblast proliferation, migration and fibronectin synthesis. bFGF is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bFGF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 3172, + "geneName": "fibroblast growth factor 2", + "description": null, + "geneSymbol": "FGF2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2247, + "officialSymbol": "FGF2", + "officialFullName": "fibroblast growth factor 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2829, + "assayComponentEndpointName": "BSK_MyoF_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_VCAM1 was analyzed at the endpoint, BSK_MyoF_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1083, + "assayComponentName": "BSK_MyoF_VCAM1", + "assayComponentDesc": "BSK_MyoF_VCAM1 is an assay component measured in the BSK_MyoF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2831, + "assayComponentEndpointName": "BSK_MyoF_CollagenI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenI was analyzed at the endpoint, BSK_MyoF_CollagenI, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1084, + "assayComponentName": "BSK_MyoF_CollagenI", + "assayComponentDesc": "BSK_MyoF_CollagenI is an assay component measured in the BSK_MyoF assay. It measures Collagen I antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen I is involved in tissue remodeling and fibrosis, and is the most common fibrillar collagen that is found in skin, bone, tendons and other connective tissues. Collagen I is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen I antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2452, + "geneName": "collagen type I alpha 1 chain", + "description": null, + "geneSymbol": "COL1A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1277, + "officialSymbol": "COL1A1", + "officialFullName": "collagen type I alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2833, + "assayComponentEndpointName": "BSK_MyoF_CollagenIII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenIII was analyzed at the endpoint, BSK_MyoF_CollagenIII, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1085, + "assayComponentName": "BSK_MyoF_CollagenIII", + "assayComponentDesc": "BSK_MyoF_CollagenIII is an assay component measured in the BSK_MyoF assay. It measures Collagen III antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen III is an extracellular matrix protein and fibrillar collagen found in extensible connective tissues (skin, lung and vascular system) and is involved in cell adhesion, cell migration, tissue remodeling. Collagen III is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen III antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 70, + "geneName": "collagen, type III, alpha 1", + "description": null, + "geneSymbol": "COL3A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1281, + "officialSymbol": "COL3A1", + "officialFullName": "collagen, type III, alpha 1", + "uniprotAccessionNumber": "P02461" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2835, + "assayComponentEndpointName": "BSK_MyoF_CollagenIV", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenIV was analyzed at the endpoint, BSK_MyoF_CollagenIV, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1086, + "assayComponentName": "BSK_MyoF_CollagenIV", + "assayComponentDesc": "BSK_MyoF_CollagenIV is an assay component measured in the BSK_MyoF assay. It measures Collagen IV antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen IV is the major structural component of the basal lamina. Collagen IV is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen IV antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2456, + "geneName": "collagen type IV alpha 1 chain", + "description": null, + "geneSymbol": "COL4A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1282, + "officialSymbol": "COL4A1", + "officialFullName": "collagen type IV alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2837, + "assayComponentEndpointName": "BSK_MyoF_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_IL8 was analyzed at the endpoint, BSK_MyoF_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1087, + "assayComponentName": "BSK_MyoF_IL8", + "assayComponentDesc": "BSK_MyoF_IL8 is an assay component measured in the BSK_MyoF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2839, + "assayComponentEndpointName": "BSK_MyoF_Decorin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_Decorin was analyzed at the endpoint, BSK_MyoF_Decorin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'decorin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "decorin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1088, + "assayComponentName": "BSK_MyoF_Decorin", + "assayComponentDesc": "BSK_MyoF_Decorin is an assay component measured in the BSK_MyoF assay. It measures Decorin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Decorin is a proteoglycan that is a component of connective tissue and is involved in collagen and matrix assembly. Decorin is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Decorin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2723, + "geneName": "decorin", + "description": null, + "geneSymbol": "DCN", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1634, + "officialSymbol": "DCN", + "officialFullName": "decorin", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2841, + "assayComponentEndpointName": "BSK_MyoF_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_MMP1 was analyzed at the endpoint, BSK_MyoF_MMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1089, + "assayComponentName": "BSK_MyoF_MMP1", + "assayComponentDesc": "BSK_MyoF_MMP1 is an assay component measured in the BSK_MyoF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades collagens I, II and III and is involved in the process of tissue remodeling. MMP-1 is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2843, + "assayComponentEndpointName": "BSK_MyoF_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_PAI1 was analyzed at the endpoint, BSK_MyoF_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1090, + "assayComponentName": "BSK_MyoF_PAI1", + "assayComponentDesc": "BSK_MyoF_PAI1 is an assay component measured in the BSK_MyoF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2845, + "assayComponentEndpointName": "BSK_MyoF_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_SRB was analyzed at the endpoint, BSK_MyoF_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1091, + "assayComponentName": "BSK_MyoF_SRB", + "assayComponentDesc": "BSK_MyoF_SRB is an assay component measured in the BSK_MyoF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the MyoF system is a measure of the total protein content of lung fibroblasts. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2847, + "assayComponentEndpointName": "BSK_MyoF_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_TIMP1 was analyzed at the endpoint, BSK_MyoF_TIMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1092, + "assayComponentName": "BSK_MyoF_TIMP1", + "assayComponentDesc": "BSK_MyoF_TIMP1 is an assay component measured in the BSK_MyoF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-1 is a tissue inhibitor of matrix metalloprotease-7 (MMP-7) and other MMPs, and is involved in tissue remodeling, angiogenesis and fibrosis. TIMP-1 is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2849, + "assayComponentEndpointName": "BSK_BF4T_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MCP1 was analyzed at the endpoint, BSK_BF4T_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2719, + "assayComponentName": "BSK_BF4T_MCP1", + "assayComponentDesc": "BSK_BF4T_MCP1 is an assay component measured in the BSK_BF4T assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2851, + "assayComponentEndpointName": "BSK_BF4T_Eotaxin3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_Eotaxin3 was analyzed at the endpoint, BSK_BF4T_Eotaxin3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2720, + "assayComponentName": "BSK_BF4T_Eotaxin3", + "assayComponentDesc": "BSK_BF4T_Eotaxin3 is an assay component measured in the BSK_BF4T assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Eotaxin-3/CCL26 is a chemokine that mediates recruitment of eosinophils and basophils into tissue sites. Eotaxin-3 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Eotaxin-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 365, + "geneName": "chemokine (C-C motif) ligand 26", + "description": null, + "geneSymbol": "CCL26", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10344, + "officialSymbol": "CCL26", + "officialFullName": "chemokine (C-C motif) ligand 26", + "uniprotAccessionNumber": "Q9Y258" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2853, + "assayComponentEndpointName": "BSK_BF4T_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_VCAM1 was analyzed at the endpoint, BSK_BF4T_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2721, + "assayComponentName": "BSK_BF4T_VCAM1", + "assayComponentDesc": "BSK_BF4T_VCAM1 is an assay component measured in the BSK_BF4T assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2855, + "assayComponentEndpointName": "BSK_BF4T_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_ICAM1 was analyzed at the endpoint, BSK_BF4T_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2722, + "assayComponentName": "BSK_BF4T_ICAM1", + "assayComponentDesc": "BSK_BF4T_ICAM1 is an assay component measured in the BSK_BF4T assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2857, + "assayComponentEndpointName": "BSK_BF4T_CD90", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_CD90 was analyzed at the endpoint, BSK_BF4T_CD90, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2723, + "assayComponentName": "BSK_BF4T_CD90", + "assayComponentDesc": "BSK_BF4T_CD90 is an assay component measured in the BSK_BF4T assay. It measures CD90 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD90 is a cell surface glycoprotein that mediates cell-cell and cell-matrix interactions. CD90 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD90 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6890, + "geneName": "Thy-1 cell surface antigen", + "description": null, + "geneSymbol": "THY1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7070, + "officialSymbol": "THY1", + "officialFullName": "Thy-1 cell surface antigen", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2859, + "assayComponentEndpointName": "BSK_BF4T_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_IL8 was analyzed at the endpoint, BSK_BF4T_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2724, + "assayComponentName": "BSK_BF4T_IL8", + "assayComponentDesc": "BSK_BF4T_IL8 is an assay component measured in the BSK_BF4T assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2861, + "assayComponentEndpointName": "BSK_BF4T_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_IL1a was analyzed at the endpoint, BSK_BF4T_IL1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2725, + "assayComponentName": "BSK_BF4T_IL1a", + "assayComponentDesc": "BSK_BF4T_IL1a is an assay component measured in the BSK_BF4T assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 1 alpha (IL-1a) is a secreted proinflammatory cytokine involved in endothelial cell activation and neutrophil recruitment. Secreted IL-1? (sIL-1?)is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2863, + "assayComponentEndpointName": "BSK_BF4T_Keratin818", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_Keratin818 was analyzed at the endpoint, BSK_BF4T_Keratin818, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2726, + "assayComponentName": "BSK_BF4T_Keratin818", + "assayComponentDesc": "BSK_BF4T_Keratin818 is an assay component measured in the BSK_BF4T assay. It measures Keratin 8/18 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Keratin 8/18 is an intermediate filament heterodimer of fibrous structural poteins involved in Epithelial cell death, EMT, COPD, Lung Inflammation. Keratin 8/18 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Keratin 8/18 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4459, + "geneName": "keratin 18", + "description": null, + "geneSymbol": "KRT18", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3875, + "officialSymbol": "KRT18", + "officialFullName": "keratin 18", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2865, + "assayComponentEndpointName": "BSK_BF4T_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP1 was analyzed at the endpoint, BSK_BF4T_MMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2727, + "assayComponentName": "BSK_BF4T_MMP1", + "assayComponentDesc": "BSK_BF4T_MMP1 is an assay component measured in the BSK_BF4T assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades collagens I, II and III and is involved in the process of tissue remodeling. MMP-1 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2867, + "assayComponentEndpointName": "BSK_BF4T_MMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP3 was analyzed at the endpoint, BSK_BF4T_MMP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2728, + "assayComponentName": "BSK_BF4T_MMP3", + "assayComponentDesc": "BSK_BF4T_MMP3 is an assay component measured in the BSK_BF4T assay. It measures MMP-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-3 (MMP-3) is an enzyme involved in tissue remodeling that can activate other MMPs (MMP-1, MMP-7 and MMP-9) and degrade collagens (II, III, IV, IX and X), proteoglycans, fibronectin, laminin and elastin. MMP-3 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2869, + "assayComponentEndpointName": "BSK_BF4T_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP9 was analyzed at the endpoint, BSK_BF4T_MMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2729, + "assayComponentName": "BSK_BF4T_MMP9", + "assayComponentDesc": "BSK_BF4T_MMP9 is an assay component measured in the BSK_BF4T assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-9 (MMP-9) is a gelatinase B that degrades collagen IV and gelatin and is involved in airway matrix remodeling. MMP-9 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2871, + "assayComponentEndpointName": "BSK_BF4T_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_PAI1 was analyzed at the endpoint, BSK_BF4T_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2730, + "assayComponentName": "BSK_BF4T_PAI1", + "assayComponentDesc": "BSK_BF4T_PAI1 is an assay component measured in the BSK_BF4T assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2873, + "assayComponentEndpointName": "BSK_BF4T_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_SRB was analyzed at the endpoint, BSK_BF4T_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2731, + "assayComponentName": "BSK_BF4T_SRB", + "assayComponentDesc": "BSK_BF4T_SRB is an assay component measured in the BSK_BF4T assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the BF4T system is a measure of the total protein content of bronchial epithelial cells and dermal fibroblasts. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2875, + "assayComponentEndpointName": "BSK_BF4T_tPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_tPA was analyzed at the endpoint, BSK_BF4T_tPA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2732, + "assayComponentName": "BSK_BF4T_tPA", + "assayComponentDesc": "BSK_BF4T_tPA is an assay component measured in the BSK_BF4T assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue plasminogen activator (tPA) is a serine protease that catalyzes the cleavage of plasminogen to plasmin and regulates clot degradation. tPA is involved in fibrinolyis, cell migration and tissue remodeling. tPA is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "tPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 239, + "geneName": "plasminogen activator, tissue", + "description": null, + "geneSymbol": "PLAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5327, + "officialSymbol": "PLAT", + "officialFullName": "plasminogen activator, tissue", + "uniprotAccessionNumber": "P00750" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2877, + "assayComponentEndpointName": "BSK_BF4T_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4TA was analyzed at the endpoint, BSK_BF4TA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2733, + "assayComponentName": "BSK_BF4T_uPA", + "assayComponentDesc": "BSK_BF4TA is an assay component measured in the BSK_BF4T assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Urokinse plasminogen activator (uPA) is a serine protease with thrombolytic activity. Triggers fibrinolysis and extracellular matrix degradation. uPA is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2879, + "assayComponentEndpointName": "BSK_BE3C_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_ICAM1 was analyzed at the endpoint, BSK_BE3C_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2734, + "assayComponentName": "BSK_BE3C_ICAM1", + "assayComponentDesc": "BSK_BE3C_ICAM1 is an assay component measured in the BSK_BE3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2881, + "assayComponentEndpointName": "BSK_BE3C_ITAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_ITAC was analyzed at the endpoint, BSK_BE3C_ITAC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2735, + "assayComponentName": "BSK_BE3C_ITAC", + "assayComponentDesc": "BSK_BE3C_ITAC is an assay component measured in the BSK_BE3C assay. It measures I-TAC antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interferon inducible T Cell Alpha Chemoattractant (I-TAC/CXCL11) is a chemokine that mediates T cell and monocyte chemotaxis. I-TAC is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation. ", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "I-TAC antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6313, + "geneName": "C-X-C motif chemokine ligand 11", + "description": null, + "geneSymbol": "CXCL11", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6373, + "officialSymbol": "CXCL11", + "officialFullName": "C-X-C motif chemokine ligand 11", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2883, + "assayComponentEndpointName": "BSK_BE3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IL8 was analyzed at the endpoint, BSK_BE3C_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2736, + "assayComponentName": "BSK_BE3C_IL8", + "assayComponentDesc": "BSK_BE3C_IL8 is an assay component measured in the BSK_BE3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 1943, + "assayComponentEndpointName": "ATG_M_06_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_06_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1871, + "assayComponentName": "ATG_M_06_XSP1", + "assayComponentDesc": "ATG_M_06_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2885, + "assayComponentEndpointName": "BSK_BE3C_EGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_EGFR was analyzed at the endpoint, BSK_BE3C_EGFR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2737, + "assayComponentName": "BSK_BE3C_EGFR", + "assayComponentDesc": "BSK_BE3C_EGFR is an assay component measured in the BSK_BE3C assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Epidermal growth factor receptor (EGFR) is a cell surface receptor for epidermal growth factor involved in cell proliferation, cell differentiation, tissue remodeling and tumor growth. EGFR is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "EGFR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2887, + "assayComponentEndpointName": "BSK_BE3C_Keratin818", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_Keratin818 was analyzed at the endpoint, BSK_BE3C_Keratin818, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2738, + "assayComponentName": "BSK_BE3C_Keratin818", + "assayComponentDesc": "BSK_BE3C_Keratin818 is an assay component measured in the BSK_BE3C assay. It measures Keratin 8/18 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Keratin 8/18 is an intermediate filament heterodimer of fibrous structural poteins involved in Epithelial cell death, EMT, COPD, Lung Inflammation. Keratin 8/18 is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Keratin 8/18 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4459, + "geneName": "keratin 18", + "description": null, + "geneSymbol": "KRT18", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3875, + "officialSymbol": "KRT18", + "officialFullName": "keratin 18", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2889, + "assayComponentEndpointName": "BSK_BE3C_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MMP9 was analyzed at the endpoint, BSK_BE3C_MMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2739, + "assayComponentName": "BSK_BE3C_MMP9", + "assayComponentDesc": "BSK_BE3C_MMP9 is an assay component measured in the BSK_BE3C assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-9 (MMP-9) is a gelatinase B that degrades collagen IV and gelatin and is involved in airway matrix remodeling. MMP-9 is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2891, + "assayComponentEndpointName": "BSK_CASM3C_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_PAI1 was analyzed at the endpoint, BSK_CASM3C_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2740, + "assayComponentName": "BSK_CASM3C_PAI1", + "assayComponentDesc": "BSK_CASM3C_PAI1 is an assay component measured in the BSK_CASM3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2893, + "assayComponentEndpointName": "BSK_hDFCGF_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MCP1 was analyzed at the endpoint, BSK_hDFCGF_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2741, + "assayComponentName": "BSK_hDFCGF_MCP1", + "assayComponentDesc": "BSK_hDFCGF_MCP1 is an assay component measured in the BSK_hDFCGF assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2895, + "assayComponentEndpointName": "BSK_hDFCGF_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_ICAM1 was analyzed at the endpoint, BSK_hDFCGF_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2742, + "assayComponentName": "BSK_hDFCGF_ICAM1", + "assayComponentDesc": "BSK_hDFCGF_ICAM1 is an assay component measured in the BSK_hDFCGF assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2897, + "assayComponentEndpointName": "BSK_hDFCGF_CollagenI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_CollagenI was analyzed at the endpoint, BSK_hDFCGF_CollagenI, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2743, + "assayComponentName": "BSK_hDFCGF_CollagenI", + "assayComponentDesc": "BSK_hDFCGF_CollagenI is an assay component measured in the BSK_hDFCGF assay. It measures Collagen I antibody related to regulation of gene protein expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen I is involved in tissue remodeling and fibrosis, and is the most common fibrillar collagen that is found in skin, bone, tendons and other connective tissues. Collagen I is categorized as a tissue remodeling-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene protein expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen I antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2452, + "geneName": "collagen type I alpha 1 chain", + "description": null, + "geneSymbol": "COL1A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1277, + "officialSymbol": "COL1A1", + "officialFullName": "collagen type I alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2899, + "assayComponentEndpointName": "BSK_hDFCGF_ITAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_ITAC was analyzed at the endpoint, BSK_hDFCGF_ITAC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2744, + "assayComponentName": "BSK_hDFCGF_ITAC", + "assayComponentDesc": "BSK_hDFCGF_ITAC is an assay component measured in the BSK_hDFCGF assay. It measures I-TAC antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interferon inducible T Cell Alpha Chemoattractant (I-TAC/CXCL11) is a chemokine that mediates T cell and monocyte chemotaxis. I-TAC is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "I-TAC antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6313, + "geneName": "C-X-C motif chemokine ligand 11", + "description": null, + "geneSymbol": "CXCL11", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6373, + "officialSymbol": "CXCL11", + "officialFullName": "C-X-C motif chemokine ligand 11", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2901, + "assayComponentEndpointName": "BSK_hDFCGF_TIMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_TIMP2 was analyzed at the endpoint, BSK_hDFCGF_TIMP2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2745, + "assayComponentName": "BSK_hDFCGF_TIMP2", + "assayComponentDesc": "BSK_hDFCGF_TIMP2 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-2 is a tissue inhibitor of matrix metalloproteases and is involved in tissue remodeling, angiogenesis and fibrosis. TIMP-2 is categorized as a tissue remodeling-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 325, + "geneName": "TIMP metallopeptidase inhibitor 2", + "description": null, + "geneSymbol": "TIMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7077, + "officialSymbol": "TIMP2", + "officialFullName": "TIMP metallopeptidase inhibitor 2", + "uniprotAccessionNumber": "Q96MC4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2903, + "assayComponentEndpointName": "BSK_KF3CT_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IL8 was analyzed at the endpoint, BSK_KF3CT_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2746, + "assayComponentName": "BSK_KF3CT_IL8", + "assayComponentDesc": "BSK_KF3CT_IL8 is an assay component measured in the BSK_KF3CT assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2905, + "assayComponentEndpointName": "BSK_KF3CT_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MIG was analyzed at the endpoint, BSK_KF3CT_MIG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2747, + "assayComponentName": "BSK_KF3CT_MIG", + "assayComponentDesc": "BSK_KF3CT_MIG is an assay component measured in the BSK_KF3CT assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monokine induced by gamma interferon (MIG/CXCL9) is a chemokine that mediates T cell recruitment. MIG is categorized as an inflammation-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2907, + "assayComponentEndpointName": "BSK_KF3CT_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_PAI1 was analyzed at the endpoint, BSK_KF3CT_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2748, + "assayComponentName": "BSK_KF3CT_PAI1", + "assayComponentDesc": "BSK_KF3CT_PAI1 is an assay component measured in the BSK_KF3CT assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2909, + "assayComponentEndpointName": "BSK_IMphg_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MCP1 was analyzed at the endpoint, BSK_IMphg_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2749, + "assayComponentName": "BSK_IMphg_MCP1", + "assayComponentDesc": "BSK_IMphg_MCP1 is an assay component measured in the BSK_IMphg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2911, + "assayComponentEndpointName": "BSK_IMphg_MIP1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MIP1a was analyzed at the endpoint, BSK_IMphg_MIP1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2750, + "assayComponentName": "BSK_IMphg_MIP1a", + "assayComponentDesc": "BSK_IMphg_MIP1a is an assay component measured in the BSK_IMphg assay. It measures MIP-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Macrophage inflammatory protein 1 alpha (MIP-1a/CCL3) is a pro-inflammatory chemokine that mediates leukocyte recruitment to sites of inflammation. MIP-1a is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIP-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6291, + "geneName": "C-C motif chemokine ligand 3", + "description": null, + "geneSymbol": "CCL3", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6348, + "officialSymbol": "CCL3", + "officialFullName": "C-C motif chemokine ligand 3", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2913, + "assayComponentEndpointName": "BSK_IMphg_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_VCAM1 was analyzed at the endpoint, BSK_IMphg_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2751, + "assayComponentName": "BSK_IMphg_VCAM1", + "assayComponentDesc": "BSK_IMphg_VCAM1 is an assay component measured in the BSK_IMphg assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2915, + "assayComponentEndpointName": "BSK_IMphg_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_CD40 was analyzed at the endpoint, BSK_IMphg_CD40, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2752, + "assayComponentName": "BSK_IMphg_CD40", + "assayComponentDesc": "BSK_IMphg_CD40 is an assay component measured in the BSK_IMphg assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD40 is a cell surface adhesion receptor and costimulatory receptor for T cell activation that is expressed on antigen presenting cells, endothelial cells, smooth muscle cells, fibroblasts and epithelial cells. CD40 is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2917, + "assayComponentEndpointName": "BSK_IMphg_ESelectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_ESelectin was analyzed at the endpoint, BSK_IMphg_ESelectin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2753, + "assayComponentName": "BSK_IMphg_ESelectin", + "assayComponentDesc": "BSK_IMphg_ESelectin is an assay component measured in the BSK_IMphg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-Selectin/CD62E is a cell adhesion molecule expressed only on endothelial cells that mediates leukocyte-endothelial cell interactions. E-Selectin is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2919, + "assayComponentEndpointName": "BSK_IMphg_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_CD69 was analyzed at the endpoint, BSK_IMphg_CD69, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2754, + "assayComponentName": "BSK_IMphg_CD69", + "assayComponentDesc": "BSK_IMphg_CD69 is an assay component measured in the BSK_IMphg assay. It measures CD69 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD69 is a cell surface activation antigen that is induced early during immune activation and is involved in macrophage activation. CD69 is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2921, + "assayComponentEndpointName": "BSK_IMphg_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL8 was analyzed at the endpoint, BSK_IMphg_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2755, + "assayComponentName": "BSK_IMphg_IL8", + "assayComponentDesc": "BSK_IMphg_IL8 is an assay component measured in the BSK_IMphg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2923, + "assayComponentEndpointName": "BSK_IMphg_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL1a was analyzed at the endpoint, BSK_IMphg_IL1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2756, + "assayComponentName": "BSK_IMphg_IL1a", + "assayComponentDesc": "BSK_IMphg_IL1a is an assay component measured in the BSK_IMphg assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 1alpha (IL-1a) is a secreted proinflammatory cytokine involved in endothelial cell activation and neutrophil recruitment. Secreted IL-1a (sIL-1a) is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2925, + "assayComponentEndpointName": "BSK_IMphg_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MCSF was analyzed at the endpoint, BSK_IMphg_MCSF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2757, + "assayComponentName": "BSK_IMphg_MCSF", + "assayComponentDesc": "BSK_IMphg_MCSF is an assay component measured in the BSK_IMphg assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Macrophage colony-stimulating factor (M-CSF) is a secreted and cell surface cytokine that mediates macrophage differentiation. M-CSF is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2927, + "assayComponentEndpointName": "BSK_IMphg_IL10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL10 was analyzed at the endpoint, BSK_IMphg_IL10, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2758, + "assayComponentName": "BSK_IMphg_IL10", + "assayComponentDesc": "BSK_IMphg_IL10 is an assay component measured in the BSK_IMphg assay. It measures IL-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 10 (IL-10) is a secreted anti-inflammatory cytokine. Secreted IL-10 (sIL-10) is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4232, + "geneName": "interleukin 10", + "description": null, + "geneSymbol": "IL10", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3586, + "officialSymbol": "IL10", + "officialFullName": "interleukin 10", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2929, + "assayComponentEndpointName": "BSK_IMphg_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_SRB was analyzed at the endpoint, BSK_IMphg_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2759, + "assayComponentName": "BSK_IMphg_SRB", + "assayComponentDesc": "BSK_IMphg_SRB is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the lMphg system is a measure of the total protein content of venular endothelial cells and macrophages. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2931, + "assayComponentEndpointName": "BSK_IMphg_SRB.Mphg", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_SRB.Mphg was analyzed at the endpoint, BSK_IMphg_SRB.Mphg, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2760, + "assayComponentName": "BSK_IMphg_SRB.Mphg", + "assayComponentDesc": "BSK_IMphg_SRB.Mphg is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB-Mphg in the lMphg system is a measure of the total protein content of macrophages alone. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2933, + "assayComponentEndpointName": "BSK_LPS_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_Thrombodulin was analyzed at the endpoint, BSK_LPS_Thrombomodulin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2761, + "assayComponentName": "BSK_LPS_Thrombomodulin", + "assayComponentDesc": "BSK_LPS_Thrombomodulin is an assay component measured in the BSK_LPS assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin/CD141 is a cell surface receptor for complement factor 3b with anti-coagulant, anti-inflammatory and cytoprotective activities during the process of fibrinolysis, coagulation and thrombosis. Thrombomodulin is categorized as a hemostasis-related activity in the LPS system modeling monocyte-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2935, + "assayComponentEndpointName": "BSK_LPS_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_CD69 was analyzed at the endpoint, BSK_LPS_CD69, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2762, + "assayComponentName": "BSK_LPS_CD69", + "assayComponentDesc": "BSK_LPS_CD69 is an assay component measured in the BSK_LPS assay. It measures CD69 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD69 is a cell surface activation antigen. CD69 is categorized as an immunomodulatory-related activity in the LPS system modeling monocyte-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2938, + "assayComponentEndpointName": "IUF_NPC2a_radial_glia_migration_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2a_radial_glia_migration_72hr component was analyzed at the endpoint IUF_NPC2a_radial_glia_migration_72hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SRC kinase inhibitor PP2", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2763, + "assayComponentName": "IUF_NPC2a_radial_glia_migration_72hr", + "assayComponentDesc": "IUF_NPC2a_radial glia_migration_72hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The migration distance of radial glia at 72 hr is assessed in µm from the edge of the sphere core to the edge of the migration area based on brightfield images of each well. Therefore, each plate is scanned using a high content imaging device. Images are exported and the migration distance is measured manually in four directions using ImageJ. The mean of four measures per well is used as raw data input.", + "assayComponentTargetDesc": "Changes in the migration distance of radial glia are indicative of radial glia migration during neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "radial glia migration", + "biologicalProcessTarget": "migration during neurodevelopment", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "Automated phase contrast imaging ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of radial glia at 72hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2940, + "assayComponentEndpointName": "IUF_NPC2a_radial_glia_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2a_radial_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ radial_glia_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2764, + "assayComponentName": "IUF_NPC2a_radial_glia_migration_120hr", + "assayComponentDesc": "IUF_NPC2a_radial_glia_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The migration distance of radial glia at 120 hr is assessed in µm from the edge of the sphere core to the edge of the migration area based on fluorescent images of Hoechst-positive nuclei. With the identification of each nucleus position around the sphere core, migration-related parameters can be calculated. First, a nuclei density distribution is calculated for which an algorithm determines relatively more and less dense nuclei areas. This calculation identifies the sphere core by the densest nuclei area in the image. The algorithm further assumes that nuclei density decreases from the sphere core to the periphery. When the nuclei density hits a pre-defined threshold, the outer boundaries of the migration area are determined and the sphere itself is mapped out in a polynomial bounding box. Derived from this box, the size of the migration area and the migration distance are calculated for each well.", + "assayComponentTargetDesc": "Changes in the migration distance of radial glia are indicative of radial glia migration during neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "radial glia migration", + "biologicalProcessTarget": "migration during neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst 33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of radial glia at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2942, + "assayComponentEndpointName": "IUF_NPC2b_neuronal_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2b_neuronal_migration_120hr component was analyzed at the endpoint IUF_NPC2b_neuronal_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2765, + "assayComponentName": "IUF_NPC2b_neuronal_migration_120hr", + "assayComponentDesc": "IUF_NPC2b_neuronal_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Neuronal migration distance at 120 hr is the mean distance of all neurons from the edge of the sphere core to each individual neuron (see IUF_NPC3_neuronal_differentiation_120hr). Neuronal migration is normalized to radial glia migration distance at 120 hr.", + "assayComponentTargetDesc": "Changes in the migration distance of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "neuronal migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of neurons at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2944, + "assayComponentEndpointName": "IUF_NPC2c_oligodendrocyte_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2c_oligodendrocyte_migration_120hr component was analyzed at the endpoint IUF_NPC2c_oligodendrocyte_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2766, + "assayComponentName": "IUF_NPC2c_oligodendrocyte_migration_120hr", + "assayComponentDesc": "IUF_NPC2b_oligodendrocyte_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Oligodendrocyte migration distance at 120 hr is the mean distance of all oligodendrocytes from the edge of the sphere core to each individual oligodendrocyte (see IUF_NPC5_oligodendrocyte_differentiation_120hr). Oligodendrocyte migration is normalized to radial glia migration distance at 120 hr.", + "assayComponentTargetDesc": "Changes in the migration distance of oligodendrocytes are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "oligodendrocyte migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "O4 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of oligodendrocytes at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2946, + "assayComponentEndpointName": "IUF_NPC3_neuronal_differentiation_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC3_neuronal_differentiation_120hr component was analyzed at the endpoint IUF_NPC3_neuronal_differentiation_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2767, + "assayComponentName": "IUF_NPC3_neuronal_differentiation_120hr", + "assayComponentDesc": "IUF_NPC3_neuronal_differentiation_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Neuronal differentiation is determined as the number of all TUBB3 positive cells in percent of the number of Hoechst-positive nuclei in the total neurosphere migration area (see IUF_NPC2a_ glia_migration_120hr) after 120 hr of migration/differentiation. Neurons are automatically identified using a convolutional neural network (CNN) that was trained using manually annotated images of differentiated neurons. ", + "assayComponentTargetDesc": "Changes in the neuronal differentiation are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal differentiation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neuronal differentiation at 120 hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2948, + "assayComponentEndpointName": "IUF_NPC4_neurite_length_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC4_neurite_length_120hr component was analyzed at the endpoint IUF_NPC4_neurite_length_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2768, + "assayComponentName": "IUF_NPC4_neurite_length_120hr", + "assayComponentDesc": "IUF_NPC4_neurite_length_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The neurite length at 120 hr is the mean length in um of all neurons (see IUF_NPC3_neuronal_differentiation_120hr) that are identified by the skeletonization algorithm in Omnisphero.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal morphology", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "morphology", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2950, + "assayComponentEndpointName": "IUF_NPC4_neurite_area_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC4_neurite_area_120hr component was analyzed at the endpoint IUF_NPC4_neurite_area_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2769, + "assayComponentName": "IUF_NPC4_neurite_area_120hr", + "assayComponentDesc": "IUF_NPC4_neurite_area_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The neurite area at 120 hr is the mean area in pixel (without nuclei) of all neurons (see IUF_NPC3_neuronal_differentiation_120hr) that are identified by the skeletonization algorithm in Omnisphero.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal morphology", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "morphology", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2952, + "assayComponentEndpointName": "IUF_NPC5_oligodendrocyte_differentiation_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC5_oligodendrocyte_differentiation_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_differentiation_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "BMP7", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2770, + "assayComponentName": "IUF_NPC5_oligodendrocyte_differentiation_120hr", + "assayComponentDesc": "IUF_NPC5_oligodendrocyte_differentiation_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Oligodendrocyte differentiation at 120 hr is determined as the number of all O4-positive cells in percent of the number of Hoechst-positive nuclei in the total neurosphere migration area (see IUF_NPC2a_ glia_migration_120hr) after 120 hr of migration/differentiation. Oligodendrocytes are automatically identified using a convolutional neural network (CNN) that was trained using manually annotated images of differentiated oligodendrocytes.", + "assayComponentTargetDesc": "Changes in the oligodendrocyte differentiation are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "oligodendrocyte differentiation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "O4 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "oligodendrocyte differentiation at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2954, + "assayComponentEndpointName": "IUF_NPC2-5_cytotoxicity_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cytotoxicity_72hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_72hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2771, + "assayComponentName": "IUF_NPC2-5_cytotoxicity_72hr", + "assayComponentDesc": "IUF_NPC2-5_cytotoxicity_72hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure the cytotoxicity at 72 hr as assessed by membrane integrity related to the LDH dependent reduction of resazurin to resorufin in the supernatant of each well. The cytotoxicity is measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2956, + "assayComponentEndpointName": "IUF_NPC2-5_cytotoxicity_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cytotoxicity_120hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_120hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2772, + "assayComponentName": "IUF_NPC2-5_cytotoxicity_120hr", + "assayComponentDesc": "IUF_NPC2-5_cytotoxicity_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure cytotoxicity at 120hr due to loss of membrane integrity. LDH measurements are performed from medium supernatants of each well and are based on the reduction of resazurin to resorufin measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2958, + "assayComponentEndpointName": "IUF_NPC2-5_cell_number_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cell_number_120hr component was analyzed at the endpoint IUF_NPC2-5_cell_number_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cell count", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2773, + "assayComponentName": "IUF_NPC2-5_cell_number_120hr", + "assayComponentDesc": "IUF_NPC2-5_cell number_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The cell number at 120 hr is assessed as the number of all Hoechst-positive nuclei identified in the migration area (see IUF_NPC2a_ glia_migration_120hr).", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of cell proliferation.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst 33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2960, + "assayComponentEndpointName": "IUF-NPC2-5_viability_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_viability_120hr component was analyzed at the endpoint IUF-NPC2-5_viability_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2774, + "assayComponentName": "IUF-NPC2-5_viability_120hr", + "assayComponentDesc": "IUF_NPC2-5_viability_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure cell viability assessed as mitochondria-dependent reduction of resazurin to resorufin using the alamar blue viability assay. The viability is measured as a fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (mitochondrial activity) are correlated to cellular viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar blue viability assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 3019, + "assayComponentEndpointName": "VALA_TUBHUV_Agonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Agonist_CellCount was analyzed at the endpoint, VALA_TUBHUV_Agonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2805, + "assayComponentName": "VALA_TUBHUV_Agonist_CellCount", + "assayComponentDesc": "VALA_TUBHUV_Agonist_CellCount is the one of two assay components measured from the VALA_TUBHUV_Agonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 860, + "assayName": "VALA_TUBHUV_Agonist", + "assayDesc": "VALA_TUBHUV_Agonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3020, + "assayComponentEndpointName": "VALA_TUBHUV_Agonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Agonist_TubuleLength was analyzed at the endpoint, VALA_TUBHUV_Agonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2806, + "assayComponentName": "VALA_TUBHUV_Agonist_TubuleLength", + "assayComponentDesc": "VALA_TUBHUV_Agonist_TubuleLength is the one of two assay components measured from the VALA_TUBHUV_Agonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBHUV1 assay was designed to detect chemical activation of tubulogenesis, i.e. agonism.", + "assayComponentTargetDesc": "Vein growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on vein formation in basal medium, which lacks growth factors that support blood vessel growth. Tube formation agonists will increase vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 860, + "assayName": "VALA_TUBHUV_Agonist", + "assayDesc": "VALA_TUBHUV_Agonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3021, + "assayComponentEndpointName": "VALA_TUBHUV_Antagonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Antagonist_CellCount was analyzed at the endpoint, VALA_TUBHUV_Antagonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2807, + "assayComponentName": "VALA_TUBHUV_Antagonist_CellCount", + "assayComponentDesc": "VALA_TUBHUV_Antagonist_CellCount is the one of two assay components measured from the VALA_TUBHUV_Antagonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 861, + "assayName": "VALA_TUBHUV_Antagonist", + "assayDesc": "VALA_TUBHUV_Antagonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3022, + "assayComponentEndpointName": "VALA_TUBHUV_Antagonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Antagonist_TubuleLength was analyzed at the endpoint, VALA_TUBHUV_Antagonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2808, + "assayComponentName": "VALA_TUBHUV_Antagonist_TubuleLength", + "assayComponentDesc": "VALA_TUBHUV_Antagonist_TubuleLength is the one of two assay components measured from the VALA_TUBHUV_Antagonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBHUV_Antagonist assay was designed to detect chemical suppression of tubulogenesis, i.e. antagonism.", + "assayComponentTargetDesc": "Vein growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on vein formation in complete medium, which contains growth factors that support vein endothelial cell proliferation. Tube formation antagonists will decrease vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 861, + "assayName": "VALA_TUBHUV_Antagonist", + "assayDesc": "VALA_TUBHUV_Antagonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3023, + "assayComponentEndpointName": "VALA_TUBIPS_Agonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Agonist_CellCount was analyzed at the endpoint, VALA_TUBIPS_Agonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2809, + "assayComponentName": "VALA_TUBIPS_Agonist_CellCount", + "assayComponentDesc": "VALA_TUBIPS_Agonist_CellCount is the one of two assay components measured from the VALA_TUBIPS_Agonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 862, + "assayName": "VALA_TUBIPS_Agonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3024, + "assayComponentEndpointName": "VALA_TUBIPS_Agonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Agonist_TubuleLength was analyzed at the endpoint, VALA_TUBIPS_Agonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2810, + "assayComponentName": "VALA_TUBIPS_Agonist_TubuleLength", + "assayComponentDesc": "VALA_TUBIPS_Agonist_TubuleLength is the one of two assay components measured from the VALA_TUBIPS_Agonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBIPS1 assay was designed to detect chemical activation of tubulogenesis, i.e. agonism.", + "assayComponentTargetDesc": "Blood vessel growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on blood vessel formation in basal medium, which lacks growth factors that support vessel growth. Tube formation agonists will increase vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 862, + "assayName": "VALA_TUBIPS_Agonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3025, + "assayComponentEndpointName": "VALA_TUBIPS_Antagonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Antagonist_CellCount was analyzed at the endpoint, VALA_TUBIPS_Antagonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2811, + "assayComponentName": "VALA_TUBIPS_Antagonist_CellCount", + "assayComponentDesc": "VALA_TUBIPS_Antagonist_CellCount is the one of two assay components measured from the VALA_TUBIPS_Antagonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 863, + "assayName": "VALA_TUBIPS_Antagonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3026, + "assayComponentEndpointName": "VALA_TUBIPS_Antagonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Antagonist_TubuleLength was analyzed at the endpoint, VALA_TUBIPS_Antagonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2812, + "assayComponentName": "VALA_TUBIPS_Antagonist_TubuleLength", + "assayComponentDesc": "VALA_TUBIPS_Antagonist_TubuleLength is the one of two assay components measured from the VALA_TUBIPS_Antagonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBIPS_Antagonist assay was designed to detect chemical suppression of tubulogenesis, i.e. antagonism.", + "assayComponentTargetDesc": "Blood vessel growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on blood vessel formation in complete medium, which contains growth factors that support vascular endothelial cell proliferation. Tube formation antagonists will decrease vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 863, + "assayName": "VALA_TUBIPS_Antagonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3027, + "assayComponentEndpointName": "VALA_MIGHUV1_ScratchOnly_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV1_ScratchOnly_CellCount was analyzed at the endpoint, VALA_MIGHUV1_ScratchOnly_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "BIO-acetoxime", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2813, + "assayComponentName": "VALA_MIGHUV1_ScratchOnly_CellCount", + "assayComponentDesc": "VALA_MIGHUV1_ScratchOnly_CellCount is the one of two assay components measured from the VALA_MIGHUV1_ScratchOnly assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 864, + "assayName": "VALA_MIGHUV1_ScratchOnly", + "assayDesc": "VALA_MIGHUV1_ScratchOnly is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3028, + "assayComponentEndpointName": "VALA_MIGHUV1_ScratchOnly_WoundArea", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV1_ScratchOnly_WoundArea was analyzed at the endpoint, VALA_MIGHUV1_ScratchOnly_WoundArea, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2814, + "assayComponentName": "VALA_MIGHUV1_ScratchOnly_WoundArea", + "assayComponentDesc": "VALA_MIGHUV1_ScratchOnly_WoundArea is the one of two assay components measured from the VALA_MIGHUV1_ScratchOnly assay. It is designed to make measurements of endothelial migration, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in basal medium, which lacks growth factors that support capillary growth. Tube formation agonists will increase capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "endothelial migration in wound recovery", + "aid": 864, + "assayName": "VALA_MIGHUV1_ScratchOnly", + "assayDesc": "VALA_MIGHUV1_ScratchOnly is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3029, + "assayComponentEndpointName": "VALA_MIGHUV2_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_CellCount was analyzed at the endpoint, VALA_MIGHUV2_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "BIO-acetoxime", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2815, + "assayComponentName": "VALA_MIGHUV2_CellCount", + "assayComponentDesc": "VALA_MIGHUV2_CellCount is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3030, + "assayComponentEndpointName": "VALA_MIGHUV2_Bcatenin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_BCatenin was analyzed at the endpoint, VALA_MIGHUV2_BCatenin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2816, + "assayComponentName": "VALA_MIGHUV2_Bcatenin", + "assayComponentDesc": "VALA_MIGHUV2_Bcatenin is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of nuclear translocation of CTNB, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in complete medium, which contains growth factors that support capillary endothelial cell proliferation. Tube formation antagonists will decrease capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CTNB", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear translocation of CTNB", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3031, + "assayComponentEndpointName": "VALA_MIGHUV2_WoundArea", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_WoundArea was analyzed at the endpoint, VALA_MIGHUV2_WoundArea, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2817, + "assayComponentName": "VALA_MIGHUV2_WoundArea", + "assayComponentDesc": "VALA_MIGHUV2_WoundArea is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of endothelial migration, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in complete medium, which contains growth factors that support capillary endothelial cell proliferation. Tube formation antagonists will decrease capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "endothelial migration in wound recovery", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3032, + "assayComponentEndpointName": "CCTE_GLTED_hIYD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Nitro-L-tyrosine (0.05 M NaOH for model inhibitor (MNT))", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "dehalogenase", + "intendedTargetFamilySub": "iodotyrosine deiodinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2818, + "assayComponentName": "CCTE_GLTED_hIYD", + "assayComponentDesc": "CCTE_GLTED_hIYD is the assay component measured from the CCTE_GLTED_hIYD assay. It measures substrate involved in regulation of catalytic activity using spectrophotometry. The assay measures the deiodination activity of human IYD on the substrate monoiodotyrosine (MIT). After 3h incubation of substrate, enzyme, and test chemical, the components are applied to a 96-well Dowex column. Free iodide is not retained by the column and is separated from interfering assay components. The free iodide is measured by the Sandell-Kolthoff reaction in which the rate of reduction of cerium (Ce+4 to Ce+3) by arsenic (As+3 to As+5) is increased by the presence of iodide. This is observed as the loss of yellow color in the reaction and the quantified by the change in absorbance at 420 nm. The change in reaction rate is proportional to the amount of iodide present.", + "assayComponentTargetDesc": "The iodide recycling enzyme, iodotyrosine deiodinase (IYD), is one conserved putative molecular target that plays an essential role in maintaining adequate levels of free iodide in the thyroid gland for hormone synthesis.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Monoiodotyrosine (MIT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 866, + "assayName": "CCTE_GLTED_hIYD", + "assayDesc": "CCTE_GLTED_hIYD is a cell-free, single-readout assay that uses human iodotyrosine deiodinase (hIYD) enzyme produced with baculovirus-insect cell system. The assay is based on iodide release measured by the Sandell-Kolthoff method and is run in 96-well plate format with assay plates run in triplicate (n=3) with measurements taken at 3 hours after chemical dosing. Platewise-normalization was used based on positive control (3-Nitro-L-tyrosine, MNT) and negative/solvent controls (DMSO, NaOH).", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "baculovirus-insect cells", + "cellShortName": "SF-21", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.65, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 24338, + "geneName": "iodotyrosine deiodinase", + "description": null, + "geneSymbol": "IYD", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 389434, + "officialSymbol": "IYD", + "officialFullName": "iodotyrosine deiodinase", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105073", + "url": "https://pubmed.ncbi.nlm.nih.gov/33352258/", + "pmid": 33352258, + "title": "In vitro screening for chemical inhibition of the iodide recycling enzyme, iodotyrosine deiodinase", + "author": "Olker JH, Korte JJ, Denny JS, Haselman JT, Hartig PC, Cardon MC, Hornung MW, Degitz SJ", + "citation": "Olker JH, Korte JJ, Denny JS, Haselman JT, Hartig PC, Cardon MC, Hornung MW, Degitz SJ. In vitro screening for chemical inhibition of the iodide recycling enzyme, iodotyrosine deiodinase. Toxicol In Vitro. 2021 Mar;71:105073. doi: 10.1016/j.tiv.2020.105073. Epub 2020 Dec 29. PMID: 33352258; PMCID: PMC8130633.", + "otherId": "0", + "citationId": 239, + "otherSource": "" + } + }, + { + "aeid": 3067, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. This assay endpoint is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GlutaNeurons. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2836, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GlutaNeurons. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3068, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2837, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3069, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2838, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3070, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2839, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3072, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_autofluor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_autofluor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_autofluor, was analyzed with bidirectional fitting relative to median test wells for the baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand autofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Tracer Fluorogenic Probe", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2841, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_autofluor", + "assayComponentDesc": "CCTE_Deisenroth_5AR_NBTE_autofluor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of a compound's autofluorescence, as detected by fluorescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "autofluorescence probe", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3074, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_donor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_donor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_donor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in the donor luminescence as related to 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact luminescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2842, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_donor", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_donor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of donor luminescence, as detected by bioluminescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "The technology is based on the concept of Bioluminescence Resonance Energy Transfer BRET. Target proteins fused to NanoLuc luciferase generate luminescence signal in the presence of furimazine substrate. BRET occurs when custom fluorescent tracers, bound to the target protein, resonate luminescent energy from the luciferase enzyme to the tracer molecule to yield a lower-energy fluorescent emission signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "donor luminescence emission", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "luciferase substrate: furimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-specified", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3076, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_acceptor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_acceptor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_acceptor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in the acceptor fluorescence as related to 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2843, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_acceptor", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_acceptor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of resonant fluorescence generated by bioluminescent energy transfer to a target fluorophore, as detected by fluorescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "The technology is based on the concept of Bioluminescence Resonance Energy Transfer BRET. Target proteins fused to NanoLuc luciferase generate luminescence signal in the presence of furimazine substrate. BRET occurs when custom fluorescent tracers, bound to the target protein, resonate luminescent energy from the luciferase enzyme to the tracer molecule to yield a lower-energy fluorescent emission signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "acceptor fluorescence emission", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tracer fluorogenic probe: MC547-NanoBRET 590 SE", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-specified", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3078, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_ratio was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_ratio, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is 5-alpha reductase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "5-alpha reductase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2844, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_ratio", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_ratio is one of four assay components calculated from the CCTE_Deisenroth_5AR NBTE assay. It is designed to measure the ratio of target acceptor fluorophore resonance to donor bioluminescent signals.", + "assayComponentTargetDesc": "The ratio of acceptor signal fluorescence to donor signal luminescence yields a normalized quantitative value in milliBRET Units mBU that can be used to evaluate direct disruption of small molecule target protein interactions of 5 alpha reductase.", + "parameterReadoutType": "single", + "assayDesignType": "ratiometric", + "assayDesignTypeSub": "ratio", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Bioluminescence Resonance Energy Transfer", + "detectionTechnologyTypeSub": "Bioluminescence Resonance Energy Transfer Ratio", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "ratio", + "keyAssayReagent": "acceptor/donor", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3086, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_Asystole", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "cessation of beating", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2848, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_Asystole", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_Chronotopy is a phenotype derived from the peak.freq.avg parameter and uses an EC95 as its POD (95% decrease in beat rate, compared to controls). Peak.Freq.Avg measures the average peak frequency, in beats per second, uisng Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. There is no preprocessing performed on the data used to model this phenotype.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in peak frequency, which can be an indication of the cessation of beating", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "beating", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average peak frequency, in beats per second", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 3087, + "assayComponentEndpointName": "IUF_NPC1_cytotoxicity_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1_cytotoxicity_72hr component was analyzed at the endpoint IUF_NPC1_cytotoxicity_72hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2849, + "assayComponentName": "IUF_NPC1_cytotoxicity_72hr", + "assayComponentDesc": "IUF_NPC1_cytotoxicity_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cytotoxicity at 72 hrs due to loss of membrane integrity. LDH measurements are performed from medium supernatants of each well and are based on the reduction of resazurin to resorufin measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 3088, + "assayComponentEndpointName": "CCTE_GLTED_hTBG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTBG was analyzed at the assay endpoint CCTE_GLTED_hTBG in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from thyroxine-binding globulin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'hormone carrier protein'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3,5,3,5-tetraiodothyronine (T4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2850, + "assayComponentName": "CCTE_GLTED_hTBG", + "assayComponentDesc": "CCTE_GLTED_hTBG is the assay component measured from the CCTE_GLTED_hTBG assay. It is designed to make measurements of fluorescent polarization, using a form of binding reporter, as detected with Fluorescence signals by Fluorescence technology.", + "assayComponentTargetDesc": "Thyroxine-binding globulin (TBG) is one the major transport proteins responsible for binding to and transporting thyroid hormones to the necessary tissues.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ANSA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 870, + "assayName": "CCTE_GLTED_hTBG", + "assayDesc": "CCTE_GLTED_hTBG is a cell-free, single-readout assay designed to test the chemicals' ability to displace T4 from the human thyroxine-binding globulin (TBG) protein. TBG is incubated in presence of test chemical for 2 hours during which disrupting chemicals displace ANSA from the TBG protein. Results read fluorescence at 380 excitation and 475 emission.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3089, + "assayComponentEndpointName": "CCTE_GLTED_hTTR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTTR was analyzed at the assay endpoint CCTE_GLTED_hTTR in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from transthyretin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'hormone carrier protein'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3,5,3,5-tetraiodothyronine (T4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2851, + "assayComponentName": "CCTE_GLTED_hTTR", + "assayComponentDesc": "CCTE_GLTED_hTTR is the assay component measured from the CCTE_GLTED_hTTR assay. It is designed to make measurements of fluorescent polarization, using a form of binding reporter, as detected with Fluorescence signals by Fluorescence technology.", + "assayComponentTargetDesc": "Transthyretin (TTR) is one the major transport proteins responsible for binding to and transporting thyroid hormones to the necessary tissues.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ANSA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 871, + "assayName": "CCTE_GLTED_hTTR", + "assayDesc": "CCTE_GLTED_hTTR is a cell-free, single-readout assay designed to test the chemicals' ability to displace T4 from the human transthyretin (TTR) protein. TTR is incubated in presence of test chemical for 2 hours during which disrupting chemicals displace ANSA from the TTR protein. Results read fluorescence at 380 excitation and 475 emission.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3090, + "assayComponentEndpointName": "CCTE_GLTED_hTPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTPO was analyzed at the assay endpoint CCTE_GLTED_hTPO in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter (the Amplex UltraRed assay), loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'peroxidase'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methimizole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2852, + "assayComponentName": "CCTE_GLTED_hTPO", + "assayComponentDesc": "CCTE_GLTED_hTPO is the assay component measured from the CCTE_GLTED_hTPO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Fluorescence technology.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Amplex UltraRed", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 872, + "assayName": "CCTE_GLTED_hTPO", + "assayDesc": "CCTE_GLTED_hTPO is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human thyroperoxidase (TPO) protein. Uninhibited enzyme converts Amplex UltraRed to a fluorescent product. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.                                               ", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3091, + "assayComponentEndpointName": "CCTE_GLTED_xDIO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_xDIO3 was analyzed at the assay endpoint CCTE_GLTED_xDIO3 in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand deiodinase Type 3 activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 3", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2853, + "assayComponentName": "CCTE_GLTED_xDIO3", + "assayComponentDesc": "CCTE_GLTED_xDIO3 is the assay component measured from the CCTE_GLTED_xDIO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO3 inactivates both T4 and T3 by removing an inner ring iodine, producing reverse T3 (rT3) and diiodotyrosine (T2), respectively.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3',5-triiodothyronine (T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 873, + "assayName": "CCTE_GLTED_xDIO3", + "assayDesc": "CCTE_GLTED_xDIO3 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward Xenopus (frog) iodothyronine Deiodinase Type 3 (DIO3) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 8355, + "organism": "xenopus (frog)", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3092, + "assayComponentEndpointName": "CCTE_GLTED_xIYD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_xIYD was analyzed at the assay endpoint CCTE_GLTED_xIYD in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Nitro-L-tyrosine (MNT)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "dehalogenase", + "intendedTargetFamilySub": "iodotyrosine deiodinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2854, + "assayComponentName": "CCTE_GLTED_xIYD", + "assayComponentDesc": "CCTE_GLTED_xIYD is the assay component measured from the CCTE_GLTED_xIYD assay. It measures substrate involved in regulation of catalytic activity using spectrophotometry. The assay measures the deiodination activity of Xenopus (frog) IYD on the substrate monoiodotyrosine (MIT). After 3h incubation of substrate, enzyme, and test chemical, the components are applied to a 96-well Dowex column. Free iodide is not retained by the column and is separated from interfering assay components. The free iodide is measured by the Sandell-Kolthoff reaction in which the rate of reduction of cerium (Ce+4 to Ce+3) by arsenic (As+3 to As+5) is increased by the presence of iodide. This is observed as the loss of yellow color in the reaction and the quantified by the change in absorbance at 420 nm. The change in reaction rate is proportional to the amount of iodide present.", + "assayComponentTargetDesc": "The iodide recycling enzyme, iodotyrosine deiodinase (IYD), is one conserved putative molecular target that plays an essential role in maintaining adequate levels of free iodide in the thyroid gland for hormone synthesis.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-iodotyrosine (MIT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 874, + "assayName": "CCTE_GLTED_xIYD", + "assayDesc": "CCTE_GLTED_xIYD is a cell-free, single-readout assay that uses Xenopus (frog) iodotyrosine deiodinase (xIYD) enzyme from liver microsomes. Assay is based on iodide release measured by the Sandell-Kolthoff method and is run in 96-well plate format with assay plates run in triplicate (n=3) with measurements taken at 3 hours after chemical dosing. Platewise-normalization was used based on positive control (3-Nitro-L-tyrosine, MNT) and negative/solvent controls (DMSO, NaOH).", + "timepointHr": 3.0, + "organismId": 8355, + "organism": "xenopus (frog)", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "frog liver", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3094, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 was analyzed into 2 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of endoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is SRY-related HMG-box.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB431542", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "SRY-related HMG-box", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2855, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay and it measures an increase in the percentage of cells in an endoderm state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Sox17+ cells are determined by calculating the number of Sox17+ cells divided by cell count. A cell is Sox17+ if the cell Sox17 mean intensity is 5x BMAD above the pluripotent control median cell Sox17 mean. The assay endpoints were analyzed with bidirectional fitting relative to 0.2% DMSO control in the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 was designed to measure changes in cellular Sox17 expression. Changes are indicative of changes in Sox17 gene expression due to perturbations in endoderm differentiation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3095, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of pluripotency or ectoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is SRY-related HMG-box.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "SRY-related HMG-box", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2856, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in the percentage of cells in an ectodermal or pluripotent state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Sox2+ cells are determined by calculating the number of Sox2+ cells divided by cell count. A cell is Sox2+ if the cell Sox2 mean intensity is 5x BMAD above the directed endoderm control median cell Sox2 mean. The assay endpoint was analyzed with bidirectional fitting with the 0.2% DMSO control median percent Sox2 in the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay subtracted.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 was designed to measure changes in cellular Sox2 expression. Changes are indicative of changes in Sox2 protein expression due to perturbations in endoderm differentiation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3096, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of mesoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is T-box protein.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "T-box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2857, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in the percentage of cells in an endoderm state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Bra+ cells are determined by calculating the number of Bra+ cells divided by cell count. A cell is Bra+ if the cell Bra mean intensity is 5x BMAD above the pluripotent control median cell Bra mean. The assay endpoint was analyzed with bidirectional fitting with the 0.2% DMSO control median percent Bra in the DEVTOX_RUES2-GLR assay subtracted.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra was designed to measure changes in cellular Bra expression. Changes are indicative of changes in Bra gene expression due to perturbations in endoderm differentiation", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3098, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount was analyzed into 2 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline activity. Using nuclei counting, gain or loss-of-signal activity can be used to understand changes in cell viability. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2858, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in cell count. It is designed to make measurements of nuclei count, a form of cell viability, as detected with optical fluorescence microscopy by Perkin Elmer Harmony nuclei detection algorithm. The assay endpoints were analyzed with bidirectional fitting relative to 0.2% DMSO control in the DEVTOX_RUES2-GLR assay.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount was designed to measure changes in the number cells. Changes are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "Perkin Elmer Harmony nuclei detection algorithm ", + "keyAssayReagentType": "stain", + "keyAssayReagent": "fluorescent signal", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3099, + "assayComponentEndpointName": "ATG_frGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2860, + "assayComponentName": "ATG_frGR_EcoTox2", + "assayComponentDesc": "ATG_frGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frGR, also known as african clawed frog (Xenopus laevis) glucocorticoid receptor. [NCBI Reference Sequence: NP_001081531.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3101, + "assayComponentEndpointName": "ATG_rtGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2861, + "assayComponentName": "ATG_rtGR_EcoTox2", + "assayComponentDesc": "ATG_rtGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtGR, also known as rainbow trout (Oncorhynchus mykiss) glucocorticoid receptor. [NCBI Reference Sequence: NP_001118202.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3103, + "assayComponentEndpointName": "ATG_jmGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2862, + "assayComponentName": "ATG_jmGR_EcoTox2", + "assayComponentDesc": "ATG_jmGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element mGR, also known as japanese medaka (Oryzias latipes) glucocorticoid receptor. [NCBI Reference Sequence: NNP_001292330.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3105, + "assayComponentEndpointName": "ATG_zfGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2863, + "assayComponentName": "ATG_zfGR_EcoTox2", + "assayComponentDesc": "ATG_zfGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfGR, also known as zebrafish (Danio rerio) glucocorticoid receptor. [NCBI Reference Sequence: NP_001018547.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3107, + "assayComponentEndpointName": "ATG_hPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2864, + "assayComponentName": "ATG_hPPARa_EcoTox2", + "assayComponentDesc": "ATG_hPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hPPARg, which is responsive to the human peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_005027.2]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3109, + "assayComponentEndpointName": "ATG_frPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2865, + "assayComponentName": "ATG_frPPARa_EcoTox2", + "assayComponentDesc": "ATG_frPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frPPARg, which is responsive to the african clawed frog (Xenopus laevis) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001083282.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3111, + "assayComponentEndpointName": "ATG_rtPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2866, + "assayComponentName": "ATG_rtPPARa_EcoTox2", + "assayComponentDesc": "ATG_rtPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtPPARg, which is responsive to the rainbow trout (Oncorhynchus mykiss) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: XP_021473593.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3113, + "assayComponentEndpointName": "ATG_jmPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2867, + "assayComponentName": "ATG_jmPPARa_EcoTox2", + "assayComponentDesc": "ATG_jmPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmPPARg, which is responsive to the japanese medaka (Oryzias latipes) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001158347.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3115, + "assayComponentEndpointName": "ATG_zfPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2868, + "assayComponentName": "ATG_zfPPARa_EcoTox2", + "assayComponentDesc": "ATG_zfPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfPPARg, which is responsive to the zebrafish (Danio rerio) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001154805.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3117, + "assayComponentEndpointName": "ATG_hPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2869, + "assayComponentName": "ATG_hPPARg_EcoTox2", + "assayComponentDesc": "ATG_hPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hPPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001341595.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3119, + "assayComponentEndpointName": "ATG_frPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2870, + "assayComponentName": "ATG_frPPARg_EcoTox2", + "assayComponentDesc": "ATG_frPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frPPARg, which is responsive to the african clawed frog (Xenopus laevis) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001081312.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3121, + "assayComponentEndpointName": "ATG_rtPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2871, + "assayComponentName": "ATG_rtPPARg_EcoTox2", + "assayComponentDesc": "ATG_rtPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtPPARg, which is responsive to the rainbow trout (Oncorhynchus mykiss) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: XP_021470054.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3123, + "assayComponentEndpointName": "ATG_jmPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2872, + "assayComponentName": "ATG_jmPPARg_EcoTox2", + "assayComponentDesc": "ATG_jmPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmPPARg, which is responsive to the japanese medaka (Oryzias latipes) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001158348.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1945, + "assayComponentEndpointName": "ATG_M_19_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_19_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1872, + "assayComponentName": "ATG_M_19_XSP1", + "assayComponentDesc": "ATG_M_19_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1947, + "assayComponentEndpointName": "ATG_M_32_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_32_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1873, + "assayComponentName": "ATG_M_32_XSP1", + "assayComponentDesc": "ATG_M_32_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1949, + "assayComponentEndpointName": "ATG_M_61_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_61_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1874, + "assayComponentName": "ATG_M_61_XSP1", + "assayComponentDesc": "ATG_M_61_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1951, + "assayComponentEndpointName": "ATG_hPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1875, + "assayComponentName": "ATG_hPPARg_XSP1", + "assayComponentDesc": "ATG_hPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [GeneSymbol:PPARG | GeneID: 5468| Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1953, + "assayComponentEndpointName": "ATG_mPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1876, + "assayComponentName": "ATG_mPPARg_XSP1", + "assayComponentDesc": "ATG_mPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the mouse peroxisome proliferator activated receptor gamma. [GeneSymbol:Pparg | GeneID: 19016| Uniprot_SwissProt_Accession:P37238].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-mPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1478, + "geneName": "peroxisome proliferator activated receptor gamma", + "description": "peroxisome proliferator activated receptor gamma [ Mus musculus(house mouse) ]", + "geneSymbol": "Pparg", + "organismId": 2, + "trackStatus": null, + "entrezGeneId": 19016, + "officialSymbol": "Pparg", + "officialFullName": "peroxisome proliferator activated receptor gamma", + "uniprotAccessionNumber": "P37238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1955, + "assayComponentEndpointName": "ATG_zfPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1877, + "assayComponentName": "ATG_zfPPARg_XSP1", + "assayComponentDesc": "ATG_zfPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1471, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": "peroxisome proliferator-activated receptor gamma [ Danio rerio(zebrafish) ]", + "geneSymbol": "pparg", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 557037, + "officialSymbol": "pparg", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "A6XMH6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1957, + "assayComponentEndpointName": "ATG_mPXR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPXR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1878, + "assayComponentName": "ATG_mPXR_XSP1", + "assayComponentDesc": "ATG_mPXR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PXR, which is responsive to the mouse pregnane X receptor. [GeneSymbol: NR1IA | GeneID: 8856| Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NA", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1959, + "assayComponentEndpointName": "ATG_frTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1879, + "assayComponentName": "ATG_frTRa_XSP1", + "assayComponentDesc": "ATG_frTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the frog thyroid hormone receptor, alpha L homeolog. [GeneSymbol: thra.L | GeneID: 397942| Uniprot_SwissProt_Accession: P15204].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1482, + "geneName": "thyroid hormone receptor, alpha L homeolog", + "description": "thyroid hormone receptor, alpha L homeolog [ Xenopus laevis(African clawed frog) ]", + "geneSymbol": "thra.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 397942, + "officialSymbol": "thra.L", + "officialFullName": "thyroid hormone receptor, alpha L homeolog", + "uniprotAccessionNumber": "P15204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1961, + "assayComponentEndpointName": "ATG_hTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1880, + "assayComponentName": "ATG_hTRa_XSP1", + "assayComponentDesc": "ATG_hTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 7067| Uniprot_SwissProt_Accession: P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1963, + "assayComponentEndpointName": "ATG_trTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1881, + "assayComponentName": "ATG_trTRa_XSP1", + "assayComponentDesc": "ATG_trTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the turtle thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 101949057| Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1466, + "geneName": "thyroid hormone receptor, alpha", + "description": "thyroid hormone receptor, alpha [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "THRA", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101949057, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1965, + "assayComponentEndpointName": "ATG_zfTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1882, + "assayComponentName": "ATG_zfTRa_XSP1", + "assayComponentDesc": "ATG_zfTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, alpha a. [GeneSymbol: thraa | GeneID: 30670| Uniprot_SwissProt_Accession: Q98867].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1472, + "geneName": "thyroid hormone receptor alpha a", + "description": "thyroid hormone receptor alpha a [ Danio rerio (zebrafish) ]", + "geneSymbol": "thraa", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30670, + "officialSymbol": "thraa", + "officialFullName": "thyroid hormone receptor alpha a", + "uniprotAccessionNumber": "Q98867" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1967, + "assayComponentEndpointName": "ATG_hTRb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1883, + "assayComponentName": "ATG_hTRb_XSP1", + "assayComponentDesc": "ATG_hTRb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, beta. [GeneSymbol: THRB | GeneID: 7068| Uniprot_SwissProt_Accession: P10828].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1969, + "assayComponentEndpointName": "ATG_zfTRb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1884, + "assayComponentName": "ATG_zfTRb_XSP1", + "assayComponentDesc": "ATG_zfTRb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, beta. [GeneSymbol: thrb | GeneID: 30607| Uniprot_SwissProt_Accession: Q9PVE4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1473, + "geneName": "thyroid hormone receptor beta", + "description": "thyroid hormone receptor beta [ Danio rerio (zebrafish) ]", + "geneSymbol": "thrb", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30607, + "officialSymbol": "thrb", + "officialFullName": "thyroid hormone receptor beta", + "uniprotAccessionNumber": "Q9PVE4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1971, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_XTT_Cytotoxicity_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1885, + "assayComponentName": "ATG_XTT_Cytotoxicity_XSP1", + "assayComponentDesc": "ATG_XTT_Cytotoxicity_XSP1 is an assay component measured from the ATG_XSP1_XTT_Cytotoxicity_multi-species assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 570, + "assayName": "ATG_XSP1_XTT_Cytotoxicity_multi-species", + "assayDesc": "ATG_XSP1_XTT_Cytotoxicity_multi-species is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1973, + "assayComponentEndpointName": "ATG_M_06_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_06_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1886, + "assayComponentName": "ATG_M_06_XSP2", + "assayComponentDesc": "ATG_M_06_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1014, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45G", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45G was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45G, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "mutagenicity response", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 648, + "assayComponentName": "LTEA_HepaRG_GADD45G", + "assayComponentDesc": "LTEA_HepaRG_GADD45G is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 369, + "geneName": "growth arrest and DNA-damage-inducible, gamma", + "description": null, + "geneSymbol": "GADD45G", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10912, + "officialSymbol": "GADD45G", + "officialFullName": "growth arrest and DNA-damage-inducible, gamma", + "uniprotAccessionNumber": "O95257" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1016, + "assayComponentEndpointName": "LTEA_HepaRG_GCLC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GCLC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ligase", + "intendedTargetFamilySub": "C-N ligase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 649, + "assayComponentName": "LTEA_HepaRG_GCLC", + "assayComponentDesc": "LTEA_HepaRG_GCLC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 142, + "geneName": "glutamate-cysteine ligase, catalytic subunit", + "description": null, + "geneSymbol": "GCLC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2729, + "officialSymbol": "GCLC", + "officialFullName": "glutamate-cysteine ligase, catalytic subunit", + "uniprotAccessionNumber": "P48506" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1018, + "assayComponentEndpointName": "LTEA_HepaRG_GCLM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GCLM was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLM, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ligase", + "intendedTargetFamilySub": "C-N ligase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 650, + "assayComponentName": "LTEA_HepaRG_GCLM", + "assayComponentDesc": "LTEA_HepaRG_GCLM is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 143, + "geneName": "glutamate-cysteine ligase, modifier subunit", + "description": null, + "geneSymbol": "GCLM", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2730, + "officialSymbol": "GCLM", + "officialFullName": "glutamate-cysteine ligase, modifier subunit", + "uniprotAccessionNumber": "P48507" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1026, + "assayComponentEndpointName": "LTEA_HepaRG_GSTA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GSTA2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTA2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 654, + "assayComponentName": "LTEA_HepaRG_GSTA2", + "assayComponentDesc": "LTEA_HepaRG_GSTA2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1028, + "assayComponentEndpointName": "LTEA_HepaRG_GSTM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GSTM3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTM3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 655, + "assayComponentName": "LTEA_HepaRG_GSTM3", + "assayComponentDesc": "LTEA_HepaRG_GSTM3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 148, + "geneName": "glutathione S-transferase mu 3 (brain)", + "description": null, + "geneSymbol": "GSTM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2947, + "officialSymbol": "GSTM3", + "officialFullName": "glutathione S-transferase mu 3 (brain)", + "uniprotAccessionNumber": "P21266" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1030, + "assayComponentEndpointName": "LTEA_HepaRG_HGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is hepatocyte growth factor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "hepatocyte growth factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 656, + "assayComponentName": "LTEA_HepaRG_HGF", + "assayComponentDesc": "LTEA_HepaRG_HGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 151, + "geneName": "hepatocyte growth factor (hepapoietin A; scatter factor)", + "description": null, + "geneSymbol": "HGF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3082, + "officialSymbol": "HGF", + "officialFullName": "hepatocyte growth factor (hepapoietin A; scatter factor)", + "uniprotAccessionNumber": "P14210" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1032, + "assayComponentEndpointName": "LTEA_HepaRG_HIF1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HIF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HIF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 657, + "assayComponentName": "LTEA_HepaRG_HIF1A", + "assayComponentDesc": "LTEA_HepaRG_HIF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1034, + "assayComponentEndpointName": "LTEA_HepaRG_HMGCS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HMGCS2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HMGCS2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 658, + "assayComponentName": "LTEA_HepaRG_HMGCS2", + "assayComponentDesc": "LTEA_HepaRG_HMGCS2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1036, + "assayComponentEndpointName": "LTEA_HepaRG_HSPA1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HSPA1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HSPA1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 659, + "assayComponentName": "LTEA_HepaRG_HSPA1A", + "assayComponentDesc": "LTEA_HepaRG_HSPA1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 162, + "geneName": "heat shock 70kDa protein 1A", + "description": null, + "geneSymbol": "HSPA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3303, + "officialSymbol": "HSPA1A", + "officialFullName": "heat shock 70kDa protein 1A", + "uniprotAccessionNumber": "P08107" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1038, + "assayComponentEndpointName": "LTEA_HepaRG_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ICAM1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 660, + "assayComponentName": "LTEA_HepaRG_ICAM1", + "assayComponentDesc": "LTEA_HepaRG_ICAM1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1040, + "assayComponentEndpointName": "LTEA_HepaRG_IGF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IGF1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGF1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is insulin-like.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "insulin-like", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 661, + "assayComponentName": "LTEA_HepaRG_IGF1", + "assayComponentDesc": "LTEA_HepaRG_IGF1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 171, + "geneName": "insulin-like growth factor 1 (somatomedin C)", + "description": null, + "geneSymbol": "IGF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3479, + "officialSymbol": "IGF1", + "officialFullName": "insulin-like growth factor 1 (somatomedin C)", + "uniprotAccessionNumber": "P05019" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1042, + "assayComponentEndpointName": "LTEA_HepaRG_IGFBP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IGFBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGFBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is hormone carrier protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 662, + "assayComponentName": "LTEA_HepaRG_IGFBP1", + "assayComponentDesc": "LTEA_HepaRG_IGFBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 173, + "geneName": "insulin-like growth factor binding protein 1", + "description": null, + "geneSymbol": "IGFBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3484, + "officialSymbol": "IGFBP1", + "officialFullName": "insulin-like growth factor binding protein 1", + "uniprotAccessionNumber": "P08833" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1044, + "assayComponentEndpointName": "LTEA_HepaRG_IL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IL6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 663, + "assayComponentName": "LTEA_HepaRG_IL6", + "assayComponentDesc": "LTEA_HepaRG_IL6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1046, + "assayComponentEndpointName": "LTEA_HepaRG_IL6R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IL6R was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6R, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is JAK-STAT cytokine receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "JAK-STAT cytokine receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 664, + "assayComponentName": "LTEA_HepaRG_IL6R", + "assayComponentDesc": "LTEA_HepaRG_IL6R is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 176, + "geneName": "interleukin 6 receptor", + "description": null, + "geneSymbol": "IL6R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3570, + "officialSymbol": "IL6R", + "officialFullName": "interleukin 6 receptor", + "uniprotAccessionNumber": "P08887" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1048, + "assayComponentEndpointName": "LTEA_HepaRG_JUN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_JUN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_JUN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 665, + "assayComponentName": "LTEA_HepaRG_JUN", + "assayComponentDesc": "LTEA_HepaRG_JUN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1050, + "assayComponentEndpointName": "LTEA_HepaRG_KCNK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KCNK1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KCNK1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 666, + "assayComponentName": "LTEA_HepaRG_KCNK1", + "assayComponentDesc": "LTEA_HepaRG_KCNK1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Hyperplasia.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 185, + "geneName": "potassium channel, subfamily K, member 1", + "description": null, + "geneSymbol": "KCNK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3775, + "officialSymbol": "KCNK1", + "officialFullName": "potassium channel, subfamily K, member 1", + "uniprotAccessionNumber": "O00180" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1052, + "assayComponentEndpointName": "LTEA_HepaRG_KRT19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KRT19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KRT19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the filaments intended target family, where the subfamily is keratin.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "filaments", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 667, + "assayComponentName": "LTEA_HepaRG_KRT19", + "assayComponentDesc": "LTEA_HepaRG_KRT19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 187, + "geneName": "keratin 19", + "description": null, + "geneSymbol": "KRT19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3880, + "officialSymbol": "KRT19", + "officialFullName": "keratin 19", + "uniprotAccessionNumber": "P08727" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1054, + "assayComponentEndpointName": "LTEA_HepaRG_LIPC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LIPC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LIPC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "lipase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 668, + "assayComponentName": "LTEA_HepaRG_LIPC", + "assayComponentDesc": "LTEA_HepaRG_LIPC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 192, + "geneName": "lipase, hepatic", + "description": null, + "geneSymbol": "LIPC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3990, + "officialSymbol": "LIPC", + "officialFullName": "lipase, hepatic", + "uniprotAccessionNumber": "P11150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1056, + "assayComponentEndpointName": "LTEA_HepaRG_LPL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LPL was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LPL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "lipase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 669, + "assayComponentName": "LTEA_HepaRG_LPL", + "assayComponentDesc": "LTEA_HepaRG_LPL is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 194, + "geneName": "lipoprotein lipase", + "description": null, + "geneSymbol": "LPL", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4023, + "officialSymbol": "LPL", + "officialFullName": "lipoprotein lipase", + "uniprotAccessionNumber": "P06858" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1058, + "assayComponentEndpointName": "LTEA_HepaRG_MIR122", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MIR122 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MIR122, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the microrna intended target family, where the subfamily is post-transcriptional regulation.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "miRNA", + "intendedTargetFamily": "microrna", + "intendedTargetFamilySub": "post-transcriptional regulation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 670, + "assayComponentName": "LTEA_HepaRG_MIR122", + "assayComponentDesc": "LTEA_HepaRG_MIR122 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of MicroRNA.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 457, + "geneName": "microRNA 122", + "description": null, + "geneSymbol": "MIR122", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 406906, + "officialSymbol": "MIR122", + "officialFullName": "microRNA 122", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1060, + "assayComponentEndpointName": "LTEA_HepaRG_MMP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 671, + "assayComponentName": "LTEA_HepaRG_MMP10", + "assayComponentDesc": "LTEA_HepaRG_MMP10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 208, + "geneName": "matrix metallopeptidase 10 (stromelysin 2)", + "description": null, + "geneSymbol": "MMP10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4319, + "officialSymbol": "MMP10", + "officialFullName": "matrix metallopeptidase 10 (stromelysin 2)", + "uniprotAccessionNumber": "P09238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1062, + "assayComponentEndpointName": "LTEA_HepaRG_MMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 672, + "assayComponentName": "LTEA_HepaRG_MMP3", + "assayComponentDesc": "LTEA_HepaRG_MMP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1064, + "assayComponentEndpointName": "LTEA_HepaRG_MYC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MYC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MYC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 673, + "assayComponentName": "LTEA_HepaRG_MYC", + "assayComponentDesc": "LTEA_HepaRG_MYC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 213, + "geneName": "v-myc avian myelocytomatosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4609, + "officialSymbol": "MYC", + "officialFullName": "v-myc avian myelocytomatosis viral oncogene homolog", + "uniprotAccessionNumber": "P01106" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1066, + "assayComponentEndpointName": "LTEA_HepaRG_NFE2L2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NFE2L2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFE2L2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 674, + "assayComponentName": "LTEA_HepaRG_NFE2L2", + "assayComponentDesc": "LTEA_HepaRG_NFE2L2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation/injury.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1068, + "assayComponentEndpointName": "LTEA_HepaRG_NFKB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NFKB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFKB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 675, + "assayComponentName": "LTEA_HepaRG_NFKB1", + "assayComponentDesc": "LTEA_HepaRG_NFKB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1070, + "assayComponentEndpointName": "LTEA_HepaRG_NQO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NQO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NQO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is quinone-acceptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "quinone-acceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 676, + "assayComponentName": "LTEA_HepaRG_NQO1", + "assayComponentDesc": "LTEA_HepaRG_NQO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with NQO1 include Tardive Dyskinesia and Childhood Leukemia. .", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 98, + "geneName": "NAD(P)H dehydrogenase, quinone 1", + "description": null, + "geneSymbol": "NQO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1728, + "officialSymbol": "NQO1", + "officialFullName": "NAD(P)H dehydrogenase, quinone 1", + "uniprotAccessionNumber": "P15559" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 3125, + "assayComponentEndpointName": "ATG_zfPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Triphenyl phosphate", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2873, + "assayComponentName": "ATG_zfPPARg_EcoTox2", + "assayComponentDesc": "ATG_zfPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish (Danio rerio) peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6 | NCBI Reference Sequence: NP_571542.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3127, + "assayComponentEndpointName": "ATG_hRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2874, + "assayComponentName": "ATG_hRXRb_EcoTox2", + "assayComponentDesc": "ATG_hRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hRXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702 |NCBI Reference Sequence: NP_068811.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3129, + "assayComponentEndpointName": "ATG_frRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2875, + "assayComponentName": "ATG_frRXRb_EcoTox2", + "assayComponentDesc": "ATG_frRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frRXRb, also known as african clawed frog (Xenopus laevis) retinoid X receptor, beta [NCBI Reference Sequence: NP_001080936.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3131, + "assayComponentEndpointName": "ATG_rtRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2876, + "assayComponentName": "ATG_rtRXRb_EcoTox2", + "assayComponentDesc": "ATG_rtRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtRXRb, also known as rainbow trout (Oncorhynchus mykiss) retinoid X receptor, beta [NCBI Reference Sequence: XP_021427688.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3133, + "assayComponentEndpointName": "ATG_jmRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2877, + "assayComponentName": "ATG_jmRXRb_EcoTox2", + "assayComponentDesc": "ATG_jmRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmRXRb, also known as japanese medaka (Oryzias latipes) retinoid X receptor, beta [NCBI Reference Sequence: XP_020562828.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3135, + "assayComponentEndpointName": "ATG_zfRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2878, + "assayComponentName": "ATG_zfRXRb_EcoTox2", + "assayComponentDesc": "ATG_zfRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfRXRb, also known as zebrafish (Danio rerio) retinoid X receptor, beta [NCBI Reference Sequence: NP_571350.1 ].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3137, + "assayComponentEndpointName": "ATG_hERa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2879, + "assayComponentName": "ATG_hERa_EcoTox2", + "assayComponentDesc": "ATG_hERa_EcoTox2 is one of 29 assay components measured or calculated from the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372 | NCBI Reference Sequence: NP_000116.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3139, + "assayComponentEndpointName": "ATG_zfER1_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2880, + "assayComponentName": "ATG_zfER1_EcoTox2", + "assayComponentDesc": "ATG_zfER1_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfER, which is responsive to the zebrafish (Danio rerio) estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717 | NCBI Reference Sequence: NP_694491.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3141, + "assayComponentEndpointName": "ATG_frER1_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2881, + "assayComponentName": "ATG_frER1_EcoTox2", + "assayComponentDesc": "ATG_frER1_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the african clawed frog (Xenopus laevis) estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7 | NCBI Reference Sequence: NP_001083086.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3143, + "assayComponentEndpointName": "ATG_hAR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "11-keto Testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2882, + "assayComponentName": "ATG_hAR_EcoTox2", + "assayComponentDesc": "ATG_hAR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275 | NCBI Reference Sequence: NP_000035.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3145, + "assayComponentEndpointName": "ATG_zfAR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "11-keto Testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2883, + "assayComponentName": "ATG_zfAR_EcoTox2", + "assayComponentDesc": "ATG_zfAR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish (Danio rerio) androgen receptor. [GeneSymbol:AR | GeneID:100005148 | NCBI Reference Sequence: NP_001076592.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3147, + "assayComponentEndpointName": "ATG_M_61_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_61_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2884, + "assayComponentName": "ATG_M_61_EcoTox2", + "assayComponentDesc": "ATG_M_61_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3149, + "assayComponentEndpointName": "ATG_M_06_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_06_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2885, + "assayComponentName": "ATG_M_06_EcoTox2", + "assayComponentDesc": "ATG_M_06_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3151, + "assayComponentEndpointName": "ATG_M_32_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_32_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2886, + "assayComponentName": "ATG_M_32_EcoTox2", + "assayComponentDesc": "ATG_M_32_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3153, + "assayComponentEndpointName": "ATG_M_19_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_19_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2887, + "assayComponentName": "ATG_M_19_EcoTox2", + "assayComponentDesc": "ATG_M_19_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3155, + "assayComponentEndpointName": "ATG_hGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2859, + "assayComponentName": "ATG_hGR_EcoTox2", + "assayComponentDesc": "ATG_hGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hGR, also known as human glucocorticoid receptor isoform alpha. [NCBI Reference Sequence: NP_000167.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-GR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3161, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using Homogenous Time Resolved Fluorescence technology was used to understand synthesis of estradiol in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "forskolin for gain; prochloraz for loss", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2891, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL is one of 3 assay components calculated in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with Homogenous Time Resolved Fluorescence immunoassay technology.", + "assayComponentTargetDesc": "Changes in the fluorescence ratio are indicative of induction (gain of signal) or inhibition (loss of signal) of steroid hormone biosynthesis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence ratio", + "detectionTechnology": "Homogenous Time Resolved Fluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "estradiol", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3162, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using Homogenous Time Resolved Fluorescence technology was used to understand synthesis of testosterone in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "forskolin for gain; prochloraz for loss", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2892, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE is one of 3 assay components calculated in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with Homogenous Time Resolved Fluorescence immunoassay technology.", + "assayComponentTargetDesc": "Changes in the fluorescence ratio are indicative of induction (gain of signal) or inhibition (loss of signal) of steroid hormone biosynthesis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence ratio", + "detectionTechnology": "Homogenous Time Resolved Fluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "testosterone", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3163, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity using CellTiter-Glo 2.0 technology was used to understand viability in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity", + "assayFunctionType": "viability", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2893, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX is one of 3 assay components measured in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of adenosine triphosphate (ATP), a form of viability reporter, as detected with luminescence intensity signals by CellTiter-Glo 2.0 cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes in luminescence intensity, proportional to the amount of ATP present, are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "CellTiter-Glo 2.0", + "keyAssayReagentType": "luciferase co-factor", + "keyAssayReagent": "luciferin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "ATP", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3164, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GABANeurons. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2894, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GABANeurons. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3165, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2895, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3166, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2896, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3167, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2897, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1975, + "assayComponentEndpointName": "ATG_trERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1887, + "assayComponentName": "ATG_trERa_XSP2", + "assayComponentDesc": "ATG_trERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the turtle estrogen receptor. [GeneSymbol:ESR1 | GeneID: 101933533| Uniprot_SwissProt_Accession:B6E1V9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1465, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "ESR1", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101933533, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "B6E1V9" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1977, + "assayComponentEndpointName": "ATG_hERb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1888, + "assayComponentName": "ATG_hERb_XSP2", + "assayComponentDesc": "ATG_hERb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR2 | GeneID: 2100| Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ER-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1979, + "assayComponentEndpointName": "ATG_trAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1889, + "assayComponentName": "ATG_trAR_XSP2", + "assayComponentDesc": "ATG_trAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the turtle androgen receptor. [GeneSymbol:AR | GeneID:101947425 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1464, + "geneName": "androgen receptor", + "description": "PREDICTED: Chrysemys picta bellii androgen receptor (AR), mRNA", + "geneSymbol": "AR", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101947425, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1981, + "assayComponentEndpointName": "ATG_GAL4_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_GAL4_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1890, + "assayComponentName": "ATG_GAL4_XSP2", + "assayComponentDesc": "ATG_GAL4_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1983, + "assayComponentEndpointName": "ATG_zfER1_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1891, + "assayComponentName": "ATG_zfER1_XSP2", + "assayComponentDesc": "ATG_zfER1_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1468, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "esr1", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 259252, + "officialSymbol": "esr1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P57717" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1985, + "assayComponentEndpointName": "ATG_chERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1892, + "assayComponentName": "ATG_chERa_XSP2", + "assayComponentDesc": "ATG_chERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the chicken estrogen receptor. [GeneSymbol:ESR1 | GeneID: 396099| Uniprot_SwissProt_Accession:P06212].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1475, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 (chicken)", + "geneSymbol": "ESR1", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 396099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P06212" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1987, + "assayComponentEndpointName": "ATG_zfER2a_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2a_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1893, + "assayComponentName": "ATG_zfER2a_XSP2", + "assayComponentDesc": "ATG_zfER2a_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2a | GeneID: 317734| Uniprot_SwissProt_Accession:Q7ZU32].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1469, + "geneName": "estrogen receptor 2a", + "description": "estrogen receptor 2a [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2a", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317734, + "officialSymbol": "esr2a", + "officialFullName": "estrogen receptor 2a", + "uniprotAccessionNumber": "Q7ZU32" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1989, + "assayComponentEndpointName": "ATG_hAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1894, + "assayComponentName": "ATG_hAR_XSP2", + "assayComponentDesc": "ATG_hAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1991, + "assayComponentEndpointName": "ATG_chAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1895, + "assayComponentName": "ATG_chAR_XSP2", + "assayComponentDesc": "ATG_chAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the chicken androgen receptor. [GeneSymbol:ar | GeneID:422165| Uniprot_SwissProt_Accession:Q2ACE0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1474, + "geneName": "androgen receptor", + "description": "androgen receptor (chicken)", + "geneSymbol": "AR", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 422165, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "Q2ACE0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1993, + "assayComponentEndpointName": "ATG_frER1_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1896, + "assayComponentName": "ATG_frER1_XSP2", + "assayComponentDesc": "ATG_frER1_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1480, + "geneName": "estrogen receptor 1 L homeolog", + "description": "estrogen receptor 1 L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "esr1.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 398734, + "officialSymbol": "esr1.L", + "officialFullName": "estrogen receptor 1 L homeolog", + "uniprotAccessionNumber": "Q6W5G7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1995, + "assayComponentEndpointName": "ATG_frAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1897, + "assayComponentName": "ATG_frAR_XSP2", + "assayComponentDesc": "ATG_frAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the frog androgen receptor. [GeneSymbol:ar.L | GeneID:399456| Uniprot_SwissProt_Accession:P70048].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1479, + "geneName": "androgen receptor L homeolog", + "description": "androgen receptor L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "ar.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 399456, + "officialSymbol": "ar.L", + "officialFullName": "androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) L homeolog", + "uniprotAccessionNumber": "P70048" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1997, + "assayComponentEndpointName": "ATG_zfAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1898, + "assayComponentName": "ATG_zfAR_XSP2", + "assayComponentDesc": "ATG_zfAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish androgen receptor. [GeneSymbol:AR | GeneID:100005148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1467, + "geneName": "androgen receptor", + "description": "androgen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "ar", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 100005148, + "officialSymbol": "ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "A4GT83" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1999, + "assayComponentEndpointName": "ATG_zfER2b_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2b_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1899, + "assayComponentName": "ATG_zfER2b_XSP2", + "assayComponentDesc": "ATG_zfER2b_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2b | GeneID: 317733| Uniprot_SwissProt_Accession:Q5PR29].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1470, + "geneName": "estrogen receptor 2b", + "description": "estrogen receptor 2b [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2b", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317733, + "officialSymbol": "esr2b", + "officialFullName": "estrogen receptor 2b", + "uniprotAccessionNumber": "Q5PR29" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2001, + "assayComponentEndpointName": "ATG_hERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1900, + "assayComponentName": "ATG_hERa_XSP2", + "assayComponentDesc": "ATG_hERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2003, + "assayComponentEndpointName": "ATG_M_19_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_19_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1901, + "assayComponentName": "ATG_M_19_XSP2", + "assayComponentDesc": "ATG_M_19_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2005, + "assayComponentEndpointName": "ATG_M_32_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_32_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1902, + "assayComponentName": "ATG_M_32_XSP2", + "assayComponentDesc": "ATG_M_32_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2023, + "assayComponentEndpointName": "ATG_M_61_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_61_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1911, + "assayComponentName": "ATG_M_61_XSP2", + "assayComponentDesc": "ATG_M_61_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1072, + "assayComponentEndpointName": "LTEA_HepaRG_PDK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PDK4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PDK4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 677, + "assayComponentName": "LTEA_HepaRG_PDK4", + "assayComponentDesc": "LTEA_HepaRG_PDK4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with PDK4 include Platelet Glycoprotein Iv Deficiency and Diabetes Mellitus, Noninsulin-Dependent. .", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 234, + "geneName": "pyruvate dehydrogenase kinase, isozyme 4", + "description": null, + "geneSymbol": "PDK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5166, + "officialSymbol": "PDK4", + "officialFullName": "pyruvate dehydrogenase kinase, isozyme 4", + "uniprotAccessionNumber": "Q16654" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1074, + "assayComponentEndpointName": "LTEA_HepaRG_PEG10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PEG10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PEG10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 678, + "assayComponentName": "LTEA_HepaRG_PEG10", + "assayComponentDesc": "LTEA_HepaRG_PEG10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 375, + "geneName": "paternally expressed 10", + "description": null, + "geneSymbol": "PEG10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23089, + "officialSymbol": "PEG10", + "officialFullName": "paternally expressed 10", + "uniprotAccessionNumber": "Q86TG7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1076, + "assayComponentEndpointName": "LTEA_HepaRG_PPP2R4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PPP2R4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PPP2R4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 679, + "assayComponentName": "LTEA_HepaRG_PPP2R4", + "assayComponentDesc": "LTEA_HepaRG_PPP2R4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 254, + "geneName": "protein phosphatase 2A activator, regulatory subunit 4", + "description": null, + "geneSymbol": "PPP2R4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5524, + "officialSymbol": "PPP2R4", + "officialFullName": "protein phosphatase 2A activator, regulatory subunit 4", + "uniprotAccessionNumber": "Q15257" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1078, + "assayComponentEndpointName": "LTEA_HepaRG_PTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PTEN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PTEN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 680, + "assayComponentName": "LTEA_HepaRG_PTEN", + "assayComponentDesc": "LTEA_HepaRG_PTEN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1080, + "assayComponentEndpointName": "LTEA_HepaRG_SDHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SDHB was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SDHB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is ubiquinone.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "ubiquinone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 681, + "assayComponentName": "LTEA_HepaRG_SDHB", + "assayComponentDesc": "LTEA_HepaRG_SDHB is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 292, + "geneName": "succinate dehydrogenase complex, subunit B, iron sulfur (Ip)", + "description": null, + "geneSymbol": "SDHB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6390, + "officialSymbol": "SDHB", + "officialFullName": "succinate dehydrogenase complex, subunit B, iron sulfur (Ip)", + "uniprotAccessionNumber": "P21912" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1082, + "assayComponentEndpointName": "LTEA_HepaRG_SLC22A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC22A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC22A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic cation transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic cation transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 682, + "assayComponentName": "LTEA_HepaRG_SLC22A1", + "assayComponentDesc": "LTEA_HepaRG_SLC22A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 300, + "geneName": "solute carrier family 22 (organic cation transporter), member 1", + "description": null, + "geneSymbol": "SLC22A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6580, + "officialSymbol": "SLC22A1", + "officialFullName": "solute carrier family 22 (organic cation transporter), member 1", + "uniprotAccessionNumber": "O15245" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1084, + "assayComponentEndpointName": "LTEA_HepaRG_SLCO1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLCO1B1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLCO1B1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 683, + "assayComponentName": "LTEA_HepaRG_SLCO1B1", + "assayComponentDesc": "LTEA_HepaRG_SLCO1B1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1086, + "assayComponentEndpointName": "LTEA_HepaRG_STAT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_STAT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_STAT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "stat protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 684, + "assayComponentName": "LTEA_HepaRG_STAT3", + "assayComponentDesc": "LTEA_HepaRG_STAT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 305, + "geneName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "description": null, + "geneSymbol": "STAT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6774, + "officialSymbol": "STAT3", + "officialFullName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "uniprotAccessionNumber": "P40763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1088, + "assayComponentEndpointName": "LTEA_HepaRG_SULT2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SULT2A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SULT2A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 685, + "assayComponentName": "LTEA_HepaRG_SULT2A1", + "assayComponentDesc": "LTEA_HepaRG_SULT2A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1090, + "assayComponentEndpointName": "LTEA_HepaRG_TGFA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TGFA was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "EGF-like domain", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 686, + "assayComponentName": "LTEA_HepaRG_TGFA", + "assayComponentDesc": "LTEA_HepaRG_TGFA is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 318, + "geneName": "transforming growth factor, alpha", + "description": null, + "geneSymbol": "TGFA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7039, + "officialSymbol": "TGFA", + "officialFullName": "transforming growth factor, alpha", + "uniprotAccessionNumber": "P01135" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1092, + "assayComponentEndpointName": "LTEA_HepaRG_TGFB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TGFB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 687, + "assayComponentName": "LTEA_HepaRG_TGFB1", + "assayComponentDesc": "LTEA_HepaRG_TGFB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1094, + "assayComponentEndpointName": "LTEA_HepaRG_THRSP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_THRSP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_THRSP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is NR mediated metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "NR mediated metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 688, + "assayComponentName": "LTEA_HepaRG_THRSP", + "assayComponentDesc": "LTEA_HepaRG_THRSP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 323, + "geneName": "thyroid hormone responsive", + "description": null, + "geneSymbol": "THRSP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7069, + "officialSymbol": "THRSP", + "officialFullName": "thyroid hormone responsive", + "uniprotAccessionNumber": "Q92748" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1096, + "assayComponentEndpointName": "LTEA_HepaRG_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TIMP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 689, + "assayComponentName": "LTEA_HepaRG_TIMP1", + "assayComponentDesc": "LTEA_HepaRG_TIMP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1098, + "assayComponentEndpointName": "LTEA_HepaRG_TNFRSF1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TNFRSF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TNFRSF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "TNF receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 690, + "assayComponentName": "LTEA_HepaRG_TNFRSF1A", + "assayComponentDesc": "LTEA_HepaRG_TNFRSF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 328, + "geneName": "tumor necrosis factor receptor superfamily, member 1A", + "description": null, + "geneSymbol": "TNFRSF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7132, + "officialSymbol": "TNFRSF1A", + "officialFullName": "tumor necrosis factor receptor superfamily, member 1A", + "uniprotAccessionNumber": "P19438" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1100, + "assayComponentEndpointName": "LTEA_HepaRG_TP53", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TP53 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TP53, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 691, + "assayComponentName": "LTEA_HepaRG_TP53", + "assayComponentDesc": "LTEA_HepaRG_TP53 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1102, + "assayComponentEndpointName": "LTEA_HepaRG_UGT1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_UGT1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 692, + "assayComponentName": "LTEA_HepaRG_UGT1A1", + "assayComponentDesc": "LTEA_HepaRG_UGT1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1104, + "assayComponentEndpointName": "LTEA_HepaRG_UGT1A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_UGT1A6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 693, + "assayComponentName": "LTEA_HepaRG_UGT1A6", + "assayComponentDesc": "LTEA_HepaRG_UGT1A6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 429, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A6", + "description": null, + "geneSymbol": "UGT1A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54578, + "officialSymbol": "UGT1A6", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A6", + "uniprotAccessionNumber": "P19224" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1106, + "assayComponentEndpointName": "LTEA_HepaRG_XBP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_XBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_XBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 694, + "assayComponentName": "LTEA_HepaRG_XBP1", + "assayComponentDesc": "LTEA_HepaRG_XBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with XBP1 include Major Affective Disorder 7 and Bipolar Disorde.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 337, + "geneName": "X-box binding protein 1", + "description": null, + "geneSymbol": "XBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7494, + "officialSymbol": "XBP1", + "officialFullName": "X-box binding protein 1", + "uniprotAccessionNumber": "P17861" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1108, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 695, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1109, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 696, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1110, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 697, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1111, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 698, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1112, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 699, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1113, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 700, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 161, + "geneName": "heat shock transcription factor 1", + "description": null, + "geneSymbol": "HSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3297, + "officialSymbol": "HSF1", + "officialFullName": "heat shock transcription factor 1", + "uniprotAccessionNumber": "Q00613" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1114, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 701, + "assayComponentName": "TOX21_p53_BLA_p1_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p1_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1115, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 702, + "assayComponentName": "TOX21_p53_BLA_p1_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p1_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1116, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 703, + "assayComponentName": "TOX21_p53_BLA_p1_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p1_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1117, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 704, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1118, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 705, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1119, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 706, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1120, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 707, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1121, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 708, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1122, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 709, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1123, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 710, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1124, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 711, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1125, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 712, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1126, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 713, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1127, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 714, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1128, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 715, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1129, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 716, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1130, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 717, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1131, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 718, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ratio was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1132, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1alpha,25-Dihydroxy vitamin D3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 719, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1133, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 720, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Antagonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 2007, + "assayComponentEndpointName": "ATG_frER2_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER2_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1903, + "assayComponentName": "ATG_frER2_XSP2", + "assayComponentDesc": "ATG_frER2_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr2.L | GeneID: 100174814| Uniprot_SwissProt_Accession:A0A1L8FA50].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1481, + "geneName": "estrogen receptor 2 L homeolog", + "description": "estrogen receptor 2 L homeolog [ Xenopus laevis (African clawed frog) ]", + "geneSymbol": "esr2.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 100174814, + "officialSymbol": "esr2.L", + "officialFullName": "estrogen receptor 2 L homeolog", + "uniprotAccessionNumber": "A0A1L8FA50" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2009, + "assayComponentEndpointName": "ATG_mPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1904, + "assayComponentName": "ATG_mPPARg_XSP2", + "assayComponentDesc": "ATG_mPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the mouse peroxisome proliferator activated receptor gamma. [GeneSymbol:Pparg | GeneID: 19016| Uniprot_SwissProt_Accession:P37238].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-mPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1478, + "geneName": "peroxisome proliferator activated receptor gamma", + "description": "peroxisome proliferator activated receptor gamma [ Mus musculus(house mouse) ]", + "geneSymbol": "Pparg", + "organismId": 2, + "trackStatus": null, + "entrezGeneId": 19016, + "officialSymbol": "Pparg", + "officialFullName": "peroxisome proliferator activated receptor gamma", + "uniprotAccessionNumber": "P37238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2011, + "assayComponentEndpointName": "ATG_zfPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1905, + "assayComponentName": "ATG_zfPPARg_XSP2", + "assayComponentDesc": "ATG_zfPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1471, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": "peroxisome proliferator-activated receptor gamma [ Danio rerio(zebrafish) ]", + "geneSymbol": "pparg", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 557037, + "officialSymbol": "pparg", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "A6XMH6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2013, + "assayComponentEndpointName": "ATG_hPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1906, + "assayComponentName": "ATG_hPPARg_XSP2", + "assayComponentDesc": "ATG_hPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [GeneSymbol:PPARG | GeneID: 5468| Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2015, + "assayComponentEndpointName": "ATG_mPXR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPXR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1907, + "assayComponentName": "ATG_mPXR_XSP2", + "assayComponentDesc": "ATG_mPXR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PXR, which is responsive to the mouse pregnane X receptor. [GeneSymbol: NR1IA | GeneID: 8856| Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NA", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2017, + "assayComponentEndpointName": "ATG_trTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1908, + "assayComponentName": "ATG_trTRa_XSP2", + "assayComponentDesc": "ATG_trTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the turtle thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 101949057| Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1466, + "geneName": "thyroid hormone receptor, alpha", + "description": "thyroid hormone receptor, alpha [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "THRA", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101949057, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2019, + "assayComponentEndpointName": "ATG_zfTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1909, + "assayComponentName": "ATG_zfTRa_XSP2", + "assayComponentDesc": "ATG_zfTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, alpha a. [GeneSymbol: thraa | GeneID: 30670| Uniprot_SwissProt_Accession: Q98867].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1472, + "geneName": "thyroid hormone receptor alpha a", + "description": "thyroid hormone receptor alpha a [ Danio rerio (zebrafish) ]", + "geneSymbol": "thraa", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30670, + "officialSymbol": "thraa", + "officialFullName": "thyroid hormone receptor alpha a", + "uniprotAccessionNumber": "Q98867" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2021, + "assayComponentEndpointName": "ATG_zfTRb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1910, + "assayComponentName": "ATG_zfTRb_XSP2", + "assayComponentDesc": "ATG_zfTRb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, beta. [GeneSymbol: thrb | GeneID: 30607| Uniprot_SwissProt_Accession: Q9PVE4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1473, + "geneName": "thyroid hormone receptor beta", + "description": "thyroid hormone receptor beta [ Danio rerio (zebrafish) ]", + "geneSymbol": "thrb", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30607, + "officialSymbol": "thrb", + "officialFullName": "thyroid hormone receptor beta", + "uniprotAccessionNumber": "Q9PVE4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2025, + "assayComponentEndpointName": "ATG_frTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1912, + "assayComponentName": "ATG_frTRa_XSP2", + "assayComponentDesc": "ATG_frTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the frog thyroid hormone receptor, alpha L homeolog. [GeneSymbol: thra.L | GeneID: 397942| Uniprot_SwissProt_Accession: P15204].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1482, + "geneName": "thyroid hormone receptor, alpha L homeolog", + "description": "thyroid hormone receptor, alpha L homeolog [ Xenopus laevis(African clawed frog) ]", + "geneSymbol": "thra.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 397942, + "officialSymbol": "thra.L", + "officialFullName": "thyroid hormone receptor, alpha L homeolog", + "uniprotAccessionNumber": "P15204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2027, + "assayComponentEndpointName": "ATG_hTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1913, + "assayComponentName": "ATG_hTRa_XSP2", + "assayComponentDesc": "ATG_hTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 7067| Uniprot_SwissProt_Accession: P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2029, + "assayComponentEndpointName": "ATG_hTRb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1914, + "assayComponentName": "ATG_hTRb_XSP2", + "assayComponentDesc": "ATG_hTRb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, beta. [GeneSymbol: THRB | GeneID: 7068| Uniprot_SwissProt_Accession: P10828].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2031, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_XTT_Cytotoxicity_XSP2 was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1915, + "assayComponentName": "ATG_XTT_Cytotoxicity_XSP2", + "assayComponentDesc": "ATG_XTT_Cytotoxicity_XSP2 is an assay component measured from the ATG_XSP2_XTT_Cytotoxicity_multi-species assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 572, + "assayName": "ATG_XSP2_XTT_Cytotoxicity_multi-species", + "assayDesc": "ATG_XSP2_XTT_Cytotoxicity_multi-species is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2037, + "assayComponentEndpointName": "CPHEA_Stoker_NIS_Inhibition_RAIU", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CPHEA_Stoker_NIS_Inhibition_RAIU was analyzed at the endpoint, CPHEA_Stoker_NIS_Inhibition_RAIU, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Measures of radioactive substrate uptake for loss-of-signal activity can be used to understand the effects on transporter function at the pathway level as they relate to the sodium-iodide symporter, gene SLC5A5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium-iodide symporter (NIS).", + "assayFunctionType": "transporter", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NaClO4", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "sodium-iodide symporter (NIS)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1919, + "assayComponentName": "CPHEA_Stoker_NIS_Inhibition_RAIU", + "assayComponentDesc": "CPHEA_Stoker_NIS_Inhibition_RAIU is one of 2 assay components measured from the CPHEA_Stoker_NIS assay. It is designed to make measurements of radioactive substrate uptake to understand transporter function, as detected with 125-i signals by MicroBeta radioactivity plate reader technology.", + "assayComponentTargetDesc": "The sodium iodide symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into the thyroid gland as the initial step of thyroid hormone biosynthesis. Inhibition of iodide uptake through the thyroid NIS can result in decreased thyroid hormone biosynthesis. The radioactive iodide uptake (RAIU) assay can be used to detect thyroid disrupting chemicals that inhibit the human sodium iodide symporter (NIS).", + "parameterReadoutType": "single", + "assayDesignType": "transporter function", + "assayDesignTypeSub": "radioactive substrate uptake", + "biologicalProcessTarget": "regulation of transporter activity", + "detectionTechnologyType": "radiometry", + "detectionTechnologyTypeSub": "radiodetection", + "detectionTechnology": "MicroBeta radioactivity plate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "125-I", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "substrate uptake", + "aid": 574, + "assayName": "CPHEA_Stoker_NIS", + "assayDesc": "CPHEA_Stoker_NIS is a cell-based, single-readout assay that uses hNIS-HEK293T-EPA, a novel human kidney cell line expressing human NIS, with measurements taken at 2 hours after chemical dosing in a 96-well plate. This radioactive iodide uptake (RAIU) assay is used to identify inhibitors of NIS-mediated iodide uptake. A parallel cytoxicity assay (Cell Titer Glo, Promega) was also run in the same cell line.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": null, + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 21, + "assaySourceName": "CPHEA_STOKER", + "assaySourceLongName": "CPHEA Stoker and Laws Labs", + "assaySourceDesc": "The Stoker and Laws laboratories at the EPA Center for Public Health and Environmental Assessment work on the development and implementation of high-throughput assays, particularly related to the sodium-iodide cotransporter (NIS).", + "gene": { + "geneId": 1462, + "geneName": "solute carrier family 5 member 5", + "description": null, + "geneSymbol": "SLC5A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6528, + "officialSymbol": "SLC5A5", + "officialFullName": "solute carrier family 5 member 5", + "uniprotAccessionNumber": "Q92911" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1007/s00204-021-03006-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33656581/", + "pmid": 33656581, + "title": "Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition", + "author": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE", + "citation": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE. Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition. Arch Toxicol. 2021 May;95(5):1723-1737. doi: 10.1007/s00204-021-03006-2. Epub 2021 Mar 3. PMID: 33656581.", + "otherId": "0", + "citationId": 241, + "otherSource": "" + } + }, + { + "aeid": 2038, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1920, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ch1", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ch1 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of TSH", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2039, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1921, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ch2", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ch2 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the acceptor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of TSH", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2040, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1922, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ratio", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_HTRF_Agonist assay. It is designed to make measurements of TSHR agonism, with cAMP as an indicator of TSHR activation.", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ratio was designed to target receptor activation through increased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of TSH.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2041, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1923, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ch1", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ch1 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1854, + "assayComponentEndpointName": "TOX21_MMP_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_MMP_ratio was analyzed into 1 assay endpoint. The assay endpoin, TOX21_MMP_ratio, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 534, + "assayComponentName": "TOX21_MMP_ratio", + "assayComponentDesc": "TOX21_MMP_ratio is one of 2 assay component(s) measured or calculated from the TOX21_MMP assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by homogenous mitochondrial membrane potential assay technology.", + "assayComponentTargetDesc": "Mito-MPS is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "multiple", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 2042, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTFR_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTFR_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1924, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ch2", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ch2 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2043, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1925, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ratio", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_Antagonist assay. It is designed to make measurements of TSHR antagonism, with cAMP as an indicator of TSHR activation.", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ratio was designed to target receptor inhibition through decreased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2044, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss of signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1926, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ch1", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ch1 is an assay readout measuring endogenous cAMP and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activity at the protein (receptor) level, specifically mapping to TSRH gene(s) using a positive control of forskolin", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2045, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1927, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ch2", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ch2 is an assay readout measuring endogenous cAMP and detected with specific antibody. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_Agonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of forskolin", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2046, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1928, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ratio", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_wt assay. It is designed to indicate background cAMP activity.", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_ratio was designed to target background cAMP generation in cells lacking TSHR", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2047, + "assayComponentEndpointName": "TOX21_CAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CITCO", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "xenobiotic", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1929, + "assayComponentName": "TOX21_CAR_Agonist", + "assayComponentDesc": "TOX21_CAR_Agonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_CAR_Agonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 578, + "assayName": "TOX21_CAR_Agonist", + "assayDesc": "TOX21_CAR_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2048, + "assayComponentEndpointName": "TOX21_CAR_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1930, + "assayComponentName": "TOX21_CAR_Agonist_viability", + "assayComponentDesc": "TOX21_CAR_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 578, + "assayName": "TOX21_CAR_Agonist", + "assayDesc": "TOX21_CAR_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2049, + "assayComponentEndpointName": "TOX21_CAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "xenobiotic", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1931, + "assayComponentName": "TOX21_CAR_Antagonist", + "assayComponentDesc": "TOX21_CAR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_CAR_Antagonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3] stimulated with CITCO", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 579, + "assayName": "TOX21_CAR_Antagonist", + "assayDesc": "TOX21_CAR_Antagonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2050, + "assayComponentEndpointName": "TOX21_CAR_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1932, + "assayComponentName": "TOX21_CAR_Antagonist_viability", + "assayComponentDesc": "TOX21_CAR_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 579, + "assayName": "TOX21_CAR_Antagonist", + "assayDesc": "TOX21_CAR_Antagonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2053, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1935, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 580, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 48 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2054, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1936, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 580, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 48 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2055, + "assayComponentEndpointName": "TOX21_ERR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Genistein", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1937, + "assayComponentName": "TOX21_ERR_Agonist", + "assayComponentDesc": "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2057, + "assayComponentEndpointName": "TOX21_ERR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "XCT790", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1939, + "assayComponentName": "TOX21_ERR_Antagonist", + "assayComponentDesc": "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2059, + "assayComponentEndpointName": "TOX21_ERR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1941, + "assayComponentName": "TOX21_ERR_viability", + "assayComponentDesc": "TOX21_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2060, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1942, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_viability", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2061, + "assayComponentEndpointName": "TOX21_HDAC_Inhibition", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Trichostatin A", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1943, + "assayComponentName": "TOX21_HDAC_Inhibition", + "assayComponentDesc": "TOX21_HDAC_Inhibition is one of one assay component(s) measured or calculated from the TOX21_HDAC_Inhibition assay. It is designed to make measurements of HDAC activity as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_HDAC_Inhibition was designed to target enzymatic activity specifically mapping to HDAC1 gene(s) using a positive control of Trichostatin A", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 582, + "assayName": "TOX21_HDAC_Inhibition", + "assayDesc": "TOX21_HDAC_Inhibition is a cell-based, single-readout assay that uses HCT-116, a human colon cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "colon", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1459, + "geneName": "histone deacetylase 1", + "description": "histone deacetylase 1", + "geneSymbol": "HDAC1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3065, + "officialSymbol": "HDAC1", + "officialFullName": "histone deacetylase 1", + "uniprotAccessionNumber": "Q13547" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057116629381", + "url": "https://pubmed.ncbi.nlm.nih.gov/26858181/", + "pmid": 26858181, + "title": "Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay", + "author": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M", + "citation": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen. 2016 Jul;21(6):643-52. doi: 10.1177/1087057116629381. Epub 2016 Feb 8. PMID: 26858181; PMCID: PMC4917448.", + "otherId": "0", + "citationId": 273, + "otherSource": "" + } + }, + { + "aeid": 2062, + "assayComponentEndpointName": "TOX21_HDAC_Inhibition_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1944, + "assayComponentName": "TOX21_HDAC_Inhibition_viability", + "assayComponentDesc": "TOX21_HDAC_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 582, + "assayName": "TOX21_HDAC_Inhibition", + "assayDesc": "TOX21_HDAC_Inhibition is a cell-based, single-readout assay that uses HCT-116, a human colon cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "colon", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1177/1087057116629381", + "url": "https://pubmed.ncbi.nlm.nih.gov/26858181/", + "pmid": 26858181, + "title": "Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay", + "author": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M", + "citation": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen. 2016 Jul;21(6):643-52. doi: 10.1177/1087057116629381. Epub 2016 Feb 8. PMID: 26858181; PMCID: PMC4917448.", + "otherId": "0", + "citationId": 273, + "otherSource": "" + } + }, + { + "aeid": 2063, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1945, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2064, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1946, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2065, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "hypoxia-response element", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1947, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2066, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1948, + "assayComponentName": "TOX21_HRE_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2067, + "assayComponentEndpointName": "TOX21_LUC_Biochem", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_LUC_Biochem used a type of viability reporter where loss-of-signal activity can be used to understand inhibition of luciferase enzymatic activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the enzyme intended target family, where the subfamily is luciferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PTC124", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "enzyme", + "intendedTargetFamilySub": "luciferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1949, + "assayComponentName": "TOX21_LUC_Biochem", + "assayComponentDesc": "TOX21_LUC_Biochem is an assay readout measuring inhibition of luciferase enzymatic activity and designed using Km levels of luciferin and ATP. ", + "assayComponentTargetDesc": "TOX21_LUC_Biochem was designed to target enzymatic activity, specifically mapping to Firefly luciferase gene(s) using a positive control of PTC-124", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "artifact detection", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 584, + "assayName": "TOX21_LUC_Biochem", + "assayDesc": "TOX21_LUC_Biochem is a cell-free, single-readout assay that uses purified luciferase enzyme. Measurements were taken 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 7054, + "organism": "firefly", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "firefly luciferase (Fluc)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2068, + "assayComponentEndpointName": "TOX21_PGC_ERR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Genistein", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1950, + "assayComponentName": "TOX21_PGC_ERR_Agonist", + "assayComponentDesc": "TOX21_PGC_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101| in the presence of PGC1a expression", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2070, + "assayComponentEndpointName": "TOX21_PGC_ERR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "XCT790", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1952, + "assayComponentName": "TOX21_PGC_ERR_Antagonist", + "assayComponentDesc": "TOX21_PGC_ERR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|in the presence of PGC1a expression", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2072, + "assayComponentEndpointName": "TOX21_PGC_ERR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1954, + "assayComponentName": "TOX21_PGC_ERR_viability", + "assayComponentDesc": "TOX21_PGC_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2074, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1956, + "assayComponentName": "TOX21_RT_HEK293_FLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 0 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_00hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2075, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1957, + "assayComponentName": "TOX21_RT_HEK293_FLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2077, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1959, + "assayComponentName": "TOX21_RT_HEK293_FLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2078, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1960, + "assayComponentName": "TOX21_RT_HEK293_FLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2080, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1962, + "assayComponentName": "TOX21_RT_HEK293_FLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2082, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1964, + "assayComponentName": "TOX21_RT_HEK293_FLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2084, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1966, + "assayComponentName": "TOX21_RT_HEK293_GLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_00hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2086, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1968, + "assayComponentName": "TOX21_RT_HEK293_GLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2088, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1970, + "assayComponentName": "TOX21_RT_HEK293_GLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2089, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1971, + "assayComponentName": "TOX21_RT_HEK293_GLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2091, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1973, + "assayComponentName": "TOX21_RT_HEK293_GLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2093, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1975, + "assayComponentName": "TOX21_RT_HEK293_GLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2094, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1976, + "assayComponentName": "TOX21_RT_HEPG2_FLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_00hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 0 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_00hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2095, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1977, + "assayComponentName": "TOX21_RT_HEPG2_FLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_08hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2096, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1978, + "assayComponentName": "TOX21_RT_HEPG2_FLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_16hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2097, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1979, + "assayComponentName": "TOX21_RT_HEPG2_FLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_24hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2098, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1980, + "assayComponentName": "TOX21_RT_HEPG2_FLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_32hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2099, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1981, + "assayComponentName": "TOX21_RT_HEPG2_FLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_40hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2100, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1982, + "assayComponentName": "TOX21_RT_HEPG2_GLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_00hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2101, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1983, + "assayComponentName": "TOX21_RT_HEPG2_GLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2102, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1984, + "assayComponentName": "TOX21_RT_HEPG2_GLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2103, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1985, + "assayComponentName": "TOX21_RT_HEPG2_GLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2105, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1987, + "assayComponentName": "TOX21_RT_HEPG2_GLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2106, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SHH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1988, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Agonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_SHH_3T3_GLI3_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by Gli3, part of the sonic hedgehog (Shh) pathway", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 588, + "assayName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Agonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 6390, + "geneName": "sonic hedgehog", + "description": null, + "geneSymbol": "SHH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6469, + "officialSymbol": "SHH", + "officialFullName": "sonic hedgehog", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2107, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1989, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Agonist_viability", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 588, + "assayName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Agonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2108, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyclopamine", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1990, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_SHH_3T3_GLI3_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonism of Gli3 activation using conditioned medium, part of the sonic hedgehog (Shh) pathway", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 589, + "assayName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Antagonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 6390, + "geneName": "sonic hedgehog", + "description": null, + "geneSymbol": "SHH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6469, + "officialSymbol": "SHH", + "officialFullName": "sonic hedgehog", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2109, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1991, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Antagonist_viability", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 589, + "assayName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Antagonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2110, + "assayComponentEndpointName": "CPHEA_Stoker_NIS_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CPHEA_Stoker_NIS_Cytotoxicity was analyzed at the endpoint, CPHEA_Stoker_NIS_Cytotoxicity, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "b-naphthoquinone", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1992, + "assayComponentName": "CPHEA_Stoker_NIS_Cytotoxicity", + "assayComponentDesc": "CPHEA_Stoker_NIS_Cytotoxicity is one of 2 assay components measured from the CPHEA_Stoker_NIS assay. It is designed to make measurements of atp content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo Fluor] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Luciferase", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 574, + "assayName": "CPHEA_Stoker_NIS", + "assayDesc": "CPHEA_Stoker_NIS is a cell-based, single-readout assay that uses hNIS-HEK293T-EPA, a novel human kidney cell line expressing human NIS, with measurements taken at 2 hours after chemical dosing in a 96-well plate. This radioactive iodide uptake (RAIU) assay is used to identify inhibitors of NIS-mediated iodide uptake. A parallel cytoxicity assay (Cell Titer Glo, Promega) was also run in the same cell line.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": null, + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 21, + "assaySourceName": "CPHEA_STOKER", + "assaySourceLongName": "CPHEA Stoker and Laws Labs", + "assaySourceDesc": "The Stoker and Laws laboratories at the EPA Center for Public Health and Environmental Assessment work on the development and implementation of high-throughput assays, particularly related to the sodium-iodide cotransporter (NIS).", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1007/s00204-021-03006-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33656581/", + "pmid": 33656581, + "title": "Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition", + "author": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE", + "citation": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE. Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition. Arch Toxicol. 2021 May;95(5):1723-1737. doi: 10.1007/s00204-021-03006-2. Epub 2021 Mar 3. PMID: 33656581.", + "otherId": "0", + "citationId": 241, + "otherSource": "" + } + }, + { + "aeid": 2113, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1999, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2114, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2000, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1134, + "assayComponentEndpointName": "TOX21_DT40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 721, + "assayComponentName": "TOX21_DT40", + "assayComponentDesc": "TOX21_DT40 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level in isogenic wildtype cells using a positive control of tetraoctylammonium bromide. Results from the wild-type cells can be compared to TOX21_DT40_100 (aeid 2130) and TOX21_DT40_657 (aeid 2131) isogenic cell line assays which contain DNA repair enzyme deletions to detect DNA-damaging agents", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1136, + "assayComponentEndpointName": "LTEA_HepaRG_LDH_cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LDH_cytotoxicity was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LDH_cytotoxicity, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for loss-of-signal activity can be used to understand cell death. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 722, + "assayComponentName": "LTEA_HepaRG_LDH_cytotoxicity", + "assayComponentDesc": "LTEA_HepaRG_LDH_cytotoxicity is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of cell viability / cytotoxicity.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": null, + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1185, + "assayComponentEndpointName": "TOX21_ARE_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 747, + "assayComponentName": "TOX21_ARE_BLA_agonist_viability", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1186, + "assayComponentEndpointName": "TOX21_HSE_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 748, + "assayComponentName": "TOX21_HSE_BLA_agonist_viability", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1187, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 749, + "assayComponentName": "TOX21_p53_BLA_p1_viability", + "assayComponentDesc": "TOX21_p53_BLA_p1_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1188, + "assayComponentEndpointName": "TOX21_FXR_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 750, + "assayComponentName": "TOX21_FXR_BLA_agonist_viability", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1189, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 751, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1190, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 752, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1191, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 753, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1192, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 754, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1193, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifepristone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 755, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1194, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifepristone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 756, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1195, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 757, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1196, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 758, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1197, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 759, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1198, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 760, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1199, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 761, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1200, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 762, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1201, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1alpha,25-Dihydroxy vitamin D3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 763, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1202, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 764, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 2115, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2001, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch2 was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2116, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2002, + "assayComponentName": "TOX21_ERb_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2117, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1995, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2118, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1996, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2119, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1997, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2120, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1998, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2121, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2003, + "assayComponentName": "TOX21_PR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2122, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2004, + "assayComponentName": "TOX21_PR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2123, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2005, + "assayComponentName": "TOX21_PR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2124, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2006, + "assayComponentName": "TOX21_PR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_viability is a component of the TOX21_PR_BLA_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2125, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2007, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2126, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2008, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2127, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2009, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2128, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2010, + "assayComponentName": "TOX21_PR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_viability is a component of the TOX21_PR_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2130, + "assayComponentEndpointName": "TOX21_DT40_100", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2012, + "assayComponentName": "TOX21_DT40_100", + "assayComponentDesc": "TOX21_DT40_100 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40_100 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Ku70 and Rad54 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_100 cells have Ku70 and Rad54 gene deletions (-/-) which are involved in reparing chromosomal breaks. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Rev3(-/-) (DT40_657; aeid 2131) to evaluate potential DNA-damaging agents", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "regulation of DNA repair", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7782, + "geneName": "RAD54 like (S. cerevisiae)", + "description": null, + "geneSymbol": "RAD54L", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 8438, + "officialSymbol": "RAD54L", + "officialFullName": "RAD54 like (S. cerevisiae)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2131, + "assayComponentEndpointName": "TOX21_DT40_657", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2013, + "assayComponentName": "TOX21_DT40_657", + "assayComponentDesc": "TOX21_DT40_657 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40_657 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Rev3 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_657 cells have Rev3 gene deletions (-/-) which is involved in DNA repair. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Ku70/Rad54 (DT40_100; aeid 2130) to evaluate potential DNA-damaging agents. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "regulation of DNA repair", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 5996, + "geneName": "REV3 like, DNA directed polymerase zeta catalytic subunit", + "description": null, + "geneSymbol": "REV3L", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5980, + "officialSymbol": "REV3L", + "officialFullName": "REV3 like, DNA directed polymerase zeta catalytic subunit", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2143, + "assayComponentEndpointName": "CEETOX_H295R_11DCORT_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_11DCORT_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_11DCORT_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2023, + "assayComponentName": "CEETOX_H295R_11DCORT_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2145, + "assayComponentEndpointName": "CEETOX_H295R_OHPREG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPREG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPREG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxypregnenolone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2024, + "assayComponentName": "CEETOX_H295R_OHPREG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxypregnenolone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2147, + "assayComponentEndpointName": "CEETOX_H295R_OHPROG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPROG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPROG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxyprogesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2025, + "assayComponentName": "CEETOX_H295R_OHPROG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxyprogesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2149, + "assayComponentEndpointName": "CEETOX_H295R_ANDR_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ANDR_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ANDR_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Androstenedione", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2026, + "assayComponentName": "CEETOX_H295R_ANDR_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Androstenedione", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 1203, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 765, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1204, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 766, + "assayComponentName": "ATG_XTT_Cytotoxicity", + "assayComponentDesc": "ATG_XTT_Cytotoxicity is one of one assay component(s) measured or calculated from the ATG_XTT_Cytotoxicity assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 386, + "assayName": "ATG_XTT_Cytotoxicity", + "assayDesc": "ATG_XTT_Cytotoxicity is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1315, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 890, + "assayComponentName": "TOX21_p53_BLA_p2_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p2_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1316, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 891, + "assayComponentName": "TOX21_p53_BLA_p2_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p2_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1317, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 892, + "assayComponentName": "TOX21_p53_BLA_p2_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p2_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1318, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 893, + "assayComponentName": "TOX21_p53_BLA_p2_viability", + "assayComponentDesc": "TOX21_p53_BLA_p2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1319, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 894, + "assayComponentName": "TOX21_p53_BLA_p3_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p3_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1320, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 895, + "assayComponentName": "TOX21_p53_BLA_p3_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p3_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1321, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 896, + "assayComponentName": "TOX21_p53_BLA_p3_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p3_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1322, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 897, + "assayComponentName": "TOX21_p53_BLA_p3_viability", + "assayComponentDesc": "TOX21_p53_BLA_p3_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1323, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 898, + "assayComponentName": "TOX21_p53_BLA_p4_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p4_ch1 is an assay readout measuring reporter gene via transcripton factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1324, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 899, + "assayComponentName": "TOX21_p53_BLA_p4_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p4_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1325, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 900, + "assayComponentName": "TOX21_p53_BLA_p4_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p4_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1)reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1326, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 901, + "assayComponentName": "TOX21_p53_BLA_p4_viability", + "assayComponentDesc": "TOX21_p53_BLA_p4_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1327, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 902, + "assayComponentName": "TOX21_p53_BLA_p5_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p5_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ch1 was designed measure uncleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1328, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 903, + "assayComponentName": "TOX21_p53_BLA_p5_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p5_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ch2 was designed measure cleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1329, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 904, + "assayComponentName": "TOX21_p53_BLA_p5_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p5_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1330, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 905, + "assayComponentName": "TOX21_p53_BLA_p5_viability", + "assayComponentDesc": "TOX21_p53_BLA_p5_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1331, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 906, + "assayComponentName": "TOX21_VDR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Agonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1340, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 907, + "assayComponentName": "TOX21_ESRE_BLA_ch1", + "assayComponentDesc": "TOX21_ESRE_BLA_ch1 is an assay readout measuring transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1341, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 908, + "assayComponentName": "TOX21_ESRE_BLA_ch2", + "assayComponentDesc": "TOX21_ESRE_BLA_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1342, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 909, + "assayComponentName": "TOX21_ESRE_BLA_ratio", + "assayComponentDesc": "TOX21_ESRE_BLA_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ratio was designed to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 373, + "geneName": "activating transcription factor 6", + "description": null, + "geneSymbol": "ATF6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 22926, + "officialSymbol": "ATF6", + "officialFullName": "activating transcription factor 6", + "uniprotAccessionNumber": "P18850" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1343, + "assayComponentEndpointName": "TOX21_ESRE_BLA_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 910, + "assayComponentName": "TOX21_ESRE_BLA_viability", + "assayComponentDesc": "TOX21_ESRE_BLA_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1344, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 911, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ch1", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1345, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 912, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ch2", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ch2 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1346, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 913, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ratio", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1347, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 914, + "assayComponentName": "TOX21_NFkB_BLA_agonist_viability", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1348, + "assayComponentEndpointName": "ATG_NUR77_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint, ATG_NUR77_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 915, + "assayComponentName": "ATG_NUR77_TRANS2", + "assayComponentDesc": "ATG_NUR77_TRANS2 is one of 24 assay components measured from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-NURR77 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 155, + "geneName": "nuclear receptor subfamily 4, group A, member 1", + "description": null, + "geneSymbol": "NR4A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3164, + "officialSymbol": "NR4A1", + "officialFullName": "nuclear receptor subfamily 4, group A, member 1", + "uniprotAccessionNumber": "P22736" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1349, + "assayComponentEndpointName": "ATG_GCNF_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GCNF_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR6A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 916, + "assayComponentName": "ATG_GCNF_TRANS2", + "assayComponentDesc": "ATG_GCNF_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-GCNF RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 140, + "geneName": "nuclear receptor subfamily 6, group A, member 1", + "description": null, + "geneSymbol": "NR6A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2649, + "officialSymbol": "NR6A1", + "officialFullName": "nuclear receptor subfamily 6, group A, member 1", + "uniprotAccessionNumber": "Q15406" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1350, + "assayComponentEndpointName": "ATG_COUP_TF2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_COUP_TF2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 917, + "assayComponentName": "ATG_COUP_TF2_TRANS2", + "assayComponentDesc": "ATG_COUP_TF2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TF2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 317, + "geneName": "nuclear receptor subfamily 2, group F, member 2", + "description": null, + "geneSymbol": "NR2F2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7026, + "officialSymbol": "NR2F2", + "officialFullName": "nuclear receptor subfamily 2, group F, member 2", + "uniprotAccessionNumber": "P24468" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1351, + "assayComponentEndpointName": "ATG_PNR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_PNR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 918, + "assayComponentName": "ATG_PNR_TRANS2", + "assayComponentDesc": "ATG_PNR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PNR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 360, + "geneName": "nuclear receptor subfamily 2, group E, member 3", + "description": null, + "geneSymbol": "NR2E3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10002, + "officialSymbol": "NR2E3", + "officialFullName": "nuclear receptor subfamily 2, group E, member 3", + "uniprotAccessionNumber": "Q9Y5X4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1352, + "assayComponentEndpointName": "ATG_LRH1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_LRH1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 919, + "assayComponentName": "ATG_LRH1_TRANS2", + "assayComponentDesc": "ATG_LRH1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-LRH1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 135, + "geneName": "nuclear receptor subfamily 5, group A, member 2", + "description": null, + "geneSymbol": "NR5A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2494, + "officialSymbol": "NR5A2", + "officialFullName": "nuclear receptor subfamily 5, group A, member 2", + "uniprotAccessionNumber": "O00482" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1353, + "assayComponentEndpointName": "ATG_Rev_ERB_A_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_Rev_ERB_A_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 920, + "assayComponentName": "ATG_Rev_ERB_A_TRANS2", + "assayComponentDesc": "ATG_Rev_ERB_A_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-erb-a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 355, + "geneName": "nuclear receptor subfamily 1, group D, member 1", + "description": null, + "geneSymbol": "NR1D1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9572, + "officialSymbol": "NR1D1", + "officialFullName": "nuclear receptor subfamily 1, group D, member 1", + "uniprotAccessionNumber": "P20393" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1354, + "assayComponentEndpointName": "ATG_HNF4g_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_HNF4g_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4G. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 921, + "assayComponentName": "ATG_HNF4g_TRANS2", + "assayComponentDesc": "ATG_HNF4g_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-HNF4-g RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 158, + "geneName": "hepatocyte nuclear factor 4, gamma", + "description": null, + "geneSymbol": "HNF4G", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3174, + "officialSymbol": "HNF4G", + "officialFullName": "hepatocyte nuclear factor 4, gamma", + "uniprotAccessionNumber": "Q14541" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1355, + "assayComponentEndpointName": "ATG_ERRb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_ERRb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 922, + "assayComponentName": "ATG_ERRb_TRANS2", + "assayComponentDesc": "ATG_ERRb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 120, + "geneName": "estrogen-related receptor beta", + "description": null, + "geneSymbol": "ESRRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2103, + "officialSymbol": "ESRRB", + "officialFullName": "estrogen-related receptor beta", + "uniprotAccessionNumber": "O95718" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1356, + "assayComponentEndpointName": "ATG_MR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_MR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 923, + "assayComponentName": "ATG_MR_TRANS2", + "assayComponentDesc": "ATG_MR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-MR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 202, + "geneName": "nuclear receptor subfamily 3, group C, member 2", + "description": null, + "geneSymbol": "NR3C2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4306, + "officialSymbol": "NR3C2", + "officialFullName": "nuclear receptor subfamily 3, group C, member 2", + "uniprotAccessionNumber": "P08235" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2151, + "assayComponentEndpointName": "CEETOX_H295R_CORTIC_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTIC_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTIC_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Corticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2027, + "assayComponentName": "CEETOX_H295R_CORTIC_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Corticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2153, + "assayComponentEndpointName": "CEETOX_H295R_CORTISOL_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTISOL_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTISOL_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Cortisol ", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2028, + "assayComponentName": "CEETOX_H295R_CORTISOL_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Cortisol ", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2157, + "assayComponentEndpointName": "CEETOX_H295R_DOC_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_DOC_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_DOC_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycorticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2030, + "assayComponentName": "CEETOX_H295R_DOC_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycorticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2159, + "assayComponentEndpointName": "CEETOX_H295R_ESTRADIOL_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRADIOL_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRADIOL_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2031, + "assayComponentName": "CEETOX_H295R_ESTRADIOL_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estradiol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2161, + "assayComponentEndpointName": "CEETOX_H295R_ESTRONE_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRONE_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRONE_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estrone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2032, + "assayComponentName": "CEETOX_H295R_ESTRONE_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estrone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2165, + "assayComponentEndpointName": "CEETOX_H295R_PROG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_PROG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_PROG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Progesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2034, + "assayComponentName": "CEETOX_H295R_PROG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Progesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2167, + "assayComponentEndpointName": "CEETOX_H295R_TESTO_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_TESTO_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_TESTO_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2035, + "assayComponentName": "CEETOX_H295R_TESTO_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Testosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2211, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2073, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an ER antagonist. Changes are indicative of transcriptional gene expression that may not be due to direct regulation by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "artifact detection", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 640, + "assayName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Agonist.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2212, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2074, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 640, + "assayName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Agonist.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2213, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2075, + "assayComponentName": "TOX21_RT_HEPG2_GLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2214, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2275, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2215, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2276, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2216, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2277, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2217, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2278, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2218, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2279, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2219, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2280, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2220, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2281, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_viability is a component of the TOX21_PR_BLA_Followup_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2221, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2282, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_viability is a component of the TOX21_PR_BLA_Followup_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2222, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_LUC_Followup_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2283, + "assayComponentName": "TOX21_PR_LUC_Followup_Agonist", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Agonist is one of one assay component(s) measured or calculated from the TOX21_PR_LUC_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PR_LUC_Agonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human Progesterone receptor (PR)", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2223, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2284, + "assayComponentName": "TOX21_PR_LUC_Followup_Antagonist", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PR_LUC_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PR_LUC_Antagonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human Progesterone receptor (PR)", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2224, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_LUC_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2285, + "assayComponentName": "TOX21_PR_LUC_Followup_Agonist_viability", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2225, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_LUC_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2286, + "assayComponentName": "TOX21_PR_LUC_Followup_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2226, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Agonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist_Followup, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2287, + "assayComponentName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Agonist_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 644, + "assayName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_LUC_GH3_Agonist assay. TOX21_TR_LUC_GH3_Agonist_Followup is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2227, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Antagonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist_Followup, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2288, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist_Followup is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 645, + "assayName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is a secondary assay for the TOX21_TR_LUC_GH3_Agonist assay. TOX21_TR_LUC_GH3_Agonist_Followup is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2228, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2289, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2229, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2290, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2230, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2291, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ratio is assay component calculated in the TOX21_TRA_COA_Agonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2231, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2292, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2232, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2293, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2233, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2294, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ratio is assay component calculated in the TOX21_TRA_COA_Antagonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2234, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2295, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2235, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2296, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2236, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2297, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2237, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TRB_BLA_Agonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2298, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_viability", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_viability is a component of the TOX21_TRB_BLA_Agonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2238, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2299, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2239, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2300, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2240, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2301, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2241, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRB_BLA_Antagonist_Followup_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2302, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_viability", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_viability is a component of the TOX21_TRB_BLA_Antagonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2242, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2303, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2243, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2304, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 1357, + "assayComponentEndpointName": "ATG_COUP_TF1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_COUP_TF1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 924, + "assayComponentName": "ATG_COUP_TF1_TRANS2", + "assayComponentDesc": "ATG_COUP_TF1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 316, + "geneName": "nuclear receptor subfamily 2, group F, member 1", + "description": null, + "geneSymbol": "NR2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7025, + "officialSymbol": "NR2F1", + "officialFullName": "nuclear receptor subfamily 2, group F, member 1", + "uniprotAccessionNumber": "P10589" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1358, + "assayComponentEndpointName": "ATG_NOR1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_NOR1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 925, + "assayComponentName": "ATG_NOR1_TRANS2", + "assayComponentDesc": "ATG_NOR1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-NOR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 341, + "geneName": "nuclear receptor subfamily 4, group A, member 3", + "description": null, + "geneSymbol": "NR4A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8013, + "officialSymbol": "NR4A3", + "officialFullName": "nuclear receptor subfamily 4, group A, member 3", + "uniprotAccessionNumber": "Q92570" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1359, + "assayComponentEndpointName": "ATG_TR4_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TR4_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 926, + "assayComponentName": "ATG_TR4_TRANS2", + "assayComponentDesc": "ATG_TR4_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TR4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 331, + "geneName": "nuclear receptor subfamily 2, group C, member 2", + "description": null, + "geneSymbol": "NR2C2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7182, + "officialSymbol": "NR2C2", + "officialFullName": "nuclear receptor subfamily 2, group C, member 2", + "uniprotAccessionNumber": "P49116" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1360, + "assayComponentEndpointName": "ATG_DAX1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_DAX1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 927, + "assayComponentName": "ATG_DAX1_TRANS2", + "assayComponentDesc": "ATG_DAX1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-DAX1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 20, + "geneName": "nuclear receptor subfamily 0, group B, member 1", + "description": null, + "geneSymbol": "NR0B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 190, + "officialSymbol": "NR0B1", + "officialFullName": "nuclear receptor subfamily 0, group B, member 1", + "uniprotAccessionNumber": "P51843" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1361, + "assayComponentEndpointName": "ATG_Rev_ERB_B_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_Rev_ERB_B_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 928, + "assayComponentName": "ATG_Rev_ERB_B_TRANS2", + "assayComponentDesc": "ATG_Rev_ERB_B_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-erb-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 358, + "geneName": "nuclear receptor subfamily 1, group D, member 2", + "description": null, + "geneSymbol": "NR1D2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9975, + "officialSymbol": "NR1D2", + "officialFullName": "nuclear receptor subfamily 1, group D, member 2", + "uniprotAccessionNumber": "Q14995" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1362, + "assayComponentEndpointName": "ATG_RORa_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_RORa_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 929, + "assayComponentName": "ATG_RORa_TRANS2", + "assayComponentDesc": "ATG_RORa_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ROR-a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 284, + "geneName": "RAR-related orphan receptor A", + "description": null, + "geneSymbol": "RORA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6095, + "officialSymbol": "RORA", + "officialFullName": "RAR-related orphan receptor A", + "uniprotAccessionNumber": "P35398" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1363, + "assayComponentEndpointName": "ATG_PR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_PR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 930, + "assayComponentName": "ATG_PR_TRANS2", + "assayComponentDesc": "ATG_PR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1364, + "assayComponentEndpointName": "ATG_RXRg_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_RXRg_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 931, + "assayComponentName": "ATG_RXRg_TRANS2", + "assayComponentDesc": "ATG_RXRg_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-RXR-g RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 6215, + "geneName": "retinoid X receptor gamma", + "description": null, + "geneSymbol": "RXRG", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6258, + "officialSymbol": "RXRG", + "officialFullName": "retinoid X receptor gamma", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1365, + "assayComponentEndpointName": "ATG_SF_1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_SF_1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 932, + "assayComponentName": "ATG_SF_1_TRANS2", + "assayComponentDesc": "ATG_SF_1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-SF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 136, + "geneName": "nuclear receptor subfamily 5, group A, member 1", + "description": null, + "geneSymbol": "NR5A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2516, + "officialSymbol": "NR5A1", + "officialFullName": "nuclear receptor subfamily 5, group A, member 1", + "uniprotAccessionNumber": "Q13285" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1366, + "assayComponentEndpointName": "ATG_SHP_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_SHP_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 933, + "assayComponentName": "ATG_SHP_TRANS2", + "assayComponentDesc": "ATG_SHP_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-SHP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 342, + "geneName": "nuclear receptor subfamily 0, group B, member 2", + "description": null, + "geneSymbol": "NR0B2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8431, + "officialSymbol": "NR0B2", + "officialFullName": "nuclear receptor subfamily 0, group B, member 2", + "uniprotAccessionNumber": "Q15466" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1367, + "assayComponentEndpointName": "ATG_ERb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_ERb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 934, + "assayComponentName": "ATG_ERb_TRANS2", + "assayComponentDesc": "ATG_ERb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ER-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1368, + "assayComponentEndpointName": "ATG_TLX_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TLX_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 935, + "assayComponentName": "ATG_TLX_TRANS2", + "assayComponentDesc": "ATG_TLX_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TLX RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 326, + "geneName": "nuclear receptor subfamily 2, group E, member 1", + "description": null, + "geneSymbol": "NR2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7101, + "officialSymbol": "NR2E1", + "officialFullName": "nuclear receptor subfamily 2, group E, member 1", + "uniprotAccessionNumber": "Q9Y466" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2251, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2312, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2252, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2313, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2253, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2314, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2254, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TR_RXR_BLA_Agonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2315, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_viability", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_viability is a component of the TOX21_TR_RXR_BLA_Agonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2255, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM TA_Antagonist", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2316, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2256, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM TA_Antagonist", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2317, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2257, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T21_TR_RXR_BLA_Antagonist", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2318, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2258, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TR_RXR_BLA_Antagonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2319, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability is a component of the TOX21_TR_RXR_BLA_Antagonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2277, + "assayComponentEndpointName": "NVS_ENZ_hPDE1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE1A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD1A1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2320, + "assayComponentName": "NVS_ENZ_hPDE1A1", + "assayComponentDesc": "NVS_ENZ_hPDE1A1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 1A [GeneSymbol:PDE1A | GeneID:5136 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 655, + "assayName": "NVS_ENZ_hPDE1A1", + "assayDesc": "NVS_ENZ_hPDE1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5353, + "geneName": "phosphodiesterase 1A", + "description": null, + "geneSymbol": "PDE1A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5136, + "officialSymbol": "PDE1A", + "officialFullName": "phosphodiesterase 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2279, + "assayComponentEndpointName": "NVS_ENZ_hPDE1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE1B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE1B1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE1B1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2321, + "assayComponentName": "NVS_ENZ_hPDE1B1", + "assayComponentDesc": "NVS_ENZ_hPDE1B1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE1B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 1B [GeneSymbol:PDE1B | GeneID:5153 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 656, + "assayName": "NVS_ENZ_hPDE1B1", + "assayDesc": "NVS_ENZ_hPDE1B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5369, + "geneName": "phosphodiesterase 1B", + "description": null, + "geneSymbol": "PDE1B", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5153, + "officialSymbol": "PDE1B", + "officialFullName": "phosphodiesterase 1B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2281, + "assayComponentEndpointName": "NVS_ENZ_hPDE2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2322, + "assayComponentName": "NVS_ENZ_hPDE2A", + "assayComponentDesc": "NVS_ENZ_hPDE2A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE2A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 2A [GeneSymbol:PDE2A | GeneID:5138 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 657, + "assayName": "NVS_ENZ_hPDE2A", + "assayDesc": "NVS_ENZ_hPDE2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5355, + "geneName": "phosphodiesterase 2A", + "description": null, + "geneSymbol": "PDE2A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5138, + "officialSymbol": "PDE2A", + "officialFullName": "phosphodiesterase 2A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2283, + "assayComponentEndpointName": "NVS_ENZ_hPDE3A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE3A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE3A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD3A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2323, + "assayComponentName": "NVS_ENZ_hPDE3A", + "assayComponentDesc": "NVS_ENZ_hPDE3A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE3A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 3A [GeneSymbol:PDE3A | GeneID:5139 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 658, + "assayName": "NVS_ENZ_hPDE3A", + "assayDesc": "NVS_ENZ_hPDE3A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5356, + "geneName": "phosphodiesterase 3A", + "description": null, + "geneSymbol": "PDE3A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5139, + "officialSymbol": "PDE3A", + "officialFullName": "phosphodiesterase 3A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1369, + "assayComponentEndpointName": "ATG_THRb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_THRb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 936, + "assayComponentName": "ATG_THRb_TRANS2", + "assayComponentDesc": "ATG_THRb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1370, + "assayComponentEndpointName": "ATG_EAR2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_EAR2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 937, + "assayComponentName": "ATG_EAR2_TRANS2", + "assayComponentDesc": "ATG_EAR2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-EAR2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 116, + "geneName": "nuclear receptor subfamily 2, group F, member 6", + "description": null, + "geneSymbol": "NR2F6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2063, + "officialSymbol": "NR2F6", + "officialFullName": "nuclear receptor subfamily 2, group F, member 6", + "uniprotAccessionNumber": "P10588" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1371, + "assayComponentEndpointName": "ATG_TR2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TR2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 938, + "assayComponentName": "ATG_TR2_TRANS2", + "assayComponentDesc": "ATG_TR2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TR2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 330, + "geneName": "nuclear receptor subfamily 2, group C, member 1", + "description": null, + "geneSymbol": "NR2C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7181, + "officialSymbol": "NR2C1", + "officialFullName": "nuclear receptor subfamily 2, group C, member 1", + "uniprotAccessionNumber": "P13056" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1372, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_MORT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_MORT was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_MORT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 939, + "assayComponentName": "Tanguay_ZF_120hpf_MORT", + "assayComponentDesc": "Tanguay_ZF_120hpf_Mort is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_Mort assay. It is designed to make measurements of mortality as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Mortality is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "embryonic mortality", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic mortality", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 2285, + "assayComponentEndpointName": "NVS_ENZ_hPDE4B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPD4B1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2324, + "assayComponentName": "NVS_ENZ_hPDE4B1", + "assayComponentDesc": "NVS_ENZ_hPDE4B1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4b, cAMP-specific [GeneSymbol:PDE4B | GeneID:5142 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 659, + "assayName": "NVS_ENZ_hPDE4B1", + "assayDesc": "NVS_ENZ_hPDE4B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5358, + "geneName": "phosphodiesterase 4B", + "description": null, + "geneSymbol": "PDE4B", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5142, + "officialSymbol": "PDE4B", + "officialFullName": "phosphodiesterase 4B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2287, + "assayComponentEndpointName": "NVS_ENZ_hPDE4C1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPD4C1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPD4C1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2325, + "assayComponentName": "NVS_ENZ_hPDE4C1", + "assayComponentDesc": "NVS_ENZ_hPDE4C1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4C1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4C, cAMP-specific [GeneSymbol:PDE4C | GeneID:5143 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 660, + "assayName": "NVS_ENZ_hPDE4C1", + "assayDesc": "NVS_ENZ_hPDE4C1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5359, + "geneName": "phosphodiesterase 4C", + "description": null, + "geneSymbol": "PDE4C", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5143, + "officialSymbol": "PDE4C", + "officialFullName": "phosphodiesterase 4C", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2289, + "assayComponentEndpointName": "NVS_ENZ_hPDE4D3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE4D3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2326, + "assayComponentName": "NVS_ENZ_hPDE4D3", + "assayComponentDesc": "NVS_ENZ_hPDE4D3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4D3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4D, cAMP-specific [GeneSymbol:PDE4D | GeneID:5144 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 661, + "assayName": "NVS_ENZ_hPDE4D3", + "assayDesc": "NVS_ENZ_hPDE4D3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5360, + "geneName": "phosphodiesterase 4D", + "description": null, + "geneSymbol": "PDE4D", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5144, + "officialSymbol": "PDE4D", + "officialFullName": "phosphodiesterase 4D", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2291, + "assayComponentEndpointName": "NVS_ENZ_hPDE7A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE7A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE7A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2327, + "assayComponentName": "NVS_ENZ_hPDE7A", + "assayComponentDesc": "NVS_ENZ_hPDE7A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE7A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 7A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5150 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 662, + "assayName": "NVS_ENZ_hPDE7A", + "assayDesc": "NVS_ENZ_hPDE7A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5366, + "geneName": "phosphodiesterase 7A", + "description": null, + "geneSymbol": "PDE7A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5150, + "officialSymbol": "PDE7A", + "officialFullName": "phosphodiesterase 7A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2293, + "assayComponentEndpointName": "NVS_ENZ_hPDE8A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE8A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE8A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2328, + "assayComponentName": "NVS_ENZ_hPDE8A1", + "assayComponentDesc": "NVS_ENZ_hPDE8A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE8A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 8A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5151 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 663, + "assayName": "NVS_ENZ_hPDE8A1", + "assayDesc": "NVS_ENZ_hPDE8A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5367, + "geneName": "phosphodiesterase 8A", + "description": null, + "geneSymbol": "PDE8A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5151, + "officialSymbol": "PDE8A", + "officialFullName": "phosphodiesterase 8A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2295, + "assayComponentEndpointName": "NVS_ENZ_hPDE9A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE9A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE9A2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2329, + "assayComponentName": "NVS_ENZ_hPDE9A2", + "assayComponentDesc": "NVS_ENZ_hPDE9A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE9A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 9A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5152 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 664, + "assayName": "NVS_ENZ_hPDE9A2", + "assayDesc": "NVS_ENZ_hPDE9A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5368, + "geneName": "phosphodiesterase 9A", + "description": null, + "geneSymbol": "PDE9A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5152, + "officialSymbol": "PDE9A", + "officialFullName": "phosphodiesterase 9A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2297, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2330, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2298, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2334, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2299, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2335, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2300, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2331, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2301, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N12", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2336, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2302, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N24", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2337, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2303, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2332, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2304, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2338, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2305, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2339, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2306, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2333, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2307, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N12", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2340, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2308, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N24", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2341, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2309, + "assayComponentEndpointName": "CCTE_GLTED_hDIO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "6-propyl-thiouracil (PTU)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 1", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2342, + "assayComponentName": "CCTE_GLTED_hDIO1", + "assayComponentDesc": "CCTE_GLTED_hDIO1 is the assay component measured from the CCTE_GLTED_hDIO1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO1 targets both the outer and inner rings, and thus can convert T4 to T3 or inactivate either of these thyroid hormones. ", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3’,5’-triiodo-L-thyronine (reverse T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 667, + "assayName": "CCTE_GLTED_hDIO1", + "assayDesc": "CCTE_GLTED_hDIO1 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 1 (DIO1) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2789, + "geneName": "iodothyronine deiodinase 1", + "description": null, + "geneSymbol": "DIO1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1733, + "officialSymbol": "DIO1", + "officialFullName": "iodothyronine deiodinase 1", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 2362, + "assayComponentEndpointName": "TOX21_PXR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_PXR_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "46 uM rifampicin ", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2369, + "assayComponentName": "TOX21_PXR_viability", + "assayComponentDesc": "TOX21_PXR_viability is a component of the TOX21_PXR assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 670, + "assayName": "TOX21_PXR", + "assayDesc": "The TOX21_PXR is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing on a microplate: 1536-well plate. To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.bcp.2020.114368", + "url": "https://pubmed.ncbi.nlm.nih.gov/33333074/", + "pmid": 33333074, + "title": "Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library", + "author": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M", + "citation": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M. Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol. 2021 Feb;184:114368. doi: 10.1016/j.bcp.2020.114368. Epub 2020 Dec 14. PMID: 33333074.", + "otherId": "0", + "citationId": 288, + "otherSource": "" + } + }, + { + "aeid": 2363, + "assayComponentEndpointName": "TOX21_PXR_agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "46 uM rifampicin ", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2370, + "assayComponentName": "TOX21_PXR_agonist", + "assayComponentDesc": "TOX21_PXR_agonist is one of one assay component(s) measured or calculated from the TOX21_PXR assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 670, + "assayName": "TOX21_PXR", + "assayDesc": "The TOX21_PXR is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing on a microplate: 1536-well plate. To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.bcp.2020.114368", + "url": "https://pubmed.ncbi.nlm.nih.gov/33333074/", + "pmid": 33333074, + "title": "Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library", + "author": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M", + "citation": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M. Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol. 2021 Feb;184:114368. doi: 10.1016/j.bcp.2020.114368. Epub 2020 Dec 14. PMID: 33333074.", + "otherId": "0", + "citationId": 288, + "otherSource": "" + } + }, + { + "aeid": 2364, + "assayComponentEndpointName": "TOX21_TRHR_HEK293_agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRHR_HEK293_Agonist used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TRH", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2371, + "assayComponentName": "TOX21_TRHR_HEK293_agonist", + "assayComponentDesc": "TOX21_TRHR_HEK293_Agonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", + "assayComponentTargetDesc": "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay. Activation of this GPCR is indicated by increased intracellular calcium as measured in this cell-based fluorescent reporter assay.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "intracellular calcium", + "biologicalProcessTarget": "receptor activation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FDSS 7000EX kinetic plate reader ", + "keyAssayReagentType": "chemical", + "keyAssayReagent": "intracellular calcium", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "intracellular calcium", + "aid": 671, + "assayName": "TOX21_TRHR_HEK293", + "assayDesc": "TOX21_TRHR_HEK293 assay is a cell-based assay, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. It has the potential to screen G protein-coupled receptors. A compound/drug can either activate (agonist) or suppress (antagonist) GPCRs that can be monitored by levels of intracellular calcium. Using this assay, the Tox21 10K compound library was screened to identify potential TRHR agonists.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7000, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "TRHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7201, + "officialSymbol": "TRHR", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2365, + "assayComponentEndpointName": "TOX21_TRHR_HEK293_antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRHR_HEK293_Antagonist used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T293", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2372, + "assayComponentName": "TOX21_TRHR_HEK293_antagonist", + "assayComponentDesc": "TOX21_TRHR_HEK293_Antagonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", + "assayComponentTargetDesc": "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Inactivation of this GPCR is indicated by decreased intracellular calcium as measured in this cell-based fluorescent assay.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "intracellular calcium", + "biologicalProcessTarget": "receptor activation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FDSS 7000EX kinetic plate reader ", + "keyAssayReagentType": "chemical", + "keyAssayReagent": "intracellular calcium", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "intracellular calcium", + "aid": 671, + "assayName": "TOX21_TRHR_HEK293", + "assayDesc": "TOX21_TRHR_HEK293 assay is a cell-based assay, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. It has the potential to screen G protein-coupled receptors. A compound/drug can either activate (agonist) or suppress (antagonist) GPCRs that can be monitored by levels of intracellular calcium. Using this assay, the Tox21 10K compound library was screened to identify potential TRHR agonists.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7000, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "TRHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7201, + "officialSymbol": "TRHR", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2366, + "assayComponentEndpointName": "TOX21_CASP3_HEPG2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_HEPG2 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity following compound treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "apoptosis", + "intendedTargetFamilySub": "caspase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2373, + "assayComponentName": "TOX21_CASP3_HEPG2", + "assayComponentDesc": "TOX21_CASP3_HEPG2 is a component of the TOX21_CASP3_HEPG2 assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "caspase activity", + "biologicalProcessTarget": "apoptosis", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Caspase-Glo 3/7", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Caspase-Glo 3/7 reagent", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 672, + "assayName": "TOX21_CASP3_HEPG2", + "assayDesc": "The TOX21_CASP3_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. HepG2 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1373, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_YSE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_YSE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 940, + "assayComponentName": "Tanguay_ZF_120hpf_YSE", + "assayComponentDesc": "Tanguay_ZF_120hpf_YSE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_YSE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "extraembryonic membrane development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1374, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_AXIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_AXIS was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 941, + "assayComponentName": "Tanguay_ZF_120hpf_AXIS", + "assayComponentDesc": "Tanguay_ZF_120hpf_AXIS is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_AXIS assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "body axis morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1375, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_EYE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_EYE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_EYE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 942, + "assayComponentName": "Tanguay_ZF_120hpf_EYE", + "assayComponentDesc": "Tanguay_ZF_120hpf_EYE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_EYE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic eye development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1376, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SNOU", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SNOU was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SNOU, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 943, + "assayComponentName": "Tanguay_ZF_120hpf_SNOU", + "assayComponentDesc": "Tanguay_ZF_120hpf_SNOU is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SNOU assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic snout morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1377, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_JAW", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_JAW was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_JAW, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 944, + "assayComponentName": "Tanguay_ZF_120hpf_JAW", + "assayComponentDesc": "Tanguay_ZF_120hpf_JAW is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_JAW assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic jaw development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1378, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_OTIC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_OTIC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_OTIC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 945, + "assayComponentName": "Tanguay_ZF_120hpf_OTIC", + "assayComponentDesc": "Tanguay_ZF_120hpf_OTIC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_OTIC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "otic vesicle morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1379, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 946, + "assayComponentName": "Tanguay_ZF_120hpf_PE", + "assayComponentDesc": "Tanguay_ZF_120hpf_PE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1380, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_BRAI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_BRAI was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_BRAI, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 947, + "assayComponentName": "Tanguay_ZF_120hpf_BRAI", + "assayComponentDesc": "Tanguay_ZF_120hpf_BRAI is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_BRAI assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "brain morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1381, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SOMI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SOMI was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SOMI, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 948, + "assayComponentName": "Tanguay_ZF_120hpf_SOMI", + "assayComponentDesc": "Tanguay_ZF_120hpf_SOMI is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SOMI assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "somitogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1382, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PFIN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PFIN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PFIN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 949, + "assayComponentName": "Tanguay_ZF_120hpf_PFIN", + "assayComponentDesc": "Tanguay_ZF_120hpf_PFIN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PFIN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "pectoral fin morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1383, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_CFIN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_CFIN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CFIN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 950, + "assayComponentName": "Tanguay_ZF_120hpf_CFIN", + "assayComponentDesc": "Tanguay_ZF_120hpf_CFIN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_CFIN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "caudal fin morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1384, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PIG was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PIG, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 951, + "assayComponentName": "Tanguay_ZF_120hpf_PIG", + "assayComponentDesc": "Tanguay_ZF_120hpf_PIG is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PIG assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic pigmentation", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1385, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_CIRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_CIRC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CIRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 952, + "assayComponentName": "Tanguay_ZF_120hpf_CIRC", + "assayComponentDesc": "Tanguay_ZF_120hpf_CIRC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_CIRC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "angiogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1386, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_TRUN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_TRUN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TRUN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 953, + "assayComponentName": "Tanguay_ZF_120hpf_TRUN", + "assayComponentDesc": "Tanguay_ZF_120hpf_TRUN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_TRUN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1387, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SWIM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SWIM was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SWIM, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 954, + "assayComponentName": "Tanguay_ZF_120hpf_SWIM", + "assayComponentDesc": "Tanguay_ZF_120hpf_SWIM is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SWIM assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "swim bladder morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1388, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_NC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_NC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_NC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 955, + "assayComponentName": "Tanguay_ZF_120hpf_NC", + "assayComponentDesc": "Tanguay_ZF_120hpf_NC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_NC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic notochord morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1389, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_TR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_TR was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 956, + "assayComponentName": "Tanguay_ZF_120hpf_TR", + "assayComponentDesc": "Tanguay_ZF_120hpf_TR is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_TR assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic functional response", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1390, + "assayComponentEndpointName": "LTEA_HepaRG_SLC22A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC22A6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC22A6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 957, + "assayComponentName": "LTEA_HepaRG_SLC22A6", + "assayComponentDesc": "LTEA_HepaRG_SLC22A6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 353, + "geneName": "solute carrier family 22 (organic anion transporter), member 6", + "description": null, + "geneSymbol": "SLC22A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9356, + "officialSymbol": "SLC22A6", + "officialFullName": "solute carrier family 22 (organic anion transporter), member 6", + "uniprotAccessionNumber": "Q4U2R8" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1392, + "assayComponentEndpointName": "LTEA_HepaRG_KLK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KLK3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KLK3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is Cellular remodeling.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "Cellular remodeling", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 958, + "assayComponentName": "LTEA_HepaRG_KLK3", + "assayComponentDesc": "LTEA_HepaRG_KLK3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cellular remodeling.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 25, + "geneName": "kallikrein-related peptidase 3", + "description": null, + "geneSymbol": "KLK3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 354, + "officialSymbol": "KLK3", + "officialFullName": "kallikrein-related peptidase 3", + "uniprotAccessionNumber": "P07288" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1394, + "assayComponentEndpointName": "LTEA_HepaRG_SLC10A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC10A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC10A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium/bile acid cotransporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "sodium/bile acid cotransporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 959, + "assayComponentName": "LTEA_HepaRG_SLC10A1", + "assayComponentDesc": "LTEA_HepaRG_SLC10A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 299, + "geneName": "solute carrier family 10 (sodium/bile acid cotransporter), member 1", + "description": null, + "geneSymbol": "SLC10A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6554, + "officialSymbol": "SLC10A1", + "officialFullName": "solute carrier family 10 (sodium/bile acid cotransporter), member 1", + "uniprotAccessionNumber": "Q14973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1396, + "assayComponentEndpointName": "LTEA_HepaRG_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 960, + "assayComponentName": "LTEA_HepaRG_MMP1", + "assayComponentDesc": "LTEA_HepaRG_MMP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1398, + "assayComponentEndpointName": "LTEA_HepaRG_CYP24A1_1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP24A1_1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP24A1_1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 961, + "assayComponentName": "LTEA_HepaRG_CYP24A1_1", + "assayComponentDesc": "LTEA_HepaRG_CYP24A1_1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1507, + "assayComponentEndpointName": "CCTE_Padilla_ZF_144hpf_TERATOSCORE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defect as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the malformation intended target family, where the subfamily is total.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "total", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 962, + "assayComponentName": "CCTE_Padilla_ZF_144hpf_TERATOSCORE", + "assayComponentDesc": "CCTE_Padilla_ZF_144hpf_TERATOSCORE is one of one assay component(s) measured or calculated from the CCTE_Padilla_ZF_144hpf assay. It is designed to make measurements of developmental malformations and mortality as detected with brightfield microscopy.", + "assayComponentTargetDesc": "Individual embryos were examined daily for malformations, failure to hatch and mortality. Results were scored by customized rubric and a composite score derived.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "embryo development", + "biologicalProcessTarget": "regulation of development", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "physical feature", + "aid": 410, + "assayName": "CCTE_Padilla_ZF_144hpf", + "assayDesc": "Zebrafish embryos were exposed to chemicals starting 6 hr post-fertilization for 5 days in 96-well plates. Developing larvae were examined microscopically daily for malformation and mortality. ", + "timepointHr": 144.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.4, + "asid": 12, + "assaySourceName": "CCTE_PADILLA", + "assaySourceLongName": "CCTE Padilla Lab", + "assaySourceDesc": "The Padilla laboratory at the EPA Center for Computational Toxicology focuses on the development and screening of zebrafish assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2011.10.018", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22182468", + "pmid": 22182468, + "title": "Zebrafish developmental screening of the ToxCast™ Phase I chemical library", + "author": "Padilla S, Corum D, Padnos B, Hunter DL, Beam A, Houck KA, Sipes N, Kleinstreuer N, Knudsen T, Dix DJ, Reif DM", + "citation": "Padilla S, Corum D, Padnos B, Hunter DL, Beam A, Houck KA, Sipes N, Kleinstreuer N, Knudsen T, Dix DJ, Reif DM. Zebrafish developmental screening of the ToxCast™ Phase I chemical library. Reprod Toxicol. 2012 Apr;33(2):174-87. doi: 10.1016/j.reprotox.2011.10.018. Epub 2011 Dec 9. PubMed PMID: 22182468.", + "otherId": "0", + "citationId": 217, + "otherSource": "" + } + }, + { + "aeid": 2367, + "assayComponentEndpointName": "TOX21_CASP3_HEPG2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_HEPG2_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2374, + "assayComponentName": "TOX21_CASP3_HEPG2_viability", + "assayComponentDesc": "TOX21_CASP3_HEPG2_viability is a component of the TOX21_CASP3_HEPG2 assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay ", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 672, + "assayName": "TOX21_CASP3_HEPG2", + "assayDesc": "The TOX21_CASP3_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. HepG2 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2368, + "assayComponentEndpointName": "TOX21_CASP3_CHO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_CHO was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "apoptosis", + "intendedTargetFamilySub": "caspase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2375, + "assayComponentName": "TOX21_CASP3_CHO", + "assayComponentDesc": "TOX21_CASP3_CHO is a component of the TOX21_CASP3_CHO assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "caspase activity", + "biologicalProcessTarget": "apoptosis", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Caspase-Glo 3/7", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Caspase-Glo 3/7 reagent", + "technologicalTargetType": "chemical ", + "technologicalTargetTypeSub": "ATP", + "aid": 678, + "assayName": "TOX21_CASP3_CHO", + "assayDesc": "The TOX21_CASP3_CHO is a cell-based, single-readout assay that uses CHO-K1, a hamster ovary cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. Wild type CHO-K1 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2369, + "assayComponentEndpointName": "TOX21_CASP3_CHO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2376, + "assayComponentName": "TOX21_CASP3_CHO_viability", + "assayComponentDesc": "TOX21_CASP3_CHO_viability is a component of the TOX21_CASP3_CHO assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay ", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 678, + "assayName": "TOX21_CASP3_CHO", + "assayDesc": "The TOX21_CASP3_CHO is a cell-based, single-readout assay that uses CHO-K1, a hamster ovary cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. Wild type CHO-K1 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2370, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2377, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2371, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2378, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2372, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "growth factor receptor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2379, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2373, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_SBE_BLA_Antagonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2380, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_viability is a component of the TOX21_SBE_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2374, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2381, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2375, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_SBE_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2382, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2376, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "growth factor receptor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2383, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2377, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_SBE_BLA_Agonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2384, + "assayComponentName": "TOX21_SBE_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_viability is a component of the TOX21_SBE_BLA_Agonist assay. This component measures cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2386, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DMSO", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2393, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Loss of DHT-induced red fluorescence in nucleolar region of the cell nucleus is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2387, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "dihydroxytestosterone (DHT)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2394, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Increased red fluorescence in nucleolar region of the cell nucleus is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2390, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DMSO", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2397, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Decrease of the ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2391, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "dihydroxytestosterone (DHT)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2398, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Increased ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2442, + "assayComponentEndpointName": "CCTE_Simmons_MITO_basal_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Fenpyroximate", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2440, + "assayComponentName": "CCTE_Simmons_MITO_basal_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_basal_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of basal respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Basal respiration rate is caculated from the oxygen consumption rates at T6 (36 min) following test compound injection, at 18 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "basal respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2444, + "assayComponentEndpointName": "CCTE_Simmons_MITO_max_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Fenpyroximate", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2441, + "assayComponentName": "CCTE_Simmons_MITO_max_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_max_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of maximal respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Maximal respiration is calculated as oxygen consumption rates at T9 (54 min)following test compound injection at T6 and FCCP (uncoupler reagent), at 36 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "maximal respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2446, + "assayComponentEndpointName": "CCTE_Simmons_MITO_inhib_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "none", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2442, + "assayComponentName": "CCTE_Simmons_MITO_inhib_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_inhib_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of inhibited respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Inhibited respiration is calculated from the oxygen consumption rates at T12 (54 min) following test compound injection at T6, uncoupling at T9, and rotenone/antimycin A (electron transport chain inhibitor reagents), at 54 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "inhibited respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2450, + "assayComponentEndpointName": "CCTE_Simmons_MITO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "blank wells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2443, + "assayComponentName": "CCTE_Simmons_MITO_viability", + "assayComponentDesc": "CCTE_Simmons_MITO_viability is one of 4 assay components measured from the CCTE_Simmons_MITO assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology. ", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2451, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2445, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_MCF7", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a full screening experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 1508, + "assayComponentEndpointName": "CCTE_Simmons_AUR_TPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "methimazole (MMI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 963, + "assayComponentName": "CCTE_Simmons_AUR_TPO", + "assayComponentDesc": "CCTE_Simmons_AUR_TPO is the assay component measured from the CCTE_Simmons_AUR_TPO assay. It is designed to make measurements of thyroperoxidase (TPO) activity as detected with fluorescence intensity signals by Fluorescence using the Amplex UltraRed technology as a form of enzyme activity reporter.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Amplex UltraRed", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 411, + "assayName": "CCTE_Simmons_AUR_TPO", + "assayDesc": "CCTE_Simmons_AUR_TPO is a biochemical, single-readout assay that uses microsomes from rat thyroid gland in a tissue-based cell-free assay.Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "thyroid gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat thyroid gland", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 498, + "geneName": "thyroid peroxidase", + "description": null, + "geneSymbol": "Tpo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54314, + "officialSymbol": "Tpo", + "officialFullName": "thyroid peroxidase", + "uniprotAccessionNumber": "P14650" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1509, + "assayComponentEndpointName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "LUCINH1;LUCINH2", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 964, + "assayComponentName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "assayComponentDesc": "CCTE_Simmons_CellTiterGLO_HEK293T is the assay component measured from the CCTE_Simmons_CellTiterGLO_HEK293T assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology. This is a secondary cytotoxicity assay to CCTE_Simmons_AUR_TPO to estimate a cellular tolerance limit.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo Fluor] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo fluor", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 412, + "assayName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "assayDesc": "CCTE_Simmons_CellTiterGLO_HEK293T is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1611, + "assayComponentEndpointName": "CLD_ABCB1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_6hr was analyzed at the endpoint, CLD_ABCB1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 838, + "assayComponentName": "CLD_ABCB1_6hr", + "assayComponentDesc": "CLD_ABCB1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1612, + "assayComponentEndpointName": "CLD_ABCB11_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_6hr was analyzed at the endpoint, CLD_ABCB11_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 839, + "assayComponentName": "CLD_ABCB11_6hr", + "assayComponentDesc": "CLD_ABCB11_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1613, + "assayComponentEndpointName": "CLD_ABCG2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_6hr was analyzed at the endpoint, CLD_ABCG2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 840, + "assayComponentName": "CLD_ABCG2_6hr", + "assayComponentDesc": "CLD_ABCG2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1614, + "assayComponentEndpointName": "CLD_ACTIN_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_6hr was analyzed at the endpoint, CLD_ACTIN_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 841, + "assayComponentName": "CLD_ACTIN_6hr", + "assayComponentDesc": "CLD_ACTIN_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1615, + "assayComponentEndpointName": "CLD_CYP1A1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_6hr was analyzed at the endpoint, CLD_CYP1A1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 842, + "assayComponentName": "CLD_CYP1A1_6hr", + "assayComponentDesc": "CLD_CYP1A1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1616, + "assayComponentEndpointName": "CLD_CYP1A2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_6hr was analyzed at the endpoint, CLD_CYP1A2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 843, + "assayComponentName": "CLD_CYP1A2_6hr", + "assayComponentDesc": "CLD_CYP1A2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1617, + "assayComponentEndpointName": "CLD_CYP2B6_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 844, + "assayComponentName": "CLD_CYP2B6_6hr", + "assayComponentDesc": "CLD_CYP2B6_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1618, + "assayComponentEndpointName": "CLD_CYP2C19_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_6hr was analyzed at the endpoint, CLD_CYP2C19_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 845, + "assayComponentName": "CLD_CYP2C19_6hr", + "assayComponentDesc": "CLD_CYP2C19_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1619, + "assayComponentEndpointName": "CLD_CYP2C9_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_6hr was analyzed at the endpoint, CLD_CYP2C9_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 846, + "assayComponentName": "CLD_CYP2C9_6hr", + "assayComponentDesc": "CLD_CYP2C9_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1620, + "assayComponentEndpointName": "CLD_CYP3A4_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_6hr was analyzed at the endpoint, CLD_CYP3A4_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 847, + "assayComponentName": "CLD_CYP3A4_6hr", + "assayComponentDesc": "CLD_CYP3A4_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1621, + "assayComponentEndpointName": "CLD_GAPDH_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_6hr was analyzed at the endpoint, CLD_GAPDH_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 848, + "assayComponentName": "CLD_GAPDH_6hr", + "assayComponentDesc": "CLD_GAPDH_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1622, + "assayComponentEndpointName": "CLD_GSTA2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_6hr was analyzed at the endpoint, CLD_GSTA2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 849, + "assayComponentName": "CLD_GSTA2_6hr", + "assayComponentDesc": "CLD_GSTA2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1623, + "assayComponentEndpointName": "CLD_HMGCS2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_6hr was analyzed at the endpoint, CLD_HMGCS2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 850, + "assayComponentName": "CLD_HMGCS2_6hr", + "assayComponentDesc": "CLD_HMGCS2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1624, + "assayComponentEndpointName": "CLD_SLCO1B1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_6hr was analyzed at the endpoint, CLD_SLCO1B1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 851, + "assayComponentName": "CLD_SLCO1B1_6hr", + "assayComponentDesc": "CLD_SLCO1B1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1625, + "assayComponentEndpointName": "CLD_SULT2A_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_6hr was analyzed at the endpoint, CLD_SULT2A_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 852, + "assayComponentName": "CLD_SULT2A_6hr", + "assayComponentDesc": "CLD_SULT2A_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1626, + "assayComponentEndpointName": "CLD_UGT1A1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_6hr was analyzed at the endpoint, CLD_UGT1A1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 853, + "assayComponentName": "CLD_UGT1A1_6hr", + "assayComponentDesc": "CLD_UGT1A1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1627, + "assayComponentEndpointName": "CLD_ABCB1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_24hr was analyzed at the endpoint, CLD_ABCB1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 854, + "assayComponentName": "CLD_ABCB1_24hr", + "assayComponentDesc": "CLD_ABCB1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1628, + "assayComponentEndpointName": "CLD_ABCB11_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_24hr was analyzed at the endpoint, CLD_ABCB11_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 855, + "assayComponentName": "CLD_ABCB11_24hr", + "assayComponentDesc": "CLD_ABCB11_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1629, + "assayComponentEndpointName": "CLD_ABCG2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_24hr was analyzed at the endpoint, CLD_ABCG2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 856, + "assayComponentName": "CLD_ABCG2_24hr", + "assayComponentDesc": "CLD_ABCG2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1630, + "assayComponentEndpointName": "CLD_ACTIN_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_24hr was analyzed at the endpoint, CLD_ACTIN_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 857, + "assayComponentName": "CLD_ACTIN_24hr", + "assayComponentDesc": "CLD_ACTIN_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1631, + "assayComponentEndpointName": "CLD_CYP1A1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_24hr was analyzed at the endpoint, CLD_CYP1A1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 858, + "assayComponentName": "CLD_CYP1A1_24hr", + "assayComponentDesc": "CLD_CYP1A1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1632, + "assayComponentEndpointName": "CLD_CYP1A2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_24hr was analyzed at the endpoint, CLD_CYP1A2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 859, + "assayComponentName": "CLD_CYP1A2_24hr", + "assayComponentDesc": "CLD_CYP1A2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1633, + "assayComponentEndpointName": "CLD_CYP2B6_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 860, + "assayComponentName": "CLD_CYP2B6_24hr", + "assayComponentDesc": "CLD_CYP2B6_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1634, + "assayComponentEndpointName": "CLD_CYP2C19_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_24hr was analyzed at the endpoint, CLD_CYP2C19_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 861, + "assayComponentName": "CLD_CYP2C19_24hr", + "assayComponentDesc": "CLD_CYP2C19_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1635, + "assayComponentEndpointName": "CLD_CYP2C9_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_24hr was analyzed at the endpoint, CLD_CYP2C9_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 862, + "assayComponentName": "CLD_CYP2C9_24hr", + "assayComponentDesc": "CLD_CYP2C9_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1636, + "assayComponentEndpointName": "CLD_CYP3A4_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 863, + "assayComponentName": "CLD_CYP3A4_24hr", + "assayComponentDesc": "CLD_CYP3A4_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1637, + "assayComponentEndpointName": "CLD_GAPDH_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_24hr was analyzed at the endpoint, CLD_GAPDH_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 864, + "assayComponentName": "CLD_GAPDH_24hr", + "assayComponentDesc": "CLD_GAPDH_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1638, + "assayComponentEndpointName": "CLD_GSTA2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_24hr was analyzed at the endpoint, CLD_GSTA2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 865, + "assayComponentName": "CLD_GSTA2_24hr", + "assayComponentDesc": "CLD_GSTA2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1639, + "assayComponentEndpointName": "CLD_HMGCS2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_24hr was analyzed at the endpoint, CLD_HMGCS2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 866, + "assayComponentName": "CLD_HMGCS2_24hr", + "assayComponentDesc": "CLD_HMGCS2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1640, + "assayComponentEndpointName": "CLD_SLCO1B1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_24hr was analyzed at the endpoint, CLD_SLCO1B1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 867, + "assayComponentName": "CLD_SLCO1B1_24hr", + "assayComponentDesc": "CLD_SLCO1B1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1641, + "assayComponentEndpointName": "CLD_SULT2A_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_24hr was analyzed at the endpoint, CLD_SULT2A_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 868, + "assayComponentName": "CLD_SULT2A_24hr", + "assayComponentDesc": "CLD_SULT2A_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1642, + "assayComponentEndpointName": "CLD_UGT1A1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_24hr was analyzed at the endpoint, CLD_UGT1A1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 869, + "assayComponentName": "CLD_UGT1A1_24hr", + "assayComponentDesc": "CLD_UGT1A1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1643, + "assayComponentEndpointName": "CLD_ABCB1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_48hr was analyzed at the endpoint, CLD_ABCB1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 870, + "assayComponentName": "CLD_ABCB1_48hr", + "assayComponentDesc": "CLD_ABCB1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1644, + "assayComponentEndpointName": "CLD_ABCB11_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_48hr was analyzed at the endpoint, CLD_ABCB11_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 871, + "assayComponentName": "CLD_ABCB11_48hr", + "assayComponentDesc": "CLD_ABCB11_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1645, + "assayComponentEndpointName": "CLD_ABCG2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_48hr was analyzed at the endpoint, CLD_ABCG2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 872, + "assayComponentName": "CLD_ABCG2_48hr", + "assayComponentDesc": "CLD_ABCG2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1646, + "assayComponentEndpointName": "CLD_ACTIN_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_48hr was analyzed at the endpoint, CLD_ACTIN_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 873, + "assayComponentName": "CLD_ACTIN_48hr", + "assayComponentDesc": "CLD_ACTIN_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1647, + "assayComponentEndpointName": "CLD_CYP1A1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_48hr was analyzed at the endpoint, CLD_CYP1A1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 874, + "assayComponentName": "CLD_CYP1A1_48hr", + "assayComponentDesc": "CLD_CYP1A1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1648, + "assayComponentEndpointName": "CLD_CYP1A2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_48hr was analyzed at the endpoint, CLD_CYP1A2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 875, + "assayComponentName": "CLD_CYP1A2_48hr", + "assayComponentDesc": "CLD_CYP1A2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1649, + "assayComponentEndpointName": "CLD_CYP2B6_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 876, + "assayComponentName": "CLD_CYP2B6_48hr", + "assayComponentDesc": "CLD_CYP2B6_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1650, + "assayComponentEndpointName": "CLD_CYP2C19_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_48hr was analyzed at the endpoint, CLD_CYP2C19_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 877, + "assayComponentName": "CLD_CYP2C19_48hr", + "assayComponentDesc": "CLD_CYP2C19_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1651, + "assayComponentEndpointName": "CLD_CYP2C9_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_48hr was analyzed at the endpoint, CLD_CYP2C9_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 878, + "assayComponentName": "CLD_CYP2C9_48hr", + "assayComponentDesc": "CLD_CYP2C9_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1652, + "assayComponentEndpointName": "CLD_CYP3A4_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 879, + "assayComponentName": "CLD_CYP3A4_48hr", + "assayComponentDesc": "CLD_CYP3A4_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1653, + "assayComponentEndpointName": "CLD_GAPDH_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_48hr was analyzed at the endpoint, CLD_GAPDH_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 880, + "assayComponentName": "CLD_GAPDH_48hr", + "assayComponentDesc": "CLD_GAPDH_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1654, + "assayComponentEndpointName": "CLD_GSTA2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_48hr was analyzed at the endpoint, CLD_GSTA2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 881, + "assayComponentName": "CLD_GSTA2_48hr", + "assayComponentDesc": "CLD_GSTA2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1655, + "assayComponentEndpointName": "CLD_HMGCS2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_48hr was analyzed at the endpoint, CLD_HMGCS2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 882, + "assayComponentName": "CLD_HMGCS2_48hr", + "assayComponentDesc": "CLD_HMGCS2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1656, + "assayComponentEndpointName": "CLD_SLCO1B1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_48hr was analyzed at the endpoint, CLD_SLCO1B1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 883, + "assayComponentName": "CLD_SLCO1B1_48hr", + "assayComponentDesc": "CLD_SLCO1B1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1657, + "assayComponentEndpointName": "CLD_SULT2A_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_48hr was analyzed at the endpoint, CLD_SULT2A_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 884, + "assayComponentName": "CLD_SULT2A_48hr", + "assayComponentDesc": "CLD_SULT2A_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1658, + "assayComponentEndpointName": "CLD_UGT1A1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_48hr was analyzed at the endpoint, CLD_UGT1A1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 885, + "assayComponentName": "CLD_UGT1A1_48hr", + "assayComponentDesc": "CLD_UGT1A1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1659, + "assayComponentEndpointName": "TOX21_RAR_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Retinol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1013, + "assayComponentName": "TOX21_RAR_LUC_Agonist", + "assayComponentDesc": "TOX21_RAR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RAR_LUC_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha [GeneSymbol:RARA]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 425, + "assayName": "TOX21_RAR_LUC_Agonist", + "assayDesc": "TOX21_RAR_LUC_Agonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1660, + "assayComponentEndpointName": "TOX21_RAR_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1014, + "assayComponentName": "TOX21_RAR_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_RAR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 425, + "assayName": "TOX21_RAR_LUC_Agonist", + "assayDesc": "TOX21_RAR_LUC_Agonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1661, + "assayComponentEndpointName": "TOX21_RORg_LUC_CHO_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TO-901317", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1015, + "assayComponentName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayComponentDesc": "TOX21_RORg_LUC_CHO_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RORg_LUC_CHO_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RORg_LUC_CHO_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoid-related orphan receptor gamma [GeneSymbol:NR1F3]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 426, + "assayName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayDesc": "TOX21_RORg_LUC_CHO_Antagonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 17 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 17.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 286, + "geneName": "RAR-related orphan receptor C", + "description": null, + "geneSymbol": "RORC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6097, + "officialSymbol": "RORC", + "officialFullName": "RAR-related orphan receptor C", + "uniprotAccessionNumber": "P51449" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1662, + "assayComponentEndpointName": "TOX21_RORg_LUC_CHO_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1016, + "assayComponentName": "TOX21_RORg_LUC_CHO_Antagonist_viability", + "assayComponentDesc": "TOX21_RORg_LUC_CHO_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 426, + "assayName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayDesc": "TOX21_RORg_LUC_CHO_Antagonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 17 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 17.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1664, + "assayComponentEndpointName": "CEETOX_H295R_MTT_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CEETOX_H295R_MTT_cell_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter in the MTT cytotoxicity assay, gain or loss-of-signal activity can be used to monitor cellular processes to understand changes in proliferation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1017, + "assayComponentName": "CEETOX_H295R_MTT_cell_viability", + "assayComponentDesc": "CEETOX_H295R_MTT_cell_viability is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by MTT cytotoxicity assay technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "MTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": null, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 1682, + "assayComponentEndpointName": "STM_H9_CystineISnorm_perc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_CystineISnorm_perc was analyzed at the assay endpoint STM_H9_CystineISnorm_perc in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Cystine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1027, + "assayComponentName": "STM_H9_CystineISnorm_perc", + "assayComponentDesc": "STM_H9_CystineISnorm_perc is one of 10 components calculated in the STM_H9_secretome assay. It measures the integrated area of the endogenous cystine normalized to the spiked-in isotopically labeled standard and to the median value of the 0.1% DMSO neutral control treatment using UPLC-HRMS technology.", + "assayComponentTargetDesc": "Changes in cystine utilization relative to the neutral control.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "metabolite detection", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "integrated area of the endogenous cystine normalized to the spiked-in isotopically labeled standard normalized the median value of the 0.1% DMSO neutral control treatment ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "cystine/C13Cystine/DMSO", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "cystine/C13Cystine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1688, + "assayComponentEndpointName": "STM_H9_OrnithineISnorm_perc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Ornithine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1030, + "assayComponentName": "STM_H9_OrnithineISnorm_perc", + "assayComponentDesc": "STM_H9_OrnithineISnorm is one of 10 components calculated in the STM_H9_secretome assay. It measures the integrated area of the endogenous ornithine normalized to the spiked-in isotopically labeled standard and to the median value of the 0.1% DMSO neutral control treatment using UPLC-HRMS technology.", + "assayComponentTargetDesc": "Changes in ornithine release relative to the neutral control. ", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "metabolite detection", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "integrated area of the endogenous ornithine normalized to the spiked-in isotopically labeled standard normalized the median value of the 0.1% DMSO neutral control treatment ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Ornithine/C13Ornithine/DMSO", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "ornithine/C13Ornithine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1690, + "assayComponentEndpointName": "STM_H9_OrnCyssISnorm_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_OrnCyssISnorm_ratio was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_ratio in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Ornithine/Cystine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1031, + "assayComponentName": "STM_H9_OrnCyssISnorm_ratio", + "assayComponentDesc": "STM_H9_OrnCyssISnorm_ratio is one of 10 components calculated in the STM_H9_secretome assay. It is the ratio value of OrnISnorm_perc to CyssISnorm_perc.", + "assayComponentTargetDesc": "Change in the ratio value of Orn release to Cyss utilization, indicative of the targeted biomarker of the assay. ", + "parameterReadoutType": "single", + "assayDesignType": "ratiometric", + "assayDesignTypeSub": "metabolite ratio", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Orn:Cyss ratio calculated from DMSO-normalized values ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "ratio", + "keyAssayReagent": "ornithine/cystine", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "ornithine/cystine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1744, + "assayComponentEndpointName": "NVS_ENZ_hPPP3CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP3CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP3CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP3CA.\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1034, + "assayComponentName": "NVS_ENZ_hPPP3CA", + "assayComponentDesc": "NVS_ENZ_hPPP3CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP3CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 3, catalytic subunit, alpha isozyme [GeneSymbol:PPP3CA | GeneID:5530 |.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 429, + "assayName": "NVS_ENZ_hPPP3CA", + "assayDesc": "NVS_ENZ_hPPP3CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5655, + "geneName": "protein phosphatase 3 catalytic subunit alpha", + "description": null, + "geneSymbol": "PPP3CA", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5530, + "officialSymbol": "PPP3CA", + "officialFullName": "protein phosphatase 3 catalytic subunit alpha", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1746, + "assayComponentEndpointName": "ATG_GPCR_ADORA2A_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADORA2A_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1035, + "assayComponentName": "ATG_GPCR_ADORA2A_TRANS", + "assayComponentDesc": "ATG_GPCR_ADORA2A_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADORA2A, which is responsive to the adenosine A2a receptor [GeneSymbol:ADORA2A| GeneID:135 | Uniprot_SwissProt_Accession:P29274].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADORA2A RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1748, + "assayComponentEndpointName": "ATG_GPCR_ADORA2B_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADORA2B_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1036, + "assayComponentName": "ATG_GPCR_ADORA2B_TRANS", + "assayComponentDesc": "ATG_GPCR_ADORA2B_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADORA2B, which is responsive to the adenosine A2b receptor [GeneSymbol:ADORA2B| GeneID:136 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADORA2B RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 482, + "geneName": "adenosine A2b receptor", + "description": null, + "geneSymbol": "ADORA2B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 136, + "officialSymbol": "ADORA2B", + "officialFullName": "adenosine A2b receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1750, + "assayComponentEndpointName": "ATG_GPCR_ADRA1A_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRA1A_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1037, + "assayComponentName": "ATG_GPCR_ADRA1A_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRA1A_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRA1A, which is responsive to the adrenoceptor alpha 1A. [GeneSymbol:ADRA1A| GeneID:148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRA1A RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 483, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "ADRA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 148, + "officialSymbol": "ADRA1A", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1752, + "assayComponentEndpointName": "ATG_GPCR_ADRA2B_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRA2B_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1038, + "assayComponentName": "ATG_GPCR_ADRA2B_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRA2B_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRA2B, which is responsive to the adrenoceptor alpha 2B. [GeneSymbol:ADRA2B| GeneID:151 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRA2B RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 484, + "geneName": "adrenoceptor alpha 2B", + "description": null, + "geneSymbol": "ADRA2B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 151, + "officialSymbol": "ADRA2B ", + "officialFullName": "adrenoceptor alpha 2B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1754, + "assayComponentEndpointName": "ATG_GPCR_ADRB2_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRB2_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1039, + "assayComponentName": "ATG_GPCR_ADRB2_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRB2_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRB2, which is responsive to the adrenoceptor beta 2, surface. [GeneSymbol:ADRB2| GeneID:154 | Uniprot_SwissProt_Accession: P07550].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRB2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1756, + "assayComponentEndpointName": "ATG_GPCR_ADRB3_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRB3_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1040, + "assayComponentName": "ATG_GPCR_ADRB3_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRB3_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRB3, which is responsive to the adrenoceptor beta 3. [GeneSymbol:ADRB3| GeneID:155 | Uniprot_SwissProt_Accession: P13945].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRB3 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1758, + "assayComponentEndpointName": "ATG_GPCR_CHRM3_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_CHRM3_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CHRM3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1041, + "assayComponentName": "ATG_GPCR_CHRM3_TRANS", + "assayComponentDesc": "ATG_GPCR_CHRM3_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene CHRM3, which is responsive to the cholinergic receptor, muscarinic 3. [GeneSymbol:CHRM3| GeneID:1131 | Uniprot_SwissProt_Accession: P20309].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CHRM3 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1760, + "assayComponentEndpointName": "ATG_GPCR_DRD1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_DRD1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1042, + "assayComponentName": "ATG_GPCR_DRD1_TRANS", + "assayComponentDesc": "ATG_GPCR_DRD1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene DRD1, which is responsive to the dopamine receptor D1. [GeneSymbol:DRD1| GeneID:1812 | Uniprot_SwissProt_Accession: P21728].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "DRD1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1762, + "assayComponentEndpointName": "ATG_GPCR_DRD5_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_DRD5_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD5. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1043, + "assayComponentName": "ATG_GPCR_DRD5_TRANS", + "assayComponentDesc": "ATG_GPCR_DRD5_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene DRD5, which is responsive to the dopamine receptor D5. [GeneSymbol:DRD5| GeneID:1816 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "DRD5 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 485, + "geneName": "dopamine receptor D5", + "description": null, + "geneSymbol": "DRD5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1816, + "officialSymbol": "DRD5", + "officialFullName": "dopamine receptor D5", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1764, + "assayComponentEndpointName": "ATG_GPCR_EDNRA_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_EDNRA_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EDNRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1044, + "assayComponentName": "ATG_GPCR_EDNRA_TRANS", + "assayComponentDesc": "ATG_GPCR_EDNRA_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene EDNRA, which is responsive to the endothelin receptor type A. [GeneSymbol:EDNRA| GeneID: 1909 | Uniprot_SwissProt_Accession: P25101].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "EDNRA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 105, + "geneName": "endothelin receptor type A", + "description": null, + "geneSymbol": "EDNRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1909, + "officialSymbol": "EDNRA", + "officialFullName": "endothelin receptor type A", + "uniprotAccessionNumber": "P25101" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1766, + "assayComponentEndpointName": "ATG_GPCR_GCGR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GCGR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GCGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1045, + "assayComponentName": "ATG_GPCR_GCGR_TRANS", + "assayComponentDesc": "ATG_GPCR_GCGR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GCGR, which is responsive to the glucagon receptor. [GeneSymbol: GCGR| GeneID: 2642 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GCGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 486, + "geneName": "glucagon receptor", + "description": null, + "geneSymbol": "GCGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2642, + "officialSymbol": "GCGR", + "officialFullName": "glucagon receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1768, + "assayComponentEndpointName": "ATG_GPCR_GPBAR1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GPBAR1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPBAR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1046, + "assayComponentName": "ATG_GPCR_GPBAR1_TRANS", + "assayComponentDesc": "ATG_GPCR_GPBAR1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GPBAR1, which is responsive to the G protein-coupled bile acid receptor 1. [GeneSymbol: GPBAR1| GeneID: 1501306 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GPBAR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 487, + "geneName": "G protein-coupled bile acid receptor 1", + "description": null, + "geneSymbol": "GPBAR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 151306, + "officialSymbol": "GPBAR1", + "officialFullName": "G protein-coupled bile acid receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1770, + "assayComponentEndpointName": "ATG_GPCR_GPR40_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GPR40_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPR40. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1047, + "assayComponentName": "ATG_GPCR_GPR40_TRANS", + "assayComponentDesc": "ATG_GPCR_GPR40_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene FFAR1, which is responsive to the free fatty acid receptor 1. [GeneSymbol: FFAR1| GeneID: 2864 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GPR40 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 488, + "geneName": "free fatty acid receptor 1", + "description": null, + "geneSymbol": "FFAR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2864, + "officialSymbol": "FFAR1", + "officialFullName": "free fatty acid receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1772, + "assayComponentEndpointName": "ATG_GPCR_GQ_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GQ_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAQ. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1048, + "assayComponentName": "ATG_GPCR_GQ_TRANS", + "assayComponentDesc": "ATG_GPCR_GQ_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAQ, which is responsive to the G protein subunit alpha q. [GeneSymbol: GNAQ| GeneID: 2776 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GQ RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3599, + "geneName": "G protein subunit alpha q", + "description": null, + "geneSymbol": "GNAQ", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2776, + "officialSymbol": "GNAQ", + "officialFullName": "G protein subunit alpha q", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1774, + "assayComponentEndpointName": "ATG_GPCR_GS1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GS1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1049, + "assayComponentName": "ATG_GPCR_GS1_TRANS", + "assayComponentDesc": "ATG_GPCR_GS1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAS, which is responsive to the GNAS complex locus. [GeneSymbol: GNAS| GeneID: 2778 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GS1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3601, + "geneName": "GNAS complex locus", + "description": null, + "geneSymbol": "GNAS", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2778, + "officialSymbol": "GNAS", + "officialFullName": "GNAS complex locus", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1776, + "assayComponentEndpointName": "ATG_GPCR_GS_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GS_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1050, + "assayComponentName": "ATG_GPCR_GS_TRANS", + "assayComponentDesc": "ATG_GPCR_GS_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAS, which is responsive to the GNAS complex locus. [GeneSymbol: GNAS| GeneID: 2778 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GS RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3601, + "geneName": "GNAS complex locus", + "description": null, + "geneSymbol": "GNAS", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2778, + "officialSymbol": "GNAS", + "officialFullName": "GNAS complex locus", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1778, + "assayComponentEndpointName": "ATG_GPCR_HRH1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HRH1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HRH1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1051, + "assayComponentName": "ATG_GPCR_HRH1_TRANS", + "assayComponentDesc": "ATG_GPCR_HRH1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HRH1, which is responsive to the histamine receptor H1. [GeneSymbol: HRH1| GeneID: 3269 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HRH1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1780, + "assayComponentEndpointName": "ATG_GPCR_HTR6_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HTR6_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1052, + "assayComponentName": "ATG_GPCR_HTR6_TRANS", + "assayComponentDesc": "ATG_GPCR_HTR6_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HTR6, which is responsive to the 5-hydroxytryptamine (serotonin) receptor 6, G. [GeneSymbol: HTR6| GeneID: 3362 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HTR6 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1782, + "assayComponentEndpointName": "ATG_GPCR_HTR7_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HTR7_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR7. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1053, + "assayComponentName": "ATG_GPCR_HTR7_TRANS", + "assayComponentDesc": "ATG_GPCR_HTR7_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HTR7, which is responsive to the 5-hydroxytryptamine (serotonin) receptor 7. [GeneSymbol: HTR7| GeneID: 3363 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HTR7 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1784, + "assayComponentEndpointName": "ATG_GPCR_LPAR4_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_LPAR4_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene LPAR4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1054, + "assayComponentName": "ATG_GPCR_LPAR4_TRANS", + "assayComponentDesc": "ATG_GPCR_LPAR4_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene LPAR4, which is responsive to the lysophosphatidic acid receptor 4. [GeneSymbol: LPAR4| GeneID: 2846 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "LPAR4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 489, + "geneName": "lysophosphatidic acid receptor 4", + "description": null, + "geneSymbol": "LPAR4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2846, + "officialSymbol": "LPAR4", + "officialFullName": "lysophosphatidic acid receptor 4", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2452, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2446, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_MCF7", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a full screening experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2244, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2305, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ratio is assay component calculated in the TOX21_TRB_COA_Agonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2245, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2306, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2246, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2307, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2247, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2308, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ratio is assay component calculated in the TOX21_TRB_COA_Antagonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2453, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_CellCount_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_CellCount_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in cell count. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2444, + "assayComponentName": "CCTE_Harrill_HTTr_CellCount_MCF7", + "assayComponentDesc": "This is a cell-based assay that evaluates cell viability and cell growth in MCF-7 cells. This was part of a full screening experiment. High content imaging is used to count the number of Hoechst-labeled nuclei that are present in an assay well in 384-well format.", + "assayComponentTargetDesc": "Count of Hoechst-labeled nuclei indicates live cell number", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 683, + "assayName": "CCTE_Harrill_HTTr_CellCount", + "assayDesc": "This is a cell-based assay that evaluates cell viability and cell growth using high content imaging to count the number of Hoechst-labeled nuclei that are present in an assay well in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2454, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_spike_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrodotoxin", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2447, + "assayComponentName": "CCTE_Shafer_MEA_acute_spike_number", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_spike_number is a component of the CCTE_Shafer_MEA_acute assay. It measures the total number of spikes (action potential firings) in a 40-minute recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the spike number in each well. ", + "assayComponentTargetDesc": "The number of spikes is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2456, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_firing_rate_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrodotoxin", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2448, + "assayComponentName": "CCTE_Shafer_MEA_acute_firing_rate_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_firing_rate_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the frequency number of spikes (action potential firings) as the total number of spikes divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The firing rate is divided by the number of electrodes to report a well-mean value. The recordings before and after chemical treatment are used to calculate a percent change in the mean firing rate in each well.", + "assayComponentTargetDesc": "The mean firing rate is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2458, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2449, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_number", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_number is a component of the CCTE_Shafer_MEA_acute assay. It measures the total number of single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the burst number in each well.", + "assayComponentTargetDesc": "The number of bursts is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2460, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2450, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_duration_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average time from the first spike (action potential firing) to the last spike in a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean burst duration in each well.", + "assayComponentTargetDesc": "The mean burst duration is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 90, + "assayComponentEndpointName": "ATG_M_61_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_61_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_61_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 59, + "assayComponentName": "ATG_M_61_CIS", + "assayComponentDesc": "ATG_M_61_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2462, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_burst_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_burst_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2451, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of spikes (action potential firings) in a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of spikes per burst in each well.", + "assayComponentTargetDesc": "The mean number of spikes in a burst is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2464, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_interburst_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_interburst_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_interburst_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2452, + "assayComponentName": "CCTE_Shafer_MEA_acute_interburst_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_interburst_interval_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average time between the start of consecutive single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean inter-burst interval in each well.", + "assayComponentTargetDesc": "The mean inter-burst interval is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2466, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_percentage_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2453, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_percentage_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_percentage_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the percentage of spikes (action potential firing) in a single-electrode burst (temporally-clustered groups of spikes) as the number of spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The average of the burst percentages across electrodes is calculated to report a well-level value. The recordings before and after chemical treatment are used to calculate a percent change in the mean burst percentage in each well.", + "assayComponentTargetDesc": "The mean percent of spikes in bursts is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2468, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_percentage_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2454, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_percentage_std", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_percentage_std is a component of the CCTE_Shafer_MEA_acute assay. It measures the percentage of spikes (action potential firing) in a single-electrode burst (temporally-clustered groups of spikes) as the number of spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The standard deviation of the burst percentages across electrodes is calculated to report a well-level value. The recordings before and after chemical treatment are used to calculate a percent change in the standard deviation of the burst percentage in each well.", + "assayComponentTargetDesc": "The standard deviation of the percent of spikes in bursts is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2470, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2455, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of spikes (action potential firings) in a network burst (temporally-clustered group of spikes across multiple electrodes) as the total number of spikes in a network burst divided by the number of network bursts during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of spikes in a network burst in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the mean number of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2472, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2456, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std is a component of the CCTE_Shafer_MEA_acute assay. It measures the standard deviation of the number of spikes (action potential firings) in a network burst (temporally-clustered group of spikes across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the standard deviation of the number of spikes in network bursts in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the standard deviation of the number of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2474, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2457, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of electrodes with activity during a network burst (a temporally-clustered group of action potential firing across multiple electrodes) in a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of electrodes participating in network bursts in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the average number of electrodes participating in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2476, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_network_burst_percentage", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_network_burst_percentage was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_network_burst_percentage, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2458, + "assayComponentName": "CCTE_Shafer_MEA_acute_network_burst_percentage", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_network_burst_percentage is a component of the CCTE_Shafer_MEA_acute assay. It measures the percent of spikes (action potential firings) in network bursts (temporally-clustered groups of spikes across multiple electrodes) as the number of spikes occuring in network bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the network burst percentage in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the percent of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2478, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_cross_correlation_area", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2459, + "assayComponentName": "CCTE_Shafer_MEA_acute_cross_correlation_area", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_cross_correlation_area is a component of the CCTE_Shafer_MEA_acute assay. It measures the area under the well-wide pooled inter-electrode cross-correlation of action potential firing (not normalized to auto-correlations) within a window centered around 0 for the phase lag during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the cross correlation area in each well.", + "assayComponentTargetDesc": "The cross correlation area is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2480, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2460, + "assayComponentName": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM is a component of the CCTE_Shafer_MEA_acute assay. It measures the distance along the x-axis (phase lag) from the left half maximum height to the center of the cross-correlogram of action potential firing during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. Smaller values indicate a narrower correlogram (greater synchrony). The recordings before and after chemical treatment are used to calculate a percent change in the half width at half maximum of the cross-correlogram in each well.", + "assayComponentTargetDesc": "The half width at half maximum of the cross-correlogram is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2482, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_synchrony_index", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2461, + "assayComponentName": "CCTE_Shafer_MEA_acute_synchrony_index", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_synchrony_index is a component of the CCTE_Shafer_MEA_acute assay. It measures the synchrony of the neural network as a unitless measure between 0 (low synchrony) to 1 (high synchrony) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the synchrony index in each well.", + "assayComponentTargetDesc": "The synchrony index is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2484, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_LUC_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Active, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2462, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_LUC_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2485, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_CTox_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Active, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2463, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_CTox_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2486, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Inactive, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2464, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2487, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Inactive, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2465, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2488, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Active, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2466, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2489, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_CTox_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Active, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2467, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_CTox_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2490, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Inactive, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2468, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2491, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Inactive, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2469, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2492, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates the shift in metabolism-dependent changes between positive (active) and negative (inactive) assay modes. The metabolic curve shift response is defined as the pairwise difference between the positive (AEID 2488) and negative (AEID 2490) normalized response values at each concentration for a given chemical across replicate experiments. The pairwise differences form the basis for a concentration-response curve. Standard curve fit analysis identfiied chemicals where the calculated shift was greater than the shift-derived baseline cutoff. A positive hit designation in this endpoint indicates a significant shift trend in the positive direction for bioactivation. ", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2470, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift is one of two analysis components calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to evaluate the shift in metabolism-dependent changes of the inducible luciferase reporter between positive (active) and negative (inactive) assay modes.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift was designed to measure the shift in bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]between metabolism positive (active) and negative (inactive) assay modes. Shifts are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. Positive shifts are indicative of bioactivation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2494, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_firing_rate_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2471, + "assayComponentName": "CCTE_Shafer_MEA_dev_firing_rate_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_firing_rate_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the frequency of spikes (action potential firings) as the total number of spikes divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The firing rate is averaged across the active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Mean firing rate is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2496, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_burst_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2472, + "assayComponentName": "CCTE_Shafer_MEA_dev_burst_rate", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_burst_rate is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the frequency of single-electrode bursts (temporally-clustered groups of action potential firing) as the total number of bursts divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean bursting rate is averaged across the active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean bursting rate is a measure of general activity in the network. Changes in mean burst rate are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2498, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_active_electrodes_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2473, + "assayComponentName": "CCTE_Shafer_MEA_dev_active_electrodes_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_active_electrodes_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of electrodes in a well with a mean firing rate of at least 5 spikes (action potential firings) per minute during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of active electrodes is a measure of general activity in the network. Changes in the number of active electrodes are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2500, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_bursting_electrodes_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2474, + "assayComponentName": "CCTE_Shafer_MEA_dev_bursting_electrodes_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_bursting_electrodes_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of electrodes in a well with a burst rate of at least 1 burst (temporally-clustered group of action potential firing) every 2 minutes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of actively bursting electrodes is a measure of general activity in a network. Changes in the number of actively bursting electrodes are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2502, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2475, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between spikes (action potential firings) within a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean inter-spike interval within bursts is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The inter-spike interval within bursts is a measure of bursting activity in the network. Changes in the inter-spike interval within bursts are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2504, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_burst_spike_percent", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2476, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_burst_spike_percent", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_burst_spike_percent is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the percentage of spikes (action potential firings) in a single-electrode burst (temporally-clustered group of spikes) as the total number spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The percent of spikes in bursts is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The percent of spikes in bursts is a measure of bursting activity in a network. Changes in the percent of spikes in bursts are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2506, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_burst_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2477, + "assayComponentName": "CCTE_Shafer_MEA_dev_burst_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_burst_duration_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval from the first spike (action potential firing) to the last spike in a singe-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean burst duration is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean burst duration is a measure of bursting activity in a network. Changes in the mean burst duration are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2508, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_interburst_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2478, + "assayComponentName": "CCTE_Shafer_MEA_dev_interburst_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_interburst_interval_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between consecutive single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean inter-burst interval is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean inter-burst interval is a measure of bursting activity in a network. Changes in the mean inter-burst interval are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2510, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2479, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of network spikes is a measure of the network connectivity. Changes in the number of network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2512, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_peak", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2480, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_peak", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_peak is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average number of electrodes participating at the peak of a network spike (the peak of a temporally-clustered group of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The network spike peak is a measure of the network connectivity. Changes in the network spike peak are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2514, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_spike_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2481, + "assayComponentName": "CCTE_Shafer_MEA_dev_spike_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_spike_duration_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average duration of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean network spike duration is a measure of the network connectivity. Changes in the mean network spike duration are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 1786, + "assayComponentEndpointName": "ATG_GPCR_MC1R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC1R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC1R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1055, + "assayComponentName": "ATG_GPCR_MC1R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC1R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC1R, which is responsive to the melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC1R| GeneID: 4157 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC1R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 490, + "geneName": "melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)", + "description": null, + "geneSymbol": "MC1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4157, + "officialSymbol": "MC1R", + "officialFullName": "melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1788, + "assayComponentEndpointName": "ATG_GPCR_MC2R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC2R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC2R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1056, + "assayComponentName": "ATG_GPCR_MC2R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC2R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC2R, which is responsive to the melanocortin 2 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC2R| GeneID: 4158 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC2R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 491, + "geneName": "melanocortin 2 receptor (adrenocorticotropic hormone)", + "description": null, + "geneSymbol": "MC2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4158, + "officialSymbol": "MC2R", + "officialFullName": "melanocortin 2 receptor (adrenocorticotropic hormone)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1790, + "assayComponentEndpointName": "ATG_GPCR_MC3R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC3R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC3R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1057, + "assayComponentName": "ATG_GPCR_MC3R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC3R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC3R, which is responsive to the melanocortin 3 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC3R| GeneID: 4159 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC3R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 492, + "geneName": "melanocortin 3 receptor", + "description": null, + "geneSymbol": "MC3R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4159, + "officialSymbol": "MC3R", + "officialFullName": "melanocortin 3 receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1792, + "assayComponentEndpointName": "ATG_GPCR_MC4R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC4R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC4R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1058, + "assayComponentName": "ATG_GPCR_MC4R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC4R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC4R, which is responsive to the melanocortin 4 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC4R| GeneID: 4160 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC4R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 493, + "geneName": "melanocortin 4 receptor", + "description": null, + "geneSymbol": "MC4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4160, + "officialSymbol": "MC4R", + "officialFullName": "melanocortin 4 receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1794, + "assayComponentEndpointName": "ATG_GPCR_PTGDR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_PTGDR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGDR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1059, + "assayComponentName": "ATG_GPCR_PTGDR_TRANS", + "assayComponentDesc": "ATG_GPCR_PTGDR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene PTGDR, which is responsive to the prostaglandin D2 receptor (DP). [GeneSymbol: PTGDR| GeneID: 5729 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PTGDR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 494, + "geneName": "prostaglandin D2 receptor (DP)", + "description": null, + "geneSymbol": "PTGDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5729, + "officialSymbol": "PTGDR", + "officialFullName": "prostaglandin D2 receptor (DP)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1796, + "assayComponentEndpointName": "ATG_GPCR_PTGIR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_PTGIR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGIR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1060, + "assayComponentName": "ATG_GPCR_PTGIR_TRANS", + "assayComponentDesc": "ATG_GPCR_PTGIR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene PTGIR, which is responsive to the prostaglandin I2 (prostacyclin) receptor (IP). [GeneSymbol: PTGIR| GeneID: 5739 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PTGIR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 495, + "geneName": "prostaglandin I2 (prostacyclin) receptor (IP)", + "description": null, + "geneSymbol": "PTGIR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5739, + "officialSymbol": "PTGIR", + "officialFullName": "prostaglandin I2 (prostacyclin) receptor (IP)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1797, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_ActivityScore", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "NA", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "total", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1061, + "assayComponentName": "Tanguay_ZF_120hpf_ActivityScore", + "assayComponentDesc": "Tanguay_ZF_120hpf_ActivityScore is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_ActivityScore assay. It is designed to make measurements of developmental malformations and mortality as detected with brightfield microscopy and combines scoring from 18 other assay components measuring more specific morphologies.", + "assayComponentTargetDesc": "An algorithm was used to combine results from 18 Tanquay_AF_120hpr assay components", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "NA", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1816, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nilutamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1120, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals following addition of luciferin substrate and ATP.", + "assayComponentTargetDesc": "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 441, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1817, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1121, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 441, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1818, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1122, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1819, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1123, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1820, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1124, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1821, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1125, + "assayComponentName": "TOX21_RXR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1822, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1126, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signal following addition of luciferin substrate and ATP.", + "assayComponentTargetDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an AR agonist. Changes are indicative of transcriptional gene expression that may not be due to direct regulation by the human androgen receptor [GeneSymbol: NR3C4 | GeneID: NR3C4 | Uniprot_SwissProt_Accession:].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 443, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for agonist specificity. This particular screening for measuring luciferase reporter gene activity using MDA-kb2 cells against Tox21 10K library compounds is a confirmation study on agonist mode screening in the presence of AR-antagonist compound (Nilutamide) at 3.0uM final concentration. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1823, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1127, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 443, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for agonist specificity. This particular screening for measuring luciferase reporter gene activity using MDA-kb2 cells against Tox21 10K library compounds is a confirmation study on agonist mode screening in the presence of AR-antagonist compound (Nilutamide) at 3.0uM final concentration. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1824, + "assayComponentEndpointName": "CCTE_Simmons_GUA_TPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_GUA_TPO was analyzed at the endpoint, CCTE_Simmons_GUA_TPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1128, + "assayComponentName": "CCTE_Simmons_GUA_TPO", + "assayComponentDesc": "CCTE_Simmons_GUA_TPO is the assay component measured from the CCTE_Simmons_GUA_TPO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by enzyme activity technology. This is an orthogonal assay to CCTE_Simmons_AUR_TPO run for confirmation.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Guaiacol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 444, + "assayName": "CCTE_Simmons_GUA_TPO", + "assayDesc": "CCTE_Simmons_GUA_TPO is a biochemical, single-readout assay that uses microsomes from porcine thyroid gland in a tissue-based cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9823, + "organism": "pig", + "tissue": "thyroid gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "porcine thyroid gland", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 499, + "geneName": "thyroid peroxidase", + "description": null, + "geneSymbol": "TPO", + "organismId": 5, + "trackStatus": "live", + "entrezGeneId": 445522, + "officialSymbol": "TPO", + "officialFullName": null, + "uniprotAccessionNumber": "P09933" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1825, + "assayComponentEndpointName": "ArunA_CellTiter_hNP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_CellTiter_hNP was analyzed at the endpoint, ArunA_CellTiter_hNP, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1129, + "assayComponentName": "ArunA_CellTiter_hNP", + "assayComponentDesc": "ArunA_CellTiter_hNP is an assay component measured from the ArunA_CellTiter_hNP assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of [3H]-thymidine labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "3H-thymidine", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 445, + "assayName": "ArunA_CellTiter_hNP", + "assayDesc": "ArunA_CellTiter_hNP is a cell-based, single-readout assay that uses human H9-derived neuroprogenitor stem cells (hNP1).Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived neuroprogenitor stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1826, + "assayComponentEndpointName": "ArunA_CellTiter_hNC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_CellTiter_hNC was analyzed at the endpoint, ArunA_CellTiter_hNC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1130, + "assayComponentName": "ArunA_CellTiter_hNC", + "assayComponentDesc": "ArunA_CellTiter_hNC is an assay component measured from the ArunA_CellTiter_hNC assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of [3H]-thymidine labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "3H-thymidine", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 446, + "assayName": "ArunA_CellTiter_hNC", + "assayDesc": "ArunA_CellTiter_hNC is a cell-based, single-readout assay that uses human H9-derived embryonic neural crest stem cells (hNC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic neural crest stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1827, + "assayComponentEndpointName": "ArunA_Migration_hNP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_Migration_hNP was analyzed at the endpoint, ArunA_Migration_hNP, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of distribution reporter, loss-of-signal activity can be used to understand the cell migration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1131, + "assayComponentName": "ArunA_Migration_hNP", + "assayComponentDesc": "ArunA_Migration_hNP is an assay component measured from the ArunA_Migration_hNP assay. It is designed to make measurements of cell migration, a form of distribution reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to Ki-67 expression is indicative of the cell migration.", + "parameterReadoutType": "single", + "assayDesignType": "distribution reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Calcein-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "Ki-67", + "aid": 447, + "assayName": "ArunA_Migration_hNP", + "assayDesc": "ArunA_Migration_hNP is a cell-based, single-readout assay that uses human H9-derived neuroprogenitor stem cells (hNP1). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived neuroprogenitor stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1829, + "assayComponentEndpointName": "ArunA_Migration_hNC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_Migration_hNC was analyzed at the endpoint, ArunA_Migration_hNC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of distribution reporter, loss-of-signal activity can be used to understand the cell migration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1132, + "assayComponentName": "ArunA_Migration_hNC", + "assayComponentDesc": "ArunA_Migration_hNC is an assay component measured from the ArunA_Migration_hNC assay. It is designed to make measurements of cell migration, a form of distribution reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to Ki-67 expression is indicative of the cell migration.", + "parameterReadoutType": "single", + "assayDesignType": "distribution reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Calcein-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "Ki-67", + "aid": 448, + "assayName": "ArunA_Migration_hNC", + "assayDesc": "ArunA_Migration_hNC is a cell-based, single-readout assay that uses human H9-derived embryonic neural crest stem cells (hNC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic neural crest stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 2516, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_duration_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2482, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_duration_std", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_duration_std is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the standard deviation of the duration of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The standard deviation of network spike duration is a measure of network connectivity. Changes in the standard deviation of network spike duration are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2518, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2483, + "assayComponentName": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between network spikes (temporally-clustered groups of actional potential firing across multiple electrodes) as the average time between peaks of consecutive network spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The inter-network spike interval is a measure of the network connectivity. Changes in the inter-network spike interval are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2520, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2484, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average number of spikes (action potential firings) in a network spike (temporally-clustered group of spikes across multiple electrodes) as the number of spikes that occur within a 0.05 s time window at the peak of a network spike divided by the total number of network spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean number of spikes in network spikes is a measure of the network connectivity. Changes in the mean number of network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2522, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2485, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the percent of spikes (action potential firings) in a network spike (temporally-clustered group of spikes across multiple electrodes) as the number of spikes that occur within a 0.05 s time window at the peak of a network spike divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The percent of spikes in network spikes is a measure of the network connectivity. Changes in the percent of spikes in network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2524, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2486, + "assayComponentName": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the correlation coefficent of spikes (action potential firings) between every pair of electrodes in a well during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The pairwise correlations are averaged across active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Electrical activity is captured from neurons cultured over electrodes. Increases in correlation coefficient indicate that the activity of individual neurons in the network is more synchronous, reflecting increased coordination of activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2526, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_mutual_information_norm", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2487, + "assayComponentName": "CCTE_Shafer_MEA_dev_mutual_information_norm", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_mutual_information_norm is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It is a measure of shared information between electrodes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Normalized Mutual Information is a normalized measure of complexity and synchrony in a network that is robust to changes in network size. It is a scalar (rather than pairwise) measure of mutual information in a multivariate network (See Ball et al., Neural Networks. 2017. 95, 29-43 for further information).", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2529, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_LDH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2488, + "assayComponentName": "CCTE_Shafer_MEA_dev_LDH", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_LDH is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the lactate dehydrogenase enzyme activity using spectrophotometry.", + "assayComponentTargetDesc": "Changes in enzymatic activity (of lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells) indicates cell loss or death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "lactate dehydrogenase activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "spectrophotometry", + "detectionTechnologyTypeSub": "absorbance", + "detectionTechnology": "enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tetrazolium salt", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2530, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_AB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2489, + "assayComponentName": "CCTE_Shafer_MEA_dev_AB", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_AB is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the resazurin reduction using fluorescence.", + "assayComponentTargetDesc": "Changes in enzymatic activity (decrease in mitochondrial enzyme, alamar blue reduction) are indicative of compromised cellular metabolism, possibly indicating cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "mitochondrial enzyme activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "resazurin reduction: alamar blue dye converted into fluorescent end product", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "alamar blue (resazurin)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: mitochondrial enzyme", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2532, + "assayComponentEndpointName": "CCTE_GLTED_hDIO2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 2", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2490, + "assayComponentName": "CCTE_GLTED_hDIO2", + "assayComponentDesc": "CCTE_GLTED_hDIO2 is the assay component measured from the CCTE_GLTED_hDIO2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO2 is important for converting T4 to T3 though the removal of the 5’ outer ring iodine.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "thyroxine (T4)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 686, + "assayName": "CCTE_GLTED_hDIO2", + "assayDesc": "CCTE_GLTED_hDIO2 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 2 (DIO2) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2790, + "geneName": "iodothyronine deiodinase 2", + "description": null, + "geneSymbol": "DIO2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1734, + "officialSymbol": "DIO2", + "officialFullName": "iodothyronine deiodinase 2", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 198, + "assayComponentEndpointName": "BSK_BE3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 140, + "assayComponentName": "BSK_BE3C_SRB", + "assayComponentDesc": "BSK_BE3C_SRB is an assay component measured in the BSK_BE3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the BE3C system is a measure of the total protein content of bronchial epithelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2533, + "assayComponentEndpointName": "CCTE_GLTED_hDIO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 3", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2491, + "assayComponentName": "CCTE_GLTED_hDIO3", + "assayComponentDesc": "CCTE_GLTED_hDIO3 is the assay component measured from the CCTE_GLTED_hDIO3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO3 inactivates both T4 and T3 by removing an inner ring iodine, producing reverse T3 (rT3) and diiodotyrosine (T2), respectively.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3'5-triiodothyronine (T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 687, + "assayName": "CCTE_GLTED_hDIO3", + "assayDesc": "CCTE_GLTED_hDIO3 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 3 (DIO3) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2791, + "geneName": "iodothyronine deiodinase 3", + "description": null, + "geneSymbol": "DIO3", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1735, + "officialSymbol": "DIO3", + "officialFullName": "iodothyronine deiodinase 3", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 2540, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_LDH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_LDH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tritonx100", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2495, + "assayComponentName": "CCTE_Shafer_MEA_acute_LDH", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_LDH is a component of the CCTE_Shafer_MEA_acute assay. It measures the lactate dehydrogenase enzyme activity using spectrophotometry.", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Increases in extracellular LDH indicate cell loss or death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "lactate dehydrogenase activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "spectrophotometry", + "detectionTechnologyTypeSub": "absorbance", + "detectionTechnology": "enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tetrazolium salt", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2541, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_AB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_AB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2496, + "assayComponentName": "CCTE_Shafer_MEA_acute_AB", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_AB is a component of the CCTE_Shafer_MEA_acute assay. It measures the resazurin reduction using fluorescence.", + "assayComponentTargetDesc": "Changes in enzymatic activity (decrease in mitochondrial enzyme, alamar blue reduction) are indicative of compromised cellular metabolism, possibly indicating cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "mitochondrial enzyme activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "resazurin reduction: alamar blue dye converted into fluorescent end product", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "alamar blue (resazurin)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: mitochondrial enzyme", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2545, + "assayComponentEndpointName": "UKN5_HCS_SBAD2_neurite_outgrowth", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN5_HCS_SBAD2_neurite_outgrowth was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Narciclasine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2500, + "assayComponentName": "UKN5_HCS_SBAD2_neurite_outgrowth", + "assayComponentDesc": "UKN5_HCS_SBAD2_neurite_outgrowth is an assay component measured from the UKN5_HCS_SBAD2 assay. It is designed to make measurements of neurite outgrowth, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33339", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area", + "aid": 691, + "assayName": "UKN5_HCS_SBAD2", + "assayDesc": "UKN5_HCS_SBAD2 is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses SBAD2 (peripheral neurons differentiated from iPSC), a human peripheral nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN5, also referred to as PeriTox, is an assay that uses human iPSC line SBAD2 as a model of peripheral neurons. Following 24 hr chemical exposures in multi-well plates, neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein-AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "peripheral nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "SBAD2 (peripheral neurons differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 535, + "assayComponentEndpointName": "NVS_ENZ_hPTPN13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN13, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 309, + "assayComponentName": "NVS_ENZ_hPTPN13", + "assayComponentDesc": "NVS_ENZ_hPTPN13 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) [GeneSymbol:PTPN13 | GeneID:5783 | Uniprot_SwissProt_Accession:Q12923].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 123, + "assayName": "NVS_ENZ_hPTPN13", + "assayDesc": "NVS_ENZ_hPTPN13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 272, + "geneName": "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)", + "description": null, + "geneSymbol": "PTPN13", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5783, + "officialSymbol": "PTPN13", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)", + "uniprotAccessionNumber": "Q12923" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1831, + "assayComponentEndpointName": "ArunA_NOG_NucleusCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NucleusCount was analyzed at the endpoint, ArunA_NOG_NucleusCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1133, + "assayComponentName": "ArunA_NOG_NucleusCount", + "assayComponentDesc": "ArunA_NOG_NucleusCount is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of viability related to the number of neurons, using a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of Hoechst 33,258 labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33258 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1833, + "assayComponentEndpointName": "ArunA_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NeuriteLength was analyzed at the endpoint, ArunA_NOG_NeuriteLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1134, + "assayComponentName": "ArunA_NOG_NeuriteLength", + "assayComponentDesc": "ArunA_NOG_NeuriteLength is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to neurite length, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1835, + "assayComponentEndpointName": "ArunA_NOG_NeuritesPerNeuron", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NeuritesPerNeuron was analyzed at the endpoint, ArunA_NOG_NeuritesPerNeuron, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1135, + "assayComponentName": "ArunA_NOG_NeuritesPerNeuron", + "assayComponentDesc": "ArunA_NOG_NeuritesPerNeuron is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to number of neurites per neuron, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurites per neuron", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1838, + "assayComponentEndpointName": "ArunA_NOG_BranchPointsPerNeurite", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_BranchPointsPerNeurite was analyzed at the endpoint, ArunA_NOG_BranchPointsPerNeurite, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1136, + "assayComponentName": "ArunA_NOG_BranchPointsPerNeurite", + "assayComponentDesc": "ArunA_NOG_BranchPointsPerNeurite is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to branch points per neurite, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "branch points per neurite", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 2552, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C19_Omeprazole was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C19_Omeprazole, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2505, + "assayComponentName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C19_Omeprazole is an assay component calculated from the ERF_CR_ADME_hCYP2C19_Omeprazole assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of 5-hydroxyomeprazole with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of 5-hydroxyomeprazole produced from the regulation of catalytic activity reaction involving the key substrate, omeprazole, are indicative of changes in enzyme function and kinetics related to the gene CYP2C19.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "omeprazole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 728, + "assayName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "assayDesc": "ERF_CR_ADME_hCYP2C19_Omeprazole is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2C19 inhibition (HLM, omeprazole substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2553, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C8 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C8, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C8. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2506, + "assayComponentName": "ERF_CR_ADME_hCYP2C8", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C8 is an assay component calculated from the ERF_CR_ADME_hCYP2C8 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of desethylamodiaquine with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of desethylamodiaquine produced from the regulation of catalytic activity reaction involving the key substrate, amodiaquine, are indicative of changes in enzyme function and kinetics related to the gene CYP2C8.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "amodiaquine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 821, + "assayName": "ERF_CR_ADME_hCYP2C8", + "assayDesc": "ERF_CR_ADME_hCYP2C8 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2C8 inhibition (HLM, amodiaquine substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2554, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C9 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C9, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2507, + "assayComponentName": "ERF_CR_ADME_hCYP2C9", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C9 is an assay component calculated from the ERF_CR_ADME_hCYP2C9 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-methoxy-4-trifluoromethylcoumarin (MFC), are indicative of changes in enzyme function and kinetics related to the gene CYP2C9.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 815, + "assayName": "ERF_CR_ADME_hCYP2C9", + "assayDesc": "ERF_CR_ADME_hCYP2C9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See CYP2C9 inhibition (recombinant, MFC substrate).", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2555, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2E1 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2E1, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2E1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2508, + "assayComponentName": "ERF_CR_ADME_hCYP2E1", + "assayComponentDesc": "ERF_CR_ADME_hCYP2E1 is an assay component calculated from the ERF_CR_ADME_hCYP2E1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of 6-hydroxychlorzoxazone with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of 6-hydroxychlorzoxazone produced from the regulation of catalytic activity reaction involving the key substrate, Chlorzoxazone, are indicative of changes in enzyme function and kinetics related to the gene CYP2E1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Chlorzoxazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 743, + "assayName": "ERF_CR_ADME_hCYP2E1", + "assayDesc": "ERF_CR_ADME_hCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2E1 inhibition (recombinant, EC substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1839, + "assayComponentEndpointName": "TOX21_RAR_LUC_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ER50891", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1137, + "assayComponentName": "TOX21_RAR_LUC_Antagonist", + "assayComponentDesc": "TOX21_RAR_LUC_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RAR_LUC_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha [GeneSymbol:RARA]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 450, + "assayName": "TOX21_RAR_LUC_Antagonist", + "assayDesc": "TOX21_RAR_LUC_Antagonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1840, + "assayComponentEndpointName": "TOX21_RAR_LUC_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1138, + "assayComponentName": "TOX21_RAR_LUC_Antagonist_viability", + "assayComponentDesc": "TOX21_RAR_LUC_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 450, + "assayName": "TOX21_RAR_LUC_Antagonist", + "assayDesc": "TOX21_RAR_LUC_Antagonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1841, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1139, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ch1", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch1 is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch1 was designed to measure donor labeled antibody emission to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "detection of DNA damage", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1842, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1140, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ch2", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch2 is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch2 was designed to measure acceptor labeled antibody emission to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2556, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP3A4 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP3A4, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP3A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2509, + "assayComponentName": "ERF_CR_ADME_hCYP3A4", + "assayComponentDesc": "ERF_CR_ADME_hCYP3A4 is an assay component calculated from the ERF_CR_ADME_hCYP3A4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-benzyloxy-4-trifluoromethylcoumarin (BFC), are indicative of changes in enzyme function and kinetics related to the gene CYP3A4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 809, + "assayName": "ERF_CR_ADME_hCYP3A4", + "assayDesc": "ERF_CR_ADME_hCYP3A4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP3A4 inhibition (recombinant, BFC substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2557, + "assayComponentEndpointName": "ERF_PL_ENZ_bPDE1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_bPDE1 was analyzed at the assay endpoint, ERF_PL_ENZ_bPDE1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Isobutyl-1-methylxanthine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2510, + "assayComponentName": "ERF_PL_ENZ_bPDE1", + "assayComponentDesc": "ERF_PL_ENZ_bPDE1 is an assay component calculated from the ERF_PL_ENZ_bPDE1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 711, + "assayName": "ERF_PL_ENZ_bPDE1", + "assayDesc": "ERF_PL_ENZ_bPDE1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE1 (Non-Selective) Bovine Phosphodiesterase Enzymatic Assay, Panlabs.", + "timepointHr": 0.33, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "bovine brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2558, + "assayComponentEndpointName": "ERF_CR_ENZ_hABL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hABL1 was analyzed at the assay endpoint, ERF_CR_ENZ_hABL1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ABL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2511, + "assayComponentName": "ERF_CR_ENZ_hABL1", + "assayComponentDesc": "ERF_CR_ENZ_hABL1 is an assay component calculated from the ERF_CR_ENZ_hABL1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in enzyme function and kinetics related to the gene ABL1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 791, + "assayName": "ERF_CR_ENZ_hABL1", + "assayDesc": "ERF_CR_ENZ_hABL1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Abl Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1, + "geneName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "ABL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25, + "officialSymbol": "ABL1", + "officialFullName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P00519" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2559, + "assayComponentEndpointName": "ERF_CR_ENZ_hAKT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAKT2 was analyzed at the assay endpoint, ERF_CR_ENZ_hAKT2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2512, + "assayComponentName": "ERF_CR_ENZ_hAKT2", + "assayComponentDesc": "ERF_CR_ENZ_hAKT2 is an assay component calculated from the ERF_CR_ENZ_hAKT2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene AKT2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 781, + "assayName": "ERF_CR_ENZ_hAKT2", + "assayDesc": "ERF_CR_ENZ_hAKT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Akt2 (PKBbeta) Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 23, + "geneName": "v-akt murine thymoma viral oncogene homolog 2", + "description": null, + "geneSymbol": "AKT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 208, + "officialSymbol": "AKT2", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 2", + "uniprotAccessionNumber": "P31751" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2560, + "assayComponentEndpointName": "ERF_CR_ENZ_hAKT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAKT3 was analyzed at the assay endpoint, ERF_CR_ENZ_hAKT3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2513, + "assayComponentName": "ERF_CR_ENZ_hAKT3", + "assayComponentDesc": "ERF_CR_ENZ_hAKT3 is an assay component calculated from the ERF_CR_ENZ_hAKT3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene AKT3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 782, + "assayName": "ERF_CR_ENZ_hAKT3", + "assayDesc": "ERF_CR_ENZ_hAKT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Akt3 (PKBgamma) Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 359, + "geneName": "v-akt murine thymoma viral oncogene homolog 3", + "description": null, + "geneSymbol": "AKT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10000, + "officialSymbol": "AKT3", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 3", + "uniprotAccessionNumber": "Q9Y243" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2561, + "assayComponentEndpointName": "ERF_CR_ENZ_hAURKA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAURKA was analyzed at the assay endpoint, ERF_CR_ENZ_hAURKA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AURKA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2514, + "assayComponentName": "ERF_CR_ENZ_hAURKA", + "assayComponentDesc": "ERF_CR_ENZ_hAURKA is an assay component calculated from the ERF_CR_ENZ_hAURKA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE , are indicative of changes in enzyme function and kinetics related to the gene AURKA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 774, + "assayName": "ERF_CR_ENZ_hAURKA", + "assayDesc": "ERF_CR_ENZ_hAURKA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Aurora-A Human Other Protein Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 306, + "geneName": "aurora kinase A", + "description": null, + "geneSymbol": "AURKA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6790, + "officialSymbol": "AURKA", + "officialFullName": "aurora kinase A", + "uniprotAccessionNumber": "O14965" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2562, + "assayComponentEndpointName": "ERF_PL_ENZ_hBTK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hBTK was analyzed at the assay endpoint, ERF_PL_ENZ_hBTK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene BTK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is tyrosine kinase (tk).", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": " tyrosine kinase (tk)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2515, + "assayComponentName": "ERF_PL_ENZ_hBTK", + "assayComponentDesc": "ERF_PL_ENZ_hBTK is an assay component calculated from the ERF_PL_ENZ_hBTK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, Poly(Glu:Tyr), are indicative of changes in enzyme function and kinetics related to the gene BTK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Poly(Glu:Tyr)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 726, + "assayName": "ERF_PL_ENZ_hBTK", + "assayDesc": "ERF_PL_ENZ_hBTK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See BTK Human TK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 36, + "geneName": "Bruton agammaglobulinemia tyrosine kinase", + "description": null, + "geneSymbol": "BTK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 695, + "officialSymbol": "BTK", + "officialFullName": "Bruton agammaglobulinemia tyrosine kinase", + "uniprotAccessionNumber": "Q06187" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2563, + "assayComponentEndpointName": "ERF_CR_ENZ_hCDK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hCDK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hCDK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CDK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2516, + "assayComponentName": "ERF_CR_ENZ_hCDK2", + "assayComponentDesc": "ERF_CR_ENZ_hCDK2 is an assay component calculated from the ERF_CR_ENZ_hCDK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene CDK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 780, + "assayName": "ERF_CR_ENZ_hCDK2", + "assayDesc": "ERF_CR_ENZ_hCDK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CDK2 /CyclinA Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 55, + "geneName": "cyclin-dependent kinase 2", + "description": null, + "geneSymbol": "CDK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1017, + "officialSymbol": "CDK2", + "officialFullName": "cyclin-dependent kinase 2", + "uniprotAccessionNumber": "P24941" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2564, + "assayComponentEndpointName": "ERF_PL_ENZ_hCHK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCHK1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCHK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CHEK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2517, + "assayComponentName": "ERF_PL_ENZ_hCHK1", + "assayComponentDesc": "ERF_PL_ENZ_hCHK1 is an assay component calculated from the ERF_PL_ENZ_hCHK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CHKtide, are indicative of changes in enzyme function and kinetics related to the gene CHEK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CHKtide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 719, + "assayName": "ERF_PL_ENZ_hCHK1", + "assayDesc": "ERF_PL_ENZ_hCHK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CHK1 Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 60, + "geneName": "checkpoint kinase 1", + "description": null, + "geneSymbol": "CHEK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1111, + "officialSymbol": "CHEK1", + "officialFullName": "checkpoint kinase 1", + "uniprotAccessionNumber": "O14757" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2566, + "assayComponentEndpointName": "ERF_CR_ENZ_hCSF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hCSF1R was analyzed at the assay endpoint, ERF_CR_ENZ_hCSF1R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSF1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2519, + "assayComponentName": "ERF_CR_ENZ_hCSF1R", + "assayComponentDesc": "ERF_CR_ENZ_hCSF1R is an assay component calculated from the ERF_CR_ENZ_hCSF1R assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in receptor function and kinetics related to the gene CSF1R.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 793, + "assayName": "ERF_CR_ENZ_hCSF1R", + "assayDesc": "ERF_CR_ENZ_hCSF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Fms (CSFR) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 73, + "geneName": "colony stimulating factor 1 receptor", + "description": null, + "geneSymbol": "CSF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1436, + "officialSymbol": "CSF1R", + "officialFullName": "colony stimulating factor 1 receptor", + "uniprotAccessionNumber": "P07333" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2567, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK1A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK1A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "IC 261", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2520, + "assayComponentName": "ERF_PL_ENZ_hCSNK1A1", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK1A1 is an assay component calculated from the ERF_PL_ENZ_hCSNK1A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK1 substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene CSNK1A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK1 substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 720, + "assayName": "ERF_PL_ENZ_hCSNK1A1", + "assayDesc": "ERF_PL_ENZ_hCSNK1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK1alpha Human CK1 Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 74, + "geneName": "casein kinase 1, alpha 1", + "description": null, + "geneSymbol": "CSNK1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1452, + "officialSymbol": "CSNK1A1", + "officialFullName": "casein kinase 1, alpha 1", + "uniprotAccessionNumber": "P48729" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2568, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK1D", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK1D was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK1D, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "IC 261", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2521, + "assayComponentName": "ERF_PL_ENZ_hCSNK1D", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK1D is an assay component calculated from the ERF_PL_ENZ_hCSNK1D assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK1tide, are indicative of changes in enzyme function and kinetics related to the gene CSNK1D.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK1tide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 722, + "assayName": "ERF_PL_ENZ_hCSNK1D", + "assayDesc": "ERF_PL_ENZ_hCSNK1D is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK1delta Human CK1 Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 75, + "geneName": "casein kinase 1, delta", + "description": null, + "geneSymbol": "CSNK1D", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1453, + "officialSymbol": "CSNK1D", + "officialFullName": "casein kinase 1, delta", + "uniprotAccessionNumber": "P48730" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1843, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "histone H2A", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1141, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ratio", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ratio is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the the ratio of acceptor (d2)-conjugated antibody emission (ch2) to donor (Europium-cryptate)-conjugated antibody emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ratio was designed to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1844, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1142, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1845, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1143, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1846, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1144, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2569, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK2A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK2A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK2A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "hypericin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2522, + "assayComponentName": "ERF_PL_ENZ_hCSNK2A1", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK2A1 is an assay component calculated from the ERF_PL_ENZ_hCSNK2A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK2 substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene CSNK2A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK2 substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 723, + "assayName": "ERF_PL_ENZ_hCSNK2A1", + "assayDesc": "ERF_PL_ENZ_hCSNK2A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK2 (alpha1/alpha2/beta) Human Other Protein Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 76, + "geneName": "casein kinase 2, alpha 1 polypeptide", + "description": null, + "geneSymbol": "CSNK2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1457, + "officialSymbol": "CSNK2A1", + "officialFullName": "casein kinase 2, alpha 1 polypeptide", + "uniprotAccessionNumber": "Q8NEV1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2570, + "assayComponentEndpointName": "ERF_PL_ENZ_hCYP19A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCYP19A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCYP19A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP19A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2523, + "assayComponentName": "ERF_PL_ENZ_hCYP19A1", + "assayComponentDesc": "ERF_PL_ENZ_hCYP19A1 is an assay component calculated from the ERF_PL_ENZ_hCYP19A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, dibenzylfluorescein, are indicative of changes in enzyme function and kinetics related to the gene CYP19A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "dibenzylfluorescein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 698, + "assayName": "ERF_PL_ENZ_hCYP19A1", + "assayDesc": "ERF_PL_ENZ_hCYP19A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate. See CYP19A1 Human CYP450 Enzymatic Assay, Panlabs.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect BTI-TN-5B1-4 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2571, + "assayComponentEndpointName": "ERF_CR_ENZ_hDUSP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hDUSP3 was analyzed at the assay endpoint, ERF_CR_ENZ_hDUSP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DUSP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is dual-specific kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "dual-specific kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2524, + "assayComponentName": "ERF_CR_ENZ_hDUSP3", + "assayComponentDesc": "ERF_CR_ENZ_hDUSP3 is an assay component calculated from the ERF_CR_ENZ_hDUSP3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-4-methylumbelliferyl, are indicative of changes in enzyme function and kinetics related to the gene DUSP3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4-methylumbelliferyl", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 703, + "assayName": "ERF_CR_ENZ_hDUSP3", + "assayDesc": "ERF_PL_ENZ_hDUSP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See VHR Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 102, + "geneName": "dual specificity phosphatase 3", + "description": null, + "geneSymbol": "DUSP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1845, + "officialSymbol": "DUSP3", + "officialFullName": "dual specificity phosphatase 3", + "uniprotAccessionNumber": "P51452" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2572, + "assayComponentEndpointName": "ERF_CR_ENZ_hDYRK1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hDYRK1A was analyzed at the assay endpoint, ERF_CR_ENZ_hDYRK1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DYRK1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2525, + "assayComponentName": "ERF_CR_ENZ_hDYRK1A", + "assayComponentDesc": "ERF_CR_ENZ_hDYRK1A is an assay component calculated from the ERF_CR_ENZ_hDYRK1A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene DYRK1A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 766, + "assayName": "ERF_CR_ENZ_hDYRK1A", + "assayDesc": "ERF_CR_ENZ_hDYRK1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See DYRK1A Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 103, + "geneName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "description": null, + "geneSymbol": "DYRK1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1859, + "officialSymbol": "DYRK1A", + "officialFullName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "uniprotAccessionNumber": "Q13627" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1847, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1145, + "assayComponentName": "TOX21_AP1_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1848, + "assayComponentEndpointName": "CCTE_Simmons_QuantiLum_inhib_2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_QuantiLum_inhib_2 was analyzed at the endpoint, CCTE_Simmons_QuantiLum_inhib_2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand inhibition of firefly luciferase. This is an assay endpoint to indicate nonspecific protein inhibition for comparison to aeid 1508 for thyroperoxidase inhibition. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monooxygenase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "b-naphthoquinone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1146, + "assayComponentName": "CCTE_Simmons_QuantiLum_inhib_2", + "assayComponentDesc": "CCTE_Simmons_QuantiLum_inhib_2 is the assay component measured from the CCTE_Simmons_QuantiLum_inhib_2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with bioluminescence signals by Luciferase-coupled Quantilum levels technology. This is a secondary assay to CCTE_Simmons_AUR_TPO to to evaluate nonspecific enzyme inhibition.", + "assayComponentTargetDesc": "CCTE_Simmons_QuantiLum_inhib_2 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Luciferase detection reagent] and is used to understand nonspecific enzyme inhibition.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled Quantilum levels", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Luciferase detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 453, + "assayName": "CCTE_Simmons_QuantiLum_inhib_2", + "assayDesc": "CCTE_Simmons_QuantiLum_inhib_2 is a biochemical, single-readout assay that uses purified luciferase enzyme in a cell-free assay.Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 0, + "organism": "E.coli", + "tissue": "purified enzyme", + "cellFormat": "cell-free", + "cellFreeComponentSource": "overexpression in E. coli", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 497, + "geneName": "luciferase [Cloning vector pGL3-Basic, complete sequence]", + "description": null, + "geneSymbol": null, + "organismId": 12, + "trackStatus": "live", + "entrezGeneId": null, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "U47295" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1850, + "assayComponentEndpointName": "ACEA_AR_agonist_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1802, + "assayComponentName": "ACEA_AR_agonist_AUC_viability", + "assayComponentDesc": "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 533, + "assayName": "ACEA_AR_agonist", + "assayDesc": "ACEA_AR_agonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1852, + "assayComponentEndpointName": "ACEA_ER_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_ER_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1804, + "assayComponentName": "ACEA_ER_AUC_viability", + "assayComponentDesc": "ACEA_ER_AUC_viability is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 1, + "assayName": "ACEA_ER", + "assayDesc": "ACEA_ER is a cell-based, single-readout assay that uses T47D, a human breast cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "T47D", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16481145", + "pmid": 16481145, + "title": "Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity", + "author": "Xing JZ, Zhu L, Gabos S, Xie L", + "citation": "Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006 Sep;20(6):995-1004. Epub 2006 Feb 14. PubMed PMID: 16481145.", + "otherId": "0", + "citationId": 209, + "otherSource": "" + } + }, + { + "aeid": 1855, + "assayComponentEndpointName": "ACEA_AR_agonist_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1829, + "assayComponentName": "ACEA_AR_agonist_80hr", + "assayComponentDesc": "ACEA_AR_agonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 533, + "assayName": "ACEA_AR_agonist", + "assayDesc": "ACEA_AR_agonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1856, + "assayComponentEndpointName": "ACEA_AR_antagonist_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1830, + "assayComponentName": "ACEA_AR_antagonist_80hr", + "assayComponentDesc": "ACEA_AR_antagonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 534, + "assayName": "ACEA_AR_antagonist", + "assayDesc": "ACEA_AR_antagonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1857, + "assayComponentEndpointName": "ACEA_AR_antagonist_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1831, + "assayComponentName": "ACEA_AR_antagonist_AUC_viability", + "assayComponentDesc": "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 534, + "assayName": "ACEA_AR_antagonist", + "assayDesc": "ACEA_AR_antagonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1858, + "assayComponentEndpointName": "STM_H9_NormalizedViability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_Viability was analyzed at the assay endpoint STM_H9_Viability_Norm in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1114, + "assayComponentName": "STM_H9_NormalizedViability", + "assayComponentDesc": "STM_H9_NormalizedViability is a component calculated in the STM_H9_viability assay. It measures cell viability using background corrected relative fluorescence units (RFU) value from the CellTiterFluor Assay normalized to the value of the 0.1% DMSO neutral control treatment (by 96-well plate)", + "assayComponentTargetDesc": "Changes in fluorescence are indicative of changes in cell viability. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescent signal proportional to the number of living cells", + "detectionTechnology": "CellTiter-FluorTM", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescent signal", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "living cells", + "aid": 437, + "assayName": "STM_H9_viability", + "assayDesc": "STM_H9_viability utilizes undifferentiated H9 cells to measure cell viability.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 89, + "assayComponentEndpointName": "ATG_M_32_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_32_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_32_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 58, + "assayComponentName": "ATG_M_32_CIS", + "assayComponentDesc": "ATG_M_32_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1913, + "assayComponentEndpointName": "ATG_chAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1856, + "assayComponentName": "ATG_chAR_XSP1", + "assayComponentDesc": "ATG_chAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the chicken androgen receptor. [GeneSymbol:ar | GeneID:422165| Uniprot_SwissProt_Accession:Q2ACE0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1474, + "geneName": "androgen receptor", + "description": "androgen receptor (chicken)", + "geneSymbol": "AR", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 422165, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "Q2ACE0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1915, + "assayComponentEndpointName": "ATG_frAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1857, + "assayComponentName": "ATG_frAR_XSP1", + "assayComponentDesc": "ATG_frAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the frog androgen receptor. [GeneSymbol:ar.L | GeneID:399456| Uniprot_SwissProt_Accession:P70048].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1479, + "geneName": "androgen receptor L homeolog", + "description": "androgen receptor L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "ar.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 399456, + "officialSymbol": "ar.L", + "officialFullName": "androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) L homeolog", + "uniprotAccessionNumber": "P70048" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1917, + "assayComponentEndpointName": "ATG_hAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1858, + "assayComponentName": "ATG_hAR_XSP1", + "assayComponentDesc": "ATG_hAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1919, + "assayComponentEndpointName": "ATG_trAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1859, + "assayComponentName": "ATG_trAR_XSP1", + "assayComponentDesc": "ATG_trAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the turtle androgen receptor. [GeneSymbol:AR | GeneID:101947425 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1464, + "geneName": "androgen receptor", + "description": "PREDICTED: Chrysemys picta bellii androgen receptor (AR), mRNA", + "geneSymbol": "AR", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101947425, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2573, + "assayComponentEndpointName": "ERF_CR_ENZ_hEGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEGFR was analyzed at the assay endpoint, ERF_CR_ENZ_hEGFR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EGFR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "hydrochloride", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2526, + "assayComponentName": "ERF_CR_ENZ_hEGFR", + "assayComponentDesc": "ERF_CR_ENZ_hEGFR is an assay component calculated from the ERF_CR_ENZ_hEGFR assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene EGFR.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 768, + "assayName": "ERF_CR_ENZ_hEGFR", + "assayDesc": "ERF_CR_ENZ_hEGFR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See EGFR Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 628, + "assayComponentEndpointName": "NVS_GPCR_hAdra2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdra2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 365, + "assayComponentName": "NVS_GPCR_hAdra2A", + "assayComponentDesc": "NVS_GPCR_hAdra2A is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdra2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2A [GeneSymbol:ADRA2A | GeneID:150 | Uniprot_SwissProt_Accession:P08913].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 179, + "assayName": "NVS_GPCR_hAdra2A", + "assayDesc": "NVS_GPCR_hAdra2A is a biochemical, single-readout assay that uses extracted gene-proteins from HT29 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HT29", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 13, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "ADRA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 150, + "officialSymbol": "ADRA2A", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P08913" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 629, + "assayComponentEndpointName": "NVS_GPCR_hAdra2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 366, + "assayComponentName": "NVS_GPCR_hAdra2C", + "assayComponentDesc": "NVS_GPCR_hAdra2C is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdra2C assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2C [GeneSymbol:ADRA2C | GeneID:152 | Uniprot_SwissProt_Accession:P18825].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 180, + "assayName": "NVS_GPCR_hAdra2C", + "assayDesc": "NVS_GPCR_hAdra2C is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 14, + "geneName": "adrenoceptor alpha 2C", + "description": null, + "geneSymbol": "ADRA2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 152, + "officialSymbol": "ADRA2C", + "officialFullName": "adrenoceptor alpha 2C", + "uniprotAccessionNumber": "P18825" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 630, + "assayComponentEndpointName": "NVS_GPCR_hAdrb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 367, + "assayComponentName": "NVS_GPCR_hAdrb1", + "assayComponentDesc": "NVS_GPCR_hAdrb1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 1 [GeneSymbol:ADRB1 | GeneID:153 | Uniprot_SwissProt_Accession:P08588].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 181, + "assayName": "NVS_GPCR_hAdrb1", + "assayDesc": "NVS_GPCR_hAdrb1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroepithelioma cells in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neuroepithelioma cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 15, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "ADRB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 153, + "officialSymbol": "ADRB1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P08588" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/39246", + "pmid": 39246, + "title": "Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes", + "author": "Minneman KP, Hegstrand LR, Molinoff PB", + "citation": "Minneman KP, Hegstrand LR, Molinoff PB. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol. 1979 Jul;16(1):34-46. PubMed PMID: 39246.", + "otherId": "0", + "citationId": 2, + "otherSource": "" + } + }, + { + "aeid": 519, + "assayComponentEndpointName": "NVS_ENZ_hPKD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKD2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKD2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 301, + "assayComponentName": "NVS_ENZ_hPKD2", + "assayComponentDesc": "NVS_ENZ_hPKD2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKD2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase D2 [GeneSymbol:PRKD2 | GeneID:25865 | Uniprot_SwissProt_Accession:Q9BZL6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 115, + "assayName": "NVS_ENZ_hPKD2", + "assayDesc": "NVS_ENZ_hPKD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 416, + "geneName": "protein kinase D2", + "description": null, + "geneSymbol": "PRKD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25865, + "officialSymbol": "PRKD2", + "officialFullName": "protein kinase D2", + "uniprotAccessionNumber": "Q9BZL6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 521, + "assayComponentEndpointName": "NVS_ENZ_hPPM1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPM1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPM1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium fluoride", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 302, + "assayComponentName": "NVS_ENZ_hPPM1A", + "assayComponentDesc": "NVS_ENZ_hPPM1A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPM1A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:FDP(non-fluorescent) --> fluorescein + fluorescein monophosphate] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase, Mg2+/Mn2+ dependent, 1A [GeneSymbol:PPM1A | GeneID:5494 | Uniprot_SwissProt_Accession:P35813].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 116, + "assayName": "NVS_ENZ_hPPM1A", + "assayDesc": "NVS_ENZ_hPPM1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 251, + "geneName": "protein phosphatase, Mg2+/Mn2+ dependent, 1A", + "description": null, + "geneSymbol": "PPM1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5494, + "officialSymbol": "PPM1A", + "officialFullName": "protein phosphatase, Mg2+/Mn2+ dependent, 1A", + "uniprotAccessionNumber": "P35813" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 523, + "assayComponentEndpointName": "NVS_ENZ_hPPP1CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP1CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "calyculin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 303, + "assayComponentName": "NVS_ENZ_hPPP1CA", + "assayComponentDesc": "NVS_ENZ_hPPP1CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP1CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 1, catalytic subunit, alpha isozyme [GeneSymbol:PPP1CA | GeneID:5499 | Uniprot_SwissProt_Accession:P62136].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 117, + "assayName": "NVS_ENZ_hPPP1CA", + "assayDesc": "NVS_ENZ_hPPP1CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 252, + "geneName": "protein phosphatase 1, catalytic subunit, alpha isozyme", + "description": null, + "geneSymbol": "PPP1CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5499, + "officialSymbol": "PPP1CA", + "officialFullName": "protein phosphatase 1, catalytic subunit, alpha isozyme", + "uniprotAccessionNumber": "P62136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7882291", + "pmid": 7882291, + "title": "Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor", + "author": "Sogawa K, Yamada T, Oka S, Kawasaki K, Mori S, Tanaka H, Norimatsu H, Cai Y, Kuwabara H, Shima H, et al", + "citation": "Sogawa K, Yamada T, Oka S, Kawasaki K, Mori S, Tanaka H, Norimatsu H, Cai Y, Kuwabara H, Shima H, et al. Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor. Cancer Lett. 1995 Feb 10;89(1):1-6. PubMed PMID: 7882291.", + "otherId": "0", + "citationId": 148, + "otherSource": "" + } + }, + { + "aeid": 525, + "assayComponentEndpointName": "NVS_ENZ_hPPP2CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP2CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "calyculin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 304, + "assayComponentName": "NVS_ENZ_hPPP2CA", + "assayComponentDesc": "NVS_ENZ_hPPP2CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP2CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 2, catalytic subunit, alpha isozyme [GeneSymbol:PPP2CA | GeneID:5515 | Uniprot_SwissProt_Accession:P67775].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 118, + "assayName": "NVS_ENZ_hPPP2CA", + "assayDesc": "NVS_ENZ_hPPP2CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 253, + "geneName": "protein phosphatase 2, catalytic subunit, alpha isozyme", + "description": null, + "geneSymbol": "PPP2CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5515, + "officialSymbol": "PPP2CA", + "officialFullName": "protein phosphatase 2, catalytic subunit, alpha isozyme", + "uniprotAccessionNumber": "P67775" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/343651a0", + "url": "#http://www.ncbi.nlm.nih.gov/pubmed/2154696#", + "pmid": 2154696, + "title": "Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase", + "author": "Anderson NG, Maller JL, Tonks NK, Sturgill TW", + "citation": "Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature. 1990 Feb 15;343(6259):651-3. PubMed PMID: 2154696.", + "otherId": "0", + "citationId": 207, + "otherSource": "" + } + }, + { + "aeid": 527, + "assayComponentEndpointName": "NVS_ENZ_hPTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTEN was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "bpV (bipy)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 305, + "assayComponentName": "NVS_ENZ_hPTEN", + "assayComponentDesc": "NVS_ENZ_hPTEN is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTEN assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP3 --> fluorescein-PIP2] involving the key substrate [Fluorescein-labeled PIP3 (phosphoinositol triphosphate(3,4,5))] are indicative of changes in enzyme function and kinetics for the human phosphatase and tensin homolog [GeneSymbol:PTEN | GeneID:5728 | Uniprot_SwissProt_Accession:P60484].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled PIP3 (phosphoinositol triphosphate(3,4,5))", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 119, + "assayName": "NVS_ENZ_hPTEN", + "assayDesc": "NVS_ENZ_hPTEN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 529, + "assayComponentEndpointName": "NVS_ENZ_hPTPN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 306, + "assayComponentName": "NVS_ENZ_hPTPN1", + "assayComponentDesc": "NVS_ENZ_hPTPN1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 1 [GeneSymbol:PTPN1 | GeneID:5770 | Uniprot_SwissProt_Accession:P18031].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 120, + "assayName": "NVS_ENZ_hPTPN1", + "assayDesc": "NVS_ENZ_hPTPN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 265, + "geneName": "protein tyrosine phosphatase, non-receptor type 1", + "description": null, + "geneSymbol": "PTPN1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5770, + "officialSymbol": "PTPN1", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 1", + "uniprotAccessionNumber": "P18031" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1335746", + "pmid": 1335746, + "title": "1002 protein phosphatases?", + "author": "Charbonneau H, Tonks NK", + "citation": "Charbonneau H, Tonks NK. 1002 protein phosphatases? Annu Rev Cell Biol. 1992;8:463-93. Review. PubMed PMID: 1335746.", + "otherId": "0", + "citationId": 15, + "otherSource": "" + } + }, + { + "aeid": 531, + "assayComponentEndpointName": "NVS_ENZ_hPTPN11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN11, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 307, + "assayComponentName": "NVS_ENZ_hPTPN11", + "assayComponentDesc": "NVS_ENZ_hPTPN11 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 11 [GeneSymbol:PTPN11 | GeneID:5781 | Uniprot_SwissProt_Accession:Q06124].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 121, + "assayName": "NVS_ENZ_hPTPN11", + "assayDesc": "NVS_ENZ_hPTPN11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 270, + "geneName": "protein tyrosine phosphatase, non-receptor type 11", + "description": null, + "geneSymbol": "PTPN11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5781, + "officialSymbol": "PTPN11", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 11", + "uniprotAccessionNumber": "Q06124" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 533, + "assayComponentEndpointName": "NVS_ENZ_hPTPN12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN12, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 308, + "assayComponentName": "NVS_ENZ_hPTPN12", + "assayComponentDesc": "NVS_ENZ_hPTPN12 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 12 [GeneSymbol:PTPN12 | GeneID:5782 | Uniprot_SwissProt_Accession:Q05209].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 122, + "assayName": "NVS_ENZ_hPTPN12", + "assayDesc": "NVS_ENZ_hPTPN12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 271, + "geneName": "protein tyrosine phosphatase, non-receptor type 12", + "description": null, + "geneSymbol": "PTPN12", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5782, + "officialSymbol": "PTPN12", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 12", + "uniprotAccessionNumber": "Q05209" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 537, + "assayComponentEndpointName": "NVS_ENZ_hPTPN14", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN14, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 310, + "assayComponentName": "NVS_ENZ_hPTPN14", + "assayComponentDesc": "NVS_ENZ_hPTPN14 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN14 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 14 [GeneSymbol:PTPN14 | GeneID:5784 | Uniprot_SwissProt_Accession:Q15678].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 124, + "assayName": "NVS_ENZ_hPTPN14", + "assayDesc": "NVS_ENZ_hPTPN14 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 273, + "geneName": "protein tyrosine phosphatase, non-receptor type 14", + "description": null, + "geneSymbol": "PTPN14", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5784, + "officialSymbol": "PTPN14", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 14", + "uniprotAccessionNumber": "Q15678" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 539, + "assayComponentEndpointName": "NVS_ENZ_hPTPN2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 311, + "assayComponentName": "NVS_ENZ_hPTPN2", + "assayComponentDesc": "NVS_ENZ_hPTPN2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, AMP-activated, gamma 1 non-catalytic subunit [GeneSymbol:PRKAG1 | GeneID:5571 | Uniprot_SwissProt_Accession:P54619].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 125, + "assayName": "NVS_ENZ_hPTPN2", + "assayDesc": "NVS_ENZ_hPTPN2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 266, + "geneName": "protein tyrosine phosphatase, non-receptor type 2", + "description": null, + "geneSymbol": "PTPN2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5771, + "officialSymbol": "PTPN2", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 2", + "uniprotAccessionNumber": "P17706" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 541, + "assayComponentEndpointName": "NVS_ENZ_hPTPN4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 312, + "assayComponentName": "NVS_ENZ_hPTPN4", + "assayComponentDesc": "NVS_ENZ_hPTPN4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) [GeneSymbol:PTPN4 | GeneID:5775 | Uniprot_SwissProt_Accession:P29074].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 126, + "assayName": "NVS_ENZ_hPTPN4", + "assayDesc": "NVS_ENZ_hPTPN4 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 267, + "geneName": "protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)", + "description": null, + "geneSymbol": "PTPN4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5775, + "officialSymbol": "PTPN4", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)", + "uniprotAccessionNumber": "P29074" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 543, + "assayComponentEndpointName": "NVS_ENZ_hPTPN6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 313, + "assayComponentName": "NVS_ENZ_hPTPN6", + "assayComponentDesc": "NVS_ENZ_hPTPN6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 6 [GeneSymbol:PTPN6 | GeneID:5777 | Uniprot_SwissProt_Accession:P29350].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 127, + "assayName": "NVS_ENZ_hPTPN6", + "assayDesc": "NVS_ENZ_hPTPN6 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 268, + "geneName": "protein tyrosine phosphatase, non-receptor type 6", + "description": null, + "geneSymbol": "PTPN6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5777, + "officialSymbol": "PTPN6", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 6", + "uniprotAccessionNumber": "P29350" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 545, + "assayComponentEndpointName": "NVS_ENZ_hPTPN9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 314, + "assayComponentName": "NVS_ENZ_hPTPN9", + "assayComponentDesc": "NVS_ENZ_hPTPN9 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 9 [GeneSymbol:PTPN9 | GeneID:5780 | Uniprot_SwissProt_Accession:P43378].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 128, + "assayName": "NVS_ENZ_hPTPN9", + "assayDesc": "NVS_ENZ_hPTPN9 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 269, + "geneName": "protein tyrosine phosphatase, non-receptor type 9", + "description": null, + "geneSymbol": "PTPN9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5780, + "officialSymbol": "PTPN9", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 9", + "uniprotAccessionNumber": "P43378" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 547, + "assayComponentEndpointName": "NVS_ENZ_hPTPRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRB was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 315, + "assayComponentName": "NVS_ENZ_hPTPRB", + "assayComponentDesc": "NVS_ENZ_hPTPRB is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRB assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, B [GeneSymbol:PTPRB | GeneID:5787 | Uniprot_SwissProt_Accession:P23467].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 129, + "assayName": "NVS_ENZ_hPTPRB", + "assayDesc": "NVS_ENZ_hPTPRB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 274, + "geneName": "protein tyrosine phosphatase, receptor type, B", + "description": null, + "geneSymbol": "PTPRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5787, + "officialSymbol": "PTPRB", + "officialFullName": "protein tyrosine phosphatase, receptor type, B", + "uniprotAccessionNumber": "P23467" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1335746", + "pmid": 1335746, + "title": "1002 protein phosphatases?", + "author": "Charbonneau H, Tonks NK", + "citation": "Charbonneau H, Tonks NK. 1002 protein phosphatases? Annu Rev Cell Biol. 1992;8:463-93. Review. PubMed PMID: 1335746.", + "otherId": "0", + "citationId": 15, + "otherSource": "" + } + }, + { + "aeid": 549, + "assayComponentEndpointName": "NVS_ENZ_hPTPRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 316, + "assayComponentName": "NVS_ENZ_hPTPRC", + "assayComponentDesc": "NVS_ENZ_hPTPRC is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction [Reaction:pNPP --> p-nitrophenol] involving the key substrate [para-Nitrophenylphosphate (pNPP)] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, C [GeneSymbol:PTPRC | GeneID:5788 | Uniprot_SwissProt_Accession:P08575].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "para-Nitrophenylphosphate (pNPP)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 130, + "assayName": "NVS_ENZ_hPTPRC", + "assayDesc": "NVS_ENZ_hPTPRC is a biochemical, single-readout assay that uses extracted gene-proteins from yeast cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "yeast cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 275, + "geneName": "protein tyrosine phosphatase, receptor type, C", + "description": null, + "geneSymbol": "PTPRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5788, + "officialSymbol": "PTPRC", + "officialFullName": "protein tyrosine phosphatase, receptor type, C", + "uniprotAccessionNumber": "P08575" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8031864", + "pmid": 8031864, + "title": "High level expression and purification of the enzymatically active cytoplasmic region of human CD45 phosphatase from yeast", + "author": "Pacitti A, Stevis P, Evans M, Trowbridge I, Higgins TJ", + "citation": "Pacitti A, Stevis P, Evans M, Trowbridge I, Higgins TJ. High level expression and purification of the enzymatically active cytoplasmic region of human CD45 phosphatase from yeast. Biochim Biophys Acta. 1994 Jun 30;1222(2):277-86. PubMed PMID: 8031864.", + "otherId": "0", + "citationId": 153, + "otherSource": "" + } + }, + { + "aeid": 1921, + "assayComponentEndpointName": "ATG_zfAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1860, + "assayComponentName": "ATG_zfAR_XSP1", + "assayComponentDesc": "ATG_zfAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish androgen receptor. [GeneSymbol:AR | GeneID:100005148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1467, + "geneName": "androgen receptor", + "description": "androgen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "ar", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 100005148, + "officialSymbol": "ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "A4GT83" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1923, + "assayComponentEndpointName": "ATG_frER1_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1861, + "assayComponentName": "ATG_frER1_XSP1", + "assayComponentDesc": "ATG_frER1_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1480, + "geneName": "estrogen receptor 1 L homeolog", + "description": "estrogen receptor 1 L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "esr1.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 398734, + "officialSymbol": "esr1.L", + "officialFullName": "estrogen receptor 1 L homeolog", + "uniprotAccessionNumber": "Q6W5G7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1925, + "assayComponentEndpointName": "ATG_zfER1_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1862, + "assayComponentName": "ATG_zfER1_XSP1", + "assayComponentDesc": "ATG_zfER1_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1468, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "esr1", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 259252, + "officialSymbol": "esr1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P57717" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1927, + "assayComponentEndpointName": "ATG_zfER2a_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2a_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1863, + "assayComponentName": "ATG_zfER2a_XSP1", + "assayComponentDesc": "ATG_zfER2a_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2a | GeneID: 317734| Uniprot_SwissProt_Accession:Q7ZU32].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1469, + "geneName": "estrogen receptor 2a", + "description": "estrogen receptor 2a [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2a", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317734, + "officialSymbol": "esr2a", + "officialFullName": "estrogen receptor 2a", + "uniprotAccessionNumber": "Q7ZU32" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1929, + "assayComponentEndpointName": "ATG_zfER2b_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2b_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1864, + "assayComponentName": "ATG_zfER2b_XSP1", + "assayComponentDesc": "ATG_zfER2b_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2b | GeneID: 317733| Uniprot_SwissProt_Accession:Q5PR29].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1470, + "geneName": "estrogen receptor 2b", + "description": "estrogen receptor 2b [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2b", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317733, + "officialSymbol": "esr2b", + "officialFullName": "estrogen receptor 2b", + "uniprotAccessionNumber": "Q5PR29" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1931, + "assayComponentEndpointName": "ATG_frER2_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER2_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1865, + "assayComponentName": "ATG_frER2_XSP1", + "assayComponentDesc": "ATG_frER2_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr2.L | GeneID: 100174814| Uniprot_SwissProt_Accession:A0A1L8FA50].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1481, + "geneName": "estrogen receptor 2 L homeolog", + "description": "estrogen receptor 2 L homeolog [ Xenopus laevis (African clawed frog) ]", + "geneSymbol": "esr2.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 100174814, + "officialSymbol": "esr2.L", + "officialFullName": "estrogen receptor 2 L homeolog", + "uniprotAccessionNumber": "A0A1L8FA50" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1933, + "assayComponentEndpointName": "ATG_chERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1866, + "assayComponentName": "ATG_chERa_XSP1", + "assayComponentDesc": "ATG_chERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the chicken estrogen receptor. [GeneSymbol:ESR1 | GeneID: 396099| Uniprot_SwissProt_Accession:P06212].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1475, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 (chicken)", + "geneSymbol": "ESR1", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 396099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P06212" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1935, + "assayComponentEndpointName": "ATG_hERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1867, + "assayComponentName": "ATG_hERa_XSP1", + "assayComponentDesc": "ATG_hERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1937, + "assayComponentEndpointName": "ATG_trERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1868, + "assayComponentName": "ATG_trERa_XSP1", + "assayComponentDesc": "ATG_trERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the turtle estrogen receptor. [GeneSymbol:ESR1 | GeneID: 101933533| Uniprot_SwissProt_Accession:B6E1V9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1465, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "ESR1", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101933533, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "B6E1V9" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1939, + "assayComponentEndpointName": "ATG_hERb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1869, + "assayComponentName": "ATG_hERb_XSP1", + "assayComponentDesc": "ATG_hERb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR2 | GeneID: 2100| Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1941, + "assayComponentEndpointName": "ATG_GAL4_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_GAL4_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1870, + "assayComponentName": "ATG_GAL4_XSP1", + "assayComponentDesc": "ATG_GAL4_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 631, + "assayComponentEndpointName": "NVS_GPCR_hAdrb2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 368, + "assayComponentName": "NVS_GPCR_hAdrb2", + "assayComponentDesc": "NVS_GPCR_hAdrb2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 2, surface [GeneSymbol:ADRB2 | GeneID:154 | Uniprot_SwissProt_Accession:P07550].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 182, + "assayName": "NVS_GPCR_hAdrb2", + "assayDesc": "NVS_GPCR_hAdrb2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/39246", + "pmid": 39246, + "title": "Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes", + "author": "Minneman KP, Hegstrand LR, Molinoff PB", + "citation": "Minneman KP, Hegstrand LR, Molinoff PB. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol. 1979 Jul;16(1):34-46. PubMed PMID: 39246.", + "otherId": "0", + "citationId": 2, + "otherSource": "" + } + }, + { + "aeid": 2, + "assayComponentEndpointName": "ACEA_ER_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_ER_80hr was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1, + "assayComponentName": "ACEA_ER_80hr", + "assayComponentDesc": "ACEA_ER_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 1, + "assayName": "ACEA_ER", + "assayDesc": "ACEA_ER is a cell-based, single-readout assay that uses T47D, a human breast cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "T47D", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16481145", + "pmid": 16481145, + "title": "Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity", + "author": "Xing JZ, Zhu L, Gabos S, Xie L", + "citation": "Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006 Sep;20(6):995-1004. Epub 2006 Feb 14. PubMed PMID: 16481145.", + "otherId": "0", + "citationId": 209, + "otherSource": "" + } + }, + { + "aeid": 4, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2, + "assayComponentName": "APR_HepG2_CellCycleArrest_1hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 6, + "assayComponentEndpointName": "APR_HepG2_CellLoss_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 3, + "assayComponentName": "APR_HepG2_CellLoss_1hr", + "assayComponentDesc": "APR_HepG2_CellLoss_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 8, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 4, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_1hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 10, + "assayComponentEndpointName": "APR_HepG2_MitoMass_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 5, + "assayComponentName": "APR_HepG2_MitoMass_1hr", + "assayComponentDesc": "APR_HepG2_MitoMass_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 12, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 6, + "assayComponentName": "APR_HepG2_MitoMembPot_1hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 14, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 7, + "assayComponentName": "APR_HepG2_MitoticArrest_1hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 16, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 8, + "assayComponentName": "APR_HepG2_NuclearSize_1hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 18, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 9, + "assayComponentName": "APR_HepG2_P-H2AX_1hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 20, + "assayComponentEndpointName": "APR_HepG2_p53Act_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 10, + "assayComponentName": "APR_HepG2_p53Act_1hr", + "assayComponentDesc": "APR_HepG2_p53Act_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 22, + "assayComponentEndpointName": "APR_HepG2_StressKinase_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 11, + "assayComponentName": "APR_HepG2_StressKinase_1hr", + "assayComponentDesc": "APR_HepG2_StressKinase_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 24, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 12, + "assayComponentName": "APR_HepG2_CellCycleArrest_24hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 26, + "assayComponentEndpointName": "APR_HepG2_CellLoss_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 13, + "assayComponentName": "APR_HepG2_CellLoss_24hr", + "assayComponentDesc": "APR_HepG2_CellLoss_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 28, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 14, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_24hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 30, + "assayComponentEndpointName": "APR_HepG2_MitoMass_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 15, + "assayComponentName": "APR_HepG2_MitoMass_24hr", + "assayComponentDesc": "APR_HepG2_MitoMass_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 32, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 16, + "assayComponentName": "APR_HepG2_MitoMembPot_24hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 34, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 17, + "assayComponentName": "APR_HepG2_MitoticArrest_24hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 36, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 18, + "assayComponentName": "APR_HepG2_NuclearSize_24hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 38, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 19, + "assayComponentName": "APR_HepG2_P-H2AX_24hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 40, + "assayComponentEndpointName": "APR_HepG2_p53Act_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 20, + "assayComponentName": "APR_HepG2_p53Act_24hr", + "assayComponentDesc": "APR_HepG2_p53Act_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 42, + "assayComponentEndpointName": "APR_HepG2_StressKinase_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 21, + "assayComponentName": "APR_HepG2_StressKinase_24hr", + "assayComponentDesc": "APR_HepG2_StressKinase_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 44, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 22, + "assayComponentName": "APR_HepG2_CellCycleArrest_72hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 46, + "assayComponentEndpointName": "APR_HepG2_CellLoss_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 23, + "assayComponentName": "APR_HepG2_CellLoss_72hr", + "assayComponentDesc": "APR_HepG2_CellLoss_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 48, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 24, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_72hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 551, + "assayComponentEndpointName": "NVS_ENZ_hPTPRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 317, + "assayComponentName": "NVS_ENZ_hPTPRF", + "assayComponentDesc": "NVS_ENZ_hPTPRF is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRF assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, F [GeneSymbol:PTPRF | GeneID:5792 | Uniprot_SwissProt_Accession:P10586].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 131, + "assayName": "NVS_ENZ_hPTPRF", + "assayDesc": "NVS_ENZ_hPTPRF is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 276, + "geneName": "protein tyrosine phosphatase, receptor type, F", + "description": null, + "geneSymbol": "PTPRF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5792, + "officialSymbol": "PTPRF", + "officialFullName": "protein tyrosine phosphatase, receptor type, F", + "uniprotAccessionNumber": "P10586" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 553, + "assayComponentEndpointName": "NVS_ENZ_hPTPRM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRM was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRM, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 318, + "assayComponentName": "NVS_ENZ_hPTPRM", + "assayComponentDesc": "NVS_ENZ_hPTPRM is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRM assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, M [GeneSymbol:PTPRM | GeneID:5797 | Uniprot_SwissProt_Accession:P28827].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 132, + "assayName": "NVS_ENZ_hPTPRM", + "assayDesc": "NVS_ENZ_hPTPRM is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 277, + "geneName": "protein tyrosine phosphatase, receptor type, M", + "description": null, + "geneSymbol": "PTPRM", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5797, + "officialSymbol": "PTPRM", + "officialFullName": "protein tyrosine phosphatase, receptor type, M", + "uniprotAccessionNumber": "P28827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 555, + "assayComponentEndpointName": "NVS_ENZ_hRAF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hRAF1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hRAF1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 319, + "assayComponentName": "NVS_ENZ_hRAF1", + "assayComponentDesc": "NVS_ENZ_hRAF1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hRAF1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Raf-1 proto-oncogene, serine/threonine kinase [GeneSymbol:RAF1 | GeneID:5894 | Uniprot_SwissProt_Accession:P04049].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 133, + "assayName": "NVS_ENZ_hRAF1", + "assayDesc": "NVS_ENZ_hRAF1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 278, + "geneName": "Raf-1 proto-oncogene, serine/threonine kinase", + "description": null, + "geneSymbol": "RAF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5894, + "officialSymbol": "RAF1", + "officialFullName": "Raf-1 proto-oncogene, serine/threonine kinase", + "uniprotAccessionNumber": "P04049" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 557, + "assayComponentEndpointName": "NVS_ENZ_hROCK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hROCK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hROCK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 320, + "assayComponentName": "NVS_ENZ_hROCK1", + "assayComponentDesc": "NVS_ENZ_hROCK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hROCK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Rho-associated, coiled-coil containing protein kinase 1 [GeneSymbol:ROCK1 | GeneID:6093 | Uniprot_SwissProt_Accession:Q13464].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 134, + "assayName": "NVS_ENZ_hROCK1", + "assayDesc": "NVS_ENZ_hROCK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 283, + "geneName": "Rho-associated, coiled-coil containing protein kinase 1", + "description": null, + "geneSymbol": "ROCK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6093, + "officialSymbol": "ROCK1", + "officialFullName": "Rho-associated, coiled-coil containing protein kinase 1", + "uniprotAccessionNumber": "Q13464" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 559, + "assayComponentEndpointName": "NVS_ENZ_hSGK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSGK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSGK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 321, + "assayComponentName": "NVS_ENZ_hSGK1", + "assayComponentDesc": "NVS_ENZ_hSGK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSGK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human serum/glucocorticoid regulated kinase 1 [GeneSymbol:SGK1 | GeneID:6446 | Uniprot_SwissProt_Accession:O00141].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 135, + "assayName": "NVS_ENZ_hSGK1", + "assayDesc": "NVS_ENZ_hSGK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 295, + "geneName": "serum/glucocorticoid regulated kinase 1", + "description": null, + "geneSymbol": "SGK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6446, + "officialSymbol": "SGK1", + "officialFullName": "serum/glucocorticoid regulated kinase 1", + "uniprotAccessionNumber": "O00141" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 561, + "assayComponentEndpointName": "NVS_ENZ_hSIRT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Suramin;Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 322, + "assayComponentName": "NVS_ENZ_hSIRT1", + "assayComponentDesc": "NVS_ENZ_hSIRT1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 1 [GeneSymbol:SIRT1 | GeneID:23411 | Uniprot_SwissProt_Accession:Q96EB6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 136, + "assayName": "NVS_ENZ_hSIRT1", + "assayDesc": "NVS_ENZ_hSIRT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 377, + "geneName": "sirtuin 1", + "description": null, + "geneSymbol": "SIRT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23411, + "officialSymbol": "SIRT1", + "officialFullName": "sirtuin 1", + "uniprotAccessionNumber": "Q96EB6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 563, + "assayComponentEndpointName": "NVS_ENZ_hSIRT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Suramin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 323, + "assayComponentName": "NVS_ENZ_hSIRT2", + "assayComponentDesc": "NVS_ENZ_hSIRT2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 2 [GeneSymbol:SIRT2 | GeneID:22933 | Uniprot_SwissProt_Accession:Q8IXJ6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 137, + "assayName": "NVS_ENZ_hSIRT2", + "assayDesc": "NVS_ENZ_hSIRT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 374, + "geneName": "sirtuin 2", + "description": null, + "geneSymbol": "SIRT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 22933, + "officialSymbol": "SIRT2", + "officialFullName": "sirtuin 2", + "uniprotAccessionNumber": "Q8IXJ6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 565, + "assayComponentEndpointName": "NVS_ENZ_hSIRT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nicotinamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 324, + "assayComponentName": "NVS_ENZ_hSIRT3", + "assayComponentDesc": "NVS_ENZ_hSIRT3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 3 [GeneSymbol:SIRT3 | GeneID:23410 | Uniprot_SwissProt_Accession:Q9NTG7].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 138, + "assayName": "NVS_ENZ_hSIRT3", + "assayDesc": "NVS_ENZ_hSIRT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 376, + "geneName": "sirtuin 3", + "description": null, + "geneSymbol": "SIRT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23410, + "officialSymbol": "SIRT3", + "officialFullName": "sirtuin 3", + "uniprotAccessionNumber": "Q9NTG7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 567, + "assayComponentEndpointName": "NVS_ENZ_hSRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSRC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 325, + "assayComponentName": "NVS_ENZ_hSRC", + "assayComponentDesc": "NVS_ENZ_hSRC is one of one assay component(s) measured or calculated from the NVS_ENZ_hSRC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:SRC | GeneID:6714 | Uniprot_SwissProt_Accession:P12931].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 139, + "assayName": "NVS_ENZ_hSRC", + "assayDesc": "NVS_ENZ_hSRC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 569, + "assayComponentEndpointName": "NVS_ENZ_hSyk", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSyk was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSyk, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 326, + "assayComponentName": "NVS_ENZ_hSyk", + "assayComponentDesc": "NVS_ENZ_hSyk is one of one assay component(s) measured or calculated from the NVS_ENZ_hSyk assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human spleen tyrosine kinase [GeneSymbol:SYK | GeneID:6850 | Uniprot_SwissProt_Accession:P43405].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 140, + "assayName": "NVS_ENZ_hSyk", + "assayDesc": "NVS_ENZ_hSyk is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 308, + "geneName": "spleen tyrosine kinase", + "description": null, + "geneSymbol": "SYK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6850, + "officialSymbol": "SYK", + "officialFullName": "spleen tyrosine kinase", + "uniprotAccessionNumber": "P43405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 571, + "assayComponentEndpointName": "NVS_ENZ_hTie2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hTie2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 327, + "assayComponentName": "NVS_ENZ_hTie2", + "assayComponentDesc": "NVS_ENZ_hTie2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hTie2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human TEK tyrosine kinase, endothelial [GeneSymbol:TEK | GeneID:7010 | Uniprot_SwissProt_Accession:Q02763].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 141, + "assayName": "NVS_ENZ_hTie2", + "assayDesc": "NVS_ENZ_hTie2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 313, + "geneName": "TEK tyrosine kinase, endothelial", + "description": null, + "geneSymbol": "TEK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7010, + "officialSymbol": "TEK", + "officialFullName": "TEK tyrosine kinase, endothelial", + "uniprotAccessionNumber": "Q02763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 573, + "assayComponentEndpointName": "NVS_ENZ_hTrkA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hTrkA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 328, + "assayComponentName": "NVS_ENZ_hTrkA", + "assayComponentDesc": "NVS_ENZ_hTrkA is one of one assay component(s) measured or calculated from the NVS_ENZ_hTrkA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human neurotrophic tyrosine kinase, receptor, type 1 [GeneSymbol:NTRK1 | GeneID:4914 | Uniprot_SwissProt_Accession:P04629].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 142, + "assayName": "NVS_ENZ_hTrkA", + "assayDesc": "NVS_ENZ_hTrkA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 222, + "geneName": "neurotrophic tyrosine kinase, receptor, type 1", + "description": null, + "geneSymbol": "NTRK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4914, + "officialSymbol": "NTRK1", + "officialFullName": "neurotrophic tyrosine kinase, receptor, type 1", + "uniprotAccessionNumber": "P04629" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 575, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 329, + "assayComponentName": "NVS_ENZ_hVEGFR1", + "assayComponentDesc": "NVS_ENZ_hVEGFR1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fms-related tyrosine kinase 1 [GeneSymbol:FLT1 | GeneID:2321 | Uniprot_SwissProt_Accession:P17948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 143, + "assayName": "NVS_ENZ_hVEGFR1", + "assayDesc": "NVS_ENZ_hVEGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 131, + "geneName": "fms-related tyrosine kinase 1", + "description": null, + "geneSymbol": "FLT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2321, + "officialSymbol": "FLT1", + "officialFullName": "fms-related tyrosine kinase 1", + "uniprotAccessionNumber": "P17948" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 577, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 330, + "assayComponentName": "NVS_ENZ_hVEGFR2", + "assayComponentDesc": "NVS_ENZ_hVEGFR2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human kinase insert domain receptor (a type III receptor tyrosine kinase) [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 144, + "assayName": "NVS_ENZ_hVEGFR2", + "assayDesc": "NVS_ENZ_hVEGFR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 579, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 331, + "assayComponentName": "NVS_ENZ_hVEGFR3", + "assayComponentDesc": "NVS_ENZ_hVEGFR3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fms-related tyrosine kinase 4 [GeneSymbol:FLT4 | GeneID:2324 | Uniprot_SwissProt_Accession:P35916].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 145, + "assayName": "NVS_ENZ_hVEGFR3", + "assayDesc": "NVS_ENZ_hVEGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 132, + "geneName": "fms-related tyrosine kinase 4", + "description": null, + "geneSymbol": "FLT4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2324, + "officialSymbol": "FLT4", + "officialFullName": "fms-related tyrosine kinase 4", + "uniprotAccessionNumber": "P35916" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 581, + "assayComponentEndpointName": "NVS_ENZ_hZAP70", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hZAP70 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hZAP70, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 332, + "assayComponentName": "NVS_ENZ_hZAP70", + "assayComponentDesc": "NVS_ENZ_hZAP70 is one of one assay component(s) measured or calculated from the NVS_ENZ_hZAP70 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human zeta-chain (TCR) associated protein kinase 70kDa [GeneSymbol:ZAP70 | GeneID:7535 | Uniprot_SwissProt_Accession:P43403].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 146, + "assayName": "NVS_ENZ_hZAP70", + "assayDesc": "NVS_ENZ_hZAP70 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 338, + "geneName": "zeta-chain (TCR) associated protein kinase 70kDa", + "description": null, + "geneSymbol": "ZAP70", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7535, + "officialSymbol": "ZAP70", + "officialFullName": "zeta-chain (TCR) associated protein kinase 70kDa", + "uniprotAccessionNumber": "P43403" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 583, + "assayComponentEndpointName": "NVS_ENZ_oCOX1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_oCOX1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SC-560", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 333, + "assayComponentName": "NVS_ENZ_oCOX1", + "assayComponentDesc": "NVS_ENZ_oCOX1 is one of one assay component(s) measured or calculated from the NVS_ENZ_oCOX1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS1 | GeneID:443551 | Uniprot_SwissProt_Accession:P05979].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid;N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 147, + "assayName": "NVS_ENZ_oCOX1", + "assayDesc": "NVS_ENZ_oCOX1 is a biochemical, single-readout assay that uses extracted gene-proteins from Ovine seminal vesicles in a tissue-based cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.66, + "organismId": 9940, + "organism": "sheep", + "tissue": "testis", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Ovine seminal vesicles", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 461, + "geneName": "prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)", + "description": "provisional", + "geneSymbol": "PTGS1", + "organismId": 6, + "trackStatus": "live", + "entrezGeneId": 443551, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P05979" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9789085", + "pmid": 9789085, + "title": "Pharmacological analysis of cyclooxygenase-1 in inflammation", + "author": "Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC", + "citation": "Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8. PubMed PMID: 9789085; PubMed Central PMCID: PMC23795.", + "otherId": "0", + "citationId": 175, + "otherSource": "" + } + }, + { + "aeid": 585, + "assayComponentEndpointName": "NVS_ENZ_oCOX2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_oCOX2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DuP-697", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 334, + "assayComponentName": "NVS_ENZ_oCOX2", + "assayComponentDesc": "NVS_ENZ_oCOX2 is one of one assay component(s) measured or calculated from the NVS_ENZ_oCOX2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS2 | GeneID:443460 | Uniprot_SwissProt_Accession:P79208].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid;N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 148, + "assayName": "NVS_ENZ_oCOX2", + "assayDesc": "NVS_ENZ_oCOX2 is a biochemical, single-readout assay that uses extracted gene-proteins from Ovine placenta in a tissue-based cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.66, + "organismId": 9940, + "organism": "sheep", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Ovine placenta", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 460, + "geneName": "prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)", + "description": "provisional", + "geneSymbol": "PTGS2", + "organismId": 6, + "trackStatus": "live", + "entrezGeneId": 443460, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P79208" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8831731", + "pmid": 8831731, + "title": "Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells", + "author": "Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP", + "citation": "Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol. 1996 Oct 11;52(7):1113-25. PubMed PMID: 8831731.", + "otherId": "0", + "citationId": 167, + "otherSource": "" + } + }, + { + "aeid": 587, + "assayComponentEndpointName": "NVS_ENZ_pMTHFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_pMTHFR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_pMTHFR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is methylenetetrahydrofolate reductase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Sulfasalazine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "methylenetetrahydrofolate reductase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 335, + "assayComponentName": "NVS_ENZ_pMTHFR", + "assayComponentDesc": "NVS_ENZ_pMTHFR is one of one assay component(s) measured or calculated from the NVS_ENZ_pMTHFR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:5-[14C]-methyltetrahydrofolate + menadione --> H[14C]HO + THF] involving the key substrate [5-[14C]-methyltetrahydrofolate] are indicative of changes in enzyme function and kinetics for the pig methylenetetrahydrofolate reductase (NAD(P)H) [GeneSymbol:MTHFR | GeneID:397180 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "5-[14C]-methyltetrahydrofolate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 149, + "assayName": "NVS_ENZ_pMTHFR", + "assayDesc": "NVS_ENZ_pMTHFR is a biochemical, single-readout assay that uses extracted gene-proteins from Porcine kidney in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9823, + "organism": "pig", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Porcine kidney", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 456, + "geneName": "methylenetetrahydrofolate reductase (NAD(P)H)", + "description": "model", + "geneSymbol": "MTHFR", + "organismId": 5, + "trackStatus": "live", + "entrezGeneId": 397180, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/508720", + "pmid": 508720, + "title": "Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications", + "author": "Matthews RG, Haywood BJ", + "citation": "Matthews RG, Haywood BJ. Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications. Biochemistry. 1979 Oct 30;18(22):4845-51. PubMed PMID: 508720.", + "otherId": "0", + "citationId": 10, + "otherSource": "" + } + }, + { + "aeid": 589, + "assayComponentEndpointName": "NVS_ENZ_rabI2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rabI2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rabI2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is imidazoline receptor.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "2-BFI", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "imidazoline receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 336, + "assayComponentName": "NVS_ENZ_rabI2C", + "assayComponentDesc": "NVS_ENZ_rabI2C is one of one assay component(s) measured or calculated from the NVS_ENZ_rabI2C assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-2-BFI] are indicative of a change in enzyme function and kinetics for the rabbit creatine kinase, brain [GeneSymbol:CKB | GeneID:100009085 | Uniprot_SwissProt_Accession:P00567].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-2-BFI", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 150, + "assayName": "NVS_ENZ_rabI2C", + "assayDesc": "NVS_ENZ_rabI2C is a biochemical, single-readout assay that uses extracted gene-proteins from Rabbit brain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 9986, + "organism": "rabbit", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rabbit brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 467, + "geneName": "creatine kinase, brain", + "description": "provisional", + "geneSymbol": "CKB", + "organismId": 9, + "trackStatus": "live", + "entrezGeneId": 100009085, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P00567" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1972896", + "pmid": 1972896, + "title": "Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain", + "author": "Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT", + "citation": "Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT. Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol. 1990 Apr;99(4):803-9. PubMed PMID: 1972896; PubMed Central PMCID: PMC1917565.", + "otherId": "0", + "citationId": 27, + "otherSource": "" + } + }, + { + "aeid": 591, + "assayComponentEndpointName": "NVS_ENZ_rACFSKBinding", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rACFSKBinding, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 337, + "assayComponentName": "NVS_ENZ_rACFSKBinding", + "assayComponentDesc": "NVS_ENZ_rACFSKBinding is one of one assay component(s) measured or calculated from the NVS_ENZ_rACFSKBinding assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-forskolin] are indicative of a change in enzyme function and kinetics for the Norway rat adenylate cyclase 5 [GeneSymbol:Adcy5 | GeneID:64532 | Uniprot_SwissProt_Accession:Q04400].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 151, + "assayName": "NVS_ENZ_rACFSKBinding", + "assayDesc": "NVS_ENZ_rACFSKBinding is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3159185", + "pmid": 3159185, + "title": "High-affinity binding of forskolin to rat brain membranes", + "author": "Seamon KB, Daly JW", + "citation": "Seamon KB, Daly JW. High-affinity binding of forskolin to rat brain membranes. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1985;19:125-35. PubMed PMID: 3159185.", + "otherId": "0", + "citationId": 97, + "otherSource": "" + } + }, + { + "aeid": 593, + "assayComponentEndpointName": "NVS_ENZ_rAChE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rAChE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rAChE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is acetylcholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "acetylcholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 338, + "assayComponentName": "NVS_ENZ_rAChE", + "assayComponentDesc": "NVS_ENZ_rAChE is one of one assay component(s) measured or calculated from the NVS_ENZ_rAChE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the Norway rat acetylcholinesterase [GeneSymbol:Ache | GeneID:83817 | Uniprot_SwissProt_Accession:P37136].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "acetylthiocholine;Ellman\"s reagent (DTNB)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 152, + "assayName": "NVS_ENZ_rAChE", + "assayDesc": "NVS_ENZ_rAChE is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 441, + "geneName": "acetylcholinesterase", + "description": "provisional", + "geneSymbol": "Ache", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 83817, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P37136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 595, + "assayComponentEndpointName": "NVS_ENZ_rCNOS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rCNOS was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is nitric oxide synthase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitro-L-Arginine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "nitric oxide synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 339, + "assayComponentName": "NVS_ENZ_rCNOS", + "assayComponentDesc": "NVS_ENZ_rCNOS is one of one assay component(s) measured or calculated from the NVS_ENZ_rCNOS assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitro-L-Arginine] are indicative of a change in enzyme function and kinetics for the Norway rat nitric oxide synthase 1, neuronal [GeneSymbol:Nos1 | GeneID:24598 | Uniprot_SwissProt_Accession:P29476].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitro-L-Arginine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 153, + "assayName": "NVS_ENZ_rCNOS", + "assayDesc": "NVS_ENZ_rCNOS is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 392, + "geneName": "nitric oxide synthase 1, neuronal", + "description": null, + "geneSymbol": "Nos1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24598, + "officialSymbol": "Nos1", + "officialFullName": "nitric oxide synthase 1, neuronal", + "uniprotAccessionNumber": "P29476" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7689392", + "pmid": 7689392, + "title": "Characterization of the binding of [3H]-L-NG-nitro-arginine in rat brain", + "author": "Michel AD, Phul RK, Stewart TL, Humphrey PP", + "citation": "Michel AD, Phul RK, Stewart TL, Humphrey PP. Characterization of the binding of [3H]-L-NG-nitro-arginine in rat brain. Br J Pharmacol. 1993 Jun;109(2):287-8. PubMed PMID: 7689392; PubMed Central PMCID: PMC2175700.", + "otherId": "0", + "citationId": 144, + "otherSource": "" + } + }, + { + "aeid": 597, + "assayComponentEndpointName": "NVS_ENZ_rCOMT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rCOMT was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rCOMT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the methyltransferase intended target family, where the subfamily is o-methyltransferase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "OR-486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "methyltransferase", + "intendedTargetFamilySub": "o-methyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 340, + "assayComponentName": "NVS_ENZ_rCOMT", + "assayComponentDesc": "NVS_ENZ_rCOMT is one of one assay component(s) measured or calculated from the NVS_ENZ_rCOMT assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by HPLC and Spectrophotometry technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction involving the key substrate [3,4-dihydroxybenzoid acid] are indicative of changes in enzyme function and kinetics for the Norway rat catechol-O-methyltransferase [GeneSymbol:Comt | GeneID:24267 | Uniprot_SwissProt_Accession:P22734].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC and Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,4-dihydroxybenzoid acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 154, + "assayName": "NVS_ENZ_rCOMT", + "assayDesc": "NVS_ENZ_rCOMT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat dorsal striatum in a tissue-based cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat dorsal striatum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 383, + "geneName": "catechol-O-methyltransferase", + "description": null, + "geneSymbol": "Comt", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24267, + "officialSymbol": "Comt", + "officialFullName": "catechol-O-methyltransferase", + "uniprotAccessionNumber": "P22734" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2291472", + "pmid": 2291472, + "title": "Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection", + "author": "Smit NP, Pavel S, Kammeyer A, Westerhof W", + "citation": "Smit NP, Pavel S, Kammeyer A, Westerhof W. Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection. Anal Biochem. 1990 Nov 1;190(2):286-91. PubMed PMID: 2291472.", + "otherId": "0", + "citationId": 42, + "otherSource": "" + } + }, + { + "aeid": 599, + "assayComponentEndpointName": "NVS_ENZ_hDYRK1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hDYRK1a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is dual-specific kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "dual-specific kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 341, + "assayComponentName": "NVS_ENZ_hDYRK1a", + "assayComponentDesc": "NVS_ENZ_hDYRK1a is one of one assay component(s) measured or calculated from the NVS_ENZ_hDYRK1a assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A [GeneSymbol:DYRK1A | GeneID:1859 | Uniprot_SwissProt_Accession:Q13627].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 155, + "assayName": "NVS_ENZ_hDYRK1a", + "assayDesc": "NVS_ENZ_hDYRK1a is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 103, + "geneName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "description": null, + "geneSymbol": "DYRK1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1859, + "officialSymbol": "DYRK1A", + "officialFullName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "uniprotAccessionNumber": "Q13627" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 601, + "assayComponentEndpointName": "NVS_ENZ_rMAOAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOAC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 41-1049;Tetrindole mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 342, + "assayComponentName": "NVS_ENZ_rMAOAC", + "assayComponentDesc": "NVS_ENZ_rMAOAC is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOAC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Serotonin (5HT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 156, + "assayName": "NVS_ENZ_rMAOAC", + "assayDesc": "NVS_ENZ_rMAOAC is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 417, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "Maoa", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29253, + "officialSymbol": "Maoa", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": "P21396" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 603, + "assayComponentEndpointName": "NVS_ENZ_rMAOAP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOAP was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 41-1049;Tetrindole mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 343, + "assayComponentName": "NVS_ENZ_rMAOAP", + "assayComponentDesc": "NVS_ENZ_rMAOAP is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOAP assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Serotonin (5HT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 157, + "assayName": "NVS_ENZ_rMAOAP", + "assayDesc": "NVS_ENZ_rMAOAP is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver mitochondrial membranes in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver mitochondrial membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 417, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "Maoa", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29253, + "officialSymbol": "Maoa", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": "P21396" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 605, + "assayComponentEndpointName": "NVS_ENZ_rMAOBC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOBC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOBC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 16-6491", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 344, + "assayComponentName": "NVS_ENZ_rMAOBC", + "assayComponentDesc": "NVS_ENZ_rMAOBC is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOBC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Phenylethylamine (PEA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 158, + "assayName": "NVS_ENZ_rMAOBC", + "assayDesc": "NVS_ENZ_rMAOBC is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 415, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "Maob", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25750, + "officialSymbol": "Maob", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": "P19643" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 607, + "assayComponentEndpointName": "NVS_ENZ_rMAOBP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOBP was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOBP, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 16-6491", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 345, + "assayComponentName": "NVS_ENZ_rMAOBP", + "assayComponentDesc": "NVS_ENZ_rMAOBP is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOBP assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Phenylethylamine (PEA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 159, + "assayName": "NVS_ENZ_rMAOBP", + "assayDesc": "NVS_ENZ_rMAOBP is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 415, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "Maob", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25750, + "officialSymbol": "Maob", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": "P19643" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 609, + "assayComponentEndpointName": "NVS_GPCR_bAdoR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5\"-N-ethylcarboxamidoadenosine (NECA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 346, + "assayComponentName": "NVS_GPCR_bAdoR_NonSelective", + "assayComponentDesc": "NVS_GPCR_bAdoR_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bAdoR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-5\"-N-ethylcarboxamidoadenosine] are indicative of a change in receptor function and kinetics for the cattle adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:282133 | Uniprot_SwissProt_Accession:P28190].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-5\"-N-ethylcarboxamidoadenosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 160, + "assayName": "NVS_GPCR_bAdoR_NonSelective", + "assayDesc": "NVS_GPCR_bAdoR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 451, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 282133, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P28190" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1846425", + "pmid": 1846425, + "title": "Role of adenosine receptors in caffeine tolerance", + "author": "Holtzman SG, Mante S, Minneman KP", + "citation": "Holtzman SG, Mante S, Minneman KP. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther. 1991 Jan;256(1):62-8. PubMed PMID: 1846425.", + "otherId": "0", + "citationId": 25, + "otherSource": "" + } + }, + { + "aeid": 610, + "assayComponentEndpointName": "NVS_GPCR_bAT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Angiotensin II", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 347, + "assayComponentName": "NVS_GPCR_bAT2", + "assayComponentDesc": "NVS_GPCR_bAT2 is one of one assay component(s) measured or calculated from the NVS_GPCR_bAT2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Tyr4-Angiotensin II] are indicative of a change in receptor function and kinetics for the cattle angiotensin II receptor, type 2 [GeneSymbol:AGTR2 | GeneID:407157 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Tyr4-Angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 161, + "assayName": "NVS_GPCR_bAT2", + "assayDesc": "NVS_GPCR_bAT2 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 458, + "geneName": "angiotensin II receptor, type 2", + "description": null, + "geneSymbol": "AGTR2", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 407157, + "officialSymbol": "AGTR2", + "officialFullName": "angiotensin II receptor, type 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/187587", + "pmid": 187587, + "title": "Angiotensin II binding to mammalian brain membranes", + "author": "Bennett JP Jr, Snyder SH", + "citation": "Bennett JP Jr, Snyder SH. Angiotensin II binding to mammalian brain membranes. J Biol Chem. 1976 Dec 10;251(23):7423-30. PubMed PMID: 187587.", + "otherId": "0", + "citationId": 4, + "otherSource": "" + } + }, + { + "aeid": 611, + "assayComponentEndpointName": "NVS_GPCR_bDR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bDR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bDR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Spiperone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 348, + "assayComponentName": "NVS_GPCR_bDR_NonSelective", + "assayComponentDesc": "NVS_GPCR_bDR_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bDR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Spiperone] are indicative of a change in receptor function and kinetics for the cattle dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:281125 | Uniprot_SwissProt_Accession:Q95136].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 162, + "assayName": "NVS_GPCR_bDR_NonSelective", + "assayDesc": "NVS_GPCR_bDR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 449, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 281125, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "Q95136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23126", + "pmid": 23126, + "title": "Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding", + "author": "Leysen JE, Gommeren W, Laduron PM", + "citation": "Leysen JE, Gommeren W, Laduron PM. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol. 1978 Feb 1;27(3):307-16. PubMed PMID: 23126.", + "otherId": "0", + "citationId": 1, + "otherSource": "" + } + }, + { + "aeid": 50, + "assayComponentEndpointName": "APR_HepG2_MitoMass_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 25, + "assayComponentName": "APR_HepG2_MitoMass_72hr", + "assayComponentDesc": "APR_HepG2_MitoMass_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 52, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 26, + "assayComponentName": "APR_HepG2_MitoMembPot_72hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 54, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 27, + "assayComponentName": "APR_HepG2_MitoticArrest_72hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 56, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 28, + "assayComponentName": "APR_HepG2_NuclearSize_72hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 58, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 29, + "assayComponentName": "APR_HepG2_P-H2AX_72hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 60, + "assayComponentEndpointName": "APR_HepG2_p53Act_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 30, + "assayComponentName": "APR_HepG2_p53Act_72hr", + "assayComponentDesc": "APR_HepG2_p53Act_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 62, + "assayComponentEndpointName": "APR_HepG2_StressKinase_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 31, + "assayComponentName": "APR_HepG2_StressKinase_72hr", + "assayComponentDesc": "APR_HepG2_StressKinase_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 63, + "assayComponentEndpointName": "ATG_Ahr_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ahr_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain or loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "6-formylindolo carbazole", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 32, + "assayComponentName": "ATG_Ahr_CIS", + "assayComponentDesc": "ATG_Ahr_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AhRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 21, + "geneName": "aryl hydrocarbon receptor", + "description": null, + "geneSymbol": "AHR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 196, + "officialSymbol": "AHR", + "officialFullName": "aryl hydrocarbon receptor", + "uniprotAccessionNumber": "P35869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 64, + "assayComponentEndpointName": "ATG_AP_1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 33, + "assayComponentName": "ATG_AP_1_CIS", + "assayComponentDesc": "ATG_AP_1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AP-1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 134, + "geneName": "FBJ murine osteosarcoma viral oncogene homolog", + "description": null, + "geneSymbol": "FOS", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2353, + "officialSymbol": "FOS", + "officialFullName": "FBJ murine osteosarcoma viral oncogene homolog", + "uniprotAccessionNumber": "P01100" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 65, + "assayComponentEndpointName": "ATG_AP_2_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-turn-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-turn-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 34, + "assayComponentName": "ATG_AP_2_CIS", + "assayComponentDesc": "ATG_AP_2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AP-2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 314, + "geneName": "transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)", + "description": null, + "geneSymbol": "TFAP2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7020, + "officialSymbol": "TFAP2A", + "officialFullName": "transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)", + "uniprotAccessionNumber": "P05549" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 66, + "assayComponentEndpointName": "ATG_BRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_BRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "Smad protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 35, + "assayComponentName": "ATG_BRE_CIS", + "assayComponentDesc": "ATG_BRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "BRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 67, + "assayComponentEndpointName": "ATG_C_EBP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_C_EBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 36, + "assayComponentName": "ATG_C_EBP_CIS", + "assayComponentDesc": "ATG_C_EBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "C/EBP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 58, + "geneName": "CCAAT/enhancer binding protein (C/EBP), beta", + "description": null, + "geneSymbol": "CEBPB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1051, + "officialSymbol": "CEBPB", + "officialFullName": "CCAAT/enhancer binding protein (C/EBP), beta", + "uniprotAccessionNumber": "P17676" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 68, + "assayComponentEndpointName": "ATG_CMV_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CMV_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_CMV_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 37, + "assayComponentName": "ATG_CMV_CIS", + "assayComponentDesc": "ATG_CMV_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene CMV, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CMV RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 69, + "assayComponentEndpointName": "ATG_CRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_CRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 38, + "assayComponentName": "ATG_CRE_CIS", + "assayComponentDesc": "ATG_CRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 366, + "geneName": "cAMP responsive element binding protein 3", + "description": null, + "geneSymbol": "CREB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10488, + "officialSymbol": "CREB3", + "officialFullName": "cAMP responsive element binding protein 3", + "uniprotAccessionNumber": "O43889" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 70, + "assayComponentEndpointName": "ATG_DR4_LXR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR4_LXR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 39, + "assayComponentName": "ATG_DR4_LXR_CIS", + "assayComponentDesc": "ATG_DR4_LXR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "LXRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 332, + "geneName": "nuclear receptor subfamily 1, group H, member 2", + "description": null, + "geneSymbol": "NR1H2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7376, + "officialSymbol": "NR1H2", + "officialFullName": "nuclear receptor subfamily 1, group H, member 2", + "uniprotAccessionNumber": "P55055" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 71, + "assayComponentEndpointName": "ATG_DR5_RAR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR5_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 40, + "assayComponentName": "ATG_DR5_RAR_CIS", + "assayComponentDesc": "ATG_DR5_RAR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "RARE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 612, + "assayComponentEndpointName": "NVS_GPCR_bH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tripolidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 349, + "assayComponentName": "NVS_GPCR_bH1", + "assayComponentDesc": "NVS_GPCR_bH1 is one of one assay component(s) measured or calculated from the NVS_GPCR_bH1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Pyrilamine] are indicative of a change in receptor function and kinetics for the cattle histamine receptor H1 [GeneSymbol:HRH1 | GeneID:281231 | Uniprot_SwissProt_Accession:P30546].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 163, + "assayName": "NVS_GPCR_bH1", + "assayDesc": "NVS_GPCR_bH1 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 450, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 281231, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P30546" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/448359", + "pmid": 448359, + "title": "Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes", + "author": "Chang RS, Tran VT, Snyder SH", + "citation": "Chang RS, Tran VT, Snyder SH. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J Neurochem. 1979 Jun;32(6):1653-63. PubMed PMID: 448359.", + "otherId": "0", + "citationId": 8, + "otherSource": "" + } + }, + { + "aeid": 613, + "assayComponentEndpointName": "NVS_GPCR_bNPY_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bNPY_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bNPY_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 350, + "assayComponentName": "NVS_GPCR_bNPY_NonSelective", + "assayComponentDesc": "NVS_GPCR_bNPY_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bNPY_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the cattle neuropeptide Y [GeneSymbol:NPY | GeneID:504216 | Uniprot_SwissProt_Accession:Q6RUW3].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 164, + "assayName": "NVS_GPCR_bNPY_NonSelective", + "assayDesc": "NVS_GPCR_bNPY_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine hippocampal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine hippocampal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 462, + "geneName": "neuropeptide Y", + "description": null, + "geneSymbol": "NPY", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 504216, + "officialSymbol": "NPY", + "officialFullName": "neuropeptide Y", + "uniprotAccessionNumber": "Q6RUW3" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 614, + "assayComponentEndpointName": "NVS_GPCR_g5HT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_g5HT4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_g5HT4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Serotonin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 351, + "assayComponentName": "NVS_GPCR_g5HT4", + "assayComponentDesc": "NVS_GPCR_g5HT4 is one of one assay component(s) measured or calculated from the NVS_GPCR_g5HT4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR-113808] are indicative of a change in receptor function and kinetics for the domestic guinea pig 5 hydroxytryptamine (serotonin) receptor 4 [GeneSymbol:Htr4 | GeneID:100135548 | Uniprot_SwissProt_Accession:O70528].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR-113808", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 165, + "assayName": "NVS_GPCR_g5HT4", + "assayDesc": "NVS_GPCR_g5HT4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 471, + "geneName": "5 hydroxytryptamine (serotonin) receptor 4", + "description": "provisional", + "geneSymbol": "Htr4", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135548, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70528" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8358562", + "pmid": 8358562, + "title": "Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain", + "author": "Grossman CJ, Kilpatrick GJ, Bunce KT", + "citation": "Grossman CJ, Kilpatrick GJ, Bunce KT. Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br J Pharmacol. 1993 Jul;109(3):618-24. PubMed PMID: 8358562; PubMed Central PMCID: PMC2175660.", + "otherId": "0", + "citationId": 159, + "otherSource": "" + } + }, + { + "aeid": 615, + "assayComponentEndpointName": "NVS_GPCR_gANPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gANPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gANPA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nppa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is guanylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rat ANP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "guanylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 352, + "assayComponentName": "NVS_GPCR_gANPA", + "assayComponentDesc": "NVS_GPCR_gANPA is one of one assay component(s) measured or calculated from the NVS_GPCR_gANPA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Atrial natiuretic peptide] are indicative of a change in receptor function and kinetics for the domestic guinea pig natriuretic peptide A [GeneSymbol:Nppa | GeneID:100135578 | Uniprot_SwissProt_Accession:P27596].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Atrial natiuretic peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 166, + "assayName": "NVS_GPCR_gANPA", + "assayDesc": "NVS_GPCR_gANPA is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 472, + "geneName": "natriuretic peptide A", + "description": "model", + "geneSymbol": "Nppa", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135578, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P27596" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2408776", + "pmid": 2408776, + "title": "Vascular and adrenal receptors for atrial natriuretic factor in the rat", + "author": "Schiffrin EL, Chartier L, Thibault G, St-Louis J, Cantin M, Genest J", + "citation": "Schiffrin EL, Chartier L, Thibault G, St-Louis J, Cantin M, Genest J. Vascular and adrenal receptors for atrial natriuretic factor in the rat. Circ Res. 1985 Jun;56(6):801-7. PubMed PMID: 2408776.", + "otherId": "0", + "citationId": 45, + "otherSource": "" + } + }, + { + "aeid": 616, + "assayComponentEndpointName": "NVS_GPCR_gBK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gBK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gBK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Bdkrb2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Bradykinin TFA salt", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 353, + "assayComponentName": "NVS_GPCR_gBK2", + "assayComponentDesc": "NVS_GPCR_gBK2 is one of one assay component(s) measured or calculated from the NVS_GPCR_gBK2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Bradykinin] are indicative of a change in receptor function and kinetics for the domestic guinea pig bradykinin receptor, beta 2 [GeneSymbol:Bdkrb2 | GeneID:100135486 | Uniprot_SwissProt_Accession:O70526].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Bradykinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 167, + "assayName": "NVS_GPCR_gBK2", + "assayDesc": "NVS_GPCR_gBK2 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig ileum membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "intestinal", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig ileum membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 468, + "geneName": "bradykinin receptor, beta 2", + "description": "provisional", + "geneSymbol": "Bdkrb2", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135486, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70526" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1315547", + "pmid": 1315547, + "title": "Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea pig ileum", + "author": "Ransom RW, Young GS, Schneck K, Goodman CB", + "citation": "Ransom RW, Young GS, Schneck K, Goodman CB. Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea pig ileum. Biochem Pharmacol. 1992 Apr 15;43(8):1823-7. PubMed PMID: 1315547.", + "otherId": "0", + "citationId": 13, + "otherSource": "" + } + }, + { + "aeid": 617, + "assayComponentEndpointName": "NVS_GPCR_gH2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gH2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gH2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tiotidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 354, + "assayComponentName": "NVS_GPCR_gH2", + "assayComponentDesc": "NVS_GPCR_gH2 is one of one assay component(s) measured or calculated from the NVS_GPCR_gH2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Aminopotentidine] are indicative of a change in receptor function and kinetics for the domestic guinea pig histamine receptor H2 [GeneSymbol:Hrh2 | GeneID:100135540 | Uniprot_SwissProt_Accession:P47747].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Aminopotentidine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 168, + "assayName": "NVS_GPCR_gH2", + "assayDesc": "NVS_GPCR_gH2 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 470, + "geneName": "histamine receptor H2", + "description": null, + "geneSymbol": "Hrh2", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135540, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P47747" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1979518", + "pmid": 1979518, + "title": "Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates", + "author": "Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM", + "citation": "Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 1990 Sep 3;526(2):322-7. PubMed PMID: 1979518.", + "otherId": "0", + "citationId": 28, + "otherSource": "" + } + }, + { + "aeid": 618, + "assayComponentEndpointName": "NVS_GPCR_gLTB4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene B4 (LTB4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 355, + "assayComponentName": "NVS_GPCR_gLTB4", + "assayComponentDesc": "NVS_GPCR_gLTB4 is one of one assay component(s) measured or calculated from the NVS_GPCR_gLTB4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the domestic guinea pig leukotriene B4 receptor [GeneSymbol:Ltb4r | GeneID:100379538 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 169, + "assayName": "NVS_GPCR_gLTB4", + "assayDesc": "NVS_GPCR_gLTB4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig spleen membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "spleen", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig spleen membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 477, + "geneName": "leukotriene B4 receptor", + "description": "provisional", + "geneSymbol": "Ltb4r", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100379538, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2168834", + "pmid": 2168834, + "title": "Evidence for two leukotriene receptor types in the guinea-pig isolated ileum", + "author": "Gardiner PJ, Abram TS, Cuthbert NJ", + "citation": "Gardiner PJ, Abram TS, Cuthbert NJ. Evidence for two leukotriene receptor types in the guinea-pig isolated ileum. Eur J Pharmacol. 1990 Jul 3;182(2):291-9. PubMed PMID: 2168834.", + "otherId": "0", + "citationId": 34, + "otherSource": "" + } + }, + { + "aeid": 619, + "assayComponentEndpointName": "NVS_GPCR_gLTD4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gLTD4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTD4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cysltr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene D4 (LTD4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 356, + "assayComponentName": "NVS_GPCR_gLTD4", + "assayComponentDesc": "NVS_GPCR_gLTD4 is one of one assay component(s) measured or calculated from the NVS_GPCR_gLTD4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene D4] are indicative of a change in receptor function and kinetics for the domestic guinea pig cysteinyl leukotriene receptor 1 [GeneSymbol:Cysltr1 | GeneID:100135514 | Uniprot_SwissProt_Accession:Q2NNR5].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene D4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 170, + "assayName": "NVS_GPCR_gLTD4", + "assayDesc": "NVS_GPCR_gLTD4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig lung membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "lung", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig lung membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 469, + "geneName": "cysteinyl leukotriene receptor 1", + "description": "provisional", + "geneSymbol": "Cysltr1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135514, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "Q2NNR5" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2397744", + "pmid": 2397744, + "title": "The inhibition of [3H]leukotriene D4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum", + "author": "Norman P, Abram TS, Cuthbert NJ, Gardiner PJ", + "citation": "Norman P, Abram TS, Cuthbert NJ, Gardiner PJ. The inhibition of [3H]leukotriene D4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum. Eur J Pharmacol. 1990 Jul 3;182(2):301-12. PubMed PMID: 2397744.", + "otherId": "0", + "citationId": 43, + "otherSource": "" + } + }, + { + "aeid": 620, + "assayComponentEndpointName": "NVS_GPCR_gMPeripheral_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gMPeripheral_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gMPeripheral_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrm3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Atropine sulfate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 357, + "assayComponentName": "NVS_GPCR_gMPeripheral_NonSelective", + "assayComponentDesc": "NVS_GPCR_gMPeripheral_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_gMPeripheral_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Quinuclidinyl benzilate] are indicative of a change in receptor function and kinetics for the domestic guinea pig cholinergic receptor, muscarinic 3, cardiac [GeneSymbol:Chrm3 | GeneID:100379235 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Quinuclidinyl benzilate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 171, + "assayName": "NVS_GPCR_gMPeripheral_NonSelective", + "assayDesc": "NVS_GPCR_gMPeripheral_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig bladder membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "bladder", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig bladder membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 476, + "geneName": "cholinergic receptor, muscarinic 3, cardiac", + "description": "provisional", + "geneSymbol": "Chrm3", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100379235, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6546770", + "pmid": 6546770, + "title": "Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain", + "author": "Luthin GR, Wolfe BB", + "citation": "Luthin GR, Wolfe BB. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J Pharmacol Exp Ther. 1984 Mar;228(3):648-55. PubMed PMID: 6546770.", + "otherId": "0", + "citationId": 128, + "otherSource": "" + } + }, + { + "aeid": 621, + "assayComponentEndpointName": "NVS_GPCR_gOpiateK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gOpiateK was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gOpiateK, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprk1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "U-69593", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 358, + "assayComponentName": "NVS_GPCR_gOpiateK", + "assayComponentDesc": "NVS_GPCR_gOpiateK is one of one assay component(s) measured or calculated from the NVS_GPCR_gOpiateK assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-U-69593] are indicative of a change in receptor function and kinetics for the domestic guinea pig opioid receptor, kappa 1 [GeneSymbol:Oprk1 | GeneID:100135587 | Uniprot_SwissProt_Accession:P41144].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-U-69593", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 172, + "assayName": "NVS_GPCR_gOpiateK", + "assayDesc": "NVS_GPCR_gOpiateK is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 473, + "geneName": "opioid receptor, kappa 1", + "description": "provisional", + "geneSymbol": "Oprk1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135587, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P41144" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1336192", + "pmid": 1336192, + "title": "Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain", + "author": "Rothman RB, Bykov V, Xue BG, Xu H, De Costa BR, Jacobson AE, Rice KC, Kleinman JE, Brady LS", + "citation": "Rothman RB, Bykov V, Xue BG, Xu H, De Costa BR, Jacobson AE, Rice KC, Kleinman JE, Brady LS. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides. 1992 Sep-Oct;13(5):977-87. PubMed PMID: 1336192.", + "otherId": "0", + "citationId": 16, + "otherSource": "" + } + }, + { + "aeid": 622, + "assayComponentEndpointName": "NVS_GPCR_h5HT2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketanserin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 359, + "assayComponentName": "NVS_GPCR_h5HT2A", + "assayComponentDesc": "NVS_GPCR_h5HT2A is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Ketanserin] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled [GeneSymbol:HTR2A | GeneID:3356 | Uniprot_SwissProt_Accession:P28223].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Ketanserin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 173, + "assayName": "NVS_GPCR_h5HT2A", + "assayDesc": "NVS_GPCR_h5HT2A is a biochemical, single-readout assay that uses extracted gene-proteins from Human cortex in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 164, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled", + "description": null, + "geneSymbol": "HTR2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3356, + "officialSymbol": "HTR2A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled", + "uniprotAccessionNumber": "P28223" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7099138", + "pmid": 7099138, + "title": "[3H]Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role", + "author": "Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM", + "citation": "Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM. [3H]Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol. 1982 Mar;21(2):301-14. PubMed PMID: 7099138.", + "otherId": "0", + "citationId": 133, + "otherSource": "" + } + }, + { + "aeid": 623, + "assayComponentEndpointName": "NVS_GPCR_h5HT5A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methiothepin mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 360, + "assayComponentName": "NVS_GPCR_h5HT5A", + "assayComponentDesc": "NVS_GPCR_h5HT5A is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT5A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled [GeneSymbol:HTR5A | GeneID:3361 | Uniprot_SwissProt_Accession:P47898].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 174, + "assayName": "NVS_GPCR_h5HT5A", + "assayDesc": "NVS_GPCR_h5HT5A is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 167, + "geneName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "description": null, + "geneSymbol": "HTR5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3361, + "officialSymbol": "HTR5A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "uniprotAccessionNumber": "P47898" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7988681", + "pmid": 7988681, + "title": "Cloning and characterisation of the human 5-HT5A serotonin receptor", + "author": "Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M", + "citation": "Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M. Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. PubMed PMID: 7988681.", + "otherId": "0", + "citationId": 151, + "otherSource": "" + } + }, + { + "aeid": 624, + "assayComponentEndpointName": "NVS_GPCR_h5HT6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methiothepin mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 361, + "assayComponentName": "NVS_GPCR_h5HT6", + "assayComponentDesc": "NVS_GPCR_h5HT6 is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT6 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled [GeneSymbol:HTR6 | GeneID:3362 | Uniprot_SwissProt_Accession:P50406].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 175, + "assayName": "NVS_GPCR_h5HT6", + "assayDesc": "NVS_GPCR_h5HT6 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7680751", + "pmid": 7680751, + "title": "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs", + "author": "Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR", + "citation": "Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. PubMed PMID: 7680751.", + "otherId": "0", + "citationId": 142, + "otherSource": "" + } + }, + { + "aeid": 625, + "assayComponentEndpointName": "NVS_GPCR_h5HT7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT7, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-carboxamidotryptamine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 362, + "assayComponentName": "NVS_GPCR_h5HT7", + "assayComponentDesc": "NVS_GPCR_h5HT7 is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT7 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled [GeneSymbol:HTR7 | GeneID:3363 | Uniprot_SwissProt_Accession:P34969].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 176, + "assayName": "NVS_GPCR_h5HT7", + "assayDesc": "NVS_GPCR_h5HT7 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8394362", + "pmid": 8394362, + "title": "Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype", + "author": "Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR", + "citation": "Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. PubMed PMID: 8394362.", + "otherId": "0", + "citationId": 164, + "otherSource": "" + } + }, + { + "aeid": 626, + "assayComponentEndpointName": "NVS_GPCR_hAdoRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "2-chloroadenosine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 363, + "assayComponentName": "NVS_GPCR_hAdoRA1", + "assayComponentDesc": "NVS_GPCR_hAdoRA1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdoRA1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-8-Cyclopentyl-1,3-dipropylxanthine] are indicative of a change in receptor function and kinetics for the human adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:134 | Uniprot_SwissProt_Accession:P30542].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-8-Cyclopentyl-1,3-dipropylxanthine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 177, + "assayName": "NVS_GPCR_hAdoRA1", + "assayDesc": "NVS_GPCR_hAdoRA1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 10, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 134, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P30542" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3574492", + "pmid": 3574492, + "title": "Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes", + "author": "Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC", + "citation": "Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59-63. PubMed PMID: 3574492.", + "otherId": "0", + "citationId": 100, + "otherSource": "" + } + }, + { + "aeid": 627, + "assayComponentEndpointName": "NVS_GPCR_hAdoRA2a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5\"-N-ethylcarboxamidoadenosine (NECA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 364, + "assayComponentName": "NVS_GPCR_hAdoRA2a", + "assayComponentDesc": "NVS_GPCR_hAdoRA2a is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdoRA2a assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGS 21680] are indicative of a change in receptor function and kinetics for the human adenosine A2a receptor [GeneSymbol:ADORA2A | GeneID:135 | Uniprot_SwissProt_Accession:P29274].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGS 21680", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 178, + "assayName": "NVS_GPCR_hAdoRA2a", + "assayDesc": "NVS_GPCR_hAdoRA2a is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2600819", + "pmid": 2600819, + "title": "[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain", + "author": "Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M", + "citation": "Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888-93. PubMed PMID: 2600819.", + "otherId": "0", + "citationId": 63, + "otherSource": "" + } + }, + { + "aeid": 2547, + "assayComponentEndpointName": "UKN5_HCS_SBAD2_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN5_HCS_SBAD2_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2501, + "assayComponentName": "UKN5_HCS_SBAD2_cell_viability", + "assayComponentDesc": "UKN5_HCS_SBAD2_cell_viability is an assay component measured from the UKN5_HCS_SBAD2 assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33340", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 691, + "assayName": "UKN5_HCS_SBAD2", + "assayDesc": "UKN5_HCS_SBAD2 is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses SBAD2 (peripheral neurons differentiated from iPSC), a human peripheral nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN5, also referred to as PeriTox, is an assay that uses human iPSC line SBAD2 as a model of peripheral neurons. Following 24 hr chemical exposures in multi-well plates, neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein-AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "peripheral nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "SBAD2 (peripheral neurons differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2549, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2A6 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2A6, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2A6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2502, + "assayComponentName": "ERF_CR_ADME_hCYP2A6", + "assayComponentDesc": "ERF_CR_ADME_hCYP2A6 is an assay component calculated from the ERF_CR_ADME_hCYP2A6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the regulation of catalytic activity reaction involving the key substrate, Coumarin, are indicative of changes in enzyme function and kinetics related to the gene CYP2A6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Coumarin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 812, + "assayName": "ERF_CR_ADME_hCYP2A6", + "assayDesc": "ERF_CR_ADME_hCYP2A6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP2A6 inhibition (recombinant- coumarin substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 80, + "geneName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "description": null, + "geneSymbol": "CYP2A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1548, + "officialSymbol": "CYP2A6", + "officialFullName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "uniprotAccessionNumber": "P11509" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2550, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2B6 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2B6, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2B6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2503, + "assayComponentName": "ERF_CR_ADME_hCYP2B6", + "assayComponentDesc": "ERF_CR_ADME_hCYP2B6 is an assay component calculated from the ERF_CR_ADME_hCYP2B6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-ethoxy-4-trifluoromethylcoumarin (EFC), are indicative of changes in enzyme function and kinetics related to the gene CYP2B6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-4-trifluoromethylcoumarin (EFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 816, + "assayName": "ERF_CR_ADME_hCYP2B6", + "assayDesc": "ERF_CR_ADME_hCYP2B6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP2B6 inhibition (recombinant, EFC substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2551, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C19_CEC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C19_CEC was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C19_CEC, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2504, + "assayComponentName": "ERF_CR_ADME_hCYP2C19_CEC", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C19_CEC is an assay component calculated from the ERF_CR_ADME_hCYP2C19_CEC assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, CEC, are indicative of changes in enzyme function and kinetics related to the gene CYP2C19.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CEC", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 808, + "assayName": "ERF_CR_ADME_hCYP2C19_CEC", + "assayDesc": "ERF_CR_ADME_hCYP2C19_CEC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.83 hour after chemical dosing in a 96-well plate. See CYP2C19 inhibition (recombinant, CEC substrate).", + "timepointHr": 0.83, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 632, + "assayComponentEndpointName": "NVS_GPCR_hAdrb3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 369, + "assayComponentName": "NVS_GPCR_hAdrb3", + "assayComponentDesc": "NVS_GPCR_hAdrb3 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 3 [GeneSymbol:ADRB3 | GeneID:155 | Uniprot_SwissProt_Accession:P13945].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 183, + "assayName": "NVS_GPCR_hAdrb3", + "assayDesc": "NVS_GPCR_hAdrb3 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC pretreated with isoproteronol and 8-bromo-cAMP in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC pretreated with isoproteronol and 8-bromo-cAMP", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7996434", + "pmid": 7996434, + "title": "Influence of cell type upon the desensitization of the beta 3-adrenergic receptor", + "author": "Chaudhry A, Granneman JG", + "citation": "Chaudhry A, Granneman JG. Influence of cell type upon the desensitization of the beta 3-adrenergic receptor. J Pharmacol Exp Ther. 1994 Dec;271(3):1253-8. PubMed PMID: 7996434.", + "otherId": "0", + "citationId": 152, + "otherSource": "" + } + }, + { + "aeid": 633, + "assayComponentEndpointName": "NVS_GPCR_hAT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Angiotensin II", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 370, + "assayComponentName": "NVS_GPCR_hAT1", + "assayComponentDesc": "NVS_GPCR_hAT1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAT1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Sar1,[125I-Try4],Ile8-Angiotensin II] are indicative of a change in receptor function and kinetics for the human angiotensin II receptor, type 1 [GeneSymbol:AGTR1 | GeneID:185 | Uniprot_SwissProt_Accession:P30556].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Sar1,[125I-Try4],Ile8-Angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 184, + "assayName": "NVS_GPCR_hAT1", + "assayDesc": "NVS_GPCR_hAT1 is a biochemical, single-readout assay that uses extracted gene-proteins from KAN-TS in a tissue-based cell-free assay. Measurements were taken 3 hours after chemical dosing in a 48-well plate.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "KAN-TS", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 19, + "geneName": "angiotensin II receptor, type 1", + "description": null, + "geneSymbol": "AGTR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 185, + "officialSymbol": "AGTR1", + "officialFullName": "angiotensin II receptor, type 1", + "uniprotAccessionNumber": "P30556" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/187587", + "pmid": 187587, + "title": "Angiotensin II binding to mammalian brain membranes", + "author": "Bennett JP Jr, Snyder SH", + "citation": "Bennett JP Jr, Snyder SH. Angiotensin II binding to mammalian brain membranes. J Biol Chem. 1976 Dec 10;251(23):7423-30. PubMed PMID: 187587.", + "otherId": "0", + "citationId": 4, + "otherSource": "" + } + }, + { + "aeid": 634, + "assayComponentEndpointName": "NVS_GPCR_hC5a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hC5a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hC5a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene C5AR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "human rC5a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 371, + "assayComponentName": "NVS_GPCR_hC5a", + "assayComponentDesc": "NVS_GPCR_hC5a is one of one assay component(s) measured or calculated from the NVS_GPCR_hC5a assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-BH-rC5a] are indicative of a change in receptor function and kinetics for the human complement component 5a receptor 1 [GeneSymbol:C5AR1 | GeneID:728 | Uniprot_SwissProt_Accession:P21730].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-BH-rC5a", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 185, + "assayName": "NVS_GPCR_hC5a", + "assayDesc": "NVS_GPCR_hC5a is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 38, + "geneName": "complement component 5a receptor 1", + "description": null, + "geneSymbol": "C5AR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 728, + "officialSymbol": "C5AR1", + "officialFullName": "complement component 5a receptor 1", + "uniprotAccessionNumber": "P21730" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2153739", + "pmid": 2153739, + "title": "The role of formylpeptide receptors, C5a receptors, and cytosolic-free calcium in neutrophil priming", + "author": "Zimmerli W, Reber AM, Dahinden CA", + "citation": "Zimmerli W, Reber AM, Dahinden CA. The role of formylpeptide receptors, C5a receptors, and cytosolic-free calcium in neutrophil priming. J Infect Dis. 1990 Feb;161(2):242-9. PubMed PMID: 2153739.", + "otherId": "0", + "citationId": 30, + "otherSource": "" + } + }, + { + "aeid": 635, + "assayComponentEndpointName": "NVS_GPCR_hDRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R(+)-SCH 23390", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 372, + "assayComponentName": "NVS_GPCR_hDRD1", + "assayComponentDesc": "NVS_GPCR_hDRD1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SCH 23390] are indicative of a change in receptor function and kinetics for the human dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:1812 | Uniprot_SwissProt_Accession:P21728].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SCH 23390", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 186, + "assayName": "NVS_GPCR_hDRD1", + "assayDesc": "NVS_GPCR_hDRD1 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6387355", + "pmid": 6387355, + "title": "Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum", + "author": "Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A", + "citation": "Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 1984 Oct 29;35(18):1885-93. PubMed PMID: 6387355.", + "otherId": "0", + "citationId": 124, + "otherSource": "" + } + }, + { + "aeid": 636, + "assayComponentEndpointName": "NVS_GPCR_hDRD2s", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD2s was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD2s, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 373, + "assayComponentName": "NVS_GPCR_hDRD2s", + "assayComponentDesc": "NVS_GPCR_hDRD2s is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD2s assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Raclopride] are indicative of a change in receptor function and kinetics for the human dopamine receptor D2 [GeneSymbol:DRD2 | GeneID:1813 | Uniprot_SwissProt_Accession:P14416].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Raclopride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 187, + "assayName": "NVS_GPCR_hDRD2s", + "assayDesc": "NVS_GPCR_hDRD2s is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 100, + "geneName": "dopamine receptor D2", + "description": null, + "geneSymbol": "DRD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1813, + "officialSymbol": "DRD2", + "officialFullName": "dopamine receptor D2", + "uniprotAccessionNumber": "P14416" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6149442", + "pmid": 6149442, + "title": "125I-Spiperone: a novel ligand for D2 dopamine receptors", + "author": "Gundlach AL, Largent BL, Snyder SH", + "citation": "Gundlach AL, Largent BL, Snyder SH. 125I-Spiperone: a novel ligand for D2 dopamine receptors. Life Sci. 1984 Nov 5;35(19):1981-8. PubMed PMID: 6149442.", + "otherId": "0", + "citationId": 112, + "otherSource": "" + } + }, + { + "aeid": 637, + "assayComponentEndpointName": "NVS_GPCR_hDRD4.4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD4.4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD4.4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 374, + "assayComponentName": "NVS_GPCR_hDRD4.4", + "assayComponentDesc": "NVS_GPCR_hDRD4.4 is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD4.4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-YM-09151-2] are indicative of a change in receptor function and kinetics for the human dopamine receptor D4 [GeneSymbol:DRD4 | GeneID:1815 | Uniprot_SwissProt_Accession:P21917].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-YM-09151-2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 188, + "assayName": "NVS_GPCR_hDRD4.4", + "assayDesc": "NVS_GPCR_hDRD4.4 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 101, + "geneName": "dopamine receptor D4", + "description": null, + "geneSymbol": "DRD4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1815, + "officialSymbol": "DRD4", + "officialFullName": "dopamine receptor D4", + "uniprotAccessionNumber": "P21917" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1319557", + "pmid": 1319557, + "title": "Multiple dopamine D4 receptor variants in the human population", + "author": "Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V", + "citation": "Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature. 1992 Jul 9;358(6382):149-52. PubMed PMID: 1319557.", + "otherId": "0", + "citationId": 14, + "otherSource": "" + } + }, + { + "aeid": 638, + "assayComponentEndpointName": "NVS_GPCR_hETA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hETA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Endothelin-1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 375, + "assayComponentName": "NVS_GPCR_hETA", + "assayComponentDesc": "NVS_GPCR_hETA is one of one assay component(s) measured or calculated from the NVS_GPCR_hETA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Endothelin-1] are indicative of a change in receptor function and kinetics for the human endothelin receptor type A [GeneSymbol:EDNRA | GeneID:1909 | Uniprot_SwissProt_Accession:P25101].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Endothelin-1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 189, + "assayName": "NVS_GPCR_hETA", + "assayDesc": "NVS_GPCR_hETA is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroblastoma cells (SH-SY5Y) in a cell-free assay. Measurements were taken 3 hours after chemical dosing in a 96-well plate.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neuroblastoma cells (SH-SY5Y)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 105, + "geneName": "endothelin receptor type A", + "description": null, + "geneSymbol": "EDNRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1909, + "officialSymbol": "EDNRA", + "officialFullName": "endothelin receptor type A", + "uniprotAccessionNumber": "P25101" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1700206", + "pmid": 1700206, + "title": "Tissue specificity of endothelin binding sites", + "author": "Bolger GT, Liard F, Krogsrud R, Thibeault D, Jaramillo J", + "citation": "Bolger GT, Liard F, Krogsrud R, Thibeault D, Jaramillo J. Tissue specificity of endothelin binding sites. J Cardiovasc Pharmacol. 1990 Sep;16(3):367-75. PubMed PMID: 1700206.", + "otherId": "0", + "citationId": 20, + "otherSource": "" + } + }, + { + "aeid": 639, + "assayComponentEndpointName": "NVS_GPCR_hETB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hETB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Endothelin-1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 376, + "assayComponentName": "NVS_GPCR_hETB", + "assayComponentDesc": "NVS_GPCR_hETB is one of one assay component(s) measured or calculated from the NVS_GPCR_hETB assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Endothelin-1] are indicative of a change in receptor function and kinetics for the human endothelin receptor type B [GeneSymbol:EDNRB | GeneID:1910 | Uniprot_SwissProt_Accession:P24530].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Endothelin-1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 190, + "assayName": "NVS_GPCR_hETB", + "assayDesc": "NVS_GPCR_hETB is a biochemical, single-readout assay that uses extracted gene-proteins from Human astrocytoma cells in a cell-free assay. Measurements were taken 4 hours after chemical dosing in a 96-well plate.", + "timepointHr": 4.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human astrocytoma cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 106, + "geneName": "endothelin receptor type B", + "description": null, + "geneSymbol": "EDNRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1910, + "officialSymbol": "EDNRB", + "officialFullName": "endothelin receptor type B", + "uniprotAccessionNumber": "P24530" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7616437", + "pmid": 7616437, + "title": "Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization", + "author": "Wu-Wong JR, Chiou WJ, Magnuson SR, Opgenorth TJ", + "citation": "Wu-Wong JR, Chiou WJ, Magnuson SR, Opgenorth TJ. Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization. J Pharmacol Exp Ther. 1995 Jul;274(1):499-507. PubMed PMID: 7616437.", + "otherId": "0", + "citationId": 141, + "otherSource": "" + } + }, + { + "aeid": 640, + "assayComponentEndpointName": "NVS_GPCR_hH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tripolidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 377, + "assayComponentName": "NVS_GPCR_hH1", + "assayComponentDesc": "NVS_GPCR_hH1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hH1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Pyrilamine] are indicative of a change in receptor function and kinetics for the human histamine receptor H1 [GeneSymbol:HRH1 | GeneID:3269 | Uniprot_SwissProt_Accession:P35367].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 191, + "assayName": "NVS_GPCR_hH1", + "assayDesc": "NVS_GPCR_hH1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/448359", + "pmid": 448359, + "title": "Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes", + "author": "Chang RS, Tran VT, Snyder SH", + "citation": "Chang RS, Tran VT, Snyder SH. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J Neurochem. 1979 Jun;32(6):1653-63. PubMed PMID: 448359.", + "otherId": "0", + "citationId": 8, + "otherSource": "" + } + }, + { + "aeid": 641, + "assayComponentEndpointName": "NVS_GPCR_hLTB4_BLT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hLTB4_BLT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hLTB4_BLT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene LTB4R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene B4 (LTB4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 378, + "assayComponentName": "NVS_GPCR_hLTB4_BLT1", + "assayComponentDesc": "NVS_GPCR_hLTB4_BLT1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hLTB4_BLT1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the human leukotriene B4 receptor [GeneSymbol:LTB4R | GeneID:1241 | Uniprot_SwissProt_Accession:Q15722].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 192, + "assayName": "NVS_GPCR_hLTB4_BLT1", + "assayDesc": "NVS_GPCR_hLTB4_BLT1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human neutrophils in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 68, + "geneName": "leukotriene B4 receptor", + "description": null, + "geneSymbol": "LTB4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1241, + "officialSymbol": "LTB4R", + "officialFullName": "leukotriene B4 receptor", + "uniprotAccessionNumber": "Q15722" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9177352", + "pmid": 9177352, + "title": "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", + "author": "Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T", + "citation": "Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4. PubMed PMID: 9177352.", + "otherId": "0", + "citationId": 172, + "otherSource": "" + } + }, + { + "aeid": 642, + "assayComponentEndpointName": "NVS_GPCR_hM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 379, + "assayComponentName": "NVS_GPCR_hM1", + "assayComponentDesc": "NVS_GPCR_hM1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 1 [GeneSymbol:CHRM1 | GeneID:1128 | Uniprot_SwissProt_Accession:P11229].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 193, + "assayName": "NVS_GPCR_hM1", + "assayDesc": "NVS_GPCR_hM1 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 61, + "geneName": "cholinergic receptor, muscarinic 1", + "description": null, + "geneSymbol": "CHRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1128, + "officialSymbol": "CHRM1", + "officialFullName": "cholinergic receptor, muscarinic 1", + "uniprotAccessionNumber": "P11229" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 643, + "assayComponentEndpointName": "NVS_GPCR_hM2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 380, + "assayComponentName": "NVS_GPCR_hM2", + "assayComponentDesc": "NVS_GPCR_hM2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 2 [GeneSymbol:CHRM2 | GeneID:1129 | Uniprot_SwissProt_Accession:P08172].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 194, + "assayName": "NVS_GPCR_hM2", + "assayDesc": "NVS_GPCR_hM2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 62, + "geneName": "cholinergic receptor, muscarinic 2", + "description": null, + "geneSymbol": "CHRM2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1129, + "officialSymbol": "CHRM2", + "officialFullName": "cholinergic receptor, muscarinic 2", + "uniprotAccessionNumber": "P08172" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 644, + "assayComponentEndpointName": "NVS_GPCR_hM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 381, + "assayComponentName": "NVS_GPCR_hM3", + "assayComponentDesc": "NVS_GPCR_hM3 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 3 [GeneSymbol:CHRM3 | GeneID:1131 | Uniprot_SwissProt_Accession:P20309].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 195, + "assayName": "NVS_GPCR_hM3", + "assayDesc": "NVS_GPCR_hM3 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 645, + "assayComponentEndpointName": "NVS_GPCR_hM4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 382, + "assayComponentName": "NVS_GPCR_hM4", + "assayComponentDesc": "NVS_GPCR_hM4 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 4 [GeneSymbol:CHRM4 | GeneID:1132 | Uniprot_SwissProt_Accession:P08173].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 196, + "assayName": "NVS_GPCR_hM4", + "assayDesc": "NVS_GPCR_hM4 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 64, + "geneName": "cholinergic receptor, muscarinic 4", + "description": null, + "geneSymbol": "CHRM4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1132, + "officialSymbol": "CHRM4", + "officialFullName": "cholinergic receptor, muscarinic 4", + "uniprotAccessionNumber": "P08173" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 646, + "assayComponentEndpointName": "NVS_GPCR_hM5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 383, + "assayComponentName": "NVS_GPCR_hM5", + "assayComponentDesc": "NVS_GPCR_hM5 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 5 [GeneSymbol:CHRM5 | GeneID:1133 | Uniprot_SwissProt_Accession:P08912].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 197, + "assayName": "NVS_GPCR_hM5", + "assayDesc": "NVS_GPCR_hM5 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 65, + "geneName": "cholinergic receptor, muscarinic 5", + "description": null, + "geneSymbol": "CHRM5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1133, + "officialSymbol": "CHRM5", + "officialFullName": "cholinergic receptor, muscarinic 5", + "uniprotAccessionNumber": "P08912" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 647, + "assayComponentEndpointName": "NVS_GPCR_hNK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Neurokinin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 384, + "assayComponentName": "NVS_GPCR_hNK2", + "assayComponentDesc": "NVS_GPCR_hNK2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNK2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Neurokinin A] are indicative of a change in receptor function and kinetics for the human tachykinin receptor 2 [GeneSymbol:TACR2 | GeneID:6865 | Uniprot_SwissProt_Accession:P21452].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Neurokinin A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 198, + "assayName": "NVS_GPCR_hNK2", + "assayDesc": "NVS_GPCR_hNK2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 4 hours after chemical dosing in a 96-well plate.", + "timepointHr": 4.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 309, + "geneName": "tachykinin receptor 2", + "description": null, + "geneSymbol": "TACR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6865, + "officialSymbol": "TACR2", + "officialFullName": "tachykinin receptor 2", + "uniprotAccessionNumber": "P21452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 648, + "assayComponentEndpointName": "NVS_GPCR_hNPY1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNPY1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 385, + "assayComponentName": "NVS_GPCR_hNPY1", + "assayComponentDesc": "NVS_GPCR_hNPY1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNPY1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the human neuropeptide Y receptor Y1 [GeneSymbol:NPY1R | GeneID:4886 | Uniprot_SwissProt_Accession:P25929].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 199, + "assayName": "NVS_GPCR_hNPY1", + "assayDesc": "NVS_GPCR_hNPY1 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 219, + "geneName": "neuropeptide Y receptor Y1", + "description": null, + "geneSymbol": "NPY1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4886, + "officialSymbol": "NPY1R", + "officialFullName": "neuropeptide Y receptor Y1", + "uniprotAccessionNumber": "P25929" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 649, + "assayComponentEndpointName": "NVS_GPCR_hNPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY2R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 386, + "assayComponentName": "NVS_GPCR_hNPY2", + "assayComponentDesc": "NVS_GPCR_hNPY2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNPY2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the human neuropeptide Y receptor Y2 [GeneSymbol:NPY2R | GeneID:4887 | Uniprot_SwissProt_Accession:P49146].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 200, + "assayName": "NVS_GPCR_hNPY2", + "assayDesc": "NVS_GPCR_hNPY2 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 650, + "assayComponentEndpointName": "NVS_GPCR_hNTS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNTS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NTSR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "neurotensin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 387, + "assayComponentName": "NVS_GPCR_hNTS", + "assayComponentDesc": "NVS_GPCR_hNTS is one of one assay component(s) measured or calculated from the NVS_GPCR_hNTS assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-neurotensin] are indicative of a change in receptor function and kinetics for the human neurotensin receptor 1 (high affinity) [GeneSymbol:NTSR1 | GeneID:4923 | Uniprot_SwissProt_Accession:P30989].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 201, + "assayName": "NVS_GPCR_hNTS", + "assayDesc": "NVS_GPCR_hNTS is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 223, + "geneName": "neurotensin receptor 1 (high affinity)", + "description": null, + "geneSymbol": "NTSR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4923, + "officialSymbol": "NTSR1", + "officialFullName": "neurotensin receptor 1 (high affinity)", + "uniprotAccessionNumber": "P30989" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6744039", + "pmid": 6744039, + "title": "Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution", + "author": "Goedert M, Pittaway K, Williams BJ, Emson PC", + "citation": "Goedert M, Pittaway K, Williams BJ, Emson PC. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res. 1984 Jun 18;304(1):71-81. PubMed PMID: 6744039.", + "otherId": "0", + "citationId": 129, + "otherSource": "" + } + }, + { + "aeid": 651, + "assayComponentEndpointName": "NVS_GPCR_hOpiate_D1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hOpiate_D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_D1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naltriben methanesulfonate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 388, + "assayComponentName": "NVS_GPCR_hOpiate_D1", + "assayComponentDesc": "NVS_GPCR_hOpiate_D1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_D1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naltrindole] are indicative of a change in receptor function and kinetics for the human opioid receptor, delta 1 [GeneSymbol:OPRD1 | GeneID:4985 | Uniprot_SwissProt_Accession:P41143].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naltrindole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 202, + "assayName": "NVS_GPCR_hOpiate_D1", + "assayDesc": "NVS_GPCR_hOpiate_D1 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 225, + "geneName": "opioid receptor, delta 1", + "description": null, + "geneSymbol": "OPRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4985, + "officialSymbol": "OPRD1", + "officialFullName": "opioid receptor, delta 1", + "uniprotAccessionNumber": "P41143" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7605911", + "pmid": 7605911, + "title": "Human delta opioid receptor: a stable cell line for functional studies of opioids", + "author": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI", + "citation": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI. Human delta opioid receptor: a stable cell line for functional studies of opioids. Neuroreport. 1995 Mar 7;6(4):613-6. PubMed PMID: 7605911.", + "otherId": "0", + "citationId": 140, + "otherSource": "" + } + }, + { + "aeid": 72, + "assayComponentEndpointName": "ATG_E_Box_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E_Box_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 41, + "assayComponentName": "ATG_E_Box_CIS", + "assayComponentDesc": "ATG_E_Box_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Ebox RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 333, + "geneName": "upstream transcription factor 1", + "description": null, + "geneSymbol": "USF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7391, + "officialSymbol": "USF1", + "officialFullName": "upstream transcription factor 1", + "uniprotAccessionNumber": "P22415" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 73, + "assayComponentEndpointName": "ATG_E2F_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E2F_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is E2F transcription factor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "E2F transcription factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 42, + "assayComponentName": "ATG_E2F_CIS", + "assayComponentDesc": "ATG_E2F_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "E2F RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 104, + "geneName": "E2F transcription factor 1", + "description": null, + "geneSymbol": "E2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1869, + "officialSymbol": "E2F1", + "officialFullName": "E2F transcription factor 1", + "uniprotAccessionNumber": "Q01094" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 74, + "assayComponentEndpointName": "ATG_EGR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_EGR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 43, + "assayComponentName": "ATG_EGR_CIS", + "assayComponentDesc": "ATG_EGR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene EGR, which is responsive to the endogenous human early growth response 1 [GeneSymbol:EGR1 | GeneID:1958 | Uniprot_SwissProt_Accession:P18146].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "EGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 109, + "geneName": "early growth response 1", + "description": null, + "geneSymbol": "EGR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1958, + "officialSymbol": "EGR1", + "officialFullName": "early growth response 1", + "uniprotAccessionNumber": "P18146" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 75, + "assayComponentEndpointName": "ATG_ERE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ERE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 44, + "assayComponentName": "ATG_ERE_CIS", + "assayComponentDesc": "ATG_ERE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 76, + "assayComponentEndpointName": "ATG_Ets_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ets_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is winged helix-turn-helix.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "winged helix-turn-helix", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 45, + "assayComponentName": "ATG_Ets_CIS", + "assayComponentDesc": "ATG_Ets_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Ets RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 122, + "geneName": "v-ets avian erythroblastosis virus E26 oncogene homolog 1", + "description": null, + "geneSymbol": "ETS1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2113, + "officialSymbol": "ETS1", + "officialFullName": "v-ets avian erythroblastosis virus E26 oncogene homolog 1", + "uniprotAccessionNumber": "P14921" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 77, + "assayComponentEndpointName": "ATG_FoxA2_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxA2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 46, + "assayComponentName": "ATG_FoxA2_CIS", + "assayComponentDesc": "ATG_FoxA2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "FoxA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 156, + "geneName": "forkhead box A2", + "description": null, + "geneSymbol": "FOXA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3170, + "officialSymbol": "FOXA2", + "officialFullName": "forkhead box A2", + "uniprotAccessionNumber": "Q9Y261" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 78, + "assayComponentEndpointName": "ATG_FoxO_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxO_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 47, + "assayComponentName": "ATG_FoxO_CIS", + "assayComponentDesc": "ATG_FoxO_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "FoxO RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 129, + "geneName": "forkhead box O1", + "description": null, + "geneSymbol": "FOXO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2308, + "officialSymbol": "FOXO1", + "officialFullName": "forkhead box O1", + "uniprotAccessionNumber": "Q12778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 79, + "assayComponentEndpointName": "ATG_GATA_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GATA_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is GATA proteins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "GATA proteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 48, + "assayComponentName": "ATG_GATA_CIS", + "assayComponentDesc": "ATG_GATA_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GATA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 139, + "geneName": "GATA binding protein 1 (globin transcription factor 1)", + "description": null, + "geneSymbol": "GATA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2623, + "officialSymbol": "GATA1", + "officialFullName": "GATA binding protein 1 (globin transcription factor 1)", + "uniprotAccessionNumber": "P15976" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 80, + "assayComponentEndpointName": "ATG_GLI_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GLI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 49, + "assayComponentName": "ATG_GLI_CIS", + "assayComponentDesc": "ATG_GLI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GLI RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 144, + "geneName": "GLI family zinc finger 1", + "description": null, + "geneSymbol": "GLI1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2735, + "officialSymbol": "GLI1", + "officialFullName": "GLI family zinc finger 1", + "uniprotAccessionNumber": "P08151" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 81, + "assayComponentEndpointName": "ATG_GRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 50, + "assayComponentName": "ATG_GRE_CIS", + "assayComponentDesc": "ATG_GRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 82, + "assayComponentEndpointName": "ATG_HIF1a_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HIF1a_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 51, + "assayComponentName": "ATG_HIF1a_CIS", + "assayComponentDesc": "ATG_HIF1a_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HIF1a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 83, + "assayComponentEndpointName": "ATG_HNF6_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HNF6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "homeobox protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 52, + "assayComponentName": "ATG_HNF6_CIS", + "assayComponentDesc": "ATG_HNF6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HNF6 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 159, + "geneName": "one cut homeobox 1", + "description": null, + "geneSymbol": "ONECUT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3175, + "officialSymbol": "ONECUT1", + "officialFullName": "one cut homeobox 1", + "uniprotAccessionNumber": "Q9UBC0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 84, + "assayComponentEndpointName": "ATG_HSE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HSE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Geldanamycin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 53, + "assayComponentName": "ATG_HSE_CIS", + "assayComponentDesc": "ATG_HSE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HSE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 161, + "geneName": "heat shock transcription factor 1", + "description": null, + "geneSymbol": "HSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3297, + "officialSymbol": "HSF1", + "officialFullName": "heat shock transcription factor 1", + "uniprotAccessionNumber": "Q00613" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 85, + "assayComponentEndpointName": "ATG_IR1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_IR1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 54, + "assayComponentName": "ATG_IR1_CIS", + "assayComponentDesc": "ATG_IR1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "IR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 86, + "assayComponentEndpointName": "ATG_ISRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ISRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "interferon regulatory factors", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 55, + "assayComponentName": "ATG_ISRE_CIS", + "assayComponentDesc": "ATG_ISRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ISRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 180, + "geneName": "interferon regulatory factor 1", + "description": null, + "geneSymbol": "IRF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3659, + "officialSymbol": "IRF1", + "officialFullName": "interferon regulatory factor 1", + "uniprotAccessionNumber": "P10914" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 87, + "assayComponentEndpointName": "ATG_M_06_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_06_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_06_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 56, + "assayComponentName": "ATG_M_06_CIS", + "assayComponentDesc": "ATG_M_06_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 88, + "assayComponentEndpointName": "ATG_M_19_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_19_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_19_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 57, + "assayComponentName": "ATG_M_19_CIS", + "assayComponentDesc": "ATG_M_19_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 91, + "assayComponentEndpointName": "ATG_MRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_MRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 60, + "assayComponentName": "ATG_MRE_CIS", + "assayComponentDesc": "ATG_MRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element MRE, which is responsive to the endogenous human metal-regulatory transcription factor 1 [GeneSymbol:MTF1 | GeneID:4520 | Uniprot_SwissProt_Accession:Q14872].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 211, + "geneName": "metal-regulatory transcription factor 1", + "description": null, + "geneSymbol": "MTF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4520, + "officialSymbol": "MTF1", + "officialFullName": "metal-regulatory transcription factor 1", + "uniprotAccessionNumber": "Q14872" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 104, + "assayComponentEndpointName": "ATG_RORE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_RORE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 73, + "assayComponentName": "ATG_RORE_CIS", + "assayComponentDesc": "ATG_RORE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "RORE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 284, + "geneName": "RAR-related orphan receptor A", + "description": null, + "geneSymbol": "RORA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6095, + "officialSymbol": "RORA", + "officialFullName": "RAR-related orphan receptor A", + "uniprotAccessionNumber": "P35398" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 92, + "assayComponentEndpointName": "ATG_Myb_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is MYB proteins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "MYB proteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 61, + "assayComponentName": "ATG_Myb_CIS", + "assayComponentDesc": "ATG_Myb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Myb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 212, + "geneName": "v-myb avian myeloblastosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4602, + "officialSymbol": "MYB", + "officialFullName": "v-myb avian myeloblastosis viral oncogene homolog", + "uniprotAccessionNumber": "P10242" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 93, + "assayComponentEndpointName": "ATG_Myc_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myc_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 62, + "assayComponentName": "ATG_Myc_CIS", + "assayComponentDesc": "ATG_Myc_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Myc RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 213, + "geneName": "v-myc avian myelocytomatosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4609, + "officialSymbol": "MYC", + "officialFullName": "v-myc avian myelocytomatosis viral oncogene homolog", + "uniprotAccessionNumber": "P01106" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 94, + "assayComponentEndpointName": "ATG_NF_kB_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NF_kB_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 63, + "assayComponentName": "ATG_NF_kB_CIS", + "assayComponentDesc": "ATG_NF_kB_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NF-kB RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 95, + "assayComponentEndpointName": "ATG_NFI_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NFI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "nuclear factor I", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 64, + "assayComponentName": "ATG_NFI_CIS", + "assayComponentDesc": "ATG_NFI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NFI RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 216, + "geneName": "nuclear factor I/A", + "description": null, + "geneSymbol": "NFIA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4774, + "officialSymbol": "NFIA", + "officialFullName": "nuclear factor I/A", + "uniprotAccessionNumber": "Q12857" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 96, + "assayComponentEndpointName": "ATG_NRF1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "nuclear respiratory factors", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 65, + "assayComponentName": "ATG_NRF1_CIS", + "assayComponentDesc": "ATG_NRF1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NRF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 221, + "geneName": "nuclear respiratory factor 1", + "description": null, + "geneSymbol": "NRF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4899, + "officialSymbol": "NRF1", + "officialFullName": "nuclear respiratory factor 1", + "uniprotAccessionNumber": "Q16656" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 97, + "assayComponentEndpointName": "ATG_NRF2_ARE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF2_ARE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 66, + "assayComponentName": "ATG_NRF2_ARE_CIS", + "assayComponentDesc": "ATG_NRF2_ARE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ARE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 98, + "assayComponentEndpointName": "ATG_Oct_MLP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Oct_MLP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "POU domain protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 67, + "assayComponentName": "ATG_Oct_MLP_CIS", + "assayComponentDesc": "ATG_Oct_MLP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Oct RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 245, + "geneName": "POU class 2 homeobox 1", + "description": null, + "geneSymbol": "POU2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5451, + "officialSymbol": "POU2F1", + "officialFullName": "POU class 2 homeobox 1", + "uniprotAccessionNumber": "P14859" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 99, + "assayComponentEndpointName": "ATG_p53_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_p53_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 68, + "assayComponentName": "ATG_p53_CIS", + "assayComponentDesc": "ATG_p53_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "p53 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 652, + "assayComponentEndpointName": "NVS_GPCR_hOpiate_mu", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 389, + "assayComponentName": "NVS_GPCR_hOpiate_mu", + "assayComponentDesc": "NVS_GPCR_hOpiate_mu is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_mu assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diprenorphine] are indicative of a change in receptor function and kinetics for the human opioid receptor, mu 1 [GeneSymbol:OPRM1 | GeneID:4988 | Uniprot_SwissProt_Accession:P35372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diprenorphine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 203, + "assayName": "NVS_GPCR_hOpiate_mu", + "assayDesc": "NVS_GPCR_hOpiate_mu is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 2.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 227, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "OPRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4988, + "officialSymbol": "OPRM1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P35372" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7605911", + "pmid": 7605911, + "title": "Human delta opioid receptor: a stable cell line for functional studies of opioids", + "author": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI", + "citation": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI. Human delta opioid receptor: a stable cell line for functional studies of opioids. Neuroreport. 1995 Mar 7;6(4):613-6. PubMed PMID: 7605911.", + "otherId": "0", + "citationId": 140, + "otherSource": "" + } + }, + { + "aeid": 653, + "assayComponentEndpointName": "NVS_GPCR_hORL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hORL1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hORL1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRL1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nociceptin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 390, + "assayComponentName": "NVS_GPCR_hORL1", + "assayComponentDesc": "NVS_GPCR_hORL1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hORL1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nociceptin] are indicative of a change in receptor function and kinetics for the human opiate receptor-like 1 [GeneSymbol:OPRL1 | GeneID:4987 | Uniprot_SwissProt_Accession:P41146].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nociceptin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 204, + "assayName": "NVS_GPCR_hORL1", + "assayDesc": "NVS_GPCR_hORL1 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 226, + "geneName": "opiate receptor-like 1", + "description": null, + "geneSymbol": "OPRL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4987, + "officialSymbol": "OPRL1", + "officialFullName": "opiate receptor-like 1", + "uniprotAccessionNumber": "P41146" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7481766", + "pmid": 7481766, + "title": "Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor", + "author": "Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O", + "citation": "Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995 Nov 3;270(5237):792-4. PubMed PMID: 7481766.", + "otherId": "0", + "citationId": 138, + "otherSource": "" + } + }, + { + "aeid": 654, + "assayComponentEndpointName": "NVS_GPCR_hPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hPY2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene P2RY1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ADPbS", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 391, + "assayComponentName": "NVS_GPCR_hPY2", + "assayComponentDesc": "NVS_GPCR_hPY2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hPY2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[35S]-d-ATPaS] are indicative of a change in receptor function and kinetics for the human purinergic receptor P2Y, G-protein coupled, 1 [GeneSymbol:P2RY1 | GeneID:5028 | Uniprot_SwissProt_Accession:P47900].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[35S]-d-ATPaS", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 205, + "assayName": "NVS_GPCR_hPY2", + "assayDesc": "NVS_GPCR_hPY2 is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 228, + "geneName": "purinergic receptor P2Y, G-protein coupled, 1", + "description": null, + "geneSymbol": "P2RY1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5028, + "officialSymbol": "P2RY1", + "officialFullName": "purinergic receptor P2Y, G-protein coupled, 1", + "uniprotAccessionNumber": "P47900" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2495280", + "pmid": 2495280, + "title": "Guanine nucleotide-sensitive interaction of a radiolabeled agonist with a phospholipase C-linked P2y-purinergic receptor", + "author": "Cooper CL, Morris AJ, Harden TK", + "citation": "Cooper CL, Morris AJ, Harden TK. Guanine nucleotide-sensitive interaction of a radiolabeled agonist with a phospholipase C-linked P2y-purinergic receptor. J Biol Chem. 1989 Apr 15;264(11):6202-6. PubMed PMID: 2495280.", + "otherId": "0", + "citationId": 55, + "otherSource": "" + } + }, + { + "aeid": 655, + "assayComponentEndpointName": "NVS_GPCR_hTXA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Pinane-thromboxane A2", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 392, + "assayComponentName": "NVS_GPCR_hTXA2", + "assayComponentDesc": "NVS_GPCR_hTXA2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hTXA2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SQ 29,548] are indicative of a change in receptor function and kinetics for the human thromboxane A2 receptor [GeneSymbol:TBXA2R | GeneID:6915 | Uniprot_SwissProt_Accession:P21731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SQ 29,548", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 206, + "assayName": "NVS_GPCR_hTXA2", + "assayDesc": "NVS_GPCR_hTXA2 is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelets in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 310, + "geneName": "thromboxane A2 receptor", + "description": null, + "geneSymbol": "TBXA2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6915, + "officialSymbol": "TBXA2R", + "officialFullName": "thromboxane A2 receptor", + "uniprotAccessionNumber": "P21731" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2968449", + "pmid": 2968449, + "title": "Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets", + "author": "Hedberg A, Hall SE, Ogletree ML, Harris DN, Liu EC", + "citation": "Hedberg A, Hall SE, Ogletree ML, Harris DN, Liu EC. Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92. PubMed PMID: 2968449.", + "otherId": "0", + "citationId": 80, + "otherSource": "" + } + }, + { + "aeid": 656, + "assayComponentEndpointName": "NVS_GPCR_hV1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hV1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hV1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AVPR1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 393, + "assayComponentName": "NVS_GPCR_hV1A", + "assayComponentDesc": "NVS_GPCR_hV1A is one of one assay component(s) measured or calculated from the NVS_GPCR_hV1A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(Phenylac[1], D-Tyr(Me)[2], Arg[6,8],Lys-NH2[9])-Vasopressin] are indicative of a change in receptor function and kinetics for the human arginine vasopressin receptor 1A [GeneSymbol:AVPR1A | GeneID:552 | Uniprot_SwissProt_Accession:P37288].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(Phenylac[1], D-Tyr(Me)[2], Arg[6,8],Lys-NH2[9])-Vasopressin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 207, + "assayName": "NVS_GPCR_hV1A", + "assayDesc": "NVS_GPCR_hV1A is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelets in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 29, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "AVPR1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 552, + "officialSymbol": "AVPR1A", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P37288" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3010940", + "pmid": 3010940, + "title": "Nature and properties of human platelet vasopressin receptors", + "author": "Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C", + "citation": "Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C. Nature and properties of human platelet vasopressin receptors. Biochem J. 1986 Feb 1;233(3):631-6. PubMed PMID: 3010940; PubMed Central PMCID: PMC1153078.", + "otherId": "0", + "citationId": 91, + "otherSource": "" + } + }, + { + "aeid": 657, + "assayComponentEndpointName": "NVS_GPCR_mCCKAPeripheral", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cholecystokinin 8 (CCK-8) (26-33) sulfated", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 394, + "assayComponentName": "NVS_GPCR_mCCKAPeripheral", + "assayComponentDesc": "NVS_GPCR_mCCKAPeripheral is one of one assay component(s) measured or calculated from the NVS_GPCR_mCCKAPeripheral assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-cholecystokinin] are indicative of a change in receptor function and kinetics for the house mouse cholecystokinin A receptor [GeneSymbol:Cckar | GeneID:12425 | Uniprot_SwissProt_Accession:O08786].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-cholecystokinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 208, + "assayName": "NVS_GPCR_mCCKAPeripheral", + "assayDesc": "NVS_GPCR_mCCKAPeripheral is a biochemical, single-readout assay that uses extracted gene-proteins from Mouse pancreatic membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "pancreas", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Mouse pancreatic membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 370, + "geneName": "cholecystokinin A receptor", + "description": null, + "geneSymbol": "Cckar", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 12425, + "officialSymbol": "Cckar", + "officialFullName": "cholecystokinin A receptor", + "uniprotAccessionNumber": "O08786" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2984502", + "pmid": 2984502, + "title": "Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe", + "author": "Wennogle LP, Steel DJ, Petrack B", + "citation": "Wennogle LP, Steel DJ, Petrack B. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci. 1985 Apr 15;36(15):1485-92. PubMed PMID: 2984502.", + "otherId": "0", + "citationId": 81, + "otherSource": "" + } + }, + { + "aeid": 658, + "assayComponentEndpointName": "NVS_GPCR_mCKKBCentral", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_mCKKBCentral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCKKBCentral, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckbr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cholecystokinin 8 (CCK-8) (26-33) sulfated", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 395, + "assayComponentName": "NVS_GPCR_mCKKBCentral", + "assayComponentDesc": "NVS_GPCR_mCKKBCentral is one of one assay component(s) measured or calculated from the NVS_GPCR_mCKKBCentral assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-cholecystokinin] are indicative of a change in receptor function and kinetics for the house mouse cholecystokinin B receptor [GeneSymbol:Cckbr | GeneID:12426 | Uniprot_SwissProt_Accession:P56481].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-cholecystokinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 209, + "assayName": "NVS_GPCR_mCKKBCentral", + "assayDesc": "NVS_GPCR_mCKKBCentral is a biochemical, single-readout assay that uses extracted gene-proteins from Mouse forebrain membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Mouse forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 371, + "geneName": "cholecystokinin B receptor", + "description": null, + "geneSymbol": "Cckbr", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 12426, + "officialSymbol": "Cckbr", + "officialFullName": "cholecystokinin B receptor", + "uniprotAccessionNumber": "P56481" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2984502", + "pmid": 2984502, + "title": "Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe", + "author": "Wennogle LP, Steel DJ, Petrack B", + "citation": "Wennogle LP, Steel DJ, Petrack B. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci. 1985 Apr 15;36(15):1485-92. PubMed PMID: 2984502.", + "otherId": "0", + "citationId": 81, + "otherSource": "" + } + }, + { + "aeid": 659, + "assayComponentEndpointName": "NVS_GPCR_p5HT2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mianserin HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 396, + "assayComponentName": "NVS_GPCR_p5HT2C", + "assayComponentDesc": "NVS_GPCR_p5HT2C is one of one assay component(s) measured or calculated from the NVS_GPCR_p5HT2C assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Mesulergine] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled [GeneSymbol:HTR2C | GeneID:3358 | Uniprot_SwissProt_Accession:P28335].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Mesulergine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 210, + "assayName": "NVS_GPCR_p5HT2C", + "assayDesc": "NVS_GPCR_p5HT2C is a biochemical, single-readout assay that uses extracted gene-proteins from Pig choroid plexus membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9823, + "organism": "pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Pig choroid plexus membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 165, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "description": null, + "geneSymbol": "HTR2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3358, + "officialSymbol": "HTR2C", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "uniprotAccessionNumber": "P28335" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2935410", + "pmid": 2935410, + "title": "Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin", + "author": "Hoyer D, Engel G, Kalkman HO", + "citation": "Hoyer D, Engel G, Kalkman HO. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol. 1985 Nov 26;118(1-2):13-23. PubMed PMID: 2935410.", + "otherId": "0", + "citationId": 78, + "otherSource": "" + } + }, + { + "aeid": 660, + "assayComponentEndpointName": "NVS_GPCR_r5HT_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_r5HT_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methysergide maleate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 397, + "assayComponentName": "NVS_GPCR_r5HT_NonSelective", + "assayComponentDesc": "NVS_GPCR_r5HT_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_r5HT_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 211, + "assayName": "NVS_GPCR_r5HT_NonSelective", + "assayDesc": "NVS_GPCR_r5HT_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 390, + "geneName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "description": null, + "geneSymbol": "Htr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24473, + "officialSymbol": "Htr1a", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "uniprotAccessionNumber": "P19327" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/530254", + "pmid": 530254, + "title": "Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol", + "author": "Peroutka SJ, Snyder SH", + "citation": "Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687-99. PubMed PMID: 530254.", + "otherId": "0", + "citationId": 11, + "otherSource": "" + } + }, + { + "aeid": 661, + "assayComponentEndpointName": "NVS_GPCR_r5HT1_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_r5HT1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT1_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Serotonin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 398, + "assayComponentName": "NVS_GPCR_r5HT1_NonSelective", + "assayComponentDesc": "NVS_GPCR_r5HT1_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_r5HT1_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Hydroxytryptamine binoxalate] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Hydroxytryptamine binoxalate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 212, + "assayName": "NVS_GPCR_r5HT1_NonSelective", + "assayDesc": "NVS_GPCR_r5HT1_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 390, + "geneName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "description": null, + "geneSymbol": "Htr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24473, + "officialSymbol": "Htr1a", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "uniprotAccessionNumber": "P19327" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/530254", + "pmid": 530254, + "title": "Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol", + "author": "Peroutka SJ, Snyder SH", + "citation": "Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687-99. PubMed PMID: 530254.", + "otherId": "0", + "citationId": 11, + "otherSource": "" + } + }, + { + "aeid": 662, + "assayComponentEndpointName": "NVS_GPCR_rabPAF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "C16-PAF", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 399, + "assayComponentName": "NVS_GPCR_rabPAF", + "assayComponentDesc": "NVS_GPCR_rabPAF is one of one assay component(s) measured or calculated from the NVS_GPCR_rabPAF assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Hexadecyl-2-[3H]-acetyl-sn-glyceryl-3-phosphorylcholine] are indicative of a change in receptor function and kinetics for the rabbit platelet-activating factor receptor [GeneSymbol:PTAFR | GeneID:100354046 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Hexadecyl-2-[3H]-acetyl-sn-glyceryl-3-phosphorylcholine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 213, + "assayName": "NVS_GPCR_rabPAF", + "assayDesc": "NVS_GPCR_rabPAF is a biochemical, single-readout assay that uses extracted gene-proteins from Rabbit platelets in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9986, + "organism": "rabbit", + "tissue": "vascular", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rabbit platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 475, + "geneName": "platelet-activating factor receptor", + "description": "model", + "geneSymbol": "PTAFR", + "organismId": 9, + "trackStatus": "live", + "entrezGeneId": 100354046, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2999126", + "pmid": 2999126, + "title": "Trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor", + "author": "Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY", + "citation": "Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY. Trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. J Biol Chem. 1985 Dec 15;260(29):15639-45. PubMed PMID: 2999126.", + "otherId": "0", + "citationId": 84, + "otherSource": "" + } + }, + { + "aeid": 663, + "assayComponentEndpointName": "NVS_GPCR_rAdra1_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 400, + "assayComponentName": "NVS_GPCR_rAdra1_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdra1_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1A [GeneSymbol:Adra1a | GeneID:29412 | Uniprot_SwissProt_Accession:P43140].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-7-Methoxy-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 214, + "assayName": "NVS_GPCR_rAdra1_NonSelective", + "assayDesc": "NVS_GPCR_rAdra1_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 419, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "Adra1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29412, + "officialSymbol": "Adra1a", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": "P43140" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2879884", + "pmid": 2879884, + "title": "Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan", + "author": "Reader TA, Brière R, Grondin L", + "citation": "Reader TA, Brière R, Grondin L. Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan. J Neural Transm. 1987;68(1-2):79-95. PubMed PMID: 2879884.", + "otherId": "0", + "citationId": 73, + "otherSource": "" + } + }, + { + "aeid": 100, + "assayComponentEndpointName": "ATG_Pax6_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Pax6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "paired box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 69, + "assayComponentName": "ATG_Pax6_CIS", + "assayComponentDesc": "ATG_Pax6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Pax, which is responsive to the endogenous human paired box 6 [GeneSymbol:PAX6 | GeneID:5080 | Uniprot_SwissProt_Accession:P26367].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Pax RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 231, + "geneName": "paired box 6", + "description": null, + "geneSymbol": "PAX6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5080, + "officialSymbol": "PAX6", + "officialFullName": "paired box 6", + "uniprotAccessionNumber": "P26367" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 101, + "assayComponentEndpointName": "ATG_PBREM_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PBREM_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 70, + "assayComponentName": "ATG_PBREM_CIS", + "assayComponentDesc": "ATG_PBREM_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PBREM RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 102, + "assayComponentEndpointName": "ATG_PPRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PPRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 71, + "assayComponentName": "ATG_PPRE_CIS", + "assayComponentDesc": "ATG_PPRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PPRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 103, + "assayComponentEndpointName": "ATG_PXRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PXRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rifampicin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 72, + "assayComponentName": "ATG_PXRE_CIS", + "assayComponentDesc": "ATG_PXRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PXRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 105, + "assayComponentEndpointName": "ATG_Sox_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sox_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "HMG box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 74, + "assayComponentName": "ATG_Sox_CIS", + "assayComponentDesc": "ATG_Sox_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "SOX RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 301, + "geneName": "SRY (sex determining region Y)-box 1", + "description": null, + "geneSymbol": "SOX1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6656, + "officialSymbol": "SOX1", + "officialFullName": "SRY (sex determining region Y)-box 1", + "uniprotAccessionNumber": "O00570" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 106, + "assayComponentEndpointName": "ATG_Sp1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 75, + "assayComponentName": "ATG_Sp1_CIS", + "assayComponentDesc": "ATG_Sp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Sp1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 302, + "geneName": "Sp1 transcription factor", + "description": null, + "geneSymbol": "SP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6667, + "officialSymbol": "SP1", + "officialFullName": "Sp1 transcription factor", + "uniprotAccessionNumber": "P08047" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 107, + "assayComponentEndpointName": "ATG_SREBP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_SREBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 76, + "assayComponentName": "ATG_SREBP_CIS", + "assayComponentDesc": "ATG_SREBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "SREBP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 304, + "geneName": "sterol regulatory element binding transcription factor 1", + "description": null, + "geneSymbol": "SREBF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6720, + "officialSymbol": "SREBF1", + "officialFullName": "sterol regulatory element binding transcription factor 1", + "uniprotAccessionNumber": "P36956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 108, + "assayComponentEndpointName": "ATG_STAT3_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_STAT3_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "stat protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 77, + "assayComponentName": "ATG_STAT3_CIS", + "assayComponentDesc": "ATG_STAT3_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "STAT RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 305, + "geneName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "description": null, + "geneSymbol": "STAT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6774, + "officialSymbol": "STAT3", + "officialFullName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "uniprotAccessionNumber": "P40763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 109, + "assayComponentEndpointName": "ATG_TA_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TA_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TA_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 78, + "assayComponentName": "ATG_TA_CIS", + "assayComponentDesc": "ATG_TA_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TA, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 110, + "assayComponentEndpointName": "ATG_TAL_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TAL_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TAL_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 79, + "assayComponentName": "ATG_TAL_CIS", + "assayComponentDesc": "ATG_TAL_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TAL, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TAL RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 111, + "assayComponentEndpointName": "ATG_TCF_b_cat_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TCF_b_cat_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "HMG box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 80, + "assayComponentName": "ATG_TCF_b_cat_CIS", + "assayComponentDesc": "ATG_TCF_b_cat_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TCF/b-cat, which is responsive to the endogenous human transcription factor 7 (T-cell specific, HMG-box) and transcription factor 7-like 2 (T-cell specific, HMG-box) and lymphoid enhancer-binding factor 1 and transcription factor 7-like 1 (T-cell specific, HMG-box) [GeneSymbol:TCF7 & TCF7L2 & LEF1 & TCF7L1 | GeneID:6932 & 6934 & 51176 & 83439 | Uniprot_SwissProt_Accession:P36402 & Q9NQB0 & Q9UJU2 & Q9HCS4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TCF/b-cat RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 311, + "geneName": "transcription factor 7 (T-cell specific, HMG-box)", + "description": null, + "geneSymbol": "TCF7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6932, + "officialSymbol": "TCF7", + "officialFullName": "transcription factor 7 (T-cell specific, HMG-box)", + "uniprotAccessionNumber": "P36402" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 112, + "assayComponentEndpointName": "ATG_TGFb_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TGFb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 81, + "assayComponentName": "ATG_TGFb_CIS", + "assayComponentDesc": "ATG_TGFb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TGF RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 178, + "assayComponentEndpointName": "BSK_4H_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 130, + "assayComponentName": "BSK_4H_SRB", + "assayComponentDesc": "BSK_4H_SRB is an assay component measured in the BSK_4H assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the 4H system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 664, + "assayComponentEndpointName": "NVS_GPCR_rAdra1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 401, + "assayComponentName": "NVS_GPCR_rAdra1A", + "assayComponentDesc": "NVS_GPCR_rAdra1A is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1A [GeneSymbol:Adra1a | GeneID:29412 | Uniprot_SwissProt_Accession:P43140].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 215, + "assayName": "NVS_GPCR_rAdra1A", + "assayDesc": "NVS_GPCR_rAdra1A is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes (pretreated with chlorethyl clonidine-CEC) in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes (pretreated with chlorethyl clonidine-CEC)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 419, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "Adra1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29412, + "officialSymbol": "Adra1a", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": "P43140" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2569345", + "pmid": 2569345, + "title": "Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists", + "author": "Hanft G, Gross G", + "citation": "Hanft G, Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691-700. PubMed PMID: 2569345; PubMed Central PMCID: PMC1854578.", + "otherId": "0", + "citationId": 61, + "otherSource": "" + } + }, + { + "aeid": 665, + "assayComponentEndpointName": "NVS_GPCR_rAdra1B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1B, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 402, + "assayComponentName": "NVS_GPCR_rAdra1B", + "assayComponentDesc": "NVS_GPCR_rAdra1B is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1B assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1B [GeneSymbol:Adra1b | GeneID:24173 | Uniprot_SwissProt_Accession:P15823].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-7-Methoxy-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 216, + "assayName": "NVS_GPCR_rAdra1B", + "assayDesc": "NVS_GPCR_rAdra1B is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 379, + "geneName": "adrenoceptor alpha 1B", + "description": null, + "geneSymbol": "Adra1b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24173, + "officialSymbol": "Adra1b", + "officialFullName": "adrenoceptor alpha 1B", + "uniprotAccessionNumber": "P15823" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2569345", + "pmid": 2569345, + "title": "Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists", + "author": "Hanft G, Gross G", + "citation": "Hanft G, Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691-700. PubMed PMID: 2569345; PubMed Central PMCID: PMC1854578.", + "otherId": "0", + "citationId": 61, + "otherSource": "" + } + }, + { + "aeid": 666, + "assayComponentEndpointName": "NVS_GPCR_rAdra2_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra2_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra2_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 403, + "assayComponentName": "NVS_GPCR_rAdra2_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdra2_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra2_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-RX 821002] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2A [GeneSymbol:Adra2a | GeneID:25083 | Uniprot_SwissProt_Accession:P22909].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-RX 821002", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 217, + "assayName": "NVS_GPCR_rAdra2_NonSelective", + "assayDesc": "NVS_GPCR_rAdra2_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1.25 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.25, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 402, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "Adra2a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25083, + "officialSymbol": "Adra2a", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P22909" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2879884", + "pmid": 2879884, + "title": "Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan", + "author": "Reader TA, Brière R, Grondin L", + "citation": "Reader TA, Brière R, Grondin L. Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan. J Neural Transm. 1987;68(1-2):79-95. PubMed PMID: 2879884.", + "otherId": "0", + "citationId": 73, + "otherSource": "" + } + }, + { + "aeid": 667, + "assayComponentEndpointName": "NVS_GPCR_rAdrb_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdrb_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdrb_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adrb1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 404, + "assayComponentName": "NVS_GPCR_rAdrb_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdrb_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdrb_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-DHA] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor beta 1 [GeneSymbol:Adrb1 | GeneID:24925 | Uniprot_SwissProt_Accession:P18090].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-DHA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 218, + "assayName": "NVS_GPCR_rAdrb_NonSelective", + "assayDesc": "NVS_GPCR_rAdrb_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 398, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "Adrb1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24925, + "officialSymbol": "Adrb1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P18090" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2163719", + "pmid": 2163719, + "title": "Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain", + "author": "Arango V, Ernsberger P, Reis DJ, Mann JJ", + "citation": "Arango V, Ernsberger P, Reis DJ, Mann JJ. Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res. 1990 May 14;516(1):113-21. PubMed PMID: 2163719.", + "otherId": "0", + "citationId": 31, + "otherSource": "" + } + }, + { + "aeid": 668, + "assayComponentEndpointName": "NVS_GPCR_rCRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rCRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rCRF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Crhr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is secretin receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tyr0-oCRF", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "secretin receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 405, + "assayComponentName": "NVS_GPCR_rCRF", + "assayComponentDesc": "NVS_GPCR_rCRF is one of one assay component(s) measured or calculated from the NVS_GPCR_rCRF assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Tyr-oCRF] are indicative of a change in receptor function and kinetics for the Norway rat corticotropin releasing hormone receptor 1 [GeneSymbol:Crhr1 | GeneID:58959 | Uniprot_SwissProt_Accession:P35353].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Tyr-oCRF", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 219, + "assayName": "NVS_GPCR_rCRF", + "assayDesc": "NVS_GPCR_rCRF is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 431, + "geneName": "corticotropin releasing hormone receptor 1", + "description": null, + "geneSymbol": "Crhr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 58959, + "officialSymbol": "Crhr1", + "officialFullName": "corticotropin releasing hormone receptor 1", + "uniprotAccessionNumber": "P35353" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3001239", + "pmid": 3001239, + "title": "Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study", + "author": "De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ", + "citation": "De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci. 1985\nDec;5(12):3189-203. PubMed PMID: 3001239.", + "otherId": "0", + "citationId": 86, + "otherSource": "" + } + }, + { + "aeid": 669, + "assayComponentEndpointName": "NVS_GPCR_rGABBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGABBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGABBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabbr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-Baclofen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 406, + "assayComponentName": "NVS_GPCR_rGABBR", + "assayComponentDesc": "NVS_GPCR_rGABBR is one of one assay component(s) measured or calculated from the NVS_GPCR_rGABBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGP 54626A] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) B receptor 1 [GeneSymbol:Gabbr1 | GeneID:81657 | Uniprot_SwissProt_Accession:Q9Z0U4].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGP 54626A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 220, + "assayName": "NVS_GPCR_rGABBR", + "assayDesc": "NVS_GPCR_rGABBR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 437, + "geneName": "gamma-aminobutyric acid (GABA) B receptor 1", + "description": null, + "geneSymbol": "Gabbr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81657, + "officialSymbol": "Gabbr1", + "officialFullName": "gamma-aminobutyric acid (GABA) B receptor 1", + "uniprotAccessionNumber": "Q9Z0U4" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2850843", + "pmid": 2850843, + "title": "Evidence for pharmacologically distinct subsets of GABAB receptors", + "author": "Scherer RW, Ferkany JW, Enna SJ", + "citation": "Scherer RW, Ferkany JW, Enna SJ. Evidence for pharmacologically distinct subsets of GABAB receptors. Brain Res Bull. 1988 Sep;21(3):439-43. PubMed PMID: 2850843.", + "otherId": "0", + "citationId": 70, + "otherSource": "" + } + }, + { + "aeid": 670, + "assayComponentEndpointName": "NVS_GPCR_rGalanin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGalanin was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGalanin, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Galr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine Galanin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 407, + "assayComponentName": "NVS_GPCR_rGalanin", + "assayComponentDesc": "NVS_GPCR_rGalanin is one of one assay component(s) measured or calculated from the NVS_GPCR_rGalanin assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Galanin] are indicative of a change in receptor function and kinetics for the Norway rat galanin receptor 1 [GeneSymbol:Galr1 | GeneID:50577 | Uniprot_SwissProt_Accession:Q62805].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Galanin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 221, + "assayName": "NVS_GPCR_rGalanin", + "assayDesc": "NVS_GPCR_rGalanin is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 423, + "geneName": "galanin receptor 1", + "description": null, + "geneSymbol": "Galr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50577, + "officialSymbol": "Galr1", + "officialFullName": "galanin receptor 1", + "uniprotAccessionNumber": "Q62805" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2436195", + "pmid": 2436195, + "title": "Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system", + "author": "Skofitsch G, Sills MA, Jacobowitz DM", + "citation": "Skofitsch G, Sills MA, Jacobowitz DM. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides. 1986 Nov-Dec;7(6):1029-42. PubMed PMID: 2436195.", + "otherId": "0", + "citationId": 51, + "otherSource": "" + } + }, + { + "aeid": 671, + "assayComponentEndpointName": "NVS_GPCR_rGHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGHB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGHB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspan17. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NCS-382", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 408, + "assayComponentName": "NVS_GPCR_rGHB", + "assayComponentDesc": "NVS_GPCR_rGHB is one of one assay component(s) measured or calculated from the NVS_GPCR_rGHB assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-NCS-382] are indicative of a change in receptor function and kinetics for the Norway rat tetraspanin 17 [GeneSymbol:Tspan17 | GeneID:306771 | Uniprot_SwissProt_Accession:Q4V8E0].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-NCS-382", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 222, + "assayName": "NVS_GPCR_rGHB", + "assayDesc": "NVS_GPCR_rGHB is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 454, + "geneName": "tetraspanin 17", + "description": null, + "geneSymbol": "Tspan17", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 306771, + "officialSymbol": "Tspan17", + "officialFullName": "tetraspanin 17", + "uniprotAccessionNumber": "Q4V8E0" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10869864", + "pmid": 10869864, + "title": "Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors", + "author": "Bourguignon JJ, Schmitt M, Didier B", + "citation": "Bourguignon JJ, Schmitt M, Didier B. Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors. Alcohol. 2000 Apr;20(3):227-36. Review. PubMed PMID: 10869864.", + "otherId": "0", + "citationId": 182, + "otherSource": "" + } + }, + { + "aeid": 672, + "assayComponentEndpointName": "NVS_GPCR_rH3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rH3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rH3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "N-a-methylhistamine (NAMH)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 409, + "assayComponentName": "NVS_GPCR_rH3", + "assayComponentDesc": "NVS_GPCR_rH3 is one of one assay component(s) measured or calculated from the NVS_GPCR_rH3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylhistamine] are indicative of a change in receptor function and kinetics for the Norway rat histamine receptor H3 [GeneSymbol:Hrh3 | GeneID:85268 | Uniprot_SwissProt_Accession:Q9QYN8].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylhistamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 223, + "assayName": "NVS_GPCR_rH3", + "assayDesc": "NVS_GPCR_rH3 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 442, + "geneName": "histamine receptor H3", + "description": null, + "geneSymbol": "Hrh3", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 85268, + "officialSymbol": "Hrh3", + "officialFullName": "histamine receptor H3", + "uniprotAccessionNumber": "Q9QYN8" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2172771", + "pmid": 2172771, + "title": "Identification of two H3-histamine receptor subtypes", + "author": "West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA", + "citation": "West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA. Identification of two H3-histamine receptor subtypes. Mol Pharmacol. 1990 Nov;38(5):610-3. PubMed PMID: 2172771.", + "otherId": "0", + "citationId": 37, + "otherSource": "" + } + }, + { + "aeid": 673, + "assayComponentEndpointName": "NVS_GPCR_rmAdra2B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmAdra2B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmAdra2B, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl;Norepinephrine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 410, + "assayComponentName": "NVS_GPCR_rmAdra2B", + "assayComponentDesc": "NVS_GPCR_rmAdra2B is one of one assay component(s) measured or calculated from the NVS_GPCR_rmAdra2B assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2B [GeneSymbol:Adra2b | GeneID:24174 | Uniprot_SwissProt_Accession:P19328].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 224, + "assayName": "NVS_GPCR_rmAdra2B", + "assayDesc": "NVS_GPCR_rmAdra2B is a biochemical, single-readout assay that uses extracted gene-proteins from neuroglioma/blastoma hybrid cells in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "neuroglioma/blastoma hybrid cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 380, + "geneName": "adrenoceptor alpha 2B", + "description": null, + "geneSymbol": "Adra2b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24174, + "officialSymbol": "Adra2b", + "officialFullName": "adrenoceptor alpha 2B", + "uniprotAccessionNumber": "P19328" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 674, + "assayComponentEndpointName": "NVS_GPCR_rmMGluR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmMGluR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-Glutamate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 411, + "assayComponentName": "NVS_GPCR_rmMGluR1", + "assayComponentDesc": "NVS_GPCR_rmMGluR1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rmMGluR1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Quisqualic acid] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, metabotropic 1 [GeneSymbol:Grm1 | GeneID:24414 | Uniprot_SwissProt_Accession:P23385].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Quisqualic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 225, + "assayName": "NVS_GPCR_rmMGluR1", + "assayDesc": "NVS_GPCR_rmMGluR1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cerebellum in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cerebellum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 388, + "geneName": "glutamate receptor, metabotropic 1", + "description": null, + "geneSymbol": "Grm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24414, + "officialSymbol": "Grm1", + "officialFullName": "glutamate receptor, metabotropic 1", + "uniprotAccessionNumber": "P23385" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11814808", + "pmid": 11814808, + "title": "[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5", + "author": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R", + "citation": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002 Feb 11;12(3):407-9. PubMed PMID: 11814808.", + "otherId": "0", + "citationId": 186, + "otherSource": "" + } + }, + { + "aeid": 675, + "assayComponentEndpointName": "NVS_GPCR_rmMGluR5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmMGluR5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MPEP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 412, + "assayComponentName": "NVS_GPCR_rmMGluR5", + "assayComponentDesc": "NVS_GPCR_rmMGluR5 is one of one assay component(s) measured or calculated from the NVS_GPCR_rmMGluR5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-2-Methyl-6-phenylethynylpyridine] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, metabotropic 5 [GeneSymbol:Grm5 | GeneID:24418 | Uniprot_SwissProt_Accession:P31424].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-2-Methyl-6-phenylethynylpyridine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 226, + "assayName": "NVS_GPCR_rmMGluR5", + "assayDesc": "NVS_GPCR_rmMGluR5 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat whole brain in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat whole brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 389, + "geneName": "glutamate receptor, metabotropic 5", + "description": null, + "geneSymbol": "Grm5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24418, + "officialSymbol": "Grm5", + "officialFullName": "glutamate receptor, metabotropic 5", + "uniprotAccessionNumber": "P31424" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11814808", + "pmid": 11814808, + "title": "[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5", + "author": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R", + "citation": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002 Feb 11;12(3):407-9. PubMed PMID: 11814808.", + "otherId": "0", + "citationId": 186, + "otherSource": "" + } + }, + { + "aeid": 676, + "assayComponentEndpointName": "NVS_GPCR_rNK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Substance P", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 413, + "assayComponentName": "NVS_GPCR_rNK1", + "assayComponentDesc": "NVS_GPCR_rNK1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rNK1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Substance P] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 1 [GeneSymbol:Tacr1 | GeneID:24807 | Uniprot_SwissProt_Accession:P14600].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Substance P", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 227, + "assayName": "NVS_GPCR_rNK1", + "assayDesc": "NVS_GPCR_rNK1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat submaxillary gland membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "salivary gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat submaxillary gland membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 393, + "geneName": "tachykinin receptor 1", + "description": null, + "geneSymbol": "Tacr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24807, + "officialSymbol": "Tacr1", + "officialFullName": "tachykinin receptor 1", + "uniprotAccessionNumber": "P14600" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 677, + "assayComponentEndpointName": "NVS_GPCR_rNK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Eledoisin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 414, + "assayComponentName": "NVS_GPCR_rNK3", + "assayComponentDesc": "NVS_GPCR_rNK3 is one of one assay component(s) measured or calculated from the NVS_GPCR_rNK3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Eledoisin] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 3 [GeneSymbol:Tacr3 | GeneID:24808 | Uniprot_SwissProt_Accession:P16177].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Eledoisin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 228, + "assayName": "NVS_GPCR_rNK3", + "assayDesc": "NVS_GPCR_rNK3 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 394, + "geneName": "tachykinin receptor 3", + "description": null, + "geneSymbol": "Tacr3", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24808, + "officialSymbol": "Tacr3", + "officialFullName": "tachykinin receptor 3", + "uniprotAccessionNumber": "P16177" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 678, + "assayComponentEndpointName": "NVS_GPCR_rNTS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNTS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ntsr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Neurotensin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 415, + "assayComponentName": "NVS_GPCR_rNTS", + "assayComponentDesc": "NVS_GPCR_rNTS is one of one assay component(s) measured or calculated from the NVS_GPCR_rNTS assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-neurotensin] are indicative of a change in receptor function and kinetics for the Norway rat neurotensin receptor 1 [GeneSymbol:Ntsr1 | GeneID:366274 | Uniprot_SwissProt_Accession:P20789].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 229, + "assayName": "NVS_GPCR_rNTS", + "assayDesc": "NVS_GPCR_rNTS is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 455, + "geneName": "neurotensin receptor 1", + "description": null, + "geneSymbol": "Ntsr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 366274, + "officialSymbol": "Ntsr1", + "officialFullName": "neurotensin receptor 1", + "uniprotAccessionNumber": "P20789" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6744039", + "pmid": 6744039, + "title": "Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution", + "author": "Goedert M, Pittaway K, Williams BJ, Emson PC", + "citation": "Goedert M, Pittaway K, Williams BJ, Emson PC. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res. 1984 Jun 18;304(1):71-81. PubMed PMID: 6744039.", + "otherId": "0", + "citationId": 129, + "otherSource": "" + } + }, + { + "aeid": 679, + "assayComponentEndpointName": "NVS_GPCR_rOpiate_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOpiate_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 416, + "assayComponentName": "NVS_GPCR_rOpiate_NonSelective", + "assayComponentDesc": "NVS_GPCR_rOpiate_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rOpiate_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor function and kinetics for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naloxone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 230, + "assayName": "NVS_GPCR_rOpiate_NonSelective", + "assayDesc": "NVS_GPCR_rOpiate_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 411, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "Oprm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25601, + "officialSymbol": "Oprm1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P33535" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/4127185", + "pmid": 4127185, + "title": "Regional distribution of opiate receptor binding in monkey and human brain", + "author": "Kuhar MJ, Pert CB, Snyder SH", + "citation": "Kuhar MJ, Pert CB, Snyder SH. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973 Oct 26;245(5426):447-50. PubMed PMID: 4127185.", + "otherId": "0", + "citationId": 106, + "otherSource": "" + } + }, + { + "aeid": 680, + "assayComponentEndpointName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOpiate_NonSelectiveNa was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelectiveNa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 417, + "assayComponentName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "assayComponentDesc": "NVS_GPCR_rOpiate_NonSelectiveNa is one of one assay component(s) measured or calculated from the NVS_GPCR_rOpiate_NonSelectiveNa assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor binding affinity due to allosteric binding of sodium ions for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naloxone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 231, + "assayName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "assayDesc": "NVS_GPCR_rOpiate_NonSelectiveNa is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 411, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "Oprm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25601, + "officialSymbol": "Oprm1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P33535" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/4127185", + "pmid": 4127185, + "title": "Regional distribution of opiate receptor binding in monkey and human brain", + "author": "Kuhar MJ, Pert CB, Snyder SH", + "citation": "Kuhar MJ, Pert CB, Snyder SH. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973 Oct 26;245(5426):447-50. PubMed PMID: 4127185.", + "otherId": "0", + "citationId": 106, + "otherSource": "" + } + }, + { + "aeid": 681, + "assayComponentEndpointName": "NVS_GPCR_rOXT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOXT was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOXT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oxtr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxytocin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 418, + "assayComponentName": "NVS_GPCR_rOXT", + "assayComponentDesc": "NVS_GPCR_rOXT is one of one assay component(s) measured or calculated from the NVS_GPCR_rOXT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Oxytocin] are indicative of a change in receptor function and kinetics for the Norway rat oxytocin receptor [GeneSymbol:Oxtr | GeneID:25342 | Uniprot_SwissProt_Accession:P70536].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Oxytocin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 232, + "assayName": "NVS_GPCR_rOXT", + "assayDesc": "NVS_GPCR_rOXT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat uterine membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 406, + "geneName": "oxytocin receptor", + "description": null, + "geneSymbol": "Oxtr", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25342, + "officialSymbol": "Oxtr", + "officialFullName": "oxytocin receptor", + "uniprotAccessionNumber": "P70536" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2163875", + "pmid": 2163875, + "title": "Identification of functional oxytocin receptors in lactating rat mammary gland in vitro", + "author": "Pettibone DJ, Woyden CJ, Totaro JA", + "citation": "Pettibone DJ, Woyden CJ, Totaro JA. Identification of functional oxytocin receptors in lactating rat mammary gland in vitro. Eur J Pharmacol. 1990 Apr 25;188(4-5):235-41. PubMed PMID: 2163875.", + "otherId": "0", + "citationId": 32, + "otherSource": "" + } + }, + { + "aeid": 682, + "assayComponentEndpointName": "NVS_GPCR_rSST", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Somatostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 419, + "assayComponentName": "NVS_GPCR_rSST", + "assayComponentDesc": "NVS_GPCR_rSST is one of one assay component(s) measured or calculated from the NVS_GPCR_rSST assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Somatostatin-14 (Tyr11)] are indicative of a change in receptor function and kinetics for the Norway rat somatostatin receptor 1 [GeneSymbol:Sstr1 | GeneID:25033 | Uniprot_SwissProt_Accession:P28646].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Somatostatin-14 (Tyr11)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 233, + "assayName": "NVS_GPCR_rSST", + "assayDesc": "NVS_GPCR_rSST is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 400, + "geneName": "somatostatin receptor 1", + "description": null, + "geneSymbol": "Sstr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25033, + "officialSymbol": "Sstr1", + "officialFullName": "somatostatin receptor 1", + "uniprotAccessionNumber": "P28646" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2572690", + "pmid": 2572690, + "title": "Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain", + "author": "Raynor K, Reisine T", + "citation": "Raynor K, Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther. 1989 Nov;251(2):510-7. PubMed PMID: 2572690.", + "otherId": "0", + "citationId": 62, + "otherSource": "" + } + }, + { + "aeid": 683, + "assayComponentEndpointName": "NVS_GPCR_rTRH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rTRH was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rTRH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Trhr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TRH", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 420, + "assayComponentName": "NVS_GPCR_rTRH", + "assayComponentDesc": "NVS_GPCR_rTRH is one of one assay component(s) measured or calculated from the NVS_GPCR_rTRH assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-(3-methylHis[2])-TRH] are indicative of a change in receptor function and kinetics for the Norway rat thyrotropin releasing hormone receptor [GeneSymbol:Trhr | GeneID:25570 | Uniprot_SwissProt_Accession:Q01717].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-(3-methylHis[2])-TRH", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 234, + "assayName": "NVS_GPCR_rTRH", + "assayDesc": "NVS_GPCR_rTRH is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 4 hours after chemical dosing in a 48-well plate.", + "timepointHr": 4.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 410, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "Trhr", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25570, + "officialSymbol": "Trhr", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": "Q01717" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/169955", + "pmid": 169955, + "title": "Thyrotropin releasing hormone (TRH): apparent receptor binding in rat brain membranes", + "author": "Burt DR, Snyder SH", + "citation": "Burt DR, Snyder SH. Thyrotropin releasing hormone (TRH): apparent receptor binding in rat brain membranes. Brain Res. 1975 Aug 8;93(2):309-28. PubMed PMID: 169955.", + "otherId": "0", + "citationId": 3, + "otherSource": "" + } + }, + { + "aeid": 684, + "assayComponentEndpointName": "NVS_GPCR_rV1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rV1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rV1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Avpr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 421, + "assayComponentName": "NVS_GPCR_rV1", + "assayComponentDesc": "NVS_GPCR_rV1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rV1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[phenylanyl-3,4,5-3H(N)]-L-Arg8-Vasopressin] are indicative of a change in receptor function and kinetics for the Norway rat arginine vasopressin receptor 1A [GeneSymbol:Avpr1a | GeneID:25107 | Uniprot_SwissProt_Accession:P30560].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[phenylanyl-3,4,5-3H(N)]-L-Arg8-Vasopressin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 235, + "assayName": "NVS_GPCR_rV1", + "assayDesc": "NVS_GPCR_rV1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 404, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "Avpr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25107, + "officialSymbol": "Avpr1a", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P30560" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3004905", + "pmid": 3004905, + "title": "Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium", + "author": "Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR", + "citation": "Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR. Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium. Endocrinology. 1986 Mar;118(3):990-7. PubMed PMID: 3004905.", + "otherId": "0", + "citationId": 88, + "otherSource": "" + } + }, + { + "aeid": 685, + "assayComponentEndpointName": "NVS_GPCR_rVIP_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rVIP_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rVIP_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Vipr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is secretin receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Vasoactive intestinal peptide (VIP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "secretin receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 422, + "assayComponentName": "NVS_GPCR_rVIP_NonSelective", + "assayComponentDesc": "NVS_GPCR_rVIP_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rVIP_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Vasoactive intestinal peptide] are indicative of a change in receptor function and kinetics for the Norway rat vasoactive intestinal peptide receptor 1 [GeneSymbol:Vipr1 | GeneID:24875 | Uniprot_SwissProt_Accession:P30083].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Vasoactive intestinal peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 236, + "assayName": "NVS_GPCR_rVIP_NonSelective", + "assayDesc": "NVS_GPCR_rVIP_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 395, + "geneName": "vasoactive intestinal peptide receptor 1", + "description": null, + "geneSymbol": "Vipr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24875, + "officialSymbol": "Vipr1", + "officialFullName": "vasoactive intestinal peptide receptor 1", + "uniprotAccessionNumber": "P30083" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2472937", + "pmid": 2472937, + "title": "Distribution of vasoactive intestinal polypeptide and substance P receptors in human colon and small intestine", + "author": "Korman LY, Sayadi H, Bass B, Moody TW, Harmon JW", + "citation": "Korman LY, Sayadi H, Bass B, Moody TW, Harmon JW. Distribution of vasoactive intestinal polypeptide and substance P receptors in human colon and small intestine. Dig Dis Sci. 1989 Jul;34(7):1100-8. PubMed PMID: 2472937.", + "otherId": "0", + "citationId": 54, + "otherSource": "" + } + }, + { + "aeid": 686, + "assayComponentEndpointName": "NVS_IC_hKhERGCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_hKhERGCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_hKhERGCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene KCNH2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Terfenadine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 423, + "assayComponentName": "NVS_IC_hKhERGCh", + "assayComponentDesc": "NVS_IC_hKhERGCh is one of one assay component(s) measured or calculated from the NVS_IC_hKhERGCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Astemizole] are indicative of a change in receptor function and kinetics for the human potassium voltage-gated channel, subfamily H (eag-related), member 2 [GeneSymbol:KCNH2 | GeneID:3757 | Uniprot_SwissProt_Accession:Q12809].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Astemizole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 237, + "assayName": "NVS_IC_hKhERGCh", + "assayDesc": "NVS_IC_hKhERGCh is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 184, + "geneName": "potassium voltage-gated channel, subfamily H (eag-related), member 2", + "description": null, + "geneSymbol": "KCNH2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3757, + "officialSymbol": "KCNH2", + "officialFullName": "potassium voltage-gated channel, subfamily H (eag-related), member 2", + "uniprotAccessionNumber": "Q12809" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10376921", + "pmid": 10376921, + "title": "Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole", + "author": "Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT", + "citation": "Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999 Jun;10(6):836-43. PubMed PMID: 10376921.", + "otherId": "0", + "citationId": 177, + "otherSource": "" + } + }, + { + "aeid": 687, + "assayComponentEndpointName": "NVS_IC_rCaBTZCHL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaBTZCHL was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaBTZCHL, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Diltiazem HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 424, + "assayComponentName": "NVS_IC_rCaBTZCHL", + "assayComponentDesc": "NVS_IC_rCaBTZCHL is one of one assay component(s) measured or calculated from the NVS_IC_rCaBTZCHL assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diltiazem] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diltiazem", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 238, + "assayName": "NVS_IC_rCaBTZCHL", + "assayDesc": "NVS_IC_rCaBTZCHL is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2410283", + "pmid": 2410283, + "title": "[3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex", + "author": "Schoemaker H, Langer SZ", + "citation": "Schoemaker H, Langer SZ. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex. Eur J Pharmacol. 1985 May 8;111(2):273-7. PubMed PMID: 2410283.", + "otherId": "0", + "citationId": 46, + "otherSource": "" + } + }, + { + "aeid": 688, + "assayComponentEndpointName": "NVS_IC_rCaChN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaChN was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaChN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "W-Conotoxin GVIA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 425, + "assayComponentName": "NVS_IC_rCaChN", + "assayComponentDesc": "NVS_IC_rCaChN is one of one assay component(s) measured or calculated from the NVS_IC_rCaChN assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-o-conotoxin GVIA] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, N type, alpha 1B subunit [GeneSymbol:Cacna1b | GeneID:257648 | Uniprot_SwissProt_Accession:Q02294].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-o-conotoxin GVIA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 239, + "assayName": "NVS_IC_rCaChN", + "assayDesc": "NVS_IC_rCaChN is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 446, + "geneName": "calcium channel, voltage-dependent, N type, alpha 1B subunit", + "description": null, + "geneSymbol": "Cacna1b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 257648, + "officialSymbol": "Cacna1b", + "officialFullName": "calcium channel, voltage-dependent, N type, alpha 1B subunit", + "uniprotAccessionNumber": "Q02294" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2172254", + "pmid": 2172254, + "title": "The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels", + "author": "Pullan LM, Keith RA, LaMonte D, Stumpo RJ, Salama AI", + "citation": "Pullan LM, Keith RA, LaMonte D, Stumpo RJ, Salama AI. The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels. J Auton Pharmacol. 1990 Aug;10(4):213-9. PubMed PMID: 2172254.", + "otherId": "0", + "citationId": 36, + "otherSource": "" + } + }, + { + "aeid": 689, + "assayComponentEndpointName": "NVS_IC_rCaDHPRCh_L", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nifedipine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 426, + "assayComponentName": "NVS_IC_rCaDHPRCh_L", + "assayComponentDesc": "NVS_IC_rCaDHPRCh_L is one of one assay component(s) measured or calculated from the NVS_IC_rCaDHPRCh_L assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrendipine] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrendipine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 240, + "assayName": "NVS_IC_rCaDHPRCh_L", + "assayDesc": "NVS_IC_rCaDHPRCh_L is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6422256", + "pmid": 6422256, + "title": "Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine", + "author": "Gould RJ, Murphy KM, Snyder SH", + "citation": "Gould RJ, Murphy KM, Snyder SH. Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine. Mol Pharmacol. 1984 Mar;25(2):235-41. PubMed PMID: 6422256.", + "otherId": "0", + "citationId": 125, + "otherSource": "" + } + }, + { + "aeid": 690, + "assayComponentEndpointName": "NVS_IC_rKAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grik1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Kainic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 427, + "assayComponentName": "NVS_IC_rKAR", + "assayComponentDesc": "NVS_IC_rKAR is one of one assay component(s) measured or calculated from the NVS_IC_rKAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Kainic acid] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, ionotropic, kainate 1 [GeneSymbol:Grik1 | GeneID:29559 | Uniprot_SwissProt_Accession:P22756].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Kainic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 241, + "assayName": "NVS_IC_rKAR", + "assayDesc": "NVS_IC_rKAR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 420, + "geneName": "glutamate receptor, ionotropic, kainate 1", + "description": null, + "geneSymbol": "Grik1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29559, + "officialSymbol": "Grik1", + "officialFullName": "glutamate receptor, ionotropic, kainate 1", + "uniprotAccessionNumber": "P22756" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/492142", + "pmid": 492142, + "title": "Specific binding of [3H]kainic acid to receptor sites in rat brain", + "author": "London ED, Coyle JT", + "citation": "London ED, Coyle JT. Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol. 1979 May;15(3):492-505. PubMed PMID: 492142.", + "otherId": "0", + "citationId": 9, + "otherSource": "" + } + }, + { + "aeid": 691, + "assayComponentEndpointName": "NVS_IC_rKATPCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKATPCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKATPCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnj1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Glibenclamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 428, + "assayComponentName": "NVS_IC_rKATPCh", + "assayComponentDesc": "NVS_IC_rKATPCh is one of one assay component(s) measured or calculated from the NVS_IC_rKATPCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Glibenclamide] are indicative of a change in receptor function and kinetics for the Norway rat potassium inwardly-rectifying channel, subfamily J, member 1 [GeneSymbol:Kcnj1 | GeneID:24521 | Uniprot_SwissProt_Accession:P35560].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Glibenclamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 242, + "assayName": "NVS_IC_rKATPCh", + "assayDesc": "NVS_IC_rKATPCh is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 391, + "geneName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "description": null, + "geneSymbol": "Kcnj1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24521, + "officialSymbol": "Kcnj1", + "officialFullName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "uniprotAccessionNumber": "P35560" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3144003", + "pmid": 3144003, + "title": "Characterization, purification, and affinity labeling of the brain [3H]glibenclamide-binding protein, a putative neuronal ATP-regulated K+ channel", + "author": "Bernardi H, Fosset M, Lazdunski M", + "citation": "Bernardi H, Fosset M, Lazdunski M. Characterization, purification, and affinity labeling of the brain [3H]glibenclamide-binding protein, a putative neuronal ATP-regulated K+ channel. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9816-20. PubMed PMID: 3144003; PubMed Central PMCID: PMC282872.", + "otherId": "0", + "citationId": 96, + "otherSource": "" + } + }, + { + "aeid": 692, + "assayComponentEndpointName": "NVS_IC_rKCaCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKCaCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKCaCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnn1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Apamin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 429, + "assayComponentName": "NVS_IC_rKCaCh", + "assayComponentDesc": "NVS_IC_rKCaCh is one of one assay component(s) measured or calculated from the NVS_IC_rKCaCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Apamin] are indicative of a change in receptor function and kinetics for the Norway rat potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 [GeneSymbol:Kcnn1 | GeneID:54261 | Uniprot_SwissProt_Accession:P70606].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Apamin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 243, + "assayName": "NVS_IC_rKCaCh", + "assayDesc": "NVS_IC_rKCaCh is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 428, + "geneName": "potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1", + "description": "provisional", + "geneSymbol": "Kcnn1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54261, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P70606" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/428392", + "pmid": 428392, + "title": "Bee venom neurotoxin (apamin): iodine labeling and characterization of binding sites", + "author": "Habermann E, Fischer K", + "citation": "Habermann E, Fischer K. Bee venom neurotoxin (apamin): iodine labeling and characterization of binding sites. Eur J Biochem. 1979 Mar;94(2):355-64. PubMed PMID: 428392.", + "otherId": "0", + "citationId": 6, + "otherSource": "" + } + }, + { + "aeid": 693, + "assayComponentEndpointName": "NVS_IC_rNaCh_site2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is sodium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Aconitine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "sodium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 430, + "assayComponentName": "NVS_IC_rNaCh_site2", + "assayComponentDesc": "NVS_IC_rNaCh_site2 is one of one assay component(s) measured or calculated from the NVS_IC_rNaCh_site2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Batrachotoxin] are indicative of a change in receptor function and kinetics for the Norway rat sodium channel, voltage-gated, type I, alpha subunit [GeneSymbol:Scn1a | GeneID:81574 | Uniprot_SwissProt_Accession:P04774].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Batrachotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 244, + "assayName": "NVS_IC_rNaCh_site2", + "assayDesc": "NVS_IC_rNaCh_site2 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 436, + "geneName": "sodium channel, voltage-gated, type I, alpha subunit", + "description": null, + "geneSymbol": "Scn1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81574, + "officialSymbol": "Scn1a", + "officialFullName": "sodium channel, voltage-gated, type I, alpha subunit", + "uniprotAccessionNumber": "P04774" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6300644", + "pmid": 6300644, + "title": "Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex", + "author": "Creveling CR, McNeal ET, Daly JW, Brown GB", + "citation": "Creveling CR, McNeal ET, Daly JW, Brown GB. Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex. Mol Pharmacol. 1983 Mar;23(2):350-8. PubMed PMID: 6300644.", + "otherId": "0", + "citationId": 117, + "otherSource": "" + } + }, + { + "aeid": 694, + "assayComponentEndpointName": "NVS_LGIC_bGABAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GABA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 431, + "assayComponentName": "NVS_LGIC_bGABAR_Agonist", + "assayComponentDesc": "NVS_LGIC_bGABAR_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABAR_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GABA] are indicative of a change in receptor agonist activity for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:GABRA1 | GeneID:780973 | Uniprot_SwissProt_Accession:P08219].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GABA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 245, + "assayName": "NVS_LGIC_bGABAR_Agonist", + "assayDesc": "NVS_LGIC_bGABAR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 465, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 780973, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P08219" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/191147", + "pmid": 191147, + "title": "Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain", + "author": "Enna SJ, Collins JF, Snyder SH", + "citation": "Enna SJ, Collins JF, Snyder SH. Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain. Brain Res. 1977 Mar 18;124(1):185-90. PubMed PMID: 191147.", + "otherId": "0", + "citationId": 5, + "otherSource": "" + } + }, + { + "aeid": 695, + "assayComponentEndpointName": "NVS_LGIC_bGABARa1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 15-1788 (Flumazenil)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 432, + "assayComponentName": "NVS_LGIC_bGABARa1", + "assayComponentDesc": "NVS_LGIC_bGABARa1 is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABARa1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Flunitrazepam] are indicative of a change in receptor function and kinetics for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:GABRA1 | GeneID:780973 | Uniprot_SwissProt_Accession:P08219].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Flunitrazepam", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 246, + "assayName": "NVS_LGIC_bGABARa1", + "assayDesc": "NVS_LGIC_bGABARa1 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cortical membranes in a tissue-based cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 465, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 780973, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P08219" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3005837", + "pmid": 3005837, + "title": "Regional difference in brain benzodiazepine receptor carbohydrates", + "author": "Sweetnam PM, Tallman JF", + "citation": "Sweetnam PM, Tallman JF. Regional difference in brain benzodiazepine receptor carbohydrates. Mol Pharmacol. 1986 Mar;29(3):299-306. PubMed PMID: 3005837.", + "otherId": "0", + "citationId": 89, + "otherSource": "" + } + }, + { + "aeid": 696, + "assayComponentEndpointName": "NVS_LGIC_bGABARa5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABARa5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-655,708", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 433, + "assayComponentName": "NVS_LGIC_bGABARa5", + "assayComponentDesc": "NVS_LGIC_bGABARa5 is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABARa5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-RY80] are indicative of a change in receptor function and kinetics for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 5 [GeneSymbol:GABRA5 | GeneID:523515 | Uniprot_SwissProt_Accession:Q08E50].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-RY80", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 247, + "assayName": "NVS_LGIC_bGABARa5", + "assayDesc": "NVS_LGIC_bGABARa5 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine hippocampal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine hippocampal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 463, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 5", + "description": null, + "geneSymbol": "GABRA5", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 523515, + "officialSymbol": "GABRA5", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 5", + "uniprotAccessionNumber": "Q08E50" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11173064", + "pmid": 11173064, + "title": "Evaluation of native GABA(A) receptors containing an alpha 5 subunit", + "author": "Li M, Szabo A, Rosenberg HC", + "citation": "Li M, Szabo A, Rosenberg HC. Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol. 2001 Feb 9;413(1):63-72. PubMed PMID: 11173064.", + "otherId": "0", + "citationId": 185, + "otherSource": "" + } + }, + { + "aeid": 697, + "assayComponentEndpointName": "NVS_LGIC_h5HT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_h5HT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_h5HT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR3A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MDL-72222", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 434, + "assayComponentName": "NVS_LGIC_h5HT3", + "assayComponentDesc": "NVS_LGIC_h5HT3 is one of one assay component(s) measured or calculated from the NVS_LGIC_h5HT3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR 65630] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic [GeneSymbol:HTR3A | GeneID:3359 | Uniprot_SwissProt_Accession:P46098].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR 65630", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 248, + "assayName": "NVS_LGIC_h5HT3", + "assayDesc": "NVS_LGIC_h5HT3 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 166, + "geneName": "5-hydroxytryptamine (serotonin) receptor 3A, ionotropic", + "description": null, + "geneSymbol": "HTR3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3359, + "officialSymbol": "HTR3A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 3A, ionotropic", + "uniprotAccessionNumber": "P46098" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1840227", + "pmid": 1840227, + "title": "5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists", + "author": "Tyers MB", + "citation": "Tyers MB. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists. Therapie. 1991 Nov-Dec;46(6):431-5. Review. PubMed PMID: 1840227.", + "otherId": "0", + "citationId": 23, + "otherSource": "" + } + }, + { + "aeid": 698, + "assayComponentEndpointName": "NVS_LGIC_hNNR_NBungSens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_hNNR_NBungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_hNNR_NBungSens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRNA2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-Epibatidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 435, + "assayComponentName": "NVS_LGIC_hNNR_NBungSens", + "assayComponentDesc": "NVS_LGIC_hNNR_NBungSens is one of one assay component(s) measured or calculated from the NVS_LGIC_hNNR_NBungSens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Epibatidine] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, nicotinic, alpha 2 (neuronal) [GeneSymbol:CHRNA2 | GeneID:1135 | Uniprot_SwissProt_Accession:Q15822].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Epibatidine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 249, + "assayName": "NVS_LGIC_hNNR_NBungSens", + "assayDesc": "NVS_LGIC_hNNR_NBungSens is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroblastoma membrane cells in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human neuroblastoma membrane cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 66, + "geneName": "cholinergic receptor, nicotinic, alpha 2 (neuronal)", + "description": null, + "geneSymbol": "CHRNA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1135, + "officialSymbol": "CHRNA2", + "officialFullName": "cholinergic receptor, nicotinic, alpha 2 (neuronal)", + "uniprotAccessionNumber": "Q15822" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2197155", + "pmid": 2197155, + "title": "Nicotine receptors in the mammalian brain", + "author": "Luetje CW, Patrick J, Séguéla P", + "citation": "Luetje CW, Patrick J, Séguéla P. Nicotine receptors in the mammalian brain. FASEB J. 1990 Jul;4(10):2753-60. Review. PubMed PMID: 2197155.", + "otherId": "0", + "citationId": 40, + "otherSource": "" + } + }, + { + "aeid": 699, + "assayComponentEndpointName": "NVS_LGIC_rAMPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rAMPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rAMPA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gria1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-AMPA HBr", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 436, + "assayComponentName": "NVS_LGIC_rAMPA", + "assayComponentDesc": "NVS_LGIC_rAMPA is one of one assay component(s) measured or calculated from the NVS_LGIC_rAMPA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-AMPA] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, ionotropic, AMPA 1 [GeneSymbol:Gria1 | GeneID:50592 | Uniprot_SwissProt_Accession:P19490].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-AMPA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 250, + "assayName": "NVS_LGIC_rAMPA", + "assayDesc": "NVS_LGIC_rAMPA is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 424, + "geneName": "glutamate receptor, ionotropic, AMPA 1", + "description": null, + "geneSymbol": "Gria1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50592, + "officialSymbol": "Gria1", + "officialFullName": "glutamate receptor, ionotropic, AMPA 1", + "uniprotAccessionNumber": "P19490" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2890112", + "pmid": 2890112, + "title": "Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay", + "author": "Murphy DE, Snowhill EW, Williams M", + "citation": "Murphy DE, Snowhill EW, Williams M. Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay. Neurochem Res. 1987 Sep;12(9):775-81. PubMed PMID: 2890112.", + "otherId": "0", + "citationId": 75, + "otherSource": "" + } + }, + { + "aeid": 700, + "assayComponentEndpointName": "NVS_LGIC_rGABAR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GABA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 437, + "assayComponentName": "NVS_LGIC_rGABAR_NonSelective", + "assayComponentDesc": "NVS_LGIC_rGABAR_NonSelective is one of one assay component(s) measured or calculated from the NVS_LGIC_rGABAR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GABA] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:Gabra1 | GeneID:29705 | Uniprot_SwissProt_Accession:P62813].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GABA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 251, + "assayName": "NVS_LGIC_rGABAR_NonSelective", + "assayDesc": "NVS_LGIC_rGABAR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat whole brain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat whole brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 421, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "Gabra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29705, + "officialSymbol": "Gabra1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P62813" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/191147", + "pmid": 191147, + "title": "Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain", + "author": "Enna SJ, Collins JF, Snyder SH", + "citation": "Enna SJ, Collins JF, Snyder SH. Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain. Brain Res. 1977 Mar 18;124(1):185-90. PubMed PMID: 191147.", + "otherId": "0", + "citationId": 5, + "otherSource": "" + } + }, + { + "aeid": 701, + "assayComponentEndpointName": "NVS_LGIC_rGABARa6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGABARa6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABARa6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-655,708", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 438, + "assayComponentName": "NVS_LGIC_rGABARa6", + "assayComponentDesc": "NVS_LGIC_rGABARa6 is one of one assay component(s) measured or calculated from the NVS_LGIC_rGABARa6 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Ro 15-4513] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) A receptor, alpha 6 [GeneSymbol:Gabra6 | GeneID:29708 | Uniprot_SwissProt_Accession:P30191].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Ro 15-4513", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 252, + "assayName": "NVS_LGIC_rGABARa6", + "assayDesc": "NVS_LGIC_rGABARa6 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 422, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 6", + "description": null, + "geneSymbol": "Gabra6", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29708, + "officialSymbol": "Gabra6", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 6", + "uniprotAccessionNumber": "P30191" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9281599", + "pmid": 9281599, + "title": "Cerebellar gamma-aminobutyric acid type A receptors: pharmacological subtypes revealed by mutant mouse lines", + "author": "Mäkelä R, Uusi-Oukari M, Homanics GE, Quinlan JJ, Firestone LL, Wisden W, Korpi ER", + "citation": "Mäkelä R, Uusi-Oukari M, Homanics GE, Quinlan JJ, Firestone LL, Wisden W, Korpi ER. Cerebellar gamma-aminobutyric acid type A receptors: pharmacological subtypes revealed by mutant mouse lines. Mol Pharmacol. 1997 Sep;52(3):380-8. PubMed PMID: 9281599.", + "otherId": "0", + "citationId": 173, + "otherSource": "" + } + }, + { + "aeid": 702, + "assayComponentEndpointName": "NVS_LGIC_rGluNMDA_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGluNMDA_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "N-methyl-D-aspartate (NMDA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 439, + "assayComponentName": "NVS_LGIC_rGluNMDA_Agonist", + "assayComponentDesc": "NVS_LGIC_rGluNMDA_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_rGluNMDA_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGP 39653] are indicative of a change in receptor agonist activity for the Norway rat glutamate receptor, ionotropic, N-methyl D-aspartate 1 [GeneSymbol:Grin1 | GeneID:24408 | Uniprot_SwissProt_Accession:P35439].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGP 39653", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 253, + "assayName": "NVS_LGIC_rGluNMDA_Agonist", + "assayDesc": "NVS_LGIC_rGluNMDA_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2899170", + "pmid": 2899170, + "title": "CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist", + "author": "Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, et al", + "citation": "Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, et al. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther. 1988 Jul;246(1):65-75. PubMed PMID: 2899170.", + "otherId": "0", + "citationId": 76, + "otherSource": "" + } + }, + { + "aeid": 703, + "assayComponentEndpointName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGluNMDA_MK801_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_MK801_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+)-MK-801", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 440, + "assayComponentName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "assayComponentDesc": "NVS_LGIC_rGluNMDA_MK801_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_rGluNMDA_MK801_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-801] are indicative of a change in receptor agonist activity for the Norway rat glutamate receptor, ionotropic, N-methyl D-aspartate 1 [GeneSymbol:Grin1 | GeneID:24408 | Uniprot_SwissProt_Accession:P35439].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-801", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 254, + "assayName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "assayDesc": "NVS_LGIC_rGluNMDA_MK801_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2468076", + "pmid": 2468076, + "title": "Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels", + "author": "Javitt DC, Zukin SR", + "citation": "Javitt DC, Zukin SR. Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol Pharmacol. 1989 Apr;35(4):387-93. PubMed PMID: 2468076.", + "otherId": "0", + "citationId": 53, + "otherSource": "" + } + }, + { + "aeid": 704, + "assayComponentEndpointName": "NVS_LGIC_rGlyRStrySens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGlyRStrySens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGlyRStrySens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Glra1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Strychnine nitrate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 441, + "assayComponentName": "NVS_LGIC_rGlyRStrySens", + "assayComponentDesc": "NVS_LGIC_rGlyRStrySens is one of one assay component(s) measured or calculated from the NVS_LGIC_rGlyRStrySens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-strychnine] are indicative of a change in receptor function and kinetics for the Norway rat glycine receptor, alpha 1 [GeneSymbol:Glra1 | GeneID:25674 | Uniprot_SwissProt_Accession:P07727].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-strychnine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 255, + "assayName": "NVS_LGIC_rGlyRStrySens", + "assayDesc": "NVS_LGIC_rGlyRStrySens is a biochemical, single-readout assay that uses extracted gene-proteins from Rat spinal cord membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat spinal cord membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 414, + "geneName": "glycine receptor, alpha 1", + "description": null, + "geneSymbol": "Glra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25674, + "officialSymbol": "Glra1", + "officialFullName": "glycine receptor, alpha 1", + "uniprotAccessionNumber": "P07727" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2542450", + "pmid": 2542450, + "title": "Thermodynamics of agonist and antagonist interaction with the strychnine-sensitive glycine receptor", + "author": "Ruiz-Gómez A, García-Calvo M, Vázquez J, Marvizón JC, Valdivieso F, Mayor F Jr", + "citation": "Ruiz-Gómez A, García-Calvo M, Vázquez J, Marvizón JC, Valdivieso F, Mayor F Jr. Thermodynamics of agonist and antagonist interaction with the strychnine-sensitive glycine receptor. J Neurochem. 1989 Jun;52(6):1775-80. PubMed PMID: 2542450.", + "otherId": "0", + "citationId": 56, + "otherSource": "" + } + }, + { + "aeid": 705, + "assayComponentEndpointName": "NVS_LGIC_rNNR_BungSens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rNNR_BungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rNNR_BungSens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrna7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyllycaconitine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 442, + "assayComponentName": "NVS_LGIC_rNNR_BungSens", + "assayComponentDesc": "NVS_LGIC_rNNR_BungSens is one of one assay component(s) measured or calculated from the NVS_LGIC_rNNR_BungSens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-a-bungarotoxin] are indicative of a change in receptor function and kinetics for the Norway rat cholinergic receptor, nicotinic, alpha 7 (neuronal) [GeneSymbol:Chrna7 | GeneID:25302 | Uniprot_SwissProt_Accession:Q05941].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-a-bungarotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 256, + "assayName": "NVS_LGIC_rNNR_BungSens", + "assayDesc": "NVS_LGIC_rNNR_BungSens is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 405, + "geneName": "cholinergic receptor, nicotinic, alpha 7 (neuronal)", + "description": null, + "geneSymbol": "Chrna7", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25302, + "officialSymbol": "Chrna7", + "officialFullName": "cholinergic receptor, nicotinic, alpha 7 (neuronal)", + "uniprotAccessionNumber": "Q05941" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2197155", + "pmid": 2197155, + "title": "Nicotine receptors in the mammalian brain", + "author": "Luetje CW, Patrick J, Séguéla P", + "citation": "Luetje CW, Patrick J, Séguéla P. Nicotine receptors in the mammalian brain. FASEB J. 1990 Jul;4(10):2753-60. Review. PubMed PMID: 2197155.", + "otherId": "0", + "citationId": 40, + "otherSource": "" + } + }, + { + "aeid": 706, + "assayComponentEndpointName": "NVS_MP_hPBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 443, + "assayComponentName": "NVS_MP_hPBR", + "assayComponentDesc": "NVS_MP_hPBR is one of one assay component(s) measured or calculated from the NVS_MP_hPBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the human translocator protein (18kDa) [GeneSymbol:TSPO | GeneID:706 | Uniprot_SwissProt_Accession:P30536].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 257, + "assayName": "NVS_MP_hPBR", + "assayDesc": "NVS_MP_hPBR is a biochemical, single-readout assay that uses extracted gene-proteins from Human colonic cell membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human colonic cell membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 37, + "geneName": "translocator protein (18kDa)", + "description": null, + "geneSymbol": "TSPO", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 706, + "officialSymbol": "TSPO", + "officialFullName": "translocator protein (18kDa)", + "uniprotAccessionNumber": "P30536" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2837399", + "pmid": 2837399, + "title": "Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105", + "author": "Skowro?ski R, Fanestil DD, Beaumont K", + "citation": "Skowro?ski R, Fanestil DD, Beaumont K. Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105. Eur J Pharmacol. 1988 Mar 29;148(2):187-93. PubMed PMID: 2837399.", + "otherId": "0", + "citationId": 68, + "otherSource": "" + } + }, + { + "aeid": 707, + "assayComponentEndpointName": "NVS_MP_rPBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 444, + "assayComponentName": "NVS_MP_rPBR", + "assayComponentDesc": "NVS_MP_rPBR is one of one assay component(s) measured or calculated from the NVS_MP_rPBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the Norway rat translocator protein [GeneSymbol:Tspo | GeneID:24230 | Uniprot_SwissProt_Accession:P16257].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 258, + "assayName": "NVS_MP_rPBR", + "assayDesc": "NVS_MP_rPBR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat kidney membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat kidney membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 382, + "geneName": "translocator protein", + "description": null, + "geneSymbol": "Tspo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24230, + "officialSymbol": "Tspo", + "officialFullName": "translocator protein", + "uniprotAccessionNumber": "P16257" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2837399", + "pmid": 2837399, + "title": "Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105", + "author": "Skowro?ski R, Fanestil DD, Beaumont K", + "citation": "Skowro?ski R, Fanestil DD, Beaumont K. Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105. Eur J Pharmacol. 1988 Mar 29;148(2):187-93. PubMed PMID: 2837399.", + "otherId": "0", + "citationId": 68, + "otherSource": "" + } + }, + { + "aeid": 708, + "assayComponentEndpointName": "NVS_NR_bER", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_bER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bER, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 445, + "assayComponentName": "NVS_NR_bER", + "assayComponentDesc": "NVS_NR_bER is one of one assay component(s) measured or calculated from the NVS_NR_bER assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the cattle estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:407238 | Uniprot_SwissProt_Accession:P49884].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 259, + "assayName": "NVS_NR_bER", + "assayDesc": "NVS_NR_bER is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine uterine membranes in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 459, + "geneName": "estrogen receptor 1", + "description": "provisional", + "geneSymbol": "ESR1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 407238, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P49884" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 709, + "assayComponentEndpointName": "NVS_NR_bPR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Promegestone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 446, + "assayComponentName": "NVS_NR_bPR", + "assayComponentDesc": "NVS_NR_bPR is one of one assay component(s) measured or calculated from the NVS_NR_bPR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the cattle progesterone receptor-like [GeneSymbol:PGR | GeneID:100848466 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Promegestone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 260, + "assayName": "NVS_NR_bPR", + "assayDesc": "NVS_NR_bPR is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine uterine membranes in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 479, + "geneName": "progesterone receptor-like", + "description": "provisional", + "geneSymbol": "PGR", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 100848466, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2419120", + "pmid": 2419120, + "title": "Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues", + "author": "Traish AM, Müller RE, Wotiz HH", + "citation": "Traish AM, Müller RE, Wotiz HH. Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues. Endocrinology. 1986 Apr;118(4):1327-33. PubMed PMID: 2419120.", + "otherId": "0", + "citationId": 48, + "otherSource": "" + } + }, + { + "aeid": 710, + "assayComponentEndpointName": "NVS_NR_cAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 447, + "assayComponentName": "NVS_NR_cAR", + "assayComponentDesc": "NVS_NR_cAR is one of one assay component(s) measured or calculated from the NVS_NR_cAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the chimpanzee androgen receptor [GeneSymbol:AR | GeneID:747460 | Uniprot_SwissProt_Accession:O97775].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 261, + "assayName": "NVS_NR_cAR", + "assayDesc": "NVS_NR_cAR is a biochemical, single-readout assay that uses extracted gene-proteins from Sf9/Sf21 in a cell-free assay. Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9598, + "organism": "chimpanzee", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Sf9/Sf21", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 464, + "geneName": "androgen receptor", + "description": "provisional", + "geneSymbol": "AR", + "organismId": 7, + "trackStatus": "live", + "entrezGeneId": 747460, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O97775" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 711, + "assayComponentEndpointName": "NVS_NR_hAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 448, + "assayComponentName": "NVS_NR_hAR", + "assayComponentDesc": "NVS_NR_hAR is one of one assay component(s) measured or calculated from the NVS_NR_hAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 262, + "assayName": "NVS_NR_hAR", + "assayDesc": "NVS_NR_hAR is a biochemical, single-readout assay that uses extracted gene-proteins from LnCAP in a cell-free assay. Measurements were taken 20 hours after chemical dosing in a 96-well plate.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "LnCAP", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/436741", + "pmid": 436741, + "title": "Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors", + "author": "Zava DT, Landrum B, Horwitz KB, McGuire WL", + "citation": "Zava DT, Landrum B, Horwitz KB, McGuire WL. Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors. Endocrinology. 1979 Apr;104(4):1007-12. PubMed PMID: 436741.", + "otherId": "0", + "citationId": 7, + "otherSource": "" + } + }, + { + "aeid": 712, + "assayComponentEndpointName": "NVS_NR_hCAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hCAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CITCO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 449, + "assayComponentName": "NVS_NR_hCAR_Agonist", + "assayComponentDesc": "NVS_NR_hCAR_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hCAR_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 263, + "assayName": "NVS_NR_hCAR_Agonist", + "assayDesc": "NVS_NR_hCAR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12611900", + "pmid": 12611900, + "title": "Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes", + "author": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT", + "citation": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83. Epub 2003 Feb 27. PubMed PMID: 12611900.", + "otherId": "0", + "citationId": 195, + "otherSource": "" + } + }, + { + "aeid": 713, + "assayComponentEndpointName": "NVS_NR_hCAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 450, + "assayComponentName": "NVS_NR_hCAR_Antagonist", + "assayComponentDesc": "NVS_NR_hCAR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hCAR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 264, + "assayName": "NVS_NR_hCAR_Antagonist", + "assayDesc": "NVS_NR_hCAR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12611900", + "pmid": 12611900, + "title": "Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes", + "author": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT", + "citation": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83. Epub 2003 Feb 27. PubMed PMID: 12611900.", + "otherId": "0", + "citationId": 195, + "otherSource": "" + } + }, + { + "aeid": 714, + "assayComponentEndpointName": "NVS_NR_hER", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 451, + "assayComponentName": "NVS_NR_hER", + "assayComponentDesc": "NVS_NR_hER is one of one assay component(s) measured or calculated from the NVS_NR_hER assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 265, + "assayName": "NVS_NR_hER", + "assayDesc": "NVS_NR_hER is a biochemical, single-readout assay that uses extracted gene-proteins from MCF7 in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "MCF7", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 715, + "assayComponentEndpointName": "NVS_NR_hFXR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hFXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 452, + "assayComponentName": "NVS_NR_hFXR_Agonist", + "assayComponentDesc": "NVS_NR_hFXR_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hFXR_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 266, + "assayName": "NVS_NR_hFXR_Agonist", + "assayDesc": "NVS_NR_hFXR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11988537", + "pmid": 11988537, + "title": "A natural product that lowers cholesterol as an antagonist ligand for FXR", + "author": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD", + "citation": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2. PubMed PMID: 11988537.", + "otherId": "0", + "citationId": 188, + "otherSource": "" + } + }, + { + "aeid": 716, + "assayComponentEndpointName": "NVS_NR_hFXR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 453, + "assayComponentName": "NVS_NR_hFXR_Antagonist", + "assayComponentDesc": "NVS_NR_hFXR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hFXR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 267, + "assayName": "NVS_NR_hFXR_Antagonist", + "assayDesc": "NVS_NR_hFXR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11988537", + "pmid": 11988537, + "title": "A natural product that lowers cholesterol as an antagonist ligand for FXR", + "author": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD", + "citation": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2. PubMed PMID: 11988537.", + "otherId": "0", + "citationId": 188, + "otherSource": "" + } + }, + { + "aeid": 717, + "assayComponentEndpointName": "NVS_NR_hGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Triamcinolone acetonide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 454, + "assayComponentName": "NVS_NR_hGR", + "assayComponentDesc": "NVS_NR_hGR is one of one assay component(s) measured or calculated from the NVS_NR_hGR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dexamethasone] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dexamethasone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 268, + "assayName": "NVS_NR_hGR", + "assayDesc": "NVS_NR_hGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 16 hours after chemical dosing in a 96-well plate.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8061598", + "pmid": 8061598, + "title": "Binding of [3H]triamcinolone acetonide to glucocorticoid receptors in brain cytosol fractions of rats with intact adrenals", + "author": "Han D, Ogita K, Kashiwai K, Narita S, Yoneda Y", + "citation": "Han D, Ogita K, Kashiwai K, Narita S, Yoneda Y. Binding of [3H]triamcinolone acetonide to glucocorticoid receptors in brain cytosol fractions of rats with intact adrenals. Neurochem Int. 1994 Apr;24(4):339-48. PubMed PMID: 8061598.", + "otherId": "0", + "citationId": 154, + "otherSource": "" + } + }, + { + "aeid": 718, + "assayComponentEndpointName": "NVS_NR_hPPARa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPPARa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 455, + "assayComponentName": "NVS_NR_hPPARa", + "assayComponentDesc": "NVS_NR_hPPARa is one of one assay component(s) measured or calculated from the NVS_NR_hPPARa assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluoromone PPAR green] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluoromone PPAR green", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 269, + "assayName": "NVS_NR_hPPARa", + "assayDesc": "NVS_NR_hPPARa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/15497675", + "pmid": 15497675, + "title": "Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res", + "author": "van Raalte DH, Li M, Pritchard PH, Wasan KM", + "citation": "van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res. 2004 Sep;21(9):1531-8. Review. PubMed PMID: 15497675.", + "otherId": "0", + "citationId": 199, + "otherSource": "" + } + }, + { + "aeid": 719, + "assayComponentEndpointName": "NVS_NR_hPPARg", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ciglitazone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 456, + "assayComponentName": "NVS_NR_hPPARg", + "assayComponentDesc": "NVS_NR_hPPARg is one of one assay component(s) measured or calculated from the NVS_NR_hPPARg assay. It is designed to make measurements of fluorescent polarization, a form of binding reporter, as detected with fluorescence polarization signals by Fluorescence Polarization technology.", + "assayComponentTargetDesc": "Changes to fluorescence polarization signals produced from the receptor-ligand binding of the key ligand [Fluorescent Ligand] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence polarization", + "detectionTechnology": "Fluorescence Polarization", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluorescent Ligand", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 270, + "assayName": "NVS_NR_hPPARg", + "assayDesc": "NVS_NR_hPPARg is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9744270", + "pmid": 9744270, + "title": "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma", + "author": "Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV", + "citation": "Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998 Sep 10;395(6698):137-43. PubMed PMID: 9744270.", + "otherId": "0", + "citationId": 174, + "otherSource": "" + } + }, + { + "aeid": 720, + "assayComponentEndpointName": "NVS_NR_hPR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Promegestone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 457, + "assayComponentName": "NVS_NR_hPR", + "assayComponentDesc": "NVS_NR_hPR is one of one assay component(s) measured or calculated from the NVS_NR_hPR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the human progesterone receptor [GeneSymbol:PGR | GeneID:5241 | Uniprot_SwissProt_Accession:P06401].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Promegestone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 271, + "assayName": "NVS_NR_hPR", + "assayDesc": "NVS_NR_hPR is a biochemical, single-readout assay that uses extracted gene-proteins from T47D in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "T47D", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2419120", + "pmid": 2419120, + "title": "Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues", + "author": "Traish AM, Müller RE, Wotiz HH", + "citation": "Traish AM, Müller RE, Wotiz HH. Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues. Endocrinology. 1986 Apr;118(4):1327-33. PubMed PMID: 2419120.", + "otherId": "0", + "citationId": 48, + "otherSource": "" + } + }, + { + "aeid": 721, + "assayComponentEndpointName": "NVS_NR_hPXR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TO901317", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 458, + "assayComponentName": "NVS_NR_hPXR", + "assayComponentDesc": "NVS_NR_hPXR is one of one assay component(s) measured or calculated from the NVS_NR_hPXR assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluormone PXR (SXR) green] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluormone PXR (SXR) green", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 272, + "assayName": "NVS_NR_hPXR", + "assayDesc": "NVS_NR_hPXR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12663745", + "pmid": 12663745, + "title": "Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor", + "author": "Rosenfeld JM, Vargas R Jr, Xie W, Evans RM", + "citation": "Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol. 2003 Jul;17(7):1268-82. Epub 2003 Mar 27. PubMed PMID: 12663745", + "otherId": "0", + "citationId": 196, + "otherSource": "" + } + }, + { + "aeid": 722, + "assayComponentEndpointName": "NVS_NR_hRAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RO415253", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 459, + "assayComponentName": "NVS_NR_hRAR_Antagonist", + "assayComponentDesc": "NVS_NR_hRAR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hRAR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 273, + "assayName": "NVS_NR_hRAR_Antagonist", + "assayDesc": "NVS_NR_hRAR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10567548", + "pmid": 10567548, + "title": "Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta", + "author": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP", + "citation": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol. 1999 Dec;19(12):8226-39. PubMed PMID: 10567548; PubMed Central PMCID: PMC84907.", + "otherId": "0", + "citationId": 179, + "otherSource": "" + } + }, + { + "aeid": 723, + "assayComponentEndpointName": "NVS_NR_hRARa_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hRARa_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRARa_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TTNPB", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 460, + "assayComponentName": "NVS_NR_hRARa_Agonist", + "assayComponentDesc": "NVS_NR_hRARa_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hRARa_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 274, + "assayName": "NVS_NR_hRARa_Agonist", + "assayDesc": "NVS_NR_hRARa_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10567548", + "pmid": 10567548, + "title": "Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta", + "author": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP", + "citation": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol. 1999 Dec;19(12):8226-39. PubMed PMID: 10567548; PubMed Central PMCID: PMC84907.", + "otherId": "0", + "citationId": 179, + "otherSource": "" + } + }, + { + "aeid": 724, + "assayComponentEndpointName": "NVS_NR_hTRa_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hTRa_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hTRa_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene THRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Bisphenol A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 461, + "assayComponentName": "NVS_NR_hTRa_Antagonist", + "assayComponentDesc": "NVS_NR_hTRa_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hTRa_Antagonist assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with chemiluminescence signals by AlphaLISA immunoassay technology.", + "assayComponentTargetDesc": "Changes to chemiluminescence signals produced from the receptor-ligand binding of the key ligand [3,3\",5-triiodo-L-thyronine] are indicative of a change in receptor antagonist activity for the human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "AlphaLISA immunoassay", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "3,3\",5-triiodo-L-thyronine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 275, + "assayName": "NVS_NR_hTRa_Antagonist", + "assayDesc": "NVS_NR_hTRa_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12414890", + "pmid": 12414890, + "title": "Thyroid hormone action is disrupted by bisphenol A as an antagonist", + "author": "Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, Hataya Y, Shimatsu A, Kuzuya H, Nakao K", + "citation": "Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, Hataya Y, Shimatsu A, Kuzuya H, Nakao K. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab. 2002 Nov;87(11):5185-90. PubMed PMID: 12414890.", + "otherId": "0", + "citationId": 192, + "otherSource": "" + } + }, + { + "aeid": 725, + "assayComponentEndpointName": "NVS_NR_mERa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 462, + "assayComponentName": "NVS_NR_mERa", + "assayComponentDesc": "NVS_NR_mERa is one of one assay component(s) measured or calculated from the NVS_NR_mERa assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the house mouse estrogen receptor 1 (alpha) [GeneSymbol:Esr1 | GeneID:13982 | Uniprot_SwissProt_Accession:P19785].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 276, + "assayName": "NVS_NR_mERa", + "assayDesc": "NVS_NR_mERa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 372, + "geneName": "estrogen receptor 1 (alpha)", + "description": null, + "geneSymbol": "Esr1", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 13982, + "officialSymbol": "Esr1", + "officialFullName": "estrogen receptor 1 (alpha)", + "uniprotAccessionNumber": "P19785" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 726, + "assayComponentEndpointName": "NVS_NR_rAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 463, + "assayComponentName": "NVS_NR_rAR", + "assayComponentDesc": "NVS_NR_rAR is one of one assay component(s) measured or calculated from the NVS_NR_rAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the Norway rat androgen receptor [GeneSymbol:Ar | GeneID:24208 | Uniprot_SwissProt_Accession:P15207].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 277, + "assayName": "NVS_NR_rAR", + "assayDesc": "NVS_NR_rAR is a biochemical, single-readout assay that uses extracted gene-proteins from Testosterone pre-treated rat prostate in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 10116, + "organism": "rat", + "tissue": "prostate", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Testosterone pre-treated rat prostate", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 381, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "Ar", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24208, + "officialSymbol": "Ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P15207" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 727, + "assayComponentEndpointName": "NVS_NR_rMR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_rMR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rMR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nr3c2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Spironolactone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 464, + "assayComponentName": "NVS_NR_rMR", + "assayComponentDesc": "NVS_NR_rMR is one of one assay component(s) measured or calculated from the NVS_NR_rMR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Aldosterone] are indicative of a change in receptor function and kinetics for the Norway rat nuclear receptor subfamily 3, group C, member 2 [GeneSymbol:Nr3c2 | GeneID:25672 | Uniprot_SwissProt_Accession:P22199].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Aldosterone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 278, + "assayName": "NVS_NR_rMR", + "assayDesc": "NVS_NR_rMR is a biochemical, single-readout assay that uses extracted gene-proteins from Adrenalectomized rat brain supernatant in a tissue-based cell-free assay. Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Adrenalectomized rat brain supernatant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 413, + "geneName": "nuclear receptor subfamily 3, group C, member 2", + "description": null, + "geneSymbol": "Nr3c2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25672, + "officialSymbol": "Nr3c2", + "officialFullName": "nuclear receptor subfamily 3, group C, member 2", + "uniprotAccessionNumber": "P22199" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6227474", + "pmid": 6227474, + "title": "Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone", + "author": "Beaumont K, Fanestil DD", + "citation": "Beaumont K, Fanestil DD. Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. PubMed PMID: 6227474.", + "otherId": "0", + "citationId": 113, + "otherSource": "" + } + }, + { + "aeid": 728, + "assayComponentEndpointName": "NVS_OR_gSIGMA_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is chaperone.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "chaperone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 465, + "assayComponentName": "NVS_OR_gSIGMA_NonSelective", + "assayComponentDesc": "NVS_OR_gSIGMA_NonSelective is one of one assay component(s) measured or calculated from the NVS_OR_gSIGMA_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[5-3H]-(1,3-di-O-2-tolylguanidine-DI-[p-Ring-3H]] are indicative of a change in receptor function and kinetics for the domestic guinea pig sigma non-opioid intracellular receptor 1 [GeneSymbol:Sigmar1 | GeneID:100135589 | Uniprot_SwissProt_Accession:Q60492].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[5-3H]-(1,3-di-O-2-tolylguanidine-DI-[p-Ring-3H]", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 279, + "assayName": "NVS_OR_gSIGMA_NonSelective", + "assayDesc": "NVS_OR_gSIGMA_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig brain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 474, + "geneName": "sigma non-opioid intracellular receptor 1", + "description": "provisional", + "geneSymbol": "Sigmar1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135589, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "Q60492" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1675607", + "pmid": 1675607, + "title": "[3H]DTG and [3H](+)-3-PPP label pharmacologically distinct sigma binding sites in guinea pig brain membranes", + "author": "Karbon EW, Naper K, Pontecorvo MJ", + "citation": "Karbon EW, Naper K, Pontecorvo MJ. [3H]DTG and [3H](+)-3-PPP label pharmacologically distinct sigma binding sites in guinea pig brain membranes. Eur J Pharmacol. 1991 Jan 25;193(1):21-7. PubMed PMID: 1675607.", + "otherId": "0", + "citationId": 18, + "otherSource": "" + } + }, + { + "aeid": 729, + "assayComponentEndpointName": "NVS_OR_hFKBP12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_OR_hFKBP12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_hFKBP12, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene FKBP1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is chaperone.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FK506", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "chaperone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 466, + "assayComponentName": "NVS_OR_hFKBP12", + "assayComponentDesc": "NVS_OR_hFKBP12 is one of one assay component(s) measured or calculated from the NVS_OR_hFKBP12 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dihydro-FK506] are indicative of a change in enzyme function and kinetics for the human FK506 binding protein 1A, 12kDa [GeneSymbol:FKBP1A | GeneID:2280 | Uniprot_SwissProt_Accession:P62942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydro-FK506", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 280, + "assayName": "NVS_OR_hFKBP12", + "assayDesc": "NVS_OR_hFKBP12 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 128, + "geneName": "FK506 binding protein 1A, 12kDa", + "description": null, + "geneSymbol": "FKBP1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2280, + "officialSymbol": "FKBP1A", + "officialFullName": "FK506 binding protein 1A, 12kDa", + "uniprotAccessionNumber": "P62942" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7685169", + "pmid": 7685169, + "title": "Detection of the FK506-FKBP-calcineurin complex by a simple binding assay", + "author": "Asami M, Kuno T, Mukai H, Tanaka C", + "citation": "Asami M, Kuno T, Mukai H, Tanaka C. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. Biochem Biophys Res Commun. 1993 May 14;192(3):1388-94. PubMed PMID: 7685169.", + "otherId": "0", + "citationId": 143, + "otherSource": "" + } + }, + { + "aeid": 730, + "assayComponentEndpointName": "NVS_TR_gDAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GBR-12909", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 467, + "assayComponentName": "NVS_TR_gDAT", + "assayComponentDesc": "NVS_TR_gDAT is one of one assay component(s) measured or calculated from the NVS_TR_gDAT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the domestic guinea pig solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 [GeneSymbol:Slc6a3 | GeneID:100714898 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-WIN,35,428", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 281, + "assayName": "NVS_TR_gDAT", + "assayDesc": "NVS_TR_gDAT is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 478, + "geneName": "solute carrier family 6 (neurotransmitter transporter, dopamine), member 3", + "description": "model", + "geneSymbol": "Slc6a3", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100714898, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2811854", + "pmid": 2811854, + "title": "Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane", + "author": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA", + "citation": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol. 1989 Oct;36(4):518-24. PubMed PMID: 2811854.", + "otherId": "0", + "citationId": 65, + "otherSource": "" + } + }, + { + "aeid": 731, + "assayComponentEndpointName": "NVS_TR_hAdoT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hAdoT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC29A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitrobenzylthioinosine (NBTI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 468, + "assayComponentName": "NVS_TR_hAdoT", + "assayComponentDesc": "NVS_TR_hAdoT is one of one assay component(s) measured or calculated from the NVS_TR_hAdoT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrobenzylthioinosine] are indicative of a change in transporter function and kinetics for the human solute carrier family 29 (equilibrative nucleoside transporter), member 1 [GeneSymbol:SLC29A1 | GeneID:2030 | Uniprot_SwissProt_Accession:Q99808].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 282, + "assayName": "NVS_TR_hAdoT", + "assayDesc": "NVS_TR_hAdoT is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 112, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "SLC29A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2030, + "officialSymbol": "SLC29A1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "Q99808" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7086410", + "pmid": 7086410, + "title": "[3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain", + "author": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM", + "citation": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM. [3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain. J Neurochem. 1982 Jul;39(1):184-91. PubMed PMID: 7086410.", + "otherId": "0", + "citationId": 132, + "otherSource": "" + } + }, + { + "aeid": 113, + "assayComponentEndpointName": "ATG_VDRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_VDRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 82, + "assayComponentName": "ATG_VDRE_CIS", + "assayComponentDesc": "ATG_VDRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "VDRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 335, + "geneName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "description": null, + "geneSymbol": "VDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7421, + "officialSymbol": "VDR", + "officialFullName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "uniprotAccessionNumber": "P11473" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 114, + "assayComponentEndpointName": "ATG_Xbp1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Xbp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 83, + "assayComponentName": "ATG_Xbp1_CIS", + "assayComponentDesc": "ATG_Xbp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Xbp1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 337, + "geneName": "X-box binding protein 1", + "description": null, + "geneSymbol": "XBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7494, + "officialSymbol": "XBP1", + "officialFullName": "X-box binding protein 1", + "uniprotAccessionNumber": "P17861" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 115, + "assayComponentEndpointName": "ATG_AR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_AR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "6a-Fluorotestosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 84, + "assayComponentName": "ATG_AR_TRANS", + "assayComponentDesc": "ATG_AR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 116, + "assayComponentEndpointName": "ATG_CAR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_CAR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 85, + "assayComponentName": "ATG_CAR_TRANS", + "assayComponentDesc": "ATG_CAR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-CAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 117, + "assayComponentEndpointName": "ATG_ERa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 86, + "assayComponentName": "ATG_ERa_TRANS", + "assayComponentDesc": "ATG_ERa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERa, also known as human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 118, + "assayComponentEndpointName": "ATG_ERRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 87, + "assayComponentName": "ATG_ERRa_TRANS", + "assayComponentDesc": "ATG_ERRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRa, also known as human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101 | Uniprot_SwissProt_Accession:P11474].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 119, + "assayComponentEndpointName": "ATG_ERRg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERRg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 88, + "assayComponentName": "ATG_ERRg_TRANS", + "assayComponentDesc": "ATG_ERRg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERRg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 121, + "geneName": "estrogen-related receptor gamma", + "description": null, + "geneSymbol": "ESRRG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2104, + "officialSymbol": "ESRRG", + "officialFullName": "estrogen-related receptor gamma", + "uniprotAccessionNumber": "P62508" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 120, + "assayComponentEndpointName": "ATG_FXR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_FXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 89, + "assayComponentName": "ATG_FXR_TRANS", + "assayComponentDesc": "ATG_FXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-FXR, also known as human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-FXR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 121, + "assayComponentEndpointName": "ATG_GAL4_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GAL4_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_GAL4_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 90, + "assayComponentName": "ATG_GAL4_TRANS", + "assayComponentDesc": "ATG_GAL4_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-gal4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 122, + "assayComponentEndpointName": "ATG_GR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_GR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 91, + "assayComponentName": "ATG_GR_TRANS", + "assayComponentDesc": "ATG_GR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-GR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 123, + "assayComponentEndpointName": "ATG_HNF4a_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_HNF4a_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 92, + "assayComponentName": "ATG_HNF4a_TRANS", + "assayComponentDesc": "ATG_HNF4a_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-HNF4a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 157, + "geneName": "hepatocyte nuclear factor 4, alpha", + "description": null, + "geneSymbol": "HNF4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3172, + "officialSymbol": "HNF4A", + "officialFullName": "hepatocyte nuclear factor 4, alpha", + "uniprotAccessionNumber": "P41235" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 124, + "assayComponentEndpointName": "ATG_Hpa5_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Hpa5_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_Hpa5_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 93, + "assayComponentName": "ATG_Hpa5_TRANS", + "assayComponentDesc": "ATG_Hpa5_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-Hpa5, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-Hpa5 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 125, + "assayComponentEndpointName": "ATG_LXRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 94, + "assayComponentName": "ATG_LXRa_TRANS", + "assayComponentDesc": "ATG_LXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-LXRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 363, + "geneName": "nuclear receptor subfamily 1, group H, member 3", + "description": null, + "geneSymbol": "NR1H3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10062, + "officialSymbol": "NR1H3", + "officialFullName": "nuclear receptor subfamily 1, group H, member 3", + "uniprotAccessionNumber": "Q13133" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 126, + "assayComponentEndpointName": "ATG_LXRb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 95, + "assayComponentName": "ATG_LXRb_TRANS", + "assayComponentDesc": "ATG_LXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-LXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 332, + "geneName": "nuclear receptor subfamily 1, group H, member 2", + "description": null, + "geneSymbol": "NR1H2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7376, + "officialSymbol": "NR1H2", + "officialFullName": "nuclear receptor subfamily 1, group H, member 2", + "uniprotAccessionNumber": "P55055" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 127, + "assayComponentEndpointName": "ATG_M_06_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_06_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_06_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 96, + "assayComponentName": "ATG_M_06_TRANS", + "assayComponentDesc": "ATG_M_06_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 128, + "assayComponentEndpointName": "ATG_M_19_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_19_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_19_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 97, + "assayComponentName": "ATG_M_19_TRANS", + "assayComponentDesc": "ATG_M_19_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 129, + "assayComponentEndpointName": "ATG_M_32_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_32_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_32_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 98, + "assayComponentName": "ATG_M_32_TRANS", + "assayComponentDesc": "ATG_M_32_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 130, + "assayComponentEndpointName": "ATG_M_61_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_61_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_61_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 99, + "assayComponentName": "ATG_M_61_TRANS", + "assayComponentDesc": "ATG_M_61_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 131, + "assayComponentEndpointName": "ATG_NURR1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_NURR1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 100, + "assayComponentName": "ATG_NURR1_TRANS", + "assayComponentDesc": "ATG_NURR1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-NURR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 132, + "assayComponentEndpointName": "ATG_PPARa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW0742", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 101, + "assayComponentName": "ATG_PPARa_TRANS", + "assayComponentDesc": "ATG_PPARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 133, + "assayComponentEndpointName": "ATG_PPARd_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARd_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 102, + "assayComponentName": "ATG_PPARd_TRANS", + "assayComponentDesc": "ATG_PPARd_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARd, also known as human peroxisome proliferator-activated receptor delta [GeneSymbol:PPARD | GeneID:5467 | Uniprot_SwissProt_Accession:Q03181].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARd RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 134, + "assayComponentEndpointName": "ATG_PPARg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 103, + "assayComponentName": "ATG_PPARg_TRANS", + "assayComponentDesc": "ATG_PPARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARg, also known as human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 135, + "assayComponentEndpointName": "ATG_PXR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 104, + "assayComponentName": "ATG_PXR_TRANS", + "assayComponentDesc": "ATG_PXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PXR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 136, + "assayComponentEndpointName": "ATG_RARa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 105, + "assayComponentName": "ATG_RARa_TRANS", + "assayComponentDesc": "ATG_RARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 137, + "assayComponentEndpointName": "ATG_RARb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 106, + "assayComponentName": "ATG_RARb_TRANS", + "assayComponentDesc": "ATG_RARb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 280, + "geneName": "retinoic acid receptor, beta", + "description": null, + "geneSymbol": "RARB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5915, + "officialSymbol": "RARB", + "officialFullName": "retinoic acid receptor, beta", + "uniprotAccessionNumber": "P10826" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 138, + "assayComponentEndpointName": "ATG_RARg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 107, + "assayComponentName": "ATG_RARg_TRANS", + "assayComponentDesc": "ATG_RARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 281, + "geneName": "retinoic acid receptor, gamma", + "description": null, + "geneSymbol": "RARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5916, + "officialSymbol": "RARG", + "officialFullName": "retinoic acid receptor, gamma", + "uniprotAccessionNumber": "P13631" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 139, + "assayComponentEndpointName": "ATG_RORb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RORb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 108, + "assayComponentName": "ATG_RORb_TRANS", + "assayComponentDesc": "ATG_RORb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORb, also known as human RAR-related orphan receptor B [GeneSymbol:RORB | GeneID:6096 | Uniprot_SwissProt_Accession:Q92753].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RORb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 285, + "geneName": "RAR-related orphan receptor B", + "description": null, + "geneSymbol": "RORB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6096, + "officialSymbol": "RORB", + "officialFullName": "RAR-related orphan receptor B", + "uniprotAccessionNumber": "Q92753" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 140, + "assayComponentEndpointName": "ATG_RORg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RORg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 109, + "assayComponentName": "ATG_RORg_TRANS", + "assayComponentDesc": "ATG_RORg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RORg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 286, + "geneName": "RAR-related orphan receptor C", + "description": null, + "geneSymbol": "RORC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6097, + "officialSymbol": "RORC", + "officialFullName": "RAR-related orphan receptor C", + "uniprotAccessionNumber": "P51449" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 141, + "assayComponentEndpointName": "ATG_RXRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 110, + "assayComponentName": "ATG_RXRa_TRANS", + "assayComponentDesc": "ATG_RXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RXRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 142, + "assayComponentEndpointName": "ATG_RXRb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 111, + "assayComponentName": "ATG_RXRb_TRANS", + "assayComponentDesc": "ATG_RXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 288, + "geneName": "retinoid X receptor, beta", + "description": null, + "geneSymbol": "RXRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6257, + "officialSymbol": "RXRB", + "officialFullName": "retinoid X receptor, beta", + "uniprotAccessionNumber": "P28702" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 143, + "assayComponentEndpointName": "ATG_THRa1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_THRa1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 112, + "assayComponentName": "ATG_THRa1_TRANS", + "assayComponentDesc": "ATG_THRa1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-THRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 144, + "assayComponentEndpointName": "ATG_VDR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_VDR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "1a,25-Dihydroxyvitamin D3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 113, + "assayComponentName": "ATG_VDR_TRANS", + "assayComponentDesc": "ATG_VDR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-VDR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 335, + "geneName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "description": null, + "geneSymbol": "VDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7421, + "officialSymbol": "VDR", + "officialFullName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "uniprotAccessionNumber": "P11473" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 146, + "assayComponentEndpointName": "BSK_3C_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 114, + "assayComponentName": "BSK_3C_Eselectin", + "assayComponentDesc": "BSK_3C_Eselectin is an assay component measured in the BSK_3C assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 148, + "assayComponentEndpointName": "BSK_3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 115, + "assayComponentName": "BSK_3C_HLADR", + "assayComponentDesc": "BSK_3C_HLADR is an assay component measured in the BSK_3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 150, + "assayComponentEndpointName": "BSK_3C_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 116, + "assayComponentName": "BSK_3C_ICAM1", + "assayComponentDesc": "BSK_3C_ICAM1 is an assay component measured in the BSK_3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 152, + "assayComponentEndpointName": "BSK_3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 117, + "assayComponentName": "BSK_3C_IL8", + "assayComponentDesc": "BSK_3C_IL8 is an assay component measured in the BSK_3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 154, + "assayComponentEndpointName": "BSK_3C_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 118, + "assayComponentName": "BSK_3C_MCP1", + "assayComponentDesc": "BSK_3C_MCP1 is an assay component measured in the BSK_3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 156, + "assayComponentEndpointName": "BSK_3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 119, + "assayComponentName": "BSK_3C_MIG", + "assayComponentDesc": "BSK_3C_MIG is an assay component measured in the BSK_3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 158, + "assayComponentEndpointName": "BSK_3C_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 120, + "assayComponentName": "BSK_3C_Proliferation", + "assayComponentDesc": "BSK_3C_Proliferation is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "Proliferation in the 3C system is a measure of endothelial cell profliferation which is important to the process of wound healing and angiogensis.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 160, + "assayComponentEndpointName": "BSK_3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 121, + "assayComponentName": "BSK_3C_SRB", + "assayComponentDesc": "BSK_3C_SRB is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the 3C system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 162, + "assayComponentEndpointName": "BSK_3C_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 122, + "assayComponentName": "BSK_3C_Thrombomodulin", + "assayComponentDesc": "BSK_3C_Thrombomodulin is an assay component measured in the BSK_3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 164, + "assayComponentEndpointName": "BSK_3C_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 123, + "assayComponentName": "BSK_3C_TissueFactor", + "assayComponentDesc": "BSK_3C_TissueFactor is an assay component measured in the BSK_3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 166, + "assayComponentEndpointName": "BSK_3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 124, + "assayComponentName": "BSK_3C_uPAR", + "assayComponentDesc": "BSK_3CAR is an assay component measured in the BSK_3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 168, + "assayComponentEndpointName": "BSK_3C_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 125, + "assayComponentName": "BSK_3C_VCAM1", + "assayComponentDesc": "BSK_3C_VCAM1 is an assay component measured in the BSK_3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 170, + "assayComponentEndpointName": "BSK_3C_Vis", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Vis was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Vis, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the background control. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "background control", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 126, + "assayComponentName": "BSK_3C_Vis", + "assayComponentDesc": "BSK_3C_Vis is an assay component measured in the BSK_3C assay. It measures NA related to cell morphology using light microscopy technology.", + "assayComponentTargetDesc": "Visual microscropy is used to quantify changes to the morphology of the cells.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell morphology", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 172, + "assayComponentEndpointName": "BSK_4H_Eotaxin3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_Eotaxin3 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Eotaxin3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 127, + "assayComponentName": "BSK_4H_Eotaxin3", + "assayComponentDesc": "BSK_4H_Eotaxin3 is an assay component measured in the BSK_4H assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Eotaxin-3 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 26 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL26 | GeneID:10344 | Uniprot_SwissProt_Accession:Q9Y258].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Eotaxin-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 365, + "geneName": "chemokine (C-C motif) ligand 26", + "description": null, + "geneSymbol": "CCL26", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10344, + "officialSymbol": "CCL26", + "officialFullName": "chemokine (C-C motif) ligand 26", + "uniprotAccessionNumber": "Q9Y258" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 174, + "assayComponentEndpointName": "BSK_4H_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 128, + "assayComponentName": "BSK_4H_MCP1", + "assayComponentDesc": "BSK_4H_MCP1 is an assay component measured in the BSK_4H assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 176, + "assayComponentEndpointName": "BSK_4H_Pselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_Pselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Pselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 129, + "assayComponentName": "BSK_4H_Pselectin", + "assayComponentDesc": "BSK_4H_Pselectin is an assay component measured in the BSK_4H assay. It measures P-Selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "P-Selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 294, + "geneName": "selectin P (granule membrane protein 140kDa, antigen CD62)", + "description": null, + "geneSymbol": "SELP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6403, + "officialSymbol": "SELP", + "officialFullName": "selectin P (granule membrane protein 140kDa, antigen CD62)", + "uniprotAccessionNumber": "P16109" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 180, + "assayComponentEndpointName": "BSK_4H_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4HAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_4HAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 131, + "assayComponentName": "BSK_4H_uPAR", + "assayComponentDesc": "BSK_4HAR is an assay component measured in the BSK_4H assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 182, + "assayComponentEndpointName": "BSK_4H_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 132, + "assayComponentName": "BSK_4H_VCAM1", + "assayComponentDesc": "BSK_4H_VCAM1 is an assay component measured in the BSK_4H assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 184, + "assayComponentEndpointName": "BSK_4H_VEGFRII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_VEGFRII was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VEGFRII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 133, + "assayComponentName": "BSK_4H_VEGFRII", + "assayComponentDesc": "BSK_4H_VEGFRII is an assay component measured in the BSK_4H assay. It measures VEGFRII antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VEGFRII antibody is used to tag and quantify the level of kinase insert domain receptor (a type III receptor tyrosine kinase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VEGFRII antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 186, + "assayComponentEndpointName": "BSK_BE3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 134, + "assayComponentName": "BSK_BE3C_HLADR", + "assayComponentDesc": "BSK_BE3C_HLADR is an assay component measured in the BSK_BE3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 732, + "assayComponentEndpointName": "NVS_TR_hDAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GBR-12909", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 469, + "assayComponentName": "NVS_TR_hDAT", + "assayComponentDesc": "NVS_TR_hDAT is one of one assay component(s) measured or calculated from the NVS_TR_hDAT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 3 [GeneSymbol:SLC6A3 | GeneID:6531 | Uniprot_SwissProt_Accession:Q01959].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-WIN,35,428", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 283, + "assayName": "NVS_TR_hDAT", + "assayDesc": "NVS_TR_hDAT is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 297, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "description": null, + "geneSymbol": "SLC6A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6531, + "officialSymbol": "SLC6A3", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "uniprotAccessionNumber": "Q01959" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2811854", + "pmid": 2811854, + "title": "Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane", + "author": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA", + "citation": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol. 1989 Oct;36(4):518-24. PubMed PMID: 2811854.", + "otherId": "0", + "citationId": 65, + "otherSource": "" + } + }, + { + "aeid": 733, + "assayComponentEndpointName": "NVS_TR_hNET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Desipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 470, + "assayComponentName": "NVS_TR_hNET", + "assayComponentDesc": "NVS_TR_hNET is one of one assay component(s) measured or calculated from the NVS_TR_hNET assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:SLC6A2 | GeneID:6530 | Uniprot_SwissProt_Accession:P23975].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 284, + "assayName": "NVS_TR_hNET", + "assayDesc": "NVS_TR_hNET is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 296, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "SLC6A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6530, + "officialSymbol": "SLC6A2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": "P23975" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 734, + "assayComponentEndpointName": "NVS_TR_hSERT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hSERT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Imipramine HCl;Clomipramine HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 471, + "assayComponentName": "NVS_TR_hSERT", + "assayComponentDesc": "NVS_TR_hSERT is one of one assay component(s) measured or calculated from the NVS_TR_hSERT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:SLC6A4 | GeneID:6532 | Uniprot_SwissProt_Accession:P31645].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methyl-citalopram", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 285, + "assayName": "NVS_TR_hSERT", + "assayDesc": "NVS_TR_hSERT is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelet membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human platelet membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 298, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "SLC6A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6532, + "officialSymbol": "SLC6A4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31645" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2940099", + "pmid": 2940099, + "title": "The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes", + "author": "Brown NL, Sirugue O, Worcel M", + "citation": "Brown NL, Sirugue O, Worcel M. The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. PubMed PMID: 2940099.", + "otherId": "0", + "citationId": 79, + "otherSource": "" + } + }, + { + "aeid": 735, + "assayComponentEndpointName": "NVS_TR_rAdoT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rAdoT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc29a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitrobenzylthioinosine (NBTI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 472, + "assayComponentName": "NVS_TR_rAdoT", + "assayComponentDesc": "NVS_TR_rAdoT is one of one assay component(s) measured or calculated from the NVS_TR_rAdoT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrobenzylthioinosine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 29 (equilibrative nucleoside transporter), member 1 [GeneSymbol:Slc29a1 | GeneID:63997 | Uniprot_SwissProt_Accession:O54698].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 286, + "assayName": "NVS_TR_rAdoT", + "assayDesc": "NVS_TR_rAdoT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 432, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "Slc29a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 63997, + "officialSymbol": "Slc29a1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "O54698" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7086410", + "pmid": 7086410, + "title": "[3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain", + "author": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM", + "citation": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM. [3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain. J Neurochem. 1982 Jul;39(1):184-91. PubMed PMID: 7086410.", + "otherId": "0", + "citationId": 132, + "otherSource": "" + } + }, + { + "aeid": 736, + "assayComponentEndpointName": "NVS_TR_rNET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Desipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 473, + "assayComponentName": "NVS_TR_rNET", + "assayComponentDesc": "NVS_TR_rNET is one of one assay component(s) measured or calculated from the NVS_TR_rNET assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:Slc6a2 | GeneID:83511 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 287, + "assayName": "NVS_TR_rNET", + "assayDesc": "NVS_TR_rNET is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 439, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "Slc6a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 83511, + "officialSymbol": "Slc6a2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7067730", + "pmid": 7067730, + "title": "High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline", + "author": "Raisman R, Sette M, Pimoule C, Briley M, Langer SZ", + "citation": "Raisman R, Sette M, Pimoule C, Briley M, Langer SZ. High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. Eur J Pharmacol. 1982 Mar 12;78(3):345-51. PubMed PMID: 7067730.", + "otherId": "0", + "citationId": 131, + "otherSource": "" + } + }, + { + "aeid": 737, + "assayComponentEndpointName": "NVS_TR_rSERT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rSERT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Imipramine HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 474, + "assayComponentName": "NVS_TR_rSERT", + "assayComponentDesc": "NVS_TR_rSERT is one of one assay component(s) measured or calculated from the NVS_TR_rSERT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:Slc6a4 | GeneID:25553 | Uniprot_SwissProt_Accession:P31652].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methyl-citalopram", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 288, + "assayName": "NVS_TR_rSERT", + "assayDesc": "NVS_TR_rSERT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 409, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "Slc6a4", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25553, + "officialSymbol": "Slc6a4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31652" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2940099", + "pmid": 2940099, + "title": "The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes", + "author": "Brown NL, Sirugue O, Worcel M", + "citation": "Brown NL, Sirugue O, Worcel M. The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. PubMed PMID: 2940099.", + "otherId": "0", + "citationId": 79, + "otherSource": "" + } + }, + { + "aeid": 738, + "assayComponentEndpointName": "NVS_TR_rVMAT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rVMAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rVMAT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc18a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is vesicular transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Reserpine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "vesicular transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 475, + "assayComponentName": "NVS_TR_rVMAT2", + "assayComponentDesc": "NVS_TR_rVMAT2 is one of one assay component(s) measured or calculated from the NVS_TR_rVMAT2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dihydrotetrabenazine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 18 (vesicular monoamine transporter), member 2 [GeneSymbol:Slc18a2 | GeneID:25549 | Uniprot_SwissProt_Accession:Q01827].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydrotetrabenazine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 289, + "assayName": "NVS_TR_rVMAT2", + "assayDesc": "NVS_TR_rVMAT2 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 408, + "geneName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "description": null, + "geneSymbol": "Slc18a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25549, + "officialSymbol": "Slc18a2", + "officialFullName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "uniprotAccessionNumber": "Q01827" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3748008", + "pmid": 3748008, + "title": "[3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles", + "author": "Near JA", + "citation": "Near JA. [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol Pharmacol. 1986 Sep;30(3):252-7. PubMed PMID: 3748008.", + "otherId": "0", + "citationId": 103, + "otherSource": "" + } + }, + { + "aeid": 739, + "assayComponentEndpointName": "OT_AR_ARELUC_AG_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "6-alpha-Fluorotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 476, + "assayComponentName": "OT_AR_ARELUC_AG_1440", + "assayComponentDesc": "OT_AR_ARELUC_AG_1440 is one of one assay component(s) measured or calculated from the OT_AR_ARELUC_AG_1440 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by Luciferase technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [D-luciferin] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "D-luciferin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 290, + "assayName": "OT_AR_ARELUC_AG_1440", + "assayDesc": "OT_AR_ARELUC_AG_1440 is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 740, + "assayComponentEndpointName": "OT_AR_ARSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4,5-alpha-Dihydrotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 477, + "assayComponentName": "OT_AR_ARSRC1_0480", + "assayComponentDesc": "OT_AR_ARSRC1_0480 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 291, + "assayName": "OT_AR_ARSRC1_0480", + "assayDesc": "OT_AR_ARSRC1_0480 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 741, + "assayComponentEndpointName": "OT_AR_ARSRC1_0960", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4,5-alpha-Dihydrotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 478, + "assayComponentName": "OT_AR_ARSRC1_0960", + "assayComponentDesc": "OT_AR_ARSRC1_0960 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0960 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 292, + "assayName": "OT_AR_ARSRC1_0960", + "assayDesc": "OT_AR_ARSRC1_0960 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 16 hours after chemical dosing in a 384-well plate.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 742, + "assayComponentEndpointName": "OT_ER_ERaERa_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 479, + "assayComponentName": "OT_ER_ERaERa_0480", + "assayComponentDesc": "OT_ER_ERaERa_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 293, + "assayName": "OT_ER_ERaERa_0480", + "assayDesc": "OT_ER_ERaERa_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 743, + "assayComponentEndpointName": "OT_ER_ERaERa_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 480, + "assayComponentName": "OT_ER_ERaERa_1440", + "assayComponentDesc": "OT_ER_ERaERa_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 294, + "assayName": "OT_ER_ERaERa_1440", + "assayDesc": "OT_ER_ERaERa_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 188, + "assayComponentEndpointName": "BSK_BE3C_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 135, + "assayComponentName": "BSK_BE3C_IL1a", + "assayComponentDesc": "BSK_BE3C_IL1a is an assay component measured in the BSK_BE3C assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 190, + "assayComponentEndpointName": "BSK_BE3C_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 136, + "assayComponentName": "BSK_BE3C_IP10", + "assayComponentDesc": "BSK_BE3C_IP10 is an assay component measured in the BSK_BE3C assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 192, + "assayComponentEndpointName": "BSK_BE3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 137, + "assayComponentName": "BSK_BE3C_MIG", + "assayComponentDesc": "BSK_BE3C_MIG is an assay component measured in the BSK_BE3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 194, + "assayComponentEndpointName": "BSK_BE3C_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 138, + "assayComponentName": "BSK_BE3C_MMP1", + "assayComponentDesc": "BSK_BE3C_MMP1 is an assay component measured in the BSK_BE3C assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 196, + "assayComponentEndpointName": "BSK_BE3C_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 139, + "assayComponentName": "BSK_BE3C_PAI1", + "assayComponentDesc": "BSK_BE3C_PAI1 is an assay component measured in the BSK_BE3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 200, + "assayComponentEndpointName": "BSK_BE3C_TGFb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 141, + "assayComponentName": "BSK_BE3C_TGFb1", + "assayComponentDesc": "BSK_BE3C_TGFb1 is an assay component measured in the BSK_BE3C assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TGF-b1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 202, + "assayComponentEndpointName": "BSK_BE3C_tPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_tPA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_tPA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 142, + "assayComponentName": "BSK_BE3C_tPA", + "assayComponentDesc": "BSK_BE3C_tPA is an assay component measured in the BSK_BE3C assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "tPA antibody is used to tag and quantify the level of plasminogen activator, tissue protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAT | GeneID:5327 | Uniprot_SwissProt_Accession:P00750].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "tPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 239, + "geneName": "plasminogen activator, tissue", + "description": null, + "geneSymbol": "PLAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5327, + "officialSymbol": "PLAT", + "officialFullName": "plasminogen activator, tissue", + "uniprotAccessionNumber": "P00750" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 744, + "assayComponentEndpointName": "OT_ER_ERaERb_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 481, + "assayComponentName": "OT_ER_ERaERb_0480", + "assayComponentDesc": "OT_ER_ERaERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 295, + "assayName": "OT_ER_ERaERb_0480", + "assayDesc": "OT_ER_ERaERb_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 745, + "assayComponentEndpointName": "OT_ER_ERaERb_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 482, + "assayComponentName": "OT_ER_ERaERb_1440", + "assayComponentDesc": "OT_ER_ERaERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 296, + "assayName": "OT_ER_ERaERb_1440", + "assayDesc": "OT_ER_ERaERb_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 746, + "assayComponentEndpointName": "OT_ER_ERbERb_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 483, + "assayComponentName": "OT_ER_ERbERb_0480", + "assayComponentDesc": "OT_ER_ERbERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 297, + "assayName": "OT_ER_ERbERb_0480", + "assayDesc": "OT_ER_ERbERb_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 747, + "assayComponentEndpointName": "OT_ER_ERbERb_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 484, + "assayComponentName": "OT_ER_ERbERb_1440", + "assayComponentDesc": "OT_ER_ERbERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 298, + "assayName": "OT_ER_ERbERb_1440", + "assayDesc": "OT_ER_ERbERb_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 750, + "assayComponentEndpointName": "OT_ERa_GFPERaERE_0120", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Z)-4-Hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 487, + "assayComponentName": "OT_ERa_GFPERaERE_0120", + "assayComponentDesc": "OT_ERa_GFPERaERE_0120 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0120 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", + "assayComponentTargetDesc": "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "Microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 301, + "assayName": "OT_ERa_GFPERaERE_0120", + "assayDesc": "OT_ERa_GFPERaERE_0120 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/onc.2013.550", + "url": "https://pubmed.ncbi.nlm.nih.gov/24441042/", + "pmid": 24441042, + "title": "ystems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity", + "author": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA", + "citation": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA. Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity. Oncogene. 2015 Jan 8;34(2):154-64. doi: 10.1038/onc.2013.550. Epub 2014 Jan 20. PMID: 24441042; PMCID: PMC4871123.", + "otherId": "0", + "citationId": 252, + "otherSource": "" + } + }, + { + "aeid": 751, + "assayComponentEndpointName": "OT_ERa_GFPERaERE_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Z)-4-Hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 488, + "assayComponentName": "OT_ERa_GFPERaERE_0480", + "assayComponentDesc": "OT_ERa_GFPERaERE_0480 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0480 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", + "assayComponentTargetDesc": "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "Microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 302, + "assayName": "OT_ERa_GFPERaERE_0480", + "assayDesc": "OT_ERa_GFPERaERE_0480 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/onc.2013.550", + "url": "https://pubmed.ncbi.nlm.nih.gov/24441042/", + "pmid": 24441042, + "title": "ystems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity", + "author": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA", + "citation": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA. Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity. Oncogene. 2015 Jan 8;34(2):154-64. doi: 10.1038/onc.2013.550. Epub 2014 Jan 20. PMID: 24441042; PMCID: PMC4871123.", + "otherId": "0", + "citationId": 252, + "otherSource": "" + } + }, + { + "aeid": 753, + "assayComponentEndpointName": "OT_FXR_FXRSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW4064", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 490, + "assayComponentName": "OT_FXR_FXRSRC1_0480", + "assayComponentDesc": "OT_FXR_FXRSRC1_0480 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 304, + "assayName": "OT_FXR_FXRSRC1_0480", + "assayDesc": "OT_FXR_FXRSRC1_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 754, + "assayComponentEndpointName": "OT_FXR_FXRSRC1_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW4064", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 491, + "assayComponentName": "OT_FXR_FXRSRC1_1440", + "assayComponentDesc": "OT_FXR_FXRSRC1_1440 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 305, + "assayName": "OT_FXR_FXRSRC1_1440", + "assayDesc": "OT_FXR_FXRSRC1_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 755, + "assayComponentEndpointName": "OT_NURR1_NURR1RXRa_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Isoproterenol;Fenoterol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 492, + "assayComponentName": "OT_NURR1_NURR1RXRa_0480", + "assayComponentDesc": "OT_NURR1_NURR1RXRa_0480 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 306, + "assayName": "OT_NURR1_NURR1RXRa_0480", + "assayDesc": "OT_NURR1_NURR1RXRa_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 756, + "assayComponentEndpointName": "OT_NURR1_NURR1RXRa_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Isoproterenol;Fenoterol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 493, + "assayComponentName": "OT_NURR1_NURR1RXRa_1440", + "assayComponentDesc": "OT_NURR1_NURR1RXRa_1440 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 307, + "assayName": "OT_NURR1_NURR1RXRa_1440", + "assayDesc": "OT_NURR1_NURR1RXRa_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 757, + "assayComponentEndpointName": "OT_PPARg_PPARgSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW1929", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 494, + "assayComponentName": "OT_PPARg_PPARgSRC1_0480", + "assayComponentDesc": "OT_PPARg_PPARgSRC1_0480 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 308, + "assayName": "OT_PPARg_PPARgSRC1_0480", + "assayDesc": "OT_PPARg_PPARgSRC1_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 758, + "assayComponentEndpointName": "OT_PPARg_PPARgSRC1_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW1929", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 495, + "assayComponentName": "OT_PPARg_PPARgSRC1_1440", + "assayComponentDesc": "OT_PPARg_PPARgSRC1_1440 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 309, + "assayName": "OT_PPARg_PPARgSRC1_1440", + "assayDesc": "OT_PPARg_PPARgSRC1_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 759, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 496, + "assayComponentName": "TOX21_AR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 760, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 497, + "assayComponentName": "TOX21_AR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 761, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 498, + "assayComponentName": "TOX21_AR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 ", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 762, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 499, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate ", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 212, + "assayComponentEndpointName": "BSK_CASM3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 147, + "assayComponentName": "BSK_CASM3C_IL8", + "assayComponentDesc": "BSK_CASM3C_IL8 is an assay component measured in the BSK_CASM3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 214, + "assayComponentEndpointName": "BSK_CASM3C_LDLR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_LDLR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_LDLR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is LDL receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "LDL receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 148, + "assayComponentName": "BSK_CASM3C_LDLR", + "assayComponentDesc": "BSK_CASM3C_LDLR is an assay component measured in the BSK_CASM3C assay. It measures LDLR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "LDLR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 190, + "geneName": "low density lipoprotein receptor", + "description": null, + "geneSymbol": "LDLR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3949, + "officialSymbol": "LDLR", + "officialFullName": "low density lipoprotein receptor", + "uniprotAccessionNumber": "P01130" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 216, + "assayComponentEndpointName": "BSK_CASM3C_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 149, + "assayComponentName": "BSK_CASM3C_MCP1", + "assayComponentDesc": "BSK_CASM3C_MCP1 is an assay component measured in the BSK_CASM3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 218, + "assayComponentEndpointName": "BSK_CASM3C_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 150, + "assayComponentName": "BSK_CASM3C_MCSF", + "assayComponentDesc": "BSK_CASM3C_MCSF is an assay component measured in the BSK_CASM3C assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 220, + "assayComponentEndpointName": "BSK_CASM3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 151, + "assayComponentName": "BSK_CASM3C_MIG", + "assayComponentDesc": "BSK_CASM3C_MIG is an assay component measured in the BSK_CASM3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 222, + "assayComponentEndpointName": "BSK_CASM3C_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_CASM3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 152, + "assayComponentName": "BSK_CASM3C_Proliferation", + "assayComponentDesc": "BSK_CASM3C_Proliferation is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 224, + "assayComponentEndpointName": "BSK_CASM3C_SAA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_SAA was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SAA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is apolipoproteins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "apolipoproteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 153, + "assayComponentName": "BSK_CASM3C_SAA", + "assayComponentDesc": "BSK_CASM3C_SAA is an assay component measured in the BSK_CASM3C assay. It measures SAA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant. SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "SAA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 290, + "geneName": "serum amyloid A1", + "description": null, + "geneSymbol": "SAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6288, + "officialSymbol": "SAA1", + "officialFullName": "serum amyloid A1", + "uniprotAccessionNumber": "P0DJI8" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 226, + "assayComponentEndpointName": "BSK_CASM3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 154, + "assayComponentName": "BSK_CASM3C_SRB", + "assayComponentDesc": "BSK_CASM3C_SRB is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the CASM3C system is a measure of the total protein content of coronary artery smooth muscle cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 763, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 500, + "assayComponentName": "TOX21_AR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 764, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 501, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAkb2_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 312, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 765, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nilutamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 502, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Therefore AR binding assay for screening androgen antagonists can be used to identify potential endocrine disruptors. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 313, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for antagonist specificity. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 766, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 503, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 313, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for antagonist specificity. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 767, + "assayComponentEndpointName": "TOX21_Aromatase_Inhibition", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Letrozole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 504, + "assayComponentName": "TOX21_Aromatase_Inhibition", + "assayComponentDesc": "TOX21_Aromatase_Inhibition is one of one assay component(s) measured or calculated from the TOX21_Aromatase_Inhibition assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to modulation of the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 314, + "assayName": "TOX21_Aromatase_Inhibition", + "assayDesc": "TOX21_Aromatase_Inhibition is a cell-based, single-readout assay that uses MCF-7, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfu023", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496634", + "pmid": 24496634, + "title": "AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor", + "author": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C", + "citation": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C. AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci. 2014 May;139(1):198-209. doi: 10.1093/toxsci/kfu023. Epub 2014 Feb 4. PubMed PMID: 24496634; PubMed Central PMCID: PMC4038786.", + "otherId": "0", + "citationId": 222, + "otherSource": "" + } + }, + { + "aeid": 768, + "assayComponentEndpointName": "TOX21_Aromatase_Inhibition_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 505, + "assayComponentName": "TOX21_Aromatase_Inhibition_viability", + "assayComponentDesc": "TOX21_Aromatase_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 314, + "assayName": "TOX21_Aromatase_Inhibition", + "assayDesc": "TOX21_Aromatase_Inhibition is a cell-based, single-readout assay that uses MCF-7, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfu023", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496634", + "pmid": 24496634, + "title": "AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor", + "author": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C", + "citation": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C. AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci. 2014 May;139(1):198-209. doi: 10.1093/toxsci/kfu023. Epub 2014 Feb 4. PubMed PMID: 24496634; PubMed Central PMCID: PMC4038786.", + "otherId": "0", + "citationId": 222, + "otherSource": "" + } + }, + { + "aeid": 769, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 506, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 770, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 507, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_green", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 771, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 508, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_red", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 772, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 509, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 773, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 510, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_green", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 774, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 511, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_red", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 775, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 512, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 776, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 513, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_green", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 777, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 514, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_red", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 778, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 515, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 779, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 516, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_green", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 780, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 517, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_red", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 781, + "assayComponentEndpointName": "TOX21_ELG1_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-Fluorouridine", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "atpase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 518, + "assayComponentName": "TOX21_ELG1_LUC_Agonist", + "assayComponentDesc": "TOX21_ELG1_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_ELG1_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human ATPase family, AAA domain containing 5 [GeneSymbol:ATAD5 | GeneID:79915 | Uniprot_SwissProt_Accession:Q96QE3].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 317, + "assayName": "TOX21_ELG1_LUC_Agonist", + "assayDesc": "TOX21_ELG1_LUC_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 435, + "geneName": "ATPase family, AAA domain containing 5", + "description": null, + "geneSymbol": "ATAD5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 79915, + "officialSymbol": "ATAD5", + "officialFullName": "ATPase family, AAA domain containing 5", + "uniprotAccessionNumber": "Q96QE3" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 782, + "assayComponentEndpointName": "TOX21_ELG1_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 519, + "assayComponentName": "TOX21_ELG1_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_ELG1_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 317, + "assayName": "TOX21_ELG1_LUC_Agonist", + "assayDesc": "TOX21_ELG1_LUC_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 783, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 520, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 784, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 521, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 785, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 522, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 786, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 523, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 787, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 524, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 788, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 525, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERa_LUC_VM7_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 320, + "assayName": "TOX21_ERa_LUC_VM7_Agonist", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 789, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 526, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372] using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 321, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 790, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 527, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 321, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 791, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 528, + "assayComponentName": "TOX21_GR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 792, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 529, + "assayComponentName": "TOX21_GR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 793, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 530, + "assayComponentName": "TOX21_GR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 794, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifeprostone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 531, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 795, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 532, + "assayComponentName": "TOX21_GR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 796, + "assayComponentEndpointName": "TOX21_MMP_fitc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_fitc is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 533, + "assayComponentName": "TOX21_MMP_fitc", + "assayComponentDesc": "TOX21_MMP_fitc is an assay readout measuring signaling via mitochondrial depolarization and designed using background reporter (mitochondrial membrane potential) detected with immunofluorescence.", + "assayComponentTargetDesc": "TOX21_MMP_fitc was designed to target cell morphology (organelle conformation) activity at the cellular (cellular) level, specifically mapping to NA gene(s) using a positive control of FCCP", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 798, + "assayComponentEndpointName": "TOX21_MMP_rhodamine", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_rhodamine is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 535, + "assayComponentName": "TOX21_MMP_rhodamine", + "assayComponentDesc": "TOX21_MMP_rhodamine is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence.", + "assayComponentTargetDesc": "TOX21_MMP_rhodamine was designed to target cell morphology (organelle conformation) activity at the cellular (cellular) level, specifically mapping to NA gene(s) using a positive control of FCCP", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 799, + "assayComponentEndpointName": "TOX21_MMP_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 536, + "assayComponentName": "TOX21_MMP_viability", + "assayComponentDesc": "TOX21_MMP_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 800, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 537, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 801, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 538, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 802, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 539, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity..", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 803, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "0.092 uM T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 540, + "assayComponentName": "TOX21_TR_LUC_GH3_Agonist", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Agonist is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 326, + "assayName": "TOX21_TR_LUC_GH3_Agonist", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 228, + "assayComponentEndpointName": "BSK_CASM3C_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 155, + "assayComponentName": "BSK_CASM3C_Thrombomodulin", + "assayComponentDesc": "BSK_CASM3C_Thrombomodulin is an assay component measured in the BSK_CASM3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 230, + "assayComponentEndpointName": "BSK_CASM3C_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 156, + "assayComponentName": "BSK_CASM3C_TissueFactor", + "assayComponentDesc": "BSK_CASM3C_TissueFactor is an assay component measured in the BSK_CASM3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 232, + "assayComponentEndpointName": "BSK_CASM3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 157, + "assayComponentName": "BSK_CASM3C_uPAR", + "assayComponentDesc": "BSK_CASM3CAR is an assay component measured in the BSK_CASM3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 234, + "assayComponentEndpointName": "BSK_CASM3C_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 158, + "assayComponentName": "BSK_CASM3C_VCAM1", + "assayComponentDesc": "BSK_CASM3C_VCAM1 is an assay component measured in the BSK_CASM3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 236, + "assayComponentEndpointName": "BSK_hDFCGF_CollagenIII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_CollagenIII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is collagen.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 159, + "assayComponentName": "BSK_hDFCGF_CollagenIII", + "assayComponentDesc": "BSK_hDFCGF_CollagenIII is an assay component measured in the BSK_hDFCGF assay. It measures Collagen antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen antibody is used to tag and quantify the level of collagen, type III, alpha 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:COL3A1 | GeneID:1281 | Uniprot_SwissProt_Accession:P02461].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 70, + "geneName": "collagen, type III, alpha 1", + "description": null, + "geneSymbol": "COL3A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1281, + "officialSymbol": "COL3A1", + "officialFullName": "collagen, type III, alpha 1", + "uniprotAccessionNumber": "P02461" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 238, + "assayComponentEndpointName": "BSK_hDFCGF_EGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_EGFR was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_EGFR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 160, + "assayComponentName": "BSK_hDFCGF_EGFR", + "assayComponentDesc": "BSK_hDFCGF_EGFR is an assay component measured in the BSK_hDFCGF assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "EGFR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 240, + "assayComponentEndpointName": "BSK_hDFCGF_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 161, + "assayComponentName": "BSK_hDFCGF_IL8", + "assayComponentDesc": "BSK_hDFCGF_IL8 is an assay component measured in the BSK_hDFCGF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 934, + "assayComponentEndpointName": "LTEA_HepaRG_ALPP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ALPP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ALPP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 608, + "assayComponentName": "LTEA_HepaRG_ALPP", + "assayComponentDesc": "LTEA_HepaRG_ALPP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 24, + "geneName": "alkaline phosphatase, placental", + "description": null, + "geneSymbol": "ALPP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 250, + "officialSymbol": "ALPP", + "officialFullName": "alkaline phosphatase, placental", + "uniprotAccessionNumber": "P05187" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 804, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 541, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 327, + "assayName": "TOX21_TR_LUC_GH3_Antagonist", + "assayDesc": "TOX21_TR_LUC_GH3_Antagonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 805, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 542, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist_viability", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist_viability is an assay readout measuring viability via receptor activity and designed using bioluminescence signals detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 327, + "assayName": "TOX21_TR_LUC_GH3_Antagonist", + "assayDesc": "TOX21_TR_LUC_GH3_Antagonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 806, + "assayComponentEndpointName": "TOX21_AhR_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Omeprazole", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 543, + "assayComponentName": "TOX21_AhR_LUC_Agonist", + "assayComponentDesc": "TOX21_AhR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_AhR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CALUX luciferase quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from the luciferase induction are indicative of agonist activity regulated by the receptor function and kinetics for the human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CALUX luciferase quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 328, + "assayName": "TOX21_AhR_LUC_Agonist", + "assayDesc": "TOX21_AhR_LUC_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 21, + "geneName": "aryl hydrocarbon receptor", + "description": null, + "geneSymbol": "AHR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 196, + "officialSymbol": "AHR", + "officialFullName": "aryl hydrocarbon receptor", + "uniprotAccessionNumber": "P35869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfr189", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21775728", + "pmid": 21775728, + "title": "Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness", + "author": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS", + "citation": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS. Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. Toxicol Sci. 2011 Oct;123(2):511-22. doi: 10.1093/toxsci/kfr189. Epub 2011 Jul 20. PubMed PMID: 21775728; PubMed Central PMCID: PMC3179681.", + "otherId": "0", + "citationId": 227, + "otherSource": "" + } + }, + { + "aeid": 807, + "assayComponentEndpointName": "TOX21_AhR_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 544, + "assayComponentName": "TOX21_AhR_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_AhR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 328, + "assayName": "TOX21_AhR_LUC_Agonist", + "assayDesc": "TOX21_AhR_LUC_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfr189", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21775728", + "pmid": 21775728, + "title": "Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness", + "author": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS", + "citation": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS. Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. Toxicol Sci. 2011 Oct;123(2):511-22. doi: 10.1093/toxsci/kfr189. Epub 2011 Jul 20. PubMed PMID: 21775728; PubMed Central PMCID: PMC3179681.", + "otherId": "0", + "citationId": 227, + "otherSource": "" + } + }, + { + "aeid": 891, + "assayComponentEndpointName": "CEETOX_H295R_11DCORT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_11DCORT was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_11DCORT, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 586, + "assayComponentName": "CEETOX_H295R_11DCORT", + "assayComponentDesc": "CEETOX_H295R_11DCORT is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 893, + "assayComponentEndpointName": "CEETOX_H295R_OHPREG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPREG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPREG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxypregnenolone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 587, + "assayComponentName": "CEETOX_H295R_OHPREG", + "assayComponentDesc": "CEETOX_H295R_OHPREG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxypregnenolone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 895, + "assayComponentEndpointName": "CEETOX_H295R_OHPROG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPROG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPROG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxyprogesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 588, + "assayComponentName": "CEETOX_H295R_OHPROG", + "assayComponentDesc": "CEETOX_H295R_OHPROG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxyprogesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 897, + "assayComponentEndpointName": "CEETOX_H295R_ANDR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ANDR was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ANDR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Androstenedione", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 589, + "assayComponentName": "CEETOX_H295R_ANDR", + "assayComponentDesc": "CEETOX_H295R_ANDR is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Androstenedione", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 899, + "assayComponentEndpointName": "CEETOX_H295R_CORTIC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTIC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTIC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Corticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 590, + "assayComponentName": "CEETOX_H295R_CORTIC", + "assayComponentDesc": "CEETOX_H295R_CORTIC is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Corticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 901, + "assayComponentEndpointName": "CEETOX_H295R_CORTISOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTISOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Cortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 591, + "assayComponentName": "CEETOX_H295R_CORTISOL", + "assayComponentDesc": "CEETOX_H295R_CORTISOL is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Cortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 905, + "assayComponentEndpointName": "CEETOX_H295R_DOC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_DOC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_DOC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycorticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 593, + "assayComponentName": "CEETOX_H295R_DOC", + "assayComponentDesc": "CEETOX_H295R_DOC is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycorticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 907, + "assayComponentEndpointName": "CEETOX_H295R_ESTRADIOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRADIOL was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRADIOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estradiol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 594, + "assayComponentName": "CEETOX_H295R_ESTRADIOL", + "assayComponentDesc": "CEETOX_H295R_ESTRADIOL is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estradiol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 909, + "assayComponentEndpointName": "CEETOX_H295R_ESTRONE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRONE was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRONE, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estrone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estrone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 595, + "assayComponentName": "CEETOX_H295R_ESTRONE", + "assayComponentDesc": "CEETOX_H295R_ESTRONE is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estrone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 913, + "assayComponentEndpointName": "CEETOX_H295R_PROG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_PROG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_PROG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Progesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 597, + "assayComponentName": "CEETOX_H295R_PROG", + "assayComponentDesc": "CEETOX_H295R_PROG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Progesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 915, + "assayComponentEndpointName": "CEETOX_H295R_TESTO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_TESTO was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_TESTO, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 598, + "assayComponentName": "CEETOX_H295R_TESTO", + "assayComponentDesc": "CEETOX_H295R_TESTO is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Testosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 916, + "assayComponentEndpointName": "LTEA_HepaRG_ABCB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 599, + "assayComponentName": "LTEA_HepaRG_ABCB1", + "assayComponentDesc": "LTEA_HepaRG_ABCB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 918, + "assayComponentEndpointName": "LTEA_HepaRG_ABCB11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCB11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 600, + "assayComponentName": "LTEA_HepaRG_ABCB11", + "assayComponentDesc": "LTEA_HepaRG_ABCB11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 920, + "assayComponentEndpointName": "LTEA_HepaRG_ABCC2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCC2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 601, + "assayComponentName": "LTEA_HepaRG_ABCC2", + "assayComponentDesc": "LTEA_HepaRG_ABCC2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 69, + "geneName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 2", + "description": null, + "geneSymbol": "ABCC2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1244, + "officialSymbol": "ABCC2", + "officialFullName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 2", + "uniprotAccessionNumber": "Q92887" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 922, + "assayComponentEndpointName": "LTEA_HepaRG_ABCC3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCC3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 602, + "assayComponentName": "LTEA_HepaRG_ABCC3", + "assayComponentDesc": "LTEA_HepaRG_ABCC3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 347, + "geneName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 3", + "description": null, + "geneSymbol": "ABCC3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8714, + "officialSymbol": "ABCC3", + "officialFullName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 3", + "uniprotAccessionNumber": "O15438" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 924, + "assayComponentEndpointName": "LTEA_HepaRG_ABCG2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCG2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCG2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 603, + "assayComponentName": "LTEA_HepaRG_ABCG2", + "assayComponentDesc": "LTEA_HepaRG_ABCG2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 926, + "assayComponentEndpointName": "LTEA_HepaRG_ACLY", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ACLY was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACLY, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 604, + "assayComponentName": "LTEA_HepaRG_ACLY", + "assayComponentDesc": "LTEA_HepaRG_ACLY is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 3, + "geneName": "ATP citrate lyase", + "description": null, + "geneSymbol": "ACLY", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 47, + "officialSymbol": "ACLY", + "officialFullName": "ATP citrate lyase", + "uniprotAccessionNumber": "P53396" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 928, + "assayComponentEndpointName": "LTEA_HepaRG_ACOX1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ACOX1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACOX1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 605, + "assayComponentName": "LTEA_HepaRG_ACOX1", + "assayComponentDesc": "LTEA_HepaRG_ACOX1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 4, + "geneName": "acyl-CoA oxidase 1, palmitoyl", + "description": null, + "geneSymbol": "ACOX1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51, + "officialSymbol": "ACOX1", + "officialFullName": "acyl-CoA oxidase 1, palmitoyl", + "uniprotAccessionNumber": "Q15067" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 930, + "assayComponentEndpointName": "LTEA_HepaRG_ADK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ADK was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ADK, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 606, + "assayComponentName": "LTEA_HepaRG_ADK", + "assayComponentDesc": "LTEA_HepaRG_ADK is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 9, + "geneName": "adenosine kinase", + "description": null, + "geneSymbol": "ADK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 132, + "officialSymbol": "ADK", + "officialFullName": "adenosine kinase", + "uniprotAccessionNumber": "P55263" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 932, + "assayComponentEndpointName": "LTEA_HepaRG_AFP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_AFP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_AFP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is assay control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "assay control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 607, + "assayComponentName": "LTEA_HepaRG_AFP", + "assayComponentDesc": "LTEA_HepaRG_AFP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Undifferentiated hepatocyte.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 18, + "geneName": "alpha-fetoprotein", + "description": null, + "geneSymbol": "AFP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 174, + "officialSymbol": "AFP", + "officialFullName": "alpha-fetoprotein", + "uniprotAccessionNumber": "P02771" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 204, + "assayComponentEndpointName": "BSK_BE3C_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3CA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 143, + "assayComponentName": "BSK_BE3C_uPA", + "assayComponentDesc": "BSK_BE3CA is an assay component measured in the BSK_BE3C assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 206, + "assayComponentEndpointName": "BSK_BE3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 144, + "assayComponentName": "BSK_BE3C_uPAR", + "assayComponentDesc": "BSK_BE3CAR is an assay component measured in the BSK_BE3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 208, + "assayComponentEndpointName": "BSK_CASM3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 145, + "assayComponentName": "BSK_CASM3C_HLADR", + "assayComponentDesc": "BSK_CASM3C_HLADR is an assay component measured in the BSK_CASM3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 210, + "assayComponentEndpointName": "BSK_CASM3C_IL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_IL6 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 146, + "assayComponentName": "BSK_CASM3C_IL6", + "assayComponentDesc": "BSK_CASM3C_IL6 is an assay component measured in the BSK_CASM3C assay. It measures IL-6 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-6 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 936, + "assayComponentEndpointName": "LTEA_HepaRG_APOA5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_APOA5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_APOA5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the apolipoprotein intended target family, where the subfamily is Steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "apolipoprotein", + "intendedTargetFamilySub": "Steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 609, + "assayComponentName": "LTEA_HepaRG_APOA5", + "assayComponentDesc": "LTEA_HepaRG_APOA5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 443, + "geneName": "apolipoprotein A-V", + "description": null, + "geneSymbol": "APOA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 116519, + "officialSymbol": "APOA5", + "officialFullName": "apolipoprotein A-V", + "uniprotAccessionNumber": "Q6Q788" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 938, + "assayComponentEndpointName": "LTEA_HepaRG_BAD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BAD was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAD, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 610, + "assayComponentName": "LTEA_HepaRG_BAD", + "assayComponentDesc": "LTEA_HepaRG_BAD is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 30, + "geneName": "BCL2-associated agonist of cell death", + "description": null, + "geneSymbol": "BAD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 572, + "officialSymbol": "BAD", + "officialFullName": "BCL2-associated agonist of cell death", + "uniprotAccessionNumber": "Q92934" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 940, + "assayComponentEndpointName": "LTEA_HepaRG_BAX", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BAX was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAX, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 611, + "assayComponentName": "LTEA_HepaRG_BAX", + "assayComponentDesc": "LTEA_HepaRG_BAX is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 31, + "geneName": "BCL2-associated X protein", + "description": null, + "geneSymbol": "BAX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 581, + "officialSymbol": "BAX", + "officialFullName": "BCL2-associated X protein", + "uniprotAccessionNumber": "Q07812" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 942, + "assayComponentEndpointName": "LTEA_HepaRG_BCL2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BCL2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 612, + "assayComponentName": "LTEA_HepaRG_BCL2", + "assayComponentDesc": "LTEA_HepaRG_BCL2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 34, + "geneName": "B-cell CLL/lymphoma 2", + "description": null, + "geneSymbol": "BCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 596, + "officialSymbol": "BCL2", + "officialFullName": "B-cell CLL/lymphoma 2", + "uniprotAccessionNumber": "P10415" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 944, + "assayComponentEndpointName": "LTEA_HepaRG_BCL2L11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BCL2L11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2L11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 613, + "assayComponentName": "LTEA_HepaRG_BCL2L11", + "assayComponentDesc": "LTEA_HepaRG_BCL2L11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 362, + "geneName": "BCL2-like 11 (apoptosis facilitator)", + "description": null, + "geneSymbol": "BCL2L11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10018, + "officialSymbol": "BCL2L11", + "officialFullName": "BCL2-like 11 (apoptosis facilitator)", + "uniprotAccessionNumber": "O43521" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 946, + "assayComponentEndpointName": "LTEA_HepaRG_BID", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BID was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BID, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 614, + "assayComponentName": "LTEA_HepaRG_BID", + "assayComponentDesc": "LTEA_HepaRG_BID is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 35, + "geneName": "BH3 interacting domain death agonist", + "description": null, + "geneSymbol": "BID", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 637, + "officialSymbol": "BID", + "officialFullName": "BH3 interacting domain death agonist", + "uniprotAccessionNumber": "P55957" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 948, + "assayComponentEndpointName": "LTEA_HepaRG_CASP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CASP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 615, + "assayComponentName": "LTEA_HepaRG_CASP3", + "assayComponentDesc": "LTEA_HepaRG_CASP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 950, + "assayComponentEndpointName": "LTEA_HepaRG_CASP8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CASP8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 616, + "assayComponentName": "LTEA_HepaRG_CASP8", + "assayComponentDesc": "LTEA_HepaRG_CASP8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 44, + "geneName": "caspase 8, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 841, + "officialSymbol": "CASP8", + "officialFullName": "caspase 8, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q14790" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 952, + "assayComponentEndpointName": "LTEA_HepaRG_CAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CAT was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CAT, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the catalase intended target family, where the subfamily is oxidative stress.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "catalase", + "intendedTargetFamilySub": "oxidative stress", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 617, + "assayComponentName": "LTEA_HepaRG_CAT", + "assayComponentDesc": "LTEA_HepaRG_CAT is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 46, + "geneName": "catalase", + "description": null, + "geneSymbol": "CAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 847, + "officialSymbol": "CAT", + "officialFullName": "catalase", + "uniprotAccessionNumber": "P04040" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 954, + "assayComponentEndpointName": "LTEA_HepaRG_CCND1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CCND1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CCND1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 618, + "assayComponentName": "LTEA_HepaRG_CCND1", + "assayComponentDesc": "LTEA_HepaRG_CCND1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 33, + "geneName": "cyclin D1", + "description": null, + "geneSymbol": "CCND1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 595, + "officialSymbol": "CCND1", + "officialFullName": "cyclin D1", + "uniprotAccessionNumber": "P24385" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 956, + "assayComponentEndpointName": "LTEA_HepaRG_CCND2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CCND2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CCND2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 619, + "assayComponentName": "LTEA_HepaRG_CCND2", + "assayComponentDesc": "LTEA_HepaRG_CCND2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 47, + "geneName": "cyclin D2", + "description": null, + "geneSymbol": "CCND2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 894, + "officialSymbol": "CCND2", + "officialFullName": "cyclin D2", + "uniprotAccessionNumber": "P30279" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 958, + "assayComponentEndpointName": "LTEA_HepaRG_CDKN1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CDKN1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CDKN1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 620, + "assayComponentName": "LTEA_HepaRG_CDKN1A", + "assayComponentDesc": "LTEA_HepaRG_CDKN1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 57, + "geneName": "cyclin-dependent kinase inhibitor 1A (p21, Cip1)", + "description": null, + "geneSymbol": "CDKN1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1026, + "officialSymbol": "CDKN1A", + "officialFullName": "cyclin-dependent kinase inhibitor 1A (p21, Cip1)", + "uniprotAccessionNumber": "P38936" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 960, + "assayComponentEndpointName": "LTEA_HepaRG_CFLAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CFLAR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CFLAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 621, + "assayComponentName": "LTEA_HepaRG_CFLAR", + "assayComponentDesc": "LTEA_HepaRG_CFLAR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 348, + "geneName": "CASP8 and FADD-like apoptosis regulator", + "description": null, + "geneSymbol": "CFLAR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8837, + "officialSymbol": "CFLAR", + "officialFullName": "CASP8 and FADD-like apoptosis regulator", + "uniprotAccessionNumber": "O15519" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 962, + "assayComponentEndpointName": "LTEA_HepaRG_CYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 622, + "assayComponentName": "LTEA_HepaRG_CYP1A1", + "assayComponentDesc": "LTEA_HepaRG_CYP1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 964, + "assayComponentEndpointName": "LTEA_HepaRG_CYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP1A2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 623, + "assayComponentName": "LTEA_HepaRG_CYP1A2", + "assayComponentDesc": "LTEA_HepaRG_CYP1A2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 966, + "assayComponentEndpointName": "LTEA_HepaRG_CYP24A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP24A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP24A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 624, + "assayComponentName": "LTEA_HepaRG_CYP24A1", + "assayComponentDesc": "LTEA_HepaRG_CYP24A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 968, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2B6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2B6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 625, + "assayComponentName": "LTEA_HepaRG_CYP2B6", + "assayComponentDesc": "LTEA_HepaRG_CYP2B6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 970, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 626, + "assayComponentName": "LTEA_HepaRG_CYP2C19", + "assayComponentDesc": "LTEA_HepaRG_CYP2C19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 972, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 627, + "assayComponentName": "LTEA_HepaRG_CYP2C8", + "assayComponentDesc": "LTEA_HepaRG_CYP2C8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 974, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C9 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 628, + "assayComponentName": "LTEA_HepaRG_CYP2C9", + "assayComponentDesc": "LTEA_HepaRG_CYP2C9 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 976, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2E1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2E1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 629, + "assayComponentName": "LTEA_HepaRG_CYP2E1", + "assayComponentDesc": "LTEA_HepaRG_CYP2E1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 978, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 630, + "assayComponentName": "LTEA_HepaRG_CYP3A4", + "assayComponentDesc": "LTEA_HepaRG_CYP3A4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 980, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 631, + "assayComponentName": "LTEA_HepaRG_CYP3A5", + "assayComponentDesc": "LTEA_HepaRG_CYP3A5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 91, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "description": null, + "geneSymbol": "CYP3A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1577, + "officialSymbol": "CYP3A5", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "uniprotAccessionNumber": "P20815" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 982, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A7 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A7, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 632, + "assayComponentName": "LTEA_HepaRG_CYP3A7", + "assayComponentDesc": "LTEA_HepaRG_CYP3A7 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism/Undifferentiated hepatocyte.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 81, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 7", + "description": null, + "geneSymbol": "CYP3A7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1551, + "officialSymbol": "CYP3A7", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 7", + "uniprotAccessionNumber": "P24462" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 984, + "assayComponentEndpointName": "LTEA_HepaRG_CYP4A11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP4A11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 633, + "assayComponentName": "LTEA_HepaRG_CYP4A11", + "assayComponentDesc": "LTEA_HepaRG_CYP4A11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 92, + "geneName": "cytochrome P450, family 4, subfamily A, polypeptide 11", + "description": null, + "geneSymbol": "CYP4A11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1579, + "officialSymbol": "CYP4A11", + "officialFullName": "cytochrome P450, family 4, subfamily A, polypeptide 11", + "uniprotAccessionNumber": "Q02928" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 986, + "assayComponentEndpointName": "LTEA_HepaRG_CYP4A22", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP4A22 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A22, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 634, + "assayComponentName": "LTEA_HepaRG_CYP4A22", + "assayComponentDesc": "LTEA_HepaRG_CYP4A22 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 452, + "geneName": "cytochrome P450, family 4, subfamily A, polypeptide 22", + "description": null, + "geneSymbol": "CYP4A22", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 284541, + "officialSymbol": "CYP4A22", + "officialFullName": "cytochrome P450, family 4, subfamily A, polypeptide 22", + "uniprotAccessionNumber": "Q5TCH4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 988, + "assayComponentEndpointName": "LTEA_HepaRG_CYP7A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP7A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP7A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 635, + "assayComponentName": "LTEA_HepaRG_CYP7A1", + "assayComponentDesc": "LTEA_HepaRG_CYP7A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 93, + "geneName": "cytochrome P450, family 7, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP7A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1581, + "officialSymbol": "CYP7A1", + "officialFullName": "cytochrome P450, family 7, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P22680" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 990, + "assayComponentEndpointName": "LTEA_HepaRG_DDIT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_DDIT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_DDIT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 636, + "assayComponentName": "LTEA_HepaRG_DDIT3", + "assayComponentDesc": "LTEA_HepaRG_DDIT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 97, + "geneName": "DNA-damage-inducible transcript 3", + "description": null, + "geneSymbol": "DDIT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1649, + "officialSymbol": "DDIT3", + "officialFullName": "DNA-damage-inducible transcript 3", + "uniprotAccessionNumber": "P35638" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 992, + "assayComponentEndpointName": "LTEA_HepaRG_EGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "EGF-like domain", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 637, + "assayComponentName": "LTEA_HepaRG_EGF", + "assayComponentDesc": "LTEA_HepaRG_EGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 107, + "geneName": "epidermal growth factor", + "description": null, + "geneSymbol": "EGF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1950, + "officialSymbol": "EGF", + "officialFullName": "epidermal growth factor", + "uniprotAccessionNumber": "P01133" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 994, + "assayComponentEndpointName": "LTEA_HepaRG_EGR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EGR1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGR1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 638, + "assayComponentName": "LTEA_HepaRG_EGR1", + "assayComponentDesc": "LTEA_HepaRG_EGR1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 109, + "geneName": "early growth response 1", + "description": null, + "geneSymbol": "EGR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1958, + "officialSymbol": "EGR1", + "officialFullName": "early growth response 1", + "uniprotAccessionNumber": "P18146" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 996, + "assayComponentEndpointName": "LTEA_HepaRG_EZR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EZR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EZR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is Cellular remodeling.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "membrane protein", + "intendedTargetFamilySub": "Cellular remodeling", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 639, + "assayComponentName": "LTEA_HepaRG_EZR", + "assayComponentDesc": "LTEA_HepaRG_EZR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cellular remodeling.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 336, + "geneName": "ezrin", + "description": null, + "geneSymbol": "EZR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7430, + "officialSymbol": "EZR", + "officialFullName": "ezrin", + "uniprotAccessionNumber": "P15311" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 998, + "assayComponentEndpointName": "LTEA_HepaRG_FABP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FABP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FABP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is fatty acid carrier protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "fatty acid carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 640, + "assayComponentName": "LTEA_HepaRG_FABP1", + "assayComponentDesc": "LTEA_HepaRG_FABP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 124, + "geneName": "fatty acid binding protein 1, liver", + "description": null, + "geneSymbol": "FABP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2168, + "officialSymbol": "FABP1", + "officialFullName": "fatty acid binding protein 1, liver", + "uniprotAccessionNumber": "P07148" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1000, + "assayComponentEndpointName": "LTEA_HepaRG_FAS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FAS was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FAS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "TNF receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 641, + "assayComponentName": "LTEA_HepaRG_FAS", + "assayComponentDesc": "LTEA_HepaRG_FAS is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 26, + "geneName": "Fas cell surface death receptor", + "description": null, + "geneSymbol": "FAS", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 355, + "officialSymbol": "FAS", + "officialFullName": "Fas cell surface death receptor", + "uniprotAccessionNumber": "P25445" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1002, + "assayComponentEndpointName": "LTEA_HepaRG_FASN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FASN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FASN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is fatty acid synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "fatty acid synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 642, + "assayComponentName": "LTEA_HepaRG_FASN", + "assayComponentDesc": "LTEA_HepaRG_FASN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 125, + "geneName": "fatty acid synthase", + "description": null, + "geneSymbol": "FASN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2194, + "officialSymbol": "FASN", + "officialFullName": "fatty acid synthase", + "uniprotAccessionNumber": "P49327" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1004, + "assayComponentEndpointName": "LTEA_HepaRG_FMO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FMO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FMO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is dioxygenase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "dioxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 643, + "assayComponentName": "LTEA_HepaRG_FMO3", + "assayComponentDesc": "LTEA_HepaRG_FMO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 133, + "geneName": "flavin containing monooxygenase 3", + "description": null, + "geneSymbol": "FMO3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2328, + "officialSymbol": "FMO3", + "officialFullName": "flavin containing monooxygenase 3", + "uniprotAccessionNumber": "P31513" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1006, + "assayComponentEndpointName": "LTEA_HepaRG_FOXO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FOXO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 644, + "assayComponentName": "LTEA_HepaRG_FOXO1", + "assayComponentDesc": "LTEA_HepaRG_FOXO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 129, + "geneName": "forkhead box O1", + "description": null, + "geneSymbol": "FOXO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2308, + "officialSymbol": "FOXO1", + "officialFullName": "forkhead box O1", + "uniprotAccessionNumber": "Q12778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1008, + "assayComponentEndpointName": "LTEA_HepaRG_FOXO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FOXO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 645, + "assayComponentName": "LTEA_HepaRG_FOXO3", + "assayComponentDesc": "LTEA_HepaRG_FOXO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 130, + "geneName": "forkhead box O3", + "description": null, + "geneSymbol": "FOXO3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2309, + "officialSymbol": "FOXO3", + "officialFullName": "forkhead box O3", + "uniprotAccessionNumber": "O43524" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1010, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Oxidative Stress.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Oxidative Stress", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 646, + "assayComponentName": "LTEA_HepaRG_GADD45A", + "assayComponentDesc": "LTEA_HepaRG_GADD45A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 96, + "geneName": "growth arrest and DNA-damage-inducible, alpha", + "description": null, + "geneSymbol": "GADD45A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1647, + "officialSymbol": "GADD45A", + "officialFullName": "growth arrest and DNA-damage-inducible, alpha", + "uniprotAccessionNumber": "P24522" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1012, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45B was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45B, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "mutagenicity response", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 647, + "assayComponentName": "LTEA_HepaRG_GADD45B", + "assayComponentDesc": "LTEA_HepaRG_GADD45B is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 214, + "geneName": "growth arrest and DNA-damage-inducible, beta", + "description": null, + "geneSymbol": "GADD45B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4616, + "officialSymbol": "GADD45B", + "officialFullName": "growth arrest and DNA-damage-inducible, beta", + "uniprotAccessionNumber": "O75293" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 242, + "assayComponentEndpointName": "BSK_hDFCGF_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 162, + "assayComponentName": "BSK_hDFCGF_IP10", + "assayComponentDesc": "BSK_hDFCGF_IP10 is an assay component measured in the BSK_hDFCGF assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 244, + "assayComponentEndpointName": "BSK_hDFCGF_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 163, + "assayComponentName": "BSK_hDFCGF_MCSF", + "assayComponentDesc": "BSK_hDFCGF_MCSF is an assay component measured in the BSK_hDFCGF assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 246, + "assayComponentEndpointName": "BSK_hDFCGF_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 164, + "assayComponentName": "BSK_hDFCGF_MIG", + "assayComponentDesc": "BSK_hDFCGF_MIG is an assay component measured in the BSK_hDFCGF assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 248, + "assayComponentEndpointName": "BSK_hDFCGF_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 165, + "assayComponentName": "BSK_hDFCGF_MMP1", + "assayComponentDesc": "BSK_hDFCGF_MMP1 is an assay component measured in the BSK_hDFCGF assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 250, + "assayComponentEndpointName": "BSK_hDFCGF_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 166, + "assayComponentName": "BSK_hDFCGF_PAI1", + "assayComponentDesc": "BSK_hDFCGF_PAI1 is an assay component measured in the BSK_hDFCGF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 252, + "assayComponentEndpointName": "BSK_hDFCGF_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_hDFCGF_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 167, + "assayComponentName": "BSK_hDFCGF_Proliferation", + "assayComponentDesc": "BSK_hDFCGF_Proliferation is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 254, + "assayComponentEndpointName": "BSK_hDFCGF_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 168, + "assayComponentName": "BSK_hDFCGF_SRB", + "assayComponentDesc": "BSK_hDFCGF_SRB is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 256, + "assayComponentEndpointName": "BSK_hDFCGF_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 169, + "assayComponentName": "BSK_hDFCGF_TIMP1", + "assayComponentDesc": "BSK_hDFCGF_TIMP1 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-1 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:TIMP1 | GeneID:7076 | Uniprot_SwissProt_Accession:P01033].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 258, + "assayComponentEndpointName": "BSK_hDFCGF_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 170, + "assayComponentName": "BSK_hDFCGF_VCAM1", + "assayComponentDesc": "BSK_hDFCGF_VCAM1 is an assay component measured in the BSK_hDFCGF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 260, + "assayComponentEndpointName": "BSK_KF3CT_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 171, + "assayComponentName": "BSK_KF3CT_ICAM1", + "assayComponentDesc": "BSK_KF3CT_ICAM1 is an assay component measured in the BSK_KF3CT assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 262, + "assayComponentEndpointName": "BSK_KF3CT_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 172, + "assayComponentName": "BSK_KF3CT_IL1a", + "assayComponentDesc": "BSK_KF3CT_IL1a is an assay component measured in the BSK_KF3CT assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 264, + "assayComponentEndpointName": "BSK_KF3CT_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 173, + "assayComponentName": "BSK_KF3CT_IP10", + "assayComponentDesc": "BSK_KF3CT_IP10 is an assay component measured in the BSK_KF3CT assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 266, + "assayComponentEndpointName": "BSK_KF3CT_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 174, + "assayComponentName": "BSK_KF3CT_MCP1", + "assayComponentDesc": "BSK_KF3CT_MCP1 is an assay component measured in the BSK_KF3CT assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 268, + "assayComponentEndpointName": "BSK_KF3CT_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MMP9 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MMP9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 175, + "assayComponentName": "BSK_KF3CT_MMP9", + "assayComponentDesc": "BSK_KF3CT_MMP9 is an assay component measured in the BSK_KF3CT assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-9 antibody is used to tag and quantify the level of matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 270, + "assayComponentEndpointName": "BSK_KF3CT_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 176, + "assayComponentName": "BSK_KF3CT_SRB", + "assayComponentDesc": "BSK_KF3CT_SRB is an assay component measured in the BSK_KF3CT assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and TGFb.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 272, + "assayComponentEndpointName": "BSK_KF3CT_TGFb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 177, + "assayComponentName": "BSK_KF3CT_TGFb1", + "assayComponentDesc": "BSK_KF3CT_TGFb1 is an assay component measured in the BSK_KF3CT assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TGF-b1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 274, + "assayComponentEndpointName": "BSK_KF3CT_TIMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TIMP2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 178, + "assayComponentName": "BSK_KF3CT_TIMP2", + "assayComponentDesc": "BSK_KF3CT_TIMP2 is an assay component measured in the BSK_KF3CT assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-2 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TIMP2 | GeneID:7077 | Uniprot_SwissProt_Accession:Q96MC4].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 325, + "geneName": "TIMP metallopeptidase inhibitor 2", + "description": null, + "geneSymbol": "TIMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7077, + "officialSymbol": "TIMP2", + "officialFullName": "TIMP metallopeptidase inhibitor 2", + "uniprotAccessionNumber": "Q96MC4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 276, + "assayComponentEndpointName": "BSK_KF3CT_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CTA was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CTA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 179, + "assayComponentName": "BSK_KF3CT_uPA", + "assayComponentDesc": "BSK_KF3CTA is an assay component measured in the BSK_KF3CT assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 278, + "assayComponentEndpointName": "BSK_LPS_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 180, + "assayComponentName": "BSK_LPS_CD40", + "assayComponentDesc": "BSK_LPS_CD40 is an assay component measured in the BSK_LPS assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 280, + "assayComponentEndpointName": "BSK_LPS_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 181, + "assayComponentName": "BSK_LPS_Eselectin", + "assayComponentDesc": "BSK_LPS_Eselectin is an assay component measured in the BSK_LPS assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 282, + "assayComponentEndpointName": "BSK_LPS_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 182, + "assayComponentName": "BSK_LPS_IL1a", + "assayComponentDesc": "BSK_LPS_IL1a is an assay component measured in the BSK_LPS assay. It measures IL-a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 284, + "assayComponentEndpointName": "BSK_LPS_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 183, + "assayComponentName": "BSK_LPS_IL8", + "assayComponentDesc": "BSK_LPS_IL8 is an assay component measured in the BSK_LPS assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 286, + "assayComponentEndpointName": "BSK_LPS_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 184, + "assayComponentName": "BSK_LPS_MCP1", + "assayComponentDesc": "BSK_LPS_MCP1 is an assay component measured in the BSK_LPS assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 288, + "assayComponentEndpointName": "BSK_LPS_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 185, + "assayComponentName": "BSK_LPS_MCSF", + "assayComponentDesc": "BSK_LPS_MCSF is an assay component measured in the BSK_LPS assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 290, + "assayComponentEndpointName": "BSK_LPS_PGE2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_PGE2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_PGE2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 186, + "assayComponentName": "BSK_LPS_PGE2", + "assayComponentDesc": "BSK_LPS_PGE2 is an assay component measured in the BSK_LPS assay. It measures PGE2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PGE2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 264, + "geneName": "prostaglandin E receptor 2 (subtype EP2), 53kDa", + "description": null, + "geneSymbol": "PTGER2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5732, + "officialSymbol": "PTGER2", + "officialFullName": "prostaglandin E receptor 2 (subtype EP2), 53kDa", + "uniprotAccessionNumber": "P43116" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 292, + "assayComponentEndpointName": "BSK_LPS_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 187, + "assayComponentName": "BSK_LPS_SRB", + "assayComponentDesc": "BSK_LPS_SRB is an assay component measured in the BSK_LPS assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 294, + "assayComponentEndpointName": "BSK_LPS_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 188, + "assayComponentName": "BSK_LPS_TissueFactor", + "assayComponentDesc": "BSK_LPS_TissueFactor is an assay component measured in the BSK_LPS assay. It measures CD142 Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD142 Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 296, + "assayComponentEndpointName": "BSK_LPS_TNFa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_TNFa was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TNFa, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 189, + "assayComponentName": "BSK_LPS_TNFa", + "assayComponentDesc": "BSK_LPS_TNFa is an assay component measured in the BSK_LPS assay. It measures TNF-a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TNF-a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 327, + "geneName": "tumor necrosis factor", + "description": null, + "geneSymbol": "TNF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7124, + "officialSymbol": "TNF", + "officialFullName": "tumor necrosis factor", + "uniprotAccessionNumber": "P01375" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 298, + "assayComponentEndpointName": "BSK_LPS_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 190, + "assayComponentName": "BSK_LPS_VCAM1", + "assayComponentDesc": "BSK_LPS_VCAM1 is an assay component measured in the BSK_LPS assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 300, + "assayComponentEndpointName": "BSK_SAg_CD38", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD38 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD38, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is other cytokine.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "other cytokine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 191, + "assayComponentName": "BSK_SAg_CD38", + "assayComponentDesc": "BSK_SAg_CD38 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD38 antibody is used to tag and quantify the level of CD38 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD38 | GeneID:952 | Uniprot_SwissProt_Accession:P28907].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD38 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 48, + "geneName": "CD38 molecule", + "description": null, + "geneSymbol": "CD38", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 952, + "officialSymbol": "CD38", + "officialFullName": "CD38 molecule", + "uniprotAccessionNumber": "P28907" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 302, + "assayComponentEndpointName": "BSK_SAg_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 192, + "assayComponentName": "BSK_SAg_CD40", + "assayComponentDesc": "BSK_SAg_CD40 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 304, + "assayComponentEndpointName": "BSK_SAg_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD69 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD69, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 193, + "assayComponentName": "BSK_SAg_CD69", + "assayComponentDesc": "BSK_SAg_CD69 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD69 antibody is used to tag and quantify the level of CD69 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD69 | GeneID:969 | Uniprot_SwissProt_Accession:Q07108].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 306, + "assayComponentEndpointName": "BSK_SAg_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 194, + "assayComponentName": "BSK_SAg_Eselectin", + "assayComponentDesc": "BSK_SAg_Eselectin is an assay component measured in the BSK_SAg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 308, + "assayComponentEndpointName": "BSK_SAg_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 195, + "assayComponentName": "BSK_SAg_IL8", + "assayComponentDesc": "BSK_SAg_IL8 is an assay component measured in the BSK_SAg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 310, + "assayComponentEndpointName": "BSK_SAg_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 196, + "assayComponentName": "BSK_SAg_MCP1", + "assayComponentDesc": "BSK_SAg_MCP1 is an assay component measured in the BSK_SAg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 312, + "assayComponentEndpointName": "BSK_SAg_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 197, + "assayComponentName": "BSK_SAg_MIG", + "assayComponentDesc": "BSK_SAg_MIG is an assay component measured in the BSK_SAg assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 314, + "assayComponentEndpointName": "BSK_SAg_PBMCCytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_PBMCCytotoxicity, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 198, + "assayComponentName": "BSK_SAg_PBMCCytotoxicity", + "assayComponentDesc": "BSK_SAg_PBMCCytotoxicity is an assay component measured in the BSK_SAg assay. It measures Alamar blue related to cell death using Alamar Blue Reduction technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar Blue Reduction", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Alamar blue", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 316, + "assayComponentEndpointName": "BSK_SAg_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_SAg_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 199, + "assayComponentName": "BSK_SAg_Proliferation", + "assayComponentDesc": "BSK_SAg_Proliferation is an assay component in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology. ", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 318, + "assayComponentEndpointName": "BSK_SAg_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 200, + "assayComponentName": "BSK_SAg_SRB", + "assayComponentDesc": "BSK_SAg_SRB is an assay component measured in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 319, + "assayComponentEndpointName": "NVS_ADME_hCYP19A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP19A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 201, + "assayComponentName": "NVS_ADME_hCYP19A1", + "assayComponentDesc": "NVS_ADME_hCYP19A1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP19A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBOMF+ NADPH -> fluorescein + NADP+] involving the key substrate [Di(benzyloxymethoxy)fluorescein (DBOMF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Di(benzyloxymethoxy)fluorescein (DBOMF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 15, + "assayName": "NVS_ADME_hCYP19A1", + "assayDesc": "NVS_ADME_hCYP19A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 321, + "assayComponentEndpointName": "NVS_ADME_hCYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole;Ketanserin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 202, + "assayComponentName": "NVS_ADME_hCYP1A1", + "assayComponentDesc": "NVS_ADME_hCYP1A1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 1 [GeneSymbol:CYP1A1 | GeneID:1543 | Uniprot_SwissProt_Accession:P04798].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 16, + "assayName": "NVS_ADME_hCYP1A1", + "assayDesc": "NVS_ADME_hCYP1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 323, + "assayComponentEndpointName": "NVS_ADME_hCYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Furafylline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 203, + "assayComponentName": "NVS_ADME_hCYP1A2", + "assayComponentDesc": "NVS_ADME_hCYP1A2 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 2 [GeneSymbol:CYP1A2 | GeneID:1544 | Uniprot_SwissProt_Accession:P05177].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 17, + "assayName": "NVS_ADME_hCYP1A2", + "assayDesc": "NVS_ADME_hCYP1A2 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 325, + "assayComponentEndpointName": "NVS_ADME_hCYP1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alpha-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 204, + "assayComponentName": "NVS_ADME_hCYP1B1", + "assayComponentDesc": "NVS_ADME_hCYP1B1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily B, polypeptide 1 [GeneSymbol:CYP1B1 | GeneID:1545 | Uniprot_SwissProt_Accession:Q16678].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 18, + "assayName": "NVS_ADME_hCYP1B1", + "assayDesc": "NVS_ADME_hCYP1B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 79, + "geneName": "cytochrome P450, family 1, subfamily B, polypeptide 1", + "description": null, + "geneSymbol": "CYP1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1545, + "officialSymbol": "CYP1B1", + "officialFullName": "cytochrome P450, family 1, subfamily B, polypeptide 1", + "uniprotAccessionNumber": "Q16678" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 327, + "assayComponentEndpointName": "NVS_ADME_hCYP2A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 205, + "assayComponentName": "NVS_ADME_hCYP2A6", + "assayComponentDesc": "NVS_ADME_hCYP2A6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2A6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Coumarin + NADPH -> 7-Hydroxycoumarin + NADP+] involving the key substrate [Coumarin] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily A, polypeptide 6 [GeneSymbol:CYP2A6 | GeneID:1548 | Uniprot_SwissProt_Accession:P11509].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Coumarin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 19, + "assayName": "NVS_ADME_hCYP2A6", + "assayDesc": "NVS_ADME_hCYP2A6 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 80, + "geneName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "description": null, + "geneSymbol": "CYP2A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1548, + "officialSymbol": "CYP2A6", + "officialFullName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "uniprotAccessionNumber": "P11509" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 329, + "assayComponentEndpointName": "NVS_ADME_hCYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 206, + "assayComponentName": "NVS_ADME_hCYP2B6", + "assayComponentDesc": "NVS_ADME_hCYP2B6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2B6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:EFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-ethoxy-4-trifluoromethylcoumarin (EFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily B, polypeptide 6 [GeneSymbol:CYP2B6 | GeneID:1555 | Uniprot_SwissProt_Accession:P20813].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-4-trifluoromethylcoumarin (EFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 20, + "assayName": "NVS_ADME_hCYP2B6", + "assayDesc": "NVS_ADME_hCYP2B6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 331, + "assayComponentEndpointName": "NVS_ADME_hCYP2C18", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 207, + "assayComponentName": "NVS_ADME_hCYP2C18", + "assayComponentDesc": "NVS_ADME_hCYP2C18 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C18 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 18 [GeneSymbol:CYP2C18 | GeneID:1562 | Uniprot_SwissProt_Accession:P33260].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 21, + "assayName": "NVS_ADME_hCYP2C18", + "assayDesc": "NVS_ADME_hCYP2C18 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 86, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 18", + "description": null, + "geneSymbol": "CYP2C18", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1562, + "officialSymbol": "CYP2C18", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 18", + "uniprotAccessionNumber": "P33260" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 333, + "assayComponentEndpointName": "NVS_ADME_hCYP2C19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 208, + "assayComponentName": "NVS_ADME_hCYP2C19", + "assayComponentDesc": "NVS_ADME_hCYP2C19 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C19 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 19 [GeneSymbol:CYP2C19 | GeneID:1557 | Uniprot_SwissProt_Accession:P33261].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 22, + "assayName": "NVS_ADME_hCYP2C19", + "assayDesc": "NVS_ADME_hCYP2C19 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 335, + "assayComponentEndpointName": "NVS_ADME_hCYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "quercetin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 209, + "assayComponentName": "NVS_ADME_hCYP2C8", + "assayComponentDesc": "NVS_ADME_hCYP2C8 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C8 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBOMF+ NADPH -> fluorescein + NADP+] involving the key substrate [Di(benzyloxymethoxy)fluorescein (DBOMF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 8 [GeneSymbol:CYP2C8 | GeneID:1558 | Uniprot_SwissProt_Accession:P10632].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Di(benzyloxymethoxy)fluorescein (DBOMF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 23, + "assayName": "NVS_ADME_hCYP2C8", + "assayDesc": "NVS_ADME_hCYP2C8 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 337, + "assayComponentEndpointName": "NVS_ADME_hCYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Sulfaphenazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 210, + "assayComponentName": "NVS_ADME_hCYP2C9", + "assayComponentDesc": "NVS_ADME_hCYP2C9 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 9 [GeneSymbol:CYP2C9 | GeneID:1559 | Uniprot_SwissProt_Accession:P11712].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 24, + "assayName": "NVS_ADME_hCYP2C9", + "assayDesc": "NVS_ADME_hCYP2C9 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 339, + "assayComponentEndpointName": "NVS_ADME_hCYP2D6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "quinidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 211, + "assayComponentName": "NVS_ADME_hCYP2D6", + "assayComponentDesc": "NVS_ADME_hCYP2D6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2D6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:AMMC + NADPH --> AHMC + NADP+] involving the key substrate [3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily D, polypeptide 6 [GeneSymbol:CYP2D6 | GeneID:1565 | Uniprot_SwissProt_Accession:P10635].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 25, + "assayName": "NVS_ADME_hCYP2D6", + "assayDesc": "NVS_ADME_hCYP2D6 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 87, + "geneName": "cytochrome P450, family 2, subfamily D, polypeptide 6", + "description": null, + "geneSymbol": "CYP2D6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1565, + "officialSymbol": "CYP2D6", + "officialFullName": "cytochrome P450, family 2, subfamily D, polypeptide 6", + "uniprotAccessionNumber": "P10635" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 341, + "assayComponentEndpointName": "NVS_ADME_hCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2E1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "chlormethiazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 212, + "assayComponentName": "NVS_ADME_hCYP2E1", + "assayComponentDesc": "NVS_ADME_hCYP2E1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2E1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily E, polypeptide 1 [GeneSymbol:CYP2E1 | GeneID:1571 | Uniprot_SwissProt_Accession:P05181].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 26, + "assayName": "NVS_ADME_hCYP2E1", + "assayDesc": "NVS_ADME_hCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 343, + "assayComponentEndpointName": "NVS_ADME_hCYP2J2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 213, + "assayComponentName": "NVS_ADME_hCYP2J2", + "assayComponentDesc": "NVS_ADME_hCYP2J2 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2J2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily J, polypeptide 2 [GeneSymbol:CYP2J2 | GeneID:1573 | Uniprot_SwissProt_Accession:P51589].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 27, + "assayName": "NVS_ADME_hCYP2J2", + "assayDesc": "NVS_ADME_hCYP2J2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 89, + "geneName": "cytochrome P450, family 2, subfamily J, polypeptide 2", + "description": null, + "geneSymbol": "CYP2J2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1573, + "officialSymbol": "CYP2J2", + "officialFullName": "cytochrome P450, family 2, subfamily J, polypeptide 2", + "uniprotAccessionNumber": "P51589" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 345, + "assayComponentEndpointName": "NVS_ADME_hCYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 214, + "assayComponentName": "NVS_ADME_hCYP3A4", + "assayComponentDesc": "NVS_ADME_hCYP3A4 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP3A4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBF + NADPH --> fluorescein + NADP+] involving the key substrate [Dibenzyl fluorescein (DBF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 3, subfamily A, polypeptide 4 [GeneSymbol:CYP3A4 | GeneID:1576 | Uniprot_SwissProt_Accession:P08684].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Dibenzyl fluorescein (DBF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 28, + "assayName": "NVS_ADME_hCYP3A4", + "assayDesc": "NVS_ADME_hCYP3A4 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 347, + "assayComponentEndpointName": "NVS_ADME_hCYP3A5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP3A5, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 215, + "assayComponentName": "NVS_ADME_hCYP3A5", + "assayComponentDesc": "NVS_ADME_hCYP3A5 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP3A5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 3, subfamily A, polypeptide 5 [GeneSymbol:CYP3A5 | GeneID:1577 | Uniprot_SwissProt_Accession:P20815].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 29, + "assayName": "NVS_ADME_hCYP3A5", + "assayDesc": "NVS_ADME_hCYP3A5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 91, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "description": null, + "geneSymbol": "CYP3A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1577, + "officialSymbol": "CYP3A5", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "uniprotAccessionNumber": "P20815" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 349, + "assayComponentEndpointName": "NVS_ADME_hCYP4F12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP4F12, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 216, + "assayComponentName": "NVS_ADME_hCYP4F12", + "assayComponentDesc": "NVS_ADME_hCYP4F12 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP4F12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 4, subfamily F, polypeptide 12 [GeneSymbol:CYP4F12 | GeneID:66002 | Uniprot_SwissProt_Accession:Q9HCS2].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 30, + "assayName": "NVS_ADME_hCYP4F12", + "assayDesc": "NVS_ADME_hCYP4F12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 434, + "geneName": "cytochrome P450, family 4, subfamily F, polypeptide 12", + "description": null, + "geneSymbol": "CYP4F12", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 66002, + "officialSymbol": "CYP4F12", + "officialFullName": "cytochrome P450, family 4, subfamily F, polypeptide 12", + "uniprotAccessionNumber": "Q9HCS2" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 351, + "assayComponentEndpointName": "NVS_ADME_rCYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ellipticine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 217, + "assayComponentName": "NVS_ADME_rCYP1A1", + "assayComponentDesc": "NVS_ADME_rCYP1A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 1, subfamily a, polypeptide 1 [GeneSymbol:Cyp1a1 | GeneID:24296 | Uniprot_SwissProt_Accession:P00185].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 31, + "assayName": "NVS_ADME_rCYP1A1", + "assayDesc": "NVS_ADME_rCYP1A1 is a biochemical, single-readout assay that uses extracted gene-proteins from baculovirus-insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "baculovirus-insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 384, + "geneName": "cytochrome P450, family 1, subfamily a, polypeptide 1", + "description": null, + "geneSymbol": "Cyp1a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24296, + "officialSymbol": "Cyp1a1", + "officialFullName": "cytochrome P450, family 1, subfamily a, polypeptide 1", + "uniprotAccessionNumber": "P00185" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 353, + "assayComponentEndpointName": "NVS_ADME_rCYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP1A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alpha-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 218, + "assayComponentName": "NVS_ADME_rCYP1A2", + "assayComponentDesc": "NVS_ADME_rCYP1A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP1A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 1, subfamily a, polypeptide 2 [GeneSymbol:Cyp1a2 | GeneID:24297 | Uniprot_SwissProt_Accession:P04799].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 32, + "assayName": "NVS_ADME_rCYP1A2", + "assayDesc": "NVS_ADME_rCYP1A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 385, + "geneName": "cytochrome P450, family 1, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp1a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24297, + "officialSymbol": "Cyp1a2", + "officialFullName": "cytochrome P450, family 1, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P04799" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 355, + "assayComponentEndpointName": "NVS_ADME_rCYP2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 219, + "assayComponentName": "NVS_ADME_rCYP2A1", + "assayComponentDesc": "NVS_ADME_rCYP2A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMCC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily a, polypeptide 1 [GeneSymbol:Cyp2a1 | GeneID:24894 | Uniprot_SwissProt_Accession:P11711].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 33, + "assayName": "NVS_ADME_rCYP2A1", + "assayDesc": "NVS_ADME_rCYP2A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 396, + "geneName": "cytochrome P450, family 2, subfamily a, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24894, + "officialSymbol": "Cyp2a1", + "officialFullName": "cytochrome P450, family 2, subfamily a, polypeptide 1", + "uniprotAccessionNumber": "P11711" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 357, + "assayComponentEndpointName": "NVS_ADME_rCYP2A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole;Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 220, + "assayComponentName": "NVS_ADME_rCYP2A2", + "assayComponentDesc": "NVS_ADME_rCYP2A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily a, polypeptide 2 [GeneSymbol:Cyp2a2 | GeneID:24895 | Uniprot_SwissProt_Accession:P15149].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 34, + "assayName": "NVS_ADME_rCYP2A2", + "assayDesc": "NVS_ADME_rCYP2A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.2 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.2, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 397, + "geneName": "cytochrome P450, family 2, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp2a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24895, + "officialSymbol": "Cyp2a2", + "officialFullName": "cytochrome P450, family 2, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P15149" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 359, + "assayComponentEndpointName": "NVS_ADME_rCYP2B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 221, + "assayComponentName": "NVS_ADME_rCYP2B1", + "assayComponentDesc": "NVS_ADME_rCYP2B1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily b, polypeptide 1 [GeneSymbol:Cyp2b1 | GeneID:24300 | Uniprot_SwissProt_Accession:P00176].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 35, + "assayName": "NVS_ADME_rCYP2B1", + "assayDesc": "NVS_ADME_rCYP2B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 386, + "geneName": "cytochrome P450, family 2, subfamily b, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2b1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24300, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P00176" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 361, + "assayComponentEndpointName": "NVS_ADME_rCYP2C11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 222, + "assayComponentName": "NVS_ADME_rCYP2C11", + "assayComponentDesc": "NVS_ADME_rCYP2C11 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, subfamily 2, polypeptide 11 [GeneSymbol:Cyp2c11 | GeneID:29277 | Uniprot_SwissProt_Accession:P08683].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 36, + "assayName": "NVS_ADME_rCYP2C11", + "assayDesc": "NVS_ADME_rCYP2C11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 418, + "geneName": "cytochrome P450, subfamily 2, polypeptide 11", + "description": null, + "geneSymbol": "Cyp2c11", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29277, + "officialSymbol": "Cyp2c11", + "officialFullName": "cytochrome P450, subfamily 2, polypeptide 11", + "uniprotAccessionNumber": "P08683" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 363, + "assayComponentEndpointName": "NVS_ADME_rCYP2C12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C12, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 223, + "assayComponentName": "NVS_ADME_rCYP2C12", + "assayComponentDesc": "NVS_ADME_rCYP2C12 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMCC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily c, polypeptide 12 [GeneSymbol:Cyp2c12 | GeneID:25011 | Uniprot_SwissProt_Accession:P11510].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 37, + "assayName": "NVS_ADME_rCYP2C12", + "assayDesc": "NVS_ADME_rCYP2C12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 399, + "geneName": "cytochrome P450, family 2, subfamily c, polypeptide 12", + "description": null, + "geneSymbol": "Cyp2c12", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25011, + "officialSymbol": "Cyp2c12", + "officialFullName": "cytochrome P450, family 2, subfamily c, polypeptide 12", + "uniprotAccessionNumber": "P11510" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 365, + "assayComponentEndpointName": "NVS_ADME_rCYP2C13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 224, + "assayComponentName": "NVS_ADME_rCYP2C13", + "assayComponentDesc": "NVS_ADME_rCYP2C13 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily c, polypeptide 13 [GeneSymbol:Cyp2c13 | GeneID:171521 | Uniprot_SwissProt_Accession:P20814].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 38, + "assayName": "NVS_ADME_rCYP2C13", + "assayDesc": "NVS_ADME_rCYP2C13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 445, + "geneName": "cytochrome P450, family 2, subfamily c, polypeptide 13", + "description": "provisional", + "geneSymbol": "Cyp2c13", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 171521, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P20814" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7744763", + "pmid": 7744763, + "title": "Characterization of orphan nuclear receptor binding elements in sex-differentiated members of the CYP2C gene family expressed in rat liver", + "author": "Ström A, Westin S, Eguchi H, Gustafsson JA, Mode A", + "citation": "Ström A, Westin S, Eguchi H, Gustafsson JA, Mode A. Characterization of orphan nuclear receptor binding elements in sex-differentiated members of the CYP2C gene family expressed in rat liver. J Biol Chem. 1995 May 12;270(19):11276-81. PubMed PMID: 7744763.", + "otherId": "0", + "citationId": 146, + "otherSource": "" + } + }, + { + "aeid": 367, + "assayComponentEndpointName": "NVS_ADME_rCYP2C6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 225, + "assayComponentName": "NVS_ADME_rCYP2C6", + "assayComponentDesc": "NVS_ADME_rCYP2C6 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 [GeneSymbol:Cyp2c6v1 | GeneID:293989 | Uniprot_SwissProt_Accession:P05178].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 39, + "assayName": "NVS_ADME_rCYP2C6", + "assayDesc": "NVS_ADME_rCYP2C6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 453, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1", + "description": null, + "geneSymbol": "Cyp2c6v1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 293989, + "officialSymbol": "Cyp2c6v1", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1", + "uniprotAccessionNumber": "P05178" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 369, + "assayComponentEndpointName": "NVS_ADME_rCYP2D1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 226, + "assayComponentName": "NVS_ADME_rCYP2D1", + "assayComponentDesc": "NVS_ADME_rCYP2D1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2D1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBF + NADPH --> fluorescein + NADP+] involving the key substrate [Dibenzyl Fluorescein (DBF)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily d, polypeptide 1 [GeneSymbol:Cyp2d1 | GeneID:266684 | Uniprot_SwissProt_Accession:P10633].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Dibenzyl Fluorescein (DBF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 40, + "assayName": "NVS_ADME_rCYP2D1", + "assayDesc": "NVS_ADME_rCYP2D1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 448, + "geneName": "cytochrome P450, family 2, subfamily d, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2d1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 266684, + "officialSymbol": "Cyp2d1", + "officialFullName": "cytochrome P450, family 2, subfamily d, polypeptide 1", + "uniprotAccessionNumber": "P10633" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 371, + "assayComponentEndpointName": "NVS_ADME_rCYP2D2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 227, + "assayComponentName": "NVS_ADME_rCYP2D2", + "assayComponentDesc": "NVS_ADME_rCYP2D2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2D2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:AMMC + NADPH --> AHMC + NADP+] involving the key substrate [3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily d, polypeptide 2 [GeneSymbol:Cyp2d2 | GeneID:25053 | Uniprot_SwissProt_Accession:P10634].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 41, + "assayName": "NVS_ADME_rCYP2D2", + "assayDesc": "NVS_ADME_rCYP2D2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 401, + "geneName": "cytochrome P450, family 2, subfamily d, polypeptide 2", + "description": null, + "geneSymbol": "Cyp2d2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25053, + "officialSymbol": "Cyp2d2", + "officialFullName": "cytochrome P450, family 2, subfamily d, polypeptide 2", + "uniprotAccessionNumber": "P10634" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 373, + "assayComponentEndpointName": "NVS_ADME_rCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2E1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "chlormethiazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 228, + "assayComponentName": "NVS_ADME_rCYP2E1", + "assayComponentDesc": "NVS_ADME_rCYP2E1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2E1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily e, polypeptide 1 [GeneSymbol:Cyp2e1 | GeneID:25086 | Uniprot_SwissProt_Accession:P05182].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 42, + "assayName": "NVS_ADME_rCYP2E1", + "assayDesc": "NVS_ADME_rCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 403, + "geneName": "cytochrome P450, family 2, subfamily e, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2e1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25086, + "officialSymbol": "Cyp2e1", + "officialFullName": "cytochrome P450, family 2, subfamily e, polypeptide 1", + "uniprotAccessionNumber": "P05182" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 375, + "assayComponentEndpointName": "NVS_ADME_rCYP3A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-) Verapamil HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 229, + "assayComponentName": "NVS_ADME_rCYP3A1", + "assayComponentDesc": "NVS_ADME_rCYP3A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP3A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 [GeneSymbol:Cyp3a23/3a1 | GeneID:25642 | Uniprot_SwissProt_Accession:P04800].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 43, + "assayName": "NVS_ADME_rCYP3A1", + "assayDesc": "NVS_ADME_rCYP3A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 412, + "geneName": "cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1", + "description": null, + "geneSymbol": "Cyp3a23/3a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25642, + "officialSymbol": "Cyp3a23/3a1", + "officialFullName": "cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1", + "uniprotAccessionNumber": "P04800" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 377, + "assayComponentEndpointName": "NVS_ADME_rCYP3A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-) Verapamil HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 230, + "assayComponentName": "NVS_ADME_rCYP3A2", + "assayComponentDesc": "NVS_ADME_rCYP3A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP3A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 3, subfamily a, polypeptide 2 [GeneSymbol:Cyp3a2 | GeneID:266682 | Uniprot_SwissProt_Accession:P05183].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 44, + "assayName": "NVS_ADME_rCYP3A2", + "assayDesc": "NVS_ADME_rCYP3A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 447, + "geneName": "cytochrome P450, family 3, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp3a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 266682, + "officialSymbol": "Cyp3a2", + "officialFullName": "cytochrome P450, family 3, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P05183" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 379, + "assayComponentEndpointName": "NVS_ENZ_hAbl", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAbl was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAbl, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 231, + "assayComponentName": "NVS_ENZ_hAbl", + "assayComponentDesc": "NVS_ENZ_hAbl is one of one assay component(s) measured or calculated from the NVS_ENZ_hAbl assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human ABL proto-oncogene 1, non-receptor tyrosine kinase [GeneSymbol:ABL1 | GeneID:25 | Uniprot_SwissProt_Accession:P00519].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 45, + "assayName": "NVS_ENZ_hAbl", + "assayDesc": "NVS_ENZ_hAbl is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 1, + "geneName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "ABL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25, + "officialSymbol": "ABL1", + "officialFullName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P00519" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6304726", + "pmid": 6304726, + "title": "Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity", + "author": "Reddy EP, Smith MJ, Srinivasan A", + "citation": "Reddy EP, Smith MJ, Srinivasan A. Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3623-7. PubMed PMID: 6304726; PubMed Central PMCID: PMC394102.", + "otherId": "0", + "citationId": 118, + "otherSource": "" + } + }, + { + "aeid": 381, + "assayComponentEndpointName": "NVS_ENZ_hAChE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAChE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAChE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is acetylcholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "acetylcholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 232, + "assayComponentName": "NVS_ENZ_hAChE", + "assayComponentDesc": "NVS_ENZ_hAChE is one of one assay component(s) measured or calculated from the NVS_ENZ_hAChE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrate [acetylthiocholine] are indicative of changes in enzyme function and kinetics for the human acetylcholinesterase (Yt blood group) [GeneSymbol:ACHE | GeneID:43 | Uniprot_SwissProt_Accession:P22303].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "acetylthiocholine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 46, + "assayName": "NVS_ENZ_hAChE", + "assayDesc": "NVS_ENZ_hAChE is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 2, + "geneName": "acetylcholinesterase (Yt blood group)", + "description": null, + "geneSymbol": "ACHE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 43, + "officialSymbol": "ACHE", + "officialFullName": "acetylcholinesterase (Yt blood group)", + "uniprotAccessionNumber": "P22303" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 383, + "assayComponentEndpointName": "NVS_ENZ_hACP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hACP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hACP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is acid phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "acid phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 233, + "assayComponentName": "NVS_ENZ_hACP1", + "assayComponentDesc": "NVS_ENZ_hACP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hACP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human acid phosphatase 1, soluble [GeneSymbol:ACP1 | GeneID:52 | Uniprot_SwissProt_Accession:P24666].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 47, + "assayName": "NVS_ENZ_hACP1", + "assayDesc": "NVS_ENZ_hACP1 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5, + "geneName": "acid phosphatase 1, soluble", + "description": null, + "geneSymbol": "ACP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 52, + "officialSymbol": "ACP1", + "officialFullName": "acid phosphatase 1, soluble", + "uniprotAccessionNumber": "P24666" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 385, + "assayComponentEndpointName": "NVS_ENZ_hAKT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 234, + "assayComponentName": "NVS_ENZ_hAKT1", + "assayComponentDesc": "NVS_ENZ_hAKT1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 1 [GeneSymbol:AKT1 | GeneID:207 | Uniprot_SwissProt_Accession:P31749].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 48, + "assayName": "NVS_ENZ_hAKT1", + "assayDesc": "NVS_ENZ_hAKT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 22, + "geneName": "v-akt murine thymoma viral oncogene homolog 1", + "description": null, + "geneSymbol": "AKT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 207, + "officialSymbol": "AKT1", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 1", + "uniprotAccessionNumber": "P31749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 387, + "assayComponentEndpointName": "NVS_ENZ_hAKT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 235, + "assayComponentName": "NVS_ENZ_hAKT2", + "assayComponentDesc": "NVS_ENZ_hAKT2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 2 [GeneSymbol:AKT2 | GeneID:208 | Uniprot_SwissProt_Accession:P31751].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 49, + "assayName": "NVS_ENZ_hAKT2", + "assayDesc": "NVS_ENZ_hAKT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 23, + "geneName": "v-akt murine thymoma viral oncogene homolog 2", + "description": null, + "geneSymbol": "AKT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 208, + "officialSymbol": "AKT2", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 2", + "uniprotAccessionNumber": "P31751" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 389, + "assayComponentEndpointName": "NVS_ENZ_hAKT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 236, + "assayComponentName": "NVS_ENZ_hAKT3", + "assayComponentDesc": "NVS_ENZ_hAKT3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 3 [GeneSymbol:AKT3 | GeneID:10000 | Uniprot_SwissProt_Accession:Q9Y243].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 50, + "assayName": "NVS_ENZ_hAKT3", + "assayDesc": "NVS_ENZ_hAKT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 359, + "geneName": "v-akt murine thymoma viral oncogene homolog 3", + "description": null, + "geneSymbol": "AKT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10000, + "officialSymbol": "AKT3", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 3", + "uniprotAccessionNumber": "Q9Y243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 391, + "assayComponentEndpointName": "NVS_ENZ_hAMPKa1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 237, + "assayComponentName": "NVS_ENZ_hAMPKa1", + "assayComponentDesc": "NVS_ENZ_hAMPKa1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAMPKa1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, AMP-activated, alpha 1 catalytic subunit [GeneSymbol:PRKAA1 | GeneID:5562 | Uniprot_SwissProt_Accession:Q13131].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 51, + "assayName": "NVS_ENZ_hAMPKa1", + "assayDesc": "NVS_ENZ_hAMPKa1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 255, + "geneName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "description": null, + "geneSymbol": "PRKAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5562, + "officialSymbol": "PRKAA1", + "officialFullName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "uniprotAccessionNumber": "Q13131" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 393, + "assayComponentEndpointName": "NVS_ENZ_hAurA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAurA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 238, + "assayComponentName": "NVS_ENZ_hAurA", + "assayComponentDesc": "NVS_ENZ_hAurA is one of one assay component(s) measured or calculated from the NVS_ENZ_hAurA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human aurora kinase A [GeneSymbol:AURKA | GeneID:6790 | Uniprot_SwissProt_Accession:O14965].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 52, + "assayName": "NVS_ENZ_hAurA", + "assayDesc": "NVS_ENZ_hAurA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 306, + "geneName": "aurora kinase A", + "description": null, + "geneSymbol": "AURKA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6790, + "officialSymbol": "AURKA", + "officialFullName": "aurora kinase A", + "uniprotAccessionNumber": "O14965" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 395, + "assayComponentEndpointName": "NVS_ENZ_hBACE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hBACE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is aspartate protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "OM99-02", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "aspartate protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 239, + "assayComponentName": "NVS_ENZ_hBACE", + "assayComponentDesc": "NVS_ENZ_hBACE is one of one assay component(s) measured or calculated from the NVS_ENZ_hBACE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Rh-EVNLDAEFK-Quencher (weak fluorescence)+BACE --> Rh-ENVL(increased fluorescence) + DAEFK-Quencher] involving the key substrate [Rh-EVNLDAEFK-Quencher] are indicative of changes in enzyme function and kinetics for the human beta-site APP-cleaving enzyme 1 [GeneSymbol:BACE1 | GeneID:23621 | Uniprot_SwissProt_Accession:P56817].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Rh-EVNLDAEFK-Quencher", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 53, + "assayName": "NVS_ENZ_hBACE", + "assayDesc": "NVS_ENZ_hBACE is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 378, + "geneName": "beta-site APP-cleaving enzyme 1", + "description": null, + "geneSymbol": "BACE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23621, + "officialSymbol": "BACE1", + "officialFullName": "beta-site APP-cleaving enzyme 1", + "uniprotAccessionNumber": "P56817" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10591214", + "pmid": 10591214, + "title": "Purification and cloning of amyloid precursor protein beta-secretase from human brain", + "author": "Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V", + "citation": "Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999 Dec 2;402(6761):537-40. PubMed PMID: 10591214.", + "otherId": "0", + "citationId": 180, + "otherSource": "" + } + }, + { + "aeid": 397, + "assayComponentEndpointName": "NVS_ENZ_hBTK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hBTK was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hBTK, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 240, + "assayComponentName": "NVS_ENZ_hBTK", + "assayComponentDesc": "NVS_ENZ_hBTK is one of one assay component(s) measured or calculated from the NVS_ENZ_hBTK assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Bruton agammaglobulinemia tyrosine kinase [GeneSymbol:BTK | GeneID:695 | Uniprot_SwissProt_Accession:Q06187].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 54, + "assayName": "NVS_ENZ_hBTK", + "assayDesc": "NVS_ENZ_hBTK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 36, + "geneName": "Bruton agammaglobulinemia tyrosine kinase", + "description": null, + "geneSymbol": "BTK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 695, + "officialSymbol": "BTK", + "officialFullName": "Bruton agammaglobulinemia tyrosine kinase", + "uniprotAccessionNumber": "Q06187" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 399, + "assayComponentEndpointName": "NVS_ENZ_hCASP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-YVAD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 241, + "assayComponentName": "NVS_ENZ_hCASP1", + "assayComponentDesc": "NVS_ENZ_hCASP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 1, apoptosis-related cysteine peptidase [GeneSymbol:CASP1 | GeneID:834 | Uniprot_SwissProt_Accession:P29466].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 55, + "assayName": "NVS_ENZ_hCASP1", + "assayDesc": "NVS_ENZ_hCASP1 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 39, + "geneName": "caspase 1, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 834, + "officialSymbol": "CASP1", + "officialFullName": "caspase 1, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P29466" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 401, + "assayComponentEndpointName": "NVS_ENZ_hCASP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP10 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 242, + "assayComponentName": "NVS_ENZ_hCASP10", + "assayComponentDesc": "NVS_ENZ_hCASP10 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP10 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 10, apoptosis-related cysteine peptidase [GeneSymbol:CASP10 | GeneID:843 | Uniprot_SwissProt_Accession:Q92851].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 56, + "assayName": "NVS_ENZ_hCASP10", + "assayDesc": "NVS_ENZ_hCASP10 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 45, + "geneName": "caspase 10, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 843, + "officialSymbol": "CASP10", + "officialFullName": "caspase 10, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q92851" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 403, + "assayComponentEndpointName": "NVS_ENZ_hCASP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "z-VDVAD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 243, + "assayComponentName": "NVS_ENZ_hCASP2", + "assayComponentDesc": "NVS_ENZ_hCASP2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:VDVAD-AFC --> VDVAD + AFC] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged VDVAD] are indicative of changes in enzyme function and kinetics for the human caspase 2, apoptosis-related cysteine peptidase [GeneSymbol:CASP2 | GeneID:835 | Uniprot_SwissProt_Accession:P42575].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged VDVAD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 57, + "assayName": "NVS_ENZ_hCASP2", + "assayDesc": "NVS_ENZ_hCASP2 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 40, + "geneName": "caspase 2, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 835, + "officialSymbol": "CASP2", + "officialFullName": "caspase 2, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42575" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 405, + "assayComponentEndpointName": "NVS_ENZ_hCASP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 244, + "assayComponentName": "NVS_ENZ_hCASP3", + "assayComponentDesc": "NVS_ENZ_hCASP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DEVD-AFC --> DEVD + AFC] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged DEVD] are indicative of changes in enzyme function and kinetics for the human caspase 3, apoptosis-related cysteine peptidase [GeneSymbol:CASP3 | GeneID:836 | Uniprot_SwissProt_Accession:P42574].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged DEVD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 58, + "assayName": "NVS_ENZ_hCASP3", + "assayDesc": "NVS_ENZ_hCASP3 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 407, + "assayComponentEndpointName": "NVS_ENZ_hCASP4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-LEHD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 245, + "assayComponentName": "NVS_ENZ_hCASP4", + "assayComponentDesc": "NVS_ENZ_hCASP4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 4, apoptosis-related cysteine peptidase [GeneSymbol:CASP4 | GeneID:837 | Uniprot_SwissProt_Accession:P49662].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 59, + "assayName": "NVS_ENZ_hCASP4", + "assayDesc": "NVS_ENZ_hCASP4 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 42, + "geneName": "caspase 4, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 837, + "officialSymbol": "CASP4", + "officialFullName": "caspase 4, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P49662" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 409, + "assayComponentEndpointName": "NVS_ENZ_hCASP5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-LEHD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 246, + "assayComponentName": "NVS_ENZ_hCASP5", + "assayComponentDesc": "NVS_ENZ_hCASP5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 5, apoptosis-related cysteine peptidase [GeneSymbol:CASP5 | GeneID:838 | Uniprot_SwissProt_Accession:P51878].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 60, + "assayName": "NVS_ENZ_hCASP5", + "assayDesc": "NVS_ENZ_hCASP5 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 43, + "geneName": "caspase 5, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 838, + "officialSymbol": "CASP5", + "officialFullName": "caspase 5, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P51878" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 411, + "assayComponentEndpointName": "NVS_ENZ_hCASP8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP8 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP8, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 247, + "assayComponentName": "NVS_ENZ_hCASP8", + "assayComponentDesc": "NVS_ENZ_hCASP8 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP8 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 8, apoptosis-related cysteine peptidase [GeneSymbol:CASP8 | GeneID:841 | Uniprot_SwissProt_Accession:Q14790].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 61, + "assayName": "NVS_ENZ_hCASP8", + "assayDesc": "NVS_ENZ_hCASP8 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 44, + "geneName": "caspase 8, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 841, + "officialSymbol": "CASP8", + "officialFullName": "caspase 8, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q14790" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 413, + "assayComponentEndpointName": "NVS_ENZ_hCDK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCDK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCDK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 248, + "assayComponentName": "NVS_ENZ_hCDK2", + "assayComponentDesc": "NVS_ENZ_hCDK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCDK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human cyclin-dependent kinase 2 [GeneSymbol:CDK2 | GeneID:1017 | Uniprot_SwissProt_Accession:P24941].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 62, + "assayName": "NVS_ENZ_hCDK2", + "assayDesc": "NVS_ENZ_hCDK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 55, + "geneName": "cyclin-dependent kinase 2", + "description": null, + "geneSymbol": "CDK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1017, + "officialSymbol": "CDK2", + "officialFullName": "cyclin-dependent kinase 2", + "uniprotAccessionNumber": "P24941" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 415, + "assayComponentEndpointName": "NVS_ENZ_hCDK6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCDK6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCDK6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 249, + "assayComponentName": "NVS_ENZ_hCDK6", + "assayComponentDesc": "NVS_ENZ_hCDK6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCDK6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human cyclin-dependent kinase 6 [GeneSymbol:CDK6 | GeneID:1021 | Uniprot_SwissProt_Accession:Q00534].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 63, + "assayName": "NVS_ENZ_hCDK6", + "assayDesc": "NVS_ENZ_hCDK6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 56, + "geneName": "cyclin-dependent kinase 6", + "description": null, + "geneSymbol": "CDK6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1021, + "officialSymbol": "CDK6", + "officialFullName": "cyclin-dependent kinase 6", + "uniprotAccessionNumber": "Q00534" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 417, + "assayComponentEndpointName": "NVS_ENZ_hCHK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCHK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCHK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 250, + "assayComponentName": "NVS_ENZ_hCHK1", + "assayComponentDesc": "NVS_ENZ_hCHK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCHK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human checkpoint kinase 1 [GeneSymbol:CHEK1 | GeneID:1111 | Uniprot_SwissProt_Accession:O14757].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 64, + "assayName": "NVS_ENZ_hCHK1", + "assayDesc": "NVS_ENZ_hCHK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 60, + "geneName": "checkpoint kinase 1", + "description": null, + "geneSymbol": "CHEK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1111, + "officialSymbol": "CHEK1", + "officialFullName": "checkpoint kinase 1", + "uniprotAccessionNumber": "O14757" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 419, + "assayComponentEndpointName": "NVS_ENZ_hCK1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK1a was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK1a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-iodotubericidin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 251, + "assayComponentName": "NVS_ENZ_hCK1a", + "assayComponentDesc": "NVS_ENZ_hCK1a is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK1a assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 1, alpha 1 [GeneSymbol:CSNK1A1 | GeneID:1452 | Uniprot_SwissProt_Accession:P48729].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 65, + "assayName": "NVS_ENZ_hCK1a", + "assayDesc": "NVS_ENZ_hCK1a is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 74, + "geneName": "casein kinase 1, alpha 1", + "description": null, + "geneSymbol": "CSNK1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1452, + "officialSymbol": "CSNK1A1", + "officialFullName": "casein kinase 1, alpha 1", + "uniprotAccessionNumber": "P48729" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 421, + "assayComponentEndpointName": "NVS_ENZ_hCK1D", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK1D was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK1D, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-iodotubericidin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 252, + "assayComponentName": "NVS_ENZ_hCK1D", + "assayComponentDesc": "NVS_ENZ_hCK1D is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK1D assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 1, delta [GeneSymbol:CSNK1D | GeneID:1453 | Uniprot_SwissProt_Accession:P48730].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 66, + "assayName": "NVS_ENZ_hCK1D", + "assayDesc": "NVS_ENZ_hCK1D is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 75, + "geneName": "casein kinase 1, delta", + "description": null, + "geneSymbol": "CSNK1D", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1453, + "officialSymbol": "CSNK1D", + "officialFullName": "casein kinase 1, delta", + "uniprotAccessionNumber": "P48730" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 423, + "assayComponentEndpointName": "NVS_ENZ_hCK2a2b2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK2a2b2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 253, + "assayComponentName": "NVS_ENZ_hCK2a2b2", + "assayComponentDesc": "NVS_ENZ_hCK2a2b2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK2a2b2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 2, alpha 1 polypeptide [GeneSymbol:CSNK2A1 | GeneID:1457 | Uniprot_SwissProt_Accession:Q8NEV1].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 67, + "assayName": "NVS_ENZ_hCK2a2b2", + "assayDesc": "NVS_ENZ_hCK2a2b2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 76, + "geneName": "casein kinase 2, alpha 1 polypeptide", + "description": null, + "geneSymbol": "CSNK2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1457, + "officialSymbol": "CSNK2A1", + "officialFullName": "casein kinase 2, alpha 1 polypeptide", + "uniprotAccessionNumber": "Q8NEV1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 425, + "assayComponentEndpointName": "NVS_ENZ_hCSF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCSF1R was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCSF1R, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 254, + "assayComponentName": "NVS_ENZ_hCSF1R", + "assayComponentDesc": "NVS_ENZ_hCSF1R is one of one assay component(s) measured or calculated from the NVS_ENZ_hCSF1R assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human colony stimulating factor 1 receptor [GeneSymbol:CSF1R | GeneID:1436 | Uniprot_SwissProt_Accession:P07333].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 68, + "assayName": "NVS_ENZ_hCSF1R", + "assayDesc": "NVS_ENZ_hCSF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 73, + "geneName": "colony stimulating factor 1 receptor", + "description": null, + "geneSymbol": "CSF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1436, + "officialSymbol": "CSF1R", + "officialFullName": "colony stimulating factor 1 receptor", + "uniprotAccessionNumber": "P07333" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 427, + "assayComponentEndpointName": "NVS_ENZ_hDUSP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 255, + "assayComponentName": "NVS_ENZ_hDUSP3", + "assayComponentDesc": "NVS_ENZ_hDUSP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hDUSP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DiFMUP(non-fluorescent) --> DiFMU] involving the key substrate [6,8-difluoro-4-methylumbelliferyl] are indicative of changes in enzyme function and kinetics for the human dual specificity phosphatase 3 [GeneSymbol:DUSP3 | GeneID:1845 | Uniprot_SwissProt_Accession:P51452].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4-methylumbelliferyl", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 69, + "assayName": "NVS_ENZ_hDUSP3", + "assayDesc": "NVS_ENZ_hDUSP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 102, + "geneName": "dual specificity phosphatase 3", + "description": null, + "geneSymbol": "DUSP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1845, + "officialSymbol": "DUSP3", + "officialFullName": "dual specificity phosphatase 3", + "uniprotAccessionNumber": "P51452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7852302", + "pmid": 7852302, + "title": "Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR", + "author": "Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA", + "citation": "Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem. 1995 Feb 10;270(6):2435-8. PubMed PMID: 7852302.", + "otherId": "0", + "citationId": 147, + "otherSource": "" + } + }, + { + "aeid": 429, + "assayComponentEndpointName": "NVS_ENZ_hEGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEGFR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEGFR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 256, + "assayComponentName": "NVS_ENZ_hEGFR", + "assayComponentDesc": "NVS_ENZ_hEGFR is one of one assay component(s) measured or calculated from the NVS_ENZ_hEGFR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human epidermal growth factor receptor [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 70, + "assayName": "NVS_ENZ_hEGFR", + "assayDesc": "NVS_ENZ_hEGFR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 431, + "assayComponentEndpointName": "NVS_ENZ_hElastase", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hElastase was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ursolic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 257, + "assayComponentName": "NVS_ENZ_hElastase", + "assayComponentDesc": "NVS_ENZ_hElastase is one of one assay component(s) measured or calculated from the NVS_ENZ_hElastase assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Spectrophotometry technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction involving the key substrate [MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide] are indicative of changes in enzyme function and kinetics for the human elastase, neutrophil expressed [GeneSymbol:ELANE | GeneID:1991 | Uniprot_SwissProt_Accession:P08246].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 71, + "assayName": "NVS_ENZ_hElastase", + "assayDesc": "NVS_ENZ_hElastase is a biochemical, single-readout assay that uses extracted gene-proteins from Human neutrophils in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 111, + "geneName": "elastase, neutrophil expressed", + "description": null, + "geneSymbol": "ELANE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1991, + "officialSymbol": "ELANE", + "officialFullName": "elastase, neutrophil expressed", + "uniprotAccessionNumber": "P08246" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9103531", + "pmid": 9103531, + "title": "Inhibition by boswellic acids of human leukocyte elastase", + "author": "Safayhi H, Rall B, Sailer ER, Ammon HP", + "citation": "Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997 Apr;281(1):460-3. PubMed PMID: 9103531.", + "otherId": "0", + "citationId": 171, + "otherSource": "" + } + }, + { + "aeid": 433, + "assayComponentEndpointName": "NVS_ENZ_hEphA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphA1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 258, + "assayComponentName": "NVS_ENZ_hEphA1", + "assayComponentDesc": "NVS_ENZ_hEphA1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphA1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor A1 [GeneSymbol:EPHA1 | GeneID:2041 | Uniprot_SwissProt_Accession:P21709].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 72, + "assayName": "NVS_ENZ_hEphA1", + "assayDesc": "NVS_ENZ_hEphA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 113, + "geneName": "EPH receptor A1", + "description": null, + "geneSymbol": "EPHA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2041, + "officialSymbol": "EPHA1", + "officialFullName": "EPH receptor A1", + "uniprotAccessionNumber": "P21709" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 435, + "assayComponentEndpointName": "NVS_ENZ_hEphA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphA2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 259, + "assayComponentName": "NVS_ENZ_hEphA2", + "assayComponentDesc": "NVS_ENZ_hEphA2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphA2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor A2 [GeneSymbol:EPHA2 | GeneID:1969 | Uniprot_SwissProt_Accession:P29317].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 73, + "assayName": "NVS_ENZ_hEphA2", + "assayDesc": "NVS_ENZ_hEphA2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 110, + "geneName": "EPH receptor A2", + "description": null, + "geneSymbol": "EPHA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1969, + "officialSymbol": "EPHA2", + "officialFullName": "EPH receptor A2", + "uniprotAccessionNumber": "P29317" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 437, + "assayComponentEndpointName": "NVS_ENZ_hEphB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphB1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphB1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 260, + "assayComponentName": "NVS_ENZ_hEphB1", + "assayComponentDesc": "NVS_ENZ_hEphB1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphB1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor B1 [GeneSymbol:EPHB1 | GeneID:2047 | Uniprot_SwissProt_Accession:P54762].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 74, + "assayName": "NVS_ENZ_hEphB1", + "assayDesc": "NVS_ENZ_hEphB1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 114, + "geneName": "EPH receptor B1", + "description": null, + "geneSymbol": "EPHB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2047, + "officialSymbol": "EPHB1", + "officialFullName": "EPH receptor B1", + "uniprotAccessionNumber": "P54762" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 439, + "assayComponentEndpointName": "NVS_ENZ_hEphB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphB2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphB2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 261, + "assayComponentName": "NVS_ENZ_hEphB2", + "assayComponentDesc": "NVS_ENZ_hEphB2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphB2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor B2 [GeneSymbol:EPHB2 | GeneID:2048 | Uniprot_SwissProt_Accession:P29323].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 75, + "assayName": "NVS_ENZ_hEphB2", + "assayDesc": "NVS_ENZ_hEphB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 115, + "geneName": "EPH receptor B2", + "description": null, + "geneSymbol": "EPHB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2048, + "officialSymbol": "EPHB2", + "officialFullName": "EPH receptor B2", + "uniprotAccessionNumber": "P29323" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 441, + "assayComponentEndpointName": "NVS_ENZ_hES", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hES was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is pseudocholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "pseudocholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 262, + "assayComponentName": "NVS_ENZ_hES", + "assayComponentDesc": "NVS_ENZ_hES is one of one assay component(s) measured or calculated from the NVS_ENZ_hES assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the human butyrylcholinesterase [GeneSymbol:BCHE | GeneID:590 | Uniprot_SwissProt_Accession:P06276].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "acetylthiocholine;Ellman\"s reagent (DTNB)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 76, + "assayName": "NVS_ENZ_hES", + "assayDesc": "NVS_ENZ_hES is a biochemical, single-readout assay that uses extracted gene-proteins from Human plasma in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 32, + "geneName": "butyrylcholinesterase", + "description": null, + "geneSymbol": "BCHE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 590, + "officialSymbol": "BCHE", + "officialFullName": "butyrylcholinesterase", + "uniprotAccessionNumber": "P06276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 443, + "assayComponentEndpointName": "NVS_ENZ_hFGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFGFR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "K252a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 263, + "assayComponentName": "NVS_ENZ_hFGFR1", + "assayComponentDesc": "NVS_ENZ_hFGFR1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hFGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fibroblast growth factor receptor 1 [GeneSymbol:FGFR1 | GeneID:2260 | Uniprot_SwissProt_Accession:P11362].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 77, + "assayName": "NVS_ENZ_hFGFR1", + "assayDesc": "NVS_ENZ_hFGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 126, + "geneName": "fibroblast growth factor receptor 1", + "description": null, + "geneSymbol": "FGFR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2260, + "officialSymbol": "FGFR1", + "officialFullName": "fibroblast growth factor receptor 1", + "uniprotAccessionNumber": "P11362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 445, + "assayComponentEndpointName": "NVS_ENZ_hFGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFGFR3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 264, + "assayComponentName": "NVS_ENZ_hFGFR3", + "assayComponentDesc": "NVS_ENZ_hFGFR3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hFGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fibroblast growth factor receptor 3 [GeneSymbol:FGFR3 | GeneID:2261 | Uniprot_SwissProt_Accession:P22607].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 78, + "assayName": "NVS_ENZ_hFGFR3", + "assayDesc": "NVS_ENZ_hFGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 127, + "geneName": "fibroblast growth factor receptor 3", + "description": null, + "geneSymbol": "FGFR3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2261, + "officialSymbol": "FGFR3", + "officialFullName": "fibroblast growth factor receptor 3", + "uniprotAccessionNumber": "P22607" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 447, + "assayComponentEndpointName": "NVS_ENZ_hFyn", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFyn was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFyn, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 265, + "assayComponentName": "NVS_ENZ_hFyn", + "assayComponentDesc": "NVS_ENZ_hFyn is one of one assay component(s) measured or calculated from the NVS_ENZ_hFyn assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human FYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:FYN | GeneID:2534 | Uniprot_SwissProt_Accession:P06241].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 79, + "assayName": "NVS_ENZ_hFyn", + "assayDesc": "NVS_ENZ_hFyn is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 137, + "geneName": "FYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "FYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2534, + "officialSymbol": "FYN", + "officialFullName": "FYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06241" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 449, + "assayComponentEndpointName": "NVS_ENZ_hGSK3b", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hGSK3b was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hGSK3b, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 266, + "assayComponentName": "NVS_ENZ_hGSK3b", + "assayComponentDesc": "NVS_ENZ_hGSK3b is one of one assay component(s) measured or calculated from the NVS_ENZ_hGSK3b assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human glycogen synthase kinase 3 beta [GeneSymbol:GSK3B | GeneID:2932 | Uniprot_SwissProt_Accession:P49841].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 80, + "assayName": "NVS_ENZ_hGSK3b", + "assayDesc": "NVS_ENZ_hGSK3b is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 146, + "geneName": "glycogen synthase kinase 3 beta", + "description": null, + "geneSymbol": "GSK3B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2932, + "officialSymbol": "GSK3B", + "officialFullName": "glycogen synthase kinase 3 beta", + "uniprotAccessionNumber": "P49841" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 451, + "assayComponentEndpointName": "NVS_ENZ_hHDAC3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hHDAC3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 267, + "assayComponentName": "NVS_ENZ_hHDAC3", + "assayComponentDesc": "NVS_ENZ_hHDAC3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hHDAC3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human histone deacetylase 3 [GeneSymbol:HDAC3 | GeneID:8841 | Uniprot_SwissProt_Accession:O15379].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 81, + "assayName": "NVS_ENZ_hHDAC3", + "assayDesc": "NVS_ENZ_hHDAC3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 349, + "geneName": "histone deacetylase 3", + "description": null, + "geneSymbol": "HDAC3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8841, + "officialSymbol": "HDAC3", + "officialFullName": "histone deacetylase 3", + "uniprotAccessionNumber": "O15379" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 453, + "assayComponentEndpointName": "NVS_ENZ_hHDAC6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 268, + "assayComponentName": "NVS_ENZ_hHDAC6", + "assayComponentDesc": "NVS_ENZ_hHDAC6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hHDAC6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human histone deacetylase 6 [GeneSymbol:HDAC6 | GeneID:10013 | Uniprot_SwissProt_Accession:Q9UBN7].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 82, + "assayName": "NVS_ENZ_hHDAC6", + "assayDesc": "NVS_ENZ_hHDAC6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 361, + "geneName": "histone deacetylase 6", + "description": null, + "geneSymbol": "HDAC6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10013, + "officialSymbol": "HDAC6", + "officialFullName": "histone deacetylase 6", + "uniprotAccessionNumber": "Q9UBN7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 455, + "assayComponentEndpointName": "NVS_ENZ_hIGF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIGF1R was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIGF1R, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 269, + "assayComponentName": "NVS_ENZ_hIGF1R", + "assayComponentDesc": "NVS_ENZ_hIGF1R is one of one assay component(s) measured or calculated from the NVS_ENZ_hIGF1R assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human insulin-like growth factor 1 receptor [GeneSymbol:IGF1R | GeneID:3480 | Uniprot_SwissProt_Accession:P08069].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 83, + "assayName": "NVS_ENZ_hIGF1R", + "assayDesc": "NVS_ENZ_hIGF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 172, + "geneName": "insulin-like growth factor 1 receptor", + "description": null, + "geneSymbol": "IGF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3480, + "officialSymbol": "IGF1R", + "officialFullName": "insulin-like growth factor 1 receptor", + "uniprotAccessionNumber": "P08069" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 457, + "assayComponentEndpointName": "NVS_ENZ_hIKKa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIKKa was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIKKa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 270, + "assayComponentName": "NVS_ENZ_hIKKa", + "assayComponentDesc": "NVS_ENZ_hIKKa is one of one assay component(s) measured or calculated from the NVS_ENZ_hIKKa assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human conserved helix-loop-helix ubiquitous kinase [GeneSymbol:CHUK | GeneID:1147 | Uniprot_SwissProt_Accession:O15111].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 84, + "assayName": "NVS_ENZ_hIKKa", + "assayDesc": "NVS_ENZ_hIKKa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 67, + "geneName": "conserved helix-loop-helix ubiquitous kinase", + "description": null, + "geneSymbol": "CHUK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1147, + "officialSymbol": "CHUK", + "officialFullName": "conserved helix-loop-helix ubiquitous kinase", + "uniprotAccessionNumber": "O15111" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 459, + "assayComponentEndpointName": "NVS_ENZ_hInsR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hInsR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hInsR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 271, + "assayComponentName": "NVS_ENZ_hInsR", + "assayComponentDesc": "NVS_ENZ_hInsR is one of one assay component(s) measured or calculated from the NVS_ENZ_hInsR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human insulin receptor [GeneSymbol:INSR | GeneID:3643 | Uniprot_SwissProt_Accession:P06213].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 85, + "assayName": "NVS_ENZ_hInsR", + "assayDesc": "NVS_ENZ_hInsR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 179, + "geneName": "insulin receptor", + "description": null, + "geneSymbol": "INSR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3643, + "officialSymbol": "INSR", + "officialFullName": "insulin receptor", + "uniprotAccessionNumber": "P06213" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 461, + "assayComponentEndpointName": "NVS_ENZ_hIRAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIRAK4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 272, + "assayComponentName": "NVS_ENZ_hIRAK4", + "assayComponentDesc": "NVS_ENZ_hIRAK4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hIRAK4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human interleukin-1 receptor-associated kinase 4 [GeneSymbol:IRAK4 | GeneID:51135 | Uniprot_SwissProt_Accession:Q9NWZ3].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 86, + "assayName": "NVS_ENZ_hIRAK4", + "assayDesc": "NVS_ENZ_hIRAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 425, + "geneName": "interleukin-1 receptor-associated kinase 4", + "description": null, + "geneSymbol": "IRAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51135, + "officialSymbol": "IRAK4", + "officialFullName": "interleukin-1 receptor-associated kinase 4", + "uniprotAccessionNumber": "Q9NWZ3" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 463, + "assayComponentEndpointName": "NVS_ENZ_hJak2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hJak2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hJak2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 273, + "assayComponentName": "NVS_ENZ_hJak2", + "assayComponentDesc": "NVS_ENZ_hJak2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hJak2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Janus kinase 2 [GeneSymbol:JAK2 | GeneID:3717 | Uniprot_SwissProt_Accession:O60674].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 87, + "assayName": "NVS_ENZ_hJak2", + "assayDesc": "NVS_ENZ_hJak2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 182, + "geneName": "Janus kinase 2", + "description": null, + "geneSymbol": "JAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3717, + "officialSymbol": "JAK2", + "officialFullName": "Janus kinase 2", + "uniprotAccessionNumber": "O60674" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 465, + "assayComponentEndpointName": "NVS_ENZ_hJNK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hJNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hJNK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 274, + "assayComponentName": "NVS_ENZ_hJNK2", + "assayComponentDesc": "NVS_ENZ_hJNK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hJNK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 9 [GeneSymbol:MAPK9 | GeneID:5601 | Uniprot_SwissProt_Accession:P45984].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 88, + "assayName": "NVS_ENZ_hJNK2", + "assayDesc": "NVS_ENZ_hJNK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 262, + "geneName": "mitogen-activated protein kinase 9", + "description": null, + "geneSymbol": "MAPK9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5601, + "officialSymbol": "MAPK9", + "officialFullName": "mitogen-activated protein kinase 9", + "uniprotAccessionNumber": "P45984" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 467, + "assayComponentEndpointName": "NVS_ENZ_hLck", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLck was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLck, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 275, + "assayComponentName": "NVS_ENZ_hLck", + "assayComponentDesc": "NVS_ENZ_hLck is one of one assay component(s) measured or calculated from the NVS_ENZ_hLck assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LCK proto-oncogene, Src family tyrosine kinase [GeneSymbol:LCK | GeneID:3932 | Uniprot_SwissProt_Accession:P06239].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 89, + "assayName": "NVS_ENZ_hLck", + "assayDesc": "NVS_ENZ_hLck is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 188, + "geneName": "LCK proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LCK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3932, + "officialSymbol": "LCK", + "officialFullName": "LCK proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06239" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 469, + "assayComponentEndpointName": "NVS_ENZ_hLynA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLynA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLynA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 276, + "assayComponentName": "NVS_ENZ_hLynA", + "assayComponentDesc": "NVS_ENZ_hLynA is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:LYN | GeneID:4067 | Uniprot_SwissProt_Accession:P07948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 90, + "assayName": "NVS_ENZ_hLynA", + "assayDesc": "NVS_ENZ_hLynA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 471, + "assayComponentEndpointName": "NVS_ENZ_hLynB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLynB was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLynB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 277, + "assayComponentName": "NVS_ENZ_hLynB", + "assayComponentDesc": "NVS_ENZ_hLynB is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynB assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:LYN | GeneID:4067 | Uniprot_SwissProt_Accession:P07948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 91, + "assayName": "NVS_ENZ_hLynB", + "assayDesc": "NVS_ENZ_hLynB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8106508", + "pmid": 8106508, + "title": "Src family tyrosine kinase p53/56lyn, a serine kinase and Fc epsilon RI associate with alpha-galactosyl derivatives of ganglioside GD1b in rat basophilic leukemia RBL-2H3 cells", + "author": "Minoguchi K, Swaim WD, Berenstein EH, Siraganian RP", + "citation": "Minoguchi K, Swaim WD, Berenstein EH, Siraganian RP. Src family tyrosine kinase p53/56lyn, a serine kinase and Fc epsilon RI associate with alpha-galactosyl derivatives of ganglioside GD1b in rat basophilic leukemia RBL-2H3 cells. J Biol Chem. 1994 Feb 18;269(7):5249-54. PubMed PMID: 8106508.", + "otherId": "0", + "citationId": 157, + "otherSource": "" + } + }, + { + "aeid": 473, + "assayComponentEndpointName": "NVS_ENZ_hMAPK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "K252a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 278, + "assayComponentName": "NVS_ENZ_hMAPK1", + "assayComponentDesc": "NVS_ENZ_hMAPK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 1 [GeneSymbol:MAPK1 | GeneID:5594 | Uniprot_SwissProt_Accession:P28482].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 92, + "assayName": "NVS_ENZ_hMAPK1", + "assayDesc": "NVS_ENZ_hMAPK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 259, + "geneName": "mitogen-activated protein kinase 1", + "description": null, + "geneSymbol": "MAPK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5594, + "officialSymbol": "MAPK1", + "officialFullName": "mitogen-activated protein kinase 1", + "uniprotAccessionNumber": "P28482" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 475, + "assayComponentEndpointName": "NVS_ENZ_hMAPK11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK11, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 279, + "assayComponentName": "NVS_ENZ_hMAPK11", + "assayComponentDesc": "NVS_ENZ_hMAPK11 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 11 [GeneSymbol:MAPK11 | GeneID:5600 | Uniprot_SwissProt_Accession:Q15759].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 93, + "assayName": "NVS_ENZ_hMAPK11", + "assayDesc": "NVS_ENZ_hMAPK11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 261, + "geneName": "mitogen-activated protein kinase 11", + "description": null, + "geneSymbol": "MAPK11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5600, + "officialSymbol": "MAPK11", + "officialFullName": "mitogen-activated protein kinase 11", + "uniprotAccessionNumber": "Q15759" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6304726", + "pmid": 6304726, + "title": "Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity", + "author": "Reddy EP, Smith MJ, Srinivasan A", + "citation": "Reddy EP, Smith MJ, Srinivasan A. Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3623-7. PubMed PMID: 6304726; PubMed Central PMCID: PMC394102.", + "otherId": "0", + "citationId": 118, + "otherSource": "" + } + }, + { + "aeid": 477, + "assayComponentEndpointName": "NVS_ENZ_hMAPK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 280, + "assayComponentName": "NVS_ENZ_hMAPK3", + "assayComponentDesc": "NVS_ENZ_hMAPK3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 3 [GeneSymbol:MAPK3 | GeneID:5595 | Uniprot_SwissProt_Accession:P27361].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 94, + "assayName": "NVS_ENZ_hMAPK3", + "assayDesc": "NVS_ENZ_hMAPK3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 260, + "geneName": "mitogen-activated protein kinase 3", + "description": null, + "geneSymbol": "MAPK3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5595, + "officialSymbol": "MAPK3", + "officialFullName": "mitogen-activated protein kinase 3", + "uniprotAccessionNumber": "P27361" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 479, + "assayComponentEndpointName": "NVS_ENZ_hMAPKAPK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPKAPK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 281, + "assayComponentName": "NVS_ENZ_hMAPKAPK2", + "assayComponentDesc": "NVS_ENZ_hMAPKAPK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPKAPK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase-activated protein kinase 2 [GeneSymbol:MAPKAPK2 | GeneID:9261 | Uniprot_SwissProt_Accession:P49137].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 95, + "assayName": "NVS_ENZ_hMAPKAPK2", + "assayDesc": "NVS_ENZ_hMAPKAPK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 352, + "geneName": "mitogen-activated protein kinase-activated protein kinase 2", + "description": null, + "geneSymbol": "MAPKAPK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9261, + "officialSymbol": "MAPKAPK2", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 2", + "uniprotAccessionNumber": "P49137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 481, + "assayComponentEndpointName": "NVS_ENZ_hMAPKAPK5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPKAPK5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 282, + "assayComponentName": "NVS_ENZ_hMAPKAPK5", + "assayComponentDesc": "NVS_ENZ_hMAPKAPK5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPKAPK5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase-activated protein kinase 5 [GeneSymbol:MAPKAPK5 | GeneID:8550 | Uniprot_SwissProt_Accession:Q8IW41].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 96, + "assayName": "NVS_ENZ_hMAPKAPK5", + "assayDesc": "NVS_ENZ_hMAPKAPK5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 343, + "geneName": "mitogen-activated protein kinase-activated protein kinase 5", + "description": null, + "geneSymbol": "MAPKAPK5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8550, + "officialSymbol": "MAPKAPK5", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 5", + "uniprotAccessionNumber": "Q8IW41" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 483, + "assayComponentEndpointName": "NVS_ENZ_hMARK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMARK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMARK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 283, + "assayComponentName": "NVS_ENZ_hMARK1", + "assayComponentDesc": "NVS_ENZ_hMARK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMARK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human MAP/microtubule affinity-regulating kinase 1 [GeneSymbol:MARK1 | GeneID:4139 | Uniprot_SwissProt_Accession:Q9P0L2].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 97, + "assayName": "NVS_ENZ_hMARK1", + "assayDesc": "NVS_ENZ_hMARK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 198, + "geneName": "MAP/microtubule affinity-regulating kinase 1", + "description": null, + "geneSymbol": "MARK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4139, + "officialSymbol": "MARK1", + "officialFullName": "MAP/microtubule affinity-regulating kinase 1", + "uniprotAccessionNumber": "Q9P0L2" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 485, + "assayComponentEndpointName": "NVS_ENZ_hMet", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMet was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMet, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 284, + "assayComponentName": "NVS_ENZ_hMet", + "assayComponentDesc": "NVS_ENZ_hMet is one of one assay component(s) measured or calculated from the NVS_ENZ_hMet assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human MET proto-oncogene, receptor tyrosine kinase [GeneSymbol:MET | GeneID:4233 | Uniprot_SwissProt_Accession:P08581].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 98, + "assayName": "NVS_ENZ_hMet", + "assayDesc": "NVS_ENZ_hMet is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 200, + "geneName": "MET proto-oncogene, receptor tyrosine kinase", + "description": null, + "geneSymbol": "MET", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4233, + "officialSymbol": "MET", + "officialFullName": "MET proto-oncogene, receptor tyrosine kinase", + "uniprotAccessionNumber": "P08581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 487, + "assayComponentEndpointName": "NVS_ENZ_hMMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 285, + "assayComponentName": "NVS_ENZ_hMMP1", + "assayComponentDesc": "NVS_ENZ_hMMP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 1 (interstitial collagenase) [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 99, + "assayName": "NVS_ENZ_hMMP1", + "assayDesc": "NVS_ENZ_hMMP1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 489, + "assayComponentEndpointName": "NVS_ENZ_hMMP13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP13, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tyr-Hydroxamic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 286, + "assayComponentName": "NVS_ENZ_hMMP13", + "assayComponentDesc": "NVS_ENZ_hMMP13 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 13 (collagenase 3) [GeneSymbol:MMP13 | GeneID:4322 | Uniprot_SwissProt_Accession:P45452].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 100, + "assayName": "NVS_ENZ_hMMP13", + "assayDesc": "NVS_ENZ_hMMP13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 209, + "geneName": "matrix metallopeptidase 13 (collagenase 3)", + "description": null, + "geneSymbol": "MMP13", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4322, + "officialSymbol": "MMP13", + "officialFullName": "matrix metallopeptidase 13 (collagenase 3)", + "uniprotAccessionNumber": "P45452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 491, + "assayComponentEndpointName": "NVS_ENZ_hMMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 287, + "assayComponentName": "NVS_ENZ_hMMP2", + "assayComponentDesc": "NVS_ENZ_hMMP2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) [GeneSymbol:MMP2 | GeneID:4313 | Uniprot_SwissProt_Accession:P08253].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 101, + "assayName": "NVS_ENZ_hMMP2", + "assayDesc": "NVS_ENZ_hMMP2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 204, + "geneName": "matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4313, + "officialSymbol": "MMP2", + "officialFullName": "matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)", + "uniprotAccessionNumber": "P08253" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 493, + "assayComponentEndpointName": "NVS_ENZ_hMMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 288, + "assayComponentName": "NVS_ENZ_hMMP3", + "assayComponentDesc": "NVS_ENZ_hMMP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Mca-RPKPVENvalWRK-Dnp-NH2 --> McaRPK + PVENvalWRK(DNP)NH2] involving the key substrate [Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys(Dnp)NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 3 (stromelysin 1, progelatinase) [GeneSymbol:MMP3 | GeneID:4314 | Uniprot_SwissProt_Accession:P08254].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys(Dnp)NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 102, + "assayName": "NVS_ENZ_hMMP3", + "assayDesc": "NVS_ENZ_hMMP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 495, + "assayComponentEndpointName": "NVS_ENZ_hMMP7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP7, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 289, + "assayComponentName": "NVS_ENZ_hMMP7", + "assayComponentDesc": "NVS_ENZ_hMMP7 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP7 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 7 (matrilysin, uterine) [GeneSymbol:MMP7 | GeneID:4316 | Uniprot_SwissProt_Accession:P09237].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 103, + "assayName": "NVS_ENZ_hMMP7", + "assayDesc": "NVS_ENZ_hMMP7 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 206, + "geneName": "matrix metallopeptidase 7 (matrilysin, uterine)", + "description": null, + "geneSymbol": "MMP7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4316, + "officialSymbol": "MMP7", + "officialFullName": "matrix metallopeptidase 7 (matrilysin, uterine)", + "uniprotAccessionNumber": "P09237" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 497, + "assayComponentEndpointName": "NVS_ENZ_hMMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP9, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 290, + "assayComponentName": "NVS_ENZ_hMMP9", + "assayComponentDesc": "NVS_ENZ_hMMP9 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 104, + "assayName": "NVS_ENZ_hMMP9", + "assayDesc": "NVS_ENZ_hMMP9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8368516", + "pmid": 8368516, + "title": "A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)", + "author": "Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM", + "citation": "Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem. 1993 Jul;212(1):58-64. PubMed PMID: 8368516.", + "otherId": "0", + "citationId": 160, + "otherSource": "" + } + }, + { + "aeid": 499, + "assayComponentEndpointName": "NVS_ENZ_hMsk1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMsk1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMsk1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 291, + "assayComponentName": "NVS_ENZ_hMsk1", + "assayComponentDesc": "NVS_ENZ_hMsk1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMsk1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human ribosomal protein S6 kinase, 90kDa, polypeptide 5 [GeneSymbol:RPS6KA5 | GeneID:9252 | Uniprot_SwissProt_Accession:O75582].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 105, + "assayName": "NVS_ENZ_hMsk1", + "assayDesc": "NVS_ENZ_hMsk1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 351, + "geneName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "description": null, + "geneSymbol": "RPS6KA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9252, + "officialSymbol": "RPS6KA5", + "officialFullName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "uniprotAccessionNumber": "O75582" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 501, + "assayComponentEndpointName": "NVS_ENZ_hNEK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hNEK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 292, + "assayComponentName": "NVS_ENZ_hNEK2", + "assayComponentDesc": "NVS_ENZ_hNEK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hNEK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human NIMA-related kinase 2 [GeneSymbol:NEK2 | GeneID:4751 | Uniprot_SwissProt_Accession:P51955].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 106, + "assayName": "NVS_ENZ_hNEK2", + "assayDesc": "NVS_ENZ_hNEK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 215, + "geneName": "NIMA-related kinase 2", + "description": null, + "geneSymbol": "NEK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4751, + "officialSymbol": "NEK2", + "officialFullName": "NIMA-related kinase 2", + "uniprotAccessionNumber": "P51955" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 503, + "assayComponentEndpointName": "NVS_ENZ_hPAK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPAK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPAK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 293, + "assayComponentName": "NVS_ENZ_hPAK2", + "assayComponentDesc": "NVS_ENZ_hPAK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPAK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human p21 protein (Cdc42/Rac)-activated kinase 2 [GeneSymbol:PAK2 | GeneID:5062 | Uniprot_SwissProt_Accession:Q13177].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 107, + "assayName": "NVS_ENZ_hPAK2", + "assayDesc": "NVS_ENZ_hPAK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 230, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 2", + "description": null, + "geneSymbol": "PAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5062, + "officialSymbol": "PAK2", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 2", + "uniprotAccessionNumber": "Q13177" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 505, + "assayComponentEndpointName": "NVS_ENZ_hPAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPAK4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPAK4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 294, + "assayComponentName": "NVS_ENZ_hPAK4", + "assayComponentDesc": "NVS_ENZ_hPAK4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPAK4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human p21 protein (Cdc42/Rac)-activated kinase 4 [GeneSymbol:PAK4 | GeneID:10298 | Uniprot_SwissProt_Accession:O96013].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 108, + "assayName": "NVS_ENZ_hPAK4", + "assayDesc": "NVS_ENZ_hPAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 364, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "description": null, + "geneSymbol": "PAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10298, + "officialSymbol": "PAK4", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "uniprotAccessionNumber": "O96013" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 507, + "assayComponentEndpointName": "NVS_ENZ_hPDE10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE10 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE10, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trequinsin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 295, + "assayComponentName": "NVS_ENZ_hPDE10", + "assayComponentDesc": "NVS_ENZ_hPDE10 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE10 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 10A [GeneSymbol:PDE10A | GeneID:10846 | Uniprot_SwissProt_Accession:Q9Y233].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 109, + "assayName": "NVS_ENZ_hPDE10", + "assayDesc": "NVS_ENZ_hPDE10 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 509, + "assayComponentEndpointName": "NVS_ENZ_hPDE4A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE4A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trequinsin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 296, + "assayComponentName": "NVS_ENZ_hPDE4A1", + "assayComponentDesc": "NVS_ENZ_hPDE4A1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4A, cAMP-specific [GeneSymbol:PDE4A | GeneID:5141 | Uniprot_SwissProt_Accession:P27815].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 110, + "assayName": "NVS_ENZ_hPDE4A1", + "assayDesc": "NVS_ENZ_hPDE4A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 232, + "geneName": "phosphodiesterase 4A, cAMP-specific", + "description": null, + "geneSymbol": "PDE4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5141, + "officialSymbol": "PDE4A", + "officialFullName": "phosphodiesterase 4A, cAMP-specific", + "uniprotAccessionNumber": "P27815" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 511, + "assayComponentEndpointName": "NVS_ENZ_hPDE5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dipyridamole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 297, + "assayComponentName": "NVS_ENZ_hPDE5", + "assayComponentDesc": "NVS_ENZ_hPDE5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic GMP --> Flourescent 5?-GMP] involving the key substrate [Fluorescent cyclic GMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 5A, cGMP-specific [GeneSymbol:PDE5A | GeneID:8654 | Uniprot_SwissProt_Accession:O76074].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic GMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 111, + "assayName": "NVS_ENZ_hPDE5", + "assayDesc": "NVS_ENZ_hPDE5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 346, + "geneName": "phosphodiesterase 5A, cGMP-specific", + "description": null, + "geneSymbol": "PDE5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8654, + "officialSymbol": "PDE5A", + "officialFullName": "phosphodiesterase 5A, cGMP-specific", + "uniprotAccessionNumber": "O76074" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 513, + "assayComponentEndpointName": "NVS_ENZ_hPI3Ka", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPI3Ka, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is phosphoinositol kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PI-103", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "phosphoinositol kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 298, + "assayComponentName": "NVS_ENZ_hPI3Ka", + "assayComponentDesc": "NVS_ENZ_hPI3Ka is one of one assay component(s) measured or calculated from the NVS_ENZ_hPI3Ka assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP2 + ATP --> fluorescein-PIP3 + ADP] involving the key substrate [Fluorescein-labeled PIP2 (phosphoinositol (4,5)bisphosphate)] are indicative of changes in enzyme function and kinetics for the human phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [GeneSymbol:PIK3CA | GeneID:5290 | Uniprot_SwissProt_Accession:P42336].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled PIP2 (phosphoinositol (4,5)bisphosphate)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 112, + "assayName": "NVS_ENZ_hPI3Ka", + "assayDesc": "NVS_ENZ_hPI3Ka is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 237, + "geneName": "phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha", + "description": null, + "geneSymbol": "PIK3CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5290, + "officialSymbol": "PIK3CA", + "officialFullName": "phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha", + "uniprotAccessionNumber": "P42336" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 515, + "assayComponentEndpointName": "NVS_ENZ_hPKA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "H 89", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 299, + "assayComponentName": "NVS_ENZ_hPKA", + "assayComponentDesc": "NVS_ENZ_hPKA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, cAMP-dependent, catalytic, alpha [GeneSymbol:PRKACA | GeneID:5566 | Uniprot_SwissProt_Accession:P17612].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 113, + "assayName": "NVS_ENZ_hPKA", + "assayDesc": "NVS_ENZ_hPKA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 256, + "geneName": "protein kinase, cAMP-dependent, catalytic, alpha", + "description": null, + "geneSymbol": "PRKACA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5566, + "officialSymbol": "PRKACA", + "officialFullName": "protein kinase, cAMP-dependent, catalytic, alpha", + "uniprotAccessionNumber": "P17612" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10998351", + "pmid": 10998351, + "title": "Specificity and mechanism of action of some commonly used protein kinase inhibitors", + "author": "Davies SP, Reddy H, Caivano M, Cohen P", + "citation": "Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. PubMed PMID: 10998351; PubMed Central PMCID: PMC1221339.", + "otherId": "0", + "citationId": 184, + "otherSource": "" + } + }, + { + "aeid": 517, + "assayComponentEndpointName": "NVS_ENZ_hPKCz", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKCz was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKCz, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 300, + "assayComponentName": "NVS_ENZ_hPKCz", + "assayComponentDesc": "NVS_ENZ_hPKCz is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKCz assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase C, zeta [GeneSymbol:PRKCZ | GeneID:5590 | Uniprot_SwissProt_Accession:Q05513].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 114, + "assayName": "NVS_ENZ_hPKCz", + "assayDesc": "NVS_ENZ_hPKCz is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 258, + "geneName": "protein kinase C, zeta", + "description": null, + "geneSymbol": "PRKCZ", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5590, + "officialSymbol": "PRKCZ", + "officialFullName": "protein kinase C, zeta", + "uniprotAccessionNumber": "Q05513" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json new file mode 100644 index 00000000..a329279d --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json @@ -0,0 +1,9207 @@ +[ + { + "aeid": 704, + "m4id": 1842410, + "spid": "LEGTV002G10", + "chid": 32577, + "casn": "79538-32-2", + "chnm": "Tefluthrin", + "dtxsid": "DTXSID5032577", + "bmad": 3.7634679299683276, + "respMax": 22.88978034849851, + "respMin": -26.552798250251374, + "maxMean": 22.88978034849851, + "maxMeanConc": 0.7781512503836436, + "maxMed": 22.88978034849851, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 9, + "m5id": 5037056, + "modl": "exp4", + "hitc": 0.2411318116914611, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + -0.22184874961635637, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812 + ], + "resp": [ + -26.552798250251374, + 7.643488716816449, + 22.88978034849851, + 7.9412465922401445, + 19.249048936986245, + 22.72625970498906, + 20.26645313099273, + 10.220169791958208 + ] + }, + "mc4Param": { + "pow_a": 8.051875026642751, + "pow_p": 0.3000002363252646, + "exp2_a": 2586.5273948186914, + "exp2_b": 5061.903524643174, + "exp3_a": 16.991620306804258, + "exp3_b": 61.307930252068054, + "exp3_p": 0.3000001542012486, + "exp5_p": 0.41109358960702536, + "gnls_p": 0.5634256102787089, + "gnls_q": 7.950665366879992, + "hill_p": 0.5634498524518311, + "pow_er": 2.1767434212836925, + "cnst_er": 2.8698019137772666, + "exp2_er": 2.623207281861648, + "exp3_er": 2.3192847401467107, + "exp4_er": 2.1056134978195313, + "exp4_ga": 1.0188231249900932, + "exp4_tp": 20.260251446603277, + "exp5_er": 1.9820127172223416, + "exp5_ga": 0.4248866702697808, + "exp5_tp": 20.7377426492478, + "gnls_er": 1.99625942425146, + "gnls_ga": 0.3960985797099487, + "gnls_la": 4930.779736400695, + "gnls_tp": 21.81742856245767, + "hill_er": 1.996272080662291, + "hill_ga": 0.39605546778034006, + "hill_tp": 21.817114896556166, + "poly1_a": 0.5150479432537712, + "poly2_a": 2323.882444395881, + "poly2_b": 4567.207855100587, + "pow_aic": 68.5758988456374, + "pow_cov": 1, + "pow_rme": 12.721053786887008, + "pow_top": 26.03684923789126, + "all_bmed": 0, + "cnst_aic": 72.9602916781216, + "cnst_rme": 18.54949195654765, + "exp2_aic": 73.57241312566146, + "exp2_cov": 1, + "exp2_rme": 15.498838859238056, + "exp2_top": 25.67555887819936, + "exp3_aic": 71.90187282888056, + "exp3_cov": 1, + "exp3_rme": 13.226439348308494, + "exp3_top": 26.53564273777775, + "exp4_aic": 67.91716461253762, + "exp4_cov": 1, + "exp4_rme": 12.291600328368528, + "exp4_top": 20.260251446603277, + "exp5_aic": 68.74654825043743, + "exp5_cov": 1, + "exp5_rme": 12.205391269508892, + "exp5_top": 20.7377426492478, + "gnls_aic": 72.70908001073246, + "gnls_cov": 0, + "gnls_rme": 12.08907864204856, + "gnls_top": 21.62406269958069, + "hill_aic": 68.70908001125854, + "hill_cov": 1, + "hill_rme": 12.089052602788728, + "hill_top": 21.817114896556166, + "poly1_er": 2.6233806365269072, + "poly2_er": 2.623494262991935, + "pow_a_sd": 18.263178960432903, + "pow_ac50": 4.960637316196675, + "pow_p_sd": 0.697941144406865, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 32716.581509859232, + "exp2_ac50": 25.06173541792207, + "exp2_b_sd": 63813.265454996756, + "exp3_a_sd": null, + "exp3_ac50": 9.809731117071673, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.0188231249900932, + "exp5_ac50": 0.4248866702697808, + "exp5_p_sd": 0.34799669960865676, + "gnls_ac50": 0.3838306742682284, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.39605546778034006, + "hill_p_sd": 0.635744845964724, + "poly1_aic": 71.56605507092407, + "poly1_cov": 1, + "poly1_rme": 15.493294256204988, + "poly1_top": 25.75239716268856, + "poly2_aic": 73.57994628381844, + "poly2_cov": 1, + "poly2_rme": 15.50431136692914, + "poly2_top": 25.719470980222596, + "pow_er_sd": 1.15655148324573, + "exp2_er_sd": 0.3073701019975029, + "exp3_er_sd": null, + "exp4_er_sd": 0.387701061369176, + "exp4_ga_sd": 1.301060030418642, + "exp4_tp_sd": 4.791141733238257, + "exp5_er_sd": 0.3929731812861924, + "exp5_ga_sd": 0.8430161520344103, + "exp5_tp_sd": 5.937095261163485, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3920891185604444, + "hill_ga_sd": 1.2602581620806317, + "hill_tp_sd": 10.912262369817968, + "poly1_a_sd": 0.2454616975843716, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 20164.124461380256, + "poly2_ac50": 25.135359225205608, + "poly2_b_sd": 39136.75145557223, + "poly1_er_sd": 0.3073969378754904, + "poly2_er_sd": 0.3073430361679298, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4935.719934078368 + }, + "mc5Param": { + "er": 2.1056134978195313, + "ga": 1.0188231249900932, + "tp": 20.260251446603277, + "ac5": 0.07539350363763271, + "bmd": 0.9015999983866408, + "bmr": 9.289141683881516, + "mll": -30.95858230626881, + "top": 20.260251446603277, + "ac10": 0.15486426667184697, + "ac20": 0.3279877876552497, + "ac50": 1.0188231249900932, + "bmdl": 0.015249773022781948, + "bmdu": 3.811435874108677, + "rmse": 12.291600328368528, + "ac1sd": 0.6104667435797823, + "caikwt": 0.07436025429585817, + "hitcall": 0.2411318116914611, + "top_over_cutoff": 0.8972332532835738 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842408, + "spid": "LEGTV002F02", + "chid": 34634, + "casn": "68157-60-8", + "chnm": "Forchlorfenuron", + "dtxsid": "DTXSID1034634", + "bmad": 3.7634679299683276, + "respMax": 30.305480403437308, + "respMin": -15.782463123633022, + "maxMean": 30.305480403437308, + "maxMeanConc": 1.6989700043360187, + "maxMed": 30.305480403437308, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 7, + "m5id": 5037054, + "modl": "poly1", + "hitc": 0.6460864720880574, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + -0.22184874961635637, + -1.154901959985743 + ], + "resp": [ + 17.312197447937717, + 5.892444361517972, + -5.621637590571268, + 30.305480403437308, + -12.047921136921975, + -0.9033802904499949, + 3.9506691129976836, + -15.782463123633022 + ] + }, + "mc4Param": { + "pow_a": 0.1234505358742655, + "pow_p": 1.4039572198662018, + "exp2_a": 11.704126631709482, + "exp2_b": 39.21885087510036, + "exp3_a": 6.797876599868359, + "exp3_b": 27.227754995685633, + "exp3_p": 0.8670700138038412, + "exp5_p": 2.243572303903159, + "gnls_p": 3.417276045729987, + "gnls_q": 7.9999995152294145, + "hill_p": 3.410031445934874, + "pow_er": 2.053160430913364, + "cnst_er": 2.4831651329165245, + "exp2_er": 2.0477140196724335, + "exp3_er": 2.045418371135353, + "exp4_er": 2.1440692417744724, + "exp4_ga": 27.444981809921984, + "exp4_tp": 36.36657640836127, + "exp5_er": 2.056168804647671, + "exp5_ga": 33.29374622826353, + "exp5_tp": 36.366576245073674, + "gnls_er": 2.0583941068083926, + "gnls_ga": 31.61205104146836, + "gnls_la": 1534.1122637713574, + "gnls_tp": 36.36657643578302, + "hill_er": 2.058279940276527, + "hill_ga": 31.61029453570885, + "hill_tp": 36.36657616615269, + "poly1_a": 0.5785182000394039, + "poly2_a": 12.459385888548155, + "poly2_b": 44.18199252652262, + "pow_aic": 65.0995287126822, + "pow_cov": 1, + "pow_rme": 9.38736161655436, + "pow_top": 29.976034738668837, + "all_bmed": 0, + "cnst_aic": 67.9344363146865, + "cnst_rme": 14.5564438526066, + "exp2_aic": 65.01101796690389, + "exp2_cov": 1, + "exp2_rme": 9.336855219455533, + "exp2_top": 30.177138850514144, + "exp3_aic": 67.00414392078824, + "exp3_cov": 1, + "exp3_rme": 9.328883445138253, + "exp3_top": 30.184512709969923, + "exp4_aic": 65.8649681972613, + "exp4_cov": 1, + "exp4_rme": 9.540601853567534, + "exp4_top": 36.36657640836127, + "exp5_aic": 67.2557220191338, + "exp5_cov": 1, + "exp5_rme": 9.530978553849964, + "exp5_top": 36.366576245073674, + "gnls_aic": 71.33940383936331, + "gnls_cov": 1, + "gnls_rme": 9.604561582504878, + "gnls_top": 36.36043012871301, + "hill_aic": 67.33939320817458, + "hill_cov": 1, + "hill_rme": 9.604376235570829, + "hill_top": 36.36657616615269, + "poly1_er": 2.085652025408799, + "poly2_er": 2.049820013105159, + "pow_a_sd": 0.5753788358968032, + "pow_ac50": 30.517899763456313, + "pow_p_sd": 1.208640790059217, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 41.73861131597536, + "exp2_ac50": 32.48057507982734, + "exp2_b_sd": 80.2181969794621, + "exp3_a_sd": 55.46148196934477, + "exp3_ac50": 32.61409306497238, + "exp3_b_sd": 155.31132615599387, + "exp3_p_sd": 1.7685350503057042, + "exp4_ac50": 27.444981809921984, + "exp5_ac50": 33.29374622826353, + "exp5_p_sd": 3.435165237165201, + "gnls_ac50": 31.60892429289404, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 31.61029453570885, + "hill_p_sd": 23.432436210259, + "poly1_aic": 63.26368385628203, + "poly1_cov": 1, + "poly1_rme": 9.335379666909818, + "poly1_top": 28.92591000197019, + "poly2_aic": 65.04407548989566, + "poly2_cov": 1, + "poly2_rme": 9.347372572279864, + "poly2_top": 30.056881540429895, + "pow_er_sd": 0.33301411643671863, + "exp2_er_sd": 0.3322758677027563, + "exp3_er_sd": 0.3319875527085669, + "exp4_er_sd": 0.3157481584060974, + "exp4_ga_sd": 34.059639655609715, + "exp4_tp_sd": 26.977496390379052, + "exp5_er_sd": 0.334389570780719, + "exp5_ga_sd": 37.91927313278114, + "exp5_tp_sd": 50.504063030446645, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.33640069974138875, + "hill_ga_sd": 126.4453565783159, + "hill_tp_sd": 150.73989659276037, + "poly1_a_sd": 0.13788942465596515, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 81.28656120170228, + "poly2_ac50": 31.22468556738295, + "poly2_b_sd": 189.87096202288063, + "poly1_er_sd": 0.31798965447224936, + "poly2_er_sd": 0.3317697682239624, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1534.1764211860095 + }, + "mc5Param": { + "a": 0.5785182000394039, + "er": 2.085652025408799, + "ac5": 2.4999999999999996, + "acc": 39.03214726567279, + "bmd": 16.05678383713566, + "bmr": 9.289141683881516, + "mll": -29.631841928141014, + "top": 28.92591000197019, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 11.311189751842544, + "bmdu": 29.51384383733146, + "rmse": 9.335379666909818, + "ac1sd": 11.902730791056827, + "caikwt": 0.08823518845609243, + "hitcall": 0.6460864720880574, + "top_over_cutoff": 1.2809953718322074 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842409, + "spid": "LEGTV002F07", + "chid": 32392, + "casn": "66441-23-4", + "chnm": "Fenoxaprop-ethyl", + "dtxsid": "DTXSID2032392", + "bmad": 3.7634679299683276, + "respMax": 11.82202000041872, + "respMin": -15.519375841783155, + "maxMean": 11.82202000041872, + "maxMeanConc": -1.6989700043360187, + "maxMed": 11.82202000041872, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 8, + "m5id": 5037055, + "modl": "poly1", + "hitc": 1.4322271531083211E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 1.6989700043360187 + ], + "resp": [ + 11.82202000041872, + 1.5536961694941236, + -15.519375841783155, + -3.18010844609448, + -2.140589126080783, + 8.784412793010326, + -2.3157498063462607, + -0.3023091900039757 + ] + }, + "mc4Param": { + "pow_a": 0.0000011632431730420026, + "pow_p": 0.371275158646456, + "exp2_a": 0.000001797829505777648, + "exp2_b": 72.74913416945634, + "exp3_a": 0.0000055005758644098394, + "exp3_b": 57.760844012588784, + "exp3_p": 6.22085425509824, + "exp5_p": 0.8997002598611641, + "gnls_p": 6.745015045169553, + "gnls_q": 7.999999994872401, + "hill_p": 7.540290076592129, + "pow_er": 1.8022541315256504, + "cnst_er": 1.8015796789499128, + "exp2_er": 1.8007494516437397, + "exp3_er": 1.8021894413500723, + "exp4_er": 1.80158870051793, + "exp4_ga": 7.782862626322558, + "exp4_tp": 3.226750921155688E-9, + "exp5_er": 1.8015912094733963, + "exp5_ga": 8.441755009402286, + "exp5_tp": 7.302557281932975E-10, + "gnls_er": 1.563319486875444, + "gnls_ga": 0.0021571134721910935, + "gnls_la": 0.3339308415916757, + "gnls_tp": 7.623928704938419, + "hill_er": 1.8015890186604628, + "hill_ga": 157.94452896356304, + "hill_tp": 1.8955153678433672, + "poly1_a": 5.662423411973493E-10, + "poly2_a": 0.000022326254566998696, + "poly2_b": 56.36270470222716, + "pow_aic": 61.5780037237116, + "pow_cov": 1, + "pow_rme": 7.748713087460874, + "pow_top": 0.0000049711385820584395, + "all_bmed": 0, + "cnst_aic": 57.57799866553477, + "cnst_rme": 7.748712496775653, + "exp2_aic": 61.578004749066096, + "exp2_cov": 1, + "exp2_rme": 7.748712562373631, + "exp2_top": 0.0000017768428039737286, + "exp3_aic": 63.57800185669078, + "exp3_cov": 1, + "exp3_rme": 7.748712510532352, + "exp3_top": 0.000002767495920583712, + "exp4_aic": 61.577998666698214, + "exp4_cov": 1, + "exp4_rme": 7.748712497203208, + "exp4_top": 3.226750921155688E-9, + "exp5_aic": 63.57799866627887, + "exp5_cov": 1, + "exp5_rme": 7.74871249686776, + "exp5_top": 7.302557281932975E-10, + "gnls_aic": 64.94555137524486, + "gnls_cov": 1, + "gnls_rme": 6.978798723259373, + "gnls_top": 7.6239285577032945, + "hill_aic": 63.57800538783228, + "hill_cov": 1, + "hill_rme": 7.748714090611704, + "hill_top": 1.8955153678433672, + "poly1_er": 1.801569355455974, + "poly2_er": 1.8017915647795937, + "pow_a_sd": null, + "pow_ac50": 7.72982644524005, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.213607891471405, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.42645739987168, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 7.782862626322558, + "exp5_ac50": 8.441755009402286, + "exp5_p_sd": null, + "gnls_ac50": 0.0021571134162010203, + "gnls_p_sd": 1886.6181378919537, + "gnls_q_sd": 13.897596369316378, + "hill_ac50": 157.94452896356304, + "hill_p_sd": null, + "poly1_aic": 59.577998670402955, + "poly1_cov": 1, + "poly1_rme": 7.748712498123487, + "poly1_top": 2.831211705986746E-8, + "poly2_aic": 61.57800229689971, + "poly2_cov": 1, + "poly2_rme": 7.748713685123689, + "poly2_top": 0.00003737589473088489, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.39059567343598767, + "gnls_ga_sd": 1.343381900673757, + "gnls_la_sd": 0.3212711194493188, + "gnls_tp_sd": 3.818735746599816, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.1026000354392676, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.58306067150831, + "poly2_b_sd": null, + "poly1_er_sd": 0.34707929934562703, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.3339308431136041 + }, + "mc5Param": { + "a": 5.662423411973493E-10, + "er": 1.801569355455974, + "ac5": 2.5, + "bmd": 16404887109.358751, + "bmr": 9.289141683881516, + "mll": -27.78899933520148, + "top": 2.831211705986746E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 62.41443596324167, + "rmse": 7.748712498123487, + "ac1sd": 12160776211.533545, + "caikwt": 0.7310585791085764, + "hitcall": 0.000014322271531083213, + "top_over_cutoff": 1.253813308483351E-9 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842411, + "spid": "LEGTV002H08", + "chid": 34742, + "casn": "NOCAS_34742", + "chnm": "Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin A3)", + "dtxsid": "DTXSID8034742", + "bmad": 3.7634679299683276, + "respMax": 73.67532078350177, + "respMin": -5.395088130329359, + "maxMean": 73.67532078350177, + "maxMeanConc": 0.7781512503836436, + "maxMed": 73.67532078350177, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 6, + "tmpi": 10, + "m5id": 5037057, + "modl": "exp4", + "hitc": 0.9999994968056571, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.22184874961635637, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 52.505652872749074, + -5.395088130329359, + 73.67532078350177, + 5.395088130329359, + 72.53691394012041, + 19.22317269185714, + 30.263301277685446, + 69.87972321355599 + ] + }, + "mc4Param": { + "pow_a": 28.147886385576328, + "pow_p": 0.30000009689641516, + "exp2_a": 6119.261472113918, + "exp2_b": 3551.239003137988, + "exp3_a": 975.1669226858538, + "exp3_b": 153230.6117998245, + "exp3_p": 0.3000003501105035, + "exp5_p": 1.094805881965073, + "gnls_p": 1.3647130188568126, + "gnls_q": 0.5619058173970354, + "hill_p": 1.59050714992454, + "pow_er": 2.63553254897771, + "cnst_er": 3.795906798840122, + "exp2_er": 3.3954987701188113, + "exp3_er": 2.727845635618811, + "exp4_er": 1.4689672679270718, + "exp4_ga": 1.099878418012791, + "exp4_tp": 72.48760653689077, + "exp5_er": 1.385097799783372, + "exp5_ga": 1.132980663465564, + "exp5_tp": 72.29651505256778, + "gnls_er": 1.3581230433996936, + "gnls_ga": 1.3915857757652723, + "gnls_la": 524.1224234965719, + "gnls_tp": 88.41038117121148, + "hill_er": 1.5970021189190942, + "hill_ga": 1.077282613722834, + "hill_tp": 73.26305717696057, + "poly1_a": 1.7397504631410787, + "poly2_a": 8413.5045447357, + "poly2_b": 4888.583862175059, + "pow_aic": 73.54169876654271, + "pow_cov": 1, + "pow_rme": 15.2861480042891, + "pow_top": 91.02002602025269, + "all_bmed": 0, + "cnst_aic": 88.28390953083002, + "cnst_rme": 49.58992816204983, + "exp2_aic": 86.10951984809975, + "exp2_cov": 1, + "exp2_rme": 34.328944054173824, + "exp2_top": 86.76609362549449, + "exp3_aic": 75.92329672154494, + "exp3_cov": 1, + "exp3_rme": 15.630160935729108, + "exp3_top": 91.8010727392276, + "exp4_aic": 59.2793317878772, + "exp4_cov": 1, + "exp4_rme": 8.238704361671774, + "exp4_top": 72.48760653689077, + "exp5_aic": 61.10190561453248, + "exp5_cov": 1, + "exp5_rme": 8.62848952975195, + "exp5_top": 72.29651505256778, + "gnls_aic": 65.36002423995862, + "gnls_cov": 1, + "gnls_rme": 9.055176915896654, + "gnls_top": 75.01351487350438, + "hill_aic": 63.48641699639106, + "hill_cov": 1, + "hill_rme": 9.621896825468774, + "hill_top": 73.26305717696057, + "poly1_er": 3.393356939188565, + "poly2_er": 3.3954441024657243, + "pow_a_sd": 8.463344228881985, + "pow_ac50": 4.960631989323517, + "pow_p_sd": 0.09202961052734752, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 44830.330426869536, + "exp2_ac50": 25.087996729753247, + "exp2_b_sd": 25840.49536754701, + "exp3_a_sd": 1604.028096378901, + "exp3_ac50": 5.3422803072846445, + "exp3_b_sd": 660507.3822297514, + "exp3_p_sd": 0.10541901370789264, + "exp4_ac50": 1.099878418012791, + "exp5_ac50": 1.132980663465564, + "exp5_p_sd": 0.2147453097848282, + "gnls_ac50": 1.158904104169734, + "gnls_p_sd": 0.3461607578247413, + "gnls_q_sd": 0.7944942746221946, + "hill_ac50": 1.077282613722834, + "hill_p_sd": 0.4118849346917922, + "poly1_aic": 84.09047084550053, + "poly1_cov": 1, + "poly1_rme": 34.282455965850914, + "poly1_top": 86.98752315705393, + "poly2_aic": 86.11783010298875, + "poly2_cov": 1, + "poly2_rme": 34.3417360780736, + "poly2_top": 86.93271261079072, + "pow_er_sd": 0.32772739565048525, + "exp2_er_sd": 0.3154107490786174, + "exp3_er_sd": 0.34995551663162316, + "exp4_er_sd": 0.3801021109960385, + "exp4_ga_sd": 0.15804671767015727, + "exp4_tp_sd": 2.557860936885942, + "exp5_er_sd": 0.4212709024359285, + "exp5_ga_sd": 0.1485229561872174, + "exp5_tp_sd": 2.346998337980212, + "gnls_er_sd": 0.4418044445090503, + "gnls_ga_sd": 0.4322859035235454, + "gnls_la_sd": 1067.6005455781465, + "gnls_tp_sd": 26.852332203983984, + "hill_er_sd": 0.39657332639532145, + "hill_ga_sd": 0.16949083304776472, + "hill_tp_sd": 3.4053560285886713, + "poly1_a_sd": 0.5875701839815818, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 52103.4262311332, + "poly2_ac50": 25.12655125481741, + "poly2_b_sd": 29886.906099027077, + "poly1_er_sd": 0.31507639708506446, + "poly2_er_sd": 0.31533923357704763, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 902.1729967630253 + }, + "mc5Param": { + "er": 1.4689672679270718, + "ga": 1.099878418012791, + "tp": 72.48760653689077, + "ac5": 0.08139164245040806, + "acc": 0.59228230830365, + "bmd": 0.21760526858009044, + "bmr": 9.289141683881516, + "mll": -26.6396658939386, + "top": 72.48760653689077, + "ac10": 0.167184921951392, + "ac20": 0.3540817637185837, + "ac50": 1.099878418012791, + "bmdl": 0.17276594676938292, + "bmdu": 0.2697433120933787, + "rmse": 8.238704361671774, + "ac1sd": 0.15838472357506664, + "caikwt": 5.031943424985008E-7, + "hitcall": 0.9999994968056573, + "top_over_cutoff": 3.210142342371477 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842412, + "spid": "LEGTV003B07", + "chid": 23892, + "casn": "71751-41-2", + "chnm": "Abamectin", + "dtxsid": "DTXSID8023892", + "bmad": 3.7634679299683276, + "respMax": 77.95705815614956, + "respMin": -28.22028225978724, + "maxMean": 77.95705815614956, + "maxMeanConc": 1.6989700043360187, + "maxMed": 77.95705815614956, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 5, + "tmpi": 11, + "m5id": 5037058, + "modl": "hill", + "hitc": 0.9999986614193673, + "fitc": 41, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + 64.23854892075744, + -28.22028225978724, + 71.52551303778179, + -8.36715608785845, + 77.90911291815605, + 1.215720341597959, + 77.60553886175157, + 77.95705815614956 + ] + }, + "mc4Param": { + "pow_a": 30.822288131348024, + "pow_p": 0.3000004325120875, + "exp2_a": 9745.30422459993, + "exp2_b": 4985.4095456974865, + "exp3_a": 743.0734773552446, + "exp3_b": 48000.25079936882, + "exp3_p": 0.30036500057781645, + "exp5_p": 4.387719474863923, + "gnls_p": 5.312129658102232, + "gnls_q": 6.044467438794108, + "hill_p": 5.312112708921902, + "pow_er": 3.2500407355444447, + "cnst_er": 4.016143460737711, + "exp2_er": 3.6767003773089906, + "exp3_er": 3.320916603363695, + "exp4_er": 2.55983470322537, + "exp4_ga": 0.4227743529273414, + "exp4_tp": 77.51175315148927, + "exp5_er": 1.566158921380688, + "exp5_ga": 0.4808129543908409, + "exp5_tp": 76.49260417613746, + "gnls_er": 1.5661710124267216, + "gnls_ga": 0.43921987635195425, + "gnls_la": 3693.146065235527, + "gnls_tp": 76.49829109592685, + "hill_er": 1.56618318750266, + "hill_ga": 0.4392211414112244, + "hill_tp": 76.4982866415209, + "poly1_a": 1.964864684075168, + "poly2_a": 13315.496644004026, + "poly2_b": 6833.361453964935, + "pow_aic": 83.17121500215309, + "pow_cov": 1, + "pow_rme": 27.538007561894084, + "pow_top": 99.66819933343275, + "all_bmed": 0, + "cnst_aic": 91.47566405075946, + "cnst_rme": 59.45598607857977, + "exp2_aic": 90.43010743722112, + "exp2_cov": 1, + "exp2_rme": 44.39325952551422, + "exp2_top": 98.2300154558304, + "exp3_aic": 85.41740122713443, + "exp3_cov": 1, + "exp3_rme": 27.91524176610176, + "exp3_top": 100.72988078777028, + "exp4_aic": 73.1330171088266, + "exp4_cov": 1, + "exp4_rme": 15.554088816265924, + "exp4_top": 77.51175315148927, + "exp5_aic": 64.42879073216514, + "exp5_cov": 1, + "exp5_rme": 10.586877659593066, + "exp5_top": 76.49260417613746, + "gnls_aic": 68.42786525704236, + "gnls_cov": 1, + "gnls_rme": 10.586540812021129, + "gnls_top": 76.49829109470431, + "hill_aic": 64.42786525848331, + "hill_cov": 1, + "hill_rme": 10.58654076385496, + "hill_top": 76.4982866415209, + "poly1_er": 3.675479917703469, + "poly2_er": 3.6753004741857582, + "pow_a_sd": 14.109693155432794, + "pow_ac50": 4.960644811507054, + "pow_p_sd": 0.13040289753508288, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 95296.73353627026, + "exp2_ac50": 25.06268265173192, + "exp2_b_sd": 48443.778447988494, + "exp3_a_sd": 1550.6811753333395, + "exp3_ac50": 5.520304040411192, + "exp3_b_sd": 261983.9706240629, + "exp3_p_sd": 0.14665644781542486, + "exp4_ac50": 0.4227743529273414, + "exp5_ac50": 0.4808129543908409, + "exp5_p_sd": 3.3678395549353852, + "gnls_ac50": 0.4392198767408624, + "gnls_p_sd": 3.3958255218054663, + "gnls_q_sd": 151123.9464489836, + "hill_ac50": 0.4392211414112244, + "hill_p_sd": 3.3956061053853364, + "poly1_aic": 88.41948218774404, + "poly1_cov": 1, + "poly1_rme": 44.36648863230358, + "poly1_top": 98.2432342037584, + "poly2_aic": 90.43488820771466, + "poly2_cov": 1, + "poly2_rme": 44.40668518959494, + "poly2_top": 98.14296226438184, + "pow_er_sd": 0.30358860504155505, + "exp2_er_sd": 0.3103300882267534, + "exp3_er_sd": 0.31482864784179443, + "exp4_er_sd": 0.3265560847968896, + "exp4_ga_sd": 0.18734711782917823, + "exp4_tp_sd": 6.138860820650144, + "exp5_er_sd": 0.42334596392662655, + "exp5_ga_sd": 0.08381003754668022, + "exp5_tp_sd": 2.37147868048167, + "gnls_er_sd": 0.4232676288363896, + "gnls_ga_sd": 0.09134632329842142, + "gnls_la_sd": 397472143.96622753, + "gnls_tp_sd": 2.3747859083019507, + "hill_er_sd": 0.4232684668587263, + "hill_ga_sd": 0.09134005178183088, + "hill_tp_sd": 2.3748058180813865, + "poly1_a_sd": 0.744525928526376, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 108969.20708301498, + "poly2_ac50": 25.090797462838403, + "poly2_b_sd": 55447.95612242906, + "poly1_er_sd": 0.31021542326112006, + "poly2_er_sd": 0.3101964438666455, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3693.146065255056 + }, + "mc5Param": { + "p": 5.312112708921902, + "er": 1.56618318750266, + "ga": 0.4392211414112244, + "tp": 76.4982866415209, + "ac5": 0.25232432887622686, + "acc": 0.37284383772523594, + "bmd": 0.3026161445689406, + "bmr": 9.289141683881516, + "mll": -28.213932629241658, + "top": 76.4982866415209, + "ac10": 0.2904343777444861, + "ac20": 0.3383343045279963, + "ac50": 0.4392211414112244, + "bmdl": 0.24652928226101983, + "bmdu": 0.34140137679409, + "rmse": 10.58654076385496, + "ac1sd": 0.28414838641852014, + "caikwt": 0.0000013385806326866767, + "hitcall": 0.9999986614193672, + "top_over_cutoff": 3.3877568980269706 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842413, + "spid": "Strychnine nitrate", + "chid": null, + "casn": null, + "chnm": null, + "dtxsid": null, + "bmad": 3.7634679299683276, + "respMax": 101.90302651672913, + "respMin": -13.656252398863883, + "maxMean": 90.10574793432083, + "maxMeanConc": 0.0, + "maxMed": 92.78949471220062, + "maxMedConc": 1.0, + "logcMax": 1.0, + "logcMin": -2.0, + "nconc": 5, + "npts": 120, + "nrep": 28.0, + "nmedGtbl": 4, + "tmpi": 12, + "m5id": 5037059, + "modl": "hill", + "hitc": 0.9999999999995097, + "fitc": 41, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": null, + "stkc": null, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + 0, + -1, + -1.3010299956639813, + -1.3010299956639813, + 0, + -2, + -1, + 1, + 1, + -2, + -2, + 0, + 0, + 0, + -2, + -2, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + -2, + 1, + -1.3010299956639813, + 0, + -1, + -1.3010299956639813, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + -1, + 0, + -2, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + -1.3010299956639813, + 1, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + -1.3010299956639813, + -1, + -1.3010299956639813, + -2, + -1.3010299956639813, + 1, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + 0, + -1, + -2, + 0, + 0, + 0, + 0, + -2, + -2, + 0, + 0, + -1, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + 1, + 0, + -1.3010299956639813, + 0, + -1, + 0, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + -1.3010299956639813, + 1, + -2, + 0, + 1, + 0, + 0, + 1, + -2, + 0, + 0, + -2, + -2, + 0, + -1.3010299956639813, + 0, + 0, + -2, + -1, + -1.3010299956639813, + -1.3010299956639813, + -1.3010299956639813 + ], + "resp": [ + 87.54658046017934, + 78.13232047400955, + 70.93317595233076, + 57.12698428271491, + 99.1261742792355, + 37.51266678271632, + 67.39566754400876, + 87.16917249987551, + 97.84412575893514, + 36.182153851871945, + 18.676759780138298, + 86.14639524902825, + 92.14700970993877, + 88.8633754305396, + 52.588582215844326, + 15.582133819049302, + 6.7437112326760795, + 90.99910854039037, + 93.537388378317, + 4.532945470243127, + 98.29029571012077, + 87.5125820151942, + 95.77948529616398, + 76.69719021917145, + 79.44282282360146, + 93.41848845767122, + 43.82855649076092, + 60.078635480642816, + 48.55573840229915, + 93.38936767278678, + 68.38088898210545, + 94.44174081967034, + 70.23063280229242, + 67.58951070420052, + 88.25476716259126, + 78.28663544945115, + 73.35709503155529, + 87.41418530525512, + 34.29624566401982, + 51.689530650495065, + 94.77671619175891, + 9.717713327456835, + 68.42696208430887, + 89.1457018171264, + 98.63621639131843, + 21.819867325289668, + 73.31442418286787, + 84.44684859725044, + 101.90302651672913, + 52.3796866174266, + 76.70392442439466, + 95.96954413243368, + 37.932664452132045, + 85.53995501238715, + 93.19761923373274, + 9.374938681003872, + 97.00772826137256, + 94.52068000480857, + 70.03934960306947, + 70.2207854474335, + 80.60056702989422, + 49.65332555177622, + 50.62118183723142, + -13.656252398863883, + 25.103929419420417, + 84.06775274470809, + 93.89545097387872, + 13.05234184109041, + 68.04669508697455, + 88.31017585712213, + 95.74909219574056, + 71.26573270110495, + 29.657483179306475, + 89.44967487095494, + 87.91122190917191, + 89.16083809801721, + 94.23105830572473, + 11.031715473484446, + 35.95756511831335, + 83.96484285494779, + 91.13344836386635, + 74.37468254708669, + 75.90341444167755, + 84.57925357612386, + 98.09697348327087, + 80.87025230976089, + 95.69038769184029, + 88.16849658860856, + 80.80349695840118, + 81.03526087553716, + 70.7375590556676, + 89.62211351249503, + 92.83767649850626, + 69.7285258942436, + 77.48304372596083, + 85.86002702419643, + 32.2784448599929, + 46.17015103402697, + 80.62410063741106, + 95.95106666573619, + 10.20724914281911, + 79.02545835944098, + 87.98083471817364, + 91.89339887484604, + 95.37517669787248, + 92.18962175161448, + 25.413153770849384, + 85.26467195488401, + 94.339523858436, + 21.432040978539256, + 30.458993571633304, + 93.86466610169768, + 70.85250358307763, + 84.70694885833929, + 90.17107266940845, + 42.17348917186203, + 67.85218078295692, + 80.66923781410267, + 52.40470406123019, + 66.29938729985028 + ] + }, + "mc4Param": { + "pow_a": 87.09928260115939, + "pow_p": 0.30000001846938457, + "exp2_a": 31883.447199556984, + "exp2_b": 2940.8756880830274, + "exp3_a": 91.76407834702847, + "exp3_b": 10.74787786809403, + "exp3_p": 5.705870147581669, + "exp5_p": 0.7347141145071212, + "gnls_p": 1.14249184755643, + "gnls_q": 7.1666617485862645, + "hill_p": 1.1425173709866314, + "pow_er": 3.2609559647059276, + "cnst_er": 4.280418232198627, + "exp2_er": 4.136618684570908, + "exp3_er": 4.195352905645352, + "exp4_er": 2.22008241758199, + "exp4_ga": 0.022051638521133003, + "exp4_tp": 89.00270902788958, + "exp5_er": 2.1777043891985155, + "exp5_ga": 0.020174723818180185, + "exp5_tp": 90.09083963206248, + "gnls_er": 2.1414728444590416, + "gnls_ga": 0.019239355601206622, + "gnls_la": 152.60173969793468, + "gnls_tp": 90.96174103754969, + "hill_er": 2.141463902181826, + "hill_ga": 0.019239408518013583, + "hill_tp": 90.96158402591846, + "poly1_a": 10.857285554865078, + "poly2_a": 43956.72490990105, + "poly2_b": 4063.958522468021, + "pow_aic": 1201.4051365890562, + "pow_cov": 1, + "pow_rme": 38.55227695861075, + "pow_top": 173.78592362556904, + "all_bmed": 0, + "cnst_aic": 1403.090413337808, + "cnst_rme": 74.8904479807055, + "exp2_aic": 1374.4311656282052, + "exp2_cov": 1, + "exp2_rme": 65.81746775643614, + "exp2_top": 108.5993407555391, + "exp3_aic": 1391.1625030286802, + "exp3_cov": 1, + "exp3_rme": 70.11489384972245, + "exp3_top": 86.24941190716868, + "exp4_aic": 958.5585213667588, + "exp4_cov": 1, + "exp4_rme": 17.136859425351332, + "exp4_top": 89.00270902788958, + "exp5_aic": 951.462915769895, + "exp5_cov": 1, + "exp5_rme": 16.563670044171328, + "exp5_top": 90.09083963206248, + "gnls_aic": 949.1076392567716, + "gnls_cov": 1, + "gnls_rme": 16.523174598011288, + "gnls_top": 90.94223261829664, + "hill_aic": 945.1076391339816, + "hill_cov": 1, + "hill_rme": 16.52318715556179, + "hill_top": 90.96158402591846, + "poly1_er": 4.136728636883216, + "poly2_er": 4.136765485844394, + "pow_a_sd": null, + "pow_ac50": 0.9921257986045094, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 199788.2012717345, + "exp2_ac50": 5.004250432627864, + "exp2_b_sd": 18377.639690188746, + "exp3_a_sd": null, + "exp3_ac50": 9.093200201104786, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.022051638521133003, + "exp5_ac50": 0.020174723818180185, + "exp5_p_sd": 0.0740314724723753, + "gnls_ac50": 0.01923213377527789, + "gnls_p_sd": 0.11328716035704128, + "gnls_q_sd": 5416.430149594935, + "hill_ac50": 0.019239408518013583, + "hill_p_sd": 0.11328905952344805, + "poly1_aic": 1372.405512117827, + "poly1_cov": 1, + "poly1_rme": 65.81045931392097, + "poly1_top": 108.57285554865078, + "poly2_aic": 1374.4425868107508, + "poly2_cov": 1, + "poly2_rme": 65.82134141098302, + "poly2_top": 108.42848666577588, + "pow_er_sd": null, + "exp2_er_sd": 0.07550543011989125, + "exp3_er_sd": null, + "exp4_er_sd": 0.08755079994277236, + "exp4_ga_sd": 0.0017581307838751255, + "exp4_tp_sd": 1.2648745704125903, + "exp5_er_sd": 0.08793429019100046, + "exp5_ga_sd": 0.001896252806984504, + "exp5_tp_sd": 1.229548672184863, + "gnls_er_sd": 0.08841293445887041, + "gnls_ga_sd": 0.0016388070613483495, + "gnls_la_sd": 314310.1153126622, + "gnls_tp_sd": 1.3592077185077482, + "hill_er_sd": 0.08841259880190765, + "hill_ga_sd": 0.001638789350228368, + "hill_tp_sd": 1.3591867915855804, + "poly1_a_sd": 1.724413789883238, + "poly1_ac50": 5, + "poly2_a_sd": 229686.482934115, + "poly2_ac50": 5.006136528441479, + "poly2_b_sd": 21186.121669100652, + "poly1_er_sd": 0.07551023114530929, + "poly2_er_sd": 0.07551301062757607, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 152.6093800236882 + }, + "mc5Param": { + "p": 1.1425173709866314, + "er": 2.141463902181826, + "ga": 0.019239408518013583, + "tp": 90.96158402591846, + "ac5": 0.001462007378119528, + "acc": 0.007294932270379909, + "bmd": 0.002869845955059214, + "bmr": 9.289141683881516, + "mll": -468.55381956699074, + "top": 90.96158402591846, + "ac10": 0.0028117791882338312, + "ac20": 0.005717847375539592, + "ac50": 0.019239408518013583, + "bmdl": 0.002556132850019782, + "bmdu": 0.003219636919114361, + "rmse": 16.52318715556179, + "ac1sd": 0.0021529836063463184, + "caikwt": 3.550619862824629E-100, + "hitcall": 0.9999999999995096, + "top_over_cutoff": 4.028269746527992 + }, + "mc6Param": null + }, + { + "aeid": 704, + "m4id": 1842414, + "spid": "TP0000202A12", + "chid": 40755, + "casn": "113776-20-8", + "chnm": "Fenoxaprop-(2S)-ethyl", + "dtxsid": "DTXSID0040755", + "bmad": 3.7634679299683276, + "respMax": 2.1463056962554306, + "respMin": -31.174537622350467, + "maxMean": 2.1463056962554306, + "maxMeanConc": 0.3010299956639812, + "maxMed": 2.1463056962554306, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 13, + "m5id": 5037060, + "modl": "poly1", + "hitc": 3.112525321590652E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + -6.001541932753394, + -22.555888323094198, + 2.1463056962554306, + 1.48208851017487, + -31.174537622350467, + -1.4820885101748698, + -18.65401670786573, + -1.8956068394961023 + ] + }, + "mc4Param": { + "pow_a": 7.93772851385601E-8, + "pow_p": 0.3920636582682493, + "exp2_a": 0.000006112271332380458, + "exp2_b": 53.427073060892454, + "exp3_a": 0.00004898139853742899, + "exp3_b": 51.88258897771602, + "exp3_p": 2.324270887717195, + "exp5_p": 0.7819736441489689, + "gnls_p": 0.3273711734771393, + "gnls_q": 5.276277742389474, + "hill_p": 2.275897186558642, + "pow_er": 2.455992402942634, + "cnst_er": 2.4560891502518984, + "exp2_er": 2.4574807100236153, + "exp3_er": 2.4557796019426146, + "exp4_er": 2.456099699774736, + "exp4_ga": 2.3234618330958865, + "exp4_tp": 3.9607133152532646E-9, + "exp5_er": 2.4560842486541183, + "exp5_ga": 3.1011214463834262, + "exp5_tp": 5.124637982443043E-9, + "gnls_er": 2.45606236272885, + "gnls_ga": 2.0776018550817037, + "gnls_la": 105.43975814448936, + "gnls_tp": 2.3963648893966506E-8, + "hill_er": 2.456123173511501, + "hill_ga": 86.3108381026584, + "hill_tp": 4.991236675789709E-8, + "poly1_a": 5.0558047407700206E-11, + "poly2_a": 0.000050849272267483245, + "poly2_b": 54.52806494231579, + "pow_aic": 72.32793038983723, + "pow_cov": 1, + "pow_rme": 15.318305641270856, + "pow_top": 3.6796002210498555E-7, + "all_bmed": 0, + "cnst_aic": 68.32793015445507, + "cnst_rme": 15.318305491530715, + "exp2_aic": 72.32794851195803, + "exp2_cov": 1, + "exp2_rme": 15.318307841595969, + "exp2_top": 0.00000947030777995316, + "exp3_aic": 74.32794792480452, + "exp3_cov": 1, + "exp3_rme": 15.318319988232922, + "exp3_top": 0.00007364243647945785, + "exp4_aic": 72.32793015872747, + "exp4_cov": 1, + "exp4_rme": 15.318305493705283, + "exp4_top": 3.9607133152532646E-9, + "exp5_aic": 74.32793015704087, + "exp5_cov": 1, + "exp5_rme": 15.31830549412419, + "exp5_top": 5.124637982443043E-9, + "gnls_aic": 78.32793016843104, + "gnls_cov": 1, + "gnls_rme": 15.31830550116845, + "gnls_top": 1.7376669540347054E-8, + "hill_aic": 74.32793016978079, + "hill_cov": 1, + "hill_rme": 15.318305493880896, + "hill_top": 4.991236675789709E-8, + "poly1_er": 2.456091603321706, + "poly2_er": 2.458795669607504, + "pow_a_sd": null, + "pow_ac50": 8.534164879531097, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.647334567122023, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 40.44683070951887, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.3234618330958865, + "exp5_ac50": 3.1011214463834262, + "exp5_p_sd": null, + "gnls_ac50": 0.3706914715054184, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 86.3108381026584, + "hill_p_sd": null, + "poly1_aic": 70.32793015555615, + "poly1_cov": 1, + "poly1_rme": 15.31830549222699, + "poly1_top": 2.5279023703850103E-9, + "poly2_aic": 72.32801460829577, + "poly2_cov": 1, + "poly2_rme": 15.318327400684396, + "poly2_top": 0.00008938146834261408, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.67152733580562, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 108.5387707140687 + }, + "mc5Param": { + "a": 5.0558047407700206E-11, + "er": 2.456091603321706, + "ac5": 2.4999999999999996, + "bmd": 183732208029.59137, + "bmr": 9.289141683881516, + "mll": -33.16396507777807, + "top": 2.5279023703850103E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 55.118208071787095, + "rmse": 15.31830549222699, + "ac1sd": 136198819888.5036, + "caikwt": 0.7310585787382466, + "hitcall": 0.0003112525321590652, + "top_over_cutoff": 1.1194915688689839E-10 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842415, + "spid": "TP0000202E12", + "chid": 32488, + "casn": "117718-60-2", + "chnm": "Thiazopyr", + "dtxsid": "DTXSID1032488", + "bmad": 3.7634679299683276, + "respMax": 6.446936756495938, + "respMin": -27.99639047559999, + "maxMean": 6.446936756495938, + "maxMeanConc": -0.6989700043360187, + "maxMed": 6.446936756495938, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 14, + "m5id": 5037061, + "modl": "poly1", + "hitc": 3.46254861405938E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + 2.3401929572491063, + -9.617064235516741, + -24.581899003404654, + -5.427697641004625, + 5.427697641004625, + -9.142353819653172, + -27.99639047559999, + 6.446936756495938 + ] + }, + "mc4Param": { + "pow_a": 8.291778304541115E-8, + "pow_p": 0.759489844462891, + "exp2_a": 0.000005100967135478326, + "exp2_b": 66.78668129818874, + "exp3_a": 0.00000795052649415302, + "exp3_b": 59.8550913973304, + "exp3_p": 6.3695090638042515, + "exp5_p": 2.1989554286217405, + "gnls_p": 7.325020891066998, + "gnls_q": 7.999920644098824, + "hill_p": 5.230822870987461, + "pow_er": 2.4449412532586106, + "cnst_er": 2.444612267004776, + "exp2_er": 2.4454237030104045, + "exp3_er": 2.4444001292182183, + "exp4_er": 2.4446018093199684, + "exp4_ga": 5.268966164997101, + "exp4_tp": 2.503020809468994E-9, + "exp5_er": 2.4445975509803857, + "exp5_ga": 4.6875957305191935, + "exp5_tp": 1.1081629207669447E-9, + "gnls_er": 2.4231904512610143, + "gnls_ga": 0.004416803248006645, + "gnls_la": 0.82966745174129, + "gnls_tp": 2.40116151835256, + "hill_er": 2.444611179532325, + "hill_ga": 142.56639582523107, + "hill_tp": 0.00006917638723040847, + "poly1_a": 4.602316355764391E-10, + "poly2_a": 0.000012228970875458648, + "poly2_b": 51.825063680254665, + "pow_aic": 71.6355163848002, + "pow_cov": 1, + "pow_rme": 14.448605421396229, + "pow_top": 0.0000016180731311326594, + "all_bmed": 0, + "cnst_aic": 67.63551484073298, + "cnst_rme": 14.44860501974752, + "exp2_aic": 71.63552232788017, + "exp2_cov": 1, + "exp2_rme": 14.448606013868249, + "exp2_top": 0.000005683236291608053, + "exp3_aic": 73.63551565609121, + "exp3_cov": 1, + "exp3_rme": 14.448605256905164, + "exp3_top": 0.0000029758177359879932, + "exp4_aic": 71.63551484106912, + "exp4_cov": 1, + "exp4_rme": 14.448605020839846, + "exp4_top": 2.503020809468994E-9, + "exp5_aic": 73.63551484062032, + "exp5_cov": 1, + "exp5_rme": 14.448605020276853, + "exp5_top": 1.1081629207669447E-9, + "gnls_aic": 77.44750709660826, + "gnls_cov": 1, + "gnls_rme": 14.365799933750845, + "gnls_top": 2.401161508659121, + "hill_aic": 73.6355148837213, + "hill_cov": 1, + "hill_rme": 14.448605043026824, + "hill_top": 0.00006917638723040847, + "poly1_er": 2.444589406786654, + "poly2_er": 2.4442589836933477, + "pow_a_sd": null, + "pow_ac50": 20.072979750096557, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.57372140444595, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.38400488151858, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 5.268966164997101, + "exp5_ac50": 4.6875957305191935, + "exp5_p_sd": null, + "gnls_ac50": 0.004416803145331396, + "gnls_p_sd": 1521.0342465884344, + "gnls_q_sd": 78.00215408532839, + "hill_ac50": 142.56639582523107, + "hill_p_sd": null, + "poly1_aic": 69.63551484744472, + "poly1_cov": 1, + "poly1_rme": 14.448605024451211, + "poly1_top": 2.3011581778821953E-8, + "poly2_aic": 71.63552116107905, + "poly2_cov": 1, + "poly2_rme": 14.448608809150656, + "poly2_top": 0.0000231811467637089, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.33687191979010667, + "gnls_ga_sd": 1.384790805886578, + "gnls_la_sd": 4.751505700203281, + "gnls_tp_sd": 5.895901623091699, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.4194146457345064, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.8068290375481, + "poly2_b_sd": null, + "poly1_er_sd": 0.5297759747014638, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.8296674525635499 + }, + "mc5Param": { + "a": 4.602316355764391E-10, + "er": 2.444589406786654, + "ac5": 2.5, + "bmd": 20183622693.053, + "bmr": 9.289141683881516, + "mll": -32.81775742372236, + "top": 2.3011581778821953E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 51.81424943318225, + "rmse": 14.448605024451211, + "ac1sd": 14961914524.131208, + "caikwt": 0.7310585792898094, + "hitcall": 0.000346254861405938, + "top_over_cutoff": 1.0190770058816301E-9 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842416, + "spid": "TP0000267A05", + "chid": 20605, + "casn": "104-76-7", + "chnm": "2-Ethyl-1-hexanol", + "dtxsid": "DTXSID5020605", + "bmad": 3.7634679299683276, + "respMax": 8.917578703786559, + "respMin": -27.524983015647525, + "maxMean": 8.917578703786559, + "maxMeanConc": 1.3010299956639813, + "maxMed": 8.917578703786559, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 15, + "m5id": 5037062, + "modl": "poly1", + "hitc": 2.7345343716299954E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.3010299956639813, + -0.22184874961635637, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + -0.6989700043360187 + ], + "resp": [ + 8.917578703786559, + 2.303464923343869, + -2.654003487492171, + 5.234355203561155, + -1.2708393819946822, + 3.560451307578698, + 1.2708393819946822, + -27.524983015647525 + ] + }, + "mc4Param": { + "pow_a": 1.3409798272664342, + "pow_p": 0.30000125329590954, + "exp2_a": 0.000009166742411061137, + "exp2_b": 71.96205294539993, + "exp3_a": 0.00006076828394343419, + "exp3_b": 62.86725328613552, + "exp3_p": 7.737091326965924, + "exp5_p": 7.999225969557049, + "gnls_p": 7.999875866687627, + "gnls_q": 7.928505491369158, + "hill_p": 7.999295227329135, + "pow_er": 1.6343827564280675, + "cnst_er": 1.7486670966982418, + "exp2_er": 1.747752679520703, + "exp3_er": 1.7491987890837994, + "exp4_er": 1.4661518060319405, + "exp4_ga": 0.5858515967961853, + "exp4_tp": 4.070715215170674, + "exp5_er": 1.4537496560481071, + "exp5_ga": 0.5879387517028682, + "exp5_tp": 4.129989453625999, + "gnls_er": 1.453809084181787, + "gnls_ga": 0.5829865127961461, + "gnls_la": 2656.355330614829, + "gnls_tp": 4.13074242306633, + "hill_er": 1.453742415592828, + "hill_ga": 0.582943689295207, + "hill_tp": 4.130157183529929, + "poly1_a": 0.006514257261741929, + "poly2_a": 0.000027619479202203845, + "poly2_b": 55.994704795242086, + "pow_aic": 62.72267287754171, + "pow_cov": 1, + "pow_rme": 10.626636623495806, + "pow_top": 4.336260608140496, + "all_bmed": 0, + "cnst_aic": 59.54309904759475, + "cnst_rme": 10.564107501908008, + "exp2_aic": 63.54310497598492, + "exp2_cov": 1, + "exp2_rme": 10.564107437382722, + "exp2_top": 0.000009197264782794135, + "exp3_aic": 65.54310319994451, + "exp3_cov": 1, + "exp3_rme": 10.564107854679628, + "exp3_top": 0.000011262424950383531, + "exp4_aic": 61.53985639831838, + "exp4_cov": 1, + "exp4_rme": 10.486648481057117, + "exp4_top": 4.070715215170674, + "exp5_aic": 63.21877166657443, + "exp5_cov": 1, + "exp5_rme": 10.19418095478504, + "exp5_top": 4.129989453625999, + "gnls_aic": 67.21889618297809, + "gnls_cov": 1, + "gnls_rme": 10.194291475779997, + "gnls_top": 4.130742423066309, + "hill_aic": 63.218896291500144, + "hill_cov": 1, + "hill_rme": 10.194281256916245, + "hill_top": 4.130157183529929, + "poly1_er": 1.7507922358775536, + "poly2_er": 1.749512892071607, + "pow_a_sd": 3.295794305479151, + "pow_ac50": 4.960676169539393, + "pow_p_sd": 0.5672534752096554, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.2579276272496, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.9617423857624, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.5858515967961853, + "exp5_ac50": 0.5879387517028682, + "exp5_p_sd": 98.74044274222942, + "gnls_ac50": 0.5829865133961057, + "gnls_p_sd": 74.31411976207677, + "gnls_q_sd": 6357704.376873938, + "hill_ac50": 0.582943689295207, + "hill_p_sd": 74.30108138165775, + "poly1_aic": 61.53965299852143, + "poly1_cov": 1, + "poly1_rme": 10.559185088231294, + "poly1_top": 0.3257128630870964, + "poly2_aic": 63.543106176613115, + "poly2_cov": 1, + "poly2_rme": 10.564107377657889, + "poly2_top": 0.00004668482556197718, + "pow_er_sd": 0.4819729825595672, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.42833896312172504, + "exp4_ga_sd": 1.0334925947270197, + "exp4_tp_sd": 2.6528735376099615, + "exp5_er_sd": 0.42414936250544655, + "exp5_ga_sd": 0.2459821670424215, + "exp5_tp_sd": 2.444384508491113, + "gnls_er_sd": 0.42415640100500435, + "gnls_ga_sd": 0.32464475146069505, + "gnls_la_sd": 8816666864.83012, + "gnls_tp_sd": 2.4443852082427937, + "hill_er_sd": 0.4241479766226494, + "hill_ga_sd": 0.32494411453400046, + "hill_tp_sd": 2.4443739248424277, + "poly1_a_sd": 0.11187540886288934, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.600594333963585, + "poly2_b_sd": null, + "poly1_er_sd": 0.3807131709053242, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2656.355330614833 + }, + "mc5Param": { + "a": 0.006514257261741929, + "er": 1.7507922358775536, + "ac5": 2.4999999999999996, + "bmd": 1425.9709604096254, + "bmr": 9.289141683881516, + "mll": -28.769826499260716, + "top": 0.3257128630870964, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 35.11258847587849, + "rmse": 10.559185088231294, + "ac1sd": 1057.0577912599151, + "caikwt": 0.7307196766051358, + "hitcall": 0.00027345343716299954, + "top_over_cutoff": 0.014424323042295618 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842417, + "spid": "TP0000267B05", + "chid": 34287, + "casn": "104-67-6", + "chnm": "5-Heptyldihydro-2(3H)-furanone", + "dtxsid": "DTXSID4034287", + "bmad": 3.7634679299683276, + "respMax": 2.5626891439251516, + "respMin": -8.146024449386633, + "maxMean": 2.5626891439251516, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.5626891439251516, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 16, + "m5id": 5037063, + "modl": "poly1", + "hitc": 1.807739510130505E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.3010299956639813, + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + -0.6989700043360187 + ], + "resp": [ + -6.177917513479251, + -7.198652565084555, + -8.146024449386633, + -6.691171080481884, + -2.56268914392515, + 2.5626891439251516, + -2.808406691690573, + -1.4980285452563038 + ] + }, + "mc4Param": { + "pow_a": 5.2359519867188026E-8, + "pow_p": 0.38277275314144577, + "exp2_a": 0.000011087622110252254, + "exp2_b": 59.03037755815387, + "exp3_a": 0.000011323074766607115, + "exp3_b": 58.09532026397317, + "exp3_p": 3.173411562559084, + "exp5_p": 1.8704058411614604, + "gnls_p": 4.0745292599201, + "gnls_q": 7.9950187264172525, + "hill_p": 3.453820607013757, + "pow_er": 1.5839659163624915, + "cnst_er": 1.5838738330644857, + "exp2_er": 1.5830676537547204, + "exp3_er": 1.5842203728625608, + "exp4_er": 1.583875903464905, + "exp4_ga": 2.6417915753408012, + "exp4_tp": 1.5063871691541615E-9, + "exp5_er": 1.5838758461193252, + "exp5_ga": 1.4518069133691405, + "exp5_tp": 5.003350528655981E-10, + "gnls_er": 1.569937001781506, + "gnls_ga": 0.002000000005206344, + "gnls_la": 0.06324555337954348, + "gnls_tp": 1.6871203757458295, + "hill_er": 1.5838672292493845, + "hill_ga": 0.0032734995034449416, + "hill_tp": 1.5616538074162555E-9, + "poly1_a": 4.100095671825759E-11, + "poly2_a": 0.000003605359587272573, + "poly2_b": 56.69107597259129, + "pow_aic": 56.66259887682483, + "pow_cov": 1, + "pow_rme": 5.2960214297578565, + "pow_top": 2.3405346854235685E-7, + "all_bmed": 0, + "cnst_aic": 52.66259853073265, + "cnst_rme": 5.296021351915426, + "exp2_aic": 56.66261266299513, + "exp2_cov": 1, + "exp2_rme": 5.2960232653217565, + "exp2_top": 0.000014776347844907314, + "exp3_aic": 58.662602705894976, + "exp3_cov": 1, + "exp3_rme": 5.296022056507032, + "exp3_top": 0.00000974958415866995, + "exp4_aic": 56.662598532902635, + "exp4_cov": 1, + "exp4_rme": 5.296021352581836, + "exp4_top": 1.5063871691541615E-9, + "exp5_aic": 58.662598531608296, + "exp5_cov": 1, + "exp5_rme": 5.296021352180456, + "exp5_top": 5.003350528655981E-10, + "gnls_aic": 62.508666224566085, + "gnls_cov": 1, + "gnls_rme": 5.262039104915749, + "gnls_top": 1.686834446740104, + "hill_aic": 58.66259853487741, + "hill_cov": 1, + "hill_rme": 5.296021353114272, + "hill_top": 1.5616538074162555E-9, + "poly1_er": 1.5838907558030877, + "poly2_er": 1.584058977857187, + "pow_a_sd": null, + "pow_ac50": 8.175687415188362, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.142811088618416, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.03157273784789, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.6417915753408012, + "exp5_ac50": 1.4518069133691405, + "exp5_p_sd": null, + "gnls_ac50": 0.0019998336398390293, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.0032734995034449416, + "hill_p_sd": null, + "poly1_aic": 54.6625985350956, + "poly1_cov": 1, + "poly1_rme": 5.296021352230097, + "poly1_top": 2.050047835912879E-9, + "poly2_aic": 56.6626016317032, + "poly2_cov": 1, + "poly2_rme": 5.296022098645178, + "poly2_top": 0.000005984354139645306, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.12305820350276302, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.56750321043185, + "poly2_b_sd": null, + "poly1_er_sd": 0.387494804373577, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.06324822341628866 + }, + "mc5Param": { + "a": 4.100095671825759E-11, + "er": 1.5838907558030877, + "ac5": 2.4999999999999996, + "bmd": 226559144649.05865, + "bmr": 9.289141683881516, + "mll": -25.3312992675478, + "top": 2.050047835912879E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 116.03234310631164, + "rmse": 5.296021352230097, + "ac1sd": 167945993068.24213, + "caikwt": 0.7310585790589084, + "hitcall": 1.807739510130505E-7, + "top_over_cutoff": 9.078717971742852E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842418, + "spid": "TP0000267C07", + "chid": 26525, + "casn": "88-18-6", + "chnm": "2-tert-Butylphenol", + "dtxsid": "DTXSID2026525", + "bmad": 3.7634679299683276, + "respMax": 4.284991950831092, + "respMin": -17.752010560601963, + "maxMean": 4.284991950831092, + "maxMeanConc": -0.6989700043360187, + "maxMed": 4.284991950831092, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 17, + "m5id": 5037064, + "modl": "poly1", + "hitc": 1.080834578284038E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436 + ], + "resp": [ + -3.429511618336063, + -10.303773152544004, + 4.284991950831092, + -17.752010560601963, + -11.184188881006792, + 3.429511618336063, + -11.946623245214802, + -14.030114108296962 + ] + }, + "mc4Param": { + "pow_a": 1.1688027459778409E-7, + "pow_p": 0.3542167430597227, + "exp2_a": 0.00001402914266781098, + "exp2_b": 62.43720598776625, + "exp3_a": 8.518851392561705E-7, + "exp3_b": 55.14935347186949, + "exp3_p": 5.08068979673058, + "exp5_p": 0.934648289336587, + "gnls_p": 5.502938821699771, + "gnls_q": 7.707236696501689, + "hill_p": 1.330809264220454, + "pow_er": 2.294643719896335, + "cnst_er": 2.294672403578953, + "exp2_er": 2.2949759846580298, + "exp3_er": 2.2939792210930836, + "exp4_er": 2.2946893862543956, + "exp4_ga": 1.6265408298714532, + "exp4_tp": 1.7029436841556618E-10, + "exp5_er": 2.294667883086028, + "exp5_ga": 9.989504833632218, + "exp5_tp": 1.1382103679305392E-9, + "gnls_er": 2.2946723713323243, + "gnls_ga": 0.04465268081832286, + "gnls_la": 1.4750833148086038, + "gnls_tp": 9.842124013532871E-9, + "hill_er": 2.294684574430046, + "hill_ga": 113.24013298211491, + "hill_tp": 3.8147986424229266E-8, + "poly1_a": 1.930068017745631E-10, + "poly2_a": 0.000008995913833305391, + "poly2_b": 60.79500343541555, + "pow_aic": 68.01728590637344, + "pow_cov": 1, + "pow_rme": 10.769388915092584, + "pow_top": 4.672451958820215E-7, + "all_bmed": 0, + "cnst_aic": 64.01728561110329, + "cnst_rme": 10.769388711778616, + "exp2_aic": 68.01729252056795, + "exp2_cov": 1, + "exp2_rme": 10.769393202636683, + "exp2_top": 0.000017218419324428374, + "exp3_aic": 70.01729110083275, + "exp3_cov": 1, + "exp3_rme": 10.769388859159086, + "exp3_top": 7.124009276524897E-7, + "exp4_aic": 68.01728561547779, + "exp4_cov": 1, + "exp4_rme": 10.769388711877632, + "exp4_top": 1.7029436841556618E-10, + "exp5_aic": 70.01728561164555, + "exp5_cov": 1, + "exp5_rme": 10.769388712196594, + "exp5_top": 1.1382103679305392E-9, + "gnls_aic": 74.01728561314724, + "gnls_cov": 1, + "gnls_rme": 10.769388713041575, + "gnls_top": 9.841866233302444E-9, + "hill_aic": 70.0172856168267, + "hill_cov": 1, + "hill_rme": 10.769388714323313, + "hill_top": 3.8147986424229266E-8, + "poly1_er": 2.2946661884606754, + "poly2_er": 2.2951725166659296, + "pow_a_sd": null, + "pow_ac50": 7.065178187371053, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.87674555498022, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.83746128233124, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.6265408298714532, + "exp5_ac50": 9.989504833632218, + "exp5_p_sd": null, + "gnls_ac50": 0.04465225444658185, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 113.24013298211491, + "hill_p_sd": null, + "poly1_aic": 66.01728561475585, + "poly1_cov": 1, + "poly1_rme": 10.769388714484304, + "poly1_top": 9.650340088728157E-9, + "poly2_aic": 68.01729292719538, + "poly2_cov": 1, + "poly2_rme": 10.769392172059073, + "poly2_top": 0.000013483408486187177, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.29967162033605704, + "exp4_ga_sd": 2.700161867338397, + "exp4_tp_sd": 0.000018830151796886426, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.379822973030592, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.475093338726149 + }, + "mc5Param": { + "a": 1.930068017745631E-10, + "er": 2.2946661884606754, + "ac5": 2.4999999999999996, + "bmd": 48128571627.913246, + "bmr": 9.289141683881516, + "mll": -31.008642807377925, + "top": 9.650340088728157E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 64.94939269971773, + "rmse": 10.769388714484304, + "ac1sd": 35677221369.839325, + "caikwt": 0.7310585789890732, + "hitcall": 0.0001080834578284038, + "top_over_cutoff": 4.2736912994009806E-10 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842419, + "spid": "TP0000267C12", + "chid": 21217, + "casn": "58-14-0", + "chnm": "Pyrimethamine", + "dtxsid": "DTXSID9021217", + "bmad": 3.7634679299683276, + "respMax": 27.43198135493239, + "respMin": -9.573031880730055, + "maxMean": 27.43198135493239, + "maxMeanConc": 1.6989700043360187, + "maxMed": 27.43198135493239, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 18, + "m5id": 5037065, + "modl": "exp5", + "hitc": 0.9993015893938282, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + 0.7781512503836436 + ], + "resp": [ + -1.3626102221550411, + 1.362610222155042, + 26.100011514016813, + 5.083220148547186, + -9.573031880730055, + 12.263055448994821, + 27.43198135493239, + 19.028440712908623 + ] + }, + "mc4Param": { + "pow_a": 8.615918330641122, + "pow_p": 0.3256460648100804, + "exp2_a": 5515.924011580759, + "exp2_b": 8569.91582576029, + "exp3_a": 190.5815796850594, + "exp3_b": 18144.73145449149, + "exp3_p": 0.32098963519530016, + "exp5_p": 0.6697053366805052, + "gnls_p": 0.8182614183023493, + "gnls_q": 6.583211395264323, + "hill_p": 0.8182571770652887, + "pow_er": 1.363988503208183, + "cnst_er": 2.6252428146846465, + "exp2_er": 2.109704617961689, + "exp3_er": 1.5388722444020404, + "exp4_er": 0.9165567589387242, + "exp4_ga": 2.8867935103137805, + "exp4_tp": 26.682134872783596, + "exp5_er": 0.4118882359089413, + "exp5_ga": 2.6834018978246137, + "exp5_tp": 27.76803833586464, + "gnls_er": 0.5050076143816886, + "gnls_ga": 3.278943112805881, + "gnls_la": 4931.293978658584, + "gnls_tp": 30.974706420358636, + "hill_er": 0.5049887009187453, + "hill_ga": 3.2789253729229126, + "hill_tp": 30.974702991700216, + "poly1_a": 0.6448409372956132, + "poly2_a": 7685.079924681028, + "poly2_b": 11973.64247334707, + "pow_aic": 56.39160653523915, + "pow_cov": 1, + "pow_rme": 6.526761203406884, + "pow_top": 30.80097539574928, + "all_bmed": 0, + "cnst_aic": 69.92173854270355, + "cnst_rme": 16.07553951933683, + "exp2_aic": 65.29200171582212, + "exp2_cov": 1, + "exp2_rme": 9.191283585871052, + "exp2_top": 32.27596638509631, + "exp3_aic": 58.79084317495332, + "exp3_cov": 1, + "exp3_rme": 6.506169486296934, + "exp3_top": 31.014883737948537, + "exp4_aic": 50.88878665018997, + "exp4_cov": 1, + "exp4_rme": 4.969757377064164, + "exp4_top": 26.682134872783596, + "exp5_aic": 50.77303496851002, + "exp5_cov": 1, + "exp5_rme": 5.679144326208646, + "exp5_top": 27.76803833586464, + "gnls_aic": 55.27492786162859, + "gnls_cov": 1, + "gnls_rme": 5.673955293548314, + "gnls_top": 30.762420047102612, + "hill_aic": 51.27492786216142, + "hill_cov": 1, + "hill_rme": 5.6739736678642325, + "hill_top": 30.974702991700216, + "poly1_er": 2.108328509307753, + "poly2_er": 2.108918234235728, + "pow_a_sd": 1.9065377706614512, + "pow_ac50": 5.950610001585547, + "pow_p_sd": 0.06581177305373388, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 54261.41693977886, + "exp2_ac50": 25.03646471717236, + "exp2_b_sd": 83920.69797802145, + "exp3_a_sd": 319.30330931872754, + "exp3_ac50": 6.473920870323869, + "exp3_b_sd": 71486.21897878859, + "exp3_p_sd": 0.089062666508518, + "exp4_ac50": 2.8867935103137805, + "exp5_ac50": 2.6834018978246137, + "exp5_p_sd": 0.11428693722103664, + "gnls_ac50": 3.224472657149256, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 3.2789253729229126, + "hill_p_sd": 0.21665202304453965, + "poly1_aic": 63.28151185739537, + "poly1_cov": 1, + "poly1_rme": 9.185966970005357, + "poly1_top": 32.242046864780654, + "poly2_aic": 65.29643872279352, + "poly2_cov": 1, + "poly2_rme": 9.195851294815698, + "poly2_top": 32.22566397929895, + "pow_er_sd": 0.3611517914109552, + "exp2_er_sd": 0.3104544270600404, + "exp3_er_sd": 0.3808951094369049, + "exp4_er_sd": 0.3893880417326298, + "exp4_ga_sd": 0.8092255223155269, + "exp4_tp_sd": 1.7181047521648634, + "exp5_er_sd": 0.4652947689906473, + "exp5_ga_sd": 0.5440220897387579, + "exp5_tp_sd": 1.4682435434842378, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.44727516724237865, + "hill_ga_sd": 1.168035860526126, + "hill_tp_sd": 3.400651941209022, + "poly1_a_sd": 0.16629458913826986, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 63485.654673403085, + "poly2_ac50": 25.051980695483746, + "poly2_b_sd": 98453.01686169056, + "poly1_er_sd": 0.3103337077565139, + "poly2_er_sd": 0.31046879681961925, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4937.830903270403 + }, + "mc5Param": { + "p": 0.6697053366805052, + "er": 0.4118882359089413, + "ga": 2.6834018978246137, + "tp": 27.76803833586464, + "ac5": 0.05498375432560493, + "acc": 10.043861366765938, + "bmd": 1.2128892362955723, + "bmr": 9.289141683881516, + "mll": -21.38651748425501, + "top": 27.76803833586464, + "ac10": 0.16107667754826716, + "ac20": 0.4939400347473494, + "ac50": 2.6834018978246137, + "bmdl": 0.949215313715193, + "bmdu": 1.5372925871551637, + "rmse": 5.679144326208646, + "ac1sd": 0.7117500271731652, + "caikwt": 0.00006948349796016499, + "hitcall": 0.9993015893938282, + "top_over_cutoff": 1.2297185668723691 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842420, + "spid": "TP0000267E12", + "chid": 21311, + "casn": "732-26-3", + "chnm": "2,4,6-Tris(tert-butyl)phenol", + "dtxsid": "DTXSID2021311", + "bmad": 3.7634679299683276, + "respMax": 2.3455034490210025, + "respMin": -8.881536046239422, + "maxMean": 2.3455034490210025, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.3455034490210025, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 19, + "m5id": 5037066, + "modl": "poly1", + "hitc": 2.529472360487395E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187 + ], + "resp": [ + -3.6871319675490226, + -8.202809310965216, + -2.3455034490210025, + -8.881536046239422, + 0.7714118421935772, + -3.442445468033866, + -8.217215474183769, + 2.3455034490210025 + ] + }, + "mc4Param": { + "pow_a": 4.4603222633107216E-8, + "pow_p": 0.3980715850861712, + "exp2_a": 0.00001500803162618182, + "exp2_b": 72.63641229778418, + "exp3_a": 0.000025895984061395693, + "exp3_b": 53.44323652739063, + "exp3_p": 6.684140439183912, + "exp5_p": 2.7549650881782495, + "gnls_p": 0.3000033566349074, + "gnls_q": 7.985201719769872, + "hill_p": 1.3414224872456235, + "pow_er": 1.6007569268879631, + "cnst_er": 1.600789396957988, + "exp2_er": 1.6013100926069517, + "exp3_er": 1.6012445517694611, + "exp4_er": 1.6007994489950037, + "exp4_ga": 1.8057489415221024, + "exp4_tp": 5.397987738417918E-10, + "exp5_er": 1.60079357288877, + "exp5_ga": 1.7684454448433695, + "exp5_tp": 8.377821726470055E-10, + "gnls_er": 1.5999160615939398, + "gnls_ga": 0.009427709959484824, + "gnls_la": 0.2982914089167051, + "gnls_tp": 0.2960388226873033, + "hill_er": 1.6007857351745025, + "hill_ga": 0.21326314555729145, + "hill_tp": 8.179987554374146E-10, + "poly1_a": 1.665857611967683E-11, + "poly2_a": 0.000003342211026439361, + "poly2_b": 54.331449188426035, + "pow_aic": 57.26619984359718, + "pow_cov": 1, + "pow_rme": 5.598366077511932, + "pow_top": 2.1167907095144258E-7, + "all_bmed": 0, + "cnst_aic": 53.26619960913695, + "cnst_rme": 5.598366003993902, + "exp2_aic": 57.266210263276776, + "exp2_cov": 1, + "exp2_rme": 5.5983683837974345, + "exp2_top": 0.000014864682387656134, + "exp3_aic": 59.26620901814293, + "exp3_cov": 1, + "exp3_rme": 5.598367798358593, + "exp3_top": 0.00002325120872148169, + "exp4_aic": 57.266199610517305, + "exp4_cov": 1, + "exp4_rme": 5.598366004275409, + "exp4_top": 5.397987738417918E-10, + "exp5_aic": 59.26619961039384, + "exp5_cov": 1, + "exp5_rme": 5.598366004426082, + "exp5_top": 8.377821726470055E-10, + "gnls_aic": 63.261593119240175, + "gnls_cov": 1, + "gnls_rme": 5.597589879481962, + "gnls_top": 0.20617373336031528, + "hill_aic": 59.26619961110041, + "hill_cov": 1, + "hill_rme": 5.598366004550358, + "hill_top": 8.179987554374146E-10, + "poly1_er": 1.600789285333053, + "poly2_er": 1.600935631744412, + "pow_a_sd": null, + "pow_ac50": 8.764946038692628, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.219899561165725, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 46.07206390886932, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.8057489415221024, + "exp5_ac50": 1.7684454448433695, + "exp5_p_sd": null, + "gnls_ac50": 0.0011666221360965088, + "gnls_p_sd": 3.279849567472979, + "gnls_q_sd": 92.59655516899352, + "hill_ac50": 0.21326314555729145, + "hill_p_sd": null, + "poly1_aic": 55.26619960963536, + "poly1_cov": 1, + "poly1_rme": 5.598366004146862, + "poly1_top": 8.329288059838414E-10, + "poly2_aic": 57.266202776564455, + "poly2_cov": 1, + "poly2_rme": 5.598366884119417, + "poly2_top": 0.000005906314023332767, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.31071019075343265, + "gnls_ga_sd": 0.7914627160677781, + "gnls_la_sd": 1.8738093020015376, + "gnls_tp_sd": 4.103388080871007, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.15082807920588523, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.681166613865575, + "poly2_b_sd": null, + "poly1_er_sd": 0.4455631080651304, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.30262790841870524 + }, + "mc5Param": { + "a": 1.665857611967683E-11, + "er": 1.600789285333053, + "ac5": 2.5, + "bmd": 557619187687.316, + "bmr": 9.289141683881516, + "mll": -25.63309980481768, + "top": 8.329288059838414E-10, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 119.31078194095286, + "rmse": 5.598366004146862, + "ac1sd": 413357440835.6679, + "caikwt": 0.7310585786790016, + "hitcall": 2.529472360487395E-7, + "top_over_cutoff": 3.688658180359248E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842421, + "spid": "TP0000267H05", + "chid": 26252, + "casn": "101-02-0", + "chnm": "Triphenyl phosphite", + "dtxsid": "DTXSID0026252", + "bmad": 3.7634679299683276, + "respMax": 2.153448557173647, + "respMin": -10.47000653188537, + "maxMean": 2.153448557173647, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.153448557173647, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 20, + "m5id": 5037067, + "modl": "poly1", + "hitc": 1.9363278182448674E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + -1.6989700043360187, + 1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + -8.233558829804824, + 2.153448557173647, + -5.178906539470438, + -7.2693827013629715, + -2.153448557173647, + -8.802875120938111, + -4.04098335160478, + -10.47000653188537 + ] + }, + "mc4Param": { + "pow_a": 3.4292130710908686E-8, + "pow_p": 0.33928487781574906, + "exp2_a": 0.0000127162267603712, + "exp2_b": 59.471246282597455, + "exp3_a": 0.000005456305245978216, + "exp3_b": 57.114981601771404, + "exp3_p": 4.737468297497621, + "exp5_p": 2.059721964231659, + "gnls_p": 3.7705534652747152, + "gnls_q": 7.98088765765917, + "hill_p": 1.8558453157097723, + "pow_er": 1.8316691732485768, + "cnst_er": 1.8316611738832205, + "exp2_er": 1.83171063967293, + "exp3_er": 1.8308588373067065, + "exp4_er": 1.831667717841896, + "exp4_ga": 2.39650583299111, + "exp4_tp": 9.736616090061843E-11, + "exp5_er": 1.8316409278190295, + "exp5_ga": 0.91710788966815, + "exp5_tp": 4.769155469756227E-10, + "gnls_er": 1.826653351166183, + "gnls_ga": 0.0020000000000068045, + "gnls_la": 0.06324555325220907, + "gnls_tp": 1.3708737937327125, + "hill_er": 1.8316765475841592, + "hill_ga": 0.1570478773337086, + "hill_tp": 4.665489172046982E-10, + "poly1_a": 1.6553661788288878E-11, + "poly2_a": 0.0000040937639725312225, + "poly2_b": 57.77189852066546, + "pow_aic": 60.52616872375968, + "pow_cov": 1, + "pow_rme": 6.709809695768132, + "pow_top": 1.2930916305837965E-7, + "all_bmed": 0, + "cnst_aic": 56.52616859619864, + "cnst_rme": 6.709809645256235, + "exp2_aic": 60.526175980843824, + "exp2_cov": 1, + "exp2_rme": 6.709812374327744, + "exp2_top": 0.000016761097647759444, + "exp3_aic": 62.52617699352762, + "exp3_cov": 1, + "exp3_rme": 6.709810021618865, + "exp3_top": 0.000003836214039161115, + "exp4_aic": 60.52616859672308, + "exp4_cov": 1, + "exp4_rme": 6.709809645302461, + "exp4_top": 9.736616090061843E-11, + "exp5_aic": 62.52616860177177, + "exp5_cov": 1, + "exp5_rme": 6.709809645540375, + "exp5_top": 4.769155469756227E-10, + "gnls_aic": 66.46070980336975, + "gnls_cov": 1, + "gnls_rme": 6.690902645418204, + "gnls_top": 1.3705036887888815, + "hill_aic": 62.52616859958253, + "hill_cov": 1, + "hill_rme": 6.709809645620258, + "hill_top": 4.665489172046982E-10, + "poly1_er": 1.8315037737657676, + "poly2_er": 1.8310229156461169, + "pow_a_sd": null, + "pow_ac50": 6.482186378904536, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.106803250288905, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.336210554612904, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.39650583299111, + "exp5_ac50": 0.91710788966815, + "exp5_p_sd": null, + "gnls_ac50": 0.001999713670738839, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.1570478773337086, + "hill_p_sd": null, + "poly1_aic": 58.5261688787493, + "poly1_cov": 1, + "poly1_rme": 6.7098096454111325, + "poly1_top": 8.276830894144437E-10, + "poly2_aic": 60.52617604664733, + "poly2_cov": 1, + "poly2_rme": 6.709810691449007, + "poly2_top": 0.000006609445990107358, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.2972944391380977, + "exp4_ga_sd": 2.7511788983437424, + "exp4_tp_sd": 0.000018170256552519125, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.232877570932672, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.51687497965734, + "poly2_b_sd": null, + "poly1_er_sd": 0.4976104385069312, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.06324979854754481 + }, + "mc5Param": { + "a": 1.6553661788288878E-11, + "er": 1.8315037737657676, + "ac5": 2.5, + "bmd": 561153284553.225, + "bmr": 9.289141683881516, + "mll": -27.26308443937465, + "top": 8.276830894144437E-10, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 97.36337686032884, + "rmse": 6.7098096454111325, + "ac1sd": 415977230951.2416, + "caikwt": 0.7310586064064195, + "hitcall": 0.0000019363278182448674, + "top_over_cutoff": 3.665427316933053E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842422, + "spid": "TP0000267H07", + "chid": 22187, + "casn": "2416-94-6", + "chnm": "2,3,6-Trimethylphenol", + "dtxsid": "DTXSID6022187", + "bmad": 3.7634679299683276, + "respMax": 2.4546434804120567, + "respMin": -6.590039447466564, + "maxMean": 2.4546434804120567, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.4546434804120567, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 21, + "m5id": 5037068, + "modl": "poly1", + "hitc": 1.1548465742145037E-8, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + -0.6193413590687559, + -2.946862891147046, + -2.4546434804120567, + -2.0619838822007726, + -6.1122061271300225, + -6.590039447466564, + 2.4546434804120567, + -5.079836079239133 + ] + }, + "mc4Param": { + "pow_a": 3.767364113336769E-8, + "pow_p": 0.3793361095119566, + "exp2_a": 0.000013714158244907544, + "exp2_b": 62.473953885282626, + "exp3_a": 0.000003218586676112593, + "exp3_b": 54.793432376427845, + "exp3_p": 4.934528552083529, + "exp5_p": 2.5321434240687077, + "gnls_p": 1.7215545335763185, + "gnls_q": 5.9509617790505365, + "hill_p": 1.7113570602226835, + "pow_er": 1.3001645899703465, + "cnst_er": 1.3001163668151825, + "exp2_er": 1.2988900114548922, + "exp3_er": 1.299714305686752, + "exp4_er": 1.300111607345526, + "exp4_ga": 2.4635749935922417, + "exp4_tp": 2.141208914552821E-10, + "exp5_er": 1.3001191325357075, + "exp5_ga": 0.8329186071996519, + "exp5_tp": 9.468502830411367E-10, + "gnls_er": 1.300129441131634, + "gnls_ga": 0.02488389878063567, + "gnls_la": 0.8513441076183489, + "gnls_tp": 5.029312168256246E-10, + "hill_er": 1.3001098844504215, + "hill_ga": 1.3104070841784885, + "hill_tp": 2.3984539370057496E-10, + "poly1_a": 6.429960167444698E-12, + "poly2_a": 0.00010731334828336232, + "poly2_b": 52.50758262350933, + "pow_aic": 52.26528261409156, + "pow_cov": 1, + "pow_rme": 4.061439597937862, + "pow_top": 1.661568568423234E-7, + "all_bmed": 0, + "cnst_aic": 48.26528238427001, + "cnst_rme": 4.0614395482423795, + "exp2_aic": 52.265309193522334, + "exp2_cov": 1, + "exp2_rme": 4.061441753257708, + "exp2_top": 0.000016817443713639312, + "exp3_aic": 54.26528524536559, + "exp3_cov": 1, + "exp3_rme": 4.061439734220189, + "exp3_top": 0.0000028641829217196966, + "exp4_aic": 52.26528238577886, + "exp4_cov": 1, + "exp4_rme": 4.06143954832149, + "exp4_top": 2.141208914552821E-10, + "exp5_aic": 54.26528238551149, + "exp5_cov": 1, + "exp5_rme": 4.0614395486267245, + "exp5_top": 9.468502830411367E-10, + "gnls_aic": 58.26528238429869, + "gnls_cov": 1, + "gnls_rme": 4.061439548428354, + "gnls_top": 4.953675513002026E-10, + "hill_aic": 54.26528238638662, + "hill_cov": 1, + "hill_rme": 4.061439548335382, + "hill_top": 2.3984539370057496E-10, + "poly1_er": 1.3004069598601156, + "poly2_er": 1.3007699140477382, + "pow_a_sd": null, + "pow_ac50": 8.042653781004834, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.874021672293665, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.74689545963496, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.4635749935922417, + "exp5_ac50": 0.8329186071996519, + "exp5_p_sd": null, + "gnls_ac50": 0.02445288131245627, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 1.3104070841784885, + "hill_p_sd": 3186952.8147538053, + "poly1_aic": 50.26528324291422, + "poly1_cov": 1, + "poly1_rme": 4.061439548291606, + "poly1_top": 3.2149800837223486E-10, + "poly2_aic": 52.26540339182091, + "poly2_cov": 1, + "poly2_rme": 4.061464432547128, + "poly2_top": 0.00019949668932343944, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.30383111979982436, + "hill_ga_sd": 748711.7747256848, + "hill_tp_sd": 0.0000505315540909725, + "poly1_a_sd": 0.09096805428665258, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.772089863628302, + "poly2_b_sd": null, + "poly1_er_sd": 0.3809692717546628, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.8550161183126147 + }, + "mc5Param": { + "a": 6.429960167444698E-12, + "er": 1.3004069598601156, + "ac5": 2.4999999999999996, + "bmd": 1444665509891.1868, + "bmr": 9.289141683881516, + "mll": -23.13264162145711, + "top": 3.2149800837223486E-10, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 149.5912710282903, + "rmse": 4.061439548291606, + "ac1sd": 1070915870934.9048, + "caikwt": 0.7310586630398459, + "hitcall": 1.1548465742145036E-8, + "top_over_cutoff": 1.4237666533224164E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842423, + "spid": "TP0000268B05", + "chid": 47331, + "casn": "331623-06-4", + "chnm": "MK-547", + "dtxsid": "DTXSID4047331", + "bmad": 3.7634679299683276, + "respMax": 16.160587759184914, + "respMin": -11.834811380876454, + "maxMean": 16.160587759184914, + "maxMeanConc": -0.1549019599857432, + "maxMed": 16.160587759184914, + "maxMedConc": -0.1549019599857432, + "logcMax": 1.7781512503836436, + "logcMin": -1.5228787452803376, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 22, + "m5id": 5037069, + "modl": "poly1", + "hitc": 5.913901142194764E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 22.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.5228787452803376, + 1.7781512503836436, + 0.3010299956639812, + 0.7781512503836436, + -1.0969100130080565, + 1.3010299956639813, + -0.6989700043360187, + -0.1549019599857432 + ], + "resp": [ + 1.0328742333020546, + -0.4101716381589, + -11.834811380876454, + -10.26235792055114, + -1.0328742333020546, + 1.4772968670590867, + -2.9469637282292744, + 16.160587759184914 + ] + }, + "mc4Param": { + "pow_a": 3.435232205446152E-7, + "pow_p": 0.40195886003095355, + "exp2_a": 0.00019185757540890645, + "exp2_b": 78.54636736109194, + "exp3_a": 0.000069246181189659, + "exp3_b": 73.10867338686336, + "exp3_p": 7.6208172674503984, + "exp5_p": 7.998247691004145, + "gnls_p": 7.901592218199406, + "gnls_q": 7.849018931807445, + "hill_p": 7.87734028198097, + "pow_er": 1.8213430667936583, + "cnst_er": 1.8213936756952465, + "exp2_er": 1.823591487999136, + "exp3_er": 1.822387183035188, + "exp4_er": 1.821353215471985, + "exp4_ga": 12.168837805792837, + "exp4_tp": 5.0263714950386055E-8, + "exp5_er": 1.8191975210324889, + "exp5_ga": 14.786689747990971, + "exp5_tp": 0.5317549737304359, + "gnls_er": 1.8213944981829744, + "gnls_ga": 0.1534550745988045, + "gnls_la": 19.550756854420513, + "gnls_tp": 4.787909883851375E-9, + "hill_er": 1.8214163821547027, + "hill_ga": 189.7269026616281, + "hill_tp": 5.920760401696781, + "poly1_a": 2.7530546982407402E-9, + "poly2_a": 0.0002694160974739683, + "poly2_b": 74.60371505672451, + "pow_aic": 62.11585875969622, + "pow_cov": 1, + "pow_rme": 8.060026848987192, + "pow_top": 0.0000017811469363016915, + "all_bmed": 0, + "cnst_aic": 58.115858404353595, + "cnst_rme": 8.06002673396659, + "exp2_aic": 62.11590472013238, + "exp2_cov": 1, + "exp2_rme": 8.060029785010771, + "exp2_top": 0.0002199817611461118, + "exp3_aic": 64.11586654613095, + "exp3_cov": 1, + "exp3_rme": 8.060026843281152, + "exp3_top": 0.000017196997763967384, + "exp4_aic": 62.115858433032486, + "exp4_cov": 1, + "exp4_rme": 8.06002673633787, + "exp4_top": 5.0263714950386055E-8, + "exp5_aic": 64.09764769253101, + "exp5_cov": 1, + "exp5_rme": 8.055656964717214, + "exp5_top": 0.5317549737304359, + "gnls_aic": 68.11585840669358, + "gnls_cov": 1, + "gnls_rme": 8.060026734552624, + "gnls_top": 4.7879098346713356E-9, + "hill_aic": 64.11587669600377, + "hill_cov": 1, + "hill_rme": 8.060031073676338, + "hill_top": 5.920760401696781, + "poly1_er": 1.821434550339795, + "poly2_er": 1.821797531197728, + "pow_a_sd": null, + "pow_ac50": 10.696551181133351, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 35.59499774025152, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 55.17214374903797, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 12.168837805792837, + "exp5_ac50": 14.786689747990971, + "exp5_p_sd": 121.15686871088236, + "gnls_ac50": 0.1534550738830234, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 189.7269026616281, + "hill_p_sd": null, + "poly1_aic": 60.11585841484666, + "poly1_cov": 1, + "poly1_rme": 8.06002673693981, + "poly1_top": 1.651832818944444E-7, + "poly2_aic": 62.115872817500886, + "poly2_cov": 1, + "poly2_rme": 8.06003160725891, + "poly2_top": 0.0003909407381656776, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.3534660798818326, + "exp5_ga_sd": 95.93402528978984, + "exp5_tp_sd": 3.9415248388741375, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.08777291902049782, + "poly1_ac50": 30, + "poly2_a_sd": null, + "poly2_ac50": 36.38355504948771, + "poly2_b_sd": null, + "poly1_er_sd": 0.3531459297080129, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 19.55075690425482 + }, + "mc5Param": { + "a": 2.7530546982407402E-9, + "er": 1.821434550339795, + "ac5": 3, + "bmd": 3374121730.9694114, + "bmr": 9.289141683881516, + "mll": -28.05792920742333, + "top": 1.651832818944444E-7, + "ac10": 6, + "ac20": 12, + "ac50": 30, + "bmdl": 62.30001927366413, + "rmse": 8.06002673693981, + "ac1sd": 2501202172.6978583, + "caikwt": 0.7310585796615361, + "hitcall": 0.00005913901142194764, + "top_over_cutoff": 7.3152070097855445E-9 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842424, + "spid": "TP0000268B09", + "chid": 47376, + "casn": "648917-13-9", + "chnm": "AVE2865", + "dtxsid": "DTXSID5047376", + "bmad": 3.7634679299683276, + "respMax": 5.797527205844785, + "respMin": -6.504798500619806, + "maxMean": 5.797527205844785, + "maxMeanConc": -0.5228787452803376, + "maxMed": 5.797527205844785, + "maxMedConc": -0.5228787452803376, + "logcMax": 1.3010299956639813, + "logcMin": -2.0, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 23, + "m5id": 5037070, + "modl": "poly1", + "hitc": 3.401746069045992E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 10.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1, + -0.5228787452803376, + -0.045757490560675115, + 0.47712125471966244, + -1.5228787452803376, + 1.3010299956639813, + 0.9030899869919435, + -2 + ], + "resp": [ + -0.45517858919509946, + 5.797527205844785, + -2.9328129243560577, + -6.504798500619806, + 2.0703869723867707, + 4.550643071685755, + 4.546273464789026, + -2.0703869723867707 + ] + }, + "mc4Param": { + "pow_a": 0.14645761569514076, + "pow_p": 1.1773046495484434, + "exp2_a": 270.97367161658156, + "exp2_b": 1116.4642123562155, + "exp3_a": 77.63471895063142, + "exp3_b": 252.08672173141304, + "exp3_p": 1.0981475406737444, + "exp5_p": 7.999999743873548, + "gnls_p": 7.9999999387204035, + "gnls_q": 7.925643774573192, + "hill_p": 7.999999862236661, + "pow_er": 1.1356265219229824, + "cnst_er": 1.3302829497154869, + "exp2_er": 1.132103795624519, + "exp3_er": 1.1430097651086235, + "exp4_er": 1.1201406029443286, + "exp4_ga": 12.576918087774663, + "exp4_tp": 6.957032563345469, + "exp5_er": 1.004007264778901, + "exp5_ga": 6.457229934853941, + "exp5_tp": 4.594738721200484, + "gnls_er": 1.2052015972921115, + "gnls_ga": 0.15589819888208656, + "gnls_la": 1408.8515612814258, + "gnls_tp": 2.45585111669779, + "hill_er": 1.0057274858019496, + "hill_ga": 5.840707041021681, + "hill_tp": 4.711097825805859, + "poly1_a": 0.24532316641680385, + "poly2_a": 217.59829371138036, + "poly2_b": 906.2718506374296, + "pow_aic": 50.20843275953963, + "pow_cov": 1, + "pow_rme": 3.69500181123112, + "pow_top": 4.982193866207102, + "all_bmed": 0, + "cnst_aic": 48.583528700455965, + "cnst_rme": 4.103082128822365, + "exp2_aic": 50.23261652082196, + "exp2_cov": 1, + "exp2_rme": 3.719604002845105, + "exp2_top": 4.897878431815489, + "exp3_aic": 52.21936455943542, + "exp3_cov": 1, + "exp3_rme": 3.703490261604697, + "exp3_top": 4.954803407260803, + "exp4_aic": 50.24261958999962, + "exp4_cov": 1, + "exp4_rme": 3.763007325226026, + "exp4_top": 6.957032563345469, + "exp5_aic": 50.606708255855864, + "exp5_cov": 1, + "exp5_rme": 3.416863170565935, + "exp5_top": 4.594738721200484, + "gnls_aic": 57.65043497612462, + "gnls_cov": 1, + "gnls_rme": 4.156168266214812, + "gnls_top": 2.455851116697789, + "hill_aic": 50.630370136769535, + "hill_cov": 1, + "hill_rme": 3.421658551377129, + "hill_top": 4.711097825805859, + "poly1_er": 1.1314827238691518, + "poly2_er": 1.1323596578117343, + "pow_a_sd": 0.5502364753741223, + "pow_ac50": 11.10032704166267, + "pow_p_sd": 1.2632680919710386, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 9140.874480213712, + "exp2_ac50": 10.04478364010083, + "exp2_b_sd": 37407.68771741646, + "exp3_a_sd": 1098.7341775704554, + "exp3_ac50": 10.788816917549276, + "exp3_b_sd": 3010.335602136789, + "exp3_p_sd": 1.1986941560896456, + "exp4_ac50": 12.576918087774663, + "exp5_ac50": 6.457229934853941, + "exp5_p_sd": 19.477000675370935, + "gnls_ac50": 0.15589819885359768, + "gnls_p_sd": 20.48523584343925, + "gnls_q_sd": 1762638.0146021335, + "hill_ac50": 5.840707041021681, + "hill_p_sd": 12.47501198328628, + "poly1_aic": 48.23172628107896, + "poly1_cov": 1, + "poly1_rme": 3.7202526561507, + "poly1_top": 4.906463328336078, + "poly2_aic": 50.23384580295357, + "poly2_cov": 1, + "poly2_rme": 3.7190286910920456, + "poly2_top": 4.908027255021525, + "pow_er_sd": 0.32075020244933933, + "exp2_er_sd": 0.32108258944317647, + "exp3_er_sd": 0.3216124902903471, + "exp4_er_sd": 0.32786527141411564, + "exp4_ga_sd": 33.74243671026672, + "exp4_tp_sd": 11.6108227506599, + "exp5_er_sd": 0.334854491636641, + "exp5_ga_sd": 5.3898863226067535, + "exp5_tp_sd": 2.1620411463879097, + "gnls_er_sd": 0.3500317149484511, + "gnls_ga_sd": 0.22054662364571845, + "gnls_la_sd": 2265909239.9199414, + "gnls_tp_sd": 2.2937771724887908, + "hill_er_sd": 0.3351225283208879, + "hill_ga_sd": 4.352134509212842, + "hill_tp_sd": 2.1279907242956564, + "poly1_a_sd": 0.13312558050871134, + "poly1_ac50": 10.000000000000002, + "poly2_a_sd": 4836.680590090178, + "poly2_ac50": 10.107947086330844, + "poly2_b_sd": 19734.212048261263, + "poly1_er_sd": 0.32103720561443533, + "poly2_er_sd": 0.32112575048366343, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1408.8515612792864 + }, + "mc5Param": { + "a": 0.24532316641680385, + "er": 1.1314827238691518, + "ac5": 1.0000000000000002, + "bmd": 37.86491842396683, + "bmr": 9.289141683881516, + "mll": -22.11586314053948, + "top": 4.906463328336078, + "ac10": 2.0000000000000004, + "ac20": 4.000000000000001, + "ac50": 10.000000000000002, + "bmdl": 18.73361680529658, + "bmdu": 1570.6186096996776, + "rmse": 3.7202526561507, + "ac1sd": 28.068879484037673, + "caikwt": 0.45613773535386626, + "hitcall": 3.401746069045992E-7, + "top_over_cutoff": 0.21728467022247083 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842425, + "spid": "TP0000268D09", + "chid": 47371, + "casn": "725228-45-5", + "chnm": "AVE5638", + "dtxsid": "DTXSID0047371", + "bmad": 3.7634679299683276, + "respMax": 9.829527801511304, + "respMin": -2.5563201140688663, + "maxMean": 9.829527801511304, + "maxMeanConc": 1.6989700043360187, + "maxMed": 9.829527801511304, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 24, + "m5id": 5037071, + "modl": "pow", + "hitc": 8.283608352293161E-12, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + 0.5431239666670336, + 4.285106967299528, + 2.5563201140688663, + 9.829527801511304, + 5.709719432762615, + 2.4081165876987582, + -2.5563201140688663, + 6.207106279335564 + ] + }, + "mc4Param": { + "pow_a": 2.6134169605347974, + "pow_p": 0.3224547315138239, + "exp2_a": 1847.8710307754577, + "exp2_b": 8594.958431701696, + "exp3_a": 5.951942308809372, + "exp3_b": 55.65624351376668, + "exp3_p": 0.3000009915091093, + "exp5_p": 0.408031291772936, + "gnls_p": 0.5036307275286347, + "gnls_q": 6.983373974900997, + "hill_p": 0.5036130799544578, + "pow_er": 0.6271801481986525, + "cnst_er": 1.483673944403286, + "exp2_er": 0.901885423620896, + "exp3_er": 0.617447007576443, + "exp4_er": 0.7472251905007579, + "exp4_ga": 12.860918984697772, + "exp4_tp": 10.29314061205533, + "exp5_er": 0.6664687774625762, + "exp5_ga": 10.227134832516548, + "exp5_tp": 11.795433349193852, + "gnls_er": 0.6844246765693558, + "gnls_ga": 8.727972134778678, + "gnls_la": 476.21374917073217, + "gnls_tp": 11.795433358441182, + "hill_er": 0.6844058554512551, + "hill_ga": 8.729066041588078, + "hill_tp": 11.795433359489715, + "poly1_a": 0.2155653486726829, + "poly2_a": 1619.371664147901, + "poly2_b": 7562.841340094379, + "pow_aic": 41.42019910503057, + "pow_cov": 1, + "pow_rme": 2.0570817824284617, + "pow_top": 9.226768448403208, + "all_bmed": 0, + "cnst_aic": 51.47828396257371, + "cnst_rme": 5.065500679597487, + "exp2_aic": 46.2016811403628, + "exp2_cov": 1, + "exp2_rme": 2.8349639096704293, + "exp2_top": 10.781066320544063, + "exp3_aic": 43.432265040834096, + "exp3_cov": 1, + "exp3_rme": 2.0734102760632704, + "exp3_top": 9.723220686034583, + "exp4_aic": 44.1490672469169, + "exp4_cov": 1, + "exp4_rme": 2.5333364833268393, + "exp4_top": 10.29314061205533, + "exp5_aic": 43.87885037563678, + "exp5_cov": 1, + "exp5_rme": 2.096972769799834, + "exp5_top": 11.795433349193852, + "gnls_aic": 48.13034965100882, + "gnls_cov": 1, + "gnls_rme": 2.1256207071279647, + "gnls_top": 9.848077588604877, + "hill_aic": 44.13034863233809, + "hill_cov": 1, + "hill_rme": 2.1256162744455236, + "hill_top": 11.795433359489715, + "poly1_er": 0.901280786231684, + "poly2_er": 0.9025570210051496, + "pow_a_sd": 1.2648723107958824, + "pow_ac50": 5.826565328027652, + "pow_p_sd": 0.14109048042799285, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 20517.97016403068, + "exp2_ac50": 25.036358472451216, + "exp2_b_sd": 95129.8509706833, + "exp3_a_sd": 13.444564053482148, + "exp3_ac50": 9.976184034850611, + "exp3_b_sd": 266.0736582783042, + "exp3_p_sd": 0.216903370957182, + "exp4_ac50": 12.860918984697772, + "exp5_ac50": 10.227134832516548, + "exp5_p_sd": 0.1950562304619866, + "gnls_ac50": 4.503531056699209, + "gnls_p_sd": 0.30642623552529974, + "gnls_q_sd": 1778.4355834488583, + "hill_ac50": 8.729066041588078, + "hill_p_sd": 0.30636334171671514, + "poly1_aic": 44.19352001430043, + "poly1_cov": 1, + "poly1_rme": 2.8338486403301544, + "poly1_top": 10.778267433634143, + "poly2_aic": 46.2119706927944, + "poly2_cov": 1, + "poly2_rme": 2.8364410811775858, + "poly2_top": 10.776887264522824, + "pow_er_sd": 0.30099084110430235, + "exp2_er_sd": 0.31175385714527687, + "exp3_er_sd": 0.31176613420103494, + "exp4_er_sd": 0.33118431722536384, + "exp4_ga_sd": 11.325306882966284, + "exp4_tp_sd": 3.4851291549920576, + "exp5_er_sd": 0.3015655658242953, + "exp5_ga_sd": 28.51915767292512, + "exp5_tp_sd": 8.264821291402265, + "gnls_er_sd": 0.3022586634075119, + "gnls_ga_sd": 31.4717089520362, + "gnls_la_sd": 273214.77054124634, + "gnls_tp_sd": 9.227295756030236, + "hill_er_sd": 0.3022524501530625, + "hill_ga_sd": 31.46313562630508, + "hill_tp_sd": 9.22366258473231, + "poly1_a_sd": 0.04384146784814762, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 12062.013966135755, + "poly2_ac50": 25.08209723966715, + "poly2_b_sd": 55965.732274987706, + "poly1_er_sd": 0.31174491997287024, + "poly2_er_sd": 0.31177073301646385, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 483.7219493904507 + }, + "mc5Param": { + "a": 2.6134169605347974, + "p": 0.3224547315138239, + "er": 0.6271801481986525, + "ac5": 0.004615323183986625, + "bmd": 51.05567688873282, + "bmr": 9.289141683881516, + "mll": -17.710099552515285, + "top": 9.226768448403208, + "ac10": 0.039605864897673385, + "ac20": 0.339873172854996, + "ac50": 5.826565328027652, + "bmdl": 25.969322888853053, + "bmdu": 126.0034288976538, + "rmse": 2.0570817824284617, + "ac1sd": 20.17667574437803, + "caikwt": 0.006502515494980162, + "hitcall": 8.283608352293161E-12, + "top_over_cutoff": 0.4086110922203279 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842426, + "spid": "TP0000268F11", + "chid": 47351, + "casn": "464930-42-5", + "chnm": "SSR 240612", + "dtxsid": "DTXSID2047351", + "bmad": 3.7634679299683276, + "respMax": 56.74340329908642, + "respMin": 0.9655862698342526, + "maxMean": 56.74340329908642, + "maxMeanConc": 1.6989700043360187, + "maxMed": 56.74340329908642, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 7, + "tmpi": 25, + "m5id": 5037072, + "modl": "hill", + "hitc": 0.9999997974131798, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 19.100000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.6989700043360189, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + -1.154901959985743 + ], + "resp": [ + 44.59335472538687, + 0.9655862698342526, + 51.07450911124849, + 34.60777964222281, + 38.45466945352135, + 43.944478789484535, + 56.74340329908642, + 15.196453629289444 + ] + }, + "mc4Param": { + "pow_a": 22.29063955606957, + "pow_p": 0.3000000044703735, + "exp2_a": 7377.110355751841, + "exp2_b": 5355.437066929028, + "exp3_a": 591.2413263226587, + "exp3_b": 65665.77024490427, + "exp3_p": 0.300000305401534, + "exp5_p": 7.9983423573434145, + "gnls_p": 1.1287983917282394, + "gnls_q": 7.653239171873807, + "hill_p": 1.1288482557103248, + "pow_er": 2.5032045033922516, + "cnst_er": 3.6332397109938266, + "exp2_er": 3.29296967334806, + "exp3_er": 2.5419130229474893, + "exp4_er": 1.4570282322469614, + "exp4_ga": 0.1211168885912654, + "exp4_tp": 46.88558983477806, + "exp5_er": 1.650383818314157, + "exp5_ga": 0.07454030776539969, + "exp5_tp": 44.37027720585292, + "gnls_er": 1.305161491507147, + "gnls_ga": 0.1388302597633832, + "gnls_la": 4500.7988607575635, + "gnls_tp": 49.11672853031013, + "hill_er": 1.305166813111626, + "hill_ga": 0.13882412839547248, + "hill_tp": 49.116358486825376, + "poly1_a": 1.3848525837844712, + "poly2_a": 6214.513214531438, + "poly2_b": 4538.601931470192, + "pow_aic": 71.6277031240271, + "pow_cov": 1, + "pow_rme": 13.523494389939856, + "pow_top": 72.07979423450467, + "all_bmed": 0, + "cnst_aic": 85.17328329049076, + "cnst_rme": 39.77503672995993, + "exp2_aic": 83.88353944963814, + "exp2_cov": 1, + "exp2_rme": 28.82615638820165, + "exp2_top": 69.19748254971222, + "exp3_aic": 74.18541947887306, + "exp3_cov": 1, + "exp3_rme": 13.997699402413598, + "exp3_top": 72.72562462018436, + "exp4_aic": 55.16605989184805, + "exp4_cov": 1, + "exp4_rme": 5.0053816249751115, + "exp4_top": 46.88558983477806, + "exp5_aic": 60.83333339353628, + "exp5_cov": 1, + "exp5_rme": 6.417783643263895, + "exp5_top": 44.37027720585292, + "gnls_aic": 58.349089094862535, + "gnls_cov": 1, + "gnls_rme": 4.10385604566807, + "gnls_top": 49.11409533247871, + "hill_aic": 54.34908909384654, + "hill_cov": 1, + "hill_rme": 4.103866665590556, + "hill_top": 49.116358486825376, + "poly1_er": 3.291931983247854, + "poly2_er": 3.293092482358462, + "pow_a_sd": null, + "pow_ac50": 4.960628458191019, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 76621.24816189415, + "exp2_ac50": 25.058351701479907, + "exp2_b_sd": 55332.40931606274, + "exp3_a_sd": null, + "exp3_ac50": 5.456350237754098, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.1211168885912654, + "exp5_ac50": 0.07454030776539969, + "exp5_p_sd": null, + "gnls_ac50": 0.1388170716544355, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.13882412839547248, + "hill_p_sd": 1.0072426298983834, + "poly1_aic": 81.87415000051952, + "poly1_cov": 1, + "poly1_rme": 28.80990540590964, + "poly1_top": 69.24262918922355, + "poly2_aic": 83.8960828082405, + "poly2_cov": 1, + "poly2_rme": 28.846900317891546, + "poly2_top": 69.21708675555531, + "pow_er_sd": null, + "exp2_er_sd": 0.2979467220440815, + "exp3_er_sd": null, + "exp4_er_sd": 0.31706674559933146, + "exp4_ga_sd": 0.02771959613022985, + "exp4_tp_sd": 2.7450192626672303, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.30688202903113515, + "hill_ga_sd": 0.11148548451151348, + "hill_tp_sd": 7.894298278477134, + "poly1_a_sd": 0.49529366199526986, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 42973.45685321085, + "poly2_ac50": 25.136203021763425, + "poly2_b_sd": 30971.57960174396, + "poly1_er_sd": 0.2978316290780377, + "poly2_er_sd": 0.29791923025954864, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4500.85239695864 + }, + "mc5Param": { + "p": 1.1288482557103248, + "er": 1.305166813111626, + "ga": 0.13882412839547248, + "tp": 49.116358486825376, + "ac5": 0.0102251575317605, + "acc": 0.12033066816769825, + "bmd": 0.03823149140805884, + "bmr": 9.289141683881516, + "mll": -23.17454454692327, + "top": 49.116358486825376, + "ac10": 0.01982170312832394, + "ac20": 0.04065602361491505, + "ac50": 0.13882412839547248, + "bmdl": 0.027228374830847675, + "bmdu": 0.05629923061844972, + "rmse": 4.103866665590556, + "ac1sd": 0.027842487636980728, + "caikwt": 2.0258682012827294E-7, + "hitcall": 0.9999997974131798, + "top_over_cutoff": 2.1751373733303265 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842427, + "spid": "TP0000268G07", + "chid": 47342, + "casn": "NOCAS_47342", + "chnm": "SR125047", + "dtxsid": "DTXSID3047342", + "bmad": 3.7634679299683276, + "respMax": 16.068431608615082, + "respMin": -2.4478548285083273, + "maxMean": 16.068431608615082, + "maxMeanConc": 1.6989700043360187, + "maxMed": 16.068431608615082, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 26, + "m5id": 5037073, + "modl": "hill", + "hitc": 7.513456343366634E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 18.100000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.6989700043360189, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.2218487496163564 + ], + "resp": [ + 2.578651202272505, + 10.929576624760047, + -2.4478548285083273, + -0.9930052374030435, + 16.068431608615082, + -1.1296964636433144, + -2.031470190077792, + 0.9930052374030434 + ] + }, + "mc4Param": { + "pow_a": 0.7495851450301008, + "pow_p": 0.7934306069332071, + "exp2_a": 3745.887701077395, + "exp2_b": 11161.230229848748, + "exp3_a": 211.17258400046512, + "exp3_b": 1321.9558679160486, + "exp3_p": 0.7862869437104818, + "exp5_p": 1.5971709257356228, + "gnls_p": 1.8437972877629345, + "gnls_q": 6.0802381175989755, + "hill_p": 1.8437982520570464, + "pow_er": 0.5569604229333858, + "cnst_er": 1.496227101300069, + "exp2_er": 0.6013530822669483, + "exp3_er": 0.56192578085808, + "exp4_er": 0.3643457082349424, + "exp4_ga": 18.77713492364612, + "exp4_tp": 19.282117896825127, + "exp5_er": 0.1813537664571939, + "exp5_ga": 14.606417150732632, + "exp5_tp": 16.15853839281399, + "gnls_er": 0.16259772400318157, + "gnls_ga": 15.327772022476056, + "gnls_la": 716.9030513711922, + "gnls_tp": 17.82615761827315, + "hill_er": 0.1626080470170854, + "hill_ga": 15.32785499084368, + "hill_tp": 17.826228582259645, + "poly1_a": 0.33630167057563587, + "poly2_a": 5534.470181137269, + "poly2_b": 16509.417806231653, + "pow_aic": 40.586937969960985, + "pow_cov": 1, + "pow_rme": 1.976876645272376, + "pow_top": 16.70458816459739, + "all_bmed": 0, + "cnst_aic": 54.648400025462585, + "cnst_rme": 7.050414694167261, + "exp2_aic": 41.509916177688794, + "exp2_cov": 1, + "exp2_rme": 2.1346868197498607, + "exp2_top": 16.81844459556715, + "exp3_aic": 42.707146864839885, + "exp3_cov": 1, + "exp3_rme": 1.9923148983459509, + "exp3_top": 16.710344322133963, + "exp4_aic": 37.940991423770946, + "exp4_cov": 1, + "exp4_rme": 1.7263552245064822, + "exp4_top": 19.282117896825127, + "exp5_aic": 36.94109523557594, + "exp5_cov": 1, + "exp5_rme": 1.4202088508960418, + "exp5_top": 16.15853839281399, + "gnls_aic": 40.679025093815895, + "gnls_cov": 1, + "gnls_rme": 1.3995253107697865, + "gnls_top": 17.693918959116115, + "hill_aic": 36.67902495033333, + "hill_cov": 1, + "hill_rme": 1.3995249681145707, + "hill_top": 17.826228582259645, + "poly1_er": 0.6001608259061096, + "poly2_er": 0.6007737931510304, + "pow_a_sd": 0.45733970898996046, + "pow_ac50": 20.872138600405815, + "pow_p_sd": 0.15802993812972735, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 34356.31271501256, + "exp2_ac50": 25.02799868224741, + "exp2_b_sd": 102105.6974126556, + "exp3_a_sd": 651.7340339714862, + "exp3_ac50": 21.20970217173776, + "exp3_b_sd": 4590.856553343913, + "exp3_p_sd": 0.189049486322834, + "exp4_ac50": 18.77713492364612, + "exp5_ac50": 14.606417150732632, + "exp5_p_sd": 0.4330441605396518, + "gnls_ac50": 15.204926781653212, + "gnls_p_sd": 0.5081164715543239, + "gnls_q_sd": 4108.363521527936, + "hill_ac50": 15.32785499084368, + "hill_p_sd": 0.5081331258789696, + "poly1_aic": 39.49794234452144, + "poly1_cov": 1, + "poly1_rme": 2.1327398858741935, + "poly1_top": 16.81508352878179, + "poly2_aic": 41.514073524464166, + "poly2_cov": 1, + "poly2_rme": 2.135746785098317, + "poly2_top": 16.812318280864897, + "pow_er_sd": 0.3123867399094015, + "exp2_er_sd": 0.3173507805054053, + "exp3_er_sd": 0.3132824822426714, + "exp4_er_sd": 0.3204206492367301, + "exp4_ga_sd": 7.538812655873604, + "exp4_tp_sd": 3.614102630459925, + "exp5_er_sd": 0.3228010130363589, + "exp5_ga_sd": 2.1623706344386395, + "exp5_tp_sd": 1.213152398522362, + "gnls_er_sd": 0.3235596345274449, + "gnls_ga_sd": 3.611431409511374, + "gnls_la_sd": 1286628.173870158, + "gnls_tp_sd": 2.3538578449416696, + "hill_er_sd": 0.3235605842861329, + "hill_ga_sd": 3.611520231183444, + "hill_tp_sd": 2.353918902922515, + "poly1_a_sd": 0.035107290392205344, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 43848.155451291146, + "poly2_ac50": 25.037742786782083, + "poly2_b_sd": 130401.28963646913, + "poly1_er_sd": 0.31719198749658833, + "poly2_er_sd": 0.3173229343451282, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 718.4597781609216 + }, + "mc5Param": { + "p": 1.8437982520570464, + "er": 0.1626080470170854, + "ga": 15.32785499084368, + "tp": 17.826228582259645, + "ac5": 3.1041182593433, + "bmd": 16.046024255628595, + "bmr": 9.289141683881516, + "mll": -14.339512475166664, + "top": 17.826228582259645, + "ac10": 4.655214191434633, + "ac20": 7.226847933148336, + "ac50": 15.32785499084368, + "bmdl": 12.817356025918471, + "bmdu": 19.68919163424624, + "rmse": 1.3995249681145707, + "ac1sd": 11.924278068437353, + "caikwt": 0.0001252983526033338, + "hitcall": 7.513456343366634E-7, + "top_over_cutoff": 0.7894415874744223 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842428, + "spid": "TP0000268H11", + "chid": 47362, + "casn": "NOCAS_47362", + "chnm": "SSR150106", + "dtxsid": "DTXSID1047362", + "bmad": 3.7634679299683276, + "respMax": 32.275376253360285, + "respMin": -7.867717756019061, + "maxMean": 32.275376253360285, + "maxMeanConc": 1.6989700043360187, + "maxMed": 32.275376253360285, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 27, + "m5id": 5037074, + "modl": "poly1", + "hitc": 0.9723023592263895, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + 7.836812981967315, + -1.688479877558232, + 1.688479877558232, + 11.146812393304948, + 2.103486843396195, + -5.189794556835356, + -7.867717756019061, + 32.275376253360285 + ] + }, + "mc4Param": { + "pow_a": 0.4589901690368699, + "pow_p": 1.0864882638245654, + "exp2_a": 101.4651209324748, + "exp2_b": 181.35011628024697, + "exp3_a": 136.47408823959836, + "exp3_b": 227.43583566565215, + "exp3_p": 1.0244060811915972, + "exp5_p": 1.6543740009751935, + "gnls_p": 2.544254271420234, + "gnls_q": 7.832466215756295, + "hill_p": 2.5440165316447105, + "pow_er": 1.1937920093205483, + "cnst_er": 2.1116016336711736, + "exp2_er": 1.189397204329031, + "exp3_er": 1.1900107506641908, + "exp4_er": 1.3892245596869288, + "exp4_ga": 26.05395024269712, + "exp4_tp": 38.7304515040133, + "exp5_er": 1.236530306766801, + "exp5_ga": 28.81134072021623, + "exp5_tp": 38.73045146929248, + "gnls_er": 1.2683740002383097, + "gnls_ga": 27.607015111885687, + "gnls_la": 4998.569320195761, + "gnls_tp": 38.73045147605155, + "hill_er": 1.2684075667282575, + "hill_ga": 27.60654261703223, + "hill_tp": 38.73045149963589, + "poly1_a": 0.6372560400447195, + "poly2_a": 182.2661163816764, + "poly2_b": 326.31707791831155, + "pow_aic": 51.68671768837355, + "pow_cov": 1, + "pow_rme": 4.1789842044248235, + "pow_top": 32.18950912321905, + "all_bmed": 0, + "cnst_aic": 63.90474507028467, + "cnst_rme": 12.87598788572432, + "exp2_aic": 51.68912006250683, + "exp2_cov": 1, + "exp2_rme": 4.201398457618982, + "exp2_top": 32.211670164602985, + "exp3_aic": 53.68628653722567, + "exp3_cov": 1, + "exp3_rme": 4.193697698573126, + "exp3_top": 32.2049157281836, + "exp4_aic": 54.24612188601166, + "exp4_cov": 1, + "exp4_rme": 4.781182771456221, + "exp4_top": 38.7304515040133, + "exp5_aic": 54.07263547430031, + "exp5_cov": 1, + "exp5_rme": 4.191856927998687, + "exp5_top": 38.73045146929248, + "gnls_aic": 58.62822032794858, + "gnls_cov": 1, + "gnls_rme": 4.334693218513672, + "gnls_top": 38.727333168934166, + "hill_aic": 54.62822039910054, + "hill_cov": 1, + "hill_rme": 4.334666275617764, + "hill_top": 38.73045149963589, + "poly1_er": 1.1994211380897748, + "poly2_er": 1.1893608922995844, + "pow_a_sd": 0.2662014726962556, + "pow_ac50": 26.41818935078147, + "pow_p_sd": 0.1521243947331567, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 348.26640117274536, + "exp2_ac50": 26.717755706472612, + "exp2_b_sd": 548.865968812935, + "exp3_a_sd": 807.847513184223, + "exp3_ac50": 26.72713309062012, + "exp3_b_sd": 1098.3202531522547, + "exp3_p_sd": 0.3785039176466354, + "exp4_ac50": 26.05395024269712, + "exp5_ac50": 28.81134072021623, + "exp5_p_sd": 0.8722989388452311, + "gnls_ac50": 27.605267916591213, + "gnls_p_sd": 2.908874800565709, + "gnls_q_sd": 1691693.862361631, + "hill_ac50": 27.60654261703223, + "hill_p_sd": 2.9035455790005753, + "poly1_aic": 49.794702774441554, + "poly1_cov": 1, + "poly1_rme": 4.2304963707100685, + "poly1_top": 31.86280200223597, + "poly2_aic": 51.69217105908964, + "poly2_cov": 1, + "poly2_rme": 4.2015552080075915, + "poly2_top": 32.206999419449126, + "pow_er_sd": 0.3335534848800435, + "exp2_er_sd": 0.3352306055195441, + "exp3_er_sd": 0.33540266751937425, + "exp4_er_sd": 0.34685487937247106, + "exp4_ga_sd": 14.862078891119456, + "exp4_tp_sd": 14.104706577122425, + "exp5_er_sd": 0.33280432150032224, + "exp5_ga_sd": 14.999794914044722, + "exp5_tp_sd": 18.593299749044046, + "gnls_er_sd": 0.3380749134545, + "gnls_ga_sd": 16.756024987415838, + "gnls_la_sd": 9183669699.444252, + "gnls_tp_sd": 22.121841064908335, + "hill_er_sd": 0.33805915168123435, + "hill_ga_sd": 16.727253222611452, + "hill_tp_sd": 22.083475060963128, + "poly1_a_sd": 0.0558929749060581, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 715.013055008413, + "poly2_ac50": 26.65356756528099, + "poly2_b_sd": 1138.546206698338, + "poly1_er_sd": 0.33129334042250025, + "poly2_er_sd": 0.3350705967166628, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4998.669787345316 + }, + "mc5Param": { + "a": 0.6372560400447195, + "er": 1.1994211380897748, + "ac5": 2.5, + "acc": 35.43443476538152, + "bmd": 14.57678091717993, + "bmr": 9.289141683881516, + "mll": -22.897351387220777, + "top": 31.86280200223597, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 12.611111933962569, + "bmdu": 17.452581906257134, + "rmse": 4.2304963707100685, + "ac1sd": 10.80561965691618, + "caikwt": 0.0008623202468912801, + "hitcall": 0.9723023592263896, + "top_over_cutoff": 1.411056796335542 + }, + "mc6Param": { + "flag": [ + "Only highest conc above baseline, active", + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 6, + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842429, + "spid": "TP0000269H02", + "chid": 22422, + "casn": "101-77-9", + "chnm": "4,4'-Diaminobiphenyl methane", + "dtxsid": "DTXSID6022422", + "bmad": 3.7634679299683276, + "respMax": 6.633232578988787, + "respMin": -9.288579922195433, + "maxMean": 6.633232578988787, + "maxMeanConc": 1.6989700043360187, + "maxMed": 6.633232578988787, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 28, + "m5id": 5037075, + "modl": "poly1", + "hitc": 3.192301725566275E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812 + ], + "resp": [ + -9.288579922195433, + -1.8279384384638953, + -0.14076023490952427, + -4.745260374024319, + 1.8279384384638953, + 6.633232578988787, + -4.73269516708234, + -1.5362461344536993 + ] + }, + "mc4Param": { + "pow_a": 6.640694251968835E-8, + "pow_p": 4.708272706063721, + "exp2_a": 0.0014256880285145326, + "exp2_b": 5.922987531364045, + "exp3_a": 4.8847255820373086, + "exp3_b": 51.06429898378816, + "exp3_p": 7.307167695500869, + "exp5_p": 7.999659316310423, + "gnls_p": 7.997921197479794, + "gnls_q": 7.999530335677372, + "hill_p": 7.987088871124498, + "pow_er": 1.1589254476238335, + "cnst_er": 1.4044782982786244, + "exp2_er": 1.1606772582682774, + "exp3_er": 1.158287286339332, + "exp4_er": 1.3005392690341286, + "exp4_ga": 47.86270321881696, + "exp4_tp": 7.959879066255224, + "exp5_er": 1.1586163655292807, + "exp5_ga": 44.27571832190897, + "exp5_tp": 7.895000592298389, + "gnls_er": 1.1573094818936194, + "gnls_ga": 40.56058652494757, + "gnls_la": 1282.63837357557, + "gnls_tp": 7.842544176863125, + "hill_er": 1.158759147911965, + "hill_ga": 40.89369026010592, + "hill_tp": 7.959875816540536, + "poly1_a": 0.10491644651330384, + "poly2_a": 0.0006507393642465428, + "poly2_b": 0.5070793867700588, + "pow_aic": 51.41328997449672, + "pow_cov": 1, + "pow_rme": 4.1877013763156805, + "pow_top": 6.628688104808383, + "all_bmed": 0, + "cnst_aic": 50.45420871184967, + "cnst_rme": 4.799166261950659, + "exp2_aic": 51.41291348555145, + "exp2_cov": 1, + "exp2_rme": 4.1880775010710165, + "exp2_top": 6.608583802396452, + "exp3_aic": 53.40921189505927, + "exp3_cov": 1, + "exp3_rme": 4.187148881312595, + "exp3_top": 6.628127374590708, + "exp4_aic": 53.10846032712193, + "exp4_cov": 1, + "exp4_rme": 4.550125713330075, + "exp4_top": 7.959879066255224, + "exp5_aic": 53.40936435022408, + "exp5_cov": 1, + "exp5_rme": 4.187167470953343, + "exp5_top": 7.895000592298389, + "gnls_aic": 57.410191575677814, + "gnls_cov": 1, + "gnls_rme": 4.18726579424983, + "gnls_top": 7.842528457243228, + "hill_aic": 53.41002025565312, + "hill_cov": 1, + "hill_rme": 4.187247227286038, + "hill_top": 7.959875816540536, + "poly1_er": 1.2638071352336775, + "poly2_er": 1.1976543273745366, + "pow_a_sd": 0.0000013788954939727336, + "pow_ac50": 43.15524701052844, + "pow_p_sd": 0.1097737662077741, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.012170331308111916, + "exp2_ac50": 45.89577526124489, + "exp2_b_sd": 6.001913269342651, + "exp3_a_sd": null, + "exp3_ac50": 46.66683218601111, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 47.86270321881696, + "exp5_ac50": 44.27571832190897, + "exp5_p_sd": 93.77195086112552, + "gnls_ac50": 40.56056619473948, + "gnls_p_sd": 43.59115160559422, + "gnls_q_sd": 2768980.6256247056, + "hill_ac50": 40.89369026010592, + "hill_p_sd": 56.475026137838405, + "poly1_aic": 50.713583537593315, + "poly1_cov": 1, + "poly1_rme": 4.48292241263243, + "poly1_top": 5.245822325665192, + "poly2_aic": 51.658540260325886, + "poly2_cov": 1, + "poly2_rme": 4.236574457386872, + "poly2_top": 6.391126680630588, + "pow_er_sd": 0.3390660571566805, + "exp2_er_sd": 0.33931424884331485, + "exp3_er_sd": null, + "exp4_er_sd": 0.32712745799309023, + "exp4_ga_sd": 85.09550371327019, + "exp4_tp_sd": 12.38636011110518, + "exp5_er_sd": 0.3391901097874664, + "exp5_ga_sd": 365.25436041198617, + "exp5_tp_sd": 196.19908115352908, + "gnls_er_sd": 0.33907426314020656, + "gnls_ga_sd": 78.57769638557588, + "gnls_la_sd": 1447381779.2912436, + "gnls_tp_sd": 22.236006501316705, + "hill_er_sd": 0.33920566149277925, + "hill_ga_sd": 189.84478002949493, + "hill_tp_sd": 57.07566436306677, + "poly1_a_sd": 0.06310343610315335, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.017222480464774936, + "poly2_ac50": 35.28153125132216, + "poly2_b_sd": 6.752089022420825, + "poly1_er_sd": 0.32616650584201273, + "poly2_er_sd": 0.3369788768607837, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1282.6390163455906 + }, + "mc5Param": { + "a": 0.10491644651330384, + "er": 1.2638071352336775, + "ac5": 2.5, + "bmd": 88.53847030268618, + "bmr": 9.289141683881516, + "mll": -23.356791768796658, + "top": 5.245822325665192, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 44.58314427339827, + "rmse": 4.48292241263243, + "ac1sd": 65.63266886781777, + "caikwt": 0.5323764880588537, + "hitcall": 3.192301725566275E-7, + "top_over_cutoff": 0.23231331772011585 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842432, + "spid": "TP0000394E04", + "chid": 20501, + "casn": "1095-90-5", + "chnm": "Methadone hydrochloride", + "dtxsid": "DTXSID2020501", + "bmad": 3.7634679299683276, + "respMax": 53.57668637905514, + "respMin": -4.581867196614961, + "maxMean": 53.57668637905514, + "maxMeanConc": 1.6020599913279625, + "maxMed": 53.57668637905514, + "maxMedConc": 1.6020599913279625, + "logcMax": 1.6020599913279625, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 31, + "m5id": 5037078, + "modl": "hill", + "hitc": 0.9999279506725846, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 14.5, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1, + -0.3979400086720376, + 1.6020599913279625, + 0, + -1.6989700043360187, + 0.6020599913279624, + -1.3010299956639813, + -1 + ], + "resp": [ + 21.936647794421265, + -1.740228546008569, + 53.57668637905514, + 0.9551787559185203, + 4.581867196614961, + 5.153028957639964, + -4.581867196614961, + -4.44713457988105 + ] + }, + "mc4Param": { + "pow_a": 2.4561136581257776, + "pow_p": 0.8384142205134059, + "exp2_a": 11320.853419470812, + "exp2_b": 8346.744546958991, + "exp3_a": 1237.9308992517135, + "exp3_b": 1768.9351199634818, + "exp3_p": 0.8316744236700095, + "exp5_p": 1.8016780602346592, + "gnls_p": 1.9766627273478856, + "gnls_q": 4.997108159683513, + "hill_p": 1.9766497079181975, + "pow_er": 1.2490116616663218, + "cnst_er": 2.3406712762674364, + "exp2_er": 1.2565016352167926, + "exp3_er": 1.2497067897586192, + "exp4_er": 1.191255314619447, + "exp4_ga": 16.812978981896514, + "exp4_tp": 64.29202364758979, + "exp5_er": 0.8491056586507115, + "exp5_ga": 11.658831182973834, + "exp5_tp": 53.66634267307796, + "gnls_er": 0.8492765164139605, + "gnls_ga": 13.128901045410975, + "gnls_la": 2844.841004379705, + "gnls_tp": 59.500838623136616, + "hill_er": 0.8492543606297048, + "hill_ga": 13.128917895765634, + "hill_tp": 59.50093497422053, + "poly1_a": 1.35953439410823, + "poly2_a": 16188.436536049236, + "poly2_b": 11947.622892743011, + "pow_aic": 51.10023509243637, + "pow_cov": 1, + "pow_rme": 3.696125539873346, + "pow_top": 54.13003887794411, + "all_bmed": 0, + "cnst_aic": 70.10511686201906, + "cnst_rme": 20.748302126586477, + "exp2_aic": 52.14437661600831, + "exp2_cov": 1, + "exp2_rme": 4.1749638213440265, + "exp2_top": 54.38299031459843, + "exp3_aic": 53.16631363814249, + "exp3_cov": 1, + "exp3_rme": 3.712832014242786, + "exp3_top": 54.12213234353056, + "exp4_aic": 50.26961153208619, + "exp4_cov": 1, + "exp4_rme": 3.527127666309079, + "exp4_top": 64.29202364758979, + "exp5_aic": 48.01142321272821, + "exp5_cov": 1, + "exp5_rme": 2.8599881028288165, + "exp5_top": 53.66634267307796, + "gnls_aic": 52.00868220033195, + "gnls_cov": 1, + "gnls_rme": 2.859115773918567, + "gnls_top": 59.447789496359654, + "hill_aic": 48.00868220032641, + "hill_cov": 1, + "hill_rme": 2.8591158241549053, + "hill_top": 59.50093497422053, + "poly1_er": 1.2550642041651328, + "poly2_er": 1.2548228259159553, + "pow_a_sd": 0.5793958854691459, + "pow_ac50": 17.498995862103317, + "pow_p_sd": 0.06471940367191595, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 91463.2886733445, + "exp2_ac50": 20.023961414836553, + "exp2_b_sd": 67271.17368852775, + "exp3_a_sd": null, + "exp3_ac50": 17.605958078074853, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 16.812978981896514, + "exp5_ac50": 11.658831182973834, + "exp5_p_sd": 0.4678540387944143, + "gnls_ac50": 13.11706285853708, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 13.128917895765634, + "hill_p_sd": 0.5437164914820396, + "poly1_aic": 50.12897105076053, + "poly1_cov": 1, + "poly1_rme": 4.169192622228223, + "poly1_top": 54.38137576432922, + "poly2_aic": 52.15043963754287, + "poly2_cov": 1, + "poly2_rme": 4.1773867080169955, + "poly2_top": 54.3794684457665, + "pow_er_sd": 0.2953728072048604, + "exp2_er_sd": 0.32180507236787287, + "exp3_er_sd": null, + "exp4_er_sd": 0.32050596955935456, + "exp4_ga_sd": 4.7195276601323375, + "exp4_tp_sd": 9.472791030891605, + "exp5_er_sd": 0.3379311586462701, + "exp5_ga_sd": 1.1444511740381855, + "exp5_tp_sd": 2.171328717403055, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.33765766287101917, + "hill_ga_sd": 2.6322294581745154, + "hill_tp_sd": 6.46954953419342, + "poly1_a_sd": 0.08016047186257787, + "poly1_ac50": 20.000000000000007, + "poly2_a_sd": 111138.19550808848, + "poly2_ac50": 20.033367656805616, + "poly2_b_sd": 81749.64462524683, + "poly1_er_sd": 0.3215405880389804, + "poly2_er_sd": 0.3217023608890684, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2845.828862866811 + }, + "mc5Param": { + "p": 1.9766497079181975, + "er": 0.8492543606297048, + "ga": 13.128917895765634, + "tp": 59.50093497422053, + "ac5": 2.9600505790971923, + "acc": 10.2377822240795, + "bmd": 5.590946990603684, + "bmr": 9.289141683881516, + "mll": -20.00434110016321, + "top": 59.50093497422053, + "ac10": 4.31987731652492, + "ac20": 6.510927354274445, + "ac50": 13.128917895765634, + "bmdl": 4.96194145242722, + "bmdu": 6.331117452796167, + "rmse": 2.8591158241549053, + "ac1sd": 4.69288250612793, + "caikwt": 0.000015915242721747014, + "hitcall": 0.9999279506725846, + "top_over_cutoff": 2.6350224527585864 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842430, + "spid": "TP0000270A03", + "chid": 40713, + "casn": "1034-01-1", + "chnm": "Octyl gallate", + "dtxsid": "DTXSID4040713", + "bmad": 3.7634679299683276, + "respMax": 4.0110100385645735, + "respMin": -1753.9651348778787, + "maxMean": 4.0110100385645735, + "maxMeanConc": -0.6989700043360187, + "maxMed": 4.0110100385645735, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 29, + "m5id": 5037076, + "modl": "poly1", + "hitc": 0.09452569552120044, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + -2.8074617052802946, + 1.0764716849676692, + -3.8481164198730133, + -66.04011500681993, + -22.1044677990717, + -650.3289764196767, + 4.0110100385645735, + -1753.9651348778787 + ] + }, + "mc4Param": { + "pow_a": 0.000005430954273073871, + "pow_p": 0.44356001645759247, + "exp2_a": 0.0002868758851047003, + "exp2_b": 52.29564518101915, + "exp3_a": 0.00007065373025385777, + "exp3_b": 53.07437818010606, + "exp3_p": 7.856638077526047, + "exp5_p": 6.364784886246265, + "gnls_p": 1.0994616555400518, + "gnls_q": 6.028016384412763, + "hill_p": 1.4277336875116893, + "pow_er": 5.478367634135051, + "cnst_er": 5.135878672216937, + "exp2_er": 5.477689913583649, + "exp3_er": 5.48013831055958, + "exp4_er": 5.478384004342792, + "exp4_ga": 0.016244348117744, + "exp4_tp": 5.294724775052426E-7, + "exp5_er": 5.478340674314374, + "exp5_ga": 6.3316531519675445, + "exp5_tp": 2.3312427416913565E-7, + "gnls_er": 5.478333661045958, + "gnls_ga": 0.06561651513532632, + "gnls_la": 4.027166880955711, + "gnls_tp": 0.005795299244329243, + "hill_er": 5.478301864378817, + "hill_ga": 65.48576851856772, + "hill_tp": 5.147568284752382E-7, + "poly1_a": 9.803449957825028E-9, + "poly2_a": 0.0003985692201837858, + "poly2_b": 57.57648587989856, + "pow_aic": 128.0195917417057, + "pow_cov": 1, + "pow_rme": 661.8356526940903, + "pow_top": 0.00003079436898408721, + "all_bmed": 0, + "cnst_aic": 124.3587136415083, + "cnst_rme": 661.8356398173057, + "exp2_aic": 128.01959637464324, + "exp2_cov": 1, + "exp2_rme": 661.8358088666978, + "exp2_top": 0.0004594424423992509, + "exp3_aic": 130.0196021965711, + "exp3_cov": 1, + "exp3_rme": 661.8356601754986, + "exp3_top": 0.00006144291346564819, + "exp4_aic": 128.01959135584116, + "exp4_cov": 1, + "exp4_rme": 661.8356400664329, + "exp4_top": 5.294724775052426E-7, + "exp5_aic": 130.01959133366273, + "exp5_cov": 1, + "exp5_rme": 661.8356399242966, + "exp5_top": 2.3312427416913565E-7, + "gnls_aic": 134.0195953824525, + "gnls_cov": 1, + "gnls_rme": 661.8356575450581, + "gnls_top": 0.005607028353241692, + "hill_aic": 130.01959132750963, + "hill_cov": 1, + "hill_rme": 661.8356398963703, + "hill_top": 5.147568284752382E-7, + "poly1_er": 5.47830425526447, + "poly2_er": 5.47782475358971, + "pow_a_sd": null, + "pow_ac50": 10.478569298304585, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.761010400258353, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 46.61973121962576, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.016244348117744, + "exp5_ac50": 6.3316531519675445, + "exp5_p_sd": 570927.6166739571, + "gnls_ac50": 0.06184991600912808, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 65.48576851856772, + "hill_p_sd": null, + "poly1_aic": 126.0195913302737, + "poly1_cov": 1, + "poly1_rme": 661.8356400045014, + "poly1_top": 4.901724978912513E-7, + "poly2_aic": 128.0195974654655, + "poly2_cov": 1, + "poly2_rme": 661.8358775325804, + "poly2_top": 0.0006466969391063058, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.5650956309919339, + "exp5_ga_sd": 30541.074886739865, + "exp5_tp_sd": 0.010891154955251125, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999993, + "poly2_a_sd": null, + "poly2_ac50": 30.525963440706303, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4.056814023436538 + }, + "mc5Param": { + "a": 9.803449957825028E-9, + "er": 5.47830425526447, + "ac5": 2.4999999999999996, + "bmd": 947538032.4114374, + "bmr": 9.289141683881516, + "mll": -61.00979566513685, + "top": 4.901724978912513E-7, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999993, + "bmdl": 1.5904077965907737, + "rmse": 661.8356400045014, + "ac1sd": 702400320.542207, + "caikwt": 0.6964477131643466, + "hitcall": 0.09452569552120044, + "top_over_cutoff": 2.1707483054305203E-8 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842431, + "spid": "TP0000270G03", + "chid": 24538, + "casn": "1143-38-0", + "chnm": "Anthralin", + "dtxsid": "DTXSID7024538", + "bmad": 3.7634679299683276, + "respMax": 1.07185605243019, + "respMin": -9693.875949218062, + "maxMean": 1.07185605243019, + "maxMeanConc": -1.6989700043360187, + "maxMed": 1.07185605243019, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 30, + "m5id": 5037077, + "modl": "poly1", + "hitc": 0.1121664647692, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + -290.8004336479407, + -1119.7932814002315, + -3511.304770127347, + -14.130840021191842, + 1.07185605243019, + -9693.875949218062, + -5531.363440142849, + -9.227773090281191 + ] + }, + "mc4Param": { + "pow_a": 0.000016295912787337223, + "pow_p": 0.32150472408902353, + "exp2_a": 0.0005108027295935569, + "exp2_b": 117.05732896371232, + "exp3_a": 0.0007637855137420518, + "exp3_b": 66.37880128554707, + "exp3_p": 1.1690184802745147, + "exp5_p": 1.213976459225782, + "gnls_p": 1.465333545857999, + "gnls_q": 5.282627284696863, + "hill_p": 1.2584446172819073, + "pow_er": 7.913005745260049, + "cnst_er": 7.913106054805518, + "exp2_er": 7.91304122261628, + "exp3_er": 7.912357342166467, + "exp4_er": 7.9130904419643535, + "exp4_ga": 1.5991852149246326, + "exp4_tp": 2.547300452544774E-7, + "exp5_er": 7.913138104543472, + "exp5_ga": 1.0314696395590963, + "exp5_tp": 8.788694104592858E-7, + "gnls_er": 7.913096858909503, + "gnls_ga": 0.007141805168919414, + "gnls_la": 0.22621165840625276, + "gnls_tp": 0.7142118359098187, + "hill_er": 7.913164719748869, + "hill_ga": 0.07017612467977288, + "hill_tp": 0.0000014705482139499703, + "poly1_a": 7.358333303060364E-9, + "poly2_a": 0.02215910584118531, + "poly2_b": 158.14203618196245, + "pow_aic": 160.88623145756264, + "pow_cov": 1, + "pow_rme": 4156.850720832816, + "pow_top": 0.00005731991981836795, + "all_bmed": 0, + "cnst_aic": 156.88623127229403, + "cnst_rme": 4156.850693149301, + "exp2_aic": 160.8862316267931, + "exp2_cov": 1, + "exp2_rme": 4156.850791480489, + "exp2_top": 0.00027219093118124426, + "exp3_aic": 162.88623595855358, + "exp3_cov": 1, + "exp3_rme": 4156.850967911036, + "exp3_top": 0.0008022692602122777, + "exp4_aic": 160.88623127463256, + "exp4_cov": 1, + "exp4_rme": 4156.85069329631, + "exp4_top": 2.547300452544774E-7, + "exp5_aic": 162.88623128180765, + "exp5_cov": 1, + "exp5_rme": 4156.850693669871, + "exp5_top": 8.788694104592858E-7, + "gnls_aic": 166.88623633191477, + "gnls_cov": 1, + "gnls_rme": 4156.851147731188, + "gnls_top": 0.691919808292708, + "hill_aic": 162.8862313001522, + "hill_cov": 1, + "hill_rme": 4156.850694038434, + "hill_top": 0.0000014705482139499703, + "poly1_er": 7.913114168722814, + "poly2_er": 7.913479042407319, + "pow_a_sd": null, + "pow_ac50": 5.7896734789017446, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 27.64958084229515, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 31.74103567254259, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.5991852149246326, + "exp5_ac50": 1.0314696395590963, + "exp5_p_sd": null, + "gnls_ac50": 0.006843854769952966, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.07017612467977288, + "hill_p_sd": null, + "poly1_aic": 158.88623127321256, + "poly1_cov": 1, + "poly1_rme": 4156.850693286225, + "poly1_top": 3.679166651530182E-7, + "poly2_aic": 160.88624315935962, + "poly2_cov": 1, + "poly2_rme": 4156.854008688916, + "poly2_top": 0.009221198742038497, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 124.06407111097684, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 27.96064454439664, + "poly2_b_sd": null, + "poly1_er_sd": 0.5644466155491178, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.22837814263899145 + }, + "mc5Param": { + "a": 7.358333303060364E-9, + "er": 7.913114168722814, + "ac5": 2.5, + "bmd": 1262397516.0269134, + "bmr": 9.289141683881516, + "mll": -77.44311563660628, + "top": 3.679166651530182E-7, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 0.2092540156485721, + "rmse": 4156.850693286225, + "ac1sd": 935802458.1370742, + "caikwt": 0.7310585787203021, + "hitcall": 0.1121664647692, + "top_over_cutoff": 1.629333511889013E-8 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842433, + "spid": "TP0000397C04", + "chid": 47303, + "casn": "179465-71-5", + "chnm": "CJ-013790", + "dtxsid": "DTXSID2047303", + "bmad": 3.7634679299683276, + "respMax": 4.713376683939935, + "respMin": -8.665862529755879, + "maxMean": 4.713376683939935, + "maxMeanConc": 1.6989700043360187, + "maxMed": 4.713376683939935, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 32, + "m5id": 5037079, + "modl": "poly1", + "hitc": 1.4657563430328811E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + 1.3010299956639813, + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + -0.6989700043360187 + ], + "resp": [ + 4.713376683939935, + -2.842277469047785, + -8.665862529755879, + -6.370529795363219, + -4.8381205032263255, + 0.16783502687974627, + -0.16783502687974627, + -8.177282570884165 + ] + }, + "mc4Param": { + "pow_a": 4.7151852041982344E-8, + "pow_p": 4.707056641849134, + "exp2_a": 0.00013619254967583104, + "exp2_b": 4.786378022525692, + "exp3_a": 5.900683408927318, + "exp3_b": 53.44092756539992, + "exp3_p": 7.988441200666841, + "exp5_p": 7.999984075925836, + "gnls_p": 7.999997843476933, + "gnls_q": 2.098633684006826, + "hill_p": 7.999998966110843, + "pow_er": 1.4971788764551808, + "cnst_er": 1.5930907333079742, + "exp2_er": 1.4281119149809516, + "exp3_er": 1.495216359023091, + "exp4_er": 1.574893735475315, + "exp4_ga": 89.43517285381708, + "exp4_tp": 5.656051760011978, + "exp5_er": 1.4954679802518542, + "exp5_ga": 44.42715506006904, + "exp5_tp": 5.651471625387929, + "gnls_er": 1.4957921628108226, + "gnls_ga": 41.23384355892483, + "gnls_la": 3602.128748083291, + "gnls_tp": 5.656047237666198, + "hill_er": 1.4957815691417695, + "hill_ga": 41.23453451042785, + "hill_tp": 5.656051677235107, + "poly1_a": 0.050926851808962656, + "poly2_a": 0.000012052724389524282, + "poly2_b": 0.08546364297195863, + "pow_aic": 55.84673202895972, + "pow_cov": 1, + "pow_rme": 5.177530614120443, + "pow_top": 4.684322627141668, + "all_bmed": 0, + "cnst_aic": 52.95155071753253, + "cnst_rme": 5.434921591825441, + "exp2_aic": 55.8743139942496, + "exp2_cov": 1, + "exp2_rme": 5.173806472402641, + "exp2_top": 4.687233137067029, + "exp3_aic": 57.826834706209766, + "exp3_cov": 1, + "exp3_rme": 5.173298710256261, + "exp3_top": 4.718858031320078, + "exp4_aic": 56.73903934336423, + "exp4_cov": 1, + "exp4_rme": 5.385431090855095, + "exp4_top": 5.656051760011978, + "exp5_aic": 57.82823857314273, + "exp5_cov": 1, + "exp5_rme": 5.173596106096281, + "exp5_top": 5.651471625387929, + "gnls_aic": 61.83188800877744, + "gnls_cov": 1, + "gnls_rme": 5.17436656145897, + "gnls_top": 5.650466885579585, + "hill_aic": 57.83188406117348, + "hill_cov": 1, + "hill_rme": 5.174365789583489, + "hill_top": 5.656051677235107, + "poly1_er": 1.5665690518106064, + "poly2_er": 1.5387462152993685, + "pow_a_sd": 0.0000014616637059530786, + "pow_ac50": 43.15360567910734, + "pow_p_sd": 0.21842337803021228, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.0017043622702050344, + "exp2_ac50": 46.68247463584101, + "exp2_b_sd": 5.752295568125435, + "exp3_a_sd": null, + "exp3_ac50": 46.62733184577904, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 89.43517285381708, + "exp5_ac50": 44.42715506006904, + "exp5_p_sd": 37.67996399295617, + "gnls_ac50": 41.22454200269515, + "gnls_p_sd": 26.8489978675531, + "gnls_q_sd": 365.5344008388901, + "hill_ac50": 41.23453451042785, + "hill_p_sd": 26.882057159993813, + "poly1_aic": 54.65643655278332, + "poly1_cov": 1, + "poly1_rme": 5.369694576790002, + "poly1_top": 2.5463425904481323, + "poly2_aic": 56.11124549509633, + "poly2_cov": 1, + "poly2_rme": 5.235979290613626, + "poly2_top": 4.132416873278887, + "pow_er_sd": 0.3189018135141268, + "exp2_er_sd": 0.3138862113183906, + "exp3_er_sd": null, + "exp4_er_sd": 0.30874656566105163, + "exp4_ga_sd": 367.1517518690402, + "exp4_tp_sd": 24.085287988419147, + "exp5_er_sd": 0.31920776352680286, + "exp5_ga_sd": 128.5331012831714, + "exp5_tp_sd": 50.817238104594026, + "gnls_er_sd": 0.31925198781323405, + "gnls_ga_sd": 84.12979470825537, + "gnls_la_sd": 2666741.0444864347, + "gnls_tp_sd": 19.50597783562384, + "hill_er_sd": 0.31925103598267796, + "hill_ga_sd": 84.43629556899846, + "hill_tp_sd": 19.57120334180694, + "poly1_a_sd": 0.08732727070509533, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.00005470985934134532, + "poly2_ac50": 35.34283609938913, + "poly2_b_sd": 0.1930930384385403, + "poly1_er_sd": 0.3092301889812486, + "poly2_er_sd": 0.3174997459048597, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3605.517232480094 + }, + "mc5Param": { + "a": 0.050926851808962656, + "er": 1.5665690518106064, + "ac5": 2.4999999999999996, + "bmd": 182.4016477344219, + "bmr": 9.289141683881516, + "mll": -25.32821827639166, + "top": 2.5463425904481323, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 48.45564360274376, + "rmse": 5.369694576790002, + "ac1sd": 135.21248905442692, + "caikwt": 0.7010793489765594, + "hitcall": 0.0000014657563430328811, + "top_over_cutoff": 0.11276578933008924 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842434, + "spid": "TP0000397C07", + "chid": 47290, + "casn": "402910-27-4", + "chnm": "UK-416244", + "dtxsid": "DTXSID0047290", + "bmad": 3.7634679299683276, + "respMax": 20.562993899193387, + "respMin": -1.7128786948219439, + "maxMean": 20.562993899193387, + "maxMeanConc": 1.6989700043360187, + "maxMed": 20.562993899193387, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 33, + "m5id": 5037080, + "modl": "poly1", + "hitc": 0.013162763209107189, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436 + ], + "resp": [ + 1.7128786948219457, + 6.79192117713184, + 0.983536383364406, + 20.562993899193387, + 4.434828570684111, + -1.7128786948219439, + 3.81112438722068, + 3.4559450294617946 + ] + }, + "mc4Param": { + "pow_a": 0.6465352316272346, + "pow_p": 0.8777358322696996, + "exp2_a": 89.17261706113294, + "exp2_b": 242.1062343156615, + "exp3_a": 1.1322547120812192, + "exp3_b": 2.3290546411674624, + "exp3_p": 0.3515182576728658, + "exp5_p": 1.5578879657662703, + "gnls_p": 2.6086058918752, + "gnls_q": 6.488574895843359, + "hill_p": 2.608552656586586, + "pow_er": 0.592938019227486, + "cnst_er": 1.6023141970056376, + "exp2_er": 0.5815399491932731, + "exp3_er": 0.4027853746799608, + "exp4_er": 0.7852662330946163, + "exp4_ga": 25.08568386766411, + "exp4_tp": 24.675592673186735, + "exp5_er": 0.725548250986497, + "exp5_ga": 28.642999510263735, + "exp5_tp": 24.67559255717096, + "gnls_er": 0.7768842111175422, + "gnls_ga": 28.03423084450281, + "gnls_la": 1207.440421430461, + "gnls_tp": 24.675592520708317, + "hill_er": 0.7767855542995623, + "hill_ga": 28.03395361240333, + "hill_tp": 24.675592678367664, + "poly1_a": 0.40607178858594234, + "poly2_a": 177.31422405471238, + "poly2_b": 478.93026660415705, + "pow_aic": 41.233991570138386, + "pow_cov": 1, + "pow_rme": 2.079136922898597, + "pow_top": 20.03729289908219, + "all_bmed": 0, + "cnst_aic": 56.08828664046871, + "cnst_rme": 8.077268192520862, + "exp2_aic": 41.31836603558712, + "exp2_cov": 1, + "exp2_rme": 2.124397197473024, + "exp2_top": 20.455613509941355, + "exp3_aic": 40.32224322278512, + "exp3_cov": 1, + "exp3_rme": 1.7472047427116597, + "exp3_top": 20.256515991910604, + "exp4_aic": 43.99983839294445, + "exp4_cov": 1, + "exp4_rme": 2.4212957674199513, + "exp4_top": 24.675592673186735, + "exp5_aic": 45.31966847370493, + "exp5_cov": 1, + "exp5_rme": 2.3636821866975195, + "exp5_top": 24.67559255717096, + "gnls_aic": 50.24980681608249, + "gnls_cov": 1, + "gnls_rme": 2.506821099601261, + "gnls_top": 24.634723410831995, + "hill_aic": 46.24980691570314, + "hill_cov": 1, + "hill_rme": 2.506818523624102, + "hill_top": 24.675592678367664, + "poly1_er": 0.5923846502517791, + "poly2_er": 0.5823674792019434, + "pow_a_sd": 0.6278658064575703, + "pow_ac50": 22.699069305947805, + "pow_p_sd": 0.2549454765062092, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 359.0395021231347, + "exp2_ac50": 26.288468365058172, + "exp2_b_sd": 886.5958914663547, + "exp3_a_sd": null, + "exp3_ac50": 24.811922046316333, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 25.08568386766411, + "exp5_ac50": 28.642999510263735, + "exp5_p_sd": 1.0227938367314742, + "gnls_ac50": 27.998654408803787, + "gnls_p_sd": 5.461532170943338, + "gnls_q_sd": 22759.167333341324, + "hill_ac50": 28.03395361240333, + "hill_p_sd": 5.452818557413982, + "poly1_aic": 39.39114515732258, + "poly1_cov": 1, + "poly1_rme": 2.122723532583719, + "poly1_top": 20.303589429297116, + "poly2_aic": 41.325165646100416, + "poly2_cov": 1, + "poly2_rme": 2.1244698512830005, + "poly2_top": 20.44407341622616, + "pow_er_sd": 0.3108099654396902, + "exp2_er_sd": 0.3178770115917476, + "exp3_er_sd": null, + "exp4_er_sd": 0.33443563742176596, + "exp4_ga_sd": 13.749752885288313, + "exp4_tp_sd": 8.11750344400524, + "exp5_er_sd": 0.32227571811133654, + "exp5_ga_sd": 12.37560260555014, + "exp5_tp_sd": 10.526695614436056, + "gnls_er_sd": 0.3501482582991739, + "gnls_ga_sd": 29.843090634836496, + "gnls_la_sd": 13481202.453940429, + "gnls_tp_sd": 25.420327925189305, + "hill_er_sd": 0.3500296892891899, + "hill_ga_sd": 29.79588241284215, + "hill_tp_sd": 25.3801674852378, + "poly1_a_sd": 0.030791471721265937, + "poly1_ac50": 25, + "poly2_a_sd": 792.2766056136632, + "poly2_ac50": 26.179002210991253, + "poly2_b_sd": 1966.159052634094, + "poly1_er_sd": 0.31366046598015807, + "poly2_er_sd": 0.31747777530209154, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1208.036729727654 + }, + "mc5Param": { + "a": 0.40607178858594234, + "er": 0.5923846502517791, + "ac5": 2.5, + "bmd": 22.87561447257627, + "bmr": 9.289141683881516, + "mll": -17.69557257866129, + "top": 20.303589429297116, + "ac10": 5, + "ac20": 10, + "ac50": 25, + "bmdl": 20.16263893407659, + "bmdu": 26.70412321005569, + "rmse": 2.122723532583719, + "ac1sd": 16.95746069130932, + "caikwt": 0.00023667860169117045, + "hitcall": 0.013162763209107187, + "top_over_cutoff": 0.8991524929981263 + }, + "mc6Param": { + "flag": [ + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842435, + "spid": "TP0000880C04", + "chid": 33923, + "casn": "32809-16-8", + "chnm": "Procymidone", + "dtxsid": "DTXSID9033923", + "bmad": 3.7634679299683276, + "respMax": 3.8699568062787453, + "respMin": -24.489107339892946, + "maxMean": 3.8699568062787453, + "maxMeanConc": -1.6989700043360187, + "maxMed": 3.8699568062787453, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 34, + "m5id": 5037081, + "modl": "poly1", + "hitc": 2.0097205336309178E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436 + ], + "resp": [ + -16.749193727335452, + -3.8699568062787457, + -24.489107339892946, + -2.381126076423389, + -0.43391299854400067, + -11.816416045813897, + 3.8699568062787453, + -18.88319457236392 + ] + }, + "mc4Param": { + "pow_a": 1.952362597456107E-7, + "pow_p": 0.39552329951433673, + "exp2_a": 0.0000013815285997456324, + "exp2_b": 57.36258080607493, + "exp3_a": 0.0001480645519160266, + "exp3_b": 58.52389350028799, + "exp3_p": 3.781832639454812, + "exp5_p": 2.151688320633654, + "gnls_p": 4.527989650709323, + "gnls_q": 5.108399001356277, + "hill_p": 1.303035732677177, + "pow_er": 2.418785008334611, + "cnst_er": 2.4188909137985077, + "exp2_er": 2.4174176897085324, + "exp3_er": 2.419726742963499, + "exp4_er": 2.4189096181956495, + "exp4_ga": 12.65722171867288, + "exp4_tp": 1.0355875462847547E-9, + "exp5_er": 2.4189155605747237, + "exp5_ga": 2.333940770138562, + "exp5_tp": 7.523689804982252E-10, + "gnls_er": 2.418842358875211, + "gnls_ga": 0.006221346383250256, + "gnls_la": 0.1981088801387234, + "gnls_tp": 1.090792464590304E-7, + "hill_er": 2.4188877929803674, + "hill_ga": 11.485567544481444, + "hill_tp": 2.7451333346567636E-9, + "poly1_a": 2.0842008078263976E-11, + "poly2_a": 0.000005049104462465559, + "poly2_b": 54.21786559908971, + "pow_aic": 70.76387560116336, + "pow_cov": 1, + "pow_rme": 13.286580877800748, + "pow_top": 9.173661286959486E-7, + "all_bmed": 0, + "cnst_aic": 66.76387501055429, + "cnst_rme": 13.28658048320367, + "exp2_aic": 70.7638964289917, + "exp2_cov": 1, + "exp2_rme": 13.28658095149074, + "exp2_top": 0.0000019214971296937626, + "exp3_aic": 72.76390545298773, + "exp3_cov": 1, + "exp3_rme": 13.28659824551256, + "exp3_top": 0.00010892669639514888, + "exp4_aic": 70.7638750136908, + "exp4_cov": 1, + "exp4_rme": 13.286580483579051, + "exp4_top": 1.0355875462847547E-9, + "exp5_aic": 72.76387501605065, + "exp5_cov": 1, + "exp5_rme": 13.2865804836615, + "exp5_top": 7.523689804982252E-10, + "gnls_aic": 76.76387503731891, + "gnls_cov": 1, + "gnls_rme": 13.286580484397929, + "gnls_top": 1.090255384568449E-7, + "hill_aic": 72.76387501190618, + "hill_cov": 1, + "hill_rme": 13.286580484182, + "hill_top": 2.7451333346567636E-9, + "poly1_er": 2.4189004532043645, + "poly2_er": 2.418496776366225, + "pow_a_sd": null, + "pow_ac50": 8.667164755308963, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.28360145565822, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 43.05544733482424, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 12.65722171867288, + "exp5_ac50": 2.333940770138562, + "exp5_p_sd": null, + "gnls_ac50": 0.006219991242649403, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 11.485567544481444, + "hill_p_sd": 182115.5261684, + "poly1_aic": 68.7638750114407, + "poly1_cov": 1, + "poly1_rme": 13.286580483490953, + "poly1_top": 1.0421004039131984E-9, + "poly2_aic": 70.76387916054314, + "poly2_cov": 1, + "poly2_rme": 13.286582613515252, + "poly2_top": 0.00000895038468449257, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.32318093486450644, + "hill_ga_sd": 39787.827708636134, + "hill_tp_sd": 0.00014220966225169602, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.68674937055745, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.19814706168674365 + }, + "mc5Param": { + "a": 2.0842008078263976E-11, + "er": 2.4189004532043645, + "ac5": 2.4999999999999996, + "bmd": 445693219626.4291, + "bmr": 9.289141683881516, + "mll": -32.38193750572035, + "top": 1.0421004039131984E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 58.80191266271995, + "rmse": 13.286580483490953, + "ac1sd": 330387857395.42554, + "caikwt": 0.731058578717145, + "hitcall": 0.00020097205336309175, + "top_over_cutoff": 4.614982879730862E-11 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842436, + "spid": "TP0000881A11", + "chid": 48175, + "casn": "151506-44-4", + "chnm": "Difpas-pyrazole", + "dtxsid": "DTXSID6048175", + "bmad": 3.7634679299683276, + "respMax": 9.134362565846857, + "respMin": -9.785612022505717, + "maxMean": 9.134362565846857, + "maxMeanConc": 0.3010299956639812, + "maxMed": 9.134362565846857, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 35, + "m5id": 5037082, + "modl": "poly1", + "hitc": 1.1947725092996029E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187 + ], + "resp": [ + 9.134362565846857, + -9.785612022505717, + 3.535593024563581, + 6.742445658286296, + -0.3105023663836639, + 5.823097242106741, + -4.029995470890604, + -3.535593024563581 + ] + }, + "mc4Param": { + "pow_a": 0.5017775225188548, + "pow_p": 0.6591192202685694, + "exp2_a": 453.975198070989, + "exp2_b": 3365.723487674608, + "exp3_a": 47.11060086418455, + "exp3_b": 932.6075153090944, + "exp3_p": 0.6902242901855664, + "exp5_p": 7.999996307955874, + "gnls_p": 7.999999981968314, + "gnls_q": 3.2727881400777346, + "hill_p": 7.999999785978309, + "pow_er": 1.531638797544549, + "cnst_er": 1.7262662747276574, + "exp2_er": 1.5506701363683515, + "exp3_er": 1.536100270032405, + "exp4_er": 1.5089274250976916, + "exp4_ga": 13.628170726573147, + "exp4_tp": 6.977505107544097, + "exp5_er": 1.289488315288251, + "exp5_ga": 1.4438188583318046, + "exp5_tp": 6.178082350961625, + "gnls_er": 1.2953710144587984, + "gnls_ga": 1.10862617843866, + "gnls_la": 4151.891415636962, + "gnls_tp": 6.166337115180187, + "hill_er": 1.4438381777640448, + "hill_ga": 12.482180184563882, + "hill_tp": 6.342080307914102, + "poly1_a": 0.13564844128161777, + "poly2_a": 383.3454143719398, + "poly2_b": 2877.2229593527345, + "pow_aic": 56.75504382566062, + "pow_cov": 1, + "pow_rme": 5.641059195157223, + "pow_top": 6.612032619018348, + "all_bmed": 0, + "cnst_aic": 54.94826792526694, + "cnst_rme": 6.12272333576879, + "exp2_aic": 56.83709901722125, + "exp2_cov": 1, + "exp2_rme": 5.590761673925524, + "exp2_top": 6.794438217682005, + "exp3_aic": 58.76709884295892, + "exp3_cov": 1, + "exp3_rme": 5.627994848984627, + "exp3_top": 6.686017631086944, + "exp4_aic": 56.60430600619944, + "exp4_cov": 1, + "exp4_rme": 5.64803429898856, + "exp4_top": 6.977505107544097, + "exp5_aic": 57.43232581617384, + "exp5_cov": 1, + "exp5_rme": 6.1785465480449275, + "exp5_top": 6.178082350961625, + "gnls_aic": 61.48247646171176, + "gnls_cov": 1, + "gnls_rme": 6.1821614427506155, + "gnls_top": 6.166337058698889, + "hill_aic": 57.56759946363208, + "hill_cov": 1, + "hill_rme": 5.261298696231139, + "hill_top": 6.342080307914102, + "poly1_er": 1.5502075397868125, + "poly2_er": 1.550523396666215, + "pow_a_sd": 1.8425110941903395, + "pow_ac50": 17.468453440300433, + "pow_p_sd": 0.9672892572791348, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 8922.735205678156, + "exp2_ac50": 25.09284693992692, + "exp2_b_sd": 65504.294285102085, + "exp3_a_sd": 613.2900449736795, + "exp3_ac50": 19.20254148908469, + "exp3_b_sd": 11915.632924850908, + "exp3_p_sd": 1.5295163260514226, + "exp4_ac50": 13.628170726573147, + "exp5_ac50": 1.4438188583318046, + "exp5_p_sd": 26.276043660735045, + "gnls_ac50": 1.1086261757300446, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 12.482180184563882, + "hill_p_sd": 15.808942438750206, + "poly1_aic": 54.834448290805426, + "poly1_cov": 1, + "poly1_rme": 5.59051462132586, + "poly1_top": 6.782422064080888, + "poly2_aic": 56.84053243854048, + "poly2_cov": 1, + "poly2_rme": 5.5908588367326715, + "poly2_top": 6.777492495111021, + "pow_er_sd": 0.32653699413281, + "exp2_er_sd": 0.31815485619140227, + "exp3_er_sd": 0.32790889345958, + "exp4_er_sd": 0.33416716724015716, + "exp4_ga_sd": 31.79171894098858, + "exp4_tp_sd": 6.352844098132389, + "exp5_er_sd": 0.3758220092286442, + "exp5_ga_sd": 1.9804842288363265, + "exp5_tp_sd": 2.143982334536147, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.332730110230082, + "hill_ga_sd": 15.134790376842096, + "hill_tp_sd": 2.8528600881389283, + "poly1_a_sd": 0.08178965120744121, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 5071.424671946927, + "poly2_ac50": 25.213497375344687, + "poly2_b_sd": 37395.91769567147, + "poly1_er_sd": 0.31814280871376166, + "poly2_er_sd": 0.3181039857589696, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4151.891438876929 + }, + "mc5Param": { + "a": 0.13564844128161777, + "er": 1.5502075397868125, + "ac5": 2.5, + "bmd": 68.47953132462807, + "bmr": 9.289141683881516, + "mll": -25.417224145402713, + "top": 6.782422064080888, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 31.540364959678023, + "rmse": 5.59051462132586, + "ac1sd": 50.763181115365505, + "caikwt": 0.48577638435279785, + "hitcall": 0.00011947725092996028, + "top_over_cutoff": 0.3003622452433992 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842437, + "spid": "TP0000900G07", + "chid": 20337, + "casn": "50-41-9", + "chnm": "Clomiphene citrate (1:1)", + "dtxsid": "DTXSID8020337", + "bmad": 3.7634679299683276, + "respMax": 10.898789471139123, + "respMin": -5.515280710520811, + "maxMean": 10.898789471139123, + "maxMeanConc": -0.6989700043360187, + "maxMed": 10.898789471139123, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6020599913279625, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 36, + "m5id": 5037083, + "modl": "exp5", + "hitc": 9.661810864110531E-17, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 16.799999237060547, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 1.6020599913279625, + 0.6989700043360189, + -1.2218487496163564, + 1, + -0.6989700043360187, + -0.3010299956639812, + -1.6989700043360187 + ], + "resp": [ + 9.542989087509472, + 7.659697931946032, + 2.722279533841609, + 8.963514885797641, + 3.4847031705862404, + 10.898789471139123, + 4.5850191008881405, + -5.515280710520811 + ] + }, + "mc4Param": { + "pow_a": 2.894877828291989, + "pow_p": 0.30000009184154497, + "exp2_a": 507.19665769285456, + "exp2_b": 2390.670092115083, + "exp3_a": 6.049534282925707, + "exp3_b": 57.69378050863092, + "exp3_p": 0.3000001376282075, + "exp5_p": 7.99999942640795, + "gnls_p": 7.999793902840986, + "gnls_q": 0.3000000006452066, + "hill_p": 7.999999962514539, + "pow_er": 1.5751148789361489, + "cnst_er": 1.9204039795995531, + "exp2_er": 1.7462217494828138, + "exp3_er": 1.60658050250781, + "exp4_er": 1.3106985883527575, + "exp4_ga": 0.027758750868336332, + "exp4_tp": 6.630252961291825, + "exp5_er": 1.1618953320857577, + "exp5_ga": 0.04402078526015048, + "exp5_tp": 6.928768027059429, + "gnls_er": 1.078426077644248, + "gnls_ga": 0.044919076585011514, + "gnls_la": 2.255723019139164, + "gnls_tp": 13.078546805362636, + "hill_er": 1.1679042852770425, + "hill_ga": 0.03577555974551571, + "hill_tp": 6.9330269168075835, + "poly1_a": 0.21403725104232135, + "poly2_a": 618.1481332192153, + "poly2_b": 2934.2080821756736, + "pow_aic": 56.78989112699861, + "pow_cov": 1, + "pow_rme": 5.417311928123108, + "pow_top": 8.75484344876054, + "all_bmed": 0, + "cnst_aic": 57.84110962062907, + "cnst_rme": 7.244502292220726, + "exp2_aic": 59.61899839531536, + "exp2_cov": 1, + "exp2_rme": 6.4909481098367, + "exp2_top": 8.557660172303574, + "exp3_aic": 59.43480588967103, + "exp3_cov": 1, + "exp3_rme": 5.672416841872105, + "exp3_top": 8.769641636805533, + "exp4_aic": 52.464863303353795, + "exp4_cov": 1, + "exp4_rme": 4.153583197446473, + "exp4_top": 6.630252961291825, + "exp5_aic": 51.72994045013513, + "exp5_cov": 1, + "exp5_rme": 3.4066258677428043, + "exp5_top": 6.928768027059429, + "gnls_aic": 54.51261883419981, + "gnls_cov": 1, + "gnls_rme": 3.182126811772757, + "gnls_top": 9.472157188065228, + "hill_aic": 51.823001877133166, + "hill_cov": 1, + "hill_rme": 3.426451464532569, + "hill_top": 6.9330269168075835, + "poly1_er": 1.7457558826110058, + "poly2_er": 1.7452968782570826, + "pow_a_sd": null, + "pow_ac50": 3.968505436961949, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 7886.209158743144, + "exp2_ac50": 20.0836575769218, + "exp2_b_sd": 36834.91963316086, + "exp3_a_sd": null, + "exp3_ac50": 7.634424142811094, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.027758750868336332, + "exp5_ac50": 0.04402078526015048, + "exp5_p_sd": 16.740985051144577, + "gnls_ac50": 0.04432778118356064, + "gnls_p_sd": 12.005109141069354, + "gnls_q_sd": 0.4874284554370162, + "hill_ac50": 0.03577555974551571, + "hill_p_sd": 8.198400789158134, + "poly1_aic": 57.614782432250024, + "poly1_cov": 1, + "poly1_rme": 6.489573055026577, + "poly1_top": 8.561490041692856, + "poly2_aic": 59.62160290345598, + "poly2_cov": 1, + "poly2_rme": 6.491849855433758, + "poly2_top": 8.541656153189367, + "pow_er_sd": null, + "exp2_er_sd": 0.31177602076055916, + "exp3_er_sd": null, + "exp4_er_sd": 0.30388057834208093, + "exp4_ga_sd": 0.02693013869703401, + "exp4_tp_sd": 1.661867218808188, + "exp5_er_sd": 0.29468062372775733, + "exp5_ga_sd": 0.03680809630884936, + "exp5_tp_sd": 1.4295227932907637, + "gnls_er_sd": 0.3065288310832348, + "gnls_ga_sd": 0.031029309418172207, + "gnls_la_sd": 24.854379539431022, + "gnls_tp_sd": 20.121310783219784, + "hill_er_sd": 0.2958893567650495, + "hill_ga_sd": 0.020109201282715105, + "hill_tp_sd": 1.444345524585305, + "poly1_a_sd": 0.1246611948311575, + "poly1_ac50": 20.000000000000004, + "poly2_a_sd": 7675.09337419141, + "poly2_ac50": 20.1344835005275, + "poly2_b_sd": 35962.194179144324, + "poly1_er_sd": 0.3117610061713438, + "poly2_er_sd": 0.3116647419349434, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 14.889197885456817 + }, + "mc5Param": { + "p": 7.99999942640795, + "er": 1.1618953320857577, + "ga": 0.04402078526015048, + "tp": 6.928768027059429, + "ac5": 0.031791583986919426, + "bmr": 9.289141683881516, + "mll": -21.86497022506757, + "top": 6.928768027059429, + "ac10": 0.03478478563989077, + "ac20": 0.03820565423269564, + "ac50": 0.04402078526015048, + "rmse": 3.4066258677428043, + "ac1sd": 0.056474950476798486, + "caikwt": 0.04497698241958925, + "hitcall": 9.661810864110532E-17, + "top_over_cutoff": 0.30684323413014714 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842438, + "spid": "TP0000901C02", + "chid": 44742, + "casn": "929-59-9", + "chnm": "2,2'-[Ethane-1,2-diylbis(oxy)]diethanamine", + "dtxsid": "DTXSID9044742", + "bmad": 3.7634679299683276, + "respMax": 2.102135732023357, + "respMin": -13.866850456669049, + "maxMean": 2.102135732023357, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.102135732023357, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 37, + "m5id": 5037084, + "modl": "poly1", + "hitc": 1.6909241923219796E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + 2.102135732023357, + -9.412448215112468, + -13.866850456669049, + -2.1021357320233576, + -12.917586117741852, + -10.97561525557232, + -6.22147697413914, + -2.080189161400509 + ] + }, + "mc4Param": { + "pow_a": 3.4446382511039494E-8, + "pow_p": 0.405668436564102, + "exp2_a": 0.0000035767163069793493, + "exp2_b": 54.19534891303776, + "exp3_a": 0.00010379978775640668, + "exp3_b": 59.37620949215037, + "exp3_p": 5.888770426636071, + "exp5_p": 1.9821606540096437, + "gnls_p": 0.30001012009352335, + "gnls_q": 7.999995713520498, + "hill_p": 1.7490788379969926, + "pow_er": 2.071207160271089, + "cnst_er": 2.071211568093979, + "exp2_er": 2.087900394504249, + "exp3_er": 2.0726661672288493, + "exp4_er": 2.071198368794665, + "exp4_ga": 1.5550293796779942, + "exp4_tp": 6.854934679554375E-10, + "exp5_er": 2.071188089956425, + "exp5_ga": 1.075853940567168, + "exp5_tp": 7.285098719222379E-11, + "gnls_er": 2.0848424617077885, + "gnls_ga": 0.0036576464311942544, + "gnls_la": 0.11566493705462633, + "gnls_tp": 2.508032612116657, + "hill_er": 2.0712056577390427, + "hill_ga": 0.0943243612038477, + "hill_tp": 1.0236527737537164E-10, + "poly1_a": 2.7800312881203852E-11, + "poly2_a": 0.00000627535807537266, + "poly2_b": 60.95260835116624, + "pow_aic": 64.64743364497741, + "pow_cov": 1, + "pow_rme": 8.804003396114856, + "pow_top": 1.6840777009062426E-7, + "all_bmed": 0, + "cnst_aic": 60.647433518627345, + "cnst_rme": 8.804003324454703, + "exp2_aic": 64.65038867128672, + "exp2_cov": 1, + "exp2_rme": 8.804004670425206, + "exp2_top": 0.0000054215645424565595, + "exp3_aic": 66.64747052230402, + "exp3_cov": 1, + "exp3_rme": 8.804011695015834, + "exp3_top": 0.00004549404939612168, + "exp4_aic": 64.64743351699708, + "exp4_cov": 1, + "exp4_rme": 8.804003324877298, + "exp4_top": 6.854934679554375E-10, + "exp5_aic": 66.6474335170417, + "exp5_cov": 1, + "exp5_rme": 8.804003324503169, + "exp5_top": 7.285098719222379E-11, + "gnls_aic": 70.7685853545882, + "gnls_cov": 1, + "gnls_rme": 8.85030950797314, + "gnls_top": 1.7467856376852715, + "hill_aic": 66.64743351725284, + "hill_cov": 1, + "hill_rme": 8.804003324534168, + "hill_top": 1.0236527737537164E-10, + "poly1_er": 2.071181356064919, + "poly2_er": 2.0591467602950058, + "pow_a_sd": null, + "pow_ac50": 9.055465992561412, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.57258064410303, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.10566579953819, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.5550293796779942, + "exp5_ac50": 1.075853940567168, + "exp5_p_sd": null, + "gnls_ac50": 0.00045274899531010966, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.0943243612038477, + "hill_p_sd": null, + "poly1_aic": 62.647433519300336, + "poly1_cov": 1, + "poly1_rme": 8.804003324837579, + "poly1_top": 1.3900156440601922E-9, + "poly2_aic": 64.648984881928, + "poly2_cov": 1, + "poly2_rme": 8.80400563504064, + "poly2_top": 0.000009370471461854893, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.372856253972696, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.11734082051568114 + }, + "mc5Param": { + "a": 2.7800312881203852E-11, + "er": 2.071181356064919, + "ac5": 2.4999999999999996, + "bmd": 334138026560.1983, + "bmr": 9.289141683881516, + "mll": -29.323716759650168, + "top": 1.3900156440601922E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 83.31772378411256, + "rmse": 8.804003324837579, + "ac1sd": 247693125693.253, + "caikwt": 0.7310585786961639, + "hitcall": 0.000016909241923219796, + "top_over_cutoff": 6.155739289426647E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842439, + "spid": "TP0000901G06", + "chid": 37717, + "casn": "1478-61-1", + "chnm": "Bisphenol AF", + "dtxsid": "DTXSID7037717", + "bmad": 3.7634679299683276, + "respMax": 25.02709988877963, + "respMin": -5.116640339141512, + "maxMean": 25.02709988877963, + "maxMeanConc": 1.6989700043360187, + "maxMed": 25.02709988877963, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 38, + "m5id": 5037085, + "modl": "poly1", + "hitc": 0.4839809180427277, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + 5.116640339141512, + 25.02709988877963, + -1.5045979142152461, + 18.349042537758507, + -5.116640339141512, + 5.529082512613025, + 0.5975072132046018, + -1.187660181498737 + ] + }, + "mc4Param": { + "pow_a": 0.07159436973182562, + "pow_p": 1.4960735696348564, + "exp2_a": 8.456409712931872, + "exp2_b": 36.37151003282228, + "exp3_a": 4.7469347723334465, + "exp3_b": 24.593641736552343, + "exp3_p": 0.854675613605653, + "exp5_p": 2.264198460682199, + "gnls_p": 3.318653605103369, + "gnls_q": 5.8042879403945875, + "hill_p": 3.319207509571538, + "pow_er": 1.298769240423112, + "cnst_er": 2.069727518985843, + "exp2_er": 1.3076817798550966, + "exp3_er": 1.3140568468982357, + "exp4_er": 1.6046703279553285, + "exp4_ga": 26.25609903911517, + "exp4_tp": 30.03251983398266, + "exp5_er": 1.2910910235308246, + "exp5_ga": 33.09797478746359, + "exp5_tp": 30.032519004305016, + "gnls_er": 1.2904522494318973, + "gnls_ga": 30.9993505952315, + "gnls_la": 1379.821215621746, + "gnls_tp": 30.032519583217184, + "hill_er": 1.2906396868889318, + "hill_ga": 31.00480635661345, + "hill_tp": 30.032519453725904, + "poly1_a": 0.4801784188472726, + "poly2_a": 7.581640517436643, + "poly2_b": 36.27786078315009, + "pow_aic": 56.35279588835657, + "pow_cov": 1, + "pow_rme": 6.682149859256472, + "pow_top": 24.92659682737705, + "all_bmed": 0, + "cnst_aic": 62.96436169588917, + "cnst_rme": 11.456467755742704, + "exp2_aic": 56.21699568284793, + "exp2_cov": 1, + "exp2_rme": 6.540814233283506, + "exp2_top": 24.979385566604833, + "exp3_aic": 58.20667037507905, + "exp3_cov": 1, + "exp3_rme": 6.502564689513747, + "exp3_top": 24.95932460632071, + "exp4_aic": 58.1094254225183, + "exp4_cov": 1, + "exp4_rme": 6.2731787855341095, + "exp4_top": 30.03251983398266, + "exp5_aic": 58.55393829008341, + "exp5_cov": 1, + "exp5_rme": 6.871326153335053, + "exp5_top": 30.032519004305016, + "gnls_aic": 62.67232565633159, + "gnls_cov": 1, + "gnls_rme": 6.968000583173041, + "gnls_top": 30.013400810194607, + "hill_aic": 58.67232739427216, + "hill_cov": 1, + "hill_rme": 6.968054555449975, + "hill_top": 30.032519453725904, + "poly1_er": 1.4547327831413472, + "poly2_er": 1.3132567568023277, + "pow_a_sd": 0.08813493434702901, + "pow_ac50": 31.459849478540292, + "pow_p_sd": 0.3186339393901382, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 16.387643242603666, + "exp2_ac50": 32.98997403636759, + "exp2_b_sd": 38.85953499547879, + "exp3_a_sd": 22.27340883508407, + "exp3_ac50": 33.09824724111999, + "exp3_b_sd": 83.07150496858122, + "exp3_p_sd": 1.0925857934998315, + "exp4_ac50": 26.25609903911517, + "exp5_ac50": 33.09797478746359, + "exp5_p_sd": 2.3249446576593304, + "gnls_ac50": 30.98745994826971, + "gnls_p_sd": 11.859185725142751, + "gnls_q_sd": 30210.660566019513, + "hill_ac50": 31.00480635661345, + "hill_p_sd": 11.897866553982782, + "poly1_aic": 54.92956695032407, + "poly1_cov": 1, + "poly1_rme": 6.304845114135714, + "poly1_top": 24.008920942363627, + "poly2_aic": 56.27311149656675, + "poly2_cov": 1, + "poly2_rme": 6.561527988769902, + "poly2_top": 24.851306266956673, + "pow_er_sd": 0.38981300436821936, + "exp2_er_sd": 0.3898189614605816, + "exp3_er_sd": 0.39290796815857126, + "exp4_er_sd": 0.34668313066113043, + "exp4_ga_sd": 26.90625013028702, + "exp4_tp_sd": 17.283997953709413, + "exp5_er_sd": 0.39740593076852454, + "exp5_ga_sd": 32.129634015331355, + "exp5_tp_sd": 33.76175010764305, + "gnls_er_sd": 0.39760125645615085, + "gnls_ga_sd": 69.85697532885499, + "gnls_la_sd": 23813357.443562742, + "gnls_tp_sd": 66.51521302449146, + "hill_er_sd": 0.3976143434895321, + "hill_ga_sd": 70.09052961350474, + "hill_tp_sd": 66.73515623997775, + "poly1_a_sd": 0.07512526413723014, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 25.10493170570885, + "poly2_ac50": 31.720545290878295, + "poly2_b_sd": 76.80867364470046, + "poly1_er_sd": 0.3462602829941217, + "poly2_er_sd": 0.39170875683118345, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1380.1223141739165 + }, + "mc5Param": { + "a": 0.4801784188472726, + "er": 1.4547327831413472, + "ac5": 2.5, + "acc": 47.02586933002523, + "bmd": 19.34518778703392, + "bmr": 9.289141683881516, + "mll": -25.464783475162037, + "top": 24.008920942363627, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 15.225799349328566, + "bmdu": 27.980142000769774, + "rmse": 6.304845114135714, + "ac1sd": 14.340391243168211, + "caikwt": 0.017681488290464575, + "hitcall": 0.4839809180427277, + "top_over_cutoff": 1.0632445654348772 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842440, + "spid": "TP0000901G12", + "chid": 48511, + "casn": "1062243-51-9", + "chnm": "Ro 3280", + "dtxsid": "DTXSID4048511", + "bmad": 3.7634679299683276, + "respMax": 10.325057625042314, + "respMin": -8.983764245071658, + "maxMean": 10.325057625042314, + "maxMeanConc": -0.22184874961635637, + "maxMed": 10.325057625042314, + "maxMedConc": -0.22184874961635637, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 39, + "m5id": 5037086, + "modl": "poly1", + "hitc": 7.3098271082847474E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 18.600000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 0.6989700043360189, + -1.2218487496163564, + 1.6989700043360187, + 1.3010299956639813 + ], + "resp": [ + 6.480097196924522, + -0.2515554731701046, + 10.325057625042314, + 1.142930253550185, + -7.730923290188433, + 0.2515554731701055, + 3.1098381663147343, + -8.983764245071658 + ] + }, + "mc4Param": { + "pow_a": 9.6342481700584E-7, + "pow_p": 0.4432645042337321, + "exp2_a": 0.000007399967893446319, + "exp2_b": 3.861528561537906, + "exp3_a": 6.923699292827273, + "exp3_b": 56.58306462368016, + "exp3_p": 7.999746381582563, + "exp5_p": 7.998319899204924, + "gnls_p": 7.999999733938488, + "gnls_q": 7.999994914873606, + "hill_p": 7.999985522691064, + "pow_er": 1.6764333208273414, + "cnst_er": 1.6757159315047794, + "exp2_er": 1.6351776912730394, + "exp3_er": 1.6339748313050555, + "exp4_er": 1.6757250594077964, + "exp4_ga": 6.289265154206966, + "exp4_tp": 1.6850922680145134E-10, + "exp5_er": 1.634304344180973, + "exp5_ga": 0.07106828066816326, + "exp5_tp": 1.535161759146987, + "gnls_er": 1.3295228996669055, + "gnls_ga": 0.063224292527447, + "gnls_la": 1.999327678425197, + "gnls_tp": 7.298128558374947, + "hill_er": 1.6340694275967216, + "hill_ga": 57.330818894657035, + "hill_tp": 12.377335603468827, + "poly1_a": 0.009461767869048447, + "poly2_a": 0.000028686825557986437, + "poly2_b": 0.1807498952770959, + "pow_aic": 58.61519395624266, + "pow_cov": 1, + "pow_rme": 6.125537217447439, + "pow_top": 0.000005456459372025317, + "all_bmed": 0, + "cnst_aic": 54.6151883619927, + "cnst_rme": 6.125536842485228, + "exp2_aic": 58.19296056082926, + "exp2_cov": 1, + "exp2_rme": 6.026299220676452, + "exp2_top": 3.1086952065074684, + "exp3_aic": 60.19312750281706, + "exp3_cov": 1, + "exp3_rme": 6.026368174940302, + "exp3_top": 3.1178027036730622, + "exp4_aic": 58.61518836239423, + "exp4_cov": 1, + "exp4_rme": 6.125536842509785, + "exp4_top": 1.6850922680145134E-10, + "exp5_aic": 60.35216613544548, + "exp5_cov": 1, + "exp5_rme": 6.133102241580869, + "exp5_top": 1.535161759146987, + "gnls_aic": 59.638816472495165, + "gnls_cov": 1, + "gnls_rme": 4.6551870260688855, + "gnls_top": 7.298113962072281, + "hill_aic": 60.193622806346006, + "hill_cov": 1, + "hill_rme": 6.026559284171812, + "hill_top": 12.377335603468827, + "poly1_er": 1.671396299010503, + "poly2_er": 1.647533881452146, + "pow_a_sd": null, + "pow_ac50": 10.467658378845464, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.000019653592135234332, + "exp2_ac50": 47.323401556905104, + "exp2_b_sd": 0.7800950706885615, + "exp3_a_sd": null, + "exp3_ac50": 46.359485549724944, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 6.289265154206966, + "exp5_ac50": 0.07106828066816326, + "exp5_p_sd": 1263.5073660910928, + "gnls_ac50": 0.06322426071869278, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 57.330818894657035, + "hill_p_sd": null, + "poly1_aic": 56.6071465334128, + "poly1_cov": 1, + "poly1_rme": 6.1384421956539885, + "poly1_top": 0.4730883934524223, + "poly2_aic": 58.411074893876496, + "poly2_cov": 1, + "poly2_rme": 6.104875979378861, + "poly2_top": 2.2030965746019064, + "pow_er_sd": null, + "exp2_er_sd": 0.3255205050681696, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.3352032946991091, + "exp5_ga_sd": 1.911154416144701, + "exp5_tp_sd": 2.910113134475448, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.10408741267075336, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.0008879455965969786, + "poly2_ac50": 35.32892649963858, + "poly2_b_sd": 2.826738198600287, + "poly1_er_sd": 0.32131033280129584, + "poly2_er_sd": 0.3251646386415122, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.9993286780943216 + }, + "mc5Param": { + "a": 0.009461767869048447, + "er": 1.671396299010503, + "ac5": 2.5, + "bmd": 981.755398403756, + "bmr": 9.289141683881516, + "mll": -26.3035732667064, + "top": 0.4730883934524223, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 53.80832634227983, + "rmse": 6.1384421956539885, + "ac1sd": 727.7653064520059, + "caikwt": 0.7302672847993994, + "hitcall": 0.0000073098271082847474, + "top_over_cutoff": 0.020950906728217367 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842441, + "spid": "TP0000902A09", + "chid": 48167, + "casn": "138472-01-2", + "chnm": "FR 409", + "dtxsid": "DTXSID2048167", + "bmad": 3.7634679299683276, + "respMax": 8.45824139096988, + "respMin": -4.715592708196917, + "maxMean": 8.45824139096988, + "maxMeanConc": 0.7781512503836436, + "maxMed": 8.45824139096988, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 40, + "m5id": 5037087, + "modl": "poly1", + "hitc": 4.349091266397037E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + -1.2342590439036523, + 5.370932466583148, + 0.8322209040287843, + 5.089877121352194, + -4.715592708196917, + 8.45824139096988, + -0.8322209040287843, + 1.8604769341122718 + ] + }, + "mc4Param": { + "pow_a": 1.0221806706745422, + "pow_p": 0.39639742374359954, + "exp2_a": 281.84163059484536, + "exp2_b": 2710.1819410276626, + "exp3_a": 3.070336657854594, + "exp3_b": 58.38202827572274, + "exp3_p": 0.3178065838682131, + "exp5_p": 7.999999556088412, + "gnls_p": 7.997950401679715, + "gnls_q": 0.5167742299566985, + "hill_p": 7.999999636255, + "pow_er": 1.0920563687798213, + "cnst_er": 1.3248432907908116, + "exp2_er": 1.070134684601057, + "exp3_er": 1.0900745687259326, + "exp4_er": 1.0812481377946803, + "exp4_ga": 1.7811347250586496, + "exp4_tp": 4.400696875885273, + "exp5_er": 0.9781436965607416, + "exp5_ga": 4.374536235061529, + "exp5_tp": 5.114592012835368, + "gnls_er": 0.9363241065953332, + "gnls_ga": 3.483652859252365, + "gnls_la": 110.16277693301092, + "gnls_tp": 7.783031273259884, + "hill_er": 0.8800553465055232, + "hill_ga": 0.3510818534236002, + "hill_tp": 4.414701379307003, + "poly1_a": 0.10489123022206318, + "poly2_a": 173.98996532557754, + "poly2_b": 1734.46106467781, + "pow_aic": 49.80239750036858, + "pow_cov": 1, + "pow_rme": 3.6268956792336415, + "pow_top": 4.819422456676002, + "all_bmed": 0, + "cnst_aic": 49.12848756125315, + "cnst_rme": 4.40031788290068, + "exp2_aic": 50.12082719543147, + "exp2_cov": 1, + "exp2_rme": 3.8215443365906254, + "exp2_top": 5.247941640101082, + "exp3_aic": 51.822662540403314, + "exp3_cov": 1, + "exp3_rme": 3.640408829394019, + "exp3_top": 4.884063849755363, + "exp4_aic": 49.4849553439781, + "exp4_cov": 1, + "exp4_rme": 3.556633163595015, + "exp4_top": 4.400696875885273, + "exp5_aic": 49.523866255353845, + "exp5_cov": 1, + "exp5_rme": 3.0787945193813617, + "exp5_top": 5.114592012835368, + "gnls_aic": 53.04563717615321, + "gnls_cov": 1, + "gnls_rme": 3.0191908372849388, + "gnls_top": 6.2867229683220325, + "hill_aic": 50.23685799735487, + "hill_cov": 1, + "hill_rme": 3.720806929349788, + "hill_top": 4.414701379307003, + "poly1_er": 1.0697380575582094, + "poly2_er": 1.068876338903681, + "pow_a_sd": 1.94288100342848, + "pow_ac50": 8.700724003011597, + "pow_p_sd": 0.5142804521178921, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 5978.121364138775, + "exp2_ac50": 25.115304276643503, + "exp2_b_sd": 56967.1422829092, + "exp3_a_sd": 34.884204794475934, + "exp3_ac50": 10.816909274054677, + "exp3_b_sd": 1339.2381888478171, + "exp3_p_sd": 0.7494980203805416, + "exp4_ac50": 1.7811347250586496, + "exp5_ac50": 4.374536235061529, + "exp5_p_sd": 17.23262161929217, + "gnls_ac50": 3.4336886835483624, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.3510818534236002, + "hill_p_sd": 11.55230396465234, + "poly1_aic": 48.11858673318644, + "poly1_cov": 1, + "poly1_rme": 3.820595413798474, + "poly1_top": 5.244561511103158, + "poly2_aic": 50.12696585786312, + "poly2_cov": 1, + "poly2_rme": 3.825332733168213, + "poly2_top": 5.160266984567867, + "pow_er_sd": 0.3358088728357998, + "exp2_er_sd": 0.35301842299911645, + "exp3_er_sd": 0.3388919198692416, + "exp4_er_sd": 0.32586774663917945, + "exp4_ga_sd": 2.5289267272649596, + "exp4_tp_sd": 2.0456398887627545, + "exp5_er_sd": 0.3174460886892625, + "exp5_ga_sd": 3.746745018855691, + "exp5_tp_sd": 1.8569699379647628, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3730906919696318, + "hill_ga_sd": 0.2783296229902509, + "hill_tp_sd": 1.4930457823064731, + "poly1_a_sd": 0.04854843979303387, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 2374.099369826869, + "poly2_ac50": 25.35017708616761, + "poly2_b_sd": 23458.53218916691, + "poly1_er_sd": 0.3529581302897474, + "poly2_er_sd": 0.3530822082323522, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 234.01464386723652 + }, + "mc5Param": { + "a": 0.10489123022206318, + "er": 1.0697380575582094, + "ac5": 2.5, + "bmd": 88.55975532192402, + "bmr": 9.289141683881516, + "mll": -22.05929336659322, + "top": 5.244561511103158, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 47.61937513459634, + "bmdu": 515.5480279689932, + "rmse": 3.820595413798474, + "ac1sd": 65.64844723641512, + "caikwt": 0.37637801032969415, + "hitcall": 4.349091266397037E-7, + "top_over_cutoff": 0.23225748204827024 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842442, + "spid": "TP0000904A04", + "chid": 20932, + "casn": "59-67-6", + "chnm": "Nicotinic acid", + "dtxsid": "DTXSID1020932", + "bmad": 3.7634679299683276, + "respMax": 7.808154220734798, + "respMin": -15.587583552949539, + "maxMean": 7.808154220734798, + "maxMeanConc": -0.6989700043360187, + "maxMed": 7.808154220734798, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 41, + "m5id": 5037088, + "modl": "poly1", + "hitc": 1.2842082484215337E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + -1.154901959985743 + ], + "resp": [ + -6.4591483450512746, + 3.0224966031679426, + -15.587583552949539, + 7.808154220734798, + -0.12052294495462057, + -3.3880170099974922, + -12.541681485061535, + -3.0224966031679426 + ] + }, + "mc4Param": { + "pow_a": 5.543622267971873E-7, + "pow_p": 0.364373857362965, + "exp2_a": 5.894362630259528E-7, + "exp2_b": 68.55078029862463, + "exp3_a": 0.0000037615601832033385, + "exp3_b": 69.7561028814606, + "exp3_p": 4.517972377107961, + "exp5_p": 3.4371838689355867, + "gnls_p": 0.30000354623098807, + "gnls_q": 7.948653448964739, + "hill_p": 4.575319604381713, + "pow_er": 1.92339375580289, + "cnst_er": 1.9230667378989736, + "exp2_er": 1.9230442720434788, + "exp3_er": 1.9235351607245372, + "exp4_er": 1.923073891482418, + "exp4_ga": 5.720368939603105, + "exp4_tp": 1.5289441124987554E-10, + "exp5_er": 1.9230858205598875, + "exp5_ga": 3.7080047981398536, + "exp5_tp": 1.358730549491495E-9, + "gnls_er": 1.9069579723705967, + "gnls_ga": 0.03296521485727647, + "gnls_la": 1.0424516568136877, + "gnls_tp": 3.0470136554132834, + "hill_er": 1.923067740437899, + "hill_ga": 144.92218389271736, + "hill_tp": 0.000003918510318302473, + "poly1_a": 2.3821419834720777E-10, + "poly2_a": 0.0000380194771302548, + "poly2_b": 112.44605954378144, + "pow_aic": 62.85990744190046, + "pow_cov": 1, + "pow_rme": 8.160259534186697, + "pow_top": 0.000002305971230116009, + "all_bmed": 0, + "cnst_aic": 58.859904654421854, + "cnst_rme": 8.16025858692367, + "exp2_aic": 62.859904981765446, + "exp2_cov": 1, + "exp2_rme": 8.160258762264611, + "exp2_top": 6.329410925446836E-7, + "exp3_aic": 64.8599070905033, + "exp3_cov": 1, + "exp3_rme": 8.16025876987888, + "exp3_top": 9.357200976922738E-7, + "exp4_aic": 62.85990465443332, + "exp4_cov": 1, + "exp4_rme": 8.160258586995395, + "exp4_top": 1.5289441124987554E-10, + "exp5_aic": 64.85990465768748, + "exp5_cov": 1, + "exp5_rme": 8.160258587645599, + "exp5_top": 1.358730549491495E-9, + "gnls_aic": 68.58354633450392, + "gnls_cov": 1, + "gnls_rme": 8.047045534239281, + "gnls_top": 2.1214791438989553, + "hill_aic": 64.85990466538351, + "hill_cov": 1, + "hill_rme": 8.160258592771067, + "hill_top": 0.000003918510318302473, + "poly1_er": 1.923120606473471, + "poly2_er": 1.923450892386962, + "pow_a_sd": null, + "pow_ac50": 7.461275077538203, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.46105839655378, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 43.40360563362071, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 5.720368939603105, + "exp5_ac50": 3.7080047981398536, + "exp5_p_sd": null, + "gnls_ac50": 0.0040734772355949045, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 144.92218389271736, + "hill_p_sd": null, + "poly1_aic": 60.85990468448603, + "poly1_cov": 1, + "poly1_rme": 8.16025859051074, + "poly1_top": 1.1910709917360389E-8, + "poly2_aic": 62.859918528385, + "poly2_cov": 1, + "poly2_rme": 8.160265420971498, + "poly2_top": 0.00002442287818225344, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 28.760383699947685, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.0577383522061834 + }, + "mc5Param": { + "a": 2.3821419834720777E-10, + "er": 1.923120606473471, + "ac5": 2.5, + "bmd": 38994911925.2001, + "bmr": 9.289141683881516, + "mll": -28.429952342243016, + "top": 1.1910709917360389E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 93.8246790996463, + "rmse": 8.16025859051074, + "ac1sd": 28906532190.659824, + "caikwt": 0.731058581585493, + "hitcall": 0.000012842082484215337, + "top_over_cutoff": 5.27470502339785E-10 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842403, + "spid": "LEGTV001B10", + "chid": 23900, + "casn": "17804-35-2", + "chnm": "Benomyl", + "dtxsid": "DTXSID5023900", + "bmad": 3.7634679299683276, + "respMax": 25.59444974532059, + "respMin": -1.2102612303412605, + "maxMean": 25.59444974532059, + "maxMeanConc": 0.7781512503836436, + "maxMed": 25.59444974532059, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 2, + "m5id": 5037049, + "modl": "exp4", + "hitc": 8.838707536646198E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + 0.3010299956639812, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 2.9023483672510224, + -1.2102612303412605, + 25.59444974532059, + 1.2102612303412605, + 13.08335350830972, + 13.91717341460287, + 3.6279354590637736, + 13.918360177919546 + ] + }, + "mc4Param": { + "pow_a": 5.205810100365427, + "pow_p": 0.300000106525784, + "exp2_a": 2468.049539504221, + "exp2_b": 7225.095324245473, + "exp3_a": 81.926086402836, + "exp3_b": 11971.021959945418, + "exp3_p": 0.30000050892105745, + "exp5_p": 1.932308954909185, + "gnls_p": 2.2122108268358556, + "gnls_q": 0.8596878616497325, + "hill_p": 3.867980719774923, + "pow_er": 1.3575665310341234, + "cnst_er": 2.320091490701855, + "exp2_er": 1.904101077761098, + "exp3_er": 1.5530301363053958, + "exp4_er": 0.829982332161024, + "exp4_ga": 0.7837526624913668, + "exp4_tp": 14.691482524381094, + "exp5_er": 0.6597965319495738, + "exp5_ga": 0.9532308456224, + "exp5_tp": 14.297652679638324, + "gnls_er": 0.7867729444839626, + "gnls_ga": 1.7121229667458349, + "gnls_la": 54.1420821270971, + "gnls_tp": 26.63271573330083, + "hill_er": 0.6818282209423071, + "hill_ga": 0.8455244118283385, + "hill_tp": 14.238251015246254, + "poly1_a": 0.3429912490465289, + "poly2_a": 2011.137320298468, + "poly2_b": 6041.169272414498, + "pow_aic": 56.93013758751977, + "pow_cov": 1, + "pow_rme": 6.662842960817711, + "pow_top": 16.833696930224765, + "all_bmed": 0, + "cnst_aic": 65.41421720746133, + "cnst_rme": 12.44072681214264, + "exp2_aic": 64.45225922740426, + "exp2_cov": 1, + "exp2_rme": 10.010167810133272, + "exp2_top": 17.13893736437594, + "exp3_aic": 59.42851423204404, + "exp3_cov": 1, + "exp3_rme": 6.738763578058861, + "exp3_top": 17.471290115830215, + "exp4_aic": 48.68746759593549, + "exp4_cov": 1, + "exp4_rme": 4.18881846478536, + "exp4_top": 14.691482524381094, + "exp5_aic": 49.657707875948965, + "exp5_cov": 1, + "exp5_rme": 4.220695557928282, + "exp5_top": 14.297652679638324, + "gnls_aic": 51.15685979133812, + "gnls_cov": 1, + "gnls_rme": 2.7507444039260966, + "gnls_top": 21.79102332025044, + "hill_aic": 50.061396997873935, + "hill_cov": 1, + "hill_rme": 4.276429269729576, + "hill_top": 14.238251015246254, + "poly1_er": 1.9034889654893083, + "poly2_er": 1.9018795046605577, + "pow_a_sd": 2.0943271829959196, + "pow_ac50": 4.96063235721311, + "pow_p_sd": 0.11002382159571332, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 29513.6753956216, + "exp2_ac50": 25.04325193819569, + "exp2_b_sd": 86084.5411190017, + "exp3_a_sd": 150.0984224223333, + "exp3_ac50": 5.804399305999619, + "exp3_b_sd": 59137.001224216314, + "exp3_p_sd": 0.14658200866607235, + "exp4_ac50": 0.7837526624913668, + "exp5_ac50": 0.9532308456224, + "exp5_p_sd": 1.0630755148028903, + "gnls_ac50": 1.5013800743653127, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.8455244118283385, + "hill_p_sd": 3.878619687420101, + "poly1_aic": 62.445202743928206, + "poly1_cov": 1, + "poly1_rme": 10.006455332888448, + "poly1_top": 17.149562452326442, + "poly2_aic": 64.4652608512803, + "poly2_cov": 1, + "poly2_rme": 10.02747933976459, + "poly2_top": 16.783030687308678, + "pow_er_sd": 0.4080138155151314, + "exp2_er_sd": 0.3680437573619178, + "exp3_er_sd": 0.4222055989380574, + "exp4_er_sd": 0.39592940969417895, + "exp4_ga_sd": 0.31194015228918653, + "exp4_tp_sd": 1.6633876035629098, + "exp5_er_sd": 0.44034681277537735, + "exp5_ga_sd": 0.24033727643017272, + "exp5_tp_sd": 1.384891857432722, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.4472823050404181, + "hill_ga_sd": 0.2970999212415293, + "hill_tp_sd": 1.42857712990458, + "poly1_a_sd": 0.12552318478451832, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 17285.66623585318, + "poly2_ac50": 25.102605828879497, + "poly2_b_sd": 52518.880955116154, + "poly1_er_sd": 0.3680092384332859, + "poly2_er_sd": 0.36881665372257216, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 83.00745848531592 + }, + "mc5Param": { + "er": 0.829982332161024, + "ga": 0.7837526624913668, + "tp": 14.691482524381094, + "ac5": 0.057998152732469395, + "bmd": 1.1312085709028028, + "bmr": 9.289141683881516, + "mll": -21.343733797967744, + "top": 14.691482524381094, + "ac10": 0.11913282919448194, + "ac20": 0.25231200149874355, + "ac50": 0.7837526624913668, + "bmdl": 0.5939237424805409, + "bmdu": 2.1007406685525587, + "rmse": 4.18881846478536, + "ac1sd": 0.7151040430592887, + "caikwt": 0.00023320141532168285, + "hitcall": 0.00008838707536646198, + "top_over_cutoff": 0.6506181177291949 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842402, + "spid": "DMSO", + "chid": null, + "casn": null, + "chnm": null, + "dtxsid": null, + "bmad": 3.7634679299683276, + "respMax": 29.154644659004813, + "respMin": -64.01776227967419, + "maxMean": -2.786975848040293, + "maxMeanConc": -2.0, + "maxMed": -1.8549943011561494, + "maxMedConc": -2.0, + "logcMax": -2.0, + "logcMin": -2.0, + "nconc": 1, + "npts": 60, + "nrep": 60.0, + "nmedGtbl": 0, + "tmpi": 1, + "m5id": 5037048, + "modl": "none", + "hitc": 0.0, + "fitc": 2, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": null, + "stkc": null, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2 + ], + "resp": [ + -11.154261912892895, + -0.3085213350118397, + -10.769705425508318, + 4.175375587545503, + -10.98141849274888, + -12.376517295353013, + 0, + -64.01776227967419, + 0, + 0, + 7.302396825405491, + -23.726740442131682, + 20.578950616404875, + -2.1637598929705573, + 8.221941787379146, + -3.3615951256467733, + -13.00838695625285, + 0, + -8.147282382442452, + -16.675358684435366, + -7.366722199083715, + -4.547070003657009, + 6.727984535614843, + -14.413034459122256, + -3.3130697596828527, + -4.033069414485719, + -15.264672272410884, + -11.574027922167316, + -1.8116084217961972, + -2.683274758192687, + 13.045441512530893, + 11.771596698177454, + 1.822950768406886, + -6.366163269382269, + 10.919639964829472, + 7.646339314405353, + -5.425526716521953, + -23.59240555574474, + 29.154644659004813, + -1.8983801805161016, + 0, + -13.802724260910109, + 4.979838314070986, + 8.416800860440848, + -0.2717465644121584, + 3.9578867653660548, + -1.1225186138635874, + -21.297944237672343, + 8.682142820122102, + 15.423542211616034, + -8.54044397300711, + 0, + -3.629592160884692, + 5.3958263838470995, + -9.059839600469063, + 17.31012973696578, + -18.631736544948375, + -6.017477029882166, + 9.453622918139667, + -0.8512450188087707 + ] + }, + "mc4Param": { + "pow_a": null, + "pow_p": null, + "exp2_a": null, + "exp2_b": null, + "exp3_a": null, + "exp3_b": null, + "exp3_p": null, + "exp5_p": null, + "gnls_p": null, + "gnls_q": null, + "hill_p": null, + "pow_er": null, + "cnst_er": null, + "exp2_er": null, + "exp3_er": null, + "exp4_er": null, + "exp4_ga": null, + "exp4_tp": null, + "exp5_er": null, + "exp5_ga": null, + "exp5_tp": null, + "gnls_er": null, + "gnls_ga": null, + "gnls_la": null, + "gnls_tp": null, + "hill_er": null, + "hill_ga": null, + "hill_tp": null, + "poly1_a": null, + "poly2_a": null, + "poly2_b": null, + "pow_aic": null, + "pow_cov": null, + "pow_rme": null, + "all_bmed": 0, + "cnst_aic": null, + "cnst_rme": null, + "exp2_aic": null, + "exp2_cov": null, + "exp2_rme": null, + "exp3_aic": null, + "exp3_cov": null, + "exp3_rme": null, + "exp4_aic": null, + "exp4_cov": null, + "exp4_rme": null, + "exp5_aic": null, + "exp5_cov": null, + "exp5_rme": null, + "gnls_aic": null, + "gnls_cov": null, + "gnls_rme": null, + "hill_aic": null, + "hill_cov": null, + "hill_rme": null, + "poly1_er": null, + "poly2_er": null, + "pow_a_sd": null, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp5_p_sd": null, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_p_sd": null, + "poly1_aic": null, + "poly1_cov": null, + "poly1_rme": null, + "poly2_aic": null, + "poly2_cov": null, + "poly2_rme": null, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly2_a_sd": null, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": null, + "cnst_success": null, + "exp2_success": null, + "exp3_success": null, + "exp4_success": null, + "exp5_success": null, + "gnls_success": null, + "hill_success": null, + "poly1_success": null, + "poly2_success": null + }, + "mc5Param": { + "bmr": 9.289141683881516, + "hitcall": 0 + }, + "mc6Param": null + }, + { + "aeid": 704, + "m4id": 1842404, + "spid": "LEGTV001C03", + "chid": 22162, + "casn": "1689-84-5", + "chnm": "Bromoxynil", + "dtxsid": "DTXSID3022162", + "bmad": 3.7634679299683276, + "respMax": 17.24432669518075, + "respMin": -16.748848993380015, + "maxMean": 17.24432669518075, + "maxMeanConc": -0.6989700043360187, + "maxMed": 17.24432669518075, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 3, + "m5id": 5037050, + "modl": "poly1", + "hitc": 0.0029920822873240717, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.22184874961635637, + -0.6989700043360187 + ], + "resp": [ + 8.524600212493528, + 9.072860762252425, + -3.8916282997793408, + -10.455090309750185, + -10.227272727272725, + -16.748848993380015, + -3.3236167488489907, + 17.24432669518075 + ] + }, + "mc4Param": { + "pow_a": 1.725949077512417E-7, + "pow_p": 4.5253782558540285, + "exp2_a": 0.00001640418685242636, + "exp2_b": 3.8001515537909256, + "exp3_a": 12.90516865711751, + "exp3_b": 54.422945490831, + "exp3_p": 7.998344245445021, + "exp5_p": 7.999993694423218, + "gnls_p": 0.4241648347027184, + "gnls_q": 7.9998847670280355, + "hill_p": 7.999087698843317, + "pow_er": 2.2542985187481523, + "cnst_er": 2.323734743510376, + "exp2_er": 2.251755277558436, + "exp3_er": 2.253232239765138, + "exp4_er": 2.323771099104438, + "exp4_ga": 11.86923471702094, + "exp4_tp": 7.755465672199024E-8, + "exp5_er": 2.25311336300597, + "exp5_ga": 51.61988856711754, + "exp5_tp": 20.5725635581771, + "gnls_er": 2.232648918042158, + "gnls_ga": 0.011612337436387274, + "gnls_la": 0.3672143632370176, + "gnls_tp": 12.14436282748164, + "hill_er": 2.2521666902515927, + "hill_ga": 52.29053788518011, + "hill_tp": 20.688317160612986, + "poly1_a": 0.059264731838513336, + "poly2_a": 0.00008746164302267517, + "poly2_b": 0.17995434389891726, + "pow_aic": 67.60619394277374, + "pow_cov": 1, + "pow_rme": 10.63489778795089, + "pow_top": 8.423835804546373, + "all_bmed": 0, + "cnst_aic": 64.42755044014181, + "cnst_rme": 11.028222754070327, + "exp2_aic": 67.57203572586648, + "exp2_cov": 1, + "exp2_rme": 10.609032886271716, + "exp2_top": 8.494289345379501, + "exp3_aic": 69.57232094962438, + "exp3_cov": 1, + "exp3_rme": 10.60924696767611, + "exp3_top": 8.535257141972448, + "exp4_aic": 68.42755045762016, + "exp4_cov": 1, + "exp4_rme": 11.028222760170856, + "exp4_top": 7.755465672199024E-8, + "exp5_aic": 69.57309089671247, + "exp5_cov": 1, + "exp5_rme": 10.609830072861923, + "exp5_top": 20.5725635581771, + "gnls_aic": 73.41799184836066, + "gnls_cov": 1, + "gnls_rme": 10.614494151590849, + "gnls_top": 9.287173487099578, + "hill_aic": 69.57365995839154, + "hill_cov": 1, + "hill_rme": 10.610269740695813, + "hill_top": 20.688317160612986, + "poly1_er": 2.308829204544371, + "poly2_er": 2.2585407128453037, + "pow_a_sd": 0.0000018803876981312193, + "pow_ac50": 42.89924007169241, + "pow_p_sd": 0.2615425978878468, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.00006528915415492634, + "exp2_ac50": 47.36594300362757, + "exp2_b_sd": 1.1482590548973135, + "exp3_a_sd": null, + "exp3_ac50": 46.53251133220428, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 11.86923471702094, + "exp5_ac50": 51.61988856711754, + "exp5_p_sd": null, + "gnls_ac50": 0.003749285947936685, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 52.29053788518011, + "hill_p_sd": 34.94604828343594, + "poly1_aic": 66.3487573617917, + "poly1_cov": 1, + "poly1_rme": 11.07211531968513, + "poly1_top": 2.9632365919256665, + "poly2_aic": 67.91979710905, + "poly2_cov": 1, + "poly2_rme": 10.858529674694983, + "poly2_top": 6.776309423253431, + "pow_er_sd": 0.3074409916401629, + "exp2_er_sd": 0.3064920897367097, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3066098414034118, + "hill_ga_sd": 433.0782348506896, + "hill_tp_sd": 798.217144794448, + "poly1_a_sd": 0.2008290041071431, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.001526277534281327, + "poly2_ac50": 35.32904249953417, + "poly2_b_sd": 1.5875043868026275, + "poly1_er_sd": 0.3041166431752558, + "poly2_er_sd": 0.3058854737291205, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.3727404712005974 + }, + "mc5Param": { + "a": 0.059264731838513336, + "er": 2.308829204544371, + "ac5": 2.4999999999999996, + "bmd": 156.73979103107902, + "bmr": 9.289141683881516, + "mll": -31.17437868089585, + "top": 2.9632365919256665, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 25.23802000566871, + "rmse": 11.07211531968513, + "ac1sd": 116.18961529360936, + "caikwt": 0.7232426117655388, + "hitcall": 0.0029920822873240717, + "top_over_cutoff": 0.13122810517083394 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842405, + "spid": "LEGTV001C05", + "chid": 20440, + "casn": "120-36-5", + "chnm": "Dichlorprop", + "dtxsid": "DTXSID0020440", + "bmad": 3.7634679299683276, + "respMax": 12.401136092711798, + "respMin": -8.612173606576068, + "maxMean": 12.401136092711798, + "maxMeanConc": -0.22184874961635637, + "maxMed": 12.401136092711798, + "maxMedConc": -0.22184874961635637, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 4, + "m5id": 5037051, + "modl": "exp5", + "hitc": 7.715427065113419E-15, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 0.3010299956639812, + 1.3010299956639813 + ], + "resp": [ + 10.364772833286688, + 8.905785158234078, + 12.401136092711798, + -0.6942500855179268, + 10.618476018699921, + 0.6942500855179268, + -8.612173606576068, + 6.03652911237573 + ] + }, + "mc4Param": { + "pow_a": 3.121611710249508, + "pow_p": 0.300000440805151, + "exp2_a": 844.7352530391539, + "exp2_b": 4140.505458874806, + "exp3_a": 6.529613004062455, + "exp3_b": 62.365867529043086, + "exp3_p": 0.30000012065047343, + "exp5_p": 7.384612447046498, + "gnls_p": 7.998079908874962, + "gnls_q": 0.3000000007152951, + "hill_p": 7.999999550286872, + "pow_er": 1.7128917398097694, + "cnst_er": 2.064484274768512, + "exp2_er": 1.854098740521344, + "exp3_er": 1.7364617533808766, + "exp4_er": 1.3051553103733522, + "exp4_ga": 0.09070126641098608, + "exp4_tp": 8.97564962535527, + "exp5_er": 0.9338117444364008, + "exp5_ga": 0.09437221560468234, + "exp5_tp": 9.445184350204824, + "gnls_er": 0.5389629722138889, + "gnls_ga": 0.1650117092406103, + "gnls_la": 59.04702616089972, + "gnls_tp": 14.881363229750573, + "hill_er": 0.9350004825335526, + "hill_ga": 0.09546411869143644, + "hill_tp": 9.449887679873935, + "poly1_a": 0.20536815823136903, + "poly2_a": 687.7206271707939, + "poly2_b": 3402.532885448278, + "pow_aic": 59.62983960478393, + "pow_cov": 1, + "pow_rme": 6.671243317314767, + "pow_top": 10.094170392107534, + "all_bmed": 0, + "cnst_aic": 60.19666751493744, + "cnst_rme": 8.402789111634103, + "exp2_aic": 61.531032617462245, + "exp2_cov": 1, + "exp2_rme": 7.3615053364472125, + "exp2_top": 10.262711761047347, + "exp3_aic": 62.09365177604067, + "exp3_cov": 1, + "exp3_rme": 6.794901875497607, + "exp3_top": 10.116872077829878, + "exp4_aic": 56.12885991920658, + "exp4_cov": 1, + "exp4_rme": 6.681915704324382, + "exp4_top": 8.97564962535527, + "exp5_aic": 55.557492165112755, + "exp5_cov": 1, + "exp5_rme": 6.608895943346805, + "exp5_top": 9.445184350204824, + "gnls_aic": 57.520569181463856, + "gnls_cov": 1, + "gnls_rme": 6.998426262818015, + "gnls_top": 12.249786804248052, + "hill_aic": 55.56652951607745, + "hill_cov": 1, + "hill_rme": 6.610861943383319, + "hill_top": 9.449887679873935, + "poly1_er": 1.853314780351189, + "poly2_er": 1.8543795698394705, + "pow_a_sd": null, + "pow_ac50": 4.960645128343272, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 14008.70342854903, + "exp2_ac50": 25.075473418488187, + "exp2_b_sd": 68253.83508399563, + "exp3_a_sd": null, + "exp3_ac50": 9.780888763356495, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.09070126641098608, + "exp5_ac50": 0.09437221560468234, + "exp5_p_sd": 269.96048261662713, + "gnls_ac50": 0.1635254438108516, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.09546411869143644, + "hill_p_sd": 14.519583400029104, + "poly1_aic": 59.527349525667354, + "poly1_cov": 1, + "poly1_rme": 7.360105587021132, + "poly1_top": 10.26840791156845, + "poly2_aic": 61.53621082274063, + "poly2_cov": 1, + "poly2_rme": 7.363476010280246, + "poly2_top": 10.254517159159812, + "pow_er_sd": null, + "exp2_er_sd": 0.31997257287398145, + "exp3_er_sd": null, + "exp4_er_sd": 0.370650678068716, + "exp4_ga_sd": 0.06239224387281597, + "exp4_tp_sd": 1.9164242059007173, + "exp5_er_sd": 0.431497487479637, + "exp5_ga_sd": 1.032106503926616, + "exp5_tp_sd": 1.3000343253660858, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.43172822082146006, + "hill_ga_sd": 0.05953029354685805, + "hill_tp_sd": 1.3057088570476094, + "poly1_a_sd": 0.10793537826384712, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 7498.910083446686, + "poly2_ac50": 25.181017025347085, + "poly2_b_sd": 36576.65297284068, + "poly1_er_sd": 0.31993419285597785, + "poly2_er_sd": 0.3199628347203704, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 194.37172917375648 + }, + "mc5Param": { + "p": 7.384612447046498, + "er": 0.9338117444364008, + "ga": 0.09437221560468234, + "tp": 9.445184350204824, + "ac5": 0.06633147903190056, + "bmd": 0.12006740302572848, + "bmr": 9.289141683881516, + "mll": -23.778746082556378, + "top": 9.445184350204824, + "ac10": 0.07312288030740835, + "ac20": 0.0809443375202312, + "ac50": 0.09437221560468234, + "bmdl": 0.08803437994217998, + "bmdu": 0.24201185048064888, + "rmse": 6.608895943346805, + "ac1sd": 0.10282304939527366, + "caikwt": 0.08951365853820019, + "hitcall": 7.715427065113419E-15, + "top_over_cutoff": 0.41828372686944937 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842406, + "spid": "LEGTV002C04", + "chid": 20442, + "casn": "94-75-7", + "chnm": "2,4-Dichlorophenoxyacetic acid", + "dtxsid": "DTXSID0020442", + "bmad": 3.7634679299683276, + "respMax": 6.370859881086669, + "respMin": -24.72241823635355, + "maxMean": 6.370859881086669, + "maxMeanConc": -1.6989700043360187, + "maxMed": 6.370859881086669, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 5, + "m5id": 5037052, + "modl": "poly1", + "hitc": 0.002042012002651702, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + -0.22184874961635637, + 1.3010299956639813 + ], + "resp": [ + -21.311944042400853, + -24.72241823635355, + 4.233132626308943, + 6.370859881086669, + -2.027415652400837, + -6.370859881086669, + -24.42384722229375, + 4.914918420921617 + ] + }, + "mc4Param": { + "pow_a": 3.3072505400423485E-7, + "pow_p": 0.48940737393325506, + "exp2_a": 0.0001178398873513196, + "exp2_b": 63.34951489094878, + "exp3_a": 0.0001841064325533645, + "exp3_b": 55.65163739945494, + "exp3_p": 6.824418075268488, + "exp5_p": 7.707370645935452, + "gnls_p": 7.997415906240865, + "gnls_q": 7.989198554360788, + "hill_p": 2.571992160004071, + "pow_er": 2.5239488469935676, + "cnst_er": 2.5242223192710633, + "exp2_er": 2.525053668986501, + "exp3_er": 2.523884767735848, + "exp4_er": 2.5241938891100872, + "exp4_ga": 1.6515772735986691, + "exp4_tp": 6.617210716178248E-9, + "exp5_er": 2.524199907336932, + "exp5_ga": 10.178571517103231, + "exp5_tp": 5.172831559020237E-10, + "gnls_er": 2.5242279860451324, + "gnls_ga": 0.004183840961600125, + "gnls_la": 0.4674883095224845, + "gnls_tp": 1.1951706709070964E-9, + "hill_er": 2.524223618395549, + "hill_ga": 148.03344804359023, + "hill_tp": 2.733414071151221E-7, + "poly1_a": 3.75351162131322E-10, + "poly2_a": 0.00002346265382550711, + "poly2_b": 59.967965785150426, + "pow_aic": 72.58967090276546, + "pow_cov": 1, + "pow_rme": 14.955280470099757, + "pow_top": 0.0000022436522447587723, + "all_bmed": 0, + "cnst_aic": 68.58966978130083, + "cnst_rme": 14.955279986723223, + "exp2_aic": 72.58970163671296, + "exp2_cov": 1, + "exp2_rme": 14.95530781824828, + "exp2_top": 0.00014161915125562188, + "exp3_aic": 74.5896936496435, + "exp3_cov": 1, + "exp3_rme": 14.955303510350245, + "exp3_top": 0.00011387453660103208, + "exp4_aic": 72.58966979064168, + "exp4_cov": 1, + "exp4_rme": 14.955279988191776, + "exp4_top": 6.617210716178248E-9, + "exp5_aic": 74.58966978654288, + "exp5_cov": 1, + "exp5_rme": 14.955279986808964, + "exp5_top": 5.172831559020237E-10, + "gnls_aic": 78.58966978173339, + "gnls_cov": 0, + "gnls_rme": 14.955279986965122, + "gnls_top": 1.1951706553283066E-9, + "hill_aic": 74.58966978433192, + "hill_cov": 1, + "hill_rme": 14.955279989922763, + "hill_top": 2.733414071151221E-7, + "poly1_er": 2.524225595579482, + "poly2_er": 2.5192954625514083, + "pow_a_sd": null, + "pow_ac50": 12.13051274192964, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.809987412922897, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.922737651566834, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.6515772735986691, + "exp5_ac50": 10.178571517103231, + "exp5_p_sd": null, + "gnls_ac50": 0.004183841731103657, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 148.03344804359023, + "hill_p_sd": null, + "poly1_aic": 70.58966978459904, + "poly1_cov": 1, + "poly1_rme": 14.955279990364838, + "poly1_top": 1.8767558106566096E-8, + "poly2_aic": 72.58990187798537, + "poly2_cov": 1, + "poly2_rme": 14.95528704942522, + "poly2_top": 0.00003587357796415024, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.7543725426808853, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.416665901382313, + "poly2_b_sd": null, + "poly1_er_sd": 0.4477482735353781, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.46748831104898736 + }, + "mc5Param": { + "a": 3.75351162131322E-10, + "er": 2.524225595579482, + "ac5": 2.4999999999999996, + "bmd": 24747869784.486176, + "bmr": 9.289141683881516, + "mll": -33.29483489229952, + "top": 1.8767558106566096E-8, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 32.07314681587885, + "rmse": 14.955279990364838, + "ac1sd": 18345344540.019405, + "caikwt": 0.7310585789542388, + "hitcall": 0.002042012002651702, + "top_over_cutoff": 8.311287379883885E-10 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842407, + "spid": "LEGTV002C05", + "chid": 24159, + "casn": "82558-50-7", + "chnm": "Isoxaben", + "dtxsid": "DTXSID8024159", + "bmad": 3.7634679299683276, + "respMax": 5.49720635915255, + "respMin": -42.51947478602658, + "maxMean": 5.49720635915255, + "maxMeanConc": -1.6989700043360187, + "maxMed": 5.49720635915255, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 6, + "m5id": 5037053, + "modl": "poly1", + "hitc": 0.005642489777948826, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + 0.3010299956639812, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + -25.365997806861397, + -17.548550487285034, + -34.678529552780105, + 5.49720635915255, + -33.60688227782604, + -42.51947478602658, + -5.497206359152553, + -17.438893556824596 + ] + }, + "mc4Param": { + "pow_a": 6.226170694933507E-8, + "pow_p": 0.4042163870931334, + "exp2_a": 0.0001012762858506541, + "exp2_b": 57.270518532764584, + "exp3_a": 0.0000182768161808948, + "exp3_b": 54.022410694191784, + "exp3_p": 6.142965107596046, + "exp5_p": 2.8793235821658465, + "gnls_p": 3.493285104003668, + "gnls_q": 7.031846474264492, + "hill_p": 1.0379684048996836, + "pow_er": 3.173306223014833, + "cnst_er": 3.173629962494881, + "exp2_er": 3.1736428876942693, + "exp3_er": 3.1731540297554797, + "exp4_er": 3.173621981878118, + "exp4_ga": 3.8258649261720423, + "exp4_tp": 3.8520423020123184E-9, + "exp5_er": 3.1736383043942484, + "exp5_ga": 2.271771952781368, + "exp5_tp": 5.262533058108749E-11, + "gnls_er": 3.1736202534985587, + "gnls_ga": 0.005952471727474193, + "gnls_la": 0.18861860617718257, + "gnls_tp": 1.6686711949450346E-7, + "hill_er": 3.17364751679775, + "hill_ga": 20.040557914497292, + "hill_tp": 1.1614522693913956E-8, + "poly1_a": 3.659932631449042E-9, + "poly2_a": 0.000013026598523821235, + "poly2_b": 57.387744641763376, + "pow_aic": 82.14157800030708, + "pow_cov": 1, + "pow_rme": 26.114813220190868, + "pow_top": 3.0267220450413394E-7, + "all_bmed": 0, + "cnst_aic": 78.14157681500255, + "cnst_rme": 26.114813127316296, + "exp2_aic": 82.14159084553305, + "exp2_cov": 1, + "exp2_rme": 26.114831275368346, + "exp2_top": 0.00014119949389863312, + "exp3_aic": 84.14158033084956, + "exp3_cov": 1, + "exp3_rme": 26.1148144541783, + "exp3_top": 0.000015755848523068117, + "exp4_aic": 82.14157681587226, + "exp4_cov": 1, + "exp4_rme": 26.11481312868518, + "exp4_top": 3.8520423020123184E-9, + "exp5_aic": 84.14157681658645, + "exp5_cov": 1, + "exp5_rme": 26.114813127337793, + "exp5_top": 5.262533058108749E-11, + "gnls_aic": 88.14157682092178, + "gnls_cov": 1, + "gnls_rme": 26.11481313545457, + "gnls_top": 1.6676819541873118E-7, + "hill_aic": 84.14157682143528, + "hill_cov": 1, + "hill_rme": 26.114813129178945, + "hill_top": 1.1614522693913956E-8, + "poly1_er": 3.1736110292974504, + "poly2_er": 3.177870228427013, + "pow_a_sd": null, + "pow_ac50": 9.000054430731787, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.29159091667016, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.711967424362975, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.8258649261720423, + "exp5_ac50": 2.271771952781368, + "exp5_p_sd": null, + "gnls_ac50": 0.0059504517433272355, + "gnls_p_sd": 224765.9170368504, + "gnls_q_sd": 180670.09083156497, + "hill_ac50": 20.040557914497292, + "hill_p_sd": null, + "poly1_aic": 80.14157683765278, + "poly1_cov": 1, + "poly1_rme": 26.114813154277936, + "poly1_top": 1.829966315724521E-7, + "poly2_aic": 82.14177676316693, + "poly2_cov": 1, + "poly2_rme": 26.11481578856423, + "poly2_top": 0.000021238186978110477, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.3015548243048596, + "gnls_ga_sd": 485.41916773439993, + "gnls_la_sd": 289.43404331885483, + "gnls_tp_sd": 0.003781427130691287, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.6673078948731034, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.534768764417112, + "poly2_b_sd": null, + "poly1_er_sd": 0.4166433568135868, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.188650105801014 + }, + "mc5Param": { + "a": 3.659932631449042E-9, + "er": 3.1736110292974504, + "ac5": 2.5, + "bmd": 2538063570.9143515, + "bmr": 9.289141683881516, + "mll": -38.07078841882639, + "top": 1.829966315724521E-7, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 23.5430889035458, + "rmse": 26.114813154277936, + "ac1sd": 1881440749.3805425, + "caikwt": 0.7310585808566573, + "hitcall": 0.005642489777948826, + "top_over_cutoff": 8.104078249888357E-9 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json new file mode 100644 index 00000000..4ddd3f32 --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json @@ -0,0 +1,1064 @@ +[ + { + "aeid": 3094, + "m4id": 822141, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 6.75211217879369, + "respMax": 101.97489068160048, + "respMin": -5.852474808193342, + "maxMean": 101.28943947387002, + "maxMeanConc": 2.3010299956639813, + "maxMed": 101.164780328344, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 3, + "tmpi": 42, + "m5id": 7598924, + "modl": "exp5", + "hitc": 0.9999999999966847, + "fitc": 42, + "coff": 20.25633653638107, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 0.6989700043360189, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1, + 1.4771212547196624, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + 1.9030899869919435, + 1, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 1.9030899869919435, + 0.6989700043360189, + -0.3010299956639812, + -1.3010299956639813, + -6, + 2.3010299956639813, + -6, + 1, + -3 + ], + "resp": [ + 7.427232859032931, + -3.750051787305786, + 101.07307228396438, + 98.9002717861462, + 17.02699226830727, + 17.699805850864504, + 2.9964941201219695, + -2.3418378029464026, + 100.8533065571916, + 58.64570278003023, + 5.964872358375655, + 49.11565073337273, + 14.83512968293488, + -3.9755251250928403, + 8.861038251024265, + -2.503018132836884, + 10.01979188930157, + 99.31356213766618, + 101.39305781992614, + 19.77117858122105, + 52.084973469960936, + 6.965386514618434, + 12.337528884815498, + -5.852474808193342, + 2.4837211637883, + 101.25648837272361, + 45.27350419250797, + 101.25648837272361, + 10.373412937556623, + 8.43972728547434, + -3.9875658920796426, + 1.7693315847934825, + 101.97489068160048, + 14.296296110011324, + 6.899162035880055, + -0.9777667971902465 + ] + }, + "mc4Param": { + "pow_a": 8.980263423505296, + "pow_p": 0.4658605032164628, + "exp2_a": 20906.920443662984, + "exp2_b": 38271.293496514474, + "exp3_a": 1485.9514343897358, + "exp3_b": 65459.19750014387, + "exp3_p": 0.46157030104511454, + "exp5_p": 1.4598137263404865, + "gnls_p": 2.0882292940940737, + "gnls_q": 7.993467618938603, + "hill_p": 2.08823290079987, + "pow_er": 2.153005726183071, + "cnst_er": 3.5592259949766554, + "exp2_er": 2.6995029704246463, + "exp3_er": 2.1600743867360332, + "exp4_er": 1.7944788900032378, + "exp4_ga": 28.42183560284198, + "exp4_tp": 105.35849603526988, + "exp5_er": 1.6323860710514544, + "exp5_ga": 29.136304634949504, + "exp5_tp": 102.86194850536708, + "gnls_er": 1.7852653451471712, + "gnls_ga": 29.224488415897408, + "gnls_la": 3787.921673603752, + "gnls_tp": 106.40480941826632, + "hill_er": 1.785256872105232, + "hill_ga": 29.22430650665218, + "hill_tp": 106.40450294071316, + "poly1_a": 0.5474828009413533, + "poly2_a": 27146.761600523227, + "poly2_b": 49818.73895889866, + "pow_aic": 286.2961627225351, + "pow_cov": 1, + "pow_rme": 12.749288084437351, + "pow_top": 105.98589412140464, + "all_bmed": 0, + "cnst_aic": 384.3251737754444, + "cnst_rme": 51.114626158662446, + "exp2_aic": 328.2752622937805, + "exp2_cov": 1, + "exp2_rme": 23.28731820786984, + "exp2_top": 109.54238551681884, + "exp3_aic": 288.7695452039763, + "exp3_cov": 1, + "exp3_rme": 12.853976257861472, + "exp3_top": 106.23398734408596, + "exp4_aic": 252.15096836877743, + "exp4_cov": 1, + "exp4_rme": 7.153206032224669, + "exp4_top": 105.35849603526988, + "exp5_aic": 242.37818996364612, + "exp5_cov": 1, + "exp5_rme": 6.04671272377595, + "exp5_top": 102.86194850536708, + "gnls_aic": 256.43287140229086, + "gnls_cov": 1, + "gnls_rme": 6.883032818734613, + "gnls_top": 106.3485222050823, + "hill_aic": 252.43287141156785, + "hill_cov": 1, + "hill_rme": 6.883035058943881, + "hill_top": 106.40450294071316, + "poly1_er": 2.698231249887153, + "poly2_er": 2.69823328798644, + "pow_a_sd": 1.6459870762064353, + "pow_ac50": 45.16993304352483, + "pow_p_sd": 0.0359070833296379, + "all_onesd": 13.177463361669563, + "exp2_a_sd": 80054.91579295504, + "exp2_ac50": 100.13064607578782, + "exp2_b_sd": 146042.59634222218, + "exp3_a_sd": 1557.2108093448396, + "exp3_ac50": 46.23219211065147, + "exp3_b_sd": 126993.03927633302, + "exp3_p_sd": 0.04175006048618471, + "exp4_ac50": 28.42183560284198, + "exp5_ac50": 29.136304634949504, + "exp5_p_sd": 0.16077431744640758, + "gnls_ac50": 29.209685841672393, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 29.22430650665218, + "hill_p_sd": 0.3854703745468205, + "poly1_aic": 326.2063457159531, + "poly1_cov": 1, + "poly1_rme": 23.266335897780746, + "poly1_top": 109.49656018827066, + "poly2_aic": 328.3117909623189, + "poly2_cov": 1, + "poly2_rme": 23.312627580644826, + "poly2_top": 109.41964530134416, + "pow_er_sd": 0.17588811957512163, + "exp2_er_sd": 0.18414085537434977, + "exp3_er_sd": 0.17616560477044965, + "exp4_er_sd": 0.14951537674258722, + "exp4_ga_sd": 2.504500211345132, + "exp4_tp_sd": 3.090966159056836, + "exp5_er_sd": 0.1494114951654834, + "exp5_ga_sd": 1.6840648875294664, + "exp5_tp_sd": 2.1361083422870157, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.14832567590990886, + "hill_ga_sd": 1.96787729051603, + "hill_tp_sd": 3.504225659847863, + "poly1_a_sd": 0.039187291314295165, + "poly1_ac50": 100, + "poly2_a_sd": 84355.29653483114, + "poly2_ac50": 100.1999242731534, + "poly2_b_sd": 154185.56825938867, + "poly1_er_sd": 0.1840572310279764, + "poly2_er_sd": 0.18411448898547148, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3788.3863573521858 + }, + "mc5Param": { + "p": 1.4598137263404865, + "er": 1.6323860710514544, + "ga": 29.136304634949504, + "tp": 102.86194850536708, + "ac5": 4.895974620693649, + "acc": 13.246002431318528, + "bmd": 11.994507756086188, + "bmr": 17.776398074892242, + "mll": -117.18909498182306, + "top": 102.86194850536708, + "ac10": 8.01655754617927, + "ac20": 13.404172123946616, + "ac50": 29.136304634949504, + "bmdl": 11.03986268985668, + "bmdu": 12.963072648031766, + "rmse": 6.04671272377595, + "ac1sd": 9.600739034050022, + "caikwt": 1.5017723494623147E-31, + "hitcall": 0.9999999999966848, + "top_over_cutoff": 5.078013406847952 + }, + "mc6Param": null + }, + { + "aeid": 3098, + "m4id": 822345, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 6.292361272058492, + "respMax": 98.60944617597698, + "respMin": -15.487892591704627, + "maxMean": 97.61114262807376, + "maxMeanConc": 2.3010299956639813, + "maxMed": 97.67386193907646, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 3, + "tmpi": 42, + "m5id": 7599128, + "modl": "exp5", + "hitc": 0.9999999999589282, + "fitc": 42, + "coff": 18.877083816175475, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -6, + 1.4771212547196624, + -1.3010299956639813, + -3, + 1.9030899869919435, + 1.9030899869919435, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 0.6989700043360189, + -0.3010299956639812, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1, + -3, + 0.6989700043360189, + 1.4771212547196624, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 1, + 0.6989700043360189, + -1.3010299956639813, + 2.3010299956639813, + 1.9030899869919435, + 1, + 1, + -0.3010299956639812, + -6, + -6 + ], + "resp": [ + -15.487892591704627, + 40.445936226324626, + -3.308559098537521, + 2.4871891013623295, + 95.05061867266592, + 94.2402094469292, + 41.223955492527544, + 13.285839270091238, + 12.403185338714955, + 5.966930265995686, + 3.2590462497004555, + 97.74742391564821, + 37.58280214973128, + 13.203930026359934, + 1.8653867132104287, + 7.428820770153813, + -0.5751258087706687, + 96.48740045816517, + 10.046907385185994, + 6.577942620268354, + 0.2397506593143131, + 45.626647495806374, + 10.740829537281229, + 3.4763845600575403, + 98.60944617597698, + 96.61951570366818, + 36.849676336609924, + 25.084364454443193, + 14.135733033370828, + 97.60029996250469, + 94.17685118619698, + 5.586801649793776, + 16.462976276060388, + 6.709801102324467, + -0.6374203224596925, + 4.330751609032399 + ] + }, + "mc4Param": { + "pow_a": 8.718852311483452, + "pow_p": 0.4621192452087188, + "exp2_a": 30733.63862806683, + "exp2_b": 58053.22582237376, + "exp3_a": 95.1637174921906, + "exp3_b": 487.2146854984712, + "exp3_p": 0.36448949067095376, + "exp5_p": 1.5921607117432042, + "gnls_p": 2.5006151066661264, + "gnls_q": 7.884701749657575, + "hill_p": 2.5005615803454724, + "pow_er": 2.1386687105738353, + "cnst_er": 3.5130386164195015, + "exp2_er": 2.6970289699940606, + "exp3_er": 2.2185744921064368, + "exp4_er": 2.011051198182322, + "exp4_ga": 32.650308081937, + "exp4_tp": 102.35617680593612, + "exp5_er": 1.7482328153387492, + "exp5_ga": 33.60823929102817, + "exp5_tp": 99.05623958289912, + "gnls_er": 1.8712349808607216, + "gnls_ga": 33.56038699307263, + "gnls_la": 5782.338770572877, + "gnls_tp": 101.44815858342024, + "hill_er": 1.8712200758466104, + "hill_ga": 33.56045811387879, + "hill_tp": 101.4484696652948, + "poly1_a": 0.5305416047533859, + "poly2_a": 27673.0817955942, + "poly2_b": 52368.24882950644, + "pow_aic": 284.11914879686157, + "pow_cov": 1, + "pow_rme": 12.167746147199564, + "pow_top": 100.8810435335372, + "all_bmed": 0, + "cnst_aic": 380.5440532323087, + "cnst_rme": 48.52148017787647, + "exp2_aic": 324.77731273488877, + "exp2_cov": 1, + "exp2_rme": 21.596356868481895, + "exp2_top": 106.06349428140288, + "exp3_aic": 288.16578474486806, + "exp3_cov": 1, + "exp3_rme": 12.654705150741076, + "exp3_top": 100.90413703157488, + "exp4_aic": 266.6070682545724, + "exp4_cov": 1, + "exp4_rme": 8.542515933428906, + "exp4_top": 102.35617680593612, + "exp5_aic": 257.6591381302885, + "exp5_cov": 1, + "exp5_rme": 8.397684028922718, + "exp5_top": 99.05623958289912, + "gnls_aic": 269.9181398445775, + "gnls_cov": 1, + "gnls_rme": 9.43263682314636, + "gnls_top": 101.43815067391468, + "hill_aic": 265.9181398398791, + "hill_cov": 1, + "hill_rme": 9.432603290521724, + "hill_top": 101.4484696652948, + "poly1_er": 2.6974150875559637, + "poly2_er": 2.6974910028623347, + "pow_a_sd": 1.6532680814195877, + "pow_ac50": 44.62909211616844, + "pow_p_sd": 0.037632545643377605, + "all_onesd": 13.014601637003002, + "exp2_a_sd": 144770.52933512983, + "exp2_ac50": 100.08612781558456, + "exp2_b_sd": 273004.74414100195, + "exp3_a_sd": 144.74203282152968, + "exp3_ac50": 46.69029054309706, + "exp3_b_sd": 1335.7880545481178, + "exp3_p_sd": 0.09938750851619732, + "exp4_ac50": 32.650308081937, + "exp5_ac50": 33.60823929102817, + "exp5_p_sd": 0.1861700465060868, + "gnls_ac50": 33.55773915040644, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.56045811387879, + "hill_p_sd": 0.6962069108870773, + "poly1_aic": 322.7320181754561, + "poly1_cov": 1, + "poly1_rme": 21.576688972834244, + "poly1_top": 106.10832095067718, + "poly2_aic": 324.83200434183965, + "poly2_cov": 1, + "poly2_rme": 21.612975364548863, + "poly2_top": 106.09011722019908, + "pow_er_sd": 0.17201036124649297, + "exp2_er_sd": 0.1724789031231027, + "exp3_er_sd": 0.1778243849070398, + "exp4_er_sd": 0.14816738537311727, + "exp4_ga_sd": 3.8800102860948154, + "exp4_tp_sd": 3.881300977472912, + "exp5_er_sd": 0.16675857577462103, + "exp5_ga_sd": 1.909160862868152, + "exp5_tp_sd": 2.442228657418365, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.16807331852131832, + "hill_ga_sd": 1.9630919114427805, + "hill_tp_sd": 4.0603354568457, + "poly1_a_sd": 0.03909925746514938, + "poly1_ac50": 100, + "poly2_a_sd": 88278.60946926908, + "poly2_ac50": 100.190228208773, + "poly2_b_sd": 166328.9016942867, + "poly1_er_sd": 0.17246325393606268, + "poly2_er_sd": 0.1725193110812217, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 5782.479713707603 + }, + "mc5Param": { + "p": 1.5921607117432042, + "er": 1.7482328153387492, + "ga": 33.60823929102817, + "tp": 99.05623958289912, + "ac5": 6.549950475444407, + "acc": 15.942801656366925, + "bmd": 15.15768602592679, + "bmr": 17.556697608317048, + "mll": -124.82956906514426, + "top": 99.05623958289912, + "ac10": 10.294039781041006, + "ac20": 16.492264340792413, + "ac50": 33.60823929102817, + "bmdl": 13.9632920083894, + "bmdu": 16.36542533906654, + "rmse": 8.397684028922718, + "ac1sd": 12.353374802821008, + "caikwt": 2.0695681448366308E-27, + "hitcall": 0.9999999999589282, + "top_over_cutoff": 5.24743337199252 + }, + "mc6Param": null + }, + { + "aeid": 3095, + "m4id": 1150437, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 0.1635842394403502, + "respMax": 11.45832139758188, + "respMin": 0.04981319925745456, + "maxMean": 4.937025241580714, + "maxMeanConc": 1.9030899869919435, + "maxMed": 5.454860652403362, + "maxMedConc": 1.9030899869919435, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 2, + "tmpi": 42, + "m5id": 7598992, + "modl": "exp5", + "hitc": 0.9999998831449819, + "fitc": 42, + "coff": 0.4907527183210506, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -0.3010299956639812, + -1.3010299956639813, + 2.3010299956639813, + 0.6989700043360189, + -0.3010299956639812, + -6, + 2.3010299956639813, + 1, + -3, + 0.6989700043360189, + 1.4771212547196624, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 1, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1.9030899869919435, + 1, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + -6, + 1.9030899869919435, + 1.4771212547196624, + 0.6989700043360189, + -3, + 1.4771212547196624, + -1.3010299956639813 + ], + "resp": [ + 0.2882675039415536, + 0.2293577923201378, + 2.12765731100286, + 0.2760905500803271, + 0.2223210266269225, + 0.2859185064112817, + 3.726705759810087, + 0.169779282809137, + 0.2335357255129443, + 0.3364575742259655, + 0.2644336595666082, + 1.101262393197357, + 0.4222553297999173, + 1.724134958388003, + 6.3829741964722, + 0.1518602827691616, + 0.500500483800451, + 0.4657932906610395, + 0.6850736830999858, + 11.45832139758188, + 0.362318825993606, + 4.526747108334523, + 0.2382843463520162, + 0.22948937953272, + 0.3481086018076444, + 0.3596198212273357, + 0.461420136851573, + 0.5216095250469567, + 6.565653249670075, + 0.2280501658369403, + 2.272726411846056, + 0.3340757114300033, + 0.04981319925745456, + 0.222937819595298, + 0.4805766727842742, + 0.1649776062932452 + ] + }, + "mc4Param": { + "pow_a": 0.07306340900696351, + "pow_p": 0.6909308897469263, + "exp2_a": 489.25456473992574, + "exp2_b": 30770.895494055152, + "exp3_a": 16.86144381389201, + "exp3_b": 2819.131595534077, + "exp3_p": 0.6927530157131045, + "exp5_p": 4.565817027769467, + "gnls_p": 7.955761313099027, + "gnls_q": 0.5644747159243586, + "hill_p": 7.999999975199726, + "pow_er": -0.4956759683416578, + "cnst_er": -0.06367288253941095, + "exp2_er": -0.4920846292443089, + "exp3_er": -0.4952315996998395, + "exp4_er": -0.48780818578433305, + "exp4_ga": 62.936593572598966, + "exp4_tp": 3.160545685691406, + "exp5_er": -0.5427393909605482, + "exp5_ga": 45.24973438082952, + "exp5_tp": 3.6092716297582976, + "gnls_er": -0.5743685279270239, + "gnls_ga": 40.39441528906965, + "gnls_la": 1277.3835717446193, + "gnls_tp": 4.9743882398250925, + "hill_er": -0.5418420584767905, + "hill_ga": 39.362832742773776, + "hill_tp": 3.598558047969296, + "poly1_a": 0.015951258753982463, + "poly2_a": 689.1656998074085, + "poly2_b": 43422.635840414565, + "pow_aic": 119.27110226117928, + "pow_cov": 1, + "pow_rme": 1.970612708065348, + "pow_top": 2.841532541460785, + "all_bmed": 0, + "cnst_aic": 147.02320231677632, + "cnst_rme": 2.7213080260384577, + "exp2_aic": 121.536640649848, + "exp2_cov": 1, + "exp2_rme": 1.9806070196866243, + "exp2_top": 3.190339433218957, + "exp3_aic": 121.41570410348348, + "exp3_cov": 1, + "exp3_rme": 1.964500358062248, + "exp3_top": 2.9245335937115775, + "exp4_aic": 117.40649569667184, + "exp4_cov": 1, + "exp4_rme": 1.9143914875326904, + "exp4_top": 3.160545685691406, + "exp5_aic": 108.69371063135708, + "exp5_cov": 1, + "exp5_rme": 1.5839688744886915, + "exp5_top": 3.6092716297582976, + "gnls_aic": 110.23531348142146, + "gnls_cov": 1, + "gnls_rme": 1.540743257946914, + "gnls_top": 4.114035106463596, + "hill_aic": 108.7802965738098, + "hill_cov": 1, + "hill_rme": 1.5870073319060576, + "hill_top": 3.598558047969296, + "poly1_er": -0.49322275683035666, + "poly2_er": -0.4931857994848398, + "pow_a_sd": 0.06098198965840179, + "pow_ac50": 73.34025784745266, + "pow_p_sd": 0.17664309055759367, + "all_onesd": 0.8923597763803547, + "exp2_a_sd": 3184.6202015618323, + "exp2_ac50": 100.16249092262407, + "exp2_b_sd": 199490.5906912948, + "exp3_a_sd": 58.61911836048125, + "exp3_ac50": 77.81121531926684, + "exp3_b_sd": 9986.108641207353, + "exp3_p_sd": 0.29683220702002194, + "exp4_ac50": 62.936593572598966, + "exp5_ac50": 45.24973438082952, + "exp5_p_sd": 4.213044861329193, + "gnls_ac50": 39.827322985728394, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 39.362832742773776, + "hill_p_sd": 5.573024297626113, + "poly1_aic": 119.51285294787452, + "poly1_cov": 1, + "poly1_rme": 1.9801146542527, + "poly1_top": 3.190251750796493, + "poly2_aic": 121.54640180031528, + "poly2_cov": 1, + "poly2_rme": 1.981069269414523, + "poly2_top": 3.1888433746628246, + "pow_er_sd": 0.19875859625257855, + "exp2_er_sd": 0.19669797020202764, + "exp3_er_sd": 0.19724985616593993, + "exp4_er_sd": 0.1965661043023219, + "exp4_ga_sd": 34.81821712492219, + "exp4_tp_sd": 1.0390395652442248, + "exp5_er_sd": 0.1840458110753714, + "exp5_ga_sd": 16.99176937771065, + "exp5_tp_sd": 0.663162309702829, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.18392569712837312, + "hill_ga_sd": 7.865147277595785, + "hill_tp_sd": 0.6707173101135189, + "poly1_a_sd": 0.003422826182028237, + "poly1_ac50": 100, + "poly2_a_sd": 3794.628359530953, + "poly2_ac50": 100.2292375794687, + "poly2_b_sd": 237831.70254565787, + "poly1_er_sd": 0.19659363721503492, + "poly2_er_sd": 0.196607292096659, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2372.2570284464873 + }, + "mc5Param": { + "p": 4.565817027769467, + "er": -0.5427393909605482, + "ga": 45.24973438082952, + "tp": 3.6092716297582976, + "ac5": 25.583338192735063, + "acc": 32.177479924985796, + "bmd": 40.242151032551405, + "bmr": 1.2037933383370985, + "mll": -50.346855315678546, + "top": 3.6092716297582976, + "ac10": 29.9520321053751, + "ac20": 35.30253965284071, + "ac50": 45.24973438082952, + "bmdl": 33.264446410375136, + "bmdu": 53.793763933888144, + "rmse": 1.5839688744886915, + "ac1sd": 37.21757330690621, + "caikwt": 4.751783349020907E-9, + "hitcall": 0.999999883144982, + "top_over_cutoff": 7.354562685065171 + }, + "mc6Param": { + "flag": [ + "Noisy data" + ], + "mc6MthdId": [ + 10 + ] + } + }, + { + "aeid": 3096, + "m4id": 1150505, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 0.257990171134824, + "respMax": 12.49998697918023, + "respMin": 0.0, + "maxMean": 5.541738410783121, + "maxMeanConc": 2.3010299956639813, + "maxMed": 4.833483331976126, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 7, + "tmpi": 42, + "m5id": 7599060, + "modl": "exp5", + "hitc": 0.9999998559756664, + "fitc": 42, + "coff": 0.7739705134044719, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + 1.9030899869919435, + -1.3010299956639813, + 2.3010299956639813, + -6, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 0.6989700043360189, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1, + 1.4771212547196624, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + 1.9030899869919435, + 1, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 0.6989700043360189, + -0.3010299956639812, + -6, + 1, + -3 + ], + "resp": [ + 4.526747108334523, + 0.824888031466226, + 4.347823386445102, + 0.4561003316738806, + 0.7789416927493502, + 0.8941877572233543, + 0, + 5.673754841308623, + 1.057438090424463, + 1.601601548161443, + 0.7860261779905042, + 1.266348323306034, + 12.49998697918023, + 0.5233494153240975, + 0.6619009620889339, + 0.3966504893499123, + 0.6597819661565701, + 0.7658389239768177, + 0.8219881628053387, + 0.7946680134665979, + 1.341281635835031, + 5.050502499746212, + 3.030301882461408, + 0.9870918379995505, + 0.7423904698444517, + 0.9801095134012823, + 0.2988791955447274, + 0.6880733769604134, + 0.916522147225114, + 5.319143277507151, + 0.8810572334378359, + 0.7454444852168833, + 0.5113383612419217, + 1.119847483444187, + 0.5093378484274108, + 0.4670714510258886 + ] + }, + "mc4Param": { + "pow_a": 0.256129166457669, + "pow_p": 0.5644406772111492, + "exp2_a": 1129.3096760444655, + "exp2_b": 39317.04061124209, + "exp3_a": 0.8720019016302841, + "exp3_b": 22.670011403864912, + "exp3_p": 0.30000305864361876, + "exp5_p": 3.190253095690696, + "gnls_p": 4.264093872089519, + "gnls_q": 0.6791167117000405, + "hill_p": 7.176325755057048, + "pow_er": -0.034773780653756595, + "cnst_er": 0.3936756503357535, + "exp2_er": 0.049717571642521746, + "exp3_er": -0.06866643163594202, + "exp4_er": -0.0334255933863206, + "exp4_ga": 54.83941521805386, + "exp4_tp": 5.528448444550952, + "exp5_er": -0.12470418879335174, + "exp5_ga": 47.982496654915074, + "exp5_tp": 4.7906449817634, + "gnls_er": -0.123418231619115, + "gnls_ga": 48.10588765537344, + "gnls_la": 1521.241791470397, + "gnls_tp": 5.939435678991746, + "hill_er": -0.12226946714558153, + "hill_ga": 38.87908122770836, + "hill_tp": 4.727067329887222, + "poly1_a": 0.028809872811533375, + "poly2_a": 1571.4797602650003, + "poly2_b": 54739.707244964055, + "pow_aic": 131.0854979041203, + "pow_cov": 1, + "pow_rme": 1.7655265144654924, + "pow_top": 5.096288028509811, + "all_bmed": 0, + "cnst_aic": 163.6015491080996, + "cnst_rme": 2.940288361762558, + "exp2_aic": 137.69447001575364, + "exp2_cov": 1, + "exp2_rme": 1.8398294934860109, + "exp2_top": 5.759267997099814, + "exp3_aic": 132.21816633784778, + "exp3_cov": 1, + "exp3_rme": 1.7676923268681453, + "exp3_top": 5.085763779463437, + "exp4_aic": 129.8610022030918, + "exp4_cov": 1, + "exp4_rme": 1.7411782753483664, + "exp4_top": 5.528448444550952, + "exp5_aic": 126.4266045032358, + "exp5_cov": 1, + "exp5_rme": 1.7108365520435371, + "exp5_top": 4.7906449817634, + "gnls_aic": 130.5159804184214, + "gnls_cov": 1, + "gnls_rme": 1.71478488931515, + "gnls_top": 4.942677854612155, + "hill_aic": 126.56736784290752, + "hill_cov": 1, + "hill_rme": 1.7154496972433324, + "hill_top": 4.727067329887222, + "poly1_er": 0.048751930612820536, + "poly2_er": 0.04920885674061179, + "pow_a_sd": 0.1568794096944919, + "pow_ac50": 58.57409370876723, + "pow_p_sd": 0.12743956516601432, + "all_onesd": 0.40082905954467335, + "exp2_a_sd": 6523.3330851199225, + "exp2_ac50": 100.1271711840828, + "exp2_b_sd": 226568.13671898856, + "exp3_a_sd": null, + "exp3_ac50": 63.9739161348579, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 54.83941521805386, + "exp5_ac50": 47.982496654915074, + "exp5_p_sd": 1.6269771671859927, + "gnls_ac50": 46.104045082264136, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 38.87908122770836, + "hill_p_sd": 78.09046476767209, + "poly1_aic": 135.66432541001384, + "poly1_cov": 1, + "poly1_rme": 1.839223539922158, + "poly1_top": 5.761974562306676, + "poly2_aic": 137.70745803349075, + "poly2_cov": 1, + "poly2_rme": 1.8399012025826664, + "poly2_top": 5.762622726294994, + "pow_er_sd": 0.16005952572503318, + "exp2_er_sd": 0.16512363320736548, + "exp3_er_sd": null, + "exp4_er_sd": 0.1553647531392489, + "exp4_ga_sd": 22.623173556633372, + "exp4_tp_sd": 1.0746491215089478, + "exp5_er_sd": 0.1550298307298998, + "exp5_ga_sd": 11.027654963611443, + "exp5_tp_sd": 0.5822266175525593, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.15517480648449222, + "hill_ga_sd": 110.91755377399213, + "hill_tp_sd": 1.3037185004938374, + "poly1_a_sd": 0.004437974865094146, + "poly1_ac50": 100, + "poly2_a_sd": 7620.57224036576, + "poly2_ac50": 100.18201711241991, + "poly2_b_sd": 264301.4890716433, + "poly1_er_sd": 0.1650477137056485, + "poly2_er_sd": 0.16508964434676754, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2505.4734619566725 + }, + "mc5Param": { + "p": 3.190253095690696, + "er": -0.12470418879335174, + "ga": 47.982496654915074, + "tp": 4.7906449817634, + "ac5": 21.21481348706796, + "acc": 31.23504395850078, + "bmd": 27.67407473473264, + "bmr": 0.5407184013257643, + "mll": -59.213302251617904, + "top": 4.7906449817634, + "ac10": 26.584628460854177, + "ac20": 33.634697200724105, + "ac50": 47.982496654915074, + "bmdl": 21.832233757697352, + "bmdu": 34.85027881622872, + "rmse": 1.7108365520435371, + "ac1sd": 25.06997712418609, + "caikwt": 8.463760056913385E-9, + "hitcall": 0.9999998559756664, + "top_over_cutoff": 6.18969960585545 + }, + "mc6Param": { + "flag": [ + "Noisy data" + ], + "mc6MthdId": [ + 10 + ] + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json new file mode 100644 index 00000000..dff7f002 --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json @@ -0,0 +1,211 @@ +{ + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } +} diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json new file mode 100644 index 00000000..64c6f26b --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json @@ -0,0 +1,1715 @@ +[ + { + "aeid": 623, + "m4id": 1833668, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.208854513532483, + "respMax": 29.901771956856702, + "respMin": -7.501926040061633, + "maxMean": 29.901771956856702, + "maxMeanConc": 1.3010299956639813, + "maxMed": 29.901771956856702, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 173, + "m5id": 5028314, + "modl": "exp5", + "hitc": 0.3882324490933417, + "fitc": 15, + "coff": 25.253127081194897, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -1.6989700043360187, + 1.3010299956639813, + 0.3010299956639812, + 0.7781512503836436, + -0.22184874961635637, + -1.154901959985743, + 1.6989700043360187 + ], + "resp": [ + 5.209938366718028, + -4.959553158705701, + 29.901771956856702, + -4.651386748844375, + -7.501926040061633, + -1.3578582434514619, + 4.9595531587057025, + 20.02118644067797 + ] + }, + "mc4Param": { + "pow_a": 0.44336623130581354, + "pow_p": 0.9925644596727824, + "exp2_a": 1721.5267035510278, + "exp2_b": 4025.7260629221983, + "exp3_a": 1149.7862297572626, + "exp3_b": 3865.930582986358, + "exp3_p": 0.917722768672351, + "exp5_p": 7.999998569591368, + "gnls_p": 7.999999998725721, + "gnls_q": 6.1299493285886815, + "hill_p": 7.999999995602079, + "pow_er": 1.9125454943910825, + "cnst_er": 2.2713874650689845, + "exp2_er": 1.9114072623315592, + "exp3_er": 1.9217973647521511, + "exp4_er": 1.941838889601473, + "exp4_ga": 13.263284766380592, + "exp4_tp": 24.09270151565037, + "exp5_er": 1.5919951761954754, + "exp5_ga": 14.42814252864356, + "exp5_tp": 24.957524183833613, + "gnls_er": 1.602022603368262, + "gnls_ga": 11.075019190563058, + "gnls_la": 4057.2571930089903, + "gnls_tp": 24.99533986136314, + "hill_er": 1.6020268977019103, + "hill_ga": 11.07620152627384, + "hill_tp": 24.995330944202244, + "poly1_a": 0.4304809360209948, + "poly2_a": 1481.0924717053826, + "poly2_b": 3489.637064916511, + "pow_aic": 63.54642686971948, + "pow_cov": 1, + "pow_rme": 9.110378433889926, + "pow_top": 21.532767773256374, + "all_bmed": 0, + "cnst_aic": 65.7380627468674, + "cnst_rme": 13.467830827162247, + "exp2_aic": 63.5509972646931, + "exp2_cov": 1, + "exp2_rme": 9.128808609267953, + "exp2_top": 21.514900150579237, + "exp3_aic": 65.56286926134463, + "exp3_cov": 1, + "exp3_rme": 9.029227555570293, + "exp3_top": 21.464382238767605, + "exp4_aic": 62.98697633687659, + "exp4_cov": 1, + "exp4_rme": 8.155246492992447, + "exp4_top": 24.09270151565037, + "exp5_aic": 58.33551786266656, + "exp5_cov": 1, + "exp5_rme": 5.064097391524118, + "exp5_top": 24.957524183833613, + "gnls_aic": 62.50680467218653, + "gnls_cov": 1, + "gnls_rme": 5.12230318637964, + "gnls_top": 24.995339798729216, + "hill_aic": 58.50680471790864, + "hill_cov": 1, + "hill_rme": 5.12229712088364, + "hill_top": 24.995330944202244, + "poly1_er": 1.9115526550839648, + "poly2_er": 1.9107008970876125, + "pow_a_sd": 1.30795225093553, + "pow_ac50": 24.870523119834353, + "pow_p_sd": 0.7451572698575011, + "all_onesd": 5.871582120667167, + "exp2_a_sd": 26000.97172895427, + "exp2_ac50": 25.077625249843255, + "exp2_b_sd": 60411.57063986761, + "exp3_a_sd": null, + "exp3_ac50": 23.61210508379751, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 13.263284766380592, + "exp5_ac50": 14.42814252864356, + "exp5_p_sd": 14.257258147825569, + "gnls_ac50": 11.075019183625043, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 11.07620152627384, + "hill_p_sd": 5.6132273415436185, + "poly1_aic": 61.5465618387384, + "poly1_cov": 1, + "poly1_rme": 9.121069696481047, + "poly1_top": 21.524046801049735, + "poly2_aic": 63.5566347758779, + "poly2_cov": 1, + "poly2_rme": 9.136999205494709, + "poly2_top": 21.52535837501469, + "pow_er_sd": 0.35032444517103617, + "exp2_er_sd": 0.33775432638513775, + "exp3_er_sd": null, + "exp4_er_sd": 0.31898399504554403, + "exp4_ga_sd": 16.437658831836973, + "exp4_tp_sd": 9.402421344167246, + "exp5_er_sd": 0.2866421065447428, + "exp5_ga_sd": 10.811848496418005, + "exp5_tp_sd": 4.504679302336407, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.2889737774748023, + "hill_ga_sd": 4.654460027967879, + "hill_tp_sd": 4.624285420174428, + "poly1_a_sd": 0.12591284476723125, + "poly1_ac50": 24.999999999999993, + "poly2_a_sd": 15244.347569196254, + "poly2_ac50": 25.176562967913593, + "poly2_b_sd": 35357.40607056334, + "poly1_er_sd": 0.3376542920341601, + "poly2_er_sd": 0.33789398129427817, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4057.257196326073 + }, + "mc5Param": { + "p": 7.999998569591368, + "er": 1.5919951761954754, + "ga": 14.42814252864356, + "tp": 24.957524183833613, + "ac5": 10.419929728081096, + "bmd": 13.391740000924123, + "bmr": 7.920764280780008, + "mll": -25.16775893133328, + "top": 24.957524183833613, + "ac10": 11.400974094782285, + "ac20": 12.522189530406145, + "ac50": 14.42814252864356, + "bmdl": 6.346138919905622, + "bmdu": 16.86891434152304, + "rmse": 5.064097391524118, + "ac1sd": 12.813544894047944, + "caikwt": 0.024097080019334458, + "hitcall": 0.3882324490933417, + "top_over_cutoff": 0.9882944042371128 + }, + "mc6Param": { + "flag": [ + "Borderline", + "Average number of replicates per conc is less than 2", + "Multiple points above baseline, inactive" + ], + "mc6MthdId": [ + 11, + 13, + 8 + ] + } + }, + { + "aeid": 626, + "m4id": 1834094, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.884792210388105, + "respMax": 29.6569605105704, + "respMin": -0.8775428799361791, + "maxMean": 29.6569605105704, + "maxMeanConc": 1.3010299956639813, + "maxMed": 29.6569605105704, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 127, + "m5id": 5028740, + "modl": "exp4", + "hitc": 0.01954693088289667, + "fitc": 13, + "coff": 29.30875326232863, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.6989700043360187, + 0.7781512503836436, + -0.22184874961635637, + -1.6989700043360187, + 1.3010299956639813, + 0.3010299956639812, + -0.6989700043360187 + ], + "resp": [ + -0.8775428799361791, + 14.818508177104107, + 7.818109293976865, + 0.6182688472277631, + 0.8775428799361791, + 29.6569605105704, + 14.000797766254488, + 11.22856003191065 + ] + }, + "mc4Param": { + "pow_a": 6.104769005070028, + "pow_p": 0.30000061702105263, + "exp2_a": 2626.4817742925065, + "exp2_b": 6939.1379984058385, + "exp3_a": 120.15711077915388, + "exp3_b": 23397.765294430603, + "exp3_p": 0.30000031698770585, + "exp5_p": 0.594894190079819, + "gnls_p": 0.8731492533237095, + "gnls_q": 7.968128567118133, + "hill_p": 0.699837429056946, + "pow_er": 1.7335248446140346, + "cnst_er": 2.380613185122028, + "exp2_er": 2.060944039839989, + "exp3_er": 1.8546380117175023, + "exp4_er": 1.742284415011934, + "exp4_ga": 2.8193975022647706, + "exp4_tp": 19.007523606809062, + "exp5_er": 1.6978383675225492, + "exp5_ga": 1.6927866800008955, + "exp5_tp": 18.11557823124747, + "gnls_er": 1.6327825441519803, + "gnls_ga": 1.735452996784926, + "gnls_la": 54.87984244327055, + "gnls_tp": 24.19390328229074, + "hill_er": 1.6938476048310585, + "hill_ga": 1.813379328743659, + "hill_tp": 19.44068645643118, + "poly1_a": 0.37984578052812146, + "poly2_a": 2264.1081940817717, + "poly2_b": 6022.235022571993, + "pow_aic": 60.00263716196596, + "pow_cov": 1, + "pow_rme": 6.885998407649498, + "pow_top": 19.740642572392304, + "all_bmed": 0, + "cnst_aic": 66.57834307933227, + "cnst_rme": 13.621084951805804, + "exp2_aic": 65.81071829753414, + "exp2_cov": 1, + "exp2_rme": 10.22892676304634, + "exp2_top": 18.99347662794126, + "exp3_aic": 62.2288005070792, + "exp3_cov": 1, + "exp3_rme": 6.886283476321515, + "exp3_top": 20.58121443270486, + "exp4_aic": 59.581830457686145, + "exp4_cov": 1, + "exp4_rme": 6.490262952004159, + "exp4_top": 19.007523606809062, + "exp5_aic": 60.930401394432195, + "exp5_cov": 1, + "exp5_rme": 6.304211108274938, + "exp5_top": 18.11557823124747, + "gnls_aic": 64.01083808276202, + "gnls_cov": 1, + "gnls_rme": 5.921058456285511, + "gnls_top": 22.158867072863508, + "hill_aic": 61.05594929038858, + "hill_cov": 1, + "hill_rme": 6.438553620903468, + "hill_top": 19.44068645643118, + "poly1_er": 2.059622051495357, + "poly2_er": 2.0605577889775617, + "pow_a_sd": 3.149959838854599, + "pow_ac50": 4.960651860666694, + "pow_p_sd": 0.1482676079125486, + "all_onesd": 7.091261826118074, + "exp2_a_sd": 30938.21312122273, + "exp2_ac50": 25.045034314642436, + "exp2_b_sd": 81312.38225224172, + "exp3_a_sd": 303.1118237953914, + "exp3_ac50": 5.644138602314242, + "exp3_b_sd": 141170.26637545082, + "exp3_p_sd": 0.17783524373196458, + "exp4_ac50": 2.8193975022647706, + "exp5_ac50": 1.6927866800008955, + "exp5_p_sd": 0.40135476309182777, + "gnls_ac50": 1.4306730373148124, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 1.813379328743659, + "hill_p_sd": 0.6752166489168941, + "poly1_aic": 63.80340730003342, + "poly1_cov": 1, + "poly1_rme": 10.22362919651012, + "poly1_top": 18.99228902640607, + "poly2_aic": 65.82009863445656, + "poly2_cov": 1, + "poly2_rme": 10.238688730082709, + "poly2_top": 18.953977151594913, + "pow_er_sd": 0.3335635504694223, + "exp2_er_sd": 0.34947041875452034, + "exp3_er_sd": 0.34371770733317997, + "exp4_er_sd": 0.3221439177850666, + "exp4_ga_sd": 4.969271064671941, + "exp4_tp_sd": 7.484672815601464, + "exp5_er_sd": 0.3208267776910146, + "exp5_ga_sd": 2.2579559312184383, + "exp5_tp_sd": 5.794590169915659, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.32586972894861654, + "hill_ga_sd": 3.8056187634873897, + "hill_tp_sd": 9.540592027517304, + "poly1_a_sd": 0.160075249411384, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 17871.438263865843, + "poly2_ac50": 25.102925760278133, + "poly2_b_sd": 47059.40366080807, + "poly1_er_sd": 0.3493877366290281, + "poly2_er_sd": 0.3495083063258392, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 55.428544878921535 + }, + "mc5Param": { + "er": 1.742284415011934, + "ga": 2.8193975022647706, + "tp": 19.007523606809062, + "ac5": 0.2086370544887254, + "bmd": 2.8461708745717997, + "bmr": 9.56611220343328, + "mll": -26.790915228843073, + "top": 19.007523606809062, + "ac10": 0.4285571419954925, + "ac20": 0.9076432666342852, + "ac50": 2.8193975022647706, + "bmdl": 0.42381147732328206, + "bmdu": 10.478324051348984, + "rmse": 6.490262952004159, + "ac1sd": 1.899255719797609, + "caikwt": 0.029361884721225712, + "hitcall": 0.01954693088289667, + "top_over_cutoff": 0.6485271972056202 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Multiple points above baseline, inactive", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 8, + 9 + ] + } + }, + { + "aeid": 645, + "m4id": 1836233, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.4265572687763393, + "respMax": 7.386363636363637, + "respMin": -9.09090909090909, + "maxMean": 7.386363636363637, + "maxMeanConc": 1.6989700043360187, + "maxMed": 7.386363636363637, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 134, + "m5id": 5030879, + "modl": "poly1", + "hitc": 4.481617968402787E-5, + "fitc": 13, + "coff": 20.559343612658036, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.6989700043360187, + -1.154901959985743, + -0.6989700043360187, + -0.22184874961635637, + 1.3010299956639813, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + -7.702020202020201, + 2.904040404040405, + -2.904040404040403, + -0.9469696969696955, + -8.143939393939391, + -3.5984848484848477, + -9.09090909090909, + 7.386363636363637 + ] + }, + "mc4Param": { + "pow_a": 7.38792442803479E-8, + "pow_p": 4.707344288793977, + "exp2_a": 9.720535659483423E-7, + "exp2_b": 3.155293427742727, + "exp3_a": 10.992475308914631, + "exp3_b": 54.33735479981147, + "exp3_p": 7.997291932162272, + "exp5_p": 7.999998484010299, + "gnls_p": 7.999999892071809, + "gnls_q": 2.9607003309368434, + "hill_p": 7.9999961146922605, + "pow_er": 1.5635126278095273, + "cnst_er": 1.719984746193826, + "exp2_er": 1.5591089362306945, + "exp3_er": 1.559419875600755, + "exp4_er": 1.6883920413738989, + "exp4_ga": 74.80480041333628, + "exp4_tp": 8.863636346356905, + "exp5_er": 1.5607744582298897, + "exp5_ga": 44.417660789138985, + "exp5_tp": 8.863603105060312, + "gnls_er": 1.561195254781372, + "gnls_ga": 41.16217714273171, + "gnls_la": 1968.4261784520863, + "gnls_tp": 8.863620744215016, + "hill_er": 1.5615418348405026, + "hill_ga": 41.134292358351026, + "hill_tp": 8.85885765273257, + "poly1_a": 0.0916727261027705, + "poly2_a": 0.00003275646438816725, + "poly2_b": 0.11084829353336607, + "pow_aic": 56.802529668867656, + "pow_cov": 1, + "pow_rme": 5.474106464958057, + "pow_top": 7.347831543130136, + "all_bmed": 0, + "cnst_aic": 54.82949934043421, + "cnst_rme": 6.057646057469498, + "exp2_aic": 56.76807692440605, + "exp2_cov": 1, + "exp2_rme": 5.465880012590823, + "exp2_top": 7.407786706660837, + "exp3_aic": 58.76914315577856, + "exp3_cov": 1, + "exp3_rme": 5.466134248427126, + "exp3_top": 7.388890198629367, + "exp4_aic": 58.3862013644993, + "exp4_cov": 1, + "exp4_rme": 5.91931768956607, + "exp4_top": 8.863636346356905, + "exp5_aic": 58.771451215856445, + "exp5_cov": 1, + "exp5_rme": 5.466684000894818, + "exp5_top": 8.863603105060312, + "gnls_aic": 62.777644709625726, + "gnls_cov": 1, + "gnls_rme": 5.468147134258676, + "gnls_top": 8.859894820651965, + "hill_aic": 58.77767023528245, + "hill_cov": 1, + "hill_rme": 5.468153598929289, + "hill_top": 8.85885765273257, + "poly1_er": 1.6708188343034331, + "poly2_er": 1.603520396966836, + "pow_a_sd": 0.0000014804515060319311, + "pow_ac50": 43.15399398938185, + "pow_p_sd": 0.148714056473758, + "all_onesd": 9.788806432103662, + "exp2_a_sd": 0.00000229547866974318, + "exp2_ac50": 47.81291767075994, + "exp2_b_sd": 0.1144483227925822, + "exp3_a_sd": null, + "exp3_ac50": 46.540170334040354, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 74.80480041333628, + "exp5_ac50": 44.417660789138985, + "exp5_p_sd": 30.83791719208217, + "gnls_ac50": 41.157961075007606, + "gnls_p_sd": 20.623651182531617, + "gnls_q_sd": 917.2489266479544, + "hill_ac50": 41.134292358351026, + "hill_p_sd": 20.755167151874623, + "poly1_aic": 56.20208741239672, + "poly1_cov": 1, + "poly1_rme": 5.879174343453156, + "poly1_top": 4.5836363051385245, + "poly2_aic": 57.24725841856889, + "poly2_cov": 1, + "poly2_rme": 5.591373578271515, + "poly2_top": 6.679450797669966, + "pow_er_sd": 0.31476622758872136, + "exp2_er_sd": 0.31494236846040924, + "exp3_er_sd": null, + "exp4_er_sd": 0.3050999358871871, + "exp4_ga_sd": 206.23903994982948, + "exp4_tp_sd": 24.866384140473222, + "exp5_er_sd": 0.3151258300122656, + "exp5_ga_sd": 133.05442859689597, + "exp5_tp_sd": 82.18120992121477, + "gnls_er_sd": 0.31519605639597137, + "gnls_ga_sd": 64.74140517770995, + "gnls_la_sd": 2232417.631488272, + "gnls_tp_sd": 23.216264261253723, + "hill_er_sd": 0.3152310297032542, + "hill_ga_sd": 66.03127922964485, + "hill_tp_sd": 23.585311596930016, + "poly1_a_sd": 0.10105939936781418, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.000828471087305424, + "poly2_ac50": 35.339127399684344, + "poly2_b_sd": 1.4052316063819617, + "poly1_er_sd": 0.30563589696444254, + "poly2_er_sd": 0.31148611469958, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1968.9852136355971 + }, + "mc5Param": { + "a": 0.0916727261027705, + "er": 1.6708188343034331, + "ac5": 2.5, + "bmd": 144.0461131493368, + "bmr": 13.20509987690784, + "mll": -26.10104370619836, + "top": 4.5836363051385245, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 52.7459473602489, + "rmse": 5.879174343453156, + "ac1sd": 106.77992079268851, + "caikwt": 0.6651420101678049, + "hitcall": 0.00004481617968402787, + "top_over_cutoff": 0.22294662667715023 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 9 + ] + } + }, + { + "aeid": 647, + "m4id": 1836494, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 2.8724632813460445, + "respMax": 24.5911214953271, + "respMin": -15.344176851186198, + "maxMean": 24.5911214953271, + "maxMeanConc": -0.6989700043360187, + "maxMed": 24.5911214953271, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 176, + "m5id": 5031140, + "modl": "poly1", + "hitc": 7.691234876598405E-4, + "fitc": 13, + "coff": 20.0, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -0.6989700043360187, + 1.3010299956639813, + 0.7781512503836436 + ], + "resp": [ + 0.31002875629043825, + -4.23705966930266, + 4.23705966930266, + -10.65330697340043, + -15.344176851186198, + 24.5911214953271, + -3.338425593098491, + 4.084291876347951 + ] + }, + "mc4Param": { + "pow_a": 0.0000015333586251507758, + "pow_p": 0.3766871063745604, + "exp2_a": 0.0000011936693923752977, + "exp2_b": 75.25835790295875, + "exp3_a": 0.0006569488939842799, + "exp3_b": 96.83528802743167, + "exp3_p": 7.800663857633126, + "exp5_p": 7.937542044894579, + "gnls_p": 0.729162061739079, + "gnls_q": 7.999999989113995, + "hill_p": 7.874824062203916, + "pow_er": 2.14936705216903, + "cnst_er": 2.149647244900154, + "exp2_er": 2.1499314425778753, + "exp3_er": 2.150315520704397, + "exp4_er": 2.149639800584959, + "exp4_ga": 19.434543462158643, + "exp4_tp": 1.1341713592504431E-9, + "exp5_er": 2.1496833837069445, + "exp5_ga": 116.5095827986136, + "exp5_tp": 0.0024033220782305803, + "gnls_er": 2.16232385103293, + "gnls_ga": 0.014951651893028646, + "gnls_la": 0.4728127504187675, + "gnls_tp": 11.2206197033088, + "hill_er": 2.1496462163421155, + "hill_ga": 158.06723237834862, + "hill_tp": 0.09087731268651236, + "poly1_a": 1.2510975773993083E-9, + "poly2_a": 0.000010622282859787738, + "poly2_b": 65.91494218290552, + "pow_aic": 67.2883088418402, + "pow_cov": 1, + "pow_rme": 11.277677799643604, + "pow_top": 0.000006693046390825522, + "all_bmed": 0, + "cnst_aic": 63.288305947678175, + "cnst_rme": 11.277676854033178, + "exp2_aic": 67.2883069898754, + "exp2_cov": 1, + "exp2_rme": 11.27767700055377, + "exp2_top": 0.0000011259662475929594, + "exp3_aic": 69.28831082872938, + "exp3_cov": 1, + "exp3_rme": 11.27767730254966, + "exp3_top": 0.000003797491381994292, + "exp4_aic": 67.28830594801778, + "exp4_cov": 1, + "exp4_rme": 11.277676854167195, + "exp4_top": 1.1341713592504431E-9, + "exp5_aic": 69.2883064884335, + "exp5_cov": 1, + "exp5_rme": 11.277677092560204, + "exp5_top": 0.0024033220782305803, + "gnls_aic": 72.17919094570237, + "gnls_cov": 1, + "gnls_rme": 9.771294007073369, + "gnls_top": 9.896104475278875, + "hill_aic": 69.28830869470625, + "hill_cov": 1, + "hill_rme": 11.277678096478796, + "hill_top": 0.09087731268651236, + "poly1_er": 2.1496851424365406, + "poly2_er": 2.1489661386583347, + "pow_a_sd": null, + "pow_ac50": 7.939966888042317, + "pow_p_sd": null, + "all_onesd": 10.104413980537656, + "exp2_a_sd": null, + "exp2_ac50": 29.078168746553875, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.7572447748528, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 19.434543462158643, + "exp5_ac50": 116.5095827986136, + "exp5_p_sd": null, + "gnls_ac50": 0.01079980647197256, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 158.06723237834862, + "hill_p_sd": null, + "poly1_aic": 65.28830598103433, + "poly1_cov": 1, + "poly1_rme": 11.2776768623634, + "poly1_top": 6.255487886996541E-8, + "poly2_aic": 67.28831401939081, + "poly2_cov": 1, + "poly2_rme": 11.277678682582888, + "poly2_top": 0.000014169663550936488, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.4105028884852779, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.16200653088329, + "poly2_b_sd": null, + "poly1_er_sd": 0.6280287466170111, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.47847525919124695 + }, + "mc5Param": { + "a": 1.2510975773993083E-9, + "er": 2.1496851424365406, + "ac5": 2.4999999999999996, + "bmd": 10895116980.467772, + "bmr": 13.6308544597453, + "mll": -30.644152990517163, + "top": 6.255487886996541E-8, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 86.00840841895133, + "rmse": 11.2776768623634, + "ac1sd": 8076439570.398645, + "caikwt": 0.7310585819091135, + "hitcall": 0.0007691234876598405, + "top_over_cutoff": 3.12774394349827E-9 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 9 + ] + } + }, + { + "aeid": 679, + "m4id": 1839401, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 5.621579363521706, + "respMax": 14.08123821744849, + "respMin": -6.612486732252886, + "maxMean": 14.08123821744849, + "maxMeanConc": 0.3010299956639812, + "maxMed": 14.08123821744849, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 133, + "m5id": 5034047, + "modl": "exp4", + "hitc": 3.7196432829375366E-15, + "fitc": 13, + "coff": 33.72947618113024, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + -1.154901959985743, + 0.7781512503836436, + -0.22184874961635637, + -0.6989700043360187, + 1.3010299956639813, + 1.6989700043360187 + ], + "resp": [ + 2.2780919791518146, + 14.08123821744849, + -2.2780919791518137, + -6.612486732252886, + 10.679150230502348, + 13.089523628471415, + 4.467468276222602, + 6.318616035359553 + ] + }, + "mc4Param": { + "pow_a": 2.240045406368432, + "pow_p": 0.30000049943105944, + "exp2_a": 112.98083072982448, + "exp2_b": 865.8254929535174, + "exp3_a": 4.545028620685052, + "exp3_b": 65.7285988399926, + "exp3_p": 0.3000003150791311, + "exp5_p": 7.999999018346869, + "gnls_p": 0.300091098903469, + "gnls_q": 7.550849029707361, + "hill_p": 0.30000000017227746, + "pow_er": 1.9084326032965633, + "cnst_er": 2.050383693644464, + "exp2_er": 1.951409270215791, + "exp3_er": 1.9203767699862313, + "exp4_er": 1.6754549302442965, + "exp4_ga": 0.07329301415768419, + "exp4_tp": 7.710786101521187, + "exp5_er": 1.513226499207291, + "exp5_ga": 0.1453438995327829, + "exp5_tp": 8.610190191604286, + "gnls_er": 1.8470198467698633, + "gnls_ga": 0.29231631165137606, + "gnls_la": 59.66977501585602, + "gnls_tp": 9.655899171708228, + "hill_er": 1.882783861146438, + "hill_ga": 54.87345686534822, + "hill_tp": 16.841921803354463, + "poly1_a": 0.13427234808054894, + "poly2_a": 163.94604679311635, + "poly2_b": 1270.0524640798787, + "pow_aic": 62.22501034060233, + "pow_cov": 1, + "pow_rme": 7.635077607201984, + "pow_top": 7.243503453530403, + "all_bmed": 0, + "cnst_aic": 60.31637953410401, + "cnst_rme": 8.643268453824428, + "exp2_aic": 63.20845198455855, + "exp2_cov": 1, + "exp2_rme": 8.236056037957985, + "exp2_top": 6.716525076559469, + "exp3_aic": 64.52332339400041, + "exp3_cov": 1, + "exp3_rme": 7.810212289193087, + "exp3_top": 6.873721691967609, + "exp4_aic": 59.07676009097395, + "exp4_cov": 1, + "exp4_rme": 6.585985949819935, + "exp4_top": 7.710786101521187, + "exp5_aic": 59.34963698633271, + "exp5_cov": 1, + "exp5_rme": 6.313571586200532, + "exp5_top": 8.610190191604286, + "gnls_aic": 66.68700367035977, + "gnls_cov": 1, + "gnls_rme": 7.005486126644505, + "gnls_top": 7.69073998343443, + "hill_aic": 63.70370651182299, + "hill_cov": 1, + "hill_rme": 7.371748953581798, + "hill_top": 16.841921803354463, + "poly1_er": 1.9514160891689865, + "poly2_er": 1.953269884448892, + "pow_a_sd": null, + "pow_ac50": 4.960647368144271, + "pow_p_sd": null, + "all_onesd": 9.193701942255004, + "exp2_a_sd": 2618.1000472689234, + "exp2_ac50": 25.360877092869007, + "exp2_b_sd": 19534.177463369564, + "exp3_a_sd": null, + "exp3_ac50": 9.693473276544648, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.07329301415768419, + "exp5_ac50": 0.1453438995327829, + "exp5_p_sd": 21.257608326450363, + "gnls_ac50": 0.07386566609090593, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 54.87345686534822, + "hill_p_sd": null, + "poly1_aic": 61.20659443782829, + "poly1_cov": 1, + "poly1_rme": 8.235017480262172, + "poly1_top": 6.713617404027446, + "poly2_aic": 63.209083993314835, + "poly2_cov": 1, + "poly2_rme": 8.236417282123691, + "poly2_top": 6.708398029005737, + "pow_er_sd": null, + "exp2_er_sd": 0.32176579624163837, + "exp3_er_sd": null, + "exp4_er_sd": 0.32290193845118853, + "exp4_ga_sd": 0.07925814316759382, + "exp4_tp_sd": 2.776801163350604, + "exp5_er_sd": 0.3377590868121545, + "exp5_ga_sd": 0.14972218569452714, + "exp5_tp_sd": 2.4071558977199987, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.11707993441117576, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 3437.347970091856, + "poly2_ac50": 25.473296332973103, + "poly2_b_sd": 25758.50715822951, + "poly1_er_sd": 0.32179810050301344, + "poly2_er_sd": 0.32190869935481625, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 60.347790496302295 + }, + "mc5Param": { + "er": 1.6754549302442965, + "ga": 0.07329301415768419, + "tp": 7.710786101521187, + "ac5": 0.005423725663435604, + "bmr": 12.402303920102002, + "mll": -26.538380045486974, + "top": 7.710786101521187, + "ac10": 0.01114076487987984, + "ac20": 0.023595080416335745, + "ac50": 0.07329301415768419, + "rmse": 6.585985949819935, + "caikwt": 0.34982472852238994, + "hitcall": 3.7196432829375366E-15, + "top_over_cutoff": 0.22860675511572107 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 714, + "m4id": 1847540, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.065604241325404, + "respMax": 90.80446870746331, + "respMin": -5.707883228590463, + "maxMean": 90.62049611334439, + "maxMeanConc": 1.6989700043360187, + "maxMed": 90.62049611334439, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 16, + "nrep": 2.0, + "nmedGtbl": 6, + "tmpi": 1280, + "m5id": 5042186, + "modl": "hill", + "hitc": 0.9999999999990554, + "fitc": 42, + "coff": 24.393625447952424, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -0.6989700043360187, + 0.7781512503836436, + 0.3010299956639812, + -0.22184874961635637, + -0.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + 0.7781512503836436, + 1.3010299956639813, + 0.3010299956639812, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + -1.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 23.65294390222711, + 14.242737988357604, + 72.43005879116106, + 46.484959502640294, + 55.886726620789105, + 28.84492825461404, + 5.707883228590464, + 88.63403737583766, + 80.03489098177559, + 80.0297093264599, + 74.69438203693808, + 3.5586226430884302, + -5.707883228590463, + 90.80446870746331, + -3.5586226430884302, + 90.43652351922545 + ] + }, + "mc4Param": { + "pow_a": 32.911138431472224, + "pow_p": 0.3000000797458051, + "exp2_a": 10308.09931192428, + "exp2_b": 4751.077023800089, + "exp3_a": 1269.4299811454289, + "exp3_b": 214861.03156835592, + "exp3_p": 0.30000013149029114, + "exp5_p": 0.7104729913327161, + "gnls_p": 0.955542591689892, + "gnls_q": 7.509065539947891, + "hill_p": 0.9555341491157984, + "pow_er": 2.641957951988852, + "cnst_er": 3.95904849507247, + "exp2_er": 3.4960111520069024, + "exp3_er": 2.6880458922007326, + "exp4_er": 2.098857080265625, + "exp4_ga": 0.7897221222126788, + "exp4_tp": 83.97402405983311, + "exp5_er": 1.9948049077180752, + "exp5_ga": 1.2342906618623586, + "exp5_tp": 87.8897045568669, + "gnls_er": 1.9847399896737128, + "gnls_ga": 1.0031443070703985, + "gnls_la": 557.0432143919979, + "gnls_tp": 91.01391582017716, + "hill_er": 1.9847477692501443, + "hill_ga": 1.003191124397109, + "hill_tp": 91.01447500018872, + "poly1_a": 2.1865425331680353, + "poly2_a": 14664.260556155692, + "poly2_b": 6767.106371403012, + "pow_aic": 141.82653772826615, + "pow_cov": 1, + "pow_rme": 16.068716512669607, + "pow_top": 106.42264340458804, + "all_bmed": 0, + "cnst_aic": 179.848625362541, + "cnst_rme": 58.56882891622411, + "exp2_aic": 169.61132698024198, + "exp2_cov": 1, + "exp2_rme": 38.21336628800247, + "exp2_top": 109.05454587381912, + "exp3_aic": 144.43145465266923, + "exp3_cov": 0, + "exp3_rme": 16.37845865253221, + "exp3_top": 107.50377103361215, + "exp4_aic": 126.23812256465268, + "exp4_cov": 1, + "exp4_rme": 10.334639998161537, + "exp4_top": 83.97402405983311, + "exp5_aic": 125.99404191588884, + "exp5_cov": 1, + "exp5_rme": 10.04248749715944, + "exp5_top": 87.8897045568669, + "gnls_aic": 128.4085145582657, + "gnls_cov": 1, + "gnls_rme": 9.09129189490256, + "gnls_top": 90.40700949566956, + "hill_aic": 124.40851436294564, + "hill_cov": 1, + "hill_rme": 9.09135696458556, + "hill_top": 91.01447500018872, + "poly1_er": 3.4963072277205045, + "poly2_er": 3.4967033306110524, + "pow_a_sd": 5.539590328742932, + "pow_ac50": 4.960631334085256, + "pow_p_sd": 0.05065285664483593, + "all_onesd": 36.16048671325037, + "exp2_a_sd": 58049.23115375191, + "exp2_ac50": 25.065774256310934, + "exp2_b_sd": 26637.78941676024, + "exp3_a_sd": null, + "exp3_ac50": 5.304622230963994, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.7897221222126788, + "exp5_ac50": 1.2342906618623586, + "exp5_p_sd": 0.11448338011960948, + "gnls_ac50": 0.9892404145079376, + "gnls_p_sd": 0.19605463854823008, + "gnls_q_sd": 4028.2837050226367, + "hill_ac50": 1.003191124397109, + "hill_p_sd": 0.1960536175489813, + "poly1_aic": 167.57928052693967, + "poly1_cov": 1, + "poly1_rme": 38.170211145924405, + "poly1_top": 109.32712665840177, + "poly2_aic": 169.62385203407865, + "poly2_cov": 1, + "poly2_rme": 38.225046010433935, + "poly2_top": 109.15012495603122, + "pow_er_sd": 0.22682743340833847, + "exp2_er_sd": 0.22434251903225583, + "exp3_er_sd": null, + "exp4_er_sd": 0.23345662340053935, + "exp4_ga_sd": 0.2852253940608193, + "exp4_tp_sd": 3.843251237417471, + "exp5_er_sd": 0.26681973494160827, + "exp5_ga_sd": 0.3934957270117465, + "exp5_tp_sd": 4.10415190766761, + "gnls_er_sd": 0.2447595646202884, + "gnls_ga_sd": 0.4933082047260317, + "gnls_la_sd": 720123.8796452188, + "gnls_tp_sd": 6.100726679795194, + "hill_er_sd": 0.24476191439739545, + "hill_ga_sd": 0.49331894680155614, + "hill_tp_sd": 6.10085139691297, + "poly1_a_sd": 0.45742366357273334, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 70563.77452581785, + "poly2_ac50": 25.091679894774504, + "poly2_b_sd": 32307.63616776071, + "poly1_er_sd": 0.22427708068428584, + "poly2_er_sd": 0.22436205738666837, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 557.6818189423375 + }, + "mc5Param": { + "p": 0.9555341491157984, + "er": 1.9847477692501443, + "ga": 1.003191124397109, + "tp": 91.01447500018872, + "ac5": 0.04603871449945376, + "acc": 0.3505460195302733, + "bmd": 1.1664879741712382, + "bmr": 48.78049657617475, + "mll": -58.20425718147282, + "top": 91.01447500018872, + "ac10": 0.1006318431871514, + "ac20": 0.23512931816587768, + "ac50": 1.003191124397109, + "bmdl": 0.7135391211625854, + "bmdu": 1.7796567328157402, + "rmse": 9.09135696458556, + "ac1sd": 0.6486166660027173, + "caikwt": 9.148141181839124E-13, + "hitcall": 0.9999999999990554, + "top_over_cutoff": 3.7310761860463177 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 9 + ] + } + }, + { + "aeid": 719, + "m4id": 1850045, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.036116152450091, + "respMax": 107.21526582248697, + "respMin": -2.7450872741675525, + "maxMean": 107.21526582248697, + "maxMeanConc": 1.6989700043360187, + "maxMed": 107.21526582248697, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 5, + "tmpi": 907, + "m5id": 5044691, + "modl": "hill", + "hitc": 0.9999985006475061, + "fitc": 42, + "coff": 24.21669691470054, + "actp": null, + "modelType": 2, + "chidRep": 0, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.154901959985743 + ], + "resp": [ + 107.21526582248697, + 30.195960015843077, + 23.92147481774581, + -2.7450872741675525, + 70.82325167352285, + 87.60749957843302, + 6.666640522978341, + 2.745087274167552 + ] + }, + "mc4Param": { + "pow_a": 26.38188579595087, + "pow_p": 0.373321688144596, + "exp2_a": 10555.066230255175, + "exp2_b": 4397.549085127513, + "exp3_a": 784.0385960885498, + "exp3_b": 12122.72093512508, + "exp3_p": 0.3638067662358064, + "exp5_p": 0.6706734088210354, + "gnls_p": 0.7940478448675982, + "gnls_q": 4.635795527795299, + "hill_p": 0.7940457988465808, + "pow_er": 2.233770712846338, + "cnst_er": 3.823652826194619, + "exp2_er": 3.112037332406609, + "exp3_er": 2.2207623331779267, + "exp4_er": 1.9257018004052453, + "exp4_ga": 3.8261863681864567, + "exp4_tp": 101.17371650605573, + "exp5_er": 1.851583883281417, + "exp5_ga": 4.388513514529561, + "exp5_tp": 108.53396863931586, + "gnls_er": 1.763196258086566, + "gnls_ga": 5.230735872271651, + "gnls_la": 3728.9702818099768, + "gnls_tp": 123.23260400266716, + "hill_er": 1.7632048386470296, + "hill_ga": 5.230720817485771, + "hill_tp": 123.23247985508776, + "poly1_a": 2.4157216564524493, + "poly2_a": 14475.570423248031, + "poly2_b": 6050.547391426295, + "pow_aic": 66.99572995533279, + "pow_cov": 1, + "pow_rme": 10.165270166462872, + "pow_top": 113.64967185920248, + "all_bmed": 0, + "cnst_aic": 89.66837566455231, + "cnst_rme": 56.71162606585343, + "exp2_aic": 82.18838027457493, + "exp2_cov": 1, + "exp2_rme": 27.76912571036805, + "exp2_top": 120.69563618612736, + "exp3_aic": 69.31400616583988, + "exp3_cov": 1, + "exp3_rme": 10.392779268529251, + "exp3_top": 113.91588681399294, + "exp4_aic": 63.470739630590785, + "exp4_cov": 1, + "exp4_rme": 8.85897961514353, + "exp4_top": 101.17371650605573, + "exp5_aic": 63.473426195943134, + "exp5_cov": 1, + "exp5_rme": 7.367611470284465, + "exp5_top": 108.53396863931586, + "gnls_aic": 66.84742309100423, + "gnls_cov": 1, + "gnls_rme": 7.41641546707749, + "gnls_top": 121.09148833061737, + "hill_aic": 62.84742306797685, + "hill_cov": 1, + "hill_rme": 7.41641875777227, + "hill_top": 123.23247985508776, + "poly1_er": 3.1106053488018537, + "poly2_er": 3.114821770788662, + "pow_a_sd": 5.3252399545122096, + "pow_ac50": 7.809343150454362, + "pow_p_sd": 0.056051948310051315, + "all_onesd": 11.631725174057522, + "exp2_a_sd": 62396.56299440558, + "exp2_ac50": 25.07106192806109, + "exp2_b_sd": 25839.769114659568, + "exp3_a_sd": 1271.834084672146, + "exp3_ac50": 8.152864786253309, + "exp3_b_sd": 47172.61248160081, + "exp3_p_sd": 0.060040388923249574, + "exp4_ac50": 3.8261863681864567, + "exp5_ac50": 4.388513514529561, + "exp5_p_sd": 0.1399475195939742, + "gnls_ac50": 5.006742473448925, + "gnls_p_sd": 0.1854347139300874, + "gnls_q_sd": 6795.493494626446, + "hill_ac50": 5.230720817485771, + "hill_p_sd": 0.1854307163440282, + "poly1_aic": 80.15930580117441, + "poly1_cov": 1, + "poly1_rme": 27.713999426199813, + "poly1_top": 120.78608282262245, + "poly2_aic": 82.20131097823085, + "poly2_cov": 1, + "poly2_rme": 27.795630326649007, + "poly2_top": 120.61051231658656, + "pow_er_sd": 0.2974052783401845, + "exp2_er_sd": 0.33465921260039705, + "exp3_er_sd": 0.29489066888069415, + "exp4_er_sd": 0.3357623948715002, + "exp4_ga_sd": 0.8745068218026666, + "exp4_tp_sd": 7.947871781710462, + "exp5_er_sd": 0.3159497283524588, + "exp5_ga_sd": 1.9622995568669583, + "exp5_tp_sd": 10.681406923273569, + "gnls_er_sd": 0.3405846164664119, + "gnls_ga_sd": 3.020438938884526, + "gnls_la_sd": 23405695.431429833, + "gnls_tp_sd": 17.604579650183712, + "hill_er_sd": 0.34058479447409523, + "hill_ga_sd": 3.020385246373638, + "hill_tp_sd": 17.60426841589827, + "poly1_a_sd": 0.46291777018798136, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 72067.05274661083, + "poly2_ac50": 25.102448102487468, + "poly2_b_sd": 29880.417835129876, + "poly1_er_sd": 0.33437412905907915, + "poly2_er_sd": 0.33496016443302623, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3748.429832774264 + }, + "mc5Param": { + "p": 0.7940457988465808, + "er": 1.7632048386470296, + "ga": 5.230720817485771, + "tp": 123.23247985508776, + "ac5": 0.1282724896705554, + "acc": 0.887855091317106, + "bmd": 0.46326275977400544, + "bmr": 15.691197259803596, + "mll": -27.423711533988424, + "top": 123.23247985508776, + "ac10": 0.3287108931871063, + "ac20": 0.9127320943550252, + "ac50": 5.230720817485771, + "bmdl": 0.33623832625756866, + "bmdu": 0.651275873448465, + "rmse": 7.41641875777227, + "ac1sd": 0.3032690510690583, + "caikwt": 0.0000014993516184967038, + "hitcall": 0.999998500647506, + "top_over_cutoff": 5.088740231136994 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + } +] From d2c6998696075b8abd22ec35156ad0970ac8421c Mon Sep 17 00:00:00 2001 From: cthunes Date: Thu, 18 Apr 2024 18:04:04 -0400 Subject: [PATCH 02/32] 231 added tables to vignette and other small updates --- vignettes/Data_retrieval_via_API.Rmd | 112 +++++++++++++++++++-------- 1 file changed, 81 insertions(+), 31 deletions(-) diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd index 420badc7..2f6bb2b8 100644 --- a/vignettes/Data_retrieval_via_API.Rmd +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -11,22 +11,6 @@ vignette: > %\VignetteEngine{knitr::rmarkdown} %\usepackage[utf8]{inputenc} --- - - - - - ```{css, echo=FALSE} .scroll-300 { @@ -45,6 +29,11 @@ $(document).ready(function() { ```{r setup, include = FALSE} devtools::load_all() +library(DT) +# helper function for printing +printFormattedTable <- function(res_dt, widen = c()) { + datatable(res_dt, style = 'bootstrap', class = 'table-bordered table-condensed', rownames = FALSE, options = list(scrollX = TRUE, autoWidth = TRUE, dom = 't', columnDefs = list(list(width = '1000px', targets = widen)))) +} library(httptest) start_vignette("api") ``` @@ -151,8 +140,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val=704, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By spid ```{r data_by_spid} @@ -162,8 +153,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val="TP0000904H05", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By m4id ```{r data_by_m4id} @@ -173,8 +166,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By DTXSID ```{r data_by_dtxsid} @@ -184,54 +179,84 @@ mc5 <- tcplLoadData(lvl=5, # data level val="DTXSID30944145", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By level In addition to level 5 data, levels 3, 4, 6, and 'agg' are available to pull from the API. -```{r data_levels} + +#### mc3 + +```{r data_level_3} mc3 <- tcplLoadData(lvl=3, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 3 parameters +``` + +```{r, echo = FALSE} +printFormattedTable(mc3) +``` -head(mc3) +#### mc4 +```{r data_level_4} mc4 <- tcplLoadData(lvl=4, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 4 parameters +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc4) +``` +#### mc6 + +```{r data_level_6} mc6 <- tcplLoadData(lvl=6, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 6 parameters +``` + +```{r, echo = FALSE} +printFormattedTable(mc6, 17) +``` -head(mc6) +#### agg +```{r data_level_agg} agg <- tcplLoadData(lvl="agg", # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just agg level parameters +``` + +```{r, echo = FALSE} +printFormattedTable(agg) +``` -head(agg) +### add.fld = TRUE -all_fields <- tcplLoadData(lvl=5, # data level +```{r data_level_5_all} +all_fields <- tcplLoadData(lvl=3, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=TRUE) # include all fields - -head(all_fields) ``` +```{r, echo = FALSE} +printFormattedTable(all_fields, 175) +``` ## Load Assay Annotations @@ -244,10 +269,35 @@ To load aeid and aenm as well any other mapped annotations by request, use list("protein", c("Colorimetric", "Fluorescence"))). + +```{r load_aeid_plus} # subset all aeids by using multiple fields -- val must be same length in list form! -aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), val = list("protein", "Colorimetric")) -head(aeids) +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), + val = list("protein", c("Colorimetric", "Fluorescence"))) # list length == 2! +``` + +```{r, echo = FALSE} +printFormattedTable(aeids) +``` + +Add any available fields to the output as desired. If all fields are desired consider using tcplQueryAPI(resource = "assay"). + +```{r load_aeid_all} +# subset all aeids by using multiple fields -- val must be same length in list form! +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), + val = list("protein", c("Colorimetric", "Fluorescence")), + add.fld = c("acid", "assay_component_desc", "signal_direction", "organism")) +``` + +```{r, echo = FALSE} +printFormattedTable(aeids, 5) ``` ### Load acid (in development-tbd) From 0f11ff30d3f257ee93bec44ed3520ebd806fefd8 Mon Sep 17 00:00:00 2001 From: cthunes Date: Mon, 13 May 2024 16:54:40 -0400 Subject: [PATCH 03/32] 235 refactored tcplPlot + utils to support API plotting --- R/tcplPlot.R | 4 ++-- R/tcplPlotUtils.R | 49 +++++++++++++++++++++++------------------------ 2 files changed, 26 insertions(+), 27 deletions(-) diff --git a/R/tcplPlot.R b/R/tcplPlot.R index 4d9d31ec..b0885893 100644 --- a/R/tcplPlot.R +++ b/R/tcplPlot.R @@ -68,7 +68,7 @@ tcplPlot <- function(dat = NULL, type = "mc", fld = "m4id", val = NULL, compare. list2env(validated_vars, envir = environment()) # check_tcpl_db_schema is a user-defined function found in v3_schema_functions.R file - if (check_tcpl_db_schema() | !is.null(dat)) { + if (check_tcpl_db_schema() | !is.null(dat) | getOption("TCPL_DRVR") == "API") { # check if user supplied data. If not, load from db connection if(is.null(dat)){ dat <- tcplPlotLoadData(lvl = lvl, fld = fld, val = val, type = type,flags = flags, compare = FALSE) #code defined in tcplPlotUtils.R @@ -114,7 +114,7 @@ tcplPlot <- function(dat = NULL, type = "mc", fld = "m4id", val = NULL, compare. nrow = ncol = 1 } # error message for output="console" and multi=FALSE to avoid multiple plots in console - if(nrow(dat) > 1 && output == "console" && multi == FALSE) stop("More than 1 concentration series returned for given field/val combination. Set output to pdf or reduce the number of curves to 1. Current number of curves: ", nrow(input)) + if(nrow(dat[compare == FALSE]) != 1 && output == "console" && multi == FALSE) stop("More than 1 concentration series returned for given field/val combination. Set output to pdf or reduce the number of curves to 1. Current number of curves: ", nrow(dat)) if(is.null(nrow)){ nrow <- ifelse(verbose,2,2) } diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index 2b15f3a4..476feb12 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -1,13 +1,13 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ # check that input combination is unique - input <- tcplLoadData(lvl = lvl, fld = fld, val = val, type = type) - if (nrow(input) == 0) stop("No data for fld/val provided") + dat <- tcplLoadData(lvl = lvl, fld = fld, val = val, type = type)[, compare := compare] + if (nrow(dat) == 0) stop("No data for fld/val provided") mcLoadDat <- function(m4id = NULL,flags) { l4 <- tcplLoadData(lvl = 4, fld = "m4id", val = m4id, add.fld = T) - dat <- l4[input, on = "m4id"] + dat <- l4[dat, on = "m4id"] if (flags == TRUE) { l6 <- tcplLoadData(lvl=6, fld='m4id', val=m4id, type='mc') if (nrow(l6) > 0) { @@ -21,37 +21,36 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ } dat <- dat[l6, on = "m4id"] } - tcplPrepOtpt(dat) - } - - scLoadDat <- function(s2id = NULL) { - tcplPrepOtpt(input) + dat } # load dat - if (type == "mc") { - dat <- mcLoadDat(input$m4id,flags = flags)[, compare := compare] - } else { # type == 'sc' - dat <- scLoadDat(input$s2id)[, compare := compare] + if (getOption("TCPL_DRVR") != "API") { + if (type == "mc") { + dat <- mcLoadDat(dat$m4id,flags = flags) + agg <- tcplLoadData(lvl = "agg", fld = "m4id", val = dat$m4id) + } else { # type == 'sc' + agg <- tcplLoadData(lvl = "agg", fld = "s2id", val = dat$s2id, type = "sc") + } + + # unlog concs + if (!("conc" %in% colnames(agg))) agg <- mutate(agg, conc = 10^logc) + + #determine if we're single conc or multiconc based on dat + join_condition <- c("m4id","s2id")[c("m4id","s2id") %in% colnames(dat)] + conc_resp_table <- agg %>% group_by(.data[[join_condition]]) %>% summarise(conc = list(conc), resp = list(resp)) %>% as.data.table() + dat <- dat[conc_resp_table, on = join_condition] + + } else { + # fix flags from API for plotting + dat <- dat %>% rowwise() %>% mutate(flag = paste(flag, collapse = ';\n')) %>% ungroup() %>% as.data.table() } # add normalized data type for y axis ndt <- tcplLoadAeid(fld = "aeid", val = dat$aeid, add.fld = "normalized_data_type") dat <- dat[ndt, on = "aeid"] - if("m4id" %in% colnames(dat)){ - agg <- tcplLoadData(lvl = "agg", fld = "m4id", val = dat$m4id) - } - if("s2id" %in% colnames(dat)){ - agg <- tcplLoadData(lvl = "agg", fld = "s2id", val = dat$s2id, type = "sc") - } - # unlog concs - if (!("conc" %in% colnames(agg))) agg <- mutate(agg, conc = 10^logc) - - #determine if we're single conc or multiconc based on dat - join_condition <- c("m4id","s2id")[c("m4id","s2id") %in% colnames(dat)] - conc_resp_table <- agg %>% group_by(.data[[join_condition]]) %>% summarise(conc = list(conc), resp = list(resp)) %>% as.data.table() - dat <- dat[conc_resp_table, on = join_condition] + dat <- tcplPrepOtpt(dat) # correct concentration unit label for x-axis dat <- dat[is.na(conc_unit), conc_unit:="\u03BCM"] From 0424f9eb8f8afff3681afeaf9d7afa20d4628792 Mon Sep 17 00:00:00 2001 From: cthunes Date: Wed, 15 May 2024 12:44:11 -0400 Subject: [PATCH 04/32] 247+248 fixed wllt with sc and obscure well types bug --- R/tcplPlot.R | 8 ++++---- 1 file changed, 4 insertions(+), 4 deletions(-) diff --git a/R/tcplPlot.R b/R/tcplPlot.R index b0885893..726816e7 100644 --- a/R/tcplPlot.R +++ b/R/tcplPlot.R @@ -861,7 +861,7 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( # check if dtxsid is NA, pull wllt in from lvl 3 if (is.na(dat$dsstox_substance_id) | is.na(dat$chnm)) { - wllt <- unique(tcplLoadData(lvl = 0, fld = list("spid","acid"), + wllt <- unique(tcplLoadData(type = ifelse(lvl == 2, "sc", "mc"), lvl = 0, fld = list("spid","acid"), list(dat$spid, tcplLoadAcid(fld = "aeid", val = dat$aeid)$acid))$wllt) if (length(wllt) == 1) { if (wllt == 'c' | wllt == 'p') { @@ -885,8 +885,8 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( dat$chnm <- "" } else { - data$dsstox_substance_id <- paste0("Well type: ", wllt) - data$chnm <- "" + dat$dsstox_substance_id <- paste0("Well type: ", wllt) + dat$chnm <- "" } } else { @@ -1160,7 +1160,7 @@ tcplggplotCompare <- function(dat, compare.dat, lvl = 5, verbose = FALSE, flags check_wllt <- function(data) { # check if dtxsid is NA, pull wllt in from lvl 3 if (is.na(data$dsstox_substance_id) | is.na(data$chnm)) { - wllt <- unique(tcplLoadData(lvl = 0, fld = list("spid","acid"), + wllt <- unique(tcplLoadData(type = ifelse(lvl == 2, "sc", "mc"), lvl = 0, fld = list("spid","acid"), list(data$spid, tcplLoadAcid(fld = "aeid", val = data$aeid)$acid))$wllt) if (length(wllt) == 1) { if (wllt == 'c' | wllt == 'p') { From e28322f24659404e85acecdccdcd3cebebf8b9a1 Mon Sep 17 00:00:00 2001 From: cthunes Date: Wed, 15 May 2024 18:46:21 -0400 Subject: [PATCH 05/32] Resolve newfound order bug with single conc plotting --- R/tcplPlotUtils.R | 7 +++---- 1 file changed, 3 insertions(+), 4 deletions(-) diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index 476feb12..ebfc0ce7 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -4,6 +4,9 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ dat <- tcplLoadData(lvl = lvl, fld = fld, val = val, type = type)[, compare := compare] if (nrow(dat) == 0) stop("No data for fld/val provided") + # set order to given order + dat <- dat[order(match(get(fld[1]), val[[1]]))] + dat$order <- 1:nrow(dat) mcLoadDat <- function(m4id = NULL,flags) { l4 <- tcplLoadData(lvl = 4, fld = "m4id", val = m4id, add.fld = T) @@ -56,10 +59,6 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ dat <- dat[is.na(conc_unit), conc_unit:="\u03BCM"] dat <- dat[conc_unit=="uM", conc_unit:="\u03BCM"] dat <- dat[conc_unit=="mg/l", conc_unit:="mg/L"] - - # set order to given order - dat <- dat[order(match(get(fld[1]), val[[1]]))] - dat$order <- 1:nrow(dat) dat } From 4f25d60180c6bedbf6a09be48afcf3b7bc8eca01 Mon Sep 17 00:00:00 2001 From: cthunes Date: Fri, 17 May 2024 10:47:28 -0400 Subject: [PATCH 06/32] 206 improve cutoff direction for sc, wllt output fix for length > 1 --- R/tcplPlot.R | 193 +++++++++++++++++++++++++++++++-------------------- 1 file changed, 118 insertions(+), 75 deletions(-) diff --git a/R/tcplPlot.R b/R/tcplPlot.R index 726816e7..c7abf6cc 100644 --- a/R/tcplPlot.R +++ b/R/tcplPlot.R @@ -132,7 +132,7 @@ tcplPlot <- function(dat = NULL, type = "mc", fld = "m4id", val = NULL, compare. # tcplPlotlyplot is the user-defined function found in tcplPlot.R file used to connect tcpl and plotly packages # tcplggplot is the user-defined function found in tcplPlot.R file used to connect tcpl and ggplot2 packages return(tcplPlotlyPlot(dat, lvl)), - return(ggsave(filename=paste0(fileprefix,"_",paste0(dat$m4id, collapse = "_"),".",output), + return(ggsave(filename=paste0(fileprefix,"_",paste0(ifelse(type=="mc",dat$m4id,dat$s2id), collapse = "_"),".",output), plot= if(is.null(compare.val)) tcplggplot(dat,verbose = verbose, lvl = lvl, flags = flags, yrange = yrange) else tcplggplotCompare(dat[compare == FALSE],dat[compare == TRUE],verbose = verbose, lvl = lvl, flags = flags, yrange = yrange), width = 7, height = 5, dpi=dpi)) ) } else { @@ -399,6 +399,22 @@ tcplPlotlyPlot <- function(dat, lvl = 5){ } } + } else if (lvl == 2) { #single conc + # main data + if (!is.null(dat$coff) && dat$max_med < 0) { + dat$coff <- dat$coff * -1 + } + if (!is.null(dat$coff) && !is.null(dat$hitc) && dat$hitc < 0) { + dat$coff <- dat$coff * -1 + } + + # compare data + if (!is.null(compare.dat$coff) && compare.dat$max_med < 0) { + compare.dat$coff <- compare.dat$coff * -1 + } + if (!is.null(compare.dat$coff) && !is.null(compare.dat$hitc) && compare.dat$hitc < 0) { + compare.dat$coff <- compare.dat$coff * -1 + } } # function for truncating decimals @@ -500,7 +516,7 @@ tcplPlotlyPlot <- function(dat, lvl = 5){ inherit = FALSE, hoverinfo = "text", text = ~ paste( - "
", paste0("Cut Off B (", specify_decimal(dat$coff,2), ")") + "
", paste0("Cut Off B (", specify_decimal(compare.dat$coff,2), ")") ) ) } @@ -831,31 +847,41 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( range() # check if model_type is 3 or 4, which means an override method was assigned - if (lvl == 5 && dat$model_type == 3) { # gain direction - # leave coff but bmr should flip if top is negative - if (!is.null(dat$top) && !is.na(dat$top) && !is.null(dat$bmr)) { - if (dat$top < 0) { - dat$bmr <- dat$bmr * -1 + if (lvl == 5) { + if (dat$model_type == 3) { # gain direction + # leave coff but bmr should flip if top is negative + if (!is.null(dat$top) && !is.na(dat$top) && !is.null(dat$bmr)) { + if (dat$top < 0) { + dat$bmr <- dat$bmr * -1 + } + } + } else if (dat$model_type == 4) { # loss direction + # coff and bmr(if top < 0) should be negative + if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { + dat$coff <- dat$coff * -1 + if (dat$top < 0) { + dat$bmr <- dat$bmr * -1 + } + } + } else { # bidirectional + # check if winning model has negative top. If so coff,bmr should be negative + if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { + if (dat$top < 0) { + dat$coff <- dat$coff * -1 + dat$bmr <- dat$bmr * -1 + } } } - } else if (lvl == 5 && dat$model_type == 4) { # loss direction - # coff and bmr(if top < 0) should be negative - if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { + } else { #single conc + if (!is.null(dat$coff) && dat$max_med < 0) { dat$coff <- dat$coff * -1 - if (dat$top < 0) { - dat$bmr <- dat$bmr * -1 - } } - } else { # bidirectional - # check if winning model has negative top. If so coff,bmr should be negative - if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { - if (dat$top < 0) { - dat$coff <- dat$coff * -1 - dat$bmr <- dat$bmr * -1 - } + if (!is.null(dat$coff) && !is.null(dat$hitc) && dat$hitc < 0) { + dat$coff <- dat$coff * -1 } } + # check if ac50 is null and assign NA if it is dat$ac50 <- ifelse(is.null(dat$ac50), NA, dat$ac50) @@ -884,14 +910,15 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( dat$dsstox_substance_id <- "Viability control" dat$chnm <- "" } - else { - dat$dsstox_substance_id <- paste0("Well type: ", wllt) - dat$chnm <- "" - } } else { - warning(paste0("wllt for SPID: ", dat$spid, " is missing or length > 1. + if (length(wllt) > 1) { + dat$dsstox_substance_id <- paste0("Well type: ", paste(wllt, collapse = ", ")) + dat$chnm <- "" + } else { + warning(paste0("wllt for SPID: ", dat$spid, " is missing. Leaving dsstox_substance_id and chnm as NA.")) + } } } @@ -915,7 +942,7 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( if (lvl == 2) { gg <- ggplot(l3_dat, aes(x = conc)) + geom_hline(aes(yintercept = dat$max_med, linetype = "Max Median"), color="red") + - geom_hline(aes(yintercept = ifelse(dat$max_med >= 0, dat$coff, dat$coff * -1), linetype="Cutoff"), color="blue") + + geom_hline(aes(yintercept = dat$coff, linetype="Cutoff"), color="blue") + geom_point(aes(y = resp)) + scale_x_continuous(limits = l3_range, trans = ifelse(0 %in% l3_dat$conc,"identity","log10")) + scale_y_continuous(limits = yrange) + @@ -1093,62 +1120,77 @@ tcplggplotCompare <- function(dat, compare.dat, lvl = 5, verbose = FALSE, flags if (dat$conc_unit != compare.dat$conc_unit || dat$normalized_data_type != compare.dat$normalized_data_type) stop("Units do not match.") - # main data # check if model_type is 3 or 4, which means an override method was assigned - if (lvl == 5 && dat$model_type == 3) { # gain direction - # leave coff but bmr should flip if top is negative - if (!is.null(dat$top) && !is.na(dat$top) && !is.null(dat$bmr)) { - if (dat$top < 0) { - dat$bmr <- dat$bmr * -1 - } - } - } else if (lvl == 5 && dat$model_type == 4) { # loss direction - # coff and bmr(if top < 0) should be negative - if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { - dat$coff <- dat$coff * -1 - if (dat$top < 0) { - dat$bmr <- dat$bmr * -1 + if (lvl == 5) { + # main data + if (dat$model_type == 3) { # gain direction + # leave coff but bmr should flip if top is negative + if (!is.null(dat$top) && !is.na(dat$top) && !is.null(dat$bmr)) { + if (dat$top < 0) { + dat$bmr <- dat$bmr * -1 + } } - } - } else { # bidirectional - # check if winning model has negative top. If so coff,bmr should be negative - if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { - if (dat$top < 0) { + } else if (dat$model_type == 4) { # loss direction + # coff and bmr(if top < 0) should be negative + if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { dat$coff <- dat$coff * -1 - dat$bmr <- dat$bmr * -1 + if (dat$top < 0) { + dat$bmr <- dat$bmr * -1 + } } - } - } - - # compare data - # check if model_type is 3 or 4, which means an override method was assigned - if (lvl == 5 && compare.dat$model_type == 3) { # gain direction - # leave coff but bmr should flip if top is negative - if (!is.null(compare.dat$top) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { - if (compare.dat$top < 0) { - compare.dat$bmr <- compare.dat$bmr * -1 + } else { # bidirectional + # check if winning model has negative top. If so coff,bmr should be negative + if (!is.null(dat$top) && !is.null(dat$coff) && !is.na(dat$top) && !is.null(dat$bmr)) { + if (dat$top < 0) { + dat$coff <- dat$coff * -1 + dat$bmr <- dat$bmr * -1 + } } } - } else if (lvl == 5 && compare.dat$model_type == 4) { # loss direction - # coff and bmr(if top < 0) should be negative - if (!is.null(compare.dat$top) && !is.null(compare.dat$coff) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { - compare.dat$coff <- compare.dat$coff * -1 - if (compare.dat$top < 0) { - compare.dat$bmr <- compare.dat$bmr * -1 + + # compare data + if (compare.dat$model_type == 3) { # gain direction + # leave coff but bmr should flip if top is negative + if (!is.null(compare.dat$top) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { + if (compare.dat$top < 0) { + compare.dat$bmr <- compare.dat$bmr * -1 + } } - } - } else { # bidirectional - # check if winning model has negative top. If so coff,bmr should be negative - if (!is.null(compare.dat$top) && !is.null(compare.dat$coff) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { - if (compare.dat$top < 0) { + } else if (compare.dat$model_type == 4) { # loss direction + # coff and bmr(if top < 0) should be negative + if (!is.null(compare.dat$top) && !is.null(compare.dat$coff) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { compare.dat$coff <- compare.dat$coff * -1 - compare.dat$bmr <- compare.dat$bmr * -1 + if (compare.dat$top < 0) { + compare.dat$bmr <- compare.dat$bmr * -1 + } + } + } else { # bidirectional + # check if winning model has negative top. If so coff,bmr should be negative + if (!is.null(compare.dat$top) && !is.null(compare.dat$coff) && !is.na(compare.dat$top) && !is.null(compare.dat$bmr)) { + if (compare.dat$top < 0) { + compare.dat$coff <- compare.dat$coff * -1 + compare.dat$bmr <- compare.dat$bmr * -1 + } } } + } else { #single conc + # main data + if (!is.null(dat$coff) && dat$max_med < 0) { + dat$coff <- dat$coff * -1 + } + if (!is.null(dat$coff) && !is.null(dat$hitc) && dat$hitc < 0) { + dat$coff <- dat$coff * -1 + } + + # compare data + if (!is.null(compare.dat$coff) && compare.dat$max_med < 0) { + compare.dat$coff <- compare.dat$coff * -1 + } + if (!is.null(compare.dat$coff) && !is.null(compare.dat$hitc) && compare.dat$hitc < 0) { + compare.dat$coff <- compare.dat$coff * -1 + } } - - # check if data is outside bounds of yrange. If so, expand yrange bounds if (!identical(yrange, c(NA,NA))) { yrange[1] <- min(dat$resp_min, dat$coff, yrange[1], unlist(dat$resp), @@ -1183,14 +1225,15 @@ tcplggplotCompare <- function(dat, compare.dat, lvl = 5, verbose = FALSE, flags data$dsstox_substance_id <- "Viability control" data$chnm <- "" } - else { - data$dsstox_substance_id <- paste0("Well type: ", wllt) - data$chnm <- "" - } } else { - warning(paste0("wllt for SPID: ", data$spid, " is missing or length > 1. + if (length(wllt) > 1) { + data$dsstox_substance_id <- paste0("Well type: ", paste(wllt, collapse = ", ")) + data$chnm <- "" + } else { + warning(paste0("wllt for SPID: ", data$spid, " is missing. Leaving dsstox_substance_id and chnm as NA.")) + } } } return(data) From e16ae5cdf4f336c5375f2177ccbed1fd7500da70 Mon Sep 17 00:00:00 2001 From: cthunes Date: Fri, 17 May 2024 15:18:27 -0400 Subject: [PATCH 07/32] moved away from using tcplPrepOtpt with API plotting --- R/tcplPlotUtils.R | 10 +++++++--- 1 file changed, 7 insertions(+), 3 deletions(-) diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index ebfc0ce7..5c771006 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -44,17 +44,21 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ conc_resp_table <- agg %>% group_by(.data[[join_condition]]) %>% summarise(conc = list(conc), resp = list(resp)) %>% as.data.table() dat <- dat[conc_resp_table, on = join_condition] + dat <- tcplPrepOtpt(dat) + } else { # fix flags from API for plotting - dat <- dat %>% rowwise() %>% mutate(flag = paste(flag, collapse = ';\n')) %>% ungroup() %>% as.data.table() + if (is.null(dat$flag)) { + flag <- NA + } + dat <- dat %>% rowwise() %>% mutate(flag = ifelse(is.na(flag) || flag == "NULL", "None", paste(flag, collapse = ';\n'))) %>% ungroup() %>% as.data.table() + dat$conc_unit <- dat$tested_conc_unit } # add normalized data type for y axis ndt <- tcplLoadAeid(fld = "aeid", val = dat$aeid, add.fld = "normalized_data_type") dat <- dat[ndt, on = "aeid"] - dat <- tcplPrepOtpt(dat) - # correct concentration unit label for x-axis dat <- dat[is.na(conc_unit), conc_unit:="\u03BCM"] dat <- dat[conc_unit=="uM", conc_unit:="\u03BCM"] From b2326c2d49368f10bd2ac0c5cc528adbd55baf76 Mon Sep 17 00:00:00 2001 From: cthunes Date: Fri, 17 May 2024 15:20:31 -0400 Subject: [PATCH 08/32] limit wllt check to non-API usage, add back output for single wllt --- R/tcplPlot.R | 16 +++++++++++++--- 1 file changed, 13 insertions(+), 3 deletions(-) diff --git a/R/tcplPlot.R b/R/tcplPlot.R index c7abf6cc..7942f9ad 100644 --- a/R/tcplPlot.R +++ b/R/tcplPlot.R @@ -886,7 +886,7 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( dat$ac50 <- ifelse(is.null(dat$ac50), NA, dat$ac50) # check if dtxsid is NA, pull wllt in from lvl 3 - if (is.na(dat$dsstox_substance_id) | is.na(dat$chnm)) { + if (getOption("TCPL_DRVR") != "API" && (is.na(dat$dsstox_substance_id) | is.na(dat$chnm))) { wllt <- unique(tcplLoadData(type = ifelse(lvl == 2, "sc", "mc"), lvl = 0, fld = list("spid","acid"), list(dat$spid, tcplLoadAcid(fld = "aeid", val = dat$aeid)$acid))$wllt) if (length(wllt) == 1) { @@ -910,6 +910,10 @@ tcplggplot <- function(dat, lvl = 5, verbose = FALSE, flags = FALSE, yrange = c( dat$dsstox_substance_id <- "Viability control" dat$chnm <- "" } + else { + dat$dsstox_substance_id <- paste0("Well type: ", wllt) + dat$chnm <- "" + } } else { if (length(wllt) > 1) { @@ -1225,6 +1229,10 @@ tcplggplotCompare <- function(dat, compare.dat, lvl = 5, verbose = FALSE, flags data$dsstox_substance_id <- "Viability control" data$chnm <- "" } + else { + data$dsstox_substance_id <- paste0("Well type: ", wllt) + data$chnm <- "" + } } else { if (length(wllt) > 1) { @@ -1238,8 +1246,10 @@ tcplggplotCompare <- function(dat, compare.dat, lvl = 5, verbose = FALSE, flags } return(data) } - dat <- check_wllt(dat) - compare.dat <- check_wllt(compare.dat) + if (getOption("TCPL_DRVR") != "API") { + dat <- check_wllt(dat) + compare.dat <- check_wllt(compare.dat) + } dat$winning_model_string <- paste0("Model A(", dat$modl, ")") compare.dat$winning_model_string <- paste0("Model B(", compare.dat$modl, ")") From e94c1d3c28434502d6663473d619aa6dd2e99961 Mon Sep 17 00:00:00 2001 From: cthunes Date: Wed, 17 Apr 2024 17:24:16 -0400 Subject: [PATCH 09/32] 231 add initial api data retrieval vignette with json api responses --- DESCRIPTION | 3 +- vignettes/Data_retrieval_via_API.Rmd | 283 + .../0/api-ccte.epa.gov/bioactivity/assay.json | 109160 +++++++++++++++ .../bioactivity/data/search/by-aeid/704.json | 9207 ++ .../data/search/by-dtxsid/DTXSID30944145.json | 1064 + .../data/search/by-m4id/1842443.json | 211 + .../data/search/by-spid/TP0000904H05.json | 1715 + 7 files changed, 121642 insertions(+), 1 deletion(-) create mode 100644 vignettes/Data_retrieval_via_API.Rmd create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json create mode 100644 vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json diff --git a/DESCRIPTION b/DESCRIPTION index a1a190f4..f3c22322 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -57,7 +57,8 @@ Suggests: kableExtra, colorspace, magrittr, - vdiffr + vdiffr, + httptest License: MIT + file LICENSE LazyData: true RoxygenNote: 7.2.3 diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd new file mode 100644 index 00000000..420badc7 --- /dev/null +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -0,0 +1,283 @@ +--- +title: Data Retrieval with tcpl via API +author: "Center for Computational Toxicology and Exposure, US EPA" +output: + prettydoc::html_pretty: + theme: architect + toc: yes + toc_depth: 4 +vignette: > + %\VignetteIndexEntry{Data Retrieval via API} + %\VignetteEngine{knitr::rmarkdown} + %\usepackage[utf8]{inputenc} +--- + + + + + + +```{css, echo=FALSE} +.scroll-300 { + max-height: 300px; + overflow-y: auto; +} + +.noticebox { + padding: 1em; + background: lightgray; + color: blue; + border: 2px solid black; + border-radius: 10px; +} +``` + +```{r setup, include = FALSE} +devtools::load_all() +library(httptest) +start_vignette("api") +``` + +# Introduction + +This vignette describes how the user can retrieve ToxCast data (invitrodb v4.1) from the CCTE Bioactivity API, using tcpl. The API documentation can be found at . tcpl interfaces to the CCTE API through the R package ccdR (), which wraps the API endpoints and provides helpful functions for storing meta-information related to your connection. + +::: {.noticebox data-latex=""} + +**NOTE:** Users must have a personal API key for full functionality of many of these functions and executing the examples in this vignette. To obtain an API key, send an email request to . + +::: + +## Setup API Connection + +After loading tcpl, use the function tcplConf to set options for connecting to the API. Where a regular database connection requires 5 different options to be filled, using an API connection requires just two: $TCPL_PASS and $TCPL_DRVR . These two can be set using tcplConf like the following: + +```{r setup-api} +tcplConf(pass = "", + drvr = "API") +``` + +## Overview of Key Functions + +To support different data retrieval needs within tcpl, there are a number of functions which query the API and return information to the local R session. + +## Overview of Data Nomenclature + +Throughout this vignette we will use abbreviated designations for data retrieved from the database or to refer to processing steps within tcpl. For data from single concentration assays we use 'SC.' 'MC' is used for assay data with multiple concentrations. A particular data or processing level is indicated by appending the level id/number to the end of the 'SC' or 'MC' designation. For example, if we are discussing single concentration data from level 2 processing, then we will use the abbreviation 'SC2.' + +### Assay Elements + +The tcplLoadAsid, tcplLoadAid, tcplLoadAcid, and tcplLoadAeid functions load relevant assay ids and names for the respective assay elements based on the user specified parameters. + +```{r tcplLoad, eval = FALSE} +# List all assay source IDs +tcplLoadAsid() +# Create table of all assay endpoint ids (aeids) per assay source +aeids <- tcplLoadAeid(fld="asid", # field to query on + val=14, # value for each field + # values should match their corresponding 'fld' + add.fld = c("aid", "anm", "acid", "acnm")) # additional fields to return +``` + +### Data + +tcplQueryAPI is a general querying function which is flexible enough to handle most kinds of queries users may have for the API. Unlike tcplQuery, tcplQueryAPI does not use accept a MySQL query but instead has a few arguments which can be set to mimic a request to the various API endpoints. tcplQueryAPI is used mostly as a helper function to other tcplLoad functions, but is available to users for more specific and/or personalized requests. + +```{r tcplQueryAPI, eval = FALSE} +# Request and load all assays+annotations for specified asid +data <- tcplQueryAPI(resource = "data", # resource to query from API, either 'data' or 'assay' + fld = "aeid", val = 891, # field and val to query on + return_fld = c("spid", "chnm", "hitcall")) # specify the return fields, leave NULL for all fields +``` + +The tcplLoadData function can be used to load data from the CCTE API into the R session. To add useful chemical and assay annotation information, mapped to the retrieved data, remove add.fld = FALSE or conversely set add.fld = TRUE. When connected to the API as the data source, only MC (multiple concentration) screening data is available. In addition, only levels 3, 4, 5, 6, and 'agg' are available. The output will look as similar as possible to regular tcplLoadData output, though some less common columns may be missing and the column order may differ. + +```{r tcplLoadData, eval=FALSE} +# Load multi concentration data from level 4 +mc4_dat <- tcplLoadData( + lvl = 4, # data level + fld = 'aeid', # field to query on + val = 891, # value for each field + # values should match their corresponding 'fld' + type = 'mc', # data type, default, not necessary + add.fld = FALSE # FALSE will only show fields/columns which are usually + # returned for this level, default TRUE will return all available + ) +# Print the first 6 rows of 'mc2_fmtd' +head(mc4_dat) +``` + +When loading data, the user must indicate the applicable fields and ids which are query-able via the CCTE API. These such fields include and are limited to "AEID", "m4id", "SPID", and "DTXSID". Any other fields will result in error. While supplying multiple ids (val) are valid, multiple fields are not, so combinations of fields are not compatible with tcplLoadData when connected to the API. If some or no data is found, tcplLoadData will return whatever it finds, and list in output which val(s) were not found. Examples of loading data are detailed in later sections. + +### Assay Annotations + +Assay source, assay, assay component, and assay endpoint are registered via tcpl scripting into a collection of tables, which in the CCTE APIs are joined into one. The annotations capture four types of information: + +i. Identification information +ii. Design information such as the technology, format, and objective aspects that decompress the assay’s innovations, +iii. Target information, such as the target of technological measurement, +biological intended target, and biological process, and +iv. Analysis information about how the data were processed and analyzed. + +```{r annotation_query_ex, eval = FALSE} +# load all assays and their annotations +assays <- tcplQueryAPI(resource = "assay") +``` + +# Retrieving Processed Multi-Concentration (MC) Data and Annotations + +The goal of MC processing is to estimate the hitcall, potency, efficacy, and other curve-fitting parameters for sample-assay endpoint pairs. API data is stored for levels 3 through 6, users can inspect the activity hitcalls, model parameters, concentration-response plots, and the applied methods for the multiple concentration data. + +## Load Data + +Load filtered data on a sample by endpoint level. Set add.fld = FALSE to limit fields to those which are defaults for each level when loading from invitrodb directly. Leaving add.fld = TRUE (default) will return all of the API's fields, which contain fields from levels 3 through 6. + +### By aeid +```{r data_by_aeid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="aeid", # fields to query on + val=704, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By spid +```{r data_by_spid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="spid", # fields to query on + val="TP0000904H05", # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By m4id +```{r data_by_m4id} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By DTXSID +```{r data_by_dtxsid} +# Load Level 5 MC data for an aeid +mc5 <- tcplLoadData(lvl=5, # data level + fld="dtxsid", # fields to query on + val="DTXSID30944145", # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # return additional parameters from mc5_param + +head(mc5) +``` +### By level + +In addition to level 5 data, levels 3, 4, 6, and 'agg' are available to pull from the API. +```{r data_levels} +mc3 <- tcplLoadData(lvl=3, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 3 parameters + +head(mc3) + +mc4 <- tcplLoadData(lvl=4, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 4 parameters + +head(mc5) + +mc6 <- tcplLoadData(lvl=6, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just level 6 parameters + +head(mc6) + +agg <- tcplLoadData(lvl="agg", # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=FALSE) # restrict to just agg level parameters + +head(agg) + +all_fields <- tcplLoadData(lvl=5, # data level + fld="m4id", # fields to query on + val=1842443, # values should match their corresponding 'fld' + type = "mc", # data type, default, not needed + add.fld=TRUE) # include all fields + +head(all_fields) +``` + + +## Load Assay Annotations + +Load and filter mapped annotation data on an assay component endpoint level (aeid). + +### Load aeid + +To load aeid and aenm as well any other mapped annotations by request, use tcplLoadAeid. Any available field in the API annotations table can be subset using this function. + +```{r load_aeid} +# load aeid and aenm for given acid +aeid <- tcplLoadAeid(fld = "acid", val = 400) +head(aeid) +# subset all aeids by using multiple fields -- val must be same length in list form! +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), val = list("protein", "Colorimetric")) +head(aeids) +``` + +### Load acid (in development-tbd) +### Load aid (in development-tbd) +### Load asid (in development-tbd) +### Load unit (in development-tbd) +### Load concentration unit (in development-tbd) + +# Plotting (in development-tbd) + +tcplPlot is tcpl’s single flexible plotting function, allowing for interactive yet consistent visualization of concentration-response curves via customizable parameters. As a standalone plotting utility built with the R library plotly to display the additional curve-fitting models, tcplPlot implements the R library plumber to provide representational state transfer-application programming interface (REST API) functionality. The tcplPlot function requires the selection of a level (`lvl`), field (`fld`), and value (`val`) to load the necessary data and display the associated plots. Level 4, `lvl = 4`, plots the concentration-response series fit by all models. Level 5, `lvl = 5`, extends Level 4 plotting by highlighting the winning model with activity hit call presented. Level 6 multi-concentration plotting, including lists of flags, are not currently supported by tcplPlot. Moreover, only multi-concentration plotting is currently supported. + +Customization of output is possible by specifying parameters, including `output`, `verbose`, `multi`, `by`, `fileprefix`, `nrow`, `ncol`, and `dpi`. + +- The `output` parameter indicates how the plots will be presented. In addition to outputs viewable with the R console, tcplPlot supports a variety of publication-quality file type options, including raster graphics (PNG, JPG, and TIFF) to retain color quality when printing to photograph and vector graphics (SVG and PDF) to retain image resolution when scaled to large formats. + +- The `verbose` parameter results in a plot that includes a table containing potency and model performance metrics; `verbose = FALSE` is default and the only option in console outputs. When `verbose = TRUE` the model aic values are listed in descending order and generally the winning model will be listed first. + +- The `multi` parameter allows for single or multiple plots per page. `multi = TRUE` is the default option for PDF outputs, whereas `multi = FALSE` is the only option for other outputs. If using the parameter option `multi = TRUE`, the default number of plots per page is set by the `verbose` parameter. The default number of plots per page is either 6 plots per page (`verbose = FALSE`) or 4 plots per page (`verbose = TRUE`). + +- The `by` parameter indicates how files should be divided, typically by $aeid$ or $spid$. + +- The `fileprefix` parameter allows the user to set a custom filename prefix. The standard filename is tcplPlot_sysDate().output (example: tcplPlot_2023_08_02.jpg) or, if `by` parameter is set, tcplPlot_sysDate()_by.output (example: tcplPlot_2023_08_02_aeid_80.pdf). When a `fileprefix` is assigned the default _tcplPlot_ prefix is replaced with the new filename. (example: myplot_2023_08_02_aeid_80.pdf or myplot_2023_08_02.jpg). + +- The `nrow` parameter specifies the number of rows for the multiple plots per page; this is 2 by default. The `ncol` parameter specifies the number of columns for the multiple plots per page; this is 3 by default. If `verbose = FALSE`, `ncol` is 2. `nrow` and `ncol` can customize the number of plots included per page. Both `nrow` and `ncol` must be greater than 0. While there is no hard coded upper limit to the number of rows and columns, the underlying technology has a dimension limitation of `nrow = 9` and `ncol = 7`. + +- The `dpi` parameter specifies image print resolution for image file output types (PNG, JPG, TIFF, SVG); this is 600 by default. + +The following examples demonstrate tcplPlot functionality through available the variety of customization options: + +```{r, include=FALSE} +end_vignette() +``` \ No newline at end of file diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json new file mode 100644 index 00000000..39709efb --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/assay.json @@ -0,0 +1,109160 @@ +[ + { + "aeid": 2574, + "assayComponentEndpointName": "ERF_CR_ENZ_hELANE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hELANE was analyzed at the assay endpoint, ERF_CR_ENZ_hELANE, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ELANE. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine peptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3',4'dichloroisocoumarin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine peptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2527, + "assayComponentName": "ERF_CR_ENZ_hELANE", + "assayComponentDesc": "ERF_CR_ENZ_hELANE is an assay component calculated from the ERF_CR_ENZ_hELANE assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by absorbance with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in absorbance produced from the regulation of catalytic activity reaction involving the key substrate, MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide, are indicative of changes in enzyme function and kinetics related to the gene ELANE.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 729, + "assayName": "ERF_CR_ENZ_hELANE", + "assayDesc": "ERF_CR_ENZ_hELANE is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Neutrophil Elastase Human Chymotrypsin Serine Peptidase Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 111, + "geneName": "elastase, neutrophil expressed", + "description": null, + "geneSymbol": "ELANE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1991, + "officialSymbol": "ELANE", + "officialFullName": "elastase, neutrophil expressed", + "uniprotAccessionNumber": "P08246" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2575, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHA1 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2528, + "assayComponentName": "ERF_CR_ENZ_hEPHA1", + "assayComponentDesc": "ERF_CR_ENZ_hEPHA1 is an assay component calculated from the ERF_CR_ENZ_hEPHA1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl-beta Abeta Abeta AAEEEIYEEIEAKKK, are indicative of changes in receptor function and kinetics related to the gene EPHA1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl-beta Abeta Abeta AAEEEIYEEIEAKKK", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 731, + "assayName": "ERF_CR_ENZ_hEPHA1", + "assayDesc": "ERF_CR_ENZ_hEPHA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See EphA1 Human RTK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 113, + "geneName": "EPH receptor A1", + "description": null, + "geneSymbol": "EPHA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2041, + "officialSymbol": "EPHA1", + "officialFullName": "EPH receptor A1", + "uniprotAccessionNumber": "P21709" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2576, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHA2 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHA2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2529, + "assayComponentName": "ERF_CR_ENZ_hEPHA2", + "assayComponentDesc": "ERF_CR_ENZ_hEPHA2 is an assay component calculated from the ERF_CR_ENZ_hEPHA2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide , are indicative of changes in receptor function and kinetics related to the gene EPHA2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 790, + "assayName": "ERF_CR_ENZ_hEPHA2", + "assayDesc": "ERF_CR_ENZ_hEPHA2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See EphA2 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 110, + "geneName": "EPH receptor A2", + "description": null, + "geneSymbol": "EPHA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1969, + "officialSymbol": "EPHA2", + "officialFullName": "EPH receptor A2", + "uniprotAccessionNumber": "P29317" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2577, + "assayComponentEndpointName": "ERF_CR_ENZ_hEPHB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEPHB2 was analyzed at the assay endpoint, ERF_CR_ENZ_hEPHB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP2", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2530, + "assayComponentName": "ERF_CR_ENZ_hEPHB2", + "assayComponentDesc": "ERF_CR_ENZ_hEPHB2 is an assay component calculated from the ERF_CR_ENZ_hEPHB2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in receptor function and kinetics related to the gene EPHB2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 789, + "assayName": "ERF_CR_ENZ_hEPHB2", + "assayDesc": "ERF_CR_ENZ_hEPHB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See EphB2 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 115, + "geneName": "EPH receptor B2", + "description": null, + "geneSymbol": "EPHB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2048, + "officialSymbol": "EPHB2", + "officialFullName": "EPH receptor B2", + "uniprotAccessionNumber": "P29323" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2578, + "assayComponentEndpointName": "ERF_CR_ENZ_hFGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFGFR1 was analyzed at the assay endpoint, ERF_CR_ENZ_hFGFR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2531, + "assayComponentName": "ERF_CR_ENZ_hFGFR1", + "assayComponentDesc": "ERF_CR_ENZ_hFGFR1 is an assay component calculated from the ERF_CR_ENZ_hFGFR1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD , are indicative of changes in receptor function and kinetics related to the gene FGFR1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 770, + "assayName": "ERF_CR_ENZ_hFGFR1", + "assayDesc": "ERF_CR_ENZ_hFGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FGFR Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 126, + "geneName": "fibroblast growth factor receptor 1", + "description": null, + "geneSymbol": "FGFR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2260, + "officialSymbol": "FGFR1", + "officialFullName": "fibroblast growth factor receptor 1", + "uniprotAccessionNumber": "P11362" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2579, + "assayComponentEndpointName": "ERF_CR_ENZ_hFGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFGFR3 was analyzed at the assay endpoint, ERF_CR_ENZ_hFGFR3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2532, + "assayComponentName": "ERF_CR_ENZ_hFGFR3", + "assayComponentDesc": "ERF_CR_ENZ_hFGFR3 is an assay component calculated from the ERF_CR_ENZ_hFGFR3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene FGFR3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 775, + "assayName": "ERF_CR_ENZ_hFGFR3", + "assayDesc": "ERF_CR_ENZ_hFGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See FGFR3 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 127, + "geneName": "fibroblast growth factor receptor 3", + "description": null, + "geneSymbol": "FGFR3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2261, + "officialSymbol": "FGFR3", + "officialFullName": "fibroblast growth factor receptor 3", + "uniprotAccessionNumber": "P22607" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2580, + "assayComponentEndpointName": "ERF_CR_ENZ_hFLT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFLT1 was analyzed at the assay endpoint, ERF_CR_ENZ_hFLT1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2533, + "assayComponentName": "ERF_CR_ENZ_hFLT1", + "assayComponentDesc": "ERF_CR_ENZ_hFLT1 is an assay component calculated from the ERF_CR_ENZ_hFLT1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in enzyme function and kinetics related to the gene FLT1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 792, + "assayName": "ERF_CR_ENZ_hFLT1", + "assayDesc": "ERF_CR_ENZ_hFLT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Flt-1 (VEGFR1) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 131, + "geneName": "fms-related tyrosine kinase 1", + "description": null, + "geneSymbol": "FLT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2321, + "officialSymbol": "FLT1", + "officialFullName": "fms-related tyrosine kinase 1", + "uniprotAccessionNumber": "P17948" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2581, + "assayComponentEndpointName": "ERF_CR_ENZ_hFLT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFLT4 was analyzed at the assay endpoint, ERF_CR_ENZ_hFLT4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2534, + "assayComponentName": "ERF_CR_ENZ_hFLT4", + "assayComponentDesc": "ERF_CR_ENZ_hFLT4 is an assay component calculated from the ERF_CR_ENZ_hFLT4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene FLT4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 776, + "assayName": "ERF_CR_ENZ_hFLT4", + "assayDesc": "ERF_CR_ENZ_hFLT4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See FLT4 Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 132, + "geneName": "fms-related tyrosine kinase 4", + "description": null, + "geneSymbol": "FLT4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2324, + "officialSymbol": "FLT4", + "officialFullName": "fms-related tyrosine kinase 4", + "uniprotAccessionNumber": "P35916" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2582, + "assayComponentEndpointName": "ERF_CR_ENZ_hFYN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hFYN was analyzed at the assay endpoint, ERF_CR_ENZ_hFYN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2535, + "assayComponentName": "ERF_CR_ENZ_hFYN", + "assayComponentDesc": "ERF_CR_ENZ_hFYN is an assay component calculated from the ERF_CR_ENZ_hFYN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl-beta Abeta Abeta AYQAEENTYDEYEN, are indicative of changes in enzyme function and kinetics related to the gene FYN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl-beta Abeta Abeta AYQAEENTYDEYEN", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 747, + "assayName": "ERF_CR_ENZ_hFYN", + "assayDesc": "ERF_CR_ENZ_hFYN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Fyn Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 137, + "geneName": "FYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "FYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2534, + "officialSymbol": "FYN", + "officialFullName": "FYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06241" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2583, + "assayComponentEndpointName": "ERF_CR_ENZ_hGSK3b", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hGSK3b was analyzed at the assay endpoint, ERF_CR_ENZ_hGSK3b, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene GSK3B. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2536, + "assayComponentName": "ERF_CR_ENZ_hGSK3b", + "assayComponentDesc": "ERF_CR_ENZ_hGSK3b is an assay component calculated from the ERF_CR_ENZ_hGSK3b assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide , are indicative of changes in enzyme function and kinetics related to the gene GSK3B.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 773, + "assayName": "ERF_CR_ENZ_hGSK3b", + "assayDesc": "ERF_CR_ENZ_hGSK3b is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See GSK3beta Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 146, + "geneName": "glycogen synthase kinase 3 beta", + "description": null, + "geneSymbol": "GSK3B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2932, + "officialSymbol": "GSK3B", + "officialFullName": "glycogen synthase kinase 3 beta", + "uniprotAccessionNumber": "P49841" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2584, + "assayComponentEndpointName": "ERF_CR_ENZ_hHDAC6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hHDAC6 was analyzed at the assay endpoint, ERF_CR_ENZ_hHDAC6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene HDAC6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "epigenetic enzyme", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2537, + "assayComponentName": "ERF_CR_ENZ_hHDAC6", + "assayComponentDesc": "ERF_CR_ENZ_hHDAC6 is an assay component calculated from the ERF_CR_ENZ_hHDAC6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, fluorogenic HDAC substrate, are indicative of changes in enzyme function and kinetics related to the gene HDAC6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorogenic HDAC substrate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 756, + "assayName": "ERF_CR_ENZ_hHDAC6", + "assayDesc": "ERF_CR_ENZ_hHDAC6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See HDAC6 Human Histone Deacetylase (HDAC) Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 361, + "geneName": "histone deacetylase 6", + "description": null, + "geneSymbol": "HDAC6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10013, + "officialSymbol": "HDAC6", + "officialFullName": "histone deacetylase 6", + "uniprotAccessionNumber": "Q9UBN7" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2585, + "assayComponentEndpointName": "ERF_CR_ENZ_hIRAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hIRAK4 was analyzed at the assay endpoint, ERF_CR_ENZ_hIRAK4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene IRAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2538, + "assayComponentName": "ERF_CR_ENZ_hIRAK4", + "assayComponentDesc": "ERF_CR_ENZ_hIRAK4 is an assay component calculated from the ERF_CR_ENZ_hIRAK4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-FLGFTYVAP, are indicative of changes in enzyme function and kinetics related to the gene IRAK4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-FLGFTYVAP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 784, + "assayName": "ERF_CR_ENZ_hIRAK4", + "assayDesc": "ERF_CR_ENZ_hIRAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See IRAK4 Human TKL Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 425, + "geneName": "interleukin-1 receptor-associated kinase 4", + "description": null, + "geneSymbol": "IRAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51135, + "officialSymbol": "IRAK4", + "officialFullName": "interleukin-1 receptor-associated kinase 4", + "uniprotAccessionNumber": "Q9NWZ3" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2586, + "assayComponentEndpointName": "ERF_CR_ENZ_hJAK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hJAK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hJAK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene JAK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2539, + "assayComponentName": "ERF_CR_ENZ_hJAK2", + "assayComponentDesc": "ERF_CR_ENZ_hJAK2 is an assay component calculated from the ERF_CR_ENZ_hJAK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene JAK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 771, + "assayName": "ERF_CR_ENZ_hJAK2", + "assayDesc": "ERF_CR_ENZ_hJAK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See JAK2 Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 182, + "geneName": "Janus kinase 2", + "description": null, + "geneSymbol": "JAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3717, + "officialSymbol": "JAK2", + "officialFullName": "Janus kinase 2", + "uniprotAccessionNumber": "O60674" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2587, + "assayComponentEndpointName": "ERF_CR_ENZ_hKDR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hKDR was analyzed at the assay endpoint, ERF_CR_ENZ_hKDR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene KDR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2540, + "assayComponentName": "ERF_CR_ENZ_hKDR", + "assayComponentDesc": "ERF_CR_ENZ_hKDR is an assay component calculated from the ERF_CR_ENZ_hKDR assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene KDR.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 767, + "assayName": "ERF_CR_ENZ_hKDR", + "assayDesc": "ERF_CR_ENZ_hKDR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See KDR (VEGFR2) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2588, + "assayComponentEndpointName": "ERF_CR_ENZ_hLCK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hLCK was analyzed at the assay endpoint, ERF_CR_ENZ_hLCK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LCK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2541, + "assayComponentName": "ERF_CR_ENZ_hLCK", + "assayComponentDesc": "ERF_CR_ENZ_hLCK is an assay component calculated from the ERF_CR_ENZ_hLCK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene LCK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 778, + "assayName": "ERF_CR_ENZ_hLCK", + "assayDesc": "ERF_CR_ENZ_hLCK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Lck Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 188, + "geneName": "LCK proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LCK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3932, + "officialSymbol": "LCK", + "officialFullName": "LCK proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06239" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2589, + "assayComponentEndpointName": "ERF_CR_ENZ_hLYN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hLYN was analyzed at the assay endpoint, ERF_CR_ENZ_hLYN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2542, + "assayComponentName": "ERF_CR_ENZ_hLYN", + "assayComponentDesc": "ERF_CR_ENZ_hLYN is an assay component calculated from the ERF_CR_ENZ_hLYN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + His-tagged Rb truncated protein, are indicative of changes in enzyme function and kinetics related to the gene LYN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + His-tagged Rb truncated protein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 750, + "assayName": "ERF_CR_ENZ_hLYN", + "assayDesc": "ERF_CR_ENZ_hLYN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See LYN (B) Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2590, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAOA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAOA was analyzed at the assay endpoint, ERF_CR_ENZ_hMAOA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "clorgiline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2543, + "assayComponentName": "ERF_CR_ENZ_hMAOA", + "assayComponentDesc": "ERF_CR_ENZ_hMAOA is an assay component calculated from the ERF_CR_ENZ_hMAOA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, kynuramine, are indicative of changes in enzyme function and kinetics related to the gene MAOA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "kynuramine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 732, + "assayName": "ERF_CR_ENZ_hMAOA", + "assayDesc": "ERF_CR_ENZ_hMAOA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See Monoamine Oxidase A (MAO-A) Human Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4645, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "MAOA", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 4128, + "officialSymbol": "MAOA", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2591, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAOB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAOB was analyzed at the assay endpoint, ERF_CR_ENZ_hMAOB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "deprenyl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2544, + "assayComponentName": "ERF_CR_ENZ_hMAOB", + "assayComponentDesc": "ERF_CR_ENZ_hMAOB is an assay component calculated from the ERF_CR_ENZ_hMAOB assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by luminescent intensity with luminescence technology.", + "assayComponentTargetDesc": "Changes in luminescent intensity produced from the regulation of catalytic activity reaction involving the key substrate, D-Luciferin derivative, are indicative of changes in enzyme function and kinetics related to the gene MAOB.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "Luciferase", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "D-Luciferin derivative", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 800, + "assayName": "ERF_CR_ENZ_hMAOB", + "assayDesc": "ERF_CR_ENZ_hMAOB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Monoamine Oxidase B (MAO-B) Human Enzymatic Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4646, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "MAOB", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 4129, + "officialSymbol": "MAOB", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2592, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAPK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAPK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMAPK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2545, + "assayComponentName": "ERF_CR_ENZ_hMAPK1", + "assayComponentDesc": "ERF_CR_ENZ_hMAPK1 is an assay component calculated from the ERF_CR_ENZ_hMAPK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene MAPK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 772, + "assayName": "ERF_CR_ENZ_hMAPK1", + "assayDesc": "ERF_CR_ENZ_hMAPK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See ERK2 (MAPK1) Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 259, + "geneName": "mitogen-activated protein kinase 1", + "description": null, + "geneSymbol": "MAPK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5594, + "officialSymbol": "MAPK1", + "officialFullName": "mitogen-activated protein kinase 1", + "uniprotAccessionNumber": "P28482" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2593, + "assayComponentEndpointName": "ERF_KP_ENZ_hMAPK11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hMAPK11 was analyzed at the assay endpoint, ERF_KP_ENZ_hMAPK11, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PP1 Analog II. 1NM-PP1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2546, + "assayComponentName": "ERF_KP_ENZ_hMAPK11", + "assayComponentDesc": "ERF_KP_ENZ_hMAPK11 is an assay component calculated from the ERF_KP_ENZ_hMAPK11 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, myelin basic protein, are indicative of changes in enzyme function and kinetics related to the gene MAPK11.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "myelin basic protein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 701, + "assayName": "ERF_KP_ENZ_hMAPK11", + "assayDesc": "ERF_KP_ENZ_hMAPK11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See SAPK2 (p38beta) Human CMGC Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 261, + "geneName": "mitogen-activated protein kinase 11", + "description": null, + "geneSymbol": "MAPK11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5600, + "officialSymbol": "MAPK11", + "officialFullName": "mitogen-activated protein kinase 11", + "uniprotAccessionNumber": "Q15759" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2594, + "assayComponentEndpointName": "ERF_CR_ENZ_hMAPKAPK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMAPKAPK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hMAPKAPK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2547, + "assayComponentName": "ERF_CR_ENZ_hMAPKAPK2", + "assayComponentDesc": "ERF_CR_ENZ_hMAPKAPK2 is an assay component calculated from the ERF_CR_ENZ_hMAPKAPK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + CREBtide, are indicative of changes in enzyme function and kinetics related to the gene MAPKAPK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + CREBtide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 799, + "assayName": "ERF_CR_ENZ_hMAPKAPK2", + "assayDesc": "ERF_CR_ENZ_hMAPKAPK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See MAPKAPK2 Human CAMK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 352, + "geneName": "mitogen-activated protein kinase-activated protein kinase 2", + "description": null, + "geneSymbol": "MAPKAPK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9261, + "officialSymbol": "MAPKAPK2", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 2", + "uniprotAccessionNumber": "P49137" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2595, + "assayComponentEndpointName": "ERF_PL_ENZ_hMAPKAPK5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hMAPKAPK5 was analyzed at the assay endpoint, ERF_PL_ENZ_hMAPKAPK5, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2548, + "assayComponentName": "ERF_PL_ENZ_hMAPKAPK5", + "assayComponentDesc": "ERF_PL_ENZ_hMAPKAPK5 is an assay component calculated from the ERF_PL_ENZ_hMAPKAPK5 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, PRAK substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene MAPKAPK5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "PRAK substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 725, + "assayName": "ERF_PL_ENZ_hMAPKAPK5", + "assayDesc": "ERF_PL_ENZ_hMAPKAPK5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PRAK Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 343, + "geneName": "mitogen-activated protein kinase-activated protein kinase 5", + "description": null, + "geneSymbol": "MAPKAPK5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8550, + "officialSymbol": "MAPKAPK5", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 5", + "uniprotAccessionNumber": "Q8IW41" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2596, + "assayComponentEndpointName": "ERF_CR_ENZ_hMARK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMARK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMARK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MARK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2549, + "assayComponentName": "ERF_CR_ENZ_hMARK1", + "assayComponentDesc": "ERF_CR_ENZ_hMARK1 is an assay component calculated from the ERF_CR_ENZ_hMARK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene MARK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 796, + "assayName": "ERF_CR_ENZ_hMARK1", + "assayDesc": "ERF_CR_ENZ_hMARK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See MARK1 Human CAMK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 198, + "geneName": "MAP/microtubule affinity-regulating kinase 1", + "description": null, + "geneSymbol": "MARK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4139, + "officialSymbol": "MARK1", + "officialFullName": "MAP/microtubule affinity-regulating kinase 1", + "uniprotAccessionNumber": "Q9P0L2" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2597, + "assayComponentEndpointName": "ERF_CR_ENZ_hMET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMET was analyzed at the assay endpoint, ERF_CR_ENZ_hMET, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MET. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2550, + "assayComponentName": "ERF_CR_ENZ_hMET", + "assayComponentDesc": "ERF_CR_ENZ_hMET is an assay component calculated from the ERF_CR_ENZ_hMET assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene MET.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 769, + "assayName": "ERF_CR_ENZ_hMET", + "assayDesc": "ERF_CR_ENZ_hMET is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Met Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 200, + "geneName": "MET proto-oncogene, receptor tyrosine kinase", + "description": null, + "geneSymbol": "MET", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4233, + "officialSymbol": "MET", + "officialFullName": "MET proto-oncogene, receptor tyrosine kinase", + "uniprotAccessionNumber": "P08581" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2598, + "assayComponentEndpointName": "ERF_CR_ENZ_hMMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMMP3 was analyzed at the assay endpoint, ERF_CR_ENZ_hMMP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ilomastat", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metallopeptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2551, + "assayComponentName": "ERF_CR_ENZ_hMMP3", + "assayComponentDesc": "ERF_CR_ENZ_hMMP3 is an assay component calculated from the ERF_CR_ENZ_hMMP3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, NFF-2 , are indicative of changes in enzyme function and kinetics related to the gene MMP3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NFF-2 ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 823, + "assayName": "ERF_CR_ENZ_hMMP3", + "assayDesc": "ERF_CR_ENZ_hMMP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See MMP3 Human Matrix Metallopeptidase Enzymatic Assay, Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2599, + "assayComponentEndpointName": "ERF_CR_ENZ_hMMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMMP9 was analyzed at the assay endpoint, ERF_CR_ENZ_hMMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ilomastat", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metallopeptidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2552, + "assayComponentName": "ERF_CR_ENZ_hMMP9", + "assayComponentDesc": "ERF_CR_ENZ_hMMP9 is an assay component calculated from the ERF_CR_ENZ_hMMP9 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, NFF-2 , are indicative of changes in enzyme function and kinetics related to the gene MMP9.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NFF-2 ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 824, + "assayName": "ERF_CR_ENZ_hMMP9", + "assayDesc": "ERF_CR_ENZ_hMMP9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See MMP9 Human Matrix Metallopeptidase Enzymatic Assay, Cerep.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2600, + "assayComponentEndpointName": "ERF_CR_ENZ_hMSK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hMSK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hMSK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MSK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2553, + "assayComponentName": "ERF_CR_ENZ_hMSK1", + "assayComponentDesc": "ERF_CR_ENZ_hMSK1 is an assay component calculated from the ERF_CR_ENZ_hMSK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, Histone H3 full length, are indicative of changes in enzyme function and kinetics related to the gene RPS6KA5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Histone H3 full length", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 805, + "assayName": "ERF_CR_ENZ_hMSK1", + "assayDesc": "ERF_CR_ENZ_hMSK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See MSK1 Human AGC Kinase Enzymatic Radiometric Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 351, + "geneName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "description": null, + "geneSymbol": "RPS6KA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9252, + "officialSymbol": "RPS6KA5", + "officialFullName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "uniprotAccessionNumber": "O75582" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2601, + "assayComponentEndpointName": "ERF_CR_ENZ_hNEK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hNEK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hNEK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NEK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2554, + "assayComponentName": "ERF_CR_ENZ_hNEK2", + "assayComponentDesc": "ERF_CR_ENZ_hNEK2 is an assay component calculated from the ERF_CR_ENZ_hNEK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-FLGFTYVAP, are indicative of changes in enzyme function and kinetics related to the gene NEK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-FLGFTYVAP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 785, + "assayName": "ERF_CR_ENZ_hNEK2", + "assayDesc": "ERF_CR_ENZ_hNEK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NEK2 Human Other Protein Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 215, + "geneName": "NIMA-related kinase 2", + "description": null, + "geneSymbol": "NEK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4751, + "officialSymbol": "NEK2", + "officialFullName": "NIMA-related kinase 2", + "uniprotAccessionNumber": "P51955" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2602, + "assayComponentEndpointName": "ERF_CR_ENZ_hNTRK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hNTRK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hNTRK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NTRK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2555, + "assayComponentName": "ERF_CR_ENZ_hNTRK1", + "assayComponentDesc": "ERF_CR_ENZ_hNTRK1 is an assay component calculated from the ERF_CR_ENZ_hNTRK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene NTRK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 777, + "assayName": "ERF_CR_ENZ_hNTRK1", + "assayDesc": "ERF_CR_ENZ_hNTRK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See TRKA Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 222, + "geneName": "neurotrophic tyrosine kinase, receptor, type 1", + "description": null, + "geneSymbol": "NTRK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4914, + "officialSymbol": "NTRK1", + "officialFullName": "neurotrophic tyrosine kinase, receptor, type 1", + "uniprotAccessionNumber": "P04629" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2603, + "assayComponentEndpointName": "ERF_CR_ENZ_hPAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPAK4 was analyzed at the assay endpoint, ERF_CR_ENZ_hPAK4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2556, + "assayComponentName": "ERF_CR_ENZ_hPAK4", + "assayComponentDesc": "ERF_CR_ENZ_hPAK4 is an assay component calculated from the ERF_CR_ENZ_hPAK4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene PAK4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 797, + "assayName": "ERF_CR_ENZ_hPAK4", + "assayDesc": "ERF_CR_ENZ_hPAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PAK4 Human STE Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 364, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "description": null, + "geneSymbol": "PAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10298, + "officialSymbol": "PAK4", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "uniprotAccessionNumber": "O96013" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2604, + "assayComponentEndpointName": "ERF_CR_ENZ_hPDE10A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPDE10A was analyzed at the assay endpoint, ERF_CR_ENZ_hPDE10A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE10A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "papaverine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2557, + "assayComponentName": "ERF_CR_ENZ_hPDE10A", + "assayComponentDesc": "ERF_CR_ENZ_hPDE10A is an assay component calculated from the ERF_CR_ENZ_hPDE10A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE10A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 813, + "assayName": "ERF_CR_ENZ_hPDE10A", + "assayDesc": "ERF_CR_ENZ_hPDE10A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE10A2 Human Phosphodiesterase Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2605, + "assayComponentEndpointName": "ERF_CR_ENZ_hPDE4A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPDE4A was analyzed at the assay endpoint, ERF_CR_ENZ_hPDE4A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 20-1724", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2558, + "assayComponentName": "ERF_CR_ENZ_hPDE4A", + "assayComponentDesc": "ERF_CR_ENZ_hPDE4A is an assay component calculated from the ERF_CR_ENZ_hPDE4A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE4A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 811, + "assayName": "ERF_CR_ENZ_hPDE4A", + "assayDesc": "ERF_CR_ENZ_hPDE4A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE4A1A Human Phosphodiesterase Enzymatic Assay, Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 232, + "geneName": "phosphodiesterase 4A, cAMP-specific", + "description": null, + "geneSymbol": "PDE4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5141, + "officialSymbol": "PDE4A", + "officialFullName": "phosphodiesterase 4A, cAMP-specific", + "uniprotAccessionNumber": "P27815" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2606, + "assayComponentEndpointName": "ERF_PL_ENZ_hPDE4D2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPDE4D2 was analyzed at the assay endpoint, ERF_PL_ENZ_hPDE4D2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rolipram", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2559, + "assayComponentName": "ERF_PL_ENZ_hPDE4D2", + "assayComponentDesc": "ERF_PL_ENZ_hPDE4D2 is an assay component calculated from the ERF_PL_ENZ_hPDE4D2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, FAM-cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE4D.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "FAM-cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 712, + "assayName": "ERF_PL_ENZ_hPDE4D2", + "assayDesc": "ERF_PL_ENZ_hPDE4D2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PDE4D2 Human Phosphodiesterase Enzymatic Assay, Panlabs.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5360, + "geneName": "phosphodiesterase 4D", + "description": null, + "geneSymbol": "PDE4D", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5144, + "officialSymbol": "PDE4D", + "officialFullName": "phosphodiesterase 4D", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2607, + "assayComponentEndpointName": "ERF_KP_ENZ_hPKD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hPKD2 was analyzed at the assay endpoint, ERF_KP_ENZ_hPKD2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2560, + "assayComponentName": "ERF_KP_ENZ_hPKD2", + "assayComponentDesc": "ERF_KP_ENZ_hPKD2 is an assay component calculated from the ERF_KP_ENZ_hPKD2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, KKLNRTLSVA, are indicative of changes in enzyme function and kinetics related to the gene PRKD2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "KKLNRTLSVA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 702, + "assayName": "ERF_KP_ENZ_hPKD2", + "assayDesc": "ERF_KP_ENZ_hPKD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See PKD2 Human Protein Ser/Thr Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 416, + "geneName": "protein kinase D2", + "description": null, + "geneSymbol": "PRKD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25865, + "officialSymbol": "PRKD2", + "officialFullName": "protein kinase D2", + "uniprotAccessionNumber": "Q9BZL6" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2608, + "assayComponentEndpointName": "ERF_KP_ENZ_hPRKAA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_KP_ENZ_hPRKAA1 was analyzed at the assay endpoint, ERF_KP_ENZ_hPRKAA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKAA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2561, + "assayComponentName": "ERF_KP_ENZ_hPRKAA1", + "assayComponentDesc": "ERF_KP_ENZ_hPRKAA1 is an assay component calculated from the ERF_KP_ENZ_hPRKAA1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, AMARAASAAALAR, are indicative of changes in enzyme function and kinetics related to the gene PRKAA1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "AMARAASAAALAR", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 705, + "assayName": "ERF_KP_ENZ_hPRKAA1", + "assayDesc": "ERF_KP_ENZ_hPRKAA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See AMPKalpha1 Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], KinaseProfiler.", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 255, + "geneName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "description": null, + "geneSymbol": "PRKAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5562, + "officialSymbol": "PRKAA1", + "officialFullName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "uniprotAccessionNumber": "Q13131" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2609, + "assayComponentEndpointName": "ERF_PL_ENZ_hPRKACA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPRKACA was analyzed at the assay endpoint, ERF_PL_ENZ_hPRKACA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKACA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1-(5-ISOQUINOLINESULFONYL)-2-M", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2562, + "assayComponentName": "ERF_PL_ENZ_hPRKACA", + "assayComponentDesc": "ERF_PL_ENZ_hPRKACA is an assay component calculated from the ERF_PL_ENZ_hPRKACA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, PKA substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene PRKACA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "PKA substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 727, + "assayName": "ERF_PL_ENZ_hPRKACA", + "assayDesc": "ERF_PL_ENZ_hPRKACA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PKA Human AGC Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 256, + "geneName": "protein kinase, cAMP-dependent, catalytic, alpha", + "description": null, + "geneSymbol": "PRKACA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5566, + "officialSymbol": "PRKACA", + "officialFullName": "protein kinase, cAMP-dependent, catalytic, alpha", + "uniprotAccessionNumber": "P17612" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2610, + "assayComponentEndpointName": "ERF_PL_ENZ_hPRKCZ", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPRKCZ was analyzed at the assay endpoint, ERF_PL_ENZ_hPRKCZ, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKCZ. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2563, + "assayComponentName": "ERF_PL_ENZ_hPRKCZ", + "assayComponentDesc": "ERF_PL_ENZ_hPRKCZ is an assay component calculated from the ERF_PL_ENZ_hPRKCZ assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, histone, are indicative of changes in enzyme function and kinetics related to the gene PRKCZ.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "histone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 730, + "assayName": "ERF_PL_ENZ_hPRKCZ", + "assayDesc": "ERF_PL_ENZ_hPRKCZ is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PKCzeta Human PKC Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 258, + "geneName": "protein kinase C, zeta", + "description": null, + "geneSymbol": "PRKCZ", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5590, + "officialSymbol": "PRKCZ", + "officialFullName": "protein kinase C, zeta", + "uniprotAccessionNumber": "Q05513" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2611, + "assayComponentEndpointName": "ERF_PL_ENZ_hPTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPTEN was analyzed at the assay endpoint, ERF_PL_ENZ_hPTEN, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTEN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(NH4)6Mo7O24", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2564, + "assayComponentName": "ERF_PL_ENZ_hPTEN", + "assayComponentDesc": "ERF_PL_ENZ_hPTEN is an assay component calculated from the ERF_PL_ENZ_hPTEN assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, DiFMUP, are indicative of changes in enzyme function and kinetics related to the gene PTEN.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DiFMUP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 733, + "assayName": "ERF_PL_ENZ_hPTEN", + "assayDesc": "ERF_PL_ENZ_hPTEN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See PTEN Human Phosphatase Enzymatic Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2612, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTGS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTGS2 was analyzed at the assay endpoint, ERF_CR_ENZ_hPTGS2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTGS2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ns-398", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "stress response", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2565, + "assayComponentName": "ERF_CR_ENZ_hPTGS2", + "assayComponentDesc": "ERF_CR_ENZ_hPTGS2 is an assay component calculated from the ERF_CR_ENZ_hPTGS2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate;substrate, arachidonic acid; ADHP, are indicative of changes in enzyme function and kinetics related to the gene PTGS2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid; ADHP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 817, + "assayName": "ERF_CR_ENZ_hPTGS2", + "assayDesc": "ERF_CR_ENZ_hPTGS2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.083 hour after chemical dosing in a 96-well plate. See COX2 Human Cyclooxygenase Enzymatic Assay, Cerep.", + "timepointHr": 0.083, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5831, + "geneName": "prostaglandin-endoperoxide synthase 2", + "description": null, + "geneSymbol": "PTGS2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5743, + "officialSymbol": "PTGS2", + "officialFullName": "prostaglandin-endoperoxide synthase 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2613, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTPN11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTPN11 was analyzed at the assay endpoint, ERF_CR_ENZ_hPTPN11, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPN11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "protein tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2566, + "assayComponentName": "ERF_CR_ENZ_hPTPN11", + "assayComponentDesc": "ERF_CR_ENZ_hPTPN11 is an assay component calculated from the ERF_CR_ENZ_hPTPN11 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-4, are indicative of changes in enzyme function and kinetics related to the gene PTPN11.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 704, + "assayName": "ERF_CR_ENZ_hPTPN11", + "assayDesc": "ERF_PL_ENZ_hPTPN11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See SHP2 Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 270, + "geneName": "protein tyrosine phosphatase, non-receptor type 11", + "description": null, + "geneSymbol": "PTPN11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5781, + "officialSymbol": "PTPN11", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 11", + "uniprotAccessionNumber": "Q06124" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2614, + "assayComponentEndpointName": "ERF_CR_ENZ_hPTPRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hPTPRB was analyzed at the assay endpoint, ERF_CR_ENZ_hPTPRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTPRB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "protein tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2567, + "assayComponentName": "ERF_CR_ENZ_hPTPRB", + "assayComponentDesc": "ERF_CR_ENZ_hPTPRB is an assay component calculated from the ERF_CR_ENZ_hPTPRB assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-5, are indicative of changes in enzyme function and kinetics related to the gene PTPRB.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-5", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 706, + "assayName": "ERF_CR_ENZ_hPTPRB", + "assayDesc": "ERF_PL_ENZ_hPTPRB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See PTPbeta Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 274, + "geneName": "protein tyrosine phosphatase, receptor type, B", + "description": null, + "geneSymbol": "PTPRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5787, + "officialSymbol": "PTPRB", + "officialFullName": "protein tyrosine phosphatase, receptor type, B", + "uniprotAccessionNumber": "P23467" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2615, + "assayComponentEndpointName": "ERF_PL_ENZ_hPTPRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hPTPRF was analyzed at the assay endpoint, ERF_PL_ENZ_hPTPRF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPRF. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(NH4)6Mo7O24", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2568, + "assayComponentName": "ERF_PL_ENZ_hPTPRF", + "assayComponentDesc": "ERF_PL_ENZ_hPTPRF is an assay component calculated from the ERF_PL_ENZ_hPTPRF assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, DiFMUP, are indicative of changes in enzyme function and kinetics related to the gene PTPRF.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DiFMUP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 734, + "assayName": "ERF_PL_ENZ_hPTPRF", + "assayDesc": "ERF_PL_ENZ_hPTPRF is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See LAR Human Phosphatase Enzymatic Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 276, + "geneName": "protein tyrosine phosphatase, receptor type, F", + "description": null, + "geneSymbol": "PTPRF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5792, + "officialSymbol": "PTPRF", + "officialFullName": "protein tyrosine phosphatase, receptor type, F", + "uniprotAccessionNumber": "P10586" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2617, + "assayComponentEndpointName": "ERF_CR_ENZ_hRAF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hRAF1 was analyzed at the assay endpoint, ERF_CR_ENZ_hRAF1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene RAF1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2570, + "assayComponentName": "ERF_CR_ENZ_hRAF1", + "assayComponentDesc": "ERF_CR_ENZ_hRAF1 is an assay component calculated from the ERF_CR_ENZ_hRAF1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + inactive MEK1, are indicative of changes in enzyme function and kinetics related to the gene RAF1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + inactive MEK1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 724, + "assayName": "ERF_CR_ENZ_hRAF1", + "assayDesc": "ERF_CR_ENZ_hRAF1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See c-Raf (Raf-1) Human TKL Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 278, + "geneName": "Raf-1 proto-oncogene, serine/threonine kinase", + "description": null, + "geneSymbol": "RAF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5894, + "officialSymbol": "RAF1", + "officialFullName": "Raf-1 proto-oncogene, serine/threonine kinase", + "uniprotAccessionNumber": "P04049" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2618, + "assayComponentEndpointName": "ERF_CR_ENZ_hROCK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hROCK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hROCK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ROCK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2571, + "assayComponentName": "ERF_CR_ENZ_hROCK1", + "assayComponentDesc": "ERF_CR_ENZ_hROCK1 is an assay component calculated from the ERF_CR_ENZ_hROCK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene ROCK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 798, + "assayName": "ERF_CR_ENZ_hROCK1", + "assayDesc": "ERF_CR_ENZ_hROCK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See ROCK1 Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 283, + "geneName": "Rho-associated, coiled-coil containing protein kinase 1", + "description": null, + "geneSymbol": "ROCK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6093, + "officialSymbol": "ROCK1", + "officialFullName": "Rho-associated, coiled-coil containing protein kinase 1", + "uniprotAccessionNumber": "Q13464" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2619, + "assayComponentEndpointName": "ERF_CR_ENZ_hSGK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSGK1 was analyzed at the assay endpoint, ERF_CR_ENZ_hSGK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SGK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2572, + "assayComponentName": "ERF_CR_ENZ_hSGK1", + "assayComponentDesc": "ERF_CR_ENZ_hSGK1 is an assay component calculated from the ERF_CR_ENZ_hSGK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE , are indicative of changes in enzyme function and kinetics related to the gene SGK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 783, + "assayName": "ERF_CR_ENZ_hSGK1", + "assayDesc": "ERF_CR_ENZ_hSGK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See SGK1 Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 295, + "geneName": "serum/glucocorticoid regulated kinase 1", + "description": null, + "geneSymbol": "SGK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6446, + "officialSymbol": "SGK1", + "officialFullName": "serum/glucocorticoid regulated kinase 1", + "uniprotAccessionNumber": "O00141" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2620, + "assayComponentEndpointName": "ERF_CR_ENZ_hSIRT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSIRT3 was analyzed at the assay endpoint, ERF_CR_ENZ_hSIRT3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SIRT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nicotinamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "epigenetic enzyme", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2573, + "assayComponentName": "ERF_CR_ENZ_hSIRT3", + "assayComponentDesc": "ERF_CR_ENZ_hSIRT3 is an assay component calculated from the ERF_CR_ENZ_hSIRT3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, fluoro-lysine sirtuin 2 deacetylase substrate, are indicative of changes in enzyme function and kinetics related to the gene SIRT3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluoro-lysine sirtuin 2 deacetylase substrate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 761, + "assayName": "ERF_CR_ENZ_hSIRT3", + "assayDesc": "ERF_CR_ENZ_hSIRT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate. See Sirtuin 3 Human Histone Deacetylase (HDAC) Enzymatic Antagonist Assay, Cerep.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 376, + "geneName": "sirtuin 3", + "description": null, + "geneSymbol": "SIRT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23410, + "officialSymbol": "SIRT3", + "officialFullName": "sirtuin 3", + "uniprotAccessionNumber": "Q9NTG7" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2621, + "assayComponentEndpointName": "ERF_CR_ENZ_hSRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSRC was analyzed at the assay endpoint, ERF_CR_ENZ_hSRC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SRC. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2574, + "assayComponentName": "ERF_CR_ENZ_hSRC", + "assayComponentDesc": "ERF_CR_ENZ_hSRC is an assay component calculated from the ERF_CR_ENZ_hSRC assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-Poly GAT[EAY(1:1:1)]n, are indicative of changes in enzyme function and kinetics related to the gene SRC.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-Poly GAT[EAY(1:1:1)]n", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 779, + "assayName": "ERF_CR_ENZ_hSRC", + "assayDesc": "ERF_CR_ENZ_hSRC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Src Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2622, + "assayComponentEndpointName": "ERF_CR_ENZ_hSYK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hSYK was analyzed at the assay endpoint, ERF_CR_ENZ_hSYK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SYK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is spleen tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "spleen tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2575, + "assayComponentName": "ERF_CR_ENZ_hSYK", + "assayComponentDesc": "ERF_CR_ENZ_hSYK is an assay component calculated from the ERF_CR_ENZ_hSYK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in enzyme function and kinetics related to the gene SYK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 765, + "assayName": "ERF_CR_ENZ_hSYK", + "assayDesc": "ERF_CR_ENZ_hSYK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Syk Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 308, + "geneName": "spleen tyrosine kinase", + "description": null, + "geneSymbol": "SYK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6850, + "officialSymbol": "SYK", + "officialFullName": "spleen tyrosine kinase", + "uniprotAccessionNumber": "P43405" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2623, + "assayComponentEndpointName": "ERF_CR_ENZ_hZAP70", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hZAP70 was analyzed at the assay endpoint, ERF_CR_ENZ_hZAP70, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ZAP70. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is protein tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "protein tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2576, + "assayComponentName": "ERF_CR_ENZ_hZAP70", + "assayComponentDesc": "ERF_CR_ENZ_hZAP70 is an assay component calculated from the ERF_CR_ENZ_hZAP70 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + biotinyl- beta Abeta Abeta ADEEEYFIPP, are indicative of changes in enzyme function and kinetics related to the gene ZAP70.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + biotinyl- beta Abeta Abeta ADEEEYFIPP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 832, + "assayName": "ERF_CR_ENZ_hZAP70", + "assayDesc": "ERF_CR_ENZ_hZAP70 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See ZAP70 Human TK Kinase Enzymatic HTRF Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 338, + "geneName": "zeta-chain (TCR) associated protein kinase 70kDa", + "description": null, + "geneSymbol": "ZAP70", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7535, + "officialSymbol": "ZAP70", + "officialFullName": "zeta-chain (TCR) associated protein kinase 70kDa", + "uniprotAccessionNumber": "P43403" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2624, + "assayComponentEndpointName": "ERF_CR_ENZ_rACFSK_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_rACFSK_Agonist was analyzed at the assay endpoint, ERF_CR_ENZ_rACFSK_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cAMP", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2577, + "assayComponentName": "ERF_CR_ENZ_rACFSK_Agonist", + "assayComponentDesc": "ERF_CR_ENZ_rACFSK_Agonist is an assay component calculated from the ERF_CR_ENZ_rACFSK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand, [3H]-forskolin, are indicative of changes in enzyme function and kinetics related to the gene ADCY5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 786, + "assayName": "ERF_CR_ENZ_rACFSK_Agonist", + "assayDesc": "ERF_CR_ENZ_rACFSK_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Adenylyl Cyclase Hamster Enzymatic Agonist Assay, Cerep.", + "timepointHr": 0.16, + "organismId": null, + "organism": "hamster", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2625, + "assayComponentEndpointName": "ERF_CR_ENZ_rACFSK_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_rACFSK_Antagonist was analyzed at the assay endpoint, ERF_CR_ENZ_rACFSK_Antagonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cAMP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2578, + "assayComponentName": "ERF_CR_ENZ_rACFSK_Antagonist", + "assayComponentDesc": "ERF_CR_ENZ_rACFSK_Antagonist is an assay component calculated from the ERF_CR_ENZ_rACFSK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with HTRF technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand, [3H]-forskolin, are indicative of changes in enzyme function and kinetics related to the gene ADCY5.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HTRF", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 787, + "assayName": "ERF_CR_ENZ_rACFSK_Antagonist", + "assayDesc": "ERF_CR_ENZ_rACFSK_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See Adenylyl Cyclase Hamster Enzymatic Antagonist Assay, Cerep.", + "timepointHr": 0.16, + "organismId": null, + "organism": "hamster", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2626, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_g5HT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_g5HT4 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_g5HT4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR4 (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CHEMBL83954", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2579, + "assayComponentName": "ERF_PL_GPCR_binding_g5HT4", + "assayComponentDesc": "ERF_PL_GPCR_binding_g5HT4 is an assay component calculated from the ERF_PL_GPCR_binding_g5HT4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-GR-113808, are indicative of changes in receptor function and kinetics related to the gene HTR4 (homolog).", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR-113808", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 764, + "assayName": "ERF_PL_GPCR_g5HT4", + "assayDesc": "ERF_PL_GPCR_g5HT4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See 5-HT4 Guinea Pig Serotonin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 471, + "geneName": "5 hydroxytryptamine (serotonin) receptor 4", + "description": "provisional", + "geneSymbol": "Htr4", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135548, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70528" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2627, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_gANPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_gANPA was analyzed at the assay endpoint, ERF_PL_GPCR_binding_gANPA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ANPA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is guanylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ANF (rat)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "guanylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2580, + "assayComponentName": "ERF_PL_GPCR_binding_gANPA", + "assayComponentDesc": "ERF_PL_GPCR_binding_gANPA is an assay component calculated from the ERF_PL_GPCR_binding_gANPA assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]Atrial Natriuretic Factor (ANF) rat, are indicative of changes in receptor function and kinetics related to the gene ANPA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]Atrial Natriuretic Factor (ANF) rat", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 746, + "assayName": "ERF_PL_GPCR_gANPA", + "assayDesc": "ERF_PL_GPCR_gANPA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Atrial Natriuretic Factor (ANF, Non-Selective) Guinea Pig Binding Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "adrenal gland membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 472, + "geneName": "natriuretic peptide A", + "description": "model", + "geneSymbol": "Nppa", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135578, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P27596" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2628, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADORA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADORA1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADORA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CPA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenosine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2581, + "assayComponentName": "ERF_CR_GPCR_binding_hADORA1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADORA1 is an assay component calculated from the ERF_CR_GPCR_binding_hADORA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-8-Cyclopentyl-1,3-dipropylxanthine (CCPA), are indicative of changes in receptor function and kinetics related to the gene ADORA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-8-Cyclopentyl-1,3-dipropylxanthine (CCPA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 820, + "assayName": "ERF_CR_GPCR_hADORA1", + "assayDesc": "ERF_CR_GPCR_hADORA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See A1 Human Adenosine GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 10, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 134, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P30542" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2629, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADORA2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADORA2A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADORA2A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NECA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adenosine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2582, + "assayComponentName": "ERF_CR_GPCR_binding_hADORA2A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADORA2A is an assay component calculated from the ERF_CR_GPCR_binding_hADORA2A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-CGS 21680, are indicative of changes in receptor function and kinetics related to the gene ADORA2A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGS 21680", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 810, + "assayName": "ERF_CR_GPCR_hADORA2A", + "assayDesc": "ERF_CR_GPCR_hADORA2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See A2A Human Adenosine GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2630, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADRA1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADRA1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADRA1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRA1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "WB-4101", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2583, + "assayComponentName": "ERF_CR_GPCR_binding_hADRA1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADRA1A is an assay component calculated from the ERF_CR_GPCR_binding_hADRA1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Prazosin, are indicative of changes in receptor function and kinetics related to the gene ADRA1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 753, + "assayName": "ERF_CR_GPCR_hADRA1A", + "assayDesc": "ERF_CR_GPCR_hADRA1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha1A Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 483, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "ADRA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 148, + "officialSymbol": "ADRA1A", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2631, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRA2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRA2A was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRA2A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "yohimbine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2584, + "assayComponentName": "ERF_PL_GPCR_binding_hADRA2A", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRA2A is an assay component calculated from the ERF_PL_GPCR_binding_hADRA2A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, rauwolscine, are indicative of changes in receptor function and kinetics related to the gene ADRA2A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "rauwolscine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 738, + "assayName": "ERF_PL_GPCR_hADRA2A", + "assayDesc": "ERF_PL_GPCR_hADRA2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha2A Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 13, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "ADRA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 150, + "officialSymbol": "ADRA2A", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P08913" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2632, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRA2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRA2C was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRA2C, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "yohimbine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2585, + "assayComponentName": "ERF_PL_GPCR_binding_hADRA2C", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRA2C is an assay component calculated from the ERF_PL_GPCR_binding_hADRA2C assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, rauwolscine, are indicative of changes in receptor function and kinetics related to the gene ADRA2C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "rauwolscine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 739, + "assayName": "ERF_PL_GPCR_hADRA2C", + "assayDesc": "ERF_PL_GPCR_hADRA2C is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See alpha2C Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 14, + "geneName": "adrenoceptor alpha 2C", + "description": null, + "geneSymbol": "ADRA2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 152, + "officialSymbol": "ADRA2C", + "officialFullName": "adrenoceptor alpha 2C", + "uniprotAccessionNumber": "P18825" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2633, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRB1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRB1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "S(-)-Propranolol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2586, + "assayComponentName": "ERF_PL_GPCR_binding_hADRB1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRB1 is an assay component calculated from the ERF_PL_GPCR_binding_hADRB1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I] Cyanopindolol, are indicative of changes in receptor function and kinetics related to the gene ADRB1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I] Cyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 740, + "assayName": "ERF_PL_GPCR_hADRB1", + "assayDesc": "ERF_PL_GPCR_hADRB1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See beta1 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 15, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "ADRB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 153, + "officialSymbol": "ADRB1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P08588" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2634, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hADRB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hADRB2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hADRB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ICI 118551", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2587, + "assayComponentName": "ERF_CR_GPCR_binding_hADRB2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hADRB2 is an assay component calculated from the ERF_CR_GPCR_binding_hADRB2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H](-)CGP 12177, are indicative of changes in receptor function and kinetics related to the gene ADRB2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H](-)CGP 12177", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 736, + "assayName": "ERF_CR_GPCR_hADRB2", + "assayDesc": "ERF_CR_GPCR_hADRB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See beta2 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2635, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hADRB3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hADRB3 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hADRB3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "alprenolol ", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "adrenoceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2588, + "assayComponentName": "ERF_PL_GPCR_binding_hADRB3", + "assayComponentDesc": "ERF_PL_GPCR_binding_hADRB3 is an assay component calculated from the ERF_PL_GPCR_binding_hADRB3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, cyanopindolol, are indicative of changes in receptor function and kinetics related to the gene ADRB3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "cyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 741, + "assayName": "ERF_PL_GPCR_hADRB3", + "assayDesc": "ERF_PL_GPCR_hADRB3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See beta3 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant HEK-293 cells", + "cellShortName": "HEK293", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2636, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hAGTR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hAGTR1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hAGTR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "saralasin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "angiotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2589, + "assayComponentName": "ERF_PL_GPCR_binding_hAGTR1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hAGTR1 is an assay component calculated from the ERF_PL_GPCR_binding_hAGTR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, angiotensin II, are indicative of changes in receptor function and kinetics related to the gene AGTR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 744, + "assayName": "ERF_PL_GPCR_hAGTR1", + "assayDesc": "ERF_PL_GPCR_hAGTR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 3 hour after chemical dosing in a 96-well plate. See AT1 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 19, + "geneName": "angiotensin II receptor, type 1", + "description": null, + "geneSymbol": "AGTR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 185, + "officialSymbol": "AGTR1", + "officialFullName": "angiotensin II receptor, type 1", + "uniprotAccessionNumber": "P30556" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2637, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hAGTR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hAGTR2 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hAGTR2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "saralasin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor ", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "angiotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2590, + "assayComponentName": "ERF_PL_GPCR_binding_hAGTR2", + "assayComponentDesc": "ERF_PL_GPCR_binding_hAGTR2 is an assay component calculated from the ERF_PL_GPCR_binding_hAGTR2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I] CGP-42112A, are indicative of changes in receptor function and kinetics related to the gene AGTR2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I] CGP-42112A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 745, + "assayName": "ERF_PL_GPCR_hAGTR2", + "assayDesc": "ERF_PL_GPCR_hAGTR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 3 hour after chemical dosing in a 96-well plate. See AT2 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1620, + "geneName": "angiotensin II receptor type 2", + "description": null, + "geneSymbol": "AGTR2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 186, + "officialSymbol": "AGTR2", + "officialFullName": "angiotensin II receptor type 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2638, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hAVPR1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hAVPR1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hAVPR1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene AVPR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "[d(CH2)51,Tyr(Me)2]-AVP", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "vasopressin and oxytocin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2591, + "assayComponentName": "ERF_CR_GPCR_binding_hAVPR1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hAVPR1A is an assay component calculated from the ERF_CR_GPCR_binding_hAVPR1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]AVP, are indicative of changes in receptor function and kinetics related to the gene AVPR1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]AVP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 714, + "assayName": "ERF_CR_GPCR_hAVPR1A", + "assayDesc": "ERF_CR_GPCR_hAVPR1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See V1A Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 29, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "AVPR1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 552, + "officialSymbol": "AVPR1A", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P37288" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2639, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hBDKRB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hBDKRB2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hBDKRB2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene BDKRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is bradykinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Npc 567", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "bradykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2592, + "assayComponentName": "ERF_CR_GPCR_binding_hBDKRB2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hBDKRB2 is an assay component calculated from the ERF_CR_GPCR_binding_hBDKRB2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Bradykinin, are indicative of changes in receptor function and kinetics related to the gene BDKRB2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Bradykinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 795, + "assayName": "ERF_CR_GPCR_hBDKRB2", + "assayDesc": "ERF_CR_GPCR_hBDKRB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See B2 Human Bradykinin GPCR Binding (Agonist Radioligand) Assay, Cerep - ITEM 33.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1955, + "geneName": "bradykinin receptor B2", + "description": null, + "geneSymbol": "BDKRB2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 624, + "officialSymbol": "BDKRB2", + "officialFullName": "bradykinin receptor B2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2640, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hCCKAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hCCKAR was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hCCKAR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CCKAR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "devazepide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "cholecystokinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2593, + "assayComponentName": "ERF_PL_GPCR_binding_hCCKAR", + "assayComponentDesc": "ERF_PL_GPCR_binding_hCCKAR is an assay component calculated from the ERF_PL_GPCR_binding_hCCKAR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] L-364,718, are indicative of changes in receptor function and kinetics related to the gene CCKAR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] L-364,718", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 748, + "assayName": "ERF_PL_GPCR_hCCKAR", + "assayDesc": "ERF_PL_GPCR_hCCKAR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CCK1 (CCKA) Human Cholecystokinin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant astrocytoma cells", + "cellShortName": "1321-N1", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 2158, + "geneName": "cholecystokinin A receptor", + "description": null, + "geneSymbol": "CCKAR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 886, + "officialSymbol": "CCKAR", + "officialFullName": "cholecystokinin A receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2641, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCCKBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCCKBR was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCCKBR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CCKBR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CCK-8s", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "cholecystokinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2594, + "assayComponentName": "ERF_CR_GPCR_binding_hCCKBR", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCCKBR is an assay component calculated from the ERF_CR_GPCR_binding_hCCKBR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]CCK-8s, are indicative of changes in receptor function and kinetics related to the gene CCKBR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]CCK-8s", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 814, + "assayName": "ERF_CR_GPCR_hCCKBR", + "assayDesc": "ERF_CR_GPCR_hCCKBR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CCK2 (CCKB) Human Cholecystokinin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 2159, + "geneName": "cholecystokinin B receptor", + "description": null, + "geneSymbol": "CCKBR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 887, + "officialSymbol": "CCKBR", + "officialFullName": "cholecystokinin B receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2642, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "pirenzepine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2595, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM1 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]pirenzepine, are indicative of changes in receptor function and kinetics related to the gene CHRM1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]pirenzepine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 835, + "assayName": "ERF_CR_GPCR_hCHRM1", + "assayDesc": "ERF_CR_GPCR_hCHRM1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M1 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 61, + "geneName": "cholinergic receptor, muscarinic 1", + "description": null, + "geneSymbol": "CHRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1128, + "officialSymbol": "CHRM1", + "officialFullName": "cholinergic receptor, muscarinic 1", + "uniprotAccessionNumber": "P11229" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2643, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "methoctramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2596, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM2 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]AF-DX 384, are indicative of changes in receptor function and kinetics related to the gene CHRM2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]AF-DX 384", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 836, + "assayName": "ERF_CR_GPCR_hCHRM2", + "assayDesc": "ERF_CR_GPCR_hCHRM2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M2 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 62, + "geneName": "cholinergic receptor, muscarinic 2", + "description": null, + "geneSymbol": "CHRM2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1129, + "officialSymbol": "CHRM2", + "officialFullName": "cholinergic receptor, muscarinic 2", + "uniprotAccessionNumber": "P08172" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2644, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM3 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2597, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM3", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM3 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 837, + "assayName": "ERF_CR_GPCR_hCHRM3", + "assayDesc": "ERF_CR_GPCR_hCHRM3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M3 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2645, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM4 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2598, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM4", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM4 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 838, + "assayName": "ERF_CR_GPCR_hCHRM4", + "assayDesc": "ERF_CR_GPCR_hCHRM4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M4 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 64, + "geneName": "cholinergic receptor, muscarinic 4", + "description": null, + "geneSymbol": "CHRM4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1132, + "officialSymbol": "CHRM4", + "officialFullName": "cholinergic receptor, muscarinic 4", + "uniprotAccessionNumber": "P08173" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2646, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCHRM5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCHRM5 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCHRM5, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-Damp methiodide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "acetylcholine (Muscarinic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2599, + "assayComponentName": "ERF_CR_GPCR_binding_hCHRM5", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCHRM5 is an assay component calculated from the ERF_CR_GPCR_binding_hCHRM5 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]4-DAMP, are indicative of changes in receptor function and kinetics related to the gene CHRM5.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]4-DAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 839, + "assayName": "ERF_CR_GPCR_hCHRM5", + "assayDesc": "ERF_CR_GPCR_hCHRM5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See M5 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 65, + "geneName": "cholinergic receptor, muscarinic 5", + "description": null, + "geneSymbol": "CHRM5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1133, + "officialSymbol": "CHRM5", + "officialFullName": "cholinergic receptor, muscarinic 5", + "uniprotAccessionNumber": "P08912" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2647, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hCYSLTR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hCYSLTR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hCYSLTR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CYSLTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "leukotriene D4", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "leukotriene", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2600, + "assayComponentName": "ERF_CR_GPCR_binding_hCYSLTR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hCYSLTR1 is an assay component calculated from the ERF_CR_GPCR_binding_hCYSLTR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]LTD4, are indicative of changes in receptor function and kinetics related to the gene CYSLTR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]LTD4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 833, + "assayName": "ERF_CR_GPCR_hCYSLTR1", + "assayDesc": "ERF_CR_GPCR_hCYSLTR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See CysLT1 Human Leukotriene GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 9689, + "geneName": "cysteinyl leukotriene receptor 1", + "description": null, + "geneSymbol": "CYSLTR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 10800, + "officialSymbol": "CYSLTR1", + "officialFullName": "cysteinyl leukotriene receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2648, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hDRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hDRD1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hDRD1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SCH 23390", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2601, + "assayComponentName": "ERF_CR_GPCR_binding_hDRD1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hDRD1 is an assay component calculated from the ERF_CR_GPCR_binding_hDRD1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-SCH 23390, are indicative of changes in receptor function and kinetics related to the gene DRD1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SCH 23390", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 819, + "assayName": "ERF_CR_GPCR_hDRD1", + "assayDesc": "ERF_CR_GPCR_hDRD1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See D1 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2649, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hDRD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hDRD2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hDRD2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "butaclamol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2602, + "assayComponentName": "ERF_CR_GPCR_binding_hDRD2", + "assayComponentDesc": "ERF_CR_GPCR_binding_hDRD2 is an assay component calculated from the ERF_CR_GPCR_binding_hDRD2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]methyl-spiperone, are indicative of changes in receptor function and kinetics related to the gene DRD2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]methyl-spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 708, + "assayName": "ERF_CR_GPCR_hDRD2", + "assayDesc": "ERF_CR_GPCR_hDRD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See D2L Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant HEK-293 cells", + "cellShortName": "HEK293", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 100, + "geneName": "dopamine receptor D2", + "description": null, + "geneSymbol": "DRD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1813, + "officialSymbol": "DRD2", + "officialFullName": "dopamine receptor D2", + "uniprotAccessionNumber": "P14416" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2650, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hDRD4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hDRD4 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hDRD4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "spiperone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "dopamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2603, + "assayComponentName": "ERF_PL_GPCR_binding_hDRD4", + "assayComponentDesc": "ERF_PL_GPCR_binding_hDRD4 is an assay component calculated from the ERF_PL_GPCR_binding_hDRD4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] Spiperone, are indicative of changes in receptor function and kinetics related to the gene DRD4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 749, + "assayName": "ERF_PL_GPCR_hDRD4", + "assayDesc": "ERF_PL_GPCR_hDRD4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See D4.2 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 101, + "geneName": "dopamine receptor D4", + "description": null, + "geneSymbol": "DRD4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1815, + "officialSymbol": "DRD4", + "officialFullName": "dopamine receptor D4", + "uniprotAccessionNumber": "P21917" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2651, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hGALR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hGALR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hGALR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GALR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is galanin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "galanin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "galanin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2604, + "assayComponentName": "ERF_CR_GPCR_binding_hGALR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hGALR1 is an assay component calculated from the ERF_CR_GPCR_binding_hGALR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Galanin, are indicative of changes in receptor function and kinetics related to the gene GALR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Galanin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 826, + "assayName": "ERF_CR_GPCR_hGALR1", + "assayDesc": "ERF_CR_GPCR_hGALR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GAL1 Human Galanin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 3457, + "geneName": "galanin receptor 1", + "description": null, + "geneSymbol": "GALR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2587, + "officialSymbol": "GALR1", + "officialFullName": "galanin receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2652, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHRH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHRH1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHRH1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene HRH1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is histamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "pyrilamine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "histamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2605, + "assayComponentName": "ERF_CR_GPCR_binding_hHRH1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHRH1 is an assay component calculated from the ERF_CR_GPCR_binding_hHRH1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Pyrilamine, are indicative of changes in receptor function and kinetics related to the gene HRH1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 834, + "assayName": "ERF_CR_GPCR_hHRH1", + "assayDesc": "ERF_CR_GPCR_hHRH1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See H1 Human Histamine GPCR Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2653, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR1A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "8-OH-DPAT", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2606, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR1A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR1A is an assay component calculated from the ERF_CR_GPCR_binding_hHTR1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]8-OH-DPAT, are indicative of changes in receptor function and kinetics related to the gene HTR1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]8-OH-DPAT", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 700, + "assayName": "ERF_CR_GPCR_hHTR1A", + "assayDesc": "ERF_CR_GPCR_hHTR1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See 5-HT1A Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 4067, + "geneName": "5-hydroxytryptamine receptor 1A", + "description": null, + "geneSymbol": "HTR1A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3350, + "officialSymbol": "HTR1A", + "officialFullName": "5-hydroxytryptamine receptor 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2654, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR5A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR5A was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR5A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR5A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2607, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR5A", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR5A is an assay component calculated from the ERF_CR_GPCR_binding_hHTR5A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR5A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 707, + "assayName": "ERF_CR_GPCR_hHTR5A", + "assayDesc": "ERF_CR_GPCR_hHTR5A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT5A Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 167, + "geneName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "description": null, + "geneSymbol": "HTR5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3361, + "officialSymbol": "HTR5A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "uniprotAccessionNumber": "P47898" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2655, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR6 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2608, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR6", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR6 is an assay component calculated from the ERF_CR_GPCR_binding_hHTR6 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR6.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 709, + "assayName": "ERF_CR_GPCR_hHTR6", + "assayDesc": "ERF_CR_GPCR_hHTR6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT6 Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2656, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hHTR7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hHTR7 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hHTR7, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR7. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "serotonin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2609, + "assayComponentName": "ERF_CR_GPCR_binding_hHTR7", + "assayComponentDesc": "ERF_CR_GPCR_binding_hHTR7 is an assay component calculated from the ERF_CR_GPCR_binding_hHTR7 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-lysergic acid diethylamide (LSD), are indicative of changes in receptor function and kinetics related to the gene HTR7.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide (LSD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 710, + "assayName": "ERF_CR_GPCR_hHTR7", + "assayDesc": "ERF_CR_GPCR_hHTR7 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See 5-HT7 Human Serotonin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2657, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hLTB4R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hLTB4R was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hLTB4R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene LTB4R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "LTB4", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "leukotriene", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2610, + "assayComponentName": "ERF_PL_GPCR_binding_hLTB4R", + "assayComponentDesc": "ERF_PL_GPCR_binding_hLTB4R is an assay component calculated from the ERF_PL_GPCR_binding_hLTB4R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Leukotriene B4, are indicative of changes in receptor function and kinetics related to the gene LTB4R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 757, + "assayName": "ERF_PL_GPCR_hLTB4R", + "assayDesc": "ERF_PL_GPCR_hLTB4R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See BLT1 (LTB4) Human Leukotriene GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human histiocytic lymphoma U-937 cells", + "cellShortName": "U-937", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 68, + "geneName": "leukotriene B4 receptor", + "description": null, + "geneSymbol": "LTB4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1241, + "officialSymbol": "LTB4R", + "officialFullName": "leukotriene B4 receptor", + "uniprotAccessionNumber": "Q15722" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2658, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNPY1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNPY1R was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNPY1R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NPY", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neuropeptide Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2611, + "assayComponentName": "ERF_CR_GPCR_binding_hNPY1R", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNPY1R is an assay component calculated from the ERF_CR_GPCR_binding_hNPY1R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Peptide YY, are indicative of changes in receptor function and kinetics related to the gene NPY1R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 693, + "assayName": "ERF_CR_GPCR_hNPY1R", + "assayDesc": "ERF_CR_GPCR_hNPY1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Y1 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 219, + "geneName": "neuropeptide Y receptor Y1", + "description": null, + "geneSymbol": "NPY1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4886, + "officialSymbol": "NPY1R", + "officialFullName": "neuropeptide Y receptor Y1", + "uniprotAccessionNumber": "P25929" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2659, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNPY2R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNPY2R was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNPY2R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY2R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NPY", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neuropeptide Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2612, + "assayComponentName": "ERF_CR_GPCR_binding_hNPY2R", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNPY2R is an assay component calculated from the ERF_CR_GPCR_binding_hNPY2R assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Peptide YY, are indicative of changes in receptor function and kinetics related to the gene NPY2R.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 694, + "assayName": "ERF_CR_GPCR_hNPY2R", + "assayDesc": "ERF_CR_GPCR_hNPY2R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Y2 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2660, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hNTSR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hNTSR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hNTSR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NTSR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neurotensin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "neurotensin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "neurotensin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2613, + "assayComponentName": "ERF_CR_GPCR_binding_hNTSR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hNTSR1 is an assay component calculated from the ERF_CR_GPCR_binding_hNTSR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]Tyr3-neurotensin, are indicative of changes in receptor function and kinetics related to the gene NTSR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]Tyr3-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 695, + "assayName": "ERF_CR_GPCR_hNTSR1", + "assayDesc": "ERF_CR_GPCR_hNTSR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NT1 Human Neurotensin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 223, + "geneName": "neurotensin receptor 1 (high affinity)", + "description": null, + "geneSymbol": "NTSR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4923, + "officialSymbol": "NTSR1", + "officialFullName": "neurotensin receptor 1 (high affinity)", + "uniprotAccessionNumber": "P30989" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2661, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRD1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRD1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DPDPE", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2614, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRD1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRD1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRD1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]DADLE, are indicative of changes in receptor function and kinetics related to the gene OPRD1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]DADLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 696, + "assayName": "ERF_CR_GPCR_hOPRD1", + "assayDesc": "ERF_CR_GPCR_hOPRD1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See delta (DOP) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 225, + "geneName": "opioid receptor, delta 1", + "description": null, + "geneSymbol": "OPRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4985, + "officialSymbol": "OPRD1", + "officialFullName": "opioid receptor, delta 1", + "uniprotAccessionNumber": "P41143" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2662, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRL1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRL1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nociceptin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2615, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRL1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRL1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRL1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]nociceptin, are indicative of changes in receptor function and kinetics related to the gene OPRL1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]nociceptin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 803, + "assayName": "ERF_CR_GPCR_hOPRL1", + "assayDesc": "ERF_CR_GPCR_hOPRL1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See NOP (ORL1) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 226, + "geneName": "opiate receptor-like 1", + "description": null, + "geneSymbol": "OPRL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4987, + "officialSymbol": "OPRL1", + "officialFullName": "opiate receptor-like 1", + "uniprotAccessionNumber": "P41146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2663, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOPRM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOPRM1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOPRM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DAMGO", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "opioid", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2616, + "assayComponentName": "ERF_CR_GPCR_binding_hOPRM1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOPRM1 is an assay component calculated from the ERF_CR_GPCR_binding_hOPRM1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]DAMGO, are indicative of changes in receptor function and kinetics related to the gene OPRM1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]DAMGO", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 697, + "assayName": "ERF_CR_GPCR_hOPRM1", + "assayDesc": "ERF_CR_GPCR_hOPRM1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See mu (MOP) Human Opioid GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 227, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "OPRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4988, + "officialSymbol": "OPRM1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P35372" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2664, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hOXTR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hOXTR was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hOXTR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OXTR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "oxytocin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "vasopressin and oxytocin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2617, + "assayComponentName": "ERF_CR_GPCR_binding_hOXTR", + "assayComponentDesc": "ERF_CR_GPCR_binding_hOXTR is an assay component calculated from the ERF_CR_GPCR_binding_hOXTR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Oxytocin, are indicative of changes in receptor function and kinetics related to the gene OXTR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Oxytocin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 807, + "assayName": "ERF_CR_GPCR_hOXTR", + "assayDesc": "ERF_CR_GPCR_hOXTR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See OT Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Chem-1 RBL cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 5269, + "geneName": "oxytocin receptor", + "description": null, + "geneSymbol": "OXTR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5021, + "officialSymbol": "OXTR", + "officialFullName": "oxytocin receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2665, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hTACR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hTACR1 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hTACR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-703606", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "tachykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2618, + "assayComponentName": "ERF_PL_GPCR_binding_hTACR1", + "assayComponentDesc": "ERF_PL_GPCR_binding_hTACR1 is an assay component calculated from the ERF_PL_GPCR_binding_hTACR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Substance P, are indicative of changes in receptor function and kinetics related to the gene TACR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Substance P", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 759, + "assayName": "ERF_PL_GPCR_hTACR1", + "assayDesc": "ERF_PL_GPCR_hTACR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See NK1 Human Tachykinin GPCR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 6719, + "geneName": "tachykinin receptor 1", + "description": null, + "geneSymbol": "TACR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6869, + "officialSymbol": "TACR1", + "officialFullName": "tachykinin receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2666, + "assayComponentEndpointName": "ERF_PL_GPCR_binding_hTACR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_GPCR_binding_hTACR2 was analyzed at the assay endpoint, ERF_PL_GPCR_binding_hTACR2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MEN-10376", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "tachykinin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2619, + "assayComponentName": "ERF_PL_GPCR_binding_hTACR2", + "assayComponentDesc": "ERF_PL_GPCR_binding_hTACR2 is an assay component calculated from the ERF_PL_GPCR_binding_hTACR2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] SR-48968, are indicative of changes in receptor function and kinetics related to the gene TACR2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] SR-48968", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 760, + "assayName": "ERF_PL_GPCR_hTACR2", + "assayDesc": "ERF_PL_GPCR_hTACR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See NK2 Human Tachykinin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 309, + "geneName": "tachykinin receptor 2", + "description": null, + "geneSymbol": "TACR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6865, + "officialSymbol": "TACR2", + "officialFullName": "tachykinin receptor 2", + "uniprotAccessionNumber": "P21452" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2667, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_hVIPR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_hVIPR1 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_hVIPR1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene VIPR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is VIP and PACAP.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "VIP ", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "VIP and PACAP", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2620, + "assayComponentName": "ERF_CR_GPCR_binding_hVIPR1", + "assayComponentDesc": "ERF_CR_GPCR_binding_hVIPR1 is an assay component calculated from the ERF_CR_GPCR_binding_hVIPR1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Vasoactive intestinal peptide (VIP), are indicative of changes in receptor function and kinetics related to the gene VIPR1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Vasoactive intestinal peptide (VIP)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 713, + "assayName": "ERF_CR_GPCR_hVIPR1", + "assayDesc": "ERF_CR_GPCR_hVIPR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See VIP1 (VPAC1) Human VIP and PACAP GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 7188, + "geneName": "vasoactive intestinal peptide receptor 1", + "description": null, + "geneSymbol": "VIPR1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7433, + "officialSymbol": "VIPR1", + "officialFullName": "vasoactive intestinal peptide receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2668, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_rGHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_rGHB was analyzed at the assay endpoint, ERF_CR_GPCR_binding_rGHB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPAN17. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is ghb .", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NCS382", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "ghb ", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2621, + "assayComponentName": "ERF_CR_GPCR_binding_rGHB", + "assayComponentDesc": "ERF_CR_GPCR_binding_rGHB is an assay component calculated from the ERF_CR_GPCR_binding_rGHB assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-NCS-382, are indicative of changes in receptor function and kinetics related to the gene TSPAN17.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-NCS-382", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 806, + "assayName": "ERF_CR_GPCR_rGHB", + "assayDesc": "ERF_CR_GPCR_rGHB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GHB Rat Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat cerebral cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 454, + "geneName": "tetraspanin 17", + "description": null, + "geneSymbol": "Tspan17", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 306771, + "officialSymbol": "Tspan17", + "officialFullName": "tetraspanin 17", + "uniprotAccessionNumber": "Q4V8E0" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2669, + "assayComponentEndpointName": "ERF_CR_GPCR_binding_rPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_GPCR_binding_rPY2 was analyzed at the assay endpoint, ERF_CR_GPCR_binding_rPY2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene P2RY1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is P2Y.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "datpalphas", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "P2Y", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2622, + "assayComponentName": "ERF_CR_GPCR_binding_rPY2", + "assayComponentDesc": "ERF_CR_GPCR_binding_rPY2 is an assay component calculated from the ERF_CR_GPCR_binding_rPY2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [35S]dATPalpha S, are indicative of changes in receptor function and kinetics related to the gene P2RY1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[35S]dATPalpha S", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 699, + "assayName": "ERF_CR_GPCR_rPY2", + "assayDesc": "ERF_CR_GPCR_rPY2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Non-Selective Rat P2Y GPCR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2670, + "assayComponentEndpointName": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rCACNA1C_Dihydropyridine was analyzed at the assay endpoint, ERF_CR_IC_binding_rCACNA1C_Dihydropyridine, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nitrendipine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Calcium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2623, + "assayComponentName": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine", + "assayComponentDesc": "ERF_CR_IC_binding_rCACNA1C_Dihydropyridine is an assay component calculated from the ERF_CR_IC_binding_rCACNA1C_Dihydropyridine assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nitrendipine, are indicative of changes in transporter function and kinetics related to the gene CACNA1C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrendipine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 715, + "assayName": "ERF_CR_IC_rCACNA1C_Dihydropyridine", + "assayDesc": "ERF_CR_IC_rCACNA1C_Dihydropyridine is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.5 hour after chemical dosing in a 96-well plate. See Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Dihydropyridine Site) Assay, Cerep.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2671, + "assayComponentEndpointName": "ERF_CR_IC_binding_rCACNA1C_Diltiazem", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rCACNA1C_Diltiazem was analyzed at the assay endpoint, ERF_CR_IC_binding_rCACNA1C_Diltiazem, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "diltiazem", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Calcium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2624, + "assayComponentName": "ERF_CR_IC_binding_rCACNA1C_Diltiazem", + "assayComponentDesc": "ERF_CR_IC_binding_rCACNA1C_Diltiazem is an assay component calculated from the ERF_CR_IC_binding_rCACNA1C_Diltiazem assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Diltiazem, are indicative of changes in transporter function and kinetics related to the gene CACNA1C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diltiazem", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 716, + "assayName": "ERF_CR_IC_rCACNA1C_Diltiazem", + "assayDesc": "ERF_CR_IC_rCACNA1C_Diltiazem is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Diltiazem Site) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2672, + "assayComponentEndpointName": "ERF_CR_IC_binding_rKCNJ1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rKCNJ1 was analyzed at the assay endpoint, ERF_CR_IC_binding_rKCNJ1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene KCNJ1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "glyburide potassium salt", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Potassium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2625, + "assayComponentName": "ERF_CR_IC_binding_rKCNJ1", + "assayComponentDesc": "ERF_CR_IC_binding_rKCNJ1 is an assay component calculated from the ERF_CR_IC_binding_rKCNJ1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Glibenclamide, are indicative of changes in transporter function and kinetics related to the gene KCNJ1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Glibenclamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 717, + "assayName": "ERF_CR_IC_rKCNJ1", + "assayDesc": "ERF_CR_IC_rKCNJ1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See KATP Rat Potassium Ion Channel Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 391, + "geneName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "description": null, + "geneSymbol": "Kcnj1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24521, + "officialSymbol": "Kcnj1", + "officialFullName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "uniprotAccessionNumber": "P35560" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2673, + "assayComponentEndpointName": "ERF_CR_IC_binding_rKCNN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rKCNN1 was analyzed at the assay endpoint, ERF_CR_IC_binding_rKCNN1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene Kcnn1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "apamin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Potassium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2626, + "assayComponentName": "ERF_CR_IC_binding_rKCNN1", + "assayComponentDesc": "ERF_CR_IC_binding_rKCNN1 is an assay component calculated from the ERF_CR_IC_binding_rKCNN1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [125I]-Apamin, are indicative of changes in transporter function and kinetics related to the gene Kcnn1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Apamin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 718, + "assayName": "ERF_CR_IC_rKCNN1", + "assayDesc": "ERF_CR_IC_rKCNN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See SKCa (Non-Selective) Rat Potassium Ion Channel [125I] Apamin Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 428, + "geneName": "potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1", + "description": "provisional", + "geneSymbol": "Kcnn1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54261, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P70606" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2674, + "assayComponentEndpointName": "ERF_CR_IC_binding_rSCN1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_IC_binding_rSCN1A was analyzed at the assay endpoint, ERF_CR_IC_binding_rSCN1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SCN1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Sodium).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "veratridine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "voltage gated (Sodium)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2627, + "assayComponentName": "ERF_CR_IC_binding_rSCN1A", + "assayComponentDesc": "ERF_CR_IC_binding_rSCN1A is an assay component calculated from the ERF_CR_IC_binding_rSCN1A assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Batrachotoxin, are indicative of changes in transporter function and kinetics related to the gene SCN1A.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Batrachotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 721, + "assayName": "ERF_CR_IC_rSCN1A", + "assayDesc": "ERF_CR_IC_rSCN1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Non-Selective Rat Sodium Ion Channel [3H] Batrachotoxinin Binding (Site 2) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 436, + "geneName": "sodium channel, voltage-gated, type I, alpha subunit", + "description": null, + "geneSymbol": "Scn1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81574, + "officialSymbol": "Scn1a", + "officialFullName": "sodium channel, voltage-gated, type I, alpha subunit", + "uniprotAccessionNumber": "P04774" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2675, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_hGABRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_hGABRA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_hGABRA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GABRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "muscimol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2628, + "assayComponentName": "ERF_CR_LGIC_binding_hGABRA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_hGABRA1 is an assay component calculated from the ERF_CR_LGIC_binding_hGABRA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]muscimol, are indicative of changes in transporter function and kinetics related to the gene GABRA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]muscimol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 788, + "assayName": "ERF_CR_LGIC_hGABRA1", + "assayDesc": "ERF_CR_LGIC_hGABRA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See GABAA (alpha1/beta2/gamma2) Human GABAA Ion Channel Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "CHO", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 3427, + "geneName": "gamma-aminobutyric acid type A receptor alpha1 subunit", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2554, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid type A receptor alpha1 subunit", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2676, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGLRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGLRA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGLRA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GLRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glycine).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "strychnine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glycine)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2629, + "assayComponentName": "ERF_CR_LGIC_binding_rGLRA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGLRA1 is an assay component calculated from the ERF_CR_LGIC_binding_rGLRA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-strychnine, are indicative of changes in transporter function and kinetics related to the gene GLRA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-strychnine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 831, + "assayName": "ERF_CR_LGIC_rGLRA1", + "assayDesc": "ERF_CR_LGIC_rGLRA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Non-Selective Rat Glycine Ion Channel [3H] Strychnine Binding Assay, Cerep.", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "spinal cord", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat spinal cord membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 414, + "geneName": "glycine receptor, alpha 1", + "description": null, + "geneSymbol": "Glra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25674, + "officialSymbol": "Glra1", + "officialFullName": "glycine receptor, alpha 1", + "uniprotAccessionNumber": "P07727" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2677, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGRIA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGRIA1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGRIA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-Glutamate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2630, + "assayComponentName": "ERF_CR_LGIC_binding_rGRIA1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGRIA1 is an assay component calculated from the ERF_CR_LGIC_binding_rGRIA1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-AMPA, are indicative of changes in transporter function and kinetics related to the gene GRIA1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-AMPA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 827, + "assayName": "ERF_CR_LGIC_rGRIA1", + "assayDesc": "ERF_CR_LGIC_rGRIA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Glutamate (AMPA, Non-Selective) Rat Ion Channel [3H] AMPA Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 424, + "geneName": "glutamate receptor, ionotropic, AMPA 1", + "description": null, + "geneSymbol": "Gria1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50592, + "officialSymbol": "Gria1", + "officialFullName": "glutamate receptor, ionotropic, AMPA 1", + "uniprotAccessionNumber": "P19490" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2678, + "assayComponentEndpointName": "ERF_CR_LGIC_binding_rGRIK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_LGIC_binding_rGRIK1 was analyzed at the assay endpoint, ERF_CR_LGIC_binding_rGRIK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "kainic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2631, + "assayComponentName": "ERF_CR_LGIC_binding_rGRIK1", + "assayComponentDesc": "ERF_CR_LGIC_binding_rGRIK1 is an assay component calculated from the ERF_CR_LGIC_binding_rGRIK1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Kainic acid, are indicative of changes in transporter function and kinetics related to the gene GRIK1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Kainic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 830, + "assayName": "ERF_CR_LGIC_rGRIK1", + "assayDesc": "ERF_CR_LGIC_rGRIK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Glutamate (Kianate, Non-Selective) Rat Ion Channel [3H] Kainic acid Binding Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 420, + "geneName": "glutamate receptor, ionotropic, kainate 1", + "description": null, + "geneSymbol": "Grik1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29559, + "officialSymbol": "Grik1", + "officialFullName": "glutamate receptor, ionotropic, kainate 1", + "uniprotAccessionNumber": "P22756" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2679, + "assayComponentEndpointName": "ERF_PL_LGIC_binding_rGRIN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_LGIC_binding_rGRIN1 was analyzed at the assay endpoint, ERF_PL_LGIC_binding_rGRIN1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIN1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated (glutamate, Ionotropic)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2632, + "assayComponentName": "ERF_PL_LGIC_binding_rGRIN1", + "assayComponentDesc": "ERF_PL_LGIC_binding_rGRIN1 is an assay component calculated from the ERF_PL_LGIC_binding_rGRIN1 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-MK-801, are indicative of changes in transporter function and kinetics related to the gene GRIN1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-801", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 752, + "assayName": "ERF_PL_LGIC_rGRIN1", + "assayDesc": "ERF_PL_LGIC_rGRIN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See Glutamate (Kainate, Non-Selective) Rat Ion Channel [3H] Kainic acid Binding Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat cortex membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2680, + "assayComponentEndpointName": "ERF_CR_MP_binding_hTSPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_MP_binding_hTSPO was analyzed at the assay endpoint, ERF_CR_MP_binding_hTSPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is mitochondrial associated translocator protein.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK 11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "membrane protein", + "intendedTargetFamilySub": "mitochondrial associated translocator protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2633, + "assayComponentName": "ERF_CR_MP_binding_hTSPO", + "assayComponentDesc": "ERF_CR_MP_binding_hTSPO is an assay component calculated from the ERF_CR_MP_hTSPO assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-PK11195, are indicative of changes in receptor function and kinetics related to the gene TSPO.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 804, + "assayName": "ERF_CR_MP_hTSPO", + "assayDesc": "ERF_CR_MP_hTSPO is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PBR Human Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous U-118-MG", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 37, + "geneName": "translocator protein (18kDa)", + "description": null, + "geneSymbol": "TSPO", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 706, + "officialSymbol": "TSPO", + "officialFullName": "translocator protein (18kDa)", + "uniprotAccessionNumber": "P30536" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2681, + "assayComponentEndpointName": "ERF_PL_NR_binding_hAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hAR was analyzed at the assay endpoint, ERF_PL_NR_binding_hAR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is androgens.", + "assayFunctionType": "radioligand binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2634, + "assayComponentName": "ERF_PL_NR_binding_hAR", + "assayComponentDesc": "ERF_PL_NR_binding_hAR is an assay component calculated from the ERF_PL_NR_binding_hAR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-methyltrienolone, are indicative of changes in receptor function and kinetics related to the gene AR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 742, + "assayName": "ERF_PL_NR_hAR", + "assayDesc": "ERF_PL_NR_hAR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 20 hour after chemical dosing in a 96-well plate. See AR Human Androgen NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human LNCaP clone FGC cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2682, + "assayComponentEndpointName": "ERF_PL_NR_COA_hFXR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hFXR_Antagonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hFXR_Antagonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Z-Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "liver X receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2635, + "assayComponentName": "ERF_PL_NR_COA_hFXR_Antagonist", + "assayComponentDesc": "ERF_PL_NR_COA_hFXR_Antagonist is an assay component calculated from the ERF_PL_NR_COA_hFXR_Antagonist assay. It is designed to measure TR-FRET using a type of binding reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the receptor binding reaction involving the key ligand;antibody, Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody, are indicative of changes in receptor function and kinetics related to the gene NR1H4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 794, + "assayName": "ERF_PL_NR_COA_hFXR_Antagonist", + "assayDesc": "ERF_PL_NR_COA_hFXR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FXR Human Liver X Receptor-Like NHR Functional Antagonist Coactivator Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2683, + "assayComponentEndpointName": "ERF_CR_NR_binding_hGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hGR was analyzed at the assay endpoint, ERF_CR_NR_binding_hGR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NR3C1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "triamcinolone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2636, + "assayComponentName": "ERF_CR_NR_binding_hGR", + "assayComponentDesc": "ERF_CR_NR_binding_hGR is an assay component calculated from the ERF_CR_NR_binding_hGR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-dexamethasone, are indicative of changes in receptor function and kinetics related to the gene NR3C1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dexamethasone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 822, + "assayName": "ERF_CR_NR_hGR", + "assayDesc": "ERF_CR_NR_hGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 6 hour after chemical dosing in a 96-well plate. See GR Human Glucocorticoid NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous IM-9 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2684, + "assayComponentEndpointName": "ERF_PL_NR_binding_hHTR2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hHTR2C was analyzed at the assay endpoint, ERF_PL_NR_binding_hHTR2C, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB 242084", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "serotonin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2637, + "assayComponentName": "ERF_PL_NR_binding_hHTR2C", + "assayComponentDesc": "ERF_PL_NR_binding_hHTR2C is an assay component calculated from the ERF_PL_NR_binding_hHTR2C assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Mesulergine, are indicative of changes in receptor function and kinetics related to the gene HTR2C.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Mesulergine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 763, + "assayName": "ERF_PL_NR_hHTR2C", + "assayDesc": "ERF_PL_NR_hHTR2C is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See 5-HT2C Human Serotonin GPCR Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO-K1 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 165, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "description": null, + "geneSymbol": "HTR2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3358, + "officialSymbol": "HTR2C", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "uniprotAccessionNumber": "P28335" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2685, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPGR was analyzed at the assay endpoint, ERF_CR_NR_binding_hPGR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PGR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2638, + "assayComponentName": "ERF_CR_NR_binding_hPGR", + "assayComponentDesc": "ERF_CR_NR_binding_hPGR is an assay component calculated from the ERF_CR_NR_binding_hPGR assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]progesterone, are indicative of changes in receptor function and kinetics related to the gene PGR.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]progesterone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 754, + "assayName": "ERF_CR_NR_hPGR", + "assayDesc": "ERF_CR_NR_hPGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 20 hour after chemical dosing in a 96-well plate. See PR Human Progesterone NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human endogenous T47D cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2686, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPPARA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPPARA was analyzed at the assay endpoint, ERF_CR_NR_binding_hPPARA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW 7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2639, + "assayComponentName": "ERF_CR_NR_binding_hPPARA", + "assayComponentDesc": "ERF_CR_NR_binding_hPPARA is an assay component calculated from the ERF_CR_NR_binding_hPPARA assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]WY 14643, are indicative of changes in receptor function and kinetics related to the gene PPARA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]WY 14643", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 828, + "assayName": "ERF_CR_NR_hPPARA", + "assayDesc": "ERF_CR_NR_hPPARA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See PPARalpha Human NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2687, + "assayComponentEndpointName": "ERF_CR_NR_binding_hPPARG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_NR_binding_hPPARG was analyzed at the assay endpoint, ERF_CR_NR_binding_hPPARG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARG. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2640, + "assayComponentName": "ERF_CR_NR_binding_hPPARG", + "assayComponentDesc": "ERF_CR_NR_binding_hPPARG is an assay component calculated from the ERF_CR_NR_binding_hPPARG assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]rosiglitazone, are indicative of changes in receptor function and kinetics related to the gene PPARG.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]rosiglitazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 829, + "assayName": "ERF_CR_NR_hPPARG", + "assayDesc": "ERF_CR_NR_hPPARG is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See PPARgamma Human NHR Binding (Agonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2688, + "assayComponentEndpointName": "ERF_PL_NR_binding_hRARa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hRARa was analyzed at the assay endpoint, ERF_PL_NR_binding_hRARa, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene RARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is retinoic acid receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "retinoic acid receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2641, + "assayComponentName": "ERF_PL_NR_binding_hRARa", + "assayComponentDesc": "ERF_PL_NR_binding_hRARa is an assay component calculated from the ERF_PL_NR_binding_hRARa assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] 9-cis-Retinoic acid, are indicative of changes in receptor function and kinetics related to the gene RARA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] 9-cis-Retinoic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 762, + "assayName": "ERF_PL_NR_hRARa", + "assayDesc": "ERF_PL_NR_hRARa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See RARalpha Human Retinoic Acid NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2689, + "assayComponentEndpointName": "ERF_PL_NR_COA_hTHRA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hTHRA_Agonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hTHRA_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of agonist, gain-of-signal activity can be used to understand changes in protein-protein interaction as they relate to gene THRA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2642, + "assayComponentName": "ERF_PL_NR_COA_hTHRA", + "assayComponentDesc": "ERF_PL_NR_COA_hTHRA is an assay component calculated from the ERF_PL_NR_COA_hTHRA assay. It is designed to measure TR-FRET using a type of inducible reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the regulation of transcription factor activity reaction involving the key ligand; antibody, liothyronine, are indicative of changes in receptor function and kinetics related to the gene THRA.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "liothyronine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 802, + "assayName": "ERF_PL_NR_COA_hTHRA", + "assayDesc": "ERF_PL_NR_COA_hTHRA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See TRalpha Human Thyroid Hormone NHR Functional Agonist Coactivator Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2690, + "assayComponentEndpointName": "ERF_PL_NR_binding_rI2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_rI2 was analyzed at the assay endpoint, ERF_PL_NR_binding_rI2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene NISCH (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is imidazoline receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "idazoxan", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "imidazoline receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2643, + "assayComponentName": "ERF_PL_NR_binding_rI2", + "assayComponentDesc": "ERF_PL_NR_binding_rI2 is an assay component calculated from the ERF_PL_NR_binding_rI2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H] Idazoxan, are indicative of changes in receptor function and kinetics related to the gene NISCH (homolog), gene id 100009085.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Idazoxan", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 755, + "assayName": "ERF_PL_NR_rI2", + "assayDesc": "ERF_PL_NR_rI2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Imidazoline I2, Central Rat Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 9986, + "organism": "rabbit", + "tissue": "cerebral cortex", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat cerebral cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 10019, + "geneName": "nischarin", + "description": null, + "geneSymbol": "NISCH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 11188, + "officialSymbol": "NISCH", + "officialFullName": "nischarin", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2691, + "assayComponentEndpointName": "ERF_PL_TR_binding_hSLC35B3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_hSLC35B3 was analyzed at the assay endpoint, ERF_PL_TR_binding_hSLC35B3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC29A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "nitrobenzylthioinosine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2644, + "assayComponentName": "ERF_PL_TR_binding_hSLC35B3", + "assayComponentDesc": "ERF_PL_TR_binding_hSLC35B3 is an assay component calculated from the ERF_PL_TR_binding_hSLC35B3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nitrobenzylthioinosine, are indicative of changes in transporter function and kinetics related to the gene SLC29A1.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 737, + "assayName": "ERF_PL_TR_hSLC35B3", + "assayDesc": "ERF_PL_TR_hSLC35B3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See Adenosine Human Transporter Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human u937 cells CRL-1593", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 112, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "SLC29A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2030, + "officialSymbol": "SLC29A1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "Q99808" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2692, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A2 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "protriptyline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2645, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A2", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A2 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-Nisoxetine, are indicative of changes in transporter function and kinetics related to the gene SLC6A2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 801, + "assayName": "ERF_CR_TR_hSLC6A2", + "assayDesc": "ERF_CR_TR_hSLC6A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See NET Human Norepinephrine Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 296, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "SLC6A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6530, + "officialSymbol": "SLC6A2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": "P23975" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2693, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A3 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SLC6A3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "BTCP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2646, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A3", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A3 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A3 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]BTCP, are indicative of changes in transporter function and kinetics related to the gene SLC6A3.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]BTCP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 825, + "assayName": "ERF_CR_TR_hSLC6A3", + "assayDesc": "ERF_CR_TR_hSLC6A3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hour after chemical dosing in a 96-well plate. See DAT Human Dopamine Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 297, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "description": null, + "geneSymbol": "SLC6A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6531, + "officialSymbol": "SLC6A3", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "uniprotAccessionNumber": "Q01959" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2694, + "assayComponentEndpointName": "ERF_CR_TR_binding_hSLC6A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_TR_binding_hSLC6A4 was analyzed at the assay endpoint, ERF_CR_TR_binding_hSLC6A4, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "imipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "SLC6 / Monoamine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2647, + "assayComponentName": "ERF_CR_TR_binding_hSLC6A4", + "assayComponentDesc": "ERF_CR_TR_binding_hSLC6A4 is an assay component calculated from the ERF_CR_TR_binding_hSLC6A4 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]imipramine, are indicative of changes in transporter function and kinetics related to the gene SLC6A4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]imipramine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 818, + "assayName": "ERF_CR_TR_hSLC6A4", + "assayDesc": "ERF_CR_TR_hSLC6A4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See SET Human Serotonin Transporter Binding (Antagonist Radioligand) Assay, Cerep.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant CHO cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 298, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "SLC6A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6532, + "officialSymbol": "SLC6A4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31645" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2695, + "assayComponentEndpointName": "ERF_PL_TR_binding_rSLC18A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_rSLC18A2 was analyzed at the assay endpoint, ERF_PL_TR_binding_rSLC18A2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC18A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is vesicular transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrabenazine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "vesicular transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2648, + "assayComponentName": "ERF_PL_TR_binding_rSLC18A2", + "assayComponentDesc": "ERF_PL_TR_binding_rSLC18A2 is an assay component calculated from the ERF_PL_TR_binding_rSLC18A2 assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-dihydrotetrabenazine, are indicative of changes in transporter function and kinetics related to the gene SLC18A2.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydrotetrabenazine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 758, + "assayName": "ERF_PL_TR_rSLC18A2", + "assayDesc": "ERF_PL_TR_rSLC18A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See VMAT2 Rat Vesicular Monoamine Transporter Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat brain minus cerebellum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 408, + "geneName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "description": null, + "geneSymbol": "Slc18a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25549, + "officialSymbol": "Slc18a2", + "officialFullName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "uniprotAccessionNumber": "Q01827" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2696, + "assayComponentEndpointName": "ERF_PL_TR_binding_rTSPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_TR_binding_rTSPO was analyzed at the assay endpoint, ERF_PL_TR_binding_rTSPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "diazepam", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2649, + "assayComponentName": "ERF_PL_TR_binding_rTSPO", + "assayComponentDesc": "ERF_PL_TR_binding_rTSPO is an assay component calculated from the ERF_PL_TR_binding_rTSPO assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the receptor binding reaction involving the key ligand, [3H]-PK11195, are indicative of changes in transporter function and kinetics related to the gene TSPO.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 751, + "assayName": "ERF_PL_TR_rTSPO", + "assayDesc": "ERF_PL_TR_rTSPO is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See PBR Rat Binding (Antagonist Radioligand) Assay, Panlabs.", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "heart", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "male Wistar rat heart", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 382, + "geneName": "translocator protein", + "description": null, + "geneSymbol": "Tspo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24230, + "officialSymbol": "Tspo", + "officialFullName": "translocator protein", + "uniprotAccessionNumber": "P16257" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2697, + "assayComponentEndpointName": "UKN2_HCS_IMR90_neural_migration", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN2_HCS_IMR90_neural_migration was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neural crest cell migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cytochalasin D", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural crest cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2650, + "assayComponentName": "UKN2_HCS_IMR90_neural_migration", + "assayComponentDesc": "UKN2_HCS_IMR90_neural_migration is an assay component measured from the UKN2_HCS_IMR90 assay. It is designed to make measurements of neural crest cell migration, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of migrated cells are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neural crest cell migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33341", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of migrated cells", + "aid": 840, + "assayName": "UKN2_HCS_IMR90", + "assayDesc": "UKN2_HCS_IMR90 is a cell-based, multiplexed-readout assay screening for neural crest cell migration and cell viability that uses IMR90 (neural crest cells differentiated from iPSC), a human embryo cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN2, also known as cMINC, is an assay that uses IMR90 cells (neural crest cells differentiated from iPSC) as a model of neural crest cell migration. 24 hr after cell seeding, cell migration was initiated and proceeded for 24 hr. Then, chemical was applied, and after 24 hr of exposure migration and viability were assessed using high-content imaging of cells stained with calcein-AM and Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "IMR90 (neural crest cells differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-1977-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/28477266/", + "pmid": 28477266, + "title": "Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library", + "author": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M", + "citation": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M. Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266.", + "otherId": "0", + "citationId": 280, + "otherSource": "" + } + }, + { + "aeid": 2699, + "assayComponentEndpointName": "UKN2_HCS_IMR90_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN2_HCS_IMR90_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2651, + "assayComponentName": "UKN2_HCS_IMR90_cell_viability", + "assayComponentDesc": "UKN2_HCS_IMR90_cell_viability is an assay component measured from the UKN2_HCS_IMR90 assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33342", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 840, + "assayName": "UKN2_HCS_IMR90", + "assayDesc": "UKN2_HCS_IMR90 is a cell-based, multiplexed-readout assay screening for neural crest cell migration and cell viability that uses IMR90 (neural crest cells differentiated from iPSC), a human embryo cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN2, also known as cMINC, is an assay that uses IMR90 cells (neural crest cells differentiated from iPSC) as a model of neural crest cell migration. 24 hr after cell seeding, cell migration was initiated and proceeded for 24 hr. Then, chemical was applied, and after 24 hr of exposure migration and viability were assessed using high-content imaging of cells stained with calcein-AM and Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "IMR90 (neural crest cells differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-1977-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/28477266/", + "pmid": 28477266, + "title": "Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library", + "author": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M", + "citation": "Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, Leist M. Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266.", + "otherId": "0", + "citationId": 280, + "otherSource": "" + } + }, + { + "aeid": 2701, + "assayComponentEndpointName": "UKN4_HCS_LUHMES_neurite_outgrowth", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN4_HCS_LUHMES_neurite_outgrowth was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Narciclasine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2652, + "assayComponentName": "UKN4_HCS_LUHMES_neurite_outgrowth", + "assayComponentDesc": "UKN4_HCS_LUHMES_neurite_outgrowth is an assay component measured from the UKN4_HCS_LHUMES assay. It is designed to make measurements of neurite outgrowth, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33343", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area", + "aid": 841, + "assayName": "UKN4_HCS_LUHMES", + "assayDesc": "UKN4_HCS_LUHMES is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses LUHMES, a human central nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN4, also referred to as NeuriTox, is an assay that uses LUHMES neuronal precursors as a model of dopaminergic neuronal differentiation. Following a 2-day differentiation period, cells are exposed to chemicals for 24 hr and neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "central nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "LUHMES", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2703, + "assayComponentEndpointName": "UKN4_HCS_LUHMES_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN4_HCS_LUHMES_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2653, + "assayComponentName": "UKN4_HCS_LUHMES_cell_viability", + "assayComponentDesc": "UKN4_HCS_LUHMES_cell_viability is an assay component measured from the UKN4_HCS_LHUMES assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33344", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 841, + "assayName": "UKN4_HCS_LUHMES", + "assayDesc": "UKN4_HCS_LUHMES is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses LUHMES, a human central nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN4, also referred to as NeuriTox, is an assay that uses LUHMES neuronal precursors as a model of dopaminergic neuronal differentiation. Following a 2-day differentiation period, cells are exposed to chemicals for 24 hr and neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "central nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "LUHMES", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2705, + "assayComponentEndpointName": "ERF_PL_NR_binding_hPPARG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_binding_hPPARG was analyzed at the assay endpoint, ERF_PL_NR_binding_hPPARG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding receptor, gain-of-signal activity can be used to understand changes in binding receptor as they relate to gene PPARG.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2654, + "assayComponentName": "ERF_PL_NR_binding_hPPARG", + "assayComponentDesc": "ERF_PL_NR_binding_hPPARG is an assay component calculated from the ERF_PL_NR_hPPARG assay. It is designed to measure radioligand binding using a type of binding reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in radiometry produced from the receptor binding reaction involving the ligand [3H] Rosiglitazone are indicative of changes in receptor function and kinetics related to the gene PPARG.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H] Rosiglitazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 842, + "assayName": "ERF_PL_NR_hPPARG", + "assayDesc": "ERF_PL_NR_hPPARG is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 24 hour after chemical dosing in a 96-well plate. See PPARgamma Human NHR Binding (Agonist Radioligand) Assay, Panlabs.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2731, + "assayComponentEndpointName": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_HCS_1.5hr_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, TAMU_HCS_1.5hr_Cytotoxicity, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2667, + "assayComponentName": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity", + "assayComponentDesc": "TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity is a phenotype derived from the Total.Cells parameter and uses an EC10 as its POD (10% decrease in total cell count, compared to controls). Total Cells measures the total number of nuclei (cell count) using HCS Fluorescent Imaging technology. There is no preprocessing performed on the data to model this phenotype.", + "assayComponentTargetDesc": "Changes in the total number of nuclei (cell count) is used to quantify changes in cell number, which can be an indication of cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye; MitoTracker Orange; Ca+2 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 843, + "assayName": "TAMU_HCS_1.5hr", + "assayDesc": "TAMU_HCS_1.5hr is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2760, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_QT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_QT was analyzed into 1 assay endpoints. This assay endpoint, TAMU_PeakParms_SingleDonor1434_QT_Prolongation, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is QT interval.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "QT interval", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2682, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_QT", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_QT is a phenotype derived from the decay.rise.ratio.avg parameter and uses an EC05 as its POD (5% increase in decay/rise ratio, compared to controls). Decay.Rise.Ratio.Average measures as the average ratio between the rise time and the decay time of the calcium flux, using Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. Before modeling, data is preprocessed to remove data points where there is a cessation of beating (where peak.freq.avg equals 0) and data points after they develop of a severe notch phenotype in order to avoid capturing non monotonic effects related to an advanced pathology.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in the QT interval, which can be an indication of an increased QT interval, a significant risk factor for severe arrhythmia. ", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "QT interval", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average ratio between the rise time and the decay time of the calcium flux", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2767, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_Chronotropy", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_Chronotropy was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Chronotropy_Negative, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is lowered beat rate.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "lowered beat rate", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2685, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_Chronotropy", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_Chronotopy is a phenotype derived from the peak.freq.avg parameter and uses an EC05 as its POD (5% increase in beat rate, compared to controls). Peak.Freq.Avg measures the average peak frequency, in beats per second, uisng Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. Before modeling, data is preprocessed to remove data points where there is a cessation of beating (where peak.freq.avg equals 0) to ensure the capture of the upwards response that isn't confounded by the drop in beat rate at higher concentrations and to ensure the drop in beat rate is captured before asystole, which is captured elsewhere.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in peak frequency, which can be an indication of elevated or lowered beat rate.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "beating", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average peak frequency, in beats per second", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 2771, + "assayComponentEndpointName": "IUF_NPC1b_proliferation_BrdU_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1b_proliferation_BrdU component was analyzed at the endpoint IUF_NPC1b_proliferation_BrdU in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain or loss-of-signal activity can be used to understand cell proliferation effects.", + "assayFunctionType": "cell proliferation", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "media without growth factors", + "signalDirection": "bidirectional", + "intendedTargetType": "dna", + "intendedTargetTypeSub": "dna-unspecified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2687, + "assayComponentName": "IUF_NPC1b_proliferation_BrdU_72hr", + "assayComponentDesc": "IUF_NPC1b_proliferation_BrdU_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell proliferation as assessed by the incorporation of Bromodeoxyuridine (BrdU) in the last 16 h of a 72 h compound exposure using a luminescence-based cell proliferation ELISA.", + "assayComponentTargetDesc": "Changes to chemiluminescence signals based on BrdU incorporation during DNA synthesis in proliferating cells are correlated to proliferation of the system.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Chemiluminescence", + "detectionTechnologyTypeSub": "luminescence intensity", + "detectionTechnology": "Luminescence-based cell proliferation ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "BrdU antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "BrdU labeled DNA", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2773, + "assayComponentEndpointName": "IUF_NPC1a_proliferation_area_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1a_proliferation_area component was analyzed at the endpoint IUF_NPC1a_proliferation_area in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain or loss-of-signal activity can be used to understand cell proliferation effects.", + "assayFunctionType": "cell proliferation", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "media without growth factors", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "sphere size", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2688, + "assayComponentName": "IUF_NPC1a_proliferation_area_72hr", + "assayComponentDesc": "IUF_NPC1a_proliferation_area_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell proliferation as assessed by an increase in sphere area over 72 h using automated phase contrast imaging.", + "assayComponentTargetDesc": "Changes in sphere size based on microscopic measurements are correlated to the proliferation of the system. ", + "parameterReadoutType": "multiplexed", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Increases in sphere area", + "detectionTechnology": "Automated phase contrast imaging ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "sphere size", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2775, + "assayComponentEndpointName": "IUF_NPC1_viability_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1_viability component was analyzed at the endpoint IUF_NPC1_viability in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2689, + "assayComponentName": "IUF_NPC1_viability_72hr", + "assayComponentDesc": "IUF_NPC1_viability_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cell viability assessed as mitochondria-dependent reduction of resazurin to resorufin using the alamar blue cell viability assay. Viability is measured as a fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in mitochondrial activity are correlated to cellular viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar blue viability assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2776, + "assayComponentEndpointName": "ERF_PL_NR_COA_hFXR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_NR_COA_hFXR_Agonist was analyzed at the assay endpoint, ERF_PL_NR_COA_hFXR_Agonist, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2690, + "assayComponentName": "ERF_PL_NR_COA_binding_hFXR_Agonist", + "assayComponentDesc": "ERF_PL_NR_COA_hFXR_Agonist is an assay component calculated from the ERF_PL_NR_COA_hFXR_Agonist assay. It is designed to measure TR-FRET using a type of binding reporter as detected by fluorescence intensity with FRET: TR-FRET technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the receptor binding reaction involving the key ligand;antibody, Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody, are indicative of changes in receptor function and kinetics related to the gene NR1H4.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "FRET", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FRET: TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide; Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 847, + "assayName": "ERF_PL_NR_COA_hFXR_Agonist", + "assayDesc": "ERF_PL_NR_COA_hFXR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate. See FXR Human Liver X Receptor-Like NHR Functional Agonist Coactivator Assay, Panlabs.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2777, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2699, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the number of branch points using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2778, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2698, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2779, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2697, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures neurite outgrowth related to the neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2780, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2696, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_Cortical_NOG assay. It measures cell viability related to the number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 850, + "assayName": "CCTE_Mundy_HCI_Cortical_NOG", + "assayDesc": "CCTE_Mundy_HCI_Cortical_NOG is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2781, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2707, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of branch points using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2782, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2702, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of cell body-associated synapses (synaptophysin puncta) per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of cell body-associated synapses (synaptophysin puncta) per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of cell body-associated synapses (synaptophysin puncta) per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2783, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2706, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2784, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2705, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2785, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2704, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurite-associated synapses (synaptophysin puncta) per unit length of neurite", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2786, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2703, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of neurite-associated synapses (synaptophysin puncta) per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurite-associated synapses (synaptophysin puncta) per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurite-associated synapses (synaptophysin puncta) per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2787, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2701, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MAP2 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2788, + "assayComponentEndpointName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "synaptogenesis and neurite maturation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2708, + "assayComponentName": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount", + "assayComponentDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount is one of eight components of the CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur assay. It measures synaptogenesis and neurite maturation related to number of synpases per neuron using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of synpases per neuron are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "synaptogenesis and neurite maturation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Synaptophysin antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of synpases per neuron", + "aid": 852, + "assayName": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur", + "assayDesc": "CCTE_Mundy_HCI_Cortical_Synap&Neurite_Matur is a multiplexed, cell-based-readout assay that uses rat primary cortical cells with measurements taken at 288.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 288.33, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "rat primary cortical cells", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2789, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects. This assay component endpoint is considered less reliable by experts on the assay due to low occurrence of branch points in the hN2 cells. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2695, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the hN2 cells. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2790, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2694, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2791, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2693, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2792, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2692, + "assayComponentName": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_hN2_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_hN2_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 849, + "assayName": "CCTE_Mundy_HCI_hN2_NOG", + "assayDesc": "CCTE_Mundy_HCI_hN2_NOG is a multiplexed, cell-based-readout assay that uses immature neurons derived from hNP1 neuroprogenitor cells with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "immature neurons derived from hNP1 neuroprogenitor cells", + "cellShortName": "hN2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2793, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine (0.1 uM)", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2691, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_Casp3_7 is one component of the CCTE_Mundy_HCI_hNP1_Casp3_7 assay. It measures apoptosis related to caspase activation using Luminescent Reporter.", + "assayComponentTargetDesc": "Changes in the caspase activation are indicative of cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "apoptosis", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "Luminescent Reporter", + "keyAssayReagentType": "luciferase assay", + "keyAssayReagent": "Caspase-Glo 3/7 detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase activation", + "aid": 848, + "assayName": "CCTE_Mundy_HCI_hNP1_Casp3_7", + "assayDesc": "CCTE_Mundy_HCI_hNP1_Casp3_7 is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.5 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.5, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2794, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_CellTiter was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_CellTiter in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine (0.1 uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cell count", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2700, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_CellTiter is one component of the CCTE_Mundy_HCI_hNP1_CellTiter assay. It measures cell viability related to ATP content using Luminescent Reporter.", + "assayComponentTargetDesc": "Changes in the ATP content are indicative of cell viability.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "Luminescent Reporter", + "keyAssayReagentType": "luciferase assay", + "keyAssayReagent": "CellTiter-Glo assay buffer", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "ATP content", + "aid": 851, + "assayName": "CCTE_Mundy_HCI_hNP1_CellTiter", + "assayDesc": "CCTE_Mundy_HCI_hNP1_CellTiter is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.5 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.5, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2797, + "assayComponentEndpointName": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "aphidicolin (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2710, + "assayComponentName": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten", + "assayComponentDesc": "CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten is one of three components of the CCTE_Mundy_HCI_hNP1_Pro assay. It measures proliferation related to percentage of BrdU positive cells using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the percentage of BrdU positive cells are indicative of cell proliferation.", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "proliferation", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Brdu antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "percentage of BrdU positive cells", + "aid": 853, + "assayName": "CCTE_Mundy_HCI_hNP1_Pro", + "assayDesc": "CCTE_Mundy_HCI_hNP1_Pro is a multiplexed, cell-based-readout assay that uses neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells with measurements taken at 26.25 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 26.25, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural stem cells derived from a neuroepithelial cell lineage of WA09 embryonic cells", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 2808, + "assayComponentEndpointName": "UTOR_hL-FABP_binding_Kd", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UTOR_hL-FABP_binding was analyzed into 1 assay endpoint. This assay enddpoint, UTOR_hL-FABP_binding_Kd, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, measures of fluorescence for loss-of-signal activity can be used to understand competitive binding of L-FABP. Furthermore, this assay endpoint can be referred to as the primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is fatty acid binding protein.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1,8-ANS", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "fatty acid binding protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2717, + "assayComponentName": "UTOR_hL-FABP_binding_Kd", + "assayComponentDesc": "UTOR_hL-FABP_binding_Kd is the calculated from the UTOR_hL-FABP_binding assay. It is a measuremnt of hL-FABP binding affinity as detected with fluorescence intensity signals by size-exclusion chromatography-co-elution (SECC) and nontarget analysis (NTA) technology by mass spectroscopy. An IC50 was obtained from dose-response curves and converted into its corresponding dissociation constant (Kd) concentration for tcpl processing as a single concentration value.", + "assayComponentTargetDesc": "Liver fatty acid binding protein (L-FABP) is a primarily expressed in the liver where it is involved in the binding, transport and metabolism of long-chain fatty acids and other hydrophobic molecules including xenobiotics like PFAS. The binding of PFAS to hL-FABP with increasing concentrations displaces 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) resulting in the loss of fluorescence intensity of the latter.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescence displacement", + "biologicalProcessTarget": "L-FABP binding affinity", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "size-exclusion chromatography-co-elution (SECC) and mass spectrometry using an LC-Orbitrap for non-targeted analysis (NTA)", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "1-anilinonaphthalene-8-sulfonic acid (1,8-ANS)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "hL-FABP protein-bound 1,8-ANS", + "aid": 855, + "assayName": "UTOR_hL-FABP_binding", + "assayDesc": "UTOR_hL-FABP_binding is a cell-free, single-readout assay that uses extracted liver fatty acid binding proteins (hL-FABP) from E. coli lysates with measurements taken at 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "BL 21 (DE3) strain of E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "biochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "NA", + "dilutionSolventPercentMax": null, + "asid": 32, + "assaySourceName": "UTOR", + "assaySourceLongName": "University of Toronto, Peng Laboratory", + "assaySourceDesc": "The Peng Lab at the University of Toronto screened PFAS binding to hL-FABP through a Material Transfer Agreement for the PFAS screening library.", + "gene": { + "geneId": 124, + "geneName": "fatty acid binding protein 1, liver", + "description": null, + "geneSymbol": "FABP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2168, + "officialSymbol": "FABP1", + "officialFullName": "fatty acid binding protein 1, liver", + "uniprotAccessionNumber": "P07148" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.est.0c00049", + "url": "https://pubmed.ncbi.nlm.nih.gov/32249562/", + "pmid": 32249562, + "title": "Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty Acid Binding Protein", + "author": "Yang D, Han J, Hall DR, Sun J, Fu J, Kutarna S, Houck KA, LaLone CA, Doering JA, Ng CA, Peng H", + "citation": "Yang D, Han J, Hall DR, Sun J, Fu J, Kutarna S, Houck KA, LaLone CA, Doering JA, Ng CA, Peng H. Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty Acid Binding Protein. Environ Sci Technol. 2020 May 5;54(9):5676-5686. doi: 10.1021/acs.est.0c00049. Epub 2020 Apr 16. PMID: 32249562; PMCID: PMC7477755.", + "otherId": "0", + "citationId": 243, + "otherSource": "" + } + }, + { + "aeid": 2809, + "assayComponentEndpointName": "BSK_BT_Bcell_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_Bcell_Proliferation was analyzed at the endpoint, BSK_BT_Bcell_Proliferation, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1068, + "assayComponentName": "BSK_BT_Bcell_Proliferation", + "assayComponentDesc": "BSK_BT_Bcell_Proliferation is an assay component measured in the BSK_BT assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", + "assayComponentTargetDesc": "B cell proliferation is a critical event driving both adaptive immunity (antibody production) as well as auto-immune diseases where B cells are key disease players (Lupus, MS, RA etc). Inhibition of B cell proliferation is considered an immune supressive effect.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2811, + "assayComponentEndpointName": "BSK_BT_PBMCCytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_PBMCCytotoxicity was analyzed at the endpoint, BSK_BT_PBMCCytotoxicity, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1069, + "assayComponentName": "BSK_BT_PBMCCytotoxicity", + "assayComponentDesc": "BSK_BT_PBMCCytotoxicity is an assay component measured in the BSK_BT assay. It measures dehydrogenase activity, a form of viability reporter, as detected with fluorescence intensity signals by Alamar Blue Reduction technology.", + "assayComponentTargetDesc": "PBMC Cytotoxicity in the BT system is a measure of the cell death of PBMC. Cell viability of non-adherent cells is measured by alamarBlue® staining, a method based on a cell permeable compound that emitts fluorescence after entering cells. The number of living cells is proportional to the amount of fluorescence produced", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar Blue Reduction", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Alamar blue", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2813, + "assayComponentEndpointName": "BSK_BT_sIgG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_sIgG was analyzed at the endpoint, BSK_BT_sIgG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'immunoglobulin' intended target family, where the subfamily is 'IgG'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "immunoglobulin", + "intendedTargetFamilySub": "IgG", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1070, + "assayComponentName": "BSK_BT_sIgG", + "assayComponentDesc": "BSK_BT_sIgG is an assay component measured in the BSK_BT assay. It measures secreted IgG related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Secreted IgG (sIgG) is produced by B cells and is the main type of antibody found in blood and extracellular fluid that mediates the immune response against pathogens. sIgG is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IgG", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4172, + "geneName": "immunoglobulin heavy constant gamma 1 (G1m marker)", + "description": null, + "geneSymbol": "IGHG1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3500, + "officialSymbol": "IGHG1", + "officialFullName": "immunoglobulin heavy constant gamma 1 (G1m marker)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2815, + "assayComponentEndpointName": "BSK_BT_xIL17A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL17A was analyzed at the endpoint, BSK_BT_xIL17A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1071, + "assayComponentName": "BSK_BT_xIL17A", + "assayComponentDesc": "BSK_BT_xIL17A is an assay component measured in the BSK_BT assay. It measures secreted IL-17A related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 17A (IL-17A) is a proinflammatory cytokine produced by T cells that induces cytokine production and mediates monocyte and neutrophil recruitment to sites of inflammation. Secreted IL-17A (sIL-17A) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-17A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4248, + "geneName": "interleukin 17A", + "description": null, + "geneSymbol": "IL17A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3605, + "officialSymbol": "IL17A", + "officialFullName": "interleukin 17A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2817, + "assayComponentEndpointName": "BSK_BT_xIL17F", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL17F was analyzed at the endpoint, BSK_BT_xIL17F, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1072, + "assayComponentName": "BSK_BT_xIL17F", + "assayComponentDesc": "BSK_BT_xIL17F is an assay component measured in the BSK_BT assay. It measures secreted IL-17F related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 17F (IL-17F) is a proinflammatory cytokine produced by T cells that induces cytokine, chemokine and adhesion molecule production and mediates neutrophil recruitment to sites of inflammation. Secreted IL-17F (sIL-17F) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-17F", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 18205, + "geneName": "interleukin 17F", + "description": null, + "geneSymbol": "IL17F", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 112744, + "officialSymbol": "IL17F", + "officialFullName": "interleukin 17F", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2819, + "assayComponentEndpointName": "BSK_BT_xIL2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL2 was analyzed at the endpoint, BSK_BT_xIL2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1073, + "assayComponentName": "BSK_BT_xIL2", + "assayComponentDesc": "BSK_BT_xIL2 is an assay component measured in the BSK_BT assay. It measures secreted IL-2 related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 2 (IL-2) is a secreted proinflammatory cytokine produced by T cells that regulates lymphocyte proliferation and promotes T cell differentiation. Secreted IL-2 (IL-2) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4213, + "geneName": "interleukin 2", + "description": null, + "geneSymbol": "IL2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3558, + "officialSymbol": "IL2", + "officialFullName": "interleukin 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2821, + "assayComponentEndpointName": "BSK_BT_xIL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xIL6 was analyzed at the endpoint, BSK_BT_xIL6, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1074, + "assayComponentName": "BSK_BT_xIL6", + "assayComponentDesc": "BSK_BT_xIL6 is an assay component measured in the BSK_BT assay. It measures secreted IL-6 related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Interleukin 6 (IL-6) is a secreted proinflammatory cytokine and acute phase reactant. Secreted IL-6 (sIL-6) is categorized as an immunomodulatory-related activity in the BT system modeling T cell depdendent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted IL-6", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2823, + "assayComponentEndpointName": "BSK_BT_xTNFa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BT_xTNFa was analyzed at the endpoint, BSK_BT_xTNFa, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of cytokine quantitation reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1075, + "assayComponentName": "BSK_BT_xTNFa", + "assayComponentDesc": "BSK_BT_xTNFa is an assay component of the BSK_BT assay. It measures secreted TNF-alpha related to regulation of gene expression using LumineX xMAP technology.", + "assayComponentTargetDesc": "Tumor necrosis factor alpha (TNF-alpha) is a secreted proinflammatory cytokine involved in Th1 inflammation. Secreted TNF-alpha is categorized as an inflammation-related activity in the BT system modeling T cell dependent B cell activation.", + "parameterReadoutType": "single", + "assayDesignType": "cytokine quantitation reporter", + "assayDesignTypeSub": "cytokine-specific antibody bead-based method", + "biologicalProcessTarget": "regulation of gene protein expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LumineX xMAP", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "secreted TNF-alpha", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 433, + "assayName": "BSK_BT", + "assayDesc": "BSK_BT is a cell-based, multiplexed-readout assay that uses B cell and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "B and peripheral blood mononuclear cells", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 327, + "geneName": "tumor necrosis factor", + "description": null, + "geneSymbol": "TNF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7124, + "officialSymbol": "TNF", + "officialFullName": "tumor necrosis factor", + "uniprotAccessionNumber": "P01375" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2825, + "assayComponentEndpointName": "BSK_MyoF_ACTA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_ACTA1 was analyzed at the endpoint, BSK_MyoF_ACTA1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'actin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "actin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1081, + "assayComponentName": "BSK_MyoF_ACTA1", + "assayComponentDesc": "BSK_MyoF_ACTA1 is an assay component measured in the BSK_MyoF assay. It measures a-SMA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "alpha-Smooth muscle actin (a-SMA) is a protein involved in muscle contraction, cell motility, structure and integrity and is a marker for activated myofibroblast phenotype. a-SMA is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "a-SMA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 1526, + "geneName": "actin, alpha 1, skeletal muscle", + "description": null, + "geneSymbol": "ACTA1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 58, + "officialSymbol": "ACTA1", + "officialFullName": "actin, alpha 1, skeletal muscle", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2827, + "assayComponentEndpointName": "BSK_MyoF_bFGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_bFGF was analyzed at the endpoint, BSK_MyoF_bFGF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'basic fibroblast growth factor '.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "basic fibroblast growth factor ", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1082, + "assayComponentName": "BSK_MyoF_bFGF", + "assayComponentDesc": "BSK_MyoF_bFGF is an assay component measured in the BSK_MyoF assay. It measures bFGF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Basic fibroblast growth factor (bFGF) is a pro-fibrotic growth factor that drives fibroblast proliferation, migration and fibronectin synthesis. bFGF is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bFGF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 3172, + "geneName": "fibroblast growth factor 2", + "description": null, + "geneSymbol": "FGF2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2247, + "officialSymbol": "FGF2", + "officialFullName": "fibroblast growth factor 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2829, + "assayComponentEndpointName": "BSK_MyoF_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_VCAM1 was analyzed at the endpoint, BSK_MyoF_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1083, + "assayComponentName": "BSK_MyoF_VCAM1", + "assayComponentDesc": "BSK_MyoF_VCAM1 is an assay component measured in the BSK_MyoF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2831, + "assayComponentEndpointName": "BSK_MyoF_CollagenI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenI was analyzed at the endpoint, BSK_MyoF_CollagenI, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1084, + "assayComponentName": "BSK_MyoF_CollagenI", + "assayComponentDesc": "BSK_MyoF_CollagenI is an assay component measured in the BSK_MyoF assay. It measures Collagen I antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen I is involved in tissue remodeling and fibrosis, and is the most common fibrillar collagen that is found in skin, bone, tendons and other connective tissues. Collagen I is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen I antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2452, + "geneName": "collagen type I alpha 1 chain", + "description": null, + "geneSymbol": "COL1A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1277, + "officialSymbol": "COL1A1", + "officialFullName": "collagen type I alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2833, + "assayComponentEndpointName": "BSK_MyoF_CollagenIII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenIII was analyzed at the endpoint, BSK_MyoF_CollagenIII, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1085, + "assayComponentName": "BSK_MyoF_CollagenIII", + "assayComponentDesc": "BSK_MyoF_CollagenIII is an assay component measured in the BSK_MyoF assay. It measures Collagen III antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen III is an extracellular matrix protein and fibrillar collagen found in extensible connective tissues (skin, lung and vascular system) and is involved in cell adhesion, cell migration, tissue remodeling. Collagen III is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen III antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 70, + "geneName": "collagen, type III, alpha 1", + "description": null, + "geneSymbol": "COL3A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1281, + "officialSymbol": "COL3A1", + "officialFullName": "collagen, type III, alpha 1", + "uniprotAccessionNumber": "P02461" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2835, + "assayComponentEndpointName": "BSK_MyoF_CollagenIV", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_CollagenIV was analyzed at the endpoint, BSK_MyoF_CollagenIV, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1086, + "assayComponentName": "BSK_MyoF_CollagenIV", + "assayComponentDesc": "BSK_MyoF_CollagenIV is an assay component measured in the BSK_MyoF assay. It measures Collagen IV antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen IV is the major structural component of the basal lamina. Collagen IV is categorized a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen IV antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2456, + "geneName": "collagen type IV alpha 1 chain", + "description": null, + "geneSymbol": "COL4A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1282, + "officialSymbol": "COL4A1", + "officialFullName": "collagen type IV alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2837, + "assayComponentEndpointName": "BSK_MyoF_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_IL8 was analyzed at the endpoint, BSK_MyoF_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1087, + "assayComponentName": "BSK_MyoF_IL8", + "assayComponentDesc": "BSK_MyoF_IL8 is an assay component measured in the BSK_MyoF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2839, + "assayComponentEndpointName": "BSK_MyoF_Decorin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_Decorin was analyzed at the endpoint, BSK_MyoF_Decorin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'decorin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "decorin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1088, + "assayComponentName": "BSK_MyoF_Decorin", + "assayComponentDesc": "BSK_MyoF_Decorin is an assay component measured in the BSK_MyoF assay. It measures Decorin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Decorin is a proteoglycan that is a component of connective tissue and is involved in collagen and matrix assembly. Decorin is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Decorin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2723, + "geneName": "decorin", + "description": null, + "geneSymbol": "DCN", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1634, + "officialSymbol": "DCN", + "officialFullName": "decorin", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2841, + "assayComponentEndpointName": "BSK_MyoF_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_MMP1 was analyzed at the endpoint, BSK_MyoF_MMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1089, + "assayComponentName": "BSK_MyoF_MMP1", + "assayComponentDesc": "BSK_MyoF_MMP1 is an assay component measured in the BSK_MyoF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades collagens I, II and III and is involved in the process of tissue remodeling. MMP-1 is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2843, + "assayComponentEndpointName": "BSK_MyoF_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_PAI1 was analyzed at the endpoint, BSK_MyoF_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1090, + "assayComponentName": "BSK_MyoF_PAI1", + "assayComponentDesc": "BSK_MyoF_PAI1 is an assay component measured in the BSK_MyoF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2845, + "assayComponentEndpointName": "BSK_MyoF_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_SRB was analyzed at the endpoint, BSK_MyoF_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1091, + "assayComponentName": "BSK_MyoF_SRB", + "assayComponentDesc": "BSK_MyoF_SRB is an assay component measured in the BSK_MyoF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the MyoF system is a measure of the total protein content of lung fibroblasts. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2847, + "assayComponentEndpointName": "BSK_MyoF_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_MyoF_TIMP1 was analyzed at the endpoint, BSK_MyoF_TIMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1092, + "assayComponentName": "BSK_MyoF_TIMP1", + "assayComponentDesc": "BSK_MyoF_TIMP1 is an assay component measured in the BSK_MyoF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-1 is a tissue inhibitor of matrix metalloprotease-7 (MMP-7) and other MMPs, and is involved in tissue remodeling, angiogenesis and fibrosis. TIMP-1 is categorized as a tissue remodeling-related activity in the MyoF system modeling pulmonary myofibroblast development.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 435, + "assayName": "BSK_MyoF", + "assayDesc": "BSK_MyoF is a cell-based, multiplexed-readout assay that uses lung fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "lung fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2849, + "assayComponentEndpointName": "BSK_BF4T_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MCP1 was analyzed at the endpoint, BSK_BF4T_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2719, + "assayComponentName": "BSK_BF4T_MCP1", + "assayComponentDesc": "BSK_BF4T_MCP1 is an assay component measured in the BSK_BF4T assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2851, + "assayComponentEndpointName": "BSK_BF4T_Eotaxin3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_Eotaxin3 was analyzed at the endpoint, BSK_BF4T_Eotaxin3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2720, + "assayComponentName": "BSK_BF4T_Eotaxin3", + "assayComponentDesc": "BSK_BF4T_Eotaxin3 is an assay component measured in the BSK_BF4T assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Eotaxin-3/CCL26 is a chemokine that mediates recruitment of eosinophils and basophils into tissue sites. Eotaxin-3 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Eotaxin-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 365, + "geneName": "chemokine (C-C motif) ligand 26", + "description": null, + "geneSymbol": "CCL26", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10344, + "officialSymbol": "CCL26", + "officialFullName": "chemokine (C-C motif) ligand 26", + "uniprotAccessionNumber": "Q9Y258" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2853, + "assayComponentEndpointName": "BSK_BF4T_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_VCAM1 was analyzed at the endpoint, BSK_BF4T_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2721, + "assayComponentName": "BSK_BF4T_VCAM1", + "assayComponentDesc": "BSK_BF4T_VCAM1 is an assay component measured in the BSK_BF4T assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2855, + "assayComponentEndpointName": "BSK_BF4T_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_ICAM1 was analyzed at the endpoint, BSK_BF4T_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2722, + "assayComponentName": "BSK_BF4T_ICAM1", + "assayComponentDesc": "BSK_BF4T_ICAM1 is an assay component measured in the BSK_BF4T assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2857, + "assayComponentEndpointName": "BSK_BF4T_CD90", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_CD90 was analyzed at the endpoint, BSK_BF4T_CD90, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2723, + "assayComponentName": "BSK_BF4T_CD90", + "assayComponentDesc": "BSK_BF4T_CD90 is an assay component measured in the BSK_BF4T assay. It measures CD90 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD90 is a cell surface glycoprotein that mediates cell-cell and cell-matrix interactions. CD90 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD90 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6890, + "geneName": "Thy-1 cell surface antigen", + "description": null, + "geneSymbol": "THY1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7070, + "officialSymbol": "THY1", + "officialFullName": "Thy-1 cell surface antigen", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2859, + "assayComponentEndpointName": "BSK_BF4T_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_IL8 was analyzed at the endpoint, BSK_BF4T_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2724, + "assayComponentName": "BSK_BF4T_IL8", + "assayComponentDesc": "BSK_BF4T_IL8 is an assay component measured in the BSK_BF4T assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2861, + "assayComponentEndpointName": "BSK_BF4T_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_IL1a was analyzed at the endpoint, BSK_BF4T_IL1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2725, + "assayComponentName": "BSK_BF4T_IL1a", + "assayComponentDesc": "BSK_BF4T_IL1a is an assay component measured in the BSK_BF4T assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 1 alpha (IL-1a) is a secreted proinflammatory cytokine involved in endothelial cell activation and neutrophil recruitment. Secreted IL-1? (sIL-1?)is categorized as an inflammation-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2863, + "assayComponentEndpointName": "BSK_BF4T_Keratin818", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_Keratin818 was analyzed at the endpoint, BSK_BF4T_Keratin818, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2726, + "assayComponentName": "BSK_BF4T_Keratin818", + "assayComponentDesc": "BSK_BF4T_Keratin818 is an assay component measured in the BSK_BF4T assay. It measures Keratin 8/18 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Keratin 8/18 is an intermediate filament heterodimer of fibrous structural poteins involved in Epithelial cell death, EMT, COPD, Lung Inflammation. Keratin 8/18 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Keratin 8/18 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4459, + "geneName": "keratin 18", + "description": null, + "geneSymbol": "KRT18", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3875, + "officialSymbol": "KRT18", + "officialFullName": "keratin 18", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2865, + "assayComponentEndpointName": "BSK_BF4T_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP1 was analyzed at the endpoint, BSK_BF4T_MMP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2727, + "assayComponentName": "BSK_BF4T_MMP1", + "assayComponentDesc": "BSK_BF4T_MMP1 is an assay component measured in the BSK_BF4T assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades collagens I, II and III and is involved in the process of tissue remodeling. MMP-1 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2867, + "assayComponentEndpointName": "BSK_BF4T_MMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP3 was analyzed at the endpoint, BSK_BF4T_MMP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2728, + "assayComponentName": "BSK_BF4T_MMP3", + "assayComponentDesc": "BSK_BF4T_MMP3 is an assay component measured in the BSK_BF4T assay. It measures MMP-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-3 (MMP-3) is an enzyme involved in tissue remodeling that can activate other MMPs (MMP-1, MMP-7 and MMP-9) and degrade collagens (II, III, IV, IX and X), proteoglycans, fibronectin, laminin and elastin. MMP-3 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2869, + "assayComponentEndpointName": "BSK_BF4T_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_MMP9 was analyzed at the endpoint, BSK_BF4T_MMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2729, + "assayComponentName": "BSK_BF4T_MMP9", + "assayComponentDesc": "BSK_BF4T_MMP9 is an assay component measured in the BSK_BF4T assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-9 (MMP-9) is a gelatinase B that degrades collagen IV and gelatin and is involved in airway matrix remodeling. MMP-9 is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2871, + "assayComponentEndpointName": "BSK_BF4T_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_PAI1 was analyzed at the endpoint, BSK_BF4T_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2730, + "assayComponentName": "BSK_BF4T_PAI1", + "assayComponentDesc": "BSK_BF4T_PAI1 is an assay component measured in the BSK_BF4T assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2873, + "assayComponentEndpointName": "BSK_BF4T_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_SRB was analyzed at the endpoint, BSK_BF4T_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2731, + "assayComponentName": "BSK_BF4T_SRB", + "assayComponentDesc": "BSK_BF4T_SRB is an assay component measured in the BSK_BF4T assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the BF4T system is a measure of the total protein content of bronchial epithelial cells and dermal fibroblasts. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2875, + "assayComponentEndpointName": "BSK_BF4T_tPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4T_tPA was analyzed at the endpoint, BSK_BF4T_tPA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2732, + "assayComponentName": "BSK_BF4T_tPA", + "assayComponentDesc": "BSK_BF4T_tPA is an assay component measured in the BSK_BF4T assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue plasminogen activator (tPA) is a serine protease that catalyzes the cleavage of plasminogen to plasmin and regulates clot degradation. tPA is involved in fibrinolyis, cell migration and tissue remodeling. tPA is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "tPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 239, + "geneName": "plasminogen activator, tissue", + "description": null, + "geneSymbol": "PLAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5327, + "officialSymbol": "PLAT", + "officialFullName": "plasminogen activator, tissue", + "uniprotAccessionNumber": "P00750" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2877, + "assayComponentEndpointName": "BSK_BF4T_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BF4TA was analyzed at the endpoint, BSK_BF4TA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2733, + "assayComponentName": "BSK_BF4T_uPA", + "assayComponentDesc": "BSK_BF4TA is an assay component measured in the BSK_BF4T assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Urokinse plasminogen activator (uPA) is a serine protease with thrombolytic activity. Triggers fibrinolysis and extracellular matrix degradation. uPA is categorized as a tissue remodeling-related activity in the BF4T system modeling Th2 airway inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 857, + "assayName": "BSK_BF4T", + "assayDesc": "BSK_BF4T is a cell-based, multiplexed-readout assay that uses bronchial epithelial cells and dermal fibroblasts, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells and dermal fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2879, + "assayComponentEndpointName": "BSK_BE3C_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_ICAM1 was analyzed at the endpoint, BSK_BE3C_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2734, + "assayComponentName": "BSK_BE3C_ICAM1", + "assayComponentDesc": "BSK_BE3C_ICAM1 is an assay component measured in the BSK_BE3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2881, + "assayComponentEndpointName": "BSK_BE3C_ITAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_ITAC was analyzed at the endpoint, BSK_BE3C_ITAC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2735, + "assayComponentName": "BSK_BE3C_ITAC", + "assayComponentDesc": "BSK_BE3C_ITAC is an assay component measured in the BSK_BE3C assay. It measures I-TAC antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interferon inducible T Cell Alpha Chemoattractant (I-TAC/CXCL11) is a chemokine that mediates T cell and monocyte chemotaxis. I-TAC is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation. ", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "I-TAC antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6313, + "geneName": "C-X-C motif chemokine ligand 11", + "description": null, + "geneSymbol": "CXCL11", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6373, + "officialSymbol": "CXCL11", + "officialFullName": "C-X-C motif chemokine ligand 11", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2883, + "assayComponentEndpointName": "BSK_BE3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IL8 was analyzed at the endpoint, BSK_BE3C_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2736, + "assayComponentName": "BSK_BE3C_IL8", + "assayComponentDesc": "BSK_BE3C_IL8 is an assay component measured in the BSK_BE3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 1943, + "assayComponentEndpointName": "ATG_M_06_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_06_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1871, + "assayComponentName": "ATG_M_06_XSP1", + "assayComponentDesc": "ATG_M_06_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2885, + "assayComponentEndpointName": "BSK_BE3C_EGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_EGFR was analyzed at the endpoint, BSK_BE3C_EGFR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2737, + "assayComponentName": "BSK_BE3C_EGFR", + "assayComponentDesc": "BSK_BE3C_EGFR is an assay component measured in the BSK_BE3C assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Epidermal growth factor receptor (EGFR) is a cell surface receptor for epidermal growth factor involved in cell proliferation, cell differentiation, tissue remodeling and tumor growth. EGFR is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "EGFR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2887, + "assayComponentEndpointName": "BSK_BE3C_Keratin818", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_Keratin818 was analyzed at the endpoint, BSK_BE3C_Keratin818, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2738, + "assayComponentName": "BSK_BE3C_Keratin818", + "assayComponentDesc": "BSK_BE3C_Keratin818 is an assay component measured in the BSK_BE3C assay. It measures Keratin 8/18 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Keratin 8/18 is an intermediate filament heterodimer of fibrous structural poteins involved in Epithelial cell death, EMT, COPD, Lung Inflammation. Keratin 8/18 is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Keratin 8/18 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4459, + "geneName": "keratin 18", + "description": null, + "geneSymbol": "KRT18", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3875, + "officialSymbol": "KRT18", + "officialFullName": "keratin 18", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2889, + "assayComponentEndpointName": "BSK_BE3C_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MMP9 was analyzed at the endpoint, BSK_BE3C_MMP9, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2739, + "assayComponentName": "BSK_BE3C_MMP9", + "assayComponentDesc": "BSK_BE3C_MMP9 is an assay component measured in the BSK_BE3C assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Matrix metalloproteinase-9 (MMP-9) is a gelatinase B that degrades collagen IV and gelatin and is involved in airway matrix remodeling. MMP-9 is categorized as a tissue remodeling-related activity in the BE3C system modeling Th1 lung inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2891, + "assayComponentEndpointName": "BSK_CASM3C_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_PAI1 was analyzed at the endpoint, BSK_CASM3C_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2740, + "assayComponentName": "BSK_CASM3C_PAI1", + "assayComponentDesc": "BSK_CASM3C_PAI1 is an assay component measured in the BSK_CASM3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2893, + "assayComponentEndpointName": "BSK_hDFCGF_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MCP1 was analyzed at the endpoint, BSK_hDFCGF_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2741, + "assayComponentName": "BSK_hDFCGF_MCP1", + "assayComponentDesc": "BSK_hDFCGF_MCP1 is an assay component measured in the BSK_hDFCGF assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2895, + "assayComponentEndpointName": "BSK_hDFCGF_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_ICAM1 was analyzed at the endpoint, BSK_hDFCGF_ICAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2742, + "assayComponentName": "BSK_hDFCGF_ICAM1", + "assayComponentDesc": "BSK_hDFCGF_ICAM1 is an assay component measured in the BSK_hDFCGF assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Intercellular Adhesion Molecule 1 (ICAM-1/CD54) is a cell adhesion molecule that mediates leukocyte-endothelial cell adhesion and leukocyte recruitment. ICAM-1 is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2897, + "assayComponentEndpointName": "BSK_hDFCGF_CollagenI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_CollagenI was analyzed at the endpoint, BSK_hDFCGF_CollagenI, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2743, + "assayComponentName": "BSK_hDFCGF_CollagenI", + "assayComponentDesc": "BSK_hDFCGF_CollagenI is an assay component measured in the BSK_hDFCGF assay. It measures Collagen I antibody related to regulation of gene protein expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen I is involved in tissue remodeling and fibrosis, and is the most common fibrillar collagen that is found in skin, bone, tendons and other connective tissues. Collagen I is categorized as a tissue remodeling-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene protein expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen I antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 2452, + "geneName": "collagen type I alpha 1 chain", + "description": null, + "geneSymbol": "COL1A1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1277, + "officialSymbol": "COL1A1", + "officialFullName": "collagen type I alpha 1 chain", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2899, + "assayComponentEndpointName": "BSK_hDFCGF_ITAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_ITAC was analyzed at the endpoint, BSK_hDFCGF_ITAC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2744, + "assayComponentName": "BSK_hDFCGF_ITAC", + "assayComponentDesc": "BSK_hDFCGF_ITAC is an assay component measured in the BSK_hDFCGF assay. It measures I-TAC antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interferon inducible T Cell Alpha Chemoattractant (I-TAC/CXCL11) is a chemokine that mediates T cell and monocyte chemotaxis. I-TAC is categorized as an inflammation-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "I-TAC antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6313, + "geneName": "C-X-C motif chemokine ligand 11", + "description": null, + "geneSymbol": "CXCL11", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6373, + "officialSymbol": "CXCL11", + "officialFullName": "C-X-C motif chemokine ligand 11", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2901, + "assayComponentEndpointName": "BSK_hDFCGF_TIMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_TIMP2 was analyzed at the endpoint, BSK_hDFCGF_TIMP2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2745, + "assayComponentName": "BSK_hDFCGF_TIMP2", + "assayComponentDesc": "BSK_hDFCGF_TIMP2 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-2 is a tissue inhibitor of matrix metalloproteases and is involved in tissue remodeling, angiogenesis and fibrosis. TIMP-2 is categorized as a tissue remodeling-related activity in the HDF3CGF system modeling Th1 inflammation involved in wound healing and matrix remodeling of the skin.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 325, + "geneName": "TIMP metallopeptidase inhibitor 2", + "description": null, + "geneSymbol": "TIMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7077, + "officialSymbol": "TIMP2", + "officialFullName": "TIMP metallopeptidase inhibitor 2", + "uniprotAccessionNumber": "Q96MC4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2903, + "assayComponentEndpointName": "BSK_KF3CT_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IL8 was analyzed at the endpoint, BSK_KF3CT_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2746, + "assayComponentName": "BSK_KF3CT_IL8", + "assayComponentDesc": "BSK_KF3CT_IL8 is an assay component measured in the BSK_KF3CT assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2905, + "assayComponentEndpointName": "BSK_KF3CT_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MIG was analyzed at the endpoint, BSK_KF3CT_MIG, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2747, + "assayComponentName": "BSK_KF3CT_MIG", + "assayComponentDesc": "BSK_KF3CT_MIG is an assay component measured in the BSK_KF3CT assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monokine induced by gamma interferon (MIG/CXCL9) is a chemokine that mediates T cell recruitment. MIG is categorized as an inflammation-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2907, + "assayComponentEndpointName": "BSK_KF3CT_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_PAI1 was analyzed at the endpoint, BSK_KF3CT_PAI1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2748, + "assayComponentName": "BSK_KF3CT_PAI1", + "assayComponentDesc": "BSK_KF3CT_PAI1 is an assay component measured in the BSK_KF3CT assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Plasminogen activator inhibitor-1 (PAI-I) is a serine proteinase inhibitor and inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) and is involved in tissue remodeling and fibrinolysis. PAI-I is categorized as a tissue remodeling-related activity in the KF3CT system modeling Th1 cutaneous inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2909, + "assayComponentEndpointName": "BSK_IMphg_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MCP1 was analyzed at the endpoint, BSK_IMphg_MCP1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2749, + "assayComponentName": "BSK_IMphg_MCP1", + "assayComponentDesc": "BSK_IMphg_MCP1 is an assay component measured in the BSK_IMphg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemoattractant cytokine (chemokine) that regulates the recruitment of monocytes and T cells into sites of inflammation. MCP-1 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2911, + "assayComponentEndpointName": "BSK_IMphg_MIP1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MIP1a was analyzed at the endpoint, BSK_IMphg_MIP1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2750, + "assayComponentName": "BSK_IMphg_MIP1a", + "assayComponentDesc": "BSK_IMphg_MIP1a is an assay component measured in the BSK_IMphg assay. It measures MIP-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Macrophage inflammatory protein 1 alpha (MIP-1a/CCL3) is a pro-inflammatory chemokine that mediates leukocyte recruitment to sites of inflammation. MIP-1a is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIP-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 6291, + "geneName": "C-C motif chemokine ligand 3", + "description": null, + "geneSymbol": "CCL3", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6348, + "officialSymbol": "CCL3", + "officialFullName": "C-C motif chemokine ligand 3", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2913, + "assayComponentEndpointName": "BSK_IMphg_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_VCAM1 was analyzed at the endpoint, BSK_IMphg_VCAM1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2751, + "assayComponentName": "BSK_IMphg_VCAM1", + "assayComponentDesc": "BSK_IMphg_VCAM1 is an assay component measured in the BSK_IMphg assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Vascular Cell Adhesion Molecule 1 (VCAM-1/CD106) is a cell adhesion molecule that mediates adhesion of monocytes and T cells to endothelial cells. VCAM-1 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2915, + "assayComponentEndpointName": "BSK_IMphg_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_CD40 was analyzed at the endpoint, BSK_IMphg_CD40, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2752, + "assayComponentName": "BSK_IMphg_CD40", + "assayComponentDesc": "BSK_IMphg_CD40 is an assay component measured in the BSK_IMphg assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD40 is a cell surface adhesion receptor and costimulatory receptor for T cell activation that is expressed on antigen presenting cells, endothelial cells, smooth muscle cells, fibroblasts and epithelial cells. CD40 is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2917, + "assayComponentEndpointName": "BSK_IMphg_ESelectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_ESelectin was analyzed at the endpoint, BSK_IMphg_ESelectin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2753, + "assayComponentName": "BSK_IMphg_ESelectin", + "assayComponentDesc": "BSK_IMphg_ESelectin is an assay component measured in the BSK_IMphg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-Selectin/CD62E is a cell adhesion molecule expressed only on endothelial cells that mediates leukocyte-endothelial cell interactions. E-Selectin is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2919, + "assayComponentEndpointName": "BSK_IMphg_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_CD69 was analyzed at the endpoint, BSK_IMphg_CD69, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2754, + "assayComponentName": "BSK_IMphg_CD69", + "assayComponentDesc": "BSK_IMphg_CD69 is an assay component measured in the BSK_IMphg assay. It measures CD69 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD69 is a cell surface activation antigen that is induced early during immune activation and is involved in macrophage activation. CD69 is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2921, + "assayComponentEndpointName": "BSK_IMphg_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL8 was analyzed at the endpoint, BSK_IMphg_IL8, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2755, + "assayComponentName": "BSK_IMphg_IL8", + "assayComponentDesc": "BSK_IMphg_IL8 is an assay component measured in the BSK_IMphg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 8 (IL-8/CXCL8) is a chemokine that mediates neutrophil recruitment into acute inflammatory sites. IL-8 is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2923, + "assayComponentEndpointName": "BSK_IMphg_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL1a was analyzed at the endpoint, BSK_IMphg_IL1a, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2756, + "assayComponentName": "BSK_IMphg_IL1a", + "assayComponentDesc": "BSK_IMphg_IL1a is an assay component measured in the BSK_IMphg assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 1alpha (IL-1a) is a secreted proinflammatory cytokine involved in endothelial cell activation and neutrophil recruitment. Secreted IL-1a (sIL-1a) is categorized as an inflammation-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2925, + "assayComponentEndpointName": "BSK_IMphg_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_MCSF was analyzed at the endpoint, BSK_IMphg_MCSF, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2757, + "assayComponentName": "BSK_IMphg_MCSF", + "assayComponentDesc": "BSK_IMphg_MCSF is an assay component measured in the BSK_IMphg assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Macrophage colony-stimulating factor (M-CSF) is a secreted and cell surface cytokine that mediates macrophage differentiation. M-CSF is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2927, + "assayComponentEndpointName": "BSK_IMphg_IL10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_IL10 was analyzed at the endpoint, BSK_IMphg_IL10, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2758, + "assayComponentName": "BSK_IMphg_IL10", + "assayComponentDesc": "BSK_IMphg_IL10 is an assay component measured in the BSK_IMphg assay. It measures IL-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Interleukin 10 (IL-10) is a secreted anti-inflammatory cytokine. Secreted IL-10 (sIL-10) is categorized as an immunomodulatory-related activity in the lMphg system modeling macrophage-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 4232, + "geneName": "interleukin 10", + "description": null, + "geneSymbol": "IL10", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3586, + "officialSymbol": "IL10", + "officialFullName": "interleukin 10", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2929, + "assayComponentEndpointName": "BSK_IMphg_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_SRB was analyzed at the endpoint, BSK_IMphg_SRB, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2759, + "assayComponentName": "BSK_IMphg_SRB", + "assayComponentDesc": "BSK_IMphg_SRB is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the lMphg system is a measure of the total protein content of venular endothelial cells and macrophages. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2931, + "assayComponentEndpointName": "BSK_IMphg_SRB.Mphg", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_IMphg_SRB.Mphg was analyzed at the endpoint, BSK_IMphg_SRB.Mphg, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2760, + "assayComponentName": "BSK_IMphg_SRB.Mphg", + "assayComponentDesc": "BSK_IMphg_SRB.Mphg is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB-Mphg in the lMphg system is a measure of the total protein content of macrophages alone. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 856, + "assayName": "BSK_IMphg", + "assayDesc": "BSK_IMphg is a cell-based, multiplexed-readout assay that uses venular endothelial cells and macrophages, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "venular endothelial cells and macrophages", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.3389/fdata.2019.00047", + "url": "https://pubmed.ncbi.nlm.nih.gov/33693370/", + "pmid": 33693370, + "title": "Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition", + "author": "Berg EL", + "citation": "Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019 Dec 11;2:47. doi: 10.3389/fdata.2019.00047. PMID: 33693370; PMCID: PMC7931891.", + "otherId": "0", + "citationId": 287, + "otherSource": "" + } + }, + { + "aeid": 2933, + "assayComponentEndpointName": "BSK_LPS_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_Thrombodulin was analyzed at the endpoint, BSK_LPS_Thrombomodulin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2761, + "assayComponentName": "BSK_LPS_Thrombomodulin", + "assayComponentDesc": "BSK_LPS_Thrombomodulin is an assay component measured in the BSK_LPS assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin/CD141 is a cell surface receptor for complement factor 3b with anti-coagulant, anti-inflammatory and cytoprotective activities during the process of fibrinolysis, coagulation and thrombosis. Thrombomodulin is categorized as a hemostasis-related activity in the LPS system modeling monocyte-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2935, + "assayComponentEndpointName": "BSK_LPS_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_CD69 was analyzed at the endpoint, BSK_LPS_CD69, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2762, + "assayComponentName": "BSK_LPS_CD69", + "assayComponentDesc": "BSK_LPS_CD69 is an assay component measured in the BSK_LPS assay. It measures CD69 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD69 is a cell surface activation antigen. CD69 is categorized as an immunomodulatory-related activity in the LPS system modeling monocyte-driven Th1 vascular inflammation.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2938, + "assayComponentEndpointName": "IUF_NPC2a_radial_glia_migration_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2a_radial_glia_migration_72hr component was analyzed at the endpoint IUF_NPC2a_radial_glia_migration_72hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SRC kinase inhibitor PP2", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2763, + "assayComponentName": "IUF_NPC2a_radial_glia_migration_72hr", + "assayComponentDesc": "IUF_NPC2a_radial glia_migration_72hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The migration distance of radial glia at 72 hr is assessed in µm from the edge of the sphere core to the edge of the migration area based on brightfield images of each well. Therefore, each plate is scanned using a high content imaging device. Images are exported and the migration distance is measured manually in four directions using ImageJ. The mean of four measures per well is used as raw data input.", + "assayComponentTargetDesc": "Changes in the migration distance of radial glia are indicative of radial glia migration during neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "radial glia migration", + "biologicalProcessTarget": "migration during neurodevelopment", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "Automated phase contrast imaging ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of radial glia at 72hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2940, + "assayComponentEndpointName": "IUF_NPC2a_radial_glia_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2a_radial_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ radial_glia_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2764, + "assayComponentName": "IUF_NPC2a_radial_glia_migration_120hr", + "assayComponentDesc": "IUF_NPC2a_radial_glia_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The migration distance of radial glia at 120 hr is assessed in µm from the edge of the sphere core to the edge of the migration area based on fluorescent images of Hoechst-positive nuclei. With the identification of each nucleus position around the sphere core, migration-related parameters can be calculated. First, a nuclei density distribution is calculated for which an algorithm determines relatively more and less dense nuclei areas. This calculation identifies the sphere core by the densest nuclei area in the image. The algorithm further assumes that nuclei density decreases from the sphere core to the periphery. When the nuclei density hits a pre-defined threshold, the outer boundaries of the migration area are determined and the sphere itself is mapped out in a polynomial bounding box. Derived from this box, the size of the migration area and the migration distance are calculated for each well.", + "assayComponentTargetDesc": "Changes in the migration distance of radial glia are indicative of radial glia migration during neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "radial glia migration", + "biologicalProcessTarget": "migration during neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst 33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of radial glia at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2942, + "assayComponentEndpointName": "IUF_NPC2b_neuronal_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2b_neuronal_migration_120hr component was analyzed at the endpoint IUF_NPC2b_neuronal_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2765, + "assayComponentName": "IUF_NPC2b_neuronal_migration_120hr", + "assayComponentDesc": "IUF_NPC2b_neuronal_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Neuronal migration distance at 120 hr is the mean distance of all neurons from the edge of the sphere core to each individual neuron (see IUF_NPC3_neuronal_differentiation_120hr). Neuronal migration is normalized to radial glia migration distance at 120 hr.", + "assayComponentTargetDesc": "Changes in the migration distance of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "neuronal migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of neurons at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2944, + "assayComponentEndpointName": "IUF_NPC2c_oligodendrocyte_migration_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2c_oligodendrocyte_migration_120hr component was analyzed at the endpoint IUF_NPC2c_oligodendrocyte_migration_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor cell migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2766, + "assayComponentName": "IUF_NPC2c_oligodendrocyte_migration_120hr", + "assayComponentDesc": "IUF_NPC2b_oligodendrocyte_migration_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Oligodendrocyte migration distance at 120 hr is the mean distance of all oligodendrocytes from the edge of the sphere core to each individual oligodendrocyte (see IUF_NPC5_oligodendrocyte_differentiation_120hr). Oligodendrocyte migration is normalized to radial glia migration distance at 120 hr.", + "assayComponentTargetDesc": "Changes in the migration distance of oligodendrocytes are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "migration reporter", + "assayDesignTypeSub": "oligodendrocyte migration", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "migration distance", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "O4 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "migration distance of oligodendrocytes at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2946, + "assayComponentEndpointName": "IUF_NPC3_neuronal_differentiation_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC3_neuronal_differentiation_120hr component was analyzed at the endpoint IUF_NPC3_neuronal_differentiation_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2767, + "assayComponentName": "IUF_NPC3_neuronal_differentiation_120hr", + "assayComponentDesc": "IUF_NPC3_neuronal_differentiation_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Neuronal differentiation is determined as the number of all TUBB3 positive cells in percent of the number of Hoechst-positive nuclei in the total neurosphere migration area (see IUF_NPC2a_ glia_migration_120hr) after 120 hr of migration/differentiation. Neurons are automatically identified using a convolutional neural network (CNN) that was trained using manually annotated images of differentiated neurons. ", + "assayComponentTargetDesc": "Changes in the neuronal differentiation are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal differentiation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neuronal differentiation at 120 hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2948, + "assayComponentEndpointName": "IUF_NPC4_neurite_length_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC4_neurite_length_120hr component was analyzed at the endpoint IUF_NPC4_neurite_length_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, gain or loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2768, + "assayComponentName": "IUF_NPC4_neurite_length_120hr", + "assayComponentDesc": "IUF_NPC4_neurite_length_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The neurite length at 120 hr is the mean length in um of all neurons (see IUF_NPC3_neuronal_differentiation_120hr) that are identified by the skeletonization algorithm in Omnisphero.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal morphology", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "morphology", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2950, + "assayComponentEndpointName": "IUF_NPC4_neurite_area_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC4_neurite_area_120hr component was analyzed at the endpoint IUF_NPC4_neurite_area_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2769, + "assayComponentName": "IUF_NPC4_neurite_area_120hr", + "assayComponentDesc": "IUF_NPC4_neurite_area_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The neurite area at 120 hr is the mean area in pixel (without nuclei) of all neurons (see IUF_NPC3_neuronal_differentiation_120hr) that are identified by the skeletonization algorithm in Omnisphero.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "neuronal morphology", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "morphology", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2952, + "assayComponentEndpointName": "IUF_NPC5_oligodendrocyte_differentiation_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC5_oligodendrocyte_differentiation_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_differentiation_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "BMP7", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural progenitor differentiation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2770, + "assayComponentName": "IUF_NPC5_oligodendrocyte_differentiation_120hr", + "assayComponentDesc": "IUF_NPC5_oligodendrocyte_differentiation_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. Oligodendrocyte differentiation at 120 hr is determined as the number of all O4-positive cells in percent of the number of Hoechst-positive nuclei in the total neurosphere migration area (see IUF_NPC2a_ glia_migration_120hr) after 120 hr of migration/differentiation. Oligodendrocytes are automatically identified using a convolutional neural network (CNN) that was trained using manually annotated images of differentiated oligodendrocytes.", + "assayComponentTargetDesc": "Changes in the oligodendrocyte differentiation are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "differentiation reporter", + "assayDesignTypeSub": "oligodendrocyte differentiation", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "High content image analysis", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "O4 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "oligodendrocyte differentiation at 120hr", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2954, + "assayComponentEndpointName": "IUF_NPC2-5_cytotoxicity_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cytotoxicity_72hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_72hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2771, + "assayComponentName": "IUF_NPC2-5_cytotoxicity_72hr", + "assayComponentDesc": "IUF_NPC2-5_cytotoxicity_72hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure the cytotoxicity at 72 hr as assessed by membrane integrity related to the LDH dependent reduction of resazurin to resorufin in the supernatant of each well. The cytotoxicity is measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2956, + "assayComponentEndpointName": "IUF_NPC2-5_cytotoxicity_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cytotoxicity_120hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_120hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2772, + "assayComponentName": "IUF_NPC2-5_cytotoxicity_120hr", + "assayComponentDesc": "IUF_NPC2-5_cytotoxicity_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure cytotoxicity at 120hr due to loss of membrane integrity. LDH measurements are performed from medium supernatants of each well and are based on the reduction of resazurin to resorufin measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2958, + "assayComponentEndpointName": "IUF_NPC2-5_cell_number_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_cell_number_120hr component was analyzed at the endpoint IUF_NPC2-5_cell_number_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cell count", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2773, + "assayComponentName": "IUF_NPC2-5_cell_number_120hr", + "assayComponentDesc": "IUF_NPC2-5_cell number_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. The cell number at 120 hr is assessed as the number of all Hoechst-positive nuclei identified in the migration area (see IUF_NPC2a_ glia_migration_120hr).", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of cell proliferation.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence microscopy", + "detectionTechnologyTypeSub": "cell identification", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst 33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 2960, + "assayComponentEndpointName": "IUF-NPC2-5_viability_120hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC2-5_viability_120hr component was analyzed at the endpoint IUF-NPC2-5_viability_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2774, + "assayComponentName": "IUF-NPC2-5_viability_120hr", + "assayComponentDesc": "IUF_NPC2-5_viability_120hr is one of 12 assay components measured from the IUF_NPC2-5 assay. It is designed to measure cell viability assessed as mitochondria-dependent reduction of resazurin to resorufin using the alamar blue viability assay. The viability is measured as a fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (mitochondrial activity) are correlated to cellular viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar blue viability assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 858, + "assayName": "IUF_NPC2-5", + "assayDesc": "IUF_NPC2-5 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 or 120 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. In the neural progenitor cell migration and differentiation assay (NPC2-5), hNPC’s grown as spheres are plated on an extracellular matrix and migrate and differentiate out of the sphere core. The processes radial glia migration, neuronal and oligodendrocyte migration as well as neuronal differentiation, neuronal morphology and oligodendrocyte differentiation are studied using automated phase contrast imaging and automated fluorescence imaging in combination with high content image analysis. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 3019, + "assayComponentEndpointName": "VALA_TUBHUV_Agonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Agonist_CellCount was analyzed at the endpoint, VALA_TUBHUV_Agonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2805, + "assayComponentName": "VALA_TUBHUV_Agonist_CellCount", + "assayComponentDesc": "VALA_TUBHUV_Agonist_CellCount is the one of two assay components measured from the VALA_TUBHUV_Agonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 860, + "assayName": "VALA_TUBHUV_Agonist", + "assayDesc": "VALA_TUBHUV_Agonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3020, + "assayComponentEndpointName": "VALA_TUBHUV_Agonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Agonist_TubuleLength was analyzed at the endpoint, VALA_TUBHUV_Agonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2806, + "assayComponentName": "VALA_TUBHUV_Agonist_TubuleLength", + "assayComponentDesc": "VALA_TUBHUV_Agonist_TubuleLength is the one of two assay components measured from the VALA_TUBHUV_Agonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBHUV1 assay was designed to detect chemical activation of tubulogenesis, i.e. agonism.", + "assayComponentTargetDesc": "Vein growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on vein formation in basal medium, which lacks growth factors that support blood vessel growth. Tube formation agonists will increase vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 860, + "assayName": "VALA_TUBHUV_Agonist", + "assayDesc": "VALA_TUBHUV_Agonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3021, + "assayComponentEndpointName": "VALA_TUBHUV_Antagonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Antagonist_CellCount was analyzed at the endpoint, VALA_TUBHUV_Antagonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2807, + "assayComponentName": "VALA_TUBHUV_Antagonist_CellCount", + "assayComponentDesc": "VALA_TUBHUV_Antagonist_CellCount is the one of two assay components measured from the VALA_TUBHUV_Antagonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 861, + "assayName": "VALA_TUBHUV_Antagonist", + "assayDesc": "VALA_TUBHUV_Antagonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3022, + "assayComponentEndpointName": "VALA_TUBHUV_Antagonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBHUV_Antagonist_TubuleLength was analyzed at the endpoint, VALA_TUBHUV_Antagonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2808, + "assayComponentName": "VALA_TUBHUV_Antagonist_TubuleLength", + "assayComponentDesc": "VALA_TUBHUV_Antagonist_TubuleLength is the one of two assay components measured from the VALA_TUBHUV_Antagonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBHUV_Antagonist assay was designed to detect chemical suppression of tubulogenesis, i.e. antagonism.", + "assayComponentTargetDesc": "Vein growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on vein formation in complete medium, which contains growth factors that support vein endothelial cell proliferation. Tube formation antagonists will decrease vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 861, + "assayName": "VALA_TUBHUV_Antagonist", + "assayDesc": "VALA_TUBHUV_Antagonist is a cell-based, multiplexed assay that uses human umbilical vein endothelial cells (HUVEC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3023, + "assayComponentEndpointName": "VALA_TUBIPS_Agonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Agonist_CellCount was analyzed at the endpoint, VALA_TUBIPS_Agonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2809, + "assayComponentName": "VALA_TUBIPS_Agonist_CellCount", + "assayComponentDesc": "VALA_TUBIPS_Agonist_CellCount is the one of two assay components measured from the VALA_TUBIPS_Agonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 862, + "assayName": "VALA_TUBIPS_Agonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3024, + "assayComponentEndpointName": "VALA_TUBIPS_Agonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Agonist_TubuleLength was analyzed at the endpoint, VALA_TUBIPS_Agonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2810, + "assayComponentName": "VALA_TUBIPS_Agonist_TubuleLength", + "assayComponentDesc": "VALA_TUBIPS_Agonist_TubuleLength is the one of two assay components measured from the VALA_TUBIPS_Agonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBIPS1 assay was designed to detect chemical activation of tubulogenesis, i.e. agonism.", + "assayComponentTargetDesc": "Blood vessel growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on blood vessel formation in basal medium, which lacks growth factors that support vessel growth. Tube formation agonists will increase vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 862, + "assayName": "VALA_TUBIPS_Agonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3025, + "assayComponentEndpointName": "VALA_TUBIPS_Antagonist_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Antagonist_CellCount was analyzed at the endpoint, VALA_TUBIPS_Antagonist_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2811, + "assayComponentName": "VALA_TUBIPS_Antagonist_CellCount", + "assayComponentDesc": "VALA_TUBIPS_Antagonist_CellCount is the one of two assay components measured from the VALA_TUBIPS_Antagonist assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 863, + "assayName": "VALA_TUBIPS_Antagonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3026, + "assayComponentEndpointName": "VALA_TUBIPS_Antagonist_TubuleLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_TUBIPS_Antagonist_TubuleLength was analyzed at the endpoint, VALA_TUBIPS_Antagonist_TubuleLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is tubulogenesis.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "suramin", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "tubulogenesis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2812, + "assayComponentName": "VALA_TUBIPS_Antagonist_TubuleLength", + "assayComponentDesc": "VALA_TUBIPS_Antagonist_TubuleLength is the one of two assay components measured from the VALA_TUBIPS_Antagonist assay. It is designed to make measurements of tubulogenesis, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. This VALA_TUBIPS_Antagonist assay was designed to detect chemical suppression of tubulogenesis, i.e. antagonism.", + "assayComponentTargetDesc": "Blood vessel growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on blood vessel formation in complete medium, which contains growth factors that support vascular endothelial cell proliferation. Tube formation antagonists will decrease vessel growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "tubulogenesis", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD31 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mean tubule length", + "aid": 863, + "assayName": "VALA_TUBIPS_Antagonist", + "assayDesc": "VALA_TUBIPS_Agonist is a cell-based, multiplexed assay that uses human iPS-derived endothelial cells (iPSC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "iPS-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "iPSC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3027, + "assayComponentEndpointName": "VALA_MIGHUV1_ScratchOnly_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV1_ScratchOnly_CellCount was analyzed at the endpoint, VALA_MIGHUV1_ScratchOnly_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "BIO-acetoxime", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2813, + "assayComponentName": "VALA_MIGHUV1_ScratchOnly_CellCount", + "assayComponentDesc": "VALA_MIGHUV1_ScratchOnly_CellCount is the one of two assay components measured from the VALA_MIGHUV1_ScratchOnly assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 864, + "assayName": "VALA_MIGHUV1_ScratchOnly", + "assayDesc": "VALA_MIGHUV1_ScratchOnly is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3028, + "assayComponentEndpointName": "VALA_MIGHUV1_ScratchOnly_WoundArea", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV1_ScratchOnly_WoundArea was analyzed at the endpoint, VALA_MIGHUV1_ScratchOnly_WoundArea, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2814, + "assayComponentName": "VALA_MIGHUV1_ScratchOnly_WoundArea", + "assayComponentDesc": "VALA_MIGHUV1_ScratchOnly_WoundArea is the one of two assay components measured from the VALA_MIGHUV1_ScratchOnly assay. It is designed to make measurements of endothelial migration, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in basal medium, which lacks growth factors that support capillary growth. Tube formation agonists will increase capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "endothelial migration in wound recovery", + "aid": 864, + "assayName": "VALA_MIGHUV1_ScratchOnly", + "assayDesc": "VALA_MIGHUV1_ScratchOnly is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3029, + "assayComponentEndpointName": "VALA_MIGHUV2_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_CellCount was analyzed at the endpoint, VALA_MIGHUV2_CellCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "BIO-acetoxime", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2815, + "assayComponentName": "VALA_MIGHUV2_CellCount", + "assayComponentDesc": "VALA_MIGHUV2_CellCount is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of DAPI labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "DAPI", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3030, + "assayComponentEndpointName": "VALA_MIGHUV2_Bcatenin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_BCatenin was analyzed at the endpoint, VALA_MIGHUV2_BCatenin, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2816, + "assayComponentName": "VALA_MIGHUV2_Bcatenin", + "assayComponentDesc": "VALA_MIGHUV2_Bcatenin is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of nuclear translocation of CTNB, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in complete medium, which contains growth factors that support capillary endothelial cell proliferation. Tube formation antagonists will decrease capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CTNB", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear translocation of CTNB", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3031, + "assayComponentEndpointName": "VALA_MIGHUV2_WoundArea", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component VALA_MIGHUV2_WoundArea was analyzed at the endpoint, VALA_MIGHUV2_WoundArea, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2817, + "assayComponentName": "VALA_MIGHUV2_WoundArea", + "assayComponentDesc": "VALA_MIGHUV2_WoundArea is the one of two assay components measured from the VALA_MIGHUV2 assay. It is designed to make measurements of endothelial migration, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Capillary growth supports angiogenesis, which is critical for development, maturation, and reproductive function. Dysregulation of angiogenesis can lead to birth defects, macular degeneration, impaired wound healing, and tumor growth. This assay measures compound effects on capillary network formation in complete medium, which contains growth factors that support capillary endothelial cell proliferation. Tube formation antagonists will decrease capillary growth in these conditions.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (angiogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "endothelial migration in wound recovery", + "aid": 865, + "assayName": "VALA_MIGHUV2_Bcatenin", + "assayDesc": "VALA_MIGHUV2_BCatenin is a cell-based, multiplexed assay that uses umbilical vein-derived endothelial cells (HUVEC). Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "umbilical vein-derived endothelial cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HUVEC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 10, + "assaySourceName": "VALA", + "assaySourceLongName": "VALA Sciences", + "assaySourceDesc": "Vala Sciences, a Contract Research Organization (CRO), provides cell-based assay services.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 3032, + "assayComponentEndpointName": "CCTE_GLTED_hIYD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Nitro-L-tyrosine (0.05 M NaOH for model inhibitor (MNT))", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "dehalogenase", + "intendedTargetFamilySub": "iodotyrosine deiodinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2818, + "assayComponentName": "CCTE_GLTED_hIYD", + "assayComponentDesc": "CCTE_GLTED_hIYD is the assay component measured from the CCTE_GLTED_hIYD assay. It measures substrate involved in regulation of catalytic activity using spectrophotometry. The assay measures the deiodination activity of human IYD on the substrate monoiodotyrosine (MIT). After 3h incubation of substrate, enzyme, and test chemical, the components are applied to a 96-well Dowex column. Free iodide is not retained by the column and is separated from interfering assay components. The free iodide is measured by the Sandell-Kolthoff reaction in which the rate of reduction of cerium (Ce+4 to Ce+3) by arsenic (As+3 to As+5) is increased by the presence of iodide. This is observed as the loss of yellow color in the reaction and the quantified by the change in absorbance at 420 nm. The change in reaction rate is proportional to the amount of iodide present.", + "assayComponentTargetDesc": "The iodide recycling enzyme, iodotyrosine deiodinase (IYD), is one conserved putative molecular target that plays an essential role in maintaining adequate levels of free iodide in the thyroid gland for hormone synthesis.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Monoiodotyrosine (MIT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 866, + "assayName": "CCTE_GLTED_hIYD", + "assayDesc": "CCTE_GLTED_hIYD is a cell-free, single-readout assay that uses human iodotyrosine deiodinase (hIYD) enzyme produced with baculovirus-insect cell system. The assay is based on iodide release measured by the Sandell-Kolthoff method and is run in 96-well plate format with assay plates run in triplicate (n=3) with measurements taken at 3 hours after chemical dosing. Platewise-normalization was used based on positive control (3-Nitro-L-tyrosine, MNT) and negative/solvent controls (DMSO, NaOH).", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "baculovirus-insect cells", + "cellShortName": "SF-21", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.65, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 24338, + "geneName": "iodotyrosine deiodinase", + "description": null, + "geneSymbol": "IYD", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 389434, + "officialSymbol": "IYD", + "officialFullName": "iodotyrosine deiodinase", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105073", + "url": "https://pubmed.ncbi.nlm.nih.gov/33352258/", + "pmid": 33352258, + "title": "In vitro screening for chemical inhibition of the iodide recycling enzyme, iodotyrosine deiodinase", + "author": "Olker JH, Korte JJ, Denny JS, Haselman JT, Hartig PC, Cardon MC, Hornung MW, Degitz SJ", + "citation": "Olker JH, Korte JJ, Denny JS, Haselman JT, Hartig PC, Cardon MC, Hornung MW, Degitz SJ. In vitro screening for chemical inhibition of the iodide recycling enzyme, iodotyrosine deiodinase. Toxicol In Vitro. 2021 Mar;71:105073. doi: 10.1016/j.tiv.2020.105073. Epub 2020 Dec 29. PMID: 33352258; PMCID: PMC8130633.", + "otherId": "0", + "citationId": 239, + "otherSource": "" + } + }, + { + "aeid": 3067, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. This assay endpoint is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GlutaNeurons. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2836, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GlutaNeurons. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3068, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2837, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3069, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2838, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3070, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (10uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2839, + "assayComponentName": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGluta_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_iCellGluta_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 867, + "assayName": "CCTE_Mundy_HCI_iCellGluta_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGluta_NOG is a multiplexed, cell-based-readout assay that uses iCell® GlutaNeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human glutamatergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GlutaNeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.15, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.taap.2018.04.001", + "url": "https://pubmed.ncbi.nlm.nih.gov/29626487/", + "pmid": 29626487, + "title": "Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment", + "author": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR", + "citation": "Harrill JA, Freudenrich T, Wallace K, Ball K, Shafer TJ, Mundy WR. Testing for developmental neurotoxicity using a battery of in vitro assays for key cellular events in neurodevelopment. Toxicol Appl Pharmacol. 2018 Sep 1;354:24-39. doi: 10.1016/j.taap.2018.04.001. Epub 2018 Apr 5. PMID: 29626487.", + "otherId": "0", + "citationId": 240, + "otherSource": "" + } + }, + { + "aeid": 3072, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_autofluor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_autofluor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_autofluor, was analyzed with bidirectional fitting relative to median test wells for the baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand autofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Tracer Fluorogenic Probe", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2841, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_autofluor", + "assayComponentDesc": "CCTE_Deisenroth_5AR_NBTE_autofluor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of a compound's autofluorescence, as detected by fluorescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "autofluorescence probe", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3074, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_donor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_donor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_donor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in the donor luminescence as related to 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact luminescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2842, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_donor", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_donor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of donor luminescence, as detected by bioluminescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "The technology is based on the concept of Bioluminescence Resonance Energy Transfer BRET. Target proteins fused to NanoLuc luciferase generate luminescence signal in the presence of furimazine substrate. BRET occurs when custom fluorescent tracers, bound to the target protein, resonate luminescent energy from the luciferase enzyme to the tracer molecule to yield a lower-energy fluorescent emission signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "donor luminescence emission", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "luciferase substrate: furimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-specified", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3076, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_acceptor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_acceptor was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_acceptor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in the acceptor fluorescence as related to 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves an artifact detection function.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2843, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_acceptor", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_acceptor is one of four assay components measured from the CCTE_Deisenroth_5AR NBTE assay. It is designed to make measurements of resonant fluorescence generated by bioluminescent energy transfer to a target fluorophore, as detected by fluorescence intensity emission signals using spectrometry technology.", + "assayComponentTargetDesc": "The technology is based on the concept of Bioluminescence Resonance Energy Transfer BRET. Target proteins fused to NanoLuc luciferase generate luminescence signal in the presence of furimazine substrate. BRET occurs when custom fluorescent tracers, bound to the target protein, resonate luminescent energy from the luciferase enzyme to the tracer molecule to yield a lower-energy fluorescent emission signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "acceptor fluorescence emission", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tracer fluorogenic probe: MC547-NanoBRET 590 SE", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-specified", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3078, + "assayComponentEndpointName": "CCTE_Deisenroth_5AR_NBTE_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_5AR NBTE_ratio was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_ratio, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is 5-alpha reductase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dutasteride, Finasteride", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "5-alpha reductase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2844, + "assayComponentName": "CCTE_Deisenroth_5AR_NBTE_ratio", + "assayComponentDesc": "CCTE_Deisenroth_5AR NBTE_ratio is one of four assay components calculated from the CCTE_Deisenroth_5AR NBTE assay. It is designed to measure the ratio of target acceptor fluorophore resonance to donor bioluminescent signals.", + "assayComponentTargetDesc": "The ratio of acceptor signal fluorescence to donor signal luminescence yields a normalized quantitative value in milliBRET Units mBU that can be used to evaluate direct disruption of small molecule target protein interactions of 5 alpha reductase.", + "parameterReadoutType": "single", + "assayDesignType": "ratiometric", + "assayDesignTypeSub": "ratio", + "biologicalProcessTarget": "regulation of 5alpha-reductase enzyme activity", + "detectionTechnologyType": "Bioluminescence Resonance Energy Transfer", + "detectionTechnologyTypeSub": "Bioluminescence Resonance Energy Transfer Ratio", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "ratio", + "keyAssayReagent": "acceptor/donor", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 869, + "assayName": "CCTE_Deisenroth_5AR_NBTE", + "assayDesc": "CCTE_Deisenroth_5AR NBTE (5alpha-reductase NanoBRET Target Engagement Assay) is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 5 hours after chemical dosing in a 384 well plate. This assay includes a primary and secondary screen as well as an autofluorscence screen.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.3, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2018.08.017", + "url": "https://pubmed.ncbi.nlm.nih.gov/30205137/", + "pmid": 30205137, + "title": "", + "author": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS", + "citation": "Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018 Oct;81:272-280. doi: 10.1016/j.reprotox.2018.08.017. Epub 2018 Sep 8. PMID: 30205137; PMCID: PMC7171594.", + "otherId": "0", + "citationId": 262, + "otherSource": "" + } + }, + { + "aeid": 3086, + "assayComponentEndpointName": "TAMU_PeakParms_SingleDonor1434_Asystole", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.", + "assayFunctionType": "cardiac function", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential ", + "intendedTargetFamily": "cardiomyocyte function", + "intendedTargetFamilySub": "cessation of beating", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2848, + "assayComponentName": "TAMU_PeakParms_SingleDonor1434_Asystole", + "assayComponentDesc": "TAMU_PeakParms_SingleDonor1434_Chronotopy is a phenotype derived from the peak.freq.avg parameter and uses an EC95 as its POD (95% decrease in beat rate, compared to controls). Peak.Freq.Avg measures the average peak frequency, in beats per second, uisng Fluorescence intensity as a functional reporter from Calcium (Ca+2) flux assay technology. There is no preprocessing performed on the data used to model this phenotype.", + "assayComponentTargetDesc": "Changes in the calcium flux readouts is used to quantify changes in peak frequency, which can be an indication of the cessation of beating", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "beating", + "biologicalProcessTarget": "cardiac function", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Calcium (Ca+2) flux assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Ca+2 dye reagent", + "technologicalTargetType": "calcium influx rate", + "technologicalTargetTypeSub": "average peak frequency, in beats per second", + "aid": 845, + "assayName": "TAMU_PeakParms", + "assayDesc": "TAMU_PeakParms is a cell-based, multiplexed-readout assay that uses iPSC-derived cardiomyocytes with measurements taken at 1.5 hours after chemical dosing in a microplate: 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "heart", + "cellFormat": "cell-based", + "cellFreeComponentSource": "iPSC-derived cardiomyocytes", + "cellShortName": "NA", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 29, + "assaySourceName": "TAMU", + "assaySourceLongName": "Texas A&M University", + "assaySourceDesc": null, + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.1c00203", + "url": "https://pubmed.ncbi.nlm.nih.gov/34448577/", + "pmid": 34448577, + "title": "Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors", + "author": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I", + "citation": "Burnett SD, Blanchette AD, Chiu WA, Rusyn I. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021 Aug 27. doi: 10.1021/acs.chemrestox.1c00203. Epub ahead of print. PMID: 34448577.", + "otherId": "0", + "citationId": 286, + "otherSource": "" + } + }, + { + "aeid": 3087, + "assayComponentEndpointName": "IUF_NPC1_cytotoxicity_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the IUF_NPC1_cytotoxicity_72hr component was analyzed at the endpoint IUF_NPC1_cytotoxicity_72hr in the positive analysis fitting direction relative to the dynamic range and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cytotoxicity effects.", + "assayFunctionType": "cytotoxicity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "lysed cells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "enzyme activity", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2849, + "assayComponentName": "IUF_NPC1_cytotoxicity_72hr", + "assayComponentDesc": "IUF_NPC1_cytotoxicity_72hr is one of 4 assay components measured from the IUF_NPC1 assay. It is designed to measure cytotoxicity at 72 hrs due to loss of membrane integrity. LDH measurements are performed from medium supernatants of each well and are based on the reduction of resazurin to resorufin measured as fluorescence signal (relative fluorescence unit) in a multiplate reader. ", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells), indicates cell loss or death.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "membrane integrity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "resazurin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 846, + "assayName": "IUF_NPC1", + "assayDesc": "IUF_NPC1 is a cell-based, multiplexed assay that uses hNPC, a human primary neural progenitor cells, with measurements taken at 72 hours after chemical dosing in a 96-well plate. Human neural progenitor cells (hNPC) are generated from human fetal brain cortex at gestational week (GW) 16-19. Grown in suspension culture and under proliferative conditions (proliferation media and growth factors), these cells represent neural progenitor cell proliferation. In the NPC1 assay, hNPC's are exposed to the test compound for 72h. Cell proliferation is assessed as an increase in sphere area using automated phase contrast imaging and as incorporation of Bromodeoxyuridine (BrdU) during DNA synthesis using a luminescence-based cell proliferation ELISA. In parallel, the cell viability is assessed using an alamar blue viability assay and the cytotoxicity using a lactate dehydrogenase dependent membrane integrity assay.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "primary cell", + "cellFreeComponentSource": "neural progenitor cells", + "cellShortName": "hNPC", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 30, + "assaySourceName": "IUF", + "assaySourceLongName": "Leibniz Research Institute for Environmental Medicine", + "assaySourceDesc": "Leibniz Research Institute for Environmental Medicine (IUF) is a German research institution in Düsseldorf. The IUF research mission is the molecular prevention of environmentally induced health disorders.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1007/s00204-015-1568-8", + "url": "https://pubmed.ncbi.nlm.nih.gov/26216354/", + "pmid": 26216354, + "title": "Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events", + "author": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E.", + "citation": "Baumann J, Gassmann K, Masjosthusmann S, DeBoer D, Bendt F, Giersiefer S, Fritsche E. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol. 2016 Jun;90(6):1415-27. doi: 10.1007/s00204-015-1568-8. Epub 2015 Jul 28. PMID: 26216354.", + "otherId": "0", + "citationId": 279, + "otherSource": "" + } + }, + { + "aeid": 3088, + "assayComponentEndpointName": "CCTE_GLTED_hTBG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTBG was analyzed at the assay endpoint CCTE_GLTED_hTBG in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from thyroxine-binding globulin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'hormone carrier protein'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3,5,3,5-tetraiodothyronine (T4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2850, + "assayComponentName": "CCTE_GLTED_hTBG", + "assayComponentDesc": "CCTE_GLTED_hTBG is the assay component measured from the CCTE_GLTED_hTBG assay. It is designed to make measurements of fluorescent polarization, using a form of binding reporter, as detected with Fluorescence signals by Fluorescence technology.", + "assayComponentTargetDesc": "Thyroxine-binding globulin (TBG) is one the major transport proteins responsible for binding to and transporting thyroid hormones to the necessary tissues.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ANSA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 870, + "assayName": "CCTE_GLTED_hTBG", + "assayDesc": "CCTE_GLTED_hTBG is a cell-free, single-readout assay designed to test the chemicals' ability to displace T4 from the human thyroxine-binding globulin (TBG) protein. TBG is incubated in presence of test chemical for 2 hours during which disrupting chemicals displace ANSA from the TBG protein. Results read fluorescence at 380 excitation and 475 emission.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3089, + "assayComponentEndpointName": "CCTE_GLTED_hTTR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTTR was analyzed at the assay endpoint CCTE_GLTED_hTTR in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from transthyretin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'hormone carrier protein'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3,5,3,5-tetraiodothyronine (T4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2851, + "assayComponentName": "CCTE_GLTED_hTTR", + "assayComponentDesc": "CCTE_GLTED_hTTR is the assay component measured from the CCTE_GLTED_hTTR assay. It is designed to make measurements of fluorescent polarization, using a form of binding reporter, as detected with Fluorescence signals by Fluorescence technology.", + "assayComponentTargetDesc": "Transthyretin (TTR) is one the major transport proteins responsible for binding to and transporting thyroid hormones to the necessary tissues.", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ANSA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 871, + "assayName": "CCTE_GLTED_hTTR", + "assayDesc": "CCTE_GLTED_hTTR is a cell-free, single-readout assay designed to test the chemicals' ability to displace T4 from the human transthyretin (TTR) protein. TTR is incubated in presence of test chemical for 2 hours during which disrupting chemicals displace ANSA from the TTR protein. Results read fluorescence at 380 excitation and 475 emission.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3090, + "assayComponentEndpointName": "CCTE_GLTED_hTPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hTPO was analyzed at the assay endpoint CCTE_GLTED_hTPO in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter (the Amplex UltraRed assay), loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'peroxidase'.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methimizole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2852, + "assayComponentName": "CCTE_GLTED_hTPO", + "assayComponentDesc": "CCTE_GLTED_hTPO is the assay component measured from the CCTE_GLTED_hTPO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Fluorescence technology.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Amplex UltraRed", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 872, + "assayName": "CCTE_GLTED_hTPO", + "assayDesc": "CCTE_GLTED_hTPO is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human thyroperoxidase (TPO) protein. Uninhibited enzyme converts Amplex UltraRed to a fluorescent product. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.                                               ", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3091, + "assayComponentEndpointName": "CCTE_GLTED_xDIO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_xDIO3 was analyzed at the assay endpoint CCTE_GLTED_xDIO3 in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand deiodinase Type 3 activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 3", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2853, + "assayComponentName": "CCTE_GLTED_xDIO3", + "assayComponentDesc": "CCTE_GLTED_xDIO3 is the assay component measured from the CCTE_GLTED_xDIO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO3 inactivates both T4 and T3 by removing an inner ring iodine, producing reverse T3 (rT3) and diiodotyrosine (T2), respectively.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3',5-triiodothyronine (T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 873, + "assayName": "CCTE_GLTED_xDIO3", + "assayDesc": "CCTE_GLTED_xDIO3 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward Xenopus (frog) iodothyronine Deiodinase Type 3 (DIO3) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 8355, + "organism": "xenopus (frog)", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3092, + "assayComponentEndpointName": "CCTE_GLTED_xIYD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_xIYD was analyzed at the assay endpoint CCTE_GLTED_xIYD in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Nitro-L-tyrosine (MNT)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "dehalogenase", + "intendedTargetFamilySub": "iodotyrosine deiodinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2854, + "assayComponentName": "CCTE_GLTED_xIYD", + "assayComponentDesc": "CCTE_GLTED_xIYD is the assay component measured from the CCTE_GLTED_xIYD assay. It measures substrate involved in regulation of catalytic activity using spectrophotometry. The assay measures the deiodination activity of Xenopus (frog) IYD on the substrate monoiodotyrosine (MIT). After 3h incubation of substrate, enzyme, and test chemical, the components are applied to a 96-well Dowex column. Free iodide is not retained by the column and is separated from interfering assay components. The free iodide is measured by the Sandell-Kolthoff reaction in which the rate of reduction of cerium (Ce+4 to Ce+3) by arsenic (As+3 to As+5) is increased by the presence of iodide. This is observed as the loss of yellow color in the reaction and the quantified by the change in absorbance at 420 nm. The change in reaction rate is proportional to the amount of iodide present.", + "assayComponentTargetDesc": "The iodide recycling enzyme, iodotyrosine deiodinase (IYD), is one conserved putative molecular target that plays an essential role in maintaining adequate levels of free iodide in the thyroid gland for hormone synthesis.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-iodotyrosine (MIT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 874, + "assayName": "CCTE_GLTED_xIYD", + "assayDesc": "CCTE_GLTED_xIYD is a cell-free, single-readout assay that uses Xenopus (frog) iodotyrosine deiodinase (xIYD) enzyme from liver microsomes. Assay is based on iodide release measured by the Sandell-Kolthoff method and is run in 96-well plate format with assay plates run in triplicate (n=3) with measurements taken at 3 hours after chemical dosing. Platewise-normalization was used based on positive control (3-Nitro-L-tyrosine, MNT) and negative/solvent controls (DMSO, NaOH).", + "timepointHr": 3.0, + "organismId": 8355, + "organism": "xenopus (frog)", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "frog liver", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3094, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 was analyzed into 2 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain or loss-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of endoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is SRY-related HMG-box.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB431542", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "SRY-related HMG-box", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2855, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay and it measures an increase in the percentage of cells in an endoderm state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Sox17+ cells are determined by calculating the number of Sox17+ cells divided by cell count. A cell is Sox17+ if the cell Sox17 mean intensity is 5x BMAD above the pluripotent control median cell Sox17 mean. The assay endpoints were analyzed with bidirectional fitting relative to 0.2% DMSO control in the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox17 was designed to measure changes in cellular Sox17 expression. Changes are indicative of changes in Sox17 gene expression due to perturbations in endoderm differentiation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3095, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of pluripotency or ectoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is SRY-related HMG-box.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "SRY-related HMG-box", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2856, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in the percentage of cells in an ectodermal or pluripotent state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Sox2+ cells are determined by calculating the number of Sox2+ cells divided by cell count. A cell is Sox2+ if the cell Sox2 mean intensity is 5x BMAD above the directed endoderm control median cell Sox2 mean. The assay endpoint was analyzed with bidirectional fitting with the 0.2% DMSO control median percent Sox2 in the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay subtracted.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Sox2 was designed to measure changes in cellular Sox2 expression. Changes are indicative of changes in Sox2 protein expression due to perturbations in endoderm differentiation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3096, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in gene expression. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of mesoderm differentiation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transcription factor intended target family, where the subfamily is T-box protein.", + "assayFunctionType": "gene expression", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "transcription factor", + "intendedTargetFamilySub": "T-box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2857, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in the percentage of cells in an endoderm state. It is designed to make measurements of inducible reporter a form of fluorescent protein induction as detected with optical fluorescence microscopy. Percentage Bra+ cells are determined by calculating the number of Bra+ cells divided by cell count. A cell is Bra+ if the cell Bra mean intensity is 5x BMAD above the pluripotent control median cell Bra mean. The assay endpoint was analyzed with bidirectional fitting with the 0.2% DMSO control median percent Bra in the DEVTOX_RUES2-GLR assay subtracted.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_Bra was designed to measure changes in cellular Bra expression. Changes are indicative of changes in Bra gene expression due to perturbations in endoderm differentiation", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transcription factor", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3098, + "assayComponentEndpointName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount was analyzed into 2 assay endpoint. This assay endpoint, CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline activity. Using nuclei counting, gain or loss-of-signal activity can be used to understand changes in cell viability. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves as a measure of cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2858, + "assayComponentName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount", + "assayComponentDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount is one of 4 assay components calculated from the CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay that measures an increase in cell count. It is designed to make measurements of nuclei count, a form of cell viability, as detected with optical fluorescence microscopy by Perkin Elmer Harmony nuclei detection algorithm. The assay endpoints were analyzed with bidirectional fitting relative to 0.2% DMSO control in the DEVTOX_RUES2-GLR assay.", + "assayComponentTargetDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo_CellCount was designed to measure changes in the number cells. Changes are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "microscopy", + "detectionTechnologyTypeSub": "optical microscopy: fluorescence microscopy", + "detectionTechnology": "Perkin Elmer Harmony nuclei detection algorithm ", + "keyAssayReagentType": "stain", + "keyAssayReagent": "fluorescent signal", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 875, + "assayName": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo", + "assayDesc": "CCTE_Deisenroth_DEVTOX_RUES2-GLR_Endo assay is a cell-based, multiplex-readout assay that uses RUES2-GLR, a human pluripotent cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "pluripotent cell line", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "RUES2-GLR", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3099, + "assayComponentEndpointName": "ATG_frGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2860, + "assayComponentName": "ATG_frGR_EcoTox2", + "assayComponentDesc": "ATG_frGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frGR, also known as african clawed frog (Xenopus laevis) glucocorticoid receptor. [NCBI Reference Sequence: NP_001081531.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3101, + "assayComponentEndpointName": "ATG_rtGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2861, + "assayComponentName": "ATG_rtGR_EcoTox2", + "assayComponentDesc": "ATG_rtGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtGR, also known as rainbow trout (Oncorhynchus mykiss) glucocorticoid receptor. [NCBI Reference Sequence: NP_001118202.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3103, + "assayComponentEndpointName": "ATG_jmGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2862, + "assayComponentName": "ATG_jmGR_EcoTox2", + "assayComponentDesc": "ATG_jmGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element mGR, also known as japanese medaka (Oryzias latipes) glucocorticoid receptor. [NCBI Reference Sequence: NNP_001292330.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3105, + "assayComponentEndpointName": "ATG_zfGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2863, + "assayComponentName": "ATG_zfGR_EcoTox2", + "assayComponentDesc": "ATG_zfGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfGR, also known as zebrafish (Danio rerio) glucocorticoid receptor. [NCBI Reference Sequence: NP_001018547.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3107, + "assayComponentEndpointName": "ATG_hPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2864, + "assayComponentName": "ATG_hPPARa_EcoTox2", + "assayComponentDesc": "ATG_hPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hPPARg, which is responsive to the human peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_005027.2]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3109, + "assayComponentEndpointName": "ATG_frPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2865, + "assayComponentName": "ATG_frPPARa_EcoTox2", + "assayComponentDesc": "ATG_frPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frPPARg, which is responsive to the african clawed frog (Xenopus laevis) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001083282.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3111, + "assayComponentEndpointName": "ATG_rtPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2866, + "assayComponentName": "ATG_rtPPARa_EcoTox2", + "assayComponentDesc": "ATG_rtPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtPPARg, which is responsive to the rainbow trout (Oncorhynchus mykiss) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: XP_021473593.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3113, + "assayComponentEndpointName": "ATG_jmPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2867, + "assayComponentName": "ATG_jmPPARa_EcoTox2", + "assayComponentDesc": "ATG_jmPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmPPARg, which is responsive to the japanese medaka (Oryzias latipes) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001158347.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3115, + "assayComponentEndpointName": "ATG_zfPPARa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARa. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2868, + "assayComponentName": "ATG_zfPPARa_EcoTox2", + "assayComponentDesc": "ATG_zfPPARa_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfPPARg, which is responsive to the zebrafish (Danio rerio) peroxisome proliferator activated receptor alpha. NCBI Reference Sequence: NP_001154805.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3117, + "assayComponentEndpointName": "ATG_hPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2869, + "assayComponentName": "ATG_hPPARg_EcoTox2", + "assayComponentDesc": "ATG_hPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hPPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001341595.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3119, + "assayComponentEndpointName": "ATG_frPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2870, + "assayComponentName": "ATG_frPPARg_EcoTox2", + "assayComponentDesc": "ATG_frPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frPPARg, which is responsive to the african clawed frog (Xenopus laevis) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001081312.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3121, + "assayComponentEndpointName": "ATG_rtPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2871, + "assayComponentName": "ATG_rtPPARg_EcoTox2", + "assayComponentDesc": "ATG_rtPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtPPARg, which is responsive to the rainbow trout (Oncorhynchus mykiss) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: XP_021470054.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3123, + "assayComponentEndpointName": "ATG_jmPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2872, + "assayComponentName": "ATG_jmPPARg_EcoTox2", + "assayComponentDesc": "ATG_jmPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmPPARg, which is responsive to the japanese medaka (Oryzias latipes) peroxisome proliferator activated receptor gamma. [NCBI Reference Sequence: NP_001158348.1]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1945, + "assayComponentEndpointName": "ATG_M_19_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_19_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1872, + "assayComponentName": "ATG_M_19_XSP1", + "assayComponentDesc": "ATG_M_19_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1947, + "assayComponentEndpointName": "ATG_M_32_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_32_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1873, + "assayComponentName": "ATG_M_32_XSP1", + "assayComponentDesc": "ATG_M_32_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1949, + "assayComponentEndpointName": "ATG_M_61_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_61_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1874, + "assayComponentName": "ATG_M_61_XSP1", + "assayComponentDesc": "ATG_M_61_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1951, + "assayComponentEndpointName": "ATG_hPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1875, + "assayComponentName": "ATG_hPPARg_XSP1", + "assayComponentDesc": "ATG_hPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [GeneSymbol:PPARG | GeneID: 5468| Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1953, + "assayComponentEndpointName": "ATG_mPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1876, + "assayComponentName": "ATG_mPPARg_XSP1", + "assayComponentDesc": "ATG_mPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the mouse peroxisome proliferator activated receptor gamma. [GeneSymbol:Pparg | GeneID: 19016| Uniprot_SwissProt_Accession:P37238].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-mPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1478, + "geneName": "peroxisome proliferator activated receptor gamma", + "description": "peroxisome proliferator activated receptor gamma [ Mus musculus(house mouse) ]", + "geneSymbol": "Pparg", + "organismId": 2, + "trackStatus": null, + "entrezGeneId": 19016, + "officialSymbol": "Pparg", + "officialFullName": "peroxisome proliferator activated receptor gamma", + "uniprotAccessionNumber": "P37238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1955, + "assayComponentEndpointName": "ATG_zfPPARg_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1877, + "assayComponentName": "ATG_zfPPARg_XSP1", + "assayComponentDesc": "ATG_zfPPARg_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1471, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": "peroxisome proliferator-activated receptor gamma [ Danio rerio(zebrafish) ]", + "geneSymbol": "pparg", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 557037, + "officialSymbol": "pparg", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "A6XMH6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1957, + "assayComponentEndpointName": "ATG_mPXR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPXR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1878, + "assayComponentName": "ATG_mPXR_XSP1", + "assayComponentDesc": "ATG_mPXR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PXR, which is responsive to the mouse pregnane X receptor. [GeneSymbol: NR1IA | GeneID: 8856| Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NA", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1959, + "assayComponentEndpointName": "ATG_frTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1879, + "assayComponentName": "ATG_frTRa_XSP1", + "assayComponentDesc": "ATG_frTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the frog thyroid hormone receptor, alpha L homeolog. [GeneSymbol: thra.L | GeneID: 397942| Uniprot_SwissProt_Accession: P15204].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1482, + "geneName": "thyroid hormone receptor, alpha L homeolog", + "description": "thyroid hormone receptor, alpha L homeolog [ Xenopus laevis(African clawed frog) ]", + "geneSymbol": "thra.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 397942, + "officialSymbol": "thra.L", + "officialFullName": "thyroid hormone receptor, alpha L homeolog", + "uniprotAccessionNumber": "P15204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1961, + "assayComponentEndpointName": "ATG_hTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1880, + "assayComponentName": "ATG_hTRa_XSP1", + "assayComponentDesc": "ATG_hTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 7067| Uniprot_SwissProt_Accession: P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1963, + "assayComponentEndpointName": "ATG_trTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1881, + "assayComponentName": "ATG_trTRa_XSP1", + "assayComponentDesc": "ATG_trTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the turtle thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 101949057| Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1466, + "geneName": "thyroid hormone receptor, alpha", + "description": "thyroid hormone receptor, alpha [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "THRA", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101949057, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1965, + "assayComponentEndpointName": "ATG_zfTRa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1882, + "assayComponentName": "ATG_zfTRa_XSP1", + "assayComponentDesc": "ATG_zfTRa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, alpha a. [GeneSymbol: thraa | GeneID: 30670| Uniprot_SwissProt_Accession: Q98867].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1472, + "geneName": "thyroid hormone receptor alpha a", + "description": "thyroid hormone receptor alpha a [ Danio rerio (zebrafish) ]", + "geneSymbol": "thraa", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30670, + "officialSymbol": "thraa", + "officialFullName": "thyroid hormone receptor alpha a", + "uniprotAccessionNumber": "Q98867" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1967, + "assayComponentEndpointName": "ATG_hTRb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1883, + "assayComponentName": "ATG_hTRb_XSP1", + "assayComponentDesc": "ATG_hTRb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, beta. [GeneSymbol: THRB | GeneID: 7068| Uniprot_SwissProt_Accession: P10828].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1969, + "assayComponentEndpointName": "ATG_zfTRb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1884, + "assayComponentName": "ATG_zfTRb_XSP1", + "assayComponentDesc": "ATG_zfTRb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, beta. [GeneSymbol: thrb | GeneID: 30607| Uniprot_SwissProt_Accession: Q9PVE4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1473, + "geneName": "thyroid hormone receptor beta", + "description": "thyroid hormone receptor beta [ Danio rerio (zebrafish) ]", + "geneSymbol": "thrb", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30607, + "officialSymbol": "thrb", + "officialFullName": "thyroid hormone receptor beta", + "uniprotAccessionNumber": "Q9PVE4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1971, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_XTT_Cytotoxicity_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1885, + "assayComponentName": "ATG_XTT_Cytotoxicity_XSP1", + "assayComponentDesc": "ATG_XTT_Cytotoxicity_XSP1 is an assay component measured from the ATG_XSP1_XTT_Cytotoxicity_multi-species assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 570, + "assayName": "ATG_XSP1_XTT_Cytotoxicity_multi-species", + "assayDesc": "ATG_XSP1_XTT_Cytotoxicity_multi-species is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1973, + "assayComponentEndpointName": "ATG_M_06_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_06_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1886, + "assayComponentName": "ATG_M_06_XSP2", + "assayComponentDesc": "ATG_M_06_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1014, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45G", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45G was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45G, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "mutagenicity response", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 648, + "assayComponentName": "LTEA_HepaRG_GADD45G", + "assayComponentDesc": "LTEA_HepaRG_GADD45G is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 369, + "geneName": "growth arrest and DNA-damage-inducible, gamma", + "description": null, + "geneSymbol": "GADD45G", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10912, + "officialSymbol": "GADD45G", + "officialFullName": "growth arrest and DNA-damage-inducible, gamma", + "uniprotAccessionNumber": "O95257" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1016, + "assayComponentEndpointName": "LTEA_HepaRG_GCLC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GCLC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ligase", + "intendedTargetFamilySub": "C-N ligase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 649, + "assayComponentName": "LTEA_HepaRG_GCLC", + "assayComponentDesc": "LTEA_HepaRG_GCLC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 142, + "geneName": "glutamate-cysteine ligase, catalytic subunit", + "description": null, + "geneSymbol": "GCLC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2729, + "officialSymbol": "GCLC", + "officialFullName": "glutamate-cysteine ligase, catalytic subunit", + "uniprotAccessionNumber": "P48506" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1018, + "assayComponentEndpointName": "LTEA_HepaRG_GCLM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GCLM was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLM, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ligase", + "intendedTargetFamilySub": "C-N ligase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 650, + "assayComponentName": "LTEA_HepaRG_GCLM", + "assayComponentDesc": "LTEA_HepaRG_GCLM is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 143, + "geneName": "glutamate-cysteine ligase, modifier subunit", + "description": null, + "geneSymbol": "GCLM", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2730, + "officialSymbol": "GCLM", + "officialFullName": "glutamate-cysteine ligase, modifier subunit", + "uniprotAccessionNumber": "P48507" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1026, + "assayComponentEndpointName": "LTEA_HepaRG_GSTA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GSTA2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTA2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 654, + "assayComponentName": "LTEA_HepaRG_GSTA2", + "assayComponentDesc": "LTEA_HepaRG_GSTA2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1028, + "assayComponentEndpointName": "LTEA_HepaRG_GSTM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GSTM3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTM3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 655, + "assayComponentName": "LTEA_HepaRG_GSTM3", + "assayComponentDesc": "LTEA_HepaRG_GSTM3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 148, + "geneName": "glutathione S-transferase mu 3 (brain)", + "description": null, + "geneSymbol": "GSTM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2947, + "officialSymbol": "GSTM3", + "officialFullName": "glutathione S-transferase mu 3 (brain)", + "uniprotAccessionNumber": "P21266" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1030, + "assayComponentEndpointName": "LTEA_HepaRG_HGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is hepatocyte growth factor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "hepatocyte growth factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 656, + "assayComponentName": "LTEA_HepaRG_HGF", + "assayComponentDesc": "LTEA_HepaRG_HGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 151, + "geneName": "hepatocyte growth factor (hepapoietin A; scatter factor)", + "description": null, + "geneSymbol": "HGF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3082, + "officialSymbol": "HGF", + "officialFullName": "hepatocyte growth factor (hepapoietin A; scatter factor)", + "uniprotAccessionNumber": "P14210" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1032, + "assayComponentEndpointName": "LTEA_HepaRG_HIF1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HIF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HIF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 657, + "assayComponentName": "LTEA_HepaRG_HIF1A", + "assayComponentDesc": "LTEA_HepaRG_HIF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1034, + "assayComponentEndpointName": "LTEA_HepaRG_HMGCS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HMGCS2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HMGCS2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 658, + "assayComponentName": "LTEA_HepaRG_HMGCS2", + "assayComponentDesc": "LTEA_HepaRG_HMGCS2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1036, + "assayComponentEndpointName": "LTEA_HepaRG_HSPA1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_HSPA1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HSPA1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 659, + "assayComponentName": "LTEA_HepaRG_HSPA1A", + "assayComponentDesc": "LTEA_HepaRG_HSPA1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 162, + "geneName": "heat shock 70kDa protein 1A", + "description": null, + "geneSymbol": "HSPA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3303, + "officialSymbol": "HSPA1A", + "officialFullName": "heat shock 70kDa protein 1A", + "uniprotAccessionNumber": "P08107" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1038, + "assayComponentEndpointName": "LTEA_HepaRG_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ICAM1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 660, + "assayComponentName": "LTEA_HepaRG_ICAM1", + "assayComponentDesc": "LTEA_HepaRG_ICAM1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1040, + "assayComponentEndpointName": "LTEA_HepaRG_IGF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IGF1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGF1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is insulin-like.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "insulin-like", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 661, + "assayComponentName": "LTEA_HepaRG_IGF1", + "assayComponentDesc": "LTEA_HepaRG_IGF1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 171, + "geneName": "insulin-like growth factor 1 (somatomedin C)", + "description": null, + "geneSymbol": "IGF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3479, + "officialSymbol": "IGF1", + "officialFullName": "insulin-like growth factor 1 (somatomedin C)", + "uniprotAccessionNumber": "P05019" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1042, + "assayComponentEndpointName": "LTEA_HepaRG_IGFBP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IGFBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGFBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is hormone carrier protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "hormone carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 662, + "assayComponentName": "LTEA_HepaRG_IGFBP1", + "assayComponentDesc": "LTEA_HepaRG_IGFBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 173, + "geneName": "insulin-like growth factor binding protein 1", + "description": null, + "geneSymbol": "IGFBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3484, + "officialSymbol": "IGFBP1", + "officialFullName": "insulin-like growth factor binding protein 1", + "uniprotAccessionNumber": "P08833" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1044, + "assayComponentEndpointName": "LTEA_HepaRG_IL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IL6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 663, + "assayComponentName": "LTEA_HepaRG_IL6", + "assayComponentDesc": "LTEA_HepaRG_IL6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1046, + "assayComponentEndpointName": "LTEA_HepaRG_IL6R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_IL6R was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6R, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is JAK-STAT cytokine receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "JAK-STAT cytokine receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 664, + "assayComponentName": "LTEA_HepaRG_IL6R", + "assayComponentDesc": "LTEA_HepaRG_IL6R is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 176, + "geneName": "interleukin 6 receptor", + "description": null, + "geneSymbol": "IL6R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3570, + "officialSymbol": "IL6R", + "officialFullName": "interleukin 6 receptor", + "uniprotAccessionNumber": "P08887" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1048, + "assayComponentEndpointName": "LTEA_HepaRG_JUN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_JUN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_JUN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 665, + "assayComponentName": "LTEA_HepaRG_JUN", + "assayComponentDesc": "LTEA_HepaRG_JUN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1050, + "assayComponentEndpointName": "LTEA_HepaRG_KCNK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KCNK1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KCNK1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 666, + "assayComponentName": "LTEA_HepaRG_KCNK1", + "assayComponentDesc": "LTEA_HepaRG_KCNK1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Hyperplasia.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 185, + "geneName": "potassium channel, subfamily K, member 1", + "description": null, + "geneSymbol": "KCNK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3775, + "officialSymbol": "KCNK1", + "officialFullName": "potassium channel, subfamily K, member 1", + "uniprotAccessionNumber": "O00180" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1052, + "assayComponentEndpointName": "LTEA_HepaRG_KRT19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KRT19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KRT19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the filaments intended target family, where the subfamily is keratin.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "filaments", + "intendedTargetFamilySub": "keratin", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 667, + "assayComponentName": "LTEA_HepaRG_KRT19", + "assayComponentDesc": "LTEA_HepaRG_KRT19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 187, + "geneName": "keratin 19", + "description": null, + "geneSymbol": "KRT19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3880, + "officialSymbol": "KRT19", + "officialFullName": "keratin 19", + "uniprotAccessionNumber": "P08727" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1054, + "assayComponentEndpointName": "LTEA_HepaRG_LIPC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LIPC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LIPC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "lipase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 668, + "assayComponentName": "LTEA_HepaRG_LIPC", + "assayComponentDesc": "LTEA_HepaRG_LIPC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 192, + "geneName": "lipase, hepatic", + "description": null, + "geneSymbol": "LIPC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3990, + "officialSymbol": "LIPC", + "officialFullName": "lipase, hepatic", + "uniprotAccessionNumber": "P11150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1056, + "assayComponentEndpointName": "LTEA_HepaRG_LPL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LPL was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LPL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "lipase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 669, + "assayComponentName": "LTEA_HepaRG_LPL", + "assayComponentDesc": "LTEA_HepaRG_LPL is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 194, + "geneName": "lipoprotein lipase", + "description": null, + "geneSymbol": "LPL", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4023, + "officialSymbol": "LPL", + "officialFullName": "lipoprotein lipase", + "uniprotAccessionNumber": "P06858" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1058, + "assayComponentEndpointName": "LTEA_HepaRG_MIR122", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MIR122 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MIR122, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the microrna intended target family, where the subfamily is post-transcriptional regulation.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "miRNA", + "intendedTargetFamily": "microrna", + "intendedTargetFamilySub": "post-transcriptional regulation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 670, + "assayComponentName": "LTEA_HepaRG_MIR122", + "assayComponentDesc": "LTEA_HepaRG_MIR122 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of MicroRNA.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 457, + "geneName": "microRNA 122", + "description": null, + "geneSymbol": "MIR122", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 406906, + "officialSymbol": "MIR122", + "officialFullName": "microRNA 122", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1060, + "assayComponentEndpointName": "LTEA_HepaRG_MMP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 671, + "assayComponentName": "LTEA_HepaRG_MMP10", + "assayComponentDesc": "LTEA_HepaRG_MMP10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 208, + "geneName": "matrix metallopeptidase 10 (stromelysin 2)", + "description": null, + "geneSymbol": "MMP10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4319, + "officialSymbol": "MMP10", + "officialFullName": "matrix metallopeptidase 10 (stromelysin 2)", + "uniprotAccessionNumber": "P09238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1062, + "assayComponentEndpointName": "LTEA_HepaRG_MMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 672, + "assayComponentName": "LTEA_HepaRG_MMP3", + "assayComponentDesc": "LTEA_HepaRG_MMP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1064, + "assayComponentEndpointName": "LTEA_HepaRG_MYC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MYC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MYC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 673, + "assayComponentName": "LTEA_HepaRG_MYC", + "assayComponentDesc": "LTEA_HepaRG_MYC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 213, + "geneName": "v-myc avian myelocytomatosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4609, + "officialSymbol": "MYC", + "officialFullName": "v-myc avian myelocytomatosis viral oncogene homolog", + "uniprotAccessionNumber": "P01106" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1066, + "assayComponentEndpointName": "LTEA_HepaRG_NFE2L2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NFE2L2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFE2L2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 674, + "assayComponentName": "LTEA_HepaRG_NFE2L2", + "assayComponentDesc": "LTEA_HepaRG_NFE2L2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation/injury.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1068, + "assayComponentEndpointName": "LTEA_HepaRG_NFKB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NFKB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFKB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 675, + "assayComponentName": "LTEA_HepaRG_NFKB1", + "assayComponentDesc": "LTEA_HepaRG_NFKB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1070, + "assayComponentEndpointName": "LTEA_HepaRG_NQO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_NQO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NQO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is quinone-acceptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "quinone-acceptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 676, + "assayComponentName": "LTEA_HepaRG_NQO1", + "assayComponentDesc": "LTEA_HepaRG_NQO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with NQO1 include Tardive Dyskinesia and Childhood Leukemia. .", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 98, + "geneName": "NAD(P)H dehydrogenase, quinone 1", + "description": null, + "geneSymbol": "NQO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1728, + "officialSymbol": "NQO1", + "officialFullName": "NAD(P)H dehydrogenase, quinone 1", + "uniprotAccessionNumber": "P15559" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 3125, + "assayComponentEndpointName": "ATG_zfPPARg_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Triphenyl phosphate", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2873, + "assayComponentName": "ATG_zfPPARg_EcoTox2", + "assayComponentDesc": "ATG_zfPPARg_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish (Danio rerio) peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6 | NCBI Reference Sequence: NP_571542.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3127, + "assayComponentEndpointName": "ATG_hRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2874, + "assayComponentName": "ATG_hRXRb_EcoTox2", + "assayComponentDesc": "ATG_hRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hRXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702 |NCBI Reference Sequence: NP_068811.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-hRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3129, + "assayComponentEndpointName": "ATG_frRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2875, + "assayComponentName": "ATG_frRXRb_EcoTox2", + "assayComponentDesc": "ATG_frRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element frRXRb, also known as african clawed frog (Xenopus laevis) retinoid X receptor, beta [NCBI Reference Sequence: NP_001080936.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3131, + "assayComponentEndpointName": "ATG_rtRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_rtRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2876, + "assayComponentName": "ATG_rtRXRb_EcoTox2", + "assayComponentDesc": "ATG_rtRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element rtRXRb, also known as rainbow trout (Oncorhynchus mykiss) retinoid X receptor, beta [NCBI Reference Sequence: XP_021427688.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-rtRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3133, + "assayComponentEndpointName": "ATG_jmRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_jmRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2877, + "assayComponentName": "ATG_jmRXRb_EcoTox2", + "assayComponentDesc": "ATG_jmRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element jmRXRb, also known as japanese medaka (Oryzias latipes) retinoid X receptor, beta [NCBI Reference Sequence: XP_020562828.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-jmRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3135, + "assayComponentEndpointName": "ATG_zfRXRb_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfRXRb_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRb. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Bexarotene", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2878, + "assayComponentName": "ATG_zfRXRb_EcoTox2", + "assayComponentDesc": "ATG_zfRXRb_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfRXRb, also known as zebrafish (Danio rerio) retinoid X receptor, beta [NCBI Reference Sequence: NP_571350.1 ].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfRXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3137, + "assayComponentEndpointName": "ATG_hERa_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2879, + "assayComponentName": "ATG_hERa_EcoTox2", + "assayComponentDesc": "ATG_hERa_EcoTox2 is one of 29 assay components measured or calculated from the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372 | NCBI Reference Sequence: NP_000116.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3139, + "assayComponentEndpointName": "ATG_zfER1_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2880, + "assayComponentName": "ATG_zfER1_EcoTox2", + "assayComponentDesc": "ATG_zfER1_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element zfER, which is responsive to the zebrafish (Danio rerio) estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717 | NCBI Reference Sequence: NP_694491.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3141, + "assayComponentEndpointName": "ATG_frER1_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2881, + "assayComponentName": "ATG_frER1_EcoTox2", + "assayComponentDesc": "ATG_frER1_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the african clawed frog (Xenopus laevis) estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7 | NCBI Reference Sequence: NP_001083086.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3143, + "assayComponentEndpointName": "ATG_hAR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "11-keto Testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2882, + "assayComponentName": "ATG_hAR_EcoTox2", + "assayComponentDesc": "ATG_hAR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275 | NCBI Reference Sequence: NP_000035.2].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3145, + "assayComponentEndpointName": "ATG_zfAR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "11-keto Testosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2883, + "assayComponentName": "ATG_zfAR_EcoTox2", + "assayComponentDesc": "ATG_zfAR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish (Danio rerio) androgen receptor. [GeneSymbol:AR | GeneID:100005148 | NCBI Reference Sequence: NP_001076592.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3147, + "assayComponentEndpointName": "ATG_M_61_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_61_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2884, + "assayComponentName": "ATG_M_61_EcoTox2", + "assayComponentDesc": "ATG_M_61_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3149, + "assayComponentEndpointName": "ATG_M_06_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_06_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2885, + "assayComponentName": "ATG_M_06_EcoTox2", + "assayComponentDesc": "ATG_M_06_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3151, + "assayComponentEndpointName": "ATG_M_32_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_32_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2886, + "assayComponentName": "ATG_M_32_EcoTox2", + "assayComponentDesc": "ATG_M_32_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3153, + "assayComponentEndpointName": "ATG_M_19_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_M_19_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2887, + "assayComponentName": "ATG_M_19_EcoTox2", + "assayComponentDesc": "ATG_M_19_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3155, + "assayComponentEndpointName": "ATG_hGR_EcoTox2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hGR_EcoTox2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene for glucocorticoid receptor. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2859, + "assayComponentName": "ATG_hGR_EcoTox2", + "assayComponentDesc": "ATG_hGR_EcoTox2 is one of 29 assay components calculated in the ATG_EcoTox2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element hGR, also known as human glucocorticoid receptor isoform alpha. [NCBI Reference Sequence: NP_000167.1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-GR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 876, + "assayName": "ATG_EcoTox2", + "assayDesc": "ATG_EcoTox2 is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), african clawed frog (Xenopus laevis), rainbow trout (Oncorhynchus mykiss), japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). The ECOTOX2-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3161, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using Homogenous Time Resolved Fluorescence technology was used to understand synthesis of estradiol in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "forskolin for gain; prochloraz for loss", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2891, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_ESTRADIOL is one of 3 assay components calculated in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with Homogenous Time Resolved Fluorescence immunoassay technology.", + "assayComponentTargetDesc": "Changes in the fluorescence ratio are indicative of induction (gain of signal) or inhibition (loss of signal) of steroid hormone biosynthesis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence ratio", + "detectionTechnology": "Homogenous Time Resolved Fluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "estradiol", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3162, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using Homogenous Time Resolved Fluorescence technology was used to understand synthesis of testosterone in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "forskolin for gain; prochloraz for loss", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2892, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_TESTOSTERONE is one of 3 assay components calculated in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with Homogenous Time Resolved Fluorescence immunoassay technology.", + "assayComponentTargetDesc": "Changes in the fluorescence ratio are indicative of induction (gain of signal) or inhibition (loss of signal) of steroid hormone biosynthesis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence ratio", + "detectionTechnology": "Homogenous Time Resolved Fluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "testosterone", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3163, + "assayComponentEndpointName": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity using CellTiter-Glo 2.0 technology was used to understand viability in the H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity", + "assayFunctionType": "viability", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2893, + "assayComponentName": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX", + "assayComponentDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL_CTOX is one of 3 assay components measured in the CCTE_Deisenroth_H295R-HTRF_384WELL assay (2 hormones and 1 viability components). It is designed to make measurements of adenosine triphosphate (ATP), a form of viability reporter, as detected with luminescence intensity signals by CellTiter-Glo 2.0 cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes in luminescence intensity, proportional to the amount of ATP present, are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "CellTiter-Glo 2.0", + "keyAssayReagentType": "luciferase co-factor", + "keyAssayReagent": "luciferin", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "ATP", + "aid": 879, + "assayName": "CCTE_Deisenroth_H295R-HTRF_384WELL", + "assayDesc": "CCTE_Deisenroth_H295R-HTRF_384WELL assay is a cell-based, multiplex-readout assay that uses H295R, a human adrenocortical carcinoma cell line, with measurements taken at 48 hours after chemical dosing in a 384-well microplate", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell-based", + "cellFreeComponentSource": "NA", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplex", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3164, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_BPCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GABANeurons. Use data with caution.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2894, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_BPCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to number of branch points using High Content Imaging of fluorescently labelled markers. This assay component is considered less reliable by experts on the assay due to low occurrence of branch points in the iCell GABANeurons. Use data with caution.", + "assayComponentTargetDesc": "Changes in the number of branch points are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of branch points", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3165, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2895, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to number of neurites using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurites are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurites", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3166, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth (initiation)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2896, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuriteLength is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures neurite outgrowth related to neurite length using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the neurite length are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 3167, + "assayComponentEndpointName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand developmental effects.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rac 1 inhibitor (30uM)", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2897, + "assayComponentName": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount", + "assayComponentDesc": "CCTE_Mundy_HCI_iCellGABA_NOG_NeuronCount is one of four components of the CCTE_Mundy_HCI_iCellGABA_NOG assay. It measures cell viability related to number of neurons using High Content Imaging of fluorescently labelled markers.", + "assayComponentTargetDesc": "Changes in the number of neurons are indicative of neurodevelopment.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TUBB3 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of neurons", + "aid": 880, + "assayName": "CCTE_Mundy_HCI_iCellGABA_NOG", + "assayDesc": "CCTE_Mundy_HCI_iCellGABA_NOG is a multiplexed, cell-based-readout assay that uses iCell GABANeurons from FUJIFILM Cellular Dynamics, Inc. (FCDI), human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells, with measurements taken at 50.33 hours after chemical dosing in a microplate: 96-well plate.", + "timepointHr": 50.33, + "organismId": 9606, + "organism": "human", + "tissue": "neural", + "cellFormat": "secondary cell", + "cellFreeComponentSource": "human GABAergic enriched neurons derived from induced pluripotent stem (iPS) cells", + "cellShortName": "iCell GABANeurons", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.1, + "asid": 31, + "assaySourceName": "CCTE_MUNDY", + "assaySourceLongName": "CCTE Mundy Lab", + "assaySourceDesc": "The Mundy Lab at the EPA Center for Computational Toxicology and Exposure utilizes high content imaging to characterize chemical effects in neurodevelopment.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1975, + "assayComponentEndpointName": "ATG_trERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1887, + "assayComponentName": "ATG_trERa_XSP2", + "assayComponentDesc": "ATG_trERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the turtle estrogen receptor. [GeneSymbol:ESR1 | GeneID: 101933533| Uniprot_SwissProt_Accession:B6E1V9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1465, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "ESR1", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101933533, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "B6E1V9" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1977, + "assayComponentEndpointName": "ATG_hERb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1888, + "assayComponentName": "ATG_hERb_XSP2", + "assayComponentDesc": "ATG_hERb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR2 | GeneID: 2100| Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ER-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1979, + "assayComponentEndpointName": "ATG_trAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1889, + "assayComponentName": "ATG_trAR_XSP2", + "assayComponentDesc": "ATG_trAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the turtle androgen receptor. [GeneSymbol:AR | GeneID:101947425 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1464, + "geneName": "androgen receptor", + "description": "PREDICTED: Chrysemys picta bellii androgen receptor (AR), mRNA", + "geneSymbol": "AR", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101947425, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1981, + "assayComponentEndpointName": "ATG_GAL4_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_GAL4_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1890, + "assayComponentName": "ATG_GAL4_XSP2", + "assayComponentDesc": "ATG_GAL4_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1983, + "assayComponentEndpointName": "ATG_zfER1_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1891, + "assayComponentName": "ATG_zfER1_XSP2", + "assayComponentDesc": "ATG_zfER1_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1468, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "esr1", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 259252, + "officialSymbol": "esr1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P57717" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1985, + "assayComponentEndpointName": "ATG_chERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1892, + "assayComponentName": "ATG_chERa_XSP2", + "assayComponentDesc": "ATG_chERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the chicken estrogen receptor. [GeneSymbol:ESR1 | GeneID: 396099| Uniprot_SwissProt_Accession:P06212].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1475, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 (chicken)", + "geneSymbol": "ESR1", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 396099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P06212" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1987, + "assayComponentEndpointName": "ATG_zfER2a_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2a_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1893, + "assayComponentName": "ATG_zfER2a_XSP2", + "assayComponentDesc": "ATG_zfER2a_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2a | GeneID: 317734| Uniprot_SwissProt_Accession:Q7ZU32].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1469, + "geneName": "estrogen receptor 2a", + "description": "estrogen receptor 2a [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2a", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317734, + "officialSymbol": "esr2a", + "officialFullName": "estrogen receptor 2a", + "uniprotAccessionNumber": "Q7ZU32" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1989, + "assayComponentEndpointName": "ATG_hAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1894, + "assayComponentName": "ATG_hAR_XSP2", + "assayComponentDesc": "ATG_hAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1991, + "assayComponentEndpointName": "ATG_chAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1895, + "assayComponentName": "ATG_chAR_XSP2", + "assayComponentDesc": "ATG_chAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the chicken androgen receptor. [GeneSymbol:ar | GeneID:422165| Uniprot_SwissProt_Accession:Q2ACE0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1474, + "geneName": "androgen receptor", + "description": "androgen receptor (chicken)", + "geneSymbol": "AR", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 422165, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "Q2ACE0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1993, + "assayComponentEndpointName": "ATG_frER1_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1896, + "assayComponentName": "ATG_frER1_XSP2", + "assayComponentDesc": "ATG_frER1_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1480, + "geneName": "estrogen receptor 1 L homeolog", + "description": "estrogen receptor 1 L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "esr1.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 398734, + "officialSymbol": "esr1.L", + "officialFullName": "estrogen receptor 1 L homeolog", + "uniprotAccessionNumber": "Q6W5G7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1995, + "assayComponentEndpointName": "ATG_frAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1897, + "assayComponentName": "ATG_frAR_XSP2", + "assayComponentDesc": "ATG_frAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the frog androgen receptor. [GeneSymbol:ar.L | GeneID:399456| Uniprot_SwissProt_Accession:P70048].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1479, + "geneName": "androgen receptor L homeolog", + "description": "androgen receptor L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "ar.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 399456, + "officialSymbol": "ar.L", + "officialFullName": "androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) L homeolog", + "uniprotAccessionNumber": "P70048" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1997, + "assayComponentEndpointName": "ATG_zfAR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1898, + "assayComponentName": "ATG_zfAR_XSP2", + "assayComponentDesc": "ATG_zfAR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish androgen receptor. [GeneSymbol:AR | GeneID:100005148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1467, + "geneName": "androgen receptor", + "description": "androgen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "ar", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 100005148, + "officialSymbol": "ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "A4GT83" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1999, + "assayComponentEndpointName": "ATG_zfER2b_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2b_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1899, + "assayComponentName": "ATG_zfER2b_XSP2", + "assayComponentDesc": "ATG_zfER2b_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2b | GeneID: 317733| Uniprot_SwissProt_Accession:Q5PR29].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1470, + "geneName": "estrogen receptor 2b", + "description": "estrogen receptor 2b [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2b", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317733, + "officialSymbol": "esr2b", + "officialFullName": "estrogen receptor 2b", + "uniprotAccessionNumber": "Q5PR29" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2001, + "assayComponentEndpointName": "ATG_hERa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1900, + "assayComponentName": "ATG_hERa_XSP2", + "assayComponentDesc": "ATG_hERa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2003, + "assayComponentEndpointName": "ATG_M_19_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_19_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1901, + "assayComponentName": "ATG_M_19_XSP2", + "assayComponentDesc": "ATG_M_19_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2005, + "assayComponentEndpointName": "ATG_M_32_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_32_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1902, + "assayComponentName": "ATG_M_32_XSP2", + "assayComponentDesc": "ATG_M_32_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2023, + "assayComponentEndpointName": "ATG_M_61_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_M_61_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1911, + "assayComponentName": "ATG_M_61_XSP2", + "assayComponentDesc": "ATG_M_61_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1072, + "assayComponentEndpointName": "LTEA_HepaRG_PDK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PDK4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PDK4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 677, + "assayComponentName": "LTEA_HepaRG_PDK4", + "assayComponentDesc": "LTEA_HepaRG_PDK4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with PDK4 include Platelet Glycoprotein Iv Deficiency and Diabetes Mellitus, Noninsulin-Dependent. .", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 234, + "geneName": "pyruvate dehydrogenase kinase, isozyme 4", + "description": null, + "geneSymbol": "PDK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5166, + "officialSymbol": "PDK4", + "officialFullName": "pyruvate dehydrogenase kinase, isozyme 4", + "uniprotAccessionNumber": "Q16654" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1074, + "assayComponentEndpointName": "LTEA_HepaRG_PEG10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PEG10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PEG10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 678, + "assayComponentName": "LTEA_HepaRG_PEG10", + "assayComponentDesc": "LTEA_HepaRG_PEG10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 375, + "geneName": "paternally expressed 10", + "description": null, + "geneSymbol": "PEG10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23089, + "officialSymbol": "PEG10", + "officialFullName": "paternally expressed 10", + "uniprotAccessionNumber": "Q86TG7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1076, + "assayComponentEndpointName": "LTEA_HepaRG_PPP2R4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PPP2R4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PPP2R4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 679, + "assayComponentName": "LTEA_HepaRG_PPP2R4", + "assayComponentDesc": "LTEA_HepaRG_PPP2R4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 254, + "geneName": "protein phosphatase 2A activator, regulatory subunit 4", + "description": null, + "geneSymbol": "PPP2R4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5524, + "officialSymbol": "PPP2R4", + "officialFullName": "protein phosphatase 2A activator, regulatory subunit 4", + "uniprotAccessionNumber": "Q15257" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1078, + "assayComponentEndpointName": "LTEA_HepaRG_PTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_PTEN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PTEN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 680, + "assayComponentName": "LTEA_HepaRG_PTEN", + "assayComponentDesc": "LTEA_HepaRG_PTEN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1080, + "assayComponentEndpointName": "LTEA_HepaRG_SDHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SDHB was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SDHB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is ubiquinone.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "ubiquinone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 681, + "assayComponentName": "LTEA_HepaRG_SDHB", + "assayComponentDesc": "LTEA_HepaRG_SDHB is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 292, + "geneName": "succinate dehydrogenase complex, subunit B, iron sulfur (Ip)", + "description": null, + "geneSymbol": "SDHB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6390, + "officialSymbol": "SDHB", + "officialFullName": "succinate dehydrogenase complex, subunit B, iron sulfur (Ip)", + "uniprotAccessionNumber": "P21912" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1082, + "assayComponentEndpointName": "LTEA_HepaRG_SLC22A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC22A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC22A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic cation transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic cation transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 682, + "assayComponentName": "LTEA_HepaRG_SLC22A1", + "assayComponentDesc": "LTEA_HepaRG_SLC22A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 300, + "geneName": "solute carrier family 22 (organic cation transporter), member 1", + "description": null, + "geneSymbol": "SLC22A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6580, + "officialSymbol": "SLC22A1", + "officialFullName": "solute carrier family 22 (organic cation transporter), member 1", + "uniprotAccessionNumber": "O15245" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1084, + "assayComponentEndpointName": "LTEA_HepaRG_SLCO1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLCO1B1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLCO1B1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 683, + "assayComponentName": "LTEA_HepaRG_SLCO1B1", + "assayComponentDesc": "LTEA_HepaRG_SLCO1B1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1086, + "assayComponentEndpointName": "LTEA_HepaRG_STAT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_STAT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_STAT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "stat protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 684, + "assayComponentName": "LTEA_HepaRG_STAT3", + "assayComponentDesc": "LTEA_HepaRG_STAT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 305, + "geneName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "description": null, + "geneSymbol": "STAT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6774, + "officialSymbol": "STAT3", + "officialFullName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "uniprotAccessionNumber": "P40763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1088, + "assayComponentEndpointName": "LTEA_HepaRG_SULT2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SULT2A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SULT2A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 685, + "assayComponentName": "LTEA_HepaRG_SULT2A1", + "assayComponentDesc": "LTEA_HepaRG_SULT2A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1090, + "assayComponentEndpointName": "LTEA_HepaRG_TGFA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TGFA was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "EGF-like domain", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 686, + "assayComponentName": "LTEA_HepaRG_TGFA", + "assayComponentDesc": "LTEA_HepaRG_TGFA is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 318, + "geneName": "transforming growth factor, alpha", + "description": null, + "geneSymbol": "TGFA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7039, + "officialSymbol": "TGFA", + "officialFullName": "transforming growth factor, alpha", + "uniprotAccessionNumber": "P01135" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1092, + "assayComponentEndpointName": "LTEA_HepaRG_TGFB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TGFB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 687, + "assayComponentName": "LTEA_HepaRG_TGFB1", + "assayComponentDesc": "LTEA_HepaRG_TGFB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1094, + "assayComponentEndpointName": "LTEA_HepaRG_THRSP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_THRSP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_THRSP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is NR mediated metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "NR mediated metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 688, + "assayComponentName": "LTEA_HepaRG_THRSP", + "assayComponentDesc": "LTEA_HepaRG_THRSP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 323, + "geneName": "thyroid hormone responsive", + "description": null, + "geneSymbol": "THRSP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7069, + "officialSymbol": "THRSP", + "officialFullName": "thyroid hormone responsive", + "uniprotAccessionNumber": "Q92748" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1096, + "assayComponentEndpointName": "LTEA_HepaRG_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TIMP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 689, + "assayComponentName": "LTEA_HepaRG_TIMP1", + "assayComponentDesc": "LTEA_HepaRG_TIMP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1098, + "assayComponentEndpointName": "LTEA_HepaRG_TNFRSF1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TNFRSF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TNFRSF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "TNF receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 690, + "assayComponentName": "LTEA_HepaRG_TNFRSF1A", + "assayComponentDesc": "LTEA_HepaRG_TNFRSF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 328, + "geneName": "tumor necrosis factor receptor superfamily, member 1A", + "description": null, + "geneSymbol": "TNFRSF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7132, + "officialSymbol": "TNFRSF1A", + "officialFullName": "tumor necrosis factor receptor superfamily, member 1A", + "uniprotAccessionNumber": "P19438" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1100, + "assayComponentEndpointName": "LTEA_HepaRG_TP53", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_TP53 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TP53, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 691, + "assayComponentName": "LTEA_HepaRG_TP53", + "assayComponentDesc": "LTEA_HepaRG_TP53 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1102, + "assayComponentEndpointName": "LTEA_HepaRG_UGT1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_UGT1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 692, + "assayComponentName": "LTEA_HepaRG_UGT1A1", + "assayComponentDesc": "LTEA_HepaRG_UGT1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1104, + "assayComponentEndpointName": "LTEA_HepaRG_UGT1A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_UGT1A6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 693, + "assayComponentName": "LTEA_HepaRG_UGT1A6", + "assayComponentDesc": "LTEA_HepaRG_UGT1A6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 429, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A6", + "description": null, + "geneSymbol": "UGT1A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54578, + "officialSymbol": "UGT1A6", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A6", + "uniprotAccessionNumber": "P19224" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1106, + "assayComponentEndpointName": "LTEA_HepaRG_XBP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_XBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_XBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 694, + "assayComponentName": "LTEA_HepaRG_XBP1", + "assayComponentDesc": "LTEA_HepaRG_XBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with XBP1 include Major Affective Disorder 7 and Bipolar Disorde.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 337, + "geneName": "X-box binding protein 1", + "description": null, + "geneSymbol": "XBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7494, + "officialSymbol": "XBP1", + "officialFullName": "X-box binding protein 1", + "uniprotAccessionNumber": "P17861" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1108, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 695, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1109, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 696, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1110, + "assayComponentEndpointName": "TOX21_ARE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Beta-Naphthoflavone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 697, + "assayComponentName": "TOX21_ARE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ARE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1111, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 698, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1112, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 699, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1113, + "assayComponentEndpointName": "TOX21_HSE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 700, + "assayComponentName": "TOX21_HSE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity", + "assayComponentTargetDesc": "TOX21_HSE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 161, + "geneName": "heat shock transcription factor 1", + "description": null, + "geneSymbol": "HSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3297, + "officialSymbol": "HSF1", + "officialFullName": "heat shock transcription factor 1", + "uniprotAccessionNumber": "Q00613" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1114, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 701, + "assayComponentName": "TOX21_p53_BLA_p1_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p1_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1115, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 702, + "assayComponentName": "TOX21_p53_BLA_p1_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p1_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1116, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 703, + "assayComponentName": "TOX21_p53_BLA_p1_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p1_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p1_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1117, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 704, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1118, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 705, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1119, + "assayComponentEndpointName": "TOX21_FXR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Chenodeoxycholic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 706, + "assayComponentName": "TOX21_FXR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1120, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 707, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1121, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 708, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1122, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 709, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1123, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 710, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1124, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-165,041", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 711, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1125, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 712, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1126, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 713, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1127, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 714, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1128, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 715, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1129, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 716, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1130, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 717, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1131, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Calcitriol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 718, + "assayComponentName": "TOX21_VDR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Agonist_ratio was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1132, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1alpha,25-Dihydroxy vitamin D3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 719, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1133, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 720, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Antagonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 2007, + "assayComponentEndpointName": "ATG_frER2_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER2_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1903, + "assayComponentName": "ATG_frER2_XSP2", + "assayComponentDesc": "ATG_frER2_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr2.L | GeneID: 100174814| Uniprot_SwissProt_Accession:A0A1L8FA50].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1481, + "geneName": "estrogen receptor 2 L homeolog", + "description": "estrogen receptor 2 L homeolog [ Xenopus laevis (African clawed frog) ]", + "geneSymbol": "esr2.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 100174814, + "officialSymbol": "esr2.L", + "officialFullName": "estrogen receptor 2 L homeolog", + "uniprotAccessionNumber": "A0A1L8FA50" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2009, + "assayComponentEndpointName": "ATG_mPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1904, + "assayComponentName": "ATG_mPPARg_XSP2", + "assayComponentDesc": "ATG_mPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the mouse peroxisome proliferator activated receptor gamma. [GeneSymbol:Pparg | GeneID: 19016| Uniprot_SwissProt_Accession:P37238].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-mPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1478, + "geneName": "peroxisome proliferator activated receptor gamma", + "description": "peroxisome proliferator activated receptor gamma [ Mus musculus(house mouse) ]", + "geneSymbol": "Pparg", + "organismId": 2, + "trackStatus": null, + "entrezGeneId": 19016, + "officialSymbol": "Pparg", + "officialFullName": "peroxisome proliferator activated receptor gamma", + "uniprotAccessionNumber": "P37238" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2011, + "assayComponentEndpointName": "ATG_zfPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1905, + "assayComponentName": "ATG_zfPPARg_XSP2", + "assayComponentDesc": "ATG_zfPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the zebrafish peroxisome proliferator activated receptor gamma. [GeneSymbol: pparg | GeneID: 557037| Uniprot_SwissProt_Accession:A6XMH6].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfPPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1471, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": "peroxisome proliferator-activated receptor gamma [ Danio rerio(zebrafish) ]", + "geneSymbol": "pparg", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 557037, + "officialSymbol": "pparg", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "A6XMH6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2013, + "assayComponentEndpointName": "ATG_hPPARg_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hPPARg_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1906, + "assayComponentName": "ATG_hPPARg_XSP2", + "assayComponentDesc": "ATG_hPPARg_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PPARg, which is responsive to the human peroxisome proliferator activated receptor gamma. [GeneSymbol:PPARG | GeneID: 5468| Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2015, + "assayComponentEndpointName": "ATG_mPXR_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_mPXR_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1907, + "assayComponentName": "ATG_mPXR_XSP2", + "assayComponentDesc": "ATG_mPXR_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element PXR, which is responsive to the mouse pregnane X receptor. [GeneSymbol: NR1IA | GeneID: 8856| Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NA", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2017, + "assayComponentEndpointName": "ATG_trTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1908, + "assayComponentName": "ATG_trTRa_XSP2", + "assayComponentDesc": "ATG_trTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the turtle thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 101949057| Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1466, + "geneName": "thyroid hormone receptor, alpha", + "description": "thyroid hormone receptor, alpha [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "THRA", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101949057, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2019, + "assayComponentEndpointName": "ATG_zfTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1909, + "assayComponentName": "ATG_zfTRa_XSP2", + "assayComponentDesc": "ATG_zfTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, alpha a. [GeneSymbol: thraa | GeneID: 30670| Uniprot_SwissProt_Accession: Q98867].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1472, + "geneName": "thyroid hormone receptor alpha a", + "description": "thyroid hormone receptor alpha a [ Danio rerio (zebrafish) ]", + "geneSymbol": "thraa", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30670, + "officialSymbol": "thraa", + "officialFullName": "thyroid hormone receptor alpha a", + "uniprotAccessionNumber": "Q98867" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2021, + "assayComponentEndpointName": "ATG_zfTRb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfTRb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1910, + "assayComponentName": "ATG_zfTRb_XSP2", + "assayComponentDesc": "ATG_zfTRb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the zebrafish thyroid hormone receptor, beta. [GeneSymbol: thrb | GeneID: 30607| Uniprot_SwissProt_Accession: Q9PVE4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfTRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1473, + "geneName": "thyroid hormone receptor beta", + "description": "thyroid hormone receptor beta [ Danio rerio (zebrafish) ]", + "geneSymbol": "thrb", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 30607, + "officialSymbol": "thrb", + "officialFullName": "thyroid hormone receptor beta", + "uniprotAccessionNumber": "Q9PVE4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2025, + "assayComponentEndpointName": "ATG_frTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1912, + "assayComponentName": "ATG_frTRa_XSP2", + "assayComponentDesc": "ATG_frTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the frog thyroid hormone receptor, alpha L homeolog. [GeneSymbol: thra.L | GeneID: 397942| Uniprot_SwissProt_Accession: P15204].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frTRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1482, + "geneName": "thyroid hormone receptor, alpha L homeolog", + "description": "thyroid hormone receptor, alpha L homeolog [ Xenopus laevis(African clawed frog) ]", + "geneSymbol": "thra.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 397942, + "officialSymbol": "thra.L", + "officialFullName": "thyroid hormone receptor, alpha L homeolog", + "uniprotAccessionNumber": "P15204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2027, + "assayComponentEndpointName": "ATG_hTRa_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRa_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1913, + "assayComponentName": "ATG_hTRa_XSP2", + "assayComponentDesc": "ATG_hTRa_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, alpha. [GeneSymbol: THRA | GeneID: 7067| Uniprot_SwissProt_Accession: P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2029, + "assayComponentEndpointName": "ATG_hTRb_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hTRb_XSP2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1914, + "assayComponentName": "ATG_hTRb_XSP2", + "assayComponentDesc": "ATG_hTRb_XSP2 is one of 29 assay components measured or calculated from the ATG_XSP2_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element TRa, which is responsive to the human thyroid hormone receptor, beta. [GeneSymbol: THRB | GeneID: 7068| Uniprot_SwissProt_Accession: P10828].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 571, + "assayName": "ATG_XSP2_multi-species_TRANS", + "assayDesc": "ATG_XSP2_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp2 included 3 nM 6-alpha-fluorotestosterone and 1.5 nM norgestrel to stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2031, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity_XSP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_XTT_Cytotoxicity_XSP2 was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_XSP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1915, + "assayComponentName": "ATG_XTT_Cytotoxicity_XSP2", + "assayComponentDesc": "ATG_XTT_Cytotoxicity_XSP2 is an assay component measured from the ATG_XSP2_XTT_Cytotoxicity_multi-species assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence Intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 572, + "assayName": "ATG_XSP2_XTT_Cytotoxicity_multi-species", + "assayDesc": "ATG_XSP2_XTT_Cytotoxicity_multi-species is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2037, + "assayComponentEndpointName": "CPHEA_Stoker_NIS_Inhibition_RAIU", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CPHEA_Stoker_NIS_Inhibition_RAIU was analyzed at the endpoint, CPHEA_Stoker_NIS_Inhibition_RAIU, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Measures of radioactive substrate uptake for loss-of-signal activity can be used to understand the effects on transporter function at the pathway level as they relate to the sodium-iodide symporter, gene SLC5A5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium-iodide symporter (NIS).", + "assayFunctionType": "transporter", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NaClO4", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "sodium-iodide symporter (NIS)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1919, + "assayComponentName": "CPHEA_Stoker_NIS_Inhibition_RAIU", + "assayComponentDesc": "CPHEA_Stoker_NIS_Inhibition_RAIU is one of 2 assay components measured from the CPHEA_Stoker_NIS assay. It is designed to make measurements of radioactive substrate uptake to understand transporter function, as detected with 125-i signals by MicroBeta radioactivity plate reader technology.", + "assayComponentTargetDesc": "The sodium iodide symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into the thyroid gland as the initial step of thyroid hormone biosynthesis. Inhibition of iodide uptake through the thyroid NIS can result in decreased thyroid hormone biosynthesis. The radioactive iodide uptake (RAIU) assay can be used to detect thyroid disrupting chemicals that inhibit the human sodium iodide symporter (NIS).", + "parameterReadoutType": "single", + "assayDesignType": "transporter function", + "assayDesignTypeSub": "radioactive substrate uptake", + "biologicalProcessTarget": "regulation of transporter activity", + "detectionTechnologyType": "radiometry", + "detectionTechnologyTypeSub": "radiodetection", + "detectionTechnology": "MicroBeta radioactivity plate reader", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "125-I", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "substrate uptake", + "aid": 574, + "assayName": "CPHEA_Stoker_NIS", + "assayDesc": "CPHEA_Stoker_NIS is a cell-based, single-readout assay that uses hNIS-HEK293T-EPA, a novel human kidney cell line expressing human NIS, with measurements taken at 2 hours after chemical dosing in a 96-well plate. This radioactive iodide uptake (RAIU) assay is used to identify inhibitors of NIS-mediated iodide uptake. A parallel cytoxicity assay (Cell Titer Glo, Promega) was also run in the same cell line.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": null, + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 21, + "assaySourceName": "CPHEA_STOKER", + "assaySourceLongName": "CPHEA Stoker and Laws Labs", + "assaySourceDesc": "The Stoker and Laws laboratories at the EPA Center for Public Health and Environmental Assessment work on the development and implementation of high-throughput assays, particularly related to the sodium-iodide cotransporter (NIS).", + "gene": { + "geneId": 1462, + "geneName": "solute carrier family 5 member 5", + "description": null, + "geneSymbol": "SLC5A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6528, + "officialSymbol": "SLC5A5", + "officialFullName": "solute carrier family 5 member 5", + "uniprotAccessionNumber": "Q92911" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1007/s00204-021-03006-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33656581/", + "pmid": 33656581, + "title": "Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition", + "author": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE", + "citation": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE. Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition. Arch Toxicol. 2021 May;95(5):1723-1737. doi: 10.1007/s00204-021-03006-2. Epub 2021 Mar 3. PMID: 33656581.", + "otherId": "0", + "citationId": 241, + "otherSource": "" + } + }, + { + "aeid": 2038, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1920, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ch1", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ch1 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of TSH", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2039, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1921, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ch2", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ch2 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the acceptor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of TSH", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2040, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TSH", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1922, + "assayComponentName": "TOX21_TSHR_HTRF_Agonist_ratio", + "assayComponentDesc": "TOX21_TSHR_HTRF_Agonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_HTRF_Agonist assay. It is designed to make measurements of TSHR agonism, with cAMP as an indicator of TSHR activation.", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Agonist_ratio was designed to target receptor activation through increased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of TSH.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 575, + "assayName": "TOX21_TSHR_Agonist", + "assayDesc": "Tox21_TSHR_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2041, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1923, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ch1", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ch1 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1854, + "assayComponentEndpointName": "TOX21_MMP_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_MMP_ratio was analyzed into 1 assay endpoint. The assay endpoin, TOX21_MMP_ratio, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 534, + "assayComponentName": "TOX21_MMP_ratio", + "assayComponentDesc": "TOX21_MMP_ratio is one of 2 assay component(s) measured or calculated from the TOX21_MMP assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by homogenous mitochondrial membrane potential assay technology.", + "assayComponentTargetDesc": "Mito-MPS is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "multiple", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 2042, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTFR_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTFR_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1924, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ch2", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ch2 is an assay readout measuring endogenous cAMP generated by receptor activity and detected with specific antibody. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2043, + "assayComponentEndpointName": "TOX21_TSHR_HTRF_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "no TSH stimulation", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1925, + "assayComponentName": "TOX21_TSHR_HTRF_Antagonist_ratio", + "assayComponentDesc": "TOX21_TSHR_HTRF_Antagonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_Antagonist assay. It is designed to make measurements of TSHR antagonism, with cAMP as an indicator of TSHR activation.", + "assayComponentTargetDesc": "TOX21_TSHR_HTRF_Antagonist_ratio was designed to target receptor inhibition through decreased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 576, + "assayName": "TOX21_TSHR_Antagonist", + "assayDesc": "Tox21_TSHR_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2044, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss of signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1926, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ch1", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ch1 is an assay readout measuring endogenous cAMP and detected with specific antibody. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_ch1 was designed to measure labeled anti-cAMP antibody donor emission to target receptor activity at the protein (receptor) level, specifically mapping to TSRH gene(s) using a positive control of forskolin", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2045, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1927, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ch2", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ch2 is an assay readout measuring endogenous cAMP and detected with specific antibody. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_Agonist_ch2 was designed to measure labeled cAMP acceptor emission to target receptor activation, specifically mapping to TSHR gene(s) using a positive control of forskolin", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2046, + "assayComponentEndpointName": "TOX21_TSHR_wt_Agonist_HTRF_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TSHR_HTRF_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1928, + "assayComponentName": "TOX21_TSHR_wt_Agonist_HTRF_ratio", + "assayComponentDesc": "TOX21_TSHR_wt_Agonist_HTRF_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_wt assay. It is designed to indicate background cAMP activity.", + "assayComponentTargetDesc": "TOX21_TSHR_wt_HTRF_ratio was designed to target background cAMP generation in cells lacking TSHR", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "cAMP measurement", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "d2-labeled cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 577, + "assayName": "TOX21_TSHR_wt", + "assayDesc": "Tox21_TSHR_wt is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1460, + "geneName": "thyroid stimulating hormone receptor", + "description": "thyroid stimulating hormone receptor", + "geneSymbol": "TSHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7253, + "officialSymbol": "TSHR", + "officialFullName": "thyroid stimulating hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2047, + "assayComponentEndpointName": "TOX21_CAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CITCO", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "xenobiotic", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1929, + "assayComponentName": "TOX21_CAR_Agonist", + "assayComponentDesc": "TOX21_CAR_Agonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_CAR_Agonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 578, + "assayName": "TOX21_CAR_Agonist", + "assayDesc": "TOX21_CAR_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2048, + "assayComponentEndpointName": "TOX21_CAR_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1930, + "assayComponentName": "TOX21_CAR_Agonist_viability", + "assayComponentDesc": "TOX21_CAR_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 578, + "assayName": "TOX21_CAR_Agonist", + "assayDesc": "TOX21_CAR_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2049, + "assayComponentEndpointName": "TOX21_CAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "xenobiotic", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1931, + "assayComponentName": "TOX21_CAR_Antagonist", + "assayComponentDesc": "TOX21_CAR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_CAR_Antagonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3] stimulated with CITCO", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 579, + "assayName": "TOX21_CAR_Antagonist", + "assayDesc": "TOX21_CAR_Antagonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2050, + "assayComponentEndpointName": "TOX21_CAR_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1932, + "assayComponentName": "TOX21_CAR_Antagonist_viability", + "assayComponentDesc": "TOX21_CAR_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 579, + "assayName": "TOX21_CAR_Antagonist", + "assayDesc": "TOX21_CAR_Antagonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfy242", + "url": "https://pubmed.ncbi.nlm.nih.gov/30247703/", + "pmid": 30247703, + "title": "Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library", + "author": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M", + "citation": "Lynch C, Mackowiak B, Huang R, Li L, Heyward S, Sakamuru S, Wang H, Xia M. Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242. PMID: 30247703; PMCID: PMC6657574.", + "otherId": "0", + "citationId": 272, + "otherSource": "" + } + }, + { + "aeid": 2053, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1935, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 580, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 48 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2054, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1936, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 580, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 48 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2055, + "assayComponentEndpointName": "TOX21_ERR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Genistein", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1937, + "assayComponentName": "TOX21_ERR_Agonist", + "assayComponentDesc": "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2057, + "assayComponentEndpointName": "TOX21_ERR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "XCT790", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1939, + "assayComponentName": "TOX21_ERR_Antagonist", + "assayComponentDesc": "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2059, + "assayComponentEndpointName": "TOX21_ERR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1941, + "assayComponentName": "TOX21_ERR_viability", + "assayComponentDesc": "TOX21_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 581, + "assayName": "TOX21_ERR", + "assayDesc": "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ERR-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2060, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1942, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_viability", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2061, + "assayComponentEndpointName": "TOX21_HDAC_Inhibition", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Trichostatin A", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1943, + "assayComponentName": "TOX21_HDAC_Inhibition", + "assayComponentDesc": "TOX21_HDAC_Inhibition is one of one assay component(s) measured or calculated from the TOX21_HDAC_Inhibition assay. It is designed to make measurements of HDAC activity as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_HDAC_Inhibition was designed to target enzymatic activity specifically mapping to HDAC1 gene(s) using a positive control of Trichostatin A", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 582, + "assayName": "TOX21_HDAC_Inhibition", + "assayDesc": "TOX21_HDAC_Inhibition is a cell-based, single-readout assay that uses HCT-116, a human colon cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "colon", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 1459, + "geneName": "histone deacetylase 1", + "description": "histone deacetylase 1", + "geneSymbol": "HDAC1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 3065, + "officialSymbol": "HDAC1", + "officialFullName": "histone deacetylase 1", + "uniprotAccessionNumber": "Q13547" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057116629381", + "url": "https://pubmed.ncbi.nlm.nih.gov/26858181/", + "pmid": 26858181, + "title": "Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay", + "author": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M", + "citation": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen. 2016 Jul;21(6):643-52. doi: 10.1177/1087057116629381. Epub 2016 Feb 8. PMID: 26858181; PMCID: PMC4917448.", + "otherId": "0", + "citationId": 273, + "otherSource": "" + } + }, + { + "aeid": 2062, + "assayComponentEndpointName": "TOX21_HDAC_Inhibition_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1944, + "assayComponentName": "TOX21_HDAC_Inhibition_viability", + "assayComponentDesc": "TOX21_HDAC_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 582, + "assayName": "TOX21_HDAC_Inhibition", + "assayDesc": "TOX21_HDAC_Inhibition is a cell-based, single-readout assay that uses HCT-116, a human colon cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "colon", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1177/1087057116629381", + "url": "https://pubmed.ncbi.nlm.nih.gov/26858181/", + "pmid": 26858181, + "title": "Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay", + "author": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M", + "citation": "Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen. 2016 Jul;21(6):643-52. doi: 10.1177/1087057116629381. Epub 2016 Feb 8. PMID: 26858181; PMCID: PMC4917448.", + "otherId": "0", + "citationId": 273, + "otherSource": "" + } + }, + { + "aeid": 2063, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1945, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2064, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1946, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2065, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cobalt(II)chloride hexahydrate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "hypoxia-response element", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1947, + "assayComponentName": "TOX21_HRE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_HRE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2066, + "assayComponentEndpointName": "TOX21_HRE_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1948, + "assayComponentName": "TOX21_HRE_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_HRE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 583, + "assayName": "TOX21_HRE_BLA_Agonist", + "assayDesc": "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2067, + "assayComponentEndpointName": "TOX21_LUC_Biochem", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_LUC_Biochem used a type of viability reporter where loss-of-signal activity can be used to understand inhibition of luciferase enzymatic activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the enzyme intended target family, where the subfamily is luciferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PTC124", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "enzyme", + "intendedTargetFamilySub": "luciferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1949, + "assayComponentName": "TOX21_LUC_Biochem", + "assayComponentDesc": "TOX21_LUC_Biochem is an assay readout measuring inhibition of luciferase enzymatic activity and designed using Km levels of luciferin and ATP. ", + "assayComponentTargetDesc": "TOX21_LUC_Biochem was designed to target enzymatic activity, specifically mapping to Firefly luciferase gene(s) using a positive control of PTC-124", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "artifact detection", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 584, + "assayName": "TOX21_LUC_Biochem", + "assayDesc": "TOX21_LUC_Biochem is a cell-free, single-readout assay that uses purified luciferase enzyme. Measurements were taken 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 7054, + "organism": "firefly", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "firefly luciferase (Fluc)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2068, + "assayComponentEndpointName": "TOX21_PGC_ERR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Genistein", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1950, + "assayComponentName": "TOX21_PGC_ERR_Agonist", + "assayComponentDesc": "TOX21_PGC_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101| in the presence of PGC1a expression", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2070, + "assayComponentEndpointName": "TOX21_PGC_ERR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "XCT790", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1952, + "assayComponentName": "TOX21_PGC_ERR_Antagonist", + "assayComponentDesc": "TOX21_PGC_ERR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|in the presence of PGC1a expression", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2072, + "assayComponentEndpointName": "TOX21_PGC_ERR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1954, + "assayComponentName": "TOX21_PGC_ERR_viability", + "assayComponentDesc": "TOX21_PGC_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 585, + "assayName": "TOX21_PGC_ERR", + "assayDesc": "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PGC/ERR HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2074, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1956, + "assayComponentName": "TOX21_RT_HEK293_FLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 0 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_00hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2075, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1957, + "assayComponentName": "TOX21_RT_HEK293_FLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2077, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1959, + "assayComponentName": "TOX21_RT_HEK293_FLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2078, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1960, + "assayComponentName": "TOX21_RT_HEK293_FLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2080, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1962, + "assayComponentName": "TOX21_RT_HEK293_FLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2082, + "assayComponentEndpointName": "TOX21_RT_HEK293_FLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1964, + "assayComponentName": "TOX21_RT_HEK293_FLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_FLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HEK293_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2084, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1966, + "assayComponentName": "TOX21_RT_HEK293_GLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_00hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2086, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1968, + "assayComponentName": "TOX21_RT_HEK293_GLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2088, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1970, + "assayComponentName": "TOX21_RT_HEK293_GLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2089, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1971, + "assayComponentName": "TOX21_RT_HEK293_GLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2091, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1973, + "assayComponentName": "TOX21_RT_HEK293_GLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2093, + "assayComponentEndpointName": "TOX21_RT_HEK293_GLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1975, + "assayComponentName": "TOX21_RT_HEK293_GLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEK293_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEK293_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 586, + "assayName": "TOX21_RT_HEK293", + "assayDesc": "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2094, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1976, + "assayComponentName": "TOX21_RT_HEPG2_FLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_00hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 0 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_00hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2095, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1977, + "assayComponentName": "TOX21_RT_HEPG2_FLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_08hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2096, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1978, + "assayComponentName": "TOX21_RT_HEPG2_FLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_16hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2097, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1979, + "assayComponentName": "TOX21_RT_HEPG2_FLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_24hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2098, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1980, + "assayComponentName": "TOX21_RT_HEPG2_FLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_32hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2099, + "assayComponentEndpointName": "TOX21_RT_HEPG2_FLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1981, + "assayComponentName": "TOX21_RT_HEPG2_FLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HepG2_FLO_40hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", + "assayComponentTargetDesc": "TOX21_RT_HepG2_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased viable cells present in the culture", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dead cells", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence emission", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2100, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_00hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1982, + "assayComponentName": "TOX21_RT_HEPG2_GLO_00hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_00hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_00hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2101, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_08hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1983, + "assayComponentName": "TOX21_RT_HEPG2_GLO_08hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2102, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_16hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1984, + "assayComponentName": "TOX21_RT_HEPG2_GLO_16hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2103, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_32hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1985, + "assayComponentName": "TOX21_RT_HEPG2_GLO_32hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2105, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_40hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1987, + "assayComponentName": "TOX21_RT_HEPG2_GLO_40hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2106, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SHH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1988, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Agonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_SHH_3T3_GLI3_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by Gli3, part of the sonic hedgehog (Shh) pathway", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 588, + "assayName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Agonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 6390, + "geneName": "sonic hedgehog", + "description": null, + "geneSymbol": "SHH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6469, + "officialSymbol": "SHH", + "officialFullName": "sonic hedgehog", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2107, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1989, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Agonist_viability", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 588, + "assayName": "TOX21_SHH_3T3_GLI3_Agonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Agonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2108, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyclopamine", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1990, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_SHH_3T3_GLI3_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonism of Gli3 activation using conditioned medium, part of the sonic hedgehog (Shh) pathway", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 589, + "assayName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Antagonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 6390, + "geneName": "sonic hedgehog", + "description": null, + "geneSymbol": "SHH", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6469, + "officialSymbol": "SHH", + "officialFullName": "sonic hedgehog", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2109, + "assayComponentEndpointName": "TOX21_SHH_3T3_GLI3_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1991, + "assayComponentName": "TOX21_SHH_3T3_GLI3_Antagonist_viability", + "assayComponentDesc": "TOX21_SHH_3T3_GLI3_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 589, + "assayName": "TOX21_SHH_3T3_GLI3_Antagonist", + "assayDesc": "TOX21_SHH_3T3_GLI3_Antagonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", + "timepointHr": 24.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "NIH/3T3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2110, + "assayComponentEndpointName": "CPHEA_Stoker_NIS_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CPHEA_Stoker_NIS_Cytotoxicity was analyzed at the endpoint, CPHEA_Stoker_NIS_Cytotoxicity, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "b-naphthoquinone", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1992, + "assayComponentName": "CPHEA_Stoker_NIS_Cytotoxicity", + "assayComponentDesc": "CPHEA_Stoker_NIS_Cytotoxicity is one of 2 assay components measured from the CPHEA_Stoker_NIS assay. It is designed to make measurements of atp content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo Fluor] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Luciferase", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 574, + "assayName": "CPHEA_Stoker_NIS", + "assayDesc": "CPHEA_Stoker_NIS is a cell-based, single-readout assay that uses hNIS-HEK293T-EPA, a novel human kidney cell line expressing human NIS, with measurements taken at 2 hours after chemical dosing in a 96-well plate. This radioactive iodide uptake (RAIU) assay is used to identify inhibitors of NIS-mediated iodide uptake. A parallel cytoxicity assay (Cell Titer Glo, Promega) was also run in the same cell line.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": null, + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 21, + "assaySourceName": "CPHEA_STOKER", + "assaySourceLongName": "CPHEA Stoker and Laws Labs", + "assaySourceDesc": "The Stoker and Laws laboratories at the EPA Center for Public Health and Environmental Assessment work on the development and implementation of high-throughput assays, particularly related to the sodium-iodide cotransporter (NIS).", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1007/s00204-021-03006-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33656581/", + "pmid": 33656581, + "title": "Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition", + "author": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE", + "citation": "Wang J, Richard AM, Murr AS, Buckalew AR, Lougee RR, Shobair M, Hallinger DR, Laws SC, Stoker TE. Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition. Arch Toxicol. 2021 May;95(5):1723-1737. doi: 10.1007/s00204-021-03006-2. Epub 2021 Mar 3. PMID: 33656581.", + "otherId": "0", + "citationId": 241, + "otherSource": "" + } + }, + { + "aeid": 2113, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1999, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2114, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2000, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1134, + "assayComponentEndpointName": "TOX21_DT40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 721, + "assayComponentName": "TOX21_DT40", + "assayComponentDesc": "TOX21_DT40 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level in isogenic wildtype cells using a positive control of tetraoctylammonium bromide. Results from the wild-type cells can be compared to TOX21_DT40_100 (aeid 2130) and TOX21_DT40_657 (aeid 2131) isogenic cell line assays which contain DNA repair enzyme deletions to detect DNA-damaging agents", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1136, + "assayComponentEndpointName": "LTEA_HepaRG_LDH_cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_LDH_cytotoxicity was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LDH_cytotoxicity, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for loss-of-signal activity can be used to understand cell death. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 722, + "assayComponentName": "LTEA_HepaRG_LDH_cytotoxicity", + "assayComponentDesc": "LTEA_HepaRG_LDH_cytotoxicity is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of cell viability / cytotoxicity.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": null, + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1185, + "assayComponentEndpointName": "TOX21_ARE_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 747, + "assayComponentName": "TOX21_ARE_BLA_agonist_viability", + "assayComponentDesc": "TOX21_ARE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 372, + "assayName": "TOX21_ARE_BLA_Agonist", + "assayDesc": "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": " doi: 10.1289/EHP2589", + "url": "https://pubmed.ncbi.nlm.nih.gov/30059008/", + "pmid": 30059008, + "title": "Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies", + "author": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A", + "citation": "Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A. Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies. Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. PMID: 30059008; PMCID: PMC6112376.", + "otherId": "0", + "citationId": 275, + "otherSource": "" + } + }, + { + "aeid": 1186, + "assayComponentEndpointName": "TOX21_HSE_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 748, + "assayComponentName": "TOX21_HSE_BLA_agonist_viability", + "assayComponentDesc": "TOX21_HSE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 373, + "assayName": "TOX21_HSE_BLA_Agonist", + "assayDesc": "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1187, + "assayComponentEndpointName": "TOX21_p53_BLA_p1_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 749, + "assayComponentName": "TOX21_p53_BLA_p1_viability", + "assayComponentDesc": "TOX21_p53_BLA_p1_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 374, + "assayName": "TOX21_p53_BLA_p1", + "assayDesc": "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1188, + "assayComponentEndpointName": "TOX21_FXR_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 750, + "assayComponentName": "TOX21_FXR_BLA_agonist_viability", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 375, + "assayName": "TOX21_FXR_BLA_Agonist", + "assayDesc": "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1189, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 751, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1190, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 752, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1191, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 753, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_FXR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1192, + "assayComponentEndpointName": "TOX21_FXR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 754, + "assayComponentName": "TOX21_FXR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_FXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_FXR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 376, + "assayName": "TOX21_FXR_BLA_Antagonist", + "assayDesc": "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1193, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifepristone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 755, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1194, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifepristone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 756, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1195, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 757, + "assayComponentName": "TOX21_PPARd_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_PPARd_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 377, + "assayName": "TOX21_PPARd_BLA_Agonist", + "assayDesc": "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1196, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 758, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1197, + "assayComponentEndpointName": "TOX21_PPARd_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARd_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MK886", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 759, + "assayComponentName": "TOX21_PPARd_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PPARd_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARD_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 378, + "assayName": "TOX21_PPARd_BLA_Antagonist", + "assayDesc": "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1198, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 760, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1199, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW9662", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 761, + "assayComponentName": "TOX21_PPARg_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PPARg_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 379, + "assayName": "TOX21_PPARg_BLA_Antagonist", + "assayDesc": "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1200, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 762, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1201, + "assayComponentEndpointName": "TOX21_VDR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_VDR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1alpha,25-Dihydroxy vitamin D3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 763, + "assayComponentName": "TOX21_VDR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_VDR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_VDR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 381, + "assayName": "TOX21_VDR_BLA_Antagonist", + "assayDesc": "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1202, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 764, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 2115, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2001, + "assayComponentName": "TOX21_ERb_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Agonist_ch2 was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2116, + "assayComponentEndpointName": "TOX21_ERb_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2002, + "assayComponentName": "TOX21_ERb_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_ERb_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 593, + "assayName": "TOX21_ERb_BLA_Agonist", + "assayDesc": "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2117, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1995, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2118, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1996, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2119, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1997, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERb_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2120, + "assayComponentEndpointName": "TOX21_ERb_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1998, + "assayComponentName": "TOX21_ERb_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_ERb_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 592, + "assayName": "TOX21_ERb_BLA_Antagonist", + "assayDesc": "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2121, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2003, + "assayComponentName": "TOX21_PR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2122, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2004, + "assayComponentName": "TOX21_PR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2123, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2005, + "assayComponentName": "TOX21_PR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2124, + "assayComponentEndpointName": "TOX21_PR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2006, + "assayComponentName": "TOX21_PR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Agonist_viability is a component of the TOX21_PR_BLA_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 594, + "assayName": "TOX21_PR_BLA_Agonist", + "assayDesc": "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2125, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2007, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2126, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2008, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2127, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2009, + "assayComponentName": "TOX21_PR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2128, + "assayComponentEndpointName": "TOX21_PR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2010, + "assayComponentName": "TOX21_PR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Antagonist_viability is a component of the TOX21_PR_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 595, + "assayName": "TOX21_PR_BLA_Antagonist", + "assayDesc": "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2130, + "assayComponentEndpointName": "TOX21_DT40_100", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2012, + "assayComponentName": "TOX21_DT40_100", + "assayComponentDesc": "TOX21_DT40_100 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40_100 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Ku70 and Rad54 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_100 cells have Ku70 and Rad54 gene deletions (-/-) which are involved in reparing chromosomal breaks. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Rev3(-/-) (DT40_657; aeid 2131) to evaluate potential DNA-damaging agents", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "regulation of DNA repair", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7782, + "geneName": "RAD54 like (S. cerevisiae)", + "description": null, + "geneSymbol": "RAD54L", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 8438, + "officialSymbol": "RAD54L", + "officialFullName": "RAD54 like (S. cerevisiae)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2131, + "assayComponentEndpointName": "TOX21_DT40_657", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tetraoctyl ammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "DNA repair", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2013, + "assayComponentName": "TOX21_DT40_657", + "assayComponentDesc": "TOX21_DT40_657 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", + "assayComponentTargetDesc": "TOX21_DT40_657 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Rev3 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_657 cells have Rev3 gene deletions (-/-) which is involved in DNA repair. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Ku70/Rad54 (DT40_100; aeid 2130) to evaluate potential DNA-damaging agents. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "regulation of DNA repair", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 382, + "assayName": "TOX21_DT40", + "assayDesc": "TOX21_DT40 is a cell-based, single-readout assay that uses DT40, a chicken lymphoblast cell line, with measurements taken at 40 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 40.0, + "organismId": 9031, + "organism": "chicken", + "tissue": "lymphoblast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "DT40", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 5996, + "geneName": "REV3 like, DNA directed polymerase zeta catalytic subunit", + "description": null, + "geneSymbol": "REV3L", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5980, + "officialSymbol": "REV3L", + "officialFullName": "REV3 like, DNA directed polymerase zeta catalytic subunit", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2143, + "assayComponentEndpointName": "CEETOX_H295R_11DCORT_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_11DCORT_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_11DCORT_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2023, + "assayComponentName": "CEETOX_H295R_11DCORT_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2145, + "assayComponentEndpointName": "CEETOX_H295R_OHPREG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPREG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPREG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxypregnenolone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2024, + "assayComponentName": "CEETOX_H295R_OHPREG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxypregnenolone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2147, + "assayComponentEndpointName": "CEETOX_H295R_OHPROG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPROG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPROG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxyprogesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2025, + "assayComponentName": "CEETOX_H295R_OHPROG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxyprogesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2149, + "assayComponentEndpointName": "CEETOX_H295R_ANDR_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ANDR_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ANDR_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Androstenedione", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2026, + "assayComponentName": "CEETOX_H295R_ANDR_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Androstenedione", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 1203, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 765, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 1204, + "assayComponentEndpointName": "ATG_XTT_Cytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 766, + "assayComponentName": "ATG_XTT_Cytotoxicity", + "assayComponentDesc": "ATG_XTT_Cytotoxicity is one of one assay component(s) measured or calculated from the ATG_XTT_Cytotoxicity assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "XTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "XTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 386, + "assayName": "ATG_XTT_Cytotoxicity", + "assayDesc": "ATG_XTT_Cytotoxicity is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1315, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 890, + "assayComponentName": "TOX21_p53_BLA_p2_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p2_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1316, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 891, + "assayComponentName": "TOX21_p53_BLA_p2_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p2_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1317, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 892, + "assayComponentName": "TOX21_p53_BLA_p2_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p2_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p2_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1318, + "assayComponentEndpointName": "TOX21_p53_BLA_p2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 893, + "assayComponentName": "TOX21_p53_BLA_p2_viability", + "assayComponentDesc": "TOX21_p53_BLA_p2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 402, + "assayName": "TOX21_p53_BLA_p2", + "assayDesc": "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1319, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 894, + "assayComponentName": "TOX21_p53_BLA_p3_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p3_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1320, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 895, + "assayComponentName": "TOX21_p53_BLA_p3_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p3_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1321, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 896, + "assayComponentName": "TOX21_p53_BLA_p3_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p3_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p3_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1322, + "assayComponentEndpointName": "TOX21_p53_BLA_p3_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 897, + "assayComponentName": "TOX21_p53_BLA_p3_viability", + "assayComponentDesc": "TOX21_p53_BLA_p3_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 403, + "assayName": "TOX21_p53_BLA_p3", + "assayDesc": "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1323, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 898, + "assayComponentName": "TOX21_p53_BLA_p4_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p4_ch1 is an assay readout measuring reporter gene via transcripton factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1324, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 899, + "assayComponentName": "TOX21_p53_BLA_p4_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p4_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1325, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 900, + "assayComponentName": "TOX21_p53_BLA_p4_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p4_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1)reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p4_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1326, + "assayComponentEndpointName": "TOX21_p53_BLA_p4_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 901, + "assayComponentName": "TOX21_p53_BLA_p4_viability", + "assayComponentDesc": "TOX21_p53_BLA_p4_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 404, + "assayName": "TOX21_p53_BLA_p4", + "assayDesc": "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1327, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 902, + "assayComponentName": "TOX21_p53_BLA_p5_ch1", + "assayComponentDesc": "TOX21_p53_BLA_p5_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ch1 was designed measure uncleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1328, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 903, + "assayComponentName": "TOX21_p53_BLA_p5_ch2", + "assayComponentDesc": "TOX21_p53_BLA_p5_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ch2 was designed measure cleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1329, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mitomycin C;Nutlin3", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 904, + "assayComponentName": "TOX21_p53_BLA_p5_ratio", + "assayComponentDesc": "TOX21_p53_BLA_p5_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_p53_BLA_p5_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1330, + "assayComponentEndpointName": "TOX21_p53_BLA_p5_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 905, + "assayComponentName": "TOX21_p53_BLA_p5_viability", + "assayComponentDesc": "TOX21_p53_BLA_p5_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 405, + "assayName": "TOX21_p53_BLA_p5", + "assayDesc": "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HCT116", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1002/em.21934", + "url": "https://pubmed.ncbi.nlm.nih.gov/25537651/", + "pmid": 25537651, + "title": "An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity", + "author": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA", + "citation": "Kligerman AD, Young RR, Stankowski LF Jr, Pant K, Lawlor T, Aardema MJ, Houck KA. An evaluation of 25 selected ToxCast chemicals in medium-throughput assays to detect genotoxicity. Environ Mol Mutagen. 2015 Jun;56(5):468-76. doi: 10.1002/em.21934. Epub 2014 Dec 23. PMID: 25537651.", + "otherId": "0", + "citationId": 259, + "otherSource": "" + } + }, + { + "aeid": 1331, + "assayComponentEndpointName": "TOX21_VDR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 906, + "assayComponentName": "TOX21_VDR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_VDR_BLA_Agonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Agonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 380, + "assayName": "TOX21_VDR_BLA_Agonist", + "assayDesc": "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1038/s41598-018-27055-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/29891985/", + "pmid": 29891985, + "title": "Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays", + "author": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW", + "citation": "Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Sci Rep. 2018 Jun 11;8(1):8883. doi: 10.1038/s41598-018-27055-3. PMID: 29891985; PMCID: PMC5995905.", + "otherId": "0", + "citationId": 270, + "otherSource": "" + } + }, + { + "aeid": 1340, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 907, + "assayComponentName": "TOX21_ESRE_BLA_ch1", + "assayComponentDesc": "TOX21_ESRE_BLA_ch1 is an assay readout measuring transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1341, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 908, + "assayComponentName": "TOX21_ESRE_BLA_ch2", + "assayComponentDesc": "TOX21_ESRE_BLA_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1342, + "assayComponentEndpointName": "TOX21_ESRE_BLA_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17-AAG", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 909, + "assayComponentName": "TOX21_ESRE_BLA_ratio", + "assayComponentDesc": "TOX21_ESRE_BLA_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ESRE_BLA_ratio was designed to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 373, + "geneName": "activating transcription factor 6", + "description": null, + "geneSymbol": "ATF6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 22926, + "officialSymbol": "ATF6", + "officialFullName": "activating transcription factor 6", + "uniprotAccessionNumber": "P18850" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1343, + "assayComponentEndpointName": "TOX21_ESRE_BLA_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 910, + "assayComponentName": "TOX21_ESRE_BLA_viability", + "assayComponentDesc": "TOX21_ESRE_BLA_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 406, + "assayName": "TOX21_ESRE_BLA", + "assayDesc": "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1344, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 911, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ch1", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1345, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 912, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ch2", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ch2 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1346, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TNFa", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 913, + "assayComponentName": "TOX21_NFkB_BLA_agonist_ratio", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_NFkB_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1347, + "assayComponentEndpointName": "TOX21_NFkB_BLA_agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 914, + "assayComponentName": "TOX21_NFkB_BLA_agonist_viability", + "assayComponentDesc": "TOX21_NFkB_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 407, + "assayName": "TOX21_NFkB_BLA_Agonist", + "assayDesc": "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1348, + "assayComponentEndpointName": "ATG_NUR77_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint, ATG_NUR77_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 915, + "assayComponentName": "ATG_NUR77_TRANS2", + "assayComponentDesc": "ATG_NUR77_TRANS2 is one of 24 assay components measured from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-NURR77 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 155, + "geneName": "nuclear receptor subfamily 4, group A, member 1", + "description": null, + "geneSymbol": "NR4A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3164, + "officialSymbol": "NR4A1", + "officialFullName": "nuclear receptor subfamily 4, group A, member 1", + "uniprotAccessionNumber": "P22736" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1349, + "assayComponentEndpointName": "ATG_GCNF_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GCNF_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR6A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 916, + "assayComponentName": "ATG_GCNF_TRANS2", + "assayComponentDesc": "ATG_GCNF_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-GCNF RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 140, + "geneName": "nuclear receptor subfamily 6, group A, member 1", + "description": null, + "geneSymbol": "NR6A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2649, + "officialSymbol": "NR6A1", + "officialFullName": "nuclear receptor subfamily 6, group A, member 1", + "uniprotAccessionNumber": "Q15406" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1350, + "assayComponentEndpointName": "ATG_COUP_TF2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_COUP_TF2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 917, + "assayComponentName": "ATG_COUP_TF2_TRANS2", + "assayComponentDesc": "ATG_COUP_TF2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TF2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 317, + "geneName": "nuclear receptor subfamily 2, group F, member 2", + "description": null, + "geneSymbol": "NR2F2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7026, + "officialSymbol": "NR2F2", + "officialFullName": "nuclear receptor subfamily 2, group F, member 2", + "uniprotAccessionNumber": "P24468" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1351, + "assayComponentEndpointName": "ATG_PNR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_PNR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 918, + "assayComponentName": "ATG_PNR_TRANS2", + "assayComponentDesc": "ATG_PNR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PNR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 360, + "geneName": "nuclear receptor subfamily 2, group E, member 3", + "description": null, + "geneSymbol": "NR2E3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10002, + "officialSymbol": "NR2E3", + "officialFullName": "nuclear receptor subfamily 2, group E, member 3", + "uniprotAccessionNumber": "Q9Y5X4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1352, + "assayComponentEndpointName": "ATG_LRH1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_LRH1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 919, + "assayComponentName": "ATG_LRH1_TRANS2", + "assayComponentDesc": "ATG_LRH1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-LRH1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 135, + "geneName": "nuclear receptor subfamily 5, group A, member 2", + "description": null, + "geneSymbol": "NR5A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2494, + "officialSymbol": "NR5A2", + "officialFullName": "nuclear receptor subfamily 5, group A, member 2", + "uniprotAccessionNumber": "O00482" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1353, + "assayComponentEndpointName": "ATG_Rev_ERB_A_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_Rev_ERB_A_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 920, + "assayComponentName": "ATG_Rev_ERB_A_TRANS2", + "assayComponentDesc": "ATG_Rev_ERB_A_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-erb-a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 355, + "geneName": "nuclear receptor subfamily 1, group D, member 1", + "description": null, + "geneSymbol": "NR1D1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9572, + "officialSymbol": "NR1D1", + "officialFullName": "nuclear receptor subfamily 1, group D, member 1", + "uniprotAccessionNumber": "P20393" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1354, + "assayComponentEndpointName": "ATG_HNF4g_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_HNF4g_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4G. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 921, + "assayComponentName": "ATG_HNF4g_TRANS2", + "assayComponentDesc": "ATG_HNF4g_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-HNF4-g RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 158, + "geneName": "hepatocyte nuclear factor 4, gamma", + "description": null, + "geneSymbol": "HNF4G", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3174, + "officialSymbol": "HNF4G", + "officialFullName": "hepatocyte nuclear factor 4, gamma", + "uniprotAccessionNumber": "Q14541" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1355, + "assayComponentEndpointName": "ATG_ERRb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_ERRb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 922, + "assayComponentName": "ATG_ERRb_TRANS2", + "assayComponentDesc": "ATG_ERRb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 120, + "geneName": "estrogen-related receptor beta", + "description": null, + "geneSymbol": "ESRRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2103, + "officialSymbol": "ESRRB", + "officialFullName": "estrogen-related receptor beta", + "uniprotAccessionNumber": "O95718" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1356, + "assayComponentEndpointName": "ATG_MR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_MR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 923, + "assayComponentName": "ATG_MR_TRANS2", + "assayComponentDesc": "ATG_MR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-MR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 202, + "geneName": "nuclear receptor subfamily 3, group C, member 2", + "description": null, + "geneSymbol": "NR3C2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4306, + "officialSymbol": "NR3C2", + "officialFullName": "nuclear receptor subfamily 3, group C, member 2", + "uniprotAccessionNumber": "P08235" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2151, + "assayComponentEndpointName": "CEETOX_H295R_CORTIC_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTIC_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTIC_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Corticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2027, + "assayComponentName": "CEETOX_H295R_CORTIC_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Corticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2153, + "assayComponentEndpointName": "CEETOX_H295R_CORTISOL_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTISOL_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTISOL_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Cortisol ", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2028, + "assayComponentName": "CEETOX_H295R_CORTISOL_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Cortisol ", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2157, + "assayComponentEndpointName": "CEETOX_H295R_DOC_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_DOC_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_DOC_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycorticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2030, + "assayComponentName": "CEETOX_H295R_DOC_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycorticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2159, + "assayComponentEndpointName": "CEETOX_H295R_ESTRADIOL_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRADIOL_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRADIOL_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2031, + "assayComponentName": "CEETOX_H295R_ESTRADIOL_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estradiol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2161, + "assayComponentEndpointName": "CEETOX_H295R_ESTRONE_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRONE_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRONE_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estrone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2032, + "assayComponentName": "CEETOX_H295R_ESTRONE_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estrone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2165, + "assayComponentEndpointName": "CEETOX_H295R_PROG_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_PROG_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_PROG_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Progesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2034, + "assayComponentName": "CEETOX_H295R_PROG_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Progesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2167, + "assayComponentEndpointName": "CEETOX_H295R_TESTO_noMTC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_TESTO_noMTC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_TESTO_noMTC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "prochloraz; forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2035, + "assayComponentName": "CEETOX_H295R_TESTO_noMTC", + "assayComponentDesc": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC).", + "assayComponentTargetDesc": "steroid hormone biosynthesis", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "HPLC-MS-MS", + "detectionTechnologyTypeSub": "HPLC-MS-MS", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "pre-stimulation", + "keyAssayReagent": "forskolin", + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Testosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 2211, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2073, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an ER antagonist. Changes are indicative of transcriptional gene expression that may not be due to direct regulation by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "artifact detection", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 640, + "assayName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Agonist.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2212, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2074, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 640, + "assayName": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Agonist.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 2213, + "assayComponentEndpointName": "TOX21_RT_HEPG2_GLO_24hr_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability. The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2075, + "assayComponentName": "TOX21_RT_HEPG2_GLO_24hr_viability", + "assayComponentDesc": "TOX21_RT_HEPG2_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", + "assayComponentTargetDesc": "TOX21_RT_HEPG2_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "metabolic activity", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "RealTime-Glo MT Cell Viability Assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "NanoLuc/profurimazine", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 587, + "assayName": "TOX21_RT_HEPG2", + "assayDesc": "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2214, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2275, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2215, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2276, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ch1", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2216, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2277, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2217, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2278, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ch2", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2218, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2279, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2219, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2280, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_ratio", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2220, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2281, + "assayComponentName": "TOX21_PR_BLA_Followup_Agonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Agonist_viability is a component of the TOX21_PR_BLA_Followup_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2221, + "assayComponentEndpointName": "TOX21_PR_BLA_Followup_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_BLA_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2282, + "assayComponentName": "TOX21_PR_BLA_Followup_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_BLA_Followup_Antagonist_viability is a component of the TOX21_PR_BLA_Followup_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 642, + "assayName": "TOX21_PR_BLA_Followup", + "assayDesc": "TOX21_PR_BLA_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay. The compounds were also tested for auto fluorescence that may interfere with the biological target readout resulting in potential false positives and/or negatives. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "PR-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2222, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_LUC_Followup_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "promegestone (R5020)", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2283, + "assayComponentName": "TOX21_PR_LUC_Followup_Agonist", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Agonist is one of one assay component(s) measured or calculated from the TOX21_PR_LUC_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PR_LUC_Agonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human Progesterone receptor (PR)", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2223, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RU486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2284, + "assayComponentName": "TOX21_PR_LUC_Followup_Antagonist", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PR_LUC_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_PR_LUC_Antagonist assay was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human Progesterone receptor (PR)", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2224, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_LUC_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2285, + "assayComponentName": "TOX21_PR_LUC_Followup_Agonist_viability", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2225, + "assayComponentEndpointName": "TOX21_PR_LUC_Followup_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_PR_LUC_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2286, + "assayComponentName": "TOX21_PR_LUC_Followup_Antagonist_viability", + "assayComponentDesc": "TOX21_PR_LUC_Followup_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 643, + "assayName": "TOX21_PR_LUC_Followup", + "assayDesc": "TOX21_PR_LUC_Followup is a secondary assay for specificity for the TOX21_PR_BLA_Agonist assay. To differentiate true PR agonists from cytotoxic substances, this follow up assay is multiplexed with a cell viability assay.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293-PR-A", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2226, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Agonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist_Followup, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2287, + "assayComponentName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Agonist_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 644, + "assayName": "TOX21_TR_LUC_GH3_Agonist_Followup", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_LUC_GH3_Agonist assay. TOX21_TR_LUC_GH3_Agonist_Followup is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2227, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Antagonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist_Followup, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2288, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist_Followup is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist_Followup assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 645, + "assayName": "TOX21_TR_LUC_GH3_Antagonist_Followup", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist_Followup is a secondary assay for the TOX21_TR_LUC_GH3_Agonist assay. TOX21_TR_LUC_GH3_Agonist_Followup is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2228, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2289, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2229, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2290, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2230, + "assayComponentEndpointName": "TOX21_TRA_COA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2291, + "assayComponentName": "TOX21_TRA_COA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRA_COA_Agonist_Followup_ratio is assay component calculated in the TOX21_TRA_COA_Agonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 646, + "assayName": "TOX21_TRA_COA_Agonist_Followup", + "assayDesc": "TOX21_TRa_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2231, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2292, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2232, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2293, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2233, + "assayComponentEndpointName": "TOX21_TRA_COA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2294, + "assayComponentName": "TOX21_TRA_COA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRA_COA_Antagonist_Followup_ratio is assay component calculated in the TOX21_TRA_COA_Antagonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 647, + "assayName": "TOX21_TRA_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRa_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2234, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2295, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2235, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2296, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2236, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2297, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2237, + "assayComponentEndpointName": "TOX21_TRB_BLA_Agonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TRB_BLA_Agonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2298, + "assayComponentName": "TOX21_TRB_BLA_Agonist_Followup_viability", + "assayComponentDesc": "TOX21_TRB_BLA_Agonist_Followup_viability is a component of the TOX21_TRB_BLA_Agonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 648, + "assayName": "TOX21_TRB_BLA_Agonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla). This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2238, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2299, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2239, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2300, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2240, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2301, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2241, + "assayComponentEndpointName": "TOX21_TRB_BLA_Antagonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRB_BLA_Antagonist_Followup_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2302, + "assayComponentName": "TOX21_TRB_BLA_Antagonist_Followup_viability", + "assayComponentDesc": "TOX21_TRB_BLA_Antagonist_Followup_viability is a component of the TOX21_TRB_BLA_Antagonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 649, + "assayName": "TOX21_TRB_BLA_Antagonist_Followup", + "assayDesc": "The GeneBLAzer TRb-UAS-bla HEK293T assay kit for human TRb (ThermoFisherScientific Catalog No. K1684) was used as a secondary assay for specificity (TRb-bla).This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "TRb-UAS-bla-HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2242, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2303, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2243, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2304, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 1357, + "assayComponentEndpointName": "ATG_COUP_TF1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_COUP_TF1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 924, + "assayComponentName": "ATG_COUP_TF1_TRANS2", + "assayComponentDesc": "ATG_COUP_TF1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 316, + "geneName": "nuclear receptor subfamily 2, group F, member 1", + "description": null, + "geneSymbol": "NR2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7025, + "officialSymbol": "NR2F1", + "officialFullName": "nuclear receptor subfamily 2, group F, member 1", + "uniprotAccessionNumber": "P10589" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1358, + "assayComponentEndpointName": "ATG_NOR1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_NOR1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 925, + "assayComponentName": "ATG_NOR1_TRANS2", + "assayComponentDesc": "ATG_NOR1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-NOR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 341, + "geneName": "nuclear receptor subfamily 4, group A, member 3", + "description": null, + "geneSymbol": "NR4A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8013, + "officialSymbol": "NR4A3", + "officialFullName": "nuclear receptor subfamily 4, group A, member 3", + "uniprotAccessionNumber": "Q92570" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1359, + "assayComponentEndpointName": "ATG_TR4_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TR4_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 926, + "assayComponentName": "ATG_TR4_TRANS2", + "assayComponentDesc": "ATG_TR4_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TR4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 331, + "geneName": "nuclear receptor subfamily 2, group C, member 2", + "description": null, + "geneSymbol": "NR2C2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7182, + "officialSymbol": "NR2C2", + "officialFullName": "nuclear receptor subfamily 2, group C, member 2", + "uniprotAccessionNumber": "P49116" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1360, + "assayComponentEndpointName": "ATG_DAX1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_DAX1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 927, + "assayComponentName": "ATG_DAX1_TRANS2", + "assayComponentDesc": "ATG_DAX1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-DAX1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 20, + "geneName": "nuclear receptor subfamily 0, group B, member 1", + "description": null, + "geneSymbol": "NR0B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 190, + "officialSymbol": "NR0B1", + "officialFullName": "nuclear receptor subfamily 0, group B, member 1", + "uniprotAccessionNumber": "P51843" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1361, + "assayComponentEndpointName": "ATG_Rev_ERB_B_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_Rev_ERB_B_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 928, + "assayComponentName": "ATG_Rev_ERB_B_TRANS2", + "assayComponentDesc": "ATG_Rev_ERB_B_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-erb-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 358, + "geneName": "nuclear receptor subfamily 1, group D, member 2", + "description": null, + "geneSymbol": "NR1D2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9975, + "officialSymbol": "NR1D2", + "officialFullName": "nuclear receptor subfamily 1, group D, member 2", + "uniprotAccessionNumber": "Q14995" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1362, + "assayComponentEndpointName": "ATG_RORa_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_RORa_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 929, + "assayComponentName": "ATG_RORa_TRANS2", + "assayComponentDesc": "ATG_RORa_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ROR-a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 284, + "geneName": "RAR-related orphan receptor A", + "description": null, + "geneSymbol": "RORA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6095, + "officialSymbol": "RORA", + "officialFullName": "RAR-related orphan receptor A", + "uniprotAccessionNumber": "P35398" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1363, + "assayComponentEndpointName": "ATG_PR_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_PR_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 930, + "assayComponentName": "ATG_PR_TRANS2", + "assayComponentDesc": "ATG_PR_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-PR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1364, + "assayComponentEndpointName": "ATG_RXRg_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_RXRg_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 931, + "assayComponentName": "ATG_RXRg_TRANS2", + "assayComponentDesc": "ATG_RXRg_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-RXR-g RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 6215, + "geneName": "retinoid X receptor gamma", + "description": null, + "geneSymbol": "RXRG", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 6258, + "officialSymbol": "RXRG", + "officialFullName": "retinoid X receptor gamma", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1365, + "assayComponentEndpointName": "ATG_SF_1_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_SF_1_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 932, + "assayComponentName": "ATG_SF_1_TRANS2", + "assayComponentDesc": "ATG_SF_1_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-SF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 136, + "geneName": "nuclear receptor subfamily 5, group A, member 1", + "description": null, + "geneSymbol": "NR5A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2516, + "officialSymbol": "NR5A1", + "officialFullName": "nuclear receptor subfamily 5, group A, member 1", + "uniprotAccessionNumber": "Q13285" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1366, + "assayComponentEndpointName": "ATG_SHP_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_SHP_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 933, + "assayComponentName": "ATG_SHP_TRANS2", + "assayComponentDesc": "ATG_SHP_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-SHP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 342, + "geneName": "nuclear receptor subfamily 0, group B, member 2", + "description": null, + "geneSymbol": "NR0B2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8431, + "officialSymbol": "NR0B2", + "officialFullName": "nuclear receptor subfamily 0, group B, member 2", + "uniprotAccessionNumber": "Q15466" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1367, + "assayComponentEndpointName": "ATG_ERb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_ERb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 934, + "assayComponentName": "ATG_ERb_TRANS2", + "assayComponentDesc": "ATG_ERb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ER-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1368, + "assayComponentEndpointName": "ATG_TLX_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TLX_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 935, + "assayComponentName": "ATG_TLX_TRANS2", + "assayComponentDesc": "ATG_TLX_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TLX RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 326, + "geneName": "nuclear receptor subfamily 2, group E, member 1", + "description": null, + "geneSymbol": "NR2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7101, + "officialSymbol": "NR2E1", + "officialFullName": "nuclear receptor subfamily 2, group E, member 1", + "uniprotAccessionNumber": "Q9Y466" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2251, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2312, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2252, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2313, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2253, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2314, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2254, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Agonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TR_RXR_BLA_Agonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2315, + "assayComponentName": "TOX21_TR_RXR_BLA_Agonist_Followup_viability", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Agonist_Followup_viability is a component of the TOX21_TR_RXR_BLA_Agonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 653, + "assayName": "TOX21_TR_RXR_BLA_Agonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2255, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM TA_Antagonist", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2316, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2256, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM TA_Antagonist", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2317, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2257, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T21_TR_RXR_BLA_Antagonist", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2318, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Activity at the RXR portion of the TR:RXR heterodimer is specifically screened to assess contribution in GH3-TRE-Luc signal in TOX21_TR_LUC_GH3 assays.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2258, + "assayComponentEndpointName": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_TR_RXR_BLA_Antagonist_Followup_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2319, + "assayComponentName": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability", + "assayComponentDesc": "TOX21_TR_RXR_BLA_Antagonist_Followup_viability is a component of the TOX21_TR_RXR_BLA_Antagonist_Followup assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 654, + "assayName": "TOX21_TR_RXR_BLA_Antagonist_Followup", + "assayDesc": "GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific Catalog No. K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "RXRa-UAS-bla HEK 293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2277, + "assayComponentEndpointName": "NVS_ENZ_hPDE1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE1A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD1A1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2320, + "assayComponentName": "NVS_ENZ_hPDE1A1", + "assayComponentDesc": "NVS_ENZ_hPDE1A1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 1A [GeneSymbol:PDE1A | GeneID:5136 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 655, + "assayName": "NVS_ENZ_hPDE1A1", + "assayDesc": "NVS_ENZ_hPDE1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5353, + "geneName": "phosphodiesterase 1A", + "description": null, + "geneSymbol": "PDE1A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5136, + "officialSymbol": "PDE1A", + "officialFullName": "phosphodiesterase 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2279, + "assayComponentEndpointName": "NVS_ENZ_hPDE1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE1B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE1B1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE1B1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2321, + "assayComponentName": "NVS_ENZ_hPDE1B1", + "assayComponentDesc": "NVS_ENZ_hPDE1B1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE1B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 1B [GeneSymbol:PDE1B | GeneID:5153 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 656, + "assayName": "NVS_ENZ_hPDE1B1", + "assayDesc": "NVS_ENZ_hPDE1B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5369, + "geneName": "phosphodiesterase 1B", + "description": null, + "geneSymbol": "PDE1B", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5153, + "officialSymbol": "PDE1B", + "officialFullName": "phosphodiesterase 1B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2281, + "assayComponentEndpointName": "NVS_ENZ_hPDE2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2322, + "assayComponentName": "NVS_ENZ_hPDE2A", + "assayComponentDesc": "NVS_ENZ_hPDE2A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE2A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 2A [GeneSymbol:PDE2A | GeneID:5138 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 657, + "assayName": "NVS_ENZ_hPDE2A", + "assayDesc": "NVS_ENZ_hPDE2A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5355, + "geneName": "phosphodiesterase 2A", + "description": null, + "geneSymbol": "PDE2A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5138, + "officialSymbol": "PDE2A", + "officialFullName": "phosphodiesterase 2A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2283, + "assayComponentEndpointName": "NVS_ENZ_hPDE3A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE3A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE3A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD3A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2323, + "assayComponentName": "NVS_ENZ_hPDE3A", + "assayComponentDesc": "NVS_ENZ_hPDE3A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE3A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 3A [GeneSymbol:PDE3A | GeneID:5139 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 658, + "assayName": "NVS_ENZ_hPDE3A", + "assayDesc": "NVS_ENZ_hPDE3A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5356, + "geneName": "phosphodiesterase 3A", + "description": null, + "geneSymbol": "PDE3A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5139, + "officialSymbol": "PDE3A", + "officialFullName": "phosphodiesterase 3A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1369, + "assayComponentEndpointName": "ATG_THRb_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_THRb_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 936, + "assayComponentName": "ATG_THRb_TRANS2", + "assayComponentDesc": "ATG_THRb_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-THR-b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1370, + "assayComponentEndpointName": "ATG_EAR2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_EAR2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 937, + "assayComponentName": "ATG_EAR2_TRANS2", + "assayComponentDesc": "ATG_EAR2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-EAR2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 116, + "geneName": "nuclear receptor subfamily 2, group F, member 6", + "description": null, + "geneSymbol": "NR2F6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2063, + "officialSymbol": "NR2F6", + "officialFullName": "nuclear receptor subfamily 2, group F, member 6", + "uniprotAccessionNumber": "P10588" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1371, + "assayComponentEndpointName": "ATG_TR2_TRANS2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_TR2_TRANS2 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 938, + "assayComponentName": "ATG_TR2_TRANS2", + "assayComponentDesc": "ATG_TR2_TRANS2 is one of 24 assay components measured or calculated from the ATG_TRANS2 assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factors.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-TR2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 408, + "assayName": "ATG_TRANS2", + "assayDesc": "ATG_TRANS2 is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 330, + "geneName": "nuclear receptor subfamily 2, group C, member 1", + "description": null, + "geneSymbol": "NR2C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7181, + "officialSymbol": "NR2C1", + "officialFullName": "nuclear receptor subfamily 2, group C, member 1", + "uniprotAccessionNumber": "P13056" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1372, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_MORT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_MORT was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_MORT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 939, + "assayComponentName": "Tanguay_ZF_120hpf_MORT", + "assayComponentDesc": "Tanguay_ZF_120hpf_Mort is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_Mort assay. It is designed to make measurements of mortality as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Mortality is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "embryonic mortality", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic mortality", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 2285, + "assayComponentEndpointName": "NVS_ENZ_hPDE4B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPD4B1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2324, + "assayComponentName": "NVS_ENZ_hPDE4B1", + "assayComponentDesc": "NVS_ENZ_hPDE4B1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4b, cAMP-specific [GeneSymbol:PDE4B | GeneID:5142 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 659, + "assayName": "NVS_ENZ_hPDE4B1", + "assayDesc": "NVS_ENZ_hPDE4B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5358, + "geneName": "phosphodiesterase 4B", + "description": null, + "geneSymbol": "PDE4B", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5142, + "officialSymbol": "PDE4B", + "officialFullName": "phosphodiesterase 4B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2287, + "assayComponentEndpointName": "NVS_ENZ_hPDE4C1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPD4C1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPD4C1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2325, + "assayComponentName": "NVS_ENZ_hPDE4C1", + "assayComponentDesc": "NVS_ENZ_hPDE4C1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4C1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4C, cAMP-specific [GeneSymbol:PDE4C | GeneID:5143 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 660, + "assayName": "NVS_ENZ_hPDE4C1", + "assayDesc": "NVS_ENZ_hPDE4C1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5359, + "geneName": "phosphodiesterase 4C", + "description": null, + "geneSymbol": "PDE4C", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5143, + "officialSymbol": "PDE4C", + "officialFullName": "phosphodiesterase 4C", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2289, + "assayComponentEndpointName": "NVS_ENZ_hPDE4D3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE4D3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2326, + "assayComponentName": "NVS_ENZ_hPDE4D3", + "assayComponentDesc": "NVS_ENZ_hPDE4D3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4D3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4D, cAMP-specific [GeneSymbol:PDE4D | GeneID:5144 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 661, + "assayName": "NVS_ENZ_hPDE4D3", + "assayDesc": "NVS_ENZ_hPDE4D3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5360, + "geneName": "phosphodiesterase 4D", + "description": null, + "geneSymbol": "PDE4D", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5144, + "officialSymbol": "PDE4D", + "officialFullName": "phosphodiesterase 4D", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2291, + "assayComponentEndpointName": "NVS_ENZ_hPDE7A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE7A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE7A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2327, + "assayComponentName": "NVS_ENZ_hPDE7A", + "assayComponentDesc": "NVS_ENZ_hPDE7A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE7A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 7A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5150 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 662, + "assayName": "NVS_ENZ_hPDE7A", + "assayDesc": "NVS_ENZ_hPDE7A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5366, + "geneName": "phosphodiesterase 7A", + "description": null, + "geneSymbol": "PDE7A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5150, + "officialSymbol": "PDE7A", + "officialFullName": "phosphodiesterase 7A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2293, + "assayComponentEndpointName": "NVS_ENZ_hPDE8A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE8A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE8A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2328, + "assayComponentName": "NVS_ENZ_hPDE8A1", + "assayComponentDesc": "NVS_ENZ_hPDE8A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE8A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 8A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5151 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 663, + "assayName": "NVS_ENZ_hPDE8A1", + "assayDesc": "NVS_ENZ_hPDE8A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5367, + "geneName": "phosphodiesterase 8A", + "description": null, + "geneSymbol": "PDE8A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5151, + "officialSymbol": "PDE8A", + "officialFullName": "phosphodiesterase 8A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2295, + "assayComponentEndpointName": "NVS_ENZ_hPDE9A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE9A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE9A2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.\r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2329, + "assayComponentName": "NVS_ENZ_hPDE9A2", + "assayComponentDesc": "NVS_ENZ_hPDE9A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE9A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 9A, cAMP-specific [GeneSymbol:PDE4D | GeneID:5152 | .", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 664, + "assayName": "NVS_ENZ_hPDE9A2", + "assayDesc": "NVS_ENZ_hPDE9A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": null, + "dilutionSolventPercentMax": null, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5368, + "geneName": "phosphodiesterase 9A", + "description": null, + "geneSymbol": "PDE9A", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5152, + "officialSymbol": "PDE9A", + "officialFullName": "phosphodiesterase 9A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 2297, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2330, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2298, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2334, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2299, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nlity", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2335, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2300, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2331, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2301, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N12", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2336, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2302, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N24", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2337, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a pilot experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2303, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2332, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2304, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2338, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2305, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM Nosis", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2339, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2306, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2333, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2307, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N12", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2340, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 12 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2308, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N24", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2341, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a pilot experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in phenol red-free DMEM + 10% charcoal-stripped fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 24 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2309, + "assayComponentEndpointName": "CCTE_GLTED_hDIO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "6-propyl-thiouracil (PTU)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 1", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2342, + "assayComponentName": "CCTE_GLTED_hDIO1", + "assayComponentDesc": "CCTE_GLTED_hDIO1 is the assay component measured from the CCTE_GLTED_hDIO1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO1 targets both the outer and inner rings, and thus can convert T4 to T3 or inactivate either of these thyroid hormones. ", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3’,5’-triiodo-L-thyronine (reverse T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 667, + "assayName": "CCTE_GLTED_hDIO1", + "assayDesc": "CCTE_GLTED_hDIO1 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 1 (DIO1) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2789, + "geneName": "iodothyronine deiodinase 1", + "description": null, + "geneSymbol": "DIO1", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1733, + "officialSymbol": "DIO1", + "officialFullName": "iodothyronine deiodinase 1", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 2362, + "assayComponentEndpointName": "TOX21_PXR_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_PXR_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "46 uM rifampicin ", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2369, + "assayComponentName": "TOX21_PXR_viability", + "assayComponentDesc": "TOX21_PXR_viability is a component of the TOX21_PXR assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 670, + "assayName": "TOX21_PXR", + "assayDesc": "The TOX21_PXR is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing on a microplate: 1536-well plate. To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.bcp.2020.114368", + "url": "https://pubmed.ncbi.nlm.nih.gov/33333074/", + "pmid": 33333074, + "title": "Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library", + "author": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M", + "citation": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M. Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol. 2021 Feb;184:114368. doi: 10.1016/j.bcp.2020.114368. Epub 2020 Dec 14. PMID: 33333074.", + "otherId": "0", + "citationId": 288, + "otherSource": "" + } + }, + { + "aeid": 2363, + "assayComponentEndpointName": "TOX21_PXR_agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "46 uM rifampicin ", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2370, + "assayComponentName": "TOX21_PXR_agonist", + "assayComponentDesc": "TOX21_PXR_agonist is one of one assay component(s) measured or calculated from the TOX21_PXR assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 670, + "assayName": "TOX21_PXR", + "assayDesc": "The TOX21_PXR is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing on a microplate: 1536-well plate. To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.bcp.2020.114368", + "url": "https://pubmed.ncbi.nlm.nih.gov/33333074/", + "pmid": 33333074, + "title": "Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library", + "author": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M", + "citation": "Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M. Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol. 2021 Feb;184:114368. doi: 10.1016/j.bcp.2020.114368. Epub 2020 Dec 14. PMID: 33333074.", + "otherId": "0", + "citationId": 288, + "otherSource": "" + } + }, + { + "aeid": 2364, + "assayComponentEndpointName": "TOX21_TRHR_HEK293_agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRHR_HEK293_Agonist used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TRH", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2371, + "assayComponentName": "TOX21_TRHR_HEK293_agonist", + "assayComponentDesc": "TOX21_TRHR_HEK293_Agonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", + "assayComponentTargetDesc": "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay. Activation of this GPCR is indicated by increased intracellular calcium as measured in this cell-based fluorescent reporter assay.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "intracellular calcium", + "biologicalProcessTarget": "receptor activation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FDSS 7000EX kinetic plate reader ", + "keyAssayReagentType": "chemical", + "keyAssayReagent": "intracellular calcium", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "intracellular calcium", + "aid": 671, + "assayName": "TOX21_TRHR_HEK293", + "assayDesc": "TOX21_TRHR_HEK293 assay is a cell-based assay, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. It has the potential to screen G protein-coupled receptors. A compound/drug can either activate (agonist) or suppress (antagonist) GPCRs that can be monitored by levels of intracellular calcium. Using this assay, the Tox21 10K compound library was screened to identify potential TRHR agonists.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7000, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "TRHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7201, + "officialSymbol": "TRHR", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2365, + "assayComponentEndpointName": "TOX21_TRHR_HEK293_antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TRHR_HEK293_Antagonist used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T293", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "thyrotropin-releasing hormone receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2372, + "assayComponentName": "TOX21_TRHR_HEK293_antagonist", + "assayComponentDesc": "TOX21_TRHR_HEK293_Antagonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", + "assayComponentTargetDesc": "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Inactivation of this GPCR is indicated by decreased intracellular calcium as measured in this cell-based fluorescent assay.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "intracellular calcium", + "biologicalProcessTarget": "receptor activation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "FDSS 7000EX kinetic plate reader ", + "keyAssayReagentType": "chemical", + "keyAssayReagent": "intracellular calcium", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "intracellular calcium", + "aid": 671, + "assayName": "TOX21_TRHR_HEK293", + "assayDesc": "TOX21_TRHR_HEK293 assay is a cell-based assay, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. It has the potential to screen G protein-coupled receptors. A compound/drug can either activate (agonist) or suppress (antagonist) GPCRs that can be monitored by levels of intracellular calcium. Using this assay, the Tox21 10K compound library was screened to identify potential TRHR agonists.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 7000, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "TRHR", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 7201, + "officialSymbol": "TRHR", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": null + }, + { + "aeid": 2366, + "assayComponentEndpointName": "TOX21_CASP3_HEPG2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_HEPG2 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity following compound treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "apoptosis", + "intendedTargetFamilySub": "caspase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2373, + "assayComponentName": "TOX21_CASP3_HEPG2", + "assayComponentDesc": "TOX21_CASP3_HEPG2 is a component of the TOX21_CASP3_HEPG2 assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "caspase activity", + "biologicalProcessTarget": "apoptosis", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Caspase-Glo 3/7", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Caspase-Glo 3/7 reagent", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 672, + "assayName": "TOX21_CASP3_HEPG2", + "assayDesc": "The TOX21_CASP3_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. HepG2 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1373, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_YSE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_YSE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 940, + "assayComponentName": "Tanguay_ZF_120hpf_YSE", + "assayComponentDesc": "Tanguay_ZF_120hpf_YSE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_YSE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "extraembryonic membrane development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1374, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_AXIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_AXIS was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 941, + "assayComponentName": "Tanguay_ZF_120hpf_AXIS", + "assayComponentDesc": "Tanguay_ZF_120hpf_AXIS is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_AXIS assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "body axis morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1375, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_EYE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_EYE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_EYE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 942, + "assayComponentName": "Tanguay_ZF_120hpf_EYE", + "assayComponentDesc": "Tanguay_ZF_120hpf_EYE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_EYE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic eye development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1376, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SNOU", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SNOU was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SNOU, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 943, + "assayComponentName": "Tanguay_ZF_120hpf_SNOU", + "assayComponentDesc": "Tanguay_ZF_120hpf_SNOU is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SNOU assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic snout morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1377, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_JAW", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_JAW was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_JAW, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 944, + "assayComponentName": "Tanguay_ZF_120hpf_JAW", + "assayComponentDesc": "Tanguay_ZF_120hpf_JAW is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_JAW assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic jaw development", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1378, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_OTIC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_OTIC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_OTIC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 945, + "assayComponentName": "Tanguay_ZF_120hpf_OTIC", + "assayComponentDesc": "Tanguay_ZF_120hpf_OTIC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_OTIC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "otic vesicle morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1379, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PE was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 946, + "assayComponentName": "Tanguay_ZF_120hpf_PE", + "assayComponentDesc": "Tanguay_ZF_120hpf_PE is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PE assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1380, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_BRAI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_BRAI was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_BRAI, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 947, + "assayComponentName": "Tanguay_ZF_120hpf_BRAI", + "assayComponentDesc": "Tanguay_ZF_120hpf_BRAI is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_BRAI assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "brain morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1381, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SOMI", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SOMI was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SOMI, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 948, + "assayComponentName": "Tanguay_ZF_120hpf_SOMI", + "assayComponentDesc": "Tanguay_ZF_120hpf_SOMI is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SOMI assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "somitogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1382, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PFIN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PFIN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PFIN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 949, + "assayComponentName": "Tanguay_ZF_120hpf_PFIN", + "assayComponentDesc": "Tanguay_ZF_120hpf_PFIN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PFIN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "pectoral fin morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1383, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_CFIN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_CFIN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CFIN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 950, + "assayComponentName": "Tanguay_ZF_120hpf_CFIN", + "assayComponentDesc": "Tanguay_ZF_120hpf_CFIN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_CFIN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "caudal fin morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1384, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_PIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_PIG was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PIG, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 951, + "assayComponentName": "Tanguay_ZF_120hpf_PIG", + "assayComponentDesc": "Tanguay_ZF_120hpf_PIG is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_PIG assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic pigmentation", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1385, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_CIRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_CIRC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CIRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 952, + "assayComponentName": "Tanguay_ZF_120hpf_CIRC", + "assayComponentDesc": "Tanguay_ZF_120hpf_CIRC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_CIRC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "angiogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1386, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_TRUN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_TRUN was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TRUN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 953, + "assayComponentName": "Tanguay_ZF_120hpf_TRUN", + "assayComponentDesc": "Tanguay_ZF_120hpf_TRUN is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_TRUN assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1387, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_SWIM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_SWIM was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SWIM, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 954, + "assayComponentName": "Tanguay_ZF_120hpf_SWIM", + "assayComponentDesc": "Tanguay_ZF_120hpf_SWIM is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_SWIM assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "swim bladder morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1388, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_NC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_NC was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_NC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 955, + "assayComponentName": "Tanguay_ZF_120hpf_NC", + "assayComponentDesc": "Tanguay_ZF_120hpf_NC is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_NC assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic notochord morphogenesis", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1389, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_TR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_TR was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 956, + "assayComponentName": "Tanguay_ZF_120hpf_TR", + "assayComponentDesc": "Tanguay_ZF_120hpf_TR is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_TR assay. It is designed to make measurements of morphology as detected with brightfield microscopy of developing zebrafish embryos.", + "assayComponentTargetDesc": "Morphology is measured by light microscopic examination of developing zebrafish embryos.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "embryonic functional response", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1390, + "assayComponentEndpointName": "LTEA_HepaRG_SLC22A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC22A6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC22A6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 957, + "assayComponentName": "LTEA_HepaRG_SLC22A6", + "assayComponentDesc": "LTEA_HepaRG_SLC22A6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 353, + "geneName": "solute carrier family 22 (organic anion transporter), member 6", + "description": null, + "geneSymbol": "SLC22A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9356, + "officialSymbol": "SLC22A6", + "officialFullName": "solute carrier family 22 (organic anion transporter), member 6", + "uniprotAccessionNumber": "Q4U2R8" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1392, + "assayComponentEndpointName": "LTEA_HepaRG_KLK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_KLK3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KLK3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is Cellular remodeling.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "Cellular remodeling", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 958, + "assayComponentName": "LTEA_HepaRG_KLK3", + "assayComponentDesc": "LTEA_HepaRG_KLK3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cellular remodeling.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 25, + "geneName": "kallikrein-related peptidase 3", + "description": null, + "geneSymbol": "KLK3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 354, + "officialSymbol": "KLK3", + "officialFullName": "kallikrein-related peptidase 3", + "uniprotAccessionNumber": "P07288" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1394, + "assayComponentEndpointName": "LTEA_HepaRG_SLC10A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_SLC10A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC10A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium/bile acid cotransporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "sodium/bile acid cotransporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 959, + "assayComponentName": "LTEA_HepaRG_SLC10A1", + "assayComponentDesc": "LTEA_HepaRG_SLC10A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 299, + "geneName": "solute carrier family 10 (sodium/bile acid cotransporter), member 1", + "description": null, + "geneSymbol": "SLC10A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6554, + "officialSymbol": "SLC10A1", + "officialFullName": "solute carrier family 10 (sodium/bile acid cotransporter), member 1", + "uniprotAccessionNumber": "Q14973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1396, + "assayComponentEndpointName": "LTEA_HepaRG_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_MMP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 960, + "assayComponentName": "LTEA_HepaRG_MMP1", + "assayComponentDesc": "LTEA_HepaRG_MMP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1398, + "assayComponentEndpointName": "LTEA_HepaRG_CYP24A1_1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP24A1_1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP24A1_1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 961, + "assayComponentName": "LTEA_HepaRG_CYP24A1_1", + "assayComponentDesc": "LTEA_HepaRG_CYP24A1_1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1507, + "assayComponentEndpointName": "CCTE_Padilla_ZF_144hpf_TERATOSCORE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defect as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the malformation intended target family, where the subfamily is total.", + "assayFunctionType": "developmental defect", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "total", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 962, + "assayComponentName": "CCTE_Padilla_ZF_144hpf_TERATOSCORE", + "assayComponentDesc": "CCTE_Padilla_ZF_144hpf_TERATOSCORE is one of one assay component(s) measured or calculated from the CCTE_Padilla_ZF_144hpf assay. It is designed to make measurements of developmental malformations and mortality as detected with brightfield microscopy.", + "assayComponentTargetDesc": "Individual embryos were examined daily for malformations, failure to hatch and mortality. Results were scored by customized rubric and a composite score derived.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "embryo development", + "biologicalProcessTarget": "regulation of development", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "physical feature", + "aid": 410, + "assayName": "CCTE_Padilla_ZF_144hpf", + "assayDesc": "Zebrafish embryos were exposed to chemicals starting 6 hr post-fertilization for 5 days in 96-well plates. Developing larvae were examined microscopically daily for malformation and mortality. ", + "timepointHr": 144.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.4, + "asid": 12, + "assaySourceName": "CCTE_PADILLA", + "assaySourceLongName": "CCTE Padilla Lab", + "assaySourceDesc": "The Padilla laboratory at the EPA Center for Computational Toxicology focuses on the development and screening of zebrafish assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2011.10.018", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22182468", + "pmid": 22182468, + "title": "Zebrafish developmental screening of the ToxCast™ Phase I chemical library", + "author": "Padilla S, Corum D, Padnos B, Hunter DL, Beam A, Houck KA, Sipes N, Kleinstreuer N, Knudsen T, Dix DJ, Reif DM", + "citation": "Padilla S, Corum D, Padnos B, Hunter DL, Beam A, Houck KA, Sipes N, Kleinstreuer N, Knudsen T, Dix DJ, Reif DM. Zebrafish developmental screening of the ToxCast™ Phase I chemical library. Reprod Toxicol. 2012 Apr;33(2):174-87. doi: 10.1016/j.reprotox.2011.10.018. Epub 2011 Dec 9. PubMed PMID: 22182468.", + "otherId": "0", + "citationId": 217, + "otherSource": "" + } + }, + { + "aeid": 2367, + "assayComponentEndpointName": "TOX21_CASP3_HEPG2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_HEPG2_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2374, + "assayComponentName": "TOX21_CASP3_HEPG2_viability", + "assayComponentDesc": "TOX21_CASP3_HEPG2_viability is a component of the TOX21_CASP3_HEPG2 assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay ", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 672, + "assayName": "TOX21_CASP3_HEPG2", + "assayDesc": "The TOX21_CASP3_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. HepG2 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2368, + "assayComponentEndpointName": "TOX21_CASP3_CHO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_CHO was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "apoptosis", + "intendedTargetFamilySub": "caspase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2375, + "assayComponentName": "TOX21_CASP3_CHO", + "assayComponentDesc": "TOX21_CASP3_CHO is a component of the TOX21_CASP3_CHO assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "caspase activity", + "biologicalProcessTarget": "apoptosis", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Caspase-Glo 3/7", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Caspase-Glo 3/7 reagent", + "technologicalTargetType": "chemical ", + "technologicalTargetTypeSub": "ATP", + "aid": 678, + "assayName": "TOX21_CASP3_CHO", + "assayDesc": "The TOX21_CASP3_CHO is a cell-based, single-readout assay that uses CHO-K1, a hamster ovary cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. Wild type CHO-K1 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2369, + "assayComponentEndpointName": "TOX21_CASP3_CHO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2376, + "assayComponentName": "TOX21_CASP3_CHO_viability", + "assayComponentDesc": "TOX21_CASP3_CHO_viability is a component of the TOX21_CASP3_CHO assay. This component measures cell viability using the CellTiter-Fluor assay system.", + "assayComponentTargetDesc": "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "living cells", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Cell Titer Fluor assay ", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Fluor reagent", + "technologicalTargetType": "cell morphology", + "technologicalTargetTypeSub": "cellular", + "aid": 678, + "assayName": "TOX21_CASP3_CHO", + "assayDesc": "The TOX21_CASP3_CHO is a cell-based, single-readout assay that uses CHO-K1, a hamster ovary cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. Wild type CHO-K1 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", + "timepointHr": 16.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 2370, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2377, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ch1", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2371, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2378, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ch2", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2372, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "growth factor receptor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2379, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2373, + "assayComponentEndpointName": "TOX21_SBE_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_SBE_BLA_Antagonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2380, + "assayComponentName": "TOX21_SBE_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_SBE_BLA_Antagonist_viability is a component of the TOX21_SBE_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 679, + "assayName": "TOX21_SBE_BLA_Antagonist", + "assayDesc": "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2374, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2381, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2375, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_SBE_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2382, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2376, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_SBE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TGFb", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "growth factor receptor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2383, + "assayComponentName": "TOX21_SBE_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2377, + "assayComponentEndpointName": "TOX21_SBE_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint TOX21_SBE_BLA_Agonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2384, + "assayComponentName": "TOX21_SBE_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_SBE_BLA_Agonist_viability is a component of the TOX21_SBE_BLA_Agonist assay. This component measures cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 680, + "assayName": "TOX21_SBE_BLA_Agonist", + "assayDesc": "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", + "timepointHr": 5.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00228", + "url": "https://pubmed.ncbi.nlm.nih.gov/31652400/", + "pmid": 31652400, + "title": "Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway", + "author": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M", + "citation": "Wei Z, Sakamuru S, Zhang L, Zhao J, Huang R, Kleinstreuer NC, Chen Y, Shu Y, Knudsen TB, Xia M. Identification and Profiling of Environmental Chemicals That Inhibit the TGF?/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11. PMID: 31652400; PMCID: PMC7341485.", + "otherId": "0", + "citationId": 282, + "otherSource": "" + } + }, + { + "aeid": 2386, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DMSO", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2393, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Loss of DHT-induced red fluorescence in nucleolar region of the cell nucleus is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2387, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "dihydroxytestosterone (DHT)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2394, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Increased red fluorescence in nucleolar region of the cell nucleus is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2390, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DMSO", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2397, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Decrease of the ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2391, + "assayComponentEndpointName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "dihydroxytestosterone (DHT)", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2398, + "assayComponentName": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", + "assayComponentDesc": "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", + "assayComponentTargetDesc": "Increased ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein-protein binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor binding", + "aid": 681, + "assayName": "UPITT_AR_TIF2_PPIB", + "assayDesc": "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "bone", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "U2OS", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 25, + "assaySourceName": "UPITT", + "assaySourceLongName": "University of Pittsburgh Johnston Lab", + "assaySourceDesc": "The Johnston Lab at the University of Pittsburgh ran androgen receptor nuclear translocation assays under a Material Transfer Agreement (MTA) for the ToxCast Phase 1, Phase 2, and E1K chemicals. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 2442, + "assayComponentEndpointName": "CCTE_Simmons_MITO_basal_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Fenpyroximate", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2440, + "assayComponentName": "CCTE_Simmons_MITO_basal_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_basal_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of basal respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Basal respiration rate is caculated from the oxygen consumption rates at T6 (36 min) following test compound injection, at 18 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "basal respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2444, + "assayComponentEndpointName": "CCTE_Simmons_MITO_max_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Fenpyroximate", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2441, + "assayComponentName": "CCTE_Simmons_MITO_max_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_max_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of maximal respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Maximal respiration is calculated as oxygen consumption rates at T9 (54 min)following test compound injection at T6 and FCCP (uncoupler reagent), at 36 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "maximal respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2446, + "assayComponentEndpointName": "CCTE_Simmons_MITO_inhib_resp_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for gain or loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.", + "assayFunctionType": "cellular respiration", + "normalizedDataType": "fold_induction", + "burstAssay": 0, + "keyPositiveControl": "none", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "mitochondria", + "intendedTargetFamilySub": "respiration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2442, + "assayComponentName": "CCTE_Simmons_MITO_inhib_resp_rate", + "assayComponentDesc": "CCTE_Simmons_MITO_inhib_resp_rate is one of 4 assay components calculated from the CCTE_Simmons_MITO assay. It is designed to make measurements of inhibited respiration using a form of respirometric reporter, as detected with bioluminescence signals by Seahorse XF96 technology. ", + "assayComponentTargetDesc": "Inhibited respiration is calculated from the oxygen consumption rates at T12 (54 min) following test compound injection at T6, uncoupling at T9, and rotenone/antimycin A (electron transport chain inhibitor reagents), at 54 min elapsed exposure.", + "parameterReadoutType": "single", + "assayDesignType": "respirometric reporter", + "assayDesignTypeSub": "inhibited respiration", + "biologicalProcessTarget": "cellular oxygen consumption", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "oxygen consumption rate", + "detectionTechnology": "Seahorse XF96", + "keyAssayReagentType": "fluorescent oxygen sensor", + "keyAssayReagent": "Seahorse assay cartridge", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "dissolved oxygen", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2450, + "assayComponentEndpointName": "CCTE_Simmons_MITO_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "blank wells", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2443, + "assayComponentName": "CCTE_Simmons_MITO_viability", + "assayComponentDesc": "CCTE_Simmons_MITO_viability is one of 4 assay components measured from the CCTE_Simmons_MITO assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology. ", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 682, + "assayName": "CCTE_Simmons_MITO", + "assayDesc": "CCTE_Simmons_MITO is cell-based, respirometric assay using HepG2 cells and a Seahorse XF Analyzer to measure oxygen consumption rates over four temporal phases spanning a total of 72 minutes: pre-injection (pre-treatment), basal (following test compound injection), maximal (following FCCP uncoupler injection), and inhibited (following rotenone/antimycin A injection)", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa059", + "url": "https://pubmed.ncbi.nlm.nih.gov/32374859/", + "pmid": 32374859, + "title": "Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries", + "author": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO", + "citation": "Hallinger DR, Lindsay HB, Paul Friedman K, Suarez DA, Simmons SO. Respirometric Screening and Characterization of Mitochondrial Toxicants Within the ToxCast Phase I and II Chemical Libraries. Toxicol Sci. 2020 Jul 1;176(1):175-192. doi: 10.1093/toxsci/kfaa059. PMID: 32374859.", + "otherId": "0", + "citationId": 235, + "otherSource": "" + } + }, + { + "aeid": 2451, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Viability_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2445, + "assayComponentName": "CCTE_Harrill_HTTr_Viability_MCF7", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a full screening experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "membrane impermeable stain for DNA", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "propidium iodide", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nuclear DNA", + "aid": 665, + "assayName": "CCTE_Harrill_HTTr_Viability", + "assayDesc": "This is a cell-based assay that evaluates cell viability using high content imaging to evaluate membrane integrity using propidium iodide dye exclusion in a 384 well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 1508, + "assayComponentEndpointName": "CCTE_Simmons_AUR_TPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "methimazole (MMI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 963, + "assayComponentName": "CCTE_Simmons_AUR_TPO", + "assayComponentDesc": "CCTE_Simmons_AUR_TPO is the assay component measured from the CCTE_Simmons_AUR_TPO assay. It is designed to make measurements of thyroperoxidase (TPO) activity as detected with fluorescence intensity signals by Fluorescence using the Amplex UltraRed technology as a form of enzyme activity reporter.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Amplex UltraRed", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 411, + "assayName": "CCTE_Simmons_AUR_TPO", + "assayDesc": "CCTE_Simmons_AUR_TPO is a biochemical, single-readout assay that uses microsomes from rat thyroid gland in a tissue-based cell-free assay.Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "thyroid gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "rat thyroid gland", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 498, + "geneName": "thyroid peroxidase", + "description": null, + "geneSymbol": "Tpo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54314, + "officialSymbol": "Tpo", + "officialFullName": "thyroid peroxidase", + "uniprotAccessionNumber": "P14650" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1509, + "assayComponentEndpointName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "LUCINH1;LUCINH2", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 964, + "assayComponentName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "assayComponentDesc": "CCTE_Simmons_CellTiterGLO_HEK293T is the assay component measured from the CCTE_Simmons_CellTiterGLO_HEK293T assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology. This is a secondary cytotoxicity assay to CCTE_Simmons_AUR_TPO to estimate a cellular tolerance limit.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo Fluor] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo fluor", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 412, + "assayName": "CCTE_Simmons_CellTiterGLO_HEK293T", + "assayDesc": "CCTE_Simmons_CellTiterGLO_HEK293T is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1611, + "assayComponentEndpointName": "CLD_ABCB1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_6hr was analyzed at the endpoint, CLD_ABCB1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 838, + "assayComponentName": "CLD_ABCB1_6hr", + "assayComponentDesc": "CLD_ABCB1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1612, + "assayComponentEndpointName": "CLD_ABCB11_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_6hr was analyzed at the endpoint, CLD_ABCB11_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 839, + "assayComponentName": "CLD_ABCB11_6hr", + "assayComponentDesc": "CLD_ABCB11_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1613, + "assayComponentEndpointName": "CLD_ABCG2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_6hr was analyzed at the endpoint, CLD_ABCG2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 840, + "assayComponentName": "CLD_ABCG2_6hr", + "assayComponentDesc": "CLD_ABCG2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1614, + "assayComponentEndpointName": "CLD_ACTIN_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_6hr was analyzed at the endpoint, CLD_ACTIN_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 841, + "assayComponentName": "CLD_ACTIN_6hr", + "assayComponentDesc": "CLD_ACTIN_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1615, + "assayComponentEndpointName": "CLD_CYP1A1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_6hr was analyzed at the endpoint, CLD_CYP1A1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 842, + "assayComponentName": "CLD_CYP1A1_6hr", + "assayComponentDesc": "CLD_CYP1A1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1616, + "assayComponentEndpointName": "CLD_CYP1A2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_6hr was analyzed at the endpoint, CLD_CYP1A2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 843, + "assayComponentName": "CLD_CYP1A2_6hr", + "assayComponentDesc": "CLD_CYP1A2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1617, + "assayComponentEndpointName": "CLD_CYP2B6_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 844, + "assayComponentName": "CLD_CYP2B6_6hr", + "assayComponentDesc": "CLD_CYP2B6_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1618, + "assayComponentEndpointName": "CLD_CYP2C19_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_6hr was analyzed at the endpoint, CLD_CYP2C19_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 845, + "assayComponentName": "CLD_CYP2C19_6hr", + "assayComponentDesc": "CLD_CYP2C19_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1619, + "assayComponentEndpointName": "CLD_CYP2C9_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_6hr was analyzed at the endpoint, CLD_CYP2C9_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 846, + "assayComponentName": "CLD_CYP2C9_6hr", + "assayComponentDesc": "CLD_CYP2C9_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1620, + "assayComponentEndpointName": "CLD_CYP3A4_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_6hr was analyzed at the endpoint, CLD_CYP3A4_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 847, + "assayComponentName": "CLD_CYP3A4_6hr", + "assayComponentDesc": "CLD_CYP3A4_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1621, + "assayComponentEndpointName": "CLD_GAPDH_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_6hr was analyzed at the endpoint, CLD_GAPDH_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 848, + "assayComponentName": "CLD_GAPDH_6hr", + "assayComponentDesc": "CLD_GAPDH_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1622, + "assayComponentEndpointName": "CLD_GSTA2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_6hr was analyzed at the endpoint, CLD_GSTA2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 849, + "assayComponentName": "CLD_GSTA2_6hr", + "assayComponentDesc": "CLD_GSTA2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1623, + "assayComponentEndpointName": "CLD_HMGCS2_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_6hr was analyzed at the endpoint, CLD_HMGCS2_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 850, + "assayComponentName": "CLD_HMGCS2_6hr", + "assayComponentDesc": "CLD_HMGCS2_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1624, + "assayComponentEndpointName": "CLD_SLCO1B1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_6hr was analyzed at the endpoint, CLD_SLCO1B1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 851, + "assayComponentName": "CLD_SLCO1B1_6hr", + "assayComponentDesc": "CLD_SLCO1B1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1625, + "assayComponentEndpointName": "CLD_SULT2A_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_6hr was analyzed at the endpoint, CLD_SULT2A_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 852, + "assayComponentName": "CLD_SULT2A_6hr", + "assayComponentDesc": "CLD_SULT2A_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1626, + "assayComponentEndpointName": "CLD_UGT1A1_6hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_6hr was analyzed at the endpoint, CLD_UGT1A1_6hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 853, + "assayComponentName": "CLD_UGT1A1_6hr", + "assayComponentDesc": "CLD_UGT1A1_6hr is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 399, + "assayName": "CLD_6hr", + "assayDesc": "CLD_6hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 6 hours after chemical dosing in a 96-well plate.", + "timepointHr": 6.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1627, + "assayComponentEndpointName": "CLD_ABCB1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_24hr was analyzed at the endpoint, CLD_ABCB1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 854, + "assayComponentName": "CLD_ABCB1_24hr", + "assayComponentDesc": "CLD_ABCB1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1628, + "assayComponentEndpointName": "CLD_ABCB11_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_24hr was analyzed at the endpoint, CLD_ABCB11_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 855, + "assayComponentName": "CLD_ABCB11_24hr", + "assayComponentDesc": "CLD_ABCB11_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1629, + "assayComponentEndpointName": "CLD_ABCG2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_24hr was analyzed at the endpoint, CLD_ABCG2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 856, + "assayComponentName": "CLD_ABCG2_24hr", + "assayComponentDesc": "CLD_ABCG2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1630, + "assayComponentEndpointName": "CLD_ACTIN_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_24hr was analyzed at the endpoint, CLD_ACTIN_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 857, + "assayComponentName": "CLD_ACTIN_24hr", + "assayComponentDesc": "CLD_ACTIN_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1631, + "assayComponentEndpointName": "CLD_CYP1A1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_24hr was analyzed at the endpoint, CLD_CYP1A1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 858, + "assayComponentName": "CLD_CYP1A1_24hr", + "assayComponentDesc": "CLD_CYP1A1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1632, + "assayComponentEndpointName": "CLD_CYP1A2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_24hr was analyzed at the endpoint, CLD_CYP1A2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 859, + "assayComponentName": "CLD_CYP1A2_24hr", + "assayComponentDesc": "CLD_CYP1A2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1633, + "assayComponentEndpointName": "CLD_CYP2B6_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 860, + "assayComponentName": "CLD_CYP2B6_24hr", + "assayComponentDesc": "CLD_CYP2B6_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1634, + "assayComponentEndpointName": "CLD_CYP2C19_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_24hr was analyzed at the endpoint, CLD_CYP2C19_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 861, + "assayComponentName": "CLD_CYP2C19_24hr", + "assayComponentDesc": "CLD_CYP2C19_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1635, + "assayComponentEndpointName": "CLD_CYP2C9_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_24hr was analyzed at the endpoint, CLD_CYP2C9_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 862, + "assayComponentName": "CLD_CYP2C9_24hr", + "assayComponentDesc": "CLD_CYP2C9_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1636, + "assayComponentEndpointName": "CLD_CYP3A4_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 863, + "assayComponentName": "CLD_CYP3A4_24hr", + "assayComponentDesc": "CLD_CYP3A4_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1637, + "assayComponentEndpointName": "CLD_GAPDH_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_24hr was analyzed at the endpoint, CLD_GAPDH_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 864, + "assayComponentName": "CLD_GAPDH_24hr", + "assayComponentDesc": "CLD_GAPDH_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1638, + "assayComponentEndpointName": "CLD_GSTA2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_24hr was analyzed at the endpoint, CLD_GSTA2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 865, + "assayComponentName": "CLD_GSTA2_24hr", + "assayComponentDesc": "CLD_GSTA2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1639, + "assayComponentEndpointName": "CLD_HMGCS2_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_24hr was analyzed at the endpoint, CLD_HMGCS2_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 866, + "assayComponentName": "CLD_HMGCS2_24hr", + "assayComponentDesc": "CLD_HMGCS2_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1640, + "assayComponentEndpointName": "CLD_SLCO1B1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_24hr was analyzed at the endpoint, CLD_SLCO1B1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 867, + "assayComponentName": "CLD_SLCO1B1_24hr", + "assayComponentDesc": "CLD_SLCO1B1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1641, + "assayComponentEndpointName": "CLD_SULT2A_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_24hr was analyzed at the endpoint, CLD_SULT2A_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 868, + "assayComponentName": "CLD_SULT2A_24hr", + "assayComponentDesc": "CLD_SULT2A_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1642, + "assayComponentEndpointName": "CLD_UGT1A1_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_24hr was analyzed at the endpoint, CLD_UGT1A1_24hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 869, + "assayComponentName": "CLD_UGT1A1_24hr", + "assayComponentDesc": "CLD_UGT1A1_24hr is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 400, + "assayName": "CLD_24hr", + "assayDesc": "CLD_24hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1643, + "assayComponentEndpointName": "CLD_ABCB1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB1_48hr was analyzed at the endpoint, CLD_ABCB1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 870, + "assayComponentName": "CLD_ABCB1_48hr", + "assayComponentDesc": "CLD_ABCB1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1644, + "assayComponentEndpointName": "CLD_ABCB11_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCB11_48hr was analyzed at the endpoint, CLD_ABCB11_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 871, + "assayComponentName": "CLD_ABCB11_48hr", + "assayComponentDesc": "CLD_ABCB11_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCB11 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1645, + "assayComponentEndpointName": "CLD_ABCG2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ABCG2_48hr was analyzed at the endpoint, CLD_ABCG2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 872, + "assayComponentName": "CLD_ABCG2_48hr", + "assayComponentDesc": "CLD_ABCG2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ABCG2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1646, + "assayComponentEndpointName": "CLD_ACTIN_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_ACTIN_48hr was analyzed at the endpoint, CLD_ACTIN_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 873, + "assayComponentName": "CLD_ACTIN_48hr", + "assayComponentDesc": "CLD_ACTIN_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "ACTIN qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 7, + "geneName": "actin, beta", + "description": null, + "geneSymbol": "ACTB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 60, + "officialSymbol": "ACTB", + "officialFullName": "actin, beta", + "uniprotAccessionNumber": "P60709" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1647, + "assayComponentEndpointName": "CLD_CYP1A1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A1_48hr was analyzed at the endpoint, CLD_CYP1A1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 874, + "assayComponentName": "CLD_CYP1A1_48hr", + "assayComponentDesc": "CLD_CYP1A1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1648, + "assayComponentEndpointName": "CLD_CYP1A2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP1A2_48hr was analyzed at the endpoint, CLD_CYP1A2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 875, + "assayComponentName": "CLD_CYP1A2_48hr", + "assayComponentDesc": "CLD_CYP1A2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP1A2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1649, + "assayComponentEndpointName": "CLD_CYP2B6_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 876, + "assayComponentName": "CLD_CYP2B6_48hr", + "assayComponentDesc": "CLD_CYP2B6_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2B6 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1650, + "assayComponentEndpointName": "CLD_CYP2C19_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C19_48hr was analyzed at the endpoint, CLD_CYP2C19_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 877, + "assayComponentName": "CLD_CYP2C19_48hr", + "assayComponentDesc": "CLD_CYP2C19_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C19 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1651, + "assayComponentEndpointName": "CLD_CYP2C9_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP2C9_48hr was analyzed at the endpoint, CLD_CYP2C9_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 878, + "assayComponentName": "CLD_CYP2C9_48hr", + "assayComponentDesc": "CLD_CYP2C9_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP2C9 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1652, + "assayComponentEndpointName": "CLD_CYP3A4_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 879, + "assayComponentName": "CLD_CYP3A4_48hr", + "assayComponentDesc": "CLD_CYP3A4_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "CYP3A4 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1653, + "assayComponentEndpointName": "CLD_GAPDH_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GAPDH_48hr was analyzed at the endpoint, CLD_GAPDH_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 880, + "assayComponentName": "CLD_GAPDH_48hr", + "assayComponentDesc": "CLD_GAPDH_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GAPDH qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 138, + "geneName": "glyceraldehyde-3-phosphate dehydrogenase", + "description": null, + "geneSymbol": "GAPDH", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2597, + "officialSymbol": "GAPDH", + "officialFullName": "glyceraldehyde-3-phosphate dehydrogenase", + "uniprotAccessionNumber": "P04406" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1654, + "assayComponentEndpointName": "CLD_GSTA2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_GSTA2_48hr was analyzed at the endpoint, CLD_GSTA2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "alkyl and aryl transferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 881, + "assayComponentName": "CLD_GSTA2_48hr", + "assayComponentDesc": "CLD_GSTA2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "GSTA2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 147, + "geneName": "glutathione S-transferase alpha 2", + "description": null, + "geneSymbol": "GSTA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2939, + "officialSymbol": "GSTA2", + "officialFullName": "glutathione S-transferase alpha 2", + "uniprotAccessionNumber": "P09210" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1655, + "assayComponentEndpointName": "CLD_HMGCS2_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_HMGCS2_48hr was analyzed at the endpoint, CLD_HMGCS2_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "HMG-CoA synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 882, + "assayComponentName": "CLD_HMGCS2_48hr", + "assayComponentDesc": "CLD_HMGCS2_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "HMGCS2 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 154, + "geneName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "description": null, + "geneSymbol": "HMGCS2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3158, + "officialSymbol": "HMGCS2", + "officialFullName": "3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)", + "uniprotAccessionNumber": "P54868" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1656, + "assayComponentEndpointName": "CLD_SLCO1B1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SLCO1B1_48hr was analyzed at the endpoint, CLD_SLCO1B1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "organic anion transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 883, + "assayComponentName": "CLD_SLCO1B1_48hr", + "assayComponentDesc": "CLD_SLCO1B1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SLCO1B1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 367, + "geneName": "solute carrier organic anion transporter family, member 1B1", + "description": null, + "geneSymbol": "SLCO1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10599, + "officialSymbol": "SLCO1B1", + "officialFullName": "solute carrier organic anion transporter family, member 1B1", + "uniprotAccessionNumber": "Q9Y6L6" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1657, + "assayComponentEndpointName": "CLD_SULT2A_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_SULT2A_48hr was analyzed at the endpoint, CLD_SULT2A_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "sulfotransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 884, + "assayComponentName": "CLD_SULT2A_48hr", + "assayComponentDesc": "CLD_SULT2A_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "SULT2A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 307, + "geneName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "description": null, + "geneSymbol": "SULT2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6822, + "officialSymbol": "SULT2A1", + "officialFullName": "sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1", + "uniprotAccessionNumber": "Q06520" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1658, + "assayComponentEndpointName": "CLD_UGT1A1_48hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CLD_UGT1A1_48hr was analyzed at the endpoint, CLD_UGT1A1_48hr, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "gain", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transferase", + "intendedTargetFamilySub": "glucuronosyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 885, + "assayComponentName": "CLD_UGT1A1_48hr", + "assayComponentDesc": "CLD_UGT1A1_48hr is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": null, + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "Quantitative Nuclease Protection Assay (qNPA)", + "keyAssayReagentType": "coupled substrate", + "keyAssayReagent": "UGT1A1 qNPA probes", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 401, + "assayName": "CLD_48hr", + "assayDesc": "CLD_48hr is a cell-based, multiplexed-readout assay that uses hepatocyte, a human liver primary cell, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "primary cell", + "cellFreeComponentSource": "", + "cellShortName": "hepatocyte", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 11, + "assaySourceName": "CLD", + "assaySourceLongName": "CellzDirect", + "assaySourceDesc": "Formerly CellzDirect, this Contract Research Organization (CRO) is now part of the Invitrogen brand of Thermo Fisher providing cell-based in vitro assay screening services using primary hepatocytes.", + "gene": { + "geneId": 430, + "geneName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "description": null, + "geneSymbol": "UGT1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 54658, + "officialSymbol": "UGT1A1", + "officialFullName": "UDP glucuronosyltransferase 1 family, polypeptide A1", + "uniprotAccessionNumber": "P22309" + }, + "assayList": null, + "citations": { + "doi": " doi: 10.1080/10937404.2010.483949", + "url": "https://pubmed.ncbi.nlm.nih.gov/20574906/", + "pmid": 20574906, + "title": "Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals", + "author": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS", + "citation": "Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949. PMID: 20574906.", + "otherId": "0", + "citationId": 246, + "otherSource": "" + } + }, + { + "aeid": 1659, + "assayComponentEndpointName": "TOX21_RAR_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Retinol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1013, + "assayComponentName": "TOX21_RAR_LUC_Agonist", + "assayComponentDesc": "TOX21_RAR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RAR_LUC_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha [GeneSymbol:RARA]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 425, + "assayName": "TOX21_RAR_LUC_Agonist", + "assayDesc": "TOX21_RAR_LUC_Agonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1660, + "assayComponentEndpointName": "TOX21_RAR_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1014, + "assayComponentName": "TOX21_RAR_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_RAR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 425, + "assayName": "TOX21_RAR_LUC_Agonist", + "assayDesc": "TOX21_RAR_LUC_Agonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1661, + "assayComponentEndpointName": "TOX21_RORg_LUC_CHO_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TO-901317", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1015, + "assayComponentName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayComponentDesc": "TOX21_RORg_LUC_CHO_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RORg_LUC_CHO_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RORg_LUC_CHO_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoid-related orphan receptor gamma [GeneSymbol:NR1F3]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 426, + "assayName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayDesc": "TOX21_RORg_LUC_CHO_Antagonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 17 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 17.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 286, + "geneName": "RAR-related orphan receptor C", + "description": null, + "geneSymbol": "RORC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6097, + "officialSymbol": "RORC", + "officialFullName": "RAR-related orphan receptor C", + "uniprotAccessionNumber": "P51449" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1662, + "assayComponentEndpointName": "TOX21_RORg_LUC_CHO_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1016, + "assayComponentName": "TOX21_RORg_LUC_CHO_Antagonist_viability", + "assayComponentDesc": "TOX21_RORg_LUC_CHO_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTox Green", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 426, + "assayName": "TOX21_RORg_LUC_CHO_Antagonist", + "assayDesc": "TOX21_RORg_LUC_CHO_Antagonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 17 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 17.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1664, + "assayComponentEndpointName": "CEETOX_H295R_MTT_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CEETOX_H295R_MTT_cell_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter in the MTT cytotoxicity assay, gain or loss-of-signal activity can be used to monitor cellular processes to understand changes in proliferation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1017, + "assayComponentName": "CEETOX_H295R_MTT_cell_viability", + "assayComponentDesc": "CEETOX_H295R_MTT_cell_viability is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by MTT cytotoxicity assay technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "MTT cytotoxicity assay", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MTT reagent", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": null, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 1682, + "assayComponentEndpointName": "STM_H9_CystineISnorm_perc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_CystineISnorm_perc was analyzed at the assay endpoint STM_H9_CystineISnorm_perc in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Cystine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1027, + "assayComponentName": "STM_H9_CystineISnorm_perc", + "assayComponentDesc": "STM_H9_CystineISnorm_perc is one of 10 components calculated in the STM_H9_secretome assay. It measures the integrated area of the endogenous cystine normalized to the spiked-in isotopically labeled standard and to the median value of the 0.1% DMSO neutral control treatment using UPLC-HRMS technology.", + "assayComponentTargetDesc": "Changes in cystine utilization relative to the neutral control.", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "metabolite detection", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "integrated area of the endogenous cystine normalized to the spiked-in isotopically labeled standard normalized the median value of the 0.1% DMSO neutral control treatment ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "cystine/C13Cystine/DMSO", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "cystine/C13Cystine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1688, + "assayComponentEndpointName": "STM_H9_OrnithineISnorm_perc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Ornithine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1030, + "assayComponentName": "STM_H9_OrnithineISnorm_perc", + "assayComponentDesc": "STM_H9_OrnithineISnorm is one of 10 components calculated in the STM_H9_secretome assay. It measures the integrated area of the endogenous ornithine normalized to the spiked-in isotopically labeled standard and to the median value of the 0.1% DMSO neutral control treatment using UPLC-HRMS technology.", + "assayComponentTargetDesc": "Changes in ornithine release relative to the neutral control. ", + "parameterReadoutType": "single", + "assayDesignType": "biochemical reporter", + "assayDesignTypeSub": "metabolite detection", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "integrated area of the endogenous ornithine normalized to the spiked-in isotopically labeled standard normalized the median value of the 0.1% DMSO neutral control treatment ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Ornithine/C13Ornithine/DMSO", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "ornithine/C13Ornithine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1690, + "assayComponentEndpointName": "STM_H9_OrnCyssISnorm_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_OrnCyssISnorm_ratio was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_ratio in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain or loss-of-signal activity can be used to understand relative metabolite change.", + "assayFunctionType": "relative metabolite change", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Methotrexate", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "secretome metabolite", + "intendedTargetFamily": "metabolite", + "intendedTargetFamilySub": "Ornithine/Cystine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1031, + "assayComponentName": "STM_H9_OrnCyssISnorm_ratio", + "assayComponentDesc": "STM_H9_OrnCyssISnorm_ratio is one of 10 components calculated in the STM_H9_secretome assay. It is the ratio value of OrnISnorm_perc to CyssISnorm_perc.", + "assayComponentTargetDesc": "Change in the ratio value of Orn release to Cyss utilization, indicative of the targeted biomarker of the assay. ", + "parameterReadoutType": "single", + "assayDesignType": "ratiometric", + "assayDesignTypeSub": "metabolite ratio", + "biologicalProcessTarget": "metabolism", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Orn:Cyss ratio calculated from DMSO-normalized values ", + "detectionTechnology": "UPLC-HRMS", + "keyAssayReagentType": "ratio", + "keyAssayReagent": "ornithine/cystine", + "technologicalTargetType": "metabolite", + "technologicalTargetTypeSub": "ornithine/cystine", + "aid": 428, + "assayName": "STM_H9_secretome", + "assayDesc": "STM_H9_secretome utilizes undifferentiated H9 cells to measure relative changes in two metabolites, ornithine (ORN) and cystine (CYSS) in the secretome, targeting a critical drop in the ORN/CYSS ratio as a biomarker for developmental toxicity.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 1744, + "assayComponentEndpointName": "NVS_ENZ_hPPP3CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP3CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP3CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP3CA.\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1034, + "assayComponentName": "NVS_ENZ_hPPP3CA", + "assayComponentDesc": "NVS_ENZ_hPPP3CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP3CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 3, catalytic subunit, alpha isozyme [GeneSymbol:PPP3CA | GeneID:5530 |.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 429, + "assayName": "NVS_ENZ_hPPP3CA", + "assayDesc": "NVS_ENZ_hPPP3CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5655, + "geneName": "protein phosphatase 3 catalytic subunit alpha", + "description": null, + "geneSymbol": "PPP3CA", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 5530, + "officialSymbol": "PPP3CA", + "officialFullName": "protein phosphatase 3 catalytic subunit alpha", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1746, + "assayComponentEndpointName": "ATG_GPCR_ADORA2A_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADORA2A_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1035, + "assayComponentName": "ATG_GPCR_ADORA2A_TRANS", + "assayComponentDesc": "ATG_GPCR_ADORA2A_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADORA2A, which is responsive to the adenosine A2a receptor [GeneSymbol:ADORA2A| GeneID:135 | Uniprot_SwissProt_Accession:P29274].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADORA2A RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1748, + "assayComponentEndpointName": "ATG_GPCR_ADORA2B_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADORA2B_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1036, + "assayComponentName": "ATG_GPCR_ADORA2B_TRANS", + "assayComponentDesc": "ATG_GPCR_ADORA2B_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADORA2B, which is responsive to the adenosine A2b receptor [GeneSymbol:ADORA2B| GeneID:136 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADORA2B RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 482, + "geneName": "adenosine A2b receptor", + "description": null, + "geneSymbol": "ADORA2B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 136, + "officialSymbol": "ADORA2B", + "officialFullName": "adenosine A2b receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1750, + "assayComponentEndpointName": "ATG_GPCR_ADRA1A_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRA1A_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1037, + "assayComponentName": "ATG_GPCR_ADRA1A_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRA1A_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRA1A, which is responsive to the adrenoceptor alpha 1A. [GeneSymbol:ADRA1A| GeneID:148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRA1A RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 483, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "ADRA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 148, + "officialSymbol": "ADRA1A", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1752, + "assayComponentEndpointName": "ATG_GPCR_ADRA2B_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRA2B_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1038, + "assayComponentName": "ATG_GPCR_ADRA2B_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRA2B_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRA2B, which is responsive to the adrenoceptor alpha 2B. [GeneSymbol:ADRA2B| GeneID:151 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRA2B RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 484, + "geneName": "adrenoceptor alpha 2B", + "description": null, + "geneSymbol": "ADRA2B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 151, + "officialSymbol": "ADRA2B ", + "officialFullName": "adrenoceptor alpha 2B", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1754, + "assayComponentEndpointName": "ATG_GPCR_ADRB2_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRB2_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1039, + "assayComponentName": "ATG_GPCR_ADRB2_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRB2_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRB2, which is responsive to the adrenoceptor beta 2, surface. [GeneSymbol:ADRB2| GeneID:154 | Uniprot_SwissProt_Accession: P07550].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRB2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1756, + "assayComponentEndpointName": "ATG_GPCR_ADRB3_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_ADRB3_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1040, + "assayComponentName": "ATG_GPCR_ADRB3_TRANS", + "assayComponentDesc": "ATG_GPCR_ADRB3_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene ADRB3, which is responsive to the adrenoceptor beta 3. [GeneSymbol:ADRB3| GeneID:155 | Uniprot_SwissProt_Accession: P13945].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ADRB3 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1758, + "assayComponentEndpointName": "ATG_GPCR_CHRM3_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_CHRM3_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CHRM3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1041, + "assayComponentName": "ATG_GPCR_CHRM3_TRANS", + "assayComponentDesc": "ATG_GPCR_CHRM3_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene CHRM3, which is responsive to the cholinergic receptor, muscarinic 3. [GeneSymbol:CHRM3| GeneID:1131 | Uniprot_SwissProt_Accession: P20309].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CHRM3 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1760, + "assayComponentEndpointName": "ATG_GPCR_DRD1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_DRD1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1042, + "assayComponentName": "ATG_GPCR_DRD1_TRANS", + "assayComponentDesc": "ATG_GPCR_DRD1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene DRD1, which is responsive to the dopamine receptor D1. [GeneSymbol:DRD1| GeneID:1812 | Uniprot_SwissProt_Accession: P21728].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "DRD1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1762, + "assayComponentEndpointName": "ATG_GPCR_DRD5_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_DRD5_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD5. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1043, + "assayComponentName": "ATG_GPCR_DRD5_TRANS", + "assayComponentDesc": "ATG_GPCR_DRD5_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene DRD5, which is responsive to the dopamine receptor D5. [GeneSymbol:DRD5| GeneID:1816 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "DRD5 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 485, + "geneName": "dopamine receptor D5", + "description": null, + "geneSymbol": "DRD5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1816, + "officialSymbol": "DRD5", + "officialFullName": "dopamine receptor D5", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1764, + "assayComponentEndpointName": "ATG_GPCR_EDNRA_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_EDNRA_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EDNRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1044, + "assayComponentName": "ATG_GPCR_EDNRA_TRANS", + "assayComponentDesc": "ATG_GPCR_EDNRA_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene EDNRA, which is responsive to the endothelin receptor type A. [GeneSymbol:EDNRA| GeneID: 1909 | Uniprot_SwissProt_Accession: P25101].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "EDNRA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 105, + "geneName": "endothelin receptor type A", + "description": null, + "geneSymbol": "EDNRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1909, + "officialSymbol": "EDNRA", + "officialFullName": "endothelin receptor type A", + "uniprotAccessionNumber": "P25101" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1766, + "assayComponentEndpointName": "ATG_GPCR_GCGR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GCGR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GCGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1045, + "assayComponentName": "ATG_GPCR_GCGR_TRANS", + "assayComponentDesc": "ATG_GPCR_GCGR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GCGR, which is responsive to the glucagon receptor. [GeneSymbol: GCGR| GeneID: 2642 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GCGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 486, + "geneName": "glucagon receptor", + "description": null, + "geneSymbol": "GCGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2642, + "officialSymbol": "GCGR", + "officialFullName": "glucagon receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1768, + "assayComponentEndpointName": "ATG_GPCR_GPBAR1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GPBAR1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPBAR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1046, + "assayComponentName": "ATG_GPCR_GPBAR1_TRANS", + "assayComponentDesc": "ATG_GPCR_GPBAR1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GPBAR1, which is responsive to the G protein-coupled bile acid receptor 1. [GeneSymbol: GPBAR1| GeneID: 1501306 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GPBAR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 487, + "geneName": "G protein-coupled bile acid receptor 1", + "description": null, + "geneSymbol": "GPBAR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 151306, + "officialSymbol": "GPBAR1", + "officialFullName": "G protein-coupled bile acid receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1770, + "assayComponentEndpointName": "ATG_GPCR_GPR40_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GPR40_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPR40. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1047, + "assayComponentName": "ATG_GPCR_GPR40_TRANS", + "assayComponentDesc": "ATG_GPCR_GPR40_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene FFAR1, which is responsive to the free fatty acid receptor 1. [GeneSymbol: FFAR1| GeneID: 2864 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GPR40 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 488, + "geneName": "free fatty acid receptor 1", + "description": null, + "geneSymbol": "FFAR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2864, + "officialSymbol": "FFAR1", + "officialFullName": "free fatty acid receptor 1", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1772, + "assayComponentEndpointName": "ATG_GPCR_GQ_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GQ_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAQ. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1048, + "assayComponentName": "ATG_GPCR_GQ_TRANS", + "assayComponentDesc": "ATG_GPCR_GQ_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAQ, which is responsive to the G protein subunit alpha q. [GeneSymbol: GNAQ| GeneID: 2776 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GQ RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3599, + "geneName": "G protein subunit alpha q", + "description": null, + "geneSymbol": "GNAQ", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2776, + "officialSymbol": "GNAQ", + "officialFullName": "G protein subunit alpha q", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1774, + "assayComponentEndpointName": "ATG_GPCR_GS1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GS1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1049, + "assayComponentName": "ATG_GPCR_GS1_TRANS", + "assayComponentDesc": "ATG_GPCR_GS1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAS, which is responsive to the GNAS complex locus. [GeneSymbol: GNAS| GeneID: 2778 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GS1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3601, + "geneName": "GNAS complex locus", + "description": null, + "geneSymbol": "GNAS", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2778, + "officialSymbol": "GNAS", + "officialFullName": "GNAS complex locus", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1776, + "assayComponentEndpointName": "ATG_GPCR_GS_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_GS_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1050, + "assayComponentName": "ATG_GPCR_GS_TRANS", + "assayComponentDesc": "ATG_GPCR_GS_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene GNAS, which is responsive to the GNAS complex locus. [GeneSymbol: GNAS| GeneID: 2778 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GS RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 3601, + "geneName": "GNAS complex locus", + "description": null, + "geneSymbol": "GNAS", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 2778, + "officialSymbol": "GNAS", + "officialFullName": "GNAS complex locus", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1778, + "assayComponentEndpointName": "ATG_GPCR_HRH1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HRH1_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HRH1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1051, + "assayComponentName": "ATG_GPCR_HRH1_TRANS", + "assayComponentDesc": "ATG_GPCR_HRH1_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HRH1, which is responsive to the histamine receptor H1. [GeneSymbol: HRH1| GeneID: 3269 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HRH1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1780, + "assayComponentEndpointName": "ATG_GPCR_HTR6_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HTR6_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1052, + "assayComponentName": "ATG_GPCR_HTR6_TRANS", + "assayComponentDesc": "ATG_GPCR_HTR6_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HTR6, which is responsive to the 5-hydroxytryptamine (serotonin) receptor 6, G. [GeneSymbol: HTR6| GeneID: 3362 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HTR6 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1782, + "assayComponentEndpointName": "ATG_GPCR_HTR7_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_HTR7_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR7. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1053, + "assayComponentName": "ATG_GPCR_HTR7_TRANS", + "assayComponentDesc": "ATG_GPCR_HTR7_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene HTR7, which is responsive to the 5-hydroxytryptamine (serotonin) receptor 7. [GeneSymbol: HTR7| GeneID: 3363 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HTR7 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1784, + "assayComponentEndpointName": "ATG_GPCR_LPAR4_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_LPAR4_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene LPAR4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1054, + "assayComponentName": "ATG_GPCR_LPAR4_TRANS", + "assayComponentDesc": "ATG_GPCR_LPAR4_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene LPAR4, which is responsive to the lysophosphatidic acid receptor 4. [GeneSymbol: LPAR4| GeneID: 2846 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "LPAR4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 489, + "geneName": "lysophosphatidic acid receptor 4", + "description": null, + "geneSymbol": "LPAR4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2846, + "officialSymbol": "LPAR4", + "officialFullName": "lysophosphatidic acid receptor 4", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2452, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_Apoptosis_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "apoptosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2446, + "assayComponentName": "CCTE_Harrill_HTTr_Apoptosis_MCF7", + "assayComponentDesc": "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a full screening experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", + "assayComponentTargetDesc": "Caspase 3/7 kit", + "parameterReadoutType": "multiplexed", + "assayDesignType": "apoptosis reporter", + "assayDesignTypeSub": "Caspase 3/7 activity", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellEvent Caspase 3/7 Green detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "caspase", + "aid": 666, + "assayName": "CCTE_Harrill_HTTr_Apoptosis", + "assayDesc": "This is a cell-based assay that evaluates apoptosis using high content imaging to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2244, + "assayComponentEndpointName": "TOX21_TRB_COA_Agonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2305, + "assayComponentName": "TOX21_TRB_COA_Agonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_COA_Agonist_Followup_ratio is assay component calculated in the TOX21_TRB_COA_Agonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the agonist to the TR causes a conformational change that results in an increase in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 650, + "assayName": "TOX21_TRB_COA_Agonist_Followup", + "assayDesc": "TOX21_TRb_COA_Agonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2245, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2306, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ch1", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ch1 is an assay readout measuring emission signals generated by coactivator recruitment. The ch1 signal is derived from donor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2246, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2307, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ch2", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ch2 is an assay readout measuring emission signals generated by coactivator (SRC-2) recruitment. The ch2 signal is derived from acceptor emission and is used to calculate TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1).", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2247, + "assayComponentEndpointName": "TOX21_TRB_COA_Antagonist_Followup_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2308, + "assayComponentName": "TOX21_TRB_COA_Antagonist_Followup_ratio", + "assayComponentDesc": "TOX21_TRB_COA_Antagonist_Followup_ratio is assay component calculated in the TOX21_TRB_COA_Antagonist_Followup assay. The TR-FRET ratio of acceptor emission (ch2) to donor emission (ch1) is indicative of the resonance energy transfer to the fluorescein tag on the coactivator peptide following recruitment to the receptor.", + "assayComponentTargetDesc": "Terbium-labeled anti-GST antibody indirectly labels TR by binding to the GST tag. Binding of the antagonist to the TR causes a conformational change that results in an decrease in the affinity of the TR for a coactivator peptide. The close proximity of the fluorescein-labeled SRC-2 coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "coactivator recruitment", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescein-labeled SRC-2 coactivator peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 651, + "assayName": "TOX21_TRB_COA_Antagonist_Followup", + "assayDesc": "TOX21_TRb_COA_Antagonist_Followup is a secondary assay for specificity for the TOX21_TR_GH3_LUC_Agonist assay. The LanthaScreen TR-FRET TR coactivator assay kits were used to determine TR activity in a cell-free functional assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-free", + "assayFormatTypeSub": "cell-free format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 322, + "geneName": "thyroid hormone receptor, beta", + "description": null, + "geneSymbol": "THRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7068, + "officialSymbol": "THRB", + "officialFullName": "thyroid hormone receptor, beta", + "uniprotAccessionNumber": "P10828" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1289/EHP5314", + "url": "https://pubmed.ncbi.nlm.nih.gov/31566444/", + "pmid": 31566444, + "title": "Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library", + "author": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA", + "citation": "Paul-Friedman K, Martin M, Crofton KM, Hsu CW, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, Varticovski L, Raziuddin R, Hager GL, Houck KA. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30. PMID: 31566444; PMCID: PMC6792352.", + "otherId": "0", + "citationId": 249, + "otherSource": "" + } + }, + { + "aeid": 2453, + "assayComponentEndpointName": "CCTE_Harrill_HTTr_CellCount_MCF7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay component endpoint CCTE_Harrill_HTTr_CellCount_MCF7 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in cell count. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cell count.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM N6", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2444, + "assayComponentName": "CCTE_Harrill_HTTr_CellCount_MCF7", + "assayComponentDesc": "This is a cell-based assay that evaluates cell viability and cell growth in MCF-7 cells. This was part of a full screening experiment. High content imaging is used to count the number of Hoechst-labeled nuclei that are present in an assay well in 384-well format.", + "assayComponentTargetDesc": "Count of Hoechst-labeled nuclei indicates live cell number", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "nucleus", + "aid": 683, + "assayName": "CCTE_Harrill_HTTr_CellCount", + "assayDesc": "This is a cell-based assay that evaluates cell viability and cell growth using high content imaging to count the number of Hoechst-labeled nuclei that are present in an assay well in 384-well format.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": null, + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfab009", + "url": "https://pubmed.ncbi.nlm.nih.gov/33538836/", + "pmid": 33538836, + "title": "High-Throughput Transcriptomics Platform for Screening Environmental Chemicals", + "author": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS", + "citation": "Harrill JA, Everett LJ, Haggard DE, Sheffield T, Bundy JL, Willis CM, Thomas RS, Shah I, Judson RS. High-Throughput Transcriptomics Platform for Screening Environmental Chemicals. Toxicol Sci. 2021 Apr 27;181(1):68-89. doi: 10.1093/toxsci/kfab009. PMID: 33538836.", + "otherId": "0", + "citationId": 265, + "otherSource": "" + } + }, + { + "aeid": 2454, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_spike_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrodotoxin", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2447, + "assayComponentName": "CCTE_Shafer_MEA_acute_spike_number", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_spike_number is a component of the CCTE_Shafer_MEA_acute assay. It measures the total number of spikes (action potential firings) in a 40-minute recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the spike number in each well. ", + "assayComponentTargetDesc": "The number of spikes is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2456, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_firing_rate_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetrodotoxin", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2448, + "assayComponentName": "CCTE_Shafer_MEA_acute_firing_rate_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_firing_rate_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the frequency number of spikes (action potential firings) as the total number of spikes divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The firing rate is divided by the number of electrodes to report a well-mean value. The recordings before and after chemical treatment are used to calculate a percent change in the mean firing rate in each well.", + "assayComponentTargetDesc": "The mean firing rate is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2458, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2449, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_number", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_number is a component of the CCTE_Shafer_MEA_acute assay. It measures the total number of single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the burst number in each well.", + "assayComponentTargetDesc": "The number of bursts is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2460, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2450, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_duration_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average time from the first spike (action potential firing) to the last spike in a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean burst duration in each well.", + "assayComponentTargetDesc": "The mean burst duration is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 90, + "assayComponentEndpointName": "ATG_M_61_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_61_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_61_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 59, + "assayComponentName": "ATG_M_61_CIS", + "assayComponentDesc": "ATG_M_61_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 2462, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_burst_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_burst_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2451, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_burst_spike_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of spikes (action potential firings) in a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of spikes per burst in each well.", + "assayComponentTargetDesc": "The mean number of spikes in a burst is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2464, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_interburst_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_interburst_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_interburst_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2452, + "assayComponentName": "CCTE_Shafer_MEA_acute_interburst_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_interburst_interval_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average time between the start of consecutive single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean inter-burst interval in each well.", + "assayComponentTargetDesc": "The mean inter-burst interval is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2466, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_percentage_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2453, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_percentage_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_percentage_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the percentage of spikes (action potential firing) in a single-electrode burst (temporally-clustered groups of spikes) as the number of spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The average of the burst percentages across electrodes is calculated to report a well-level value. The recordings before and after chemical treatment are used to calculate a percent change in the mean burst percentage in each well.", + "assayComponentTargetDesc": "The mean percent of spikes in bursts is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2468, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_burst_percentage_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2454, + "assayComponentName": "CCTE_Shafer_MEA_acute_burst_percentage_std", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_burst_percentage_std is a component of the CCTE_Shafer_MEA_acute assay. It measures the percentage of spikes (action potential firing) in a single-electrode burst (temporally-clustered groups of spikes) as the number of spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The standard deviation of the burst percentages across electrodes is calculated to report a well-level value. The recordings before and after chemical treatment are used to calculate a percent change in the standard deviation of the burst percentage in each well.", + "assayComponentTargetDesc": "The standard deviation of the percent of spikes in bursts is a measure of bursting activity in a neural network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2470, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2455, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of spikes (action potential firings) in a network burst (temporally-clustered group of spikes across multiple electrodes) as the total number of spikes in a network burst divided by the number of network bursts during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of spikes in a network burst in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the mean number of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2472, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2456, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std is a component of the CCTE_Shafer_MEA_acute assay. It measures the standard deviation of the number of spikes (action potential firings) in a network burst (temporally-clustered group of spikes across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the standard deviation of the number of spikes in network bursts in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the standard deviation of the number of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2474, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2457, + "assayComponentName": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean is a component of the CCTE_Shafer_MEA_acute assay. It measures the average number of electrodes with activity during a network burst (a temporally-clustered group of action potential firing across multiple electrodes) in a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the mean number of electrodes participating in network bursts in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the average number of electrodes participating in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2476, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_network_burst_percentage", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_network_burst_percentage was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_network_burst_percentage, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2458, + "assayComponentName": "CCTE_Shafer_MEA_acute_network_burst_percentage", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_network_burst_percentage is a component of the CCTE_Shafer_MEA_acute assay. It measures the percent of spikes (action potential firings) in network bursts (temporally-clustered groups of spikes across multiple electrodes) as the number of spikes occuring in network bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the network burst percentage in each well.", + "assayComponentTargetDesc": "Networks bursts occur as the result of network connectivity. Changes in the percent of spikes in a network burst are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2478, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_cross_correlation_area", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2459, + "assayComponentName": "CCTE_Shafer_MEA_acute_cross_correlation_area", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_cross_correlation_area is a component of the CCTE_Shafer_MEA_acute assay. It measures the area under the well-wide pooled inter-electrode cross-correlation of action potential firing (not normalized to auto-correlations) within a window centered around 0 for the phase lag during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the cross correlation area in each well.", + "assayComponentTargetDesc": "The cross correlation area is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2480, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2460, + "assayComponentName": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_cross_correlation_HWHM is a component of the CCTE_Shafer_MEA_acute assay. It measures the distance along the x-axis (phase lag) from the left half maximum height to the center of the cross-correlogram of action potential firing during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. Smaller values indicate a narrower correlogram (greater synchrony). The recordings before and after chemical treatment are used to calculate a percent change in the half width at half maximum of the cross-correlogram in each well.", + "assayComponentTargetDesc": "The half width at half maximum of the cross-correlogram is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2482, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_synchrony_index", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neuroactivity", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2461, + "assayComponentName": "CCTE_Shafer_MEA_acute_synchrony_index", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_synchrony_index is a component of the CCTE_Shafer_MEA_acute assay. It measures the synchrony of the neural network as a unitless measure between 0 (low synchrony) to 1 (high synchrony) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The recordings before and after chemical treatment are used to calculate a percent change in the synchrony index in each well.", + "assayComponentTargetDesc": "The synchrony index is a measure of the synchrony of a neural network. Changes in the synchrony are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2484, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_LUC_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Active, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2462, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_LUC_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Active was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2485, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_CTox_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Active, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2463, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_CTox_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Active is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2486, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Inactive, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2464, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_LUC_Inactive was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2487, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Inactive, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2465, + "assayComponentName": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_96WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_96WELL_CTox_Inactive is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 684, + "assayName": "CCTE_Deisenroth_AIME_96WELL", + "assayDesc": "CCTE_Deisenroth_AIME_96WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2488, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Active, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2466, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Active was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2489, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_CTox_Active", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Active, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2467, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_CTox_Active", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Active is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2490, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Inactive, was analyzed in the positive analysis fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2468, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Inactive was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2491, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Inactive, was analyzed with bidirectional fitting in the ERTA assay.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2469, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is one of four assay components measured or calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to make measurements of a protease substrate, a type of viabiliy indicator, as detected with substrate cleavage to a fluorescent probe in living cells.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_CTox_Inactive is designed to make measurements of a protease substrate [Gly-Phe-AFCoumarin], a type of viabiliy indicator. The non-flourescent substrate is enzymatically converted to a fluorescent probe in living cells. Changes in the signal are indicative of cytotoxicity. ", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "protease substrate", + "keyAssayReagent": "Gly-Phe-AFCoumarin", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "fluorogenic probe", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2492, + "assayComponentEndpointName": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates the shift in metabolism-dependent changes between positive (active) and negative (inactive) assay modes. The metabolic curve shift response is defined as the pairwise difference between the positive (AEID 2488) and negative (AEID 2490) normalized response values at each concentration for a given chemical across replicate experiments. The pairwise differences form the basis for a concentration-response curve. Standard curve fit analysis identfiied chemicals where the calculated shift was greater than the shift-derived baseline cutoff. A positive hit designation in this endpoint indicates a significant shift trend in the positive direction for bioactivation. ", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17beta-estradiol", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2470, + "assayComponentName": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift", + "assayComponentDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift is one of two analysis components calculated from the CCTE_Deisenroth_AIME_384WELL assay. It is designed to evaluate the shift in metabolism-dependent changes of the inducible luciferase reporter between positive (active) and negative (inactive) assay modes.", + "assayComponentTargetDesc": "CCTE_Deisenroth_AIME_384WELL_LUC_Shift was designed to measure the shift in bioluminescence signals produced from an enzymatic reaction involving the key substrate [Bright-Glo]between metabolism positive (active) and negative (inactive) assay modes. Shifts are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. Positive shifts are indicative of bioactivation.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of estrogen receptor activity", + "detectionTechnologyType": "Luminescense", + "detectionTechnologyTypeSub": "Luminescence intensity", + "detectionTechnology": "multimode microplate reader", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE linked luciferase reporter enzyme", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 685, + "assayName": "CCTE_Deisenroth_AIME_384WELL", + "assayDesc": "CCTE_Deisenroth_AIME_384WELL (AIME metabolism assay) is a cell-based, single-readout assay that uses VM7Luc4E2, a human mammary gland/breast cell line, with measurements taken at 24 hour after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "mammary gland/breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7Luc4E2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa147", + "url": "https://pubmed.ncbi.nlm.nih.gov/32991717/", + "pmid": 32991717, + "title": "The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence", + "author": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS", + "citation": "Deisenroth C, DeGroot DE, Zurlinden T, Eicher A, McCord J, Lee MY, Carmichael P, Thomas RS. The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence. Toxicol Sci. 2020 Dec 1;178(2):281-301. doi: 10.1093/toxsci/kfaa147. PMID: 32991717; PMCID: PMC8154005.", + "otherId": "0", + "citationId": 254, + "otherSource": "" + } + }, + { + "aeid": 2494, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_firing_rate_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2471, + "assayComponentName": "CCTE_Shafer_MEA_dev_firing_rate_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_firing_rate_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the frequency of spikes (action potential firings) as the total number of spikes divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The firing rate is averaged across the active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Mean firing rate is a measure of general activity in the network. Changes in electrical activity are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2496, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_burst_rate", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2472, + "assayComponentName": "CCTE_Shafer_MEA_dev_burst_rate", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_burst_rate is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the frequency of single-electrode bursts (temporally-clustered groups of action potential firing) as the total number of bursts divided by the length of the recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean bursting rate is averaged across the active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean bursting rate is a measure of general activity in the network. Changes in mean burst rate are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2498, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_active_electrodes_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2473, + "assayComponentName": "CCTE_Shafer_MEA_dev_active_electrodes_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_active_electrodes_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of electrodes in a well with a mean firing rate of at least 5 spikes (action potential firings) per minute during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of active electrodes is a measure of general activity in the network. Changes in the number of active electrodes are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2500, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_bursting_electrodes_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2474, + "assayComponentName": "CCTE_Shafer_MEA_dev_bursting_electrodes_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_bursting_electrodes_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of electrodes in a well with a burst rate of at least 1 burst (temporally-clustered group of action potential firing) every 2 minutes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of actively bursting electrodes is a measure of general activity in a network. Changes in the number of actively bursting electrodes are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2502, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2475, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_burst_interspike_interval is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between spikes (action potential firings) within a single-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean inter-spike interval within bursts is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The inter-spike interval within bursts is a measure of bursting activity in the network. Changes in the inter-spike interval within bursts are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2504, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_burst_spike_percent", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2476, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_burst_spike_percent", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_burst_spike_percent is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the percentage of spikes (action potential firings) in a single-electrode burst (temporally-clustered group of spikes) as the total number spikes in bursts divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The percent of spikes in bursts is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The percent of spikes in bursts is a measure of bursting activity in a network. Changes in the percent of spikes in bursts are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2506, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_burst_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2477, + "assayComponentName": "CCTE_Shafer_MEA_dev_burst_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_burst_duration_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval from the first spike (action potential firing) to the last spike in a singe-electrode burst (temporally-clustered group of spikes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean burst duration is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean burst duration is a measure of bursting activity in a network. Changes in the mean burst duration are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2508, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_interburst_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: bursting activity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2478, + "assayComponentName": "CCTE_Shafer_MEA_dev_interburst_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_interburst_interval_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between consecutive single-electrode bursts (temporally-clustered groups of action potential firing) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The mean inter-burst interval is averaged across the actively bursting electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean inter-burst interval is a measure of bursting activity in a network. Changes in the mean inter-burst interval are indicative of effects on the spontaneous neural activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "spontaneous neural activity ", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2510, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_number", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2479, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_number", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_number is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the number of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The number of network spikes is a measure of the network connectivity. Changes in the number of network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2512, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_peak", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2480, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_peak", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_peak is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average number of electrodes participating at the peak of a network spike (the peak of a temporally-clustered group of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The network spike peak is a measure of the network connectivity. Changes in the network spike peak are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2514, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_spike_duration_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2481, + "assayComponentName": "CCTE_Shafer_MEA_dev_spike_duration_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_spike_duration_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average duration of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean network spike duration is a measure of the network connectivity. Changes in the mean network spike duration are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 1786, + "assayComponentEndpointName": "ATG_GPCR_MC1R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC1R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC1R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1055, + "assayComponentName": "ATG_GPCR_MC1R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC1R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC1R, which is responsive to the melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC1R| GeneID: 4157 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC1R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 490, + "geneName": "melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)", + "description": null, + "geneSymbol": "MC1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4157, + "officialSymbol": "MC1R", + "officialFullName": "melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1788, + "assayComponentEndpointName": "ATG_GPCR_MC2R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC2R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC2R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1056, + "assayComponentName": "ATG_GPCR_MC2R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC2R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC2R, which is responsive to the melanocortin 2 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC2R| GeneID: 4158 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC2R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 491, + "geneName": "melanocortin 2 receptor (adrenocorticotropic hormone)", + "description": null, + "geneSymbol": "MC2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4158, + "officialSymbol": "MC2R", + "officialFullName": "melanocortin 2 receptor (adrenocorticotropic hormone)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1790, + "assayComponentEndpointName": "ATG_GPCR_MC3R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC3R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC3R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1057, + "assayComponentName": "ATG_GPCR_MC3R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC3R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC3R, which is responsive to the melanocortin 3 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC3R| GeneID: 4159 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC3R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 492, + "geneName": "melanocortin 3 receptor", + "description": null, + "geneSymbol": "MC3R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4159, + "officialSymbol": "MC3R", + "officialFullName": "melanocortin 3 receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1792, + "assayComponentEndpointName": "ATG_GPCR_MC4R_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_MC4R_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC4R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1058, + "assayComponentName": "ATG_GPCR_MC4R_TRANS", + "assayComponentDesc": "ATG_GPCR_MC4R_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene MC4R, which is responsive to the melanocortin 4 receptor (alpha melanocyte stimulating hormone receptor). [GeneSymbol: MC4R| GeneID: 4160 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MC4R RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 493, + "geneName": "melanocortin 4 receptor", + "description": null, + "geneSymbol": "MC4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4160, + "officialSymbol": "MC4R", + "officialFullName": "melanocortin 4 receptor", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1794, + "assayComponentEndpointName": "ATG_GPCR_PTGDR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_PTGDR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGDR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1059, + "assayComponentName": "ATG_GPCR_PTGDR_TRANS", + "assayComponentDesc": "ATG_GPCR_PTGDR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene PTGDR, which is responsive to the prostaglandin D2 receptor (DP). [GeneSymbol: PTGDR| GeneID: 5729 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PTGDR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 494, + "geneName": "prostaglandin D2 receptor (DP)", + "description": null, + "geneSymbol": "PTGDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5729, + "officialSymbol": "PTGDR", + "officialFullName": "prostaglandin D2 receptor (DP)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1796, + "assayComponentEndpointName": "ATG_GPCR_PTGIR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_GPCR_PTGIR_TRANS was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGIR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "NA", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1060, + "assayComponentName": "ATG_GPCR_PTGIR_TRANS", + "assayComponentDesc": "ATG_GPCR_PTGIR_TRANS is one of 35 assay components measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene PTGIR, which is responsive to the prostaglandin I2 (prostacyclin) receptor (IP). [GeneSymbol: PTGIR| GeneID: 5739 | Uniprot_SwissProt_Accession: NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PTGIR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 430, + "assayName": "ATG_GPCR_TRANS", + "assayDesc": "ATG_GPCR is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 495, + "geneName": "prostaglandin I2 (prostacyclin) receptor (IP)", + "description": null, + "geneSymbol": "PTGIR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5739, + "officialSymbol": "PTGIR", + "officialFullName": "prostaglandin I2 (prostacyclin) receptor (IP)", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1797, + "assayComponentEndpointName": "Tanguay_ZF_120hpf_ActivityScore", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.", + "assayFunctionType": "NA", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "organism", + "intendedTargetTypeSub": "malformation", + "intendedTargetFamily": "malformation", + "intendedTargetFamilySub": "total", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1061, + "assayComponentName": "Tanguay_ZF_120hpf_ActivityScore", + "assayComponentDesc": "Tanguay_ZF_120hpf_ActivityScore is one of one assay component(s) measured or calculated from the Tanguay_ZF_120hpf_ActivityScore assay. It is designed to make measurements of developmental malformations and mortality as detected with brightfield microscopy and combines scoring from 18 other assay components measuring more specific morphologies.", + "assayComponentTargetDesc": "An algorithm was used to combine results from 18 Tanquay_AF_120hpr assay components", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "anatomical entity", + "biologicalProcessTarget": "regulation of morphogenesis", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "embryonic development", + "technologicalTargetTypeSub": "NA", + "aid": 409, + "assayName": "Tanguay_ZF_120hpf", + "assayDesc": "Tanguay_ZF_120hpf is a whole embryo, multiplexed endpoint assay using zebrafish larvae exposed for 120 hr", + "timepointHr": 120.0, + "organismId": 7955, + "organism": "zebrafish", + "tissue": "ova", + "cellFormat": "whole embryo", + "cellFreeComponentSource": "NA", + "cellShortName": "dechorionated zebrafish embryo", + "cellGrowthMode": "suspension", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.7, + "asid": 13, + "assaySourceName": "TANGUAY", + "assaySourceLongName": "Tanguay Lab", + "assaySourceDesc": "The Tanguay Lab, based at the Oregon State University Sinnhuber Aquatic Research Laboratory, uses zebrafish as a systems toxicology model.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kft235", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24136191", + "pmid": 24136191, + "title": "Multidimensional in vivo hazard assessment using zebrafish", + "author": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL", + "citation": "Truong L, Reif DM, St Mary L, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci. 2014 Jan;137(1):212-33. doi: 10.1093/toxsci/kft235. Epub 2013 Oct 17. PubMed PMID: 24136191; PubMed Central PMCID: PMC3871932.", + "otherId": "0", + "citationId": 220, + "otherSource": "" + } + }, + { + "aeid": 1816, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nilutamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1120, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals following addition of luciferin substrate and ATP.", + "assayComponentTargetDesc": "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 441, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1817, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1121, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 441, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1818, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1122, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1819, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1123, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1820, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1124, + "assayComponentName": "TOX21_RXR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_RXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1821, + "assayComponentEndpointName": "TOX21_RXR_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1125, + "assayComponentName": "TOX21_RXR_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_RXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 442, + "assayName": "TOX21_RXR_BLA_Agonist", + "assayDesc": "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1822, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1126, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signal following addition of luciferin substrate and ATP.", + "assayComponentTargetDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an AR agonist. Changes are indicative of transcriptional gene expression that may not be due to direct regulation by the human androgen receptor [GeneSymbol: NR3C4 | GeneID: NR3C4 | Uniprot_SwissProt_Accession:].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 443, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for agonist specificity. This particular screening for measuring luciferase reporter gene activity using MDA-kb2 cells against Tox21 10K library compounds is a confirmation study on agonist mode screening in the presence of AR-antagonist compound (Nilutamide) at 3.0uM final concentration. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1823, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1127, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 443, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for agonist specificity. This particular screening for measuring luciferase reporter gene activity using MDA-kb2 cells against Tox21 10K library compounds is a confirmation study on agonist mode screening in the presence of AR-antagonist compound (Nilutamide) at 3.0uM final concentration. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1016/j.yrtph.2020.104764", + "url": "https://pubmed.ncbi.nlm.nih.gov/32798611/", + "pmid": 32798611, + "title": "Selecting a minimal set of androgen receptor assays for screening chemicals", + "author": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N", + "citation": "Judson R, Houck K, Paul Friedman K, Brown J, Browne P, Johnston PA, Close DA, Mansouri K, Kleinstreuer N. Selecting a minimal set of androgen receptor assays for screening chemicals. Regul Toxicol Pharmacol. 2020 Nov;117:104764. doi: 10.1016/j.yrtph.2020.104764. Epub 2020 Aug 14. PMID: 32798611; PMCID: PMC8356084.", + "otherId": "0", + "citationId": 283, + "otherSource": "" + } + }, + { + "aeid": 1824, + "assayComponentEndpointName": "CCTE_Simmons_GUA_TPO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_GUA_TPO was analyzed at the endpoint, CCTE_Simmons_GUA_TPO, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "peroxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1128, + "assayComponentName": "CCTE_Simmons_GUA_TPO", + "assayComponentDesc": "CCTE_Simmons_GUA_TPO is the assay component measured from the CCTE_Simmons_GUA_TPO assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by enzyme activity technology. This is an orthogonal assay to CCTE_Simmons_AUR_TPO run for confirmation.", + "assayComponentTargetDesc": "A well-characterized MIE for adverse thyroid-mediated outcomes is inhibition of TPO. TPO catalyzes iodine oxidation in the presence of hydrogen peroxide, regulates nonspecific iodination of tyrosyl residues of thyroglobulin to form TH precursors, monoiodotyrosine (MIT), and diiodotyrosine (DIT), and modulates coupling of these iodotyrosyl residues.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Guaiacol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 444, + "assayName": "CCTE_Simmons_GUA_TPO", + "assayDesc": "CCTE_Simmons_GUA_TPO is a biochemical, single-readout assay that uses microsomes from porcine thyroid gland in a tissue-based cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9823, + "organism": "pig", + "tissue": "thyroid gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "porcine thyroid gland", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 499, + "geneName": "thyroid peroxidase", + "description": null, + "geneSymbol": "TPO", + "organismId": 5, + "trackStatus": "live", + "entrezGeneId": 445522, + "officialSymbol": "TPO", + "officialFullName": null, + "uniprotAccessionNumber": "P09933" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1825, + "assayComponentEndpointName": "ArunA_CellTiter_hNP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_CellTiter_hNP was analyzed at the endpoint, ArunA_CellTiter_hNP, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1129, + "assayComponentName": "ArunA_CellTiter_hNP", + "assayComponentDesc": "ArunA_CellTiter_hNP is an assay component measured from the ArunA_CellTiter_hNP assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of [3H]-thymidine labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "3H-thymidine", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 445, + "assayName": "ArunA_CellTiter_hNP", + "assayDesc": "ArunA_CellTiter_hNP is a cell-based, single-readout assay that uses human H9-derived neuroprogenitor stem cells (hNP1).Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived neuroprogenitor stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1826, + "assayComponentEndpointName": "ArunA_CellTiter_hNC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_CellTiter_hNC was analyzed at the endpoint, ArunA_CellTiter_hNC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1130, + "assayComponentName": "ArunA_CellTiter_hNC", + "assayComponentDesc": "ArunA_CellTiter_hNC is an assay component measured from the ArunA_CellTiter_hNC assay. It is designed to make measurements of viability, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of [3H]-thymidine labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "3H-thymidine", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 446, + "assayName": "ArunA_CellTiter_hNC", + "assayDesc": "ArunA_CellTiter_hNC is a cell-based, single-readout assay that uses human H9-derived embryonic neural crest stem cells (hNC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic neural crest stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1827, + "assayComponentEndpointName": "ArunA_Migration_hNP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_Migration_hNP was analyzed at the endpoint, ArunA_Migration_hNP, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of distribution reporter, loss-of-signal activity can be used to understand the cell migration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1131, + "assayComponentName": "ArunA_Migration_hNP", + "assayComponentDesc": "ArunA_Migration_hNP is an assay component measured from the ArunA_Migration_hNP assay. It is designed to make measurements of cell migration, a form of distribution reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to Ki-67 expression is indicative of the cell migration.", + "parameterReadoutType": "single", + "assayDesignType": "distribution reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Calcein-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "Ki-67", + "aid": 447, + "assayName": "ArunA_Migration_hNP", + "assayDesc": "ArunA_Migration_hNP is a cell-based, single-readout assay that uses human H9-derived neuroprogenitor stem cells (hNP1). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived neuroprogenitor stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNP1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1829, + "assayComponentEndpointName": "ArunA_Migration_hNC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_Migration_hNC was analyzed at the endpoint, ArunA_Migration_hNC, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of distribution reporter, loss-of-signal activity can be used to understand the cell migration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "cytochalasin D", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "migration", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "migration", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1132, + "assayComponentName": "ArunA_Migration_hNC", + "assayComponentDesc": "ArunA_Migration_hNC is an assay component measured from the ArunA_Migration_hNC assay. It is designed to make measurements of cell migration, a form of distribution reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to Ki-67 expression is indicative of the cell migration.", + "parameterReadoutType": "single", + "assayDesignType": "distribution reporter", + "assayDesignTypeSub": "cell migration", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Calcein-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "Ki-67", + "aid": 448, + "assayName": "ArunA_Migration_hNC", + "assayDesc": "ArunA_Migration_hNC is a cell-based, single-readout assay that uses human H9-derived embryonic neural crest stem cells (hNC). Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic neural crest stem cells", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNC", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 2516, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_network_spike_duration_std", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2482, + "assayComponentName": "CCTE_Shafer_MEA_dev_network_spike_duration_std", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_network_spike_duration_std is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the standard deviation of the duration of network spikes (temporally-clustered groups of action potential firing across multiple electrodes) during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The standard deviation of network spike duration is a measure of network connectivity. Changes in the standard deviation of network spike duration are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2518, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2483, + "assayComponentName": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average time interval between network spikes (temporally-clustered groups of actional potential firing across multiple electrodes) as the average time between peaks of consecutive network spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The inter-network spike interval is a measure of the network connectivity. Changes in the inter-network spike interval are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2520, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2484, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the average number of spikes (action potential firings) in a network spike (temporally-clustered group of spikes across multiple electrodes) as the number of spikes that occur within a 0.05 s time window at the peak of a network spike divided by the total number of network spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The mean number of spikes in network spikes is a measure of the network connectivity. Changes in the mean number of network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2522, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2485, + "assayComponentName": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_per_network_spike_spike_percent is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the percent of spikes (action potential firings) in a network spike (temporally-clustered group of spikes across multiple electrodes) as the number of spikes that occur within a 0.05 s time window at the peak of a network spike divided by the total number of spikes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "The percent of spikes in network spikes is a measure of the network connectivity. Changes in the percent of spikes in network spikes are indicative of changes in coordinated neural network activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2524, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2486, + "assayComponentName": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_correlation_coefficient_mean is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the correlation coefficent of spikes (action potential firings) between every pair of electrodes in a well during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. The pairwise correlations are averaged across active electrodes to report a well-mean value. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Electrical activity is captured from neurons cultured over electrodes. Increases in correlation coefficient indicate that the activity of individual neurons in the network is more synchronous, reflecting increased coordination of activity.", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2526, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_mutual_information_norm", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain or loss-of-signal activity can be used to understand electrical activity.", + "assayFunctionType": "electrical activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "extracellular", + "intendedTargetTypeSub": "action potential", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neural network function: network connectivity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2487, + "assayComponentName": "CCTE_Shafer_MEA_dev_mutual_information_norm", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_mutual_information_norm is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It is a measure of shared information between electrodes during a recording in a microelectrode array (MEA) using Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector. To collapse across multiple recordings made on days post-plating 5, 7, 9 and 12, the trapezoidal area-under-the-curve of the component is calculated.", + "assayComponentTargetDesc": "Normalized Mutual Information is a normalized measure of complexity and synchrony in a network that is robust to changes in network size. It is a scalar (rather than pairwise) measure of mutual information in a multivariate network (See Ball et al., Neural Networks. 2017. 95, 29-43 for further information).", + "parameterReadoutType": "single", + "assayDesignType": "functional reporter", + "assayDesignTypeSub": "electrical activity", + "biologicalProcessTarget": "functional neural network activity", + "detectionTechnologyType": "microelectrode array (MEA)", + "detectionTechnologyTypeSub": "extracellular measurements of action potential “spikes” and groups of spikes, or bursts ", + "detectionTechnology": "Axion Biosystems Maestro 768 channel amplifier with the AxIS adaptive spike detector ", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "electrical activity", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2529, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_LDH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2488, + "assayComponentName": "CCTE_Shafer_MEA_dev_LDH", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_LDH is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the lactate dehydrogenase enzyme activity using spectrophotometry.", + "assayComponentTargetDesc": "Changes in enzymatic activity (of lactate dehydrogenase) are indicative of compromised cell health. Reductions in the total LDH (in cells) indicates cell loss or death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "lactate dehydrogenase activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "spectrophotometry", + "detectionTechnologyTypeSub": "absorbance", + "detectionTechnology": "enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tetrazolium salt", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2530, + "assayComponentEndpointName": "CCTE_Shafer_MEA_dev_AB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2489, + "assayComponentName": "CCTE_Shafer_MEA_dev_AB", + "assayComponentDesc": "CCTE_Shafer_MEA_dev_AB is 1 of 19 assay components of the CCTE_Shafer_MEA_dev assay. It measures the resazurin reduction using fluorescence.", + "assayComponentTargetDesc": "Changes in enzymatic activity (decrease in mitochondrial enzyme, alamar blue reduction) are indicative of compromised cellular metabolism, possibly indicating cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "mitochondrial enzyme activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "resazurin reduction: alamar blue dye converted into fluorescent end product", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "alamar blue (resazurin)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: mitochondrial enzyme", + "aid": 573, + "assayName": "CCTE_Shafer_MEA_dev", + "assayDesc": "CCTE_Shafer_MEA_dev assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_dev assay uses primary cultures of rat cortical neurons. Recordings are made on days post-plating 5, 7, 9 and 12. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. ", + "timepointHr": 0.25, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO, water, or ethanol", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-017-2035-5", + "url": "https://pubmed.ncbi.nlm.nih.gov/28766123/", + "pmid": 28766123, + "title": "Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates", + "author": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ", + "citation": "Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ. Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates. Arch Toxicol. 2018 Jan;92(1):487-500. doi: 10.1007/s00204-017-2035-5. Epub 2017 Aug 2. PMID: 28766123; PMCID: PMC6438628.", + "otherId": "0", + "citationId": 233, + "otherSource": "" + } + }, + { + "aeid": 2532, + "assayComponentEndpointName": "CCTE_GLTED_hDIO2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 2", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2490, + "assayComponentName": "CCTE_GLTED_hDIO2", + "assayComponentDesc": "CCTE_GLTED_hDIO2 is the assay component measured from the CCTE_GLTED_hDIO2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO2 is important for converting T4 to T3 though the removal of the 5’ outer ring iodine.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "thyroxine (T4)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 686, + "assayName": "CCTE_GLTED_hDIO2", + "assayDesc": "CCTE_GLTED_hDIO2 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 2 (DIO2) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2790, + "geneName": "iodothyronine deiodinase 2", + "description": null, + "geneSymbol": "DIO2", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1734, + "officialSymbol": "DIO2", + "officialFullName": "iodothyronine deiodinase 2", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 198, + "assayComponentEndpointName": "BSK_BE3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 140, + "assayComponentName": "BSK_BE3C_SRB", + "assayComponentDesc": "BSK_BE3C_SRB is an assay component measured in the BSK_BE3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the BE3C system is a measure of the total protein content of bronchial epithelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 2533, + "assayComponentEndpointName": "CCTE_GLTED_hDIO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "xanthohumol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "deiodinase", + "intendedTargetFamilySub": "deiodinase Type 3", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2491, + "assayComponentName": "CCTE_GLTED_hDIO3", + "assayComponentDesc": "CCTE_GLTED_hDIO3 is the assay component measured from the CCTE_GLTED_hDIO3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by spectrophotometry.", + "assayComponentTargetDesc": "Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. DIO3 inactivates both T4 and T3 by removing an inner ring iodine, producing reverse T3 (rT3) and diiodotyrosine (T2), respectively.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,3'5-triiodothyronine (T3)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 687, + "assayName": "CCTE_GLTED_hDIO3", + "assayDesc": "CCTE_GLTED_hDIO3 is a cell-free, single-readout assay designed to test the inhibitory activity of chemicals toward human iodothyronine Deiodinase type 3 (DIO3) enzyme. Enzyme is incubated in presence of test chemical for 3 hours during which uninhibited enzyme liberates free iodide from substrate. Free iodide is measured in a second step using the Sandell-Kolthoff method.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 24, + "assaySourceName": "CCTE_GLTED", + "assaySourceLongName": "CCTE Great Lakes Toxicology and Ecology Division", + "assaySourceDesc": "The EPA CCTE Great Lakes Toxicology and Ecology Division focuses on ecotoxicology and stressors of water resources, including devleopment and implementation of in vitro and in vivo assays.", + "gene": { + "geneId": 2791, + "geneName": "iodothyronine deiodinase 3", + "description": null, + "geneSymbol": "DIO3", + "organismId": 1, + "trackStatus": null, + "entrezGeneId": 1735, + "officialSymbol": "DIO3", + "officialFullName": "iodothyronine deiodinase 3", + "uniprotAccessionNumber": null + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfx27", + "url": "https://pubmed.ncbi.nlm.nih.gov/29228274/", + "pmid": 29228274, + "title": "Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity", + "author": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ", + "citation": "Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity. Toxicol Sci. 2018 Apr 1;162(2):570-581. doi: 10.1093/toxsci/kfx279. PMID: 29228274; PMCID: PMC6639810.", + "otherId": "0", + "citationId": 238, + "otherSource": "" + } + }, + { + "aeid": 2540, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_LDH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_LDH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tritonx100", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2495, + "assayComponentName": "CCTE_Shafer_MEA_acute_LDH", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_LDH is a component of the CCTE_Shafer_MEA_acute assay. It measures the lactate dehydrogenase enzyme activity using spectrophotometry.", + "assayComponentTargetDesc": "Changes in enzymatic activity (increase in lactate dehydrogenase) are indicative of compromised cell health. Increases in extracellular LDH indicate cell loss or death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "lactate dehydrogenase activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "spectrophotometry", + "detectionTechnologyTypeSub": "absorbance", + "detectionTechnology": "enzyme activity", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "tetrazolium salt", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: lactate dehydrogenase", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2541, + "assayComponentEndpointName": "CCTE_Shafer_MEA_acute_AB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Shafer_MEA_acute_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_AB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.", + "assayFunctionType": "cell viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2496, + "assayComponentName": "CCTE_Shafer_MEA_acute_AB", + "assayComponentDesc": "CCTE_Shafer_MEA_acute_AB is a component of the CCTE_Shafer_MEA_acute assay. It measures the resazurin reduction using fluorescence.", + "assayComponentTargetDesc": "Changes in enzymatic activity (decrease in mitochondrial enzyme, alamar blue reduction) are indicative of compromised cellular metabolism, possibly indicating cell death.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "mitochondrial enzyme activity", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "fluorescence", + "detectionTechnologyTypeSub": "fluorescence intensity", + "detectionTechnology": "resazurin reduction: alamar blue dye converted into fluorescent end product", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "alamar blue (resazurin)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme: mitochondrial enzyme", + "aid": 877, + "assayName": "CCTE_Shafer_MEA_acute", + "assayDesc": "CCTE_Shafer_MEA_acute assay is conducted using Axion Biosystems 48 well microelectrode array (MEA) plates and Maestro recording system. Each well of the MEA plate contains a grid of 16 microelectrodes embedded in the culture surface. Electrically active cells, such as neurons, can be cultured over the electrodes, and electrical activity in these cells can be recorded extracellularly. The spontaneous firing of neurons is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data. Because the recordings do not impact the health of the cells, multiple recordings can be made from the same neural network over time in culture. The CCTE_Shafer_MEA_acute assay uses primary cultures of rat cortical neurons. As these cultures mature over time, neural networks develop functional activity and form cohesive networks in which electrical activity can be highly coordinated. Baseline 40-minute recordings are made on days post-plating 13 or 15, followed by a secondary 40-minute recording after chemical exposure.", + "timepointHr": 0.666666666666667, + "organismId": 10116, + "organism": "rat", + "tissue": "cortical", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "primary cortical cell culture", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO or water", + "dilutionSolventPercentMax": 0.2, + "asid": 20, + "assaySourceName": "CCTE_SHAFER", + "assaySourceLongName": "CCTE Shafer Lab", + "assaySourceDesc": "The Shafer lab at the EPA Center for Computational Toxicology and Exposure focus on developmental neurotoxicity (DNT) hazard identificaton using microelectrode array (MEA) assays.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 2545, + "assayComponentEndpointName": "UKN5_HCS_SBAD2_neurite_outgrowth", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN5_HCS_SBAD2_neurite_outgrowth was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain or loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Narciclasine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2500, + "assayComponentName": "UKN5_HCS_SBAD2_neurite_outgrowth", + "assayComponentDesc": "UKN5_HCS_SBAD2_neurite_outgrowth is an assay component measured from the UKN5_HCS_SBAD2 assay. It is designed to make measurements of neurite outgrowth, a form of morphology reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the neurite area are indicative of neurodevelopment.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurodevelopment", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33339", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite area", + "aid": 691, + "assayName": "UKN5_HCS_SBAD2", + "assayDesc": "UKN5_HCS_SBAD2 is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses SBAD2 (peripheral neurons differentiated from iPSC), a human peripheral nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN5, also referred to as PeriTox, is an assay that uses human iPSC line SBAD2 as a model of peripheral neurons. Following 24 hr chemical exposures in multi-well plates, neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein-AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "peripheral nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "SBAD2 (peripheral neurons differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 535, + "assayComponentEndpointName": "NVS_ENZ_hPTPN13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN13, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 309, + "assayComponentName": "NVS_ENZ_hPTPN13", + "assayComponentDesc": "NVS_ENZ_hPTPN13 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) [GeneSymbol:PTPN13 | GeneID:5783 | Uniprot_SwissProt_Accession:Q12923].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 123, + "assayName": "NVS_ENZ_hPTPN13", + "assayDesc": "NVS_ENZ_hPTPN13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 272, + "geneName": "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)", + "description": null, + "geneSymbol": "PTPN13", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5783, + "officialSymbol": "PTPN13", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)", + "uniprotAccessionNumber": "Q12923" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 1831, + "assayComponentEndpointName": "ArunA_NOG_NucleusCount", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NucleusCount was analyzed at the endpoint, ArunA_NOG_NucleusCount, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cell count", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1133, + "assayComponentName": "ArunA_NOG_NucleusCount", + "assayComponentDesc": "ArunA_NOG_NucleusCount is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of viability related to the number of neurons, using a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to the number of Hoechst 33,258 labelled nuceli is indicative of the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33258 dye", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "labelled nuclei", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1833, + "assayComponentEndpointName": "ArunA_NOG_NeuriteLength", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NeuriteLength was analyzed at the endpoint, ArunA_NOG_NeuriteLength, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1134, + "assayComponentName": "ArunA_NOG_NeuriteLength", + "assayComponentDesc": "ArunA_NOG_NeuriteLength is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to neurite length, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurite length", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1835, + "assayComponentEndpointName": "ArunA_NOG_NeuritesPerNeuron", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_NeuritesPerNeuron was analyzed at the endpoint, ArunA_NOG_NeuritesPerNeuron, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1135, + "assayComponentName": "ArunA_NOG_NeuritesPerNeuron", + "assayComponentDesc": "ArunA_NOG_NeuritesPerNeuron is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to number of neurites per neuron, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "neurites per neuron", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 1838, + "assayComponentEndpointName": "ArunA_NOG_BranchPointsPerNeurite", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ArunA_NOG_BranchPointsPerNeurite was analyzed at the endpoint, ArunA_NOG_BranchPointsPerNeurite, with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, gain-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.", + "assayFunctionType": "developmental", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "morphology", + "intendedTargetFamily": "neurodevelopment", + "intendedTargetFamilySub": "neurite outgrowth", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1136, + "assayComponentName": "ArunA_NOG_BranchPointsPerNeurite", + "assayComponentDesc": "ArunA_NOG_BranchPointsPerNeurite is an assay component measured from the ArunA_NOG assay. It is designed to make measurements of neurite outgrowth related to branch points per neurite, using a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology. ", + "assayComponentTargetDesc": "Changes in fluorescence intensity related to bIII-tubulin/DyLight1 488 antibody labelling is indicative of the neurite outgrowth.", + "parameterReadoutType": "multiple", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "neurite outgrowth", + "biologicalProcessTarget": "neurovascular unit NVU development (neurogenic outcomes)", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "bIII-tubulin/DyLight1 488 antibody", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "branch points per neurite", + "aid": 449, + "assayName": "ArunA_NOG", + "assayDesc": "ArunA_NOG (Neurite Outgrowth) is a cell-based, image-based assay that uses human H9-derived embryonic differentiated neurons (hNN). Measurements were taken 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "H9-derived embryonic differentiated neurons", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "hNN", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "image-based", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 16, + "assaySourceName": "ARUNA", + "assaySourceLongName": "ArunA Biomedical", + "assaySourceDesc": "ArunA Biomedical is a privately owned biotechnology company and Contract Research Organization (CRO) formerly providing toxicology screening using neural stem cell-based assays. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.reprotox.2020.06.010", + "url": "https://pubmed.ncbi.nlm.nih.gov/32590145/", + "pmid": 32590145, + "title": " A cross-platform approach to characterize and screen potential neurovascular unit toxicants", + "author": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T, Knudsen TB. A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxicol. 2020 Jun 24;96:300-315. doi: 10.1016/j.reprotox.2020.06.010. Epub ahead of print. PMID: 32590145.", + "otherId": "0", + "citationId": 250, + "otherSource": "" + } + }, + { + "aeid": 2552, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C19_Omeprazole was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C19_Omeprazole, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2505, + "assayComponentName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C19_Omeprazole is an assay component calculated from the ERF_CR_ADME_hCYP2C19_Omeprazole assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of 5-hydroxyomeprazole with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of 5-hydroxyomeprazole produced from the regulation of catalytic activity reaction involving the key substrate, omeprazole, are indicative of changes in enzyme function and kinetics related to the gene CYP2C19.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "omeprazole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 728, + "assayName": "ERF_CR_ADME_hCYP2C19_Omeprazole", + "assayDesc": "ERF_CR_ADME_hCYP2C19_Omeprazole is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2C19 inhibition (HLM, omeprazole substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2553, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C8 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C8, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C8. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2506, + "assayComponentName": "ERF_CR_ADME_hCYP2C8", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C8 is an assay component calculated from the ERF_CR_ADME_hCYP2C8 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of desethylamodiaquine with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of desethylamodiaquine produced from the regulation of catalytic activity reaction involving the key substrate, amodiaquine, are indicative of changes in enzyme function and kinetics related to the gene CYP2C8.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "amodiaquine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 821, + "assayName": "ERF_CR_ADME_hCYP2C8", + "assayDesc": "ERF_CR_ADME_hCYP2C8 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2C8 inhibition (HLM, amodiaquine substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2554, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C9 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C9, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2507, + "assayComponentName": "ERF_CR_ADME_hCYP2C9", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C9 is an assay component calculated from the ERF_CR_ADME_hCYP2C9 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-methoxy-4-trifluoromethylcoumarin (MFC), are indicative of changes in enzyme function and kinetics related to the gene CYP2C9.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 815, + "assayName": "ERF_CR_ADME_hCYP2C9", + "assayDesc": "ERF_CR_ADME_hCYP2C9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate. See CYP2C9 inhibition (recombinant, MFC substrate).", + "timepointHr": 0.66, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2555, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2E1 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2E1, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2E1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2508, + "assayComponentName": "ERF_CR_ADME_hCYP2E1", + "assayComponentDesc": "ERF_CR_ADME_hCYP2E1 is an assay component calculated from the ERF_CR_ADME_hCYP2E1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by peak area response of 6-hydroxychlorzoxazone with HPLC-MS/MS technology.", + "assayComponentTargetDesc": "Changes in peak area response of 6-hydroxychlorzoxazone produced from the regulation of catalytic activity reaction involving the key substrate, Chlorzoxazone, are indicative of changes in enzyme function and kinetics related to the gene CYP2E1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Mass spectrometry", + "detectionTechnologyTypeSub": "Peak intensity", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Chlorzoxazone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 743, + "assayName": "ERF_CR_ADME_hCYP2E1", + "assayDesc": "ERF_CR_ADME_hCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.16 hour after chemical dosing in a 96-well plate. See CYP2E1 inhibition (recombinant, EC substrate).", + "timepointHr": 0.16, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human liver microsomes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1839, + "assayComponentEndpointName": "TOX21_RAR_LUC_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ER50891", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1137, + "assayComponentName": "TOX21_RAR_LUC_Antagonist", + "assayComponentDesc": "TOX21_RAR_LUC_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", + "assayComponentTargetDesc": "TOX21_RAR_LUC_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha [GeneSymbol:RARA]", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 450, + "assayName": "TOX21_RAR_LUC_Antagonist", + "assayDesc": "TOX21_RAR_LUC_Antagonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1840, + "assayComponentEndpointName": "TOX21_RAR_LUC_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1138, + "assayComponentName": "TOX21_RAR_LUC_Antagonist_viability", + "assayComponentDesc": "TOX21_RAR_LUC_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 450, + "assayName": "TOX21_RAR_LUC_Antagonist", + "assayDesc": "TOX21_RAR_LUC_Antagonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 6.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "embryo", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "C3H10T1/2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1841, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1139, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ch1", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch1 is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the donor (Europium-cryptate) antibody emission and is used to calculate the ratio of acceptor (d2) emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch1 was designed to measure donor labeled antibody emission to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "detection of DNA damage", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1842, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1140, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ch2", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch2 is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the acceptor (d2) antibody emission and is used to calculate the ratio of acceptor emission (ch2) to donor emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ch2 was designed to measure acceptor labeled antibody emission to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 2556, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP3A4 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP3A4, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP3A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2509, + "assayComponentName": "ERF_CR_ADME_hCYP3A4", + "assayComponentDesc": "ERF_CR_ADME_hCYP3A4 is an assay component calculated from the ERF_CR_ADME_hCYP3A4 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-benzyloxy-4-trifluoromethylcoumarin (BFC), are indicative of changes in enzyme function and kinetics related to the gene CYP3A4.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 809, + "assayName": "ERF_CR_ADME_hCYP3A4", + "assayDesc": "ERF_CR_ADME_hCYP3A4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP3A4 inhibition (recombinant, BFC substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2557, + "assayComponentEndpointName": "ERF_PL_ENZ_bPDE1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_bPDE1 was analyzed at the assay endpoint, ERF_PL_ENZ_bPDE1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "3-Isobutyl-1-methylxanthine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2510, + "assayComponentName": "ERF_PL_ENZ_bPDE1", + "assayComponentDesc": "ERF_PL_ENZ_bPDE1 is an assay component calculated from the ERF_PL_ENZ_bPDE1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, [3H]cAMP + cAMP, are indicative of changes in enzyme function and kinetics related to the gene PDE1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[3H]cAMP + cAMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 711, + "assayName": "ERF_PL_ENZ_bPDE1", + "assayDesc": "ERF_PL_ENZ_bPDE1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate. See PDE1 (Non-Selective) Bovine Phosphodiesterase Enzymatic Assay, Panlabs.", + "timepointHr": 0.33, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "cell-free", + "cellFreeComponentSource": "bovine brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2558, + "assayComponentEndpointName": "ERF_CR_ENZ_hABL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hABL1 was analyzed at the assay endpoint, ERF_CR_ENZ_hABL1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ABL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2511, + "assayComponentName": "ERF_CR_ENZ_hABL1", + "assayComponentDesc": "ERF_CR_ENZ_hABL1 is an assay component calculated from the ERF_CR_ENZ_hABL1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in enzyme function and kinetics related to the gene ABL1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 791, + "assayName": "ERF_CR_ENZ_hABL1", + "assayDesc": "ERF_CR_ENZ_hABL1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Abl Human TK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 1, + "geneName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "ABL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25, + "officialSymbol": "ABL1", + "officialFullName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P00519" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2559, + "assayComponentEndpointName": "ERF_CR_ENZ_hAKT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAKT2 was analyzed at the assay endpoint, ERF_CR_ENZ_hAKT2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2512, + "assayComponentName": "ERF_CR_ENZ_hAKT2", + "assayComponentDesc": "ERF_CR_ENZ_hAKT2 is an assay component calculated from the ERF_CR_ENZ_hAKT2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene AKT2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 781, + "assayName": "ERF_CR_ENZ_hAKT2", + "assayDesc": "ERF_CR_ENZ_hAKT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Akt2 (PKBbeta) Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 23, + "geneName": "v-akt murine thymoma viral oncogene homolog 2", + "description": null, + "geneSymbol": "AKT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 208, + "officialSymbol": "AKT2", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 2", + "uniprotAccessionNumber": "P31751" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2560, + "assayComponentEndpointName": "ERF_CR_ENZ_hAKT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAKT3 was analyzed at the assay endpoint, ERF_CR_ENZ_hAKT3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2513, + "assayComponentName": "ERF_CR_ENZ_hAKT3", + "assayComponentDesc": "ERF_CR_ENZ_hAKT3 is an assay component calculated from the ERF_CR_ENZ_hAKT3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE, are indicative of changes in enzyme function and kinetics related to the gene AKT3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 782, + "assayName": "ERF_CR_ENZ_hAKT3", + "assayDesc": "ERF_CR_ENZ_hAKT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See Akt3 (PKBgamma) Human AGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 359, + "geneName": "v-akt murine thymoma viral oncogene homolog 3", + "description": null, + "geneSymbol": "AKT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10000, + "officialSymbol": "AKT3", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 3", + "uniprotAccessionNumber": "Q9Y243" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2561, + "assayComponentEndpointName": "ERF_CR_ENZ_hAURKA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hAURKA was analyzed at the assay endpoint, ERF_CR_ENZ_hAURKA, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AURKA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2514, + "assayComponentName": "ERF_CR_ENZ_hAURKA", + "assayComponentDesc": "ERF_CR_ENZ_hAURKA is an assay component calculated from the ERF_CR_ENZ_hAURKA assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-RRRSLLE , are indicative of changes in enzyme function and kinetics related to the gene AURKA.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-RRRSLLE ", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 774, + "assayName": "ERF_CR_ENZ_hAURKA", + "assayDesc": "ERF_CR_ENZ_hAURKA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Aurora-A Human Other Protein Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 306, + "geneName": "aurora kinase A", + "description": null, + "geneSymbol": "AURKA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6790, + "officialSymbol": "AURKA", + "officialFullName": "aurora kinase A", + "uniprotAccessionNumber": "O14965" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2562, + "assayComponentEndpointName": "ERF_PL_ENZ_hBTK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hBTK was analyzed at the assay endpoint, ERF_PL_ENZ_hBTK, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene BTK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is tyrosine kinase (tk).", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": " tyrosine kinase (tk)", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2515, + "assayComponentName": "ERF_PL_ENZ_hBTK", + "assayComponentDesc": "ERF_PL_ENZ_hBTK is an assay component calculated from the ERF_PL_ENZ_hBTK assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, Poly(Glu:Tyr), are indicative of changes in enzyme function and kinetics related to the gene BTK.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Poly(Glu:Tyr)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 726, + "assayName": "ERF_PL_ENZ_hBTK", + "assayDesc": "ERF_PL_ENZ_hBTK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See BTK Human TK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 36, + "geneName": "Bruton agammaglobulinemia tyrosine kinase", + "description": null, + "geneSymbol": "BTK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 695, + "officialSymbol": "BTK", + "officialFullName": "Bruton agammaglobulinemia tyrosine kinase", + "uniprotAccessionNumber": "Q06187" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2563, + "assayComponentEndpointName": "ERF_CR_ENZ_hCDK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hCDK2 was analyzed at the assay endpoint, ERF_CR_ENZ_hCDK2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CDK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2516, + "assayComponentName": "ERF_CR_ENZ_hCDK2", + "assayComponentDesc": "ERF_CR_ENZ_hCDK2 is an assay component calculated from the ERF_CR_ENZ_hCDK2 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene CDK2.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 780, + "assayName": "ERF_CR_ENZ_hCDK2", + "assayDesc": "ERF_CR_ENZ_hCDK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CDK2 /CyclinA Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 55, + "geneName": "cyclin-dependent kinase 2", + "description": null, + "geneSymbol": "CDK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1017, + "officialSymbol": "CDK2", + "officialFullName": "cyclin-dependent kinase 2", + "uniprotAccessionNumber": "P24941" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2564, + "assayComponentEndpointName": "ERF_PL_ENZ_hCHK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCHK1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCHK1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CHEK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2517, + "assayComponentName": "ERF_PL_ENZ_hCHK1", + "assayComponentDesc": "ERF_PL_ENZ_hCHK1 is an assay component calculated from the ERF_PL_ENZ_hCHK1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CHKtide, are indicative of changes in enzyme function and kinetics related to the gene CHEK1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CHKtide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 719, + "assayName": "ERF_PL_ENZ_hCHK1", + "assayDesc": "ERF_PL_ENZ_hCHK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CHK1 Human CAMK Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect Sf21 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 60, + "geneName": "checkpoint kinase 1", + "description": null, + "geneSymbol": "CHEK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1111, + "officialSymbol": "CHEK1", + "officialFullName": "checkpoint kinase 1", + "uniprotAccessionNumber": "O14757" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2566, + "assayComponentEndpointName": "ERF_CR_ENZ_hCSF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hCSF1R was analyzed at the assay endpoint, ERF_CR_ENZ_hCSF1R, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSF1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2519, + "assayComponentName": "ERF_CR_ENZ_hCSF1R", + "assayComponentDesc": "ERF_CR_ENZ_hCSF1R is an assay component calculated from the ERF_CR_ENZ_hCSF1R assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-TK peptide, are indicative of changes in receptor function and kinetics related to the gene CSF1R.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-TK peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 793, + "assayName": "ERF_CR_ENZ_hCSF1R", + "assayDesc": "ERF_CR_ENZ_hCSF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See Fms (CSFR) Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 73, + "geneName": "colony stimulating factor 1 receptor", + "description": null, + "geneSymbol": "CSF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1436, + "officialSymbol": "CSF1R", + "officialFullName": "colony stimulating factor 1 receptor", + "uniprotAccessionNumber": "P07333" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2567, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK1A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK1A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "IC 261", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2520, + "assayComponentName": "ERF_PL_ENZ_hCSNK1A1", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK1A1 is an assay component calculated from the ERF_PL_ENZ_hCSNK1A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK1 substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene CSNK1A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK1 substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 720, + "assayName": "ERF_PL_ENZ_hCSNK1A1", + "assayDesc": "ERF_PL_ENZ_hCSNK1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK1alpha Human CK1 Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 74, + "geneName": "casein kinase 1, alpha 1", + "description": null, + "geneSymbol": "CSNK1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1452, + "officialSymbol": "CSNK1A1", + "officialFullName": "casein kinase 1, alpha 1", + "uniprotAccessionNumber": "P48729" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2568, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK1D", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK1D was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK1D, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "IC 261", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2521, + "assayComponentName": "ERF_PL_ENZ_hCSNK1D", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK1D is an assay component calculated from the ERF_PL_ENZ_hCSNK1D assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK1tide, are indicative of changes in enzyme function and kinetics related to the gene CSNK1D.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK1tide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 722, + "assayName": "ERF_PL_ENZ_hCSNK1D", + "assayDesc": "ERF_PL_ENZ_hCSNK1D is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK1delta Human CK1 Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 75, + "geneName": "casein kinase 1, delta", + "description": null, + "geneSymbol": "CSNK1D", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1453, + "officialSymbol": "CSNK1D", + "officialFullName": "casein kinase 1, delta", + "uniprotAccessionNumber": "P48730" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1843, + "assayComponentEndpointName": "TOX21_H2AX_HTRF_CHO_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Etoposide", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "histone H2A", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1141, + "assayComponentName": "TOX21_H2AX_HTRF_CHO_Agonist_ratio", + "assayComponentDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ratio is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the the ratio of acceptor (d2)-conjugated antibody emission (ch2) to donor (Europium-cryptate)-conjugated antibody emission (ch1) used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_H2AX_HTRF_CHO_Agonist_ratio was designed to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Homogeneous Time Resolved Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 451, + "assayName": "TOX21_H2AX_HTRF_CHO_Agonist", + "assayDesc": "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.9b00053", + "url": "https://pubmed.ncbi.nlm.nih.gov/31243984/", + "pmid": 31243984, + "title": "Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays", + "author": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL", + "citation": "Hsieh JH, Smith-Roe SL, Huang R, Sedykh A, Shockley KR, Auerbach SS, Merrick BA, Xia M, Tice RR, Witt KL. Identifying Compounds with Genotoxicity Potential Using Tox21 High-Throughput Screening Assays. Chem Res Toxicol. 2019 Jul 15;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053. Epub 2019 Jun 18. PMID: 31243984; PMCID: PMC6740247.", + "otherId": "0", + "citationId": 274, + "otherSource": "" + } + }, + { + "aeid": 1844, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1142, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ch1 is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1845, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1143, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": null + }, + { + "aeid": 1846, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "EGF", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1144, + "assayComponentName": "TOX21_AP1_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AP1_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2569, + "assayComponentEndpointName": "ERF_PL_ENZ_hCSNK2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCSNK2A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCSNK2A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK2A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "hypericin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2522, + "assayComponentName": "ERF_PL_ENZ_hCSNK2A1", + "assayComponentDesc": "ERF_PL_ENZ_hCSNK2A1 is an assay component calculated from the ERF_PL_ENZ_hCSNK2A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by scintillation counting with radiometry technology.", + "assayComponentTargetDesc": "Changes in scintillation counting produced from the regulation of catalytic activity reaction involving the key substrate, CK2 substrate peptide, are indicative of changes in enzyme function and kinetics related to the gene CSNK2A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CK2 substrate peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 723, + "assayName": "ERF_PL_ENZ_hCSNK2A1", + "assayDesc": "ERF_PL_ENZ_hCSNK2A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CK2 (alpha1/alpha2/beta) Human Other Protein Kinase Enzymatic Radiometric Assay [10 uM ATP], Panlabs.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant Sf21 insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 76, + "geneName": "casein kinase 2, alpha 1 polypeptide", + "description": null, + "geneSymbol": "CSNK2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1457, + "officialSymbol": "CSNK2A1", + "officialFullName": "casein kinase 2, alpha 1 polypeptide", + "uniprotAccessionNumber": "Q8NEV1" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2570, + "assayComponentEndpointName": "ERF_PL_ENZ_hCYP19A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_PL_ENZ_hCYP19A1 was analyzed at the assay endpoint, ERF_PL_ENZ_hCYP19A1, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP19A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2523, + "assayComponentName": "ERF_PL_ENZ_hCYP19A1", + "assayComponentDesc": "ERF_PL_ENZ_hCYP19A1 is an assay component calculated from the ERF_PL_ENZ_hCYP19A1 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, dibenzylfluorescein, are indicative of changes in enzyme function and kinetics related to the gene CYP19A1.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "dibenzylfluorescein", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 698, + "assayName": "ERF_PL_ENZ_hCYP19A1", + "assayDesc": "ERF_PL_ENZ_hCYP19A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate. See CYP19A1 Human CYP450 Enzymatic Assay, Panlabs.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect BTI-TN-5B1-4 cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2571, + "assayComponentEndpointName": "ERF_CR_ENZ_hDUSP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hDUSP3 was analyzed at the assay endpoint, ERF_CR_ENZ_hDUSP3, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DUSP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is dual-specific kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium orthovanadate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "dual-specific kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2524, + "assayComponentName": "ERF_CR_ENZ_hDUSP3", + "assayComponentDesc": "ERF_CR_ENZ_hDUSP3 is an assay component calculated from the ERF_CR_ENZ_hDUSP3 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with spectrophotometry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, 6,8-difluoro-4-methylumbelliferyl, are indicative of changes in enzyme function and kinetics related to the gene DUSP3.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Colorimetric", + "detectionTechnologyTypeSub": "Absorbance ", + "detectionTechnology": "spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4-methylumbelliferyl", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 703, + "assayName": "ERF_CR_ENZ_hDUSP3", + "assayDesc": "ERF_PL_ENZ_hDUSP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See VHR Human Phosphatase Enzymatic Assay, PhosphataseProfiler.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human full length recombinant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 102, + "geneName": "dual specificity phosphatase 3", + "description": null, + "geneSymbol": "DUSP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1845, + "officialSymbol": "DUSP3", + "officialFullName": "dual specificity phosphatase 3", + "uniprotAccessionNumber": "P51452" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2572, + "assayComponentEndpointName": "ERF_CR_ENZ_hDYRK1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hDYRK1A was analyzed at the assay endpoint, ERF_CR_ENZ_hDYRK1A, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DYRK1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2525, + "assayComponentName": "ERF_CR_ENZ_hDYRK1A", + "assayComponentDesc": "ERF_CR_ENZ_hDYRK1A is an assay component calculated from the ERF_CR_ENZ_hDYRK1A assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide, are indicative of changes in enzyme function and kinetics related to the gene DYRK1A.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CFFKNIVTPRTPPPSQGK-amide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 766, + "assayName": "ERF_CR_ENZ_hDYRK1A", + "assayDesc": "ERF_CR_ENZ_hDYRK1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See DYRK1A Human CMGC Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 103, + "geneName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "description": null, + "geneSymbol": "DYRK1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1859, + "officialSymbol": "DYRK1A", + "officialFullName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "uniprotAccessionNumber": "Q13627" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1847, + "assayComponentEndpointName": "TOX21_AP1_BLA_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1145, + "assayComponentName": "TOX21_AP1_BLA_Agonist_viability", + "assayComponentDesc": "TOX21_AP1_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 452, + "assayName": "TOX21_AP1_BLA_Agonist", + "assayDesc": "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "ME-180", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": null, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1848, + "assayComponentEndpointName": "CCTE_Simmons_QuantiLum_inhib_2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CCTE_Simmons_QuantiLum_inhib_2 was analyzed at the endpoint, CCTE_Simmons_QuantiLum_inhib_2, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand inhibition of firefly luciferase. This is an assay endpoint to indicate nonspecific protein inhibition for comparison to aeid 1508 for thyroperoxidase inhibition. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monooxygenase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "b-naphthoquinone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1146, + "assayComponentName": "CCTE_Simmons_QuantiLum_inhib_2", + "assayComponentDesc": "CCTE_Simmons_QuantiLum_inhib_2 is the assay component measured from the CCTE_Simmons_QuantiLum_inhib_2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with bioluminescence signals by Luciferase-coupled Quantilum levels technology. This is a secondary assay to CCTE_Simmons_AUR_TPO to to evaluate nonspecific enzyme inhibition.", + "assayComponentTargetDesc": "CCTE_Simmons_QuantiLum_inhib_2 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Luciferase detection reagent] and is used to understand nonspecific enzyme inhibition.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase-coupled Quantilum levels", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Luciferase detection reagent", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 453, + "assayName": "CCTE_Simmons_QuantiLum_inhib_2", + "assayDesc": "CCTE_Simmons_QuantiLum_inhib_2 is a biochemical, single-readout assay that uses purified luciferase enzyme in a cell-free assay.Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 0, + "organism": "E.coli", + "tissue": "purified enzyme", + "cellFormat": "cell-free", + "cellFreeComponentSource": "overexpression in E. coli", + "cellShortName": "", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.2, + "asid": 17, + "assaySourceName": "CCTE", + "assaySourceLongName": "CCTE Labs", + "assaySourceDesc": "The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.", + "gene": { + "geneId": 497, + "geneName": "luciferase [Cloning vector pGL3-Basic, complete sequence]", + "description": null, + "geneSymbol": null, + "organismId": 12, + "trackStatus": "live", + "entrezGeneId": null, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "U47295" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1021/tx400310w", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24383450", + "pmid": 24383450, + "title": "Development of a thyroperoxidase inhibition assay for high-throughput screening", + "author": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO", + "citation": "Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem Res Toxicol. 2014 Mar 17;27(3):387-99. doi: 10.1021/tx400310w. Epub 2014 Jan 14. PubMed PMID: 24383450.", + "otherId": "0", + "citationId": 218, + "otherSource": "" + } + }, + { + "aeid": 1850, + "assayComponentEndpointName": "ACEA_AR_agonist_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1802, + "assayComponentName": "ACEA_AR_agonist_AUC_viability", + "assayComponentDesc": "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 533, + "assayName": "ACEA_AR_agonist", + "assayDesc": "ACEA_AR_agonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1852, + "assayComponentEndpointName": "ACEA_ER_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_ER_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1804, + "assayComponentName": "ACEA_ER_AUC_viability", + "assayComponentDesc": "ACEA_ER_AUC_viability is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 1, + "assayName": "ACEA_ER", + "assayDesc": "ACEA_ER is a cell-based, single-readout assay that uses T47D, a human breast cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "T47D", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16481145", + "pmid": 16481145, + "title": "Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity", + "author": "Xing JZ, Zhu L, Gabos S, Xie L", + "citation": "Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006 Sep;20(6):995-1004. Epub 2006 Feb 14. PubMed PMID: 16481145.", + "otherId": "0", + "citationId": 209, + "otherSource": "" + } + }, + { + "aeid": 1855, + "assayComponentEndpointName": "ACEA_AR_agonist_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "testosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1829, + "assayComponentName": "ACEA_AR_agonist_80hr", + "assayComponentDesc": "ACEA_AR_agonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 533, + "assayName": "ACEA_AR_agonist", + "assayDesc": "ACEA_AR_agonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1856, + "assayComponentEndpointName": "ACEA_AR_antagonist_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1830, + "assayComponentName": "ACEA_AR_antagonist_80hr", + "assayComponentDesc": "ACEA_AR_antagonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 534, + "assayName": "ACEA_AR_antagonist", + "assayDesc": "ACEA_AR_antagonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 1857, + "assayComponentEndpointName": "ACEA_AR_antagonist_AUC_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "MG 132", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 1831, + "assayComponentName": "ACEA_AR_antagonist_AUC_viability", + "assayComponentDesc": "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 534, + "assayName": "ACEA_AR_antagonist", + "assayDesc": "ACEA_AR_antagonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "prostate", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "22Rv1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 1858, + "assayComponentEndpointName": "STM_H9_NormalizedViability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component STM_H9_Viability was analyzed at the assay endpoint STM_H9_Viability_Norm in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1114, + "assayComponentName": "STM_H9_NormalizedViability", + "assayComponentDesc": "STM_H9_NormalizedViability is a component calculated in the STM_H9_viability assay. It measures cell viability using background corrected relative fluorescence units (RFU) value from the CellTiterFluor Assay normalized to the value of the 0.1% DMSO neutral control treatment (by 96-well plate)", + "assayComponentTargetDesc": "Changes in fluorescence are indicative of changes in cell viability. ", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell viability", + "biologicalProcessTarget": "cell viability", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "fluorescent signal proportional to the number of living cells", + "detectionTechnology": "CellTiter-FluorTM", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "fluorescent signal", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "living cells", + "aid": 437, + "assayName": "STM_H9_viability", + "assayDesc": "STM_H9_viability utilizes undifferentiated H9 cells to measure cell viability.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-based", + "cellFreeComponentSource": "H9 embryonic stem cell line", + "cellShortName": "hESC", + "cellGrowthMode": "monolayer", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "metabolomic", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 14, + "assaySourceName": "STM", + "assaySourceLongName": "Stemina Biomarker Discovery", + "assaySourceDesc": "Stemina Biomarker Discovery is a Contract Research Organization (CRO) that provides stem cell-based developmental toxicity screening for chemical compounds. ", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfaa014", + "url": "https://pubmed.ncbi.nlm.nih.gov/32073639/", + "pmid": 32073639, + "title": "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity", + "author": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB", + "citation": "Zurlinden TJ, Saili KS, Rush N, Kothiya P, Judson RS, Houck KA, Hunter ES, Baker NC, Palmer JA, Thomas RS, Knudsen TB. Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicol Sci. 2020 Apr 1;174(2):189-209. doi: 10.1093/toxsci/kfaa014. PMID: 32073639.", + "otherId": "0", + "citationId": 248, + "otherSource": "" + } + }, + { + "aeid": 89, + "assayComponentEndpointName": "ATG_M_32_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_32_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_32_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 58, + "assayComponentName": "ATG_M_32_CIS", + "assayComponentDesc": "ATG_M_32_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 1913, + "assayComponentEndpointName": "ATG_chAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1856, + "assayComponentName": "ATG_chAR_XSP1", + "assayComponentDesc": "ATG_chAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the chicken androgen receptor. [GeneSymbol:ar | GeneID:422165| Uniprot_SwissProt_Accession:Q2ACE0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1474, + "geneName": "androgen receptor", + "description": "androgen receptor (chicken)", + "geneSymbol": "AR", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 422165, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "Q2ACE0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1915, + "assayComponentEndpointName": "ATG_frAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1857, + "assayComponentName": "ATG_frAR_XSP1", + "assayComponentDesc": "ATG_frAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the frog androgen receptor. [GeneSymbol:ar.L | GeneID:399456| Uniprot_SwissProt_Accession:P70048].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1479, + "geneName": "androgen receptor L homeolog", + "description": "androgen receptor L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "ar.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 399456, + "officialSymbol": "ar.L", + "officialFullName": "androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) L homeolog", + "uniprotAccessionNumber": "P70048" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1917, + "assayComponentEndpointName": "ATG_hAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1858, + "assayComponentName": "ATG_hAR_XSP1", + "assayComponentDesc": "ATG_hAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the human androgen receptor. [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1919, + "assayComponentEndpointName": "ATG_trAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1859, + "assayComponentName": "ATG_trAR_XSP1", + "assayComponentDesc": "ATG_trAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the turtle androgen receptor. [GeneSymbol:AR | GeneID:101947425 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1464, + "geneName": "androgen receptor", + "description": "PREDICTED: Chrysemys picta bellii androgen receptor (AR), mRNA", + "geneSymbol": "AR", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101947425, + "officialSymbol": "NA", + "officialFullName": "NA", + "uniprotAccessionNumber": "NA" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 2573, + "assayComponentEndpointName": "ERF_CR_ENZ_hEGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ENZ_hEGFR was analyzed at the assay endpoint, ERF_CR_ENZ_hEGFR, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EGFR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "hydrochloride", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2526, + "assayComponentName": "ERF_CR_ENZ_hEGFR", + "assayComponentDesc": "ERF_CR_ENZ_hEGFR is an assay component calculated from the ERF_CR_ENZ_hEGFR assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity with LANCE technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity produced from the regulation of catalytic activity reaction involving the key substrate, ATP + Ulight-CAGAGAIETDKEYYTVKD, are indicative of changes in receptor function and kinetics related to the gene EGFR.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "LANCE", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "ATP + Ulight-CAGAGAIETDKEYYTVKD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 768, + "assayName": "ERF_CR_ENZ_hEGFR", + "assayDesc": "ERF_CR_ENZ_hEGFR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate. See EGFR Human RTK Kinase Enzymatic LANCE Assay [Km ATP], Cerep.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 628, + "assayComponentEndpointName": "NVS_GPCR_hAdra2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdra2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 365, + "assayComponentName": "NVS_GPCR_hAdra2A", + "assayComponentDesc": "NVS_GPCR_hAdra2A is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdra2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2A [GeneSymbol:ADRA2A | GeneID:150 | Uniprot_SwissProt_Accession:P08913].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 179, + "assayName": "NVS_GPCR_hAdra2A", + "assayDesc": "NVS_GPCR_hAdra2A is a biochemical, single-readout assay that uses extracted gene-proteins from HT29 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HT29", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 13, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "ADRA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 150, + "officialSymbol": "ADRA2A", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P08913" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 629, + "assayComponentEndpointName": "NVS_GPCR_hAdra2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 366, + "assayComponentName": "NVS_GPCR_hAdra2C", + "assayComponentDesc": "NVS_GPCR_hAdra2C is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdra2C assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2C [GeneSymbol:ADRA2C | GeneID:152 | Uniprot_SwissProt_Accession:P18825].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 180, + "assayName": "NVS_GPCR_hAdra2C", + "assayDesc": "NVS_GPCR_hAdra2C is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 14, + "geneName": "adrenoceptor alpha 2C", + "description": null, + "geneSymbol": "ADRA2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 152, + "officialSymbol": "ADRA2C", + "officialFullName": "adrenoceptor alpha 2C", + "uniprotAccessionNumber": "P18825" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 630, + "assayComponentEndpointName": "NVS_GPCR_hAdrb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 367, + "assayComponentName": "NVS_GPCR_hAdrb1", + "assayComponentDesc": "NVS_GPCR_hAdrb1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 1 [GeneSymbol:ADRB1 | GeneID:153 | Uniprot_SwissProt_Accession:P08588].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 181, + "assayName": "NVS_GPCR_hAdrb1", + "assayDesc": "NVS_GPCR_hAdrb1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroepithelioma cells in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neuroepithelioma cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 15, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "ADRB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 153, + "officialSymbol": "ADRB1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P08588" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/39246", + "pmid": 39246, + "title": "Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes", + "author": "Minneman KP, Hegstrand LR, Molinoff PB", + "citation": "Minneman KP, Hegstrand LR, Molinoff PB. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol. 1979 Jul;16(1):34-46. PubMed PMID: 39246.", + "otherId": "0", + "citationId": 2, + "otherSource": "" + } + }, + { + "aeid": 519, + "assayComponentEndpointName": "NVS_ENZ_hPKD2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKD2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKD2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 301, + "assayComponentName": "NVS_ENZ_hPKD2", + "assayComponentDesc": "NVS_ENZ_hPKD2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKD2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase D2 [GeneSymbol:PRKD2 | GeneID:25865 | Uniprot_SwissProt_Accession:Q9BZL6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 115, + "assayName": "NVS_ENZ_hPKD2", + "assayDesc": "NVS_ENZ_hPKD2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 416, + "geneName": "protein kinase D2", + "description": null, + "geneSymbol": "PRKD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25865, + "officialSymbol": "PRKD2", + "officialFullName": "protein kinase D2", + "uniprotAccessionNumber": "Q9BZL6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 521, + "assayComponentEndpointName": "NVS_ENZ_hPPM1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPM1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPM1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "sodium fluoride", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 302, + "assayComponentName": "NVS_ENZ_hPPM1A", + "assayComponentDesc": "NVS_ENZ_hPPM1A is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPM1A assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:FDP(non-fluorescent) --> fluorescein + fluorescein monophosphate] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase, Mg2+/Mn2+ dependent, 1A [GeneSymbol:PPM1A | GeneID:5494 | Uniprot_SwissProt_Accession:P35813].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 116, + "assayName": "NVS_ENZ_hPPM1A", + "assayDesc": "NVS_ENZ_hPPM1A is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 251, + "geneName": "protein phosphatase, Mg2+/Mn2+ dependent, 1A", + "description": null, + "geneSymbol": "PPM1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5494, + "officialSymbol": "PPM1A", + "officialFullName": "protein phosphatase, Mg2+/Mn2+ dependent, 1A", + "uniprotAccessionNumber": "P35813" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 523, + "assayComponentEndpointName": "NVS_ENZ_hPPP1CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP1CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "calyculin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 303, + "assayComponentName": "NVS_ENZ_hPPP1CA", + "assayComponentDesc": "NVS_ENZ_hPPP1CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP1CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 1, catalytic subunit, alpha isozyme [GeneSymbol:PPP1CA | GeneID:5499 | Uniprot_SwissProt_Accession:P62136].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 117, + "assayName": "NVS_ENZ_hPPP1CA", + "assayDesc": "NVS_ENZ_hPPP1CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 252, + "geneName": "protein phosphatase 1, catalytic subunit, alpha isozyme", + "description": null, + "geneSymbol": "PPP1CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5499, + "officialSymbol": "PPP1CA", + "officialFullName": "protein phosphatase 1, catalytic subunit, alpha isozyme", + "uniprotAccessionNumber": "P62136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7882291", + "pmid": 7882291, + "title": "Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor", + "author": "Sogawa K, Yamada T, Oka S, Kawasaki K, Mori S, Tanaka H, Norimatsu H, Cai Y, Kuwabara H, Shima H, et al", + "citation": "Sogawa K, Yamada T, Oka S, Kawasaki K, Mori S, Tanaka H, Norimatsu H, Cai Y, Kuwabara H, Shima H, et al. Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor. Cancer Lett. 1995 Feb 10;89(1):1-6. PubMed PMID: 7882291.", + "otherId": "0", + "citationId": 148, + "otherSource": "" + } + }, + { + "aeid": 525, + "assayComponentEndpointName": "NVS_ENZ_hPPP2CA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPPP2CA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "calyculin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "serine/threonine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 304, + "assayComponentName": "NVS_ENZ_hPPP2CA", + "assayComponentDesc": "NVS_ENZ_hPPP2CA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPPP2CA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein phosphatase 2, catalytic subunit, alpha isozyme [GeneSymbol:PPP2CA | GeneID:5515 | Uniprot_SwissProt_Accession:P67775].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 118, + "assayName": "NVS_ENZ_hPPP2CA", + "assayDesc": "NVS_ENZ_hPPP2CA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 253, + "geneName": "protein phosphatase 2, catalytic subunit, alpha isozyme", + "description": null, + "geneSymbol": "PPP2CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5515, + "officialSymbol": "PPP2CA", + "officialFullName": "protein phosphatase 2, catalytic subunit, alpha isozyme", + "uniprotAccessionNumber": "P67775" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/343651a0", + "url": "#http://www.ncbi.nlm.nih.gov/pubmed/2154696#", + "pmid": 2154696, + "title": "Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase", + "author": "Anderson NG, Maller JL, Tonks NK, Sturgill TW", + "citation": "Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature. 1990 Feb 15;343(6259):651-3. PubMed PMID: 2154696.", + "otherId": "0", + "citationId": 207, + "otherSource": "" + } + }, + { + "aeid": 527, + "assayComponentEndpointName": "NVS_ENZ_hPTEN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTEN was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "bpV (bipy)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 305, + "assayComponentName": "NVS_ENZ_hPTEN", + "assayComponentDesc": "NVS_ENZ_hPTEN is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTEN assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP3 --> fluorescein-PIP2] involving the key substrate [Fluorescein-labeled PIP3 (phosphoinositol triphosphate(3,4,5))] are indicative of changes in enzyme function and kinetics for the human phosphatase and tensin homolog [GeneSymbol:PTEN | GeneID:5728 | Uniprot_SwissProt_Accession:P60484].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled PIP3 (phosphoinositol triphosphate(3,4,5))", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 119, + "assayName": "NVS_ENZ_hPTEN", + "assayDesc": "NVS_ENZ_hPTEN is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 263, + "geneName": "phosphatase and tensin homolog", + "description": null, + "geneSymbol": "PTEN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5728, + "officialSymbol": "PTEN", + "officialFullName": "phosphatase and tensin homolog", + "uniprotAccessionNumber": "P60484" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 529, + "assayComponentEndpointName": "NVS_ENZ_hPTPN1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 306, + "assayComponentName": "NVS_ENZ_hPTPN1", + "assayComponentDesc": "NVS_ENZ_hPTPN1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 1 [GeneSymbol:PTPN1 | GeneID:5770 | Uniprot_SwissProt_Accession:P18031].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 120, + "assayName": "NVS_ENZ_hPTPN1", + "assayDesc": "NVS_ENZ_hPTPN1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 265, + "geneName": "protein tyrosine phosphatase, non-receptor type 1", + "description": null, + "geneSymbol": "PTPN1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5770, + "officialSymbol": "PTPN1", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 1", + "uniprotAccessionNumber": "P18031" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1335746", + "pmid": 1335746, + "title": "1002 protein phosphatases?", + "author": "Charbonneau H, Tonks NK", + "citation": "Charbonneau H, Tonks NK. 1002 protein phosphatases? Annu Rev Cell Biol. 1992;8:463-93. Review. PubMed PMID: 1335746.", + "otherId": "0", + "citationId": 15, + "otherSource": "" + } + }, + { + "aeid": 531, + "assayComponentEndpointName": "NVS_ENZ_hPTPN11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN11, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 307, + "assayComponentName": "NVS_ENZ_hPTPN11", + "assayComponentDesc": "NVS_ENZ_hPTPN11 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 11 [GeneSymbol:PTPN11 | GeneID:5781 | Uniprot_SwissProt_Accession:Q06124].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 121, + "assayName": "NVS_ENZ_hPTPN11", + "assayDesc": "NVS_ENZ_hPTPN11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 270, + "geneName": "protein tyrosine phosphatase, non-receptor type 11", + "description": null, + "geneSymbol": "PTPN11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5781, + "officialSymbol": "PTPN11", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 11", + "uniprotAccessionNumber": "Q06124" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 533, + "assayComponentEndpointName": "NVS_ENZ_hPTPN12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN12, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 308, + "assayComponentName": "NVS_ENZ_hPTPN12", + "assayComponentDesc": "NVS_ENZ_hPTPN12 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 12 [GeneSymbol:PTPN12 | GeneID:5782 | Uniprot_SwissProt_Accession:Q05209].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 122, + "assayName": "NVS_ENZ_hPTPN12", + "assayDesc": "NVS_ENZ_hPTPN12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 271, + "geneName": "protein tyrosine phosphatase, non-receptor type 12", + "description": null, + "geneSymbol": "PTPN12", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5782, + "officialSymbol": "PTPN12", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 12", + "uniprotAccessionNumber": "Q05209" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 537, + "assayComponentEndpointName": "NVS_ENZ_hPTPN14", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN14, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 310, + "assayComponentName": "NVS_ENZ_hPTPN14", + "assayComponentDesc": "NVS_ENZ_hPTPN14 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN14 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 14 [GeneSymbol:PTPN14 | GeneID:5784 | Uniprot_SwissProt_Accession:Q15678].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 124, + "assayName": "NVS_ENZ_hPTPN14", + "assayDesc": "NVS_ENZ_hPTPN14 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 273, + "geneName": "protein tyrosine phosphatase, non-receptor type 14", + "description": null, + "geneSymbol": "PTPN14", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5784, + "officialSymbol": "PTPN14", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 14", + "uniprotAccessionNumber": "Q15678" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 539, + "assayComponentEndpointName": "NVS_ENZ_hPTPN2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 311, + "assayComponentName": "NVS_ENZ_hPTPN2", + "assayComponentDesc": "NVS_ENZ_hPTPN2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, AMP-activated, gamma 1 non-catalytic subunit [GeneSymbol:PRKAG1 | GeneID:5571 | Uniprot_SwissProt_Accession:P54619].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 125, + "assayName": "NVS_ENZ_hPTPN2", + "assayDesc": "NVS_ENZ_hPTPN2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 266, + "geneName": "protein tyrosine phosphatase, non-receptor type 2", + "description": null, + "geneSymbol": "PTPN2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5771, + "officialSymbol": "PTPN2", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 2", + "uniprotAccessionNumber": "P17706" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 541, + "assayComponentEndpointName": "NVS_ENZ_hPTPN4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 312, + "assayComponentName": "NVS_ENZ_hPTPN4", + "assayComponentDesc": "NVS_ENZ_hPTPN4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) [GeneSymbol:PTPN4 | GeneID:5775 | Uniprot_SwissProt_Accession:P29074].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 126, + "assayName": "NVS_ENZ_hPTPN4", + "assayDesc": "NVS_ENZ_hPTPN4 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 267, + "geneName": "protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)", + "description": null, + "geneSymbol": "PTPN4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5775, + "officialSymbol": "PTPN4", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)", + "uniprotAccessionNumber": "P29074" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 543, + "assayComponentEndpointName": "NVS_ENZ_hPTPN6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 313, + "assayComponentName": "NVS_ENZ_hPTPN6", + "assayComponentDesc": "NVS_ENZ_hPTPN6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 6 [GeneSymbol:PTPN6 | GeneID:5777 | Uniprot_SwissProt_Accession:P29350].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 127, + "assayName": "NVS_ENZ_hPTPN6", + "assayDesc": "NVS_ENZ_hPTPN6 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 268, + "geneName": "protein tyrosine phosphatase, non-receptor type 6", + "description": null, + "geneSymbol": "PTPN6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5777, + "officialSymbol": "PTPN6", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 6", + "uniprotAccessionNumber": "P29350" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 545, + "assayComponentEndpointName": "NVS_ENZ_hPTPN9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is non-receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "non-receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 314, + "assayComponentName": "NVS_ENZ_hPTPN9", + "assayComponentDesc": "NVS_ENZ_hPTPN9 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPN9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 9 [GeneSymbol:PTPN9 | GeneID:5780 | Uniprot_SwissProt_Accession:P43378].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 128, + "assayName": "NVS_ENZ_hPTPN9", + "assayDesc": "NVS_ENZ_hPTPN9 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 269, + "geneName": "protein tyrosine phosphatase, non-receptor type 9", + "description": null, + "geneSymbol": "PTPN9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5780, + "officialSymbol": "PTPN9", + "officialFullName": "protein tyrosine phosphatase, non-receptor type 9", + "uniprotAccessionNumber": "P43378" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 547, + "assayComponentEndpointName": "NVS_ENZ_hPTPRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRB was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 315, + "assayComponentName": "NVS_ENZ_hPTPRB", + "assayComponentDesc": "NVS_ENZ_hPTPRB is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRB assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, B [GeneSymbol:PTPRB | GeneID:5787 | Uniprot_SwissProt_Accession:P23467].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 129, + "assayName": "NVS_ENZ_hPTPRB", + "assayDesc": "NVS_ENZ_hPTPRB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 274, + "geneName": "protein tyrosine phosphatase, receptor type, B", + "description": null, + "geneSymbol": "PTPRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5787, + "officialSymbol": "PTPRB", + "officialFullName": "protein tyrosine phosphatase, receptor type, B", + "uniprotAccessionNumber": "P23467" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1335746", + "pmid": 1335746, + "title": "1002 protein phosphatases?", + "author": "Charbonneau H, Tonks NK", + "citation": "Charbonneau H, Tonks NK. 1002 protein phosphatases? Annu Rev Cell Biol. 1992;8:463-93. Review. PubMed PMID: 1335746.", + "otherId": "0", + "citationId": 15, + "otherSource": "" + } + }, + { + "aeid": 549, + "assayComponentEndpointName": "NVS_ENZ_hPTPRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 316, + "assayComponentName": "NVS_ENZ_hPTPRC", + "assayComponentDesc": "NVS_ENZ_hPTPRC is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction [Reaction:pNPP --> p-nitrophenol] involving the key substrate [para-Nitrophenylphosphate (pNPP)] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, C [GeneSymbol:PTPRC | GeneID:5788 | Uniprot_SwissProt_Accession:P08575].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "para-Nitrophenylphosphate (pNPP)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 130, + "assayName": "NVS_ENZ_hPTPRC", + "assayDesc": "NVS_ENZ_hPTPRC is a biochemical, single-readout assay that uses extracted gene-proteins from yeast cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "yeast cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 275, + "geneName": "protein tyrosine phosphatase, receptor type, C", + "description": null, + "geneSymbol": "PTPRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5788, + "officialSymbol": "PTPRC", + "officialFullName": "protein tyrosine phosphatase, receptor type, C", + "uniprotAccessionNumber": "P08575" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8031864", + "pmid": 8031864, + "title": "High level expression and purification of the enzymatically active cytoplasmic region of human CD45 phosphatase from yeast", + "author": "Pacitti A, Stevis P, Evans M, Trowbridge I, Higgins TJ", + "citation": "Pacitti A, Stevis P, Evans M, Trowbridge I, Higgins TJ. High level expression and purification of the enzymatically active cytoplasmic region of human CD45 phosphatase from yeast. Biochim Biophys Acta. 1994 Jun 30;1222(2):277-86. PubMed PMID: 8031864.", + "otherId": "0", + "citationId": 153, + "otherSource": "" + } + }, + { + "aeid": 1921, + "assayComponentEndpointName": "ATG_zfAR_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfAR_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1860, + "assayComponentName": "ATG_zfAR_XSP1", + "assayComponentDesc": "ATG_zfAR_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element AR, which is responsive to the zebrafish androgen receptor. [GeneSymbol:AR | GeneID:100005148 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1467, + "geneName": "androgen receptor", + "description": "androgen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "ar", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 100005148, + "officialSymbol": "ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "A4GT83" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1923, + "assayComponentEndpointName": "ATG_frER1_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER1_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1861, + "assayComponentName": "ATG_frER1_XSP1", + "assayComponentDesc": "ATG_frER1_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr1.L | GeneID: 398734 | Uniprot_SwissProt_Accession:Q6W5G7].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1480, + "geneName": "estrogen receptor 1 L homeolog", + "description": "estrogen receptor 1 L homeolog [Xenopus laevis (African clawed frog)]", + "geneSymbol": "esr1.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 398734, + "officialSymbol": "esr1.L", + "officialFullName": "estrogen receptor 1 L homeolog", + "uniprotAccessionNumber": "Q6W5G7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1925, + "assayComponentEndpointName": "ATG_zfER1_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER1_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1862, + "assayComponentName": "ATG_zfER1_XSP1", + "assayComponentDesc": "ATG_zfER1_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr1 | GeneID: 259252| Uniprot_SwissProt_Accession:P57717].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1468, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor [Danio rerio (zebrafish)]", + "geneSymbol": "esr1", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 259252, + "officialSymbol": "esr1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P57717" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1927, + "assayComponentEndpointName": "ATG_zfER2a_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2a_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1863, + "assayComponentName": "ATG_zfER2a_XSP1", + "assayComponentDesc": "ATG_zfER2a_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2a | GeneID: 317734| Uniprot_SwissProt_Accession:Q7ZU32].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1469, + "geneName": "estrogen receptor 2a", + "description": "estrogen receptor 2a [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2a", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317734, + "officialSymbol": "esr2a", + "officialFullName": "estrogen receptor 2a", + "uniprotAccessionNumber": "Q7ZU32" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1929, + "assayComponentEndpointName": "ATG_zfER2b_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_zfER2b_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1864, + "assayComponentName": "ATG_zfER2b_XSP1", + "assayComponentDesc": "ATG_zfER2b_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the zebrafish estrogen receptor. [GeneSymbol:esr2b | GeneID: 317733| Uniprot_SwissProt_Accession:Q5PR29].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-zfER2b RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1470, + "geneName": "estrogen receptor 2b", + "description": "estrogen receptor 2b [ Danio rerio (zebrafish) ]", + "geneSymbol": "esr2b", + "organismId": 43, + "trackStatus": null, + "entrezGeneId": 317733, + "officialSymbol": "esr2b", + "officialFullName": "estrogen receptor 2b", + "uniprotAccessionNumber": "Q5PR29" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1931, + "assayComponentEndpointName": "ATG_frER2_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_frER2_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1865, + "assayComponentName": "ATG_frER2_XSP1", + "assayComponentDesc": "ATG_frER2_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the frog estrogen receptor. [GeneSymbol:esr2.L | GeneID: 100174814| Uniprot_SwissProt_Accession:A0A1L8FA50].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-frER2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1481, + "geneName": "estrogen receptor 2 L homeolog", + "description": "estrogen receptor 2 L homeolog [ Xenopus laevis (African clawed frog) ]", + "geneSymbol": "esr2.L", + "organismId": 46, + "trackStatus": null, + "entrezGeneId": 100174814, + "officialSymbol": "esr2.L", + "officialFullName": "estrogen receptor 2 L homeolog", + "uniprotAccessionNumber": "A0A1L8FA50" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1933, + "assayComponentEndpointName": "ATG_chERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_chERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1866, + "assayComponentName": "ATG_chERa_XSP1", + "assayComponentDesc": "ATG_chERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the chicken estrogen receptor. [GeneSymbol:ESR1 | GeneID: 396099| Uniprot_SwissProt_Accession:P06212].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-chERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1475, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 (chicken)", + "geneSymbol": "ESR1", + "organismId": 45, + "trackStatus": null, + "entrezGeneId": 396099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P06212" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1935, + "assayComponentEndpointName": "ATG_hERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1867, + "assayComponentName": "ATG_hERa_XSP1", + "assayComponentDesc": "ATG_hERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR1 | GeneID: 2099| Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1937, + "assayComponentEndpointName": "ATG_trERa_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_trERa_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1868, + "assayComponentName": "ATG_trERa_XSP1", + "assayComponentDesc": "ATG_trERa_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the turtle estrogen receptor. [GeneSymbol:ESR1 | GeneID: 101933533| Uniprot_SwissProt_Accession:B6E1V9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-trERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 1465, + "geneName": "estrogen receptor 1", + "description": "estrogen receptor 1 [ Chrysemys picta (painted turtle) ]", + "geneSymbol": "ESR1", + "organismId": 42, + "trackStatus": null, + "entrezGeneId": 101933533, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "B6E1V9" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1939, + "assayComponentEndpointName": "ATG_hERb_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint ATG_hERb_XSP1 was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1869, + "assayComponentName": "ATG_hERb_XSP1", + "assayComponentDesc": "ATG_hERb_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the trans-acting reporter gene response element ER, which is responsive to the human estrogen receptor. [GeneSymbol:ESR2 | GeneID: 2100| Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-ERb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 1941, + "assayComponentEndpointName": "ATG_GAL4_XSP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "This assay endpoint, ATG_GAL4_XSP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1870, + "assayComponentName": "ATG_GAL4_XSP1", + "assayComponentDesc": "ATG_GAL4_XSP1 is one of 29 assay components measured or calculated from the ATG_XSP1_multi-species_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "gal4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 569, + "assayName": "ATG_XSP1_multi-species_TRANS", + "assayDesc": "ATG_XSP1_multi-species_TRANS is a cell-based, multiplexed assay created by modifying the existing Attagene TRANS-FACTORIAL system to include a panel of nuclear receptors from some or all the following species: human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), zebrafish (Danio rerio), chicken (Gallus gallus), and turtle (Chrysemys picta). The ECOTOX-FACTORIAL format uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate. Xsp1 included 3 nM 6-alpha-fluorotestosterone to partially stimulate the androgen receptor.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1016/j.tiv.2020.105016", + "url": "https://pubmed.ncbi.nlm.nih.gov/33049310/", + "pmid": 33049310, + "title": "Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment.", + "author": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S", + "citation": "Houck KA, Simha A, Bone A, Doering JA, Vliet SMF, LaLone C, Medvedev A, Makarov S. Evaluation of a multiplexed, multispecies nuclear receptor assay for chemical hazard assessment. Toxicol In Vitro. 2021 Apr;72:105016. doi: 10.1016/j.tiv.2020.105016. Epub 2020 Oct 10. PMID: 33049310.", + "otherId": "0", + "citationId": 237, + "otherSource": "" + } + }, + { + "aeid": 631, + "assayComponentEndpointName": "NVS_GPCR_hAdrb2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 368, + "assayComponentName": "NVS_GPCR_hAdrb2", + "assayComponentDesc": "NVS_GPCR_hAdrb2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 2, surface [GeneSymbol:ADRB2 | GeneID:154 | Uniprot_SwissProt_Accession:P07550].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 182, + "assayName": "NVS_GPCR_hAdrb2", + "assayDesc": "NVS_GPCR_hAdrb2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 16, + "geneName": "adrenoceptor beta 2, surface", + "description": null, + "geneSymbol": "ADRB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 154, + "officialSymbol": "ADRB2", + "officialFullName": "adrenoceptor beta 2, surface", + "uniprotAccessionNumber": "P07550" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/39246", + "pmid": 39246, + "title": "Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes", + "author": "Minneman KP, Hegstrand LR, Molinoff PB", + "citation": "Minneman KP, Hegstrand LR, Molinoff PB. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol. 1979 Jul;16(1):34-46. PubMed PMID: 39246.", + "otherId": "0", + "citationId": 2, + "otherSource": "" + } + }, + { + "aeid": 2, + "assayComponentEndpointName": "ACEA_ER_80hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ACEA_ER_80hr was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 1, + "assayComponentName": "ACEA_ER_80hr", + "assayComponentDesc": "ACEA_ER_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", + "assayComponentTargetDesc": "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", + "parameterReadoutType": "single", + "assayDesignType": "growth reporter", + "assayDesignTypeSub": "real-time cell-growth kinetics", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Label Free Technology", + "detectionTechnologyTypeSub": "Electrical Sensor: Impedance", + "detectionTechnology": "RT-CES", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 1, + "assayName": "ACEA_ER", + "assayDesc": "ACEA_ER is a cell-based, single-readout assay that uses T47D, a human breast cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", + "timepointHr": 80.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "T47D", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 1, + "assaySourceName": "ACEA", + "assaySourceLongName": "ACEA Biosciences", + "assaySourceDesc": "ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that developed a real-time, label-free, cell growth assay system called xCELLigence based on a microelectronic impedance readout .", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16481145", + "pmid": 16481145, + "title": "Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity", + "author": "Xing JZ, Zhu L, Gabos S, Xie L", + "citation": "Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006 Sep;20(6):995-1004. Epub 2006 Feb 14. PubMed PMID: 16481145.", + "otherId": "0", + "citationId": 209, + "otherSource": "" + } + }, + { + "aeid": 4, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2, + "assayComponentName": "APR_HepG2_CellCycleArrest_1hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 6, + "assayComponentEndpointName": "APR_HepG2_CellLoss_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 3, + "assayComponentName": "APR_HepG2_CellLoss_1hr", + "assayComponentDesc": "APR_HepG2_CellLoss_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 8, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 4, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_1hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 10, + "assayComponentEndpointName": "APR_HepG2_MitoMass_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 5, + "assayComponentName": "APR_HepG2_MitoMass_1hr", + "assayComponentDesc": "APR_HepG2_MitoMass_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 12, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 6, + "assayComponentName": "APR_HepG2_MitoMembPot_1hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 14, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 7, + "assayComponentName": "APR_HepG2_MitoticArrest_1hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 16, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 8, + "assayComponentName": "APR_HepG2_NuclearSize_1hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 18, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 9, + "assayComponentName": "APR_HepG2_P-H2AX_1hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 20, + "assayComponentEndpointName": "APR_HepG2_p53Act_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 10, + "assayComponentName": "APR_HepG2_p53Act_1hr", + "assayComponentDesc": "APR_HepG2_p53Act_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 22, + "assayComponentEndpointName": "APR_HepG2_StressKinase_1hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_1hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 11, + "assayComponentName": "APR_HepG2_StressKinase_1hr", + "assayComponentDesc": "APR_HepG2_StressKinase_1hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_1hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 2, + "assayName": "APR_HepG2_1hr", + "assayDesc": "APR_HepG2_1hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 24, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 12, + "assayComponentName": "APR_HepG2_CellCycleArrest_24hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 26, + "assayComponentEndpointName": "APR_HepG2_CellLoss_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 13, + "assayComponentName": "APR_HepG2_CellLoss_24hr", + "assayComponentDesc": "APR_HepG2_CellLoss_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 28, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 14, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_24hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 30, + "assayComponentEndpointName": "APR_HepG2_MitoMass_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 15, + "assayComponentName": "APR_HepG2_MitoMass_24hr", + "assayComponentDesc": "APR_HepG2_MitoMass_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 32, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 16, + "assayComponentName": "APR_HepG2_MitoMembPot_24hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 34, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 17, + "assayComponentName": "APR_HepG2_MitoticArrest_24hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 36, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 18, + "assayComponentName": "APR_HepG2_NuclearSize_24hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 38, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 19, + "assayComponentName": "APR_HepG2_P-H2AX_24hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 40, + "assayComponentEndpointName": "APR_HepG2_p53Act_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 20, + "assayComponentName": "APR_HepG2_p53Act_24hr", + "assayComponentDesc": "APR_HepG2_p53Act_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 42, + "assayComponentEndpointName": "APR_HepG2_StressKinase_24hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 21, + "assayComponentName": "APR_HepG2_StressKinase_24hr", + "assayComponentDesc": "APR_HepG2_StressKinase_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 3, + "assayName": "APR_HepG2_24hr", + "assayDesc": "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 44, + "assayComponentEndpointName": "APR_HepG2_CellCycleArrest_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 22, + "assayComponentName": "APR_HepG2_CellCycleArrest_72hr", + "assayComponentDesc": "APR_HepG2_CellCycleArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 46, + "assayComponentEndpointName": "APR_HepG2_CellLoss_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin;Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 23, + "assayComponentName": "APR_HepG2_CellLoss_72hr", + "assayComponentDesc": "APR_HepG2_CellLoss_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "cell number", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 48, + "assayComponentEndpointName": "APR_HepG2_MicrotubuleCSK_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 24, + "assayComponentName": "APR_HepG2_MicrotubuleCSK_72hr", + "assayComponentDesc": "APR_HepG2_MicrotubuleCSK_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", + "parameterReadoutType": "single", + "assayDesignType": "conformation reporter", + "assayDesignTypeSub": "protein conformation", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-a-tubulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 339, + "geneName": "tubulin, alpha 1a", + "description": null, + "geneSymbol": "TUBA1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7846, + "officialSymbol": "TUBA1A", + "officialFullName": "tubulin, alpha 1a", + "uniprotAccessionNumber": "Q71U36" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 551, + "assayComponentEndpointName": "NVS_ENZ_hPTPRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 317, + "assayComponentName": "NVS_ENZ_hPTPRF", + "assayComponentDesc": "NVS_ENZ_hPTPRF is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRF assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, F [GeneSymbol:PTPRF | GeneID:5792 | Uniprot_SwissProt_Accession:P10586].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 131, + "assayName": "NVS_ENZ_hPTPRF", + "assayDesc": "NVS_ENZ_hPTPRF is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 276, + "geneName": "protein tyrosine phosphatase, receptor type, F", + "description": null, + "geneSymbol": "PTPRF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5792, + "officialSymbol": "PTPRF", + "officialFullName": "protein tyrosine phosphatase, receptor type, F", + "uniprotAccessionNumber": "P10586" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1943774", + "pmid": 1943774, + "title": "Use of vanadate as protein-phosphotyrosine phosphatase inhibitor", + "author": "Gordon JA", + "citation": "Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. Review. PubMed PMID: 1943774.", + "otherId": "0", + "citationId": 26, + "otherSource": "" + } + }, + { + "aeid": 553, + "assayComponentEndpointName": "NVS_ENZ_hPTPRM", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPTPRM was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPTPRM, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptor tyrosine phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "receptor tyrosine phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 318, + "assayComponentName": "NVS_ENZ_hPTPRM", + "assayComponentDesc": "NVS_ENZ_hPTPRM is one of one assay component(s) measured or calculated from the NVS_ENZ_hPTPRM assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, M [GeneSymbol:PTPRM | GeneID:5797 | Uniprot_SwissProt_Accession:P28827].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 132, + "assayName": "NVS_ENZ_hPTPRM", + "assayDesc": "NVS_ENZ_hPTPRM is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1.33 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 277, + "geneName": "protein tyrosine phosphatase, receptor type, M", + "description": null, + "geneSymbol": "PTPRM", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5797, + "officialSymbol": "PTPRM", + "officialFullName": "protein tyrosine phosphatase, receptor type, M", + "uniprotAccessionNumber": "P28827" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 555, + "assayComponentEndpointName": "NVS_ENZ_hRAF1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hRAF1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hRAF1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 319, + "assayComponentName": "NVS_ENZ_hRAF1", + "assayComponentDesc": "NVS_ENZ_hRAF1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hRAF1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Raf-1 proto-oncogene, serine/threonine kinase [GeneSymbol:RAF1 | GeneID:5894 | Uniprot_SwissProt_Accession:P04049].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 133, + "assayName": "NVS_ENZ_hRAF1", + "assayDesc": "NVS_ENZ_hRAF1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 278, + "geneName": "Raf-1 proto-oncogene, serine/threonine kinase", + "description": null, + "geneSymbol": "RAF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5894, + "officialSymbol": "RAF1", + "officialFullName": "Raf-1 proto-oncogene, serine/threonine kinase", + "uniprotAccessionNumber": "P04049" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 557, + "assayComponentEndpointName": "NVS_ENZ_hROCK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hROCK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hROCK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 320, + "assayComponentName": "NVS_ENZ_hROCK1", + "assayComponentDesc": "NVS_ENZ_hROCK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hROCK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Rho-associated, coiled-coil containing protein kinase 1 [GeneSymbol:ROCK1 | GeneID:6093 | Uniprot_SwissProt_Accession:Q13464].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 134, + "assayName": "NVS_ENZ_hROCK1", + "assayDesc": "NVS_ENZ_hROCK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 283, + "geneName": "Rho-associated, coiled-coil containing protein kinase 1", + "description": null, + "geneSymbol": "ROCK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6093, + "officialSymbol": "ROCK1", + "officialFullName": "Rho-associated, coiled-coil containing protein kinase 1", + "uniprotAccessionNumber": "Q13464" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 559, + "assayComponentEndpointName": "NVS_ENZ_hSGK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSGK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSGK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 321, + "assayComponentName": "NVS_ENZ_hSGK1", + "assayComponentDesc": "NVS_ENZ_hSGK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSGK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human serum/glucocorticoid regulated kinase 1 [GeneSymbol:SGK1 | GeneID:6446 | Uniprot_SwissProt_Accession:O00141].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 135, + "assayName": "NVS_ENZ_hSGK1", + "assayDesc": "NVS_ENZ_hSGK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 295, + "geneName": "serum/glucocorticoid regulated kinase 1", + "description": null, + "geneSymbol": "SGK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6446, + "officialSymbol": "SGK1", + "officialFullName": "serum/glucocorticoid regulated kinase 1", + "uniprotAccessionNumber": "O00141" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 561, + "assayComponentEndpointName": "NVS_ENZ_hSIRT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Suramin;Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 322, + "assayComponentName": "NVS_ENZ_hSIRT1", + "assayComponentDesc": "NVS_ENZ_hSIRT1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 1 [GeneSymbol:SIRT1 | GeneID:23411 | Uniprot_SwissProt_Accession:Q96EB6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 136, + "assayName": "NVS_ENZ_hSIRT1", + "assayDesc": "NVS_ENZ_hSIRT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 377, + "geneName": "sirtuin 1", + "description": null, + "geneSymbol": "SIRT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23411, + "officialSymbol": "SIRT1", + "officialFullName": "sirtuin 1", + "uniprotAccessionNumber": "Q96EB6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 563, + "assayComponentEndpointName": "NVS_ENZ_hSIRT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Suramin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 323, + "assayComponentName": "NVS_ENZ_hSIRT2", + "assayComponentDesc": "NVS_ENZ_hSIRT2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 2 [GeneSymbol:SIRT2 | GeneID:22933 | Uniprot_SwissProt_Accession:Q8IXJ6].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 137, + "assayName": "NVS_ENZ_hSIRT2", + "assayDesc": "NVS_ENZ_hSIRT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 374, + "geneName": "sirtuin 2", + "description": null, + "geneSymbol": "SIRT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 22933, + "officialSymbol": "SIRT2", + "officialFullName": "sirtuin 2", + "uniprotAccessionNumber": "Q8IXJ6" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 565, + "assayComponentEndpointName": "NVS_ENZ_hSIRT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSIRT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is protein deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nicotinamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "protein deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 324, + "assayComponentName": "NVS_ENZ_hSIRT3", + "assayComponentDesc": "NVS_ENZ_hSIRT3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hSIRT3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 3 [GeneSymbol:SIRT3 | GeneID:23410 | Uniprot_SwissProt_Accession:Q9NTG7].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 138, + "assayName": "NVS_ENZ_hSIRT3", + "assayDesc": "NVS_ENZ_hSIRT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 376, + "geneName": "sirtuin 3", + "description": null, + "geneSymbol": "SIRT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23410, + "officialSymbol": "SIRT3", + "officialFullName": "sirtuin 3", + "uniprotAccessionNumber": "Q9NTG7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 567, + "assayComponentEndpointName": "NVS_ENZ_hSRC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSRC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSRC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 325, + "assayComponentName": "NVS_ENZ_hSRC", + "assayComponentDesc": "NVS_ENZ_hSRC is one of one assay component(s) measured or calculated from the NVS_ENZ_hSRC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:SRC | GeneID:6714 | Uniprot_SwissProt_Accession:P12931].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 139, + "assayName": "NVS_ENZ_hSRC", + "assayDesc": "NVS_ENZ_hSRC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 569, + "assayComponentEndpointName": "NVS_ENZ_hSyk", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hSyk was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hSyk, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 326, + "assayComponentName": "NVS_ENZ_hSyk", + "assayComponentDesc": "NVS_ENZ_hSyk is one of one assay component(s) measured or calculated from the NVS_ENZ_hSyk assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human spleen tyrosine kinase [GeneSymbol:SYK | GeneID:6850 | Uniprot_SwissProt_Accession:P43405].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 140, + "assayName": "NVS_ENZ_hSyk", + "assayDesc": "NVS_ENZ_hSyk is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 308, + "geneName": "spleen tyrosine kinase", + "description": null, + "geneSymbol": "SYK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6850, + "officialSymbol": "SYK", + "officialFullName": "spleen tyrosine kinase", + "uniprotAccessionNumber": "P43405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 571, + "assayComponentEndpointName": "NVS_ENZ_hTie2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hTie2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 327, + "assayComponentName": "NVS_ENZ_hTie2", + "assayComponentDesc": "NVS_ENZ_hTie2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hTie2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human TEK tyrosine kinase, endothelial [GeneSymbol:TEK | GeneID:7010 | Uniprot_SwissProt_Accession:Q02763].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 141, + "assayName": "NVS_ENZ_hTie2", + "assayDesc": "NVS_ENZ_hTie2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 313, + "geneName": "TEK tyrosine kinase, endothelial", + "description": null, + "geneSymbol": "TEK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7010, + "officialSymbol": "TEK", + "officialFullName": "TEK tyrosine kinase, endothelial", + "uniprotAccessionNumber": "Q02763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 573, + "assayComponentEndpointName": "NVS_ENZ_hTrkA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hTrkA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 328, + "assayComponentName": "NVS_ENZ_hTrkA", + "assayComponentDesc": "NVS_ENZ_hTrkA is one of one assay component(s) measured or calculated from the NVS_ENZ_hTrkA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human neurotrophic tyrosine kinase, receptor, type 1 [GeneSymbol:NTRK1 | GeneID:4914 | Uniprot_SwissProt_Accession:P04629].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 142, + "assayName": "NVS_ENZ_hTrkA", + "assayDesc": "NVS_ENZ_hTrkA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 222, + "geneName": "neurotrophic tyrosine kinase, receptor, type 1", + "description": null, + "geneSymbol": "NTRK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4914, + "officialSymbol": "NTRK1", + "officialFullName": "neurotrophic tyrosine kinase, receptor, type 1", + "uniprotAccessionNumber": "P04629" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 575, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 329, + "assayComponentName": "NVS_ENZ_hVEGFR1", + "assayComponentDesc": "NVS_ENZ_hVEGFR1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fms-related tyrosine kinase 1 [GeneSymbol:FLT1 | GeneID:2321 | Uniprot_SwissProt_Accession:P17948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 143, + "assayName": "NVS_ENZ_hVEGFR1", + "assayDesc": "NVS_ENZ_hVEGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 131, + "geneName": "fms-related tyrosine kinase 1", + "description": null, + "geneSymbol": "FLT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2321, + "officialSymbol": "FLT1", + "officialFullName": "fms-related tyrosine kinase 1", + "uniprotAccessionNumber": "P17948" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 577, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 330, + "assayComponentName": "NVS_ENZ_hVEGFR2", + "assayComponentDesc": "NVS_ENZ_hVEGFR2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human kinase insert domain receptor (a type III receptor tyrosine kinase) [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 144, + "assayName": "NVS_ENZ_hVEGFR2", + "assayDesc": "NVS_ENZ_hVEGFR2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 579, + "assayComponentEndpointName": "NVS_ENZ_hVEGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hVEGFR3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 331, + "assayComponentName": "NVS_ENZ_hVEGFR3", + "assayComponentDesc": "NVS_ENZ_hVEGFR3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fms-related tyrosine kinase 4 [GeneSymbol:FLT4 | GeneID:2324 | Uniprot_SwissProt_Accession:P35916].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 145, + "assayName": "NVS_ENZ_hVEGFR3", + "assayDesc": "NVS_ENZ_hVEGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 132, + "geneName": "fms-related tyrosine kinase 4", + "description": null, + "geneSymbol": "FLT4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2324, + "officialSymbol": "FLT4", + "officialFullName": "fms-related tyrosine kinase 4", + "uniprotAccessionNumber": "P35916" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 581, + "assayComponentEndpointName": "NVS_ENZ_hZAP70", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hZAP70 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hZAP70, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 332, + "assayComponentName": "NVS_ENZ_hZAP70", + "assayComponentDesc": "NVS_ENZ_hZAP70 is one of one assay component(s) measured or calculated from the NVS_ENZ_hZAP70 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human zeta-chain (TCR) associated protein kinase 70kDa [GeneSymbol:ZAP70 | GeneID:7535 | Uniprot_SwissProt_Accession:P43403].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 146, + "assayName": "NVS_ENZ_hZAP70", + "assayDesc": "NVS_ENZ_hZAP70 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 338, + "geneName": "zeta-chain (TCR) associated protein kinase 70kDa", + "description": null, + "geneSymbol": "ZAP70", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7535, + "officialSymbol": "ZAP70", + "officialFullName": "zeta-chain (TCR) associated protein kinase 70kDa", + "uniprotAccessionNumber": "P43403" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 583, + "assayComponentEndpointName": "NVS_ENZ_oCOX1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_oCOX1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SC-560", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 333, + "assayComponentName": "NVS_ENZ_oCOX1", + "assayComponentDesc": "NVS_ENZ_oCOX1 is one of one assay component(s) measured or calculated from the NVS_ENZ_oCOX1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS1 | GeneID:443551 | Uniprot_SwissProt_Accession:P05979].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid;N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 147, + "assayName": "NVS_ENZ_oCOX1", + "assayDesc": "NVS_ENZ_oCOX1 is a biochemical, single-readout assay that uses extracted gene-proteins from Ovine seminal vesicles in a tissue-based cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.66, + "organismId": 9940, + "organism": "sheep", + "tissue": "testis", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Ovine seminal vesicles", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 461, + "geneName": "prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)", + "description": "provisional", + "geneSymbol": "PTGS1", + "organismId": 6, + "trackStatus": "live", + "entrezGeneId": 443551, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P05979" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9789085", + "pmid": 9789085, + "title": "Pharmacological analysis of cyclooxygenase-1 in inflammation", + "author": "Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC", + "citation": "Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8. PubMed PMID: 9789085; PubMed Central PMCID: PMC23795.", + "otherId": "0", + "citationId": 175, + "otherSource": "" + } + }, + { + "aeid": 585, + "assayComponentEndpointName": "NVS_ENZ_oCOX2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_oCOX2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is cyclooxygenase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "DuP-697", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "cyclooxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 334, + "assayComponentName": "NVS_ENZ_oCOX2", + "assayComponentDesc": "NVS_ENZ_oCOX2 is one of one assay component(s) measured or calculated from the NVS_ENZ_oCOX2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS2 | GeneID:443460 | Uniprot_SwissProt_Accession:P79208].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "arachidonic acid;N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 148, + "assayName": "NVS_ENZ_oCOX2", + "assayDesc": "NVS_ENZ_oCOX2 is a biochemical, single-readout assay that uses extracted gene-proteins from Ovine placenta in a tissue-based cell-free assay. Measurements were taken 0.66 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.66, + "organismId": 9940, + "organism": "sheep", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Ovine placenta", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 460, + "geneName": "prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)", + "description": "provisional", + "geneSymbol": "PTGS2", + "organismId": 6, + "trackStatus": "live", + "entrezGeneId": 443460, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P79208" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8831731", + "pmid": 8831731, + "title": "Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells", + "author": "Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP", + "citation": "Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol. 1996 Oct 11;52(7):1113-25. PubMed PMID: 8831731.", + "otherId": "0", + "citationId": 167, + "otherSource": "" + } + }, + { + "aeid": 587, + "assayComponentEndpointName": "NVS_ENZ_pMTHFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_pMTHFR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_pMTHFR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is methylenetetrahydrofolate reductase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Sulfasalazine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "methylenetetrahydrofolate reductase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 335, + "assayComponentName": "NVS_ENZ_pMTHFR", + "assayComponentDesc": "NVS_ENZ_pMTHFR is one of one assay component(s) measured or calculated from the NVS_ENZ_pMTHFR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:5-[14C]-methyltetrahydrofolate + menadione --> H[14C]HO + THF] involving the key substrate [5-[14C]-methyltetrahydrofolate] are indicative of changes in enzyme function and kinetics for the pig methylenetetrahydrofolate reductase (NAD(P)H) [GeneSymbol:MTHFR | GeneID:397180 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "5-[14C]-methyltetrahydrofolate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 149, + "assayName": "NVS_ENZ_pMTHFR", + "assayDesc": "NVS_ENZ_pMTHFR is a biochemical, single-readout assay that uses extracted gene-proteins from Porcine kidney in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9823, + "organism": "pig", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Porcine kidney", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 456, + "geneName": "methylenetetrahydrofolate reductase (NAD(P)H)", + "description": "model", + "geneSymbol": "MTHFR", + "organismId": 5, + "trackStatus": "live", + "entrezGeneId": 397180, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/508720", + "pmid": 508720, + "title": "Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications", + "author": "Matthews RG, Haywood BJ", + "citation": "Matthews RG, Haywood BJ. Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications. Biochemistry. 1979 Oct 30;18(22):4845-51. PubMed PMID: 508720.", + "otherId": "0", + "citationId": 10, + "otherSource": "" + } + }, + { + "aeid": 589, + "assayComponentEndpointName": "NVS_ENZ_rabI2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rabI2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rabI2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is imidazoline receptor.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "2-BFI", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "imidazoline receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 336, + "assayComponentName": "NVS_ENZ_rabI2C", + "assayComponentDesc": "NVS_ENZ_rabI2C is one of one assay component(s) measured or calculated from the NVS_ENZ_rabI2C assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-2-BFI] are indicative of a change in enzyme function and kinetics for the rabbit creatine kinase, brain [GeneSymbol:CKB | GeneID:100009085 | Uniprot_SwissProt_Accession:P00567].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-2-BFI", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 150, + "assayName": "NVS_ENZ_rabI2C", + "assayDesc": "NVS_ENZ_rabI2C is a biochemical, single-readout assay that uses extracted gene-proteins from Rabbit brain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 9986, + "organism": "rabbit", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rabbit brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 467, + "geneName": "creatine kinase, brain", + "description": "provisional", + "geneSymbol": "CKB", + "organismId": 9, + "trackStatus": "live", + "entrezGeneId": 100009085, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P00567" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1972896", + "pmid": 1972896, + "title": "Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain", + "author": "Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT", + "citation": "Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT. Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol. 1990 Apr;99(4):803-9. PubMed PMID: 1972896; PubMed Central PMCID: PMC1917565.", + "otherId": "0", + "citationId": 27, + "otherSource": "" + } + }, + { + "aeid": 591, + "assayComponentEndpointName": "NVS_ENZ_rACFSKBinding", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rACFSKBinding, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is adenylyl cyclase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "adenylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 337, + "assayComponentName": "NVS_ENZ_rACFSKBinding", + "assayComponentDesc": "NVS_ENZ_rACFSKBinding is one of one assay component(s) measured or calculated from the NVS_ENZ_rACFSKBinding assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-forskolin] are indicative of a change in enzyme function and kinetics for the Norway rat adenylate cyclase 5 [GeneSymbol:Adcy5 | GeneID:64532 | Uniprot_SwissProt_Accession:Q04400].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-forskolin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 151, + "assayName": "NVS_ENZ_rACFSKBinding", + "assayDesc": "NVS_ENZ_rACFSKBinding is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 433, + "geneName": "adenylate cyclase 5", + "description": null, + "geneSymbol": "Adcy5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 64532, + "officialSymbol": "Adcy5", + "officialFullName": "adenylate cyclase 5", + "uniprotAccessionNumber": "Q04400" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3159185", + "pmid": 3159185, + "title": "High-affinity binding of forskolin to rat brain membranes", + "author": "Seamon KB, Daly JW", + "citation": "Seamon KB, Daly JW. High-affinity binding of forskolin to rat brain membranes. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1985;19:125-35. PubMed PMID: 3159185.", + "otherId": "0", + "citationId": 97, + "otherSource": "" + } + }, + { + "aeid": 593, + "assayComponentEndpointName": "NVS_ENZ_rAChE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rAChE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rAChE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is acetylcholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "acetylcholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 338, + "assayComponentName": "NVS_ENZ_rAChE", + "assayComponentDesc": "NVS_ENZ_rAChE is one of one assay component(s) measured or calculated from the NVS_ENZ_rAChE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the Norway rat acetylcholinesterase [GeneSymbol:Ache | GeneID:83817 | Uniprot_SwissProt_Accession:P37136].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "acetylthiocholine;Ellman\"s reagent (DTNB)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 152, + "assayName": "NVS_ENZ_rAChE", + "assayDesc": "NVS_ENZ_rAChE is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 441, + "geneName": "acetylcholinesterase", + "description": "provisional", + "geneSymbol": "Ache", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 83817, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P37136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 595, + "assayComponentEndpointName": "NVS_ENZ_rCNOS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rCNOS was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is nitric oxide synthase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitro-L-Arginine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "nitric oxide synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 339, + "assayComponentName": "NVS_ENZ_rCNOS", + "assayComponentDesc": "NVS_ENZ_rCNOS is one of one assay component(s) measured or calculated from the NVS_ENZ_rCNOS assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitro-L-Arginine] are indicative of a change in enzyme function and kinetics for the Norway rat nitric oxide synthase 1, neuronal [GeneSymbol:Nos1 | GeneID:24598 | Uniprot_SwissProt_Accession:P29476].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitro-L-Arginine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 153, + "assayName": "NVS_ENZ_rCNOS", + "assayDesc": "NVS_ENZ_rCNOS is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 392, + "geneName": "nitric oxide synthase 1, neuronal", + "description": null, + "geneSymbol": "Nos1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24598, + "officialSymbol": "Nos1", + "officialFullName": "nitric oxide synthase 1, neuronal", + "uniprotAccessionNumber": "P29476" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7689392", + "pmid": 7689392, + "title": "Characterization of the binding of [3H]-L-NG-nitro-arginine in rat brain", + "author": "Michel AD, Phul RK, Stewart TL, Humphrey PP", + "citation": "Michel AD, Phul RK, Stewart TL, Humphrey PP. Characterization of the binding of [3H]-L-NG-nitro-arginine in rat brain. Br J Pharmacol. 1993 Jun;109(2):287-8. PubMed PMID: 7689392; PubMed Central PMCID: PMC2175700.", + "otherId": "0", + "citationId": 144, + "otherSource": "" + } + }, + { + "aeid": 597, + "assayComponentEndpointName": "NVS_ENZ_rCOMT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rCOMT was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rCOMT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the methyltransferase intended target family, where the subfamily is o-methyltransferase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "OR-486", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "methyltransferase", + "intendedTargetFamilySub": "o-methyltransferase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 340, + "assayComponentName": "NVS_ENZ_rCOMT", + "assayComponentDesc": "NVS_ENZ_rCOMT is one of one assay component(s) measured or calculated from the NVS_ENZ_rCOMT assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by HPLC and Spectrophotometry technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction involving the key substrate [3,4-dihydroxybenzoid acid] are indicative of changes in enzyme function and kinetics for the Norway rat catechol-O-methyltransferase [GeneSymbol:Comt | GeneID:24267 | Uniprot_SwissProt_Accession:P22734].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC and Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3,4-dihydroxybenzoid acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 154, + "assayName": "NVS_ENZ_rCOMT", + "assayDesc": "NVS_ENZ_rCOMT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat dorsal striatum in a tissue-based cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat dorsal striatum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 383, + "geneName": "catechol-O-methyltransferase", + "description": null, + "geneSymbol": "Comt", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24267, + "officialSymbol": "Comt", + "officialFullName": "catechol-O-methyltransferase", + "uniprotAccessionNumber": "P22734" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2291472", + "pmid": 2291472, + "title": "Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection", + "author": "Smit NP, Pavel S, Kammeyer A, Westerhof W", + "citation": "Smit NP, Pavel S, Kammeyer A, Westerhof W. Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection. Anal Biochem. 1990 Nov 1;190(2):286-91. PubMed PMID: 2291472.", + "otherId": "0", + "citationId": 42, + "otherSource": "" + } + }, + { + "aeid": 599, + "assayComponentEndpointName": "NVS_ENZ_hDYRK1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hDYRK1a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is dual-specific kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "dual-specific kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 341, + "assayComponentName": "NVS_ENZ_hDYRK1a", + "assayComponentDesc": "NVS_ENZ_hDYRK1a is one of one assay component(s) measured or calculated from the NVS_ENZ_hDYRK1a assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A [GeneSymbol:DYRK1A | GeneID:1859 | Uniprot_SwissProt_Accession:Q13627].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 155, + "assayName": "NVS_ENZ_hDYRK1a", + "assayDesc": "NVS_ENZ_hDYRK1a is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 103, + "geneName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "description": null, + "geneSymbol": "DYRK1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1859, + "officialSymbol": "DYRK1A", + "officialFullName": "dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A", + "uniprotAccessionNumber": "Q13627" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 601, + "assayComponentEndpointName": "NVS_ENZ_rMAOAC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOAC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 41-1049;Tetrindole mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 342, + "assayComponentName": "NVS_ENZ_rMAOAC", + "assayComponentDesc": "NVS_ENZ_rMAOAC is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOAC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Serotonin (5HT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 156, + "assayName": "NVS_ENZ_rMAOAC", + "assayDesc": "NVS_ENZ_rMAOAC is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 417, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "Maoa", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29253, + "officialSymbol": "Maoa", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": "P21396" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 603, + "assayComponentEndpointName": "NVS_ENZ_rMAOAP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOAP was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 41-1049;Tetrindole mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 343, + "assayComponentName": "NVS_ENZ_rMAOAP", + "assayComponentDesc": "NVS_ENZ_rMAOAP is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOAP assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Serotonin (5HT)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 157, + "assayName": "NVS_ENZ_rMAOAP", + "assayDesc": "NVS_ENZ_rMAOAP is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver mitochondrial membranes in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver mitochondrial membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 417, + "geneName": "monoamine oxidase A", + "description": null, + "geneSymbol": "Maoa", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29253, + "officialSymbol": "Maoa", + "officialFullName": "monoamine oxidase A", + "uniprotAccessionNumber": "P21396" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 605, + "assayComponentEndpointName": "NVS_ENZ_rMAOBC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOBC was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOBC, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 16-6491", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 344, + "assayComponentName": "NVS_ENZ_rMAOBC", + "assayComponentDesc": "NVS_ENZ_rMAOBC is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOBC assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Phenylethylamine (PEA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 158, + "assayName": "NVS_ENZ_rMAOBC", + "assayDesc": "NVS_ENZ_rMAOBC is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 415, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "Maob", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25750, + "officialSymbol": "Maob", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": "P19643" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 607, + "assayComponentEndpointName": "NVS_ENZ_rMAOBP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_rMAOBP was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_rMAOBP, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monoamine oxidase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 16-6491", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "monoamine oxidase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 345, + "assayComponentName": "NVS_ENZ_rMAOBP", + "assayComponentDesc": "NVS_ENZ_rMAOBP is one of one assay component(s) measured or calculated from the NVS_ENZ_rMAOBP assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "[14C]-Phenylethylamine (PEA)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 159, + "assayName": "NVS_ENZ_rMAOBP", + "assayDesc": "NVS_ENZ_rMAOBP is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain in a tissue-based cell-free assay. Measurements were taken 1.17 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.17, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 415, + "geneName": "monoamine oxidase B", + "description": null, + "geneSymbol": "Maob", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25750, + "officialSymbol": "Maob", + "officialFullName": "monoamine oxidase B", + "uniprotAccessionNumber": "P19643" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/14201142", + "pmid": 14201142, + "title": "RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA", + "author": "OTSUKA S, KOBAYASHI Y", + "citation": "OTSUKA S, KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE\nDETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995-1006. PubMed\nPMID: 14201142.", + "otherId": "0", + "citationId": 198, + "otherSource": "" + } + }, + { + "aeid": 609, + "assayComponentEndpointName": "NVS_GPCR_bAdoR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5\"-N-ethylcarboxamidoadenosine (NECA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 346, + "assayComponentName": "NVS_GPCR_bAdoR_NonSelective", + "assayComponentDesc": "NVS_GPCR_bAdoR_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bAdoR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-5\"-N-ethylcarboxamidoadenosine] are indicative of a change in receptor function and kinetics for the cattle adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:282133 | Uniprot_SwissProt_Accession:P28190].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-5\"-N-ethylcarboxamidoadenosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 160, + "assayName": "NVS_GPCR_bAdoR_NonSelective", + "assayDesc": "NVS_GPCR_bAdoR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 451, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 282133, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P28190" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1846425", + "pmid": 1846425, + "title": "Role of adenosine receptors in caffeine tolerance", + "author": "Holtzman SG, Mante S, Minneman KP", + "citation": "Holtzman SG, Mante S, Minneman KP. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther. 1991 Jan;256(1):62-8. PubMed PMID: 1846425.", + "otherId": "0", + "citationId": 25, + "otherSource": "" + } + }, + { + "aeid": 610, + "assayComponentEndpointName": "NVS_GPCR_bAT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Angiotensin II", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 347, + "assayComponentName": "NVS_GPCR_bAT2", + "assayComponentDesc": "NVS_GPCR_bAT2 is one of one assay component(s) measured or calculated from the NVS_GPCR_bAT2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Tyr4-Angiotensin II] are indicative of a change in receptor function and kinetics for the cattle angiotensin II receptor, type 2 [GeneSymbol:AGTR2 | GeneID:407157 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Tyr4-Angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 161, + "assayName": "NVS_GPCR_bAT2", + "assayDesc": "NVS_GPCR_bAT2 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 458, + "geneName": "angiotensin II receptor, type 2", + "description": null, + "geneSymbol": "AGTR2", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 407157, + "officialSymbol": "AGTR2", + "officialFullName": "angiotensin II receptor, type 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/187587", + "pmid": 187587, + "title": "Angiotensin II binding to mammalian brain membranes", + "author": "Bennett JP Jr, Snyder SH", + "citation": "Bennett JP Jr, Snyder SH. Angiotensin II binding to mammalian brain membranes. J Biol Chem. 1976 Dec 10;251(23):7423-30. PubMed PMID: 187587.", + "otherId": "0", + "citationId": 4, + "otherSource": "" + } + }, + { + "aeid": 611, + "assayComponentEndpointName": "NVS_GPCR_bDR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bDR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bDR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Spiperone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 348, + "assayComponentName": "NVS_GPCR_bDR_NonSelective", + "assayComponentDesc": "NVS_GPCR_bDR_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bDR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Spiperone] are indicative of a change in receptor function and kinetics for the cattle dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:281125 | Uniprot_SwissProt_Accession:Q95136].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Spiperone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 162, + "assayName": "NVS_GPCR_bDR_NonSelective", + "assayDesc": "NVS_GPCR_bDR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 449, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 281125, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "Q95136" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23126", + "pmid": 23126, + "title": "Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding", + "author": "Leysen JE, Gommeren W, Laduron PM", + "citation": "Leysen JE, Gommeren W, Laduron PM. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol. 1978 Feb 1;27(3):307-16. PubMed PMID: 23126.", + "otherId": "0", + "citationId": 1, + "otherSource": "" + } + }, + { + "aeid": 50, + "assayComponentEndpointName": "APR_HepG2_MitoMass_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 25, + "assayComponentName": "APR_HepG2_MitoMass_72hr", + "assayComponentDesc": "APR_HepG2_MitoMass_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the morphology of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 52, + "assayComponentEndpointName": "APR_HepG2_MitoMembPot_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 26, + "assayComponentName": "APR_HepG2_MitoMembPot_72hr", + "assayComponentDesc": "APR_HepG2_MitoMembPot_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", + "parameterReadoutType": "single", + "assayDesignType": "membrane potential reporter", + "assayDesignTypeSub": "dye binding", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "MitoTracker Red", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 54, + "assayComponentEndpointName": "APR_HepG2_MitoticArrest_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "arrest", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 27, + "assayComponentName": "APR_HepG2_MitoticArrest_72hr", + "assayComponentDesc": "APR_HepG2_MitoticArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 150, + "geneName": "H3 histone, family 3A", + "description": null, + "geneSymbol": "H3F3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3020, + "officialSymbol": "H3F3A", + "officialFullName": "H3 histone, family 3A", + "uniprotAccessionNumber": "P84243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 56, + "assayComponentEndpointName": "APR_HepG2_NuclearSize_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Paclitaxel;CCCP", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "organelle conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 28, + "assayComponentName": "APR_HepG2_NuclearSize_72hr", + "assayComponentDesc": "APR_HepG2_NuclearSize_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell cycle", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Hoechst-33342 dye", + "technologicalTargetType": "dna", + "technologicalTargetTypeSub": "dna-unspecified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 58, + "assayComponentEndpointName": "APR_HepG2_P-H2AX_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "cellular response to DNA damage stimulus", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 29, + "assayComponentName": "APR_HepG2_P-H2AX_72hr", + "assayComponentDesc": "APR_HepG2_P-H2AX_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-histone-H2AX antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 149, + "geneName": "H2A histone family, member X", + "description": null, + "geneSymbol": "H2AFX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3014, + "officialSymbol": "H2AFX", + "officialFullName": "H2A histone family, member X", + "uniprotAccessionNumber": "P16104" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 60, + "assayComponentEndpointName": "APR_HepG2_p53Act_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 30, + "assayComponentName": "APR_HepG2_p53Act_72hr", + "assayComponentDesc": "APR_HepG2_p53Act_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dna content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-p53 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 62, + "assayComponentEndpointName": "APR_HepG2_StressKinase_72hr", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", + "assayFunctionType": "signaling", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Camptothecin;Anisomycin", + "signalDirection": "bidirectional", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "stress response", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 31, + "assayComponentName": "APR_HepG2_StressKinase_72hr", + "assayComponentDesc": "APR_HepG2_StressKinase_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", + "assayComponentTargetDesc": "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "oxidative phosphorylation", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "anti-phospho-c-jun antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 4, + "assayName": "APR_HepG2_72hr", + "assayDesc": "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", + "timepointHr": 72.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 2, + "assaySourceName": "APR", + "assaySourceLongName": "Apredica", + "assaySourceDesc": "Apredica, a part of Cyprotex, is a preclinical Contract Research Organization (CRO) that provides services including the CellCiphr High Content Imaging system.", + "gene": { + "geneId": 183, + "geneName": "jun proto-oncogene", + "description": null, + "geneSymbol": "JUN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3725, + "officialSymbol": "JUN", + "officialFullName": "jun proto-oncogene", + "uniprotAccessionNumber": "P05412" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057110376413", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/20639501", + "pmid": 20639501, + "title": "Early safety assessment using cellular systems biology yields insights into mechanisms of action", + "author": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA", + "citation": "Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010 Aug;15(7):783-97. doi: 10.1177/1087057110376413. Epub 2010 Jul 16. PubMed PMID: 20639501.", + "otherId": "0", + "citationId": 225, + "otherSource": "" + } + }, + { + "aeid": 63, + "assayComponentEndpointName": "ATG_Ahr_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ahr_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain or loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "6-formylindolo carbazole", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 32, + "assayComponentName": "ATG_Ahr_CIS", + "assayComponentDesc": "ATG_Ahr_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AhRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 21, + "geneName": "aryl hydrocarbon receptor", + "description": null, + "geneSymbol": "AHR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 196, + "officialSymbol": "AHR", + "officialFullName": "aryl hydrocarbon receptor", + "uniprotAccessionNumber": "P35869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 64, + "assayComponentEndpointName": "ATG_AP_1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 33, + "assayComponentName": "ATG_AP_1_CIS", + "assayComponentDesc": "ATG_AP_1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AP-1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 134, + "geneName": "FBJ murine osteosarcoma viral oncogene homolog", + "description": null, + "geneSymbol": "FOS", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2353, + "officialSymbol": "FOS", + "officialFullName": "FBJ murine osteosarcoma viral oncogene homolog", + "uniprotAccessionNumber": "P01100" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 65, + "assayComponentEndpointName": "ATG_AP_2_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-turn-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-turn-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 34, + "assayComponentName": "ATG_AP_2_CIS", + "assayComponentDesc": "ATG_AP_2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "AP-2 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 314, + "geneName": "transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)", + "description": null, + "geneSymbol": "TFAP2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7020, + "officialSymbol": "TFAP2A", + "officialFullName": "transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)", + "uniprotAccessionNumber": "P05549" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 66, + "assayComponentEndpointName": "ATG_BRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_BRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "Smad protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 35, + "assayComponentName": "ATG_BRE_CIS", + "assayComponentDesc": "ATG_BRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "BRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 196, + "geneName": "SMAD family member 1", + "description": null, + "geneSymbol": "SMAD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4086, + "officialSymbol": "SMAD1", + "officialFullName": "SMAD family member 1", + "uniprotAccessionNumber": "Q15797" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 67, + "assayComponentEndpointName": "ATG_C_EBP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_C_EBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 36, + "assayComponentName": "ATG_C_EBP_CIS", + "assayComponentDesc": "ATG_C_EBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "C/EBP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 58, + "geneName": "CCAAT/enhancer binding protein (C/EBP), beta", + "description": null, + "geneSymbol": "CEBPB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1051, + "officialSymbol": "CEBPB", + "officialFullName": "CCAAT/enhancer binding protein (C/EBP), beta", + "uniprotAccessionNumber": "P17676" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 68, + "assayComponentEndpointName": "ATG_CMV_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CMV_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_CMV_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 37, + "assayComponentName": "ATG_CMV_CIS", + "assayComponentDesc": "ATG_CMV_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene CMV, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CMV RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 69, + "assayComponentEndpointName": "ATG_CRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_CRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Forskolin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 38, + "assayComponentName": "ATG_CRE_CIS", + "assayComponentDesc": "ATG_CRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "CRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 366, + "geneName": "cAMP responsive element binding protein 3", + "description": null, + "geneSymbol": "CREB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10488, + "officialSymbol": "CREB3", + "officialFullName": "cAMP responsive element binding protein 3", + "uniprotAccessionNumber": "O43889" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 70, + "assayComponentEndpointName": "ATG_DR4_LXR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR4_LXR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 39, + "assayComponentName": "ATG_DR4_LXR_CIS", + "assayComponentDesc": "ATG_DR4_LXR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "LXRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 332, + "geneName": "nuclear receptor subfamily 1, group H, member 2", + "description": null, + "geneSymbol": "NR1H2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7376, + "officialSymbol": "NR1H2", + "officialFullName": "nuclear receptor subfamily 1, group H, member 2", + "uniprotAccessionNumber": "P55055" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 71, + "assayComponentEndpointName": "ATG_DR5_RAR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR5_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 40, + "assayComponentName": "ATG_DR5_RAR_CIS", + "assayComponentDesc": "ATG_DR5_RAR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "RARE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 612, + "assayComponentEndpointName": "NVS_GPCR_bH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tripolidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 349, + "assayComponentName": "NVS_GPCR_bH1", + "assayComponentDesc": "NVS_GPCR_bH1 is one of one assay component(s) measured or calculated from the NVS_GPCR_bH1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Pyrilamine] are indicative of a change in receptor function and kinetics for the cattle histamine receptor H1 [GeneSymbol:HRH1 | GeneID:281231 | Uniprot_SwissProt_Accession:P30546].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 163, + "assayName": "NVS_GPCR_bH1", + "assayDesc": "NVS_GPCR_bH1 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 450, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 281231, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P30546" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/448359", + "pmid": 448359, + "title": "Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes", + "author": "Chang RS, Tran VT, Snyder SH", + "citation": "Chang RS, Tran VT, Snyder SH. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J Neurochem. 1979 Jun;32(6):1653-63. PubMed PMID: 448359.", + "otherId": "0", + "citationId": 8, + "otherSource": "" + } + }, + { + "aeid": 613, + "assayComponentEndpointName": "NVS_GPCR_bNPY_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_bNPY_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bNPY_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 350, + "assayComponentName": "NVS_GPCR_bNPY_NonSelective", + "assayComponentDesc": "NVS_GPCR_bNPY_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_bNPY_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the cattle neuropeptide Y [GeneSymbol:NPY | GeneID:504216 | Uniprot_SwissProt_Accession:Q6RUW3].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 164, + "assayName": "NVS_GPCR_bNPY_NonSelective", + "assayDesc": "NVS_GPCR_bNPY_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine hippocampal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine hippocampal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 462, + "geneName": "neuropeptide Y", + "description": null, + "geneSymbol": "NPY", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 504216, + "officialSymbol": "NPY", + "officialFullName": "neuropeptide Y", + "uniprotAccessionNumber": "Q6RUW3" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 614, + "assayComponentEndpointName": "NVS_GPCR_g5HT4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_g5HT4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_g5HT4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Serotonin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 351, + "assayComponentName": "NVS_GPCR_g5HT4", + "assayComponentDesc": "NVS_GPCR_g5HT4 is one of one assay component(s) measured or calculated from the NVS_GPCR_g5HT4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR-113808] are indicative of a change in receptor function and kinetics for the domestic guinea pig 5 hydroxytryptamine (serotonin) receptor 4 [GeneSymbol:Htr4 | GeneID:100135548 | Uniprot_SwissProt_Accession:O70528].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR-113808", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 165, + "assayName": "NVS_GPCR_g5HT4", + "assayDesc": "NVS_GPCR_g5HT4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 471, + "geneName": "5 hydroxytryptamine (serotonin) receptor 4", + "description": "provisional", + "geneSymbol": "Htr4", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135548, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70528" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8358562", + "pmid": 8358562, + "title": "Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain", + "author": "Grossman CJ, Kilpatrick GJ, Bunce KT", + "citation": "Grossman CJ, Kilpatrick GJ, Bunce KT. Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br J Pharmacol. 1993 Jul;109(3):618-24. PubMed PMID: 8358562; PubMed Central PMCID: PMC2175660.", + "otherId": "0", + "citationId": 159, + "otherSource": "" + } + }, + { + "aeid": 615, + "assayComponentEndpointName": "NVS_GPCR_gANPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gANPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gANPA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nppa. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is guanylyl cyclase.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "rat ANP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "guanylyl cyclase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 352, + "assayComponentName": "NVS_GPCR_gANPA", + "assayComponentDesc": "NVS_GPCR_gANPA is one of one assay component(s) measured or calculated from the NVS_GPCR_gANPA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Atrial natiuretic peptide] are indicative of a change in receptor function and kinetics for the domestic guinea pig natriuretic peptide A [GeneSymbol:Nppa | GeneID:100135578 | Uniprot_SwissProt_Accession:P27596].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Atrial natiuretic peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 166, + "assayName": "NVS_GPCR_gANPA", + "assayDesc": "NVS_GPCR_gANPA is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 472, + "geneName": "natriuretic peptide A", + "description": "model", + "geneSymbol": "Nppa", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135578, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P27596" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2408776", + "pmid": 2408776, + "title": "Vascular and adrenal receptors for atrial natriuretic factor in the rat", + "author": "Schiffrin EL, Chartier L, Thibault G, St-Louis J, Cantin M, Genest J", + "citation": "Schiffrin EL, Chartier L, Thibault G, St-Louis J, Cantin M, Genest J. Vascular and adrenal receptors for atrial natriuretic factor in the rat. Circ Res. 1985 Jun;56(6):801-7. PubMed PMID: 2408776.", + "otherId": "0", + "citationId": 45, + "otherSource": "" + } + }, + { + "aeid": 616, + "assayComponentEndpointName": "NVS_GPCR_gBK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gBK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gBK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Bdkrb2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Bradykinin TFA salt", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 353, + "assayComponentName": "NVS_GPCR_gBK2", + "assayComponentDesc": "NVS_GPCR_gBK2 is one of one assay component(s) measured or calculated from the NVS_GPCR_gBK2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Bradykinin] are indicative of a change in receptor function and kinetics for the domestic guinea pig bradykinin receptor, beta 2 [GeneSymbol:Bdkrb2 | GeneID:100135486 | Uniprot_SwissProt_Accession:O70526].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Bradykinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 167, + "assayName": "NVS_GPCR_gBK2", + "assayDesc": "NVS_GPCR_gBK2 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig ileum membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "intestinal", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig ileum membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 468, + "geneName": "bradykinin receptor, beta 2", + "description": "provisional", + "geneSymbol": "Bdkrb2", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135486, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O70526" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1315547", + "pmid": 1315547, + "title": "Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea pig ileum", + "author": "Ransom RW, Young GS, Schneck K, Goodman CB", + "citation": "Ransom RW, Young GS, Schneck K, Goodman CB. Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea pig ileum. Biochem Pharmacol. 1992 Apr 15;43(8):1823-7. PubMed PMID: 1315547.", + "otherId": "0", + "citationId": 13, + "otherSource": "" + } + }, + { + "aeid": 617, + "assayComponentEndpointName": "NVS_GPCR_gH2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gH2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gH2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tiotidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 354, + "assayComponentName": "NVS_GPCR_gH2", + "assayComponentDesc": "NVS_GPCR_gH2 is one of one assay component(s) measured or calculated from the NVS_GPCR_gH2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Aminopotentidine] are indicative of a change in receptor function and kinetics for the domestic guinea pig histamine receptor H2 [GeneSymbol:Hrh2 | GeneID:100135540 | Uniprot_SwissProt_Accession:P47747].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Aminopotentidine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 168, + "assayName": "NVS_GPCR_gH2", + "assayDesc": "NVS_GPCR_gH2 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 470, + "geneName": "histamine receptor H2", + "description": null, + "geneSymbol": "Hrh2", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135540, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P47747" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1979518", + "pmid": 1979518, + "title": "Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates", + "author": "Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM", + "citation": "Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 1990 Sep 3;526(2):322-7. PubMed PMID: 1979518.", + "otherId": "0", + "citationId": 28, + "otherSource": "" + } + }, + { + "aeid": 618, + "assayComponentEndpointName": "NVS_GPCR_gLTB4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene B4 (LTB4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 355, + "assayComponentName": "NVS_GPCR_gLTB4", + "assayComponentDesc": "NVS_GPCR_gLTB4 is one of one assay component(s) measured or calculated from the NVS_GPCR_gLTB4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the domestic guinea pig leukotriene B4 receptor [GeneSymbol:Ltb4r | GeneID:100379538 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 169, + "assayName": "NVS_GPCR_gLTB4", + "assayDesc": "NVS_GPCR_gLTB4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig spleen membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "spleen", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig spleen membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 477, + "geneName": "leukotriene B4 receptor", + "description": "provisional", + "geneSymbol": "Ltb4r", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100379538, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2168834", + "pmid": 2168834, + "title": "Evidence for two leukotriene receptor types in the guinea-pig isolated ileum", + "author": "Gardiner PJ, Abram TS, Cuthbert NJ", + "citation": "Gardiner PJ, Abram TS, Cuthbert NJ. Evidence for two leukotriene receptor types in the guinea-pig isolated ileum. Eur J Pharmacol. 1990 Jul 3;182(2):291-9. PubMed PMID: 2168834.", + "otherId": "0", + "citationId": 34, + "otherSource": "" + } + }, + { + "aeid": 619, + "assayComponentEndpointName": "NVS_GPCR_gLTD4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gLTD4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTD4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cysltr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene D4 (LTD4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 356, + "assayComponentName": "NVS_GPCR_gLTD4", + "assayComponentDesc": "NVS_GPCR_gLTD4 is one of one assay component(s) measured or calculated from the NVS_GPCR_gLTD4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene D4] are indicative of a change in receptor function and kinetics for the domestic guinea pig cysteinyl leukotriene receptor 1 [GeneSymbol:Cysltr1 | GeneID:100135514 | Uniprot_SwissProt_Accession:Q2NNR5].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene D4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 170, + "assayName": "NVS_GPCR_gLTD4", + "assayDesc": "NVS_GPCR_gLTD4 is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig lung membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "lung", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig lung membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 469, + "geneName": "cysteinyl leukotriene receptor 1", + "description": "provisional", + "geneSymbol": "Cysltr1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135514, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "Q2NNR5" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2397744", + "pmid": 2397744, + "title": "The inhibition of [3H]leukotriene D4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum", + "author": "Norman P, Abram TS, Cuthbert NJ, Gardiner PJ", + "citation": "Norman P, Abram TS, Cuthbert NJ, Gardiner PJ. The inhibition of [3H]leukotriene D4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum. Eur J Pharmacol. 1990 Jul 3;182(2):301-12. PubMed PMID: 2397744.", + "otherId": "0", + "citationId": 43, + "otherSource": "" + } + }, + { + "aeid": 620, + "assayComponentEndpointName": "NVS_GPCR_gMPeripheral_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gMPeripheral_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gMPeripheral_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrm3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Atropine sulfate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 357, + "assayComponentName": "NVS_GPCR_gMPeripheral_NonSelective", + "assayComponentDesc": "NVS_GPCR_gMPeripheral_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_gMPeripheral_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Quinuclidinyl benzilate] are indicative of a change in receptor function and kinetics for the domestic guinea pig cholinergic receptor, muscarinic 3, cardiac [GeneSymbol:Chrm3 | GeneID:100379235 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Quinuclidinyl benzilate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 171, + "assayName": "NVS_GPCR_gMPeripheral_NonSelective", + "assayDesc": "NVS_GPCR_gMPeripheral_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig bladder membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "bladder", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig bladder membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 476, + "geneName": "cholinergic receptor, muscarinic 3, cardiac", + "description": "provisional", + "geneSymbol": "Chrm3", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100379235, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6546770", + "pmid": 6546770, + "title": "Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain", + "author": "Luthin GR, Wolfe BB", + "citation": "Luthin GR, Wolfe BB. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J Pharmacol Exp Ther. 1984 Mar;228(3):648-55. PubMed PMID: 6546770.", + "otherId": "0", + "citationId": 128, + "otherSource": "" + } + }, + { + "aeid": 621, + "assayComponentEndpointName": "NVS_GPCR_gOpiateK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_gOpiateK was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gOpiateK, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprk1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "U-69593", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 358, + "assayComponentName": "NVS_GPCR_gOpiateK", + "assayComponentDesc": "NVS_GPCR_gOpiateK is one of one assay component(s) measured or calculated from the NVS_GPCR_gOpiateK assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-U-69593] are indicative of a change in receptor function and kinetics for the domestic guinea pig opioid receptor, kappa 1 [GeneSymbol:Oprk1 | GeneID:100135587 | Uniprot_SwissProt_Accession:P41144].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-U-69593", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 172, + "assayName": "NVS_GPCR_gOpiateK", + "assayDesc": "NVS_GPCR_gOpiateK is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 473, + "geneName": "opioid receptor, kappa 1", + "description": "provisional", + "geneSymbol": "Oprk1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135587, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P41144" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1336192", + "pmid": 1336192, + "title": "Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain", + "author": "Rothman RB, Bykov V, Xue BG, Xu H, De Costa BR, Jacobson AE, Rice KC, Kleinman JE, Brady LS", + "citation": "Rothman RB, Bykov V, Xue BG, Xu H, De Costa BR, Jacobson AE, Rice KC, Kleinman JE, Brady LS. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides. 1992 Sep-Oct;13(5):977-87. PubMed PMID: 1336192.", + "otherId": "0", + "citationId": 16, + "otherSource": "" + } + }, + { + "aeid": 622, + "assayComponentEndpointName": "NVS_GPCR_h5HT2A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT2A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketanserin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 359, + "assayComponentName": "NVS_GPCR_h5HT2A", + "assayComponentDesc": "NVS_GPCR_h5HT2A is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Ketanserin] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled [GeneSymbol:HTR2A | GeneID:3356 | Uniprot_SwissProt_Accession:P28223].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Ketanserin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 173, + "assayName": "NVS_GPCR_h5HT2A", + "assayDesc": "NVS_GPCR_h5HT2A is a biochemical, single-readout assay that uses extracted gene-proteins from Human cortex in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human cortex", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 164, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled", + "description": null, + "geneSymbol": "HTR2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3356, + "officialSymbol": "HTR2A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled", + "uniprotAccessionNumber": "P28223" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7099138", + "pmid": 7099138, + "title": "[3H]Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role", + "author": "Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM", + "citation": "Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM. [3H]Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol. 1982 Mar;21(2):301-14. PubMed PMID: 7099138.", + "otherId": "0", + "citationId": 133, + "otherSource": "" + } + }, + { + "aeid": 623, + "assayComponentEndpointName": "NVS_GPCR_h5HT5A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methiothepin mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 360, + "assayComponentName": "NVS_GPCR_h5HT5A", + "assayComponentDesc": "NVS_GPCR_h5HT5A is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT5A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled [GeneSymbol:HTR5A | GeneID:3361 | Uniprot_SwissProt_Accession:P47898].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 174, + "assayName": "NVS_GPCR_h5HT5A", + "assayDesc": "NVS_GPCR_h5HT5A is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 167, + "geneName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "description": null, + "geneSymbol": "HTR5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3361, + "officialSymbol": "HTR5A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled", + "uniprotAccessionNumber": "P47898" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7988681", + "pmid": 7988681, + "title": "Cloning and characterisation of the human 5-HT5A serotonin receptor", + "author": "Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M", + "citation": "Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M. Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. PubMed PMID: 7988681.", + "otherId": "0", + "citationId": 151, + "otherSource": "" + } + }, + { + "aeid": 624, + "assayComponentEndpointName": "NVS_GPCR_h5HT6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methiothepin mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 361, + "assayComponentName": "NVS_GPCR_h5HT6", + "assayComponentDesc": "NVS_GPCR_h5HT6 is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT6 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled [GeneSymbol:HTR6 | GeneID:3362 | Uniprot_SwissProt_Accession:P50406].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 175, + "assayName": "NVS_GPCR_h5HT6", + "assayDesc": "NVS_GPCR_h5HT6 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 168, + "geneName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "description": null, + "geneSymbol": "HTR6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3362, + "officialSymbol": "HTR6", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled", + "uniprotAccessionNumber": "P50406" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7680751", + "pmid": 7680751, + "title": "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs", + "author": "Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR", + "citation": "Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. PubMed PMID: 7680751.", + "otherId": "0", + "citationId": 142, + "otherSource": "" + } + }, + { + "aeid": 625, + "assayComponentEndpointName": "NVS_GPCR_h5HT7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_h5HT7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT7, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-carboxamidotryptamine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 362, + "assayComponentName": "NVS_GPCR_h5HT7", + "assayComponentDesc": "NVS_GPCR_h5HT7 is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT7 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled [GeneSymbol:HTR7 | GeneID:3363 | Uniprot_SwissProt_Accession:P34969].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 176, + "assayName": "NVS_GPCR_h5HT7", + "assayDesc": "NVS_GPCR_h5HT7 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 169, + "geneName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "description": null, + "geneSymbol": "HTR7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3363, + "officialSymbol": "HTR7", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled", + "uniprotAccessionNumber": "P34969" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8394362", + "pmid": 8394362, + "title": "Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype", + "author": "Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR", + "citation": "Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. PubMed PMID: 8394362.", + "otherId": "0", + "citationId": 164, + "otherSource": "" + } + }, + { + "aeid": 626, + "assayComponentEndpointName": "NVS_GPCR_hAdoRA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "2-chloroadenosine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 363, + "assayComponentName": "NVS_GPCR_hAdoRA1", + "assayComponentDesc": "NVS_GPCR_hAdoRA1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdoRA1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-8-Cyclopentyl-1,3-dipropylxanthine] are indicative of a change in receptor function and kinetics for the human adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:134 | Uniprot_SwissProt_Accession:P30542].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-8-Cyclopentyl-1,3-dipropylxanthine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 177, + "assayName": "NVS_GPCR_hAdoRA1", + "assayDesc": "NVS_GPCR_hAdoRA1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 10, + "geneName": "adenosine A1 receptor", + "description": null, + "geneSymbol": "ADORA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 134, + "officialSymbol": "ADORA1", + "officialFullName": "adenosine A1 receptor", + "uniprotAccessionNumber": "P30542" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3574492", + "pmid": 3574492, + "title": "Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes", + "author": "Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC", + "citation": "Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59-63. PubMed PMID: 3574492.", + "otherId": "0", + "citationId": 100, + "otherSource": "" + } + }, + { + "aeid": 627, + "assayComponentEndpointName": "NVS_GPCR_hAdoRA2a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5\"-N-ethylcarboxamidoadenosine (NECA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 364, + "assayComponentName": "NVS_GPCR_hAdoRA2a", + "assayComponentDesc": "NVS_GPCR_hAdoRA2a is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdoRA2a assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGS 21680] are indicative of a change in receptor function and kinetics for the human adenosine A2a receptor [GeneSymbol:ADORA2A | GeneID:135 | Uniprot_SwissProt_Accession:P29274].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGS 21680", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 178, + "assayName": "NVS_GPCR_hAdoRA2a", + "assayDesc": "NVS_GPCR_hAdoRA2a is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 11, + "geneName": "adenosine A2a receptor", + "description": null, + "geneSymbol": "ADORA2A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 135, + "officialSymbol": "ADORA2A", + "officialFullName": "adenosine A2a receptor", + "uniprotAccessionNumber": "P29274" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2600819", + "pmid": 2600819, + "title": "[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain", + "author": "Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M", + "citation": "Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888-93. PubMed PMID: 2600819.", + "otherId": "0", + "citationId": 63, + "otherSource": "" + } + }, + { + "aeid": 2547, + "assayComponentEndpointName": "UKN5_HCS_SBAD2_cell_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "The assay endpoint UKN5_HCS_SBAD2_cell_viability was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain or loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "nucleus", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "viability", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 2501, + "assayComponentName": "UKN5_HCS_SBAD2_cell_viability", + "assayComponentDesc": "UKN5_HCS_SBAD2_cell_viability is an assay component measured from the UKN5_HCS_SBAD2 assay. It is designed to make measurements of enzyme activity, a form of viability reporter, as detected with Fluorescence intensity signals by HCS Fluorescent Imaging.", + "assayComponentTargetDesc": "Changes in the number of Hoechst labelled nuclei are indicative of viability.", + "parameterReadoutType": "multiplexed", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "cytotoxicity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "HCS Fluorescent Imaging", + "keyAssayReagentType": "stain;stain", + "keyAssayReagent": "calcein-AM; Hoechst 33340", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "number of Hoechst labelled nuclei", + "aid": 691, + "assayName": "UKN5_HCS_SBAD2", + "assayDesc": "UKN5_HCS_SBAD2 is a cell-based, multiplexed-readout assay screening for neurite outgrowth and cell viability that uses SBAD2 (peripheral neurons differentiated from iPSC), a human peripheral nervous system cell line, with measurements taken at 3 hours after chemical dosing in a microplate: 96-well plate. UKN5, also referred to as PeriTox, is an assay that uses human iPSC line SBAD2 as a model of peripheral neurons. Following 24 hr chemical exposures in multi-well plates, neurite area is evaluated as a marker of neurite outgrowth using high-content imaging of cells stained with calcein-AM. Cell viability is assessed using stain Hoechst H-33342.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "peripheral nervous system", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "SBAD2 (peripheral neurons differentiated from iPSC)", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 27, + "assaySourceName": "UKN", + "assaySourceLongName": "University of Konstanz", + "assaySourceDesc": "The Leist research group at the University of Konstanz conducts high content imaging assays for neurotoxicity.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1007/s00204-013-1072-y", + "url": "https://pubmed.ncbi.nlm.nih.gov/23670202/", + "pmid": 23670202, + "title": "Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants", + "author": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M", + "citation": "Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013 Dec;87(12):2215-31. doi: 10.1007/s00204-013-1072-y. Epub 2013 May 14. PMID: 23670202.", + "otherId": "0", + "citationId": 278, + "otherSource": "" + } + }, + { + "aeid": 2549, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2A6 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2A6, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2A6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2502, + "assayComponentName": "ERF_CR_ADME_hCYP2A6", + "assayComponentDesc": "ERF_CR_ADME_hCYP2A6 is an assay component calculated from the ERF_CR_ADME_hCYP2A6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of 7-hydroxy-coumarin with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of 7-hydroxy-coumarin produced from the regulation of catalytic activity reaction involving the key substrate, Coumarin, are indicative of changes in enzyme function and kinetics related to the gene CYP2A6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Coumarin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 812, + "assayName": "ERF_CR_ADME_hCYP2A6", + "assayDesc": "ERF_CR_ADME_hCYP2A6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP2A6 inhibition (recombinant- coumarin substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 80, + "geneName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "description": null, + "geneSymbol": "CYP2A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1548, + "officialSymbol": "CYP2A6", + "officialFullName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "uniprotAccessionNumber": "P11509" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2550, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2B6 was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2B6, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2B6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2503, + "assayComponentName": "ERF_CR_ADME_hCYP2B6", + "assayComponentDesc": "ERF_CR_ADME_hCYP2B6 is an assay component calculated from the ERF_CR_ADME_hCYP2B6 assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, 7-ethoxy-4-trifluoromethylcoumarin (EFC), are indicative of changes in enzyme function and kinetics related to the gene CYP2B6.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-4-trifluoromethylcoumarin (EFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 816, + "assayName": "ERF_CR_ADME_hCYP2B6", + "assayDesc": "ERF_CR_ADME_hCYP2B6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate. See CYP2B6 inhibition (recombinant, EFC substrate).", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 2551, + "assayComponentEndpointName": "ERF_CR_ADME_hCYP2C19_CEC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ERF_CR_ADME_hCYP2C19_CEC was analyzed at the assay endpoint, ERF_CR_ADME_hCYP2C19_CEC, in the positive analysis fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp ", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 2504, + "assayComponentName": "ERF_CR_ADME_hCYP2C19_CEC", + "assayComponentDesc": "ERF_CR_ADME_hCYP2C19_CEC is an assay component calculated from the ERF_CR_ADME_hCYP2C19_CEC assay. It is designed to measure enzyme activity using a type of enzyme reporter as detected by fluorescence intensity of HFC with fluorimetry technology.", + "assayComponentTargetDesc": "Changes in fluorescence intensity of HFC produced from the regulation of catalytic activity reaction involving the key substrate, CEC, are indicative of changes in enzyme function and kinetics related to the gene CYP2C19.", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorimetry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CEC", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 808, + "assayName": "ERF_CR_ADME_hCYP2C19_CEC", + "assayDesc": "ERF_CR_ADME_hCYP2C19_CEC is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.83 hour after chemical dosing in a 96-well plate. See CYP2C19 inhibition (recombinant, CEC substrate).", + "timepointHr": 0.83, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "human recombinant cyp", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 0.0, + "asid": 28, + "assaySourceName": "ERF", + "assaySourceLongName": "Eurofins", + "assaySourceDesc": "Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 632, + "assayComponentEndpointName": "NVS_GPCR_hAdrb3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAdrb3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 369, + "assayComponentName": "NVS_GPCR_hAdrb3", + "assayComponentDesc": "NVS_GPCR_hAdrb3 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 3 [GeneSymbol:ADRB3 | GeneID:155 | Uniprot_SwissProt_Accession:P13945].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(-)-Iodocyanopindolol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 183, + "assayName": "NVS_GPCR_hAdrb3", + "assayDesc": "NVS_GPCR_hAdrb3 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC pretreated with isoproteronol and 8-bromo-cAMP in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC pretreated with isoproteronol and 8-bromo-cAMP", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 17, + "geneName": "adrenoceptor beta 3", + "description": null, + "geneSymbol": "ADRB3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 155, + "officialSymbol": "ADRB3", + "officialFullName": "adrenoceptor beta 3", + "uniprotAccessionNumber": "P13945" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7996434", + "pmid": 7996434, + "title": "Influence of cell type upon the desensitization of the beta 3-adrenergic receptor", + "author": "Chaudhry A, Granneman JG", + "citation": "Chaudhry A, Granneman JG. Influence of cell type upon the desensitization of the beta 3-adrenergic receptor. J Pharmacol Exp Ther. 1994 Dec;271(3):1253-8. PubMed PMID: 7996434.", + "otherId": "0", + "citationId": 152, + "otherSource": "" + } + }, + { + "aeid": 633, + "assayComponentEndpointName": "NVS_GPCR_hAT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hAT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Angiotensin II", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 370, + "assayComponentName": "NVS_GPCR_hAT1", + "assayComponentDesc": "NVS_GPCR_hAT1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hAT1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Sar1,[125I-Try4],Ile8-Angiotensin II] are indicative of a change in receptor function and kinetics for the human angiotensin II receptor, type 1 [GeneSymbol:AGTR1 | GeneID:185 | Uniprot_SwissProt_Accession:P30556].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Sar1,[125I-Try4],Ile8-Angiotensin II", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 184, + "assayName": "NVS_GPCR_hAT1", + "assayDesc": "NVS_GPCR_hAT1 is a biochemical, single-readout assay that uses extracted gene-proteins from KAN-TS in a tissue-based cell-free assay. Measurements were taken 3 hours after chemical dosing in a 48-well plate.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "KAN-TS", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 19, + "geneName": "angiotensin II receptor, type 1", + "description": null, + "geneSymbol": "AGTR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 185, + "officialSymbol": "AGTR1", + "officialFullName": "angiotensin II receptor, type 1", + "uniprotAccessionNumber": "P30556" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/187587", + "pmid": 187587, + "title": "Angiotensin II binding to mammalian brain membranes", + "author": "Bennett JP Jr, Snyder SH", + "citation": "Bennett JP Jr, Snyder SH. Angiotensin II binding to mammalian brain membranes. J Biol Chem. 1976 Dec 10;251(23):7423-30. PubMed PMID: 187587.", + "otherId": "0", + "citationId": 4, + "otherSource": "" + } + }, + { + "aeid": 634, + "assayComponentEndpointName": "NVS_GPCR_hC5a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hC5a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hC5a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene C5AR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "human rC5a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 371, + "assayComponentName": "NVS_GPCR_hC5a", + "assayComponentDesc": "NVS_GPCR_hC5a is one of one assay component(s) measured or calculated from the NVS_GPCR_hC5a assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-BH-rC5a] are indicative of a change in receptor function and kinetics for the human complement component 5a receptor 1 [GeneSymbol:C5AR1 | GeneID:728 | Uniprot_SwissProt_Accession:P21730].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-BH-rC5a", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 185, + "assayName": "NVS_GPCR_hC5a", + "assayDesc": "NVS_GPCR_hC5a is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 38, + "geneName": "complement component 5a receptor 1", + "description": null, + "geneSymbol": "C5AR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 728, + "officialSymbol": "C5AR1", + "officialFullName": "complement component 5a receptor 1", + "uniprotAccessionNumber": "P21730" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2153739", + "pmid": 2153739, + "title": "The role of formylpeptide receptors, C5a receptors, and cytosolic-free calcium in neutrophil priming", + "author": "Zimmerli W, Reber AM, Dahinden CA", + "citation": "Zimmerli W, Reber AM, Dahinden CA. The role of formylpeptide receptors, C5a receptors, and cytosolic-free calcium in neutrophil priming. J Infect Dis. 1990 Feb;161(2):242-9. PubMed PMID: 2153739.", + "otherId": "0", + "citationId": 30, + "otherSource": "" + } + }, + { + "aeid": 635, + "assayComponentEndpointName": "NVS_GPCR_hDRD1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R(+)-SCH 23390", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 372, + "assayComponentName": "NVS_GPCR_hDRD1", + "assayComponentDesc": "NVS_GPCR_hDRD1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SCH 23390] are indicative of a change in receptor function and kinetics for the human dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:1812 | Uniprot_SwissProt_Accession:P21728].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SCH 23390", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 186, + "assayName": "NVS_GPCR_hDRD1", + "assayDesc": "NVS_GPCR_hDRD1 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 99, + "geneName": "dopamine receptor D1", + "description": null, + "geneSymbol": "DRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1812, + "officialSymbol": "DRD1", + "officialFullName": "dopamine receptor D1", + "uniprotAccessionNumber": "P21728" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6387355", + "pmid": 6387355, + "title": "Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum", + "author": "Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A", + "citation": "Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 1984 Oct 29;35(18):1885-93. PubMed PMID: 6387355.", + "otherId": "0", + "citationId": 124, + "otherSource": "" + } + }, + { + "aeid": 636, + "assayComponentEndpointName": "NVS_GPCR_hDRD2s", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD2s was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD2s, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 373, + "assayComponentName": "NVS_GPCR_hDRD2s", + "assayComponentDesc": "NVS_GPCR_hDRD2s is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD2s assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Raclopride] are indicative of a change in receptor function and kinetics for the human dopamine receptor D2 [GeneSymbol:DRD2 | GeneID:1813 | Uniprot_SwissProt_Accession:P14416].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Raclopride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 187, + "assayName": "NVS_GPCR_hDRD2s", + "assayDesc": "NVS_GPCR_hDRD2s is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 100, + "geneName": "dopamine receptor D2", + "description": null, + "geneSymbol": "DRD2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1813, + "officialSymbol": "DRD2", + "officialFullName": "dopamine receptor D2", + "uniprotAccessionNumber": "P14416" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6149442", + "pmid": 6149442, + "title": "125I-Spiperone: a novel ligand for D2 dopamine receptors", + "author": "Gundlach AL, Largent BL, Snyder SH", + "citation": "Gundlach AL, Largent BL, Snyder SH. 125I-Spiperone: a novel ligand for D2 dopamine receptors. Life Sci. 1984 Nov 5;35(19):1981-8. PubMed PMID: 6149442.", + "otherId": "0", + "citationId": 112, + "otherSource": "" + } + }, + { + "aeid": 637, + "assayComponentEndpointName": "NVS_GPCR_hDRD4.4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hDRD4.4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD4.4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 374, + "assayComponentName": "NVS_GPCR_hDRD4.4", + "assayComponentDesc": "NVS_GPCR_hDRD4.4 is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD4.4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-YM-09151-2] are indicative of a change in receptor function and kinetics for the human dopamine receptor D4 [GeneSymbol:DRD4 | GeneID:1815 | Uniprot_SwissProt_Accession:P21917].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-YM-09151-2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 188, + "assayName": "NVS_GPCR_hDRD4.4", + "assayDesc": "NVS_GPCR_hDRD4.4 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 101, + "geneName": "dopamine receptor D4", + "description": null, + "geneSymbol": "DRD4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1815, + "officialSymbol": "DRD4", + "officialFullName": "dopamine receptor D4", + "uniprotAccessionNumber": "P21917" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1319557", + "pmid": 1319557, + "title": "Multiple dopamine D4 receptor variants in the human population", + "author": "Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V", + "citation": "Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature. 1992 Jul 9;358(6382):149-52. PubMed PMID: 1319557.", + "otherId": "0", + "citationId": 14, + "otherSource": "" + } + }, + { + "aeid": 638, + "assayComponentEndpointName": "NVS_GPCR_hETA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hETA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Endothelin-1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 375, + "assayComponentName": "NVS_GPCR_hETA", + "assayComponentDesc": "NVS_GPCR_hETA is one of one assay component(s) measured or calculated from the NVS_GPCR_hETA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Endothelin-1] are indicative of a change in receptor function and kinetics for the human endothelin receptor type A [GeneSymbol:EDNRA | GeneID:1909 | Uniprot_SwissProt_Accession:P25101].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Endothelin-1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 189, + "assayName": "NVS_GPCR_hETA", + "assayDesc": "NVS_GPCR_hETA is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroblastoma cells (SH-SY5Y) in a cell-free assay. Measurements were taken 3 hours after chemical dosing in a 96-well plate.", + "timepointHr": 3.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neuroblastoma cells (SH-SY5Y)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 105, + "geneName": "endothelin receptor type A", + "description": null, + "geneSymbol": "EDNRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1909, + "officialSymbol": "EDNRA", + "officialFullName": "endothelin receptor type A", + "uniprotAccessionNumber": "P25101" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1700206", + "pmid": 1700206, + "title": "Tissue specificity of endothelin binding sites", + "author": "Bolger GT, Liard F, Krogsrud R, Thibeault D, Jaramillo J", + "citation": "Bolger GT, Liard F, Krogsrud R, Thibeault D, Jaramillo J. Tissue specificity of endothelin binding sites. J Cardiovasc Pharmacol. 1990 Sep;16(3):367-75. PubMed PMID: 1700206.", + "otherId": "0", + "citationId": 20, + "otherSource": "" + } + }, + { + "aeid": 639, + "assayComponentEndpointName": "NVS_GPCR_hETB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hETB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Endothelin-1", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 376, + "assayComponentName": "NVS_GPCR_hETB", + "assayComponentDesc": "NVS_GPCR_hETB is one of one assay component(s) measured or calculated from the NVS_GPCR_hETB assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Endothelin-1] are indicative of a change in receptor function and kinetics for the human endothelin receptor type B [GeneSymbol:EDNRB | GeneID:1910 | Uniprot_SwissProt_Accession:P24530].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Endothelin-1", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 190, + "assayName": "NVS_GPCR_hETB", + "assayDesc": "NVS_GPCR_hETB is a biochemical, single-readout assay that uses extracted gene-proteins from Human astrocytoma cells in a cell-free assay. Measurements were taken 4 hours after chemical dosing in a 96-well plate.", + "timepointHr": 4.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human astrocytoma cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 106, + "geneName": "endothelin receptor type B", + "description": null, + "geneSymbol": "EDNRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1910, + "officialSymbol": "EDNRB", + "officialFullName": "endothelin receptor type B", + "uniprotAccessionNumber": "P24530" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7616437", + "pmid": 7616437, + "title": "Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization", + "author": "Wu-Wong JR, Chiou WJ, Magnuson SR, Opgenorth TJ", + "citation": "Wu-Wong JR, Chiou WJ, Magnuson SR, Opgenorth TJ. Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization. J Pharmacol Exp Ther. 1995 Jul;274(1):499-507. PubMed PMID: 7616437.", + "otherId": "0", + "citationId": 141, + "otherSource": "" + } + }, + { + "aeid": 640, + "assayComponentEndpointName": "NVS_GPCR_hH1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tripolidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 377, + "assayComponentName": "NVS_GPCR_hH1", + "assayComponentDesc": "NVS_GPCR_hH1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hH1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Pyrilamine] are indicative of a change in receptor function and kinetics for the human histamine receptor H1 [GeneSymbol:HRH1 | GeneID:3269 | Uniprot_SwissProt_Accession:P35367].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Pyrilamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 191, + "assayName": "NVS_GPCR_hH1", + "assayDesc": "NVS_GPCR_hH1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 160, + "geneName": "histamine receptor H1", + "description": null, + "geneSymbol": "HRH1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3269, + "officialSymbol": "HRH1", + "officialFullName": "histamine receptor H1", + "uniprotAccessionNumber": "P35367" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/448359", + "pmid": 448359, + "title": "Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes", + "author": "Chang RS, Tran VT, Snyder SH", + "citation": "Chang RS, Tran VT, Snyder SH. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J Neurochem. 1979 Jun;32(6):1653-63. PubMed PMID: 448359.", + "otherId": "0", + "citationId": 8, + "otherSource": "" + } + }, + { + "aeid": 641, + "assayComponentEndpointName": "NVS_GPCR_hLTB4_BLT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hLTB4_BLT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hLTB4_BLT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene LTB4R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Leukotriene B4 (LTB4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 378, + "assayComponentName": "NVS_GPCR_hLTB4_BLT1", + "assayComponentDesc": "NVS_GPCR_hLTB4_BLT1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hLTB4_BLT1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the human leukotriene B4 receptor [GeneSymbol:LTB4R | GeneID:1241 | Uniprot_SwissProt_Accession:Q15722].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Leukotriene B4", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 192, + "assayName": "NVS_GPCR_hLTB4_BLT1", + "assayDesc": "NVS_GPCR_hLTB4_BLT1 is a biochemical, single-readout assay that uses extracted gene-proteins from Human neutrophils in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 68, + "geneName": "leukotriene B4 receptor", + "description": null, + "geneSymbol": "LTB4R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1241, + "officialSymbol": "LTB4R", + "officialFullName": "leukotriene B4 receptor", + "uniprotAccessionNumber": "Q15722" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9177352", + "pmid": 9177352, + "title": "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", + "author": "Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T", + "citation": "Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4. PubMed PMID: 9177352.", + "otherId": "0", + "citationId": 172, + "otherSource": "" + } + }, + { + "aeid": 642, + "assayComponentEndpointName": "NVS_GPCR_hM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 379, + "assayComponentName": "NVS_GPCR_hM1", + "assayComponentDesc": "NVS_GPCR_hM1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 1 [GeneSymbol:CHRM1 | GeneID:1128 | Uniprot_SwissProt_Accession:P11229].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 193, + "assayName": "NVS_GPCR_hM1", + "assayDesc": "NVS_GPCR_hM1 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 61, + "geneName": "cholinergic receptor, muscarinic 1", + "description": null, + "geneSymbol": "CHRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1128, + "officialSymbol": "CHRM1", + "officialFullName": "cholinergic receptor, muscarinic 1", + "uniprotAccessionNumber": "P11229" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 643, + "assayComponentEndpointName": "NVS_GPCR_hM2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 380, + "assayComponentName": "NVS_GPCR_hM2", + "assayComponentDesc": "NVS_GPCR_hM2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 2 [GeneSymbol:CHRM2 | GeneID:1129 | Uniprot_SwissProt_Accession:P08172].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 194, + "assayName": "NVS_GPCR_hM2", + "assayDesc": "NVS_GPCR_hM2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 62, + "geneName": "cholinergic receptor, muscarinic 2", + "description": null, + "geneSymbol": "CHRM2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1129, + "officialSymbol": "CHRM2", + "officialFullName": "cholinergic receptor, muscarinic 2", + "uniprotAccessionNumber": "P08172" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 644, + "assayComponentEndpointName": "NVS_GPCR_hM3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 381, + "assayComponentName": "NVS_GPCR_hM3", + "assayComponentDesc": "NVS_GPCR_hM3 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 3 [GeneSymbol:CHRM3 | GeneID:1131 | Uniprot_SwissProt_Accession:P20309].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 195, + "assayName": "NVS_GPCR_hM3", + "assayDesc": "NVS_GPCR_hM3 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 63, + "geneName": "cholinergic receptor, muscarinic 3", + "description": null, + "geneSymbol": "CHRM3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1131, + "officialSymbol": "CHRM3", + "officialFullName": "cholinergic receptor, muscarinic 3", + "uniprotAccessionNumber": "P20309" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 645, + "assayComponentEndpointName": "NVS_GPCR_hM4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 382, + "assayComponentName": "NVS_GPCR_hM4", + "assayComponentDesc": "NVS_GPCR_hM4 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 4 [GeneSymbol:CHRM4 | GeneID:1132 | Uniprot_SwissProt_Accession:P08173].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 196, + "assayName": "NVS_GPCR_hM4", + "assayDesc": "NVS_GPCR_hM4 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 64, + "geneName": "cholinergic receptor, muscarinic 4", + "description": null, + "geneSymbol": "CHRM4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1132, + "officialSymbol": "CHRM4", + "officialFullName": "cholinergic receptor, muscarinic 4", + "uniprotAccessionNumber": "P08173" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 646, + "assayComponentEndpointName": "NVS_GPCR_hM5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hM5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methylscopolamine bromide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 383, + "assayComponentName": "NVS_GPCR_hM5", + "assayComponentDesc": "NVS_GPCR_hM5 is one of one assay component(s) measured or calculated from the NVS_GPCR_hM5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 5 [GeneSymbol:CHRM5 | GeneID:1133 | Uniprot_SwissProt_Accession:P08912].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylscopolamine chloride", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 197, + "assayName": "NVS_GPCR_hM5", + "assayDesc": "NVS_GPCR_hM5 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 65, + "geneName": "cholinergic receptor, muscarinic 5", + "description": null, + "geneSymbol": "CHRM5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1133, + "officialSymbol": "CHRM5", + "officialFullName": "cholinergic receptor, muscarinic 5", + "uniprotAccessionNumber": "P08912" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2704370", + "pmid": 2704370, + "title": "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells", + "author": "Buckley NJ, Bonner TI, Buckley CM, Brann MR", + "citation": "Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. PubMed PMID: 2704370.", + "otherId": "0", + "citationId": 64, + "otherSource": "" + } + }, + { + "aeid": 647, + "assayComponentEndpointName": "NVS_GPCR_hNK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Neurokinin A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 384, + "assayComponentName": "NVS_GPCR_hNK2", + "assayComponentDesc": "NVS_GPCR_hNK2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNK2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Neurokinin A] are indicative of a change in receptor function and kinetics for the human tachykinin receptor 2 [GeneSymbol:TACR2 | GeneID:6865 | Uniprot_SwissProt_Accession:P21452].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Neurokinin A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 198, + "assayName": "NVS_GPCR_hNK2", + "assayDesc": "NVS_GPCR_hNK2 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 4 hours after chemical dosing in a 96-well plate.", + "timepointHr": 4.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 309, + "geneName": "tachykinin receptor 2", + "description": null, + "geneSymbol": "TACR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6865, + "officialSymbol": "TACR2", + "officialFullName": "tachykinin receptor 2", + "uniprotAccessionNumber": "P21452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 648, + "assayComponentEndpointName": "NVS_GPCR_hNPY1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNPY1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 385, + "assayComponentName": "NVS_GPCR_hNPY1", + "assayComponentDesc": "NVS_GPCR_hNPY1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNPY1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the human neuropeptide Y receptor Y1 [GeneSymbol:NPY1R | GeneID:4886 | Uniprot_SwissProt_Accession:P25929].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 199, + "assayName": "NVS_GPCR_hNPY1", + "assayDesc": "NVS_GPCR_hNPY1 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 219, + "geneName": "neuropeptide Y receptor Y1", + "description": null, + "geneSymbol": "NPY1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4886, + "officialSymbol": "NPY1R", + "officialFullName": "neuropeptide Y receptor Y1", + "uniprotAccessionNumber": "P25929" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 649, + "assayComponentEndpointName": "NVS_GPCR_hNPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY2R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine neuropeptide Y", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 386, + "assayComponentName": "NVS_GPCR_hNPY2", + "assayComponentDesc": "NVS_GPCR_hNPY2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hNPY2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Peptide YY] are indicative of a change in receptor function and kinetics for the human neuropeptide Y receptor Y2 [GeneSymbol:NPY2R | GeneID:4887 | Uniprot_SwissProt_Accession:P49146].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Peptide YY", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 200, + "assayName": "NVS_GPCR_hNPY2", + "assayDesc": "NVS_GPCR_hNPY2 is a biochemical, single-readout assay that uses extracted gene-proteins from SK-N-MC in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SK-N-MC", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 220, + "geneName": "neuropeptide Y receptor Y2", + "description": null, + "geneSymbol": "NPY2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4887, + "officialSymbol": "NPY2R", + "officialFullName": "neuropeptide Y receptor Y2", + "uniprotAccessionNumber": "P49146" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2170863", + "pmid": 2170863, + "title": "Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites", + "author": "Martel JC, Fournier A, St Pierre S, Quirion R", + "citation": "Martel JC, Fournier A, St Pierre S, Quirion R. Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [125I]peptide YY receptor sites. Neuroscience. 1990;36(1):255-83. PubMed PMID: 2170863.", + "otherId": "0", + "citationId": 35, + "otherSource": "" + } + }, + { + "aeid": 650, + "assayComponentEndpointName": "NVS_GPCR_hNTS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNTS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NTSR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "neurotensin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 387, + "assayComponentName": "NVS_GPCR_hNTS", + "assayComponentDesc": "NVS_GPCR_hNTS is one of one assay component(s) measured or calculated from the NVS_GPCR_hNTS assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-neurotensin] are indicative of a change in receptor function and kinetics for the human neurotensin receptor 1 (high affinity) [GeneSymbol:NTSR1 | GeneID:4923 | Uniprot_SwissProt_Accession:P30989].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 201, + "assayName": "NVS_GPCR_hNTS", + "assayDesc": "NVS_GPCR_hNTS is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 223, + "geneName": "neurotensin receptor 1 (high affinity)", + "description": null, + "geneSymbol": "NTSR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4923, + "officialSymbol": "NTSR1", + "officialFullName": "neurotensin receptor 1 (high affinity)", + "uniprotAccessionNumber": "P30989" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6744039", + "pmid": 6744039, + "title": "Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution", + "author": "Goedert M, Pittaway K, Williams BJ, Emson PC", + "citation": "Goedert M, Pittaway K, Williams BJ, Emson PC. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res. 1984 Jun 18;304(1):71-81. PubMed PMID: 6744039.", + "otherId": "0", + "citationId": 129, + "otherSource": "" + } + }, + { + "aeid": 651, + "assayComponentEndpointName": "NVS_GPCR_hOpiate_D1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hOpiate_D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_D1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naltriben methanesulfonate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 388, + "assayComponentName": "NVS_GPCR_hOpiate_D1", + "assayComponentDesc": "NVS_GPCR_hOpiate_D1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_D1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naltrindole] are indicative of a change in receptor function and kinetics for the human opioid receptor, delta 1 [GeneSymbol:OPRD1 | GeneID:4985 | Uniprot_SwissProt_Accession:P41143].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naltrindole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 202, + "assayName": "NVS_GPCR_hOpiate_D1", + "assayDesc": "NVS_GPCR_hOpiate_D1 is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 225, + "geneName": "opioid receptor, delta 1", + "description": null, + "geneSymbol": "OPRD1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4985, + "officialSymbol": "OPRD1", + "officialFullName": "opioid receptor, delta 1", + "uniprotAccessionNumber": "P41143" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7605911", + "pmid": 7605911, + "title": "Human delta opioid receptor: a stable cell line for functional studies of opioids", + "author": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI", + "citation": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI. Human delta opioid receptor: a stable cell line for functional studies of opioids. Neuroreport. 1995 Mar 7;6(4):613-6. PubMed PMID: 7605911.", + "otherId": "0", + "citationId": 140, + "otherSource": "" + } + }, + { + "aeid": 72, + "assayComponentEndpointName": "ATG_E_Box_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E_Box_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 41, + "assayComponentName": "ATG_E_Box_CIS", + "assayComponentDesc": "ATG_E_Box_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Ebox RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 333, + "geneName": "upstream transcription factor 1", + "description": null, + "geneSymbol": "USF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7391, + "officialSymbol": "USF1", + "officialFullName": "upstream transcription factor 1", + "uniprotAccessionNumber": "P22415" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 73, + "assayComponentEndpointName": "ATG_E2F_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E2F_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is E2F transcription factor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "E2F transcription factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 42, + "assayComponentName": "ATG_E2F_CIS", + "assayComponentDesc": "ATG_E2F_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "E2F RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 104, + "geneName": "E2F transcription factor 1", + "description": null, + "geneSymbol": "E2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1869, + "officialSymbol": "E2F1", + "officialFullName": "E2F transcription factor 1", + "uniprotAccessionNumber": "Q01094" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 74, + "assayComponentEndpointName": "ATG_EGR_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_EGR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 43, + "assayComponentName": "ATG_EGR_CIS", + "assayComponentDesc": "ATG_EGR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene EGR, which is responsive to the endogenous human early growth response 1 [GeneSymbol:EGR1 | GeneID:1958 | Uniprot_SwissProt_Accession:P18146].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "EGR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 109, + "geneName": "early growth response 1", + "description": null, + "geneSymbol": "EGR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1958, + "officialSymbol": "EGR1", + "officialFullName": "early growth response 1", + "uniprotAccessionNumber": "P18146" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 75, + "assayComponentEndpointName": "ATG_ERE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ERE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 44, + "assayComponentName": "ATG_ERE_CIS", + "assayComponentDesc": "ATG_ERE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ERE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 76, + "assayComponentEndpointName": "ATG_Ets_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ets_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is winged helix-turn-helix.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "winged helix-turn-helix", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 45, + "assayComponentName": "ATG_Ets_CIS", + "assayComponentDesc": "ATG_Ets_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Ets RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 122, + "geneName": "v-ets avian erythroblastosis virus E26 oncogene homolog 1", + "description": null, + "geneSymbol": "ETS1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2113, + "officialSymbol": "ETS1", + "officialFullName": "v-ets avian erythroblastosis virus E26 oncogene homolog 1", + "uniprotAccessionNumber": "P14921" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 77, + "assayComponentEndpointName": "ATG_FoxA2_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxA2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 46, + "assayComponentName": "ATG_FoxA2_CIS", + "assayComponentDesc": "ATG_FoxA2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "FoxA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 156, + "geneName": "forkhead box A2", + "description": null, + "geneSymbol": "FOXA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3170, + "officialSymbol": "FOXA2", + "officialFullName": "forkhead box A2", + "uniprotAccessionNumber": "Q9Y261" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 78, + "assayComponentEndpointName": "ATG_FoxO_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxO_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 47, + "assayComponentName": "ATG_FoxO_CIS", + "assayComponentDesc": "ATG_FoxO_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "FoxO RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 129, + "geneName": "forkhead box O1", + "description": null, + "geneSymbol": "FOXO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2308, + "officialSymbol": "FOXO1", + "officialFullName": "forkhead box O1", + "uniprotAccessionNumber": "Q12778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 79, + "assayComponentEndpointName": "ATG_GATA_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GATA_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is GATA proteins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "GATA proteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 48, + "assayComponentName": "ATG_GATA_CIS", + "assayComponentDesc": "ATG_GATA_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GATA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 139, + "geneName": "GATA binding protein 1 (globin transcription factor 1)", + "description": null, + "geneSymbol": "GATA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2623, + "officialSymbol": "GATA1", + "officialFullName": "GATA binding protein 1 (globin transcription factor 1)", + "uniprotAccessionNumber": "P15976" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 80, + "assayComponentEndpointName": "ATG_GLI_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GLI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 49, + "assayComponentName": "ATG_GLI_CIS", + "assayComponentDesc": "ATG_GLI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GLI RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 144, + "geneName": "GLI family zinc finger 1", + "description": null, + "geneSymbol": "GLI1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2735, + "officialSymbol": "GLI1", + "officialFullName": "GLI family zinc finger 1", + "uniprotAccessionNumber": "P08151" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 81, + "assayComponentEndpointName": "ATG_GRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 50, + "assayComponentName": "ATG_GRE_CIS", + "assayComponentDesc": "ATG_GRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 82, + "assayComponentEndpointName": "ATG_HIF1a_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HIF1a_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 51, + "assayComponentName": "ATG_HIF1a_CIS", + "assayComponentDesc": "ATG_HIF1a_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HIF1a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 152, + "geneName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "description": null, + "geneSymbol": "HIF1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3091, + "officialSymbol": "HIF1A", + "officialFullName": "hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)", + "uniprotAccessionNumber": "Q16665" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 83, + "assayComponentEndpointName": "ATG_HNF6_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HNF6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "homeobox protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 52, + "assayComponentName": "ATG_HNF6_CIS", + "assayComponentDesc": "ATG_HNF6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HNF6 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 159, + "geneName": "one cut homeobox 1", + "description": null, + "geneSymbol": "ONECUT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3175, + "officialSymbol": "ONECUT1", + "officialFullName": "one cut homeobox 1", + "uniprotAccessionNumber": "Q9UBC0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 84, + "assayComponentEndpointName": "ATG_HSE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HSE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Geldanamycin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "heat shock protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 53, + "assayComponentName": "ATG_HSE_CIS", + "assayComponentDesc": "ATG_HSE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "HSE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 161, + "geneName": "heat shock transcription factor 1", + "description": null, + "geneSymbol": "HSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3297, + "officialSymbol": "HSF1", + "officialFullName": "heat shock transcription factor 1", + "uniprotAccessionNumber": "Q00613" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 85, + "assayComponentEndpointName": "ATG_IR1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_IR1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 54, + "assayComponentName": "ATG_IR1_CIS", + "assayComponentDesc": "ATG_IR1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "IR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 86, + "assayComponentEndpointName": "ATG_ISRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ISRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "interferon regulatory factors", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 55, + "assayComponentName": "ATG_ISRE_CIS", + "assayComponentDesc": "ATG_ISRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ISRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 180, + "geneName": "interferon regulatory factor 1", + "description": null, + "geneSymbol": "IRF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3659, + "officialSymbol": "IRF1", + "officialFullName": "interferon regulatory factor 1", + "uniprotAccessionNumber": "P10914" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 87, + "assayComponentEndpointName": "ATG_M_06_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_06_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_06_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 56, + "assayComponentName": "ATG_M_06_CIS", + "assayComponentDesc": "ATG_M_06_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 88, + "assayComponentEndpointName": "ATG_M_19_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_19_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_M_19_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 57, + "assayComponentName": "ATG_M_19_CIS", + "assayComponentDesc": "ATG_M_19_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "M19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 91, + "assayComponentEndpointName": "ATG_MRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_MRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 60, + "assayComponentName": "ATG_MRE_CIS", + "assayComponentDesc": "ATG_MRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element MRE, which is responsive to the endogenous human metal-regulatory transcription factor 1 [GeneSymbol:MTF1 | GeneID:4520 | Uniprot_SwissProt_Accession:Q14872].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "MRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 211, + "geneName": "metal-regulatory transcription factor 1", + "description": null, + "geneSymbol": "MTF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4520, + "officialSymbol": "MTF1", + "officialFullName": "metal-regulatory transcription factor 1", + "uniprotAccessionNumber": "Q14872" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 104, + "assayComponentEndpointName": "ATG_RORE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_RORE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 73, + "assayComponentName": "ATG_RORE_CIS", + "assayComponentDesc": "ATG_RORE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "RORE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 284, + "geneName": "RAR-related orphan receptor A", + "description": null, + "geneSymbol": "RORA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6095, + "officialSymbol": "RORA", + "officialFullName": "RAR-related orphan receptor A", + "uniprotAccessionNumber": "P35398" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 92, + "assayComponentEndpointName": "ATG_Myb_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is MYB proteins.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "MYB proteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 61, + "assayComponentName": "ATG_Myb_CIS", + "assayComponentDesc": "ATG_Myb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Myb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 212, + "geneName": "v-myb avian myeloblastosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4602, + "officialSymbol": "MYB", + "officialFullName": "v-myb avian myeloblastosis viral oncogene homolog", + "uniprotAccessionNumber": "P10242" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 93, + "assayComponentEndpointName": "ATG_Myc_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myc_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 62, + "assayComponentName": "ATG_Myc_CIS", + "assayComponentDesc": "ATG_Myc_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Myc RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 213, + "geneName": "v-myc avian myelocytomatosis viral oncogene homolog", + "description": null, + "geneSymbol": "MYC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4609, + "officialSymbol": "MYC", + "officialFullName": "v-myc avian myelocytomatosis viral oncogene homolog", + "uniprotAccessionNumber": "P01106" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 94, + "assayComponentEndpointName": "ATG_NF_kB_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NF_kB_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "NF-kappa B", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 63, + "assayComponentName": "ATG_NF_kB_CIS", + "assayComponentDesc": "ATG_NF_kB_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NF-kB RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 218, + "geneName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "description": null, + "geneSymbol": "NFKB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4790, + "officialSymbol": "NFKB1", + "officialFullName": "nuclear factor of kappa light polypeptide gene enhancer in B-cells 1", + "uniprotAccessionNumber": "P19838" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 95, + "assayComponentEndpointName": "ATG_NFI_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NFI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "nuclear factor I", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 64, + "assayComponentName": "ATG_NFI_CIS", + "assayComponentDesc": "ATG_NFI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NFI RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 216, + "geneName": "nuclear factor I/A", + "description": null, + "geneSymbol": "NFIA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4774, + "officialSymbol": "NFIA", + "officialFullName": "nuclear factor I/A", + "uniprotAccessionNumber": "Q12857" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 96, + "assayComponentEndpointName": "ATG_NRF1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "nuclear respiratory factors", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 65, + "assayComponentName": "ATG_NRF1_CIS", + "assayComponentDesc": "ATG_NRF1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "NRF1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 221, + "geneName": "nuclear respiratory factor 1", + "description": null, + "geneSymbol": "NRF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4899, + "officialSymbol": "NRF1", + "officialFullName": "nuclear respiratory factor 1", + "uniprotAccessionNumber": "Q16656" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 97, + "assayComponentEndpointName": "ATG_NRF2_ARE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF2_ARE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 66, + "assayComponentName": "ATG_NRF2_ARE_CIS", + "assayComponentDesc": "ATG_NRF2_ARE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "ARE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 217, + "geneName": "nuclear factor, erythroid 2-like 2", + "description": null, + "geneSymbol": "NFE2L2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4780, + "officialSymbol": "NFE2L2", + "officialFullName": "nuclear factor, erythroid 2-like 2", + "uniprotAccessionNumber": "Q16236" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 98, + "assayComponentEndpointName": "ATG_Oct_MLP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Oct_MLP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "POU domain protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 67, + "assayComponentName": "ATG_Oct_MLP_CIS", + "assayComponentDesc": "ATG_Oct_MLP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Oct RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 245, + "geneName": "POU class 2 homeobox 1", + "description": null, + "geneSymbol": "POU2F1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5451, + "officialSymbol": "POU2F1", + "officialFullName": "POU class 2 homeobox 1", + "uniprotAccessionNumber": "P14859" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 99, + "assayComponentEndpointName": "ATG_p53_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_p53_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "tumor suppressor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 68, + "assayComponentName": "ATG_p53_CIS", + "assayComponentDesc": "ATG_p53_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "p53 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 329, + "geneName": "tumor protein p53", + "description": null, + "geneSymbol": "TP53", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7157, + "officialSymbol": "TP53", + "officialFullName": "tumor protein p53", + "uniprotAccessionNumber": "P04637" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 652, + "assayComponentEndpointName": "NVS_GPCR_hOpiate_mu", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 389, + "assayComponentName": "NVS_GPCR_hOpiate_mu", + "assayComponentDesc": "NVS_GPCR_hOpiate_mu is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_mu assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diprenorphine] are indicative of a change in receptor function and kinetics for the human opioid receptor, mu 1 [GeneSymbol:OPRM1 | GeneID:4988 | Uniprot_SwissProt_Accession:P35372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diprenorphine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 203, + "assayName": "NVS_GPCR_hOpiate_mu", + "assayDesc": "NVS_GPCR_hOpiate_mu is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 2.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 227, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "OPRM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4988, + "officialSymbol": "OPRM1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P35372" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7605911", + "pmid": 7605911, + "title": "Human delta opioid receptor: a stable cell line for functional studies of opioids", + "author": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI", + "citation": "Malatynska E, Wang Y, Knapp RJ, Santoro G, Li X, Waite S, Roeske WR, Yamamura HI. Human delta opioid receptor: a stable cell line for functional studies of opioids. Neuroreport. 1995 Mar 7;6(4):613-6. PubMed PMID: 7605911.", + "otherId": "0", + "citationId": 140, + "otherSource": "" + } + }, + { + "aeid": 653, + "assayComponentEndpointName": "NVS_GPCR_hORL1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hORL1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hORL1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRL1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nociceptin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 390, + "assayComponentName": "NVS_GPCR_hORL1", + "assayComponentDesc": "NVS_GPCR_hORL1 is one of one assay component(s) measured or calculated from the NVS_GPCR_hORL1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nociceptin] are indicative of a change in receptor function and kinetics for the human opiate receptor-like 1 [GeneSymbol:OPRL1 | GeneID:4987 | Uniprot_SwissProt_Accession:P41146].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nociceptin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 204, + "assayName": "NVS_GPCR_hORL1", + "assayDesc": "NVS_GPCR_hORL1 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 226, + "geneName": "opiate receptor-like 1", + "description": null, + "geneSymbol": "OPRL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4987, + "officialSymbol": "OPRL1", + "officialFullName": "opiate receptor-like 1", + "uniprotAccessionNumber": "P41146" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7481766", + "pmid": 7481766, + "title": "Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor", + "author": "Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O", + "citation": "Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995 Nov 3;270(5237):792-4. PubMed PMID: 7481766.", + "otherId": "0", + "citationId": 138, + "otherSource": "" + } + }, + { + "aeid": 654, + "assayComponentEndpointName": "NVS_GPCR_hPY2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hPY2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene P2RY1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ADPbS", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 391, + "assayComponentName": "NVS_GPCR_hPY2", + "assayComponentDesc": "NVS_GPCR_hPY2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hPY2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[35S]-d-ATPaS] are indicative of a change in receptor function and kinetics for the human purinergic receptor P2Y, G-protein coupled, 1 [GeneSymbol:P2RY1 | GeneID:5028 | Uniprot_SwissProt_Accession:P47900].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[35S]-d-ATPaS", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 205, + "assayName": "NVS_GPCR_hPY2", + "assayDesc": "NVS_GPCR_hPY2 is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 228, + "geneName": "purinergic receptor P2Y, G-protein coupled, 1", + "description": null, + "geneSymbol": "P2RY1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5028, + "officialSymbol": "P2RY1", + "officialFullName": "purinergic receptor P2Y, G-protein coupled, 1", + "uniprotAccessionNumber": "P47900" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2495280", + "pmid": 2495280, + "title": "Guanine nucleotide-sensitive interaction of a radiolabeled agonist with a phospholipase C-linked P2y-purinergic receptor", + "author": "Cooper CL, Morris AJ, Harden TK", + "citation": "Cooper CL, Morris AJ, Harden TK. Guanine nucleotide-sensitive interaction of a radiolabeled agonist with a phospholipase C-linked P2y-purinergic receptor. J Biol Chem. 1989 Apr 15;264(11):6202-6. PubMed PMID: 2495280.", + "otherId": "0", + "citationId": 55, + "otherSource": "" + } + }, + { + "aeid": 655, + "assayComponentEndpointName": "NVS_GPCR_hTXA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Pinane-thromboxane A2", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 392, + "assayComponentName": "NVS_GPCR_hTXA2", + "assayComponentDesc": "NVS_GPCR_hTXA2 is one of one assay component(s) measured or calculated from the NVS_GPCR_hTXA2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SQ 29,548] are indicative of a change in receptor function and kinetics for the human thromboxane A2 receptor [GeneSymbol:TBXA2R | GeneID:6915 | Uniprot_SwissProt_Accession:P21731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-SQ 29,548", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 206, + "assayName": "NVS_GPCR_hTXA2", + "assayDesc": "NVS_GPCR_hTXA2 is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelets in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 310, + "geneName": "thromboxane A2 receptor", + "description": null, + "geneSymbol": "TBXA2R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6915, + "officialSymbol": "TBXA2R", + "officialFullName": "thromboxane A2 receptor", + "uniprotAccessionNumber": "P21731" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2968449", + "pmid": 2968449, + "title": "Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets", + "author": "Hedberg A, Hall SE, Ogletree ML, Harris DN, Liu EC", + "citation": "Hedberg A, Hall SE, Ogletree ML, Harris DN, Liu EC. Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92. PubMed PMID: 2968449.", + "otherId": "0", + "citationId": 80, + "otherSource": "" + } + }, + { + "aeid": 656, + "assayComponentEndpointName": "NVS_GPCR_hV1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_hV1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hV1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AVPR1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 393, + "assayComponentName": "NVS_GPCR_hV1A", + "assayComponentDesc": "NVS_GPCR_hV1A is one of one assay component(s) measured or calculated from the NVS_GPCR_hV1A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(Phenylac[1], D-Tyr(Me)[2], Arg[6,8],Lys-NH2[9])-Vasopressin] are indicative of a change in receptor function and kinetics for the human arginine vasopressin receptor 1A [GeneSymbol:AVPR1A | GeneID:552 | Uniprot_SwissProt_Accession:P37288].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-(Phenylac[1], D-Tyr(Me)[2], Arg[6,8],Lys-NH2[9])-Vasopressin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 207, + "assayName": "NVS_GPCR_hV1A", + "assayDesc": "NVS_GPCR_hV1A is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelets in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 29, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "AVPR1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 552, + "officialSymbol": "AVPR1A", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P37288" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3010940", + "pmid": 3010940, + "title": "Nature and properties of human platelet vasopressin receptors", + "author": "Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C", + "citation": "Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C. Nature and properties of human platelet vasopressin receptors. Biochem J. 1986 Feb 1;233(3):631-6. PubMed PMID: 3010940; PubMed Central PMCID: PMC1153078.", + "otherId": "0", + "citationId": 91, + "otherSource": "" + } + }, + { + "aeid": 657, + "assayComponentEndpointName": "NVS_GPCR_mCCKAPeripheral", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cholecystokinin 8 (CCK-8) (26-33) sulfated", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 394, + "assayComponentName": "NVS_GPCR_mCCKAPeripheral", + "assayComponentDesc": "NVS_GPCR_mCCKAPeripheral is one of one assay component(s) measured or calculated from the NVS_GPCR_mCCKAPeripheral assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-cholecystokinin] are indicative of a change in receptor function and kinetics for the house mouse cholecystokinin A receptor [GeneSymbol:Cckar | GeneID:12425 | Uniprot_SwissProt_Accession:O08786].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-cholecystokinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 208, + "assayName": "NVS_GPCR_mCCKAPeripheral", + "assayDesc": "NVS_GPCR_mCCKAPeripheral is a biochemical, single-readout assay that uses extracted gene-proteins from Mouse pancreatic membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "pancreas", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Mouse pancreatic membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 370, + "geneName": "cholecystokinin A receptor", + "description": null, + "geneSymbol": "Cckar", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 12425, + "officialSymbol": "Cckar", + "officialFullName": "cholecystokinin A receptor", + "uniprotAccessionNumber": "O08786" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2984502", + "pmid": 2984502, + "title": "Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe", + "author": "Wennogle LP, Steel DJ, Petrack B", + "citation": "Wennogle LP, Steel DJ, Petrack B. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci. 1985 Apr 15;36(15):1485-92. PubMed PMID: 2984502.", + "otherId": "0", + "citationId": 81, + "otherSource": "" + } + }, + { + "aeid": 658, + "assayComponentEndpointName": "NVS_GPCR_mCKKBCentral", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_mCKKBCentral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCKKBCentral, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckbr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cholecystokinin 8 (CCK-8) (26-33) sulfated", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 395, + "assayComponentName": "NVS_GPCR_mCKKBCentral", + "assayComponentDesc": "NVS_GPCR_mCKKBCentral is one of one assay component(s) measured or calculated from the NVS_GPCR_mCKKBCentral assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-cholecystokinin] are indicative of a change in receptor function and kinetics for the house mouse cholecystokinin B receptor [GeneSymbol:Cckbr | GeneID:12426 | Uniprot_SwissProt_Accession:P56481].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-cholecystokinin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 209, + "assayName": "NVS_GPCR_mCKKBCentral", + "assayDesc": "NVS_GPCR_mCKKBCentral is a biochemical, single-readout assay that uses extracted gene-proteins from Mouse forebrain membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Mouse forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 371, + "geneName": "cholecystokinin B receptor", + "description": null, + "geneSymbol": "Cckbr", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 12426, + "officialSymbol": "Cckbr", + "officialFullName": "cholecystokinin B receptor", + "uniprotAccessionNumber": "P56481" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2984502", + "pmid": 2984502, + "title": "Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe", + "author": "Wennogle LP, Steel DJ, Petrack B", + "citation": "Wennogle LP, Steel DJ, Petrack B. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci. 1985 Apr 15;36(15):1485-92. PubMed PMID: 2984502.", + "otherId": "0", + "citationId": 81, + "otherSource": "" + } + }, + { + "aeid": 659, + "assayComponentEndpointName": "NVS_GPCR_p5HT2C", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mianserin HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 396, + "assayComponentName": "NVS_GPCR_p5HT2C", + "assayComponentDesc": "NVS_GPCR_p5HT2C is one of one assay component(s) measured or calculated from the NVS_GPCR_p5HT2C assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Mesulergine] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled [GeneSymbol:HTR2C | GeneID:3358 | Uniprot_SwissProt_Accession:P28335].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Mesulergine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 210, + "assayName": "NVS_GPCR_p5HT2C", + "assayDesc": "NVS_GPCR_p5HT2C is a biochemical, single-readout assay that uses extracted gene-proteins from Pig choroid plexus membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9823, + "organism": "pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Pig choroid plexus membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 165, + "geneName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "description": null, + "geneSymbol": "HTR2C", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3358, + "officialSymbol": "HTR2C", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled", + "uniprotAccessionNumber": "P28335" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2935410", + "pmid": 2935410, + "title": "Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin", + "author": "Hoyer D, Engel G, Kalkman HO", + "citation": "Hoyer D, Engel G, Kalkman HO. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol. 1985 Nov 26;118(1-2):13-23. PubMed PMID: 2935410.", + "otherId": "0", + "citationId": 78, + "otherSource": "" + } + }, + { + "aeid": 660, + "assayComponentEndpointName": "NVS_GPCR_r5HT_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_r5HT_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methysergide maleate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 397, + "assayComponentName": "NVS_GPCR_r5HT_NonSelective", + "assayComponentDesc": "NVS_GPCR_r5HT_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_r5HT_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Lysergic acid diethylamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 211, + "assayName": "NVS_GPCR_r5HT_NonSelective", + "assayDesc": "NVS_GPCR_r5HT_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 390, + "geneName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "description": null, + "geneSymbol": "Htr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24473, + "officialSymbol": "Htr1a", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "uniprotAccessionNumber": "P19327" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/530254", + "pmid": 530254, + "title": "Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol", + "author": "Peroutka SJ, Snyder SH", + "citation": "Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687-99. PubMed PMID: 530254.", + "otherId": "0", + "citationId": 11, + "otherSource": "" + } + }, + { + "aeid": 661, + "assayComponentEndpointName": "NVS_GPCR_r5HT1_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_r5HT1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT1_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Serotonin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 398, + "assayComponentName": "NVS_GPCR_r5HT1_NonSelective", + "assayComponentDesc": "NVS_GPCR_r5HT1_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_r5HT1_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Hydroxytryptamine binoxalate] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Hydroxytryptamine binoxalate", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 212, + "assayName": "NVS_GPCR_r5HT1_NonSelective", + "assayDesc": "NVS_GPCR_r5HT1_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 390, + "geneName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "description": null, + "geneSymbol": "Htr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24473, + "officialSymbol": "Htr1a", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled", + "uniprotAccessionNumber": "P19327" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/530254", + "pmid": 530254, + "title": "Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol", + "author": "Peroutka SJ, Snyder SH", + "citation": "Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687-99. PubMed PMID: 530254.", + "otherId": "0", + "citationId": 11, + "otherSource": "" + } + }, + { + "aeid": 662, + "assayComponentEndpointName": "NVS_GPCR_rabPAF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "C16-PAF", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 399, + "assayComponentName": "NVS_GPCR_rabPAF", + "assayComponentDesc": "NVS_GPCR_rabPAF is one of one assay component(s) measured or calculated from the NVS_GPCR_rabPAF assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Hexadecyl-2-[3H]-acetyl-sn-glyceryl-3-phosphorylcholine] are indicative of a change in receptor function and kinetics for the rabbit platelet-activating factor receptor [GeneSymbol:PTAFR | GeneID:100354046 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Hexadecyl-2-[3H]-acetyl-sn-glyceryl-3-phosphorylcholine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 213, + "assayName": "NVS_GPCR_rabPAF", + "assayDesc": "NVS_GPCR_rabPAF is a biochemical, single-readout assay that uses extracted gene-proteins from Rabbit platelets in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9986, + "organism": "rabbit", + "tissue": "vascular", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rabbit platelets", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 475, + "geneName": "platelet-activating factor receptor", + "description": "model", + "geneSymbol": "PTAFR", + "organismId": 9, + "trackStatus": "live", + "entrezGeneId": 100354046, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2999126", + "pmid": 2999126, + "title": "Trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor", + "author": "Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY", + "citation": "Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY. Trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. J Biol Chem. 1985 Dec 15;260(29):15639-45. PubMed PMID: 2999126.", + "otherId": "0", + "citationId": 84, + "otherSource": "" + } + }, + { + "aeid": 663, + "assayComponentEndpointName": "NVS_GPCR_rAdra1_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 400, + "assayComponentName": "NVS_GPCR_rAdra1_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdra1_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1A [GeneSymbol:Adra1a | GeneID:29412 | Uniprot_SwissProt_Accession:P43140].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-7-Methoxy-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 214, + "assayName": "NVS_GPCR_rAdra1_NonSelective", + "assayDesc": "NVS_GPCR_rAdra1_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 419, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "Adra1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29412, + "officialSymbol": "Adra1a", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": "P43140" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2879884", + "pmid": 2879884, + "title": "Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan", + "author": "Reader TA, Brière R, Grondin L", + "citation": "Reader TA, Brière R, Grondin L. Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan. J Neural Transm. 1987;68(1-2):79-95. PubMed PMID: 2879884.", + "otherId": "0", + "citationId": 73, + "otherSource": "" + } + }, + { + "aeid": 100, + "assayComponentEndpointName": "ATG_Pax6_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Pax6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "paired box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 69, + "assayComponentName": "ATG_Pax6_CIS", + "assayComponentDesc": "ATG_Pax6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Pax, which is responsive to the endogenous human paired box 6 [GeneSymbol:PAX6 | GeneID:5080 | Uniprot_SwissProt_Accession:P26367].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Pax RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 231, + "geneName": "paired box 6", + "description": null, + "geneSymbol": "PAX6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5080, + "officialSymbol": "PAX6", + "officialFullName": "paired box 6", + "uniprotAccessionNumber": "P26367" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 101, + "assayComponentEndpointName": "ATG_PBREM_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PBREM_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 70, + "assayComponentName": "ATG_PBREM_CIS", + "assayComponentDesc": "ATG_PBREM_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PBREM RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 102, + "assayComponentEndpointName": "ATG_PPRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PPRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 71, + "assayComponentName": "ATG_PPRE_CIS", + "assayComponentDesc": "ATG_PPRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PPRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 103, + "assayComponentEndpointName": "ATG_PXRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PXRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rifampicin", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 72, + "assayComponentName": "ATG_PXRE_CIS", + "assayComponentDesc": "ATG_PXRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "PXRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 105, + "assayComponentEndpointName": "ATG_Sox_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sox_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "HMG box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 74, + "assayComponentName": "ATG_Sox_CIS", + "assayComponentDesc": "ATG_Sox_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "SOX RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 301, + "geneName": "SRY (sex determining region Y)-box 1", + "description": null, + "geneSymbol": "SOX1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6656, + "officialSymbol": "SOX1", + "officialFullName": "SRY (sex determining region Y)-box 1", + "uniprotAccessionNumber": "O00570" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 106, + "assayComponentEndpointName": "ATG_Sp1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 75, + "assayComponentName": "ATG_Sp1_CIS", + "assayComponentDesc": "ATG_Sp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Sp1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 302, + "geneName": "Sp1 transcription factor", + "description": null, + "geneSymbol": "SP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6667, + "officialSymbol": "SP1", + "officialFullName": "Sp1 transcription factor", + "uniprotAccessionNumber": "P08047" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 107, + "assayComponentEndpointName": "ATG_SREBP_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_SREBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 76, + "assayComponentName": "ATG_SREBP_CIS", + "assayComponentDesc": "ATG_SREBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "SREBP RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 304, + "geneName": "sterol regulatory element binding transcription factor 1", + "description": null, + "geneSymbol": "SREBF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6720, + "officialSymbol": "SREBF1", + "officialFullName": "sterol regulatory element binding transcription factor 1", + "uniprotAccessionNumber": "P36956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 108, + "assayComponentEndpointName": "ATG_STAT3_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_STAT3_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "stat protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 77, + "assayComponentName": "ATG_STAT3_CIS", + "assayComponentDesc": "ATG_STAT3_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "STAT RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 305, + "geneName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "description": null, + "geneSymbol": "STAT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6774, + "officialSymbol": "STAT3", + "officialFullName": "signal transducer and activator of transcription 3 (acute-phase response factor)", + "uniprotAccessionNumber": "P40763" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 109, + "assayComponentEndpointName": "ATG_TA_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TA_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TA_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 78, + "assayComponentName": "ATG_TA_CIS", + "assayComponentDesc": "ATG_TA_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TA, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TA RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 110, + "assayComponentEndpointName": "ATG_TAL_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TAL_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TAL_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \n\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 79, + "assayComponentName": "ATG_TAL_CIS", + "assayComponentDesc": "ATG_TAL_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TAL, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TAL RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 111, + "assayComponentEndpointName": "ATG_TCF_b_cat_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TCF_b_cat_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "HMG box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 80, + "assayComponentName": "ATG_TCF_b_cat_CIS", + "assayComponentDesc": "ATG_TCF_b_cat_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TCF/b-cat, which is responsive to the endogenous human transcription factor 7 (T-cell specific, HMG-box) and transcription factor 7-like 2 (T-cell specific, HMG-box) and lymphoid enhancer-binding factor 1 and transcription factor 7-like 1 (T-cell specific, HMG-box) [GeneSymbol:TCF7 & TCF7L2 & LEF1 & TCF7L1 | GeneID:6932 & 6934 & 51176 & 83439 | Uniprot_SwissProt_Accession:P36402 & Q9NQB0 & Q9UJU2 & Q9HCS4].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TCF/b-cat RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 311, + "geneName": "transcription factor 7 (T-cell specific, HMG-box)", + "description": null, + "geneSymbol": "TCF7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6932, + "officialSymbol": "TCF7", + "officialFullName": "transcription factor 7 (T-cell specific, HMG-box)", + "uniprotAccessionNumber": "P36402" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 112, + "assayComponentEndpointName": "ATG_TGFb_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TGFb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 81, + "assayComponentName": "ATG_TGFb_CIS", + "assayComponentDesc": "ATG_TGFb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "TGF RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 178, + "assayComponentEndpointName": "BSK_4H_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 130, + "assayComponentName": "BSK_4H_SRB", + "assayComponentDesc": "BSK_4H_SRB is an assay component measured in the BSK_4H assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the 4H system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 664, + "assayComponentEndpointName": "NVS_GPCR_rAdra1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1A, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 401, + "assayComponentName": "NVS_GPCR_rAdra1A", + "assayComponentDesc": "NVS_GPCR_rAdra1A is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1A [GeneSymbol:Adra1a | GeneID:29412 | Uniprot_SwissProt_Accession:P43140].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 215, + "assayName": "NVS_GPCR_rAdra1A", + "assayDesc": "NVS_GPCR_rAdra1A is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes (pretreated with chlorethyl clonidine-CEC) in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes (pretreated with chlorethyl clonidine-CEC)", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 419, + "geneName": "adrenoceptor alpha 1A", + "description": null, + "geneSymbol": "Adra1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29412, + "officialSymbol": "Adra1a", + "officialFullName": "adrenoceptor alpha 1A", + "uniprotAccessionNumber": "P43140" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2569345", + "pmid": 2569345, + "title": "Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists", + "author": "Hanft G, Gross G", + "citation": "Hanft G, Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691-700. PubMed PMID: 2569345; PubMed Central PMCID: PMC1854578.", + "otherId": "0", + "citationId": 61, + "otherSource": "" + } + }, + { + "aeid": 665, + "assayComponentEndpointName": "NVS_GPCR_rAdra1B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra1B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1B, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 402, + "assayComponentName": "NVS_GPCR_rAdra1B", + "assayComponentDesc": "NVS_GPCR_rAdra1B is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra1B assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1B [GeneSymbol:Adra1b | GeneID:24173 | Uniprot_SwissProt_Accession:P15823].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-7-Methoxy-Prazosin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 216, + "assayName": "NVS_GPCR_rAdra1B", + "assayDesc": "NVS_GPCR_rAdra1B is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 379, + "geneName": "adrenoceptor alpha 1B", + "description": null, + "geneSymbol": "Adra1b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24173, + "officialSymbol": "Adra1b", + "officialFullName": "adrenoceptor alpha 1B", + "uniprotAccessionNumber": "P15823" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2569345", + "pmid": 2569345, + "title": "Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists", + "author": "Hanft G, Gross G", + "citation": "Hanft G, Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691-700. PubMed PMID: 2569345; PubMed Central PMCID: PMC1854578.", + "otherId": "0", + "citationId": 61, + "otherSource": "" + } + }, + { + "aeid": 666, + "assayComponentEndpointName": "NVS_GPCR_rAdra2_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdra2_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra2_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Phentolamine mesylate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 403, + "assayComponentName": "NVS_GPCR_rAdra2_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdra2_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdra2_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-RX 821002] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2A [GeneSymbol:Adra2a | GeneID:25083 | Uniprot_SwissProt_Accession:P22909].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-RX 821002", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 217, + "assayName": "NVS_GPCR_rAdra2_NonSelective", + "assayDesc": "NVS_GPCR_rAdra2_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1.25 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.25, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 402, + "geneName": "adrenoceptor alpha 2A", + "description": null, + "geneSymbol": "Adra2a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25083, + "officialSymbol": "Adra2a", + "officialFullName": "adrenoceptor alpha 2A", + "uniprotAccessionNumber": "P22909" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2879884", + "pmid": 2879884, + "title": "Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan", + "author": "Reader TA, Brière R, Grondin L", + "citation": "Reader TA, Brière R, Grondin L. Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan. J Neural Transm. 1987;68(1-2):79-95. PubMed PMID: 2879884.", + "otherId": "0", + "citationId": 73, + "otherSource": "" + } + }, + { + "aeid": 667, + "assayComponentEndpointName": "NVS_GPCR_rAdrb_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rAdrb_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdrb_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adrb1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alprenolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 404, + "assayComponentName": "NVS_GPCR_rAdrb_NonSelective", + "assayComponentDesc": "NVS_GPCR_rAdrb_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rAdrb_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-DHA] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor beta 1 [GeneSymbol:Adrb1 | GeneID:24925 | Uniprot_SwissProt_Accession:P18090].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-DHA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 218, + "assayName": "NVS_GPCR_rAdrb_NonSelective", + "assayDesc": "NVS_GPCR_rAdrb_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 398, + "geneName": "adrenoceptor beta 1", + "description": null, + "geneSymbol": "Adrb1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24925, + "officialSymbol": "Adrb1", + "officialFullName": "adrenoceptor beta 1", + "uniprotAccessionNumber": "P18090" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2163719", + "pmid": 2163719, + "title": "Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain", + "author": "Arango V, Ernsberger P, Reis DJ, Mann JJ", + "citation": "Arango V, Ernsberger P, Reis DJ, Mann JJ. Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res. 1990 May 14;516(1):113-21. PubMed PMID: 2163719.", + "otherId": "0", + "citationId": 31, + "otherSource": "" + } + }, + { + "aeid": 668, + "assayComponentEndpointName": "NVS_GPCR_rCRF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rCRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rCRF, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Crhr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is secretin receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tyr0-oCRF", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "secretin receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 405, + "assayComponentName": "NVS_GPCR_rCRF", + "assayComponentDesc": "NVS_GPCR_rCRF is one of one assay component(s) measured or calculated from the NVS_GPCR_rCRF assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Tyr-oCRF] are indicative of a change in receptor function and kinetics for the Norway rat corticotropin releasing hormone receptor 1 [GeneSymbol:Crhr1 | GeneID:58959 | Uniprot_SwissProt_Accession:P35353].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Tyr-oCRF", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 219, + "assayName": "NVS_GPCR_rCRF", + "assayDesc": "NVS_GPCR_rCRF is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 431, + "geneName": "corticotropin releasing hormone receptor 1", + "description": null, + "geneSymbol": "Crhr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 58959, + "officialSymbol": "Crhr1", + "officialFullName": "corticotropin releasing hormone receptor 1", + "uniprotAccessionNumber": "P35353" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3001239", + "pmid": 3001239, + "title": "Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study", + "author": "De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ", + "citation": "De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci. 1985\nDec;5(12):3189-203. PubMed PMID: 3001239.", + "otherId": "0", + "citationId": 86, + "otherSource": "" + } + }, + { + "aeid": 669, + "assayComponentEndpointName": "NVS_GPCR_rGABBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGABBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGABBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabbr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-Baclofen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 406, + "assayComponentName": "NVS_GPCR_rGABBR", + "assayComponentDesc": "NVS_GPCR_rGABBR is one of one assay component(s) measured or calculated from the NVS_GPCR_rGABBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGP 54626A] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) B receptor 1 [GeneSymbol:Gabbr1 | GeneID:81657 | Uniprot_SwissProt_Accession:Q9Z0U4].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGP 54626A", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 220, + "assayName": "NVS_GPCR_rGABBR", + "assayDesc": "NVS_GPCR_rGABBR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 437, + "geneName": "gamma-aminobutyric acid (GABA) B receptor 1", + "description": null, + "geneSymbol": "Gabbr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81657, + "officialSymbol": "Gabbr1", + "officialFullName": "gamma-aminobutyric acid (GABA) B receptor 1", + "uniprotAccessionNumber": "Q9Z0U4" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2850843", + "pmid": 2850843, + "title": "Evidence for pharmacologically distinct subsets of GABAB receptors", + "author": "Scherer RW, Ferkany JW, Enna SJ", + "citation": "Scherer RW, Ferkany JW, Enna SJ. Evidence for pharmacologically distinct subsets of GABAB receptors. Brain Res Bull. 1988 Sep;21(3):439-43. PubMed PMID: 2850843.", + "otherId": "0", + "citationId": 70, + "otherSource": "" + } + }, + { + "aeid": 670, + "assayComponentEndpointName": "NVS_GPCR_rGalanin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGalanin was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGalanin, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Galr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "porcine Galanin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 407, + "assayComponentName": "NVS_GPCR_rGalanin", + "assayComponentDesc": "NVS_GPCR_rGalanin is one of one assay component(s) measured or calculated from the NVS_GPCR_rGalanin assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Galanin] are indicative of a change in receptor function and kinetics for the Norway rat galanin receptor 1 [GeneSymbol:Galr1 | GeneID:50577 | Uniprot_SwissProt_Accession:Q62805].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Galanin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 221, + "assayName": "NVS_GPCR_rGalanin", + "assayDesc": "NVS_GPCR_rGalanin is a biochemical, single-readout assay that uses extracted gene-proteins from Rat brain membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 423, + "geneName": "galanin receptor 1", + "description": null, + "geneSymbol": "Galr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50577, + "officialSymbol": "Galr1", + "officialFullName": "galanin receptor 1", + "uniprotAccessionNumber": "Q62805" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2436195", + "pmid": 2436195, + "title": "Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system", + "author": "Skofitsch G, Sills MA, Jacobowitz DM", + "citation": "Skofitsch G, Sills MA, Jacobowitz DM. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides. 1986 Nov-Dec;7(6):1029-42. PubMed PMID: 2436195.", + "otherId": "0", + "citationId": 51, + "otherSource": "" + } + }, + { + "aeid": 671, + "assayComponentEndpointName": "NVS_GPCR_rGHB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rGHB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGHB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspan17. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "NCS-382", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 408, + "assayComponentName": "NVS_GPCR_rGHB", + "assayComponentDesc": "NVS_GPCR_rGHB is one of one assay component(s) measured or calculated from the NVS_GPCR_rGHB assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-NCS-382] are indicative of a change in receptor function and kinetics for the Norway rat tetraspanin 17 [GeneSymbol:Tspan17 | GeneID:306771 | Uniprot_SwissProt_Accession:Q4V8E0].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-NCS-382", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 222, + "assayName": "NVS_GPCR_rGHB", + "assayDesc": "NVS_GPCR_rGHB is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 454, + "geneName": "tetraspanin 17", + "description": null, + "geneSymbol": "Tspan17", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 306771, + "officialSymbol": "Tspan17", + "officialFullName": "tetraspanin 17", + "uniprotAccessionNumber": "Q4V8E0" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10869864", + "pmid": 10869864, + "title": "Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors", + "author": "Bourguignon JJ, Schmitt M, Didier B", + "citation": "Bourguignon JJ, Schmitt M, Didier B. Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors. Alcohol. 2000 Apr;20(3):227-36. Review. PubMed PMID: 10869864.", + "otherId": "0", + "citationId": 182, + "otherSource": "" + } + }, + { + "aeid": 672, + "assayComponentEndpointName": "NVS_GPCR_rH3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rH3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rH3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "N-a-methylhistamine (NAMH)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 409, + "assayComponentName": "NVS_GPCR_rH3", + "assayComponentDesc": "NVS_GPCR_rH3 is one of one assay component(s) measured or calculated from the NVS_GPCR_rH3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylhistamine] are indicative of a change in receptor function and kinetics for the Norway rat histamine receptor H3 [GeneSymbol:Hrh3 | GeneID:85268 | Uniprot_SwissProt_Accession:Q9QYN8].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methylhistamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 223, + "assayName": "NVS_GPCR_rH3", + "assayDesc": "NVS_GPCR_rH3 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 442, + "geneName": "histamine receptor H3", + "description": null, + "geneSymbol": "Hrh3", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 85268, + "officialSymbol": "Hrh3", + "officialFullName": "histamine receptor H3", + "uniprotAccessionNumber": "Q9QYN8" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2172771", + "pmid": 2172771, + "title": "Identification of two H3-histamine receptor subtypes", + "author": "West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA", + "citation": "West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA. Identification of two H3-histamine receptor subtypes. Mol Pharmacol. 1990 Nov;38(5):610-3. PubMed PMID: 2172771.", + "otherId": "0", + "citationId": 37, + "otherSource": "" + } + }, + { + "aeid": 673, + "assayComponentEndpointName": "NVS_GPCR_rmAdra2B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmAdra2B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmAdra2B, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxymetazoline HCl;Norepinephrine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 410, + "assayComponentName": "NVS_GPCR_rmAdra2B", + "assayComponentDesc": "NVS_GPCR_rmAdra2B is one of one assay component(s) measured or calculated from the NVS_GPCR_rmAdra2B assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2B [GeneSymbol:Adra2b | GeneID:24174 | Uniprot_SwissProt_Accession:P19328].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-912", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 224, + "assayName": "NVS_GPCR_rmAdra2B", + "assayDesc": "NVS_GPCR_rmAdra2B is a biochemical, single-readout assay that uses extracted gene-proteins from neuroglioma/blastoma hybrid cells in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "neuroglioma/blastoma hybrid cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 380, + "geneName": "adrenoceptor alpha 2B", + "description": null, + "geneSymbol": "Adra2b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24174, + "officialSymbol": "Adra2b", + "officialFullName": "adrenoceptor alpha 2B", + "uniprotAccessionNumber": "P19328" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2564617", + "pmid": 2564617, + "title": "[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors", + "author": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R", + "citation": "Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.", + "otherId": "0", + "citationId": 60, + "otherSource": "" + } + }, + { + "aeid": 674, + "assayComponentEndpointName": "NVS_GPCR_rmMGluR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmMGluR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-Glutamate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 411, + "assayComponentName": "NVS_GPCR_rmMGluR1", + "assayComponentDesc": "NVS_GPCR_rmMGluR1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rmMGluR1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Quisqualic acid] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, metabotropic 1 [GeneSymbol:Grm1 | GeneID:24414 | Uniprot_SwissProt_Accession:P23385].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Quisqualic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 225, + "assayName": "NVS_GPCR_rmMGluR1", + "assayDesc": "NVS_GPCR_rmMGluR1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cerebellum in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cerebellum", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 388, + "geneName": "glutamate receptor, metabotropic 1", + "description": null, + "geneSymbol": "Grm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24414, + "officialSymbol": "Grm1", + "officialFullName": "glutamate receptor, metabotropic 1", + "uniprotAccessionNumber": "P23385" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11814808", + "pmid": 11814808, + "title": "[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5", + "author": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R", + "citation": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002 Feb 11;12(3):407-9. PubMed PMID: 11814808.", + "otherId": "0", + "citationId": 186, + "otherSource": "" + } + }, + { + "aeid": 675, + "assayComponentEndpointName": "NVS_GPCR_rmMGluR5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rmMGluR5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is metabotropic glutamate receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MPEP", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "metabotropic glutamate receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 412, + "assayComponentName": "NVS_GPCR_rmMGluR5", + "assayComponentDesc": "NVS_GPCR_rmMGluR5 is one of one assay component(s) measured or calculated from the NVS_GPCR_rmMGluR5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-2-Methyl-6-phenylethynylpyridine] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, metabotropic 5 [GeneSymbol:Grm5 | GeneID:24418 | Uniprot_SwissProt_Accession:P31424].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-2-Methyl-6-phenylethynylpyridine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 226, + "assayName": "NVS_GPCR_rmMGluR5", + "assayDesc": "NVS_GPCR_rmMGluR5 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat whole brain in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat whole brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 389, + "geneName": "glutamate receptor, metabotropic 5", + "description": null, + "geneSymbol": "Grm5", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24418, + "officialSymbol": "Grm5", + "officialFullName": "glutamate receptor, metabotropic 5", + "uniprotAccessionNumber": "P31424" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11814808", + "pmid": 11814808, + "title": "[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5", + "author": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R", + "citation": "Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002 Feb 11;12(3):407-9. PubMed PMID: 11814808.", + "otherId": "0", + "citationId": 186, + "otherSource": "" + } + }, + { + "aeid": 676, + "assayComponentEndpointName": "NVS_GPCR_rNK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Substance P", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 413, + "assayComponentName": "NVS_GPCR_rNK1", + "assayComponentDesc": "NVS_GPCR_rNK1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rNK1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Substance P] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 1 [GeneSymbol:Tacr1 | GeneID:24807 | Uniprot_SwissProt_Accession:P14600].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Substance P", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 227, + "assayName": "NVS_GPCR_rNK1", + "assayDesc": "NVS_GPCR_rNK1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat submaxillary gland membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "salivary gland", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat submaxillary gland membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 393, + "geneName": "tachykinin receptor 1", + "description": null, + "geneSymbol": "Tacr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24807, + "officialSymbol": "Tacr1", + "officialFullName": "tachykinin receptor 1", + "uniprotAccessionNumber": "P14600" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 677, + "assayComponentEndpointName": "NVS_GPCR_rNK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Eledoisin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 414, + "assayComponentName": "NVS_GPCR_rNK3", + "assayComponentDesc": "NVS_GPCR_rNK3 is one of one assay component(s) measured or calculated from the NVS_GPCR_rNK3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Eledoisin] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 3 [GeneSymbol:Tacr3 | GeneID:24808 | Uniprot_SwissProt_Accession:P16177].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Eledoisin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 228, + "assayName": "NVS_GPCR_rNK3", + "assayDesc": "NVS_GPCR_rNK3 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 394, + "geneName": "tachykinin receptor 3", + "description": null, + "geneSymbol": "Tacr3", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24808, + "officialSymbol": "Tacr3", + "officialFullName": "tachykinin receptor 3", + "uniprotAccessionNumber": "P16177" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1718474", + "pmid": 1718474, + "title": "Pharmacology of neurokinin receptors", + "author": "Regoli D, Nantel F", + "citation": "Regoli D, Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777-83. Review. PubMed PMID: 1718474.", + "otherId": "0", + "citationId": 22, + "otherSource": "" + } + }, + { + "aeid": 678, + "assayComponentEndpointName": "NVS_GPCR_rNTS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNTS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ntsr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Neurotensin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 415, + "assayComponentName": "NVS_GPCR_rNTS", + "assayComponentDesc": "NVS_GPCR_rNTS is one of one assay component(s) measured or calculated from the NVS_GPCR_rNTS assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-neurotensin] are indicative of a change in receptor function and kinetics for the Norway rat neurotensin receptor 1 [GeneSymbol:Ntsr1 | GeneID:366274 | Uniprot_SwissProt_Accession:P20789].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-neurotensin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 229, + "assayName": "NVS_GPCR_rNTS", + "assayDesc": "NVS_GPCR_rNTS is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 455, + "geneName": "neurotensin receptor 1", + "description": null, + "geneSymbol": "Ntsr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 366274, + "officialSymbol": "Ntsr1", + "officialFullName": "neurotensin receptor 1", + "uniprotAccessionNumber": "P20789" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6744039", + "pmid": 6744039, + "title": "Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution", + "author": "Goedert M, Pittaway K, Williams BJ, Emson PC", + "citation": "Goedert M, Pittaway K, Williams BJ, Emson PC. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res. 1984 Jun 18;304(1):71-81. PubMed PMID: 6744039.", + "otherId": "0", + "citationId": 129, + "otherSource": "" + } + }, + { + "aeid": 679, + "assayComponentEndpointName": "NVS_GPCR_rOpiate_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOpiate_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 416, + "assayComponentName": "NVS_GPCR_rOpiate_NonSelective", + "assayComponentDesc": "NVS_GPCR_rOpiate_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rOpiate_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor function and kinetics for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naloxone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 230, + "assayName": "NVS_GPCR_rOpiate_NonSelective", + "assayDesc": "NVS_GPCR_rOpiate_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 411, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "Oprm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25601, + "officialSymbol": "Oprm1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P33535" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/4127185", + "pmid": 4127185, + "title": "Regional distribution of opiate receptor binding in monkey and human brain", + "author": "Kuhar MJ, Pert CB, Snyder SH", + "citation": "Kuhar MJ, Pert CB, Snyder SH. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973 Oct 26;245(5426):447-50. PubMed PMID: 4127185.", + "otherId": "0", + "citationId": 106, + "otherSource": "" + } + }, + { + "aeid": 680, + "assayComponentEndpointName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOpiate_NonSelectiveNa was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelectiveNa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Naloxone HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 417, + "assayComponentName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "assayComponentDesc": "NVS_GPCR_rOpiate_NonSelectiveNa is one of one assay component(s) measured or calculated from the NVS_GPCR_rOpiate_NonSelectiveNa assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor binding affinity due to allosteric binding of sodium ions for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Naloxone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 231, + "assayName": "NVS_GPCR_rOpiate_NonSelectiveNa", + "assayDesc": "NVS_GPCR_rOpiate_NonSelectiveNa is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 411, + "geneName": "opioid receptor, mu 1", + "description": null, + "geneSymbol": "Oprm1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25601, + "officialSymbol": "Oprm1", + "officialFullName": "opioid receptor, mu 1", + "uniprotAccessionNumber": "P33535" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/4127185", + "pmid": 4127185, + "title": "Regional distribution of opiate receptor binding in monkey and human brain", + "author": "Kuhar MJ, Pert CB, Snyder SH", + "citation": "Kuhar MJ, Pert CB, Snyder SH. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973 Oct 26;245(5426):447-50. PubMed PMID: 4127185.", + "otherId": "0", + "citationId": 106, + "otherSource": "" + } + }, + { + "aeid": 681, + "assayComponentEndpointName": "NVS_GPCR_rOXT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rOXT was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOXT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oxtr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Oxytocin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 418, + "assayComponentName": "NVS_GPCR_rOXT", + "assayComponentDesc": "NVS_GPCR_rOXT is one of one assay component(s) measured or calculated from the NVS_GPCR_rOXT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Oxytocin] are indicative of a change in receptor function and kinetics for the Norway rat oxytocin receptor [GeneSymbol:Oxtr | GeneID:25342 | Uniprot_SwissProt_Accession:P70536].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Oxytocin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 232, + "assayName": "NVS_GPCR_rOXT", + "assayDesc": "NVS_GPCR_rOXT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat uterine membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 406, + "geneName": "oxytocin receptor", + "description": null, + "geneSymbol": "Oxtr", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25342, + "officialSymbol": "Oxtr", + "officialFullName": "oxytocin receptor", + "uniprotAccessionNumber": "P70536" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2163875", + "pmid": 2163875, + "title": "Identification of functional oxytocin receptors in lactating rat mammary gland in vitro", + "author": "Pettibone DJ, Woyden CJ, Totaro JA", + "citation": "Pettibone DJ, Woyden CJ, Totaro JA. Identification of functional oxytocin receptors in lactating rat mammary gland in vitro. Eur J Pharmacol. 1990 Apr 25;188(4-5):235-41. PubMed PMID: 2163875.", + "otherId": "0", + "citationId": 32, + "otherSource": "" + } + }, + { + "aeid": 682, + "assayComponentEndpointName": "NVS_GPCR_rSST", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Somatostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 419, + "assayComponentName": "NVS_GPCR_rSST", + "assayComponentDesc": "NVS_GPCR_rSST is one of one assay component(s) measured or calculated from the NVS_GPCR_rSST assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Somatostatin-14 (Tyr11)] are indicative of a change in receptor function and kinetics for the Norway rat somatostatin receptor 1 [GeneSymbol:Sstr1 | GeneID:25033 | Uniprot_SwissProt_Accession:P28646].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Somatostatin-14 (Tyr11)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 233, + "assayName": "NVS_GPCR_rSST", + "assayDesc": "NVS_GPCR_rSST is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 400, + "geneName": "somatostatin receptor 1", + "description": null, + "geneSymbol": "Sstr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25033, + "officialSymbol": "Sstr1", + "officialFullName": "somatostatin receptor 1", + "uniprotAccessionNumber": "P28646" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2572690", + "pmid": 2572690, + "title": "Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain", + "author": "Raynor K, Reisine T", + "citation": "Raynor K, Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther. 1989 Nov;251(2):510-7. PubMed PMID: 2572690.", + "otherId": "0", + "citationId": 62, + "otherSource": "" + } + }, + { + "aeid": 683, + "assayComponentEndpointName": "NVS_GPCR_rTRH", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rTRH was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rTRH, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Trhr. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TRH", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 420, + "assayComponentName": "NVS_GPCR_rTRH", + "assayComponentDesc": "NVS_GPCR_rTRH is one of one assay component(s) measured or calculated from the NVS_GPCR_rTRH assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-(3-methylHis[2])-TRH] are indicative of a change in receptor function and kinetics for the Norway rat thyrotropin releasing hormone receptor [GeneSymbol:Trhr | GeneID:25570 | Uniprot_SwissProt_Accession:Q01717].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-(3-methylHis[2])-TRH", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 234, + "assayName": "NVS_GPCR_rTRH", + "assayDesc": "NVS_GPCR_rTRH is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 4 hours after chemical dosing in a 48-well plate.", + "timepointHr": 4.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 410, + "geneName": "thyrotropin releasing hormone receptor", + "description": null, + "geneSymbol": "Trhr", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25570, + "officialSymbol": "Trhr", + "officialFullName": "thyrotropin releasing hormone receptor", + "uniprotAccessionNumber": "Q01717" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/169955", + "pmid": 169955, + "title": "Thyrotropin releasing hormone (TRH): apparent receptor binding in rat brain membranes", + "author": "Burt DR, Snyder SH", + "citation": "Burt DR, Snyder SH. Thyrotropin releasing hormone (TRH): apparent receptor binding in rat brain membranes. Brain Res. 1975 Aug 8;93(2):309-28. PubMed PMID: 169955.", + "otherId": "0", + "citationId": 3, + "otherSource": "" + } + }, + { + "aeid": 684, + "assayComponentEndpointName": "NVS_GPCR_rV1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rV1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rV1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Avpr1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 421, + "assayComponentName": "NVS_GPCR_rV1", + "assayComponentDesc": "NVS_GPCR_rV1 is one of one assay component(s) measured or calculated from the NVS_GPCR_rV1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[phenylanyl-3,4,5-3H(N)]-L-Arg8-Vasopressin] are indicative of a change in receptor function and kinetics for the Norway rat arginine vasopressin receptor 1A [GeneSymbol:Avpr1a | GeneID:25107 | Uniprot_SwissProt_Accession:P30560].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[phenylanyl-3,4,5-3H(N)]-L-Arg8-Vasopressin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 235, + "assayName": "NVS_GPCR_rV1", + "assayDesc": "NVS_GPCR_rV1 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat liver membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "liver", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat liver membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 404, + "geneName": "arginine vasopressin receptor 1A", + "description": null, + "geneSymbol": "Avpr1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25107, + "officialSymbol": "Avpr1a", + "officialFullName": "arginine vasopressin receptor 1A", + "uniprotAccessionNumber": "P30560" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3004905", + "pmid": 3004905, + "title": "Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium", + "author": "Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR", + "citation": "Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR. Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium. Endocrinology. 1986 Mar;118(3):990-7. PubMed PMID: 3004905.", + "otherId": "0", + "citationId": 88, + "otherSource": "" + } + }, + { + "aeid": 685, + "assayComponentEndpointName": "NVS_GPCR_rVIP_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_GPCR_rVIP_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rVIP_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Vipr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is secretin receptor.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Vasoactive intestinal peptide (VIP)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "secretin receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 422, + "assayComponentName": "NVS_GPCR_rVIP_NonSelective", + "assayComponentDesc": "NVS_GPCR_rVIP_NonSelective is one of one assay component(s) measured or calculated from the NVS_GPCR_rVIP_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Vasoactive intestinal peptide] are indicative of a change in receptor function and kinetics for the Norway rat vasoactive intestinal peptide receptor 1 [GeneSymbol:Vipr1 | GeneID:24875 | Uniprot_SwissProt_Accession:P30083].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Vasoactive intestinal peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 236, + "assayName": "NVS_GPCR_rVIP_NonSelective", + "assayDesc": "NVS_GPCR_rVIP_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 395, + "geneName": "vasoactive intestinal peptide receptor 1", + "description": null, + "geneSymbol": "Vipr1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24875, + "officialSymbol": "Vipr1", + "officialFullName": "vasoactive intestinal peptide receptor 1", + "uniprotAccessionNumber": "P30083" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2472937", + "pmid": 2472937, + "title": "Distribution of vasoactive intestinal polypeptide and substance P receptors in human colon and small intestine", + "author": "Korman LY, Sayadi H, Bass B, Moody TW, Harmon JW", + "citation": "Korman LY, Sayadi H, Bass B, Moody TW, Harmon JW. Distribution of vasoactive intestinal polypeptide and substance P receptors in human colon and small intestine. Dig Dis Sci. 1989 Jul;34(7):1100-8. PubMed PMID: 2472937.", + "otherId": "0", + "citationId": 54, + "otherSource": "" + } + }, + { + "aeid": 686, + "assayComponentEndpointName": "NVS_IC_hKhERGCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_hKhERGCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_hKhERGCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene KCNH2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Terfenadine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 423, + "assayComponentName": "NVS_IC_hKhERGCh", + "assayComponentDesc": "NVS_IC_hKhERGCh is one of one assay component(s) measured or calculated from the NVS_IC_hKhERGCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Astemizole] are indicative of a change in receptor function and kinetics for the human potassium voltage-gated channel, subfamily H (eag-related), member 2 [GeneSymbol:KCNH2 | GeneID:3757 | Uniprot_SwissProt_Accession:Q12809].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Astemizole", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 237, + "assayName": "NVS_IC_hKhERGCh", + "assayDesc": "NVS_IC_hKhERGCh is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 184, + "geneName": "potassium voltage-gated channel, subfamily H (eag-related), member 2", + "description": null, + "geneSymbol": "KCNH2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3757, + "officialSymbol": "KCNH2", + "officialFullName": "potassium voltage-gated channel, subfamily H (eag-related), member 2", + "uniprotAccessionNumber": "Q12809" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10376921", + "pmid": 10376921, + "title": "Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole", + "author": "Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT", + "citation": "Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999 Jun;10(6):836-43. PubMed PMID: 10376921.", + "otherId": "0", + "citationId": 177, + "otherSource": "" + } + }, + { + "aeid": 687, + "assayComponentEndpointName": "NVS_IC_rCaBTZCHL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaBTZCHL was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaBTZCHL, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Diltiazem HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 424, + "assayComponentName": "NVS_IC_rCaBTZCHL", + "assayComponentDesc": "NVS_IC_rCaBTZCHL is one of one assay component(s) measured or calculated from the NVS_IC_rCaBTZCHL assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diltiazem] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Diltiazem", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 238, + "assayName": "NVS_IC_rCaBTZCHL", + "assayDesc": "NVS_IC_rCaBTZCHL is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2410283", + "pmid": 2410283, + "title": "[3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex", + "author": "Schoemaker H, Langer SZ", + "citation": "Schoemaker H, Langer SZ. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex. Eur J Pharmacol. 1985 May 8;111(2):273-7. PubMed PMID: 2410283.", + "otherId": "0", + "citationId": 46, + "otherSource": "" + } + }, + { + "aeid": 688, + "assayComponentEndpointName": "NVS_IC_rCaChN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaChN was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaChN, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1b. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "W-Conotoxin GVIA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 425, + "assayComponentName": "NVS_IC_rCaChN", + "assayComponentDesc": "NVS_IC_rCaChN is one of one assay component(s) measured or calculated from the NVS_IC_rCaChN assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-o-conotoxin GVIA] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, N type, alpha 1B subunit [GeneSymbol:Cacna1b | GeneID:257648 | Uniprot_SwissProt_Accession:Q02294].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-o-conotoxin GVIA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 239, + "assayName": "NVS_IC_rCaChN", + "assayDesc": "NVS_IC_rCaChN is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 446, + "geneName": "calcium channel, voltage-dependent, N type, alpha 1B subunit", + "description": null, + "geneSymbol": "Cacna1b", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 257648, + "officialSymbol": "Cacna1b", + "officialFullName": "calcium channel, voltage-dependent, N type, alpha 1B subunit", + "uniprotAccessionNumber": "Q02294" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2172254", + "pmid": 2172254, + "title": "The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels", + "author": "Pullan LM, Keith RA, LaMonte D, Stumpo RJ, Salama AI", + "citation": "Pullan LM, Keith RA, LaMonte D, Stumpo RJ, Salama AI. The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels. J Auton Pharmacol. 1990 Aug;10(4):213-9. PubMed PMID: 2172254.", + "otherId": "0", + "citationId": 36, + "otherSource": "" + } + }, + { + "aeid": 689, + "assayComponentEndpointName": "NVS_IC_rCaDHPRCh_L", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is calcium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nifedipine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "calcium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 426, + "assayComponentName": "NVS_IC_rCaDHPRCh_L", + "assayComponentDesc": "NVS_IC_rCaDHPRCh_L is one of one assay component(s) measured or calculated from the NVS_IC_rCaDHPRCh_L assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrendipine] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrendipine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 240, + "assayName": "NVS_IC_rCaDHPRCh_L", + "assayDesc": "NVS_IC_rCaDHPRCh_L is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 407, + "geneName": "calcium channel, voltage-dependent, P/Q type, alpha 1A subunit", + "description": null, + "geneSymbol": "Cacna1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25398, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P54282" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6422256", + "pmid": 6422256, + "title": "Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine", + "author": "Gould RJ, Murphy KM, Snyder SH", + "citation": "Gould RJ, Murphy KM, Snyder SH. Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine. Mol Pharmacol. 1984 Mar;25(2):235-41. PubMed PMID: 6422256.", + "otherId": "0", + "citationId": 125, + "otherSource": "" + } + }, + { + "aeid": 690, + "assayComponentEndpointName": "NVS_IC_rKAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grik1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Kainic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 427, + "assayComponentName": "NVS_IC_rKAR", + "assayComponentDesc": "NVS_IC_rKAR is one of one assay component(s) measured or calculated from the NVS_IC_rKAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Kainic acid] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, ionotropic, kainate 1 [GeneSymbol:Grik1 | GeneID:29559 | Uniprot_SwissProt_Accession:P22756].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Kainic acid", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 241, + "assayName": "NVS_IC_rKAR", + "assayDesc": "NVS_IC_rKAR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 420, + "geneName": "glutamate receptor, ionotropic, kainate 1", + "description": null, + "geneSymbol": "Grik1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29559, + "officialSymbol": "Grik1", + "officialFullName": "glutamate receptor, ionotropic, kainate 1", + "uniprotAccessionNumber": "P22756" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/492142", + "pmid": 492142, + "title": "Specific binding of [3H]kainic acid to receptor sites in rat brain", + "author": "London ED, Coyle JT", + "citation": "London ED, Coyle JT. Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol. 1979 May;15(3):492-505. PubMed PMID: 492142.", + "otherId": "0", + "citationId": 9, + "otherSource": "" + } + }, + { + "aeid": 691, + "assayComponentEndpointName": "NVS_IC_rKATPCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKATPCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKATPCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnj1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Glibenclamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 428, + "assayComponentName": "NVS_IC_rKATPCh", + "assayComponentDesc": "NVS_IC_rKATPCh is one of one assay component(s) measured or calculated from the NVS_IC_rKATPCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Glibenclamide] are indicative of a change in receptor function and kinetics for the Norway rat potassium inwardly-rectifying channel, subfamily J, member 1 [GeneSymbol:Kcnj1 | GeneID:24521 | Uniprot_SwissProt_Accession:P35560].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Glibenclamide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 242, + "assayName": "NVS_IC_rKATPCh", + "assayDesc": "NVS_IC_rKATPCh is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 391, + "geneName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "description": null, + "geneSymbol": "Kcnj1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24521, + "officialSymbol": "Kcnj1", + "officialFullName": "potassium inwardly-rectifying channel, subfamily J, member 1", + "uniprotAccessionNumber": "P35560" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3144003", + "pmid": 3144003, + "title": "Characterization, purification, and affinity labeling of the brain [3H]glibenclamide-binding protein, a putative neuronal ATP-regulated K+ channel", + "author": "Bernardi H, Fosset M, Lazdunski M", + "citation": "Bernardi H, Fosset M, Lazdunski M. Characterization, purification, and affinity labeling of the brain [3H]glibenclamide-binding protein, a putative neuronal ATP-regulated K+ channel. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9816-20. PubMed PMID: 3144003; PubMed Central PMCID: PMC282872.", + "otherId": "0", + "citationId": 96, + "otherSource": "" + } + }, + { + "aeid": 692, + "assayComponentEndpointName": "NVS_IC_rKCaCh", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rKCaCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKCaCh, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnn1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Apamin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "potassium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 429, + "assayComponentName": "NVS_IC_rKCaCh", + "assayComponentDesc": "NVS_IC_rKCaCh is one of one assay component(s) measured or calculated from the NVS_IC_rKCaCh assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Apamin] are indicative of a change in receptor function and kinetics for the Norway rat potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 [GeneSymbol:Kcnn1 | GeneID:54261 | Uniprot_SwissProt_Accession:P70606].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-Apamin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 243, + "assayName": "NVS_IC_rKCaCh", + "assayDesc": "NVS_IC_rKCaCh is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 428, + "geneName": "potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1", + "description": "provisional", + "geneSymbol": "Kcnn1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 54261, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P70606" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/428392", + "pmid": 428392, + "title": "Bee venom neurotoxin (apamin): iodine labeling and characterization of binding sites", + "author": "Habermann E, Fischer K", + "citation": "Habermann E, Fischer K. Bee venom neurotoxin (apamin): iodine labeling and characterization of binding sites. Eur J Biochem. 1979 Mar;94(2):355-64. PubMed PMID: 428392.", + "otherId": "0", + "citationId": 6, + "otherSource": "" + } + }, + { + "aeid": 693, + "assayComponentEndpointName": "NVS_IC_rNaCh_site2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is sodium channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Aconitine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "sodium channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 430, + "assayComponentName": "NVS_IC_rNaCh_site2", + "assayComponentDesc": "NVS_IC_rNaCh_site2 is one of one assay component(s) measured or calculated from the NVS_IC_rNaCh_site2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Batrachotoxin] are indicative of a change in receptor function and kinetics for the Norway rat sodium channel, voltage-gated, type I, alpha subunit [GeneSymbol:Scn1a | GeneID:81574 | Uniprot_SwissProt_Accession:P04774].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Batrachotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 244, + "assayName": "NVS_IC_rNaCh_site2", + "assayDesc": "NVS_IC_rNaCh_site2 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 436, + "geneName": "sodium channel, voltage-gated, type I, alpha subunit", + "description": null, + "geneSymbol": "Scn1a", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 81574, + "officialSymbol": "Scn1a", + "officialFullName": "sodium channel, voltage-gated, type I, alpha subunit", + "uniprotAccessionNumber": "P04774" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6300644", + "pmid": 6300644, + "title": "Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex", + "author": "Creveling CR, McNeal ET, Daly JW, Brown GB", + "citation": "Creveling CR, McNeal ET, Daly JW, Brown GB. Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex. Mol Pharmacol. 1983 Mar;23(2):350-8. PubMed PMID: 6300644.", + "otherId": "0", + "citationId": 117, + "otherSource": "" + } + }, + { + "aeid": 694, + "assayComponentEndpointName": "NVS_LGIC_bGABAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GABA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 431, + "assayComponentName": "NVS_LGIC_bGABAR_Agonist", + "assayComponentDesc": "NVS_LGIC_bGABAR_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABAR_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GABA] are indicative of a change in receptor agonist activity for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:GABRA1 | GeneID:780973 | Uniprot_SwissProt_Accession:P08219].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GABA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 245, + "assayName": "NVS_LGIC_bGABAR_Agonist", + "assayDesc": "NVS_LGIC_bGABAR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 465, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 780973, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P08219" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/191147", + "pmid": 191147, + "title": "Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain", + "author": "Enna SJ, Collins JF, Snyder SH", + "citation": "Enna SJ, Collins JF, Snyder SH. Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain. Brain Res. 1977 Mar 18;124(1):185-90. PubMed PMID: 191147.", + "otherId": "0", + "citationId": 5, + "otherSource": "" + } + }, + { + "aeid": 695, + "assayComponentEndpointName": "NVS_LGIC_bGABARa1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ro 15-1788 (Flumazenil)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 432, + "assayComponentName": "NVS_LGIC_bGABARa1", + "assayComponentDesc": "NVS_LGIC_bGABARa1 is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABARa1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Flunitrazepam] are indicative of a change in receptor function and kinetics for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:GABRA1 | GeneID:780973 | Uniprot_SwissProt_Accession:P08219].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Flunitrazepam", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 246, + "assayName": "NVS_LGIC_bGABARa1", + "assayDesc": "NVS_LGIC_bGABARa1 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine cortical membranes in a tissue-based cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 465, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "GABRA1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 780973, + "officialSymbol": "GABRA1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P08219" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3005837", + "pmid": 3005837, + "title": "Regional difference in brain benzodiazepine receptor carbohydrates", + "author": "Sweetnam PM, Tallman JF", + "citation": "Sweetnam PM, Tallman JF. Regional difference in brain benzodiazepine receptor carbohydrates. Mol Pharmacol. 1986 Mar;29(3):299-306. PubMed PMID: 3005837.", + "otherId": "0", + "citationId": 89, + "otherSource": "" + } + }, + { + "aeid": 696, + "assayComponentEndpointName": "NVS_LGIC_bGABARa5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_bGABARa5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-655,708", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 433, + "assayComponentName": "NVS_LGIC_bGABARa5", + "assayComponentDesc": "NVS_LGIC_bGABARa5 is one of one assay component(s) measured or calculated from the NVS_LGIC_bGABARa5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-RY80] are indicative of a change in receptor function and kinetics for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 5 [GeneSymbol:GABRA5 | GeneID:523515 | Uniprot_SwissProt_Accession:Q08E50].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-RY80", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 247, + "assayName": "NVS_LGIC_bGABARa5", + "assayDesc": "NVS_LGIC_bGABARa5 is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine hippocampal membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine hippocampal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 463, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 5", + "description": null, + "geneSymbol": "GABRA5", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 523515, + "officialSymbol": "GABRA5", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 5", + "uniprotAccessionNumber": "Q08E50" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11173064", + "pmid": 11173064, + "title": "Evaluation of native GABA(A) receptors containing an alpha 5 subunit", + "author": "Li M, Szabo A, Rosenberg HC", + "citation": "Li M, Szabo A, Rosenberg HC. Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol. 2001 Feb 9;413(1):63-72. PubMed PMID: 11173064.", + "otherId": "0", + "citationId": 185, + "otherSource": "" + } + }, + { + "aeid": 697, + "assayComponentEndpointName": "NVS_LGIC_h5HT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_h5HT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_h5HT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR3A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "MDL-72222", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 434, + "assayComponentName": "NVS_LGIC_h5HT3", + "assayComponentDesc": "NVS_LGIC_h5HT3 is one of one assay component(s) measured or calculated from the NVS_LGIC_h5HT3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR 65630] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic [GeneSymbol:HTR3A | GeneID:3359 | Uniprot_SwissProt_Accession:P46098].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GR 65630", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 248, + "assayName": "NVS_LGIC_h5HT3", + "assayDesc": "NVS_LGIC_h5HT3 is a biochemical, single-readout assay that uses extracted gene-proteins from HEK293 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "HEK293", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 166, + "geneName": "5-hydroxytryptamine (serotonin) receptor 3A, ionotropic", + "description": null, + "geneSymbol": "HTR3A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3359, + "officialSymbol": "HTR3A", + "officialFullName": "5-hydroxytryptamine (serotonin) receptor 3A, ionotropic", + "uniprotAccessionNumber": "P46098" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1840227", + "pmid": 1840227, + "title": "5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists", + "author": "Tyers MB", + "citation": "Tyers MB. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists. Therapie. 1991 Nov-Dec;46(6):431-5. Review. PubMed PMID: 1840227.", + "otherId": "0", + "citationId": 23, + "otherSource": "" + } + }, + { + "aeid": 698, + "assayComponentEndpointName": "NVS_LGIC_hNNR_NBungSens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_hNNR_NBungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_hNNR_NBungSens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRNA2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-Epibatidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 435, + "assayComponentName": "NVS_LGIC_hNNR_NBungSens", + "assayComponentDesc": "NVS_LGIC_hNNR_NBungSens is one of one assay component(s) measured or calculated from the NVS_LGIC_hNNR_NBungSens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Epibatidine] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, nicotinic, alpha 2 (neuronal) [GeneSymbol:CHRNA2 | GeneID:1135 | Uniprot_SwissProt_Accession:Q15822].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Epibatidine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 249, + "assayName": "NVS_LGIC_hNNR_NBungSens", + "assayDesc": "NVS_LGIC_hNNR_NBungSens is a biochemical, single-readout assay that uses extracted gene-proteins from Human neuroblastoma membrane cells in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human neuroblastoma membrane cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 66, + "geneName": "cholinergic receptor, nicotinic, alpha 2 (neuronal)", + "description": null, + "geneSymbol": "CHRNA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1135, + "officialSymbol": "CHRNA2", + "officialFullName": "cholinergic receptor, nicotinic, alpha 2 (neuronal)", + "uniprotAccessionNumber": "Q15822" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2197155", + "pmid": 2197155, + "title": "Nicotine receptors in the mammalian brain", + "author": "Luetje CW, Patrick J, Séguéla P", + "citation": "Luetje CW, Patrick J, Séguéla P. Nicotine receptors in the mammalian brain. FASEB J. 1990 Jul;4(10):2753-60. Review. PubMed PMID: 2197155.", + "otherId": "0", + "citationId": 40, + "otherSource": "" + } + }, + { + "aeid": 699, + "assayComponentEndpointName": "NVS_LGIC_rAMPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rAMPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rAMPA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gria1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-)-AMPA HBr", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 436, + "assayComponentName": "NVS_LGIC_rAMPA", + "assayComponentDesc": "NVS_LGIC_rAMPA is one of one assay component(s) measured or calculated from the NVS_LGIC_rAMPA assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-AMPA] are indicative of a change in receptor function and kinetics for the Norway rat glutamate receptor, ionotropic, AMPA 1 [GeneSymbol:Gria1 | GeneID:50592 | Uniprot_SwissProt_Accession:P19490].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-AMPA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 250, + "assayName": "NVS_LGIC_rAMPA", + "assayDesc": "NVS_LGIC_rAMPA is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 424, + "geneName": "glutamate receptor, ionotropic, AMPA 1", + "description": null, + "geneSymbol": "Gria1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 50592, + "officialSymbol": "Gria1", + "officialFullName": "glutamate receptor, ionotropic, AMPA 1", + "uniprotAccessionNumber": "P19490" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2890112", + "pmid": 2890112, + "title": "Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay", + "author": "Murphy DE, Snowhill EW, Williams M", + "citation": "Murphy DE, Snowhill EW, Williams M. Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay. Neurochem Res. 1987 Sep;12(9):775-81. PubMed PMID: 2890112.", + "otherId": "0", + "citationId": 75, + "otherSource": "" + } + }, + { + "aeid": 700, + "assayComponentEndpointName": "NVS_LGIC_rGABAR_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GABA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 437, + "assayComponentName": "NVS_LGIC_rGABAR_NonSelective", + "assayComponentDesc": "NVS_LGIC_rGABAR_NonSelective is one of one assay component(s) measured or calculated from the NVS_LGIC_rGABAR_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GABA] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:Gabra1 | GeneID:29705 | Uniprot_SwissProt_Accession:P62813].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-GABA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 251, + "assayName": "NVS_LGIC_rGABAR_NonSelective", + "assayDesc": "NVS_LGIC_rGABAR_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Rat whole brain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat whole brain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 421, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "description": null, + "geneSymbol": "Gabra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29705, + "officialSymbol": "Gabra1", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 1", + "uniprotAccessionNumber": "P62813" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/191147", + "pmid": 191147, + "title": "Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain", + "author": "Enna SJ, Collins JF, Snyder SH", + "citation": "Enna SJ, Collins JF, Snyder SH. Stereospecificity and structure--activity requirements of GABA receptor binding in rat brain. Brain Res. 1977 Mar 18;124(1):185-90. PubMed PMID: 191147.", + "otherId": "0", + "citationId": 5, + "otherSource": "" + } + }, + { + "aeid": 701, + "assayComponentEndpointName": "NVS_LGIC_rGABARa6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGABARa6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABARa6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "L-655,708", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 438, + "assayComponentName": "NVS_LGIC_rGABARa6", + "assayComponentDesc": "NVS_LGIC_rGABARa6 is one of one assay component(s) measured or calculated from the NVS_LGIC_rGABARa6 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Ro 15-4513] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) A receptor, alpha 6 [GeneSymbol:Gabra6 | GeneID:29708 | Uniprot_SwissProt_Accession:P30191].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Ro 15-4513", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 252, + "assayName": "NVS_LGIC_rGABARa6", + "assayDesc": "NVS_LGIC_rGABARa6 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cerebellar membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cerebellar membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 422, + "geneName": "gamma-aminobutyric acid (GABA) A receptor, alpha 6", + "description": null, + "geneSymbol": "Gabra6", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29708, + "officialSymbol": "Gabra6", + "officialFullName": "gamma-aminobutyric acid (GABA) A receptor, alpha 6", + "uniprotAccessionNumber": "P30191" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9281599", + "pmid": 9281599, + "title": "Cerebellar gamma-aminobutyric acid type A receptors: pharmacological subtypes revealed by mutant mouse lines", + "author": "Mäkelä R, Uusi-Oukari M, Homanics GE, Quinlan JJ, Firestone LL, Wisden W, Korpi ER", + "citation": "Mäkelä R, Uusi-Oukari M, Homanics GE, Quinlan JJ, Firestone LL, Wisden W, Korpi ER. Cerebellar gamma-aminobutyric acid type A receptors: pharmacological subtypes revealed by mutant mouse lines. Mol Pharmacol. 1997 Sep;52(3):380-8. PubMed PMID: 9281599.", + "otherId": "0", + "citationId": 173, + "otherSource": "" + } + }, + { + "aeid": 702, + "assayComponentEndpointName": "NVS_LGIC_rGluNMDA_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGluNMDA_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "N-methyl-D-aspartate (NMDA)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 439, + "assayComponentName": "NVS_LGIC_rGluNMDA_Agonist", + "assayComponentDesc": "NVS_LGIC_rGluNMDA_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_rGluNMDA_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGP 39653] are indicative of a change in receptor agonist activity for the Norway rat glutamate receptor, ionotropic, N-methyl D-aspartate 1 [GeneSymbol:Grin1 | GeneID:24408 | Uniprot_SwissProt_Accession:P35439].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-CGP 39653", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 253, + "assayName": "NVS_LGIC_rGluNMDA_Agonist", + "assayDesc": "NVS_LGIC_rGluNMDA_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2899170", + "pmid": 2899170, + "title": "CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist", + "author": "Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, et al", + "citation": "Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, et al. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther. 1988 Jul;246(1):65-75. PubMed PMID: 2899170.", + "otherId": "0", + "citationId": 76, + "otherSource": "" + } + }, + { + "aeid": 703, + "assayComponentEndpointName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGluNMDA_MK801_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_MK801_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+)-MK-801", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 440, + "assayComponentName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "assayComponentDesc": "NVS_LGIC_rGluNMDA_MK801_Agonist is one of one assay component(s) measured or calculated from the NVS_LGIC_rGluNMDA_MK801_Agonist assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-801] are indicative of a change in receptor agonist activity for the Norway rat glutamate receptor, ionotropic, N-methyl D-aspartate 1 [GeneSymbol:Grin1 | GeneID:24408 | Uniprot_SwissProt_Accession:P35439].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-MK-801", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 254, + "assayName": "NVS_LGIC_rGluNMDA_MK801_Agonist", + "assayDesc": "NVS_LGIC_rGluNMDA_MK801_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 1.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 387, + "geneName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "description": null, + "geneSymbol": "Grin1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24408, + "officialSymbol": "Grin1", + "officialFullName": "glutamate receptor, ionotropic, N-methyl D-aspartate 1", + "uniprotAccessionNumber": "P35439" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2468076", + "pmid": 2468076, + "title": "Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels", + "author": "Javitt DC, Zukin SR", + "citation": "Javitt DC, Zukin SR. Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol Pharmacol. 1989 Apr;35(4):387-93. PubMed PMID: 2468076.", + "otherId": "0", + "citationId": 53, + "otherSource": "" + } + }, + { + "aeid": 704, + "assayComponentEndpointName": "NVS_LGIC_rGlyRStrySens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rGlyRStrySens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGlyRStrySens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Glra1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Strychnine nitrate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 441, + "assayComponentName": "NVS_LGIC_rGlyRStrySens", + "assayComponentDesc": "NVS_LGIC_rGlyRStrySens is one of one assay component(s) measured or calculated from the NVS_LGIC_rGlyRStrySens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-strychnine] are indicative of a change in receptor function and kinetics for the Norway rat glycine receptor, alpha 1 [GeneSymbol:Glra1 | GeneID:25674 | Uniprot_SwissProt_Accession:P07727].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-strychnine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 255, + "assayName": "NVS_LGIC_rGlyRStrySens", + "assayDesc": "NVS_LGIC_rGlyRStrySens is a biochemical, single-readout assay that uses extracted gene-proteins from Rat spinal cord membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat spinal cord membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 414, + "geneName": "glycine receptor, alpha 1", + "description": null, + "geneSymbol": "Glra1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25674, + "officialSymbol": "Glra1", + "officialFullName": "glycine receptor, alpha 1", + "uniprotAccessionNumber": "P07727" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2542450", + "pmid": 2542450, + "title": "Thermodynamics of agonist and antagonist interaction with the strychnine-sensitive glycine receptor", + "author": "Ruiz-Gómez A, García-Calvo M, Vázquez J, Marvizón JC, Valdivieso F, Mayor F Jr", + "citation": "Ruiz-Gómez A, García-Calvo M, Vázquez J, Marvizón JC, Valdivieso F, Mayor F Jr. Thermodynamics of agonist and antagonist interaction with the strychnine-sensitive glycine receptor. J Neurochem. 1989 Jun;52(6):1775-80. PubMed PMID: 2542450.", + "otherId": "0", + "citationId": 56, + "otherSource": "" + } + }, + { + "aeid": 705, + "assayComponentEndpointName": "NVS_LGIC_rNNR_BungSens", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_LGIC_rNNR_BungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rNNR_BungSens, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrna7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated ion channel.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyllycaconitine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "ion channel", + "intendedTargetFamilySub": "ligand-gated ion channel", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 442, + "assayComponentName": "NVS_LGIC_rNNR_BungSens", + "assayComponentDesc": "NVS_LGIC_rNNR_BungSens is one of one assay component(s) measured or calculated from the NVS_LGIC_rNNR_BungSens assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-a-bungarotoxin] are indicative of a change in receptor function and kinetics for the Norway rat cholinergic receptor, nicotinic, alpha 7 (neuronal) [GeneSymbol:Chrna7 | GeneID:25302 | Uniprot_SwissProt_Accession:Q05941].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[125I]-a-bungarotoxin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 256, + "assayName": "NVS_LGIC_rNNR_BungSens", + "assayDesc": "NVS_LGIC_rNNR_BungSens is a biochemical, single-readout assay that uses extracted gene-proteins from Rat cortical membranes in a tissue-based cell-free assay. Measurements were taken 2.5 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.5, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat cortical membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 405, + "geneName": "cholinergic receptor, nicotinic, alpha 7 (neuronal)", + "description": null, + "geneSymbol": "Chrna7", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25302, + "officialSymbol": "Chrna7", + "officialFullName": "cholinergic receptor, nicotinic, alpha 7 (neuronal)", + "uniprotAccessionNumber": "Q05941" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2197155", + "pmid": 2197155, + "title": "Nicotine receptors in the mammalian brain", + "author": "Luetje CW, Patrick J, Séguéla P", + "citation": "Luetje CW, Patrick J, Séguéla P. Nicotine receptors in the mammalian brain. FASEB J. 1990 Jul;4(10):2753-60. Review. PubMed PMID: 2197155.", + "otherId": "0", + "citationId": 40, + "otherSource": "" + } + }, + { + "aeid": 706, + "assayComponentEndpointName": "NVS_MP_hPBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 443, + "assayComponentName": "NVS_MP_hPBR", + "assayComponentDesc": "NVS_MP_hPBR is one of one assay component(s) measured or calculated from the NVS_MP_hPBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the human translocator protein (18kDa) [GeneSymbol:TSPO | GeneID:706 | Uniprot_SwissProt_Accession:P30536].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 257, + "assayName": "NVS_MP_hPBR", + "assayDesc": "NVS_MP_hPBR is a biochemical, single-readout assay that uses extracted gene-proteins from Human colonic cell membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "intestinal", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human colonic cell membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 37, + "geneName": "translocator protein (18kDa)", + "description": null, + "geneSymbol": "TSPO", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 706, + "officialSymbol": "TSPO", + "officialFullName": "translocator protein (18kDa)", + "uniprotAccessionNumber": "P30536" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2837399", + "pmid": 2837399, + "title": "Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105", + "author": "Skowro?ski R, Fanestil DD, Beaumont K", + "citation": "Skowro?ski R, Fanestil DD, Beaumont K. Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105. Eur J Pharmacol. 1988 Mar 29;148(2):187-93. PubMed PMID: 2837399.", + "otherId": "0", + "citationId": 68, + "otherSource": "" + } + }, + { + "aeid": 707, + "assayComponentEndpointName": "NVS_MP_rPBR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PK11195", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "cholesterol transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 444, + "assayComponentName": "NVS_MP_rPBR", + "assayComponentDesc": "NVS_MP_rPBR is one of one assay component(s) measured or calculated from the NVS_MP_rPBR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the Norway rat translocator protein [GeneSymbol:Tspo | GeneID:24230 | Uniprot_SwissProt_Accession:P16257].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-PK11195", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 258, + "assayName": "NVS_MP_rPBR", + "assayDesc": "NVS_MP_rPBR is a biochemical, single-readout assay that uses extracted gene-proteins from Rat kidney membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "kidney", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat kidney membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 382, + "geneName": "translocator protein", + "description": null, + "geneSymbol": "Tspo", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24230, + "officialSymbol": "Tspo", + "officialFullName": "translocator protein", + "uniprotAccessionNumber": "P16257" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2837399", + "pmid": 2837399, + "title": "Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105", + "author": "Skowro?ski R, Fanestil DD, Beaumont K", + "citation": "Skowro?ski R, Fanestil DD, Beaumont K. Photoaffinity labeling of peripheral-type benzodiazepine receptors in rat kidney mitochondria with [3H]PK 14105. Eur J Pharmacol. 1988 Mar 29;148(2):187-93. PubMed PMID: 2837399.", + "otherId": "0", + "citationId": 68, + "otherSource": "" + } + }, + { + "aeid": 708, + "assayComponentEndpointName": "NVS_NR_bER", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_bER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bER, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 445, + "assayComponentName": "NVS_NR_bER", + "assayComponentDesc": "NVS_NR_bER is one of one assay component(s) measured or calculated from the NVS_NR_bER assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the cattle estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:407238 | Uniprot_SwissProt_Accession:P49884].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 259, + "assayName": "NVS_NR_bER", + "assayDesc": "NVS_NR_bER is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine uterine membranes in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 459, + "geneName": "estrogen receptor 1", + "description": "provisional", + "geneSymbol": "ESR1", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 407238, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P49884" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 709, + "assayComponentEndpointName": "NVS_NR_bPR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Promegestone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 446, + "assayComponentName": "NVS_NR_bPR", + "assayComponentDesc": "NVS_NR_bPR is one of one assay component(s) measured or calculated from the NVS_NR_bPR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the cattle progesterone receptor-like [GeneSymbol:PGR | GeneID:100848466 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Promegestone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 260, + "assayName": "NVS_NR_bPR", + "assayDesc": "NVS_NR_bPR is a biochemical, single-readout assay that uses extracted gene-proteins from Bovine uterine membranes in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9913, + "organism": "bovine", + "tissue": "uterus", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Bovine uterine membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 479, + "geneName": "progesterone receptor-like", + "description": "provisional", + "geneSymbol": "PGR", + "organismId": 4, + "trackStatus": "live", + "entrezGeneId": 100848466, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2419120", + "pmid": 2419120, + "title": "Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues", + "author": "Traish AM, Müller RE, Wotiz HH", + "citation": "Traish AM, Müller RE, Wotiz HH. Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues. Endocrinology. 1986 Apr;118(4):1327-33. PubMed PMID: 2419120.", + "otherId": "0", + "citationId": 48, + "otherSource": "" + } + }, + { + "aeid": 710, + "assayComponentEndpointName": "NVS_NR_cAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 447, + "assayComponentName": "NVS_NR_cAR", + "assayComponentDesc": "NVS_NR_cAR is one of one assay component(s) measured or calculated from the NVS_NR_cAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the chimpanzee androgen receptor [GeneSymbol:AR | GeneID:747460 | Uniprot_SwissProt_Accession:O97775].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 261, + "assayName": "NVS_NR_cAR", + "assayDesc": "NVS_NR_cAR is a biochemical, single-readout assay that uses extracted gene-proteins from Sf9/Sf21 in a cell-free assay. Measurements were taken 72 hours after chemical dosing in a 96-well plate.", + "timepointHr": 72.0, + "organismId": 9598, + "organism": "chimpanzee", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Sf9/Sf21", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 464, + "geneName": "androgen receptor", + "description": "provisional", + "geneSymbol": "AR", + "organismId": 7, + "trackStatus": "live", + "entrezGeneId": 747460, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "O97775" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 711, + "assayComponentEndpointName": "NVS_NR_hAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 448, + "assayComponentName": "NVS_NR_hAR", + "assayComponentDesc": "NVS_NR_hAR is one of one assay component(s) measured or calculated from the NVS_NR_hAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 262, + "assayName": "NVS_NR_hAR", + "assayDesc": "NVS_NR_hAR is a biochemical, single-readout assay that uses extracted gene-proteins from LnCAP in a cell-free assay. Measurements were taken 20 hours after chemical dosing in a 96-well plate.", + "timepointHr": 20.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "LnCAP", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/436741", + "pmid": 436741, + "title": "Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors", + "author": "Zava DT, Landrum B, Horwitz KB, McGuire WL", + "citation": "Zava DT, Landrum B, Horwitz KB, McGuire WL. Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors. Endocrinology. 1979 Apr;104(4):1007-12. PubMed PMID: 436741.", + "otherId": "0", + "citationId": 7, + "otherSource": "" + } + }, + { + "aeid": 712, + "assayComponentEndpointName": "NVS_NR_hCAR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hCAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CITCO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 449, + "assayComponentName": "NVS_NR_hCAR_Agonist", + "assayComponentDesc": "NVS_NR_hCAR_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hCAR_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 263, + "assayName": "NVS_NR_hCAR_Agonist", + "assayDesc": "NVS_NR_hCAR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12611900", + "pmid": 12611900, + "title": "Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes", + "author": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT", + "citation": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83. Epub 2003 Feb 27. PubMed PMID: 12611900.", + "otherId": "0", + "citationId": 195, + "otherSource": "" + } + }, + { + "aeid": 713, + "assayComponentEndpointName": "NVS_NR_hCAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 450, + "assayComponentName": "NVS_NR_hCAR_Antagonist", + "assayComponentDesc": "NVS_NR_hCAR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hCAR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 264, + "assayName": "NVS_NR_hCAR_Antagonist", + "assayDesc": "NVS_NR_hCAR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12611900", + "pmid": 12611900, + "title": "Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes", + "author": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT", + "citation": "Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83. Epub 2003 Feb 27. PubMed PMID: 12611900.", + "otherId": "0", + "citationId": 195, + "otherSource": "" + } + }, + { + "aeid": 714, + "assayComponentEndpointName": "NVS_NR_hER", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 451, + "assayComponentName": "NVS_NR_hER", + "assayComponentDesc": "NVS_NR_hER is one of one assay component(s) measured or calculated from the NVS_NR_hER assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 265, + "assayName": "NVS_NR_hER", + "assayDesc": "NVS_NR_hER is a biochemical, single-readout assay that uses extracted gene-proteins from MCF7 in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "MCF7", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 715, + "assayComponentEndpointName": "NVS_NR_hFXR_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hFXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 452, + "assayComponentName": "NVS_NR_hFXR_Agonist", + "assayComponentDesc": "NVS_NR_hFXR_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hFXR_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 266, + "assayName": "NVS_NR_hFXR_Agonist", + "assayDesc": "NVS_NR_hFXR_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11988537", + "pmid": 11988537, + "title": "A natural product that lowers cholesterol as an antagonist ligand for FXR", + "author": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD", + "citation": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2. PubMed PMID: 11988537.", + "otherId": "0", + "citationId": 188, + "otherSource": "" + } + }, + { + "aeid": 716, + "assayComponentEndpointName": "NVS_NR_hFXR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Guggulsterone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 453, + "assayComponentName": "NVS_NR_hFXR_Antagonist", + "assayComponentDesc": "NVS_NR_hFXR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hFXR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 267, + "assayName": "NVS_NR_hFXR_Antagonist", + "assayDesc": "NVS_NR_hFXR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/11988537", + "pmid": 11988537, + "title": "A natural product that lowers cholesterol as an antagonist ligand for FXR", + "author": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD", + "citation": "Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2. PubMed PMID: 11988537.", + "otherId": "0", + "citationId": 188, + "otherSource": "" + } + }, + { + "aeid": 717, + "assayComponentEndpointName": "NVS_NR_hGR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Triamcinolone acetonide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 454, + "assayComponentName": "NVS_NR_hGR", + "assayComponentDesc": "NVS_NR_hGR is one of one assay component(s) measured or calculated from the NVS_NR_hGR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dexamethasone] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dexamethasone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 268, + "assayName": "NVS_NR_hGR", + "assayDesc": "NVS_NR_hGR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 16 hours after chemical dosing in a 96-well plate.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8061598", + "pmid": 8061598, + "title": "Binding of [3H]triamcinolone acetonide to glucocorticoid receptors in brain cytosol fractions of rats with intact adrenals", + "author": "Han D, Ogita K, Kashiwai K, Narita S, Yoneda Y", + "citation": "Han D, Ogita K, Kashiwai K, Narita S, Yoneda Y. Binding of [3H]triamcinolone acetonide to glucocorticoid receptors in brain cytosol fractions of rats with intact adrenals. Neurochem Int. 1994 Apr;24(4):339-48. PubMed PMID: 8061598.", + "otherId": "0", + "citationId": 154, + "otherSource": "" + } + }, + { + "aeid": 718, + "assayComponentEndpointName": "NVS_NR_hPPARa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPPARa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 455, + "assayComponentName": "NVS_NR_hPPARa", + "assayComponentDesc": "NVS_NR_hPPARa is one of one assay component(s) measured or calculated from the NVS_NR_hPPARa assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluoromone PPAR green] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluoromone PPAR green", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 269, + "assayName": "NVS_NR_hPPARa", + "assayDesc": "NVS_NR_hPPARa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/15497675", + "pmid": 15497675, + "title": "Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res", + "author": "van Raalte DH, Li M, Pritchard PH, Wasan KM", + "citation": "van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res. 2004 Sep;21(9):1531-8. Review. PubMed PMID: 15497675.", + "otherId": "0", + "citationId": 199, + "otherSource": "" + } + }, + { + "aeid": 719, + "assayComponentEndpointName": "NVS_NR_hPPARg", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ciglitazone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 456, + "assayComponentName": "NVS_NR_hPPARg", + "assayComponentDesc": "NVS_NR_hPPARg is one of one assay component(s) measured or calculated from the NVS_NR_hPPARg assay. It is designed to make measurements of fluorescent polarization, a form of binding reporter, as detected with fluorescence polarization signals by Fluorescence Polarization technology.", + "assayComponentTargetDesc": "Changes to fluorescence polarization signals produced from the receptor-ligand binding of the key ligand [Fluorescent Ligand] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fluorescent polarization", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence polarization", + "detectionTechnology": "Fluorescence Polarization", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluorescent Ligand", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 270, + "assayName": "NVS_NR_hPPARg", + "assayDesc": "NVS_NR_hPPARg is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9744270", + "pmid": 9744270, + "title": "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma", + "author": "Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV", + "citation": "Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998 Sep 10;395(6698):137-43. PubMed PMID: 9744270.", + "otherId": "0", + "citationId": 174, + "otherSource": "" + } + }, + { + "aeid": 720, + "assayComponentEndpointName": "NVS_NR_hPR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Promegestone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 457, + "assayComponentName": "NVS_NR_hPR", + "assayComponentDesc": "NVS_NR_hPR is one of one assay component(s) measured or calculated from the NVS_NR_hPR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the human progesterone receptor [GeneSymbol:PGR | GeneID:5241 | Uniprot_SwissProt_Accession:P06401].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Promegestone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 271, + "assayName": "NVS_NR_hPR", + "assayDesc": "NVS_NR_hPR is a biochemical, single-readout assay that uses extracted gene-proteins from T47D in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "T47D", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2419120", + "pmid": 2419120, + "title": "Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues", + "author": "Traish AM, Müller RE, Wotiz HH", + "citation": "Traish AM, Müller RE, Wotiz HH. Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues. Endocrinology. 1986 Apr;118(4):1327-33. PubMed PMID: 2419120.", + "otherId": "0", + "citationId": 48, + "otherSource": "" + } + }, + { + "aeid": 721, + "assayComponentEndpointName": "NVS_NR_hPXR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TO901317", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 458, + "assayComponentName": "NVS_NR_hPXR", + "assayComponentDesc": "NVS_NR_hPXR is one of one assay component(s) measured or calculated from the NVS_NR_hPXR assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluormone PXR (SXR) green] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "Fluormone PXR (SXR) green", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 272, + "assayName": "NVS_NR_hPXR", + "assayDesc": "NVS_NR_hPXR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12663745", + "pmid": 12663745, + "title": "Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor", + "author": "Rosenfeld JM, Vargas R Jr, Xie W, Evans RM", + "citation": "Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol. 2003 Jul;17(7):1268-82. Epub 2003 Mar 27. PubMed PMID: 12663745", + "otherId": "0", + "citationId": 196, + "otherSource": "" + } + }, + { + "aeid": 722, + "assayComponentEndpointName": "NVS_NR_hRAR_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "RO415253", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 459, + "assayComponentName": "NVS_NR_hRAR_Antagonist", + "assayComponentDesc": "NVS_NR_hRAR_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hRAR_Antagonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 273, + "assayName": "NVS_NR_hRAR_Antagonist", + "assayDesc": "NVS_NR_hRAR_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10567548", + "pmid": 10567548, + "title": "Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta", + "author": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP", + "citation": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol. 1999 Dec;19(12):8226-39. PubMed PMID: 10567548; PubMed Central PMCID: PMC84907.", + "otherId": "0", + "citationId": 179, + "otherSource": "" + } + }, + { + "aeid": 723, + "assayComponentEndpointName": "NVS_NR_hRARa_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hRARa_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRARa_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "TTNPB", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 460, + "assayComponentName": "NVS_NR_hRARa_Agonist", + "assayComponentDesc": "NVS_NR_hRARa_Agonist is one of one assay component(s) measured or calculated from the NVS_NR_hRARa_Agonist assay. It is designed to make measurements of fluorescent resonance energy transfer, a form of binding reporter, as detected with fluorescent resonance energy transfer signals by Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology.", + "assayComponentTargetDesc": "Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "fret", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "FRET: TR-FRET", + "detectionTechnology": "TR-FRET", + "keyAssayReagentType": "ligand;antibody", + "keyAssayReagent": "Fluorescein-labeled coactivator peptide;Terbium-labeled anti-GST antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 274, + "assayName": "NVS_NR_hRARa_Agonist", + "assayDesc": "NVS_NR_hRARa_Agonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10567548", + "pmid": 10567548, + "title": "Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta", + "author": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP", + "citation": "Chang Cy, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol. 1999 Dec;19(12):8226-39. PubMed PMID: 10567548; PubMed Central PMCID: PMC84907.", + "otherId": "0", + "citationId": 179, + "otherSource": "" + } + }, + { + "aeid": 724, + "assayComponentEndpointName": "NVS_NR_hTRa_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_hTRa_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hTRa_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene THRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Bisphenol A", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 461, + "assayComponentName": "NVS_NR_hTRa_Antagonist", + "assayComponentDesc": "NVS_NR_hTRa_Antagonist is one of one assay component(s) measured or calculated from the NVS_NR_hTRa_Antagonist assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with chemiluminescence signals by AlphaLISA immunoassay technology.", + "assayComponentTargetDesc": "Changes to chemiluminescence signals produced from the receptor-ligand binding of the key ligand [3,3\",5-triiodo-L-thyronine] are indicative of a change in receptor antagonist activity for the human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Chemiluminescence", + "detectionTechnology": "AlphaLISA immunoassay", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "3,3\",5-triiodo-L-thyronine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 275, + "assayName": "NVS_NR_hTRa_Antagonist", + "assayDesc": "NVS_NR_hTRa_Antagonist is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12414890", + "pmid": 12414890, + "title": "Thyroid hormone action is disrupted by bisphenol A as an antagonist", + "author": "Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, Hataya Y, Shimatsu A, Kuzuya H, Nakao K", + "citation": "Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, Hataya Y, Shimatsu A, Kuzuya H, Nakao K. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab. 2002 Nov;87(11):5185-90. PubMed PMID: 12414890.", + "otherId": "0", + "citationId": 192, + "otherSource": "" + } + }, + { + "aeid": 725, + "assayComponentEndpointName": "NVS_NR_mERa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 462, + "assayComponentName": "NVS_NR_mERa", + "assayComponentDesc": "NVS_NR_mERa is one of one assay component(s) measured or calculated from the NVS_NR_mERa assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the house mouse estrogen receptor 1 (alpha) [GeneSymbol:Esr1 | GeneID:13982 | Uniprot_SwissProt_Accession:P19785].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-estradiol", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 276, + "assayName": "NVS_NR_mERa", + "assayDesc": "NVS_NR_mERa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 10090, + "organism": "mouse", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 372, + "geneName": "estrogen receptor 1 (alpha)", + "description": null, + "geneSymbol": "Esr1", + "organismId": 2, + "trackStatus": "live", + "entrezGeneId": 13982, + "officialSymbol": "Esr1", + "officialFullName": "estrogen receptor 1 (alpha)", + "uniprotAccessionNumber": "P19785" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2090365", + "pmid": 2090365, + "title": "Transient elevation of estrogen receptors in the neonatal rat hippocampus", + "author": "O'Keefe JA, Handa RJ", + "citation": "O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Brain Res Dev Brain Res. 1990 Dec 1;57(1):119-27. PubMed PMID: 2090365.", + "otherId": "0", + "citationId": 29, + "otherSource": "" + } + }, + { + "aeid": 726, + "assayComponentEndpointName": "NVS_NR_rAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Methyltrienolone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 463, + "assayComponentName": "NVS_NR_rAR", + "assayComponentDesc": "NVS_NR_rAR is one of one assay component(s) measured or calculated from the NVS_NR_rAR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the Norway rat androgen receptor [GeneSymbol:Ar | GeneID:24208 | Uniprot_SwissProt_Accession:P15207].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-methyltrienolone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 277, + "assayName": "NVS_NR_rAR", + "assayDesc": "NVS_NR_rAR is a biochemical, single-readout assay that uses extracted gene-proteins from Testosterone pre-treated rat prostate in a tissue-based cell-free assay. Measurements were taken 18 hours after chemical dosing in a 96-well plate.", + "timepointHr": 18.0, + "organismId": 10116, + "organism": "rat", + "tissue": "prostate", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Testosterone pre-treated rat prostate", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 381, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "Ar", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24208, + "officialSymbol": "Ar", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P15207" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 727, + "assayComponentEndpointName": "NVS_NR_rMR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_NR_rMR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rMR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nr3c2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Spironolactone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 464, + "assayComponentName": "NVS_NR_rMR", + "assayComponentDesc": "NVS_NR_rMR is one of one assay component(s) measured or calculated from the NVS_NR_rMR assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Aldosterone] are indicative of a change in receptor function and kinetics for the Norway rat nuclear receptor subfamily 3, group C, member 2 [GeneSymbol:Nr3c2 | GeneID:25672 | Uniprot_SwissProt_Accession:P22199].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Lysate-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Aldosterone", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 278, + "assayName": "NVS_NR_rMR", + "assayDesc": "NVS_NR_rMR is a biochemical, single-readout assay that uses extracted gene-proteins from Adrenalectomized rat brain supernatant in a tissue-based cell-free assay. Measurements were taken 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Adrenalectomized rat brain supernatant", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 413, + "geneName": "nuclear receptor subfamily 3, group C, member 2", + "description": null, + "geneSymbol": "Nr3c2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25672, + "officialSymbol": "Nr3c2", + "officialFullName": "nuclear receptor subfamily 3, group C, member 2", + "uniprotAccessionNumber": "P22199" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6227474", + "pmid": 6227474, + "title": "Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone", + "author": "Beaumont K, Fanestil DD", + "citation": "Beaumont K, Fanestil DD. Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. PubMed PMID: 6227474.", + "otherId": "0", + "citationId": 113, + "otherSource": "" + } + }, + { + "aeid": 728, + "assayComponentEndpointName": "NVS_OR_gSIGMA_NonSelective", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is chaperone.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Haloperidol", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "chaperone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 465, + "assayComponentName": "NVS_OR_gSIGMA_NonSelective", + "assayComponentDesc": "NVS_OR_gSIGMA_NonSelective is one of one assay component(s) measured or calculated from the NVS_OR_gSIGMA_NonSelective assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[5-3H]-(1,3-di-O-2-tolylguanidine-DI-[p-Ring-3H]] are indicative of a change in receptor function and kinetics for the domestic guinea pig sigma non-opioid intracellular receptor 1 [GeneSymbol:Sigmar1 | GeneID:100135589 | Uniprot_SwissProt_Accession:Q60492].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[5-3H]-(1,3-di-O-2-tolylguanidine-DI-[p-Ring-3H]", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 279, + "assayName": "NVS_OR_gSIGMA_NonSelective", + "assayDesc": "NVS_OR_gSIGMA_NonSelective is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig brain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig brain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 474, + "geneName": "sigma non-opioid intracellular receptor 1", + "description": "provisional", + "geneSymbol": "Sigmar1", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100135589, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "Q60492" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1675607", + "pmid": 1675607, + "title": "[3H]DTG and [3H](+)-3-PPP label pharmacologically distinct sigma binding sites in guinea pig brain membranes", + "author": "Karbon EW, Naper K, Pontecorvo MJ", + "citation": "Karbon EW, Naper K, Pontecorvo MJ. [3H]DTG and [3H](+)-3-PPP label pharmacologically distinct sigma binding sites in guinea pig brain membranes. Eur J Pharmacol. 1991 Jan 25;193(1):21-7. PubMed PMID: 1675607.", + "otherId": "0", + "citationId": 18, + "otherSource": "" + } + }, + { + "aeid": 729, + "assayComponentEndpointName": "NVS_OR_hFKBP12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_OR_hFKBP12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_hFKBP12, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene FKBP1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is chaperone.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FK506", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "chaperone", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 466, + "assayComponentName": "NVS_OR_hFKBP12", + "assayComponentDesc": "NVS_OR_hFKBP12 is one of one assay component(s) measured or calculated from the NVS_OR_hFKBP12 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dihydro-FK506] are indicative of a change in enzyme function and kinetics for the human FK506 binding protein 1A, 12kDa [GeneSymbol:FKBP1A | GeneID:2280 | Uniprot_SwissProt_Accession:P62942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydro-FK506", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 280, + "assayName": "NVS_OR_hFKBP12", + "assayDesc": "NVS_OR_hFKBP12 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 48-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 128, + "geneName": "FK506 binding protein 1A, 12kDa", + "description": null, + "geneSymbol": "FKBP1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2280, + "officialSymbol": "FKBP1A", + "officialFullName": "FK506 binding protein 1A, 12kDa", + "uniprotAccessionNumber": "P62942" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7685169", + "pmid": 7685169, + "title": "Detection of the FK506-FKBP-calcineurin complex by a simple binding assay", + "author": "Asami M, Kuno T, Mukai H, Tanaka C", + "citation": "Asami M, Kuno T, Mukai H, Tanaka C. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. Biochem Biophys Res Commun. 1993 May 14;192(3):1388-94. PubMed PMID: 7685169.", + "otherId": "0", + "citationId": 143, + "otherSource": "" + } + }, + { + "aeid": 730, + "assayComponentEndpointName": "NVS_TR_gDAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GBR-12909", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 467, + "assayComponentName": "NVS_TR_gDAT", + "assayComponentDesc": "NVS_TR_gDAT is one of one assay component(s) measured or calculated from the NVS_TR_gDAT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the domestic guinea pig solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 [GeneSymbol:Slc6a3 | GeneID:100714898 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-WIN,35,428", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 281, + "assayName": "NVS_TR_gDAT", + "assayDesc": "NVS_TR_gDAT is a biochemical, single-readout assay that uses extracted gene-proteins from Guinea pig striatal membranes in a tissue-based cell-free assay. Measurements were taken 2 hours after chemical dosing in a 48-well plate.", + "timepointHr": 2.0, + "organismId": 10141, + "organism": "guinea pig", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Guinea pig striatal membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 478, + "geneName": "solute carrier family 6 (neurotransmitter transporter, dopamine), member 3", + "description": "model", + "geneSymbol": "Slc6a3", + "organismId": 10, + "trackStatus": "live", + "entrezGeneId": 100714898, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2811854", + "pmid": 2811854, + "title": "Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane", + "author": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA", + "citation": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol. 1989 Oct;36(4):518-24. PubMed PMID: 2811854.", + "otherId": "0", + "citationId": 65, + "otherSource": "" + } + }, + { + "aeid": 731, + "assayComponentEndpointName": "NVS_TR_hAdoT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hAdoT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC29A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitrobenzylthioinosine (NBTI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 468, + "assayComponentName": "NVS_TR_hAdoT", + "assayComponentDesc": "NVS_TR_hAdoT is one of one assay component(s) measured or calculated from the NVS_TR_hAdoT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrobenzylthioinosine] are indicative of a change in transporter function and kinetics for the human solute carrier family 29 (equilibrative nucleoside transporter), member 1 [GeneSymbol:SLC29A1 | GeneID:2030 | Uniprot_SwissProt_Accession:Q99808].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 282, + "assayName": "NVS_TR_hAdoT", + "assayDesc": "NVS_TR_hAdoT is a biochemical, single-readout assay that uses extracted gene-proteins from U937 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "U937", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 112, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "SLC29A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2030, + "officialSymbol": "SLC29A1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "Q99808" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7086410", + "pmid": 7086410, + "title": "[3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain", + "author": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM", + "citation": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM. [3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain. J Neurochem. 1982 Jul;39(1):184-91. PubMed PMID: 7086410.", + "otherId": "0", + "citationId": 132, + "otherSource": "" + } + }, + { + "aeid": 113, + "assayComponentEndpointName": "ATG_VDRE_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_VDRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 82, + "assayComponentName": "ATG_VDRE_CIS", + "assayComponentDesc": "ATG_VDRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "VDRE RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 335, + "geneName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "description": null, + "geneSymbol": "VDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7421, + "officialSymbol": "VDR", + "officialFullName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "uniprotAccessionNumber": "P11473" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 114, + "assayComponentEndpointName": "ATG_Xbp1_CIS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Xbp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 83, + "assayComponentName": "ATG_Xbp1_CIS", + "assayComponentDesc": "ATG_Xbp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "Xbp1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 5, + "assayName": "ATG_CIS", + "assayDesc": "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 337, + "geneName": "X-box binding protein 1", + "description": null, + "geneSymbol": "XBP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7494, + "officialSymbol": "XBP1", + "officialFullName": "X-box binding protein 1", + "uniprotAccessionNumber": "P17861" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 115, + "assayComponentEndpointName": "ATG_AR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_AR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "6a-Fluorotestosterone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 84, + "assayComponentName": "ATG_AR_TRANS", + "assayComponentDesc": "ATG_AR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-AR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 116, + "assayComponentEndpointName": "ATG_CAR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_CAR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 85, + "assayComponentName": "ATG_CAR_TRANS", + "assayComponentDesc": "ATG_CAR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-CAR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 356, + "geneName": "nuclear receptor subfamily 1, group I, member 3", + "description": null, + "geneSymbol": "NR1I3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9970, + "officialSymbol": "NR1I3", + "officialFullName": "nuclear receptor subfamily 1, group I, member 3", + "uniprotAccessionNumber": "Q14994" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 117, + "assayComponentEndpointName": "ATG_ERa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 86, + "assayComponentName": "ATG_ERa_TRANS", + "assayComponentDesc": "ATG_ERa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERa, also known as human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 118, + "assayComponentEndpointName": "ATG_ERRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 87, + "assayComponentName": "ATG_ERRa_TRANS", + "assayComponentDesc": "ATG_ERRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRa, also known as human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101 | Uniprot_SwissProt_Accession:P11474].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 119, + "geneName": "estrogen-related receptor alpha", + "description": null, + "geneSymbol": "ESRRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2101, + "officialSymbol": "ESRRA", + "officialFullName": "estrogen-related receptor alpha", + "uniprotAccessionNumber": "P11474" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 119, + "assayComponentEndpointName": "ATG_ERRg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERRg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 88, + "assayComponentName": "ATG_ERRg_TRANS", + "assayComponentDesc": "ATG_ERRg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-ERRg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 121, + "geneName": "estrogen-related receptor gamma", + "description": null, + "geneSymbol": "ESRRG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2104, + "officialSymbol": "ESRRG", + "officialFullName": "estrogen-related receptor gamma", + "uniprotAccessionNumber": "P62508" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 120, + "assayComponentEndpointName": "ATG_FXR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_FXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "CDCA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 89, + "assayComponentName": "ATG_FXR_TRANS", + "assayComponentDesc": "ATG_FXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-FXR, also known as human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-FXR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 357, + "geneName": "nuclear receptor subfamily 1, group H, member 4", + "description": null, + "geneSymbol": "NR1H4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9971, + "officialSymbol": "NR1H4", + "officialFullName": "nuclear receptor subfamily 1, group H, member 4", + "uniprotAccessionNumber": "Q96RI1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 121, + "assayComponentEndpointName": "ATG_GAL4_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GAL4_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_GAL4_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 90, + "assayComponentName": "ATG_GAL4_TRANS", + "assayComponentDesc": "ATG_GAL4_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-gal4, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-gal4 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 466, + "geneName": "Gal4p", + "description": "provisional", + "geneSymbol": "GAL4", + "organismId": 8, + "trackStatus": "live", + "entrezGeneId": 855828, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P04386" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 122, + "assayComponentEndpointName": "ATG_GR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_GR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 91, + "assayComponentName": "ATG_GR_TRANS", + "assayComponentDesc": "ATG_GR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-GR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 123, + "assayComponentEndpointName": "ATG_HNF4a_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_HNF4a_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 92, + "assayComponentName": "ATG_HNF4a_TRANS", + "assayComponentDesc": "ATG_HNF4a_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-HNF4a RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 157, + "geneName": "hepatocyte nuclear factor 4, alpha", + "description": null, + "geneSymbol": "HNF4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3172, + "officialSymbol": "HNF4A", + "officialFullName": "hepatocyte nuclear factor 4, alpha", + "uniprotAccessionNumber": "P41235" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 124, + "assayComponentEndpointName": "ATG_Hpa5_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_Hpa5_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_Hpa5_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 93, + "assayComponentName": "ATG_Hpa5_TRANS", + "assayComponentDesc": "ATG_Hpa5_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-Hpa5, which is used as a basal promoter.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-Hpa5 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 125, + "assayComponentEndpointName": "ATG_LXRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 94, + "assayComponentName": "ATG_LXRa_TRANS", + "assayComponentDesc": "ATG_LXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-LXRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 363, + "geneName": "nuclear receptor subfamily 1, group H, member 3", + "description": null, + "geneSymbol": "NR1H3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10062, + "officialSymbol": "NR1H3", + "officialFullName": "nuclear receptor subfamily 1, group H, member 3", + "uniprotAccessionNumber": "Q13133" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 126, + "assayComponentEndpointName": "ATG_LXRb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 95, + "assayComponentName": "ATG_LXRb_TRANS", + "assayComponentDesc": "ATG_LXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-LXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 332, + "geneName": "nuclear receptor subfamily 1, group H, member 2", + "description": null, + "geneSymbol": "NR1H2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7376, + "officialSymbol": "NR1H2", + "officialFullName": "nuclear receptor subfamily 1, group H, member 2", + "uniprotAccessionNumber": "P55055" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 127, + "assayComponentEndpointName": "ATG_M_06_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_06_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_06_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 96, + "assayComponentName": "ATG_M_06_TRANS", + "assayComponentDesc": "ATG_M_06_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_06 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 128, + "assayComponentEndpointName": "ATG_M_19_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_19_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_19_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 97, + "assayComponentName": "ATG_M_19_TRANS", + "assayComponentDesc": "ATG_M_19_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_19 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 129, + "assayComponentEndpointName": "ATG_M_32_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_32_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_32_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 98, + "assayComponentName": "ATG_M_32_TRANS", + "assayComponentDesc": "ATG_M_32_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_32 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 130, + "assayComponentEndpointName": "ATG_M_61_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_M_61_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_M_61_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . \r\n\r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.", + "assayFunctionType": "background control", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "internal marker", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 99, + "assayComponentName": "ATG_M_61_TRANS", + "assayComponentDesc": "ATG_M_61_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-M_61 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 131, + "assayComponentEndpointName": "ATG_NURR1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_NURR1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 100, + "assayComponentName": "ATG_NURR1_TRANS", + "assayComponentDesc": "ATG_NURR1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-NURR1 RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 132, + "assayComponentEndpointName": "ATG_PPARa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW0742", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 101, + "assayComponentName": "ATG_PPARa_TRANS", + "assayComponentDesc": "ATG_PPARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 248, + "geneName": "peroxisome proliferator-activated receptor alpha", + "description": null, + "geneSymbol": "PPARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5465, + "officialSymbol": "PPARA", + "officialFullName": "peroxisome proliferator-activated receptor alpha", + "uniprotAccessionNumber": "Q07869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 133, + "assayComponentEndpointName": "ATG_PPARd_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARd_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "GW7647", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 102, + "assayComponentName": "ATG_PPARd_TRANS", + "assayComponentDesc": "ATG_PPARd_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARd, also known as human peroxisome proliferator-activated receptor delta [GeneSymbol:PPARD | GeneID:5467 | Uniprot_SwissProt_Accession:Q03181].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARd RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 249, + "geneName": "peroxisome proliferator-activated receptor delta", + "description": null, + "geneSymbol": "PPARD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5467, + "officialSymbol": "PPARD", + "officialFullName": "peroxisome proliferator-activated receptor delta", + "uniprotAccessionNumber": "Q03181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 134, + "assayComponentEndpointName": "ATG_PPARg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 103, + "assayComponentName": "ATG_PPARg_TRANS", + "assayComponentDesc": "ATG_PPARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARg, also known as human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PPARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 135, + "assayComponentEndpointName": "ATG_PXR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T0901317", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 104, + "assayComponentName": "ATG_PXR_TRANS", + "assayComponentDesc": "ATG_PXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-PXR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 350, + "geneName": "nuclear receptor subfamily 1, group I, member 2", + "description": null, + "geneSymbol": "NR1I2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8856, + "officialSymbol": "NR1I2", + "officialFullName": "nuclear receptor subfamily 1, group I, member 2", + "uniprotAccessionNumber": "O75469" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 136, + "assayComponentEndpointName": "ATG_RARa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 105, + "assayComponentName": "ATG_RARa_TRANS", + "assayComponentDesc": "ATG_RARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 279, + "geneName": "retinoic acid receptor, alpha", + "description": null, + "geneSymbol": "RARA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5914, + "officialSymbol": "RARA", + "officialFullName": "retinoic acid receptor, alpha", + "uniprotAccessionNumber": "P10276" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 137, + "assayComponentEndpointName": "ATG_RARb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 106, + "assayComponentName": "ATG_RARb_TRANS", + "assayComponentDesc": "ATG_RARb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 280, + "geneName": "retinoic acid receptor, beta", + "description": null, + "geneSymbol": "RARB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5915, + "officialSymbol": "RARB", + "officialFullName": "retinoic acid receptor, beta", + "uniprotAccessionNumber": "P10826" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 138, + "assayComponentEndpointName": "ATG_RARg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Retinoic Acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 107, + "assayComponentName": "ATG_RARg_TRANS", + "assayComponentDesc": "ATG_RARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RARg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 281, + "geneName": "retinoic acid receptor, gamma", + "description": null, + "geneSymbol": "RARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5916, + "officialSymbol": "RARG", + "officialFullName": "retinoic acid receptor, gamma", + "uniprotAccessionNumber": "P13631" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 139, + "assayComponentEndpointName": "ATG_RORb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RORb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 108, + "assayComponentName": "ATG_RORb_TRANS", + "assayComponentDesc": "ATG_RORb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORb, also known as human RAR-related orphan receptor B [GeneSymbol:RORB | GeneID:6096 | Uniprot_SwissProt_Accession:Q92753].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RORb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 285, + "geneName": "RAR-related orphan receptor B", + "description": null, + "geneSymbol": "RORB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6096, + "officialSymbol": "RORB", + "officialFullName": "RAR-related orphan receptor B", + "uniprotAccessionNumber": "Q92753" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 140, + "assayComponentEndpointName": "ATG_RORg_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RORg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "NA", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "orphan", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 109, + "assayComponentName": "ATG_RORg_TRANS", + "assayComponentDesc": "ATG_RORg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RORg RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 286, + "geneName": "RAR-related orphan receptor C", + "description": null, + "geneSymbol": "RORC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6097, + "officialSymbol": "RORC", + "officialFullName": "RAR-related orphan receptor C", + "uniprotAccessionNumber": "P51449" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 141, + "assayComponentEndpointName": "ATG_RXRa_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 110, + "assayComponentName": "ATG_RXRa_TRANS", + "assayComponentDesc": "ATG_RXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RXRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 287, + "geneName": "retinoid X receptor, alpha", + "description": null, + "geneSymbol": "RXRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6256, + "officialSymbol": "RXRA", + "officialFullName": "retinoid X receptor, alpha", + "uniprotAccessionNumber": "P19793" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 142, + "assayComponentEndpointName": "ATG_RXRb_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "9-cis-Retinoic acid", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 111, + "assayComponentName": "ATG_RXRb_TRANS", + "assayComponentDesc": "ATG_RXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-RXRb RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 288, + "geneName": "retinoid X receptor, beta", + "description": null, + "geneSymbol": "RXRB", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6257, + "officialSymbol": "RXRB", + "officialFullName": "retinoid X receptor, beta", + "uniprotAccessionNumber": "P28702" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 143, + "assayComponentEndpointName": "ATG_THRa1_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_THRa1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 112, + "assayComponentName": "ATG_THRa1_TRANS", + "assayComponentDesc": "ATG_THRa1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-THRa RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 144, + "assayComponentEndpointName": "ATG_VDR_TRANS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_VDR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "1a,25-Dihydroxyvitamin D3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transcription factor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 113, + "assayComponentName": "ATG_VDR_TRANS", + "assayComponentDesc": "ATG_VDR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "RT-PCR and Capillary electrophoresis", + "keyAssayReagentType": "inducer", + "keyAssayReagent": "GAL4-VDR RTU", + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 6, + "assayName": "ATG_TRANS", + "assayDesc": "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 24-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 3, + "assaySourceName": "ATG", + "assaySourceLongName": "Attagene", + "assaySourceDesc": "Attagene Inc. is a Contract Research Organization (CRO) offering a unique screening service using its proprietary multiplexed pathway profiling platform, the FACTORIAL.", + "gene": { + "geneId": 335, + "geneName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "description": null, + "geneSymbol": "VDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7421, + "officialSymbol": "VDR", + "officialFullName": "vitamin D (1,25- dihydroxyvitamin D3) receptor", + "uniprotAccessionNumber": "P11473" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/nmeth.1186", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/18297081", + "pmid": 18297081, + "title": "Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors", + "author": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S", + "citation": "Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, Gambarian M, Diatchenko L, Makarov S. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat Methods. 2008 Mar;5(3):253-60. doi: 10.1038/nmeth.1186. Epub 2008 Feb 24. PubMed PMID: 18297081.", + "otherId": "0", + "citationId": 211, + "otherSource": "" + } + }, + { + "aeid": 146, + "assayComponentEndpointName": "BSK_3C_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 114, + "assayComponentName": "BSK_3C_Eselectin", + "assayComponentDesc": "BSK_3C_Eselectin is an assay component measured in the BSK_3C assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 148, + "assayComponentEndpointName": "BSK_3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 115, + "assayComponentName": "BSK_3C_HLADR", + "assayComponentDesc": "BSK_3C_HLADR is an assay component measured in the BSK_3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 150, + "assayComponentEndpointName": "BSK_3C_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 116, + "assayComponentName": "BSK_3C_ICAM1", + "assayComponentDesc": "BSK_3C_ICAM1 is an assay component measured in the BSK_3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 152, + "assayComponentEndpointName": "BSK_3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 117, + "assayComponentName": "BSK_3C_IL8", + "assayComponentDesc": "BSK_3C_IL8 is an assay component measured in the BSK_3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 154, + "assayComponentEndpointName": "BSK_3C_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 118, + "assayComponentName": "BSK_3C_MCP1", + "assayComponentDesc": "BSK_3C_MCP1 is an assay component measured in the BSK_3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 156, + "assayComponentEndpointName": "BSK_3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 119, + "assayComponentName": "BSK_3C_MIG", + "assayComponentDesc": "BSK_3C_MIG is an assay component measured in the BSK_3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 158, + "assayComponentEndpointName": "BSK_3C_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 120, + "assayComponentName": "BSK_3C_Proliferation", + "assayComponentDesc": "BSK_3C_Proliferation is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "Proliferation in the 3C system is a measure of endothelial cell profliferation which is important to the process of wound healing and angiogensis.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 160, + "assayComponentEndpointName": "BSK_3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 121, + "assayComponentName": "BSK_3C_SRB", + "assayComponentDesc": "BSK_3C_SRB is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the 3C system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 162, + "assayComponentEndpointName": "BSK_3C_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 122, + "assayComponentName": "BSK_3C_Thrombomodulin", + "assayComponentDesc": "BSK_3C_Thrombomodulin is an assay component measured in the BSK_3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 164, + "assayComponentEndpointName": "BSK_3C_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 123, + "assayComponentName": "BSK_3C_TissueFactor", + "assayComponentDesc": "BSK_3C_TissueFactor is an assay component measured in the BSK_3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 166, + "assayComponentEndpointName": "BSK_3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 124, + "assayComponentName": "BSK_3C_uPAR", + "assayComponentDesc": "BSK_3CAR is an assay component measured in the BSK_3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 168, + "assayComponentEndpointName": "BSK_3C_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 125, + "assayComponentName": "BSK_3C_VCAM1", + "assayComponentDesc": "BSK_3C_VCAM1 is an assay component measured in the BSK_3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 170, + "assayComponentEndpointName": "BSK_3C_Vis", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_3C_Vis was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Vis, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the background control. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "background control", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 126, + "assayComponentName": "BSK_3C_Vis", + "assayComponentDesc": "BSK_3C_Vis is an assay component measured in the BSK_3C assay. It measures NA related to cell morphology using light microscopy technology.", + "assayComponentTargetDesc": "Visual microscropy is used to quantify changes to the morphology of the cells.", + "parameterReadoutType": "single", + "assayDesignType": "morphology reporter", + "assayDesignTypeSub": "cell phenotype", + "biologicalProcessTarget": "cell morphology", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "light microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 7, + "assayName": "BSK_3C", + "assayDesc": "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 172, + "assayComponentEndpointName": "BSK_4H_Eotaxin3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_Eotaxin3 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Eotaxin3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 127, + "assayComponentName": "BSK_4H_Eotaxin3", + "assayComponentDesc": "BSK_4H_Eotaxin3 is an assay component measured in the BSK_4H assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Eotaxin-3 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 26 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL26 | GeneID:10344 | Uniprot_SwissProt_Accession:Q9Y258].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Eotaxin-3 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 365, + "geneName": "chemokine (C-C motif) ligand 26", + "description": null, + "geneSymbol": "CCL26", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10344, + "officialSymbol": "CCL26", + "officialFullName": "chemokine (C-C motif) ligand 26", + "uniprotAccessionNumber": "Q9Y258" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 174, + "assayComponentEndpointName": "BSK_4H_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 128, + "assayComponentName": "BSK_4H_MCP1", + "assayComponentDesc": "BSK_4H_MCP1 is an assay component measured in the BSK_4H assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 176, + "assayComponentEndpointName": "BSK_4H_Pselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_Pselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Pselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 129, + "assayComponentName": "BSK_4H_Pselectin", + "assayComponentDesc": "BSK_4H_Pselectin is an assay component measured in the BSK_4H assay. It measures P-Selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "P-Selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 294, + "geneName": "selectin P (granule membrane protein 140kDa, antigen CD62)", + "description": null, + "geneSymbol": "SELP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6403, + "officialSymbol": "SELP", + "officialFullName": "selectin P (granule membrane protein 140kDa, antigen CD62)", + "uniprotAccessionNumber": "P16109" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 180, + "assayComponentEndpointName": "BSK_4H_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4HAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_4HAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 131, + "assayComponentName": "BSK_4H_uPAR", + "assayComponentDesc": "BSK_4HAR is an assay component measured in the BSK_4H assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 182, + "assayComponentEndpointName": "BSK_4H_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 132, + "assayComponentName": "BSK_4H_VCAM1", + "assayComponentDesc": "BSK_4H_VCAM1 is an assay component measured in the BSK_4H assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 184, + "assayComponentEndpointName": "BSK_4H_VEGFRII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_4H_VEGFRII was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VEGFRII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 133, + "assayComponentName": "BSK_4H_VEGFRII", + "assayComponentDesc": "BSK_4H_VEGFRII is an assay component measured in the BSK_4H assay. It measures VEGFRII antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VEGFRII antibody is used to tag and quantify the level of kinase insert domain receptor (a type III receptor tyrosine kinase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VEGFRII antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 8, + "assayName": "BSK_4H", + "assayDesc": "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 186, + "geneName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "description": null, + "geneSymbol": "KDR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3791, + "officialSymbol": "KDR", + "officialFullName": "kinase insert domain receptor (a type III receptor tyrosine kinase)", + "uniprotAccessionNumber": "P35968" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 186, + "assayComponentEndpointName": "BSK_BE3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 134, + "assayComponentName": "BSK_BE3C_HLADR", + "assayComponentDesc": "BSK_BE3C_HLADR is an assay component measured in the BSK_BE3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 732, + "assayComponentEndpointName": "NVS_TR_hDAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GBR-12909", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 469, + "assayComponentName": "NVS_TR_hDAT", + "assayComponentDesc": "NVS_TR_hDAT is one of one assay component(s) measured or calculated from the NVS_TR_hDAT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 3 [GeneSymbol:SLC6A3 | GeneID:6531 | Uniprot_SwissProt_Accession:Q01959].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-WIN,35,428", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 283, + "assayName": "NVS_TR_hDAT", + "assayDesc": "NVS_TR_hDAT is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 297, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "description": null, + "geneSymbol": "SLC6A3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6531, + "officialSymbol": "SLC6A3", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 3", + "uniprotAccessionNumber": "Q01959" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2811854", + "pmid": 2811854, + "title": "Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane", + "author": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA", + "citation": "Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol. 1989 Oct;36(4):518-24. PubMed PMID: 2811854.", + "otherId": "0", + "citationId": 65, + "otherSource": "" + } + }, + { + "aeid": 733, + "assayComponentEndpointName": "NVS_TR_hNET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Desipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 470, + "assayComponentName": "NVS_TR_hNET", + "assayComponentDesc": "NVS_TR_hNET is one of one assay component(s) measured or calculated from the NVS_TR_hNET assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:SLC6A2 | GeneID:6530 | Uniprot_SwissProt_Accession:P23975].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 284, + "assayName": "NVS_TR_hNET", + "assayDesc": "NVS_TR_hNET is a biochemical, single-readout assay that uses extracted gene-proteins from CHO in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "CHO", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 296, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "SLC6A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6530, + "officialSymbol": "SLC6A2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": "P23975" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 734, + "assayComponentEndpointName": "NVS_TR_hSERT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_hSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hSERT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Imipramine HCl;Clomipramine HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 471, + "assayComponentName": "NVS_TR_hSERT", + "assayComponentDesc": "NVS_TR_hSERT is one of one assay component(s) measured or calculated from the NVS_TR_hSERT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:SLC6A4 | GeneID:6532 | Uniprot_SwissProt_Accession:P31645].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methyl-citalopram", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 285, + "assayName": "NVS_TR_hSERT", + "assayDesc": "NVS_TR_hSERT is a biochemical, single-readout assay that uses extracted gene-proteins from Human platelet membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Human platelet membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 298, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "SLC6A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6532, + "officialSymbol": "SLC6A4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31645" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2940099", + "pmid": 2940099, + "title": "The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes", + "author": "Brown NL, Sirugue O, Worcel M", + "citation": "Brown NL, Sirugue O, Worcel M. The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. PubMed PMID: 2940099.", + "otherId": "0", + "citationId": 79, + "otherSource": "" + } + }, + { + "aeid": 735, + "assayComponentEndpointName": "NVS_TR_rAdoT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rAdoT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc29a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nitrobenzylthioinosine (NBTI)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "nucleoside transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 472, + "assayComponentName": "NVS_TR_rAdoT", + "assayComponentDesc": "NVS_TR_rAdoT is one of one assay component(s) measured or calculated from the NVS_TR_rAdoT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrobenzylthioinosine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 29 (equilibrative nucleoside transporter), member 1 [GeneSymbol:Slc29a1 | GeneID:63997 | Uniprot_SwissProt_Accession:O54698].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nitrobenzylthioinosine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 286, + "assayName": "NVS_TR_rAdoT", + "assayDesc": "NVS_TR_rAdoT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 432, + "geneName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "description": null, + "geneSymbol": "Slc29a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 63997, + "officialSymbol": "Slc29a1", + "officialFullName": "solute carrier family 29 (equilibrative nucleoside transporter), member 1", + "uniprotAccessionNumber": "O54698" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7086410", + "pmid": 7086410, + "title": "[3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain", + "author": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM", + "citation": "Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM. [3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain. J Neurochem. 1982 Jul;39(1):184-91. PubMed PMID: 7086410.", + "otherId": "0", + "citationId": 132, + "otherSource": "" + } + }, + { + "aeid": 736, + "assayComponentEndpointName": "NVS_TR_rNET", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Desipramine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 473, + "assayComponentName": "NVS_TR_rNET", + "assayComponentDesc": "NVS_TR_rNET is one of one assay component(s) measured or calculated from the NVS_TR_rNET assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:Slc6a2 | GeneID:83511 | Uniprot_SwissProt_Accession:NA].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-Nisoxetine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 287, + "assayName": "NVS_TR_rNET", + "assayDesc": "NVS_TR_rNET is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 48-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 48-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 439, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "description": null, + "geneSymbol": "Slc6a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 83511, + "officialSymbol": "Slc6a2", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 2", + "uniprotAccessionNumber": null + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7067730", + "pmid": 7067730, + "title": "High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline", + "author": "Raisman R, Sette M, Pimoule C, Briley M, Langer SZ", + "citation": "Raisman R, Sette M, Pimoule C, Briley M, Langer SZ. High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. Eur J Pharmacol. 1982 Mar 12;78(3):345-51. PubMed PMID: 7067730.", + "otherId": "0", + "citationId": 131, + "otherSource": "" + } + }, + { + "aeid": 737, + "assayComponentEndpointName": "NVS_TR_rSERT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rSERT, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is neurotransmitter transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Imipramine HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "neurotransmitter transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 474, + "assayComponentName": "NVS_TR_rSERT", + "assayComponentDesc": "NVS_TR_rSERT is one of one assay component(s) measured or calculated from the NVS_TR_rSERT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:Slc6a4 | GeneID:25553 | Uniprot_SwissProt_Accession:P31652].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-N-methyl-citalopram", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 288, + "assayName": "NVS_TR_rSERT", + "assayDesc": "NVS_TR_rSERT is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain membranes in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain membranes", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 409, + "geneName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "description": null, + "geneSymbol": "Slc6a4", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25553, + "officialSymbol": "Slc6a4", + "officialFullName": "solute carrier family 6 (neurotransmitter transporter), member 4", + "uniprotAccessionNumber": "P31652" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/2940099", + "pmid": 2940099, + "title": "The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes", + "author": "Brown NL, Sirugue O, Worcel M", + "citation": "Brown NL, Sirugue O, Worcel M. The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. PubMed PMID: 2940099.", + "otherId": "0", + "citationId": 79, + "otherSource": "" + } + }, + { + "aeid": 738, + "assayComponentEndpointName": "NVS_TR_rVMAT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_TR_rVMAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rVMAT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc18a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is vesicular transporter.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Reserpine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "transporter", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "vesicular transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 475, + "assayComponentName": "NVS_TR_rVMAT2", + "assayComponentDesc": "NVS_TR_rVMAT2 is one of one assay component(s) measured or calculated from the NVS_TR_rVMAT2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.", + "assayComponentTargetDesc": "Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dihydrotetrabenazine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 18 (vesicular monoamine transporter), member 2 [GeneSymbol:Slc18a2 | GeneID:25549 | Uniprot_SwissProt_Accession:Q01827].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "radioligand binding", + "biologicalProcessTarget": "receptor binding", + "detectionTechnologyType": "Radiometry", + "detectionTechnologyTypeSub": "Scintillation counting", + "detectionTechnology": "Filter-based radiodetection", + "keyAssayReagentType": "ligand", + "keyAssayReagent": "[3H]-dihydrotetrabenazine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "transporter", + "aid": 289, + "assayName": "NVS_TR_rVMAT2", + "assayDesc": "NVS_TR_rVMAT2 is a biochemical, single-readout assay that uses extracted gene-proteins from Rat forebrain in a tissue-based cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "brain", + "cellFormat": "tissue-based cell-free", + "cellFreeComponentSource": "Rat forebrain", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 408, + "geneName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "description": null, + "geneSymbol": "Slc18a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25549, + "officialSymbol": "Slc18a2", + "officialFullName": "solute carrier family 18 (vesicular monoamine transporter), member 2", + "uniprotAccessionNumber": "Q01827" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/3748008", + "pmid": 3748008, + "title": "[3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles", + "author": "Near JA", + "citation": "Near JA. [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol Pharmacol. 1986 Sep;30(3):252-7. PubMed PMID: 3748008.", + "otherId": "0", + "citationId": 103, + "otherSource": "" + } + }, + { + "aeid": 739, + "assayComponentEndpointName": "OT_AR_ARELUC_AG_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "6-alpha-Fluorotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 476, + "assayComponentName": "OT_AR_ARELUC_AG_1440", + "assayComponentDesc": "OT_AR_ARELUC_AG_1440 is one of one assay component(s) measured or calculated from the OT_AR_ARELUC_AG_1440 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by Luciferase technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [D-luciferin] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "Luciferase", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "D-luciferin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 290, + "assayName": "OT_AR_ARELUC_AG_1440", + "assayDesc": "OT_AR_ARELUC_AG_1440 is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 10029, + "organism": "chinese hamster", + "tissue": "ovary", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "CHO-K1", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 740, + "assayComponentEndpointName": "OT_AR_ARSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4,5-alpha-Dihydrotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 477, + "assayComponentName": "OT_AR_ARSRC1_0480", + "assayComponentDesc": "OT_AR_ARSRC1_0480 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 291, + "assayName": "OT_AR_ARSRC1_0480", + "assayDesc": "OT_AR_ARSRC1_0480 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 741, + "assayComponentEndpointName": "OT_AR_ARSRC1_0960", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4,5-alpha-Dihydrotestosterone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 478, + "assayComponentName": "OT_AR_ARSRC1_0960", + "assayComponentDesc": "OT_AR_ARSRC1_0960 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0960 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 292, + "assayName": "OT_AR_ARSRC1_0960", + "assayDesc": "OT_AR_ARSRC1_0960 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 16 hours after chemical dosing in a 384-well plate.", + "timepointHr": 16.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 742, + "assayComponentEndpointName": "OT_ER_ERaERa_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 479, + "assayComponentName": "OT_ER_ERaERa_0480", + "assayComponentDesc": "OT_ER_ERaERa_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 293, + "assayName": "OT_ER_ERaERa_0480", + "assayDesc": "OT_ER_ERaERa_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 743, + "assayComponentEndpointName": "OT_ER_ERaERa_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 480, + "assayComponentName": "OT_ER_ERaERa_1440", + "assayComponentDesc": "OT_ER_ERaERa_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 294, + "assayName": "OT_ER_ERaERa_1440", + "assayDesc": "OT_ER_ERaERa_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 188, + "assayComponentEndpointName": "BSK_BE3C_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 135, + "assayComponentName": "BSK_BE3C_IL1a", + "assayComponentDesc": "BSK_BE3C_IL1a is an assay component measured in the BSK_BE3C assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 190, + "assayComponentEndpointName": "BSK_BE3C_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 136, + "assayComponentName": "BSK_BE3C_IP10", + "assayComponentDesc": "BSK_BE3C_IP10 is an assay component measured in the BSK_BE3C assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 192, + "assayComponentEndpointName": "BSK_BE3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 137, + "assayComponentName": "BSK_BE3C_MIG", + "assayComponentDesc": "BSK_BE3C_MIG is an assay component measured in the BSK_BE3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 194, + "assayComponentEndpointName": "BSK_BE3C_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 138, + "assayComponentName": "BSK_BE3C_MMP1", + "assayComponentDesc": "BSK_BE3C_MMP1 is an assay component measured in the BSK_BE3C assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 196, + "assayComponentEndpointName": "BSK_BE3C_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 139, + "assayComponentName": "BSK_BE3C_PAI1", + "assayComponentDesc": "BSK_BE3C_PAI1 is an assay component measured in the BSK_BE3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 200, + "assayComponentEndpointName": "BSK_BE3C_TGFb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 141, + "assayComponentName": "BSK_BE3C_TGFb1", + "assayComponentDesc": "BSK_BE3C_TGFb1 is an assay component measured in the BSK_BE3C assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TGF-b1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 202, + "assayComponentEndpointName": "BSK_BE3C_tPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3C_tPA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_tPA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 142, + "assayComponentName": "BSK_BE3C_tPA", + "assayComponentDesc": "BSK_BE3C_tPA is an assay component measured in the BSK_BE3C assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "tPA antibody is used to tag and quantify the level of plasminogen activator, tissue protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAT | GeneID:5327 | Uniprot_SwissProt_Accession:P00750].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "tPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 239, + "geneName": "plasminogen activator, tissue", + "description": null, + "geneSymbol": "PLAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5327, + "officialSymbol": "PLAT", + "officialFullName": "plasminogen activator, tissue", + "uniprotAccessionNumber": "P00750" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 744, + "assayComponentEndpointName": "OT_ER_ERaERb_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 481, + "assayComponentName": "OT_ER_ERaERb_0480", + "assayComponentDesc": "OT_ER_ERaERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 295, + "assayName": "OT_ER_ERaERb_0480", + "assayDesc": "OT_ER_ERaERb_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 745, + "assayComponentEndpointName": "OT_ER_ERaERb_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 482, + "assayComponentName": "OT_ER_ERaERb_1440", + "assayComponentDesc": "OT_ER_ERaERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 296, + "assayName": "OT_ER_ERaERb_1440", + "assayDesc": "OT_ER_ERaERb_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 746, + "assayComponentEndpointName": "OT_ER_ERbERb_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 483, + "assayComponentName": "OT_ER_ERbERb_0480", + "assayComponentDesc": "OT_ER_ERbERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 297, + "assayName": "OT_ER_ERbERb_0480", + "assayDesc": "OT_ER_ERbERb_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 747, + "assayComponentEndpointName": "OT_ER_ERbERb_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 484, + "assayComponentName": "OT_ER_ERbERb_1440", + "assayComponentDesc": "OT_ER_ERbERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 298, + "assayName": "OT_ER_ERbERb_1440", + "assayDesc": "OT_ER_ERbERb_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 118, + "geneName": "estrogen receptor 2 (ER beta)", + "description": null, + "geneSymbol": "ESR2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2100, + "officialSymbol": "ESR2", + "officialFullName": "estrogen receptor 2 (ER beta)", + "uniprotAccessionNumber": "Q92731" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 750, + "assayComponentEndpointName": "OT_ERa_GFPERaERE_0120", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Z)-4-Hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 487, + "assayComponentName": "OT_ERa_GFPERaERE_0120", + "assayComponentDesc": "OT_ERa_GFPERaERE_0120 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0120 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", + "assayComponentTargetDesc": "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "Microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 301, + "assayName": "OT_ERa_GFPERaERE_0120", + "assayDesc": "OT_ERa_GFPERaERE_0120 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 2 hours after chemical dosing in a 384-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/onc.2013.550", + "url": "https://pubmed.ncbi.nlm.nih.gov/24441042/", + "pmid": 24441042, + "title": "ystems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity", + "author": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA", + "citation": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA. Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity. Oncogene. 2015 Jan 8;34(2):154-64. doi: 10.1038/onc.2013.550. Epub 2014 Jan 20. PMID: 24441042; PMCID: PMC4871123.", + "otherId": "0", + "citationId": 252, + "otherSource": "" + } + }, + { + "aeid": 751, + "assayComponentEndpointName": "OT_ERa_GFPERaERE_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(Z)-4-Hydroxytamoxifen", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 488, + "assayComponentName": "OT_ERa_GFPERaERE_0480", + "assayComponentDesc": "OT_ERa_GFPERaERE_0480 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0480 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", + "assayComponentTargetDesc": "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "fluorescent protein induction", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Microscopy", + "detectionTechnologyTypeSub": "Optical microscopy: Fluorescence microscopy", + "detectionTechnology": "Microscopy", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 302, + "assayName": "OT_ERa_GFPERaERE_0480", + "assayDesc": "OT_ERa_GFPERaERE_0480 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1038/onc.2013.550", + "url": "https://pubmed.ncbi.nlm.nih.gov/24441042/", + "pmid": 24441042, + "title": "ystems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity", + "author": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA", + "citation": "Bolt MJ, Stossi F, Callison AM, Mancini MG, Dandekar R, Mancini MA. Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-? protein levels and activity. Oncogene. 2015 Jan 8;34(2):154-64. doi: 10.1038/onc.2013.550. Epub 2014 Jan 20. PMID: 24441042; PMCID: PMC4871123.", + "otherId": "0", + "citationId": 252, + "otherSource": "" + } + }, + { + "aeid": 753, + "assayComponentEndpointName": "OT_FXR_FXRSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW4064", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 490, + "assayComponentName": "OT_FXR_FXRSRC1_0480", + "assayComponentDesc": "OT_FXR_FXRSRC1_0480 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 304, + "assayName": "OT_FXR_FXRSRC1_0480", + "assayDesc": "OT_FXR_FXRSRC1_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 754, + "assayComponentEndpointName": "OT_FXR_FXRSRC1_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW4064", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 491, + "assayComponentName": "OT_FXR_FXRSRC1_1440", + "assayComponentDesc": "OT_FXR_FXRSRC1_1440 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 305, + "assayName": "OT_FXR_FXRSRC1_1440", + "assayDesc": "OT_FXR_FXRSRC1_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 303, + "geneName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "SRC", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6714, + "officialSymbol": "SRC", + "officialFullName": "SRC proto-oncogene, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P12931" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 755, + "assayComponentEndpointName": "OT_NURR1_NURR1RXRa_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Isoproterenol;Fenoterol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 492, + "assayComponentName": "OT_NURR1_NURR1RXRa_0480", + "assayComponentDesc": "OT_NURR1_NURR1RXRa_0480 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 306, + "assayName": "OT_NURR1_NURR1RXRa_0480", + "assayDesc": "OT_NURR1_NURR1RXRa_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 756, + "assayComponentEndpointName": "OT_NURR1_NURR1RXRa_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Isoproterenol;Fenoterol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 493, + "assayComponentName": "OT_NURR1_NURR1RXRa_1440", + "assayComponentDesc": "OT_NURR1_NURR1RXRa_1440 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 307, + "assayName": "OT_NURR1_NURR1RXRa_1440", + "assayDesc": "OT_NURR1_NURR1RXRa_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 224, + "geneName": "nuclear receptor subfamily 4, group A, member 2", + "description": null, + "geneSymbol": "NR4A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4929, + "officialSymbol": "NR4A2", + "officialFullName": "nuclear receptor subfamily 4, group A, member 2", + "uniprotAccessionNumber": "P43354" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 757, + "assayComponentEndpointName": "OT_PPARg_PPARgSRC1_0480", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW1929", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 494, + "assayComponentName": "OT_PPARg_PPARgSRC1_0480", + "assayComponentDesc": "OT_PPARg_PPARgSRC1_0480 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 308, + "assayName": "OT_PPARg_PPARgSRC1_0480", + "assayDesc": "OT_PPARg_PPARgSRC1_0480 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", + "timepointHr": 8.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 758, + "assayComponentEndpointName": "OT_PPARg_PPARgSRC1_1440", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "binding", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "GW1929", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 495, + "assayComponentName": "OT_PPARg_PPARgSRC1_1440", + "assayComponentDesc": "OT_PPARg_PPARgSRC1_1440 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "protein fragment complementation assay", + "biologicalProcessTarget": "protein stabilization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Protein-fragment Complementation", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 309, + "assayName": "OT_PPARg_PPARgSRC1_1440", + "assayDesc": "OT_PPARg_PPARgSRC1_1440 is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "protein complex format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 6, + "assaySourceName": "OT", + "assaySourceLongName": "Odyssey Thera", + "assaySourceDesc": "Odyssey Thera is a drug discovery company focusing on high-throughput screening with a particular focus on developing novel protein:protein interaction assays using protein-fragment complementation technology. ", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/16680159", + "pmid": 16680159, + "title": "Identifying off-target effects and hidden phenotypes of drugs in human cells", + "author": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK", + "citation": "MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7. PubMed PMID: 16680159.", + "otherId": "0", + "citationId": 230, + "otherSource": "" + } + }, + { + "aeid": 759, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 496, + "assayComponentName": "TOX21_AR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 760, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 497, + "assayComponentName": "TOX21_AR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 761, + "assayComponentEndpointName": "TOX21_AR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 498, + "assayComponentName": "TOX21_AR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_AR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_AR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 ", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 310, + "assayName": "TOX21_AR_BLA_Agonist", + "assayDesc": "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 762, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Cyproterone acetate", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 499, + "assayComponentName": "TOX21_AR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_AR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate ", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 212, + "assayComponentEndpointName": "BSK_CASM3C_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 147, + "assayComponentName": "BSK_CASM3C_IL8", + "assayComponentDesc": "BSK_CASM3C_IL8 is an assay component measured in the BSK_CASM3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 214, + "assayComponentEndpointName": "BSK_CASM3C_LDLR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_LDLR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_LDLR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is LDL receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "misc protein", + "intendedTargetFamilySub": "LDL receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 148, + "assayComponentName": "BSK_CASM3C_LDLR", + "assayComponentDesc": "BSK_CASM3C_LDLR is an assay component measured in the BSK_CASM3C assay. It measures LDLR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "LDLR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 190, + "geneName": "low density lipoprotein receptor", + "description": null, + "geneSymbol": "LDLR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3949, + "officialSymbol": "LDLR", + "officialFullName": "low density lipoprotein receptor", + "uniprotAccessionNumber": "P01130" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 216, + "assayComponentEndpointName": "BSK_CASM3C_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 149, + "assayComponentName": "BSK_CASM3C_MCP1", + "assayComponentDesc": "BSK_CASM3C_MCP1 is an assay component measured in the BSK_CASM3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 218, + "assayComponentEndpointName": "BSK_CASM3C_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 150, + "assayComponentName": "BSK_CASM3C_MCSF", + "assayComponentDesc": "BSK_CASM3C_MCSF is an assay component measured in the BSK_CASM3C assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 220, + "assayComponentEndpointName": "BSK_CASM3C_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 151, + "assayComponentName": "BSK_CASM3C_MIG", + "assayComponentDesc": "BSK_CASM3C_MIG is an assay component measured in the BSK_CASM3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 222, + "assayComponentEndpointName": "BSK_CASM3C_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_CASM3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 152, + "assayComponentName": "BSK_CASM3C_Proliferation", + "assayComponentDesc": "BSK_CASM3C_Proliferation is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 224, + "assayComponentEndpointName": "BSK_CASM3C_SAA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_SAA was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SAA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is apolipoproteins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "apolipoproteins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 153, + "assayComponentName": "BSK_CASM3C_SAA", + "assayComponentDesc": "BSK_CASM3C_SAA is an assay component measured in the BSK_CASM3C assay. It measures SAA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant. SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "SAA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 290, + "geneName": "serum amyloid A1", + "description": null, + "geneSymbol": "SAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6288, + "officialSymbol": "SAA1", + "officialFullName": "serum amyloid A1", + "uniprotAccessionNumber": "P0DJI8" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 226, + "assayComponentEndpointName": "BSK_CASM3C_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 154, + "assayComponentName": "BSK_CASM3C_SRB", + "assayComponentDesc": "BSK_CASM3C_SRB is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "SRB in the CASM3C system is a measure of the total protein content of coronary artery smooth muscle cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 763, + "assayComponentEndpointName": "TOX21_AR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 500, + "assayComponentName": "TOX21_AR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_AR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 311, + "assayName": "TOX21_AR_BLA_Antagonist", + "assayDesc": "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 764, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "R1881", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 501, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Agonist", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Agonist is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAkb2_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 312, + "assayName": "TOX21_AR_LUC_MDAKB2_Agonist", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Agonist is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 765, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Nilutamide", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 502, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Therefore AR binding assay for screening androgen antagonists can be used to identify potential endocrine disruptors. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 313, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for antagonist specificity. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP AR", + "description": "Androgen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 766, + "assayComponentEndpointName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 503, + "assayComponentName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", + "assayComponentDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 313, + "assayName": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", + "assayDesc": "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for antagonist specificity. ", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MDA-kb2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1021/acs.chemrestox.6b00347", + "url": "https://pubmed.ncbi.nlm.nih.gov/27933809/", + "pmid": 27933809, + "title": "Development and Validation of a Computational Model for Androgen Receptor Activity", + "author": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R", + "citation": "Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, Thomas RS, Casey WM, Dix DJ, Allen D, Sakamuru S, Xia M, Huang R, Judson R. Development and Validation of a Computational Model for Androgen Receptor Activity. Chem Res Toxicol. 2017 Apr 17;30(4):946-964. doi: 10.1021/acs.chemrestox.6b00347. Epub 2016 Dec 9. PMID: 27933809; PMCID: PMC5396026.", + "otherId": "0", + "citationId": 266, + "otherSource": "" + } + }, + { + "aeid": 767, + "assayComponentEndpointName": "TOX21_Aromatase_Inhibition", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "inducer", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Letrozole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 504, + "assayComponentName": "TOX21_Aromatase_Inhibition", + "assayComponentDesc": "TOX21_Aromatase_Inhibition is one of one assay component(s) measured or calculated from the TOX21_Aromatase_Inhibition assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to modulation of the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 314, + "assayName": "TOX21_Aromatase_Inhibition", + "assayDesc": "TOX21_Aromatase_Inhibition is a cell-based, single-readout assay that uses MCF-7, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfu023", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496634", + "pmid": 24496634, + "title": "AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor", + "author": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C", + "citation": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C. AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci. 2014 May;139(1):198-209. doi: 10.1093/toxsci/kfu023. Epub 2014 Feb 4. PubMed PMID: 24496634; PubMed Central PMCID: PMC4038786.", + "otherId": "0", + "citationId": 222, + "otherSource": "" + } + }, + { + "aeid": 768, + "assayComponentEndpointName": "TOX21_Aromatase_Inhibition_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 505, + "assayComponentName": "TOX21_Aromatase_Inhibition_viability", + "assayComponentDesc": "TOX21_Aromatase_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 314, + "assayName": "TOX21_Aromatase_Inhibition", + "assayDesc": "TOX21_Aromatase_Inhibition is a cell-based, single-readout assay that uses MCF-7, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "MCF7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfu023", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496634", + "pmid": 24496634, + "title": "AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor", + "author": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C", + "citation": "Chen S, Zhou D, Hsin LY, Kanaya N, Wong C, Yip R, Sakamuru S, Xia M, Yuan YC, Witt K, Teng C. AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci. 2014 May;139(1):198-209. doi: 10.1093/toxsci/kfu023. Epub 2014 Feb 4. PubMed PMID: 24496634; PubMed Central PMCID: PMC4038786.", + "otherId": "0", + "citationId": 222, + "otherSource": "" + } + }, + { + "aeid": 769, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 506, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 770, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 507, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_green", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 771, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Cell_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 508, + "assayComponentName": "TOX21_AutoFluor_HEK293_Cell_red", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Cell_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 772, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 509, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 773, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 510, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_green", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 774, + "assayComponentEndpointName": "TOX21_AutoFluor_HEK293_Media_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEK293_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 511, + "assayComponentName": "TOX21_AutoFluor_HEK293_Media_red", + "assayComponentDesc": "TOX21_AutoFluor_HEK293_Media_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEK293 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 315, + "assayName": "TOX21_AutoFluor_HEK293", + "assayDesc": "TOX21_AutoFluor_HEK293 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 775, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 512, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 776, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 513, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_green", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 777, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Cell_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 514, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Cell_red", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Cell_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 778, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_blue", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_blue, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 515, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_blue", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_blue is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 779, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_green", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_green, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 516, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_green", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_green is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 780, + "assayComponentEndpointName": "TOX21_AutoFluor_HEPG2_Media_red", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AutoFluor_HEPG2_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_red, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.", + "assayFunctionType": "background control", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Fluorescein;Rose Bengal Sodium;Triamterene", + "signalDirection": "gain", + "intendedTargetType": "chemical", + "intendedTargetTypeSub": "physical feature", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "artifact fluorescence", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 517, + "assayComponentName": "TOX21_AutoFluor_HEPG2_Media_red", + "assayComponentDesc": "TOX21_AutoFluor_HEPG2_Media_red is one of 6 assay component(s) measured or calculated from the TOX21_AutoFluor_HEPG2 assay. It is designed to make measurements of artifacts, a form of background reporter, as detected with fluorescence intensity signals by Autofluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "autofluorescence", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Autofluorescence", + "keyAssayReagentType": "NA", + "keyAssayReagent": "NA", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "physical feature", + "aid": 316, + "assayName": "TOX21_AutoFluor_HEPG2", + "assayDesc": "TOX21_AutoFluor_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "physicochemical format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41598-020-60747-3", + "url": "https://pubmed.ncbi.nlm.nih.gov/32132587/", + "pmid": 32132587, + "title": "High-Throughput Screening to Predict Chemical-Assay Interference", + "author": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC", + "citation": "Borrel A, Huang R, Sakamuru S, Xia M, Simeonov A, Mansouri K, Houck KA, Judson RS, Kleinstreuer NC. High-Throughput Screening to Predict Chemical-Assay Interference. Sci Rep. 2020 Mar 4;10(1):3986. doi: 10.1038/s41598-020-60747-3. PMID: 32132587; PMCID: PMC7055224.", + "otherId": "0", + "citationId": 276, + "otherSource": "" + } + }, + { + "aeid": 781, + "assayComponentEndpointName": "TOX21_ELG1_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-Fluorouridine", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "atpase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 518, + "assayComponentName": "TOX21_ELG1_LUC_Agonist", + "assayComponentDesc": "TOX21_ELG1_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_ELG1_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human ATPase family, AAA domain containing 5 [GeneSymbol:ATAD5 | GeneID:79915 | Uniprot_SwissProt_Accession:Q96QE3].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 317, + "assayName": "TOX21_ELG1_LUC_Agonist", + "assayDesc": "TOX21_ELG1_LUC_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 435, + "geneName": "ATPase family, AAA domain containing 5", + "description": null, + "geneSymbol": "ATAD5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 79915, + "officialSymbol": "ATAD5", + "officialFullName": "ATPase family, AAA domain containing 5", + "uniprotAccessionNumber": "Q96QE3" + }, + "assayList": null, + "citations": null + }, + { + "aeid": 782, + "assayComponentEndpointName": "TOX21_ELG1_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 519, + "assayComponentName": "TOX21_ELG1_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_ELG1_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 317, + "assayName": "TOX21_ELG1_LUC_Agonist", + "assayDesc": "TOX21_ELG1_LUC_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": null + }, + { + "aeid": 783, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 520, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 784, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 521, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 785, + "assayComponentEndpointName": "TOX21_ERa_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 522, + "assayComponentName": "TOX21_ERa_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_ERa_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 318, + "assayName": "TOX21_ERa_BLA_Agonist", + "assayDesc": "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 786, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 523, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_ERa_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 787, + "assayComponentEndpointName": "TOX21_ERa_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 524, + "assayComponentName": "TOX21_ERa_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_ERa_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 319, + "assayName": "TOX21_ERa_BLA_Antagonist", + "assayDesc": "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 788, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "17b-Estradiol", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 525, + "assayComponentName": "TOX21_ERa_LUC_VM7_Agonist", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "TOX21_ERa_LUC_VM7_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 320, + "assayName": "TOX21_ERa_LUC_VM7_Agonist", + "assayDesc": "TOX21_ERa_LUC_VM7_Agonist is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 789, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "4-hydroxytamoxifen", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 526, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372] using a positive control of 4-hydroxytamoxifen", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 321, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP ER", + "description": "Estrogen receptor assays used in EDSP models" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 790, + "assayComponentEndpointName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 527, + "assayComponentName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", + "assayComponentDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 321, + "assayName": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", + "assayDesc": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2.", + "timepointHr": 22.0, + "organismId": 9606, + "organism": "human", + "tissue": "breast", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "VM7", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfv168", + "url": "https://pubmed.ncbi.nlm.nih.gov/26272952/", + "pmid": 26272952, + "title": "Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor", + "author": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS", + "citation": "Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, Houck KA, Martin MT, Sipes N, Richard AM, Mansouri K, Setzer RW, Knudsen TB, Crofton KM, Thomas RS. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci. 2015 Nov;148(1):137-54. doi: 10.1093/toxsci/kfv168. Epub 2015 Aug 13. PMID: 26272952; PMCID: PMC4635633.", + "otherId": "0", + "citationId": 277, + "otherSource": "" + } + }, + { + "aeid": 791, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "loss", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 528, + "assayComponentName": "TOX21_GR_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 792, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 529, + "assayComponentName": "TOX21_GR_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 793, + "assayComponentEndpointName": "TOX21_GR_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dexamethasone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 530, + "assayComponentName": "TOX21_GR_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_GR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_GR_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 322, + "assayName": "TOX21_GR_BLA_Agonist", + "assayDesc": "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 794, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Mifeprostone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 531, + "assayComponentName": "TOX21_GR_BLA_Antagonist_ratio", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", + "assayComponentTargetDesc": "TOX21_GR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 795, + "assayComponentEndpointName": "TOX21_GR_BLA_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 532, + "assayComponentName": "TOX21_GR_BLA_Antagonist_viability", + "assayComponentDesc": "TOX21_GR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 323, + "assayName": "TOX21_GR_BLA_Antagonist", + "assayDesc": "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "cervix", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HeLa", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 796, + "assayComponentEndpointName": "TOX21_MMP_fitc", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_fitc is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "gain", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 533, + "assayComponentName": "TOX21_MMP_fitc", + "assayComponentDesc": "TOX21_MMP_fitc is an assay readout measuring signaling via mitochondrial depolarization and designed using background reporter (mitochondrial membrane potential) detected with immunofluorescence.", + "assayComponentTargetDesc": "TOX21_MMP_fitc was designed to target cell morphology (organelle conformation) activity at the cellular (cellular) level, specifically mapping to NA gene(s) using a positive control of FCCP", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 798, + "assayComponentEndpointName": "TOX21_MMP_rhodamine", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_rhodamine is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "signaling", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "FCCP", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "mitochondria", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 535, + "assayComponentName": "TOX21_MMP_rhodamine", + "assayComponentDesc": "TOX21_MMP_rhodamine is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence.", + "assayComponentTargetDesc": "TOX21_MMP_rhodamine was designed to target cell morphology (organelle conformation) activity at the cellular (cellular) level, specifically mapping to NA gene(s) using a positive control of FCCP", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "mitochondrial depolarization", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "homogenous mitochondrial membrane potential assay", + "keyAssayReagentType": "stain", + "keyAssayReagent": "Mito-MPS", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "mitochondria", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 799, + "assayComponentEndpointName": "TOX21_MMP_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 536, + "assayComponentName": "TOX21_MMP_viability", + "assayComponentDesc": "TOX21_MMP_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 324, + "assayName": "TOX21_MMP", + "assayDesc": "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1152/physiolgenomics.00161.2011", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/22433785", + "pmid": 22433785, + "title": "Application of a homogenous membrane potential assay to assess mitochondrial function", + "author": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M", + "citation": "Sakamuru S, Li X, Attene-Ramos MS, Huang R, Lu J, Shou L, Shen M, Tice RR, Austin CP, Xia M. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol Genomics. 2012 May 1;44(9):495-503. doi: 10.1152/physiolgenomics.00161.2011. Epub 2012 Mar 20. PubMed PMID: 22433785; PubMed Central PMCID: PMC3426425.", + "otherId": "0", + "citationId": 219, + "otherSource": "" + } + }, + { + "aeid": 800, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ch1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "substrate", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "channel 1", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 537, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ch1", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ch1 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the uncleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone.", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 801, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ch2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.", + "assayFunctionType": "product", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "pathway", + "intendedTargetTypeSub": "pathway-specified", + "intendedTargetFamily": "channel 2", + "intendedTargetFamilySub": "baseline control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 538, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ch2", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ch2 is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the cleaved reporter gene substrate and is used to calculate the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", + "parameterReadoutType": "single", + "assayDesignType": "background reporter", + "assayDesignTypeSub": "artifact detection", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 802, + "assayComponentEndpointName": "TOX21_PPARg_BLA_Agonist_ratio", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "ratio", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Rosiglitazone", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 539, + "assayComponentName": "TOX21_PPARg_BLA_Agonist_ratio", + "assayComponentDesc": "TOX21_PPARg_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity..", + "assayComponentTargetDesc": "TOX21_PPARg_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", + "parameterReadoutType": "multiple", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "beta lactamase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "GAL4 b-lactamase reporter gene", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CCF4-AM", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 325, + "assayName": "TOX21_PPARg_BLA_Agonist", + "assayDesc": "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "kidney", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HEK293T", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 250, + "geneName": "peroxisome proliferator-activated receptor gamma", + "description": null, + "geneSymbol": "PPARG", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5468, + "officialSymbol": "PPARG", + "officialFullName": "peroxisome proliferator-activated receptor gamma", + "uniprotAccessionNumber": "P37231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1289/ehp.1002952", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21543282", + "pmid": 21543282, + "title": "Chemical genomics profiling of environmental chemical modulation of human nuclear receptors", + "author": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP", + "citation": "Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, Dix DJ, Judson RS, Witt KL, Kavlock RJ, Tice RR, Austin CP. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4. PubMed PMID: 21543282; PubMed Central PMCID: PMC3237348.", + "otherId": "0", + "citationId": 221, + "otherSource": "" + } + }, + { + "aeid": 803, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "0.092 uM T3", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 540, + "assayComponentName": "TOX21_TR_LUC_GH3_Agonist", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Agonist is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 326, + "assayName": "TOX21_TR_LUC_GH3_Agonist", + "assayDesc": "TOX21_TR_LUC_GH3_Agonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 1.0, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 228, + "assayComponentEndpointName": "BSK_CASM3C_Thrombomodulin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 155, + "assayComponentName": "BSK_CASM3C_Thrombomodulin", + "assayComponentDesc": "BSK_CASM3C_Thrombomodulin is an assay component measured in the BSK_CASM3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Thrombomodulin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 320, + "geneName": "thrombomodulin", + "description": null, + "geneSymbol": "THBD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7056, + "officialSymbol": "THBD", + "officialFullName": "thrombomodulin", + "uniprotAccessionNumber": "P07204" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 230, + "assayComponentEndpointName": "BSK_CASM3C_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 156, + "assayComponentName": "BSK_CASM3C_TissueFactor", + "assayComponentDesc": "BSK_CASM3C_TissueFactor is an assay component measured in the BSK_CASM3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 232, + "assayComponentEndpointName": "BSK_CASM3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 157, + "assayComponentName": "BSK_CASM3C_uPAR", + "assayComponentDesc": "BSK_CASM3CAR is an assay component measured in the BSK_CASM3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 234, + "assayComponentEndpointName": "BSK_CASM3C_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 158, + "assayComponentName": "BSK_CASM3C_VCAM1", + "assayComponentDesc": "BSK_CASM3C_VCAM1 is an assay component measured in the BSK_CASM3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 236, + "assayComponentEndpointName": "BSK_hDFCGF_CollagenIII", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_CollagenIII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is collagen.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "collagen", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 159, + "assayComponentName": "BSK_hDFCGF_CollagenIII", + "assayComponentDesc": "BSK_hDFCGF_CollagenIII is an assay component measured in the BSK_hDFCGF assay. It measures Collagen antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "Collagen antibody is used to tag and quantify the level of collagen, type III, alpha 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:COL3A1 | GeneID:1281 | Uniprot_SwissProt_Accession:P02461].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "Collagen antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 70, + "geneName": "collagen, type III, alpha 1", + "description": null, + "geneSymbol": "COL3A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1281, + "officialSymbol": "COL3A1", + "officialFullName": "collagen, type III, alpha 1", + "uniprotAccessionNumber": "P02461" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 238, + "assayComponentEndpointName": "BSK_hDFCGF_EGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_EGFR was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_EGFR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 160, + "assayComponentName": "BSK_hDFCGF_EGFR", + "assayComponentDesc": "BSK_hDFCGF_EGFR is an assay component measured in the BSK_hDFCGF assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "EGFR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 240, + "assayComponentEndpointName": "BSK_hDFCGF_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 161, + "assayComponentName": "BSK_hDFCGF_IL8", + "assayComponentDesc": "BSK_hDFCGF_IL8 is an assay component measured in the BSK_hDFCGF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 934, + "assayComponentEndpointName": "LTEA_HepaRG_ALPP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ALPP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ALPP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 608, + "assayComponentName": "LTEA_HepaRG_ALPP", + "assayComponentDesc": "LTEA_HepaRG_ALPP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 24, + "geneName": "alkaline phosphatase, placental", + "description": null, + "geneSymbol": "ALPP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 250, + "officialSymbol": "ALPP", + "officialFullName": "alkaline phosphatase, placental", + "uniprotAccessionNumber": "P05187" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 804, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", + "assayFunctionType": "antagonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "1 nM T3", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "nuclear receptor", + "intendedTargetFamilySub": "non-steroidal", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 541, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 327, + "assayName": "TOX21_TR_LUC_GH3_Antagonist", + "assayDesc": "TOX21_TR_LUC_GH3_Antagonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 321, + "geneName": "thyroid hormone receptor, alpha", + "description": null, + "geneSymbol": "THRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7067, + "officialSymbol": "THRA", + "officialFullName": "thyroid hormone receptor, alpha", + "uniprotAccessionNumber": "P10827" + }, + "assayList": { + "name": "EDSP thyroid", + "description": "Thyroid pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 805, + "assayComponentEndpointName": "TOX21_TR_LUC_GH3_Antagonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 542, + "assayComponentName": "TOX21_TR_LUC_GH3_Antagonist_viability", + "assayComponentDesc": "TOX21_TR_LUC_GH3_Antagonist_viability is an assay readout measuring viability via receptor activity and designed using bioluminescence signals detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 327, + "assayName": "TOX21_TR_LUC_GH3_Antagonist", + "assayDesc": "TOX21_TR_LUC_GH3_Antagonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 28.0, + "organismId": 10116, + "organism": "rat", + "tissue": "pituitary gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "GH3", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.2174/2213988501408010036", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/24772387", + "pmid": 24772387, + "title": "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform", + "author": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ", + "citation": "Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genomics Transl Med. 2014 Mar 7;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PubMed PMID: 24772387; PubMed Central PMCID: PMC3999704.", + "otherId": "0", + "citationId": 223, + "otherSource": "" + } + }, + { + "aeid": 806, + "assayComponentEndpointName": "TOX21_AhR_LUC_Agonist", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.", + "assayFunctionType": "agonist", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Omeprazole", + "signalDirection": "gain", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic helix-loop-helix protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 543, + "assayComponentName": "TOX21_AhR_LUC_Agonist", + "assayComponentDesc": "TOX21_AhR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_AhR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CALUX luciferase quantitation technology.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from the luciferase induction are indicative of agonist activity regulated by the receptor function and kinetics for the human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "luciferase induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CALUX luciferase quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "One-Glo", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 328, + "assayName": "TOX21_AhR_LUC_Agonist", + "assayDesc": "TOX21_AhR_LUC_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": { + "geneId": 21, + "geneName": "aryl hydrocarbon receptor", + "description": null, + "geneSymbol": "AHR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 196, + "officialSymbol": "AHR", + "officialFullName": "aryl hydrocarbon receptor", + "uniprotAccessionNumber": "P35869" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1093/toxsci/kfr189", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21775728", + "pmid": 21775728, + "title": "Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness", + "author": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS", + "citation": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS. Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. Toxicol Sci. 2011 Oct;123(2):511-22. doi: 10.1093/toxsci/kfr189. Epub 2011 Jul 20. PubMed PMID: 21775728; PubMed Central PMCID: PMC3179681.", + "otherId": "0", + "citationId": 227, + "otherSource": "" + } + }, + { + "aeid": 807, + "assayComponentEndpointName": "TOX21_AhR_LUC_Agonist_viability", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "percent_activity", + "burstAssay": 1, + "keyPositiveControl": "tetraoctylammonium bromide", + "signalDirection": "loss", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 544, + "assayComponentName": "TOX21_AhR_LUC_Agonist_viability", + "assayComponentDesc": "TOX21_AhR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", + "assayComponentTargetDesc": "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "ATP content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Luminescence", + "detectionTechnologyTypeSub": "Bioluminescence", + "detectionTechnology": "CellTiter-Glo Luciferase-coupled ATP quantitation", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "CellTiter-Glo", + "technologicalTargetType": "chemical", + "technologicalTargetTypeSub": "ATP", + "aid": 328, + "assayName": "TOX21_AhR_LUC_Agonist", + "assayDesc": "TOX21_AhR_LUC_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "NA", + "cellShortName": "HepG2", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 1536-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 7, + "assaySourceName": "TOX21", + "assaySourceLongName": "Tox21/NCGC", + "assaySourceDesc": "Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.", + "gene": null, + "assayList": { + "name": "cytotoxicity burst", + "description": "Assays used to defne the cytotoxicity burst region" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfr189", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/21775728", + "pmid": 21775728, + "title": "Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness", + "author": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS", + "citation": "He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, Denison MS. Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. Toxicol Sci. 2011 Oct;123(2):511-22. doi: 10.1093/toxsci/kfr189. Epub 2011 Jul 20. PubMed PMID: 21775728; PubMed Central PMCID: PMC3179681.", + "otherId": "0", + "citationId": 227, + "otherSource": "" + } + }, + { + "aeid": 891, + "assayComponentEndpointName": "CEETOX_H295R_11DCORT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_11DCORT was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_11DCORT, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 586, + "assayComponentName": "CEETOX_H295R_11DCORT", + "assayComponentDesc": "CEETOX_H295R_11DCORT is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 893, + "assayComponentEndpointName": "CEETOX_H295R_OHPREG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPREG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPREG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxypregnenolone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 587, + "assayComponentName": "CEETOX_H295R_OHPREG", + "assayComponentDesc": "CEETOX_H295R_OHPREG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxypregnenolone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 895, + "assayComponentEndpointName": "CEETOX_H295R_OHPROG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_OHPROG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_OHPROG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "17alpha-hydroxyprogesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 588, + "assayComponentName": "CEETOX_H295R_OHPROG", + "assayComponentDesc": "CEETOX_H295R_OHPROG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "17alpha-hydroxyprogesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 897, + "assayComponentEndpointName": "CEETOX_H295R_ANDR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ANDR was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ANDR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Androstenedione", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 589, + "assayComponentName": "CEETOX_H295R_ANDR", + "assayComponentDesc": "CEETOX_H295R_ANDR is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Androstenedione", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 899, + "assayComponentEndpointName": "CEETOX_H295R_CORTIC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTIC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTIC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Corticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 590, + "assayComponentName": "CEETOX_H295R_CORTIC", + "assayComponentDesc": "CEETOX_H295R_CORTIC is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Corticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 901, + "assayComponentEndpointName": "CEETOX_H295R_CORTISOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_CORTISOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Cortisol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 591, + "assayComponentName": "CEETOX_H295R_CORTISOL", + "assayComponentDesc": "CEETOX_H295R_CORTISOL is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Cortisol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 905, + "assayComponentEndpointName": "CEETOX_H295R_DOC", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_DOC was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_DOC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "11-Deoxycorticosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "glucocorticoids", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 593, + "assayComponentName": "CEETOX_H295R_DOC", + "assayComponentDesc": "CEETOX_H295R_DOC is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "11-Deoxycorticosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 145, + "geneName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "description": null, + "geneSymbol": "NR3C1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2908, + "officialSymbol": "NR3C1", + "officialFullName": "nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)", + "uniprotAccessionNumber": "P04150" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 907, + "assayComponentEndpointName": "CEETOX_H295R_ESTRADIOL", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRADIOL was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRADIOL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estradiol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estradiol", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 594, + "assayComponentName": "CEETOX_H295R_ESTRADIOL", + "assayComponentDesc": "CEETOX_H295R_ESTRADIOL is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estradiol", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 909, + "assayComponentEndpointName": "CEETOX_H295R_ESTRONE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_ESTRONE was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_ESTRONE, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Estrone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Estrone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "estrogens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 595, + "assayComponentName": "CEETOX_H295R_ESTRONE", + "assayComponentDesc": "CEETOX_H295R_ESTRONE is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Estrone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 117, + "geneName": "estrogen receptor 1", + "description": null, + "geneSymbol": "ESR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2099, + "officialSymbol": "ESR1", + "officialFullName": "estrogen receptor 1", + "uniprotAccessionNumber": "P03372" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 913, + "assayComponentEndpointName": "CEETOX_H295R_PROG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_PROG was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_PROG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Progesterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "progestagens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 597, + "assayComponentName": "CEETOX_H295R_PROG", + "assayComponentDesc": "CEETOX_H295R_PROG is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Progesterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 235, + "geneName": "progesterone receptor", + "description": null, + "geneSymbol": "PGR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5241, + "officialSymbol": "PGR", + "officialFullName": "progesterone receptor", + "uniprotAccessionNumber": "P06401" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 915, + "assayComponentEndpointName": "CEETOX_H295R_TESTO", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component CEETOX_H295R_TESTO was analyzed into 1 assay endpoint. This assay endpoint, CEETOX_H295R_TESTO, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain or loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.", + "assayFunctionType": "detection of steroid hormone", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "Prochloraz;Forskolin", + "signalDirection": "bidirectional", + "intendedTargetType": "molecular messenger", + "intendedTargetTypeSub": "Testosterone", + "intendedTargetFamily": "steroid hormone", + "intendedTargetFamilySub": "androgens", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 598, + "assayComponentName": "CEETOX_H295R_TESTO", + "assayComponentDesc": "CEETOX_H295R_TESTO is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology.", + "assayComponentTargetDesc": null, + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "hormone induction", + "biologicalProcessTarget": "regulation of steroid hormone biosynthetic process", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "HPLC-MS-MS", + "keyAssayReagentType": "inducer", + "keyAssayReagent": null, + "technologicalTargetType": "molecular messenger", + "technologicalTargetTypeSub": "Testosterone", + "aid": 370, + "assayName": "CEETOX_H295R", + "assayDesc": "CEETOX_H295R is a cell-based, multiplexed-readout assay that uses H295R, a human adrenal gland cell line, with measurements taken at 48 hours after chemical dosing in a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "adrenal gland", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "H295R", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.1, + "asid": 8, + "assaySourceName": "CEETOX", + "assaySourceLongName": "Ceetox/OpAns", + "assaySourceDesc": "Ceetox, a part of Cyprotex, is a Contract Research Organization (CRO) that in coordination with OpAns, an analytical laboratory, provide ADME-tox services.", + "gene": { + "geneId": 27, + "geneName": "androgen receptor", + "description": null, + "geneSymbol": "AR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 367, + "officialSymbol": "AR", + "officialFullName": "androgen receptor", + "uniprotAccessionNumber": "P10275" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "doi: 10.1093/toxsci/kfw002", + "url": "https://pubmed.ncbi.nlm.nih.gov/26781511/", + "pmid": 26781511, + "title": "High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells", + "author": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT", + "citation": "Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicol Sci. 2016 Apr;150(2):323-32. doi: 10.1093/toxsci/kfw002. Epub 2016 Jan 18. PMID: 26781511; PMCID: PMC4809454.", + "otherId": "0", + "citationId": 245, + "otherSource": "" + } + }, + { + "aeid": 916, + "assayComponentEndpointName": "LTEA_HepaRG_ABCB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 599, + "assayComponentName": "LTEA_HepaRG_ABCB1", + "assayComponentDesc": "LTEA_HepaRG_ABCB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 236, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "description": null, + "geneSymbol": "ABCB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5243, + "officialSymbol": "ABCB1", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 1", + "uniprotAccessionNumber": "P08183" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 918, + "assayComponentEndpointName": "LTEA_HepaRG_ABCB11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCB11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 600, + "assayComponentName": "LTEA_HepaRG_ABCB11", + "assayComponentDesc": "LTEA_HepaRG_ABCB11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 345, + "geneName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "description": null, + "geneSymbol": "ABCB11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8647, + "officialSymbol": "ABCB11", + "officialFullName": "ATP-binding cassette, sub-family B (MDR/TAP), member 11", + "uniprotAccessionNumber": "O95342" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 920, + "assayComponentEndpointName": "LTEA_HepaRG_ABCC2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCC2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 601, + "assayComponentName": "LTEA_HepaRG_ABCC2", + "assayComponentDesc": "LTEA_HepaRG_ABCC2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 69, + "geneName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 2", + "description": null, + "geneSymbol": "ABCC2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1244, + "officialSymbol": "ABCC2", + "officialFullName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 2", + "uniprotAccessionNumber": "Q92887" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 922, + "assayComponentEndpointName": "LTEA_HepaRG_ABCC3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCC3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 602, + "assayComponentName": "LTEA_HepaRG_ABCC3", + "assayComponentDesc": "LTEA_HepaRG_ABCC3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 347, + "geneName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 3", + "description": null, + "geneSymbol": "ABCC3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8714, + "officialSymbol": "ABCC3", + "officialFullName": "ATP-binding cassette, sub-family C (CFTR/MRP), member 3", + "uniprotAccessionNumber": "O15438" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 924, + "assayComponentEndpointName": "LTEA_HepaRG_ABCG2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ABCG2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCG2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "ABC transporter", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 603, + "assayComponentName": "LTEA_HepaRG_ABCG2", + "assayComponentDesc": "LTEA_HepaRG_ABCG2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 354, + "geneName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "description": null, + "geneSymbol": "ABCG2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9429, + "officialSymbol": "ABCG2", + "officialFullName": "ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)", + "uniprotAccessionNumber": "Q9UNQ0" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 926, + "assayComponentEndpointName": "LTEA_HepaRG_ACLY", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ACLY was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACLY, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 604, + "assayComponentName": "LTEA_HepaRG_ACLY", + "assayComponentDesc": "LTEA_HepaRG_ACLY is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 3, + "geneName": "ATP citrate lyase", + "description": null, + "geneSymbol": "ACLY", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 47, + "officialSymbol": "ACLY", + "officialFullName": "ATP citrate lyase", + "uniprotAccessionNumber": "P53396" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 928, + "assayComponentEndpointName": "LTEA_HepaRG_ACOX1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ACOX1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACOX1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 605, + "assayComponentName": "LTEA_HepaRG_ACOX1", + "assayComponentDesc": "LTEA_HepaRG_ACOX1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 4, + "geneName": "acyl-CoA oxidase 1, palmitoyl", + "description": null, + "geneSymbol": "ACOX1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51, + "officialSymbol": "ACOX1", + "officialFullName": "acyl-CoA oxidase 1, palmitoyl", + "uniprotAccessionNumber": "Q15067" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 930, + "assayComponentEndpointName": "LTEA_HepaRG_ADK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_ADK was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ADK, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 606, + "assayComponentName": "LTEA_HepaRG_ADK", + "assayComponentDesc": "LTEA_HepaRG_ADK is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 9, + "geneName": "adenosine kinase", + "description": null, + "geneSymbol": "ADK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 132, + "officialSymbol": "ADK", + "officialFullName": "adenosine kinase", + "uniprotAccessionNumber": "P55263" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 932, + "assayComponentEndpointName": "LTEA_HepaRG_AFP", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_AFP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_AFP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is assay control.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "background measurement", + "intendedTargetFamilySub": "assay control", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 607, + "assayComponentName": "LTEA_HepaRG_AFP", + "assayComponentDesc": "LTEA_HepaRG_AFP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Undifferentiated hepatocyte.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 18, + "geneName": "alpha-fetoprotein", + "description": null, + "geneSymbol": "AFP", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 174, + "officialSymbol": "AFP", + "officialFullName": "alpha-fetoprotein", + "uniprotAccessionNumber": "P02771" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 204, + "assayComponentEndpointName": "BSK_BE3C_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3CA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 143, + "assayComponentName": "BSK_BE3C_uPA", + "assayComponentDesc": "BSK_BE3CA is an assay component measured in the BSK_BE3C assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 206, + "assayComponentEndpointName": "BSK_BE3C_uPAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_BE3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 144, + "assayComponentName": "BSK_BE3C_uPAR", + "assayComponentDesc": "BSK_BE3CAR is an assay component measured in the BSK_BE3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPAR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 9, + "assayName": "BSK_BE3C", + "assayDesc": "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "lung", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "bronchial epithelial cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 241, + "geneName": "plasminogen activator, urokinase receptor", + "description": null, + "geneSymbol": "PLAUR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5329, + "officialSymbol": "PLAUR", + "officialFullName": "plasminogen activator, urokinase receptor", + "uniprotAccessionNumber": "Q03405" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 208, + "assayComponentEndpointName": "BSK_CASM3C_HLADR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "MHC Class II", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 145, + "assayComponentName": "BSK_CASM3C_HLADR", + "assayComponentDesc": "BSK_CASM3C_HLADR is an assay component measured in the BSK_CASM3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "HLA-DR antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 153, + "geneName": "major histocompatibility complex, class II, DR alpha", + "description": null, + "geneSymbol": "HLA-DRA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3122, + "officialSymbol": "HLA-DRA", + "officialFullName": "major histocompatibility complex, class II, DR alpha", + "uniprotAccessionNumber": "P01903" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 210, + "assayComponentEndpointName": "BSK_CASM3C_IL6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_CASM3C_IL6 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 146, + "assayComponentName": "BSK_CASM3C_IL6", + "assayComponentDesc": "BSK_CASM3C_IL6 is an assay component measured in the BSK_CASM3C assay. It measures IL-6 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-6 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 10, + "assayName": "BSK_CASM3C", + "assayDesc": "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "coronary artery smooth muscle cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 175, + "geneName": "interleukin 6", + "description": null, + "geneSymbol": "IL6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3569, + "officialSymbol": "IL6", + "officialFullName": "interleukin 6", + "uniprotAccessionNumber": "P05231" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 936, + "assayComponentEndpointName": "LTEA_HepaRG_APOA5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_APOA5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_APOA5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the apolipoprotein intended target family, where the subfamily is Steatosis.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "apolipoprotein", + "intendedTargetFamilySub": "Steatosis", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 609, + "assayComponentName": "LTEA_HepaRG_APOA5", + "assayComponentDesc": "LTEA_HepaRG_APOA5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 443, + "geneName": "apolipoprotein A-V", + "description": null, + "geneSymbol": "APOA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 116519, + "officialSymbol": "APOA5", + "officialFullName": "apolipoprotein A-V", + "uniprotAccessionNumber": "Q6Q788" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 938, + "assayComponentEndpointName": "LTEA_HepaRG_BAD", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BAD was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAD, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 610, + "assayComponentName": "LTEA_HepaRG_BAD", + "assayComponentDesc": "LTEA_HepaRG_BAD is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 30, + "geneName": "BCL2-associated agonist of cell death", + "description": null, + "geneSymbol": "BAD", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 572, + "officialSymbol": "BAD", + "officialFullName": "BCL2-associated agonist of cell death", + "uniprotAccessionNumber": "Q92934" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 940, + "assayComponentEndpointName": "LTEA_HepaRG_BAX", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BAX was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAX, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 611, + "assayComponentName": "LTEA_HepaRG_BAX", + "assayComponentDesc": "LTEA_HepaRG_BAX is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 31, + "geneName": "BCL2-associated X protein", + "description": null, + "geneSymbol": "BAX", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 581, + "officialSymbol": "BAX", + "officialFullName": "BCL2-associated X protein", + "uniprotAccessionNumber": "Q07812" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 942, + "assayComponentEndpointName": "LTEA_HepaRG_BCL2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BCL2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 612, + "assayComponentName": "LTEA_HepaRG_BCL2", + "assayComponentDesc": "LTEA_HepaRG_BCL2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 34, + "geneName": "B-cell CLL/lymphoma 2", + "description": null, + "geneSymbol": "BCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 596, + "officialSymbol": "BCL2", + "officialFullName": "B-cell CLL/lymphoma 2", + "uniprotAccessionNumber": "P10415" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 944, + "assayComponentEndpointName": "LTEA_HepaRG_BCL2L11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BCL2L11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2L11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 613, + "assayComponentName": "LTEA_HepaRG_BCL2L11", + "assayComponentDesc": "LTEA_HepaRG_BCL2L11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 362, + "geneName": "BCL2-like 11 (apoptosis facilitator)", + "description": null, + "geneSymbol": "BCL2L11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10018, + "officialSymbol": "BCL2L11", + "officialFullName": "BCL2-like 11 (apoptosis facilitator)", + "uniprotAccessionNumber": "O43521" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 946, + "assayComponentEndpointName": "LTEA_HepaRG_BID", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_BID was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BID, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 614, + "assayComponentName": "LTEA_HepaRG_BID", + "assayComponentDesc": "LTEA_HepaRG_BID is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 35, + "geneName": "BH3 interacting domain death agonist", + "description": null, + "geneSymbol": "BID", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 637, + "officialSymbol": "BID", + "officialFullName": "BH3 interacting domain death agonist", + "uniprotAccessionNumber": "P55957" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 948, + "assayComponentEndpointName": "LTEA_HepaRG_CASP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CASP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 615, + "assayComponentName": "LTEA_HepaRG_CASP3", + "assayComponentDesc": "LTEA_HepaRG_CASP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 950, + "assayComponentEndpointName": "LTEA_HepaRG_CASP8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CASP8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 616, + "assayComponentName": "LTEA_HepaRG_CASP8", + "assayComponentDesc": "LTEA_HepaRG_CASP8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 44, + "geneName": "caspase 8, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 841, + "officialSymbol": "CASP8", + "officialFullName": "caspase 8, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q14790" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 952, + "assayComponentEndpointName": "LTEA_HepaRG_CAT", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CAT was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CAT, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the catalase intended target family, where the subfamily is oxidative stress.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "catalase", + "intendedTargetFamilySub": "oxidative stress", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 617, + "assayComponentName": "LTEA_HepaRG_CAT", + "assayComponentDesc": "LTEA_HepaRG_CAT is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 46, + "geneName": "catalase", + "description": null, + "geneSymbol": "CAT", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 847, + "officialSymbol": "CAT", + "officialFullName": "catalase", + "uniprotAccessionNumber": "P04040" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 954, + "assayComponentEndpointName": "LTEA_HepaRG_CCND1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CCND1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CCND1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 618, + "assayComponentName": "LTEA_HepaRG_CCND1", + "assayComponentDesc": "LTEA_HepaRG_CCND1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 33, + "geneName": "cyclin D1", + "description": null, + "geneSymbol": "CCND1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 595, + "officialSymbol": "CCND1", + "officialFullName": "cyclin D1", + "uniprotAccessionNumber": "P24385" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 956, + "assayComponentEndpointName": "LTEA_HepaRG_CCND2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CCND2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CCND2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 619, + "assayComponentName": "LTEA_HepaRG_CCND2", + "assayComponentDesc": "LTEA_HepaRG_CCND2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 47, + "geneName": "cyclin D2", + "description": null, + "geneSymbol": "CCND2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 894, + "officialSymbol": "CCND2", + "officialFullName": "cyclin D2", + "uniprotAccessionNumber": "P30279" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 958, + "assayComponentEndpointName": "LTEA_HepaRG_CDKN1A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CDKN1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CDKN1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 620, + "assayComponentName": "LTEA_HepaRG_CDKN1A", + "assayComponentDesc": "LTEA_HepaRG_CDKN1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 57, + "geneName": "cyclin-dependent kinase inhibitor 1A (p21, Cip1)", + "description": null, + "geneSymbol": "CDKN1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1026, + "officialSymbol": "CDKN1A", + "officialFullName": "cyclin-dependent kinase inhibitor 1A (p21, Cip1)", + "uniprotAccessionNumber": "P38936" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 960, + "assayComponentEndpointName": "LTEA_HepaRG_CFLAR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CFLAR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CFLAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 621, + "assayComponentName": "LTEA_HepaRG_CFLAR", + "assayComponentDesc": "LTEA_HepaRG_CFLAR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 348, + "geneName": "CASP8 and FADD-like apoptosis regulator", + "description": null, + "geneSymbol": "CFLAR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8837, + "officialSymbol": "CFLAR", + "officialFullName": "CASP8 and FADD-like apoptosis regulator", + "uniprotAccessionNumber": "O15519" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 962, + "assayComponentEndpointName": "LTEA_HepaRG_CYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 622, + "assayComponentName": "LTEA_HepaRG_CYP1A1", + "assayComponentDesc": "LTEA_HepaRG_CYP1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 964, + "assayComponentEndpointName": "LTEA_HepaRG_CYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP1A2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 623, + "assayComponentName": "LTEA_HepaRG_CYP1A2", + "assayComponentDesc": "LTEA_HepaRG_CYP1A2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 966, + "assayComponentEndpointName": "LTEA_HepaRG_CYP24A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP24A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP24A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 624, + "assayComponentName": "LTEA_HepaRG_CYP24A1", + "assayComponentDesc": "LTEA_HepaRG_CYP24A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 95, + "geneName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP24A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1591, + "officialSymbol": "CYP24A1", + "officialFullName": "cytochrome P450, family 24, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "Q07973" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 968, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2B6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2B6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 625, + "assayComponentName": "LTEA_HepaRG_CYP2B6", + "assayComponentDesc": "LTEA_HepaRG_CYP2B6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 970, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 626, + "assayComponentName": "LTEA_HepaRG_CYP2C19", + "assayComponentDesc": "LTEA_HepaRG_CYP2C19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 972, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 627, + "assayComponentName": "LTEA_HepaRG_CYP2C8", + "assayComponentDesc": "LTEA_HepaRG_CYP2C8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 974, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2C9 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 628, + "assayComponentName": "LTEA_HepaRG_CYP2C9", + "assayComponentDesc": "LTEA_HepaRG_CYP2C9 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 976, + "assayComponentEndpointName": "LTEA_HepaRG_CYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP2E1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2E1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 629, + "assayComponentName": "LTEA_HepaRG_CYP2E1", + "assayComponentDesc": "LTEA_HepaRG_CYP2E1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 978, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 630, + "assayComponentName": "LTEA_HepaRG_CYP3A4", + "assayComponentDesc": "LTEA_HepaRG_CYP3A4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 980, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 631, + "assayComponentName": "LTEA_HepaRG_CYP3A5", + "assayComponentDesc": "LTEA_HepaRG_CYP3A5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 91, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "description": null, + "geneSymbol": "CYP3A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1577, + "officialSymbol": "CYP3A5", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "uniprotAccessionNumber": "P20815" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 982, + "assayComponentEndpointName": "LTEA_HepaRG_CYP3A7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP3A7 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A7, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 632, + "assayComponentName": "LTEA_HepaRG_CYP3A7", + "assayComponentDesc": "LTEA_HepaRG_CYP3A7 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism/Undifferentiated hepatocyte.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 81, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 7", + "description": null, + "geneSymbol": "CYP3A7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1551, + "officialSymbol": "CYP3A7", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 7", + "uniprotAccessionNumber": "P24462" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 984, + "assayComponentEndpointName": "LTEA_HepaRG_CYP4A11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP4A11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 633, + "assayComponentName": "LTEA_HepaRG_CYP4A11", + "assayComponentDesc": "LTEA_HepaRG_CYP4A11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 92, + "geneName": "cytochrome P450, family 4, subfamily A, polypeptide 11", + "description": null, + "geneSymbol": "CYP4A11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1579, + "officialSymbol": "CYP4A11", + "officialFullName": "cytochrome P450, family 4, subfamily A, polypeptide 11", + "uniprotAccessionNumber": "Q02928" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 986, + "assayComponentEndpointName": "LTEA_HepaRG_CYP4A22", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP4A22 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A22, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 634, + "assayComponentName": "LTEA_HepaRG_CYP4A22", + "assayComponentDesc": "LTEA_HepaRG_CYP4A22 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 452, + "geneName": "cytochrome P450, family 4, subfamily A, polypeptide 22", + "description": null, + "geneSymbol": "CYP4A22", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 284541, + "officialSymbol": "CYP4A22", + "officialFullName": "cytochrome P450, family 4, subfamily A, polypeptide 22", + "uniprotAccessionNumber": "Q5TCH4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 988, + "assayComponentEndpointName": "LTEA_HepaRG_CYP7A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_CYP7A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP7A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 635, + "assayComponentName": "LTEA_HepaRG_CYP7A1", + "assayComponentDesc": "LTEA_HepaRG_CYP7A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 93, + "geneName": "cytochrome P450, family 7, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP7A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1581, + "officialSymbol": "CYP7A1", + "officialFullName": "cytochrome P450, family 7, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P22680" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 990, + "assayComponentEndpointName": "LTEA_HepaRG_DDIT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_DDIT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_DDIT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "basic leucine zipper", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 636, + "assayComponentName": "LTEA_HepaRG_DDIT3", + "assayComponentDesc": "LTEA_HepaRG_DDIT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 97, + "geneName": "DNA-damage-inducible transcript 3", + "description": null, + "geneSymbol": "DDIT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1649, + "officialSymbol": "DDIT3", + "officialFullName": "DNA-damage-inducible transcript 3", + "uniprotAccessionNumber": "P35638" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 992, + "assayComponentEndpointName": "LTEA_HepaRG_EGF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "EGF-like domain", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 637, + "assayComponentName": "LTEA_HepaRG_EGF", + "assayComponentDesc": "LTEA_HepaRG_EGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 107, + "geneName": "epidermal growth factor", + "description": null, + "geneSymbol": "EGF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1950, + "officialSymbol": "EGF", + "officialFullName": "epidermal growth factor", + "uniprotAccessionNumber": "P01133" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 994, + "assayComponentEndpointName": "LTEA_HepaRG_EGR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EGR1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGR1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "zinc finger", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 638, + "assayComponentName": "LTEA_HepaRG_EGR1", + "assayComponentDesc": "LTEA_HepaRG_EGR1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 109, + "geneName": "early growth response 1", + "description": null, + "geneSymbol": "EGR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1958, + "officialSymbol": "EGR1", + "officialFullName": "early growth response 1", + "uniprotAccessionNumber": "P18146" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 996, + "assayComponentEndpointName": "LTEA_HepaRG_EZR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_EZR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EZR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is Cellular remodeling.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "membrane protein", + "intendedTargetFamilySub": "Cellular remodeling", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 639, + "assayComponentName": "LTEA_HepaRG_EZR", + "assayComponentDesc": "LTEA_HepaRG_EZR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cellular remodeling.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 336, + "geneName": "ezrin", + "description": null, + "geneSymbol": "EZR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7430, + "officialSymbol": "EZR", + "officialFullName": "ezrin", + "uniprotAccessionNumber": "P15311" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 998, + "assayComponentEndpointName": "LTEA_HepaRG_FABP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FABP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FABP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is fatty acid carrier protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "transporter", + "intendedTargetFamilySub": "fatty acid carrier protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 640, + "assayComponentName": "LTEA_HepaRG_FABP1", + "assayComponentDesc": "LTEA_HepaRG_FABP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 124, + "geneName": "fatty acid binding protein 1, liver", + "description": null, + "geneSymbol": "FABP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2168, + "officialSymbol": "FABP1", + "officialFullName": "fatty acid binding protein 1, liver", + "uniprotAccessionNumber": "P07148" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1000, + "assayComponentEndpointName": "LTEA_HepaRG_FAS", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FAS was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FAS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cytokine receptor", + "intendedTargetFamilySub": "TNF receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 641, + "assayComponentName": "LTEA_HepaRG_FAS", + "assayComponentDesc": "LTEA_HepaRG_FAS is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 26, + "geneName": "Fas cell surface death receptor", + "description": null, + "geneSymbol": "FAS", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 355, + "officialSymbol": "FAS", + "officialFullName": "Fas cell surface death receptor", + "uniprotAccessionNumber": "P25445" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1002, + "assayComponentEndpointName": "LTEA_HepaRG_FASN", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FASN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FASN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is fatty acid synthase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "lyase", + "intendedTargetFamilySub": "fatty acid synthase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 642, + "assayComponentName": "LTEA_HepaRG_FASN", + "assayComponentDesc": "LTEA_HepaRG_FASN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 125, + "geneName": "fatty acid synthase", + "description": null, + "geneSymbol": "FASN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2194, + "officialSymbol": "FASN", + "officialFullName": "fatty acid synthase", + "uniprotAccessionNumber": "P49327" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1004, + "assayComponentEndpointName": "LTEA_HepaRG_FMO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FMO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FMO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is dioxygenase.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "oxidoreductase", + "intendedTargetFamilySub": "dioxygenase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 643, + "assayComponentName": "LTEA_HepaRG_FMO3", + "assayComponentDesc": "LTEA_HepaRG_FMO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 133, + "geneName": "flavin containing monooxygenase 3", + "description": null, + "geneSymbol": "FMO3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2328, + "officialSymbol": "FMO3", + "officialFullName": "flavin containing monooxygenase 3", + "uniprotAccessionNumber": "P31513" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1006, + "assayComponentEndpointName": "LTEA_HepaRG_FOXO1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FOXO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 644, + "assayComponentName": "LTEA_HepaRG_FOXO1", + "assayComponentDesc": "LTEA_HepaRG_FOXO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 129, + "geneName": "forkhead box O1", + "description": null, + "geneSymbol": "FOXO1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2308, + "officialSymbol": "FOXO1", + "officialFullName": "forkhead box O1", + "uniprotAccessionNumber": "Q12778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1008, + "assayComponentEndpointName": "LTEA_HepaRG_FOXO3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_FOXO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "dna binding", + "intendedTargetFamilySub": "forkhead box protein", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 645, + "assayComponentName": "LTEA_HepaRG_FOXO3", + "assayComponentDesc": "LTEA_HepaRG_FOXO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 130, + "geneName": "forkhead box O3", + "description": null, + "geneSymbol": "FOXO3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2309, + "officialSymbol": "FOXO3", + "officialFullName": "forkhead box O3", + "uniprotAccessionNumber": "O43524" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1010, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45A", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Oxidative Stress.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "Oxidative Stress", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 646, + "assayComponentName": "LTEA_HepaRG_GADD45A", + "assayComponentDesc": "LTEA_HepaRG_GADD45A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 96, + "geneName": "growth arrest and DNA-damage-inducible, alpha", + "description": null, + "geneSymbol": "GADD45A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1647, + "officialSymbol": "GADD45A", + "officialFullName": "growth arrest and DNA-damage-inducible, alpha", + "uniprotAccessionNumber": "P24522" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 1012, + "assayComponentEndpointName": "LTEA_HepaRG_GADD45B", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component LTEA_HepaRG_GADD45B was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45B, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", + "assayFunctionType": "reporter gene", + "normalizedDataType": "log2_fold_induction", + "burstAssay": 0, + "keyPositiveControl": null, + "signalDirection": "bidirectional", + "intendedTargetType": "rna", + "intendedTargetTypeSub": "mRNA", + "intendedTargetFamily": "mutagenicity response", + "intendedTargetFamilySub": "Cell proliferation, survival, death", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 647, + "assayComponentName": "LTEA_HepaRG_GADD45B", + "assayComponentDesc": "LTEA_HepaRG_GADD45B is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", + "assayComponentTargetDesc": "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", + "parameterReadoutType": "single", + "assayDesignType": "inducible reporter", + "assayDesignTypeSub": "mRNA induction", + "biologicalProcessTarget": "regulation of transcription factor activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluidigm qRT-PCR", + "keyAssayReagentType": null, + "keyAssayReagent": null, + "technologicalTargetType": "rna", + "technologicalTargetTypeSub": "mRNA", + "aid": 371, + "assayName": "LTEA_HepaRG", + "assayDesc": "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", + "timepointHr": 48.0, + "organismId": 9606, + "organism": "human", + "tissue": "liver", + "cellFormat": "cell line", + "cellFreeComponentSource": "", + "cellShortName": "HepaRG", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.5, + "asid": 9, + "assaySourceName": "LTEA", + "assaySourceLongName": "LifeTech/Expression Analysis", + "assaySourceDesc": "Life Technologies, acquired by Thermo Fisher, is a Contract Research Organization (CRO) that provides transcriptomics and expression screening.", + "gene": { + "geneId": 214, + "geneName": "growth arrest and DNA-damage-inducible, beta", + "description": null, + "geneSymbol": "GADD45B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4616, + "officialSymbol": "GADD45B", + "officialFullName": "growth arrest and DNA-damage-inducible, beta", + "uniprotAccessionNumber": "O75293" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1038/s41540-020-00166-2", + "url": "https://pubmed.ncbi.nlm.nih.gov/33504769/", + "pmid": 33504769, + "title": "High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures", + "author": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF", + "citation": "Franzosa JA, Bonzo JA, Jack J, Baker NC, Kothiya P, Witek RP, Hurban P, Siferd S, Hester S, Shah I, Ferguson SS, Houck KA, Wambaugh JF. High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures. NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2. PMID: 33504769; PMCID: PMC7840683.", + "otherId": "0", + "citationId": 247, + "otherSource": "" + } + }, + { + "aeid": 242, + "assayComponentEndpointName": "BSK_hDFCGF_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 162, + "assayComponentName": "BSK_hDFCGF_IP10", + "assayComponentDesc": "BSK_hDFCGF_IP10 is an assay component measured in the BSK_hDFCGF assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 244, + "assayComponentEndpointName": "BSK_hDFCGF_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 163, + "assayComponentName": "BSK_hDFCGF_MCSF", + "assayComponentDesc": "BSK_hDFCGF_MCSF is an assay component measured in the BSK_hDFCGF assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 246, + "assayComponentEndpointName": "BSK_hDFCGF_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 164, + "assayComponentName": "BSK_hDFCGF_MIG", + "assayComponentDesc": "BSK_hDFCGF_MIG is an assay component measured in the BSK_hDFCGF assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 248, + "assayComponentEndpointName": "BSK_hDFCGF_MMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 165, + "assayComponentName": "BSK_hDFCGF_MMP1", + "assayComponentDesc": "BSK_hDFCGF_MMP1 is an assay component measured in the BSK_hDFCGF assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 250, + "assayComponentEndpointName": "BSK_hDFCGF_PAI1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "plasmogen activator inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 166, + "assayComponentName": "BSK_hDFCGF_PAI1", + "assayComponentDesc": "BSK_hDFCGF_PAI1 is an assay component measured in the BSK_hDFCGF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PAI-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 229, + "geneName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "description": null, + "geneSymbol": "SERPINE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5054, + "officialSymbol": "SERPINE1", + "officialFullName": "serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1", + "uniprotAccessionNumber": "P05121" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 252, + "assayComponentEndpointName": "BSK_hDFCGF_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_hDFCGF_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 167, + "assayComponentName": "BSK_hDFCGF_Proliferation", + "assayComponentDesc": "BSK_hDFCGF_Proliferation is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 254, + "assayComponentEndpointName": "BSK_hDFCGF_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 168, + "assayComponentName": "BSK_hDFCGF_SRB", + "assayComponentDesc": "BSK_hDFCGF_SRB is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 256, + "assayComponentEndpointName": "BSK_hDFCGF_TIMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 169, + "assayComponentName": "BSK_hDFCGF_TIMP1", + "assayComponentDesc": "BSK_hDFCGF_TIMP1 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-1 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:TIMP1 | GeneID:7076 | Uniprot_SwissProt_Accession:P01033].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 324, + "geneName": "TIMP metallopeptidase inhibitor 1", + "description": null, + "geneSymbol": "TIMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7076, + "officialSymbol": "TIMP1", + "officialFullName": "TIMP metallopeptidase inhibitor 1", + "uniprotAccessionNumber": "P01033" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 258, + "assayComponentEndpointName": "BSK_hDFCGF_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 170, + "assayComponentName": "BSK_hDFCGF_VCAM1", + "assayComponentDesc": "BSK_hDFCGF_VCAM1 is an assay component measured in the BSK_hDFCGF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 11, + "assayName": "BSK_hDFCGF", + "assayDesc": "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell", + "cellFreeComponentSource": "NA", + "cellShortName": "foreskin fibroblast", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 260, + "assayComponentEndpointName": "BSK_KF3CT_ICAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 171, + "assayComponentName": "BSK_KF3CT_ICAM1", + "assayComponentDesc": "BSK_KF3CT_ICAM1 is an assay component measured in the BSK_KF3CT assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "ICAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 170, + "geneName": "intercellular adhesion molecule 1", + "description": null, + "geneSymbol": "ICAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3383, + "officialSymbol": "ICAM1", + "officialFullName": "intercellular adhesion molecule 1", + "uniprotAccessionNumber": "P05362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 262, + "assayComponentEndpointName": "BSK_KF3CT_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 172, + "assayComponentName": "BSK_KF3CT_IL1a", + "assayComponentDesc": "BSK_KF3CT_IL1a is an assay component measured in the BSK_KF3CT assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-1a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 264, + "assayComponentEndpointName": "BSK_KF3CT_IP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 173, + "assayComponentName": "BSK_KF3CT_IP10", + "assayComponentDesc": "BSK_KF3CT_IP10 is an assay component measured in the BSK_KF3CT assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IP-10 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 178, + "geneName": "chemokine (C-X-C motif) ligand 10", + "description": null, + "geneSymbol": "CXCL10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3627, + "officialSymbol": "CXCL10", + "officialFullName": "chemokine (C-X-C motif) ligand 10", + "uniprotAccessionNumber": "P02778" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 266, + "assayComponentEndpointName": "BSK_KF3CT_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 174, + "assayComponentName": "BSK_KF3CT_MCP1", + "assayComponentDesc": "BSK_KF3CT_MCP1 is an assay component measured in the BSK_KF3CT assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 268, + "assayComponentEndpointName": "BSK_KF3CT_MMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_MMP9 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MMP9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 175, + "assayComponentName": "BSK_KF3CT_MMP9", + "assayComponentDesc": "BSK_KF3CT_MMP9 is an assay component measured in the BSK_KF3CT assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MMP-9 antibody is used to tag and quantify the level of matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MMP-9 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 270, + "assayComponentEndpointName": "BSK_KF3CT_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 176, + "assayComponentName": "BSK_KF3CT_SRB", + "assayComponentDesc": "BSK_KF3CT_SRB is an assay component measured in the BSK_KF3CT assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and TGFb.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 272, + "assayComponentEndpointName": "BSK_KF3CT_TGFb1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "growth factor", + "intendedTargetFamilySub": "transforming growth factor beta", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 177, + "assayComponentName": "BSK_KF3CT_TGFb1", + "assayComponentDesc": "BSK_KF3CT_TGFb1 is an assay component measured in the BSK_KF3CT assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TGF-b1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 319, + "geneName": "transforming growth factor, beta 1", + "description": null, + "geneSymbol": "TGFB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7040, + "officialSymbol": "TGFB1", + "officialFullName": "transforming growth factor, beta 1", + "uniprotAccessionNumber": "P01137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 274, + "assayComponentEndpointName": "BSK_KF3CT_TIMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TIMP2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease inhibitor", + "intendedTargetFamilySub": "metalloproteinase inhibitor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 178, + "assayComponentName": "BSK_KF3CT_TIMP2", + "assayComponentDesc": "BSK_KF3CT_TIMP2 is an assay component measured in the BSK_KF3CT assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TIMP-2 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TIMP2 | GeneID:7077 | Uniprot_SwissProt_Accession:Q96MC4].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TIMP-2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 325, + "geneName": "TIMP metallopeptidase inhibitor 2", + "description": null, + "geneSymbol": "TIMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7077, + "officialSymbol": "TIMP2", + "officialFullName": "TIMP metallopeptidase inhibitor 2", + "uniprotAccessionNumber": "Q96MC4" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 276, + "assayComponentEndpointName": "BSK_KF3CT_uPA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_KF3CTA was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CTA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 179, + "assayComponentName": "BSK_KF3CT_uPA", + "assayComponentDesc": "BSK_KF3CTA is an assay component measured in the BSK_KF3CT assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "uPA antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 12, + "assayName": "BSK_KF3CT", + "assayDesc": "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "skin", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "keratinocytes and foreskin fibroblasts", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 240, + "geneName": "plasminogen activator, urokinase", + "description": null, + "geneSymbol": "PLAU", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5328, + "officialSymbol": "PLAU", + "officialFullName": "plasminogen activator, urokinase", + "uniprotAccessionNumber": "P00749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 278, + "assayComponentEndpointName": "BSK_LPS_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 180, + "assayComponentName": "BSK_LPS_CD40", + "assayComponentDesc": "BSK_LPS_CD40 is an assay component measured in the BSK_LPS assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 280, + "assayComponentEndpointName": "BSK_LPS_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 181, + "assayComponentName": "BSK_LPS_Eselectin", + "assayComponentDesc": "BSK_LPS_Eselectin is an assay component measured in the BSK_LPS assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 282, + "assayComponentEndpointName": "BSK_LPS_IL1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 182, + "assayComponentName": "BSK_LPS_IL1a", + "assayComponentDesc": "BSK_LPS_IL1a is an assay component measured in the BSK_LPS assay. It measures IL-a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 174, + "geneName": "interleukin 1, alpha", + "description": null, + "geneSymbol": "IL1A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3552, + "officialSymbol": "IL1A", + "officialFullName": "interleukin 1, alpha", + "uniprotAccessionNumber": "P01583" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 284, + "assayComponentEndpointName": "BSK_LPS_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 183, + "assayComponentName": "BSK_LPS_IL8", + "assayComponentDesc": "BSK_LPS_IL8 is an assay component measured in the BSK_LPS assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 286, + "assayComponentEndpointName": "BSK_LPS_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 184, + "assayComponentName": "BSK_LPS_MCP1", + "assayComponentDesc": "BSK_LPS_MCP1 is an assay component measured in the BSK_LPS assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 288, + "assayComponentEndpointName": "BSK_LPS_MCSF", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "colony stimulating factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 185, + "assayComponentName": "BSK_LPS_MCSF", + "assayComponentDesc": "BSK_LPS_MCSF is an assay component measured in the BSK_LPS assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "M-CSF antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 72, + "geneName": "colony stimulating factor 1 (macrophage)", + "description": null, + "geneSymbol": "CSF1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1435, + "officialSymbol": "CSF1", + "officialFullName": "colony stimulating factor 1 (macrophage)", + "uniprotAccessionNumber": "P09603" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 290, + "assayComponentEndpointName": "BSK_LPS_PGE2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_PGE2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_PGE2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "gpcr", + "intendedTargetFamilySub": "rhodopsin-like receptor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 186, + "assayComponentName": "BSK_LPS_PGE2", + "assayComponentDesc": "BSK_LPS_PGE2 is an assay component measured in the BSK_LPS assay. It measures PGE2 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "PGE2 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 264, + "geneName": "prostaglandin E receptor 2 (subtype EP2), 53kDa", + "description": null, + "geneSymbol": "PTGER2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5732, + "officialSymbol": "PTGER2", + "officialFullName": "prostaglandin E receptor 2 (subtype EP2), 53kDa", + "uniprotAccessionNumber": "P43116" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 292, + "assayComponentEndpointName": "BSK_LPS_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 187, + "assayComponentName": "BSK_LPS_SRB", + "assayComponentDesc": "BSK_LPS_SRB is an assay component measured in the BSK_LPS assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 294, + "assayComponentEndpointName": "BSK_LPS_TissueFactor", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "coagulation factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 188, + "assayComponentName": "BSK_LPS_TissueFactor", + "assayComponentDesc": "BSK_LPS_TissueFactor is an assay component measured in the BSK_LPS assay. It measures CD142 Tissue Factor antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD142 Tissue Factor antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 123, + "geneName": "coagulation factor III (thromboplastin, tissue factor)", + "description": null, + "geneSymbol": "F3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2152, + "officialSymbol": "F3", + "officialFullName": "coagulation factor III (thromboplastin, tissue factor)", + "uniprotAccessionNumber": "P13726" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 296, + "assayComponentEndpointName": "BSK_LPS_TNFa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_TNFa was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TNFa, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 189, + "assayComponentName": "BSK_LPS_TNFa", + "assayComponentDesc": "BSK_LPS_TNFa is an assay component measured in the BSK_LPS assay. It measures TNF-a antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "TNF-a antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 327, + "geneName": "tumor necrosis factor", + "description": null, + "geneSymbol": "TNF", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7124, + "officialSymbol": "TNF", + "officialFullName": "tumor necrosis factor", + "uniprotAccessionNumber": "P01375" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 298, + "assayComponentEndpointName": "BSK_LPS_VCAM1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_LPS_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "Immunoglobulin CAM", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 190, + "assayComponentName": "BSK_LPS_VCAM1", + "assayComponentDesc": "BSK_LPS_VCAM1 is an assay component measured in the BSK_LPS assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "VCAM-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 13, + "assayName": "BSK_LPS", + "assayDesc": "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 334, + "geneName": "vascular cell adhesion molecule 1", + "description": null, + "geneSymbol": "VCAM1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 7412, + "officialSymbol": "VCAM1", + "officialFullName": "vascular cell adhesion molecule 1", + "uniprotAccessionNumber": "P19320" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 300, + "assayComponentEndpointName": "BSK_SAg_CD38", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD38 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD38, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is other cytokine.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "other cytokine", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 191, + "assayComponentName": "BSK_SAg_CD38", + "assayComponentDesc": "BSK_SAg_CD38 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD38 antibody is used to tag and quantify the level of CD38 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD38 | GeneID:952 | Uniprot_SwissProt_Accession:P28907].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD38 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 48, + "geneName": "CD38 molecule", + "description": null, + "geneSymbol": "CD38", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 952, + "officialSymbol": "CD38", + "officialFullName": "CD38 molecule", + "uniprotAccessionNumber": "P28907" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 302, + "assayComponentEndpointName": "BSK_SAg_CD40", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 192, + "assayComponentName": "BSK_SAg_CD40", + "assayComponentDesc": "BSK_SAg_CD40 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD40 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 49, + "geneName": "CD40 molecule, TNF receptor superfamily member 5", + "description": null, + "geneSymbol": "CD40", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 958, + "officialSymbol": "CD40", + "officialFullName": "CD40 molecule, TNF receptor superfamily member 5", + "uniprotAccessionNumber": "P25942" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 304, + "assayComponentEndpointName": "BSK_SAg_CD69", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_CD69 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD69, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "inflammatory factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 193, + "assayComponentName": "BSK_SAg_CD69", + "assayComponentDesc": "BSK_SAg_CD69 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", + "assayComponentTargetDesc": "CD69 antibody is used to tag and quantify the level of CD69 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD69 | GeneID:969 | Uniprot_SwissProt_Accession:Q07108].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "CD69 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 50, + "geneName": "CD69 molecule", + "description": null, + "geneSymbol": "CD69", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 969, + "officialSymbol": "CD69", + "officialFullName": "CD69 molecule", + "uniprotAccessionNumber": "Q07108" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 306, + "assayComponentEndpointName": "BSK_SAg_Eselectin", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cell adhesion molecules", + "intendedTargetFamilySub": "selectins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 194, + "assayComponentName": "BSK_SAg_Eselectin", + "assayComponentDesc": "BSK_SAg_Eselectin is an assay component measured in the BSK_SAg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "E-selectin antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 293, + "geneName": "selectin E", + "description": null, + "geneSymbol": "SELE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6401, + "officialSymbol": "SELE", + "officialFullName": "selectin E", + "uniprotAccessionNumber": "P16581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 308, + "assayComponentEndpointName": "BSK_SAg_IL8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "interleukins", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 195, + "assayComponentName": "BSK_SAg_IL8", + "assayComponentDesc": "BSK_SAg_IL8 is an assay component measured in the BSK_SAg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "IL-8 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 177, + "geneName": "chemokine (C-X-C motif) ligand 8", + "description": null, + "geneSymbol": "CXCL8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3576, + "officialSymbol": "CXCL8", + "officialFullName": "chemokine (C-X-C motif) ligand 8", + "uniprotAccessionNumber": "P10145" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 310, + "assayComponentEndpointName": "BSK_SAg_MCP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 196, + "assayComponentName": "BSK_SAg_MCP1", + "assayComponentDesc": "BSK_SAg_MCP1 is an assay component measured in the BSK_SAg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MCP-1 antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 291, + "geneName": "chemokine (C-C motif) ligand 2", + "description": null, + "geneSymbol": "CCL2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6347, + "officialSymbol": "CCL2", + "officialFullName": "chemokine (C-C motif) ligand 2", + "uniprotAccessionNumber": "P13500" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 312, + "assayComponentEndpointName": "BSK_SAg_MIG", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-specified", + "intendedTargetFamily": "cytokine", + "intendedTargetFamilySub": "chemotactic factor", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 197, + "assayComponentName": "BSK_SAg_MIG", + "assayComponentDesc": "BSK_SAg_MIG is an assay component measured in the BSK_SAg assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", + "assayComponentTargetDesc": "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", + "parameterReadoutType": "single", + "assayDesignType": "binding reporter", + "assayDesignTypeSub": "immunoassay: elisa", + "biologicalProcessTarget": "regulation of gene expression", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "ELISA", + "keyAssayReagentType": "antibody", + "keyAssayReagent": "MIG antibody", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-specified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": { + "geneId": 201, + "geneName": "chemokine (C-X-C motif) ligand 9", + "description": null, + "geneSymbol": "CXCL9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4283, + "officialSymbol": "CXCL9", + "officialFullName": "chemokine (C-X-C motif) ligand 9", + "uniprotAccessionNumber": "Q07325" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 314, + "assayComponentEndpointName": "BSK_SAg_PBMCCytotoxicity", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_PBMCCytotoxicity, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "cytotoxicity", + "cellViabilityAssay": 1, + "dataUsability": 1, + "acid": 198, + "assayComponentName": "BSK_SAg_PBMCCytotoxicity", + "assayComponentDesc": "BSK_SAg_PBMCCytotoxicity is an assay component measured in the BSK_SAg assay. It measures Alamar blue related to cell death using Alamar Blue Reduction technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "dehydrogenase activity determination", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Alamar Blue Reduction", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Alamar blue", + "technologicalTargetType": "cellular", + "technologicalTargetTypeSub": "cellular", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 316, + "assayComponentEndpointName": "BSK_SAg_Proliferation", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_SAg_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", + "assayFunctionType": "viability", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "cellular", + "intendedTargetTypeSub": "cellular", + "intendedTargetFamily": "cell cycle", + "intendedTargetFamilySub": "proliferation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 199, + "assayComponentName": "BSK_SAg_Proliferation", + "assayComponentDesc": "BSK_SAg_Proliferation is an assay component in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology. ", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell proliferation", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 318, + "assayComponentEndpointName": "BSK_SAg_SRB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component BSK_SAg_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", + "assayFunctionType": "signaling", + "normalizedDataType": "log10_fold_induction", + "burstAssay": 0, + "keyPositiveControl": "colchicine", + "signalDirection": "bidirectional", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "protein-unspecified", + "intendedTargetFamily": "cell morphology", + "intendedTargetFamilySub": "cell conformation", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 200, + "assayComponentName": "BSK_SAg_SRB", + "assayComponentDesc": "BSK_SAg_SRB is an assay component measured in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", + "assayComponentTargetDesc": "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", + "parameterReadoutType": "single", + "assayDesignType": "viability reporter", + "assayDesignTypeSub": "protein content", + "biologicalProcessTarget": "cell death", + "detectionTechnologyType": "Spectrophotometry", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Sulforhodamine staining", + "keyAssayReagentType": "stain", + "keyAssayReagent": "0.1% sulforhodamine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "protein-unspecified", + "aid": 14, + "assayName": "BSK_SAg", + "assayDesc": "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", + "timepointHr": 24.0, + "organismId": 9606, + "organism": "human", + "tissue": "vascular", + "cellFormat": "primary cell co-culture", + "cellFreeComponentSource": "NA", + "cellShortName": "umbilical vein endothelium and peripheral blood mononuclear cells", + "cellGrowthMode": "adherent", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "cell-based", + "assayFormatTypeSub": "cell-based format", + "contentReadoutType": "multiplexed", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.2, + "asid": 4, + "assaySourceName": "BSK", + "assaySourceLongName": "Bioseek", + "assaySourceDesc": "Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.", + "gene": null, + "assayList": null, + "citations": { + "doi": "doi: 10.1177/1087057109345525", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/19773588", + "pmid": 19773588, + "title": "Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems", + "author": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL", + "citation": "Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J Biomol Screen. 2009 Oct;14(9):1054-66. doi: 10.1177/1087057109345525. Epub 2009 Sep 22. PubMed PMID: 19773588.", + "otherId": "0", + "citationId": 213, + "otherSource": "" + } + }, + { + "aeid": 319, + "assayComponentEndpointName": "NVS_ADME_hCYP19A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP19A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "steroidogenesis-related", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 201, + "assayComponentName": "NVS_ADME_hCYP19A1", + "assayComponentDesc": "NVS_ADME_hCYP19A1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP19A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBOMF+ NADPH -> fluorescein + NADP+] involving the key substrate [Di(benzyloxymethoxy)fluorescein (DBOMF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Di(benzyloxymethoxy)fluorescein (DBOMF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 15, + "assayName": "NVS_ADME_hCYP19A1", + "assayDesc": "NVS_ADME_hCYP19A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 94, + "geneName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP19A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1588, + "officialSymbol": "CYP19A1", + "officialFullName": "cytochrome P450, family 19, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P11511" + }, + "assayList": { + "name": "EDSP steroidogenesis", + "description": "Steroidogenesis pathway assays used in EDSP" + }, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 321, + "assayComponentEndpointName": "NVS_ADME_hCYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole;Ketanserin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 202, + "assayComponentName": "NVS_ADME_hCYP1A1", + "assayComponentDesc": "NVS_ADME_hCYP1A1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 1 [GeneSymbol:CYP1A1 | GeneID:1543 | Uniprot_SwissProt_Accession:P04798].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 16, + "assayName": "NVS_ADME_hCYP1A1", + "assayDesc": "NVS_ADME_hCYP1A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 77, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "description": null, + "geneSymbol": "CYP1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1543, + "officialSymbol": "CYP1A1", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 1", + "uniprotAccessionNumber": "P04798" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 323, + "assayComponentEndpointName": "NVS_ADME_hCYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Furafylline", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 203, + "assayComponentName": "NVS_ADME_hCYP1A2", + "assayComponentDesc": "NVS_ADME_hCYP1A2 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 2 [GeneSymbol:CYP1A2 | GeneID:1544 | Uniprot_SwissProt_Accession:P05177].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 17, + "assayName": "NVS_ADME_hCYP1A2", + "assayDesc": "NVS_ADME_hCYP1A2 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 78, + "geneName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "description": null, + "geneSymbol": "CYP1A2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1544, + "officialSymbol": "CYP1A2", + "officialFullName": "cytochrome P450, family 1, subfamily A, polypeptide 2", + "uniprotAccessionNumber": "P05177" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 325, + "assayComponentEndpointName": "NVS_ADME_hCYP1B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alpha-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 204, + "assayComponentName": "NVS_ADME_hCYP1B1", + "assayComponentDesc": "NVS_ADME_hCYP1B1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP1B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily B, polypeptide 1 [GeneSymbol:CYP1B1 | GeneID:1545 | Uniprot_SwissProt_Accession:Q16678].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 18, + "assayName": "NVS_ADME_hCYP1B1", + "assayDesc": "NVS_ADME_hCYP1B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 79, + "geneName": "cytochrome P450, family 1, subfamily B, polypeptide 1", + "description": null, + "geneSymbol": "CYP1B1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1545, + "officialSymbol": "CYP1B1", + "officialFullName": "cytochrome P450, family 1, subfamily B, polypeptide 1", + "uniprotAccessionNumber": "Q16678" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 327, + "assayComponentEndpointName": "NVS_ADME_hCYP2A6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 205, + "assayComponentName": "NVS_ADME_hCYP2A6", + "assayComponentDesc": "NVS_ADME_hCYP2A6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2A6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Coumarin + NADPH -> 7-Hydroxycoumarin + NADP+] involving the key substrate [Coumarin] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily A, polypeptide 6 [GeneSymbol:CYP2A6 | GeneID:1548 | Uniprot_SwissProt_Accession:P11509].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Coumarin", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 19, + "assayName": "NVS_ADME_hCYP2A6", + "assayDesc": "NVS_ADME_hCYP2A6 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 80, + "geneName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "description": null, + "geneSymbol": "CYP2A6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1548, + "officialSymbol": "CYP2A6", + "officialFullName": "cytochrome P450, family 2, subfamily A, polypeptide 6", + "uniprotAccessionNumber": "P11509" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 329, + "assayComponentEndpointName": "NVS_ADME_hCYP2B6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 206, + "assayComponentName": "NVS_ADME_hCYP2B6", + "assayComponentDesc": "NVS_ADME_hCYP2B6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2B6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:EFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-ethoxy-4-trifluoromethylcoumarin (EFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily B, polypeptide 6 [GeneSymbol:CYP2B6 | GeneID:1555 | Uniprot_SwissProt_Accession:P20813].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-4-trifluoromethylcoumarin (EFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 20, + "assayName": "NVS_ADME_hCYP2B6", + "assayDesc": "NVS_ADME_hCYP2B6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 82, + "geneName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "description": null, + "geneSymbol": "CYP2B6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1555, + "officialSymbol": "CYP2B6", + "officialFullName": "cytochrome P450, family 2, subfamily B, polypeptide 6", + "uniprotAccessionNumber": "P20813" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 331, + "assayComponentEndpointName": "NVS_ADME_hCYP2C18", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 207, + "assayComponentName": "NVS_ADME_hCYP2C18", + "assayComponentDesc": "NVS_ADME_hCYP2C18 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C18 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 18 [GeneSymbol:CYP2C18 | GeneID:1562 | Uniprot_SwissProt_Accession:P33260].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 21, + "assayName": "NVS_ADME_hCYP2C18", + "assayDesc": "NVS_ADME_hCYP2C18 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 86, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 18", + "description": null, + "geneSymbol": "CYP2C18", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1562, + "officialSymbol": "CYP2C18", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 18", + "uniprotAccessionNumber": "P33260" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 333, + "assayComponentEndpointName": "NVS_ADME_hCYP2C19", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 208, + "assayComponentName": "NVS_ADME_hCYP2C19", + "assayComponentDesc": "NVS_ADME_hCYP2C19 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C19 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 19 [GeneSymbol:CYP2C19 | GeneID:1557 | Uniprot_SwissProt_Accession:P33261].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 22, + "assayName": "NVS_ADME_hCYP2C19", + "assayDesc": "NVS_ADME_hCYP2C19 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 83, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "description": null, + "geneSymbol": "CYP2C19", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1557, + "officialSymbol": "CYP2C19", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 19", + "uniprotAccessionNumber": "P33261" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 335, + "assayComponentEndpointName": "NVS_ADME_hCYP2C8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "quercetin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 209, + "assayComponentName": "NVS_ADME_hCYP2C8", + "assayComponentDesc": "NVS_ADME_hCYP2C8 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C8 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBOMF+ NADPH -> fluorescein + NADP+] involving the key substrate [Di(benzyloxymethoxy)fluorescein (DBOMF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 8 [GeneSymbol:CYP2C8 | GeneID:1558 | Uniprot_SwissProt_Accession:P10632].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Di(benzyloxymethoxy)fluorescein (DBOMF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 23, + "assayName": "NVS_ADME_hCYP2C8", + "assayDesc": "NVS_ADME_hCYP2C8 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 84, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "description": null, + "geneSymbol": "CYP2C8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1558, + "officialSymbol": "CYP2C8", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 8", + "uniprotAccessionNumber": "P10632" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 337, + "assayComponentEndpointName": "NVS_ADME_hCYP2C9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Sulfaphenazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 210, + "assayComponentName": "NVS_ADME_hCYP2C9", + "assayComponentDesc": "NVS_ADME_hCYP2C9 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2C9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 9 [GeneSymbol:CYP2C9 | GeneID:1559 | Uniprot_SwissProt_Accession:P11712].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 24, + "assayName": "NVS_ADME_hCYP2C9", + "assayDesc": "NVS_ADME_hCYP2C9 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 85, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "description": null, + "geneSymbol": "CYP2C9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1559, + "officialSymbol": "CYP2C9", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 9", + "uniprotAccessionNumber": "P11712" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 339, + "assayComponentEndpointName": "NVS_ADME_hCYP2D6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "quinidine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 211, + "assayComponentName": "NVS_ADME_hCYP2D6", + "assayComponentDesc": "NVS_ADME_hCYP2D6 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2D6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:AMMC + NADPH --> AHMC + NADP+] involving the key substrate [3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily D, polypeptide 6 [GeneSymbol:CYP2D6 | GeneID:1565 | Uniprot_SwissProt_Accession:P10635].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 25, + "assayName": "NVS_ADME_hCYP2D6", + "assayDesc": "NVS_ADME_hCYP2D6 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 87, + "geneName": "cytochrome P450, family 2, subfamily D, polypeptide 6", + "description": null, + "geneSymbol": "CYP2D6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1565, + "officialSymbol": "CYP2D6", + "officialFullName": "cytochrome P450, family 2, subfamily D, polypeptide 6", + "uniprotAccessionNumber": "P10635" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 341, + "assayComponentEndpointName": "NVS_ADME_hCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2E1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "chlormethiazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 212, + "assayComponentName": "NVS_ADME_hCYP2E1", + "assayComponentDesc": "NVS_ADME_hCYP2E1 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2E1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily E, polypeptide 1 [GeneSymbol:CYP2E1 | GeneID:1571 | Uniprot_SwissProt_Accession:P05181].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 26, + "assayName": "NVS_ADME_hCYP2E1", + "assayDesc": "NVS_ADME_hCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 88, + "geneName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "description": null, + "geneSymbol": "CYP2E1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1571, + "officialSymbol": "CYP2E1", + "officialFullName": "cytochrome P450, family 2, subfamily E, polypeptide 1", + "uniprotAccessionNumber": "P05181" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 343, + "assayComponentEndpointName": "NVS_ADME_hCYP2J2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 213, + "assayComponentName": "NVS_ADME_hCYP2J2", + "assayComponentDesc": "NVS_ADME_hCYP2J2 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2J2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily J, polypeptide 2 [GeneSymbol:CYP2J2 | GeneID:1573 | Uniprot_SwissProt_Accession:P51589].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 27, + "assayName": "NVS_ADME_hCYP2J2", + "assayDesc": "NVS_ADME_hCYP2J2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 89, + "geneName": "cytochrome P450, family 2, subfamily J, polypeptide 2", + "description": null, + "geneSymbol": "CYP2J2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1573, + "officialSymbol": "CYP2J2", + "officialFullName": "cytochrome P450, family 2, subfamily J, polypeptide 2", + "uniprotAccessionNumber": "P51589" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 345, + "assayComponentEndpointName": "NVS_ADME_hCYP3A4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 214, + "assayComponentName": "NVS_ADME_hCYP3A4", + "assayComponentDesc": "NVS_ADME_hCYP3A4 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP3A4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBF + NADPH --> fluorescein + NADP+] involving the key substrate [Dibenzyl fluorescein (DBF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 3, subfamily A, polypeptide 4 [GeneSymbol:CYP3A4 | GeneID:1576 | Uniprot_SwissProt_Accession:P08684].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Dibenzyl fluorescein (DBF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 28, + "assayName": "NVS_ADME_hCYP3A4", + "assayDesc": "NVS_ADME_hCYP3A4 is a biochemical, single-readout assay that uses extracted gene-proteins from insect cells in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 90, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "description": null, + "geneSymbol": "CYP3A4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1576, + "officialSymbol": "CYP3A4", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 4", + "uniprotAccessionNumber": "P08684" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 347, + "assayComponentEndpointName": "NVS_ADME_hCYP3A5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP3A5, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 215, + "assayComponentName": "NVS_ADME_hCYP3A5", + "assayComponentDesc": "NVS_ADME_hCYP3A5 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP3A5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 3, subfamily A, polypeptide 5 [GeneSymbol:CYP3A5 | GeneID:1577 | Uniprot_SwissProt_Accession:P20815].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-(benzyloxymethoxy)-4-(trifluormethyl)-2H-coumarin (BOMFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 29, + "assayName": "NVS_ADME_hCYP3A5", + "assayDesc": "NVS_ADME_hCYP3A5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 91, + "geneName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "description": null, + "geneSymbol": "CYP3A5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1577, + "officialSymbol": "CYP3A5", + "officialFullName": "cytochrome P450, family 3, subfamily A, polypeptide 5", + "uniprotAccessionNumber": "P20815" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 349, + "assayComponentEndpointName": "NVS_ADME_hCYP4F12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_hCYP4F12, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 216, + "assayComponentName": "NVS_ADME_hCYP4F12", + "assayComponentDesc": "NVS_ADME_hCYP4F12 is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP4F12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 4, subfamily F, polypeptide 12 [GeneSymbol:CYP4F12 | GeneID:66002 | Uniprot_SwissProt_Accession:Q9HCS2].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 30, + "assayName": "NVS_ADME_hCYP4F12", + "assayDesc": "NVS_ADME_hCYP4F12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 434, + "geneName": "cytochrome P450, family 4, subfamily F, polypeptide 12", + "description": null, + "geneSymbol": "CYP4F12", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 66002, + "officialSymbol": "CYP4F12", + "officialFullName": "cytochrome P450, family 4, subfamily F, polypeptide 12", + "uniprotAccessionNumber": "Q9HCS2" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 351, + "assayComponentEndpointName": "NVS_ADME_rCYP1A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "ellipticine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 217, + "assayComponentName": "NVS_ADME_rCYP1A1", + "assayComponentDesc": "NVS_ADME_rCYP1A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP1A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 1, subfamily a, polypeptide 1 [GeneSymbol:Cyp1a1 | GeneID:24296 | Uniprot_SwissProt_Accession:P00185].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Resorufin Benzyl Ether (BzRes)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 31, + "assayName": "NVS_ADME_rCYP1A1", + "assayDesc": "NVS_ADME_rCYP1A1 is a biochemical, single-readout assay that uses extracted gene-proteins from baculovirus-insect cells in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "baculovirus-insect cells", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 384, + "geneName": "cytochrome P450, family 1, subfamily a, polypeptide 1", + "description": null, + "geneSymbol": "Cyp1a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24296, + "officialSymbol": "Cyp1a1", + "officialFullName": "cytochrome P450, family 1, subfamily a, polypeptide 1", + "uniprotAccessionNumber": "P00185" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 353, + "assayComponentEndpointName": "NVS_ADME_rCYP1A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP1A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Alpha-Naphthoflavone", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 218, + "assayComponentName": "NVS_ADME_rCYP1A2", + "assayComponentDesc": "NVS_ADME_rCYP1A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP1A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 1, subfamily a, polypeptide 2 [GeneSymbol:Cyp1a2 | GeneID:24297 | Uniprot_SwissProt_Accession:P04799].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-ethoxy-3-cyanocoumarin (CEC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 32, + "assayName": "NVS_ADME_rCYP1A2", + "assayDesc": "NVS_ADME_rCYP1A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 385, + "geneName": "cytochrome P450, family 1, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp1a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24297, + "officialSymbol": "Cyp1a2", + "officialFullName": "cytochrome P450, family 1, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P04799" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 355, + "assayComponentEndpointName": "NVS_ADME_rCYP2A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 219, + "assayComponentName": "NVS_ADME_rCYP2A1", + "assayComponentDesc": "NVS_ADME_rCYP2A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMCC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily a, polypeptide 1 [GeneSymbol:Cyp2a1 | GeneID:24894 | Uniprot_SwissProt_Accession:P11711].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 33, + "assayName": "NVS_ADME_rCYP2A1", + "assayDesc": "NVS_ADME_rCYP2A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 396, + "geneName": "cytochrome P450, family 2, subfamily a, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24894, + "officialSymbol": "Cyp2a1", + "officialFullName": "cytochrome P450, family 2, subfamily a, polypeptide 1", + "uniprotAccessionNumber": "P11711" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "", + "pmid": 0, + "title": "High throughput screening for inhibition of cytochrome P450 metabolism", + "author": "Crespi CL, Miller VP, and Penman BW", + "citation": "Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8: 457-471.", + "otherId": "0", + "citationId": 203, + "otherSource": "" + } + }, + { + "aeid": 357, + "assayComponentEndpointName": "NVS_ADME_rCYP2A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole;Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 220, + "assayComponentName": "NVS_ADME_rCYP2A2", + "assayComponentDesc": "NVS_ADME_rCYP2A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily a, polypeptide 2 [GeneSymbol:Cyp2a2 | GeneID:24895 | Uniprot_SwissProt_Accession:P15149].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 34, + "assayName": "NVS_ADME_rCYP2A2", + "assayDesc": "NVS_ADME_rCYP2A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.2 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.2, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 397, + "geneName": "cytochrome P450, family 2, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp2a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24895, + "officialSymbol": "Cyp2a2", + "officialFullName": "cytochrome P450, family 2, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P15149" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 359, + "assayComponentEndpointName": "NVS_ADME_rCYP2B1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 221, + "assayComponentName": "NVS_ADME_rCYP2B1", + "assayComponentDesc": "NVS_ADME_rCYP2B1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2B1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily b, polypeptide 1 [GeneSymbol:Cyp2b1 | GeneID:24300 | Uniprot_SwissProt_Accession:P00176].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 35, + "assayName": "NVS_ADME_rCYP2B1", + "assayDesc": "NVS_ADME_rCYP2B1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 386, + "geneName": "cytochrome P450, family 2, subfamily b, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2b1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 24300, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P00176" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 361, + "assayComponentEndpointName": "NVS_ADME_rCYP2C11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 222, + "assayComponentName": "NVS_ADME_rCYP2C11", + "assayComponentDesc": "NVS_ADME_rCYP2C11 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, subfamily 2, polypeptide 11 [GeneSymbol:Cyp2c11 | GeneID:29277 | Uniprot_SwissProt_Accession:P08683].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 36, + "assayName": "NVS_ADME_rCYP2C11", + "assayDesc": "NVS_ADME_rCYP2C11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 418, + "geneName": "cytochrome P450, subfamily 2, polypeptide 11", + "description": null, + "geneSymbol": "Cyp2c11", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 29277, + "officialSymbol": "Cyp2c11", + "officialFullName": "cytochrome P450, subfamily 2, polypeptide 11", + "uniprotAccessionNumber": "P08683" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 363, + "assayComponentEndpointName": "NVS_ADME_rCYP2C12", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C12, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tranylcypromine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 223, + "assayComponentName": "NVS_ADME_rCYP2C12", + "assayComponentDesc": "NVS_ADME_rCYP2C12 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C12 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMCC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily c, polypeptide 12 [GeneSymbol:Cyp2c12 | GeneID:25011 | Uniprot_SwissProt_Accession:P11510].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 37, + "assayName": "NVS_ADME_rCYP2C12", + "assayDesc": "NVS_ADME_rCYP2C12 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 399, + "geneName": "cytochrome P450, family 2, subfamily c, polypeptide 12", + "description": null, + "geneSymbol": "Cyp2c12", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25011, + "officialSymbol": "Cyp2c12", + "officialFullName": "cytochrome P450, family 2, subfamily c, polypeptide 12", + "uniprotAccessionNumber": "P11510" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 365, + "assayComponentEndpointName": "NVS_ADME_rCYP2C13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Clotrimazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 224, + "assayComponentName": "NVS_ADME_rCYP2C13", + "assayComponentDesc": "NVS_ADME_rCYP2C13 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily c, polypeptide 13 [GeneSymbol:Cyp2c13 | GeneID:171521 | Uniprot_SwissProt_Accession:P20814].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 38, + "assayName": "NVS_ADME_rCYP2C13", + "assayDesc": "NVS_ADME_rCYP2C13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 445, + "geneName": "cytochrome P450, family 2, subfamily c, polypeptide 13", + "description": "provisional", + "geneSymbol": "Cyp2c13", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 171521, + "officialSymbol": null, + "officialFullName": null, + "uniprotAccessionNumber": "P20814" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7744763", + "pmid": 7744763, + "title": "Characterization of orphan nuclear receptor binding elements in sex-differentiated members of the CYP2C gene family expressed in rat liver", + "author": "Ström A, Westin S, Eguchi H, Gustafsson JA, Mode A", + "citation": "Ström A, Westin S, Eguchi H, Gustafsson JA, Mode A. Characterization of orphan nuclear receptor binding elements in sex-differentiated members of the CYP2C gene family expressed in rat liver. J Biol Chem. 1995 May 12;270(19):11276-81. PubMed PMID: 7744763.", + "otherId": "0", + "citationId": 146, + "otherSource": "" + } + }, + { + "aeid": 367, + "assayComponentEndpointName": "NVS_ADME_rCYP2C6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ketoconazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 225, + "assayComponentName": "NVS_ADME_rCYP2C6", + "assayComponentDesc": "NVS_ADME_rCYP2C6 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2C6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 [GeneSymbol:Cyp2c6v1 | GeneID:293989 | Uniprot_SwissProt_Accession:P05178].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 39, + "assayName": "NVS_ADME_rCYP2C6", + "assayDesc": "NVS_ADME_rCYP2C6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 453, + "geneName": "cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1", + "description": null, + "geneSymbol": "Cyp2c6v1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 293989, + "officialSymbol": "Cyp2c6v1", + "officialFullName": "cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1", + "uniprotAccessionNumber": "P05178" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 369, + "assayComponentEndpointName": "NVS_ADME_rCYP2D1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 226, + "assayComponentName": "NVS_ADME_rCYP2D1", + "assayComponentDesc": "NVS_ADME_rCYP2D1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2D1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBF + NADPH --> fluorescein + NADP+] involving the key substrate [Dibenzyl Fluorescein (DBF)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily d, polypeptide 1 [GeneSymbol:Cyp2d1 | GeneID:266684 | Uniprot_SwissProt_Accession:P10633].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Dibenzyl Fluorescein (DBF)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 40, + "assayName": "NVS_ADME_rCYP2D1", + "assayDesc": "NVS_ADME_rCYP2D1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 448, + "geneName": "cytochrome P450, family 2, subfamily d, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2d1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 266684, + "officialSymbol": "Cyp2d1", + "officialFullName": "cytochrome P450, family 2, subfamily d, polypeptide 1", + "uniprotAccessionNumber": "P10633" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 371, + "assayComponentEndpointName": "NVS_ADME_rCYP2D2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Propranolol HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 227, + "assayComponentName": "NVS_ADME_rCYP2D2", + "assayComponentDesc": "NVS_ADME_rCYP2D2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2D2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:AMMC + NADPH --> AHMC + NADP+] involving the key substrate [3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily d, polypeptide 2 [GeneSymbol:Cyp2d2 | GeneID:25053 | Uniprot_SwissProt_Accession:P10634].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 41, + "assayName": "NVS_ADME_rCYP2D2", + "assayDesc": "NVS_ADME_rCYP2D2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.75 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.75, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 401, + "geneName": "cytochrome P450, family 2, subfamily d, polypeptide 2", + "description": null, + "geneSymbol": "Cyp2d2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25053, + "officialSymbol": "Cyp2d2", + "officialFullName": "cytochrome P450, family 2, subfamily d, polypeptide 2", + "uniprotAccessionNumber": "P10634" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 373, + "assayComponentEndpointName": "NVS_ADME_rCYP2E1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP2E1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "chlormethiazole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 228, + "assayComponentName": "NVS_ADME_rCYP2E1", + "assayComponentDesc": "NVS_ADME_rCYP2E1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP2E1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily e, polypeptide 1 [GeneSymbol:Cyp2e1 | GeneID:25086 | Uniprot_SwissProt_Accession:P05182].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-methoxy-4-trifluoromethylcoumarin (MFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 42, + "assayName": "NVS_ADME_rCYP2E1", + "assayDesc": "NVS_ADME_rCYP2E1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 403, + "geneName": "cytochrome P450, family 2, subfamily e, polypeptide 1", + "description": null, + "geneSymbol": "Cyp2e1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25086, + "officialSymbol": "Cyp2e1", + "officialFullName": "cytochrome P450, family 2, subfamily e, polypeptide 1", + "uniprotAccessionNumber": "P05182" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 375, + "assayComponentEndpointName": "NVS_ADME_rCYP3A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-) Verapamil HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 229, + "assayComponentName": "NVS_ADME_rCYP3A1", + "assayComponentDesc": "NVS_ADME_rCYP3A1 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP3A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 [GeneSymbol:Cyp3a23/3a1 | GeneID:25642 | Uniprot_SwissProt_Accession:P04800].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 43, + "assayName": "NVS_ADME_rCYP3A1", + "assayDesc": "NVS_ADME_rCYP3A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 412, + "geneName": "cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1", + "description": null, + "geneSymbol": "Cyp3a23/3a1", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 25642, + "officialSymbol": "Cyp3a23/3a1", + "officialFullName": "cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1", + "uniprotAccessionNumber": "P04800" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 377, + "assayComponentEndpointName": "NVS_ADME_rCYP3A2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive analysis fitting direction relative to Acetonitrile as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "(+/-) Verapamil HCl", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "cyp", + "intendedTargetFamilySub": "xenobiotic metabolism", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 230, + "assayComponentName": "NVS_ADME_rCYP3A2", + "assayComponentDesc": "NVS_ADME_rCYP3A2 is one of one assay component(s) measured or calculated from the NVS_ADME_rCYP3A2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-benzyloxy-4-trifluoromethylcoumarin (BFC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 3, subfamily a, polypeptide 2 [GeneSymbol:Cyp3a2 | GeneID:266682 | Uniprot_SwissProt_Accession:P05183].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-benzyloxy-4-trifluoromethylcoumarin (BFC)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 44, + "assayName": "NVS_ADME_rCYP3A2", + "assayDesc": "NVS_ADME_rCYP3A2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.5 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.5, + "organismId": 10116, + "organism": "rat", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "Acetonitrile", + "dilutionSolventPercentMax": 2.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 447, + "geneName": "cytochrome P450, family 3, subfamily a, polypeptide 2", + "description": null, + "geneSymbol": "Cyp3a2", + "organismId": 3, + "trackStatus": "live", + "entrezGeneId": 266682, + "officialSymbol": "Cyp3a2", + "officialFullName": "cytochrome P450, family 3, subfamily a, polypeptide 2", + "uniprotAccessionNumber": "P05183" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/12065444", + "pmid": 12065444, + "title": "Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4", + "author": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL", + "citation": "Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002 Jul;30(7):845-52. PubMed PMID: 12065444.", + "otherId": "0", + "citationId": 191, + "otherSource": "" + } + }, + { + "aeid": 379, + "assayComponentEndpointName": "NVS_ENZ_hAbl", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAbl was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAbl, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 231, + "assayComponentName": "NVS_ENZ_hAbl", + "assayComponentDesc": "NVS_ENZ_hAbl is one of one assay component(s) measured or calculated from the NVS_ENZ_hAbl assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human ABL proto-oncogene 1, non-receptor tyrosine kinase [GeneSymbol:ABL1 | GeneID:25 | Uniprot_SwissProt_Accession:P00519].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 45, + "assayName": "NVS_ENZ_hAbl", + "assayDesc": "NVS_ENZ_hAbl is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 1, + "geneName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "description": null, + "geneSymbol": "ABL1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 25, + "officialSymbol": "ABL1", + "officialFullName": "ABL proto-oncogene 1, non-receptor tyrosine kinase", + "uniprotAccessionNumber": "P00519" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6304726", + "pmid": 6304726, + "title": "Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity", + "author": "Reddy EP, Smith MJ, Srinivasan A", + "citation": "Reddy EP, Smith MJ, Srinivasan A. Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3623-7. PubMed PMID: 6304726; PubMed Central PMCID: PMC394102.", + "otherId": "0", + "citationId": 118, + "otherSource": "" + } + }, + { + "aeid": 381, + "assayComponentEndpointName": "NVS_ENZ_hAChE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAChE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAChE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is acetylcholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "acetylcholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 232, + "assayComponentName": "NVS_ENZ_hAChE", + "assayComponentDesc": "NVS_ENZ_hAChE is one of one assay component(s) measured or calculated from the NVS_ENZ_hAChE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrate [acetylthiocholine] are indicative of changes in enzyme function and kinetics for the human acetylcholinesterase (Yt blood group) [GeneSymbol:ACHE | GeneID:43 | Uniprot_SwissProt_Accession:P22303].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "acetylthiocholine", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 46, + "assayName": "NVS_ENZ_hAChE", + "assayDesc": "NVS_ENZ_hAChE is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0.33 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.33, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 2, + "geneName": "acetylcholinesterase (Yt blood group)", + "description": null, + "geneSymbol": "ACHE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 43, + "officialSymbol": "ACHE", + "officialFullName": "acetylcholinesterase (Yt blood group)", + "uniprotAccessionNumber": "P22303" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 383, + "assayComponentEndpointName": "NVS_ENZ_hACP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hACP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hACP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is acid phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "acid phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 233, + "assayComponentName": "NVS_ENZ_hACP1", + "assayComponentDesc": "NVS_ENZ_hACP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hACP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human acid phosphatase 1, soluble [GeneSymbol:ACP1 | GeneID:52 | Uniprot_SwissProt_Accession:P24666].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled phosphopeptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 47, + "assayName": "NVS_ENZ_hACP1", + "assayDesc": "NVS_ENZ_hACP1 is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 384-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 5, + "geneName": "acid phosphatase 1, soluble", + "description": null, + "geneSymbol": "ACP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 52, + "officialSymbol": "ACP1", + "officialFullName": "acid phosphatase 1, soluble", + "uniprotAccessionNumber": "P24666" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 385, + "assayComponentEndpointName": "NVS_ENZ_hAKT1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 234, + "assayComponentName": "NVS_ENZ_hAKT1", + "assayComponentDesc": "NVS_ENZ_hAKT1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 1 [GeneSymbol:AKT1 | GeneID:207 | Uniprot_SwissProt_Accession:P31749].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 48, + "assayName": "NVS_ENZ_hAKT1", + "assayDesc": "NVS_ENZ_hAKT1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 22, + "geneName": "v-akt murine thymoma viral oncogene homolog 1", + "description": null, + "geneSymbol": "AKT1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 207, + "officialSymbol": "AKT1", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 1", + "uniprotAccessionNumber": "P31749" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 387, + "assayComponentEndpointName": "NVS_ENZ_hAKT2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 235, + "assayComponentName": "NVS_ENZ_hAKT2", + "assayComponentDesc": "NVS_ENZ_hAKT2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 2 [GeneSymbol:AKT2 | GeneID:208 | Uniprot_SwissProt_Accession:P31751].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 49, + "assayName": "NVS_ENZ_hAKT2", + "assayDesc": "NVS_ENZ_hAKT2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 23, + "geneName": "v-akt murine thymoma viral oncogene homolog 2", + "description": null, + "geneSymbol": "AKT2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 208, + "officialSymbol": "AKT2", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 2", + "uniprotAccessionNumber": "P31751" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 389, + "assayComponentEndpointName": "NVS_ENZ_hAKT3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAKT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAKT3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 236, + "assayComponentName": "NVS_ENZ_hAKT3", + "assayComponentDesc": "NVS_ENZ_hAKT3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAKT3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human v-akt murine thymoma viral oncogene homolog 3 [GeneSymbol:AKT3 | GeneID:10000 | Uniprot_SwissProt_Accession:Q9Y243].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 50, + "assayName": "NVS_ENZ_hAKT3", + "assayDesc": "NVS_ENZ_hAKT3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 359, + "geneName": "v-akt murine thymoma viral oncogene homolog 3", + "description": null, + "geneSymbol": "AKT3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10000, + "officialSymbol": "AKT3", + "officialFullName": "v-akt murine thymoma viral oncogene homolog 3", + "uniprotAccessionNumber": "Q9Y243" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 391, + "assayComponentEndpointName": "NVS_ENZ_hAMPKa1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 237, + "assayComponentName": "NVS_ENZ_hAMPKa1", + "assayComponentDesc": "NVS_ENZ_hAMPKa1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hAMPKa1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, AMP-activated, alpha 1 catalytic subunit [GeneSymbol:PRKAA1 | GeneID:5562 | Uniprot_SwissProt_Accession:Q13131].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 51, + "assayName": "NVS_ENZ_hAMPKa1", + "assayDesc": "NVS_ENZ_hAMPKa1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 255, + "geneName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "description": null, + "geneSymbol": "PRKAA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5562, + "officialSymbol": "PRKAA1", + "officialFullName": "protein kinase, AMP-activated, alpha 1 catalytic subunit", + "uniprotAccessionNumber": "Q13131" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 393, + "assayComponentEndpointName": "NVS_ENZ_hAurA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hAurA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 238, + "assayComponentName": "NVS_ENZ_hAurA", + "assayComponentDesc": "NVS_ENZ_hAurA is one of one assay component(s) measured or calculated from the NVS_ENZ_hAurA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human aurora kinase A [GeneSymbol:AURKA | GeneID:6790 | Uniprot_SwissProt_Accession:O14965].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 52, + "assayName": "NVS_ENZ_hAurA", + "assayDesc": "NVS_ENZ_hAurA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 306, + "geneName": "aurora kinase A", + "description": null, + "geneSymbol": "AURKA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 6790, + "officialSymbol": "AURKA", + "officialFullName": "aurora kinase A", + "uniprotAccessionNumber": "O14965" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 395, + "assayComponentEndpointName": "NVS_ENZ_hBACE", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hBACE was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is aspartate protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "OM99-02", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "aspartate protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 239, + "assayComponentName": "NVS_ENZ_hBACE", + "assayComponentDesc": "NVS_ENZ_hBACE is one of one assay component(s) measured or calculated from the NVS_ENZ_hBACE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Rh-EVNLDAEFK-Quencher (weak fluorescence)+BACE --> Rh-ENVL(increased fluorescence) + DAEFK-Quencher] involving the key substrate [Rh-EVNLDAEFK-Quencher] are indicative of changes in enzyme function and kinetics for the human beta-site APP-cleaving enzyme 1 [GeneSymbol:BACE1 | GeneID:23621 | Uniprot_SwissProt_Accession:P56817].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Rh-EVNLDAEFK-Quencher", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 53, + "assayName": "NVS_ENZ_hBACE", + "assayDesc": "NVS_ENZ_hBACE is a biochemical, single-readout assay that uses extracted gene-proteins from SF9 in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "SF9", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 378, + "geneName": "beta-site APP-cleaving enzyme 1", + "description": null, + "geneSymbol": "BACE1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 23621, + "officialSymbol": "BACE1", + "officialFullName": "beta-site APP-cleaving enzyme 1", + "uniprotAccessionNumber": "P56817" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10591214", + "pmid": 10591214, + "title": "Purification and cloning of amyloid precursor protein beta-secretase from human brain", + "author": "Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V", + "citation": "Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999 Dec 2;402(6761):537-40. PubMed PMID: 10591214.", + "otherId": "0", + "citationId": 180, + "otherSource": "" + } + }, + { + "aeid": 397, + "assayComponentEndpointName": "NVS_ENZ_hBTK", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hBTK was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hBTK, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 240, + "assayComponentName": "NVS_ENZ_hBTK", + "assayComponentDesc": "NVS_ENZ_hBTK is one of one assay component(s) measured or calculated from the NVS_ENZ_hBTK assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Bruton agammaglobulinemia tyrosine kinase [GeneSymbol:BTK | GeneID:695 | Uniprot_SwissProt_Accession:Q06187].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 54, + "assayName": "NVS_ENZ_hBTK", + "assayDesc": "NVS_ENZ_hBTK is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 36, + "geneName": "Bruton agammaglobulinemia tyrosine kinase", + "description": null, + "geneSymbol": "BTK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 695, + "officialSymbol": "BTK", + "officialFullName": "Bruton agammaglobulinemia tyrosine kinase", + "uniprotAccessionNumber": "Q06187" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 399, + "assayComponentEndpointName": "NVS_ENZ_hCASP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-YVAD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 241, + "assayComponentName": "NVS_ENZ_hCASP1", + "assayComponentDesc": "NVS_ENZ_hCASP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 1, apoptosis-related cysteine peptidase [GeneSymbol:CASP1 | GeneID:834 | Uniprot_SwissProt_Accession:P29466].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 55, + "assayName": "NVS_ENZ_hCASP1", + "assayDesc": "NVS_ENZ_hCASP1 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 39, + "geneName": "caspase 1, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 834, + "officialSymbol": "CASP1", + "officialFullName": "caspase 1, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P29466" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 401, + "assayComponentEndpointName": "NVS_ENZ_hCASP10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP10 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 242, + "assayComponentName": "NVS_ENZ_hCASP10", + "assayComponentDesc": "NVS_ENZ_hCASP10 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP10 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 10, apoptosis-related cysteine peptidase [GeneSymbol:CASP10 | GeneID:843 | Uniprot_SwissProt_Accession:Q92851].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 56, + "assayName": "NVS_ENZ_hCASP10", + "assayDesc": "NVS_ENZ_hCASP10 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 45, + "geneName": "caspase 10, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP10", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 843, + "officialSymbol": "CASP10", + "officialFullName": "caspase 10, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q92851" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 403, + "assayComponentEndpointName": "NVS_ENZ_hCASP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "z-VDVAD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 243, + "assayComponentName": "NVS_ENZ_hCASP2", + "assayComponentDesc": "NVS_ENZ_hCASP2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:VDVAD-AFC --> VDVAD + AFC] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged VDVAD] are indicative of changes in enzyme function and kinetics for the human caspase 2, apoptosis-related cysteine peptidase [GeneSymbol:CASP2 | GeneID:835 | Uniprot_SwissProt_Accession:P42575].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged VDVAD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 57, + "assayName": "NVS_ENZ_hCASP2", + "assayDesc": "NVS_ENZ_hCASP2 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 40, + "geneName": "caspase 2, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 835, + "officialSymbol": "CASP2", + "officialFullName": "caspase 2, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42575" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 405, + "assayComponentEndpointName": "NVS_ENZ_hCASP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 244, + "assayComponentName": "NVS_ENZ_hCASP3", + "assayComponentDesc": "NVS_ENZ_hCASP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DEVD-AFC --> DEVD + AFC] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged DEVD] are indicative of changes in enzyme function and kinetics for the human caspase 3, apoptosis-related cysteine peptidase [GeneSymbol:CASP3 | GeneID:836 | Uniprot_SwissProt_Accession:P42574].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged DEVD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 58, + "assayName": "NVS_ENZ_hCASP3", + "assayDesc": "NVS_ENZ_hCASP3 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 41, + "geneName": "caspase 3, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 836, + "officialSymbol": "CASP3", + "officialFullName": "caspase 3, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P42574" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 407, + "assayComponentEndpointName": "NVS_ENZ_hCASP4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-LEHD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 245, + "assayComponentName": "NVS_ENZ_hCASP4", + "assayComponentDesc": "NVS_ENZ_hCASP4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 4, apoptosis-related cysteine peptidase [GeneSymbol:CASP4 | GeneID:837 | Uniprot_SwissProt_Accession:P49662].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 59, + "assayName": "NVS_ENZ_hCASP4", + "assayDesc": "NVS_ENZ_hCASP4 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 42, + "geneName": "caspase 4, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 837, + "officialSymbol": "CASP4", + "officialFullName": "caspase 4, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P49662" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 409, + "assayComponentEndpointName": "NVS_ENZ_hCASP5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-LEHD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 246, + "assayComponentName": "NVS_ENZ_hCASP5", + "assayComponentDesc": "NVS_ENZ_hCASP5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 5, apoptosis-related cysteine peptidase [GeneSymbol:CASP5 | GeneID:838 | Uniprot_SwissProt_Accession:P51878].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 60, + "assayName": "NVS_ENZ_hCASP5", + "assayDesc": "NVS_ENZ_hCASP5 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 2 hours after chemical dosing in a 96-well plate.", + "timepointHr": 2.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 43, + "geneName": "caspase 5, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 838, + "officialSymbol": "CASP5", + "officialFullName": "caspase 5, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "P51878" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 411, + "assayComponentEndpointName": "NVS_ENZ_hCASP8", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCASP8 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCASP8, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ac-DEVD-CHO", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "cysteine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 247, + "assayComponentName": "NVS_ENZ_hCASP8", + "assayComponentDesc": "NVS_ENZ_hCASP8 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCASP8 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 8, apoptosis-related cysteine peptidase [GeneSymbol:CASP8 | GeneID:841 | Uniprot_SwissProt_Accession:Q14790].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "7-amino-4-trifluoromethylcoumarin-tagged LEHD", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 61, + "assayName": "NVS_ENZ_hCASP8", + "assayDesc": "NVS_ENZ_hCASP8 is a biochemical, single-readout assay that uses extracted gene-proteins from E. coli in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "E. coli", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 44, + "geneName": "caspase 8, apoptosis-related cysteine peptidase", + "description": null, + "geneSymbol": "CASP8", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 841, + "officialSymbol": "CASP8", + "officialFullName": "caspase 8, apoptosis-related cysteine peptidase", + "uniprotAccessionNumber": "Q14790" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9092497", + "pmid": 9092497, + "title": "Substrate specificities of caspase family proteases", + "author": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW", + "citation": "Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997 Apr 11;272(15):9677-82. PubMed PMID: 9092497.", + "otherId": "0", + "citationId": 170, + "otherSource": "" + } + }, + { + "aeid": 413, + "assayComponentEndpointName": "NVS_ENZ_hCDK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCDK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCDK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 248, + "assayComponentName": "NVS_ENZ_hCDK2", + "assayComponentDesc": "NVS_ENZ_hCDK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCDK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human cyclin-dependent kinase 2 [GeneSymbol:CDK2 | GeneID:1017 | Uniprot_SwissProt_Accession:P24941].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 62, + "assayName": "NVS_ENZ_hCDK2", + "assayDesc": "NVS_ENZ_hCDK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 55, + "geneName": "cyclin-dependent kinase 2", + "description": null, + "geneSymbol": "CDK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1017, + "officialSymbol": "CDK2", + "officialFullName": "cyclin-dependent kinase 2", + "uniprotAccessionNumber": "P24941" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 415, + "assayComponentEndpointName": "NVS_ENZ_hCDK6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCDK6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCDK6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 249, + "assayComponentName": "NVS_ENZ_hCDK6", + "assayComponentDesc": "NVS_ENZ_hCDK6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCDK6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human cyclin-dependent kinase 6 [GeneSymbol:CDK6 | GeneID:1021 | Uniprot_SwissProt_Accession:Q00534].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 63, + "assayName": "NVS_ENZ_hCDK6", + "assayDesc": "NVS_ENZ_hCDK6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 56, + "geneName": "cyclin-dependent kinase 6", + "description": null, + "geneSymbol": "CDK6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1021, + "officialSymbol": "CDK6", + "officialFullName": "cyclin-dependent kinase 6", + "uniprotAccessionNumber": "Q00534" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 417, + "assayComponentEndpointName": "NVS_ENZ_hCHK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCHK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCHK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 250, + "assayComponentName": "NVS_ENZ_hCHK1", + "assayComponentDesc": "NVS_ENZ_hCHK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCHK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human checkpoint kinase 1 [GeneSymbol:CHEK1 | GeneID:1111 | Uniprot_SwissProt_Accession:O14757].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 64, + "assayName": "NVS_ENZ_hCHK1", + "assayDesc": "NVS_ENZ_hCHK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 60, + "geneName": "checkpoint kinase 1", + "description": null, + "geneSymbol": "CHEK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1111, + "officialSymbol": "CHEK1", + "officialFullName": "checkpoint kinase 1", + "uniprotAccessionNumber": "O14757" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 419, + "assayComponentEndpointName": "NVS_ENZ_hCK1a", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK1a was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK1a, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-iodotubericidin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 251, + "assayComponentName": "NVS_ENZ_hCK1a", + "assayComponentDesc": "NVS_ENZ_hCK1a is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK1a assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 1, alpha 1 [GeneSymbol:CSNK1A1 | GeneID:1452 | Uniprot_SwissProt_Accession:P48729].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 65, + "assayName": "NVS_ENZ_hCK1a", + "assayDesc": "NVS_ENZ_hCK1a is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 74, + "geneName": "casein kinase 1, alpha 1", + "description": null, + "geneSymbol": "CSNK1A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1452, + "officialSymbol": "CSNK1A1", + "officialFullName": "casein kinase 1, alpha 1", + "uniprotAccessionNumber": "P48729" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 421, + "assayComponentEndpointName": "NVS_ENZ_hCK1D", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK1D was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK1D, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "5-iodotubericidin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 252, + "assayComponentName": "NVS_ENZ_hCK1D", + "assayComponentDesc": "NVS_ENZ_hCK1D is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK1D assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 1, delta [GeneSymbol:CSNK1D | GeneID:1453 | Uniprot_SwissProt_Accession:P48730].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 66, + "assayName": "NVS_ENZ_hCK1D", + "assayDesc": "NVS_ENZ_hCK1D is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 75, + "geneName": "casein kinase 1, delta", + "description": null, + "geneSymbol": "CSNK1D", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1453, + "officialSymbol": "CSNK1D", + "officialFullName": "casein kinase 1, delta", + "uniprotAccessionNumber": "P48730" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 423, + "assayComponentEndpointName": "NVS_ENZ_hCK2a2b2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCK2a2b2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 253, + "assayComponentName": "NVS_ENZ_hCK2a2b2", + "assayComponentDesc": "NVS_ENZ_hCK2a2b2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK2a2b2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 2, alpha 1 polypeptide [GeneSymbol:CSNK2A1 | GeneID:1457 | Uniprot_SwissProt_Accession:Q8NEV1].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 67, + "assayName": "NVS_ENZ_hCK2a2b2", + "assayDesc": "NVS_ENZ_hCK2a2b2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 76, + "geneName": "casein kinase 2, alpha 1 polypeptide", + "description": null, + "geneSymbol": "CSNK2A1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1457, + "officialSymbol": "CSNK2A1", + "officialFullName": "casein kinase 2, alpha 1 polypeptide", + "uniprotAccessionNumber": "Q8NEV1" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 425, + "assayComponentEndpointName": "NVS_ENZ_hCSF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hCSF1R was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hCSF1R, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 254, + "assayComponentName": "NVS_ENZ_hCSF1R", + "assayComponentDesc": "NVS_ENZ_hCSF1R is one of one assay component(s) measured or calculated from the NVS_ENZ_hCSF1R assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human colony stimulating factor 1 receptor [GeneSymbol:CSF1R | GeneID:1436 | Uniprot_SwissProt_Accession:P07333].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 68, + "assayName": "NVS_ENZ_hCSF1R", + "assayDesc": "NVS_ENZ_hCSF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 73, + "geneName": "colony stimulating factor 1 receptor", + "description": null, + "geneSymbol": "CSF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1436, + "officialSymbol": "CSF1R", + "officialFullName": "colony stimulating factor 1 receptor", + "uniprotAccessionNumber": "P07333" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 427, + "assayComponentEndpointName": "NVS_ENZ_hDUSP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ammonium Molybdate (NH4MoO4)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "phosphatase", + "intendedTargetFamilySub": "dual-specific phosphatase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 255, + "assayComponentName": "NVS_ENZ_hDUSP3", + "assayComponentDesc": "NVS_ENZ_hDUSP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hDUSP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DiFMUP(non-fluorescent) --> DiFMU] involving the key substrate [6,8-difluoro-4-methylumbelliferyl] are indicative of changes in enzyme function and kinetics for the human dual specificity phosphatase 3 [GeneSymbol:DUSP3 | GeneID:1845 | Uniprot_SwissProt_Accession:P51452].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "6,8-difluoro-4-methylumbelliferyl", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 69, + "assayName": "NVS_ENZ_hDUSP3", + "assayDesc": "NVS_ENZ_hDUSP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 102, + "geneName": "dual specificity phosphatase 3", + "description": null, + "geneSymbol": "DUSP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1845, + "officialSymbol": "DUSP3", + "officialFullName": "dual specificity phosphatase 3", + "uniprotAccessionNumber": "P51452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/7852302", + "pmid": 7852302, + "title": "Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR", + "author": "Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA", + "citation": "Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem. 1995 Feb 10;270(6):2435-8. PubMed PMID: 7852302.", + "otherId": "0", + "citationId": 147, + "otherSource": "" + } + }, + { + "aeid": 429, + "assayComponentEndpointName": "NVS_ENZ_hEGFR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEGFR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEGFR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 256, + "assayComponentName": "NVS_ENZ_hEGFR", + "assayComponentDesc": "NVS_ENZ_hEGFR is one of one assay component(s) measured or calculated from the NVS_ENZ_hEGFR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human epidermal growth factor receptor [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 70, + "assayName": "NVS_ENZ_hEGFR", + "assayDesc": "NVS_ENZ_hEGFR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 108, + "geneName": "epidermal growth factor receptor", + "description": null, + "geneSymbol": "EGFR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1956, + "officialSymbol": "EGFR", + "officialFullName": "epidermal growth factor receptor", + "uniprotAccessionNumber": "P00533" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 431, + "assayComponentEndpointName": "NVS_ENZ_hElastase", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hElastase was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Ursolic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "serine protease", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 257, + "assayComponentName": "NVS_ENZ_hElastase", + "assayComponentDesc": "NVS_ENZ_hElastase is one of one assay component(s) measured or calculated from the NVS_ENZ_hElastase assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Spectrophotometry technology.", + "assayComponentTargetDesc": "Changes to absorbance signals produced from an enzymatic reaction involving the key substrate [MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide] are indicative of changes in enzyme function and kinetics for the human elastase, neutrophil expressed [GeneSymbol:ELANE | GeneID:1991 | Uniprot_SwissProt_Accession:P08246].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Absorbance", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 71, + "assayName": "NVS_ENZ_hElastase", + "assayDesc": "NVS_ENZ_hElastase is a biochemical, single-readout assay that uses extracted gene-proteins from Human neutrophils in a cell-free assay. Measurements were taken 1.5 hours after chemical dosing in a 96-well plate.", + "timepointHr": 1.5, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human neutrophils", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 111, + "geneName": "elastase, neutrophil expressed", + "description": null, + "geneSymbol": "ELANE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1991, + "officialSymbol": "ELANE", + "officialFullName": "elastase, neutrophil expressed", + "uniprotAccessionNumber": "P08246" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/9103531", + "pmid": 9103531, + "title": "Inhibition by boswellic acids of human leukocyte elastase", + "author": "Safayhi H, Rall B, Sailer ER, Ammon HP", + "citation": "Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997 Apr;281(1):460-3. PubMed PMID: 9103531.", + "otherId": "0", + "citationId": 171, + "otherSource": "" + } + }, + { + "aeid": 433, + "assayComponentEndpointName": "NVS_ENZ_hEphA1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphA1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 258, + "assayComponentName": "NVS_ENZ_hEphA1", + "assayComponentDesc": "NVS_ENZ_hEphA1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphA1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor A1 [GeneSymbol:EPHA1 | GeneID:2041 | Uniprot_SwissProt_Accession:P21709].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 72, + "assayName": "NVS_ENZ_hEphA1", + "assayDesc": "NVS_ENZ_hEphA1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 113, + "geneName": "EPH receptor A1", + "description": null, + "geneSymbol": "EPHA1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2041, + "officialSymbol": "EPHA1", + "officialFullName": "EPH receptor A1", + "uniprotAccessionNumber": "P21709" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 435, + "assayComponentEndpointName": "NVS_ENZ_hEphA2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphA2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 259, + "assayComponentName": "NVS_ENZ_hEphA2", + "assayComponentDesc": "NVS_ENZ_hEphA2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphA2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor A2 [GeneSymbol:EPHA2 | GeneID:1969 | Uniprot_SwissProt_Accession:P29317].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 73, + "assayName": "NVS_ENZ_hEphA2", + "assayDesc": "NVS_ENZ_hEphA2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 110, + "geneName": "EPH receptor A2", + "description": null, + "geneSymbol": "EPHA2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1969, + "officialSymbol": "EPHA2", + "officialFullName": "EPH receptor A2", + "uniprotAccessionNumber": "P29317" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 437, + "assayComponentEndpointName": "NVS_ENZ_hEphB1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphB1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphB1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 260, + "assayComponentName": "NVS_ENZ_hEphB1", + "assayComponentDesc": "NVS_ENZ_hEphB1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphB1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor B1 [GeneSymbol:EPHB1 | GeneID:2047 | Uniprot_SwissProt_Accession:P54762].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 74, + "assayName": "NVS_ENZ_hEphB1", + "assayDesc": "NVS_ENZ_hEphB1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 114, + "geneName": "EPH receptor B1", + "description": null, + "geneSymbol": "EPHB1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2047, + "officialSymbol": "EPHB1", + "officialFullName": "EPH receptor B1", + "uniprotAccessionNumber": "P54762" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 439, + "assayComponentEndpointName": "NVS_ENZ_hEphB2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hEphB2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hEphB2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 261, + "assayComponentName": "NVS_ENZ_hEphB2", + "assayComponentDesc": "NVS_ENZ_hEphB2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hEphB2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human EPH receptor B2 [GeneSymbol:EPHB2 | GeneID:2048 | Uniprot_SwissProt_Accession:P29323].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 75, + "assayName": "NVS_ENZ_hEphB2", + "assayDesc": "NVS_ENZ_hEphB2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 115, + "geneName": "EPH receptor B2", + "description": null, + "geneSymbol": "EPHB2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2048, + "officialSymbol": "EPHB2", + "officialFullName": "EPH receptor B2", + "uniprotAccessionNumber": "P29323" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 441, + "assayComponentEndpointName": "NVS_ENZ_hES", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hES was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is pseudocholinesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "physostigmine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "pseudocholinesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 262, + "assayComponentName": "NVS_ENZ_hES", + "assayComponentDesc": "NVS_ENZ_hES is one of one assay component(s) measured or calculated from the NVS_ENZ_hES assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.", + "assayComponentTargetDesc": "Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the human butyrylcholinesterase [GeneSymbol:BCHE | GeneID:590 | Uniprot_SwissProt_Accession:P06276].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Absorbance ", + "detectionTechnologyTypeSub": "Colorimetric", + "detectionTechnology": "Spectrophotometry", + "keyAssayReagentType": "substrate;substrate", + "keyAssayReagent": "acetylthiocholine;Ellman\"s reagent (DTNB)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 76, + "assayName": "NVS_ENZ_hES", + "assayDesc": "NVS_ENZ_hES is a biochemical, single-readout assay that uses extracted gene-proteins from Human plasma in a cell-free assay. Measurements were taken 0.25 hour after chemical dosing in a 96-well plate.", + "timepointHr": 0.25, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "Human plasma", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 32, + "geneName": "butyrylcholinesterase", + "description": null, + "geneSymbol": "BCHE", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 590, + "officialSymbol": "BCHE", + "officialFullName": "butyrylcholinesterase", + "uniprotAccessionNumber": "P06276" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/13726518", + "pmid": 13726518, + "title": "A new and rapid colorimetric determination of acetylcholinesterase activity", + "author": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM", + "citation": "ELLMAN GL, COURTNEY KD, ANDRES V Jr, FEATHER-STONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. PubMed PMID: 13726518.", + "otherId": "0", + "citationId": 197, + "otherSource": "" + } + }, + { + "aeid": 443, + "assayComponentEndpointName": "NVS_ENZ_hFGFR1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFGFR1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "K252a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 263, + "assayComponentName": "NVS_ENZ_hFGFR1", + "assayComponentDesc": "NVS_ENZ_hFGFR1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hFGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fibroblast growth factor receptor 1 [GeneSymbol:FGFR1 | GeneID:2260 | Uniprot_SwissProt_Accession:P11362].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 77, + "assayName": "NVS_ENZ_hFGFR1", + "assayDesc": "NVS_ENZ_hFGFR1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 126, + "geneName": "fibroblast growth factor receptor 1", + "description": null, + "geneSymbol": "FGFR1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2260, + "officialSymbol": "FGFR1", + "officialFullName": "fibroblast growth factor receptor 1", + "uniprotAccessionNumber": "P11362" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 445, + "assayComponentEndpointName": "NVS_ENZ_hFGFR3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFGFR3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 264, + "assayComponentName": "NVS_ENZ_hFGFR3", + "assayComponentDesc": "NVS_ENZ_hFGFR3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hFGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fibroblast growth factor receptor 3 [GeneSymbol:FGFR3 | GeneID:2261 | Uniprot_SwissProt_Accession:P22607].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 78, + "assayName": "NVS_ENZ_hFGFR3", + "assayDesc": "NVS_ENZ_hFGFR3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 127, + "geneName": "fibroblast growth factor receptor 3", + "description": null, + "geneSymbol": "FGFR3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2261, + "officialSymbol": "FGFR3", + "officialFullName": "fibroblast growth factor receptor 3", + "uniprotAccessionNumber": "P22607" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 447, + "assayComponentEndpointName": "NVS_ENZ_hFyn", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hFyn was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hFyn, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 265, + "assayComponentName": "NVS_ENZ_hFyn", + "assayComponentDesc": "NVS_ENZ_hFyn is one of one assay component(s) measured or calculated from the NVS_ENZ_hFyn assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human FYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:FYN | GeneID:2534 | Uniprot_SwissProt_Accession:P06241].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 79, + "assayName": "NVS_ENZ_hFyn", + "assayDesc": "NVS_ENZ_hFyn is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 137, + "geneName": "FYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "FYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2534, + "officialSymbol": "FYN", + "officialFullName": "FYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06241" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 449, + "assayComponentEndpointName": "NVS_ENZ_hGSK3b", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hGSK3b was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hGSK3b, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 266, + "assayComponentName": "NVS_ENZ_hGSK3b", + "assayComponentDesc": "NVS_ENZ_hGSK3b is one of one assay component(s) measured or calculated from the NVS_ENZ_hGSK3b assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human glycogen synthase kinase 3 beta [GeneSymbol:GSK3B | GeneID:2932 | Uniprot_SwissProt_Accession:P49841].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 80, + "assayName": "NVS_ENZ_hGSK3b", + "assayDesc": "NVS_ENZ_hGSK3b is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 146, + "geneName": "glycogen synthase kinase 3 beta", + "description": null, + "geneSymbol": "GSK3B", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 2932, + "officialSymbol": "GSK3B", + "officialFullName": "glycogen synthase kinase 3 beta", + "uniprotAccessionNumber": "P49841" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 451, + "assayComponentEndpointName": "NVS_ENZ_hHDAC3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hHDAC3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 267, + "assayComponentName": "NVS_ENZ_hHDAC3", + "assayComponentDesc": "NVS_ENZ_hHDAC3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hHDAC3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human histone deacetylase 3 [GeneSymbol:HDAC3 | GeneID:8841 | Uniprot_SwissProt_Accession:O15379].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 81, + "assayName": "NVS_ENZ_hHDAC3", + "assayDesc": "NVS_ENZ_hHDAC3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 349, + "geneName": "histone deacetylase 3", + "description": null, + "geneSymbol": "HDAC3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8841, + "officialSymbol": "HDAC3", + "officialFullName": "histone deacetylase 3", + "uniprotAccessionNumber": "O15379" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 453, + "assayComponentEndpointName": "NVS_ENZ_hHDAC6", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is histone deacetylase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trichostatin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "hydrolase", + "intendedTargetFamilySub": "histone deacetylase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 268, + "assayComponentName": "NVS_ENZ_hHDAC6", + "assayComponentDesc": "NVS_ENZ_hHDAC6 is one of one assay component(s) measured or calculated from the NVS_ENZ_hHDAC6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human histone deacetylase 6 [GeneSymbol:HDAC6 | GeneID:10013 | Uniprot_SwissProt_Accession:Q9UBN7].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled acetylated-peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 82, + "assayName": "NVS_ENZ_hHDAC6", + "assayDesc": "NVS_ENZ_hHDAC6 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 361, + "geneName": "histone deacetylase 6", + "description": null, + "geneSymbol": "HDAC6", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10013, + "officialSymbol": "HDAC6", + "officialFullName": "histone deacetylase 6", + "uniprotAccessionNumber": "Q9UBN7" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 455, + "assayComponentEndpointName": "NVS_ENZ_hIGF1R", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIGF1R was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIGF1R, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 269, + "assayComponentName": "NVS_ENZ_hIGF1R", + "assayComponentDesc": "NVS_ENZ_hIGF1R is one of one assay component(s) measured or calculated from the NVS_ENZ_hIGF1R assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human insulin-like growth factor 1 receptor [GeneSymbol:IGF1R | GeneID:3480 | Uniprot_SwissProt_Accession:P08069].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 83, + "assayName": "NVS_ENZ_hIGF1R", + "assayDesc": "NVS_ENZ_hIGF1R is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 172, + "geneName": "insulin-like growth factor 1 receptor", + "description": null, + "geneSymbol": "IGF1R", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3480, + "officialSymbol": "IGF1R", + "officialFullName": "insulin-like growth factor 1 receptor", + "uniprotAccessionNumber": "P08069" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 457, + "assayComponentEndpointName": "NVS_ENZ_hIKKa", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIKKa was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIKKa, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 270, + "assayComponentName": "NVS_ENZ_hIKKa", + "assayComponentDesc": "NVS_ENZ_hIKKa is one of one assay component(s) measured or calculated from the NVS_ENZ_hIKKa assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human conserved helix-loop-helix ubiquitous kinase [GeneSymbol:CHUK | GeneID:1147 | Uniprot_SwissProt_Accession:O15111].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 84, + "assayName": "NVS_ENZ_hIKKa", + "assayDesc": "NVS_ENZ_hIKKa is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 67, + "geneName": "conserved helix-loop-helix ubiquitous kinase", + "description": null, + "geneSymbol": "CHUK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 1147, + "officialSymbol": "CHUK", + "officialFullName": "conserved helix-loop-helix ubiquitous kinase", + "uniprotAccessionNumber": "O15111" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 459, + "assayComponentEndpointName": "NVS_ENZ_hInsR", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hInsR was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hInsR, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 271, + "assayComponentName": "NVS_ENZ_hInsR", + "assayComponentDesc": "NVS_ENZ_hInsR is one of one assay component(s) measured or calculated from the NVS_ENZ_hInsR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human insulin receptor [GeneSymbol:INSR | GeneID:3643 | Uniprot_SwissProt_Accession:P06213].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 85, + "assayName": "NVS_ENZ_hInsR", + "assayDesc": "NVS_ENZ_hInsR is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 179, + "geneName": "insulin receptor", + "description": null, + "geneSymbol": "INSR", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3643, + "officialSymbol": "INSR", + "officialFullName": "insulin receptor", + "uniprotAccessionNumber": "P06213" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 461, + "assayComponentEndpointName": "NVS_ENZ_hIRAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hIRAK4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 272, + "assayComponentName": "NVS_ENZ_hIRAK4", + "assayComponentDesc": "NVS_ENZ_hIRAK4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hIRAK4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human interleukin-1 receptor-associated kinase 4 [GeneSymbol:IRAK4 | GeneID:51135 | Uniprot_SwissProt_Accession:Q9NWZ3].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 86, + "assayName": "NVS_ENZ_hIRAK4", + "assayDesc": "NVS_ENZ_hIRAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 425, + "geneName": "interleukin-1 receptor-associated kinase 4", + "description": null, + "geneSymbol": "IRAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 51135, + "officialSymbol": "IRAK4", + "officialFullName": "interleukin-1 receptor-associated kinase 4", + "uniprotAccessionNumber": "Q9NWZ3" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 463, + "assayComponentEndpointName": "NVS_ENZ_hJak2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hJak2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hJak2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 273, + "assayComponentName": "NVS_ENZ_hJak2", + "assayComponentDesc": "NVS_ENZ_hJak2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hJak2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human Janus kinase 2 [GeneSymbol:JAK2 | GeneID:3717 | Uniprot_SwissProt_Accession:O60674].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 87, + "assayName": "NVS_ENZ_hJak2", + "assayDesc": "NVS_ENZ_hJak2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 182, + "geneName": "Janus kinase 2", + "description": null, + "geneSymbol": "JAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3717, + "officialSymbol": "JAK2", + "officialFullName": "Janus kinase 2", + "uniprotAccessionNumber": "O60674" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 465, + "assayComponentEndpointName": "NVS_ENZ_hJNK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hJNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hJNK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 274, + "assayComponentName": "NVS_ENZ_hJNK2", + "assayComponentDesc": "NVS_ENZ_hJNK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hJNK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 9 [GeneSymbol:MAPK9 | GeneID:5601 | Uniprot_SwissProt_Accession:P45984].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 88, + "assayName": "NVS_ENZ_hJNK2", + "assayDesc": "NVS_ENZ_hJNK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 262, + "geneName": "mitogen-activated protein kinase 9", + "description": null, + "geneSymbol": "MAPK9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5601, + "officialSymbol": "MAPK9", + "officialFullName": "mitogen-activated protein kinase 9", + "uniprotAccessionNumber": "P45984" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 467, + "assayComponentEndpointName": "NVS_ENZ_hLck", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLck was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLck, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 275, + "assayComponentName": "NVS_ENZ_hLck", + "assayComponentDesc": "NVS_ENZ_hLck is one of one assay component(s) measured or calculated from the NVS_ENZ_hLck assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LCK proto-oncogene, Src family tyrosine kinase [GeneSymbol:LCK | GeneID:3932 | Uniprot_SwissProt_Accession:P06239].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 89, + "assayName": "NVS_ENZ_hLck", + "assayDesc": "NVS_ENZ_hLck is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 188, + "geneName": "LCK proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LCK", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 3932, + "officialSymbol": "LCK", + "officialFullName": "LCK proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P06239" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 469, + "assayComponentEndpointName": "NVS_ENZ_hLynA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLynA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLynA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 276, + "assayComponentName": "NVS_ENZ_hLynA", + "assayComponentDesc": "NVS_ENZ_hLynA is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:LYN | GeneID:4067 | Uniprot_SwissProt_Accession:P07948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 90, + "assayName": "NVS_ENZ_hLynA", + "assayDesc": "NVS_ENZ_hLynA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 471, + "assayComponentEndpointName": "NVS_ENZ_hLynB", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hLynB was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hLynB, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "non-receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 277, + "assayComponentName": "NVS_ENZ_hLynB", + "assayComponentDesc": "NVS_ENZ_hLynB is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynB assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human LYN proto-oncogene, Src family tyrosine kinase [GeneSymbol:LYN | GeneID:4067 | Uniprot_SwissProt_Accession:P07948].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 91, + "assayName": "NVS_ENZ_hLynB", + "assayDesc": "NVS_ENZ_hLynB is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 195, + "geneName": "LYN proto-oncogene, Src family tyrosine kinase", + "description": null, + "geneSymbol": "LYN", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4067, + "officialSymbol": "LYN", + "officialFullName": "LYN proto-oncogene, Src family tyrosine kinase", + "uniprotAccessionNumber": "P07948" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8106508", + "pmid": 8106508, + "title": "Src family tyrosine kinase p53/56lyn, a serine kinase and Fc epsilon RI associate with alpha-galactosyl derivatives of ganglioside GD1b in rat basophilic leukemia RBL-2H3 cells", + "author": "Minoguchi K, Swaim WD, Berenstein EH, Siraganian RP", + "citation": "Minoguchi K, Swaim WD, Berenstein EH, Siraganian RP. Src family tyrosine kinase p53/56lyn, a serine kinase and Fc epsilon RI associate with alpha-galactosyl derivatives of ganglioside GD1b in rat basophilic leukemia RBL-2H3 cells. J Biol Chem. 1994 Feb 18;269(7):5249-54. PubMed PMID: 8106508.", + "otherId": "0", + "citationId": 157, + "otherSource": "" + } + }, + { + "aeid": 473, + "assayComponentEndpointName": "NVS_ENZ_hMAPK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "K252a", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 278, + "assayComponentName": "NVS_ENZ_hMAPK1", + "assayComponentDesc": "NVS_ENZ_hMAPK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 1 [GeneSymbol:MAPK1 | GeneID:5594 | Uniprot_SwissProt_Accession:P28482].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 92, + "assayName": "NVS_ENZ_hMAPK1", + "assayDesc": "NVS_ENZ_hMAPK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 259, + "geneName": "mitogen-activated protein kinase 1", + "description": null, + "geneSymbol": "MAPK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5594, + "officialSymbol": "MAPK1", + "officialFullName": "mitogen-activated protein kinase 1", + "uniprotAccessionNumber": "P28482" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 475, + "assayComponentEndpointName": "NVS_ENZ_hMAPK11", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK11, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "SB203580", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 279, + "assayComponentName": "NVS_ENZ_hMAPK11", + "assayComponentDesc": "NVS_ENZ_hMAPK11 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 11 [GeneSymbol:MAPK11 | GeneID:5600 | Uniprot_SwissProt_Accession:Q15759].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 93, + "assayName": "NVS_ENZ_hMAPK11", + "assayDesc": "NVS_ENZ_hMAPK11 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 0 hour after chemical dosing in a 384-well plate.", + "timepointHr": 0.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 261, + "geneName": "mitogen-activated protein kinase 11", + "description": null, + "geneSymbol": "MAPK11", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5600, + "officialSymbol": "MAPK11", + "officialFullName": "mitogen-activated protein kinase 11", + "uniprotAccessionNumber": "Q15759" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/6304726", + "pmid": 6304726, + "title": "Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity", + "author": "Reddy EP, Smith MJ, Srinivasan A", + "citation": "Reddy EP, Smith MJ, Srinivasan A. Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3623-7. PubMed PMID: 6304726; PubMed Central PMCID: PMC394102.", + "otherId": "0", + "citationId": 118, + "otherSource": "" + } + }, + { + "aeid": 477, + "assayComponentEndpointName": "NVS_ENZ_hMAPK3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPK3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 280, + "assayComponentName": "NVS_ENZ_hMAPK3", + "assayComponentDesc": "NVS_ENZ_hMAPK3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase 3 [GeneSymbol:MAPK3 | GeneID:5595 | Uniprot_SwissProt_Accession:P27361].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 94, + "assayName": "NVS_ENZ_hMAPK3", + "assayDesc": "NVS_ENZ_hMAPK3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 260, + "geneName": "mitogen-activated protein kinase 3", + "description": null, + "geneSymbol": "MAPK3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5595, + "officialSymbol": "MAPK3", + "officialFullName": "mitogen-activated protein kinase 3", + "uniprotAccessionNumber": "P27361" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 479, + "assayComponentEndpointName": "NVS_ENZ_hMAPKAPK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPKAPK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 281, + "assayComponentName": "NVS_ENZ_hMAPKAPK2", + "assayComponentDesc": "NVS_ENZ_hMAPKAPK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPKAPK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase-activated protein kinase 2 [GeneSymbol:MAPKAPK2 | GeneID:9261 | Uniprot_SwissProt_Accession:P49137].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 95, + "assayName": "NVS_ENZ_hMAPKAPK2", + "assayDesc": "NVS_ENZ_hMAPKAPK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 352, + "geneName": "mitogen-activated protein kinase-activated protein kinase 2", + "description": null, + "geneSymbol": "MAPKAPK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9261, + "officialSymbol": "MAPKAPK2", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 2", + "uniprotAccessionNumber": "P49137" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 481, + "assayComponentEndpointName": "NVS_ENZ_hMAPKAPK5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMAPKAPK5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 282, + "assayComponentName": "NVS_ENZ_hMAPKAPK5", + "assayComponentDesc": "NVS_ENZ_hMAPKAPK5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPKAPK5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human mitogen-activated protein kinase-activated protein kinase 5 [GeneSymbol:MAPKAPK5 | GeneID:8550 | Uniprot_SwissProt_Accession:Q8IW41].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 96, + "assayName": "NVS_ENZ_hMAPKAPK5", + "assayDesc": "NVS_ENZ_hMAPKAPK5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 343, + "geneName": "mitogen-activated protein kinase-activated protein kinase 5", + "description": null, + "geneSymbol": "MAPKAPK5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8550, + "officialSymbol": "MAPKAPK5", + "officialFullName": "mitogen-activated protein kinase-activated protein kinase 5", + "uniprotAccessionNumber": "Q8IW41" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 483, + "assayComponentEndpointName": "NVS_ENZ_hMARK1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMARK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMARK1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 283, + "assayComponentName": "NVS_ENZ_hMARK1", + "assayComponentDesc": "NVS_ENZ_hMARK1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMARK1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human MAP/microtubule affinity-regulating kinase 1 [GeneSymbol:MARK1 | GeneID:4139 | Uniprot_SwissProt_Accession:Q9P0L2].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 97, + "assayName": "NVS_ENZ_hMARK1", + "assayDesc": "NVS_ENZ_hMARK1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 198, + "geneName": "MAP/microtubule affinity-regulating kinase 1", + "description": null, + "geneSymbol": "MARK1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4139, + "officialSymbol": "MARK1", + "officialFullName": "MAP/microtubule affinity-regulating kinase 1", + "uniprotAccessionNumber": "Q9P0L2" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 485, + "assayComponentEndpointName": "NVS_ENZ_hMet", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMet was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMet, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "receptor", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "receptor tyrosine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 284, + "assayComponentName": "NVS_ENZ_hMet", + "assayComponentDesc": "NVS_ENZ_hMet is one of one assay component(s) measured or calculated from the NVS_ENZ_hMet assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human MET proto-oncogene, receptor tyrosine kinase [GeneSymbol:MET | GeneID:4233 | Uniprot_SwissProt_Accession:P08581].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "receptor", + "aid": 98, + "assayName": "NVS_ENZ_hMet", + "assayDesc": "NVS_ENZ_hMet is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 200, + "geneName": "MET proto-oncogene, receptor tyrosine kinase", + "description": null, + "geneSymbol": "MET", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4233, + "officialSymbol": "MET", + "officialFullName": "MET proto-oncogene, receptor tyrosine kinase", + "uniprotAccessionNumber": "P08581" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 487, + "assayComponentEndpointName": "NVS_ENZ_hMMP1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 285, + "assayComponentName": "NVS_ENZ_hMMP1", + "assayComponentDesc": "NVS_ENZ_hMMP1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 1 (interstitial collagenase) [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 99, + "assayName": "NVS_ENZ_hMMP1", + "assayDesc": "NVS_ENZ_hMMP1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 203, + "geneName": "matrix metallopeptidase 1 (interstitial collagenase)", + "description": null, + "geneSymbol": "MMP1", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4312, + "officialSymbol": "MMP1", + "officialFullName": "matrix metallopeptidase 1 (interstitial collagenase)", + "uniprotAccessionNumber": "P03956" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 489, + "assayComponentEndpointName": "NVS_ENZ_hMMP13", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP13 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP13, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Tyr-Hydroxamic acid", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 286, + "assayComponentName": "NVS_ENZ_hMMP13", + "assayComponentDesc": "NVS_ENZ_hMMP13 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP13 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 13 (collagenase 3) [GeneSymbol:MMP13 | GeneID:4322 | Uniprot_SwissProt_Accession:P45452].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 100, + "assayName": "NVS_ENZ_hMMP13", + "assayDesc": "NVS_ENZ_hMMP13 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 209, + "geneName": "matrix metallopeptidase 13 (collagenase 3)", + "description": null, + "geneSymbol": "MMP13", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4322, + "officialSymbol": "MMP13", + "officialFullName": "matrix metallopeptidase 13 (collagenase 3)", + "uniprotAccessionNumber": "P45452" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 491, + "assayComponentEndpointName": "NVS_ENZ_hMMP2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 287, + "assayComponentName": "NVS_ENZ_hMMP2", + "assayComponentDesc": "NVS_ENZ_hMMP2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) [GeneSymbol:MMP2 | GeneID:4313 | Uniprot_SwissProt_Accession:P08253].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 101, + "assayName": "NVS_ENZ_hMMP2", + "assayDesc": "NVS_ENZ_hMMP2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 204, + "geneName": "matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4313, + "officialSymbol": "MMP2", + "officialFullName": "matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)", + "uniprotAccessionNumber": "P08253" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 493, + "assayComponentEndpointName": "NVS_ENZ_hMMP3", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP3, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 288, + "assayComponentName": "NVS_ENZ_hMMP3", + "assayComponentDesc": "NVS_ENZ_hMMP3 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Mca-RPKPVENvalWRK-Dnp-NH2 --> McaRPK + PVENvalWRK(DNP)NH2] involving the key substrate [Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys(Dnp)NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 3 (stromelysin 1, progelatinase) [GeneSymbol:MMP3 | GeneID:4314 | Uniprot_SwissProt_Accession:P08254].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys(Dnp)NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 102, + "assayName": "NVS_ENZ_hMMP3", + "assayDesc": "NVS_ENZ_hMMP3 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 205, + "geneName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "description": null, + "geneSymbol": "MMP3", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4314, + "officialSymbol": "MMP3", + "officialFullName": "matrix metallopeptidase 3 (stromelysin 1, progelatinase)", + "uniprotAccessionNumber": "P08254" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 495, + "assayComponentEndpointName": "NVS_ENZ_hMMP7", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP7, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 289, + "assayComponentName": "NVS_ENZ_hMMP7", + "assayComponentDesc": "NVS_ENZ_hMMP7 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP7 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 7 (matrilysin, uterine) [GeneSymbol:MMP7 | GeneID:4316 | Uniprot_SwissProt_Accession:P09237].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 103, + "assayName": "NVS_ENZ_hMMP7", + "assayDesc": "NVS_ENZ_hMMP7 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 206, + "geneName": "matrix metallopeptidase 7 (matrilysin, uterine)", + "description": null, + "geneSymbol": "MMP7", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4316, + "officialSymbol": "MMP7", + "officialFullName": "matrix metallopeptidase 7 (matrilysin, uterine)", + "uniprotAccessionNumber": "P09237" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/1537400", + "pmid": 1537400, + "title": "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases", + "author": "Knight CG, Willenbrock F, Murphy G", + "citation": "Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263-6. PubMed PMID: 1537400.", + "otherId": "0", + "citationId": 17, + "otherSource": "" + } + }, + { + "aeid": 497, + "assayComponentEndpointName": "NVS_ENZ_hMMP9", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMMP9 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMMP9, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Galardin (GM6001)", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "protease", + "intendedTargetFamilySub": "matrix metalloproteinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 290, + "assayComponentName": "NVS_ENZ_hMMP9", + "assayComponentDesc": "NVS_ENZ_hMMP9 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP9 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 104, + "assayName": "NVS_ENZ_hMMP9", + "assayDesc": "NVS_ENZ_hMMP9 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 96-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 96-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 207, + "geneName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "description": null, + "geneSymbol": "MMP9", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4318, + "officialSymbol": "MMP9", + "officialFullName": "matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)", + "uniprotAccessionNumber": "P14780" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/8368516", + "pmid": 8368516, + "title": "A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)", + "author": "Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM", + "citation": "Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem. 1993 Jul;212(1):58-64. PubMed PMID: 8368516.", + "otherId": "0", + "citationId": 160, + "otherSource": "" + } + }, + { + "aeid": 499, + "assayComponentEndpointName": "NVS_ENZ_hMsk1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hMsk1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hMsk1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 291, + "assayComponentName": "NVS_ENZ_hMsk1", + "assayComponentDesc": "NVS_ENZ_hMsk1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hMsk1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human ribosomal protein S6 kinase, 90kDa, polypeptide 5 [GeneSymbol:RPS6KA5 | GeneID:9252 | Uniprot_SwissProt_Accession:O75582].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 105, + "assayName": "NVS_ENZ_hMsk1", + "assayDesc": "NVS_ENZ_hMsk1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 351, + "geneName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "description": null, + "geneSymbol": "RPS6KA5", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 9252, + "officialSymbol": "RPS6KA5", + "officialFullName": "ribosomal protein S6 kinase, 90kDa, polypeptide 5", + "uniprotAccessionNumber": "O75582" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 501, + "assayComponentEndpointName": "NVS_ENZ_hNEK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hNEK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 292, + "assayComponentName": "NVS_ENZ_hNEK2", + "assayComponentDesc": "NVS_ENZ_hNEK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hNEK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human NIMA-related kinase 2 [GeneSymbol:NEK2 | GeneID:4751 | Uniprot_SwissProt_Accession:P51955].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 106, + "assayName": "NVS_ENZ_hNEK2", + "assayDesc": "NVS_ENZ_hNEK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 215, + "geneName": "NIMA-related kinase 2", + "description": null, + "geneSymbol": "NEK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 4751, + "officialSymbol": "NEK2", + "officialFullName": "NIMA-related kinase 2", + "uniprotAccessionNumber": "P51955" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 503, + "assayComponentEndpointName": "NVS_ENZ_hPAK2", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPAK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPAK2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 293, + "assayComponentName": "NVS_ENZ_hPAK2", + "assayComponentDesc": "NVS_ENZ_hPAK2 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPAK2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human p21 protein (Cdc42/Rac)-activated kinase 2 [GeneSymbol:PAK2 | GeneID:5062 | Uniprot_SwissProt_Accession:Q13177].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 107, + "assayName": "NVS_ENZ_hPAK2", + "assayDesc": "NVS_ENZ_hPAK2 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 230, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 2", + "description": null, + "geneSymbol": "PAK2", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5062, + "officialSymbol": "PAK2", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 2", + "uniprotAccessionNumber": "Q13177" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 505, + "assayComponentEndpointName": "NVS_ENZ_hPAK4", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPAK4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPAK4, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 294, + "assayComponentName": "NVS_ENZ_hPAK4", + "assayComponentDesc": "NVS_ENZ_hPAK4 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPAK4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human p21 protein (Cdc42/Rac)-activated kinase 4 [GeneSymbol:PAK4 | GeneID:10298 | Uniprot_SwissProt_Accession:O96013].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 108, + "assayName": "NVS_ENZ_hPAK4", + "assayDesc": "NVS_ENZ_hPAK4 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 364, + "geneName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "description": null, + "geneSymbol": "PAK4", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10298, + "officialSymbol": "PAK4", + "officialFullName": "p21 protein (Cdc42/Rac)-activated kinase 4", + "uniprotAccessionNumber": "O96013" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 507, + "assayComponentEndpointName": "NVS_ENZ_hPDE10", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE10 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE10, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trequinsin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 295, + "assayComponentName": "NVS_ENZ_hPDE10", + "assayComponentDesc": "NVS_ENZ_hPDE10 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE10 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 10A [GeneSymbol:PDE10A | GeneID:10846 | Uniprot_SwissProt_Accession:Q9Y233].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 109, + "assayName": "NVS_ENZ_hPDE10", + "assayDesc": "NVS_ENZ_hPDE10 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 368, + "geneName": "phosphodiesterase 10A", + "description": null, + "geneSymbol": "PDE10A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 10846, + "officialSymbol": "PDE10A", + "officialFullName": "phosphodiesterase 10A", + "uniprotAccessionNumber": "Q9Y233" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 509, + "assayComponentEndpointName": "NVS_ENZ_hPDE4A1", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE4A1, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "trequinsin", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 296, + "assayComponentName": "NVS_ENZ_hPDE4A1", + "assayComponentDesc": "NVS_ENZ_hPDE4A1 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE4A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4A, cAMP-specific [GeneSymbol:PDE4A | GeneID:5141 | Uniprot_SwissProt_Accession:P27815].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic AMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 110, + "assayName": "NVS_ENZ_hPDE4A1", + "assayDesc": "NVS_ENZ_hPDE4A1 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 232, + "geneName": "phosphodiesterase 4A, cAMP-specific", + "description": null, + "geneSymbol": "PDE4A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5141, + "officialSymbol": "PDE4A", + "officialFullName": "phosphodiesterase 4A, cAMP-specific", + "uniprotAccessionNumber": "P27815" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 511, + "assayComponentEndpointName": "NVS_ENZ_hPDE5", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPDE5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Dipyridamole", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "esterase", + "intendedTargetFamilySub": "phosphodiesterase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 297, + "assayComponentName": "NVS_ENZ_hPDE5", + "assayComponentDesc": "NVS_ENZ_hPDE5 is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic GMP --> Flourescent 5?-GMP] involving the key substrate [Fluorescent cyclic GMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 5A, cGMP-specific [GeneSymbol:PDE5A | GeneID:8654 | Uniprot_SwissProt_Accession:O76074].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescent cyclic GMP", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 111, + "assayName": "NVS_ENZ_hPDE5", + "assayDesc": "NVS_ENZ_hPDE5 is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 346, + "geneName": "phosphodiesterase 5A, cGMP-specific", + "description": null, + "geneSymbol": "PDE5A", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 8654, + "officialSymbol": "PDE5A", + "officialFullName": "phosphodiesterase 5A, cGMP-specific", + "uniprotAccessionNumber": "O76074" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 513, + "assayComponentEndpointName": "NVS_ENZ_hPI3Ka", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPI3Ka, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is phosphoinositol kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "PI-103", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "phosphoinositol kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 298, + "assayComponentName": "NVS_ENZ_hPI3Ka", + "assayComponentDesc": "NVS_ENZ_hPI3Ka is one of one assay component(s) measured or calculated from the NVS_ENZ_hPI3Ka assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP2 + ATP --> fluorescein-PIP3 + ADP] involving the key substrate [Fluorescein-labeled PIP2 (phosphoinositol (4,5)bisphosphate)] are indicative of changes in enzyme function and kinetics for the human phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [GeneSymbol:PIK3CA | GeneID:5290 | Uniprot_SwissProt_Accession:P42336].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled PIP2 (phosphoinositol (4,5)bisphosphate)", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 112, + "assayName": "NVS_ENZ_hPI3Ka", + "assayDesc": "NVS_ENZ_hPI3Ka is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 237, + "geneName": "phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha", + "description": null, + "geneSymbol": "PIK3CA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5290, + "officialSymbol": "PIK3CA", + "officialFullName": "phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha", + "uniprotAccessionNumber": "P42336" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + }, + { + "aeid": 515, + "assayComponentEndpointName": "NVS_ENZ_hPKA", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKA was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKA, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "H 89", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 299, + "assayComponentName": "NVS_ENZ_hPKA", + "assayComponentDesc": "NVS_ENZ_hPKA is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, cAMP-dependent, catalytic, alpha [GeneSymbol:PRKACA | GeneID:5566 | Uniprot_SwissProt_Accession:P17612].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 113, + "assayName": "NVS_ENZ_hPKA", + "assayDesc": "NVS_ENZ_hPKA is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 256, + "geneName": "protein kinase, cAMP-dependent, catalytic, alpha", + "description": null, + "geneSymbol": "PRKACA", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5566, + "officialSymbol": "PRKACA", + "officialFullName": "protein kinase, cAMP-dependent, catalytic, alpha", + "uniprotAccessionNumber": "P17612" + }, + "assayList": null, + "citations": { + "doi": "", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/10998351", + "pmid": 10998351, + "title": "Specificity and mechanism of action of some commonly used protein kinase inhibitors", + "author": "Davies SP, Reddy H, Caivano M, Cohen P", + "citation": "Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. PubMed PMID: 10998351; PubMed Central PMCID: PMC1221339.", + "otherId": "0", + "citationId": 184, + "otherSource": "" + } + }, + { + "aeid": 517, + "assayComponentEndpointName": "NVS_ENZ_hPKCz", + "exportReady": 1, + "internalReady": 1, + "assayComponentEndpointDesc": "Data from the assay component NVS_ENZ_hPKCz was analyzed into 1 assay endpoint. This assay endpoint, NVS_ENZ_hPKCz, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", + "assayFunctionType": "enzymatic activity", + "normalizedDataType": "percent_activity", + "burstAssay": 0, + "keyPositiveControl": "Staurosporine", + "signalDirection": "loss", + "intendedTargetType": "protein", + "intendedTargetTypeSub": "enzyme", + "intendedTargetFamily": "kinase", + "intendedTargetFamilySub": "serine/threonine kinase", + "cellViabilityAssay": 0, + "dataUsability": 1, + "acid": 300, + "assayComponentName": "NVS_ENZ_hPKCz", + "assayComponentDesc": "NVS_ENZ_hPKCz is one of one assay component(s) measured or calculated from the NVS_ENZ_hPKCz assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.", + "assayComponentTargetDesc": "Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase C, zeta [GeneSymbol:PRKCZ | GeneID:5590 | Uniprot_SwissProt_Accession:Q05513].", + "parameterReadoutType": "single", + "assayDesignType": "enzyme reporter", + "assayDesignTypeSub": "enzyme activity", + "biologicalProcessTarget": "regulation of catalytic activity", + "detectionTechnologyType": "Fluorescence", + "detectionTechnologyTypeSub": "Fluorescence intensity", + "detectionTechnology": "Fluorescence and electrophoretic mobility shift", + "keyAssayReagentType": "substrate", + "keyAssayReagent": "Fluorescein-labeled peptide", + "technologicalTargetType": "protein", + "technologicalTargetTypeSub": "enzyme", + "aid": 114, + "assayName": "NVS_ENZ_hPKCz", + "assayDesc": "NVS_ENZ_hPKCz is a biochemical, single-readout assay that uses extracted gene-proteins in a cell-free assay. Measurements were taken 1 hour after chemical dosing in a 384-well plate.", + "timepointHr": 1.0, + "organismId": 9606, + "organism": "human", + "tissue": "NA", + "cellFormat": "cell-free", + "cellFreeComponentSource": "NA", + "cellShortName": "NA", + "cellGrowthMode": "NA", + "assayFootprint": "microplate: 384-well plate", + "assayFormatType": "biochemical", + "assayFormatTypeSub": "protein single format", + "contentReadoutType": "single", + "dilutionSolvent": "DMSO", + "dilutionSolventPercentMax": 0.0, + "asid": 5, + "assaySourceName": "NVS", + "assaySourceLongName": "Novascreen", + "assaySourceDesc": "NovaScreen, part of PerkinElmer, a human and environmental health company, provides a large diverse suite of cell-free binding and biochemical assays.", + "gene": { + "geneId": 258, + "geneName": "protein kinase C, zeta", + "description": null, + "geneSymbol": "PRKCZ", + "organismId": 1, + "trackStatus": "live", + "entrezGeneId": 5590, + "officialSymbol": "PRKCZ", + "officialFullName": "protein kinase C, zeta", + "uniprotAccessionNumber": "Q05513" + }, + "assayList": null, + "citations": { + "doi": "doi: 10.1021/tx400021f", + "url": "http://www.ncbi.nlm.nih.gov/pubmed/23611293", + "pmid": 23611293, + "title": "Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays", + "author": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB", + "citation": "Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. PubMed PMID: 23611293; PubMed Central PMCID: PMC3685188.", + "otherId": "0", + "citationId": 215, + "otherSource": "" + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json new file mode 100644 index 00000000..a329279d --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-aeid/704.json @@ -0,0 +1,9207 @@ +[ + { + "aeid": 704, + "m4id": 1842410, + "spid": "LEGTV002G10", + "chid": 32577, + "casn": "79538-32-2", + "chnm": "Tefluthrin", + "dtxsid": "DTXSID5032577", + "bmad": 3.7634679299683276, + "respMax": 22.88978034849851, + "respMin": -26.552798250251374, + "maxMean": 22.88978034849851, + "maxMeanConc": 0.7781512503836436, + "maxMed": 22.88978034849851, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 9, + "m5id": 5037056, + "modl": "exp4", + "hitc": 0.2411318116914611, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + -0.22184874961635637, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812 + ], + "resp": [ + -26.552798250251374, + 7.643488716816449, + 22.88978034849851, + 7.9412465922401445, + 19.249048936986245, + 22.72625970498906, + 20.26645313099273, + 10.220169791958208 + ] + }, + "mc4Param": { + "pow_a": 8.051875026642751, + "pow_p": 0.3000002363252646, + "exp2_a": 2586.5273948186914, + "exp2_b": 5061.903524643174, + "exp3_a": 16.991620306804258, + "exp3_b": 61.307930252068054, + "exp3_p": 0.3000001542012486, + "exp5_p": 0.41109358960702536, + "gnls_p": 0.5634256102787089, + "gnls_q": 7.950665366879992, + "hill_p": 0.5634498524518311, + "pow_er": 2.1767434212836925, + "cnst_er": 2.8698019137772666, + "exp2_er": 2.623207281861648, + "exp3_er": 2.3192847401467107, + "exp4_er": 2.1056134978195313, + "exp4_ga": 1.0188231249900932, + "exp4_tp": 20.260251446603277, + "exp5_er": 1.9820127172223416, + "exp5_ga": 0.4248866702697808, + "exp5_tp": 20.7377426492478, + "gnls_er": 1.99625942425146, + "gnls_ga": 0.3960985797099487, + "gnls_la": 4930.779736400695, + "gnls_tp": 21.81742856245767, + "hill_er": 1.996272080662291, + "hill_ga": 0.39605546778034006, + "hill_tp": 21.817114896556166, + "poly1_a": 0.5150479432537712, + "poly2_a": 2323.882444395881, + "poly2_b": 4567.207855100587, + "pow_aic": 68.5758988456374, + "pow_cov": 1, + "pow_rme": 12.721053786887008, + "pow_top": 26.03684923789126, + "all_bmed": 0, + "cnst_aic": 72.9602916781216, + "cnst_rme": 18.54949195654765, + "exp2_aic": 73.57241312566146, + "exp2_cov": 1, + "exp2_rme": 15.498838859238056, + "exp2_top": 25.67555887819936, + "exp3_aic": 71.90187282888056, + "exp3_cov": 1, + "exp3_rme": 13.226439348308494, + "exp3_top": 26.53564273777775, + "exp4_aic": 67.91716461253762, + "exp4_cov": 1, + "exp4_rme": 12.291600328368528, + "exp4_top": 20.260251446603277, + "exp5_aic": 68.74654825043743, + "exp5_cov": 1, + "exp5_rme": 12.205391269508892, + "exp5_top": 20.7377426492478, + "gnls_aic": 72.70908001073246, + "gnls_cov": 0, + "gnls_rme": 12.08907864204856, + "gnls_top": 21.62406269958069, + "hill_aic": 68.70908001125854, + "hill_cov": 1, + "hill_rme": 12.089052602788728, + "hill_top": 21.817114896556166, + "poly1_er": 2.6233806365269072, + "poly2_er": 2.623494262991935, + "pow_a_sd": 18.263178960432903, + "pow_ac50": 4.960637316196675, + "pow_p_sd": 0.697941144406865, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 32716.581509859232, + "exp2_ac50": 25.06173541792207, + "exp2_b_sd": 63813.265454996756, + "exp3_a_sd": null, + "exp3_ac50": 9.809731117071673, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.0188231249900932, + "exp5_ac50": 0.4248866702697808, + "exp5_p_sd": 0.34799669960865676, + "gnls_ac50": 0.3838306742682284, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.39605546778034006, + "hill_p_sd": 0.635744845964724, + "poly1_aic": 71.56605507092407, + "poly1_cov": 1, + "poly1_rme": 15.493294256204988, + "poly1_top": 25.75239716268856, + "poly2_aic": 73.57994628381844, + "poly2_cov": 1, + "poly2_rme": 15.50431136692914, + "poly2_top": 25.719470980222596, + "pow_er_sd": 1.15655148324573, + "exp2_er_sd": 0.3073701019975029, + "exp3_er_sd": null, + "exp4_er_sd": 0.387701061369176, + "exp4_ga_sd": 1.301060030418642, + "exp4_tp_sd": 4.791141733238257, + "exp5_er_sd": 0.3929731812861924, + "exp5_ga_sd": 0.8430161520344103, + "exp5_tp_sd": 5.937095261163485, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3920891185604444, + "hill_ga_sd": 1.2602581620806317, + "hill_tp_sd": 10.912262369817968, + "poly1_a_sd": 0.2454616975843716, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 20164.124461380256, + "poly2_ac50": 25.135359225205608, + "poly2_b_sd": 39136.75145557223, + "poly1_er_sd": 0.3073969378754904, + "poly2_er_sd": 0.3073430361679298, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4935.719934078368 + }, + "mc5Param": { + "er": 2.1056134978195313, + "ga": 1.0188231249900932, + "tp": 20.260251446603277, + "ac5": 0.07539350363763271, + "bmd": 0.9015999983866408, + "bmr": 9.289141683881516, + "mll": -30.95858230626881, + "top": 20.260251446603277, + "ac10": 0.15486426667184697, + "ac20": 0.3279877876552497, + "ac50": 1.0188231249900932, + "bmdl": 0.015249773022781948, + "bmdu": 3.811435874108677, + "rmse": 12.291600328368528, + "ac1sd": 0.6104667435797823, + "caikwt": 0.07436025429585817, + "hitcall": 0.2411318116914611, + "top_over_cutoff": 0.8972332532835738 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842408, + "spid": "LEGTV002F02", + "chid": 34634, + "casn": "68157-60-8", + "chnm": "Forchlorfenuron", + "dtxsid": "DTXSID1034634", + "bmad": 3.7634679299683276, + "respMax": 30.305480403437308, + "respMin": -15.782463123633022, + "maxMean": 30.305480403437308, + "maxMeanConc": 1.6989700043360187, + "maxMed": 30.305480403437308, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 7, + "m5id": 5037054, + "modl": "poly1", + "hitc": 0.6460864720880574, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + -0.22184874961635637, + -1.154901959985743 + ], + "resp": [ + 17.312197447937717, + 5.892444361517972, + -5.621637590571268, + 30.305480403437308, + -12.047921136921975, + -0.9033802904499949, + 3.9506691129976836, + -15.782463123633022 + ] + }, + "mc4Param": { + "pow_a": 0.1234505358742655, + "pow_p": 1.4039572198662018, + "exp2_a": 11.704126631709482, + "exp2_b": 39.21885087510036, + "exp3_a": 6.797876599868359, + "exp3_b": 27.227754995685633, + "exp3_p": 0.8670700138038412, + "exp5_p": 2.243572303903159, + "gnls_p": 3.417276045729987, + "gnls_q": 7.9999995152294145, + "hill_p": 3.410031445934874, + "pow_er": 2.053160430913364, + "cnst_er": 2.4831651329165245, + "exp2_er": 2.0477140196724335, + "exp3_er": 2.045418371135353, + "exp4_er": 2.1440692417744724, + "exp4_ga": 27.444981809921984, + "exp4_tp": 36.36657640836127, + "exp5_er": 2.056168804647671, + "exp5_ga": 33.29374622826353, + "exp5_tp": 36.366576245073674, + "gnls_er": 2.0583941068083926, + "gnls_ga": 31.61205104146836, + "gnls_la": 1534.1122637713574, + "gnls_tp": 36.36657643578302, + "hill_er": 2.058279940276527, + "hill_ga": 31.61029453570885, + "hill_tp": 36.36657616615269, + "poly1_a": 0.5785182000394039, + "poly2_a": 12.459385888548155, + "poly2_b": 44.18199252652262, + "pow_aic": 65.0995287126822, + "pow_cov": 1, + "pow_rme": 9.38736161655436, + "pow_top": 29.976034738668837, + "all_bmed": 0, + "cnst_aic": 67.9344363146865, + "cnst_rme": 14.5564438526066, + "exp2_aic": 65.01101796690389, + "exp2_cov": 1, + "exp2_rme": 9.336855219455533, + "exp2_top": 30.177138850514144, + "exp3_aic": 67.00414392078824, + "exp3_cov": 1, + "exp3_rme": 9.328883445138253, + "exp3_top": 30.184512709969923, + "exp4_aic": 65.8649681972613, + "exp4_cov": 1, + "exp4_rme": 9.540601853567534, + "exp4_top": 36.36657640836127, + "exp5_aic": 67.2557220191338, + "exp5_cov": 1, + "exp5_rme": 9.530978553849964, + "exp5_top": 36.366576245073674, + "gnls_aic": 71.33940383936331, + "gnls_cov": 1, + "gnls_rme": 9.604561582504878, + "gnls_top": 36.36043012871301, + "hill_aic": 67.33939320817458, + "hill_cov": 1, + "hill_rme": 9.604376235570829, + "hill_top": 36.36657616615269, + "poly1_er": 2.085652025408799, + "poly2_er": 2.049820013105159, + "pow_a_sd": 0.5753788358968032, + "pow_ac50": 30.517899763456313, + "pow_p_sd": 1.208640790059217, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 41.73861131597536, + "exp2_ac50": 32.48057507982734, + "exp2_b_sd": 80.2181969794621, + "exp3_a_sd": 55.46148196934477, + "exp3_ac50": 32.61409306497238, + "exp3_b_sd": 155.31132615599387, + "exp3_p_sd": 1.7685350503057042, + "exp4_ac50": 27.444981809921984, + "exp5_ac50": 33.29374622826353, + "exp5_p_sd": 3.435165237165201, + "gnls_ac50": 31.60892429289404, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 31.61029453570885, + "hill_p_sd": 23.432436210259, + "poly1_aic": 63.26368385628203, + "poly1_cov": 1, + "poly1_rme": 9.335379666909818, + "poly1_top": 28.92591000197019, + "poly2_aic": 65.04407548989566, + "poly2_cov": 1, + "poly2_rme": 9.347372572279864, + "poly2_top": 30.056881540429895, + "pow_er_sd": 0.33301411643671863, + "exp2_er_sd": 0.3322758677027563, + "exp3_er_sd": 0.3319875527085669, + "exp4_er_sd": 0.3157481584060974, + "exp4_ga_sd": 34.059639655609715, + "exp4_tp_sd": 26.977496390379052, + "exp5_er_sd": 0.334389570780719, + "exp5_ga_sd": 37.91927313278114, + "exp5_tp_sd": 50.504063030446645, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.33640069974138875, + "hill_ga_sd": 126.4453565783159, + "hill_tp_sd": 150.73989659276037, + "poly1_a_sd": 0.13788942465596515, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 81.28656120170228, + "poly2_ac50": 31.22468556738295, + "poly2_b_sd": 189.87096202288063, + "poly1_er_sd": 0.31798965447224936, + "poly2_er_sd": 0.3317697682239624, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1534.1764211860095 + }, + "mc5Param": { + "a": 0.5785182000394039, + "er": 2.085652025408799, + "ac5": 2.4999999999999996, + "acc": 39.03214726567279, + "bmd": 16.05678383713566, + "bmr": 9.289141683881516, + "mll": -29.631841928141014, + "top": 28.92591000197019, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 11.311189751842544, + "bmdu": 29.51384383733146, + "rmse": 9.335379666909818, + "ac1sd": 11.902730791056827, + "caikwt": 0.08823518845609243, + "hitcall": 0.6460864720880574, + "top_over_cutoff": 1.2809953718322074 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842409, + "spid": "LEGTV002F07", + "chid": 32392, + "casn": "66441-23-4", + "chnm": "Fenoxaprop-ethyl", + "dtxsid": "DTXSID2032392", + "bmad": 3.7634679299683276, + "respMax": 11.82202000041872, + "respMin": -15.519375841783155, + "maxMean": 11.82202000041872, + "maxMeanConc": -1.6989700043360187, + "maxMed": 11.82202000041872, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 8, + "m5id": 5037055, + "modl": "poly1", + "hitc": 1.4322271531083211E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 1.6989700043360187 + ], + "resp": [ + 11.82202000041872, + 1.5536961694941236, + -15.519375841783155, + -3.18010844609448, + -2.140589126080783, + 8.784412793010326, + -2.3157498063462607, + -0.3023091900039757 + ] + }, + "mc4Param": { + "pow_a": 0.0000011632431730420026, + "pow_p": 0.371275158646456, + "exp2_a": 0.000001797829505777648, + "exp2_b": 72.74913416945634, + "exp3_a": 0.0000055005758644098394, + "exp3_b": 57.760844012588784, + "exp3_p": 6.22085425509824, + "exp5_p": 0.8997002598611641, + "gnls_p": 6.745015045169553, + "gnls_q": 7.999999994872401, + "hill_p": 7.540290076592129, + "pow_er": 1.8022541315256504, + "cnst_er": 1.8015796789499128, + "exp2_er": 1.8007494516437397, + "exp3_er": 1.8021894413500723, + "exp4_er": 1.80158870051793, + "exp4_ga": 7.782862626322558, + "exp4_tp": 3.226750921155688E-9, + "exp5_er": 1.8015912094733963, + "exp5_ga": 8.441755009402286, + "exp5_tp": 7.302557281932975E-10, + "gnls_er": 1.563319486875444, + "gnls_ga": 0.0021571134721910935, + "gnls_la": 0.3339308415916757, + "gnls_tp": 7.623928704938419, + "hill_er": 1.8015890186604628, + "hill_ga": 157.94452896356304, + "hill_tp": 1.8955153678433672, + "poly1_a": 5.662423411973493E-10, + "poly2_a": 0.000022326254566998696, + "poly2_b": 56.36270470222716, + "pow_aic": 61.5780037237116, + "pow_cov": 1, + "pow_rme": 7.748713087460874, + "pow_top": 0.0000049711385820584395, + "all_bmed": 0, + "cnst_aic": 57.57799866553477, + "cnst_rme": 7.748712496775653, + "exp2_aic": 61.578004749066096, + "exp2_cov": 1, + "exp2_rme": 7.748712562373631, + "exp2_top": 0.0000017768428039737286, + "exp3_aic": 63.57800185669078, + "exp3_cov": 1, + "exp3_rme": 7.748712510532352, + "exp3_top": 0.000002767495920583712, + "exp4_aic": 61.577998666698214, + "exp4_cov": 1, + "exp4_rme": 7.748712497203208, + "exp4_top": 3.226750921155688E-9, + "exp5_aic": 63.57799866627887, + "exp5_cov": 1, + "exp5_rme": 7.74871249686776, + "exp5_top": 7.302557281932975E-10, + "gnls_aic": 64.94555137524486, + "gnls_cov": 1, + "gnls_rme": 6.978798723259373, + "gnls_top": 7.6239285577032945, + "hill_aic": 63.57800538783228, + "hill_cov": 1, + "hill_rme": 7.748714090611704, + "hill_top": 1.8955153678433672, + "poly1_er": 1.801569355455974, + "poly2_er": 1.8017915647795937, + "pow_a_sd": null, + "pow_ac50": 7.72982644524005, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.213607891471405, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.42645739987168, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 7.782862626322558, + "exp5_ac50": 8.441755009402286, + "exp5_p_sd": null, + "gnls_ac50": 0.0021571134162010203, + "gnls_p_sd": 1886.6181378919537, + "gnls_q_sd": 13.897596369316378, + "hill_ac50": 157.94452896356304, + "hill_p_sd": null, + "poly1_aic": 59.577998670402955, + "poly1_cov": 1, + "poly1_rme": 7.748712498123487, + "poly1_top": 2.831211705986746E-8, + "poly2_aic": 61.57800229689971, + "poly2_cov": 1, + "poly2_rme": 7.748713685123689, + "poly2_top": 0.00003737589473088489, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.39059567343598767, + "gnls_ga_sd": 1.343381900673757, + "gnls_la_sd": 0.3212711194493188, + "gnls_tp_sd": 3.818735746599816, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.1026000354392676, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.58306067150831, + "poly2_b_sd": null, + "poly1_er_sd": 0.34707929934562703, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.3339308431136041 + }, + "mc5Param": { + "a": 5.662423411973493E-10, + "er": 1.801569355455974, + "ac5": 2.5, + "bmd": 16404887109.358751, + "bmr": 9.289141683881516, + "mll": -27.78899933520148, + "top": 2.831211705986746E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 62.41443596324167, + "rmse": 7.748712498123487, + "ac1sd": 12160776211.533545, + "caikwt": 0.7310585791085764, + "hitcall": 0.000014322271531083213, + "top_over_cutoff": 1.253813308483351E-9 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842411, + "spid": "LEGTV002H08", + "chid": 34742, + "casn": "NOCAS_34742", + "chnm": "Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin A3)", + "dtxsid": "DTXSID8034742", + "bmad": 3.7634679299683276, + "respMax": 73.67532078350177, + "respMin": -5.395088130329359, + "maxMean": 73.67532078350177, + "maxMeanConc": 0.7781512503836436, + "maxMed": 73.67532078350177, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 6, + "tmpi": 10, + "m5id": 5037057, + "modl": "exp4", + "hitc": 0.9999994968056571, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.22184874961635637, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 52.505652872749074, + -5.395088130329359, + 73.67532078350177, + 5.395088130329359, + 72.53691394012041, + 19.22317269185714, + 30.263301277685446, + 69.87972321355599 + ] + }, + "mc4Param": { + "pow_a": 28.147886385576328, + "pow_p": 0.30000009689641516, + "exp2_a": 6119.261472113918, + "exp2_b": 3551.239003137988, + "exp3_a": 975.1669226858538, + "exp3_b": 153230.6117998245, + "exp3_p": 0.3000003501105035, + "exp5_p": 1.094805881965073, + "gnls_p": 1.3647130188568126, + "gnls_q": 0.5619058173970354, + "hill_p": 1.59050714992454, + "pow_er": 2.63553254897771, + "cnst_er": 3.795906798840122, + "exp2_er": 3.3954987701188113, + "exp3_er": 2.727845635618811, + "exp4_er": 1.4689672679270718, + "exp4_ga": 1.099878418012791, + "exp4_tp": 72.48760653689077, + "exp5_er": 1.385097799783372, + "exp5_ga": 1.132980663465564, + "exp5_tp": 72.29651505256778, + "gnls_er": 1.3581230433996936, + "gnls_ga": 1.3915857757652723, + "gnls_la": 524.1224234965719, + "gnls_tp": 88.41038117121148, + "hill_er": 1.5970021189190942, + "hill_ga": 1.077282613722834, + "hill_tp": 73.26305717696057, + "poly1_a": 1.7397504631410787, + "poly2_a": 8413.5045447357, + "poly2_b": 4888.583862175059, + "pow_aic": 73.54169876654271, + "pow_cov": 1, + "pow_rme": 15.2861480042891, + "pow_top": 91.02002602025269, + "all_bmed": 0, + "cnst_aic": 88.28390953083002, + "cnst_rme": 49.58992816204983, + "exp2_aic": 86.10951984809975, + "exp2_cov": 1, + "exp2_rme": 34.328944054173824, + "exp2_top": 86.76609362549449, + "exp3_aic": 75.92329672154494, + "exp3_cov": 1, + "exp3_rme": 15.630160935729108, + "exp3_top": 91.8010727392276, + "exp4_aic": 59.2793317878772, + "exp4_cov": 1, + "exp4_rme": 8.238704361671774, + "exp4_top": 72.48760653689077, + "exp5_aic": 61.10190561453248, + "exp5_cov": 1, + "exp5_rme": 8.62848952975195, + "exp5_top": 72.29651505256778, + "gnls_aic": 65.36002423995862, + "gnls_cov": 1, + "gnls_rme": 9.055176915896654, + "gnls_top": 75.01351487350438, + "hill_aic": 63.48641699639106, + "hill_cov": 1, + "hill_rme": 9.621896825468774, + "hill_top": 73.26305717696057, + "poly1_er": 3.393356939188565, + "poly2_er": 3.3954441024657243, + "pow_a_sd": 8.463344228881985, + "pow_ac50": 4.960631989323517, + "pow_p_sd": 0.09202961052734752, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 44830.330426869536, + "exp2_ac50": 25.087996729753247, + "exp2_b_sd": 25840.49536754701, + "exp3_a_sd": 1604.028096378901, + "exp3_ac50": 5.3422803072846445, + "exp3_b_sd": 660507.3822297514, + "exp3_p_sd": 0.10541901370789264, + "exp4_ac50": 1.099878418012791, + "exp5_ac50": 1.132980663465564, + "exp5_p_sd": 0.2147453097848282, + "gnls_ac50": 1.158904104169734, + "gnls_p_sd": 0.3461607578247413, + "gnls_q_sd": 0.7944942746221946, + "hill_ac50": 1.077282613722834, + "hill_p_sd": 0.4118849346917922, + "poly1_aic": 84.09047084550053, + "poly1_cov": 1, + "poly1_rme": 34.282455965850914, + "poly1_top": 86.98752315705393, + "poly2_aic": 86.11783010298875, + "poly2_cov": 1, + "poly2_rme": 34.3417360780736, + "poly2_top": 86.93271261079072, + "pow_er_sd": 0.32772739565048525, + "exp2_er_sd": 0.3154107490786174, + "exp3_er_sd": 0.34995551663162316, + "exp4_er_sd": 0.3801021109960385, + "exp4_ga_sd": 0.15804671767015727, + "exp4_tp_sd": 2.557860936885942, + "exp5_er_sd": 0.4212709024359285, + "exp5_ga_sd": 0.1485229561872174, + "exp5_tp_sd": 2.346998337980212, + "gnls_er_sd": 0.4418044445090503, + "gnls_ga_sd": 0.4322859035235454, + "gnls_la_sd": 1067.6005455781465, + "gnls_tp_sd": 26.852332203983984, + "hill_er_sd": 0.39657332639532145, + "hill_ga_sd": 0.16949083304776472, + "hill_tp_sd": 3.4053560285886713, + "poly1_a_sd": 0.5875701839815818, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 52103.4262311332, + "poly2_ac50": 25.12655125481741, + "poly2_b_sd": 29886.906099027077, + "poly1_er_sd": 0.31507639708506446, + "poly2_er_sd": 0.31533923357704763, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 902.1729967630253 + }, + "mc5Param": { + "er": 1.4689672679270718, + "ga": 1.099878418012791, + "tp": 72.48760653689077, + "ac5": 0.08139164245040806, + "acc": 0.59228230830365, + "bmd": 0.21760526858009044, + "bmr": 9.289141683881516, + "mll": -26.6396658939386, + "top": 72.48760653689077, + "ac10": 0.167184921951392, + "ac20": 0.3540817637185837, + "ac50": 1.099878418012791, + "bmdl": 0.17276594676938292, + "bmdu": 0.2697433120933787, + "rmse": 8.238704361671774, + "ac1sd": 0.15838472357506664, + "caikwt": 5.031943424985008E-7, + "hitcall": 0.9999994968056573, + "top_over_cutoff": 3.210142342371477 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842412, + "spid": "LEGTV003B07", + "chid": 23892, + "casn": "71751-41-2", + "chnm": "Abamectin", + "dtxsid": "DTXSID8023892", + "bmad": 3.7634679299683276, + "respMax": 77.95705815614956, + "respMin": -28.22028225978724, + "maxMean": 77.95705815614956, + "maxMeanConc": 1.6989700043360187, + "maxMed": 77.95705815614956, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 5, + "tmpi": 11, + "m5id": 5037058, + "modl": "hill", + "hitc": 0.9999986614193673, + "fitc": 41, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + 64.23854892075744, + -28.22028225978724, + 71.52551303778179, + -8.36715608785845, + 77.90911291815605, + 1.215720341597959, + 77.60553886175157, + 77.95705815614956 + ] + }, + "mc4Param": { + "pow_a": 30.822288131348024, + "pow_p": 0.3000004325120875, + "exp2_a": 9745.30422459993, + "exp2_b": 4985.4095456974865, + "exp3_a": 743.0734773552446, + "exp3_b": 48000.25079936882, + "exp3_p": 0.30036500057781645, + "exp5_p": 4.387719474863923, + "gnls_p": 5.312129658102232, + "gnls_q": 6.044467438794108, + "hill_p": 5.312112708921902, + "pow_er": 3.2500407355444447, + "cnst_er": 4.016143460737711, + "exp2_er": 3.6767003773089906, + "exp3_er": 3.320916603363695, + "exp4_er": 2.55983470322537, + "exp4_ga": 0.4227743529273414, + "exp4_tp": 77.51175315148927, + "exp5_er": 1.566158921380688, + "exp5_ga": 0.4808129543908409, + "exp5_tp": 76.49260417613746, + "gnls_er": 1.5661710124267216, + "gnls_ga": 0.43921987635195425, + "gnls_la": 3693.146065235527, + "gnls_tp": 76.49829109592685, + "hill_er": 1.56618318750266, + "hill_ga": 0.4392211414112244, + "hill_tp": 76.4982866415209, + "poly1_a": 1.964864684075168, + "poly2_a": 13315.496644004026, + "poly2_b": 6833.361453964935, + "pow_aic": 83.17121500215309, + "pow_cov": 1, + "pow_rme": 27.538007561894084, + "pow_top": 99.66819933343275, + "all_bmed": 0, + "cnst_aic": 91.47566405075946, + "cnst_rme": 59.45598607857977, + "exp2_aic": 90.43010743722112, + "exp2_cov": 1, + "exp2_rme": 44.39325952551422, + "exp2_top": 98.2300154558304, + "exp3_aic": 85.41740122713443, + "exp3_cov": 1, + "exp3_rme": 27.91524176610176, + "exp3_top": 100.72988078777028, + "exp4_aic": 73.1330171088266, + "exp4_cov": 1, + "exp4_rme": 15.554088816265924, + "exp4_top": 77.51175315148927, + "exp5_aic": 64.42879073216514, + "exp5_cov": 1, + "exp5_rme": 10.586877659593066, + "exp5_top": 76.49260417613746, + "gnls_aic": 68.42786525704236, + "gnls_cov": 1, + "gnls_rme": 10.586540812021129, + "gnls_top": 76.49829109470431, + "hill_aic": 64.42786525848331, + "hill_cov": 1, + "hill_rme": 10.58654076385496, + "hill_top": 76.4982866415209, + "poly1_er": 3.675479917703469, + "poly2_er": 3.6753004741857582, + "pow_a_sd": 14.109693155432794, + "pow_ac50": 4.960644811507054, + "pow_p_sd": 0.13040289753508288, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 95296.73353627026, + "exp2_ac50": 25.06268265173192, + "exp2_b_sd": 48443.778447988494, + "exp3_a_sd": 1550.6811753333395, + "exp3_ac50": 5.520304040411192, + "exp3_b_sd": 261983.9706240629, + "exp3_p_sd": 0.14665644781542486, + "exp4_ac50": 0.4227743529273414, + "exp5_ac50": 0.4808129543908409, + "exp5_p_sd": 3.3678395549353852, + "gnls_ac50": 0.4392198767408624, + "gnls_p_sd": 3.3958255218054663, + "gnls_q_sd": 151123.9464489836, + "hill_ac50": 0.4392211414112244, + "hill_p_sd": 3.3956061053853364, + "poly1_aic": 88.41948218774404, + "poly1_cov": 1, + "poly1_rme": 44.36648863230358, + "poly1_top": 98.2432342037584, + "poly2_aic": 90.43488820771466, + "poly2_cov": 1, + "poly2_rme": 44.40668518959494, + "poly2_top": 98.14296226438184, + "pow_er_sd": 0.30358860504155505, + "exp2_er_sd": 0.3103300882267534, + "exp3_er_sd": 0.31482864784179443, + "exp4_er_sd": 0.3265560847968896, + "exp4_ga_sd": 0.18734711782917823, + "exp4_tp_sd": 6.138860820650144, + "exp5_er_sd": 0.42334596392662655, + "exp5_ga_sd": 0.08381003754668022, + "exp5_tp_sd": 2.37147868048167, + "gnls_er_sd": 0.4232676288363896, + "gnls_ga_sd": 0.09134632329842142, + "gnls_la_sd": 397472143.96622753, + "gnls_tp_sd": 2.3747859083019507, + "hill_er_sd": 0.4232684668587263, + "hill_ga_sd": 0.09134005178183088, + "hill_tp_sd": 2.3748058180813865, + "poly1_a_sd": 0.744525928526376, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 108969.20708301498, + "poly2_ac50": 25.090797462838403, + "poly2_b_sd": 55447.95612242906, + "poly1_er_sd": 0.31021542326112006, + "poly2_er_sd": 0.3101964438666455, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3693.146065255056 + }, + "mc5Param": { + "p": 5.312112708921902, + "er": 1.56618318750266, + "ga": 0.4392211414112244, + "tp": 76.4982866415209, + "ac5": 0.25232432887622686, + "acc": 0.37284383772523594, + "bmd": 0.3026161445689406, + "bmr": 9.289141683881516, + "mll": -28.213932629241658, + "top": 76.4982866415209, + "ac10": 0.2904343777444861, + "ac20": 0.3383343045279963, + "ac50": 0.4392211414112244, + "bmdl": 0.24652928226101983, + "bmdu": 0.34140137679409, + "rmse": 10.58654076385496, + "ac1sd": 0.28414838641852014, + "caikwt": 0.0000013385806326866767, + "hitcall": 0.9999986614193672, + "top_over_cutoff": 3.3877568980269706 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842413, + "spid": "Strychnine nitrate", + "chid": null, + "casn": null, + "chnm": null, + "dtxsid": null, + "bmad": 3.7634679299683276, + "respMax": 101.90302651672913, + "respMin": -13.656252398863883, + "maxMean": 90.10574793432083, + "maxMeanConc": 0.0, + "maxMed": 92.78949471220062, + "maxMedConc": 1.0, + "logcMax": 1.0, + "logcMin": -2.0, + "nconc": 5, + "npts": 120, + "nrep": 28.0, + "nmedGtbl": 4, + "tmpi": 12, + "m5id": 5037059, + "modl": "hill", + "hitc": 0.9999999999995097, + "fitc": 41, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": null, + "stkc": null, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + 0, + -1, + -1.3010299956639813, + -1.3010299956639813, + 0, + -2, + -1, + 1, + 1, + -2, + -2, + 0, + 0, + 0, + -2, + -2, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + -2, + 1, + -1.3010299956639813, + 0, + -1, + -1.3010299956639813, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + -1, + 0, + -2, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + -1.3010299956639813, + 1, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + -1.3010299956639813, + -1, + -1.3010299956639813, + -2, + -1.3010299956639813, + 1, + -2, + 0, + 0, + -2, + -1.3010299956639813, + 0, + 0, + -1, + -2, + 0, + 0, + 0, + 0, + -2, + -2, + 0, + 0, + -1, + -1.3010299956639813, + 0, + -2, + -1.3010299956639813, + 1, + 0, + -1.3010299956639813, + 0, + -1, + 0, + 0, + -1, + -1.3010299956639813, + 1, + -2, + -1.3010299956639813, + -1.3010299956639813, + 1, + -2, + 0, + 1, + 0, + 0, + 1, + -2, + 0, + 0, + -2, + -2, + 0, + -1.3010299956639813, + 0, + 0, + -2, + -1, + -1.3010299956639813, + -1.3010299956639813, + -1.3010299956639813 + ], + "resp": [ + 87.54658046017934, + 78.13232047400955, + 70.93317595233076, + 57.12698428271491, + 99.1261742792355, + 37.51266678271632, + 67.39566754400876, + 87.16917249987551, + 97.84412575893514, + 36.182153851871945, + 18.676759780138298, + 86.14639524902825, + 92.14700970993877, + 88.8633754305396, + 52.588582215844326, + 15.582133819049302, + 6.7437112326760795, + 90.99910854039037, + 93.537388378317, + 4.532945470243127, + 98.29029571012077, + 87.5125820151942, + 95.77948529616398, + 76.69719021917145, + 79.44282282360146, + 93.41848845767122, + 43.82855649076092, + 60.078635480642816, + 48.55573840229915, + 93.38936767278678, + 68.38088898210545, + 94.44174081967034, + 70.23063280229242, + 67.58951070420052, + 88.25476716259126, + 78.28663544945115, + 73.35709503155529, + 87.41418530525512, + 34.29624566401982, + 51.689530650495065, + 94.77671619175891, + 9.717713327456835, + 68.42696208430887, + 89.1457018171264, + 98.63621639131843, + 21.819867325289668, + 73.31442418286787, + 84.44684859725044, + 101.90302651672913, + 52.3796866174266, + 76.70392442439466, + 95.96954413243368, + 37.932664452132045, + 85.53995501238715, + 93.19761923373274, + 9.374938681003872, + 97.00772826137256, + 94.52068000480857, + 70.03934960306947, + 70.2207854474335, + 80.60056702989422, + 49.65332555177622, + 50.62118183723142, + -13.656252398863883, + 25.103929419420417, + 84.06775274470809, + 93.89545097387872, + 13.05234184109041, + 68.04669508697455, + 88.31017585712213, + 95.74909219574056, + 71.26573270110495, + 29.657483179306475, + 89.44967487095494, + 87.91122190917191, + 89.16083809801721, + 94.23105830572473, + 11.031715473484446, + 35.95756511831335, + 83.96484285494779, + 91.13344836386635, + 74.37468254708669, + 75.90341444167755, + 84.57925357612386, + 98.09697348327087, + 80.87025230976089, + 95.69038769184029, + 88.16849658860856, + 80.80349695840118, + 81.03526087553716, + 70.7375590556676, + 89.62211351249503, + 92.83767649850626, + 69.7285258942436, + 77.48304372596083, + 85.86002702419643, + 32.2784448599929, + 46.17015103402697, + 80.62410063741106, + 95.95106666573619, + 10.20724914281911, + 79.02545835944098, + 87.98083471817364, + 91.89339887484604, + 95.37517669787248, + 92.18962175161448, + 25.413153770849384, + 85.26467195488401, + 94.339523858436, + 21.432040978539256, + 30.458993571633304, + 93.86466610169768, + 70.85250358307763, + 84.70694885833929, + 90.17107266940845, + 42.17348917186203, + 67.85218078295692, + 80.66923781410267, + 52.40470406123019, + 66.29938729985028 + ] + }, + "mc4Param": { + "pow_a": 87.09928260115939, + "pow_p": 0.30000001846938457, + "exp2_a": 31883.447199556984, + "exp2_b": 2940.8756880830274, + "exp3_a": 91.76407834702847, + "exp3_b": 10.74787786809403, + "exp3_p": 5.705870147581669, + "exp5_p": 0.7347141145071212, + "gnls_p": 1.14249184755643, + "gnls_q": 7.1666617485862645, + "hill_p": 1.1425173709866314, + "pow_er": 3.2609559647059276, + "cnst_er": 4.280418232198627, + "exp2_er": 4.136618684570908, + "exp3_er": 4.195352905645352, + "exp4_er": 2.22008241758199, + "exp4_ga": 0.022051638521133003, + "exp4_tp": 89.00270902788958, + "exp5_er": 2.1777043891985155, + "exp5_ga": 0.020174723818180185, + "exp5_tp": 90.09083963206248, + "gnls_er": 2.1414728444590416, + "gnls_ga": 0.019239355601206622, + "gnls_la": 152.60173969793468, + "gnls_tp": 90.96174103754969, + "hill_er": 2.141463902181826, + "hill_ga": 0.019239408518013583, + "hill_tp": 90.96158402591846, + "poly1_a": 10.857285554865078, + "poly2_a": 43956.72490990105, + "poly2_b": 4063.958522468021, + "pow_aic": 1201.4051365890562, + "pow_cov": 1, + "pow_rme": 38.55227695861075, + "pow_top": 173.78592362556904, + "all_bmed": 0, + "cnst_aic": 1403.090413337808, + "cnst_rme": 74.8904479807055, + "exp2_aic": 1374.4311656282052, + "exp2_cov": 1, + "exp2_rme": 65.81746775643614, + "exp2_top": 108.5993407555391, + "exp3_aic": 1391.1625030286802, + "exp3_cov": 1, + "exp3_rme": 70.11489384972245, + "exp3_top": 86.24941190716868, + "exp4_aic": 958.5585213667588, + "exp4_cov": 1, + "exp4_rme": 17.136859425351332, + "exp4_top": 89.00270902788958, + "exp5_aic": 951.462915769895, + "exp5_cov": 1, + "exp5_rme": 16.563670044171328, + "exp5_top": 90.09083963206248, + "gnls_aic": 949.1076392567716, + "gnls_cov": 1, + "gnls_rme": 16.523174598011288, + "gnls_top": 90.94223261829664, + "hill_aic": 945.1076391339816, + "hill_cov": 1, + "hill_rme": 16.52318715556179, + "hill_top": 90.96158402591846, + "poly1_er": 4.136728636883216, + "poly2_er": 4.136765485844394, + "pow_a_sd": null, + "pow_ac50": 0.9921257986045094, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 199788.2012717345, + "exp2_ac50": 5.004250432627864, + "exp2_b_sd": 18377.639690188746, + "exp3_a_sd": null, + "exp3_ac50": 9.093200201104786, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.022051638521133003, + "exp5_ac50": 0.020174723818180185, + "exp5_p_sd": 0.0740314724723753, + "gnls_ac50": 0.01923213377527789, + "gnls_p_sd": 0.11328716035704128, + "gnls_q_sd": 5416.430149594935, + "hill_ac50": 0.019239408518013583, + "hill_p_sd": 0.11328905952344805, + "poly1_aic": 1372.405512117827, + "poly1_cov": 1, + "poly1_rme": 65.81045931392097, + "poly1_top": 108.57285554865078, + "poly2_aic": 1374.4425868107508, + "poly2_cov": 1, + "poly2_rme": 65.82134141098302, + "poly2_top": 108.42848666577588, + "pow_er_sd": null, + "exp2_er_sd": 0.07550543011989125, + "exp3_er_sd": null, + "exp4_er_sd": 0.08755079994277236, + "exp4_ga_sd": 0.0017581307838751255, + "exp4_tp_sd": 1.2648745704125903, + "exp5_er_sd": 0.08793429019100046, + "exp5_ga_sd": 0.001896252806984504, + "exp5_tp_sd": 1.229548672184863, + "gnls_er_sd": 0.08841293445887041, + "gnls_ga_sd": 0.0016388070613483495, + "gnls_la_sd": 314310.1153126622, + "gnls_tp_sd": 1.3592077185077482, + "hill_er_sd": 0.08841259880190765, + "hill_ga_sd": 0.001638789350228368, + "hill_tp_sd": 1.3591867915855804, + "poly1_a_sd": 1.724413789883238, + "poly1_ac50": 5, + "poly2_a_sd": 229686.482934115, + "poly2_ac50": 5.006136528441479, + "poly2_b_sd": 21186.121669100652, + "poly1_er_sd": 0.07551023114530929, + "poly2_er_sd": 0.07551301062757607, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 152.6093800236882 + }, + "mc5Param": { + "p": 1.1425173709866314, + "er": 2.141463902181826, + "ga": 0.019239408518013583, + "tp": 90.96158402591846, + "ac5": 0.001462007378119528, + "acc": 0.007294932270379909, + "bmd": 0.002869845955059214, + "bmr": 9.289141683881516, + "mll": -468.55381956699074, + "top": 90.96158402591846, + "ac10": 0.0028117791882338312, + "ac20": 0.005717847375539592, + "ac50": 0.019239408518013583, + "bmdl": 0.002556132850019782, + "bmdu": 0.003219636919114361, + "rmse": 16.52318715556179, + "ac1sd": 0.0021529836063463184, + "caikwt": 3.550619862824629E-100, + "hitcall": 0.9999999999995096, + "top_over_cutoff": 4.028269746527992 + }, + "mc6Param": null + }, + { + "aeid": 704, + "m4id": 1842414, + "spid": "TP0000202A12", + "chid": 40755, + "casn": "113776-20-8", + "chnm": "Fenoxaprop-(2S)-ethyl", + "dtxsid": "DTXSID0040755", + "bmad": 3.7634679299683276, + "respMax": 2.1463056962554306, + "respMin": -31.174537622350467, + "maxMean": 2.1463056962554306, + "maxMeanConc": 0.3010299956639812, + "maxMed": 2.1463056962554306, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 13, + "m5id": 5037060, + "modl": "poly1", + "hitc": 3.112525321590652E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + -6.001541932753394, + -22.555888323094198, + 2.1463056962554306, + 1.48208851017487, + -31.174537622350467, + -1.4820885101748698, + -18.65401670786573, + -1.8956068394961023 + ] + }, + "mc4Param": { + "pow_a": 7.93772851385601E-8, + "pow_p": 0.3920636582682493, + "exp2_a": 0.000006112271332380458, + "exp2_b": 53.427073060892454, + "exp3_a": 0.00004898139853742899, + "exp3_b": 51.88258897771602, + "exp3_p": 2.324270887717195, + "exp5_p": 0.7819736441489689, + "gnls_p": 0.3273711734771393, + "gnls_q": 5.276277742389474, + "hill_p": 2.275897186558642, + "pow_er": 2.455992402942634, + "cnst_er": 2.4560891502518984, + "exp2_er": 2.4574807100236153, + "exp3_er": 2.4557796019426146, + "exp4_er": 2.456099699774736, + "exp4_ga": 2.3234618330958865, + "exp4_tp": 3.9607133152532646E-9, + "exp5_er": 2.4560842486541183, + "exp5_ga": 3.1011214463834262, + "exp5_tp": 5.124637982443043E-9, + "gnls_er": 2.45606236272885, + "gnls_ga": 2.0776018550817037, + "gnls_la": 105.43975814448936, + "gnls_tp": 2.3963648893966506E-8, + "hill_er": 2.456123173511501, + "hill_ga": 86.3108381026584, + "hill_tp": 4.991236675789709E-8, + "poly1_a": 5.0558047407700206E-11, + "poly2_a": 0.000050849272267483245, + "poly2_b": 54.52806494231579, + "pow_aic": 72.32793038983723, + "pow_cov": 1, + "pow_rme": 15.318305641270856, + "pow_top": 3.6796002210498555E-7, + "all_bmed": 0, + "cnst_aic": 68.32793015445507, + "cnst_rme": 15.318305491530715, + "exp2_aic": 72.32794851195803, + "exp2_cov": 1, + "exp2_rme": 15.318307841595969, + "exp2_top": 0.00000947030777995316, + "exp3_aic": 74.32794792480452, + "exp3_cov": 1, + "exp3_rme": 15.318319988232922, + "exp3_top": 0.00007364243647945785, + "exp4_aic": 72.32793015872747, + "exp4_cov": 1, + "exp4_rme": 15.318305493705283, + "exp4_top": 3.9607133152532646E-9, + "exp5_aic": 74.32793015704087, + "exp5_cov": 1, + "exp5_rme": 15.31830549412419, + "exp5_top": 5.124637982443043E-9, + "gnls_aic": 78.32793016843104, + "gnls_cov": 1, + "gnls_rme": 15.31830550116845, + "gnls_top": 1.7376669540347054E-8, + "hill_aic": 74.32793016978079, + "hill_cov": 1, + "hill_rme": 15.318305493880896, + "hill_top": 4.991236675789709E-8, + "poly1_er": 2.456091603321706, + "poly2_er": 2.458795669607504, + "pow_a_sd": null, + "pow_ac50": 8.534164879531097, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.647334567122023, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 40.44683070951887, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.3234618330958865, + "exp5_ac50": 3.1011214463834262, + "exp5_p_sd": null, + "gnls_ac50": 0.3706914715054184, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 86.3108381026584, + "hill_p_sd": null, + "poly1_aic": 70.32793015555615, + "poly1_cov": 1, + "poly1_rme": 15.31830549222699, + "poly1_top": 2.5279023703850103E-9, + "poly2_aic": 72.32801460829577, + "poly2_cov": 1, + "poly2_rme": 15.318327400684396, + "poly2_top": 0.00008938146834261408, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.67152733580562, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 108.5387707140687 + }, + "mc5Param": { + "a": 5.0558047407700206E-11, + "er": 2.456091603321706, + "ac5": 2.4999999999999996, + "bmd": 183732208029.59137, + "bmr": 9.289141683881516, + "mll": -33.16396507777807, + "top": 2.5279023703850103E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 55.118208071787095, + "rmse": 15.31830549222699, + "ac1sd": 136198819888.5036, + "caikwt": 0.7310585787382466, + "hitcall": 0.0003112525321590652, + "top_over_cutoff": 1.1194915688689839E-10 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842415, + "spid": "TP0000202E12", + "chid": 32488, + "casn": "117718-60-2", + "chnm": "Thiazopyr", + "dtxsid": "DTXSID1032488", + "bmad": 3.7634679299683276, + "respMax": 6.446936756495938, + "respMin": -27.99639047559999, + "maxMean": 6.446936756495938, + "maxMeanConc": -0.6989700043360187, + "maxMed": 6.446936756495938, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 14, + "m5id": 5037061, + "modl": "poly1", + "hitc": 3.46254861405938E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + 2.3401929572491063, + -9.617064235516741, + -24.581899003404654, + -5.427697641004625, + 5.427697641004625, + -9.142353819653172, + -27.99639047559999, + 6.446936756495938 + ] + }, + "mc4Param": { + "pow_a": 8.291778304541115E-8, + "pow_p": 0.759489844462891, + "exp2_a": 0.000005100967135478326, + "exp2_b": 66.78668129818874, + "exp3_a": 0.00000795052649415302, + "exp3_b": 59.8550913973304, + "exp3_p": 6.3695090638042515, + "exp5_p": 2.1989554286217405, + "gnls_p": 7.325020891066998, + "gnls_q": 7.999920644098824, + "hill_p": 5.230822870987461, + "pow_er": 2.4449412532586106, + "cnst_er": 2.444612267004776, + "exp2_er": 2.4454237030104045, + "exp3_er": 2.4444001292182183, + "exp4_er": 2.4446018093199684, + "exp4_ga": 5.268966164997101, + "exp4_tp": 2.503020809468994E-9, + "exp5_er": 2.4445975509803857, + "exp5_ga": 4.6875957305191935, + "exp5_tp": 1.1081629207669447E-9, + "gnls_er": 2.4231904512610143, + "gnls_ga": 0.004416803248006645, + "gnls_la": 0.82966745174129, + "gnls_tp": 2.40116151835256, + "hill_er": 2.444611179532325, + "hill_ga": 142.56639582523107, + "hill_tp": 0.00006917638723040847, + "poly1_a": 4.602316355764391E-10, + "poly2_a": 0.000012228970875458648, + "poly2_b": 51.825063680254665, + "pow_aic": 71.6355163848002, + "pow_cov": 1, + "pow_rme": 14.448605421396229, + "pow_top": 0.0000016180731311326594, + "all_bmed": 0, + "cnst_aic": 67.63551484073298, + "cnst_rme": 14.44860501974752, + "exp2_aic": 71.63552232788017, + "exp2_cov": 1, + "exp2_rme": 14.448606013868249, + "exp2_top": 0.000005683236291608053, + "exp3_aic": 73.63551565609121, + "exp3_cov": 1, + "exp3_rme": 14.448605256905164, + "exp3_top": 0.0000029758177359879932, + "exp4_aic": 71.63551484106912, + "exp4_cov": 1, + "exp4_rme": 14.448605020839846, + "exp4_top": 2.503020809468994E-9, + "exp5_aic": 73.63551484062032, + "exp5_cov": 1, + "exp5_rme": 14.448605020276853, + "exp5_top": 1.1081629207669447E-9, + "gnls_aic": 77.44750709660826, + "gnls_cov": 1, + "gnls_rme": 14.365799933750845, + "gnls_top": 2.401161508659121, + "hill_aic": 73.6355148837213, + "hill_cov": 1, + "hill_rme": 14.448605043026824, + "hill_top": 0.00006917638723040847, + "poly1_er": 2.444589406786654, + "poly2_er": 2.4442589836933477, + "pow_a_sd": null, + "pow_ac50": 20.072979750096557, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.57372140444595, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.38400488151858, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 5.268966164997101, + "exp5_ac50": 4.6875957305191935, + "exp5_p_sd": null, + "gnls_ac50": 0.004416803145331396, + "gnls_p_sd": 1521.0342465884344, + "gnls_q_sd": 78.00215408532839, + "hill_ac50": 142.56639582523107, + "hill_p_sd": null, + "poly1_aic": 69.63551484744472, + "poly1_cov": 1, + "poly1_rme": 14.448605024451211, + "poly1_top": 2.3011581778821953E-8, + "poly2_aic": 71.63552116107905, + "poly2_cov": 1, + "poly2_rme": 14.448608809150656, + "poly2_top": 0.0000231811467637089, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.33687191979010667, + "gnls_ga_sd": 1.384790805886578, + "gnls_la_sd": 4.751505700203281, + "gnls_tp_sd": 5.895901623091699, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.4194146457345064, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.8068290375481, + "poly2_b_sd": null, + "poly1_er_sd": 0.5297759747014638, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.8296674525635499 + }, + "mc5Param": { + "a": 4.602316355764391E-10, + "er": 2.444589406786654, + "ac5": 2.5, + "bmd": 20183622693.053, + "bmr": 9.289141683881516, + "mll": -32.81775742372236, + "top": 2.3011581778821953E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 51.81424943318225, + "rmse": 14.448605024451211, + "ac1sd": 14961914524.131208, + "caikwt": 0.7310585792898094, + "hitcall": 0.000346254861405938, + "top_over_cutoff": 1.0190770058816301E-9 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842416, + "spid": "TP0000267A05", + "chid": 20605, + "casn": "104-76-7", + "chnm": "2-Ethyl-1-hexanol", + "dtxsid": "DTXSID5020605", + "bmad": 3.7634679299683276, + "respMax": 8.917578703786559, + "respMin": -27.524983015647525, + "maxMean": 8.917578703786559, + "maxMeanConc": 1.3010299956639813, + "maxMed": 8.917578703786559, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 15, + "m5id": 5037062, + "modl": "poly1", + "hitc": 2.7345343716299954E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.3010299956639813, + -0.22184874961635637, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + -0.6989700043360187 + ], + "resp": [ + 8.917578703786559, + 2.303464923343869, + -2.654003487492171, + 5.234355203561155, + -1.2708393819946822, + 3.560451307578698, + 1.2708393819946822, + -27.524983015647525 + ] + }, + "mc4Param": { + "pow_a": 1.3409798272664342, + "pow_p": 0.30000125329590954, + "exp2_a": 0.000009166742411061137, + "exp2_b": 71.96205294539993, + "exp3_a": 0.00006076828394343419, + "exp3_b": 62.86725328613552, + "exp3_p": 7.737091326965924, + "exp5_p": 7.999225969557049, + "gnls_p": 7.999875866687627, + "gnls_q": 7.928505491369158, + "hill_p": 7.999295227329135, + "pow_er": 1.6343827564280675, + "cnst_er": 1.7486670966982418, + "exp2_er": 1.747752679520703, + "exp3_er": 1.7491987890837994, + "exp4_er": 1.4661518060319405, + "exp4_ga": 0.5858515967961853, + "exp4_tp": 4.070715215170674, + "exp5_er": 1.4537496560481071, + "exp5_ga": 0.5879387517028682, + "exp5_tp": 4.129989453625999, + "gnls_er": 1.453809084181787, + "gnls_ga": 0.5829865127961461, + "gnls_la": 2656.355330614829, + "gnls_tp": 4.13074242306633, + "hill_er": 1.453742415592828, + "hill_ga": 0.582943689295207, + "hill_tp": 4.130157183529929, + "poly1_a": 0.006514257261741929, + "poly2_a": 0.000027619479202203845, + "poly2_b": 55.994704795242086, + "pow_aic": 62.72267287754171, + "pow_cov": 1, + "pow_rme": 10.626636623495806, + "pow_top": 4.336260608140496, + "all_bmed": 0, + "cnst_aic": 59.54309904759475, + "cnst_rme": 10.564107501908008, + "exp2_aic": 63.54310497598492, + "exp2_cov": 1, + "exp2_rme": 10.564107437382722, + "exp2_top": 0.000009197264782794135, + "exp3_aic": 65.54310319994451, + "exp3_cov": 1, + "exp3_rme": 10.564107854679628, + "exp3_top": 0.000011262424950383531, + "exp4_aic": 61.53985639831838, + "exp4_cov": 1, + "exp4_rme": 10.486648481057117, + "exp4_top": 4.070715215170674, + "exp5_aic": 63.21877166657443, + "exp5_cov": 1, + "exp5_rme": 10.19418095478504, + "exp5_top": 4.129989453625999, + "gnls_aic": 67.21889618297809, + "gnls_cov": 1, + "gnls_rme": 10.194291475779997, + "gnls_top": 4.130742423066309, + "hill_aic": 63.218896291500144, + "hill_cov": 1, + "hill_rme": 10.194281256916245, + "hill_top": 4.130157183529929, + "poly1_er": 1.7507922358775536, + "poly2_er": 1.749512892071607, + "pow_a_sd": 3.295794305479151, + "pow_ac50": 4.960676169539393, + "pow_p_sd": 0.5672534752096554, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.2579276272496, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.9617423857624, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.5858515967961853, + "exp5_ac50": 0.5879387517028682, + "exp5_p_sd": 98.74044274222942, + "gnls_ac50": 0.5829865133961057, + "gnls_p_sd": 74.31411976207677, + "gnls_q_sd": 6357704.376873938, + "hill_ac50": 0.582943689295207, + "hill_p_sd": 74.30108138165775, + "poly1_aic": 61.53965299852143, + "poly1_cov": 1, + "poly1_rme": 10.559185088231294, + "poly1_top": 0.3257128630870964, + "poly2_aic": 63.543106176613115, + "poly2_cov": 1, + "poly2_rme": 10.564107377657889, + "poly2_top": 0.00004668482556197718, + "pow_er_sd": 0.4819729825595672, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.42833896312172504, + "exp4_ga_sd": 1.0334925947270197, + "exp4_tp_sd": 2.6528735376099615, + "exp5_er_sd": 0.42414936250544655, + "exp5_ga_sd": 0.2459821670424215, + "exp5_tp_sd": 2.444384508491113, + "gnls_er_sd": 0.42415640100500435, + "gnls_ga_sd": 0.32464475146069505, + "gnls_la_sd": 8816666864.83012, + "gnls_tp_sd": 2.4443852082427937, + "hill_er_sd": 0.4241479766226494, + "hill_ga_sd": 0.32494411453400046, + "hill_tp_sd": 2.4443739248424277, + "poly1_a_sd": 0.11187540886288934, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.600594333963585, + "poly2_b_sd": null, + "poly1_er_sd": 0.3807131709053242, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2656.355330614833 + }, + "mc5Param": { + "a": 0.006514257261741929, + "er": 1.7507922358775536, + "ac5": 2.4999999999999996, + "bmd": 1425.9709604096254, + "bmr": 9.289141683881516, + "mll": -28.769826499260716, + "top": 0.3257128630870964, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 35.11258847587849, + "rmse": 10.559185088231294, + "ac1sd": 1057.0577912599151, + "caikwt": 0.7307196766051358, + "hitcall": 0.00027345343716299954, + "top_over_cutoff": 0.014424323042295618 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842417, + "spid": "TP0000267B05", + "chid": 34287, + "casn": "104-67-6", + "chnm": "5-Heptyldihydro-2(3H)-furanone", + "dtxsid": "DTXSID4034287", + "bmad": 3.7634679299683276, + "respMax": 2.5626891439251516, + "respMin": -8.146024449386633, + "maxMean": 2.5626891439251516, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.5626891439251516, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 16, + "m5id": 5037063, + "modl": "poly1", + "hitc": 1.807739510130505E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.3010299956639813, + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + -0.6989700043360187 + ], + "resp": [ + -6.177917513479251, + -7.198652565084555, + -8.146024449386633, + -6.691171080481884, + -2.56268914392515, + 2.5626891439251516, + -2.808406691690573, + -1.4980285452563038 + ] + }, + "mc4Param": { + "pow_a": 5.2359519867188026E-8, + "pow_p": 0.38277275314144577, + "exp2_a": 0.000011087622110252254, + "exp2_b": 59.03037755815387, + "exp3_a": 0.000011323074766607115, + "exp3_b": 58.09532026397317, + "exp3_p": 3.173411562559084, + "exp5_p": 1.8704058411614604, + "gnls_p": 4.0745292599201, + "gnls_q": 7.9950187264172525, + "hill_p": 3.453820607013757, + "pow_er": 1.5839659163624915, + "cnst_er": 1.5838738330644857, + "exp2_er": 1.5830676537547204, + "exp3_er": 1.5842203728625608, + "exp4_er": 1.583875903464905, + "exp4_ga": 2.6417915753408012, + "exp4_tp": 1.5063871691541615E-9, + "exp5_er": 1.5838758461193252, + "exp5_ga": 1.4518069133691405, + "exp5_tp": 5.003350528655981E-10, + "gnls_er": 1.569937001781506, + "gnls_ga": 0.002000000005206344, + "gnls_la": 0.06324555337954348, + "gnls_tp": 1.6871203757458295, + "hill_er": 1.5838672292493845, + "hill_ga": 0.0032734995034449416, + "hill_tp": 1.5616538074162555E-9, + "poly1_a": 4.100095671825759E-11, + "poly2_a": 0.000003605359587272573, + "poly2_b": 56.69107597259129, + "pow_aic": 56.66259887682483, + "pow_cov": 1, + "pow_rme": 5.2960214297578565, + "pow_top": 2.3405346854235685E-7, + "all_bmed": 0, + "cnst_aic": 52.66259853073265, + "cnst_rme": 5.296021351915426, + "exp2_aic": 56.66261266299513, + "exp2_cov": 1, + "exp2_rme": 5.2960232653217565, + "exp2_top": 0.000014776347844907314, + "exp3_aic": 58.662602705894976, + "exp3_cov": 1, + "exp3_rme": 5.296022056507032, + "exp3_top": 0.00000974958415866995, + "exp4_aic": 56.662598532902635, + "exp4_cov": 1, + "exp4_rme": 5.296021352581836, + "exp4_top": 1.5063871691541615E-9, + "exp5_aic": 58.662598531608296, + "exp5_cov": 1, + "exp5_rme": 5.296021352180456, + "exp5_top": 5.003350528655981E-10, + "gnls_aic": 62.508666224566085, + "gnls_cov": 1, + "gnls_rme": 5.262039104915749, + "gnls_top": 1.686834446740104, + "hill_aic": 58.66259853487741, + "hill_cov": 1, + "hill_rme": 5.296021353114272, + "hill_top": 1.5616538074162555E-9, + "poly1_er": 1.5838907558030877, + "poly2_er": 1.584058977857187, + "pow_a_sd": null, + "pow_ac50": 8.175687415188362, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.142811088618416, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.03157273784789, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.6417915753408012, + "exp5_ac50": 1.4518069133691405, + "exp5_p_sd": null, + "gnls_ac50": 0.0019998336398390293, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.0032734995034449416, + "hill_p_sd": null, + "poly1_aic": 54.6625985350956, + "poly1_cov": 1, + "poly1_rme": 5.296021352230097, + "poly1_top": 2.050047835912879E-9, + "poly2_aic": 56.6626016317032, + "poly2_cov": 1, + "poly2_rme": 5.296022098645178, + "poly2_top": 0.000005984354139645306, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.12305820350276302, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.56750321043185, + "poly2_b_sd": null, + "poly1_er_sd": 0.387494804373577, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.06324822341628866 + }, + "mc5Param": { + "a": 4.100095671825759E-11, + "er": 1.5838907558030877, + "ac5": 2.4999999999999996, + "bmd": 226559144649.05865, + "bmr": 9.289141683881516, + "mll": -25.3312992675478, + "top": 2.050047835912879E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 116.03234310631164, + "rmse": 5.296021352230097, + "ac1sd": 167945993068.24213, + "caikwt": 0.7310585790589084, + "hitcall": 1.807739510130505E-7, + "top_over_cutoff": 9.078717971742852E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842418, + "spid": "TP0000267C07", + "chid": 26525, + "casn": "88-18-6", + "chnm": "2-tert-Butylphenol", + "dtxsid": "DTXSID2026525", + "bmad": 3.7634679299683276, + "respMax": 4.284991950831092, + "respMin": -17.752010560601963, + "maxMean": 4.284991950831092, + "maxMeanConc": -0.6989700043360187, + "maxMed": 4.284991950831092, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 17, + "m5id": 5037064, + "modl": "poly1", + "hitc": 1.080834578284038E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436 + ], + "resp": [ + -3.429511618336063, + -10.303773152544004, + 4.284991950831092, + -17.752010560601963, + -11.184188881006792, + 3.429511618336063, + -11.946623245214802, + -14.030114108296962 + ] + }, + "mc4Param": { + "pow_a": 1.1688027459778409E-7, + "pow_p": 0.3542167430597227, + "exp2_a": 0.00001402914266781098, + "exp2_b": 62.43720598776625, + "exp3_a": 8.518851392561705E-7, + "exp3_b": 55.14935347186949, + "exp3_p": 5.08068979673058, + "exp5_p": 0.934648289336587, + "gnls_p": 5.502938821699771, + "gnls_q": 7.707236696501689, + "hill_p": 1.330809264220454, + "pow_er": 2.294643719896335, + "cnst_er": 2.294672403578953, + "exp2_er": 2.2949759846580298, + "exp3_er": 2.2939792210930836, + "exp4_er": 2.2946893862543956, + "exp4_ga": 1.6265408298714532, + "exp4_tp": 1.7029436841556618E-10, + "exp5_er": 2.294667883086028, + "exp5_ga": 9.989504833632218, + "exp5_tp": 1.1382103679305392E-9, + "gnls_er": 2.2946723713323243, + "gnls_ga": 0.04465268081832286, + "gnls_la": 1.4750833148086038, + "gnls_tp": 9.842124013532871E-9, + "hill_er": 2.294684574430046, + "hill_ga": 113.24013298211491, + "hill_tp": 3.8147986424229266E-8, + "poly1_a": 1.930068017745631E-10, + "poly2_a": 0.000008995913833305391, + "poly2_b": 60.79500343541555, + "pow_aic": 68.01728590637344, + "pow_cov": 1, + "pow_rme": 10.769388915092584, + "pow_top": 4.672451958820215E-7, + "all_bmed": 0, + "cnst_aic": 64.01728561110329, + "cnst_rme": 10.769388711778616, + "exp2_aic": 68.01729252056795, + "exp2_cov": 1, + "exp2_rme": 10.769393202636683, + "exp2_top": 0.000017218419324428374, + "exp3_aic": 70.01729110083275, + "exp3_cov": 1, + "exp3_rme": 10.769388859159086, + "exp3_top": 7.124009276524897E-7, + "exp4_aic": 68.01728561547779, + "exp4_cov": 1, + "exp4_rme": 10.769388711877632, + "exp4_top": 1.7029436841556618E-10, + "exp5_aic": 70.01728561164555, + "exp5_cov": 1, + "exp5_rme": 10.769388712196594, + "exp5_top": 1.1382103679305392E-9, + "gnls_aic": 74.01728561314724, + "gnls_cov": 1, + "gnls_rme": 10.769388713041575, + "gnls_top": 9.841866233302444E-9, + "hill_aic": 70.0172856168267, + "hill_cov": 1, + "hill_rme": 10.769388714323313, + "hill_top": 3.8147986424229266E-8, + "poly1_er": 2.2946661884606754, + "poly2_er": 2.2951725166659296, + "pow_a_sd": null, + "pow_ac50": 7.065178187371053, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.87674555498022, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.83746128233124, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.6265408298714532, + "exp5_ac50": 9.989504833632218, + "exp5_p_sd": null, + "gnls_ac50": 0.04465225444658185, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 113.24013298211491, + "hill_p_sd": null, + "poly1_aic": 66.01728561475585, + "poly1_cov": 1, + "poly1_rme": 10.769388714484304, + "poly1_top": 9.650340088728157E-9, + "poly2_aic": 68.01729292719538, + "poly2_cov": 1, + "poly2_rme": 10.769392172059073, + "poly2_top": 0.000013483408486187177, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.29967162033605704, + "exp4_ga_sd": 2.700161867338397, + "exp4_tp_sd": 0.000018830151796886426, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.379822973030592, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.475093338726149 + }, + "mc5Param": { + "a": 1.930068017745631E-10, + "er": 2.2946661884606754, + "ac5": 2.4999999999999996, + "bmd": 48128571627.913246, + "bmr": 9.289141683881516, + "mll": -31.008642807377925, + "top": 9.650340088728157E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 64.94939269971773, + "rmse": 10.769388714484304, + "ac1sd": 35677221369.839325, + "caikwt": 0.7310585789890732, + "hitcall": 0.0001080834578284038, + "top_over_cutoff": 4.2736912994009806E-10 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842419, + "spid": "TP0000267C12", + "chid": 21217, + "casn": "58-14-0", + "chnm": "Pyrimethamine", + "dtxsid": "DTXSID9021217", + "bmad": 3.7634679299683276, + "respMax": 27.43198135493239, + "respMin": -9.573031880730055, + "maxMean": 27.43198135493239, + "maxMeanConc": 1.6989700043360187, + "maxMed": 27.43198135493239, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 18, + "m5id": 5037065, + "modl": "exp5", + "hitc": 0.9993015893938282, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + 0.7781512503836436 + ], + "resp": [ + -1.3626102221550411, + 1.362610222155042, + 26.100011514016813, + 5.083220148547186, + -9.573031880730055, + 12.263055448994821, + 27.43198135493239, + 19.028440712908623 + ] + }, + "mc4Param": { + "pow_a": 8.615918330641122, + "pow_p": 0.3256460648100804, + "exp2_a": 5515.924011580759, + "exp2_b": 8569.91582576029, + "exp3_a": 190.5815796850594, + "exp3_b": 18144.73145449149, + "exp3_p": 0.32098963519530016, + "exp5_p": 0.6697053366805052, + "gnls_p": 0.8182614183023493, + "gnls_q": 6.583211395264323, + "hill_p": 0.8182571770652887, + "pow_er": 1.363988503208183, + "cnst_er": 2.6252428146846465, + "exp2_er": 2.109704617961689, + "exp3_er": 1.5388722444020404, + "exp4_er": 0.9165567589387242, + "exp4_ga": 2.8867935103137805, + "exp4_tp": 26.682134872783596, + "exp5_er": 0.4118882359089413, + "exp5_ga": 2.6834018978246137, + "exp5_tp": 27.76803833586464, + "gnls_er": 0.5050076143816886, + "gnls_ga": 3.278943112805881, + "gnls_la": 4931.293978658584, + "gnls_tp": 30.974706420358636, + "hill_er": 0.5049887009187453, + "hill_ga": 3.2789253729229126, + "hill_tp": 30.974702991700216, + "poly1_a": 0.6448409372956132, + "poly2_a": 7685.079924681028, + "poly2_b": 11973.64247334707, + "pow_aic": 56.39160653523915, + "pow_cov": 1, + "pow_rme": 6.526761203406884, + "pow_top": 30.80097539574928, + "all_bmed": 0, + "cnst_aic": 69.92173854270355, + "cnst_rme": 16.07553951933683, + "exp2_aic": 65.29200171582212, + "exp2_cov": 1, + "exp2_rme": 9.191283585871052, + "exp2_top": 32.27596638509631, + "exp3_aic": 58.79084317495332, + "exp3_cov": 1, + "exp3_rme": 6.506169486296934, + "exp3_top": 31.014883737948537, + "exp4_aic": 50.88878665018997, + "exp4_cov": 1, + "exp4_rme": 4.969757377064164, + "exp4_top": 26.682134872783596, + "exp5_aic": 50.77303496851002, + "exp5_cov": 1, + "exp5_rme": 5.679144326208646, + "exp5_top": 27.76803833586464, + "gnls_aic": 55.27492786162859, + "gnls_cov": 1, + "gnls_rme": 5.673955293548314, + "gnls_top": 30.762420047102612, + "hill_aic": 51.27492786216142, + "hill_cov": 1, + "hill_rme": 5.6739736678642325, + "hill_top": 30.974702991700216, + "poly1_er": 2.108328509307753, + "poly2_er": 2.108918234235728, + "pow_a_sd": 1.9065377706614512, + "pow_ac50": 5.950610001585547, + "pow_p_sd": 0.06581177305373388, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 54261.41693977886, + "exp2_ac50": 25.03646471717236, + "exp2_b_sd": 83920.69797802145, + "exp3_a_sd": 319.30330931872754, + "exp3_ac50": 6.473920870323869, + "exp3_b_sd": 71486.21897878859, + "exp3_p_sd": 0.089062666508518, + "exp4_ac50": 2.8867935103137805, + "exp5_ac50": 2.6834018978246137, + "exp5_p_sd": 0.11428693722103664, + "gnls_ac50": 3.224472657149256, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 3.2789253729229126, + "hill_p_sd": 0.21665202304453965, + "poly1_aic": 63.28151185739537, + "poly1_cov": 1, + "poly1_rme": 9.185966970005357, + "poly1_top": 32.242046864780654, + "poly2_aic": 65.29643872279352, + "poly2_cov": 1, + "poly2_rme": 9.195851294815698, + "poly2_top": 32.22566397929895, + "pow_er_sd": 0.3611517914109552, + "exp2_er_sd": 0.3104544270600404, + "exp3_er_sd": 0.3808951094369049, + "exp4_er_sd": 0.3893880417326298, + "exp4_ga_sd": 0.8092255223155269, + "exp4_tp_sd": 1.7181047521648634, + "exp5_er_sd": 0.4652947689906473, + "exp5_ga_sd": 0.5440220897387579, + "exp5_tp_sd": 1.4682435434842378, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.44727516724237865, + "hill_ga_sd": 1.168035860526126, + "hill_tp_sd": 3.400651941209022, + "poly1_a_sd": 0.16629458913826986, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 63485.654673403085, + "poly2_ac50": 25.051980695483746, + "poly2_b_sd": 98453.01686169056, + "poly1_er_sd": 0.3103337077565139, + "poly2_er_sd": 0.31046879681961925, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4937.830903270403 + }, + "mc5Param": { + "p": 0.6697053366805052, + "er": 0.4118882359089413, + "ga": 2.6834018978246137, + "tp": 27.76803833586464, + "ac5": 0.05498375432560493, + "acc": 10.043861366765938, + "bmd": 1.2128892362955723, + "bmr": 9.289141683881516, + "mll": -21.38651748425501, + "top": 27.76803833586464, + "ac10": 0.16107667754826716, + "ac20": 0.4939400347473494, + "ac50": 2.6834018978246137, + "bmdl": 0.949215313715193, + "bmdu": 1.5372925871551637, + "rmse": 5.679144326208646, + "ac1sd": 0.7117500271731652, + "caikwt": 0.00006948349796016499, + "hitcall": 0.9993015893938282, + "top_over_cutoff": 1.2297185668723691 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842420, + "spid": "TP0000267E12", + "chid": 21311, + "casn": "732-26-3", + "chnm": "2,4,6-Tris(tert-butyl)phenol", + "dtxsid": "DTXSID2021311", + "bmad": 3.7634679299683276, + "respMax": 2.3455034490210025, + "respMin": -8.881536046239422, + "maxMean": 2.3455034490210025, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.3455034490210025, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 19, + "m5id": 5037066, + "modl": "poly1", + "hitc": 2.529472360487395E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187 + ], + "resp": [ + -3.6871319675490226, + -8.202809310965216, + -2.3455034490210025, + -8.881536046239422, + 0.7714118421935772, + -3.442445468033866, + -8.217215474183769, + 2.3455034490210025 + ] + }, + "mc4Param": { + "pow_a": 4.4603222633107216E-8, + "pow_p": 0.3980715850861712, + "exp2_a": 0.00001500803162618182, + "exp2_b": 72.63641229778418, + "exp3_a": 0.000025895984061395693, + "exp3_b": 53.44323652739063, + "exp3_p": 6.684140439183912, + "exp5_p": 2.7549650881782495, + "gnls_p": 0.3000033566349074, + "gnls_q": 7.985201719769872, + "hill_p": 1.3414224872456235, + "pow_er": 1.6007569268879631, + "cnst_er": 1.600789396957988, + "exp2_er": 1.6013100926069517, + "exp3_er": 1.6012445517694611, + "exp4_er": 1.6007994489950037, + "exp4_ga": 1.8057489415221024, + "exp4_tp": 5.397987738417918E-10, + "exp5_er": 1.60079357288877, + "exp5_ga": 1.7684454448433695, + "exp5_tp": 8.377821726470055E-10, + "gnls_er": 1.5999160615939398, + "gnls_ga": 0.009427709959484824, + "gnls_la": 0.2982914089167051, + "gnls_tp": 0.2960388226873033, + "hill_er": 1.6007857351745025, + "hill_ga": 0.21326314555729145, + "hill_tp": 8.179987554374146E-10, + "poly1_a": 1.665857611967683E-11, + "poly2_a": 0.000003342211026439361, + "poly2_b": 54.331449188426035, + "pow_aic": 57.26619984359718, + "pow_cov": 1, + "pow_rme": 5.598366077511932, + "pow_top": 2.1167907095144258E-7, + "all_bmed": 0, + "cnst_aic": 53.26619960913695, + "cnst_rme": 5.598366003993902, + "exp2_aic": 57.266210263276776, + "exp2_cov": 1, + "exp2_rme": 5.5983683837974345, + "exp2_top": 0.000014864682387656134, + "exp3_aic": 59.26620901814293, + "exp3_cov": 1, + "exp3_rme": 5.598367798358593, + "exp3_top": 0.00002325120872148169, + "exp4_aic": 57.266199610517305, + "exp4_cov": 1, + "exp4_rme": 5.598366004275409, + "exp4_top": 5.397987738417918E-10, + "exp5_aic": 59.26619961039384, + "exp5_cov": 1, + "exp5_rme": 5.598366004426082, + "exp5_top": 8.377821726470055E-10, + "gnls_aic": 63.261593119240175, + "gnls_cov": 1, + "gnls_rme": 5.597589879481962, + "gnls_top": 0.20617373336031528, + "hill_aic": 59.26619961110041, + "hill_cov": 1, + "hill_rme": 5.598366004550358, + "hill_top": 8.179987554374146E-10, + "poly1_er": 1.600789285333053, + "poly2_er": 1.600935631744412, + "pow_a_sd": null, + "pow_ac50": 8.764946038692628, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.219899561165725, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 46.07206390886932, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.8057489415221024, + "exp5_ac50": 1.7684454448433695, + "exp5_p_sd": null, + "gnls_ac50": 0.0011666221360965088, + "gnls_p_sd": 3.279849567472979, + "gnls_q_sd": 92.59655516899352, + "hill_ac50": 0.21326314555729145, + "hill_p_sd": null, + "poly1_aic": 55.26619960963536, + "poly1_cov": 1, + "poly1_rme": 5.598366004146862, + "poly1_top": 8.329288059838414E-10, + "poly2_aic": 57.266202776564455, + "poly2_cov": 1, + "poly2_rme": 5.598366884119417, + "poly2_top": 0.000005906314023332767, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.31071019075343265, + "gnls_ga_sd": 0.7914627160677781, + "gnls_la_sd": 1.8738093020015376, + "gnls_tp_sd": 4.103388080871007, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.15082807920588523, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.681166613865575, + "poly2_b_sd": null, + "poly1_er_sd": 0.4455631080651304, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.30262790841870524 + }, + "mc5Param": { + "a": 1.665857611967683E-11, + "er": 1.600789285333053, + "ac5": 2.5, + "bmd": 557619187687.316, + "bmr": 9.289141683881516, + "mll": -25.63309980481768, + "top": 8.329288059838414E-10, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 119.31078194095286, + "rmse": 5.598366004146862, + "ac1sd": 413357440835.6679, + "caikwt": 0.7310585786790016, + "hitcall": 2.529472360487395E-7, + "top_over_cutoff": 3.688658180359248E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842421, + "spid": "TP0000267H05", + "chid": 26252, + "casn": "101-02-0", + "chnm": "Triphenyl phosphite", + "dtxsid": "DTXSID0026252", + "bmad": 3.7634679299683276, + "respMax": 2.153448557173647, + "respMin": -10.47000653188537, + "maxMean": 2.153448557173647, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.153448557173647, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 20, + "m5id": 5037067, + "modl": "poly1", + "hitc": 1.9363278182448674E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + -1.6989700043360187, + 1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + -8.233558829804824, + 2.153448557173647, + -5.178906539470438, + -7.2693827013629715, + -2.153448557173647, + -8.802875120938111, + -4.04098335160478, + -10.47000653188537 + ] + }, + "mc4Param": { + "pow_a": 3.4292130710908686E-8, + "pow_p": 0.33928487781574906, + "exp2_a": 0.0000127162267603712, + "exp2_b": 59.471246282597455, + "exp3_a": 0.000005456305245978216, + "exp3_b": 57.114981601771404, + "exp3_p": 4.737468297497621, + "exp5_p": 2.059721964231659, + "gnls_p": 3.7705534652747152, + "gnls_q": 7.98088765765917, + "hill_p": 1.8558453157097723, + "pow_er": 1.8316691732485768, + "cnst_er": 1.8316611738832205, + "exp2_er": 1.83171063967293, + "exp3_er": 1.8308588373067065, + "exp4_er": 1.831667717841896, + "exp4_ga": 2.39650583299111, + "exp4_tp": 9.736616090061843E-11, + "exp5_er": 1.8316409278190295, + "exp5_ga": 0.91710788966815, + "exp5_tp": 4.769155469756227E-10, + "gnls_er": 1.826653351166183, + "gnls_ga": 0.0020000000000068045, + "gnls_la": 0.06324555325220907, + "gnls_tp": 1.3708737937327125, + "hill_er": 1.8316765475841592, + "hill_ga": 0.1570478773337086, + "hill_tp": 4.665489172046982E-10, + "poly1_a": 1.6553661788288878E-11, + "poly2_a": 0.0000040937639725312225, + "poly2_b": 57.77189852066546, + "pow_aic": 60.52616872375968, + "pow_cov": 1, + "pow_rme": 6.709809695768132, + "pow_top": 1.2930916305837965E-7, + "all_bmed": 0, + "cnst_aic": 56.52616859619864, + "cnst_rme": 6.709809645256235, + "exp2_aic": 60.526175980843824, + "exp2_cov": 1, + "exp2_rme": 6.709812374327744, + "exp2_top": 0.000016761097647759444, + "exp3_aic": 62.52617699352762, + "exp3_cov": 1, + "exp3_rme": 6.709810021618865, + "exp3_top": 0.000003836214039161115, + "exp4_aic": 60.52616859672308, + "exp4_cov": 1, + "exp4_rme": 6.709809645302461, + "exp4_top": 9.736616090061843E-11, + "exp5_aic": 62.52616860177177, + "exp5_cov": 1, + "exp5_rme": 6.709809645540375, + "exp5_top": 4.769155469756227E-10, + "gnls_aic": 66.46070980336975, + "gnls_cov": 1, + "gnls_rme": 6.690902645418204, + "gnls_top": 1.3705036887888815, + "hill_aic": 62.52616859958253, + "hill_cov": 1, + "hill_rme": 6.709809645620258, + "hill_top": 4.665489172046982E-10, + "poly1_er": 1.8315037737657676, + "poly2_er": 1.8310229156461169, + "pow_a_sd": null, + "pow_ac50": 6.482186378904536, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.106803250288905, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.336210554612904, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.39650583299111, + "exp5_ac50": 0.91710788966815, + "exp5_p_sd": null, + "gnls_ac50": 0.001999713670738839, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.1570478773337086, + "hill_p_sd": null, + "poly1_aic": 58.5261688787493, + "poly1_cov": 1, + "poly1_rme": 6.7098096454111325, + "poly1_top": 8.276830894144437E-10, + "poly2_aic": 60.52617604664733, + "poly2_cov": 1, + "poly2_rme": 6.709810691449007, + "poly2_top": 0.000006609445990107358, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": 0.2972944391380977, + "exp4_ga_sd": 2.7511788983437424, + "exp4_tp_sd": 0.000018170256552519125, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.232877570932672, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.51687497965734, + "poly2_b_sd": null, + "poly1_er_sd": 0.4976104385069312, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.06324979854754481 + }, + "mc5Param": { + "a": 1.6553661788288878E-11, + "er": 1.8315037737657676, + "ac5": 2.5, + "bmd": 561153284553.225, + "bmr": 9.289141683881516, + "mll": -27.26308443937465, + "top": 8.276830894144437E-10, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 97.36337686032884, + "rmse": 6.7098096454111325, + "ac1sd": 415977230951.2416, + "caikwt": 0.7310586064064195, + "hitcall": 0.0000019363278182448674, + "top_over_cutoff": 3.665427316933053E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842422, + "spid": "TP0000267H07", + "chid": 22187, + "casn": "2416-94-6", + "chnm": "2,3,6-Trimethylphenol", + "dtxsid": "DTXSID6022187", + "bmad": 3.7634679299683276, + "respMax": 2.4546434804120567, + "respMin": -6.590039447466564, + "maxMean": 2.4546434804120567, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.4546434804120567, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 21, + "m5id": 5037068, + "modl": "poly1", + "hitc": 1.1548465742145037E-8, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + -0.6193413590687559, + -2.946862891147046, + -2.4546434804120567, + -2.0619838822007726, + -6.1122061271300225, + -6.590039447466564, + 2.4546434804120567, + -5.079836079239133 + ] + }, + "mc4Param": { + "pow_a": 3.767364113336769E-8, + "pow_p": 0.3793361095119566, + "exp2_a": 0.000013714158244907544, + "exp2_b": 62.473953885282626, + "exp3_a": 0.000003218586676112593, + "exp3_b": 54.793432376427845, + "exp3_p": 4.934528552083529, + "exp5_p": 2.5321434240687077, + "gnls_p": 1.7215545335763185, + "gnls_q": 5.9509617790505365, + "hill_p": 1.7113570602226835, + "pow_er": 1.3001645899703465, + "cnst_er": 1.3001163668151825, + "exp2_er": 1.2988900114548922, + "exp3_er": 1.299714305686752, + "exp4_er": 1.300111607345526, + "exp4_ga": 2.4635749935922417, + "exp4_tp": 2.141208914552821E-10, + "exp5_er": 1.3001191325357075, + "exp5_ga": 0.8329186071996519, + "exp5_tp": 9.468502830411367E-10, + "gnls_er": 1.300129441131634, + "gnls_ga": 0.02488389878063567, + "gnls_la": 0.8513441076183489, + "gnls_tp": 5.029312168256246E-10, + "hill_er": 1.3001098844504215, + "hill_ga": 1.3104070841784885, + "hill_tp": 2.3984539370057496E-10, + "poly1_a": 6.429960167444698E-12, + "poly2_a": 0.00010731334828336232, + "poly2_b": 52.50758262350933, + "pow_aic": 52.26528261409156, + "pow_cov": 1, + "pow_rme": 4.061439597937862, + "pow_top": 1.661568568423234E-7, + "all_bmed": 0, + "cnst_aic": 48.26528238427001, + "cnst_rme": 4.0614395482423795, + "exp2_aic": 52.265309193522334, + "exp2_cov": 1, + "exp2_rme": 4.061441753257708, + "exp2_top": 0.000016817443713639312, + "exp3_aic": 54.26528524536559, + "exp3_cov": 1, + "exp3_rme": 4.061439734220189, + "exp3_top": 0.0000028641829217196966, + "exp4_aic": 52.26528238577886, + "exp4_cov": 1, + "exp4_rme": 4.06143954832149, + "exp4_top": 2.141208914552821E-10, + "exp5_aic": 54.26528238551149, + "exp5_cov": 1, + "exp5_rme": 4.0614395486267245, + "exp5_top": 9.468502830411367E-10, + "gnls_aic": 58.26528238429869, + "gnls_cov": 1, + "gnls_rme": 4.061439548428354, + "gnls_top": 4.953675513002026E-10, + "hill_aic": 54.26528238638662, + "hill_cov": 1, + "hill_rme": 4.061439548335382, + "hill_top": 2.3984539370057496E-10, + "poly1_er": 1.3004069598601156, + "poly2_er": 1.3007699140477382, + "pow_a_sd": null, + "pow_ac50": 8.042653781004834, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.874021672293665, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 44.74689545963496, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 2.4635749935922417, + "exp5_ac50": 0.8329186071996519, + "exp5_p_sd": null, + "gnls_ac50": 0.02445288131245627, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 1.3104070841784885, + "hill_p_sd": 3186952.8147538053, + "poly1_aic": 50.26528324291422, + "poly1_cov": 1, + "poly1_rme": 4.061439548291606, + "poly1_top": 3.2149800837223486E-10, + "poly2_aic": 52.26540339182091, + "poly2_cov": 1, + "poly2_rme": 4.061464432547128, + "poly2_top": 0.00019949668932343944, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.30383111979982436, + "hill_ga_sd": 748711.7747256848, + "hill_tp_sd": 0.0000505315540909725, + "poly1_a_sd": 0.09096805428665258, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.772089863628302, + "poly2_b_sd": null, + "poly1_er_sd": 0.3809692717546628, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.8550161183126147 + }, + "mc5Param": { + "a": 6.429960167444698E-12, + "er": 1.3004069598601156, + "ac5": 2.4999999999999996, + "bmd": 1444665509891.1868, + "bmr": 9.289141683881516, + "mll": -23.13264162145711, + "top": 3.2149800837223486E-10, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 149.5912710282903, + "rmse": 4.061439548291606, + "ac1sd": 1070915870934.9048, + "caikwt": 0.7310586630398459, + "hitcall": 1.1548465742145036E-8, + "top_over_cutoff": 1.4237666533224164E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842423, + "spid": "TP0000268B05", + "chid": 47331, + "casn": "331623-06-4", + "chnm": "MK-547", + "dtxsid": "DTXSID4047331", + "bmad": 3.7634679299683276, + "respMax": 16.160587759184914, + "respMin": -11.834811380876454, + "maxMean": 16.160587759184914, + "maxMeanConc": -0.1549019599857432, + "maxMed": 16.160587759184914, + "maxMedConc": -0.1549019599857432, + "logcMax": 1.7781512503836436, + "logcMin": -1.5228787452803376, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 22, + "m5id": 5037069, + "modl": "poly1", + "hitc": 5.913901142194764E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 22.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.5228787452803376, + 1.7781512503836436, + 0.3010299956639812, + 0.7781512503836436, + -1.0969100130080565, + 1.3010299956639813, + -0.6989700043360187, + -0.1549019599857432 + ], + "resp": [ + 1.0328742333020546, + -0.4101716381589, + -11.834811380876454, + -10.26235792055114, + -1.0328742333020546, + 1.4772968670590867, + -2.9469637282292744, + 16.160587759184914 + ] + }, + "mc4Param": { + "pow_a": 3.435232205446152E-7, + "pow_p": 0.40195886003095355, + "exp2_a": 0.00019185757540890645, + "exp2_b": 78.54636736109194, + "exp3_a": 0.000069246181189659, + "exp3_b": 73.10867338686336, + "exp3_p": 7.6208172674503984, + "exp5_p": 7.998247691004145, + "gnls_p": 7.901592218199406, + "gnls_q": 7.849018931807445, + "hill_p": 7.87734028198097, + "pow_er": 1.8213430667936583, + "cnst_er": 1.8213936756952465, + "exp2_er": 1.823591487999136, + "exp3_er": 1.822387183035188, + "exp4_er": 1.821353215471985, + "exp4_ga": 12.168837805792837, + "exp4_tp": 5.0263714950386055E-8, + "exp5_er": 1.8191975210324889, + "exp5_ga": 14.786689747990971, + "exp5_tp": 0.5317549737304359, + "gnls_er": 1.8213944981829744, + "gnls_ga": 0.1534550745988045, + "gnls_la": 19.550756854420513, + "gnls_tp": 4.787909883851375E-9, + "hill_er": 1.8214163821547027, + "hill_ga": 189.7269026616281, + "hill_tp": 5.920760401696781, + "poly1_a": 2.7530546982407402E-9, + "poly2_a": 0.0002694160974739683, + "poly2_b": 74.60371505672451, + "pow_aic": 62.11585875969622, + "pow_cov": 1, + "pow_rme": 8.060026848987192, + "pow_top": 0.0000017811469363016915, + "all_bmed": 0, + "cnst_aic": 58.115858404353595, + "cnst_rme": 8.06002673396659, + "exp2_aic": 62.11590472013238, + "exp2_cov": 1, + "exp2_rme": 8.060029785010771, + "exp2_top": 0.0002199817611461118, + "exp3_aic": 64.11586654613095, + "exp3_cov": 1, + "exp3_rme": 8.060026843281152, + "exp3_top": 0.000017196997763967384, + "exp4_aic": 62.115858433032486, + "exp4_cov": 1, + "exp4_rme": 8.06002673633787, + "exp4_top": 5.0263714950386055E-8, + "exp5_aic": 64.09764769253101, + "exp5_cov": 1, + "exp5_rme": 8.055656964717214, + "exp5_top": 0.5317549737304359, + "gnls_aic": 68.11585840669358, + "gnls_cov": 1, + "gnls_rme": 8.060026734552624, + "gnls_top": 4.7879098346713356E-9, + "hill_aic": 64.11587669600377, + "hill_cov": 1, + "hill_rme": 8.060031073676338, + "hill_top": 5.920760401696781, + "poly1_er": 1.821434550339795, + "poly2_er": 1.821797531197728, + "pow_a_sd": null, + "pow_ac50": 10.696551181133351, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 35.59499774025152, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 55.17214374903797, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 12.168837805792837, + "exp5_ac50": 14.786689747990971, + "exp5_p_sd": 121.15686871088236, + "gnls_ac50": 0.1534550738830234, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 189.7269026616281, + "hill_p_sd": null, + "poly1_aic": 60.11585841484666, + "poly1_cov": 1, + "poly1_rme": 8.06002673693981, + "poly1_top": 1.651832818944444E-7, + "poly2_aic": 62.115872817500886, + "poly2_cov": 1, + "poly2_rme": 8.06003160725891, + "poly2_top": 0.0003909407381656776, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.3534660798818326, + "exp5_ga_sd": 95.93402528978984, + "exp5_tp_sd": 3.9415248388741375, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.08777291902049782, + "poly1_ac50": 30, + "poly2_a_sd": null, + "poly2_ac50": 36.38355504948771, + "poly2_b_sd": null, + "poly1_er_sd": 0.3531459297080129, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 19.55075690425482 + }, + "mc5Param": { + "a": 2.7530546982407402E-9, + "er": 1.821434550339795, + "ac5": 3, + "bmd": 3374121730.9694114, + "bmr": 9.289141683881516, + "mll": -28.05792920742333, + "top": 1.651832818944444E-7, + "ac10": 6, + "ac20": 12, + "ac50": 30, + "bmdl": 62.30001927366413, + "rmse": 8.06002673693981, + "ac1sd": 2501202172.6978583, + "caikwt": 0.7310585796615361, + "hitcall": 0.00005913901142194764, + "top_over_cutoff": 7.3152070097855445E-9 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842424, + "spid": "TP0000268B09", + "chid": 47376, + "casn": "648917-13-9", + "chnm": "AVE2865", + "dtxsid": "DTXSID5047376", + "bmad": 3.7634679299683276, + "respMax": 5.797527205844785, + "respMin": -6.504798500619806, + "maxMean": 5.797527205844785, + "maxMeanConc": -0.5228787452803376, + "maxMed": 5.797527205844785, + "maxMedConc": -0.5228787452803376, + "logcMax": 1.3010299956639813, + "logcMin": -2.0, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 23, + "m5id": 5037070, + "modl": "poly1", + "hitc": 3.401746069045992E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 10.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1, + -0.5228787452803376, + -0.045757490560675115, + 0.47712125471966244, + -1.5228787452803376, + 1.3010299956639813, + 0.9030899869919435, + -2 + ], + "resp": [ + -0.45517858919509946, + 5.797527205844785, + -2.9328129243560577, + -6.504798500619806, + 2.0703869723867707, + 4.550643071685755, + 4.546273464789026, + -2.0703869723867707 + ] + }, + "mc4Param": { + "pow_a": 0.14645761569514076, + "pow_p": 1.1773046495484434, + "exp2_a": 270.97367161658156, + "exp2_b": 1116.4642123562155, + "exp3_a": 77.63471895063142, + "exp3_b": 252.08672173141304, + "exp3_p": 1.0981475406737444, + "exp5_p": 7.999999743873548, + "gnls_p": 7.9999999387204035, + "gnls_q": 7.925643774573192, + "hill_p": 7.999999862236661, + "pow_er": 1.1356265219229824, + "cnst_er": 1.3302829497154869, + "exp2_er": 1.132103795624519, + "exp3_er": 1.1430097651086235, + "exp4_er": 1.1201406029443286, + "exp4_ga": 12.576918087774663, + "exp4_tp": 6.957032563345469, + "exp5_er": 1.004007264778901, + "exp5_ga": 6.457229934853941, + "exp5_tp": 4.594738721200484, + "gnls_er": 1.2052015972921115, + "gnls_ga": 0.15589819888208656, + "gnls_la": 1408.8515612814258, + "gnls_tp": 2.45585111669779, + "hill_er": 1.0057274858019496, + "hill_ga": 5.840707041021681, + "hill_tp": 4.711097825805859, + "poly1_a": 0.24532316641680385, + "poly2_a": 217.59829371138036, + "poly2_b": 906.2718506374296, + "pow_aic": 50.20843275953963, + "pow_cov": 1, + "pow_rme": 3.69500181123112, + "pow_top": 4.982193866207102, + "all_bmed": 0, + "cnst_aic": 48.583528700455965, + "cnst_rme": 4.103082128822365, + "exp2_aic": 50.23261652082196, + "exp2_cov": 1, + "exp2_rme": 3.719604002845105, + "exp2_top": 4.897878431815489, + "exp3_aic": 52.21936455943542, + "exp3_cov": 1, + "exp3_rme": 3.703490261604697, + "exp3_top": 4.954803407260803, + "exp4_aic": 50.24261958999962, + "exp4_cov": 1, + "exp4_rme": 3.763007325226026, + "exp4_top": 6.957032563345469, + "exp5_aic": 50.606708255855864, + "exp5_cov": 1, + "exp5_rme": 3.416863170565935, + "exp5_top": 4.594738721200484, + "gnls_aic": 57.65043497612462, + "gnls_cov": 1, + "gnls_rme": 4.156168266214812, + "gnls_top": 2.455851116697789, + "hill_aic": 50.630370136769535, + "hill_cov": 1, + "hill_rme": 3.421658551377129, + "hill_top": 4.711097825805859, + "poly1_er": 1.1314827238691518, + "poly2_er": 1.1323596578117343, + "pow_a_sd": 0.5502364753741223, + "pow_ac50": 11.10032704166267, + "pow_p_sd": 1.2632680919710386, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 9140.874480213712, + "exp2_ac50": 10.04478364010083, + "exp2_b_sd": 37407.68771741646, + "exp3_a_sd": 1098.7341775704554, + "exp3_ac50": 10.788816917549276, + "exp3_b_sd": 3010.335602136789, + "exp3_p_sd": 1.1986941560896456, + "exp4_ac50": 12.576918087774663, + "exp5_ac50": 6.457229934853941, + "exp5_p_sd": 19.477000675370935, + "gnls_ac50": 0.15589819885359768, + "gnls_p_sd": 20.48523584343925, + "gnls_q_sd": 1762638.0146021335, + "hill_ac50": 5.840707041021681, + "hill_p_sd": 12.47501198328628, + "poly1_aic": 48.23172628107896, + "poly1_cov": 1, + "poly1_rme": 3.7202526561507, + "poly1_top": 4.906463328336078, + "poly2_aic": 50.23384580295357, + "poly2_cov": 1, + "poly2_rme": 3.7190286910920456, + "poly2_top": 4.908027255021525, + "pow_er_sd": 0.32075020244933933, + "exp2_er_sd": 0.32108258944317647, + "exp3_er_sd": 0.3216124902903471, + "exp4_er_sd": 0.32786527141411564, + "exp4_ga_sd": 33.74243671026672, + "exp4_tp_sd": 11.6108227506599, + "exp5_er_sd": 0.334854491636641, + "exp5_ga_sd": 5.3898863226067535, + "exp5_tp_sd": 2.1620411463879097, + "gnls_er_sd": 0.3500317149484511, + "gnls_ga_sd": 0.22054662364571845, + "gnls_la_sd": 2265909239.9199414, + "gnls_tp_sd": 2.2937771724887908, + "hill_er_sd": 0.3351225283208879, + "hill_ga_sd": 4.352134509212842, + "hill_tp_sd": 2.1279907242956564, + "poly1_a_sd": 0.13312558050871134, + "poly1_ac50": 10.000000000000002, + "poly2_a_sd": 4836.680590090178, + "poly2_ac50": 10.107947086330844, + "poly2_b_sd": 19734.212048261263, + "poly1_er_sd": 0.32103720561443533, + "poly2_er_sd": 0.32112575048366343, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1408.8515612792864 + }, + "mc5Param": { + "a": 0.24532316641680385, + "er": 1.1314827238691518, + "ac5": 1.0000000000000002, + "bmd": 37.86491842396683, + "bmr": 9.289141683881516, + "mll": -22.11586314053948, + "top": 4.906463328336078, + "ac10": 2.0000000000000004, + "ac20": 4.000000000000001, + "ac50": 10.000000000000002, + "bmdl": 18.73361680529658, + "bmdu": 1570.6186096996776, + "rmse": 3.7202526561507, + "ac1sd": 28.068879484037673, + "caikwt": 0.45613773535386626, + "hitcall": 3.401746069045992E-7, + "top_over_cutoff": 0.21728467022247083 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842425, + "spid": "TP0000268D09", + "chid": 47371, + "casn": "725228-45-5", + "chnm": "AVE5638", + "dtxsid": "DTXSID0047371", + "bmad": 3.7634679299683276, + "respMax": 9.829527801511304, + "respMin": -2.5563201140688663, + "maxMean": 9.829527801511304, + "maxMeanConc": 1.6989700043360187, + "maxMed": 9.829527801511304, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 24, + "m5id": 5037071, + "modl": "pow", + "hitc": 8.283608352293161E-12, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + 0.5431239666670336, + 4.285106967299528, + 2.5563201140688663, + 9.829527801511304, + 5.709719432762615, + 2.4081165876987582, + -2.5563201140688663, + 6.207106279335564 + ] + }, + "mc4Param": { + "pow_a": 2.6134169605347974, + "pow_p": 0.3224547315138239, + "exp2_a": 1847.8710307754577, + "exp2_b": 8594.958431701696, + "exp3_a": 5.951942308809372, + "exp3_b": 55.65624351376668, + "exp3_p": 0.3000009915091093, + "exp5_p": 0.408031291772936, + "gnls_p": 0.5036307275286347, + "gnls_q": 6.983373974900997, + "hill_p": 0.5036130799544578, + "pow_er": 0.6271801481986525, + "cnst_er": 1.483673944403286, + "exp2_er": 0.901885423620896, + "exp3_er": 0.617447007576443, + "exp4_er": 0.7472251905007579, + "exp4_ga": 12.860918984697772, + "exp4_tp": 10.29314061205533, + "exp5_er": 0.6664687774625762, + "exp5_ga": 10.227134832516548, + "exp5_tp": 11.795433349193852, + "gnls_er": 0.6844246765693558, + "gnls_ga": 8.727972134778678, + "gnls_la": 476.21374917073217, + "gnls_tp": 11.795433358441182, + "hill_er": 0.6844058554512551, + "hill_ga": 8.729066041588078, + "hill_tp": 11.795433359489715, + "poly1_a": 0.2155653486726829, + "poly2_a": 1619.371664147901, + "poly2_b": 7562.841340094379, + "pow_aic": 41.42019910503057, + "pow_cov": 1, + "pow_rme": 2.0570817824284617, + "pow_top": 9.226768448403208, + "all_bmed": 0, + "cnst_aic": 51.47828396257371, + "cnst_rme": 5.065500679597487, + "exp2_aic": 46.2016811403628, + "exp2_cov": 1, + "exp2_rme": 2.8349639096704293, + "exp2_top": 10.781066320544063, + "exp3_aic": 43.432265040834096, + "exp3_cov": 1, + "exp3_rme": 2.0734102760632704, + "exp3_top": 9.723220686034583, + "exp4_aic": 44.1490672469169, + "exp4_cov": 1, + "exp4_rme": 2.5333364833268393, + "exp4_top": 10.29314061205533, + "exp5_aic": 43.87885037563678, + "exp5_cov": 1, + "exp5_rme": 2.096972769799834, + "exp5_top": 11.795433349193852, + "gnls_aic": 48.13034965100882, + "gnls_cov": 1, + "gnls_rme": 2.1256207071279647, + "gnls_top": 9.848077588604877, + "hill_aic": 44.13034863233809, + "hill_cov": 1, + "hill_rme": 2.1256162744455236, + "hill_top": 11.795433359489715, + "poly1_er": 0.901280786231684, + "poly2_er": 0.9025570210051496, + "pow_a_sd": 1.2648723107958824, + "pow_ac50": 5.826565328027652, + "pow_p_sd": 0.14109048042799285, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 20517.97016403068, + "exp2_ac50": 25.036358472451216, + "exp2_b_sd": 95129.8509706833, + "exp3_a_sd": 13.444564053482148, + "exp3_ac50": 9.976184034850611, + "exp3_b_sd": 266.0736582783042, + "exp3_p_sd": 0.216903370957182, + "exp4_ac50": 12.860918984697772, + "exp5_ac50": 10.227134832516548, + "exp5_p_sd": 0.1950562304619866, + "gnls_ac50": 4.503531056699209, + "gnls_p_sd": 0.30642623552529974, + "gnls_q_sd": 1778.4355834488583, + "hill_ac50": 8.729066041588078, + "hill_p_sd": 0.30636334171671514, + "poly1_aic": 44.19352001430043, + "poly1_cov": 1, + "poly1_rme": 2.8338486403301544, + "poly1_top": 10.778267433634143, + "poly2_aic": 46.2119706927944, + "poly2_cov": 1, + "poly2_rme": 2.8364410811775858, + "poly2_top": 10.776887264522824, + "pow_er_sd": 0.30099084110430235, + "exp2_er_sd": 0.31175385714527687, + "exp3_er_sd": 0.31176613420103494, + "exp4_er_sd": 0.33118431722536384, + "exp4_ga_sd": 11.325306882966284, + "exp4_tp_sd": 3.4851291549920576, + "exp5_er_sd": 0.3015655658242953, + "exp5_ga_sd": 28.51915767292512, + "exp5_tp_sd": 8.264821291402265, + "gnls_er_sd": 0.3022586634075119, + "gnls_ga_sd": 31.4717089520362, + "gnls_la_sd": 273214.77054124634, + "gnls_tp_sd": 9.227295756030236, + "hill_er_sd": 0.3022524501530625, + "hill_ga_sd": 31.46313562630508, + "hill_tp_sd": 9.22366258473231, + "poly1_a_sd": 0.04384146784814762, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 12062.013966135755, + "poly2_ac50": 25.08209723966715, + "poly2_b_sd": 55965.732274987706, + "poly1_er_sd": 0.31174491997287024, + "poly2_er_sd": 0.31177073301646385, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 483.7219493904507 + }, + "mc5Param": { + "a": 2.6134169605347974, + "p": 0.3224547315138239, + "er": 0.6271801481986525, + "ac5": 0.004615323183986625, + "bmd": 51.05567688873282, + "bmr": 9.289141683881516, + "mll": -17.710099552515285, + "top": 9.226768448403208, + "ac10": 0.039605864897673385, + "ac20": 0.339873172854996, + "ac50": 5.826565328027652, + "bmdl": 25.969322888853053, + "bmdu": 126.0034288976538, + "rmse": 2.0570817824284617, + "ac1sd": 20.17667574437803, + "caikwt": 0.006502515494980162, + "hitcall": 8.283608352293161E-12, + "top_over_cutoff": 0.4086110922203279 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842426, + "spid": "TP0000268F11", + "chid": 47351, + "casn": "464930-42-5", + "chnm": "SSR 240612", + "dtxsid": "DTXSID2047351", + "bmad": 3.7634679299683276, + "respMax": 56.74340329908642, + "respMin": 0.9655862698342526, + "maxMean": 56.74340329908642, + "maxMeanConc": 1.6989700043360187, + "maxMed": 56.74340329908642, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 7, + "tmpi": 25, + "m5id": 5037072, + "modl": "hill", + "hitc": 0.9999997974131798, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 19.100000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.6989700043360189, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + -1.154901959985743 + ], + "resp": [ + 44.59335472538687, + 0.9655862698342526, + 51.07450911124849, + 34.60777964222281, + 38.45466945352135, + 43.944478789484535, + 56.74340329908642, + 15.196453629289444 + ] + }, + "mc4Param": { + "pow_a": 22.29063955606957, + "pow_p": 0.3000000044703735, + "exp2_a": 7377.110355751841, + "exp2_b": 5355.437066929028, + "exp3_a": 591.2413263226587, + "exp3_b": 65665.77024490427, + "exp3_p": 0.300000305401534, + "exp5_p": 7.9983423573434145, + "gnls_p": 1.1287983917282394, + "gnls_q": 7.653239171873807, + "hill_p": 1.1288482557103248, + "pow_er": 2.5032045033922516, + "cnst_er": 3.6332397109938266, + "exp2_er": 3.29296967334806, + "exp3_er": 2.5419130229474893, + "exp4_er": 1.4570282322469614, + "exp4_ga": 0.1211168885912654, + "exp4_tp": 46.88558983477806, + "exp5_er": 1.650383818314157, + "exp5_ga": 0.07454030776539969, + "exp5_tp": 44.37027720585292, + "gnls_er": 1.305161491507147, + "gnls_ga": 0.1388302597633832, + "gnls_la": 4500.7988607575635, + "gnls_tp": 49.11672853031013, + "hill_er": 1.305166813111626, + "hill_ga": 0.13882412839547248, + "hill_tp": 49.116358486825376, + "poly1_a": 1.3848525837844712, + "poly2_a": 6214.513214531438, + "poly2_b": 4538.601931470192, + "pow_aic": 71.6277031240271, + "pow_cov": 1, + "pow_rme": 13.523494389939856, + "pow_top": 72.07979423450467, + "all_bmed": 0, + "cnst_aic": 85.17328329049076, + "cnst_rme": 39.77503672995993, + "exp2_aic": 83.88353944963814, + "exp2_cov": 1, + "exp2_rme": 28.82615638820165, + "exp2_top": 69.19748254971222, + "exp3_aic": 74.18541947887306, + "exp3_cov": 1, + "exp3_rme": 13.997699402413598, + "exp3_top": 72.72562462018436, + "exp4_aic": 55.16605989184805, + "exp4_cov": 1, + "exp4_rme": 5.0053816249751115, + "exp4_top": 46.88558983477806, + "exp5_aic": 60.83333339353628, + "exp5_cov": 1, + "exp5_rme": 6.417783643263895, + "exp5_top": 44.37027720585292, + "gnls_aic": 58.349089094862535, + "gnls_cov": 1, + "gnls_rme": 4.10385604566807, + "gnls_top": 49.11409533247871, + "hill_aic": 54.34908909384654, + "hill_cov": 1, + "hill_rme": 4.103866665590556, + "hill_top": 49.116358486825376, + "poly1_er": 3.291931983247854, + "poly2_er": 3.293092482358462, + "pow_a_sd": null, + "pow_ac50": 4.960628458191019, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 76621.24816189415, + "exp2_ac50": 25.058351701479907, + "exp2_b_sd": 55332.40931606274, + "exp3_a_sd": null, + "exp3_ac50": 5.456350237754098, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.1211168885912654, + "exp5_ac50": 0.07454030776539969, + "exp5_p_sd": null, + "gnls_ac50": 0.1388170716544355, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.13882412839547248, + "hill_p_sd": 1.0072426298983834, + "poly1_aic": 81.87415000051952, + "poly1_cov": 1, + "poly1_rme": 28.80990540590964, + "poly1_top": 69.24262918922355, + "poly2_aic": 83.8960828082405, + "poly2_cov": 1, + "poly2_rme": 28.846900317891546, + "poly2_top": 69.21708675555531, + "pow_er_sd": null, + "exp2_er_sd": 0.2979467220440815, + "exp3_er_sd": null, + "exp4_er_sd": 0.31706674559933146, + "exp4_ga_sd": 0.02771959613022985, + "exp4_tp_sd": 2.7450192626672303, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.30688202903113515, + "hill_ga_sd": 0.11148548451151348, + "hill_tp_sd": 7.894298278477134, + "poly1_a_sd": 0.49529366199526986, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 42973.45685321085, + "poly2_ac50": 25.136203021763425, + "poly2_b_sd": 30971.57960174396, + "poly1_er_sd": 0.2978316290780377, + "poly2_er_sd": 0.29791923025954864, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4500.85239695864 + }, + "mc5Param": { + "p": 1.1288482557103248, + "er": 1.305166813111626, + "ga": 0.13882412839547248, + "tp": 49.116358486825376, + "ac5": 0.0102251575317605, + "acc": 0.12033066816769825, + "bmd": 0.03823149140805884, + "bmr": 9.289141683881516, + "mll": -23.17454454692327, + "top": 49.116358486825376, + "ac10": 0.01982170312832394, + "ac20": 0.04065602361491505, + "ac50": 0.13882412839547248, + "bmdl": 0.027228374830847675, + "bmdu": 0.05629923061844972, + "rmse": 4.103866665590556, + "ac1sd": 0.027842487636980728, + "caikwt": 2.0258682012827294E-7, + "hitcall": 0.9999997974131798, + "top_over_cutoff": 2.1751373733303265 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842427, + "spid": "TP0000268G07", + "chid": 47342, + "casn": "NOCAS_47342", + "chnm": "SR125047", + "dtxsid": "DTXSID3047342", + "bmad": 3.7634679299683276, + "respMax": 16.068431608615082, + "respMin": -2.4478548285083273, + "maxMean": 16.068431608615082, + "maxMeanConc": 1.6989700043360187, + "maxMed": 16.068431608615082, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 26, + "m5id": 5037073, + "modl": "hill", + "hitc": 7.513456343366634E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 18.100000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.6989700043360189, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.2218487496163564 + ], + "resp": [ + 2.578651202272505, + 10.929576624760047, + -2.4478548285083273, + -0.9930052374030435, + 16.068431608615082, + -1.1296964636433144, + -2.031470190077792, + 0.9930052374030434 + ] + }, + "mc4Param": { + "pow_a": 0.7495851450301008, + "pow_p": 0.7934306069332071, + "exp2_a": 3745.887701077395, + "exp2_b": 11161.230229848748, + "exp3_a": 211.17258400046512, + "exp3_b": 1321.9558679160486, + "exp3_p": 0.7862869437104818, + "exp5_p": 1.5971709257356228, + "gnls_p": 1.8437972877629345, + "gnls_q": 6.0802381175989755, + "hill_p": 1.8437982520570464, + "pow_er": 0.5569604229333858, + "cnst_er": 1.496227101300069, + "exp2_er": 0.6013530822669483, + "exp3_er": 0.56192578085808, + "exp4_er": 0.3643457082349424, + "exp4_ga": 18.77713492364612, + "exp4_tp": 19.282117896825127, + "exp5_er": 0.1813537664571939, + "exp5_ga": 14.606417150732632, + "exp5_tp": 16.15853839281399, + "gnls_er": 0.16259772400318157, + "gnls_ga": 15.327772022476056, + "gnls_la": 716.9030513711922, + "gnls_tp": 17.82615761827315, + "hill_er": 0.1626080470170854, + "hill_ga": 15.32785499084368, + "hill_tp": 17.826228582259645, + "poly1_a": 0.33630167057563587, + "poly2_a": 5534.470181137269, + "poly2_b": 16509.417806231653, + "pow_aic": 40.586937969960985, + "pow_cov": 1, + "pow_rme": 1.976876645272376, + "pow_top": 16.70458816459739, + "all_bmed": 0, + "cnst_aic": 54.648400025462585, + "cnst_rme": 7.050414694167261, + "exp2_aic": 41.509916177688794, + "exp2_cov": 1, + "exp2_rme": 2.1346868197498607, + "exp2_top": 16.81844459556715, + "exp3_aic": 42.707146864839885, + "exp3_cov": 1, + "exp3_rme": 1.9923148983459509, + "exp3_top": 16.710344322133963, + "exp4_aic": 37.940991423770946, + "exp4_cov": 1, + "exp4_rme": 1.7263552245064822, + "exp4_top": 19.282117896825127, + "exp5_aic": 36.94109523557594, + "exp5_cov": 1, + "exp5_rme": 1.4202088508960418, + "exp5_top": 16.15853839281399, + "gnls_aic": 40.679025093815895, + "gnls_cov": 1, + "gnls_rme": 1.3995253107697865, + "gnls_top": 17.693918959116115, + "hill_aic": 36.67902495033333, + "hill_cov": 1, + "hill_rme": 1.3995249681145707, + "hill_top": 17.826228582259645, + "poly1_er": 0.6001608259061096, + "poly2_er": 0.6007737931510304, + "pow_a_sd": 0.45733970898996046, + "pow_ac50": 20.872138600405815, + "pow_p_sd": 0.15802993812972735, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 34356.31271501256, + "exp2_ac50": 25.02799868224741, + "exp2_b_sd": 102105.6974126556, + "exp3_a_sd": 651.7340339714862, + "exp3_ac50": 21.20970217173776, + "exp3_b_sd": 4590.856553343913, + "exp3_p_sd": 0.189049486322834, + "exp4_ac50": 18.77713492364612, + "exp5_ac50": 14.606417150732632, + "exp5_p_sd": 0.4330441605396518, + "gnls_ac50": 15.204926781653212, + "gnls_p_sd": 0.5081164715543239, + "gnls_q_sd": 4108.363521527936, + "hill_ac50": 15.32785499084368, + "hill_p_sd": 0.5081331258789696, + "poly1_aic": 39.49794234452144, + "poly1_cov": 1, + "poly1_rme": 2.1327398858741935, + "poly1_top": 16.81508352878179, + "poly2_aic": 41.514073524464166, + "poly2_cov": 1, + "poly2_rme": 2.135746785098317, + "poly2_top": 16.812318280864897, + "pow_er_sd": 0.3123867399094015, + "exp2_er_sd": 0.3173507805054053, + "exp3_er_sd": 0.3132824822426714, + "exp4_er_sd": 0.3204206492367301, + "exp4_ga_sd": 7.538812655873604, + "exp4_tp_sd": 3.614102630459925, + "exp5_er_sd": 0.3228010130363589, + "exp5_ga_sd": 2.1623706344386395, + "exp5_tp_sd": 1.213152398522362, + "gnls_er_sd": 0.3235596345274449, + "gnls_ga_sd": 3.611431409511374, + "gnls_la_sd": 1286628.173870158, + "gnls_tp_sd": 2.3538578449416696, + "hill_er_sd": 0.3235605842861329, + "hill_ga_sd": 3.611520231183444, + "hill_tp_sd": 2.353918902922515, + "poly1_a_sd": 0.035107290392205344, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 43848.155451291146, + "poly2_ac50": 25.037742786782083, + "poly2_b_sd": 130401.28963646913, + "poly1_er_sd": 0.31719198749658833, + "poly2_er_sd": 0.3173229343451282, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 718.4597781609216 + }, + "mc5Param": { + "p": 1.8437982520570464, + "er": 0.1626080470170854, + "ga": 15.32785499084368, + "tp": 17.826228582259645, + "ac5": 3.1041182593433, + "bmd": 16.046024255628595, + "bmr": 9.289141683881516, + "mll": -14.339512475166664, + "top": 17.826228582259645, + "ac10": 4.655214191434633, + "ac20": 7.226847933148336, + "ac50": 15.32785499084368, + "bmdl": 12.817356025918471, + "bmdu": 19.68919163424624, + "rmse": 1.3995249681145707, + "ac1sd": 11.924278068437353, + "caikwt": 0.0001252983526033338, + "hitcall": 7.513456343366634E-7, + "top_over_cutoff": 0.7894415874744223 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842428, + "spid": "TP0000268H11", + "chid": 47362, + "casn": "NOCAS_47362", + "chnm": "SSR150106", + "dtxsid": "DTXSID1047362", + "bmad": 3.7634679299683276, + "respMax": 32.275376253360285, + "respMin": -7.867717756019061, + "maxMean": 32.275376253360285, + "maxMeanConc": 1.6989700043360187, + "maxMed": 32.275376253360285, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 27, + "m5id": 5037074, + "modl": "poly1", + "hitc": 0.9723023592263895, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + 7.836812981967315, + -1.688479877558232, + 1.688479877558232, + 11.146812393304948, + 2.103486843396195, + -5.189794556835356, + -7.867717756019061, + 32.275376253360285 + ] + }, + "mc4Param": { + "pow_a": 0.4589901690368699, + "pow_p": 1.0864882638245654, + "exp2_a": 101.4651209324748, + "exp2_b": 181.35011628024697, + "exp3_a": 136.47408823959836, + "exp3_b": 227.43583566565215, + "exp3_p": 1.0244060811915972, + "exp5_p": 1.6543740009751935, + "gnls_p": 2.544254271420234, + "gnls_q": 7.832466215756295, + "hill_p": 2.5440165316447105, + "pow_er": 1.1937920093205483, + "cnst_er": 2.1116016336711736, + "exp2_er": 1.189397204329031, + "exp3_er": 1.1900107506641908, + "exp4_er": 1.3892245596869288, + "exp4_ga": 26.05395024269712, + "exp4_tp": 38.7304515040133, + "exp5_er": 1.236530306766801, + "exp5_ga": 28.81134072021623, + "exp5_tp": 38.73045146929248, + "gnls_er": 1.2683740002383097, + "gnls_ga": 27.607015111885687, + "gnls_la": 4998.569320195761, + "gnls_tp": 38.73045147605155, + "hill_er": 1.2684075667282575, + "hill_ga": 27.60654261703223, + "hill_tp": 38.73045149963589, + "poly1_a": 0.6372560400447195, + "poly2_a": 182.2661163816764, + "poly2_b": 326.31707791831155, + "pow_aic": 51.68671768837355, + "pow_cov": 1, + "pow_rme": 4.1789842044248235, + "pow_top": 32.18950912321905, + "all_bmed": 0, + "cnst_aic": 63.90474507028467, + "cnst_rme": 12.87598788572432, + "exp2_aic": 51.68912006250683, + "exp2_cov": 1, + "exp2_rme": 4.201398457618982, + "exp2_top": 32.211670164602985, + "exp3_aic": 53.68628653722567, + "exp3_cov": 1, + "exp3_rme": 4.193697698573126, + "exp3_top": 32.2049157281836, + "exp4_aic": 54.24612188601166, + "exp4_cov": 1, + "exp4_rme": 4.781182771456221, + "exp4_top": 38.7304515040133, + "exp5_aic": 54.07263547430031, + "exp5_cov": 1, + "exp5_rme": 4.191856927998687, + "exp5_top": 38.73045146929248, + "gnls_aic": 58.62822032794858, + "gnls_cov": 1, + "gnls_rme": 4.334693218513672, + "gnls_top": 38.727333168934166, + "hill_aic": 54.62822039910054, + "hill_cov": 1, + "hill_rme": 4.334666275617764, + "hill_top": 38.73045149963589, + "poly1_er": 1.1994211380897748, + "poly2_er": 1.1893608922995844, + "pow_a_sd": 0.2662014726962556, + "pow_ac50": 26.41818935078147, + "pow_p_sd": 0.1521243947331567, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 348.26640117274536, + "exp2_ac50": 26.717755706472612, + "exp2_b_sd": 548.865968812935, + "exp3_a_sd": 807.847513184223, + "exp3_ac50": 26.72713309062012, + "exp3_b_sd": 1098.3202531522547, + "exp3_p_sd": 0.3785039176466354, + "exp4_ac50": 26.05395024269712, + "exp5_ac50": 28.81134072021623, + "exp5_p_sd": 0.8722989388452311, + "gnls_ac50": 27.605267916591213, + "gnls_p_sd": 2.908874800565709, + "gnls_q_sd": 1691693.862361631, + "hill_ac50": 27.60654261703223, + "hill_p_sd": 2.9035455790005753, + "poly1_aic": 49.794702774441554, + "poly1_cov": 1, + "poly1_rme": 4.2304963707100685, + "poly1_top": 31.86280200223597, + "poly2_aic": 51.69217105908964, + "poly2_cov": 1, + "poly2_rme": 4.2015552080075915, + "poly2_top": 32.206999419449126, + "pow_er_sd": 0.3335534848800435, + "exp2_er_sd": 0.3352306055195441, + "exp3_er_sd": 0.33540266751937425, + "exp4_er_sd": 0.34685487937247106, + "exp4_ga_sd": 14.862078891119456, + "exp4_tp_sd": 14.104706577122425, + "exp5_er_sd": 0.33280432150032224, + "exp5_ga_sd": 14.999794914044722, + "exp5_tp_sd": 18.593299749044046, + "gnls_er_sd": 0.3380749134545, + "gnls_ga_sd": 16.756024987415838, + "gnls_la_sd": 9183669699.444252, + "gnls_tp_sd": 22.121841064908335, + "hill_er_sd": 0.33805915168123435, + "hill_ga_sd": 16.727253222611452, + "hill_tp_sd": 22.083475060963128, + "poly1_a_sd": 0.0558929749060581, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 715.013055008413, + "poly2_ac50": 26.65356756528099, + "poly2_b_sd": 1138.546206698338, + "poly1_er_sd": 0.33129334042250025, + "poly2_er_sd": 0.3350705967166628, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4998.669787345316 + }, + "mc5Param": { + "a": 0.6372560400447195, + "er": 1.1994211380897748, + "ac5": 2.5, + "acc": 35.43443476538152, + "bmd": 14.57678091717993, + "bmr": 9.289141683881516, + "mll": -22.897351387220777, + "top": 31.86280200223597, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 12.611111933962569, + "bmdu": 17.452581906257134, + "rmse": 4.2304963707100685, + "ac1sd": 10.80561965691618, + "caikwt": 0.0008623202468912801, + "hitcall": 0.9723023592263896, + "top_over_cutoff": 1.411056796335542 + }, + "mc6Param": { + "flag": [ + "Only highest conc above baseline, active", + "Average number of replicates per conc is less than 2", + "Less than 50% efficacy" + ], + "mc6MthdId": [ + 6, + 13, + 17 + ] + } + }, + { + "aeid": 704, + "m4id": 1842429, + "spid": "TP0000269H02", + "chid": 22422, + "casn": "101-77-9", + "chnm": "4,4'-Diaminobiphenyl methane", + "dtxsid": "DTXSID6022422", + "bmad": 3.7634679299683276, + "respMax": 6.633232578988787, + "respMin": -9.288579922195433, + "maxMean": 6.633232578988787, + "maxMeanConc": 1.6989700043360187, + "maxMed": 6.633232578988787, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 28, + "m5id": 5037075, + "modl": "poly1", + "hitc": 3.192301725566275E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812 + ], + "resp": [ + -9.288579922195433, + -1.8279384384638953, + -0.14076023490952427, + -4.745260374024319, + 1.8279384384638953, + 6.633232578988787, + -4.73269516708234, + -1.5362461344536993 + ] + }, + "mc4Param": { + "pow_a": 6.640694251968835E-8, + "pow_p": 4.708272706063721, + "exp2_a": 0.0014256880285145326, + "exp2_b": 5.922987531364045, + "exp3_a": 4.8847255820373086, + "exp3_b": 51.06429898378816, + "exp3_p": 7.307167695500869, + "exp5_p": 7.999659316310423, + "gnls_p": 7.997921197479794, + "gnls_q": 7.999530335677372, + "hill_p": 7.987088871124498, + "pow_er": 1.1589254476238335, + "cnst_er": 1.4044782982786244, + "exp2_er": 1.1606772582682774, + "exp3_er": 1.158287286339332, + "exp4_er": 1.3005392690341286, + "exp4_ga": 47.86270321881696, + "exp4_tp": 7.959879066255224, + "exp5_er": 1.1586163655292807, + "exp5_ga": 44.27571832190897, + "exp5_tp": 7.895000592298389, + "gnls_er": 1.1573094818936194, + "gnls_ga": 40.56058652494757, + "gnls_la": 1282.63837357557, + "gnls_tp": 7.842544176863125, + "hill_er": 1.158759147911965, + "hill_ga": 40.89369026010592, + "hill_tp": 7.959875816540536, + "poly1_a": 0.10491644651330384, + "poly2_a": 0.0006507393642465428, + "poly2_b": 0.5070793867700588, + "pow_aic": 51.41328997449672, + "pow_cov": 1, + "pow_rme": 4.1877013763156805, + "pow_top": 6.628688104808383, + "all_bmed": 0, + "cnst_aic": 50.45420871184967, + "cnst_rme": 4.799166261950659, + "exp2_aic": 51.41291348555145, + "exp2_cov": 1, + "exp2_rme": 4.1880775010710165, + "exp2_top": 6.608583802396452, + "exp3_aic": 53.40921189505927, + "exp3_cov": 1, + "exp3_rme": 4.187148881312595, + "exp3_top": 6.628127374590708, + "exp4_aic": 53.10846032712193, + "exp4_cov": 1, + "exp4_rme": 4.550125713330075, + "exp4_top": 7.959879066255224, + "exp5_aic": 53.40936435022408, + "exp5_cov": 1, + "exp5_rme": 4.187167470953343, + "exp5_top": 7.895000592298389, + "gnls_aic": 57.410191575677814, + "gnls_cov": 1, + "gnls_rme": 4.18726579424983, + "gnls_top": 7.842528457243228, + "hill_aic": 53.41002025565312, + "hill_cov": 1, + "hill_rme": 4.187247227286038, + "hill_top": 7.959875816540536, + "poly1_er": 1.2638071352336775, + "poly2_er": 1.1976543273745366, + "pow_a_sd": 0.0000013788954939727336, + "pow_ac50": 43.15524701052844, + "pow_p_sd": 0.1097737662077741, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.012170331308111916, + "exp2_ac50": 45.89577526124489, + "exp2_b_sd": 6.001913269342651, + "exp3_a_sd": null, + "exp3_ac50": 46.66683218601111, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 47.86270321881696, + "exp5_ac50": 44.27571832190897, + "exp5_p_sd": 93.77195086112552, + "gnls_ac50": 40.56056619473948, + "gnls_p_sd": 43.59115160559422, + "gnls_q_sd": 2768980.6256247056, + "hill_ac50": 40.89369026010592, + "hill_p_sd": 56.475026137838405, + "poly1_aic": 50.713583537593315, + "poly1_cov": 1, + "poly1_rme": 4.48292241263243, + "poly1_top": 5.245822325665192, + "poly2_aic": 51.658540260325886, + "poly2_cov": 1, + "poly2_rme": 4.236574457386872, + "poly2_top": 6.391126680630588, + "pow_er_sd": 0.3390660571566805, + "exp2_er_sd": 0.33931424884331485, + "exp3_er_sd": null, + "exp4_er_sd": 0.32712745799309023, + "exp4_ga_sd": 85.09550371327019, + "exp4_tp_sd": 12.38636011110518, + "exp5_er_sd": 0.3391901097874664, + "exp5_ga_sd": 365.25436041198617, + "exp5_tp_sd": 196.19908115352908, + "gnls_er_sd": 0.33907426314020656, + "gnls_ga_sd": 78.57769638557588, + "gnls_la_sd": 1447381779.2912436, + "gnls_tp_sd": 22.236006501316705, + "hill_er_sd": 0.33920566149277925, + "hill_ga_sd": 189.84478002949493, + "hill_tp_sd": 57.07566436306677, + "poly1_a_sd": 0.06310343610315335, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.017222480464774936, + "poly2_ac50": 35.28153125132216, + "poly2_b_sd": 6.752089022420825, + "poly1_er_sd": 0.32616650584201273, + "poly2_er_sd": 0.3369788768607837, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1282.6390163455906 + }, + "mc5Param": { + "a": 0.10491644651330384, + "er": 1.2638071352336775, + "ac5": 2.5, + "bmd": 88.53847030268618, + "bmr": 9.289141683881516, + "mll": -23.356791768796658, + "top": 5.245822325665192, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 44.58314427339827, + "rmse": 4.48292241263243, + "ac1sd": 65.63266886781777, + "caikwt": 0.5323764880588537, + "hitcall": 3.192301725566275E-7, + "top_over_cutoff": 0.23231331772011585 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842432, + "spid": "TP0000394E04", + "chid": 20501, + "casn": "1095-90-5", + "chnm": "Methadone hydrochloride", + "dtxsid": "DTXSID2020501", + "bmad": 3.7634679299683276, + "respMax": 53.57668637905514, + "respMin": -4.581867196614961, + "maxMean": 53.57668637905514, + "maxMeanConc": 1.6020599913279625, + "maxMed": 53.57668637905514, + "maxMedConc": 1.6020599913279625, + "logcMax": 1.6020599913279625, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 31, + "m5id": 5037078, + "modl": "hill", + "hitc": 0.9999279506725846, + "fitc": 42, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 14.5, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1, + -0.3979400086720376, + 1.6020599913279625, + 0, + -1.6989700043360187, + 0.6020599913279624, + -1.3010299956639813, + -1 + ], + "resp": [ + 21.936647794421265, + -1.740228546008569, + 53.57668637905514, + 0.9551787559185203, + 4.581867196614961, + 5.153028957639964, + -4.581867196614961, + -4.44713457988105 + ] + }, + "mc4Param": { + "pow_a": 2.4561136581257776, + "pow_p": 0.8384142205134059, + "exp2_a": 11320.853419470812, + "exp2_b": 8346.744546958991, + "exp3_a": 1237.9308992517135, + "exp3_b": 1768.9351199634818, + "exp3_p": 0.8316744236700095, + "exp5_p": 1.8016780602346592, + "gnls_p": 1.9766627273478856, + "gnls_q": 4.997108159683513, + "hill_p": 1.9766497079181975, + "pow_er": 1.2490116616663218, + "cnst_er": 2.3406712762674364, + "exp2_er": 1.2565016352167926, + "exp3_er": 1.2497067897586192, + "exp4_er": 1.191255314619447, + "exp4_ga": 16.812978981896514, + "exp4_tp": 64.29202364758979, + "exp5_er": 0.8491056586507115, + "exp5_ga": 11.658831182973834, + "exp5_tp": 53.66634267307796, + "gnls_er": 0.8492765164139605, + "gnls_ga": 13.128901045410975, + "gnls_la": 2844.841004379705, + "gnls_tp": 59.500838623136616, + "hill_er": 0.8492543606297048, + "hill_ga": 13.128917895765634, + "hill_tp": 59.50093497422053, + "poly1_a": 1.35953439410823, + "poly2_a": 16188.436536049236, + "poly2_b": 11947.622892743011, + "pow_aic": 51.10023509243637, + "pow_cov": 1, + "pow_rme": 3.696125539873346, + "pow_top": 54.13003887794411, + "all_bmed": 0, + "cnst_aic": 70.10511686201906, + "cnst_rme": 20.748302126586477, + "exp2_aic": 52.14437661600831, + "exp2_cov": 1, + "exp2_rme": 4.1749638213440265, + "exp2_top": 54.38299031459843, + "exp3_aic": 53.16631363814249, + "exp3_cov": 1, + "exp3_rme": 3.712832014242786, + "exp3_top": 54.12213234353056, + "exp4_aic": 50.26961153208619, + "exp4_cov": 1, + "exp4_rme": 3.527127666309079, + "exp4_top": 64.29202364758979, + "exp5_aic": 48.01142321272821, + "exp5_cov": 1, + "exp5_rme": 2.8599881028288165, + "exp5_top": 53.66634267307796, + "gnls_aic": 52.00868220033195, + "gnls_cov": 1, + "gnls_rme": 2.859115773918567, + "gnls_top": 59.447789496359654, + "hill_aic": 48.00868220032641, + "hill_cov": 1, + "hill_rme": 2.8591158241549053, + "hill_top": 59.50093497422053, + "poly1_er": 1.2550642041651328, + "poly2_er": 1.2548228259159553, + "pow_a_sd": 0.5793958854691459, + "pow_ac50": 17.498995862103317, + "pow_p_sd": 0.06471940367191595, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 91463.2886733445, + "exp2_ac50": 20.023961414836553, + "exp2_b_sd": 67271.17368852775, + "exp3_a_sd": null, + "exp3_ac50": 17.605958078074853, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 16.812978981896514, + "exp5_ac50": 11.658831182973834, + "exp5_p_sd": 0.4678540387944143, + "gnls_ac50": 13.11706285853708, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 13.128917895765634, + "hill_p_sd": 0.5437164914820396, + "poly1_aic": 50.12897105076053, + "poly1_cov": 1, + "poly1_rme": 4.169192622228223, + "poly1_top": 54.38137576432922, + "poly2_aic": 52.15043963754287, + "poly2_cov": 1, + "poly2_rme": 4.1773867080169955, + "poly2_top": 54.3794684457665, + "pow_er_sd": 0.2953728072048604, + "exp2_er_sd": 0.32180507236787287, + "exp3_er_sd": null, + "exp4_er_sd": 0.32050596955935456, + "exp4_ga_sd": 4.7195276601323375, + "exp4_tp_sd": 9.472791030891605, + "exp5_er_sd": 0.3379311586462701, + "exp5_ga_sd": 1.1444511740381855, + "exp5_tp_sd": 2.171328717403055, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.33765766287101917, + "hill_ga_sd": 2.6322294581745154, + "hill_tp_sd": 6.46954953419342, + "poly1_a_sd": 0.08016047186257787, + "poly1_ac50": 20.000000000000007, + "poly2_a_sd": 111138.19550808848, + "poly2_ac50": 20.033367656805616, + "poly2_b_sd": 81749.64462524683, + "poly1_er_sd": 0.3215405880389804, + "poly2_er_sd": 0.3217023608890684, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2845.828862866811 + }, + "mc5Param": { + "p": 1.9766497079181975, + "er": 0.8492543606297048, + "ga": 13.128917895765634, + "tp": 59.50093497422053, + "ac5": 2.9600505790971923, + "acc": 10.2377822240795, + "bmd": 5.590946990603684, + "bmr": 9.289141683881516, + "mll": -20.00434110016321, + "top": 59.50093497422053, + "ac10": 4.31987731652492, + "ac20": 6.510927354274445, + "ac50": 13.128917895765634, + "bmdl": 4.96194145242722, + "bmdu": 6.331117452796167, + "rmse": 2.8591158241549053, + "ac1sd": 4.69288250612793, + "caikwt": 0.000015915242721747014, + "hitcall": 0.9999279506725846, + "top_over_cutoff": 2.6350224527585864 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842430, + "spid": "TP0000270A03", + "chid": 40713, + "casn": "1034-01-1", + "chnm": "Octyl gallate", + "dtxsid": "DTXSID4040713", + "bmad": 3.7634679299683276, + "respMax": 4.0110100385645735, + "respMin": -1753.9651348778787, + "maxMean": 4.0110100385645735, + "maxMeanConc": -0.6989700043360187, + "maxMed": 4.0110100385645735, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 29, + "m5id": 5037076, + "modl": "poly1", + "hitc": 0.09452569552120044, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + -2.8074617052802946, + 1.0764716849676692, + -3.8481164198730133, + -66.04011500681993, + -22.1044677990717, + -650.3289764196767, + 4.0110100385645735, + -1753.9651348778787 + ] + }, + "mc4Param": { + "pow_a": 0.000005430954273073871, + "pow_p": 0.44356001645759247, + "exp2_a": 0.0002868758851047003, + "exp2_b": 52.29564518101915, + "exp3_a": 0.00007065373025385777, + "exp3_b": 53.07437818010606, + "exp3_p": 7.856638077526047, + "exp5_p": 6.364784886246265, + "gnls_p": 1.0994616555400518, + "gnls_q": 6.028016384412763, + "hill_p": 1.4277336875116893, + "pow_er": 5.478367634135051, + "cnst_er": 5.135878672216937, + "exp2_er": 5.477689913583649, + "exp3_er": 5.48013831055958, + "exp4_er": 5.478384004342792, + "exp4_ga": 0.016244348117744, + "exp4_tp": 5.294724775052426E-7, + "exp5_er": 5.478340674314374, + "exp5_ga": 6.3316531519675445, + "exp5_tp": 2.3312427416913565E-7, + "gnls_er": 5.478333661045958, + "gnls_ga": 0.06561651513532632, + "gnls_la": 4.027166880955711, + "gnls_tp": 0.005795299244329243, + "hill_er": 5.478301864378817, + "hill_ga": 65.48576851856772, + "hill_tp": 5.147568284752382E-7, + "poly1_a": 9.803449957825028E-9, + "poly2_a": 0.0003985692201837858, + "poly2_b": 57.57648587989856, + "pow_aic": 128.0195917417057, + "pow_cov": 1, + "pow_rme": 661.8356526940903, + "pow_top": 0.00003079436898408721, + "all_bmed": 0, + "cnst_aic": 124.3587136415083, + "cnst_rme": 661.8356398173057, + "exp2_aic": 128.01959637464324, + "exp2_cov": 1, + "exp2_rme": 661.8358088666978, + "exp2_top": 0.0004594424423992509, + "exp3_aic": 130.0196021965711, + "exp3_cov": 1, + "exp3_rme": 661.8356601754986, + "exp3_top": 0.00006144291346564819, + "exp4_aic": 128.01959135584116, + "exp4_cov": 1, + "exp4_rme": 661.8356400664329, + "exp4_top": 5.294724775052426E-7, + "exp5_aic": 130.01959133366273, + "exp5_cov": 1, + "exp5_rme": 661.8356399242966, + "exp5_top": 2.3312427416913565E-7, + "gnls_aic": 134.0195953824525, + "gnls_cov": 1, + "gnls_rme": 661.8356575450581, + "gnls_top": 0.005607028353241692, + "hill_aic": 130.01959132750963, + "hill_cov": 1, + "hill_rme": 661.8356398963703, + "hill_top": 5.147568284752382E-7, + "poly1_er": 5.47830425526447, + "poly2_er": 5.47782475358971, + "pow_a_sd": null, + "pow_ac50": 10.478569298304585, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.761010400258353, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 46.61973121962576, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.016244348117744, + "exp5_ac50": 6.3316531519675445, + "exp5_p_sd": 570927.6166739571, + "gnls_ac50": 0.06184991600912808, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 65.48576851856772, + "hill_p_sd": null, + "poly1_aic": 126.0195913302737, + "poly1_cov": 1, + "poly1_rme": 661.8356400045014, + "poly1_top": 4.901724978912513E-7, + "poly2_aic": 128.0195974654655, + "poly2_cov": 1, + "poly2_rme": 661.8358775325804, + "poly2_top": 0.0006466969391063058, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.5650956309919339, + "exp5_ga_sd": 30541.074886739865, + "exp5_tp_sd": 0.010891154955251125, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999993, + "poly2_a_sd": null, + "poly2_ac50": 30.525963440706303, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4.056814023436538 + }, + "mc5Param": { + "a": 9.803449957825028E-9, + "er": 5.47830425526447, + "ac5": 2.4999999999999996, + "bmd": 947538032.4114374, + "bmr": 9.289141683881516, + "mll": -61.00979566513685, + "top": 4.901724978912513E-7, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999993, + "bmdl": 1.5904077965907737, + "rmse": 661.8356400045014, + "ac1sd": 702400320.542207, + "caikwt": 0.6964477131643466, + "hitcall": 0.09452569552120044, + "top_over_cutoff": 2.1707483054305203E-8 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842431, + "spid": "TP0000270G03", + "chid": 24538, + "casn": "1143-38-0", + "chnm": "Anthralin", + "dtxsid": "DTXSID7024538", + "bmad": 3.7634679299683276, + "respMax": 1.07185605243019, + "respMin": -9693.875949218062, + "maxMean": 1.07185605243019, + "maxMeanConc": -1.6989700043360187, + "maxMed": 1.07185605243019, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 30, + "m5id": 5037077, + "modl": "poly1", + "hitc": 0.1121664647692, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187 + ], + "resp": [ + -290.8004336479407, + -1119.7932814002315, + -3511.304770127347, + -14.130840021191842, + 1.07185605243019, + -9693.875949218062, + -5531.363440142849, + -9.227773090281191 + ] + }, + "mc4Param": { + "pow_a": 0.000016295912787337223, + "pow_p": 0.32150472408902353, + "exp2_a": 0.0005108027295935569, + "exp2_b": 117.05732896371232, + "exp3_a": 0.0007637855137420518, + "exp3_b": 66.37880128554707, + "exp3_p": 1.1690184802745147, + "exp5_p": 1.213976459225782, + "gnls_p": 1.465333545857999, + "gnls_q": 5.282627284696863, + "hill_p": 1.2584446172819073, + "pow_er": 7.913005745260049, + "cnst_er": 7.913106054805518, + "exp2_er": 7.91304122261628, + "exp3_er": 7.912357342166467, + "exp4_er": 7.9130904419643535, + "exp4_ga": 1.5991852149246326, + "exp4_tp": 2.547300452544774E-7, + "exp5_er": 7.913138104543472, + "exp5_ga": 1.0314696395590963, + "exp5_tp": 8.788694104592858E-7, + "gnls_er": 7.913096858909503, + "gnls_ga": 0.007141805168919414, + "gnls_la": 0.22621165840625276, + "gnls_tp": 0.7142118359098187, + "hill_er": 7.913164719748869, + "hill_ga": 0.07017612467977288, + "hill_tp": 0.0000014705482139499703, + "poly1_a": 7.358333303060364E-9, + "poly2_a": 0.02215910584118531, + "poly2_b": 158.14203618196245, + "pow_aic": 160.88623145756264, + "pow_cov": 1, + "pow_rme": 4156.850720832816, + "pow_top": 0.00005731991981836795, + "all_bmed": 0, + "cnst_aic": 156.88623127229403, + "cnst_rme": 4156.850693149301, + "exp2_aic": 160.8862316267931, + "exp2_cov": 1, + "exp2_rme": 4156.850791480489, + "exp2_top": 0.00027219093118124426, + "exp3_aic": 162.88623595855358, + "exp3_cov": 1, + "exp3_rme": 4156.850967911036, + "exp3_top": 0.0008022692602122777, + "exp4_aic": 160.88623127463256, + "exp4_cov": 1, + "exp4_rme": 4156.85069329631, + "exp4_top": 2.547300452544774E-7, + "exp5_aic": 162.88623128180765, + "exp5_cov": 1, + "exp5_rme": 4156.850693669871, + "exp5_top": 8.788694104592858E-7, + "gnls_aic": 166.88623633191477, + "gnls_cov": 1, + "gnls_rme": 4156.851147731188, + "gnls_top": 0.691919808292708, + "hill_aic": 162.8862313001522, + "hill_cov": 1, + "hill_rme": 4156.850694038434, + "hill_top": 0.0000014705482139499703, + "poly1_er": 7.913114168722814, + "poly2_er": 7.913479042407319, + "pow_a_sd": null, + "pow_ac50": 5.7896734789017446, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 27.64958084229515, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 31.74103567254259, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.5991852149246326, + "exp5_ac50": 1.0314696395590963, + "exp5_p_sd": null, + "gnls_ac50": 0.006843854769952966, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.07017612467977288, + "hill_p_sd": null, + "poly1_aic": 158.88623127321256, + "poly1_cov": 1, + "poly1_rme": 4156.850693286225, + "poly1_top": 3.679166651530182E-7, + "poly2_aic": 160.88624315935962, + "poly2_cov": 1, + "poly2_rme": 4156.854008688916, + "poly2_top": 0.009221198742038497, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 124.06407111097684, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 27.96064454439664, + "poly2_b_sd": null, + "poly1_er_sd": 0.5644466155491178, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.22837814263899145 + }, + "mc5Param": { + "a": 7.358333303060364E-9, + "er": 7.913114168722814, + "ac5": 2.5, + "bmd": 1262397516.0269134, + "bmr": 9.289141683881516, + "mll": -77.44311563660628, + "top": 3.679166651530182E-7, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 0.2092540156485721, + "rmse": 4156.850693286225, + "ac1sd": 935802458.1370742, + "caikwt": 0.7310585787203021, + "hitcall": 0.1121664647692, + "top_over_cutoff": 1.629333511889013E-8 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842433, + "spid": "TP0000397C04", + "chid": 47303, + "casn": "179465-71-5", + "chnm": "CJ-013790", + "dtxsid": "DTXSID2047303", + "bmad": 3.7634679299683276, + "respMax": 4.713376683939935, + "respMin": -8.665862529755879, + "maxMean": 4.713376683939935, + "maxMeanConc": 1.6989700043360187, + "maxMed": 4.713376683939935, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 32, + "m5id": 5037079, + "modl": "poly1", + "hitc": 1.4657563430328811E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + 1.3010299956639813, + -0.22184874961635637, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + -1.6989700043360187, + -0.6989700043360187 + ], + "resp": [ + 4.713376683939935, + -2.842277469047785, + -8.665862529755879, + -6.370529795363219, + -4.8381205032263255, + 0.16783502687974627, + -0.16783502687974627, + -8.177282570884165 + ] + }, + "mc4Param": { + "pow_a": 4.7151852041982344E-8, + "pow_p": 4.707056641849134, + "exp2_a": 0.00013619254967583104, + "exp2_b": 4.786378022525692, + "exp3_a": 5.900683408927318, + "exp3_b": 53.44092756539992, + "exp3_p": 7.988441200666841, + "exp5_p": 7.999984075925836, + "gnls_p": 7.999997843476933, + "gnls_q": 2.098633684006826, + "hill_p": 7.999998966110843, + "pow_er": 1.4971788764551808, + "cnst_er": 1.5930907333079742, + "exp2_er": 1.4281119149809516, + "exp3_er": 1.495216359023091, + "exp4_er": 1.574893735475315, + "exp4_ga": 89.43517285381708, + "exp4_tp": 5.656051760011978, + "exp5_er": 1.4954679802518542, + "exp5_ga": 44.42715506006904, + "exp5_tp": 5.651471625387929, + "gnls_er": 1.4957921628108226, + "gnls_ga": 41.23384355892483, + "gnls_la": 3602.128748083291, + "gnls_tp": 5.656047237666198, + "hill_er": 1.4957815691417695, + "hill_ga": 41.23453451042785, + "hill_tp": 5.656051677235107, + "poly1_a": 0.050926851808962656, + "poly2_a": 0.000012052724389524282, + "poly2_b": 0.08546364297195863, + "pow_aic": 55.84673202895972, + "pow_cov": 1, + "pow_rme": 5.177530614120443, + "pow_top": 4.684322627141668, + "all_bmed": 0, + "cnst_aic": 52.95155071753253, + "cnst_rme": 5.434921591825441, + "exp2_aic": 55.8743139942496, + "exp2_cov": 1, + "exp2_rme": 5.173806472402641, + "exp2_top": 4.687233137067029, + "exp3_aic": 57.826834706209766, + "exp3_cov": 1, + "exp3_rme": 5.173298710256261, + "exp3_top": 4.718858031320078, + "exp4_aic": 56.73903934336423, + "exp4_cov": 1, + "exp4_rme": 5.385431090855095, + "exp4_top": 5.656051760011978, + "exp5_aic": 57.82823857314273, + "exp5_cov": 1, + "exp5_rme": 5.173596106096281, + "exp5_top": 5.651471625387929, + "gnls_aic": 61.83188800877744, + "gnls_cov": 1, + "gnls_rme": 5.17436656145897, + "gnls_top": 5.650466885579585, + "hill_aic": 57.83188406117348, + "hill_cov": 1, + "hill_rme": 5.174365789583489, + "hill_top": 5.656051677235107, + "poly1_er": 1.5665690518106064, + "poly2_er": 1.5387462152993685, + "pow_a_sd": 0.0000014616637059530786, + "pow_ac50": 43.15360567910734, + "pow_p_sd": 0.21842337803021228, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.0017043622702050344, + "exp2_ac50": 46.68247463584101, + "exp2_b_sd": 5.752295568125435, + "exp3_a_sd": null, + "exp3_ac50": 46.62733184577904, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 89.43517285381708, + "exp5_ac50": 44.42715506006904, + "exp5_p_sd": 37.67996399295617, + "gnls_ac50": 41.22454200269515, + "gnls_p_sd": 26.8489978675531, + "gnls_q_sd": 365.5344008388901, + "hill_ac50": 41.23453451042785, + "hill_p_sd": 26.882057159993813, + "poly1_aic": 54.65643655278332, + "poly1_cov": 1, + "poly1_rme": 5.369694576790002, + "poly1_top": 2.5463425904481323, + "poly2_aic": 56.11124549509633, + "poly2_cov": 1, + "poly2_rme": 5.235979290613626, + "poly2_top": 4.132416873278887, + "pow_er_sd": 0.3189018135141268, + "exp2_er_sd": 0.3138862113183906, + "exp3_er_sd": null, + "exp4_er_sd": 0.30874656566105163, + "exp4_ga_sd": 367.1517518690402, + "exp4_tp_sd": 24.085287988419147, + "exp5_er_sd": 0.31920776352680286, + "exp5_ga_sd": 128.5331012831714, + "exp5_tp_sd": 50.817238104594026, + "gnls_er_sd": 0.31925198781323405, + "gnls_ga_sd": 84.12979470825537, + "gnls_la_sd": 2666741.0444864347, + "gnls_tp_sd": 19.50597783562384, + "hill_er_sd": 0.31925103598267796, + "hill_ga_sd": 84.43629556899846, + "hill_tp_sd": 19.57120334180694, + "poly1_a_sd": 0.08732727070509533, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.00005470985934134532, + "poly2_ac50": 35.34283609938913, + "poly2_b_sd": 0.1930930384385403, + "poly1_er_sd": 0.3092301889812486, + "poly2_er_sd": 0.3174997459048597, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3605.517232480094 + }, + "mc5Param": { + "a": 0.050926851808962656, + "er": 1.5665690518106064, + "ac5": 2.4999999999999996, + "bmd": 182.4016477344219, + "bmr": 9.289141683881516, + "mll": -25.32821827639166, + "top": 2.5463425904481323, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 48.45564360274376, + "rmse": 5.369694576790002, + "ac1sd": 135.21248905442692, + "caikwt": 0.7010793489765594, + "hitcall": 0.0000014657563430328811, + "top_over_cutoff": 0.11276578933008924 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842434, + "spid": "TP0000397C07", + "chid": 47290, + "casn": "402910-27-4", + "chnm": "UK-416244", + "dtxsid": "DTXSID0047290", + "bmad": 3.7634679299683276, + "respMax": 20.562993899193387, + "respMin": -1.7128786948219439, + "maxMean": 20.562993899193387, + "maxMeanConc": 1.6989700043360187, + "maxMed": 20.562993899193387, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 33, + "m5id": 5037080, + "modl": "poly1", + "hitc": 0.013162763209107189, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436 + ], + "resp": [ + 1.7128786948219457, + 6.79192117713184, + 0.983536383364406, + 20.562993899193387, + 4.434828570684111, + -1.7128786948219439, + 3.81112438722068, + 3.4559450294617946 + ] + }, + "mc4Param": { + "pow_a": 0.6465352316272346, + "pow_p": 0.8777358322696996, + "exp2_a": 89.17261706113294, + "exp2_b": 242.1062343156615, + "exp3_a": 1.1322547120812192, + "exp3_b": 2.3290546411674624, + "exp3_p": 0.3515182576728658, + "exp5_p": 1.5578879657662703, + "gnls_p": 2.6086058918752, + "gnls_q": 6.488574895843359, + "hill_p": 2.608552656586586, + "pow_er": 0.592938019227486, + "cnst_er": 1.6023141970056376, + "exp2_er": 0.5815399491932731, + "exp3_er": 0.4027853746799608, + "exp4_er": 0.7852662330946163, + "exp4_ga": 25.08568386766411, + "exp4_tp": 24.675592673186735, + "exp5_er": 0.725548250986497, + "exp5_ga": 28.642999510263735, + "exp5_tp": 24.67559255717096, + "gnls_er": 0.7768842111175422, + "gnls_ga": 28.03423084450281, + "gnls_la": 1207.440421430461, + "gnls_tp": 24.675592520708317, + "hill_er": 0.7767855542995623, + "hill_ga": 28.03395361240333, + "hill_tp": 24.675592678367664, + "poly1_a": 0.40607178858594234, + "poly2_a": 177.31422405471238, + "poly2_b": 478.93026660415705, + "pow_aic": 41.233991570138386, + "pow_cov": 1, + "pow_rme": 2.079136922898597, + "pow_top": 20.03729289908219, + "all_bmed": 0, + "cnst_aic": 56.08828664046871, + "cnst_rme": 8.077268192520862, + "exp2_aic": 41.31836603558712, + "exp2_cov": 1, + "exp2_rme": 2.124397197473024, + "exp2_top": 20.455613509941355, + "exp3_aic": 40.32224322278512, + "exp3_cov": 1, + "exp3_rme": 1.7472047427116597, + "exp3_top": 20.256515991910604, + "exp4_aic": 43.99983839294445, + "exp4_cov": 1, + "exp4_rme": 2.4212957674199513, + "exp4_top": 24.675592673186735, + "exp5_aic": 45.31966847370493, + "exp5_cov": 1, + "exp5_rme": 2.3636821866975195, + "exp5_top": 24.67559255717096, + "gnls_aic": 50.24980681608249, + "gnls_cov": 1, + "gnls_rme": 2.506821099601261, + "gnls_top": 24.634723410831995, + "hill_aic": 46.24980691570314, + "hill_cov": 1, + "hill_rme": 2.506818523624102, + "hill_top": 24.675592678367664, + "poly1_er": 0.5923846502517791, + "poly2_er": 0.5823674792019434, + "pow_a_sd": 0.6278658064575703, + "pow_ac50": 22.699069305947805, + "pow_p_sd": 0.2549454765062092, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 359.0395021231347, + "exp2_ac50": 26.288468365058172, + "exp2_b_sd": 886.5958914663547, + "exp3_a_sd": null, + "exp3_ac50": 24.811922046316333, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 25.08568386766411, + "exp5_ac50": 28.642999510263735, + "exp5_p_sd": 1.0227938367314742, + "gnls_ac50": 27.998654408803787, + "gnls_p_sd": 5.461532170943338, + "gnls_q_sd": 22759.167333341324, + "hill_ac50": 28.03395361240333, + "hill_p_sd": 5.452818557413982, + "poly1_aic": 39.39114515732258, + "poly1_cov": 1, + "poly1_rme": 2.122723532583719, + "poly1_top": 20.303589429297116, + "poly2_aic": 41.325165646100416, + "poly2_cov": 1, + "poly2_rme": 2.1244698512830005, + "poly2_top": 20.44407341622616, + "pow_er_sd": 0.3108099654396902, + "exp2_er_sd": 0.3178770115917476, + "exp3_er_sd": null, + "exp4_er_sd": 0.33443563742176596, + "exp4_ga_sd": 13.749752885288313, + "exp4_tp_sd": 8.11750344400524, + "exp5_er_sd": 0.32227571811133654, + "exp5_ga_sd": 12.37560260555014, + "exp5_tp_sd": 10.526695614436056, + "gnls_er_sd": 0.3501482582991739, + "gnls_ga_sd": 29.843090634836496, + "gnls_la_sd": 13481202.453940429, + "gnls_tp_sd": 25.420327925189305, + "hill_er_sd": 0.3500296892891899, + "hill_ga_sd": 29.79588241284215, + "hill_tp_sd": 25.3801674852378, + "poly1_a_sd": 0.030791471721265937, + "poly1_ac50": 25, + "poly2_a_sd": 792.2766056136632, + "poly2_ac50": 26.179002210991253, + "poly2_b_sd": 1966.159052634094, + "poly1_er_sd": 0.31366046598015807, + "poly2_er_sd": 0.31747777530209154, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1208.036729727654 + }, + "mc5Param": { + "a": 0.40607178858594234, + "er": 0.5923846502517791, + "ac5": 2.5, + "bmd": 22.87561447257627, + "bmr": 9.289141683881516, + "mll": -17.69557257866129, + "top": 20.303589429297116, + "ac10": 5, + "ac20": 10, + "ac50": 25, + "bmdl": 20.16263893407659, + "bmdu": 26.70412321005569, + "rmse": 2.122723532583719, + "ac1sd": 16.95746069130932, + "caikwt": 0.00023667860169117045, + "hitcall": 0.013162763209107187, + "top_over_cutoff": 0.8991524929981263 + }, + "mc6Param": { + "flag": [ + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842435, + "spid": "TP0000880C04", + "chid": 33923, + "casn": "32809-16-8", + "chnm": "Procymidone", + "dtxsid": "DTXSID9033923", + "bmad": 3.7634679299683276, + "respMax": 3.8699568062787453, + "respMin": -24.489107339892946, + "maxMean": 3.8699568062787453, + "maxMeanConc": -1.6989700043360187, + "maxMed": 3.8699568062787453, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 34, + "m5id": 5037081, + "modl": "poly1", + "hitc": 2.0097205336309178E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436 + ], + "resp": [ + -16.749193727335452, + -3.8699568062787457, + -24.489107339892946, + -2.381126076423389, + -0.43391299854400067, + -11.816416045813897, + 3.8699568062787453, + -18.88319457236392 + ] + }, + "mc4Param": { + "pow_a": 1.952362597456107E-7, + "pow_p": 0.39552329951433673, + "exp2_a": 0.0000013815285997456324, + "exp2_b": 57.36258080607493, + "exp3_a": 0.0001480645519160266, + "exp3_b": 58.52389350028799, + "exp3_p": 3.781832639454812, + "exp5_p": 2.151688320633654, + "gnls_p": 4.527989650709323, + "gnls_q": 5.108399001356277, + "hill_p": 1.303035732677177, + "pow_er": 2.418785008334611, + "cnst_er": 2.4188909137985077, + "exp2_er": 2.4174176897085324, + "exp3_er": 2.419726742963499, + "exp4_er": 2.4189096181956495, + "exp4_ga": 12.65722171867288, + "exp4_tp": 1.0355875462847547E-9, + "exp5_er": 2.4189155605747237, + "exp5_ga": 2.333940770138562, + "exp5_tp": 7.523689804982252E-10, + "gnls_er": 2.418842358875211, + "gnls_ga": 0.006221346383250256, + "gnls_la": 0.1981088801387234, + "gnls_tp": 1.090792464590304E-7, + "hill_er": 2.4188877929803674, + "hill_ga": 11.485567544481444, + "hill_tp": 2.7451333346567636E-9, + "poly1_a": 2.0842008078263976E-11, + "poly2_a": 0.000005049104462465559, + "poly2_b": 54.21786559908971, + "pow_aic": 70.76387560116336, + "pow_cov": 1, + "pow_rme": 13.286580877800748, + "pow_top": 9.173661286959486E-7, + "all_bmed": 0, + "cnst_aic": 66.76387501055429, + "cnst_rme": 13.28658048320367, + "exp2_aic": 70.7638964289917, + "exp2_cov": 1, + "exp2_rme": 13.28658095149074, + "exp2_top": 0.0000019214971296937626, + "exp3_aic": 72.76390545298773, + "exp3_cov": 1, + "exp3_rme": 13.28659824551256, + "exp3_top": 0.00010892669639514888, + "exp4_aic": 70.7638750136908, + "exp4_cov": 1, + "exp4_rme": 13.286580483579051, + "exp4_top": 1.0355875462847547E-9, + "exp5_aic": 72.76387501605065, + "exp5_cov": 1, + "exp5_rme": 13.2865804836615, + "exp5_top": 7.523689804982252E-10, + "gnls_aic": 76.76387503731891, + "gnls_cov": 1, + "gnls_rme": 13.286580484397929, + "gnls_top": 1.090255384568449E-7, + "hill_aic": 72.76387501190618, + "hill_cov": 1, + "hill_rme": 13.286580484182, + "hill_top": 2.7451333346567636E-9, + "poly1_er": 2.4189004532043645, + "poly2_er": 2.418496776366225, + "pow_a_sd": null, + "pow_ac50": 8.667164755308963, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.28360145565822, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 43.05544733482424, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 12.65722171867288, + "exp5_ac50": 2.333940770138562, + "exp5_p_sd": null, + "gnls_ac50": 0.006219991242649403, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 11.485567544481444, + "hill_p_sd": 182115.5261684, + "poly1_aic": 68.7638750114407, + "poly1_cov": 1, + "poly1_rme": 13.286580483490953, + "poly1_top": 1.0421004039131984E-9, + "poly2_aic": 70.76387916054314, + "poly2_cov": 1, + "poly2_rme": 13.286582613515252, + "poly2_top": 0.00000895038468449257, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.32318093486450644, + "hill_ga_sd": 39787.827708636134, + "hill_tp_sd": 0.00014220966225169602, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.68674937055745, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.19814706168674365 + }, + "mc5Param": { + "a": 2.0842008078263976E-11, + "er": 2.4189004532043645, + "ac5": 2.4999999999999996, + "bmd": 445693219626.4291, + "bmr": 9.289141683881516, + "mll": -32.38193750572035, + "top": 1.0421004039131984E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 58.80191266271995, + "rmse": 13.286580483490953, + "ac1sd": 330387857395.42554, + "caikwt": 0.731058578717145, + "hitcall": 0.00020097205336309175, + "top_over_cutoff": 4.614982879730862E-11 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842436, + "spid": "TP0000881A11", + "chid": 48175, + "casn": "151506-44-4", + "chnm": "Difpas-pyrazole", + "dtxsid": "DTXSID6048175", + "bmad": 3.7634679299683276, + "respMax": 9.134362565846857, + "respMin": -9.785612022505717, + "maxMean": 9.134362565846857, + "maxMeanConc": 0.3010299956639812, + "maxMed": 9.134362565846857, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 35, + "m5id": 5037082, + "modl": "poly1", + "hitc": 1.1947725092996029E-4, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187 + ], + "resp": [ + 9.134362565846857, + -9.785612022505717, + 3.535593024563581, + 6.742445658286296, + -0.3105023663836639, + 5.823097242106741, + -4.029995470890604, + -3.535593024563581 + ] + }, + "mc4Param": { + "pow_a": 0.5017775225188548, + "pow_p": 0.6591192202685694, + "exp2_a": 453.975198070989, + "exp2_b": 3365.723487674608, + "exp3_a": 47.11060086418455, + "exp3_b": 932.6075153090944, + "exp3_p": 0.6902242901855664, + "exp5_p": 7.999996307955874, + "gnls_p": 7.999999981968314, + "gnls_q": 3.2727881400777346, + "hill_p": 7.999999785978309, + "pow_er": 1.531638797544549, + "cnst_er": 1.7262662747276574, + "exp2_er": 1.5506701363683515, + "exp3_er": 1.536100270032405, + "exp4_er": 1.5089274250976916, + "exp4_ga": 13.628170726573147, + "exp4_tp": 6.977505107544097, + "exp5_er": 1.289488315288251, + "exp5_ga": 1.4438188583318046, + "exp5_tp": 6.178082350961625, + "gnls_er": 1.2953710144587984, + "gnls_ga": 1.10862617843866, + "gnls_la": 4151.891415636962, + "gnls_tp": 6.166337115180187, + "hill_er": 1.4438381777640448, + "hill_ga": 12.482180184563882, + "hill_tp": 6.342080307914102, + "poly1_a": 0.13564844128161777, + "poly2_a": 383.3454143719398, + "poly2_b": 2877.2229593527345, + "pow_aic": 56.75504382566062, + "pow_cov": 1, + "pow_rme": 5.641059195157223, + "pow_top": 6.612032619018348, + "all_bmed": 0, + "cnst_aic": 54.94826792526694, + "cnst_rme": 6.12272333576879, + "exp2_aic": 56.83709901722125, + "exp2_cov": 1, + "exp2_rme": 5.590761673925524, + "exp2_top": 6.794438217682005, + "exp3_aic": 58.76709884295892, + "exp3_cov": 1, + "exp3_rme": 5.627994848984627, + "exp3_top": 6.686017631086944, + "exp4_aic": 56.60430600619944, + "exp4_cov": 1, + "exp4_rme": 5.64803429898856, + "exp4_top": 6.977505107544097, + "exp5_aic": 57.43232581617384, + "exp5_cov": 1, + "exp5_rme": 6.1785465480449275, + "exp5_top": 6.178082350961625, + "gnls_aic": 61.48247646171176, + "gnls_cov": 1, + "gnls_rme": 6.1821614427506155, + "gnls_top": 6.166337058698889, + "hill_aic": 57.56759946363208, + "hill_cov": 1, + "hill_rme": 5.261298696231139, + "hill_top": 6.342080307914102, + "poly1_er": 1.5502075397868125, + "poly2_er": 1.550523396666215, + "pow_a_sd": 1.8425110941903395, + "pow_ac50": 17.468453440300433, + "pow_p_sd": 0.9672892572791348, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 8922.735205678156, + "exp2_ac50": 25.09284693992692, + "exp2_b_sd": 65504.294285102085, + "exp3_a_sd": 613.2900449736795, + "exp3_ac50": 19.20254148908469, + "exp3_b_sd": 11915.632924850908, + "exp3_p_sd": 1.5295163260514226, + "exp4_ac50": 13.628170726573147, + "exp5_ac50": 1.4438188583318046, + "exp5_p_sd": 26.276043660735045, + "gnls_ac50": 1.1086261757300446, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 12.482180184563882, + "hill_p_sd": 15.808942438750206, + "poly1_aic": 54.834448290805426, + "poly1_cov": 1, + "poly1_rme": 5.59051462132586, + "poly1_top": 6.782422064080888, + "poly2_aic": 56.84053243854048, + "poly2_cov": 1, + "poly2_rme": 5.5908588367326715, + "poly2_top": 6.777492495111021, + "pow_er_sd": 0.32653699413281, + "exp2_er_sd": 0.31815485619140227, + "exp3_er_sd": 0.32790889345958, + "exp4_er_sd": 0.33416716724015716, + "exp4_ga_sd": 31.79171894098858, + "exp4_tp_sd": 6.352844098132389, + "exp5_er_sd": 0.3758220092286442, + "exp5_ga_sd": 1.9804842288363265, + "exp5_tp_sd": 2.143982334536147, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.332730110230082, + "hill_ga_sd": 15.134790376842096, + "hill_tp_sd": 2.8528600881389283, + "poly1_a_sd": 0.08178965120744121, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 5071.424671946927, + "poly2_ac50": 25.213497375344687, + "poly2_b_sd": 37395.91769567147, + "poly1_er_sd": 0.31814280871376166, + "poly2_er_sd": 0.3181039857589696, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4151.891438876929 + }, + "mc5Param": { + "a": 0.13564844128161777, + "er": 1.5502075397868125, + "ac5": 2.5, + "bmd": 68.47953132462807, + "bmr": 9.289141683881516, + "mll": -25.417224145402713, + "top": 6.782422064080888, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 31.540364959678023, + "rmse": 5.59051462132586, + "ac1sd": 50.763181115365505, + "caikwt": 0.48577638435279785, + "hitcall": 0.00011947725092996028, + "top_over_cutoff": 0.3003622452433992 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842437, + "spid": "TP0000900G07", + "chid": 20337, + "casn": "50-41-9", + "chnm": "Clomiphene citrate (1:1)", + "dtxsid": "DTXSID8020337", + "bmad": 3.7634679299683276, + "respMax": 10.898789471139123, + "respMin": -5.515280710520811, + "maxMean": 10.898789471139123, + "maxMeanConc": -0.6989700043360187, + "maxMed": 10.898789471139123, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6020599913279625, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 36, + "m5id": 5037083, + "modl": "exp5", + "hitc": 9.661810864110531E-17, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 16.799999237060547, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.3010299956639812, + 1.6020599913279625, + 0.6989700043360189, + -1.2218487496163564, + 1, + -0.6989700043360187, + -0.3010299956639812, + -1.6989700043360187 + ], + "resp": [ + 9.542989087509472, + 7.659697931946032, + 2.722279533841609, + 8.963514885797641, + 3.4847031705862404, + 10.898789471139123, + 4.5850191008881405, + -5.515280710520811 + ] + }, + "mc4Param": { + "pow_a": 2.894877828291989, + "pow_p": 0.30000009184154497, + "exp2_a": 507.19665769285456, + "exp2_b": 2390.670092115083, + "exp3_a": 6.049534282925707, + "exp3_b": 57.69378050863092, + "exp3_p": 0.3000001376282075, + "exp5_p": 7.99999942640795, + "gnls_p": 7.999793902840986, + "gnls_q": 0.3000000006452066, + "hill_p": 7.999999962514539, + "pow_er": 1.5751148789361489, + "cnst_er": 1.9204039795995531, + "exp2_er": 1.7462217494828138, + "exp3_er": 1.60658050250781, + "exp4_er": 1.3106985883527575, + "exp4_ga": 0.027758750868336332, + "exp4_tp": 6.630252961291825, + "exp5_er": 1.1618953320857577, + "exp5_ga": 0.04402078526015048, + "exp5_tp": 6.928768027059429, + "gnls_er": 1.078426077644248, + "gnls_ga": 0.044919076585011514, + "gnls_la": 2.255723019139164, + "gnls_tp": 13.078546805362636, + "hill_er": 1.1679042852770425, + "hill_ga": 0.03577555974551571, + "hill_tp": 6.9330269168075835, + "poly1_a": 0.21403725104232135, + "poly2_a": 618.1481332192153, + "poly2_b": 2934.2080821756736, + "pow_aic": 56.78989112699861, + "pow_cov": 1, + "pow_rme": 5.417311928123108, + "pow_top": 8.75484344876054, + "all_bmed": 0, + "cnst_aic": 57.84110962062907, + "cnst_rme": 7.244502292220726, + "exp2_aic": 59.61899839531536, + "exp2_cov": 1, + "exp2_rme": 6.4909481098367, + "exp2_top": 8.557660172303574, + "exp3_aic": 59.43480588967103, + "exp3_cov": 1, + "exp3_rme": 5.672416841872105, + "exp3_top": 8.769641636805533, + "exp4_aic": 52.464863303353795, + "exp4_cov": 1, + "exp4_rme": 4.153583197446473, + "exp4_top": 6.630252961291825, + "exp5_aic": 51.72994045013513, + "exp5_cov": 1, + "exp5_rme": 3.4066258677428043, + "exp5_top": 6.928768027059429, + "gnls_aic": 54.51261883419981, + "gnls_cov": 1, + "gnls_rme": 3.182126811772757, + "gnls_top": 9.472157188065228, + "hill_aic": 51.823001877133166, + "hill_cov": 1, + "hill_rme": 3.426451464532569, + "hill_top": 6.9330269168075835, + "poly1_er": 1.7457558826110058, + "poly2_er": 1.7452968782570826, + "pow_a_sd": null, + "pow_ac50": 3.968505436961949, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 7886.209158743144, + "exp2_ac50": 20.0836575769218, + "exp2_b_sd": 36834.91963316086, + "exp3_a_sd": null, + "exp3_ac50": 7.634424142811094, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.027758750868336332, + "exp5_ac50": 0.04402078526015048, + "exp5_p_sd": 16.740985051144577, + "gnls_ac50": 0.04432778118356064, + "gnls_p_sd": 12.005109141069354, + "gnls_q_sd": 0.4874284554370162, + "hill_ac50": 0.03577555974551571, + "hill_p_sd": 8.198400789158134, + "poly1_aic": 57.614782432250024, + "poly1_cov": 1, + "poly1_rme": 6.489573055026577, + "poly1_top": 8.561490041692856, + "poly2_aic": 59.62160290345598, + "poly2_cov": 1, + "poly2_rme": 6.491849855433758, + "poly2_top": 8.541656153189367, + "pow_er_sd": null, + "exp2_er_sd": 0.31177602076055916, + "exp3_er_sd": null, + "exp4_er_sd": 0.30388057834208093, + "exp4_ga_sd": 0.02693013869703401, + "exp4_tp_sd": 1.661867218808188, + "exp5_er_sd": 0.29468062372775733, + "exp5_ga_sd": 0.03680809630884936, + "exp5_tp_sd": 1.4295227932907637, + "gnls_er_sd": 0.3065288310832348, + "gnls_ga_sd": 0.031029309418172207, + "gnls_la_sd": 24.854379539431022, + "gnls_tp_sd": 20.121310783219784, + "hill_er_sd": 0.2958893567650495, + "hill_ga_sd": 0.020109201282715105, + "hill_tp_sd": 1.444345524585305, + "poly1_a_sd": 0.1246611948311575, + "poly1_ac50": 20.000000000000004, + "poly2_a_sd": 7675.09337419141, + "poly2_ac50": 20.1344835005275, + "poly2_b_sd": 35962.194179144324, + "poly1_er_sd": 0.3117610061713438, + "poly2_er_sd": 0.3116647419349434, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 14.889197885456817 + }, + "mc5Param": { + "p": 7.99999942640795, + "er": 1.1618953320857577, + "ga": 0.04402078526015048, + "tp": 6.928768027059429, + "ac5": 0.031791583986919426, + "bmr": 9.289141683881516, + "mll": -21.86497022506757, + "top": 6.928768027059429, + "ac10": 0.03478478563989077, + "ac20": 0.03820565423269564, + "ac50": 0.04402078526015048, + "rmse": 3.4066258677428043, + "ac1sd": 0.056474950476798486, + "caikwt": 0.04497698241958925, + "hitcall": 9.661810864110532E-17, + "top_over_cutoff": 0.30684323413014714 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842438, + "spid": "TP0000901C02", + "chid": 44742, + "casn": "929-59-9", + "chnm": "2,2'-[Ethane-1,2-diylbis(oxy)]diethanamine", + "dtxsid": "DTXSID9044742", + "bmad": 3.7634679299683276, + "respMax": 2.102135732023357, + "respMin": -13.866850456669049, + "maxMean": 2.102135732023357, + "maxMeanConc": -1.6989700043360187, + "maxMed": 2.102135732023357, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 37, + "m5id": 5037084, + "modl": "poly1", + "hitc": 1.6909241923219796E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + 2.102135732023357, + -9.412448215112468, + -13.866850456669049, + -2.1021357320233576, + -12.917586117741852, + -10.97561525557232, + -6.22147697413914, + -2.080189161400509 + ] + }, + "mc4Param": { + "pow_a": 3.4446382511039494E-8, + "pow_p": 0.405668436564102, + "exp2_a": 0.0000035767163069793493, + "exp2_b": 54.19534891303776, + "exp3_a": 0.00010379978775640668, + "exp3_b": 59.37620949215037, + "exp3_p": 5.888770426636071, + "exp5_p": 1.9821606540096437, + "gnls_p": 0.30001012009352335, + "gnls_q": 7.999995713520498, + "hill_p": 1.7490788379969926, + "pow_er": 2.071207160271089, + "cnst_er": 2.071211568093979, + "exp2_er": 2.087900394504249, + "exp3_er": 2.0726661672288493, + "exp4_er": 2.071198368794665, + "exp4_ga": 1.5550293796779942, + "exp4_tp": 6.854934679554375E-10, + "exp5_er": 2.071188089956425, + "exp5_ga": 1.075853940567168, + "exp5_tp": 7.285098719222379E-11, + "gnls_er": 2.0848424617077885, + "gnls_ga": 0.0036576464311942544, + "gnls_la": 0.11566493705462633, + "gnls_tp": 2.508032612116657, + "hill_er": 2.0712056577390427, + "hill_ga": 0.0943243612038477, + "hill_tp": 1.0236527737537164E-10, + "poly1_a": 2.7800312881203852E-11, + "poly2_a": 0.00000627535807537266, + "poly2_b": 60.95260835116624, + "pow_aic": 64.64743364497741, + "pow_cov": 1, + "pow_rme": 8.804003396114856, + "pow_top": 1.6840777009062426E-7, + "all_bmed": 0, + "cnst_aic": 60.647433518627345, + "cnst_rme": 8.804003324454703, + "exp2_aic": 64.65038867128672, + "exp2_cov": 1, + "exp2_rme": 8.804004670425206, + "exp2_top": 0.0000054215645424565595, + "exp3_aic": 66.64747052230402, + "exp3_cov": 1, + "exp3_rme": 8.804011695015834, + "exp3_top": 0.00004549404939612168, + "exp4_aic": 64.64743351699708, + "exp4_cov": 1, + "exp4_rme": 8.804003324877298, + "exp4_top": 6.854934679554375E-10, + "exp5_aic": 66.6474335170417, + "exp5_cov": 1, + "exp5_rme": 8.804003324503169, + "exp5_top": 7.285098719222379E-11, + "gnls_aic": 70.7685853545882, + "gnls_cov": 1, + "gnls_rme": 8.85030950797314, + "gnls_top": 1.7467856376852715, + "hill_aic": 66.64743351725284, + "hill_cov": 1, + "hill_rme": 8.804003324534168, + "hill_top": 1.0236527737537164E-10, + "poly1_er": 2.071181356064919, + "poly2_er": 2.0591467602950058, + "pow_a_sd": null, + "pow_ac50": 9.055465992561412, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.57258064410303, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.10566579953819, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.5550293796779942, + "exp5_ac50": 1.075853940567168, + "exp5_p_sd": null, + "gnls_ac50": 0.00045274899531010966, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.0943243612038477, + "hill_p_sd": null, + "poly1_aic": 62.647433519300336, + "poly1_cov": 1, + "poly1_rme": 8.804003324837579, + "poly1_top": 1.3900156440601922E-9, + "poly2_aic": 64.648984881928, + "poly2_cov": 1, + "poly2_rme": 8.80400563504064, + "poly2_top": 0.000009370471461854893, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.372856253972696, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.11734082051568114 + }, + "mc5Param": { + "a": 2.7800312881203852E-11, + "er": 2.071181356064919, + "ac5": 2.4999999999999996, + "bmd": 334138026560.1983, + "bmr": 9.289141683881516, + "mll": -29.323716759650168, + "top": 1.3900156440601922E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 83.31772378411256, + "rmse": 8.804003324837579, + "ac1sd": 247693125693.253, + "caikwt": 0.7310585786961639, + "hitcall": 0.000016909241923219796, + "top_over_cutoff": 6.155739289426647E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842439, + "spid": "TP0000901G06", + "chid": 37717, + "casn": "1478-61-1", + "chnm": "Bisphenol AF", + "dtxsid": "DTXSID7037717", + "bmad": 3.7634679299683276, + "respMax": 25.02709988877963, + "respMin": -5.116640339141512, + "maxMean": 25.02709988877963, + "maxMeanConc": 1.6989700043360187, + "maxMed": 25.02709988877963, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 38, + "m5id": 5037085, + "modl": "poly1", + "hitc": 0.4839809180427277, + "fitc": 15, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637 + ], + "resp": [ + 5.116640339141512, + 25.02709988877963, + -1.5045979142152461, + 18.349042537758507, + -5.116640339141512, + 5.529082512613025, + 0.5975072132046018, + -1.187660181498737 + ] + }, + "mc4Param": { + "pow_a": 0.07159436973182562, + "pow_p": 1.4960735696348564, + "exp2_a": 8.456409712931872, + "exp2_b": 36.37151003282228, + "exp3_a": 4.7469347723334465, + "exp3_b": 24.593641736552343, + "exp3_p": 0.854675613605653, + "exp5_p": 2.264198460682199, + "gnls_p": 3.318653605103369, + "gnls_q": 5.8042879403945875, + "hill_p": 3.319207509571538, + "pow_er": 1.298769240423112, + "cnst_er": 2.069727518985843, + "exp2_er": 1.3076817798550966, + "exp3_er": 1.3140568468982357, + "exp4_er": 1.6046703279553285, + "exp4_ga": 26.25609903911517, + "exp4_tp": 30.03251983398266, + "exp5_er": 1.2910910235308246, + "exp5_ga": 33.09797478746359, + "exp5_tp": 30.032519004305016, + "gnls_er": 1.2904522494318973, + "gnls_ga": 30.9993505952315, + "gnls_la": 1379.821215621746, + "gnls_tp": 30.032519583217184, + "hill_er": 1.2906396868889318, + "hill_ga": 31.00480635661345, + "hill_tp": 30.032519453725904, + "poly1_a": 0.4801784188472726, + "poly2_a": 7.581640517436643, + "poly2_b": 36.27786078315009, + "pow_aic": 56.35279588835657, + "pow_cov": 1, + "pow_rme": 6.682149859256472, + "pow_top": 24.92659682737705, + "all_bmed": 0, + "cnst_aic": 62.96436169588917, + "cnst_rme": 11.456467755742704, + "exp2_aic": 56.21699568284793, + "exp2_cov": 1, + "exp2_rme": 6.540814233283506, + "exp2_top": 24.979385566604833, + "exp3_aic": 58.20667037507905, + "exp3_cov": 1, + "exp3_rme": 6.502564689513747, + "exp3_top": 24.95932460632071, + "exp4_aic": 58.1094254225183, + "exp4_cov": 1, + "exp4_rme": 6.2731787855341095, + "exp4_top": 30.03251983398266, + "exp5_aic": 58.55393829008341, + "exp5_cov": 1, + "exp5_rme": 6.871326153335053, + "exp5_top": 30.032519004305016, + "gnls_aic": 62.67232565633159, + "gnls_cov": 1, + "gnls_rme": 6.968000583173041, + "gnls_top": 30.013400810194607, + "hill_aic": 58.67232739427216, + "hill_cov": 1, + "hill_rme": 6.968054555449975, + "hill_top": 30.032519453725904, + "poly1_er": 1.4547327831413472, + "poly2_er": 1.3132567568023277, + "pow_a_sd": 0.08813493434702901, + "pow_ac50": 31.459849478540292, + "pow_p_sd": 0.3186339393901382, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 16.387643242603666, + "exp2_ac50": 32.98997403636759, + "exp2_b_sd": 38.85953499547879, + "exp3_a_sd": 22.27340883508407, + "exp3_ac50": 33.09824724111999, + "exp3_b_sd": 83.07150496858122, + "exp3_p_sd": 1.0925857934998315, + "exp4_ac50": 26.25609903911517, + "exp5_ac50": 33.09797478746359, + "exp5_p_sd": 2.3249446576593304, + "gnls_ac50": 30.98745994826971, + "gnls_p_sd": 11.859185725142751, + "gnls_q_sd": 30210.660566019513, + "hill_ac50": 31.00480635661345, + "hill_p_sd": 11.897866553982782, + "poly1_aic": 54.92956695032407, + "poly1_cov": 1, + "poly1_rme": 6.304845114135714, + "poly1_top": 24.008920942363627, + "poly2_aic": 56.27311149656675, + "poly2_cov": 1, + "poly2_rme": 6.561527988769902, + "poly2_top": 24.851306266956673, + "pow_er_sd": 0.38981300436821936, + "exp2_er_sd": 0.3898189614605816, + "exp3_er_sd": 0.39290796815857126, + "exp4_er_sd": 0.34668313066113043, + "exp4_ga_sd": 26.90625013028702, + "exp4_tp_sd": 17.283997953709413, + "exp5_er_sd": 0.39740593076852454, + "exp5_ga_sd": 32.129634015331355, + "exp5_tp_sd": 33.76175010764305, + "gnls_er_sd": 0.39760125645615085, + "gnls_ga_sd": 69.85697532885499, + "gnls_la_sd": 23813357.443562742, + "gnls_tp_sd": 66.51521302449146, + "hill_er_sd": 0.3976143434895321, + "hill_ga_sd": 70.09052961350474, + "hill_tp_sd": 66.73515623997775, + "poly1_a_sd": 0.07512526413723014, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 25.10493170570885, + "poly2_ac50": 31.720545290878295, + "poly2_b_sd": 76.80867364470046, + "poly1_er_sd": 0.3462602829941217, + "poly2_er_sd": 0.39170875683118345, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1380.1223141739165 + }, + "mc5Param": { + "a": 0.4801784188472726, + "er": 1.4547327831413472, + "ac5": 2.5, + "acc": 47.02586933002523, + "bmd": 19.34518778703392, + "bmr": 9.289141683881516, + "mll": -25.464783475162037, + "top": 24.008920942363627, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 15.225799349328566, + "bmdu": 27.980142000769774, + "rmse": 6.304845114135714, + "ac1sd": 14.340391243168211, + "caikwt": 0.017681488290464575, + "hitcall": 0.4839809180427277, + "top_over_cutoff": 1.0632445654348772 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Borderline", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 11, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842440, + "spid": "TP0000901G12", + "chid": 48511, + "casn": "1062243-51-9", + "chnm": "Ro 3280", + "dtxsid": "DTXSID4048511", + "bmad": 3.7634679299683276, + "respMax": 10.325057625042314, + "respMin": -8.983764245071658, + "maxMean": 10.325057625042314, + "maxMeanConc": -0.22184874961635637, + "maxMed": 10.325057625042314, + "maxMedConc": -0.22184874961635637, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 39, + "m5id": 5037086, + "modl": "poly1", + "hitc": 7.3098271082847474E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 18.600000381469727, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 0.6989700043360189, + -1.2218487496163564, + 1.6989700043360187, + 1.3010299956639813 + ], + "resp": [ + 6.480097196924522, + -0.2515554731701046, + 10.325057625042314, + 1.142930253550185, + -7.730923290188433, + 0.2515554731701055, + 3.1098381663147343, + -8.983764245071658 + ] + }, + "mc4Param": { + "pow_a": 9.6342481700584E-7, + "pow_p": 0.4432645042337321, + "exp2_a": 0.000007399967893446319, + "exp2_b": 3.861528561537906, + "exp3_a": 6.923699292827273, + "exp3_b": 56.58306462368016, + "exp3_p": 7.999746381582563, + "exp5_p": 7.998319899204924, + "gnls_p": 7.999999733938488, + "gnls_q": 7.999994914873606, + "hill_p": 7.999985522691064, + "pow_er": 1.6764333208273414, + "cnst_er": 1.6757159315047794, + "exp2_er": 1.6351776912730394, + "exp3_er": 1.6339748313050555, + "exp4_er": 1.6757250594077964, + "exp4_ga": 6.289265154206966, + "exp4_tp": 1.6850922680145134E-10, + "exp5_er": 1.634304344180973, + "exp5_ga": 0.07106828066816326, + "exp5_tp": 1.535161759146987, + "gnls_er": 1.3295228996669055, + "gnls_ga": 0.063224292527447, + "gnls_la": 1.999327678425197, + "gnls_tp": 7.298128558374947, + "hill_er": 1.6340694275967216, + "hill_ga": 57.330818894657035, + "hill_tp": 12.377335603468827, + "poly1_a": 0.009461767869048447, + "poly2_a": 0.000028686825557986437, + "poly2_b": 0.1807498952770959, + "pow_aic": 58.61519395624266, + "pow_cov": 1, + "pow_rme": 6.125537217447439, + "pow_top": 0.000005456459372025317, + "all_bmed": 0, + "cnst_aic": 54.6151883619927, + "cnst_rme": 6.125536842485228, + "exp2_aic": 58.19296056082926, + "exp2_cov": 1, + "exp2_rme": 6.026299220676452, + "exp2_top": 3.1086952065074684, + "exp3_aic": 60.19312750281706, + "exp3_cov": 1, + "exp3_rme": 6.026368174940302, + "exp3_top": 3.1178027036730622, + "exp4_aic": 58.61518836239423, + "exp4_cov": 1, + "exp4_rme": 6.125536842509785, + "exp4_top": 1.6850922680145134E-10, + "exp5_aic": 60.35216613544548, + "exp5_cov": 1, + "exp5_rme": 6.133102241580869, + "exp5_top": 1.535161759146987, + "gnls_aic": 59.638816472495165, + "gnls_cov": 1, + "gnls_rme": 4.6551870260688855, + "gnls_top": 7.298113962072281, + "hill_aic": 60.193622806346006, + "hill_cov": 1, + "hill_rme": 6.026559284171812, + "hill_top": 12.377335603468827, + "poly1_er": 1.671396299010503, + "poly2_er": 1.647533881452146, + "pow_a_sd": null, + "pow_ac50": 10.467658378845464, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.000019653592135234332, + "exp2_ac50": 47.323401556905104, + "exp2_b_sd": 0.7800950706885615, + "exp3_a_sd": null, + "exp3_ac50": 46.359485549724944, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 6.289265154206966, + "exp5_ac50": 0.07106828066816326, + "exp5_p_sd": 1263.5073660910928, + "gnls_ac50": 0.06322426071869278, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 57.330818894657035, + "hill_p_sd": null, + "poly1_aic": 56.6071465334128, + "poly1_cov": 1, + "poly1_rme": 6.1384421956539885, + "poly1_top": 0.4730883934524223, + "poly2_aic": 58.411074893876496, + "poly2_cov": 1, + "poly2_rme": 6.104875979378861, + "poly2_top": 2.2030965746019064, + "pow_er_sd": null, + "exp2_er_sd": 0.3255205050681696, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": 0.3352032946991091, + "exp5_ga_sd": 1.911154416144701, + "exp5_tp_sd": 2.910113134475448, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.10408741267075336, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.0008879455965969786, + "poly2_ac50": 35.32892649963858, + "poly2_b_sd": 2.826738198600287, + "poly1_er_sd": 0.32131033280129584, + "poly2_er_sd": 0.3251646386415122, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.9993286780943216 + }, + "mc5Param": { + "a": 0.009461767869048447, + "er": 1.671396299010503, + "ac5": 2.5, + "bmd": 981.755398403756, + "bmr": 9.289141683881516, + "mll": -26.3035732667064, + "top": 0.4730883934524223, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 53.80832634227983, + "rmse": 6.1384421956539885, + "ac1sd": 727.7653064520059, + "caikwt": 0.7302672847993994, + "hitcall": 0.0000073098271082847474, + "top_over_cutoff": 0.020950906728217367 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842441, + "spid": "TP0000902A09", + "chid": 48167, + "casn": "138472-01-2", + "chnm": "FR 409", + "dtxsid": "DTXSID2048167", + "bmad": 3.7634679299683276, + "respMax": 8.45824139096988, + "respMin": -4.715592708196917, + "maxMean": 8.45824139096988, + "maxMeanConc": 0.7781512503836436, + "maxMed": 8.45824139096988, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 40, + "m5id": 5037087, + "modl": "poly1", + "hitc": 4.349091266397037E-7, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + -1.2342590439036523, + 5.370932466583148, + 0.8322209040287843, + 5.089877121352194, + -4.715592708196917, + 8.45824139096988, + -0.8322209040287843, + 1.8604769341122718 + ] + }, + "mc4Param": { + "pow_a": 1.0221806706745422, + "pow_p": 0.39639742374359954, + "exp2_a": 281.84163059484536, + "exp2_b": 2710.1819410276626, + "exp3_a": 3.070336657854594, + "exp3_b": 58.38202827572274, + "exp3_p": 0.3178065838682131, + "exp5_p": 7.999999556088412, + "gnls_p": 7.997950401679715, + "gnls_q": 0.5167742299566985, + "hill_p": 7.999999636255, + "pow_er": 1.0920563687798213, + "cnst_er": 1.3248432907908116, + "exp2_er": 1.070134684601057, + "exp3_er": 1.0900745687259326, + "exp4_er": 1.0812481377946803, + "exp4_ga": 1.7811347250586496, + "exp4_tp": 4.400696875885273, + "exp5_er": 0.9781436965607416, + "exp5_ga": 4.374536235061529, + "exp5_tp": 5.114592012835368, + "gnls_er": 0.9363241065953332, + "gnls_ga": 3.483652859252365, + "gnls_la": 110.16277693301092, + "gnls_tp": 7.783031273259884, + "hill_er": 0.8800553465055232, + "hill_ga": 0.3510818534236002, + "hill_tp": 4.414701379307003, + "poly1_a": 0.10489123022206318, + "poly2_a": 173.98996532557754, + "poly2_b": 1734.46106467781, + "pow_aic": 49.80239750036858, + "pow_cov": 1, + "pow_rme": 3.6268956792336415, + "pow_top": 4.819422456676002, + "all_bmed": 0, + "cnst_aic": 49.12848756125315, + "cnst_rme": 4.40031788290068, + "exp2_aic": 50.12082719543147, + "exp2_cov": 1, + "exp2_rme": 3.8215443365906254, + "exp2_top": 5.247941640101082, + "exp3_aic": 51.822662540403314, + "exp3_cov": 1, + "exp3_rme": 3.640408829394019, + "exp3_top": 4.884063849755363, + "exp4_aic": 49.4849553439781, + "exp4_cov": 1, + "exp4_rme": 3.556633163595015, + "exp4_top": 4.400696875885273, + "exp5_aic": 49.523866255353845, + "exp5_cov": 1, + "exp5_rme": 3.0787945193813617, + "exp5_top": 5.114592012835368, + "gnls_aic": 53.04563717615321, + "gnls_cov": 1, + "gnls_rme": 3.0191908372849388, + "gnls_top": 6.2867229683220325, + "hill_aic": 50.23685799735487, + "hill_cov": 1, + "hill_rme": 3.720806929349788, + "hill_top": 4.414701379307003, + "poly1_er": 1.0697380575582094, + "poly2_er": 1.068876338903681, + "pow_a_sd": 1.94288100342848, + "pow_ac50": 8.700724003011597, + "pow_p_sd": 0.5142804521178921, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 5978.121364138775, + "exp2_ac50": 25.115304276643503, + "exp2_b_sd": 56967.1422829092, + "exp3_a_sd": 34.884204794475934, + "exp3_ac50": 10.816909274054677, + "exp3_b_sd": 1339.2381888478171, + "exp3_p_sd": 0.7494980203805416, + "exp4_ac50": 1.7811347250586496, + "exp5_ac50": 4.374536235061529, + "exp5_p_sd": 17.23262161929217, + "gnls_ac50": 3.4336886835483624, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.3510818534236002, + "hill_p_sd": 11.55230396465234, + "poly1_aic": 48.11858673318644, + "poly1_cov": 1, + "poly1_rme": 3.820595413798474, + "poly1_top": 5.244561511103158, + "poly2_aic": 50.12696585786312, + "poly2_cov": 1, + "poly2_rme": 3.825332733168213, + "poly2_top": 5.160266984567867, + "pow_er_sd": 0.3358088728357998, + "exp2_er_sd": 0.35301842299911645, + "exp3_er_sd": 0.3388919198692416, + "exp4_er_sd": 0.32586774663917945, + "exp4_ga_sd": 2.5289267272649596, + "exp4_tp_sd": 2.0456398887627545, + "exp5_er_sd": 0.3174460886892625, + "exp5_ga_sd": 3.746745018855691, + "exp5_tp_sd": 1.8569699379647628, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3730906919696318, + "hill_ga_sd": 0.2783296229902509, + "hill_tp_sd": 1.4930457823064731, + "poly1_a_sd": 0.04854843979303387, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 2374.099369826869, + "poly2_ac50": 25.35017708616761, + "poly2_b_sd": 23458.53218916691, + "poly1_er_sd": 0.3529581302897474, + "poly2_er_sd": 0.3530822082323522, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 234.01464386723652 + }, + "mc5Param": { + "a": 0.10489123022206318, + "er": 1.0697380575582094, + "ac5": 2.5, + "bmd": 88.55975532192402, + "bmr": 9.289141683881516, + "mll": -22.05929336659322, + "top": 5.244561511103158, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 47.61937513459634, + "bmdu": 515.5480279689932, + "rmse": 3.820595413798474, + "ac1sd": 65.64844723641512, + "caikwt": 0.37637801032969415, + "hitcall": 4.349091266397037E-7, + "top_over_cutoff": 0.23225748204827024 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842442, + "spid": "TP0000904A04", + "chid": 20932, + "casn": "59-67-6", + "chnm": "Nicotinic acid", + "dtxsid": "DTXSID1020932", + "bmad": 3.7634679299683276, + "respMax": 7.808154220734798, + "respMin": -15.587583552949539, + "maxMean": 7.808154220734798, + "maxMeanConc": -0.6989700043360187, + "maxMed": 7.808154220734798, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 41, + "m5id": 5037088, + "modl": "poly1", + "hitc": 1.2842082484215337E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.6989700043360187, + 1.3010299956639813, + -0.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + 1.6989700043360187, + -1.154901959985743 + ], + "resp": [ + -6.4591483450512746, + 3.0224966031679426, + -15.587583552949539, + 7.808154220734798, + -0.12052294495462057, + -3.3880170099974922, + -12.541681485061535, + -3.0224966031679426 + ] + }, + "mc4Param": { + "pow_a": 5.543622267971873E-7, + "pow_p": 0.364373857362965, + "exp2_a": 5.894362630259528E-7, + "exp2_b": 68.55078029862463, + "exp3_a": 0.0000037615601832033385, + "exp3_b": 69.7561028814606, + "exp3_p": 4.517972377107961, + "exp5_p": 3.4371838689355867, + "gnls_p": 0.30000354623098807, + "gnls_q": 7.948653448964739, + "hill_p": 4.575319604381713, + "pow_er": 1.92339375580289, + "cnst_er": 1.9230667378989736, + "exp2_er": 1.9230442720434788, + "exp3_er": 1.9235351607245372, + "exp4_er": 1.923073891482418, + "exp4_ga": 5.720368939603105, + "exp4_tp": 1.5289441124987554E-10, + "exp5_er": 1.9230858205598875, + "exp5_ga": 3.7080047981398536, + "exp5_tp": 1.358730549491495E-9, + "gnls_er": 1.9069579723705967, + "gnls_ga": 0.03296521485727647, + "gnls_la": 1.0424516568136877, + "gnls_tp": 3.0470136554132834, + "hill_er": 1.923067740437899, + "hill_ga": 144.92218389271736, + "hill_tp": 0.000003918510318302473, + "poly1_a": 2.3821419834720777E-10, + "poly2_a": 0.0000380194771302548, + "poly2_b": 112.44605954378144, + "pow_aic": 62.85990744190046, + "pow_cov": 1, + "pow_rme": 8.160259534186697, + "pow_top": 0.000002305971230116009, + "all_bmed": 0, + "cnst_aic": 58.859904654421854, + "cnst_rme": 8.16025858692367, + "exp2_aic": 62.859904981765446, + "exp2_cov": 1, + "exp2_rme": 8.160258762264611, + "exp2_top": 6.329410925446836E-7, + "exp3_aic": 64.8599070905033, + "exp3_cov": 1, + "exp3_rme": 8.16025876987888, + "exp3_top": 9.357200976922738E-7, + "exp4_aic": 62.85990465443332, + "exp4_cov": 1, + "exp4_rme": 8.160258586995395, + "exp4_top": 1.5289441124987554E-10, + "exp5_aic": 64.85990465768748, + "exp5_cov": 1, + "exp5_rme": 8.160258587645599, + "exp5_top": 1.358730549491495E-9, + "gnls_aic": 68.58354633450392, + "gnls_cov": 1, + "gnls_rme": 8.047045534239281, + "gnls_top": 2.1214791438989553, + "hill_aic": 64.85990466538351, + "hill_cov": 1, + "hill_rme": 8.160258592771067, + "hill_top": 0.000003918510318302473, + "poly1_er": 1.923120606473471, + "poly2_er": 1.923450892386962, + "pow_a_sd": null, + "pow_ac50": 7.461275077538203, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.46105839655378, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 43.40360563362071, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 5.720368939603105, + "exp5_ac50": 3.7080047981398536, + "exp5_p_sd": null, + "gnls_ac50": 0.0040734772355949045, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 144.92218389271736, + "hill_p_sd": null, + "poly1_aic": 60.85990468448603, + "poly1_cov": 1, + "poly1_rme": 8.16025859051074, + "poly1_top": 1.1910709917360389E-8, + "poly2_aic": 62.859918528385, + "poly2_cov": 1, + "poly2_rme": 8.160265420971498, + "poly2_top": 0.00002442287818225344, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 28.760383699947685, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1.0577383522061834 + }, + "mc5Param": { + "a": 2.3821419834720777E-10, + "er": 1.923120606473471, + "ac5": 2.5, + "bmd": 38994911925.2001, + "bmr": 9.289141683881516, + "mll": -28.429952342243016, + "top": 1.1910709917360389E-8, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 93.8246790996463, + "rmse": 8.16025859051074, + "ac1sd": 28906532190.659824, + "caikwt": 0.731058581585493, + "hitcall": 0.000012842082484215337, + "top_over_cutoff": 5.27470502339785E-10 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842403, + "spid": "LEGTV001B10", + "chid": 23900, + "casn": "17804-35-2", + "chnm": "Benomyl", + "dtxsid": "DTXSID5023900", + "bmad": 3.7634679299683276, + "respMax": 25.59444974532059, + "respMin": -1.2102612303412605, + "maxMean": 25.59444974532059, + "maxMeanConc": 0.7781512503836436, + "maxMed": 25.59444974532059, + "maxMedConc": 0.7781512503836436, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 4, + "tmpi": 2, + "m5id": 5037049, + "modl": "exp4", + "hitc": 8.838707536646198E-5, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + 0.3010299956639812, + -0.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 2.9023483672510224, + -1.2102612303412605, + 25.59444974532059, + 1.2102612303412605, + 13.08335350830972, + 13.91717341460287, + 3.6279354590637736, + 13.918360177919546 + ] + }, + "mc4Param": { + "pow_a": 5.205810100365427, + "pow_p": 0.300000106525784, + "exp2_a": 2468.049539504221, + "exp2_b": 7225.095324245473, + "exp3_a": 81.926086402836, + "exp3_b": 11971.021959945418, + "exp3_p": 0.30000050892105745, + "exp5_p": 1.932308954909185, + "gnls_p": 2.2122108268358556, + "gnls_q": 0.8596878616497325, + "hill_p": 3.867980719774923, + "pow_er": 1.3575665310341234, + "cnst_er": 2.320091490701855, + "exp2_er": 1.904101077761098, + "exp3_er": 1.5530301363053958, + "exp4_er": 0.829982332161024, + "exp4_ga": 0.7837526624913668, + "exp4_tp": 14.691482524381094, + "exp5_er": 0.6597965319495738, + "exp5_ga": 0.9532308456224, + "exp5_tp": 14.297652679638324, + "gnls_er": 0.7867729444839626, + "gnls_ga": 1.7121229667458349, + "gnls_la": 54.1420821270971, + "gnls_tp": 26.63271573330083, + "hill_er": 0.6818282209423071, + "hill_ga": 0.8455244118283385, + "hill_tp": 14.238251015246254, + "poly1_a": 0.3429912490465289, + "poly2_a": 2011.137320298468, + "poly2_b": 6041.169272414498, + "pow_aic": 56.93013758751977, + "pow_cov": 1, + "pow_rme": 6.662842960817711, + "pow_top": 16.833696930224765, + "all_bmed": 0, + "cnst_aic": 65.41421720746133, + "cnst_rme": 12.44072681214264, + "exp2_aic": 64.45225922740426, + "exp2_cov": 1, + "exp2_rme": 10.010167810133272, + "exp2_top": 17.13893736437594, + "exp3_aic": 59.42851423204404, + "exp3_cov": 1, + "exp3_rme": 6.738763578058861, + "exp3_top": 17.471290115830215, + "exp4_aic": 48.68746759593549, + "exp4_cov": 1, + "exp4_rme": 4.18881846478536, + "exp4_top": 14.691482524381094, + "exp5_aic": 49.657707875948965, + "exp5_cov": 1, + "exp5_rme": 4.220695557928282, + "exp5_top": 14.297652679638324, + "gnls_aic": 51.15685979133812, + "gnls_cov": 1, + "gnls_rme": 2.7507444039260966, + "gnls_top": 21.79102332025044, + "hill_aic": 50.061396997873935, + "hill_cov": 1, + "hill_rme": 4.276429269729576, + "hill_top": 14.238251015246254, + "poly1_er": 1.9034889654893083, + "poly2_er": 1.9018795046605577, + "pow_a_sd": 2.0943271829959196, + "pow_ac50": 4.96063235721311, + "pow_p_sd": 0.11002382159571332, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 29513.6753956216, + "exp2_ac50": 25.04325193819569, + "exp2_b_sd": 86084.5411190017, + "exp3_a_sd": 150.0984224223333, + "exp3_ac50": 5.804399305999619, + "exp3_b_sd": 59137.001224216314, + "exp3_p_sd": 0.14658200866607235, + "exp4_ac50": 0.7837526624913668, + "exp5_ac50": 0.9532308456224, + "exp5_p_sd": 1.0630755148028903, + "gnls_ac50": 1.5013800743653127, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.8455244118283385, + "hill_p_sd": 3.878619687420101, + "poly1_aic": 62.445202743928206, + "poly1_cov": 1, + "poly1_rme": 10.006455332888448, + "poly1_top": 17.149562452326442, + "poly2_aic": 64.4652608512803, + "poly2_cov": 1, + "poly2_rme": 10.02747933976459, + "poly2_top": 16.783030687308678, + "pow_er_sd": 0.4080138155151314, + "exp2_er_sd": 0.3680437573619178, + "exp3_er_sd": 0.4222055989380574, + "exp4_er_sd": 0.39592940969417895, + "exp4_ga_sd": 0.31194015228918653, + "exp4_tp_sd": 1.6633876035629098, + "exp5_er_sd": 0.44034681277537735, + "exp5_ga_sd": 0.24033727643017272, + "exp5_tp_sd": 1.384891857432722, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.4472823050404181, + "hill_ga_sd": 0.2970999212415293, + "hill_tp_sd": 1.42857712990458, + "poly1_a_sd": 0.12552318478451832, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 17285.66623585318, + "poly2_ac50": 25.102605828879497, + "poly2_b_sd": 52518.880955116154, + "poly1_er_sd": 0.3680092384332859, + "poly2_er_sd": 0.36881665372257216, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 83.00745848531592 + }, + "mc5Param": { + "er": 0.829982332161024, + "ga": 0.7837526624913668, + "tp": 14.691482524381094, + "ac5": 0.057998152732469395, + "bmd": 1.1312085709028028, + "bmr": 9.289141683881516, + "mll": -21.343733797967744, + "top": 14.691482524381094, + "ac10": 0.11913282919448194, + "ac20": 0.25231200149874355, + "ac50": 0.7837526624913668, + "bmdl": 0.5939237424805409, + "bmdu": 2.1007406685525587, + "rmse": 4.18881846478536, + "ac1sd": 0.7151040430592887, + "caikwt": 0.00023320141532168285, + "hitcall": 0.00008838707536646198, + "top_over_cutoff": 0.6506181177291949 + }, + "mc6Param": { + "flag": [ + "Multiple points above baseline, inactive", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 8, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842402, + "spid": "DMSO", + "chid": null, + "casn": null, + "chnm": null, + "dtxsid": null, + "bmad": 3.7634679299683276, + "respMax": 29.154644659004813, + "respMin": -64.01776227967419, + "maxMean": -2.786975848040293, + "maxMeanConc": -2.0, + "maxMed": -1.8549943011561494, + "maxMedConc": -2.0, + "logcMax": -2.0, + "logcMin": -2.0, + "nconc": 1, + "npts": 60, + "nrep": 60.0, + "nmedGtbl": 0, + "tmpi": 1, + "m5id": 5037048, + "modl": "none", + "hitc": 0.0, + "fitc": 2, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": null, + "stkc": null, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2, + -2 + ], + "resp": [ + -11.154261912892895, + -0.3085213350118397, + -10.769705425508318, + 4.175375587545503, + -10.98141849274888, + -12.376517295353013, + 0, + -64.01776227967419, + 0, + 0, + 7.302396825405491, + -23.726740442131682, + 20.578950616404875, + -2.1637598929705573, + 8.221941787379146, + -3.3615951256467733, + -13.00838695625285, + 0, + -8.147282382442452, + -16.675358684435366, + -7.366722199083715, + -4.547070003657009, + 6.727984535614843, + -14.413034459122256, + -3.3130697596828527, + -4.033069414485719, + -15.264672272410884, + -11.574027922167316, + -1.8116084217961972, + -2.683274758192687, + 13.045441512530893, + 11.771596698177454, + 1.822950768406886, + -6.366163269382269, + 10.919639964829472, + 7.646339314405353, + -5.425526716521953, + -23.59240555574474, + 29.154644659004813, + -1.8983801805161016, + 0, + -13.802724260910109, + 4.979838314070986, + 8.416800860440848, + -0.2717465644121584, + 3.9578867653660548, + -1.1225186138635874, + -21.297944237672343, + 8.682142820122102, + 15.423542211616034, + -8.54044397300711, + 0, + -3.629592160884692, + 5.3958263838470995, + -9.059839600469063, + 17.31012973696578, + -18.631736544948375, + -6.017477029882166, + 9.453622918139667, + -0.8512450188087707 + ] + }, + "mc4Param": { + "pow_a": null, + "pow_p": null, + "exp2_a": null, + "exp2_b": null, + "exp3_a": null, + "exp3_b": null, + "exp3_p": null, + "exp5_p": null, + "gnls_p": null, + "gnls_q": null, + "hill_p": null, + "pow_er": null, + "cnst_er": null, + "exp2_er": null, + "exp3_er": null, + "exp4_er": null, + "exp4_ga": null, + "exp4_tp": null, + "exp5_er": null, + "exp5_ga": null, + "exp5_tp": null, + "gnls_er": null, + "gnls_ga": null, + "gnls_la": null, + "gnls_tp": null, + "hill_er": null, + "hill_ga": null, + "hill_tp": null, + "poly1_a": null, + "poly2_a": null, + "poly2_b": null, + "pow_aic": null, + "pow_cov": null, + "pow_rme": null, + "all_bmed": 0, + "cnst_aic": null, + "cnst_rme": null, + "exp2_aic": null, + "exp2_cov": null, + "exp2_rme": null, + "exp3_aic": null, + "exp3_cov": null, + "exp3_rme": null, + "exp4_aic": null, + "exp4_cov": null, + "exp4_rme": null, + "exp5_aic": null, + "exp5_cov": null, + "exp5_rme": null, + "gnls_aic": null, + "gnls_cov": null, + "gnls_rme": null, + "hill_aic": null, + "hill_cov": null, + "hill_rme": null, + "poly1_er": null, + "poly2_er": null, + "pow_a_sd": null, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp5_p_sd": null, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_p_sd": null, + "poly1_aic": null, + "poly1_cov": null, + "poly1_rme": null, + "poly2_aic": null, + "poly2_cov": null, + "poly2_rme": null, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": null, + "poly2_a_sd": null, + "poly2_b_sd": null, + "poly1_er_sd": null, + "poly2_er_sd": null, + "pow_success": null, + "cnst_success": null, + "exp2_success": null, + "exp3_success": null, + "exp4_success": null, + "exp5_success": null, + "gnls_success": null, + "hill_success": null, + "poly1_success": null, + "poly2_success": null + }, + "mc5Param": { + "bmr": 9.289141683881516, + "hitcall": 0 + }, + "mc6Param": null + }, + { + "aeid": 704, + "m4id": 1842404, + "spid": "LEGTV001C03", + "chid": 22162, + "casn": "1689-84-5", + "chnm": "Bromoxynil", + "dtxsid": "DTXSID3022162", + "bmad": 3.7634679299683276, + "respMax": 17.24432669518075, + "respMin": -16.748848993380015, + "maxMean": 17.24432669518075, + "maxMeanConc": -0.6989700043360187, + "maxMed": 17.24432669518075, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 3, + "m5id": 5037050, + "modl": "poly1", + "hitc": 0.0029920822873240717, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -1.6989700043360187, + 0.3010299956639812, + 0.7781512503836436, + -1.154901959985743, + 1.3010299956639813, + -0.22184874961635637, + -0.6989700043360187 + ], + "resp": [ + 8.524600212493528, + 9.072860762252425, + -3.8916282997793408, + -10.455090309750185, + -10.227272727272725, + -16.748848993380015, + -3.3236167488489907, + 17.24432669518075 + ] + }, + "mc4Param": { + "pow_a": 1.725949077512417E-7, + "pow_p": 4.5253782558540285, + "exp2_a": 0.00001640418685242636, + "exp2_b": 3.8001515537909256, + "exp3_a": 12.90516865711751, + "exp3_b": 54.422945490831, + "exp3_p": 7.998344245445021, + "exp5_p": 7.999993694423218, + "gnls_p": 0.4241648347027184, + "gnls_q": 7.9998847670280355, + "hill_p": 7.999087698843317, + "pow_er": 2.2542985187481523, + "cnst_er": 2.323734743510376, + "exp2_er": 2.251755277558436, + "exp3_er": 2.253232239765138, + "exp4_er": 2.323771099104438, + "exp4_ga": 11.86923471702094, + "exp4_tp": 7.755465672199024E-8, + "exp5_er": 2.25311336300597, + "exp5_ga": 51.61988856711754, + "exp5_tp": 20.5725635581771, + "gnls_er": 2.232648918042158, + "gnls_ga": 0.011612337436387274, + "gnls_la": 0.3672143632370176, + "gnls_tp": 12.14436282748164, + "hill_er": 2.2521666902515927, + "hill_ga": 52.29053788518011, + "hill_tp": 20.688317160612986, + "poly1_a": 0.059264731838513336, + "poly2_a": 0.00008746164302267517, + "poly2_b": 0.17995434389891726, + "pow_aic": 67.60619394277374, + "pow_cov": 1, + "pow_rme": 10.63489778795089, + "pow_top": 8.423835804546373, + "all_bmed": 0, + "cnst_aic": 64.42755044014181, + "cnst_rme": 11.028222754070327, + "exp2_aic": 67.57203572586648, + "exp2_cov": 1, + "exp2_rme": 10.609032886271716, + "exp2_top": 8.494289345379501, + "exp3_aic": 69.57232094962438, + "exp3_cov": 1, + "exp3_rme": 10.60924696767611, + "exp3_top": 8.535257141972448, + "exp4_aic": 68.42755045762016, + "exp4_cov": 1, + "exp4_rme": 11.028222760170856, + "exp4_top": 7.755465672199024E-8, + "exp5_aic": 69.57309089671247, + "exp5_cov": 1, + "exp5_rme": 10.609830072861923, + "exp5_top": 20.5725635581771, + "gnls_aic": 73.41799184836066, + "gnls_cov": 1, + "gnls_rme": 10.614494151590849, + "gnls_top": 9.287173487099578, + "hill_aic": 69.57365995839154, + "hill_cov": 1, + "hill_rme": 10.610269740695813, + "hill_top": 20.688317160612986, + "poly1_er": 2.308829204544371, + "poly2_er": 2.2585407128453037, + "pow_a_sd": 0.0000018803876981312193, + "pow_ac50": 42.89924007169241, + "pow_p_sd": 0.2615425978878468, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 0.00006528915415492634, + "exp2_ac50": 47.36594300362757, + "exp2_b_sd": 1.1482590548973135, + "exp3_a_sd": null, + "exp3_ac50": 46.53251133220428, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 11.86923471702094, + "exp5_ac50": 51.61988856711754, + "exp5_p_sd": null, + "gnls_ac50": 0.003749285947936685, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 52.29053788518011, + "hill_p_sd": 34.94604828343594, + "poly1_aic": 66.3487573617917, + "poly1_cov": 1, + "poly1_rme": 11.07211531968513, + "poly1_top": 2.9632365919256665, + "poly2_aic": 67.91979710905, + "poly2_cov": 1, + "poly2_rme": 10.858529674694983, + "poly2_top": 6.776309423253431, + "pow_er_sd": 0.3074409916401629, + "exp2_er_sd": 0.3064920897367097, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.3066098414034118, + "hill_ga_sd": 433.0782348506896, + "hill_tp_sd": 798.217144794448, + "poly1_a_sd": 0.2008290041071431, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.001526277534281327, + "poly2_ac50": 35.32904249953417, + "poly2_b_sd": 1.5875043868026275, + "poly1_er_sd": 0.3041166431752558, + "poly2_er_sd": 0.3058854737291205, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.3727404712005974 + }, + "mc5Param": { + "a": 0.059264731838513336, + "er": 2.308829204544371, + "ac5": 2.4999999999999996, + "bmd": 156.73979103107902, + "bmr": 9.289141683881516, + "mll": -31.17437868089585, + "top": 2.9632365919256665, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 25.23802000566871, + "rmse": 11.07211531968513, + "ac1sd": 116.18961529360936, + "caikwt": 0.7232426117655388, + "hitcall": 0.0029920822873240717, + "top_over_cutoff": 0.13122810517083394 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842405, + "spid": "LEGTV001C05", + "chid": 20440, + "casn": "120-36-5", + "chnm": "Dichlorprop", + "dtxsid": "DTXSID0020440", + "bmad": 3.7634679299683276, + "respMax": 12.401136092711798, + "respMin": -8.612173606576068, + "maxMean": 12.401136092711798, + "maxMeanConc": -0.22184874961635637, + "maxMed": 12.401136092711798, + "maxMedConc": -0.22184874961635637, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 4, + "m5id": 5037051, + "modl": "exp5", + "hitc": 7.715427065113419E-15, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + 0.3010299956639812, + 1.3010299956639813 + ], + "resp": [ + 10.364772833286688, + 8.905785158234078, + 12.401136092711798, + -0.6942500855179268, + 10.618476018699921, + 0.6942500855179268, + -8.612173606576068, + 6.03652911237573 + ] + }, + "mc4Param": { + "pow_a": 3.121611710249508, + "pow_p": 0.300000440805151, + "exp2_a": 844.7352530391539, + "exp2_b": 4140.505458874806, + "exp3_a": 6.529613004062455, + "exp3_b": 62.365867529043086, + "exp3_p": 0.30000012065047343, + "exp5_p": 7.384612447046498, + "gnls_p": 7.998079908874962, + "gnls_q": 0.3000000007152951, + "hill_p": 7.999999550286872, + "pow_er": 1.7128917398097694, + "cnst_er": 2.064484274768512, + "exp2_er": 1.854098740521344, + "exp3_er": 1.7364617533808766, + "exp4_er": 1.3051553103733522, + "exp4_ga": 0.09070126641098608, + "exp4_tp": 8.97564962535527, + "exp5_er": 0.9338117444364008, + "exp5_ga": 0.09437221560468234, + "exp5_tp": 9.445184350204824, + "gnls_er": 0.5389629722138889, + "gnls_ga": 0.1650117092406103, + "gnls_la": 59.04702616089972, + "gnls_tp": 14.881363229750573, + "hill_er": 0.9350004825335526, + "hill_ga": 0.09546411869143644, + "hill_tp": 9.449887679873935, + "poly1_a": 0.20536815823136903, + "poly2_a": 687.7206271707939, + "poly2_b": 3402.532885448278, + "pow_aic": 59.62983960478393, + "pow_cov": 1, + "pow_rme": 6.671243317314767, + "pow_top": 10.094170392107534, + "all_bmed": 0, + "cnst_aic": 60.19666751493744, + "cnst_rme": 8.402789111634103, + "exp2_aic": 61.531032617462245, + "exp2_cov": 1, + "exp2_rme": 7.3615053364472125, + "exp2_top": 10.262711761047347, + "exp3_aic": 62.09365177604067, + "exp3_cov": 1, + "exp3_rme": 6.794901875497607, + "exp3_top": 10.116872077829878, + "exp4_aic": 56.12885991920658, + "exp4_cov": 1, + "exp4_rme": 6.681915704324382, + "exp4_top": 8.97564962535527, + "exp5_aic": 55.557492165112755, + "exp5_cov": 1, + "exp5_rme": 6.608895943346805, + "exp5_top": 9.445184350204824, + "gnls_aic": 57.520569181463856, + "gnls_cov": 1, + "gnls_rme": 6.998426262818015, + "gnls_top": 12.249786804248052, + "hill_aic": 55.56652951607745, + "hill_cov": 1, + "hill_rme": 6.610861943383319, + "hill_top": 9.449887679873935, + "poly1_er": 1.853314780351189, + "poly2_er": 1.8543795698394705, + "pow_a_sd": null, + "pow_ac50": 4.960645128343272, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": 14008.70342854903, + "exp2_ac50": 25.075473418488187, + "exp2_b_sd": 68253.83508399563, + "exp3_a_sd": null, + "exp3_ac50": 9.780888763356495, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.09070126641098608, + "exp5_ac50": 0.09437221560468234, + "exp5_p_sd": 269.96048261662713, + "gnls_ac50": 0.1635254438108516, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 0.09546411869143644, + "hill_p_sd": 14.519583400029104, + "poly1_aic": 59.527349525667354, + "poly1_cov": 1, + "poly1_rme": 7.360105587021132, + "poly1_top": 10.26840791156845, + "poly2_aic": 61.53621082274063, + "poly2_cov": 1, + "poly2_rme": 7.363476010280246, + "poly2_top": 10.254517159159812, + "pow_er_sd": null, + "exp2_er_sd": 0.31997257287398145, + "exp3_er_sd": null, + "exp4_er_sd": 0.370650678068716, + "exp4_ga_sd": 0.06239224387281597, + "exp4_tp_sd": 1.9164242059007173, + "exp5_er_sd": 0.431497487479637, + "exp5_ga_sd": 1.032106503926616, + "exp5_tp_sd": 1.3000343253660858, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.43172822082146006, + "hill_ga_sd": 0.05953029354685805, + "hill_tp_sd": 1.3057088570476094, + "poly1_a_sd": 0.10793537826384712, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 7498.910083446686, + "poly2_ac50": 25.181017025347085, + "poly2_b_sd": 36576.65297284068, + "poly1_er_sd": 0.31993419285597785, + "poly2_er_sd": 0.3199628347203704, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 194.37172917375648 + }, + "mc5Param": { + "p": 7.384612447046498, + "er": 0.9338117444364008, + "ga": 0.09437221560468234, + "tp": 9.445184350204824, + "ac5": 0.06633147903190056, + "bmd": 0.12006740302572848, + "bmr": 9.289141683881516, + "mll": -23.778746082556378, + "top": 9.445184350204824, + "ac10": 0.07312288030740835, + "ac20": 0.0809443375202312, + "ac50": 0.09437221560468234, + "bmdl": 0.08803437994217998, + "bmdu": 0.24201185048064888, + "rmse": 6.608895943346805, + "ac1sd": 0.10282304939527366, + "caikwt": 0.08951365853820019, + "hitcall": 7.715427065113419E-15, + "top_over_cutoff": 0.41828372686944937 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842406, + "spid": "LEGTV002C04", + "chid": 20442, + "casn": "94-75-7", + "chnm": "2,4-Dichlorophenoxyacetic acid", + "dtxsid": "DTXSID0020442", + "bmad": 3.7634679299683276, + "respMax": 6.370859881086669, + "respMin": -24.72241823635355, + "maxMean": 6.370859881086669, + "maxMeanConc": -1.6989700043360187, + "maxMed": 6.370859881086669, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 5, + "m5id": 5037052, + "modl": "poly1", + "hitc": 0.002042012002651702, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + -1.154901959985743, + -0.22184874961635637, + 1.3010299956639813 + ], + "resp": [ + -21.311944042400853, + -24.72241823635355, + 4.233132626308943, + 6.370859881086669, + -2.027415652400837, + -6.370859881086669, + -24.42384722229375, + 4.914918420921617 + ] + }, + "mc4Param": { + "pow_a": 3.3072505400423485E-7, + "pow_p": 0.48940737393325506, + "exp2_a": 0.0001178398873513196, + "exp2_b": 63.34951489094878, + "exp3_a": 0.0001841064325533645, + "exp3_b": 55.65163739945494, + "exp3_p": 6.824418075268488, + "exp5_p": 7.707370645935452, + "gnls_p": 7.997415906240865, + "gnls_q": 7.989198554360788, + "hill_p": 2.571992160004071, + "pow_er": 2.5239488469935676, + "cnst_er": 2.5242223192710633, + "exp2_er": 2.525053668986501, + "exp3_er": 2.523884767735848, + "exp4_er": 2.5241938891100872, + "exp4_ga": 1.6515772735986691, + "exp4_tp": 6.617210716178248E-9, + "exp5_er": 2.524199907336932, + "exp5_ga": 10.178571517103231, + "exp5_tp": 5.172831559020237E-10, + "gnls_er": 2.5242279860451324, + "gnls_ga": 0.004183840961600125, + "gnls_la": 0.4674883095224845, + "gnls_tp": 1.1951706709070964E-9, + "hill_er": 2.524223618395549, + "hill_ga": 148.03344804359023, + "hill_tp": 2.733414071151221E-7, + "poly1_a": 3.75351162131322E-10, + "poly2_a": 0.00002346265382550711, + "poly2_b": 59.967965785150426, + "pow_aic": 72.58967090276546, + "pow_cov": 1, + "pow_rme": 14.955280470099757, + "pow_top": 0.0000022436522447587723, + "all_bmed": 0, + "cnst_aic": 68.58966978130083, + "cnst_rme": 14.955279986723223, + "exp2_aic": 72.58970163671296, + "exp2_cov": 1, + "exp2_rme": 14.95530781824828, + "exp2_top": 0.00014161915125562188, + "exp3_aic": 74.5896936496435, + "exp3_cov": 1, + "exp3_rme": 14.955303510350245, + "exp3_top": 0.00011387453660103208, + "exp4_aic": 72.58966979064168, + "exp4_cov": 1, + "exp4_rme": 14.955279988191776, + "exp4_top": 6.617210716178248E-9, + "exp5_aic": 74.58966978654288, + "exp5_cov": 1, + "exp5_rme": 14.955279986808964, + "exp5_top": 5.172831559020237E-10, + "gnls_aic": 78.58966978173339, + "gnls_cov": 0, + "gnls_rme": 14.955279986965122, + "gnls_top": 1.1951706553283066E-9, + "hill_aic": 74.58966978433192, + "hill_cov": 1, + "hill_rme": 14.955279989922763, + "hill_top": 2.733414071151221E-7, + "poly1_er": 2.524225595579482, + "poly2_er": 2.5192954625514083, + "pow_a_sd": null, + "pow_ac50": 12.13051274192964, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.809987412922897, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.922737651566834, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 1.6515772735986691, + "exp5_ac50": 10.178571517103231, + "exp5_p_sd": null, + "gnls_ac50": 0.004183841731103657, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 148.03344804359023, + "hill_p_sd": null, + "poly1_aic": 70.58966978459904, + "poly1_cov": 1, + "poly1_rme": 14.955279990364838, + "poly1_top": 1.8767558106566096E-8, + "poly2_aic": 72.58990187798537, + "poly2_cov": 1, + "poly2_rme": 14.95528704942522, + "poly2_top": 0.00003587357796415024, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.7543725426808853, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.416665901382313, + "poly2_b_sd": null, + "poly1_er_sd": 0.4477482735353781, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.46748831104898736 + }, + "mc5Param": { + "a": 3.75351162131322E-10, + "er": 2.524225595579482, + "ac5": 2.4999999999999996, + "bmd": 24747869784.486176, + "bmr": 9.289141683881516, + "mll": -33.29483489229952, + "top": 1.8767558106566096E-8, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 32.07314681587885, + "rmse": 14.955279990364838, + "ac1sd": 18345344540.019405, + "caikwt": 0.7310585789542388, + "hitcall": 0.002042012002651702, + "top_over_cutoff": 8.311287379883885E-10 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842407, + "spid": "LEGTV002C05", + "chid": 24159, + "casn": "82558-50-7", + "chnm": "Isoxaben", + "dtxsid": "DTXSID8024159", + "bmad": 3.7634679299683276, + "respMax": 5.49720635915255, + "respMin": -42.51947478602658, + "maxMean": 5.49720635915255, + "maxMeanConc": -1.6989700043360187, + "maxMed": 5.49720635915255, + "maxMedConc": -1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 6, + "m5id": 5037053, + "modl": "poly1", + "hitc": 0.005642489777948826, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + -1.6989700043360187, + 0.7781512503836436, + 0.3010299956639812, + -1.154901959985743, + 1.3010299956639813 + ], + "resp": [ + -25.365997806861397, + -17.548550487285034, + -34.678529552780105, + 5.49720635915255, + -33.60688227782604, + -42.51947478602658, + -5.497206359152553, + -17.438893556824596 + ] + }, + "mc4Param": { + "pow_a": 6.226170694933507E-8, + "pow_p": 0.4042163870931334, + "exp2_a": 0.0001012762858506541, + "exp2_b": 57.270518532764584, + "exp3_a": 0.0000182768161808948, + "exp3_b": 54.022410694191784, + "exp3_p": 6.142965107596046, + "exp5_p": 2.8793235821658465, + "gnls_p": 3.493285104003668, + "gnls_q": 7.031846474264492, + "hill_p": 1.0379684048996836, + "pow_er": 3.173306223014833, + "cnst_er": 3.173629962494881, + "exp2_er": 3.1736428876942693, + "exp3_er": 3.1731540297554797, + "exp4_er": 3.173621981878118, + "exp4_ga": 3.8258649261720423, + "exp4_tp": 3.8520423020123184E-9, + "exp5_er": 3.1736383043942484, + "exp5_ga": 2.271771952781368, + "exp5_tp": 5.262533058108749E-11, + "gnls_er": 3.1736202534985587, + "gnls_ga": 0.005952471727474193, + "gnls_la": 0.18861860617718257, + "gnls_tp": 1.6686711949450346E-7, + "hill_er": 3.17364751679775, + "hill_ga": 20.040557914497292, + "hill_tp": 1.1614522693913956E-8, + "poly1_a": 3.659932631449042E-9, + "poly2_a": 0.000013026598523821235, + "poly2_b": 57.387744641763376, + "pow_aic": 82.14157800030708, + "pow_cov": 1, + "pow_rme": 26.114813220190868, + "pow_top": 3.0267220450413394E-7, + "all_bmed": 0, + "cnst_aic": 78.14157681500255, + "cnst_rme": 26.114813127316296, + "exp2_aic": 82.14159084553305, + "exp2_cov": 1, + "exp2_rme": 26.114831275368346, + "exp2_top": 0.00014119949389863312, + "exp3_aic": 84.14158033084956, + "exp3_cov": 1, + "exp3_rme": 26.1148144541783, + "exp3_top": 0.000015755848523068117, + "exp4_aic": 82.14157681587226, + "exp4_cov": 1, + "exp4_rme": 26.11481312868518, + "exp4_top": 3.8520423020123184E-9, + "exp5_aic": 84.14157681658645, + "exp5_cov": 1, + "exp5_rme": 26.114813127337793, + "exp5_top": 5.262533058108749E-11, + "gnls_aic": 88.14157682092178, + "gnls_cov": 1, + "gnls_rme": 26.11481313545457, + "gnls_top": 1.6676819541873118E-7, + "hill_aic": 84.14157682143528, + "hill_cov": 1, + "hill_rme": 26.114813129178945, + "hill_top": 1.1614522693913956E-8, + "poly1_er": 3.1736110292974504, + "poly2_er": 3.177870228427013, + "pow_a_sd": null, + "pow_ac50": 9.000054430731787, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 30.29159091667016, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.711967424362975, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.8258649261720423, + "exp5_ac50": 2.271771952781368, + "exp5_p_sd": null, + "gnls_ac50": 0.0059504517433272355, + "gnls_p_sd": 224765.9170368504, + "gnls_q_sd": 180670.09083156497, + "hill_ac50": 20.040557914497292, + "hill_p_sd": null, + "poly1_aic": 80.14157683765278, + "poly1_cov": 1, + "poly1_rme": 26.114813154277936, + "poly1_top": 1.829966315724521E-7, + "poly2_aic": 82.14177676316693, + "poly2_cov": 1, + "poly2_rme": 26.11481578856423, + "poly2_top": 0.000021238186978110477, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": 0.3015548243048596, + "gnls_ga_sd": 485.41916773439993, + "gnls_la_sd": 289.43404331885483, + "gnls_tp_sd": 0.003781427130691287, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.6673078948731034, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.534768764417112, + "poly2_b_sd": null, + "poly1_er_sd": 0.4166433568135868, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.188650105801014 + }, + "mc5Param": { + "a": 3.659932631449042E-9, + "er": 3.1736110292974504, + "ac5": 2.5, + "bmd": 2538063570.9143515, + "bmr": 9.289141683881516, + "mll": -38.07078841882639, + "top": 1.829966315724521E-7, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 23.5430889035458, + "rmse": 26.114813154277936, + "ac1sd": 1881440749.3805425, + "caikwt": 0.7310585808566573, + "hitcall": 0.005642489777948826, + "top_over_cutoff": 8.104078249888357E-9 + }, + "mc6Param": { + "flag": [ + "Model directionality questionable", + "Bmd > ac50, indication of high baseline variability", + "Noisy data", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 5, + 9, + 10, + 13 + ] + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json new file mode 100644 index 00000000..4ddd3f32 --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-dtxsid/DTXSID30944145.json @@ -0,0 +1,1064 @@ +[ + { + "aeid": 3094, + "m4id": 822141, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 6.75211217879369, + "respMax": 101.97489068160048, + "respMin": -5.852474808193342, + "maxMean": 101.28943947387002, + "maxMeanConc": 2.3010299956639813, + "maxMed": 101.164780328344, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 3, + "tmpi": 42, + "m5id": 7598924, + "modl": "exp5", + "hitc": 0.9999999999966847, + "fitc": 42, + "coff": 20.25633653638107, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 0.6989700043360189, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1, + 1.4771212547196624, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + 1.9030899869919435, + 1, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 1.9030899869919435, + 0.6989700043360189, + -0.3010299956639812, + -1.3010299956639813, + -6, + 2.3010299956639813, + -6, + 1, + -3 + ], + "resp": [ + 7.427232859032931, + -3.750051787305786, + 101.07307228396438, + 98.9002717861462, + 17.02699226830727, + 17.699805850864504, + 2.9964941201219695, + -2.3418378029464026, + 100.8533065571916, + 58.64570278003023, + 5.964872358375655, + 49.11565073337273, + 14.83512968293488, + -3.9755251250928403, + 8.861038251024265, + -2.503018132836884, + 10.01979188930157, + 99.31356213766618, + 101.39305781992614, + 19.77117858122105, + 52.084973469960936, + 6.965386514618434, + 12.337528884815498, + -5.852474808193342, + 2.4837211637883, + 101.25648837272361, + 45.27350419250797, + 101.25648837272361, + 10.373412937556623, + 8.43972728547434, + -3.9875658920796426, + 1.7693315847934825, + 101.97489068160048, + 14.296296110011324, + 6.899162035880055, + -0.9777667971902465 + ] + }, + "mc4Param": { + "pow_a": 8.980263423505296, + "pow_p": 0.4658605032164628, + "exp2_a": 20906.920443662984, + "exp2_b": 38271.293496514474, + "exp3_a": 1485.9514343897358, + "exp3_b": 65459.19750014387, + "exp3_p": 0.46157030104511454, + "exp5_p": 1.4598137263404865, + "gnls_p": 2.0882292940940737, + "gnls_q": 7.993467618938603, + "hill_p": 2.08823290079987, + "pow_er": 2.153005726183071, + "cnst_er": 3.5592259949766554, + "exp2_er": 2.6995029704246463, + "exp3_er": 2.1600743867360332, + "exp4_er": 1.7944788900032378, + "exp4_ga": 28.42183560284198, + "exp4_tp": 105.35849603526988, + "exp5_er": 1.6323860710514544, + "exp5_ga": 29.136304634949504, + "exp5_tp": 102.86194850536708, + "gnls_er": 1.7852653451471712, + "gnls_ga": 29.224488415897408, + "gnls_la": 3787.921673603752, + "gnls_tp": 106.40480941826632, + "hill_er": 1.785256872105232, + "hill_ga": 29.22430650665218, + "hill_tp": 106.40450294071316, + "poly1_a": 0.5474828009413533, + "poly2_a": 27146.761600523227, + "poly2_b": 49818.73895889866, + "pow_aic": 286.2961627225351, + "pow_cov": 1, + "pow_rme": 12.749288084437351, + "pow_top": 105.98589412140464, + "all_bmed": 0, + "cnst_aic": 384.3251737754444, + "cnst_rme": 51.114626158662446, + "exp2_aic": 328.2752622937805, + "exp2_cov": 1, + "exp2_rme": 23.28731820786984, + "exp2_top": 109.54238551681884, + "exp3_aic": 288.7695452039763, + "exp3_cov": 1, + "exp3_rme": 12.853976257861472, + "exp3_top": 106.23398734408596, + "exp4_aic": 252.15096836877743, + "exp4_cov": 1, + "exp4_rme": 7.153206032224669, + "exp4_top": 105.35849603526988, + "exp5_aic": 242.37818996364612, + "exp5_cov": 1, + "exp5_rme": 6.04671272377595, + "exp5_top": 102.86194850536708, + "gnls_aic": 256.43287140229086, + "gnls_cov": 1, + "gnls_rme": 6.883032818734613, + "gnls_top": 106.3485222050823, + "hill_aic": 252.43287141156785, + "hill_cov": 1, + "hill_rme": 6.883035058943881, + "hill_top": 106.40450294071316, + "poly1_er": 2.698231249887153, + "poly2_er": 2.69823328798644, + "pow_a_sd": 1.6459870762064353, + "pow_ac50": 45.16993304352483, + "pow_p_sd": 0.0359070833296379, + "all_onesd": 13.177463361669563, + "exp2_a_sd": 80054.91579295504, + "exp2_ac50": 100.13064607578782, + "exp2_b_sd": 146042.59634222218, + "exp3_a_sd": 1557.2108093448396, + "exp3_ac50": 46.23219211065147, + "exp3_b_sd": 126993.03927633302, + "exp3_p_sd": 0.04175006048618471, + "exp4_ac50": 28.42183560284198, + "exp5_ac50": 29.136304634949504, + "exp5_p_sd": 0.16077431744640758, + "gnls_ac50": 29.209685841672393, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 29.22430650665218, + "hill_p_sd": 0.3854703745468205, + "poly1_aic": 326.2063457159531, + "poly1_cov": 1, + "poly1_rme": 23.266335897780746, + "poly1_top": 109.49656018827066, + "poly2_aic": 328.3117909623189, + "poly2_cov": 1, + "poly2_rme": 23.312627580644826, + "poly2_top": 109.41964530134416, + "pow_er_sd": 0.17588811957512163, + "exp2_er_sd": 0.18414085537434977, + "exp3_er_sd": 0.17616560477044965, + "exp4_er_sd": 0.14951537674258722, + "exp4_ga_sd": 2.504500211345132, + "exp4_tp_sd": 3.090966159056836, + "exp5_er_sd": 0.1494114951654834, + "exp5_ga_sd": 1.6840648875294664, + "exp5_tp_sd": 2.1361083422870157, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.14832567590990886, + "hill_ga_sd": 1.96787729051603, + "hill_tp_sd": 3.504225659847863, + "poly1_a_sd": 0.039187291314295165, + "poly1_ac50": 100, + "poly2_a_sd": 84355.29653483114, + "poly2_ac50": 100.1999242731534, + "poly2_b_sd": 154185.56825938867, + "poly1_er_sd": 0.1840572310279764, + "poly2_er_sd": 0.18411448898547148, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3788.3863573521858 + }, + "mc5Param": { + "p": 1.4598137263404865, + "er": 1.6323860710514544, + "ga": 29.136304634949504, + "tp": 102.86194850536708, + "ac5": 4.895974620693649, + "acc": 13.246002431318528, + "bmd": 11.994507756086188, + "bmr": 17.776398074892242, + "mll": -117.18909498182306, + "top": 102.86194850536708, + "ac10": 8.01655754617927, + "ac20": 13.404172123946616, + "ac50": 29.136304634949504, + "bmdl": 11.03986268985668, + "bmdu": 12.963072648031766, + "rmse": 6.04671272377595, + "ac1sd": 9.600739034050022, + "caikwt": 1.5017723494623147E-31, + "hitcall": 0.9999999999966848, + "top_over_cutoff": 5.078013406847952 + }, + "mc6Param": null + }, + { + "aeid": 3098, + "m4id": 822345, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 6.292361272058492, + "respMax": 98.60944617597698, + "respMin": -15.487892591704627, + "maxMean": 97.61114262807376, + "maxMeanConc": 2.3010299956639813, + "maxMed": 97.67386193907646, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 3, + "tmpi": 42, + "m5id": 7599128, + "modl": "exp5", + "hitc": 0.9999999999589282, + "fitc": 42, + "coff": 18.877083816175475, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -6, + 1.4771212547196624, + -1.3010299956639813, + -3, + 1.9030899869919435, + 1.9030899869919435, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 0.6989700043360189, + -0.3010299956639812, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1, + -3, + 0.6989700043360189, + 1.4771212547196624, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 1, + 0.6989700043360189, + -1.3010299956639813, + 2.3010299956639813, + 1.9030899869919435, + 1, + 1, + -0.3010299956639812, + -6, + -6 + ], + "resp": [ + -15.487892591704627, + 40.445936226324626, + -3.308559098537521, + 2.4871891013623295, + 95.05061867266592, + 94.2402094469292, + 41.223955492527544, + 13.285839270091238, + 12.403185338714955, + 5.966930265995686, + 3.2590462497004555, + 97.74742391564821, + 37.58280214973128, + 13.203930026359934, + 1.8653867132104287, + 7.428820770153813, + -0.5751258087706687, + 96.48740045816517, + 10.046907385185994, + 6.577942620268354, + 0.2397506593143131, + 45.626647495806374, + 10.740829537281229, + 3.4763845600575403, + 98.60944617597698, + 96.61951570366818, + 36.849676336609924, + 25.084364454443193, + 14.135733033370828, + 97.60029996250469, + 94.17685118619698, + 5.586801649793776, + 16.462976276060388, + 6.709801102324467, + -0.6374203224596925, + 4.330751609032399 + ] + }, + "mc4Param": { + "pow_a": 8.718852311483452, + "pow_p": 0.4621192452087188, + "exp2_a": 30733.63862806683, + "exp2_b": 58053.22582237376, + "exp3_a": 95.1637174921906, + "exp3_b": 487.2146854984712, + "exp3_p": 0.36448949067095376, + "exp5_p": 1.5921607117432042, + "gnls_p": 2.5006151066661264, + "gnls_q": 7.884701749657575, + "hill_p": 2.5005615803454724, + "pow_er": 2.1386687105738353, + "cnst_er": 3.5130386164195015, + "exp2_er": 2.6970289699940606, + "exp3_er": 2.2185744921064368, + "exp4_er": 2.011051198182322, + "exp4_ga": 32.650308081937, + "exp4_tp": 102.35617680593612, + "exp5_er": 1.7482328153387492, + "exp5_ga": 33.60823929102817, + "exp5_tp": 99.05623958289912, + "gnls_er": 1.8712349808607216, + "gnls_ga": 33.56038699307263, + "gnls_la": 5782.338770572877, + "gnls_tp": 101.44815858342024, + "hill_er": 1.8712200758466104, + "hill_ga": 33.56045811387879, + "hill_tp": 101.4484696652948, + "poly1_a": 0.5305416047533859, + "poly2_a": 27673.0817955942, + "poly2_b": 52368.24882950644, + "pow_aic": 284.11914879686157, + "pow_cov": 1, + "pow_rme": 12.167746147199564, + "pow_top": 100.8810435335372, + "all_bmed": 0, + "cnst_aic": 380.5440532323087, + "cnst_rme": 48.52148017787647, + "exp2_aic": 324.77731273488877, + "exp2_cov": 1, + "exp2_rme": 21.596356868481895, + "exp2_top": 106.06349428140288, + "exp3_aic": 288.16578474486806, + "exp3_cov": 1, + "exp3_rme": 12.654705150741076, + "exp3_top": 100.90413703157488, + "exp4_aic": 266.6070682545724, + "exp4_cov": 1, + "exp4_rme": 8.542515933428906, + "exp4_top": 102.35617680593612, + "exp5_aic": 257.6591381302885, + "exp5_cov": 1, + "exp5_rme": 8.397684028922718, + "exp5_top": 99.05623958289912, + "gnls_aic": 269.9181398445775, + "gnls_cov": 1, + "gnls_rme": 9.43263682314636, + "gnls_top": 101.43815067391468, + "hill_aic": 265.9181398398791, + "hill_cov": 1, + "hill_rme": 9.432603290521724, + "hill_top": 101.4484696652948, + "poly1_er": 2.6974150875559637, + "poly2_er": 2.6974910028623347, + "pow_a_sd": 1.6532680814195877, + "pow_ac50": 44.62909211616844, + "pow_p_sd": 0.037632545643377605, + "all_onesd": 13.014601637003002, + "exp2_a_sd": 144770.52933512983, + "exp2_ac50": 100.08612781558456, + "exp2_b_sd": 273004.74414100195, + "exp3_a_sd": 144.74203282152968, + "exp3_ac50": 46.69029054309706, + "exp3_b_sd": 1335.7880545481178, + "exp3_p_sd": 0.09938750851619732, + "exp4_ac50": 32.650308081937, + "exp5_ac50": 33.60823929102817, + "exp5_p_sd": 0.1861700465060868, + "gnls_ac50": 33.55773915040644, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.56045811387879, + "hill_p_sd": 0.6962069108870773, + "poly1_aic": 322.7320181754561, + "poly1_cov": 1, + "poly1_rme": 21.576688972834244, + "poly1_top": 106.10832095067718, + "poly2_aic": 324.83200434183965, + "poly2_cov": 1, + "poly2_rme": 21.612975364548863, + "poly2_top": 106.09011722019908, + "pow_er_sd": 0.17201036124649297, + "exp2_er_sd": 0.1724789031231027, + "exp3_er_sd": 0.1778243849070398, + "exp4_er_sd": 0.14816738537311727, + "exp4_ga_sd": 3.8800102860948154, + "exp4_tp_sd": 3.881300977472912, + "exp5_er_sd": 0.16675857577462103, + "exp5_ga_sd": 1.909160862868152, + "exp5_tp_sd": 2.442228657418365, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.16807331852131832, + "hill_ga_sd": 1.9630919114427805, + "hill_tp_sd": 4.0603354568457, + "poly1_a_sd": 0.03909925746514938, + "poly1_ac50": 100, + "poly2_a_sd": 88278.60946926908, + "poly2_ac50": 100.190228208773, + "poly2_b_sd": 166328.9016942867, + "poly1_er_sd": 0.17246325393606268, + "poly2_er_sd": 0.1725193110812217, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 5782.479713707603 + }, + "mc5Param": { + "p": 1.5921607117432042, + "er": 1.7482328153387492, + "ga": 33.60823929102817, + "tp": 99.05623958289912, + "ac5": 6.549950475444407, + "acc": 15.942801656366925, + "bmd": 15.15768602592679, + "bmr": 17.556697608317048, + "mll": -124.82956906514426, + "top": 99.05623958289912, + "ac10": 10.294039781041006, + "ac20": 16.492264340792413, + "ac50": 33.60823929102817, + "bmdl": 13.9632920083894, + "bmdu": 16.36542533906654, + "rmse": 8.397684028922718, + "ac1sd": 12.353374802821008, + "caikwt": 2.0695681448366308E-27, + "hitcall": 0.9999999999589282, + "top_over_cutoff": 5.24743337199252 + }, + "mc6Param": null + }, + { + "aeid": 3095, + "m4id": 1150437, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 0.1635842394403502, + "respMax": 11.45832139758188, + "respMin": 0.04981319925745456, + "maxMean": 4.937025241580714, + "maxMeanConc": 1.9030899869919435, + "maxMed": 5.454860652403362, + "maxMedConc": 1.9030899869919435, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 2, + "tmpi": 42, + "m5id": 7598992, + "modl": "exp5", + "hitc": 0.9999998831449819, + "fitc": 42, + "coff": 0.4907527183210506, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + -0.3010299956639812, + -1.3010299956639813, + 2.3010299956639813, + 0.6989700043360189, + -0.3010299956639812, + -6, + 2.3010299956639813, + 1, + -3, + 0.6989700043360189, + 1.4771212547196624, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 1, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1.9030899869919435, + 1, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + -6, + 1.9030899869919435, + 1.4771212547196624, + 0.6989700043360189, + -3, + 1.4771212547196624, + -1.3010299956639813 + ], + "resp": [ + 0.2882675039415536, + 0.2293577923201378, + 2.12765731100286, + 0.2760905500803271, + 0.2223210266269225, + 0.2859185064112817, + 3.726705759810087, + 0.169779282809137, + 0.2335357255129443, + 0.3364575742259655, + 0.2644336595666082, + 1.101262393197357, + 0.4222553297999173, + 1.724134958388003, + 6.3829741964722, + 0.1518602827691616, + 0.500500483800451, + 0.4657932906610395, + 0.6850736830999858, + 11.45832139758188, + 0.362318825993606, + 4.526747108334523, + 0.2382843463520162, + 0.22948937953272, + 0.3481086018076444, + 0.3596198212273357, + 0.461420136851573, + 0.5216095250469567, + 6.565653249670075, + 0.2280501658369403, + 2.272726411846056, + 0.3340757114300033, + 0.04981319925745456, + 0.222937819595298, + 0.4805766727842742, + 0.1649776062932452 + ] + }, + "mc4Param": { + "pow_a": 0.07306340900696351, + "pow_p": 0.6909308897469263, + "exp2_a": 489.25456473992574, + "exp2_b": 30770.895494055152, + "exp3_a": 16.86144381389201, + "exp3_b": 2819.131595534077, + "exp3_p": 0.6927530157131045, + "exp5_p": 4.565817027769467, + "gnls_p": 7.955761313099027, + "gnls_q": 0.5644747159243586, + "hill_p": 7.999999975199726, + "pow_er": -0.4956759683416578, + "cnst_er": -0.06367288253941095, + "exp2_er": -0.4920846292443089, + "exp3_er": -0.4952315996998395, + "exp4_er": -0.48780818578433305, + "exp4_ga": 62.936593572598966, + "exp4_tp": 3.160545685691406, + "exp5_er": -0.5427393909605482, + "exp5_ga": 45.24973438082952, + "exp5_tp": 3.6092716297582976, + "gnls_er": -0.5743685279270239, + "gnls_ga": 40.39441528906965, + "gnls_la": 1277.3835717446193, + "gnls_tp": 4.9743882398250925, + "hill_er": -0.5418420584767905, + "hill_ga": 39.362832742773776, + "hill_tp": 3.598558047969296, + "poly1_a": 0.015951258753982463, + "poly2_a": 689.1656998074085, + "poly2_b": 43422.635840414565, + "pow_aic": 119.27110226117928, + "pow_cov": 1, + "pow_rme": 1.970612708065348, + "pow_top": 2.841532541460785, + "all_bmed": 0, + "cnst_aic": 147.02320231677632, + "cnst_rme": 2.7213080260384577, + "exp2_aic": 121.536640649848, + "exp2_cov": 1, + "exp2_rme": 1.9806070196866243, + "exp2_top": 3.190339433218957, + "exp3_aic": 121.41570410348348, + "exp3_cov": 1, + "exp3_rme": 1.964500358062248, + "exp3_top": 2.9245335937115775, + "exp4_aic": 117.40649569667184, + "exp4_cov": 1, + "exp4_rme": 1.9143914875326904, + "exp4_top": 3.160545685691406, + "exp5_aic": 108.69371063135708, + "exp5_cov": 1, + "exp5_rme": 1.5839688744886915, + "exp5_top": 3.6092716297582976, + "gnls_aic": 110.23531348142146, + "gnls_cov": 1, + "gnls_rme": 1.540743257946914, + "gnls_top": 4.114035106463596, + "hill_aic": 108.7802965738098, + "hill_cov": 1, + "hill_rme": 1.5870073319060576, + "hill_top": 3.598558047969296, + "poly1_er": -0.49322275683035666, + "poly2_er": -0.4931857994848398, + "pow_a_sd": 0.06098198965840179, + "pow_ac50": 73.34025784745266, + "pow_p_sd": 0.17664309055759367, + "all_onesd": 0.8923597763803547, + "exp2_a_sd": 3184.6202015618323, + "exp2_ac50": 100.16249092262407, + "exp2_b_sd": 199490.5906912948, + "exp3_a_sd": 58.61911836048125, + "exp3_ac50": 77.81121531926684, + "exp3_b_sd": 9986.108641207353, + "exp3_p_sd": 0.29683220702002194, + "exp4_ac50": 62.936593572598966, + "exp5_ac50": 45.24973438082952, + "exp5_p_sd": 4.213044861329193, + "gnls_ac50": 39.827322985728394, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 39.362832742773776, + "hill_p_sd": 5.573024297626113, + "poly1_aic": 119.51285294787452, + "poly1_cov": 1, + "poly1_rme": 1.9801146542527, + "poly1_top": 3.190251750796493, + "poly2_aic": 121.54640180031528, + "poly2_cov": 1, + "poly2_rme": 1.981069269414523, + "poly2_top": 3.1888433746628246, + "pow_er_sd": 0.19875859625257855, + "exp2_er_sd": 0.19669797020202764, + "exp3_er_sd": 0.19724985616593993, + "exp4_er_sd": 0.1965661043023219, + "exp4_ga_sd": 34.81821712492219, + "exp4_tp_sd": 1.0390395652442248, + "exp5_er_sd": 0.1840458110753714, + "exp5_ga_sd": 16.99176937771065, + "exp5_tp_sd": 0.663162309702829, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.18392569712837312, + "hill_ga_sd": 7.865147277595785, + "hill_tp_sd": 0.6707173101135189, + "poly1_a_sd": 0.003422826182028237, + "poly1_ac50": 100, + "poly2_a_sd": 3794.628359530953, + "poly2_ac50": 100.2292375794687, + "poly2_b_sd": 237831.70254565787, + "poly1_er_sd": 0.19659363721503492, + "poly2_er_sd": 0.196607292096659, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2372.2570284464873 + }, + "mc5Param": { + "p": 4.565817027769467, + "er": -0.5427393909605482, + "ga": 45.24973438082952, + "tp": 3.6092716297582976, + "ac5": 25.583338192735063, + "acc": 32.177479924985796, + "bmd": 40.242151032551405, + "bmr": 1.2037933383370985, + "mll": -50.346855315678546, + "top": 3.6092716297582976, + "ac10": 29.9520321053751, + "ac20": 35.30253965284071, + "ac50": 45.24973438082952, + "bmdl": 33.264446410375136, + "bmdu": 53.793763933888144, + "rmse": 1.5839688744886915, + "ac1sd": 37.21757330690621, + "caikwt": 4.751783349020907E-9, + "hitcall": 0.999999883144982, + "top_over_cutoff": 7.354562685065171 + }, + "mc6Param": { + "flag": [ + "Noisy data" + ], + "mc6MthdId": [ + 10 + ] + } + }, + { + "aeid": 3096, + "m4id": 1150505, + "spid": "ES211_47_47", + "chid": 944145, + "casn": "21535-47-7", + "chnm": "Mianserin hydrochloride", + "dtxsid": "DTXSID30944145", + "bmad": 0.257990171134824, + "respMax": 12.49998697918023, + "respMin": 0.0, + "maxMean": 5.541738410783121, + "maxMeanConc": 2.3010299956639813, + "maxMed": 4.833483331976126, + "maxMedConc": 2.3010299956639813, + "logcMax": 2.3010299956639813, + "logcMin": -6.0, + "nconc": 9, + "npts": 36, + "nrep": 4.0, + "nmedGtbl": 7, + "tmpi": 42, + "m5id": 7599060, + "modl": "exp5", + "hitc": 0.9999998559756664, + "fitc": 42, + "coff": 0.7739705134044719, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 100.0, + "stkcUnit": null, + "testedConcUnit": null, + "mc3Param": { + "logc": [ + 1.9030899869919435, + -1.3010299956639813, + 2.3010299956639813, + -6, + -0.3010299956639812, + -3, + 2.3010299956639813, + 1.9030899869919435, + 0.6989700043360189, + 0.6989700043360189, + -1.3010299956639813, + -6, + 2.3010299956639813, + 1.4771212547196624, + 1, + 1.4771212547196624, + 1, + -1.3010299956639813, + -0.3010299956639812, + -3, + -6, + 1.9030899869919435, + 1.9030899869919435, + 1, + 1.4771212547196624, + -0.3010299956639812, + 0.6989700043360189, + -1.3010299956639813, + -3, + 2.3010299956639813, + 1.4771212547196624, + 0.6989700043360189, + -0.3010299956639812, + -6, + 1, + -3 + ], + "resp": [ + 4.526747108334523, + 0.824888031466226, + 4.347823386445102, + 0.4561003316738806, + 0.7789416927493502, + 0.8941877572233543, + 0, + 5.673754841308623, + 1.057438090424463, + 1.601601548161443, + 0.7860261779905042, + 1.266348323306034, + 12.49998697918023, + 0.5233494153240975, + 0.6619009620889339, + 0.3966504893499123, + 0.6597819661565701, + 0.7658389239768177, + 0.8219881628053387, + 0.7946680134665979, + 1.341281635835031, + 5.050502499746212, + 3.030301882461408, + 0.9870918379995505, + 0.7423904698444517, + 0.9801095134012823, + 0.2988791955447274, + 0.6880733769604134, + 0.916522147225114, + 5.319143277507151, + 0.8810572334378359, + 0.7454444852168833, + 0.5113383612419217, + 1.119847483444187, + 0.5093378484274108, + 0.4670714510258886 + ] + }, + "mc4Param": { + "pow_a": 0.256129166457669, + "pow_p": 0.5644406772111492, + "exp2_a": 1129.3096760444655, + "exp2_b": 39317.04061124209, + "exp3_a": 0.8720019016302841, + "exp3_b": 22.670011403864912, + "exp3_p": 0.30000305864361876, + "exp5_p": 3.190253095690696, + "gnls_p": 4.264093872089519, + "gnls_q": 0.6791167117000405, + "hill_p": 7.176325755057048, + "pow_er": -0.034773780653756595, + "cnst_er": 0.3936756503357535, + "exp2_er": 0.049717571642521746, + "exp3_er": -0.06866643163594202, + "exp4_er": -0.0334255933863206, + "exp4_ga": 54.83941521805386, + "exp4_tp": 5.528448444550952, + "exp5_er": -0.12470418879335174, + "exp5_ga": 47.982496654915074, + "exp5_tp": 4.7906449817634, + "gnls_er": -0.123418231619115, + "gnls_ga": 48.10588765537344, + "gnls_la": 1521.241791470397, + "gnls_tp": 5.939435678991746, + "hill_er": -0.12226946714558153, + "hill_ga": 38.87908122770836, + "hill_tp": 4.727067329887222, + "poly1_a": 0.028809872811533375, + "poly2_a": 1571.4797602650003, + "poly2_b": 54739.707244964055, + "pow_aic": 131.0854979041203, + "pow_cov": 1, + "pow_rme": 1.7655265144654924, + "pow_top": 5.096288028509811, + "all_bmed": 0, + "cnst_aic": 163.6015491080996, + "cnst_rme": 2.940288361762558, + "exp2_aic": 137.69447001575364, + "exp2_cov": 1, + "exp2_rme": 1.8398294934860109, + "exp2_top": 5.759267997099814, + "exp3_aic": 132.21816633784778, + "exp3_cov": 1, + "exp3_rme": 1.7676923268681453, + "exp3_top": 5.085763779463437, + "exp4_aic": 129.8610022030918, + "exp4_cov": 1, + "exp4_rme": 1.7411782753483664, + "exp4_top": 5.528448444550952, + "exp5_aic": 126.4266045032358, + "exp5_cov": 1, + "exp5_rme": 1.7108365520435371, + "exp5_top": 4.7906449817634, + "gnls_aic": 130.5159804184214, + "gnls_cov": 1, + "gnls_rme": 1.71478488931515, + "gnls_top": 4.942677854612155, + "hill_aic": 126.56736784290752, + "hill_cov": 1, + "hill_rme": 1.7154496972433324, + "hill_top": 4.727067329887222, + "poly1_er": 0.048751930612820536, + "poly2_er": 0.04920885674061179, + "pow_a_sd": 0.1568794096944919, + "pow_ac50": 58.57409370876723, + "pow_p_sd": 0.12743956516601432, + "all_onesd": 0.40082905954467335, + "exp2_a_sd": 6523.3330851199225, + "exp2_ac50": 100.1271711840828, + "exp2_b_sd": 226568.13671898856, + "exp3_a_sd": null, + "exp3_ac50": 63.9739161348579, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 54.83941521805386, + "exp5_ac50": 47.982496654915074, + "exp5_p_sd": 1.6269771671859927, + "gnls_ac50": 46.104045082264136, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 38.87908122770836, + "hill_p_sd": 78.09046476767209, + "poly1_aic": 135.66432541001384, + "poly1_cov": 1, + "poly1_rme": 1.839223539922158, + "poly1_top": 5.761974562306676, + "poly2_aic": 137.70745803349075, + "poly2_cov": 1, + "poly2_rme": 1.8399012025826664, + "poly2_top": 5.762622726294994, + "pow_er_sd": 0.16005952572503318, + "exp2_er_sd": 0.16512363320736548, + "exp3_er_sd": null, + "exp4_er_sd": 0.1553647531392489, + "exp4_ga_sd": 22.623173556633372, + "exp4_tp_sd": 1.0746491215089478, + "exp5_er_sd": 0.1550298307298998, + "exp5_ga_sd": 11.027654963611443, + "exp5_tp_sd": 0.5822266175525593, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.15517480648449222, + "hill_ga_sd": 110.91755377399213, + "hill_tp_sd": 1.3037185004938374, + "poly1_a_sd": 0.004437974865094146, + "poly1_ac50": 100, + "poly2_a_sd": 7620.57224036576, + "poly2_ac50": 100.18201711241991, + "poly2_b_sd": 264301.4890716433, + "poly1_er_sd": 0.1650477137056485, + "poly2_er_sd": 0.16508964434676754, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 2505.4734619566725 + }, + "mc5Param": { + "p": 3.190253095690696, + "er": -0.12470418879335174, + "ga": 47.982496654915074, + "tp": 4.7906449817634, + "ac5": 21.21481348706796, + "acc": 31.23504395850078, + "bmd": 27.67407473473264, + "bmr": 0.5407184013257643, + "mll": -59.213302251617904, + "top": 4.7906449817634, + "ac10": 26.584628460854177, + "ac20": 33.634697200724105, + "ac50": 47.982496654915074, + "bmdl": 21.832233757697352, + "bmdu": 34.85027881622872, + "rmse": 1.7108365520435371, + "ac1sd": 25.06997712418609, + "caikwt": 8.463760056913385E-9, + "hitcall": 0.9999998559756664, + "top_over_cutoff": 6.18969960585545 + }, + "mc6Param": { + "flag": [ + "Noisy data" + ], + "mc6MthdId": [ + 10 + ] + } + } +] diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json new file mode 100644 index 00000000..dff7f002 --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-m4id/1842443.json @@ -0,0 +1,211 @@ +{ + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } +} diff --git a/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json new file mode 100644 index 00000000..64c6f26b --- /dev/null +++ b/vignettes/api/0/api-ccte.epa.gov/bioactivity/data/search/by-spid/TP0000904H05.json @@ -0,0 +1,1715 @@ +[ + { + "aeid": 623, + "m4id": 1833668, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.208854513532483, + "respMax": 29.901771956856702, + "respMin": -7.501926040061633, + "maxMean": 29.901771956856702, + "maxMeanConc": 1.3010299956639813, + "maxMed": 29.901771956856702, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 173, + "m5id": 5028314, + "modl": "exp5", + "hitc": 0.3882324490933417, + "fitc": 15, + "coff": 25.253127081194897, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.6989700043360187, + -1.6989700043360187, + 1.3010299956639813, + 0.3010299956639812, + 0.7781512503836436, + -0.22184874961635637, + -1.154901959985743, + 1.6989700043360187 + ], + "resp": [ + 5.209938366718028, + -4.959553158705701, + 29.901771956856702, + -4.651386748844375, + -7.501926040061633, + -1.3578582434514619, + 4.9595531587057025, + 20.02118644067797 + ] + }, + "mc4Param": { + "pow_a": 0.44336623130581354, + "pow_p": 0.9925644596727824, + "exp2_a": 1721.5267035510278, + "exp2_b": 4025.7260629221983, + "exp3_a": 1149.7862297572626, + "exp3_b": 3865.930582986358, + "exp3_p": 0.917722768672351, + "exp5_p": 7.999998569591368, + "gnls_p": 7.999999998725721, + "gnls_q": 6.1299493285886815, + "hill_p": 7.999999995602079, + "pow_er": 1.9125454943910825, + "cnst_er": 2.2713874650689845, + "exp2_er": 1.9114072623315592, + "exp3_er": 1.9217973647521511, + "exp4_er": 1.941838889601473, + "exp4_ga": 13.263284766380592, + "exp4_tp": 24.09270151565037, + "exp5_er": 1.5919951761954754, + "exp5_ga": 14.42814252864356, + "exp5_tp": 24.957524183833613, + "gnls_er": 1.602022603368262, + "gnls_ga": 11.075019190563058, + "gnls_la": 4057.2571930089903, + "gnls_tp": 24.99533986136314, + "hill_er": 1.6020268977019103, + "hill_ga": 11.07620152627384, + "hill_tp": 24.995330944202244, + "poly1_a": 0.4304809360209948, + "poly2_a": 1481.0924717053826, + "poly2_b": 3489.637064916511, + "pow_aic": 63.54642686971948, + "pow_cov": 1, + "pow_rme": 9.110378433889926, + "pow_top": 21.532767773256374, + "all_bmed": 0, + "cnst_aic": 65.7380627468674, + "cnst_rme": 13.467830827162247, + "exp2_aic": 63.5509972646931, + "exp2_cov": 1, + "exp2_rme": 9.128808609267953, + "exp2_top": 21.514900150579237, + "exp3_aic": 65.56286926134463, + "exp3_cov": 1, + "exp3_rme": 9.029227555570293, + "exp3_top": 21.464382238767605, + "exp4_aic": 62.98697633687659, + "exp4_cov": 1, + "exp4_rme": 8.155246492992447, + "exp4_top": 24.09270151565037, + "exp5_aic": 58.33551786266656, + "exp5_cov": 1, + "exp5_rme": 5.064097391524118, + "exp5_top": 24.957524183833613, + "gnls_aic": 62.50680467218653, + "gnls_cov": 1, + "gnls_rme": 5.12230318637964, + "gnls_top": 24.995339798729216, + "hill_aic": 58.50680471790864, + "hill_cov": 1, + "hill_rme": 5.12229712088364, + "hill_top": 24.995330944202244, + "poly1_er": 1.9115526550839648, + "poly2_er": 1.9107008970876125, + "pow_a_sd": 1.30795225093553, + "pow_ac50": 24.870523119834353, + "pow_p_sd": 0.7451572698575011, + "all_onesd": 5.871582120667167, + "exp2_a_sd": 26000.97172895427, + "exp2_ac50": 25.077625249843255, + "exp2_b_sd": 60411.57063986761, + "exp3_a_sd": null, + "exp3_ac50": 23.61210508379751, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 13.263284766380592, + "exp5_ac50": 14.42814252864356, + "exp5_p_sd": 14.257258147825569, + "gnls_ac50": 11.075019183625043, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 11.07620152627384, + "hill_p_sd": 5.6132273415436185, + "poly1_aic": 61.5465618387384, + "poly1_cov": 1, + "poly1_rme": 9.121069696481047, + "poly1_top": 21.524046801049735, + "poly2_aic": 63.5566347758779, + "poly2_cov": 1, + "poly2_rme": 9.136999205494709, + "poly2_top": 21.52535837501469, + "pow_er_sd": 0.35032444517103617, + "exp2_er_sd": 0.33775432638513775, + "exp3_er_sd": null, + "exp4_er_sd": 0.31898399504554403, + "exp4_ga_sd": 16.437658831836973, + "exp4_tp_sd": 9.402421344167246, + "exp5_er_sd": 0.2866421065447428, + "exp5_ga_sd": 10.811848496418005, + "exp5_tp_sd": 4.504679302336407, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.2889737774748023, + "hill_ga_sd": 4.654460027967879, + "hill_tp_sd": 4.624285420174428, + "poly1_a_sd": 0.12591284476723125, + "poly1_ac50": 24.999999999999993, + "poly2_a_sd": 15244.347569196254, + "poly2_ac50": 25.176562967913593, + "poly2_b_sd": 35357.40607056334, + "poly1_er_sd": 0.3376542920341601, + "poly2_er_sd": 0.33789398129427817, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 4057.257196326073 + }, + "mc5Param": { + "p": 7.999998569591368, + "er": 1.5919951761954754, + "ga": 14.42814252864356, + "tp": 24.957524183833613, + "ac5": 10.419929728081096, + "bmd": 13.391740000924123, + "bmr": 7.920764280780008, + "mll": -25.16775893133328, + "top": 24.957524183833613, + "ac10": 11.400974094782285, + "ac20": 12.522189530406145, + "ac50": 14.42814252864356, + "bmdl": 6.346138919905622, + "bmdu": 16.86891434152304, + "rmse": 5.064097391524118, + "ac1sd": 12.813544894047944, + "caikwt": 0.024097080019334458, + "hitcall": 0.3882324490933417, + "top_over_cutoff": 0.9882944042371128 + }, + "mc6Param": { + "flag": [ + "Borderline", + "Average number of replicates per conc is less than 2", + "Multiple points above baseline, inactive" + ], + "mc6MthdId": [ + 11, + 13, + 8 + ] + } + }, + { + "aeid": 626, + "m4id": 1834094, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.884792210388105, + "respMax": 29.6569605105704, + "respMin": -0.8775428799361791, + "maxMean": 29.6569605105704, + "maxMeanConc": 1.3010299956639813, + "maxMed": 29.6569605105704, + "maxMedConc": 1.3010299956639813, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 2, + "tmpi": 127, + "m5id": 5028740, + "modl": "exp4", + "hitc": 0.01954693088289667, + "fitc": 13, + "coff": 29.30875326232863, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.154901959985743, + 1.6989700043360187, + 0.7781512503836436, + -0.22184874961635637, + -1.6989700043360187, + 1.3010299956639813, + 0.3010299956639812, + -0.6989700043360187 + ], + "resp": [ + -0.8775428799361791, + 14.818508177104107, + 7.818109293976865, + 0.6182688472277631, + 0.8775428799361791, + 29.6569605105704, + 14.000797766254488, + 11.22856003191065 + ] + }, + "mc4Param": { + "pow_a": 6.104769005070028, + "pow_p": 0.30000061702105263, + "exp2_a": 2626.4817742925065, + "exp2_b": 6939.1379984058385, + "exp3_a": 120.15711077915388, + "exp3_b": 23397.765294430603, + "exp3_p": 0.30000031698770585, + "exp5_p": 0.594894190079819, + "gnls_p": 0.8731492533237095, + "gnls_q": 7.968128567118133, + "hill_p": 0.699837429056946, + "pow_er": 1.7335248446140346, + "cnst_er": 2.380613185122028, + "exp2_er": 2.060944039839989, + "exp3_er": 1.8546380117175023, + "exp4_er": 1.742284415011934, + "exp4_ga": 2.8193975022647706, + "exp4_tp": 19.007523606809062, + "exp5_er": 1.6978383675225492, + "exp5_ga": 1.6927866800008955, + "exp5_tp": 18.11557823124747, + "gnls_er": 1.6327825441519803, + "gnls_ga": 1.735452996784926, + "gnls_la": 54.87984244327055, + "gnls_tp": 24.19390328229074, + "hill_er": 1.6938476048310585, + "hill_ga": 1.813379328743659, + "hill_tp": 19.44068645643118, + "poly1_a": 0.37984578052812146, + "poly2_a": 2264.1081940817717, + "poly2_b": 6022.235022571993, + "pow_aic": 60.00263716196596, + "pow_cov": 1, + "pow_rme": 6.885998407649498, + "pow_top": 19.740642572392304, + "all_bmed": 0, + "cnst_aic": 66.57834307933227, + "cnst_rme": 13.621084951805804, + "exp2_aic": 65.81071829753414, + "exp2_cov": 1, + "exp2_rme": 10.22892676304634, + "exp2_top": 18.99347662794126, + "exp3_aic": 62.2288005070792, + "exp3_cov": 1, + "exp3_rme": 6.886283476321515, + "exp3_top": 20.58121443270486, + "exp4_aic": 59.581830457686145, + "exp4_cov": 1, + "exp4_rme": 6.490262952004159, + "exp4_top": 19.007523606809062, + "exp5_aic": 60.930401394432195, + "exp5_cov": 1, + "exp5_rme": 6.304211108274938, + "exp5_top": 18.11557823124747, + "gnls_aic": 64.01083808276202, + "gnls_cov": 1, + "gnls_rme": 5.921058456285511, + "gnls_top": 22.158867072863508, + "hill_aic": 61.05594929038858, + "hill_cov": 1, + "hill_rme": 6.438553620903468, + "hill_top": 19.44068645643118, + "poly1_er": 2.059622051495357, + "poly2_er": 2.0605577889775617, + "pow_a_sd": 3.149959838854599, + "pow_ac50": 4.960651860666694, + "pow_p_sd": 0.1482676079125486, + "all_onesd": 7.091261826118074, + "exp2_a_sd": 30938.21312122273, + "exp2_ac50": 25.045034314642436, + "exp2_b_sd": 81312.38225224172, + "exp3_a_sd": 303.1118237953914, + "exp3_ac50": 5.644138602314242, + "exp3_b_sd": 141170.26637545082, + "exp3_p_sd": 0.17783524373196458, + "exp4_ac50": 2.8193975022647706, + "exp5_ac50": 1.6927866800008955, + "exp5_p_sd": 0.40135476309182777, + "gnls_ac50": 1.4306730373148124, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 1.813379328743659, + "hill_p_sd": 0.6752166489168941, + "poly1_aic": 63.80340730003342, + "poly1_cov": 1, + "poly1_rme": 10.22362919651012, + "poly1_top": 18.99228902640607, + "poly2_aic": 65.82009863445656, + "poly2_cov": 1, + "poly2_rme": 10.238688730082709, + "poly2_top": 18.953977151594913, + "pow_er_sd": 0.3335635504694223, + "exp2_er_sd": 0.34947041875452034, + "exp3_er_sd": 0.34371770733317997, + "exp4_er_sd": 0.3221439177850666, + "exp4_ga_sd": 4.969271064671941, + "exp4_tp_sd": 7.484672815601464, + "exp5_er_sd": 0.3208267776910146, + "exp5_ga_sd": 2.2579559312184383, + "exp5_tp_sd": 5.794590169915659, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": 0.32586972894861654, + "hill_ga_sd": 3.8056187634873897, + "hill_tp_sd": 9.540592027517304, + "poly1_a_sd": 0.160075249411384, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 17871.438263865843, + "poly2_ac50": 25.102925760278133, + "poly2_b_sd": 47059.40366080807, + "poly1_er_sd": 0.3493877366290281, + "poly2_er_sd": 0.3495083063258392, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 55.428544878921535 + }, + "mc5Param": { + "er": 1.742284415011934, + "ga": 2.8193975022647706, + "tp": 19.007523606809062, + "ac5": 0.2086370544887254, + "bmd": 2.8461708745717997, + "bmr": 9.56611220343328, + "mll": -26.790915228843073, + "top": 19.007523606809062, + "ac10": 0.4285571419954925, + "ac20": 0.9076432666342852, + "ac50": 2.8193975022647706, + "bmdl": 0.42381147732328206, + "bmdu": 10.478324051348984, + "rmse": 6.490262952004159, + "ac1sd": 1.899255719797609, + "caikwt": 0.029361884721225712, + "hitcall": 0.01954693088289667, + "top_over_cutoff": 0.6485271972056202 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Multiple points above baseline, inactive", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 8, + 9 + ] + } + }, + { + "aeid": 645, + "m4id": 1836233, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.4265572687763393, + "respMax": 7.386363636363637, + "respMin": -9.09090909090909, + "maxMean": 7.386363636363637, + "maxMeanConc": 1.6989700043360187, + "maxMed": 7.386363636363637, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 134, + "m5id": 5030879, + "modl": "poly1", + "hitc": 4.481617968402787E-5, + "fitc": 13, + "coff": 20.559343612658036, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + -1.6989700043360187, + -1.154901959985743, + -0.6989700043360187, + -0.22184874961635637, + 1.3010299956639813, + 0.3010299956639812, + 1.6989700043360187 + ], + "resp": [ + -7.702020202020201, + 2.904040404040405, + -2.904040404040403, + -0.9469696969696955, + -8.143939393939391, + -3.5984848484848477, + -9.09090909090909, + 7.386363636363637 + ] + }, + "mc4Param": { + "pow_a": 7.38792442803479E-8, + "pow_p": 4.707344288793977, + "exp2_a": 9.720535659483423E-7, + "exp2_b": 3.155293427742727, + "exp3_a": 10.992475308914631, + "exp3_b": 54.33735479981147, + "exp3_p": 7.997291932162272, + "exp5_p": 7.999998484010299, + "gnls_p": 7.999999892071809, + "gnls_q": 2.9607003309368434, + "hill_p": 7.9999961146922605, + "pow_er": 1.5635126278095273, + "cnst_er": 1.719984746193826, + "exp2_er": 1.5591089362306945, + "exp3_er": 1.559419875600755, + "exp4_er": 1.6883920413738989, + "exp4_ga": 74.80480041333628, + "exp4_tp": 8.863636346356905, + "exp5_er": 1.5607744582298897, + "exp5_ga": 44.417660789138985, + "exp5_tp": 8.863603105060312, + "gnls_er": 1.561195254781372, + "gnls_ga": 41.16217714273171, + "gnls_la": 1968.4261784520863, + "gnls_tp": 8.863620744215016, + "hill_er": 1.5615418348405026, + "hill_ga": 41.134292358351026, + "hill_tp": 8.85885765273257, + "poly1_a": 0.0916727261027705, + "poly2_a": 0.00003275646438816725, + "poly2_b": 0.11084829353336607, + "pow_aic": 56.802529668867656, + "pow_cov": 1, + "pow_rme": 5.474106464958057, + "pow_top": 7.347831543130136, + "all_bmed": 0, + "cnst_aic": 54.82949934043421, + "cnst_rme": 6.057646057469498, + "exp2_aic": 56.76807692440605, + "exp2_cov": 1, + "exp2_rme": 5.465880012590823, + "exp2_top": 7.407786706660837, + "exp3_aic": 58.76914315577856, + "exp3_cov": 1, + "exp3_rme": 5.466134248427126, + "exp3_top": 7.388890198629367, + "exp4_aic": 58.3862013644993, + "exp4_cov": 1, + "exp4_rme": 5.91931768956607, + "exp4_top": 8.863636346356905, + "exp5_aic": 58.771451215856445, + "exp5_cov": 1, + "exp5_rme": 5.466684000894818, + "exp5_top": 8.863603105060312, + "gnls_aic": 62.777644709625726, + "gnls_cov": 1, + "gnls_rme": 5.468147134258676, + "gnls_top": 8.859894820651965, + "hill_aic": 58.77767023528245, + "hill_cov": 1, + "hill_rme": 5.468153598929289, + "hill_top": 8.85885765273257, + "poly1_er": 1.6708188343034331, + "poly2_er": 1.603520396966836, + "pow_a_sd": 0.0000014804515060319311, + "pow_ac50": 43.15399398938185, + "pow_p_sd": 0.148714056473758, + "all_onesd": 9.788806432103662, + "exp2_a_sd": 0.00000229547866974318, + "exp2_ac50": 47.81291767075994, + "exp2_b_sd": 0.1144483227925822, + "exp3_a_sd": null, + "exp3_ac50": 46.540170334040354, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 74.80480041333628, + "exp5_ac50": 44.417660789138985, + "exp5_p_sd": 30.83791719208217, + "gnls_ac50": 41.157961075007606, + "gnls_p_sd": 20.623651182531617, + "gnls_q_sd": 917.2489266479544, + "hill_ac50": 41.134292358351026, + "hill_p_sd": 20.755167151874623, + "poly1_aic": 56.20208741239672, + "poly1_cov": 1, + "poly1_rme": 5.879174343453156, + "poly1_top": 4.5836363051385245, + "poly2_aic": 57.24725841856889, + "poly2_cov": 1, + "poly2_rme": 5.591373578271515, + "poly2_top": 6.679450797669966, + "pow_er_sd": 0.31476622758872136, + "exp2_er_sd": 0.31494236846040924, + "exp3_er_sd": null, + "exp4_er_sd": 0.3050999358871871, + "exp4_ga_sd": 206.23903994982948, + "exp4_tp_sd": 24.866384140473222, + "exp5_er_sd": 0.3151258300122656, + "exp5_ga_sd": 133.05442859689597, + "exp5_tp_sd": 82.18120992121477, + "gnls_er_sd": 0.31519605639597137, + "gnls_ga_sd": 64.74140517770995, + "gnls_la_sd": 2232417.631488272, + "gnls_tp_sd": 23.216264261253723, + "hill_er_sd": 0.3152310297032542, + "hill_ga_sd": 66.03127922964485, + "hill_tp_sd": 23.585311596930016, + "poly1_a_sd": 0.10105939936781418, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 0.000828471087305424, + "poly2_ac50": 35.339127399684344, + "poly2_b_sd": 1.4052316063819617, + "poly1_er_sd": 0.30563589696444254, + "poly2_er_sd": 0.31148611469958, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 1968.9852136355971 + }, + "mc5Param": { + "a": 0.0916727261027705, + "er": 1.6708188343034331, + "ac5": 2.5, + "bmd": 144.0461131493368, + "bmr": 13.20509987690784, + "mll": -26.10104370619836, + "top": 4.5836363051385245, + "ac10": 5, + "ac20": 10, + "ac50": 24.999999999999996, + "bmdl": 52.7459473602489, + "rmse": 5.879174343453156, + "ac1sd": 106.77992079268851, + "caikwt": 0.6651420101678049, + "hitcall": 0.00004481617968402787, + "top_over_cutoff": 0.22294662667715023 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 9 + ] + } + }, + { + "aeid": 647, + "m4id": 1836494, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 2.8724632813460445, + "respMax": 24.5911214953271, + "respMin": -15.344176851186198, + "maxMean": 24.5911214953271, + "maxMeanConc": -0.6989700043360187, + "maxMed": 24.5911214953271, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 1, + "tmpi": 176, + "m5id": 5031140, + "modl": "poly1", + "hitc": 7.691234876598405E-4, + "fitc": 13, + "coff": 20.0, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + 0.3010299956639812, + -0.6989700043360187, + 1.3010299956639813, + 0.7781512503836436 + ], + "resp": [ + 0.31002875629043825, + -4.23705966930266, + 4.23705966930266, + -10.65330697340043, + -15.344176851186198, + 24.5911214953271, + -3.338425593098491, + 4.084291876347951 + ] + }, + "mc4Param": { + "pow_a": 0.0000015333586251507758, + "pow_p": 0.3766871063745604, + "exp2_a": 0.0000011936693923752977, + "exp2_b": 75.25835790295875, + "exp3_a": 0.0006569488939842799, + "exp3_b": 96.83528802743167, + "exp3_p": 7.800663857633126, + "exp5_p": 7.937542044894579, + "gnls_p": 0.729162061739079, + "gnls_q": 7.999999989113995, + "hill_p": 7.874824062203916, + "pow_er": 2.14936705216903, + "cnst_er": 2.149647244900154, + "exp2_er": 2.1499314425778753, + "exp3_er": 2.150315520704397, + "exp4_er": 2.149639800584959, + "exp4_ga": 19.434543462158643, + "exp4_tp": 1.1341713592504431E-9, + "exp5_er": 2.1496833837069445, + "exp5_ga": 116.5095827986136, + "exp5_tp": 0.0024033220782305803, + "gnls_er": 2.16232385103293, + "gnls_ga": 0.014951651893028646, + "gnls_la": 0.4728127504187675, + "gnls_tp": 11.2206197033088, + "hill_er": 2.1496462163421155, + "hill_ga": 158.06723237834862, + "hill_tp": 0.09087731268651236, + "poly1_a": 1.2510975773993083E-9, + "poly2_a": 0.000010622282859787738, + "poly2_b": 65.91494218290552, + "pow_aic": 67.2883088418402, + "pow_cov": 1, + "pow_rme": 11.277677799643604, + "pow_top": 0.000006693046390825522, + "all_bmed": 0, + "cnst_aic": 63.288305947678175, + "cnst_rme": 11.277676854033178, + "exp2_aic": 67.2883069898754, + "exp2_cov": 1, + "exp2_rme": 11.27767700055377, + "exp2_top": 0.0000011259662475929594, + "exp3_aic": 69.28831082872938, + "exp3_cov": 1, + "exp3_rme": 11.27767730254966, + "exp3_top": 0.000003797491381994292, + "exp4_aic": 67.28830594801778, + "exp4_cov": 1, + "exp4_rme": 11.277676854167195, + "exp4_top": 1.1341713592504431E-9, + "exp5_aic": 69.2883064884335, + "exp5_cov": 1, + "exp5_rme": 11.277677092560204, + "exp5_top": 0.0024033220782305803, + "gnls_aic": 72.17919094570237, + "gnls_cov": 1, + "gnls_rme": 9.771294007073369, + "gnls_top": 9.896104475278875, + "hill_aic": 69.28830869470625, + "hill_cov": 1, + "hill_rme": 11.277678096478796, + "hill_top": 0.09087731268651236, + "poly1_er": 2.1496851424365406, + "poly2_er": 2.1489661386583347, + "pow_a_sd": null, + "pow_ac50": 7.939966888042317, + "pow_p_sd": null, + "all_onesd": 10.104413980537656, + "exp2_a_sd": null, + "exp2_ac50": 29.078168746553875, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 45.7572447748528, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 19.434543462158643, + "exp5_ac50": 116.5095827986136, + "exp5_p_sd": null, + "gnls_ac50": 0.01079980647197256, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 158.06723237834862, + "hill_p_sd": null, + "poly1_aic": 65.28830598103433, + "poly1_cov": 1, + "poly1_rme": 11.2776768623634, + "poly1_top": 6.255487886996541E-8, + "poly2_aic": 67.28831401939081, + "poly2_cov": 1, + "poly2_rme": 11.277678682582888, + "poly2_top": 0.000014169663550936488, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.4105028884852779, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.16200653088329, + "poly2_b_sd": null, + "poly1_er_sd": 0.6280287466170111, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.47847525919124695 + }, + "mc5Param": { + "a": 1.2510975773993083E-9, + "er": 2.1496851424365406, + "ac5": 2.4999999999999996, + "bmd": 10895116980.467772, + "bmr": 13.6308544597453, + "mll": -30.644152990517163, + "top": 6.255487886996541E-8, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 86.00840841895133, + "rmse": 11.2776768623634, + "ac1sd": 8076439570.398645, + "caikwt": 0.7310585819091135, + "hitcall": 0.0007691234876598405, + "top_over_cutoff": 3.12774394349827E-9 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2", + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 13, + 9 + ] + } + }, + { + "aeid": 679, + "m4id": 1839401, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 5.621579363521706, + "respMax": 14.08123821744849, + "respMin": -6.612486732252886, + "maxMean": 14.08123821744849, + "maxMeanConc": 0.3010299956639812, + "maxMed": 14.08123821744849, + "maxMedConc": 0.3010299956639812, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 133, + "m5id": 5034047, + "modl": "exp4", + "hitc": 3.7196432829375366E-15, + "fitc": 13, + "coff": 33.72947618113024, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -1.6989700043360187, + 0.3010299956639812, + -1.154901959985743, + 0.7781512503836436, + -0.22184874961635637, + -0.6989700043360187, + 1.3010299956639813, + 1.6989700043360187 + ], + "resp": [ + 2.2780919791518146, + 14.08123821744849, + -2.2780919791518137, + -6.612486732252886, + 10.679150230502348, + 13.089523628471415, + 4.467468276222602, + 6.318616035359553 + ] + }, + "mc4Param": { + "pow_a": 2.240045406368432, + "pow_p": 0.30000049943105944, + "exp2_a": 112.98083072982448, + "exp2_b": 865.8254929535174, + "exp3_a": 4.545028620685052, + "exp3_b": 65.7285988399926, + "exp3_p": 0.3000003150791311, + "exp5_p": 7.999999018346869, + "gnls_p": 0.300091098903469, + "gnls_q": 7.550849029707361, + "hill_p": 0.30000000017227746, + "pow_er": 1.9084326032965633, + "cnst_er": 2.050383693644464, + "exp2_er": 1.951409270215791, + "exp3_er": 1.9203767699862313, + "exp4_er": 1.6754549302442965, + "exp4_ga": 0.07329301415768419, + "exp4_tp": 7.710786101521187, + "exp5_er": 1.513226499207291, + "exp5_ga": 0.1453438995327829, + "exp5_tp": 8.610190191604286, + "gnls_er": 1.8470198467698633, + "gnls_ga": 0.29231631165137606, + "gnls_la": 59.66977501585602, + "gnls_tp": 9.655899171708228, + "hill_er": 1.882783861146438, + "hill_ga": 54.87345686534822, + "hill_tp": 16.841921803354463, + "poly1_a": 0.13427234808054894, + "poly2_a": 163.94604679311635, + "poly2_b": 1270.0524640798787, + "pow_aic": 62.22501034060233, + "pow_cov": 1, + "pow_rme": 7.635077607201984, + "pow_top": 7.243503453530403, + "all_bmed": 0, + "cnst_aic": 60.31637953410401, + "cnst_rme": 8.643268453824428, + "exp2_aic": 63.20845198455855, + "exp2_cov": 1, + "exp2_rme": 8.236056037957985, + "exp2_top": 6.716525076559469, + "exp3_aic": 64.52332339400041, + "exp3_cov": 1, + "exp3_rme": 7.810212289193087, + "exp3_top": 6.873721691967609, + "exp4_aic": 59.07676009097395, + "exp4_cov": 1, + "exp4_rme": 6.585985949819935, + "exp4_top": 7.710786101521187, + "exp5_aic": 59.34963698633271, + "exp5_cov": 1, + "exp5_rme": 6.313571586200532, + "exp5_top": 8.610190191604286, + "gnls_aic": 66.68700367035977, + "gnls_cov": 1, + "gnls_rme": 7.005486126644505, + "gnls_top": 7.69073998343443, + "hill_aic": 63.70370651182299, + "hill_cov": 1, + "hill_rme": 7.371748953581798, + "hill_top": 16.841921803354463, + "poly1_er": 1.9514160891689865, + "poly2_er": 1.953269884448892, + "pow_a_sd": null, + "pow_ac50": 4.960647368144271, + "pow_p_sd": null, + "all_onesd": 9.193701942255004, + "exp2_a_sd": 2618.1000472689234, + "exp2_ac50": 25.360877092869007, + "exp2_b_sd": 19534.177463369564, + "exp3_a_sd": null, + "exp3_ac50": 9.693473276544648, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.07329301415768419, + "exp5_ac50": 0.1453438995327829, + "exp5_p_sd": 21.257608326450363, + "gnls_ac50": 0.07386566609090593, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 54.87345686534822, + "hill_p_sd": null, + "poly1_aic": 61.20659443782829, + "poly1_cov": 1, + "poly1_rme": 8.235017480262172, + "poly1_top": 6.713617404027446, + "poly2_aic": 63.209083993314835, + "poly2_cov": 1, + "poly2_rme": 8.236417282123691, + "poly2_top": 6.708398029005737, + "pow_er_sd": null, + "exp2_er_sd": 0.32176579624163837, + "exp3_er_sd": null, + "exp4_er_sd": 0.32290193845118853, + "exp4_ga_sd": 0.07925814316759382, + "exp4_tp_sd": 2.776801163350604, + "exp5_er_sd": 0.3377590868121545, + "exp5_ga_sd": 0.14972218569452714, + "exp5_tp_sd": 2.4071558977199987, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.11707993441117576, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 3437.347970091856, + "poly2_ac50": 25.473296332973103, + "poly2_b_sd": 25758.50715822951, + "poly1_er_sd": 0.32179810050301344, + "poly2_er_sd": 0.32190869935481625, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 60.347790496302295 + }, + "mc5Param": { + "er": 1.6754549302442965, + "ga": 0.07329301415768419, + "tp": 7.710786101521187, + "ac5": 0.005423725663435604, + "bmr": 12.402303920102002, + "mll": -26.538380045486974, + "top": 7.710786101521187, + "ac10": 0.01114076487987984, + "ac20": 0.023595080416335745, + "ac50": 0.07329301415768419, + "rmse": 6.585985949819935, + "caikwt": 0.34982472852238994, + "hitcall": 3.7196432829375366E-15, + "top_over_cutoff": 0.22860675511572107 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + }, + { + "aeid": 704, + "m4id": 1842443, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 3.7634679299683276, + "respMax": 5.412234762165331, + "respMin": -10.497225111686998, + "maxMean": 5.412234762165331, + "maxMeanConc": -0.6989700043360187, + "maxMed": 5.412234762165331, + "maxMedConc": -0.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 0, + "tmpi": 42, + "m5id": 5037089, + "modl": "poly1", + "hitc": 1.3111515548405657E-6, + "fitc": 13, + "coff": 22.580807579809964, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.6989700043360187, + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.154901959985743 + ], + "resp": [ + -10.497225111686998, + -8.271301702212094, + 5.412234762165331, + -0.5697089223331855, + -5.4107315723966085, + -1.152645914630851, + -9.935332776150975, + 0.5697089223331855 + ] + }, + "mc4Param": { + "pow_a": 5.868021963410569E-8, + "pow_p": 0.31010469927487905, + "exp2_a": 0.00000820221770260021, + "exp2_b": 63.67412912081, + "exp3_a": 0.000015100154689265508, + "exp3_b": 66.7682650559194, + "exp3_p": 4.045012130124175, + "exp5_p": 2.5184566900851344, + "gnls_p": 1.004146220375644, + "gnls_q": 7.988324375445398, + "hill_p": 2.638717782813107, + "pow_er": 1.748991997794754, + "cnst_er": 1.749320687470586, + "exp2_er": 1.7502584913338175, + "exp3_er": 1.7494323994898786, + "exp4_er": 1.7493097643658628, + "exp4_ga": 3.3432891621411227, + "exp4_tp": 3.7125542218244536E-10, + "exp5_er": 1.7493111824172694, + "exp5_ga": 3.185722315810508, + "exp5_tp": 5.594093755272163E-10, + "gnls_er": 1.7165456563641568, + "gnls_ga": 0.015706640010627146, + "gnls_la": 0.4966875709539269, + "gnls_tp": 2.580846160887361, + "hill_er": 1.749345944481645, + "hill_ga": 33.73657111465509, + "hill_tp": 4.159714315410043E-9, + "poly1_a": 2.671599719093895E-11, + "poly2_a": 0.000005233244887677393, + "poly2_b": 60.3011801386689, + "pow_aic": 59.65799055310836, + "pow_cov": 1, + "pow_rme": 6.498682968118529, + "pow_top": 1.9740143842658864E-7, + "all_bmed": 0, + "cnst_aic": 55.65798921703397, + "cnst_rme": 6.498682892070479, + "exp2_aic": 59.65800315845096, + "exp2_cov": 1, + "exp2_rme": 6.4986846045958355, + "exp2_top": 0.000009784846486708034, + "exp3_aic": 61.657991223897305, + "exp3_cov": 1, + "exp3_rme": 6.4986834826679445, + "exp3_top": 0.00000549637162559571, + "exp4_aic": 59.65798921968127, + "exp4_cov": 1, + "exp4_rme": 6.498682892244033, + "exp4_top": 3.7125542218244536E-10, + "exp5_aic": 61.65798921951322, + "exp5_cov": 1, + "exp5_rme": 6.498682892347669, + "exp5_top": 5.594093755272163E-10, + "gnls_aic": 65.24298472190893, + "gnls_cov": 1, + "gnls_rme": 6.371147760432374, + "gnls_top": 2.422030692633518, + "hill_aic": 61.65798922272976, + "hill_cov": 1, + "hill_rme": 6.498682892532436, + "hill_top": 4.159714315410043E-9, + "poly1_er": 1.7493384697041403, + "poly2_er": 1.749869269967504, + "pow_a_sd": null, + "pow_ac50": 5.348516727471637, + "pow_p_sd": null, + "all_onesd": 6.885946392795786, + "exp2_a_sd": null, + "exp2_ac50": 29.786661402010136, + "exp2_b_sd": null, + "exp3_a_sd": null, + "exp3_ac50": 42.90853049989956, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 3.3432891621411227, + "exp5_ac50": 3.185722315810508, + "exp5_p_sd": null, + "gnls_ac50": 0.013892709273921892, + "gnls_p_sd": null, + "gnls_q_sd": null, + "hill_ac50": 33.73657111465509, + "hill_p_sd": null, + "poly1_aic": 57.65798921945516, + "poly1_cov": 1, + "poly1_rme": 6.49868289233687, + "poly1_top": 1.335799859546947E-9, + "poly2_aic": 59.65799619491047, + "poly2_cov": 1, + "poly2_rme": 6.498684235032681, + "poly2_top": 0.000007937241563467504, + "pow_er_sd": null, + "exp2_er_sd": null, + "exp3_er_sd": null, + "exp4_er_sd": null, + "exp4_ga_sd": null, + "exp4_tp_sd": null, + "exp5_er_sd": null, + "exp5_ga_sd": null, + "exp5_tp_sd": null, + "gnls_er_sd": null, + "gnls_ga_sd": null, + "gnls_la_sd": null, + "gnls_tp_sd": null, + "hill_er_sd": null, + "hill_ga_sd": null, + "hill_tp_sd": null, + "poly1_a_sd": 0.32379470628075435, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": null, + "poly2_ac50": 30.40176401368837, + "poly2_b_sd": null, + "poly1_er_sd": 0.7320994661619505, + "poly2_er_sd": null, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 0.5007494385640836 + }, + "mc5Param": { + "a": 2.671599719093895E-11, + "er": 1.7493384697041403, + "ac5": 2.4999999999999996, + "bmd": 347699605501.9814, + "bmr": 9.289141683881516, + "mll": -26.82899460972758, + "top": 1.335799859546947E-9, + "ac10": 4.999999999999999, + "ac20": 9.999999999999998, + "ac50": 24.999999999999996, + "bmdl": 108.3553281419698, + "rmse": 6.49868289233687, + "ac1sd": 257746186435.86465, + "caikwt": 0.7310585788680222, + "hitcall": 0.0000013111515548405657, + "top_over_cutoff": 5.915642542126427E-11 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability", + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 9, + 13 + ] + } + }, + { + "aeid": 714, + "m4id": 1847540, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.065604241325404, + "respMax": 90.80446870746331, + "respMin": -5.707883228590463, + "maxMean": 90.62049611334439, + "maxMeanConc": 1.6989700043360187, + "maxMed": 90.62049611334439, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 16, + "nrep": 2.0, + "nmedGtbl": 6, + "tmpi": 1280, + "m5id": 5042186, + "modl": "hill", + "hitc": 0.9999999999990554, + "fitc": 42, + "coff": 24.393625447952424, + "actp": null, + "modelType": 2, + "chidRep": 1, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + -0.22184874961635637, + -0.6989700043360187, + 0.7781512503836436, + 0.3010299956639812, + -0.22184874961635637, + -0.6989700043360187, + -1.154901959985743, + 1.3010299956639813, + 0.7781512503836436, + 1.3010299956639813, + 0.3010299956639812, + -1.154901959985743, + -1.6989700043360187, + 1.6989700043360187, + -1.6989700043360187, + 1.6989700043360187 + ], + "resp": [ + 23.65294390222711, + 14.242737988357604, + 72.43005879116106, + 46.484959502640294, + 55.886726620789105, + 28.84492825461404, + 5.707883228590464, + 88.63403737583766, + 80.03489098177559, + 80.0297093264599, + 74.69438203693808, + 3.5586226430884302, + -5.707883228590463, + 90.80446870746331, + -3.5586226430884302, + 90.43652351922545 + ] + }, + "mc4Param": { + "pow_a": 32.911138431472224, + "pow_p": 0.3000000797458051, + "exp2_a": 10308.09931192428, + "exp2_b": 4751.077023800089, + "exp3_a": 1269.4299811454289, + "exp3_b": 214861.03156835592, + "exp3_p": 0.30000013149029114, + "exp5_p": 0.7104729913327161, + "gnls_p": 0.955542591689892, + "gnls_q": 7.509065539947891, + "hill_p": 0.9555341491157984, + "pow_er": 2.641957951988852, + "cnst_er": 3.95904849507247, + "exp2_er": 3.4960111520069024, + "exp3_er": 2.6880458922007326, + "exp4_er": 2.098857080265625, + "exp4_ga": 0.7897221222126788, + "exp4_tp": 83.97402405983311, + "exp5_er": 1.9948049077180752, + "exp5_ga": 1.2342906618623586, + "exp5_tp": 87.8897045568669, + "gnls_er": 1.9847399896737128, + "gnls_ga": 1.0031443070703985, + "gnls_la": 557.0432143919979, + "gnls_tp": 91.01391582017716, + "hill_er": 1.9847477692501443, + "hill_ga": 1.003191124397109, + "hill_tp": 91.01447500018872, + "poly1_a": 2.1865425331680353, + "poly2_a": 14664.260556155692, + "poly2_b": 6767.106371403012, + "pow_aic": 141.82653772826615, + "pow_cov": 1, + "pow_rme": 16.068716512669607, + "pow_top": 106.42264340458804, + "all_bmed": 0, + "cnst_aic": 179.848625362541, + "cnst_rme": 58.56882891622411, + "exp2_aic": 169.61132698024198, + "exp2_cov": 1, + "exp2_rme": 38.21336628800247, + "exp2_top": 109.05454587381912, + "exp3_aic": 144.43145465266923, + "exp3_cov": 0, + "exp3_rme": 16.37845865253221, + "exp3_top": 107.50377103361215, + "exp4_aic": 126.23812256465268, + "exp4_cov": 1, + "exp4_rme": 10.334639998161537, + "exp4_top": 83.97402405983311, + "exp5_aic": 125.99404191588884, + "exp5_cov": 1, + "exp5_rme": 10.04248749715944, + "exp5_top": 87.8897045568669, + "gnls_aic": 128.4085145582657, + "gnls_cov": 1, + "gnls_rme": 9.09129189490256, + "gnls_top": 90.40700949566956, + "hill_aic": 124.40851436294564, + "hill_cov": 1, + "hill_rme": 9.09135696458556, + "hill_top": 91.01447500018872, + "poly1_er": 3.4963072277205045, + "poly2_er": 3.4967033306110524, + "pow_a_sd": 5.539590328742932, + "pow_ac50": 4.960631334085256, + "pow_p_sd": 0.05065285664483593, + "all_onesd": 36.16048671325037, + "exp2_a_sd": 58049.23115375191, + "exp2_ac50": 25.065774256310934, + "exp2_b_sd": 26637.78941676024, + "exp3_a_sd": null, + "exp3_ac50": 5.304622230963994, + "exp3_b_sd": null, + "exp3_p_sd": null, + "exp4_ac50": 0.7897221222126788, + "exp5_ac50": 1.2342906618623586, + "exp5_p_sd": 0.11448338011960948, + "gnls_ac50": 0.9892404145079376, + "gnls_p_sd": 0.19605463854823008, + "gnls_q_sd": 4028.2837050226367, + "hill_ac50": 1.003191124397109, + "hill_p_sd": 0.1960536175489813, + "poly1_aic": 167.57928052693967, + "poly1_cov": 1, + "poly1_rme": 38.170211145924405, + "poly1_top": 109.32712665840177, + "poly2_aic": 169.62385203407865, + "poly2_cov": 1, + "poly2_rme": 38.225046010433935, + "poly2_top": 109.15012495603122, + "pow_er_sd": 0.22682743340833847, + "exp2_er_sd": 0.22434251903225583, + "exp3_er_sd": null, + "exp4_er_sd": 0.23345662340053935, + "exp4_ga_sd": 0.2852253940608193, + "exp4_tp_sd": 3.843251237417471, + "exp5_er_sd": 0.26681973494160827, + "exp5_ga_sd": 0.3934957270117465, + "exp5_tp_sd": 4.10415190766761, + "gnls_er_sd": 0.2447595646202884, + "gnls_ga_sd": 0.4933082047260317, + "gnls_la_sd": 720123.8796452188, + "gnls_tp_sd": 6.100726679795194, + "hill_er_sd": 0.24476191439739545, + "hill_ga_sd": 0.49331894680155614, + "hill_tp_sd": 6.10085139691297, + "poly1_a_sd": 0.45742366357273334, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 70563.77452581785, + "poly2_ac50": 25.091679894774504, + "poly2_b_sd": 32307.63616776071, + "poly1_er_sd": 0.22427708068428584, + "poly2_er_sd": 0.22436205738666837, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 557.6818189423375 + }, + "mc5Param": { + "p": 0.9555341491157984, + "er": 1.9847477692501443, + "ga": 1.003191124397109, + "tp": 91.01447500018872, + "ac5": 0.04603871449945376, + "acc": 0.3505460195302733, + "bmd": 1.1664879741712382, + "bmr": 48.78049657617475, + "mll": -58.20425718147282, + "top": 91.01447500018872, + "ac10": 0.1006318431871514, + "ac20": 0.23512931816587768, + "ac50": 1.003191124397109, + "bmdl": 0.7135391211625854, + "bmdu": 1.7796567328157402, + "rmse": 9.09135696458556, + "ac1sd": 0.6486166660027173, + "caikwt": 9.148141181839124E-13, + "hitcall": 0.9999999999990554, + "top_over_cutoff": 3.7310761860463177 + }, + "mc6Param": { + "flag": [ + "Bmd > ac50, indication of high baseline variability" + ], + "mc6MthdId": [ + 9 + ] + } + }, + { + "aeid": 719, + "m4id": 1850045, + "spid": "TP0000904H05", + "chid": 45232, + "casn": "51-24-1", + "chnm": "Tiratricol", + "dtxsid": "DTXSID2045232", + "bmad": 4.036116152450091, + "respMax": 107.21526582248697, + "respMin": -2.7450872741675525, + "maxMean": 107.21526582248697, + "maxMeanConc": 1.6989700043360187, + "maxMed": 107.21526582248697, + "maxMedConc": 1.6989700043360187, + "logcMax": 1.6989700043360187, + "logcMin": -1.6989700043360187, + "nconc": 8, + "npts": 8, + "nrep": 1.0, + "nmedGtbl": 5, + "tmpi": 907, + "m5id": 5044691, + "modl": "hill", + "hitc": 0.9999985006475061, + "fitc": 42, + "coff": 24.21669691470054, + "actp": null, + "modelType": 2, + "chidRep": 0, + "stkc": 20.0, + "stkcUnit": "mM", + "testedConcUnit": "uM", + "mc3Param": { + "logc": [ + 1.6989700043360187, + -0.22184874961635637, + 0.3010299956639812, + -1.6989700043360187, + 0.7781512503836436, + 1.3010299956639813, + -0.6989700043360187, + -1.154901959985743 + ], + "resp": [ + 107.21526582248697, + 30.195960015843077, + 23.92147481774581, + -2.7450872741675525, + 70.82325167352285, + 87.60749957843302, + 6.666640522978341, + 2.745087274167552 + ] + }, + "mc4Param": { + "pow_a": 26.38188579595087, + "pow_p": 0.373321688144596, + "exp2_a": 10555.066230255175, + "exp2_b": 4397.549085127513, + "exp3_a": 784.0385960885498, + "exp3_b": 12122.72093512508, + "exp3_p": 0.3638067662358064, + "exp5_p": 0.6706734088210354, + "gnls_p": 0.7940478448675982, + "gnls_q": 4.635795527795299, + "hill_p": 0.7940457988465808, + "pow_er": 2.233770712846338, + "cnst_er": 3.823652826194619, + "exp2_er": 3.112037332406609, + "exp3_er": 2.2207623331779267, + "exp4_er": 1.9257018004052453, + "exp4_ga": 3.8261863681864567, + "exp4_tp": 101.17371650605573, + "exp5_er": 1.851583883281417, + "exp5_ga": 4.388513514529561, + "exp5_tp": 108.53396863931586, + "gnls_er": 1.763196258086566, + "gnls_ga": 5.230735872271651, + "gnls_la": 3728.9702818099768, + "gnls_tp": 123.23260400266716, + "hill_er": 1.7632048386470296, + "hill_ga": 5.230720817485771, + "hill_tp": 123.23247985508776, + "poly1_a": 2.4157216564524493, + "poly2_a": 14475.570423248031, + "poly2_b": 6050.547391426295, + "pow_aic": 66.99572995533279, + "pow_cov": 1, + "pow_rme": 10.165270166462872, + "pow_top": 113.64967185920248, + "all_bmed": 0, + "cnst_aic": 89.66837566455231, + "cnst_rme": 56.71162606585343, + "exp2_aic": 82.18838027457493, + "exp2_cov": 1, + "exp2_rme": 27.76912571036805, + "exp2_top": 120.69563618612736, + "exp3_aic": 69.31400616583988, + "exp3_cov": 1, + "exp3_rme": 10.392779268529251, + "exp3_top": 113.91588681399294, + "exp4_aic": 63.470739630590785, + "exp4_cov": 1, + "exp4_rme": 8.85897961514353, + "exp4_top": 101.17371650605573, + "exp5_aic": 63.473426195943134, + "exp5_cov": 1, + "exp5_rme": 7.367611470284465, + "exp5_top": 108.53396863931586, + "gnls_aic": 66.84742309100423, + "gnls_cov": 1, + "gnls_rme": 7.41641546707749, + "gnls_top": 121.09148833061737, + "hill_aic": 62.84742306797685, + "hill_cov": 1, + "hill_rme": 7.41641875777227, + "hill_top": 123.23247985508776, + "poly1_er": 3.1106053488018537, + "poly2_er": 3.114821770788662, + "pow_a_sd": 5.3252399545122096, + "pow_ac50": 7.809343150454362, + "pow_p_sd": 0.056051948310051315, + "all_onesd": 11.631725174057522, + "exp2_a_sd": 62396.56299440558, + "exp2_ac50": 25.07106192806109, + "exp2_b_sd": 25839.769114659568, + "exp3_a_sd": 1271.834084672146, + "exp3_ac50": 8.152864786253309, + "exp3_b_sd": 47172.61248160081, + "exp3_p_sd": 0.060040388923249574, + "exp4_ac50": 3.8261863681864567, + "exp5_ac50": 4.388513514529561, + "exp5_p_sd": 0.1399475195939742, + "gnls_ac50": 5.006742473448925, + "gnls_p_sd": 0.1854347139300874, + "gnls_q_sd": 6795.493494626446, + "hill_ac50": 5.230720817485771, + "hill_p_sd": 0.1854307163440282, + "poly1_aic": 80.15930580117441, + "poly1_cov": 1, + "poly1_rme": 27.713999426199813, + "poly1_top": 120.78608282262245, + "poly2_aic": 82.20131097823085, + "poly2_cov": 1, + "poly2_rme": 27.795630326649007, + "poly2_top": 120.61051231658656, + "pow_er_sd": 0.2974052783401845, + "exp2_er_sd": 0.33465921260039705, + "exp3_er_sd": 0.29489066888069415, + "exp4_er_sd": 0.3357623948715002, + "exp4_ga_sd": 0.8745068218026666, + "exp4_tp_sd": 7.947871781710462, + "exp5_er_sd": 0.3159497283524588, + "exp5_ga_sd": 1.9622995568669583, + "exp5_tp_sd": 10.681406923273569, + "gnls_er_sd": 0.3405846164664119, + "gnls_ga_sd": 3.020438938884526, + "gnls_la_sd": 23405695.431429833, + "gnls_tp_sd": 17.604579650183712, + "hill_er_sd": 0.34058479447409523, + "hill_ga_sd": 3.020385246373638, + "hill_tp_sd": 17.60426841589827, + "poly1_a_sd": 0.46291777018798136, + "poly1_ac50": 24.999999999999996, + "poly2_a_sd": 72067.05274661083, + "poly2_ac50": 25.102448102487468, + "poly2_b_sd": 29880.417835129876, + "poly1_er_sd": 0.33437412905907915, + "poly2_er_sd": 0.33496016443302623, + "pow_success": 1, + "cnst_success": 1, + "exp2_success": 1, + "exp3_success": 1, + "exp4_success": 1, + "exp5_success": 1, + "gnls_success": 1, + "hill_success": 1, + "poly1_success": 1, + "poly2_success": 1, + "gnls_ac50_loss": 3748.429832774264 + }, + "mc5Param": { + "p": 0.7940457988465808, + "er": 1.7632048386470296, + "ga": 5.230720817485771, + "tp": 123.23247985508776, + "ac5": 0.1282724896705554, + "acc": 0.887855091317106, + "bmd": 0.46326275977400544, + "bmr": 15.691197259803596, + "mll": -27.423711533988424, + "top": 123.23247985508776, + "ac10": 0.3287108931871063, + "ac20": 0.9127320943550252, + "ac50": 5.230720817485771, + "bmdl": 0.33623832625756866, + "bmdu": 0.651275873448465, + "rmse": 7.41641875777227, + "ac1sd": 0.3032690510690583, + "caikwt": 0.0000014993516184967038, + "hitcall": 0.999998500647506, + "top_over_cutoff": 5.088740231136994 + }, + "mc6Param": { + "flag": [ + "Average number of replicates per conc is less than 2" + ], + "mc6MthdId": [ + 13 + ] + } + } +] From 242b338bbf7217dacff25b3c8248fccc0761895d Mon Sep 17 00:00:00 2001 From: cthunes Date: Thu, 18 Apr 2024 18:04:04 -0400 Subject: [PATCH 10/32] 231 added tables to vignette and other small updates --- vignettes/Data_retrieval_via_API.Rmd | 112 +++++++++++++++++++-------- 1 file changed, 81 insertions(+), 31 deletions(-) diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd index 420badc7..2f6bb2b8 100644 --- a/vignettes/Data_retrieval_via_API.Rmd +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -11,22 +11,6 @@ vignette: > %\VignetteEngine{knitr::rmarkdown} %\usepackage[utf8]{inputenc} --- - - - - - ```{css, echo=FALSE} .scroll-300 { @@ -45,6 +29,11 @@ $(document).ready(function() { ```{r setup, include = FALSE} devtools::load_all() +library(DT) +# helper function for printing +printFormattedTable <- function(res_dt, widen = c()) { + datatable(res_dt, style = 'bootstrap', class = 'table-bordered table-condensed', rownames = FALSE, options = list(scrollX = TRUE, autoWidth = TRUE, dom = 't', columnDefs = list(list(width = '1000px', targets = widen)))) +} library(httptest) start_vignette("api") ``` @@ -151,8 +140,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val=704, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By spid ```{r data_by_spid} @@ -162,8 +153,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val="TP0000904H05", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By m4id ```{r data_by_m4id} @@ -173,8 +166,10 @@ mc5 <- tcplLoadData(lvl=5, # data level val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By DTXSID ```{r data_by_dtxsid} @@ -184,54 +179,84 @@ mc5 <- tcplLoadData(lvl=5, # data level val="DTXSID30944145", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # return additional parameters from mc5_param +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc5) ``` ### By level In addition to level 5 data, levels 3, 4, 6, and 'agg' are available to pull from the API. -```{r data_levels} + +#### mc3 + +```{r data_level_3} mc3 <- tcplLoadData(lvl=3, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 3 parameters +``` + +```{r, echo = FALSE} +printFormattedTable(mc3) +``` -head(mc3) +#### mc4 +```{r data_level_4} mc4 <- tcplLoadData(lvl=4, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 4 parameters +``` -head(mc5) +```{r, echo = FALSE} +printFormattedTable(mc4) +``` +#### mc6 + +```{r data_level_6} mc6 <- tcplLoadData(lvl=6, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just level 6 parameters +``` + +```{r, echo = FALSE} +printFormattedTable(mc6, 17) +``` -head(mc6) +#### agg +```{r data_level_agg} agg <- tcplLoadData(lvl="agg", # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=FALSE) # restrict to just agg level parameters +``` + +```{r, echo = FALSE} +printFormattedTable(agg) +``` -head(agg) +### add.fld = TRUE -all_fields <- tcplLoadData(lvl=5, # data level +```{r data_level_5_all} +all_fields <- tcplLoadData(lvl=3, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed add.fld=TRUE) # include all fields - -head(all_fields) ``` +```{r, echo = FALSE} +printFormattedTable(all_fields, 175) +``` ## Load Assay Annotations @@ -244,10 +269,35 @@ To load aeid and aenm as well any other mapped annotations by request, use list("protein", c("Colorimetric", "Fluorescence"))). + +```{r load_aeid_plus} # subset all aeids by using multiple fields -- val must be same length in list form! -aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), val = list("protein", "Colorimetric")) -head(aeids) +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), + val = list("protein", c("Colorimetric", "Fluorescence"))) # list length == 2! +``` + +```{r, echo = FALSE} +printFormattedTable(aeids) +``` + +Add any available fields to the output as desired. If all fields are desired consider using tcplQueryAPI(resource = "assay"). + +```{r load_aeid_all} +# subset all aeids by using multiple fields -- val must be same length in list form! +aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type"), + val = list("protein", c("Colorimetric", "Fluorescence")), + add.fld = c("acid", "assay_component_desc", "signal_direction", "organism")) +``` + +```{r, echo = FALSE} +printFormattedTable(aeids, 5) ``` ### Load acid (in development-tbd) From 66aeaa7f388e80655b526fa816589916f49c3ee6 Mon Sep 17 00:00:00 2001 From: Carter Thunes <135260183+cthunes@users.noreply.github.com> Date: Thu, 23 May 2024 10:38:16 -0400 Subject: [PATCH 11/32] Update tcplPlotUtils.R add in index to flag na/null check --- R/tcplPlotUtils.R | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index 5c771006..e772a0ef 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -51,7 +51,7 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ if (is.null(dat$flag)) { flag <- NA } - dat <- dat %>% rowwise() %>% mutate(flag = ifelse(is.na(flag) || flag == "NULL", "None", paste(flag, collapse = ';\n'))) %>% ungroup() %>% as.data.table() + dat <- dat %>% rowwise() %>% mutate(flag = ifelse(is.na(flag[1]) || flag[1] == "NULL", "None", paste(flag, collapse = ';\n'))) %>% ungroup() %>% as.data.table() dat$conc_unit <- dat$tested_conc_unit } @@ -217,4 +217,4 @@ tcplPlotSetYRange <- function(dat,yuniform,yrange,type){ } } } - \ No newline at end of file + From 1c3131c9d95ceb9eb00c931a5f0271a1f032d559 Mon Sep 17 00:00:00 2001 From: cthunes Date: Thu, 23 May 2024 18:20:23 -0400 Subject: [PATCH 12/32] 231 add rest of tcplLoadXxxx functions and plotting examples --- vignettes/Data_retrieval_via_API.Rmd | 204 +++++++++++++++++++++++---- vignettes/img/API_plot_1847540.jpg | Bin 0 -> 1806255 bytes vignettes/img/API_plot_704.png | Bin 0 -> 401951 bytes vignettes/img/API_plot_compare.png | Bin 0 -> 406411 bytes 4 files changed, 179 insertions(+), 25 deletions(-) create mode 100644 vignettes/img/API_plot_1847540.jpg create mode 100644 vignettes/img/API_plot_704.png create mode 100644 vignettes/img/API_plot_compare.png diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd index 2f6bb2b8..771f8012 100644 --- a/vignettes/Data_retrieval_via_API.Rmd +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -50,7 +50,7 @@ This vignette describes how the user can retrieve ToxCast data (invitrodb v4.1) ## Setup API Connection -After loading tcpl, use the function tcplConf to set options for connecting to the API. Where a regular database connection requires 5 different options to be filled, using an API connection requires just two: $TCPL_PASS and $TCPL_DRVR . These two can be set using tcplConf like the following: +After loading tcpl, use the function tcplConf to set options for connecting to the API. While a regular database connection requires 5 different options to be filled, using an API connection requires just two: $TCPL_PASS and $TCPL_DRVR . These two can be set using tcplConf like the following: ```{r setup-api} tcplConf(pass = "", @@ -103,11 +103,9 @@ mc4_dat <- tcplLoadData( add.fld = FALSE # FALSE will only show fields/columns which are usually # returned for this level, default TRUE will return all available ) -# Print the first 6 rows of 'mc2_fmtd' -head(mc4_dat) ``` -When loading data, the user must indicate the applicable fields and ids which are query-able via the CCTE API. These such fields include and are limited to "AEID", "m4id", "SPID", and "DTXSID". Any other fields will result in error. While supplying multiple ids (val) are valid, multiple fields are not, so combinations of fields are not compatible with tcplLoadData when connected to the API. If some or no data is found, tcplLoadData will return whatever it finds, and list in output which val(s) were not found. Examples of loading data are detailed in later sections. +When loading data, the user must indicate the applicable fields and ids which are query-able via the CCTE API. These such fields include and are limited to "AEID", "m4id", "SPID", and "DTXSID". Any other fields will result in error. While supplying multiple ids (through `val`) are valid, multiple fields are not, so combinations of fields are not compatible with tcplLoadData when connected to the API. If some or no data is found, tcplLoadData will return whatever it finds, and list in output which val(s) were not found. Examples of loading data are detailed in later sections. ### Assay Annotations @@ -139,7 +137,7 @@ mc5 <- tcplLoadData(lvl=5, # data level fld="aeid", # fields to query on val=704, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed - add.fld=FALSE) # return additional parameters from mc5_param + add.fld=FALSE) # restrict to just level 5 parameters ``` ```{r, echo = FALSE} @@ -152,7 +150,7 @@ mc5 <- tcplLoadData(lvl=5, # data level fld="spid", # fields to query on val="TP0000904H05", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed - add.fld=FALSE) # return additional parameters from mc5_param + add.fld=FALSE) # restrict to just level 5 parameters ``` ```{r, echo = FALSE} @@ -165,7 +163,7 @@ mc5 <- tcplLoadData(lvl=5, # data level fld="m4id", # fields to query on val=1842443, # values should match their corresponding 'fld' type = "mc", # data type, default, not needed - add.fld=FALSE) # return additional parameters from mc5_param + add.fld=FALSE) # restrict to just level 5 parameters ``` ```{r, echo = FALSE} @@ -178,7 +176,7 @@ mc5 <- tcplLoadData(lvl=5, # data level fld="dtxsid", # fields to query on val="DTXSID30944145", # values should match their corresponding 'fld' type = "mc", # data type, default, not needed - add.fld=FALSE) # return additional parameters from mc5_param + add.fld=FALSE) # restrict to just level 5 parameters ``` ```{r, echo = FALSE} @@ -275,7 +273,7 @@ aeid <- tcplLoadAeid(fld = "acid", val = 400) printFormattedTable(aeid) ``` -Subset with as many 'fld's as you want! tcplLoadAeid joins the criteria with multiple 'fld' and 'val' as an "AND" rather than "OR", meaning the subset contains rows where all are TRUE. Make sure that 'val' has the same length that 'fld' does. Use a list for 'val' if you want to combine fields of different types (i.e. numeric and string), or of different element lengths (list("protein", c("Colorimetric", "Fluorescence"))). +Subset with as many `fld`s as desired. tcplLoadAeid joins the criteria with multiple `fld` and `val` as an "AND" rather than "OR", meaning the subset returns rows where all are TRUE. Make sure that `val` has the same length that `fld` does. Use a list for `val` if you want to combine fields of different types (i.e. numeric and string), or of different element lengths (list("protein", c("Colorimetric", "Fluorescence"))). ```{r load_aeid_plus} # subset all aeids by using multiple fields -- val must be same length in list form! @@ -300,33 +298,189 @@ aeids <- tcplLoadAeid(fld = c("intended_target_type", "detection_technology_type printFormattedTable(aeids, 5) ``` -### Load acid (in development-tbd) -### Load aid (in development-tbd) -### Load asid (in development-tbd) -### Load unit (in development-tbd) -### Load concentration unit (in development-tbd) +### Load acid -# Plotting (in development-tbd) +Use tcplLoadAcid to load acid and acnm, as well as any other mapped fields. -tcplPlot is tcpl’s single flexible plotting function, allowing for interactive yet consistent visualization of concentration-response curves via customizable parameters. As a standalone plotting utility built with the R library plotly to display the additional curve-fitting models, tcplPlot implements the R library plumber to provide representational state transfer-application programming interface (REST API) functionality. The tcplPlot function requires the selection of a level (`lvl`), field (`fld`), and value (`val`) to load the necessary data and display the associated plots. Level 4, `lvl = 4`, plots the concentration-response series fit by all models. Level 5, `lvl = 5`, extends Level 4 plotting by highlighting the winning model with activity hit call presented. Level 6 multi-concentration plotting, including lists of flags, are not currently supported by tcplPlot. Moreover, only multi-concentration plotting is currently supported. +```{r load_acid} +# load acid and acnm for given aeid +acid <- tcplLoadAcid(fld = "aeid", val = c(663,891)) +``` + +```{r, echo = FALSE} +printFormattedTable(acid) +``` + +Like tcplLoadAeid, tcplLoadAcid can subset with as many `fld`s as desired and can add any available additional fields. + +```{r load_acid_all} +# subset all acids by using multiple fields -- val must be same length in list form! +acids <- tcplLoadAcid(fld = c("organism", "tissue"), + val = list("rat", "liver"), + add.fld = c("aeid", "aid", "asid", "signal_direction")) +``` + +```{r, echo = FALSE} +printFormattedTable(acids) +``` + +### Load aid + +Use tcplLoadAid to load aid and anm, as well as any other mapped fields. + +```{r load_aid} +# load aid and anm for given aeid +aid <- tcplLoadAid(fld = "aeid", val = 663) +``` + +```{r, echo = FALSE} +printFormattedTable(aid) +``` + +Like tcplLoadAeid and tcplLoadAcid, tcplLoadAid can subset with as many `fld`s as desired and can add any available additional fields. + +```{r load_aid_all} +# subset all aids by using multiple fields -- val must be same length in list form! +aids <- tcplLoadAid(fld = c("organism", "tissue"), + val = list("rat", "liver"), + add.fld = c("aeid", "acid", "asid", "signal_direction")) +``` + +```{r, echo = FALSE} +printFormattedTable(aids) +``` + +### Load asid + +Use tcplLoadAsid to load asid and asnm, as well as any other mapped fields. + +```{r load_asid} +# load asid and asnm for given aeid +asid <- tcplLoadAsid(fld = "aeid", val = 663) +``` + +```{r, echo = FALSE} +printFormattedTable(asid) +``` + +Like the other tcplLoad functions, tcplLoadAsid can subset with as many `fld`s as desired and can add any available additional fields. + +```{r load_asid_all} +# subset all asids by using multiple fields -- val must be same length in list form! +asids <- tcplLoadAsid(fld = c("organism", "tissue"), + val = list("rat", "liver"), + add.fld = c("aeid", "acid", "asid", "signal_direction")) +``` + +```{r, echo = FALSE} +printFormattedTable(asids) +``` + +### Load unit + +To load the normalized data type, or response unit, use tcplLoadUnit. Notice how tcplLoadUnit does not use `fld` and `val`, but uses `aeid` as input. + +```{r load_unit} +# load resp_unit for given aeid +unit <- tcplLoadUnit(aeid = c(663, 891)) +``` + +```{r, echo = FALSE} +printFormattedTable(unit) +``` + +### Load concentration unit + +Use tcplLoadConcUnit to load the concentration unit for a specific `spid` or multiple `spid`s. + +```{r load_conc_unit} +# load conc_unit for given spid +conc_unit <- tcplLoadConcUnit(spid = "TP0000904H05") +``` + +```{r, echo = FALSE} +printFormattedTable(conc_unit) +``` + +# Plotting + +tcplPlot is tcpl’s single flexible plotting function, allowing for interactive and consistent visualization of concentration-response curves via customizable parameters. For more details on implementation, parameters and specific customization instructions, refer to the main Data Retrieval vignette. This section will instead focus on the limitations of using the CCTE API as a data source for tcplPlot. + +Like when loading data, the user must indicate the applicable fields and ids which are query-able via the CCTE API. These such fields include and are limited to "AEID", "m4id", "SPID", and "DTXSID". Any other fields will result in error. While supplying multiple ids (through `val`) are valid, multiple fields are not, so combinations of fields are not compatible with tcplPlot when connected to the API. For example, if `fld = "spid"`, no aeid can be specified, meaning every matching spid will be plotted. If `fld = "aeid"`, every sample within the given endpoint(s) will be plotted. If `fld = "m4id"`, only one plot will output for every each m4id input. Therefore, if looking for a specific aeid/spid combo, one should determine the corresponding m4id, like below. + +```{r plot_aeid_spid, eval = FALSE} +# load all matching spids and then subset using the aeid desired to find m4id +mc5 <- tcplLoadData(lvl = 5, + fld = "spid", + val = "TP0000904H05", + type = "mc", + add.fld = FALSE) # 8 rows of data +m4id <- mc5[aeid == 714]$m4id # subset to 1 aeid extract m4id + +# default parameters used here: fld = "m4id", type = "mc" (type can never be "sc" when connected to API) +tcplPlot(val = m4id, output = "jpg", verbose = TRUE, flags = TRUE) +``` -Customization of output is possible by specifying parameters, including `output`, `verbose`, `multi`, `by`, `fileprefix`, `nrow`, `ncol`, and `dpi`. +
![API-sourced plot with parameters: output = "jpg", verbose = TRUE, and flags = TRUE for m4id 1847540](img/API_plot_1847540.jpg)
-- The `output` parameter indicates how the plots will be presented. In addition to outputs viewable with the R console, tcplPlot supports a variety of publication-quality file type options, including raster graphics (PNG, JPG, and TIFF) to retain color quality when printing to photograph and vector graphics (SVG and PDF) to retain image resolution when scaled to large formats. +Use the "compare" feature to supply more m4ids to `compare.val` and compare them one to one with the m4ids in `val`. `val` and `compare.val` must be the same length! -- The `verbose` parameter results in a plot that includes a table containing potency and model performance metrics; `verbose = FALSE` is default and the only option in console outputs. When `verbose = TRUE` the model aic values are listed in descending order and generally the winning model will be listed first. +```{r plot_m4id_compare, eval = FALSE} +# using the data pulled in the previous code chunk 'mc5' +m4id <- mc5$m4id # create m4id vector length == 8 -- The `multi` parameter allows for single or multiple plots per page. `multi = TRUE` is the default option for PDF outputs, whereas `multi = FALSE` is the only option for other outputs. If using the parameter option `multi = TRUE`, the default number of plots per page is set by the `verbose` parameter. The default number of plots per page is either 6 plots per page (`verbose = FALSE`) or 4 plots per page (`verbose = TRUE`). +# default parameters used here: fld = "m4id", type = "mc" (type can never be "sc" when connected to API) +tcplPlot(val = m4id[1:4], + compare.val = m4id[5:8], + output = "pdf", + verbose = TRUE, + multi = TRUE, + flags = TRUE, + yuniform = TRUE, + fileprefix = "API_plot_compare") +``` + +
![API-sourced plot with parameters: output = "pdf", verbose = TRUE, multi = TRUE, flags = TRUE, and yuniform = TRUE for m4ids 1833668, 1834094, 1836233, and 1836494, compared with m4ids 1839401, 1842443, 1847540, and 1850045](img/API_plot_compare.png)
+ +Supply `fld = "aeid"` to plot every curve available in the API for the given endpoint(s). + +```{r plot_aeid, eval = FALSE} +# plot all curves across endpoint(s) +tcplPlot(fld = 'aeid', + val = 704, + output = "pdf", + verbose = TRUE, + multi = TRUE, + yrange = c(-100,100), + fileprefix = "API_plot_704") +``` + +
![Plots with parameters: output = "pdf", verbose = TRUE, multi = TRUE, and yrange = c(-100,100) for aeid 704](img/API_plot_704.png)
-- The `by` parameter indicates how files should be divided, typically by $aeid$ or $spid$. +## Standalone Format Plot with API -- The `fileprefix` parameter allows the user to set a custom filename prefix. The standard filename is tcplPlot_sysDate().output (example: tcplPlot_2023_08_02.jpg) or, if `by` parameter is set, tcplPlot_sysDate()_by.output (example: tcplPlot_2023_08_02_aeid_80.pdf). When a `fileprefix` is assigned the default _tcplPlot_ prefix is replaced with the new filename. (example: myplot_2023_08_02_aeid_80.pdf or myplot_2023_08_02.jpg). +Suppose you have a database where you process dose-response data and wish to make comparison to how it was previously processed in invitrodb v4.1. The API connection supports tcplPlot's standalone plotting feature! Using the utility function tcplPlotLoadData while connected to the API, you can pass along that data to tcplPlot's `dat` parameter and use `compare.val` for the database data. -- The `nrow` parameter specifies the number of rows for the multiple plots per page; this is 2 by default. The `ncol` parameter specifies the number of columns for the multiple plots per page; this is 3 by default. If `verbose = FALSE`, `ncol` is 2. `nrow` and `ncol` can customize the number of plots included per page. Both `nrow` and `ncol` must be greater than 0. While there is no hard coded upper limit to the number of rows and columns, the underlying technology has a dimension limitation of `nrow = 9` and `ncol = 7`. +```{r plot_standalone, eval = FALSE} +# while connected to the CCTE API using tcplConf +api_data <- tcplPlotLoadData(lvl = 5, fld = "aeid", val = 704, type = "mc", flags = TRUE) -- The `dpi` parameter specifies image print resolution for image file output types (PNG, JPG, TIFF, SVG); this is 600 by default. +# fill with database connection information +tcplConf(user="", pass="", db="", drvr="", host="") + +# add +tcplPlot(dat = api_data, + fld = 'aeid', + val = 704, + compare.val = 704, + output = "pdf", + verbose = TRUE, + multi = TRUE, + flags = TRUE, + fileprefix = "API_plot_704") +``` -The following examples demonstrate tcplPlot functionality through available the variety of customization options: +
![Plots with parameters: dat = api_data from tcplPlotLoadData(), output = "pdf", verbose = TRUE, multi = TRUE, and flags = TRUE for comparison of aeid 704 to current database version](img/API_plot_standalone.png)
```{r, include=FALSE} end_vignette() diff --git a/vignettes/img/API_plot_1847540.jpg b/vignettes/img/API_plot_1847540.jpg new file mode 100644 index 0000000000000000000000000000000000000000..34da45b5749409206fbd2cea40a91f6a08b44720 GIT binary patch literal 1806255 zcmeFZcT`i`);1ml0i}cV5)=>+6lsFAh)Nd`5kij$ND~k-fDnj)6lqZuP^1V*lM{qv1s7K5>~=2|;@J!|hZ=X~Z|oAQma z4r11H@Vw&)asd7OP)0#lK=ibFDT=9iuq=OcASfwhnG+6w77)i83n})O3D{iu3Xj9 z*3s3|H@RhM1~s>^w0Cg4>*Va>>irPze3e7XrT!_=UhP1b!j#3xQt<{6gRt0>2RW zg}^Taej)G+fnNyxLf{tyzYzF^z+XjRdL!t(ABz#Ds-y;Y)t76l>}Kw;xT?){`u1x= znoHK|8*MC9OS?EOsO4hZ%!FCgtpm{oxBN!lW1;QpQW5pU#wm4;{h7`c8@4g4&ae9E z4k>GJWs#HTAJJuNQa}u)(+h`;A`}p49YP%c^9t~0t%eY?w+XVzJWBz^e*OI!ekbpr zC4Sx9zY>OLXW1>f3!8sQBr6~^o=qdJh90h1B<*EuKw`lx@04L|!W5AIkR#c}iVMt& z0O!|aqn|2ZpLcWeO&h=32YowTA*~@ygqXk$VC*g^k(4uvO*4(fW7JjVRuD`ViFd^yBXHPwZEQA&~v(sM?V*R^HP9gOS08FNDRLb zjyUOc6jPgj7;n*A=QgKz`a2yBDay+{{hxsu5+|MOiAdi*k0Mc5Q9!fsr+kcT7)wP3V`PAIpY)_(7+k_wfg1;KiGQxCWWu6uHK__^|4IEV_I9*0%6_ zRvp`jJdyHSII<|wsA(jlA6{f!bgt>x1;xTI$J3s0UZ!8^-J$V$*Q+5$gtY8uE+uQ1 zByq=N51kIz{Y-^BI&j3Rn@*XA@b?=Om(+Bw{9}D6c4|SgBF;`rwHNMmS)BC{Gm^Du z(>pnu;;?EG7lF?ByYd{rfElGQHPd`S$kl<7^|_PJGDp5-+=7d}1_|nzOuU}nh@3cq zH+%Q+ki*2S_F4GlXg9eqK#;o8hr&acZQnzFJFfy)vkGG&&fJ%$XBVlK1H&O zDWEH()|?a&7JbAb{$y=kJ(hGZ@__>CCE$)C@hhJa9U?t8WV|RK4MHJgTfO||Bq3tc zdZR)Y?&fv4Rs>Jm)}W0Ukkn@z%&{DzZLzQ?VpofSdVP6gobUG=DR7u z9LtzlJHD5auy30}kouo-B&}>en1M=SDV$(+X__(33i8FDQ9^wC4>~QBO-9?&4JoR+ zt2A5xC|-A9YXuMAwE_CQ1O+MfxHNFpu@t)cjKIUI7i`AbMWP@jUus`%^Gbk7ZfX5N zXZ^tD18Zd~Oy1qK)z5TJARS-($}Y;?pd#YjY>Ir!t!^|_^p&loUM9fK42_&lbh(f? z5+!$?R&Tbiz?GXYVwUQiXZ!iP<>=MEuG4*^#@c$HI@J74-7k|z_4|wA48w>5E9Yd3 zcOzD=5*^CC;wb$YQb7F0;$&{8=AL~X9WvDz5?}K#4YK}O4*6aG zzbDSmAhu31gj1>M(2JA(ube?H>Ys5AlJz?>{n&`D=@y`;|+(32?ji3X=P;IuD)sa7wGSkSz`H~Mbn zf>Ipqwfo(LQ~n9vI^S(hqh`=7D+?Yk3cpP#^U5}>lm;(DFM<;uCPSj?An4SZ>!tR7 zQw~_h$xCPwB-)^9|N>=vz6b(MWkR0+sap?2D3e77k}Vt)AiXv)+a!>CT>K z=GT=+=`xyGy;>bzg--V>M5mX!TF$?5)aacs?Hco{V7U@5JR8+Hpl0~ig&T5rpuFos zXJAHM!JDetdqNS6npjRKnFCFa>>bRYfTo&c$YJwg6z zoyBy${<^9GnAHUem2+}9Z`-#1jaT``13wxvr+QMfno_CE!{wbgKjZ{wrX z;>VedK6K zqZC@^>%4)`$t{e${}n6qsx$C-j&8BN2{CqRO>jhYl5J__lz@WQ=XtsG%lYwAuLj5> zeyTb?al0-4{_PP=0uT0La(mx9M0HmHcO65%S`~2DrCZn~%I=i}TMSL|AgJKtN#MvS zlND*XHpqn=QYxdfERWB<+nU7-91nC1H^aNO*;3>ta;jXt9^cCrbX8; zjI+pD9`X3-PKcEw4-o`rzf>kT+z6Co`Zvu7JFB6;*%Tp{XkI*4Nj?T*zYbb<76s`k zQ|A|(m=Ir26`dSDN7A#ezs_stElbz?gpRh_&}hafq%6Xr7B3dJqwE;=r3HMMRe
  • @jk)$jg~~!f$2nUdDcMsOZQ#*S)wM64y4}`5-TyGfQVP3^GdhkDD#D< zj!|0iO1#i3&vfz>aaz*eEhVj|I{0G>GTKE3_*OC#FV0xpdF~L~X4*T)w#=lFZuDE` zkz0*+%zC4-wt?)YBgyN}vs6FaGLHXpACy!3&bfP)^MpgG07&ZPfQE#h$hA9_LSi4J zRU!qtPzO`MSXiQj==*t!uutzXFlW-q+mngFz^}|igebI0dCgcIY0eA&@{Iz*P`xK0 zxz&ya3hN^D?!BXcdLH`e%r75>mJ+L{q?V3cnK5t_CkJFTL6mNssZVe1p@QkMgW0Vl zAwR~2*!F6IZQN6LaXSUDQ z3a{`TN{)SRV?M44_n?4$%te`twnd^onwT||GkJE@RtCmn2^MeM{2flxZ7R08HgKtNWG*N1d1Msr zDfw)an3F%tyL(=HB21>u2OjcO;v?Xprl){DsiMeAwDKqie|B{KU-wJ?^7TI) z!bp9UK}b)WuB@NTDtw^tfyf1)Vdq&B@jYtfG1zZOL|?7nEcHvC*bR#N*dbZHm4e9A zwJ(bu<5aJO8oJHYv+p)_&A0`O@2g-%a~3+iwlYq}^(o!IMOd>w%x#mQg4t@ixTERP z9&t(ZufB-=f(1F`s3b3}X~_B=-``>|aQ9RD(f&~z@Z>%2DpQNe4&Wdz_~=hi+%ron zx5kAuttf>9(OGZVPrQg%DgSUR{^YpYlMSK0nH#1k*1uB^U9B|ad8tEq z1p6-f_`!P}d+W-`pN4-^a{SW%L;=AnCq`f7Kn=YWf9ayB$j4%<78qNde=^I`LC0lQD?^aW&o{N1NB zD;JBmr6$W88PiM}UM_`yQf_|i&juwa&2(|J4td)wLL1ydc-3-|lKo7Ny&^!{rz#3u zEAswuNZ)^YhPG^*7{D`hf*zdxc4;0`+DQRPE&>Buu?E~isU{6>z%49Xrhpu4=>@Pq zhpWzPs(a}65=R#E(`niVe8N=NYNZ|ZD{_w%DL11tA6(=@^lnv=iM}U_>D>szxeMfQ z16RciQf>zMpC_#tHK$2_MOfL15h4Nzwa(wq*X~_^b)Tw@hx%*8f@P2Z{(AJx=rNfx z)yeWv9m%ktKs;tX|4AqYqVlaM>f0ZV=s%mtUul`Y5cq|_KO=ySP;;VyL~xOiRWWZ0 zD9aKffKMl(YytA|LqZQZ)|KephTKy33ne!}A^VC2SG0&uvn*^bHaItlY z$NIX988Lp^p)m`O-t1`;I@Omks8GbaelJH_iZ5ulCkZKtv7}3W)nZskw#>O@qWfm=Jh{A~-#5 zcwqvbT0qTOS4Nx`Ieb0iIX8eMUYsT3&Q5nkQb2e8-s~xQ*HnffG~eb2LbV!7V+0<( zxYYUN;KF&N$^zW;I5AZ7=6-QB(uqg;$LZjNV}yIR$?)#w2~Iq1NcN5m7rFbq*SsP1 z8IIL&jieR(#!2=%y{UpH2S;ZO@38dP-*3&do1`Wh)yz(+OZ^?`at{r0)BxZ8q$Vz< zRrDs;%y3T+^*;DUfDi>_9lYZdf^g3!E?lN!-PJlo~;NT`w1h4_bAUc%2SA=Il^e{usUC}VVK~m(kk4ex@_DdIU z>X)ihKb9!Bymwib?u_no?iN4|YVZ!JN#==#S30<#vpp%- zW&@MZ1AW&MyhS!uickZi{b~#%x6i7h`NpL5X(Hcfc5C2;!gDqkLU%T}^}K|_a?59} z!dxyr=WxD=oe=3Am=M?us-IapC(>I+sB^ntB*A{lolg0n#h-8S_v5Nz`R9QZhyHG4 zi@(S2_hr zQ`yJq;O(dP{T7<9j%3E(Y3Dr)&Y^%dw2iXtQJ3lN{Vi#SSrWA7Tmk1`ZHHT+i-hAn zyDYeR7%gT%sa-3|U+E82R}kXaT&MmNgpp7B>uGLAblkq8Xa=waU-U z9*)mZlP%imlqn#G9icHeEvADQFzW^r^s^PzKb!9hUf&P~Z*^a~h&>R`Bh2P04&tCT zHUL$z5nE?xKZRm4DzLR1LnLlehbly5qUMcmGkIe!;KNWMYKj^~k0QLbtUfU__6bEn zUaLP=>?V%3acR(R4(ylD3t~GwLCW&F{t{#d0tnZ(AD8i-SlbeBGsayzfSw1PVNASp z|9w{fTk0hk|FTMW!ORA`p6`9zjhhXxKzVW&Pn+JOu0LkUMtJ5e^P!{b^u)#+1M2n3 zw~xH-xGR4Ay}AlWBVi}E84PNif-p%lv+WoZ>IKN{dbG3bLPY~o(un9H4IUyb3l-7j z_I=cQn>z->Nwq$gkTumJV{^N$fi9caPe4$u*?{^<;LR0w+b{K_CDez59YPD@7^#Zl zky_UuuxJvCn;yWL0bU zHRAj2>uL7P3&M}pHG8gs6^Z3|bp(T*U|brzjmMgjHaHN>+jX3dT8SA#q_-p zdZF*#hif6ab5|1JBEq4IT7iGD-r(jy`S(dM1vK}QTZP@HfaGm$@DvbP57Dr*%ko3< zcS4vt0`N@Ylcsz20e!KD>wz&L=dy|3E5! z(7}7g=zw+%xmapF*&?$it|1E8F78-zwBql?Fm`B50$$A5eyXR1_J&S`LnAK*g!-wg z*0GK0k&JIq%pD=}6cG441%!u>qe3C9yqZFSFKC>|8b1}#67qKnE9rOZ_`fuGn?B8r za(`Az^q32#fYc_GAn_mb#EDw7qYlz!{%T=lk5X*UT%qeRGMgV^m;n;Lt_%LrHS4`6 z#rJ)ON!;XXG1poBru8=a&g_=6{NVfaoS&EZuIFZ1OIs#{jmKaU3?eNrXiTw6B@HN~ z8fjOVmrF6!@}kZpv6kHn{3Hy`BGS!zR8AK}7VhNd3@XH5(y;ePW?PQ&r+{h#l~2`! zKSB864NTTrPDO?n^54Z%{osGti@IfxJM3R-HZz39>x#e~cOWlMs z^mJq3S(lkneq?^%>;jn+JRy*V6%6|Sr3s?68N-Yhk6C}mr;(~Y&2%vQElf*1{q?ut zH1C-Cy1yZ<^*Kzdb3OTkCfVeI{P*a@aSG_|>`w7`gA5;E$poL*%a*s-Ft2u>+-HVZPVG!G5+fRGVvLuEl(@J->*1IDM16HkLUaUKI2%_m zym*#SI8WAKp@;N2s&U50o4V_9xioPqLQ4aqeRbEZXxe$ zSACMYgYFz2(G6I5>ruUuG8drKBok8!g%SW_LJOPH&nB4tBmGswrFfyeMgC&{g^NOm zwm<>W34#%Khz)S3Ku9=3@qwM+Q-jfOJzx0ioCDa#c6z9J6sKT37@2X4Nu%j>ChJ$W zr*0Am@;_)d_=H+~)xAHpG5K+~$wcp(`Suf?nxUt;BVX3n$B-Ip+af*+_E>MqhT3XQ zr_&H$wBh8C4(1&XI2!`JMUKYmEhKs5rc5~;K%eJ%l# z&_;b)Dgc!ZEDFaVmMflQ5OJb=pyz}ccMR<{vt2NRtZ^c!d}xwHg|AP|Pm?H=;bDAL zw61|9AtVmnqWj=zRzI+fOJPoRKYH5z#pPwFGMW3zKmePy?TaG6&`K{&wo~0&gy?XVZj!|hSBO>)y)_Blkg(nzp%&;6k{J=;GP}VNSfXg| zIdw|)^KI{swQS_iw`Ui1T=#pXdrpl|;Tdh)Z~u z0|q?}zW&o~*@58wEBW(0Mm&VOa{-Lo?TSAH5m=ZkZu0Z4P9KI0tISX z86`EF9>e!)P(yO%fz*23F|%Rh@YaA7%fX@|!W$oI!k62s?x7X2Si;#-|Wq*!iT zYAp5{ZNi+YuZWw+T^bY*(R`UGb&=QHKZKUay8>|dIM>R2FVxWHtFbe_`)JYL**w5{ z-W5i?Ofsc_E_atwK#$o0EuknwIvE7GJ{e9HfZKBnNlZ>6vo>%ddrJ#}FcD1y$q>95 zMl2wQr2<|yNDNRS&Oi`IrWLj=y#gUp$xuKXI=?@|8itJsYvDt-3UV#)ULII0nsxF0 ztoSZ6`c(>J{P~N*Q1?w#6Ir;QEU{P#t>Mab_vAOgSQLp~wQiYmcpltwq}KCE5I3GS z9j~KRQ{P*z>gG3Mv(@Et>eReAwP*~pF6WMWpcTw)(9p!B^lMpdsy-PW-ZvsITB39t z@_Jja>(-#6sye?x^#FRo-2H5poPmfB^*uU+7NW#<2v;huMb+pSY^8Z|?X z*TH6LAJ%^8S1VBZ?%|PgHAY=K=&sNd+pRz9SR1%Wjpg#0H_z(d;6Z*?4M z;IjZid94I*?=~T$WQohItMH?7f*ylPy7^7rsY-ck-Bd!eIO?U1Clt^Ld;DPZw`B$a zmGSo;&rQNoRXmMHQ;w)(i|MkVKrwaKxl!Kta3%KgzGL{%Z?mp-Lk@XpYGpid_F<~Z z>cy=p)v$K2ih=k4&&lvBU64jcHd)oh=wy15a&qt_rw(8(r1q6&P{%X z3cU@SQU8RkH{HZGd2$nr2W6zorjMqCN_zQ_Evt5@H`vx`)mL;Zh`h6brv{7JyC-j4 z<+XD>N1z@yKN9qq!&0T^QxE?VSJC}MpZyTw&kT~jAA~wTacqN6D13uzB{Ew9oCILTbQJdjRI z)g~&ci~{2I^O-d7e{)Ryv*^|D8P5XeJiYcqSp4^An>5b!lN_f<1MRQh6HS+X&XE|d zx%<2xyG*aXvVx)~78v1^BHVXkFMfzelw7@T$xAn(y$jA0-Yps#FB-w(b)G(?far-q z3+4kUktYRC9WDtR4j7NUAd5eC1Gfr^^^-)V4^r)KJ`jF#KYI6__pY(d10!M@RUz_( zUy{)#Dq0GGBQiedGe98aU?JQHROZdZ|h&o zWM$ce*PfFM$zMt5m5T(ar+Q)$n)i}qmpU9hW+lb8(`={78)x^TzV>P`5^*hD9o|AI ziDv6^@i4vb>)`dR$ya~Ssro&M9^dxbqhH6(E$D<}VjtoISo^q9uft#$bV?^q;j>S& zs+HAdmUP97?~nJ--wX;pUF_O$M9nM5s_g5?$YdC=V_CX1-Pe#8+q{bH&OxVeB<@0m z5%)oR%vofkf3soExV8EC)q}fX!BmmUB_~%VLzD@B z(isLNT_A?K%pTH=oss5?tzcjOCJ-i`C37H7C-h3B!e|f(C1Hd|{3swzrQ^}GS?*72 zE9g$@Eq*3`~hq(OQOn=%{oM(xh61-IYym!p76?t3kTs5%f5MxZYL zh^8VM@zm3>Sa`b7ib`C1M%_>n_tBYWM(pc60#hFpf6%qCgas)MAp#1QRf58QSXx_i zM`@}VRNeLt`GordX4T*%;wwcpe9@M%t=^QPo%#@_gI6JZD!~5#z^rX57syjB(1sIL-hk zuUy#JxAC?+)fEXDiE^4F%er>Yu{3;33XpJ&4E}VIQ0}|M9&e|Uj(S(W7V9eiNK>>hSFC z3slgV`olSYpHz6@d3(+>Bl#!1q7tIBlTmw~Z4LbJ4bE%#%9=*5zw9b|XLK;Ejf}-= zlG{Hm&?Ns|`F;te5MA&;BaVAc1R%N)|D5hHG!qD5%%KyJ&Zs>}R^&GonL}p%-;0Y6 z2tXRcb5%0{lL&IZnKRoxfI_+|s6%c7 zT4iSbUQ9Uiv;4~s{_*AflKw*A7Xp8d!0!U9(>(wg*}gNwa&XL=0$LpU*T8HB@gxN# ziULv%{gH=YvA`>vSIBxo(d2F5QP$AkkC=)e#jA54E>S?+h=fH`pxiRnk~7ar8OQ(!+CX0x;*q7 zj6C9W=%rYa!Svz9g%zeMT+F7M0X9fDn7K~8n-4v_CbA$d? z@qU0oc{`1MRToQ#`m-}kX$bmtBWe6sBgV0h0FSjJ-DW9Uh{KV zd@MB!!7{zu8btN3M-9y=0c#>hD;unM_v0Hj+fTV0*tECENB*dmho|c%r?GM85XWXB z(YSzbU6JV9CcCpeHz0NOIx{L9ww{}_SZ)m({8i{m{p#Ho=m*II{6Zdh!Zr&pcnn=~ z4}ErrK|;p;v_(;FjNXaJ2fVuNr!XBQb(I6sZ|lom->pcK6}@?~-BCn1>fm(e*5r+n z5JI10@`zu{bKQuOFJnR^>gy}|?>W`iy|$|eW{huN2)iL?$X!`6;vTbG`9k_a@5y)z zfz9`{dYJ^msNu&n!j@zB2o2zGrg2{CP{jANqzhRSf3%=|e6hJ!^Qsa&hXd;^$VVTJ zk?52G21t~+wSY|%3n;~?t4zucU&5~E`iLBKJvN%U*a}cb;@Bh&HN4b#Dt>8bFRqgo z0$2SAp15}eN!2YigrPwwA8?lVHJC*lo`wVIQHbl1!8RSaK=b?R)f?C%1U=D#K*x^VC&EI5 z(1I;cfP1TDlC``Vp*ef#N`{W*EX_psYDc(I5vhnTU>u0cL*MaqsGWj6*n>B@Q8Jo* zf_ZdPbTftsLp+03Qi~8|2>m^<(<4oyp2pedE%-6`sp7WMr;Ve-i?&P^Lld0tCbv*s zF1j7MPxsgYsd(&{jXt0=Fm!(BdMRw(MW_4>&=vmc>98V^hVma-YrnbNhGro!8yPZQ`|r+wBfnGM3NeWan78@jcuR%5oR%dbd)d z`;M0plCiC>g|G)Kl;e<4HOIiLb*EtZ_z~@8ypmM9SMNb6j0Z4gnov_cyfEj3*Hf28 zE1uWX8Fns=J=B=OwP`>$vxxF-&=HM!Kh~#b-+7=p9#roNvQ#NfH|ZCUpgAFu(~@V zsR*MPb1~__*qjS|nwBa488DDAp{Tb<>V1Bey4s&cRXku+t%K*?K4TyhP=`zs88c13 z`_G~Uba=zoP0~dm-i1f1?5#|rNiQ3ikvI~p8{QKvV3l8JNhdH>Q9xhs{$4(#PmITiq8scfpj+vHHBEr*=#dxy z`#W4ERqKRVP-&)1+R1*0{v9`o;xz|>ccID}Z+Ga%9!NnfzAE&vE|s|Km%oJilrZ1a zOab5U4_&{=nO?Y<>=gNMSmDsJQ>xa2PExoVNGZ|W6^PmsnelD@i~_C9h&sJ7sQEnH zJ$_#$3t1+o@iugst^>@05wiB9gRzOIjo1v?cKfUZ5Aq*oJl~-K-_Xz{rfzP{eo`Sm z<(=`i->7{RC>292nvqnK-(0v= zU-`muAn)wk+xM?r9DNpedEIWiSbnB5^4(@nbLvgPgkjRnw-v#`jf@K(nmY{D5q%hg z&Eim{C^eH@=MNvvYF~*c^L|UUXgCTa-EYCd9`e>1&!nnqg+-N*HS&JyZdvXkN{DZw z<4IC)yJk=)mPVwdO^fI0yJ>yI%{&`5Az^`~SQL`kHu8quTO3gj4}Lf5;_q0~=;HCl_(YIH+T4zK zb-|!N+6?lPq?qehs#)Eqs2tiXM?#~L#aEXD*eIZ(MMHaHdb6c(v;u#sh)JZHyi6x? zFEgk+_apew2K*Q%Zi=!Vs+*5!{)kB*Ljo()z3Qf$5tRkPVWZ$e=x# zeW%~hgX=D&^%Q#?lIy11Dg_j=zd}s3lJ%uGvE&8Ji3GvHS};ex zmb;jj^;?C#M&WgzWTm&hOm=F4aDeHF{3e65B5TLMNggbu9q;n%s#7WHw_Va%N!Jh} zQ|?C47*v^PkWCfj$6)uM@wD!5$TR!*b$`JT@dkkAfQy)}zD)U$^Kfrq$brVv}i6@EH_``O=MA{^*s*;o5tV9iK1m zeCmMc6MtO#x(?h3Zh~jH?Y#o;v$jvl@?Lb(sNxl0g1I{SB(euUo7j*rOn|+El)?=O|S6*`^Ihq)cmtk z63c;lJEB`g58N)7NnNgso~;aa-$`dQm{HZeyzKvAJ>jLd0=R|cpurD(NymRnCT`+r z;BC%s=tb-Afux3qfl?da53-hENSSf4zNMw*y?9YswGzR+D2u17 zM=$8H^Q2iY4`@lZ5RSYNeadJg9pQQ^@lF60jCR?#&$Xt0K129$ZEQo8#pe!o57$_e zx}98%ew3#R3Gh|zZXSR2kqqDT$PGMQP%z=j&N4CH{o}*#U1?-$VDt3&d1nk?-}c9z z;j^b6r{8=}1$l+8La632aW`AqCSE)cdv}9l+4Pe556)edh=+}tL^p#zEX1KK>PVn| z9u4_U*~;}YK)e66O3{pmStKnnOhPu%|JeC+_K@_%@81}#ir+(?Ghvua*d(V?agBrF%v4Pouf}7w>TFX zjv_cc0j{1$ZRE*i8zn7qGj4%E zpQy_Nok6C@--2jCg842kZePfX#54UZL5#J7H^pp>^uu!FZlAXl``)`BC+${t_I6qVXHQ+Oube` zmgr%IaEd~^gqU%2o7m{>`a4QzDt_cAfm?Z}u`}9@p{Tp99|Oe4F_(6ekP%mSYsx+!WShzxtussv?C%6WTdFC%u_%k;!PDb zLHW7FsP2=zn6pg1#*h0Xj#@2iYf?ZD18@L6TxJyJ{_xPm2+x^vSsr1@|2B*2-Hqdw z12LiG#oat0^2_AvtY(idP}GTbE%zhLzcXk6VyYduNZP4fs*p~=F++1&v*pm4JVGQ!) zwJhS36q&gLqiI{?O<&jxO=42EU3E;hJ}L@ zosdYqCbCf(ne%_BiT~dCg@DYW_atnA$ohvO+|P7%Bo?-Hqs{=}pRLe`e1m|I5!W!6 z;g>{is)Pag>r3guur0mq$^8`wImUJ0X$ne;4^$%8^Z>3tALccY6EMEh4Jn{v0LsNS zw9e1+Z`tbqCV5H_CKS-A@Nx>smILTlQJ4;}-t8GhNE{H6-9K9(-U`{0aD(kkL&(vt z#Jk`fAZAeqNkz!B>@QM46X0$PZ^Yq41YL$M>Hdz$8dWfPqezIegSi zibZ7Mfh0S9AjxilWlM1jg{6S@B)2FaTneNemlM5Ci1O`s3*i zpA;jv-Js2B@<5zur3Fl2uLhpYBG?TQEAW)-070gD2pJWR`C~?S`^?Ys)3kfPJ7l(> z5Y`$ycE`XiazygRwxeALM8tHXuxLk$A)3FcB@xF~b~9tKvzaDHyI|77YT1mNOUdi$ z*?>ar!s&rkMYee9fwMn3D_h?{J@v~ot~Mq2JMzR?#m%odeZ3#^s>sWccsH)9aQ)1eTGCJaq>Vcn`@}Me6#u54=`fLs&J0* zEeHSsaROaHW^i+|B--UXLSfv_4m}9C2LTKN%yH--1$4B$v45^W{YndRr;}xV=ih(XRu5!>UHQ#9IbnQb+_EvyMKOCoPqD7u{^#cGo98u! zUgdcd-Nuw9_brPiPdLc_+@hV&BaFIsOUdj5%+k;W&Ti-_$1?|P)E;n;)&kw8`pVyt_F||Ininczn-R<2K{Iz?Mm`X){W7HX z914M&;ar4)Fv4%F(8Mb{7aP1}WpZo5Rfm?4tOq(69sKcana40z!y+8%c4?Q%_hSq6lKqp%-*GItH}WYq$urRf;_%A>xAx1srA^$wqGZc>iwu%p;XZ zY~|&NF<)BX*$ACvwrWe>9YxPTz9pVx92PJVH|8NMT8+j{;f7o@PMmpsf)PXqg8rN1 zn|*y>wKz9%F$%*Ek-Tmyh`i2TTm39w_?Uir3oDY3=+?$}uLcrRo~m)n(OE{!xVC0p z%xH!l5{porWx8MkZnNx8KOOrhc) z9=bJM@MpxyVhdcB=Jw9rcZ>-fGO}i*UW(b}Tpk3<01&n?wl<0;a{+IQ+8^M{Da55A z&eI=hl+ZfE`^xFN_(l7Ps&sCW^yWtFPM)Hn1zL@GoAqeOji_7l=X*M@Kfu;|X~+;Q zrYHGVZn!3w+CJL+B+NjQaU$=oUHZ$E?N}4ondarlgyH&Oi zu-VRjI-e}*LXP4HVs#(+--g(WemSUE5cCh6?JH9gnL10|cx2^(eZoApS5r3rZs4eQ zT)hT<$wu+vU_Ueo@zZL7$s7hYle!-H{$xU*KbMy(WOSMkss+ZhW8O)vo^p4KI_BBekn0)+)kwZ+@;N_$2pd9a z&|ZR(;Ps}RS?-GVG3EW@?SnwYJ&6rP2+<~qxy)O{qCM? z-FDSsr(^aDKst+V>*E>(K?B3`hRTcK^Cyz!mkX)D8R*)F2jAdlFAR~#=J{XUbnbco zfhH*YL!H;u8x|qwk1qbPT?4GG%2j3+jx-<4j8i}1!xh73Q8eHDerQD-40w3F4VP?f zDle4~3n__Nr;Cv-lo9Yd-Hc6^wzSRihSSJiKgU`0T2q?yrPF;iyVwV|tVEGqBBXVw zW~UhKMg6t>nJs=h2sXw?FpH%o~ItSCRp8f21MX3t5))?oO|Qy7a@U>iDVj{rLWUlyz=oDkeOmpuBw$C8zfI>bhbR0-q8Z3PFef1ECoGEw8N)y);@Eun>UW0p79GvO#E7t7aE z<0D!Zg~Fc6lHt412slTfpPT+b5AAxNWc#*sFzQFqnZBYk4kcI`8HGM+FYWBqu_+0G zcq6-OiRM#b^T}Fq5(A~RDMzW}^;RY0KMSzd_3M6Y zex*P7uT|JH#at4=TxXaqHlIaZqO-=eLrx%kAt(|w8X{Zv`R@5|EmWW9rZ6hsoLgatjQ=7R5B7o< z_o2V#%_k-%R>PiJzUtH9Cx)zkG$ANGHHR~auj6*?tkEq+*Id9%BuyXl`~&`$LY43r zyKeg*ilH-RISQz7vT&{Rt;5(EGr=o*2jz$6&<+e$UpMgft>ewk@OZ+7=SB}rsvGcw zid&wKAC?vZ*j@fGBIr;b`_5$i#JVR5Zisj@B`Ce30qHHg5Md!>?{Z>SOZ5%#RyY&b zofRR;UIj)bEAx`l2XgE#3DzjbW#pLyZgc$g;J3G3M_Lo!Jb(7$+WWZx8IwKew;F8J zLndl!vmxoiv6v^xj!=>_M~Q% zuQ>5Ki- zj?btU@B1kZF8L276^*`$l`<}`e zNEVKpR)Lxu8e?DMZH2>*czl{lIh<*NWN>*=hDJP*+kBZp(F?=#zO z*^D#PBp4G*fw$OQ#8Vqb=o16c)eCB ztqyj;_TN|jzc($&AR1|I4&WXvjyP}``c`&tJ)m~)o{$fY#pb9C+ORbFvxMi=CTaHz zm$=nqd|y1{_wd1|FnXxV4!vIt;^;*vDvs4$czyJR&DxK;l*gmql`&KHUQ2Q1rB;fi zfVSy@lp!OFa;y64)M?)Tuu8111})eL)6h-w$Enlrpwp1f026LyLa;{GI82h&wd?KdEn7Zy#+0782+r6Jlkd&o?m(> z)c2*$>afx-cuxw~Z@N7gsAy|9%MxO#6ivF~Th#O3m21~m)%VOj=eB|4=Z`OB#_h}t zohOQA`8BjC`H$`AWO({|S3byTi*dh{1uFKJ*!Z*VeI&@{HH{;i+sW6IVtqub-9n{w zKFo#jv>7=H;0yrft?@jOp}EiH{Dk7S`0vGxMMBN-C+vCEUwYffGy_y-^OOvW-n(W$ z+#Q3&D!H-%W?kbL2ZC`I+;k9X3Sgav@EoxFKs0?X8k1>I5j7zOX=!Z+li=oL&V_XT z9iDp{oUTtrB;waHE1w$SW$y#_qo5f;ATG2WYV)&%S!U{Xiq<+8&6tp`S<3?N#WY1t z!{iZ=io_o?;t{9943r2l%wEH$&9WrWY0Of|3s&V8+muzqy|O%>!biGYfN(t?5l z0wN+kBot}V6chxcNfRj%=?I~N^iJq4^qK&HKtlXqJm=i+ZqMC&f9IS#{_&6T?=dsb z_nq$wuvl4ZmS;XwTjaJqQ;}~ZGaX>6{QJsH*FcJ-+cv4b{BC+jIWPS>|0^{TH}&%Z zZ}lsd&ur(`!DLJP>Q3;BZ0&>>iYLa^PKIpD(#%?cLSKHL1i-!!Vl#GR{rI9mjQoO| zP{phBY%9;0S~{pW=-7;IBw#JWCoHg2U!z+LOC;RD$^U-?&?;4ripM)CC2s?740N|Io&>H8Un z^MWlaLhR2pZkb?elU{igr&vtuXgBPAiEGvIJ%4AHCFOQQ08KxKpg+iCx(wwHJxQ>? z(o`Q86GC_(9UXu8cGiZ#mGqFKOrIsS7(j#uCl~|b{L-+0M6k3t+fuEqs0>}Y{*1c6 z_9=F*JC>0rsg_@DCb5#O@eV-_=`uzyhjjwh$Bc(%8mWutAri_JKC5O<(^X--qIjmQ zjMkg+T3^OU*`Dfy)h?shIU&qzrR)y4AwIPMeH#6C=*bBi8Lld42kQ}b=8+HZ`n?U> zB3?G)H*71@_2FS2EdoqNEzBOJ5kGf{o9f%TmC!&0BiR%`8<1{q&z!c0isx@E#-z4y za)g7%b_$}FHT)@J#ErV!#l?ZQy$svmSQy)O&+Udbfu53vnhB^peV2xDkll0I8yL*_ zZx7c&GIG=zw##qF@?E{TxP5x1=aP<5Bo~z#6ShWVk%dLh5XI{xi@^PDz>Bv;2s)bC z;K5k2sL8Skoq|A;w&5)Rj#Vs+oN$0`YfNjf{@Li$pUF@0<5>bH`;RvY`~ZpMOx~ql zXcFDS1U;$Zs&M_R*&ux_Kj;UjRall)Wly3NQ8dkoYFy`8ij>f~CGrru(b93`rgG@> ziCm{uJZ+whqpmi4VVpSu(BYUPfH|-2t8lMf5VtvhQtN zyF>%Np8VR#CD8$DKBvbQuG>5E;RE-7{(y)5fxuI+;vu{;5%tP^-7)tYe8)zIgV3$u zz1)>=P6bM`9Zs-wZmrWzVX1gnPctVxudax|cp+T6iUi`B-c6 z)oCUU=MVQp$J#%ItN@X*&*QBn3YU6A=cVUB@60uBJ{NAIx=K$1p0Cd(GF%Tfc100}gVI+nB8^G6NIspVG7tA5VBMv`6^@ja> zOl=r6Pp?=W1l~KWCK%=|+2$SP)1(hGT)2G6jOco!ywqz`&*o&L45(G|kS;Bcju$L> zwB2)ROmb;zr(G%Sw&ozU$ai{KZfEJurh3>bigXu(&z93HK46@SOVY(eV8I#jfldU(oWOlr!SUw zzOiyRcQ2JBB3fv#-~So_UFf(V_=#1}00g)7iI`WL^>OK;PVl8e$pWz)hCI3|)SwT0 z55EBpJ}jvY$}C0S+TcE|bGuOv?M!u(r7bi&Jd=;gTh~j%G${xz-Z_;N$a#2nx&nVT z%Yu7C-un~Xoci4+{nwysA?5d|W2M9dtY`K_QS-Eynq`MegG3l~-M^OdZki2pqQb%1 zbGuAY?^8}}$6$s;=02_z)>Cl>JM9{_hC*P3f(fiqaw8`jr2xB^jd9Pg5Plp0HdL`a zag9TK=^7h0s+p4>3Ke|S;C)x&8M8XJ7kYlKGIcVh9?DAmreD!Z2nbl~830Se|{WN*|WcLQk^OnKNr-+Erj-wOVi7%^Q%PaGCixYmzoeKK&X#e$@$ zw|VNB?tQHlVFm2vdL%1Rud&-^_$Vf?U0X7|q~$PWE4#AVcx7z# zle_V#_!z9obqc2JRXe8ACTiMNxl2TZCRrq=>8jg2ZJ&|S7ex}Ml z2U}3W!RY!tW!B+Yl{1oO!r#4rzP^(S){J&IvGl}an!Zh7;|9ZKc4u&+OjQ(oT&S;) zP=DgR#>{)xdBda=iuTB}yA^s_S<68}7bBW4Uf6zz_iHk`5!8&*dH(9T#kX4*9Uk6$ zN)E~%Hf#j**hmVTt(0y#-yFVrt)?>g!M6>5lnsns(K+pVXxtX&T;^GYq7yXRX9Cv0 zzuM6Y0O}8O6s;s}jNYElTo#1C;*v0N?5K68-H%Fo=;@hRhYTIyy%Z~zd;MfDAyQe5 z>3yE;`~yWlN^@tvQf2Q{RiiDKqb<%Loxx_W8NwgXX2|XIB@u}CTh0$Aj;EUeqS^Mz zf6VuDXrwOaWN1r}>EMM=&4QCu|Lr#GG_UM_a_)=eU^~V04y;?Bt`}_$Z5(7y)EW1m z(`Kl-1%^Ydg-zwBjlm4Y4PFU1e;XI^k zCL;J@x8iQzQ>PJQPu^SZyjVa^%IWCB+qM)L<&u*%sAWh5Noyb`iE#i`O5Sb639)1Mo&M%%d_w>{6BPji0KDh-7 z0g_gktw8Gg8BqCU7E6*ve)j`1EQ7ZIgZ0kc#iW8ja*%w)zCZAsn%Y0IICwUE!{5Kz`;% z0PtW0LP|xHB5M0N+y8MeB|YT|^0qB@BJ3C=GQ?=<^VI#1$SmudNqup|9qhG36Vn6b zpGys_la`E53K7m$8gAQ_PfR5|=~Yy7`-n@HZ-pX^hLO| z8w1aw{nu$}7d%)Nyc|ucA}Tm+ut|)a>7B(2KBU(B-vNe&bKH=W1&tI!1Kif#>XRGt ze)Pc9qryIsj5_mGfa&fq%dW3d5Gu?;ga8IFOAe2U6vz3$9kk=g<;t4$g*oSt~Mghl=O(GO16!p#|B)}RNgH4vady*l}$N`YfQmHkB=;#;){K3-_usd zF9>lT8APP{^kIf5JY6D+63N30dv>0pxxLmx>vC&to{`UWyppEI4%O9hGUY{NG<_W& zlkr7tCayG<2?_qepeF|DPkv6Z+j=9+|B_oW;AvbN&)<0kR@^XYOnKt^g8$_y78yJfsmxz3hMNNp0=pgKxMvYq3Pm zq$rvBrI4*~%B8nxazxHL>^?#y8YrV$kid8Qy%DA}x0|H2MRdQaV=pW`rz6mO`<@sE;wid&8a2sMUTYwb3ls0`q&P1dBjN(YWo0u0p2Q^-)Yy%YrW#Pv)`kW1ZAmbcQ zY=H;HyG0!7OcCHi2$d+`#b-_nnz45Yc8i?tC_r-Pz206IEWX1p`xV1K;s_#Ob-Ci}w)r0bpE%(`+n zcSJ4W$ck#@O3@}}Rakk|^GZqQXwe%yWs~Y)t~z0bIi#Xhh6(8N0gWb78!e?(pVH1k z(+5|Rk<&~D(4&40|T)x=-@u!nzbM6LS&)g3}-?NEDD9T+Sp*ASPvzj6Hs==$FLl-(S5 zDlqWFhv{~G%I+Ctx|b8K*vS!BSJ$EI_&5t#ACXl(=qE*`vsOQN-LViEC{ zN#Tc-XTA%;PbS$h&s9LM^YzezS~yR7+qJKt;g>;(r9=bqCSR{F3UN4O1Q4X_q{q3$ zNF4u8{p9#*(r5R3RlM}u)oZpwlR|Y9CF5YWrDt=)V=aRM;k>FfQ45u{r2CXrOY&i& z=QgQkdS91&#JJ4(uw&hKSxGN8V5_x-j^!kICxHmoI7Jkidv;Ur4m5ib}@ObRRJi{ap3neiv(-~8Z-;)rR@~w zf6G?>WchjvV8Cap3S~0vC_HtKUp_@whRg7NO8G$f{4d_#6pPOqUu4Vn%rt4XeetR# z>e{mwj_V(In+}JDyQ5-XjOp%ZRvM4V&uJT{8Qh5z2)NmDXL4Is(9)?L-kP!GTCTP< zzKD@D8sq<(*3B&$a66MWzeYeH(YB~t`51A&L3kT$K7eoE+)uq3^WeGXJU7Pn zBm6YJ^OfOhV@)nLex9VBB33)IQ`7o^&>@$HxkkK-O*)Ah3G*{QXSgwys;&{HmGU_%Ugo%vobM=zH7;!5cE2|Ph-P?jd@URyw{4`4F~ zFX1^90KH@3A8=r+9lkNLvMM;?eu4MQ+h@l-{O6T3_lI}0u~qe&Mez-|;wTxCg4X5n z>i~F+`!H{cdnd4_T+mMd@Y!+E$9TACT06RyifB#?aN9s(Iw%uP`NnoC-JA}{+BWAHr6JVQ2{ zJeOBD%rqDB_fuPjPae{BDfWoyDE;HXjqt0at8Ov+KFK|HtA%eL`0*#n-`aY3D1tPv zOu#Ci-cPB}&Z_RRk#QNmezE3_Uc$LO2`Y{K%_I*zuorZVpXr;lmWo%fKf`YRJ+tGj z7rS>VWw*2P8DPLA7U3D|#U1SB71zcewYT?;h9=&dS##RzM9X8qQ+o8vuwxZhwzqpz zJ67jRM#pr%H_wLa&O>jIu(^LWe1O7;LnKW`FgK(v?!tLCJL;IE0<$5y-c*BBFk_;4 z%^uQMQQ=fn<}A*&Q{kvo4{wf_Jc!o(h?m1;740I04!2^Yn-o(sp}2CfSJNYZYXQXL z&Dw>zYRdHYa6tGn=cR8)?sACef_Mvm_o8USp%E6Og@qnVk4`vm579gG(A+KY>Q368 zqt9y81nYmM?m={#F-0#M#y7;=Vl6IWI+7x=-con8Zs^V%f`f&r&*#A#e3mJ$b$Y!BlqT zmK0RAp+nXJ@UV+Oq=wq0vmUm4mU2Lz`vMq7m1i|APL4tz2Uu*7`yfmc`s8nje6SM? z$nV$`AkK3Iyw6^QU-yU3ICcT2?P*#{sL=t*52{?a0cj(?dvXi8M}Y!W5Px(vZ+imy zT>YJ;C9=4kbC(V|fYwx9Z{_x~{nr(XFh)2C*B=nefoIUlT4GLa4NjCzRSqun^^(+6 zdM0n!gFZ#1n#yL9yfl3>O23asHRgn(qq^4#o5OpSi5``Lmgy z% zgMHB_df@t*%jI^4r&b?R%!_Ppyt!n)3YEEcOjF6zpgph#M!%?hzLzj2BOKyVfV^l_ zn4uZ_#U&|TgiesRGCLWl;Rx1y31`V#rjJlQx2;0g@#rC|+ZvUeay3R33s4Xw(Gdmo z2Tt(9Z>@No?HpOfJ zJHe64&?A{uRizBPSG24wS|yg3wDvHK!}b6=Ef}uqU_oWGzP@%S@O9+et_LTZT@0Gdm^8ImPm=vW8_wLbRf-J3O;G!1)Wd>+EUA>m$X-oR2C8pz*I% zMYQ<$F*oaet0+UUT611DVJy4U_=u-&M~mY{Kni$ z#;NS>$l2);_IV&p*kK!oH}FZl9N_%TFYO*j`-inhGR>vMjdC5AK5WJjKc9|$%^U9z zzk96hJ6NX{eIe+vC2htO46v4KC6bX{;2VHzs|j47fk@Fy3l+c!f2mK&SF~A!c5hteS$?sstkQiW->pF$LOa!9pXAJ8h zgfZmSkt_tnP3R^uX8N>)(&(GPp{wkrrBI3Ri!y1}@|NBzD;M>Yj#hyyPJDuE}1zlurHj0UX+blwvvN)Mz z`Hm?ZJ<)k}y_?L4J7h#>tQDtqXtDznxh{mE@}0*ucy1vNkwMYEr+OYos+3+Tn)%jD zs5UPnOPK9Ls;fX}lKl%~(_V`mU3C}R@Os8BhCFI8?^8jQPNeDC8@Ul_qc%#h)lz2k zX8_&smZWX-K(gd^QoB)WNa1ZNIiv;o#1 z;)DkF*zkDCoLB_cN;vBoomS=w0)zZqrxyet-Cy!c~SmL>jYR z87i%?6Kp*!UFxUPle5atlj3g(y-h1Lis>=33M{ne997L&G;n#t+*O;Mltmr22GpR( z)Pb3ZjkS-W8@Y5;vNlk;Scavs5(}=TeDX#2Jl96pQN_zxF8XL=c6;eVnJws&P~mKs zu}}xzCS1*2*#rmtB5oqo?(BWL2ZenMNf-9UFXrWrxJXoZLh5MacG>iM3E-n{zMfpZ z13TL%Rz+U==476JOW5MuXM%@hE$#&dD5@%j)!2HH=(nSVVh6q5b^=<86 zt>fiOY@95r+y}KctKM@#omK8xuqdN0{Opq7WQTpm`_gc50<3rw{$SEe!7vJ9^Fm_OXZWtd zJ#4XKDfo(T8$gXD&ZA@D0Df7x8+W-Zq67UxR{6f{z0GxBy)V=$(sRf{w(yMnlE7Lc zcsti<(>zR`8zS;S#C@kmXppKaZWB7p*rb1Nq;5)7`El5q#U?6&862&9N|7`fwE|ku zafj9+19uQm%y7S@%%0a5usbrglwNbJ(nUSlnhhk7p9HUwk*K22-|e?Z=Dcf@ zN8jmp8}4V+G@79eXdZN)H_Nv8#>*y6=FT6ess-e7MY!hWKQ%& zf5z?jC|;WKv<%el5lwYwzf?~9j*{n2miJ&N$#FAQ#jM6L8EO`kU!iMz!_-PycGh2` z%l2sUFXTZCCHKDwQApzpZ9Xr4L$B5@MZfvh( zEO;lqpLqo-Ng^zX1-N`Nqcd+xrb7Ei6Lh_J>qwPpsHZPg%{Jdw^KR61XKfQsw9g~p z!@5lHbJDRY@u&MP5^Hp{w1a-VLKc(a5oddfW^t8U^@}?zi1t$aQHtMCxdmyEAf1n6 zYl^Zl+8~_;EhzNa!IB^!}`4aaX zQvF4oqIz}Tc1ApG!+}_q<3naV1ON<9LI?hbhq{5LZb9#D5U1mbM%H({uH*wLLVph+ z+Ck>0bmsIlbZ?e+)8qFq_IM8{|9(b}eg?r98z>jP;2Z+hoI|!-8f6-e$=akrooUPV zK|)0j+^QN3c$six9r=i%dyRu1X@Nk>TJjDw`S5m*I2-YET@9M6Y(RWOn0@4=%2dYd z{XX9LEl^@V9#NS);TB`|t)D;(c6B|wJuJ)P>$3m?c`^{I%m&sgv{9x@dwzl6zD0T3 zb2HbdY=J;PNem2S>pFf0lSlAUts5I_2AUwynkRdJK)kg%MC}H)aWMW&UV-_9qQ>!S zx~Hr=$FHs+ulf!DyE=4Fm-Gna_<}(kIzcGb_IZ4a(w(gfUUYJ_qlUvqG~XWpXxuK|D5QrmqN=&dPUM!!PvpIQ;eSMy-0kN+w#3X#Ww?SG`gE^bmwnN z+fZRz?-0?pAv?iJ%h%n}M}GDU^_THd+3gPD1iX+BTza~{qadwDv9vnjd8E&vg9*2% z6>A4Esv6CSe=>i+$2`%*T(?Y1W#w`nvr@sUjY`{XyZqM$3mz*tXMW-D_1;N4G3*c@ zl<+{+<5mtv<-oj7+S~jUp_=qSO4`wf$oab?lm?V(i1S)UuwMdig{f-~-QWW7>GnBD zkZq@Pgb!M-N7ZfRbf3ko$ZdTZ0G)1Z3#sPZ9J82o2!HX~Oo7gsz0b1pZA}$^V7LiK zQ!2bK^8=(^N>WaF#ZQ$7pvHBo zde)RXKixMO>I~g=Ws$PqJ;vlfRG0<_DV}ioY7=8OkX|7AA+7MX2Y!$g$~l2^t%n?Q zJG*MxD>js?{n%Je%Q}sK&EH{{u9{pAQs%?y3^!+(78pgh6+e&c)>>||Si5Mu3_VQj z)WvrOV*5oTLz!DcT;!}Rn=W{1JoAjuRoUyTQNGk$;WR}gXdg|b{yIGtZp0zcl5}g7 z7u)+^J6F9@T4E6$aN~JqpDS(Y)(mrax%|TNA299xM)fPVULu+k zVCd7v&F>={$jiSa!p;{95KICrawS_ppk z3r;$IXqbJiXvlEKV7H|ftPwTR<*Zy6w`-nY(SYU`+}#V$MT+;&SnPplyFdz5FcF|S zucZE367*I-YId(86sZCNROZ67zRnS+h(S^FOY%kJD#JGs3m}LJXyu5PF|GutO!6*t zac|Md89PV1fqm`wDGWNq)9KV{PTOC_h~P3NGHO_TNE>eNi74!lqmvKn-G4K>qqq(F zlfg*SeOJP!-l|}lTa_kqN`@WsGK?bq=QpxQmssZA-n)+21C{5t`rD5MI`9|Qi${Kd zo(yEJv}q(vKbWvDq4cAYvllMxG5p-TrzSXG!`-L(<#}{}0%hO|*xTR;#cLW@vqpi0 z7Z9X{KT*Zc2L&xSD;!Wc5Ugs?oX2IV(4t;9ZMsPR@uhfu688x4L~YObEaYaA#QiH1 zO=p$ykTJ7N98ZHbKwK(AIgBeTDbwf^YBRW5f^Uwf(AY7|BGWqFCTro_t9%qiMb~Z- z=r>v4ijtpOth4O*FCnQ$4cnCIae1kDNaM%x`;Q*IY41pJali0#HXK=@RlTF^jrmXY zgWIQMh94(6SUh5=vv*(*KZp7FiTx0|=}UfbuN29X>zo0Xty{gLdL^q$HS4yLe^_yB z=E&gCl`kX4jRLQv7e3Q~J`evUtC))dXmd(FBQa@JdsM&Zi0VJHivNvi?Pq!ssNKi# zU^@flt?JoVqHb59OGvz%?8T2jF(Z*RZ|B!SUo6>%a&n%R5Uqxou8$#Nufb1p83pxs;}gM$uT6Guty?9?6kXd4NXaa30*{t2k5; zvMA$Ql)kmMOuorAQ1IqX2e{3{!Y91aG2FFgg8BuNffz_KvMrOA38J=TtyiH-g2E@s zO&PN6%NX`Qf0GD(6d*vptc@Z`q`@>OpDOJaoxGJ})6MbljYhkOZL7MMTQhIq5`{fRZ2>;g37FUdXFn#;nZ)z3Ip5Ld+#C1m2V;8q z9JGURyRIq&c@+w%!R1prAt74VLOQ6Km%M_$E7xO22iU$W895gb3ZDATor#kn7=ZkC zIZ1J~KpnbnF}m2k%cQ7H3#mdyZWpuL>&eYEvR|Gh)tnI{eRvVS^o zX7qRmtYl*p(Y3ZjAx%!Z@`^xhxW9lhI(MW*G2$?>1RramMOK(HPUzuIA5USK(zx;_ z31+Z5lBnSeHzu~_r%`xtxgCqlx7Tk5;ZjpHJ5kv#tDOQ(6>O80`c0fmHsw$3RRc=P z9&D&2W=?dulE35Ej}XQ0;2X>1p2o%Be2^!05B^#xYiEn+2S`%Uvj)M~ujrVU5ucIK z$8H-E4H2YY^4h0GwngMCiccjd)XE=0M`UOe)2ZJdS-(D?oxi3>qykpFkU#lSrkjRJ zN%z+G?HamP1+PUDf{Ri!&y4V1R74;83+K9|~ep>U9-YX!4+L79X+Nz%4mx7lbI)U+x9 z(f%y>0!8KgzHLK=#iYG!wS3OArE`bm#_Zjxk4IXNGJV-SxLLMpP^a(!t>y%1DZlPh zGTpp$(ah27S`llBbPpDuY4p-m7&j`@VBplBo0va(3nUC+UQ3)m3oUm$9hg!Bxxq)|Y#?hrGUPrrr zEjEE#1AFo*k3;UA-189zLD?R6C4KSwg02-p#WvO40`AGPme<8M=b{h+Kf_R=Czh1j+|S6orML znJ&;ko_uRk-ESZ`?Kvy?VA0%gxjsd&96M8-&CQFXyW{fUHSz4E-mDcc4-Pxkk%C>d zc)0F&-6wE358s7!^fI9&=$RwXJzL+D*tCm#Ul30*YFn~2aBfrYCeG|AVlcyIF;*WJ zU51|~9jdXh^Oa3Ct43ZLO`MP0BWd@nY?+FU==4tB6BT`}ang1WJm(oTx@oX9X8d;- z?%ei;n^r! zRRFyQ50v6<8%qoUSlcE5%4FswAax+!Mh1Xbkq$stP+Gv%Oy(r+)Fy4nE+Ds$0eC=l zQMl)n-Y)kGD2Wb;jHjMLE8#N9;qs9EmwbSm8UlM^2ylO>xuI48WD9>{1Q0d^yhXL5 zKfmGbTEhgih&#D8;LODHQR{g%z?TSXjs>{xOmSClaK% z5x~nG>!nG@>*-kC>>d`35usZ<=}(S*OJOC9dAY(&fjUq9o4q2^p8B>~_eRW&Be_~i zgDp+M1CP?R-|3TTWismhkqNJn@po=;!C_+*=tH9dEWtD?;OcD(DM%vo9Di^6Gn zk)I}(jSQmw2~4^z-5Q?30}^|0?l=%~g|)Bj1!O+5POYq8X5ZKRe0gu+U3!YwRsFAp zx5lTPLlJ3)TzTY&II&mb`Qe#ME|cLSEo$Kh`#%Gr`{tm8WbErU@_~p3qt^)GCZoGbN2!oSW16n)~fanVM-{SoaTi@FD3k~IkWL^Pn#4@9--c3+Wj{axfnoz zm9x>g$^vA}_`xJv;Ny_e3=^SrLpE*$Khc*Lus!Z~zv@kQR)Aim{4TjbQ4M%Mqi6!r zKCvP6WMUgA?HjiJRlCBrWAh->)J%(#H!k!J{fZviQt3-s6_HxbZie=c)Nhn@s|xKJ zeu0gp2P8PV3+;V#OElO!2cQcs5M`DC3iYzQJnm+x4xn9gwuGF}rZmpJA0Yj4GBuHl zv`I*N(`oSVx!#=ZcK}#Spr+y}>4Kr$XvKxy7(vVxZ7o-`tjqj*e zH^Mk9i1|WzRB6Te)Fxn;pCg<6CJQ@D<4Fc=X?A>IcjN+t^_d~P|UblP~ zv}%1#CHGKI1$tott}qn_sr9h6**o*Tu*l|Uj;}hr40Iw|aEp2)?+=IWQcvq<>{ZoA z95XGWWkWGwN%={lNMIGv)+gu?kioos-<~szo3S?SSSTA&UJ1{DgXQCw02G0us>=+w zS%q-KS|hw@|D<7e)uF9>Tc`jTLoS)lPg-Z%(g;wAyJVS9&|p+5;>be&BJ8MLo{W9c z%}DK7ttG_6Y@+>5_@5uFJ;Y9pEP$EB0 zrXWL}*2dnX9&B^+=~aLVgbH@@zG-{rgz@-@a`Wo!eG3P5{nto|f9bBfkxBaOTee&K z&8hd<7SuI1Q5Csjw>MfCKT&47b3(QR1a>jw1~KQ|A06pKKDQoF+hch{UYy{PF_elaiaOd5NHPH*xxY7J`jh5Lzp5Xi0Qv1<`nMzXudjd2z+W@)AI-o& zH&fyUjDiTWgTwG$=K*c7QzLRi$<2>aYX}8cg8w*k@d-hPY!>K7jsw=FMzfj!fgB*o zffvxL<-}c1OudrFF1wV2+aeeB>+gXNlj_e&<1g3i+_8lnBP`FDcUNN5?3l0e^SnYH zOUBesut?v^g-uS8SgunSBcQnZ5Jo$CUF%hG^I{lAmz_%xp=Z0jy2^oBp+jJRO< zv(L$vk)EIna`Uf-$F+lJG*g1Ln*}~x_{1TYSj`abK3!ZAIqiP@+{4=&n)3`m_aC7z zhtMj-EIbX2hxoeiXlt6$@o2}y%O2k~vMq4zyk)>qms!sNcb&e{bxG`v_4WIWZez=* zd2=JG%{}I4z^{^yJ;F}}Gpe+etEHT`;=sD*y!0rBQu!<=E>A-0u+9LYi5`(jCxd?^ z!qPN>2s^7p%jY@YW$26pPvOe}l+nv7{g+&BU!&=;>s9Jeyne5hHW!4;iL^N47+|#3 z!m?_aD(-6^cHEgr)rwI4&bzzC+C+vC;p2?>^JN7=VVwIRBd=wH%L_Gnc{ED$m>hw2 zFBHgSU-I>*cGCjtRS&mknE9XPvTQZoT3z-tK{f#GF4`xnj>pH#26dwbE6b>Z;Y08W4gD|OD~X%8D|~zU>6k>;SX70mqwY%c=+XYUbg2Fj*(fAyvMs_dv1+S&V%(TVf{-~iPmz!qBm+#GoUfkR4BK0fj zY4sLm3l;ROBv%wa&F^G?K$uV2LB*gY;1>gH*j)CaBTW`|!Yx?7J(bz8Po!|3M$th{EO!rZFMJI9oe8F1hGwRCfQmy4p!D7W zZ%WTjK!B8J3{Z0od-el#>9@*FOdV|ZJc1kO_(-fu_(SH*;r;`0^c23bAK zRb_%19Y5X+)4;ieWNJ!?7QL0wgbvePMwFq-D$Zn}BPLhbbYDL-wmtXoHL~#7(|sp^ z$jcbm3f(;ozXrf>n|$rVQ)%%NLzA3v(!ahuZE z5$IIgS@KA%b}bsmcmiP+fZVLIcx0V<%woMs(Guv$a1+3DH=^D5(^rcp++3C+2sy0K zeor8fJ(u3>Tot!3Ce@YPBjGzaplffTB#F-x1*XH9LDD0V2pfBgw_wZXU`oJ+k`;_g z)-;n#TT-0yy;?u+r#Pza@@lN)axg(xrsL-?x5j*6LgIO|PqR050GdCJ&&^t2auR=FZu9 z-U9w)CA5bbf->h)T5%I~ZxZQyr;wz@t4Je~&{Tib5Q2;N{8EiPTpVyD&N(c@EXndE zB=I^Vv$~s*p8pTfdOFj-?JO+VOuPag5t_G_$9SgbTTx{W$FywUo872pW#YmScs5?R zVJA@n|8A_m#$+aX_add z2cmTR{RghRR2N4;1(TsxIYSy!E*NXmQ|8p(^xWQ>tIKAwQ|%s@dJ3dqz%DgT!M0E= z z3<}YUV_aru5i9d$ z&`edI277~k`@j8_e|}|c1EM>9yuvu$%#2pfLbSHFUDM|q$#40#=lxbRfpQmcKr$ZY z>#QVmuRndm$oR3+?MH`GXiF3!57nHY$KcYmugE8|7QZ&;ibwX0NGwI2J42^bHc2`z zJpDdBl0MSfH1gh{r2Gd~f!Atq{gYo+C3P6TYID(O==-KUr$fDZ7_E6$E5$|2!uX2t^a!@1dx;6br>IP^)6$1gnGnU&&T9wiqIS%mQMe*EL zBq;CGmQD5&ZE>hu__5(JJ#_E2uzb-DWgCfpflmGPF3&`!KODLbOI_GQ_@t|5*tlfb z+Z;gLBr2zu)iv2q(GoXXs-xC`D<#+!7IJ5Drs^Cj!y=RiW3~ZlSehO*zASq}^ zdDyOMkK4JH(oqLxS@S9!LTdNAgLORQ6Ls^E@tj{}` zfuFrz3(`&<^m;X!ybzv|JpnVeDZVs5-tpR4B|z(ullN!&xZS$Oq(WvC(&-G!|FzBb z^=D#fDw~>0&z>LiG*5EuK|jN1u2N@Dj5ga&S#o+seqhWxrq}~E;eN?GC^Y&4^+C~w zq_VWLBWXmuPm^Ssd1&bxSjrDWdz!YGeuqc6Z5{)(<q%4B6fk<>~Wjh%^ssx?#Y z&N(fQpTl!cSjFGzFX9mFT)VNMo%C@Ah*@vS5!O$-g*z0qe||C?8fmq2*8NOp_jBYs zYnzFqaEH&_#%@+OVV*%`ZzPAztFB%&J8|NUY%#7Q8NI`@3!+Hcv!-OiCGhA^j`mXt zs$OdX8&qV=Vd3H)sFefDsQTjpX+}}yi~g@PVrOW(eEi9-0J%iO&`7;2OKeftl~%pb z(+}Uwxl?WNJwWm_ezOq5?FH_S67U5wA$C>OVlQd4b@CSvO#F@&9qY7Cc#R|Xxd{vJ0C@|c!ML=`#UAAWan5=%B27Kk$T3kI@cSUuw!DEnZ_=)!&OR0 zFTd!N-XVDH!;t@V{210M^8x7-P_5H7=6Q*-$7Cg;5QOnu%2MDQP{`${fGw|08{4dM^>`%b^zjB5B0@wd-(EHa` zRFw<|@)IfIQd7P_q8bv5DkWd~cy+4k=;E-H?0Kt0 zjrWc^*umS0#RvIeqSdv)Is`{=q4l%d9Y;dHu#XS!#^ddh8qru>M=&@5z;ju5O{RZf z`0%-_5`Jp>JVGLZYE`(V%dwNBulJ5B+;ZB_wD*%{_KO3f|ca2v9<+O`JH;=rIE zpyjua_T@jmT<|!kDfoMe5ba6C;|1DXaV~G5-_wxRErD4}{Inz4o|7*8|E{iLWD4c; zRMCCfZH4lpce1{u;1ek;sT{l$&khNmXPuj1f-^c|J5MxOZDu6VoT*IE7`w6Gg{&B? zChN(fWQewt#u2=3i3-pJDWZhv%98Su)tcY_TqEtYdxKYmjg7+tt0M_%=b0+#1YSw8 z(RasdNUG@IrZLAg@SLPPC$XfSlW8Zwd886@E8FeCkcCq}$C3X+riy8xHQ9O;G*HnVbx<;SHkdqzBn1|i@sFEtXz%uL_`6w}D z|66**(WNM>+g~I0IYu`X1xmh&>pA*$(4#&gXy9s;v7V*?XRU&)`x=zcHTOi8k+GP} z(wh0hm~JSwGXD?I(?yFq`Lv2p+A!#!>GWz8Ufqd2-v8c~RwjMfpnGeoI4=hQD*eQWgDLiy5YF@2rOVM%T zQMOrw*UuD{hiY?yuP!fWTv1>#yfAC>bMbFLhR^N|gF(YX-|vi?Oq>qZnmJ-1Qn&aT zI(elca61@X>{l&Q{G9bN+vV>MZ@W|74Y{~y2__yxo!WlCS!^ZjnRzQ0eFr7=00F31)IzSK&+am?;#{HuFqk@Iq`L=GFSkt7WZ52&$>M-J&c%Uz6CCmbudpI zs1Vxr$LHL#!4cIvZuYjdDsA`f9D5$*)m-O!gtur4S|}d&Fhnn~R_1v?;^X`4#Yv@p zZ?CTDat)p%pw1CZrvmV>h^^(b5negWVo$$HDi-p+Mvf~OQjP$PV87KdO;2eWS})74SAzVMJE1c-Uji zP$3Y_H*C}k>CCL4u;IpPjPu`CR)%h}o*SVk-<(0kH$dKcxH)ehvW1(821>3{eRed z53r`TZEYB(L_|SEdI<`MiijY+MO2!I5s_Y^A|fDCqy$I^ML-aUfZ!GoRCT#Z)?6&dnq|x}-ti8kwd>vmKEI$u z09@2xhs{B~Tm;as;E4`c(@xvMj=2KuQI-1dG}(bj^-nGg zJl=rU-01L5KJ{uQCYQoGp$o1lzg*axJnk&WFiU7&IqitLtaN6=J0W_b+FzM5naruh z;pOVREKD;p`e|>vV`Uy>&ByXI%BPg5=_idkxNxxRCK}n`%Nt(`u6$FqNAoS&Z`lP3 zwNP7=3y5dg&k%VeL>Ei-6^=F;r5ZaBDFI3U5DLL8f6vv03p;v$+i<}1Fa8H(+JzHs1$mUtGbB!q8!9up~ zlEdi6eoegPRU*Vx7d(Xwz224&YubF=urBVOOmfpB<8U$?9muEZCk#cyWKxJL0UHh` zgLj6_lr%q0a388;X?zY2zYniBg));NhW&42bc+j%ydw_03=^an`;iC!aVLaM+E?AI z#gaI;j||?KQHN@&YZqxZWJnj{@5yFo4cQLVa4)B634wM$*Rb^A8p<7>4drFqrkl~& zl)n)S1Fu}7f#}2Fro+uPwnvM^O3qjrcQdy!fL1Y;;tu%2qM#x6;S-WMk3iP6wA)5w z93`Z|p{ovu387pA(zFGBew6H406C3sEL9BbsIyZP)V8*{)!UwM915wx#7k7$pgBes zIpr8L=KVxs-d=@XaMD($E@K~K_Y#%Oo@SVjoKF5g7i;KtRJp8Hcx|^lfXdz61YSSh z4MZd;;}pAh-)VxJNx^$`MG)Y8DEFO)Cj&B>fVc-#Qxs>Rey8d9PScd}H`gTpa2GV$ z2F!)()&b7K)oUnHmjBwO7s)y%rg0=LBGk%XHqyW2f|g!1dURvzUFBY4C6GAc>;XL4 zFB9P@cMEl*PCUSGA>kPk5E~4KiHW&IYsP$(9kPr#zl+2*>^XUw4!0cFZ0np6HP-yZE4}FqBiM;+!vZF799bz9$jx;4t&)Q_QI# zVE`HO)!>$twu&!%sxonC7_i;XsUOj@)aL*AAAk|D>zs6A|!IuNcuyWiDmT}Z3l9Qy22cM-Fk}*&5I?X-n%~AXZIVXLV zEG|NjKw|JZtYIw-kxnw3s_F`t0PFM$Xt^GO1@7j$*6eKom6yJt*g7T6CSTV9XmY-h zT*CMp+xJahJxM{oL}Uw~PK|=frm_)IWIYrBja@LBq}@%8Qeb4LORe7wIe}ZfY~X!6KM7e(dlNk;}4_yMI%f;xclhP zQZBpc4;53H5ZC$;4i4F7OZv?sdqvs8-mJGgZ%F!r%%u{cTY>fz4su8ad1%%5q%W4?XB`skdaS*+^)$ z6XfFar-fdqKor9qNg>#bMCYQG?DXYoTNQ5O&eo#07Y<6qOpH)PFE05AMrcVt;W^`J zR8GxG+=DurE>PJiyh#nS{EiK*tqkGy>MZBBVEy{znS>?SP1B*_LDNQi`y)9ej>eUJeI_@zDkjIU=k~9MnuRPF+{wVO?j>&w5~TS>uLXuSBLUhnmNDZ^f<7U( zt6v?CCV=z0Y~L*?3ZFMrTCg-B`m8pW+9f?M@yQZvRb_`OjyF-|f^SwnALjD&6))$eBGv?Vbucs{3 zrO`}_^YF()7$ z?nB7)S=9aDhvr{{9|kCZ1hFMK7lnHUP$Y_HRfnRc^#-b!>QH+e{lw3(rRcp$*pWtR z8L*=L<)e?$c+A!eKr-<|%12W*CuBN{96+tWP<@Mk%ohQIAWBs2(~(pP@P`zZfC$O> zs4IHFFav``I|Wq@p+am{IG%ySnzjmsNS+F3{D{smzaFHm@O;et8u@S;7^I z3HKFMv~#P@d}d)na%(|4|K4R23lp(JQ(C95^5rXNYAoh3?-$MHS3W*$u1(is6)SpX ze$>FP7DU1Xr2CuMhX}qo;?gj~&ztp89;jotB^p=^-&i?pYnt=;P%$JquDVruS%t3P2xOQPL0b?cGE={#6C@7RXpvEsxv%W0WLOqSRUrv+= z&0UXIQ61X6^tcc@t0X3N>DUR@USF1*Q-6Gm4`dtCVbpU|w+;L}9vU%V5MpfZ`9VWS zl&o=4c4s5+#bi>$S?Wn!91fivuBv2WD00tvHiRoIX_BjEcxj+qA_#RXogA1Bvs8_c zCKIfUV*;DwgzrnCo>|d4VobNuQyRbQXf~jZnaVdgT3XZY7JwyD8tiM}hH%Ms^mD3U zk#pEsWgBSgf$Du~nAj{NgvV+D%t}#vgy*jEe8sZdf@s|1+E4e`$k>1d$-3`uLDO4B zir#I2C9Ns49|6h>Al+k0Z?XEwW5U*Q5;RK3R&7!BemmLWE`)YJ-D4oR--l~(cx6;I zNjSDApbydbnmAPB!|>O150B>ZA-H!sJ|>*5#+DYATC9y|8!pw8NYMew;4*HaZ>vL%?MdR`tVlL&$UH0Ty+iUdpW z_&OhoLJQy>p64}FIfLt0c9DvzCi@SOdhE8v=Y)7*%7IH-NVOA7jr5 zFrvXqimOkE4eaExb z^#aApRznq7eLSt7Ynf?gy)+|n^{l{XVc(9g{mfC-Isn!`aI&B%LMMB-)jgxrNE$`Qu!ns730kMb@QQ zchM+qN~`KLZqVl-(K^YmQj+1dV~8lEvOI~e{VZS7yLr$%z!Cd;LW04B%v*oV)}0*n zbhkZ|^tm9ib%)v4i^cq(cXi$9#X*6;Yg~o&@gYreCcv>Ftg&Fpqy;{%T7o zs`~kgr5P!Ga-1Sk&be9gmYHA!y<%YC^5oQ_{z$}is!)}uV^dNviWoZ&8ya#|Dt@cN zXkgI#=|v{gML~=lv9Y=tlV$m+Jhvn@{d4!|u$FKLE+70^;F$-A{m+RuJ^YldZ18BN z;l+Wk+SUCdwF$qZ(nhW?v%F{jv$CF-hXlg{hRSarpksaMZFK#zpuZH0-8N{dxxO7u z2M^WGowWKerr>QtGbQCI3BID_g?``M0^v{54C_;qg$WvunzYj znN`)u`NUOxt-z@$d${p@X@up#W%;ng8=Bn_W6AT*;QE!&@@C(J;ZsbbXNR8-wtOA( zE|4Q8)dVag+ChTH+1=0w6iTjfmg|?y6-MS4Z9Q)t$f795lx)S#E!zI1yDbJf1_( z;#>&>VlAO~DqR_DplVH>JUM~1lwK=llwKIlF^U9|p%`7Nb6r7Gq5%gTf$XGot>)q( zo7GPHcMw)(E;bZJL{UQ}uNM;g)Zzd+WTGbiJI&T=By@9^>Ke^$2L)s!gHk9eBLucPl~pjW^Ir%s=pSAk|O`usvW2jPL^ z3`m`y+{AVJ4K!NB@w+e6-)*R-XYSl(Nub!`EsUBKC;N)!3=DV$OVP_$5(D~n64Mua zRaPc6eMO1O(Q?mav~C#f_|pf;f~9Y{&2{J3Hh;i;!g!NeCm1P8DIHTsZ?mye-}&7O z5AHa@@40^7$$36|S!|3-2S12nUbqAgxbv(Ll_6+sb#F}_WQkw@aUNxbIF7+WTw-RdJ6kr`syvPQ`S#z?Sa4m|IO@onyItn#7b2#sv8(# zL}uVNe{;b(CNx^$puf}?AZ$Vh&}T;g07R@WJAHFA`hXhuqYb8be@Kv+CLIuAxO~_j zk8k#U7gppI*ij3vXHWJA^2h0&63^}>KS&%TP$be+Dn2z2t+>ZRx2)*GcB3?l|GW?$ zm6tko)QSd*%ox*IUcEj|O{>&4x()c{eMPZ-jv`y0A}%O>OX2KHcz|&Y+qj)v)NW-| z83c&@sh*%HLl2NWvAx9`-W?eCiRsg--|UbKP?c7de3&WXEE%3iOI$;y+b?d#TM}wp zZXmz*?Hoz;j`F^bEh6g^Ny?zf+1;DC{uSA(;eeOF?B-{#b1QENZ#H`Lj~gM)MH?|Z zrT!Go^8rPA_+Y~O`3}7>gwKrnQv;-FpdA%2!MUfBfUB@w! z?3;2Ys_ENhvIF}tEQ17WD}|F}cV~0DT~e3BfrzFZ~u`Vpa4c z&dTbdZOSrX)#vKR8cZ63AK*B0^rxsWM5iyEcMtEq@%Z6U>9?a;Xp1`+`+8RZ_9R7| z2n&AK#uF!D+L^(;^r3Rn@#(E(ClXL?0<0X(EZv+0#=mg4Kqkk~tG=Fc!CI8-tGqQTO zwBs03^t{;O^hB5S*}FjCto63qq_2uvUb7l*eVomf)vjE(HnHt?t?-%FsFZ+u8m|D0 zhyct2_H@swe%JT_l~<|$KqO8?8x%yd!H_cGn(gpZy{ZSpDZAxVBoXnBH4N?Chdifi zbG-y7Z8mz2^wiOV=?Z!A09VTvzh=)r>L4~{;i1u2d2-4=Tz1J-E><5Aby~y8B`>`@ zj1_i#sa!U7l7-FOw$$u>WkLLOq|~K=7&p~tcSFgqExr^>9D>K;b<0PO&b%5I4v9?Q z%g$UEqBH6lXZDeLL_OX6zHlIKqIVMn=e(U%PlI#Sz%T7<3C^Yf+wsfpU?4@QlxMF{N-s}M608ytS?^IOys(&1olZqdzYk7-J*HOrkjln>M||E?Pvc4UWib-`c8y zz`euJGcYqabjm158D_&fxOlPFU9-!^X;S3sIL+SVvJ@l+=`aZivE(8l6C7gfl; zDsStb#jqe~w}L;lPz}nm;4d`3h=(_&X92|m7@kVEm2J{ys@9dtKv^FRiR6Fk+t5+c z^6h;1#z?isP4uhbZ03|W@3j&+p2SQW+hg3Hd(X{%Wlq^Wyp5TfYkZGCCGEib8Lb|& zr5q+(+{^qdqD|4)vy-uj1}sA{Cl@I{&3a!NRN^OBEZ$=)&ctN-G@^Q{> z8Jqe+kjqM6h>#j7@{5MZCEUlzRNDg3?fQ^(zAUu0ywy5w)j#cu>)Y5+K|(E=fKJS_D_mMGR*nb6e=#)mgkX&3ElQIDX!t&V&Gtog4pW3Fv|PJdgrEktqt1T4Eq zUAP2+5$`FE52%xsijm4l+ncCGc!EXsWYg%2rqgO-o7?bXxDn*g`SQymPYk178&QB;*iQE4}1P!gV?r%*O zzym*Z&hdxcK>vSuKhgW~3B5g^V1t1RQGIM(nx-D65=h8>U2mTz5>@}d6?ud=Z}Co z<_u=MJbfFkT@xp?^;)I;Aj|y&vsf>p(F;dqwkdDq!;WiyQqgrc>Arv~%Lv`aypOTS ztl|7C%{(WP*oK#6?SvU$B_4M={d{kx>xpl`S6@#I0B9t!)C-(1j<8U=<7aa(wg|u* zo?Jf%h3G}D0A_~O6gWuP#GbF*J@a5^y|}H?^VzHOcM^S)g~qS|s<8ob1YR(p;7Yhn z|2D|9$Ak5AaCfHio`zhhEj)A9@4i{dy^fL1rOHv;_!KAfBtf< z{5szifO(D0oZ{zIFTJ$rmHIZts&ao?ADK?N2a`jXlRqU&pm$lWuCZxq9zEZAxVW9R zng0rHCyVgJ#C_}&av8~483x`I2%bG15y4}Uz-}K4icow8N)XVlt!YGzlAcaY!Lg8U zDlDIM`T3*^<jhwsfELcES9 zuq2)!fS5++FgNG;B>d!f{1lh|6rI9}_o#2U zm7V+X)F3au|_9ZNQoQ3sDUPW3^>-;$1&in}r5^7C)T@x3$Q592CumZqa8jtTq-7EWL;>fF->Ap=EH-a$( zW;SSMe_@OBc#fXL;A!4B5j3qgn05bIN1Ug{jK{0rd0GFaARL&4qr8$h4%B8dT-q<| zjey`W+h;6A0EUNL9Kd$7V>4kyi9*Uz%ew&o7|$OTko&R(wD}LAvpxVMxm9i-b(#+3 zkRN>tVMR^HlcTA%y#Sh>;m3+{FafeYRg<5ET6YXJ--tmYfMBXnL@>ZFcL=h6|8FYF zErUA01UVt?a zIgP~i#q0;v0jE`vPmihe7LUe@oQBl*ML=q9P3QQ9?mJ09#C>NM+Lz;IFI~}# z5v(Y2j)~=_&7`O!k?D(uip6mj3%HjS!}4wINBsJLqdB&BLyX_FNPfR$uDB^~A92>sVFf1xwlbdTWb;FYDr8zkn`7*pSuRM(;kRM{ZdwoR7 za(X={t5r|+=594{zx(t_Yv$_cb+!bwW4+8~P&^4zTOJX4beqKS))9NLgTAp&^PIrq zt%PZBAMU)g&Sj=ufa%8i`0$8ELF1|Q2lrlT_OV*%z8&G*yk%+HCQ|w-+&WZ!zNKCe zopGu>Ug?trz;#pnO2^Ter~Sl>FOflN;9KelkKc1n^8cQ5vKjST0K&Rl&C0fLoaXLd zvMxcWR^cAVI1r-vH6`=6XoN3fKm+{X+crNG9E(N$w!+wt;=J9>Cjgv62}mmc7)`7mRq{mhg?*M;=GWn-jS55UN`FcIR)!rq!Ud<|77qj|wZleN>+4YJ}=zc?0S zGqKf}fe_*DcAG_gd+kCrKXcyUmkm1R>uge*Ve;9NkW>dW2@AShJA z$>W}C>%mBse`o}Lk4cfTmd^<)ig+8ko)|?(c#f}*q04F;6wnUS%! zD&t)mU9$mY==(<;9nM*c1F?~QNn_XL2RNuIIw3+Bc3Gp7WKnjb!^5ens_F69PfRlxd|#0?MAec?5E=4vx_Q9x<wWSMI0jX4Rt+_ZU7FXX$xJyFfpG_Dp7fzhjib?>j2*L z*#X40#M4#J!sTuvYK)zw_wv70JzXjt=Ybtm2FVsq36o^L3EP%GojnMgWC>{Nr6db1 zdB+Evgh^kT0Rzsx|77NT76#%;Ip;DqY1vu38L<>SET!NV#UfLk8Ui-+pzAASK9I+ zY0Sa9^M=cBcNNKbv)ANs` zhjV!tZ*%X&Hpw@7r3YXSk!|XF)xF)S4f}*n#+t<(l)g7=HEpwK#)W5JOk^etO(rqv zvJ(dO%x;ARnLN33=u5C0Ix;Equ~nE++J5`%$^IfQMM3c_Q78Nq5Ow2%qDzyH3iu8Z!&;f#CoVl5#mX8lDaud1M_ixgAr#+v-c8J zDVah~z1jTyMnX5*_S=8#6k>DePzb%7cNbep_M{m7r_!p=uQ{e3;a9DfH8%NVpZayr zy=z2}NSYIQ7|$v9euT)~QjV>%sHqWMKA#&^Eo1dTolc5;>s**b)iV_K{uSk$Lzrhd z98+UkQs!nM$>`SCWxQXV20KAl69d@6^%5Y&b)snK@tI21t~B#0v9Icc>a&S_ESFX; zXbTMTFG7MWnaME|&=Vr}Hs3Y7X#M=JSAVl|0pbYh9S zs&Ae?$K2yAp`^i`l)Ea+guNelU_LC(m+xH2vWv5bC{EV}j?wuRrZ*}cgsQzn)ojtZ zoJ-40{kml8It0W*+51!4OSDqBK@=7z%~Sudi&$Ny{;tBMn_B`LeR$)q)21-C)!p;H ze7gr#Q*eRs^i7wCZW z9oofY@$WPdIJFeYane}ksi2;yCZLjIY-#kl0~>m=0HWUhU5^hVeC1B$Ra6z!?TqhVOMInovUgKh0E`u4$>-hXcXpLR<*3Fy7eml5-+7&+MM?DV5Ym%B?WQ@-z z>ZTTtxaf!uO*mw+h#qK#1pd2nq#Ep&Q6D={s)s4psMd5W$(l3X?WvXYt>#Y`<{k(h ziK3a_%7JoywXnk;9$4Q!Q#qU+&;21trPf2~B+Y}DAknJ(@TR&Y1EOJR`k?yksQK59 z6OzkJWrK%kg?$xNmS(ESw_(Qs9~+Q7**c7(D!_m@`NO8S?MOZGx&gAoS-t8G1koda zIK*L{DexZC__mTG@N)OvqW|WuiT>d!^vx(tB+6&HxEmK)Oe9VT0VjN`|LS)Zs*$^L z_D`=f=jQ-fOSO#!MV-j9!ysJT!a91e!YuBVTlmAafeXyyF=j-ipB zfE;^S!+a;_$GMl1o?P+Un5}wUTYZ$GFyShmX8J~g+r4V0mPL%^veQBIT?Tlk{UCxD zpcYL8T^X{@j3T|ZA2UC;`f(jZb7qsqChU(o=jN4^1BrW;I(QF%WeYsNhYq!&R~2Vv z|9BiSbP9d^5~7~DX8jK4IC*pe%?WR|0QT2>>8|3hL&I`io6nOQ!p1KGnUEmc9S@YQ0`r?vK;<~%U4dF8pHVZ zNb+S0z2{#l%Im4PK1CHo$o43s?)y*2TWGMKV)}|ZpS+s`33=M7CA zK61~j<2eYEU2S1ls~rimw_bC&u9OU<&c3P4ponKPbY2q4ZmQnur4j3TcMq>a zK-4a;D#B+E)w40uyXp$|kIa?32$3;*D^bWmBxl+}iI>J(hNSf2)T-2Sx=>-R!;mhY zjdjcTw7~@)S010FC$XEc^T*G;ybCNgD!aHZUQgm}Qf#|zcaY^~LuT)^KB)O7Q?^zN zv-(Z{&p{^B{+PDg2iS03MQZHOHT4$m`zZ%HZVw1XEnTZF4fN0vFM9ssrBtI9ZCq-O zn#e#1%JJ}WteGtn-A z$9rlfwvU%$_};4!52*%3|M4xRc9QBK{I)miU@YdH?g!ZTKFA zfpr^8?*$D2Qm9{S&qXXXdT2X5x!BY>xYa`ajGxh4@0uK_60QACQ`ksZYj&HeNGU1h zva)%+JB@niyqd9NLtL_q295!PQ&dlUImx2O%q&c@umrgZDU{#7gSib#*`W18W zf6pbIf3u&?{mn>vTK(fO^8aJ&?T;pb*iwbtgOU)gdoeUZ<3J&^@&dDKVHewcSyw`L zmPbv*KWK1SUp}B{BO$@ zlj>mnwomF{%%eAe>5+H(=(6l_l%(aQOo|9;AoiOGk}k; z#&VPYGUicpmA{U8g95S*-hTVw)k&nT_IH{@BA4bYncc8`GU>1Li0b|8JTgiqYi@e< zJvkjQ*JxyG`{bf-YGH6p)f?&}mA9I?c%I6-_jZFfB)N=aFl1^L#%B9?a>nr?s=PXA zr9RgS@(g8z)R=m-j4*JIjm6UqnaO*a4JIvPCM$?bFg05*gNTr{+H~8J{9)6}6;`1@ zTKx^HfMY!}s+H8giC z@eyp_+14Ye@4wAW=Z0}1L*Fg>@Q}T&{=+y5)i%Meu@kvl_pP6ee^30E($#gOv?RA| zxTsn0xBF{P@*by#a&6I%0Nb&!FNEjM3%4tPV=PG78z?7#Zh1~^kdE_ZyUU*3vQ zfB%LX(!vr(s;D!adqGi28=5zS*vIh}3cr|5fm=MYxlrRKGxME>w^AezUR^)rkQZpR zS@ym{N(*bJ8TeJhoV$>)66HbKCO3 za&uGjliF5K!XWRL4^0aIRRR7{C#(a>@!K9|q4c)yWV7z=mV}g>OMLSx%uc!JTP{ek z*>MhP*AO+{O?ZsYwf}rb+qLEV&VcT@!(TT*qCJ1mIS5D}VQQA;ltHY?=-287m^q% zz4Oc&UhCK!psG|TwUQfr)eDxR6JY;1iD%a6TYY?Xaas4GG;gRgZm4en{>q&P2mVd5 z1s)Y3aIu_JlJAym3$g26eqstw-Mw*ki+cZJ=b>6*SAyk#&n0+bTdzegg7ID&Jg6~O zBFE2{_MA3Wa_i6;t@$f!UG0|t_5~J5w+$TbbM-M*`Xxit#>TBcg8F9sr8o5DQaQ2P z(|L@%uY37+BBXq*fuoRwX~Dn+iAo7OiK4-T7V$4J4@$d4oU}%;zs&VHN3TgVu=siP z$L2dDC%yHMX`g4+o`hwKU_HhBHD=bERg=RK86<#1P8_}k1{`MgEc^RWD<5d~?EPL$ zc7>n*w8{w_eNaZlZm`{XUx?|%ec*_rou?c~EXe`)6D*9VJAy0&*dii*TJpUKagKJw z5?S29K>Lx%OJeLytC(|IGnXOZNZSb}U5)x0Q}Ni`#}1g>+*s~Y4-L<8&RE`wZ1Y9& z?DW=f#Dxd@7MY2gejSFHnVpxq_BrQ{L|bL1Pz()KW-^J@=L8vNN%qUJ^Lp}PZgAu} z&so*}!^^yPTy5xFSoAEpNt~0=aJQA`JWc6o^H}8DhW8($3Ageli#0WzGzB*ROwu3S zqLr9^rLR(sxN@_n*xs?wvaaXNsWD7=&n4zNk=+p+-;xd&iR%D$PSy!xhWqDY@v~9l zi{w$Ei@zRxE&rhVAkN0(EpV&>k>V$tUnra49~B>EyS{6XHK@r7tWu(%xm&p&f<9qr z$sI&|W8!&Ik!es!Dl)78aq{!l&F9gxN2bFr(T*7TQ67?=r@A=cL*iGj^|WDeV{p;n_FERqBa2L`IMxa9^f|~3OB6t5=HfzTQ{GsFUV0_$#!$ZEZ^<@5IXRiD z(Q8q#E4*gunUQFx9rHC=;fm%h`+wfKN^!qsE|wbvm8C(`7Txnl20Qm1y|v)(h<6cc z(*`O=*FWNfN|5~oiWPj1SpIoxzsX-U6r zXhc53dh>{n;Z9U_IAU!IV2v{|Z^FktH zq?=f)(X9dZi5o_&wUI4h0(+$b&fP~6cC5XCCiI~tEaH7k&|$!;N&Uwk;2seWn_=XY zS&OT69;_xU(}l)eksRLN?nPBEztsH1XA}$vs%e$>U9j#`7IkJ%h|rM<+h(=FHgStl z7wEkG8vpPHQFf5Sh^J|iZ15+Wmz9PO$V0YjWv1iMbxC{+Vb{iZt6nm1*4$*-BkFpd zP9~-|D_XJ21+6@wt@_9Y9EK5Wdd3I|QqzasyTqms!PLZ4tDw2l=fqe7sq%fW#{yh^ zKy{_w2FuHo=|=T?#Oh|A7leR%o>1@({6z~m;TOzJBI+AKAyKTF!&2j;Kkql$FdezV z*5Q#0$mf4rhRDw^?tOf(prABjY>1taPcM&M^Bwz2tgLLgLzt|gA!&H{%0A6gUB>#s zs@0|@oNj(lTickD_oF+)&KjQ#1bhub^9{x3#$SA=If}5DO5(?+?(bDavR~ds6C_1H zUy2O6i@LtOHT9jQ9>xhzZ+6UlGz1;WJzDfgc=v|(+L7sdzkqwNNOCn1*En{TG`wgk z8@-u*)q#gmwf8upUIAD`*7N2j(gWQvhsYY6&E^HWBA;Iqq(tMQtdBT{%`o!cp&E=( zP7w2oC&7otzAnYW9+XAxrCnRQedB$EWWsx)tfaPzB>zPAfl8rC-eG>1_HVDHU_~v! zD)CCPX@3#X-!@9Y0qx6gsHpxL*8KU)PYwLkz)ubQ)WA;-{M5it4gA!=PYwLkz)ubQ z)WA;-{M5it4gA!=PYwLkz)ubQ)WH9%G+^Uaj%6*H z#>7UZLo@8;B=_MlDX~`pxF9KF!{~NjPEoib@~U3hUutIq(6KNN3;sQb;7aSX>&dsgEe!c6?aEi=n%_NWo>j{$yh`4~ zi%S{s1Pm>HoSQY7V#TV^o`y&rb&CTxuW;K&W%LQ)41yt2UB|*n^W2i#FYQMWj3iAp z(uj|4p-fs@cDc^kmeJ)~>(1+QeTTPT2N8PR2oG@d;||-*tmUXS7dh`&Dtt(Vje}LV znxqr1VE*Rm;Y+4=b`>cF3E^WiESlh($jf;Im3Rf23WzK?gm3ntS8;PnQhNL1bOeiGPKAUCu|3?O-{d_m>( z0O0OiAnE}CD!oq=_xlUbKimSq3Ncjxc=#i<0I6Z_KGhs#(&N`uGhfsMI{=Sn)udbi z=ZbO=M592OSGkT;7if(1+kfQ)E-j}$ojE!4FL5Hl97Hx zOLQ};M-rg6^D`7A6Y%p|5?N}HqS#3E9^K)EBFCYtCPCH~_8Nud!Gavc4?}8}J>@KsVtf}^x|)Xc@x{%R%0+Vk9~j23xilI7$inD>#7Y;X81+QmGLu3JmC zol%8WVuKq5N)#JW7Q#EQGz~ddep%LeRTIa^FnCY&oi#OCaAK{|Ri+zv^-gifbnzF7 z<&zEtjgCUeclj>fR-4VVXKS_p02{e7Y#lnLsZk?;Hzfdo=!!<+u2p{uENN%2j0pF2 zs?`R?ZOi@sov;J&+~28GY(>cZi^a+d^!C!G6me?l@4 z{%9Z^F-*ENl^#Y>A+Z_u6jfQZ6qG({(A$gU9R8®0XZ_M-jlct{evvd!em^SF|j z)FlD+m6_4RR(P!h*QgUz96hym~%&Nb&^AI&gDV#;X0K zXp~pnboCG8$NcpV|J$g)89`uT#jlBoH4x%qAW7pnz(x2^2XR6YFZJZvR-8dqcmnv# z*;Z2Z)bWJ3Zf0KxYxj=-UMP0EYx5Z?H($VOq1386{>h!B-I+i;6KZ#&Oo>pJh3q$v zHHWrnAlUgaR|hi0)>P8qxs)~hBktKSGN1rFWx?=B9(7vaRswBEMp zNus06;NEIXmf!;Gz`6wKJ z6s7gnQtm*^tLcj>hol$X6#t5;!`|rkxkRQ88)NyTl4<2vGo2Xo&pQKf`J^eieE^)X^d8%teE?ias%jV8 zO#3I%^C{~GD?RX#21j->wCSVm&gsleGsArC>&QgW_Sa4~O|<9f;VVt3=VM~Tr0~1F z>$>{iN^P#P!QdHcn$O8I`j6&{h@N{59ZzdMyQg$4rTmCat_t)C~w*)yDJgN)q23ML=RD^%M{!5lY$9-IHz&I*wpIHLCo^{F8U zLOf~lFkn~PQaB4BQ@a;?%EvZ`D;e0=oI{SFCazR<)nkQw5C$n}smY_M9fkbqd{T05 zcRfL0_q=$vAk5@wZIWSBTrArCwd`m21gDnKe!pq3)yBO22t{d1SG3Xex}B-YkomCW zkaN9|hau=C5{-MGYucY{dgeo!1Rv$v7iG``Oh!wu<@HPS3G!0f%cyef+&H(gkqAEN zd7P;4x0nrX9{W~}yM@6F+A3XJMkBj;(a`D2rzEy(ME)pjvXHLlna>EgYmQI%n0QqTkfd-ozxQ5O3kO7|X6qr4l`wv)QpkAkeWjVV*ms(TwN`2MNiWa) z*!wMa08m=2I$R@v_bR+((}>#P->e%95j3XYXh-As@gJdG1;C3LHu31lFddWF5-qw6 zA=RXBXK#oi<>0+a$Aq6d$%WH z7q!NMmDBN&E0(Dfj%crkRc;(_r#%nttC&5Z%|c^UIyK`0>m6Q;;z|u1 z3#nt;fjWVRS|KmK)uaf`DsT4vwqM4>h!zi+qCBF0kS`Xdy9U-HCC(Rl56oMX4M7ef z^E;eWA>{lIaJD`6eoV2UMY|2#fsX=#!*7#`qQiW+f8G}!o4$LQJg}*;%WJ%_ko4;6 z6F$FXm^*Yrtf3e(1ZpZRko!8+481}5!0R;4;<8(SI$$Z1N$pmZsfxrl4Jdlq%p4mI z7W95S8cja@0!sdW*n1DKrnc>0Gztn9h=?dXC@3l-(nMM!7K(@w5u+dk1w}wWdVquo zsB|JAprAwrr3n#f(n4<{AT{)kbVw*6q;VJSbI&`Q{r{hR&e`wXci;WqH~IL&nsctO z<{ER%F@B@1ji#$?ANl!>=3yFQjAR|id*8-}qNW?mzZQHUigk{3Ab|R}b16CNAY6i4 z_9KUr4+#NoUvrIt8WNk{=cQ5;8ShrXDYaJ2dwN^)Xb13A1Mhag9y7i3ij2096Zm8O)IE!Dw+?soD8dl z&Em`AmgyU9BT71xt9BiB_mZr<3 zBW*tw#WWq^u+ZFhx%@JBY9_>Y}404 z@2RBEG>*|LVWT21mwP9%Use!j!c{OW-!Xh&CsBGRW;bUX>)c&c_K@qH`@{q04r;A(84$-aQWG=;Uq;*@cHHuieSLX*nb!da zcU&3%q06649x=hsag3UFi_F?vCV%uX*QxGZdRBK%XINJzZQaKD4BF?QL!=U=ASzes#k2ncP{Qf%oW9*+T2 z&C@3MY8DDraqm@tjM!hWTkYCrfCea7J3v~I zrn|nn@zuJz5OP-)TgmYwj?yfG_G!)04|=Gf=}?%_de3ASzkd=F2spX#2A{L5)v%{9 zF14II{F%H`IGwK-ZTAdq`i?3Y%RHsIgK)Bhwlvz1s#1xyyI6YHtc&g6GMNce_t^9xuE{HP73ShvEuSkU< zA6~`lI5=awAwdG;Y#6O0kp}%~aJmLEr)hj9QW=wV4kK1jzYenUkwV~*8+&s!CciK{ z3(}vTdjqn@?}h?=&ug2-%vJ5Y)7AM{z23%mfE;To|Mg(_2Y|CGeTnetdg#WzsItR? zyUKfC85da@8Vhjg)^8UXce2_g>-r8qmgJi?0zt~!=}2IQ=pQ>U_pJ6RPV!L6I-a7;irb~y{c3)KvPfIWOG;ZOsr9IKHJ-~(7f z2{CMOYyVL!t^EnYQ_5p z?k{{zRP9lt1ND2GMQ9;4I_B(wb|{I8%wB^PgliTRHx4>!yX3en6D&5``(T+0s50{c z1@Q!JX?^G2H2z**6kP8Ww0Ykv7pcd9pxL4`Zq7#`j7SF;OOA@D^MC%Czajtr~yk)k|%_vs?R7G|f9djB9GLeyJN7XLL-lgotawbA~T73630hVBa#bqn|GqHHvf^gQb&SIp7M7YBCeOo$k6XwxmqiPdUNbx~$Y^FIT?Wg+cQ^+@6 zvfr6H!K++1U~jw-&e5_isu-DJB>DFaOjC@4P> z?gO1~5s=Y#y*M=5JK*8juu1s_wxIaWVwYMNM5%x0Pc!w(&Z#tW?Mo$tj76(G&3(VYHFfKLW2ZSe*d9oA%(b`e z8MAIjU6%YI(Fgy=A5CDt_~TXE8&tIys%wBd`E!;K3bISrn3AnU`bcz5|oNiRT7d`d9!TS{@RVFG>U z6}uaKrF_;wb8=s)O<;lf0WMn5JKAD>Qd`o4%n_l4riVKuSApz!nA*HYsEw2dGY{Se zCuU6RCq7Vn_Hk6k+Wv64c+tK**rk8{;#v_~7*@RwTIK;Hw1w}bOm`xXQt}y&f@N{I z!Wc_(0L2sHONSGgNFXhKKbXyI09NY3<{^oj?}DQNV-5hxoK(&Oh0zrN=&uL%zvL!_ zJ2Zn)jDBr`a8Y}%uI#}$ks99{9k;HhTzL5A`xWP!l7L~AuoXFRl80u zr2qK42`Ck%0UKtp%qLjJuX*H!YG!%&c}G2l=Ds1!>_K5GSLr3q^z<{rcNN3BeiawT z*r_8sCCKZbfQ1!r{K}0-N>$b(pU)W1Ujflc-wXf@iSMp<@jm_^x5|N2I2`e>UCL(i z(*jaZ4e<7dD-9pMw$DlJJ&|B?g!a<%{o^wh&Q8p8CHNtHmFD>x6Q4xuOf%V6jqm5y8o~yn>>yv3m%J zjrQwUsioMjG`$+?ce$D!)lit*HW7EAhnIA-E46%Rk;~+-^sZU{UilYTtlfm&jsLm& z|8L{R|NCP;e?ZZR{xq!-O++=66L+oCf!OBmAa!0kCUw#8)Ty`N*1ytQ^ld?=n7~i# zA6?)_!Ax7{mSy#4Bj66rht~M&3;Zo%YOfJNOb5zpP%$K9%ALOd164OU-#P*vIM!F5 zg@1EJri!hCVpI))JC}$jC!-{h!>n4EV`PTk_8~;a)IK~6l~y%h=GR@<rNXh3@Ut9Ffl zmo7i`GCe5ECw9k07mv2;>(;XUw%y97EsRdy6jGM)tWEmO?vd?C8La*BS;6+k5>8K6 z5<=$|Xqzm}3D4M9?pCtD_2=HRat|8$Q|2F4`_i4vpdk$1>6Xg}Ok3(&;;DrwGM)7G4*M z=`qZ^Svr7(I{`?{Kbh8w&@(%{0kr)3v7#kj$6p{P5Yl?395vs(&aU~g_4=1o3DG@H zwHg0;CwdMD$$`aFmae8jatj+cBi}j%tb=^+ z0cj3%HVtXnd=nj}5;g=dnu)vvu&`HH+8pG6&s*g7Go@+SnY4v!gqnG>P4aop8}LUN z_9E#HydnMtbv1(2<;;a)SoIr^TA$+utt;vVYJ!Kpct5p!&~N(4^|n}(_Nm(Z4<6VZ z>=QFYb&7FQY-*3qk8**iJ{eQ(>0bZ$L-Wq^&ooP9x;NUdv-C6Ca-;~n9px}_lW1{{ z=X3RIp(M$1trZqXI@f|$TkS5so7~@&g)Vy{awp`BqOQ(2{~0<6Zd*>l1jIsdAMzc{MLAX?g9j8S(p6z{m)lp2 zBWuRTmn2Ldys*%o1s(KwbatVK_?(a=Gqv;YLV;D=MSISu=0mmnY|Z+c1g`Ingx?AN z*DtPlSC@)0;cg@PAISsnPvpF?kD0Vjbbka3jlHI&>C|Q6Ru7Xy<&TyI%@^yr4v4g0 zjEM~U($ACQ(8NWFoYs}jRNu{8AU(dYAK(I-q@a`Wm0p2gS`G6|-{pmMm$4Ph^f*^) z@A#6W7|9j=E`}6H2f#TXEHI!|Z3Cy?rfj!eLhZllsLzsLYr<=<9iha!LK)Wv$ zt8jeO?c;hUuv}X?$d5ZflQigf<6D4Y7Ci?EMxz|KE=PO?pOcxw1rVjh<;dFc>FONL zlr;|tko<9SAMY#4N8(Qqa5GKU;DCTl^C2xtjXc0RgHzW z>_8X49Vf~-C-%OFBAa6Zbs&{*T^Y-Q54>1EO?qx!E z-$qs6EN~C+v^IKn{Vq@uw7Mb3JzMRyLgF3_<;F>~#N1cy!_k8N3&Cp#HVd_Ko5*wQ zA1zkD{3;5V;a+CuYsB7oW@-#py|bdyn<+p zULOCA8w%7hFH>-Q4OEaxY^*Z~k{W*By=FlE67l*7rt7pvT2=|v8}`_cccC7 z>7R}oXwT@8ujHq6HH@2?-qJsD&7LRMFOrvAg01|YcP=h$db#6&@M~!(-Q?;)c+VE3 zP0NX)Zm8#5nO*ATGp{PXL#f=t>J-IQx&M{kjWmaIzodh&>!4thpNYfG0cx2UNqv|E zDi|=C-zE099ZC?~gOYO1gpI@$q|jW3o6^&5R3O$R{`HIFU4(qsy5wh^;yc7-aI_DZ zwop-;OWJggL2dVf#Ui@EU1qLd;n=V*m!HlhGHwUcVk5bcEN{iq?Il@CyBb}-=N7h0JhNg*aX2dl3tAn~;anzglkqiRAhnUg zk6Ah8W`)j~tA0XJv(JIlMn~^FerslWUh(??Gw#Q7Xz zYSW$$gGHxJE_+Rx8e>nBPCtV5s~lG_l7@Id)9gxVk`#_>l$bZEJu|U)M-6kLt!`=L z;9M`C0)WbLqb67&0!!8z+5TZvR^2F=h!%HH9Y z*}mg4uN@>FCHB1r*JPv5e<~kd;GGsOsg>_8Ta0c}*|P!OaE;y~9_+LruLijBn2)}k z9rC<1AriQO_;64N(OfmnfnRh5l>4$pk7vB#0t!GxFTSO9Q}*j^{a6%Z`PBH!<1soo zl6V~=0zFhOah>G+{ZU%pRZ+awBBG;kpGl}1&l9hb+8*VDTUlvlY44J18y~;jZS7lY zOV2+SVi=(H8Hf1F&`y#-=IZBOS9-bjdEb^$@|ij0jY&h>QW~ z@!v@?wlF~rk5u&o6i)In)g2Fm_8={;TQ4b($Kf`J_DVHVOJnDibEbzb9Ox1dVm98t zNCDS8sxQ$n`oz!fAN|Svj9`aI>ef+Kw23}7G4 zN6o_y>1M|30KS4@3TGYUEZW}-ikr3X0utXJX~U-~w*eTZSh3SbU7qS$;TPvQ8VY@} z%ThfqD@O|LA*1=>O7&a5miS)_wD9z}D#v~jf5j(>l!w|i3P8eokrl3L_dgA~4|9qzTE?(@3$9=qPK{82#oZ2)FMTDZEv&dMsmm&nVw6yI}zQN z!ae$xkh*Md-eBG`r)&l_l>N|tSGTwK2Yrt-_pH``)|KAjMfkO=Q2>Mu158Wh$y)64 zc4$47kmEU65N^{kFO0M<5 z29*eoN!{@kyY6E=4BLEE0^4SjRDpv3{=_}{hY_1)ygzfT{Bu3PkWw@vsLCGX>gv`4 ze2}l7TJoQPNvT4d}@kJ}8deNt* zDT8QL*Z|iHaVGAXOb=h@1%&qQPYQyfe*gU+K$+nOf4AoT_JJTw8yzL^(bSeM;hk5kwc-w`stCy7h{pJKs*%1Rfc9%gZk)CV9MgqT8dxms3YirhHq_FfCQ0ZT6594ya^AQ^ zW)y~-ck@1anB=c>Vlo`?>9yJq!WAG*5S`I0A1qOY^a*|P{eqNR8wz0;98mdAlWx{? zarxJY*@;w>NNPxb<;HVO@RQS>6`t=f@A3+3bbr$&2Tl?TTA4zbw);0U%{+cUm*mOq zRM7fmG+MLXq>3yy|DLhPjN|{m@QU*7C=<0Yv%B*<^CjG4TDD^sp65D{0EZpfE+NMZ zhqHh4EOyn*5US?^pyFGBSL!o zE1Yhe9$XRTGl?^59)U_<-DHnXtEcNdyLN%4C8i}-K87fqq&K}8;W;U$f2lBhy7kVB z2-sDft2&Q71$+n{zufaSv7`V0&;KJ=fDpr0rw!OUR>OxGw*uQ-YkH=WgQRP}!x;rV zn%s^iYmTF(VLv;W*V&NVmtiWG?K9I*k!Unf*R$wN;*V!5e>T6FW=4(~t-ZG*vNo38 zau<^TRK32^-=SE>QM3mG(ijE!c7-WUEVkVdP%|zDQ9T2>Ua5OrZwB$sYAu77LIF`@ zaEF72JJPT;K_4jX-u+WT+-k1hNCTvv#r1=uNpsbJc7Dj<g6{6g=bRW zvYo5_D#Ku3rLPsW!wk>fqJG88aH8OI7)WN&b?^z4vvqVABw%jBVZpUg9!k4=mI+F4 zW1c1(SKWhD&~I`TyH5u!-4-r^RXT3Ft!>DZ`|#Mi)*%I}T>f7TTOtViG{>1WzQ{M{ z_dKz{=bYzUXMW77OA-AIo+^b=BfUYjQPHjQ4?h%=%=vR2oj1+xG|x3TfcsHNMt&7mj96Hc+V49vC5LLCx&kKPrU`iGTv&D5&Eju<+VIzEAm=3U zP`f~y{ID6MnypySwo+v2WE&%=@HQf9g7>j#Dp#WL2y{0Jp+muj&bzW4y828$gnUnt zvRbQr%XM69vZiE^z0ad^fxZ>S-fplCswNcyw%l+U29OGMfB?4oQd;3EmS#8zE}i5C zLeYd&0GAdW=Fx?K!DUV?b2m`3AOtAZ@sD?C0dj4t53jPeK-NJVK-r#=>0?Ar+V<#o+zfC$3aOp{mA?HA^78a=Tbl3J_n~9?t6k` zOvWu@gOHrbQn2#5~Q!a7E?_39YOMn_?$|U=&aMHAB@+It!sYN?AvG1fF ztJ}@{-gOIt*^|tY&(1@xhV!1uj%1>1LK?;gPB=>#Yx(2hPu8 z&uy7QKAc+Zq<@UJOEG~myi;Nx#CP1>3LdkYdjq8pUT?E^+odz;=(e|!-zy!Y#SFt_ zCl8uV$JuATd%&2Re}C(}qp<}yEFz5#g!F}YC9}Nr0V}I8fv^s$%TL3Sl1k}YHucf8 ziF|}7cJugM*t&OsR~P9Cgf9Chf12c`n-JA$jX)_&N1$qtj~r`nG-a^HaZSc+l|jKy zz959N6|wcEq|%K9jTb(6K(-M@X~-J!y(Oic%hZCe;cM@-`RiV435(vj$@|IfD@~R> zQNcb%j-F%ZC+9X+c{J`km2jbg`^V_cGB-=J+H%JL=mAQ=6N2MPiDssQB=Ldalf@%@ zv;zchaHI<_<2F&7dBkRdnrVd%>!6{)VgSBuLso-KGfDJrnolK%PBf-^Y_KC$WXQUb zDk!XxJ}-BKouNC(0fl@nYZ*s6d8(|~R&RAbuTNUB2&S*KMAA5*X>3^}6ucv&-W9xOSjr8!aV7_{`j2^uSDSU9a8Lb6(+(UsD=A@Y{&ejqhx)qU>&dl}+j+Hh4XcQlKV+H#lYFzSCp`v8Yy ztP>eghCnFv=_jh|%fz}+3!dqz!m9t>>wv)(GuV%D>mc7KEX5VO zX~1TJh5Y`}i%Ot1gZgduu8a$da~XGZ@0_cey9nA6RX@a=+doA;O*fCXOYV`5wYS@O ze&>E^+oPb}32=~G<^nt`zje9S4BDbmWOwtL;MFX3!?Pf(MHEK{x}I?nTd$o9)Wv>? zq$^xni=qavgCfK1)PR*bqWJQsC4#E>g0 zC;@OZ{?2MuT)ik)w!lHd);Qbwn|-m1u$5SJQmoDQc!e+2_L=-Z6C1*UX-x)??D7np zWiNc=~Hx zmB*)lI+bx^kG9SsVgn~%L>=KvIj5Dgj7(Jzi|~}Gg3T~@;Yqqko!Hjx>pw=Bb z7A;}@#%#HCYp5R)M~0UXzz_2FG!uG1rl+0ak$8?jqR8q%j?nX5CT0F?exa=8u(Y3Y zytePMh@EzAgL35B$pF&$5L+U6G8gwGfxFXQnCpjqh6vhnQ+$YZ`%11J;oc*B= ziPKfHphuq(TE4eRu&3=BEpVIL@5no?C?uCN#>0`dmgN5toNDBY*G78%+4Q>vpk*RP zq(er@aDRuDhcafO=WRq>Jx!C_LAxOLl)nM^EZS!W*?u77sa;~Ay`%$9#+Ckfi{?cGdbnEUZnPP?crCr zw?figi2uB^jlG{HJuJ5Mn>^-jTrPER0Pe1GOp{u>dX_%MApM2j4m=-Pn0&wFKBf9Y z^~b(ZzP_6{Ih$3(#m{uyI|1t|k7_{AOt_#T zUHljq39s4;E{vml46TMEYZCZ+y^pXE@IxX|17~&WrAM}K^&5DJZ8T>9Oh-ce&>|k` zcT6TnM09%-zx6}kf^IU7{fBfyJlFO~8Tem6%IMz8%+=JsdpT0&hU$s$7*IX5;xBaK z$@%3l?#cazAv60r2zl&9@2mp7g*;dx7fE`6_!oLV(L#nu{>n2d;j$-XPfrMjk5qYj z!wYfI0qq#>bm$?P@=&8!<7kL}h(SS(qwh} zQ{emwo!A^k%Gyng&W~WgUu{63oyj+%=bFwwjN5x&&1%P0d^Bm1$t{_SE*V+aIqkzu zkt#F>w4mCcgKrc#Q{dlb)_gemdWhx}kEd=hPE@4X@pVv;W!3YhS6i=3kGnBTw{p)R zuQ0_a4Yaljbw{hgw5hT4&faz0Yf{X!5{y(rvJV(F&a@d8%m3oo;ktORKy!=}9qA*n z2h&b!E9EM7W-F1yd%IPp3qAMrB`j`*>cRGKL#OS2%xtu1TF?lM$v@OvV!D&0v!_S9 zU;M_@3TSI>x50l%DU18x+)1akRm+>4YjjJUR@`e9QJ7VK-*R$0P}lE2?_35%EaDED z&e<=a$eSNCF!`%d{bAqWm@L*0XaRKPuXX?D4B!U(BH6AyZY92Uf9(Evmrxz2yBa0Q z{W{+&r=d^&`5qr%IDkSJk#&L&w-RVE8hX2@o*zEvgFrTrCBi!vS3`Oe(bxluUxTuGEqdU6C${epz#SQG{1KmU>VhNd|h zOG$p>K2Tq3+*bE&Z1p+cq8{zB)~b38T0X?e3|^Iv;}js)0KQR{+Pyw(4=G27`<6_21u6zRQZrLq6`!l z+CP&F+s=rO71A|or$=>pP(cx+=3L|}$)hEnuD!c;gn3p~PAWW4PF<1yyfC{(a;lMI zXwWZ5##p=6vfa8y+Q_U}U zS6msy=_)FAh~S^g(A(b&H#olJI6r@)=0|d#(R>7rWBxdJFH?Z*UTSlw*JkR2xjn1D z`en~P>NiX)41}phHxM4gkt%^$Zsj+XCAqA`Ad9b0o(p1ky<3KjfX^cpW_pg~0ueFQ zVb+fp?6D696e~`WxQiC$kFpA}^KJ{K?&zYEAfqGj4$c2#eY>8#% z6=WquR64x)u)u850mFQ#!I)heN)$kxROw^xgfzgdXIR5+_$c9CS7BJeqNAjFeA)2h zJdn$nQ`l&0TJ})DQ#Zyj-uMS`+Hbk$$MXb36Uq~(a38^o zpMY17-b2nTy?3z9o?o{e#Olkde&?osKxn%<2Ri@ zB?B0xmp@W|u-lfso1)%(*}VCB+fPmfapQpF-@N@!>7*$C(}_r?1|a2~CcAyiSj=cX z)n8Mx_g>AyTh-l~FA*f5$TuJngcXa~q@&YazNl-y`OP&?|# zWnw#cyl;u8&#vXjZ3jBX^UCh0Zp!T>qYd0Zpp1#2&`~0lyY1gxA$aX}w;@@tCP}uq z&?43Ee}x3IVQ>!Aov`fGjs>moMzvY?@)NI<*u6RrNgNbp?bMLtZuvYnwUSBs?qoCk zz;oQi<`LbwxV5c%QgMhFgmpw$wz_BxP<^m~@LVcV?}O((cTcep#jN_fUXkAaT@@_ZdjKW(z+PX#plNdM$@P}gx7OGMU|-3VJ0pnzGAfS`wS zwjHcE?3m05ggy*rKj}zkC;<>1q6)TB0b%V(pG>14CkFq`AOaw54ZyAK{sC!2uF07E z9ccsLrFxV93AK4cW{1~7hqfoKgYE!mY>Ocxi`@iSl(2DgP{SzyP8`Uhu=HEZf6uTmPM$N)&zpBvkjTORvnj@LMFtWY4GxcEp z=e#ZR^PqZTO#z+Na9+(*@Q0AU+W*m&@Py6XYQLYG3A1^0cI`tET(yfno{g*AN_^Ey za4gAaurX|cdnQe!#6ai%#-Z*ZBWXPBpC zUQlYw!ge9DVkRmdWxh&HIgynPIbz9b1@}`WIogHCHJr$j=Q?KZ6_ER6KHA#uI$>K| z|8gDV>c5H!EL+)L02f7b|H$oQjL{YY@&_ybtS_U=7|qrKv@Dlapa|gKQl% zTAVj%m(q3Fc+@Fet5OntzU~mwy*1asv^+sNe6bgknRrJY5muwhwL4T3ED^lcd#OX& zaXTtOy}_PZ81|&vTt#q9RN>UJhM&xw9M4QAQJOsdEcZUv#beK-q_ITTd(a_2AegO{ zJWygcg5|wwcf)#B#ffX@l}jqxM)TYftbaBw*X~BH-D6r?>Knyj^Gw5vdS}TzB&JCP z%$RU{1QB*q{D_w6_;%*j$qVic3k5X*<)P;@fpi=nU7MeJ73l0bTo>MrSv}JSTX@s4 zB>h-J5fZ9lpF9~=f8y%x0}A!~RgR}AidymYLc-AXL*U)DqhJvmy40fnz60C7f4La; zEiJTGh||4x6sdsXsFbHw*7W!UX+&0UD|a~&Vd`Xb)~d^2)U6Bpj~e>v)4h`LqLp@ zEB5za@@F^jNZ=wv@k6qQFe(OL3lokdD`wyR60_SF!SO)!&c(md>$=iLg8vekmJ}=GH4ytAf>^vg63ln6ZWy*Gxe!3-kUV{16BEpo^6k@6*q=8Emm03}PWUv0v?Kiy=e#6uGCxw^9MLI{HE6 zIn{Fe-uP*E$xv*L%wOm|hTp|BTnBOEamzDnQr$K(n7GL(-*Ffx{+_xio8vMKIfA2I zU}BSz^+y`?OlL_KUW1R(q!`C~2Fb$K73&}%s8f2BrN-7fZE|VwexcNmC%jy``${K} z){xY_Ld9V4zfPNG)Dl~7A_zMx;07d(i7QwT$JT350rOQSL&C%vH>4d`o>oz8_ zgKcTghzALQb~AQJKPV`&i3=lqu2DGBr&~oDvViF9EagORIsBTJuJklcS&H?=;RPP1~w}Mr_$;my)d>!>aE!w&dC$aLU-efBD`H{Sc~?C@^D!Yn`2uy=!z+#ouzKETGTT3|E4-dR>#E26#tl7vKESO*b+ zv+Bpp&xIZ%wzdI3y978(&!?2$A6yez!O{WQwkO2Ur?GTVWqKX70&tn!{qI@v*fGZr z!1D|cjBRBxvPgYIYsUmu6gw7a3&i9D=zd}(AYkH{kp@T>4Yurzc*Ar84rIM_AhMo| z9e!!eu7Y~i)g^lU+MTvTBqHgmwvMEq-86EODGK>VBA{=g0$?qE zZ~gq!_n6^E<}ZuoiwC;g0j-htf-XK|m?BMa4a`Cs}L(38?ge<5yZGcqkBN%cm z^aR2Qe|)|Vvf>PeQ{jedZrh1fH1APwq!{h4?4?s#W;N*aqDR<{I!#!&rp|b~FoS=1 zA#4uqF&vnCw4&NWXfbmRAQ6NF00LO8Kw_`jeaie&`0Y3E-{axgA1X5+#P%3h7M}Oy zD4P=!@%topgds|u761V>xr_fG!*~i;`@B|aOgy$!jm@sg#LtwN+Zn*2YxW-F8o@bDO!`B%Wyaj}h zP;RtJduGayIvY__bh7hj?`&EEGpV)?y=g>60eO0WJ?2(IHeY}z=!yL^RZ(V z=y=!in7ir#vSw5^ZUKR z%%6+ls?WbHbYJodVMT-YClSaLj8le-+i6p2Yd2cP?d|!#JSVJJ)|i%l27x1iJdlk> zwQ(&aM5u8NP;T?W!z3BjO-jtdEQn)_AVyodPWhSR=!lE97r)WjB64i!I_QSRy&?t( z)JBuvFuiN7gS;GBdsmXlmh4Ld{_N#J`r#S)P%SgMgo`y*x~xy?a-)i20{$-nVFzVt z1o9%Fyyte6`s1F^Kri0({TP~bFGqpE5FP?OxTcF1`|$nzSDuu*fVb0G)`NbS&*~B8 z|76-yKYA6ZNg@q$V#gvL;7xHX$YBhIti#sZAG895?6fQ*e%I&4v(bJF6Z!pbRh9OdYqGxwt(w}%uSs%AeCx7?(RboqGrf(;rd`YvKZ>uXxp;dhxmat+>C%>2 zeF3n!ofEmpZ6&yh#$DByl2!6ubWXceEaPzS{yG=-kAFIG0c#E0hl#yaN^W1gt6t48 z_$Bv;pco|OdX?qB`e8;3gEi}IYsh&WYt5g??PPZH2 z2g3tDB3X>g>D`JQPs6~ISeU0>ld8XwP5Rk#4+nRecw9{knnV3`K9zen@ z2|v}X#nQtyVU{D1Kw<6Z)C>2szeZGL1;~8mysOH|S0^wG<5jYQ>|vg5Rm!*|sr;rY z{BWqMS(zkXokaLqLQ?4_qc#SRn0|k9%}mK{I{*G(7GeJ4*Sk&br&4-)FFNj=3zp*c zSFP~%HTQLN6wAoDLC)-Ye>PC@^-)2AKMuMKyh)r0j{bA-+bhp?khltDrLi z#C-G@{;EKqMabPVEU(}$a%tc~vGjK5(3E&<$H;{Z&m&Qvl8czsVU~MCRUuD8 zR;=e=t+Q(9v17r z?Vb^Kji1X*1iMKxeR1?O=->?Xa01IE%AG)|!3RD}d##2Pju@9{_c$4ty1m z0BvB){K)O3@?5gLY5R$jIhZSU>e2FjXK80(ff95+KWMJw)z5`3E2^L7uh%+p3<0)T z|4D6bdPm8*iW!~upVK( zdisCu$F*MSa|$>gw5t`w)_pYp|Vk z2-RjC^!#M$Ita;!os>nM-+-F70Vv(fh#YHM`XshHnSB;`ODyz7V9j&A-)ywsxUax> zCU7m%aRkob0-X8Y3jg#0blrLtiZsjrBfwsHTwr|Iv3Ob(ySxoMxt(}~5R^V*I|CJ? zb&i$|$oO9~Sg@9!Cmcks+3;zMvfj00S$jIB+|u&2Io@cmVJCI%VBI}Q30wv7dvE*?PPMK(HE+lLV>;u;8%LMP0XMh6g~l6cV0k4?O?*Ol)r{8y8NrAWJh} zz<97-H-P2S&OnzB!Pk!Z2m`8N27w(0pn7Ha#j8wZfFYYAS;Dzg7N!*GNP6beLKI?X zM<=6VxR(y6vtovPn`8RkN&h&l!{jYiq=u23dz3QNt3KH*c|-d72i@%*ED%RCW)7ZX8_ramG^)A5m-%3R1BSdKqN4A&m~ zD0-02VU8qwR3XVg?z}d$LHm-a(?%H4u+qzC&M$8-E*)A3EFA{2?tLsG_IkHI{76?7 z@p<_uV3G$DfV@NMa{VoS1QE<`@sVO2c=ibm+cjcv4yk4Vn|OhefTTayVLU5FP(vuv zUB$|l!!+bx+r4XTTY!XziRB>HZ9iC_@Gu-z zwTm24T@Vcb?Hpi?Y)?J(=^5#AUU@;GOalCZRzGfxOZqeH!W3k?#;&BQbXI77q_4m1 zSlB^F=TcW65TZp*ryRF+N*<6pEoH~vS~Pe{>YDZu`XP@6majyREz1foUn=ct@H{H0 zFreGIe^q8xXK0&UJ$a(s`A7{pFOrLKIwg6DLzy65iQiTiFH+H?3z_YCkN>{Avl!2d zK5*!v<1QNsY_@GM_LSmno#0YyKn9t1kJNj6pw;p5;RD`!yYSk(^&nSK%gR-#bSjoS zkZdCrw*_;Aw$;!h=Xt@hMODNK7w-I@%w2Lw{%9*M)|uS4aM#KWA#(!tK9n<7ga|g+EXjFsmimZ zTcHxzyVHR4Td1wk-3s>Qo^0_$uPL}hSNdps9Nm@}NBH>bpCn>g9}8(n_P{!b8irm6 zF$~s+iGqt6^#5`~c@pQ-vJP5=FE2250wB%%4+L>m z;yP#yKQ&0*2Us{R>YIy@+q6GZxT-WIFLg*P&1Q;KWjR{)aX!>Jt|jXGgY=B4)bdF~ zivk7&Qe6#(On}n~({7b5B7EPT>qxjN1F43T?7(}_=K-Pf8W{R*xKDpS)u2qf$~lRz zPK*a54G5X~!xOAsgKO$efFG*N6pVHa35HDq_K^Bs99tC$2oe>MG(a3Vx5~cKhoyXj z4eOybfN*1A8KfOxv~dVIi71Z!0jyC}K7{Fv`~7?!<}tYd{IVQ&Yz~m7MFHRR*ve-5 zfzm~HV1dF7H-9}Bl9f;_hjp0HPMFaz;22x`-oigG@{<|A^hpd$^&*$Birxr&XPg`Z zM@=YRfPZz2UvzBx48V@vGZm}Uc~_hHoTBGY`0GYK=rGZ-zEo|kt%@kpUM!v2XCwUS zkorrwvFfdT%l9+^VxJM+a}hl?g5;St=O;NRh27v2`!1dK`ctr%Lc$OLg@tn;BDzxK zo~_93n8_E`PUjB)$=`A1#zjpb_#-U6mXptXjiE_vwTBxNl1r9r^d9cffAHNI{d$Pd zqIcW-wA#+q=I(`>C|fUk($j^H3i=j)rrMTKV-wqaf-jABXZ=7BeVTog;*HuIisdl! zk*1t`dlW_S(r09ruOY-6!~II~Hd^p+u*u(luZ>b;0eK`K05${QdyO&^xE>_?oVe&Z zDAQ;iq(n%7*V-@{o_$kqzEDcQlkQ*0-_+IwAcU+obpT)P+}ecOE25wJLJn5WH*)#D*+47 zeD*u!MeLFqdNcCmKa(H9&3U8&GNE-I_(7zfz2YFdRnXyKD97E2S!NPpCb`kZARpqX ziZ95A_*Mw@PZDiKnT^^VnzaWB4_PmwA8u7al|SK#-Laxp#*`%EV@3ug4ALDg*Nk-B z9(%Imam+WqWRNUTguDMc)YW|+`CC-Cbo#fbFL<1O>oxr;-uEX|;NRo6|Dn?}by|mq z#?v#hccdlpW=Q2rhB=W_GHT?_4w}M{fd*snG+IT~QS$04j!Dr^V~N&d|ZI zRGVSobazI7c<1#??#jMN8%llC^3w*ASg8fY9x~)d?{S>85OVKD8YbgZ?&xOPK_b3r77kJUPmBcA*Zp zv!PRhimkk*8bjFJ{#Ub{k#8$$W|VR%%?Cwf&6*f5?;7KY#m|^rHH4swP{mmp;nvjsTyGCMP=FfsIZfE3^SkX-StDcEPJ9XNA{9?F(wJE4;&;^UnM zdQ)??wnT^RkvrXV%=s-wlH@>!R^sKzjgh%_*>HVkT-cxu|ZyUkwA+&b1=g(oGY8#!+Ag>6QR9&Kyfu z*+&n>zrtnwuoP1Y3j*hQ%p8I{Pg|dq46fYyBzz0{!}&h5N>4|n{3-`om6wsHt^?*r5RVk*|E#%W2i%uK5W6s{s}s0N&U&@a8+jG8!PC z8;fT#Y~9j}>{0+iHg9(C`Ax#x|BIwHZ_yu28-8F6|D9>$v&OWU`a9F+fA%9jAU^!C zU9NjoR(#Y^0kWJ?J}Fx_H#dYoy$N+Ewk>l;E(eSX@O04{Dm^u{>EWlKi z!rQlMc8Z2;DOimvZ|<8|nL438fJWY9w}shSXBISx_f&6>xP7@recVr zm3w!vU*UJR-`;;H>)bT_lTrNPoII6mx4;X>S-L2rj4pFK)5K1!N5Xzb>s!|5<9w<9 z^iT%xFg#?i8Y_^;=pI{C-m$UsYi_i~k-C+ACQ*zIs%QmPh!Ca&wOh%p`(}A;b5?_` zY_Uts+@(zDO6H7mfQ~#y1f|n9ZyWQu#8<*B?u)_QQTe_%mtpe=JBu`r*w0>3BhY{n zxeR?PpzdOIeQC3mR{jnNKOuDj2Vqp>ZV9yhEqXP4>i1cy9gbiPK#B zQr$1EA`Xtgf_+5DaWADJi{7H6zny+qi?xkic=(9l87~iH>i}+LPii(< z5=L)Wd#}P#BaQo{+$u~zKGX1v7s=UC`=ztzOhNmWO?04JcqqfYiQB&C<`j>)X|2DE zrkUNoLE~dGlULY^tuIMha+!898GBtEcJYPJI;Li#k3*u;PzRBGh)UrVt_O3erDV~d zIhz};b?L{x5Hr=|R4^J0|FV?}mNeeV71e`wH`|hJtvV7K#9)c&@*(dx%BT&)jAu{t za_pK_KTI`#4aa^d$)!ejCT*6`YmvFl`zC3`T)Gxwj1FE88IwuSLrIgoA88|GNrW*1EEH^1lDDC_pu zMlE)6-*k1N3H5~6i_7Z^3Ehjwjo`$bsf)WO@*3QBVGWR9k!|tI4m^N4wqk z#@scvE_w`4#Vz0_OIXKnZ!)Ls>CZ#=06J=S^6LU}lkpQh@lm*fr{GeLGe~b9cB%!; zg4@j(&1kk6XJj_Jq{n^=raKJkebfka3i1}Ik&qXdw@8aQ(_%t!bGUs+ zlB1(Pc+8sj4!eU<6+t+T7|2v_DO!CLAj*nA4|FuPT}t!czaLH9DN zG3!I2vjDY3DJ{ZAeX-9nvAK8rqAjMScf_jP zFv)vR%8P2E4atAAAD`(>PL01$43<0lG}dv4(}_V<_7U#Y=X7y=AnqkNo+yMKh2w^U zTvw+Jwl6L*e8UHq>dy&~zJYuGTGyhoFMWCvw)I-B;wkYb@H<0E>g!6+X}bdB{(<;k z@1)n@Kj7Yhs+v6~P46)c(r&#SEXx0=&cAMIuF6&0Pk=G;SLYi6v+3U;`>9jw_`aJ} znRXoaMOLwtGWh3?rtX5{2K$$zww!r(a9_`{fdITM(^+Uy&5i2Ve8I5Ps%q=&vu8d& zQh(|64B!=<%*HjJ7}4Ags)c|JBROr}|J`zG_&qwhOwWmKEzdQ*2=4i7UH9V4(C$mv zkONoac5OZ*U*HUv@Eu5(E;7fIMf}x1v=#CSsZ(vyX?ACp7F)J8&%~*(r&l5fvg~=| zsB}3OYw54f_J6z@ix`I|_R0->7~#ISTh8pXM03Gs0Qs!J@CB}bw)z8P~FLpHy=@ir9RZkTg1UIG$^%lxUlsR3DGS7w$>6QG& zz8@=eTAUU{yr25KDN3zj6^eQ0z2hXi;$u71&lj+arKX}CbhJpyV`#SZ%mV=iPp`2L z4+IyC@_cLXj<#q{c)YS2pTh~8QE)s?+p``YOOqO&$b$!o#Ooc{pRaN!?ao)%6MS?> z$Y@6dT7j%t*>VfZue3k>nuYz%{xkjcV-Llade#v$#p#G4&!AT=I+CUq+slgE>xyGP z#nx?7oy_Biy1Z7>=9i*2*jeZ+U07gVqodV#$m#qdhUNh&D|dNp${r%4rUXunYT1RY zG`0Eo;X5SNw2zhel>b9Pt+e| zQ?iAqC=&D>&9BGm=z_bZhf!&GFz*}KF-c5W=0g@%jo60Y@$u;wRN}e*7$>V;>!;w& zTu}19VVG^B%hG(X(rZ<${KbNsyvgJ+*5uLCt3D+dbqAdb)VvF! zM5}+Ge+BPwo$!JaF~V*c9^!d8A(uaq&tqcUsH~IKa)T9ny~5aFlz7_|cI%v@x{Z{^ z_St5Rn$rWs={O>j6Y<*T%X6NqG(Cpt-Kv!pX;ZMa!mnAieN$fLS!(KTJ8lTuH0W^d zX%c(1LGL@{_4#nV`>5*gke!y#7#g?s+73(1+O-J{_T9S$_RfP3qTo*nV+!4wpn?5$ zb&(p~e13OJ$?TV0WXzap#yfZPQuQJ$Q z#HV{{L6@5Qqhj6f?3dvrOY!q_6&J8Iel`sM7?*%gG>*r&TGTw2I+u^Q7Q2adll6L?M~>X_!};Gd*xA;aJwL?oWO2 zf{k{DsLz;3QoiedJ~a2A`3Ik1ze+jy)pfitE?Hp$XyxOt{ea+;Cjs8i69wXw4afsO zPi*L49gF=C@ndixS2Mvc92^D(z*$=v^xt4qQWQeI|0-N zE=?Gj5^~|pfVHCG=HOcMb9^Z76-Y$b^TX{{7$t-g7B1({uZ)1-wHGPHv<6;iJ`O_= zWrv&r5OuRTG5r(@A)lY0ul;5&KOC_PegvU*JP~ zj8oK>Y|A%qID`z0Q{C3uQgx=#=~wIZ8$V2b^J}`_AASp z&U5^m#m+gNt4(IZt z39!=Cc8WZBWoMOD-PQ+9btnM7fln-OQu1D>?rJ_{r08B)?Crl40igC-cxwra`lS7# z>Bf+>$O2Kgv(Mw~LDm~O;vhqP(q^=}=k@Djd+ls?NjJ*yLF*(Iv#qF3t&PO6e513z z7g|4`(tfVD9Tu%VZcdyTOiPFowSWE$l9u)~*!xiU0gSBE7koS}ZF=%=mD+w;Rlob6 z)-;kHf*IaR3wSf2zngIdI`gqgGD_)4Emf(AFl0i(R>J{yTyc@Yd$Adb1Imoce zl+!d@C%Gz2X@^vH>SbtI**<}nCS2?d$U|ODmGi@x?NiTHIX?Ed?vfpQ+VnYyav^_F zKb)z<7NtbKNjaeDn7(V*IfHO!Ek;=3Uk_PERv-bX-GsaXFN`x<@kp78mwgdEv5^}% z;P_Nh2ZkGU{yT&lQQ5CEa#g**Co0E0+SM?5`X=YPK9?QKXC&1983a7& zQmB5$8BA^6D+~#2PZRE(BFJx-Nh}0XQAiLs6^HHGllNp%dV6 zEQb_m;e0r6PAN!@&p+_K)yMrH1(l+|@U!hIbteQ_o9WTg< zHu`u!gQ55qEiaN>lo=0cPp;kP1Pbjz5 zgSsKvsX_v^pTXS^*>TkFF)({Es_4sG^!DpE~MGiefNCUizMr;c0-_r8BtpXDkp^dX^@<*qn+MNc9K9@ zg}8$Aip}^|bs5N|p#_yq)0g*EU-?_e9)Fv*OyQim|CpSVaF8LD@@=`LFz$MbPS_v| zx1x*crc94;w=c^KYah0vYU(#mr?@CqzCw!<7|6NM)!b21mC&0h{fhgyi8CHi2_(Id zt3jve$`~r4Ul>bPA6}rvm}#(6L}pdbJ-T&pDBR=QCvuO>;%`*K{&(qqj@mutE@t57_hb-Zq*h4 zPaSH8ugfGq6}*@7U6NckX&Epg@K6anS^+DjbGiFxucwAw*wnlC&b!JTk5>|)zOzaB z6P7z@Ck6y)NcZe%mAOvw)3G}ua^j{wt8hc_eW3AoPyZXgBk0$xW`SR^nmeK8Q9x-- zfB^_;@woTXGa3y3zlESjb#{AA39R=rHGF@5St7jJninH98YjcZY-e+nx?qL0+_@fT zDam#1p-0r*$O#~XP#OeT9aETf1BFc?NgDoTNg~lR+t7NW2d|zOtfGAlW=}1{eCLse zP%v`9N)<+Y``pdgtd)dBy@?lzsbh<*Z$~*O+7YN0GB}q+2L+k8tcs#97Yy8Smw4ss z5fjt2@^nm~imJA#UkQ?&kSKl1%gApAri1s2+V6za^_+vl2CN>zgt|JEgQ;;;sG!;> z!_yZeyzcP1)cEtfg+SI_!proSb)imm&MNIZ?KoU`kSNZ#F9QPEaDf(O=X9MSWR{l~ zu(Kd=h$wmMz}sX9M0ly79J(rND&GknMg2OYAqqT=(YmkDcVJ7X*xz`Gg9OO7G)09`{NIq=m0fr&x>8pRY;1xFfjfB0Y{bW$v#u_;5)?PCOGimfA$(_h3M*_s{KL${qeuCC59M5 zWVtzg{iC0d9Hg>kvbHB6qLx4gge?><=R^>4@-=VuNyB3g9=poD@-=8g6M>;9lx-e1 zY0Y=o)5}n}_%Wh$q!lN4Cl|_MyX0=whduu>t)Jyq5G1Hpd%wTwcgPkTPU%U*?w4M>^3AWs)}AJk)`9F| zVf%P#by@)W-tE^{)p*N=-;Q!-pU~4O}$iTKGkD`dO{W>PFz_EP* z2v~Gl*muZr`z81v(V=g8MOBNdKg=5=kd$@m>=%MfnCYk@&IbXUOBYu!>jyK>r+68j zGi13g&cxyN1R(1@8y=nBZVcCj#r||C0%k?Qls!*+>3H2Xdo^BN<=uhwZh48sU>=o= z9I}!5O|hm^%AWuM+fnpw)@vg`5i*?SU#V1XB;44qa==a_v6N+Y84o$S$)$~=aUBS_~`jcNS zYQ2OFTr8)S&s!j>=GQk2A%*MgLmOZBeKXrDaP;iL!|#xLaIRji()-F~&|v9HSaOj4 zMO38WLO~$@;;f)jGVb`4MGxE|A6d2SX5FT>$x-19=+=2=R_!H%yw=4BagB zz1Ow9DsutEQ1B13{fc=eez@#-bz1%ioMwQRu}5rTWM!Gnc(4;>WVdRE-Epe<>z$>9 zA+A8o2PQu~ukPdc<@nEH+jq&+vcyoMI010)^Kov10sI)5-~7LbC8Y7NP_2 zQ=SUt+}TARl6sE|>2qxjW=KL|PzQpJVGBP*+V*~9Wjp1K;+{PY2Z>yV5qK1YA76Bw$cnnsmjI7n^&^>`n!b2=VOP^%z#mq#;?M!cvh;3{m6i$a^-kG@YO&@+jl; z+v$Sv@s~dBg!LtIBTal>F~(>!gQTW&MY-j6JmK}(pS-@@7oGk2;Es7U&<_2BnEA^O zh@a7>M`3wU%n(xq>!Ch7>^=n(=(9bK5)=mFp>iVL2H~#!A8JMS4bZedk;0g&wG<-(XI;1A zni%vj%YNFB5MFuDZl}KV=u58V@Gahc3R47sHVjDfmibYQ-NPU!N@h@yxQS_gKNK9RanwrS3-(}XPslf1_8Z`*~>q`^ihqj0`W%GO+0-mlkuu^fvD zgcG;x3@z2-bk`a%{>A}o+W{8=qoz0kq4;i-Jvzz)HCS&5dF{ z(LTv8zkr$O%H*JeXE!=11Jkt+&XN$m=JN%%V7x5A*kAy5up5BXJxQnglz9ITq`{;E z90bM^R`Oa|Q>>Bw4gt9t?^7}KeWsN8wQNInA^=8C|B`Kp*+>}6x&>QqMY6UnkN)Hp zRS6x2yzzt808(x?FbuC8|4PFcuhT78Jw}wwVZMVw0Bs44c;M68x#gY@v>kHZ`E2t+ zq9Q>-pbQX$2Tg{MdHD~ekwMFlZRSFU_*@#4>nq7zKr7i9!?8cDfR>v^6szdd*K!pw zS$IZx9y-L{Xkq9?u{DfT4JeHC8k5fas)|t)E@$!;#|@5riI=qHb&;ghY9s1x*!Bw3 z&*|UrMSlYf{^l$K9NmkR2B_>ihnwhMVT)(}gtwf=dIor+j4I6Xm%-IKLxw7Vc2|M{ zNjs6S82vjM^Zk_&on2mt3fFrYcpRT6Y;k_O%4yAox7BJh;mVX9h~xSMnUrpY2$xoRsV%1hv2?NR&L ztIs}7(1i;&VBy^*(6<7FSqoEVkiaf)1#i#*0LT=;c-!s7;4%cCPYw-7UL>_I{c3M< z8_)*p-E#!V*Z`();&rw+k+5)%3GTl33Cr5n(d4zlHW&nIAEICaUp>dKsde=4six}M6LajyH?Rn;6s1Q3h zx!4&|YuwOeNUU1X^!K64u-Pcj}Mip$9cTE5#w_LnS7j2L?*~`9)l#h?1 zZLjyqpBERcY2tLaF1)dk?btSN9ZPsk|{DKA?LAmWyRRF>7LM00v*m zu6NMxCiWSnahBg009PI(+D(>)(YimVbqTm>4yZpTYH=Eu059K<}vH$+)Wj|~a9T`gu8*bX;tTtpBa$(6pd?tLMm{lq)QSGy5) z(9>OMc4ozGi*=IT!Iny9UmuB_S^z5eCWYzaFocF?SmanYyWh%@> z1(==%;Z7-@)@!G-)+IjJF7w%Hw?H8uAmQFb?Q6Z+;j_az(GMv5?zve_X17~PKX$reMsSI4qWD+i8kni*Sn zvnab{2bd>^pT9Ki$TIEtS;+{LCnW)hT9mSxNV=Rt7r|Cwb&ETc!2@H5hL(m=oq=u; z*LiS$q=5ZDBlCCtp{1bxZ5ga8kJdab_N6i97`t&DOFDOGlkA zjy+;F?Un7UDR~?A>;y*qUk%6}rP{SyWHFDwR`r>cmIx;G`zt`1?h1vh=kB5om@RhU zgP-&RN7PoX)dQSP>dYL>CQ-L%uu9xYeXeD=Faq7B@&Q;37fKh_8vgn(A$+?*DlY)> z)*|>nfIj0x^NbB({8|7X^CN&S?#c24SZ+&B8)hwm58!B2p0#yaZNz$k8G8ww)?chX z^CEN?&`M;iY)HMw3UFCCH&1WZ+5g&`h>)i9A6;{@ViI#3oTq8G{! z8%qG$Smgl3p4f%&q5)%4wzm>X6$k=wi7=2FvjBP206A;GLxsl;wUE}YN8%t(l`!=sCpyAxPWA>SeW`M@5?Z}Is&IE{j{XL0O~ z>@X@g{LMx%D~=dy7J38nIHLK|+FLcpRz+>?rJ0pIPh83gNIGrGYu%)*;3vv~*P&21 z7QsTKr6b?@et(aWAU zgiZ87%~s(RM9`s{7SzEsyW1z#5?>e}l&VkWWZ%F~k-t6dQ4Tzmr4($Fn;W`Orsxs` z`x()1DcL5WORkAc`@q-f;c~3XbDyu!YUnC~8d9W+I+Y(Je_Q;nLzL?rd_w;#Qk~tR zzS}7{?)})T|G5a4Ig2{hCT1oGQ}^s1You)LluUeY*OIN>Py~AkjRn|MuE`@K2_$}A zsmd5w%RF#)lLcm`Mu+*>P?p|(=} zZsgk+-hfF(`%#J*4zFY@df3@q*}w_`4Q@nJ9F7#_`VHSV6fb1zIgBZXlXg#!)D(8h zoqrWBVDw=JEc-vW2rOUQ-klEQ+Orz{mJNHEhtt`0mV*qPZeC>IiR+zH)T{8}d>Hi% z735t~YfYIdLi`1YoO;aWH{T&Sh_`DESgbXutGS|syjsTv*%B`5EOI?S*_B+dBDbqo zDw?*O!UXmi0ZBs@0=vQ7wmRV;nw(oD2pujE!VL1^!0#c|vH6M)`y6S$b5eL=dHeRq zli&7Z&aA@9<99a^#W&a9z+0wpY}MAP200V*G?lS#+UW5jK14(NwHx~BPm5Rza~h0D z{3tF;N7Xz57bZS>GgdG3fcD`kUtpR3`xl*9*xLcP%AE(M-Mtml$vs$xoHu5MaZ|}h zj629Iv)dXL*bb&a;ScBRjU{N{;TEIVd`6-aDV+K=$Ev}VN(HcV^8fw$`Qy(APRxzw z2{6f9>N`VM?}zi9URo3dnIhPsh8Ww?h>c?hk;>;Egh+$pwM)3d=^wM9MQe1ugI9Ej zh&B=5Q?}H*l>>Ng|MtaF0u`MjLg0H?nbk3qgRQj3%*4)u2V?e8KJDgisXI99Cv1s} zK=TXt2a|R`ZLNV#=nuc^e}97h`18du#awSQU6T6(6~0a#I4INh*_<7_fbrjNgpE8T z@u(VAs<%=0{=G14D_9Y0lR;BQ1kC1tqRBQrld1~tUgkTF^LO{M>@_3!on3w0cRB)V zTqXVoH|6R`8A=XrW*%;Nbjhyy4Kd@Gz|>~+GxF4xZ#1XjkKukP=K{`YpMYSD9cG$> zE)dl#F`M&l3X9*}=Q6d0gYIvkcDJJqJRE?2zq!hpdC;pbqHW-$I9ktabuZxEC*P3? z8V;)&yOXrAy=_Wmu+He7?JS3jB#h5eUFPn}qZ;h_IQAKb@xj3O2rG(eW%QeJhlvrU zmDeruCd%2n%Q9?^1{S(0va{`C;5w}!}s%qjtlfD6$5=M4=4^AQza4=*d z?ManMhl`sG>=r3KrVe2tbHWFm@vn!IaAp zf%0m>wy+i4)LB$OfMlqlk>t4AD=0-W^CT_n^WaKvE_et!de$;m0IG47ajZKG8)$TJ z+QEBU3Z)Or&|drGHv4_V4iU4mW-de#T`@DuYt#0$h<3A0`eVU|GcYM&MCOu$m|{hT z2_lCM_Z{<$R-G@F=UA@x!jvb(I8dxkI#zMrlhI+ka)y~B{^-VkNOqvgDNQ3#rmT25 z`P;L@cN@52K2u&vF6H#M3tVsN#{H28P;N9Zqud+cqmI5dN>r(U4;ClMzi{?>Tk>Ga z_1+NaGgOidT;Pi1@1Xp4F}7#l$E?hyhm1=?-{N-Mf05*+){o+*d9%XO1h&~bj~e5n zSi;-g_~dD&VeWLR_Ru*zCsUhU-5M0CcElwEsm~4#KN={+w5%>>9h}njM6UOd{tme@ zd9qsk#gTSpV4LacNmg>Rm2dR>JYC*Z1pBqTV>bME>W?w3UyDPw{F4uvhp|DHjzp#5 z*qvF>Ur{6fH>xpbTbxtM+MQT@Dtw$QhBGgIVP+?poUpX%Xx<8xIs+zlAv_O*5cBCU%0hTeN_ z02JR?VDjI;Xd3&*6c`R(wzCR0P~B!HOsGQ0b?{5tp{!`2Y7?6)@M=PxP%T^qp4UNp z0dN9~G0t=cwcM2$90?t{f|<|f0$XjiCe@?p08_Up$fZ{&ao1>j&`IWlfBz!xjl$F! zdNkgW^~xQV??vydM((w~>5E&j=za?DxK9dS=X>NYG7wQ&w@nt}E}!Q44sq{)7RA=g z`IkfX;VO|K#fZu#o+(}`H_kn*;l;xXTMvq7@D{CVU!_6V!iZs9RlmaUc!2u`1}CYw z`shN%_^w$R4g^Z>7DE!e}=R0>4airotvwdJ+EX|irq^uAR-`U()9ZO#^ z3$sSDL_emq;dN-=8q13ca|o8xF1IrQ@I@uPrwNQ+4jEwtFHLtv#=kwSA=sKo-ix$#FI?-FOby;82DpbE;lGp-`L%L22C3X4xe)gA zex*D9ZTe-W^5d|8pA71Yqf$)GbR9VzBo8D<9y(uJQ0DLy0|WHU;96<`M92g&pM2mxJy=uqb6}TWCeZgf09$%JP|hZk zSbkZUr3<9v78~yVm?m@2s(CSGKa`joMnV9DJHynp*pvsW_|SDuW&F!T)HzBtO};!{ zo${W68Z6Ac*fhT#nlOE9nAEvb*({KAd2Tpiy}9pP7+$q z_Jri-yFU-jZm;_B0SK^-Ekqd(A?XHjCD;K&O?X*A^)eb&6A>u)w7Og{HusQ2W?h-;5E zA+m*-=T|WUR!u_(v^O|;A<8wl{2lqk)%;G)K%$4)cGiGr5e4%tTM{lEMsiL_Z_Yb# ztCL&k{d&Wo)wFolH!U^?M>9f!GR`)zm}jkJfV>R->I3$HIt3t^gbT(j9W)1()>q{` z3Ck1#cA!Ezn-5fXZN>~Ffal&-re|(8?NV6k}uH-5n{z!Qy_qcf9gBX*1UWSFjxk5tev+MZ<;dP1;EtmM7 z)5dFj_O!F*yn34g#mo(Nd~BQLGCAR#!Wubeu&m>YAnK@6^wKE`H3O&v^&?j|e8k?; zcqTKXfj}osoEDK$E$;ZS z1a{k>MUr=>Rt70ZdWiP)Z8iI?&E7P3Vg1F$G z@bj;G9V)4{uzpuhf!jx1me!ZXQ&AKcHQj%_c^uVe=jt=BeRjVA)co-9%wbXvyD3SY z-A+c)CFc_&_QU(f-vrdjOb7O92lh~r-HTNKnoAPEo=jYHNvmU&EFUP6MLYKfz3;Uw zUuytC`FEI_For&OtaRFdU#S3PhsKrI4$U)TBRJT_bzm1x`uR(I4emqcjQtM^&M)Y8 zatR%xaG>u+U4U*lSuo<;RdJ( zNBfg=@LBn6(UZ{jIj;lj41 zp}a?=cvdPkmcK=1tf@}$9M(86wcUG7td%k!d{<$RZ<_R6=M@l`xVfimqB7(93=nK3 z5%D{laVS-s=07ro>jggzQ5TyGo-bGJ&5?It+v%Fl;GG z_OF7HqflpBzk2pMc??=5^cnaPe9=K<+y{plQwAW+WlM~#1Y?FJffm*0sE;GFK18k~ znyEvheY+QFh|Lu5Di}Eu=umyr?{)DYSoyz@YISy*6S~J#2&9#cKxz6q683H~vxT3K zAIiV*PaZk4!d=1^2JD#iTAHkU%2tWGi|!xe#fol+`vFf46lQb=y9TH)q926$h~IVc z-o85@TSwKE9zR0PCDX^|pmPX+<|gtyl~i@wNzSOV$K2*?jtVcU9SWX#R((DL99MM) zLG1Dt%mn;0;TC3fFW820li>vFrH3@%-;J866TjtDyYTb^i-&u>(7`=-}g zE#}tXs=No#bOA;xpjw|~=z+hd`Qh)JnFVN%I@_Q>>hEfaO#_@@;RFoh7(76iW1<6x zE#U_5fwvM#70&-*Tf)}(g`)rD7p}1fXX!te-7Uff6Bdk^z+k%ublo|S;68ZV`WH9PKm#q01`#c{h0Z<`y--kv_@Hb{oK72a6`?0$MO4oZU73ExpaW9Ul z^2q-3Nn_^s1kXPc1pX|&_6-L8^Ba7swe}4P{PP?9Jwx=DZxGOlF3=VMM-dMFn8N4n z=zfdceBc0QN(dL}h!vZKN~4Td!n%@Rj(XdvJyR{LLc9&maLseV#Ac}=HmAeD zS_90IZ#p|^QEWlvdi&zHI=v4c5}l?26DEC-b9`d68<2tr$JHhrsNH7*b*wmHRj|B> z{CaWT&uwXAQB<&x3^;}nWzVzUMtvOKd9athid%TIQht=qfs~|S^a?4W!M6{E-Ciw- zd3XFnVsg?I#=2;qSV~jSl0%fBS77Dok4*{pG^!-Tdbqzvy%&?8{MoP-rHCiucd(9D z_I{e)x8k-x!ti92K_B6YZr@IByUTEpxFp!yd+L3aKg~oB!VEw+SXpmONbkMUlN>qF zBNr$Ot$2HYYYb$KWeP7U&u$pzUIN8~ltYq3o;RE~F?ew|(%Pa>$2WuX{-cinw!a1i zqeZ=C!U(amg8SdyIY+edYvO#KcY=wLlHIR3Kwc7|?h_^}%r zD%jyW-Q_D>;VxJKw#*bkVE(K3DZ@;OaP+HIy&VUo#NgzD+d~Zh8Xeze9Zj0*l}m=7 zLh>^GTyo}A5ISFqwyzw)B_9%qWb<_jZ=D-)+&A>%_NVaJrrc~j?Jo)wn>j`a{%QfI zJ{2aMDU_GkKPu-oGyOQqEp$mr6Vc}Gg_>12&MygLP!|>b7dc7ElRfx^%*t`Q;()9% zic zF$FoLd4u%L_poK~)qR%<%d_fie@k03*fL{rEN>&AP)xO;1;PVVvd77hyO29-bg|fGzH6*7*1V_GJa#Q4Z!9v6=H6;sA4ob1X`RX_U zGBjf*o5zjcM~UuBd3H^5e5wTd8kmsl$xfj-Er}6t3!5gz8=5v@M}+i%@;=V##JX9_ z4MT&%mR{;r)Z)gZD^(tiBF?+RSz|EEfrp@;C2u)?UkTYMWY#@F>qGGDbHyPeF-EOV zY3U}ed~|xs6xEa(9%2vI~W~$CZNk7dk4zt=&L=Gv>+X4Z9YG~)aJ^HY8 z(1)cRV}f1&NV^GoXhb#}?WmVrJ0h#ZOA&9EQ6O&duLOV>*Z6p( z3SdC2fQ)a4pR+{Y33LDG^Ap?4L1sB6s^P1|d(b*F?X!OYN^<+j%^`1$^a6Kw?hWVDOO?%pb z>Or0%YE1T}z1^1d8K4v_Eku zFYm>?DB{cU1g$vZbv8}rkJc?`HSwZ$g8Dc+#UDi|DamVAcPu`#X_9*axtdFog`geW zDh4;9EJjc3rOFr@8hoL+qsGK?>#QLnx0mZ6P}3=80-%CyIq8INxY9Of&9Pe@5v5Z$ z#4gN!#QVg+APh!+r{s1y)jxLJo9%Y|7J4odRG_4b7zQJsxR`;r6x-^h1 zZiT7)^dx-xuK;?5-z)I`8IzW>`G-dD;AH}3Qh? z=DH?RU_cB=#aBxoZOv;BFVS<48;ul^(|mzFw^1jRe|Z!uP@<_Es^yku_eRVsd|HVp zsd&cosLl&M^l7PSq7Kx{1G&v>{7l;g6^dA=S>%x`Pv%_FN4C=+X_9)?sEz2{e*oD3 z_rw4484!*g0by{Ty{&Ss%ibo1A7dT~@I`b#S?0VC$`4+(+)4fxKa#l1LK%^77G`%8 zLayz91~=BnEvfx%98!~p10qyQb*TxJt*U24Rf zeQr>qz0dyRz51%pGKu;xxp=ykIfW+wWc1hjNnvkq<*tgqPIR~4`$c3#Bpmx%U+q7; zydiCN0P9>Jg1BgQu2eSgL^w>a@wlD0XL_Gfb!>ZQ8_rc?y7i)L5 zyy@1{H}_OhBuVZsnRb+#;PdA))HWdipEo@Ln@I*bh|8X)&>F1dt$=M){>A~Aud(!d zMRWr2zoQWUa)`IGpO5B*k4%!L)D7jCu<@Pe6IYG{OcWE5-d(tYvnIodXz)IWR_}CK zk5Oa$RPhtCuz5-zLtT1#2G32Ke@Tn0te0$vf-V z+{7%_z|(nPhK>`VWM8jHM>B@zEZZ^DY}L{;HazE}TR!1ao7D7Ywj^zoy+uH^0DT*r%|~FE{J#4< zNZ&XFn>Y`nsQ^Rn66RO8Ldk6>*#Sb|A^ytj4r2?SHc_|`FPyh>+tcB+QWc2L1JTuX zQDk0qTUA9{1^NGD?@Pd;Y}@`v%BV1@M79x1kwi(^CKW@HP-MxpP)R6DwizR`hOtD2 zP|6yU>|(~2B}w)WgHd*7EMu6Z|E1@BpZ9rsp0DS5-|v6?zvK9h|8aHH-1l|eH1~a9 z*L9x1^LPHvx4RD8Ii2!_r)aa?)^$%Sx>ENSP|6kcB7`m5C7@&c*e9OYFyIH?uiu3V8=TJc55E!maM2KcKeuPb#QKf<&z-hYn0Vez1EEOUtDk2H3)%lLVo{`=?`kb z`2c(Q4V(E19#oww&cb#-C$4bd@7V*WS%)xADQ1QWE3iDYfZ^Kp^TWbyi^6Q6iA9<- zUHq3O7BFO@i~psGr2-1^{ZkX`ucU#0-!I?|+CRdN^YCeLUypeMpV3oCvFmNVL4=oa zG~7{j&orV-ngrtBYiu~Wo`FmeS8qp^wr_%0n|qM(aV;H zoIvfQ{3q;wIoQy{+7`N*L1r-xNek+`cN}B^<1w%-3HgA)J|srDdgK82UFhAFDB>^cR*_#CxYbfK>vr zhU&k2eh#;lUT;N>ODT@;oIGtJx%+`bgoL+j1k}+hktfF5XgFDDGD)dp+q^}E-8&oY z&Ea{qFk7R_=@yf_(f04uO~_&{bryaD_GURpP6aBKE1123~m5LPJ` zPQyb(-7N3m3<@soeAb{y3qk6@r!q%18pLkdw-KOB<&sWi4|S8Qz5*|Y)b;Y)v~UF{ zRriB?Yj|Yl=%l}OECn%?Qf2{>kenAgLp0U}jv!r=3SBVul=+tg}v zHPS{N?st+*3eaWA9;uu3+`1r(95?!)V%d=X)EIG+zL~HVe^+h>&vPWE+Ur14&J_+s zm_5qPKE|O3D8{4&DTde(-F(tK}p2B zlel~FM;7f`*g9S-`h#BNp};^1 zKOR2h_-sX+83Cxc=cxOR%ha~;=er5EDU94^$qnN}oVNoRo$!PVLKIdCH;&Rn!>rKK ztu5K7v2zEy+khGfeEmU}iS}e>*y6&&%EkI>1JRX&Q9$O<@Df{XfMi0d<$p8O62bxS z8rv$c);j#1Gbq7v$19yviEic}aa93m)QeJ_+3VY#*N!2$1gJi7Up1^7>(4#mW(t`N z#4f$SjH3k5`jL&)1GP8%wHNL$i(*gGvxlt$4MUQou1+XCM>UXF%-*7Ye1g$*@e;aT zYO-k}xXsso`mh#MSKIDqrNm$<_nPF*oFEgX2`m?py?^J-&z{FHOa8rAMNCAtDnETc zzT%hXgP=DKm8z>z;YJSkEGBrIE;`nGHsPw4Zja+E=z!`b6F5Sdt;J{;@!Mx8R@{9f zHo6Z1?XOSMum=+*EJ-A$hRDCT?UQzHN*#@B%001!33nHNw1_`R=OFi8Yex*hI(D7U zy>!QWbN!kVS4tzX1?y!#!*49$eZ@73FbCM1SjTKbzY1Q<+j~n|N9{3`aWooJMf!fPP=1F9Muplf7v#U&8*lmeW`5o*$2mcBzAA7)2$UI-Oh&B6kC%Mk~kiy6Vkp zON}Fs)1vrH^;(3)pX%sf%q!%+!g1EBMO3arhm`UB^*0y3UX4F-#9T)GqF2E7?Tc3z z@ahyK6E`4QkDC52+%}r@3vK7oBrDSaWTcpu&sV|c5FRdK*uvjPxuMqGaNh1_-zYMx zK2uM<@)w78Xv75~ANnAa#VOyyK5oI#A6l8Fy9}iu#RmiJF^Kckbx(k+i6g#J6mV~~&ov!y1t^?-uhz(wyK74=@b6ztXT-VTu zQb8YZfdj@fe+NkiaR4{@H%{Cz>y4$o@N}IRfXmOjGE~ngo8uKaX z7-NKn-$!o;91VVXPKMm+1jqc09UI<}4)VJyd2eYzp_4klkc5490E=s93f9)H-J#2E z?GAIxuYUUi4KI6coQ>%%cN!e6X(uc2vx?Y~t_~Xh%_X-FES_i8-=UG|0Uo5PmZ0=H zYbk~U^Tb%MH#Fha@U@9NM#S`VJ#_<>=${NT3@b;{`sg981vJ>9q1u+tD@$U1eYjzP z#S91!hp*h^8HmuTwUz?e&jrCJ5bX??w;u#qW>^;AUzLYP(rg(6yH@}JF@59D>A~Oi zQCHRg!~aM1Q^0&Kz%n0*A=p*Gt{&^L{|W=i?kD*G>T(g7;R`nl$;)p&*te|_iN+%< z@m9$u`Y{vN8y64Sti&r}47O{gg(aKl7-pu*bhQ4`@!&!1!qWE=5L~IhmVjs{f zhr=N})|U+6c^mJ5|CFcaO5<{&h0hFuhe< zfSgCjjq_R#@FwX=*05o}Nnh#2{{4o< zJ?Q-u?SPU%1)lK_spVA9W{@PHY2b}{SOZ&o-ZJ^Rt%@SYyXti-r1r???L5%uYD0#ff_p8;)Fz2_l<&k_*{LR4Uw9AQ@!-n^ zZ`EImzu8b_g4`6=+jk3}P8WRW!qH%R#LW6bdI^Gc#g7~RSY2(0-d0bcp}K|i^1CqL|_T~zm=FYRtePQ~ZOZ#@|1++OQprukCQ&nGAo|AMfd zc{Jhe0Q{jr#}}m=W!KNNDK;7M4_U3es$0Jzo<@kH%TU)i33~WkP%(MXm^J?NxNg0? zIx@gzqDDw&%qxCTcD4Nw8<^m444s@zkLc_3Vp*8D&r$V{K9`CQ z-O|JvvJ%nCv~Wvfs&wmDwX+QQQYoBbsk27)AV!=Jj!(58>-}1e9jY28a!!<;%s9}v z-W$6zK~!?-10Z)uu6;dQR9udtnf*M=Up?|+F_0O^o|n;heH8jB{wLSr?-wv8!+}^D zvB+uP*Dl+5B_z@$Y9*BZ#*k3bR;XsrxH>oEaMe6j+STm{JmbF_&UkpV%Yk`(h{0>! z%`zC-xO;n}F;W&&)u1^{`0`OX0lSIrQ)32vU=zg*Eiaw-Zmz-l~2&vmes26Id|f zsq8H+LfDVpx!A#K6k8TYH&nj_fH>eL_>uh%G>XXiJ_Fj%(l&DX&f zlqZwv`vLkL`hWTQ2Ojfv+u_u6|NQYU#MP;RNaneJ{{BoPPW@8UH;BNm|3QWqVE|v8 z0mRqe{E*x7b@sQZFTdaRp0N_JBTk)w%~1p7ndP+^fMnc2$_B7{5WBQQA9I9 zJ%X_^3Kt47@+f^!apX3@8uY**B9t9*@@HJ=uL^6i4XmLS#s*6);G;Y$=LeSh5-3iy z=ex~BxcrMz1zh+S#h}75BakqJFS-6p(BP$la7s+2kEG66uWbWjX*_#lU4}FT9voG6 z=&>`5wQ{4HnzddXIxOuNo@V9$4dN3|5W@%A5A`xqtD_GNz*=`=%W0bwR~~f{#wgFj zRs0w9P_r8Mczn{7@n!0JqzndGo6Q(4mpI{>;r7;rlh(h9g@Lf#5qds*Gh9qBy=vE_ zytIgG)nHTd0Q~(rprPd54G43hOmn~$gGD@VAB=H}i{>r6NU?31g?(KE*bf?$BcPOn z&tCA71l1ecQS{21^tk%>dnk=A1Cg;?ZD{iZ=5GmAW?pGvqShJ=Fu02+9Jq9{p~ArqC*a zl=2Nyp~4RFqG0{ubEXUMr8Iz%D6E!kcB2933Q!H3N#d(koE-|j-Y(|qht4X3tE2P- zSKJuj>-K^gKm)h}h%gnTtFLpy2?i}Mgo$24AhewK3@gx8Q>_u+(Y z+#2?Lkee)mD+%&f=q!WXOmg4QM~70Dri#dQAp0xHRxZ7cJhNl4Y0=TYPv%K=Mek|@ z>`V~0`jzSW7I^x^kqnO@Hlc4BxU9nunXxc%W4imWJ5Wd_csl=*F2(*%*Yx+DW6Gc% z{72rwuTMf-fErW_TzFvao}+S_5P@cR9bAh-mPNj%I?+EPXpZ zg|Lop4{B|Vs6^KnO`gLRg2*sjx4!*)KTva29xq&NWNZO45Jc|PciQ2PJx)0F@Mb#u zvF=gktt!L;YZb-`4=2X)YSZ|IJ&y|-@4Ul~Kez|0=K*zMetsS0A-E@$`{-jJ+KMT9 zhy?oL3)~|YlaC7R(X8wa2m0X%rX*=o0pl^s;YBNBXQRfNBSJDCxi%QS0zY{@+7K{; zifiRHznb;gx%xCZ8y=0&S--&H7c<3+i9*?!^?)}Ngebp@OEJLUS1-S7OMw>?h)dCc zy?yEYFXB?*n_-zT(+GBT9+(Q5_Fui#`YKds)ZU0Z&T+hQL@y;W6)!XtB<1%X^<4Y? zW>SRx{pOMVL;wHuX7h*NKjQqrCo0x8?n`^ssgEQi^>=Sl*w7aWGeYKNb2cZ{_~G!s}iti80rq)ovr;uj$J+k zpsID4z9G``Hdp-0d=PMl1(uwGup{Pe#K{kE7Q`%pd7F*}3-msJRz>>pH|N?@cXlEV zR34F=F^hv!b~H+slgK!*=h5|C;nUNqV!gRfw(rY2lEl%7axQ-bj5$6%0bnbN`T$?5 zS|6;6PIez>I$g&a-HhH-_)aonzXUP4optev3jhn~)n-*ys_>sJ50W=(;JgR5Uxk zL-ZHLI+u;ivTF$pWCpowYxwV|r*zn!j%F)EfVRX;z(2miMi z$4frRJnov}g?=`$twq5RIjs*;)(SI-hJk9yFpDZBXsG20r0LkZGi!J;r1ToGmY|%A zk2&AUKacGe#`woXpuF>4n;rei& z^y|{=tu1Ra5OO|JP%1v89GTiOl)QC9RsZ2;bE|^uqkd=Mu|$4$P88h=Co9 z({Iw~J~Hp`M2Up>s(a$9{WOlPDl<;5Iv{Gb2)k}q60CMPqD|`deke|neg>IgluQ@9 z0}{5Eg0Qd4*YC=fy^JxvB5}BCE=D$mt=7^S@Sk^jf=~t6`hI02|JCt-z*Zjn#cIpF zHmtym!Gc^bRVN_N^K*6BAK1cZyHsq0J6N{ykH9Lu;|Hekfbvo}hHSl&$^f(fi6C>A z>PqLG$qI=qw7T+$?54FH{K#`-ui2t|XjN18jchTGE^_67oWIe9SzDPI{0tf3B!;>UP~QrpY```yMSJyUy6vbkgw-|@`tYkdT0wlDfCSPul_qF;8+*S*%3 z6b&*~;s&ZoP5N)V8M_tacbeynhTDXmIKubbhM#V>ky^~w;{zUvBj8(Wst)-8WBp&^ zu~rJdla~Do1Icp7L9$$c0~S=4_-kgdQ+MAY4J2s-8?vbe)klKKya`dcVCO(9kZ?Z3 zqpO+V<3xwx57NJY1f1ERnEu*?+=3#8#ik>>xuoF+L=`3kSeVX~ZrV~!HI*2ttpDfaS zzMTj0bOv_DGb=vnvF*$8{PC6W0{25PxjmARHv8E@B^p{^vu=3V#^tBAq)!}b{oH%{ zjZLUlWX+2B;371BdA<&jUzh4|u-JNQss0<6xNYuyo6pfq5pu9xQhg43nGEkC8x_S{ z;x|~m=r3*Bs1~$dmLUg^4eE9xcM;H3+!QsV&p^IAV4v~K=Pv! zt0l0o1$OdE=R$Uq)SK&e&tzX>5}q=7uN_w}YTx_uB=uyF?ATj#!#sf}Jac`g^0nmN z%8IUv{b<&jx*lk9P-+c0hN!T!G)!{L(pAvvn2oNQo=>eduDde(AHGKy|dam&F~t(lOt zScC0_eg$3_24*bRjTU1Zvx`q`?V-ngw2L_eDGQGCO{U#lj>M9VcZAYBUPO3ApMP#H z<;D{cwBzoW){I=waNLn$y~|NH;T=k^T+!Yj4DT5H$9&e)G&!^9z)8>vT1UI&MZ zGat)S4u=p!5j7b!4a$F`GldSLaxz3r!J2?FPS_^cl3;qJ)+Bjo1!1_9H(}rk=U_`< zuiPL}?oXIpu3nzM@!liUg^56pvuPT7x&DKQTG*6>C7T~}^5%Jzrh_?-|1>sejD;Ae z&s1J$#vDMM>TUsce)pft*rE{Z_6ukQVAx?9IkASy ziD328^*Mw-E(NDVvQ2Mcsau1{*J_m%S3!_3*Pwss7HF|gQl=_|Y^u+mbbn|hx@DtY zk$ObX#p+Q?uD2Di*U-9w8Ys*1vf#l-76y4Eu4-I@hya(~(Qvf>@Cn6N5%;e}APZs)+V$4W%tYoQ85?e)mc2t)(rYw@+tE8y z`o>nQwB?7k@BLg5=JiG#AUKPGkTrx%N=sk?Y5ny>E1D1a^*wa-Rph0_bL&eHtV_NS zd=~n^P>xEq1up^jqSknTKf1X|w>~>>1{g8tFGA#gfR(YIhRuQcKg z2^}Kv(T)4w5)ghH$71zG{fv!*Q0e&9-5NLtv2(fj}z7Ab5Nw1i}RwTZi!h zC-y@@wKY3?z}~l$-^SItfN_-#D)QU`g<_=k3;?+!^eN{=zsYA*`1mk^oQ16XcvrAmc3W_ z!p5{WFWt=yWdr9gZ|4ZvUZu{6Uo`af+1Xu~EK0JRh#yGBtQpUp6zgn%_q6;|;L*!E zw+uDER+tRJL)@mX)vI)^q!nk7j+WV%)w{XQWjGz$5h)avxTU2O|7>!sY-Jxn^H)~}aHWH$Qj1ncXC7N8I@S`JW2>DgK$Z6h#mTMhmJ=ev(n@xz-XpG^+RhH=mi zBj};C?POG~w6=D4eC>==J#NKShw{5u(F~4WbG?n zUHjn6JHc95HwFq!^{vVcz?jh>oI-ZRR!@IlJfUp8)#bG8eJ8-~`pkphdJe0R_EJpO z>{#ms-^&yF@1D;bO6CN`Ke{)>>pVV~w19JEy6wB- zByV-^J9I3m)TMq<36qr`h~^ze2wKV73EQ;Qo)-R6*I?4U&x6TjScpMVx`%RbH7rH8 zTUn>$QHDX+eh7QmYd5oTgvL362qf~}^ns7#=5xBTouR#sdA`u4Ev?9}hBB|Yg-Gy~ z_+3IaK-^`;->Aijw?m${R@@pw<89-}DvE_d4J_T$2*7jqv-wF`|O7+I}V@{X^e-A2GUE zId*t^!Gn%f>g|G$6P0omqgb=nonH}rOuhjGm8bXQjWxCPH@n5{?!W)A-At%~ zy@bCp4-fKzI>G6I4m*`OE?+6K#~pn8^%_rhm<`suyU+{EJaCY-pq$Qzz}ZKvlfOZD znpIf5cEAM(HeiHVI-r#wFaTzz1$K}Fteg+9|HfhLUPQi95EoV;`bp>B{f5If?7wxU zYYYoviadXpf8oVIrsQBiStNHAd@5u6%4Tgh;E^J@#+6=n+qq}ymh5nRzGgp?AZA-A#TfZI)))r*+LitfD}%X6+3DsqkZ2cRxZ7 zuc=TP=-sGxeR}$7gpkykOwk(xXZd_NDh0;lXdlh{kWLOfx2l8#bjfG3Qd}W?5FqIv z_cQYM%V{iIyTXKB0rtU};`hqK znUBnxPzBoW45^ab9V1og+9I%H);jD{a$oShl3!%#QEP8FUu=IC9`sZ}3cE|7ka4hg zw#$t{T>j#;6}8k3T!$VxdzxJ#>E+}ScK+SKZsKejn4+&uyQkXiiRRq^*BOm1H^P!m z)vv0i{$fe|W&`>zEbafXyHbF%4$XnOi9QT&g#(B-Lu&x{GxXZ=p!4eM#xO_u#f#L(k3 zke-o)paB1j`fdS6ziLMuvo~Zy5KQL^PWJYArxjs9FoD28P$Ko;In3Th%2$_@P_f<< z)n4}Y@+P)z%iP~Rm)j2RBqvia3 zYg>)5!!IhLjY^yqM=h$!q;Mib9-U03aSFZ_36c_bd$~_zwX_zHLH?70UZ^ROgy#BA zsTR46I40SUg4bsyj6kbYpL>3B+e}KdV+)L9^U=O^nX@?c+-H{a;fQLG=nPuu?hGes zese3`(`$6zV>!+Y=t{mWiA-D@{)oNiX?di!?d=_h*NZ4J*P(e)oMx4sOFsUvo^rJ` z00XJ#NE$Xm@NX7`e42;)m0-(X>^A%8uEUU0YG_V;itOZUWdksw4L@v^BQ1F?stJBHs6%Jw!Mu4Jp z6nNYPFQ7Aes>zI%`jzfh6sI(dl5p~j&qz!r;AFhS{^_t(GthvtE~v;BsZAl(hMhi; zeu@|mbhtsyHi`Q~#1NsxYo{M$4@#{7)P9?mU=4P&;^7ZZl-Spii}>(@-9GKZV&Gd% zx^MPzT!(gedYqQLY4uxKmc-28k|R58fEUn%PWiLF`fHOD?xNhg`xlomXcYA{rxW#f z?QWd|cUk~e1|fBUID9%sG5zWAR;lf8t^r9;U#CfwAk)ORk9mf=fj_K2{~LsKRAmwW zjKHM}A3F3Ph1Doy0y4AC1JeGA+@Q@}_7=O7u+PzMh^0l`pATEOvDyH8Iyv|?H$j9R z6;kIq{&4;nBF6>6Z^MsPp-OED8*f+m3iQQ+{7Hi(-Dy}yW_x=Ys+k)+j-miqFZ%fE zQ`K-BHf*l^>+e6a!XOZ4fjrcnN(c6Cj{xpE$DVJH*%XnLZm{}p9RyJQR`p}|uBhDn z23h*Z%d#K-lh9=q_5gRH|> z8=z+V;kkim%w9i*K(_Sd+fP(&nICbJRxP#WYf-#R-CDA$Yt!;mco*T&$EOU#VAlr3 zXwGN7rmnwg(WDOfN+ZA-v5C3PmOKk%gP^sT*Mc#F229}kiq;Ypj zZUnc9e#Me<2T#*5ZL>6Q&EJ};CS6aJ;!90GjYJDCOVw%$buq=VS-5irab2!A-|qg< zsL0f<$rx{sB5@IPsjxt0BJ{>L$dyiqorOU0q?U@XMa+f_C#LQW1} z@U|`XZo+77g`};>PeB>)j>9vhJA_Byl0-d95&7DrD6#sP=AtL-bslQuHzh7qs{iMm zU5mKtJ+2Bt7Na5MhJp|86gkk;lsrQcAZj3kuVrJO`h4X;9$kB10ADZ0nXQ~K?MP*cuj^zrm{Yp?lanmkTc+KsMM&U3%pU@%PnB1QYB=q8ovZu4?2rJ({ z4}W9dFrnNRr!b@>H}u)hFpw>B(aY|m!iX>ShAn+tmL&JrNiyP{{0<*J0o&|zc0k>GG!$CnYZBq!=+(zul71CRA z={(BAAjicgT6sJh=TZ;{BYY+lN)hCbW?k&v)Sb9{VZi1j z?nfx5B186~cMkPcTsw2~_!?#gtXV3#?EZ`)eL;ZAC@Q6@)IWLAQMiW!rJNwP3Lr<+ z;_0kDD|!O?L)(PK13D*N5;Yc@Iw#hQ_L+~iN9Ihgzk3))7@d|wGf3O?{9 zT571tK*SK$f0U?x58YPE_<(6-mWZvxV24n==jq6rxcEa!#In0Sp4`hXT$U0UG0V49 zH>?0)m>`@-!3D`5bkM-Mtzpjb&z~HfJ+dS-H|Q#mZ>gOB?}@2);ij6F%8eF4%%K;k z2`RB=w_@b6w8HD`_eAfvaD5aj2X*v2ac!#+YQIk_sO@sb6)1_UL;g~E1aTdtOYT<1 zviwp36!iKJH?&ZdG5jOP!3G_}UKUtDM!}eKhKv!jR`C;v`9{QS)IZM{{d3S(Pk@WJNQ0e8 z`#%|DR!ytFYo*MQEUL?C32h8_R7ls*nOsZP(@R;Q-X7srJf1= ztYpP;l<#M{%UNHZ#|}GBVa|ju^7?SP3^f}=lxz!P6&H`meNQyy#}gc+H}_OY9DxbH zVrpaN?IhwptmkO(=nNW`n@!MLTXaj8?|9uy1i#7IPEe+KHP+Ms^()AjZ@RIAxSPbZ zufy7Hhfqvo#XTKPsC*Im1_}3QnU<0e-_VxYBA*e+OvO_1%Jg-x1gZ}78zjjz1~Df1 z4RZBwpL;1cxnZUHS2Mp{jTY6qIWB=WQ5UfwAw=9puxdDy=kT zak?z?e(*lt)K_p%F@2uo%R%s2VajYT@!+;5#XH}rIoh#27RH5XktXB3Uyai+h&>XNO-m-l{Z9#VETF0G&h3^M?&JZ#{I z-Ru!#)a9roUH$~rG{3V4Aq(VE!CWub%V`-l+zzh7FMBB@NMYcOKdu`ShHbP3M7CSIAY8L>!n~hAbU6!+0<$b?@g|Xw!jaR}!PX zB;LN;L0RWzc9(Fdk1kVP)GIA6#Lxh=;IkT?i5{pCs*2g$?2=pT$5-dA9TBn=>(8sC9TKS0wH1@CL!`W)yQ+VPVem>Oc@OSAWP!JZ$@fs`Mpehi@Mi`jTkM(`ivC%r{j7*n*%bZS7bwNWusx~EQ$3`8?~m_`eM$Up#R>t5*>*V~X^S#82sX^Up{bgAIX1D%>Lf~ZRi4KaXdQ>gh z$Rdp89@9gd(6$V)*<_>RiF3JlzhVNKD1J4%t4?3u#MxQ4v{7&2*eN*~CHtfsuJBar&DE_x% zA6{fg>xz57d3-G6g9Y*mvr+lahu)&2wESzth1v@&(OV1d?YO8|QI_wsSC45w1K&8d z-{VS+@SXckesPia_HwBdn>xJ>L4;#!hA><(9*--hTOBCIZJPpo>u3|r^gJ1Aj#qb% z*D7T7{m)-e;M>V9%;-0ymG8kF0T4anLX6~$A!Y%B`ONyK1bGG@p$7kI>{;kM{yu4w zS(T>9e)D&TBBzcQuS6d`q`yF%9!T%tw05I<1NBy!nyVX+AZg7j4~jTr04IEF`gmW* zim&|#f&y9#wU&Of>e_C0579WT()luK_yJ4JEBOpB5QA=61H>5xI9x@??>sl~-XWt9 zQ+=&77~w0ED_2R_=CK(i?vb%EWmLaV(!OW?5p>cP&6iqC4vpK^>nQn^(e(MZM=wBC zFJx}9ZqREQp*&u^3>#cO8M?yWo$4nYDt(@;y&*W2LdkEL zybY$;$Pb+h!mI7q2lvYdxp4Z6)p`y-@Eh)Vjjtzc7|NiY!+RekjmpoUVguP{j|ZsO zfC}n;G6gC&Jl1Spt=Iq$!`)I*VRDs_LahO`de3Z#mhLT@urJLp-*VF}bUj(>GjH=Z z2nRlVQ%cmSP;(`fb%&+BMMcf(g3sutY43e3;+MEtBZ5zkd}6n>iDcZV@T$}6#p|I0 zvw*8o@ZeBUt7X;Tkf@@BZmXNP07x`ivX1@Fx@3O8A%ZIOztL7P{_Rd`+=abv@8G0e z(Kb^qaZ2!(xDC550Ye)LipuHQ|}zD91fO@UY^8`zlliYry!n9)veLVTLtJ{ZO) zZpM6a0C@3 zWP`vke8ZGH&{Ox4f5Iv-JM_9?Xy`Gg+~q@35{n}nsIY)L+v1aJE4F=L_sS)h+uWkO zzZ;t;!XN21w+;gq`wfgL;)3iLiM|d_H|xYw@a4daJ(e2|f*8Oi3HWgcIQQEt{-+Ml zCBUE__9rVMmJB~0Y_iOle|=rvNX(i0u!PMmUFMDEApdgZ7uNOO>0`pSIUSxo2e)NJ zl&%%sq;y!?NBL?^)qrpt{z^sr0#QI*S_517zdzs&MP(Sul!~9FaitzQ zSfO)N>gqVps4vF<7L3qduk1ePR12dcl}S^)IyddS!hCg_+qSnr7+iyJOnStP*-BC{ zoDyMA{3IOqscmsPBs}5yfg}zZZ>1)~P_+BwYAJ$$@#gU$5Ccn7)g!6W)cp;g0Z(=705TG{Ze|_))TYw58ydBOKyCYre6((-=9JXvP&ZW0xoPsU0A4T*k z)Q~Py&qci1d|5*Ww$B*KEW~k2GcwO0`jzLCrv-;*^E|TZFN7$Hr$Qg@;bdFX-;Ks} zWWZKhVr4`j(~D953l~x;KfRD~{A7Dd>%x7FLmihl z>Kb!bu_t_?bNGUTIjX#H-TZb39f^Vfi7@y~1_ac;{`0|)K#b=%65o?w5xsDre~6&* z-3QBu7m!8@0xwGpjOG6f7~Dy3413bqN5N~tLTiJ`Qur67`WZLSTz@gp0Fo=n)+2%n zDPk(1B*>g=HrI*hy`l$h(ZCnU} z>tQ89F0NG|!Jy=Qk#W*^(%IzMJ%em$1^PBsrLv7K_|~~sGT*Lvd)zyd{sZq~SYOoP zl}q>t&0Tb1)EauOFbJNO(G9tHm-6<`nG?jyl$7 zYt!dyNVjIzc_Av{!QxiQl%N|X=r9X|BYk-jtv>3nmOiW9wZ>7P!_bE^%pJWCNK)Hk zPT!gGDnQ}(YAo>$nmt21fV*})7u!c<<02}yke!&(VlHfu^tOO@8%q|!jzmr-(`JEb zLdO54?)F8B4D$hk7yHSyd)4^I5K(|XzhI=Tbp1++pYBy{kLSh_VM;>$e!PF@3|eiN zwZ?EGz1XDHrjfDt%ayAWtw}~i0a>gt-Tm##+9W}$WBRkk7@GOJy5`PQ^;93(vutI` z?EQuH>I%dChT1VQQ~9ys3E4WHI?S_~O#4Yx09y*|>8V3AvFJIc(g;NU=grRO+GRb> z5eSJQyV5;`4F+W{cGJCIpwts)uHdGY)+Qz^Y8o4sLR6R=2!(VMVB4S66dyNh*~NGS z>S$HT$h7wr1ErTtgJpWoRKy8fyRgkzv=)Ggvr)F;{9J0B%Npk9+tx(@du zFJ`2~UA_eon*E52ucX@e3`V!Q2VJ2QjY=b5RY$+zf0(dR&eu zuGxR$$``H0-faXpH91)1t)^n9a-59q`;l7iDt=rnwEMcnO8d~mKwE$R}-5m1uI7rbq7t*w!(^}%(xN7p{Xm0nowp!!M zE*>2-dZb$!BYI%})S6b+)&96wi-DKLme9vMl4Ls|J3>EWo zCz+ta%x5ucU#h$l(_0uw5r9*+Snn7{ZL}BX?-ViYy4gE$(^lk&o*?60jUVD6T9^vk zOt(BwiOA^n$-mk)e`R;iJ6+;{sVG15&0u%1$HVI0`g?9V?TZPAiW9c$d@$B#&%GMN zeIapGTp1L^IXV>DQUaLoY3>~H4S6lG66-=?wDUGBBtz%F+fRtVr)H1+<3arD637AQ z5x%^+0MFpYv9>Le5d}DAh=m#J9+G|Ei<;bvWS_{9V^@RsUc2IFBHoXgYr#VB0^Duu zcI=q)Vl2iMWo`-!L(AEc6?iUO?@rnMz%kIurbdF1tNDbbB~@{eUSC~gtwed-74Eer zL}$#l?vxU&j66>2*sRv|vkTGY+2dvd@UGl~Ci;7oxah5J3sO&^AHz0z`|S7(Xo@5uhpt7Yl2JU|PCKFJU#(F~T#UsA8rF+4 z{6F%eOqmi?Iu#$dRwdg1<#`UV4_@zxH8SJ~Ow|~7E{qmGIfP|+1K?h{>No885=5^( zJ^PBx#{-bBi3iQfI#9mqV``chqs3e#;X)KzE51>N3j*`vZC!v8K3DdDQT zkj&hp5R|;2fE}5x2Yd?rbFdWZp@FIQ6nuFZM+E%~Mg|!D`a`3vjihC@+kkGiCz=VP zW2A3pKP^8I2GwtTjZl$%tWfz464a*iu1us>x6-vdL2BOl&&HKI4VzWj6QR8XJiy4= z(ZtE)8S@VH*;fKlx41OaK;rXBy1e@!!>n_`^9!-fjCI{j+@WOg=B=g~NPW5&l^B9r zm&=6TSRvrli&sv5gXHj~HW!QML~O@Y3N6f@C-P~6Xhk*5C)?$D&w%*>^o)F~;}x-Y zjbX`4=gF@m^L#|ndSEvYXPJ)b<(I#{y8PMl+2=a7*qH5znY{Xo+LxJ!>A(=>)>z5; z5OdAbrg^@kSi3aLU2c~Ww*N{*W#~$aZs(Npv@FS_eV_60haq>QcQm zCFHmM6Oj7#1DeXv2VTVSn&icI*srnk_0tMKi4Vqy?cVbZ5^vT5FCa4SsUHE^!s%=~ z16KTHlPr3mv8Jt`0Q6J-7G{77%`W70_V9My zb6*hw%3LWg7+|)5ka;A#HF@sz)ISB}gJ>X0Guqu2WQyy4&lDd41*w=ZZxk3Ckifow zf!{^n0y0BTr-8F)%$w{x30RonlMpz19KLqI}|JCP`mb+d$2{|5Y{R_r* z1GLZQ8;0eAYjOu0II3nFa}Nw!N2N_#Bci*{<`q{IZ&NxPI=p|fLI{#ss5moz1;G|r^2d&yYb8=PASn1$@VcWsRM-I*fZq!N zM;m?^k@~yw|F4g-dr<)kyqmw|y5I!IolREb z7WMgVq^b?<9p27I@Z&-KxYD+Q3z~Izj*I9yIOgRUYgI|OHo#-; zO$+UTl*~`L=b%U>cH{{VW~g#UtnA4i76v6Kci?lU*&EOr-q)X$BjRkNEjgL!*3;lt7Mf2et%4!UA z6Af>`R6)BnAuLN>==5?uspIlX&tevpy2L|Lzu^wOxqgWERVHV zub*C6i&mz#y!8qSbG?r_{k8Mp_)Kc3Yv?+o!idi!BVpGxyg|6oo}3)I2ooCLw(_Jo z%dWj2xpjQ&hE#j8(#A%i4_-7pKc%}KAuu7X*e1WImT~p z?Q)R4W0kz3BwNKw1TvG)20(pRL)LbIi|h~BIU^@f-BpGi7D{-A&&ZyT{mmQtzk?DT z^+-1E@|wHRhFZGs1@sj;jyB4qJiof(#UtMoo0yMgwMiP?-EYNJI~RjLTuO4@p_!M# z9Yj6HMUbY>5D2@eUHF$eElee1oAH`=9&0^{OBbNJC1^wt&*uRc@$8gw;1Sj!C`DaxoKPwe9oX8JoJln z>;nHEh}M8eotqR2ewy50NNeNcfCGVF-rYr{@!kipiQWalsb+R@?Kj9wFK{m`#)wy) z774)ez5_s&8{OKB1K1oYf>A_dm=gT(DcNJceT@h=SkGO*-hUgflgbp_ro+!(aMWW- z3(T8MOQj#Q-rJ@OA1ryjAGeh1Y&b4~k0;uR9eGB*8kO-4vhHovJ#2+YG*)k&y-%|s z(<8|6>UP%qG2&8h9sus_Eos+@T6TK&%TW@JD-z zT@YScS#5x23i3)&;Rh-$SOb)Bv3q^%*~`ZS7bX9_(*(J;Dd|o(Z+TUP#fL7>*Dqe( zfOvv7d+|vx3lwj1MNRG-)!j1jek)d$j@N$`bFOo$V2s#x;X|ZM=cCr8heR&3#G9zD}r zkx~5W_${KrUD!k*L7zUGu8e!D--GL~@DmAGxyg+^t2{xF|62!gHV zTXEfPUd2=6SQ-v8U~ym#t#~$I!BksnvEMp}p^9RqR;t8>RaWFMhA;wAx-54yd^c!7 zDs&X6$j`pTRX;)T35?FA7-HJ?Az5?6U^O9Mpy$y|vWKe6*=N_!mT5PDdw<+4nfZU% zdlPV|+rEETQIsShAtoUeQVCfn%AO=4l&S1V$Trp?S+b2K6fqT2Stk2FBfDf@vm5(9 zV;!?y|5MlfJkNDq_j7k0*L6R~`@YBjeU7t3esliL-;8t4^Lu`m&-e4S!ybX|clEwx zg!<~QxTR4F*=l^aojLygH7TPO&1x#5=XI=s+TZpPp(?dzRHGxiq5Is7zv%kAO<5#4 z7j=#nYB!AzN_3t_9j;J(l&rew4B0YQx=-ck8z|h&_Q?d);O5hhUJkjEY(zL z2Iwaqzz+W3%^B>!nX^jMO&2U#-OoXs+uzG{tC}QwBAT>}Hl!v?&^pF=o7L`_^-}Se z(8e_1^2{ErHL!0A;Coj)UUC&;y(Qk|ordJhZ;*D{sds;I8rA^(${p7*ejOdWe{K7Q z2xg8;khaYNlk&dUg}OzI8(*-PmoNv8>vHZj*4g)%heX>9rH=&Bn%<^vvj*TSc9Wcj zbm(~Z;JdE-=;MrnvtvJ0Mw-(Wt-nFvC4z0&gD$k2L`RaGZ&PknzN8NJ3zWd#R|Rie z`75)Q>D!tBc0QhED)pR%oi7olYH<^Kx96{|Dy$i3z+(IF*TcV<2vBe_hjN>8x(7dQ zhB(8pHGEkHyHJF;Dw<-N+?$Q`;zU7`NCOxRqnNqVZu{1LY;x23Ij zDd*-9^mT^VuB<|BwZd+(rRAl;6;*}%-89C~iDjjO#NE>fIo*RQyt1{<+Thq7JyYcy z*D&PGhu`y!=8|&knY44rbUd&IFa~~9QDg~GevJ7QWllks>Cp^Zix_Zbd1vk-8C`it z)UBcMHFaL}l9v&*jXCA##vfRQs_pyh9V~<`18vqIXA^dEi^}vV4*FJ(?PpY_%TS(i zjMDta`}kHn6@YAeC$O|=nu9UQ&mEzG`VLoP-ND8jgQM$29`&4>K?A+%!z}=GkukOc` zpmRhQLIK;l+3NvVE&9-)j91@FM7h8k<7_qN3^5@?I)NZsE8Q}(F%4O6^!`FRw?jQY z*OE@rBCzDUS9%1K^C0JZ!*?iXivgDoQ9pGmK!M+aHFD765i5Bz+eaJ^;`~da`(3<0 zTL*meCk#G{@CVZy2RLc>k5bFWuOs6R;60+0HIa?Mzx1jBUhultN@%>K#BknIyI|6zQ&1z$DcJ6dGZ^AW^9$6$QzuIh z@2dkgoXq~)TW1jknV;JWI1ae+zS?&Oub~$}LbX=1ZpOLs9C_*=S>r4qnzC>IIfVXp z-&q{JUo%$!-0 zG5nEBpFTQleErtj_yMbk(AS4Aq#bj-w24L)44dk8EbFu;AY3hFf6b;pD1 zcsBE+8BFu&K!mHj)-BK7wYYp&MLUDubWPX0TB{_D`fj_A125aQiP}u=(bO?NnRynU%rPKam!P|5Ws(9e#vfV{B!8iE=;j&CCXE7(7icpBW)wu7 zVn${-jpPm^kKY1rK?86cElK!7aVcFr^#~t%G!_2|v3_P7yg>pMLeRCHpMYYL`)EW1 zD2db3w`IV&8P@^>ah`a$O%-<9dL$E7@Znc#Qo&3@T_OfJ=){&5pNUZCj&)n|E7sfOjKz}XlJk8tNyHWsTzyBF5S3rolyj-wbn$FhwnY4^)R+= zi7zbxEQ{S0tBA;vUC$0Drmd0HZI1&L*$=INnke?W&+z`E0)Z#5n+TkdPGBIdq^y? zIewU?%_6}0|B_q4u+ zDq8EyTGa>PTxT%rlBY5A%B-XFL>EKJCwAjdc(n-rv6rW*@M zn2w?<&7-y!{(k2SVmJIcjE7j%rK)Libn?L3waoHnRfbq(4r6!d_GncKdqO=%yrAQz zVUR4nLf4t))edE$i3R_S6Bu{A$g?Q|I?Vp!t+=<5m)kCWEw3oJp?Qfk=A(hO2GwG`czJgb_}#ukI>(}(4TQTb zGq6)s5zvQIN&?<&u)V~acb_yH#IGx#*q0h}C`m7Jxauh)1U<8K2U^p{4q+nB==2zW z9TZD3Xk2{on0Fz3x#3gjIE^3vlBnJw_xMw*;dhJG9CdSc$I(01Zi=^zSn+GM4b@7r zU9N^tikd~@p2#0f3L;I&=gz;w^fH`dIHWwu2D96JbT`xSRVH+y|AAc$hddaJpc8G| zA}PW^d>Zuau$24({Bs8oI725>00Qxg5$wNQ#TYT{MD-}GRAQAA@HkW8rT~W_OjE%S z^T7Sg2+}0B@z#c-?r-u10H^Z5#x;8nleG|yP45tWKn~2h{vOEuP~v+rO^phpfh4?l z-LQNIN(2c@g(H?!(dn5xAm`s>n14#$4f_*7^BUJv=%g=xh8p;r0w@3YD?GTCm~kK! zMPHXHO7HaPdMQjJRiFtdt3|A}B%^5Gc8mb>I$pu#!e<$tw1v3!&<TqfIPxXrP@SmH?06UpDA5HB0yM2QOn>{{-zn%W)v<}kuLi|YFyZTzG zr5c@+thd5lpn&9RObUl6@GY|UmPxnC&1La&?9vSA5#(d-c?}`5z)?$(>?9b=oQc?@ zD`rC%JMV31G+f!RW~9-Z+2ZAu?>gY_rsch{xi~vO@IUtW4g=-N1r(9RBcp0*k1O`M zTg+GgH(jZA^$bp>j_ia3U%|Ugqv#7bduhT0+Gq9#T#rB>Wvid6(yf&Qp)bF_-i?h) zABW$5?tfzR{ym&|8pV&8j2i*VZ-)sC%}50Hp0I=RFLa&`)WaJ;1v~%h69m>)(-CsMx~zWIgD_hiwzHpgh}_K`)(s01H%ehrgRp8g0FYA6@m@; zdo3{&g-?Ok(1I$R0g@ZwtO*9rzt=PWj2P*k^v*2P%<`m#k7v zTD3bezdTKv*UoHy{`jo0d|JHq*<~M1g~YnD@={D$%={|OH0=5HIpJ5$<*1vwCkwK? zO>sIGTEx~tx#5RJ@wqb==gc%hN@XwIaJ--ijj+AF!?$diXgmj~lzbYuBUy#0w<@I9`&cENe*aKSk?*gjx7iV7I*nA@X^DC#w<@mQs%A;ujBFi5{hF zS3y^M8on}Z>;sAheU9C@dvzCKpA`49L|R^9!Ku)>Lx}T(LXjG?bZzA7Qgq-bvu>?W zw{;07=4)^JJJB>{O2eZVS;05-(3Snu7%p#d=%HA>6dXxg)Kn!TCz^4MFHd7K((k}8 zbQPi<(BGej>$<-?4=dSe+!;VqejBp@;5NWr0ZKajKk)+k0`V>WJBAS_tMCTftoqHySdgZup@fJ;_vkdipv<~u}cCsA5z7isJl+viIc=Gaf#vZUi zyhG;^)(8%SH8F9erVDet+k8!cVg1#vOAv!L>Z<5RYBEKSio)4pS+5fV^pM}4v3FW9 zjQJQrw;Dl(y}3}*g9_mM1L1O?9ecv?2W$hVy};xU`YHE1lo2tRWdqsh)unO(5YNB9 z+LZE%fSLbh0dnq{p}>a_ebO|8|L(UR9O3kR!x%nLwZa;}B+!=->$`r=8lG-qkbawX z8b6E-^Oki_g`t;o*!Pclca%)s@e0^ppS6S3De;2s7kqZzZiCuWeg6(?qRg>Oq$5Hp znZ=x#QRAj0j-MKd@WqyuTod(QQ=5o$T4tT;dW#M%q#oR=F?p2A143`Vy zuf2yfhjH4G_*Q}n2U{R|NXwS2KwiG1t_KuDzVO#$&h)LzkFwYmCn}}#HzyhImzFy> zf7FZZsbT~`raYqo<+~b&x2`R7r3@BE$ZM1uGeZ(>D&8}TlrD}Cp>@C>8;6EK@d*@e z!r5em^pg4Y&a;Lp4bzDdr=K=0d&yu}2}W3=E{>G~)SA8C+8MBx^4nbnVR2Ep+wa4^ z-plh!X;}%N7_7N^55r`PMmM&oKEKf2DnxDXnulyGiO`-t{MVpnbb#I108ttwA3-OX z%>lfM05p~pKff$NMJPdNqeNTZ#-yB!s}kmP=^#c=p9V~Mq)Oy{bBiY!N3j*!LA?4>Dsgf_~NrzfG=i4%!-@M?6iL63`c{8!kgH!d;!Lg%s$y|c0VPexC89Ntpxd38+N4q++HDsOiB5bYTojJGkN>}*ye z&eW8A`m@IXK_htmcqnn?YGsG3mHOd<(eF9|t$m?ap>G+C+LZ(d-<0I2$%S6^r^+I* z-``a}M+8!cw0qF9VRfAR|G*8;iR?5jNDy{W6nG*)r9s^))anfi@K)S6g;9A5alYV> zjR_t{llOxt8Yr_X0a9ydjoIDa1e}fj)C-@;G33gDJV>nr1kVP@usdix ztIGvgb`_LZ>Y_UX0&W>a6NCd@bB9D5iSJ8rO(!ODY+FLiO9aU^V!;I71`5M1SblIw zMY8TK{3Lqy&hc_T_A1xv5>gcKdsLl~_+C?Mc0J=0{E5-_*+X}$_KnGn-|^8n0~lnv z7RPZCBKkcFvZ9m(rn6%Vcs|D*r8G{!Si6phFaulbnb&ybsv7yR>tV5Xq)YN`RQyrv z?$E#Axjiwi4v@m9iNWs&G?JF=2bbKBhew1cf7ui-M2s1%HB=*kW>Bq9VAUyzmKhi< z9#~f9<~*i;I20B;6b?PTAT7Yi*k9BGcDT`ZgG~dU zI8_cq_0U4zY{6r@cQoOcuDz4QHhvx41m zVNF%>Mh4HH4f6(Xz)Y^syIZ{?_1aM^)FP7i{@Pg&?ne_RFyO-lQYVbhj=LweUOJ+B zL7nCEc7j59kyA8G3Q+X3gR;}g+W1P?xAi?W-4X&DJOPZVK27Rr6p<#>32ZbsMaj#s2&X2SQm zeWtf0wlrRftd?Sk+sA4k?{|Owj4pr4I^g0MeP{Y`^uWrpWrS}>MqJ6$D?Qi8j{5A6 zZOBmsyc{yK@dL#*^5j?Mumanu$H${K^h@?aRMH3wNUiO#FV30{6Un=6o{yA8lpa+? zz$<*EfT=khGuj}>(7|5m%KPM;CyfB7*iB39X%WUoy6k%=;yEupd2fS?BM|$BT(|gq z8h&FI{ZJToI0=5CJ7E|Hb_p9m?u}GfZ$<;PKoqD2pF=?Ej>8{Wv?YoAfO(|VN2>%x zT|y<=!+N(3 za^wnCk%_SoE)k$$;4#+5KCmF|;UKn@C^n|UMs7r8yrtVj>r>wp+9|qg;H^Gpd=oAx zi=5XO@`Q*4%qovX*79sX2bc}>`&^KFA0~QNn`(bpPK#)Gy9!r&#?Q2<{3nB3eovBZ zjQt%DSZ32{M@oG_^qe~@TT{DB|40c!);KSW6G)Ijj{b=>Sj{vZg^U0?YR z046UH2tHvuV8!Od0BM(j{__`d?G{bQM?z1%*XD4pC1`~SJx;%S)Z(1NA$6x~@uy~< zmi*Wx2y zZ(9>VIZkWj4R!s*ZB|@c%_biDT-!vDkAMA@IIrw#8$nI?LmU5_$PB4fNF6G8X$)~V zzCcY*aqfbNwDS}S7mm_PQB>x;{&42YXb5_27;d|@23gde*?qSmL`Y#DE#W)HN!Jl5Kit;?@Us<|%=BGn3`HX^s={{Bm)zq~}-;RYxzW9wM z{SREy&(XCo1>a7<&TJxd@ng}pvZ<6>^q7EtxyL@+@)XWUcbQR zLn#PQz@ZfAYqFxV4@o?jAmAWx#M%HSnj7p_;CHi`Dp?KDBoAC+pVJVevnHz&1Clh& z;e=nm?K0tpfi5Jeb-Hm{_Of!r^pVOJIt&47dmY$HT7R#+-X<@8maI}2Qs5J zP&tI1A^8oI7q763d=j*0ao>E~Aged6c61di>9A4v#)hKL@4R$>3pk3&Moe@5=wM|Tc!OpDT~t}Pjr{uIiFJo6QsVa3L|@IDqzd!2FMb+#)h_ap_BoMc#(Z?Z z5&lfU=mU@)ZlwB@+5+oGx$J?7lA!Vsq}|WU2uZvG;BNs6>JC}9i`r^#&1{#9Q=uNL zxzru$@$<0*atDhoaf%1Kj6jJYJJ+KwA|DoSkprT9>U>h)EV!8owl7Kf$mwhr>jkTL zM%MkKF44anWYZgA)A2{y{p;fV-=F`N%>ZW-j*lO52=1=eDI#xPQ4DuCm*01kWrL9s zpEY`D7EcVQDT|Dj9psxTuPNv5*Qj#%a0wb{MGRICuI1zVxZ3R>l z)@{Hn<4M#)`;v(~f+y3h#&)uyVY@DYGU*M(?GQ)S_zRRC{EhuzOF0f(+h4~SknY>RsSXY^VU z(Pa7`!E0}KLK01Dq>@H~k%UG2vDU2Hhg>1#{ZLwH=$}&RhE{?WdMZumlu#7iWb8mx z)SH;g^f9^*RaBm8(jC-P%&f+or`*lsx!VxrE$f!RK19zqHKcx;hyO#yTl4nlDsDbc zxKTYctmuk%3BE1(Y$wjk&%B~MWJ>T#568Ng=iy8Af@t0S#0G*}qpdqXH-2j1j;`YY z_XMY7X*QnkQUZ}G>U0*ab2xr>e9KB$g{E!l?T@4KzN^ zvAi}uQ7SZft$0PK{;D3bVy2(<+nB4=Plv+n=Mr6uqSFWFdTsLtdWD08*A0$BzG4Qu zE-u&$Y8Q58by*f>X&=y@{d5i*=TrRNws$}+!7ju2eY4%|_@fCOx9%a%6dHc|2T=Nl z#8aNNQDk9!i}n*8+fUq$=_dlkQE0FRwaFR`a^*QU8)}f-Cr6HfbJ`n9VnP=w9YZup z105w`9O&(;E*o8aKTd7VKcVq8YDN?oQC`@=$b0L+!W7C0+XQF7DGsq^kJ!w1f#u7P zM%e*y4%pmMv)Pb^HeB;F>o$GCEU-)%0dF`Gu${(HDx5*L> z5LVn|b-4ZV#Y)LqNA=i;^#f!6t@W}hJ^>a!cZ}HZg7t^s&ULGEeVti`o_S(s=8i`! zMXYr1xnH1aOSlq6t9~1j}{aZ@avLz|{j(QdHsPcFlS91nT zE7y3wG1nua%J@a{D@FgIW)SNCg#MH{|LN2_j0^Rh!u>r|Q^tEzsqYri0v2DG z00%xh4Zkk6ma)V(!6fl`u|nMXOrtntiObT1`6QDn$?rC5EBGxs8EOOG$IIPv+)ma| z85mYJ<)V$o=Ts!Rch`c5h$4$JC|qW_Oi}j1$)-~4URaIn70g0+2Q0pZY}NhUJ|AJ2 zrcvkr&ien(`u}g%`kF&Mga_VNT!{t}fE1%DIF6JKJXfPlQRDvJsOJW0d4p54o=ed(_)@0>(nzT+uD)UA8Zndk|@NE9A`h z{;}1)z9g*YI>aAyA)$8UP<-2s%9xp3pI<#gUJRUs55*e_ZA|8o?fH9Vq4eIC63;6H z#8cjS3AcW{FS(E3mbsBoDwd_W&}6wepqSb2yO;PCR8dtiRaDv3PQF=fby%U3D|+II z@$J~YnC7JdFQX5ApaGcvYH!`b!$VK~Lg(bg6)m}|^VY29)}39nadZ;Y zrj4aCBP2^fl><>y8P@p9Z|;nX5IKkL7dpqj7F2R~=vo>qr&p?ceP~TXwJOh?r<}8FY!EJ1=O7_mq9*NJ)Fl$hlaS z@;q%pljmWXWgJOOQ?;zvSS7YQq6$};px<#Z*;Y`;=vp3Dqv=$!;lin#p3x=83>_%P zQ-FW;t^O52Yv}@|=m7Psdfym;v~ga9QnZWJN0@j8w$L=KTylDb*T3EoD)8^$V77LD9CmQd$j&{( zM(%F%*QZD9ye>^RvNGe=eAde_^NyA`dujR_26TT}&9PNsFa@P>v2_g*xn ze$SDjY-B~KZp*sZZR7*M0u?$U9#*fUP>w0|**tfuu<()3v<$ z;URhT9VG|C_kULWf(}y9dD}LQW`8IrRb{^!TX63)xw*%ba1#_0KLAgUNSL*Qa;Hut% zM=|KlpchX^G)U}+aMJW$kGbYEx{bO}3<@yD5N{Uy_f2Pj%5AG5K8bvL{-EGJMd@+h zPd=)D`h@p=pzWN%Z4C~*gT#c|C|e$vYEwQ5M_Z05iP0}9`IFE@FOos*r zW0ck-o=*C3(bE{0OcD90z{#XrSb_o}nt{pQz6s)~_T`CEm_JzLoBv#_2Y9$a9+{ai zfO-Tw*>NOgyA+a7+{52-79cIlBgS@Pw1`tU7>FcQ%0y8fcGoFOayrF6UK+5;ll*;)JFlZ2ihO9#2&a~?IQIZr0GczC>si2J1ep3WMQ@pHT1I*D|AQ}3!{SN#B zGmb8?TL!q4&{J8u?C@e$d{AOvS<9m1*?p16orN+wxIRMPtc2DQWWrovOt#rxStAX* z$6n$XFKGF&dB&0s5`Q*~2y)-d&Q}l`p3n3wCp07Z?^e)Fsvc_PQfw27o!9NeKnZ=} z4hl{ahqLYNw?I(Sv@z_|0! zs-{vJRdf()-NvAqVY^2BL^}~{mJw@}b?&NcGnB&QkF;!4LqDRT6xdECXSCrmiJ>~4 zDLRRtzZ{wo1Deu_y^0BnJeB#I-uSDDZYXFd8h2W1-b4Cf4a1e!`2a2va&+^~`om4q zPW$aQeT(|W6;|x6DgChFG0OIsklWDrC{$D5Dmo5o!)LTKdRQkhcQ9i>eIH-3w1vp3 zD|P5#oZH-HbhWyD%d35qWW*UD9jq$F)KeD{OD9_#~_?T*#{N><3MUd9RS*>Q2aE^o2{WzNcd`N;It* z$nGfXcHuj_I_0<5F6`3e6Gr8DhTflyG6370{R`MVXKWC}v%od_{1f&M%CD3W?T{`b z*iRqd{z5la2BDoq5|tIej#7CK?teOqASOb`8Sn_|{zM3k8Qg;dPNF|NH1)4O!fq1v z{78H+l&x^kR34tage$X*Jayy5@v1RU@oQDLHcZzJcqv8?OzP#PEBePoxG)QO8a+>5yBCb`IFIUn(UJ&pU5{%ast^repQ%FZtJMXix#sy|mmk?P#$$|rYX>*AuW8bAcPq%e5WInxD+3s;Pqu_ft z|3s|OJje|F&!u()W~Q8R`wr}`hG22=^Ypkj{HO5P?fp+lt1NQWIMTc_UuA`kSPmla zN3{s9z9`#XF0Q_tOiN2RTT5rknN%U55pxsv=0ih3F#|g;*)<0dTdmmSHz^!myZnhp zHA=^OtqH845W<5QCHu*x(>I+9*sGEE&H?6B>sp>~GyzaVA?wae3#cb?=DOQcxZdJk z#&MVlMG!wj5riGQ*vKb6G%PVFGQsHb@;KW(*FzfT2D%!05CK9f6W9E^>{~jidA{e| zHJ|R{f9r<+lc7UKPIv2e{(PepiYJNNggZafAhEdng-M| zoZc-Q@k~#(FDZCs6`t}+|24$Cz3;Dg3=JrKbjY6FN!Yd;S>{Mo*w_{1=+mG@PEzj? z->BqizE$vOaJV{FJ>|{0R@Ra^n6nKj9aEfY{4hQu$*bh1&06qRmjSgSJHm z5Y#~PANZB{U-2siAmwm>!w&{Av0th1Y(Xv{ClZ{p+Gdh?cbZnc|1WfREx;JvKf8vR z8};{WO8s_OnIRe?8mP_=Q#byb-(d88RU3FkpTY6b?ISK|(i+(NmpQi_f)SI(o!Es| z2$jz05145HiZ;2Wr|JP|kN`L1qi11*Bp3NY9XZMAGm%z)Pt;4zG&YB1FQEmAQ{YUd z9adx}Bd!O#eaukvuG9P0eo$jew26N(ScG#DaSQ_lPPO`5gu`6>a?i!twwIq|6L&T7 zPk9IqI!@v+R-d~cuQyr7v|2rX|5V%Kd`D`uR$lbbAw={NO!D?a8BdG6CTq#7UCP20 zFK0U%(~UKjnV^lE=vP@%yp

    E%INzvwagYa?QnN@@7_=I|F3W%fKYlz;1=~gN6C` zM9bR70LaP@B%N6&V)o=mJLoEXH*{e@m&(xhrSJy}v&S4{bx$tPLjVv0aGm`0($Mm` zNFXkbzJA`|#rko)s&Twf3RmbYR^E?>`t1QNO@GL7y5DDHeyYZKAqP5bW4h?;hVRockh^DoU zQasC%VKfC8*8tJ#l+ewO_ljlCL{tw!52PXTLFPMu&IG_QBf07}G2Eg1I6mDLZ~2<) zSj<{;8nOsZ+J?+N3_aYP%r!pg-uZqo;-yACD-+&F02jnCl!gJjw>{9?HWkt64%BV* zORyLOU_3UXt9(G^2F%Y?CZiFltq7lq9ofz~hJs)q+t0xf6`91^>ZktUU1aLJW};)p zAY-o7ztLGV5HXybyp+a%!E~fPcS!wvby-PUiRCdW!1#z4rMg>Nd)YF4i{Hx4a%bCg z%*l~l=2nNo^v#&6w402P`KW#GwfF`XinfFYFE0DINm4bV|&9Bu$QeO$sn0Ktt40Czus^xaqIF zA6)iEv}v9L5}9w`cH%l9@~#!sBLt>I9PoeJWxu5aok@EMmO$h)N{icQesK`y%eYtD zp=&Rb^b(q%rF5uiG?FkYpoo|~a9`Uk@^e)X7@D3Ja(kC(E^%0dBQuvl>Z9sUN9Ol| z)}hML^fnT=PauxI;lvA9MJ7Q8{gXlRAwog700>vFd;NGg+qJ}_%g1B5Zzw!Dt*+nx z^qi_U6l`0TA-Hy(5lOt!eA9#V#UiwKhxu6zdMvUB$m1}IjMKOTCv3J@0Qr4VN&hoQ zmFJ$~B^;$ZkvFQLN#KVYo>dqi-VFsot)sTD*HA62UpUm76B?Jy=I}6Fc0_%&-MIae zDe)C?ztC0>Q|1eZ{nl^pw|j=Wqg{v+1jG6XjY51;>67@a_$pOvh3vpr&_K!dbF+$S z@_l9AT*ORsr!*6y>77z-ujYFv@>2|}zoDvM%^r2(Pvu(}+-X17RE7M+D01;ZhY&sz zC8y)%IPV~REJRP^URq?h#xXa#nGfiL#H|VP(E?2c!Hm{evmv>pmf#Z{H;oU!)rS%mbe7|f5W|lo}sJ1&;|G&OQ?k&zBt{l zQbXu3lmstBV>!%?K4U$UsXyUdqaUa@V{C|OAuwoo4l_O z1h3ma8?;@PuyW7|J_Y3(YLZUwca-`RY$+z>6&Hb@}2&@ipMqL7w5m&mQi<}~~h)_VOInRCWtI`7Nqz~YPb{>(&Cuc+`h`Xl_-#4x&o)kRE ztv-C8g8U%lp5s+N!d^hg2+Udc$`ZXa%1~=jbBde=jox60+#pzGydRz=rMD*gFkf-C z7YMzj_!83XwS^9oQj}g%?>XzTFl)k_X?x)2+r=tc>S(36@yEGhPo%x@F&pdHDl`CYRbP1nVI6Hw z*49y;lH|7xcmp*U*DV_LB*Dgvkce@CcGlpPsn+!OZ&qI+FMMf-e8Oi8I#hZt?X=%0 znLiG?{{;;He+DpoMl{LBLENga^ttd;i}OvOR>Q}m$B`<3?Pbvk=yU%4NmV1_DBYUE za4aT24jX#GlYPFDwM((i+nONwMIX*vmp?~z%T3toeNqfy?J7P-Z%NiA=x~}4{EP!V zyvPT7u=fIu)M`jO)ikU7X&riPi*vx6k+8DKU*s+IK|2Df=d|f&UaP-OKRd+w0j7U9 zqY42Q=KTfh8k1)wT^n2wYbym+=w+pdDpKHv)KAC4uJ?5nuK#gi{$ZW|@8$nJGhh@) zxlPoBM6i=#8mnV{g4Zq-?{i6gWBxt(@~Hm=g9oe*`7D~)0WDldo@IG*u}0J}K}&A0 z;!776BL6w{pAYt~`(!H@AMl|vKEqluc}V@`)Xj`}MfJDGc(%iCb-Ic(>UoJ@Z}pNd zL7xAbuG{U2RJkOzcI0E)yvf0Lnh_G7|GScYrrPLm9dkr!oR&A z&9?=B1-K~&v94ewien8`I!_Q|bwFfaD?&%Ln|=snT9>~prubayD=`3v4ENTi9~@oK z7tfr$cw}BcMe$%eGwTDLCz#{J)CtJps?9A@ck{z-mOW)5H;`8fcGvXB>Jdf9rz_*izrWl_P=(4hx=*a@n(H(AB(-dS) zv}HANa7I?q$%Demhw(YdW23CfsdFF6B{W;1`)fJ^^GnN4L^{TYq|s_K&aMjH@!5+$ zQc!nDi%__dZJOfU%2p^H-I8fsscGCFz{tNRvi(En|5Zq3ks9nF1-)^3Zm|MIgKY7% z7hh)uB337Nz0QkmXZ@PzEl;4Y<7dx}X};29(m9}cE$8Xc(X*Gin@=m!Q8Ir%xClD# z;;jspATW6GM_6em{``f+QEtrfOJ4{asK5%rZDA>lr1xc~0NiOPGhBUD%g)=1=r_Sw zd(-y_9yuB3pGj=4EnB_l`MwAnK9S)Yw2o*=AF1O~VL>edG3r}C)QGJR6(e*u%Ud!f< zL%~CK|IMVLJ6sL;4~wZ?Ynvq0_)JZTB?SU@)SMQk@1Ijk!i$8|zdb z=nwBSf6xyKV1T!#1HkJ)WBetXk2g?a9YF0WqrrX4HKtzz*hCL5sSQB zwD1^=DfJz8G8LFK{n8RtZeeeLltMJAfi$Skk6@$=T0i0YEtB}3M0EfQY#7`@IE*^r+`y2(@T3*Hs&v~9OJI0$kuS&>zIH4{=eTjSBM;dnwIC=6lC-C z>Ba>q%n3`zZRrJalb$MOzVC(FP#-V1yz4BmyQ^e)bS>>gtI@C;hxI(uW=_&=YU)OL zxpbITN4CrMZS&R`eOZ|6Q9aZL!GVgRuMKwz#UbAe=bS#wCpeT2M`~_ZiM-*@@HaEH zG|wRp)>?_Wlytjl7Y{8r2$AyH+gbIi(BgTyectvsNzSr659QJam)*@{e2kyZGJYI0 z>VqDnu-cD752$CTHH%MXw3NSQ-H0)N^9!AY3j}r3ZUGhS%UFbm1POMfTE?&HPY<^; zlA6x9Bl6@}+dfKdwAEng2jQ$WY;zrX%^s)M9?#HIEndz-zwrU8b|2Xx$2Bx88UGRfq$R`s_oOO;Zm&sjU#oFEeXC^Z)wByQF#P$Vh;;+6XS3TwgneOo!GY6QQ6=J?>LMThY) zqrwpT@Ybo5di@UEjijeO3mJG+1M)E3?W;U5@j=hh17354^x)*Z>m(N->-S$@~FP>TUvZ^3g(>Qu7oYBmRaw3UF_FG&R zEV3@A+#OuoQp|@vAnMmhD;>g5y^pvj$-%tVsNN!)V%$~=O`tFI2^-fv&`-Ql19DLO zzTJ>$6M$UI@vv5!q}@5#vndg%AZb3%deFqCm;U@^tim(z&eEyZzRtq8fBd;xWfa(Y7e4)kWRDeH@w(x75bcMyVH5Lpq%)us95i18q9pildYS-)<7Jl zmEU(UEc+}?Ks>wK>NHpX7XLF>##~MU$T^10kI?rFj4VsXSF1rSD-E`V&8kQ;pJ>L% z`Wnm>iHJ-%tC5{o$$;s;qty5fqscfg`q`1pZ3|}@AAD<^mOZ9;H+y-)_K}eJrfCl> z#$b^()e}7x-Qq%HClYYF2fwSEBMz8UW?gw?<$n4?WDUGky_$TL+Ba*;xKcCJLEoq>zt#f;h|gkjzz`!kvo`4i>*?x9jB_ zSc;00?VZ(DpC(EPU*;lgKisOJn*UfqN7mj4{=Obe+v(2DvRfjnV{X}>2C_c^-aA9j z>1fyV(OTicvhcbSWd4cv$TyoO{<_2v{r7f0Mh>I}QBA8n%T0&tJNq>n7K=Y&g);jg zY8$X-!NfU=2w|c&g)c9%o_4g*>vmB8x8<9bd_jcQ$PXeT|Bl$0UkSn5I2@Xfcd$?E zH=Prx=eaj+tWHkzW1Q4|f97v@indiqjO*An$l>$5-g%_EjXF7>)T-S#HH?Ki4@&+0 zmGZauzEMAh1K)xK<)A=X+kv{>lvTDht(kb|W!wl9i0+q4L0U?1%g>U-^N zMsyjGZ8t~h?w1PVYoRmuzW}M^Rz%W0^&(j$ZU<}i6pk{$pACI)QcC`48hb2cE+BGt z-ZSzw+pLf1G@qzppEnzh-Pu}*g&dWKfzgfK0_KR-?+l#zDXvQ1#T$jQSM00J1*GyPHrx@9a zKeH0QP<_JySJ=AE)$w`_c|UwzHpjFc!mFT*E7yD^c-}Vt@KZErj(Z~}eCD;+0qeId zPe#rWzvB>`1KRhw!>)aP!3ocH#;C4aD@^p8D;|6(5ro=bD8W0b>h69lzU;8HWy$@3 zbBr&L-J5O78)J3&u5rWk39s3l<%yU+6}4~02hLg1twxhlzRxOE9L4Z>pXsh}@ZlUD zdSWuG@jZS#=s*?!O{o5$B4b~`Ms|97W#DV+_*@}r{D}q*n{#ZSt^ppMZ7(jqC^lYD z_*|ga|H!3OWxvq9bdW$FJ6l_a`_?S!S(+>rOu2PD2N-UgqobU8nD{;m$^|!TuIJ|| z?{L7}dgXlVjYZw@sXIQb(--7>Az>8~mJ_TjcV~-7&s-~wym8?{)RP>g;5BZ(1=hL| zt~^3;P|mvPO5Dji4X3!zYseZwu55<`Kkn%B3h`_r1@BW3U>fvca2YU4qrOohHz^*g0tUxwxn3fLPtP3#hFS21q01PTyO&*Jd!`V1iZr zKw%&z`}2LPv-bgfuHy1>+GWyoC3DRvh;_M?Uo7g$65p^7U_S4BAcKnA#kk7YC#7A7 z1?mP)^t9Nc`(YY|FYKeLrl#%>Ib5nD(fQ0Lg!zI4sMhf2?f#l0(RQZ>1^k=8)|8Am z`LENFdnAtRC^8{gX}P&U;wO6bimuQn#05K5OwiBn+RCx3g0Q;k^4sm(lcyl({Ya?? zZZs9{PTvzU3sn+L#52|m>o+7;D?dUWMDel~nsIKM^Hps;0Qz3&bj2?G)-A&H=O|Ob z|HIyQfHk>oX-7a%KswS13W|z|f*?I2(nLT&K)MJ>lcKaxgLJ6^0t!l0sz4G@iu7KU z-lSLQB|%Dnkn?Xm=gu6x_ntd*@612*%yXXPIS1MM`#!R>_g-ti>s{}v%WSM$(F^ju z)8r&`Co16ERAoc=#wRtF8-+a&PS6_+E1rBpaToStRm0iz-h!uPMtHixLJ?gk%089; zdO#lZ^EQ78Cf}t(xJRKIECRFVi6d>-KR!l{wV~G8j*8=mDyCh*}Fweg; zK+Z@a_We`AA?y9XXJ`R}@Qe#atkDG2vO&AQlIi|QXZw#?@tC*Yg}4uRso;%Yn-(I( zqrCRgcZDwetR%yRx2yXy{8PS1HYu);a>k_ zjMWRRcTR6i&Nh&px$Bm8`eyq#dM=3lPJ`|85wQLV0RUedyl)U%v)K1$@3 zO6BhdK$Pne=fcB`#f0b*R<2wbHsy(cMRCzZPbHwpI;5X#fR4072uFBywcZt6t)mv% zs0P9}-3O+>C<;AOV)m4l+!E}L=cF2pe@^9gdGwsh zE3b}v|DsIJ3mm4=lpf#OwLwtGw87NXJWyYtNG+L(Hha8y%vn|x|7i-wW+00UEm#r7 z!v&v=@@%+E$1GozkwaTGRcbFO|j}H5V%rOp$fDiprN|3_pB3 zY-@|{M5mc|+oi+a1n8#CQc7SH(nyOSh&T0`w$~CE{$dd#7xe9NJ@Yp#qAwHe$sp9ZDDsElzmi{&C``P@UN*HHsbAt@#E$_twfKK4wSH4F+2=M=-3=@m&HS3^AY z`nwc3>G?EIrdhwyWV(BX6GD;xH@ayrZ0xQhBVbg9jk+zl*7KUL34)GnhNtsW-$vRF zim|ppj2b1V;;PNsX)9?Tcn@SQN{$DLju#lHI%h1peb#xbm0OwJs>It%AGU+h=yk0+ zVpnBdkT9p#yYf7TBwgP}=UJ3e7BBNR6J*wsFWrD|myKY1^1IAT`{cR-=r}tKye-3sFgl3({`8(Z9 zs#v_8a7s^BPURP`yX2fDA5hi08FgR`eE?S)?btBRDXlr>rSia@@akNvTw!-_94{tS zVh(y$h6eB;+?!~b;3?gP90>j!@1NSc6!JAM&9{3rb<)ZwHGoWrNb@GoSX6-;c~WF} z_?&4Bg;Uj-quI(!%74CbcU!*efw$D#p#{kYCOYZwA1JJP#rmj7@a-o3b4{Hn%Fcg} zX@?20Gz<}ZS+EJ2D3#*<<0M@11D>RM@_zSe>t5Z?7k&CE@L45zy!^oUNs4hd)^4TaFx5kgVy z=kZa3T>hH`;95Mv6iYKtZeoiAE~8i>++&AkCuZ1aKhF_&Pgjm$^+E<}$Edpt?n1oa z6v+WkEnp(Zz4@du)Z*B0AGFeV|25&te&X~U*XMC`ws~Kp_eF0CAg0S`2SnG`RwyQ` zmaEw7a_gT5=!Bd{EM%J*0_MmU-x5qB!Wwq$7lo(iu zu~hY7f31|TKW8;;m!tI6x${QJ83go&Z|*s$p9w#)0r$y9TXxvk049*)uhSxrCw$s8 zyG0B^yb(-x?C_x4EJ}*OH}kLw=FuixViQg=KQq+moZoAo zB<=v>p}*CUX$@}-r9;f$Ll6!JfZU8sMD08t{2&kT$%*q&f`Sy0MX4UT%ZdcP>0Lk| zJ_8WOE*u3hm>)p4cVPIipRwZTA8(lY-+le&_+wu&9837BYr}vmFTAMbXeeup*s2h+ zG*yPe;9qIoGB|ksgVco|9gUxI6%_WwK!uI*966#^X0-cRg&T$6 za~Xb0R`^yG1zT4UMQnpa$gUO>cU%)u>G8i$hji zB`7GOUhB2E>BTK<_iq=yXI-`bs(;Vv(9q%|8d|QanAl|uf6p3f&EDeD$Z+fX`U%p) z-Wg7A$;ZaUgbUH3u#HPFA_=f8^?Klsqe`8k-KPeGIKMmuj(Pa!$pFQc%JKl>9GLWY zD!|{PSNiu`)PY+7N8@*Q0NI($THmIsqSjI`eVQ_CpeUER2TOw3rq4AXxW*OD6YGn^ zXyI=4h|7>Z)s8TtRAoey&=W@{ZtO}Z(fSbD5~Y9anb}Hqf^KdrL`zkCI`poLgyC<;w|+g7?h`Ej2G_UG(EC#fi5TQ!WG!4W6J$ zAS14W+&x*@sXbTOzGVcBEZNwYv3xeXl+n&2Q1TArUP~DPzZbsJyQh~AiX}68dAQQN zo0?Zc#nLU@)mS^d_HBAqs91Z&R7r_lfxU_S+(}4w_C*L6gn7f|VVY*{!?$mFD6>-` zhdK}aRTrj3SIInYz<1#TV}#tIDh1!H+8tRyh>1l^Y3v;yMa*a9LV?N&49CCkzk0B= z>vm)_Dxoc#qFAEFJ4|u;QE>6MI@2vmfR=ZunmWQ6i7InIF_amom%L4=9K-U1#GYe7 zdk=6V6$D+FJN4uME4u-~C}emG|6=Ow^BL5}QzHGVfDHpYX3BEO7Ro5CAi^1684Ily z$@2|2WhUILu$P~*3e7N&E$)`bE4tBk+09oyJ|1q5&D4m$N(k>o-m)k;ZU`ua!llc(x{P3zQ~Z!Axp-hP6}FF#UhBvdq~ zo7g%5%8*dc0T~?ARQ8>vY7=hRv$)2%H0Dw2o?s*>Iq{jWwIc`B5}3mrg2VBdP3-DV z^;|^M*$=8thZXY6#?zpCsk4ALJ}L{G_mCur4c4g#X|B8PpHrfP0h+Ov`91@`SF;$*S;6 zJgKyR8K?P*;%FnwrN@|YDeqG0uDg9h^2NQZ9|tLZ-7t21NaGl{BPG7$c30?0DUXg= zmG*m%FK7pBppjlx%PUieVz|S%x(`)r1q;$&4y`f1d@39L5?Fo#kW_2s$hcot=bpm# z>KBMlrpjzJE&S!o;|=e*eVoY}U}z#&#yHBc%WHcpk{V(VulhMY+SEDNTG)p@B|tip z?fC_=EC3~jCFByj04G`F-^uzpFmQH@TY(X4^TFBeo!#sxuU=(m;T=&K;fdif!`QAH zOk&+~6#hr%)x3w(Y`2Gw=a6S+7;$)gdSr0+TJVrE50H;Mib-~fG}*h>cei)rQ-Gs~ zgQ~)rTf-`3+(&rdh<^Eb4|V%t6Qux~sBy@@@1h4A@sGPG0>||8E&l2bzuSiYcicd) ztBO*zO|>3Dv$3zOTXN;f`|>wm&*Z#Ru6BA&WRnrOnC|=sC20VkNXJH#_b6? z=yJet=ZM~&9dG^puO~e5+?5oVGH)rM5!)UQ(gB>n_e)Z_f?XqoOX}@=0BiM{a<90q zYW@6z>E;|Q(NEw;LC%eXRV^^H76FvGfzUb~4!RW?DCOd#5U$ANou|^5y2Ujx%!{}C zujujF?%?(RA&Ein+*cz|9@V;o)+f5Y)VG4+o)rG32p#Nen$J<$#jDU&y*ASVtB}g3 zDPx$)lS^EL(`=#8^={cfq$>~Yw!kcANThDu9CrbUx&Azg$VgpJyJG{rrcwHoVlRFs zi924l4E@DMcYF!MuY7x2%AM0gc|=C+RoSElZ~l_Q*c4S}7|?%kB}&fk*<%U&gf zSkr}=*Z2pS2tTD3{IOCx#`*i}#C|F$A^!!q{#plB5j<#DIDolWZ6emjeBVZz5!Rpt zy&LRTO;lA=7@P@-zhlBaN4)o)ls~sdauBN+U0X}e$;c!4CyX}4)J36dt|BykIEXzFh z3Y)GL2(8yJb2XG-aqAv7x*l6|j&&xoQRi6%osyG+(nH5%qXk6+^n7_Yf+ct###{1| z(T@OCb?=+l%VUReMn$$<1xpd1EYA}8I!5{TK6Mf)D!lD+BGo-`mWD@zS#CXO5y5Af z_&Asga!p7c&%KE&uJ0gKn=obmbpOq;`p3^jTF9xJ``w803fc*;e#akD8m|19(vbXj zQyKtT7flp~+Y#xjLI!z7VzRyCFOVLy zCXJV`rm;>Vp7$zY_?AfwUXjRa8roxz0)zTMeBoPMxi1Yz^i91}WS-GaHuvnDd5uiR zK5-st_u!jk;s0X3j=phZ6Uw->)jzBFv8p0Loc`syO6>)Wyr!>4&*&Fr`3F`|pCcb4 zyv{rEO3cIs8X?W1TPw%A3UYjCufOj`De@FNK5=vNgrcxdhru2~u^Y7^!|>@wA*+8k zS&&F?5Npe}jNQsU$Bp974OPK&z4xe;8JIe>n9TV{HgozsG2fjZCm3TT+YtO0$W5gu z-NSc^v;@)0lOd*pxb~6lMOxl>6p!(*u!F`=De4z|7H$_SZZ`1A+qqa~H=ub@Zb!RbmaX4gFpGoheyyQ?RbXCg zvy4s%wQT%)W~jGFF5d8#m}FaE(Fep)v-qc;IW(+30$(-g@K*ZRqSp^xlaJcpCo3atLsqP`)arTjw2hT~U z{7zq`F#E`m`i0(5lD2`C4er3_UuXCV6$g=XB5Q^$Um>~eMIw-63b=G;V#z)yqPHW< zfHx)I;A(fkr90i@n0ASXEA|Ep430)2tfScihwL|kVPj(7Nq8Mg2v+Zh=_-HyUokK(zpw9|3k(|@~|`kTLNy3 zCO73rN11ElL$1m&Sxk7v^(O5OOm6$-N|V0c4;u{}h@;zfS8%d4>!ej+6X%}UJY89c z_n8o&h0Me56`P69)XR)^8L{1QA?;FBrznw8K^K({Em{8#7CLYUF+b)rL=d}S>!)l? zx9Fj}f=i7E8|V&00cP(=^#1Y9KS*vcvBHA-2Jx7EFEwCw2l{n3<9#f@v&|n*!zlIf z9d#@QqO&ZYIo>3Gr{6~}Egt1sB5m|#`hY_QUnsEqEcE<}`~_jNXFdbafnElweu@af zS*vLnwXyZUbJL3s!A1w{do&CKnE8NY?{oUwwZ7GYiffF_qq)Hnbh}a0z4Xm8HO#pC zn6xo#gNpvdtZVnm3ZFKegldj>`b$uJJXv|ZZzH*lO0Tqg^TMGgz~2l1p%i)~ zfgPMk3IT~`04Skq5B#Hle<|D&^a=m%a0NGQ0tk%{y3N}(Q~t$Duaa+;1bp{AQfJ;L zf6%U$2*XpYxY{-fN7ik5wx{f& zR#Qg~ErO82HU-bVfL5V^){n=rx#%HN;x%qg;3I;V>Sas{%m%S@1PDNsXb`$9;rr=8 zRQAMV$L?3yw?9-lKa04Jz!P!Medl80BfZYP4N;$C;8-2w+l5?LU#?m{3nhjpl!tEt ze=*kG^0#l=sBi}OQ-ruOpGbBsU$ktvuQ#N;T*`oRfSeJ>lk|k}!XD3R2{a@TRJDb;1FlTZROH zE=x3U9Pyx_q&sZ)Y_d;MAR^qkDf+hMIdM3$0tUli^Afvn@YF43Mw4F7%rCjpq6=NPSxL- zfNI9nY-dYmM5Zsf)sE}*tT>ucoVajO53(B(MO)!CFit`^4FBAcp=SO0ky^#4=&mQE z>uC192~$4|+l$LBD7Gk-;*y8Emw0@2>P)?u{5T?kZw9v9+OV77`Ot9cU*vxmmf`Qevb}K)WYCQl)D2quel*x zi#Lz~CS=_f`g+$@-|68od^U2sZ=^K78uwmoaHN!{wqa5h%RU*T!|g{CKPpeHi%q-O z7;`6sVK7*@BDHeA_hQKQx>B*5$Tq9hYE)qd zJh__4i3>LrtH|`p9SWu+5|y`B8-1s#_q+N_))?W?x|B;1@g1p$V51cX0JiNE_8T#1jqnPfO4IQGLaU9%1Hqtc z+eGyd1g>=zWpDQWgMas^m>iiMr(LXDcEq8$4msmKRIZq=lYwDIGf$*>QW99ExJ-QXZg*97c{#}?m=@kl z&LfFpuI4<{smF!#7QmW@x_WFHYb)+4tkjU}`}PStR8xxUL7XV$jNA&bm>S;`eRF-T zY8)#p#bj)jd$(K4AZI3x4pnmHMZ(Z z7<-94?8}|%z|GCJUH0-9$Q4vLZHO;TkG{b`oxxpK3BB0EF^@M7zqh+rH#r_q(63vF z?SIatt~2x4;;xU}gQPEcc=w4F(Rh@%XaM2p|p2BfASC?HSeLm=sBaNC$e04y@sJc_ubjV zt+MA+bU={%4%RQ0oZfG->026hysnB8ucR3Z&XZsUyYeX>NBnLE-%jB;c>a+^Vbl48 z1&|h6+wuDa5Lbtw0VOTC6jk?WZ|t4wjbYU%cAbB5O^%nQ-c@r)Pt#bz^#F?jZ#@uf z{c#3<0|B=mzBv=bPhXBeQIE@#F|S%tPwu^Slwc~o0{7JLZR$g@p!%%aki#pxG@GI! z*9br$D7befb;Qv2v7fLCKMp;t)`N116dP904{t3ficnzk3b(&?kz56oowY^jWFM?I zv|+s|jrZB9HWk-njyLvny6aCe_`JP+FtWO&??gYr!zVj}r1jrjc!OFnwJp69cuk|= z#`CKxq?FaJr%N2^y(O@j;i9K{MJohW^i=6W!M>n<+m$mmCs7m*>nK-wRmA&PMkxiK>eQbxn zwA943iwl?3a`2MltGyk*(PAmzJx=q73rog_K@{xQ@%+nwh3}Yu44O>39LukTj(VL# z+DqpdW|7zQkgD#o4WD|tF_)Y!MHbH{Q;S*D6icvmxALnSrIP-+w729I1v&~5{<7qK z=^lD&v5iU+r(3lGu-frZKa6Z2@d%znH~y=!m?|6RO!C`!CTJ4HQYVJ6>~b0QIumup!|t1` zO9(z*!E&Q(W0a=lK|vYo`IW>N&Ld1#z0>cur3ZjauWa(0LBWJX^TV&+ zuk$`8iP(MVDm$07VGJl;E>fr7cQ4=lP-Jr5iANKu9hEuqP0x14_`3!2-)ij9EQsyi z9pXr~A?H5(RPy3BMZhhSFGIFsu?D7w^3L`=bq&H4irf=eTdH9WHN|dK)g@~O`!rT~ z#?|?{5$=r@FNOl=Ogv?efTF+#*ZeUNMU}bcb5d^Fn;;LMd15ppDx_ z{b8Y#;&f*^-Zg2jdSDc~3w*A~zc&=T&`2d^Iio~!m~B&h(WgUnzEn3lW8O{GGW|=9 z)r0cTiL0rynOqtrv*^B|vhPQezdbQtSL7G;+Vd4u76s1^$%TYj&_u}8O!Tr8i6up* zB_#HDjtnbb#NB+{74lJ<{ToVS0`|C&#VV|OwdVQEe(c0Fmi8lU?SFQ5o%_$smp45i z;0QEM2S3_O_X>q5kc{_%HOD-LFw$@}$t> z;2vza3y-dm<-pxLgtED4EE#eB%h{9BR~O~YhsASg>GAw^zUQxsqE1s~Y6c}A=F^<# zQhwlN#auh$+rdqhWRL5}xmxlIM31W$01r)1k^LVHqX(yJoYg8NHmzA;i_;&kRpHke zcL%5*?n%Qh*c3O(qDbcUjogm_ZVLA`guzf(B{iHwG5)kM?@FAIQpM9&7!&L)A;(S; ze`&&={q_r&=%Sky+*|Tz2)78C>nIe*MAPE}8!gLj*+JnAuR-cmocubnwQNQql9~Qm zb_6imlxs1^FW*+6%)ZD(4H2lkey2;5>0DMdU~s3WgYsx#G}5!@cO6PB`VCN#6<wIG^-MC%?G7$l<1QBP;2mNatRZZ9)#1w_oG*ZHvUV6WUs$ z;B^omMNjC%Hjn-{Skmfkw84>0D*F9lyO+^`8e6_}3x8KM?GnJ3Eivv&t`nk6VtdOOwh)R9$Bz`smGWY zs+MhO$841aMA!4&La-;_JlO6e6+G-OtPQFw4Xx6^=pM@v?7AK-qg#**Dqssh&bs8m+vH&??_ zzt9}k(C*#%iw$FL!zWhDvf+F_v#_te*ebbuEv6XB=XLw#^o&{3EJ1YwN{z3arHXXF zxo4DjLV36&Rwi5h;rhikXWvs;+F)-}=fjO<89wMcbZPc;E!=(l;ybMO(|)z2YlVor z3*+W{x*by6-6~}cZu?u}jnh5-|5|e?<-EXaFxL}tAnTYCUv?`BKp5S`0cXx@%)o)- zrenBTdy(r7$YQ|9O^ye78)qpY&^8FWlBg4uRYRwu4_pOSnp}kBSAq(5t+w()FK^Yr z<*LGwCb}Tg6^5ojvZog#D0E@3)FzQ6aL1bU5!KfVRTf@BI?s02RX$QrujMyscV}Qb z9!p=D*l{@3=`#LarZ&6Pdxvj?{NeVO>30j-aI5MR4y<=E!@Q*9Aorw>rL1?X1F1N0 zGwmQ!g*=AW zQvhm7r=mhEw^VITiAZ{2P8<0h{S@nYhLB@b=gZvX&70X`{$|i879@4Ir`WY5@{l~5 zNeP3U8^n$W0Y%z{^*i%!rWQr9+9H`r>z2)smnHmfqg#sv?iGPW);i!V`WBzmX|QBq zU$HDN<=wCoC*zj)RipEtZ2Gp;F}PN9MQbgnP)d|I!@?6y@VP@QoEty_cg7)ooXXbC zZom1092CEszi-!pfmv0NjjC22?_D0)durql!)==H_9sMR<*SEoz7w!{Z>k)^GuCS4 zd+uT;j=Z1%;m=LpZK-0Y7Q1_0f_zJB8mAcq3l&XICD38T;?CU|dXU(CqWQ}EL}*yV zS%Mr!F6_)i(23y7QGACq>90~!Tm>AL&U<0vCzQ=1d7nUTUk9g#PKYGs2J73XBU-HH z%2QXF>6sv}T_806NR7T5Bfjkm8sC;^`$xb>{Ss@RPs8*hJHMAto=us*Wr2~nDwWGcrvQ!@vy|osL zKJ7Q7nW70ENB8ZtRq!V!j4xb|FK7|6kbmlU+Uol!RrhPN8y%(Bq<-hVSF{AP>EGV1INIP1 z4ATN~u(a)i(U2npYkddz9ha7CN0)jszv`Quz>dXFy%O2GqF-c}tTrXj`eOPM&5JW~ zGM+Ak9D#aSj_z{p48;8d1I!H&cr8!rPQ{p-Mw#qpL;B1e`<&o+x+kehLl*1KYf^{O`T z*{oP8@@JSD(@8je#W{~UlV_rYBBm2(+~zJi^8GtMICtq@c_PjK7GByYAmdhVT*H)N zEA)I`Cr|NFAa@|HJHK3IQiidi|C0Vv(aF^#Y2P%xo35e!MV|3&@JGc*PH7ySPq~mE z)?u8_;-tWz6h14-{DA)D8;Up5E@;nzi8;SqN1n2x&Imm^<@fbVULa~NLFT<5`cJpD z5*vrLd(aPrc)!^@ytTfs*5J-d!fJ6h>ga-T{C;FnW~R{>6Q$Xq(d(U`lfzaO$u2h6 za58q63G8v$Yp9pxl}EP~mOgp&;tKOf#1XR?e{ueFK$5|xRdORbD}I5*6+;P+J|ccR zb{fI{Q;5NtpYVuhh#!x&ut^nfX`nOV^$UdG0fzqy{qgD1KR*0FhgSU8KHHGUhP@IZ z&ABb~dSTqc?&(|ext7x_B~9bzQJLwEc&q9$POS4tWk9A+4EoxWXe3{9(Hzt#N-`zB zY7$8bcdqGpv`h19ORqSP?bHFm$dl|2So~kIp0xaaV<$1 zbry^>*f81{6c!IX$T(*a?seMjXc}!5s!efzaf8l{17Fkp_i$`3V8B zV=Tcd&!cyi_+q15p7;IDo-VuhL(=B+-`jXvz6vWIJKlNTV|RjjKqJH2Q$3vHbRsAm zljAdKPtt@$L)!j!=f2%4z4?PpHfLPlaM8f0Eoj8ovhcGSb<4-d=IUTJPO#K<)^bss zg0i!a3jPk+`ypJxP2v*|t_tXRQ zwjYN!_R`N1j#g_-g}EAB1Ij-W%n^JzZg`6w4)Ly zlo^7$kJ=BVG_O($dx%3^(NndJ<2QRyx#y?XSM2ZIF;lBwQGlFjnVC4$pQ{s=58y6Z zFD#EOl}=ZEKv>;C999zZ1RbzF5sZwLv`&gv%V?HNrw z=kvX!sGdoQuNxykvD~Q$XCL=B9*I|k3%aX@<~UwG;hT`9;M+jwD0bya!_tNqJdLXc zmr*tJ3KhxLd~u%`H25|}`>cmVLqax^eS}nt_hjNfo;*|h!JaJEc*=eG`2y z6&%akMKjOS_ilF-pSz81mzzj=3siT5QmC<881kI-`Ejd?V!j5Up$wlAt<2y@v}Bvi zUk1#Lzmva!;X8O6ndD%TYuNkWJ$z@&&i~5&(cag%73~YNo7GMf69VCVzKn2QgT4!* zg7VkDp;t}4-}_`+j*NYzfe;Qq^u*LUlGz!gH>PJe$&B^7ypj{gl>YV@8I9TdVh)fDW^YjNP>YfouQnf&gDcAPFbrCoM9y z_tC+1R091qNcv;Pkmc2!mm7+txJFM;J<%ys2;8b++i7H})Y4=RDv|W8A1ltk5I$1K{GFz6wv_1{9i6=ojcd^nou`MiU0))3Ckih>=?9E%7ll=>C zFR@Xtx2(s47zd9F=Vlf`3OiTp%h;QItLt)%ol6&MM6id&jtW_X6rCiEXRj|8-gy#s zbWttKI!U>()H*^@Ui!Uv+Chkei$cck9Xg{l>EAr6ujLBZ=~`cb-bBs*jTl$A{Lnyu z5Az*409QjiQ#=O*r-VYd8F40QrBTIc;W>p7*ZCMfL0bN~< zh!xKUSD9|&6KTOzc$r32ozaIqcU9sVts?A|4Lq)P=t_72ep&PrtZ-QA%nR){ICg@L=2k!#!04-fbU)Ch zKSnI{gnruA{%f6p|49erkDsk)`o>z)F}UD)0qW%Na=+&Bv&Xl*9r#l2#Pz0Z4$K?S zBu}DF3koO~?TJ292vev)ay;Qr;M?S{aNRu~kb$>T3BS=TSlMPte=o+-s&Pu?>k}E3 zHNDZ}*DcKA@5*ua`E*$*DzfR4(XagOmjH_W(Lzihe)8v>U_Ux^Wo2G)l;FLh$8PeJ zN4g%VGf^LkTQMH3DA!HMH@sSQB8beogdfCuTDH)uV`BoUcTlg5pVs`JeAWr0+ZJ-U45L6Prea%vtRJ|V*53=)cXR> z5@gIg0UM%!aG6o`PcuvDr-3op>`Z`HRb!M&$T} z(epD}5h4-(7j1s-@KNYTr`Cw&rw3F0^k6S)6|zfp>?={Cl&KQcq$Fiu?kS&$VjXz! zFiVH69m2{yR>vSm?bKLi9(gUR-3d~i*|V@2Jq4q(t`z*f$bv?{FTtjp;$&9m7qeAg5g?!F6=y&MtrLI62&1FF>ceK=bf2M|p|b z=Z<2Ycatxp0=IH~7$+SAq@{9dvKI`__-}!|JY&{s_$e?~O4q#f%#4HFfE{{Nc@qC{ z62`nJ4|Y9Fp>b&aK`;q0}?}v za@ziQaUS59m4&UIL#JjAEe_cOtzwpBJ7*4s^Il=AS{D`N$b6agG<#ND?ZxKQE5q9g zOCsMU$TYa0W##4Zhf(HaEo_w*B?G}?h1sEz#x7Ovsj_Dg^iSoWK@al?tayZ@v~$C2 z`&coW%$2y8bdO+BAHVogd&7!TB&IsWS~w`Qw_4hdNI;v69>BupIb@EvN-ik{`fTcc#p_5>2 z#hg)gx7ewcXmPjfgl?m_B@dCUN#jNXjz6#f#-iU~gZ?5oaxE{W{3teMSn$K1 z?z{&-4&dz{2k>8O2BRzR@izzY_tc3lxBi+y{`OemvV7#nI*_9}SFSdJpn*4_l1+LP zh7HN-kdn%+-$@r6Ty`nAD~|~h)5nYKz0_FjAFy8YUf>ldW7~@m>2%HA=a@A0C%|&# zvTc&Uk^&xL@T}EAQqsYa()EozAPYeIUiV#YW0Lc7PzjTF7Fpq=gIn>wk;#E69w3>t zi=DPf_rrJ&+`|(kFScTjNQ=aDru6;j9qLy0EElTk7WNAAlodNxFyTV9@!aPMw~&_E z28HN1Hit*ceC9JFB$3rP9ZbQVpjIEsl}h=-%J7hDX^%jW^hZ_AB( zq*kyRfHeZqQ#4c)&p#n}O(|}VbEtWaZ&-aEcDMxuN&nsjxr+O*q}jV2Sdv;j)OflsMC`kxmm=CkI~RvkH67rut)X?o>47^Pf~jf0F0yR?J#Dtvjl|)3rI5W zqZ!SyTxZw#1_@efQ=mt4T1ikUsSMeFIY!iya z@`eo?FUH8TUN?QsNx61@8FhK-c42;D@X*+$z%bU@llzbfJr65On@odrRAjDLKQ4mr zRwF&jJO#;5rP6-$U=L>Mh6anif)#qu2R(LHy7#~@x*Gw!rlSW-K;t^j^_i~cO5)JU zR9xHjZzj@WN7`=%bSC}bg`=dC$Ux~!+33vF1?c^91q*%I9)St^fI10i`u%w*HQ~f$ zq>if$RC!NyO5kM6)(cZe1UFmrzQC2Mc&kZTYTKN5^Sere7<&EV8U?L*vb$hvEf`z6 z#`pi_*nkQ3<-n^p7(DHDMR7Se)E*&pNyo&dinljHHWxk6diAhlgi})}Wn0PqsNyST zWWLrZ$}O5Nt;`{wo6-XynJ}2hfYVJA<+4*UOwRL%UDn{U$Z8kK_mlBVu^IbgPQ|Oq zst{jhY*gwgVo17A?4oi65E2DY#T%ZOkb9C@gm?eodcY|X$jU`9zzr2}Zb+`+605B; z>#vL_f84)Qj(2$*XEvD~?C!u?HmBG%g+TlOC>Vi|Y{KyaTgqZ{U`r8pMNyi<{7JaU zY97uv6sgem`~t@yUn(pS<(R$Td1Y|TzU7kY);nM@DSkbJMW!CmeL^&^OAT1v;1$VNvjtrNyyh@cuiN*J61if`3ix;lwJqI-V-W<>s{p@hP!U zrvYtE|Nj6FY69fM{Rr5(5IL|J;gcL^A8be|78WOHTuK#b;TiQ4zLMVraoIp4>wK9& zz`{~6CB(YFXuW0j@_i3Jjy!V3E%6DOl=vRJV{MX9;DhuJoh$79WBSsK5gmL1Zjk1& zCeA}W-9>iyi>!Zl#6I)3WSkMsQs;Xyc1X=jeb3O4{0@NHyyVSc4}(2v3fu9?)s-B$ zz=UqQA@`x7FT(ZSJG?_2ziyUj_xiEJ*zpLyqBxVD%KrYE1YQvT>O7#Yr39e3e}eb4 z0lYWy8@%_=wz=qZ=_vqISt*ntlnO6aSA!j#hq7;+zC-xkc_;?BYV%`)J#iWb=ONqJ zCke3Morf&o(Y3pv(BMqZCO8ibrMCVK{Sfvne^DWaA zz$HXlj?WNx59oqxAL}HBBzOPeL=~?@IFyYAe zfI$L?Gu-Y$yX-X+h7Gfl*y0`ht{yH$e>n+$6An)S~R8&wA;I8teU4x17gu<53!-4U1Jr z%V|-IiR|&j!1u-@vOC5Orz1q%rF5!W)|&W}rZ!Cj$0+(YRU-kEcuoJpD%2ZY%&5p# z_9}bAVtYES%@Dg*hoppSYf1(`$q-Hdq-bu%qAh;TN%>cVL-#w9lfu-i4uGCWn@3&G z2OE0ZDPJ=D3UTOE(GUQsEl89RAUWm+Mg{l900QElN#@ViEJNYY*E^tXto9vM`)zmr z^XETD;Lj2Ga|Hezfj>v!&k^`@1pYUV06eovgA5R0AIKB#B3Y%0TTm=M^N2YtfKv=*Vgi)$Op&J)KLM8%K%$u4AVeczA zQesdGVvS%*Foyn5{{ilZBfgyY;yMJKeW9SKQfz&Zdtbqk4+Ft`4?%kdHl1|g#%hL-oC1ud z3VK~S8#@1ynfJ$EG{OC29?8U;>j^E|u=bItNpbS@5Hr5@Br8q&BXC1-p2aH_jZGL4NVOPKwt&2mbCQ zDwzZm?1gt(!*}$T-l`_Q&^_~X=yTbtC`ijya+OtEHQ3blV^=lBq1p~(20%*8zaHFg zIkN0Tegh(`;j9HzHCf83vTeosk9*F?&d%zD@rix7FlX*3eCtrGSJKK-F?#H`$evwk z6NgmZ?OUpsq#2m7U%N=6=2#Ko%JdpFymHabo=SVqs5A4$$sGozLg$FDz3%AP z(i;nZiM(Uz;Bm^>q8IzAD3kPbG>+9x_uie2L$?_;$gq+mUb=dr(kf|i!<)peevDT4 z06aoU;L>?dNcK^Fe>kY428jLKeBIK583^koy>~Wt<%(SK&l6-II%IJ*(lmZ4eJ>_E zLQ|M=4ymVtL$deLi{cTVkyh~+{ruGRuP)Yo%k7}?z7A5hUD?iGmeE^r*Q~#9u_yg5 zkc{L}D}^rf)qS}06n~JnVOERTo5d=-(kNaL{=u&|d3YETZb{}5ma-011J1mCzX?P( zZA@6Y+tYJLeG)pw<@pmjzHtXo9^DrZGQ}N_pY%DuXwWt=Xipj_?D60i$ffy6mkSS;-d;shafkN9a#e1e~RQnj$~-I5^(?Fo%FT_wOg!zuLa2Tq#U|y~wLP z83El|nKhmDPYa(Gs@qAXnmSYS3&df}l4yPIulf|bjC0@(@5G&d=|^vQF2QQMjfF< z9=u_#UOp%p_kL*P6ErD*M_AcyCgN4t!)6&DffqPvJ(LQ5V@p8BS=Z3;h50vK*l87- zk(juAbqNYgy2HZu)=_a>l@>gEySP8eHD}b+SkBG?>8U?+Bz%)U>~D5OE3QoeEx2?byRGVG zHpV*h%-1?ikJlaNRjsS_{44HM*~K;LM>k-XwFF|y@D&pRXKy~j$BsUC50*FuO*+f` zCXFDE4K6;XU^c~Z^ptbplbQ9==-0Y6qW}4Z9z8W<(chVeJ0_=a(IJEr)C@~QVfv^# z=1?YgD;|r<+l-H!#G82g^U77Hp|tpGtfvMFnLZc>3(%ceZNJ)5o5fEW^)N~aWd=`d zl!amgFREf}&)zSl*5%P0efc;p=$1MK=QL-ufmN`#{p2|7e$F0+=APA{o5y%btW4R5 z;Yy2?v?dRsK9TOIG0zg0Q&dAVCTj%&VLk&!u@!iFn82xwxKxs*Ua zb8yag76dfg$177Mh5&t7?m$$4tD*jQLbs7o8|TIA=`#t6lv$}D@&=Kyl?o3P6ioYA zk|cijiE7LF2xd(s5UzuG_PVps85pWObiV9V!;l!O&wB1{lnNgfvYD%aS1$)i4)VHy zeIIb73ZD&x)dQDmp&O#s2>e9=fQ0>Z7ucjEHe~;p0hCC65&#%kKVOkbWW*dnboRXg z+26H7#BxG-om*T_OCVfqHgqN zp&dZpe(dZbe8T^fAm96sI#(rQH6XY3u7LD*6=zpzCpm_MSbd{&uentC{Xj+a=jT__ zN=j42d7h}MoJTX?qDhOZW(MPbbRZBmZ`%n1)n))aV!l&_eFc{%2BScnlbjxb)A{Qz zN(6orI)FIk$o~SV2{a|>K!3dCHlo&bl6IH907hU{0FV_BS^4Q9{|$Gr`!YVb==Q|j z%>D4_hdGP>^`rE8PEOSm>qk&t9D6eAT^E)wOq3OQFDH%3ofM;?VddnOW5$>xtlkZs z8Vwp@aqD;$XV}cASW{C+8qj?5*R+lA1R!T$J{+(y1YXx;=#uR8+;9BPV|FxnncIc0 zovm*7+^pF^JJzSbuvLK$Zwd!QZx^Omd}Dx}ow--isH`B))?xBdHogrX*F8o^vo_NcVOj3!Z0g7%k+_^y#kRW!1Hl#WLDg0~@vel)|?zZ%KoPQ9aWkzN%m8u6pl68Ag=gl3M(Wh^Z_>gPxFX->0%hKj=9WAuK(cLIE zX)tA}*3@aS?i>I2E-=dRHplzM?eNz>bZ8gmd4}2FV1%L`p>WZYyBae{`i3&`W`C`! z?arINg{{Snu#g2`}0L8y9M?$YjnYAQZi9!CbtLZIQ`E>Fsj%~JJ&A9Hr90YuIJLoF)JQT zD@u`=bW<_EJHP0mOTiPims}^=>w6O0n4GKNSDdhL_Lg&D=uRS50#s&fn|x&pqlcTT z^`ERZ{N(a1OJbfz7Oy!47Di*>e!`dmm1ucr}inKr}H|6D)DG1m5vut_;ydQ+TQ~RTCbgK+24Q z@X+WFF2ikl`z9{cn=@6rte6M;$*>ule#BA>V&js@;GP(wxhEHBYl3Le z{JqLJOxn_dt=k0D`*tu-eb2-92@j|4A4k_Iy+18=eW7Zvn||@jbmyUQ(N5oX z)Ad_xpwbIJF*2-_cJLGN2G{n!e;SY)%-56KlR&h{SAu%$w~@PI=XU)oUt_YsM_6Br z28AwEzk*6b9}zDw7x2G8fIxkv>F!?0PSQ_}DV0EWxJ4B^w~uHbEX`qptJbv$62Cx9 zaR|wsrAZ9oSrrXpfMD8Q*^epAS+R|pCd#D$0&)5Ua_(>ch-auI!#ox!$iu5mM`~ys zBrlj48b0s8leTwV{?Wx|aiNspGF95ZG4bAwJ&>Dl_$$aRunf~ExPFC~I>3Kt-tG@C z%|+BcKPXXkZ3%d|H(>34gd^F5z;o%4C0&pGG!*Ll1jmxssg zzV2&gTyx*o@_apC&!=*z_)(;r39qm(|pA7pAZtXfF@ zN=?Ip>Xlk&wNP;rBtf+&s>y|J#*NK}xU{mUO1VJ8!{wE744*;-l;#FIMJT`#{@fIL)JYH=1FA zmDBc1j9p*r%02eILc1Rg?0TpfPwEI$8vX$~=$vSd$&h*N?LmFRv`gq@qvlC`wettINTYAg71MzqYacFMPC2Y7qz1k=exh<& zd_pgB!@#6GcBsEr_DjYz)iQeXx*SA1*vco4DAK&0kvpRA;(UwG&Uh`bK#!Ws7oApD zP^C{fKnOJMa}_Nu`N%Gx^FR|XLhobO>zwEZhcg5yS#@23=_WnTioR<0G3^)Ws1QWc zSlIvFI=mqfN7$D>X)&NUdUwjAX8&i{+k}9tJs!dtdfv2(#U6wlr7oLdO6E|$S)Q#f2LJ{mk?)+c8mNPOQ}*>WhHU&u(C>GRP|o{h`KIQ3JC(w}sWKh?YT zqIQi%qe&A5`weo*%W*oBr2ED*d;Idpp{A^s|hf2|C?O z4hQT&Me$HV_K8X&I1I2%d5{@rl+1m$w@B^KSrDgw0TOq`(0c;HWij0N-S9-Rs;GO; zU7wTpL4t8`VPrk;6nguxH;M*I`~iA~j)qRMk<939svQiF0pM7K$DxQJlsraAG9a7= z5(8if2LP6kX@akxUW8J1$pDY49_?6=1h6l*zX=S|`;nBSUtXf?2Z#k8j-9*Nk0kDf zGfqTP&eKeQLH;WsSND(`7{e8R`4H(0E-VkSvj~{LC-z`zhLC^u32yS5mK`>ex3H>{ zswTZvH%`;NHm5ahs?(R>6yKJBzi;5CZVv`@Vqb1^J>ZG)c6PV(6e}6w9`4|8Xp%T& zr};!!CjhcEo;6zb+*|6R1$Kb&(LvxI;+<~n8Mcl3IKX9#2e8-;Livoz^_Cn1%;s#O z>QWsG*PaPn9FW1Y!hV20m=!YGw*!a$aK^nMRrDyeeUCD6Uql^6ZecA?K^cW`1AO*liSWWMWPDw~|)5tXU@v>*{?{Q{ac!VjZmLL7{v=?>MXxie&%@M1wTE`{*l5}eq?(cJk{nFb& z_~Yk$A|Lwy`xo}lZW(+pfWj=fuCIm+ndEPLAeXW9xQ6?EQT=8na&+yi3Oa|uF)%tm z&Q_dfv3PUY^+4w6A<|3lwgO$P>HD7WYqTSURXrG9N7J(YqM;EH!^%^HlZ&q{p9g=Q z_y%MjN>=|iF5pOdVM_?{$;BG`D+q1Z3Kq@vsGtRz3iY6xy*8BeMjy?C#Er3{Y|Ue3 zmQNu5dQflPkrb%)<3ifiDK*G`ivQ}(UI^E4!Fh0v2&yt-1qMND!4FfS8+pf0;#W2z zbq(>nGUbmpulh@%Kl1IyNRc36GSyenql*I1-xNs0-I-S2t((Aa$?ip1OhLKee(CV4 zekFcoOH0fY^Qg{TE~fSt>$W5rSdPU8W+MkoVRRmzKpw#Rxka-Vx+E#i2oJ}E)89g; zQBDvt4{)0T*3fl31rXkNi?~5aO4-xH-Q6f!IXV=_T6X-<{5RRv4v_EB?E}DFWi#aj zB$yf)aK$eAI$f3+3A>i{ssXFMYb1D1=K-!M`dQ9|p`6s|^9K2&IkI^k$Ba^JIB7&? z4{#dK_d{3xB5*;+j_n=G&m9qrHTs6DP?va4-L(vt)8P%P_MPJ9vRW9*uWJ!qxfc*u zpWX3MxbJ^&Wc4Me1EU;pRRMYT{i}`_cyVOUu}h4Sk*p;u!MEg~GTBN0`4)$VFJ1l+ zdhvg`xPGBhCJe#z0VhPS>3@ynA3qd645NNtxF3{?XUm<#93z?*3Hp*Z&FyIR2xCbX z=&DFg-FC30bly8a5zM^JeSCP-F_Dx^x|k1G$W=#WF)wfgvJri!8dD^JVR2v8ainu| zNGfVqPZP9u_6RX&03S4^piarS?$R$nip2LduUigmhsx@bfew zN}+f-FluTQd`1nC(j3HV;lmva>V!^XJbV__GK8t9yWA&a4^$%1{;1=H5z#F-d-05hH1kO1GM`6+Oj zpAl6%{`-k!=xaXc_b->%RJ3a9b9ArXO+E zD|)|Q!1b51C==?1a`iikcGn5x-&EFbTf2Oq+@BZbCX#bb-qy?`KfCYO=

    6hi&tm ztFMtE1H^!sEMWDD2G+NoP5$tuLEyVE0+y%Nz!Equd>uPj#L!K)XH)}AWNn`Hy)|lXhHr&P;rQY%^$A{1YD4}GvyTqWxGvdkGPTV4apF562^Sm_&1Xq+MuTgv$!}Vm$ z(d6AXM@JM7Z!I3X`dyaX!N0-WT`hs+93S?x#y1{JHBhU1`gmN!RzmZx@E}1mb=xci zHaSdnV;iD8_S$dnd%x3S_CttXTf?xreJ|wFI_hVf={@83C{&F&*#lT^ga!hxHaXDs zdnOxu1GV5+fH2C;I0Ud(N^AvgP+&o#U~L5ihZy<@?8YYeyV5U}a1DeK@G6Ob4->%j z-okglIgryC6i)_risAho-vHk_6$IRLXbLttFdy!0Hq|W@ox1(TB46Zv+IJtOA1Pk}CIB^WRmJzI5@+IQOMtL;wwlqvzagwGVXR zX)jK9Zj#t%Dm;O2h45l{fi>|#L{iGjf+3-vR#P}A0S8E*tSf$s98K^kq{L!S)9ar?be`panc%BEr{pw7;uZwrTUn+ed7&3{gqS~WYL>)#x=Cg9 z_V;AAqb;9k~8fe<49XJ8MfNh?@=NaWG@Im0+Px1BmqQnhLFYF&si(Eo-T|w6BcwvjO zo-B(4W6hzF=1(y8aods+g_-2EzUEE%G;CQPrzLSH zR)yE2GUhRhhK`P>%ifs}rFhx*otHvHqjW|J0Nnua)vK1nS`VD1O4?2-a;NEw#P~|) z@Er~A1-!?(5Xz7z)!w-doe5`%p9OZ0BFe5TD2(qaL|p~!#ZIh8vDL zuz9bIYG-#K_B99UAk0Y24ek^JoOx#Cej7LTN2yZyR&UO94dN004W4zk+DKO`o5}ZF zU)wsejL45(O~-@e8KARp3P<1(qKHM}4T|F)g(8Ldo|@FVDq`o@u@5Gs*Qx_x`E!LyW`ZdMKp60uW=B+qH{b<|gduj4ma)-9uRj(UAPD-(|8vLT8;-L!~zvHmVM*!*C4 z@tAN#%!VlEYh0_fP^ULc&@Wd=bu`7fs>PsP{Yh!p+v+H!!iwL5^9-7EPBkk^-GnpQ zwL@uiI^$c)c?*ZH)_Ty_o9f<5Yxqzvp=&r{iBO|5`=pgM*q8T%6c|E*Bubmy4*n$*peYY8bt^)2Ld108+$o3OLF!! zu6a3X;Oxk=lt@G(DSGMvDKQLFcl(s8QgD2zRHl_5=1C_igp?c$tsIEgvbjiwODk?{VpT8ESu&gF+|jH8q_ zB|R;XyCp5AX$+Zoem{b85)x&I&>}#%VN>IWodkND9+tn{x`=!%S1&V>8lf`++!EJ?3Ao zKm*FQe+w@CdGKcs{MiHlojveJG!%TjH9%mEL74)3ycX=bf;C|Z3r5~!v=4DC=~ogA z%EBjZ*}m%dLYRNd_XAY%pH*8j*Fm|Ew`i9N^#!Fc?=rt!-Y#VgQmc<{#P1@)8X*Hv z?hnR#Y;M^(pW-z0AETm(=_I9E#6c1>8Qhq6D5idRLE_%~j=Wo0gzA$t!$4oS6&~+( zRY%@2z3j36xBD@=8KcoUAloF{9zC}`acz^wBMqvA!$B>IEtyec`^8_^>j)(JXdK!V z>pW$3>Dwv}#dRV{HmEBPzBdF;VLH>xJgCduY1UX7-##9#dDKwx7Cqe*!^Vmw?sLfo ze|ip1ML+YFe1jE6oJ(@3qw3}(4)Y)<*oUt`?D!yB)^Dii2edMDCWTb{e1?aH4A^bD z%vzb&dFHXjQcnb~TOa7jH*=}UfB&&rg9q^u`oA_f)bV=|#TWuF=Bq>Eh&yxwl78&c_h1-(PgUDuC-%>MNXnV*R` zz+2nPY@PHSC$j<(7u_aH>=JNFjFZZ!Ge*u0Q)S}gKUvWWMC#4cdM%i zfZ$c^7IJX~^3D0DDvUn`Sj3CTG@yWF7T)jZKO*f=&3BkOxoXiAaw5Hf_V)*Q6PJGD z==?Ku1T#tm)8fz^$N_19ZK0F@S3xrX=ZTzZ-wiqBXJ*`$$rh2#ep%_PCCN!ZY(@i9?Ml_L~c5LYLy40K;fOQ+hM*Bc4S9uEc~St*Y3 z=^lW2@LMjwqxgo)`A6b!nY^3`uG@zZuyYv6+x;PHk1&f8dGk?8(Uc6++)y57%f1Ar zRAUQ|2g1S=eg95P=MI%0Q8cw0!BFj{*%vsH{bv)MossIYS%XJivOjU{yJSmbHs7*u z8t0{XXHYsUdzLmj0NHzn-)-2ZbHi6{kFvjPncys0>xjU}P!b0!kAYMvh zbF7|Na#~qW%NDvo>jsI@;R`jQUqr{NA0c8JF^aJ&rIiOe{ zGcg{*5F@>hX|Z>3SzilsUVLGyjw~AO=)oFG&PVS?$ahvVyJ7k?`*Kv56SnP+bYx$p zu`NNl-Qk!04o)V7OsEBtbIAGn_X*pS&9`A-Gl5N4J0fNZz9mo+z0LTI z@krKd_yO7y*95q2AMLP=2y?0ku-Tx+p@6$tethR{4vhH)-vKy4i|N2KIRlQayj}`D zXkTsTCUd1M-1eS({8fGk`~{@Z>Jr)G#Qa*SszsC{U;Xs)v0;n%&rzL0x5;)%K@ z+RN$u`=haaLbsmb)Aw9?A3SoHU2DAw;YhNvDkFg#^R3BWwZw8&>kguIS<>{G%TMzK z&xdcq2ftrV!c8`ew3YMXKf!n_K{>RpyiufmySy_b6znNK0k>{Zx1QUb^<5Y3O-CuV zdxBxj!%~qR}0)5*r%a}f#>dJr`1&`zRRTBuzjmIXioPi0=SCsNLPPsDQxR!n? zD47{sz~Kk4hk>9`>af|dbfM!dPZBR9XY#ynd|w?O*4WQ8iQKOaVw@#GQU1@pB2I8y z$^8H&^h0_Np9Npn;${!AZ7eDs=h>4n3tFd>$~=cpj*2z#n``5b@F9? z2f!Ho4w?B2Rp+nq+}urk|Il5Od*B0!CKtCO2B#ytOmy}Cm9yw@n&;FoT7XipdZT=# zuyD}j0CeFU#5<^_qe6)Uk3v{@6W~0fi@Zk?&ZtSf6Q^I-UP0q4HcwzANgWZc)y`8@ zHFpRe%{aT_3qL@)VS#!7=$St*uIi658yyp?W3?r*(| z$Q3Vy`cYqiN6}Yy%FYAlHUz%Li{;+?uJCyC*R!t!_TBr8)PsM)n9@@>_*xT^Q~h;&HOW3^|(jJ)V2!h^b#JPY=JH_7XbX) zsj^32{lm~__XgH~fb>S8jEH@eR3JZVY;TXnJ%(73O%EO7^#inhT3~UNA?e3!=u$*U zXpe@i2lfC2!;enQ@g(uO%H9Z}=&%pwdS|c4(=u)5m?q*(717T$Ir`tw??C)^em_0LVO(fRM>Fj66?WLFGoFsgOO$4?!bapaK4`#nV!yh;;kpj+Zv1)eqwfzC^@-GUMWyF$k9$# zt%t39-EQoO@?6QQ+a`2|w^4xJ6VoLyYHkA`##w=|N{c@dy}bb>!fAczh{mp6cZDwY zL+JZzw138g{6l{MjW)nPqe@FWI|YX@>5Ym9rZ8T%zGci;=yDDaj9A+E*G{j&o~%#z z(Qdz+?><2(a7zo<**HI;JfE~BUhnVW#E|Xsnm>pzQ|@d!zMXde$a*^>Zc;-<3CZVB z>GcdF`DX4;OyHGrj_tdcS#-tXivP~jj*h~}IkslfOz@G-PdS+R|KKXl_0!H z5k^+ZQw0@*j-OQC8$4RE;&}xm1nJ}v(9g|1=CM59p9zLB?Z+*_9&;aXjBP3Fc_Py_ z=hdfIhf6(ee5J}e(i&0JYwKt)%C4M}&4!c9!zzVU2_yEMQ!skYwpk?t)H_6-eCf0N zc3`yCRbkFuoY6~{>~#jp-(o+19guzxI{tb5XAk_@1OEj*@GE-+!%gC)J>M>)2LahA zX-PlxP8Lz2; z_XoBFwr3~lF9j0og#?=Cm4`>>-|=7HG&N?SMIs_|Zdy^C8-34Qo{>?cW@;TLJ=L8I zor!^qIGLIS36O-^<5UdVHRoSktiBynetXN-?DJ53{P@#qJx|-OK>VlDmRp9;)|D^l zCJ(ve>Bg&SoymOV8xgzQq`Hk$XPpmxmznT@vQq6E{M)RL6Z`)`dQ#D3&0U!Te$IcN zo>U@fTq60EafT8~WuDAmcgGAzUWho!hy;SLl!@Dv@bB12%rQnC#W_&Wt(0)}_!nrp zEtYYXFX(vnDgl^1KL!bm>m6Ax@4fgbdTtOPI!En;grSA$D1-(*hfv||cu>~y3NJGw z31fmZoL$)Kx4A@}TwR6)WM|6+}O&)S57fCOuwT8;5;LSzEDtI>gcz z`+0WPb@o^%w$|1_%`XA16$wWiMC1)b-tN63uaAzZ4wwSw^RO|6@2OFy56eq?@|i_X zofQO6*|gA@&q)%{!jzpwl=5@hoJf4Cv{dn;Rtu{UGZW?28gf@BD`gRfk-<_T2~bs* z83(oq7u8OW^Kp-A87I_HwO+e1uPOEuH`Mn}IxG!{I4ScbknI@aI9BkcSt zdUT5@9+F;kD>8fJj>TXi1toYAI%*wE(pa2FJq_9$T$^$@s{QeqboXa&ci~fr`>8)b z-u~dm%>rgJ03y8D7XlDg0AS{LIb_I;aZZ4j9;p8Vlo~#PbcAn#9N-%p;*7_VFX(Tv z(`n<#0SOrW2#*J(D3SJ3ZI!wgxHSDvf%bnHC+4@M07i)PVfQe=;(cW1gv+s%h`udy z=l^^zp0eMY937HSXb-ioNRr94Kr%YumuPz`se1LTH;Pb2BkjCBQdj^gLuUl-whBz2 zwEJ+gV{qke#C!sO;H#*EJR4S`VZq>z7GEwi9@&BqQcK zo-;`MmBE?_8_io^74W;Oet<%S_X4S8fs>1ol2pBAhWD`L7Dg}r`8(+mSGN^=l~pSs zA{xCLVEJH(8_n_bbn*|7>T&^MT;xmhRbE$Rj=Z71{u+S)&FZM-PLyBDDVv)j-V$?!V~-YCR!+q>36j)}n?LC;m~=I3 zGxZ)Axh58_GUb;MX&c#_m;U@IbGAr%7U&QN1iBAeHUgal4kmUDy#-wXfp*n0l}JfR zAx`}Sf)KNwA*Y@Cp^Mu<+9$p~g2m};919jK9LwtO5@G~zB7r%6~oET{eu^>n4sqZ%pfG*+QZh+ z&V+7zF6-e~a-y1NVf2;2>l5~KU?&3OIAwP$Zkv1P@)X;!hjsU?tB>3QIQK0(9iWCw zFC_6s0Jv26*pyvD{mL0B7hkr0QRmL8!OpWRy!TR%a-JEzcAn%`4@ml0j9mUSVAb4| zUod&A>oYU6-U z+XHnp)Me8#gf*0IdPcE-w0xxn&_Lo{kpk;33gnl)w~DX#($w61&rY=NZFvHr>^Gey z{ZXr0QYg-ii;~c6s98TIb-deTSSJ4114~~k3Lo;3WRFkQ+Zt;>%ATc5b&z~W<@k4z@gZE8z^1_H)MAD{PvOCZS9RfI;-<4oq$u} zpTC08peTQ!R9Xbkbs(_LVa~g*qRD|GaOA46%IA(t+qunOh7CWK6&8iuE-j0^6RtFu zyAOoU{ctb8c$h8V$XU}P&VKzT)2+i(fmDNkcyS)joe!pNKvEur!@64{#?k`vX)w|X@u>m*{B1$5$Cv7Z-%%x=#|A#zKo=k& zlNK`jC{B3YLQvS#dAnxzZbrcX?wPg!Sjje_B7winTsXNHNo;$`!VX*AZ#kg z=MNhau|wAwx`qcCHNYdJjb@`~K&NfHpo?9=bENunWj^G0n2_G@FrlvhVe$Ny$2Ip? z%D-d-)FGPhh?Oe7J|Xsw!AEHsxgpsg9omh9KR~;LOD0jpde1oulAR|F^yS0`czItf z^Ffa@PVWcq=V)_c$B;<#KD<#0G2{KK*d?}zHlOE^806tS0G(Ga{{gCQbzd|uWeif> zgf;xQ``h$^cmyN{OvRPm7pU%-*bLT-pt*sE?u=&+?DF(r`GNs|4y6-@%Q>v=i2-%# zO$_DGWjVK=d!UMnJ$7*BX>A5+d1N0Ny|}o&&DhCTkeqT0^MBpPIPSdptJ6aLSu0;Y@F2SQ35mSUlP`l4T{#M`rFF<^&})CmB9<0_%6t&UsMeyxKdVi0zZv z>u+E@ei%s?CIf>-YQUAtriG|c?F7-nxx83dThQzOw7#GlJh=u8K?pz#94j>hO+%HsIe&hL;v1M$-@Qg9keEBFnh30a4x1NjiVG+&iiJ~9LTi2ue zDLk5je0$$|g-EIR?r+CM!?x`bS7tw+Rr*XpP0og^3u9c-87)GEXL;ogi0bv6 z#`a~gnz*5S0^^Udk0EiTz*zt5%%o3=4(4@#S$ln7lboNdV#@S`Sk1dO}AqC z^EFka-=6q4!!9Fz)5zjVod^|5RUSot;fUJ29j3E|mAo>XbYPKRLykTcI`9^+MVy^l zK~J=1-&@T{plXXs4p+H4=zXwV$8GvU?s&q@Zor2Yk^*b!FBdiP>-QgzQI$`5iYfSr zE$LIF22fA+2UtAe);aEFr@;|ubsOoN>qy=tU)#yI5)HpF_r+hJ2oSFF3{oM5pdPEs zxaW;b&OoY4gU>2l3R&jtk^e4X|$cf=*Y*<&lJ9&(E!ylWob1bP^k{vxW-kXEg1!U?|@S& zD>F|o=%Zd2&g}yUsd7p#xj-&{>hub*k~Dgvr21B<4 zs}?)79Ayg{M=YIDh*n)Vv`rhvlFk3&b^9n#t~XPdhfi$x1526JS0g__mxyk`r2QDl zITqb>@#BoG$c}aNKe~)6jKQG`=XSQim>cx8cL!*fo<00#sCfdq*%Lj#Lu&0}VTfI* z^*n((2%*m7*3k)22Ztv}?svCT;$Y9B>Fb1TGf%40SBnP!QH-BKBLZ0sz*~dP74)Q8 zsmU7GadojNP3YKV05=H!K)@+Ug=XAk_@1OMGUAo+(G zPrqPR0A>?Si<9Bp(Qq*vfU+Z}U;Ftos$(&A6dQn9+S-8Kn2w)>6pI64g(7uN&U}G8 zLdKvrULlHW$oN^{Lyr!Xx4GcYC_O^{F9*06bPe@ z)TUbO80LMENe;kd3MVaofP~gMdXrYM_HeGis(R&0(dgHT^P9~Y$K%8yo1LDN@PDrg z80dhq6-|Cd0uR&Rj_)pPMHmKqJw$fgl)VTga-m+MfkD#&#YM+9k&{GWuZjnhFEZ0M z;`RgsOTqnHNq^WBM&X$pUxJ0oT73y|Rnq6^vGq8(lDh431Uq3e52SBZtI?kkzp+(Z z$#2d%R(UV#d|)rcFx{8NS_7Rh3q=-c3fB2b@Raw7DjUXphE)d77XwM|kIdMp0H**4 z?4F^E@wo4oCXtRv3Luy_OZO;eI9kg5$M6)!o3cp)FZ+rE2~xFnZ2NjewKqpRM7CwF ztv+h*fvf(OAXODNL6^RDD%&!cHNs{sbQV@t@Psp9w;tKNEz0 z#+r7rtIT?VRI&%YKu2$h0n{h_2(%5Kh(H1h47dzEuz}Y8OWhx&Qz15pc*Z3-@P#pC zW`E19BA4g^s}$kxAE0t%{69YYEx)QZp1k@HIi2hWAOb$)03fhD4gw$pRRA)0yo?19 zgI^M`3c`U5tL(pk=jgC%r1)#n!N%v%Ir00@Q+#HP*3h^%%Cjk5$oj!@$jj%FQ!sJvkOW*Ov`4r`_|;; z4`@x4s)(+4pke>{1-!(LCp1HnjO9y<>N0tDrS^^K=caPQo`SKkTk=Sda}$u{06mB> zz>6JTm1+y-@Cl`1Sc9dz>caFAR*Z)u*PxjjTW7%R?njimgCkJn{0&2NVG1@CRy7Ryi z^lm%9RBf;K;#TI03*lno+AZ7$;8)A|s%%Q`w)FEfrCMZvE~&cmd|Xe^e&C_TB5xzM zD6+4nI8j)z57WOOFXh@RqTGe!Cm#j-H<4tP2;OckVz^Kxx01@|5f&vZ?d$H%fniKz z)g29EvLsl;sP)Bs@sz=|7x_&gwI|Np?v)n~jY?SppQ41dN7kspVe1vemO+a(%<=)H*H_^0euM#Yl-}Sk}eMFehIStOEu@Nl5 zLVg|^#_gAlbJkW|24>P;aOws`O>7E>9`))2q;TO9G-nEMGwrvoqDN+3KBCt%68Xh1 z#WjRpI}O0m==dNdnl>Pvg0^Bb_hfRU&#&mtsKb=cGbTKkrvmU_umX%@0RCtOpo}(- zJ^Q-WH$^;B#NVVL@2fBYV0Vw^KAHy5+*b$q6>1zRkeSA}785Fa?g2#Cbw9b5khI?M z2q4)`3UwhTkM*WC=Va@uzrWqaC9K!==5gT1v)^hICfpjvDSBRT%0=&!?zv6}qEGR8 z?qQBuzdM1t$Ekw0{;j;hI>NU26=B=!NIECR^(VArtBU**;AzDHL=v_}!2N>WZ%ONWoSM7}xC@heTKOzSVZ5H)Dy(`dc%r4C z&uQoR)yFA3!bd1b7xluBnqHExoXCs!LCeU!b+|jtm_KaVl?N1HKm=dfDI{R#9IU#4 z^1Qh?^wL=F>tcw0#b&Mfzjk^W z1GMoJw0p;Z*Gck?gN#&0X~k2O)c8yKg5msDuq#>%fN1W&a9WZu9zM1ow#V;_fx(sW zLA*XW;&QA{j_9F|!1o6hpWEjn0!S8hrzWEL^&Op#P*vwOyBuSU`a~bUUM+sC;r@IB z9UUa;C#HUYa7s!_8)^3M}ETR@h+jVHZPZ>a`1#we$A;6Ol@fV>bs}EzB zE0-8cHiMoWIpU>~oxc^}Cioo@2Lt<=vh#E8KZP&;F->O%S}c)3ad_foL3su!99bgG z*HA+|1_;ITs!}vy02!Bt=0AWfvu0ofjtL!R97nDuLi(#=6BSHT-$GEUK;ZhFE&3ou z`W&Sq&7RtWoO>Ynhpwo<OgoC zH_7;h*DF)!@dCCHUgd%>sRf#Ej8-Wep5sCQ&!mL-Euj2GN%QODqteV`nv2nyJyi@Q zYcZk$kkJlHuC2T4>95$?uB(YIKnhTMP&4hyS7PEC8l0MZwnsE%tRo)LUT*lV=hPNab zk1_qlB~P2bu&FsT-q#Xn65tHam1UlmTy{3NaqnJgQR#ENJqJEqO`Xe42L+w~UoM{g zi9uu5@q2a+8ioBmesTQ==x)cBfH!J;4Nhk_f&M-{iU;&Es}_kKuJj%syd5{@ad|F&7Xhwg6OK+169U=#23T2z?TwXaaLt-tOF`eU#?nt4pRTb`JSUqMf~~f^VyX6 zHQ{(^)QKv$Gu4|OH(vXW@_`=M3SB(%$^*vV!QY`FIjtdKrD^Ch=JH@=x=?<#QWmuK zS@ngo>~x9(Q2fohd;k>><;N~A@5;)$OJ1ct+pQ;HQ4cJ2K+LaecVi;T=xNmlon3fp zF!3Ln*e`OQ?H=RGO}zzD{|e$+x56%SOuVsh$X{O1zkBk|xtQhzVu%S7XxF#zsJ#Y9pNHQ%#s!ZKNN> z4c&d?l40S*Rr8@; zC{2TPsRw2{mJXSerm+pRb*ofH9^x_+bn*EBc`~NdgV;ZnmwfH|(}f#ip8~usY)xI7 zx;|;k^3|s>;)98Ank(HNshfD_I=vV**i#B~&AS)gUS4_T;$0@bYvbJ?gAV!uDyHJ$ z1>T0nM{;f@v@G|z#M~_7)oo#~wP6ha__cFLp=ufQVuHD0MpQu}Z|n!T;*ZUT4lZ1H zLLj2OI~i(za5(;S@f!mnD`^?A8#a!&pPv-(eYPJrX}y?6^C4oe1veefB&b$eT3`Cu z+}*%;1(w5oFuJ}*bEo`4ZrIONe9kR z##SZ#=v<4EP$Ow**uY)kNw}!=lK);NQGDG{^7jS*k{Mbs*jufwp|gk^nT!z18Q09p zvxa|`-Mm)arokpBzV#0;417QgFbtHLv<^KK3|2I}AJ`c66-${n-~K*9PTGdo*KnTN zC+v_kL478aj3jlJY|PdzE3IQg`~{8K)w`7HHo4VQe}D)X&J_jUs*->$>HqwoLw53~ zL`(|-x)`w7yo)(RlA%SK8^i{8vR{Ll9zWEUeBb2t+A(g zIByWyH(dW+xl2oY%f#h8Npbni0vW#HL#%FJzoO4DvA9xgsAgDMlSsF!mQe^i#Epzc z91D1$nT~W1@IDqhHD#J$25oHffPHhGWE*bTI6{pW&S6jF*eVtuXIH#ZmB$YwYxEeM$~x7Lr#3C zF30=?!JjqnuA3+OT;HSCf>_@H;u(-AT*f~vmZ zM=v?|9%@9oa3I%cjUF|f{R4D!EkRdvLXw^O zXs7}?_}wxNMtL}N({tL%XC*|9Uu16|79@zQ%}b=Clv)&lDTpH@QBya|b?#bWtgMv< zaTkup`bX{hFe((x_Xc4O11t4nU)A)IinoG%1SY9y4;KFASpTUS3j!))Rb6hPx1^_4 z&ofue;&okJl&t)~=FvwfgW?5}|Lg@Yu0)ryM_H7l{>{c0R+f(avu&~#%>{Pun-9({Qzlq;oiOP3dwEQap9T;JTRk#4M73_xMcIOZMV`bVff(HBS+NR zW<6y#acKV%B68|XG?BI_Zd!(Uvy9P8BwyEU?odz}X{D1E$7;&z;rs|Sf((~Vx?{ip zdo%fT)sn`mxwmzVE_xs@k;nHV?1-z+tF;bCX5CzfvHbFU0e?U@Cxl<+SPNZp7$HVV zY{1Bq_L!eZw$Ih^lu*dC)Dg%$WIG)yzK+)3DF7?xYml<@tTx3lK+x4RP$!{94j>Ox z?wJDIVHL_KIvG5fvE*KHbK|guC=MVTPZr()2*GKzeT^E~_gzB{#K3q=|d zz}OLu9wM$148?VuZ7SYAC_hUdqIFP~IpA)&xhG9PCjo-RZp^sJ^((ocE3%-uy@8nA z?6m8k)LQ^u*WBFvf5t>$d_?b~XDoLP`uWUK`t=FhkGXz;VExrc$cbgzc9X*>!cFn$ z1r}{O)ST!xWIf7}80w0Qv`v9#9|Nz`oulX}(_WMW6MuahiLxFE&yjVG6RdHFfqrucJ-C$k8@(Wms?<|YP zGk)kf)q_^}WsWIoyBe&B*!S9@8z4W*2e;~S?grn{g>`a1!FyA+{V?B+dX{KPcg+>C z+DdJyYhA$)g9l>b)|t|jrr{jk;~akWjjbOj;X~xPVNidJ#f7LnsBxDztZ$jMksnS| zhlsZ#;-4ZeS9XNuqg^9Eayar7U!2gVlSf)N1H7kapL_maUS{+Mh(idFmf2=@Mr}^X zFx0I74`=jfioQU^Z%(KHIUa_kEJKK0V*pb#)u-YIC?S6g7O)2lY%t% zQqqI3J4-)X&NEe>?E&JCgHFu_Y4p0@E6%ez&+jtz{q3l3ILl{X?Khi5hV7wU>!bx_ zj|@7RRz8s*ZkpX$86J3Xc4)anNso|Gh9aV_A#CeJxslU4aC%ZU&8ze~>ee>_8cMrSn{5ujzw(#z z(^LKXh0mYIfA+wiJ@8-A1ONXMY`VwHwU9RM_8yNfN{cwW*Y1jc3Z#8`l_k7@4~*O# zNsVO-8#=|cZg=}JRK!YZ<~=W2`LORv(Z^F~!Y^p>-?$b18Qq_y!`dFRf2XEv{1C!j5W8o2b=ktUa{cOs+$=FBj&7#)T`#Cf+iFwMQ6h;G z$u;!6dx_TJC*!YAr{1nS7xYjb;tAJ7TqQMn&<>ViOI%_XyL7m7-@as5z6kEzr@i9* zke*D_pr;YoYFw|kncq8NBhK(|c>xszZ-q}l?U7)lgJ1osMZCh{H~R)!et=Rw*@9cN z8F$LTgX0b3L&CCE{WF)FGV4m^k+UCOGp$|u0eXeblAQmt?Sb*5X8_YSkY9q@_(Isq zK#+bW)oc;SfMjU&4-nwQBpLlJ{#WGb+V7pMe#WfK(7*)sG>zcKoGfCPG$a{aELv4? zGhVi$L*o4`>e2>~#IDKJtL`%K{k>z6g^oM3fQy z)E^*aAik2$;KwyX*10YQa~ zl@@>hOrGFOsGE5^(d==FjL@R|yuT&+MF&rnrGk~3#4>x{qmmo5r`7!Nc@*sly>LY^ z@4RZwC?kqY_C2K-ai}}tsBmrbKBT|~k_Ev+(tR{V7dNZIc8!gFojDP6C&{>xX@IY` zgJ6xG1V0i!*{KeHzp&}Mtu{P3^1l1@wM#c11~BpQ)12qbw+~}N{@4%fXS1-M9l(A8 zkbYJn+5wX={n;x}!Vr8Dy!Q78fGOB-%0s`%3I$e8K(@rKca&PJ%661me!-f$%m6qE zAU_>4dkKgPe=ui$V%xbq0~s>U<@*x+MXPIo9yGVnvW`9lXbj&d2D7xJ4S#_amt2>N zXMP!+Ubs!~T8x{wzDB|~7di+Zh|?~6iF9j z=Ivj3<*$EwYooXR(xK@O4oZK3n!ca?CbMbl2gRhmV1pVk(($6CNT}{nDqtJ-A3cb; zHQsj^uTehJjAL{1+);bB;BuAIhSPo@?(vR8T`dVghsy)a(hT!Wi*N2eHqpR@LzL!v zs&GSi|p| z*o?J^XpDztxB!-J%l^5Hz&$4Idd@N$4b*%T!RbAbQ!rL9-mxBV%iJqZ;r<5JyvXjx zmgnBoAT#TNBzO2rv>%}$bdDsBK3Vwu_T)up$7>Uhyg_UoS)(SJ%OLuJ0l)#y61G6L zCrkbP0acVptH|C4yrgB&!(~wL z+TZxwJLpuqpeqg|ZrIz}N*M+oN-PSh^KJWZ12hoVP>R|*00WJcQD5R$ScKi3l_^`7ldrEOfKNPBw?IJ+xY}w%bG(8Mc&KIAFpBS+jM`pD-phDZ zq2egGSBG^1oj?cQX5CR06exG`wm3N8SZwH(Eunapm2C)6@2;&d5`9IfqSni$%$ePz z68G&VCwVN*sk4=oN)k3O9uY`!dx6b*lW?&&?$WecY!%Gja`qUX@>N=fZniB~DY)g@ znS$+{I7K&(%eb8$;#_i9jbYy)5_ZOJq{1hRdbFoppO>xlI_gZLG*Uj0Gvj_GKNV=0 z$~uI>xKw>nab3^hN-XIe#o25+}sA7zGD8jNS7Ah@9 zDgn2(M5k0cCz625o#*ps#;iv^f-tTi>e^nv*?)c_d!T=~vfIA4xE=1AWNd}0wYR(A z;3SYHpLd@ad+D8FZmYsp z#YoQk+gq44VIul274`1FN?y_~Zb=U4@2p?Z8mX?xPbm)s%)@TM>7<${Y@!!BlG@`W z^>*}}q&vs$FL!hJswkIU4p9()F58992wC2CAb0dhVgAe+gSrW&E+)CVF8yV6HHVMc z^f0tb=AL=i)p6o3C5e=XAS(pSiL#9{AY5eh-!&gQU46y8x6ZO7N4w=eHZownZyAq5Q=WVZ5 ziQQmCmY#2fS9|3R6?BlM9zU`&kbKRMegD!y3e-Xndk#Ldy|jG^TGlGbAfoc%W?l<@ z4d^f#>mv=@N&t2s*a!euKA83zHD=qIC+ZV$l?n*)%3eYQRLg@Ia4%!3GGrH2FW|T% z^W2k@0*tLl8B_OE$3Uvk@4*b0&F@NgSqt{m&t2XKc=2q2r%8=Ou9Vr@Z-To-hC^3p zCemx-U6r*c9hPH33_jdMaup@}{#}-$ReP}mt0Ps&)meD{>f5(bQ~xy?dRo1<;;VXX zMPJ11hP!6UJL~2jtP=JNztk~yV{2HUd`KIP_mG1T9g+PBpe$C^I@y@fi>G|pZJV7+!A|E>H)#mQlq&MV-Z}u0 zd5kbJe?F|w#X}J=5&_Jy7swq&R0g&;tHj_v0W7Z;NDTpGm%;~x*oTyZ?$D^~x}G3! z&%MXIn3_6-AMd3OyVquMFBC{Op#+Zk&PCaB)zIAAPdal=IGcxD{rMoU+d2!>iBZIt z4n6#&#Qi(EpI~}IC0;9Sa3=~Q3Y7&5hD1WJtdlz}^Cww-=Un42P%{H7Yo3*RcOk`0 zwx*AD!0$-ivBz=Vu@{{(y69hT_7+5?^q%79PC-w3u;ML*Ze{WswDospnyBVou*+|D z>VS2~GmqX-uo<-n7S!kmF_Avw2Bn5hfpznl>g^o|N+3(B-kt}kvOM==pnb9N+n##b z=mpw6bLDBfQ{1VHvI62VF_2^s4smX!0K>N0X}W{W(u=<}7mimZPCqj~Wj{nh+L40v zWM|$;gglVyKfEwWFA3giZ2%$ilbzpZCl$ybAkqv)t%9d@=nVjI?5^(2V&m&z5K)E{Fzb!P?bGy`=JAg zt`X}fnfBuW+?j6Q1hN|GEy+#rsJ9rpn!p~$@=H%lLZ=7VCXE-WLb+j;6+lj-3{u=Y z)9%r%QUtj1%~sCq*AWZYpzGO{CA1S?*y?}80}9X@>tL)z2JkI;s6zEY_(a@Mm6#6| zi)SLDLOVBNCqvy9nfd{HI0fSuI9%wyokS=`lDq}$ zv9P5Q_S}hv!^VR0<53L*@MY%Oe1-8u{4uOI6TN|`U+K{%(tWmvHc4k|&_cWP8BY!i zZVjhVP#XBxTr%P*WAaWa&_VHG`nm3ESO85V7WbmR+^@xHQb50ed9*kwu1gjF=mC`1 zh)3l67e6Pe0+W>9MYluENx`7&WCDMO(6-a$8+^l9S)SxyIa_`f?>A7=#Dn)ozxL%k zp%n72^SVcFlh#;m8d&MQUITOs(b;tXy_It@tjda7ti#Z*DeA$Pr#?<-M2>dxR6lRX zw7h%208E_CcIRffQ??&wS`;7|Jc%SKQfF76>XSJpxvyDs#7}5T#UqGRlmPICHDk zDfQ7Qb5q|F60z_Ff2xs33y4cA<%`z-ckyRK)2nmy{KND+K;V(Y7}XhkMrPc{@Xa9` zdAmCT04%1wz{?3cUE_IVjF-hJqV)NZ<_e#s5=|xEh4$$; zfjL|65g-$~7g0InHw4!_yt~8o1{o8mTpCVCN0Z=-upq_F&Dvn*`zP<&m6khejisk2 z;22DrmgGiFB7Aag^Duloh{$z3e(~6H2% zZ(07kk;b%#eRbLRLZ}fzih?e}0~O@`h0nwa-tRWse=j8r%iN-v@s{lQYiE`53Rv$Z zm6m=C>dtP?7_LR3N=4L>~MLiv%mIi%oTeq;7NUxgP10H8e}1 zUG#GbIX*W;n!T7j&gV4e;!CCa)nY^}-|U;_+-0_rR6DiVjpxIQ3YO{l;_Nuj%Li;l zC++wI`1O-@&niCZFC(LLS`b;c8%EZEt8$ZROHKc8nD};hq-dBJ&Dw1l_st z;M@szhFe|LZORrzfkPD@z*_y}_g>t0-T8{O zTiQldTYEkyUEEziTB;PN-GCn!Se0UQIoqH=G1c3OJ4+qX(Q{-hYg~YFJCjCvcWuLh zvjHMdUUgS>`Ng4>R7kVRx$Y1UWy>SVrz|sN-R&9uOoSo9~In`H0)Bu4>-dPrj~xbVJcCz!F=)HA`I`RA2FSeXcZjdakzyl`^`c(iQM+dV!EYaiwjppRU&WH@l=2kQ0&ux(-@^^Z0z)TRe@y& zwmMmj(As1*tIz&ivKk;)j0(Q7w+Psl^4!#8|6mENONBRY^clq#yPuB@y`V5YXdl!= z7g1R*6+g!2-y$V# z3TCtG8RxBf@p}TO>kcNQ9T_PQ%L9GLyzuwImF5plZXGX?MR*13w4~&+UO{)%UsmZ8 zKb=I4>yFh6A?o5AQ#wZVI9Po}w~Z0{PCJ?$`4F;EATCq(l0Z-hRkls7mx#xumdR@w z!E{xucbq)0Bp*WXU9R1*^-VjM#MT;BN|e+9lBHb2YQ9*f=5}9Tb#Zy278fc^+UzFv zuni--|A4^F@fcuBUoQrDP0xY679GwB%Syv~Dhht8cuz<-&+vOxkcS-RGFckylpT|b zHdEQwb3&G8i~Q`E*T{lmO{rNQ+Q$N05SVqXO=XGWVAPCK#fh84aIFQ^qIs$Ldk%?W zf)0<4A7Rl^0Z~3;`P&2A$DBTSHT|g}whp$eQ(&C}|NRtLlrz9f4UCsLpDFTDLIWqRDc#ASJKU~xSqsYWjzP5atB5L8(*rxex?y8?YzuF+o3;6j)-Zar}R zt#g&s>u>?j=M<6qPRNRmLQl9bpDt}KrF$}3fLWBe-k!nrY>FYzPc!TU_$DGzo+jDE zvS(BCwNAXp!x9^v5dDSC9aX7yg1i-|cRU+gL?!Jvj1=1v71g`*(rfp*``DVcnr~z3 zwRxQFTg=g`c+f?9y2gt}y5sT&+mjvF;(HXvfc4PZ(T-cF8me*RtwvNeOq;v$O)qwL zs^3sgGt`LatS!@mVV+N204?grBP&I2;9vB1BH8hRomNk2@TzyJ$Sb$ka-VMcsvt)bunCDaV^SQ?d;R+Fhm+>^1MD#l*?<+J{)Q?dL}}2bVp3 z9VlNpwOOp@MAv&pwTk)*mcGOG6=<%ebOU8r0;jvogB`B7yXeh=?iM}eintkZLu7o< zg%D~pUqKo!YnJVdAWD#4`(NjQD zTE=V254o^b$BUITLzP;}+w+@W?^5(|nB1qu>*?#p6FC6oDy8d(uyv0h9*v@H3@wMY z!4+laqxOcDS1ACg3J@VCo3KJbc5`}fuTAG==m@s!o%EhwB^ob%}=K?wu@0ei*0GSa;cw=THp z*n2C2u;5!#B#mL?7R7q{_9wEPO#$kSggOeli4K~Y#x;seL_N2f zrbTw}M;tH@x(U4LUSdX%2v7jg*b8hM<*0*&+!$=RW&_PLet5r2bx7FbQEcopN*u5^ zFOW}33c4N7s4kO`&K>|J_W(0_7nX^9 zdzu(m0IY=FgROajaNe89Ef+5<26723HM!F8CUE@7k&$c254F|N+xE8N)DJf>qZ+y; zLh+2-VFPV%M`1wHi35UKX=5=?_k<9U#TL96F5oe0Gadt}lq`6+8J$ScYLgt_1A&TM zdjsy31s*w658)!(C*$pi-FY;DAJI3ga^F~qkG|^KfncMuzUvi0}5DGS>EBnZ{HI3ofIy; zB8!XwSp;M>73p1~ixYX_wj1uw8tG(fMlYdSD2>tv1$iqCUPmN(@R~X%xriQbnZ7WS zot0_oYY9l46b*vQk{X?$jbI1Sa^j{I@E{E;UC zZ&25`C8}dicU;P{j+PF`sf;mQU^=6knmOsL)FQ8z*qChHp5|yJs%`gZo)5Rt?N1vZ z;yrYh-RR+sS6D{{6e0BI3yS7Wss)ArgeGW+V&)BT5{ zJB4V`Mu>Oiu2{VZY}Wfm!5)sH(6f1ObZKH$#h1+c496o0dKAu>&YJwQm!m5Q8N39u z%kM%P#YJwE;B5yC_e!7Y^VA6?iRD|V4n1J0FeXZ4v+h0Ig(*+3CExFqOqe|#P?Ss* z#I~o7@na@ig(3T|>26WL4D#0LG|Kb|h2*JfvijLQKI>}p>PZ@QS!^)eM7?~=!PZ)f;BK9AdqnGn&=Ad2yrd8Q2> z8=f~$U1;@y$QuMVY^k@}qIeXpD-=Ch1Hv`BQ{7agIA^&aX00d`zhC7ewRx^T?@mYt z^Q-v*klRpMMv}YU$@%Pizd6*g^usubl>PRs<8H<^x05}y_w0WlXb%XyXO{87{Skt+u&f>7FsN>l0Z15gCC)!dIXILBMpEKZgmdEiMRhDpTn^ zHfuWtFa#lB23(a0PuVmhTWj$5w{XEjAE8|=`g)?1tgldun$DhXp4RO!P%&)?XWDp8 zYMPgBj&quxDEDqIOM_z5grZf9!dU026R!`QRq74#EgR_b^6~70`?;A!rd9Bj`87(Y zmKj=EvHJ<1kl*?i1vU0`n)}=_y1al0PIP&t>M5aDFe?C-yt=pguFS%{dGO;Y22*@S zrGaWtu5*i&J4{?+R+T?ijTz<&F(dHww*OT_kI8=M2OtFxhtU*aub*CS)2qDdv#HA< zEBza=4UQus!}i)Fxv%7Xor z%tc}ae_@&zH~tNKX)-21+fcUQT#4uq1xr~1u*K{fgs|T`6yz2zX8z0#ScQt=T-GFK zFFeG_Ra-Ht*h452_52nkd4o7Q$=(uJ$aBnScs!Ta(x-5#>>eL4W@{8l1g*$J+}%v1 zR&0k(5=!?aFlhn~wM?jRuUNfuApg610)C5UCbAQE{Vd0nazzl&6Dcw;LXaej z@W8uc9;#yamd?Qn#wHS_x&m*qDIB*Uf=$#24kkBO%2z*Br~=^jXay)I+g;{uAu8__ zTQ0pl?hVPUj=fn|br787v4C~%O9>=u4t&T{;5@OU{!nQfjbh8Tt5gE?739cS^h>mF zyeL*R^iu1bt-z$T?Zy*=OQ+T9xPl}A?;lr;R%J)iEe~#2)9iDk@F8`jq2se>Pd^Sh z$av;%8|0($@Cyi?jp9~}(?{PTi}_Ozq^KS+H>!#I%2pgYs;UEybcSz|-=B$BeSwPN z_z3@Sz`T{m93myyz%~H-NW-m7)){313IKnZ<3p?5paFB|atQ5-K;NhxH#!C68;^l}}(&+UQbyt`JhtS(|7OyCdpjm7>C34abS=B%6`x&3Mrh7{wq-(gA^} zohgM84|dz@g6ppF#(8r0qBo85P&NC)ld7*)OD=446l@%;U1ao`MI@AR_Ld1$5Do$n z<{|pN@%l9e0z&ZuiDX>m~bqcIgV4VW%6j-OgItA7#uug$>3anFLodW9=Sf{``1=cCB zPJwj_{4Y~L`;yB|z5;=c1c_>zO+`Fy?D2dj_SelPE**!WNen_A{6Kor5i7-J)`exz zG1bpsEkB>+wG3QZ20c!g+zNxuNqRmJohJK+<|+fJ^4>Pj`y-JAj`e20Op=yxZO7Y} z;Yo*fsmkis6STg36@YMr)142sR*9Dq-0^~^HCW#I#C~suv@aA_`%HhxdT*=`&@WTC zUigGYORPIEfWqQZWam=^({{>fI82^=lPX@jAu{gF#gI)RhabJ-qP6(a0RDM;C$CRz zfDx|qx<6z8DWw57cF1mypAiP>_j0(`rBayPu=;lFJXn_o>jLsOoxwlWZe=>H{?I-= z6w9di4m|A(1g2SZ+Af2JQ$}p=+6VGb>k2!)+{nc{XNANE%T7g=ByUuy za*XU-9H_4GhTK5+%Br+ZDA+uB{%(=JIoH;B-{{p!N%C*My{@nP|6GNOe=g#!JxJ?T zmrbJ;ws)MraF@oBF9Plhllmh4)>Yhf_5FK_k6UqJLu|n6|EiG!d}1}8X*}9NH)`4E z6J5`WQ*v2!Jp3&4?7t{e$aPz3-F*CH8o$fL=72Z_m(H&JEKT*Je-A#X7rCYHA=T)~ znI~Kl=Sh3N44h=rC-eHts9LwHf7!17rwGM8$X341gG*=c^b3Nz;MSV*$8T^(OrF(_ z-1WbV4y{L!{qIxY9FTD#3$_q!af+M=Y!@ySCrUsqgIrqn-usjm;YZT#q)md`;S1L8 z5L^nWBffXDQ~LP1iZO zk{RM>{vy3Fgm;J@UIU$_s&ONC&ski$MH(VB1;}G@2Zjc}DSimX&-jpw5HlHS3#_A1 zE&MU^@iIE{3k+-|FD=dH($D>Dz@Cij$T9f1?j)=Y+@9633`&P(X{Se?{n^_+2@sw{ z07T9PZk0x~{!~vWU3xW_I;}WE5|(Q!MV`#kNzeP)em$#1E>g@BRnq&zKrAMj4v_IMjDKE)+;GXSxWP8d|C7hMe3Jhi4V9R!3$C34D*mVm0 z_flY;O|P)wbvFHHjBuSz|M$-A^(X(Ip};zu{mm{nbMUkUfA^p``&=gme?f zUnJoL`fDG&myYwU4n@PsyYu*hpA>{h*9@LX;iCcZt2Pa`#4*h z?c%nFI3th9&ex^wwNd$51$kZHUe~wRa<7A7GC5qE7DmKQ3o=a9Qg{;RwP+~a#VVj) zJ}gw76TtdbA57wmXL%FZi*;7&>k-x8POVn}`m7USod}<2%KAw7A07$1vO7-*QT1eA zIU1(HRHom1n=h8v&G%G^Wo*K07QZuUspcj5cN*kh=sRtUS#>y>^qG4~q6>fog-w;@ zOAqIlz>9e3>*n>(bvmq%gY|i^&Idm6fwmCpjm$pNy0Uy*J~7xEO0tSL`sk?UL#p>h z7#~HPsdu$yzUS)wbc{x7)nWA|PdJe%I%I{k&she+Zxb73Cg)+Z803S5_0M%WtdE2B zdGK%M18Fa)%=XsVdnK^Q@=XA{SWmZJNZH68l(Mso5TrFaNBA=&{9kokUUqSXP*0#ALrBz_uBawJ(F z4oUc#HRct_YSof>hBVBzJaW~NcxyCt491ZJEdT!51OEMSof0I@3YXyw8*3TYomvL9 zrL+U9;%Prhfwezy_O~VRlSmg&8;#s?jU3Kt-mFV9Jz#^^_N89A_wL>M*@ap|zoVoD8m`NRWZgRqo*)Xp*YyLiDI+kLO2%j&+t! z>d*FEI1{cOm&OM;NWcv~)l&c$ge=~v7J$m_p$k?EuyNI;yiH1HewZGLqPR3N=9?Ap zTpN{K%b$J1f7L|#KfI4HJFuTg&j6`~nEstwMtJtgBH{nowNvEMo#Ei9{v2EbN zT{5k(okl}xKr-*WP&V%6Mg~M#pW7J`1gZp z>DDnn3-JFi>EA??Y=CW8ZN3p34^Ail@cjKoPPER$$019(^~)d>xcwVvs*r@#pB@i6 z77GtYSNT$@IgwMat9+@_bcB4f6I!N!0P z0-Vu4)qfWh+RkuSuSkOo9qWHOuz$Ng(T8-^)A|G$CDi_@`dK`D<1M9hM*D}K9ui2h zhL!Hc!m=O>w?E5`ERNwUJ;qO-mSLDTijxyuGb|G4< zZvj5`hssyspm!)8R(H}qm3*|Q@i%U)k=Azj|BSrZm0+AEiE8E#pTA26M}rjNtz<&z zph(Pbau1kz+CR)^fBD^t--8Ew(4=N!MwSm*VR9MN&D-$x7$7N<|Lu?R)tLBJW+ZFv zz4xOW?6WoTSxV%6wllnvGFUqx-h8^mjo?U%w3TgfK`z@E>?~uw3~Sj;64cr zH8r*GJj4&NOPvxZ4uV^~%>OF}5FjL1*%P0tpG=9*65^A6p_|@j@UvWIwLS5r{*5aw z+?kvUD>!fcY4}r)fQ)<65M?&vHXV1+XiA_7VT>lj}e5V2|Nsg(+}1 zxZ#hLB4I#G{O8`W7>{gy38?35KYteoZ@wz$j$f5?t#l`i{{Wf3{}UolLrK~&zzkaZ z`BfYkwSP5(hVp(hgHERD{4(eN{sVpIw%@fPRvnB5Htey4P^=M<=iL zCnMsEc=%#oe1e>;B9=kfu&hrK0}v7+KTMc4FZ~&Fy3{l+^X`+t(EbEDg^vS>$!CE9 z=>OV3FDAYqPTzX{{)(Eu0y|mhO*3V!2n@iY$U3}&I_2F*yO3;FB*we5XMgr-Sw169 z-3USoVEnAej9)T-G?iDI5})g>pUjBgK`0>ZLU&Dv{P0)d-))J{X2oaG009DE48YxA zu&7p+O-es3H@}Iw_)Tm8HbwIfKht+6;(vSFRErg0B6I;V^S#;%{51G)XCz-~m|ZT4 z6Y~U=^R=J9O9sc7-<0#Opp^DloYvP{{KqR3zy^Ujynq$-$I4gPpeOa!3i^sk{YvoG zKjwxa-!UXs85hX_{`Bu2+v}?p0OS6*u2w|Zbe7eUgzb>CZ`;fyi@;^Dr4dv^4nCv$ zs4EDCJ3`63=n;V$H|9>;Z$&32c<-#*^h=GDJv4KO#8Q!c5qMRV7%Lt%^Jll?x<1~& zw=o=|b@p9**^i3ywPI-XYaU*J!;&a4s zFwA|Ihh*RVhRYyIAn^sq3>be}ULDAvxFc&Bbn`hZ*nPS(W4uhYB7cDurPZx*DU4kx ztYiyk2t;ZcNsGwF@ownsf*M1d4#gZXk3Twb#O{zhs+=fXUefA8XYb(Yq|iEKMG@{w z_l%-&aMn2MdR_;rQBfSL>c8K^BJ+iP_Slsw?yi8lwa)zMH(WrJ6^Iy*i~XTn4De0o zywS$3eZF!=X^HpJ0pnW<;FNkTwgFfEv zc;Dfg!;;M7#j#K8-M5uqHLh!@cv{C7uPjlixEIUN6m-o}2<3FhG<<%S%V5df$eX5N zO7Z~~w>-4^IpJ(0Zz0)ZSF3hSoW#~U3y5r};`4T8nQQcvfSztvW{J$kN2p=i;2lne z)i)ts8i<{9I$ZGCmeTD=sA&PK$d91Kzh9+*xug$V93GAXw#sJf$Up=k4>QF&&#APBkxx4|hSHT=NB^Y*gz7`0QyZGMhkZiB#Ap%OvSlvl-t>V1~ z4>4kW*?n~3H0A=t)YZX8tR&c@PH@lrDu*yPy-ir>Gi5FEY!UBGj0|4e4M4?dXr&K! zne#-x@Gx!_z1Fl@aGo`KM-FEp>b3XL;2;@xsw5XZ;%=VZK-Sto-DOb42XIZP2$`9Q z8TR&N2CVloe87Zd8ARiE2RU+~4T+J4U=dgG;8e7=7h{a)(V6}!Q@1g}c-`xi)(+ur zS8ck=nZ{%~;6BOlGo^(k_f3lL2t~%-=!i9skBwOn^&te$r}U1dw2B@$FvObuMD3%+ zdFd2(p_JWa8&*oW6*f9RUdd)a;S!yvvz9O0)Sz|qp;H?;{7or&M$|`6_Lk*&DwV3-Pz}FiTKUEJ=GsAN@?Ec2`$WCLO&u z&7hXNKtFs-7rs`-8+f89cF_xZA*YJi^>?suWUfOb+l|SZ1nwG5haRxV!AK(!c_T-&^$&> z7QMD6{q3%N@v`FK$6ub)P~{6z_CT-c%!g}u$t-NmXb4@yN_f}s8t`gXBnhiD?YAee z<=GP%B8WgHm0MNS=s7WKG@erk-~8=QC-I13We)+D1nLs)1p%(5Il#;81IM4pv#*(f zVE=HsfT|kIYPdzqq!f&6_5pH)A89L8+=(xK?;V5d1F+>F-eu6y%~>z7OfTE3x1$hD zq-%hS4q=NF3hy{@DaA(o7@{-jV^Lqq?V~5l@w_6Q2Nm;v?$l)Q^#rR7D-8O*Mnvc7 zl5ph_SjD_Rp1WOKYKL`)hs->4;(W`2!Mkp}7zO`Hlg<=t>6m;t1L@YNLhh>~K@&eB z(*?N|BsC)vf7jX36a(N*MLC60J=gT-Pto1G_&R`*dhm++Rphn=B^O}1XYa(AO&6-jsKO~0XQv)PAz2Q;I__s9y|eIYfAT+@f;&foR~ z>di9fr@IlAOk~Gu01Lf@kcVkwta?G1%(oBk#Hg2Ou+hga`F%8bh_QGH_?Kpk9kxqJ zH8zo`%sFbe+e&&;_Pn_J6mO)P{R{YZU;zM;I$9k6*vX}dwvndrL1Jfa-;Mg|LNA?( zJfP%iD!U?UAX|+si#G-5-5zW&(9_$v7*?b*^VYF$@aiiQdu&9tp22~eX11oTQdwb|^wW{qJ@bmkA zY*rGMsE|ca;M4l|+iPIE8}mY*r5YZ2cKrC6uHrqrR9vW7UM_=H&t99rHG_ur+xeUD zjg(OR8ppHgADHQx0JnI1Gb0MUg=lQ;$WwM5jcdCF2WEQv2$<8!U2U6!U5CiX zVaaC{TnXsVdn90@|IC?*4px6j^fs#u&!n!*xAAP(%_oy686TTJ?wdAb%=&LzLT}+$rB8#h@eOmBYWyG$9!5 zL@OD$;1{H}Ty+t~VMx>-gKzKNZ%6{_YU zWWpne3HE)`_@D!P07e)ol^G5qQD=J>(~f+he``FGP zb{^P1JC)WshK~HF$6d1@5Abds%Wibd>M68KeSQzJ^zjP#4zJXF(5q=pLI`ih@4Xo9CBD@Y<-je8?rix0d^W7ccuP>XyR+|B9_v8d(-uCN->2*aL+~GasmCvOK{r$^7r)44Mqe zf<%u?>;RtZITOIm`@q4u6P!-E;_b zhKwNr-hPWL#Tq3CVLqCka?^do0M8V>4JJI#CKND4J?yO=#lBtq@Im2yJVjaaoMG2diR(>!iG$yqts)3*nbR zCT~6Ti@kzV>0He6j|sbqA>XJSdbJnqZ0mxm29S&K4yHg>NOK;AJ^l5%i;&$ii}gZ> zE(%ReA~^8y0g}5C_QEJZ`qBQrkPq}}gEh;bLxRKm5=q^8E8Oorwt%!5Hlxc+<}XCz z4SA%OL64fqC##l0)p`K;qcf{P&jC)|_4+V;0J!h6ODEX}yePs1kW-boKa>;p7Fc@Q zWx5RN-?I$5{cOOVK)(zc%mfpac`^C&w#y(TI5E<18RVZp-ccKj9FbTCg+E;eVYkCp z|1x3($xJkJMp(7Cj4k!WjLCL;HEwB$0tMZg%OHpX@5t6Y-rD92wa4v~T892ZZz zA+S?Hm>h@&*T}fd$Jr_(%Gt9Mf>9IA^l9g*>mVly!sP*oC#g>YW}#d}{XEQMb&Ora zcITJ??&osw?xUWJhc4kjL2kppe0~OSNA@QlXytk!RpNhBet$VXW#`8ih}}qhX#b>A zeS~45KXYYgKc7Om5y$thO`Ry;>5~6qK^b8J&Yd0#CBme*qpL-CyjL8_8?T*@BLZ4v z=upCQ{O$fus_q?SF60(u3>Zs9rMO58a2Z6tc7ypR1aw&JG%E@9e@{3Fb{=mTHHqtO z3UaX46B{M-hlp6k-VT{k6fhg9AfXYEBsXUtMX{G@MztyU0NJeMt2^Wh@xh@9lnY*E zijm_|K>4mg=JXU+TZUXpSkyD5BD!}jgNnhCUyo_GNvW@~+Wz%l*QC#EzlI!#k_JvE zYyFM9`5mT7$px0)Vcp*((=`8-ICHhjhN@=kwZAb*|McZPWzJmXvhg`{=I1b>Pd*zf zPW!(<(D%gSU!MJ(HgmNT_^&watYpso>aXE2xzN;}7N1(wons@z@IrBHq@XsMdzqX{Dk>T zu}W+Jhx^afklAU`cdK$~=IN%l{%p^xQ4t0StzociNYkSR9-)DKlp zK3cAizYPc^N&pr_L=bO#Jj2qFPi_VxRiHwPw3UG52@6J$u0w`IXsgIarIEM~;QN^( zOpDY&;#HJ6`9gU$;+e?A$(0^NaN}{yARYqKQp++(@GrlyAXZ8OnF&@ezoM+q0G7JW z9PGvPqEHkX*8?TdmWSdMfV<3el1p9zu#=v<@uYKJzn35$+|OWET^yBU@0z?%Mutgv zUw9qc2FEvBg2+<8bXqc=2QSypEmZAhm!L3o|7}NCtwiS4I{n+{HN<`5_sT0^oU0E* z{O7t=+#AIn=M{xm=zk1*Mq3ekkxKroi+k_1|26p5(c++m7_(zGj$Ch^z1n$!<)&-{ zqYJ`zrDWUJcC-!q5m{2Lb?F10wj2o>FFY`;^G4x{%|q;bo-2S(Y_jHv^x^M5zD3~h z6kSo9W2h0w5YaQs#0B=kz&Gi9U4iCC>Nh3cQ%*($sLkc3tx}xby4Y#asidMpSeal} z#N0ej+brYb)Sj_|P*<4K{>CcO=&sA~l&ABE`%Vlh3p%Clua?s6?0BcuM9fJFetGWD z3iu+(8i|`j5~vY2c;;mgAA=sbJQ~nKSSDc`V1pFtKsN)Km`C`_OjgPoezf+h$Qv)I zWl)_z9Jj=St%dET);I8*)Y@uoUj#f zkLb7z66gVJ0O)hrh)TH@wuu<(HcavY?(mqy!W%j0@)kKx<|WZ<$pbK@Kn*b7p#YpR za^XQQVv$Eul&}l}6s}_|I8RR~RImAWImLo{Nlq4hMAljR`90^=uP#c$aa!ru{+#u& zy!KEA=AUO4428t~#g~~jk38spJ*7S{wKb1ed3*~brep8U(AQ>HUOx)DS+jk%@fr^^ z#`p06=jf#5V%C#zHe!toeFJqJmnlRZ^%u>Y;Ftst^<@yaLzP61SOx{7&H)?T$W)_e zNr^D@C>Y=Uhb!KCQ2}cQuxs!olF%}U^AV8|D?=oYf)@x7vWya*yWf71^bR&X2PfJ+ zB_6{xRhM(++Pr#bnZ5taCABQ5i_(}9XaLQY3Eo1Kz>50q=a?Dl5DC;~54X|l+2R&< zM0TM@gsB=#PdwH4N~N?YKcK&Dvw2M0!Y!V}EsP4-fPwMQY{fFw-hw+9pQF%9k@b0H z^w_;*8f^FC7uO3$2JpI!b=W5IY8bEtCwyEcLU>BCCQ@}Du#LubnP`XlM`ejlzUW0 zFf8=o&Bcl;V(b#V4_;3lv!G3`!}dg6RimDz=8dHX*Ec<_1KATF^~90m+1SuT@Np;1X-2ql6k zOEsuii`59~E2AxqsbZS>=F6#YuL!keP|Y~69{yZ^BhQWpnVVXL#hWb2ro0#)&bdra zXrD!(q>I6&r>tjEUnwLk-hx%Q*uQ&*gWZnb*W70nQ(=5GVc&e{(AH%TMIZ9yfJjib zctNQ^e+HVy#sS^&%u4caC=WHzVM!YF~Q4n-rzXTQz_`qu^7)XT%z|WcmL|UPp7EKPM0#<{#rZyW5Daz zBR?1Uir9zmMtDXX$!oq~-(ylgbdriVdz6u>?HQoW#>_MYcPxC6q%+>JoAhxa-uw}) zNs_OZWXQWv|CjAB)+=StlQR2WFXW)LUNL>sts-dd5gM`-+j)fsz&D^mq@7GPPF6{B zfAkuEDst&K2tJ_cOWBppMBMOKt-5T0V!5L4dmmw!r=&$^#^NCTuu@=k?+B$RXqU?T5@xD>?yy3j~=M^ z&`ehdzL#jVqv;l{OPn7TZV$0@M{P1LDU_(irVqzTL&AS{mEkAkZ?=b=O`2?%{QcsiA~u=X6qIi;GjM|65+L4P)3sm^|*TQ z#eJ~0Qz*-Mdx()+%+H@(a9b&Ro~-DV9#Txa<60qsR{*#Jd0vS8YDM=f=kN=~rPV4I z9$W^Yp8_h!MMRY1PAJ2%T0-lu5@gcE>@@E$fN z_SavbMktgNuJJ1GHjgtsteDsq!}89~h(W{nu@fJW6!2P>IuAAMF&Aj1qq^Oay&dGP zoqL)<6mc_*OK&Gu=p{oRjHXelWU{PCQMqU;F~ktVPIQ2Zg`W!)6O30=7#|WpC3Zi?8qr9i)Wi4{+bmKp~5?&b>0^>nC zf6?r!4qy#Hj}dobwPU9Jcr{AG%7)_dC}s5gNi8@w0Sr&x9JrE~MJ*feFgIRA*JIUr zM#9M@v>UAH4W=0X%Z4L)K*{}s+QZTg7`;66%b=;ykH(jIvD5bC5wgyzgIWL#vi%Ru z{nPMh*8!L56Li&a?(Zp^DKK!XjE-D2@KTWj4Pv75KXLG%d7ag1R6Yl_{0f+} z=gI0FM84EN?H=+w3hE}1rM>N^?vljBXM=a_07 zpB;DqXpsItda<^|GN`t!b}41?d$kq(Lm>$;^tSqp6dU^NwT zFy0V`a)r$a6TrO-#E4h+glSRo?G@0Y2L&HPvdM!J#!zmyFO!p73{N)8scyfhMn%Q$ z@Y0o>f%T~(C}ue)cNtjQO66uT=Q^lphh1@q=F!v7~AV` zDAY!sV-u&b{-B@GBZZ8Y9u8QoV_4B!_SYVY7%LwT5}UM2IFewK!4)<*N0sNgX{ES9 zs-XUdAwIdUI&D>Y=Jn!D`5#`>1=-dfGBt_7p!yjjdMCx_J2eZ+B8TsvNbY92!Rhcu zUoVj;h4)Fs%bhOEZ?&Di=sL7*Z-Mgp&0UUBEMxK8@xclBDy^t0NI`js{$mNT!s9v} z)ZF)HXK8T|S`U?GqG{SIQ$YP!-FN1}{Vsmt$&HM!T^Db=rQB8&up}RB{rI$HaylVu z&*|58TUoAqQ(clLRu&V+#}TPh2X^M&94?HJH4UHbBp|H@mohrWHvd>qn zXz;Fgdgxim$&mhjPJJHtI|;sQHNavdZMuS*g2;`wa&f$wM&y&cC5=Y|0@tWFSdfMU zz-OqlDRuF$`hpMZ2B0Pn`ve8Q<)eWw+z%oh;V)z`91!)D95oPu=8iFn%N)6}8`g6{ z0tX7H0P{SVJy_0tH9i?bxp(ba2@iF{&w&gi9s z-GGSTX?94z$lFXrmXyfx;^##H{oOUXC+>^Gt91gN=>pU6RXb5N(dBBZku|EhQ^513 zJRpaP6C&`m|NO-45;`PC^7N~VNj+WX2d>>VqrwTzA;4w$(S+l#^9_tAYZzrt=pKZf zg`NEFrRg--F@6AK@iW$Iv!?(@z0hVJXjLY|7>g0(6GBT zAUe$CgGENE>020D5dN-=wuaoIl@l^mGb9q|x)~tNL8%d4nfaKwSm*09Vn&8_;?Ix2 zxQRIW44KzIS6=TY%ANnQq}-;i;!CIjKVko83IlmYp}g!7ZI{*FdZ2QprdbJO1yy1$Xh}I zkeP|>yEmQ|_~8Kn%0}P;s{pEpYQy0?R|zO%59rth0@KH}pWjPn^?SY&AW2EeUubYf zwbjr?p$-(ueHo6=n;W76vB)k3{{Pr}6L2Wo{(XETq%2AHWeTN8qC{dQ z$(pUj5-}u-2?=EzV+kd@P{?G-l4TL?|rp-jSQ8ilPkO%;uVoYJ#`NbQ&uC^tg8N*T+nSE4MWygn2P!O74;m za`(;rq-2q8&HjeBhNd|z;k}3M4Z11OF)_K;iucK z!DDv#SVFSGv)+Fvmi3kNS?KZBAkW6aUdW+!C( zxz*nd>2*bVI7@*KHh`N!25teTezeOkQ`hI{L9YhEe6tKT(bbdEhLFm!f3H~2>!5wou6!VezwNrU}xWs0-frNxh0L4;LULZ4=K26yD!dL(QDCvn@j5H&5^O<$?xh+<J7*RMBk5mzekr3Is1*Iu2ZffiPeX zAeM3h*?6H8*piVzP6=S_h`{RY(7r`VQ5}HB2Mo>nWHVtfZOAd|R3t7B33Nc`!8SnC zgRAoZ-Y+^k&p|mS`(VpWWxI8`{_EBKmrO(nu~i?8M4Y3lS-{Um&eke;8f<-(&vk|* zhqw}8fdfq5AFtFF?0rPWvJ40??7%KG&PP~yT2XfxFL_CbwjCzC!#k$7De%*hTO-PlXf77bQdb9SFt5+Xvb?thg)jj z0HY7}u1mov=b4WE#DpFme}<1wCy2(VIuep^;9K_$mUwU9bXM0KMn-O50NuT z+k?t?kAG$j@lW~h&zxEG-&L?UEfQ7T;fQ-7B?Ii6a&%{SSOY_DJdhrR9VaW{Duxdd zvR0cQv(83yc;2x)T9WdQ`v!yDO9>n%0P)Vhz7Th0Gi%uHZKXq4j!eUvu!D!xlLV{F zvoZ6*&zT-vZ_Wv)z3=T}S9z1d_V1QIs5fLL3wj)@=-4kE!5f<(TxQd>JO~E;|eDvKdUIHW;>5+F^5{fPojV1fs>if|0c&3vx zjF&>II>#dw10bVv(0|n5urbAITC%>=I+vi&exO%U3-)VWggG%4^GqBXEI(e$pJ* z-5sqn@UiNF?eK8CRQPFdZSqZU!@pD7`Gt6)&rC2fv0<&^pxq zY%T2~g~6n7El$hEuKLx?yA-o$maTCF`eSpd^gIli;ql6d^TGBrO8qhKotYu+O?DDc?s~47z^vE6NG(2x^7Wtm; z&gcx|e_MYWU~}&wTZwgYoalMN9`rD*#a<-4o9@7nMTPo@HVOx^-6-w2Sq{4x54~W_ zh^}!alS1V?kH~~1vN$2RQ0IEhjbnzV_o+zLzAiQ3_3?_@5}hKJ)$Deux=^Z&_dmc- zghZ~mo0$2^4J8^UIV*-TyMxt95b+b$@pmsBZ!0_4K!;&|CA55~yevZXZdm$#h$lmg z+QdaSm&2jMf|utIAg)sp%~5Mhng^?uU-ghclJL=Yv5${0OcXzzPz+S2W-c0c#UWkL}tdue#A{o=CpZU!GKCq@#KmwdM9x-JsZsDvOr1f@?lI4-Y+x;{BWg3ey^y?j^`2s%3S6f5r(o+DB6q^ zW2<%1l0DC2g!yaDm$UdTYWwJR9M9W~?5AngWDU6?vC$p;Dz)nMbhII&X~BEq@MCNa zCwX@4Y=+gbMdAFXH&k!l?qk-ui;Q&lcd|M3Vr(rpP>mso$7_a(c?li5kd^$lEWZ2F z{Hy4f$Tta$e@7s{_EY;}!wDoYR{8Pw>aUf2 z<)`+W3Fklk)P6JJ1Ryq%->%pHKE|+|M`cb+O`X4w-vrNIb!YU zXG-WoHoFj+dsg^2Tdgq&kAl^*?=AUt6*Lo#FWJ49DBIo+6a&)`u)XM*jHZ%T~-+ zx2OI)@ZO5CmvH3j5;AmqM-16`t{a$^15?+7-%+-TH?QgO6j_+6CuQ(DRi4TA=+^aH z;4;{kHUq$JOmI|wq*MrN)W%X*#bPs(d@tm?F56V)|H=9y@MFx`cJeLuXC;mtVLW=F6}>F_ zXA4F-&9^$PGuICCO?#YtqG2q%ry(dq6*j*sM7db>Ghy)pG&{skrzr@e4Q=rb6Zi*c~na%i4GxKol~{v)4*{e+58%PcHhFF|@yx z2H8MJK;p8hEldRIq2IetP`Q%{lWHyz&1Sy ztkCXluh4+=G1V~JfuTh=zovG0#&dR= zgNj1I{cPtNr52_2Pkc1gbaD{D?mTic>{DVI*WvPsnF$_Iwe0MhKprcG@UxD()Izvs ziY#G#{mCl3?gRgek1OnL;%;pfu9}k^`5HG+SQ9x6!6UIL8$WF?y&(2B@H41@l8Myv zDTbaT&SIkn#5=F)4)7g6yj53Vk6Ih-3Yq@!KsYq}eDUsX?L92BqvJ>QRWL7ZZEOhNqoOvMJmzck&BW%!EyTI zFs{?}#2k_-vcp-p{sD%$tNr%Jv79i^;(}HtOj4V_InfcFI&Yg$p69pFt02UBAY7V{ zOSM62Wh<*wx*)Xwld6#S&3($FNk_S8F{u0!zqNLrQmdVz8s4gXjuwIky1*>6Q52pJ z$5)NQiVtYKzD3i6&me}2ggjb(hh&`MaLsDy3q7oR(tFNXm#oI7QtLWi;kUAjtnj)eZRRA`t*4Y-XGMZ5UG0S92G(C2hk7$LCB5N~G;D8L)QJORDpJk0H&qxcK7kc7;RP=-l^PGYpN+Vzn!{hvV zwkG~){zLWp>Lp#j5dja_vmt2C&R~S3==5unH74de^f8VM?7)PvKxfyWTQnKpvJSuC zl5)6jp+}4l5pe7hkOSmEpFzSD&&cn1hid5U_%)UAn}NdWTl`T2uTKu)=Ga04I*^2b zuStjc+qfhG_VrK?;~+i5_-yEZ|M(}a$$u~n0c*_kwy$2~yIHEf1c8I1ww4coi=RQA zzdYJTCf)N*yzr>n7;V4&(%B%B#ksbNHaR@+9=x-q10Ru^0@ITLnLFGFQ`EIUY1v=! ziKVR2y&$yW}*1}G5}&xK$9b50gVS5;1&924WUSk$g#{pvXW~nST>(Xq*v`HNv zR(*1hKS63t$$Zz1w+v@)IN##$X$rZHQeTVNj&G@j-$A8CpFshzCC&VhbpR=DOW&p) zIxX|LhIr?-&f7hNh!%jNugQ&7HueQ%gGlq(QIn*htdpBY!^{Emo`<@%&zz8aAduk+ zDYYl!(ukrOly0KpNU15kQ^b1>h8GR5hnTbbJfz0Ewqr%Q3UOr~Lw{OBd6UOKkYPCo za~CODgGVP|_ROGc@M^g?qWJ>E6LMLDO^aUZ#R zstoZOX%0x%OBocOF{rBOv@Y#{#J(l!H?1y}yQ58#Qm0YoTc}ldJvCyrT}FN_GtJY( zdhms7Fe(KRvWDzJb26^uREO4ka}%jHGCZ7SWIdj*K|g*5>6MvE4;l;l3|comqMOLt zz(wnC2Zp@;11h^osb&O}7^DA!Bnc@8;(G{mqhgef{Pbc4X_Ny1Jimiavzdxyhi1P; zK}nkc+c%Wy1#n{mGZO$){Te>a0JaE#AO2S7g%% z0exDoew*%!E`sgngA6d{=$nB_X%t}W`u_1xybk}!zwzgeqxw>#^KKNDR@%XVr1>Jp zC7X@OW?L$-LeyuFC+`%yG#*`*a9t zTr)+3*n@||C>{9N>0HdM4wPx*Sp7#)(gOIL=oHMy@H1!)^>9!#av2i0NvnPMbR!IR zmqcX}vK_#Q@h3mP48FEvrwUm}aC!6@FW{pXiiD9a$|3bhHC zFtF*7o@_u1E%BWY+?oI(r)bN9w*wPFRJs|3Vwy|dlfQ5?>el+%CZ7!vTsv}CW_ZVN z|5LB~<;~&Elt~vIUrsU4(N(DIJp*+q4VZK18~y0ckur!iH`|Yk zwoQHiJh)Dmj{5f4*2IEn4*o%i1>PhU$rtqSiivRvO4jl$+f`o1q=@y{q6|s03E^pk z%ab(4eL%X_Qw1S*GxS^5%@rJF7D59zX7<)rEVqayeIj`y4d05_Epn+zKP!1CAx>Vt zczccV64hO}q8%(7cv1xJ>Mni4QPPMpoY|e#k7RE|62|f=b45y(LwKIaa*6ph(qZUp z5HeX?0EU;u&=fO(Vr=GPh^o2iGq`gY6Q`eZyJX_U2%nVr%Dc#T+M%$jEByvewB=8f zaHkgcPNySNu4m$W%8^i=CiU2maGbWnIY?G5liER3$ zxb~#Tl-DIVeIrg^)P}kD_^_w_gly`B{q?Lo=>MzjG)2_J#eOJK=X&`0v~af9Fp4o^SbM%7i~k zzR#T?Iv(-}wxlCfLE3;e{0g@N80@+&UoF(wekpPM7Pwl31K`yEN~(-Kj2$@^GlMcf zu2}1{5pGe`veQ?A$)WPAZ)#fDmX+MwOlI-IlyltZErd8Q?d|sfR&fo~x&ZeE5Knzj zazlTuBh*K4ha~Z1mXyD5)=C2kKEvuxA*9fQ*W0wa%ifJz=5_P47j_6B&}o{>oAu9x zkb_E4!)5WHm<|JH!$FP5YnTM-)TkUtQ2bt-y|2FJS&z> z2-}xlWeP1*6_ocJO-J7)N)OE{ykg!rP#xaaJXcU!e?dK!#*;!g5V%GioKjvhH0YB> z`&90t+wO}FCv$rjxmZNv*r_*by-)Tq$;PZUZO5|s6BBw$Z%0yBUg_b8s{u-C?EBwo za*c+{hT6BLz?(5*&cd5;tq{HTxfspMN7;l7u85tw6?|?+0SkE!eCGTi)O?n#ywSy6 zD=F3Ft6^pud2R7$sMG0qNtR{rJBGCbvjYI5h}1?!@)fNoAvFL=u6Z7^pV%~oCab$Y zh1Q*#Dk7gmwg04TpF36J%m6<=&(H*Ys4QGj&_$U;>{081edosZ4f=`xSJfioVCVCb z^@h6Tf!qOxLYFr(xdkX@^>k-A>$TA^>nGTOy~Tv6NIP@d#Hh#nF>u;P70>Lw-YZK) z%;I_z3F{A!yIZ_6>ZwY5m8c{hQ4ix`sYdMid@-a<^q?0mnH<`lEW# z^>!~3?x~48D?zEq(%WdyOWB=IGr*hE=eFQY;t+abV&6#xG2ah-JJfYUwpLzxB#CuevnAVu;>#eX?l`d7ClxLg$(C>K%r7~2KLB6TQroeF z3Pz5(;Q#R*LFkZY4+|VDPD}u12#7T-uxdWx*Ch*?`{fc+@E$&6aV9@A{ zsjtS?ACrXrQS#qp3!8ud+{#8scg5@=Dd6V^8`c;@bX3|u-jC=-1x&}vyrF28wgz`l z?me64S5%Nx(B$-o?kFEb>U3|OzG3_`DW02SpPsAlKxk35b|hqp(QayYTKUdWzV39$4q0`JqAJtgC&y)Tga8Zz(}{2|L_8 zYpIFB@Or0mnQ88MN*n;8C>J?<$yeT>BCAM^$_~Ui2HpP*(z*leJ6xAL7e6Ecq6o&U zfW1hmAKfpxq`U=1M{P#;e;8xl97ipo6^P*1i0C?w82AZ#7rSCaKhrtDD;PinMSj*L zJ7hE^eQc`NGAemu#PT^F=}QZOUj7Us&O0Lcq_l;VJ5J>bOS7J8^&uZQK}7-t>R5OZ zar(83?CIyP($5q@9-!wE@oo^8 zKR;OMM@Yjozgo-xK7amtO4Fl4c?|_5^4~xH0sefIeD#kMdq7^jKS_YhHjLzzTFjeS zbLG{3HqZM08TDt77|(*w0tbr7=M2L#y3Na$$NRHRoV~D|0{RSkr@Z-c(|3|WXTm|K zG1=5Y-%6<62yT;`_Jl6AVWuF%E&xvl7x5)J1{qI5=ftTEE=(7=g{`F*RrQfQ5!Lem zo+*#-P^47jr5+=-2hCR^{ z*VJ?LcAk(q5UlXC=h>~p_bax1N8JiU~pg%YLLAm}lq|fLXDzKI$c0zg9e-iVfLZQ2+Jevf*}+qKCT& ziTb_A2T-@R?m56NlVv{v4g#A>pE~A%Elw@?49wpMISjj9>WVULk{VMp{PfEolALR{vln1|So?*BA@z7;*K9^ZIpR zibtPE{!(j*L1BnfHF9zuJNs=_WFp9EUWVUqMtp0Rp57xWT;7l?Pg=#w!E1&G=uA4i zrfh)`=!5SUYYbfHB_%*S1)>_=vI8%#bOCB95M9V>8M3uwdl>}chjtSH$%Cc==`36K z9H$e9#P$q+H@2-OyU?^ItvE1bb4m{qT<26u%cs0BlfI9s#DpG0@??_|~mGB`OpuKwwb|;6>lOLSZa+%^*fG$HqQn4dk@dSwIm)E(Zo zQZB-{f4bM^#q+R~0h=L%b<@Kq^B7j4FMi!M47VM?`}>)$_5V*I7GUWFNW<#ffp0t< z{(8%7dqe%YejRG#a0$8_3|RhrTLn9%zYTeP3u!rhYmK!~@h8?;W#XfGX9{i-FF(j;0_lS%j z0$uHA5ChRezc74yVIg!lAHm|LB>uZ01YE#rvP4HQG#{pduG6#KR~vqu>{J zT|=;L1$`x!Pj+4>qaBXAhpg)ZTyURGkF)&+;~l3A1SZGbo?je8mK0$puV=p^=+}{= z#<@fDg8WV!*0X|@$14oSox}q$;+=&@I(?JxNaS{(ct(;IBjH5T-E|2buZoqE#RScQ zqH-Q$+luYFi+N%*o_y?eOCOK7+-z4Lf3~GI@mI?d(yX~RMIZv&>q>}7FpKbJBBm+i zQN&i8$%Ai|j%UA7I==XZYcv_NF#+H%zxFAcf_g)j1Y19YU`xm;dXtFl_zqNYPaQ>V z@UOO#wjzLg_FFur?qR8M8Aa66TN74>(2tBb&hYkN;J60rL@Ya>P8G0<1sM zvVVGjj>;H+yv|k^s$7Ol=2M8WZs;ZN*owegDQ)io?ouz`C&mVvA(2sv0+W5xLWo_N zEmwvL{j!J5Zs7D-&BrZ58;aK%8^PyAYswT~4iMpnsEZh#LyyKJw{Tb5{DIM6R^Q** zU!fe|oezn2e|eFm!D2HzHHjGj^19JX1STK1;Vf&!@r`p)f}!u$jkT5e0j_S=rQ5xA z6FwP6GkTKy<7xZkIUih^*)`N@csj@BwaOAM?um zpxTg4O`E?H$&{*_%ATc@aqPuIPZJ`1w?-Q3Erm~xUn&ggBh7@yBg zlh+rNfsDTTS@Sc5ixjnj910-*l@g8n)->(CI{?-EVVbrP{6*>6PXWlW#p!?&7?2Nt zpmD1Jw6Gk27IqU%0-+ylYheW@Qh_@J_yW$c)sk;^Kx#%Ck6-1Bek0T`(??qkC44|~ zk9bI0q09(l(IQOmdiL4I*;1QJ7Vmsg(V`X1oLYe}QJa)^4&UI1ka$urG< zbBEvX&ATczS0>Fij%I?Xtx&xb>Gop{G>p{^L&3XK-`6Z%F@Vr^K=a9V$=5=6^Z15U z@v>>Z@E=Pl9~@~VM;Kq3WdO{wgP6TWu ze(Ub`D@o||>UR9n>g@*zYuova?i(0NAJ;2R_HG|0D;O_82@6+MR@=qBeHg@|h%<%A>Syc4 z*p`&@Uu$N~J}8OXSUzrHwd?(TZ)ey`POz_HYJQ@%UY19$R7_KfQ{ax~=Nq1lyrc3n zeDYbWm-FGPVVT{!Co@giZ?-nms!nn(>P*kyj)}~GWd>R1roS);y*=zbh=E zsHp*gjyajq*&T*b&X_DfWSmVwG{Kpm`7vOW!ix4|vCIr0P)?U8U)eKYsyYtFm$?IT zQHWvT)&_7@1YZJlf!G@8@^}Vv@J}1)KXFdn)b1o}B9X7Kr|w5fKG!|0!^u8gv@_6F zn0E!uPEcAyr4wT)pFtOcZ_gjMkbJH2@`TvCyY!rWT4$zB#73UXL$45|wkXlOZN1l< zEUrF3XKEBRv`?Za&Y?Y5;ea>&PDg?7A2C^Y%k5+VV$jRS7+U!ow~|eGro*?h2>ja> zg&D4e8PyQkkGakv8s!wOEC$7yU^QUmt8-St8lBc=nU1cgkxF=kxYP)U1<<>QvzCn` z@{;RB%RC9@*Jp&c9RbF5w_~NS8lGQ5bVxm7(@K4jb(3$*Yl8)L(fx3#5!zq&o?jpS zR1P#}KouOu_NPsa^Y3?k`U25f8WTg5J5~>MpqBB<=H(S_5=_JJU1tLyxoJ7TBa9m$-t8TIZxm@gP;N=0$Q!OhLAQm!f8GPmPp zZ(~g7H3u;-4`c$aA|}iPbWH*2KKfRsVXYuXRrlQ_P(#sKOfo;Rztt6w4D#SB?8tYM zztMe=6T|e@my=ehs(m2#AHCF=IY{#BMr$RUe z)sXl_br&Ot+ALZ`SOA(LOXCcy1z^;@`L6^sH!Buj(UEYzWaURSggu6rWm`)rBpqbd z4^6t+qYwD&wSNhFA$^Z|!zpeDQfw2FBt@N$BUs!dUBSu#<>o>8p*MinVy2Hc6 zzgpP*fD!)+f%<<&jX4B4OhjG9Pqo)a-#cj4oT8CfaDE=EgV4N-Vj-)g6Wy(nG>i7; z)hiypWOTr0yTZXkv@3h1HFuBN1xw9wjE+N~IlB9;9NlP(oiSmb6^^3uCQqxbTRtv=@z`mec$h!8@pFPV~2S{gWUw!1CyVQM6 zM$=>SCqJ}7&gLQ|4D`TDEPxy+yOCUHW`Jx^#!*Uzm)X`1As)kSe3>0MFJjTe^$*Aa z)W)HoKF@Ln0s+RmQPjo@w;li+@8^H%+h5uX5ZC@!>ZpDJ-F;KF%~}Jnyb>~i2!zsR z01M5F+om+@FfZs5s0%qeja*^*metlZyB)OuDx*TAcUV`1HD1=;ZqyttiXn`-0hT$2=TCbVsSAyOH3x%A2 zh+aYe#j@lMr;D#o-!6eHB zoBM+Gz;a!u?qtUS$M?)I_36A8_{Hu^gBqP;*|pAtW9pnKt~Z&USItfvpMIWY<=S+1 zI>tA@CxnOmSaE-=hF6D-JVLb9L&6y|s{F=B>CMwR2iI2 zay(f$1>bebh+acq`n8GG{^9UrqtqStt&ji&{9kn5R|Z5Wn3*g=kbaaUSnAy?3cp4> zHBo}_!lr@Pv6vI^96T`10<$^?w4W^!ODxC_wGD=+_VBuTQr&SIrTrIubBWAndU3sT zR$F7e{IybUq|1Rqu?-2q4SiMu zb9I5oUcydUr>D!!A=YnCYA8QoH>(GYjsvKNB0dZCP)>pAg@xR*U~gt~2g{4PXZD^l z8%p-jy=2i_!_0dXQ?F^uHLPWvJXL$k-jdgp33BQBi+fIuxQ|xr9Mdq1)a?{AQQIb~ ze>2ArDoboyfQ8#HW(Geei+xk`8*>a03jrWj<2Hx|tXeL=kxHU>kaZUVH|n=o;f^kmh_L3FqzZa9cYdZxyy$-C#$uv#IDV zE7=arGosct4EMBAu*);%)R@&3Z1uesJWjpOp}7(vheM}8SflLxO7uqKEvcs`%GJKY z=0vo=Rt{eNZ;`qEt-&$3UL;z@#Q4Oz^s-k{IJg?gS5{Np9XsUaSv5L4c|X1XP(X(- zdapf#$~rlk@_h1kjAhEpiGlmRZ=k;Q_mBXAw|W+c8KcC6z2h>d{OBJ!jll4@Q3k}KKr3Rwb! z11Eie6m0e7tX~0XE81THX>E}ILx41ZCi4!hlIpCuDRCWv;~!jD(iyPJyP>Qw zdHq)1(ASCGhgXICkniX>a5?U~+j{z}V>;4zzZSb;cUkoo`3>sD zPa5az1Mw9#?E7gTAawkmB=(Qvf150(A4j&pRpgQdN*uKxuX4#@n05u-H2^?R!Kr${ z#`1XiR`f7iN20rSTH`qW?gh9v7Jw$f%2Jb1E~mx0ie1?+SVs`b+TuRmg4fxhq+KM5 zFHG8viLcfhXk#KDdP91>mjUe?he!k=F*0VWqCP)%C$8{I#E~sOe7b`7hSkQt>Ug!x zM5`UuCq0|DMFj}lTM`OVhj&&ymcE#Jae|itC01mIvm#LgKAf?NHrmzn$bGiaTG7oi zTo9wXgV`M`w7>IzS5e*`!U0XB$(r@cJB#%W^Kr+*%$r5-19Z9+To;l=d7%;qIjiX z&ZniNyfiwJYEnz7flkXKFgBRA&)oo(PrKvW(yF(BPcVjSikHB(K6ckdyk@LE3ce%a zrku2AW$5N+1Wd#k3xgaY=&q$n?@C6zNuTEq6z}kgSkP2_Im^B3JI78sp74Mnw<#@5 z>EP};Es*GkCAR>7g>I?YJw0M8#^)EfEFv!n1e|B+JbY6JwcuoUV4nsz=S- zdZ>{#@$fReU^e|sYW{y*_W;Vb*suN3@$Bso^J6W-OM9*xw_@GaudEp}^$Pa9JE=zY z#&I|h2DUo4q7@4stw}bwBM;=ykq~o+!7pswsG9Xzj-?@<-9*Z+As}mFDq02Qo)e;v zqOL-kC4n@;5R@BxQmT$i7x+Dpe&nr*B4J>fL#u7>GiW@iMX2K3OXjWE z74$*kqT`d)+iS?Bwux}qOC35&3rRne{GddsBhL-GaeG-!{KFA|vT3;`S_|KfY3M_p zQ&6VNYhL_!!i!o{mY}Z?!uSAM|KYADCj?u<^|@9CR94W*6qa)z$g(+>J6&?sM>ZD8P)!h}t~lqF*m6XhonMvBlk0 zIzgsw-3l+_kE~qDrhA3(PaRN6vnnXe;lT()jpn$7bK)7>ER>eifCK_N>V}_)_GVj21Ui*R z>7u*?E^9q|0428#S>_F;jp&n9do?oHPHyuK4WQ&MpzsUw=blKYlrXl>7~e{XQH1e+Cj8m2((+TxKMe{9*7=sZqvp?0LnT z!9#@hVrFhT{W;#`KKgXMM2h)dX5k(z|Lx-!aPr%3SxDto^;psM4Ha zCNZR?iSFAm{fP=JHkDCV;?K=7d#tKdnb1_=y9=e}`|C1u@)-9$dSbgXH*Sf})Vk20 zEbWkNEp9LOri3$q@!_P9PoJCqcJe~0KQ71LpZtx9{mB~b&ycWxmi>*1)%?U;==!a? zo8ow!US%Ucu;bW}{;!T(i7ukt_;HgJVJ zi-RyY$EvrRbZD0A-n_O~FM=u6EFGp`*I-O{EPqyd!HZPu`|A(XSe{4G4kRdmUet`w)C5kH-_j;%`Da+$q+0d9 zDDQ8-U}@o1n5J`1`0j@5o6$4qYaQe(2{XO1R=xLA?H)LWaXmM+nc2UWz7JxODf1rw zf`}fTmRh8}c&LPMzYn0%Y!Lg}+gg4hyF{ELV zvP1M2-7t61v7!@AD=!g>kX`#&+Vthm$xRkh^HVMov_}rbm*0sw9CS45gN)l_{JGHJfZ`ddN%;oO^(9yU zlI7Uy?9H}QRvHCfHGSINJ0Cjgw(2mSSvZHSh}7SXb|}3gU7H-o{*DBrC+nLRcbwUM zZWr_*;D?P6#7Cb)uvXb?%CZ$zAoJb`h9-l2mH<+!*Drbj%g`|=LV4+%vxar2QAD0e z@+L0M-Btz0^Qn|NKl6$e&>e$pE&sE2F}Uq$$FLD2hRgL;3R!2^dl8-Xuiw$sJn{~e zSc<6PwGY9vt)P8@Ot5ykZS%Dx-vX2quXS$K-H`*y4DQKz6<%{f9YS;%_87v`<>+P) zNw7)nSK-clb6w`qQEKo}ITkD@* z`HE_xBnEBg*t2ott=UP5l?`X`V>SmpV%V^zKwlH7yu8DFJfP)aGqz)V$U{iK)kB`iYzpB>kAj(}t`T#l$l0ox!J3Z-l(?ebEJhXiL z@SPlL5R)fW4^^FRK|##Y43Cj>uiAt?@9pwyk1N^qdVAsT(rj!-t%RS~+9$4B3WIcw z;8y743HgOV$?>;X>YsEyi=%=W65Z5{_tbQA8-{wc>`pqt$ntqes zwdz|M<1*iu46mi+?aU$$R{+gr4zOjkdmZToTRLuyTwQ~%P?;>^MJY-x+7t|y;wk!u z=#zqkJ2UG8hHM55jb87^HY&l!MP&HDUojrAaRXxja4e>f-lSVS=?H3jN$>4PtKp3p=#`k({xm)1N`yWztqDhM&|dUPt@w z4+^N`mjuy)<=rqSLPpK~7>lgDD8qDTGu58VOQQ!s_RF}R_qhh;E!$?9$rf&rwpnJn z5rlUD$!ruLnWb&B(7vzNvrQ%RwwMa4wF|qb4rliWq_0*-pi-19XOMiE-8)Xb5P0x3 zn0ww^1aQ`+V+)oaF(iGXp(+C@YKsMvARX{ubgNhs@ww&J-RX_RrgYnxxjNtxV12~wJ zyB@BhfNbZ$YZvRrvSzR)nK}twZxfuNaqj|BGf+Me%A4&mHghT;%~zUGalpRog^-tQ z%ldUTZku-X>k{=Fg*jl0kPZ-oG zG@%GjI#-fg4Q9uOl|`l=LzAfzr@G$ravPQfYFu$kgA!bVLSFL${}U}bzt`~?qVSJ^ z5#6_6@G}UM1Q5~TSH9EXfWK>S`}>#pQ3@0=T4lmnR1ih|(&~}W`Pk9CplkOeLeDio zR@t!LWfJx_$LP*=>{a!Z##(Xbj+r0u3PsF_hR`_Q80j@&@=7@nw%abaUCN@NUV-|+ zChlEH_KVYD8OGB%>h*&5JPrH6p;5t}RWf|MUtcR$6<~|ZdToBPGCV9(f7d>2&Xppy zw2+ainQV=7b*kK&2XfBwn#%y`N92**(F$GTADm{zF7qxHJUs&%z4sZkk0K~YNO$Bj zF{U%g?K=2=(@HUvNm`sBJ|YSIX?t{5R`!juJinR#ni|PtVMS9-$_nI+SvdR|TI^s+ z;az<56Cqn!$*@qQ2&uPsLiC-gZC0P$Nr6V5;6NZBNK=%vKuKZLfOEI1#rfbsNiNkY zI{d5nUD;XVg+S5}E}f(#2EWTE6v#(!d5dPa*h~i9^t*aws^;L+z`e-b8%V4PQ!(D7 z1i!b{TtXZ!0d_%_Xs`P#68Tq`fN`db&tYiGY3N{l{SA}u8xWw#5w*zVkC&ev2e{_W zvXfP$*-AzEz}oW6TEsYzCw+jAdB_bX8QfMCd6GCTzt?7_zp!H;@MA?hUloQ;p&mr+H=a@Yhw}GRC0?rIo!r2F-=N>nzq%`O_l+^4a+DlvSydN5zAZE zZmgCN>rR{EWUS_Vy~-O9!rsJT6#BRX{p7}JEAF1@T5r>!!c)(t%ZnP;K+M^q@7-?^ zq;&~*lv@Oi_+&ygSPCX0_@oQD_$#Sa>+IQT^;t}^@OD*8CNoHU*uVv)tQ=8mPGn|8 zg4tX}>lC~T!$^c&?ANC3JKOLmzu=IKBJ*mv<1zW@jV(sk!m0|oMmJ!4wpzu7g}tCQ zE6t3OtL5vT3#gD2(D%Q@5n})FdTINe)dp5E%lf1EGfO>z;Fq@0A>DB>PZ?z0RWrVL zhec*j9fS^I#NxBUh$ZhXOB#LPKd`9w7I#1+KbAAKa`N4c6CPeg+bbX6FOlXhOH7XE ze`^djR1fR`J=r<%Px>lnvd;|99Db+$8V zq$287^tp0k)$ks;UeunC*<;j?ZWKBRZC$4#;a-}MP4T|@85e2haQCQcC5%eKJ+eVt z@ESRzk=Rxacu2Z&TG0JDKejV02c}N;EvZ3L3)S(h?8KDiy57+leQQDE(u2NQ7gT|D ziCnmL`h0uY$vVu@GQ#~LQe^KVoNa^Im9TwGKJu+X5i@R%nf>CL#obaDZDileuXF6% zsj#|$@Ek)aTq`k&b;z`i>UD~9TR1MX%V)N4ld2Ko{noMk^rS(TSl+D6df#QKmIuyzH`eF!!E*D|W-aqY>K|1k{V*jqqVWR?b#uY)21- z*Zp$G$_s9J9upUVi|&t(>+T79asLgM-2KXFEa&8ZTdx9eX*fY z7Hm{orn<9`Ehq}BB{Lg;!qMH1;GhYuv@|CLYirHwJLQ-6in^$E5L4f^eQ=L3|BM~ z$v#{65Y}Iwq8?E4kfqSa~I&xp8dTu0Icx;H0!`M(n3_s zfDa<&EDeXwDYHlK+g0fBGE%7QX{)R$>0a|Umz=1TIRoc~?jorH>!?3%yyTJo3Ro}& z7I6EPR@t-Eh%#YDJNaw%8%ZgVZizFJJ=W}tG_@)WnX;Q9I&Lg5;h7lSg(qq6%+id? zI9PZk-^?z^E6gcf0WuhrQxEljC?t9@TmaN8EoC{(m3Cj;$RUjVdytRz)@qa8KfT*a z1}wI=!hh0ss);0t2}JKD`r;EOc+&Ijn9f-ihDJv|n~g*D8Fb<{!*x*sX_ zo3Syf3FXQfJ2ajf=-w7TPUi$z2;Dn-(~-dZ2)6sUSxKxOevB6GLho`X34H2Su|hxc zBX96WKDn^Ak+7t&YkXQ<2Btn!N-ly)b%H7axw3JRZ>s1%1T3kj1Skh9-E@+%F!N?k z*xze&`sof;(9L+y%bsc=hKLWlb?6UJg}YLjyuxn|>rNy*U`ij^V_Ep-|6}hvz@kW+ zzgJN(0fGbpVUZw8RDvjJMI;G`#3io^5+zBFDDDTn5pirs;;j7mCwACff$WNx7kdYmTdD_iPYd)WoqNq zIckM!vPRR}6n!BrJ_6&f2R}L&M@Bc=KdYK|gNC{F@FjY%h4oc(m9WL1v}-c1%EH(| zM8ekmK_^cg+4(yp#E51r){GTrjCh}{IvRD%j6q?|KjLF~g&^`?kcN15*?~Oo9Q~2( zE*=(voPE9ryqp(LbYD8jls_A2ExsIz1o z2W<>2Zd);?_YeyU=nr60 zD;Q4HnxX3ARb}&e@I`L6H*!dpbsz#8WO72r2G<$1FVVy;9#{)`!~)nL5TCMYOE-hg#-1JKnF@Tot%`V1*hs`lHXQoD4YBpdPW z$G=$Xkj%M{==5pl#3-6EghANF__Urw+}#v&adii-J#t%*c;FCLlAzxel5IxYdQYz~ zh?a<$n0(59-<(ko_LL)FZ+~PW+P?B6(9pr0R6cDVVA_~t84)zSVN9=C)*23(=p;POlz;3B#AB>fq+@yP zTkOa0S5Dd&jCFM!GtZ4HrnDw z>nmP$^*CeS8NAO{d6)*;K?aLl7<-v`%j9*QL^t&Z!sh@4V?qB8+w;q>jMQHh{m0DG zzv!x(G_C_MBHJgeGklh*INBIGGi?t-jfk?xGM4s)E{>u@yt1z*Thj3TmOU$cX$9}w zV<~vvPY4}Ek$dzCRV7}3brI6SgnQ}1O8qoir?Uu6H8|?-8qM{LTCu{wM7klVhxtb! zg|4sGrr_6SQnNDN?C?+hZ9wcuu)OlaD8hlEy89gV+feNQ%q6GKmBxNLGL|d*>9EWS zxK0U(@A&ob%q&(-N4Nucg@%uwEL1y2*}Zjl1Ba468EQ0k3#XJ*PH89;0?ej z)ToF*yNFEpGQ*2Nqf9g`dJAM?J66Xx_pk}W3_~BL62~k<7aFZ0N0%Y9O{YHMX*L7s zJ@LTe**EhQn#63y(sUli>pl#sI!Ftcqv3-H8V#^UL%A*uGmN zym6+)DE-=VuN8p;3Gm{3yaO00cRhwhES1Zm}V#7K+UM`*+me$sb+=$z`eF#_z| zHEDLPN2pE9ouMm{WtYd>%n`1DC?PS6MsKD+9}{p_dmtVM;?a$lEMvnmaE_or?R!rl z>&Ms60_!yR(?EQWQX)P}MEDb)&C(l^PqJj+0FPyL*RaRhVTRwT{a--bkG*+XVg z!~X>4KH=4}8i2af6D*a*3JY+x7KT8l)9MOYBM%~{{q0Gy9B4wAu$F_lsbJhJ{##BF z=7oB?;M*&>#j8Vo4w79|&vhOv4F-xbS54vD&DIpJ2IcUcuRoSr#o(pn-bU#alax~P z@=0IxrH5}ij6(e+27QX0ucoPf=$$&@!J4jH@O;_#WJBHv^S6~s_$wi}2*erR`D*w? zNR;cU;=Kl@OnNskqBY&#=8-c#OiPBk9{_QA&nApFlk_n}_Kx@w2rN-;dH&EQWodC3 ze;E-F>qqS&;YYb_)`)6f66dlTxpNm^zfx7JF*YU^IdGkbUid+j<^Gb|j*g=&D(UGl z61P0BGU%TtA$S1I@9L_!YebrxBYBMI?6oJj`(2ukgv2KsvV`lKvfX{1|K#pN#dCD$ z>+aGYp!6E+qH0hz&Y)Ml6?{Zu+vbcLQ}FunVu!ksM~4dI)j;}fn=|6&ro}>)+`?#e zUYMo4mH|V^F;|O9!Bh5x^OgWk)%S#> z+C1Opc-fq7>?O&wFiA#N+MWeJaT?c+UO{t>gJz`VfS0|6bc^XqczbrMF=N5YLI$H3 z4qvpXR_<_&?#jJoK%3Gt@uVE58Tq1pH3Hg~YKgiapnZjQ$A}dm3j{%H0?=j{K`FK9 z;92|?lw_{KvjYg0{aYX_C)wmpyt1DybJAR~X~*x4BVV;p)4Y~d!Fh5-3^45@B5c8trnH=jY>BpCe3ONHFvW$aIIr6qSvRJS+rrp<^ zJTS^67vf%AB?=Onqt#IO-o1T~!9WiSCQ_Z)%0rOCHBJB)9-P4m1h zJB@FF(-_&|&oPO2$kMMR;y)3*K;=9eY`Rdc$vj5Q$*{M7J!ifB8?pM&AM)Ej{nhwp z0G%gHH=kW=>PU`AC>4st3IT8tj$0tUse4SX z-+tFtbw}8=0%lN+CsvL7XWwww3;$odBs~Tgf9K7ylUSwirRt%K8awURs!*Df&FphD zL*pW?XTn6D1xiVLe7+tiCUaNAR{Kg(zJvEmLg_FA0xd~4dR^@)NeZ4|^T8+k=LYB4 zEd@CZ;x5}Uk%C9l+?6gvhu_$ay5(Y-k@3}}D`-h&+Y^tdoW1LpD(qPr() z0q+3rnuTYN16(=WbAoT(Ka>S5qJi=r_5d1K{#QrEW;WlStxhQ1-)&8M~nmn8ZpCJtLI1p?K?-d3+M_ykGfxorv>3s_V{8wAKu;Y!j2ZUhn&!Z@yfzCf)#U9C+{ zRIY7VlS|b@H2H(NW(=mE?|hB3d(tMeZ(_`3*xRdYH!8bk$>%=3f6THhC_boYB}gva zafisznygd5%;ufX1z7YHx*m-^Pxn(X1@zEmECXUK^T-MTC&BMJDy8eC* z)+`Y)x4vVljup|!qUOfa;E)+*Y<(=d18(qy|xe5T4HOf{MvS-;Cs%gfz z4(}WFAjA1s==HX3lRsvf$vQs1OH=4Pjf%@H!SJN-SFMB`btKbSf@Gc$ig3)|%)9f- zud@GOs6f-qwWh>Kb_m;tH2Q_S3SC*Q4I-||@rKV|VlT|IB-?Utb_8etH4nfl zT3U$B%}qdSUwz*rnK*gTdU2l%-8BIBuwN6d*465GAzFWqp>;W&-wsqBKt}~Ecx9BO z8!6`+ZF4BSDSNV@bXrZ>8?TGH&L`-*lCIOlE~H^(ueMml9ZjC>=yVVxX*_?^o`Ce*^#9w40*!4~Xk8W1tLYezqVxYs5qX45mnO)Bqckiw2eTjOWV2Il$#7ZEjM_)~+ zRiY;1GYh}t5GW@3``n3vhJ0Zq2i1h@mLSS~kAmT|_Yr;c0RsF#U+`Nm{~|?6J8Q5B z96$t$-RIvzCudkF0vI4q`{g#>EW#2uA0@2&jWEAdNU{8VX--Pom_r^iZ)$bGqJp*x z$&9N^^N0pt)WZ1SXi;~s@Tmof^Qbp2!S2y`u5udP!geOBYd6IOh>r=}kGgw%0>DLs zebamm-!vb5SL^+N-`8J-fKKFa6S$Pf5@jGVsRu?YJgba2r4ZcA9lf0Gw|TB%P?q4_ zn+eLB>#9gBsenD19}%t~bIl>_Y$4&K0y0`3bzHk8?WW&ccN8{wS1~kzjOU0KsrZ#x zkkW|gldCaqa?NMUN$rTVZze@6S{^xnkniP<7%yh3R4Jorz1PKgUPE}b=!7d%A1+hi zxz;6_q_ZK?Bf1v*SUkW~L!mgSw?=em2lqylX{QLElBiEBip1CF&Ev4Ji8082H_pNO zI_Yh{yqJtw1o1)_U!g7hy0U_QC7{-9rf>ra%=`A%s&)CS7mvy09ukhqB|a*?=$jD% zZV7%ma{jYU!~9vLNn)RwHJy#mEJhNcd7SFinaL)h zwELQH7E@RGj2}NcDw6n7UF}+9K_I|=q%7;V*(fZt^&WS=8nw`yu9h>#Z$q}(s07HO zd^4q8EmbMpZgBR5Ts|*(p-`j+Kj>I?H+?2fB7<(WseoXNAusOGnt1D+-mQHh4m#Gf zmLonL#^dfeGGYTgS`+I|Z)ZT9P4|4O30?$*x$gQPKv(>V^GEIOH{ZHe{?#G28)aSN z_50-p`fwS(7My94BV~0;4aQ*UtjjsA>9j(bS5i0KzNyev1l9k6dFa2&)|;v|xvKV* zMile1q>bOz&Z0VFTP`V=w9e$774Y8RcSy3qT^#q+w3vQ)AuRo~6uY@YiWQD`9?<5A z+(l@>^L&?#{Z^pm-Hw@5Q{Xq~y8AL5=nJO%YgGtByKoJAAA83eNY5r3gjgHX?rSVQ zN^y%%PoE;ynvy*@p6m6?1l5l@5AZH7u-<(z`7%lu0mMQ2#k)eOwDq2q1R3?!H(hg# z#)Is1sw5W=y*nhZ2Z-I(ghnvQ|nqWuJRys@M z!YzQ4fUPPrvWYaJlyqULevI8U-W?0zS3n|IuAe-e=Ocbhl9<5Di^TbAPV_@6+iJ7w z0NRP9Xz`KV#c|2Z|1bqqwmDJ^mZ*sZu8C#`ieEN3;6UwH#C|x9O}rw4sy)tt!&3b+ zgGGqHc;<(VtbwrKtBw{riN4q;GZ|eii{TCt2M1jsjl`=0<964Va9{G=0wo024KM1_ zWe=dW2fFQe6Woa)%Pp#>oTaOwlG=%?2L5(rWM*nLojOF1!2TJ5$QxO$w2Q2)1G(NA zb@ae~Hcdv~mv<9{M^scRjL0?p#f}38XaMVAyW?2Jrc)ceXcIU%s44exE{Ff>%>72< z=bl1w(G(dLHy6m=ti<&Sn`e(^HgI3R!>}IsNVlL-q+E-%ojPJ#B!?Zz`u?0p(A0IJ zFt3Ke&PS|NmVBhCfYn(r4_L8?4w6%K3o=z%5gqGr32#R(#&IG&Q_-QfCSxk6)PmSO?}Uv@jWNJ z-}3eXA%C$*{T~j5oWHs;KCRfK00YZzfxyJTJQ4oV>LMI9iifd)jVcGtakP{sF1T-c z+LL2kfjRDbBL(@6#xI)kpa1=ziK;`2gjc>>c+(?!ERU=DeZf^VGJ4u!w1vjAO;$hr z^lJYGb8cxL#gIn<707!X;7!IbiQrf}ovU#VrFDFTg4+z%-7=E3NoSu{8rg}-mD39h zM~^3Egw(EgD`a^szLR4sjy*d-6k*<%JDYL4C{J?040Y+vt9fO^8mZlWfkGTB$=HR& z8f-44kK~IlV2+Vk&W|Vr-{S{6Ot3$oQv5xizzpm-9_|~)v~H$+CzTrb+5PW7_U8W< zXPAHU+ZP?$0=0`TgWr6cC`ebpURC&voA*5ouFoqX|G6IYkMM4LG2i}(>i>6Rz72QJ zN2V(X$~ZbfHXWs~pRiVK9|2F$r{I-Fc(9sme%bZ)$V%`c;{VV@nVE9q{vV8T$t^B)jNB{USJ4&I(@HQ-ubtkY^_$B!dA9A@qr_psK!*r#j zpJlUwge&zc$-qK}Mx@$yI&5G`*S(O2^oO_H5s6{gfPOF3!o zn+U)(H2Ks#&%De4_`h(G-Kic43eqx^WC&{OjNYWrD~_x_@#fhH#+NywaZfZJ*_evR3KV_F&~R2e*KR%cfzNVbvCZ^T5}haE40%FgJ^6#TaaXtP^tpjtlQio`rNot{DUY_~Y<& zPWVdGN`fr50GmrKF88w?f^^$yW5?8O+h;>w6P~clxF&-_&s*tWD`AP zb+oxhatkD1HmpqVBSKtFa1~UrQX}%Dj3be>f71GByun5L`w}|pD#W0XTd$OGAn|-& zc|SYKmA3a&?ZkomD|^HMPqQ7Oa67pz1r`6Xy-FFd?*43(>=cE+q@DWL-(zQm<}tuZ ziS?I_RyP$%5AGTrq;=@d3dlkTCPK80vQNtDmWRUqQ^P`!Xz)fg5I&B;TIpe^|Fm<* zqI&89`EdVnL^K|-n#W!e1vj?4$1W{%{Isw}a-)vziE?r+aJy*+k5XQ!+G!F-g3((y z)M^@g7;knQ8)7_ic>Tx(+sthG zQB1_4p}zYSxchkSr?)NdVkinjzzB<+KeAI|vWNk5#GfVf&-U?MUH-p%86AlgoP+d2 z-h7(?0x6^h{^!225M9<*15CAcpT8p>cdSc(-W>H`YrlWhLc+iE1HL;W+>sfUkeu}I zZsZhGV|s~d?E^s_$t5{Y=!txYWz`Z^TeyA1&Pxg!2sJR}jZ3bo3YPK7X4TJrdcU3A z&K3Wtv${F4!5Y#35_~tPdntA%%fZ>wDMZ%vo!|d(RV&ux#rKIn)LxLUIEp;Y=A%ve zYld`SZ=cw0pA*yHCSU)zR zg`Q3}*VD95hgnYO_!+J=@>z0<=h}~@Vm^*w)lg}2A|{+<*#s)~bygsB}&b8#6)r0?&zQjY5E$Y}2> zQhbv3C`Be4CgYuwyuuUwh$31YY2k1|MybUo+&k6{Fbg zF)Y3}o%kUN1hd7dlDxQe+`c6~$D1z5XFs8u;_Cn%dGiOt(@^G7jeqwf@$dZn?_uZs zBkvm&oqw-IC!>^O<$@F5;y35-cx$u#hBTo#^-|%#N8%a!Eszqp8Hn`vP2#uB^w94B zq5ieKbAR%C{|1n3%sxSN47aEr$jAlS9q_?1JDkEPOB?XOWFL2={<95WD?d{gBM`}b zQgYQ3UbZf`_xqPAp!m9_s7~af7_+*8=E&)AdQ!HWjK$-P0bV-U5?QbCAK-JU#;K~{ zmg9!9wy>t*+`^IBxK`GWIal_jJ$PpUS2Fl=?A~dQ1i$uzU zQOUQyCZBj9EYobpBmTx=9@rONl(Gf-!lIzt4D0OP@BeiQsE)Dz(5iBOZ)Gg_9y}RJ_%IvtZhGJ*5jtB z7YW=`8F5u+>y5a`dS7@K?_e(bqIHVzo%TpD`9~yBPVbFi&8%-!13Fd~l8MK#_v28* zsTXZFoP3e_PH_pgh}JK(kZTmns5+2w%tKXoZqKgN*!!ekiY_PvxY{1y;-U9cPbDXnP+2uD6% z1n=hw#khhu*GxCY{C>^i{;gW<1}@~&T>n}l_yYjX+GGuEaMQSK3>k2q5Z!G({aSLBtW!7=!SRMEvx=}A zkn2qaEyQDkW1LwbGkCdrJ(Gtm%$6urrL1wfvga%x73ACbq{SEQo0a>Gzb2La#yi_! zdn|TOhV04PJ%!>|9c@pB{QoRNep8>@<#LsrE~P6`DM4GkzFeejygbcrLZi)f&ZJz~ z>7D;GUcw8ZPxEfE2#rffg}Xn0`$qj0DfzGZxA(71Lv&C5-c!H#)bBm@dv9V6@Bc9) zhMHl7+O^PkeOzeeu*8snGZuM1Ski>#(KyK$vw#srQeN@tt_^?x@=N8fclqi`VF9Fs zKJGVnIe&Bq7qf%xN+PD~>pj2QJA8BMw?Lhcj!?+@_Ne%YP)6<@+4{uNyLvoRT6TOeT1^eh4hK>16Wzp1$F`acla zKVvffY_B6_08a-^%L`)*gmSl&Uxz~c1gNKejVMgi6GCa@| z?FpqNK6DE8!jh*Rwt4maa*4GQ`>ZZ(yQpBhC{je_nb6r+*==#zFC+wtap-(}hL;eO zZ30rsy;Ez?UiE9Ldwcp6(T6@I6t0-LgrF}&k;Pi2^!AB3Sb!q5&wLoYi_;oCb18#z zT&XB*)xl%#jE~f5r<4)x*2G*ZFrlMlhL&w@?VEAM!iYZMGs|ID2Oju{!^~LX7RWuU zQp?Cbs`eP#D0J7C*-M=^GxKrSa8c`{Z09+=(qPM26ebaFJ!-@DUUFWmTdP6yJ67U7 ztf#O005C+(5#UOaxZ^N*iMRxcijOm`$&Si>s>if`Qgpr#x5O&ieNM}5=Zn9H?1co= z>}BuKWUoVvelr>rUz{?RH#4u1tU!{~29tWwqGqKHM~SD;i>rgcT;UWgaHb4bA9*Gr~tvAFYhPeksi4SPD1 z><@4)CEALL{c$HR(JH#)9XO(fgwb}6iv=0!o(`F7WdcwHfk){8fn+16r6VyG7(+ha*l(2WAACvX z#>hU?_#NTX7(0QfgbPZ>)VHW|^65sElC0aOZNAxan(gERWRb(z~>-b@U~AK_LwCNLGv5 zY!Nz1k_Vi8=b6hF578&Z1it)}U-aAL`Tu{!E#Y^UriCYwYAofB;sbCJb*-Mho{!;~ ztWW403>_;1@7r!vEh3Jh@E&eTncA7#nd_Q7%HsB8%k1O4Aq%#3RvM>FbYHQ}V9XD} zxwy*OMA%q=d9rgkV+=W{L1z8?)iOAGVeuNU!m{i6Wme8lb8>QiV^ja8 z#Gaw~?7!8}+)2~#h%pSEG8&!)5YmTWYfVcT2~Ai5Aj(aK(Pm1EQ_VWG4SReG6u@zH z3-rnnyv}B5sP^%v^?)zd=N%xDe+42F=%_owfo>XX) zUm}Bk1snN`Q96nF$ir_L`uB5wK_%X4vn7oMf`b0+3;xJQ{N3yP#^66Ef^Q_Z^Zh>i z`94*Dx<2#3#4mrpGWcyyA1a;j-y@m^^}#QHzcKjF359b{-~9Av{@ELuhcNByN;Mm) z%cxVpFV+czpDE#ode+3$B_+@Qz$K2%?7-4a_Hp`!F+Z~ga zz1Yux*e-jqpV!*}BYDF{H$(A; z5i}x3(Or4&D`z8y>@3EviI6CbjL?KKn2D#GVR=y1%3W-!`g}gJ<^l!%M91WyLH_nS z0Tnd4@6hhml4OyGTTR}_2VfVETf219FHYY?Qw@=&BBtI?+PpTayUxW^trL9{Prlgo z9o|WxkOf&7QIvvA&{C~AefDi9QDD&(YKajVvr9-dzp6gQ;x>fxJ6oc9dFkX@(408n zqm(Y`fHLf;f)-~!yB-|UXXE}>(xo@o7C4IsOp-{^H{cBp;8Q>x4wIhw(1-n`1*7X zwMl<9rL?_UmW0RX(>T{)+Tls{LX&8+WSzX5smz)5Mg+p7$!b<6->UO_cChdD-#y8> zCpq`*V0(73Z~5gva{gX+uzWu+NEer_rZM-1Rq5D2(LUO0%Wf%M$P6_G?|CsS3m$9~+sr8$TgB>Ui5AD{M5oas2-%ee= zf>&06gF>(^Al#cga?#6cdcNn=77KlE?wg-?L3dKcOu8$zb+mia-O7G76$M{GX_X9= z;cz_4m`^l{FSL6YXL76E{itb*U06734?5!g{pt+$;l_gfE2^y{{yT&DH4f8ngu zHK9dA$=yjz@hIU6sk+G_>Mc;>sFp%1TBJHwzA#LNa!!OHVYywT zEK0xU&AMo7D5G94$=!;2rq@QkCGV|Zxze-RTqgHFiuMr5<~k5oZJb-)0v(uKT{|y% zVEC<`uPAeQ=t&>fS+5nue$~d?1Ko$%X>IjrZd(Rif7Oslf!9siV{6hUWxT)ZvbO%n zCvTQxL`yWWlU|dlvFYDgU)~wkWiJrgwnUZZ?KO?3cj{Q*PW)#>rR4J+`SO>}vEGsL zIWCsr=Trh<)Y~c7{-bFqp757HrO*BX?P{=<^zBsJpYY)SLmSXPIMW|g`@D!0Z0nL;(9=uL}rF{R2SE*(kpV8W^+wV zHy=LTNaNe4MfI;eZ~K|ocg5lep-FO-eyAsXuao@`m?7Pa*#ajsLi!l93+UK#% zl)=oHnszBrNOf91xvdV*%gMZU|1)hfb~LwXa#aqwfAD zNPEnytCwI%bXB|>mFO6UhtdJPIt^TI1o1yW>kfZfvkxyCbmv4@8Gz0yw&|a za%i<78LF!)KpeZ1VR~cy7L$HMrY5eX_Rt_l8FUTUEra2G4x`twlALFPvv!`)bL^Sb z3I6f;e{!>{7W!F@Gjs8U9z(U@&6XD)L?8Un$BfE158Cp~dpbggQmd$IeqE4tZq6Ff@W+}=J7lQxEuIuQVpb$qyB0B#7=&s zngb}N$Dw+*xyI+7Z)TAO?w8FRD#59MoU%%%9AkkUuUn6JVV0nbj6A-AzX=x`S?`Rp zWg7O)jn$|z8lnIzwEB{~`LHxZ6J6#v(G#h*On6|^yd%fxdAg$r{gl0VWvDuhqevSs z3PTk%4U<%XbxnmFhpFBO>U!rg96)$1p)~MSS#CQkZE4m^rreh}NIDt{87IcuaHA9z zVW+!%vPOJ(zSjge!!nhbYe?j@WKg`rB+g{{L1N7zEKiig&V+vQ?OE4Ghj&NKM+A@b zpK!h)K4|30ZG8Ane!JowgUIKzO$iXsl0t${lmF!AfzDD!6wC{8%!V=~9?qRecfgt+ zi$l2p*{6l?Fa#q-rz{}NlMSIu*YDGc-+>HVK;SHp{{Br$eT2le1|c@y$}ORO4X0IU z88&E`iz@j2h247(IAe9~cII1s5_^S!1*Tv?DsQX7dCcy(5D3MD357th$Agga#rsOs?Pnf!uMJ#P01@$lmzO&DS_@i6KQwx$)NI+1dpfT zH*cL{A&5C|dkKrGn|A3dh75_OMDZbA)V1u9tS3rq-WrQ*mwp&U1z17BN$X`GE z4zC&N)0m8ot$|7hY8n>CA;&H}4%BcW(ZiWwsnu=Ulp9J-kYvx*l-FK5StZFXBz?E$EDnIS0L$(#9^#z!r@}6L4&7uVXuSEjS6#KkzH&&FEa!?DjoZ_JttI_ z`EcNVc!*KkCJw4&wQr6MQj@{Xrs1Z(5G4Sccd6pYr=VGxa^8oYb}+ReiyZ1CC(F2+ zj=o95u~t6#tml}Y{R#xMX;qR}+SrNv zT6%fw=_5ec#8=dkL#0>IF2hoOROkpz(W)AK*Ecy2B3I1)V5@!#E66J>BOD$y-1$J% z?9nz20c8(?REfh|An3^zV0O3y(XibAPi~(w-3PB1To}i=8gGG?RS?O=2e&{BYgLh} z_<38P_jgJY7RWb)`U&74F7^ZQ&Ald4V=}yU%ku?OUocUOZQO!yfY4GtTwmJV#TA!P9ws#rmKP5ze4JA29P3JUjhHVZd#KFVd6e<`keZGQIQF_Ty%yTHHlJDBayFpAe zCk-y)dX$qzgVTj69Ek34=%yrgHg72~bc6R)(~#_%aoLNfO&{~e;KcAE=T&2G1z^S?m8F;s8zj~67RaLu_FzWwoltAi+rtkVsSfzf zU%-;C&3Bhx>IZL%wQSTJrM{I)^T+R>%xj4r|%( ztnP5;d=$-#Q+b<*!agCZ!6ciop>rP^Q)LYHLD))yPTnNEL7Ha=^&^(rt*v;uh4>3 z$NqL9yxh!bdXmr`M$9T;mzaNu%}UA)zb5$}3bQQOxq|2VAu>*g+EL;aYAj-aHn*Lv zoR=&<8@blJ25X}syyNVTwnEWWA;TOVJnU4=1NEqdG=cj?df_*11wCh{^D_Fp&Svle zN;pwY*}f0SFPswPo}V}vcJVN{PkWPPzCX{=ycB|d5|1XRkshAq^C^GM`u>#!b_qNP zbH)@6KS6DQs*O3yt(o<}25q_rDs-Pb6kmJ31v;{^Hro%rgmxW@^xhQZr^q!(r)3(= z%hEowZ?d8RUhau_;V6uft-;d0^y$j!@ISHG{qceuXnA0?Y~WhwJ0V(hA`q6A=tixv znvulePsTIPD<9aK-S1zZGoo0AoFLh-4AaU`pek+dSk#^_BK27ZdwMw)%5Xr>J?Yms zvb(U->s9MSSY0F3d*)f{)7tqQp5o{0b2SF~U}8u0!H@4}R>DK?Xz2D$zRe7nd<=NI z?W*av6O72VV3qRe?!6qsDR{mYGH^*~B|geg5@qVHC!XD5a@W&5+#!*( zRy=_!aT5=(uk??Iye=}>S?x_oV=%Y>sHS`mj=7<_0Njbt3L`wQ%JfI=8qrr|KRfaJ z^SVFnuw=(n3-@@h&!<>Q-O7ZgR3wv~1xBxW_*zW7t`YCnjwVrbO~pnEbB&`y6v zHPm;%OIr|3&~{@uexx&KluB*xJ59Xg|d|v`I?{J?Ug&!~SxRm#o9% zdM@gw&NEE8tFS=*_$p{~>myeM^90TvvewGUp z3^)&D*B;|ZyL6O<50=%Ax0#-PU#zIDI(qta*-auTcAu*e)d-Ad35WkN#av?8Iq??+h&zZvUwqFewGS z@i#BT&3!*$$yO&EwBzj?KOZD=Dt$~Sq0m8UVoj*h^SE=1F&rE$5gx#taY%N5X0hy$ z6IUf4Lt#eh1qp@GYg$@RK_c<{@al+z+P0C^>w1qYC9O1-@AxOa@hC3Nu&47K*#dbA z9Ql-51E(lf7&_O>#vUn|*;J1o8|(SyUFlC3Kua7iqN|LDKDJ7>5BWAh>DTVLuR+1mn2yzPK|jMa#N+;x#>MJ<27JYG zAE!o~XZ^8L!;_JPeLdruvsx<)-NX2K-g+`jP%nN#4Zq$jaIc0F*P43wi&eqYwrSw_ zE+5{rSngokJItH^r!AIhR*7m>pCML^E|j9yJG7mKSK{L0eqRiKJ2Bar!@TF>zUH>) z;=W^W{FsY-fh@)5)#l<8`fAt#Df@=!X)&~Q*ih`$Mr0L}*QkIV>gd%4nP{U87q)5k zJ6RsC^y_*XsdMmS5iCzpk=1NRD=xYr<__eg6?na&JLWeTIfp3NwYYlj?oBleTRaq#G1WMhxeo2bk^-~l z0SqH6cj{f~ePi#+DbASAbJ?t0Qm0M>(;T$8#Da5R2&Gb10%%F^*0CVowa_9AA3-}X z!FO|{kF$kHO5rnqQ~=p!zrvLa-+0@LeTirIA^-Kmxjrd}=h|V1Nm7w?kCka2(Hu(m z_SR>g9my+rd^sxMdhz|UcW+M!4|sjQG9pyyg5xFkO7iBZuIr>Nrl+F4FE29ITKla^ z9PpDSnuKvW-a(raKH`XO&w0uc*LPWj%wj~!XBIr;f0*VueM_khx@KVrdv-KWiY~}UT4KTT;_;S{>^1L~>~oIitk~}a$kap(uc3c$bm88D$hlV=6GE|L$ZVRGW^7X*yJbHh5_1noW)J+K8j*f-_Tuo@!}e$(Mi4*~yh2r?$@=XwSrh?|XWqb7nWxAnGl;M}?+ zcZLnoi)Yp=8qCX;PZIl{2-msvf{@6$!2Q=Vv}W%n!aNFx{87Fo98%Y{_)qwyZHe82KPYdpt# zl=on@(D71t<(8WnLAImERGR|WxpLrHR~YPX`Cb1MG)!LQ;dt7KAU!Tx^9<_E$?Qlv z4L$uWkj?{%aU(RI&w$mkH|{xUgzIYTYlK=B-1g$Ogo=pk;2n z@|pbDIg%dLIf#{ezwiq9qTus21bqA8N7oOnE#y7yqmq=ie;ilaN2c)j8uH!n#370q z70RVDp9l{4QCqgboTtbnLuuo|yO(sN9p{7|xJ1;rApZE~Pu=Ct#NoB2EU#PSx-Ol+ zTM%rIBwnHK2?VXtm0B-=A0?m=Ub8t*t$mMCnB3LMtS*sQV|XA~hj>|xH+ZhtXsF1T zkvi5DS3MM(X3ilmSWioMpJlp{{A#NJe*!XbQrTRsTTEz*KxI913fZ#+)6y>_3mxpe zC@n+voh^M7z(TC7f z)l$@%dM)$&0^6UDWDvf6v_?-Kd6j>xR305WKtEtg#A;m=DOHRsrK}y858*t~<;U9h5wJ6zRye=fiEfx~@d z$b*Q;g%im4PpuJ9G~Up7yCsz$p=Lwj@Qr=54K!-|?cwFJU@^I_lEU&8;s7j6RW=6bn!-I^pWs7y)h`v0HZBafolA z!HdVy;mg!TL5qN~i_nuV(RY5o1b)V|qq;|V?)hwi?3z%#6Z|$zqks_;Ol&1f-FLvB zN|T-JEt%m*3hYwkkZH5^oGht^lDX2V`-8HP2($&Z;`J72ofXI4Evz zelWiH89A5uF`{I>K(Qk!c=u&Nzf;*(yc+JiUuCRCfSv_Z9#3H#?kTuzFL$W5KnI*;P+T-%pWQu6$O z=jGZPq$KtPAcW6KI!qqr?wL@QkIyqZQ_djyj?*kDw%P2U(}jiMLF@2=ULmT~x;urP z)FM*+ph{x#9=}#Ns#X2Z;$dz z4Bpg2nEk5iwBYWMxPb6V=asa}}-cP-(j|^vaa5GQ|NKQYqDT z;~YVRne`O8NZpgy-xDEfjNKDtC*#H|3G4ttp9PV;N2cS<;M0t?~Tc4KRvn zwbJ-u!V@xZGfJcGj}Ih*Ug!+UiAN0_K{u(juW+2S4Kvz!(5lthJs2=Gl*KtpSkDXUq_h0iW2!F{=^5JOz( zfzGDV<0uj=DN5;a=F#)VuM4!phJ6;M(LUHqJWKPB1VkZjj!L)FuD(4$?8gH|4-4>N z=^?)OPAO>_E^QCfI1kOS%qrcrB#0xu?JsT)GfZWPvZ75r_K@G}4*+idjI~;xi}{=` z?O6(j2vD4^qWs${H#sE*_DQ@=ihuqfN+-~Ef3fKhxOPL3{jz1#QAz4v)IqIf$M+)G zc|B8j(aNM2FN$#3DdO3wLOr)Q-#PR{guRe{^cKh_JFl#FeHlT8c1M*qN%?AWRkn!R zI0{2cz}zl60GMQn8X9||xzxk8}v4IO9*v8T$ zyuL`;U zG`~&Q;bCF`=n``CaQ-?A!OCzMSU_uC%iVOa;qrA2L)wxGg}Mi)w6OY z85sADtPwgQkulnzWbl@4O!u;$hNG`@tj`*=j1%dCMNQLCKuBk_48GI4a1-o8_ z=31ERuL*m!UYbrG8vpT<=%eKb4Lv+e@Bw1}5$n1%h%1C(c2hM;Hg)Q~U6^LjBNbW6 z(ONV3$D6|RrQ-Lz{@DW%3DJ*PY~@eVOT=6uB_d%?qJBVq(23{R1@%h*3QAF8P?ATq z(v=y|1j}U7ZLdC($A?txX6Q zepao-)Y(=0CMrvF(N04F!-TjhQ)$pye#g{!tri46^4>zZ{dq*XGuSrH zwyGk8FO_uTMnCf;G$*ynyj$QrjSov=Mns|gCxu~guMrfXuL-NRe>gR3xc*a1PQsP{ z$KHEDHMMQ)<3UuEYNMB^peP6^O++9f(rolzA|f?X6p)q>6ahiHf(k-VdJP?Ep@V{m z)X=;1l2Ah$zwNpAo_o$w&pqe7{~Q1J-Z*1r3>JH@1=(w_GUqqv{ATFJkTm6pK?{mY z&Oq=9+~uAn&*Q$iJA+q}-b5g?opQ%ZXWwFU2^|wl^%mmT;(%Em} zcBSiqXliJSy$LkBLcX9ent`%W4i8~9eCqSf*wFI*b*STWx}FiG=?V!+Z*tw6_~<+3 z>{8@YlN=v8r@b%NZ*M2D~B zh{-{6hm6&xg$Ee|F5{!<%g^gUv?5@O5L$vSA+6TSJg;xfCh+jBTb{vJF?6Y4WH!-x zWR?k9VByYr)myeD@Z5O#aQd_mfiLd)Ynj_CoH-*~{86WG z|J@jU!xaBKlHyo|#|2{WRAA_1_dFR`#4!7MKWtB2nIy{caL8cB>6%XA$p{~RITrxe4b5k&O5+h_^Iv`k& z0GKgvlzGG6HC&BKJ%7qh>!!q_hSX~6i=+h~(VhVY23Y)Mq7FvogJrwEyBtf#U%a(W z=Z9hLBj{W$>)v<}MlxVq)}(ov^QmjgWh;)7M4;)W(2TA4l_(tP%ypADOTzRtRy+q; z3%e9ihA7j3mmn472D#*Macn8vUotCR!@zc>_@3hz5NGhv62u+iSv>&p<<)4DTDt-7 zf_`gsF&M_}fYQS$9psF4BI4)m)&so6o%u{5Fey2ZzQF8iLfJ7*YWOzxA+@7CLt@rT zR?RuLB6I-@tYhuR9>P z0pD6MUgPQw=y+}!14}Ho%l$weKX7|<_i1qGy&cez_2eEZ*Fr?z_M6i4r|!K!M;umqqnH(eIp(-tBA)K)Z2OJZY476)(cuMclj zXI*Xf+j#I9ZkcRvv3Z7F?G9w|a3DB1N_feOWRAh2X(>r=+BTopT_eWzuVv_91%$vI zJ0MvcWZ=BsNd$|kIy38?@@V<{m)}spYd>oJi4tFwT!xp<%9PpNKX^uM-)!f(nbpe> zu0MZ+D2)k4CjpzvB=z*1dKOsDUhF)@vEEZY1=K2gJaEu1QuU6@0ta zH9(14D|3&KaU5fa^T{1x32_a*uF&{sjxmt($axa4t&BiJVc3CtAFGS@W;)5a?@cH; z%Czb~8E<2Fls(3+SSP&vpgXwTi+Z`dy}$kHl}@+#TfXK- zy*)P-W|fDK@(bJa3lJOm(}&f2-5$|++L-9cklwK0BX6Onga@;LlKwV$4IIv;4TZ}@ z;lf7@O`Ffk%rL?W6i_k{U-UTwKIOz#eUR8b$`}8SF0^6J&8_@%Ykma!-|2LOpqNz> ziI=!~akJ62&F&}_ch4WZHBwJ72!)_w3xgY9lybTI6;~{%%T>g| z_J0Ygp@U`LRji#%M~AVxq1j*_yH<3&bGb)Uov3+a-#>BDgW!(4%qyf;>~!SGvJ*QK z>yvubgBva#?WKw{*?V&1UFdno$B$O+w8AimoR6UI2V4zzQ&bwca+G9ro(eI z2TR?OMU*&E7_nH)Z}4|>!msdmg!h=(wjhQFAUkxZraol_(0DV}pLfwCTF^6ON37d5 z^b^^zNU8OH&7qb@bhX9HWwbgai>f2S-{9bkTrPm z^ekjR&LuKdV;7ve7p{#rpNE}%mHb+I%kx4#x(yN~kuZ2X}BrNS{S5AmPp0rZJ@F9+NGo)jQz=6ql)-UyE7^)U#c)^hEx(b-=d#ha=p!Gocuk35 zSP6WeX~2OZ+~BqDA{6nU)O!=SFit*k7lheZ8Zwh%2U$N3izp!&jCo($?ZZ=a7ul}e ziJZNHHRG{kROhj0J+Ma)P?#0XT<;~H6S$YIdx=$-8N|ECt)nTTA+qU>7D!K12IR^* zHCn`0aJP~bmeNFmYL;uZKfrqn&* zJ<6Ux9^|isg-!=VS{2QCJzpV}ee!eP8MrbACx0KhB9Q8Mt4cF@Lqw4J_{M#+CvgMc@Xr|>;VUG? zh4N(c6GcG4MXbEkqP9(`%0TY4D(79daRa|**0t&-y4?9lkC-myV503hHeWqqnA^VM z6^~Uu*590k$KcZrsEDs3Q+dMV2Al9)QkQw-NpDw&%;h`xVw%laJ>>40x<682gN;Z= z3L1un#b~s7%f9})j=jn#@(W=&)w(wCrYM1hgZZ5ww$U~^0pLY314vrcy^(zcBeX~7 zmH6AzvPKZ8#d+s?ivRq~`d04XB;8}l@Vx{&mAuYd159(`AITpi?#ktVbw63cob^yr z!#Vl7!kA7nC5}8h)Bf?9bbTuraBKM8j?KTuuq~cyX2yYqKIHr3mw44|9; zaQ%kfz;?N<5C3wvqBh8 zJu$uKD8s?DETk3p8R+lyT7uBHCg&4eOW*Ciad}$(nq_<@JP#seNr>G<`Ic)Nl4VVX zXivUz5lG4Z)T3Ysj?E|E@Ybj?JAKB7S7e#ynPyp(cHfLW>I_SpA@yX{<*z096#5V) zNizAFa!0ZAS=^9RA&(n#MSxEn%QUQ^+P3YqK!>Y?DWlwZrn}9&O1a~x)cWmMyx4%m zRdq=-ZUb5trh1ce&6*4EZ07Q))@5S-K)er3jJG{aVnUdtPa|)pa0|I-bQ^nu1ess5 znk-wNhASiOYXq~>KC+AfLD;fW)ixBf>`Hfq*X>WxONP5QT(=*R*^x6}9p&}bd*E7= zyt)es;=NL0XUp5&`Bj=pzTr&hJk;M<+YZbmsrHot_Rj|(^ov;qxh=rp z#Y1d!PK%J0lkJ1gIxZ!!gWS<_8?eg3xbwZ3cHnjW!soq$llN?jLui)8VE?#r0tp*kfrEe>~Tum8LpH&=~+0bY~Q$HD3 z?BA$j9Tn0OozS?}tdH>GKb|K7JV#EfAf!f0KR&UFE5g zk7KBhjql!ao|la;TD$O|HT&ti*Uui6Ev%SpWy5#jrqkTyhh)Rj9OOQk6)YTI78DrE z^&(;45|FA->#2NQ>rbFwMl}&DgQcFdG0k^hqnfJN>xpvaVB97u`7){V)9yf@;fnV> zB^U2ZQKe=v;EoAEF$*lB9A_ViaTd6^xioU=Oa7psAU;Q^Ge_vuTZ|MT9I-bE&u(5; zal(EeJ#P_AQaNe(U~R|!`mcx3t+r1>uaFOy#<2L8TSOe3uIxM| z|NMOo@(lGy&CUJ3mTx3cEd%ytbmzaRz<vgrBq=Re~!f3ji%WCPU&h(&%0X95X6{_@{DqGjNK1TuC$z*00O|54?g z8G)v#dTza#(;7j1Ap$htdVp^C*Ct#P%f^R|jH5ujJ<9l}dK$pXm;+w^XQoNJE#!hK zsd$f~=0Ar4dXdm>7N>=e-}qAb>FMF^0|n=H3*l?GEHJ>5TZKF==j9Bud~f7Q9mCV6SA^P!ue-hx(B!H3b$#gQZqg@ zM#=c5=Mfdh)~-pj=+Uc#Bcy5wtX4=ayP(4bD9LAjJ(r_Yr?w0t4`M1fPl4cT$`6ePlO$^uEsQX@U zDkN_R4y|e1af!Z4?8}LXw%n6a4v(%^6ox{jSCz>=e zs0p!x9dRS+58}gz7r)D10_%(@pxVx$o$>g8a;74AZzpsDnw%juBzKkjN^E= zVGYO(S!I;hOVMztY%`iQb&vdKi|PAzK%d*(A%*b;=z!v#0s1gce*SLO;}}kK0Bk&#ly(EPWNelKs6YPTHBH!Zyfm`d z?!gQ2TJI5Ln1fGwqwGVB@u!JNvfU_O9WDs z??pWB+3}2CP!pJl+}IU6z3?i z68?GDcH4x5rnJlBGAk%)>Hy^G_z6Pbd@l-PC zv%Pq8ma#L}g>L?b)YkNc4JI>4pw9)5Lbdq4NoTx@(`b_7FUx=z%fqTQdw$#rszlIe zBx;1LKTNmNIYcvfMyw&CG>K*5Gxjs}Fy80cr2J8PF5L#-2dxZv0g>5y;=0s2;l((Rctj^$dmRiN+q`%>0@M*NjYUR}gFIzKY-ogAX5<}Pl4Y;k9E^&HK zdju-y1Lu@M9C!r-*^GxTkyOmL6OMJbb|9_QqKAm$4{Wc2YSe>O5^W!ZWPfmNTv(Cs>0pRTCXKy_lq?^ zIB!5+kDTnGwUN0N1L*7+McVb;L(nHa;<3mJl{Yf?esX?sCJWfSAJNU33RE8;TS-z~ zJmPejUXP0!8Bn)(vvigtnaTI@){(MIDux@do3yI3kDVd?ZoEEkveIxX&0=hJhZDQ4 z!u5;BBwf-~X(=zXu=8BM(`gpDpHQuiPl%9W61siqqLn`(if!G3;>AS-*ZGKb!fle7 zl&-#vVD7i@5%90#K$-_&0&%FP>nP4STFuT>0ooEnXwWey6)^Tq&iqKu{I|RI&sYA; z_RZREZ@wQ#Eu1)2JglK{t@XWy;qk-pj?4h-PoExt2{+x$_14B|1a6=XD(B97d6}Cl z(bpb`n-0~LkbdAQc*bj{*k$0wBRC|R5G>-Z)781U%AvpS@u;Nzn^%Q}Z!TD3<+Bn& zr$8XU1T&FdcA_2~F@6pLfEI^C#naKmY z#J&SMj)??3_tSPjm!ukfeu?_ML-(&xud-q(en5hijz}ykNqz_P;W8i{=G{dR#bv*G zwW3pJf1!*Ko;IvevKq_VYA>ugr6E75Na5LoW=IB4-Qpg(Opo5&0lf}^O^6+C-$b)5 zoZmguhKb(+UEsj>LYYKju;b{!NiE;Iod9)+C3#^%EFh*8hQrq5(`%&d1OdvBb5ysD z7xmYyiV3iBLia6h$!B;Zz(*oGzmS!i3!qcy33HBx@Us;WAumObMR@Z92fzIqGAw4{ zd_6W0I~N5!XdqV(@cDMjK@>6f_f>I zIH-kMEVml2ky(A?PJSqbD~5|e84QL7lneT2OW4xS<_$J;@cEtscVebHMPk~O^NJPy z14d+O)@d$Lqqn3Z@0NIp_-8Vnk;XUCCDPNaXGP!7)lz1i1Q(f=mj<|czlL{=NZule zAKn2K1mnX8M2Ai4W#vC9*sgG$MZDS%NXE(@%}eZ#IpgtsGhj*gP!5HUk9R8-ngWV+J7vKX)93E9?(BlCC=`&@K^7d8%;WeyVy&+*iku( zV>?c0qrETeGUcl{a_Gnos5lDoaJsUvX_Rle`|flX`5a8@?bQ_X&HKCG$v-$HaC!#> z6ClyHdD?_x+fzkXEoVSG1_>mlg-PiK?;GL0z=KG|poU*M%|Xo#4F~695yk$=w=cqMV@^dN>Ck zUT{KkHU+BGT*r&Db5q@(oI83Q_wPl~KcdL6Dyj=TM|N{l8|h7$8RCsUMW<|OH!F;K>G=kve&SJG<25y4@ z4?hRW!r7?<9s-*uGmQz}Hwr4RW!V~EI4raMfhWYBh*dXZvj2IB{IWu*?oA`r{U-ZH zM-ErVU!6REWP<%qZN901}#vY{g5NYjOz#L!%3UM-4Gk(_CYr=bV(2p z%e1iRK7a{&_4vF(^?(KtSek^^qySRYlyWx$S%df^(_I&=2u^H8X2}5fO-PF_E|JjNUZbV!fNu9@^JJfKpr-mzVIKP!VC=*z(FGl z00QCb19rdp2^*&;T*e$gm%`7g;}SwNpn0_@(q{4IO2B@F!yQ2jn;a55AfH~$Fs@dx z&g-1KPyJrx$^iBQL$W8J0}x_yERLh1q@VFsO~Ko7{nr#f~(BfvPT%DZojVvzvG zBtJO{I2Q4@Q)nF_>n8u<*CygUew`wI^lLzp#rVUW(hf;oyezx@A)GX8@aubsE~qPZ z_$R^Z=b7`h!s_h$&(F{7?mzLo|ADNEn4@?>awu0d#iwlt^d^?z*MM4;wBG@3kj?|R z;RMSeS@}8UH?T_<_!oi1KmO%kWR$|wP6J0~CYWBXckzR_4;gRAZTepz z_*u(KzHg>piNRP?-rV##+8=&H{2Y+z_5@n8&_Pwx1aYV%CEBKpi8V8UPruGD+yV{eOf>Rb9W?=1`_yi!Q5>})IMRdiUtrV^uEUTY z&n)ll(k0l9?ef_}xcJ7yzUB0WiLI2pk*}S=EB9v3b!EAGlnIITIp_@n``EJoc-E=3 z9*4y44Qra@D63H(n~o#+=B+2~T`7q3V^F_x_JHiSD7_Ltot~F_qtsu(@1d^fG=oR@ zAvdE(+fxlq2je^!9a4NlIFf^m0AdG@Tq;7mZhC02-O}OA?puulS6ft5_cgk&&Bd@w zPmg$W+uh>dd-}M(w)|NY;RcK_99&S^B`T*h9(T{tq5Ff|9h7t8R5{Bye}?%>9!m~| z6L^y`N;Kxxy$LYm;8PdJ)N5G+B!9XSpOO1{uddfja@69*f=B5VbJknK4-l+}Oyb%z7vBY{9~VrJSJhgU zmw?`BK7QlSHEz1lZt=VeyZHhzAHuH03dBgWaHm_{y1!4J3Gs|4NK*aGUB2_0Ej3dI zytuZLemxUxe=`$eA+|cGC(@Q(*F%s~>aeymgIe8eqgRUTtc;eGlb zu;pW&YC$vMTHW5^*RlQQ-aoq%)l@s_#+VIAPH)f!mXRlePK5e3&2t*^JYrG$X6nS> zO#9^-|Ev0+Po5#%gtV>RW?c^_QXoVcG$-XPa1tAILKc8LFtd9rZ8m{$#7L;x4hRh# zA&FcQ)xUD9GBx;h;BfG-eXiKHbLt z-fz8_Qvx2U#=_Xe!;@4>F#vjrBY8pZt1U`~|ZiKTC z5FXkPMo@i&p66c&94Z4t?Ul2d0JFkmUtSaT$aS)g5i2siuURI%rDPf6hJG#8?#CyN zX9+HjzkVXR(%^jIHTD6~3#Uw@NpJF-WU-&PW@^JZJpvnzKcyaO84-@_PkFk;&huRK zD&=$EBrhxy53UPm_pt6?&Mg|hXUEanZcDwLzN|*7@s13hf~(?^8b>%wyt8s-OpR5< z*9IUjGcQId;P|F)mjNSx3hy4^kTAb+lbtOxq;fNSS}1HPyppbrBMZYssGShopHuZZ zl$RQPfL_E(Gy5sE{$Yeq8DEckZ8e9S^0-uKVPsNu=UW=(>`c~3WS_G*3zmN%mvDZP z?n&jzlFj>)?nK>7r;4L57l@IV_bL*nybZd{x$%7Q6FG;NOs>87So-`{mUBnmeD=kI zfVjZ9n~Mmm_u=oV)O)L#Wp{r&W;KM>kxQCaFYq>mIC<0$dc(u1!OK0k2q5(og^G`8 zJ<6$9sn5(?1SBofI|pFK#aYIGBOt$$@&G~a`=9^K2nd#M6i%^!H4mGd+W}2ZK)2f0 za#P!>a=?C*3nOQCA{vPX-P8lXo+)-2K%L=WqKLh{asOXcR{u{U9lw#Zzy0-}8N&W% zZ2ZMK`eTfZ!KX5R>Fttfk6PVV1x!&E;0%w=$V9$BzD0cpp+18B5T8^)BdOPWt^jBAApn;zUY%*KaA9cx^xd_A7C^=S3@EBr=obp|gD-sq zfOev9SG(PbRxE(L{OKgGJG@Pe-2^{Mdv zv$r1}=6k6ryo?ZKDVSr^pSsn!>!keIL<0aG;9L3#Idp9Y)DAlZ=*yR(lo*W7cb-fK^lCt(nF}j2X!v5S8KC_K;2E6~I;9$j{@N zz8^#!>cqdm6;6q%iuziBxA^-Hmu0WR;2^sEK*n&~U2rxTTi5fGvBqW28Sz4`pp<{_ zse|X{{C8nyI>$(&kyef>jGD(SyXf~I+EZ#b&5pMWg>WQZX-+*tzb!aXTvkGOgFd$6 z45kv5ofZIKLBCXb^oZ1y{4y*;Pe5w44xssMp_&&Qb_~unO~^w-g17--~%7G-;(+1PLY}qF`Gx4duq^8a_8v= zDs_@g9zGLUJRP3(5bA^-+}Nc2Vom+?oHFIz^N)}I3kpon4%u7$wF2bAYx#C-`qdTm z6FER~<5xigR>?x-to84M6bqxj&Z6<3P>Szn(fCg=#BaPm?3)*dsnrdr{V z0(c_b37zeWKWL0lhH4pf>uM?U3zZ+SV$43P$a7GwCD)%*Ntp3~>TYfEtT!r}E%mz( z*0SR1o)i(*QHSlzU5!?k#7;hRna$Nj3IV{7G2BZ7hzFKEv;E-3vrA>`211Z%z|BWQ zL0+(7AUB>3UUBV1qA5{08pt(OKrr)h6ALijy?9@L5U^oX-?jX@S{KCpu`}8PtHhhl zCmbpPw5|yPYym%L+yt@pFoL_KwS`BncWWZlqOJo5VDob%rMlM19EH2^@YJ_{^H-v5 zw!hju{~oq~jd5;ndHMXWmeVhUr9VT|^^>^i(f%6;fk{XalpIV{rTCyIAZ!Tr7tRI$ zL3zFR8_ulMpJ=guJ_!Ny{S!G=M+dl8mPtas`A5{VNWiBoY-oUxq+cq3yXqB0@Hns$ z@Rk+hRdO7?8okARZYm@0;ifGh_2DeCuOC_-LXPq~t)p`lcs>de?v2mrM4Y*;L7H-) zMsGCNzXB}Y%yM$`_xFSVdkZ|Yy0hGCZXpd&A3yoXd^}DtgFjw7^BE93G4;UNI0NCa zJ_r}ZT=tBy)kKb3RBsxup~58gVc4O^QFi&VWm0DS~T$)?}Oj_U5e?3FK8GRyk>H@$+%zRr$F^4kDmhh^b)lh=#mZ|bXQ)e?Q}+l;a#wUj+Zm)Orj>Fv(i zOnXm^AdAS!7xZKb>5QdbRTOA$1;z-s;bK zNT8#O#|!#MO!Z&g0o~LCTq?$VXliHR>Z2js(%RKs(NIe4JFu^_=jb8#NrfBF(d%Cf zzPebXXUz){|DCP~V?h`liv#>sH;Jin`+}Rbhl~X{3{y-Un-h;dqDyz|Sz~Deyp9J5 zFlcFyWZxBi*_errqjil!lMm!+b{~*edVqfEbDnS#TW?IkWTe&|&+jf}3);(e+JHNM zcHhy5^W4Q|6qM9lj+~z7Te-kRY#yiH{y8Ccu$~AiaXqWLaJot=Ef_7S8bOKOq!oH2 zf8yrkd`jUuU$pxs9GhB%*PDK_3NAFSvCDCARl9E7myM=e9IW~pzn&p~wvO4KV=4Afd2 za<(`l17`i(iSg}J`Tmux2i5ba1^p#t52W{>=}UDpqqYC)pL-iDw1g(2nsNsKV;R~0 zr+QK)sdYVlMPZd9bg{j%`f83|X7RUD+8?{3tw;qj^9g_#o-O=TEh1HKBvA$sqr?vC zlEMnb7Kr^$Oc$d6`mnjkMstxOTzpk_sh0Y=gv$^4`JFYzO%mQsu4RJ{6H>eCa3T$}n^0$K(8{u+0lb<=fG>33unXuaeT#5k{;YGPOWjB~ZmqFNLnXm`}_vHkue z{TGh%w=MiTbMyayTet#1RAX^N=Soks`k}hbPa|gaYzS!rL%t12u_?Hx+m0fC)b;(+i{b-tWjyO3r$PF0q< zPeo{ycn&G#wD=`Mz^kMzRf2b|mS^^&1xFTgwvn7sT^N%bIX^J{@}qnEZkNQR$G39; zdQbLM^c&&XtHeXV)Hay7nH+0SAL{j`FSIv&S0vUIRRPYT|KcMsubu*z!RDGh8Meip z=5<#man8!VY4VP{od9(J;3HpSPHz!>}IZ;-q&Bk0nsnbCps*H35K z#uj88H#F}b?1DK0dVhH77wDfIO&z3-h&q2yaof3tiLGEHNJZ@pO0jS)C{x)zRlS?{`PZo0xWShHa09x$@?P=vA-Zrs}PqKbg9?2|7BR(P+QUypHN!s` ztf60ERWpnX=1}6VOi; z)%{p)b@;g~ySSjJk;NN+{dX?WEpX@>w*aWMf#JdT+ zsOKtq_3o9(azmed%oUJNe(a|G*K+D@<>+KWatwqqckGPPNc)lf;npL_D^dVk6wii0 zKEcYJ<~HA^N8)vF={4dpz>jq%<3xD9@H>VBTZN6gEc;7Q9ZVjob)ga@g9*o=gWB4h z)XoOx1Vd2?f-i&%7w*qxvx#mPK6E@eS%Q-CgjX)l)CLdoks1fnOSUgTgUSVz)zxfB z*AB>f-g?(Q0V2Z|h(s!;`Wp%8RF+@jKR*9XbpMZd|Ui;qRxc@J8-Q{Tm(r1Ard?C$AIJ#`T`s?SL31IShG<%i>V#oXOxM zgB}QdwuuJ8BC)RKOU}n3qFUQg3Ku4Wpm%!!SOzc=HK!667Smimh#G882*w#2Ry`Lv) zPz}+y7fRW)@aM+i2d%#nm;kgdU(Y-s^PGtr?^Z~0>pMe9o%zG>Lu6US&(W>^>Fb$3 ztcE2hT)m?I!&Z}5W$Tf#ibN@d4lc8?Xa^L)#dwC5DKKt3? z*8SdTM}&ZNgiokh=mV*~jvuX;|M~Xkhj{39S%ZdQ$D_#tU5FG7^h;X6%8EDy5JJ#S zU|zbSgUW{#)zni-S5eTjbb?f(fDh{`T_fV`9Q3f;yGIevZfr&?U~VyMP}bGR!XpZM z=hYForcO{p)$`Sw?Tz6|pRhl5wPOJ&vu}g(r~zSZwMvQPxw!CG_a4~PP#0|#DR;op z0HVQ~Az;qg>Dt!(@m+<)81jMSQECB83t*cM?v4^;oRhVloHjLkg@aUZ9Y7k*cPXzpO0#cF!U9B&uNE3t*ky-uAUxfyOLOqgjtXd|iQ7jv1qdYjafh#y zoEo4dtQYT!+<7i7!`OETBIwkDd4o=e&2s@k5(5?;aGlJ#xT{Z1%8qLy%Q==HPioOm zDsQCnvNy`+zA8#Du82B8M|u<1MF{zEha3g&dG$>4h0l&!PaTTX3==Anwpr#=F+~KY zjFVZo8O1Uck&=#Mx4o9bry!ZJ#IA8naxA(&e(x8KlEEwfK?~)O2x=xQBR91?7Klp& zBHn8&Pqa|jaKzy@P{G)IR8&VcPM?<@#%mBYu)-b}+D0g1W1A5515qSY{<~pyf z?uKBwu77dtk^0bs?Y>ih4c=xgh4Q+njhI`SB_477p-5zY?Z{x|QcWE)knCr?|+J6vvK7zq+k* zKV4jnR)%k51uO9sW|Yfm6eD0G^{!8cCJ=#=8$Z0mMMGt z*i-;n0`LsmvbWIvb7v39&0t0V`bQNeVgWXk+Tn5qbGY-CfM+|RN)?eA!o6XI=BB)z z4uT6N*Ql)}ki5c3dK~BHTg|O-H}{_;WTnXN(mxVE+UI$*y3OD7MXiiL+(hp4+5Lvv z?nsL-vO6GY)@kVOu_&kDa-GBz7V5*4z~>9(K7(GVjZlQ;x4X;VydK}td;lG~4K?DF zVpK?KThEe4dSaqaU;&*v8Hjh%A#}fh&Lg=1YK!PUrZImz=>N^U9^pA;bTq0O@AkqX_u!ir^Vc5G-{Dhm?d>U7W8RD0qE9 zL!0I9DLLXq8H#T~TJQ4%Dh>GOElWFR;`M5q^g9e`;M z8Gb;dLrv6o*Zkrx_&ru%}d$sxt6l$-VD5fQCIN- zNi8QkrS#FXT9=pfQf33QlDC(^vw7&@4R5CV#NLbE7aYdld34?X`QBmoNrnXnmFXkF z!xLfp$}O+Qc--2&Sp3L}f5w|vOv>3fsyZ?=%{Ozl6w7V^`=`@PTv9bLfPT6u-y zjHK+w{?o4TpQ(jSu}>v>2)H%cN}Th{M)yGkbT5gv{sS?5_S-_E1#%hWas0Xys%dc;?JZ&IXn_ogO^0);J=yk!vp1>LP@s%fh?0ECUO5&8+87K7N=| zdwJ=S;F&}>i*4);Gbz`e2C_b`kbtgnf6$A6QB{0=zF$?}icUygT^n$#Gu3ExVt@pb z>D(QhIK2n8MRT6JS!>=;>W)4`SH}9gU7=?^E;e)#R2%h;KMI*%?u$8kZ(7B}iX6^2 z#0cZuIq`(YGcth_ z$>02LFQ&0Ws_kNf@pajR7x$kHd=%%@5c1AqZg6Ma6a_L>j2!Q@=w7dQp3rL%(c-By zZ1{lx9Xj9jhRaPn+cW00l%eF!LdF1{mW28GeBMS|eScenPbeOrqXP@tjpI2d-C}zO zG{l$hTrh}mKEOA2XJ(WydM&LP{6xCEJKqDQ9&cS-^6X>9D`veZp51isI4^89r@-g% z%@a(y#b?a9I&F+{9Fo^Wr1b${_ufR{=d|D;T-GQd7XQ)buI@$}c`j=X$X3f&1wlj^M_Y$R0*R>9 zCS9+mqi$;>S5nZ)!gKV*%kNOZBWy@k0`u~~i1=1XvYE-L`HzWTR5OGOfy{kDgq(33 zJk)o2DQ8m5+g`b+AS}CuS=TEn#dquY?{}SMq4S7E?jvNj8u?#)VsfZ~S?+y1V|C=@ z5ba-muYKhw%hEiast4+HE^B)m1t^{VqTy!I2PDY)^KUhW{&Nn%r#Bhiz-?x4SSgkK zsnB>(ecJ3}pwKGwF4`f+*QCi#j4NRhzZYv9BgSMWk=G{ItSWBg!ukRMEpaNkX z9j_omRxIvKd0KCLeL*UxD8Xvz{eAS&v7_=eAKEeULVx}Bq+>uHdMjjQNRVI%B~C-< z$nJH!m$v`|s1TsV6|egvjzQH7qRH;K!UZ3eaQ%{ys!z|`_-VT9`bM`cOlFxpq0LAJ zh0-y?2F$i~XzqIFS>Ed+p+FcOE5;Z5JN-P;>czN_bq6QjuLv>@AnLZ+?JFZ5Po3q< zyac%(wlRTXtOTHneX39SD_=|4Z81!lWv*U698u$y0iuXs#0JB~@oD5^d}qQ|o!ioe z#3CPLeb{$XiDo{TcK!Vd)YQm)U|w3w+(?7Bv8aXXg5}*T7ERc~Q{h1~l@{UF)06K? zUMZ=bafr538eZG5NpQFY-lvKwChjCfOk*hH=$vHWip=I14IyD;725>itDm5Faf?Xb zAey7fv=uw;SVrzG)zISQ7fL7zWFegK2;uFtc#ScacNBzwi zOh%8GHt7!0!t4@enawc%zF-_%?%<|3E~^&iJ@NEqOPsHRgTydRYw71aTI#NzWhtOY zek0}m4-Y>ofGbUy@z<4mjV>4%OXSO+KM`4530DXzDUu6LqvQysc62@%+UDpbyuX)fNod zAZ(Q^>7#>&1F!_EwvSni>YGLZGq*vUryqXcg%#)aRv7<7J^AkrmU;=Cz2SswmF($u zYIFle@WILrEF*6G2+1A1RPmr&&zNnFzkM?Ea5 zhgSB?b7|9T#z3X}5<1bs?RP1i2oCJ~Sj5Iwpj4mOEv7viA>)tU9nH%4V(4=#JRKb= zNm^K8hUJ;pa4{@!*6(pvG|*|uBiDkppvUdDup>O!TUEZ2?7b2J^ka{5)1oc5A1S=W z)Zm;#)~mT@^GD}a)1QMxMV`WOkT;v_@+>pZTOQ||yr7}3hAZpax>rH$Y>gNX@Mn@2 zU*H-#PmX(1UaYD7j5`sYc>=`n^!BJ6%PgXbMQIxgP<^}V%|KbH#|8+him`Q_<0d8* zA<5_70DOIZ{9cx&8Jl}67bdD3E<*RsN*EfO3d7v*Jr9t)V5^I}<8=MOhC&TC9&SJg zgpKp=g)v<7cW_)5k7x=Mp-*58oeLXD>*LxktV`f6!$X6zi@Y`a6BMUq!1I$lh2X^Y z$%iADySTJKN4UWROoXpn+9tv?jE?xO`AqYy1Yyh_9Vd5sd=SM-h;3CZW_mTnXZett zd#?2yk&!CHyRdW-=8+?EyX4_+=ekESpI!B6K>&4YS4nAbXRomB0aeCR{GoKpnrA^| z;qNvr8-2pZ0i?{TsPzhX?u$ry(N-c@l-05}2ysQJNPQw-!Znjmj4*UdCetpR!8qj0 zrcwi%h$@>Ub{u0&+5h8j5dc^wk}Q_@v) zH#~HL7ya0kGh0NIwYcJ4ixL-4k&uV@`P7SEs9Ug47-6zfF)qwc%0H#9q|}{L%~C1G zUt_Pzdb5+xB9kY!5&7f+=HO@RyrOsdy~~rQ8Ex->&KP??@^Wb&@$mQG-gG;?$Ag(h zpOXb0OG?(BbT7w{St0j7`uIV@=)8V^%KY(H{N33gWE}Hjihw_xqu1b9u3zR7zu}en zt=rgN=9PH|=;%-R_H{`y#4)rvwUn1czKvFBJvY$etaAC*>O})~B;K-?%leIrg=fyT zfqti?c3QvnMWdVh-e2cawVzm_p7G$n-Yt4pOsZOFen2Hymvp8XcDj~xzu)^M6AT|- zA$+1@zgW?=_F@y&)BdPd*LvUm9Jg3h!10a*?*<}}%t8RuA*Rsdz>~^`6zO6H30U~b zbNIMbjISJ?r3&Xok*-vd^os7kG$NN?mjOivfYvRxd#hl*RUS4=4C6MjBh3w)_?T6? ze#a+^$zQnVqUx!;i^ow#V*Uv*Z}8#4CX@GIt8)H=XV0BdudxsgVFP?VW7s@%7U3FB zoK8m(F|%PUH?=UY&OpYlncCD=^VNLWu;Ol9EbK@8J z4q#LByOaA<=DC&Ldnp|yCXkbvvcaOesPFH1<+Nb)wWVGjdFWS|4W8bab4Fi4Kt}j$0Ir?6%r--=O@jO0)&WhUciMnVyp|f0ZT=iNI8R|^-+oi#<5lIKLS4fHi_uj?koBBtr68WmvjUCXQAk5Zc z59Vj~s@>OZn6+}3M%{oC}7G_OmZy>=xNdwh|XG_F?L!%W~>U^?Vl zda>NOHjdrzIwRfH-FvXrF0e&S1db8l=A{62@mN#RiPjxgwy9cY0|(4~jn`50 za=~}oX#y$|nX03*Mel#>2DJ+3V;C;dQH;t|DqqlC4~^uLC3BbidX*N_fqIO%lG0RM zZkbxn>uRNXM@c%1!SYSC&;#`a@{TtB)H~|Y)3mzd{6`?7m|Yt64|nfYA-Ibz3Cxoh z7g7}7BWyJ?xpklCrc6$@QnSvTViLtJ=36FX)c2if0eCOE#+E(`-OfO(+lYkRb@vIo z*u{EVQOpzs4${sU?wI7_UHRFE#|9xP)?{08>=&JiQc!oqH(X_yJhx%Hl=#OlxQdF1 z-4Bb!cncf5C|>QWx>13PydwK#u|fif465H>zfG=>d3Vp~&HIHF1|Q)!J$8L zaZ>>=X4vh}49v$2n|bCrIiD6UiCsMaA&Pmk?5f)_BaPme67@`?&sVBXA9bU=M(T4XV5U6k){C(d`qz+;%!kX~N-xVbG2O8$s>mSF;9N}N zMjqhw6|&Ul_wv4MeJwbLo`@pGjKWR}_4c=!0GDw(kr?|>pL=rtwd%r~l+i=M840jt z)xyHG#))hB1=(KR?X+F2FEg4I<`Y^M7eaM>GBaCwwK~q^Mu(`jCy1rb+LSRfLW|AO zmjyBgo49wC873W5-#K@R(fg7!$fnjY93x$!H}k~yk-TZPWsM}SCg(P~4TL)BD{aho z80YlZ92GFF1U9C_JGE}=@HL!Q^(xuu0_OK`%OLM1cWjMut}oaT($YRxMz0XGEK3Y+ z5`D8T*J%rgdQsk9ZDP6ah^Z-3M8RqgBn|mC`NQer0dOj@{L4EX?!UXfmMUxOekQ_B#lB_3YW`MV*uGP0GY{92lzAq0GUQX)z`jm-r70J3-EEs za=Iu2-$a^(7?IL|_{8VoL<^!3AQ?%4Ci6k(>*wRfg#3QC;UAP2*XyTGHYU9#4&jyG z>n;Mu0Z45{9VlQQ2ng$yzdFaQ-Pkp%sZOncnh`C@T`QnONU|0{p;h6U@hTiK-~EI? zNql7sZJmtNrm2%Th<)=Zq6JI%W`0y_MH3L?q_l7vKCB}TC)kMto}sNvD$&c{SY$lm z003L3dmliWz=5%vC{%jtpC0+$UsZDT<{|T|%`p>HWaGd4_OH5!b`^5@`{aAja^*j? z8LA1*Yq++4-%zhcF8`SR!UXe!UgM%N?Z#aS8lkQ3*!t~STnxd_A8!wEH&;ZUXf)c( z?;}iFYBojPJfzGT*{K{qzd=Qgc%n(sL)waNCNI8f1M>}4a`ytpQPMulI@Dy!wcxWi z{L9!kM2ap_ zccM82_b56HkNWEbTQz6D>rYyAXl8LCjp$_UYaWAJhk~DM400=CoqMne%7Cd=>U-$H zG>b;lr)BLpSGT@e;n~{<;Hy@fu*{ar+Pw_GqoAI$^Gv-9D)Gie7Uj__%>@sQgn zHsFWj^>iQCk-HKUaQqe)4r2LzhG*RruVz2jrJ9O~ny*(Z$mf4TO^%D2xjrhoNX+mOQrac?YzsVPS?+AoCBKQy_StIQM;q-m?MYn49gg=m#X=m(Ut-y`*(F;cNPTppEUdvukYU@So`Z0?7Dr?g*$8&H4Zk;3+FOFnsx^tom!HrtY>vBSAu(`t83h0kr^Kc1MO;r{H% zfWdNwpKYxZ_?m$!LPPwT0Y!=F`psxxa*C&yDDckJbsZO8-mR{qb!*>1Q^r6=d-@eE zmKYqK5q@oB@DonTw9PDD$M=D7kQ@5h{dX`)HvN2%^pyVWt?VjA8Db#^Zh zY7KOR;K0mYhXOU<_}nrsy>6&AC;`W&$g?vb}Aky=QYcyNi2w#e|2-?F+D^BGCt0p)a304B}nPxQF_gMCv zl?1>wk50E_T*D#zn{ z=aXu8mN2nkVxRTAU9eGWtXu)*X9o(e6P2s9tw#;CT=(pQ(cqdC%qEtF6GyK?yF07G z??l85h!~9BHsL=zQ{h1{ipyMZ3U9`~1W(_*TK5W~ILpL8e@Xz`S^{-ja3*Wgc-%6q znsxE$(bK(DxjP#yaDi15mV81j*i7b-RY1QTnO}DO=B$+O(I%;dgKjFMES&Z2480EN$?T zvsXFqHt;eoJRcLg=e0ya*O%&UYjzK3B>6i&rsz#OFYS~h1dBZQW8;zh*qIYIW}c0 z-cW?pxP- z#r`OChn?shyh&eSi351uXwvI(i$ra9diwph$aOqNvI#N+3uM_TL%D#p>sLG4r<@;w zc7K23{afkxmrm1vMp6G846xChcQEVk8;2{bD4e~R2kd8;Ibp=zCIBQl6Tt1B!7vl= zrGT-Qk=_Kr;NsBMQs}~tEPz>d%Wqw<1w1P@t$;|y0nm}S#4e}-Y-zh0fDv+pjpXI^ zRe8%eaE;{?eNzyZMSUkY1=5Rm5BlctMLbLFX=@*|-r3e&oT{aLz)!s+>c|+!S``Z} zVTOykOiJh#yNoW%#~W=3K<=0dp&1!F)xZ2ozm<`5h?>cfu_ce!in}FvLwm>r84k?R z(aTJJQ4!$0O`_(FfBS%thIh0VfU0of)Xd4eV|nkvNTKAV(}az;+u8gGN_|;k^)V)D zsxwp%0vPE>k~TBnNzpp{j`*G=e~V2v9_wD$xI^L@k=BK5hL$e%9b=H9j&2qZ&h5{- z@s2TY-JG>&xJlsWibi@UNn7>C)E~N8#O!_H`rgA8d2n~qNhFUbgI_=WC`?cD?WHY2;s#Y(R9JbUF+1QLr)gA z2_@i%14rvjMg~fuD-<#f0^7yFuGPoU02$LPAnS#Gk6$hMmoBv|`Vz zF={0z-{zirWI}xC#|sM7G05Vc?Y3e=8kA`db1t#QOl+0~#4k6fE)s3Ahkva&&Ir6i zO7-Csn{{p75Yq@oS3G4lJrN#Mg7Tv`7r@l zs!(ccbQd9U&uI3Ro(*ZCyenaCC(4WBL2B#&V)0ZnaG?Om7BTS5CU}4CflJ{9^-i1Q z(;HJ{ccN&zAm-XI7-1a(H+N2*%`CM?JkZoKG2q_(1{B4%5F3FR*NDkAtx&8bjKpJ*?QZ+qE>EV z%w>*Z-&x%=ThDaPNch1eTqgnZr?6KMtTR?MP$PBO=TVLiAKZPDDYCsE@uqiKC6U=n z_heIY>2_PMiKo4GMc2S#ca582WjuRFThNRsgvsuU7i`OJ@Z*TS+yq26s)e{(bb=;j0InSR~ftX{i=Sk0dnCjhH$f>%$nXv2vN zOh-qlzr>Dve#dvK0BUwdH_nl){cbJY!Vb0p>{l-Om%CCVYyy!zFOyMJ4*FU^Xzn~l zPc)n`hdy4k8ct@!nnhc&o zt(IKB7gNVVNZF*cDgg5j+!6)Itk?Sa?|F^)a_Ut`b|2)_a!9})T*iuoz`PU6es5d9 zZoTA3A$6t=DOoK2<}^{$$@o{IRKAl_$LQsWr6n%9w?qpaeR9G1HF!FTBw#UN4WM?t zcE0{Rtk2-?V{b+ZKA9>awveE5hDLwg_RDH_L^mq#Uw?XpQ@6ck>t1zJ?kJj~^_%-o z%d`UlA;gM9yh6UGx7Mn&T7>;yhA8lfGyAK_g(xGXgS$TpY(L`LtNI$Y_f{Ltx|sU^HC;*j|gjS3fm_o>nBQidkeW7GY^mM8op39k}D zoOi!DzU0`!O?^J&fkn>Vb8kqOROG

    h2?Ohepbwa%UDqKr0#9^+I^H&OjO#S^+m zGlYVib>@T98==;=!4(6ND)~(}tk?;;6Lu|fG^CNrM#6}J`87qnL7y)fZC0Au6)|5wiH|ltY@C(2Q zX*(DEHA4(E%Erxoz&%6bZxg;z3KP1_FJtn zdB$Z(vx_6{mCEk*e+3==Zh!d&%h=D;|6PJpXc?F>aUJQD2a6~3Z*m7n;9WIZyO|rT zq`Kma=;%$y&2I!SqZsN6W=P%%CnhD%JxG9g^?j~%9FrYxaFvA6{ zq;PWcjTzNva1Jvt1dn!age|RuJa0(L=hBBX-IydN3cmv8^L~zb-9*$Uic1@8*B4H9 z@!{+IH`tEHLQ|oQC&7<@AoFI8{PQOL*@+v;$x6%5&&GlGb99A-U5>37Y48ihKiv`e?(FwW{?(6|wE0GV=pk`}zwnnxbYW zk|rkuKeqb=rq)^u>bFznn)LZU+Ntt)u=Ld?2j2{q-sr`-RTkstl2m;;4RwWo6X#&1 zH80)(*%w;YB%&2LHv1@9V6#t=*V4@o*%}M>L*b5t2Xf?>%3GFX-qqAfPuE;)Rei~) z{dNod#F4C8Yv1b@_+?jq+S~uW)BmETO3|B-f1mJO-vhn!JwCriJHMc5tJ?n$=l`($ z_TT82cSrj~??tuI_f!E8#{I)D`E~bwG(`J&w*P3R_V|44UyR#gA5%~USAAhtEMG|=LYX8oN?B_>=_QS!xs|TNk zZ_X{8H=6$?uk?3k`(Wo8d?T`(S+glws41y@xnf+ycM;Z-x_6p6`Ou+5Kf89m!2Qz# zeBYIUj{Ox2IsjW>mGArqKYD4q#fPJ-tj{z7ZtCl4^L;t1eCOXMjTWKf(#v0<0Ez=< zX9HrqIN!Jq6V2FQ{eiG!ZXM=&kF|DR-@x=V08B9pqa%o;xaWN#axZ7)pGufzAzvr^ z@NQtr1~6gDOd{BGyhyWkJ(uqs@n*eEb?h8iZ&24R)+lu>G$zJ}L!z^i=7QirFZ}87 zYzn!2(-111Q;R*wJ?p{2C-zTvV)v0$Ubkyj+1OC#kmaaSP=Ph^x7)k8O)qD9i)o*u zxqbWArj1T4X6rROB+Zx{fx8BV?;PW7Ip}-&{y|8N*DixM%ISvyVDI*8<4<)T{y8M)oc?SJW%4P=QrT?l@+hSKl`D6&=xo@zxmf>{8H8oNW zhNK04cd#w&d;nBv^!WJZ3Cm>@rvy#fdxL=#PWZc}MKmQ1| zq<=I3=AaOUSKHbvxUs@FtyGjO^_`!;7GCXSUmT%l``h@5vcf}bc(ph4)9IsWYY#od zn`jKp`y%=b5O6k`;UC@h{&oKPpKa~uXtVDU304>48-8{*t=;E;@w6WY75rykea)x+ zyCUs1snl1QzXf<}56yotDw>gdsp@|J<(}oCBmj(0oYXp~ZQ^)i#!L8!$%Lyb2?pq` zV`S)*HRy%4Z|=bgs2#{=q!vK6b(h4CF0?Kz=Y>5AFGtmgiAe(zt(h7UoUuA#8@i496 z?93*v$SiHNdaugm2F37>O)?Q8y;9% z`H(F&3QHwY_Jc)IjrK6|YOrKP3)+cQelvT$6F*ssyJ0!oH1`WncQ0C`jQ z@#<@Q-#hXg4v={Su|1-R2*4{@BLH_*O=#C@!=Lx^L6jAv^v^DxRfazwq=SDL{(O)Q z$^yc%Z>;?9c#A|E=vdSEmu{=S5^dwN>CZdy;O`KY-yU`42hbEqvJ5$X0FQc~{1__a z3;fNbrS!d=CUMCIxo$^>HdO4*+J?iDCtnOD)pd_?8l^<~*@^R(PpxybCu@nXve=-+ z$|uiouAd|66&+qB^o3%>w|{>1()uksTVwsi2Am=X2OsyZJVl6)_7krkJU`n{8YTGh z*T9w$v&ZX?f~Vk>4TBZLrX>auz@j_{$|C)cc@Z*T_@N$?Hna=uAN8TOojKsePm+TD zzUg;I{GJj2(@O&}MaBqafpl&XB1yrswpkH;k0~z@8i}Is+i#feU|gkegUcV!I0^b+0xY&&^UbjJxkZ%f$z6ufY zBF_xXI#ckV-Bs#P;O&Zik{Q#iv;5c%BwGJ|$aXfjwAez!Qe?KGV2!>VTkFUc0>?v7 z0f9zS%Bs_ovk8%coiaewwAQ=0+)^0Y_g2p%A6}0ZK{R*xQ>)=I86+h}%|ov=r=fuN zQ4~#*dAXMG>G670=$w;@vZ>z1lN%}aUre|+Oa`bYLg#tz(->3sRo$FEiU>J!wZm+m zpZY=M1|Mt{fQfLYHP(^GZz)goP;=Mo#xkxj(?)47TD7}U_E!g-Xjqmj8juOZ~+~&0RX=x9yOdjLcu(5wf3buQmQ$oRwYjT?hGIDJ1 z$)1UbURKrVMjlFUDm|#UYo4wBDXIG*$rdqWO#P9!{*+<(vEcXThYtGP55N22-9q_2 z5B}MCU~-N5wI3VH-aFu!8&OOCr33o6$g#;mP(HyYJ~u(6;6pNs|GJ>#Pexn<;XL@( z6_9Pyk)Z1DmCnXbf?ME=#$T9pec|8vK~Smym~(xWtNvhOm4oN|Sjwv$JU_%zZsv$l zj{6P~)HmMg%fJI4Fr5?ufT(X&|EA3EQ~l3Qo+`^F3jg7dP3aW`*%`k`baWb> zn!ohIt%|Ck?fW8@-JC>)TiG!5#hD~FEd>LcT~LD!OML6e0()-Z?QN3u=tnYzirg#1 z>8m#^-Q2tl;@HaEYv$g1Y~02S%_!jLai!h!FeB^rsm;B;Kw!ocxguS%Y7rHNFzl$h1K&9yymY_3!@S~K{K8>aM% zDn;~qP*sJ3ZgQ`vF5odelSJR{%~@ABp2x1!yU&0OrhrpJ;8;`&S{!*Pr=AuK8CZ4i zI@(Lc?@|#*;CwzaIawYVRbg%^aZbanm-hjsWqN~Z^4bgVHyFYidq^alBsvA|0#|>X z$mSSG3|QlqZ>-K=t(k)>M3rHgtN;9&U8_VoqvRw#OIv3QpWP8Q27ZuY0XTp^2&pOKAL4bY- z0b0FB|E~!G^jTS_tK%?ZWsntWDDW(|^SN|p9iN5I6e)Pui+qWd9t<4($_6+@cH*|yI76DUh z%M}pE+DU+jrO5u>4)xFNfa3tlxDx#vV7L7$F)Z+r0;ruzfL6+y#gWeZLEJ6?ae}^n zyZ@n_lw$C_0+D?7t51{9gw{e6LAV!-hYfIkCT;-wjPgI%aew!!Ic?zn?jB+TAu-vN zBs%#%=+WoA1mn=yf4wQcae@C$T;OEl-FlMK{uNN+739)(KsL(?IMYj>aXio$AS1@u zxJ6XvCE$PRnc#4SkN_gPLvH+3Y71G6nBbL6-^+K8d$GSd3!q^p2!htVQIPqBfceAA zo}&wiM*wI@e+0Sv#YvuP0-!M`W)zM=8Qv%3rp0E79K!W^g|dEg(>#suAR9kZogYjn zp)b8m`4PGl#4I^)%TKI8pCdVaHv<%O1OU>oGvdBO%A&;m6kh6RZ>g89(vedzbQLnsNG@=L>PZ9V$&Zc zmwaMT^2MCwD|l6Kcwr`gYXRpK8R{ee_p3v~AL)1n^Um%AY^iqE4R= zM!;z(A?SasU)8k82@W0agTPunhgRelE=Mh`%9B@8M*Z7u`3;r8{;xtMw1gYAgkL|| z4c2^Zmgk)QsK=IQbmYjlc!s~t&om*$lhSXt5|xO?AC5V{CWuY}VnYJK(I=63c=^Zl zALp8=yyY4!5V||@=O&?w!*p8MR+nq3le$`V!gch{g7q23TYJ*N_LN1`r!AQdnhEN( z^^3iYn-b|sl^Zaf%LosH?Wx#<47cLhGLE+zldwb7v4)=Z+`l*YtsnVo!K%XrP?QKy ziqWDcW!Jr;!3PHg_Xf8;p?+i@AaCc};v27}&1KPEl_N!wbZVPSzrXHa-wKFq)OlA} zT^iNR=*)A2);I1-ce6CH8qCm6YSQ1u_H3;k)^tC~rxkrW^@KRfG|gxLKaK*+NlmRW z^3wet@8f4G)@=JD2JEl4ifg4ue%^1?o!K#xi2FA#=jOU;C~7!9eWA~C*P@CEo_q!O zur#A!_e;02u_MEG|KeB8`~;czCDHi+5K%kDPK_0#JF>-e@Lv@o$X&F>A$gw@J0 zPkHXzMv}^DANvbk><37oFC>mYbQr^i&+qYnFQLr80;_P zqV+}EB7ta}Z&yGWJkGTXzTIk5;fto_&Le`$CCFrblWxui5#9ypq<2rMQIsn$(&i3tv2}O%Jz`T9%#K zQ*mZpN|ZdxRKQ7S@A4kU4vkhzv$T}HCzksezEOQuK#GskMHw|OEXsT#>|$Y9Rr)`8brIu}fHJ&=hP?=LR!o+Ke!(jPu7d6j7$-vdS4F3LXLz)F+5A|VV-;Ba z2iEIX#Ir}#rm2%Z#imO~Xj&ouK&yYxcFD@h{w-JajS3$_%6$T>|G<0wiq(}D`zk5& zhva(!@_R<>gH$k4! z+z&3RW~pr4tZ%?^E31xtxp}y7*Mz{{WqARvq~Ywdb`0X%u2nxd%I`9tqE~L+s&-71 zJ8wsI!fUOXGi{@Oa9?vcmF4n1%)CcL_qo?{EYJNnS5%f1X46(WiapPQFluZ`9`GrB zDNKHbcb2B7)2nzUKP?e04COnl4(GrfsK}XD$t+{QLUbgK_}maCp?<9oiqlKfTl%P)AZ4+8oB^Ekk3t9V!C{uA2XJcIro2=xl6 zqk`0k+=E+eDp>(7U{*kBiRI3s*qId&F%LS)feC$g;bDD+guq&QQWi6Db1Mo;xdIx9 zFf5#ZwE`NEDu}|Ft$HwH%?WPrwgysP0 zFu;MGYJrZ2LPt!r;iWxGY(n)!3kZ?YWDvjPT%d>?wM6U7LGsB!-J4vVm#0)sRE#9%%LOev*N)0Xz-%@ zTnYy@4hJLl5yrh-Nn!xpwk=d>`CvgM^5y5P=f@LYD;z%O{9n^Nr0A*RT>EP24DOmt z3t9F(%hVZQK4VWd89F!*^AOwDaNYKB!5rcO1E*EDIF{|H*xPU3P?w5((dQk1qI%If zYPm_me+A?hk~9wXX4;(-cmru;49-7(iWxU*yjH!G>c-i2(%Yk^M_D4smtRU11(6Qs za>~`1EMLt|%kr~jo~qirNeSmQk<7!5oD3LhM4#$~<^r211kGU|fdE4M?bO2D^z1{^ zD-@i4TFj4=^36c+FRC@wS z?{UfJ$K33_w=ln;w(J#!_KbWY$$MX2d>`5!2EPs|$cyFVgcmiry5d5Cm`(UGv zdZ-7exZiVo@6>gx_MPu;`bSo9bXO`*5f(N)`Df;#%y zjqr}^LNEsCK%90s^;s)YvnA#6f%V)$*jJ>beRFU0Tk_!O`ZBheY#}C(abm&kH$TuhTRr#~mMuUjaj{jpk7w_=E@hzxwj<;i-Rq1L883w? zVP^AMOXnS!g7n^wdANMG{<<4A#siOHnEGEV?)&yFPC9*hJJoTyB@6g;mjkRzSAAi% zJN*)z;c@#Hk%@VnXcK07Tjw6t=d7%7F8>!x&&-=4P4gR==I3qhJId>$r>Q%}S~lDZ z91J)CK7K(c9`F3rwL2rxI3sS=Li#O{`|41-mK^SnynjR@*AHgG+d@g*;Dun@`ig=G z<`qyTj2NTKkC{feuYe}|S3pK;KCSPrzvKSqnMDJ-fa@Kv`SI`1inveT z|2>7Ann02*Sqa0!GrSuj)^1S|!~hYKtRy45e@W=)ic}8alzL+>l}Hwmvk*DVNJry& zis2hMH!&RDe2RHg35v0jao&YHqJFI5mN)?WBMXQJy;G`lIVM)Gr;j_;7enwD;)u^I zLe$=@@$|Mt+emvPfBUJJZ`Srx)Y8`WU71ouhrnxy6+BHO4MK zzSx_<wGg5MT9d}EG`Yd^dJ^Y4!t7tFO4WXN+15pV$ z$Mu9XCWx~;JssEpRhldkS#%*Wgxfb*iK@!%e`&EC*WWitRsfMCLNYhZb(7!)c<94~4{1+t1YsD>N4{*uI#Uk`pcH8!kl*gz`7EiW0>hiH_GFpOjX` z8KEmuv$+4#>7}Sa%&07?EwH|t) z`?-iITA>d{Rb#_MiE^*bRBE!Da=NpDB$0o~wxcwvgo!a^N@Q<5b?{9@>|EzEXbZvJ ze%5T0tW_SP=nPH~_ z)I@rB&R2=`x55t37`Uc5nn5k%j87^iKLbz4)?E#*7u-O+4au7CZ#e3_%l3+i(k@8s7VsUH$QD&$J2bGo>xD>{qffAMQJ!N_T3JoCS+Kn~hWG^GrT}vCQ1;sNm!4 zTozMQ(xbYUIgD38lzF=AtFmHuZ@=}BW@o1}`G|Ce$?HS%dVQJRuQX2XDp^mp1AWi| z_KLW9q1NtRd?Mil#&+vr^rK7S#oA{f<~Zg^rngAvrs=0B?6|}D^{#E0BoBvPpSfvW zBBDn;ezaw=r8Z|zzsB~(qCLai`OA<3SEZ)p>Etj={_>Xxrtk9C=W8Si{NcFx+Y}%YEH6C>eAC~N@I@-yqLA! zlaFQh`)n1SbWV8z+LV|rg~GOMg0y{r{$e{p(kMY&SHiyhRE!a2UZIFSn;;0wd|u5* zynoWURWV{}Z~2kqz6UZN4*Ogk1~IvgdiAnkP9P{d1EU9${M1WVKzu$6Oz`^-buJcG z4zX=ry2Z~s5fDTapTF1*an^SqoDB4Fcdai7&-Uu%?+VvT5iTGLY* z9SJ@^SAnSa=E<7$@9mO-Ftmn1pp2(+928%W$(=--MI+O3d;M_8pfe~2ns&n+tg`QGtJj;S; zmLc4Cpq?Nm*O;PBCTX86(OZ*lBcnZ}Aqjy?6nKsTFXXe;EXZ$`{;Ng$2m8KO>MNGs zj;##JVC!0&O`aJa@O;K`P^0v1iQ+?n` z8q^BtC3puXO2h(lp{8U<0UROqFeh}T7v5D2ZD#>&y01F3sy#3U?-0?7KUaG=-F$su zu@*BsPiBqlQlPGQ9N`@1W(>>m(B@JK$d((9PYZgEQV+@7ZHmIMl;s5ZG@7VwKO%DI z#q8Z>$1L#U|H>~P$OS>IHyTD!G8qx}hIj{3UF%T4wU z4%YR~h@UMZuVALX)Nu1^lO;PkC(max#Ab-S{uXGt0?S13D#BEhwH?=be7uW7Fa^mX zd@X#*i@y^jh9Qy{9(?X-j(5Op3@e7X|Jo{w`u*DRf^ zLFz_g??Tv}WxQs+dpwx93IiQ;=Es=NvCg^=JX)(-evG3M=H^3=!1%qD?&>KhK{FhE zH_><@7y~KG(N4G!ZFZ3HO76wJ!d^Xx`NVd$GBDlf?RX*oJP#|cNeQ_zTX$JJjjx~#OZQ*dVo|J4-x?GEwt$lEh& zzDbS-h~v-W?@sO8GWqzWn&@Ux6uwnKN74$Qd$$XCFeLw8++FP#Sp`E4YlIirw3AQ=7VSpPCTq1V*lA zh1ACM>rz2y56>A-SFa$+6%ew;N znu^*+jXu_sY%&U`CFmf|#iVb{^MTd~$CZ%bd`^z*X7<*5Y3g~g%5erQZ;I~Zy6{#8 zvP?NXVTY}??{O77V&u&3&y}Jy!4P=sh48gQ;E9vS7sE{gd5BVK19lWSzxCeTcG}LVo=W?`HmYIYIBAS$n$Y2nv`H%bF=xc4gbn9hhV4`1AocW@(j9H zeb@XYs=En;YNM|6DSVK9wh0<}EtpNu_MR&489I3z!puefbjS!(My(R$dc1Zn~V5NL2x-r3I1P@2@!0UO-nS(f}QI0W6z* zoup@aNHRm-fGUlebkAfA3@o@=$ZWo{L_$upqSpefaM zMO1wSM6pad-TMoL-eW5ux;(Y`>TY?o`Wbua8+R^2^KQQ-NZJ-4F(zg9Pm%|^58Y#n zwyxYnzFff#FID^I9ap6Lp}Q)09u*uwdD{!r93yy^eP5O(o~>MOhf!l3>bz!ff%D~q z9-Y+J6@VdvpT*Un<%LujJiQe&>tC}f>~)!_2FA2$1ir^n1|b`zz-z3!v~A6k$$Py;bMuG;y2`L{G@MuRdK}7luY(V-a3NkrwXL1JO0OvU&v>72V+<=sgAi1T_5*-Tx$yU1KMgXY5$$>Zm4*ZKRFVukR53!ac zZEG1RmItuf{`2QrhF2D$AKh6$^Lk%#BC8(#>1?5#uA^FWw&^-bU`xwhLn#f|2xtlt zqu6Yv#l2HL>>`Ry-86E~b?{TNY_VWDmF631@+V9sE{0#uxOeRl=?>KZUd_YSwO=>Y zfxqIJ1QXm89wM#4is&5X5PJmH#87W{G-)xrZi_vq-!z#zTRFxWwESdHx`}*T_W+vO z*S>b5p2>5Yy;Fv>2IJWPxW$vWciY5+EKHBr)T6YB{it2=r9oaFXF0Edqarrw+*ocl z4}pzrB)jwa%mL`^tuRJh%BZ&tno?W_Kv`DWT``aqlZl!3npEFS5O+QY0Pt{hEQGjKpv91xAwBm%$dvuDf6owO)qr)bQgz z(*YJv*gQyv(x-5KG>lTq9BHrhD~u_L8*SQRI=GMN9#gMh>5t^9;0x8pOPyJ4S3srh z)V@d4i2RDP-1_IL5&nBG1#OtEhG=4#J-We|6R!Po$>8&-Ja6?zzW4#DwnOVgUIw=0 zNuy7~2=Y&HjpL9e0iJ^`$9)p)Xfn2(hHypCr|9x{bqg5zUq~&wM2+VH6C`hA991!i z=e?{Vwt}Dym)}`cKJ-Rs`f6TPN}5q8BY6Wh1T=bbYK_g<^j!+t2p>nM7+az3fq~}E z<2l0T>UMu3(zi^4FfdpelKjk$+c$Z-Y^06$l+cV-;G_!&s3>no@M0E%dq>V(kS|+K z8JT1ee7|RHUL?2_AsLzrcx;gh!3Fgebnq>8ESWw#0mAzPpwt41j=C7#C{Cw{A#Smq zPo&LuvoTG)Jq1X!OjL3C=zJ;FWzpA~j%N*V4i$Q+4R4Bq}W0T900d49>iu~{$MQ-^-c(sHK z%AoW{jYpis%~%-qKauaXE9;i^!aeY2KICt`oM4J7Rhic-ZwUp7lES46H5Yg`5Tu(N zFNwWYny?Q@k!X5io4$Ryk1B>5icpwt$(5bt zO#5EJE+F&$TBQ3q=a*!=1y(I2He7MNF3R+2^MV8=>cul+D9inAr}uD<>IscQcM>ie zAdOGFFK3(Q2%tU z>|F3g`<*)UB`^>Bp=9*d=+=1^hs|8kS-0PmyI2Pgb3DZ!elDVhvCwKp#=xYroWKyp zGj^A@XhZG7;>1dJFOI7-apJO*$66aJqB_Oki1-5{&o`ui^J-Ddmwg=Olc;G4+AZ@Y zqxua~%#bG3g9!EYYRui&$Ecr|i{e|D!ZCZxa;`@9w@h8%QzaKN=j!12mSv{w@@Nmu zyK@GU=*^+aPlB?|1W#tx27tGze(MGYT?AT3+mY3bW*uWh^g;obX>i7F41 z3)cQxvF##(8@3nv#sDyqe!rY63j1!@c92}bOPuf4vM#_;Z`CjF!2%AzRq9Zj7q*AO z@hsg6h`L7`Bf1z4Zold!aIRTb8+0Zij;v7cb!#k63B5lP=ZqiroX#61HL)rrNF~hn zuBTNw&4?#m&p%lVr`cFove+sDaTG7xqiw>TJQTo0YMm;nt1Dcrsw8s0A<$z2Y;wIyO3V58-Q(yvc#i|xLFVJ& zqd(8&-dpGsnBS?&beQ+izyZ~zT?dp%ZTs{)^_k0~DE+kreQS zSN%-=yNS|Kwz=i@2CmpXbK7!_0rJWWA3`JZNC9Fgg0mq{r(cx62!AUpPoHa+Y(PuO z*@zmer$nfy9qB%biFn*g6x7z`4Y6A{%N+$i?vCe)CmDFnOq!r8ywZ)}Re21KTqsD^5U80OlOFm&s5+X|@3=zP?yqgQnrX3?8#pogx|xq=iXdyP48Kve|+ z%hND8j7wi$0At&g*a`51`QTTD^kK^R?y?vP$$hgA9(0wTNIZF|{{>rCe}rqYJ=DdS z=R~{%RWN#&*Qvn+2XcK(Rc{tmT!ENZh>~k!S3v6tx~7T?jGU!Mc3D)Pk+9j_p48>) zR~pgpXHS(rt^!=j3X+#_h_ZIQdzKiBIN9?sf6AQOv+&EKV-T|0B<5YXT)7#)h@)0p zWc+6jWM0r!nh+J0>2+3dMZ@WhoN1cM>LQQuiJd($T2t-hj))hbuFjLw!j+*-WmW0; zBx5@k&M6D`cRjMguhTu044e#3#BgribFj&DnU#YPGxb`C2tw{?A@SOVDF)y7@i)pK z2GCOB7O%gXh^GKuN~V`%4?k%KBg6*Lt_P44?P0>Fi7UP@h6!eHk zU%STWz*3OCD?x60$>pcZ#yI0r{+hU~!q@u4b9`0iuY+!J4pYij(zCGKxGUm`f*8q-<_SLs?FdB$R{GYv&Io%RG^?u-m&%2w+F~)X|XE#d8#1| zTE#90J=Y)ftKI}cK1-fNr)79`@7l8K9L+B4i^n!P(VCgj#-ypvJU#d9v`5rSmpdGq zAu-6qxF*BLjXa=r^^bQl4LC+S>zy3dmB++3@JH){$l!d3MJt!i5em%e^1}M%pBbFX z1CfheJ@4Q@>%ZjK6K)CYpvc-qmr4IesqK|BJDmJ_!Jt?FkG=N*YijBChl8M?pa@78 zf`FnRB3)?_l`cjQh}5WvNSEFTf>eP}1QZpJBAtNrjWM_o8Su|AQ_Mw0RMFOy?w_Wwp-23*W` zD#r4x=&HQ637}JvK8m;seq{?`wTUxys;h_aGR?s84EdDn^4pkS@9W0rZOMEcs~F1` zW)gTE-BZ&}3Pp zRM&WfQc~VwVw?6C&|}z=<2ZAX-NC}rdm3}uo#5m)Qp^L(jfsfTW)?;o0pwah5 z&b^~B&!5jM{~(?2Ey#b6PQNpte6vUKe;cLwwfs%oz}KkF9PLctkn;0{`m+T_0Og7a zrd5iGm@0VXu;@~!ATgB8&~`j5AaQo52yl)$=ASB8iaeRpmiCTCId$;qU036HbRtpU zF)q9!N<-%XFH=63mWM}5yh_JBUK;^&VS>=r4MY#+a8xo=Wj?YyNghi%nAp*mg=cVs*n(8a2iO^{ zbmh)`0YzNV`vO88`~q6nhc#;Bv^}){Jy>o+?`XHr^dUCtY<5AIBq9J}6!{8}B@F1SS2s=0|i=fp=a~i01Az1ST99?SV?>$uwf9 zl=H4D?e5{MAKJ=pWgXDGLLRQ9VPuf4?R)0Lqh_9T)HxmgcTdA>r|5cM3gb4E7Mx<$ z(U#tHuitOoj4D#ukW~Y#&Q%JIEg3h(cIAZc6T29{VCR$}mzH5XZ^-Od$&u~SMbLf= zQVb9szJ9%zuV>?|r$AN0n0V`;sQd&~%1hd4&YsMu`BGsXAgdU{8zW%ZP8rA@`A|;F zT{9E3(TJecQZje(T#>o||QoF6Oq?#f3!j~SxzZ!bEZdR>_FTXMn@D6!4b)_FU zBfHotPEGwv=tg|gDi34B5#tEjyO3vFsM9@X&pA|Gc4u!6fgQaVc2zczWIXc1)ZH;{ zi28|i5Z5z-(~%PVwMXS==hP)WY%W4enVFpF<PvWd?(8zJ z&+Y6a<^C*?JY~Xb@lO1eTDOuA6Q{z1hhM4}t7X_1f|tGJaOexf=H}dhI!^N5N@Ibd zL}kkftG9+~uMz=RKC-Q_i|83e1qZpKSk9bDR>PcqS4_h6NMh{qkmyb6l5tNh7o}P@VS0O-bke@ibZ!tj{yR5q9QM2dzk!hktRR5D>0xMk zIO-v~wK%j~EZ~i&|3QfAtcTS^Ao1jQ#s)p(GRwBk#}dWx^^UxEeDek?p_Llo$Ccu8 zNtdhY!TbXfb6uRzH(7Xh1*Y2u2VW^}TC}yqTLe9;jJ!A<>QUzIZl6BV?&>PqZY#UanBLN$NS;Wx1dRufrI+CL5itU<4!sb((r zbp%v!5xH6FyUO$fDhA`+oY{!9oAY|W_FA1ak#lLl?4b=mStRU&azGY%zJ~xyL1USW zsYLMp;<3jw2bgYnRiIZa-s2B0Isk4!x2I3k%I99y5~Of6*vvV-k8eu zWS7YRtXXm6mHJ~Grgb!L4U?evmx|84ZZRN8xZWhmi??MRyWOgM+m1@c*PuLKktW5T zlFPUG+iJK1@hq+YpP=L}uq|osbcyn=Yn?2w>!=eIRcPHFc*PJGXk=fI2oB+4qc{d?rG2An|=6PDoCOjDth`NR2nLn!RRi7qNmxx_M&_SRTOTLS68KM!+APyY_ zR`$8F$#Jomkuu-~K8WBsY6;d`i`%1h8yXLApZFkeRaL3F$cTLTd0cEnfN=>A`GWnD zQRq0*m(WykFSexQ;2ZsBNkvYP)$^a7rfz#)_ssfODU3zj!dOObZjOt!xgMCSZ!%Kk z2pbBa&FCmH?5n0SFP5;9d!F8yE=BW9Pv}g?PGvZ>C%7WV<7ls?<$$NC#*-Tktmg}j zZYFHGawTLiI_u$2WcGh5B-~GCN}Ln9^Pn;fvb-t}(G+M)37v>YieTlvtR3NhD58h1 z9}}y>-pHfCEu#E5i-(4hC!HrBbuLmeSTXqOy@-Q4iY)v}H}GK zngpbBBnPYoY~RIK^&x}B@gAb%ZS6X@*;}B)Z@hNm84)6)OK~4@iZ!(U9v59R-;=wZ z*(vN8wXZ|XD0&v?$(_cGV><$b#C5%GPC}fX?<~7$6Pr7VEv60CG|GF6SXWlwnB|(< zEiVmy0bPxZ?L$0R#unTw8&Uh6jaFg-k2M)Gzb&qGB!3Mww@^qAIEKYvs9s;#2L zeit-Hc}LHP1sk6=F)W|s&>Txe7GrjVCy?{G+^%;EG1Sb(xXumr#PL8;H@5-T0o{}f zVO(zab~efRR)M96Jh)IT*u#do7WB}Y^?vxog-7#IEB!PH&6uQ;TC>J7U=`iBeCXfl z*ReCW2KdeW>B=~lC-rU#ejB29GV18BSu5Rq8sVw61xDq#rUh0?X5isBCD>k`;BA_6 zyr{z53$-N>Fu!>Vq;7<#0$W^VlQ9r^nd2?`21?UW<3{4u{x)q!k^Si-DWyUfy>S>$;@kpMC6)& zYcG0FR0k%DeKs&zfbZ<=D@*v+fqKtD+M~v(7t2hN-B{U5Btd_(+-L;QH^LYU&P;e# z?YsSp_g?{S{n@$%AdzQ${N_V`SD1F8Y(mhtq`QPVD8Jl|sol3gdsu)b3crssU(kpQ zm(cLmoRi0po)2P@2P*fiSFPtIfgXKUgL!+H;?Bke1Y)iRb$qe}olC@a<+VV(x!mb{ zXZkkR42K$RY}i%Aa_Pl1BHv#JG5-0=1%h+!i|r+P^(%V*eNL>x3S_Z1`BrTmT~+Yw zcm{-Ql1jS8je!sKr%oq|ENu#wxe{Pm^P~H0W(!rs51X^=_TOtfcEGT@u|x=>`W^>) zH+)mR`&5sWP*M-qBkI;9QFcELWmYcli!yztL8K!KaYvp@B%66My{4ct(x!Vhbb8@Z z3k6xrOo0p(>#Wu3&{D*%HdjQ&b$K;Cq-k79^MEqf5vcgg#vTF6%YBZL`b#hs)03Ph z%M?0583SnCP)#@rIQM6ikD8aOT|A8wY(3|)|9T%JY?|oj_61b?O1*DKyGyr4DacyG zzLwu9pXe+!B`|2QN52=ESZ#@~0`$RbJEXG4FQCLj6M$HQ1Uz9!z#o1kYVmXMUbJF1 zoDuIMMB`$;qW$#1gIGF6=x8`Ld2R9Y;k$TL1D%U;y|Y_(qUhDqU=c53fFC#ke%pe% z(TnRzJtuobuL)V)$p($6ttpw)M8Xa^T)>>ouP-Yd>gg`3ZZ91h0c=RVc^p~OfN8P3 z*YV&A>i*sawkqum>2xA5^2kXyXV%MoExYl#UHtvBk&^W+;Yh7h4*0N(zBbM%(Q>`{ z3L|@J^aq|j*6+*PhxD%$%*3N^NVwfQ5ggjpI!o8EXB3x@v{0%yV(RsPrL)V59Bovb zH?a?#0EB|X7V-Imd#qn*f>+nJHRrWJLN1P&)y1&K`QZ)9ZzrSmFT)^)liRQqzCFfY z6BuEF<}ZGn`&B}a#hLm#LMcai*?f{4&s`I3P*DLbVqPD=$F?@gbGxdDyS^&Ub$0Q7@bt=SKqYQtDJ2i-4-gh$=;@-ClF{LV_l^c z{L4#zMbAZIK7O8X z@3{Nj>TK+rDsWJxxJhQ>q3%<>^2Bo&?yNUo*le`yYq$Ko)RE?{uKBEBja1er4H1@d@r+U(L`nnwUU-H0?8aCH4tvo5MTe>Ng3Q~Gp-Qz<38 zzx=xmRuG9XKC*?aJo#-9vxT>9>AmA%jd0rWU+s7ot=i+LXwv=pT<#}1Y>8irz(%e3 zpRaU=VrO1EPN;FP&2-K5xj&CM)JCVM%@^~I1Jpv~Urrcrzr5HGBPHIR+Mc~7%FP(V z9g+zZ^pPTq!fOvh>f`({L1!H-UZ}m$UA})+;H(0xR=hri134cS^;(X%A>2c>_fF7d z^l{qsE4me zSDfQMyGme7@M)Ss&!C~oUC|AcMtAjobB2NJxUho5DGhtOsa18uvXR$w0tP$@-)GKA zUG~^OHC7^OwzV`=nIbH+KA(6UA!ADt$DVpUR`E=sA;aEG&LbFQ<>utb@GBqyAo#(Q{KQ_o|wE<l{cRw+gQH zWQGal?nEsqdcKo*pwz^E-#F#61XXYc<8lkvX?r;%~3qd|bxA%WAV+{edM z|Je(SGqBT-$_I=C=gZ6au`0Of#q`ss9Ls{Lob8~y>nvWseTUJ~>xE6ia;R1M;Q2Em z`(QH3&Nr878J7n*Q8u}AeFLEd`=Yo`+P6wN%8lWEqw{M$#@9vyIA2}=HQj>l6AznO zSX$-Bq$j5d-pOkyM*O?%de`hv^Wmk&_d-m#upGG6-AfwVm|)`VzB`qDfOKLY{8mvU z+~o*<+bi)jaWMri)_^zKaHsA<;DGRhL-TTnh2@y5jOx}Ch_;Zra;Wb$sNV`KuL{u6 z9*1IcnJ1pUfpU%jirN_4hGY_+l7OMcsovy6+8p}=YP&F@0hqqYcP;$zsb`|lCBca4 zm$twbRZT`JT9)Fy%t3xV&_V6iQ?En&-NS;823+b+;-K$43HEtpG?{euM5owXz}2E4 zrLn}XzD9v~6bpj<8XC_R8Ze7oG*D`EsmHV3hrE-qgvcQDCgcQ~z_s1Nq=S=pwkHV~ z2v$>3c+oa$)t8)X*?D&R&@AbYa+9pJh}VtVw`D&NfmA^Nz`#2d7IaP%w3UX2vTQVA zN}zWUpt+>rRVbSWtk*+)VsMyypsw|n6|o9+Y6@<6gyUn@@i9Wt?JuCZbqr*V zISm2m>xtTbbPdK_M}H{&LqeeP$Mw9)ZM_3NHlr{h{<0- zIPK5nY8+6-{F>OQ$c2%M&tZvY6T@Z8P$pfs7Tm-`i8Z{jI=J_(Rb(aSPO&8P9 z`x*ux@rBq!!}bT2?1Qq*#BH`N-^%~tE$Va7?o7%KH^MdJ>yZBQGGhKeFb0vQb-0yz zXZuou83Q8^Ufjsw_PfjLbKTSIUWjsq3eUV6?_Grf6|kx<5B<3=Wr7y`9&|-qVQ=RD zs|en^{^#X?cnnkkr6(v-cwSTGX!IrC5I3#Jt0!+9$_a-RNcg8Fd5TEd8|DI5r@C6{4ri-ST#BR@KO}M;N+8i%xsJ^+m`hR3!Ay8Wk^LFz-fwlc)|s}3 zwIS%NBD*J!6tU5e+s=5MBM0|}dX(UpJ_*WkEovmzN^+V`j0x}F!u(oC6a0f{oK9GM zdevhf^V`H*qL?Z^OX*IJQ5^z@)AeFI>7kvRw;*%}g2$tB1r~z|6P4_fVVPT;Jo#O{ zHI5cGGjycE_%9$I)QrWu>I(}f+X-n7LH#YAV$vP(QrQZgpLGAX?`RX)qXiof-b?6+ z%jKp|#)GzJ@4EY=Pbso;?Op&>mFi<)+Q#t?s#}9+-K|fCKp*x`HP`ck)5x)?j7sux zeC5S)YIYN(RYQKzGW+r8EcblZ$GjN3Vd{qBT0QH7hQ`;*x>tacC7*`e3 zj88q!9PU?@kL)w`3!GEUr`(3Mu)PY2yPxHJ=ga{$-FPOR*Zd9OX*jRBlZaVd&hXAu&x56H09YsVtzz-Lh?s-);vji@m+!6Ce97R0+msb^Yy_N1dl5^hf0Jn6IS34IN z_z+ftL^mFYfEv{C1e~-C9tDO?zzdWqag^Kta?)BKe!pmCA-1x0_wwxA0gL&H=Y0cx zW~0juejS}Om~Lm$oTBXRn&BYoghW;p@*H2}!i;{Uf=X`v646IRM zt@Oqs6K|HJkc*#bq7H0`!CIF_(_TLIkT!j|gr{4)*F)?hH^#%>cz?rPH5W+()qvNB zE>QMZ4@S(#5!|ZdQEBN(!P{GtIzddYCQ8MrZg86)U4AItoJNB<3d6N~?BKGlKDmxF zV0(O;PMpg50>{)%e@LJJex}+J-s4te&X{H!u?IjV$))_nm5f zgsm$@h7q2m#vtEhZ1YB{47sNtsv$7I=y0PN4sSoM_dVRQz%>U4L`?2Q{`7a>v;I*2N0WHaDN{bnd*<07bLc^R2D0t@VXo(cCSH$~W zudA@qa1o?b-8~0O`=Vzjz*oW%W8Brws8@@#ZiFjiq!b$>8O626xDRH6Epji@~Vbh3XO`oBfx(`)y5jU}t{^CLRVzv~D zT<_iO;64-DAD{AeEXshCHfBR(LEj>{{KR~cf%i520=gGw}j0@1s;B5*I$ayF^rXw1+ZQ-d9Og?sPQ0 zo#=I{yeutvM3lEH<$+W|-VF$Y!J8r+d!3YLVSano6^HkaU3F@zhtbzitpM1{)4pmR z7bR$M%*CPy*3ZL{{Ftr5()s9Zr3nSQI81{L)%<1`S|aCgw+P*|9%;v!L!{<3Q5p3t zYleS2xJqE`5l_>W+$KF@&K8sEag^6(WOk$ux_d-w9pyuTWFOk;R{>nv&~SNJr}jFd z$0wXSNmYDn*B(GB08GxNjVs%yF{2wFgmyu&_5|jdsbn|;bD?IP%s>l_!-03|w=s;A zL=PnrmgLw7%y%#yV1t9a@{EArgMDJ09Oc-c)VBhw>uhsOy+W6JX93?O?y`mUlejASa{bT3l*NtSa4ZH^u}#Ft&r3TPwntqx2iF7FYshq4j~-l6Gf*8Vy8tIT(DqeF z3ruGP=V>Q+N)Xo*BERs zOW`7V=pk&gMB{ON1j_@&r-JvlxwWHD9V~s#;nKWt5FBdflt3YK@t{s=MUOSrLiOFu zgcf@OhR+Opr9M2`;z^a_SQzj~GKjH|oL}#1o9N|g>oCpX6A{rVrfo;b zAi}cVIjTK5s()5I{Y7r=pK@;hC(-GzxPSaXehXAYB`~*muA{zy;01`e`_+m#KEUn0 zX4k77mCI^C5nM%y0a@Y1^mzHtLx`uh#)HTZ2VH zSSq)_`vq;D=AAc}T{-cZ5C)?xtf*S>EWF3@%rVhVbs3yW!y*jLTXhlmxDEKDI0FE# zCOJd-b^HfLn#!JV9fbSb506R$((WzLmvoI@3&ShEeyytT}#5x&(x;*fS{c=}s;PzzMgLj)I zEr8eLeiy?%@;rkLjKWUTa&}##+$EY5ZjRIOjW>GBraYtF!S}AG)p0}XpMcy|&V#pb znaHMB3QICaW71tK%aw-^Z^;ldSz2CV3qodNkBhFfPj@L!?uJu;0g3A+W6fw6tEL(}SQpC{AwN4}z&Jd5_aWtM#Tv>Be==3UYFsT; zIdN^}+@a-_{0ro3!`qk|5Bjd8Vr*(t$_>}8*!|AV{V&P3mx+trS$h->#Q0vxa-r5% z(PAojJk-=bttVW8OsDWXm#NCg}%*`8>kD_R>?a;O{CV1W6K6V(0 z`T`lYycKwIk8ifs#s})L3ZZLv{fqUMd|^QNxiYEk&48cK>T^NCW}b!j%5W58Uc3|z z6U4J~?uGfWn$~-TC0xiX;S*k!I(06KXd_|K?Dqi#(79m3Mrr8)E;ZX4#T=&8>LNrRJu^K6EKn^q|M_5R~7! zp%CjTOLy-e!ylU85j6wRlY>n>yZ3C*1D*vSQuLpz0{jn>Jjt&|yUAu>gD@VbLSKCf zO*HF5DHR0;OeA7T=OTmF4@+s!ZRVdRYO&S87ItmHj8g~4T(tnl29-&T?O6gKryE_0 zr;LUY3**JX@rcx4_5hp^M7aA>(5>x~{y9l2C^AJ7uWzIGZ{Z z8R&$2`yI!pCCuy)2dgJm1Ho0!w97M<^^G+Ld2x`S6>+~l%^?HJ-H*kBCFcAaLy(F% zz^%iNT5^{LU}fF`0911}6n~=t(bkU zSLhLACjc;(#oodOQd?K{`l?60#Xk9(H%pn!7nWYavdn^ZV^ekKr?&n3D0~s>gIeco z2QQ#>x*2waR13OW)(&SMJV1I;oNh2#Y^zh<4=E$`qKavky^1WBe0LIZz?R^l-3L3j zNwbSegOpnkJ-NLuA2;9acJv|l`W1TSA?!Dj|LOd7G>Uj(oEFi8VWNPcd$QfG!nVn+ zC&Iur7iN8-L(gK^(yl@j>GtEh&DVkb_Vu4Z{$DWViq48|r-YWGtJG*nW<1uyE1LC? zIOV|*_wLlFR`vc4vH5$eQBI=mQo1rJ!y#)ozAlvXuaCCppJnyGci+fJjcvVQ`?9C2 zZTj?u59Vejt51)ciqn2w!~tLT!7Kl4kN<0!#pw!)M+F0@lW#)w#NrT+lenmYFar#lo#jQ8(kf)ahU+(n4_k><^ zp|4^v^VhZf|6zelw|w-8Si+H8FWQZk1(c=8dF;?1FHIx!7+>Vz3skVvL6yDB6NSEs zB9do4j~%(SL-w0D%wR?fo&Cq2rN+mm51)oCQr&t-xHr4DuX12#GYmV#aIBzfgFTgU z_YO4+W6Jrcg!hN4lD#_R=zC^vSx;7U8-|e& zaR~!n{;Jm@NB0|jta$)FXl{R2(sp=07frT&l;sO(C6x~xxDWMUw2=03(Zv|{(&crG zvG*1g4PvV+3fVwr6lIes?`*@-Sdh}$EXf;DYI0|RYVohsYJQd8GX5pKCHxN_il)j( z#+{7i)_;7Tx0Xp8ERiwIk{U*|LA>wE_P&H3DkQEk;u zZswt2=<{{TPSum~IWI5!K=QT^jVon(`$J~3u(fQpG+oY51@E_ulgPYUBxk}F&s?^fpQ+&Jaj@EGg_V(APKmNY09uD&)Z&(adQ(@go$ zop3xp02yB`PP~w?ql#dhD{kjy@Yw296fyQ%B^%--1@OI|tX~9ZE-AR=jhXYnhvdWl zudGhC_p}%BgxpKOa;9MUN1msST1bURusIgSO5T*{2@{S))Vf90X1U#u^~_#4-*48} zWiWhgQ1e0)paCFTfbOd<#hZ;&c~Fk~y**)4^Qv;N=@#0@*{lw#s<0`N_Axn zLL(SKEl6CN8M&6`@9{8sH~Khj!xk!6j?LvVm<)f%GEmoM)<$C0L`HPd5BxcO%!{we z>FYjb@%Ag{GK~G35B`tO`q%YyJ}{f!3@e;29~yUZys-FFMbX`C?cdY^{z*mN|LShv zFnuFTH{$6&YB?|+CHn&M>Z>lszI}`h3r}C`o0TXqu#WW(29WoB-BUW1N+%)9`V&V-jtw2T@2}B(tXWM0P^UViYcT!pQ z$`NY-#4cIo(^mE15xI&+Qx|(@;z_pa9aWqCwi_b?()BND#!q)Sd9D=KBXe=^n=VLO zECBYf;u&n|>BL5O(cq5s+ptP-|9sPUF%Q!-!ZYL{lx4XydiMp`(7##{6_GV%zK(h{ zMaw>Hn$bOl-reGGgVnB5hAtQM%&!`gcESLYtSfobmhOVXHozo3f3my+`CNdkeJofY z1e%~k>fTH39O8n&?D7C9{4gOz_a+(0A_>@&3m2O#_UL;A`9JWYc<$jS2w+|^#n2Az zoIqn-JJwMm_yv6uz2I4J+2$2w?pne;fDPDFLgdxE1+o7e05+V3bXC6DqmTqW5zhxL z8_9fq|1Kt<3W+b#Tk?T=ZuFl>UwVViB+b z++^-V@c*(fD-PX0sJ;PihW!d&#`TO|sXx1eCF)2#cN+!#3+2Z{M8{ z?w(Q!)cs z_RnwhE1u`_LeK)Skmu>E4Ti|mr78zDiGtS#Bx+T{PEK>VjfjT*1GC_nZ586x4Ag{u2s;ajHuI1z(N73uV?`0$uQ;{F?4m=|RaD5rS8fY>&r_GpZB9?>FQ0c_eI5p#D-AtB(^>%g;IEQAwS za%m?iiBT0bge7Kx)65XItE+8L9(Wc?A~*BW&}iNlP_voQHugL%{;JSmSp$l@+yT^|!m1Y%?&RO?AK7=XJ~ec$*9vqxPB zDj@L#fTN62L9C0yRfvF*Ceq&c3&`*!F!kF#`LF>bm3HK=L+l=WMLW?&aQAsK*_O<_ z=*B=PspyX@CKv%acJE`9qB^Tw;XT5~s6|C+&cBKZjEgm7Q#_h|$)7tLMk8!+C__B$ z3AUIb@O}SN#3zVQx0PB~s-B|s9Wi0aDSe{F;37bC-|Tlk>{@plKK+(WF;LtzBAGu_Z{)_0onlGp^R= zJ?yVl+hW(QTS?Xu?4%}Co_-j`iYNno#?}yB-+r-hlzhH|}iO!6(UqGyuY=Ta8MA}GqduHN6mV~LvRTKo@cKf46G4q&5 z)Znw4F=fC+$On#g{Q_#zKk&pbuZDaoeh2{T*{8_2eSw(u(PO_yT!4>Q#<8{I+y^-Q zV(~XX8iDub){3ys;2$>u@qS0H+bkuONe_dKB;)8cQI@W0VXz z92{rhtf&YvPpNuHWsJRqY_u}Th5&o+aliWN$Mr=T(yH$J{!MM3?V3F{AGgh*)SWH5 z(_$)W{7DNr^97V@gjcxRH*z#`x=F6r?n7Fy)_&5R%&j^Bref^l*mJ_0Suu`snTbMc zhhf!pw~9(0^Oo5niwp`fHnhnQ&&*dAYjR0H9~}P4Kl$I8f3h%7cE8z}n+`G-yv4kl z-M52Y)D7K2_7w!yA3byC%nuvEpT8`zAZ3t>tTDSccg=@Ugfv3$e7?9&FQ5#f z`M1!%U!i=%)>eeNzT*34_UdK*#6f?B3F<(CWfaWD;YWrSnO~y!5z~**gt=&gZ<553 z6G%Ee7g&9XTjQ*7Z4E!UFHbz95)k|tYK%{A(1~ZnE{){7zJDmx>OIyx>!+~+nS^t@ z#5N2h1aAa63ToQ(W%(Jk&Grs9Uj`y?i37Xe!_3t5wlT0Owhh>610?lLf@~N7(uaL5y#a%hI_S=a1)( zpZzG@{5WCzLG`m`X`}}%(c?V+iR0Lkk+fRbt97*iYO!l}C-_KuLT{wQCPx|Pz%+8) z!!FXWu&!lOPx|q?c824DfTkhl$$Z#k=~knsR(9^|r#>n7j=FGHXX?Oiw90FWP|482 zwFLyyO}H{xDLAQ8Q&Ye40*msdkmYw8@@E^y$QG5C^OL3Xv^64CYWGDv{{`? z)12b?Aa~;l<-46IZubY=oOeJ{s_h-{OTwK5Obi~4-ik3g5iCf*e5%Apc;+a1O7_sk zIynbzj&1o?&}>OBo!Iurq|gJO??kuEZX2gnIgU``tk6%+TAz$>&@ZG(zo*!Gkw=ES z8O>Rx;OIq-(;}UD8?T%F_%J!exzK1kMHkA5Fj=?YK`g20RDlgoi#4}!cfu4EMz;vcR^ zjzOHu%R^=b7u%o~rvred=#FZEef48PkNLF9)%7(hO02ceV($7c9jQCUZ?T!yCQuqF za7?ka?`|YdB`e67fGNSQuz30TTTEaw51#XC(Y;0N6;9Jm>YRPV%WHU8l8bwt9Mvg3l(b;UCr?AL<_AJ#XEbU}KVA=~(?tjkV3awm5LUqi zc9;(lINL>}T?Y>2fGqgB==;_f%pUcTfMhEXHh_ZfB=Kpe@h*USvaShx z4?l*OO0fX1pud2UBJ+qq#tR-r;Dh0S3_W-EkFEhNPOimb9H7gRvXGx}=eR1goSRc@ zx?9KxNfrdgfkQkICmWW;yam%46eSHXBz%kk;=97)I$h$?8q_;kSys=#fUFL7%(WTm z?-8Izp#*>hk#$UxYFrk9$wv*&xzeA0*MafH11c0U9EA}N)-SZHnQh{912c8})!_5? z8)GE#4M}egdFDXk31f%12TFs5_t(uvaEBb!%PPrlgaAl;-Q&Mty89+$mOj#%I0rDJb7IguULYG(NIjYK;o#cG; zHuw@b-&8C2pi+7^^eeV6(HmY{JI_IOA2_i{ZS!bWN8RkTUYQ1|IEucnb=dzbinurx zs!C9YYFE@eB|F*EAxhTCbQijoiyVIwIZ%TvY&dkysmn9-GUPEI4+JZijQcw+s5i5I z)`C-hO`2Cvk6sprt9Kk4(r=*-NeR@betft3MLc6^NhC9?%F$#`szwiYXA8m5&zn)X zpAsXIZ0A}ZA~fKf!vk%`?y@P1#SeHNymS+J3GRWROPt>Jk93$xEyW#Va4WCV{6M5Hlleu8VRCgp&)<;RR}P3?4aJ0%eZ#G#s(j0R}~)}8PM_D40GgG zeDj8q^;YJB)MyE2W_qfn=~D-9VL`Uu(8R-q38|j)@EfomU{eNyf|3oMXyUZkJdSY6 zN^yrNnXya1|M+_)lyn_cNFUGCu?a_CjyFbPURVU+ZfP{W)3c&f25(okkuOqs24<~-yI0=tn zQ$D^E&Wc!P%4MExieEZ_%-|;mc3qks@@@klfr=j1aEfg`5c5=lO({lF%1s@B@9xiP z{7UmReuM_S67O|v2u*R&rkR$bW+iRAQ$kbq3p_kqA$tTAmM(rlD0rC5o1QQ z_|01?*gjk2XA3dlOVqH@IaN(>y7tFI1({CL3?JlUor9$R&89YJu-uW#+gaHumhS2d zZy@x-gg%qBMlhw(dF?(;3E4M6-QXaWT?>)!38XKIg@5r3J7@RRd1OO~S5bHW0+ZgW zyt2FspM`zOYbU~`X1jT+95$u=V$v+nS)Lm!_l}flzIUW-y?Mn@Hte-Y#vt_z>e6$G zyhssN@?1|5Y0Sm%wRf{}KvsdDyxuJgW*bJg`J_5_?V-DeEv5-yb$jM`zy+I=u(i{P z;6wfP#a$FY-!M7>)RWz7aCu_ZkMF-0RrIr}Pg^QY>vxXJ-%80ArJ<~Yem7L!R0Mu} zRjN%9_frKbd?QrT(?YkRCs##esP*2(i%o81pAUdG8CN;;God*al5Wv0r}Up+3*fuZ zaY@#@mb0$SQh;PqRj&D`m6ONO%bo>BqW(72CPEk z6d0r{AM)QOi&WY7SL>@)QIT0wnd>!=MpvZ`zkvE>0nT*KaUMZlGvx$Gb9wFnD{5Zs zB2glmmz=+VZf^leEFv(S;_HV!$>9O z?AJh~O$C<~w5ROApi)n?*Hu?8`{h~@;OhmAq;aEAr{b^s11GRQc)?&KAR7HUsLi+{>UA>2H6$D8?<}rt)qSyt%4H6L5RSRe+kODTnw5U7xnByr49Y~<1SM-7x87>+fDz=!_ z;?P?VcJQido5b!?Nc?$WZx|-WEy3Hv#CB3$YGKt-+;Y-KgZ^!Mjk_^l2+eKAjYXrh zF)*uvOZWBi%2;*%3u8~OW*69u^tVisv+VbD!x$PmI`;g|(eJw^!^en)WCHEu^90NXX6# zAWIDtlbAz@dve++Vwb761Y2o3A%`UG0F$X0m6kQXKyV8_ovZe31kluX5kTKH{W}6^ zfV5}j$gLm|A%KVmr~_~FNkBHb;JY+^h^BVgS+VOraiXd@*a$R+?CkJarejg@}E~<-#NZaxi$njM4%qa&1al_ z%-bzVCL7Ye>fAs35E4I*hjqgDI|ia;PMmsPdhqjoo2Y8E^dsUHEfC?mM{g^yOi+Vq z=IPDdd@np=y-DY-8+4(TB80F@mW?`!_d(Z7U5$%R{J^EC)o`2X?)CFzJaRRcECd?l zxbm?dB2J~Hiw4p~3$p;yVhBjN1J%h^TZqpY8%)aD&6>(z5<5~#v_RPt6(YPZc&?#Cl6@3=hE zIww;d2-f*;7U{&wt#*qBPSmsT(iReqJLD#)_lXVPJr%27Q(STNf-%LT&4epq(N4L& z1K)DFAIiU)2kt+WKzL8w&+5IuSE#I*81?6?2k_dkXj<(BcIT(4xxbxoZf;732 zAg%m3 zpeVsmc=+DAO1YcV4+$q`xx?@!uk{8>HgCre#*pEbr@aB2tUl!`INHV>$Tqbupsz!E zPd{ovw|dy`D0uV9ZPJz1T-rJkxW~hD!c1IH$zIR3V)+dZSrrewp1j|Sb&M!9zN>^D zITfYZ<1C)`qI%)(dG;=G;(6JC@%Z1najWP?CgY_;2S6NIBfXc?wLzy@Ku#!k?L)7% zK#8}>2Ff~)yI7Fu5l7T4nD!4TwU_WApE=1j&_j6sW>aPCyK0egtom+a=x$-o{f?bE z;ea4Cg||D-hc*#)5^EEZTgia1HAYwo=oXL&G5e}_eBmn9e|IRiV3`1MkiCfB+J5i4am}CPY4BH^#f9rl} zyn*eZx+|tbFKPR#*k&hc{7)2$)QdN)P6q1Gv&&75c@@pj1L@598pkrNOzXTas<}K` z_I&G=vNKUx2kRyA;wu@|v+*}5&)6K5?I?!!BzVA{sS;`$5}185iV_ZirUfS`%QjmG zQ7ge)OHy@*h15&(iw*ODIH_wJwH(kY_sv#d70>>oVWZ#7Bx#%=6K+DO&T^*mp- zZmZ8$v6d3Jz;4-xls8v&%-eN;mRGaq5q&i~O+RYH&7QWJ{G_z{9VYd)NozA<5xP?( zn?~p+EkVslg=JGY%q01hLVvkq!Xs{JnJhXb*^+SJAUkmt70tYG7S!YX0~?{MrAR@muwG1$+a#kqP|xzx!#x zuP`hE+z{}+gYXSV=)cN6&Iztw(HyfQ@KhxrPIMkfY^U?{bopfgb#yn$@eF;(m9E~v zFx``-;cn4~vcAU92P`pUD95;Q#$;c$YY}Yl?Mc^$?;gx*fIN7mdbOZ)z347ajEXfc zXX<5u!vL@sUs?3O2g1`CTc8=G4ZwjITx(2GzD5yWQ*qaKT?1}NJlm7f>&5mUmOY`thx-GmAKvR-eO#-uxKn%@qQKY>yJP6L_q1RqZ~`}9T*o@r zT?#Xr3#8_cq=Sy|ZjKq_a&JzYNNx=Xvt!vll^5)R zw%JPI zN6M0L_p2x%l(vEOncFV6t`vCgoD zehSFFywedx_`J_Z9m1aOV!N(dAosSD-u8d00ZQz@FXf)V1E)gk0-b>Kj9u(;oTSL;Bfjn|W-MNT+ zeDz&@1ksC5lQ!rRvghpHBibDGJ5_kwO$}JytzJEO=viAv{HWH^rOHCi+&O(@W6!y0 zWr2H9y>Ee?5`b@&LdX!loA(0wrpzL9>)iFBO_72Oxm|-*=!VUX*NFN(2m^T z>~%7If$1Dc$Ap}#MQ~f4MxI@U&ox&Vu4K=BW8Ls)G!cs-gABNuo{Y_UBoiKR6}jn# zU+W3~p`!V-TH}A|hn$5FJm0~~;W58&+|X&$JNU)r{|hYqTcq6GZhQL%{a&pJgpX?j z>!#Ue8h`=d8{`~-#tn;?YnqW8V8tyDMM7V-E3ON`tfzn_2;iAd&}#<*NZ{k%;MHmH zvdwb&_Vz6({`q}|R#x{v7TuU{(NfK5#^iR@i1$dTBUq}pFU-r#17yVNfs1sb!4No?4QIU^>g2Bw{E9R)@6u|%j#A0t*N z=GnM8G)WZ%z(`%w+G!u}PVhvhn3_ff2h+VV$VUT2_;hQ^+==FnhxDpIR1s$7s#&E$5NAebUMutbtIc+=7p%V&vS zm&0-7Of3cs?uAoa>u~kDY2%vA!c?i;D_7M~O=g3a9&zkz#_t zsLVjh?TMC?YqnOiNE-||%#{9)Dw?{=j?=c__OeR^PXha7?-OLccg{=b_6AhF!v^WU z&eeRr)+-_4cF*?8_+jpd1{Z2Yl+|DrTLYLG7QVOXXo1}w&C+0(X45m#{By@Ije9G2 z&;Ib#d?=i)*l6=mX_q)|WzsS5{)>q+@Eisthm&wJ!VP2(^-5I7Wwc~Shlw|vNz{G- zS=}UAugi%aYM$36w&kt7l9N68&OBXoBcE(j21HX$<$g!eQCxGNuyu-;f;WTL!8UTw zs5JK7GnvGw!r@CK?| z`DSJx3Hco)zY1=EZ}7znZ(WDr=?XH5Yyea&^9DZa3jhG&CRo>?6s%&P{YvQp%P7|~ zlQ>@XEWDNfoa*1%S1H(BkL&fKWIE0+y@Sh2b}Bht&j@M3b?p>N5Sa+lgSXq8#keWL1skL-m5Bm}8I;~VvJ0Ucdd zs|8AC2rcqcaO#Km*dJFMa9Zizf_5^Eq3UVD4VhP3jtaFJZ%M)pmyrx^1zK2_bYU2i zI;~v@b2Gif8s}Eq5Nb^S3iSD7%y~AcJofhxInv?#%PsVQ{Vk6 zl*y^nCHxl5O6a$q>wL&oU6;7@fmzm=YNQ2S?1U?M2qbQWG)wko?!1_4MURAlw_G!i z;L8O%2DsQ1nWiU+LEqH`*IXN2ymy#_QQSLjexlWD>eRIz)p?kSV45Hq$d$BHu7Z_r zR?WwsyidUL#^XyH;(6uRF8eC^zx&LX>JF@KaNXUeP@*G#!HULgmTVVq@m{y((_2v9M6m zs4HHV|7&88FbHRcK7-oG)S#``%X?R}k(boRmJ2k3#!$06f(f#0uMlz3bJ=(1_OkoH zW{wd&5-({$f>PX{EQ^}NXnOmeMYKN?W+Yrh%V^p6*uC$4E3%R7f6|fI#i{oClBeFm z(VF1C$q>7~SCtjgyCLGVRzi?Ii#9wZjm>za9#+~It6E`Dde7=o%Y+~0`HMfXz;)1opq4<%6JiE! zteX#V;0Gn9;JfnogE^Vs4!^SEg)ZF4BiuzlB5`V&IlVWG zEAl_|Cj51pv(V8Fnx;`W)xfkSZQhZI!{nRM)Y?RE@8Dds{cb*hug`w*d}M&No`{m- zyT}_EK&d^|%ebcvST`h4YESzXuqFvPBRB3J13{WyhQ7BuQ$M?1PPr=J;WOXoO5s3I zs>b4AwJuOPxoEp|@>@f;`|PQ=2N0{ATeE*~bb*^wV_!x<@d5Aj3v{jhy!N8e!YMRM zHtRt$s@ZNvnoNC`b?o7V3S)=4@y9-Z4*kLL(9SX3>akmUWTe7{PF~s8PutVKF`P4< z)|cg!X^igVw1AQC{RgTQQV>2Y;J+{GOM#~e5ARs+1Rd>G=x}l-@Sy=`gK~zJ8LZ^Mlj$V`J|ztw;75Hg>+dFv1hAcvS85 zpOu;ExSefi8-Y_AOxv7QW?hJD!7901taOmR-HXqu=j2qQz+LW8(PULZJGVnZ&b|Pr zyK&a)b(_*+mfXx5_Inscb}Ce)I}$WG^|!=o*LIW&+$jBaq4E0#{AWo8Ie>yFu7IEa zzVR$ii+D!MTXBi;l?`%nl^wy`~cbcA*C90+<_jbIu76k=(!<0OI}C7 z(2}M&e0_Wy(>Fp=)QqQI19CCj0Jp|qsT>o$O=;V$0l-S~Ro>EO7tvis8uC930{?pF zOUC70UUjDE?UJUjq4g1RzlNg^XXU2Aqff@Ts!dA)npw)O8u);#UQ{h-37j|- z{sd(S;~dMx>pf>(2zDQtzdClITJ`Cfw`5NXu5vayneju*4^9RZCxnY`NWP-D#MxeT z-;?f@*Tej&dr6!<_Tn$b`^5!sdP=RC&nb#ui=Rjt8Bmp=5*>M%s6cc5#elvm!=Dy1 zPOlAd+G`Hz&Ng6GB;~9^rXJmyOEUr|dU%(%B-}04DaQ~rfmva+oIiE*ux`twDbfx* z@m{doz7oRl)MCOdKjg67bDbv}XqquFhfR`b8Did?tLWAp#v+40n)P6a`;%rkmnbv{ zi-;&zV=-1-dmL$aMmePKC{S*_5n1_m3=+vA(EtP?8fJv$^K9xX2_E2WvfJi_4@Sb{`N4&Z^2=aafoV zUVnJR$dg56?b)9Aam2=yW6LlI9O(JuGe3qSeX(Hv)>tsH1!ET-h*LzJ9>96Wx%L6H zfO!9#P(oGf+cSRfVc*@=6Hx@qSJcKqM-nyl?)Dbv7PLY2-a;0Ww0(41XOL80V%g`H z5+sXbHUw=p$+niC16~#mt&xI2n6jzX)tS8)`J`A|auNvAIU-go48LPI8Cts~#^K=vB zQWAU^!K`j>5q>5caY^7wX{lf5PQO0pk$~O%PoR!u0)&>oKkSHMED*#hu+JD15j08< z)_9_LpK?#+UHD5Fp1tSLvk?xOMqas;%ZOvl`wsAb0NtNmIhm{KR4)a-t>mrH#Chr1 zp)(pEKqBZVC*wIY@=6Kz{@%s+W*ZaBR5g$M@n~tLdSNO>$u-XnJ)(PMgTquZvADen z6WXBhsw#=713U!|$NKU7kUUtQZfN?HOU>0T+p*HntiF>LGs@#c3ADALP{PB$tpwGl z5raY**WM$t`0n7)CTZ8o?Sr6ec9QMVZsmz7v2v+NYGVNTnb{Xpfq<0RY5@`Ztux?? zXxw*i<#&XPU%~%ceegWULKh!^Py#`*mH?!Joc-t$u=#~v|4+|LzfCPiULgk^(hQz% zzFPU@5jcp(Bb!spw*hR_N0&evFc(v}r_)ORAXP>~o@X>##AAb7| z&4NL&q0VN*?6x}qda-Es;#0OoaNgD9gAl`Qe?ZaQyLbQYm@)!Tdten{_+>~uaPfcp z^B6Sr?BFP(gbNz*seEew<^a$b^nQ=mvB}fP{NjoE=KcvZegIty7gBZ}VA7F4bmCz2 z9`gCh9W{7TAJ{0oNZ}rDxqWE%qdV;MZ98wd43d~_k<>_GA$>e5(I&^`yET*}_E`Fz zk#+zT5N{48y6xKDKJ_Hy>Usl*kSchjIn-J-=5GDfOCAW3(BUmo5;HR|kq`z@!h$DW+&?z(jDYLc)B<(c^wPmJ?Kak zXN!*A#V)l#ijp${V{E5)`uS)yyUm96*p&tqB?w-akt{jZ;M}TSWO0paOom#l#aQQr zGoULPT&W5bMKsgyUb?jDoM+gT1KbK_GW<9m6$#H*%lp{u0{l!ph;{3A_^je)(PqtR z%2waY>h6_!5mz%aqy9}5E=?c*DvOyUt~V>%16eb%E*301++&pSJ8r=DzN+dL-#Y2! z>A9<>D0&y)lr&lpj#X@kb*EL99Ybu4agt5E-4ZjF%)`E@>vMTu96PHK=@{y!WV~hO zFdaX!Sj~&`>EdSLt1t%&nWoed`Wau?fSDH4D9c?Ec9JH$-*5FPV+Klc+Zn9|b|0dQ zR|vPWmD(d@DO!pqy+*d2e|2-TcrMO}N{(6aYFsF?)dG(e^c+Lb47@o zm3536%Vl5{o8z;#)@oq%YevSWAlO=f?K7bgn{m4Uu_&P&>2dZp5M{-#%ii_E@j$e- zsiLgG+i3VcrO2BR?*gKdQmS#2&$J=#GkfW#w$j3=(_MC8&R>k#|>jT`+86F zE|(}NHLDtSiJPbylpEPe){o9y9Y3mZN2_-lU4H8YV`A>p)`1;|CAtl~gt3Byl#fr_ zWK=F8#-HVnsp1ZdsSsH5@@yH_pFOZzQf)4mh6ED1%j=?kWgvm2SUb$_Df?0xkv;*F!p zE@Y6n5ha_+k#_%A*n^R%L;tK2JYilPqCF87F zz>VB&HFCunuP^Do1yNG(y0-HBvH8=d@E!g9dso7*lHd6hqP_GmX18Tj3VMyFS>b)= z5$G2#%PAKmCr&gRlO-?U#T5+K(7N3-D}2@|4un`Va1_MOPb%EEd+8W>$%D>R8EaPO z!-W;9x#E;+4dloNN}CDxw}&6=zduGjDpc3L{3^xjA@7M1vLcG=nQvwYpx#2y-Xy$-~~6Y;1>;7pM~ zvkxDRsWFKg>)KzGCq2J^=<2zl$!6p+J|4>2bs)VTIc!Gn7TPpq-&wR+WaJ&U4~}H@ zs(lb9Mmh+@l)-(ylt+b`yerOkRll)Yvs5K|SugLnaqK0H#~9?RUv6wgID%k;z&JIrI^XJTp-!PWam{k?+jZR*$QfuW z4DO%A-<5i({RE8Jz2PjEZcBN|N&G(JF&tl$$cy)-LB*njIkt0XHF%NAa6U-Xf+I!yN&5y#Py<-u`)f zL=dr?Z%A2NO7)TX0EvKHUU>m$*W( zU5MsebTj5PP4(Y`1Lfq)oUUzuZs(|9x;pD#g&ov7jl*ARSg#jf`r5l;%v zbEJ0zH)(W?mj?#5%#UE7}r0zba3y-RExyrRK8j@U_KiND)^T2KIi!+!Ki zkdCDjLN6P4+)!L$W_*Y1A6Z6_7+f>m-$m#NS-l#`LT5l!+|_&k=0zo<|BlKoBBNq> z%@oB4&>eMv02wxc#AM6Z0U1SRg!mwUkhlO)k6#UVPqd$Ne-%$%`IUebQyml?W7P58 zeXjdZ^a6vG`_c!dIjOpi3O`!PPrjWSTqfC7mXsW2x;mUFxu}G(k2CjXih=Evw^Xew zNo-u*88VcIAIgU`BWc8eP_4MOB9ywhP>S)m#|h$r4Y0=;!5Xuyg7w?;AVF1rH~ox6 zyJ8Ar6dbkw$ERQi^hUs;;?rzxPb2ULI#sO6h<=Vvk5%dtBE}Bl8!^?q?GM| z2#nW8WRO$P7MR&BpQBx=4u{&Mr-GCPQ^9zOOOsPn=HOkpWaaljg=pDqE0ke1MCS5i zgdahj7r=N%IJ?DW1kJ!nBKnGTKK%6Va16pGZgqbFqJuf_72gP7sKjAy)vK|`k_wGm zcW;jPLB5$d0BGW?nZ*=|xl><`4m{9(Prq*T_nh?G1Jo$c+@66E9mCSGPUm$zfQzj-yD$ohpUu{SR#RZ{QZ|IReo6HKYW-xE9GfjjW5i|c58$r`DM3v`d7CLL7 z+odDlKXGj15NWcPQ_FggeM{JNA32;Ibd+Fb_`D=OTWClmsO=aB=~xn^QrbnvqPZ9x zI4IO*dBvO69mUDnPan8Wasz%$;4jLL2!MmC1ySrr4H?IM*7uD20^C5OkDlN>M+Z*V zH$5~}T)dv71YRHf?r~LGb!Oy(MebuLiD~Z2inHa?&J+9{SsjCrK(Z>248Lkxqif48 znb1yocb6b%m+6-pNG)U~oRY?4Rc)6SSIL`6ggQDkWNDsyYQF1!id+W7jmXTo+79$t z#%-7|i<#LJ{>D2)F8WQeQEr+unzI{;-g``Wuxz!QeCSGRSf+Kn6%xv=uwPA1 zqK%wnfy*&mt5)HTDY#I#iQZfI{`w4k2a?;Q$3P3x3xvSmU0iUhWV(h({iS5@P>d5qta4UNcVD*i2`!N>LjxIkklQ}hx15ZTVU;9lZq2mI6Mb7uwyuu(7iB+LHxthwEN-Od zv0(=$Ulrqp-Y$$8Kkzt4Jb=g3y>jcx!-O_@*yfEJw!q2Tc}pU#02}5c{%R#u7bibj zC8@h4Xi;;^irz>`3<0xc-x4#G$noOFnkERi?|(8>FBUAA$^sZM)IM>!`-W>6_Q=%W z6pJt5w_>mxV~l=YOrySh_dbBg*Rqgig&%dT+84TZc1^EkGEBE84wKN-7Z$?%ScM;9 zAe2h6ttowCiqpLgVO>(VgOAcb=jl<&+A&7lAv%<1XN}xbX_DFcNM&c??bYa+Q)K|h zepu_z*+T9LV~`*%V_UMhnh8R4vWYt6}W6~03w@+?TK^G#R+J3%^g_IPnV}_ zDHBqH$tsg3OSI!=FI4t;F=kn>(Qcr%xNncWW8#%cO7(rsI_U*VH-*aWMHOw5d(CD= zopW5Eh~`k!JT*n-rufagQ~&jX#+2@xrP?aZtt7^tN|D{Us1C9KD;KA*PYFaCX1hRk0!kk%^RrTHCEoM-;3;9j82E0&SqRd68@2eZTz;b4xs; zg5>GCa*IY!)uHX}nQ$j#j(kocD9 zP)E5t&lS~~XC%HdPj>v^EC8zedJ+X-+OHO#Sjaak(*m!8W?V|6wK}3SL*=nvkEEWdX2lE) zq!&Qftj8;@b-bFqvd*zQkCyT`8E}OSpvkaC4dn&FUeZ?3RKu-ww}r;A>dWa&7L@OA zb13E0jFtw$%;<40?P#Uq%?sFpU>2{Y3qs8-FKDHrjKNI~z{elN%qQkYLD%BOD(FQw zLhhS{iN$ikxGO`yu}sI!zOhWXzcD#HT^kaC9zBgQNk?YYjhiSe?MHZ&klau_qBI5V zuV$Y@<7xcn#kVffaL*i%Eb{DrOc8xjQ}L|n0A^C5=Cv1-b;itfcP5R>fRw?!o5oSV zMY7HSv=RBwI`-p)&tn53LpCT~=@9SUwXBb=t#h`l$e>S-4(*yYJyu9(b|7L@WHaGD zk>E2p_LdkFKPh80TqV%F|BS%6$U6mylM{Fd(f`g9{Ce3`B-e`_E0-wX9dZK3FV;{$ z!p1q%=yMAl1_hJJsAZfVx*WlAo)Uv8Q)nrF0)8kl#@bTXv2VJw^leIzroW7g5Z#l7 zT*WC>ryFhpO(M!qDrK|o5MSjyCe$|lIgyQZ4TX$JmQu>*vA$-HHs_HYTZ+J?`*mrWtCqy+s}tgSM>mjuE?=i5AJjHcI2w+7V#A^<~5jo?6KB1 zIeq8jGxZVW{jQw_2pPZYNnKk2u;h{ftm_Qn16lKs9_0F$Nf+sA#An1}4n>V0_Qnq`i1D|i3!MZ= z<cbH_EZMqp_T7Fv=^n?nZ(#hx#g|Y#oUBH+C!?5A_0Py-mX6x&4cSwxG>+`YBAdja-M;SsY2=>mqC>oetdsW^j40}nRKbvEGix}8u& z4i68r`kFvj)5EBdZWuqSEIk>eN|<+A5T+n|GK(O!vQiTOr(CGi%4*1-Q5W~%rDndz zys1JnVy4rfg#)rcLEEUe_bCu5sjrzj2vj=^jB3Ovgx(yXPkkVGx4dcs)Zfb3mLAyl>`B0F$;>#r_AV` zJ7}Si*0Ck78kKb+l@+H(RGfF>b%lblG#Amuna=%Cl~nh$=I{H+_Nra>J`#u=O)ybW zkLYARr0X?;Bu(zHm^VptVXTm6&~|!v){ZWA^x9|`%$=DZ9Gq!yKcAayy|BRT$2iNI z50nkJIhheS$iusosu7Vp$3WAF4lyHK#BvWAD>^tr$5V4NUyz?vcRRV*(f?dQEwo>q|HgKw!5-tbM#;%6Md?lh*VBwwXu1jSc~kDUR*`)!3T78P`kC5 z3(7LdiLYiDF46R4y(7Mk@9aCv5tv|8y7zwc=$Mc})tP+ImQCdlV=-f(MA1{@A- zl16+e{#tOJQ#m5SOC|fxTB7OjVdj2nZswJZQ~3h=IOLe@^~aUyg&6YY7dH+7QV`($ znMfH^qqDKxO3}W5c+6Hm%%bak(%Yw7YTNjbc+_QOC`Ot>#H$nxCMhn&L^wFIh&x{#+tq~b^=rH$qy-20hFN-`RfZP>UF8mUzY6QS z<#PJ6Xe?bEH3=zm>*{J=IBDITS-s{#m7-D-ifAVH;RunaS<^Uk%)N7^edv3~_3Wj> z>%}2ACszv$I;%mHkeK65aEie}u!3||1u zo5{GM43%rRbH9D&W_RGI-a}1KQcX7p`RcA!miHBG}S6uoJ)6L%r~4@T?n?Z3}Syq}_YP#@EKi`sw~ zO-N511V4%YC9WqTC3EWUK7~)M))S_6ZHdd?pTc^SVSpW!B~$|hp?nPM+0MWH4IBOa zPyDfj(SC8u(A(w<^YUL{A3yGzob{ld7#|G2b33G`U5+o3Uheq=c#(CB<|TMHqP@~b z4N=-Akg-PftPhCRLj(fr=?aD<=fj7Yg&sbcj=v-wxM&JR71^CGHlc6OxYlR~b6|f@ z(yIBKS`61Ul~eTNZ~x=HUz?+!QiK0T!+?NspOs~;%lhh0?~LyCfqsbo#Hj|k$`!d) zEzQnci3Glzl4@321`V#ZTNZJol=$V>o9Lt=FLI3C zyQUH1>!&*>uT<3@fh-mSAt!%Teis*7*9Q-j(Q-H6E0aYk9NQJy=$9OZA(@>vH7{@z zxPa*h&Yv?^KBT1YZg>4G{a!z@TC#$)8~4CeD>O7vtuwJp#vA8sq3J_)pd}D!b)~=_ zXOyV|AI9*-ypN^`3UzwI$Gj5;l%TIF7)e|yt)|}rM6~$1h6*)4xI}vrkIu!(jbyy` zd%9mlN!@aVc_&Rzh2b332LM;KMmdAs3*0Q`N@(5D0#Zs@Wx^Ny+qj%1Uf?zrD$p{= z*Nm9GW&;v=wcjzJIF(5s=EC>st7T5hsTTQIK9axmj1=XHM@Orq&JOOZe%gIVpX(WQ zJ+J7|TZFQcpq08UXj}fggjvwKZhYQ&Y{}C=bNb5caYC64X&2dQKDV2LjIcOUDGeq4 z4wv268?hZ=#H>kpK{MZevuVQ<(1(MEOHw?S_JA)!wTZ7|9~;DYbL88%xTP(PIlQEY z7#8^)sbkp5wmaT&0Bi%^mNcNM54#1fFqB?98u7?G~V_`+n!Wa!0&$-7t5K+o$Pg&RK2aD(f0-`?Dv=qQC8 z)0T!WrnJoJIm7qh{LOea1r#gGwLX9Z=|%Tpot6;ox%$@(^D`CS=JLg~-dkirE!wV(TRiu>8U-f_0GM!ca=LsN zXV&eJw$Dn7bY;Re!XP9qvnF=;>SbxvqNv8#nc8?z_cmb8*vFzmCoFGYLRmOQx>cC8CZ$Vx6`cl@gi3&9LUNQNFZ9MZf~as53}1T z0TL%zuiT2hsr16nV}++P9NN(5aGRb1l`NXedzYm5x|(TF-#zutc?tP&`!ONf=(5XF zTSutCb$$E&-RxKTc_`oSWfHCM%Geo3uV}7rEl2l8T>2?2qxXIWzxtDye*cJL${Ydm z77wTK&J$4my-Ira^K)(lRr{WSYj5NkZtd12Z{^t?d9&8PRfd&(C#?tTq~cA25M+YN zVWSk+1HwQ8g9!Cpgnj~4m`Ddy4Dqtqf;X3wUk1XV0}oQL+c0XofG+JF2;uc(0N%6m z>u9{C2IcX}M@XDw)&Y@B9bUo1zCQ;hx}^8ELWXGegNF@JX&|LZ+gj;ld60cj@RzCL^POOna=GTpSYVHf|$x>DdVVoMti zF#3J_8s7~WKX@DkKkz-KFM!@l=dX9q-@VB1TAN=8hCLQWyn;<<=H}>H2)79n*#F^^odNrZ>16IK${>vmuK@o4W z%Yzf0`(sP&p5|VO9OgXL;jyux#sJl0y~T9TF#P2rWzLbDRu{hvo(TVpG&cd)7gL`_xaX%urCc8tW4B~qnKn~0Qsd~()uUr?IYM@J zhP<`lVcw)l!nJ(vlM&j~87R6a(-ekK@xw>hb22Y^hpT96O+5;kfFVex;urE^0xOB{ zEw%Xz?X(cd?QqtKRR_|kzQJ4=+j!jjBMgt)iZ9ANAQs>89_go2SQ#+R4SRnkhRU~P z*04_@D1A!ul|#A_gO@yg9NB8r3bwXT3imy7{n!B?md%zGWF=O#RFdJ>hJYy^@s*GXm2ec6@8a zo$$oeq<~qQPRI-3W3)k15;h9J-j}1;Yy~IwG4Ru$ZbwKw<@= zWCjNa|yiu^BL8?2iMRa@P z9b9~0CxLC0%9y8b`YHMS-Sp38ig-}_o8gpb)rSO0ti$acva#V(wZq4fhTWA;FHl(U zOvm?jc^$}~d1yGK7Gq%^#aqKYhT4b5ymG^ks^m` zawmJ(7(ak|-@@mL-&)t~Riw(c0W7?9mxd3ZtL9q*PrGFHjm+~wji#T-_!A8;$TW8p zyz0U?7q>1W{Nf+~U?Xz$x?URySCGtjZ= z51_G8v-J)jT&RO6lMJLvLkZcP-c5Kt)OPlCl<*lKgWC&?7qqc4?ESlT^N~+gYQC_d z{vG!=(1Tw%i$69$`H6okT9X50>3wxy0hg#S{WOueP$gmcumPLRQRT8H&5l!$eFjn= zK(}*cj$bW3-mJ+{@~Al>l(TFF9Goqclw+4#Tlj9Vft_Ezjc-FwWTYS%Itt#GA8#Am zH>mA!Fm7G?#3b3{Vb+PtlUPOo`=X~h(VJI9&*Off<5^sb%o_XELgxZTDmC5x=_CyH z8RmkqM^8>-Ub(Igpq1qr)D;wH&Xc#+P0Qct0aFu1E)g$v#k#gTU2kgHTJBoOzuHpE z$@av1OwC~E-9&zo>P63g;CNbgt zEa3krc)PbpM_WDnp*AIGH;7>dCV1e0_ETEW_?^C}I1LpMl2dKG!z4;d>dIUsZHJzj zSdD^%R=itWQw^6m454~ZFf@OGB!MTPFe#rM7;u;tH& z6dLN6`If5+w<6Wm%o-%#;5N#u-DhxpnCNUa!+RGOti|S1a_0 zoAyeCT`uKj^_g1GnR~AeEHak$K^9Zm2muZQUSgQ0ml}@@+DOjGxuw~bK52I{sUaMJ zleI8dL({$EULyt-dG%~R?vdSP z+3%Kds-opi?%OA_4DHFpa}$O01l5No7H!>g_mLxF{E(=V*%~%@+o74oytb8P5F`dF zu=`VOqbaC{zG$E(IS*IF>UG*vT;rU#e)(D7pE`eHQs2>`zlWlJmHfn{zSCb{&2v97 zsjs@@56z38n3Tpp%WwRD4wDi`Wvxuc4LlXYGuJ0P}3h%$)gG8zhka1U2aG0Gu-?8!A=16}d0 zv2pg{G2e~&5ibc0S~n2iuU=Ii(e^OPQon1`%l`rUb%>bpVAP1f)Pi|=S)AQVTlOP_ zS1r?oS@dj=K*?uyku_sj9Eh;Bm!K%i8|9!#QhN>Kn>Ofcu1a(Bc{wnH#u%QFVqx1= zbr)taN0J>Mm|>A-6t|e4;s?=_K_<_@_bv}ujn2_Ml}|BXxjoiVwxNg7Xaj4?#f&HM zZYA4s36lkh_dGL?6tZ6mUL`-tGov?cEL4EKNd7`G)sO|DCIydy?_x(bhAhupG)c9W zx6H41%2*Ngv-MzJ@Fr zY{eosEHi8X`Pg!HxqWyRbf3GS_gysA1NzYVEw$6QZVsk~_>SB8GT}U`WtCpT_q*Pk zttUJp9?G%qQ+Sx8^8T%%inJ?#B~8{8gmuvweoIet{*Hc?K2s%-Z7t?=)D4{HQ5pod z>YuJx9pz9JR9~{2-@T6C58;QL>h7P0>|MChe<;W8ae-U%MgrENb_-hB>9ucUizQ}$ z1vhAp80^?=?#S!_ZGj53U(2!L)Ecf>7It2a9&ro}MGjVbD=aVotH@n0cr*VMS+1P^ zw<+f#?{kNwtx#4OBOy})xp~jOQde0(8sRTQ&Y#=fL-;qu`LB>1b#2C7+s1{iOO3Q4 zP}Dr}hM}~9f#VFr=+o8SzWxUM-Py!9eXR|g4=*0cPdgBFp&}BdZ;Z&N@@g?Vj=qEL zl4A{jgei#*Ppoej>^*t%t(cht&P9wV(7DKVVSki;TU+~^_*J{Z=dJgjcZ%9!C0E9n zWeB_R11 za3$Xs(fQ^5_grjxzh*oAdya{}dKurthklg-sROECEyDlmr~jGbKSM(jU*`~9NZ0yG zv;4@2{3>a{<`ZmW`5RHw=QILE4V3fWeK5aZYWkQ)@Fi2z$2@{oxKASYQVNRts@h;%zEAEJG2T!mTZP4nJJf3Aq;^t3#W zKYeq)x$^(X>;rvMeymAQfbCd3_F%N~4ekhu%|_T{@(cvO8a!&oppU!!=1_%!rTeEn zo+}*kRyKXFsu4RXM|zP57!@^T@q5R;c(6yjotmgD;0%&$>lC3^)J7cJ_sHIWsGpd4 zX114b4rz!LFffy60P1cEcEbaLPViML&XBS9NQRDPNl+R0zk8&}o0uAudH8S>)_3%NYp{K=iN|LT zW|iLj0D55*mi+OImBf7`E}@VS2J^$24D8$4UrhpVBiPe%sOHd9m1a-pY)JAChgtO zJ9c>omZ&Oh|BQ!@$$6rnub;fIAr1*$>tYNw ze0od-=!CV6D+Ikvf|xONIQH`3W$qq9N=o?qB9_n6cI4Q#2e)c&Hp3@Vy%3EsB5XRl z4t1=ZytTE-L+UY%Qp`_ORK!I8z)hZq6S1+epGVbStDYh8hBrJVN+-&fGFOyb_I7&t z(c7&vEX?LHfu}hGqwb2vT-qDuM?M_VSdOs@T-<%|jcrS%#_f)YvRqFjxtq(}WfRWV zo-NE_L}TT@zth;A8MOZ>kbEA#V^pZ)U7gY)xY z_&G>^)gu4R4?_n2lJhVB(u*{nyf~MdG`<%q&&FPKUU}ivZz8qNnlJS?jrWV_r!xFB zTl_cQ=b!iJ=RNvqz5M^)WP@h_Nb<$Q#0OdzKI!uJ^5RXObh-9#BEHXNt)@E=xzYig zQ7!+ANMjsed6Lm0ZZQ0|kMkU4xe2lurTF=@pU3>{pI@GvpU=k6ak0HZ{@<+==Dgog zg5YV=U{_KQc=}??Ky57_iq37b8FYF;7pg;~gz6Od7&8cd1ub_ZZYk~zh~`{ptT z1%W@FWu&?%|AGS>nTn^&IPDG5ts0v4GB}l&a4gHCsve>3JxYT8k*8ZEp+2_GeaXA=xlTb+Wa$U=tShgCWVi53&0#FjMqwo00$-_W6T(+e9q(M zR8QUpcRN_gadaNDMC3VP))>-&mN81bc0_k#%)54ar@j@z8^XFY?=AP-SAxFqer{@p!$2 z46qB2-jEe2eB;AvbFcpj%EZ=OW*#CQgaLwMae8S}K9sLlKzYz>1=}&9%U+8(PJhgf zs+0yWwT#HfDTGBvZmG%#kg)5CXk)yen;DLraVq}!EoVDQ0VBhp2k;l})m8)=hX%$P zlPmVWBC>knUItjwcTl>i*B9z3EMLy#-CTHkLavNN4TX**XrhzGbXB?c=%2NZi_ie0s}xWN?O&5QA28`AsOPSg#e5#dVxfJW{=J zf*`%*R4guYbfru?`hQl{O5{v^fX9YlSm8&vs@Iw~b5Q_##b4%-e6DT$f1L;BFbzrgfnkwUncWgb?eImPm@odn>)x@o*oip#0aS(8 zn1rm?oR^s-u1_mI0FnT<_?MBJLus5&A3&ZfDcfiMJo;y!{GWYJjk`kKS#??4f0c~{`b!vI#I7b{b|!H&5V<_bS6hD z>Tz+(#q5lhdIrL-q;G7`j|m@VMu(q|^v_57zyFc`?=jvyVXqRph~rp z=htbSiq>|n@jcFslYsIUlg}B#HqT-hT;zgY_f*+*_kD4}k5?D>PZ2rJ2-}}Vvh2rt z0pWP1sL^K#Mz2$tMgK7#&8pqAEJjK`?napT)f0^2dAJPa*R)%O!z@ptfOtV$g6U-a0z{ZJr;6@z5*f?{{qOc+^PZ60dGZpOZBmmMl4kb$*K zt?~)--7wYHz3}9IPKb*W4~@$_?sD0tCp2O6Aytv+JGBEN8Y*I}%N5cB1BM%RbMuoG z<##brhg~gZn{He;dN*WzJ8v}F{T(JV?SA~CGdO@Xpw|Ev9B>!1{9Ke%f#4xLyHcQ! zDX3M|C8V|7UQkGMK+jWD{%7FNmuJGL;^@(mk<13f{rrYE3it+Nb9H$`)Hg zpQ$e>RINy<{a7d6J$Md`7&BkZjtLAHQPH4|%4j0tp%GzAy|XnTgUnE~S@GsO-Q}$0 zRY9R0Hb!+wbbi&oILj#JYZ^wzm$O9D*OjLh#n+lC(#PMOa(N;*_K=_eeSnssdjx&C ztZHvwZhry8k*iiV1*bDGL$Pun&So)CMwTp4T)XRGRP&e?>L3hB*K$LiTp!uP~ba@pb*pfJtMHU7!AR0kTycYj{ubc0=p%-RJ*A z4}AACkBn}0<8_)gb5?Rf*Y&1VR8;=vwfyixca^-Tcp0IbLUPxWjFNInGUsZ%PN3R zig{T4qYR}rVAPih4IT?tt`$9@t~RD)OE{Zi!*r&nL#w##f!`T<{>!IkJ9GM=c=@f? zk|I=I#(hA@W#NlXJG(o>!s%EDMVVz}*u3J-p2Tb2<=dB;uV5COv_C{4yx_{a)T|w3 zGmyRS58}c{?x$Kp+m0XR@+Dmb2VAZRS-EvNePoH6W}%-T@bpc=C6sffu-*NleVNX@ zmm)nJO(LS)sUM~_xZ5{9j63^~hlQ-KTvpO;A=e^_`@#*X=SnS%MvX4_j`!&_6({!h z8Mo2Vy-Wm393;tlA1S?UXD{sBHlHUH-!rPz8gXSNgFuupGYB*aRSek^CR#{aNZnj* z#cG-j>*?wobV0>xrZF8{_eVqW;jA02*5z?M@pW8r#f*3TLZdf*XOU<~xcjl9O5$tD z7wmyka*~KDq#3cwGo~e^s~#_Rznbr|@MKuvrqtrjd{MQF?wq~t0)1B4GdQSn*S*GD zq0=b`Dgy@h7+WHJ6ib{;eGfer4`n-@LodXuh2*#283wvf7 zdx^N#e2Vxe_nN6lXQjOR!94#9mJtw<(v~6%F1Uu~bopv*j`UeuOQD>y1!KntaKot_ zpQ5QpAuoFfr_ozk_y5gxnfSy-oG(s4PWzSWzYHs6Q zK#5fL)kNbqX!66(xpu{bNGr$Lq+p!WqUn_auk$G37Y%7yg{3kMvjQ{)@&t&~$XLV# zaf;Vku&FVxR^0?Z0K`nqDUX-u;UbtPD=HJqbapF7A!bw^qgot2Z_ta!x{up~cEur< zC8jtzaa!)Kh2Ay}h3DLtc(_`9G9D3Y0zA;Sd`NAM6HU;;_HuRh|Bt=*0E;3^`$t<* zP!SLm$w2{8f+z|osX-)(fS}Mwjv}<=9GWI5NEQ$fBOF7%IUR7Z-t83WxdMN>!dcl{OFc1R_E9Zz zrNC~(;HM!aXj-W^X)jgr3b7{i9B!K@A}q2QVo5#3}$G>KH4L`EA%$Up4A$4J7aB2_VOfe zf3=VkL+&vseqLB#{A+8u0ju)?t-msIr8xVI_d@4nN41$IHWZwyI5TzGB<}iw;*LWs zKDZ42;iKD*RS^6OpMcNd({#tkRi-a^hkelryuR7NmlnXIU^p24qR1qBug+-dAjf>N zd^rZrF`k>%o8-q)nhYn6OxM)WG~dvDuwHC9?W|(YtpA?zd-ESddeQf0ZE z-1D1k-ED(Kx`wEV>uxu2)=sm&B$Ere$+vdd8B01Ou>y?)k3+6hjjvpKadQEiV~BN& zWcBl3`1+P$4oECRnrVewe3#j*N0Gr>@Nbisl9n#jeAi5m_N6C>0uI8q1x;BGiGeg?COmOffRYtbL&~?R4*NnN_Wgn^( zEXlShQxkBW9Zjm%T53*ln$}Lnom%Pli1z(T($Eq6IV60gM}A|ZGeN+axu%2Ps%{%E zt2gI)rM72iuWzt$(CN=@h|#<8NvjRz7K`x99dzLz8WN6F2*;3uX>;K)(%6@~ch)ur z-R%S76gUYKaN!B2&Ve<76_uOmRZj@ITCx^Av9#g2bK%f9XVLA3oYu|Vc3UzUWk8ju>gcsUTdFgs47x@PD+C7%>8w+ETf$Ys2ufn&ld>G7t1Uj|%oN{AIwX5W5 zBDttNbafynuqU2bzY0}9P2tp&ke4ovoea!HD~&w=7%VFGXg!#~U3Niqs7McZcBEFh z6E}4kPx62c$UfV?(kT3RIi{p^*zy~%0SV521P~BohgSfK_dA^ zBEnK`bA#%VAQac0_06ws4bAG=eE)zag{vD*Klt=_Nz{G0w0(bVwf{e3REkCA)FY{b z+^z48^k?YUKQEmAhi6h++Wx$&>ul$$qyk#w(6`pVlT`axMYZ3(d3mIsKkdJ0J>MFc z?>`&;hgbXOhf`X)p^tvmHBwVkfA`n^PhEb|x5+;St<(O9WRV7_SHCFz|Dy3*?1~bR z^!)++DldGyXZyFc@RBpoe_4sm`EoSB|C?HP%35&1-t}uOyl)BV|Kcb9k+!A*7%f!e z)qk7f{GSv<dI=BG?&ilHtp;*W@`-LExp2rY^Y@9!&Y;esi zbU|PGipn|v0b!fqM_a)l(@5GnuhpA*^Co!?GKDe|vZPk~`ZZ+rmEkSfGn^V9E25!+ z-GxGSthZa2{LsPz4%}aYm<`wC@$!d#VJaxEDxx zY%l__l2&!3%;o+q5kb9=E_~|^E_cCGddM&3VXEYOQ z{1Ca8$47UT8|9+x*D2m%{xpcJAWMf-_B1UT3fdRZuP=1)e*@Y+*s&(ZTsf zg>eq4Vr6qWg-oQg{gMoC_o_RXb`wl-sH!q$mLOfeC18zU!cc-c@hYg=ySNSC`R9%b z+^cN@o9P5cO(Jf&dyrV156U|407fFf=#7>H;DXcl;y+inpx4%wt4!9?B2Xxaj{97S z00NMD^`nC)b;A~u=>2(URfQrC%jFj$0MxR2HEJHc{G`%k?FC@{-RPFPxT=o9u`~^Q zDr`;GG&7evymIJESUJHy1NOJ04n@gdMV+C0$9h6Dcvtq68()pyw3hYiWk^B9^h6-WWk?wrQJbw;wQpUm?m&UPO9G9xOUnmVv>ii7Sa=Hq_~-A<9r(=&LsF)u&`NSp z^Zu)!F1-_5U`H-P@RxCLmEO7%c=5{QRQHB!O(*G!Mb876q&Cht0qxAblfDz4tg$x< zi7fZ3q65%i{EB86_%{^}j7O(mmaUA1l3G=Xh$hugRP8TiB>A;rB~x}MsRnb+l6e)m ztFAJG9YgvHtL314>)s`F8ZSG;WLSYHa7 zXQ{e39a{pwr&9+u5ZzrfIzr_sDmn2ADM=*W3#ALx?a?fbPm zAc6l9K?5^JoU#*#craM4i0H^(EX{S&6J(F%y>%i#f$=Pn=b0QBRK9AMPoQ>S=FXT* zcA+FQfrl4z9Abv)ks7=!e-b^VTncs4UaZW%U|sdh*b7Z!uS0s*|A_8Eh1ZkPmuxPf z=p6C3(PUvJ0}cG8f{Ofs7eQ#2i^a|EtcfnoeG*Dk^aAvRtKk zcIu?%bX@IFx8s6h)sQf|or%%eXa_?McXtKqivSd!G*o2X_wHqE6q|ne6WAHV9Za34 ztF!?skQcom7kck%ImF>+-E|^_`erzqdEch1<|uuhGUSQ9cQ-IOB!^UIqkZ^ zHOe^RPqg^3Sz@`4Rel+>KEv~0-+R1gwiQiF#eiRLckwhwlsQzozN`0}i79-?`r(%tx z{4vPmQ1)h`%~ccSLgAdx4hZJ3b!`iqnTh9XX?BIyIVcBBEQkBegX;nRkQjDB=CQ6mGR*_jzPHF zbb8B21Ngf>N*_foZXnJ?&ieTELzGBAzR@RIqXQPDTp3p0u~rrXn+$_sE19#p)Z4D91+-$Gq6rfa)9iYLZcirv}?a0 z&J|%rQ(PqtGNz`+HJzx=UfE=2Jx%nENW8@v;`;>`rX+Y2kqCnc;~y_BbXtqi%$?}9 zir#GFgC=K=O=xP$vPWJm7;g$Nj^kVcS@Q})dK2ahAwMb9R-i)@Iot0Tpc!W7O)hnnUg7g1WkhHRF%AA3kS; z?tz?LRPnxvUmW3z2PB@Ajn%ab9rST^pUZ5`F87G%A5i*LHkQ{i_(IgT{%TJasHxIsw5a{!Ehr#PheHz4tUUJxEa zhq8D(s{Ojh%*=ne@0~LL9*`(pJXza_ZFWKi*4}#QM#=m9OGqXf`cBXH800{H3^F@{ zc`N2|hGCh4izhDBR8v=1(^L1=J_D}`Y|$Taw((6-pyRGqY}yffekN6>oVmCNMyT&C zG>hIr3hOy7ppiy>3I=705!a7F6FO*X*z#vS#09kaQR_$8eIuedU&n|0WXr>Ojy4VI zb-py(XR1Fw-n6;?3C}bMR_rf!Wxybt7Gw==B;`5zuFFIo^D-ohM%yuz<} zGnJs3ZJaDm=)y-BF2L^Z@}Vc0FfYPqFon`g@%Dn_k9egIl9P@>VCN-hah~5lXX~7S zxG)sWT^^D>`~DB>H>WxR-_L|gb2Vb>0TBnng1x8%qiUSgDozusD&3ehy2p_m!Lr2^ zsE12`Y6g}YyBHp4P$DDjF@6kEY^er69x%6qJtC%)`7$5%$(_&&t(cFNcdY%GK8~(@ z&97Qe)WvxkbbfX)UT+W?KdRp0V#iR;@qBz**LHUwGC*tgT2MR6Owar_Wwk!vZao^- zqrNYoP~h`;Aa_NV+V9LKo?4+JMfGi{hG9{$-{h6ofe-vjR838PvtXro9a+OnWxz=G z;qOh8UHG!}!4IAY@h8vze%<_COOc}gktw|T2Lu_wpq)$mn{WK*^ZI}A3BOpgzcm0D zyUf17%F2It+JEl@Aw=Ro?Y~;Hzqbbe4MdUu@jLUsA({t5wT9^bRq|3-SN|Ws%)k4< z|E2~5Pw)S$slmY(wQePkxB0MJKm}eb&%weT@~JTZ+w=sEI zh$z|7sP?OGI9K?9vEm*3m!2m^OcB1vp*FammKsgy#f+N8$NXtYpwvrHJb5riQ8<#pJVO36oE6UQg9Kf>~}p)jza!o z^HpzY<(%|#5lMcT{+Dq#F7XP6>$-Rihx8drNztfMvkXE6QV&Hj!{OfYA~#t9sIlc; zpABKR2Ne@{>fIOyZYejIvof{X95n7Rf**Y@22M2gEd8X4->MT>0?=AwKp>DVsXIgl z_{ItXRQy()v692oF5uDdAd*Xe_^w9O%* zveWW~4WSOqYsrJo4*T0*51%KtJH}g-acxMIJ8s4xG63s)56)yd`@kimWVxNKL_WRU z-Ll_Pus+YDwSlh>?wOoen_4+=Sl-T^ktdwL5vCLyN7>p= zJzXwZJG2r}hlbN`FY9cB109CHwS&Hy!oSBSe;1`VSyYBr?rQK?4&GFz_IbQ*ut=or z7VeXW^LYdae8~NhIs0Bx!r9IHTS~wp{aigR+bDUIuWS30#D%4}92f{#%>hxrmQ@G( zKu-Q1U#!28Y|lC?<3j!pQxqaj*a7?T8J0PsQJTVJRKrNk>tM;};32GU1xx|`EG&;b zw+oqqrmqzj3R95%JSx^|hZZ)OZXZ#~zo96!^^oRJF=3Z)AzC3gW4ZFRy`WZ18HCq1 zh_45wC??WF`B`m53+*6hW<=0)$M)GzCoeNn;&jXmDb_X5+Sm+gczqZ+T3=@xSk~T~ zw(!^y)C~dgE*0W6xWCE4JlpHQ;`BOxg^$0s$Z#U1-a$7L2~IqeG)6~r$K_<*RPoCAR9SlN z81$$OCY%y0EVlMXH5>WFn)m#Qfm zGOQ@k&FgKZkq9SgxJf3lq-}%Z2^6Knbk{i~Ykxr(YL4bZUg`%Ve)gV@Bud;u+{aS2 z#FOBRb*lOhueP7xG*ja&zAg3StAwSTSMNSVW5$Bwi({3T*YkndI3bg$a8Va`?x4pPl;1zviK&n=;CQa)70^E5x3MZc+w-Ql zOJVI3ltC}GBx=U`UCXn=0wS8Qbjq)z!L9McCeg7IuZIO2<)C*yeZ3NpX{1kjhh2fQ zcS}o^#6hxX$V~a6=Nely-+NF!dC0r7G>6c?L^AE_`lPNdZ^Nt~!Xne){EpBuTR`Bf zi3wk)hu_0MmeXi48dT2sI9qB8l9%uX#oYj^OpvkP1_Jle;>&W5Q&wr+8 z`<=semhvv=Hlg?A<1cCq89tv`yQ3Dzg_RHXDrO(rrp{w4lUDmYmR0mMi0G8Z{xG}0 z@Kb~7)wA0$DNbLrzG2={bk3fEM+384i7%?>(g;rI0Zd2952ayi7m!<-EvhzcDZ`X& zji<$R&Gb+@dLtzZiiTJ!D!9ng{cd@gM%=&BzL;L}pVFP#zHPtU=s#%u=@@d(H&}Rc zFe#1)qIL6#$NXl1zO=?eDRQq~{&{Lvo8ZUJNMZo=+@FyFqn%f&wXZ#{Mcous`Zj=t zD8a1rmdpad^G_L{3fTO^VfJ}H zW$5H|88-=neas|V5E)}%T5QU?EQx0egK}W*d{H?#A8E{LM)}Y-oy)y$`@OsquJ%ep z!TE$meDN26e4Y|2+S+6bW18+MzIvXZ&w>RzAmmvW>~e!@&O@FIZ8A0Pd@y#S-g2|_-k^j70AD1~;Sq9GbSMRVdH3BGH?j99>5ew`tu{i>7Udmro7v&XFY$SofV$~5t${UHDNr{-+v5JF;SCa4!W-Uq+iBm znt~8C7YbMAjKlf_-VHuwVgk=9&S85eed*S96IKz-Sptx?EI5-gczVjOk}8PL*S3on zspRLF0QE%PPRi^3T)w9n^VP?+6=Tt?Mchi;RQVzbn$ax$gs%bmp%3!XNYgb>!Md@; z04IRTdovrTuXX2f$)JARb=v8Y&X?K6ym_J!_WOFHRncqEieE0~=f*dImbi;E$4V+S zc4YcGeW;?|;|R6sH}m1c_mY*nS1d1)%ChID$#Gde*nG51uas$QfA1U-YuE@Ryz4+5 z_uxiKpc$X9idsepb1)R-9MDEeR!&%*XE93liCmr)YLfFPtNEetDHk<@!53nduzJ3) zHg3Ic7yL|EH01SFR5@5>SVrp^lX(fe)=nTG^a051ASvijE6d$)0*LrMn!6W0!hnB# zjmvNC}+oV3}Uc`KWZw&9fPL7q4-!azZC$07P%i`2MP3GF)9F{>Izdz$|gwXGY1Va{NRd@l%tzLab(v zK~y++^KGiW5}BKR0mZuEA<~&rjVIRq)`Y03278jIcsg#e65)6^cJgUk_hq{ z85*sEy!_z-{&&1o4A+;WAEE5({I!XD(;Tl2^`mT;8Iou$VFF~4qF?gZHE<= zx#ZsQ@a*$T&hKB{V#MWs9{)ScqAcgQ-1Nm#d8f?D1{3pYnroKHqFy43B~J&p&A^g{ z&@P1?VmZ6%_B(HAwrJ3>thn@SlYQtLwn75 zxDl%cl||)#s7Y}k1f4WTadl~3Nf5dl z#p&-vsH~DmNrj-&vue6Y4WvxVK=vSisso-f>F3a!g@@V)eWZ4!dWA8~!)@k>+P~&oFznU9GZ|0EwSs z6sH{Xq&|6udE?A)BSR5_Sf-YEVjNVfqW|XA!JEdVSBzZL`rh&1*NmhO@(CiNT+n90 z4a~qvpk;!RP3mttcbd2mP+DHXR?g7bkX~#9s(QHzPV34ulWV^qQ||wyB5veO_^N@F z*vMCFO>05Md%}<;P9m|!L>k0HRZ`(b+X*Q#j=*P zmQ8`x)10Gm`*0jC@@VsLIkO0;Sa%(~9DNMpD2}&s3*QF62G7a$)~zrR;r-R4BT9c{ z_J8UUetL-hRDyh-G>XUPqc*0~8zeuJc;{g<&Yg)DuO(8S2Wj0WhQ`s^oVhkX7?rGa zC`J|q=NUZLj1`TxV_*x=jY>R1otPSQQ~5f12DARweA{1M@v%?4-&q1!(yJUp2gclx zkXD50rXt}>+U?0)XvR|ho>C*TMX`MN1EJujAtBAyf`n0-@-8G3DJ~TJJ<*3Zwi)p; zkUC@~GUZP^2A5REz8S%^zWWk~zPByi_;De6NixIEPI43C;^$8sjY}UT3C8Q;P}OB9 z=@xm;MqbhQ6es7PoP=!97e4}gAA{ln3-)SxFpaBtLEjuy?qsAx$Gdu_&^zBq`A3}1 zc3S$!AdPBh?t`!M@3(p+8QpD9)|w-$C9-glO3)+i4Y{Zu0;^96TS~oTdfMPjG;*~0 zOGRC|Q;Nu)KIsGoP+sz1oo0VhEltJ{V+zD| ze>_jjv;Kl<1%Ln?1-tY0I~va%?GzQx@7kq?%u$Fs5gjmZF)nN)^!o403q2^gylmvNUP()0eA?C}!7A zm@FFlpd@Si&%9|robzv_tY-QY->9ZGrG|)2pwRqw0JVpPl@%Im0@dn*m zS$|0FGVFT;$dph2*L?VrlFk)ZKobZ}&pQSof%MZplYiZzy^WE^%W6j*gS6Oz5xM{J z*hd@Ke)%yv%((c5+8gCq^P;<=w8N}^a!V5oTt*z94fW4laU!f0$AZ0FpIV_NUc7YW z%aOelIZ!F6_F3h9ThoOH8zin?C^#W5ZMM0xvlj-rw^%20cIs;8u@8 ztSz(nT0OvCmEDCGg16r;2R`-#e2W9ihbl|n|!{JN3=*0@R+Nu(q5cb1wFXQ;_VLO>49@MfJU>UB00U4b-H-7)ylWzH4&33$5*X5q-o>=?AA zmgiT=v6zwMhXPzcc%G9liCG^Nq8%QlrpWh_4~-oGE1R|0Hp^Sw$5~wU*#xc-j*iR; ziii*aF=>d!j+8V*JHcQO3(6uGg}LTl_%Qosy6q$NhZ83lwCcXl&^xe_DT}H{z-(GX znF*yU2DjzPJ_T2I!a$3l1pq-l0TGcJuZazQdm?1bPDFVXle~V1NlXxQe_Hp%BInmk zW2CSF3S{UKtN5(S_4+|)YcHugsUtPW`P|k7%Z?+`Ja<^@sY-FaJ!ntH`-RSn1_JN{ z=zwkTmszdKvgda4s{IWk1YfVxM8Q6uI)8K)A>R)+4zx#47!C1h$Pww1y?^_{Xy?_1 zJ6qS1hL1tUJr_pCibu7M(o%~Jo5a1P_D?Eu_S?2@~Km!rW#U@A5t4yB(P>4${+*=?Bt=JXlKfcqGuHcxkr){Ps=oX z)lyVKlQ`9W%z|oPK$0}aAZgta&6^p{a7dAHpq+!CK)bdko~mQK%gwpw%LlfJ?XNG2 zE8lX0JRNlQ(t)@Fj>fW}>U(8b*_11+(heu%%W-I-RS{{F5M*eIOxVh77D395&T4i! zOFmJbz9uRdbfBn&3mV#XXzZcaa9nQmcg`x%{`Ann^2R}MP;%|Spc_kx-4GI@^^NIJ zp8h&f8*e1?bv&D-`ixig$G-Iu}E!rLqdt(k|FCv=z&A7E2k0}mCs4=m)a7cs@d*lh^D)$vYbPj}%LG5C-$Dn-8_aP7;SvEG4qhro$ppL?Psups3pvZ3LziR}QkA$lZi5u6m3kd$u=^T#rFIj))1S zM+ePri~EpC&RyyL?}`rMqbSdzQpGSIT`=il88>4j0reVN!1Q?ebigsl(zeyDIsnoY zPldlezDyg~>SL=B5iI8s;6Tx0X|8E01uqvgsMD6>obT~J23<0@3zV8|tmN*HPOWbd z@-?_8aPuAuc%0$(6oQ4a!;xpk;;pb5)o8A=kd`q2RLOWK;+Y zUM+pFtRa??fkv|ft@bNwL5U!mS8kdHe1AMxD|dHgAxqL!yH&fmJcexBy1tL#7JeivTEMZ7|k}Eo6%l4`bB_Wuwe0$bEpi#vJMMwst&R=P6}0zu8J(ox_Dy{HAlk5fSAEIPlOV8#nvZWZmfY^W+zkU39xvq*Lnx*-X7w ze>}8ghRiFD6|0rvuyS>vcn@S4y&#mLqaxnUxB%MeGINxeUhox$m@piiDP9#7qq$bm zy+k$i#9F$dUZhAv`vUGhN|AC@+U*m!km5T+**u#{$?a$KA#0XouaI(?ZrzpDm(%2h zG>WS}oZnM!>RlM2F9T~r{t6{VT^koRv*4@K0Sy#TE;B1^nxJ>SwfGrMKJJYC>%_r$ zGFLm3*&2e?kgP`7iL(yor1k>(;4k;??URqzrr=y=vlST@nO+5|(k-5mtFp8ys3OO= zH?;Nwypg?eib36RUF^WnG=EC$f!3H;Y~V=njsmIZYx}&?%F*SQzmXQo1<(Do=kn|i zXMM96n0{;hlhjvb3J~i%Aj04Z^GR6{X-fakhpw&Ir>L4KUmoMWVhwMfhXL;$0%r1h z9?0Ss64nQI25N#l0~Sq+n`jY;gCDHL}_h}_cinQk9G!yz0{a$mO0 zF3%+Pv9K}B-h&qPhQccrg|W77Ed%%ZbHmMMg$yfW!hOloEM-OOFSg~$ePSZpJ_gY}o_$oRQWmfpindl|6^&|O zJpd_QtzoD$ro+B^E-d}Z{Pr$M(dnLpv7&uQa@oqP8@E6E+tt7p(V0@+3ZVS8J^ay@ z{ZWiXbAch2p`g5VoWGL_yl&pJqzy%Z&*FmXX{)d9v6jAP7)D0)GXzQ7T6vz?nht)n zsY8xaY;pq)%}}+o6(_8fR+qk8u@*`WxFDT=${7-k3;yKBf+0klsg>nUC9*5|TI^#G zGC{BFDRPgczout~saYDUcqmg+L3N;gm;3w(@lH5{HMo{Y*p5ad&?Wv8*e@6rj|+iX z^Xyc=RHwoSh+u^VsNI#YHylBZKVL zOLT<8x>#1qO5Rcwcsf4R=@>`C65V<#@rf^s0I{<4gQlTGe%IAwQ1uCr+o``w8zQ50 zCB-uNzsnr>erx-53*`$Ud6km_6b1dxha}mo`7)a({kIO} zqb$N(twrb<$fh0tIuVgqJRyaI3~-mw-FR49cH39qYC`6StORD4hUTxVjWWyl@`$aZ zB0%n95L$W>mc5)Spj0xn)nO*}S&2KhQ(rB{K^ZKus+u*Vj^M);V0rKtvQG_c^#|u_ zU7O?L>QG2p5AnCU;IN3#U0VnxfzPj@G0PJ*qq<}7Shgth=_cQ5JQw#CI| zj|-Y;!Pwbdwn?d7(Z)J4Kz{z+A=~ooI}XEnxeqJT5GDpJ=l7IaUU04`JTqRD*+o3- zha1C8(SveXraKY5w|c_qU+C91eU);19qjx^19QNa4=J(i-dtbnJdy@ilIT)gEFZqD z`SNaO|03E-&5aw!iBdfOyaP@knfc|RfXvRcFS$$6mDMfwK~(;s1_sg;M_m+wC-i?> z_|`mRwSnU5?hA>rMa9f!ftj*qEs2KRcOz3BY{TBGB`AZ6+y?yhBOm1&GLgNsLw;O# zhNI{P9o?Q`W$#33^~7{b4ilmFOLW=`VWXDM-_ zUcde5Nfcex%RIBM&vm0tg|zuxc^}|OmPpAhr`-2VR(A4f*738)Qxu2E_8ZCCeSw?` zlFSO({dfdaLQJ;TTd|HMHPl;9tt5%w z_S;4&YuT$bu!NYVz~+xZ&_4LZmJ@r-PPjmWju$#_4Nf%!YUK-Q0a3J|ACO_2XvSJiKXukSY|Uswq>0sd54(C$zvYxGL`l%cs^oMNvk zldtPjy&3fD)SveF;3p+RT>8~T;YOZ6_hs9cJ(<)!3`6@4{gBJ@ffj$?8iHL$Pa&sui!pt) z+NHUUVtxC4nBoA<%GT_=PEytnE^&<`Zme5CtSKCu{uFyoKJ}&9wfK~n>^9PC<%|os zXZvJLn|>Sdmt3W4hLq(PZq?-aw!I*tcqG!Jw*qE*G+W$tb62faPUsA+$rMgnOhk4? zWVyRoo>&=sIh`>!Rb8a3W3$Bh`kLAn!8np7-6S%)1f{N4Kk#_M=iAAgBZr)r$wo=? z3A7LoPb&+{?G~5^kf<`pxrjLFO4na~_iEkHVU6@NYTYxPx8iri4_e3ZAV?0*cxF2y zxDb5|GMZSNGjvUaa!+k$MlyAPSTgT)|q z)FLiOmfS zNa<9lpnVy1CsuGx=xrrMdbsFoM)7^5M4IUiZCBao-GhvU;KWgl|3+LXXDBX=WT@5Ce5T~h{0qljE>qc2YWisx56!ZsdwIqf zvq9DT>YN_NuafQG`eCOH98<4FibY)sjET^ELvyce|))=Uzz1fH0s`4y#OP3 zdzsnmg)hZ#_rs59hyLhj(GJ*t{Pt&d@p~ssnYLHi@t&qZfWwrTTLNE`0vNyL zm4@MSr!(Nl;`sfu2=C>YN}PEuCiqAlb{aOr1h{d}9ee_Bn`}`6as)%&+=p>EvJ<>d z=~UNhv3E^?X?v3l|3=#aJBF7HY&~*qJO(8~-W~#}uAv2qM=t=Q8t=b2L{e@y!>s;r zP5XHs|5RR6a(TIT|ER`CU*+ppC0Ij+^pwQfS>xQ#1))%Mawg{HY%&SH=R;*y-$)X$ zhB|{dg#6!{ai><4hhOz%<&|YArMz@LRCW=BxP+~1t%BM{w0@FZ==uC{FYHY1VtRz= z0zr^>_0tw0RAn`{UxVo^dpwxKV*c^fgQPgMgBVglTC5`7p-X9*>?>E+IM>6>x~N-CiW3k2`IwJ=$&nvogN%l$D}b z;n|##0x6iIyQUEeGA6U_a}2$kN~{Z%EpWRzCiU^VM}7C7hJ@d{cbL5r z|AWCEQRoW98L{p*#_x~-^=ta{YukS`_%CKBeanzUgyMOj!MU!ogU>`4xvY#YY>n;K zVK;_0bXw%Cwh_L9em)bYgSb$PAKiBGqUyDBxb{5J5-hvYlY@kU<`{_qi%B5rtpk#I zcmh*W6Y0&0r7y_V)~S-d81nf+V6n$i1QA#g@f1fe19jm!FN?ZwpjusLAH>e`{tcZ8 z!2lPjo4YUf$&h_z42w-b`#C`Ko@V0yA_11AS7SU;Y%63R73>SB-k; z!sRl7D+6NsJZR@?36?3A0Edo2{`pCTnJAlKulN{qBv#M7Q9%aSWAS7-dmqdZz3xhk3VY?MsSLY7B2~g zwO$1$ZHwZVK0!N6$j)k;xRDH0OE`Q$D#eCQQj}lgqnU*HF0I@dheVk&QdIXJ(xp3k zuiwr~7GkSrvwUoNr~2UHz=&}liDe zD`+r>j~dh;DjMkA!dWy%#|M>UFR4THE-7nkPn1st5!>Jg7>Q6Ww0k~{ZuEnPcDXu_ z`m4?)g>LMuwyaoc#P58-fG>_9?`U?}@a_5?^=%=lA#1^@FjSo_?1qU6G#HnNlE&1z z+tH1%esSRNhuXwkSZ|Ror~8N}(1bUWQGnkZ5@bv^THPQa?V0p`FEF zcMLh?nP!mMIm@s0Icao!;gk?IWQ`Eu#O}z?c=BGICOp@Gts$G_V1t&AiumSz#u;(G zjk?#iR9LY8-3gkrN_Mv(dP7fKyQRyY$h#tD7)~E5qPhg69z4@}OgUorjOk9u+NFy+ zFTZ>N{4P(Pk3InWE}r*h#oePMP72}K@s99D-52`M%6nsHENq)#@INHGyYgdM9Cccw&9Grc#i7J5F);)e z-<<_ZcmuQHhavNxWVIm1ZOYg3zA6nBx3CFw*S9{wzGyjxA=f^E8EXohfis$vwa7>G z%W$t*Tb@@CV?83J!=L0_F+HHIZ9$wkN^%vyQVEper3;}=to~rHFZ=8eP;x)~6-u7m zG}3b#YwXYHf_q(QADw--Aipi7eeXiB!dcNOtH}x;FKuG4<~S~=bri+YsA*1rOXF2( z_PGZl_gME=Tb<`>NgQvIU3M&3sCz4yZjx0bM|a+rK0XAnXofA9F)X9=0euDp8PWya zA_O6_>Os2aPe@*Zd^j}2xYDkBr46Cpl1R(x@M)52GtE9-Ayk8rWg>3l#-?$6Q$+IF z%@=5cB5F;`>8rsl=_BX!_W?W$18i9X23kw{5#qYF z!+$t%IcpzXTlpJJ?9V#NFDYrmu<=b4FTtdF!$dbk4sxS!tx!`OgK+5lLugO!9h|2; z(ag|j{a5xnyCNwDuai1}@S@5T=(O7czaX1%C|IRNpR&7F`m!-!7Xb8}&1%FVqFlKX zx=`?oOZ!|TC3&gmdIDC&I|QZ^;y=|IVM@IOd=C}V7xVdtE8la9-YFpBn)397pWBQ4 zGGEU|73IJEEvK@LI=%ezW2(!PDOT6DOto4|_7%LtVlk zrmI>x7MF159nEnJmHj;LE=9o|uJP)>gCQBG@dhl3f1QX3L`6Qqw7z{EQsDJuAWvo% zXDHRcILpGgjjdKjGg4zOg!11qrL}9Pho65t!ZL1XFj*_$rzO$Ic$Gq`g+xN3f+ct+ zgzl6}K!6K!RQ+1^<%&c#)BN**C;2gzaNaZ!$-ksy@-jL{eg2JJR{d>;@w2xyH>%w4 ziO#0NQj<&zpwX1x*`Ou|OV$RP&ugIRgP?FX#L)gvx&h~c;^@VuU^~QfNBbLKD`V<7 zBcdEcFH_P6c#3Z`ef2C#x)PaFEp#cqyeL4C*J~KENY>}Xv>v@Tu=5(rG65adX7E!S zf8N3#CBDqLMYLEQyxXOCAnK^fSv9tPQA>(mUEoWuO*bpc&8a7;V#gpyV396bc%xrc zQ;X#r)N4+LMI(h#4*+14bI-_j1OIR+vNwE-4R#iI6+7zag;|JvTs1By8c{SGXR*i? zI1+P&RG%23&)g5wxe3I_2QV^VU#Y)&FGm@d5qPtCnk!2RL!@h+j+S?=!Zv=o<>=5{ zV0u}JOVv5)ZWWb#VJ2NYgU9FiOujLEk0>iNm*oj&Wy2_EL{r1lX=D7bo=j{649T0? zal*1_nb7+97>9Ac_=Fn2*b}iZ4{|1K*srk%uB^wGc3EanSV%Yu%1?E9I?lBWe2bu$ zpKNG()c4$3c96Bai_#Tw)@f2%gemKF)|eCRd{}A!k|kF~RE?Zkh%eQ}i`3vo>KUTx zgmbv$=FzQMcC2=4j!cukuWta;On{{q=E-SSCDf|3&P5zTd6-pSvZ<+s4AXK?9C!U> ztq+cUI^!jJidea)0kYLW2Cp~#M3c|ECHMa))EcR88zA(B1C<*^$%t_c=CAb0 z)l6kx$PDT!i&>(H(wPs;TTS;gW);1rF?9i#=Uc8&dZ&0B21-$~5|Ji2Ta%Tp*#E2H zTk&6jOxb=@ZQ82dHTvRcsP}6iGJq>y*zG(WMwb(?e;P}>BnwFmV<>jdDsCTjrLrDq?uiTY-ZA&nP49MZy9}I(j61Kz6 zYotUfVnT(gr)gvB% zlr^BKctz-mwVaU4<{I>J0rYb1y3f%=_*(E+9fw~m&p;Z?cgyqBrLCVi!;iLuU+X&j zx1!ds28aJYSJXlZj*2Fz#TVA;C_VWoy8*X{&S%!r;M&teyuB>N^`$%G>eRh8x7V%D)I_wC^s)^esU-;&6k*q!%}nqnLwDVg)vv(gBP~S z4|S(YTn}t!xy@&rl$I53B|GI0is`TN*b(&ZZX<}wv2I0Hs59F>6<1N$jz-DK{U^k> zM2?_cMo6BogTqIuSD%47f-92;7{k}2FJ~T=B&nmp#-Zcg9|NqP_jCu=@0tXk8jpD5@(a!HAkpQ@zB>{ zwrIJk8y`W<`W-dwCX2UM-ZRjxI!ReBQOU;Xn1-hAfGE#F=SXlgw``yUjv- zZz9c8q7mK$mJ}TtalM6^Pfj)ootOgh`s@kVq85`6=IjlYmXKpPIOxoggv@|ZWle<4 z@FJm{L>~~TmCU55P&?*E(Z7~s#t8K>x~Q8&R93MI)NE4NugY3nj>Sp`*sh-!_x;#i zt@mN|-C^taG04^h|2$6uFw~ISTAWfRw>}2F9AvN|d2hBUP{lN(V}m15V`Rm?h@WW# zyH1*ooo_YwnHOE?bwR#e#N!&R3uqB$}w)U@H|$_&m0m3obyBtJ1?OnB}Kfsj(=sk*yUVved2} zzDop0DCXM6lhs~W7UjS3|FHL+VNES-+fh^$l-K~NktPZP0wO&T6%Y{-1){X5s5AlT zp@g6aNEZ+k6ruvsiAa-{&=C%HFh8h*^0 zSwmJ&#(0_E<%jeH$cx)&2v-=f3KVW3b5qVHt7`p>S|Y^Rza#PmxGL)9pgC-I3gXaCV zitXn8C2=Dj(sRIqX41nA`r2Cx@IDofZ&LM&vAC+%HejaKmggyYFK=043H;!s%q*C# zPea(gkkZ!R&vd>sjY zw!d+`QQg_wmt|`ypkibE+m8JA^zDT%cYkDM6*>8cCCtyM<>X$l!C&iZ{Vy8+t1a9= zO~?OhG`t7tI8vAP(3jJu)Gf@$BS-b(ps7`p9}nMlN=MQsXi9|q|BX8)Y0pCGH%I!4 zt}m-=&0zq7l%{Pgy(dSPu&|DD#3-0+;C)L5N%7tWXmP>e+F`-3X^>P;W-4$zatK*8 z7l+a}CdOHQ7T5y}Z{CLeB$^ljjJoMW$g14{S=8s% zmg0ilYKYg&+(;A{ArE_&46h&XK2sV(G)vHfUlf&$=dcR%%35|zwgT9&!Bq%8w>dVF zB+A)F!TiLN+}p}YvLtLLF8n1eWC^z2$DU9inVz%Un9}K5eWv8e1hOF$Z%jMoLXw<* zA=ziIRnOk1Y;0#Ux?fXx32WOW^=X(t5cH|O84bWgeM_uM_rN_aj!$t-oAkdyl&P8xA-D>0on#=A)&4}JDrDR;_h&rHA|=lKo6cX@bsV+^18~*RSO(OE!uw>eIBPsIcC=O16qglxtV z{LUcytt~s6<^SsEzkm4%{+zob7ypYvzXny*LT^C^@6(mHd3N|HkLa5Hj};-*sIZ}D zkA2R3?I(q}hO51dkz=kktRL$mbuU+8lYAg#-CC%S^}L&=idNDkop`j*DC6ne@;$F1 zLJJg36&r!}$Hz5QDp_*Q0wWR6}sq zGauFr%x`xWh!Os3TM&ZO7^YS@f{DKioMbioc#r6>@hYHcj29cAvkH`jVAz;-Cm=$# z;>g%dAmFwFr&8X-E$ch_Hb7H(2n#AZQ)eLvHp}O@0eVx1@*a{|6UXrbzTftEW+>-Z zxTZPhK?5_69I{U}_{sOU=iox^#J$DL0LG|rhLf(j({_gEX3ss}&mGd*S~_vG4Gobq9gv6WnG zO)qC!V1cB$VC_fyoTr&Q=Z`z<@;_m9_BP(s2L{kF#r1QxUp0nNiaL9kQ7&$iKtRUL zgZ@k7ghho>bb(gRK|$_z*C)hjZbb`s;>y1BuuJA>kw0rSf!TKNP8l^d?SlU?yMygI zv$*RTK-8rQA;D)~UfjY+T%yG8)a*36aoP!bS@ca-bZt)A(M8Id$_)ElK?*dd^1R$zM%L+pHrIo{#h0*0&kXk7}GnK%qXPua|vWvpzkhB zLy|=E;7WT=w;t-4xJ*p7RqnM(%*FqpatYrnd~}FB;eYUaUi~wU^pFz=w}C*aY=5_W z9QIu_fmz!3=OjHT=2Pw=Sz zL0e$4ZZ&!KV0N@p@w);6Bc19nv}bVRD%21DG3g{lE1AMq@9Qdip;08%n_Z*R@a55l z)#ooUE>qk8s(CAumu!xI2<1auJE~m~*QVom1Th+Oa|j@1_5ViFLxG2}+xw^@!-dNa zA9?rKi^eV9VJe>z+`^oif2PNQA7)%EM@k%a4gq>xP5 zk|jKd`L);o?Xy?Y$@6+A^NTw<4bfBeSTG~GkX27cqg}f{!N$rlQv#rt`xCXYhM| zIXR)Rj`L-5=?q19yTVd4N?!Azp~qfrH+!k_OkU;7$^QNO{0;gw1Ud_f7SpZA&qRRl zYwgi?+U8;0*7xakax9yYdetEXa!xJS-bJe1fB(7hL*D-W2)6#yD+IZ|kFuhd41zu= z{re5~kQR((#I7mYqoCDir!Id2bd%(^qD|HO* z8`11rz8(49`+$(AYa$3%QZWcDyRag=5D>n}{S@w{Jv+0_Zirz#v}Hn_S+7pcdkvxO z!=7g(-U#=BWcGv98t~l>IIfdGeBK#_StB4B0-AhwWgBfIl%N4S6%w&E z0u4b5=kI_T#8T3SXa^5>x#M?x2=aFdJ!RpKi%#~Ry6letXUUzoBX*7dp~@fUU8ale z(rt`AvQ`}q>u7&{3YkItP|>Du?k}_Q4^6%Qn1cZ&Mghri$eBl0mSz_kNC&sjn}4jx z2@g6P;rO_%%+G{xm$`iRye9LaT{v~iHWweQ*#51p-4~{l8k}VoEzKM&cZ$3iIhi}e z6<7_wxS|?`j^U;G;xO2>sm({mDN|qUzVD+;*?JCi)%}YTsat&c$loY@K!td(-~(1< zI`2({45HeF;rG z4%6bCDg;u&&l^g3J$_#yYX?&V`EZyPN_d1WlhRoNy zgTHD5g6n*jQTii_kEJ2$6-e#%yhQ&c1B8~(p?6#`cGowTk3ZXSok*0fgshKAp?Ju* zDzDL{+JaBNH{-EF`;>vu3r`A{tg1q{Sdxn`h;41WetYntiHNvcQ_rV_Ao3DPjLTHLxGS*^U?z7NYKXWaZ&Ti#? zkh=(HR{ZAu30Q9LBJsiM!X3()dNC!_4|g9hU$94ZZufMoTwi@peQmk_rBuH>aFC!E z&_H@vUOa?a@A0{u7kr6pp63<%ZT0A~20{-R0{5@sE%-X=b^UWwpG`rd><${Mg z-$tsoeYtDq^+*)nZXp~yM6S;{={XqZA~)J0B#b+ZeJnY`ww_zRbMBs0&Im~R;DyJm zr$He2fcpt;yPNiod$%gRF$4k~L0fS%c@I@h+3k>i`|9?;+0qIEaRO(wUo|;LFa`Hy zi-KN%KK*U~#JQ`ph6gr4uR>2DLd~8Kx7ciJLk!f>$yX{|3x$IS| zEr~j~&bbX(ISGHj`oZycsUcnC5z^Tyk%B3l=&`pyUWj{zO_wCG4dYIjws?@s;KfCO zI&Y(18Ad1^|LjAhf}HIFsa1~Z#OgVV!Csyt30e=XD0Sq^ej6Ry(wNIPy1jfA&0gs3 zZGAhzhIjk<(JP-DS|a^ekCew$;kPWKt|ymK_=@81dMTGG_GJp$&QsMgt7HJU2E>`^(3Ewst-;}Q2~E@ z^YZO)8b=hnL_^&dUd-0|E_|M^^`NbX_})t8l>ro4TdTr5oZ(UvgrfH!yMqAcfzdg zo-@>~lFvg|!X7sV`<$5J@?9JZgvC|SXMVJ-RZX0tT4Ny-Wj{M_GDwY(a`4l3T=f*f zvtVqOz`N*|$b`@_Q*YI{Vw^~*>8pKxjKTAcm6N>{EY;`(N72LIAy;iOs+}uPTXj6zuP(B^N~|3M)RSt2Pd201izRp<-Li6Yzey_7>8T)KMUzC-vE`hbG>lsow8d99?e_0-VFO#b;VQvVp+9{Bz{g=OtY-$;Epx z(y;PH$jVQed$KTn&q~u(w3khy9WAI3jS=@>{vVD zG%l(8-Hkcd!}lVBKqu&XJf$lrliK*;xf`uA;(jlKqQ`GKs1EI5*gYjb3sF-Chs@?G zAPP*o>%^aX$izQ{&bu#aIVGvO=2})K$&iWbh>YL z?sJ(ME>;dXAMylk{ri+Ac~-D#vodoEx_}Iy!>y8{r+37H{Uv>caq;i)1)ay=l;@R% zO!OK&jXSbChZ?dv!@jO}<&$I+-}7AiR34pMH$D*`XK~)j{;k3M5ecrt#_o!26MA2 zHgX_LaA23HGwWN8EIb=jP$ohl;|@+bK`*WyTH`MXDLbTIy8rwb_@Y0;VA@M7@lB6d zQv99msijL12ic%$9qUPUBz2kd?FFWy`R&JF6%<=URX@<~pkZ8^QQE1~yzZg5a+ymXR2iw z+u&Uo4*b|lsyDM-cyrbLeXVi*cS!X;yI+CW-&g&_e^cYO`Up*GpORbvw&R^?t?+*m z;`}M+&G)#r_7IUC8xEdPWCll<|KY_Z{f*?zck6&Z>fb*e-wv-86x{$tB?G_(wg6t*PnNtk1}}^scwE zEHU!x6lh*&i0yTbow1-`o3w)71-HPi?ftV}nA5Dz`XHk{b|&x0D^X6FwpX)Hy_24_ z?4W^Eqmf&2P)c#Abh*ulceusSK`q8WxpGVF-u0~Iv6y*1AJnKLmpQV%c9plH@@V*a z8PWwKA+!pgX%z2Ipsv>s9xtV&1DXt3Qkk!MKRv(yj35u&}Ku`N=wsORlk2Eed##TZZeK*-K z0UR_=ka^SNosqs68zft)3^~()d1bPku$hvxZCAWFqTDiV_df7z{Kmv`N z+SfW~mjr}o3_Ha3ne=H{Xu)0yro05cr$j_vR?n1*W>-e~1>wS?u<|f85bdP|@(_i8 zOqj=J(JxRMUOp*!29MrpZ~t`cT>Kgw>L0CtDJ^8}fO+RKI@m(#TQpZRX;EWO&ij{- zV_*`KtN#5)H^uO|9IMhV*9(5t++I@{-Yc< z?%@}xBYoh*Yx76ycfZG!6ED?tvwd^yRb-x45oh=SUg)nv{`_(b|2=N|?0eic`Y&)> z9}1;?gtc$J<lkwV-yD$6W6lH2zF$aM|V zo&BgzwUe00!``=7IdjP3l@O~($g-_{HwLL87oGDe@$qQ#UtMF-o9U-17BItkkISuc zwRUW^C$k?%k5%nTdMfmk>}LS*?W)_AxyaTJJS>*axCJ8z18Gn9xFgNV1Zx|*K*)YeRT2UM} z>$dkp;Ns__j&Lm@yq5l#LcA4vZ{40R8N<^lY~Mym{g9EvHya3im(;f`eCPzSAX9e@%Io?lAsR7Ug2hN<{bm7{` z^4w(BphJu3d@1~rNf*Phi}A~n@W-j}fkA35Ahn>j%MrypIjb1b203>hm?F*`v(R5Z zJ?-c@r0YFJfZZ%NenJy@h^Otlu!!zu)%9-KYD&~9S>H2K5cHLw6PQ~=;NkQml-(Bm z)S$F}vyUQ$9|r8?lR_Y`#oz7b7H}$)Gi0YhO0<^JCgT;=5Dq`lW1{EgB3!raXq%1*|Mtsr zI&^^TU@s}ij3Stt`Q(#~bjou{x67Z;L;NbS!D?qS1zc*q;xf-3Eia9}k<)or_Auc4 zf)k~1q`S53Bbj9EezQo@d01?;yY>NfHye$61$oP7yKh?2TPh&SU;uB$=hqwW=m9BiS(XvPgluKxgTYrOi2HiSZ+4bWt22X-w_fjn5O*y}c@ zglVsl0^HI!cUP<&ez%aecFKmEb96;Rgfre?47iuzD&7oZMRsd`Nff92u*Vr~7 z7J3rHmkcIjuik==Jvjk9Z6++obFzM_hA!FB9a$o}8@51-oU!nvlmeA(%cn%N{b{UKDJ@okopkThr%2Nj5A-D&K83dFr`@D)GUo+1k z@1C&%LT$x&;VMgub+dGG#@3^gMNm7du}J`sTuTcQ2K7rM zb(9fop%g^wz-ep_TGoE zM6%Y(A~97eca!-ajGxH%0J&W^yjdks!XsDk0Ko;(P>I8pDpQvX#)3u!(4Elowxx_rrR1B-%q9q%uI@dQsGKMNw=X>1x z`NE|C2FUkzuKrLHCpGVlB|ZtvSc@)!`5%Xm)CWf}k+9W?3$$Kb5jH1%(0>8lFP$F#zSh@j`r;@`V)LZ}S`C9;(Is&XK9!8s_ zb+`#=|FT;Bo0q)x^6dY!s-aGWM0V4w&V8LdL7Q_Cc{YWg3o*HPXC<`9rIzJHA z8fbj=;m#?IG;NVO;YPmqDtkYDy00Oy^W@YRGUd96yY?BL>z8(lyxxI(Mb#Lc_A!5> zW0~GqX7moEnv}1F1TW8`SqA^BbrnZ8Q*r{*{*7FVgyx}2>Dhz3UvlVIXrH8**4{}n z43YIS?*_@;S3cPzdj3gyM0#?TY-NVT1-DJT33Jo#-bNQUxwG3WUCLg9Br28}Z{sZ$ z=9X*SS6XwY#iHJ2N=UwVeta(FLrJV~plqCn5(plSY#-sL4X*DwUe1daA||&iFCiQl z49Q8EUMWS*MsYw_XT}fxuUa!1a$rif$aP!qVl}wvny)1os=Y}`+_(98VbW&lHjfv)b zp;uAdiFi@9n6H<;08Nq)RQ)PrL7w94r?P4OG7Hi>r%4A|ebbh(Y2_^B_6uaa%;rLe zLMt;}_nLWHCU_XpvAQJKG>m5LraJFCvTgM<)U(@l1))JpAW0VIM(6f!fHLT|b69}t z3a6Vklh0_+#=|wWw%0=zKN>mc8#J}-ACfMboZMtYK>qvJO*(??(htqUK-!MLMp3a%8B^pIM|KWb|WjB!P zVDfs+GQXGQjMA9SEgg{?Q$up^Up@q%k^IYoV;v-*8~*Cu{SDIXAAsoqv+_^3fe3uJJDu*LRw2x*P#J&JB=A zQW@Zb#~#Tz)Jc&EMUS}<(6d5LKma^1u7K(W&@N2Y5SNF!nGYpr^n(zKmwW(6eT#kQ zDdFE%TVCG)J>hx{)V86gjua{Ui`T>M`zjpYPi!9lVDI=1DENX7oL)s+0uO)ymeNy3 zKuGx?l6#1d9hn#EgO*=xfX+2q{K*x<48F zFwlDBFEP?-nf=*ZUsu(hIebbkfyTyTXK0RruJLZ_#^X1NB1^`~+>Hbpm$IADh;|?O zl%@<)vE=pwREt<2KuD;c>XSxcA35@RwBjN+pmA8)Fx%xvhV?lb!_qYRF;AI7KIb~r zJTe{vs?Z+}F%nt@S=a4J4NFt1F^ia5na2r15z8kKZn$SGkbD!CNe*H@oJB*RR3BPMv1xXPH#IKR=Q8p=bCj4jk_KDb$JPef&d|_p8=Lm=wY-Y zX|jfPuc!U^Z3X~Ec?PkPvOWr?i6==;pu;hHVa3ZX!;Dk+rsL#%*E%R_HU7&+W8kYX zEu7zA^(~JfeY6rX^TjFGCLWj%37K@Wik7*^n$b8JGUv;RWLX#26Fl1Sx^8*o*4INW z2gRwl9AH;4+VLONuBdD#z=7r0fZm^9{wIJQXQdCELZZsl1gh$=u2f9P_Hp2@F^_@U zi!(&hcYFYcFx3&;srMUf4l@ZAJ5+BHnjm#TH1}muHxOY91<{Z-gy%RkCkp9ZebsPJ zWzCYB0=qPr67h9xuMVtI$nc@v@}bpEDh#L*53;jry2exO;&8S6I@JFgrvunbXPdz`%G^bp|P znu*bueb9>`I|%~leebps@< z;A1c9_lk|myz6%%blTsc?= z#J>hXqUJ79V}=SS_yDo@VVQ`^LAR9fRwallMvLE9yHIsR|6zMQ^I+U3xePRmXIHf1 z=^<1b>X6f#VCSOksf^)7SGlz=mBg@$dO~5RTA*8N)8sXhyWA?Dg`yyF zY~LK>NV07b58Uw|Rth!=!0KWCMEp^}cv12kC{BIsQ|#?e?+Tm1TTco>q8JEZmmrn=qz!r%9q!o{+sC|aHd z-`K5Ak{K)YgEcT*SOW5~xjzAcQ>UO@0_fC;EBj03QrgF-X3=T33+xHfb zr|VPr_ge;YNQ1vD6#tG_=+(}GCUZNTvUZuPsKO4tgZ{XkBy~VFGUxAC__&Nhc9NjG z2@~xyt+Cq*4g^$xPJE6w=q5BkWyulAL(RVSa*SPXWICBE;b|B**I{hF@)G+=OOFt^fsd%wDt~RRZ!YoNDvAPZlwc-!pE zPr=zP)7#Bnl2djMSwW6|(f92f!|%mO6On_mZ>+mwOs3y|xDqsxFg6)**osAIP0QJP zC6})j$AcrMGAbfc3msC5bc4b#`Bd~&W1J%F0x2?qj^)SDj+PnrrWsPv!=qO*GVb@& z`YjWN%XNoeEU+Q^x=E(SB;DH|kR6jv122!Q9-63FT|u6~ZNc4wuB08=L{}H^`PH1{ zJ>T}N7AngEINBR5ijlMz>*x49vLd4~a($W8YhW||yoTZ=<5B{puFRhz<(Fcr!hK{i zghCC=!b`K~)5w+xcGCGB* zC<4x3gmO@kLn39v3qioK@GE-&-T!E3zQkP^|4O^6hW9W8D)T>!wV?XrRZEPZr?{&IVx78j)ly9Y0Re;5`Z}dZ-wLI^CIyQd3++7GHc+QBa90+3Ug=u?;gH z6-E>ErhFqd$ON_5pv6O7KkD{fWbKP$mHjZJ!<;_U0`Txc{=9J|5GQp-Ji94r3Bt#BLL8m-J5xXV#eyn6tYcX z=@8U4;yxw6ZzWXwp5*8UST(>=_FN5KHcb>L=k#&$a6$gUg)V=w%9 zV=T`zjjm-hm}DV`vpQAnwnwdJz)7-*gLqjrDY3$7RBlRT5IfA!t%rY}=)Uwi?S*Qt zn0r+piPfdOI9KhiIjdUsngg?$mcN09Xln4h z`V27$P#I`-#cKb1$9em4M5(9m%|pFY+WYFi3>@5V^Ij?9l>5}H7z7wGsGCkwRBSJr z&K0vUqvh|{|Ar01E{Juw@x7Stb0zFA$VFWb7GERO5LTl}D&fsbbES5{CU9tWZ48}M z0nc38+?bnhfT}{*j^o5_K0bO>s&nHB$LP(QKv`BPjF>S7M+I>H#<89RdKbZfpadX4wuI~{vV@aG5k z@e(G}JEGEkp+#SSnwVoNPa^g>pB1Zk3X@~m07beJX#=G*{$< z%Qs2%eKgW?k)EYnMIfxos>#d5+wZOZ)bIpdw!n}q=_)MS!=i83wD!m;f>ZnW;?KvNR!tzca8dy} zi8^jX`4K)*<&Xh=mVpZWHO|F_NT{$aP6@}Loa()2|NQvZ50E)o=8@I8-ttX;z6y$1 z%fha}W)92ZtCg$Jw<%=ILu|P|?795*hx|JCYq0MlCYLy6{Cs&yNs6WW!+NI;ip0w9 z%#hMy!FUZ~E54cuuAqqa)!)dw8k87>xU&rVRDsuQEnsZ@XfjRS+5T|W(+ZmHO=wTz zC)dXe>&f0b8EO;=WiJ^YcU+M7fHf6K_PB=gHk{4pD%!iVJxkHpg{1FdqL2rldJ|G+ z$4sMS72yHi@t?Bk3(!S|#J|AlEWk(iPjF2OzI9F8{l|H^US^-W)b?ex!!Hw0JK*a! zj4v>LEnM~5=2Pvtx#RQd=h*-N=e6SGAKgFH38apnu_8DD!ltlGK_<{dv@P0P*jf&? zuZJ6m05bDA+9BG3k9lUJy|>d&ZfXBd zvCjfjy&<;Wq%4?2cF(YTYV$_!8svSPa_XA~I7;yb_zt?%@!o*X#T>;KA1~(J?d1e` z5~Jp}`4w?4vrPmt&(W_z}Cp z-1_45f430dm0-AOfZGo8do~IHmNq&02N>MJ{|V*)#H4=$rwvJoSHF8_f8e}`eS(ul zH(n*6XEM=K1%G_%=2H zZymWNxU>OU-yzNnkH*FnSQ&?^lwh5e*sG`r`2HB#G%098g?gsX&=JGM+Jb0U4|EE zRj*8UP?zg;9OJY3R;2y@})_ zYhxda3(tQ0JUHm*q0ZXj=ZWP-5_QO0(T)l{iY-SpD>5NTcUP8JN~WMGEX~OFdYb;j zlQEv@jW|y^skzJaZ;HjQ1X?tf4?|+rZjPEG>U;AlI>u{lqPD+>3{>O%yl63vbPz-W zSyNw%4==Rz&S-kvF3f%#Ru+H)Eia45P(e^bN>I2Pn$Na=_3E>IZ_jakM0>E&w#<<9 z#mOMAplU#Ie2=O|E)@XGMZk_}=atb~Pu(H2s|yXR9Z+uiA)DSk9(Bg!HxGHER5Y4s zCzIa+dU|+YCFpB1eyHYBs~t|FSaN4g-*g)X;%llv(7O6MrD~PD)ei*X0C6r1Z3lE4 z_(77yN;V*)1iI4JMqsCS)NH0{gH;UYsnvkLUK$04N}W2p%flYaa5YeY-TO!cIBY5J98u z%5w;bsa0clmAag+*S8#VZaz_qd!sMY+@LAt|KO!n1fWT2H*PLS`qFT%u(ad2-g34a zYjlUs_}Yi5)OYvg!zdp=j^_AeB@bNhp5ZDs2?)j&2A*Ct30A`^3LGrr*x{6<%){@7 zwSyFdq=S(9p!=W>*t(JTHAafjX_jgvi{Fmd8=&5--iA5hOpxG#N`8<6nAr*7t$Rda zQ-&}qfEUae;>m4inE_{kHxK!3olz}ao0(V**eIgXng^o7 zEN_jxhYBM5n0saR>SqGK9;2+e&<-v6Wic<#_=|h-s+VQOZ9qV>n10yeFvf`4vhMN1 zwu=c*9Jf54^K#B{eyPFhBh_=%k$SpZ1DeIatSp@B%%NjdKh>^Z3PD4Nrnh>A6{fGCL8M5SA4H=Ci1w|H|*`r^beDdlcqF0mhsUWVVu2; z^C?dFs^v%Fw>@tJnT*z1KyV{RfsS>A;`=%s0X1#5PCku{P!N@f{MIPCiVZDy8eu0M zK;kcV$Y7)<3JhMUY4b*NYOjq&dlQ_7@L_RKHu4y+9wy*o*e=gW#r2DAg4x>78g8&E zf!t=y8y+&{u2Cgxp4go7<&--iHu;h`Cx6~6PY@yC$3L`%kmDi9PHnUt!g6S&^iT~y zRz6E|K^HU&k!n4C+(9mWtQLi>8=x8;FpU$;+>Ks0a)tf68<>OXC!YZ8tIHdpp$5Qf z*vJm(M~5w@3C0+5=)G?v$W^qpmBWyh)A)Mlf2oQP1m8^Mk-g_YtaRa^4bTo4BeP=6 zx9uJh%P3`{jLkwyy95+8ZGY2 zcz#P|$SN%rIXNd}du~v$jP1TLvZvz2Sn`4Vs;FKTuoR95o}A@Ci1=!OCnggjuP+OA_n47kT|&m%#=I zbRV|j^?F@-;1NYS|F&1t-S?4HmInZFD&ec!k~xZdb2ZFK{*vP^v;1PFs%>OMN1MJY zm|6H^MJqCXbKz+<8z6AC#_p3;U6$^r+n8^0b!36O0xEi#dR{0Hv+IWUem_hHp&Q3i zbP5Be!**>u(LQ_}eCzT7TEdjw>)gN+2#=2vc>@&w1p1ogtXEc{jMT^Lpe41NL3#Wx zVQ`UAnIJ(3J1O>cnok5V9X zS9Q-Lz?Ka+W6wnSf77+@ zUVmG%oyyX&L$H(XPTa@USxx~~%_rdx+h8ro3jrs=EH?Y!#@oJo^LA~Xe?D3-S@|xV zI>d2*yVq)v&#_lXzVopsn~VZD6o4XkI!Gn)coTr(wtAdHvMZ9-X6HtA~D?&>~EHtBpd}Hf>Ey9%sPD? zDn#yz8c9^hRtP;=5~O?uY2DX(%^BQQZgq|Ea_pP=lAhactNA)_o^2>|V4x9&|9(aO zEZR!XT}L+E&dYVzj05%<{jvV!^%YqD+cMGT9SRjH+m?&rPnqY$zh$pOdfLsSFWT}B zCT{iW%ld>CKCni}M9L2%f_!*{2TW^M6COh-t1b^4XWnseuYK#PxLSo_qpJ=za*+nb z%R5d3h(y^-E`4*q`}mfmLQ>LhDtwr@<9x9(MSbE8D;?E8^xkWhC4lL(jAfy=_{jJk zvweL{?zC{g`IT@Npz#3RMdZoBQyK4BR4Q2p2+UPw0jTqPek(akz@;9bEry%hX%{PnJhGy3nx zIO!a$H_guaei;;7*WxyAyQsWAp0Wpcld}yof3Mga9SAIe1|a&0(h37-^z@#NY4Ca) zp!lMj*Ft9KitErRn$NUTE@{8*y)@yS?Vm!Y`r{lw!x6*yo>lGkN!@Ud%Q08)DDTxu zGDK*N<@?@BrLG?5wW=xGBiE($I>NN}T%ZD57Ox0DNCo8HffpS2zex1}Y)!*K*(T)U zC-tw5EYDf`v7YAWeKy+v&IZFVd$Q@;NT9OgzWs+fB(kl;?t`Yb^jVd{2r2IRJWeB^e<+MpVY1YX(l(% z_x~UKeR;+JmOMX-A+bn0sUdjBiw!Z@#WvvEv#rl$IZP-DGNqde;dv^VL!_2>! zEyTpcey7zBeVp+ex)av*8)}Q6zPyXw_PK&Mf~@Gfk7efkw@;+!+P^L@iXI#hjpNxt z(B|28RV+k##5z?I*?luMP$Sp72FKdwqkwYpu+0&Dj~R$pK9RO+2>8)`Xc+Y$-T-Z% z_7$ioDJwMg6oZw?Ip0Fe`!l>omz&$@FsoEE-IIs&OV)J1<)K)q1U+*B+pquj_OI;a zxe)b4YiG(~xmc0IVf)UXz9XTfaYz_FvDzg_cef6PWmwRZ^kRW*E1e%xn0?~G- zwOj+8dTFQk^Rl11T-=oqDE<_h1z`a1Fk0rkYgf7hGa{v)y}Z*y#?Wne6q@O6 z>`?sr8uDRPj?A0>3WJ6{Jj+*mGi`b8i_-4hD7hFpe6v$OT_HHzt`t_o;9%!NcBUHE za%K7gY>YOMH%@w4_1c z07HQaa~gq&!wGG=D9OMOaGBUgrfm{K-_eBR0~z9RLr4SkDaIiU3!*4qM>4{fQDN63 zH8)&X9Knu^K5EHlu=mE%70#tQsi_s=DaJ)lw6~XE;8Gej&wS;+wZe9%aM6Rq4;3Or z`Hc47*fMv;u=A&$Z`6lahJ~90%q&-_oj>KZH>ofT1_2ffLl2CnZ>$M`wEu~%qd4~R zosULA&UcPpxzYuHctw>JlmYEI1LOU#)U2)GP*{xh&$bEs&X;d`zcm_s(v;_Eb~RX` zW7*hUT4R+jj|%UG?O6&w2@6V)3j1VylQn_lm8Hskcs(4@cbtU;(#|D7YMQy~??|5T zZ+25RN(_C1s-N}c?1USc8+|w6{|5M;D{_T;{S^tGKM?PDBhJd^(7BlcS!Jc|`keK) zu-ygfXBNGarN-ng&WY?Ca36b_#FkK5N)AkPQ;XqFQj7}S8zvhwtLX~mYrR1p3>SQ{ zEk`0*p6AewJaJeP3pr;2Y<-{VaXwQ2p;oL>eCWHXTbIz4zMQG4(_g2JCGGg0fnq*H zT+*{M&N2Th%l&Kd!+*Gh1H2d3|85t4$j<$nHTmz@>WU)Z^7;$=#nnu=OFuGyK0r;2i zZlR}oBvTkKVPlXHFl~l)(d$p(cdXM->972}#VC&S2teuak@O}#<)3ms{I>Q_NFRP( z_1~Sj_#cD7=X;We-=OQiC5ZS78sFbiL;$3|u7(DhE>LAkYS05ZlosCl&C2C{Z#O>= zroEdZWrg+xEI*3jy@rI;ETj*BPkE?H^YuTMt2Q0q( zlC&%6(o}UW|FIcg;ou{kN=T^)9;wJ%-rNjU2T#FOa@o+52{;Cz2@-u_I6PFObh}7B zcowlFP%`GdeKT#EYPifO5m?w)I}Il%GsL0%PDAFeJw8ll+u4LXmkAD)@90EYDLK48+b zVqV3s+k1M@12D|koTt7PtHOeyc#Oc3yDVHl-g03K_XNe3?K12_zQ?}9ID?!~pS;ilLcdV#% z$IKFtr|{18hQC8P4$06(n4;~=XsV9y*A?Y1N6A@L#i6B^=T2+?VfA|gkp3|{S@3wQ ztDrI$y(6g?iq_uC&oNuR$hkx=7Y;u|=cn~z#R31oM_G<9M4-f3`lz_l2FUaen}C1) zqyFJV0lMbY2B@QF1N3x(*{A)hHs9A6EdV=g^t)*S98G?@uqf;a#Hm<~y0>1EpP;m5 z5t(0rD4O=%+zrt1G2+;{Mc~2f=U%X)yl~zEe9`<3&@m#T2*9(OOF%$tAi`$zAvY0f7Un)Q z`!#F4&ANWi-n7K=Sz?^{{MaZq$D8%h5}2wu5ecH zKr3vRn_L(ex`HWSM6r1eS~RcS@}0k=LIe6HQOjO`xX--4B<9iwoi96d&OUWy?1WJF zI3Wa_f zf3EoUBibjT1bVdAmnYYw!D|HRQpJl)F%u1TXxz0NivzY%4Ug&aW(yI^wdBc%3aIlR zboLKKADEH!0cP~bebl=+=+~1Oh0X3Yy8h5R{nI-STRDtA^!0P0!W(*z#GWe2?Y6mZ z^|>rjXxr|&{`>l^9B4M``nk5Z1ckmm(!1B5xuhI^kXRP6i?*d@7;(Rj_w0U6-hgwL zGg)t_!24yjp43KZy*4-~@t~U{c6GNwima$XI>12p%AF?;QjRVu$6I1zdK3~%d<<0MDM;cVJ$p#dXg5pc|Ofu z3j4xzVs38pQU+V&f-#nz6W!9!4MxRaxL z<{b04v+S7Mr%+0RxKJRdPMyI1dO%?HD`@xIF{cbR@^O1uJq7Wyp6UwG8TC8`3x?3( zCCdZPFzVdjWZ@n31)s&!IZGwDB3pq4G&h>2hVMw%;Zrgviylv~bDG+=X0r?6_msO} zjbA|Sdmc7pc(L1`$LC!=GYN-yu*U-u_^A3yYc=0)`~@`SrMz92l`r#~oN3t2JZL|E ziSi?8M^-lPyuv2!7fZcA;}w4cn^hA@q(!}N$#dS>S!sP$>^%9>6R+R|>I4k|f4scS zm;m*)InCQj5)AK26WFac9v_=MH!JfSw`r1%jRd=z-Y-=(jF(AhwT!Z3s;%i1XzCT0 zZKDRj_1%zvzd||^H~`mas7BX9uHKO))l!ehwQS+n;Ojzn7hP#wlhe(e`uRhhQ-`JA zx@kpg)4XDSvo1+drrMn+ZpC=1q-zOmT$Z79!mpQV)GgL~xcpdYQ3;y7OtLYs(Iw?t z&b;)qmW8J@HON}VC{a&#WOC7|CjugrkskMjiiUFTVxzGymp?4k99&&LD#Z2SgB3kjgG@C|Pa!op=I0p5|YQ*mG+`dOGNL~lNmI)s{U#@|DAAkA@ znr(cV|8Un~#e3|w4^N-Oy$2NYJLqTNIg5o+EPk)E7|!%Pln}Q< zKWdPxUl<}4`n+Z|*D!O+;4&WITRFrVDa00>Q0q9Ks9H=zc|B`ZF97H-W%N_PTyG zu`HdK`v;EbRlT;{TVe#KoeCVC^rWAWV(A$}bNdMsZjkMYx}6b2YTY|hQ#5hrEZD~t z>L*g@Edc_hJc7dvZc9+oT>(UJMvDM$Wrg(WxQ1 z&P(+jucVe!zZ}WYn`1;I)q~G3y^zd*kY*9~0&E#^-H#(JNpb(YcJ@aQNtXH6u`R#< zD&9z1bTZyc06ympIBgv*XWE7z*(?WR_J0HwLn1szXmEfmI0SC`1&{=q-1$Rg?pCzH z2wTrt!trrJHx6)7`MkvX|0mFEcYFjP;OjxAibO!6G%WH=0EYw||2ladHT{ML>8qmD z1xQcay7^Zg>D!1S|4?1u1OUL|=9B>dk}cujubf}#uC;RjthO(7*9kz!0(!9HiE1go zr)2r+slTd>82SiGhaz-KK7usjbPAk_2&ufUz>a_Y)-PtNfBxhz`fK&g>bYy17OwYi zNOb_lQCoP`OVI*mNGXBLeL}Prekh~k7?KH8L$i9z13rjIcQ)gD>3r7YoIK`Caw?a! z0H^VE_JuoBqkC1HiwXDrV#6zEX#)0ZRKH zzRRafU`Nz?HFK##yng$Qy=fO?Oz+&b-siwUc+oj%+iTkBDd2u8rY22ffq}h0K|UWw zK|V%t9@5V$SF~5i$Hub$VeD-RDgX7^x!Oy+hkS#(N_)1%;+Dq+T9G{-O zz{4s{@gnP~iLb6pEOR{U{dx8FE?*TfFPaONlT>*x$hM0J?3-1d!Ko)ii3+mOQ|ytH zpQb26>^*d`tMo#uT=I-Y*tNk1m>SD54EJ-k54pltbSh}-M7Fp@9eI2E!(&%($9Kiv zaf`+kj7{BL!0#O!yTxo={`3L=lybGGF?c?BL1!q};OrTb z`FKL;09tZxcEm51q5vi8=kwe+5@*L*@=T6u=n?$2xF>g+V>eP$?^;w~sjbD>W2MqV zrd?0nvrPep&<{t=TC@^5+@aYh^&A~t%i^8{gD@(5Hfei8{j^w|VYA&ZANpB=pW(?1 z`5rQUZy8`vK!Bmfj1?3Vh(*j7INJe1Qcq7g%|fwmn(xG7lRXf#_68%ZT+Kt(i_X^a zQr>M&AcrjG($b=?teeHf5lOKcZ%@s_TN7QK@0PP#o|-M5=WrhOZLf#Q+I|GRCVECJ zR8UD#Z%AD!8IQSrb8KOCgJNjaj3R4OvIIvXi!!|5dKX!aBbXTfY~@J?UH=CidCkn(L$ZvZCN)j60kxm(!m0{Z#v3VX*n{# zNGYU%nYEI6ao0`{UdXlf47~Kqp&8L>o&NWyrNn|qLvG)e>nOjB&bsSpvvbypY+i{g zK6_JgJge~-F=!U@_`@G63;O=PBG>nGQNXggN9q8cuNWyp>0z&ve=GN~miz%b{=J>l za^OLXB#s)33GsnYTIV&NAGy|ph~_)WKr6!%;O$TyTE8v{_4F>6G#Z0e4Iu2V79d5^ zO#EE!NJAORt^-R$=>^f4$oqP+f-k03q3 z&fAXo-D^L6-~c4*W`kTge26QY;7tc$05=+lc(#L=B>{J;H7Y3K5SM%R=0$kJdNKeK zd zP+zwK`j1yW^~6B)-^L{V9hi}Cihl!Vjn{59gF4ZaGY=TcE`vvE`u zj9H-}`smxB2Z-`P^#u27z;jXaTRf6+2>D0QWX3JHcE#%Dh~K)x)Oy$&T>B#{6!prs z&!-u@Cr<-#0#M&d2tK*|E!lj7DuVT{iCY#n{|LftiV}S-zCk4U7E`3W48@2KAEAc# zo*wxKlJWl*ljLQlfAMi3LJtHRGqGF3XyQ;z!oxhDqLbPw5|$K89$G6K)ZJ(x#`p-6 z`~;Y3aEQ|$7u9q*kmqUwaVQm8<=gnB>JxU!@MN92P_Bmww8?<<(YmOfzTS!8-6}; zi#>?>M(eQ66TjwOS1KIZbPPbW7Xm^!S?TIzmzR`D=eJ286s!f1bA@PPUac}?CVJpw zFC~D{cCO5bNC1@3^}K%|=h#P(?|oDOVFxB;bDi-ch$WtQkfUm3m9hu2G-!ag3&GwB zp@g>yXaT^Fws3S4!gmuODUJ(y?S;=-Yki9B$iW(|CqceOE z+xZ+8UvoN|@0o8hYi;}W5JA~}hKlxn+|L1|)xGX!Z4%1khm;svs#Sx>r(elE;n;OD zv8Xz{%~dmD>-apz^m#S`rCbBWMPQ@E6UgfR-@Cr{n`psy205+xN0dvOWQ~9&>qb@* z?~Fh024Ji@jm<+-s-q6*D4IE~sUE667QS$)IVk2-P)5bD$cGVz^26rkI|Agb_=lT} zV8*l_sm$3qCa3bEHtR|U#*sCAns1cN_!0;DF56JOgywOaK5bcd`ZXXXAO!%&(FxJ} z?wS)G;up(bcTD6Lt%#QHzr^|hz5!rtG{DFvYe}^Bh#B+ zcF5-RNv^=S2tUj!yFa$GPM^LEW%Iz=A^mx+a)EAh;BF)C_l5+IT}R4d#+K?Scjsaq zS{W|)tlJ)wDL<}#l$9KBhnRI`E25ttq47MUrIcKq1bb~#Q1akBA6ljHxQnXvXWvIstp$@8&ueD;~y#SCtbmk?i%ZtDdS4ER5L=>s}u9UUC!{x-Sz9? z&4A{Fse~KY5s7NcG z%+6ve>%j;eH+pE&si(axKg4q2<%8B{4u@gv#F+-td?>;lgBBmZNfa*)?(Y}PZ(oRU zP(HhnU>!5UV#*A1YQ$v4mUFvbj;nVL9nh6s>zB;2_UDEO2X(ql1WvG1_etgTyYECv zRG7gT4Qez*H2f>I>}pWUG?vD4nYtY%&^xgdQ40d&b6Eenw013CYOPo{>4m@)%v)DY zGZfvMWkMoe558ZkTZfm-@GV_+gJgCDTak^zdjHljDkXqDZ^HoNseNRkbiS6@x#QS} zbL7kvU3L_9&oxQV@G3f3PUV#o@q*?I0&9==%L#%`Hb})k6pz?ZNE1NZ7gHO%$JUrR z{AxBl_l^JAha|qz7?!((DfBDQdlJfSqa(DsvuhS*@m$6}!8^0#N|QT#*Vx&*|4!-Z zq95A6GI}Vj!4Z~WQm0SZ`Cc&YG5`Rz6WLh|u5Bf^a7sViJ)RxI3=@DpYVr{DRK?O6 zT$zS5N-!h(GyF9D>nx2&%cN9!RvR~fwPN~~eWgJL;Op;a!s&X$WJ>}Rt zOQ~B&X7}M}T_AU6c}JwEusfi;r^C!$A90E3Ny{1;u1GUp^=kw6B2g&oZ=g)y(88b> z!&SRp@TAS|5jsQ@y{q`1)V)~fsF?pMZtM6(XgT&WliKUknGUEz(sC>2bhZ+ykD83X zSwz!6%esZKz>yKd?QH1>_wK(gs1{mHbNe=YPYW^^CPLWp5hP!9#($Cg{wwC=m&SmI zix3}Ei++iN#Jli>!KX6Lq!+cQA~XI=S&^)R*FT zlZV(o&j@sIV)Cp$1DYz|`S3y>C9~hVSTl4>sMp;$i0E4EXa1xy+9l# zf)Ui0)oIM3SxN1LuZ+}XzY<<*M#ro9%Hul!EB4igp3u0w-{lMDmgNa(7Dqm4?IcS;v^8?Vd&YA(I+CKBXqT?3WNJxE$wus8!8{4tsXo%t;>4AN#A91tq%ES#BX_I))t$kat{%a3Ng|& zz;vt*OGY6#M=t0Zka~jO!c*(V%M@tyH4+FxdT^v-Cv45YV98^zmHS>SoR63c_QxDk z=+g;b69Ke~dICxleID?#RgtaT8wN6f(tc&>LAe+#Mh1NakvPz6Mnm>&@Re+b%;6hp zH9KtCnI}5Rfo7_Q(%mZO>CP>2+k1F4rzCP$|D}Wz>RNZMaFR;6YPOai#mdykQ?HIoIJyk8M>(xB6P=@m-sQ5*%|u$XM*L{SzS^{2!fKNeCF=EyS-)lcF7k34Am~vZm<;R7r%}I@ zq;ku^CxS)|5;b~GWCeb&R6PYNP;<&WAL1bxeja}!#q|ZgVh2f9k~;+LR@uK0eF>MK z<5&lAA)9kChUS1HDoC+=aHfDDz*x$f*_RNKCX;;4X#JsnL8RK|sSRBed~o zB*oZfIeE~r-yAvVxyWnuxDsPJ6OsfiaQ*9r8)?LK4K(}#XVGKH;bizplB;&_VCu@# z9Bmk}VTw<@hi08uK=c$R z>V4GN?p!CC=AAR}8>WSl!_FfW#dW4XSS0HQ@jBw}fRyK7mgiwT#yC-?_xK!g@-l-> ziXEpr3Jg*}WNb~pbz8CjEN@EI6HhVhc`J@uIRh_2OA!g1>t}**p9JJZ*xu@{#nr!8 zoQPFI>w|Z_=|7s!WyLq*E+i{@$O!_YpH;(5JhZQDr9{PymrCuwo2z80(63vLH3_sn zJ@1L)?Mj`iXP@$pWgHW&g}HN(-iq#x$Sv?dH8Txb^%6!kQ&o|{(ybH{ZjXSd#LSX~ z&m@$Rc5<9?sS+hD_d*i?T=s2!Ai_cl5kB^ZN< z;$|ABRr+Dt%?q1eFJ~U!f3Z&DdktqBydgDeDlaLk2i)< zQcsP_p%=#44x$#*Cqn4Bf>K?q`B@rmZ*LeL437+Loxp|%CzW2P)@SW@w;jKk4eZ3K zt$xDK4?e-6V%KpN52v;5Lf(g2R2OFjOI(gTo%p`6(4MQd`u#ogD>`zJknt;G(VKJ^ zJNSh6GPEjWD@FEX-*00}W|d#(=G^>CB^8>pKYjPVnf|}L{OP;@wO;Hi-~EY!r8tDD zBoML)f_GOWZV(-}Ja+0IficbS2pwo)g#s?F3cSoUZLmfISk7b+N{YI|e?<54eVxXn z;9OU-d_m`)Bt$HOw60jVG67)=+&Ymx90; zJ5nXkbFh0?Cab3YhEA22LLa5+Cvn-?94Av&Q&|7ZE6j+1sU%qZ+5DK0(YU+uF)p2^ z4^07F^;UO>hF;Xt=>Z>1i21X#he{4 zR?lm9XO6E}bMz@o@L)J|l_#|1CI+IaP27up0O;}~od@_F`S04_iy{oJO4Xy9l~Exf z3nGO4s1m+Bwom!%Yea`3nwqv*x9f!idy$5Cfz|c36ukY!bS|fdxRPZchSq|_#F=o(g==!FkLrs zg1ke%hH;OriXBOMk(#EI5*l$Oouae5Y|{yo6)(k%=PE!o)uzvxvDUqkoeWvxD(LJc z0A*5nqf0w#uMYL=8VpG0y)V_=cj+Wr;ckRqp~OMo#g2Yr-vR)hSm-6~=dVVUAz3-vCF&Fj zxF}k=*wEL|Qc0*hH#S_PAuqI8@@Csr_P9y7k?---P#f_y;>CxMJ!4trRInp!M#nli z^KaP6lrE-k(4NEd`j%r)jRy1u#$OKWd(g=+H8p`#S`I6N0Q|#c|$Jc^TIhDmMZzb~q3QcVY zdmoqpzRL8FrjWjOHM2g^N%9N9?6ZmC_$3IEyC=b$VCP}Jos4rP=E6&$fX!A1GL#Hh za1r3eE_yQQuUXRf%;J}vuL4c}1L~$7aj^Z1Ui$ty{>yU`Y>Gz|WC29!?L;zwa`WA= z`#}T4puy#oun<5L>&lDa9Xc-VmaHKYtxXzuB#Zqps~qC*mb;o(XYJL8$yI8&ir`<# z+fz2YYddw!`K+PWIZ2wtzfR9be*i=n^apV)n{&El zW@3__Sz9%I^qaT#9O(?y3!!X@7nHuuUw-R=|?X)PfqoV$fkbUNwsFCS8 z`tGhAc9%pd`lq2!<&e=EBiFEd$DcuK4o2WbabmTOjwc$}%r20ba+>bPd?>4~idMrh z-djZ+pP6u3;0t3uctjzLoO(BC0+n?el@uZ6GbYKaPz)P(Q@rUbdp|7UuD92@GkD%X z37$mg3m8AusQLC^}4H7cdqe;x0H2>#XF=~0F-A`D;uD&dLI1XBM1&Sr%pJo zgy4nh1K`sfFX1B_aO{x#1mFUW9v{K&nvPp18W2Sd6p!`$(-`{Wv}L=lx>0F%G@X9w z-Fu@*;DJ6vIXcAqeTVRd)p(&x{6mpy!K4F|%OsFQI|JHMK9317#oGk4<$>DUD{|}> zzQ&h%8Yg$a6(-BMU^<(1QZ!MQI^P%gk9`O}hoowHtQy|1lNd3j55fwK3+w@O-aT1a z4n=&3K%bu7H~F1qn@;W_>GpG7$pX1EqZxhNZIUfCk;T^{d+N^5?R?EB9&gM<2AZud zb3xt#lv@E+<)WQ=>2pK;iWWwP9lf+EpS8aZ+;PXzaJZ~x>-Zzq*FUb;T1i5nXlgZa z&6r6Y-$0JS!Z7u{!bK#HL*s@pAIcrN%So^RYKwMxX~5O?d(Mos3NMnP*oA0?Hp@$q zEzt#UAoK=vqR3G5gC~OlBnvg+j!E(xvT$c)^tuhzO!%#Gh7O04$e`q$T>sq%1r;LI zL7@++&#Y!Sp<14t4j8lIRxG;J?rvr!w%3(sp`P^7Jbpgx95-{l`Cl#DKoXfJY60M?cE}RG0&iUo=ze@*XdA*#2k0g+ znFHYVK_5V{!hpZXhf zFHzi;@cmeWx?<}bH@8H2EAtjT!^rbf$KJjmwlL;DNw9aAf9`dvuG_pCtBFd#hJyI>i%4Esx)QnDa(Iw0 zH@La5__XIuQYO{mS44XJaij#zct8+TwWKrAOINgj(uyO;nm;J+38?PCdIrP?z9+Ah z6#H@lh*7gTb3L+op=#jL{6Ijw>4$Ttd?e?PTgUWEAl_#HoW{|Htu`Su%GP*yj^Goi zu0_DJmZ={>=+w7D+l(zDCVF!tIu=j7IBlZJ-Tw?Jo^NzWy`tEnxttF#*L z`{?Mqrkk6p#Zyl2jLZwxmFz|UfF6Je#GdKQE7@iOHbSnIKpRi@$&#ECd$n|}08n#z zOC3Qa2MaG)C~7-b>L9@v?x;7yVAELoc>m;$uF8BNYPIYkgU$&X$vNU6nvBU4P`2g!bqHxX#s}*U`dmz|JsM=)qy` z;<#x$>a+BB$6G0G5rsO4)#>WkHXVb``-(Riy$tggA){W# z)Pvo=&?IV2^bl5q1-#SUMR)+L;7ituYvdp2{Rj%qh9nwRqU7qsm9ke;t^>Xx8DWb@ zDzI~OxL>R8N^uWvI?cz=QG%A4cQ&S$d6sz*aF@)T+8J`4q6_&PCb#D4)iEw!aX`P` z>FT6*|D-H*^UCc@YakD$-?=wm=D_Xq533K#9WbZgPfia+VW5!K?>nGex#t3v84IwZ z;Ubed=^YR&ncGcext%;zrxI*|T@U*V)u=%rhXXhdDZp+lfJRp8ao38f%<5QHU+zla zN~p5-H^CUsL+zvz=$c*N!R32qqR60!#nj{|PJ4)xEDw-~E!z~oU9&7Oy?}*Zr zM=Ny|N5-7&6ye!zb~5JWlQL~Ly1|gtoh$lE9w^>=hLC(pMa6c)oLeI4M-X`6&*ZAi zjF6O?!A7su8ecD(Y`x7i(R*|@>I!!6gkt@U54^l&tw-JN)U#EJsuerGu{o%JhVhiP z7Qc(oAo-cK-Nj}0Z$5%3gdw|HSqYubpsE)hMXL?4$aT}jdNfL&sdb&YOQgQ#xj$BX zGg&M)$&W`kHUCUV8n?t|n5(Tnrj-=W(uU`da9+RSD5*rPVy0?o3s$@0vd+0WK|ix~ ze7$hiq>%n}swV;xOSg^z2C<#$YBCo5ejYEPVR1j(?(S%vgwYu$at-XAWVcZ!^nh!M z<~>ldN_K2#u=X#pvqMU=d1ZLT{6h`rfGAfPkO%g?o1=lzlM=S5DH(KkaZI;`8#c;P z^x@qyxpghTbvt{#l38S2r{E2kLHiQm6207KzTb3`SK!g4Tl#ItQoKG_x;qKl_)!QU zjxX{BgXj6z8&~9t3rLB$-?~e?Cyo^FY=2DNVZcqDh)3Fn0@T0&Ni@}Qr$G{qek6|}<$e1I1p zU!_(Ku@n5nFP{;ebrBT>INci=N;rFRmFaFU?$pus$~Gk=L4;^51t#<#j0yA+>#AUj zctzKOW&T~c1!Ol`H!pjdu=N_$l|?fd75E(X72Xb0!vC2VnyF3=RQ-cO823EC4I+J> zW#Y@UFm}l>h+`{wNr2DQGa!;S)tN0z;g%uiO$FVYK2LX^qQ%1D>!l@;upW6}4gL5b zH3x?T5I7VtqVSOA8cR4b2!6O2)Itp^*0UwGxvlGNM;G)NnOZEOb~ihw0+bn|89 z`gkobYENh%1s3Ty&YcMiT$$4kN2OOrhukea<(M>Uuk%*8Am}#2@?Fz`m;BW4DbA|) zmvN72dW(QbVK?TKx<2GZn%Nv2)9HKii09%p)+TDZ-2qsM@NoAB?-wdgt z(>I=|@IELPz<;wV<0$c6*Q9uYu~PeG4{ccGI{5z4(zo?+a^Vn$YmKQ|N`xn=4bGRE zVqQMRy+(U4LiQ=SaD4>5$vV`3cArka0nL)`Ah2$ncC%;{Ad5R^%#5!;*$C|PV|Uv*6!%W8*yfD^ zvwlN`g(C0H)^{dP&yw~YohRN%?DX7$ZCaDr)X~;D>S-iA)&S7F=?eV<0N1Y>4+9f; zw6pSL^^z9VNv}(u7Z8^lhnAlKthnH+vO@q5m{Dlgw^O^IuW>gF-T z6>gtknX;MV4U(iOhb#6;CH>}&!Ei56N$vc-Y@!Am(*?Fx1YJm?Z7T{|pMJVBzHaU# zNRnZZuOi)aHS;WSHx^^kD-0WgPrV$fEx=e3BRX!ub6WE31e%5VIQjPIv}I_qT^J ztUE$7p&e!QRmA=6rQjqFKe@d9>DS-#vUVuQIaz-MUGbJ6(VrND@0uQ_>6EID@4w&u z$~Yo;hKr*_6rL;{3(B%ZRorv1p_qv?Y+tx&-YeKt?+_L`6jRapycMMJ-df}RC!R}B zHqU2oWV>VE!Anm_Bn4%UQ}*h7s2ktOE*vVj!}VsM8sn?H=AfEg=gf}W+_~DwlobQ) z0sUq*KlkAy=)3j$M#a}F`tpb%1=%#$J7gZb2OkBgVL*Fu8X`OgQ)fX3W*x=8XX}9L zeZacrj3(n^R!645kU=64*XZkM;s?r=zgdC)^PY|#hl)7^!i4tc9Unh%Rs7NOZtKFn zjx+FS!-rWo0I>i^2*NR~nC-{|d8~5E?SJv{=}lUfL_0G22p@2tV$Ful5ug()dT=1p zrD7HUce1q`<5wT=cU5x7zW^sncZSb)&H;!=YJXMD$D_GKgE&qY!z3D%O6AoTj6igf zT%)l#I2Id4Si#Sw<^bDNk3r_5KZ1_u#@TvCU?BG(lZtH>^I!^MfKGH|{;j|C*StbC z2Typix0`m}EQ}<3L=!92BFDi|xRx>GCa2^k7k4Gh#Zdd)#)QPAouGJ#d1|T_f1)8* z`X#jAR?q+m|7AYNm`RR+zfq_41n&(9Y(11v7wAN>S)W9MOmtEAtLD=;pgS7p;A836 zvTnA%hZW3YNlXkC31O=(n2uQQp)6+=Zx~q(t>`sg#}pzfLha@al7Wle#YlJ z%KUr!4~c6b5EJ{WY42TR11m%L3$+f#+*RH4Q{XRWzDBsmf9PC<)roQKRKQ#VvLObcJ zQyT!@*qlDszBrk#L~4HlzQLEzD(_iS3!bXvD5wxwY01uN9$PqXp?E#6|KzC)?ANOp zDVUi?UoA{~%r!Z(YOkiJvU}U~k8>${?F#Zsz9BcGl$Tf1EzmJMe3qX-$@+kuR%`+w z#@K0`X2g9+XH9%6I5a$14#WVMcj1id3ddwnT38?yFzf|EQ$S zN;}nPh`(hiuPIsWxIFhW{@P#(>v|QJRpQHRclmJ(2$jwS$^Oz<%NTl&x_L+LIOr@d zM5BAOeKc6R`t*7~z3XOloGkiicvkfXGh}Gf8{>EhF@o9(b~SZ1WZ#VIyzc5|?xVYr zfv7o*YO}minzp%oagU?@kn2gDe>Xy`=&LvRlF`Xi;3jch58;_m#CEcC@gt}w1Q?d^ zIl0Z;%?eCBq2KFy3hyIyeZV9tBJXLouH5Z)TERz7yvuhRnQ;E^@n+*i5`0!>oEkIY zP!1l=8vstH=Z$QW?GXaOJDo;S1C=f(@l$$syoEd*QXBG-|9iomEXRw$U=p4({$6T z-9iKT@-2Rl{)eIAOUNHySzyP-uXfQF^zq+X=a;<}TZ!Y(RMQ-Ow;lgg75=y<|G%&C z3&r+)IuQc6p0uqA+k7jPq{{Q?U-jC*`#V3e6n{u}|97zz|Be0_$}+mZZem~$lum&K zF_oBSjU=cN%oEkpet-CCKEamAhfEh&ds`cxVl)!B@dZL zwQKjC@4TjPJEfwv*A3}Ab5Mp@mL{DvlfPu^EN-|Tt^&O-7UrrM-K(W%9+lm%UDMHe zxGIHc+UABV!HQS*3^TlbOCNLfktfdG;UmZx-baK#1gpABU>%J{twe2k?9(q-%rI)r z5UX5|;agREX)I95_YkEbX5sl3GZafE_0ToVHaMis0W+W}_w6L{C7R!-bk{bL-}d~y z4etl|0%-i|s+P*azlZ6QngO#T!ZXP?!OT6(vSK zI}!}T^R|>~yINzCgA5#Q@Aaq1f+It!ioxEv26Ig zIA>fEY;eC{IP>NN{3=AO6D8x79ZT?4h~tqg3CCCHV4^X{=Tm;|=~CGN1k*U3FE=iF zjNsad3sOsjTOUDApX~To)#%Awfb9vCb8JVfL{Og$`at4?Lrm4|cYQTc?xz{tZ^Gao}u{?)035)3mNQ4Q@ zLZ&YroJyY)|xGXdt#hlL0M6>W@a* z51aV=%&!0@KEWpcp-J&q{_-C>h}WMgCW6YBQ&cfK9_>gYnLU$bi6T7exA7Bxd+5$fH;YRz9`ZB{rjbzeeq^6i>xXHaa7FohYyPXhOyIDnT6loL%@w@( z*xQg*VB%jBB4%|1usLpBYtv_ErliiGk)a=E#4c8py*DjXU6)jcW~DA*WKvAb7-UFx%=dVk3I>_+yN8_50;? z=KJ4r^@KXEwY}4-Jxh5Mx~X?)HH!;LWEe>ZyEda~U`eIO^x^Q$#`S5q!ng>8d@#K< zU)5#w>7$2$N2iqEYL*h}LlE2D=Q?KXqmRSa10fGuPrxOR@mTn!kPB@HhtCq_2M0K;Ki( zr<|W~1>Z61zXn(E?Hcsg8vM8Oud$MSI)B*%zm)(4)u!Jg_+K3}fA_{egBbVQFZXv! zuNf3qDEtEG#A9Z5>$`sYyD$394}K0l@a;5f_Wc&dUwtpN?f3(qXV%ZV8!pEY>|93V2 z;OJMVfO(kxL*EYsBS46~vnln=dprUoSezNivWU`2Yux)z`_!?cj-%iklAaO6nl^g$e_n8>CtDcQ@d#WGUtE43*sv*k1=PCZ zd1;A%U6Wf;fy>nwPW^(n$zk-YHH}s_oXe&+&9z2vj%v2Lh6Lof5uE1K{1+`uo?Vva zu-j4J2iFID3E$}pU_;Xe=QP86^_y)@%-*o4d&m*;TzaY1K;IP^g!Qgne?3cAhN!OP zyc2)GrZ{d0JfS9xIKHCObt60bextA-N_jB6chC4LALUi_(QNXlq;n=kkBNK4bJ*Uv zBF`q7MY-1EoiuEp9DN96hPmxouh@fCX|2M+BX-g1T_TCKJ8M5J30locci%lKDgFj0 z7izr|*>T6(`hN8#4~mz;Rb>^`QcSt1A-@O)&Z65?ouO~R($kXZp2fw3-w@^Y<-fq! z|2M{~iZroEDvuL97e2S0{Hz`SO2~ema(vGpWj9|z0ey}Hs}Tg?(f?H<`i*D*KU4Gz z68%;}T`XB``bQo8N1OOh-TR+0pMBH${}FQaPhIoGP{H~l#x=}Gi{UyLhi#K%Gj54qD-EQUwYdVD>KTZ`?$V&3;3c2 z(jsGQ-cJ^rk@(EL2wjtQ7Vlxco+0u9etsh%H4@-OlZTa#$$aY`#r`b9=|>R5p*H|ql<5H0W^_nD_; z52Ja95g(=dYk_X)3X6&vt}HU?N&ZuY`ctt?p7hx|7}wui5&tnAxcajmVN*MLHCp-k z<0Zv)fs5zVnK{?!^&TIOG`d4BpRsAM|5ica=4pg652Pw56Mo`D&O#o6Z3S%FePWXP zbxRRGCmO+!YzV=nzjc=Kl8$T2z1z?*qr*OV(;;2$N37x-rhee3_WB3BCIRA@N;71B zVO=L}-exhb>C4ZcAVTMca&|>A{P=0nb?AH9I^qmIrFUcq5^?CzX7X~p5!`{OX1R6S z&#FIL;J>5=bXdtgothC^4VP3m)LqmA@A*I?K3}RjZIOb~HWi5eB!HhS@UsQ}EiIt_ zqV4nPLjQ>#LqC(}r^`>YIJ7loeIn7Hv(?WQ_}^;*1Wj??EsyT>3yX-K?)TeL!B36B zXNBB1v4KAsvVSWQ1n)fnUOAZY!rk0vv2%`qbGL2l!{mz1`hsKwh2_=&Fded*q4nkT zvTu)x!SJP0LIf1P-fB3Il?01p!M?lImjCSf=q#JkyXuz}MI*6tgcEkO4V z$gT{wV6UF#jGZJVAX|!^;^3LHZGGA@T+Ivb9;>rNa;I`*I0+Vw2tNKi@#zIb`-j3O zuP9WYsUJZH*W)O#Qpl<`_A%p%P`HN_1l_%AFoiEq#k!!@>fhkB#<;sp3|3<@JjEH? z<>tE9NC!%J#uRP#_Q9zNI%r0eLhz0r6e~nMKBtJb_8-gZ2b8~XI{%dXr@z{^6S}%N zLOtb2x=yrBK!40NnC}Qw+grwJmx(lu;z9_JAKGTi8&}hGjbQWqiuf&pI3+TW0(8zAh6^vsq*X*l^(? z`9h9U3fyV*I7cBen>X?-msj8vIx8VpYcfE(GyZXQgjKxe2|M{cLeZFKl6t}eY7fKa z_KdTa;LEAx*&^a_{A& z;+Ny&lsA-HQ}8KMU7l+8vykIwG2n=w6@IqE&++h+E`IWdpM3J?bnvg97VVBr9SOGk z=@<2B8TY^C7p3mDxv3;rXE88$e_`Q;UWel0H_GZuOAEqpnX_y%ISTT9oaImWk;rIP zROEJ^Fexi93?A;MAL4w?LPkFpdyMd$Td1tU*V0H!`b|m6&K$S29jCBU)4bIZ%A4n| zn7YBKdh1?!-*tA{ZL+Sm(+J(#rs)fdU%T_PWsS(39b`zcV{x9gc`;>I{Y2dJ%row0 z=-wEY9u8hYwHX6sm4%pBPZK01PG=)lV+=2}I#N&cj_WBLLnqhYu$s~e%v#@@0ECrk zv&SKA$Dkn}6z?yTDjOfZ}EqlKnY?(_zx!7P| zUkLGWW;=i--Yg6rsAW)od8&SZkECkzH4A!?W=wy?!jWttLsKJ%vrXZ}MA+%3SCYF# z7S;-`>i5?=S_mrbOk+FCVVO?a=KbTUe2OaDqS{4%cG07~O5oT7X9I2z9zaoxO?WrU z@*fr@A5`4R3;{CHPaW$Iw4N5?32@!GW6cw5JLeynko;NF`zkWvKaAMF?nb8xo(MTu zJyvqT;#T9)ff#W??EV1&I*n#hoWL87jte}3 zBBbW$8+*tqFAFH|Bch33rROLS3Y(ddTL+;!eQ{Glm)sKSxY@?&rx}HPoHE&G5ETz zzTtRQkS}Uewz5BkyIJ7Dg_1z|SV!Xl8i|ezQtc@5M4!*H@P_ z`wpv7I-gp}lza@t(HT7{Rg_s!sk0kE{qj5Pr8eLwuw=SsG=O3PKeL9pT_(Qmhz~;2 zL0Y-H*6?HwdF>jAZ!N%IJ^3H;EK65BV1E&<5Ws1jsLgcqB(Ph*RwGO}n%iGZGpJHS zmYIs?s+_I*5Pf@Sm*A^P6~SE@lvx0L4eEm)Lm!kNNG?Fw>0e!h()3+yx!Jz(=p(3; z-3XwrOBpkzkc1YywNo_fB+&Q%(-y9|KU5`rE%N&Fpy3GUy3dzh;`H%=%=?>S{#P&k z-&gZ89AoD}vz!FM6-oJRsDcUC;x6FRdEMYJqGLo^MJZgYX?SE9^6b#SX8lV1Rqd?IGXpLFV(g& zU4KKe`BxMrtt|@&o@3&S%~M*KG-JARQeM(LW}u}=fzQOlNK&SH9l$v|_`DXC z5v$p2puL4aC!vVbx-JK0uaob_B)zraxbzNGDV5v0-MprKiL2meLO&b)|K4azMU2DV zGO(Ikz+we!{dA&-xdXEed*Z}|Ll^Xml3Ri}-83`JR^sK^y62)1Yi1r4Q|jegG&WnX z-RIzK+VhAukltwDE|vS4{eP)Vx*trK?LQwZolaNRam0tkTZ20&L1xcc@^r#hmv+Oq z$vf+3&;H*V)*S(6q@;I|J&$xRF|kmW=f3Pe_h!@)lPRA^IaE*J_pDfH>!!0k4P7z- zu(+2Kh(hRdvF9Y@(m_n4lzoz(d7V1aCn9g3oy;|t=MJyc4Ib7E(q(R-KzMMEsTUQa zd;@HSa$mnSqAU&WGvOlP4DX7L+2;Sxwg(G<%kp2y85~y(>J6BnDX>7S`LN1~+-0gU zDD7ogm$j?5m}Yk*8d*m-%f=yfu;5VupM>`r)td1Au^x|DJnRib@Q&zvIKTU?zKHin z-a^@14xl+}Oyi6xz}JwWn!vHGGIY~?17&Pw$RN@cKgug>%FQk;&K2!I(yLGg$mk839Xr+d17r01%h&YxV zWon=C$f8ISPMJFoalVbImn;S#)09MFviA00Gk?FgE4{*}-zl!7&~+kq$f6_nQXX^e zeXjC;6Wfv`>fye1#HXcT|Mn^n0seyv!1R5x?eXL+;Tr5g@v>BBk7h_8k_}|CQ_|f2 z831s6Ydkv|{HL#RGL7oWkA_saYCb+Mx!R`-d$2SV0_>|Bbwe_uIqFa_n)567gY^_9 zc+IS#szU>WP#j8p(mwVi`hX{6r$k-vdbsiR`?1NJ^}TRR`qXB6>Qd(W;-ZMeSd9~l zL-JYSHcMF|9t9=32sF6eF#0PSe1X5EUgSFlDYT0b0xB zX4y=i_i#w~4owUP3Au+0UT8tT1f^RU^&0j-QTOBh@gWwD&DwVlo>?on_K!=!aqiGZ zDbqYr`y~Ps<)kkcKA1EL`g=&rGRBCUpsbPno2EEA!1 z_l}1dTDReK`o5Di2(fX-uybluMm^7LDI3|3lb@QqQs^`Jke-wYlk#aXF0jqy0{+vP z(|@o?KGSG(q#@z%9qG9%iY^Q?oK!n#bnJi*;93jDald2E2Mh!wQLa zuNcFp9rS(iuTVbywLb3K0&4o_$Gc(xy*~=qW4!fjJvsap6Yq(6doNsV|F_wNb!I-P z?=nBD?>=4rThw<6>$Dkxq_=mo9uFT>czts38%~EbsO|BFH=>}>j+nJ4@G{&Un|@>B z`ZQ04S=8pp^Y{fp0Ech&fJc(SlBZWl?pwlAoARf6Qk??p71DCswU2FHt{5hefq&lf z=i1=7g^RxYE|Z4(L?s*E#=}&7OslDg_b!}=V>s9zHJXMRUq5umgD0%@NE6UQI90A# znTR{qB&$iEy5q^Gjxhb%1^+|CkX|x3i{qrxQ#ZA>j?%!&VA}=N0fl8D^0W1MQe%A_ zO;1@m7g@t3QY)K3Uv?X8Q?2?}Uq5O1f0mEY-x!y@sFJ)hI@^}x2#>0ll2&18=z-MA zqv?cgCja%j?1l8A6EX7UfSw+;O8(EXy z=FlJRb`^i1!AVjGa>`1>gKdvvdC!v+9&~4|n282ZleSj_$)Dz`{PO>?p9-}k?mG&WQ&y6 z1k(_Q6Dc08CB=_UO!m%Yb`;;RlY2|WL6YRz1WBFe71Bqa&c0@BSWh?KN+ zjDU2EfPjL4NP~1scS|#L4BZSl3^T(wddu7X?mxcwdEfhNo^hYE_d1@lW39DUQp1!z zCIj}gg&F(8?iP5m+l6+72CP`p+|6zrx&k;OzTEYdyJh?FAIpDF zAf8#;a26{q8e9Dm66up|+Xk|p4WQ2spnVrTF);zzZX8)&vKWF;sp`dP#Me4IGX3gj9_dvmo4 zi1KhBJzZRF>p)=ORWau~H9XVDQ1q9OIs#S$^+)0z!P05HdjBvVdfk6$xKp6 z3Z;i;+)qpFc7Zp^AWHE5qTSzSk*4?|<=zk3cgi8V3cDHj%nH9fJ;pZv+?ZSC@9!_snscZ#T#s0U8!ES<#US;Udx<)%HK8dV7vgUqKlMjeUqxNYa^CkVBBHl3=1e6be=OPiB4~F#L+W zA=%*+p{KayG=T9179(;n7)*Wyg-d%Wk z77d)!qzKjg_2~Ui>N(Zwu#M<%etuK{X9}+1K#)zGYK+|x0LYDkviT&W8UIs)_Fta7 zV)gZ$-d}!x)B(T!`fj@)+rKEUv+g|X=l?A_{T~}SwNKDY*djQ>EEQdf^E&wH5)`lS zKR!mk%_d|f0@=;MA^%O<_fIGPS4sOy_YN0URJxQQKn485#|uEKps{v>P~;pT))q3S z7QW8iTa~)$i}81+!g@^|0eZ}ol?FTiV!zsggf`XUXWT9fO}H;Rwz`-_P#ediy~Z5S zFU;N|t33c5l{848wRMNcV`H{g+}_Qyuwk!yfe2S~zs_kwhDW3_^n%!j59XKIH?)cg#KsQ+}8>MmRZVPcrZ)&%*}|wni4{mCp2e0 zu1Q9Mt6pq@&lahfntp?hzAwCFiY$lK?d=CEbk^xc_QGcgmE@$vklGT=+byAYXrdf! zy;TXA!-tfggkJWaix^{@`l zgW#CpACSw6$u}6fup4dCvWR_ZYBMNGOlcHA;aYWkCXc=>&zBZe|ZDjYOlNPa`fS)U7nt;R`0=lEo+Zz?zdpx%+72QVxS@uD2M5{VxsTK94OllQzmbS zMG$yH=AksBn}oi=dNj3=;%a4?`Igtft!edx_@+WvzNF%}sbsw7rEk`)7YQYBZe}^z z`NfNWi_X6#N{YfZO!Dot+$Bq)@$VEJWi|zq!Ea z*Pm;HlrPiD0}ktNE-mR;_h+ydK z_?uRyOP7`jEA1ls{}O-wjM}~p;PGQxib6BVf1Z={n_c+#>*@c@&i_iG{)3tOR|@sZ zVErqFqWB@%^7tgW5Is;{y=(G^;*j5xh@X+sZ!2H&El0R-qI+{DfLiS!>QWAckt+*B zy|IF~p@W=`4e`h9q9Vr3C@(!_S+7Q^z2tfGIOK}N^#mD){%*k+Rqxb48W)o!8*918 zGG$g~6B4rS7M}J6T+fJ(?Jw5S9q6nqACn`0)>G$ob(HR$n`w5k zEoaaeeLm__Ke%XOwpGORJga_t zM7WdKp;z=l&${Iiph#<~l^0T&9LS}*AAaB!y_FKVu$INOL^)f=9ON^mu#JyrENz*! zBP(3Q?j^q5B(`*#t|XNqmT!_`2NZmMtt!}rGVx~Irlc60(PrYE^YboO^>hs>Yl@d= z>@J5{CAt8$s?{@oVR?UwM)qxv>EGqh*1LyfZ-P7v-Qfh?GM{;-(^B13gY8)*fk0Ei zAXj4)44WWUMcI3;Gf6IR_|*|0%L+OGd*qA`UF(X#+(9~wB)L)6DU4li> z@9A+bqUXefrdROdE;IAf?4(njg2KVjhCPaOM7*y^vEP=?=;g}1&khaMyd-;3IS4+K zdfLk5`CSrXNv$UCB9o<_50JNnhq7?w!bEwnY@NEu{inlXE2@hRZ4$?zT04`zIO-$7 zOWXS8rw<^y`ZC)C&`;(UIye@u$yHmzquF1m7JlIT>0@%q(#ymz>XPxb`whK3LVH!b*vCK zIv-IgteH*K5mAZUS6}KHtN=E|19#2RC%8#8>kTc4Db2jMuUfjg4WMmza|n?v%~-8v zhrs$lt6^;~@91gQR_#fko%=hi*_*%_ZWvQchse+?qt|8{R?w^2`rJWPVj-3{R`ey} z6tf=JVj|1@s(4XbH!JG1{7*Sa7WooxY3*$MsYgENktAyC1n@r1R z&}aX7<6h~k%m*2LJIC=m?CC9!oG-WpeBUiQk=Wm3nSUHc{d@S7@00rdn}Pcma``=@ z`kOxg3#^%*1cEyx&sgtDb?=96P=9ea|250vXJhTPGmo2yrSt}78LpsKD7_KvST;_A zHCYqB+fNUlc6L-S2+}>8wOji;@V7^R^W@+~wIe{A?-9W4V;9Oe;RtZM1g8Q%)O`xA zzej?msNTZg8d*F7_yhoV*r9WHqqCx(U&AHhXs$!MvyK1}BsjPfhX3IaAVC}NfC9v3 z!@hkYaI@zQ&f5}`2HpF#>`H(%z>x*J>vA7bt!i_QK=D3@Pp#T`g1rvMZAU)E12Fh_ zn=fY|QL?zkL&|ph_>M#Mx9@m^3?AY3b@sATYrvG?X<_(W?-3x+y)l10bsID=Z*(s4 z(h#^3E}q$IhA+l{e6%X2!i!jb`6;l#yL;dRDbD@QS4BnO{GH$KT*qn{NI-W{?`o86 zH|MH_elaae^t5IHx1H`sVS17(H}*!16Eb7tHj?9$o`=fGhM;z&Q$(}y*orMv~RL}TIWmEp0$swn-LS<*@(Ztt8ji<*^J>*@2;r#z3BB` z)>)0(v(&H2g2Jr3vYbppZkn2>LAJn}x*cBV;2cww+ox!(EpNV5-r zrTnzw)AGUqC(0YQeGE^`Fu${1(TYgddi_O!r9&79;zHThZMQxRK?kErX=wEY6LyTm zNZz;7H(D`ppvtGah`O#ui!KW-N*kN|jrjJw+XQ(rJ5ba(79ci!#kj>HjW^OJ6D}td zGnoPJ^*Z4&VG2Vd;j$pid` zT6_L2$oFqY-Rk;kzazkAJm^F9Fy!&!r69b?ZgWhv`^KL7rBO88a&rR##;|myL^k;wUt$#QH&lOV2W6eEg)9Rbd4FSBDK_JDbQT^LuV@_l^1bwlgm>MRGlariH( zG&FEmkdm-zUGQ3TCE}Lv75?Qd;624w+?^_RV1wTE9t?Xbwm`i?`ogSatlpi)jGN#V zheiWbU?UCK`}q-|*mU3jIGtZ#W{Vqz6w3iID(A`o)L4C+{<+(ky9Vp+PTVZZfqnQe z2(wx_YiDr=*|3D`L2kpAS7)(`&d^E8ia=Ft0;I#PXXolgSUKlxMSKRg!r|heTk0BN zHuKxcp2DT@UQ%RyM&4hJ0oOb#%bl>ieKiY z#G@8BgFtjh{+^KsT`7>8XY+JI^G16h2^cGd$Nz;!Z#{hZf>}fIA{bcr2|6m^(%?aS*JNN86p$E>@pV-L`&B3=qSO@* zpXNBey4(^hQsLX9Vgr4(5wOLnzUK|)flGD2mISSqgl)N}Rf0DX_3mZhx^w157SW`B z&Et_6mLk}jKswICpSF2y10s7MrdVy`7*vB9jBMM7utwbrs$=#fGPL+{d!bo?EQ6I*% z>LE};S;AnayY862?G9f zSg*Tz9&TLpbKsPbt@e!(GL6u#A%59QRK3#^%4qXH>J}r1O|XpUH;tw!OjGC>%rAUG z@{rcv{Vj!H%;D`x_OtoP~+c@~~3Y>%8JCgB7eZZX``=!CVnGuKm=JBZ|cu zxWv+ZYKGkvJ#u7~?+m+S)crD$>A80E>!Tb{#W9y4nDb)hhwOlF*whS>rh-&sn&;6z z=??ToAKi4jlott=+9N?NME`nv2ExQ4h6>{g(R%kxQzBlPLrAZ#M zAI#fz5Lb9lFSADnhpj*g>16ntKNzQ|0PS7M1Q&3C%IYbIwG7Rpk`gg%^4KSIMBqKx(L|hj9vAojT`v#I`Jw{Di>!hVHsrd3sp(OKoMvra7l?9o33wgf5-T_$^?sU2C;4{rNkO!(3 z?XjD^Uk9ZrB)KpqWdx;N5(=Z^emDKWU=bJuOap5D6=06+m-6$T%b*#|GkR~lua%66 z(=E!UvK{+k=2An@KXBemqoAALB})mXz%?>VRJQI0*kztNwruKC^igw>Mtm?G$`WP% z%zJDf^ujsJ3a~3MrG)DSUE{my`=D3tO0#~24d2PtGsL`Zo9s2o*!Qjvp4t+>P5O8* zq|tHqDbWxq-IK#9br0FYTc|f3^YnZ&8iDiy$d(SOTxQ|c{hFLaLPqr-uUG7gwJl$^ zhoVLmGxBNRwCH8K%n6Rm1#?Xx6Xq}2e|M3ul_C(YJu|K%%cs(+MAXrObPVRhzLHZt zFR{?S1e_g7T|0l+q{}4HhEMoqYvZ1l2s>P^h*7~NR6DjO8Q)Zxj$F4;7$CPk0=TJ% zo5mLkZBRcCCS=9%j(6f|LkM^yqXo9-iM$lWyX34ag&oi&$GLQEeZ(^u#@rYEZMmY7 z`Jv;gp$ZFlhKlWvx@PA{pbnGtI&xREo{!kiz(6e9i43!kZeWi6la?IK!iwVR!hrS9 zjteCb4pJP?s5M+J>J^wcnL|w|#@`{kEZNpWG=_L{_pVev?cEx|^|F`WoQa!I9jD97 zHGI5!Pfl5-|0kM)ANk+t+JC%MUfMzb=Ir<1e#!oWiv34x!JifIhP-dT@Co1ZMxZoM?vr*^6^r+i0^sXKklRYRZ5%b0A21|QNweY1F3@+}EMiArB2wW^2p zEBC7%-OS_*SL6$5H-K4Bg(kpS9hMdDg|A<~{=Ts#SJZ?@6GuVaPOfzZ@#@~1o_Ujf z>0)0fe9;WFakq~<=TSvjzK`r1Ix(BI`r{%tBG~h)@$v;_r6Eq{Jt@In>@%;V6tav5 zy|um>akg&^^)l_Nm*ZDd*^*Vh>A>!V@}J>e)xMKFgtw(5I|E;^6RY$6DbZkc5b$F4 zG)>=U-(d95N{${H~M78 zVOs>bIS!jRZ}Vxqa#qwj^02oxOCVFysfEXgBrIoBMdR}-IORO9wgBP*`6Pxrn5vFUeK>uydh3^mTt2ap-Upr=Ug zz=ga3Wo%4JxdbUez3}uHdi$05i(P?*2z>cE(Rv4)WKDcJ&DPUq!?FjbjS8NMz5GlK zJ}v=NUi!yvlY02_`z89H%J-U)LVo5LzC@Wcd7lS2q!H&mS6v8pS~2V_4bD3ZbiE9? z=i4`GNpD!`!XCN51$!$E*j?X=p)3n^c;u}@c+!6jvs~?qG5LTBRyF6k>%eSlF4TrM zpff-{&0GZC=)v4dFt<3abFs6cnjObb?R_t0rI_aZaccYa36|+<^bx@OIYp(G%J*#t z8A9|dy8jh4TOsRfwGY2n2Vwgr`_L7s!@|Sr-9+q&=litpMw0*LEd2fYxkvuHKrTE# zn(^hcU&;UOvHga3{06mr1%J!oe@=n@-4)iSpcl$lzgU*ozP!iL+*J~NM4wv}J< z8}u;|93|pPQyX_;Y0l_b_65S~9#LG%@02)asKp@g|3Dy=JOaq}67k3_`l6&9i-v z*FJ7W^dQF|aL=*SQ85Y0Y&<7nct|a(U>%F;I|59{CgVklZ^4_Vj{wLvD2A`FdWVk% zcMOQTi8rD0v5&&};3-@U6JE4&{Xe{B&qP5tV=*L%Gj@`LYMbH(5_5r;+|-6QKhI$C z)~eNbx#*e68XRMkin*aB!6-k2M)4LhQu*CFcpPi?m#~#wU&IXIpdvnsP3S8T7c)RW8yB-K$K2WM zYzbTPkPTeyYQM0a=2CKaC)L8)vAN+05ZI%2N6>dVCiH6G@hGaE_{huS5BDwieC5Y> zHfg?;L#mqUEk;KdTx~aWF%P1TqQc!JA%PBwkYFjI5 zH-Cmz&z*NxE|iQxdjPbTo+2`_IUMC)$4MmnrV;AwJs%-YbKN$CM8Dx;Tn+G{S%d54 zDXc=1b4_mFYqqpWv5o!95anezLTCzJM0nZ}tc;Ay<=~$?n<3OCifvKvN5@M{E`^Cn z)iIFtV~jo$oxgcIBY6As5x|CG7nIuVfPMmV=&d^GDBm`&h8bVxdt~A8x~XhWrIuh> z&ZR11lfBMfZMkHALotTHwjxEKD?jBlP|0k3C&xpNEWbpxTF5zQh&FbPC)+LJ#w~QX zq8a$O7@v#9x{(0jLRqY0SJ0g}wS4in~RqCTtPYgPG z7zlt$Bqy*W$`A=x2IN>3Yfo~Y9jolJJ>aRNSm(tlo?XUGh3;K}zXsNe`cgDO*Zbwe zr{%OCDiMs1$X+oztd*aHQ-mXe?=FGJ2Z~NIidQD(UxQYVuVJnKq%(3N;_I%BFwZhqeAEsysF5<_aZ)A>vT zUG{1(AxOBNc22I*EjTRct~nG<^!z|DG~JotS+0E3hn;%c*Vvzo7uwm2vB7MlDWVYK z&hUB=uwr0?SHD}Wopu1hn@Rm4cBts%1%hX&!`AtPW-4&8@(!G21 zFYrf>IGG&9O{p4q|FaMMt_u8n>5S*;UkhvU43#mib?x8kDiu>tLorR6Eek4|f>@$m zR9>A5X`|zKv#RsTe&O)F(HH}Jzw5zI76c zv2lC{mA$6xSzKA~LaqkP1(MX}gYU0fRGmh#xfqbEMX7z3B5ky3#5?T(lO2R0CtNAS z^8(mqGmV)1^~?0@H=n_JE7TE$^}%;);H<3SYtBzPi)r7N*4quu6uA2WABz3sMseDy z>IRwJQw&rC3%v4vajCIuTprlE^N>VHZ#Oq8S&23e+=O2k5IU{3}PEh z>EFE>*nYW=@i343iQ*6mu532?fUF^osozyKOD=ucmMZejONo7by_PQl18iFb{&L;? z-Q+EUPNQhh!LPMo{_}AI%*PV*eTlA#QZdt);TEa)2?KV4CtT0FNw#rHHEb)Gh5>qp z?|6sP2Zj-k9RZ%7JM?P&lld%<$?*i8jT>sDNFFE%ZOGHfdyEp4TGH)=*8)!}Jkt;8 zT^?>hXk=^TVrZFmawt$9n==nL1={XEIn;a0XYRAebz|IKcy%(Nxu4{pH~#euCc09g z{6X*Q>(CYRGCgPVV?S&56C1FU5rnRuUS;p8BEsB_fB1OXP0yBj@#V1m0>?5TPxzQe z%ialliZuaz;s3&`%Z1(bVTn{%2_`S#qdQ5Eel3O>&(m>ar_-=LefrgmSWt%aQkfT_rcB4Mfryn4( z#|yKbuXQOL%lT6BT#1eVR|tKpSLq3HffRe(9?;oaoBLR=_jtp6{i?=IZj2uT173aj z9Ej#nm(V@=oLupq4e%o7Nfps%VN|HO*+Eyhv2SPvtU~HTh` z?HJ6-xj&9)$|;?$S~kYQ-Y=WY({n!y*T z!rFv+f;LWDwuoAT#SIBAR_I8bWOi}LV7QJtpRA)LBjmFX*}EpGc4pF5VJ&={b-$Hi zeAzbuL|~#$874PfHdk1#7~$zKNp|=I)8@7%RpN{!677W4F-Tc=Eypf9>;3$a z6BldM=xZ0HtRdQt3Jvx+_RWE~yl2M`+Wnb6yOt52tM)e@2kPx4byMd3W zKI_OZ*v_>G8)8W2Z@9n*C&-ZW)d3g*qmSBvDjS6Kc089vJ@*up$7`ZE)3iA4htpL` z`;|Ln?d%zn0Y6yi^AA6f)^{?rlkSn_WJZ@I#H%L6Ap8P1gz^VFK#nOqZ& zWcM*R0O1jD<3=sXDV@Ul8nc*J`S+4W+Vo50lUWc!)b`PPz8_i9}2 zPS`(Q(xaYfFL(iMqQgfLb zOqwvgi}JI27&qtGTyj{n0z6USAei|KN7Fygt25GE)hl(A`@&R$cpDOCxo2F!9KRWA1{{iZ9W5-U5*=0` zdmzj*#?9!?630GY9TX>qw`>X2z%}&Ek0%e6O|&^iKduE$I}sqokb1gb3dDxw6DVSz z@i1}eYxQ+uVNnD^&VIBW#85fNbr3KjUMo@ih1W}GbQkz1En8eAS*CFu@TBT0hti5t zt8|*z`t}tY}y5I{*qs?l$gk zn$xrMp`PxiqX}p<#%?tjbc8ImlN>IFqSZCQwcrzS$AUR581;GPrJm3EVt1sm>>uN& z;ytguXo?iNz;kJv>61-84$bTyF$=wbBiC~jWJ=eRhkufJ^l`N`?6^F@)kdG>R=KO^%LVe<)wQ`3_{#C(7E0M^a;<^q(qUZ8yWn^=au zTVd=Bmu+iaIolJCF0z8iPB)b7xMG zb^Yfq!^fpRI(l~>UTN})9pbKe*jlU`E&>iuP*?qNIrFML@gA1cU}bcUe)6%EC_gAy>DDfP zt7aILA@!pqk7cvzDEmms(4m4nj)whfRn!h9PfX|oMM*mpY<}GoBbUb3gHpHN^whk9O8#*01hdAL zyL*bI3x%WDjde4EXnuXxuhy>WC}bBLtc%}X%BX>_bt$L)s3pY-w>h+mL%frF#235% zZ|1(jYvyV@y_8%r)#V6%qZ`NeWrW8RTxSUS2nQ?T5p(tQcN9tvrP=cM-T)4h-dV6z zS$iybt>`F(T)nnD$jyJ@LP;c{ymNfcP6qHy;fi(_nXIiS0cVo-G|Xf++;eydZ{s7* z2CM4?4Q@2pjLFxun^B??YiHw#j8dtwQpswYh9CKsyEuHg&syAVwrzrvtmuvFb?Rb& z^;LhmiGQ1C8c*OhNQWKuMrhk--_C?dT)2?N8Fr?N*}CzmV?l$OJ57nt`tDWZS?dcI z0rJu;Vxi3x%8-Fay`(qSDTXy(9s{t5#Y0Tndd1wP*G$*hWzCAU-^!ETG%#%4=~5WX z--)L;rfD3rkAy!cA*ExsX;NqD69;Q07$U@ZaZh|${UUJ7A{XPElb;Xt4E}upiLc-I zpT!)==p7TYi8y8@ZdzDELYI6?2OnR9v%Z=2Ar-;k+r2Vzs;v~aY=wK6^mw!I9w-|K z&hi1L^7T&Ip-x=jf#TObiEB2_+;dVRvpbMBSW)X@bp-JLweAIEZ?BxQ4qsB!w`G>CvCFPW|o`L zI+T`|227lwHo0mQP_5)haeiRDD7bt~ckG_!@pFY?rS~A|VrS>FajcHlTKDkbS)PJ- z8ub(pK7{HNO*V3$7zVYv-g(xHdz0A)=2v2mEJr0z#jp%>`-mu@~A29E4-1Gti@?M(VHkPgHe z6u?)bC52T&F~tUp1XIyV>`B>p5|^=Gvgd4GpffpMYi5x|z_E4Wp@O_jqk3g^L7#c_ zJZ_yx+m4ai=+zZZXB&C8$~A0U%rm&qzLnN!I-p(5gPg1{%vuw=8SSW!^D(DA0uUgM z0EkR(9GSvdd}{g5MCg<&1fyzr1gJBa#><8aEioj4M}UB=B15}#NxY%2BwDT%4@C6y zzG{<{AY=>}Ra1Z1c88Vv1f3_ViHY%tfCdoXW_}on|8py;6SRxfsEohA(U)Ic(7)#0 z={-heKl|#cr^J;oku73&`8Hgaaxs-4m6h&j*saJjCjz8bT76#hjfN?YaJ|P zj%zTJvNGi`BHs7gb+Sks!<7d(J_fybO(k@OVb!h)!Pl=s6H=D6be?9}IXNQq6{+X^ zG}CxU>6oN*fR`eiKlXB>u7XN_KJW2|I%CW(d2m|4E=7gDU2`Gz;MqPqBH8{sMI$4I zuUL1k$~1x%1`5aZgu>y;btb0w^F+!Sje$pwLUw?2|1yMg_U?!kqtNRs8lY_(jI2YX2Q^0LhxJT5peEi;Us1A!qMp=rL70 zDA}Sj066j~D>?DvtFShL++Cu6-0|EgRMwP>e?=1V#IedJ0e2ytug}(dAxb>fuWf}l zTsXBG#(EJd_>i5LBw&KDG^S1A!Y$fC>7;v@;ak}m_%T!}){Y@6<$7-sR?BDy_CtKi z#E;Yt+cZBXC>rMS+XS z7;(6TEXB2+4@x3F;j_TZv-9p(Oqpa+F4<#|Y;uWrlkCp3w1CwpIxu(pC8IX?b;~$Z zVkG^gmuVDUxqoDz+c>e5s*bD*G{_Zcb)dEr?~$L!>mem_qAJKzVj)dv&XAgwt7C@! z`}ag+jsWzhs`NJHqwS!yi^ZY@AET_Jl*h@}Eiun&4jHPNbMhAdhWY%(ZQ*O}JAD^a z1#~4jnWQTFQ`H@_7@fwIX#+k)G8$D=D697C_wu`p-?wuJ=p~FD;3>^u)j#Ee{8NB! zsbCP-N*tRE#~Ku&ogygVL)qRUPJak{?9p{ICtAz|>7avDk})zn0+5dL#FFHL}iAZ7Tzv`5vf3rqE0Q5!&uk8;0=Z($+ zUkbURo)q#3@W99NtcIyJ;Rt7TgGBkN-7{FH`fd&r>Ijf>N64E)fYWP@60XlUz9&*F zHJ^!whhm_8mt*Q8X(DU)0?qO+SRB%8Gi|G4%{txB>B*WQMHNE$UY3OzKVit6iv(t5 zIpx#_wwk-Mm>`?1qIf#bc@4Pc*YB$42%vbJICC1-K*FC%=Wiywa?Xj=aL*{(6>yV- zD67Z0n)Tm<)oYiQT!4q)vna)fiFU$Xfd6N=gIpQ<aiZ)Ue2Kp2~J{i4QtsaCE35FiYGKNTRG&|1UvPRX35@*RWeUp{0R@=vmF5z z|DF(GJ@4nS@GN`~|yY(RVS5y`YB=vwy_lEr6ZC-BADu?AHc zpfx(v{oJuH_Ff}&49uJ3xKOKO+HV5VnbyIombEXy-v7}M|4HXR9L~K6?^&&oSaY{y z9YQ?JJ@KlKPGisi;T);qDJR}Sk zq4E_wZQ%}FsbcSEx^n4}Vcwn4$}IwLw+$iQsm^nA!Q*^aJ=USo`Q?*4=gt*hw-Ktk zWrQZawcnL&rAN1UxeNu(M&&#V@_XzN*+?w8-*OHg<)?+=U?&TW)v8**DyY6WWd~f(ia5;N`Q_)wU|>&m zq0Q}BvmbO-5AoWmpO3vN19q1RgBkXfVs#OP9t(C4EZ71xJmN5_a_WkK(mfk?tOFD5 z(hLqNO^CE)KkALfKLb$jWZ*}YXFH}d7vQmjzr~y3Q48Fw7k#eE3H=Btd6sg2{d zjWSnbb1<^cn_6zv4LcDgR$H&$xVa$kmz4VBB!R2QK!urO7O6n-n_&MOdUuGO1V#=` zjQVFy*+wcwvh;d;y@F4rSsY)NC{g%PV=}*=1XulroWk|+I>k_e`pG?FuOq;{0QAbY zCP{cT8$~zXeQH~(S=@XVNPh${It7x9Iom{4ynk#6R+DxFcmeMO((RV?yE3qzf^hZNvmyjn#2R5C-W zN~2bLc<7mQC~J2(te|7r?R(H}QhMM+coJ+MPKu4b#*}2{IRx?!Avuf~cJD$TzmvF3 zvlEI#BOnEL8=ePSX%lwm)#43~DkHxXyi;L34!n4A)O5tY{G8*V)+MgfbW{(_S;o?t z7Coz=c#`{G$~@C#WR+)T&G=C%qm?dCVZ2Qe?8DiEBft#KgT6Q`)hxFeR+Qj5LXit+aei71U(}|)`0#B(fR8#Mk^xznD z8p$Z49)_A9qklaYv&ohOt;y_i=UcH%#E6vzTw~`-xH58Fl(k)GN>%y@;Gyp2D%`Ey z;4aq3aZPTo?hgM{kf)!}qeIf;IDx52Vt#TY5XRqrCfqIeRi`i$V1UqNtP$c{bv%2RBv` zUb%ZB$ju3oNHgcow0IE(tN9e00CPp&wcy;mNy^AelT(S)4&CNzFhwQ4p>0`l{>r(@{G~ zfqeF~bN+K{R5}wfClbS*B{MxqZt|(Z(04dh-KtVkL>QwIih>Vk)Z!19DnXv20fzz_ zB0frILto()l20=UAGS#-@t$7);h4D%4AT3eAF`ChHTTVpW=tlWe7$`_m&k>z1?a!Z z-r>%J*F9aVq&);GL|J6Izob;|xcHoNRROPD%FW?HHO_RQBzG)V-9WmZvd|Ya6>i+? zF3A(~K*iNnL`}mzNc;`@i(H1f_VnUU_?B)zJ$*l?+e%?d6dr~V*}RP8aE{Dzp~kiM zO}*M@cvgEx6-|5wL+HE(@zpy4x(ZVo*f0POJG+uH%yhoF%vLQ?3x2VoLt&*_t3Kwn z4oh}x0WG3`sB&_0I!>+;W{8PUh9;*o>U`b?ktkjQ5TIJ)>nbewyapKPiKKh`UvU{Z z#S^9l0ghpwbWQ6C9ZD?2h`p0cOr@##D!RP-B>?~&uhC{UaLOG6Xb?nFkikE&>him77-D-Da)1Re!8`{&%>|8y8iKoX>r11%M6neK`Lp6iTP^* z_rwQ$&b!KSn4jw+GqB-NhABeGWNGj4H4Kdfsm%1NH}p1jcOV6Ym?(sIDfS@VmRI{- znG*FrJIIL#@k+aCyl2_X$;YreaV1XE)9l%PGFg2bc4xWq7&yxkQ&AsQ2P%Qd)CCVT?*Q9=yiDIgyZuar{)Z|QzgGNc;@$7F zp!>nRZy)^4!S&~N4~Xl-nj8V_f29ZdQR~Btwje=j2cEf4<3Dl3Yw zTAz=@*m<;S47g(Q{#T`sk}fnIV=9}2m$571y-I$0pI_1X@AwL~Zz2l);H&Z*zm5Os zfvjKDK0n2WEK1d~OZ}?#`NdP^{{8#k^T14oR0B>-@x}2vxYbnaY3oWGzP?4%kIuob zOL~Wr`{nE?iR$Pqbb@x!G~O0#6LV{WPxx3SU=AIkJ9w=^%5T5>Z=x2mWhbYNnut8# zhlic;q!??4cazxmrkQCqMtUUaEJwfmz^?s#Z0)Om-4uy3enTC)an+fPmJFYhEraFc z?u)Z8SY9xT(z`M+*UuF~WKHMP5=?jxxDXx=VMLWT3RT@eo^u`vR9q!+CjEZS zsYCH0Nk|1@PNlPaOxnouh^x?`l2hdNxkPg&v6+PZoV$IyMCM9$?4viu+MOg7b0uA# z3-phS-*I^sbwP0PouNFBT1KbbkIUKBc4m@TcG{A9S;RI$!?m8Xtob|{T{b8d^d8;} z65pJyqD00erixJbcJPkAv+Ch#n_22xKL1x>0y+b>DqnUFKCd@Xeb@x*!;D_&>Ehg= zX4;E`>X&NJtk1CboHuH?iDg|7fx*squZ-03(LIyW)G;7fOfJ}^Sg8h7+~nK{;1XE6 z5NLL~!#a=N&^n0ZLu6OKde6X)og4k{_u_x*0<#UH!3dSX1o*;VsdaU8-4i zQOl{%A(EZ$q>D|jm&uw3sr4JBRZNVta zsEhF=fui&~Ma;`0^6Rs^MMzdqa6?@;i|@ob%)piKm2b3Kde+E{5%fI#0p(zy+*!WD zEE>wQR)EhUPztC0CQ+Bs7&m_HQCW`bpL+|9wM}NIo8@;qTqOb!DuoyCZqTfAsme5` zK(+9(Hht~mjgj;3!Y(&F+q&RFaa(F7UfdTw$imH{25g5JkX1cfwu)_E?c4fcA~?QEB~1K9idxHB&(^YtbR>0sZcrD4=wI z_VX3&vw8>f%K;jlNegBKp1fp)%fi{+7uqgekf1)HZhYGC+-b%jPxitSygnx`NJ^07 zZEf(*)ExZhug$0oaGk7-C_SZlKfHwbSj~wzX*%ZtdIOEzZvL2HWtCFOJ+&!nLpJ%b zSA+mkCr0ZP6}w>l`dhsg0&+@I+QZr}3}2^<+T5Z8$jo{)XW0w_sVdH-FH;UuMlXiV z&#U?{3l?xK7`)(pcr45X&iNSWQWG7QVE))7+n>wAP(%NY8SlEiFu_#-HB05+09)!- z+V3ddGeE%_MYvxUqBe@!drZukKafK?C%Ghq>pY!VKSD2}Qtxd>#?$YWIdgI*y}k{b zE1zp&x%5!so&XF1CSR-~?VG8BbKgrY4D(aOl(?3im^pi9G3CQ1Jg5+O>7F&0m#anZ zc!Z(l73sS0cODxV6&_ozB{|L3$b_K~ZZ>`tVTpQJ4;G1Sy<3A>TBK(L?~7h9e6)C@viK|MXL=feY5iJ;+Nge5J?p|+{tYy>uh8z^tZc7$1s22Wbc^OV}{ zW*T}OJ z4yGuBYxZHOK7d`qBICheYRTghaggCT=m!wWmqX?XG z_nb<|1m1*)*!AvaYM=mBZjZoYyXT?QTHq@hxLdbaxZX2pC}VCS$?D=b`t|DX{(tPf z2UJtr7B(6LMNx<}QCbiXR0ISClomi~B1S>!5D}zG2SFf2M5;h2f{IE+K%_=`Pv|I! zbb|D%bP{Sv^WUCw@A2Go&b{~C|Bdm+cyBC5#@=i0wb^aWwbq>9{APb>f6v9+4%A4S z9R|>gs{8k>VT7+uFc!b!YXPjBMm)y4>`Ccs$51m&yF3>dW~R7^ z+X=?B>3q+zqokNgD2tO`mb2Nr(rTH=i$NEQ0yE;+uIUJX1)N&L0zD=>56iX9DWZm1 z-x(^b*rHsQrdQu~j;g4f{2!zeX$4_be~@=zy2LFiXg_gJ{+=h9i%^H!3Ql{v03*R5-o`TKH@e>9ZZQ#79|Y;o>e{U_wxe8# z{d@0F1D8VppiED4oT2u$hBPxd8$H*v*_RwpJ!b#q^i-t@VOCf zBR5TcgnvM+b}L=Em>?fpthjIWYunJUJzvB^$6PuJ1M_$f*ic%NgZ6X}*sH5hcg)T2 zOnV5J)^d4l&abH24%Db)NWI3!*wm@5DeWeCV)n_5Zy*+-d6H+q7wrEeu6n67@gy2E z!STV(@ph`lNN1SHTv{OsZ9DRs7!k8KDWmB@g9Y@LqjjC5yYScdRxu z`QCmn)x)UQVXf1qSRs<}R41FcO8=)+DM_0n_wpehSyXf=bpg}d&!@nlL8l0_#iJJU zQ&R&nPg1(6b?JSm8fL7_UpBO_Lv#5c_gXZ&d5Au#Qgz=d_$-4m`7o!Qbz!;Blpx+L z0B_)tF(1)Awt{-0l3RA!WO+5T z)luzUvTLSe?tB?J^kKVPegku?<_dUCC1S~Wo~B?>(!Vi`&}g`wGBC;5D!k3SBiM9T zZiD_j+sujVf=#oQ?QnJvo{kR)p`van@ye;l_Zs&~on4%}I8eUVCLZjLj9&rUXl1<_ zaw6Yud5PEyoacb&(eMADe#xP4V^|-4xuO@7#%VTkH1?uOJzcv(1#q!V!&of+6q*v} zeUJEIX*GjWCY={Hmk{-s_&~==JTy~U%0)e7CrGK7Fl{0N7BN~cFZQ&^*>z~6(I%XQVZvtKhyX5eWe)c z0j3%!y2Y5On2RY&Rs$NofNK{F`^%Pi=kKL0=!_qQvR_Ye&vSV>i9XtT_LsvjNQi>^ zoUGqeP1dvm3iqz0_?2U^jX^DJTrt)9A(3>(TQEdCR^qRl!s-RttBL4{$=;i7YN`Rx zh)vgGvljdr77%Bw#3xXDM@gMc?(^?%3qe#qlBSNg8g8n9HdUWtI0@PhU4ht-bKZlp zap2T1fgW5o+2qvw{^-kiJg@6Z#|+0ZG9p@nHNR@_wB{1?x@uM>rr_+TVy{lG%Le7J z5udp?d&{Fi@D~Kk3vS_9X(`eTYxtJwaiGbgi(9` zYOi9PCGY~ep3c^nceY=|u(skr;_2PiY89tc%vG4LeC;A)xk%yA5UN17iDQmdR)G5v zv70On!R{vhW&Uh0JJY5EPY~IV%p@g)cfHqRu53-nUasQ~-8J!U^Uj8V68ZwXF%?8K zM%_-l8oDn^>)7gQ#!<`a^#>mjb#i}C)a3+W2sCuO(=#+Oznzz^dfijDQZ>Y#ab38I z^}>X7l#67Fx%o@g&Byj_v0BFBU9O-YTVwUNfxC(NnZ%bqQ zCO10ZRs^fERY$oNbijU>6dopfNW+|;$fAYnv)sk8{R5-RVimos)-J^w6VcNoOE43{ zIlNa65m4_xT$_RCMJ!2{Iasj2K<-bQK;uLSJSXG4|y5wfBGB9 zc4B%?+ld@7`3)5766leJ$mX`j-hWtC&a8BJ!YD)PKki8Up1kpIkyKXFNopm;)Wzx z@lPV6Rj#SqkV7$&r1iJY;kzz4Kf|RD+td%1)oNlA#X{6lm5Qy4#~{ z?|7?6{@`)O1ow^|<9Mn>|5?QT7U(c<|NHU>pN6!fmrt2#HS7j?UO9q0xdsjOe}hW% zYo*wjRURUk4(kwKWVrE`rPGtfYGMC1WnrY74QNUP>g74 z*KBROH^jW@M_gxzU{nS#Al}>wtNr;) zk;@6tmDVpm^BQe^1C>A`4q1%M^V-G(_ARK)&&)=x<+N8+wW2Ryb$Ufnl){||q-^Vs zF=7%Hqbf*bA`Zbt<`rVyU;DChLe#|%LsuC{_`fgAGzQ9_u2;?XZ}ZIm^XFgqE{%Rk z&6C3$miCXKJrBca(wR*%GPSi(Q7)Q{4wZYf{|2jv&+W4^ zyWIE79z4JN;m@0_OYf!befQ2`g{tQ+oyGsiME76_y?dg3PPO!l6+4OD`eyeiDR}~Z z<@}*{2}hY}>Gf`12^YmwBVJn?P;NwZ;QZ+#)d= zIl)~ZMHW(H6MXHA6K-=yfga{O4Q5Ba@5uQE!q1G8k6@yeH31KyeC{_8JP|o(hb{gQ z_c0LkJ4aRLA33V5rW!sG*u5N?CN?=*_;#W&9@h4Ldn-#Gxcf)iuu_|iE8Z2?Fj)+# zpHsP57)HN^c5!jDcTL`Ur^&SUbbM3rjiCGPC$YF^kY%r6DnGY6X*O0RJm1fEnQ`iHiljng{AtGvv;uc% z$b+{~{=(LGn;15LzUl&}<{Ofy80&Fl=_h7_`wiylfyHlkj!;K-cDA_P>EKhHzgQiQ!ph3#Xt zIP*r{{8MFrgMt~hIL|`%l8}z%WQ?A2b);P#aFNpDjH#vX zsUk$d&`G|0xaok@kz)r%4-r~2Q!Sf{ZzAh>5`#O<=6#?;hdfuRu7vQuq7+$PHbLhU z0Jn(X{qF_o_7n|g$L~axsNyi>{O#l*lVg}ZT(@dxtMP33(k3~qzQoLK~NB2N3}b$ zB*!!9va+`kebF^$V*-6?1H();A#6Xg(>vX1{T8?1&0UM1EaL5!#Y8stwH)>J{#Ac) zuj7~Z7AWgy6n+C4-FXkW`W5=oxD#F?TtSpiXr-AJ3n4DN_y&@Js|0mLO*akcK{o9^ z25+)?QJbx3FQX8-O+wQ_?SY6hV#v&YUlCCIy?kH57&nnW#%!akoa6 zBtsWEo-r=)f8B{%Lk_W9_&wLPq33;$Q%(DXeEJ6m)l!tWD8>=$Ewp43+3xZ;(53&R zX50UJ`My@dL~cG4d1BEg`e=`QW&9Jt&{&Bngq_YTUMGqp<8BT z%w)_YmgJmv2^lut2DpC@XVKd&U3^Lh@F$4OE$)62jRsZ;D1^LCNhmIc*oRud7?Rkg zDq#_-XF}?&coQ}r2h0}>WJproVl$9F{^&Yi?zTX6;tN3*Lf?~&^l|;C%SYX&1ARm& zxqWoT3e1ZdzDWS;7@>L^NDN@4?d5^=_74>o{Yv@h2eH`LgY_i1g}Kp%NR4eNrltZN z&9v?Xt`~{uRhbEdR~PS2dp-6Djsy^Vo^-rz>#M-Ct^L-(^9r)2HF&dA&3Vo(LjEop z+3?cpQ_r!evHddq9vIE5YP+yuq!4?zEb58=rDb80{E1@rR^E*pOdyFrZQ$@D5@aX+ z2b{r0=n8|K2D3^f5X0wuWE0BbeCSXP z@6YEs=2V;EZ ze#^^Kv4?H0X7f97UuV0|&}IDJ4Y9=V2;7WaKXP%+jdlRvA_%1VjDHRQ<1ilp&K~$- zzejW}7h^h3>^mkKVLt)iIjF4i4Rmu3x?zIJqyC7vME`)etYVpycm<4W(@5UY($!eG z;jml7m@h1_?F(_ZSKLHgjO);LEAMinj0=8!w>Ty3J-myBG~QC~5-=Teck*f3;?9Fa zTGx#9+-`&<;Z5ff{6L8grAGe*bhTPxO&FU@GPK{44l@%)jEOx)Z;w9TVTbDlo+zg9 zG)i))u5w<2QC2#r5e044Czsy7j#`JrZlN7W{>8p!wXv|eFgWe0@l&dA2}QfH|9Nfc zl4lT;>^IO-Lrv>+ZPt*gVBY95#wL+)^a;Rk#ytaNUP-}E1to?xw0~&=qJ@ST*LT%~ zPtbbJsIVUQLDRs&r~V;)H-l~($5A0w&hSX`6~6t_&pE+YZSH_SvXG0gd6?W^EG-yT z+H0v{-rY}aN_N(Y$mlp=R80%=nZ%W74%?^|AGnKFHG&(ifsh;0pK27gBC78=9I}q> z{o2;P5TpjChwco(mMHdL{E7{0RE`#{eFO3MKq*J_(4V(DKN9V-{QNK6o~27IAh#}< zLW`Ht&!#%A5H`Zv+o_g)zzv3BBQUQe<^XF?-2FBH-Edm-D8u9IBTP4=G#F0+u!eeW zqF9>K9UqBY4bPj;raCDZsChVt)1f!522~~EV*650eFIhL(3Ae)C^$)K9uo*ovruyN zeHR|!UseZROaZ9M>V5SCCJ-!>!(O!ym4^GvKu8Nbp1!}zd7N?1m~Hsw($TT8{CAAx zFXhg6%bg+3s-i`Ntnd{d=YbvJ!#ef#Nu8tWE3g^a03&ErpziHS7pTBnTbbLsN z1iC6@1pVH2D-X#ZFU;S$5@c~l)@OV8NtO=@*U zU|_t^0wU@9P4G=ceA`x+Gn7Nwqon*90x2~Qfr#oTqHo_g%s9wax>j4l+u4NTcai)8 zhqqU0w|?MY%ldpn3$(?Uk5H{Th7MQW=aDfeHXIOef{U|1wnq=*=?NRaqAfW(8&jDo zdhT$#)Yd+Z+PBc^cnno}UVIS_D~Pn8?A&GHD8H|4Y^+U_Y15`8p>^a%;wC0`ak`4M zf}MeQBP3STx3znI+5})GjzyaMxn&oP;aW$yJ`2a*7#5bmq#ua76R&-8Ii4He9j0ki z*0VuT3a==ASNg!0&rB!nhMnNU;DnQN}9y73J;9;N@&)6TKRrGhl$a}QjM=0n34@kWk^_l9K5m zz6JgJ(LI?wmR;zXrr(%dH7Mf;^hQ@7h$ zC3Lrgm6ug3`0a$Vf=v9~!tUxh{dw%G$uZ-i}MPCVB)safq zbQK)SK>nr5AMfVRGm0M-+NBH7SM+dj>&bu^5@1dmYD|gu6%(!ah|JAjn|M)!c{2cJ z)ulKv1KDmoXFfj|gjk#fRwc-Ts7F4?rBPKwT8!OSYv#zAIr#iwfbBNsFmXKUQ#Eo+ zNgHU0sQ%v2h`!z13rrp^6Tl&z5u1!&cf%?2BlPw1l+ic{V7$S+UxE)^HvqhJu zw-j4{*;+>f;lX_rgkvf*Aq~Gu@AeL-sE$x+H7!f&z~HgDIE2}llVd%JIN#pP)cq8d za5o76IrK)6owlz$py)ln;?k{tD#&={N>6U|O@9xo4<60}&51)VGF+cSeOs7I?+JWu z(7(iLHzskf2cc>Tx<@jO444fd_6pD>+6w603#S(dnr@1n)}r^7Ml^gW{j59+pa5eP1tQ?6#~&@ZxmVVu;QptPO(TIm`pcji zWD_`iOI5Ka`TSw?g@d-kmJBZ|7xI*{X^J#IU|J3VF9rH!p7K0h-Y4{-tcp>|tKY=e zknBUIc1%GT{T?+GS2_9LX=h25vN0f@-aK%Q$_6eC{F^ebxcG<|6mzEl1A5ZogeF{Wwte%*12Ukfa&-*=|_J`H=15UY2Wxc2WhEMPT#L<=zps)es{osLamy2 zO)vbU0vkiCaPDJ+`ly)3`yTIeDC#%eWfggSBqe`$#y{Epe;wWfYe1r;BkicV0nLW9 z3-aBaFFYz(qnT+0FqP$R%fd)rxk%SQr7pKePwtlJ%-Hl*1x6!RGvziE8ef`Iye7v& z0xhabUu%m9X74ksm;SYdyEE@Se0EIiB z_NYGDOhZ+)&(-(bW~@viU>Z9N@TBjIO~d-m9_x`4`>5}Gu%^uYyk(JW$Yz`UoMzyv zN7e!_$2@PMomh2*mH9dTg3m|P$+KrRgaO)?-c8nh-Z8qxoR&?}k}ued??k_%c|Iev z!(AOxUYL!AW-Y`;Yu|I@UrFCjxZO<&5iscJ{ zmjL$_u1xPqX;~ZvYidKQV^(Ibw0aByRH*{UPuP33Ot~0*m0(mX(wA?v?PctADVPpm zbYA)*ca^}G&|yZ!RY^~-K3jPzSn;Wu%JK>t^LHek(1X~0q{L>dVqaY*Hd<*jDPmDT~7+AiKUgNf}z9%XWdaUvo)shjVq8YFRm zOrNx9fIlVe{dTz^I)LMzEt`Bxjwh3?kKtJDnA{1D6AL*E7~hyn7o+@h?mLf88^jBz z=Dgzl!=!G2?dnP3O_Ez)pqk6!d1Lw0vVM3?oc8Dqs&1bXgFR9~`O9xM{*Idg!60dN8>6g5KLHGr9;0MWb5+YA;5*(2txB1CB;{7A}>EM~R^e?Kz z777y*e_y!FOVPr10}5G`A;En&(|y@1pjUBwbnCc@(y^tjM0iZ;OFQKnu*}*ZV=zlx z1T2dI$qDBmEm|PCNyDZCHtlum5Xt-J4rcFtNOtET%Kb$%t9;5CWNT+6a-@vzX`CDM zah$k51>cs$y+~RZFIJ!ilAh4o-M$_}?1O6%a2nSp z5nqqlkuU?(ya5w{rb?g>!I^$(Amkg!@)$rR2ZP_j50-BIR(Zn(0&jl2cpcn^ z0dTq_$eDcS@y#A-8dnk#-vS3tw@veY1f1>|B1(~k!sX4qb$sqWTy6l$E;n%wnFN@w z`#)?z+W;H>!VDQQYswvO`X^%sTnLyyG!^+_T8xKcX#-+v5X2v1Q5gz1 z>=WUTc=sWSvn_{gdlUUuAh&lBD8Q^~r+6A3B3YwSV7^f0Ei9p;eU}txZS&aEW9~5j zbe~+{XCkIPc}x&5xoN4$&YhZG9jJ4Y6X8`wFST<~&lROhu( ztmt8rS^gLPdzjB{vRX3NfjM+K-uk)vo{GXbmoby>u}p6oqPBBikr<|QkCcL0Kh4G) zFW&{c4B(>{K{+1uO>YQDSyx0pZL)Ht=p?OR5HdLp_Z41Wli5BYe)BO+_6~<8LC)~6x{cy z1g0)AW0ECQkH9G`{x{Tw-i+^dVc(LF6V=Gwex6ElgWJ8g^eS74SVcx!cUO>jB_>A|LXsMPX(kbEanyz z)bRa)YWS-?fX%$~VQX}twOdvPy0Ga@z-u;ea)!HVMlk7XDUhVD5xoy}nA9*1dk(dU zyu5vpA0nwUfzV|nb~>#CP+(O~K^bBw7A+st%JFO^;+(2kd>uJ~c{;U!GrzV*KDpc6 zyeVFt<6-Psi<56BKuRp+fw3_@J%{}KDVw=NyQwAtU?bC4i`Vj4i~Fu;>>yBqY5g^Q9>E_QMza-$2zbzV^z^LilO~_GC>C z5Lrvq;Da_DxB1)mojd;xBU_ZkDT#`5;3>-lP9srLI4l(T;p(7luz0B@zAOg+qlwh zfQysvGXW`)dM!HO?Q)j$spQyQ0qk8C=!PkEu@35Bc~LiSZpcCWw0X^vQs5F7a;|s> z|B?i)Pr<~b)-S?|HISkT)Pwb>6WI4{2kKeM z1rGbq#_^;?tFIY>`w01uS>%|j`|Mgjb{vg7vy}Uus+-vl@Rb{E?coiuobR=nwSD}) za@**G$egBBK0sIgJ?_whDQKlE8Kt2VJFc;B)9nHJU{+O9phWKF zp3@q4#Jm#k%i4%z_vmaf`Lp~l(yfK><&Vd<{7}lHjeq{+4P!_<$i|&t;S9OI((AKc zxZ3@LeS_;7{Ll{`i9pjS>765`a55EeU|o@z<_?xakix`L7BdRI&Wya%XFN zrXPWs9P)k6o4VcJ?c(C~F=he52)*KhVo_*|h-=3oYyL6`o-P()u-x5?hqw<6rzwV)UI} z>>iS052*Z_<+$$X>6%-M55Fz{ZTjC>-=fuv5zbA68uTh_*!5XUiQe3n4 zg?%|CTl69qV{bUZkG$|;FJ=#sIUH~oE*dyiy%6Jj`mU|bv!M1R%-w^=wpX}@uSpQn zN0rFeeY4>H)b&=Q#EG`5EgzNo){S#QQQNB_xPxLud9+we&L!Kvr7qb^tc6RS=8YV@-{q&p=% zlT$i-AffP!UzIJnD1kv`4JI*JP zi4D8djiDNQ5RpI(?2W04K=J8wZ)y<93Jxw=o_=aNC%?|Abr#BffwI&XgCA1ux$vl> zmSxtG71-W=yDeyYk8Fuy^NrZj9zV#iJ?JO=XWPli$(6_mL5YwCRgP+`Bd9w5fKlXV zrbq}%y^jLU^!x@osBFyqFz}dfU=M?@@Zo&U>Py>%YQ(-n-QcYUp4h)4KHSUM+`4n`>QLqI`5H|>S zzE0Z3FWCc&g-#3nUpzQD;y2L6gw;m!-C~a9L$W0X6W+QqVNk8BK-_jm;Ge#Y|Ia^E z%gotXEc&*}>_{%are>RBGwh!4 z$!51*M?~YRP6h*662^J`UQ?!+AJxpIC#BmT+B%e;!1aOwwJI}1^XOvPQD{j$jwJ<8 zttuX$b@<#|8~S!8R2*bO`FIa%;k^s1Pt1yv#tQjWe~LP9Chy^9?R5UAZrx$}x*!ZM z0K%jP3Hr%GcKbOg$+Baei-X@0J~DpNbZrcf0_Mu_H;`6-VDkiSN3aHP+*>QT(RfSO zc^-TN&G-Yn=nt218&3Goa$EX{#2=bhyz^n znSnIImkW?4ONQ`(CU_^1a}yePKCYF>qh>uuE-$7jaPN<6Y+*&HTjZ=V5{>uT#t-DuUl`oDq45J2M z1OVq)TomFlCAM;CB&Y}(3a7n%%!guEa4(zQOr%PT<^tvI_jiLmL-brCzNt!o)#u7g zzvx8jY;G@ZNm+;uxmE$$Vb7h0@@*Sld1=Nb6t*!D*~9J_Fzw7 zqMWBvC~=7H4NN8TDCE*loBs@3dtF)ipl!hXd3M5KVS_bY5$hY;2Kt&_Ub~a>$`uSn zPhZTONziJ@iOoof`toJJgsH3R8=aexdLKk%LT?D@%B`(70e&C@Kl}~z0FC+dA(^#< zgxjvEHsBd0a5m;ikT_K%v85_!c!)<|up3BN6e8ihei(Ul5TPGf4P>9jc>uKW-TjPRr8cBRYS58u28TR&~W>Pw&NCLcBgqk8tW43{SiT_19=S1ek zhW*ABBk?2i!LLLJXjsZuzYi1 zv@k-O{mh8{omSy*oecQ@NkIg1&#(D9EgmVkL1h*fuYWkNoU+3f@QmIqy_!M!N8_{P>J6=N|3bJHgB%sTEuEHwwHddac?O<+0itEQS2h z0Ry4%+_S$Z-CsYT8`bbl*ye9(w|~uF%KZh+Sp(lPF;{<=xZNX7Hq53(Aww1dC+hcF1Pxx<08gRQqJnXHr1tkW+v-pQ*w~uKehU# ztdeHw_sBS^VbI36L-gs?SpgHkcvd~C&^Z(`b&y|tZ=lC4UO4T4Fm1+ z)_aM(5!Etcqx?baoaPE_XAyqE(f@V<>P@}1z2JLm3$Q^z;tEV|6L9&MkbJeudP?SM zs-3-u(yIlR5W31K+be)J!a9=Gx-V1Zpk; zZ1LAYbf15>FQ;$#FDLo=w;l{zQ>|Bd65pm$&{-*>Wl(P$FZ0 zYqb8E_Z-K4UB(wX?;M~fg-+o(8Yg3pTh`oiv~18mwB)+^wQLXaQpZ54ZTHf{rRveA zC&fI_@SfL%)!4Ic94@hAZemNZE^j7rY#pTQK@j4b_$h(HdWA%9ZTWTg@o+opi4=Im zDWA)tp7*>U0K+$=aiHqboU_q?(VG&$n;$l_g}#9-&}KhvX93+RAF}d8Le0|M>R12d z(fq4+P?g@yrW3N7>7~#yE)s4ai_%cytX1Oh$DQKWxcwXZ(VNR8XLLk|$)Lr^UWEOevRn(IkX<>^X+1a$y6 zSQoEN1=eC)sBUcUBtqIm^Vm|sWhrgjI3FlM^cr9x#&FZpH{41{aJ>O`-2jQi{qdhg z1z^;DT*$hd)}{GeT5&y3mCc7LJ-&t;$ZG!k?0`3wITup=2D8=4WHpZxn?L2Y?*@Iz z6QoU77R(F!l!6;pW)FCy{5+$u=9n?1@I3>BMDX7_`MvDePY>iul@p~@gonM+)?rHC z(Y{G^8A*#eI8fBJOHQrRQ@yMkI z5q5aFM`p};CsyUt3?$SC&QBFiv2W}=(C)gQ72@*fw7|7E)>iuN!&I{>Ol%Ol{+Y?I zVYkb7hoQ=vpR&Duzh@e_@8}>&OXF7P-Z#$(>y5I*4;rMiJmTtAg@09UHY*J`)?%zHSzd}byIs))||s7>8d zg}d*M-^yzATN*8vdhWhOeUXs$)o^162*$gQfBRE;4?pDghN#dysxj2JlPQLRm8;Wc z8e-vA4T?2=$1*!B&8ci_LPwlbcE$A;9?rEp!yNq!3a zGfU7n&@$F)`8{SkuozVvTbtWPbtZQCL7VYpFjWNYOgRc0rOVE3kaZ2yq1x+Cn(=QWjg`o!no13PpVsrTNtaD@)k_AD`=|LUw)hyD^tN3 zwK+E&=tOFnU<0VPL;`OKf{0v-uq~cpYWt0f^&tGL&8hb2J8mnRo&M{Pi1EYW_mwr- z5^148G?;9^tMYj1j!C=hG#?+O)@!V$bxNV-=mePkLI$vKLf}4@nxhn!gN$T9Rk?kfKLc9%=O?k3&7EEq9Q$72uwl2KbP6ligQuGx^75I~3HHGd8s4x}c;l z9P}Pl5e22!-6fgjog+w@=a5xb#tn=HLA+HG0x&X~S*1I9=WEyvv&}0sOWeIWc-Ur; zefdS4L|4r|V!JlcD(%pdw?i)_u0AVktkNf58htFk=kOL&fW0WohV-sL&u*&mTg}V` z`K(KQVlMAi5(5p&Z?gu6sRRpt{;;do=zFQb{hMcpktW3uBm5YfuFgXT;cn}aM$;V> zcv5t+luRM68n3e0PXFuIS2!&log)6w#bx?*=}PX|6AFW`;}{O!+&e~^4(VmuI0p(b zQoc=0yhw=2udzE++iw>tM&U952_InK8|QcTznK~iI_T6Ijg@ssWiKs{ZopUNb!Cj- zic(`zzb_In9Sgq9*)_3?_1;5V2`ZxF(_D$m377S4$Va(KlqNbUu8NB@}Y zp3;5K?$&G?05cNI_YA8SH7o+9x|c7r*~1@pU|xW^PkHj zi#`MCR9%w*ARecxII^M242!v`v#I$HR^Z{{e0&uviuU@xQaw`;wCNSlc7b> z64epFgsQ_9ZWR@()6Mq=53A_(ooBL)Ms|EcB2LD z+wac2teiK2{Bm(J$e;f?l(;^7=W{VF?2|9WI}iNJr9H)ch73VmInbn?wX!>(>5cYE zv??R!rq0N5Lc#OP@FmnTxO^Xs8n|OFe+THl#V_fjCs|=YUrYCc>J7N1c_6aQBPV;U zdwZho=vswKI_Ij@87W@C0#1vp{#gEmf4+6%k&+{A~wV86GQ!5 zIcRi>Sj+@X+7uhwyp`!H9kQ<5rWe`$&qg^um#Pu z=}2O=6^U_ui<|RcK74E#1Ewu%@EJJwUp! z^{{6%U@$LG{npt^(W6H5qT_6^?IH&C)%Tl1#w9)&hefOIfd}6Kp~po*y61NNv?$K6KeS(`8zWlS1w7!=H_=G}A!6@= z2twQYdi0R46e5m?-esm0bMIJeh&?U;tZnYd5qUK*MRXT@L+~M9!1?=wkn**hOR)vi zSNsu?JIES6a8Jb|d`PcppI6oD#ol9p{)+g(XG5DZ2})`;qxV<|>Al4Ji#?OX2F+;c z3`15q8aFT(VX?dd_~6yeMLxR(a+8)_uh?TPlJE5qKIW7AeHeR%>}uIn&pG&7G2`%g zE-8A8>_?toPPxW6Icn&BhySf)ANX=`%Em>~WZI}7z%*-BSmr35chSy8*72fSxQ~AQ zJI`0;S5;*9INMBOn&2dpWQA?$XZUB}M&oUUw@?Z}>gOrBu}Osl{FF5HlpY@iy@Xi; z!n{jHY-(yN zd+o_G@C1(m4%)>}kVW{3pf1RoA(~z@NiY3TbR+1vU%--?_=C;CxV@XK9788`AZr8X z;%w1ACz&a4a;R4c+k+*r-HU}n>kkTes3msDT<8P^n z^qtjn$P_}hn@p)EAo|`yR#M1HldTcpNGxQIoLK4jao33t3%0QMNOC;71shB9m|~oA z3n!~)teAO$qCEYdan9Td%CIM5(y{!0_eswu>8Na_6}flvDf@tBJGkxA#}#Cghr_#zbH?fMk<1&p?!Owr-i6uOAn0 zk6+>O0tlQRkuXybk`|rcsa%KRDvnxu=M{p5JrNm^0{Hvy<2w~0;eqG}R>z54+3O<~ z=0kNlGs11rGZ2kSs2t<}Me6cfXwjeVbR}&7@FELnY|u$RWF2m9`^vU|qLfkFNKD;b zDgWa%1VaI&70Rs)oq%ryWChgfK9RWXsx_g+qrw%0y^jY^qoYzG1ZlELZ|zt{ds0!k zh`Yd})F>!i&H4Q*(or%4r+T3SZwj#x)*_#1VeZF|RKZXdbnH_9i0&Z@DmfCF-H?#-C|#K`ALckC?q9GL?V z<3d7i#XWF-7~Z6KqCBQTLEhCuy7Iy&)rV*s^B@QtaH$;DafZyoV6BSTlJ)05A{HBtlE`*^pO&lnaBcmt?y#V<U@G_HhGhE9 zjxUR2RNgzQfc3);&_1N-@t-1f+({89h}H5<#uPe3ny|-vl#gX#GxJ9CYe37_`e$6*a{B;JlxbZal7p14Lr6{_Cl}u>BQTa~ z8^>3l#26rH_PYwHdQ&kX4Q6@^W*tMrb!`0tR$5CrwYmW8{sjw>)qd-7wc|@~{XJX} zkYv5j`_F(4a-)&sS~V9;X_-<(_LiLLp~B3w30oQ;8~bvmA=}-Ug9AuMy|QQci(S?_ z!8^9KamA-MPgb3Swi5diZu7Q;IG(*o?XVZoy6%5}xOn3|xzEgaSv*^`O)h3n zk3-~6$|tSpx0?**_Ve+ZZ%Z&kFazDk&b+J{-JI)kFJg{dTVQnU>=glWS4~0>&tcE@ z(8tp)cA_dc8m8~W6)v?81G!lyQnpt2kyW&z;6Zy|~jU{(_`rE|(I9-Pi38dOS*3ABM9#+MEUb?G}hv(^OhsKpDv z4i1O~wNlqH&SkV$DFXw1epIPoVNK0l+x!fuov&7S7mB)Eex5v$WV!2NRMhU3bBvJn zPk_xkEHaTE8VZ;MR_S=aBHnlrz)Wj2d;?ARegipYBPUm#`Dd^FyF?y<$r zOYSF!hoH5KL)n3lN@rvguhziP+v_&g3kO_Uzc5fwKB=c9my^;mTy7nL%gYPCY8eT- z32FG_gC!Q)zK3vrCus;$AnnIIIy;CsM3;lye*%ev25-tu;`pe$@y#iBR39OEQFVH# z_mDbr3Sm5kzH4!+Lmr}ui_xAq);a^8K=5KaV-^K!_OpTI`0M{1B9|Z3c}UHC zvAk)QX<8`E<38Z4kfY|{mx#8zvDJZU$5IYo-#&Z*whnLm!y|Kt7lAVOI_eXC34fKa zl4UzB;o*2no6htQY4)Gik;)VtGECW{s^Z$TuWAOG^OYE!ifFdfxh?Wm7%LewbmGv( zTLl@i@qO%YH}lI7$8)z%o%yT1E6InmG!j}8PSAO-YATxCddZ^4tCK~tROgzv zj`BWn%260S>B9s7%n-?`MUqJ`Ym43wk6bvY))8$x;pxZU_g@S8Q;LlM!`~EE!r|Z| z4qPg{piDX5F(Ms%{Z)IAb48FyPX#7wh)Hp^aapGdrP_AJcmH(KaoO>d6-dNJfy7i< zFk3Z&Vjz{?Srk3mK$^XDp!`d9_>_voY_0gU=Q;yGa%JRZS+QvQC)w)&3lJuG@7u@mFr#7oz+i$TH0C`y=D$9qAEx=0AVzMuB7ubV%F3=0kc5IF)~|1OL*A z{OJDz-^))b+QJPLBZ5CX+DyWWzD|~2UmoZG8xqLr1#(ON)aX5ow3S}< zV)EXIC>Sz{UE9@YuKPqAibN$M# zoZImUE9BV+!orE;vlp)or-JBqwUkNUh9*LTSaIHK-8@D5ifXPCcpYgt{AyE`MyQ^= zxH>v6BR7R)BYE@zn+7L}`CRu-BWmtf2EUl`O{V zCy|VcR^~*!S{M*r?wlLC>#Kg!6{@F=Cl}_+bvlqv6E-=PErud8UaX9skn7Q)5)3XB z;>{%{f-@IGi$9+>%>& zG07O;|J`5zi^u3jpEt$QTpytEy2UYUq4hKI-F8k@EZRBOu^gcA(lB?9`1lj=o$99X zwcceP7x`&eZG@hS$C00D@5Zo(#PLR&UcF-CsfhLYA{l^+n*a1t{@mCo#kegJ+JZ>gIaeTFwhy_x1=$!!Cvv1ZZY^#W}91h-lwD&dHo=oOFFkFU&&S zDfK?vnK@>0oR>vt(vwH3QlzKKYc)Ap92T-u`>$_+JkVGASETA|J$avp z#s<`Ri(eErL?@EIyrbUEFq>1A>hsQ(zgu1!ri6inZKRisw#W#ku}zItgIrsRakHW;GSBwbWP6!NX1bqdu?HO@`lg)7n}c`kUWM<)ri@Rbj%* zB2x)X#LX9?JmP-$}mI4L1?rxBHWBw7&?O+SYl-ce$w? zq~a;*eZ$8RN{k2gHK=c1w<-Z+;q`Q)Hk)+@$nGQ)?}kpW0_$scqS0nWn|1wRsQZ?9bbT9uX&YSd-dyO1lCr-_9G|S$1<4iZT6U zGO49Y_4?0VeGhc+t;$jj8FTbRENC-CEm0@_dCq@)o^=8K!hx9 zxQbfAKc~79zYe>iLcKqGxiK;ZE(B3SGLV`J2qJB09T_vGOmXQ3%$8Cv6F1#n!p7sg zQFFC0EVSAT!boK<)P5v)9Ba4x4tuzIcLo(mJg-up4-Td?4yHG!JcggyRkpYB)m%@| z_p~7s1L1W*M_sx$)p1GsS+F^ib(gmzR8Wlyb9eq}rnQ(zdj1V0I&2AmS!}4yo=8sQ z%yVbl<`VL00c^^Rn&{$7uSKnM{~jau(F&Nv$1egIemKhjOk?ivF=mKFxGnzk*&haf zbBS%^`G5YHK7kY0fNbI)0jCb?33=c)o*IZ7NCSraf4Coi-jMhmQ0(_({Erwj@(&bl zzr%GeLU#eYK*5u%6lTDW^tu^HL}aY~owI7FM2ppq%sHSG$+LD#V#>u#WKS_--=aX% zqa7J;qI^Dkh$;5rX6*kV?mfVoTGnvkC?F_k1f-WJMO2z}q(v+g5kaI#jf#l$-b(}o zq((qMEJOsQ6X^&TdKZuydY2YTLJc8_|8kdew)^a}%enV|?lU|gGm}}#nzhz9GvD{l z`_5b?J&z>L);dCJc_I9iARM?2gep)vG)+1%y#ZZ>fJje|{I2>to$w+sk(&yXs(^)# zJg02d(~`-z$ihK{uIWHFTg&}!I>_#}&Q<~KtYRp^JR7mDbP_%}0PU@&oi0&xdO|!B zi?N+d{_8xt8if+Zw*S&;3*943d`jvW+Qa!Aa3KJj_5g*1KGb-E=Z%wlP+~=Tg(SZ~ z`;*i7_#1t%jKAnf-f)HQ*nZqslxI^pb>pjO_Z+Zt z3VY*Sfa&V&x>MEWJ$QbADz2Fy++coK$1h;=B{SJBk}x{ky@KVR4p4w?RXyvR&7PM> zTp^ajciQF?KW}tOXQz6MWqWbwi6|@?2sGc%dl;%IOUOT*vB8>V!y2e zU}J>$0DkP>sIi~lnwb0)lFxaOnrW48(`U;W^VxIoL%~8^Hx)_e4fl)e>}5|A+1IjZ zSz|2@c1PBHxN*=%z!d)12751OppDpWjxPIrs*%OQGDAM+KE@s-QCxM+Zr%w9D>I{% ztS=OmfbHHk58sYxxUQ}SU;IS-5tV}GC*7#VznX9VqFfNgWpz*Js00rO@F;EZ&c7qr z;OZBecF$%lpTj+jD;Mo4pj*yf9V(x?&?Wdk)~TeFmIgQX3Y*^6%1`1QzS7drQ{|xt)j1i?Wi5iTb8KJyW(AQC zta^N}+KqqZ15}W|%UW^CLH8Ogj68e&{jJ{_y#Jp4L3YR1 zPiH%mJOVtXSS0p3lI%wQMTkfJX21InmiHh0eBB3fc~v6RWTX@09C>9S7ryegI(()tB;QzQB&w)hC$9X- zhVMc@Kv?#+!inpHLTKe)(-Q>QLjH#D!X)ul;Bn(&?E>?$_NIcVsNJ(4rl=ZZeW|_# zo=%une)no*V4yM2WSPCj_2mtal9cs(UvOiu_h~wa?hB&}FQmyMQ#dg7!WK!}PuZ93 zrT_OI9Q~*80-gNdaDJ$)lOF=y!ALJk3A{?D3YgnK$Ft5I3I2 zC@_|E6Pffs?sJyk$+!Fp1B-n7UAy#O2mNnv&izil)#Rke>&b}UPY1bxm_P~Xq6G^IDM+@y1 zC!bUbkp!UN(oYw3t5Np7SJJcNR6HONx=>D{+>BTRfNKCZtUBG$7Z)CtjynTHO<$|e z=!2WlF@&hM@cPTRebc@~`u3epfolpW%nLUOiBx!i5b#xLO(C$9?HPZhwSSlI{&u|7 zQ(6+uD+t8B4wTJSLGi<3xV^yj)FL%k5D@Sz24wlYfM0S06_t z3~F>;gy2}+2u8hfyC0S+JqETL9KuG}UR++xIShS+%5Yl0+vkqW#fFU@EfJRv@6l(1 ztHLxUCmP-_VT>?G%eWp|*nr<=2~dK84${0U9*Gt=u`oYyD$-bnD}?gp0xg9iY1B4( zSVRzS)P&XQcq1U8bvoS{K0igu6S&(K=A8q z`+zDj<^#N?8ny=h3bO!gI4>Sv0SFj3?5n}st`-Brux4K zKIGHdausJc9r(Jy=5iBSFlt|QO~9$B?t;kUvm@qp`;AX8(nd3E#>GZWVd}|>X1(E2 z{#tB1A!8boR>7{ubhk>XLUtogJ_56IEb#O8xlO~s=0oJj*~@(yrOni8!?K7sEs#(@ z?e0*2WiQJe;TZ6Zcnmuu*ZmQd5bi*hRXG(F-1azPs6bj-LCfsU6^Dd}LYMyjkx2M*XMUloDi)LBl#Cdc9E;d`NbZV9B z)~gWZfoFQ{>X*K%tz%?1%YWDL3r-_alxw0$axj3H?1{&8O_o@bo|!`TXi*}t!6~ud9s!L5lJOoC+wd!__R}?P- z8v(oU2P7SCyMO9N?;3bQAQ+@{$NE+DKkxsNF@jM8#uIw4;>*^Os7nxInRfc3M9VZx z2#{QfR-wW7Cn@+08ss2hS&K(`+(9tLaaHx6 ziHtzZM{I-eo$Y2t%wJ#H<#oE{c&x>-p3)1gQsc%~MKavQ^c?|2y^*)NezFP9GbX!B zHFdfDtQCKnYq}S}xcT2MWE7EYci*Abvro*u{ya>Ox~|4)`-b7PX>8&DJt+b`L{n6}K-`evpMH_wo2I8tde0OS{(Rgf0Vo#Pc zUNMiOHS!9-Gi>L^*OQ(LWy14-uZH>q&g)6un)`Fo%cGh+gA8+5`4}t2_k~=aD!Prb zY(ksY58n1xY&7&zxE`n-mJy3R9IlyvAdqkIrDY5lS!sZ zVvYY^E;1m^ZXA7lxep7a-?EEJo|M)YTxqF@i7W`%2}OAlF6Zjxk;Hon#9;nC{HDdc zGqUGC?vAj2L?R~6zr2k5gpRN}6}w;{QdF60NYgyMTJconWvCkzQhir8eA+L7sr@of zSB|ljhf*GWOv9+l$pE<{^MO$BdIxa*4pHz~nBr^wqV{E<+iYCnWiuCvjx6mYCW3M1 zGSL~YR%2hTTUBIi(kjJ8BX50|WClD+&YIoqUjq;Oi}Y;=$a|;5%1pD&heh)5bHoI{ zlKMaq10G3vfrV(-8frAF4H5lH=_YDav|nr`$*_o_x$XwX5S$ILl-x{i&C2r&mwTN= zv}3wbtYzLy%vB$`1-X9j(?2LhTM$}s6A)_Kr!X7UW`w_n{ym+zlXLI=f-i6^ge)a& z>^4Kga0Gt+;QedIr2S?tr8D_Q&*I^hqWb_Jlc& z3ujZOV%2=6i1&9Vi;YM@GV8>>C;*KtGa1+k+n~nOVCTij)R=&M8F(u*00lrjui0X@ z`1(D4pH2OJB$q|<%p~|5$SJT(L5t6^qHn883qYn!F^YWyk(_I0Be!Z;3GjWt9hY8X zW{+m%yAcb(Y=R;HKgKK&hUYeVM<{Rj1{$3#j*V}9Ss+ao>)nA8sI_WD?8Drqr5$28RWFThV~?}*TE zw3Jah#t8G|BJH2*e303MG$0R+``^I7ZmfL$xzmng|3;b%@^uIA3ErmIz()|z`pdn2XlQ5iZpkz0Lsm2Y6RS@{+m>stcFUiH8hlTOJ}7%(k!)jk zB>J9wnCUpeP-WrtpEP<*NXA8J;#J~Y{4$I$Tjw{vn|*kkZ;Y|4g(_I*0rr(!vGn6gqp6L+O4p5Dq*;CfqSMxCjw4af@EG|W2?OSOxAbonuTo8 zLD4$y6=!*Y9mkI?@~E=}##zlRC@VngYy}-2d1JO!!@_S{} z$Jv~HDB|s;ZSsW;`zfEXV;N_JsK#c{YPgAnERqQ!sh&99V6JF3alLx)rkK3h7UhIR zMJp<h3A}(E-4_IP!aax1>7=yrJZvf z-HA-Iq1`&uSFzEN#HuT}g3#$vnxfv4Dm(8-b$sWI$-@YdfX)E(x86pVaI3+?HYVn! z)fex?v5QbvT9QdwQSzd9CsUV}d&nj5G7ieyB9S-NF(&o~_$EkNem%&rQpq5Dxo0Qy?9XDl+jSeBS~)-{5Mc^>8jQYvhi7I;XRzD%Z|1J-;I8R{6v7%?(-eq zTB8<GjvdG8j6+rs{hKfiZ^h~IaDT4MCYJnYIkq&oUx3ox4A1r8 zz(oML7nu2?Y6gDL+pB4i$<+3R`)M^jrg>?4Y4rh94icEQLdL6+LXBIG$`dFXkY2nV zogw)7A?rg#PMH*e7wl}i9zi-hJ;`=k(;>&^OA3dE*7GkSJrDzXYn&4A6y`Ih)lMcZ zWain2wo~pU&o8^@)>f3;bI&SYd)n}227RYbycGHva^hW>CjGmNdaidCG)+}^7C4sm z!+674HV>r)WRp%3-ib(Rn2Vl1K7I}-COS$h->sK%eoG$pfj>?#LLerD|51BG8g1HN z<`F8A0GWUZFv4ZPh-ZaoyMMsKZT^Ub12AvDkl6u)-rxC?_#J`WFIc#|$kx0+^kIBZ za^Xm>wK#c|8o9F6N;M*BN7cfZ;!iU}t*c4tdi6*-{q%o+WVU2@UOc7hf!gXPmq`}< zi2Wwp=ka2G&xwllNW!YDPt?5Qa9ov>nO9Q)y9$V){p@_dM?77tiaU(th>nJU{7<*D z+bXnC--jrOQ{-T3;72OVRtz#c_k$(Dui1ck;yVBc2ghZSsb!G+d=G*EELM-ezg#x{2CC_S<13-lNYYtghH=!I0&oO=12qG8-H%`Lmxt&BRKx0O zjuD*9O9xigWi-V^pBIVrHtWXI%~8|VxB*jI)W z31?)5^T7`+3pc395q43Jw}wA)Qm#UuL_y=AkG5H+kz6D{OueuDL=2n{*?1M%imdgG z#OoA}k;7LftrJ#KtrHd;6y;_W-TLGgSZ0uxANRqd=x(85rEa0F5l^RP&xQ9cUBXQ& zEp9uI@_Dgi5I=(R7aK)2gfl;s^XI|!~;EAO0b>Qj!%VQPid8Np!XWTt8$74 zgm@Tb{XM;nJeO4Hn&c};?te@jHloR%T6sU8e(B?rX@W2hkHn;VXlzINrj> z>^+e1kCjCzf2--&3O*;RFk3?pA|l(E&E9YG7n;p+wtvDWhq*7!1+T;U?!GuJETHZB zvOl)T?Wx_l-DV4pzRY;~PjKz9htKokWZIqd6j{1dbBTtiOsuD{-+Oa)5BtyhnjBM4 zooy+Jxl6?H$cd%oo8zWZEKF+N0^FQ6?`(;I<@d@ft@^zHWapK*)Wfug3I;~1uAVT| zi4@TA=g;d9B9;`se!0kR+lIdq0elcb6Rs2z+|&cvO<#TJVomwTH%o!-Rc z&K@DuqtBztr58tdBzuMS+m4(ihO+F;zvjC9-sH+Rkk6^BP~EravA*<&?j0J)b%8UP z%O?zehS&Y4cXS9=QFHCzFP%R{r%BMn{{X4!_RAdoorPohk#ejll@AD#|64!hN4B#6 zNk0Yny_?VoIEw@6G~%6&pqR{i*z;7qA>P&Hi6}y9?H;nRCbEpetlnD^pUl}O{#oa& zJ=k;G=_*O*j(_(ItjQF9IDN@PQ!B(J&5HVoz&L>2;ej|*>cC2Ber*iSFPhsch*NY*Hjo2iaq zYv6InSiE-?a*HpB7-#0xjn1fuT`;&xq<&|?P@0$GU zrYlCAPAoABP52Gz2WUm^g*3R7Oq}iI)2ZJ5kVQ;p*@+2Ahy7bBTHi=^a5t&f)LfMt zry*Od_r~h(qUu!tKPbgeWs_KN57PNHdGb4>B--``8o{;a@2EU7`o|Twq}PLa848^@ zRek(bTiN8e12x#B0g|=w5D_z_FBY)lt~8x3ka(I-sT+h-QypwzX}07>?jSdpmboA| z^X zERikiK_toR@}Z`HkUx_xeXcjspkFtEr*o_*4LbfnAn-XVrdl&gEPp1z=;o#CUUIJO zkH3LDp2rdIp=I%>-&B@IY@1&_EHO6TagLchcu##Pk~ms7DE{7C{Ay90rzXoYEk2@b zPt|s3fWs7)txt*V?XX6bKxDgMTmaX@@2<`=oJZ7BDt(WAhI#x|E2dU-ObOtEGxaDp z^yOB8%g;?{ROLe^Oez45#tu$ZG9Xw{yGq*)_0Df(pmL4t~S( zk1J06-OF&j4^8JS+0@WU^A%5f(rnCS@1z;#4?7%PR9M_6(mU8b!e#of1;EQO8sS(b zjc*SxCE3_nIULO|u>_D-bh(5hgwe(q!OIgu10E*?THL%uvUGNhBOvep`6bKh6lt13_7pf-jQwgYZvn0BX;#7ZOJ9&UCS!7e08x*|A!nV7Coj=W4Tw_~C# z&to*HX9@Qifx%;TU_-b{V`Z)Bb%e-gSIupiKhKU_#=AA|d{L+7Y*#;F%g8A5=72r} z=uj7p=Tnjy{!C*1WcJt`bD7d?}dTrlTXBd!LDiHY;?!RCx{0-5V^YFSO-xrJKWz`6a8xZ)}N}hKlm7!_Nf8}n5EK3wIH{6fJK1@ln@DQZT#Vc%#kE9 zabEZrz#%0Fgn?#+m&Tc9Ogm|Be0*KrDU+wCc!!}-SF?5(mFcb(;UvwYFz-1jJy@u* z`be@#RfuW={klg?u=u%p=xu1Qc{ z3TFZ0gwKm8(ZITi*H{HPyXrgM4DGY>fUFd=!g@meeP%m^`bYsN(~1_NeL*@o>0Sr% zJSv^SY!OgCofJJs>PfFxe~+<(ykXgb*V}cMktBOwAzw&)Yiy0Iq;DNWBM90)JCk81 zQVE-Ch{L=u&7TE6GO{s$=lSgBRUfC8-0ot+5qf7eN2fTzL2_SM4v;Dobn8mOpCUPqN-1^_fP9VZ(twx{Z+d+lLt2VJLw^wM~r|c!xj%2;cXkisG_On)L*cwteikmf(K@x zCCUk<1tI>ltq5t6fT6Q6GEFXc2VT8V4a*u%2u*FR*gc0OvkyXmThQmLcg@XWA$sLF zmo)hV>M__dIB`=uZt%>Ay1W5R#MZ%={CPJ^ zVx4p7nHOnf)o-WUa8K*A3IW=4ksDu8;?|Y$8tEAR0L|`g)Dx7L$;OUf=KiKeuU!8t zAiDpbpD82>-6wj5Y}uV)+j)92J+LYUr5=@EKO1D`Fpk=5dUVk7-fX8a(+{&~1t!UN&V~nO9p&|K)wVdbR56 z{9%1BXh(J}Dp|>4w$rGYhDJi|W0bAEcd?1E7RPsCa_F?EPts1Shbg*mvj4fC0D5bb zikf_sn$c91`}mc(%bbrjdM@PvROPg)u*<5{hQNr)D4^S%#w4wq15lC!`jcP2sImaV zCAH=WiL5IzC(h->f&eLJK~23M-9vVn#0pBto?#_C7qJLU{3Uy9X^Z%uE42T+CBh1@ zZ4?Ecw*()o*>5feJUJ%cKLoBq4;=x=9#!v*&DnT&9=>Ut`{5#I2x`2F1gIX zU%Aiz@v(pltM@Ax+;?oA9l{A6SbBY11`iC2c)a-j!XD-pFpJ>Tg=1tW1~w`)WZ`8v z9lSL;4L+m-CbO2xh}!r3Mdx3_cy_p#FpgZ1R7Mca5QvU5xV{^)cJSK$ND!QbKevJK9?Gwc^%-Rd}ua-3tV zJCfuHT|n7p=GvC|o=$YjhJEHMEx)vJVQY&wV~gsej0JIL@>@`bl3ZoMa<$S=ek(||bQV_W%k3oZd!%xZW8I1vefz;1PgdDNlMbhBkS zi0g?~GxGf6iGUlzLmv5tJj@y&`-S$OzQ44vE_V^i9J#(tKeV;a;rMR9u;Ajha`=M9 z%{TtW{rQdzzSVpiw60!i2U}B=Y40f`7A# z;uT%+HrZkM@T}#48b@Gi=}KWu3X{s9c`Z-gdG$h+c?_v_V5evew0bvKImYYU=u=s` z)-LeP8=3#cq5Wtp{^$}KIluviL{AJ^XZGi}|K^vwIT7%cXkeRfkoEK9hEl{QHyB~W zGY6#id&LFnysa;&)z*%vk59QT;0makCXXRaKE1s4p_*^)I%}j`qCEoxV_(oZ!APRO z+n|&_LR>VH&vP#0HTcU;zEk)FYeItwKe^z1`L1~79XiE}(?l2v8oI&OcR>ue8@r^Ep3xL7wW(H;_sx#>mK2|F2K-*Jr}e>4_ty zZu--WMQ&-&B7oz|&!z!ik{;njigvKRUQM_8xzIN;r0w);+l^PPJ!jq4E_T9l2k!l$ z6aPO7f1tcWvJv|ME(XJxhl4SHbgi$R_!a8-3*()>7#veRP0BeJ`S$Nv)L)T~zYyM` zM&Vhomc9N`QLSG)_@*icyEJ252=Gs4<1~T;pvrn8y0hnEvizQA%=hxCGhi}q3e);R z$+{NFd$N4=Ym;5hb2gVHhR1K9yA2^QzK3|^L4WVyNvC9%f}A_%Eg6zbj{r#Av7-UB zct2B01Hm%yS{`+|1Udfv4axh8ro7Wyka~0o;S;d=_AW_cP|)z8>2pdOyAX#YPd>u= z9by`$O0pOP;B6FkEK}|Q(a-Sv(ag~)#|B#}^jdHzIr57woxP*jt`LIAG@KOBLW%m@ zWp9KRj}Q-{p-&*;NNyJIu!$D^(S(ulF6fpirUg%h+nfzX9UmQ9e(CCG`Vly=FM)D0 zkk{YYV1~<&=a!?6otHd-<8p$j`dbe|3n^^2@61HX?>aCm@4f=|lB20GUtk>Dh!uF~ zNVXBZ=#c4^?tldb==!7WEw<(W%YDeSXO2OAhbL=~)TB=Xcz;US8CGl&RW@phF;^8^ zvS#*T=Nb#VfY>OY-?8iQ9JTYsW(kgq%s9?c`5{^)CDC)K%|ZX^-7; zav{t^+dr*+PiPgw0I(4CGADk=d-J0ZXc>5$IVSJ}eDMi(c0C5RVdOEH2O;t)5O=_Y z-6(P$DHl5got+ThrQJZG03ag5yJig1j=oDyht9nn{stNngOWK!{~B<(4nKDHwhEWG z!|^*j3T!0f1JG=gAHnTN9d5MYVF+mHOU+E{VY0U0WW#eqaM%Rb6?WPiq2EBP7j>5H zG7C~GefM7O#OW&8y(_z*;7ko5I@E#fIDfZnr#p-m%HXdE&=+Z14C87SrV-(AY@6_? z3OhGR0=G`~5%f0t9WJlF=3)2VnKJkeJpy0}*Ro*w5mLEZ6MjAqaU2oBRFs*l_kVfg#hl=q+3r#}nRHaH!9%RrTR2~Z3@DYPvEDDRmo`*-eZ zWbw-Mj&i@2KL}q<{|1WrdqsZM4OGZ56~N(u5G)Lywj(V#0CxPjHDJExW*E27=Q8F+zZR;kmAT zwd~NGrt<+3KM*CvsvLw6N|TV=n{t#;bL-m6zr!DvGppQH(_2Gtzrexyy`$6J zVY4xpLf+TTfekOVY@Y@!Re)pCOa&3U<|-@5};lGY?r^ z#G~Wv^D@&8u}~ZJSkOgYpm2G6a_A~KWta+|T~rNKW!W+c=8J^`@PaUXFxL`md%N%P zy8zQf&vdo`!2w^UXgr=oZ#Q3@_-fW&%rjhN$O>MMeu(Rj_m?G%^5m^`(3EZ(w|BWz zvMF9h+Dq0n`Jf;ZOyd-&xZ^Z9=61t{Mg+ zji5uC%DLG1O8~(-NK$hZChBdV(}+ZL=g5m&^K@9GN<6t&`-E|uF$8dPVnX#vngkLt zJ$T1utaNFXJxqiy2y&Ahdh5@ctw4C7a|yP{?Ore-5b$TYTFP(K_5ORNW?#ds$Xob& zIdzcO8}?cB&?JCS1_ry4OJ5V}Ospyd4ts!Fcy^irkeh)MrI$@4^+=y+-AS#iL-Olo za)28#yQbJ9!)9vS1b1fBs-NNdczedfi+}{l=;nJ$=U`lBh=*NmdS|k(gp}90xHKxj z0q4~9a$n9wE%oRC>L5ba{9Zdd;@N;Uf6k98nX>yG*9Hce^ZqybxOh&zI9;FsE1|iY5=1~ zdqH&c0YmnayC%>PtX;W7h(@h7^r9+t z_^Rv0UH(zIPl^E&Uhoo(k0esEPusjI*?nO{tbnf@VBm$m3s9al{V3v3j~c(!WEFMe zbx-&M#xn2%Ovih0O$%}myQ^Dhe6KIl{qFE%hmbu?--Jw6d`oR5xnIQacFEE>yXRf5 zI}{H93lv1sMIXhR7gXBQU`>S|Kk4|o(Qb61ZbiqI05A(t&cF^43NYrf2e#taC z>{$uFn%WU6^@ju8lHwu$Ms@`+5BLtYPxDFc`4=U2Ir}k>e6pi(K7bKV^nC*z0{rYT zn0$D{^$vjk<^_DJ7FdT?Zlee`De%QxIwW=oMNXY0{kdlAY$k;Pz+Q5t|JW9YNFJ3E zCm*r-1_}Z0tY&P7%1Q55Z){`DD0H~vPBV2xI@8|E$b?O6szRzv+l}rgypp^Mc=4U? z9oHd=Aijr<=m#?yq~Y3?i%TQb#WS?g;jz_P|nrRzE7RG|Zy^ea|78;5^ z3f2@)>*?Goy+}#ir2Ro#(!UO$3`kXe0;DQ|XmpPz?EH_yltbxner2rsk7@ZI&Zd8) zsmexB3Utya262G$qYR>#v>{oz_wdg2lJZR$Jyf04&DRSqVqgy&Bzd7X^N zfAH{mT+EOXI;G81;YY{zck=7uDnT? zfUGl2dB%kmFty7Nns1L5hU`A-3UF04`is_{r6U+SAQb$}-;|K(Gp+TKN9uA#j8ofY zf!0aq?C5h()!h=7Wf3MDh$uJ{O6jbd<@<+TjQM*i9&PuJu}FmK(XF`#sP$kiZsMJ0 z3>HGg?A<$$&B)XUb$t{Gs(*hzN0p~bCu>C67S#ZbP&tcFjyM_$h}`U)xocznLf+iW zQ}@`){dh(9Lph}LgoGI+hxgMV3)7`FP z>pL4L;5{Ku^#}aZEN=3pEm4JNPV3}fHg83n>m)(6h6QE<>}>P2G5ARbkJ*i*0=gfA@qb`JK>nY z-5n_g1tz+??M2ATb+k(`k!4@c^lA8UZ7Y|`2}<+b@Jp%;7YuJLdY=T`T97b`+;=%o zG8Sjm0u#*lo(kpB9ibJe>IxBN=5a&EmS%F-H32{z> z!-J#EX~+MW@!!UrZuq+&iuVx_0aq)U1en+X#wNZv;3& zCH?4A4w^2HeWUK^!#JWDg0pK{o^HC z=U)U$Qrm2DlU)$mEK^9Zv=AN~TatS+^sVvZKKxUDo#zYK=l~5ADi^yY z2jK;@SOI<5Ir_8k($Rx~07zdRa{X+}N9EiiKvq^GN%V4qTPv#`K$BNSO{RdHRi58M zxcV7YV1U$fm1Q2zS#5AEX8N%7lXnoO{+6WUyoMsAl>o#zNhb{@MHraLa(ANB%(!}H zKk&WMhesQQ)(e&^f$K8?M}3gZD3;6V-j}rb&Z>`YOMHDyn-~REgjfQhyhXcufLCG{ zFBc;{F0YPeK9e*XORd#my?jU|!zk1n+^|05#A#FMjPO5wQ?!MfE;*^Yp8@E^BREL- zWaET%pZhc~;rd(CSb0WqQDhc7F%EVIGbFR~dnnW|jvK>zaue}4FAm>HKBh_k5_NnD ztfC;|fOx_Gn`rHK-1H2Dbc$#)WYd*tT&-uR?Ei$wLASk3TOm{i{tlQ92j+x-*f!(J_Wylgrxg=s~kJw;f&@eB65L&By% zBxV8}^eZB9YvPV(#fpXUYh9~LW5C{u1#>R-0VN}p`rZ2o7eCjpDdQ0>o?cEj=DvZX zUIXB1CyC>z| zycfl`F!raEN^WRT5hU)ew&eR+*VZsy%_3YaQGZJRNoJHzN0d3fmcnq`&jkzkEW{h* zY*iQ?80QYIYkSr+cU+nK01aW~9rMNH7y$_gyUa}TRvR$*denr8zB}q7oVTm0Gp4$$ zzn{=eqV~l^`TOGaC6)#$>}Ahn8VicYX`n8&iN!aS|t_YBqHCDQ)y&ra!Id{+mZVuajlMcwg5b}5I$*&-_CDP ze`&5rK4-`u)9@H#J_NlgQ%B;)?PCK~N-G|2+GWDuU2Alya1Oy%(JsD6ze8o)Et~ut zx)P2cq|G>3)?2V5^m}H5#?12EIG%pczvDB7m^lLFoB_C;U*5(gho%omdrx_>33E5! z7hz%N_2wr8BbqCak-Vn|l?10BZfo<(^E9=$NTkrysL`gpHY2P3P^-$A^av)wi$yr2)at1Msew?x{O{?+O*3c{jHPKBK{I~t z8Vz|v=2KBf*xX$t<=`%6YT2f_Vgob2CBe`L1?b~1;&BF+w?J#a$duqIx~zLL(+HaqYy zdB8~BH5xM5VR3<;P}0ux)~fGWexc;77?l`nDam>y8mz=fQdOTd(`f=T+wn5tN_^iV zxR1?zwS4|LG&r5An;L%nCIQ2YzuY*|^0-=*H#@zBs^a7Ad8t!(vT8T$AdM#iWorE| z5Q_7$sd6DVFpg>aqWuos8gb`nl7p+a7ie5k^MoG}-0;?>7$v7euM5U6@0ezd$j9;N z(~HyiV7rdYD&ICbfLoa9DlhP!II3t~8NO0}v&4n(N*1fdkxk4imS*1%D39+6pdAe- zk-L13ecV+|Kbo%jrO=;`5hF> zQFNxVG->4iI761DM;nLUd3D}_CcwbH#zDxSnhi%dMXaKRa0?AA!rrh^w7b87nlJ#` z{)ksCeCr^9NBRiFxB%Sz4FZ_*2(~8&{RU!FC!L)<0Jy~fx~kI)fPGs8kOPWSP~rjj z91yf8nL}`y{68=efTwP;_X68i(KJ~eF}Z%^TOm3pM6 z&L8Y+^uJg30#DozCx`+9+&^>>OzX!EuF|se&KJE~79@N5h=@ypW_{2j$$;FFvhv8@ zL9U0)_s_p=;hcMQhMh`i;DOiT6h71P+-1I zKu_MjLheeZW0>3;R01|zw0H)VZX#MCgCvg)bi$TEl{aQrwj--!gw_h1idewqtHNAg1;)pQ4HiFdgDkk=-^PxsKB z@b7cMGw@Q=Ls0MIR6$#{^1CXDH8`rqxPTV`aWXI$)cppsEn^78ous8&dgQVeAp8?W z+v3~Ez3$nX2)=%jrd_(J2CuRV`)7UpJX*5m5fxs*s0+>mjIo(BTIQT17x7D3&G#}9 zGWbLi2ok}Eb|b9MXp};kOcn=wX%X6LQY=b7sA$v_h@{Cq zt2ITldk~;=vmU4Ew@p2nNN0Gk_mJ`)V71#W5CJ5pM#(CZtSM$CAl#yD@U+T@1M2iNwF z=2u!%C$T?(ToqWr@Rl}`4DbRLJUBtzCa4O1+0HSgPB4rkyhroGc1yksl*M0@E!_XG zzf!H(`qPoo_s*Jk!|rbB-2eIU@MAo4f&@johoM^Q9*w zHxV6^j+eN8W|-&^7lW@qg>xHqPSAgWHKN7)+&_e-C*66l6X64xDgO|{47vqXh+XlW zu_9cZGM@Lj|7BOP@B!5B)%{c*Jce1kUi@IURLAM?kK<7i`)0EO8}QhQlt4yrR-aU3 zY2~gJW5mb;hfo5^z57S|+V`V5z5ahsnpL2IA?Q*^p4;I(o zhCNQDE$dmg4!<%gVz{9oH?kmqN|QD@#}`$vLpAzvx47Z0Lz1u$57(;OtK%6V9hi>o z4YGd?%m5LBrULwV5x))x1C~?kk8seLtG^g~Mb)41h&KDZokCM;Q2My- zi^pj5(jq6fG2($`&04DdKAG3|x-a&um1s=kyWgWM%{X5|JYOC3!mz#ZOm)Y|41lvbPLlQ%kX|t8P-Bur|T*D_v z%YZqsh%Adjjbvdb$76;k0AR|la(5YM8yZ?e*Vi7>$Sd$jN>-q>(503qRh1Y@BGYD* zL3wYY8UV7sVo;KnnLuZ7jy_qwu_0zyKI8=2_ z21wHX0asutKrYV`!Cy_5C#>8pU~eyVs-XQe}HoRmQzglWz!y zx5LF)?ij?eW%8)`Qe-xFqh;)3w3@uU!~~-{ey%e5xoVzsb*0>QZ1cSP(5UWlRb7Pu zWjN<{cQ}(RhL#rQ32WJrM%JdMJH#!ZLO48?c z^?mhfdo^;^Uknrf5Gym+eR@a5f|BOzvFwL|nVUQO=MVm4eNbR2Dcn>uG7`R{{VJuX z)M-L8Rq!cXwGWH5-7B6|N7R&WTLS1AYwaTVL}lvf=gxsS)j{hCOBSkla1&%Cd2-k@ z{z2C;+LJay0HA99-mVMB_P9Gj#z}TsXUC)Ps03wiB?LP;x-1NtHhT238NeqZJ;V3; z+Ct2DQ|&yX1N?~KtQ=lC+(-PO?D?+D71lWpo!##H5Dd^{!oc9fxvcMd6dut8=shWX z`}T~!?!laBkTQ**ZO+?J-Gf1oKvPG$2DcO;$CsL0bYoKaMuQB`8H8VgO6hyNX6>-} zAZvs#ZhGBd$8v7`32C{Mf^^Cr4uNolRCqaCbpfK1=+B^lAoC2P86s-`gBzPpR4 zWOqO5(OrIRrUV(re;t2C&edG783|thxsq-v2%|DCj4Z@?mkjd1o;P-|-0Noy8y|u! z5RBeo-eL^?;?DW;rv3-uuYYcdVrQBsZp@AyrdJY$?B*CKTd!V3!^x`YdFoS+XXYaYivrO!P>ILEPy4+Y&S8UMM{yK`-x10II-*zq+ZX({ z+-S9?UwoFd{5wK9Ku0v`H^vf`T=UR@eQ83uY~Y@GM3zY|8*PG!wGAn`&PNkMt9; zGlhBHM)k+l8rTMB^%51c&m4p=>VfM&=}hfJkt1*o8ZplfJEqIUA6M85cU_}btUa^0p<-t+?GzjxqF&T7iF?Hi%=JnvaoH3}LUt+Q0O2%P z!gyUYbi0-|{jmWg7dS=atav2gJc0z@*xFYP&8j%vmy|A>DC$aw@d+!0&#MbtY zqM#sEQ92|@5tZIVX#tTY2aw*Ih?EG3^csp3X`u)zC_zDy8hS6%yL3YDAf3=d2swA~ zE#J}aJ?H)2bMF7%@2+*%X0c|nXJ;lev-f`X^ZcIQueK%#FE#fo!Bg1He+9&P4f_F` zWF~;`L+ofg0SF=K!1&0-pV3*~z$j+S=vjZwH zR&Z?zHl~PIl;XzM&jTnaDQ~j|;6&HHgOfy%P>dM>B05DUEhTKg0GGqU>r;4Ae>L~d zbab<3KaidwNq>Zw{jd80|8L=|>M&s7j=~iI3g=T;)-(=yW^syXzY^4ZCnUoIuA6pt zAU;0@IByiCyjV_)2V{dEfR}@q0YRoBpf!^C1aNxHH#Q>nhhYl|GXO5E4(H+FjIZp$ z#R1Z~h#eJP*xHig3F+_eRF@q@45XKBPbM5RT&*m4z% z?ra>m`;5I%#qGeRH4&zRe1@_3+?P`JZlRnryWkW4toQj&jcKE?UHEJNnkE)PZQO5>eq|&oJAg= z15BLdkH`xrX_8V0kjo>`zH97tp&h5p3cT!_>XiwECyl0;j}-vPLqD#3)Q4XbVN?k> z2=RuB6W{d?L#nwBA_2ieoVo?_-fKWm;ie`rt{7hNUG0#JwG`J6}5< zA+-yym+p}4-PW_%qnUsrE=u-{u80=eOU!X8C%7y?53mv{%n5&qrn#Vx2zR zG`)fv{?N!V^CsFd1}+!u29`AdfOW4zYdcfzOaae{_vpQgagfC%SN4$tcKn$?UumM) zs(!>VmT}?|1dKPiu0H^?27O$BJEociLn%S_>`;Wi)h7J?9mQjX(Q1IVu2P?f*qU|$!mP6lOs>Nr*J#btr-Ox3`)*k!Db19Ymi!y+@&HGz9-jVG^U()J^V z)JIG4Hzav;Z0qa1&n>?TJ?0BgTw_2!IW2%!d!Fpj?6Qyf>xMb~t^JzV{AG<#4Tw&f z?cihNi&}wSESz}Uu~Tg$F4qSv)EC1s4JW9kY5Hpd<%tp}j*p&*U$M>4*lG4<-~P}7 zcr=5>JDP%1E-{aQBG?ikfeWa92qVuUz;~RJqhv69sXJh~@P;LZPxW_?f9=<8_}mGa zbnv#7+SsUB2(H0&5w>TJ6gWvLA(=yoZrq9HC@%}Q0)4o}3cRfKrWVJdc9)v-pkvO= z%1(|~I;8GB0aizSfwfV{H0bi!lQ<5I;y3|q8H3k*1n!^O+2om&+0WfO_XaLQ?DbC>)bZXM=zPUmj=cr{x96aIFHyz|9eV zYvt8*^9d7U6}W0&+bMVcJogPzFcGx$LEcKnz_)18eM<%)NdOzvqN`~qO@eyz-ef>M zqlX!~+9C``(d-jP=A;k$T*@20TlEQ{o^l&C6lo34<6f)_;{K?<&GxlZub{ZPv^rc# zhwp>IMd`_or(Ys*sCm{)yqQ!wp>65GnyZ|#gc}nX#6NcXok{BO4P z;(W|8P_ZyNJT(O^SXkr5tqG&gOD-&=*nDQo@|8Bgu4Bb&yI6g&i#O5CvTPL_~LNvzDSBo{`*@keO zIb<6`Ze``_aY`dTdBPo)hv3f}L8eTzK+e1!o_hG)!5ayq39fdIC(?QhizeRiLAQG3 zBOu&iqjJ8CP!AApdQEBAH#7v#qYspR11Q<4@*h0UhdvecrCz$@znIHnqK};oV_%8i z|D#r!NWWgAjTBx&C7VTy04I+x>sYpZh!%$NKd;zES0ckjC$6UeeEK!DCKnp_20S%hEMH6{0(0QIdM@^I&TAEMqHn2xs-3x$CX6 z`J{H~;ohP3uf+04!g`Y@-uXkZG2>GZZS&I7pTKRK1j#8I}3Hyu{g}#SWI> zCv_IIu4F{g&yWTd%!p=B$S=owf3_|R!w)3*QEqcEeylYW+%c9*;f&k|o6b*=ZiCNZ z^0w-yID)jxI$NYw!kn85QqtBYyaPf9*M$(zTWVs+-teQ zn#IE+oxTb!7NWTg7ucO9zzg1&Mo=ij#~*ETY!k6jkquCz=hO=G<&d@m_5x&HargZJ z{Q=&6CWhz3Wh5L?txsXG>x!19SC8+(S`PvMw_OI__7C^uY}2QwMoi7djH+Yw*TpE` zSyH^E7M~C5vD;x%y@o$%*unQtE(Eq(l)J3aKbeU|F@wDIV#aL64om4?9VBjX&`MA= zX6QFs6GfNL?2gr_G?=j!N;w3fM>pN z`&{zs4f?S%jq=NuC#fEmTQR=Rpo7(%+hfPS6h(J7(K>!kx3rs7m{Elv1kA!~W%t{2 zH`EWF4tr#QDAT zg?eiNLg|a8?8E-M}ZXMwnC{ksJnsmv$;n$KJOsCng&RV;>uLQ|lxF{E)B-{0k z9`z+vkKv+RsI(9YKXj_rr`B-$LzMED9uh#VZ{R52R5WMJuqUzv5IZ%ke&s%pAALPd z^QmwHTlB;p{t>DVOzH;)pI_nk{CxA>!)?W+^Hg!~?wMl`Z_nRei$r{ozJimMrsy}_ zeV`-WJO>vc2Xl&t)$eaQwK$;|AoqN3V0?U-(rcDdvs@#ZK{oW#_gyaqtxe2F&gTjF zQr7^byyu1Vd3XyR1gIE+KHB|~7$^2i%4gqX!etq$0%PkY1fk+QjLK7x2Ci9hO+}gM zle)HacfcMiXe3W~PCX!PyDqf)b$Dy0VLWGg)Bsl&`0*F)MXD!yon4j45YaAylt!(h zcu8DdBqU>5c29I?moIxZ%9)%ie{g-F2g033wSv9qOW{-9nT4@5ZoIHADse}+r(?Mh z>-QWiXIh`?*DGz3B|k^Oxsaeh(VTpyZX(T`a1Y{-H1CDjfcb{lw$I1y+)q0{*X=*O zsgZvM3;v>)Zv!r-dSw^u5v1(NsS)J#_>1G=^$~&-s+pVi)(1gl#}d~<)9ycJf8l6+ zP7A*pkLc1K>)9Z7JaAK`Qh3>=NIg|fnsGA31$muWf*7NmUSCfFMcsHE%~|u5M*TQT z4JK$R;pv%!sWRKmu-)3{E+fs#PP81k&O)%qOu9YZ*=^lC_A9|V33XVeNx6=WaS^Cq zW|=s3MlX8G6e`V!!mW&XpWNSQ$jVxLeLzYqBSn0+HV$KkKJuYSmplvr>s1loddih zgn;fBC9ocm5C228t<=20O43LD=@;8Ya%gW4774Bsw2QQVRJs~xtIy+<`Pg#gOq^}} z{TMlp{(Sv;K*u4UkOS3{avilPsXnK&VLJ16Lh1fh0JcS1=l=y61#m`Bcp#cyjn&lO zDUW%1*KdxJ26iUEj1l0QF5iZ{;4kqGbauLW{rO1~^G!VA+2U&Oe79o#`Nh3XDQV?A z0g%z_(YM#}7v;#wceh$obNPueyBcWO3SXff^*CrGapKY~Yf{Mbi;aYm$J@)?D)o5D zL7$5bX1^2-EF{gJS*(b9(*U0(68O?1jq@U1t(*136ybgL;K$os0J(BrHlA)P0`jd# z3E*#}hHZEJd_dYy^^hOi|F!D8&@a>UKJs&B3@c;u8>LB!D4y9d`nLiN!cSFV2Pubo zF--GRVbv=0QW8ovr30E{i*F_5E{D)7I9zxp9xzr3CiJn`rhDOIoncE?I%a2NToh{a z@M$AScRiot1Bt(ZQc+0&8LkJOZy;^3xQSS==C^>yCJScQEW(Tm+&t#u zmH66!^}t3(Eyc&z&3ceIcAvct1l@+t&SR?7;F<#$Sxmc0E)4X*^SZD>ankAT^WS{A zb%uO+b8{D8#*I#o7wD3gvlr-UVS~&hRt)p9XYK7BdD0WV;wQuNt?F6A3lW2iN7MI* zT+PU!P){q4Qul*(oghAvb)A>^R8-LlxR~=zsm`#ALH|>Mp2zhG@VsGG~ij6`b>XBf5@N+_>=AJ^_e!xV$A79?iG1Tq_CV-fPb?y?T<$ zku*AkK1l3UYCOBN5p)I1IuFrQEckO(NUp+yVIMQ((XACJ{709?H!s?`ssyEoD`xcK zNA=gF`BAuJ7r;W)tbEqhv=Be}IwfcV&E3A9d-F4ncPwKYXUV*`+SK=|Qs( z@%N##2e8k);X<9BH+K0l2)F7|0iGWh@QY38DvSWbH(oCdGP+`wxTCdXqDDLolf}0! zLoQFC2JvUmCS?HDy7YP{??OgbPx&U$GtXA&k~vP~Q0oo-4sVWRLL=8o2&z#-9D z>4Y7=x>UPbD%4cNK8Wl!y`v}?{gZ8UEp!tHd7lX6G9xl*|1iHsF>vWT)s;3SO5vSKu?%p)d?5EAPHY=%vT&Q>kci4|A3}liOPuPLfL&ZcI5emhaQ__`NplaC9bM z9IZJ3#?eH(ATv{$wvKeUrZV=CFH}(*Fpl=iPK~2SuK|N9>u&~?5MUgQ)fVM>%r~9& zE=}CQK4TA|e;Jcj$QBJu2gANl0NQ75yxkf`bZF1JxVNB4E_mar;v;z$VBwyFMZxW` zUn}O}7cXp%8Fj9-Mbkgjyc^vXE)F<#4fc^AYH4xOAhLeY+#WlW&fl|H?H|*k?^6n2 z8g$t#8f_YLNcWyeznbvt&1Y<;9|T~Uidt*_&}C$B9aU)HUTAp@$yoCY$Vn@f8pwad z#)%`02~AGi_os&)>OPENB4lg&`H46A(yl8pXRgwF2c7}n??&wznO(9GtCXKPX&$t? zK$svUNA*;OeZ`;>9|4`?J%6ZF4KA;Ye9!tU*S#CM%vW2Pb?s9A`bFcOy+wbDA{F%y17XVxofM!dFV z;RQd}MGm?V6T@u1=;EjbA#5em%fvX&@0A|Jj$=Yqz2984+|bP-gdDd$72YHP4Xpx6 zAt$^w>2CO|1Ex#&=#O=>33~85%;d*`#3f#c5IjW1(Uzqy%mq~udtQ3T?u#&hfe0m( zo(b466wlbWkda%#s21VO(e%_|QbQX%tIV|$yZ@)&j=%DhK|}lRoLfPxmnVzMUJb-D z3pAw%v&3F;0pp9-%;bG|F+P%X=~B(h3d8&ayWwxcUVV-P55^8+XBe^EvyP3kGc{K? z`S0E;@F0Gx{ZFF`MS$uvBl81Oom-)D^14(K@kMejgN<{Qop_(aRl59q6?SW_?(hDQ z3doDP9o3R)>;a@pk84{DuUuLMRkY5F5C-A`($IXEEB#6}!ix6VS0kD%E{1i%(#(1#~Mz%5%d>678)nB$??ByF56 z8j@jkO_rI49iSK|-eE;`xYJ@=pZmxyb`V9iJIU&H8c9OtAa2)5Cpxz7yZSwOh zl%O|)MvEeuszS~U!V1$^!OztDGcjrNlg*276Kh%Wy>B@Mxj+3<2|v(&M7XJp)q8`1 zHhLi=OBMDOfl&>;z0dD zD__S{o5U36-dvGn8a6VUgFvr>RsG{QWr!hmTBeUz^3Hoh+gms9(e`Z+?OP5O9CF0@ zmF(9Bd@%HIzFXY?L_3T(ZS2BoYo_IY7l}!o8`8Cd1Le4*`5U@?Eyz~eBXdp*kJAGRZ#fEf;ad}c+rem z1Qzi;S4*`f=vYxzja~Ej(Q_|u=h$`F*_%B9e*CL`)FrC74yZO*L~lo_Y{Xq!&i$%b zfFsFUJv?~c*FTudLW?zud|FhffOyRVyT6Hq*{HJcDi`!Qek^Y#li;vD3T)l`orAXl zmHG_5?UaIp$@}U;ayxQF=FcOoH$MXrPgIl#qFKByavxs0s_7XAj-zKM;;@9cDjr>{ zhBo1E4B@PEe9JWByJB!L_4HTS8IH3c?V?){Vmw%7)?QrINIT+jwpYMC`(cvG4ammj zKwkmkT<;#hmmb=WF;a`y9by~Jno8ARat-9GQa`>ogZSmln&~bYHoI3#JCHt9qEu>E z_W6p!qV4k?kT4!xty|Q}oG0+mtIw{!I5*TnHRT+WdP2a3Cz9f> zmxg%6Df6%U+#!o4SK`YP@Y{VGOuT#sg1)+9dSUyxDNY$?IooC&_E6TQn;6EY{V zcn;kPx>+MHzJDWon<#~Q+D9-`JqKfSe{fTW*1Jl7DMo?hL09VAv+6Y2h9%kmoFach zivE398|y3m8{E*(bK^g&YNgTNS|ALVCppkemb;^{#bAsOyuPU1R~T-GIc`MI3 z3-Z!k$*h3Mjc%p`a{lY=-dCyY`7KHx%WXtRM@wbwAnz-@zFE+99Fs)o0FZ)WhMwM_ zn4MI4Vz`)&{iQW0NLcPDpd2<0iSh!}7XWvqBju{mLliGp|6{2~3`yWFibnhq4vGQ- z?Q$OOn&Y$;w$kx}Yph+pcykBvVb8p2_9r{6Lx~Mvan&)jjS6H{{l3MQQXFizZz8NW z;F>M#`f+;PRK{bMcac(f*{SzfFKZ>KHaXXjESC>IwnNzZ#__rnLM}RV>~9qLrw*I{ z?C<|q9sUshe^7N;OPcPk^0AgPz7;Sc)5XoXPHb`6oeLO3yB)y(Zjck0P;MPn{FQ)4 z*Am|Tg6*ptLB)Qvd{iBO2F-GkZi>h|woWwz^1yx~|2y=PB{E+nTrxCtmw)%I|J&H zD=qj^Y3T9h&J~x0j}cuUSGsh??Sa5KqcR|~XN(&V*VbUYr!jKI|E9+WB@3lAlh5Ha zim5cbD(e6JTC&~hRuOAI&?b6*Ycivax~wYh`}Xx9-zx^KF6GIZ7l5Z>tU7s~3f>wb zqLpqtV5wVsSM0_T3H;pO>dN`Sn2cj4wc~T?uWKueAAugKZR|@C&w1-buNazqEy}F7 zuu1;(CSU4`JJ$#$kTpwuuVx!m2K{Key;WZBn+AMtxqe<5$vGf09%ZHx(lX?(!foz# zW&&Y;2l>H8ig8?~pLJkEv7P?tZL~>M0Twj^qC+pf3YLV}r|Tm(XU*QVEhz$mK^2f! zgeBga5$Q(DUfQ>48y6ydx)k{)M^2y$r8iIh(=G=bPxBit!ta~kX$ZC55uSbt-?<5O zvxW@Auji?>f`mbr%StXbGaqWz`ebmNp{d|yqLSQZb6$-f69OCZYI=TdTa6n=4@zs9wO0qqayDH;y`hoj1GWRJgZ4gjp7 z!|+4fL)e<)aq)58e%i@cVCv_8?X3RqZ`6mslm2M|7(heB7O9Wfn%2oIpnYs8@~j(rt z5cZ76EsUtpJx?&t2VQYnLe2+mN?a?|__MXX#n3H!s42K_!KW~+cv+u3LGCIm;?pjM z^w^8uvMlg6+k@Da_m>o92)@u9>9%2(`YF5S(F2AC>qXQD+yIKo9q!`|yC$^dM`PZb&E zsO1@h?>)#$OC?Or(8?UzK5RiAaaV2)Q=MF5`D1C}f2ASp>rIUFZpP2xb^e=H@Dlh( z$=WW+kLXPp1_oH&YmH_H|_h%BYaKbq2>%p?QFQ2S6_1;*k`v5us@y za+2%f+J{p7V{oZY&oK~8X#4gNHX;dIZv9<&X$=zKe2fQE{z`yK(hK(c0UG=7p{M_w zEoEb| ze*ovp;RQJ!0MK6FkaFM49|23N!3V(N22Mo@LjmZ&I6Xb|WxTQ#^2Dbbz@q=ro(_

    9Nfz76mOpFry+Ve=H$bDV2y z&qk}oRpUvn$}e8!@8O*scTg{c-$$#1F^vY87hc$jQb)@8M-3zzo=Pgao$hYq@#|^* z)t6iG0>gf6rnP0f$&Klw0)badHK}nslar+j$Jh6ex+h6>3m1?8Q=%E5!}Ujd&yYa* zK5HGR9QXr|^X;z$``@VckuU3PsE%&*0F%#CVB-3zGVL_8oMRUl7Dxd^K%a`40+5)l z{0$fsXn^#z4~ex=XfQ6m2N)7=qJSZR*Lj*z5^_?99(Zs)Igdxsn+``P0py?q2=i#} z6igp5fB@``AxQ!ECY>xIM(So5fPo~M4(DWi*a8P!=#Ds%LDFk$5#*-L0NKn}V7NKe zi#^hYGDZytKxdmCd*7>uzMgxaY|Ek}h{q%;MMcu>p0x zXziyxL*v^I)#uG@Jyh<(8>KJz?>!>Jzi{}xs7QWdQb)^y7ybQ4#;<-rxjr-dE&X8o zpF+8oV2T>^J&+A!Aupbe>#p)y=%2v=;5kd9NYGKwx`W(S{Gen&QnhKoeo4>Hta6+kDJEz`*CB~^$Lxi zZ=d^Ez|KoEA7-Ndo&tq#J4B`zBf{|{L+gpNlCri>lse@-=IFGR(>Qfn)`Tyu4S zqTZb4>K6@-sD=7WZwC)zFHXY9;a;agtxx-B`}sr=q!YU(7cdg2eHD4Zb#xO2|lxfv0T z?`_uY#mH0}K`!YuJW@Kck^s9HD5L`6?{~JMW_X~vthdfScz+rCW5k3Q(!f4 zIWvW+(fZH&69y&<9A)J%J|s{n=+d+Ai0;{Myk!iIYEBq@sNx-#bmPIEl|>+g{r3*v zVOjiChIXF2e?MG*T*;K!;(4Y2cF*8bU#eccHuuD&>H3}*H*Vgrw7=@X5<7vQ}1Q9%RYjmA2rlR9<1kOl+%K!&lx?H2))MI)Ij zs{+2z1@#wxlyw;Qd05%XDtbf(GUl=t)_O@mqSTv4N=kt$*XPAHe?2e~QsNvBPNYnk zE?6I{y>p_UyGHER^DrahbNxQj25r^~rdS*E(OA>dSP@Uk<1{F|>O7f%CGe#Wl)|El zJ^1J0A^RKB*Y~qO@4Zviqs|$&|_9$h5MD{&VeJP$$OueJ{p=Cbhw4!n`&Z!J!>>nlSOBmajcV zn2K#$Mb@Lk!lU@M?3bm_&8?TS{iW0-lKx8VF=a~!g_wG2L5Vuw)EH+72e=`NfN+QA zfF~kC46F&KA zkcY_q31ohC>s@mit{xB^T};`i{VHZXOIx<2;yf? zs^y$X4=x+!WbB@U23DV>@UXNOZc}t|kEl8nBD!euNOuoB^4+g>Hi-!!Ekr9jU;?`7 z1t%%RuSb|pp6$$d$x=5XdR&z)kELt{^Tn`>i(mEvIU^t`t8uLdUj3Hlj{BXR0V_l* zv@ofmWjr(5EofHBK*U%2HcJS|GBFmP${>Wzdvu*mGV<>rbs2)6-@~V`)c` ziO~^Dpz*RBZ6L&qV2?*#18s`%faSo}7BY831J|OWD8EZ(KmKxoN*zuAt=epsOr2q+ zVCC=-HGJ?HZ^@bV;V86pqvIKI28R5ZF8FLUmnF;*!0&AOyrNp@;dv}p|COGI2>t}c zX@TZ$a1%Q?eC(_Ct^Fzfmz@?%ALdzq8Kr~nKWvzx2NYm6?@BN7{ZDj>uI{WPm#4Q> z$Aq2RoF4x|J&(m@uGtcHQetx8*5=tunhv z!WBH1l>2kZtF|-Uw^XGYu-Lhw=`QUm7e}7M@e+kId%qG~PN`}DT`WdFPQHe)@bz`F z+giG5QYn_`y)l+XfQ7y2iO2VWw@*@GC?H^(r1uAVntnYuk*;$z<_y0)I7`yT&aZqd znN@=d)A6?wlp$efjjZ8X-^n^Oy{dcWWitV5WT4PK$|GndG(Z+}S+rauV{_xgs0h}$r`^bhzGy9f4||rl#C3`lb9FZA;p`^xlliO{a%;&A z_D8&Y&k&B~=K}Bgl~-aZSId(mPe$w$g^v;)7xi@!Ma|(V$vqb*R6&00w>lYconkvV z-0Guq&79re!W^!_A#O}ok$9`*BfSqEmR|sJlkm;{b;U8IMw4IMJ76=48NKFzsz$|x z*QNN>pQCTe4)ln*a$PA)^=NmE=dZ0Esi#q%zTElMiZdI;%};Z@S`f^eX%_@K+7JrN zryat=171Hy6+WxKA0>TfQi0kcAyzu_&S@{&_1+p?yC3@^ALYo~n!e3b*JSXw=G4D`(OhfhSuJDpY}Rrq(t<>Bl5pA^1Kuc4fg=@)a%x=Lsv zMZ<5H2w_N*ueC9E3t&Qn`uHBhM^7m5HSXeAS<+@)r``vQW4$RD{q~V9qnA84x#XsM zTjM1B_5nR;Xt|aNtrv>pVqjEAiM`)QCGl=Y;L!4`R0sgj;19vk0QSO#7KPZ1bj|$6 zuitzkrABt)76BVTP@bmuU;DX$n`K0HNVoD|{|w5^ws(L?+|JJ!&#ZreB&cpUoKX+q zN9OS@)(thqcl75QeE7oi%;~uHE$X!??gF|Q=p++m*z!0}LtQcv{d3W35ch$k)7~dd zUt3#V1*FF6QLA&`uYVjtP|)7GiFGy&O<&1h#>%I>ap)Jh6_b9c_&M#()H81hgj+v) zf#N?krmfI=Syd_Zj@^w>=)b6+<$wMuK@TWl*-I^%5}t0blDNSxXGdH#` z8<6&X*nBGd{p_RXnKR42&_8ZmLwZ^O*R^F60AsEeo119Q90_oZB>PO+t~eOYgeRhK z26170XX|K}RMncua?DL+-0n-KKb=OiLSJt~8n-AgWkPmttR|LcR|yL>_Su2BS^%M` zujjF(zC^s$9Mfy9eyHn9ym_wY{&G7&R>wjLyj_Fd6|gl?p(NmI zx+1?4j2_Ad50y|nJXj-^cqktR&T|J3*Ko_ATcTzops0)WEInSliiIciiO(d4as&D=C=f@vwK?=HQZHn(u)r;3t~0Y{#iWbxWY9 z1`MX>i@092X1l9IM4SA3XYlAdJ&Dq95`a6^MUQ(PLa<_bM}>26lm9Aha2M>ctMTUe z+fA*LK4WAgj_{+$BF`(W^6KY?bb=>uhMcP$oGa81wQyvM^rPWTtL4m1O&IT2IUC?l-i6XCLW3tQdl)!oV7) zSWAYVIEvokvoCvMuo(G%;-i|3jF;e+Y0zl_w75;HX1m#&h9Q>2JP#|wo>i4UlFn*O zfXEqmZH0=!FYBMc^$WsRuXb$C#$dB4wNEIl)@qsiB~>jCq#m|#e-7oY3XxmQxudlw zx?~7nKT7LbEZ%s$GkE!3kwVd#b-`lP8#_qR5?nZOpd`8Tftp)4V;6CL%YdoXXM9hR z+hu4--LkXJp-F zPx^Acc$3@zXLs+xs9%q`i(~SM->U0g;JGmTqmuv8o%_=_!b>cq`g9q5K>=3ivKRfB z-ungRkrAHAi|TYnSXHdoDy8beL{w_7Z7eGB#akBNJ5MO}g2*qS!4^S?6HZ?p z_KKt%D^j%;S7&VJu~K0_PcSFo6uV}8?F|~zD6W=k{kh&ZTVyyseLE+vMY~YIoRXcG z0aWsDnw!2lE&sUe@ALAXMe_ZBXa4;jsmsSH&Qee{Cw5X6n8&{aSH1KpRNS-ZnFZ{! zKT%UXe0<n8E=^w`% zx@H)>YV5k<~QmDe9*;em=JCga47wX@%_cA#xS2Q$C49BO&mF-=Loa@;( zJU%|?XzUFd{!m#`R#O@`wo39XP=0Lt{`-W`_r$sKu24sBd(M)d0a3?1bO3(%ci9o zof@_3ZhgTS2P|DS&Vsut@H!F1>swC>m*$(|+JTjeTL9G(fE>HIiQ@$np`{9CRfc%jU%aFyl$mD)$JMhHd= zAIR8qf{y@L2Zj}K0B|K3vV1iMU@2Oz!%Y5s1i-iQBuS0vM2- zJMZ$-N&a_y1uA`o@sT(m-1?J|NYuG>ZgTsp=fXdK`AWcmYLhkyh#1Z2(W}Z-0MH)OM~~ z8I7o);+p0hewm0;N9-l@Pt>YA!xP|DgvNR=q%Q-x!p94h{c&R}yZCsk<5%sQPCEsM z=FsqMt_B#f2g2u-p{9|EG_3zg-LoU9uhP2G>lB_;FCf;c4|{y3K!X;8Yz%Bu^M{(p z1b%B^=hEuXCPdMv0_$2wDm#JIOXRVRPRE(P{t#Dq#ki^5ocid1e$lj8XbHV5Nr+Ne z`N?4I7jR|k#0FBZB7a*wz*S~IF4G1Tbk$0;&tZS8F$8>9-ZQE@G~9wFT6ib6F5 z+0DcV_q<_d0W39lm%|fDtr?RCBE74IqBCs<+QmjSZuzsJy|JbNvvp&an<`D)O0qpf zJ&5%n70Gz4Mlqfn;k8Faf$vS>>_3ptHLB14B3^OQHGSA0m9cGnj7s%zJb1p%_o|TB zZi>S6%uvtfV?clKr9CA4+f+?ZBa8vZFvlDFPVV^DV%=gC<`P~#E_Ao2#G5z-FN_gx zGGZ4GJ+SYDbuyvZaR^STZwR{sDhix6+B&RM!If%#99Rk`ip?kF}#PV<0JxxH5_%S66k|%xL z<_hP*foF{-A0IC1E3k(#Gdz;K3D3lZsM{g4*4*&mUWXEl!OK$qGrrvOCQ$uq)P6*+)`OSr&d(Mn4nY211OfzmG`quTFsCfL z%chgkN1yDwe5D8u2*VG|Lhv;B=Ki{3hq-Z>TScR5v~;TX8XZG#QZgN7IXX^gZ=aF%`5Aa4rOZ9P!soBAFC%43rrB}*}W#U~N z)Olt?SH9%N-8RQBIy_p7`aR~p$}Esknj&t z%nSdv-%0cDXX4R6h~gGQ6^ei7!af5=5Yn;n=qFWN4S>J#-<}CLz^wFFf(Lc*-JfJ} zKLY%Xzv*yAKC}uw1nQJS$Lo+0~#5Y zD_X@}qX|vcY!N9>y!A^0cidURmS=a?j1@zqFL+ot)Up*1ujlP6=h>^!_s{8%3Tfvl zkx((Team$M(PKDg5u}*#0i(jIp=%W-JeDdiEFZONR4TC=B=tcU_dL_=OrKn<+$!oi?(XFdCkFLv@(^~?+Fgh)|qyb|#g9!2An&UQc=-ARuS{iqX;yaH(9LDmNp;T}Jmj$H_x;M@?4ajmI4XKXw%qTD?5|1$VtsWV5h9KL#`+EZ6mK z_rShIqyo4Hg$eC|Lr&dmFZ{Gz|4=>M3?{;f%}rmLTzhp`nd2^IB$iIya?xHUji5zc zo@K2Yr-4>)^yA%TnW}(!XSF)J7J13?Sezdu6(E1Kr!nk|9#sqCf(w{sO~bD8&F5=5aaaq2gKQ~D+@GDW^sWGM_LlkrB zS01s!8Z%ytu>5Ew0zdcm0@0}rm*szf^-PM?%?*?6l17j5S>4e2Nwuk834klJNF?z| zpeI&-_F%Dyf()!w4PVTCQ71pDQDSa@bYL30sp# zIwwl4#cyXcm=L#m4I1WUx@XEsKIJVpGGNykV@SUJ$ntH$mN6nqntEAUV)(<5t4hs% zhWP;dhOu_Wyxy+SMt0^!xYwV&k=*%xd*vdkw5|6`Z9!zWsY%A}lF{f8P|KV;@5ie2 zpds634Y^dUmG5fsneLw(c`hE^7ybfh{eZ zdwlF3ThvF^3c|rtV|!JEg>kxZj3zPGW~Zhm{qFTKO|lp%;Dtf|L8C9*s77D#+?jmw z-0nTd!(GX`!nTNa$IkCMrYAw~)(Bh8DE44s=fA9$iS?dDbnW0f+4$TyzPfY6T)fTInSPK9BgH)KYyh#8_K6%h zaF&+wX>8I9zw6Rp@F&*v)`dj-F#)lKi;RD}urMX|AI@BWb4E`qV*H1Rbt-B@*YC=L zM<2<5J*oJ*=(q`2+lS91La>mg^MC)*)FeOrs$4iJ#;)h@r?&p_vh@%CQf<;`Zqh=v zGkRBf8+S{?u8b}}H(5gQKu?~_P5AVV)3kehn_Y^Z$2|Ek-P733)ruaK&zdl8D1EX49yPi0ZshyJ&<%a=bHj3``>Yg`TH=zCi`!EadCrk# ze1|{eelHpx%;Uq5s+eZmKhfzB{grVx0m1Xk^8xXSA?OnNBRoiiWY1pQ=#72fXrr-E z(PFgvO@fn~s?g>ns!%@O)L~a8o<|kr7Q5{_=H)%zy{;^(%DEmzvgpO;V#cqT=OSNS zjgB`blo)c`_`RMB9Y#MeUm3+hI7)XGi=9fS$qOa zK(}`vZQWuFjovArZKMvSztpCDc&A0(6v{PU6Os%#dV|N@5^^Z7sDMzA+13PVt5IR9m27jrdzAHDso#os%(r zB5!GbOJ?xb+mE;;u_%N`JaAt4f(IBN?~H#=I>FkIt3rTmlMgrJj(tmtYq*D$I_`p*N3F)L1b9oyS1ad?4Q6 z`tux@!~%#AcCk!MVwOxguxei@`oAFNI{t_95+zoE%)`FP#Z4tWUAedNJ3 zn-_&X*+Sf}sCzv{MD3e(@5z(NNP8Xp_I_SV72`Ve?Y4D5HDq2zC)A*TTFE~wk6nTj zzT8+=&~}jL+?;YA0N+RP>asj;Qf52LRvx*Y2uY)yYGog*=%MvsYQ&3_=({Fg;s_%N zpA#zPa$vU2Pa0+s~->F1Nc$=3m2pXxQ2@(yozuc8am}IwOsTE5cFt7s{`cu5Pv7OMQT|d{=YggHN@`e^pF0hZ4`9O{VPn_~Q zK2ZjT65Go$@fTyQQFc3i&to@Cv&jXG8e$q56;E>_uAF;to8U~ZUREQyE;?PHCAJwz zgpfa@O-VrDLbICRNK<`-Trk~9;l0Ks8684@0+w^q2=yFCY7ag6ZHMFo7Q1G?hs4)g zZ*C)WEZQJFHI^Rn4VC;6F4OsIx;LCJ-ch)t7YW4lWbwXhOid{?eLhB?PC^X}R9**k z2zFFk59vRn+TAi$@jVu`Ei`t>-)0%S_-#}DNnzQ^9s?}FllO3a=u^8>Wn+{3135&6 zRAI;TVXqZlXQ6DmNH>|YWsU06q%5W1!a*lDY+Cl!k)GuYG6+CUSONa$YjuO#KCkF* zH(6K6GZO;(xN8Myz4~bijL?QF(PgvMo6;%~ZyyRze26}Cct?7F1j9YE6@p`Ms|>t= z+@}F^Hh&dl*wj!YIDU)pQl*=j4t3$DYn?MPn$*~`Oi~V1;dv}sZtg)sDQ!6wFOLzM zog{1C#v~3OYI~0?#hJ%-GQj!hL1zi!uMgAv{3tN)cej1~I7@1VKnHiyUvm_;SayaG z`}@x?Nv-vsmes`U|BJmZfrol~{~uSS5=v2sQIsN)eV^o(Bu%nrt%U5#zK+O}FqRNv zlzkntGfbjn&mOXqof+#GGvoiE?!D=DyVbql-}3+Unt5^NbI$oJ=X0KO&hwo2^M2yT z@$aKgB2qQZ+8G_Ic*!{ohTRa~^Ey={GbCv;(z@6+#fYvaK8|KzTA&NjXG->PigEEJ zM5a;mI6fg>%{JIi;!39UGQiq*(05K-cj-2U_zrnAG_`kpHQ?7f$D;SYHKc;42o4vc zr-lYri*yvYR7zWx5Bdx%it%JMFoCa_RNKHht16c7pdwY%oRVfl_q={;t$Y2kkW_q| zHe|`9`KhH1&+c9=_-&U3*<|Vh*gTS3SEh{ndJTnksoZCW994QjAzNpUlOQ$!QJosHX|-JM^~mJ~>C` z7vpA!6vPUbgQ@J(D%Bi&76B5Q`lc(BTe9yRxV*0FoEGnh#6|VPy-+HHT&3ptRn>s^ zV<|T7>MwR3Q*_hgh-IE^P6IyQXtmH=1EqzG!9q{1f!eAUAT^IZa;5??t*?HI3jKK* zH4oQMVPaqTrML5^<%_nV3J<01TQwwykBqy5d7HHK^puh#k}Kkk8_gUn=qhPu1;lW@^m z`h1I?(Hz;in?8*dYV?7#VU;3w6CPGSm-oMZ9b}{67h>ObGk!F7kjb9 z=n0KZv>n3Q)J-zn%$Ya@*`|(D?XNN#%-~QPwFo!WtfwgJC+8gM$(h!L*f*AkNzoOa z>atIhYg_3a>878To-G8`6fT>tsx|iVWAx#k=DTcTIGb%;ZC7kxqTV>ofcP>cyQSLX zE6PN$Jf2!GJ>zA1EO`i-85XP?^b8%quZ$8Og45zus+NS1w=H&y^3wP1SzKY_!VL-j zbtN4jrf8R_dOXXq=KN6)8@<;AJ-rnGrM$$m%eATIB`fw^Xn_P%8jI`@6S&R;ritiMsJ+u z;&3s~b%1q^aGT6nD!QlBWr*0$tP69%m-e%-jwo73YDtd*_v^o z^_%U2ALCD%i0LjON!X9ksUj{WezQD5jYzqGF;uAwmI0Y*-3U#UTMfAPLE1N&@&n?M z$G-WdJ{u=;440$EKe6P?*^rX3pIGwOV@Lh%PQYIlpfjH(YPcBp^x<>yZ6)YMqs3Gp zzSTEB|L1a+w(Q;hyA{7BL#!qJ)oRt`RsUspdk)hqIOE8XBcE6K5ad|_purME~YQy7VXFcdVDDLaV$pKld9lrLHm7_XsQjO*- zS@}2Es$_v?0jgv=3uAoR0mslh9=&@1G=fjX{hJ4e#zZ(UEO`kS!{_9cV#uYL1bXXQ z28u90kr>6-EEA}`6PA+3eHDF_RI011m!|m*P5TZ9RR+V{CRdy~@;aLHrs(Q{%gI#4 zFh$<#-fu;kcxSiEv7lcRKUmbrh;y@tRW#Q#-I%cGIW6ubsfhvNreD=L)Vc1fC>e8P!DHyT5Y^Up{iW`^4^v^E>6zsasli;-Hsy-1jJ$Ani>>GPQ7b|*JH4KDPj zJa_@v+BYf0lWgk7TshF1K4wRiY%|N%IDqJyu&R0FE#$S#neQHgzj@EVVX)C__vC)1 z2{E%483(TY_V14bHD*tslksZgg9xuC;|~4_Mw?n0yG>dA={Px_gy4zx8zDvSY7f<9 z;}_}P*mG0>`yx0;aid>|nM&`qctuy>rg*ZuEBN+V4`)dr1o(RoX4GBRwnOtA*Bk4c z4Bt>gAR5hY1kh6%r*2qEjEax2b+llB05XiI?7iZ5Lr#%uXxevysf!dr12GT+MM;Tg__d2o=mtJS*28x%P3*a z8Zp>28Wf#=&UH4=-YXlsG%DXdyMP@Si>EK3J$VPXYur-4fgpwFfPLe#6VHjTEC!HpVzO`?G0!{*g zsjY_+(6RzT3(!Ld+aUx6Fs8{)cY#|5KnZ%UfqdeA7X81_0>zD6?W+kI76qN$1)V6= z4TaSL^CfT((WDe-f@RbNM?>pcXlti*RE6qvU5TWM1D*H|MZl6okM>n~zbXhs)2+Lq z(7jP7^I6Hn1m|b*(0ko`jH&u4&+5!m5Ka13fRf=4p%lz zX=YN=nR#uaOH)m(wE~y6%~9OhnSwV!%@4@FlDF7yBqQCyJsMnolgB~=#4l4goT9^5 z#6E0Q-M=*7=m}=vMjc9^qR=Xck>46vio$^EsfU6S>}!TYf*LtIx*MhTIp563cs&$g zzSHY)g8t0X{Bv>v@qi1VLtMd^WF=x~EEJ1y^Zg>+e%XCJT7?XI&fXe;7u11>CavbK z5;$r~y%ToJYA3h-s;D8NH$4x6Xe=@z;8Nu7Z)=%}ZMAoU_NfLOSap6*(~c5!57OJ0DkHtFCI{ynLTq7_Xo+0IB)LBh3K=@#JDC^kV zsoFi$A$O;?y72cyDLFixnXf`)(d0n<{*E&6L0uDh90^NCsuKmnmz0Y zw}eOB>#7s7`IjiN=m0VZ?H>kYd_!0HZ8`M0iu*AvNV@Oq^zWXjfeDQ3rK|XuV_CM- zQ=y22-d>-fN22)!4no6;{J96M1qad03zE9(rAMAC)Z}} z`8Q=60sV~w@NYUTU9CNQQ1~8!t5i_(2AL&_=@vBVq|44sTaw5RW)17G5#u>RtaX^0 z+K)`%cC`~Gt}3|!?rh^aX9po&XB>pj4wN$A(COGeY6a`d6QLjhNb|2$Qp~_ryp-ZC zRL_&VGKYKp{K&I|ha|HZ2dr=gs5nh50DQY{nQiQtFoF$olfNl)#_5LOi&0Fy!?}VX zntiwz12pC@WNSsD%e61otYB&3wX2sOBn$9TTxPG`vp`lhN4zwfa1)1EvS~JNmLmwmxbG1{ z3yO}a!(*wI!zb)qxHtfRp`6SR+hFKG$%-k*a7Jl0U!@Dk0)@z+SdvUs6nFSVj%Fnup)n)c_krVr1JdIqRU_o!1doG&N% zNK)AcM5ow$51=3PJmoP=xmrEaNO>^bqd4mzUy#SjZb!ydjtYDo%OT7XB3<*BY@O3N zTRD!%9ZXrKV8bAvIYZLR2f;K(_?KB+biDu2os&B-kR*8b3 z`Yvo(20p~3mPal^{5LEE0Q@fHTkrJ?lC23a>Zl?#KIP#{P)_~kr~mwn>oKVlbWu{d z>xO~c$xFGDzk~TUECX_Ka-UcEWJuPL!P;pXqH~*K?`#1Dc+2csqaXd_{2!p)Z0Z6dVNhHhA zrF_4eb;7(iTrV>rPdkn#XyWwJCX1tcDusnDBt21jM-_`az{TV?Q$U`=0Oj1dr58&1it%51d#L3>3tvETOkvsS!!O%vNGlKL4;mJd{ujl}mC`iKVm9tb&#kho0pr1imOyhAGWBwxyP;n(%92ND+gSiWVsv z=`}@fi3~et;_ryNszj&X(y%QxWo@)L}nxaQ?Cy~l3 z<^aydWT4d5?5w$e&6aM{%)(pM6LMphL>ieDta_PnFtdRkTkX?YQTKM__h?%-g|vnM zF>|o3?K&X?KGqp>GxrizD1AJr)g-M*PLb1T&oaLFBEBj~Y5C|07-NYEU_|?n449wg zY5oN5n5UZB`lAA5kGSv3jEkJD6!RR(d)jkWVwRKdf?I#^>2lUpwE+7E&so@uJCK>v z8LAVaqYiYzDim9Sx9!+g$gNhvn2V3Dd-LMxRd&NGnPlanV+wYVT?_I(dn>HYCTo_Ud+{m=k=1Q-c<^DB|>zdyVbv#!6%v!^1%?(F$HwKAjbRJBa|ux!=l$b3<46pn z+Q73kM6EzJo-9rY_~n_j@npw|Y9x16-Hj7}(i(7_3L}EJg&XqW!Jrf91=?pH&g|vT z0UP5_Bth37?0-d**-CA}xb%5at%15SuSZQw>GW|)nDsm!hUMwp2Leq1+hlG5X-nO; zCW!nMaf!gbll3bNva4s-Z3LGlE4Hmp3-7L9g7a8}#|X_#B9_y#k!LfXeH*FdS0<)! z$2`6_?jXi@IT*L*)6}?Nrvtdve|+~nxRGC(m4OPj1rir zg^(enz)6|VCnV)6fc=2u4S)gxwBy(R0VU}#M$bR?Y&TLrH*UW;qx|{cKijxZMdECJcqIgt|&@^kIi<93-im zELt)hqo(9=>5yq8e&!-D5!?r7EL2(gz9nu*K;pRw%u>K*{We5c19I3U-%$E+%iC1y@C+S*lSA zX#yFo-Rk~n3w*rQ;Im+j#aS90q@tJpL2Z+Dl!=TV1DzEcjh(0-F7iimx-*KqH{@kS zekio46qjvBjj&+v_@#FbU!~`xvR)DJR4DRcnW$z|--G>@<4bc2mfQn-Pn^H{V0!2- zsTyEX{Of8iIJHDA01LY-mrFd?I{KOs1N#=fSzF8PlDr3YF86sl>NmhKwP$ilWaZko z1qGj$Ik{{I@@OG*Lw>d96jxT}i$C|NFCF=~qx-p9XY{Z}{}VOitAmm9#-{E^P444% z??nXBif9BZ6*6HN8_FG^&jozx`rk4Vr3t|t%0dkqXN8+LbUWp6U0{J4JV}HOebDWI z{aEE6U6AfmRGk5^GD+>5UA5NtjK8%3KELz@w7rXw+AK}Rx^9<-HUYd+5I*SHYz-Du z*nAUAOlgpN_d#YuCH`B`dvst*Mf zOr68*17V@XMG z8OyP7Uo#2jff9d>+0o;3GW3@Efy6d&9Uf%DuiM`LM&Q0h(uyx3JJG>Tl450w%6S&% zWVP-Nrd1R?X!owFHKw9Fi*9aPN=mOuacM)G)1knahLF^s?n!ENQRo3Ru_ zV|o7lk%?>)GZg(stjLHn z?K~i2GOleSE$grxKK==l`g>O~oCn0)Cd!0L^m^zJ(@dCjkVlhCfGFXtLzO?uLF#T= z_uKKweaHiScMjgXwxFvQ0NbPG?c*$eG{S|hG+9=kDRGyiBaMY_O#y*pNSudWh9hWK zmevchFb)QCN!}isF_$#E7ri_=*kAb^PRUbMo@UUy9>_noks*Js!))r ziJfp9A$aum9q8*4AwOC&j`t!}&H%9~*!fcUAaz>uOOx2r%qRoM(42hq%WBBssV?60 zTM&5iR~w2yY-_ukxHy_DQ!g|z*-nXOL=R zJZU%cN+<_rjaSpt_O}&S?`Gk7VT6PyXU%RrJE|m(vp!rFyue z$}rbGn349PWLb%@{BGg&oeT}5J9&4Ir%^A$2NASaak3TR8t9N=s6_Eo#ZOynz!aAh>pAbH=(5Hpt@&$i!O zRlZf!S8|}Mp4g(^yA2l-=X}~}q}dGlL`ZrU!q|Vm__7|;RdlgQT)U0BfF$j*O7T^| z!-&O!o|TeLF~sdW!%%y%q@jw3OcRfdW>jM6@qoQ(sKDSw{>ucUhi%%(d;y5%_A_ZNej^0%$-1m&D1 zm&-c;+_EI=cF3#SS{xN<-~1SHRB6lm7KD6jhO0%698W|kSvl*p)^2+?=BhFgs5gwx zOv28=DXBh5Dm+Dl&}R^=%kN0;F5Okgia93^ceX@OlQ_HVXXcinQI}kJuH>zh)w7ow zEKqFm$g`C0_p@WcEpV=X{ydNVHy!y6Ec|gNH4%a@lJZ_rJ$qC2M`nT_n=R?G(6?Pf z|M>Ig-ARKUSXC_vT=QSL2l)9L$p~FdTlnM8rZ|WueCs=_lb2fsseY^texMdzCSqa; zPc!maAS!55%h)$8vAG&0cra3Dn2vvsGll!G(`QGeMN<$PSs63DPpOJUA>vi z+Ozi5b0+D=qxosZ`N=O2#C=C2s#>Ebb%{ftQC0}l=<|JL@x3XFa}!BL5`cKsfc1R3 zp|t^a1&AtSe^in_+0gm`b^T*Q>jTvF0-&;d-b=sX)qkv#W(S*SncS=jDFZ;)O;7n9 zr~iFRYaQ#_!P4hUG>(`s85#$?0tR)L8|O0<8%YwefPQE~NNsj`iC1eS?FK^U@tgs| zdpd*h+{VTlo!@@oQAbQ+Do5y5S56=|70I=pQ4%> z4B#&LBv{i%aHc=>47GX^Lq^5j{Zvegt23F)4@L0yCahKzj&uaI=@_m+qOn1f3ZoKA>W((y-B@0Q6uS!%dirI>LSAX{;KwHLb3#%v8Gw+TwTOhq#k zJ0%~gB|D2_9=cLu^ut2)Tw7(MZHI7)*MzO!QSWm)mJah@k2AA~Tn5Ct3EK{NwGn2f zWAzPe3^xfLf)RoxO^9QV1!tSlz8qmZKv4}VF(Zs1rHB#e4qOzm+hUa4VR@>ags$wH z>4u4#jEUi?%RDyv#wf~S0EWAWVsnZm=1jqiPXUU2&AiaG4Xh;S@pP5WVxxT@Fb`oO z?9VMruNuB3wdxVqK%wu=x+c~@c5I^E0i}~MShOdw-Nc9SpYd2~%qAvRt*(K%>bmpV zNHgcG3YeWbBr%Nx-UO}`L1EHc(wkLFAHAtw)%qxOx9O-|!G+N>1_A)M^|U#fxCZJ5 zcY)3K>~e{!>CCZPHG4d>G_JK=0r3K3GUHqOR`ph8re7R_=QwBznXiG&a-w^Cxaqc_i0B>~Zy1EU( z4#zSsqyORg%VLqqToXH2at3=t?J&!O+TMN(iX&AHhaR~}De?}U6`ATE?c*NT6>`>W z&LpuA6bz7mDA?EJeaYK|T}pTzw5;Oa;z*Zal?jw%55|Gq5?f0JxD^RU+q(8{kB z_xBCucp#h$5?sh*O>AS>-k9b+pzpD;+a2UE0=1Fq9|l{Rj4_jI=3-eq^wZVzC!GrK zJ!s@~0$?w!s~)b%|9}{{OH8@m1`yP zo(Q10atg0>fL@k7t!KilMIhxoHJOrGAw3BT}$d}my9F6c$_LaJ3)Eqh(fHkwkUnD(nj4KDM# zOgvtCR?W|M*JDolSCj&19Zt-rI#k5D|inQX(zNm1J>9IUdCMcqhQE%J7Rv3f=Hm7 z+h5*E%kw~t>GgyUi&oA-nnfPnL(a@WhjBSiPyxwzM*!R28tBU6m&)l7f4_2B=^vMN zar*t*Qawg%AjoA{U%6~|24r-CW)*krkAh%xz*>h$hRpWI{dPb5{;}& z!O_kNE>29i7w=ckD+J}OD%^_IBdfbgup?8lYz5!O-`Y{t z0`Q(xqGu7K+6oAQ1JLocI#yKTS05}OQwWFFK!~~H81B|%tM>X&^>on zz(SXFqKH98M^DalEZ<|%dw?Evbm5-{oE~$kbl*k_6WEq$hc2U`eS9%D?qOi`!$78% zaHRz;z=Q*sTsu{f57H8d0~8P81SmAoq{f<=en__+2q*8wC=>2%=_{6vR|EJbD(qrT zVCgc040v0FZiX=IVO_0r^_Ul7o~*N0IP7Aj>i**0wb!nORommz81Xy`Ez`LfVw6nh zUr6r+!m?E_bA;$#AL}|B;}O?2Zo6muv{~R`9;*px3I{tvNr#y9R&zXTcc(_;>+9O7 zkd$Rf6V-L2r-{MF-zyt`8_SN``;C>c2!+kjp~~uvrAL%-QFvFWwsPllShA)Ca+57l z=CgNv*N?*&2rg-1Se=w5D*kH!Y{{ycQ>{E!LTXV3=7Yv%_`Va|Y zvHY3-T`^YUFYm-qU}H*8W|+iRlMuTy3iuE)g3Om@`f0S)y=#xY)mHpH zHrEZKNcuEXyLmy?%~&m{+hJwTN<@Vo!zh+c=1TiQ5Azd7&tY4Vt#j#0`78d$LC(D1 zCq~!w_A9097}(Ct2A~@9hv#$Fom3(Y zY%=oRYWKg@v`N%{o6OE$2G}5U`n=~-_d_PT0T;xZQmcMx}dTJ z@kYh$9G;3tp}6&AlzwSCk3hy)>JCUOGK|Dn0jZ?%mrt7jNmc7!iI8JI*({OAQtqcW z#x;WW%4)=t4_%qSyU{#TYfZc&N0|%fmd(;TfZw@dF_6wrIE`y9E{i3f3SB(@F!;DdAu!2j8 zQ_bh|CoRmteG%Rffs&xt)sj;2Rk^AYBGqz?oaG zmf;45h>i}IJPg7D553mZgyxFDmm=;`Ox{(sC=;;hH5~LDlTw6ho~T*qWA~3g3 zU+y?@*j+P9kG?WmPNw**Qs8#U1Iy`sK4nKx82DWqsyi=^9VyB`Wh&SDP&{5m6y(ta zcl>(gOw9p`%4og8EycwX`R%+9j@+wSQnqOzt~9*2nDHGc+wCmZF2yRJmYHUzxBZ#= zMVP*<)@ zX?KZ_oi8PHO#)`{Zq}boE;{aIgF6L7_3#OM| zs8)h6MV3yifBpj|>u(-kKbb{BIwGMuMv@Nkz34u0^wC8Ujxa8aT&@~Dx1Jo^ILg$q zIy4{WxCU}|wYJcmg*W(560s{yrLZ!H*w3;*+u{G~{t(_0se8%DMKu0IY=0Km|Byb# zRyTqXH6hl8{2Aa71$88;z2#nOK;VtbdH!RC2p<+)J2kV->dE9ZdQdZ>bBo-l6ffZ++rX8mk9`N zCjkD@0W87WdjWU%)7r8C5KouDRSy|p0$jc+lh;7~TmZVqu-rnhb#g0;Pl2EKcIZl- ztDCAb{k-<2EX@k`7D!Kk;EAfStzRhQO<;4JC6d{I30q;944O?>)c|As0ax~|tuPE7 zfU<*c%9Q=IVjO7?VB>HrhLe6luY0p^x>vxV{+`9Uulvb3z^NO#?x8Nc?rpyxDEM3r zK;ho8*R14wEE_u!;6mRZLp)wRV6nUAHj789=z^vw%|a4~Crajcr6YCnXp`wMq`4G4 zVE2OC=`xl(EG1)nejKm=IPH|?!%p_Pq(f&|ZU^$6AOF|Nls!czr%im5_2l=SvzcP% zC->~X%RM{PJ&VXtl2mYZfe@VKNh>6qRseZc^$@&R4-3_R7NRfU5ih`VN5*uQXgtuPL|v8yAUt3PNPZ7EAW8vtX0_X zW6K`dQ6Qv2Bb9x3rR_3cooHNY3p?w7xTw}fWS|&6qGb>?$gIKTlMxp(P4@P1JZf=y zQfFRgKDC)WrNH?&8eYCnLK=eWg-ks*09}fZ&d9C_$okJTY6L*4|dKjwVjCMNc3mRW~5TS&J@|7dy;Q{ui1>TV2}OcA?K5 z^sQ{ORuI=Lm=mN_f3LW#?#D;mKCG%T6AkzSjr5#(MqRlGmg&ky@$}2nP#O!{+0M&} zUwpzgf4WY-)i0n(WRyJNCJ<#@NQa^IWM*u{d%ooJgy;N>i)?I}mn6khnAs}Y@n>6G z&a$1?GSeP<$o$G_iIA3>8I%9JNPk!2@9pOwLhk+fMgRQ~`@UD=-ewk;3J&GVnrj`j zls`oQxQ5aV!}fC+v|F#k+_L5A^(4-vPpHHl|heEZg+6cb7TVKMo zaD@ev-GO&?5amp^C8L&Xu#cdSVzpPV(9Ef#N3JP4#Ep*=7EO|4$s;X*@ls-6H)of* z;^g`tNmvXW$t&AsJ$c^$WlaiO9ms7jTcRA{?kgI>`Q;bTE#*Tn2JQ@uUXsSI<|kF; zSgvgWMKJS0hpBlTkccu``=c~WxN0*C4`#7uw%d17&(DKcx4a$?hOyrEsCRMD*E34& zk~PvZqsq(G+p+H$ow5^|uFh5UE~EUQF7<91GqVFP&hFf*!tz|LBTQ8&(k$LKOz2Iw z<~iP=Gj~;Fv*<=3V2LBwlkHDh>`o{?nvj%xv+lvX924)EbSF3UJu#1@5>ZJ*qxaGU zX|~o6?ko7UHFwD`BFNQ<&0xC<+>-Ja{uYYXj)w$iOsLnB{vy#n|LUE=pG?0niy%b<2-g-WWz<7>cU^A z4$J_7y!Osz+ASHi9$~9wG!Z>Tb97*DmR^xMNd#I`GP|*VkcUiPZ~oabVZaW2xVste{KhVIJuYux*kdgrYduRy2d}{)j??#w`1rCQ5UJdJO(3tP*j3P-%D3C@9 z=EF*zHUXTG&N7<-&Wp4E5a9e@1fUME*DEXt-k~gT=lD6LcYEA9MF#=~d(R)a-1Itu z0cv?}d-AB4_yY&lP#M|75A`L>4;(H#gVVR+@g(t%=g(zt(UH6tYki{=z6LtON&58s*r_ArarAXC{2mGnGO&z6TYdoMCuW99m);M*evJ7*z8b<|dC77~ zQJMyUuMbB=l-=q)N2b{0=?r*q%=b6?O7INT^J}!Sx726koWHr}VqKqrX&fkd=0%ws zGL~y>=MTMWKnwkx<>X^ji=X6`-|%|BI1+3kuPj_z9i3EeRMG`Q0m=*jdQt|9wh@A1 zM<|F^x+AI~Km?z%B#bxVzThDLlwndjNNU79uaoSW+dv`Y%WpE5MggnIsNNP08<-f{! zwu84^-R~v~Y8S?;Bg3j#tzw!-7Q4kUAw787U-KrdbGbS;&~c$rYjN_bs?PqLtTy_& z{m#e4^~_Im6hfkH1>4(4{(PJE7L~em%vNebLeC7Lxi|Ku49bpaj=yzvnS2lSa}|?1 ziY04KPv}W7no*{cP~bTSvlJ!AN>09VWwj4qHB=E2YK-DK$GY1-2v3iv_P{QtxH8)7 zuIj0Zg*F@1)ZYaKuw06Dp-{p(wxYM9Xx2bGsLO1k#tMvzt=yk@)7H1Cjfv>t99u}t zIEz(HWzw6Xi(MMLtSoSj%Mj`$4AKmlX!3UKsc(S^DTS10zTsckgTyD{+W<$=9~B@# zhER4|xTMrB`)5}L?l{8f3A`2#gYTTUIQ zR(fYOCR*<(?2S4vp%hn@OetzscEeN4eaCv1D|x9+qz52o?EV+tYDi46^fq+#7)muFED-lm{|K9-3Jlc+Qr2 z>W%BZ9>~RK&rtJb8NnQ`2a>D67uo?Elm?_HL-P|{%VlM{t$*%kUp}HV2-HW+?)((j z!gUS^tqr`QFMK&auJ%6%w$Pnb{1(|)S+!WC#I1qEK0~%>g#F>ViQG?&PhczWx+ob5 zxZI5}(GVk1x=XJq6;d~pC!h&>Gmb5;&p5JVm!0*^j? zy#q4Y23ZiB)9pl(&M^a8ml9C(v&@A}>*KHe+O!BpEiV}W>@M)Vu%dO>$xTb=joEzo43sE)x&CPPV=0JH4*{AYJ{APMam|FH6j~ z^z(nU44X?k{)%vqMZ$VQMJ!1f7>&Ouod5p8G>_O1-_&NnzF?fegKz(k(&vlVq}Kme zHWi(v^~bMay_fBD|mnTMDW z_fVpCnYvW~w@`_2{7%Z~hUDM5h4ysfcJFBk0Te$_0q`*K6Mv`FCNn|Q|l1q8f|zTGB@`D7ooUDc`E2Z+#n z$mf{hwb;k!FY&ohSvo?i`Y27r>I1?pk|wz%rz>r-xq+4Y__HowV&`Cx@+!Tu{z1V= zjN&gC){*f3Kjtj`CHn+75W z^#Wk6*o|6%*bn8xDrD_tNOy}ziR)4x(6k1kVjiHuZv#kU2f-w9S%QGwJ;>Nbeb|40 zeXV9!DV*ljc2nyT7s%DCv*v6-_+u~DC(-Wiw-1R_F9=%6;Z_IC46gz)ju(jfhNXo8 zy+XkU+`Vjf?x?&s#PO!Bo?~d%GcVczh>+Z}7#g!Q2t+|Xe`6=Z+hZKGd;JhHIw|X) z?-Hla7)Au6dGH+o4SUP+hc(|S0x8pwcEqyrCccqPk@Nt*x=F;OBEU8Bqr&}3D7~vW ztMvu;5}tqEbA;f6joCX$JUWEi^FBFu&7%^_6_c&h^;HJu8b=K86{%iTj-ZYzJ=gXqgTH$ciIRWhh-KTM-C0qAWJk%Yu7?UK0 z4n~?ItWqa<)w|B=I6UHnL#?L7B3IJRHq8nWZ*<6K`Bhup8Q5*h5|0P*$t}^t2wy)bz_^uDX%E6VJNstMSOvPw*qcRGPIt%Z!PHBc%n zLla;#R0am|e?pacG2*E@yHSmgd+~Ep|L01>CWCbz=nChdJVMLk#LJYVuAAL>ahY9h2+>#OYlqF;|^)fyeHo! z{+|?94uoYwGd>|pl$s^p0%8>-HW2R6586R8=T7%;T{0ZU!ZM)Co>DxEDI`qNOHv-B zmo832Fz%CUe$r>@J|fzafvr2FMa7B=C1PC66Jh=S)yd&(opGlj z3wz~Og&Q*Zqp!T%QzS?`>?ClDg5++}x$$XqT{k_mwWE7I)IPRI8Y7s7 zl~=+>D{uZH$v8xyayH@fR~mBmMex1D`MJr)X~FIy{S6dToh^ct-fJTE1a4n2fnx-h zR9r%J^*@n=ADtqJwjf7IF&82UZ^&g!m|2Ti4*v=2%KU9PD)c06I|BWWt z^d{6Oq(6NBPz^Rxt>3}J_Aj&yVDS#U?K(l^93-~k|2nMhhj&d^2Sh0t>3iTznR3gP zubi&FBQ$%IowfV0Xf-It7l=uKrKt#a<;I*$c=EP(i<+>GYSrUF4^y8}_Fo*2Pis|G zLa4QI1<#Aay!B4((du!~WVv&O>KWVPz#U^rdG@1TWn}ho=dhQ8Qnif5#LM-as45>E zd=|zTaNzEv=M5AY|3(QHI^DBsO)B#{0N(>m#LA8_#4=u&B&^Ge=&X7Ps0@KI_W@U4 zKwBHK`MeAeI>h?{dW_>KtZy8K>j7gLSWW^%^zRj{VHG0wB_wx84k9TWz=!}U!>)nB zS^RI;`0uW-5yObvI_S^zQtVvH?c}l9t)WxGv?uP=sHckD*rrD=!jhLVfOOM2)`U`u zHx6eE2*6y`sknW(>O_KXoENJBFaO=izdyx-%6bcL>gj(cIzRackNrpa2-~BL+M^AG zdm$Qi7AV)eM}780qvOZFW9&%gv0!bPGC&ns2A=WkfnVdyOiJz=XVeFn$&dMVb@8(Y zIFS)uQYmW-O;5ZpDYOiH0hEeGJ|@UyG!8NwyPR?MAKjDaI!OJ1fXAINiBje2nrny zQBO0Y$Oi|Py~;=Qm|;?gXsZ~WR#J7+gY(_A?<{Y3ij!O*Vxwh@_EnW3lVM%Q0(H8i zY00XoI=U&?Vh6Lz4&n+bl_pj3yn#9zWuIh9deb2WnC(zBEiqnS?MnKSP_ON5tiI<|Y&f6u1-Wm3eK^qVxjPw!JJs#t zf*0C*)gw-(_v9|mlZA3kEAy-=$lX7l}3$YhOfM|qm`yh=hb}fE^_0v&x0mq%dNI|%IR`>rFU-e zW#8^ox{n%^u`+c2%CWf1$q(|BtwGj+GpW~)K3NJYV30;=1k)^5FMdpapgi29M*Q#I zP{`yO?DgyFt6(kgeCS9(yGx0^(xmp1WS*=g@wi~BP3j>eGyg5 z9&^aJw6O`i*ykG!Oo07AXi|4p`UA3M1Ly+RSOYoI5W&ow$PF9O1{RB?qkziSy;7^= zvdRxb0;rdK0QIs?dWejj+`P8{G{z_)7`YqPu@%5@w12L8{IS>Y1%2YP%uAc$H(&p` zX@}wedvH!d`h?;b{s<{a7+)gqz+qvT3SCImXh>jzKh>SEf~Dma1lum}1o#&(e5oWd zl(c>PiV1Ar^vQVf_G)(2!vZV+IPAL#*v=K*{(#V<1=vf?6EdZy!SdDeb|PI6<_2J+ z_OC19+spEh8Mi(+cm3#?@z2h4oN1<@IjC&XWh0T&CYJPftC;Uv@_ej@y_XwCP{2mh=EHeKs~#tzHx7@ZA`<+zd2w{#XRFCg}8BZd8=_{$R}hSu*~VpjJE zxsY*~fUn7AGF8C#OE3@K2$D(3h;F&P zI%l)@8or^m&0g9PIV1i0^|2+RC`R@J`ZZjRqe`Yk7$Utrc@)oyD8a3k!C}Qvys9rAjxpkLl(L3k~~l76I{HS&Fs2P5+ANG?slddqKBq z#h?@iN~JpuvII@*s;8zNQz28{1=oD|;KM%%`XH-uskgdp^GwYanat6(WUTIzMhp6YTgY-w?`2#f@;hUUlnKW^zwB##ir-NSOS=ylGq#Z5J+>*rlsA@K? z>&mt6dWsEiTpH)-)LuwYwV?O~7hlH7u|YkzUEIqUVC%6+IukWO{H5c(Q$*~^`jeo( zHno;{(wY1;os2)E@4H9zPXii#NVnP{99%>HU>;XV%~SnS-`X^oexX1S%ttI8FY7U5 z&TVkZ{A#nvu#EeTYnLD(lSu6QB&m=Au88TxTjmT+Y&IgSVOvOU?XveR*q=2W3EqGF zxW39Yhl7BNl;8+nwi3SYtdqswo(GjibQiCjD>99Va%+@AbwrNq?k31HkD#E|C!69` zPE|9GJaaTBm%z_!g@*gu+$_A$Xdx+2mi_SNe2YlE(=d24WKw680zZuJh?gc6N#(9? zAa^#cx?=%@{og&`p-c8fWiI?jrZF%e$Pr<>YLb) zCE08S@weu2%m4n$&(~!71#IX_?#CHanu1#SvdXtuo@L`K<`eT$J-`~U9T}qMNuniK z_{bNTvKFnVhj`_Mvq`P0pl9QMFe|-$%P-W@$W8y!iB>W#D7kor1mpHK(5+_(iwOE9 zg>H4;k@J$LXRqSldneh4oR7NDmO*OLm+Ir=o{GxPx?U6Lc(*rav7Y7<_Gpk$XqqPR zX^l(SP0dbWvuhQhtc&EOhW3WfNz524Z6S{&m%yH_dtFI#!e$Lps|Q_%TH13^{QWR$ zoM>j0bW7Q5bNBmb7<*LyDA*-H3Ohb|wU+?{@peAgp%6RXcT-sU*FJQxLbnyXtO{(u zu$bvp%s6HohKyIAELM3Hks>|X`R-(=UT=sgT!k{}84OMhO14uG^!}8_5?`~;WbRLQRf9$;nR8!m5HXKAjREVGmNC^sx ziije;MMMNdK%_)KK&1(h-XRc*^bP_7LR5N}5_**m0@8a4AiX5iKtlYso^$U#=bn4| zd&hXc|Nq8vI5unU6~f+Y%{kYab3V@@xd}vsIcOG~5W>w-uX_mF<+a9D`nhPbKtc3y zc;z1F7+DKMj71~0?A_u7M-NvI8jdW|R4(}x=yGv2o6$O%?JaQHmHXV;!EeidD@SW` z^^EH3=J|=%3OEHz24y;Bjww8jEn!;Xyeqdx2|?x+0nt)YU_MgkdqrxA?8hf0&N9gJ zpPo?m`UyOwK9L3<{n>WCfcfovi^KT+ra2$t@T!_3R$N6+9BolgNvd@;FqpeuhyZ&s`%v}F@ zYN(Y?Tm4~!ld^14HR+2x<;C$fX%mfeBV$e7ifq#rzzIbQdx!)#@;CleN?!n&ANElz zC}y86YDXdC{Pn_v_nLe!J@2ymEhTMagJ}S4{=AoHCf+Rx?v*X%U!+#>fpf19am9*vw*2g*-?Aay7i^);c! z&a6v*Aj>;)(jvs2JmN8+?qt`mDSYZ&N)x`U-;fqWbJYK+F*LFNE676~IZXJNlZ3x( zW*d*jMr#KJVlG{KdGU#X~I2nl(-gy>QpbdWu4E5gfSDjm|Liet(+W$*GYJLQ8eL z_8N&%V1@1MK~m1eVX(h#T8WLj`HPUPu8iB(l%Gp_s=Vs;itLg{&*84U+F7%t?g*cV z-M*xB3&<~reQ<>DgcQXaNM7hk9PcD6D-i3IOrdIl+@8F*JxS5s{ov(6`!Wnr?JBp7ps25io~ZH5)A@|heCwD97Lw^V%cBtD zdtq=N)$~I~RNr?> zT7bVN>QBzppQs4+if;wpKMQ;SNl||;!R#j=_b_h)qV+8!>Kh#`T&ZYTsgQXclJn27 zN71WSuYS3JUK*UV>3WyU!R|Hr`Sabo+#LdWFV93q$H-Q>IEe4TAfj&6eQqLoA_J1A zMmn{0F5;$ax}u<+HM@f<__;ELub{*A7j>KLgKNsTKGmR9_6OgZh}vo?MVh45@A6Em zQTBPX5|xx^bmn5x8dFR(iccQ2a2y3^uqsbGBk0c||TYPBGWN);R6 z3fSJl?)dWzNR=WZ4oi&f?$gwe%J;Tn*RK^gbXeUa6pEeNkATlwo1?{uD89M1IX!zP z*3cz+0Su(3vYaH67E8)rQC^bIdxzk_ED(j>N}ITwGw;UGK>fS)YHcC+_LngLF2hr- zu{X~a_Vjqoy7?@m@f=GKP}H%wu8YH%Q9!}Z!?oN`tZsJBR3z58FXA;;?F7(2zN&v@ zQT?<|<1g|+sZ+x>0CLGSJ7(0j<;B&ip)HWB(h-#b0Xcr1i}Mdk0S5SE#;ikI!wh8rmcYvlj}|T3 z#p#?8qGO0=*h{i_VZSw#$lbY0lujR=l(&wgGc@aBwob#Y;$bx=g=0D<(Y@n9mX<#U zHK$nNhwxs3wQ}2C22s1p-3P~=W`k}vR)|rt-qa0+a~5hfa&|jCLDUU%9tehLqFfrAPlI^(4 z`p6}UP)|BCHW-Pp#d14F*28m#q$?iw^c7wSje8{eVV8T?mw3D^2ke=6gY6PlTrje= z;z7^H(fd?iA|VyXh7+!81HN_2jG?C;*_h>L$J0%onx!7zXbl~&nWm7;giBAQ1<3}8 zgQ=4@%=`F16!#u-GH70##F0bP1s1tx;H2XYXj`)MeC7IdR|6D( zyXa1F@2v7_Rvp3pmc<21&7II5wz-nFiD)5p(3y{(`tU`KwuNeS>-)(G`MJkq!_rstimuHW z9DYMX$%S@7y|l=+Q>J`gvK!$PBP95soqP3oSu7bBxku}&wm{)Gs2L8v_tDSjZ?$qx zk;#2ZPkHVAfKOf+^zi1D%SPt_zHKEC{VW?VemBMBW~(uVppvQdGNa6R6eKzH1;{f3 z--fq{>*3b#^%zHV)$b&!B~YnacNK$N^V>;`Y%d4H9BXDKqLRBVpnO;FW{A?IenGte z5%gn-*CnX(1gr4NGl8iWnJW}-EFQ@OAZkL_{&;6f0dVN-a`)4qpo3SBi#qvN5X-27 zA#Sv3Cpb3u#X4p3P9`Nuq&T{LrX+Zk`R3!{39$UC8klHf=Ir3*Cc1bQDCH0xBfnQ+ zgTBC9PANINfeMkW`pdF@XP|vk2r%#rDnN_DldR-5dM)*?M&}tOz1yqZvU5(0kD(!M zm!In%rI>g&SRTuyE&RyP^>~R4Bz8W=dZGWMKFL^E7Jf+W2WVL zt+eL#GZS)?PeYoO1EH7XDx1m2^4UqZE8%LuNy2C=^U95(MV#>$Du&lnF43Hj7Fe(; z3R0=<#Np~A#wvN0`0o5B3)s5BYwy@Q6I^q%Mvr;SgW__?SX@5{z#=+?8c5edSmFAM z;#2x~a(#C%qHjTQwQ1X#XHYB%JF|<6cE{oG4q9^_fQgou58yorX56w;fA0Bw9BY9| z3C-=Cz8Cioe+8ivRhQ)1l3~esp_ze%tj99?(_#j_<}BXY=|iunzJlQ5X?+nAa(VJt zi{>0LjnaVT2K(03F_B{>D*4w>kp`TUGdP{Yb(@Z|pR}fSVPtogY7tm@0_2decmK=b zrf+c^oxbZm<>;v=*E?Ch7Sefwfuq0T3IT;65117swKuk_?N|wA5|W2 zV={nfa8Z)>=tCh*lWfTqqp$!O(u|f&Xt&e>oDCXWEg|nvoOe3#ps6Sj^4@EIKpe@8 zaE@3v)4j|<2sSwbm7(0uEvf$sDw0{Tx$1VV=V=_BrBOkfXsAxMoJ9vb2m2MYO6$VX z4)L>nZS?XDQ+7c}(jc6Uc~ff{0VUkgZRTs9X1&Ptj*9|*H7R|2q``+cP}MFySky&l zVznfyIP!R;hB+oPaj8CCvgywYfV$VB=kEh%h!!}AG?xEZN$w!S#x03iI4))%)aJd%cF|nBNS4!de1SNDEqwJHqV9hD-qV`z8mflgKTQBe zD5U`&Un72g+Q@(E`AgV^Tr`7D_wdKNEB4orFWsu$Hy`VTxLtgnNZ}`At+lLTH_rNo z)4ciFJYIHr0W9!a19f>a5pFoM+0Y%v6>D@mJ;m-fICr(!9h_k$w*%=c%Ru00N3Q-m`@@KdV${l}F`O5=F*(enxW0Y!&W+aj(xuu0RLqCw$HrBNd4Nekw?JH(r{v`} zrqdAEW)lrNI$rU$5pJ&;-IA}J zvUY*}bw}dGK*x*kTG%NqRFZFzjkYvWDc_f%pr*tr7Fw)AIHb6r{#&ueK!p6nZ@x6eOE} zAA}^=?V5rHXz_+n4u>)GsK9JA+lI#|9|jYpv6Q1MgN1nTbadd1$BqF-yPEpgfOWA0 zSzi+JB#~^VSzv`kj!$`ypK^^QE9j?p5O|Z5P-}MysNn{jq7Dc3ahTn|tl4Q8z}V}z z5Ak@bUS(fe6Yd~mOvOCpoWGEj2-u~m!M`I7Fr9=DVNL+rrg5EqT0JW4svF#6t>Xu) zmYRe63TkwSsM$fB5k-jX9crE{Wm_485N2V&HO_dLX#L$!s41?{TT?W3N6vUCFKg}~ zSt`Hz2^OolgM>(}x8GO#fGet*msMN7T$=z#11mk9k|cbZgkGqo#UG@Zsx}%=i^=q+ zATE{rMgOp7rzd7%@A0xTI|&)e^eDeo2Bj$M`=#?*-`6`N&?Q_q5CaJvu}=}#aN{V_ z5rusWO!t2-4}>q-9=P$W$+&P@bLMAC zut4^_!r4~ltR(lgHtVAjNBNiRM1g!35HSAZcRN)Fq#Bpgvv1f8rC-0w5+^<-`-!@A!*wE%xv4@G=P}-4e3EUW& zzB@&nfL{W>1U<8R{ygb3ZE0l9G<777j3FsTKpUsyepz9qZUDge)t_H=H> zl&f{SVo%NsBNMaAJ;fd|{j2J?M(PP^TX`4pIXIXaR;ra20km(5%Rd8*EUO=DNfr$Qq?wO2q-cY{6Jbf;08>Mk1x*nfV@bLu*nNp z{9H=XSx6&li>4d7{;7s&T?)ZJN1j1`7Lx%O*7&}HaBWb`JEA6l;;_m35!m-ke6#oz%}4AZ+5wnfOqJ z-n0)rXP7HW-`dNioS=VmnS+nb5-xiSkDGRdH8|@gNce<(7$0vWFOa$PBpV~o6t?N5 zCk^}Dza{XKV~W2PvbprWtc%tWT+eppgq?ymWAkBrxm7aS%@;PMjT(j2@iXlS|s- z#t%lq-HzcbysjN-B*i)ze-V7RcB+i5>#$rbh{XOkgbJ9v5Vz}}?PVM+JUQ{xL zflVkycFp>G@bDQ_5I<|U&e+8~(^6($3Ip;HsZQ5XJKO5B`1u)XN&}b!Rn|x@MSEQ= zXeZ1DWk0Ulj)8$3L3$8xK`f+mjt58RNT3$&jYl;1yX z`hUrP-%f%4tI2<=Nca%2qkzco_fMh$gDas?pxh8j$xSbMkj_4Ju#Qb9=MG-7&S{Z+ zpFu~(X)BOqVMG0;5~i_1#U6V&ymX=Mt`spnIpd!}vERP9ed}-ph*dtB^GftH5IJXJ zA03GE4Ow3t7Q%{ug%8!$KW@}EdZShhqCu1+y5~ibF5^Grn;Vq|Hcq8#8ZoO3`?whc zNd&ZeWV*~V7POF)@E6Zs43EwUQ|d2GhHe}x=k=~WLr@&tIT!(7q|+FF3<5G^&Mk3GwNaH?@#4l&U;PC3w`f;#Kl})_z&5J+$6lO z@QSQG>};^Ps_Dkj_pGN9>f*$I-d3(_EntmC8AQ7n*@af^H;-snC{2_jHmVa|8r)bQ z+sS)lcFo9F)o1Q#cbca3`xi$PjM>e$x=i=h2Bx2*8O@&tpEZ0Xda+im*qQ>Ud(XS( z15-%<60Fw3!k0VdY12!;^~Fm^5@kNvdRC{%)aVgusaWJtbyz+;?Sn_227mbtuPe>F z()wZC13W<;X0)a1ngN~|XYxt@$QPFdLORszQJtFe`^2g{$ z+7Ix!y=(v16TW@7bdM)|r+81`;jq$ve%I@o<6{(>_ib7~cskI2DE`bRTsu?D9sikl z1cRbB-94KcntEKU!oB@+h?C$+rD?%4BNVcXEcT5y&JZ9g43ncfqt?AuXY63fWO$?N z;zz2nyB|kywak!*4CO|Y-&_2Zh55F!$cNPCBIa%6={O>CsN&p}yGKtX(>7b$JkZsW zMjA>ad@Pg_H)HY835()5O!4sOOsPmZFVDG}g2YaY=G#QUkXyMe_rg8NFCVrVV;NBP zsbt1{1yR@{d1%c8hJ>eV` zBIM*(XW!5`c8W-%BQbdtcw`;6>x@_0g}AZnCUW89Z#+Drt(7Rnjag7y<2fVazj`?S zrxOi+<*EG9&-w2aL1-qP8+=hI@J?rG-)ps`M6rP;*ZBzB>=Zc1$kA7)06XCAkhKIZ zo){N8DO$F0+9lFm5*<6uYTsV3ML&_3E;;IAJ9cYn{;kTI5@>(0iNuAY-why2*=6e$ z8zxk%QGN-g9GBT4CpyRBCmTrTt8sdM*U*7Gp9)Lb+==;b3F+0f$WT>1W<06^Ho=WM zGLY{!9Bse%020j)v11qlqEf26uNFDL!i-r655olvvsqRy#|9J?1TeKy*O^GW7gJI+MUq(nzEv)ROH zwE)Jx!d8wW>f{-mTl6fO^>7Q$UAp84O(}`;j91cG<+XU{8%qZ(0iarv2 zIEOXVvKm({RaWiWS{$4Y4L~w}1r?>t$RWW=03knsAYH4sp^Oj# z=w3&W2WPlf!DPr*3GDoVm)Td))}!2j@+%9#V*%DfsGCq?r!eAj+9!RuA8~YEx>fpP zGYUcHnm-ix_rx1tLB2?E9>OJC{PMYy-qjC-FyYRzEp^tRDZ+_U3*Z={7~a)oX8b8e zp1K-k=2KqQWIz8teXW^t=n3i;q6RZrzdXsd3_d1jwnca$(BFBpM1mf03?=Ii?~`vC zg=0~5S~BHLaV!iXR-1n5HsbzAA=dikH^VWlK)}Z94Mg<4mdbNl&97VMm zuFKPcNS((jxmvlv$-J7YZds7F#ZkJt#g2+c*i6NL1(Cy>l`AYnsVE5WsK-|`4vwyg zxgO=3n`FUX1h7d)aJ_4zot{$FBVS<0uOM%Wg-qV2+6nbw6GmzF8eu2iU5=Rhc;iB0 ze(Q5ED)%?f`9?#N{~T$n`No=eF9C5LauVbSE=Q8C!tJ{**&5@3cd( zuP5U2g}w_)N!EyXesN5Gd-y^UDwopvw+7}#7rAo4aB2Q@ZG)}@@0`v#U5N5;ws)|Q z>O;-JzvMvV`iUmfcM8yxcImouy7Gq4ti}^YKihHb#qGgmdjybY9mB8YH~@5{5eyNU zkKQ;K+i$VTlZ>h(u+4RP$DV8C#}lNobZ6${=3jNW=Ffv%tzDNFc~2ndv8mp0rkbL& z=ru{FT&MfHqimLxgIp88IZ)vdUU90*X!yMu-Emot;{stDn&3PZNWiQ@xiaTmMUi>$8~YJx9>?c?f*Qh9Mim#O%!LwNVa zUGV&9OSK`o_A%8d;aU49jvR|i+;cT-_=}sh)$F3K^?N%Tys>7M42SM?im<+BJG$>2 zu$R|dO;w5I^`k*ql3XhT=d>RmsSUpwB5OqHDVg}bDrt&0D7Ak}I~1&UPj^P?!N5xM zg}36s5_f+CP9hum+j5^Op#5l)=85p>=auI$Vyi|nG}zQ3eP}a>Wzu3~&{{pI_|me(Yi@qBaSClb&0-VP6H1_jrwr_>$5^Gfj+Q|+%$@HxU2kKMh= za!3#eh{XUQs_Gd`jn}m&*IO|;{FfO&SsooF?LUSLRO(Or))iq_gUZ)^?-!WhHmywO zZEiy=(=t>h#Y4(Cgn_yq2t{vwG2e1ED_?6`b4O!VLdQ|kMq-LAVncK`Xr@W>5`tNo zW~e%h-JXmgHY-E3Ko0OkfJCU_pJ7w|Ov3v@W={mr5KTPN>IwdCbV9X4PI_~D0a zUPgQbgvwFlD@Zd|`t_+@mB`&$u46U#!%;8dKH@_C&tYS{Ew*D{iFiQmn4oUAEwi>- znRZ%#a~ytSdPWVW?042gOQA!FWGOK|G)1-`3KAs?_-ms5o51#xyb_u;EF)NPY$?tk zRBC^ovFm+$(|VS%geCVv7bTGfOA0kSJ+i``Y07yBGvuc)8IZ(Wo%3e9HZMsWf)%UZ zmw2TL|B#!J9(LUK*}0(oD?#S_#WsV7%FU!PzMg1in-kTn1%9;k+FTL!xce~0bi{S6 zMw0o{nEGOsL&9)_jYn>m0~XO>AGTwCW}o=*_HFF4)Grbhz>PQb#E6P`DuzG?`oH`ZV#BDKR;5U3I^-X-*MJ>{A|Q(WWgjkl0Q zXquRBD)R_{?&Yp4kZ2tL(V-{iPEg0QPficOU69^{`d;c)fC;3Q_iWeA4vg5M!uz{M z`9|XDl=GpBotQCelRxy9e=m5K}S!vGj`Xt@R8dM+-bMd z*u}=IsmaA`Sl^) zBpN&fbHLVg8NC2g>+?H-Y2DC=j;oV+vy1_b=}@c#08#;7*twyYce^|_`Ia$_awHRJ zDG%qWEwV+wh4iYX#3N<%1I(Q1`vuOE3tJ;zckQYp1DA%o-sXm?;WejnH2U90-YP2L zL=#${D3+uFUvZOA0n3&7$85HSV=-dBdg=#)uE}@Ds_C#xIcq$(1 z84KTNeO|4QvE4QU4Us`$aLly~x`zho#@fvJ31PYeQ$c6QGfN2497D5gc!)6KF80Wv zJG!BSFFsgumH}PLam0NohxEB+M})GPvJ*mENoF_2W5x3+bw;`D$g26#x+kJp$Ra+8 z5UF*KB?zd}L}EpVjlMc6S+IL=;C?fwY#7tc1**d?r-qJggWYxc6L*+Hk4@g|VSY|r zzNjC;(Q+bo>#(PU|H=_(UtlsQyHGcKTcns!7rEI*-e{$rrMSO;NQ$jt=TOzhZ|x`B zm;c{8*PH8s)q+S$M^(dD@d64PPfOT0&w6aONV>aA48c$c9b6$^>|^}Z8=>qr+|Oaezt z?N1$I0$-_*`bKNQ(RX%#5I8yrDA6&-+8L1MTFuE+-_pM zQ?oX5x^C#)t)f$3#b(c3LWfO{wKYIRN&!0Z1njSgx)Z^8RzOd-T}BT9dQ$F4 zeg4TNSNgj`fF4}-(7WphopSKqa=DZ`_*6$#g`I)sAD-2V`P?I}OjE$&=meyD<$b)4 zx1Hi0_s3%Y@SX}2OX+(}At%J?(??$$Vpm_?3OPG09t{b2_NQ#;-sH4Jy?-TTMg#WV zuBiF|!v77Ttv*vyxKo5Oh(uBCfRD#cTaYbTiPKeeM%kgx8$~Yn|UHAI`H$(J^j`ZT^%knluwM6Xw`81+T#$nbDkcs^oILY%BL^;A(Reh=@B7 z8I!m^(LYH%gv;I(pEy`7XlL& z(1<8p{6o>uM(PKY)T|#u#wCj1jzQPo_iw{5J_MN0mbtq;nV7(wFXjL)9WR=tvNixEXHEnY)w30D$PF<^!mE=f8rcxzm8it^>B_;D|sdVGj_|0za)>96Y;<@rmBJ3?jYqzpFU zr-Fiu+x-gHR_oZ7&Q=aKpxDGAN&f5wPH6w8yQ78;n!EN>p?1`|@M+~xHgI=Cn5Oth z!wiR6!Sq!^g{5q{PaaC#WQJM!jLzP`1XE8DD&C%;e*W(EnAEXJowD7(Bh8vTLA;Q+ zG;!neHaE}3Ic;X0+f-l5xQhkugexGLL1AQ51_bqWA2+(eZ41T)=cwpN8=m0YcZWB| zqDIfYmrJSEcb5ZU`CK!1>!DQe{gNPCiF@txWzkK84?LaB@2v)_a6X*8QOgN(WRmRP z5pWIG)BjV!s{e;P_}@hy9AukB9GJ!~!Dki$K+S2r-LB2t)Gm_v+pnNpI5D%wwQ(QT zM>_cx6wZ75E9e6Pvd?2`sx|y;N9jNB=k~%UOk1qvu$$O-1y=N*^Ak_jp&~lF*?j@B zdEp1%7~H$z_P_&qIqS67Qwz?xq^jK;jNb&-8c(-c&tx!#Bw&>u?o=){p@B;UghNGo2-~? zihU#%W?+$!zkAva8s*BYZ%C1#eJuC92$5w|W>eTj3 z+CoO^?V-fobGVTkgPX#T`-4I=tO_gT&cjVs7n&!U4Zb53T2IncDobcx6!cIg|BShp-!!f93m zcjdR6@h}A)dei>VZ=u?s0<_3F?ZzysOt^m8SNjgqqLrm?`d8y&$zBK6uBLL(L9T)C zmnOT&Wm&?{Fj1r)sQtt^{4yZ^(;nr(15;$>&mhbJ9@Ct&|M}}>GC-F{u_X0>!!TD< zrpy>y|26mgiMXU8 zJn>?;xPUp=fSs5NKYJ9N&?o#dT9yY-uBkQeU!+W}?Z2I%G|_SN!kyqvNzql6b~n&~ zM%lF4sd|lRS7X(Z!rN3T9Eh%v3N`CVcY%+(2n1HADE=v_rvftJGe!o)whH1fypocR z*G3dSd3_fZ@?>bz__&f(ggN%^`(>7x-eEBoGCMMI z9CsM>l+HoQ7xY24gN6g`W9=5ch>w_l-*gVIKi93Q)-Uh?pj-ii7p<4H-gHpE5#Ho{ zl&DxHeAxT&3|Hg2#>SDHLLKD`Hm^@J~)&}j`|An%T*vT z2)RQSB%xRuB<{-nRKaKSE45dCzT`WlbI{n*sP7|F-MrIeIAsKJ2|{lKrJChT{%y zt*(y!IwjM3KqrnXxKa$m#MAq@&#h&UEJ(UFeD_F`+tM35R=8M0q9Attr9p|JjS7L| zF$F+9D?7%(M98%2v&&wma~!R&ri~aE=#X6rwq$G&kA+x1HeSnURvAde&Ij@ zh|K(>oS|wS$ob^xB^W@@^9*@!o`(d*3z`(mvt=Cm3hI*Q>B}RDHjtt^wTVdVi{2Lz z5)Y4j1tmskX8@V%{s-J;z}6+u7JT}nLARaUwVj|M(|avReedeYw&}<4$i{NYfTw)V z%aa*g?rI5KFi=@~fN|dsSVKUk$H^P7$MWkuJYJQ=b2g&j()K0GT2~n}jefHqJxM(t zq5<9mASBeSIEYE>sF3R&^EMP$=DkgtvZkDN8Ei)~NwOn9!g9ZY3>P=efug2!n#!lz zKi8D9c;FMaHzu2u{UF$=<(gq<#As2lM2m)M!^Rfx8YR0MSCwK05z5Ah=e?MpUKgxO znx>;4obx;{e|$w*6;IPIn1&@f>Q7b1H6>99xDfp0V0v*!{W*E_C6uSc)J9PCI83PL z2K;OgWB>ZvxpO*h&(Cv)RX1!y-B%xd1yLYpvlmc6((Klqs8Fmi>0YP*Hn8^Y$p4#c z8|`YQr~Rvb^B+Q8DcoMYzfjHAhgM;D^CHKvls0;_=2>);Q=Ji9ET-Ld}++INas?dv@Zl6vxe;43WK}61g{i@I5 zl2h!M^RBfBKI}Y^t*{`s)I2snO5cqT!$UJ1Gv&~%nwH?fGGRAqPf*-C8JuQpie>{JT(VfrL z+lhoWqfe|#AE~W)>N6+TZS&^RGf?Xe{SJeB&1@pxhExZb=>4m(AzfhRN4Q|R2o$5h z_BUVespD~y{JJl6h1mi~NollI?}h;$0IcOJh|YEu`2e?8mfn@Lbo{supX}vg%bc@_ z0I8;(|=4@~r{1nxQ-1g+6-ZL*pM*_!*Yc z8*I?wC71Rw%0!C4C`y__H-sV7do%>k8EGb2Lj4hG&`;!e*ek@D(g<)s`MsuwtL^;e zlsMj3^Ly^dV;iBKgLG0jnEaz5?^vVYTGE9LK>c3_WAro!2kf>J5M{Vg9aq(9^2Md* zm3;&5V?nqocYCO=I&w;2W4_tUZd=(8oR$SCTnx*;a&c*8Mv7MATYFgrOil65=M`k8HC!1H|TZimPaw5kEtYnd$wwcD-w2}8a z13UHG$zGpr`e?S}r;so0*(e7>vdl8a$L@bFx*C$1t`_D@10dN|o%z;&^hR-$BZnqo zef+^}^-8^Y*QRdDi?3Rc%bm>hemuou?Bb?AQ&V)LIxpSitb|WOnyyZ*QH0aT1Vz|6 z^;Gdm6A=i+u=KCz;^H)$ohn~V<&-PZ;X%&^nqm2%5fuaRYAA=h$L3~Vdb(Glj zT(jv4bliw7oircg>|Lf4$xpoSYA`{Z&Pa!uDAl>x6V@Cjd>&qx0vM`HW@wc;pL!jB z_Rbf*LmJ}P+tw!!fQD;sJ1dbsbfrkI!T%1nljbye~k!!`}lriN~BVW zv3_6V+1bGn-4mq|>$Uqw8a`=h@-N%lOUU2IRs7F44^TEjkC-NkeCDxT72Ft^Y(;fh zS(Q?rlOw-EBZ*sm1UXHl&vcx>h3+jHZHFT-A|)D|rdYh$PoxVIn$b@Xs#uMTnS?`w zO1&05ImB4vE(5c>^=Ws$w=?T({q;nCyi5*Wzd77gt52iL%> zNr=I~*j~(;5=L-FSRCp#GTHh$*VQ zKI0@b75>M%mfQ9>sw?v@AG}Re!#kPh&+9MU$bL;)YXw97=)XXVPPL)HJOkn@u6G3@ zA>+g6=5dEA({?K&xtZgjN*3O3$(N!i$)sy274QL*vYfhK_k~n{9 z4-y0Qc7m=_o&ZlB*EC>PV0#CNc6pOD>-LyLKMSSM>7A|)IEjky)F3b2&?ElwzF+tj ze}om28>-va8Hia`P^WcjY8%k@U^1)Nx%|TTjWInc&(v53yOWaXS2<${=cx@U9w(eG zzS(&*plc9)^F7|>VgDUns{(ZN)Lm`!g8*%&d8Xg?2{x32B+ui0n16KALdvNnNG`he&k$0koP}(AOG$xxOz|V?r~MK0LN@*HKf2_cpEZ0 z^tNg$GKd^pyQZu1v_xa>N_|>G^a9xor-lA@yFTd<_ZN#0t@b4(?HZ4R5vwF;$t^Gw zhYKWE8-k_P<3?By=&9mEt>6{c7jYNLL5{7=LkHGFz!D7D3LRdT)>b~IyL|0+-2P1a z-LIfjs~~XNC%p~&MM&XzY~a9;k5@wVC*3m+bOq z@a0e*W>Rd^bxG6>WDD%WAkeyH=%@6Gbbb5O$p*z4h54UdTvz#M9bQRP?QIt?+waG>5+B=p)5L>pO^b?Sv9omCE zIR5f5mX(HvvebfTtIj(-sqH8(m9Y@g+*a=Xn4Qag!O~Kq9y#+q!>x0Fv~HSO`HsD$ zdfy=onK-4im&Y12uz{if84J#1uHV$Le^dOs3epl_E|sK(yD{QswW87Vg`?V19MV_m z)+kiH$q$q7YKAKP0YzOl2sGe<&q3K9j#rJ!7#D;81gQ7 zbKmHXbpZ-Ck9)ZdBY7Fmt%mFLfTx+1L=TYelUxFWYekOTVtQb;8*2JD#iX-{^8>^i zGc9NyQ*PtpV$Zuik1mXzNIOPxlya?*Eg{PnZ-Ncf#x{qZ??b2OB#w+won?9wW6AgC z5+ggL{FAeNE(DYIk;kH*O+4`7!24ns_;b$ZhMqdLZI*AJxVtUiSRAS9{MG_4{VCh@ z$xS?^0wG`@&-P5G;c3_I9wh`z*FOzC8YhEKd&gM48#i@u!UEMR@W;BgzqmT-={}@8 zO{WB!jk|r@Q@)lZQcmuHyfAqL95Zh7fHW|;&8l$NHFrrK>tg_jG`=_<2m@1TRX7TuWc=knTWzcY$H9FP^?3j#*pHJ!_^GEG{G1}F2yJ0qgpbj zW-5*_ht9_lgg)*+?XJ9>yqFDgfy=!|I6O(RB5rE+=V%di~@~**1j~ug-!||az{)2fX^>2qp7sFXR z_)*m{OMHT%so;Ui&<13YQk82pD@D`feZN_%u%_|5{AT!xZ?DztL4#! z&ej??${!|G_d{%5LG*u3w4i(TAd#q$`66Dc)Jx8NTiQPr2=l6~LIMq(VebHlOc&g> zi~=*$Y3lRj{WKTjNqeeAZam?Oy55+);q`{{)K+wsAHN@1O*qbi@I|Q`Uo4yA!r)U) z?I=|5!b$2Rb(ibyS-9P)BwQ2>)ej;J<~zct2E7nM1w#6Jj!2W)GW^$uqK z4D)tc5rCwL9RC^p@K1m>O(KB^7BWXxrO);k6ZG^S>-hGTKaO%vEUILB&rw`(9HF|}F}MUuP# zK=6D8i7veWB7AM&{kfX99Ii3F6jx;oc#m$2mp}<5#=aj&P05M-w_na3gX;=FeJsBt zbW)Zj=H@+Gy8AQa(c&&v_<*@elWBWwQ`Bi}vi0MROLydN2GKmitu{|{b2Xf;>t2bF z>(_-@X6E#=cI|CvN}j=o8%~Q2742P}E3OJ-A=`Xc+d7}VIOZmxP!B!1LX>i%_Zm^O zaAFrGpO^NC>{971%^ZOSJn83BF!Gd3docx$RibbnG}DQ)=>FMM(&*z|-KvswSx%!m zd`Tx1pf-LBpqpozyf+cjO4#xggFpWiA@pHILSCF~EG`e}LJ_Yo@TGml=k(R)eODJ) zr`BAaWJUI4Qz6Q^sA~1DqgAh5k05NOktfF;(;8rLRhatDJ+;m|&xO??QlayD&}D!G zU?9f|DYBPh&LDnehkSv1(Cw_FF@fVQsk`jHu5S91qhC0dC};XeY*AZ~I*TL7j}n-! z)xehGCD8~UGT$5Z{jecaB@%pZThG^xmDJWFIcfR2q7vjTdl~W+zfG*-F3WrH1I5^t z#H5r*raP&l56}VA9K>s7&7~4jyY#9Ldav4P>suhm~2mPnZ zSDddeZf#}f(Krg-$2Rtl?XW!+VuVzR+(;*#biGORHpC-8idy)rnWq+PQkB*oU^*Ki zAHk`}uuNxNUz6kx{%AsL4EdbMh{O?Fff}vOS!gZzVb;9s}>QHEUZPSO>GyfXP> ztI0Et7|rsB&+g9NP7rTm-J7DBh1`cF5Y_MziIlw&Jq@zg3T=}cf?K>ror1(RYgt<) zUjrzP8Mq7L;Is=Vejz$Wi}L==;m2$@86D=`#ll=~=m|*E)XZ3%j0$?Z6qnN4%DJY$ zCXZ2b1G&ID9@OXIM;k8aGl-^USX;}By(UCBszcn_`Zv|CFOvjuRF4`vGcq5)iBOu8 zoK2*couWiL+s6|`mrvC~9u8!$a*FR+-Rad|vQC2DA51f;Da_3mC)?&R?d*~6iaD() zD4BNU=2pkA4jHiUt0s4hku7#f5PdH2Jj|f^=w+emlUO(R`H@0|43@c}T%vGnu~#bV zj@LzDDfud_uh$l(WPkiLulvM>?$yM3r8sIWPNo|lk14Ld6ookq{?zC zet1(mrm-U^`DILg3+c?3dD55x+ux8vau8y9LwM9}bpO^okA-C!S@nj{?VL3l8CSq( zc580fr_aqx6M?&Uw@~kfm(yEVS_7HBG|M}ZT%U97Tt(Wo$FAM7s0{v`<>D0%TjRl0 z6i1Ita{>X+W=?ay?Bpk&5=XOk&tS(#70j&Y6b`rOM+h-#0B4A7FVzWwj^?W=#ijli zJPmHNG6!W{W@Hb&%{{B^FG(3+OS@kOh`X}~F3no~_zW5^1E1m(Jcsxa-ta66c zTCiEDVyN%x#X88RRj?&x$r6Wyem0UI{Z@}*ioH4=o9y= zPRrP-U4z$Giz5CHd*1=o)Yh#V1OX8URXRaHQ6iuSqLf5LDI%gEMOsuuN(4lD4M^`z zKtU-2A~k~a5;_Pdy$DhR(n~@OA;h;m?H#&}~f7(09Iwd-1Qt~KZU zzNxq;B{sz;{!l~I_l;`cYTC>d0I6C^V{gKT@56$J(`;!M?C)9L;=6Pi?g$o?$X@h( zE0?$d5AdQ&YULN!zfYfNTmYo3vs>T3h^qcXqSmzf=at0S@o^q?i~M}7YHIKS6>fS_ zfXJ4yj_$v^9|s>%BEv}vfKbjNTbj`9siIl|d~5B})32b9&^jQx01Sva+|K^vl-*3% z&cNx9>W#@v{Zbky6UULejU7(;0hbSl=gw=Q@Aeg_yqNcr@2|cv#h`S#_j&$o?F;!b zt55eYmXBckh}(R!Gk z_2JIVrIv5Tt|ywLoET$^X)#e#d2s9fu4fz9O0?lP9pOv?q4c9PPj;Vr-xr=&G5Q^C zCzjivLnJDM6pEm^{U~!T-QlEbcoqOauVQaqsQ(pI%{jd;J+KIW7nb|*<7=1T`!5)U zDoQ`)p~mU$cDWa~Aj2&>r4Rb#FBe^>VIKYbP#3;NeV!EV%C{0xF^Oh&J)1{#%Ch<# z7yVWx9m<$Wj9~a@Ri0;XxmW>wOBinap~k%r6pwOFAJgu=0!ibGOclgDBk16nT&9&> zY|kApd;luf;bh5P5RB}OXzgZ3T=Nhm1j*Z_%gZFO>c0aSiH04zwHd84uVOk+3*?>! z%Bv7)8|<9NMRHv)e2TyCK})75WbLKq=>`|LvdzU!E_pi>HT*j)%{Dba#!9=LbWR#N z56rU{T?1I_iDw_vq_$0mtZRm+Fu~tSMG{nshYPb2DtmLKO&g3CcMjLXz2}bCC{4GLV%1PftB_e_KTICg zCY3r*o;lK@9wW5U3G*8#kDp*#yMP z#K(Njt-T`duLv6j6o&DBz@vT9Rn{ub*B;LiG!CPU1VUqMgCd2t;o zj&8LhBTsmP#hGZkiFqE8O>vF1*f)yt4J-nDt5&p+h08ArDJ>SR!&#GG+^aeMtzZQ3BBXHc+I_E&UqNY!1mC8V zbt$W_pshU_asUzwWx1THKaO>d%eimmn3aEL|)Mo*JfsH)&w zKbA4$_5+uEI#?b*f-dIs==6GU;JTDj^r}L7Y4eU!mFYe9j!J#p^x_2_F;{uOA>|#2Dz^9ulvYt}U^G?u1aF~;$bsr5gZ*@&+Xf2YOX9w(A6>;q0RSTqrXGTp9jvu@ zKd2k2)E%0-_s&GU42}c788)}G1U(`t9hcs{DL4;X9*SA%B2l0SIq!@2Uv14K$W)3a zNukF4+PFw8@9lFT_;WE*u3+DG=unK&_!d}iLab$kK&Nco#}e~f3LejBZcLp0ZdU0QCvqbGU+{HivzK-b|( z_dE|9SRfxJlufO1w#VO1(dmPEw1Ha{&ffz7-AtIuYlQvB~Bsr})s;<@flPXM?Usu=$d5MNL@Y7@Z z)%`2)pB|BLdhT<0_c0I|=izB;21`fTnpy>@hX(7Oh(fWRse?R6N9H}u>bG54w!YD3 zXD8as0>(Z#Pq`tD-wJ<94BxK_&*2gmKc@dmk#wyUvAAT&{A8M5o7Koi;rQf4ZK!S9$pb=HOv@iHyO{IW znR%{zLg(p-2Qc0RwyhX0AjL;jePTeApIB26KeYl?h_krn9o2f69}ssu0SNU58MmeZPP((A`E zTQa8*%#DwP+^tnK%Nf4B&tP|iI|gRmlk-Ig8W>rbu;Y1U4#<=O3B|m}jY1Ulw0HE~ zoP^5%qUmiHIjp$PG?X)WaP@>l2zk3j@4#gn0?iuOj>r#PlA!Up(k*Xh$~rREd=QTq z|I|LI8a@HqpIU`0HG7&(t_4-ngyr3HH!M%ZK=(d#869G-nuJs#bKykS{N-kM|y25?-geNl2Vu+mhoG9Vl=-+~Kaukr(@( zSp|!ng@*zNmNfk9%!2{(9~?pjZyWn)%Lj%N6hOT68*N+D|M>x#1j@RvSO{AsHcvjsV`%Aqk*k@f7LL+ zYIcr#TBbU}BiXU@3D>FM-9CqzUO-$N>XzPQ_^cUj8_I+V`|B;S1iTzd(OfIox+tRk}KK;-T<_{5BCWP-IvOL|t_pt);S;p)DK8wwzWoF#vvvIj_%Gnz) z13cv$0ljqsAKq4tFRgl{278buM^AJOgk*Z$oaTvjowjzGjPdw*$%$)ogAsm}m^7vF ztdMXwwFw?F3UFU~zJrrLBD6hDzB>Y^m*Nb>8$L&^m70GA4d*V}`k%YkIu+o{M26Z+ z>~DYg3fhx)lKwPg3WNhZ^KdKXfHNd&500##RG9|W6vIm&U?i~M&eI4{Uh;d!nb4R&x7hA18x!+bw$bNMW zOIaPA;@R_-?1E+^z#m&4%I?i6u5ZJPx@kklA&bSfZrf1am7 z|IwrWKt=uMTIR1`+dq8pAE~HsN(gu@DfrIJ{n$y3$D6R$h;~IDH#u=&Ahre-pju@U zwl#gEJG%Gy zY#q1~Gukr5X+&N=J=W@V7Qr`KBbb%1Pb(u@U<9N$(mfP*d1 zC^5-vc&Jx_cW!ytCg~Nr_-+T+#OOvgj$FIZ1ZG9BtTyfs2uREhw8^xr@k^2K4BQ0* z2b1shiq+=KZ560tWL)rB8`QaUXwt@!XzP7Fc>ZGzd{t{W{F$`A4r=aMaj5NL#Xd3{ zx3dC%(!e_$aYod{wR}ey|9;vQr@1~!DYM>=;{4g$UxaTi702)_ z#1&*UP87q^>6d`q1?A!bK!yVOj1UE<7$r~1lGVf`wXa-ae=Hb`De7tC>x%EmrVEqIBEg9RNw~Foj&c6} zHMF$qG>aee#hZ=PH1T&Ax*1)8)Wjg1*{V;r$=Kq})Tk372O>C`T<P5 zk7Qx%$Vn126Im5gjal~H`O?~6dxZwBy<(z+muWhVU2#x%-tVW9pFy#1BkF)gx-{O^ z=RK6LCz^Uzi%Of`&83kS$s(K76%zh12ADYB0bvp9^xQ1CAedKXN1IHgGQ<70nt2My zu(IMP-#=z<9W2tNG+!IMPl5KDKMh?1fjD{TcEq24H&%34Py_J6d?1HN4iI$@`2KGJ zUZ`vx(ab*%m+xBr>%cOSXcp7mZfrz6D1Ks`a5-Zm=Vf75nnI`p@j-b?aAM|{$Uv_y zBz={5uv(VR?oEY5%Z6Ef(p@f?b?oP>>uKTJADr3*ctwd`@M$2Q*7}kW|FN>7UYpy3 z(Pc(L3_Z(yYWy`mlQR)WZydv5vHX>T$qA3z*upCv?p7-JW(y6Kx?B*fh@}7c24&TH z@I~g$i2K^@D|~9~YXhq#3qL)}|BOfS4KmtDBXyD4fPS>5IFzYNSM*|zY`-(Bg)`nD zY*e8-loK$=WFN>~Jaj72vHj9n=;eAE%z5++TPZO^P2-_Nvzf#D3rEc$$!8ESXH~Vu7GFi?Fgq4L6%un&IM5)xsx*;wl(Pl)=b1C?@hAc&lwIpY|Id zGsT%)jH>#cLARg%pyI!N+&|g#T~7L6-Io9wv*-I!@tZO24>{?7@n2rKdF$3+bgpmL zXa7DY{crBe_{?mJKe^s-7yjS65sg{${0)*R`cgZ`;orRoq0>62nn2WQ3fWvwvL6V5 zB-K__Kd`Hx0a3(gS`pAKu%ijhFtL6|SFRAvlk33vrC0KU?7W9WAhETaga8B^q3q_s z%!8BiS#8>+GmK2A2>~E8YY4#c#pR)m9aGVZewMMGa!eD~bY2lKmHQB8F;4+f%{>&o zi{#+KE69j!7}Cz}DCD#**X3;xbM&Hy=ShH#bDPYGGt2M03@>)%9K>QT!S3Wq1}}qz zg!&VS+EZZP71Ei>4#U?$D2v52`OQs!9`*WWte-&2D%sNW--;9vGrP2R(d9aW+^u(b z_7|6=F~^~)>7aIMB~N{G`089X`X$N&e5gLlD&9-*U668FQ?mox9j=S-ZFA}8_D8p* zH_$5-Q|F~tw7Qyf?Pv!H&kCM|QJ&yp*t+}TE2t{@b>@DuypphNY39@d?=$nrl^ai7 z^o*dUi?l#6mndR*x=B(g*UE%Hx-GzkJU}br@7PcZOO4#a{-_;v-hg-n<6nSmH3664 z(E;YYa}C$wuE-0J#Y{eMH!$TMV*lu}RKJap#(f|f5!71O#LR{EZ>6UZ`2#-@u@z`O z7uZk>hATxq<?L}Qyz&x5BeO(a}uQ-pK zIhod9Esd7aI&^9adI%sJx%oazAhJVXQ+l1Pd(nh@DDfm!yjz?f;N&_nqaCI4CCZJP zC_XnW9pWJ#iU@1oe|OG0zHhG#d&xnq~#0MCczGZ36BQ6ng zsxo5$7aYs&PW3Yv9+)ol$1Wu9PHVm$kiU&RzalWO_hH?=TKNrAYD@6ADam^o#J&X(L|30Qo19?yym0Q$8AP&cp|4cn+8Odi zClDR+D+nOvD#F9&&q)g+79m94grM3#epOg!JS;8N$SO* z_A}rB(6(`6s~t5Pw*e^5qX4Lq%nwAUX@3Pt6^Kkh{O;jx!(T62gU zv0;jUP#sj-629*Y8X8PJ2m*n4LC~ce2fRTbM&QAK5Izuy21EyBAm0Getg!|f;q%ma#|f&BIVwzhUh(oXk1kl$hHI9>Y;*PiFYS+- zQWGq(G(ehh2GM2MC$p!9M)Z@MqbnDPEIdGndOe2Q#fNkO4`dSrmvWgM8KOK-EhBf` z%P-(tAUg0;lLb(W9v6EH8dm~tUn!~UqzLcqOG!IgJ1K~1Mi(NN4e9}M%sdj`RPIZY z4f-3_0lbqRkM8BbpKpSa2Yja??6(PWje4>*vz)1)=`VcyGPh7?=P49&X# zlypk4$%XY1rDI#9*J`suP!?xfvzy*D-HZe4@z3w(k*?yq;(NIy&|f4q&v5C-R=JCY zfneTF=z>j!BOQ&EVy|PfTEBcY6u83Il?&0juC^n+H6HkC*v0uuajye`RE4}xn_jVH zx~SF$o5fUhZyHK4&X*=$Pk|&@KlEX9hUIyxT@V=^I*6Ypt7X(~?SMC=>pffm^r5B1 zzGoxp<0Aw=d?r!-D+mGT<+CPYzekh)=oi9JZ*X9%1kii`_V4e2L4Hws=pcC@!H|$L z8n}mdsQCv!cAhOwe8)unm)^7aT)NzY8IH5dkUc|F)pyHlww^aP|DGI$Jh zMC9$f+TwN4GIY2Yh%n+VEY;4_u+KJ%-kADu)0g}nk+cDib3f;cqiobY*X|fx;0TR@ zd0YrNjT%0@;bp##e$ed&aCsA;y@aa>gkC?j2sQXOq4N7$LN=679RSAT@UNEJMGrtg7FNBbh^K z)Q)KSgu#;sXOE>y7Vi=6+d3(;I0&MC?3#SG4)tapMLCWMCtScE(B!a)u_QiC+CqXT zFUWUsO~U&f;67^zWfCvJMAO;zhD~7!I;13#r>dYkVu;&p6ZbkVm)~ z<6xQDqnR}shbzWvFVZ}A16`0-(H}e|#V6{iu3e!H_%`gTyu2A_HbIZAA`0{LEo5&I zD)B^$<=rc15;dYw3@D*NqGUYecGH`1`vfPkY?^N1b-;DXxBll;%#BeG!uH4>BNjcr2F@`#)Uy)QzV!L1@f)LIH> zqH47~8Qc(cU4bzwf-bc>e&}}P6xN9A%Jdm-rboRph}=6N-^w>pgFZ#rJvCS7RO*DU zjxn}ke%+*{4vHA1SUu=!-r8mkqbzw>7CsZRbR+znV2nPM(>HV_0VPZ7_I7r!tZp<= zUyCuQd;`%s^CyS1xwvb+?R5;Yl@=2e(;bItBf(a>+}8^kW-~Lc zS~!B zz+A(-26y+wKG4d1dViqU>U{h3lbRw~yQs4WJr@ovqtCP)9C{6IR^dav#|6?2SK%^x zq*tnPU6LBPxORY~*e!2v{>3tIx$LySgsA{s&zosz1l{)gg_esSo!CF=-TekA5uj*0 z9u<`ubCEJe-rnej;q-H0C=?5qa$nt^wmpsG5dQARnvQBC}xWIW6ZH zu8t_Oh|Ag3Z-81~pLV%xB4cUhh&unIa|HQ3=zRodN7)RtW#v=>dXDM#XAS!^T+EGJ zP9%SqvCOyu685m1Wx)d>!Skl#6H&Q(mDKNEH_uKi$ZP}5bYAY}io4OeXa@#!jnI#^ zy|yc+WYTu0?}lK$$vk&w5=Rm$V`8Lre|P02&FmEm7r7g_@ud6=^6}mRX&%KeVJ&|; z&#U;_G9K@x7lVPmC18ey$`MVhwdnNCV$OyuCvIf*qj~o1${8y@{ zFeca=_LQt}^VHB`xgL5m=QN$$)rUMn>lquwSv&Rx{tldKuhlgzJagsWrbBKUdZLCUQ&{t5(r`B0Jgqhy3&bH3) zra~sS@$0v{yjLEsOuGtK_6unQWyDkPl~az=t#?Jnbb8Pr&24$wjt!=9KfEIRmUg9% ze^M{r!z12)QqEA$Wn4|XgtqVA$z$FsHlUpY7>9D)V2!1XjkuJ?RnCiTG3t6cl#9yH zIrT^e~&3joXILm~0E94qEiv#kC%Ezwa1+F;%*!#Y-^*Je0`o$!m!mF)3@BhyBgc_96le;9kwaBr=o6QaOq8!7nY5eK9y^SeJ+JN zz2C-*U&HkECu5TiM|&1o!%MyFSLAk>QYXzoUFGPcVgxmEWVV(%)HbV&y}v?ag}L~i zG~ex_^OPjej1NM_0z*Gk^3jXo$b@DxH2bmUh>%5-mF&Cwk7x)KZ3i$mJsw z-3)J(3j~YkcMpsH&#K>h$l;rZd`N2Sy;Y?tXAZf7{12v*t6uYHxnNvpe48^({!yyvAb)BgxKj62)@Gpy5 znEC*V)uRy>#wI7(WMy9jP~B%n+-a0@W@?oZN3(_S@m*IsAW4gUdpA)o$TX1yNW#t- zk#*FEi%NT8llYr4v%J>PEABT;r&e!o&%a+R{wy}xO^D>KYwu##$*YIe_3;?X8Rl0r z-jc08ZIt+&ouO?vvlj^oJC6(uTEjOq1;ROmDdOcBRUzSenA&%Jr)H{atDf`@%G)No zQdv|8&=*cVzDPofgSlOF7qL)x6w7>{Ce$zD{2KOwlL!dJBOKcT{ZDEimq8x`+J$hP z1OdWHOacMJ4`(eQ2hcH7ayZmJgByfQfA3q2Ai&Gyw+4iiZc5Li2xowpp^$VkYb^~B zk}{MAn8{is$fA*dJPZ8$bG-RqdWviTe3rjWfnZq~UOZfCyzs$F{`@0Fts}RxGX*mnTTbGP4 zZ6Cg`KworlY_rQC`;AqlR~%EqjhZLJV5L(&&YounbF8=vQZg?e>zBAws?^;fU_5bc zD^H3LJSCIV&iz5L=9&%11~jBmGbowWwK^@YiKoA13ME z^m#LQP(i@p`Ur8%Moe6=+`m$dH9(sX@^22y&ap}iIg#TQkejt|I@s~>C$Xqa$#UZf zO+-WXB5-#Z4Zqx7`;@b%0*Wr{+hfGi{_+@5|FO+267&c>$b>E47GUx5HRrnTh}fGC z^C}62G)d5@%K+RzitoaTWYPPZ%5a0`NGyl{v7~n62Li(_xB2wQL?K8%fCxKnTo?OU zgSWf9y^V)jm&k0)Q1gM~k??k(ij=ryk#c<;#!pYl*8U)Xl`HP~csMLC`mLF58oQXf z*6)TX`%4Mp5P<#q1!wzfVpGZI*S=q1{x;_SbtAcN-x3II{SJ2f3&>UywbixtT9aHs zF5y$T`Mb;hZX)#~k@1V*_z7g2H@rVf)JcL@Ph9;8W2XZ;+OQSYu@hR~2h4HDx^E&lS-c?fo755ZnB zdH1bZ%X_A;Ahy6PLdspEiHK@FFkqi{%z+K2@EaGK10i4zo;1RHl(+eh4+-JOfeK4^ zI>MvU$RY~x)_LgM6B~&&HM!Y}^4P`BWz_TIm`e|;1{?)H+^?vvN)oA36N2=|AnVnV ziMZHGWbh0z;Q{)EG@bUJB{+eGGs;%I!$k-92d(cX!YQFo+8ba*&|QAb${9 z0e5#6AfKe20qQop+;(i~=9vlZmqUhpsWE`^i7y@WC(Ih$PadoJ65fQ6nSpBP(wM7UFb7YS{=(A@w2?3dJK_b}pS9jv68 zq+Z#77dQN*WkfH)H1v6td57Ysow=dc6k7$T=04-rj9n+ZoXXLrA_+OYK0ILm_B@gc z4;4%AUAGtZOs<=2`l>3_VkT?hl7dPpu8`*EN zE>+#!9R{bnT1O6IPNGAQ*u*XUS_|-zM!L)K2Ip_xNZ(;`fNb~H=t_)GHot9%J{BLr z&URwI=_Sp6FB z5r7{aMcSSJ3fjSHk}s%`q(p$J(Oj1bkei$Z^;1%KdBj%`%niOzi2VwR&{LQOhq$eU zZw76C)cUNcYWm`OzAbC64Mjq>X$$Aje^A?pVf=81ko$^BmA*G^=fm}r6EqJ_d+7Ag z3R7F&*qaq$Tl0O#2@{?7W1*CKG$o5ObxDd;OrL7 zZpK!)28ju$P#Qe-iKKKP!dgiyOj0uH^6BJDzKeFTo0NrJeJCngtJ z-K_uz;XZT}2^8SvrRN)DZu`C&QI(AStj0^-sDwMF@dLVC`GlZ%)aKTUU2Oh~UMG)wTc zO`}+utv>F@SzOZ%4zt~giqvi8_h#HhKPIS6GEc5Ch9-UT9+Y@0zq`b;1z5}(vnGZP z)O1XVc&qqU%Zl6HqtwUT*qF;xA221!rl5@Ib|n0gDfk(2^A$Bg4EJ`Gx{?bebRuz! zp8JoWJwKHXnE%4(Rd@Ujxc6O!;qMaMR{!abZ>er`m#qFw-ic1m|MFK{yJV0H(6Hou z+jxHM^&iF4|Bb-=ZxWGx7QqS=yG^)sQtG2vdgT!39rUfzF6S-VDAO;r4dU;cc0W~eO8zlsNulNo5IZSXR!k*euA;rdPn5)?E>hw)F1AkbT<)A_%PBK zuUl7WwNeQcV7>Mf8F*QvHV=Ya1T7!*_y;wfaDWFfF2yI$tM8H4oWV;wsY#E*$kpTS zZpm4j=q!MfO7a~}I&#E@&S*)y;P?x0{F(ixE?ez>a@;21`PU54^`b7^)2LT}Y310| z=d<1dFMqzW=$6u3MO<5|&2StI!=$rCR7EHB--{l4EJ+O0t8Zd@q|D&K3yh3AfJ^V& z4^L@;ofP-U<=9qCj*a8Vq`6i>sbiPEf+iHZunN!xw6_T)ps`*eFHYM&``QHT0&|)u z2bsu-VqQRK0OX{kbNq)q@8=}Fy!v1l|33WCjoO`VdqU*Zt&nd8pnOf3-u7V!K$X}* z9Z-2+)(u2OcxNw=k0x+q3w?~RpLzu~SzZ!%QCw=FpJUb3zBqDkK8>`GZ1aL!Fe3=! zVrDlEhs!!1+GN>9 znf8AA{%k9%gMB?K((9;IvRr?4N6ei*>^pp*pw;V+z6Z+4oX^J0P(btB0_-mjAyKO3B{FW-E?7u${E=tEoMvZg4P z#Heer=jkk~6-v^>cp{bW4lB^$J!Q9l)UYQcCxrc$=$ksw9SVf9XwC_p8#(D93h#rS zoH=jObS~wDfv7=j#l^+Hj&SxbC^jUH7flc>YWrL~ONA(j9%rjn%f=71m$U|(Q zge+W6V-vS=Cpvv36H{{FIbBmZ$Hm9Dd`Mn_6_b0eh-SFIF26wUs-q|WfY{a>w)eWn z>MAK?GQiWD3SBgx=NLHjYjEUu$ee}sXRG-yWcgeBAvcs2`2#SIdK^P1z)R;U3sO!- zEDkrOEqf|%0hXzGS%BZe5AGns|_T~;FxO@R&HD8$_J05JBWB5d{ z%ICO_!mZOZG@}ma5(i@~KHJNM17h{ezyew{Ifs+dcU4v|hU9^NLA3S^Y&?%X0$=x26BQk>0SbUMN}_sx6;qbe^G z*b89scArv++}7y|mREQf-)EQ|vpRUx&wIoX6ut`or4pJ6T=%t&F&mGdSZ797c1VARP0Uk zaC0pQ{B-zR99~G2d1nXvvayn~=6Gw)oDiPxqbs5@h1Hm88M;(Gs0E0w(yiIjBt6xt4_k9?<^&lv-gr_}XI1 z0s=-l9oR*9o+^^rjoO8OMC`Qrt-yF0p<{65(*Yk&Ukcl2% zb4n*LNUG{3LZw9A)9Rokd+;N1@0n~$!amr(etW$(1Vxu8ub4TyNL0u%T)J^GDo@?V zf##Shq;=js8C(`e(kAG9OZhOT*R!HEVc>Jk|DMs|)C-~)$#A7noaaB2Ie#vwR*X4r z1se98a#VkGS?`f>dsa>WXmT$iZo42fM=5_kUN*B_5L(V+rahnpdgR%9bx-fgz|p}? zbv~_8X7cSuWigRf@x*?*`%soiV~RE{ z8a$DI&Ua-aAT-Z}fVy2W;IMnmS+|o9Y`O@3BP0;1gg9?e*}N9Gm1L}^`LxyX;Z*lF zES2~~l6F)22aW!_qIaZHJe#rXmHuMa!GB^dRd24eZL5d^L<)zEo1NK5e^t6{ zKapYPhVJMs=y9x~d*kDOoZY8D2)pG!n}w^o{qAjX^5UYV$oMd?k95~&p9259Wz#&Sq`A>sJds-))1iyN@*yM3?1Z1Oleqo(Am)Io|`TIGOC`- z`Jo2a`I~K%tOUKzWO|%lNWQ$|)KU`QeP*gZl4&g*qh>0Yb0SVnIIa$4pSasspG=3> z$%?2}um`-U_c#Un^D|=9PTkkJ!jdfxF{hf}1JnIt$--MIi%ZIY^%qyfSCxHOXejctKUIL81_ z4=`8z{t_xA0h7}J|A(F-5GZ{JMM#8C9l!_f)BSpn0O7-5+=6t)WYX2e{b z1YP)O^LJnMuZj&&Z_tDGx^ z)c*3hX^g8z^X(#vV!UF4i|`swH*f90e!uc5U>228w$)yiO{sH63v_$P# z;la0(w-;CZu6{~fy;((5FkqtKMh}A1Z#zS%rKYW}l;%2=aZY9G+!vWYjWSqXh0$BK z^oLsOF4&xDyqfb~vm0>U4v%_p_JwC38OiS*H4TWfH4vFFx?i-H@qM=n{0G$qASH@6Wtt zZQ$9l&$4{<9a*;8dKptOy-`&_{h6ezjBoo10G390y zjorEu7u-v!8zt%Klh?&YcmkoHKf5RiT7{{aimbhN1J7!{mBx-7_s{oG9-OPJs65K? zyx>09q2!R<{qvN&gwo(NB!ao5Vzs~~=*leeIrSy;S2h#Amb3k##=2jAeZwG? zIph4U`f&M?Xk^Z4e#?1Fo!f_qAX?H=NN4bubeW7^*ciy5fvv|G>!4bwl?2Jdjih?NwSHvN{NT#w#zG z>R{LNG|cxqCc*ztDElhpe~?i2{JeqXg*`YKHZiSBZU$tfJRrcQjg~xwadKx&U)_(5 zB`3&y1##TWIc3F6&F(@uk{v}+HxIQL>}7y;^2pst77c6;w;HI~vt32ao@vZ*f zG~=Ib==phE#!GCkR^Rd2Fne&#ZW6ab(%7eYyMvC0Nf5foEGg_I`FT~vW9Ofx)nir2 zGNhJom8|%+AXMpABNaGF?viOFO@J-dc3vT{21$bAhDO#>j4G}*+BjXL-RpIRd+%$O zIKU5haBc5vX|j$tC%KXSyurcA~rDnOkI|+#+P@ zr-k*7PC}TFEBPY}x;xbFx^Q{>FMbw3RXVk?`%k^p)|T}y?{#eE3>f78S-1GB{p`Y!rPw7cMREnKnD7#W>Da)K zPHCav?Ni6$Md=03Yn{$#Q4V@=oG7J{Pc2W|1~=v0$I%%(@phVm zEwnd2q((`qwZck%*!15M;j{hvyzE#M8;~%~w;p!JT1ewv-?6eI_>Rii3ta2NU80kw zkyr8X5D2G-;$#YEY4q#ig_zHwE?>s%dBb)e&c!`C)0*j$(hLrR3E(ut3|0FcZnjxB zS3h2@h*0(@wQn!yobFA+bxiB#W7jyFUm?#`Ixvr3nx!rY9|#MPxfAciIl_Z)mYGUu z$v12sKNEU+(Ar^MsNDYp1Cl3~i_NC~)bg2PnduPQMu~8Pve0VNBf)ti3*9Pqho5l| z%IHd-7<+R2lc|MmEBnd-P<|5ICOmkdX(#j)f@^d>QTp{u`E!M-ajT|Iwx`3J4ir#> zL}eX6y4W^FhL6Ty#(W?j_u5OTFqATYFy;&HNo~mVm$ykxu@h>}r z(+w>98j;+GOn{HRK|6X;bn?!D^em$xMWEN|0=>@KSo&M9OZ=|aIY4M($B+=F;{$y^ zb=bV`I_wXdy2X7fzkQ>hH`o)f##gO*8Y(f_HigC8y4ps{MF(yb9lgUyd;a}aUMhio>f$oh?S0F$&5Y>dZgH*l5a*x&`MIq6`*qr^Q;x(o(?hRdB>d!(x-gF zD5-$#fU$cR4OQD?+Z^(*cWDGr6}vVXDldNaJwZA9_{;|Xz?T#{j5u=q0{(ubZkGA$ z#sdcOQ~BwR*7Z**HZE}PMp~_R`6D=_*LVp<#!&5deRqAt_#X}SRF+P*gLYqpd9;?e zD|{=zdm@uV;FdKOHM}^SA&C#VY@K)b0QRJOmqh3K#!JFjwGB)IEI^fyqt{#*cbomC z^BaMG;v_SAC?pEUD^N+w253o$%s>cya57tK zBajymgqoT83L+W*)o%#yH4F$k?56w*5)lCwo`4hG{|xRci0lp7y#NR1QYxgAk%2(O zA>c4+YXf2wE8$buJb;Q+8uE3`ub^gN;YnvY^%b-ag0DYDk;Nkk+7K|n<4FOKQ~(QY zyrZ)!!FY1)u#T^GpM$O7`e=NJX7Pv5YE%y9fF!x8=Md>X&d^<=FRdV>ye=WuW|6UX z?PGD2it=MH)fW4Y8ykB%ZVds!_#2U}kRZs&NH7kQbnc-wM8+m7_yMGG6S04IzZ*FR ziGVY~OG;R$JkLG+Gy=03(`5Mo51g+ha_prJb;5bQ1W-sTkp|+!;lg5%vC8CQ&rskV z)TYFaB3g`GHvpgFBaiP10Ul@1^kp*2n$W3Wx7H``_#aei5%}8J1wN`;!!4n1EeJ9!8-&ATojYYSaW0}Y=rz1?(-wFfEV3U%0}#Tt^{e=A zT_`kl+AVgHzjB5QNk`2i)>siLdOZW1jsTh1_m1}6ub}NHAQtL}o~)uDWN$OUWy z&J3_|6zP=>0R{L9FVW-TDN`S{wmMnHdv9y@+(=otJ+hBoAoC7L7)^<-9DBOYeuy0R zZw^C%Ur9y03Az1jlA=G6;K`ifcvSBSfs#q`xCe*aRYnV+8mdl@6U-&xL-KKKYT;w z3qr6_s6!~bS*H4{Q zx0biB7iyMz$S15U+Fm!qq;iSD2GwAXT_bW!qe)=E7!;Dp+j! z0YZ5Xb%oZ>TMX9XV2GbWa=$;~)*sFR1o5VDpt^hVQIj6EBpsbvJghcnB*|LEs2?rX zMt`ro(v?FftzK9MF#fPE5%aT4`yD@CT_25Vfre&9KbGZXx$@_2pwOk7bE|SyJlQKY zrk!o6QRxNBjGT|p3wudlZ6~g2R7I?|EV>&$+bFUSKCu+-8^9ZJ2okPUgsJMYnXW3V zOdgz-UrszkCp&XzDp2T&%CsR71x%BOaXIkdt$5w%6x3ub+V@{UR%L*XnTJrg1-*r0 zT{@L7d4PeG!5mE`Xh56knBvS=coA-F!#|6Lk#D`e5Rf^n$Twstn&tGI%w){ zDOB0_H33BX_sAbDH^KCs+&D9Fbkxix_g8LZ*(;xulSS~_(;VAK%~Y2MkA{3tI(h^O zvW~G1)M(m_ZsOsL1Y3Q4L}@AaLoqx1qZ6kJuJ?0&8LI;KZ?~aYaccovk(^7&yRRFD zI3)Sj+h-^|F!M0P4^KaRY(=jDq2QN#ZN&tMTp^!d)VaDNQedUbd>T9I>C=>?>N z8gmS9=F=yCH}6xNs6fqgHs;8u7wSoGk$-mhOTrmR4P2JW;jq>@A&O7C=zUsvxThTM z-uk%AWk)6tvg&PPW6N;PYJlWJH)9{j4{4C@}7>(&{?WO=(dVI*;c!lkz5x6B# zhoG4k(4t>QQ?UUEx~r33QnKg<&->>jTR;k3|A)QrfQl;1)nAo4^N_xJI~27 zPMrF-%Jh&JCXNTzk-RzGoVkvg)t`0u8VUl4LazxxE-ZvvMk@MvCg;QAQXwP32R$;l z=j@gIi$h@u0FAk3xiKgoY0qriekC!`=QYW+TS~7cSe&eevEnxGV)&!?@|qVWKAov3 z(`mjl)vM%)?>gmBFNvLeHEqPTt{d3-{spy-WkEn(!`q0(gCw#8)t1T2gLw1&azd`K zDlc2{O`o-3&#M9^hbad@oKSGBdLHhx9{gD2alDT7BmWa4G<#ac&AYN&@UH^r-O_cj z@g?ZPjLvKME+5H=OD?YE)CI11&ZCR**KzzDTh85dW4;0)yKISenBof$AjWE}A#D#5 z06x_scdvT({ZsRq^_@i~@}<5=*q*2B4tpD>dAcgF11+O#OHnIZpESqe#jL(c=(Z*J zPDtt2IH8=Dzh4fz*YDgy6?&N%vO6g48e#9d54|%|kT~+g;^0DCdKBQZb&n>;PX+KU_g$AdMRnttcUIuM zJRK@zH`MbfJtHbx`NI;eB=HU^s8)?cr=E9+Z~eoANA<~E#A)~EL4EZZIBD(}#Fd^= z4b@X|ie4mLq)Vr~R4^_o+&IlQWf}40SHlj^CV_g$4r8a+VpK5Mx2#mI(Q7m9oRDQmV;sx1#V6z7NOCg1fU6$DG@e4Om&94S+p_Dzn+ad zgiHi5YC!f~P7|KM`@Rub7`P=gj%K#2FRJ7)j=Yb1(DUq|)Z2L(Sz1u5I=!wje|bA& zfa1x-r+mvB_>l&woraO2$%`15TnAeBKI_wBwqJEbE_gqgO7^7uUTD?t#)~BKgeXw5 z=~w$SNRs9nS@j{=G5buk%uW=GSg*px)W*m*ZO9Tc5-(fK@;* zA&PWZREw8vS$ELk@q5==_rShe3!q+q1RM*7+6d3eHP}vUvYYHg9r*5;z?2Xy^+&Ev z6I|DrrnfnsxQuZ<1i;SWOPju~Q?@vR40B%@b~C<+F|#M2qeUApHjM4j`V_fSSdoSA z7ysh1C*jWkIHUE#t@occforq{9i_p^Pa8yTJ^0uK9pl}T&;&X;GJ5*N zhFt>h%DXV=YDI1Ao?rbrH~Oxg>mWx&HB4LU5z?sq>lAU>ejVL#N%YbYckN_ zM|al`>$02Pm-X&8xO6dPBeR-(ckPXhFw#)ZsStWifr-)ptEuIpv|~fv!MI&>FTKB5 z$HyxvoV`wp3WLsYmP_{4^s_VSFFkzjsr|F{@^9TrZ(_O8*Ox|Lh(}t}c7C-We=o7f z2yxoU5rNWM8gnNuu(4dV`u;1_x>NSn|ZS^cAQ-k!@03l*L6FQjs?ZHXTc7OY}(4JoBDtYvKfHq zu&1oA^d8#2n_^~tA$p(Reo!l-e)o?$s=EQ;^?|kKo{m=OhN|2ZOWa5y&Q}`t(J2kb z9-&QB=kT&~ykoD`m}m7aR?2f7MALqX4GRMxnpOvl>2ZNGn@q;zqn2oz4!)YR;4eX0 zT1jRWD1fS}CUFIx`_qWiHhZdR0&xpVk-P6bB^2qEuZX;Z`-dwJd8ZMl1^jC~QxD+R zy5v$!V8`+GAvo}f&>7p5MS}ik;mGWly5ES*QE%%>KRm)2WCPQX_>wPk%L_m>A-N(N5rzDaPM}57$C6 z6y8{hc|5t{y>Oj1a@O%PxMksY8s95hy;lXix7+EdkCj7}P`4oz#ba?^`q?>2)_GH~ zI7)vGZ!*n-q@U8Cke$=76?{3KZx9+b?-(71n5=_GVgr3_@CIIRr~PniOslCwu`R!F zbeE#ww#RP4IFtVs8h0M$6Xe{<%G{~_68}ssiXYdRQ@Y~e^78Bm?Ijnc>39in zl;#0C0r7Z1Z&z0OF3DQRd1(raDl4e{3V!u-y|DGQ!<6K#lP(HplLOo?Mv%_a5}e2J zlKl*KF$z9pBnek-xw&wm4iM}_I;L=Ort4*m#q(=K_qnSz0SvtsgJ>Y#Vjb-73ZZiP z*e^r<@Z__LpI!%_A#jdI;$1EAyzdI%)x6v44m-3Kjeq@)h$NV!(lp}1xd+|`2HOC} zN_SSeo>fg6k#Y=+i^SJwrvks0H%R?X^8%DVbL^Cx=)8m#+Nint8f%UE+JTH7kF=Ky{@&Pw@c~a*Y?)kWxK!Tsrj8Uhn==d)S ziT}aP{h!6n9ZI$uN`5Rp3DN&zSLdKX0?9`8gsvx;5mXx`MdgHGOh9vbx zk_wl`iNmn%-F;Q#2xhuBObj3=H4N8~iLO!auCT4TLW^&@(Ne5w>dSg$Qu-+1!-y)jRe+zPcIuY*T1jnAG(1i;vZpgjZcrE z-EEvJ^dRf#spZJTx$LbhG@4OLkO$gKK3Mgaed@NF5~rlrlfRP}oK-P>`A!L%m7BZs^ZbMESB#)P4u6n=YPqJmd&m7?2-N|0 zn1NsV&;4DctEqIKBuTmSN^Zxb(flxCkY;?Wwv!Bc{!Xep@$=8Sw2dNa9N}g+R|juV zL^fsp;3!r3&fPf>g)D>?{5bqSNaN{_Y}-7zxQ#@QL%yIB@ZJC}Ax!)SF5zz^Oh>}V zwzlAg@d|Ohhm2wXVl87TeAl^l4Y z?&wAg2U)}D#mF;fFPJb=z4U?k>_absIWLW?T;%EoNuJ_%eM8oe06xKBSCa{aUl5F;~~ zSo%}w!{1go-mgHaCgBdShmKBy4ApBKr$OekA;<2`$G~#ZuO!vNbW_g|ns2RDs)GXh zHT_~E1&!$14=o%Br~jO&zQ3#{V6Th(y(^8p44m6mN~owE5{)Wb=YLaI`g~)eB?`*i z!4eUcF9e#0uS=`u*gctkUun;MzO_VgE}fUc_kcMuEB9StCh~M#=ERD)TE!#~c6w{+ z-C0Q5yP7yWvrd9*&V<;Q=L2Ia(Aykt!t-}4x)>{cqserqF`IQ0_YAp^wAe#3T#6^) z7M@2o-I~=4I?2EwPB~oL=R@oL#5)vrzS|BtYll-t08qp?XBTGPGbG+W8QB@x3!img z-^8l{YyP0%#~02R8jg!U+P*`ieo%bK=dr)m34pAAC%<+WJLoX3`>uQ4!N~8rr;GCb zGKJlqh3)e-B*pDq^g0W>`QLO5*s_7lr?@2$8g*fZSMpM^i}=`XAZ&H`>gqQl1yM%= z5CIkAJ_|cKWrSSHLZviV*d1Kn2k%h=TNAe;>OGE=8|Kr;k;7uJV=AeG)jb!Wd8GX} zqK6~M9f{Qy{lobB%wL%w-nl%x0|CH48t!U1)P}JcAUoUx39ZiGi2B~)R>labUm$zJ zC_aQXKr`agI&epkfhHFWq3gRQnyw$=|@|JMo$fBTt5afOMI?xClznvhR)wM0Y*=#49%?_^phQ4tlTX`G;8O4RE>ga>3P~5oW^37fREC8A8HpDc2HqOw z7TZLBXx5iAu+!cmqzDyYoMH6{dkD7Q;9Um$8jJY0q@1hlzZ9pKou$YTBjoPZc4ltC zl;|kZ9;S?E#%8c{WBlu1iM$h)6%wR~j{V#!p~RlfNILErvXl6|0QqeKbFh}sI%%!4 zo?1xGXFK~Rlg{%)o6i};u9-#D(kSo4?qC|iku>}}>l*zxF@$u!x{syq=vagLGmowp z$4FsRxF)=Kn+T$K<@f#Ns%qrThhY`_^qq^wYPL9zpr%&k)kf|}=bbFz>)3_M=+0Wj z0(jU}efiS@LS=&Zu5r!{^7n%^--sy1r_rGZtJ#M0cM~H}7hB^jPPoUtiCl1*VR&jZ zS%Ah_HJq+Bn1j;c63qa(ZGMqF3Gy!m6iDI9Gw+{o?AkUo8?XN;_E^tZB8>O5Jzl08 zLv{oC5;9H6%mBCOX1A&FpOnEQ+*F&z>#t+^3Zt!}`o)&bxi~MkO*-xzs}R>AW@ZE^ zCUMOz6*UT3x9*N*z6c9S2fKIo?{ZV^ZU_3+3VY6hXhxUmUr`F%#%l<1hIuVQpaW6T zXtYw3lq3d;=bSPpR^5^bPqIL}AnQ_J%hmo#QM>n5%mly@tm2$uZ1Kgvlr`<)oxqK% z!^rk|7gQ8pd*=Pr8Ml~K<=XC70*zba)+t*jEZpQJp#7s`V!-d_X)fR$z#T29PS60hm@ z`Q{H_)+=#;C3P*;xNRy$2+&bK*g4WL5l}Jg4pr&HH;+3O%$7>LJi*>>?I@)mCH1%T zuzxRM+Ys5<&2Vc5#{6#b6Iao|`L(V0tk-Ok(o-M0bw6y`D}+ohhQ7g|!nN(psfVr4 z?ztO9(2I4ccNfW66g~3P1!EjP_TY3|-&K|bt%;Hx$rQGcvsheS9A+0D7L?6fB|B`Y zF9IUOKY2^ynkd0dHffEQ2|WWJbhKsK&On60`^9A*U+exw@kaukn=@VsORg4Z0{7Hq za3w9$y5QqoP>y8ABK?iofPwmEzsa!vIzEQ%Es=;TsLcV!M zx2zjW%{{)2ztJKw?2Y5+{!b#)_L2!9Z9Yt^t?$-3RXerO3bT0GT1hBpj2C@({=YhV>tL1i$%+zt?}eJ6w*bM+6mEVz@lY{@UUx z|08w2x(xe@vyx2rDS;fUREi~L-R2Q~r*)88X%&Ou<@m`yi7}F-u$aC6iLLz_xa9Ovn0}+P4aaMQa4Q?jxoRfO#(83# zZZzUjaoIpUkL6y%P?3>=^5ZEAY@lKbzoHh#orpj;4?CN0BPtL)Dx0~R&!E%CRM{+J z(pyX(9Vf$n1LE&>v;HjRt%MV%H6%a#Lg<-iq=W-hj&7qItrArVW3Tp$d1{k$K-kQb z=q?$KrzvQrznS@JNz(IcoFw3*g-WE^-A^;{ik`XH+1^DhPp zHJw}9y)8LqpRIKsJnMc6Zi0WM6pT*%^Dcs;imFr|il z;W1$8-I?1eE^cy_D8tj-CDq%Dcfl?)g~dy}Ree?c&5>9(ug~g`*lAxg#s9fjEX{PJMm%NmTBHwH%SmRG%U(kz-%Q4iwP^{E&-+R(V)ZxP< zymEuY3qa-3od$)a6<1ed>ek+h*2H#~K9)Frm#8CEgNSR%Ga7aifa2M?NULs4d2|C; zf0nBpQ;_lItIDa)h5mhsgL6k)4z9ireJNpnbe-55F&&yvj zEpxx<(`dw$?yhVNNOOmw3FTMh=5R)|(}6BQ?6QsF^j^OL(4+LR*UzsXHKZ2YDod3Z*Xo6d3Pq2$_Glo;;TY| z!>fp5YwgEZbeCDJw(EuY(2g_x^;y z4YE%DM%88(PHA)gn0;%i!-Y5_2&%b}VS3ze3_7~Gq%r1}*lck78C z%zEPboZVmmgpRmQd>R~@*5{mu0!@D53RSKtyCjlqz1qBA zdS-UuPF<gMa4)@xQwXo@2Zq))aTTeSuQzPXAEd){OrOEP zRznQTg_$OI*hv#dmMWIhs)@_gnG))w8`Yy&aK&k8UoWRKh_8CkaMwKKkT zr^W8VJ~5fxJNVbB2zGwo7GwTUXi1!TXwH=~-Du5K`&aUjIpB|5DjMBKrYsjhZ zYL}OE_&Mdi^7g2>vgou_;(Ajz z1jyWG8ET`HOgsWcT}}P(Mrn8V`YaY*svVmFg>quDBRD)eNL(0lY_eS>v^q{19y3yT zo`nBl*B=9#7d#1=Ap^Gw7?~YY#IZKnzB0m&x#L2wDqd9hrI^2neBmXXdV})M%KoX_ z@V5uNJyd{*J+NOwzMOdDYHQyJr;Bme2SgiIQuNPAz5-F)V!jur0(T~C>G<}}>R&06 z;(pl-PQMJsNCCmfqb%|B0^$^4O%$^1M80& z!=>_ddU(f;jlNJTy1SaL?uue}3(6Nt-+i<>S@-elcq6Svf{R>(=I=D#Lj^jy;UP1f z(#k;r2Ff&?A586uPb1-Y1t5Re$fwjLZD9F6*8Rxar;^!poTILDB?ftz@`p((< zPCqaG(*1&Q{UbahGxOK$v%i{`{xXh+_^uD7Zts#FP^CVydjPzT z(eSG2CwQj;5Gv1Oe{M&cYFh??EapHqr%_S$RPE6Sy`D)Wts7fkUrr-)Jr2mH*Mb>7 zCR5Hk-v$9e7o>*?f2-Ny{?G46x4ZfC2lK8@{rt)5d#licLtg@cOm4#J8xiC_a;j13 z=XRHmoU`%A^52M%r@+5_ne<=Y@YF(e#`0dby?d^{JQ+o4hfogjc8-8(Cl9p3Gqm$g z-UJF_E!$)7Sn(U_aO6F4arB`!AB*w2&YOn@^2L~2Ge+$I&;KeF$!Gcl?zX3A znot84%SOi4Sl$OiqL=y+7i~E1KfUyzvg4Apk0PCSI^@pEZg;SLYjLjF>lt1vGT&!H zAL~^F$4_3*+hsb`ksSb^zos>%cB!Du!9{K1#I6F*!9P)n_LJkiyRSZs3yw-p&UJgo z0Nk}FRDv6V5rlMj6PPZ`GiMEPyIs9&pjMk4P@oD@#(l;%qL_v9tAauyK_IBe_r3y_XM?pP3M%?vqwd z*t)^{SK>0>n`OL#xYBd6jZ`hjysGfP6-dETz?FVPid1LqLReK9&Z*Wve5YYNCgxm2Jny1!qsG6<9bbp?0bFz;)VIE#z(aeUsUya89jd?xxJvDaLQPF4jd|8&xF<9h@?-j zlQLLqiR2*JP_RwKTm@2X{5NxeC>0ts;Tw@SP6vz^@KPf9#5e38G&B_f@R^<~kR1{r z;iRFHK#OeJA3!dhg#!=MYy9QE>IzK$$)|vSX%|t)1Un4MsBi2@Q@Lb-^$9$O#=$o# z^Mx2he|Lhfp9yOiY!L$ zcYjs-QI)<1Ki)o2|IsSvh#9zv1TC*{WIgh#Tx-J=Bo6$a9{<3#Lfk*|`spLLk8+nu z)T#t!9;MQryfn_3BB;FAI9@R;{M#3`zg*_2AGhJ>v;SQ5|9k3|5kgJPP2;Gca3(0` ztYj{y-)$9=r2fpXJFivRM3zlyvij^hr5?28mL)mfKmPI11^##(wIKg_>i&VJ?*EE~ zihtnu?u5ig)oVAkiIN^=#&cZtxhJUplR*gmNg-hWQHcMe3ZW6IK*H9xl}R6RMmqBA z9X{G~uHaAk+9Ac-oo{3A%^hevT4uyn5ws0QuW)Zb;&^_H+8KWtLQ?-fsD;*`$m*+| zys9UUA8cd<$M7I#9)z8=U)FY(m74Y9UtzftFP$A6&*L4^^6-2}z*dvqwFOo8n_t>* z3OkWRly9%^H%Fdd-p7ooW=rRnT!YI%Y9qO)X_O|w_jwyp0GnHU(;=^w)4p@OLbyfX zVq|Psj1;Jl_e&w-O1}Ph8~La(>C@-R1oQbh?ugU~-X%4NqOV$iL4MjJ&gY`xZfmD` zC)Y&WoQ~xtyXZM3xE`P*K0KRJbpsl2fQL*);^ud)0FPW`GK}?a3S_ZUSw`n}Er)Jc%~ZikTCy-}(rt zA$n(R9AMONG_&spb@3P(csk6h_ZV6&ij54%Yl?@-XuH1as5Sw}uUU|vB?2eF#*5>L z2V*UX1Brxcd&HQZ*}6XnlePrO-M>@^nc?xLka9}g?OTsooCi|8xJcvi&?VW`F}V|N zw4+uuxVHyl-5xUUZz%Delc~g?iR|!N?USR&8Fchd8B`mUjE6^^l%)3U_|d8VC*$e~ z`Elt`xBu-I?ceBrYF|@7^CCyGQ-ymhiiS9_G!rnABjQN@FX{8ASfiBgkIx?~$>;{*wTcJdU{8)u`ib$2>C+;@sH)lI z7kO4BQIgp5%pIw;#5uc>mo`3m7SGUJLp4xeeb%XweUGvPTaLKeob|!2YBs$hVM1e(}`>^8TqZXD3sTf%Rh~dYK z#>3)=CKNXR+h;y%w2wqasjMy2sk3?zOoRdt zE^hC>?vQU67VBRFfipdMnl9GVV*E;t##Jvc+>It(B%||SuT#MTi%PT?JE#1<#;?rk zp8Ohr0Y7sS<^5go9&=k`e94Zx?>$K3o$Vqq@!`Vz%^$NxBlJ(ooA5(}G-HOj0>3BljY|BGCUvXxp@_dNiLz;@&7W@D9`jg&g{p45vbn>6s|M%6Af9JYKoXyQ5n>OD> z?Q*ilN_HwModMp{<8G39bdU0XUNQbD3gMUk|MR$Sz@`JZVLkzfY=!|VYr@7b>=8i) zF}1r7+7|sQnW4px0BH70KLVgX|M4kI9{oM){`)V{Vn~QT^m?&h>3B`7N6{=^N#^Ra z7&Uo!cf0HnsHdw?vkl2(6*I>szz-Vun@tg)=fGivi&)!&osSbZ`OkrF|A2Hl&|#zg*nED&Ijq!^5-PR-2b|hZiJi*QzQ^C1&$Di`H@!1&bkAuy zr3SOh;OtS!(uOfB3lcBg_ry00*LRg9xgz{%>RWS`Av7}Xm^qk~OZCOUFZS2B*X+it z$5tX7l-SN(^a@w+^X7Kjo@uRjT6a**dpT>eI6PJDSUJc#A0c(_&JpurtjfT;a{*_+ zW{KAx+WuN^%ypNdZm!~8y4_2$xudK43R&4^N9%>Ndgs8MTxuDmRWc%S5yde205t$E%?%C#6d(`gZH?w4Uxab)+lrZ_Nygp_ox-`oMbh zZ);P5W1jVFIN|2KuwZp5#Ym1cMvt*nnwBI6%AKmeH$`j+b)6OfjgNP7_kYg*u%*gH zZ}G?{MrA&B)p%?g9=w4+H3P()WF)#f;n-Eo9(`H6Pop9e;|2eWw6yVj(94Zk>T`y# zf8s)FwPmoJvf8?DJorn z9J6gCrrU4ynU#uuPOagwNu&bLMF~j~`<^XcVR>Be94s(#xuiaEMN@Lkz7_!5Xv$M~rVCWHCD2>r>? zTa;y2p)A$JXqI3eQYKVl*Ly6>Y*#5?-HUwWJWdHK z-1L-9NwtcPlX9)beC{k{Gls#n$3iYHo2Lm9oO0f0Marnr>YSZ_H|wK2g^rGjYrxa z3g4z~)Fo47u{TZv-%t|SMTJdr4c4-qj*}gnh%dKs$wyZ>FjDlAJk@TB4j9+XChei_ zl!ecU2kqLC%4b5IUCj#&jPgX+lLClEq0F_x@CCKz%C_h zW^}?@7cE{1hQ}esUg;}+Xg&QPHe}~V`Mz0=dI3-Z9$W#ek1^mX=pU%=`2ZP6N#BTe z7eTv!B^<)#&1{O#SUi(aph5I3R}95QNnY*cz2x}nWD^_h zb0EE_f6=VFh@)*V&tMi6SUcsPLV~4L*}j!Erho6oeBSN+S9>H9hvgowAEwT++0B&a z(@0wFpy5j0M(Ho`VntxgdE;b^cnhfk&IV2rq3ATl8_@~T0gcws?%O2AIv+R~IwYu@!hqUi(p zw&dZ{cgRVUR3&DA53<&oYfY0i7Ot_v)WJpiSx@`Em&9Z6COX*w=XnI)dpuBnR@0_6 z*O_8I+V^YzyBxVBVbK0+R{>u3IPyr?THi0XVos|jz(KijYe-uQe2*#cXt&^38E86{ zzsXM1pDGo{BLL>u&vuI!y-q7@Uuz*cts}dEb|MC9eb6=w zZj-(9jp%-YG6s<~*$ewDo>Lv~*gsELIi&8G#`e|Q;{vhW8Vv&%`((gZD$8`YI#>A3 zlXeauHT8ZDZZb}&BySG9;{a;+tWzZEC!2LTe5pt1D+^gU=mzQyYYK>smws#-peZ_k zv-0po(-l@*_1sCp7srZ>zH3k6e@bK>2L#~J5NM{FY;92-6^~m?zHYCZ?=^B0x0Raq zNJ-u$qlYLx)O1g zTN?1Eh@-47p$vz#6dwoA-46$;vka}t7RH0~y?8E>p&=Ihi^OrT+;VAHE^7`?8f(h& z(<^#-dR%1A+m%=-TiwXP3&Y9E)B~TV-dVZ-v;d_vH%03PQ${1`=Gr&(3Y|U&t@HCp zPw1sTOn2*k>4!~9V#h6eK-h8VO^1r_r%~)m4xNr!hDuiUl9MZ)ET>pn5iLAn^V9on zs=c`VkL(P6qEn~bwxr|X$wITzs=;0RI+nwiCxsU{WGr|{>!mb)lLnc2B#rD)0x&v? zo-`b?I;;N8q(~GE4u#D!I=N>D!kGh!g@{VsFyb>TM?s)dfesF&ch4ueC45AN3oS8} zx*?nSm>NRA*3>>^yfHO?!|j@MY?Rc)q`8)QUc6Ppjk?#(1SZQ)JdAH}j;QH0VV1bj zWIX9vKglAyXEs6#7l%DL;mkX-cqG$|a9ByWOYA$L8$+5+WXgz=?XPD;+`&Dwt%+OP zK29;ImvmOmI?=e1*FoIxBN(QevOGmqe-Uw`(&)~fJE8mf6l+apKhgBQ_WZNu4~(r> z661Zb!ZY_(cWP@wIv7DxLymm)P(~*i5RPUpo79HmFBt6de>0t5o7w5YFmn_4ra@B!u_O7Y$dX8dnkV-?F{y7 ze!OmPn@xd1)&Uo^TF7bg)v|9`#0Yz>hr;)QaJKnIba4TE#DoSg{qp`GJN1aZ{v)aw zzJOxK8v~G#GKvH+=1J)-tAzvV4l6?adTCf5mA03lZ-mMs@xQIn$q+mxz%=r15@w{I z*|=yku`1(ptabg^`k$Gyq%V8*w|!4ssfyDMH$rJYnJ-LlK{ zqQ=a%ox|-nb>zCMo|?aBQsaN`W);y_$F9CJTv*mQ(H*7cNY-0(Q{- zlO&raj_a0Iz7W~s7>4czQ_0waA`#aT6J8V<-(FzJ(VFM=q0*IEzwjJF-6i}N1m0g3 zAO85@AItp(a%9o7ZOwvn2HXQ86Tt=gSpyVLE6<`$WP>Cdmpe!cl@bAz_Qx`Cv&4Yc z#iDsyqt7DfXQbA6ib*A8B`@r@Z^J^t6m8*8V(<66Tq?JIeP6I?oX5y-@4_N!HaB}U zSo9-*`3#?%6ib1)R+;y7`Wpb+j>MaUeYPGRVgzr}$2f`W+vZvxH!9s)l3zK4KO_4Q zfu^lN`;|{G*_KUc^d3Er2n5jasBz~!Lw4DC_kxDj3tBv~BCQZBf(vaNewEdXCaG!Q zJAYP|JqwBid_2CCDb=!yzPMJ3oVz8F>8yb3fmrMb`B$Xd$3VVtcbMoKtE@)8iGhL| zy$3Ppc@kV?Nvl^k;N3d{pjEl+L;hK>Nh)16DwfS3Dc?;o8s1@FL{+08K*Dl9u34Wx z@d?eu#GSFsxL^(;AbPULGo^l^z7!+i`vgxtQ&slaW!u7Z!LU1w$xIen#74BkUX9Af zlTVL9NZf4sgeGc7h7S^i=T7T^G}lOP$dVSqS0N{HV%?4GETMNR?ZjN<%)j6o<8KWd zo#+9{uO{|k=^IRE!cTAN4uGG~FDHR&*GH79CFn9|`MlejnJFhxIda2%{SsjJv64uK zr@X2y`p1z0A}n>V`(8x`Sx@D*E6v&Gr*+%dFJdY8L-6v>c~ce3g)Cp?`$P$}u!j=I z9*H=>SaZ~4VL|-mo_iCb&4?T+#fGNPHBvB26UOS6&>}v`i#;`j@*c~ovWp{CM&s1I zeCBpn;LAuqV`6p?X81d;t}&i8mFs0J?mOkKp%-%IV>9H~#k3_oUZ?8&2vyyX>Rw)9u&E4@c4b5juu|BAHU8iNi( z)$-1g8^NFmHDW|N^fPB_ZTOlJZkKLbH=tI*YX){sf923~){`g9DYJ#kSSM#o0n>s9GFJFWtE z#o!q=-4=b@Z1>C$wvf^|c1z7mHw)g!v0*EthibadAS|$8|NOb4SC0nP9ny9YzAv}}eG=QNWxqtU zL$@o?3?q`CRwHTJh_!Zo;8~rJrF0v%rwAR0aa)qh#KEV}$ec}kY1C(PZx!S!w9~#6 zN@(vmjDfO|4m40APLMtmIZs}rmOEjxv0(g)jT$+^1kq5LOIwGR7Y_X;j(J-k61=4b za0T;{T3J-iy0+M^}zs;;L8brl?= zr7nx`qEmz}@y^ORKBz|TexA_BmdcJ7a5+X*FQpGtoLKualB)m{5CT36KKoI|gZ<5( zLKR153w8A)DYKH;Rw(-d3g_Bd&w)wOYpr;KUmsTb&n9U;sxpEImZxPXn9-LFxZvr-gYl z4K3Y_@P>0v$-){#`ks;#EzvJIjfTU6<}b_M_}9d!^wp)qL%AZn(F`2Si1YB`#GAkt zLhcLoDob4lNUNSJc{F2P{qqr~Gs`=nSbt>Vl^dTGE-W?Ux6ZPyf<8{t7h@v>v-<>E z=?IpY#C){A>7ea)ZdX(cUUzyO-Y8W$QqIVBdaco!9Z`K_NxROgCgeciqc_!1?fE>f z*XqxDY`-w5FMfVOoStq)s{qs5(De|@_Dy?$+`1QUt{f~yfZ8&-$SVo z9@tCKPvS>koU`t|(A2@pxPUh_1LrdB7xp)&ve&9)7+kE#Bw;R7zFu;tRkDGBiF8HL zYo)dBNFII|o+qFAz`)A0m168mA822N2-H3p?z#6Iz00EGdk4TM+7Dx@e3b#-h#>+; z=P~cEpF*vO6`YPUvB}(I6t)vqhD>l1LAZ?F)7)GQu!YroMsind3p2g8pQ`mIC`Cj`awC7(~(2ADH~dAsW=Vu84Ai`$E}0F?*lo$XCu?r%g*BfXNF5JFH) zeFf^fVLNEs^TSe98grNQa3Oa*FW>IFENkxl>X2WMfJG%CEurT=JI|`}ofHRBTTA@Z zIDLn7ms8))fj61|uqStaIe9X#dSydNl#-+Eta8%Z`XM$dM(Vb{+Sq#o{7wamlY~$5 zY@P3eIUPcd9ym!nR07}GQj@-4-B-@yd31%uRcwPh_!IBCNzcqPRxjS7|Mrys12x~n z*neXh{J_z7bXn# z6t0y#r2L{q^Hc(rUCV}aeCH;h&`_JuSyNRKqG$GjRsGb-A{tmsBmXw@EAs>KjwzKF`9)^_3nHbTUmD$)XJx5!TYY5%z12 z5x#VP+}TKNah)Ys#a8EY^H7o6$U>Es7V^Ul*y2B1Z){NL7HEXcDoS7uZ$VeybGbz$ zKpxxlmMS%nXB-{Bn! z^K@D?6Xe8H%Ur#%jC1hn^h{`i`1LIbE6oa=YdQTUa>qckJL=3)Ct*^GYRWj}D<*PA zq=upwfQc47kz;yHKd?Q2Qf?br8R1)r&aOsq;netjMZ7t&6gRAaoN|S7nFFH8+NpKG z`Pp4wEB{_XXB#LUxHUARnHAF--bdL++>orj={k6${+sfF zf?-92eFkMv!sT7f)%5{ggPDeil*>KqbLI69oZ(K4r{_5D%Zf)d=#U(t|D zKVbj{jW&u~B+g_KV@@EGZ6^u6H7}y*iZRFe=Uv5kd!xTs-v+{0nQgti;@K9ux*%8`)}1E0q%X_yIN$nrputw4s5?s ziw%H=&YMnkrWJM$Ui>V#B-+N-{YWbMv-pvjeZ+^9#Yk7&EzCO@l@Ra&VU%hwLg9|x zBLfk74P#tkE+qRho()Z4e+`^{LJRZSL+d9Q1_mkKT^SCYgb`NLBA)8GVP2s8+9Ca4 z<&7%P>Ij6&2wTiC`oSx zj-QMBnh!f0%ho;{20jm^aWmD!=v42?-sE|1Ifh`Mj-kH+q6$CojKGO*@dV2V=Hqw` zkJ#UwZxpeqClBf%zd#zOh_7oyFmK`^M>pVy=7|Q@6=H{ljs7pILv9hUM7{^atBHSJ zm_3V%Fy_QkCdKPq|ClkRELQCwdZ)Q+(*D^F(a|7;4&i`h2zoMKQXIf{X;i-a%Qbx+ zw$|-1P#WoEE-r5_A*lA2#l^TVK`XI7%0iPzeMKAMNe{h<3xw6mdUxL2NVRg%6_h=a=y4%FNY$LIujv;VQv<73 z^yfdK)*n;k3MYLCd9^FM`g$}d?U$*kxF@{s?|R^%v%pt6oS_Dlap z)a#)8!n+5#1+_u0T?7+CV`|A8zq=@2GhN7qE5M>{y3RjRQ$K(z=Uu;({ktQb?C*_q zxhpkBDdm}l%axem0$WqT_P{E+6hCLuV!AC@q&MrzBJBa1P9aV=4WA^grw%wx5chU(bPktkk`sW2(6OJuX zo8h8S`QI7^B?`Q|Qh);U(o3YAX$~RPX21O!!4vf>E|fYXRKG3_Sj~*&tNV zY7`$@=2juD|AA__;w*eDTbd)7!M|fhofO&}y8$1sr^a7OkWYkAy9Hbjr9i$NO+ol5 zP1@~Ydt458_67WqXES>qN46Mq1X11sFI8lxUZCE8eO&9rR$nLkc?R5M<;0W@JS>lh z@3$TDECcmbjIq39W z7JjF?-)`o-{&=ftH0Y_9?3oqNqpK--nIo(E+Fh@aXA*}Ngjs_;eg7YO?*SD>wl0i< zpeU#aN)C;Zlpu=a&}}4&h)R&Cl4%i%lA9noDF_G%jpQISN|w;%AUU=)IcMl5Hgxb6 z&YU^p+?hFZ=G^<ebAHC=PFR0hsi5iPvJT(MroLDXWP(d%^WSa%^JQ#v z>^ikvEjCC$tx*=gv)I}4GQhpTbVnzgR>&oFXRP;D`m`))cc>|7B8$ zmCFWDrx-chd~JBS@6W+!NB7{!%Uay|oS$f$IR>!1WueVN=D0VZpv=KsD;bac+)RDT z-2z~zb6;*_A@OokEpF$a!{N}JMHH*Y3IH*I?RHJDAf?)U59mx+An3%lI>pk(Ch3b} zL2SEB-gcLVj6jaa8^dKFKKH9Qn;c-1J6&$IO;Z{#tE71y{so86+vgmu*}F1DRqt^h z;GaK+tA?FZAU00uhdOCDkJ@zatR0S^ayP*8zZ8ya)D%-yZ|XE!?T!i%1z^Ooz0(CYrg0s+ywUkZAgcbBBhg8mH8=Z| z9>%jh%}$xL$L@B>!+96^(ug_@(_;WL2vf*ey2(fY6<%PEgjFkY*1!$r*C(0kvgO3I zjZnrKIiFu2MpCVOQRIQIziuwzM@1MQfa6zr_x|m&6bwL)izavgQ@l~g$-Gn@b@}iN zU2Rq8I6^iu^b{4@{PX>SRU;9CCC=6*9ape~7Js?`7U_Wa}v+T4=^ zf8kdQfoS-nV-?@Xt{Nx;3uHtP?0`(Np0WD>Yt*NNngAi`l7<^xW6 z?sMX!Qh((PSOvS)!-#I`E}t=I_8^V3NxV7!V^jKDBH8Z@>IRZR+5q(glP>~f)(b&m z02E_CKKBNRuIdHJ>vII@5E2If%MZPPoczP>KyT z-ppW115KqOt_`s73m;TiOC?;y-9lJ#@_rf+uL65OZWl(I3ECy_#J!n0f1^|Mh%$%F zf7_UT&20vcTfa)qpxtiB$BZ>BpoK0Xx2_mnc7AKz=vpI>$N)aR!@Y6paRkFM*-mu= zkQZ5eo%1MWgp(b!TKR;RDJrGao)7$_!Tg!Wk>?Qb_TTU9MX4GHJ0lvACu=jUoX~k` z*TpJF3I#%GFWFaMskZp5{%+q3_zA}s1C>lq&7N$aKbDxu?@S;_GFlZ~{+}zB#%M~e zTz0Y68NR}ae-5lLhoHfHy@A2D&Ea8|x0NLytm7g)$^iHbj|K{Aq_U`kj4qSJf&z$m z4WeKh_h;Y?A+sTWS;#nm5r|8%WtsTo1kf>x3KYIP;XVA!YkGHiyI<}C1C+m zDSv*MKY*^#S8p^wHep%2w5dQf4`2Kjm+Q5+WF1RaZUgmd)v-W|!j#0%!#jLHEm?jX zN*1GWXVe;hnhdmengAUX1P(x6+CVT9_^Pmy!3f8|VpV7QX)|u;R&FbSZD6~gqMe&3 z#n*!>HQhek%F(NdWxLGQq|BzFjUXJU%x!`kL%6F=<&HiPzBfi$HWWA}s)P=%f=!46 z%4TYAV231+B8Yo7*bfk#25SWI$SQ2T4HgE>OkE(5VL=keu;8gjumH9?9kA!SpP@*E zQe4lEx2BTLC;%JxT7?mQV|?1MA|0_~_}VnHd~C3Q=WsK5aF#wPdik?1P^V{+QP(YT z6?*8Z{&VIWzplmKA8WH3Lag5#K$eK?(#~s8q-#h-oT;Ve5OS;o+*9>HuG8$SbzEATa^7|_Mbn(A){(mC0DW9pkca`!c<9-;P1(p5S!_?*7;D%C0|RG<}wMR zhn!tE6v1vb!%TXOF~uR#WtE3iKhXl|1w?@K0xfQ+M8Z9+deozM-a>|$395I#z2G(+ zyxR>Gk5jyALx=MpYw^cRflcdaCqo?x>esdrtT@=Dw4CwOuz{FAW3c;hsnKL0r^~h+ z5T4da5PV-6D83+k)P{>=vtY#+G3Dwhz7F4%u5T4 z{n2COXHF%DOQF1Sj*xNIXm=NMoT#L$KQ4PN?D{#xEwV@C_kKcYvESLTKGGlT`Q))I z%4n{Wd&y(xfxon_C#Jk3GXWkhSm8PxVCychP=Dv!M*pWdy_gF(b99bBNe|W#h@oK4 ze)2{o-K$AJO&b4kRdeo21%x9`hxLcZM8yK_65OBRk{aHW*Pm zO0OsNOnj(4Ckhcw`8e=6`E1~N7X>yC^fF$o^s|?`oBWX|L?^+yZB5mf?)25y1i|NsD5YTm_>#uZ&0gL z=M}is>^9&GY^0e44cZ!14SHMAcBVb;qclHDvyoL}C59B_Ar#qW(k2x8Fp-BV()FD= zDE;Yzj0Zfx!9uKp_f74wCm9Nd!{>zTu5uP5-hUm!!IT2j3LoC4d&bpL^RbQopdF?b zJg!m@-Z`q@6jy6^OqyqNZ!q>d6z73{Elo>byisP5X7(=j?8wF5D|b|1tua}$q{rBv zwiZzTFMl(BLW}0#f9L0m|9gq}|IC*!YAswjjCPSq*Gq0^vYeTUe&&10ATuiXqn1G9 z@5dKt(!jS@aWH}R_M|E#?d*e#FjVOzAx9uM1rfW3SZ7^(@@$@`r6KC<_CBiPh2(CS z<7G+vNP{508_R~u!tHbBe3r+AV4E{kWOzMkIcGzsC#W*3Q1RKtKGczy|n$3f?irGSdL3y6l> z#h@ZRQebB~k1>V#OsBH_%C>v-fROX^#lmt8tmH@4r>Os@Z zPc0KdIwK9!F}Yx>7-gR7lPh13_0QuE(yuan9l+ac(*Ta*GDvIEdl+b5dllI)GEG?0 zjrnKZWP}Kg2)Gkh+kAH?26X)q;~T1g`SH7}@eh5|5HlMb4l9X|8Sm8nFj~Rc~kIYWPu3OWk>qNBbTotcdPo0?ziGkMj)Pe31>B>o)9AR-ANU(l$Dh|M&;_ zzzI~Z1WIeSWYHEXcfW30kmnAIjvHMqBF#EKZ{50gYS1~;uSrYkooK-hx34}Tgv93T z*0j6xBEG>s&RQeYi0^7b|EuTCEK<@8F%DQ;qyeK+Vq58JBWH#4i zxaf2HP`cePyJ``f_2fF+_|O=XuG6$wA}VLvP)i%5+(-Uw@v8S0PMqvLd0UC1e8HU~bgWkjU&jc!JW;;~b-UiZA}5`y zwyfm^h3erW@YC-~L9HhiS%_8sSwc19sxRk?BoF>^?*8L_Z^S zk~m5WG0}sS*b5cai7Cpmfl(9`eZm#sGS27^xd(jS;$DLvKlxpHF z=6tj{bk1G}wEiHgz3H8pzW3qy`u#`+%05Lg`m&{3Y6cJvNUi}YDoH&4Vhq$Dd5JGx zIyt&o>*!s;jL?j(qL_HlWaP(c6$KY~*zF4SkMTM}H;w4Ama5zY#WOTu^8?r3@ zk^>YO2pU)l~#b%kQ)xlf#ozX^z}+KpC4|?+8^zNxPBDmC&?Xl;a^!td?Pc*eObR1 zUDBL=?G07s$5|jjLbWRCdS%qk3)DBVLW1dwlrO`^{mEY_#&kAnVBLKo5dPSuZb9UhQSu<%1?tJYE)V~#h*IeVW@ zJwzVQf~;w`Ls$@**nq}dkrNLkCZ8IA3UxG+xK1NE8BIm}vKIh^hLSGficKeT`9_38 zoixI8=UT3r5k!-}k(C?5vEfZ8L?+TZ;Z_yGtG7N}7D@RKNVOo?N4osAHl1*$yl++8 zv?{CEpLa|1H5u`+E38SDSq$kDE8~%~Qd-Pd&`=%xi3^mRFSrA&N(7u9_)%-Z%)ht< zpu-8t=ZERVKC+9lq8E-VSYZb4j2EPB0<7|3XhJ+wy=tTP7qu*<5|#RbN2(-?4-nRM zk|cD)!svtuBh>|o_veNLPu6;i?4=YCpzTO=*sy6;Oo3|$bvatjF0+vK`pKjFTIPXbf*|?@ZC8cVQ*O|=Uy`Kn4+XrZqVy1) z84uVG8}|X$v{umif~&)FG1aU<*KCQ0cRj4;mU{x`8<|E0MzJwhiq|?_kRhD@tGN%kKxh$%VuW?N9+In4DpYsj0(dOT=G$is^zp zJ}>gpmU}FrM<39M{o5UL@Itu%qsjqs5jy<__MyW*{RJ)Bk5mhGX}rIYQHcL%-CK?x z97c-TaCcKo6;OklbG)+$F)Y@CUK`W5d#_;N>340qp8{QppBC|3B`9KcNKRp%Lm3Jv zr;X`oYSHB_0b0&v&Vl)H7IzVwDM&!+W)XC!LsX)oG?qO}Bi88sUFU7G9R%ACIRmiB zp<$AWd^6G46tMhG|E71Jze#rzGw$nX{a7VP*g7s{w7bRmDs1AWb`Mw-Me9#s%Y{-u zP=-G3U|jRRQAYvfsXA93gpDb4mz)^Y)47+Ts%K_V>LAK_3WTF$*kr0jo@kr`;-6af z-%6g+f(-FunOeE7KA?Ay~xW#a$&fb9+sdn5gRZLMxYbO+RtUd=|7c_yq$vp@8d zVupZVu7!xTS@Gu}zS6kkb_&x1OA1H1`xqDoikM0Ybw_VT>9zYybK6Eca#PYR2IE%I z>i#gMgw_{ymht{n(jw2)Z>$;H3|7lJMNPsR=Qa!)bj{v-cd8CYb>rU-ZzIA-({Sck zm&#aM#<;9U_K`a?Ti`hfB6Q`|H5LxRU;qCn@%}$lqejJt-dE2sXnZzo=4@aL4t?Og zkNT@^%}5%8qVdFfphSH5$J4@}kDYzJL*LCv`K;Mch7-rXXv9en!E!|SR&$}PWEyUl zEb#a%epS7yLs!A!yx=wgPj`32ARC;(Cvm=(S<7^y!^x2>pvS`Gj}%rMr{Aypct&r} zMdw@U&LZLIRuZKjUqD?nvD?izR-nrrg8IG1Z7_&RzqQSiwZVE-Z%ufUsYm8U~v zNS@JI=&{DpyjksL6bJ3c98W<^e%!S1v8^yo6TGZa~rVE+A^K04KXrJa_1=E9{?OV7dBg~JZfz1qsZ^3eH%e1$)Y z^kKVti%R2;)o%_?9xNr^|CL+Vuf62Yr+gCcqFM0d^}6+8(P`J~5JQ?#A{AZ;Y)Uv` z0!?D-Ca98yJnUUvC!-WpLdwwY=(xAxSX)qXBJXiAx*x-+B~XYl zm6omA+Fb?MxkLRWphNDb&1yOhudd1J>%W3vYl?*fYT%SZ1y`=QxrL*ccxVaFg&{-8)8fjla6p|6#bUf))po|qY+E2MEH2;d`3GsL<1?TJt-sx=ZE2A1^yUCE^flM( z)G4f(`o{DZRQfvSlv$pcUDbIP<@cOwLNK@rr#xYOec!Du@tCg5NGrE+dkf9!$mjWF zgu}Ml$YXLRvW(PS?B5Hj%f|7TmdBAlvAe@i1MXT0Q0Cjl8 ztAi{C3)&~guE<4Rcxucg%g*lVShK}24JisBz;JG)a&tBMhim$JZ8Lh zD5)2O1sv(t_h%uSDn>&{62$%1H!}SRl8q`JkaC*W1Ch(`Kpl%PfDghEu}nmJ-@PhV zo4{&DoMHot*3m8FX#RLiS+Viy%iCPf)ypYS8Mu&1o0slt&v&&yKMG#mgNA5bz5=>O zMTvi<_GdQ^9){P59MMy&zMpN74;$!sP6j-lL48?=5k^+YVlAZMkCrx>H&hIQ=~6x!!0(F33*p z1zIGa2zFA}BUZ65Z)Hkqzti)?0(smWG`XsK;=XDx zxXbOx`bDFncKnMA_v@vpeB8A7LNLv>B+h~40kJCXmED488?*S^U8Q!>a#vnC^B4b% z+qDf093A`r2&HM(cK`g(5;j<@6-$I_9-N5A-Tp0BD|3Ut7NM~KX`QfT~y7wfuCPkNo=N`&co(eAOz&&&4dtZ zO=b#y9*ivN@nd7_^u@tJM%z8DlAaG5d{e`k3S_OVawoT+0F?uLb~;Ze)J=U^lxuSf zjAyxT%l6uv(!@@RKmD4U`H|Gewx$kArd17U$Fs}AT55bmrP)vSCRY{uY7~@x`m8QG zHpS=vU_@c&(KQzK@MDYm+Jp-cfWO@q0D!H4fQ0)zg`B+Y4gs9+s7QCzzmYYf08dnE zJiM8FNu4o12dfx8c)1p;FMsVoYJi^V#?>fYjDfF~|3;T`-NSqR{B*IW+-$^t%w zGvCMv1|UoZ7zD6s03`GC17YP0fXCitfHfw0f%c?<2QexB_7xyMzQKV{-+$)|EUiUg zkhSQOxkoZHEJ(LzDBsTDZ+8^Ex;FXFw^sg^K@W)uCwpz+QU6v4sHM^?iXCnlR}y*j zJ0ND|eumV2BcrmA`M{bKm%7LFirzSC^@>FAH7b8QTFPw(6w1iJ^QWZ*ReZp$?CcY0PuRv&*Zg;kwt;ZUD| zc5RDzS06<>Ipp=LWyBiWm_L)=m<&D7-#?wbE55*bKq_OPKT*VR_cCMZW7|?o9v!Yn z4k#jTJlfJpV#jG3ev$cSQmJjV3b>UE(ljKU=$6wjY0LlW@j;LA5@}y)XRXO|`Z%#? zu%J?TVw9q>?dj*$0CeL=W7_q!h-WM2YnQr4IiP=bV_}hzKbRJ?lXoOLeGz0{<@+L5 z1a0O~@h1CVHM!Hx{}k^is&w{vGUFii=pxpP*ffu%ofBjFNXxjLwR@Qd>lq%6IzTOU zx~O`Qqs}2(2@eJwB8m(<=20t^lzK3%uhz=sW<2*y;HJJCfrnOt-Cs2q$n*R?H-5mKm+7K2L^C zXVESjlm-wOCc9`t7xvYvir#W{_-veV4O@+AF0uW4U3vpmdf#c}UBidERuTxPoArr~ zN?%$4=jbibG8~?b&PcV|DJ|(98E(0Rz3n|vos9kcp*2fJlyY=gvT{yWhOV$jL7xLL zlAi#^(7V6-s5AFnC+8LOPiE45gOgqa3KQBIZHjF7Qy7Kh73|k8lXg3`yn1rnkrt3w zj>I^b92=!~TI_>z&`8YW0mFWmHPsqJQCpzIs_dxxn%Mg63@yQt{P#z$xSk79M2i!tPhw)} z*-CJ;yzDDM)1sKM(`Gy@UIon05AqSibBCY*=^Ab4X{G}iQwI*tZfD&8Q3MJ;|Hn+g z^IZs#j^~A=c>6x%UWU`_;Z^%kz_dgpbDbw`uY=!-7ySEoO zRi3sC0YM&+mS*AOFLrL=OLnC}IGoic9`N}eqpq~;20X?f6*l&OaV^6CcZbHR0dy=8 ze9Oi986xhEB0B#hga=JKeQyy-0cg5g5W;x_n-^N}ngD%ExJIxtkesmbaoA&+E&g0> zDh;wKlOjY}K*C&4Bu3}MEjjX{i?jx@p*(k!Z)vPh9jZFg`30q36h8O`EeLgPqCbE4 zT-FYSx1q1ODKrzU2sO24D6TX?PNv;PW5gr*Kdutk$~{)`3iP-o0xA znQs^U$-L~+IA0E`2fB-=Ip^NdJ7Lwgs+G+ZeZSqIp6sghJ=*I~{su5>ubgJ4uz#`T zPVR$OD%o=~kG;6qv#H*TdmCe-YW5w8#oHM{vm?VQg*U&ELEo)9a{2n;F$qXKj03@(Q)DCJeoX@(@N}mxe0Fvi1uw!o6Q`Fkhs~-1-HlOp?;(W=OlA3h% z*(2wR=ae76vUZ-i`=uVpn5RvZLtw-xWOIKJ8xl&hk9<0J9&%V(14livZR9g{bb!Z2 zA%XWzxSiU&MyiQS0SLK1XD&vsmNhNne4oju*PY6RZ<7gUW)&v{FAnd(Fb?$Vk=9z1 zuyWzL1GXX=l4m;X*+n|(W3Zu?Ga|CfTXq+M?WfxQP+>FljjXm?wOYAY&yO@yN=-$Q z0a)x|XIQNvJEp8NB5inB+2>$8Q)L}&T62cK*Y%Gb{g)@?fqm_XcG|-Y%0i+i5bVJ$ zI0fNU&nN@s-E`A4}TvGsJQb) zEuNJ5O(u!O@E_=Q2&-X{Uqfg62WI5vVqu_EQ|bNu8G18CN4wb zAkprNSn8IqxcU2PX+oclz1d$U4o4_mB)>%VyY?3qT zW}kH{r}0Rv#!AjLKzQ`i!^zV$PtpXjpZYW=%U?$A3waBP{_Bl)aORbG5&EGqW4f-V zOyCb6?Ds`c7qH>2DOlmexy$T3wf0M2njxvezdJAkcMdD!&XA@OaMn78dt3b#Dc3Mz zBBY@TqxD*V-LFI^VgP(&KhM?1M}&U2R`+I>9plgw$b&uFrDCMsHqy`<8-q2*Z2Kjx zD2sQ!rOL^91=G^qv^TXWGw$|+Kj$}8$rT;ScDBC@lA2JGkyiCzo>wI_e9;2 z1eBYuxQ~YALDu?r;LGaxB0zJ1f(*t%_UHHe02yB&V3opCvlf13eg`FmV=}iT9xLNj17veE{z2P?VNKtOS&&v zwG!mF+n$`i`*C-RVkAj$j;MVPt}}2^oF*#H+^)I%WQ`lSH%_|=y;J;RO4w;rtLkZ& z<5@e|^D76L3%3w(M|lMgy?bTVWzsR`LLOu*R0YfotMHQqNuuB6cDzI5>KsoLceK%@ zQOo?2nuiF+w-$*BaaOzdEM+*`ic3vG@jSc+?j;SL+1D<>(E#e9ukrL9qE9x~>6Kr9 zL0}NGUHvE{Lq7w9gW1()z)Bj)K>T$F8PClT-o6QMC75q;d5Sl?E1^zCP1akVrn7aw zt)gf`;@-2x4bp~)pEgc=dv{7NGU$i`gX1patXc+0ONyy3(_;vEa?Rlf&){@A3UPAI;Y^x zt@%L1E9cVTb2%w~cNr9~9wE!TpKbAv-xOFy05G2q&yOSTT_cr)i+MoHQOn;?i}1+pR3h4Ae7}dZ3SK8#d?Ry8&Jy?o zqVkV-{AGI1XEu_GA!BE7$iYl}9h_+&@M?6{3bPmt`|+{=*uH=4ESj%LVs};>O)Pp> z$PV8Mg5h%J*e2Kg65AwVBk!oM&jPB%Ty~tEf|=0MJ%0XO1W6p3u~-rhhBNrR1gjN2 z{F)GA%oEkhv&~oPuqxB1ToB&WBqD$oT2X8K2$Z*pbdA#0Dk&J!&{Qq5EC`C|VAi4$dl0l!H7u&4jW~UA zWE$cSaqYqSR<5vm8{PzL9-D}~%-jixRn)l|&OokR@OzGJ|HPS*=ER73rLQeq7@hE! z1J;tYpN~X&aIA&}MB8#YArrZcxqNG%$eg~5wqP|4`!b@Z_cYqxf0KEdo1?>lp+fh8 z#x3rY&!U&U6x4F|hvqD_)C<&8y4|~UJYAhDlyw$1sf$x2c|-QDhi=(eWf#>H&WqALhw0r)E|^jdv5|-uL>8_Rpt$6puK%;7UXrSUG{+TbaZ3 zIvneK?p*pnbq~s>g~;dV!-ghY5WVo_)K}V0bT5V3o@4 zq^P>_nw1(;Ju4(2-mG_p)M-Yhj7PaoOW_;#0LtP9&&jNGza~4M_JcU0tqaqMw%_%jQQh>YF|Y1^1^q*ib#Z6J{d=k zf$r~8o~GL#DJMm5B36a;@Ot%2o)bP#z!kBO-fBl;dI${a?4dq#>b4@vZhl`ojX*~Y zrn7jvq}JqF?H;`dp}ZdPQkPFA$`+1*^SY|no=Tl$3<^&hF<+i4&K7^2mFEA9y4Eu!pa?2rID@EeB~+_>c7(|-->`&KE%ry2)CDl8IeH~PjnuR(SPvm(KnGS zv0YPhCr)(@^)5a$EyolS)G6reIx*2EoWav)s|q9RpdI;glGE$t?YodC16v)bBDPi? zvlFhBCWr|&m*QrBg2#k(()@~UbzG6@n()KQN?PsEXu>gsL>Xp0qLS*$2r)#vPa?Fc zF;_CydkGtf^cEk$L3g~d3b8`A%NI`OLE&#d1!hnTy?I39njid(JmJ|5KHobVE^m5v zAkTi2QR7UFn`kJgfqfsPJ&8b5HL~h|Z2piYQ=ISl8J#Zd?Z}ogVZ0C3>kQeO9e{t&E0HMu^HvW*& z&)>+B3o$(;3h=AT~y1pL1JqVkLo&X+$Bse?U zlRkG5B0nR&;2WyKu;n=$BK03%R8mc~+GDjFIG@??c<(*c_k4>W$9>W#Xkw`n-Vu{M z^_V~zf;FB(u|NvAYjg7u3s6jB^I|amyfFobtoG0iX68k7^%v%v<~#jGMa9#gqVO)< z^{o%nu${o>zBWLpQo%-`70n4}UA1hH_?yOyv(>P4=jK)JLei-!L8)O(-$#b6j}WgIW;ns{&=kUQ-!MnzPFH}imVyA&+XJsp1) z)_MoFzZtNP`k}{zZ342#pTr6*ye5Jath+B+10-{k69?8k*NAwgc+1A?8`(^fGn7=T zh1|aYorAFsw_(<&^-Bj^>dvp9zU!^XHf>-2#?9Q-lVKAQW<860fz8)jHhFyJMNrn& z)G%!M$QSv-DhTx+ys2b^Ad5o@Z-2TJEZfk}rO|{NSu^Dv8iV_JXt;eC`ik@Pu%0<# zdLq}r#%Stl#V2q|byn5j(-n6JxMbtVC;x%`QUsREUw>$y-oykUjX zL*ZUsT#3j6B+Vm>g}Bryr}tCP33l|civ|Je;3rq7`;OeeQSbFlJWGHCgZZsE`Krk~ zk|SroI&9AIoRq(00`dCuTepqE;Ty`u>idgSq%hq-yPALjp#ytZk%Q0yl|Q~f6VpOq zb-bxrcz;~f_Qo)1umov&ZX6S2u>_v1<{`S5G;il2&`PC*bGkASWi~+&BjJxktFDy^ zCK3ZF1r~zW*xcGk0en*j;6pVc1VJL8;$zxLonM^21&BnskU}pboc4YYNn};AtM5w) z00@Tl2gi3bE(M_RWsoU;9Q{EXG(HX(QzOi(MX@!u`M+8>m2u2Q~Y^2`90H`u#U{(`{}K zH47K+&SgPArUCxdsj-}T=r4Kj>jC1M>MN@N_Tro-)dDzf!4}m4DJ&(taf`qoY5PX@ zzS&5O)H%MPu?AUT6Cnj~xG^=;*H7{lP+jk)*xHP&3YiXijET~rcyB?z@6u}6h;1mq zDSsgEE+Qk!%^(uoPrr9=(=Dq6(@H|c&ZkV~A+$zTfm-wr?L=ww+=nL;X_|Bg8YeL> z6%XIvVme{%S~73RPZrts`jrQCZk%$#P;@X~gx0qM-9df63<@16l~tCajL{GET{eg% zaD5|VL(Z2J0}7`GVCsv9V0EF#F@EZZ-2 ze`W-2_CziLB3vhOU(@Ib>TB_iu=8$%h__P`U%&aFm|)o!@w%O%h3UP=(Op;*yO+BY z^Z8fa;r@GujAddfnyVSg@hXVL!-ZwKU+tZZ8RILiF0Cmqb{Z{}XHmyqsNIsYlQCa_ z1;FWw)&p7fKMgkwmJZ^WB=Uz#=2I__c%{Gr;flA3w3y8)i9{@gYK)$9{NVohp}B!! zr;#mFNCQw*5Zkht)L9|3@|SfiudA0mF0ieY_8y!FB;L<)_^T4)KSZ?yg4P8P@PE2k zRl|tCF8l##IDae*l72uOr*|8SwmWI(wvdG|f+sG7R9;IMi`}sSu-!Nv3?&6gKp_u~ zo?kuZFTC2nVV(Q0LhAoiOa4ippZ?{ll8SSRkjuIUC)sblnEt->`xn0R-@TE+)^myY z&&+-4>Hmzp`;)KEKRpF$AWGIS2Ax*i>Ckl?J&{s!sYA9#nHF^4XN~e%BhUt#Yi?H&p1a+g-4vs&C0Rd zY{w=@aUbJ+$b6oJ-79e6tBkD~XC!D$L4sxEWb#w8GrO)dJ)H>UaWQ$6if^8)or&Mq zs*XmaLt}xmcoMOg=>{fCZiT7V9*#TIg<)R4UuXU7fa=iOM|uIRg3l_C#mGY$?(AAE z+k#VW>;?HoQ{ZH@QGLWIgS0TV5dNEvQUaY4hiHvs0CvhBd>L0?Z=XR_QM=O(N*db> zjpOX}G~Jo!Y^pZLG&ez*ou4_3XDer;DK>}4FGq0?b+uQIOn*hSlbC^;)wCx%6Sgmi z%U<<#bDI-2ag*MQ9e(G=x(}`8l@(%!^IFB3%+;z-llzgRVtD1=?s*B_WioM z!{yzlt!5zpE2uHF!RpmTS;g2wB{bqL3g1m@N##vheob2B$ME-7j!%{P@eK$~4L(g3 z)z^Km{8~Zv7K)qLt3IKg?t*Nzp;pUz*!W>c!KAGCdephln2>x$d>Ww3Q)$4#u#Ceh zAJss*<~rQ`EoEdSH84M~dCmaLq7IyvbZ*#E>q6@C?PW@nJti{7ue6u~_UUdChu~?z zHs7FUEzl_DVVU?S6n<{v&@efPk>Z^zs6O5G#CSO2vbmMH^%L~9(3gI@#^oh5)PBWB2Ga8nfR2P zCbh0!^|1}>N1aZHdmUdnXLf)<1ZV?m2k-*44A)~~)_vR)bgm@k_7^%)mCJkWAXu?S z3Sn4^#=Gh16%%m2!Q=B*+d`w>YwC~Wb4MLcoD-(HUf6d|_9fk90>~vo2u81raO@Tf zEaITT2(~ZU;emQSP#9oGc%A-)=NxdE)B;f6+`VlYiGx zl*ekSOFGo2yHGwEvmA z<79~5jpyi&+ z(Fb6DmGQv*y1GVvJ&8lGqKe&sND4zCe_1JJK@i^{z30-l&{$I14n?(KQ}L=HpsHdD zIUC-2gu1!4_$B;vm8xWBw!GJR@U91wO2Ew?Yq77=s?K$5O_H4HNP1-gbacx=faCP7 zqP|D7!qYSr%prC_r1;cj3*Kf9f;;1Ze_Y*{hI2_^y?k`gSG}ozzFP1cc`w%pfL! zYye-@=y&A!)t3C_4gSi>uk0WX3-KLWzp{g*0YdzJ+yJ0|&ieD${IlM?(QjnA>Unw< z-^jG!x}`5jdEnxEIhrbebqap_+rQXCH1YMz`feVZ+d1ahh=@#p-Uq?PA)TKSAh-=* zQaNHHS9zCd(da(z2I*!M4XG9bTPV)XhMEQc28mG7>hi&Uvm5@zX0r7WO|nJ!EjhmX0L# z?h;X;BXK+9Jz0F`oM2!C_U2^3;{9v(hx?x>@haaRU^@qR*T($vaG+W;7cP71@eAkA z47sGG(Ng_W&gRWDIP=YY?JgKcrG-c_GeN|Z?@`fX-r))D{)oe$`MDd!@n1 zvciB7m{>>hacQb`uoTD(61VfgCLoE8G=@FYA!GKX3$T3DOJWf7UEQp6q*Kn4Bzia_ zZ%4mg(Wq2VM$6Vj*R-0CU+ct! ze70b;R;5h)?snYm35TvcqYIr`?UKXxCq+l3;2_G~;<6#jM@J1!zS1Q;4>jk1<}x3i zS$wx|i%nQ`LodPfQD?>Vs8^}g5S4{o&!UBYfWd!a9}(=*o2pKr4Z0{~<`ttA-=e{6`e@bmCw;U!d$*G4CxxLS6>fS!5I8``;`scUGx8Mt07RFrN!3Q(>$XP{8*1(`oqTx=8P@Y%j%HIsJc^gHxv3pV{w!1R<{0c1pG0{JE{cLHu4+N^|!q=(Yjh62dCw0YBb;W-F z4gZmq!>?<9hX9Gb3q%_jjt6XH0ckq^<+FeRztyt;obTaYf3ff{c+LgZyuQb~2}6xQ z+EK9tPe7GvBuVtBCv^PK!*WmqyEzCsQbMvr{qaS&;}(Yp)d9j}n1U3AhX{8CY=xPL z^FGaVHmzCsM0O24bQ@Na+W@oVVAO-tF0!^;sSMr0w0ZZKkokCgdi#ycTRV`{DxHKjFTcdXo`VuSqCa!>X zXT0J07*1jSn#&mjo!h-U9_=EXiur6#9-{JqI%s`L%Eq1BKDjdZ;s-uUdhi_6JU8k@ z1vrlLdr_H{;(%$;soF`SV@om(YdO}FHW!rf8=Q17#>U6E=7vko+I6nsA7yhAob|rk z^CSekG-~{)<9Qi-oRa~Ql=|V$QpOnL#v3^D>?9NRsdhVzqR2&DJ(%(I;dY5*yzOZ_ z4wo0?CmE`92vhKpsKeWGjVk|<8ol@y=(YPh{L}2f7JZ|LIdW4 zG@LlOu{6glye^zCSL#E5=aiRb`SxA_fwKQU>PEdV7=7V5Fy|YQqRkbv5cX7B_GmUbys1(0_G~>uB2^B?Kez_qul113dYC8;bQ$FJU%WQUcbDRjta;YXxzF)S&}>8k!~$`8c!_lmo~-)?gqPP<^JIh z?*YHHfwXe89c4tQNdNgR!pSO%ode|f1ip=zB()iO|Jt&ExcWl^g=`dX^c-NpKei_P z(9=^5IGIPfOd{}ybpcRHN2Iz_0c*TjZ?r=VtW%Gwkpd1VBs1@iTw#C$pcPY@x$_FM zn~-SZwn?O ztTT8CYW6bl2vQGT)^h)9f@Ck?J7lhO#doGLfYQzSvd9!PuAczgi5MDI@1-27j-1EK zTzd!N6O!T{whV%uHiTpN>&L&sPd=)MrXI1f6Yn#zJH3{?{|E@M@z%~H9K-DH@Ylb+ zID5U6^<9|55c^Af7Wge2azYa@VjXgqCkA2WXv**AHDz)eNGP5KFVSWkS;sM`WBW+T z64~F#3;@M%Pwst!12BndIWUwGWXlThXyAa%L|MVNdufTR#Wke%aqQ-l(XKG^UGyJc zpb4%$rUTWiZMM`g9x{^`12rPG53^y&H(;arsOiCwi+Pwqy}$>Bi>PA`*Fz)A&X0T1 zMv+#Xkeo#i9c}zSja*NM-zif~Ib#xCt3V)ghwnmzi3tS7|O>1WnA$hCu6Oy$Vw~8!qct9?wrrcY{=>4l;1i)t^Bl0{CBR zDF=@ZUzm2Gc)%2$$21`HJM7WX;~ zCtlyt0LmI!3+20=XA#%d=ofZKl$gI;_2w4TnoU(O>B|u{caKRWb8Keg@&)%~*4+n^ zg(9YEbJ|352JEiiS$Gqi=|lR47j*RQSbJ5pWSr3!rFQe!8Gjh7yWywUFXRZv8*ZXI z55`Pk-E>A*2@X9xgPts-s?>$bnYUxTAJ{!G)x%KFA}7SRXq(mO)yyXo`wMc#;vHI@ z85DUHG?8TadL)WJy|K=-gLKwkFj23*P$`!O|19qfw#>V@8O3%|o_y>7VedP@qFAxgnh zOZu(nKq*%6eAweV{&^PwkgIO&b6UHntGsi>CwwaLeXHo8 z{5*}PWtIneaTBy;a1}#z42wJD9)QXC=7dF%i<+fTSMwAsdS4N)bxIQiI#04x`9nj| z&kyVw^#G>!_ts$$Sb#j&BRN4h5jYmx#?!mrG#cWLd$zc-`&*t}Xz zQXnHNj$GI7x+Ce7T*PxdpeO#A9o~WpsJ?Q0;<6v>V|RL}v)Q?J-l%%%Fz5W|#EEV< zJkS6elI&ncfofYV<-Dn8!uy*}ajDs!=?10Wf>7^_j!F5Qd0)klo!#vzrIsLM}hI%jgrZ<_Qo*36MUJ|PxYv-K~ge8fEX#3%~nBg+Ml9d$_C40i81C1fGamz_yRbT93!%TPS3OWASOl!@bk2Htw5&h`T%dIdWmWX zNbXqW-Gd%>u@4_L^L{og-8?l0j<%l1oUP~^udX+#u%4Lbb!inHcuhZ?Ts(N@o`Vuk zsQ~`;kTdK!f)8zpim{}1ER&;OS15WVRcyks)uC)e*^9NbalqP!s_<8^-T9RtvK$9{4H5)4Ir#H;mp%@J-=*4LOVsc*C#NvKRyVaC-U- z30Uw7KRFk?q=8OKOW)J|IEvztMPYOwFMyiF(R__j)b@b|n?A%kSTMMt`Y?ucg6r5Y zlq&~NHyLU_d34=%ZfZ!S%6*d7jt<(l2pnIx<3IV%KcDUJXTQU5zsz5)QO6hi{O{M$ zt52owW+R?I`*=V3%0Jodz{NlEt4&3zv-6Ym1qfh&{O@LriYL|CNY4i9sCyz0sd$@G zq|bz#Xk4&Pzh}^o8}UOkA4)XIF2nUYYAL+_rR=iOqS?jVak4nJ*}RNNxL6Dtu2|M1 z%ILTyW1!5km2Ou=*^l&>C%5^aYTcgL>Z*`7Yzik4c45v<58qQM8zeMylwc(&UCJn# zeSfbi7ODOQOyqct#%ZL7k4R1UN=1q8ppMPcZsb!DkiPS-Dy*R}YSt z6(($CVdNb?1g{!-`+``mg)^3MzgD9<8iPtsQ@XA$Ny%2r(D%%7Z>-I0Lie&u5PdTd zzlH<{Y0Yz{$g*WSTATgx#>Ms<>s(-0s`sw4FWaq?K8U?sJeKmpk&O94v2IRMFs$MV zozuLY(d4R^Ajr@5!wRpEHeS(_6=E*K*)%#jhA>Ua+8@ zjv2+(*o_o+*T}h~hc-%FRIYpnWeKW{%hw)b2P>t9w2;?BM+pn)OdU#t40B6tqM)uv z3>H*SJ9kUb?kBV_e1L05PGA?by)ED6VpZE~ky;<_z1tl^P;4s=vAY|EtmU|aJ$qX& z8~08-R+mMMYp-8`McQNOkx^mePoLTD+02yGwx1bh3PIdi;$|;KZa*prA*^dj9fb4M z(>oE*)4I8U?s(`{`&O_dJKj61D>}53!@b_|M6*3W{x<~vNGX`a^~!sUxK-cHa4p^37Fmm{BW{{NsyC$D;-B4?R&_$# zFQ2oR{q25tF~MlUBqlQ^V63ntmS^!nh5oRtRrbybq`CBWx)mc=4_@MWOKOelETz-5 zQ1YGmgxdbw>Xzf9$4%%d{h}2f?zC~QH#vCxtvb~ye36tBj=LUrXZFcT znD5Jj*Vc|K)qe8L=lenN-)mdFsJ}n?JMo>ruX6*4P-+37Z-WhgX9oDJ^1lh+x7jxV ze0p+V*;0z#w%`2hA5)IsAu6AA{+X9yPF0cj+E@8IKkNLvqxAvZWccE~!lViiz3_+6 z_pj;XXNCW_ArUvyRezE;{g}QC>$#aaCyMhPH@2t z@CaxI?aov;XR{9Jr?@GMgLY1BaP8s026mslFH^E(zW&uUu7JxiZ)egE``r!<1Egl&mdoN*6)yh8Yq|}_uboH6y z^;Adtch5Mvw1uv&MGtL4y4Dfe2$h_+uY;M3QO;rYt$^6L-`L40zoUjd4-(sVf7mB9 z8AAGY9DICap-tsoX5KIjdKzL2Q(hu6L`P`K;ft44nZJ~vxvPwkcLptP9Idi-h*_A9 zZ)xF0gezQlr?4P{2uTi~RjhJiHeoF*3C$;MkzRr+$si6n#H>um2gnK|!kwe;!k+PM zuzFR93SSxT=b!`?RIgeb!|p6V4k9@EARyth3B*Y6oVXgdYyjNWzP2LksMLExuJHsQ zmm1mozS>>F%a1@J)lOIFhBm>zc*yMCg-naDul8Nx@9Xk2%7UJC^A5&d6b^Ojc(QI# zKi#;%R`mS7<;Grs81JV#ro9&U4gUpD!9WZC(~cc~b!R&&M9e1pG249$7hK1PTEZ&L z5(xnYdU=sjARf(JvYv+Mo(qY6z64p7W<1$g;F|UFK6~@Za#B$@a}lW@3D_i3ihh=S z1L6b8i>~bro6Bb|QheECBplJbvSAh%x7$~Rw%p^erP0`MQqmUaGtJv%t#TulSLm(0 zB(q1^bw(Rs-9r+WzH)t4Yco^*{&$P&+whAorzj zYA{OWJ<8&tcRfm^CYN>2*`U&?Jy_T>eU6?nxLx7?P3WNlKSqm|Q!x6cIm&fEA=GHE*R2l*hybKdqW6mYD+UqvLzAoN4I?5V(3y`o zgpPf6^u*Ap_m{^QP7%$jXSuC11^vcVPoXgfMP}$gyCF$4BOxaVGb1oHgR@9Y3MzS0%3h{ff#!= z09Ho=j4ZD@14MY#K#&BZfK5FKOW{xl*`>tC;sQEj6p(3h1r68@#c=@jBs&btSPt?Y zC95!+fIJ>hi^y06-_M1&tuyXjIA3nYSsQs(ih;hc-<1=cGRZ}Pk?bspSJ&8+2*f%( zqxf(~Zt#vhZN{N1IGZ`O;|_1Rr~p5m%aO?oWeo!tjMpm~t6B&w22Z@2zD3fApY4X5 zeSb>}8|08;O5#)$t@w0G4_oJa(n@UUDk70Do4!TABWEM~8rS8{g-f&nqx~TO$fn3+ z@{OZ~NgtrQd?S%*5;Ft3k_KTedn9vWukmvaRjHxyJu!EXv2{$UT?zI@-hN(6#W$bp zuQXmck?@EgzX&>QdD4-q9(=sw8lUc!S?GO@r+n-m7~EK9b(!zCiTmlav7)@R{oP2h>HSlOcgI6>9H4RJ^YnEiWp(_Uf7fN{BRYvK*{q zAdn-j)+cO@ict3-py7|9jNP{HO;bB2gJr#I9p_-M7-&r1XgV+(EXrew(iXqBE>7yc zGSEZt`Z%O+N&ZsslACqlM3pz%7`ZlDLw(|E=Y`$)4v>RYlBd*ly*)_ut%Q!n-^BqIHv;6pMwR2Y|tK~QUe&bq+Z+-RA3i+%cp}0B-^@pdxRg|gQ&?Ja0+{4 z&v?z7Bimy^GuUY|E?i!K?#RE}?sjp^^4Opw>zkr7zH&dhOU&yA^k%86{A+mq1iJ<` zBP2yg1#fd(sKY72donZi!XFeyET`~ak#973R4|#3!3hTDdRLfj-$k?rI_1GDMjJu5 z*=u0m0eb7<{SZKc1plwID=i4yjkSR394&O&P=QK#GulJvntZMb2&`OT2p-!KU`j*v zd0hZJoJwso>n}=!o>^KYou$GVn=F~~6!PjH3r=d#Bg{qh`Al~rDBm)O8dbgtd}@g2 z6+9V!Yz1WCDGH^Qs?&c|R@XHkW=Cl3n=o>TuV4X0Q^M4jLut5yh^YtmK;xXbyj!8V z;#A|a#euEnf?oA2$2J#zs6^Oja+6&p(6U)_BFPlD>K&byCogHsC!)$dMV!Zd6mIlF zD6nT8GXSjb%NcpqjqNW#$0=aX;2581?RZD=!cg-;#@eVyv}dW5^UX2if};Vc)L?xSCA}!8uAV_ueXZCCBSe$ zP6%?i2!0CWtsNaZM2@~gA_8RpfN(=noP!RIgN@LCQH+d%J%Y!?I z0c`N~1DJ2t-~!x4O1nN+((6S= zAnp#q-ix+QniK3ULWU%-Eves96Z>ay<4>`#1PDo+UC3Tq4wX7m0VTUH$d*t%Es7 zVIA}W=|SY6Ay1g+u?@zmhb6^6D+Ail$GsY7#c9Jz8jS!X;yDS|+)221)fwc`B0D(f z#Iue50-r*tVXkQmNA||T#o31QkBZ9)x!b$& z28wtAlciQ+o<^bE>E2yC%Js=7Z?uPfD2?YmmbIxBmd|8seYl|YG63o(80ds*zQeIn zOL%FcW-G_0E3-XY-**4Yed?}>>8YBg=HpJsW9rLa`bI)vCSIXxw(?Jhmf88Rv;U1I_r_j zq;b|a<73b(d~`RH%Z5A6-F(?C;_dNj&R<)JJQzcGz(-fu4dZrGYj6NNbhs zfJ5zM9C2(JNnZlHf!uzwU98KI0LAyqT%0Nf?ZE~oEgzH!?;iu-=;IdHO6@tdS&W~Vv~|n&6M#=LDx}~ z{@BQKlMEdwmZHEV_R3HTUmPCK)!A@GDHfSoys(6)^Xss;FfV8Cm+96Bv|h)G*{scl zUMs>TyaX8u+DO(oVo7I%mkvHyh-0)^fi{s|Gl$Bx%g4{!kWJFwiNzP#rrJE4U%`*s zt1BaV(Qmq?X!?TWmCU85sg#q1{Z|@F+SB>s$E!m|Sl*kTu2s(qP(2ysDHHcrpn>w< z>o$>kH<>h7WmH356-R+NlWd-xAWhhG-e6Re6Yk`FGh)!I_Db;yc(5o7$~?)0S~uL} z{ZI%;)KEcwBZx-)ww0TY+X9#jV~yepFsG63T#AtQnQ}5Knodc$>Nr4y=e2ZcRagCW z`y>7$!6%|;Q5?A*<2zYd$zTDCP5~^fJ$~GpwMRnc*z6mcLAo1YQpc$N8YHGyO$ijo zZ$b+r7Q$M4Zaca|+0Wy*(G&zjeCa%9h2w4;k3tWQpG7n8 z4-R1D0g#R;83H}om!u@Zr~o7+!jqC>_0PXPGxNj-=y)8NMj4B35d%^hMFkq0BE+3r zMwII>p4OHR1%4uSf4A+Gt13$NE&NpX{max2k>-~UnJq;ohwIQ{T8Hr3aX?zHQR;8G zPP@t~Cia_*s203Co}Z@{E@Nf04iGb891$q~TYa($O%#Wu*PT=+wJz?nZB1G-EU(+& z4c7=GaW)aR(L%^h{lg|*3)E=}%dtHKjmg}_fj0R}>8yt*gO38l4*&J2PdJ)M9)7Fm z8q91YO-80}dC;xHTVZynFqGnzWGuC zTZ;XH>y(tX@OO;ppH@WHhy9sd)mTWy=#5XPPD;8k0L4ZYu?Y$Kgz5wY8l?a1v;NNN z{w`|avk@ajCF7^x{>Q(_wm-g^qF*6eZ~*F5vb8t6sM4;i4^{w@NdevqRj_!w%P`b5 z{=SX=v|7XpS7%i!(ih|BOtJ3;cu96Zm6dv1zgb&1gDIaAG6pdb4nAe`h*)r&538j; z^GNZjr%0zv8E1(msk0FJ2h*vc`h50Ow!o2W0 z7%|*qGgJSB>t#M7#m#`H>z4PdPcr#L=fK98;OXQpW5!;R**P*m&YWT`ljS0uT3`6* zCjA@v$iCW-I2PTpY9%*cn_8ciB4S01UD*xOYXP#o0?HO$tRr-J0u_GK73Ma zisULopjW7g$^Gxuv&B$sI=0ZFZ(n)e^fP?YPuiH+*q^$0K`+o7hB-Y}b~Pp}rEC-} zq^pD6FNy+RoLoPdgKndGa52=)B)nnf4Qj=3D8=FYYpNCYxvQHHUzR=J+GTFxP>ArUz*&AmU0aiXiq=sKW16MXSs*g_4K7B z2TaPFh`SxUE^a5Jio3FpNsH*gO3??vbp1JHuIXCo|A2SMR1ugxAT4~LZU4Vi2y zn)E7a)rqRm!dK~M3fT5FzaNKhVhKJKzkzW2WJkzUHO>BUN`5n+ey>UW8M=MEDg^;u zUx?z5LO)Z#*rsvvn#XILUG+G0_4v&59B9OXy}CX638%r+P%#4h!+>kx%kpt3V3Z7B z8F8$#;>kO8(Ic2!BxAeQ^7w)%jo_1*xZ|`DWE%b@W@*C-aK#=|&*)NOw^aVc+x@a6$P^U<_Dx|G-`NkcsXMZ%f1mAUP(T(3kyzCq3NH^8`Ha_UvZ_C7lpK{pn_C{i0Abn&AI5Z|wf?x!9Yq%ov?+Q7}4>NZ>wF??dbT{7fop{vpjLfny=#bme^!7#VbFnkxil zNNv?IR+%5uVXVf(Ygv+ip6WIDjgSL^6&-=HxrK&JH1duoy>>C?d(oCT){2jEj^sC=*an+(0Hc~3y)Eq6r?+o{+d2-+jWk-eoLKUcm~=;d)$E(XmT z_`}n=U>@VZ$SVMN%yTqU$G5JEx~nkODkD1dLJHo>T7Ss1OZ7M6g5xvQ3ZZIM7W+w? zE!wRx>5eh0bqxvTh_R{j5f)^7=<~aG>`rITR43m@3OHpkhRYxykTn$(xFMhI zawB4^@9#h8UDxmAb)*&UC6Qr9Um-9Y^cF?m+^1B}as_uWcUGOgA9l0cFy?XzM1~d! z_M1$B_KJe$!%g&0@Jheb&6A_i0VfCR!cd)si(veXCSHVh46`!lhqFOBpiU{yYV^F; z3bZt5<`0F5rb=YB@8%c8H0iX>Z%J|mBC8Ha%ul%4tpPCv8bw5f8D9e)q1a#7VEg3PR;uE zgSGMu!#+M3izw8&FQ`*Y)gI3hXSTB&7V`()v#(18k&|3|5qL!L;Sp2D3-{Cf$;ocB z1>&$Pk{C!_zm;|XwTCO8s+@N4qxqXe_>w)rb{uElZ0rsVGQ)RI^1;*Y3trB$NjJGn zk=i@+0Whh)_sH587wafAh?kXlRViA0xrr6~h)A$jqO;(6kkHNieEhOCj+@j(^kp{+=Q1CW` z-!1p6s)HP&E%Lt2x%tI~A$y_M(;y6Nt(uvNlVDijL zEfIlExXJe^0r*jeG@jp$j!_*!>-vt~dJuSZsU7)?PB-8teD%S30J1$??Nf!Up=bch?SH1h)Hu2BZ5x*;G+z>!yx{{zk*HQJc zv_(H*{Xj{jbBPEpyw;{6x?V^xfpTb-_?FBQntPYx}brQ9x1 z8&V9Bi~!q7>Ch`!Oj+rZxSultQl_%{vp=@5D^hx;#cpw~AxS2rEGY-XTKqtO>v1(1 zFZ}R)#9Q(@e!;=>8XV-sWCk6{4a16k_z{DpU_n=&_bV0pC@zIl6p;ocdv;UV?ae_Y zQ6F)fUR5L6cDlx+eC>cpOh0GG(27jDhCu|2g}aJ*UGZM4_d#4r8=SB}2tk37?W*&h z)>si8c4D_#OR`|89x>y>5L7iH^4ORD+WPu_1NaZB?|&B6cXDtQo~|TcioZ{blg& zTf}1tpKd`M$;*c;Rr_=f%eD(WQe2Q()n_v)bL-8|7&O^>Y*beEMAECrZ^5lRLXXMV zMD)2EQ5J!oNgQK{5_E1KB<&^MkzKF|D<`;JB)V?LfsX6@Ku?L>M|fkd7$pr5rc^i@ z*Pkeze!4F&=Z2SLVl`JLSNRBR4{UebW>#RNTI2}zxdU!m3VG~|dSAi8|D;Z57|zHD z@nxEUJZztkcz_k{Bla7A=K7LxW^tQ@WRNKWO^9Vyhz(^CTU63kD1r-^#Lc;$P}S%Oszel3hP&?57eo zNU`1p44SnrMA^wHQIdEquxC=~TbmPA9zblo%(vqC3;(~p1^r5Ozc2ik_=A1j4Uzwf z$NL$Y_lvJpDgY^v4PN;YEN)8RnfU!%e*cW$k&w?3;oohe08rlh9ly`~e~AbGVI%bd zh!6jh-}u_}B^>;ReUvPK9Q*UK$B#XA@ZUmwk5BGXgY%n1O^b|T2Bg}0@oBw+LalkF3F3_Hj`@jAY;B&$iknV5 zuM zn~V@ggnjn?wF9p!*f&Fuzx`T~@6f7G_ z|8)OnWd4~1H@=w!Y!(j*ViOO&oWn^Qp?fF4WIT}M=x|Xe7j7CfK2*0-@0Na$)C{`u za{pkB#s0Ip{vjm)kl6n>xe1&5LzR7;^j%yCw|HQ52yTwNd6;3{3BicRY8*NHaAZC!z^>kxR}rl zCx;Czs?8Ujk8=%2=!OJa$Bk_@jm=anPDH;MgwYR3IhZipm-UpH`x}FqGy4oCG4?!pm5j6y}mSFUo_vXHJyCt`{$wq{5(WE!a0ptU&$ne>^vVzC8gg$F>$!?eYjYfloHC?l! zMOk{1B`FR0!_ArIQH4Z4R&NZ^1Q+G-1t6jEg|MjFVQGRl38gj-V?1uS>B3xNmL!h#^9G%~ z^M-*%^b1$j$TnLNAh;28L~iQH)$vW=hrDV<-f!RT*HbUdJru!!T$J0R06vZ`lWU z6ye37cIH5G73Xlr-|wn(8UX%#t!3MKN?*ab*-9>pB^tXcfR8*|!l5v!?pZJ&!(5fH z`D83sLzZiQ!wNJeXQc%oj2#x@~bHQy}2=PO^hzrq?Bjjm8i4TQBD10 zZaJqifzV7s4|JGp3g$jiEtRLPZ|#E+EvWE~Ds1(6DCE?6+v*^Cg6e}kcgKZKCFcqZg-gDU^i5;R{@FSiC6y;XYE>l2zRO>hzaMY(5l1xi zBhKg{gj)i5X9^yvB6H%v%fO2?9`-&csdN+5t^pTUeHO~>Y#=s!SK?8)m- z`Gir@iy%V)hxm>E4Y$v_EOIgmwQaGW3e*h}|JbUl zJ0(jB&VBtfyCJQe1HHL>w@McMe3En$Od-olEFW+3l;fzQ5k7!c=0WfNbOS+vN_|XR zozui@9xHu`7B81-x|($NE?`uBgasV1v=KwBS!y4^+g&h)wo1G)RL?iu)rv@<;l!jsA=P^VQ z*5*fsh>pCw*h(76bAZZ8#G{dvaEUfI>+!Ivk60ER>uYLGzwD+AjccgJjwd8hLw*S< zHjN@>y=SAxTEUXN`pUW9lVPEWfkld!x^tYs@y43>PoJh(cCZM{Qb|*KkeM)1COF5g z^c^wzdttj%?hNQON1N*x2dnr_Br4I`i2=$+;*ptB1$xIgM;A$;o@>QJ+PVkd0VCwn z%jIVmvQ$o#dztfIbLt*bx%$O1m>)%PbkTrl=80h$_QU=Y7uNv=c7yfmavL-jsb445 zQr_ams_eaD80jfxO}SG&CSJ0QwTl@4h(iY8j%tiB-E6Z@&bWe++C-=#6ms5t_flUd zwqD=nuAkPR4Kejwxf9g<>I!`i=};|AD348>E-^xnu+~qx%@*s z{voCRvlvT84bDR=wqH*ar9S*@HB&AsTsDLjsveD7X?io1Lz#GC%W|JNA^#^PIQkF& z``<+I|6%ZdjlrkaA5+5Dio5O2VE4IbCm8>A7mlS5FE7Vd`s(i(3xk!vL^&yvkrOa z>^D4g1=~)~AnQZlHL!Tc-Huqfno@*hePlMJ$$`0)%6)^3SU#-EpO)y8UO2(F^iid;ykUhS;!f8C7U8As*lkYx_QdxgK+oxbBAigR1_coh9^RVAQvweznQu!5` z?Q^UXkXv5mw_2BO=flPqvM5O8ml0q(yb>6kyaJg!A z@dLakWd6Mi29Cm?pii1KS8RBSG`YyXE0QQcxzxVUurVisE}K{k0AK}6(RL^x{Q0$3 zoV5&d#9U|fu0-yYLHMMCBpBgd=KvwDV$w&mD+ixv4tJwg|A-@9#42QiF`28~ToofKlKsJ(yt$VdKqVaJHN(^?Ww_cz~p@Ee?=$h^3PLyA@ppBFS6sL!;#V*zox zwA{We^}yZhY*kp-5}DAmK3*vBd_P73aPW&hpXF7xRFBRJd7Dq2Jv=hZ;JC z(gn9xw<88d#PJ44;>(tO$c`oTJMZgYY0Ac`&NsYB^{v=LldleL+Xto+ zgOuCt=%hs}{c^w)X3m0hqHasLt061Pn(|-~1(9w$rqLp3Jj%JB=+e8AK)$A(I}GFb zSaKi@7hj7TX`QK2*T{lwoEVK%OTEmJAT3G<^w2Ji*Yf1~sJAP6lPBvt)==Rt#5)tE zaKZ(We$$7Q`8PW!_}I6jSzoQ{UsW$xPyRh}LT=v&z(cB=!@9A2pNfhjZqvIe4sa*; zNV?e({S-9-vhFXDy;m5CiAw(3L){Ca_MB9nlwI~010&i?vdm$1yAD2YbF0^_tu(lz z%5wt^6Wrb!FF3!=31{RNLY+TjAGq-mXS1sSc6!cvqe?#BHSZmTbzl-Z?x^Px&ajDW z3Z3Ytu2nV7qLqu0MrLlu$chBp;AvGY+7DL)ml?c5>Web(B03Iu^8bRwIe$dj|A*Eq zgZFjd;+XUhY>vWntV#obu*v!!(6}{b`8WOy2mR0VDWU-4aeqDKTU1X1A>5#8&0>Aj z+D9DUwX8t|dIwg!qryi7KpXzvg86T#B+om5lm7Me%nk@G=Gx3^Ie510d%CcOmVHxd zpXdLXG5MLrUD&m+0~5n!>Oy)NHo(naF4H%5zgTeo^`NM_3@*xD?pZWi*Q`rTC)o<>114%h5Bo)TE z-Js1F#l5R&sPyR30K&4jjg!vUg_E!mCRQY+XyL>NE4q9VM7HX0e*J?MKlonmyBku^ zuMCY|vtHKYn1BUTaiiqXFT3R;ldQL(v~|hOr17mAtn@v9cB3W?bYTS{dIs&X)Z3*n zZK}4`G=0YWabEfb>-V_bz52B+LYeJAK7~ELg03B{$cj8CY3;igGGu9OaqRe_k!x)W z>l0w#s#bGetXhiYg#@M3{Q+#@4Rknka&GzhW_^Rae`RKpe@R*R1-bZ_goZrNZvONH z`jWKpJ0RmPu*JUu0Tj|nDSo29|9Uq3=JClt!4`jm1Mms8_!}I6gJgq0GgE)R58LqQ zZozI(`9Z`-rUPuDYY`BRRsQhxD{3dJGS9-17_GXua{Hav(Acpf?F$(Y>UB`?ZdMGe z76m0G=iin&F}e4U0+Nx2fxZ(JTF3){_Cas6ZmNt9GjoNk;OJm8l2C}Ji!*{dzib?K zL&n@Q&!!+}&KccpHLzxR#hNoh>n?^ut9QfjHZ}RUd@qW#pN7)-ad?Q>BPZ8DA#bXZ z(BO=wbk{5XR2umjLo#N^7mIztp|0-a^9RR|WBs$Ds05kXO)O=H1s|o|ao+wTLp;Y% zspzI!&B+U5uVj^C_>+bJVY3R3Q|4C}z?RchV#`VgqfR*+afhQ*r!dR?0r%|%ZkyHM z>L93Eitd+zjAiyCRJag$idX4f-58EwjA56Q<>82Ti?oXA4)y{BiG~q!;n)57!zBqG zpSVQ-koaYl9qL{MmJxO2EsC|Nt&t4CM>R;D?OT9O0vWn96et~wR+U-2Ux}(_fXDru z-C4uknh=LjqD8yda*^?aI{<7m0%AB^zrGSYuJ0?_@Up7V3SM1CbEk3I03R^{yD9?h z#~wxt?FmUn*A-jeok5!w4PB8In*wZ(k1-E75n^cLM7Ib9x4X9cn~j6SQp14`7==0f zY-bJ^B8TqJ(^TmY<)LE?8;qeRYfg&cmm~tPK8?SdFgbhRBTfb^TN_B31U#75=V+3j z$dZ|r?ND20{5T8So;K)PZ!cXTY}});L;fs#j@scdhiH4+RWQ{DhH)TwFIGaio3}+y z3BJzS_A+-ZT+v_?U zjfw&K(MN2$;qF5&z4Afhww;^DISrrO#Hka$9k|IlTIgUm*!R1E@2Z3P01$^R@K!(? z(NAS5r|szZZv;gx0F&TP1nA#3t$_m-M`Y6Hml#3^q;TszWNuBDQZ3hLt%U?A4mYK1 zaC?eFX<1JlVG%z)Wn7F4^+%Pp_1V`+){_TfYOKSZu-EcL$u!+k>jOlsIBtjQrwiPK zP0p@mA-uO>CMeI=xD)s371ANB*mtJUUWw~=<`M{TlW=?i2gpoGve7 zMfCxch}cg;7#hab3V4HrL<8wC#cy@<{$CqGZT4;T`Cm_((VqlZt#_XuZnxK{593+({m2ZZlV%R z4W%{P0M25SFtYs-;BaJS`d<7p56An}C%diz5g|4nt2(oOu1@3d<7cq_J&8VMhT6|Z z&u{Edu+q=sjZ_%C1s9kv*EkAae94hPf23!IULj3v&1;im13?LhlQb??^dLf$08?KN zJ15_Wg_Ev{`?7BA^}>pKk|RU-UbWPB2cD1V>fM>zeFQ!SQ5wC0TDGinZujHFc4aN7 z^XE-PuIsZs!!B$nF5w{Pdofa3=^PF{03 z=cq;;_uR#Htzo2oEf)!Tfxo14!c*wn)I}LP>vJmVIHyXe?poC*Hi$q6h57e{(GGGS zE|=PgW^*r6zT?JTU4d-(ie&!1rk;XUR{4(XBRS6u%#AIstSwI*yR_)hz1Np%5+fg< zq;*1Zon`@YNbC-TLGJp*km#FfUHn>Wk`l*A9JN^m6k zw{73Ps)D@_ogej}wvEy!#_W)V6b&~C8t)~t!Fc&LR%?O;Wx0IaUHzp7EvDix?Y}37 z#87W692`H;?(+xPL4Lv7DooX~OVte84(a_>vwGvkjUR3SF4sr>-5K|eK8X=2pKy8o z%*si_7o8yburCZ_hw|Oh^9K8xGr#Rkhm5Rc~=z> z&ZPW^L)!43dL44&zLH~re(@`v$9|)iK;waSkoPWOdgsS1Psjp+`=>SMWlF9oJbN&S zX4J26uf*AAtXQnoVqe^yI?WzNB{Xvfb50OGzsXn?;B#(yJeV?+**Z-{@jY%0`4(Me zg<4dHHh_dfD1C}o@nObM9I&^`h9dLHWW{sR9oI5~9}?rFc0c)qg_Gk@KY&7Rd#_j| z36w-^bGryR06xp(8uUDUkXNpJ*0#PBr`#97#y~pDhfNsvOZwfgeBNjGl>M})LiQ&| zkyCvEX!SZhhOR<(7rC?3PutIlS+cg$oN@^snYvryQY(n9OkFssHLrf5-sDh#lj!~a zi21>Vi#lh+(ihZ<6>E*oiyC;7@UzKmEpL)<+*s-757nj(<-VkcEiVeHJKZ2ad#{q$ z__(8v{`o^!P@5Ro1PC%`SEhG}Z^)r&+e`YMT=CL`DM67BKd|`4IH2vjL zW!Fvg$4CE;XS|f-RYO*EHHTgIvMGP13gBbR-;BARJ?@km$>?`<*5P(WQg=k>Gu{sE zH|q*)5~qmTRz8IYq&P+UiwZd^h>a4%nHKq>p{Khi7~H0W4Ti> z=G&Lzn#(idkBHZcbo2emO#$enNy`9?L=}z8^W+c3^r}&+joT5c#`6!|*xzClQN?eu zjH5)A?>o%~L)co_rd*n~^EYZlfi!UE(1QRoBC+%tnKQX;-VkXN`9Nf9@5AnG@QrC+ z$Z>SY+h{`GAkKx&XTduU-yB_VknX?b{<2gK^v0bDWmHSVBwJQ_&!Flyw?|og=VdZ* zdXBO<68;#YX;mxTxq{Gqy84um!6MZ*$QyqF+ULr@C!ix!WO-^~kzl(hmnIe!=7YO? zezz|NZMkJt5@9yN($h=6YJQiWf0Bt1Z$o(#p^F?{8n-_Cp+Yt@i+yCE&cd=@k`jL| zbx{*c>q?b~zT94Gzf1SHn3N{sQZ(lp$+Uqr>kz6d;@@l5U0nhk@|o9f0SR!k;Ja*W zt1x5m4r`3>zBhp6-=V1PvM2Bnr%AXQvc%4c_4lvzJUISzviu%ZVi(lkL|{=r%A`g- z&;EqPeb+?(8Bq0$+rek3)h^bLI6yulE#OHP;ftSK5ljVx|C(RKH&4sf3Lmjd`6fvm zOW!WM{@WyR03K@O-`5VPexq3ZBAWgwlUMGsZP7KpQPyQ?Fluf?5g35;q_aW?^8yYKfrI|aSjn*5OSBS5=X(k z__&TNKF}DcZ^b)ho^y5Qtb*d4o0Mf^-xZx{n}Je71~e8AxHk-FX(h3|IBAjdc;~MELc=TUGrle~__ZM56;V)7C@FiLVOW=B zt**K!ocGiVSl0j`rAf-c|hljrI{MP9Ky?FCG#+1PW1AP9xbWaEg zc2^Z%6?JYbLQe?P+4pv2DJCu@-d2stSG)hsCq1BIUqNUi-I2RJHWSd>(rYY}^U5$2 zNzjn;zoRlI@X-WQtL-RXIhOP=X^wpoMuzrTe5=P) z(aTxlG&*&2O47?)af1?Tx4u=F(VD%mO|g#bEN(8{%Midrk^}jc2{A(Z5s7Y9wr_io zpmx;|wA5rDiav6K>$So$*lovKro|U0_EZkZOPvQHK@CFHB=dTi$VD-1%X{n~&)t~~ z{Mn2K3=?V*9dcuNu?w2_WgL@Yj^*6BZ|uk7SAT%l4zeVA_#TItCXjEjrABPPy3&=m{ zk^jt*hb(YVG1kP4aLkT3&_3Oa)FY1gWoX=a0aiM1*U5=^OQr4#MUmysRugN|Wq+o~ z`((EC4b|O!?Fnal?dYWH@<(*Cdh_e|3<9UM$m#HNS2y{lcPsaMdJ)X)$Ipb(9P?$U z#~0J<7!#@lQo+}r9EM)VX7=SS8WNJ~FD}Ju0I=;ykzRz$c!`CbkD3$l9rF_VkX%a} zOs?*z@4c#$PJ<}4XX`s-%DaHqLqge&-XCW0ub2NoCH)!e`LBRV`t9ud@2vTv+kFYy zEfw|M`Qjar$(YB^_-Etr16levFZ=ZYP_|!BUlqIeh5-vZ7To;RJ>XV1AJO0Ej{l~B ztJb{Vv-{2IvugK?jQzzm0MPUL{P&GppTef~KK@#^E#Slfeh*{&at*+fZ~W=IT7hXG zQ=yC1TeTl?q#AVa>)Usj1y}c90pb{{4;Ph>l_3VQMVdi2T0m6GIZOa z_uV&MT|IjTNVa#O!X4s)NUXpcul9OSAlY@xOSOs>mruRFZui(zw&JN#t=$tfqBLlJ z_Uq<+$N01-tVmVe0u>VdJTu+pHvja-t+^M$$HLDUNKcA+U%z!I8MuG;QsQ?1x^6E#N`@J7=eh_0v_v2tw38vsJav*K6ganYrF+T(o(JGF8lLwni z%j{c-Dg)NjItI+q69#>QY^W zE%>=T7k~^|?zzpSRGaj^LpCafx?uUf3-k>t`93Qjb{p8Hi~(WQy4A@ibr0fbKXWg< z_EuHiVL<7?Vx+jy2AYxkJ1s)8`)~|Dl&2|8Utb>w)-!e8cQF{ocz!@10BIR7*Nl?8 zw!4eQ!y*`&Av!iYB=VgfaR8JeqJejLrWAdBHQ-Grk~6!L@J9cQuo=wYl`SjOAPQE7u zEc}@*?yQc%3;&0`_YP|^+uDaIDk@D>nv|e`C{;i}r9@P^7?CDj1w}wW1f+!oMd=U$ z0RO$%$zghv@x8U(tb$}t@kJU)9 zUja|;D9D+O7{aKozh$$#QpeJy2os^lZ=uc*T_#TA1H&Zp5)XU`+};NG3a{3ZtBuZq zB7BUwC;0X+ktp)ZX+s+1<_c-uF%lmD{m(l1_7=?<8Wf7%kWCLj`~%p3TFdnu z_Dfj+@}I%}Ka-OD(!%?b0{boL_@Asw7++#=_K3ZuL@8M}cSxMRC7AC_11(sZ&>^y5 z$vU;Gy`+Z+a1{58ecb)L^aKmIvcR6Cx#&%lJYIRY-}F<`1BpY3X|>x=jr;K^E#hsT z{4t_$de8J>)6;B&6^KN?@#$^)w`+Y>M<&p-g+9q=+wHTVSiWc0*m?iCDVF|Mb!qnR&B6b&4g>nv{GUFJ+1U%R7upl$ky(RSce^umns>R4 zYMUrQ42z-}nHe{iF1QWCQXTku(`pVJe|gu8L2z9Fl$8^o^x8Uaq1%oWp66i{O(PVb z7xRD@(c}k9sr0X}E-VQ3!8o&8wPm#SsLJ09ojw+NsOnv`_N7v@VUW^n|{;Df3w zNABIn_#t1z(n`AiY#0`*gUfB8a*PSjzTD=>?OW{Fem~VS6~n*0*K;ix#_n1DacH`- zD`~RVd&GpgrR4qQQR;{viVrXK5yeR~gT}?{51XRQa>1imgnop9&pUS30E{rP4*t$?S(Kr-RoKng6gCY<2&j&FG!|4`yAfQgunbsBV*grIJ21PUrSduhQJ7SLUnB? zLK8V}lvD-7x~p5@uVrVf9})Cx$Ddea{z~g!0e^2iw);Qh@i#bN&ku2I|GUQH|1hO~ z4}e8DV_@j31UdXBknSEYMV{N~*9X*H{_F65IjW(Z3IO$5gztwp#U;ZBR9JU8&~g$F zI@Q?y^N9+V@bpC`eL7nKyd7)njca=r z8~Z`&sn*r!|7us%>bl(}k+k3Bjcly=h=WtH{qDE_YN!j*^VjMI*u%^Y)jS^>`^@^t zlVTrGk~=tmOn5fed&qI+j*LR~CjIam+Ex34R5(jqrn!|lui8Nl6{??4bOUrG$6j`k zl-{=6{Hd_ab!DF69T(_1)ULpR(^8;cO3tD0)Ao(mJe|HreQ5oZpF?-D?T^^U$21UX zKNX(0{??t>xD={_Tiap{WSiA3iSvwo5Mcm6NTny7#JnMDO|TNxprE61Y%4wPOc0mI zmM~~Ak$xxIvUOaSo_yq@dW^J(d+^<+84Vn29DKteuYgqk(-MA~mPuy6VCGT30Pa0( zD;EVe&;Ks4_FM129fkD`RU2;`ln>x%hXS#~k)CcO&_Y+CTs7+gMgYAo$M}#)j*??8Z9KJ936f!|mNlXzV}3$ON>Jvg$m}@s zYW$=Us9@=GeY|6u>GRe)p+(e@rcddv8xJ8F4vC-95*O|JUZnTr^E9zXzKJZU25FP% zss^i0{B#qeSP9L9Y#`ji9BKMP{d)rXA9H%4_o`n13;N@aFSm*mA)AWJY@njSqep+# zUyB^ni|+sanwa16S6A)N^`v$v5~tqw#bR6 zy8ooXrUQw*ey!g8{_p=UtD}G6=f1b9{uFa%7-_;D`Oh_0_H}T57kt8Isq!mLYX`MO zY#JU6xIaEN_j`S%i9_zbG;RW5Q(8dY;^+c^(n|_VK85lnDgZ9nLQPV~SDMtMs_pSH zN>rQR5||p{y*=g+U)MQ{$oon|I=@s=uv$_6SFd*dbHE_*^T)qJw*Cc-$o&^$_c!ijtCq7OhAmz!;GyW{J`1E3^yF6JNP{try7%l zMBEsw+q6u|CwoS;MYru*Yiwk%g`*`r5BFJcLBaNk!*F(b+en{Utw(gn9edI494I{&OMb zc{hPk*BJ7Y+USfwwE~6#K-rK`r6g6U@{i60DXOzab5Sl25In*(zQ?DG)Ye%KCjUOAd^d1^` zb&)r=88Xgq^NIa8()K#f(E6ximh7A+m2H`Cx4>%v;605ps_m6CVHlm&0&Wya5uiyu ztUYicBUgYt+zi~#qIm-AVb6OLdXi{encGd5)~`S&8r3c+U#?H$E;Z1}*T4Ge(V@!7 zBSe?TYl!Q3kpL(5!%GI;CwZSq30aU2r45y1Up@cQ4HRbRAJ9i@Lr;0dTH-whxiL1X$RJVl_+21{`qJTonP5co{^gDcSZEK~V`B{nus^Z_Wk2+x zC|r^dZ2YJmJN@jjEf%Z>B>LIeu7?M2VGahFn5xHl*XNeqv0lHVC_9BrA*hT{VZBfw zDe>WvNcUXJPj}CmdEQL%rITb>h~FU_;!z=$I*--*@_nRVPB>273Etda3d(SpTQP3L zh~g!_aGIi*8}*-;JP#51d}18-I_Htys9>k@N|ecBF+F%`@brnf-Q|OsCle=?*UXyTF3!(N#tLllF?%8q7zH`>r*hlpOioSO%~@xd z%GPH5ftkv4n!hd?#fIN*oGmVkyNXK=|8l@YZXa!&GUc5oc#YS8z)fzN(|axms^&g3 zym%~}(#3y5Msb?77u0lcow3TbUgbpj`l>s#I@OMqjhk=Xmku$#*K6-+*(8X~!pq}A zKq~xfU{F}Zj>;2_b-FahNfc8~JLk==mr0<*H3vxe8+-A_0fx4Wd3M?m*5F%vc0IG{ zh`Dv5h0puWri%pDzoUay8ownfPQ_;5R(gyP200gs?3+1yAa(oP1a{iDLwgg%0DaUe zE)vmSpSrSTGd`U1*pgSiO@yL6Hcj`@q>>Q9MPSk{`aKSgs&MWW3T&u{m zA6qTdHM;-)9PhLXlCBTxF&PfK=d*HeITzl_^#;qupI}VCFXz$$v_=MBqaUed5Q&nks90Zpe>SG{mN-VI6+pY05+-`)$jH@UTM|@n|C6N=x z99vo1XuNr|6xk1#yB4-9Rs;3Gmv2ojT7W+mNUU6sahNQNvf8GdFdpM38NYVMiv*`x zR~YtMz_xzSR!}lylaM2t*vGj!<-5yX(UF8D%e&R}Nhc#CR*VhZ$pafAf=hjg`*J6( zm@LFyEbYA?v<9q)R>I?xQWsBuw#NwL8oIFTvzZy6N}W$tV0W??RZ{+-yVwAXk8

    K8OESK9~!Xtdx*uJSb>$jPd^ZVtm@D`GJpF zGilbH1|9$svEU)CT=XQEZ2`m4InyhrRatuExn8R#HYIBnNP2EQPUj#}4-@Q$N~E^t z*hhOk6gik08;MZU8%9#gYWDQECy5fVlNK;9!S|((qS$jc^AirUEq1wgbkkwn@Wzec z!%G{@eBpI=M&~~^JQ#R^Fp4gKy<*?U48cefBmOh^z~|0;To%2b7ex|^%fwp|ZZNQR*E_&>rX=Pmh|uqmNJHeK zo9~(Xq~b|NF+lU}3A0*W@1$f$Az#M=9hs>S5TdK9dSb3&3Bs<+AD64a7n?JzZa`gh zoiCd)8<CDRVK-)^E0e;43OW)UpU~(7E7U zc8zx+q$Od?2D~WvmBtM&N|pf; z*uK(~gJXPOvyuR{WCYam2N8k))K>rFwo&W_UZDxb1-Li+6j<2tp6ByW=x| zh9^(Mo?wQU&C}( zEIl|ppreo|T)9BGLZkhzcF%MAHxU<%b;ltg@oRo>quLu4%@PjW+ej-(1PA#YFyaz; z@zymGtG!Tp0IzR>J9^k;0PEm-TYS_lb|Vvih*q?2&*7sikIpSvewpYPWcWB((1gBU za5mJxR)$qxoO~gSYR^#RV;cy*4`Q^hIMJI@+9k=lr%7p`aCuR7CySr3lEl0F7Aldm z9BLFYrCF+UL}24iM`2dS>|3Ay%mq?n0Ls3^)N!S1rot_D^!n0H$mT9s|6T8j(UNXe zNo9#s)KCi_T-p+ux%l{4RnCZAN%3~W=l|IVUTiJZg+RW>Job{v~Q93CDgI8RvBxDrEfU__GChLa;j%ub}4L!`2Hu^t)( z^IN4DcU4wT22^407ij{~;yNyfHNYxuPCZdJ7Kq`aj^K}J$v71j)_<6Oh$R~1!Efc7 zpeJyF6k!$V2(zGVyFr);QZV2FC72kAOo^|>@%!(Vpi*027Zufim`ep1CF-eu{Z+=j z?khb%K3+x&A!sxXn9?N)EKETacNi*?I0?1Wro0UaPiRUMe%y znx5s@iB-2A=AYhPvh>KbFAq;|A`7)!YJ8;u5Vl&I1XQX7Wv#GbD?ABSJNtmaY1uVw ztIe05Az{mt+F95>sMLn^cznLm=U&w%W$F#D3TRvEo6NK*+?Tm$u6Ck!fRF?{Ww+1@%T<)DHXR3iVzd4gPrMC(%}$* zpPXl^DhizCpCZ={!(w!_`W@xm>K#AaQn~+XT_q{yxA_ZxYb_LAK><+>zXTGeR+3vc zv({ABcSRLDDyy~g0c6HsF$w?JhdmNSbk@a7Pmfhcc{|j&KX=N8+x&48!!y_m^ ziuscKZEo?fFvFL~jZwf}Y*>(c5bO5r`S~09PsJG2hz=R^Dgq_F57s2jnwf(#2EPbv z6KK3iM*Ile+O^MwCEsgZt231^1|lpng|aQ*vYNKP!vQI5v(>!ztRuyF1;+_{+_?w^ zeHF(>e|k~=FJ|z!_x=CJmj72VgV1oi0#*AOfQGgDW=D_2oCHFZwEE#ob6;uhvac)D zkL{cWkh4$#9hy=_{-s%c?U!ctF$^;>PP|J6n26`+zS-DU=f9hA|73#ynI-Lq+P|^T zzX?eE6;+xMD7exhg{WOKV&Ct;uev^A6|V(JLBUa~!y$Eeh0r3a12=i{O;@a&RLsRT zv`%jtt`X)HBX7b^;va`jh|#;}TI6{#v_6N~39E!uQL7jpiOnMUDQZ0w7f+6hjzvug zX9mS=Y{~8L;A+*OGVodA_M~LyRA|iyddG|_UjjPK1i_=O6kQU_Nb^o6wwlcy%xk&# z1&^c5$xrejU%06o$VunVk5?hw=679UwxpiGr!V5Rcm3Z2DC9es2AmWnh#yE3@y-oI z5;q>e?EOj;Nnba%#R5dosD;dny)Aeeatf7*Q6#45tg$sr%-fvkt2NSk>1OxJ7HNJO zFj{)$&N)X=PeqaIT|B+H_oLq#M&0E*c8`0m|DZZ})P84ZsyajngXgv654a@pfZgV` zhWhIOFT%%2#CCix6hw4)oD2;{CtAv$OmGm1!M)9H2ILje<_DWl$1Q} z8WAWCICneDQFH2g4uD3kL8a!ej2D$?N+d^cS@YaD*CU#>N%K%_e#ysELZXZDzI6as zV^4(K!5n28-h+2%VhU0ng!5O5j5*esly1De>zsAAwN=bQy-&w%=zf93G?!=k#g?(_ zc5$&r<>7g;CB>cQW=&`C+D~FIZ~H%0bEtr@<0Ga#`R5e2bQe@iqqLr54LV#R)V-D# zqBo=(5P^82f>FTIHRj!DZ%Axf)NPku*RXR?J} znY&-z=9;!m!n{_NssSHq<4^UN$exziljS7w1nknNaEj!QBpx6X#EpZ3XAyc8xSn;6 zrv?ffHOSH_o|nF=9h5z!ejOZZ{f0)?2+`h)QB{;D^cG~;CA>xD?HrZP*I`WTTWN%W zJwwbaWFemgd{dTRub%NbmF8%b`~XSZkK!ioPM&sjYXe_=vK9KlwzPISB@zvL{sBII zqSAJ1J18C9eRh|QVNkL;X^J5#M7@{90qo8ELN?&fsRtm(JYO|p z<$4a7)=K~8fT>-q%izr+HAiQzkAP2Gk9g4kW~bW-91>M$P#Cf}f)$-gCNN~FOvV4* z_8kSRC3|%3s90H7Xwi#XI?jUbo(UPgjr&!``WMVRZ5R&uwrXA**gFD?(g{hnhw#Pc9%`p0bw8ts?g*X-T5T`@2_d##G`2g0;@8 z=y6}&J=40WXSsm8TpzV$$?U5#tGluAX#dOT=oz+`9oZIEMIU%=@>j3Ml5AAU8-)!%1wiLs2q)v6Pw?XejhR#Uje|B1*+dMUcAEN3=19#zIL0@5bG@a^3Eu?iq{KjB%>&J$y-WA@uh4GwI+WsS4*Im*of zFuB*0eD-5?7!am+)hnd$1lcvbt<%6K>LSHKw*EqIbs!Y%n>)P0o~O1o$CHqfwJr37 z*pKa3xPS~ozv@)q@gFbV}Y=SX&OZ)<9{maRoRE*e?6WrdM-IwxQ9<;(5Z#e zK2oC`_ZbH5|K~!3mV)$~`)-^8ygkN$RDS}sCOX)q4S^2NzYymb`ZzKq@Uc;=#+@(V z;r?x|HOswt#6*5Z^aB7ucJZB=Go!}?e@1Q*+MdVUHG;#|Ri2!U;DF+I-S>FOV7gkz zN{NvVOyV|g81x2gX%H?Egh-rD10vNk>waNtC?90zI^@6^&}ooW#i};RNTXJYLnVAN zIi*8V+#MXFsw7kcP4k7Vm5D8wfc8}0Bq@XhgesN3@1Yv*!9~-qM-s@GX;iwen3Z;a z7kZ|er_xL^a3ZTH;ru}h`@1n;yz>NkFt3|Hy1oBYHo<=w*Dwc!oja$QBnCj@O*ETA zq_+XUE9Az-HA}V$DJDzL>UtxR+Uo(Eo%EMsL8%}w#3n(Ah47~%t&9OCCvWhxqM5?3 zd?OW_sCzWcrwRAgHs=*-|EbJOMm<`+vn2%ou1<{Usq+5(*MeH9_h-~R2X4m%sPaEE z`V^VgS@bBS^1+#wIswEbvAOCn5VK>^QGk{@@X9l_JF6VCUo=`7`NJ?F5UyoSECc=j zKo1%s_Y}9dTn4UfIBn2!W~GE*@Fmj=@I9^_ZJ^O zB58lc`31zN{f4sk7O|sVXTs`$)#CKNC@%a#{%}FwQz~BskhdHd8eu1_4iW)|bYp?D zFR($^H|@A4RJWSpZM`2v`*#gD+mN%_iMq*{T>^1IRc} zLC+N8SrS}w7v!5+3J<>CAO29%Z#tWvxXTI)ELN(U46I`WA6h6mhKYXgV(Cowi=ckG zc^2&#V8rL`c^~Wlc!0|_mXgR?%&C%UW9$3V8Xkw{@zEXpsaYhScswhuXE}TyF=ceu zB0M#cZ}@U*BSgtNB6VTap z-~8uKK%JUvmTLI^22{rVVk&>p%lyW-jKl0oL8^`5agEIziv5vLcf7+wyhL?izOa}} z7Txw<$caNP2qN3=(FnrKR~kkN3q}slBMj&mCRtI_*|kt)jO@@kB@+D@`+p}UNW_F^ zB-rw$hZh-b;lqUVP8sTLvj3e{z+y>_o79zCmNU~_6}a6vv2mQbo|NO;09Zr8>BMMV zA7-O2#UL)1QfL#rGBXG1VkkGpx&RaEwyZNOikRHT>jaVkt({)X95!y@SHQiYGU1g- z1_d^ufG(nmeGO#6?f<55tOtfuM8N(^5S19Q*C%RXM{h{as=N9V#{E~Bp~+M510CZX zM>^8AXEommm%I$~ihMJ^>nT9?w^F4X$6FJTwb^_<6>FPY92?T-ZOx$(u+*?^QC(jK zTwnuY6233Z2x?`K> z7SDA&O6!MP?0OK^u?^K6t&>*V=4ROA)Q;}N{BhOK@6LHpG?(W0Lf_+^8$J-@8jU&d zP4L3aIS0=}ZsII_Uuh0sAkkWhL(T9HFv9qlhRR2v<=yjxqkH%m=>y^Q5g0$CxsOr- z4?PhVs3qLK@(N39h8?AK1TZV>`_N-or{YqoQ zFFic>PGA*!f@sSSw1HZ3iR-q0RJ=9!L@^@0`U^vt$NA;`;LEjp;DxR?%BQ(x z8S2f`ELi>JMw6ryxc2DDM7d>mhb!?iEZ9bV!QE*mVDlCo`A=n5r-&7G#z_b9R|joA zNZ${N9d+OFNG2C3vvO?-^tY%;;(F(vR_e>Y77sH$AzYFOvzUi1Apk;`AUS}qv{KG% z9CfrU1Hg6!1v}1J#d(9ur#|BmcbI)eaM*@6AmE0f&h=r<*bu021YT6b1g7ji1S{J_ zrBS(vWtCRrL?VoLH(VUWKd$(EctOyyp%lJ&$k#-qaB ztLb7HHf;5{1Dd8*;|(SQ4gLjL6+QbGR9 z(e<5C;=f~+{K1N;>UGy4%d`sEu`0*|J63&lzMDS&wOLZ)`R8bg& zgByTvi4Ip#h;bBeOC2tTtirw6ROYdWlow*3lyq^7AIsZ!iVEcskG_D*cBik9Q~6aw zE`AHcsFmU(`as{A6y(}h?i8QDM_+6WmWTNvyzyg)DTnchz>?Oz@r%W|9SPR4w-oQm zZrIN6-~Q8qwM4k9Zw5u<^PLcfP-EX~qui0)FFw3BkU6u;dWrcK1zd*dh6&C~tI0Lw zVlthXn!=h)uI6xac`zjJdj|szkJ(kTZE~f=Pxg-Kmju|T+lXfvGKDGnfA+U>FdppP z`Wv=Wz=CS4Lj@>c3*> z{RJh?4+P}Dq{R7wf&5zt<1ZAkzkKRHJ;Nm))O;1R)7q}7ul_y1Rh z8M|-Hh%PJJ9evqJ85k8LRYmwK4PXnru=wCB%~T63X|}p0Uu4)S-4`;!x^s9_ip&52 zjZ*qD((~j0eXvt0g-WVm}E-Y-#tV0(3*yXZtBsMM-g@$#LXjdE9mh!*1#j zjti9NdmGpN@$yH0mg1rq8VquK+ZMB~vPRi+%U4x-X}A)U%uHX0t6ALpsk-XTSDGRp z7(M+)K}f~Hv7c^Jf{@)=N8X@p(eDFp1_P1O72@i$CB@36 zd07<2%*)vtK1}KgS6_s{%t=#dx8BaaKX^0#I`^S5D_-_u4?3S+xUgL9>F2W_hROy( z^lMHFFJx;8O8uO8p36OQ;e2q~Q0_mFr)IOU_x#UB*t10Im ztsQZx7*pw;9b+k~aD+4f%d%a?%`2d)D`V*N+nvTc$lI1)fCo#rqz9_cFz6J^#;~TR zuwr-9O^?#?uE4C0Bhq3?+N*GXJ^Vt!GN<5M_DyD=DsSEY@G|{BAy@qOI`Dr^k6*mC z|Gp~!zg7OZ(}R6>RE*d;0i;QQ2q#9VlEgVDGS50;={O1Gvj^ce*G;|% zE|vs6Y-M~N3`vGPg85PZe55%uc7*{|R94(|c3_ISoMepz=#33)hGCz*$vO#+g1Qml z)#lmrlseX#-|t%Wmik#fy8Xq{puTB#jRHrK93eeRF+Oci%dSBp&ZC%0TP; zIY}Tt>8)N5d$K7+HrnzhUmS#7xQw#Xwa=s(HUqy(9Zu$^pV!(d=x+qGNhrxqm`T7I zN0m(nSKR|-`5J4V=6z}J-W|3EwNzMfQLYr>I-Wm3lX*M|4i05~T%SC6_8ly=RfKH2 zguz8upw{@q-E}JLANrRar+V`X=5AU`4?o}%ZF{o<9%+=O)QH*W9=A#sGDb z9XxTNui)(3vh%wg`B}K^isikBEv1dMyQ`Sq`5($`k`fV!Xxpz5WUNiCCp*n^I4i7J zTHR2Wen;}|kN4b|9HSiPKW-sLKC)8r)}(R_?d7Y*)mXQ%WNA0m5emmW^L*}xT80#_ zKDoC6>zyG8S@W=F=DVqI;j1z##@|mm%ujVo_@8^BB|md9KWw#TX(41DDm~?+>rrc6 z-`|PNFx%%M5arnN#Eg67Nq;x{XQFlER{YviY%nSnakZFfQdMXuhOSt)f*zG2_O!qH zKBJh|C?BJ?51N~9a)yFdnYbu~$YvNUmGIf}`%scN@wq6oLhps7q*bf_>QOpP(hJ|* zKN(gwP<>zOP;jAqbb6%;IZMch(h8a}U$!dZ47&0qL91(2e7EPY80;=$z2LFbAY=WB z2W@E!&K$7C1MJl@*d1fn3FmMUOWDKN_%x}s;j)iK5&VaJ6~-MY7x@XpM6)TFe}TDh zMmFPug5<+|!N6xoT_O+s5JQ!R3I}oQ?NZzUyPQiT-PSi^niCTu-LQRQ^|Wi2$=?dV zfYCH|1U{X%R80V4Za#$U@Ju>WUM6}_G4L%tD?zC4SDL8k0>EYcEnw$+Zy*ZxeQ?e% zy@;#d0&>c}(i|mrU>owB=ejM%J$9Pw}Kj&tsARV)cJ2t3>MWCOa{Ol^gjV766Nl zT)i2&ni~eY_jlV1SAgIEsYBwg%evf}k90|&0DXE-HAFg-RXv~Bw6#ZPXeLDlAEE-c zB##USZVBT_C$~hIE1O}Ofg9rRn8zyoMEu)DSD|B7X@llr4~0i&8;CDxL9xn9?{VAM za0dO?0=+9IyQZz5NUq6C)%)$IykE0G1Y(r#UwG5J4`nAGC&+ui!|Odvh(==u;Z4xI z7czM?{=ngzY1fy`)+@mG#d=s29EN$fHZ==+^XmoLDO(#&&P-&{`eOSyDOO z_i*oMX4Wvsi?5ngw@!z-Y}g0Y&l_i~g6Ng1tSiC^fzx|^5Or%$KQBB|%OSqeaCuyM ze>vdTIYe$!m~S~NY;+1o9xu9J9%+veVH>t6IHq_!AVP2vfZ#a!kCl{CREQERaYCl3 z;Cc^Ehk%Ht+o?gMvU%*#+wGN!(c@fr$s7g>6?oK><8f<;!aU;)>8WtQVg9+z(<4Y- zNhjyYR~m3MeEuG$@O$rWA8hY;-d$2hP4&8frw_IEGkpHN#a=h|&w6U?8*`x;R?li9 zynJ@|yK$x6kuVthN4;0y%K7D?T{U}4@YZZC5DDTku! z@LL-u7W98QfF&B>DlEhGKXF@;+&a!ae0%UN6VI&ey~T4%Z2wedq3bT!1H_2{wC`6h z*BB*JcX|ZZsTD#U3-RmKh>YXoV%LE!!y?-b+#S{wtl%CI;DeJ#Gn9zJNoi|p*fJl=hq zpKisu5O)Q1Qit{!aw}FtWYZm$Sbbm2&bWbex09hcszyC?H$Ad>m(M|C%cK0c6M?LL z_ej$V&D`OfI3_q<>rNkHdCmRc$kJ9=i%6tEq;Z*{Bo}pW+(tg=%jhC|MgI!-OUMb; z6R1Zy=F${KsX0shw*pL&?O;%WKwM+rb!<^9b4c)hrLc+@tP>rSgBTa$uFD>b{D%PL zjGGS(fV4n&hyCCz@NvTp1a>J%7>|A_y&_Y0C*=~WpyV_?(e*10U4F-xL2ep6Q-fyE zZXzvq58@26RdD0)w4xq;E5F!Oip^PtTPjfpdJqAd3$C{TqQwQt%-{^Zs*hi306VMI z1&Td>ZmTg3s*tIZzz9TCYPl=vo>^Jt+?o4)Y^Q(97y&Mp6P&2JU_M|{P14DpvCi6`BYBQ-I13mom{R*)mYmI&bt7cuj@phAFymt__BxzdZD{A zt1Wu>!_J4C2%IIAQ2hyVWw^Q;_!k&U4^%g+f%@9x?x`Ym-UhbI8@>STm?|kA7xJzA z!uj|^H9b8Yb&^QV;j!9pV%Icdy0s(@t_+gV*xkHNWuG1cxnFjeV3at|n`=38H*h<0 zpXOH@ObF;>Wx~{ImLv4|-Aut4hoQW8)OCSo(01o#qHzNBXjk_QBEnJ3{qYd_U}s~G9UpPDf^rbaE8J^ETDj26_6>FZt->~R}1o3HL2{unLN=_k0;-}aS; z&zZTS9xSM2X41d~GOwn#St(H5D;2{TN>*qL{aOGTa{7Ab^l$*yk;3+!zZ8? zj7qoEOc%jS`4TIkxKOB>V6+FooZmaoaWm@5dE@IfHJXpm1pgb zv+0Oo0X;;q4is=U_sqkSl`jndN6{6&8L`(A2z!dg-!b%g{eKEh;^ti+PN%Rv8~v= z+-G*qrfg9C(Zz${6E)vb!tO09B><222W@(ZH!|icg69SHf+BCh50WA^^Z<7n= zJiak0-YUYq;#`loo!4FoaSnUT+YWZVZ+Yta`}FDON168C@Sr8qiA^DS z?H1CBb7qC%mm1@uj$S{*t~Jasz8{qiV_$U6fy#HLznIlbk)K=OISL}qvu~n4R_PKT z0fT2h@HQV+AKn$b1AwIX=rA!v<7`YeZb&`$^6L{pL&&rT*Wpudjjb)hAD{hEyD@G7 zaiA~fK(%@`A9W7N45@=F-qF-iNh3S`|3vbh!qnB(IScD{S*})@i=>cVKxtb#1e~>)d3QbwEFnjRF_5FaB1&Vq@na8CLOxP zfCB8d@rc1AS2a2}eQz=;DKJ0qT;%g$ZM{ut^Te(k$Pk<-spReB=LslQa%ZUsoOwsR zS82WVteb7q7i2`w%3Np0e<9GKZhZhQYo1x-Xp%>9kx#N>vl@KIxVW%EPn7&h(_RMg z8!R*-PC6=KPE@0BarSo4GTE ziS_~l?v(_*;A=4=B;(Jd#Qp)dgw~Fo33}kwhGv7iFo8X*n7Xu4OL)hAek<~f7BvPh zD}7JAKI)p5^3vqJJD*H~h2BK@^w)oCcvW~<>%7o5sz^y89h*Y5z1nR}!{}fWHf}9} zc(tq5OmSFYWnOTZ$8dL_9jKuj{33XctJQiIeB%-P82NIYx4E}efLojV8Jgl^&GvmV z13QSGH^@e`*bOvr2?0CPAP?j+OJKIB-$eS8_Va=PR;|oC{ejfagWgD!A#xIDks~9f2jJtHHLRUO z>v@PTWPML1y==QQ>gwWW9bjozr-4O`#n`|)1`}#0!*z5;wmpoVS`iPQq2GK=$({Em z@nZrDG$vu$zNt{fUgyoFz>@N?E7_vfV&w+i!rD!EE=!#L8+ao2d4y zmerV}Q#g_MX_&}j+@L~TmC;w4Yo$IuS@qgc88Q{=YUd~iW-%7sXTu#Dyx%`<9G$ve z^>Q`x!_5uKHS80BAmty4s^&g|_vckgqz^Be7HatB?&rmy|h_k=IUH7ya-Nn0qKQ9d=!&nwDY(So7XvJ|B>PJlUMoe z-P^9c)q`L^K1jRVMmTiJ%H=XO1-uQ+uBFLeY4kwk)E(ntKr_rj>~>QAD81`HOttU} zjprwGR$jhF-G!6+z7D>=8D_d(4x&1HYp-gCg>gTudt<{Q>u+L;2yoLiCH0ZWSBvA< z`wU_kpT3IZ=8~BRJlDi)yYB-U#55m|Cgc;gUOURoNCS-b%cgXm8e z__vq*Keqgs9rgSCQvZR+@lUVKcO3P7h*;#XRZCGZ>MbQ_ZXh2#*9RhRiJc3Rrtd2> zTLb0a804I}P8UJLmxCruoBBR)n4V)()DV_N@yBVkEF1cb`>VVaG$@qimwSM`B*E-MYirdf1FTUok-DY1ZF60T- zw7nmHGLrq1WA7tb|5dTFfXm`+P1lp%nG6Wre4_TTKWyLGr;zLfyjRZU)S8`;?zsd8 z|Kq%@HSl?L%wyulWM|gWbr)H?uOb*Idm*#fuF8bT#}!*u>JldyJ{eUj zl`3)XABWNJ#J3ZjC%W^9&zPD*?jdHz;=I5wUEH&=3wk}GBP zuDr*su>>8X7uRvI&v~nxk(-2ncMIV@NZctZ|Vs4eWsSZ!w3}08&83P|*ALGwK$!ync51x^E z1i!GIemy8h*6)Y<=3BZf`g8QWZ@RuwDEx^>gZ**;E@aBs5e~dfKU9B_>XdJ8)GFO5 zr`PmPpZY&}&3;Lg^i$n;jMPb8QCZu)4~Mk1h%{ECy_ zG&cPg|5^-Gk2&2*5l$~o%^MZ2RA%$84Bze5YX-Mw*W|$u6Eih%v9W^@g`TmvO|`{! zg>6F(p|3QOnRM?dI+KZ@kEUk!7uqJx>N+`do5n^Ad7~-iZw}&6hhSaDUUr{_@pnnA zjPH3Ou^^*a*KhygC{@CeeUf$X@{Ra=K)zeGs!Ey{!c`}=xV%?x&>?KXSx(OwvPUnePZ&?aYc#4v`Arrqe@H$ohTAPsi%D zt2aKGG?Wm`sp#esEI5c6{7Nn;20r(yFw}XmY}X+hx4pubt9n6Wl23AUb$FcHQIkiE++sC7^t8Yr$tx>~?I6-pYf+X6I|MOyMIp-5G}P^A4jF#YtVU2Gc9v zNr=ZK9PJNX>I6NE_*Azj-p979S%}fvc%w-E%+!(mhQc?z51U4M1F!p5^9P_EjL`Rg zag$p6D>c$Qt*<%k-lOv9xYS5`xz6XDw_e_RcWG3xOG!FYj#>z3PA?tjR4UsvYU*4TqF}uV*=`*xJMq*L>T;3S)AHgeUhADwL(AG!an_XRfAMD3; z>Am?2*|5ptC8y%~U!3l`b4WE8dYPVf|H!hM7cEJ&#RUDLO>;sGx0v zP-vN<>H=2eGu{6{hmU9oz$t<$wJj_y>Q3os<&|F~@_jIuhs;>A=Ky3RRfIa_#Dn^m3~tiDN-PWzp_%;2 zOb4vwJW4+DaR-UEILnhzA#uG}Q+&>qtmV4B!F_@a|DGyjAnM1pD6h%~OrJwBdmoJRbSMu3CIK0S{ zyWp~+CBFQIyr+?2&T=Ue%7SxGf2Wh>gi6P@2^D^DT|NT9FI+L=MCSW_Q6rv~lLn>N zZ<-9Bvw`1r%7K;fPnL~wK=&0nXgO6%xrmyd5*J_Pl>vV!F$9|5j zOJgLDa&UOCaD%>>N9XHg2HbC0r_vy1&vj*A~^M8XkR0^cw5sr>Yd$&&DAT zuWZu+-DGpEvyT^CXPX@a8k=9Ti!dbD3Q)P{#TrB^d-5Ng{9GUuujp2`VS|2QZPRiv z+W+(T3joW;zF<|jO^GN+?D{8srBT0}LHc?3)}^AL02^wo+*~BcVJZ#BEg(|;27EFsoBzc|2ral zd|x7axz;4}C7;mf*30)Vsbjtf#F8lJWfc&SHdDVlH1A)b$_ApN2|e)QP|| zA}j(}Sy0~?3#*|#fP>T|&DRzP{_C*Z#W_>8?nM%iKzb5opY7V}9pQM5KKL##VPMe% zw_s{Gn(Bf)*~b}w)qU`7G$r?a&)P&+QErv`l!|Vi)Y(@{XjPFNW9#g(x^z2Z@9;)w z!c9v%>3;jC5WspV=WDEw4-B@cER|4RS*{ff_hxz{D)p|34x`jduz)o33rDSw7j2gm z?un3_mwA|lsS`Lz+yH{l!CaoPI;~H;M@K&$KG*-Y`C|&1$xm#EqKM;EFD?wx^`7-< z{ZJNl%BnRO^0sE!WhoM=z4eubg|fFZKW{SHvMgzRxxglbbA3{O{)_^z_p~iQT2fa{ z>*nBaF0H@7wz2{MH9x16z9ca*WBJRtH}i8*Pc09W`eE5)+6vj~BhAZhf2Hv~4Avej zCkl@z1Tndom=8(wYO%M*0`_^qKkknQ2f4aWi7jD}dEOXor*Mp(>wVpf%+y%^4-gB&e>Unr^KAO5>7lnMhOV(9`{kVTz!+ zohKvEJ$Uok*`+$p8-;Z<38A{!)k83MeyrmAGpN? z%p#kwb~-J5|1riq27{iQ)4h+%D`n=~BixSG2zL7wKc%I`9m-lXJib_FKKjyWt;`0Ml{Ua_4GbXZ8uQM{D`egvYWZ@;qcgf19ze`pE zpy?mX6QFHX92M4VFXS}i-9nOHTamug-q|s zbNa^>IZB>HY^UC5<(vNq#>)&7X(n0(dc`VK&fh!CC)sgAVI$PH-kXhvN^6P+A*K1t z(g0rO4aEaCgZlwNoDW9f$>XT%rLpYq%M0S$aTHOz;%dI>NpsE4kdmC?L(Mxc6RXF4 zPC=OoveiH(_8WxDy^^zK(J35`#vd6X)=$enttMZ~6Pk2?3Rta3;wKyK>$wT5iVqe# zbMeh8dC@#2K7~oydxn*ci?Il_)(PY#*)>@CTAvb6%&IGkpd4O?&#s8+^^p%wrhYQA zD((?w&v|(x^^ktAk^3!35>F^{ByCY<>`BG#SYi5@GXE5o$Rn?ww0dSATU6WN%g129tjET}`?4gk50-A_TngxsP6y!tvTS_uEjh|#)4VHU&y((lfsH=pDV~99@GL@RsQv| zw?m9k+m0t4yp2B4;%U%&eHEwF@(^?NYZWe9-kGBQ_`K1GuXNDhlFbnc+Q0(b%dKvmJYsMelujZFf^Zah*oZ25GlOcf+@Vl zhc)oVu>!L~jtABj;ins2mO&uz%cIy7Jliu%Jj_3-nNaG8;>3U(_~Az+(( zKxNVmN}^+L@!JP;;46;_jf{nt0Fi_DKJAi=gI`Ns!{cQUQ?vuGe>|X}RnV#*127Ug zdDN|lAeebSEQ*~?s21UxDSHQTylML~K*Ysi-7w<_E6`LVjP$|sP@faM!%yBD4?Qb0JjUHLIpDo^k7KFYGxy?c;> zMoW?HfLf?ChF&RG(f^rV%Y##ZtJO767zN*jU8TM%e!`bptVjY zbI=*W{M3jlj5U|4m1$Udc|h{vhnB_135@mQhLE7uSZ#b*zUTBlhJ+k(&$sC`gsUus zXrwia13Hk%^fnL4k#uuTR1i&5+S8bd`;T7g`*OeU%kT50`NXoGLY2Jq6p(KfF5#80wS6GIwqsBGRl*kJAt!Kqz6C=E5+0Wfxr@GZ~&c#xRolA$@mD7!aYB*ckDaf@ybt&u}3R-yonld*nXn5Ja$U1lvM^B-IM{kxcV84S%rq(xj-;b=dpnAwUIx3V-Zz zY&F~Arsu^+n0(&wIn8Q&Mt@&^xuPrt_ZPOi(4gXAzdewslMU)i3nsWi3o=+?kYfhk zfqPx1KF~&*Pa0EuCv)$O1LE7J1L*aK@I`bW>k=G4rx>cbugDm}x)Z*R$@1Yg&BfHc zJtVGgM>fN(}0@bh3~h$9aQkypxIhP-}o z`lT1o5NgX|9TVEOBvq%CdAKEDl7lvX1StKq`O`fCc+cOJf}VU3KrIwUjj02@ppMGY zzJ+>G#zkra;0|v-u}usk5egZg3eGz%T^6EjgjDrmGkRCFw}Mf2mA0jkrvcpV79`hO zFMIIK3M;kKv)zebnR*}cE-CCix z6^PY?CoPQoF0ZxK$vxShL0&_hpYWmo+KJTb>fja7h`=W5gJ%yqR~@po!=7ERV?2@C zJf?Fle0~2%nBV0h*vUslv@dR1Iibv;aL$pYjyix zTFHky;_^L)k1LY~5aDWXG<)<$yY2<3sGc{4AEMzK`RhaUH*&eOJC{q^P_fxXNXNFRFpS00i$YO{Uw2h>;0qo(&`p!w}t7o_h84e6FSDwFK+1L?a3IBWlTV*mFTR^P+ z3GkHbw%Qzt#)$VaK}6vMKKC2uLKh*gpAWLurC%G~9<|J1O$;;&SL(bVHU=EPiJo-r zKqXe=zJ{%jSzOMye;^dazj>hz6(@+5ive`b^*p#M8%BE4UMzOWf@d`_``i<^R^A3{ z$+brf7c!GuFi90c@6rR2@=lgd=PcXa1`^agsb-AtFc>+S2_rIif=m1I(XB|ip>%MA zu=i@Ub4owmHsQtnvE77LVZA4|G^1RmT zk~l?!Yjq(}RE|78O=6u$?D4uxdzY2RbX`NAxB&fT>Gp1kh6NOBS|lR5=Su%p`9b?r z4<)BJ2VK!$KZuYYteh9$dq4T=;(2#e6m9jpTjvw~|vq>rT%hv_%jW`@&)S$1m+kU72=i{!0A0 zl!24Zu9R;nVJUvIW5<0M?R?I6+kWg?In}+HcB@m1?wN+^Zo%2{x!n;p9yQu8*i&TQ z4zj`fc9*n4#q=f3wB#6;!;z)iR(dt<+ht)gVT``Ws|5emx-qV^W$R}OBVmOOlB*F# zG`{sHk7GI*z0nHhiKY-SA70{s3NDT%A(HY&uM`>jj+>QlxA~#BXV~UA`k35ZFZ_06 z>xGKuoaxx*!O-$)N6>gacvLxRsmC3YuXtep;ZqxDunh-}A3o*R5wv^q__b5Mj7sP1 z?d^VhFbdBBrCo5UwbQN_up$9)PgW!VfsfK(9E^ANKwAJp7-vcy1=d2{VL*mxI?5ik z*@dET_Ktk_Fp1Po19DFqd!P+C)D162)sT$c1DOi}Y1mwg(C^E?JolkZ5N4KQ#t@nM z3;p62sj`)aSkx9^+~gaEJqj0>j+ftQ@qGDh1JFZGL%I?!nd%bja+Fs51QwOcJMP{F zL`O&8zBjg)K^n5M=9>=IC*3;R1ESqog_$o5TE|4CH{87oXQ|B5WH}Rh4TMVE{EOW! zWOp^xTP7S?4^D6rUO!zt{uC$$TwM|16Y?)IVtWQ}yhod%M7u6ARaNvVB$2iAjs+8j z<2i5AVQ^b7W?)REAh5=rvua=pz7$-ld`a(NG-W2Y}Q5v4Xri>3x^12o&%cJid3~ z0Y|sHZd`46%{9QW>>spvE8?531=mscb)UXHB;TgA_)ztTJ7|4_9af8dN3?vWGO-5& zExgQfOq@OKCe3%C{D}vNUTgxUi@elv2AJSHdDLtm+3tG0EFr?zyjqTOhz*~IEh8<> zCkFvSeq(`?9|$}#h5HY3KD%ECl4*X;RmEZrWE8ZKD}>cLf)OI@v+>jYp-Pg*Pk5|u zFpLEi?19Dvfr6mz31W_%nsrX~Q`ICck?Lawf`?Wcj8UsmHz??;X}2EKGWQrsT*h{p z0_0`$QUL!SV6f_p=!V#??(n#QcWI@lAz|1MOp5S)>rVPqJNeaFpn|CuLOHTDiw=jZ z=>msf4g8LxcsbwsOO;#D?hSkBN*+DSy7U!$bH zgTm3i<&~a_bz{x^jKwcS<32(`e{}%n<&|6|Z6Rnu&piWsN1?DshVz;i?=a55PT8A0 zi@%An&Zy7o8r0#Q&+T}1ry3|}zt&ZJ9Hkma>fLUNVlNAFvhLlgEjxd^3m?UG_v-@=`$qtTSXd8RyX;W4xg$jlfd7P@_8YV^t6q(SQWX$tx_}y!CBOa)S1e^3tN$Bkm1?STL9+ zh96y*$cuiIe$L&4%h|8&^ya2~*)dN;?Tk8Q`mf3>LO&{w94C(womb#ujPreEhG^c;@JEC1Hia@R z7d2WSCM4YT&YTKJiphcr(n~bA+rh6VF)ch(h@S#qGG|sTz*9rvY4(KWl2Yv~##^2- z3aJTEo4IryxpcE++bQ$QH8ScIRe~C+fR51VoteAjCsRVDpHA^QHTp<&%Q2@0e_peS zzmZ#608TUnHy;!C@`~K|cL##sRKTW2;7z3w$}aE+8DQ3}E&L&8jd9vj`9fj)KqTmw zQ8B`|;;EtLq>sg=w;6-Iybv^3`SCO_jiQ=BPrQX^SJ{Z$CWMt~-C>iVEZT<3%8Gpn zClLFZMKq?KTvLcnOCz%qV$vQ6dYO8$+>K^)b-V`|(N!mLb9Qx6k0L(bDrJ_>tql6m z8vLmwAN(zY-}@MYy*=t+g>|Osi^RUs1|w^g;US~&?b|050uR0G!yZR8sXR@W@wBK- z5$U_-@eEasumtosO^Aw9JgkQj78bndLJEyFW`X?ZzKQVh^9=9_+K@*^oUZ9<%jdQ~fi!1LL*j;?oB<1E+eA5xT`MxsXB-!%w5RS)0HM@Qq6&)SGE6HOJcn?CFI@R~R9_^QVfhBH|;qm7>6P~_YpWQp9 zH^$u_FQ*JA(6tc`m0M5b9$PZ3^8R4@-dU#nvEH|v2W=33<^}k^K(}ldwqLaSDvx>j z*=?cySiMhZV`Au(WBjn(e=5GOQn(GO9lpAKR(@TGwwOcGHPP*(uHST~FUlI^x>8jrTGUD)Q0QPV!9k{BJylD6Fbb&m4=qT2*hyT2#P+G( zlm*yB#xjNIAFEngS}-}E4nPN|7Md0|b{EKw4`LCNcR;@N8Agi-TL-X;ijjm}#VCOJ zZxJKw9k>Uwb?BnJt?DBN;~Yz=J-K27Llmdym5+x|E1Lh>fN}f2{1^g>-HqTiS$O{f zCB+5sZsf#XAq0}c2DfBTcEhOoMog$2@WFf~m0{>XDKP0$_5#M=3LRj=i<%2Y%{#)h zk;43B@eW{KAZNMDM_k^IyTsS+hn_8_L>+YpLa_*R%B2;v(k2+)=d5{2(n_lJYYTVQ8w7TVI}!V>4@@`EZIB26H=PIsfuxBchOwg3i3hQVcxA>V5B zRJATu@2@yI#a5rKZ8Jn=syybFh(o~3Ur8I&B|Os~rt#Iu_@Pr8JZbR0&=C-37!8zZ zhgV39v~uV8-&8vHZC{O054}5PKe2&uzT3D2=on7QZ*7Z5Ils*uGgL}HeR3N#9<_K# z78fdWxiEv zdre@7T5srJCwG0r(vxV1@A$zC5a3DHs3~oQ%O_h7rDpH$3f&h^oIzD! zrw9$+2IHvbCOV;4h;91(oROH-<+mSNy`rgWyWveNo6x7!)AkBix~DGPc7RaNj9 zaFc`Xe*OmGhQiFf-8O+>pIJe$pJ;jGWA~$>S8q(CHP1IHd%uCykA}!Hn%M%n(J#=< z_mP+0o7tB+wrc0Lrmg?}IvmF&*2>D7&RCsZJT)xkYBO086UV`!6myG)K9euwt2pF1d{$LeH|^Dvy7TIb zmqWtqIZ0w$C@?{J3{83gp$3OxgDL1HvhMaAHCYGf5L1|BV3Z*MiV^a_z?;5BZsRv1 z2#nX7$kZnC(p*(wYWQ={Ly);G$QAob(W9vr8cskz&V@Xqft=ic<&2R8mUJdS?G5s5 zOH$Mqp54T2mkBy5B%sD5*#et~$M+QXBA*#9;N19hR3;8(Vr_!T*u+R`sTl(TtCV2b)S3H z`uhm|Z&rSRxqcPk`xOEE!DH(N5_UkLkO>fsETNb509xDcQ=9+d$}d#5FX&OHv>%#$ zzfjo(aDbu9FPeP4=hJRy{FZ+FH|P5&yXB4mnJJxIQy|JPM4S8~%lFr?$Dh1G&>ufD z+6PbS!i<7VzH9OUxR;6B>oEicehEt;^;vpPZKkHC{{AKyR$|&Dc!kIQ(MPc4mfBpC z>Z?t1AlMA|1;t%qPRXCV-H~hcCGoX-6m4JvWp#HNS!Lck4L(u4y25bxQ8P?(3x(q0 zRK~3>>~xVu@!MNr1%o*YZ@l<+E5bPSyVtlWE;orB6W|pT6SmTg*YQf1TuvCTD^Tmg zP0{QkOLX{*WtXIj+Z?^TW}Bk!>7$HptxU#7Vk~|=!$LQTiTqKe@}5+#XG}BD-8O_C zF;W;}-fP);MXOR(5iKB|4b&8#B{yf4MK3OpklQyd&*WX(ln4~tc0N9|P_+9P%M@J58TZU`hB53K;Agb&-UE}`;nC*}ouN09FRcYM0rK?=eY2L1 zOdsh4&rA8wGa>;O&|80rv;Jp1HvL~bBz@29Z)ckEt&LYLjTw! zf9jyWZvOA}L;^Hr#~3USDc6I#TJ2IIrRzVwdYS9bmqD8dk0Ue%J|JtQsK9Nn0F3Th zGfj2F@vwKi9y#Gm_WFxkN9a$SDN_d@b7nl?>4i(MLo>=L+D?W_U~)jkTG8&&R#3BZ zBVUiHx`e5Du8(k4%dDiocr;s?zklEY%czQ*b?w{X@wo)ch|y18jP#4T4qNXhhqi^! z+BjE-97Cmf`Fp9j1A)LVqYeu{cqwY>mLm0&Lh+AP9pJV%fsCXBgFr6$Tlcp;P+$1A z1D)@?-|x|XxAL#tx^o0nuFkfxJ^~FiI+hTThQBgSM#%K2XAaw)2Ob+R<8WR6I_86+8 ze~ee7*F15x=giqr+q;v1DtRA-&+4Lu z`twf#;y*r;44(-Priu~-;|N;Dg&zoqvhCsEhyr%NBHgTxys$^b%U*vwS+rc(oGT@#gijC z6QBBe(JK#4ED)T9y}&z*Xg0;=K6Px!GyOecBiHE&(RDI0Wn%sU z@{&SEyw>IC{@AP!g38DHl}|NEub7N7pss7eqQlarwzAhO8dJ50UC`2G2EI!qwdZW?0Bnx zpPOSsn5T?qCb?#OOK1$sNmeT$K24Q<-cXWxA5>QIRZX5p{x4VdJcDyr-E6pr zgmof4vUO6y2R|cUaDLvx6pRJmkAyyWxKy6vIhn5@HV;s1(z_UaXRy~pt#_dVP7Ng* z!llw~Bb}8lFbRh~&yms~p`u<+*Ibba0ec}vp*M}+1=_Nar<=3QMu5sO|(@Dv*}rA+%F{ zirdM&>3|vz2Ee$V$xflk6gZkFuS1o!04B$W-J2jgBpd|qi6%e(1mm_tAAgiBt44S= z=r>gH%rrRnni;5n4kT+Cw%JOYx=!>_hRhr`61F=F5p2t7p6G-v)iSV?3P&Y>5ez*chU_ZQcU)V0SK3bG;-l(J9e3;Rd<6;o*1!In8Sq+BJ4; zd2<9(UFL>)Vez=P`^$RU`U`X%d!89H`V|J{Kr)>eNi0t%vfV5u2!9c|sk4hiP+8Q1f2~ z3K{UoBF;l;;@DL>&Bz~A3f?x9pjimo_3dSqRoC-bY<%Z^3Fd5)++{RA!Jz<=aTZdiMB0A$IZxR9_bWS}54(jQDgr~!hD@_*z}4pZCTp=$Xu z6KBcci&S#`5|7h+T4Kp7^P69+kaYW5h(G*Ylz6tbk>QQqu2j)d8>us0I zY%$dzZUGd>mMPl2?vTgJv;jzEqNtlohE6uoSg*d#!gPO)X8xk3PzZ1N%}YZccrRz# z%Y=oyYqyBm)SuWr6Xy zAM}vV_((WGc@5o~H%}EI9C`xX6@ylks7N#AJZmB*?Eq}@z$CIaPNY>Wr+>(SiJpcZ z^(ku6B^q*rZbP1N>f0xqTk_pmHbuYN0B_W$7U7-bPn>J2@}t&!;{=BJF?bV) z(1-V0BF@*>T9>%((tv5uSso2}e*{~7Rft%|iy|0(Yv({h>UMUW)?(&7mZI}vX&iQf zdJ&r}*onL>tY-5tY81mDmX)5oyQxrzd5Y8`){>sTQNg$6^2D|3cvf7&W+eu%_Us_Q9!n}s-rnNiTSU<#U^nnF;k<9s>WXQ_)rTu` zM_zA3-mSp&iI%k_+h;|HjgbpH8PbueGcymCn?6x!9Z2XpUbb#Ift05A3(hNwZIM!9 z!tOTm?ensRzfe(N{Ky*w`q49l(KOjl7fm($N|q8?jz>gnN;@@T)roPF92F{4m74Ak z@03L6I^yKcpXTFRd^i@0j38XDzl;cO@_hAey2er1WGD}DTS--|XQqmC^E>OcZ+7?!pA+3KC623hG@IO>rLtZcKhHau$)b<5Sxm9y7KNR(jZ;wjOD4Yo#S^d zIh70HQ!p0$j_0qN`LNg7=}o`2Y_`+lPLbwnsnQ7E!NY6~CXdbt ziXUE$I7Gv`Tj1?lv)QchX$DJ2j5OzJVzLJmD&{?3ubFF%tM5BIW=5{Upa18Lq{rB| zm~^{eo_mMZ|X@q-6GSF0TZuiGhV@0&g~oAPgkNw%NhMjux$9g z$ic>R3?O@g%YMoon}5jnLX!GO9q*BiaTh=Hz?vZ-)ehHiwA9BHJ>P`)R)=Zz`zf;N zraqVmKR|N6T9a2dzJl>5OQe?MXD$t1_bgr5Q?OUk*)*ZV5>9b5*g)_wv; z;wW+=GX?|Z2^d`u#+$_L z!`H<#IH+P^I{$({vzo?DuMcTC@#2xZ(p9ors%&vlP*!Q@2@U-xhZa+Eh)s1T<~^Ue z5X05o;r1*BPRaa{=^%#QH38%c*cs>mO=BWUHE;rNQ~~UhSVhd*J%#A5{Rk%L|8^oU zD@INPl!kiV5qKuj0GDqv+oJE=AZg%&sz_hThvnEpos1-NzJRGDuBzNedBJDIWdeRN|47P(`~M!&k;YoA<|6Z*h~luxmG_+*g}(jr^*H71v-HF8YL9z2CZH5DFsrA65|H!$6q&oq(k zciLD|Aj`}(yiE~9@_&D5t3UxxPWlml%$RQX1-2*4;YS&hCM%LnMP2J+l{6eT8N??L z$C~jUNW8*-x@%GH3gGfO9z)10&Qh(nZ1dm`0pDtS9G)qW=43ym!*-xF)GhaxBpmB(X>w+6p7 z-ZfvUyTr?P>5CT!{zDcl0A{H4E?hIoZ-*N0mK6 zY3_pSN&@QYWDMTWb9r68$4BX*Awm18JVlbc99=p6cZLS)n84rOfdLT)&7zFoLi2wy zO8nuQ_#e9^p478|5%?zfdCy00I-Z^??tM;~tYRAWcG)%^s{%xT_CPPdM@|uLW3ufT zdGd19R#}K)Q%m7xqm*3|E|#oL)SwMY^EOpSthn8S0M4!MU^DN&?bWfq3N`~g`Z*aQ z%^48kb>9-Qge=fk`1(no$cZU^dANCaXu3h9fM%tL*?ijlV z%@u4D*x3hLm+L-CM?9Um$aZNI5vLs*1mMQ>^j*8$-ZiA%W5r_#;qid<46`PWNoz^T z^UB_@FJ9JKcG;#~T9)Z!Y*ciltv@1ie^UKjL9y?_&_nw{Z=Qht=xT_~qVI@L1ws=v zPO=()xR(E}`Wmw{4gRhXgyUcl_&9%l;fpiAt$l}CudpB9{{ZAeFWg5xXu^dGw6Nzk z8`U~X-k(lwu_(o#?-(M>tgBDXt{JP1vjAM%&8nw{0b>)mcr`Yu$W{ml7`_UiX*gi% z{3RU>V?_kez$eWOhc|=PtjGyLKv;Z{3wC0$WG)99B{U6?h7(Ue86?IUl*-?$h=T~7 z!R8UYE}|!9pNvl*{hyTKt-FxAFZ*hmS@qH>Ye1=xCaHX4xfT@|PviGeBt>U;+L0RF zh0`(@1-g+JA@43*op6s(oQ*#%Ws8dhO(er#tKeHVkIWh;0VuV105y89igT6;DPF1M z5o4!|8oOJShJe-fD|8YrE8VbV2I}FldT&Tjf3m3G3Yhr{f1`^uYIla?&-d!<-7NNY zH1ZL~zmJ<@;MiEvyd3f^$ZD4W*#>yaH#Y+(tLW?#FLt7D_M}|>I{#j$iWzV!*V$P8 z>qCGN11d8yr7rfEWkJ-f!uA#y8-HM8sknY_bLAWSdxZj7h@cjDfxF3CFwGVnIr-%% zFctNi)n6JK#(kj*5p^cRkC{n_wQ6g&Lj)S)*?`HbJ#AY$uJlvhgLZw~M#(Nu^j4Z( z{T?VYz?e^Z5A=x1Y$P!qv*5TTE4-rF31p!4=?hd{sq<$(mCNhEx`vh?LkFW%n5pkM ztU~4}9V(AZr0Ou7h}sQp`P?46dZ&sWt+P!TBkNM*4F9ajJy9O-6Fm-o7H;iu1Lq#= zoVtDUqrK6C2X9|FUIn+Uo6m(K!9Z?rf^WbiN@8SY_?&!q9;YGKn{;cgo3!h4IFG3@ z+69Y!MD;Dh)GzKH?sPhjmI9&!W)}ujyPuNVC7O{Zilo5Iq5?F*c7m^{XZ3-yi9F@; z=%kOtIQz5Qrixe62}GxeQJ9pEa&c4jxH^1f2xRyp|R@NdefTAH&?gV%QFO zK%(h)X67G&Z!G^0qUP@JE_>b$jHKs#pb?o_P#O7mi zeuShEae7*p=-ydHI)hSeZr^HC%HZHn0G;EAK3RA?>yU;Jh>nQT>%q29Wrr%&x_=BC z)3X<~vK28lypb*xRn3B@reu1fo1mQj&sJS{u*qE}&0mcQa^i042t5&=ps3y2g@olv z96d5RDeJA0S{#v(Z*44|kf;NK4od(E3Uz;m<^Scy`Tvpl@7?VGIVAoA@-7AwC?_jF z8L<^W=`BnA<_WI0qOyEODiTZ(vbAiUkGl=vW~k>72G%%13?36Kjs=NXJD-bYeCnUK@0wo%i%lr zr)S=*FDxJQ+5-h{AT~r#4AxvUW)r_i6_VGPBi$>8dlvnA)Bfsc7jj%x@nlFAP|PPD z0o3!KdHJN;cOR`UgR4-r3p4>q1{R%i9AfqtDg{rN%Rh?F{hJQ|p91b-(#eQ4 z6~r)$)!moXn+No*LIq!>M6*me8vs7uv>9h2I?d^10u0$th4>23IdPfJ_azE_EbUZ2 ziulUURgkPRd2|_)=mmX(XdP28A_&xTUcGz3_5{O#E~R#taV~zH$48jm&EE0@?Pm*i z+f!1`^4a~!Ba@;KvyMJ4F14av&K##>;@M5?4|Zy{H!-Go)vCL>cApudvrQ-whEjnX z22&wYK4_B_vTWv%11BPEl$r76{vyPAG)z>9^0`C zKg47W9C8gZ{%q9!*Ae)y*8gA3Jw?_{ik*OeAigmO5{2ujcdc39Hcj7m&GpG41j|fW zSh`Pq+Fx$+W~X;lzQ+6PYZVDQp8S5Itp+J!a=q- zs~RgIU8!ep>s-F7AJr`sv{=FH;p*!8Sm@p9tg$QMysA#LS>an&VEi01$!Kw)7dwt?rMcaRL-?#b`u9VCiSNY&gb z-vix;Y+QFE?138FcZ3I5DIb7>Qzl%~9*7Gvje%Ef)$M_DI{|$TK=`?ac8wIz^XRM zh#0F>-X+2AH)Pg$o6wrrCV%)U--2=Csg4|^R+9MwXNclTp5=MOjE)WOGj660Oq36J zQOf5qvDo%NZc*AocU}+pRW>AMV2hRk;0v&48z4(tPL!C+o8OneK|%gcHob?C zJ}Ct5{1G!XhyWyZf4|XxUQuz|KVqW&01!Jj8er@Qxee77?M>}l-L?*WNjco`Q!BJS zR&s67T-#CRWIWrYvc$GyhsjHmT5miYFT5{#OQ(JG^@xrQ?ExP*g20!Gl30DyoBo3S zZ4c55X?!6vyF#^tL5tLrU2X?Y?QBJq-m z4S~9lHPAlj`tVpZB6fu#^K4P)mEt?bsgVwMz@g^Tcx-^`p zG$lFpgM&LgHvVXt%4`gf2am%|vUkd=9H?TQ?_?6}kD_kW9aiS?GG=(*K#HYP# z?W_Z8lZx6ff#!W*fTFDlbP*H=+#W+XY8Qr{l3Ye~qK;N=MgIY$mE8iu(ui0n&@+J% zIVtGxz*$VvFNo|<%Bz3F+5H~=HP7Jc3k{%l8L5WYwGWsWiY)NSsIJnifoOBQ-lXy5Hb&TiY@qVjHU%fllg58hb6 zfK)co)4Ddw%ivxi=Ef`M0*VGU9WQK*8P!T@alIe7r?cu(w{MsbezUlas9euXgf&QV z=7@{u+!c@s3~}o%Q-J|Udj5>t1}csxlIKMZI!ax#A+Q71#p=keW5it zPbd-i)Fif;KbN^ZFHZueUvXs9>A2Edv?4wrx^j>E%(i@syoSPiY(i&|IpkXRneL*` zR;9(yor8zB`8WAV@g!H(&PNoQ8^JfbMI%T1PS=XL4oCGwEjmzO**_9Nu;XL=`HO7l zB$2(*esjA6(wOH?kw%+GU%gRqXsubNEGOXVrCLNh{adxs64rNis9QJTOJn;qxY3Mc zh0f!*?eUpS8P^yW8N9v5&+$b8kHo;iGjyQ}ELS%V@1rPUFvx@a50Mc3?sY}I^xAaZ zBoHJ+q64RF&TvxC4BAivkm8ptoJP*EgI7H=!*MJPNK?Dm37_IwN>{{F>UR8Vip!tv zwr=ZN2j(Fn1>I5hrW-)e6bzF@h+HC!1=iZSZ$($>kmig3WFIT&0L#{|9h+tCP}=y| z$(AhhG6dYn+CCwGRs5yu6!i=8X(mFdLEItsK_X`#hl%ZJ|BzHB08K80opP{XAl!&g z8%hr-4ls;szH52zzyru~uM<(J0vJz~z7_%@?uk7RLBf=J9K!-IL<@6(i2XnnSsMrm zp9wdhHbj;n#C>8w`c;j5+Cmr@e{F%$u=)s!7!R4CBfuy}W!kAA;PARrVp z?nB}C!>EF9g#0S>PCD`@a`iDCXSIQITm!lBue@&=Up=Y9r6Cls`Rw|^xcEk0pblQv zz5pTHz@*xxF;RJ!X`hWv{womet($}OIhysk?f=Wk0#k=SepKmC=Ys3r12N=YxbMSj z*N2N)8yZ$)rVX+>yXao3>%jtC{W`eT8*pH}MDa{T$u?7c&14*%%-fY7UKMW$ez0q{ zX<|0i(Zfl!vfkw);=NK>x|bVmgc)>&=6xLb@_Pr()HkLnOne2+m8dIvL>$ZRwT1U6 z`i1z&Ou@eSdiCW3G1!-rJ`xQ+9WwUlIvJbPEREu_ODAMSf^q9A;85qP{hKEXh=E(~ z_Y{Wg`OnKfU`I^{e1tvq3^GP4@5<(b9g8AacuMIZYszL~)s-qD*wd7^{oy5p8gyYp z0pOj}nD_97c#=)f*(}duvZrCVS4Jz!9Zu6Wrg96Frr(R1>MHUYQPtlqH{!J+osXiN zPs~N}MyHG}ilavctJkGEZ=)ArC$m~yWRe3Sjk!R_v`)Y$qm3{85BA;zs;O;j14Tix zPy|IfQ2`OD(gXyeA|N0}L3)W&M2LVO9YPeOmmmlz2oXU#M0zJmFDkuD?>)f;LP&Dn z*6Te-&pqedbMOC;H~#U)b2*Z|_uM<|vew#b&F`Dv6axH5+Wfcov{~x->gEbIE{Abx zTHmKp5Y+^-N9G>u!Ta#4fGc56Jcsf6hbba!4riNWYWZ3q$aRy^mc10V%K%KVYpPYK zBcV~)JF^>KhI@xmyMgJ+({X03T2H(;12w#zM#w#Crs`OoktjddKXis--#B<=v|uSC zN|xY$2y7D6tJh1Qj}t}b7g&gTg)`*LNx!tEkC>#Yrpr_FM!1ELHtbM;p?yZ|@w~4*RP-ddEL0@>F zXa3L?2pR7b2gXf{&^ITx6A|wd%hJt6njGs-Ar{hnfhjAJ#YjbFz_5YJ&|i9L%0k4Q z<>)Uo%G`4hvS-+iL_?J+%uk@#waMVr^4uwh+RHKLzd80cp~0?Y13&=!Qdpi^fBThD z??3@Z@S`@e$Sj6w$swN@tJBM76rTGmw2W}*>Sx5BSfb&`#oM=k`}p-01`LggFm8Tv zzkR&;_R=Ecb)bnmi2Q%3pxSc<{lh)~gXbo3y)fJMc8+4q1L1-du6XxDY1u-1f7^KW zHH^zFA@p8iT#{Lx`{m+n_jhge3qp?|Q~F1ZdS+|1uk_`O%zY_hOV%#if1O=HX)oeX zR$_C4;Izr>v&6b(&YvdjuvAeOp9F*4X4R zBAOM;vhu4G){PqBR-m(AGcq=hOAYMD%$HfO8OajU z*Nczn0$KuHnS&qpw2|8Y#h*AFL`M8fVN?qw8Il3wVGfFIjBl#Xz$j_6=VV`Q?`^12)qD+U#yqKU>&bN>Ju1&-_gZAPl%6u>F8tauc z4``~oGYnk>pLS}mKtA?%8dW(#$;%$Kf(fKn@4tTn6nlOSdd;wx4c~ODvfp*(gib#t zkH+oGUHz7M`!}C*GmZB;qStQIqLZWwz|#8SZsv-uN8J!G8eZSwIOmKAzsh}W$)K5LYK-IC)w&UWG7jUeOgM$Ns+@@H}$Wde65%r*`gWLskP{~y+0)cCfAy70!(O5u0CnX|6pufH>JP}e>mEO2FwAUewC>blNp&;b^63d* zu4*o5zua_a^yI2G@5i0{&`-I3o!&R$hDQCvSB+9lt(8NqDluZ=JA-v!%eMiiKH&EI zL8H_V_#@Fe3zP>43SGZBgnH>bitrwoD;$Ng8aBq^1pfg3`c=8~&wwphCaHoNuwzh# z$VD!K94-g@^+-rTtBD^=2lWqDM1@MX&28l+(G0NR2E{w@-gyY2>bW82pN8@bP-t&Y3FY=#$4n-EM697gb!NBL9WDkcV z`Nw>&&L$r$D4ue9l8v zaQ&cD8>gECyyO4)?Ed}spL0)skJtrrTE6*je^3kK3AZ!cV9q~FnIhzUnGT{u7BPXB z0KbSyiklQODHWh&7{+MgsMb$osVuFZder@f5X7(rCG(knY-8esn(spVy z9P)(DIWt5!`F4;ft57IzJEZTT^E@scE_T0*+gRe;Vf~cxPecv7gkRC3P*k7ZzB@dMwplLqW)#`_% z(2zyuL6Lr^f8+^^DF@kT7ElZNp|X9IIP+4)Joc|!Mc{i^Wz=oB3vcN z8hBc4F6t0j(W%sMz>)uBZ6=HLgB}!B;345uNgW;W;7_Z#XjG!~Hl(+w8p3?fV4Sx*wRbJ(GDF*Gg{Pec;DrnkbeD{_6Z6uMAybAx zPLCGxgovj(FT z^<_h%C#`0;0}ten%>CU3{_WNO%h9d#;wrqv>+8#=FYun@b}w63tr0Im+rT~pMd{f2 zr!r{Kc&$&X#!>ULsODm8EHzFP$v-0OA^3dVQIl*hK{W7V0=(b?(CsY<^=uL_r>u+o zg+>MNrNPUIz2GVC9`HgNVk6@ll4nf3Kz;NSF)<7#=76WzyD-4>?p%;Fq$A{OW zIFwuJ_^nDTpLtyg{`mrmemX56VZjrps{nK-2oSpf91jrBx1HP|?NtL{J!^p2n+4dR z>VW+iU?2VVru=_xcbKgjc0G1#@lCi^v8i=jfV_cKj7oa{sF-5!bq(#SSF{#H_Xr8$ za^t<>1t}3_Z$tW{jP?Ro-OXQaI#WX@h-$b!v8c!YDfK1m!ZF%j{r_>K2$NUNtx2nFDuk*A5 zumuq{1!W)x@3I?Vd|)VHYl+$7S7R^t-eP6uoOL}_LGhVJ1o}!(gI3KgDQgA3Z=x|V zp90(;9K3N=$@Xbi*bHGKl*)$f3_%pSg>RQtZpL4xYAZ4hzZ1N40+*t3StP5luC#CU zPHj=LQ0WVg7E#-?4Sj|;t>Ccip#~otMF>o4Bg*KLelU=gp_w$OR~WR_?wT@SGr?2% zGMD)#^rWv15OYAUri7m0-%&f zT-mlxECPbPu$fs|m|DDLM z`QSUuj=%_%;)(*2_LV+Flst7JUMX<{J(ytit24DC4W8fC1YVy{v^8#SGvb6+=E}hN z|GHN{YWST5S%h-s7aI1hw1uTPpfwHVf{PzPiH4+5s>GT`XKy=jU(f~!TN(@&O*l%1 zjv!H)aR5|mQ5*EN0BJBHY98$MH6Kvv*v6C^6@W1qApoTP=xa0c=;-u%;TE)(lGEf& zq3nQ(Td)}k9vT$88?uP9v1TBG+}LOXz};f#-NE6~Ee9a62xdpjJAo2-bSMAMSKz_W zuW%sX>HKr>&jPfog=ob9W0S!?6ltF$wR2+gnjRH%7a#({JhuFR3So&N?4GA~{0tKk z6u*`q{11QUh4sI+4?rVdo+W|it|166aOTbL(4c{uwZUHv2z)={GV68k`H8_z4j_kQ zFI#`6KX@LOO`>f0qO^9BW*|?}yT~S_5*E-~`zLJ`Osq~bdW7Ba9hJB*=bKRnHB*VD zgnOsJxBCyqKHw3UXwF>OuHA%-SWRvN3TnqEs4O2Hof%VI1`@;{6dqSN(^3@MsvN4Y zHAGYf! zE(?cQtYRX3gp~q@Vo^>A4NWU!ejC?2aW)Ec-eKE#*Lc|&IYV_$1HEXCEcEZp9XR?> zSJdGpG(6Wlo#l~xhRY^sJ%=DfPW*2yJF3koXDe{X&;nVz!4CDt2Wl^OoTI`Cv$5+s zzNs@1HZ#wb#zC%u%sO!wQtFreTpLZkyeOJS?^&8$ zUIM$Z=AFL}3Vrxjr3O7$`oeT8&DqC{}HeJIS%ySfRsRp=vQQN zhkM$I{4CjnS_h=1g7W+70PQNa0Qmcz)OL|sr%=qMuG<6&IGJI!pAtg;4vG9Zk)#3j z%wq2firMXg&yD730d|(01+llY5lofl4SW^3h-0pHgwEiqJC-)gKyQGKhgx6QCrf}laQF+bP)DH3a zOa0OQdGwXKYH&ol{TA2y3#PP;&u^OYIx5W}5X%cJpZVel)Tg;auqtcCs3aF)_Afr? zrmP&Ys`0?vaFC>qzEiLiy{zcaZf5eKI<61D#b3z#e#tP0U{P>>8WFPU%1pbg`S29w zHECSi)brt&3yN_@_B03(g50nsJG24DbKU& zaX29T)*(ZEjYEafx~SY*U^Rt&gqe~aFfkoCwF0adjVD6~>kvnQl-P${>e3b9Dx}=N8kuKi*Ymz6J38vwz9183O2S zuc>b5lR#uV^b=AJyt9Z&=DUyh(v475`iIf=^%bi}%aB(xzyDr#Q>@b`mQTI#y)cth zd6~sFtJ?e`CDbYbnq}#U7g>RxC7WVD)bZjzeoj45+-F|!%CE7o1KoE{$(xOUj`I^E z-i0y|=htsMF4&tp%VX`EF>5hQuo?vUyTo33{pRtuwEM*XecP&Pz}g-+RPBSiYAZ zPmhps{+-wlRmn^S8oVr!2a2&PNUaaVlT$C;pd5^rS38IB?@XO}WbzK^lch{YX$Oi` z4tU-*H*BUgijm$@mOTDhgHdEJ8-gKz>m4Dl)1QwsK_B;MKp=vGytc2Lr9tamAhbcS z_N_8($)03V7oP`a@x)xlCXSYs!?$j_7^&@M!bhD^RhhgRCJi|DaJ=MgSUMd^n;Nte`w{MW5uUzSCZ*)@yh}zKp zJH0X=O*?B)9toh~IrAaimiQZrwBuR8q>R;95WW0%De-Rp!Z@V51G&0cuqtfTafWx# zhPk<$TYvXIMl!c#J9pR#5+p*x*HnF~fC%1Ggf1}7G)CZQf42Qo=OJJn`3ByqvPd%g z{B==GOw7^~a}jcs2)Wrk^k|R;B!*Or=56&$dPEjE+Cz1UyuTaL`z*@Vm84cBU4n$!gXTntM0D|_BFywyJoLETDYr$W8JTD=lzPsIb3ne zKsSI&8|oxmS3O6TRq=#G^Q^W~PhD(Xl~;!O6P2etaLkdDRZkBV^&Y5IY&DjeoY(j!Fe0C)f|vE$9c1@2W+EHV%eGLMv@y&}BOkPk zjM}?99(M~gb5J-h0^RRl9q2Vt&&>XQ3VK||qbH<YFF$ zICfn$%2v0~S^WWLY))iz(s}&xV(Rm={}8pa=k(9Md*TeIz}9b@b_QpJ8ZRJ@bn*qH zeGu$jOP^3$^fON9p{dJ}@>1VyAgAA-2d%-SezVTRl!Gu3*s~CK{+drxIRZ zcdwrtu?@#G(J0;WYVpfK*Im2wor<7%J9-+4oQM=}R`}!dDzro`?a1p+$IP!>IX;zI zBC3Laa_70vJ^{E9Nx$K?|b!Q>Gj9j z*So!yZVY{bV=ML4<5yg=rnI z;gjPq2zdsoj!KFR3cbOGjkd1{}CqX@@mEfZ$rNIlsMR4$35@{yAUcv zu{dI!f0yYNkE2BdCM*WbwR`kxf1cZzIHUIU3gb0f^VVgA>Y~Qw3;%_o+R%Q@%eHAE zq^yb$>HKP`H!rcYhhuJYl&YM@9|O6||41=np;yHi=P@l-5S;e;o}%l@>3r891z*6~ zhP>B08#^2_$&{vm?~L~~Cx*jP7q_{Xk`>!>%}+)_#V|7?QVIfFmh!Y&pWxCnP$nfo zp>VRfgMD{=;iJ%kQJw?ucQFP^ega!)E~4|4uo8571!fRY8bPPyJ~XM$JVq*Qd{dJWo4nhnU}Y_PCH*$~k)TlJ+?7X?k|Mu;01tBpT_;SGxYj2w>PSF| z&yTBz-P)CDfeF9oJQ&dV#(8k!7@0l8p8fcF@6LpWPW)FYR^kLO0(AE;lx{bk8C1%wlSI-PV-!WD)oHEj_NMRm9~JUYm6 zn^_%{?C6PTtkMX(FHqZEK<#(p$vBM=>t&)5xbsMv!_Tb}nDDbM@d>|;*;cRK)vs}R z{(@Y7O`hgy5Dos$&OpBXK)z=}%Laqez?Owzc|>`%%12iX8=*53*Wy7~K{P9oG8LRS z-qBcwi{GRlE(lpopW|MNX`s@TPD4R8l3z@RJ>$ov#xL&5cJn@anFg0KLcEKw0ETcX ziox~Xvt=d`NirRj)LG?|(eMG4&(R3lk^hOcE-C5?Fx@?GsJ=r|$okUF=0VMjaGCnRc|z_>ZuS2^7h(X;fyRB^*jt6r3c4q7L6Pbd6~p z(&w9hT~k}un>SZelOivcY7UTK?%eW8+)XX;Snb`B%lXXvXtt0qJ;v`jZ|)p(C?7yqebU>cYjK(L{%z># ze$#-rJn{T}F_2!`QXlYp=EHTNQ$qdXH}VH^>Mt_iJhWiD5bu=Aw)zVVosu|7=n3jp z<>hjd+=DdAS45IgDaLhA42#J}u+@txtZ?1ALu2-N0yKmp1@3-ccS$T3sILVoK!$Y9 zcGaC&ep~dE?L)@;asD99gO17pj!+__Z!8Y18he=-kW=4&#ZW4#!YGPUK(Jzqu@W&U zy9sHeFzFngX39M*%wpE=IAtks9UVV2BsT|8#0HDW?6}CfVjyL;=KRfUyN`h!&545~ENj=V20TRZ)BcLH)OCI_N5qS+;7kfG_$4vCbs~tn)tYdpxC7AN?v9ZNT z9N&v6_-P%DTNOsBmp0M3*0DGZ7X)cxZ&8ivw6b(P=~`k`_JhL90dvrqr`2bpW`Cg} zeA?$5J8ka0-9$Z8**6~{y3`MM%J41RSEgGK*qe8LX4QseQ_nxqr7RTJ%PS zsXhJ*UyaqW*9KI8m|#(hLxhRDDWqA+_C2-?lo~aBeS$Cp((Cjl0lEc&m?;*lLk8;X zW3SV;Rs2+MIVmvBUMd>_5Ir~y=u%CN>Zs`N-MrT6szJuzxAp^Wg2*y+u*FwDqsIHP zMBki!voBH>kvoe+tz??RL_X6jdUc@5E?iU(AL$b)?FEp!>=c$jkP}_5e`k#$we%$kaydvC|G1T~wH?9bzAF6@R zJe_34^1cC1>Uo*y5TS8y*z_d9=ovz*v?t#+*Zg-wgnzsG9k_=nLJ4Rp?mMji z;#$VvhWWlD_j)6UeDHeTH%z|-@HG#D2Y!;?j!Mf~{Gl%V+w=Nyhhp39q@^E}w>90U znYbU6x4(k!f91ISVW{;7yRkWLP)y+VV-utjQhzmuU`NOShyj25`hWl9x!b`5zp8G} zjBcRv^^|pd;b5|_Hg$*U_KAp@+R8{w0Ze$;N@5}Q2=1mrbVja|{%oIEi22q8V1 zf8SRc+cX%A@2GS;z;Hf+b?wYmfm8Td?-+zuH}T3juN`YkYtKU@^WE zbI9zIcwP4RT5RVDHNHF@-y|y=Ae#Pxu_?cfo7o6cBhUhm@PvtJ^UVCdWF3F3FT=%+5);wM3 z-|bpaVt#6*o`;2XDrxs)AF6S_1ZIK$J{i8sX)1qWa&i(c^Ekkkj)#ZGJ)MqcG9ao1 z`1fy~_rDJsHo)|WxmF8HNZd7YnBnwr9LuRC5DJoP1;=JP7+4~T%k9JF=ef1rQ@rS$ zg$!f?itu@ZCFPoIQ7OjO#bE~JNKHEI*u~iQXSI(;fx}Lxk>tc`K)U&fs>JUD?s`&xJ;JF0Wr~Yf^jY z%=@M!fi;Fd(&HQ(GLtyd;2nGRQtriqmOZCG*s7r9q>T;uWU%Y6+uzzp2U|UgnU_XE zk~nh=#!vJVgs_aOb70x1dZ^|quJQb{KU`&c0L2Ave-%6^H1KWFZX2A*4}8 z;1i^7>e{6nw|?IO|MXEp!YTHMn(wmMDiVZjDmI_1JOB67s_!R|!wy~<1)@H_i(+R1 zz7w=l!_F;zHnl(KMgHX^4A(Gy5;NrG@2c2PU>0%%gZ%O}T=&;URfz@>ZK(i_o^IJh z@wS;Z->%E`b7zw~I&WWnzjgY5Vy(MPw3=Zj!e0&M@JcJ=Q z^{URHYRmhL;La5uX!M$6{)U5PRcWHa+T0CX2lswMy)J*nFcNiOd3>rW4ef0GS6Z!zc!(C!xpxeBrs8(@3qLYG^Lvep4H`~Su=lUrE|4u!Jt zT?Kkco&JJHSC;v&2dK0^vL=bc{(Ixyz0Pm*IV)(Ez%048i+3O&^Qn;o~&g%RCEP$yZqyp~wwv(lawQ z3ZIo%l6p%AYV8jzG!U6ahnjo<7*~xB4{w$|z$&*SaA&u=sU6?|sg{Eyef4o7#sN@b zWP!chCqDX$%^5cZrmR$2+C}#T96GE{5GDx_{8&mqst-53+vYQK%sknD?8I$2(`Tye z7W}se;o&U=ZjPSv5IP671wi}n@x-3z*JOL^7pQe#^X&fliU(+KEBGM3)6Nz^)$+|- z-W4&|!=*=z0cI@B&>1TlfJI%~ivOCN7dkT#E}oAaFb%m?yfk>w^>Rc^#hHmm%(2up zLn7gIN3O4I{4|>=$*tb}NSZ*wq4Sfpz`(v*pQ?PXXnBIsrXo;VCHX93jd7kB#gWnPtDqECbj@IW7{cAkZ4EM`lgHEdQ~Jem5FThTVzqSH4JfXE+GYQpp7y`r2bgB}x8cF<&wu6v0P@LszxL68u<&6J&j@a; zk|9}SGQV&-v(~`xZlfFm773|LJA;|l7cxgCtau*A)YV1rG%Tj0|IPpl8 zgzScS)AkDwTE|{MEWw>@UxLG^%$^Ai+pL;a_euFdE-|Cx*0kMeJPS)tq4J*S$?Z^I zu(LqCTxZUZt*}_p{6%H1bD#WP{N;gW&lH10T%{at*YwM5LL}3R)H=IZ{{BW&F34l@ zof+<_Q^OW2WXGC1(JcCct+~1Yp^-8f6fLo#`Fy=vQ4O3p=H+XAgV}to1HKUL_aW#5)o2teLp<+6z;ack$+lifHvS1P*j6o6;siL3|vp4#Hwg9MF zES8|nz7`+|;m=f}v7I9#=pZ1?#R|}<3_Mo1fgFY6Xn^Wt1@Ok%l6RE>c0orjFo^;x zW>=G~UngQyY8miL%!BdgpqCB1;_!mLk+}0zt?Si5GXn3P`D+>J+TFGjk9WD2F1JW_~Y9fIKa=%23E*MxQ3RwWWU?B zQg54?=hdt=$-fd9M@2-4m6=SLZKff)SQg#sS;%gRN;E!9TkT;i9# z1C@ui!H?D<|Gn{zAyEFJkNhEK`CAC{|Ea)bz5b1$gx3?xbk-)LZ3=wVx61K3-nG~s zyeZ{kM7XJ!5dWZkJT(qtSjS}%j>uwp3Ud;e^7q%7P3MNrRaM4MdvR&LaamvMfBrHC!S$QZp`dpP zkV#=Y3UK4_dV_Y@1gch0D3y#N39pn8wE=FSD!|P1gHVnU2$66rsL=p>xRP+DXUi4% z`J0#bd#FiKh^S)b}bW*&A`Z^t2xRv4=#eV($a~)&@_1q>^;orzAk_3j+Hy>S>#2Y zBlJC4ODbTTMJSDbgL!on8;8-@ld!Zddb&OMjAiNt+;z;sfSUvB^MOHJf_JzixAkd2 z%}Ke$jV49%X+{mx>crz5_u`)1YZ$u)_~jhYGniv5*ypmmj_db~?z}c&Nn>`qv4;$U z)q@U_)uz2>Vtnjm#x5wplAfKt3doKyixDP$1_qy~93_S~erXZd>anYGcNsi?=GIec zJ)h~yyX}1R0bd~;d+0)x=308M>*`#A7$`hsX!N(gwa$lbY5+X?Eo=mM2NPPTc zn^JMPyVYmZmv`tlzRFV+a08bNm&FU_1g9gjDaNDK=hh)RlZHKYd{`=KDw2y);#zP= zd58-{bPW*o79wLsbW25aYgD&F0aD7;#C8GrncFm|1VTar#O_*WavJ&whgaReKIDc>Zpr2-DSsk`)_oyh)tjiR zi6*KV0C=1x=K6u1*OtmH&MjSofdYwut6A2n5M7dlpF}2}=Kt)$184O7!@UPeHySs% zpd(3MJ`0YmHg#e1EWYv9wM4I(8++{r0=uB?Qp%`hr87PX4lms;L!anf(s3|a>yQnSa}`# z=%C0k8(AgwG(dkN&!P0f!BwY|#`&45JWtEjbtPf*P##~wftqt}V$CSJk*F9=VNva> zt1W3+cq(>gsi)2c*HUi|Yhc&?Y=_m!S`vtfX{=6<@K!`ZHkeeBMgGmJ zy%X043Q`|?8a)qX@e6zRm}qz*&2y!R5A?`%DY3s#QsVGYmQxblMn}Mh7F?ZpJ<}Sn zhvCvDRYCivEG-4pNFsabr_|9iPREFmDjxwQB@Y%%$E@%Wa#jB#{brgWt~|_F9d)asYSF}4fbBUu(D*TXQd&Q=)MyJi4L+<>$Y(S5Yn~R0K{|IYjXBmS@ zc4XK+nyYCVl}YQqwW*Sc-Cu>FBl8T@Tyo|eC}ya-`<%)2gL$!*G8+WY@(QI<%hC+V}~^|dKYc-?lFI);u+8a+MA>b>0Oh_ zS2=u`gY~e{5dr5+HCi%Z!@&OIZ(3WxknNii^KT#ji6%1}?))UBul&nO9cS<-n=}G_!Fc7;%Slhe#)*J!-HFZu;$4u!-P79PY`gEP;*ouP)!qvk4 zX(Lpsr=I)HJ%1rCYPhj~*#vyUdu=7<#V7h_b|VuZNo5F@JZ$!cEe$@#>9dXJ(vk#p-w^78RK&j8oF9Wy#7DxYAGQs*+9{?!_x4XjPP@Sf!4kJs;A-Q&fvo-)voALzc_0`lY zCU(KVs5}%7yv)u69sf%?!r#(g?*CdWNX?_Vg(>ZuY>6YT=i0bk zZItb636W)Qtd!$sMPy4BtzzUB+r9h0_9R-(J|e&MBm{J#??Y_3F}A<2T+!^Py`rW- zF3ME0v*I4ugE-#hkRNzS z*M9isy~ahf^W;OQ%nBbbjyb?haMvxrKcXA6UT`Ej zos=FBK;#+71G6bP?W+h>y7b@%gH1OtX5)1_wKSKx3Bvu}@g(Gk*)dv9R}H7##cXiC zeFILf8EYD%*T}w)rrDfjlu9}aSus8Vw8N@bw7aT?HA*ffmmi_p3^&COQo3eKZoFDIudv?~7d^h$jgy5f_ zzRsl}!EXS%`EuY-b~gY*?SdyeNnEZ7G6MwA55>MEa{_(SbtFL33#9@|JI6r*;6=M` zKtc2zxEV<_@?!u3+B1QE?Oo%yfWkXOX=+e12uQ(k^jqNG55Jc7A02G3?Zive+FTZa zIkDR5L8L=wBE_SN3*~7THZ`-wYCNVyIPFry|y!;aLkk-E_}qat*Sxi1Iuk}Cn_0p4*42sf`f!`ZEv-Na2-I&m3f7p z>rNsjeVM`LW1dj?z7%8(Iv$-3K4&`XW~p+Qyr*RvE|N*4p8}Ntgx%N6;IYy9!`Gq; zG(I&fGJz*GddmFR7gZcSRP`-wsy%jdk;nu-x@1vq0l3lr$p+BvC!8sPpIW)` zoHZVoa00=y3O@Sy7QtLyOh~H=^PDwW-R$w_El}w6tJ*4U5#a(e8!O!*UP|tQkJB-j zL1GOlE+1cL_W7!HtX+GhP^#X0wn;gv;DDH$aVa-!*s3Ds@}`4=p#c7@=c$@@F$*g9 zuy|^PYrMMX&|=GH!)`9s3C(m9&1_MaclZ7mRvd>~%0wngGHYYCO5tiZowy`>au{e@ zO1&Lo&6J;sxgNWIgZ+@?9(-=8%Rd!oeynQ0EuS4jlQIFW0+awD1G1i2k^-w04usuVb@e>$zalJ<}S;V`Fkz{_vttjB;_`EyST%BcHZ$g<;p{ zn*u-xnae*cwQA?z!+d*N+fE+W-tMp5S6j>IP4RAW@B7=e^O*i96lgc*K%l)IvH#oh zZ$i|!JWyVKaVEL?_J6Ob0*t}Xp6e<5tBr2F^@z0QCmKFbAio1ex*%Bjtg-q%^??C3 zu#=$r>c^e)G-TM(rpQx7zdKwpoX^hj1|cZ=Q*s7H789c*YSbbx0~t~w4MGtoa=}hQ zB7e>D7aC)ka4w4GJF444JWjUh!;Q@Gr}fBed2}|*arypZcW%+pm%_zE3SYmDI2*BN z&7vxY?Q+zk+j`kQWJdn~eC}tUr|=wXLI&teo4%0UU<#S(=eRrFAEIB$Pke?q1TuvU zEvU%itR{OsC7+h0aJ{BcjZ>U}dZYb}>r%W{{(p zQJ`rII259WFvG&59?qB;hSfa8ep($$Pl!KU5nogj@_aPqssWE}zcb1NmoL&}p+K~C zzpty^vG23CvBi~Z4xIubOw!90o%x;vanooXvUIhau;85kx?mpq)M>ee7`9+ef|>0= zRS+dj$)Ky=8clx08FEnZA%vJrmQ_h`RJFa;4B^*ch0_YQ;7o=kDb#gr43g>0J zu0r&`2Ds5b7z#Uk&7i^(i}>N?`f*Ih<-0^B7nYttvR6J2{&%J>#9wt- zTV*e-73D%lowhCTK{c%4LG_)1H#}L#Ha5mDBs;o}YzlpT46b;wlCpp$QRuP7Q@8l& z%6)dXqZUk)%^PaCa9oJrSy5G<=yxETwIHJ%jsW_PId45JBgv@4HbtPIAVRP_o^yhWs zlMCxXy!#)%r{^uSaGRWnsN=`#hb^&QVx&A1$WeV*X&sEJ;&A2cq~mdK@)`{AlOiJD z8;GQ9(w*PB5tGgMX)cD(Z}Co-tw4hkWYQV3SRvdWWjh;2$YnD2>5&iNk36;>5;%qX4Yy$E5YP(~p z0h#$F9<=wftq-~c2h?4Dkh|;$z3kQGj5y-U4G2Gom)fS+c8-X1wJR*R?bcaI?`5ys zPqTowkbc}mzJzrmpQ!3jiP;9@K4C0hf|p-m=hiOWu2vkk`3uPzz9$P|JDn}y!@jDMjQ3Ym_}HbF3N`27KXi%} zL;K3};3(_Cb<+P!yA1Up>=^9_+ARBJOih>itU9Cg4m!DW+(Bi~1Ar*FB&ZZ-U1*;u zmXBXPx6mT|q`aCzva^@=D~>v%YEoKcRH}1)faJ#UW#(DE=~xhl?b72lGr+L|p8o8d zd3k0fitx!Zwq;zJh;~U-P7bF$dwa*qGU9#ZRJ!9N-@+lqnOYx>dPrcyy8#z_#TS}x z)#)RrtPit#2K5p4S8J<^ z-zWxuO(?(uQPg@=H3~De4wxu*iTs7Mz)#$R!R)W4`#&3Ye;wrhul#TMXG&(k^PL;J zh=}_qeX3x-ce8ekhTv6xF^r-))(%1t2J}NmX9!(@Cyx( zYcjuipG>XBRg6Y)Weg+s7<|g;(U72Xv^3Itvjb3eR=obSV42GzEghOR{JCvE@sJ8O z@8W&didN2+TJPh5`NqWXE2aH;oQVT-+NW{;l2=b4Z(L#nL{3U=r^Q$Y4c^{`nZ}7G zH6M6?!e99konh)dlYUf4iMF}P`xp6+w~CxN`04x)5a?J;WYbJ!fP@3vyBC+=ekKNM z_wwKFF@CqH8L)lr$!(DD32+EH1yJPUHQ+`aS@O2N&!sKTrzz>T6dggk@dR*3ewkRK z&1rZz%`0&&GC% zWYBFtB>MSnbproGNs8f@eDLseQ$4IIK&bVaB)|95%IAK$JA)Np%b!*O{q;NtiCCMl zJobZ>;WQ?&3EIud&NoSX?REuZ{Ue7nsoy7;TYGlc1GcXo;eM|HIZzy1ufi1ul>#%{ z2@7qkPRbRnv}Vs2vDa3tcB~! zV}7+Oylm<;`JOXZqXq6|1-#CB$A;#yW2K8^JL0O(u{Zg8=3mx6wzn8(zqsE%e$}P^ z2w>dE1Tr}8?iiw_g9>W@gP^g$sC9tpQw^3Ho>d5213{{+#(k_GlK$oJPT7{K16gMfXYo=>Y0vJnBaYBkB}7k`x}jDXlQOT z_2&U!lJxciz!wK?>95^^t;HgjT>9MBkI*{5&%QLg2tPQrk}peAK_ z+7OhLQ&z{>C2IXe6t65deu;czL_PS+-kcGl?Zv{_55-;hQ7?L&svQ^T!=YT*RPx?t zh*YO)ufr^;i81{iaOb}wt-rqpz_+te!VA)K7$oULjskZr2GnN&-wH@ub^xldW?{9H z@mh>3DXg=u%N4Fu4qcKv@35j=bQN(ExNG>2l9mnEOMq?x?RgwLE4-zs@*;!5$ZjD1 z`(0CM(ddy{W0cux8ejf|ET8wYX|T=>>qh<6ijJpB`s(({j=5}H z?s1$g2k4cl2;sMmFCR38EWc=_O)LRx{t@=gr2R`R3`SAeFCQuLWtJ(;XkiDc3xpj+ zG%&RnN3};si*rzyFTNwgKFOdNVO7)dfXMW2A7e>vZM9-HUVwqQx#mv~x#uf}YXh91 zPXIk3DiJhesygKqb+wbs4`49c?*OOg2l6Sl>G$ISuE(MB7BF5E0Cgs4zd1=wXHcZ$PJoEzg@|B4L3qU3*L|n2Am^A|UR2>f^@N)*Nca$6~w|Y0&w(EB2(3e{Cp# zvE~2wkN#iukD8SueXjtVl)-yYhq<=RR|L?w(>uR(LuQ;_6X3ZIAu8I5%^uDgKf13# zF`IuLK|Daw8azMa;Im8Lu&D$IuSSlkE;GB6=~u$AN!$uR^o8gocSed@r1bK21$4Yj zt>S`Ff4=LA+Jv*)*~Ukt!e&URXL4NnNFe@rG-J<)DfVR@xL~?n^t}r2;q-{$h&4I@*x9FaGI0@I%;fLuC?~sYp?Y@xEM#U zsVO(YJv>Mzb*<4yx7OWl#GhB3y+!Ghq((0yOl`O}*G!b6J6_U2%G+6HAjR581m#=i4<3-R1>8)p!uS7?t04n@NmH*8UR%wjbp@RD>f9RB3(Fja)pp z?w}|>3MDIUO?D%SwfOFkaPo7TpiorLk}`AUiNbqim^urL!F_k2ZJMg4_N@}(bj8`+ zz_1f9wu_$@I7@UMg%D`MdIaQLrr?bh5pgvNL+m}^#)#O!0eks{WgP@cRc5jx3t`BdeoloA^#p(uIrgR?sz5l-# z;_O~4{q=>>kFJ#lIEGc0QEo&OB^^fn!d3T&Zcbc$BmiIWPt7c{~WX{oe3f){IjY!^@u2C|#rC`D?n!jV^!$qljR& zUYXx~s^f>3`V`nxm@N`@_8vJ;VGg0!Ge1s>przQO*knNG|3(gGY z0hiQ8##P%q(K*{AvGKE(yXuAYl*Ly z-6=-YBzUV?ix_~hrw02oJ0babr}{6pWY#iegk4{tW)4%Sc$)rXx!7f@U|XY);4N*J z(G+jglhwIgkFJE>{rDsHcAyd2-)%~^wRMRv0UsGJKBe|d@kz(WrmY2PQ)ErjyWtaX zsN}n*qL$41c%zV2fE{bgSAnC5a2XZN5n>ae6(~8yJ(cO%ze<(b*Q?l5b|E9%dFVpx z1rI9k5}9o!1|_1~?4~XK6tR@NnH-6x8>yP}MF{RK-A#1Y zNpuW~yLQ;?*Vj_tp*Y}o#_z&zL6$2TAI0emjToFSdFVLfgGL_9_gZYUx>5^Ch^`gb z)oc;X8u)+|jfQ5uKNOoU*r>^JGO*m+tsTyEw4FIQboGuV(|h(KBBFCSJg00pr-IiT znO!LGW0#e2W7L#*Cto$G+9#8MpX+#&E zt1X`v!A6^KxPpY4vCtVMreCi?GDkO~Pnz#n$^hu@{AnT2&)-06b$;&}_4;i9T{POPn$!z*%E7@& z@2A`U3KO}krt8wM*m6;Fobcwt^Oz9Z1Sgl3q~_DZMS-I>O832&`g+B=c4SWAeNqUe zF1BGVLu5x#3}>YWnIIAf0G4#{GP8?+r7dS$rhr2wS3>Id!VrHhBeKTDb80)|3czwM8M^7IDTV?zg@@Scp0NDrO`*4v zSdZQ53vJ)g0{9zafnb3mbnsx-#~wOChY6YRUlrd2Ss(k@1ixi{>|+z$0dNWax+W%? zL1)|N4wDQV@_B!BB)aMg%(3y>J=ne8 z))Eg4tx7+d7+Zv0lsy%`Du;wjXgy!-Go$LVl^@^K?8@indmc`WvPfM?man-Mk40(k zz%Wa3EK+!6;WXKuyq+7!Ka^rUjE~T5tDJ~Xl%1Rld`^XA*fr`jpN=@`VcgGOg_v~YyL7$--Ge!7XwkJ-^P4i-@av4JS@3gE95-w2mZp34SZVxc0 zhOdziO(rU6bp=7+ZOF^=gLByVn3=K8->=ONGec!U^Cf^?bv8AT>IH6u2Fpts-yY3V~Z?)SeR|1i~a=eFMZ37}+# z3#deY_D{a=Plx0`-QmsQ0@fb{v=*??)QM9R)3VSbt1O6wRMI=kl8TP^DnT77HP8DLZy6ub z_|7*7@lz`X>CLZR^Hq}W9+$?N6q7$jW5s&fyQVAV-8N5yhHNJo-ify5*L6gcyrDvU z1w0#yzs%=2GEK~uc=zu38Ra^&J3um0j};D{_PWGzIEBEnF;0+7%teEjOi#F@q4D#) z&RAKNu};=_;c%{_;`HrjIV%ELLfVQuHpt7-`|`M^=OX`QnPPZkJGOJ+iT!&z(r*sh zt@|BpKcE3WY5#s-jsD?7egiPvYyB{a;lEFJ7*zN>tJf&%vf6i)p#sRnFE7I+Vq5?8 znq*8EXgV_U^N&G02g;UnT34EGSbU%%G95|&l5LCgw7^EM z(TTEQAxXT|RBt4j1&|w}R~d3G>%j!6SanwJfIjsV5-QO(%yfzHfBAfR;(Wq3{ZG#S z-^4KWl?F`CwV)eFklTm{3~v2I*tjxUK^~325y#F3q_khD(>)9xq`D4pd^iIUc1bEEVBOj{C#fW`PeF{Xd9KY2G&rZ#p(ti<}b{4%N~f)ObB$p)vX< zbSzH~U7MrZa-el!NcpbA;F~Lc86Y!e&WnX^*>lBvSL^_D>ltA2BND1O-C-bZp_!9j*p|mxe@PZ>vn+IOTra8&6@xn(E!FF_3OoTd;jb&|Jz1j29O=Fim()_ciU#C zb2xC~`Rb$=`&2^{3y?GPNwM!rTm96QANRN}$2HD5l|Z{x-6j4^zD^UiZJxrS=T2!M zy;ZiaXF8KrLUwgjR_!INAKnS=)mzlUS4^c?xX!cqyl}vt)@FDw+xApa;B*>>=~%q> zBJ5e9K&n|)q06XHgjF0|aTYT7aWPt{`~GT;id~NjFa$4jg78~ryxO#2tZ7fL*V56&r`}zTS{ZQ{z-;h6u8Psuryj6xYucoH_TH{d$$aObIfPU*1n7`E;b|tx2@kob!;ku*S~H zn3p&K?e!<#IZ3vDloaY3rz$Y}PDnnWev_wMyoEv~l!ICE=1wtC+VGv^9S}V4e`CL* zm&*g`5~Dg)T2WfGesu(9MgfoSpAqF1H{OWKin>zar!FbFRB2h|v&8iB5sgRFf*vXB zwOX3E+KXBAiut>93jQQN;kt_OT~yUJ=1ynq+o`3Mi_bRI>#OuFswAcqxH{S@CoBxP zG)+y@h-Z{Fz4df~I-hlMqoUwm0>;>z4WhKtepWEm=I09+T{IReLn1sf&idVJZDf?&M-nt&sN0aJ^zJAZHb*&pDV1(phNh$n_?zNoiYKh8tGM+3n)Gk|`W6zVER%tk$_@*NmWY7^b zwa)!^yn{wMNbrFNsN$qUL33qLOoYyuQf_#0o*TILh3MNGTZA9LKo-}*d9{=O+Z8A2 z{Tme_i-%)O+!T6l=2T;{Hj5zbJpJ_MJsEp_Y|2nUafpe2w|=6;<)eZaggmQqY&Pmr zfl42|#Dx}GQ>bNSLtH68)KG)h#Em=W*!I0qxn@3k*u{Lku|`EAlVqVwk@>z4&dhX5 zALRt0m!xQ~%#P|^lnK3$?gKKaw7B;%arXXPPHT1C;QK4{__9wyIBV!&-@|tEzD@cR z$`8t>LvVA(T0}>Ls5Xip@W8T?#_S2mpad3;&IgTQ(cAdp_t8G_` z#=-MBOtU>NYij7oZh-afehd}ANox`H2i}M25hhJH|wcjFI zyI9zjN3vFzV}?rR%Q}cN3B-l~qq@~!5lYkj5OyyWhpQ{{{DYx}xR=JG(pZ!rv=KR0 z6BGR$Bl_k`M}$CFJVvVGiE|{uik(PqTpaZ44y? z6FB$qHfner;3+-i$5DKnp@jcJHVSL1FBchNmf0h1%#y{)8b4LkF!nmsGF-(nTy=o-BmMrj41!PQ*rHd~ENhg;fnkkHsd|wbXmb+Vj)9UPlIx=oKGxCAlDClI!Z} zZ+%-vU%j9?C4B3F%9(6`7C&rHSLz&mF*!4L!D2sl4U-(-*RMtZztvFxD-~!xIR4WNI9lo2T%E~I@6l)`E|rWJ8cMVn!R6ZebimkjrEa7Mn&vFcAN25YRbg7gERLB2X8%r&{iyDvk}uF z=i$G#o_Oi%S?c3|8y-EQH z!?hH3aad5jF>IL9jYDq`NKnL{Cq+WqAGC>diS)2s#oPsv&rKB;RyeIf#B#MRJ=lR) z(8R6u6^oCwhXWqQ!LqM^h?@LiTKu0Lf4X_uE?&vcm-B5Bj&3r36aT5KA6q?<5C^mY`^|X;x@4QgQ z*wUD}0RBGHmN=2cGvfaAUUn0w;3K90k*+tUwN1ww86Pf(avG{V+v%pTzTfk=(#BYn zF4gF1>lc&E8O9f5!)KPY@;-TQgk;j6;eO$-Q5PA09fOaP%sU=Dn7TkQdgkZ?hZ0uN z1ppCq;m%_BhWGMIbkldqj>D%apc~O zUPJ7DL=MiT$B$LK7^iD1ytn)JM>qN(WT0SC%_;OOE8mqT6xT+S`Qcp{L4rQMb}vTG zB88C<5C2jw!XS9I4{o(LxVY*qkhh#s7Pk6{1BJm4Z-=HoFP;LHL`B{}d-PZfKrlBX zv5nYu^68t8Lz`a>!+~hrxbTK}AaaF&6BsZO{=d*o(UQ<%P2!|#;n2J1um;#0cebSA z%ar372z$v=bv>O6=01t19cy`H8d=NpbbSrmdn;)aFl=dS5h zu-v*2^tR4Eb^zT<)RU7Qu@OYzYG_%~ax8KSfX}hVLxCl>FV>?hD7FD^1y5jkz5HSt zy1GQSv$Gpq#MgA9T`0xz{US=<5DlrfL?t-6RTITloFWt*`8ItWdXroe_a_;7T|2& zcNxT4_n~xZS}Vn!3UCiTP@f%A}$3T0b;J6 z(x}?>&!A9Y6oP+TUhQWuGhPRE4t_@z8$#?_1s&gw-9+cKKG*PZb{!|)o{Y{}W^$x? z0nU6=1?>U|%b&nyM!~ONDTv!ar*`|kz3BbekHyss4Yd^`Hez#3;|amaLyE20;c=xr za{E}gVdeZYaC#>8iflPdJDU@{#5M6cwggJ4?{|SJ%>%FrEtx7BY3zGf!>WK=w zf3)JWAPp`Xw{zJprj=LZJ<`-`H!mjNIxcX^>)H!d$Lq=ONH4L?aV{{vO1d`njE+~7 zzoE0wMt)C08oJp4JYmzzn(?>WZu%XQW_Vo=5;Ej{8JEI1_VI>a$|o$&rt1lo0fAbH zN{oeLgr3TrXs%Njrih>^fb;jzz@#1+nDqaGfzb&`l4Y0OFrAepqLz=um^vPb9u}VX z%$1kGMbD&fwqsZ7#=0!sMOsdys_m$`S-!b;;w z)x2iJ20mtG6o-=ar@Ptph`n@oyXw zDJA5kWe<m83pbK7no+BRw~PX z{8HwWCg=UD4EII}xSt3T$&>)w#tKwoR+mOS9#Ny6)8qs_l+lirdA2JlA9u`3E$LjB zB$p(!EiQ^w2n5Kgy*guHXCs=h+S5N!LoR)#-}&GYY=wQo3G$_5CN6esU)S{|5z*q|D{&}Qn-AR7u`%K7fCXmo`)4!?>KDy8 zpIpZxUOyKf-6u3VM~oA7%8WdVw)h1bMCnZmRgMA8Ju*>WFYN1Nb4iJ>_x29}6KNPY ze9{^mH{5Jxpm`zGj78-3BAR+FXQQKQof@kIP=(W+sdkE!X{ou2hJW z({w`NGNI>yTX?y6`2t|Y-yIP9_kZ!O{jeOUv;nms3umR=@26$?GCgjp(t2xGL%A#w z!3H;;dq%53?ct*8VgP2)5>j!uqtMjBIKI39~~dn=aZE<1Y~88KFTxb7#% zv^yTbK`sZ~hNuG*>H{Epb~XaopDYO5T;JVoIy7+J--HDakDu?B#m0Q}S?Kvft3vkP z@wemG2(%Q6Bn7IDtsjYYs2b|K3A-Rmjpb*a7^LZ9JV^B^HshtA(9IWtbRLew(+svr zvdQ}^U;L^=vI!PDpshy3KkE?ueIC>o=g78oClI}I!?Wn=3~@#d=Pb1Epm!A1+O{S} zM$x!^?s=##$ESKt;%c?{ZJtsIKKg$_WXC>yuhy%-%ytL~a5hF+-?`uh^4U@3> z?|7M0f6NIuCZzuQ_|+yB?9vpmgEulE>^Ex!Iq?_N^lw)BmS>hn!$#}rGTI+M8@0em zBCfZtKlcmgY>pgxuUpjdF`ec@IBU8IbHpGhUGU;{06K9)1fP)+>*;yyET|RfG z*xW`-ZV4}0t1CpS>u73pA4Jg_VYBvBOe?MM7Cs#g-~rhyaGZ*ohSjjVSYcg~4{`!r zq@?U!7YTa+t@@U4bB7%B-U}4X$e+*N-!GN zaF+MtnSg8AHMNHQX{FEo2T*TPgA0^kN>XZPhbl+6-n-v@iOd!CxNcKGSi63mx*vbS zavh1T@KKy$BEvIVxM`thwwEtL`!E1}Lk-BZY=^%?*dEPqcHAKGDmLKv z%<59mCE-u&3A=LXw1e0O^a0n#xLS8 zCt2)%x1C8Z2BTV!ROIG5CmE(}hn{-7@!Y#!forA2KK30W#&NnSXWH77TriTflHe23@dvH&JsDWN1y4d9qc9wxjGswFg@S z;WLbl>Xd6?*4;5$3x)`5Jo9tPEJsF#t^p-v$;XRj_a^K=ToC@#qP8UHS#!(gilAEx zL-|z+))l@=q(tboWY`nyN#3WY*+Vb11+~G3z*2=YvQ<^+DO}_`+FpqgDNSnV%ChWFW!d+eCnwSewPUb%7rPV629-Ecsx^IHSQ(vl!-;pwisl0|u zBUWKYev)f}N3)2b>3LTjnF_%|L-xxHm_GU?#++-Zk;zOtDGOAgZStRTOd9lv>wFi~ z1p1Vf1{JG$qkL=8QyxTKm*h?CxDaqTLX^_P{EcU0b2J&e z^43NWFtgT5aO=Ix)a!5Og)OMQe^-z->3cTU&*iV1t0vtfS;53nnYWygNlGsOnoK4QVfVb@FjC2ZNDn)sNTkuNg&w?BgbbODmof9%9R8f^Ut*l=gW19H6@0Vg~T z2xS_;Ty`+Ny(?h!#sqc9B-w&9(tEIIu3asizpLXe}m6rfXN^v@+0!7 z#HgC6yn;Ziyug#^`H$?6P;O9k6*abH_Un+|0ZP%@pA=?_om1~Q89V$jHR4LrX#4!b zj2xA;oA&3dj;G1)moV>*!{k!IvC-{?d$m~NJm;4enw zZe^U7IPY-llXc<+EY2s>5c=`*Je|q`vx^`v{p=cYw(C$B<-FPQB}V@`m}aR^do}!SY`R9wkuK*Lf5jp zKnN1&#a?Dc+8mz`qJ&!X`j9GJTLSH6xZ4S$nt(Fd=6=xVIg z$=MW+hI?{S-OFAM-cI_OShE4+~2%trQZk@oNp86LtI z3|YcPvl1WYR10IZHu_}4a6O}}D4k5>*4OC<)>CHNx)>Pb7e-Xl!b>Q+k~e|iDY!G&0NuoWIo|z&PnO@g1jnGO};d) zFDt8T(G#deqeQrkjl)G_`n7>lm+nn+=`%^5IMb;G=)oH5pdDNT7?PnqIZI3_A2NfC zd!j%>?8ApVKTb{5+|qRh&eFwDqvG2JN&(01@0?lsmzJ6^#wST z{!7`^1AxNxM=aY{%F@J*;aNf$%H&JkR5UQV^yGiR?Up?XI+BC~!jvZh9d}xI?_1AqXfsQg?IwJsw{|m5 zweRxz3{ASBcl%SJ-tH_oQ~YcG`{fP%@{Rt9^Cx8oy3chy7<9zGMS28u?xe$?LHHi@ zzaQjv8Rrx9o5d^i`}Qex^1n^sP;3f(+^@UNz-`Da#ud8?7MfFNn^)2qiq_N>*3y(l zJxx*^R2u4!u8gjbD%t7>_K}saurTy3j{fZNXjxfeN$lG5e5AL@LBL`F8_WnMc= zJFp026*4k@*^N2)YyYtQD?GEi4ElS+Gm+4wnLOndL8ujOMzb$rQ2#A;;tAM*48ww& zMEes5hPfJ@K5JKGS05=+Go9C1;((fBACHy+j{)1;-hy!;-(b>^SqzgFG@fhSUWTUlZqn};}rO|=Rl5#GHow8%0M4OX(lwcfq+|pQ;?&NO?_3Gkpp`ck#fBSWgv)9~)W4Os;m* z9p9QddV;t7J^E_#m{9AQp5lBF(KBFmK4-N1p8l!5_rTy3iff3CzBTRNUx~(uv&k+O zwATQrMFD1}XwoO6{9B|h1~HhcYE6iYd5Ur8gA%YLMW-+Oi{lqCv#kJtMbROHb~5Pk zG;8?dLzm#&u|4-TipbMYEl)T(Sg(m>plW8zSCEkEf(Nioi4P$Q*1YOF;dT1DPapeg z?)Y}Pe1dm-n@5f>hCSl$gIiW_3%nW`XsD!W-lk5(tB0kq*|v}~o>^iK5>?)5rn(EA zw)nwA<7Hvw#>tXn+~St)+bnXNgvYl>>4x)AksWS}JeOfpcRHD`@_ zUOzW$a&VVwZ;8Jju+r_`k=oJT<00x&S5u5$Q2$HDpOa3ve`t69E4zvRWHtpV#7~gOH z25j?S$mSCQz{!+}`>O$oUs0RCI�Si~stkMbUwRZt5S~{pYekF^|f^>*Md;(Wc0R zW*}NOyf>hVe66VFIpN)-&$flP`I9MtO;gSF$lcDFHjz7FUEaU?{u+n>pXDJw&rVx6 zoa9~H(MXHzG*TmPOV7!^3Y{k2S&ny*(>a`*F+00@@NQ3C^nPi|FN^WZa{lLLg?NO$ z)cTRwS$k)#{X1VqUTXjgVcTwva03p=fS&UrSTgSsv5!WU(ox*Y93AO$@dDfpFSf46o-lE|m+$n(0+uU5@r zL-`Tr?J}L2DnbxwrkXf+WpMSyDZ0s9rE}|RmDWQ%W+~IEY@H?mreo0X0%7|-nC7+G zkF{Gq%a%Jf*VH(?$>#D1J;5qUf*ntDwguPP3ltg*bq#Gbc*u*@?#i`O;M!96B5$+~ zZZKxYKL_PyV^N2Cg(g6+n)ALysE?*rSn<1(a2Hi(cQV=$%9czRwYGOkOyXgs@!z!u z!@V_O=)z__*?rL;j?DI)_p;=&j7OG^Y|!PVjOG8_W^z;D4p1CY@P#xwX$IO=yj}J7 z?miyTkE}c;v{0F!LHP$Mq`xpmA4(VUij1570Xh8L#nB#T^nq-lJwJN07AEsF5s(NQ>Ad)LQ0y`lJ(G) z>KG?;&7h3IR2T1YP6XRho1g&DJd!o3xW=%&FdzYmWc8&jw|NAu2?3W7 zzAME?e<1%?ju(bk5qozzy_^)YphNCqKk~A7Fe(>mlh|0qYF>;w{TYNsN@~GAJZo2$ z%M)e3)xW|G9Z~Jq5H{~S_%$h0ADfGDoRsM(>R!C4|O32Y$ zcj1gXowE`ntZH0v^&7b`{+Cybt)9Dl^f_v+`S_$lG3Zz-xHa>mNr-A+8ATz(NY18Q zJilF|6|-m7J8w+$d$pP7qbeD+=}GRn7(LY;Ml0T3MMcjdTiBGu#QDHpCrsqkC0U)& zy+5hekCFEBu#Rrav`d1eP3&(m-B5{LACWs70T7>_j7Xj7l5*##ADg`t_WU+kQptIv zC7FeFtG7&#Jsos3kDIT9o3)DAI#aTg#4LEcnG}3UPmhdzz$&y7)a`!1Cmdi6&%ss| z1s}V*lXqaDHk>g@u8Y$t(LSSgJgK%em(dwmFFm}o4qA(qI)s?JwK<;ZbunzWmQ1or zGN1+1sw{R#-PgyZ2ZthlBQ?yH3qGc`&I}j4^5n7(NUne$+I5{6+s3XG5vKho?y)#=NT71m(Hap`pwV!%1(e=^s;vlT|U)=q)bM zc1+~vGLzNl20Of&#)@GWLQ=D*8I0yDWPNzQP$fi&o00ZtXLghMxOk$(=$w{`&-Z8jLc1NBP&p3MZZYJ0DB_ID?bMvPM|4s&)L*@e*U1=X^ibS#~ z7GeU?vDZA5+x`VTI*$Ih!;hNz%P?rN#HQ21oGAQAfQj<=?IixqsU0g@in{NUqTJrc z#r=T!rr*gyI3b}S-zP;eib=Nq{uh3K{oe`Lf5A&?n=XVT$Dm&HZbODER(kpe2I5a; z=!ZHaI)?8*650T`aP4GfMAv@n3Cr96*l^L<2bFox82OF;YKtQGd(m zCAx3Q&Bze~`SdBwgKE(~v9kGm#76DKqIb(2WrOIY0atw?xRVJWmf^eh z@62r8ZadC2$Ai~~?TZMe$#K$NxXbH-@1q4EG;sR!=bHy8?%9Z@#vpN*b8aj@@t{#G zw@9$V$!Vv2Iyn5)b_8KGD{jHOK=&C$ea{o9ND&7Z{DM~0`Xo?7A*85+cb`GGz!Sxp zVMtFdjvWgQlry9Qbqrd2p{00X{4?kdO{x?ezy_poxd}k7dhcBFE0h=sMEa4PKn?M) zy}!dpZOzzbtrIK3b5#(MLLcC~K&bboL_b}93B8@pw?CJzLeD8r!ZUMb${9P^q*AhF z@cqIn(Mf{4HY1iAE8J!naL?r&QCM~e&vGe#N^XK8X{Jh%I$Bw+cLCnrP+{E>b{MInnY?kR}<6EjkS6>gn}!;8V}ywY+_P+XJz)MH4ob{hTGqqzif200Ye*=pO)nNp`5|Pas6B^mDjVr>km|j z9wy>A!lhIQZeN-umbhO|*?uKyA?bpcl?b&1CQXt-oDA`GPV|BH=L?KUkM@q@)3}bS zB(NBoBZ9=tsj>y#u)8=*N2MR)1b1HDypv2?K1S4Ed0Ib2KL>&)C#+?N%b&NUxT^TV4ogp$nbg0Gu!>+m;>GR}|Y zc-kBZr--jbLR$FFnM3FMtn&tDUg|>4jtYyEPM~OPL)T}+(5$I97%xK4stCVaV#UuE zW;n&q3N3kKE4HK>vRr<18|;x+F|%Fo?RS3Th6Vpiir7Lim_JJJgaiPiCb2_EYZ(9( zk&%mj2B~1JfRkZZs2f+I-GG^&W>gg$)!QOnQv*5z6?sC8k9&dZnx|NAg@)+o(IH(j zmkHselZ=pP zNfV}^5m&!rJ@*k=@Rb|qgXNlV$9Sc-4Q(Ei);`P+x;fvP&9zaj&-JjoS$qsvVq4or zk@Vw*{I~TPLOn>{>gOaY;|Z$JXQEc;m(I6cdn}C#yMrJtUy7>_@2yQdw{28KqLP?{ zv4TdPTV*ph%tqKj+cH1Vd3+~p9QR^pzsHvo?QC6nHe6T*)qTWn$+j%-EDOPL6dVXW886T$Rwy046v&}HN zOgmBd*2~Iz%B?2Jt!8g>nc<^QuGNC!mABm%QHP$>B=;(nmt?meG&d#h5IT7D1 z+Pzb`znyw8DmJ&>Pr#vWEMi*CU^BUn81KptT3`tO{`dcw&-nM$9LP$%Tz}ev@F}gB)i-&0~U+ovHW2qLo#cIH-^xXZ%Zc z#4UzGV15tlf&yNjJ)+;HR3k^eea~pC8!Z;8{DvhZGDfH*RKvb*9CgG9IrlaTR`K@8 zY$Nt!YZ?*qBs9dbK=Mi}O?*g7gtO2|ytGtFFTnsBU)HRSt2L#i8!5F!Tns7t<7kz@vvK}+k`_TQPBnf?Zee6V4iRM+2c0JY7n`;j>EV9k5v=@OPOcaVOltr zw|9Sd9ym+{w_gLQ1%w4tpvf%I_2%_GYPc*i;RmgMarue=w0Vi6Eva{B60y$==QjtW zCrPS6g$vOehxRjYua2q#1zjuW6yA+FwR_i ziUfgs;p%t%6${(vscTkmIzK|vAC*U;gV%7g3S+-R}gxItGL?BTVaK~zq$JJ48^yI%q%3^ozA z-U6jouCAci0+oISsfhsqk69MXPQ?>?t=Cof|-z2Cb1;{2$~E#%zM&!Eyg@`$)wHjIAJ z6^6%72(P@vzFvOPWvff4$v##^Mc8m-^obD89fN%G$U}sO%CtcZV`zdInjyHJ_p@m9(Qr%Sjr0V(oy*dy>-D@7IC(Yb0UXR@Aa|n<7 z^RfFf;@=VP?L&qDfmB7d0|I`)LVw4*_Z2fFE`i?dM+{tQKQvCQdg~kU-WSXe$&ReU z4(soK`S*iy;CKD!PJN4_?lq(mOnwdu_D4qTpZ3Y+I==t-Er`0?ijlhf>OVGua##ZU zkKcl*d##S2U~v6m@%`r`Q*2`U+Q4>phkgv83jQI;`3D06WSyDWD=E{TZhG+w5P``m zP7f-H>CrEGNnaZ8IPLfk9bmWh;;p&hcBFa;U0-tn44pHVfSmgx1&N8yzjkT^&j~3N zZC)(sF5RX}AQFs5qk&w`F*fM&?vAUOEGk_tb~8>ToKDjY5-+PgYe(Y|7D}+_#eEvF zPJF(*hmR0;@AcRY0i%>?t^$=lhOhr>*Y!!4Lq6ch@IeQ$wD_R&_{R=m z*ui{*SRmv|t~G?&LYtrKOO6txYHH_aOYIp?_nJcZoDB0uTEv#%#6OvaJSXb}tcyV7^gvNuA`ODjP@?mBbjn`-y zSqppe^L?ES6Z!|j?v7K);;$@~FVHVl4xeSKc$L|-`FL?rh`26M&(Ma|!$w}Nz8Ehv zv6#^MZu=R@cJ4v<{EtMM^vQ*_YfabIAE{|}_pWdJ91H9h2I8-HBVQcRpV=7rLP2~8 zePkbLpfp|A8Mo{P;C}UvgeHM(g**wNp|mD z|BS`vrxi6yR_=aX=_?P1lL7~u7*{b)2}}zDJ02HIJc!90-mf&=1ECjEi}*x}F(e2% z8nK=SVM#t?N^@8&m9d}+1*P25*L!2k;}(-dcFW6yg<*W=4O`pQY5B0O@MR7c@z97w zh}p51x+%0GXtUHO4WVcFDS08TaEnp&Saa_R6ivQ2AtA!E!nDLo_A~=!2bj?4&F~B4H}_%{84#$ z6OdPMAf`!4#6LF!T_Z@PUCu#zBA9oefU6owkoFuvjL>NDH15d`)$ zjw4L->Nb8CP9b;LH58Nu>+(p`lLwPpXC;@OKVq2(O*coFZ1Ct+NPraKb3*btNhF>{ zid`dKXuLATy*xHt+vFT$basr^CXrW^x^RVt86o<@pwNWj`B1(P8}Ire%H^uGQLD+! z&iN-f);=jhk^-~IEpA(8734%+Jj~WzL4_XKOMdt@bt1end8gHw;Ev@a)lN%6?Q&@W zgDW>b5{qIbX!k+L);DHL>&ZesxdIHmt9}tM{j-eyV zf`Rs#%xO2uARk?=5`!Ps3^}$6KU!Z;jW56)ac4$?L_o^^s-BpOg zIDO=HnAC9lmXRtY>{@%unZ9QAhA3h&LlA1IE06yKJVyd19{Be8kV+liuu|HV|L_37 zK}A1p4IX=kcUEC5pz+fH<<3Gr#arH;>OyTTlE&=Rqtjl!($=uEb)P}5n<)vqMKq9D zfZ7~jO;jBC^8XOC^iO*?GW}}n{GJE-Lxe3h184TiVx;#-pcNBkw0~M=01eU7ngG%u}A|Gcl5bl+{{1863KKjQg)#iaXg zBOgFB`AXUL`(OJnSj>O-2VN#!%xUv2nzPw!#CLMV{>VW5J$;nPF!vv_K%Sk97PKpC zw*fevb^q?G{->Y+-;q?Htd>`NC-jIVqYwpYyRy8dy58>x-(eDk0ak#zJOH zBTJ_bcv)?Ib&=QmXpye-oZ7N&8dW)X!#}RVv?f83j%>L+cY}w-%(Xx+8J<3NY`uQ6 zAOIVg+Z!o(!6?`|Tr*7Zub%5|E4mENzq!1S?Gmjmru9Vk{KcA69|tPE6zqBB*D9aS zsGUQqM3|fQ-)hUE%}mcZc~%2kdGT@em6FgT%g5QqscyDREd|^<5i^Q@eF{o0$I>yF z%&w^iJd}{-y(X_OkOHq(K3&CZqH=F!{VB`!O`0|Ij%9|E*x+HJIS09XsFDObz(A;7OIF#@n8=X7etwlnx|xzHXA3b;N?u z_ssg~c*Kf?k+*=FB=Qnmi^2}Tdt=5ioRibWSYf83ou!sqp9q~IcPNU6KUi+#N1KsU zRweq>mC|u+LiM&-hfwTXEpHPqrX}s}-w)f)T`iWhvLF$nvZbfYh>PpJ`nDWMlH==+V4m4 zG;q5(F7iunn;^AC)O+t=@A`|?u8c29W^|NEuN|7XpajJs=Z z>rD?I?aGSh(-A@<;KyU^#`hy>NK*H$%He;%EdT$W*^eOv))alwag=oKgK6E|M1@h) z#yIsf!0tJPgv5zPz$G{47Wa=&?jNs*;a3DbeQ9ugOT{H1_%rDAI8tI%m3TBnP8BG( zd7cTGdG9wS>K@)5Uz?!S!&ISz@#p-BAsWzVTuS-j^s5^7-x>TjbqQ6C4wFPdW zXNBuZ?)|rQeiHiTsnG;o55rIA+SdY6$d^hA4t7E!=Yzcs@We z;C5=A9F8qq$GQr>&8ha)RC@T#SWJuc)u1bQ*_+asN?5P$Y=DsAk?msfq1WZsce|AC zv%1n%i1K&hj!#rFUwIiJf?no7)@4#CH!%N=3+NtPx8&*R5QvlQKVl zWz*up84-{nq$J50S4k#+8|?IA^Xw@l4T!(}P=3FXs9zhtMkzKL#@bk3NA@c!z@>Z-k<3f^^9{W2OIKpHFYH|k~bc?xoBNlhFcv0u!L4Cnk;m^Jgx+!qPf4OeSC8Q zH@OMZ0_t4AI7VbG6D7v(7+-xxwXA7Liz>lx#7~q6eJGvr3Nz*eM&CVs9)zE1yz-!ywEpyw+j1B&LPEm2m)(gi$iW(#cd_o5yl&?4>ZIGdUV4eW50ygw z*SmuclxN~C&;?9%&MoH*dCB0!&f*Fh#Y9iwVs>Uql?_{7mu3lz1LHRZ1^TcN%C<_J zu$lgJzs@$iixLR;888R&Fh}Xl{Xh2J1FXqx+ZzvpB3(dwi2{m%fFeywBA^6Bq$s^a z1Vli33pE1LI|wLBQ9wEoY0`U>UZZpZNH0N32oV0S&YbyX=FUB5&Yb()@817+o;MHd z?6uz)-d)yOd#$zC4=_{5%x<*`obi&`{FvCy$uuCba}0`7!tR?g1VcCxhALm9D3;iO z=)|@R#9>kBxW5`>U;Y(2c8yDo84viQ(ikdEr3k*!ec&hgRwF>EUJHCfz>!MEK>mFL ziNnow@|dT&kf-;5Qr~iZVziq77Zqu&U8oQJ;I`iE&{~%6qw46y65b0@nk$Rf(2!~m zohUEW&Cqma{VPC)Am^;x_Hf3U*XUE3#g!w_7@tdCuMg`SRV&0qhsp|Z+6Z!40|93RO zfA7tHw?EY`=#Q1T($KA6uBf!xL@H)A!NT1{$v!Cb(4FOW__W7=EDZfLTe5#zeCq!f z7vE3+!N1k=|30-`EtHH=>tQwV${!Ry2Fyh>urTjrjmvK-k%xzS46dJd=Q*jUC~F1& zAp-A1e~A2Spa1ca@c#!>>R#;Rtr%rvBGQ8Ef^&Lj z{;>84M(MC6>Qk&jIgi=uy-2y0C4&T}k9vAD;p=)PWm-&$M@}$GLbYMG(Qk*!rRQKxsT*gqnuie==Vy zwCIkq!eK?{1doH*YZB*QX|$=l^rs|uy?u9TZ0&qz)< zej?QdCp!-h>Ztzm7KT&7)!s8vx8uXV6UpPh~N!0Sk0guw{Y#>AK}EBd*kLPkc)Xc zw9_fzp12`zehSDX0Ahh=nphD;H+%fKZ{@5cXnzx)eD;abp8yg;-fkQ|w46ykr5JV( zeYxN(yoT&K3+W-qj1V6|+A>8nt}>q$Y(h0CqQFnn{hYkjAG7gv{leB@^OeA*m*?Y2 zzkWJtDu;Eecca_4#4sy3cSV2l|7L!ovPN2Ku+-D8#Ik$@9lgM5UY*CaFnA8FlVw%u zin7^_5XX;hvCnpu$D0}A%~+SW*L3aRR$6tGS!rp{f9Fm) z{-~~Z0-Vq=!ifa9pqIiK+n0|oXzV|4aURvK$*_(oUeZs_Tt-bE$b6djN#lgFE|nB` zDxtY821=z>hT%24?(v_FZpiqE4O;5&#uO^{W?H!>=GJ+xeiMktKSdk@SQOt8#`3!r znmst<>;-oOE$)7Jo$bKUJ)qcfSJA$i-QIooU!mrvZoa~)5dtFsT=-M8NUYX90zH!K z7}VDfV4O}j3KRHqk&SjUP&}(B{E!(4v1rja29ec015Tek?niE#0Jkx~4lfeuf#8dD zfZXs5ey9ch?KAKH4}6055Pg%29Y;%b&SjBo#9V~GKn@EDZ3Bs0K{jvT@}zW_yQZ$W zI<|xDl#ZszX>PyM8wToXRKwM7j9VG+KfRfa6{jrBFgpVyp`Fag;lKUM%KG!cga42L zyuva?RbQP^XM0M#N=I}^6D&B38oa3yG@5Y6-O)_t0&bfMw!Oi>dwIdDu_Fv-E<(GvEN@XFVgdR2V(XV0&yrYWqCeilpKtkh(02lx1Jq2D3 zL(U;o6l2nBu_r@s2T`#qf0as=&x`%%3H$+BEm0>XJLX$30_Kon?q;Zj`k$>6C@85e zt1DA^B^_*g&f$3i6Lr39@HE=M(%lC6BvIV$%=nF2zRN-!x}LNRg=GUqAqFFFC!n@0(u+-f863bPYw2r7f(r)};APCmA^qw&6 zo`+$Wi7i-S`MANaE-{4JVV&v|ueodB0zqF|%|eyh0Iv9O?9g!YLf7PdpYu<}9bR(9 zUfuuTYh)gnZknrK(39$J=SFOQ!SBX0lJ?J6YFl;d{mc)GOO239eX}}%?^Wf3UDa+# zJcT#Wb!dQvRV5+jO)DyQ*)`$zl-n9TKO_ExBa*yl*yV^@Ap)*7w01eZc4PG7eZg&# zIRZmhdCM_~h-Xp*OKDJZlP>DHSQ16Qs82wCaIuzdCB7WpMR94*I33H-Z^_BqR|=rQnJtgFg`d(p|AJ9t zy#|I6csn4Y_Qraj&@r69!A$u<;mYOo36H2|?EijCKLdW1&5&$?h1a78 z-0g9pU)1s!H>0|T$X5hy3pQ*9FasFAX@~e&UdkU+P|w=M&eJxLF_Bh{I6OZ_(%fVf zcB-<|AkTBm`D4k)Pz1ZVSxA!r%|l5sG1Ys&il+kJ?k|Nq0PC_1EviOi-6|k!+uFD` zPD^gcpSToPEE7p;^;amfg+3%Wa;F#DV`0e0g>z6mtyr7kA=&2Hg{w>DjD&upcH}mf zbz}vOewwexbkJ7t=xtRrAQWy6Sxjd&6RD?@oQ^+oji$5jwf$v#NHi{1l|98H@XlQ!W#Q6n-TXdk!J0a&Rfsu3H`=d zE8YJ*!A^U}?zcVu8xHVCBnH)W9zEt0SI9W{UyUn$xI*%PPD)GSV~p8@)Ac;g?~dNV zHTLiM3<_r-=G0jx4*A^o{$8W8`_daW4;wY#0mp;?UHy;yM02cbOG$w?+#*xO?pnur zO2w-w@q*R8JkPE&w|d+&2m0Hbdf{>WB!fInxvST*YWgSJeF+vC~s8Yi{nQOP}F!@&jDNZC%b zn8BI|KI&86kNKo!_hZZ<-`8ID!JXRlt@Iz%sDD@gZ|ajg`u6^}@iKARyfNvw_}wq& zt8pua-roWo7~h99_ZakjeQUx0J+%LK=XFkO$8K;EU+i^mlR%id9Ov}lg}C03w=e0G zKAXf0oq>H6MZe6Hk3H!u!(dLry0BKw@kY=3{R*QinVkzG=B*Gt4{dS{sqyE0HYC~O z1dnm4(#%kU@s`-PkY6b6&PI?a%}4@;d8k>BxP5iF^O6xsc`I{@p4t6~v&B~zLCe;z z-U_RI$}$7_0La9|*wfro%3@g;zA4ama_7F~dt};2G=%OZ2%zV&!oh_uEM!}sR|C{G zTcv1Lb}rURV5dUgVH3kPT-+(#?@St1f~P|e8b@jsV&4`*b~?NiP~-3lX|gYLsWWnY zNO+Fe3jB1n#L=rawMF(XDrzw@k=o}6zsVedQ0_S5>5Ww+We0{W8|$8frH1i=WRO#^ z)HMAa;Q(V!LT`VncJfsR&t`Y_e1)v9?sy`j{)*>xB2fMv1*c0qW&pi!`&I^4h043ABm?7NWcj1v+3F;=eKVnfn=N;hm$uhJ_xnq`)edZJ^rb5v z)+WfW@jSUdmy&w-Gm1|td1E&`u|pc+5VM z_(NDf{)v~P{>`-iEYq$&z%cn{Vy_*8tn}_ojncN#e{$XD(fDk!p4vw!ZNTj{XySl8 zUnTkTP`ii|`*)`t)iOXBr2I7M|O0{ zjU5GNqMgnx>PFog>+?pWZ>}`NT1JW`-=$0R3PTt=G5?KHFr#{M^|cj~!&++0*(Z>N zianH$pJEJi(H!f}B_2!KFiyF`Nix=(58I-x>V6FKZ@Brtb>#o$8wBkKuCcP+Xt776 zmfYhLPCtJY?F=y%SI^3RXLuX?Awc$)2u3I3Io~or_{Z7~`XRyJ{6DIwrRS|+A14{& zBW7ty&M}Urr6>^-F9Yd}Tt08xh}g)l1^b<$urUN`!6CVOmD%r$W0zfzMolGIWL_in zy9XiX9!phaxQ=FUS)AAAlZyzE1x%SAYnFuxe>4l5J+=8HOb7@j8&j zUfWNwn>S9KhKE;@MhL~J#Yzl{!449>Nt#9Dxv_DpHy|%jYMa8XM#Qa&%2^$3OG)WR zo$jwil)Pzi9lPhichFflrdc81S(S{zxrps<4Z?hN4+{?@_|WX&49z?1{*~_+O{;!) zTaXt=?(%L3{kXnCNl|{Qf;j4l zP9KCEONT3N7=2X!Oi#$28>T7A)y>y)XEJzT)}&XHN5&%}sBgs+i)y zy+A-4k|N7;qeN+aPe5*$gv)22JEPRm(XdE`VEX+V{+Sx@>-0^tTpnA+DNVU3X< zAN(BPcW<`Lz-0C0BvC@R8mzD$4(XK9mZ|^wjxe2e+?vu_M5aSTe%++l{1j8|g%v2x zy7P%$lPlHA`f8=zW#aLz;vbGd z2z1i#X6iq#=>IWd>-a~1o9xfOKccGk<}BY zmJD5Fesu3!chKy`(!>=J|i4VW5O1C+^2VpcDqhlR6E z)1)P{hX`pDE@_uV>fhoK<>w=WvuiCDd@Ujynb8!c^7;g!irIeZE)8kuMqX_p{*S|9 ze(~Y`Hx&LC95gMoZk-exl%ahqw)2fNd8=$B_p^Iyp9fK^nq3a)o3S{y@a1#_EeiEQ zW+T3=RJ*B*;NM3r;_0nKnuINnaPB2}9O3QNu;5itnp?(cvCa9^A#QB>2K4;O==@%Y zSXF_6MqF3rNAGUmr|D_xK!z&Pfm#K0Y3Bx=wVQrfI`2yt`-4}+M6erauAm1rnO;FC z>%>W(k@Zp=MKzJ-nLY7SCn9}stb*#nw}JTLdia)_*Y#u2gE8b0qW}*OaSEW6HKupRpbaHh zo@vw#QZIA|l0gPR5XYWp>}gUiz9@ZbsqSEacKP#cAJLT97Q97`6B<#ibgTINz>|*1 zeh)js_A`$%$!(BZx1CQfbW2^hZk36b5D{8lXOX&piD_z=0?4YS*kUkM+fK7>(}Ybo(@>pJ(zFDYr<jS z%q8jm!sWj0CmI$GpJbnZ_>68Zv1!y9T%&~%SS{9BA%yoKohW1#(R;nV zV;3d1iT0~jm?cYg_J%0;Q}ZMTEA<@|&B`ng^Nv=dn~ce^G~pLr`nUIaZ%W3xp66Cr zZwvqSnljaDrI0|37#aQC&8lm3g=Oo_$Nf6&H0g?w%T&D`>zDycx(dZRV#s|7umnK{ zbYxvvg`=7^ur?L7G;yxC_!Kz%6$qq%3NCP9EU(<~cNwvE7b@w#JyBK}tr6rUl9HZ9 zdJau%?OBMEFnUxTyK-l!V9Yw_B(qx+-?EgwBh}x#ZSWXG>BH4DTXSK+MM=z49WqFM zgeFZ#6|GByvwQy)s=Lv=+w%_d$kQo$My7xTuZsO7ajfzxUu-8kt;~nYHda0hS4nbG zp19BVE+j~DxtqI0ifZ<(+MlIX=6#QPLEt_#8LEc4izmM^RIx}u&sQs=sgmj{E1%N2 zgzocd!-8k2GcnQ~C2Qmu16dX_Rcvgm;X%>z*Nx-X0E zx9!58$1Y4nsb_rvvS+ZT2Ks;zuUb04E=gI}yqA;^c^?U_Pp!c{s(?}+La-8HiQNOv zXwL`sw&o`6NMESuX1Ajc3(gy3$0YnJW2tbretP^MFw$kITMXp*?PjsuDn1{Ack{#Q?vJ~lk zFeBU&BBRQ`DD^FESU%3q9;D$2>L78ZCY7;Q^e{~|Mt#4M0YDO@-mr|D4J0)KKG7(O z>+7(4vUSO3%OU!7FZZ|qf(9Z07K(HWcw2ASB-Nj60lwf&_Ox*Q)oH4%O|| zGLMi0`!ejdJuBdSziAs};ldJ%nNsuPGnLg!5F_y+(QbL7-SUe={7>ej_32E_f)9E6qbxezle+ zGcW3w6O&=ZO$X>`MO{@W2qgJVYh|J0x@$j$N2YNI75Z@cd&XQjpohcQ1Gk6xu%mA;S$Sm01TA`yHJ%4|rbn znPyLkUJ(>&;vWDs6cxP3)z7#U{P;6@?Fluf* zfKHsF-v*(t&7?A}q)-hJhBJ+1F0<{8Y{apDTwR%38FJ;SNTtM;8*bWW?H2Ga%{-W@ zE%$mc-)3P9Bz;dWV(7wIv{WwmyFg1Vb<`+M9qm-jwFyZ}?csMgf>8xBOqelYR)j5; zewX``yB*WK7gV)=w|N^%24?WyYeLkq*DuUC?x!5dk$&XPbY|$&k^3dw*O(sbhMDNjTqUq=&UXZ0 zE(i;AL$BCk->kx%&@z+{(9aHyaOF;xp3uO<>y9Rf5S7mM-Y&N4$DXv~JH5orVlz-C zAHnfa3*S?+FVC8IflXa?ZrE(VzJY>NLvy68f#hG5H*FIWn4re%< z;%++hLv`4KQ{k>P8(*u4JGj`Y^0eS!EQFb#PiCtvXF-w$GCWtywrLSuZQ;bbs~Vn2 zWUyCGcjdmO`+U^B9(xh*yxdwG?W}?HJy8waiT5m54aU8WLAXr~JX*_ple@Ld_1)vQ zMO6<(9+rOuHssjpbU-v6Ov56ctljCqW$IdQ)?(-I4X|r8z*Y=x34w)a4 zX4Pr~$~x(D3}+O%t>H;+N1{n~7cr&X%#oreUZaEI!#j? z`nZjzW03VNUAwgNLTe2@t*fvDUQ)2Uw9YV`#>>TewvOhgfWf5p>9eYGQfam#@ak)J z@6&5WE-u4pjav-B;aEn9U|rx>Z_*nsQtzMxLQ0f^TasEF6nhK4>mCRosx>OiZl)qt zu8-qxPSkc-EHQ;wBm+$TXn)!>B?XE##f;%>E&7~E@8y~vam_t#oZ=49=&SQVa4uv$ zTdITxSKH+)T~4bS7Eb+|pl$Pc&&||#umVLk=!~RAOzB4J$+_jiq1~7B$BNe1+laHA zjOpJk61cFnMdv>FZQQR#Ch6&wn@&tblHUDVb#IfR_2F1Isj6`JKG*a*-h14qbTsv; z@ioTD$5NJF79C8aZiDNyJB34sC$KNdzR3-$%tDktO4p{kfeY-D-bEB5U^+@J6xPX7 zco9zVovc*P8d(fJ|4Lg$smcEp&p+ClrWy-ymNEcfx~!ZR1=Aoa3} zK~(zr*(Ynz4ep!Exy)qCq6t7%XA;U668E>~+zaU$Gea`Hl7f9F^T8s6Sb$H*e^@j06$qT>Sku4c!f< ztGxke=0e_4gRFc#bLZrY>Mw>*7Yv_JNP zA^!Ew{cVmmUlE7BoS?u)O#tpDgGZ<(8K|Nntv#VS$ZjI zBlTU)e-Ry%H5|pVyRv2|99YeSp<%kyk#0F~H`sxv`B?-cAJJP5x0(Sq4s~Y`m5)@} z?tb4mT;$=g+%awSt~}6zyKFMGChWHAqSY$wugx_%1VZ=v04=a~Wm-5wa4o#3Fx7F| zq9bq?&<@jpU4b{c9?oho#$sv&nXm7SqiSUa?2R{QMk(UHbu-nqc7`4~jw z(x&1rbEhtWYwr#$1&p)bJXK;$f%iDam`|SA5w-mT5<=S6*8a+ht zISp+Xf%k=tRph_g#r=R{`X$owc}YphAKR9H;lJMt3>YM{kMKCcXYKI%Ob3I@NsZmA zYT`LFGcMxRRY$ca_-!mS9LlsV19c^^Z_b5Q`eh#&O%iR1h|m(vx?blk^Y%cbwt~a< zIKfp&YJ}r0Bf0zDg&UxK7M9abu~qDGV~`q|;u)>U0(Y#b^3WIIQnH(KhP^>Auor>Q1Xy^(M@8okqfc%yVk_>j2Z%aUuilc&RzzBamO3fp}(O;UMP zC*&DH7YaaEU2*j=DmI)PHxRwroN;2T_TG?hU!37oGlda=!Bj6bk&^fXEm6+cP3gb~ zD%*IzbIzFu-Ij&`vgQvc1ExLLkm}sSUoik7C$GPOeSulGrD8{X5M2nxFcw zv+Nywa#*MG@*oYaW+>o!CA{se2)X~Elg5+AKpT6KT?;1uJGlpS#qDJb%_pVYL6`SVZoTS|CKR%?Fk5CP`0FtB&W{8dn=)`xk4q+D?Pjs z)A~l^zCCCf*yqTRXqRCP8d%#Xm1t=dPh>NLd>FQ$Yw%p<(YU14FP|Ivlp2)3d(gIW zpKSwNU{O8^)xUlF_D?)VfbJO7D8-qcBbVK40v>%6t;D02=uQf~!Y(nZi=JfYccD^b z+h0vTxUWe@60)^^Zs99&;GtDOYgpEV5zOgA<$ilZxiDMs&Q3w)m%QzN$g8we)$Wx5 z1|U1sJ6eNgkuKy7QYS4J!P|q%?-O=+HO|t87lZqV#)l-_>_3mmwlqD9kV=Z}*&0(X ziCi8qOCmcp=X{;yenO(_-fq!^epj5_xlfhs{&)Qlg(iA$VvHqNwC^?KEL+8XH~;ZZ zpzvAv;VSr!+D@Kp-E!&*fN^{OXXEDg2LJ5mzW}q6q0viM!lF@`qgn`C+PL4M=$cIu zeqh0VphJsQS%Wopa8%#@9YJ;&#& zvy7lyS+4AA)&cn1Sn3b+dZ8A{6iOpm*we$#d2Cp^vHge36BoY3U3B=!Zb7_-k~vCo z7Ub4XZRXY*$hT`&v6~Oeb54A8=Vj}(!)uyPHNAv0YNWtXvK+uQG+hZMT>LXNfcO;O z)Y_(^tYsSL*M0CpaD?%Y=U=(QxI*DW`GWgfE;^N}n!%e` zK{#N$M4R~{g-bx)sXMg$=q@CEHM0*VuG?mn_tk3b+X=l-2Gp-(BAO~=(1Q%$z|9+{ zz(KXw3_Quc9`IzBYda=1W$~EWuV=UbsNHQ?>4u=0jqs7lM)%qde!=0_neUf6n8&4a zH~`FUbuS2(GKGJWGbUdR0LY+MC^HRzbn{`j!`KDoL+fRlpvm)bEylzHVj;k$3G>*s z%OSiyTq9E2EC(9lEw_2lEP}|Z_fRZ?9(t)#e~G;Mk~Z{e+mm=+ED-5>7CQF=7e=U_ z%sW&E5M)d-!uW3=ocBZFnuu4!*>qrQ!`3r&-3Y1Qh0JWiZFGOj`I+F?nP-&sv^#uGfy0@;R?GTA@B2DKOBu)tMwubz?|5v9xy7sK$T}X zcgxYkJr~w-QFc>qkM!LwtD&bo+dq5dgJ8v`{ifw;kLO^EW<4L_QXvLXWg*1+}n zk67_PD;EEi_W#q<3i#b1iF+yqs2L}e>p7IuqKSB>sWZ@th^blQkeQ)`LD=IRqdR6^ z5ihu)YgZ1YZXGJ2gs^q3HS|q6g6|^xmn&bi@3URGi5xZAs|~}&7#qzZBRqJ6G!0Za z(uZBH#%zf{030zTO&i`!Sgu;Pp;A?+*2(kq6UvY`+2ijcC5N51?`!mV(m27Tm-XLO z%-Wp^SOjK<&2xc#2DkhR#PiUgje_cH)~Gwam)8qfPhT66PycGNmI6t` z>jbOK9IV(;j;;)zQ<2UK^rPH~&fb6FX%UqTiO106eDGsU;+5O&bUn*6Y5uZi{E$bS zUuKtSGChP>0W;o(69uHryjLq1Bp=wr zICl~q>;yBr$_C$cymewLbP6OTaoG67hW}_rz|CqX1u9)r1R8G({r7uNkK-T)ysfWu)0#AoL@tvcDe0zdZ{ z@3g`?5%`jg#IrMaZ8*4HbCn5N;N_dX)SGYZ%4+t6c0-7}T$}s6%6mgX>26tA`sYPf z*|Nked9Kp(8^P&0JG?`29kLy$(h?)iwj2FxB{fpC3Z>tAQ>sj>#E)bZx?r^ zPDR;dF7*W$*z|E-TJ~1n;n`Aiv^s+4?abA2$_Q9zCOHkMUJJ&OwFj?g{^-8HA2cH+6ya68qIk;KDmvh*L_e|581Kk+6mDqV%` ziptB80WH!%J?cqs-}8VLGYh5=%W+l<#)}pelT;+zTu?`tN3Sh>reh-z8~?of<-seJtmwuprk3YxobjnZhHTQ zEwYz9>q~@tP#gS=aypJ;^$O%m>GfwM{{Hhs6~`bM{?tceGhk|&OSMGHsWtw1m;M$iP58x`FOlq~s7ku=OSC)A=ku(x*4tVq-(DKysT- za#lSzR|-Tb2Y)bTAZKCCP+G!ANqb3YHbOo(dlAHOQU!pA`gC|>(oo3t%B;GWva0hiM|Hb6jF@I&b;#Dc~mivrDp4iLKfL;fq8-@4pju?it}4nkw^oxTpay7l@jqx9<~dQI_H1NE- zknR8c7UPZY*RPDCS`B?afBps-@B=yE*FcUxOY=S@P^>+G_QC^FmL$#*o1c`xq2D50 zE|m0-%Ie%>0dqe(9d&RAve%EK6X>kA!=i3(E~{9kmv|Ju6M-mp(SmnhcyGKV@aX(q zt>Ev7Xmk%gA*T>A*39LZ!#gC#mO$IaTIdrRDn(YgQ1ljid$xl=sZ0e zp#!~ji-Yw2p4gve(tp(O_l)@;iTYcBY`?E@3jtpv!(;`r2~&(I-M{m8d4pq!or~}w zRyLtpc=s9hUK3Sfz*+|XMGY6X$Yp9; zc%sY;)u!8;a9%q3D!I$iA)8h|J7WLfcI8c?Qg4Z7w_P1Z2?t$c1G~x1 z_i|jckxKRLj}8NP>rV}DPti_&G1Q%CF>$x4^K5J&30Az$O?>{<*4b1Lo6evY3~BCQ z>c$W-Uv{)XK|*()c`lqX(5_vluXJ0`o8spQ?_>sb2J{X=2@gi?2DTF@=~)*@20qrEw?gc%k$h0Y_$_24=jrkh88P8t8xx8g%g#zgjjs2{pfk|* zqiJsJ*i5rR+H!~gPZQ7)X3miF9 znee(Q!<@a721`uXm?Z6^ovikp5e}JZGKLgAaugJPp>HUJXnHN+Lshac2q~SNBJ;XS zV8!l)U5l~wY8;qxYGt1>00ao+fRExsZT~|B4lo+oZSq}%zqD{67Ajg5Dj-t!`pI0zM!H-Yos->b|GmWLXxbH8tIf^n&66eY+JORqY}P5e-R~E_q9D&NY*wpvF~3e8fcXo zXnpd!x%r&)%BJ^x+|2@aI?*z_NNsfy5F}zxt!S6wU!iXK1W=b+=YCn%*NPY~9=lVl z_%Psw`CY*3P^;GWW~9KyKvv~;QB{JcWy0ew^B3Pt{4~X^o5CareLH5{ zhhA93OYZ2z6m{rub9E7Zmvc_X7s1^)h-hm`@Q``Z!Tzjz%a>4iVLl4|evhk~qJfj~ zRV(CjasTWirMU|W&uMlXgfIKl1XVEX3dLvYE+(0=y1sgnup2G(c~)+493KbhzG8ok zDyG8`OJRqw&koE{=!lq)!74>q+u|HK^(P7bH*=eDU@sP?6Q%9lZPRV^> z+$f$fc?*0kdp;eK7CzfIJG9X2BZy<2YVl!A*vMU$b2{$LLkS+6_1(&Q7@syBD>VZ}EB`pFF7IAYp&qo!N8xD(BAMz0v$}664F6 zZXrPl<&wyek@Jmd^HF)687Xt$;D3qqGoGsn4%L_h4|nD(snI;?;sUw>aBCXEnajLXaTMirB6HtW}p@hdn1-tAT?1p%}E$KL8x>Wj8BK+llFA zn6lbBk#h}m7TUl(149$1dZBwK&kau*j;z~Foi}@;n1xffC!IIW+bnJhQXROPXaCf2 za<;QqE36#IMQ{>@z_Cn!dy8{kNp!$`yVnrK{rsu-)WPE6lxpeH6qP8=>YBj8ZReJj zujCfFZDZe7wp%`dKJ7*Zb=azD?X=uQF3e%#sZbwh6ga>iwzC$#yuZM6yULGcfZ;?B`?{5 zr+G7-jk@!p{e#U1c99eXiSn$G8rK^Asvl61KelQ1Re!|)&D4`S08k4XKz5Zj`*c}tLttTXyumv;kx^EC4>5shkLETtf|dz zNr&EH=A_8gy`q%B++^|Q$%3U1qy|+&5}nD%+h}9W zWi=+k;-RXa5BchTaV@_3#htkHe=4h)c700xjzO)JHOZgI&VB5E7kX2cMPJDm9D_P} zlv;4E4qJ$_aP(6W6199AL!+o2dk!{d-GH=MQ4&71&igW+7E2Mq`Zz7>v$y#oIKr5({v=saUHr^*;FscVZa{^0EkQU24~=@)n<-C5n&i8{eHM zs`V@OB65K~g;lQeT+yRSQ2m4F7+bCl*pC|6^8N!VgTK%>3u zUX9SSLiYuvjzLGxQNZD&3l9!W0Xu&&>KKGp0vvCe+P|ZF2LQ%h&VJ-aX#5`+y$%lU zAlvqWpexC3-y&_A;J@)I76L(khp|;qJnq#oNa62&L*4m)0ns`! zxYRc-7@8od;qL@?cS3F$Sewk}OmMLUXfpR3&Zg}um4z!45Mw87H@TmMtTQ>wUR8!NJ{($hTU4k;o` z2q@q%WZmDG7B9rxHLqB!tHo!_U8oAjMprf9=dS{%dyzz?Zi7C&2Ks(p1@dHq;}+oo zlQe)cv9s8Sk87JXvYoF^R{AX8Ms_lmr0tL*fftJs9H|8c&7i`LS5y2GUxpNCPU4d$cE?WX3G{HWS1BKUs+`!b?JnU-~(H+3K_u5+?7JjvmPkUE& zaUYlu%g*0Aq$s!CabAjYX_XZilwrW`>QscbwM4hg7m*838&#?0W!>>Cyt-ukavBx& zp{7e4aybwx7_5Oju{P>$BxO3`5OsSG@hB2=Hi?B!DMP(|(J`OqoS#(apRe?Wq^eIC z8GIg9ad8v1H)zb9OHd@wP0!&OlF-rK6_1@T>Skx$%yGXEVmEXQ8YGj6*}wRQEi>NZ(r0bNe1n>GVoggM=!uU( z-u{}pUK-f4qWymGmnCb%)EW_N3HT#?OKv3}mbS_R{c1{9K ztBc5;6o5IE+NHHe$(HAI!1sK)KT}%|dof_Q*j9q`Wwh)V(kn*G`^;b|V?%SOgZh|N zQnBS)a@;=EPO~;Ae|c#C_?p3@2zRf|vZKz?w9+nd(r&X$3`4&^H%ROG9PP5e812YS z9YxA;BJF$8ux!*5m>#VWv&fZ`dUxeG-&R-6s)fj?%}7%TYxcQ-Ka6z6>>;?OBEffqM#Efr|%cQyBF+2pp4aOnTQSbL1#e?o7DpHmJ&Jo z`9{CF1Wg|-_a-X2mgi6(3yGhtQBdtGy;c69M1ZlML@kk=B34iNpgF3s))g0rwQk1i zMD9>Y$PY74e(K9NxJe5!yd1A70`qcOcWkvF&OzrWpkdx^g zq*)}~{@2L6{NJxjZ)?r4Zmn>}7R;J92UuHIbkUae(iwy1S*zrVPCi~qUX;gvT+0-T zmjP2)sjjoP-h;t6A0Ma5+0jSjx-MMKcs-p`v+`Aq$;%x3#8_z9q<_cU|8C&STi=t_ zcg1tYUVn&n^7Gh3d2QYtE$H>z&MUB;8@G};LpJZknl-im+(sSL7%k=cuhI+fQw8|{ zOtkP%FaG=~saw&{Qz4Y*elNVd^X?ZBqD>l!oJ++;5gOc}c)mR1Ht3exAq+TvUX^-u zcG!0|b)T02gfzW3>Lr9)?YlLCDG!xrd6h4(QPucD#n$S9jPYOA7nX1_03N);OlpXX z+0upNH|6hnzt(&_Y1(!mJAMSE6PTYm?R5>y8=lNlTq3?pa)>SmlNt%q?&5 zG%|3M*SBDAG;7p_$>_u6r*!una;UF&5azDH;xUN$P`qD;%C2@8GMHVtmawbE)|;(y zNU;i~bAZEe;F+?JX>0G@oZaMG=qKeLvM0Ueqox7#W?bmLN^|O#sMRrO=RkrGXgx1X zhivc919YO*DLf16|6}jH!ywo-!-|&%&eKoFl)_P z&w8HwzMmHr>fb=TDu9gy%ZJZdqAP#mZ*TuZ#UK5FiN8zcp8K#nw(wthdK?KkF>m68h4tE;Zmc{Ex<)n4Zcth;l8HeIU165*FG=uCO#vj^yt0@xSAd@ z0V}>VsCY8R_#4#;sR+4@>DXRXDYk9Z%nWIBDqetgh)4^&K#;1HLDV_1d){gh&W>~x zTS4gQI5$!zZZMQ??5$MY^8ZxSkskMmQ0@ZF-vmXT+$?><}x*K(8Rrpo?Xr-uJvR^Z(!Q{>KduXnSG8(S$c?&DlPZ*t6q0 zoxaGgdfL$ql1z8J-<0HDn{a!{pNAVX$q&A!z6F;Cc(%v;)B{%BCQ8LZ2TT$gYaN`w zvWN)ulcxcauK8VlhSI^X9kE(s^c&3*LNI-hN?rvzQPg`vFv)=H3yOX5+pYCyVe^rw&b@ZQP<}q8=eMd9bEb z*qgI;DeBEKQ4sZMajA?XTJjCVGtDT`oLq)JxM8rmLA}7<#hke!5odzTXCyx#pmea zc+wQ_)J<{w%`F=y(Gs+6#^l`=b&9*E%h#8`(42lMc=PsoX$EAOtif9>uyiQ1&@T_k z_(s$(w*);Nk&IK7XVJAlHtDhzKbYT=Vk;J9V)Pg=~uI?`@`D_%r6&AMTgHRdmLuN9%w@>p#j`U~ASjER)pLK;^7e%P}xp z56J;zD4n%rm!RRjt})eH{Xuq7|DCQRwavtni}w^*`>*&f!m6k=2c`ZTO#$idGV7= zcO%ThB=$W`p}9N;l0ESEcLK)#cW$V^0hY)H1HOZ1C>}z2yaM02_3Q3-Z8b>Y1RHKUAPaYrI;hRj?phe!ntSWqpAezJ~;^ zdu`A`Wgs}b^I#wK&Gb#zb{!O1%9KLhOd+uK`SDGl5jbeA!?CJf((v};pvXFh^7p4pFf)F*nr!T^v zBwW06X!{5yqwk=jI9DxHSqOSy(Glffe{bD!Tjjd|bXIQeLYRyRlPTJi$Zj=s@I;v)gg=fe%NYkM<{ zJYFhxpI*x@tdyL&k$AE^qHXGst$v#AKdr}ICL^-I^4-1m0?l(SC8eIgTsha44bXD+ zi~a8x)RSqtqE{z4U*3o(vAl>*@sefHnrbzHRdGp+QcpI!%p>y*)rF)|@^q=!d;a)f zm=?BcbA!UHt+%=~(S30-QLy`>)KR$`VAnf}ltTuX{AV}2a_!S^whvv!Uy|<$VAzl_ zqka`px>5S+jgr#CV|8QO`gD+XZ0%tL-IwqK%^XKmA1M2ro5Njis>+VaqjRS-_@T(R za-4E?fy&Xj$=kcqDcH1e)*tXfle}w*p*>`&G+=-lPQ4X1XGjB}6t_b*k7W^@u5}}f z%hl3(+dt7#?3yvwmD+FHT^s}fTU5QobC99H7Q}#$fd+d@Ewg1_lsO!cCJ3FE0?Xdn zint7-id*4O{FHZ_Dj|v;1!)2l{_$CR?v4*2NW*n1ORHZSyN0Pp`mG)l+AZO`>=rII zU~K{~xS}9~SoL1KXTG={k`NV_P33>KDO4BmC;-(cq zCumppStO~LT<}1s6hWP3Ri67A;@}%cVKUT?mj_39J8}?1ksYZJeIE#gPIojv;Fu)Tp+ryy#){+8s6G~@fsj0YDpV`k?H+uC=9b@A$%p71lvymd{W)bO z7lwPRQq|_9fMk#!cT^aY`uAuCP%&qzksKZ&*(ZF7s=L-rrmM4rM&+t z7eeRr+uPJT*uErMjDuE{%%Qc*Jn$aL|w!1?nZEVFXp9{AUXH>x1z8@}H4-AuFX|DKq8-&%wqNnRD8kA_0V7o%I`xweRBZ{ft4q z!dX`=RbT;g_hj6vuE)5A^r3jk#|o8jc0zi6B;XLQqZlmli4QLzIM0Th%;#@c#iAx* z%!E8FjDXCf1U)gX)Se7}J|$@}u#dP&wp+F(8KHas>aqOr(6Z;@y%E^3hq<)MYIjY5@Rcx{jngqS(X$ohCd-9KPAM z`C&mO@-M3Ehx_{epU9Ggd!l14+g7DIv->GCMBSIL1vq>3B1LOb#}p2P?_zZ_b-(Mn z|N54HI9Pw>8>lC}HwTEXWohLY1JO2pq)`UI(EM*+$Lzu+l4Bt*=|Y@5KT+*ozV?1S zX;r^$jU=!DB-j%i;bWCyL_n);l=q(u>$s|{J8fE)C*&db+K;7%5C|&|F?G!^vF-#N z323rhaF+4*V;LgQ)_J`QEeOpm+;>t-R7->}{OHUPadn0T8E>rJ80^S`0&nO0GR$M< zwW+m^NjfJU3!LA(GRUEYmqs}+VoVyI6&4BetE@;*u4N;_&?iZ(FS#RVC+si@Cfxex zy!`n5E@O}3C+kQ1%QzJ{3uD-%0K{DbSa_d2bnH6xv_fGkSrhBm{Jt@@hLEs0^OEc8 zoei?qn#3$OQ+r~a*{R}B)oV2C0(S?_W7o(0BqsepxO@Vpe#^^}W2tJV_&W5->BSvf z%23$)Dx-A-YO#0ALqSb;hWFE93{tBB9Tv)Z?r9hc8;$Nkki78H8FMwAODW1~?eu!u z{-8N}?+vxQpsP1COF%SLELlc{8HN$th~E5N=J0Rv?cbQg$xn#A6BBkGj`yOi51)=O zVO3g@)jcvY&?eWe^pH8`%0oWeu}_eP11Z;@-j7!6)V1Ng($g=NYjy;drk~kk^q;=I89e`c8NCLr zUcHsss<{jM5(?Kchnn_03jrN!j4W)?dU&bi#r{-~G?jPJ4EkZgeKBJ=bJQgG*d>rg zA1Bf)1qh?;E&K*jj8Fo?G%&I)w4e=mdjMAux>cXr(+!`cE>gdNqzD~99cWFu{tdJ~ zqD5Njpk#dj(6JOOh3bS)p)wt^qXx2vQ0Xv)j;;7_pxFxKc7F=VK>HgANkWmx0MY9i z?%6F2y0?(799>$XTugWNQ@+3ZVNZ$lcP)G|P28$?*a(U8i`h7?>7K7CF8M>PLQezs zsGg;1tMpoSF!27Z9bkd(ZB$8d&W2+JfX-rmx;wk*f8HJz2%p$4Kmj%q;A4j;k^wtD zC=eJUk{bZ7aDW)~qVIe7&Z+=q%liM;zng=D->gIz_C!n%ZPRm$pk0EurX(N67_;+5 ztHn6E*&mH)R45$s*t;+>!#Md+?$feGP^)39HS-ccVYi$kq9s;f;p9G84JaQ z!5vm=C@Cc2*00iom=@q^m@90q!=FIMMTZ{&QgrECBTHff&`%XZlW)q&7y|2s)xS8o zeRh(8q6LW^c9A9k2H>s6X?N4Ze&^ub_#M+8E*)s7PQO}0nMdC8KFU}*+v$DV!}Z!d zyo6Yh7ol0{&$!zWBaC^@Hxa%=dVhSd5uhNZb%0=1r|vx=FJu=_8%RG;v{?ilS<7o) zE$0hAc(4Z*oWzGiJ@L8v5)BM0rOz*&GtF``Hm9r#b0(2KsZ~|A{`Ez$*f@itfruAU zagQ413!1p4&F!-U=M+(>vnYo`jx$bYXCu9Bp36Bm^y}Yh4}_T+nhn}Y-W)M(mlH&4S@rm+KgRK?Kmx7YwJd-MQSp%}cbb3{<1WV5rv17K%0H?M2!&!o;9quv=qB z)$xzewO%!U)owgbpEQ0zyzxfGiNhq>T}L zwKNP-yyQ&PE?LZhG`v6^6c_FT?b&2@F6LH$vIl%hbw?NR-rbMo+Jx3q`1o-GJZs_1 zw4+?iK|1cMh_wvJ^%b&k3&wI4>=0;x=geq{x=*tj5CX4ygN#CnQW7iViw?o+oYO^> zUofEeasl0!o1aQW`IaMYt4{)c^z-Xd)|=df1B{X6XIuyFXAKF|XY=ONTEjbCq) z4vbRe-+co;fD8Tc>dyAoD?sgF^)MVOidLf@@4hr80ScH2_1m!ZoNMCY(YHWfHq#Rj+|b z^1mPSAD}b;o_X=tWApdd;q~n$>PQVcrR}ch$)xMfeQziKxGp>cMtlRUX#@3v+K1T? zK)q6c0**5kK)3*SpW2hqcL?7=0M(RTjEDoe`YT=&V;Eu~M54G=zf zc{&k-xG@zlQi9p%0f_wpEP%p}>`_NWo6~nRYL7@;Hcobx^0?=U)o`<6@aa!;T zqA%*q?ywl3dnrm2cWa@Q!a(~Gl}#2Is{~hXF*>9fzH2VnFKR-2HoYg2c$nd?kx@~^ z`^6%$`d?U9N*{pLzhTx8jGNHR2mfM!ZGE`3d^S zIqg~0F3gfE)0{CH9*hohjX->8s$Nlef;J?i;qVoVIV!!`Yx7d^cJ7WEM|&j|Qg|6k zi0m6se{S)(1xCbyk3yd0 zlMU-IJ76U1*UlgaI{hClbKn0ZHiHe;fYH&$P<0(#dJ)*jk&5&T>f|>VP@-E3)aKM z&VZ3u;LwFhS>~;=$66(uO+;f=Tv1@MaW=bIjE#M=xwDE?G3kq^`HDI!tpLtwEkj>c zoi;BS_j#`rpSd@@qA^ZkD&fyh`XI4NPk2;Uw0t-tbx`BWIeuM6AquB6R3^|22MdwA z=GeZFpjnVzyXXGpPpFPY-t|8{VFx||ttBC8?Cij=uvxwn|^&U2X*cmbebuQ>T!0Y*UJsIyf@1GO^}4T+E93QKtD z0(v+oZ=;r+!JGl}FdCmn5{>cWB3JHFjZWBewVhNQL5xB?yd9V5y$q^goUIRMJg(h* zg^7D&%l1-~6qv{Gg8j;z)G z4K&U}aL*bzwUThjujBCE8*@~9urm#;p^^=Nl>sImLv5v52b)Vr?bg!=;_j;Jcf6k; z0Jz%L=9Ta2PAi3 zKrl!ICgLFs*nvUb4P^=+O!yv{pb{Dj9M&*Y86&h2P9HFe_iabG_}(m08!LrLAgl+c z;bfOW-wc?o!9Xni=9G+YaO-ld!{ZVDIF$`Ox|p2LRPt9X(Z;oA)YIJ471+XOStyaTva)F7c$U4+o^H@MO;`9nSHzN2 zXu_=v%VF~osY#>;X85SLa27!+8*c7%y)zzZZ*bj#Z+qli3YFAv3ajBVCvi+zzW74A zS7vS_fW`+ywnsh#P|{LVt{r28S04`0KXovEU?{TOSEr?Qj+_CEbS&9oCl<|XlMeM1 zI#gQ}7n>iIm#bY%r^@Mntgy;K9QKgX?d9TZK zIXyMmujHN*OUcZ~2nK@(-ZBgMGam$EGNik@r-EOc@DJnJ&ELJ z4@_2I^6#I_P5`cHnY& zq4)vV-?s^bz#q^K6W|}v4k#b`9})-r72M$;YV~g`%8NgKN?Kdddon^NuFlIze^Xrj zgOlj;(%JNi^4Pn@0SBYi8Uf!#v@J(Vxi_QWs_67>hcP9-=<`*2w0sFW;6}5vXhO&& zSmyY&^|fcd3f<0EVgjnD{Bp=DH=wQ}D-3<{;0A7&^Pk&avJ!niOa%+j29U3NLj9M3 z3ghzlM4Etv%gvd`z7-YOAZa%rxWPb6c(n$n=`-kr9U>nE2awNmrO-KCnPeK#z|;{) z$-q?13tYF2N=0)JPC;l1_heP}4Forwu84();(L$19CCAAfcjWCh>`-IqJ0O) zenArV=dY{qrA zZ|GktENMDVT)O*ty>H6f*{-mZk}7I695+~dRP{VWxW&s zr_YH6V;CoK@)a+)*Z7F7HTG^dbeI?OeARg@NFaHwb{L}{TjQ9wr`YP0`etHK-_q+; zLF_$Z^yTI)kQY)F1uXwGfq~2rv-rJd&LV4!ECzG=t1(evV!;A0F=_wSB!>GWzHQ>* zO+zRk2vcmL83;cG*|h0a-IP1F+~_B#G>NP`p8N^E-zLVfBylgG7PHXx0kPmAFc?Yp zG^lmjcWqMaxKaPB=Dgq_EFzNb4rMe8^1}B~A2t@yMGHcUwC@WDv-t~hiy2Z{q!H}av*8*FgbQ+smp*119Y`H|;TDVgE z==rk_U2hPGEIiT1w1_nmz;kWoyTQF(Pu?kQQl86{_XpG(@m8U(i>PCSNRnYWw6g5^ zN0X^j8+zPTAm{;N$hbgYV-T5*0m(Y7LS}pxt#ZOyK^M9b*wtO=tAvZGo~-d>3~YPm znBqrY-^_ck6e0xKR-9ijLcb-bkKxCm^wqQV#oCxX6H`%7Oc1ePQu4;82#|XscH~EQ z<=>FB|63!>A9Oood;E8)_slLX&bGcP-t%@rUA;P^<={se2`!| zX;*Hi_O_&=>V8lV?Y+anAO4p18It%ayal)xRxnH;!I!OiE?z6);Vh_DdPgx-r^QPYk0Ex`&jg8{ zdZIps=?tJ*7I1b$Q7)K&Mmi=9FFI92ST+Ik(?t1TOfx)f5ADE>sbv_^vN2X+SiZb> z^s$2QBK1f~*a?B?Zy*gihJrWE1DK6ggphBUw>v81qKI>CotH#W*8A3(fv=^v+A~&C z-FR?z3!023AMxA~4w>`$o<;e&x*I~?8C*~0*oiS$uxI5|Q;coP>_;537h~lQBrT}k z1Me-cQz-x(kh}I2DhX=czin5>h4z~+Kp?hXfhlol4@!#FaPFMj4k@lv0XlLAx@EL8 zxfOwQD}OsUyJD;c%*;Lgzk&K~o%(BdT){_LBlXWP`<-s1wg55QqqHA9p4dC*T~5J^ z!ncePw;nv@QmVUP9vemv2?hL*pRnyfsKA$Y*Fs~#3xvHp;(;-KdXNtDMs=L`0Dy(o z-X{mksoT2;_B90;73`xv@gay?tapNzMr>A_pjLxM5zNn*5NyV`1uhln0zNHu*gVXD zeE!vt&qW+5=CzR!e3TEhfy$yD|Kg~??%~_~RfGk)8f`!{h@f^DT&Ie4=0KkagD?6T zsQ}uNmsuv^1$tf3XB$~s<6*U}5dA0s<=#&3F}lp+(l$X6>LT3xxUSlhdItzm-z1;K z#{sx7db_f;_G4xyCaID@QY#yc4Cvzsa?+>{y%H|J!N|&=%#yqC^0KDqL+9ta36au- zQmF@|)_}}bEZ~~96E;b-IQ{ZWQyPis`p-&0s--6{GGhp5Mw^#6c?<-zJQ5q=Os-1G`AAF{>u;b0(Zlkkz{f_Be@2apnXkNWBP@cLQs!N@`U)ClrTP zSm6b3S?{l?7;-LRwI0zqxY;KUt>{O`8pjqHqr2Xo65 z7hk}HIBL+mR+(G=2J*=|M$~D;r8Meq&A8*1n=fB@I?RPxjlBogsP8Onh1amBC?MV4 z(@h)tq7@AI++5@!Z&{wD*(CtYUP8rJVP*A3c|;zcPp;b1oCoxZFq;Ne0%-EK;Y8oz zkvHxf_tbVwqWar$enAF+(S8suFi4o`&tB;eDSUOzB}!~47LJamsM>F%(x@kVw2JYq z`G&*q0Ou$F{3%!|U@7`uAV&7D!mg3U2}q~OM9cj0t3|zcG&`?iob{+gt4*%_k;=on zO9kUrWY=r0x3;!HZw(!W%lGWN4~aBhL+zoY6wDr*GfH@SM&H=ovFh;&)yX(=Ru#s2 zS-OtM`u>9kOWg3_N1i9zglUXWGbL&BLw1F!Z<%vFLUNy#zNT(c7-U<3{%NIk-IjpNoU$-bvI2l4nfo^x^ollSw9wh^?hNrp6QjF zwil6VW^15X#CY4tO5yW`9c*p>mu)sCEx|9*=iL-iUndaUJd-9S)TgDRRYV)RV`5;3 z+b#^5sLQ2`tJU`rqn+&*#RA1oC@@=>N2;yAT#LuU41G>KZ^or44>_y8#=K|?BeskI zWSn4j(aC7JY4Up?gWobQ{ny~f^3ZRA@-H4gVE6vhn)$^FDnfyeaAUS=M5go!i-!Z> z^PxVCc+g2{8m-JEc@Kt?|8e;poLJ+q&{_?L7^|!yEct*Ft9Xaz%9ZdGZn8NV(0k*i zCy>(2ZY$lNXtWdFpwXOYFcPe6(tcq+8t&dSCm&dafw*L~?6a@9y?o!#U$EkKi?USd z0r7BeeB=%nL%OlYU`=tLB!J81o4mx9H|2Mt33a0g(2{i8>p)gdRd0A8X5K`;5M}np zVbbZq$iYEEj9N_im|0^K!Rk~>Ies?CUN53Cv>;YUT-S_Oin4ZCQ`LR4ZC_s&2jZBG zkgmmt3Kb{P6lX%@YGcyTJbfu{{!ZNw&DtK}quWi=5>xP_Xu1Bj_id>J|# zq<(xe6v?jr#a4cO-Is01pqFJc*!S)~=i+~7#c+2n58saXNvXX{@Wtn!=l_4!>@t?2 zy~u4_Z>`OA%0N;V#Rj0`#6yX*#4Z6K)C<@&765_~xv1Uk3UG1%&OQD6G5Yq@bzh-Y zE_cUD6BkzTBVuS1w3d%FN*p|-n#}Qmu^M za?5H-NkNz)2guR#vU=5+v#o|vSFY5AS$T#Byf$vz%d{;@b~xL9kYz26bMoN61$yls z$J0fH2BAfH4=(t7RBz^bH?Y4MiA`0Oe=(vPap}sS(!;_?X@+)#CrTN%0{SF-sSAwr z7Q-_QYHpTt8=L$kjLWQ@!%h;iYBQSGETU68TKU)c_qV~!dS=fpu;uvW^R4;59hH6g zgb!&;G*^uza&dP^2v#h19A8I*?w4;&Mk0f~4##j!8EIzPUhu>|K0m7fYH^=$5reiYn&nV^@wMLzcg8B*(B?4y)EHyUu1z4kMnG&@`%UY*~d%Ay>Vn8Pk7)!enAfH z^^QZ;T{%qP0)-vPZH2&gZ_`#tsiUMleyde|2JwasD1e${)O4DPy?*8&uJ=p>MJj|e6cz$9SCMb@*K8)5E{gUZF&xSbkNH!v@LwH)<& za)v+c@mEGmk%Qjq$K_%SE>gfZI#WH*<^_-NPau?1Uek-J3)PimHzt!cu#3Z8KZS{R>^dwY@|eeY4^8}%HGgj|4n;x|aS zLWO=s4Z=Ub8h3g~PMeItv`!{2EyMc1h9}_`Diq!E1Xz{x+JKT620>E|g|j}vY?>%f%tfD^I0 zx2o;I&<4vmqyQYS#HNO*cVlg)AGn@p=4oynYwSM-_mJG{{bV*7wU3hQ1HMys)lc|i zk(y}d{jl{Gj;onN47{Z3j~9ldN95Va7K!4iNAwYWI`13JuE1Sj)g#siXWp9<#rjH}9v4#!hw0;zjRbt`< z+b>_*6zHuK`xnY1?K^q>4a~n#A!a8?mw-sN63}`->h6jlfA2$#ftLRz&4AF{umAz1Yk;|3LbTf&oM`+Za%u&BAv9Eq)MwSXA`h6)d~OGnW$1 z7XUQleXq!_EWaLM9(c=^F(GVh=TF*2h%1+w9M%BGHg?&u0_i2O7f6>p0+-oEGsbsd zVs>XrgN~8GwIF%gGfad^dM;CAn+bnEy@Ct{CnpwA`V~u26Ex($Bw=Lg88<7_wq3|kRy&U zyITF*ij{ACchtUtw$f*W|Lpim_bP5~U?_)Gm8nFx6j>*Ofk*cqwGN%CLnN~-qCvQA z@+m5P=fybFd}WYlBSiuZV9)sZd_gEv9770ZoDC-$mHKHp;SB9p=zJErZRb4i9KBB^ z9zoUk3RHk8FYv(CVPZb!KgegWR;G?o_5NsWeRcUf zpz<;TFne;{Azx*Fi4!SD`D4~JmH-oT!ijSDS6h|hyGz)aY#7@vl~2m3dp~HfUt=*Q zyr`?dPhd};4=h6zF*a;>laJQvzHsghK%KmU@cKYK-Y>Nb8t9sH`T3#B7rCXES{!6m zCmsk-!viG`!SM#lG>m+Q_*PVL!74n!bktaN5++PO@zHJ&L1^iZJN+8p3_$n~HQ)uPPsWxCx9_kzvblE7Mb#3b>37?^8CmPxY&F9c4b>*bRi3 zg$J^L<-@x$0GAjcqhkv{SjcvU-B>bm=E9s3sFAv3iGmWk()iPHE!xfjY5CSG<_baQ zfOKtfwts%c8#ITlQz}`d-SH-6u^<359J6h;VY@RpUi6-*Rp+pG8az_2#zEskaWyqs*G5ttx>sc>hM~}}X!h>a=^j_RRu%YW@vVy0O-nvt z@F3BSk07{%fq`84)78G2e#;l!X!D3=Wc^dJ@De!0OU{d}mcrV6%slaa!cDK8NU0(? zDgy1F3wyU=_lVt)RcM6FQx-z+W>hVD^S{MS$)M1D&}IDjI#8`%p9 zix!?i(JnZp5N5BURr{w$RDdqvW1}6oUY%tt3iNnilf1HT>SdnC;$Ur<&2MIIw?Vzx z`3`W1oO$NFtXo=P?Y;nMO8-s_08J2vv3N9IRp7)&W~D9<#9IrsD!au^v8#dj8NzO1F#QJKIr)&tL^J-PdJ^yROIt^wT<`b7e< zWty7dR-tu0Ysl2y?%`x&w4=qZ*pN_knsa0{Yg#DkI5vU(HmDbYl^>PWglb znWOnXQZFn*`vB^j1ik8@#JWhTA1U%SeDuI(2p(xjZ6w%y5CY^;;~jXnhn#Dv1cPj7 zII(RDTC1t3z18Z|Vgo@>#zD4gDm@vh9QI4VI84m6SP5qxATeD&NFGSoOLA6|0td$O6mc9^Gz}WCY%%p{Mh?}fjZuLnhKaOqAfesVF>6q@q4X$Mj?yZ6h$%RcX; zx^5M{gtKO)_Ai`+XOsm9Xl)xRLcUfcZawLxHjhWhszfw-F9x3VcaJ>Z4vc#7TI9X| zd10wm|Kb%AEVS^D?N$1-caEw6Lt|XDJ43%-2>HN&UWi7ZQWod_REh%VD@$Y!{QmhD zKw@|8{Vl;4KY2e4ejQcvQJm1)VV8gtDT#pMl*C^VI$>sin9;zX4aw!l7x|3jP0r=yVf+zK@3sUv3~07j;mQlXI9c{moIn-FWxQWHSU@nnp|)7%@wc|YTFr>-$s7HxJsf2U<)bt{sNn@n-fEL{$JzRuMs3aqYM61y^P)86BeuU zf{b#Yq<`yy-ho&+s%Kzv9^6wo|C7jB$@KJ~HlSbX^KbY-9<@5g|r zmu2@hjw;MzF3T90kBj*mz0a~?S;2Ty;yL}r2l>2b8cBwil$M(}_mo5S`|RnFFjhmk zl17)BrfA~&c}FFo1I;xMN39PmeS~XctQnaD%HF7vZy-xmo`Xfr+&g*H-Wx|q&c2s( zGiSG4+LQK(xaOz`=GA`AI2A~pI{-IY$c0;J?jJjaHR`^X$SIc@eFnPXpAO_Q{^P^f zkSBa(@C>z!A97RSl3nl>vE@)2@??Aa17c)+yQJ-B=rE zovMQm5c{}|V^tdBPAm(=@=X1oIKq2#clq5vz%n(;OchlcFL~eLaze-9et@Cn@%x3; zU`o0BhJq$uYhp@)Bg}zKF_ypgHcQ;yC&sWj*kCbS=@+L#6|Bodb0&s8&)V}wFA%3& zWJ?83KrfVgJ&M*^msp>9_HJQB1RLE@BQ1)`HOViJei*YZTbwQpm=YIYzdUyn6(D!a ze9Q^_9%&cqXi+SbA9b%FHUq%yBv^Ag1g%rG_V<)m$r75Pth zL%zH^+;NhQcGDg{%3twlD*!L}5jXulfbP}Hn{e?vvR8wSfP3p>n%Tp|BfYWcrsi>PS*?w%=c@F&;ewkjEOcJS%rtQ+ zHIwxU@}C}C*Y*#<(@Y*;5=ylL|!u-MqmX4CQ4K5mHBu-*P5&al?+=AHKcCR}NUv5+_dxmJ zt}jzJ{D>;ucRPLB@Tl?4;wKXOBr5rj9!~U`<_l0^J(2fX?A=GYfI)^L&<=7ERtuz8 zvOQwwb^R2Vh3Bm|ub^-`P)F1h%JHhc;kBdPk0T^Ym`Kx+>$a{vw+G_-)IE z2k5XWCI)-%zCDdqU}kmm2^+HP#h`(OeVtd*36_d6i0jFKY3geGKPa`EXD6zlqyFLK zK|iFtdx2n`7wPL8^J4-sdVGZz=tNBnpDyR%1lOnlc>A5ktuP%q{8}5gNBFq52I0#_+n;xr-`=G#Ig3Y=$RkJF z7Yv|8iL4342~NUn9i59zY#TMgmXOk*svwQ0;X0fKpaW8j(5ZwQX?|?hJezB`sg4c5 z-mEa+3I_1t99pEks=sNjl=GFnAZ>uf(kq~hJ}Vy+5Ih^Ba$pvzIr34 z+wU0kB^}41W5-3f<)t)=k2WNq;NzW*FV9b!-Ele2vL*0DPAtvinkquGGpFw1hrR0i zc4i!xW=pB2d+F_aTkWwlc-8Ug^zZ_~T!%5e-eq$UC-Lx$$&aRsKgj2|lPtJtClIwQ zS|_Y;nG9BC87{U+pQ)!hI&XyT#|VE`_ke71LMN*!ivx5Is@9` zMv}MMl$M|SnY3>vV!(EBUWGBsC5124DsUs2zE7JJ8qohqNne-Kc#liDrb=H7eYfC6 zi_L+mqeOO+xh5t=uX9;~t)q91*Beros7!xcw}77)NiYQ!77Pe>ek=dbCn=9 z`937GzuswrjotDcNdI}pxzB)({@{iqLk8-d4+p+WsmFez7|$4SK^r8jru*tXAj7{* zl%nm%b|@So%)ebIdT2}tZixTj&yp&1T^vyHccX9wEZF6h5n{&5Wgp3*Pj|(GzMg!g zF}nSEiW=KD?4yn|eN&nQW19csZ*}C$X#l0+4A)q4MDr0uzYevDg}TfDcnnLXV#-=6 zG|j`QZZxcu&?g%BR#C<#;?&A%xTi}MImLRew3;^K(tKxy)Pz&LjgLK>VtewNiw#lk zOqhzYJAT>)E+%6E-LGBd%{cH<69s5V#^kx1HxkU%%0pozrstq%24qAZTwb^#n3Vq!c|@O(mmZLs}7pv#YoJQp<_JXF2vXrS>~e+k0fJ(Xaqghsm7N>{>v%({u`%19GZ|hG4v&&pM};cTc;u_ckE$P8 z*ecz*ex3IPcqep1O;gUMfg z>MA|?vQE4)%`h-7!qnnTNHVQZ>81ce$t-vr*1ugR^BUhWal*VayShas_tTBqcA8id zVoc*()VmEZcs}WP$9U&P;{D>nXUUv#^8E;BU%R04;(oZommLJq2ZVkY5pesLu2YyqKu$75S`Q@Gb;y%9v5Bx45@f~=e`!@xNG(bWA zr~CSEZ0dcNbl@Kn68{kipJfKlDtF~hQOK2IAGyA`Nrrdu15^QIl^6Dzk2n5dVb?PG zyp8DT(mH^}rB=P8OHpeh(|KW&e6+9?&u$l3L%>q20@ZVY$z&~PNaX{w!|jNtKGz&9 zKWmmDC7oqYZIZt-Oq$)oE!H&Fk6g&_8s1-^G&_8B;Pe9YSTGP*GXRf^99bMWSzLIZ zpI*UY%1v<)e+d%ddnA+P$_EgQKZ7lCM^Agtsa?D7AV_$`|G-;a5U7f_a5uW&^>P)Q z^IMpod(?+w8^2&TIlr4w8MfWFp8LLyDhC8Ja_z{Ooxb%%gKp{(K+a0+3ScPsK!_r? zwnqIZIRY@BKNXx#fu~cSMd!P=5!SSbbI>S2K@v>%zXNa=0l!tdQN_!e(KV?#41n%r zpoSaO1I7lT54!jc@QIFJ)Y<{tjBakSQG0d z`&&-htAq1h&|2Pu0QI!lM9vDvnN{Z2Pl!l< z?xngtG3;SybDl3qx-qnMLe9(J*cj!J(X%>s-#3LD%gp(i7exWlUO95w2wDSBU8zt9`wCugNUyHl;7+tk zIJXX;^pLN3_2tdk&I*7Ii5JOv8FUv%{2bv87gy^D{CqV;7V-Y}8SaW*{BQfn>B3LA za0Q5=Hp*#6o&B7r+Vk0m8!hy-SfoZ3C1E38v!Og&{OCTlWpl?b{X?}l8t7`~f4^YU z>AQGv&OehSEcT$!z?;wG*(jcs9#%_0Z0hvkZy;*5&TcN)Ni<;9??%9=_>hyIE%ul_Ut=cV=4_w~2Xe{=jk|z0YyqsK$=!`0$qz8bS|uqT7_%fJK+UrG~NALamQO zN71oxEeP%t&_}710HLG1T>US3W7l}b;d=*w4i;mufd{5!K-NP$#Aeaa;dp0h*r~&8 zIEPFyY4evS!gR3Rg_|NikA4d0a*}@v=Qcutn8*K?a4x_a*ufv@wSy9_UMvre{}Qmt zaOFU5SL`!|a({s?Yp$nXo#2!^~%k{)97ll@vBz)jY zr?+<)$aKUWWIwh>$EY9X@qR)4{hV(?m;5Ay=;)OyFk$~@7Bn9flv?-+jo0kHuh~wL zc<!&r`-@ z(If9?97X|8!4u&g1-f9!!JMs4sSA$8S@LJCTT=?3VtX=;Y=qT+-Ib=n7h2*2QmI}wx0bm zVl}bPZ4&E&iXuyL5>nKTQr5i>4|%P!Y(?gmlNfLIZ&O?OM{~Pi){C;3kA;Vj@TE=% z;bOaJ=fDnJ<*?rEl>z;FV_w4&V?{mG^@4EBHF!$VHCNp!F z@27l;bm>pe4 zJuIAi8mC6U3UZM0o)U*amP}CA-ZrGA(!v#d zzKlSI5!#s!H}l!HXxRh6gz!z_abqx<#SK?nSGgT_Y#|2Iid0} zkb;9MKM%-pP;B`bdIvp7nr?581VrSKSJY5ETj*zAty|@dx@U(wbgcwODpgutsXFaY z#(%$pgpSz7ZPhnx~pzQ!(K29a# zlMgQkj9}SIG*Y8BlbvlvQ%p7)9LjrAT`)n-`ebYgg5yhlp%3qH`@A7ib!2&ceoPn- zIFriGy934T_d6^O7q`EDOyQe(2Ee@CbnwU4wG92ACzbyLf?i;p45>R;K}7qlZ1T!> zjTU`m;*Tyy9j^lkFNG2S2bc`PCl!Y3frnUmr;dYSUK(8#OEL(PFN!87O(mfZk@;6| z7MqV(iybXo;FTwNPty2Q6vVn!J`}==&tgp%b&s9jO9ior`DfD#xx%=6xO-&RoD#$X z5@%{gmMpaI+2Gvn97vCHKWQDQO;8{x%+_7+oB0rHUY=y(kS%ttdL*3IFc<1sQKa@*Di7}`=mvPGezgfsajjXO>S?OwZS`_`R|u@uib)b0q=}?VGrK2Pl5$CxVA9K8)q_?Mxeh%lVieup8jp;Hp%IHx3d~Vj zYj##fPnC<{!1IZ0L=abOpq{N5*u3bJ{>)6ioay2Fu8Jx-pZm02`V$}OILIA0h|tjU zvdTAjv+u-rEq@vnDRw#^fqCWI!oHm=5$Ge;Ujv>Bi-73|EgGLL_I4?2&m9d*wVk~q z8K}H8x&e#i=f;*+D~k+u7;3M~7^m9Z4L>V95OTN`Z;5+{a3OZr<_#|xmYEj8JVcs# zb(!y~s-$V%0N&I6V}#%!_hqLZozkMg81G8Mvm?e74{mZBf|9cJS zPiXy5`q7`=mwyK9e|B%~H3ITl{~CVqlvw7@`CPBwdy~Y^zj%8S>JG-QQ{5-)OYQ?U zxyRKtn>@X<^#}F`pus&m*k{z<#G0fH3l0b?ekC2IzpY1wKZ96_3|n*yM|%sy|86o|ZydJZa*82zdU>tLM-YxTR)bCRdPleCa5j&1}!ae${M z+;(6k)#OxPstK#H_0vwRD`ZgXA{|l@egoTIa#LM@u%ueqS-YxV0?#%w)?yV6PFYbt zvGHthwj&l;kbzPbi7Do=X~04-zPzv^#{r%H2NlTDEze+p$&)FakZ9%-Q@Pk3kP2za zhDNxR_F;8ZPts^Nu(N@LULW{n6X4Ju^O1eHz5zSj6F(z75Vf(%3faf3eRKGva)x3* zJU5?w3?tqS%RaTRC;;7q&V0oNAg+@Ki+g&NgjLL5U~XOMAGnIzLUj}t2oTEyHc>nd z0*%)K+NM_$J-XXo0G17yHJJUH1d}Jsh?G$zCewB;^2S0Y;#&xe1RzvGTYuDSxA-GJ zU0)4L8j~)^`gv>6*mxCw)_Fd)Xlq+Rc(Lc8=W!jPT$H$&QD z@3%+Zhse$ib?ano8-{a}P(aZfm^KurOGQRX+=Z}^k58a@c8*O=)VO~KJ>PvD+WfY} zxv=@0AikbvuZLh+y9f0|ed9k`HI!zqn|(b1y3wwbwTo!}4m$Ox>#8k*^7C~1e-mU2 zgwXM3ONNC5=N%!dA4RX?41`cRWW(LTTz94<%{`({ul%4kq_2*nuGE1~ZMK(6VJo@5 zc}o*e-l{N-ra>4>p1pN?(Ipr?wv!Kyq9y)&yYqLe7gvG1xxO0lWI_H@p24{41Ixol zlUuvgsn;BO>SRaLaEzr!?sO@hLTcU++2cEs1uA5$Q!GMc&|-iya5DPvH^cyZx~1+h z`Kj9$h83YGWXn7fAc;x+pua0w@S4hRp`6(SKk}KoQ7(nqcK#bXHQZqi8k_*LBOPxn z(s1d@y28DyNC!>j*^{g5Dky&Nm*7YNXg^JSYl7@G2k}uL2=Dg=1N;)%Nk~ax-6#%h zPFQVK0vJP8dVu*~OAYN-RQaeke(5!mJQt4H)`9H597GMbFX&qiEg#-VFOAewj{AVx zkTd{GTl_`4-~a&t*kR6iimqUqJM_VVecPvK{GlB>MCx!J^6oMgEK2pQ)w9*-E$aiIW5Q zUuJBp;`NYM6re+O^<<>;mUFNVKRV?S0wA^`&pI!`;S`nfJ^99Zu;!OHDuAPW-3$56 zf&wbUY(EK)3r?NCfnoYVFXY|DhERJAbCV_d^1p+gnSswD4K;*+oZb{5r_K=uo&}c!@ z`|qIQ!75$C(r0s;yZx^-yq;M~V%nm~z;CxWewws7oqyoMLbtxMssvZhv=+r-A$0d% z-OFF@4;j^lR#vHR)bL!^+LHWjMrg^bk=xkz=@Up35^C#oiHh| z%G7hzvOGksl{3}ldFltY3mlurKZ#~mlZ{fePj!gh(ohKz%-Ux+8h{_lPhQ1a1_}j> z6>4+s3Pq-F+=Smm2vm932YRu`oG5A*vYL;%gzi;;GB|4FXby{{a?RH%pt~{d$r)j# z5~uXE`TPq=;I>`XKU-&c?mdN$6!9Wr>y&L)E9OP>#fazIU|;Z*L$fU0w@$Jsx~@rV zlWTqLWhQGOKc0Aia@{i{hj_e2?w0)5z~oeZAAR;IIl(a%5Huuf1LwytTN}lc^>AaO z=Zv>+EB{CN+g{EMXr75Sx&b*aFWXq<1}pTPr1#45lbR9E)-;Q}%F5E8lP4uxKU^RD z=5vs&`Hn1QP#4{u`rfa(GrRQOchIA!AGd`t8ILSmCt(3z68@*n7EUZ)$~s}*o@6Mo zef%}VReRT#?J>?WN(m_Jpo?BL$2V=7;B@n4e?CUh9$Py`nu7<9wCHE=XgXWp(q?CT7EtHa7NomM_X>TPLH~Np)lj(@4aVn8()_+h zGU|Lj?5EjU+{a67Tur)em-KDfsrii7+LM)oQC;C~qHw6OPoH#tu}i|P!1auhuB|8K z_hN;fDtgdp-EXk9x%pc#u*|l~5Y(5-$6zEAi`&@0n!14thJl|VD#G4pp4-b?^h zF-47Mz^Ikf5&)LLLWh1)^#U?p&42UMem#AIBxnszr`UEoY2h!DUflu!gwS@UW|ICQ z>D2*1jeqfMf8(&f2}B-eW;h>q2g=QH8PPSSDrg=FHKypo2(zV^z{K9fb)r?ov~W z+iWK`Z&O)!=SW-mL$znBb`AC#mvjKtt(_47&OKV*?itEX&ZtwtP*qL?3_1WZTYLy$ zbnW2X+4}Z8;W2nR5{3uwux&`}F#x0DyP=Hqyu|gMaLn3SQxtX=HD4(z55(=z0BbPc ze}`vA<>Yrz8$Eb;7rsxI^BDnXqy&A!zJuUI)O>TU8I-*5Ppy(z&p&?kJ1A=F4N!3t zHLq6pCcmimpXF>2jUtC83R487v~$l`xQgrC(Vl(6h*b8rA_8zA%>x`UqHVWmrbWH* zhS0hqol0_TA=ywOWTky2typ5TOOPNNHr%%Zf=mC*sO z$Qtl9qeM^MrlC6CLB5scIQ;8_b}wwE_$N{ayn!k~eAhj`Gn{ice zmUih)eWIXH%8}dIfXDxOZkKK2u2VgYde-R9J1L!`Gdi(jcLtTOTq_wM+^!DuG><#= z{3Mmb{~bcU-wk}U`TdB6`Na@pv0Ib)msSd(C&EBV+Q3wVQh$lKm-vmLMSPRa$9oA3 z2g7Xz`9cUBZ|>q9Eadfd+wR9bqoGj&3t1`b-mkv&P4vlcbxr@99pZoO$^Kx&;J?J3 zKRJ#AN#1_#hk@|oKCo=7bKczx-bq{o-Y49e?ks?BSD;?~eceudBfl((!9Q`P1fa+l z@xFcMJl1+`i%%kf*D&IY`pkhI6&yy|sS-)Lc`o z7T3ukr~6`(VcuuUedzQBk}=0sPA^{mNMHO|@@}}fh0H99`hDoU$N&8|@3PcfSV6t%U@P&Kjv zkX*waV?W@yvTPOSmka>nV<*shdFz#}Hzua)Qi%0Ixk{(;OBTG>)lT}lE^nt1 zQfd9*dSrN`AwL^&Ge06D<>+OFCwqO8Gp}la0q#IUK^8&+p94PZ>4nwk*L!~QL^X1O zYpru)8i=G%8XEn#`*?1_f8&iN@L$uk|5NAj0_OeKsOc2kchFZ6*gh`@QWdUeG{6De z|7E7PsQaE1qb4Cg%*C0GqGobE^*45|0sde0dusEL;bi%;p?emEi!L-xkR1np_I(w7 z$P!$F`lX6t%Qj-U^ku?Buh*c$zxtKGXx+sc>;YLOKKHxBS#>Zs2|dpi~sQJA|Q}$33^D-Um}+%7O9FJrj89%cr=%gI@Uq zFY1rSe%uatS(eE`sM$M!-WYgSUazuPGI~_;(Tw+=UvSFW3v1+qq!uW< zlG)*M-CFw>u65JArYIKwgkQW;S*W3jwbrKN$V$^#ERYVl_br3caWbBOES z>ix4bzdz_N|E;QsZLM8|EAP-rMMwnmK|`exhxoSqF0OetnFhXTze;oi4KDEhx`ACSteB z4#VOszP+4C)mkRdX7BjR<4b|XcY_a?9V{22^<`2|r`fgq{N+h86clRl)<<>{$}E#P zq$2ddw@@SfxSS;H`=}O%J%=W9SR-x^0;gAZ+Ce|(*a>Om zs{``~t?srKp2V~isfgGE?gwzT((J*INbb5$-whhc4}`B#FoFq$Ll(7M5Mny8*wo65 zyMNj10N2+?-?V^udA1UFD(Vw-vQ|*{ESr|No(=k56t4xWC^Xl_Jc7@x7qxFoH>WafUcG#I}0hXM9)2_(kSvz zdO9*pRJ=HLc$XczJ@_<|638EayooqZXnIoa%IeIQxfP^%fb$ArEC{|g3!I5>op7)wzhG%~ zRG8;7v_$gjp&|(Xv=k7sknI5?KuVV`lKAq*0?bZ%OH-zibDI-QYe`Q#Zt0&*@oqHthcD z?b@A}%)Wh4;d!a+$UFx}mbllP@$+n4g2n_@Aki!ch^hP=d#~%?9{Bw}^nV!+yBbn= zte%7kxDlIq-H{!jFll?3ON-ziC*MAnj1-L|C*c*pgSg387cRLC^}@CS65Jc5@{cRb zs4C3$Rs3<|78E{N33#Pd0U0S^ISOQ_So)WC0a$*JC&_vLpc`!OI|vBO@}^R`3C;Bz zti8}xNF|MWX5Q9KlxA;e)jhsW>Dzg|m_;`(CR z_Dz*mX~iHP-crvZi=i~sBlyG7?scRA|Oz2!x$^GTZrHgzvs z+FiLlUPGE51KtHgyW+a7Jj>I}dCcYgT*Ei6oL~1RM>yesL-ByH>pC z+H59VP^?`@MWWA;87$CC;99y#pY~;dy^{U}4rErkL4lOU_v0;}$DT8Ei_wD)+gT)R zoW%CmGc4Pbkd596wHv$<0yGq+MmGD0WXFsiSu_JlK^{+aEUxw7ao{nI{ueK*s>0V@ zz29S2yf9O{?mHb*bIl2ZGnmFYNQG$TxpVIB+_Tf$2GFrhX!FL>dO~wgm_$woG#CMO zF}iW<*5aac*XNb@sLDlD*a9|$c)W33zttg`eX2N*`=rDX$PSM9RU$_Adc8BpTnu&k(hlTi7)Y!CV?uqWtwmSE4 zY}y7AK^7uERpS-Sm-H&}J5cu?oQcWHp zcYsn;{F;#__h5LgdYnG{VMvp4qf2Ilrt$C#kadJ{a2K{SBzjZyi_=Je-z%uhUf9`eDpdu^+(E zKl!^{Nii)W5ML{=bM0Q=uz(P_=A#B|$`!@4_qef2=Yb_}zgt?1xOj}f<-JaJYpO6X z4*zbG{=7^5KTnYJk39R!Cr6iB`o5%o$@IrY_CMzO>huL)lz z?~;vL0oO8_C%ryGOBdqqo>=G2`V8^ZUVrUPF9xtVaK4EHM&ChT0O7iFKrYE;z9adG z!udRMOe2-XVbq7l;U=5{;1bLSM;sed&p-V-T~$7%3-C4z9Lb0C)KNqrXPC@|V|L|7 z!Yk*jVis{BV$jJmwKskgU~Vr(UVX1_MVxSugVxkngbG=H2ZPl5vb`P)May^ z8=vNWrLIw@&PIDva)pE!)(((E*Cir%(+r_3v&B|>9edB;sjsemh{9w7rW~S;RJMhP z_lWDgR)BBNi?PZUwE#LlDDh+}i31N9kGQoAs+^fG3=oUbaWW^IQln|WkdNLZhXSV= zP-SJ0Ip${kiBs#e{P{;wDF^PrD2L8c)REqBODq=PXZ%14j9ySseWrU2H{mUn4oqnt zD$gfV02)x}zr8<(!trB{onT#5l1)c@+WZfb4Y}hXSoRsOx83Q zG>N-jT3qCGk&YAq2|EhqA=lq1Ou9X=EVK9M)k=nz6~kWVWk_~G*v1lf>Gd1^uyXF? zMeCposG6n&yNSPZaHV)2p`f?(_#x7WX`>_Kawxm;7cbBS(G^_> z&t<>_F7Qb+qu2vw5ElmlSE3P#RRQv4yBR|7RXo7ZzH4I;CaFV+BBa$3K}`n?%Ys*x zD5TI_2IkjmO&d#o2TaR7x0hK{OM8MgYAra>U-Nl{8|I4+e5Tygq%hVHCgV#v(WEnj zXYLf@K5co2v~Yju*eN~QnJcMzN7t@})T6bajk*LRbc>yre473S}^S{&Ie ztIK;Adag(-s%fnaFQ_io*$O%^koYi0NK&cjqE@f2v}6Ow{Y;Wj2s2D9l1=7TXQvB@ zPrD#^b6M5hnbqDa=2?!1hu9?lTg7+)@ut>h0pZtPAfC7X$KfwaYJU+`3?ZnLD{R6M=k6T)*Zhh+hf3 zKYvTT#K>Kc&V=d;t~37qCT1jPm<;-m9cf}oy5@qe@QXkJ+m1W0T`o@Yluw~J?f8%O z6KaQSJ@3TB&M{u?iT`+U@==4Va}!mpPw7-j&l!jzEmnaXbAGXJf|?He2Lb0;y5`K-*bEkowlGc-~FNFzg4*JnPMo!aDLA?tvL#F;x!VlSdW0pZ47F#oAe0y2n5;;XjK#MZ^Wk z^4+^vQR?^R$_Xc*(E48<^VSBsR;T3~aDFE{MdA?xiNIe^v4hy1T85mu`6Z}0d#tHYI)g|>Gy85=#+YXRN~y$euP z{o8}GKRTFSKEHyu|GI!Q7k6|RmhI_aP*~NndXC365E}ack0W8OnVW!H{V^>P0xK_RIyMsglR8XDvO@?FV0u1BXfsQlcf7m5+?sNe0u5={yawsj(p*2J@^sB_RddjO&CrAe`v{jY`Zx`=!@YNsl+rfUh1G;dLW3vHBxYWQ$ z=Uu_Y#Rq`v|0!<#wrEIZS#8SO8-V>1$J=#z$~yy2oIn@&#NFyK>|dQrW-_ZtPh>bJ zW{;DKa`B{=rqXTZb;f8i&#!4TTc}R6E}O$zU_0#M(4~FohI!l(U_Q$YM~O}$R!`l>`!|mCmzj{iCH&uwltf0bi?R z8kf`I1kvPHU)4?80v$pP$J9~}oo5W6Y46q01CgGG8{(zI^S${GFbo{26^$esg%v1q zOli40sI#4=SC|y0G47VC{N{NOqIU@(wJOOHdX9MJ_nzr@KZ_XRcCa%RYC|%{?uMhi zc8eP=m56hp%WRJFw}QLw#+SuCyB7Q<8=BR&{f7;U^U2khiQ_r2_lspilg!Vz{RIK; zsDCV(@z2!kI8SM!^Oc_F=QTvU?a%Ym)#6$^u-HZIZCGe%I6)AesSn{-sUXc(mD9-i z-zcLKKWWv*kR!jRNt;OvdK`|4rwV!Q5?T`%#}19KT>8ph;)g!TpNm^QapX1gfo>_J z?WFuOo4$?Vn(HW5-LQE|_3gXQK1{RWhywJ=LEhM03O(^!m1UBANWs*(M@UG5efR~# z6VJ@32QRmN=<(Xb_)Z*7(CxoZlBKAhmq=Y(z8S>W7^RD9c+R!Oy=vL@qx{GXOT0S7 zgQc97d&F5(Gg5A*xto2tLHNrBT8ti2{YP%tkH?H1;KUchO{VSZ_T!F_#dKN_=5oUk zr0OQedO|Du;PtyeYEXS!RtM3p9QP8``xneKNLrA>Cc^*_crTu^BJ*tNDo#HwamZv5 z$P{PVm`JS$(I^LJfd7-)zFlajjJVIZEf9dzO%uGRO+Nz!kYFOn=Nub#=&1-Mc)7_& zo?+j@p>8(SO4NjYJLVo8QX-X{s)k)2LW&xcRH;b^L^;8?U#w+*_0w~hkS4AM<&8KR z8I}e3MIUwPlka5^UIP-ua+5t84VUF|a?I2&w>`gT$2;#IyK|doJDj43&v}w$FqoHe z()#KNnTQS5&y<{*)eyju8R4Cm_D-(6-?6By?Aue&<`W>$Jqcu6n~U+WBm-8?bFEb) zI)V;JxlvIEr`9O2k@Hq0!w1ljr^5fNJ(71)*e@g0i1Z|dRsHO}4~8dR6Z?>oYiRTG zQZM-i80~fTf~jRSfl$5XJGlx9__STC8U9LV`weH`WctK&@aB;Kb@r6dkH)T#8?`rD z+m&4>23I+L6qcD>`62z`v6G&{5$~d5BvEG89iE`IA>O5P-&T$)9c$^;$|T1H9il{B zdFsHj`C`lC5dUGqgEW1L&M!*mbFUDb*o(!FjRH zjEVc`u84QBc6)8(xA%BFwY&W% zZ5he|{7(SgR!I?ESlsohOaA>{9q8~yCg=b9`L8hFFY&%t*D`({*ZwC}P5-|${lxnS zAvA%6*xvk!xM8^So?VpHGQVM05^DJ2oJYCNe^xzL!%eF2tZt6KbetlHv)(fV07_(e z=V&Q6bv0gk`w_PG@dPt@Ovz%ZgO7>Ix>|(HL9Nz}&N_~Se+PMVaPL(tO;oPZBb@lp zlWZabfxHjf!zzRI+c?K{xn&Jh^-TEwnER?_`Hx~Q+>D{uCP*;UJbA!-tH`;;?8s^h zxAe*-@4)ki_v-i7OCCrzP>0Y_knvw zLL48!{7NX!;PP&4=+fN4L&rPPW0q!(hq$G*Mc(^u3Ud(ZkEuw1Rn0ViFmb%{xcuXD zk!D}fpBa;nv{28qK5E$P@?34|3Ew(uhvktETv6{DYqyHu5?oWu^e?OrDI9ZAer%~o zk|rnz@VK``;Ju?Cdq};UseMj~%AWk@JoV7y1lSxKMwb7SP$x+`T^4&kmm_jvw&kj% z|GFeKInB>fViLz_Np5Y5AGx0R!B8-$vmOI)1&GB2F73=6|OW{?2 z@?Y@jS2niv7%OKR2d>D83E5B~$fx%g7^X!#eJ+ywU|>&IWuBH>2_r9Up6GYFL~`wM zcH=TurfOOV=m;U=cCcV?uFW}Qc94;cQtKf+y71xhuG7jtX~W=N1Fq)&XKR$l+YNJI5a_1D8HX>VS~ zJUvqa#k-RksQxg3T<{o0;s9doOa%?l4IUJQHVKft<$=i-J_ms0E&bm?lP7Q#ATC@* zp#_lZOkkz1P)`p1`}XXpPfJAbK0OBDUjiJ_sk1;AgPnxzvOuW^x&Vge&7ZzLm3kcR zi<*}Kh!hO+fD+uI>`fMsl+v**#a8&0!(*O~W6PqIT5T7VLYGUH)kY2a9ZQ)Mlse2_ z4jE(YEZQ|xKTaDtX4-R(|1nS7o#9cw9S+S6INC3OTWkUN-IY|hXUwr)kNzRftp zkALT+S{ zIU(C^_B+)Lm!1w#P;W=>NR@uOHo0x!*tJUwm-l3VUBaL@c(2hL)`q<1U(Bnlzw9u( z3R;-cCsF4|9-6^TJcu*8;|h%3p;CRSSV64a=hhTJ^ck7VkYLe^ zC(&aL$86tFD}EPV66M~uIpX?g-n2%y!AG`+DF0mlX1Ts>jekdFxiHObYJfY#?lH^L zlTe-sfa88HYcxA?LUm?rG}cc91qf{S4;QczAra0>EK}?QjssoJC)ZXSKR3idQ}|S= z0oVcR3DR5;MgL*ULRA{Q;V+A?&)@Xc$v+lfn8su!A}-W1#zOwKZ+oM-qv*j`%Ax!y z*63BZKKXHLGB4?Rk#5Ff6t}TWUizI_;le9DQ&P%{Ewxkow2g*&kKQlFf4O6=StEm{ zE*^o+7|O05pXcW(b%-#!UFJ_Kpo~vLZR@$BL<$Q$>n{@rbIk3l(o49wSyx&9vRd0Q z>VU8!o<1UUAuPB?n3!CwO8g>qvKPBXAK$U%_x-W5QV}4p0V^wVm1GGg=VYrL?TI-3 z!KAX;hHhoh95+-9p-!4>quWGcB zth#ShY0N~KIs6rX7zWKr$UFau+W)jZvKAewZfb$Lan$M^^NByg<{ZaW3=7bLJmdD}P z1Mhsk(3)U3mL;gH7~$pen`S#0=ka21x^AVy*R~hC{`ohQ8Ue*X+)B56Xv3lF{PJUG z52mZ+#RFVz+kEP`hGeRd&Kfm+D_FU0ml9ayTh?&&qk-Q$9C0`Q!7e(WM*C5w`AX1Q zH$47oTlW!zfnC;Tq6C)5ngfW_Q@RnC=G^4tT`5IpG+bQsGrxqh!nqt0RZ{U1Z02@Y z#gv-jgqdh5Y5zEPm4G{;yHNaU^S)qHB0?^)YfO%({jAZk3tDr^@~3{NMm-8L)R7S4 z_7pXG>beT=_4_NlEH><-Auoj3)*EQ$Z=O*#l6|E3x*R zo!H+#bRFH?6MB(oK(>{nJa*OO>x_69cr%vunP!$AY)Uibmox~wDn%6alu^%wM(l_(Za1kS z)Tu>B-rz2fznKUa**|zPahkZfh4!FktOz6(#zYJndp|os0bKD-`N~5O%E(mUoyx9$ zp7G5()!mSP(ig=@#+vkQN-!?1FKoXjT8?Npo)gRzSww;l^8A^aT|xYIi=&|VhoFw8 zn^HR%cAH~h+ z`FhP=EV!1S|KZudxGvI>uYxzcKqP<`tI+IaUG*k_Gh@+g>A`Ztn9bAMC;2P8MH}nH z5thZZ{kFuppv?6lms=~FDzn}5!FArrFDGpk`1wcX9*tJ+j1UP zmDk5MT4@#9h^t}nS0ND$J*Wm zSKb2ncQpBmQ>egclC7Uau46xP+PJceuQTMUcbr%~QRI)>6~rNA3oOX`O=Vuq?`Ivf zrL3If3pDf>qO`XDWK|wQny?Cl6Z;h0_H|gLnM-rK*{qd6-g^2=JQ3TdqVgl2D3|~n zNI7<)!?Y8B=E@j{Fy==<@eiB!4`!VxmE0VWtDPBle)>wYkBD zSP|3+-z}}kxU=7Bap0q2f*)9yV%V7h|`|-d`{&qdFpA+~R5#a6dYXnvbsZ^eOIBK8?ig*!4Vn;Pz z1Ng09awMn>V5$K6@7o&egSP_xO-b}g>0p-6hij`sziK(tKAgZmj(AN_7NG|3seR1z z^uOL095fv;F|PhlNZzl^*`>0j`%!Wn>dJn~ouL}ljD;(Wu4>Ls@5sW-zx4+Gjd;^kz&{LDfA{?Uan275;QOmanp`n zUb^dWKzu~1Ah*if&D?P-jbLLx!FcVXDW`S#rB@WOr{0ozsYl-!E?ErZwaIBwe5&$*(?tO!}zmK<*- zXGcdSsSjKVyIuro%EIW|i z)~y!VuI$?Y(ODDMznNq>up*HUUOnU5-rDRP_AtDVPtqD&a@yT`gN}+rE9dwV36pE8{_Xx4> z(Srt}4(!HSIC{~!%iL5K*~f3D!)sJZa)5-xA4V?^FddsIfUkz${ZR3FM{^FYqDypc zahCp2SpM;z=B^GZLeV_wW$0sT1UqZiiCXSoMExa`d$jFjs1t?b!A1NY|m920~sGJMLNtS9opm^x*PPRi~nt3 zfLdBkurQxjD3OV4wYz}XFzCVRh~D$taW2z@f}7@iRbxr>ea8gG5=JV7F4%9u`N@xs zhLm_S7l!T@tlmwQiyQ7`x_g3i+HU~eUAsHgGQYq%)OD(|BK&NOM#K5bAE9ra)Sc^d z-ejQ}85+Od)#RF^AeQr5l;&x}qC>zJ6@Jf*jwUaQ@s@<5L+7VrH1@7)+UGpGL2LW= z{gV-!F^`*y>VZZF-!x|Uly=(run#SldY_vq8a?qiwfbq63oVT|whDX2^40G?p4Q~B zCQcvTzO=fUhlH8PlRkF5A0UL0qRoA;{>Cb^iSaUTO)jWR#8>cov;M&5S(zNUir0Gr zM{<#L_sG(%Wy!*@;v3nH+2>(#n0VF2%6)Y!&nvB*bwcps?rg^_2^B*h6NdM5I|eLF zO)iTaGg_RYDHLvea2Alt_M2#4-f#3q{}(F%zfk$_KCeG@&cF5N|BFz0i3%4*rLV?= zxOyveX`g>rbZbv}>bwc`$!k`M?()vP|Fpg`;_>8agpA4S^YJ4Av@2cKh%OuvQUev4 zmF@Ablj*(hQe|d;6kIJEy)KVx@F7xiUSd^_ko(nNeOhqLx~%eTNV5}IiXGT%T+7{u z;u9j=g@?gGtAx3{PM^yZ90w+oB1Oti+dD-Zryw>f(QS~Vsp1VlH)AO~fU#ELtw$%9 zOYYFFBaHGqA(LV}$WGJX(ECAaw@<~ih`sdt4st{TdBHrm2-zGu z*LzRf@%&_@_tO_?(OT7Uev5~)oR-B`mrs{eKT}wqy%nP_uwuxNB~T;S3^2tvrkclSIdGS>rJXmizop7ME~(Mf zpA|?>EwCOu`>H^umTX6`P;T$S=czvb4oYTy+PHpgpbGT~$Gdp#pbB42IRExZHHQ5y zb=^#gIH@kJ;R=4V?c=KJ!ILPQ_3hs}(5u{E<$$WyBfjlWr+d|Iit+8tJ0`#liDW{8 zXvab~o#_!Y&swGwSJ}s!pUiuRzu;agrjDNA+yyaIax4Of5*=MclgGrl%FyL6D`sb< zXKeS&E{bn}z^n|Na8|5nslw3W8Ru zF+pAH3muU9>8%?`KYL*D?7KP?Ift0jhiV?H3Nklr7$|HPV5lM#5fXnX;nk)E?X^9F z(lM>Iatyn-HLV@jeTH}0J++o(MPfgkhz-q`bwu4TGl=}!>ijA-D&d}#M$5%d&lISe z|4$s@9rvRMp0yEaII3|-d4c=NIYZF13#zMHKXO|gWPJwq+A-26pCcHTnzenC(U*YY@UWNGx<7s|Bp?UY+tK4`G&Nbc&4RRx2Cf%Bpy11e|YW$OY3)k{RiRkFa(r-8h#Bt>0D$`hg&chG(Mjmw2mlvCFY8+)t z^QUMQkc^5Ed_;?F{~8I`s=T6)*%o8RqiJ(E)VVI}#DGcs_05)DM30Xi6Gw=(?Tcj{ z^ywZhmRFDD8nE9zAfg3r@&W`FUVyKM*B^7|j2Kk^^7(JC*I%{!QR0T+>sdWlopq6n6J1B+lK@hWS>;q?-&^l={1Wu zv6RMv1O-p7DH?VGsiA%yFrK1X3JxtLi}$%@$tXffKObCKlSqtSrgKr*W5y;>?1_<; zQ{%!q{#Oe3%%g6s3hZR_e=(w6{m}J?4HbzF`0Y@oa|EWGeP`W0@#3#aA^>M3WNlWf zjmuE@9j3h!=MM+h+{DAUEZ|FC@L|W~k9ecKtFQzqjmw`3mD#BV-4q@&ath7p`Dqa# zul7+p9&Ujd>qi6-l`&HE93k_WYXz=9%CF0%f_T~b0Di@4Y$@+c8F6BlyV!G_gRhM) z+YzQ+qYfV2Cotdm(nv%n4=4G4Rs2=w(gvyY5C*z^(U}NmJVWHl=CZ~t3ll=xLRUb3 zWRm+`cRuj$R`J7r?t0`2 zZ;ywqxVxAtFQZtBBhjgTYQ9AMORmb0W1^M(YAV`k`Q_d>>1`Mg%;H8!l7fTlPA!;b zWTzpM+rjdk3CkDi#(OVCa(q^bx@5#h?7*YLm6SsZIOT1`suxE66J0;QUhIKLPz2@t|O1ZuL4&yn+zo@ zrjzUJWJM2ayvdQ5IBDLh0QAn@kgeb;mZzC$>X8K>iNxzVpKfN_cXhNKm+VH3TDI<| zko_&~2!IQ46+CP<_ST0Nb|b~EYjmBDFTJ%kQE6?5lzU~*)`b(@wBj$&Tsc{FFB^X3O?d^7j9jow#r8rXgdm-&>|To zC=I!uJ`nP!r-%|_OD^xlj*&~?PG3=eNHFz6GF)6qGKaofYAe!z{Ul>+Fc8BC7f$Ga zG24GE4zEppOKGF227?jwB*RRpvYcr{~coO|!@JO8y@VX^k?J(JA5v&*~R@;r348V?&$h>*lyqw&*15$D9hFF{UoWG${& zSW%kVa+sD$hgrl$)eo!hUQ-pq)gxewk)C$2ol~&u?bn#fNIDvt!^r#KOGF-+=yf1L z%1KaWQ73YZ>-hG4gD*uNHt;aK254o4zjyMyq)1Zc-hvdt=4hRtD z`Qm0>EC>4SI?5qz?cVO8AZnJ)3v9u=6iEi*4`Om{z>81CnP9DetCy7tF#pT|YrGc^ znuu^4ym5vY=(JigI5xO1cm)IijMPIgK%Vgh*Rz11n3!-$0$2~*fX$EoFfkqkS-MF^ zI0?sG0Uv-&ZrcKd1;fyGu&O8wplY2Z!#(ue0^Lg>P#|l_uprpzC>W>x%`Z=W^TYqe z-$gvdf%R;YoOq==7OpR4W;`4AS9wckwi6U^M*;{|DkpxeHKjw+X1DpeBt6|s=t;QX zE>z`NW+ouw0Bcpbc32qd$)_#8#?3yBdUYb{Vr5>|<=yo_d_mrfW!}sy!f7Wf4K(yF zmmPk8$J~{SC55BTso;9@x|=oo6QPfA28;cec9dfH#$qs@M*Y>-pz?h3A!*+d2zJOWIgm? zyQVBz$dOg*F|t9KECeHZprTmJa$H-XI!r3LUsgfRf=T?mPpAHUhzDa;2}~IP6nEo! ztuVBidRvq~w1du$QkS;0u#xyNIDV-F+>0qz6<#s@Aq9K^U! zUjsPZc2sQQ?#4B%sDVjJ%u))jx(d4cbPq$AU?Z56XW}$YJxbPD7)v}^MvXf#7?EhD ztFFLq=*f`YVjmW)>5Bsf9elV{zhYq9^{k?Mm(eP%eZmJC^!HzIo-2K~@3A9s38}q> z^eEe2t7i}Fds5?z?0}6CebjQV3%HapNxjbOzX~UE-RWO7%_UiTMbd6k@>swbo{79Q zhzq`zXI_SK?%iewWVgLE2T0Pmw*NLX?=}cTvaR*qu4j26z@4@Wr#kqWlTTAISNqts ze8c!ry>mjWoM)${oY(6hq^1P+MRO`zu4GhZ=;|?pW%5(;^oJst?2ndgj)1*$VU$h+ z`$(xe=Ad%7LSH!hMqLit^L|7~4q4re73wI_elnmv8LOR}i#sI01v0xmClw+mL>5*d z#!>IewHSt^b-b6OIa7M5DKD@5j*0G^HABh^Hr8!RPQ*#hWL{+loklL99qzd~K5=&F z?peIZfzKq$rIKP96jubTAd+XMuvmBh6PY5&^8I#kjOr%}kM~~olD)IU-*kd7LpH3n zHupNfylU1t3%?BGPcWsSi^5PG5d5i2r6{-j)9=MiP5 zlE9mdkfLf#q*$>7Gb;o#qq|GgB=N#9myqd!{bA|_0O(=GB|3-~fPk3cN{xOR!t0we zlyX-1qTx_BuoD(CCr~Z}X^r}I(dSFDw>Mltm zn$WH`m;mV4E1{2_WCp1+oNXA8eq##z&fe^96LOC0WoAzpVAJk#bq>3Psd{jd|M-Ttj3X%HJp=cTa)Jbp>ddbKpNZ?@F7iJ6uFe$ zZinII!)9;rvtXso3VlzSc21Zt$w*A>F8Ns?xSE)cjRW% zER2NF>^{1@8c&B*<6yv2TOHjY;e23YWDU}4F`LLNa1$Z_q%z!=e}gEUZ5@^$O0gb z#ZNCL0FjMlzQ`G^c2{xqy_QipiD_?<0ZK@Bb28vZ=W0iKmk~L|s5}Cz^Oy)c*vLN> zs>axuOoV1;^e*Nm1@sqzRAKQK*V`?4mo4>Jo&j14@vyWQse=wJhIH6M+0M0kROrS3#u-j|NsEX&l;(@3 zp_#(Zv#T)LLSaZZFem>8;QO})IhkEPPCPKmLa-l3MOKy5nOHV)`(%!T7P}u`ASo+9W^?#fL)0cUad$wP4)szYPuUXHO$T8ZsqTd1k5G&#DM)N zcL!tzeK-^%SbGcZDGs8}WG+SDXtqp~+(&1~BDlGL94&wJPg-0OPt{uNu$G{eA~7Xr zmfEH&0|E)}U6DX#ec|1g7Lauke4a*}xH+YvMNOWC;7pH!WNVFvIJLxWEK}xOD)Z zR|bP*^RN=60gdm@0-;w1$IAwI6ANI2Kt5F-P)X7Vo3sRDP6EJzIk4)}aacN^_g@2E zY)&S45B=X?r9n$JyJ)9KZW5i3JGR{_tFP8}%+1phA4F&AS{*P#Q<*_Zyyhg#>YMXY zlW@>O@U`V|;Zj*;zB`gMUtF)wCSb7J+jCQt;ZTi+Apo|w=WNWZppDjs?zP@>eed45 zQzJrk)@E-xfX|;L`IDO8*|dPe@juU|rBKpQLL1eHjQL39yB|8FHMmZo#1-PCoFK@7 z!-me>~y=KGx6Tw|IXVN4)Bk*Bl^J_@1Rbe)omhY)C1Sy-Pv>t z;0&cO*^Z>n;m+7shg=REVeR#%p`IClYa|^H(>s|&^<*uCuHIvhz(ACNKEhqhv{+qJ z45iJt+vvhv7(G@MRd}WCXKn?`8l2>!6PnVu%zL7-I496o9ZddWm1)9DdowGU+#t)2j7ml#( z>!jCC%AFG5O6;3A^7#-`-krQz6?Yihxdn2%G7Kco#x3k^%b;!hv(Vnx#M=@|%gM%6 zPQrTfhj3|LE!Z_2BwR{KMdeSg{qv9f(M0(*r)bw7xWy4ksm4F}y`N0A|Bj}RvKcov zy7~O}cLnxGSJLeMc-rqg|1vRh3$$^f4c2p47kj9u84Lz!Efb`G6k>ANq@wOASJ)OP zH1IIq38;z}a~#Od$N3c{Gj4 z27LZoBK&pRz%Tc*AB*JALi%paFB9kd?>YthFun_`TDzIPl74R;I;EiSnGg4;a!?V3 zI&=%n**Mxzmh5Sg^ba6u37OgC$vCHH&yhzC)ys?r4S`E?7e{& zk3|w5$N}jXlV>uo&kXx`%=Vg>v33CV#tt^o0X#8(v$pHyMX?x*$QrB*7<+>iNc?y_ zp1%^PQ?1iJ)VWd|UYH%@7|DKzNY6jEWOau-WqG3M8tq!-{^X>$88099mK3TSpd(RP zok(F`%)m24vwCt0?8Q!wS(=acjWs^L{rY+`LQDeeCETRek;`Uz^hH@-VJJ$HVu~U@ znw5Cx)%_Cn3zuGW<;=-z`aVNsWE$iJ*9uFWF!ZaeR3i$$Dbn#Q*Fr=&Vwi(t#_R!C zBG07|d73BI)~dHh>4R2pW~w&+&3Bib1k6@jpat5mL%*J0VY~mU{q4(OuiOuu@TXy` zEvsL0P$Z;G3;)eK`!sn!dxIaxe!)SZtPKOO5I%EIykl(t)qDL;C({I!bG0~)d`Cit zc~HSIbI9dIsWdhKO= zK+IN#?bYJW1v>lM&Zja!0y&vptIOVvCBmA8!sXbtp?n42NGoL4+MLeBAb3BlN^EF! zIr4Di)d=$-C_MaKkQKncb7B#OJE}wGt986jdh_t%GxV7LU$j^4gMJv7f2E=wJ9g~5GtK8pHSj$?HdmR)7n7?U*4lYUc5i0N zEaq=Q@Rp?AMN>Doux|cf_f57~};R`oWok0)vpK5`C$~ z^;A`s%eI5%8yrgjuxEl;@V6ND%w;4`dsFOuk`hY3?&C|QX4Vcx?Z42i`hF- z1F*kQIflrb2#~%W#ZYpno>^$7gYqTDv-*l@&-LkjccHr}5+5LG=Ecjxp+h})>>*?` zj*-!cCt~!L;@PJwmu|`;ndxM-?9&FwaCE808ZXECllLA!3N#LR8jOYnNecuO%v{Fk zpDpgNnuwj}*E(Kbf6X?mf$e{i08a|Ss(M33l~U@P@BQu}bgsOU zdjvQA5q3m3Zwqv}9KM`tssR9r|M+$No0~qVV($w8`bhG3pZr7Rw+feQB^qFBm*>-6 z9Xd?7yZVi`=C&yUtB*;8y#{RZlR252YYtnW5J8nKP!?d1Z!^(epPd6T&HJ6Sa+@(5P+@vu5kLnh5x(0^VtekP;T%3 zOXOX^hI9f#QO2f;+5eJ@vt8to>5!n*A^hver|Zaai2>sFl8NESS`OH@H%Up+GPW67 z$0wh_iVv>zW7a1{2C>kGIAu(d)u0GpPPXj4efr%#3dQy7Ixz!`cw$$u{DzNmx2VjB zg_hV{?R@&J(G45+NMy=+B`?MbXtQv{^I-^`>Cl2Dx4mW$Ym=W!nb^6b0VmeBm+5up z!pSkcP%;-Am$d#uaV_~I^fWnzo=g@cRISzCV$aY;%}a&PLk*Uh6?_|cPue_WG|kL- zJdHY36`l9UR-dI|Tso5czM<`d0@b=J;^^s+s$ zh9j-zb0b?Id6vI8jLHp^(P%5NO)-_VvMZJCYY?h8PSkGJ40f(;Y3*s&s7uH&?myGX z&mvf)lV~~m(11_*)mZ(bU-tJfY0H1sO76k;Xz zeB~0v5gA#hq&aO{d92XI&Mo~Yqti^~%quhEVb(wk`x#9U26jUiWzngqRAtRz3eTwq zoRl-NF3wi~wW6kRJVZnc09;Gd%G*1(vG*?cl43G*djXKl63gauMZrR#?p!Nbf3vl; z<_iJ?j9k5Ze~B2raF{RJpwHw65YjJgHKf~YG)a2R72rO@u@HEIhKI#a?lFGj^+R!x zqwXw5lTTmZh#qf&%rPFv!g!k_n3cya#hOZ#z*m3?px;BCc_fjxofW@4`{!f zSgHi*&LzL4z#Pj#aS`8j7XB-SKX;r%IloNZJG$4w3Zl5T{)VQE}ik|SHCT& z&B3}L-5IDYP#P@b4}J6Rbfj;;5ZJ5q>H^e#Uz+~jTl(JXmn!ege;VnkrvFqo`K`wN zQ_20)sqCk7^WReAw90+O88FaVVc$;vN8EGJb36ya<_;z|?qSlqx_`V7cED9+5#eu7 zo&qF?p)&7YKf;PSrg;D0*{Uptmp2Ja7{?)9ifQJ{-FD@<+PiDcDdxz>onZ0sx+W6c zy13w#qr2ygg2@wge8e7uWo^+O*F4axt6{Bs|7qLn4FA_ZefGccBGNq{fA~uSQtmTM zGq|zcA4)e)|2UK8SLgCS55Zrn`5Ryu|1CNE`Fq~m=sx>Nxww8FOZ_4XI>o7 zaJ)-e?#a!RXxn z1A<3cW+8p&!J$1pjO2@!@WIlfBBbnZRP*4%L-(D-^49^ttxKM{ZZ<>UU6X`;?aW#2 z8R447%b7GX4@6+j@Rdms=ufY7GMZxr*fB2!0`}#LfI&HWu?3|_kbXo*C;@DPlKew) zIdQl^VL`mJAi>+Llkk;lcm;C|pds@)2LPGD@h3t{6$c}6p#aWPKV;>J{A+ZJM-GC1 z@}|1(`FnP07c*Y##vYz)v2RgbSgoXEJhLbeKJsY40>@;CWw=~!@xJ9MeBpfIbSa^L zSsy9BtG&cFzTt-3L9X^xfqXr8C*6Fp9x-Tn&koo0!P0XJl>>+PCSul4qXyg}rsO7* zN(#5(_TbI}nb?O@v@s&Xh7XtB$2Bz;8_&cHW7ZXY;>Cq*5OGtWeRy+0= z+d>nA$cB_&!MRF8kVgXF$ftV%HRWCcQbvAVR}(0iPR+WRRf#Gt&RkiXD~TL1zBAn* zyX&ljP(wvy+~h?kXg~?2+Yr~u5!KLPx|kEsBT1hxT>`PY$uaCf2%w35=IuDxtTe8U z=PM4s>TVdccEj^(J>KaHI;aTRi)Ld9ogRAhVoCPR$ipxl^ZDgw?H8{mmibp$@05s( ziVW3r^_?w>T+b)QXZJ2rgT36W7JI5Bs~Gp^Wru*u;?~!V%A=|Q9N7wK;z7k*>sG{* zk`jwJf%$^Mu=VV?HMmv9HK>%fo7Kn3QEMXTde^)tm#tO8*&DG|p=UF^$+tjM1IoAb z-}Zh;-u|=fJ(%vi9T$Ve}zf=HWSO-2&JoqZzRP1$?oe57~}WFuZ)P|3wYx#ki+8?_PxJ4jV0F- zav}W`U%7bI0s%1N?`r_6`{GvTFfjIST)gc5PrjC~!3$@lNcNXOji*iaRJ_`QRlO*W zw|gnBS(jf}Kt8gr)<(l(9xSBPlj$D5S0}v)5hB!3cfnwrESQx}bLp9;B2BfUGig>E z|71Ys0Xc!#>3d-T&u7J^UkVp}8^*-`jbSofel6W!eYyYOs^8k;kA(IQv_;B$BRj)O4k0*cmM=ZBJ_PPx>IG+9$5h_1 z+A-6#%e5m}YX@?@Bo8@rwd|C-W~J~_WgOpB&o&YiKGRUX!mBIb-VR&hn;cjj9l+8ceyYx`Lhk4; z$=Y#mIsu_jejKguKf`hKbH$kW%zHdd)1hhl#m;w)(EMn{AcsEOf={7v?SqR3%*lfg zWm9<3I%_Q)ywiB-9 zctrML(kOR8bOt5#?-|g*PJrccEBlw#?&Ak-mbJH*>yMT zbW>edpx6;M;GdTmzGJl(NWSzND_V?&+lU5ow!b;IB=Rug`t4A~Oj8YwE&x!rEZ!yA zNdsj@S2%aWtW$YWR>}AE1PyUA5s;03UB>^VhM<8+MdL#U{$|Yh^l-;{Zv~Svua{M+ z#&1)Z&1^z+^oPn1nq^~>WxXxTltS6K^`J6EH=pghEwN*X<2b-ZpE;x!t4!j*`=s-D z!AoXn=UDeFbC^=GotbY}c=Gk#oTqocbUUQYf9rFW=O@9~68J1`xboWKy*)Bzt49{@ zE@U}c5z5ZgUc*%8dM%D2*VuOzFq6T{4wY5*mDf*D#$?6}B`M%zA2;EyZdSU?ts{0X zzUk_zp-PbI=WZI>zOvp&Xvs9IDG|0;?XmENm*`Se?Zi8}+!`-gmKRJ=zBfx(*75Kp zL~9e;ZtYxl-rc=L#CTc2$a2;;VC|(FIa$o8%*5<+Uf?EgzQdV17icQ7yh)eW5=Yv5 z%czW9-c9)X-JSgdd&K*AzYmJo-|EVLUI&ZK2+8R5ymG+c{l1v8AijiW|4b$USpPD9 zICO1_)@!sys{5HNPEMnox7R&es*yk`3ZZOzi4nI(?OS|l-90iN35=tR_WHMQo@Yp0 z4xo3aoaxV61s_69MTg`>vr+Hd`RJ6jqPZK-M)$nmuoy?pWznJ=^^r{#_Ux*W;*Y!g z1BV%Sb-hMAGS3(Dl*)(Sz(I&+v(}_JRUc(Pc>~ObF*Ra3&eR%;797?v@u$s!W z1=5PscwhdS#^Qr(Id`YTV}#`zlKCa{XXB(OX*ckY~?xEaO8e)rbrD z(b5S0R99h)2PY4&jN?=7JzS%D>z(uo;LA+`@S7aNfjUTKj6Hh$)$4{q3m1wGYSvdT zq@0l!kB_8b9EH}>mIfs)&J6F!s(H!K|GJe!;QZ$(q`qcya zJljO*5Uib3+vfqDV+G;ZiXH~w15?G&4Kv;wd35@W`GhQ@3h-xLEhalHu;77Hn5;%u z4wt1b3Ie-iq_DxwH?Kl;y#TJI=MIbp76U|>$Tpu5&swLRZ_IsY#8>9N5#4`k?t>3o z)p7||-cnhMh$Me&)}DIRqSbpz4(zUYR`|BFs6zue?jk1XDTZ4N9 z3)ByI6uwkSFFd{SN2mJXH2%j4UumJHE{dzkcocvFI}L(_bfpYD6E;J?yhW_vqXODybS- zSYXRu2&9AGbAQIyjvhH7EyMBo14e8mIG$wlN!fraZ#N2e1U-U zL$RK?wU@3FEMWsWd_fwTexoe0NpIlGEIr7ZP4;P~+?-zXC+Cwmk?FFtum{IWw#&q> z%{^*T5N!#)6>%L_S9W*N$ET;-9qipa_*QU%Rj;o_w}J#2H-nFo6r|1)0 z$b1N+$mm%l+AAKuz)0EJQ;j7NaHZ*856haLK#W!3I2?-nQJ=*43GeM)21pO%fGghg z!L-@P6u>?|th?T_ocXkcAPRVkGtF>m?QXSLXeR+kKnvjpOzBy!U@VuZsm2?GD5e1j z7V=8Q!;%U2LbL5#FiVQqNl3^$jAh*IYd{CIo2I0-2)l z*N~YfTOi>fJH-t$lY!M$AXJHC3N^#=#`x1MKJhmzstcH}RFYPY8r(J`JO4aEBuiB( zv}SOdY%`?-4`^GcqN%K5&@e?b4VCO8N#^+aYqt)VJXfG!Ow1~3pu62TeUqATu$?*4 zH#2~S+Thfg9apASrcXS{p5wbHfK)2#2zRbV6wXDVZpWT z5TvawTtJFGA7fM|++}ReWig*r=)XfQX>*oXqcy$D@N@tAW2Ahn`7$8!U%)-4vuz}B zpBB6(Ivn41cg~8Xc}Dn%!J9T`2BC`a5{|m)E#w0;ng)M@2H*E5tZ%YH{@_LfxX}E6_|Cuh zbwn>LMHjj8DJ|q9Iht~3?k_m+zJEtQ6xBBq>Hq3b*(jyXgtt?l@4+-rv?Z`o#p*9n z^rZv%TgXwiVkp5GUayo3n~1`B(fvO7ErZ|v;9oKpM8xYJ#pz#ad7j9=r{MxY#Y^H0 zTU=vs3hOc64P^`6jd92kxew#^_{Ty0p;G$y5yfvw{O$!yzk9)v|79(=G$A(Z+?3g~UbX{T zr#7^2ZCC|4OvKO1tuk!@oDTqsvOp}Pqup4W%Rc7D(S6=v4umcj`qkSNF+cG{aK!2W zi5cNQ=Xv1_ub1~52Z|%X9OQlU)-WPnu9-6G9^8=>Uwh4cF>K-Gjwi*{n2Ur43A@TP zdt7-C7)hlA(|Lylu5h@|Yq>s?v9qbfkzOwE%4JX;ag(`RRAL-yU^r|T`~*u{GpM=` zuc_3fBiL!bFTKvsLE7@T$zJZqZ!hiq;RTbTy2BzDk8`p2XqD$@`JR$xdX%745bC7N z8!9)^jgS}ysOL~7JSJ*IWBAg$5_cqa%+UtcgjIz+3{@1*y+w8y6VxGhPd>MYdv5k9 z$-&*M#+{Zdu@nKLq0XzRB|L*I2b>x)5{Xw8gt+`pQd9avlwUcmBd@%sjj3iNK@$fc z?$S!#&A#(Gbjags!Ybzk+|^#prCS z-uh2kXU(2x*8R$+`qMez=Cyoe%J`iw{R@@@%2$}=Iw~CsO-V<0Ro)p{+FSL7ZMQ_go8eBK?o`BoJabr5VXyUp9 zn22%IK4M$Fy$c)nQ%%UU;CjdjotxrWxXVR1R-N*XrjjdN z_8e|tg@VqLG3KX^IIN1_ewPy7bx~2tQ?A33dtUQEg;z``cH6unI8egbo-#Z!pO>D+ zENo#;y&sHrhY!p8yw2SIYL`a8ZiEz01a1@E(&`FL#Q5{9iQHx-;<93GoWVFUj__+< z?0%LDWKYUO9@LMD^9K9Cs`4Wj$TBRs0Zg4XfKwwEnLhy0czP=ugN0!*k@#iYOzJ!P z=LyJ6^cILcC(gz_d=+vRGOEy8J_{x$+|!7T$TMpZKMkvo2ZBI!0fX$5(Pw?O1ko@; z5!tBOeGGt7%0vyBnS!lQA&xEP;{vhVcv$5YD1quZfX+9vMuwd%e^sD;h#-k_#JfoW zA=7)Y4n>V?U%D?#vWL5~(|dh$UJn`Dy@})!j$3_+ubw1MzO~Hlf2%AVbnjBoai2>M zZg#K%eq30Q8)#)g%O_v~p})s8ML*XjjETTIHMf!m*~|av+B9hr@{pFv?ZXcG9+qwr z>yT;;wu{>fRhDTLb3qp6#<%@dv(s&?=RC{@y_!ZKEi2oU%T_s!+E(ZXnJ$adm0zP> zO`Dti!tVQpIqlQP|0WIRgO&ANoXYo3{&dw(3tzb5KNN$O7r5IKN;aETKDgy`)zUhD zGO+ypJ$J`T%T-X1t|qFgP^<1eeF=m-9(+RSHi*ILXD+?pc{>06rTs-W`RNP)!L@7w z@(CfGB!v5Q$CT=)cfsWK52lRT6G4(LZ<_ZfETw@hVmjSbCFinl!5iUuFQ*~w;=O_? zxRm#;3BRj<%j9>5_|9l(C1y|V&e_(Ox|#vHndWBta9tV6%O2t}r!r9#apr+a0GVmB zSm*QR#>8tbDzNus4BTtD3J#Z9ds8YiCiA}he(b5ZU-SdMsqmv@}eIn&H;BqVi4#z2*&%o;hqorQ zrkW)5#0}=Rv_Vcs3cccESt5>88-z%*F%EXxR+2Vzk)Ti@r;%OXRhS;<-M_c! zOjs56Dl5Uc_ZbYkpCh^uV=tAf=_xrB$juyV zkPk)TSEDs`eHiy;Uu(taE7XtDaCHGtMQ(->JwwPlv#{76Ig$<}@Mx02v zbIkulw@{~^>MjstRngTaLA!y|mFohsD^h;2xA}$V$N)I((iJnl!r}YXjr9`QJz;?-sDN7~*=Nnq zJtLO}?@tbO61!>JUSc#NRl4eJ-(YwfHK*y~w60fuKvA;iVXVmBLGdFpw#LcI&djF< zr4Aa6llCOLkC)8%@3G80n(wi%iDQQpgB&Xe>Y=HrWqP=^S2IDu)`ltYfW4vqZ3wRp zl;m`u7Lr8XAR4+iO*s3|yF`hXRNQ2fYA9DHF4}P!aNR@%ByP%oldiI#*0ai;>P7nz zlm<&5pC>^>*4Yq;b=jtS)(Iv9Ki6h4%Uo%oRbP#Hxccsjt_)PiM?n?;tXjy%~7*Yw2i?`8Y62_A&&W8O{>Dk~}a?rIZxg zeO@G1bSS0+oZ-A)J+M#9RGfp%ktC}&`Bdl)Yn25626_Wac54u~b13HC7Knnl$Y1t) z$7?zEEOtkLtcKu<-)ZYk(|)Y5Tkt}VpQ)q}lV@?(76=IJ+XrAamzKT@*?aQN!Zgym z5SMX9?4qk11m~(i*dW+TcBVP@ajrAb{{kpqe+m)A10I!0w>

    H~665W3C$vubZGn!=i4e+w7`|37Hxca{E?-7BX<600lrS$j#%Yy|&#)wmEcI4C z^agJ2CI%$(*W+Z$H6eSO=w7>}0!@YQo8nj2@zyx#O|BIqwY=rK$(FJkSKe-7p%G5Z zwZc9=xpw|2)}s7E>lYe`V=ZT)c*F#*q^UCYczLV6ihsXg;hmwX2J?~#v2D6*<&SRC z?n2l;)k!-a$f=w~x_eqNWgQVuF($zj5ag5V(t75yEHiWboKD34vqH$+zk*cw1NP<1 zsJ{PSVFrIbpnoS{{PTJ6pO}t*{x;sVK80Wl#eFuefbm*!lDJejAyYA)pcw0eg0?I2SYXyz>V3KtWd{3vP#fJgne|7-WD=c(+(F^|x&a2$uw=xZQUKGMx5jp!1O$iL(u9838hh0>Nnjoa1(;{23jhbXN;>cdE!~({z3EDbhst z$FK@tE^LPX4_u^9o}DxM<8-@F2-nb))h>);AEDmabh!9 zhNN#>uFBaz7-<$rFi>AOLLXNFn>?2HdkF55&_g#7IuEq&7Dy9Ou)&3YZh#N!$ea4*#<1yw)8~ecfy8B8T?xJxu zjrZpFdNiFkYwaf54ENT@#eOXHRhO zDWd%q*dDScxD!2gbB>B-(F>Q1GcxrbRLPF{s_htI>+z4@1-GHBQRc1nvPSM$gUFAs zED)JGL_bPu4nt9R8-&~`Hn?5!&^32fHD4S5g)EfbYF0a19V@L-;5^L+m7yUa(+Bo_ zP_-oqQ8N~0HmEdEV`}i6rH$_~6=2rD*9$6sc>&?;A`sTzT!XiFH5I)Q%G|O6pUvVbp$&izy$AS^~ZKVHt|+USFofQYHY|4Bx*C%5xKV7k6;uw>h!?Pf}98Qk2pMF08HHl#hB_Q0M+6 zhMDr5jK)NX?Xx}%ta2Td6x5O3am}a%ix~CWLX-y^Yi|pU z_C#VFhx7gTAqPz&4)1DdC@czM6R7sgjUw`lew#Y;*7&QR^FQ%TdhN%o2_Q-07YPY| zJoA4sAigh@|J4bAB?QU}pa!t(1N-T)Nmw|~7O1OX1=9F}4;k9{h z<@3L1y$H+(ta?Muq6g<%K7>mbc&An^5>!bgFSq^Q3h0Y>W{&6sG}2H147CA`6mRym z#^)WM@@=pAPvr9RYcuSCw+C*8vG*vh+Te+oJ{`M>$Nf}Fs@jT|edO8^{B(EDQw57I z>2Ibb!6(@>lT#!Ur=Zb+l}Go`WvRjUr5^>SOm} z+zIPf(2fAuLx|3Va%ZNK)M)nes3gZJ z(St-l97CI%eTudHtP#^vE{_zH3x^JezC!LzpA`Z*fS|36hw!m>nhGbz(R|CgIxofs zy(Q^+HVs^xWirpMAs&meZi-IkMJT--HW@D~z0p)j;w_}VR=*Ji*YcPH3?zzc&TST) z2{APtFWqi6Mc$zyu}02?Eb}lH5~1?!b#LqJDa$pU&6v-bdcM>|S}jgiaPuaFJHvds z98_}1&9v=}W}iui{#XQ^w=39sbkto}<4u?QHmBp*u7nr)MIBF(O`L)x81bQodR$rV za$KM*Ly8l)MtMruLtR{n<0&ivETQs(wO*i&CM;)B6-*k*Ry=r$mhozG}?AjqD z#W-FDZ(Z@_nbZAgS^Z**&zvjwP_GzcN7P&g31;l|QnPzvn688| zN=x`;n3W#!TR&^fVnJotAq~n5=+{f}CrUQe&FUEq`(zFKr~xOu84rM++^z36vYMEf z_(f;pK$acDG_EO3<x{Y~+`EP1WcHoWAyNmy7m zZpIg_Q*7NsmV6FDV(ji9dKgINh6zu)(_*R?wDZF*mIuk5tkv%>toz(Hg@J0uDEVbrQbx;09@VmziC-t!Pg3^v$o+KM{InLR zeu1s>0dV;ppUkga`{_%*C{TVu;PJlr1-9~gLJzgHE{*SLTWQfry;n^HBaOXf?i>!e zOft`OaHneLd^A$NxcL0Z#i}KCkB7l~w#S!5^}bO&ooW~)aE*ecG*|63Oo(0 zg^1`rl#J2!4`miZ&f2Kauu!u}*fuHq!*_B9@?;k{>I~>!S>Fv!AZ!5flAD9Znb#K` z9<3EJjM|+Pd^jX`OlA!Js#LJr@3gT%nM=0F$)VyGVaO@}DUSFI`Jbo||F4++0ID8> z#0vtr`N}bX^v5g+18m7y22=rdP6+l4$KDnK1V|ds^xWv&v)(hKLpC_D!H@&N5_|xl zSIW+=H0;xFU);y++HW{O6qGx2zUUGF4ZCR;f z)roU%fk`Tw-1J%e$Sb-dQA>Mt07m;co%DB~cY}md=4!Xy9MOdsr7p{n+#KH;ZsCW)05ubtul;UzjW!@4MO3Et|VM@LAm4QdU9 zI=V3{^Q>}Vpx#cAYw+L;ix?wWNot|Pf}@WHWIF@g6x=C?VvpeyMh}UK)3hI`+rRVW z2CHK`KQmZ)z{})7Gl;)Ze);950z4>JeG0%ztZiGPBVF*$wmx!#QwAV-}%fcge@ z^ahNyJkX`(uBgQmr-2KCMN*a5qYi1-3pDK!BO)7>mZ+TY)L9-Pqce^b>>!;FvA+6r zNB0uxiz>yl)f?o&*3N@HB^b#%6l>s0wM(KF6`KctiKls1SnDamc>{VzC;m17N0rjZ z4E4fThq2S%gn5~&5hd5`lDB|LoNF;30SErmHYYfa4-iB=Af~}40GkZzy9KJgNQR|Q zB#@MEs(#z7v;`vNgG?$xFsA{!TNT(Br-BzdBne)Jwm_cTgf5w{zx5}Vxj6c)>dp=9 zpDM}^8+FU;7J+j(%*AvH@OnHn%G~*%v;t_J#y!DKEhF>r$2twklX-Ed9-f0QE{>af zDLxhgrV0`=TOElJ2)sz#!{vC~6BNu$t46*-@WBg8@!J5T^C_{H&cp!(@k#8?*=YBB zCio0nat@Y$!+I4g(H-5zigo_#>PgxVlJI zn?Z(DT;r3;>N*!85OzwWVp^%74}O8DCxE2qnG^AFx6erOCN1-8(|83sxhRG~`x9?1 zkx#eH)a^1W&mMh;MX@%H==*`{~vE6HiKH*1|fjhgIJaNQL)TJ9Pto z=NFTj8+Cxe7K~E7=&wjRiFyigAsx~5Bs9faO;F>_YG5W}0&Jp!38qo_S;0U{vdxoT zjd=&yve2f4yHyr-HC}2v^SDjDIk% z>FCF$a4;%A1eygY*|7!UZY=XaJT{x8{YqND*57{9X9KgvKcmm4+_^d`>=v*dNt#E^ zeEQ595&zD)w*pjG`rZn>){|t8yT+^ZR*@mMB&^XoB-K#7s^m}|ffZoEj?+9OS!zC{ z9n2g6R+e35UD;lyjENsn#9Y8B8|I(nn^9fLP%UU#kAf@1&T>@aOoq8Jvi8|5Qe_RG zr6J-~s~W;>sODl^b)kv<%-uml4s-bCRC)4*_Cf_@x1|XV>Ifz}rEcIjIS*MO2Rv(; zaYODN5s_MtglPN+Aed#C;;T}%(*9C`kArO-r$7AKl{HzC$5+vY&qLqG;jPDdkeko6 zlx;s3T1A{H%U}OMwDUtw>-pYbadb--UiMk3tp;2=Pj2rX7Kf^*HX&~TB5aMY>e$om zq6*YhVH=J@O_~bT@Z^+r3czQJDV9UiZZi{TdUzvaYzW!W>EiDYnW=7?w&S!#Bz+C; z)D{R_RkXK1gZ;#lzqzAqcIQ@1yeD$?xJQhtRWuESzNyh8WWn0%L=eFWtz*Hdp()8p zf_kv=Bt%-^sqkD(3Vg)P}v*=D6O2 zLysl`1cW_buVL*PF&4x1IUAAZi~Q6?{2=zHxkXy2&FzVw&#g=;RNX>p)bniw?+7Qz zD7_kajm4Y2;pj0d{I$XNFGB33Y%wh(UYti1X7asGxIeL;zQ}hcp1r`TaGA{Ug)%ADBviFh5dCDSfS9TItD)&psx(K^~orb92ufB#;8QWWAC=IMXC-g-83M1|rS)8zKCX zv*8`1lrc-Jk%~Y6$$8{96_QYsu!{^i2NikKq-Y}@^>3%`lH+T58id-z`k?D*phEHU z3RNPO=nZBGE;RRutDqoHX{a$+-^V1jKA-#Mze!)HzJENyz_K$V>Od! zB}Gn7&Knll>&^!DvTX{yJQX1O<1s9LB#N9tskCf{hC-nIi5&(ZNBqV@x|pRnn~|Vx zozWXa!-oU;!G1cY6kI67XVt8jFXiYwldHH6DM2n#Go+7_`Red>x*v0@fZCe#EIm2@^iDBmcR&POae*-;C6B&BI;Ho6WEz9;njt3f-N2 zVA9vswiz0gX{NJvB+VSecb;gQ>RE93x6L#oie6>(=)n6`3Mb505AN~D_Mgh6%bV4A zS`#ZG?=EPeb>&)|2rz$oP+ig}CHMlg8|`J?m#q5%8?Gd)RvD)&b2T~L;J2?^Mp(4@=OUw zqn$z}uxZCq=HEQFg5mYp%xzl2dwkp>$?hDw>=b!^(Dw*_)dheqPaF!u3I z#TU9($qrm~%cLHcCu#&8h)}B>|Bv`*XMtn?#qz5AP$(t)_3-S+JZ4 zH`~d%1+wvWGMLfPU4#sEdkxR=LOVqz^wtXWA28)J+Wmj*y$4uR+tw}|L=0eeQRkd;kA?rcYd%Wo50!Tyu^w-Z9=0vugepxpujm?zR0u{j`d&EFhTrd;!jB});-J%cvCFF>l^6iF8S^l9Nz)? z%?ZG`%sOuPm)dWjxNQ#=0p6;ARQlCRwU5MV-u?{x5OM4r% zNwYhrM?MU-+jNRf6-{iGr&pKn(Bj(3`%GK)>QorTJmY!?ibRt-&_tpm*kmtXjfEji zN{wC~4iS>E)e|iOdn>Qp{azF%Ax@5aHnn`zM# z;(w2UjXFC151hty*C%a>JwBkQw(sIXDId4?^IVOs(-<7er}oR^DAk6q6H5thBQXd; zW$hdyoeM#)c4ARl@vZqIr^lVwR+Z85{DRtkN2EwXbBJek$5W;gql6u|Z0EvzEq79m zN?N_K;=7Q#ufm!7Nj%m5e@~aC`XhvB2n+0%`XGiv{gXiq_3h_eh1BoOT~^K136d=? zgyJT4$MVy(j`u%>N%KEhb(RaFMA#9X8teEFt*Iya+$$Qi+*lsm=;5cf4_G

    7%>q zIJo*pH`X7w!~YGVe)K>5hmQa8UHHe}?3VwHU&~n6M0)@6@n0Pfe^K(a|Bt%){pR^H ze*m)Z#{c6Z$sG`;MYi8{en-*^{)SZpj*|Zetq-Mr2gdLlqcS2ni81 z++Y}yA*;-V9s~mtT94+?bN`;n4d_M4iV&C_o=^!H&L-a^13y%F0?0Y7Zj4;%1H8xK zC*VUg@U3%&&>dUA<-9%&viuZ6JgL{?zGdRa`d2JWzlq}bIRVH2a2@OXI}=9DH_%L1 zo`bI(J(4q=d(G^%Tf4%-M%T#3WVAn@w9-@FKJ$28j7FU8J%1-*FM-WbW3!e5&+dIgQ`EPh0L#{>7?o-4O^tw&CdoI-|p@wZ)EO&=A z4|jtj)#W#KLc#6wSif#s+@{>8R`)rc`^Gl$Y zLb`>!nvXJt+vyuW>rgyl2HTA-*Q`vdXE$qZcHN48Spvw1sd!4+r z=;}3J>2wn2zo~&-_1JhuTiA0HL;1B2pea#xxMnjb!QmOc^ep7`tg+a6h`9L{KYojP zFa_7w^kHfFYC+C*ym67}EzXD#1u$%CR{)VFUy{n$W7@Cc=YEnu`vUv>Mvd=!{jzDi zX@rT+DGk+nn4hg4Kp65pl}LefUxD-|AT@63-x1$lP0e3z1PcPZm6)&>G&|Dp%k8~K! znS5}a;S7TqIIE|ed_?H8{54qOKK1l?>pN)KvbNI)9_r_zNeq1tN56q6ndgz5HEIVz zxV4!E7$>9@}A8&mMT`F+^MEmd=xHTZ&Ta}tIb-V&yEa;xy03U#CmW`n+lhdEd z@@EXRo>0YCl2QTvK8^0c{@Fna=~}{oubQAU=tDUq?jwAQ0*HV*$f%Lr@iSA$^NY^N zWbO+$QX)jXH2pee;SGYwRj%p!Vl2_=*%<`mxWKR@4X0N`N8FkoADIF$VLx0yet^{L z^HrgPMK8&BI$y_pGSx=9R)TS~Tgbq=@5V*M^mwLb-E!@fgJ|Pz!L&z^-F8a(w4qEA zGaf?Xhtsd}#_yUeWv{p{w{7>8Y8$C_lDoFMTg-8J>pd3PyYzI>m2o||}j!gEwWwvXa zBn+9r0C1;e8#=H~hh)!HsGwAbvn$*-5&Kheu-%o-w5$wF#B0rm%}QBDj(2wAy9OY; zAK|?*dh04AxoxmfCt!x9Ky_kcJk$(rG(Kqxwmem z(1Q)|7AnUc%TD|$7(^%%Puo-P~KzK9#UqIQz^Q%{CN*Xh+pfy4B*phEE$@G;p7Gl&zf?e#vy`h+~Y|G*&m zibG{HR|Wr6z)%`<|I&ziR$TTC3yVXI_J>x&&vu>ib~CyAI@{1z`Y{X3iHj`nFMUim zo>t11_@`Y>&+e;Yt*(qyt7?i~>>aDv`g#aO4w;OHC9VqPzUX_*bwRnMSj`pFXHHvB zqS`V&DwIC0nmW(1wD&9n%GujqSqJ)IDt(aN)xu_HWI zac9d4b==C&=kFG2kwo#xr!`c#wnhmP-P0(?*@StuhXDz95=JU@y2jE`6Rl7jy3L;n z$J)$sc)(r%er*YJ8D=3;=vYAU;OBUxDYN;h%7+@wAu;Xue5 zGQ!aab(_0l_|6s}Wpb>BD+v>IKfy~R15+0|9+v9&0mM<`9^`1FtwI3*oe=y&(y?|d zQCH>oIKlVGvQRS@o57x}3L+37TACgR_t zx9Wn~SG&9yJ=iL5rf7X1I#<4dO00jFzf*xfc>B^9ZGRsrk|8cCura!)S3{C~k5DH# zOpn5b9$pnyZ9d37vU8w6^k?feOcdOiG4&-5;oVav@;DwbBeT4oD%7h>RkM|p%v^)6cSNE`SKynNtcAWd!;na2>bgfaP zYukqp1|D-VwCa;3SXZWVu8`^bSJ)yr?8mW3_wyE|z~MzCJCWh$d$uI5+^^y+SBI+m zPwwh`afUEk5{8Pum!3bi4gPBX{!u#r>%&EVb}WAR4TPN~g6HnQw_W`hHUL%b-9IZD21&+up150$*%$cbFR|eO+-@8LJ^`%Zlo^9P!lU14Jo>%XnDOWFZ`rB79w7u=Cy9&E>FmSfI@`JS$*!Br#)1<*)V#2`8 z&`vkk-O~N|=jwxD3ui2x(PS=uJL|1oqORne#jPrO`Wwl{y zZ2Yn%x-2JZF6hfuee=|cEp)-ZKZ9N-_TDnPLTa{S;rsEXxV8_V(?TFcXXS4B(t#!E z7t(DpHo2qu?1G%#U$Qc;O>3*Eqzg@0oDV%e0=PJtUV7!;QPZiha)$a z^#tdP|Nb}%;jI&*y)~>^XLoXX-^Y+Drh{*(oLPUOe3~-WjTmG64HQvh`4%Q}M{QN( ztp(qnOEYaq?5#=A^UKuy3){RvyfG^bt%@^!nK+W6+N89B31L3YA6iGjV@|Kqja7I+ zxHS{<3}a$yBB@^5&zmeoH&VDcs&9^Brg@9_>v<9n}1);_;8YpJa2sg@GOtI|&o z^Gn1~xXNpt^aF9z4B_koQSM%k$FC0E3x7Bzo=_RZ>=B|vW)-+*F;Z=}nqT(+#asFL zo{}yWHJ_;_(9TcPI-4NH>t*%bq%Tv{aPJyFQuV{-rk_7S_@yrM(51LfXPyChOmkI`8c*|DL5VbeB~LZ z@-dleP#(1_RP~QlO}j%Q{g3s|!a~w_W6w0Q#IS;cI4_WnJ6C15L8z8oWp8Qtw4a!Y zP>w(}MxP=dsW8#PfCINGxzFU(&W1TFWGbMi(6n$$ZDDyCnDo5*hbYBrN_Um5o(L!%TtnLGx-z0u;}-s-56EyO{q;h}3T0cl%aZ=1?zr)L{g?8-Kik_~Mtn0iforZ%c*-K3+sg+!EjG^>S%G6cW=V zrhGV>+AS3`SUJf`=u^Snea$?dV-1&vUXn7u*L$r^1r*b;<~HU%Bm=O@OFWUdc2=)(;n4gaRs9TJ&QiQ)C4Bj~MVJWfQ%f;1_NqQt*GJ)axutlIZrjNU{ z1y(+j9ZKTLzm(*gn8I<&&z!4c*1FcLOIdpe|v(zw(6Of#^v66XUpRKx~i(# zlNQSU5oG?3f~}EHmN?K+srS>inqE;E*fqX($vT>bk0Vt@UodBzA15dj@$%y8#LWD| zsX)=n+4#UbgeLURKkX_M+)oyViQJ9JFxqqCx=T~~^gZeHG<3@TPuAN-Wuu*_$5hHR zaz+sApB-s{t(6V2r0oFAeEFH*%>0b+Gk=%q$C{wZmx^7}kC=>oDyai4v1p8Q*Xtg4Vzn}D9Gy`&UoC*sA+$!N>yLJ)02 zHVhrh^R>j8Ci1mNu-3%T)0Bi&{QTqw*wcTn1$FFy>&M54FySdd&bTyE!v6*KH0^%50)032iua6gt1R;QMeu69UpXdLVn zG=d2j(F3819$A$PSoBzTrk(Dt9q1yTQoGfaF%9CB-*%c?o(WI>?)rr;XR8Ji? z&%tZ5<4M;GF}LyOqGn{=|dV0v6F`Nd0tV z+#QhjKcqZw6B+xsUxtCW-<6Io4gCf>7TN&c;{FC|SNR4agf{~aSMwBv$N-g#s?N8owP5nRX^Hkb@@oET73eWEA!)X?L~WSN zTYmSO&3fPTZ?%*5ua$ebKC&7Q5rmmD-1E`F*6QW5#h)rZ0f7DjAX-H$g^MkM0kJ9# zhhma6)I@319>h9>3i+YM&?ZO zZP;GGCvVLGuFnJHOE7We_%{xEtF9=W;>Zrj`kM`MDS`owq*1$s4%H5Z*YndVk)>zJ z@qfH>c#&HixBIM-T``}k<;jC4*I0_>qW3QAk$N_1u1 zqU%IWQUfp$2G}dcOuP5S%17=9T;SoZ=Ah;#v;ruV;~~SFWL2AkicZpC4RpsBm?cTyK#qXt zvIOen0TMEs1s{#9|7?$~A{N%=r-uuDggji|6G#B>Fe3n38?}FjNC@m-0g{ZHwSc#q zzz0Y3;|`MHvm!GL#Aycd(}8yKXUGOCp8CKUcx7(d5iiw6pwburE+PK$gLg~t!TSBS z-v)KrzUZ*}qne-g4ssc~Un-YP>?5y2ZOJ9yK-Is_vnU4N?%vM9N=N@{UH#)12=x3_ zp2c^=2lGVjf23K|G=b-m?BX@^w0{vx{^(WzqrdJNpqge6{zxg63*=1x-BbNNwIA?) z0q!QJ9QY#{Pp|-NPav#1pIEwhHI)tihACuB@*5ME$|*{fYPLx$YWY|U1rqYHQUB~j07juGXW|$g?#B4 z>GBuf2m|+|zJ-)sXPXa{o8T5a!DlE-uVg6wA5Y;I&0Z4)@DO|tJZs#v~@#2Ms0^jA^*4G-?qyRoQw!jOPuPEXIl5gJ36-ZkMFy)&;JoAp) zDFVo#Vtcy=)jvvK$@FwtB6lyWV&u;fqH;{JJ+B3oN=wS(T6jD)ZY1GTmJ{jz6gV6s{n5fxw1vNjL!JGyAgG4`!`T0$)Nq%H5#3A7kj zoYJt-*InkJhgBuswP8tm55he@)`gCalrOvft8~l%d?Nl|y4^+MKU}`v#joil`}oKQ;m7+qYv~?O zgY^!-LKp^HI#0z+)I>Cc8ESMaW(v-&EhxuI@l=PaaCU^+g&a<0uc9q7yYb`7e@f#w zkyXEB#|E-tC;aL!kBXOANge+bmNbdf*W`e%n_%lPY@Pj1E z#PZ&Z6QFBHbepe%3D^V8I&H%C%&kJ$H_*NqwTRPOMIMkVT|tN|1V2E0>&G}HLXV&& z@TvCF23)xuf~39{UuUyW|4EsU;yiU`cwgp_F%LA4HyP4;zJuT&=YJOZ_E zo}35y#KZ%5#lIU4V{I@40&6S?oBLO7ua02bXE|R{2+p>_x6Tr4|9YdJ-cR5=23``x zIAtOVe~Pt(4t2zl)M1mWJS{NRJ7&|;$#L5ofLwRdRB~Tgl$)xLm2fvJ^T0P3(lV&G z(#?Jh%-A8nui}`!c=#pR`a``n?2A4jT4Q%a%^h-`AH69Nzc1bvh;DI3)b$$W5-H9> zl2BgX%ip&bRBD|x4BBdX2Jg$7>=@zcnLRq3sfq*bIehvYOfA>2G*ahHSek|~!$Mne zrnXhW;}b|HKnQA}oGTZ(CVN z#iF~tZfoFc;5&YQv8hSIM6v}=BkLL{guFD*!yh;!yXVPxa?G34JaHsW#|_Bi(RVAiWUkw?mk zL?gReMO=8 zj+FpeFnE<54&QQjK^9+t;I&1ZwzL2_GC%Sl3D9Q3-}u1Okq2BrH00m@{j%l$*G>4p zy9WK=P5bd45Nz_H)G${+-9;y>J)WnWY!BpExA;>V*cGo}-H?@hgfhU}; zo^P3biS+^5Q?|(qmf$=?1qK{LcFbaFZZsy`>Ve->S)o9^0N5c7@d@QSDSK8`RY^Oy z=**v2%JSPu`$?znNo=H6qLxj?2FZQ!i{*M+@*gcCnOFs$MkztFwIdC1~ z_3%f@N$&B zk!4uhmgMP_CrI})=8h|JS9=!RE&m@h7K${Hg$I3^^AFOS^zK|8jW7`ZaL1jluGR}H z6oIRca7R+v0kH7<_`c(1GlO?l;<#>!piI5PXGkJ5<2H?k^&=P0K5llXD2d*X$vk`s!YVn}BodG}vvDYe%vefalP_lJYOjyo{7`rafw zvz&^$lK!G%Aj@pa#~2V59S%{F4e_34PAv^6DW z{IQv{h`=ko;hGrTBzVuNTi-$XmIiT)>*L;iGI?3MU!blwDZBD@XFH$!eR#L(pQ$Bo zHq>wMz?n8jm7BIcOPkjT(g46n#`HS9-pWpLa zo}N^}uZBD|-|6Dc#HyUe0eZT`@$oSh7B`b|)gq&Y5EXvQrW`i@eo0SfeS^=Q?t-mO zhuHXI5P<3)XU0$1Z`0$xg1=b)x%MLFlgIO-{g{PZ@Pr(6?hEan0D3~K0-ycNs?K4_ zhTF0v7%_&BQzqlF@Jmnh+U4c(@#rX7HQ`MsHK|Rm%!~fBURb4Fgx22ULsi{Rz#H-t z-#}l*pa*Qs?nn@1)(`Lze*XYT6cb#Q2f;t?0~QnWcF5KPovmQMGiJ&^FHiTz#~Uqd zB*y#mnQLes#45@H)&})Ie3wJNdsTHR_}$1tS=$){rxb4k^vl&Vmb-l2nvfcAWM>-l z1{6_a<${4Sb^4C>cFCe`kAW+>y<-kA{bUnRVeu3-2~l3ZLkC!G6ctQt8W{G#PVf~r z0di#cZ|?T{-RSlHR@~NmMsmV0#4zGgQ!X$mQ<{CuUdx?TBH*B9)NZB%_F21?&-}iw3ys#OO9)cRdLE_o2)3M<|yi!96-!U z)6bIf@zgVy-eA;KFe?1zJs77k!=R|Ii|bhQ1{bxfzYZY?&w3A^m5I-cHCn`%uL<91 zTY2ocZMjDuRC%@LEH1Rg^g>DWUQK~~+YP|6plgYB;GU~eWt)$60ZeV0A*@ErmTS|? z&@VE`Rn6^nuSj0nEW#~v=d&R$u?frw%j%Vx-zeEtbjWJ4mKO}s~3cS&!Z^#2bVOXUG1a7WthmX~U zRNA@$CaVP3rXET{;K01wtwMrG3kRpMZPnZ22h37@V~ougNHM8SvEp{=OIhMp5phX$M{tsCEV8%~yiahKehBGQboa zlA@G|pAlhPN@eLi+rOSz9HKF+T1v$HGZRM!07Q+LQ;!3Tc>MM*65 z1BO~pCQ`!A)SLwr>gpXgwr|d0cYv&)RqcnY@JlZjqaWfrSl&`muF8 z`Fr^ZTlhuADv00D-}=YL51zy9 z{80mdi<6wtpR4}uy6)#SWwv)h7BCH)FG9BTQ7GAC-$1<7q4g_VKt8nZi@pifDGhCj zg8SXqd)7+TZ$dAP3`01EUuC{wRp!N61-kL@Q%JU7bYOWELALsD1>AYfj z5sfxqB0TrYe}fxp1T!vscSBg5tlIe?nnFr?1d4(YqbpU`+4lZe z@j2{o6Kw7Q}RLz<(Mro zK7W;u!vN~su+5DQGSl*v!)Kaa#f_N8E2Avrb;g8x%(#^H`CTE5T|!u=(7G!TZ4(@7 zy}8UQ0v*-C-a?q1Z=eU!N;B75{nT;0Z85OXW?OF^-rA>odd?^XUw80I3_uYsRrsN* zWBKQIAg8b}?L$d2c3vl(MkDiYdn0uE&n)%6|G}~i5hUFpMC8EwG-16e!dtM>U6wSA zhqMf_h!lEbEX9-w@Kz8xHKOD@p^LQS8H*iTcpQPvxyCn!kt^2y50?DLiQhoQ6S>Tl zKF3{q=K(n8;#_b#HJ&Ozv;H7;Te+a~t9?SE7-G-nqVNewn6L>zld-a!r{HMXY+O?L z0^WJe;$Z;khTZ11H$%RxGsmMZT^ZLL{y_VRagApB1(|0k=`(%xRQ-uZE-qQvgwM~l zrx4CcblLbLHC+$gC#eWQmJv~s+GURdvk&_ON?Ad|B({*vB4ClI5BnrY^?Np+d!I^&{!yZ;pe z#1wyLMCf6ak4c34OSNZ=9&5vh8l^X=vxL5>1D{s$hXv_Ns~*CG7MJ)HMysvm@!TOb z`DA8rbp0X-fW8fM$pmfi~L$!AUfLr9T1%c>Dz`VNgU6gnStAFKzAlO^1x% zoI!~s2;qW%0bnm2FPMA@LD2S>1^_bvG@H5&A(?=2IV2!bMAoLER>*Q;~e%j zDH;TXqt3+}jPYLhZaQy2S81i|NfU1Hatb7-f-0=zcsNu=-MlKK-p|K4u2|TW)HS{# z{=~1r0_ja$o-T{>N%NKOEg8Ql%GGbTvh-?ol23|y>K*E?j2|w^+ogZV}qv z;+0?C)boO%kN1uk?YTq_LWAnqU_osfetCmZtB=GHrN&Im@4aY2o$yPd$?Z7LW)UDc zu1KjNnyVnhWhX!IW*Nho>ugSQZQ>@cCs(#}&lcIMdk@;;ch3f70LF$xRQ2&5p77$q z%!JkgiDiRq^jN}?C@6`Bg{(6?PVP30HDW0lDzHX^UG>=|AUGbQJ-tM1m16NUm($8n zk-88l85HBia2i-eS}YPmRz?t~E? z(bk8b_@@yuy~{xPHP-c8`pcicXZI~_{jMS9m*}D$0A*G}{}Om~0K^CZ;YAeqVzLT7 zfKfmC9(%OW9bBW6OMvK;`+H5#R&I=3>_}NtB_C14nZQroVs-1`BICPBJHYd8&>&0v?$;|n^!>eW5(U%nD6-fVJ6 z{l`3KH}sLx8WDVbn_+oGiOE&05ucMM{4i5+IcU|3`7S+dYOp+*EJ^6p#d}0#jjKIy zSX-Y8yjM2Gh2qU^?B--ATGu6^vi^l#;}<#i2V+P0|L~{)uiRhZQPHEsE47#nSBWj@ zu1BQwY))+yd6I~J;-(sSbQ}2V1g8mY?;TU@^=Fs8l&Q`37fJQ%1I;9rAwb~Ripjc8 zsHg$UGYEm<-PsGK2Gg}nW+#@*Mtr?!SCfq4hZt($-L67SH5}7PB$JsGIbN=g*sDvk zfO>hRQ*y3hm$#;`c|^8qt<=ea`)1{*NJucX7TIT}F0!;Nq@$O^=rUy<=%x_C{aXiZD*TVpYi$ia7v4%frLqE-uUtrar zqNiNduT&$}!KmFR?MuTDQPT44vu&aE5;by)+io|h)XA*i@!-=GsiU)d_N2THzgD7N z-vpC2{K#VDia~PIA(dgEV&5oxtJeRa2@1h9vRZ!Nmfp*Bn z?A?U}@0>lr?gchntz(BFq5W6FN*;#@8Fd0zs9SSX$&)*KXp`t+M(?X);g^Zde5Wxo zK8hliPN~XN>~52meVUR>OFzdN2=a@!$S*Ep_M0aMt4G%CGk$!>{_BJNp(fv>9*bQ5 z8!zY28JM;6;(zVc^`}mk9xk|wA|l%gN4|joUxS~Hf0b`prn{zIwLmAY^an-ur+vq{ zp4r_po1o)h=~`^6dcu4v*z6_p(|MA8I02cL!a!G0;;3s>d6SOwME>Tv0H}<==dCi`O8M`)xs!)k%x?Ei%Qx$v;duS75<|a$+zE{`wc#_ZK1+VKvR3U+!GjCTu%L_S*F4Tly7^(OpLpZKcMp@9AOh zQezBK`3BQ)3!xIn?_-Y0NU@t_Vq7Ta%yOl`QPwboVNi1_XTL;5#izyeb3K15s1=6#!z|d)zR>&piS>cy_V;bcAnBp0~V84(=W*n8Y^<{ zrIb4g1u}fbikdOq^2;4t&ejR_9SN)0H*h)aHt#rIQAh)k%xU#B!1sGf&FxtkdEBCSLM7hwD%SsCbT#=}~hv zeuD37Z56U&$jL*KbeR=^^M2ZRtFy}(CmJA`gsA?j0USGa{gx5>LtBGR6VSt2X**F# zP;#WRym)4Q0n8$SpW<( z_DX{#lP7H3b8IDJ#z(H5d4R}L(&*;d*BwL@*w*p%#og<5;;Sxkz1a@F6P=NIV<&&x zANAAxhap$bTF|Ak^lUTL*N1F1WFI6dS`yoY0Be!05X}Qz86qeCfFzkk1zD*Q2M>yx z3hb-s-x3He@w<&$pRTw_{zBJ`ZSke|H1>k(IN8TaKO_NdXQ3RLgLFe ze6n@T&8g5X{U7o6=M@ zWJh%qj!4LwoQeOG2}ie0H zqaky**W+bRNTi+pAE~h}v$w86?F3ey@D&pU?5|+fB1JhITm6pVM*Rrw>{K=<`*8DRo}_a+{$lRNy<~ zZ zz$Hgn6^pFZm`AJT6Gt_fGu^u7=ue6CovVWp4)To0V6n~WqrAf-jWtY}LdpxN-kj&n zvebv8MnNT>yJI?pX8XaZ@u`^!(-d{sjJBJl7|S&$%o+l?(PUiB3718RWzElR`iNq=>z8Oj+oWBn*e& z%?XJp_tTOctTo}zMtCYXXX^H*6WW3PxOm%DVsMQ;JNB~E3lXnVQ{^+XaXDU4QqIbhdGB`cY)lvPDY{swIn|%5h7Co@ zOB*%B8o+d9_bRpg1T9#{Pi>&brd+-ZMZx+oZ)=X8O$^rRPKlT7&0_THfnN0MqUJjO zyTc6h0Yo299e1c3o@;V-!Q-0z$|r9MEQ}eWt1CSeS#x8yp?DIjr(QW84XqaEe&U@< z1sjNuF2#tP@Vb0)ml)sY=xG_Z_6eQFogHAXoA5z@(%4W{yZvy~N#<*8T0w}8;&tH% zMRgS=FLGm#vY!)l70adu$JBM{c1+CpNS3V+r_9SHy>S{gi?L^Yl0mQ8OlYP$J_QML! zckIM#4xmtr)R`JUOl?Z^wh7ug@Lv}#d?Ulp$lNHJ)3v!RCl}%qzG)8_3{93&8Tz*O zYuc)wt~|f3cepJ>rn`S@hiy%$i~v{)`Bv8tg7^U|NQ|BXj*_f2I=O#D1@L3xEgby; zS^W;3GH(U{ZG~cJH!vo3rWNJ;bhoxB2g2v`zDRJtdvXU z!9ixy$U006_=~$dfh+2FAJKnwGoMkU3!Ygp2y|#|lO22V!wp8`lkAb}5UswiHWk0Q z7nAZ|qr}xtKVahj3?(*3wurDbPN9ygc)jphD&~46Oaee@rCq&T61B@;Z#0vDc{YzE zMs24o8S3#$&DPXZxx8|QLRLkm`~`|o$u%<5t7>h;&szmTF`TZZrY2HdQUb`GmpI7D zuS1_rxo|sgF@DxW-T05u*F;1vy|Upv*}Z=U27b0;pHk>pS+)P%uV)KYNj(l${ps-S z+qWn&!d#y5FpT-pYQn9Z;em5jTES8Nma)6^n2yqI z1wRclZGZuPLH-J%F&$>IQ1sy&=vhK8+xZ?v7tT9UXGZ(I=~6Gdn7U!0k?aD&6FwXw zge1F|*r-!Bj4jQ9T(wGR?HKBRJKju=5Y$pN6j|zC*>COhY`E;!VLOj3C~Y`|!EI7v zb23a;tpL`kXY^Xprs8$VgUgE9b`Nkl8Ms}!&EFq-q;~p1so68e02@Q&_#oJNqc}F8 z_{l_Qbo^gwSqB&IlAalc9y|s1Lj|-cejft=7@q_Gs!+dW?Ec%hHgz zmuAPK*nJ@T&6H=u++clMC~IsDEij&h zxGo1hRAbkHHpC}}$-ZRqIZ$0HmnmxBwYL1ipw)n4|4=koV>QEYjwi6MfYm$Bu>&WQDo!>6iFT1isP#rcD+kRJc=`H`%FwlukK!OV)U?T(+J~!X%UCb_?|i3 zGhl7owq(^tu`jEt=Dx$4<^=CbXJp0+xy#K014?hT38K^WrwDE>o({RTdRMF52a5D; zFH^tFWR~jkW&ub2r|mvb-^RKKhSJXMW0aE<$~BRl4&$V<~x4 zB--%p=fnWruHgp|hu50cI#T*W^Vj&Ylr^?KdnKZUHRn4U@@*b{0GD;;iVMEFXuruB z)5m|FXbt%GB0|#f(C9}iYxm?{@r;dKSo~Nqwa+5RQ1l-x_kIsS_dp1uLDw$Pm@w7i%lhMz75rUsH+++w!eo+N)DY(X1 z#5L0Hbbgykje+E)TbF~%6T<$(6tx#RGl@uP_3r6=bhZm|fA)-4%f@4oEi82z)cdct zE!7=`QP{ZSO>=2PGwwG@a_PG#a-##*m{7`dVhf%*m_LKSk zJC>{7_V0=+I9IJ{m$w?J$%lmgdSg=^7ceo*PL#-mMN5un(u)r~kYQLHCJFudhGi^~ zSXcKeEl%i1j>KOm6OqvD-?a`fBW4iv288nFL~kxq9NON!*r%aEY6Ocp94MW$s!u+T zn?pwUUh{l2*)Ho*ZX{VlM;TREcv+b*FM8m2hnhM8q8n!F8;E$+9=S^flO_I0jS@*5 z0YD3jXA9wz1UO*;jO&sItc__20Cxs_8ZcD?30h71!9gQ5Z9?c-M2A1b0}Bw`m(0Tv+Y{^9D{udNDZ#@3-H} zpRynQ4;^KCc)2IJK)&>EY5m40i6z7V)!g5sqZAa%fB9(DssWQB6N<{J7v<+(Z+Jbmfa`a)x@*z8db#y8}{ zoaagP#zSas5&T(nge=r2zx(+)Uj;S@7Q-n>Hu2lA2NL7zB^nPpip+gvy2=Q}@hn0_ z25T*+Lqp*owr=I#eOXmUk;oSxK~TaBZJ>Mze84Nb0-<|thm|$6GZ%Z{`W#LJNMnBM zS(B>U4594QJC2d=Y<;YfPnf%P5akO)8-;7NcdLI!E`>hJn&1WfPPVjLWh%ML^A5Bua+$c0;2tOqZXo)Foe)3s^+xPI2D2fj>ZI5=GzVFTEV-@}I#$nH&x$PMnk`em%h z0gYZUY_s9njI#f@Ig^~GXf*7k$Q${LB9i=b*kt2{nbUQn_nG8Wj$E6%Bgatxh9sXF zH6y}sDF^wmoVMIf2FK|QhI`jeO;Q=c4EuZ>QZ!=VKJwD=4|PF%aO;>CyFbketFqWLQ=Hrtn0zWwXytwi~h6v|4U+C^~q;& zgDEriSIYYtKSq@+@jH}0-}fLb3z*{Okux&4%j=cS(9gm~?a%B0nI8v)p{k_=Y5Ija zbz1ROQiApgJ^rkKHk~@E6;0}Pps?1rLd+kJ6yce|Tw9c;oqr4udA~TpU*4ZlCqCL_ zkZ{3rFQAPzrm@ZK%j0)G3`dnL@)bPF&nai{KXqS_!X$68uM55XXHVi;(?&9^|1?BDMaFES$DQvcw~BiUYVfS&r{F{9w zB|5Lz4rp=Lb)cKmu8Mp>1+W4Rg^_zw+4psWvkB3sH_yI6+Pn$?u6}YY){oK!AOJ-% z0#`4wQ*aE5=M&h+$a@&G%VNN_S{eX_O(;s)a;Ix0ffv|t0zf>dy%ouBwqYusQ z`Z9hKGM8x+LYd`Cuf4UORVV+&U07{8wBqCunt#yj);>($?^r1h)wjdhxck?KYrEG7)$=A zT~X1p@EI@i85q&1Q#lhhYgO|8DZ|S&DGh|~{kw8T%y=|{1ckJSfYrQgPa!xX%Mwlm zY@VW~6~%s1LFeDElfnarxCKHmX30sIHwF`v(A#uE{{E9`MLC0KQrnO82FOQoGX!X3 zm326ch!exQK4(bGGaJ597pa|AKeH($y~tA%N7lo%z#SZUJK&@3=>%7~@{@?)9|#j^ zsSit)#SJ0c)djg+^$Yl(t2m}loY^m#; zoIz_si?5IAm*I~DS>_wOe|TxyK#yAL;~cc&8ugfN@I&2T-@Sb$LhMm9RoobpQ0GaG z>gSLrF{RW)R9yhSm6^PM51BtuueV0>aQH?`+uAI{6u-lb?MAone1YA_68JNo_$}1& zM&6nt(dtS{!cmTUe$K|f}5bQdJXcaHJ!QFnrP$v!IFEqWF>>f0%* z1oxfF{(P*Si1U+3@I_F>-YUNjqe*B37n6g~^w7wHCMwssw&~Di-}i?^7D{4P6kO^{ zQbRi3Gwc_iX7CxPjt3mBVnB=e>$H)3y*Y#jqfqHgkx^Dc9*3D0A)M`ddK~*Ii;v0; zuhxaBib=dE_j>k#%qxY^AOODVM7UMkYpX8-6BNbas8zxC!EMFKaT0Q?~2c;xU-q!La?W% zwQz!O>Zf!@NyolSDiUn%FMiZCQPitBQxzT?%27;`l{&zQy`gJdxJA!iNx)_Qql=k;^}uLBT}bz)SBP+V@MF@{wAJXE?W z(`ZJM+Pn>4z<=z~$Sfo)_GQ4g2dEH%1uGp)@f zk^069`1&ia;vMkX40~oibbY!mT<-kPd^8)+&9qNWXK%rvO@oL+0CUB-Eo&2I1Uusq z>e5M_n?1QPWuAyYinj{X1$9gujmTB=MID$sD+0Z^zrgZ#9MoP$8U@4$} z)`4>WCYd{%y0-_1pZsC=XL{vNj~zZOzo78<3SA(wrP4KtdZ~4s^rg|0ZddPWpNNc| zBqhgFMX!kIVyJw2XWoLl?$zDht8{IMs>-scs2RsL$-`$v2i)lsr%wr*Sl+BEEU&A4 zpM2|Ju&X2t&JrQt#u1gAT7ir$wWswMxix6#GV+z|^s=Ujk)+Dm2{p_Bbo8ktWd$cn zcd$lb#+FW}vfrL~Ghe~=$sD(qj}Sz2)9KhO`(((TkuHuQyhL4hUcC<3sL>A=zl>7f zs`XLoYU7IZehRF=1IHyGjCc!$&VU?)hx~8H0NNv7;z`#1fK`Y*Q4m*!M>ky(G-kWk zNozvAe()JQsXspodQ701au3I}$}wp=O)kahhb*|m)&LXvA++4&zMiv5m%BI`s*I}v zi0^0AnREvVoY~$e?T?MZ723eY)Z2emwpkW44Pvz!ZYfKAFwOSJDEIYM&d|l{yS&L{ zOuPVmctiz96Cu9(a76t*j=ET2@IxZ4!d8lROb;1V%)$}qY8pNW&Ad}+oAJpb$RKX% zi~5UqguAls^L|HFfV72~SW>KD_&X#09+)#s#%6yc@io)9lI$H7ZmKP|Kp%~%gG(kX zx5^5WNnc1FnB8&-5z(3muQ$=kObgN{2#6+vcGcBjTQk{%E+P)OZf9q1>B+h+$sH;B z(T#o%#J1f9QL61_xIHNJ>YnfG6{H_l*Yx zOQmO=&h(9YKX-R79t<8%tt9;yPN+!IXiXN!q2Bc>Im3jZu|@rZjYoj=Po7|{n04bj znKK&9_z6v`)XKV7DAmu_OH)7?K}8KByM4ESR|}UJ4zNbJk{km*XHk=C*>=SaGY9au)1WQ(eLVgfx_9?(}@F;ON|J( z9QE*S89tG?STbhXeti_fZv28_sVQ^Dgf|di9E`c1d~N$=(BKo%popnr4)$DL;{zwT zB%3rWKvsIjiVn^G)`5`!+yOUw)tq9`d>K)o)SvH?d=`(MRzKu1Gav}kdEd=0{rrQU zS6-6yb{oMJnOef;t$`DSAI;8C|1zQ~9VQYrsPD#!iumZd3U02FVa|9hk!X8y?MjD| z&Vx@O1ZjCp31Dzvz&=heAGa+@t!Uz7(+PUWuUe9;8Wn4zTJ>COfHu;aNoOE8%R*M3 z>F7TyAF~+o8=ZA2DSJLe6CZ2h%a zs8Gz8+P|>LlORGMQL8c-Lj0wv_N8 zM_0P?45O3Ov+ikGMSYr_gq_FV%8$zL@1BYLK)?v{kB`46Ez-69mi>2%n0s}ZBnQEg zbiPjjtP2XKN7SP@Zr%GZY+Fx86%8%R12Y3G<kBo_X&sN`8Oc!$UeK`WW|xn`K7e^mxh5;U>X_SSG^9>l1W z(ypNsMWKDFN^Ssj`A&cgIY6m01wXbhPTNmvPaA%*Yu5D|WqpCGS^}0S574l|u;^zl z_QwFvj(MN$E$_lFA11`2qs9{J`crzy^xD}uff)Kk0BwhCuiFxZaC?N36m9iLbv!`W zRTngBT4;}{6ha^Zfqyr}w-NrZ+3VQdg8<+`_C7=vV}*z>*x3Qb1Q!tDvfhv{@RCPS zG)?SK2LMj(kOlsff~Vh}0)G%5G4m2@8Khk9;A&KFR%%);YcAI$;}tFar~(#DlGHfr z;S%ajsZ(=QT4%X<=;n$jI-9G^<`0_H@J`hQ@ZfqvL|to3_TA`AJ5)Mnv9Gtyl6^#M z8hu&tBKEBKR0*RIjq(TLD`{^~8pjd3lJosMf7r0M&WbTLsA>4DCTE(pbk4i5BjiWP z*kczaN~koOrdCf}jJhY5G^nX~$S;75Ms>@6_~^wc>`vfW0%jI^$L0n zXx{g*r$u}&08PUpv>KAxIL8_W?a3nsy;im(_o;A8%Bu-~&c4^+-m>BhQD*)UJ|Pm zXC3g~H$u3z!+Bk`HT_aJ>M8naS$6zGu0dtrDxA5b7*myVvHtGq`{awpb>D{_RltgViHSnf|1tvp75yrYBo`BMF)b z;lqputijWL+T<1pdcPb3@jquZb^02+`HS7z(vCZI-2G7KH>Uz{VZ1S?md&ZsH)wIQ zn#O|JGt}^^MGg_ zAd-n4s`I$Yr0%(GhF*2FPV$`geCKuQLHipjl?iP2X!cAj*|<^`VbT~{_yzPwfkY}ub`o&LlzI$hfm!wbgJ87noY zpR)y6Eozst_vMmU)cMWAVlSo2RRZ8bzXXCW3W3aA0HRtWmZyLXh0)BI=gP{5bCy~a zU1Qz%WIXeCy~`(QrXa#&PzfAwDAXG%oAmnWhb4EW>dFo!xHxLvjYv-9|00ciPU6Pd z!(Hc#i?0|Y-I0)IC%JgH@=rlp+1WlCqqCQglAc8`tjdEQ+wBcyF z22OO8;4>#fKSL{O65_kD?%PXI*jR^{5L|7SHaEAx*)7(`$T2<}+N^rGr zdf4hqVCy~QPa^NP4?EcW(^G#i=3ji5n;!T^@6npH@|n4pZ(o~{cSKW5m|bgQ_11BD zUmUVBhPFOrT=Y`(@_osB00WRE6ObCTAnu%_Nn*t+hg#gd=N4gIVrX#5&lVfp}<+KRx!@h(<7POAgr z7cRAE2sib@2T==vqrgk=71RosN#r82G0VQGc0Hw{TB!BGVasgWz6v~P8v6yrEMxtZ z4DhN3DZ(uU$8O%cm#4kSD$96av9#pu+^_K0$ zUy#s$wqXP;|8BF}>P%V8HE&e*v=)m25LS1l3uUPpzeO z#WVJIWa$A6@8Ots$plA=57filICf{!!A7=sb}&Rh2v8O;B_-}_O|eZOe@m&gAP z!wx)#KaXKIwZIuQzvFlLD3EqA`zm^#^4+!$(ThX@u*1*vgf*XY^w8~qjCTbiRS{K5 znlu9&K7QLsNqo{YIenE?-1=sFu;3LhAuMtRgJmzB?SOOTIc8fr(QCVMZ_!Un2__IS zGU=<{-dDa%>Fedo8?u>ywF`;7$B`B`>pwAqL#Dg1$*J?p7ZoPx#pyphv9_Wgx8A;* zocsw{R3c5;wrv&4#=dme$!Xa1P0{kI{g z_Y$8wb-M_lCJz*jN(!wlS#Repz{tWt-8D@BQjm%}+Q8mLCA7HEvi$WP_x3OvIkSgh z%kz-@JU*l0)DmIH$MR;M?f@pW4i!pKn5sQGp#eX7UE;$GepXgv3m`*woXV#bqOo$& zR|?=@$#5jvc_9{L{R-g9{V{6&sb$9JSgUEK%?5_LYzCM9He&hyo^v!EQX^N2E}sA! zW_Tsw2{1f9{$P{1Y<73ZwuI&sfYuv3&V2D5B$k0Y#*eaGw(Dl@(hh+g&hyrZEj3uF zBQ#oNlE%(Ef#7}}6?zBnlWKCC@trl+A(cBRG-Sg_BgC-C(2`wbW60OF}tgmD?6LlMnK`od7-Tm7&Bjp|U*$(Y{?_<<) zhC36Q*mFsqHXPB%kz6kJcg><}rAQm6ZYq>lmpNc>cPxyj1Q@bQCQBo!hI>xhg|E@S z+_!zaF>w;sHt`Nv?h-)+VVkQxB=CJ84{<1QIiwdnE1LtgVy>1=Kdl0?&A|rQ~vFqfI^nF4yH6h4<5s6_;9d% zjom=2p>V6-f9}${3&bv(P6Tb_Fo2gw0PENdAOy=7)bTDW=hDCGnQs$uoh|7t3^e}} zAvvIaOa9&?^f+X5k{g5>s)~y17e&vX}wk#<3;-^9iQbIISrecF90j0m+%Np(*vZh-Vd=y^xO)U3hk3xEMYgn@q#nSQYmM zH)7+E@v*1T_~HU`LFo~Zh7p|r)y8X3Mm#W4yW_E1TA^iSIVE`3MQ@9%*q1WQY<}On zhmCl7AX$9hEqY}_%!y~=5m!aGCMgwcxJMe_M8i&s^M?D5rBzFGu?AN$y;u`{3Crpk zLcz*wa1)JPDl?FBYr(EfB~H8N52eHAKuex*Q>Tw}x#_{_x;Ivl<{J9## zLaqFaS{CmLTP0p`_bl>&RhRmALUAFjXFprzIfj2ZE=o{=_f`5BwfIWl6QOY;vV-`s z%F9otn{C!~yk_>h-gsezay^j13W&}=x>c#Fj-~uU_#6FjpAMuk%(ED7IJa$2kDr*f z-Oz8_)thmfEi4YDMONx8!`H7mE}QmZ5tCEcl0~G4pAt_V!|u7In*wD@+{s}F6_d`G ztR46>Ad4VPV5Yiv^C3y``*juN_n2&pB)PXNSJ4#7wMr#WUi>wvfRxQR2W@-qk%N}1 z$WGg+cHUI5-8I(jCE1W#pwx6uuQyT5Bpxe0CHm0D%}R&j&B+&p72d+b(KL6IWu0XH zQ@K(TyBrSInA`4>7<%>Gez_b18dk00c5}dzO;LV1z?5qW4)Um*(wVJNZ%I7qGlI}S zDVk(fpI;Jc-%rb2L8)qyTd3)Fjyelsc=6ue5oYm?|PRe~UX)^vlThH5)%v6knJx7Wet;b1X zW+SOyy>ZHu3)*C2TmGxEx%bK9c>d|2*oVToNr|7;hQ~5BdziMD7`-2%jE>Jho}w;# z>T)qxey)94n?LNzibI&b4JxzwgJxCx6T=$1arJ1+6hou2D7fUj^;yu}SDE<%+D|w)n<;3&5z@IjzBd2XT`XCpNoEwEXtYegjiBe}67mx~;HG}+b{~A(AJ5D= zP@k+=6FEkPb&QD$StOk%UMU%T(%D4MR-(*HJ zU*ZhAlvPjh@x*S{jIx>jjKVF=KpjRhFLE7m6VM&ZW%f?3;^#|aXgV5L2{nr|F4nC&lk*>1z-S}*f(;M4NNnFqWr1MEsnrsb*aVMaYX==Ob5sjJ*fbsB${AQ%d?`ha*t-H?7y*h86Ecw zOG!K&=5r!s8|jY{jMx9j^KqS9$T=f$!vHRDe3Ax#oRL6JzYL*(ng|xAsJ|UoHl0^L zIa|zbNLLTSo)O-<#6R>)>F^cxIJxhxN}A|@+ns8TKq;_x9h*Hc@Z=gWcW&|2XtgJY z*)2jw2riNXPhxi4QeVGiMdS)`dxb@KAo=iJlR~Rw{QIywK~mw-zI$h##kgX&EoR}G zQ9bn2>?d(LJpnc9wmA)PVbFM53Q`%@Zv677x4-H6$vS#tyma%>a2}Hty4~?Kc=;jN z)3+8~@kh-d`km8kf}m4~)3U>`N5_t!la`*D-}g#>wVceq%mlre-ZWJ_OMkTs&&wB)wh zn>5SW@*qiCMJXXnCE#wUCUO7|hf7Lhr#1DQxXl2gB5MQftWYugaU!J|!W}OUJRL+W<;R$;D`ApPx!NF)Wa#kJXt{N40PuLi7QrLTVfur}yAK$h4=Y8YK6vnA*&=+T zYJpP2vhxDKMXyqjDm93GfA}r8iJiR)r}4s8%v+8-3EQoB%S!SQSRR4Avpr|Zh~377 zKyO;7e#UXHKX(%0lJ68IP#t)=BQIgmK?OBh(=6)jJ;A(C(Woe9Y6JL3%jN!BU_pyG zX>Cf^r=`)i+WeSo^8%L;Kg<*EOrZWm53G@)0_h$aD(Yaha@s744==-N@(;eq_AE%> z*Be4HVasBtWG{#v2#zYI(1_d<*(l$AwF^#J^*7=^bVX6&N#wBxCik(9lJLTk z^dS$f0l1baIWBQ(ups6%PB8pX)06Hq8{@)(in44<_cacCMJ?HYCJ`aCy)}kaGJT-; zOE8{34;8b z+I4=PI&;I8_t`6&NH}tAw`~iVzP#u~F#R^i^LLQ=pmzqLbomC>1e4mZ3>%o#O{a)v zi;yte2M7J8dN{Rdx7^93$DKeYu2_f~?e(#|bmO|LZDvEWmatJ50--B~9A4Hn^o_SS z<4c(6jvP%bWO|s&q7QSyM0mibEkkNFPL7N(@$f56<>$wD-jJo1e6XTIKaTso%(&r$jh6ETa<8g%<5kkLUi=?hZo~c>wmr;X>{G6E1dGg5g(lg zW;Pl6@@5u?*e^AIJp~4! z;h+XTL?7TRU)0S$8iXxx*dI_~T9SVZTrj}@kc|R-=!a|+K9>I!xSgK6ROZDVJ$N|fV)8jZ~&gTU$_3ljA#gL)TC#yjpzmb%)wdWY3axLF3N=PLU-|-un z3$DPf1GMI3?mQ^

    sdoGMt&u7$ z&3QTSHQzs!JDo)YzSL9kmdW-Z8+12Qw;(OnuoZiSRuC{S?1PwR3-^0QtLI!~dFAl4sax_beNJbtr%(9Z0eE}FFchfD9+y-*& z2m)%%CEjCiv&sT67pIG!;Mg^;^cTnJ2f4N3Yxtgn=dU|CVr(Ebm^us%R2Ie6o@vr^ z1>t;+02~)%i>mKrJ$bRGn>j6f(40VyhrPr2Z2tVLMUPp0x(zK17=gNrjgc0te=h3j#q{%`q3c;Cmpb`+Zv8XJfE zuKDu5AM7><`7WUVbu=63+ei59v?H@(BaILXr`z^E>5fI-+J_v?yY_5gTG9HA3yNf@SG_Ak?j1Ptx=x(wFvVr%H;&QXW}uA!0->*dZ#kD zEk4{XiftYL*!{yakgYuFX9*H(i}4XUJqz+hN>V$E^z4GD7^E{_+kK!uhD$l<^e$j* zd&&Hs6y$6=abv5uCv0oh?EgMN`frrU{~JFQBN=E(bae50Fyrje^P_^)J{Rf4E!! zDdPQY?$%6BZH4DMbi2wh@QExKJ=yw0cDBUf7IS*7kOA{l4~r9AX@Vgb!{%y&!rNXS z60?_SBq&F-Y2ZVlZr;hT*us})3qq{HbnJ{N0%EeFms6Gw*Blo=>E+DVZnIyTIQp=t z5Y1Ep0h^obe!7!BOBorckNqc9Ak(-r()^3eu87`u^;4PodBc*zxbWzN$}sJxsT6@aN_j%Sq@JdM z@MBypE;pYKY&_`-Z)2KUIPStg}yxwBCS1Fge*2!`9A%_Nji2W(gg=M7>gM zI$2W*jbi!DhOuj>(X4jl(bwHi83xfU!=B=k)L#yGmKDq^`Y}?wX5R8`6%@uGZH%2+ z$ySS1uEjq*)_E5yzYd;66{#*4sT-n$&|34$u3^&>ob}HM6BC~z6jc_Dy|O$Z?#axn zcO_En-U%qkyI|h7zqHfNzl9ah)X5{0G9BGDnHUXe4T@b8xZhx+a?;jv>6h*rWm~dfL#JIFo}-Pu*oIft?iTW`Z6*x zc>>W^v{CWmM(j8D#4j>3?8GU4o^Sr=91T8E@#BAXc_3Y9_2q=30e;bbCq=_&8RyTm z16j4V(C@z@rIgjrwhhhqyP-(#-Z^fldEw|QBO{L@&%@9YHE6CZ3O6igJp2ggJ^a9f z=wVYc1?(-SwKk{XTqjG*-08$C#q>!SVGdMnuF2g9rOQFR%IgS7#BQ2)et45iW zuvb}nzu@b_>^04yEVQLFGW7zL`82WNENnIO%6idZd7MOQiXf#G600_l1b^?=YrBWa zHUKwvQ_#4K94ZT+@^zzSLQq&Sb}bBMslTh}18&;71^g1d7uFIo4Nps{`1RnIWr;@$ zqINO z_DvAW8K{{(U-%t3Ls>|V%DyK8Qv+4|I&K2MhG8xk;PjXt?eNV4J?i{+_G*8d;QP=I z0U9SIS^AI({BMt6V7(B-3{&*$*aWdjS<&UMwtG#hs6Odu$gyC+gkZoWw6rjiH3zDz zyRs2|w=d3)Wi^;#nWhl#g`~d4g-5cQtK_U1=2ChPM;|?8ALrRK5w<+rceFvS6mwKD z8l1sB$Dr9;ZyYhPrnqdbkhRs5$ZIDHc^b_OZCK8(+?Sx?=6BRS%@ARHV|it`EoVlq zB1F(PMI@&0Mm61qv8Tkz_m)T|!kazb=cD(!`n(P@%~7OdUaNv#fxq^-7IMZPNMK)~ z@N9&1lEk?3wB(6us-!65r1MpDEhm~4m9C5zKl5@vBorr?u)W5ZF!@%!H0E}7oG|sO z=kZHor%KXo5aCUU`VZAbVsBS#5=mL41spYcK#2j)M&#=?)hT9r-+OibT=IhhsUcB? z`EOhCy$85f{c3I-sO3@ddl$GHIFK(UTV`3NzKQ&C9ZE?AYt~2s5Q9Q=xR*Tva}C`&Qg$#?Kfw?X-Z8p8ktT z_%PshH$0@VTECbQTaV|D0Du(W*u*CLa*R?7{xGm=#CjD-MQ8`Xu;}Znbf)sJRRar4 zu5ma-9NyDE-MoHn0frfe`lZMXfw7KvfV2((N^OHmesD?u0{3_k0EI({_fjbbVn4Q0 zHvqY~c?Zp4>tMb9e^0PE1uZ25YZp1>9#bPJHjCmFGY^ROn z37+n%6v*3idp3PojZUa_xOpx_!O~0o-nE|i11EK;SEiX5fe4smyoL*1J;B89v)`s% z#o4yig(i0BH&|orN4PKf#BvitWV+EvTN3F?d6&93d2U03qg>nPlG@sX+SAs9nxm6? z66ypC10Nz=mVUmU9gl$D-^&W&a|BWJkg0&F?cx_%KLqD+z^a=?L_8zWx03G*?3r*1 z3=rO9rRc5O=KcG(@Rfn#zohEYCaAS~30m_j6+Rj1jcZ<4RII>HV3U}%5N3FJ1LN87 z8t<*sGHFG*2u3dMRoF+-tp@QO{k_mYDyogRg{U7*e^B7RhyqE<4nsHqxb5d1@5HU1 z93lj(eqF92_l2wB@4M1d0=?fqjayiW&)i}NnQbCyC1a6zrpN7GuR=mE5|#>ec}DIhXzz%zjYde~$wCKY3mz?l@xpbofQ; z)Nj?OKh4s%3xH37Iz%;1Qm%k{R=4gQ96K1^=M#bg@Dcn|Yb z5Bs3nCTRud>q3q08>$?r?< zX23F4plX%m)?9|3w{`VCG454WbqV#HgiXTMl)T{~DRF4R@=Him9$9~GW)>kIMN4=~ z_adiN4+QWyHiwu9FA{q9$@C1U?$^iF*yRVD;C6Uv6FS{DS zsPK65CuoXN*bpm8c>39mZqY@}o0m;|Ux>AsF7HkgJiVre6&Xxlxz}&2+h@Q?c;V9G zIgF1(gi@FtKf1?(icQZZ7OhD)rwpPm!7cC(3}*>11Ji5k;cP6|y{2WUp%Ssaw;&1E zjS=(WN+b6vb?f=XN|QB%>X^xw<&S&|?tuahu2xOC`1FF?3Pi^$)hSUK+$70exx=SU z+t1o(`oLR^?92x}RfQjP)h4B|kumg*b?c7)cGC*f3;+u?MB#bLr*0onWi{$icy56t zcU*#i>@nM|sp>BB1u`bC-|8#z>^xDLtoUCc}K zu1qj4^GBRmwWql5ey!1vqvNuqRmp4xH*HK2nFLlJr;+q&rb`~miUC}8t=i0rrZjNF z%1r>4Dq_`}?Zu5RIp`~V7uJl^1LnJN89>5LL~p_jv@Lv9F95K6AdtU6x}j*qWE%hE z#FYGg{Tz4GXNYe8Q#jc0XNYcFmWr=fCGz`+1FDKhF6`EU_mn^;@}M7x77;$M(^!t| z1EHy=`w_9zo1lwKwfM{Yp7TuuXDtdooWj3M$G%GqX8KsO{_v-tUY+Y~9O1PnbQioC zL{=mVfmSIMIn?={YDO(xUU>8-5c6~$f3;v^#mxFpXli8rvonuUTiojx$Y)T%mhmgo zf%wDgE!#D_aTB^pY*=DA_4a`D}Idd3+#AkXdEOAJ_ZP6a|@CTVJBCzMc4 z&6PPzm&Nu*!5ZdZ4}GzMOm%iR>TD>IuaLxHqO4qXI)nXi;$j#UScKrW^_x%uAPjk8 z@_2jE*Rrw z?d9n3%sVtrZ&z9|9p_@D2bMc!!luk$-=v_l_xkmoii6C_Frjh#q<8r;gEPibtGk(u_V|!s!|ag-=&_emL%R(crB^wAtDuJ%k9h$Wp%gXCP9|@tdc>v zL|6j7!Utu#AqllMt1cYp?Vy9>$P{{u(E1mrgK8q7C4>eJah$!nC*Tt{vcgPhfrXX? zBj*KNS)X9FW7gD9Uby|<3>%Yi&xo!C14ivoKiaWxUB904_B@h;L_Ve%C?dqiwT}I z)I$oZy&)u=-G|3R3+86RP@%Xdnz(rLJ^R@q8oA)rv?*0omI}vb-Q{O2xow+dgy4yE z`fx4>`^q)I>##FTXAU|FEy<=>BOQ#hFpbym)C$q$SXw>|&o$KxciV zAtVQ!&q(!Dv{S+l@`=ESu6m6eV~hYv^P#0*C%1t;?Jj{mIi63S&9OD1F1a%vv9OC0 zK$Wvv-Fv+G5OG zK6}!m-&FqRGYYRyRc7WUTBQJf+nN3xL3d9D=yg=_sKrGNlMjUPpjw*CDcV(B^B=#h zxh8AKcbxE`OTU*=h?NgjdE15ixldZvszi&s#q0ZgAX7Xnn#05M z(T8st1VLIr4sf(fs^X+NoyAKi+ZhO{1AK5-2&YsF2{W|aMrWQ70Wb&r)DNYhq?q>j z_Lz3HZxzBn5azzEn|&)ifBV;D55+z;=Wt1giTOOQ{8vWXe@9h7)7BOg6!eur^S`bt zT0rE~PYNfqNSo(&!QS0QGu;T7e zzrkU`P8i+zAtvWmJejWLB7d7~{hgV*s(G}_be!K3A^8i#d6h=`+BOt_!o<NnMX;%^D{5yI!>?CKPrh}oXvm`>j_dhR>pQc zx=(3+Yt|AIKF*UeB{W|VFqlnjV;C>0=^p4ahDgA>c>H!_q(=u5=oL8-QoG9ySm6il zH~dx9(%wrNUFow|7B9xk+fVrc`gh4bQ#r0Bi>N;2(OQ1qULnF~(la>1;R*H2(Ru+>yr|4j1E?+E48f92OThF#*r3Mc zHH2_3`fQO-v@*EAr|R&LMlnULX%H~Crf~=OnG;jk`nX9o&um3OX=U13SIy`(^^yapo0DG?AK$5j(fjkIrAngd z^8 zF$J|f<3=BO)pG9u`su|!o4xhYW4^{Jc>_7DF<}bqIq6TVMMsPTKudE?1x5w3dE0(C zv2U3iX@o&SAg_hX`~3WFgK8*uAKG6}7jx=nDZ!pP>p0n_b{9Lb`SJ?S6oHlXv*`s7 zC+O1dB6|-&4MTLLh)_DpqHndtYL@thT-Rt$F) zI!0W^VGAkkgEYyF<41ZBy3B7RFYHb9U1sL>wK-*3EB1Sh9v}xH7 zFDF-QR8C1qNPH$dzDYm*xxGT3#xiXAa}?!&nF;>u{e0yNxkWoLJytSAwBR|ni!y!o zA2ITl;nog;G-G`lF^WKPm`}X$g5%QdtBq18B#wBo@j6r5y4(mlH}>Rp2!}rxvXd6a~6B8kdlG{adw{&-1(dRJQNOG~#D|T3ipe#AhJ# zZpxGI{R$zzsFE83%oE{rM0Ofea=1a5Cr%%c&m;=udHF<%|G~mjTw65MJOSLRpHxtk zkKp}$&z-gEJ0`kbW-nf0)kETB;@ZUiJ zb6qp?osYVr=BZu2V+tSdlO3kSoBwnuwap6L+g#B5g8_a};0Fc%BNR|{7uxwKjQqrp zqC4!lb7;2Bi_Ml>L)H$9{ur%(P~d-$0vUpnt&yvWNN{cj@b_J_kU!D*f5Aj@?sYzZ z<5NPJFUL1^f~nFl(Ql(8{PFCierQP_4s2(h%D5Ih@5Xwx4pZTQ?$(cXSYa6A^Rld; z&ngn`r-9cLp242-EN3rFd!295l>jMtvgR{PvxsGxYgnyRnP*WgQ9s!btBYcxUFb=u z7$!aE;Kc?WfWJc-AFy({`r>s`2sd;5| ziOhYx^dx>?(gbE-TGEZv%}aUj;}|GCjv3eQ0dOzIPgEc;dcvCKF1&hm_ndMO{~^Z0 z@Cf*cj1m^8WPa{LlgE+wvGY8sx@*?+*Hu-s&5g;EZKF;NHMh7?C_*khXibpzOr*cB}r`){+J0b3#_@*kcOYlkDIF~Ox?#e0GXg2a{{&3TJO@)lm z6Q#l^xS`-K;v1t^a~J|<9h_gkeUsT7d9kbVW8~d39sZDpq~-gcCbRi*Lw&9YI^pC> zj&$V+(&_`34~KmqjGUVTa+~8Bb%W~~_0hG=nU8l%kn&$ekuRJEeaI7cLpdm0Ja#!x8yvVKroGh3AXJ+amJ~uR-W;1X^s>6#P^p zHZVnV^>S?ot~V-$5=cC!JmG|cx5HbLQ2**&@I^F5Tc}=J=zZ=!sLF?}gul=Gt#Eqh z&ws1&;9q|HA5Xvgg(c!sC;y$okA=7IBG;d6EX&<%97AW{hS@I2C7MfrVwu0akj+c9 z^Fgv=+7h>1ZuGZG-;+P_XXD}T^r7!3iV~sF&PM?VI8td<(O5=qms)DH+5UEdeB$iv zEr(eXhe;gc5RijawyCM{-~OP#`oW()o^&MfD8Q+W^Cy3(=JU^LKHb$H6n0#m^lf3w zak#FZyrEt|F=LpYgGBFbf~LZ!WLnH=zW=@K-0o*lqRQzTwMz*XiU8~Gc9dvz?j}fX zt(7rGKK@?>-yhugFYS>)4(%iu@{6>VU&MbcgnJY+^Z=<3m3b&_UxOVI!&~s=fPO%O zH7sZ@v0%d{WvY(KwJeKof&w6G-~#L5vVPK8?FMAHlY7p|)yX6ru#OPyY{%6{-yY>5 z0@ZRMyUo2J5IhNk+`uU9ny)YR9R`ppjTs@+QwCBNr5ibeg2`5xdn+lb#eKBKho_z# zN!Xz0@wZr+E|P0rTuO}yR5*M(UO~nY^lo<{>e{X0Ta8y=JCe)a0r3&7Dkz8$MKC%! zf(D3G%vp}g03iQf{8ALIOP4SBwB-hjWO;3Zj$pzyTkvXA2g}3gJWExWdP0$=4AsWR z@n@F>OA~-M)@GEI7#k3mQMpfX{jOZkCde^`LS!v}exgY%S%qU&yeKb-`rI?jMLZ-P zoAkI5&y>MyTbZPiu~p+weeNmd;>J9h1! zIkDG81vjCi1H0oDK)c@ULGgehK%hO2g!&IaAke#`zcpcyP3?oIC~TBYT`#h-hXbn~ z(&l1z$`oYj&Fe)Ca+q^7Eq6p?KnWcI(t7YJ~Od~cd zf}BB3J7{N20AY%6O?^{iZYP-weDkwx@x25gW(3pn6p;c$ZWq5uasN}yp>st1H*@(< zk%eC_g{W{wec?v-U3d83(Aaxbbwa$~yztppL4Gn+?iaE6cMp6ihn#mlNxIWE?WaDHgIxX1RvKA7e^oNaq+AHjTWaOoVO@ZOO( zrKabVSs5%q$EiRU>qqn0k zR)neL`(3(opaQbT-_(&}YUVaeT??Xoz{=?B2-%UE{|>WH$zm0?D$M#yR4ks)KvOsjsfFLzT7LYC|x#(oh4{UZaWWAWz*$k`Q39<08=GY zY4bZniOw@#uW#e5<-3xuS|B?%J)VdPEGIJ{l%UvpZWS=DNk` z#dJTJyT1^{e3+}rdSuvX8h*Nc2;!P*d@>`emAjtblN!EaEjp^@$fiUibu}dPl}~)S z_VWRfxYUpGC(-IpOiids)o1-h_j`Wisb&C~rGz2dYQI|&|6~3fOdkp_^{Jf=jZ=;` zVA1xA_7`e+>$n>qjaLsG-2@$*ot1;V$q?^Qm7wGI;XNkfSd;+8CyroE_>u(o# zygXoez=Raq8wX5LkdWCH^1VVkbE0q9uN46auu6WV_B0|-G=9%*eftCa|IsqqIJf`0 z=mv6WyATIxJm1~L|E$VS{=n>~&nNrBwx!`ltlU3GyZ-}982KlYheA1!^ZGyG44%Ga z=Gg?zo%j+d>w9caa$N`{ban?D3ndVTX~xg|67cmCSXNa01x%K9wg zYa1$S%T4aj_C%n|e_`y{S&oR2PkgrZi{j!S|0{bEI3BqY_=BkZZEpg{5B6Gtee$LI z=-O|WjC81u@|koNXrS@8QlAMjT6N}Y4Fw--Iug@)gglr9JIatC;`=rD*@`1E?eOaq840Cs9 z=KCw9?!nYqSOUn04aNRa=pkGp8ujwo2gNZ1kZ(S&eh^!al0>`6<>^f?wYtft%Zz5k zh$}-PKubK3x;$1-Uhifpy}13_k|MNlad}ri3C>4z+I_4VeAz5m zy56F3fWD2PMMok3nV#arVp%_1Fw~5AY1V3KH6Bkch!l)uL-s^TItg063}m+16&6}g z8@5!x7qt{DyNeI!!@2%+;UKM}jSX5o%^ab3w*lGu;bul1-D5tGn(q|>c*_N2q(Rr2 zoNSLH?2m^Jy`#`-0IN*j&vEOC2$2`2GrUqs*aQ8`gFd5#ZVDt+-pODSbxEChpBbzWzmgKIdf<_dXJm=} zQ*VN%ZOIVC?SWl(jJfs}R6y3QBG$QM0*p_&WTsh69hm!CK3A)Rl$*n z4nZ*P7>bj{pgqhEFdX__ZN?WhZ-PXsm2=0i)(ki^NLBlJG$H=VMMOJbIv!_HmmD-+ zr&`j$Y=T@iL82^ofwYa4(~#vxMCgND2CRF=90udL3A#$YG-Dn(o$=iq^N+?+#Y!GE zz1Dc$liuKBP3cMBtLNW}ZKWoCoxgKzB0m21l-SK0Q2=VOO*(u~jpBOiy_RHV*}kD` z=lYaSJrL(-6>2am*S=+?CDycjne!kOy|eY(Ln--)y-_y+aj7gGKJg!*kR_=Q5>Mb6)D{AsmjtDwLeCqMolQ{$3cB6dE% ztk&$5wAo(#_RanW=<$C-n@aLrRhm$um`!ckw%V|;0Ot0;mm>cQA?trIYhv6%uKX;9 z9DoXy-{yva!n12p8%)>nH7Gl^zVnBKKAs*&9BEzz997zfeWzItZtSbLt$)IU^pxC( zn`R7?Jx()uUD>{m3+eG6nxW||;S@^xmQSt4F_8MWF?FfP@pj&o)P3Rlg4SSWo6|nY z4uJ#e6!Ra)Jg~y>=v%&hH~QKA%5()6A$On=bLwiZC%8}aC6TzkSs#J2(>^Y!#waz~ z+z&O5)(cuWmXt|(m=O~$YhPUrRoOTq(!|0+bE5frny)r0<1PnHeS+Y~NVq8goDkO` z6stF{ta_nC^Gc$CeSHppOFLJCx@tbf#Y&C~7aOZ0pW*i<_oxb4?h!I2HoZ1X?0@bK zVvig!SX4B=KatC=p!rlkDD<`RxW$ofy~AP#^!K0c38Jc+w65c!zMn9G;f(dx;>-*r zQg#2lA_Dcs1(xa0bgqr1>`k3`4}7eitY_*7e3ecmNVL$k=Be~LVqb$%V9CYb+;L8+5r9Yxw2$1Dkcuox*Z?$g?rHVOBgj^aTi!6?bcX^dhe85ehG-#ULjIQL@EB+@#Kf);tvGY zch3BN=hyxXmJ3A&FV2^~U@Kwy))_K}>}UjupE8R=;ElMHhJ*+8rPC3{@ORy1wtduEZut z^*mrcn6-CGv8=$epyqYlE|{x2BhOK>L^9wE;$~Bub5{1{^i!>6wiky{=Cm3SWkeWc zJ_=uc8=hMvJ=Sqzz~LBHv7O&|=tV}s^=4@|f(+|YRnf_Amy?wrMzlr+lAP95(W>U6`KARmel!Y3b_@&$}F&B@<%^0yPs zys%B2(R?>B4Y9FL@2Ir=?xo6nW(|im(x$a)-N=#9r02ruba-R+>o-DIb39Em4|k@ZY{L} z19o8{=ql*zq`uFjTQPAD!y1?KZZ-9ED^#~T$S+u;;q*1akN&fF%Y4mmYb|n)sKm`s zJ#1o|;3W`u#J*MgaLaEt$;;t>zNb7c%1A|2jp53Z!;m1!98WTVRukV3tp{OUtQr#R zwo!WNVz`bQe&HX|5sZ;~8zNH^XN}Daxd4RQyaWF1>p{jJBN4oBD>_+P7Tgae!IYY()P&WiI1 z>701IqIs|54%Mdgv^w1@a~dLvYKSMn6bB6t(Dzdm54J06Lx&zkKla2}(*RmcA7enH~a_K9ut z$A(zTt@8IIDo+ew->^$Bxo^A_&UAP7B;ueBk8#aktIqCU(>nziEFw2S#lD*${S@xc z>7L}h33Bs?EHOf`l$)THMCf3&JC4YG6SNPCOZ5Hn%BasTjQ{rQl5)9c2srIcVa0W$NT;#aC}2y05uI^%gP>y7BLI_zH5B{z~n^ zFZ!ZF$tLKt-uR&C@9vKO_Rg=48YlwP*Ak6EJ{HUA@Ov9dFE+y2KXjuy1y}Z&W(n}M zBdu7=ispmYq~EJ;FmwW-Q4V7t7P)3DULkS+QsEN8YwORIk8L*5Nse z{Iz*%0dseB_)MD%j1`xSl{km`X?1CdGL<>uQDfO36yJC^RWGTR_B<7s3PBtDa)9@$ zGKZiV7klnA-4flBxtg=$w9B&`_r`CW@Ep6y{bI(2gm0HJQ7MIX1g z7ZGTU8k?a=<$v+E(X2xYKV2aK8ztHVF*Y<6>2^MPoLk{UB?_xO^Q!EyfM0s}#<-$e z;D+c2dXYAc{atJhdd#CIou<8CZG!r*W^kl-acQ2ukQO1@7_cazbBO?a&tMFXA)o3y zh7NNbrlK>6>N{{8w0OrP^Hw_UBR-0*p*__~wZewN%fP$B*NXn$o?54h&b#%i!5A-J zVfBJR%p5E$@#3g#lD()NV*X-u*SkQle&j2pM+Ru2l<*N}t#`)b+(#8-14 zQ+IXWdA8J7>56%1J#m}W3(sU_S^O3i-6Syknvg5A>C?HYkHPUVSJ`o~oD(t=ZzOXDSff9R?S9X@mxsG^~y zt6uqN3`qrJOD$Z+gQC{YIFI%m`j9qw{CV>Pm)Q~i(#goU!v z=5)%2C3y*@{=K~m6L^A;!HSTX){<<#fy_zu>+fzNOZN>W?7o34N?uP*{>S~#e#5wjwg*9kQ^Xt8fz7peEvSG%z_q&KDXcv>MN#1s$pBM2HVUsdKj0gy?VZ?9wVW*M z+jjw84VsVA9OXWT(>h@+3-SMzZSP9oy*o!k%>pB$K4;YpD!zm z&Z}DS1+75ef6azpn@XM~NvJDp*F+5u%NH)@>`>;&Hz#2W9B|=b(y2o9x309wukFR! z^%5z(5e@Y;|4vVH1?gSwtrE*c<^F|mh@0qna90soJJ{hs(IeEdyC*uMli6?0^cLim z88MG;8W)CT=uUnOR*MxReQpUsTxs9eeS=q?4-T$XbmUBU%f5UjmO~_E_O00x&ph=C zXit1e{uF+8cJq{xvPHHML2)6Nc2Vk)9^sf&Bf(#;+l&6GpOlApi|(mWn^Wi*&vQ-t zJ#5VK0e3I^y`gtDL4I$)F&X`@fBf$mQ2wX<;~GO{YQF4hm4m{`r*71Q0O5ID3t0VX za+MWOG-*=@?fc&F!W^}Z+@WZv$JE0)D@pO_n9N>Zr_W(bot&R>loP1}i$XB1%HcA@ z$Q#Qgg54=@_dnA=kU~Y(-YlH*h%>Gk+DsOkK(En-T%+P@c;Lr0!&aE#m~Z1eJyC8R zUlR2}hGLDHX|0}4R)iFsMymcQ3p2TBdi1Ll;Td5M5}e`7ig9lE2Es&mxF6ib2~}sl zd;9Y8*NfG;-i(7}$}+F%Wd?$in<(rW+$(Y_FW+bicBq05Z_dpw+F<0?etWAxX~TPb zKdb8S?d}gTk(KLs-2$JB!y=od`hxav;@^}t1S~|qh~BWO0)NDyH1V*!X_KWbedC(~ z3U*JZ8o`&q6TME5#93oxAga(_&|vD(L_7Vd56XuT?ikdKLR_`M-`h05s&LkJ`o-@;oFC&ocfB1X~>w-?BKh|a56YLb`a&Tl&QbsG^|a(HiYliM^w z9R3AH^$paqH@kUoY#gyPgo^h$^9{s39bCW02S{>hI_P0kS>C$M-+sgvtaA9(=%d!^ z*)}8RuP!JvZ1Z%J22B=sI6Ly8r#(tkFhMWIf(o3t@7{70xpHTEQgH*JFcJ1U(@=3l z=lMvr_G_c)T6yhSPeVg(+k63%9yV@z2?XZDFSfHKM!A;wdidmdY?YVij_TUNqXtPA%tal9W_@TrzSa8CrNi(@|(%XRwIe9NsYTjb*!OaHP7Su-?Sjaen#4NB* zPl4!^!z_{lfiJhChbol?J}u8)GZJ^A0&udKR`W0Ay#oaISJ=hybt2;|JW}Ug@m*-V z-LYT5^OsctD?O6S13ld+&s;fVLCdqSuhWOzx4yI_A9xrjEBL!J(YF(f9oo>m6K!@k zbi2XA~ql<%3gw2D{##IeF(#cbHhb}B)xW=k?uluIB^e^hKnq9GO)>Mojm zZwQsqK$!Yp~LlD+MCoNnB8|7zrsN3svdQ{v^yqe9)TFw%o00(w_~SFVlD*{Bn4JP4 zvl+gpsDf861Fo49W(zJaK2&`JS;Kgu-!f(7`y9r^@0JKB*_Vz-_(a9N(uJ%GEX3@b zFD;AqPh~)tTMVcVCp$*R^lS1jk}`Z^<)7;I`UzmlGiKJkj0H5b8M5g)Lia3getJQ8 zj5rBjtY^X-YGB;zgyVDgL$#=*ZXFcAUHafF1ql(~o(>}l<#@=LB;Fp3zm-ebe%^QV z-j0QQ3b=)hz&%qDWrfuZwiwuDy;Gf#Ty`hlslUZh9pzhsUO^G#ZEm)No~)^g zMTo53TAykydQF@cpJVG?BMBE2uCP7Fp1&o$VUGNGa7xC#$kqxW)eTssgX|N@K`*|6 z8W;gw7=JWT%%y(kY8DxUBui@{W|K1jwwnRL90q`CA0YpqU2bi%d)V|g85}G#k2S40 z->6@vd+rHm{|0j26rzrMD}DcRUdY2p#rf+I9D2dnpQ zFjyvnS9vv9&A`w3`g|2#rm1C5c+No?$5)RVa7wCGswNpB^5a!3BK)o+6?T~hd^j-T zi=nbmhkVgTE|bEu7pxu0#oFf*ME4K*QV;45G3_e)0-X4lKiEYdyTPcpSb4H+K!T&9 z{ZsFYW`MvXqx%8O?#i9*1Ferfn~`$g@GaK|zydYjGqe@lHmR}#X55_bxMX!&XGys@ z2!h`(v-S{}Nhe>%l$BSymX;U>J&s}5AuD88$Z01yJe$I!G}zfxWVHBrgWhK8ufFCVUH{ea-@mMT z2W;2nYa7TMFayuK{;$%&c0E;NcBIW6o1(pb2IrTkI^sf7!N>42CyMrdA%#Savq*^5 zN6euf)dO4kZcWyTa!csN(yFNMTiO0|Be0dNnAUf{x5aND1~MC@h4t#Nv9_&W3lGa> z&*Z)JZ=gqJ>Atmv`%t4AwK!>X(aWwy#Mi7ZweF7bZg1#jRLz&>%OZa?!pXL z!CeH<71cE=-{_fMI{ITC%Fw=+ugSc}DxS-=Y%nUEq9N1)XYG6lHI%S;OK8|Igt96`f)GXR2Z~hyI<>m~MrZ@Lm zexjgHo?dd=2Zc6Y|HH_KD>kTT;zRlX9|8I7m13i!tpZc~=u6bBI1qzxa8527f_*A~ z43ket%k6Y(|4Tf&tCN>cF9>)qSq!mBDO-Ly@7BHq^>59k3%ucqQ%8Qmfo`>()s}lrh$C-^uD~+}(UkZrTZ8S^ zCnld(?puV-B9V{x5Bq8NufQmXte!Szr9m4_Mn1)@k9&J7eF7l-%dR5+BW6tn=!(m=&}wx`wm$u;q7hc3nk--qzp|Yp@fh~T zVVw_&o$lG)(MhToL?aIP%_vu(!)X70G^NM252G6U!n>?R+p0WmqDYH74}4V#!;)e3 zRwQ9>X+BJM*Kmc+mGTjK^d-4K@GEE)58_%IRu`yhlhJDh0N$&ThS!yJ#%A|g`QDpt zU)tk|Ueuf7Cn0yL))tV>l41sv*&oJ@>7Z@K z#ifY{fk8@~?JVbO#qJE2A*k`8_5~(t>PjCpq9WUlN|`^La10RmooVPM3^JsEs5=|Z zX*202)aB{1jTCBZ7MW2X?4sV+^34e#nDD0U1{KEP&Riz4iyt39{)j*6R|j7cIff6L zZuMg+8ZHpZSoS6E zFvUhwC4IP`WL#q^6WH`|b;bdUT{LkU&5XPdehPZTL(4a`X(e&(VL4>G zi(KICs=#l}T)BQd)3Jv|*!XeMy>Umyom{e)E$!gc%>ed9C%% zUd3HC*@(w7B{g1js&amrXw$wOb!aR4Z1CM8O}X`f*j{c9y0wj|z*s0O2le)d^ zz6x?XZ_WXT3Aj~L8VjX2Qh(@?cIk9K>pABo)&1ZRzGZD6^#jOKqFb!$>}qJf$Z3o7 zNjG_feUCvd6BbAU4Jt!E0&|DNgragDN?f61lLWs7zoo7epW(4VGhr!M6WX=jC$mzY zV2|#L?hBk?!!U@$Xz>0KAI)<0)FT3eBHNdgmlQTm_&Q(?T07@qN5^fRX$!x2X`f~i z&Oa}OI~&B+hOWT-&Mjb3PwmQX6 zz@9zw?n7mdT*$fLqQcDTq?JcM(U31b4)g2ahB50@f`ZU|&VgK#WbY-Q{EhBV^omEJ zZW~$t6Y)gmtIc$VscXoR(KMeeBq`okkDL|uyE6fWSbfe|t+je#tT0D-KYjMThu(7+ zMNWS}Q1QHghGHc{T}7Bz<7}$aYre)kQ=Bzb_;lKhlBl|nv=3>S;vK9tEL6{3iQP=P z%XH>hDD^GC+==Cjg^$!*ZtjwK059bDey2&@fg}Qj!?zz3YIa)(PghD3E$xgcH z?+qy4{=ah3|9x`Nc!J(c=$H5*ZbiYac8co@afVJGIZnwISEoP9c=dATB1bITUf(Q$ zFF{u;@^pz92Nh+ky3aE#xLwyo3d<1}>^gAPG~qE92(}qR`nuvP#hJGt5<})yV*=qYw&v4=+ZRTW1H+y#mm+r+U7 z7nn_338W;3JieFu#iPCAplodyXgfc&M#Wzwh89h!zgH3O)EG%oA!&2CDtl+(D9@Nk5nR1A;xHe&b;H7oIv#0^x~{|555s zD-pJWVEd`mACMnX>!-K)7bW~xZT$Ct=xhMx$>m{&_iID#wLb(8B7wg)-eFuY2RLqwg`Y_fW5HoiQvKa#a7&t2B95aLHzUl8XlFuF8D#Ku7b2w&b45^RIb>&Gbi>cI5S;gC83>f2_dS5yay7n+BEe-v z`390Nne5FV*P@=fov*H55ikwASm$d z+jo06*D41UodsB9LJ`xDp6X->ek+h%h1$wf-8-`k)5PB-->Rb}H)0S=WjQ%;%i8UE zK4KU%a+i!G2;c4=fy{S8R^O17s-Pi|Es8)g8URKr*lfXQ5gpU-zJW%FV1g)|xt9z9 z#IwS1;_9hD?x6`l#H(h%+SzVO)AW|RU zUqoAj>0JzK!X{)$#LcQ5WHUw7NC?o+2)b<$#rEe)TvscKKiOM`a2~h?K!W*LN$^E) zcyhS(u(x%3ki`Lto#`Py48!jIYMoENATyR#cca!;J9ti@>s^8h4}&7N(tO&bMy8#% zry@atrs5Kl-V3M{$G{p+`g#-^zSMovB$DpqfntS;r@+^g2OI4-H&-`J3bJUQWEqn3 zzaj)3<~hEBA|GiJN`C*y|4r}zI?(>+mHhhz^&kDKf5w3pHusfQ&01L4GK%HAM!%W> zl@?_V4~9z7(U~fvH1Uj>^6^ubta;-Daw!I5Jr2FAtP1EKQwx8U7IgGQY3zqaZP1FU zEQNjoS`ah2JLoo?dbYn%m`6(GZEfUa^c&E^umvhyR?^p%vn(s*YF>CK9m7QjZg;aK zkhJ(K_+0OaX=7zO>$wyBb8|PJhOu`{ekOqE)E`Yw8GJUB>;BRuF}!qTt811?xk{Gi zQ%!Bz`*QE(k1y>C`YgV@YT}P}@?c7H_k=&R-IGkbJZ|{r<43Wl+FT15f!Hd1*^HWM zZH}xWrG(?lv{*$T;woN+1pn7N;L2F{;Ih4A8E^?*jd^)3r%3$nm?uf#U%hWro@et5 zndulJYQA~IXP=j^Zypb2#n0bUzxJx5R2aacA&wruWSNIeTg zoGFpxf71oy$BU4a>**1n?~VhZ@dZA4GxhsiM7eLEhcXT%wz4f$z&Fr>H)fCYbiIDZ zW@M~o#(W1=7TVCc41+U1iR*uln3cpJNhjDu$j8qE1)cM#$&3iVP1pAcU;;BuB4qx* z8DTRu$DZf0A@nus5$`>0C;Jgy&5pBCNB0WyyhH2@<|`|bq~FBfZ0E6MHHMxIkm8;y zFW5L&T@f`m_2_GWHa$nodka_D03bnhz6Vpniq+2I~-Ci*GoMWhx| zsl}-#zZ4?jyhH22e#J)AmPp+)aqN_(v!Si|Xe>XhmNyRU*m+h@%f}(L^RXTr!*=!I zL@`%K&bs=L($K8<0A&vMq7oS{5J*Bbe;jcJZ@Drj-9s&IIP&@a3#mHCI2@sPcvG#QI9cm%)Ut9u=xv#}Jp+?xC z@(Z;|iyDJgGThf`8JDut-rx?QT?Sp{oZHwwCvCxBtKCmoiv$Tm-@S_p{7kb%)W-~O zH>RE(*j3kgQ2p#ndxG7)fcJ&{o^s>M4SR*rt;iD&vaGWwAX-C~wAm&`o|Z#L1!&g! z;wI54^j?23yO!`W~)Ia@w zqH4rR_2<7|)A4=(q4{%)+N?aA`;Q3XxU6e3%~lS)&ADcdS{g0K_vUg|#$Fi6NBZXU zL}5n9J0GvSoX|d9L@9^Q^(xO`j!uKwIH%Q0xNR9-%amkN6ub_2QNI9IR-)NRtzN9Y z0pLz4QL_y^E|U1dOJuSe!i*KOJLQ2NXtu^p#01g3wuAaWD=ogl~@5~~3=1!kM9Pw06^QjHJQ{O-odxiBl z1m=YfL9snd*zCyMauTfuB0yZqRPN&;$c+5%2)UQc5H_t+iB;@+FkvjFU<1V{WgS

    O^`4V}^tj^B~ypp1K7Ndz!o{6uMFdwG)M`=qfcT))l{)sG<4haEEtECIX$XtT5kFELDR>|z?2@(c2#%1y`RNSzVR>(4RX?2 z+~li_;%do3|0!~h#~yb%{44atBeviOAE-mdxR_k);IoWZTjOW)WWe^& zs`(t$D_QY3He8}uIdr0J*WMWo<^-#cwkG*&zE$#zQJH9S%Yt2_xnr{_m_UIaCV(?WpV?HPl z4PR_$v}-mQox{gNg0I<8-z>&_4TYyKW7o>d)$>yGy^D5v7LWyxh9e*SN-=a>zkys|#t=-==di-*;?bvVs$+}Ht7{T0_zv=0q6e6;^r5cj@;%bD z2jjzehbBrcK_)GE{9dBo`>Ohkhb1bkY&|<182G~FHO;Wa=~4X zy=leroPIN&svbKBUjrYp4pzeGgl82Wj%Al>@kjV%3jvB3qhVQ%Vd-xK%zGwNP6>m&6 z|C3nwd@mRN!)hD(Lh}6=)drbnrGN$YV;> z674}8hII`99?IzxirMgyvE453M5uPu^yB$1pD*aQ%49hx3F#xw{1yd+kBDv<%jwAY zHb;wYClH>2@w*V5FJ{mnsLmH<)L!MXtGB*KC)?g*xN;gXKeS`#%MMfeq{!4t)W#6y z&*D9Em6nbV$B0jyh=_mG$OqP*sE>3+F!?~}L*%(^VyY>{)79N6&3FwitF{lhi_9Cr zT4D6fbM(PU>GuBJ){MptpF4FT7#w$vKjKHaOpc5on@z;~%M>nj%)Qnz``j`u0N^6h z$x^77wI@)Jpjvo_O@Mk#>$Uv$qENIhfLBo^I>JOf*i8^8JVtI09Zu#BbJdSFWAs4* z;lFYCIrJw~DSVynCo|JOky)1V=KA0bCLG6^n0tH{Alqy4ktV=*6pSzj76?(@+|Y)xoY!jLo29)4|bR8 zsfYrSLA9q%2>ohyN;vme7ohS+ZftJWctA6Wuw(PRU3`bu!hf-%LbZ%n1cN3NP8U;* zmamg<)6c{BeVj@HM&|6soBi$2hUtUW#@zrBgc^&AmzUOWgkvSvXB#9>Dhm3$+0`Io z1MwpngpF7CALzFV@Ff`}HtCms<>RVAYyXuYg$(~H!N8}&yVL^V{ zedO*vhL=P|TfLVr#yj#pi*8duLMXQigK-X(FWTn>Oj}wqrxZ;ZqhB5)UI)i}*L`ol znl(LoTY#+fiK%SE!bF*Oqq!yxr`0^=S%epkONclJaa8zV;B9_62dP2zhhhAC(eZ58E-@QK-Ap=nt* z%*(eUvSz6DNc%E5jpbrh-dA;xrATaezJxV4K8A8Q@5!fi5cB*xO;*loXTda=#}U|}n`y1CE*I)*Ll<6a zZYU{$_*1h`7wYJ7_5i+o4!UPopAx@>C~+qMjyFV&9dQA5layRPf{!DOJ1p{gfBD{i zeSr$z-VRxMz25Hp&2|o~vHI-qvRN;@sjI6P$hWGiiGTRLj*wvFC#~agf0r%&XWRt8 z-HyIejja#O9JCNl$a%Sb7P9q0ej39)h=e^5m_*ZhfIJ*-vQ52Z7B{|eSzFKfFyC`@ z3kEtP!}cFAA}!SSb`3vXC?AQL`+89?zxrvO<RvTE}r z{w9yTvC!k&0as|wP6n>20MW*WQ2$A9QQn%(0UKapR-1zbr(s3>UDd?6_UA$-3}?(k zPcn$^e({Td$Kn%bmxyXJoEly2XpeW2%y`!Gw+=`6dcxA!7SOzSF9-vkTB}5KGxcI* zEBc5^3SaIv8Wfd0)?ux^-R`DEf&F} zR=SVt^sikb^Q#cyUqonDV?7*N4J?aTAL8_fCPZ}ZM%9PKLf8&0fC!9BRC?y8CUnR7 zKdi8-@Hd~0nnRE3=-&IFpu>9D9Vn#mtJL#95V%yiTF>EOI)?MOFucy7mu~K2^#!P~ z4u4%a;!;^?5xMzRSC_vb^(ouphIoO5%&YsGraHQ31H3o}AsD2GCOL2zwl}E^gtZ-s z0W97}A)C3;2kvU$K*%M;CJ<{ckI5oY=htsmLuSwRLzd1_lXjJH8-Q^f(g#GpY9X3@ zXQ2doeZ;g2qDdhg(RYLXU?qBeQiO~EqWRHzH*aH^qYFBDye!kG2HGg4LQ6{7imY?= zr^SQ{x}4%!A7o`f;n@ZzB|>FQx3$cl$qC#o&`$a@dlvxWYo7wye0R8tfq%6sNoF{~ zO%6DTnAS#;YBGSz^*fNgA@GkyfHBXl!8<1d$%M53;tHU*N3M3;OY;nfJgipf&=uua zzffQRGnf_-&tJZ%8N~0UooqM`AF?ce#Y^+}c53`v9e%Ix&!4@RDq!eo&*#V?dd}VL zyW9(TCZWo3aZHtk|EypO?oiT3ky5`5l_J&4)CL`DBHz^MZ=g53iKIP!Ad=}XE6Ih7 zSHpLM&{Teq6$R|ZfE9PhjCi!*?9CwS6L@-C6?`PBDzULo+sJoMB(x0Sr zp3HEJylZ1!T@X|R#}!;#k$EY}w9PHe%BiSdUQ56)}h#xo6z^b^Jr| z1;;8VYhJv#`ge;4lL?M6qFxfavE>plbuKZc=g@Za>iu3>oxaimDV32;F&8F|0YwK| zHL<6WUPVg+jAX`58bqJhNAf`~O?N4u5naIPY zOgao$5YgG>$^LJkMFRL>rF_kyz*RtMQ!q<)ec^C=h!ZDb|zib;zl zn+35}XPS?+!I9OMmuy;9HU6aSXbzUCadHi;8$=Ge_1V*YRe5~Hizevn2CbCO_$!@@ z+mT%!-HMK`ROu#mEqQEK?8%vM?jH}Ei}Tq@N7A!2v%f3j*)~a2uihzgB)wjf$T>F_ zd8xr{S$ku%z*gH}#U)g4hFMNs!PVQ&Ja3ol)ibvP%cR^!lbjQQBq`KnD=r{@XFh0g96uV1N|!n-A%Xj z%#X;yAwPY`pN?(zuP5?9-jzuDC|OZw*~d2v#$<~x-?~REVf4SGY23dMW2UyG|JnZy zS9*VDS!Tyds5hh7Nf32TVL+)3>CZwDQ%nv%>*lAzXN76GhU0g&q*U3dso#=LXjTu| z3TA8-+NXuxv4V3sY74u{2uS*{WuH<_%!G3%;;6Z=oYzduR+G7>}5V_zueM zi)2^h>nyYUo}rL1C`yWJQ7$hIyBG?2Uy3+CiS>4&X;b)erUs#~xr3rsHT6v3zG~B2 z{$(8G3$@vA>unkvI=F6H6lZ?m_JJtO{+93kqBQDk;GNpaM@>!FpGU|%mfnD7c&9#@ zgB@976GFc}Qe)~gk!jQ*6X_B)UD%&-E*k!IdPbhm}fdQ{g)OOtUxg$u`s|#mkCgyS=|s zB*fm;f#FzwL14@CT+dI>eVRx3xL&o($9H>VZm_Q#`c^6_UPqgzY<>gDL1+-o>blAU zKFYjb({hF0wNo5rd0xzL{VdYHa<@GLGTSA(Og z_1ayH`p9>F^T%6EoO~94`>G&;^!)zdW_F>h=39g70~0popKb*TZr}kwDOMuXnzGk1 zXIzotcuCC+&6hHfC^CJ~i*^Ux0TIDj3lbsAYmwtyR$!b&u-T=k>GeJQyf1M3>lf&< zk$eVrx)CSFvQC~xL`jY}93tCmkzcHf%%cL!jwJ{L)xGDL_w721`ueQi!1!OdyJM*K z(eB2uOrA_gq0j=Ws_Eko&7Z^mmAk1~IZN-t%mdQ~X9o?b5us&DaWUM?}I_eh8i9rA=KMucY6=S#G;< zN~P=r7FFM*G8{W%1Kc%od77GddQERRb|D41lLNu$=D9khGh^B52Ts04ddMH*^1Yvl^35M~%?uxB zfRPMy87!*D9>2tJn^!039?Rv!?uT72yr~}AF|2&*WOE8c=ckiTGO?pIC^3Y;R?uc@ z4rKRtqTp=Y74KOlK$`6&HOkPztqfPo`|~@vW@!>Mj`o~%jL|l$>^mRNW31|w&tlQ; z&{S;a0;L@@Zg%F%x#VH4fBI^8L|_aup$7F6^({sGN}r7-e=s2JvWM9QHVOBq^m^jP zRbR)R>#${@UpbmrzISr+dWpjMPDZQab#!$63ygro)_pjf$1df{j$CfH+Mi`MtwC2A zq4Rx{D`!N<#{*7xo@+R~lWlMRrsQe2BY!)K)I@t209s&Ii74qPYNL~syxsmYLt8=q zkRWrjemvA4=|lgmeORyxf9W7(`n`5efEGPFN(rdclZU+>cPqB7F{Z)dVPBwbTFiw| z^Tc{LnT`T8x3PkA4ScMvx;1s>MT*`zvAkyfdb{FO z-Cycr1tz+R1UL@0=j7M_^d)kEj9h=w@$&u!!TOI0-5+UjOYwo(7SaI6D|i&Za)?f0 zK^vn0iV8|dNcb+e@t19eUbUk-obus@nw1sdX+^KvlAkoblCcfT@E0=ffb;^1_SmN^xoEmE;v8C=Xn9iT$BanZ)KXe zyY@I25Z`Qmh;I%=<5`mM?%HM<;FElbt(LSs6%#`^rDZQ3d9B|q$h#vg#xdTkV^eE! zC|}6(kyUk+^qJhE1#O3)Hf7q+A5QrP8T+Fx^+%=+ZTMZR<&!)Up^TtBJIBWjF&uWW z*B1uM$IwXk%Ry5cmw33(X>Ds5u9Qn^9(_|CrAiN68j8CW{^9`BlQa>>48;$Yk6i0c z*KBF!QS#G@dNb@(J@x7^>U72X^pM9Npl63zU0+{gHINoLud5lP;dvyp0v|lf6nS^IwG9N2-Rgz0<5Xv?r;^DoywUX-3I-avEW-R89d@2NpbI#0j5@%%aW z^T3oVF%gdAOrg#*VEW!11)l_@RqUn1&(29jVw?l&M0Z*>5}U7?Cpu2#b7`gp34m!n zuPNX06*bm&*)95$-JqvFT2_F)SiZ)R_3lxTzF|0=aJxtoarEp=w~$_-_fhTu zNsT`+JN?(ltdIb#zpU|6|K@DXmg84X_19HBV*B6^`C~TBi3jA5k7L)`*0ZE~pW@-4x3nlv5)jnacK{ixH& z&)&B7bMLCvdapSZv-~Q|1&i>2K?HvthO8- z(h0xv!GB#at3GR0r=W0sllzL{Z9tq+)to9E+!g<>ZfZ%oyWu2aCyj3xDKKn!vS88% z2QDN@owK%h9P{R*=n~ZxAg-^&@f zMvmP&RDp?!-qcA&W{<9vTYElyoXEVPqR%Z&O-;R&Q zy*uA!iEAY;`9IUIoF8`6-2W=u`6B{2SymlD7#7IW*U{s>*Lgmbg=-GgD(Ku2+cG=v z82_*@tmbsiRW(6dRu&6Am-Crf1ApR5*(*tHuiuSlv}JfQ<=;JET9Bf8e;0DrhBj{; z&eD>o$)j?&50D~GbWhf$n5w->;Nb%mZR-E@u>sq{4_kotzw)vFXhA$=T`X62Uyq&4DoNk`FJmBhG<`&R@lUvYCaQf1WpZHdAz-}^v z-lJK4Xk%!MR`qy9QACMP))V~52QJ!SJEGkD2}#`=-A6(^SFW^O>E24Eo;Mh4tC&ND zk@-$39v=}_mB3v_PBx_0&d`lIlMj`ZMLM*?n22}Jhp`qK#oDbsgw#Bd^K9TOUL;b% z;cU}kXaRhR;%PCXDxUGrO$hfxUfcdM7QJ|ym2;$2A5Gr!eQ{3yODY`^o#)z%&Os93 z*}*tZ?45-1g+Z6>4DRz{Ji%NoPs#d)@4%yrtyc^k;_mmqdl3=R70cnxz_@Q&>A;8= zYmq;Sj&xPC3>JDR{MNQ@0pS{abM3KjUJw=%D0_1zd}&0h{E^dWzzTDhJrJ$!BHvCu z_PY~@8J606FP6CWQcI)s@Typ+uNye}6ZqJfuC3<@?#1Aj6^|zNdM#H|>6}eAzc(OT zc`t&|@2WA>T|Ru)5P4zjiiX_{vF#6Dr&!5MKv=kw_XF4c%{hm*@SKgsPd)<93*$<+ z)w7lSJfSzZAx-t`bWmHmdO4yx{*$ZR1VQAPy-)I^PSvuby}g%~Zdu`VNpCyXpNxFm z0n>Pdw@JoE@;7;pOun)*d!~V?U2{yu_o#dN12Uv@c7mYZl@9KgJ+@dkmZE%X`@-Mq1_HWE=5S%JW@Svfqu#+B=I*}sl zg{2<{W#*ns479trNG@C*jXg^{7@dTtc%^%(td zEqdH>iQX?b6B;Wr(B1d0BD2Hd+bo6XZW z#&Q72ng@gHjt$|;e0;IW%}7iH@%mr^w|c@r{a69M;WKf@`^ZE+h7Er(7aa_lWyL?q zF;Get%0iSGVxJW4H{ecGA!fv}d#zwPM3WenQlm6d!VrLR+f>X`nr%N>V|N15)WFAq zkoVvN-G=VW+xwOMUqok8ke9YP5OVWN@9Ju1BtsBoKF7z*QOS|Qnq0>^w~&It+f(vk z0>3xyZXM9VE}~dTZ+#STQ2NhHC(%6UxSp5a5n=;xAUc5Wr{RQ0?>gENoi_OR|nB?k{OHS?`q?z+O1f(Iv+#|Q1xQa^v5 zxAU-*8|C%i7_nB%4eX<4GHoE6apr0QOYDa2Rn&TF^XCV;7PH`BG8kjT(!VZg^u8t0 z`C$ga7RS|ms7B-{5dzE#m}yJ2uKp6lQrOtuf-W1eC)A*-g zTr?HnBiKa=V-O8O@{MV=Sh9y9CV*e96=x@1CC_z-A(`cg;c;4-3Xj-f}rjQ`p`E}toLm1!4V*4VyOsb zf~O^`ZU#fv*d2fjkF74+pL7)gX3#1xhPH#YjeVJQYBF37izD?dTqJ@Hp)X-yZ`=4u zjEK-CFihXkLT&_~Q=S1aVWAP5$(q>mDi5Rg2?SFBo$4Y@0|9|hd9rMRL>Wx)EqK+# z(u!bcm})u@_)~Jxk_U-ucr;dR?Gwy|79Ob9qgWm7GAG2vJ zATK+`u=^RiJMk%q3)LO(p2U@#U?y!9awM19xX&Z-B!@o-ikHJu}UwR~2rZzn2}=sDL(w3_=^priir2$0LC zmsk?w`)OA;ZbKc&z|hMKorf?R+Z5aDiG49>LwrfOxe=YSfOLXSp^xHuJP^&?1~uVq zQJHVsltmkdbjehE(M0P0y49KJ0Oerf74f{vqU;qL4s&M?PHn^t%mbj!z5>5L_ZI^H z7e}BEEQgc3vAX9?KGRG|{5;>m!QJT*rtmqE$}-o9VOOdLD5?|`D`a}ija-=zJF}v! zg0U~j7NGJF{Nm9`CJ$8Xw)()|HNzbXmod|~iwsnq*?PHC4oAG7fc9CU#XmhP1K>1x zhYY;}o~lSI0MMYMXV14J24h=#KQ;lc_L1z**NHW1E9qFI;1-l*++jt%5eE>!j7r7v zZ~JyecNwI%GaN36ZBS4}&r$hOpvZkm;x7v5f-`%wW7=N}c#0w)9~DHL6j(Zez&-tx zpYg~=PQv$Alg<{VkFQqTv z0BX2~KHH+~T-l{if`#WR%j4aZ z1@Exxd7m(z2whzK%!&t+9;MUW!^*uN#YDcSeXqY6mO7~+Mi2#p z%|@R3_+fLj!O_{NAoAy-V$6N+adQO)7e3kM~9tq zY@_t#3xX}>ejot7b=HN2oq0xHRX7ICY=FEJ|Jy;|akT)(=c#}uB|E?z3?Wb z4qYw%KkU7EJd|zw2RxM`OG5T#6jGK%A;KhONfO1_C)r}MCA%>sOJxZm#3*Dp_ASOv zC0mxU@3J#v9m7oTrTc!m>v`_yUY_6c{@y>{-{-nMKIgTZ<2twFJdWf1p5G%1rQmx6 z{#Wjd4-i~1+~~50H1+8OCv}Wme7x#g0RHkEya02UWewEAeTngMmzE0G0G6G2A-$OK z4zVN2{1t9G_0;>pBI$e*_#=+t)ndRilUi@)zvl8C+j&r@|?rRF3ZeVvr3Q`V>o zlkLe1$NWSvAFDL6Ny}GF-B3*&;K%n3W}ukRlLOZsP9M@oM0udl0AXnz9uj;WLe*E? zhDLB{6ulhNrY+bJ+JKn&l{2pjKCM)Anpj~rSzuBrQ7=FAJ|-a(qyu{ZIxvKNpD2Vs z*#4|i$1_`lr~k|p=Lr*+^nE&r_aJ&F*a^3+23CbLc%9|^^PcAKp5K4sK9F=!XNwmk z--=MeCD#?Ysn?YBmfq9eoNn!@1CLpP4if#T=`rwmus;uTe4WX`lHzxlV@l81lG~Dfo7Kq2*A$mlAm!6b|tD9m6coLA_;L!B9_k=)(sMwNZiT ze12Ls1_{w&rlOn4&dkNxN@5~8J`f^#cwSWfRzc^Y0H)jSO-XT(#dK62C7?JCR$a}o zaWRm8Tsjcat=pSVTUk&7DBlY^uIT4vKEgXP6O3)h#xXdxd9Q?uY@IU5 zc)Dh`((gn2ji^Zl0fMCGB>fZF#6kpuJ2CRy)jX9ojgx)hHz==8@!aruh-Sx&)n<*d zd8u`8#4pS)uE)lSK7zzqOEo-okQL)yb?Qp>fChLSf8(ayyjUS0p;SgMacfQO^oHfU zcLL=d;m?)l#_5>qq#zcZixJ#4?h&XsHO(yPTkEqI_nAbEqp0pBGUV@^2{V7beBjfI z-Otw$`W2`^NEQGLfF-5CcSPGWg@m{2v&O{#|g ze>Bk(*=p3Z%U~w~>QoK9P66W9o!L0fdD{I>;V83wMT*tB8L&SNO+_G0YG<)NzMne% zsNL)K=6pD+Gi>)zS(x7lHIE4XPFdwM@7OfkIEVTZDrAaXRsNmR+zUYj`LWj%?JP9U z-j~kBx%8*eO7J7cG#egi7KD%dan|{HVg)7_ki@ms)-)x}f!RHwT{9mS=DjZg2G8Z) zg}-;3Z_}kJs7_> zZCSOm_csO{p$SqCQTy{h^w(cCfL|bM|JA=Rez#<`?i9RT(OlZFMDgy_S^pruPxdx= zgvsaW;;aeLY2G1KMJo605cfk_aEF1$xue$<%bq_11iM?W=B7dhV8ITy@8CwqZ<8CH zzk(FHkfVjS$se461>JxLRl0G=1s4r*zqeolh9`l8A+l zxt$DHUTk4XI#o85Vih;H%TAkbY|MV*;XzhTK#N)I8Nix;tG2+`N$W}LXu#ag-_Rr; z8bOW*d<9YCfy-Y%2KxdLF+)a719LqcxR01dI$#f3sYm*Q?^Xa9Z|mxn{^Z3N$l8h+ z33rd&+yj~AbpHzS=G;BC!;IbC0ki?{Rc=c=gKoUdjm7Kig{-A zdq>V?`rj;kw>PVDSe>kpY?O1Jk3?QAWs3=&NA3&i+0AP;k3=Uact%g5HM;g03$^MU zy+TDLkI^#dvCG-B*RQ&}Hoa4iuL7$Z!rd)}9U6i6DxmZNZQM+k|VKluL$uqdV+J z!D58^K9FO66D@z%8~?QEMY|VM=G7(;0;8JmbPV6Con!&gO%7zwmBa{V8ZgILsZ$@M4?3lGsfnFLt4YcUP25@ckML3Uoh(Faa8+#J(UCoj7>*sS$IKA}Nv z)BVug2@7t@2g07Un_Z1)VKv$yjNyZimvY*v4O@9ivT^UTrb|UqsJDpgLd)~Rqr@U0 z&Up2P^+uK}a=vRpKW3|!X!{soc4efx`L48-(5sx4F>tR!r!5t6>S^!5IsRY-rRlup zC3y`?m`QD#zJ~jQ@#FsL;s6gh$97kP>~wRGbH)ZuaL5e9TemCRth-ySUY-*xOv8kC z4KW5)BhXJ5?>>`ZP*#`^TbNgqU#KZwvP5`7OY~l+`zC6%_VrZ%>oAdiGjOxDX%XjBx_##eF1ijb1RL?vI z7`#ydRhf(_^aTKxn0nspzzK!duEjn1M`xWzDqs|Vt97HD^Z?ve)%0#)Dg77C4;_)# zxpB_%IEVA-C}g#^$~$UGLVwsjgd8G$3s{Y5b-y)Wv>ieY6T7v0C@Ef}y43$mT+{r8 z=XO^2^gs$_nOksykQ6LbT%GIaYgZQ~pM%hMbY@nP!=E0gP@FOzem=I(sH(MP=tG1< z@-jNr4He{d)fqh!%WtV}0jUU-I|VQ@k5rxmeB|%&bZcq=aOF7Z6Z^PI#)iViK{H)} zV_L>x^ZMdt#c-$kao@j+Eo+>1WwAu_RY45aCG zQ{uX0-!24Cemxdq%+39!OTct9%Lu2k71J5G(1GoZc6EUDE4sr^wAjnR`R%IMRo_FR z5Y|?%2T3njqYFez)|v{G7dl@A`)xyi|7DF^w|h`%VMw5}q>f0d^(hc-gbPPb`u+ji z4p4-t1Bl3h_B!0Pe2F5G=??vCbX4_^v-RqCWfc4Jzc}XpRR7yT`nhxs5G34|k4Lad z=eoR4y&)xdL2`s}=Jbh9bA3P?+Pq-u*9kAfJ+@~FT{s~DmI-Au%LAfUg_h3!6q_o| zz&XuGrGYIazNX@nBcJNh5diEBIlE-k9@K-nTm`5?w|ow%eJQU#Dy;C#Ei?5c8bq5| zy!MmQZesR*3S9e5=T6=M0~nMf+ZhtU9+&)&0dxMpSWU32yJrIok%1n!_w*u+i&pm| zhzBXeL&ZOQ5;y!twjgixc|GMyu?KxXcruOzC`P8$fMSG!=jJ@^{WfOC$)bvq?LIT1 zR4GxP@CoUuVK7BK6EQ$9;@9g;sB9cp)--6uYsKABls>i&;@=jM{+juS2*W|NjOSrRI;#nG60$drCI_7aR0X`#rI(gTVsCN1LrL6JhT{5`PLc047a{>rgUBay`I?SuoIx|GFqN%>K4w4~ zdS-q!;+#;wsq@IcK85{h1I<=arp_NFET}{na;97@qbR&wbA;YYH`*8O5VsL2S(*7p zG2*6=u#!?qg5*2pd;B_#v=NW@!PK#7(B#fv3JJUDrPXD>tZ;l@yWYY{#QbWYYOF8m z^Va^#$wpl)qg&{7#9@8a>&%x`hM8x`CrcAGyvHNh*;TI}O$n>0%guQo=AdZ+o#-8toP^Ml zoxUo!@T~0mwUv9n&ekt0tx|0y2v~!Ni!^DwLgjvu^_}lK6RQNcC!EHLw)9Zv$A} z{lU+m@_kYX`!9CTjg?0%uDan1DC?3q?j}0SUFLRTTWoG~O|3es_i3a!(2>7#h!~T)1x4|6CI_nPuPcZ^n`$Y zV12qS71>1Q`OIiDhMEKXJ#@DE>xPXt)!9Np-0&~%Wh_FMzl8FFUs&`Nc|I z8sEKni|fVTjO*ry9){mMLAR1^{Bq;nAWMEo|3giS&c&~Q9)0cpa-gAg;4TQ;F-pT5 zJvzSe_*Mg6mB%P6LmT2Y9O5DE&oGHws;H326RW2MoFf=qoty_P^}LR+9orq!q;Zt3 zZsVSig|gyx59iA5^W0;LXFpN*CR%WY+yAaxfplbjSN6S6jgkKB5I0@vrwmgambY~+ zhbm8fm=~Tw|5)&a?**?R{V#e2iT1VPl_pf3$>HqWwnz7TCESf30Rh=@+z|y)ri@bz zkAy!zw6N&B-{VVhrJUkn&U{B!_ugPNvB$p|m{_PQIc-l-c(zJg_q@oZzFoXgd&rvz z;)~I*A z)dv(EUqI3MDBQcG$nyNrS+8QU&b)5TGd;zzMc6d-SJZJnD-m$=yXgc~_onUC6~UE@ zewD|+Nag>Z{XNaOT>3d2vw--P0Ag~c{W1st_}2*A0NEB)0JJRhVdOf~A78@QL24k{ z$PQ}4`~9jQ^F$wL(SuWAVs?ZYET;>ZDYMEP=(cDU8B0vZB0Z7r>lS zj+Z{N-DMtk;}sX%jH=6yDVU5P?39z|XAa=y7Z$+*BZo_IQ2#NXhUx(*b%9AssQTpc z%ud!T`i8CCrgt2RaA}i{Y&o?zLvsc%PN-XBtv7D~p> z?2vVw%B>2>&Sdo zmRm)hSiTE#XV>4?f(?jkH44Y=kGX->d(34LRZBDhNaC?5v(SEC)N3?a?!W{KUd4C4 zN>?d%>Y4dh&_<`4?uDg@!$gih%9srf9yu9Vp9o5@eU;jqH1S#L*2k>>!(Z}6sw zFy*B5lN8*HkD#H|Y3K9{MIkR%GizcXTkrYgpHbHmS|_aKWX2Bn_J1_CIU>quA(xpa z&`w&VYQI~Df#Z+?U-0%%v(M}4C6ysZR4IpoX$uh!N91wBU#ckycJ?fU%=)YTPiX>4 zQ$C3IH7(Lu(B$a;Kg_ro0#?cEc$j{ESfXEaiPt#&DMUi^fk%V~wx2^G%rt54rgeoy zf#JZVcUs51%@e0K_&3l6=Mg;hil39Z9=4d57WuloIko#i{=>Z50yJ~OBpawuGY!05 zph8qe9goZ*v*+}2tc&xW48(OgjwZZH!1+;@S*JOJSH~xxTgrg8UwgNu<%7{mwSSnA zFsT1Iw-S;&VjTk$ZGF|sDKTa4S5I#SwBmpEh&VW2`UKYKeGrIrIV3rd@n~vGLXZNL zUJrl~7VHB?1c3NVteV|c4p^JFG?7E^Uom!tXp z7dmL0@w)i_D-h`>$(1gdG{08;NZ|yzf#7#A8(lJZOUb7H!am|_;xebo4q&%XcwHqu z!5^a0huN0A4d^LwIIy9#F(ehXl{KG9%*12@Ys6FZPceXmdK@{ylIjpvG0>0sK>4=e zJ-;W*&}fL4FCN+e!$o*q?#^Y{GBlL#=UwlMr3kw_7>`FkR}ca=R4{4=8AR17EWj;y z_<7=)c*7SBoxCMiMh|&iB>Cc2+tip?WuHh#AlT^q$OLNd6l}E@J8or@vc5%z|GLpU z|A^Z99Vz;qvD3sz6B5ppk zTm^y@qf?Mrz_Rby!%MUNgzjzpDTHqs`X>rxEb|TkJ^OGOSZK_2xY5GSN3| zXR52Xy}$SP{m=JgyAvOT9ABHrM5C zmgN;!)#QDJTjmEk#_)Z9gUlO(b)#UhP%pVwr(#J%3BHP}Y;>r1ygY%Fp$$BJxy$b= zmcRAJ%4d_KPurr#Uq0ltmKvJ3l30?Ga2SE%IFjQJGv?J$gFv7Q zAZXv6gFu1{B)oWbzYhp>1oRUP-Iq~r$>V0Yk6&n?V@nwfbLGQcBCkmPox5u+QK>Mv zM*=23&9JI*XsP5vR|ceG-v>dTgIa?&Y@KDBD6A-ca3O*-O$4%1 zRllAaurdboUA`mUXyt4(<;X96Lk~IX88`=UXEKdTC67HOca**yy|*~%g)4JYlcVGb zOfs!ihy@Ya8#Do`>PJjFmq*MH$%VFSb>rjwI4%z!-#`kY`GH9Yg91QUH)akuY%MjTVdB-o3)k?N{_=D z)WZ(J9S4R#wZ1XFU>Nk_{o_Qrp7mxgXP&WJf1DX%LUo6V*YEua44UFB#Zkp61{f6J zNuc6grAkdr1qc!XO0x#<$qFoIx%EBz%o0^THReEBe&N7S51l=ZPIK^Mb6}18dU?`nMmIno~bbaK*?+~kkI=sdwAaUzR8zm-EjQ8 zrsAUPzS)CbI$1WZ2Fr!68N>OW@#O|8%^C8Pd9##B%y`|LjA3|1>qweQ_PG4m_51@$ga6spR%|^1HnU_{jUuR{JAtaf5Y!wPfnTyzu=a*W`8z zM}fUtkTE_Q!XIUG?!iKhzinMBy5Z07Q4)oI6G__CtU#iupq-Qzi2 z)}?)w+|hG%uoY7)SV0VH>&-VW#lq2>Yz?>PQaw>x;noq!k$-`beY^VFYWdsf z3ClQl9(|+fguX)Yt&^3x)~RK&ZxdCbp)yu3BAfE?g>6ko|_R~q&qiN@xKv?pM zmz1TCXC8s3q{}I}9|-^1FJO`a?&aPIb>mmN8?MA3R2$_xbyP(Qc2ns*^sI^;BY(c? z>xe6NKGv*K@uj2FkH-nWUxch17zzc%?YaosciF`GuA;!-?Xd<>_`I6$97pX)pKjxxc-CzdzK~D%dO+ zKGhzCb7Pd(8LVT4-k5HWXKaqQ*yw8rSQw;ms@;#dP6(s)VOL?O$Bqba-pv>N%}mXAR@1V)<*U8+T@H5$4k zxvg&Z^c&vlMvLhy%#|mk2(J%m{O+q*B<@XD4b!|9M6dM-7V<{ zMPXsu9`vRi^p}M9ti)qH^f;Y_$3ZNsS~J6mWca>tz+=t^tHYEKY{wPHzJd+{8ji2M z01u*nEFm4UYzvgVQg671frvm&0C zpsOyxx1XIah2LmMSXxEAZyK zl>M(Km=nZ^*gaV5!|DYXX;L59c9MhK3i+M=8b8YLpVEn4Bx@jaZCVi^@{z+COORgF z){ns;-)fS}$;I3%TAkm=#otRX{}v2VCmvEcdhLf`km^4&b^b8R{Pcx?d|&8aP(LOD zc%?>&T@{DGtJu=g`$Nofa*3#`WaKp<5M*Fzb+P2}@dSnY{rwm_AVlPKNZ@RB`>b%Y z0>4|#QYoshx4?2_xKM^NFtTeFg8E#Rz&M~@W%rRPJ8mOR=j8AWxkgHUtGpUH?7p!a zMh*LhUPqdfmHq;{5&N3s_I)tgd`~F|EN|1zg=N5{<~E%iIm)bpk!)N`=+tgd(!Qd7 zHS6g7?t_;yUteMaxuB7tgCJVa1)dk**rwgB8Z`IKvu;JgOnwDXz($Q*a`e;$x{k`VxJd<$L?v+c7aT4c`qW?w~rnC12xa>O@lpzJlPe~VJI(`F2+KaKkW65YY;(d5budW9nu%d^q38*I7<2}yW3U~Ku|UV(`(@am z(-jWRN7#UmL>$)3&##CWRwFMT2qV#h{Sk^dvD=Y12@juNYYYkLj-J=ta^OPFy6pMk=gQp(txBu(xR8M$v*e z22boYLriXDH|;bpsHv&_bC$n4QgzkNI2X*`ywhzGWK?j&O{r5@&{W!`k z(uK94!vEgJh|)xIxX-tUCtw%;}ov!tC>L+p_=jpbdh_)Q`DJMUk4 z-yu8CAqyM3)W;Go_rFA)Bt7-(lMn>Igd{kP79l=JCxVM9#`zL2%RjhDPolue@2Ct# zx{vSNyum0l#fKFD_Lc#pHNW#_54gX#(E_iWK(swzzP&fRL

    Y(?ODhYOc%9|00O0B=1NIU$Lkx&gm=JXGH#vqeBy5;* zr!~BdJw!MB>K3G&Gjf|39ZiGBc!aTv2|Ox(#ld_)IKZ;1KA0$0#z$5TS)mC8=Zz~Jad#HO)~ zX1yt8@?&VDw!oJs*>dJZti93)Z^$;EkX}E5`HcHg$QtA&lQxeV6Bwd7e$%NqXgdZc z1I!hvxa%Wh|GIX5b8KVq*^=)H~|+ai2_%>V0AyMEn)odilP< zYNouI6YvKbAh>4)@a-Pv&9;2DC6X6*`!<k^)R_XL@;NAfD7FkAT|5++I3 zf%wW059p5`l~V!`an-&X8d|XX3k;#7*j8ke=GYByAM6JVeFv<8e5UKXbK78S%?rQx z!Cr0NuNBdeUf`taC%eXP?=2*hp7T9T8P2x-igeizc9H;5L^2WHUGKzRw6of;O@Bgs zO@`=y2-6dK{;4ED67h6@rmqiZR(MHoQZ-p`@@9IHP&ymv$fJLL;dJ-B^S2@Tf6jiu z*?-H(E+nR#LBp{^3U>3VWYcUvLXjDV@B+gqv7MuZUqSxkMYu&Wf81F+wE4Z)PP=C_ zYMbBc0V@g>!m}&=04FMLz|958sKF);EjWL(oXmE6Y_dz_2y&Qt-E|RQ7k9Ijy9jx5 z5)gR(9H)R~P+B1e$GK=q$nw+8YkSA3HE-hbYs}uF-!X}=Cv2WCy zfmb;2=mDDgv%_v4*ak=CgFUaF(Y8UJo|Ln~(ghjclyC4@Ayg zAfI}PM;S?plkw#bZ_c)Bbx{dwfPg5b&%)E zc7mbVSm5|kmGM{F&$gf5O!fBJ<37Bb=YPG_Iq|t@!L#1|2nx>KsU7gpUuj8RdF)&$ z<@A5@1S&KQKw5=LUYpux&S9lk!w=i$n%zrL8dj~%9Psxq$x1WoGr1yAQXcXqoZgx5 zP?ik~%Rp{|ld1dB=z%X%Pp`;#2Xhd@^tw>0y({Y%vWnt833}5g0na`5%ND|6Jo34zPT7%7#ncL@J`ny6sDZSnt_ez<# zTDX*lLmy~HH||rIIt2+qSmCmCBlQW^Z-%Zri8yk)$b3*RJVvqeJc%s1fvU?f(6AbR z`^-`NQ+|VO-wglu{hLh7mw}*R7RFI7w*km!HNc&8&ib{Un>TCy$cLG>eE?&K^_C(r zzkPRqC2Z3l&t3%J9w0R1E9Pr6z!ckZekX~fH$&cMBDQmx5Ik^Cmj~>R+bVEh^FdC> zAv(OXfk_ku^w^8zuO}cuQUSMz;b~zd>WPmtI4Mc%(9kiCHHaUEgNKjcch5qjx5915 zynOarcph@}s@w9uKg>w{j449rd@~OVW9F%SvX$a9gaSZJXjYt{0WnZd^sQPewqeu?^X@2%$8^Q}?}J_o;)N`eQ(bmNBJCcHK<_~^EF zGWKnA2dJ|5OY+Xu`7Xm3T}8s``kFlEUFU(Q*{pG2c7?~mj9z+pJ{ymm#(Mn~uub*z zJ9m&2W^C`aPd_Vji2v~ji-sPqsgn1!3fNxzyAuzvvi`9Wuh7RMLNN1V9^ zrEevKhE~G5WZwIYWUHO-v>l+i{&N0Rf{XMD-B&RWhEx4Bhdw&-*D)WNVVlm6tl6J= zCMr!}sMOljrc~n9hqL}l7JC5OHAK2*2?KwCT;beE1~q!_e^`wB+0TqR!E4jhC3+bozn zgjn3F{k{e9Y;8HBaW6njzf;exmA|XRmpF+(@P+;fivA>yr;wwOuRV3xBIm7rrFah~ zxIsc@8FEzNk24n$4o?~eN$TPfrm{CnsXyy4%dAcva5}ZgCpa(P>Vn!Q2X{P_Il@#K zmDoFOpf2C6VB}+G!P8()QYp{v8WRk$qDw}C}PWLIfFBp}+CAlt% zpo1wvTdTRe+#NF(A_#Yz9>h6E?sLimKwj|~l-*+2k#1ncuz2qagw@GgSOHvP@bvkG zllx~(0on*@ZTfVRmt>rRA6RPF5kK9Oma9JgjQyi^@AZRi^<<1)3ixJ~IB5)V=$yi_ zT`>Ta(d*j1q3l)!ckR2(C0V~AL~p@mzBA^^cWzv>4u~Y6VTI7VZS_pK6!G|Yy%9t^ zX;Z676GQpn&$7?a3D+B(47AI$j?+oa+!r?7a6r1J0^mwQ98YzFU+Gxtr8{@6sQ8lj zPMMD-u~Zvaph!87rn?u%T~YhiS~oiV5XAK;?Wpd&X1OHH2xlMYrE=hErZr1p#94vW zy7$#8Y^K{i2&Yh!G$%-0rhzj$8|{Y(t_=?74c>;sW%%~PL`0sg zI|hIgyguO1jkh-YZ0LQ`mT!uBsM$Ybx^|jd3*R)pFod82OL$!;I602V>z+Fn=9p^C zwCUdG^-<-vmt&d77WgvdClr$c*N_{%PH-dNkTvuQDbWQi5#9slvg4_0?(m&O?e{`D zx*o?xXUIHHu~_7HiXN!;5ZS7k@&Kt^0kXf@(`>+frpIWdkJLTFh9-id6;Xu1U>Rh9w)=&!_Wbe|6BzeKe_sZXR3c9qS#*9 z4E+jvj`8~nG6F2Gj%bW0DY<$|Ea@u<3%~;fvcNw?5&ZWTXs^BFS3m9lU>0Kqcn6hj z&kNJj*AYDX<+f`etE~#N5M96?^nu3ia^pJi;08`5A-m$P=0Sn>%eO;-uw}x{4s`CQ z+EF@shF!%XiMI>Ja)<(>bpcfXrt_xK6$B`4|2`wa8fF0PeX%FJV6xtw;S3YT9Cq!N zE!#4X9Z9db9px)3PaayolaCjhngZA)de+jG*co^PI^QmC-mi{~1fo#utn`=Hl;b&E zPun5+1PMKVc!|aA9p5x7FO7*UMmMa9V`niZQ2l`O{3PD+p0F^_$i_Agj;0pNY>$&&Qdjj_6Ru>ZqK9BYf zXY*#8rScrK2j~l4q85x1&KuZo|8q}B>oo3Ut^ejp|1}uEANzp+hfmvpFzjDJm2g?u z2AYh|o42vfS*tROGGtg=m@3$rEmS+ zA~Cmlsp4%2_R6ZFL)^-<3`g6=(U)h4o+LU)B%7R9A{}mGa6lDOyrO96O!+c~O#+-| ze`{UR4^PubGfv_@;oCg8tjKU=_G0z;;OH#8CMPG?nG>KvoOI7Ud0!}0onu?Ou4zrb zd%U3N$+FlP^MR)_BF(!~akxP^Jmm7~MK=auZ8tAdhCfb20luJNFk&e1+@$f8c;;!* zGM<+}P@_v7qRS5rpWV)5M3kI9aHdfpPBRU89cq}WbS4g$lWt$cw_hq$9RW#2>~oyh zp%bDz4>#{KHfb(vsCSKaYnzazO{^w)5ceaQ`{tfo*Xy5b`hu5ci~q9P&OW4~7zwPQ zpiN$%EVi}cPOm;WVvQA`zew*jnUpj8_UVK`G&`f}kcBbZ(fV!%!*F#jyhz^r0_91e z*#}gcl5avIcpqArn?C>efKCB*4Dvi}PIs-Vrf$@1s z5WnY2w~o;BlGUHqrrYR_p+PN=@d85g@Gczim>ZZ!gO5bJ-}XZ|3)Ic*lu<#}_aiyh zEB20m8b7E1WzVL5$W~ZyA?FG>$5MI(VsPymVBY>Dxc~BH4zTQyiOex9{t5#2YZ{co z$r|7Mj`&m%eB!GQtsOY-#uP3POW80jXd=Y}<_izYd~uXMOQaMlCP zjdRM+6=^=?d%U8Z$eiB-TNFo3TH6arA(An|({s+kADm?*!9}Vu4^%BAl9}%`%AA|aRmzHl<$;Ayrsu>T%sV`Qk9r++&m1LO8(7dq zN?6md4F#W5Nu=@Im?>-YO!HmdxVS<+Xf%(;Kt;?RoNeWC6J5dL8a*I^f|X^RZ=yF! zFESMeO`-391tq@BjjNFD`A_OM#gFs=VWSGc3if_WT5lm2RCbDXsyC8J1Bg*#CwWQn z=I!5=0Ka!r^BKtoS$P_d%+cKPSNKMtp2Go9r~l_o^`8{#U)uZs(;rdZ$yraa|CK#G z)A>fm_lfKKQ~{O5)05TOgQ^$mV1QrxkFHv(X_pxXC!m2-PCoXGkVcFaF>c#+JfY6e z>l$u1)PZh7g;4qtatn55_gtB}{Sy;#c-y{8)vq9yZIyZWqQ?#orukcSY{Ms8KWgI7 zsCGZHT{;m`^`r%Pl6e)|9RC6}VHBQ0F*tCQ(~~Khd|h}N9VUGm(ooK)eYmvfsnn*R z=ezPy?MzA8%~D09Lc;W3gnfCerkZ-;1-TTKFYWNVYMD>L-?$gQb7APsg27S--=~NX8PMh)fAj3!zjGH8 zfPS4dYqQrQ(Jztr4u7@}%6s$tx~!M#NV8|@swwO&xq~TXl)>~W@5_gT@T$-)`>8sN zDJe-%4RfOIsp8o=JfA1`^5_SD7f4}9xiP14`I10`Rv3YLPj`Zv?OYg)>MR~i{A_fU z4Jcd&pmqK3i%GjT0J>f433}qX{hW#450u>=^bIT9Cli5^p_R!|tLR67rsRp+B0XNJ zUbn&i3oo}2L5!?YO^@um0nqj;=OA+Sn7X^Qu6kADN9$4jJTe@w)JjHmp0!S<#g#$9 zL>h!1wgn)y-IXDQPljhS#M^G@RgTEIXZZtrFq2AqLjEYD^Nze*;F32_b%%x52Q#q* zDnYV-^-YD~!@vT>)8%R_^idMJ9!sP}$BJ02y`})XJ<{`(oxTv9xG{EdV**@E@BoOC zqt*n1F%NlB+m@tD#Iu6rL&9Kyzx2pXh**8N^hckO8}e;BkmJ>B%waoM2!V*EnDO`V z)0gZ8d1i!A&quePHk00XDPbnnaZ?(rNz##FPEnfg?ROi&h1G$sL-XEzQ3`rBg{6=s zu5+lG`(PZO%HqoS@RlqpXj(J+tjJRPjtcDzj+1his&nTe!4=V#HX(CsI+*676S=cq zX7>=FtL~Rv=>ZO)8u!E;^#2^>fP?%S{z#I#@i_xo&a@)b zaMqpVWB1}O)VyR^nNfhxYx>;?!zEwoZ=$FPL&~ff54$=KcV1<#^|BIDU|P`s3VO>% z+{R-M;$Ni`G;^%TFU=NanvGbS9wd(|6r+fyVQ3V$SO3_t2+bgGF1^Aso15azNe-H` zbbtLO;`QF@CD80nn2WvbfnIdkHbFZAPluyf*26J?2GaZzdU3MqKEbtSpea49Krg4? z)LxBqT65Rk|KI0m=0Lm{NKA#B+U-mHVjghTv+yY8JbW@l;iIjlc5z-QsNG3IiA}yg z=)i^~z6oU^m6l=9XXs;99(z2PXR%=)F>c56de_+Jhgll3eRpZ}wApIO^FEZT=+dHA z1vfrkB z{SU5M+9dLIo>ya$zXi=N2**B1ZLCW^y8(I?t{;~cw64K;HSBiJ;{6oop$tcd^iT4a z1o>|pK%N$f9o0O~p`2ms$uGpANMkoZuN3!81+VKrarld$YL6(|++Rucxb2|gtdrI~ zvQS5*qFjeHM{4on^K@$p(RcUckHGJi2;beCy@e;mf*t@u*z0m9sS_zgJ{|-~m&C_3 z$Y|RKVUFJ;&sIkvk2Zk2IS4HiTp7|0u%kuDhp>;;L3ior=@9fd*^^=8&d;RPPR7Q} zRfc`}i?=)^_YS~r=JPV?Z7atM-?l(>^yd{m>l37ftQ5@P(cu^|xRnthDpLY8d%sV= zagiwiyw&eSz`h@4EiTOUy4J%Ednk2ZWMcDhJ^jvN`7RvTRI%>2yDA;WqiOxWReh%o1wlss!b&6~EDu%z0UhP_+4`N60Hy zm-ekUu?I4?YFActoVg{Mp#`4u%5607taduD`*!b)ZEd0Dx)lx(gf=gCG$YMW<0WOl z-h}3QXrc{x-!8M~@q1>~`R%wtBXi{Bcvib4y$_kX>Uoj)Xx|LMHdg|I$MsmL5d_8( zglLp3$`M*iJE5slKk|Pv3*^@5{W$pF=SU4 z|7eSq@iAadGl|!bH2%(AL_3ABz5TIMXTy`O^3>eL%sgT)Eq!{7O||1h*d1}0Q!Vx2 zU?Vjx|2+nkJhlv>YZ2cy&%dyXNzn;mZSKFE``VWhug}HkjjaD_8pJzLYJXUZJ zobxX)Ja1+G#L!NWAtG_=ArOkYApE%^w_?Vxh+%C#^P6)3V%UO@_mQlh_OIyTl)U$^ zKLhCEkIIS^&WBK%X@D>Vc7KSxt{|8>%lWVtmj&pxzZT6Shr(MivieHSxTbk`kQm&N zHXn7_(3Hf5jrV$35U?;F(!B~Y>78IVQ+QlbPn1C?V!%Uca6D6e!4-$*n*rz6t*DWg z;WOyKEk=XgE4amQF7fW;!6f!NR7c$Q!Z@iRx|%`mBEJf)GnE-c*&%KHB&H2rn6)@h zu+ptWDCuLWA{8te8zM>&`cEKj81^1C_$EM$Yu+B~=*XXg(!Hy>h7NFsH+M_MFZ7@L zVq~NyY}NBJa(7{2G+^`W+*i;MIS4KF{;C&FV3+6i_B|m8PuxfoH)OmyaNPG2v>?=M z`7_-TF&~Zg=IpCa+r5C>J$s6JQ|l9AK(VS?SF#&>%UI)>mJwxBh=TBn|3I>AhNl@9 zo@rNvYro3w!I$2WHD33+CNKo!%yXGBCF1Q2kh$PhTygmEAs-9^J1AoLnErXjoHs4e41XLny>+racI0{KAfzq!}<#j69( zkr(om!I2z0vU|0a{*xW^PmaxRyBSutX=WiCfDv&R{!f0|$5if4%Y}pCpYY!Nz=U%yMeFcTFl7z8v;JCL} z9hG96Vfija9b(;H;gucbTX#~C>nvy*AOwSP&Uu;*Fu(ozGl;&^Fw(&+z?FY*hZU}| zpQQ4Evy}$rLJb9UQJY#)!ipD~-A31Z+$#T!d_T7%Q9K*mKeF`^ADwD>gT<3^ayT3d zPUiT%7ttwMb3#NQZ2a2~CmK0bXQ+G%nfj>jM~G+@g*pV$h|Bx@^nhTnI*qo^J%d_l zK4e1>(hHziLY~cG=sHDG zj0+Uas4uMF@q^^Tm&B<0F!5u`M-2eAZ-Jj9MR_bKHn=^9$qlLuxkNT5@kf-KG8foBX?D03G@sEDfZf9C|KK&f26#;O%*MZY3MFQxpNvW!8vSsrAhm+kJjf!5C+gO%YGbkM zWf-@VDBjD9;k5Y&J||U{v$#AMD!7;pFUzEj5N=xb7Fu9hDA~G~MHeh#J|K7z`+8`& z4FYm(bmwkvSTaD^jm$Bd7Cc$Cy_K-gu`J&P+1Jcm-!e%vC&~8qCSR%Y2Y+Oc>xX4H zcGNIWgJ#FPO`(3;y_Te6y0H{yBHX=Psra^^@Ib=@?sI-UuuZ}vw1!^Wtr^YS-=5h& zI47F%;S@_2_@&`s*TNuA@!CpIaSMuJ!IdMbh3kFam3D@tolFJ4jSnj@KDX*d*2J@T z$&q}IW{Hv$Vc+-->63QbG(B+0qi|Oq-d?NjGlyGVov?bW*r~F;5NQ&Fdsp|it$U&L z$&)nWl8^PvO&+D)o0~*zvDXpY@vi%j@l)L=8hZw8i4Qsi)+6wbX&v|4_?>jhzeomJosx8^pg3)*=-&&yQhNh8+RYtSHhOh?B_55x- zNgB@!pXbL*)y_yf@R;n9zafjYJrr+c@BII;_uf%WZCm>=CUKBe1Jw z;bvf@B9a{&WR?#)sRGLye_Q5KboAtgbYM!i*)&C^a1-{;xGGb6xu_cWQsl^_muhXW z57P$m%rZS4gw<#HQ>^{GL)fWyn~U@A66T1WW9vlvWx-KT*rsLt9iy_P)XVNUk%Cd` zaA}^`D7R;2I5R_q_0W%Mf(?i3q*SmvFryEyuKzYYwe00p$_8D>lOS7H&zH8?pLy() z%^+-`*1ukAB(kVd6Rv3Q%q)A3ZAI>c_JAwiUPr02f0N^sfuUTlLP%9~pa}i4=AY!e*AAyjhQZj43L zAe<0lR!K)sQz4VPnPXY&=KO=R#vVlJc>EO{>nGC7!z@C`ev~~VqA3eD|Q-x zWd*KEw&2Q1=v-Y;wvBcf|JVu-@B8dy^bv=G?~#0DL4VMW(k+kIjL^PQOwM??eqK+c zPOSgR#%x(6^V@BO!fbQHL&`_|Y&LSQSK0hsOLg(btn{DU?wUDqzepDRecQK=1R_lZ zfCoSOz~);yt>)7+@U6)0c#{lyuf2q2Ly=0OYFRhcdZif- zRXsP2oT8i!IwZ^VNS2l4Fp2hit3tWL)F4?>P3i^!Nw@O1M+HdX`o%&1-B*tAAeO+Z zRjPq_1avZU62Q=aHwI|QW&ZNogZ)PDgZNJNqcI2ko&VDqz4)`2{97SYb0z7wTarK1 z6#e&lUpF%^kt9IWdi-hecxSPk%6)*GT=wsrg%zgQx+kCO$;0^2pCBJFZTNUAc?H(^ z4l-9a(j#20LSv=vUHc?BV1<9i^1O;0WM%>EY+`4{G@1Fhgh$G_wOPiE!AUSCvkKw# z0929B-IvcDys<$=C0?+Rp=&>LgEL0FLF+IlqUm*YbwJZc+v;p>X3vuyoRLnn(j8o= zEQgJmx5Y0vR^*iQy8YVL06P3i_tsDfDC?qm) zR0be<0$(!Lt=tSWkqG!shr6gkQWY0d7s9>Gl$2G9N$idM+g z0n95J)|Tlivb&E5$nW6S4?{42)J?(nOwY6&*3p_XN89MSTn)Dm&t0z1Ihkl=I^>v@ zW16pMNsJcHmDe1`v{G?zPj72!V2As_XS>&@L&`;IE;zUj;q}c5didv;OMqAlDeY`M zMQQgMG*rUbef-3R-NN2~nFidrTDa+71_47lwN`>h~J07wLlBbl|g#+A`N_H7`wLwi4QHNY7_*yf-> zA@#F#D7l0Tf%T+wASl7j@kLz)7g(C-kNQ>JTINar>D{Boa`y?4VPgWs^^pBQ)P@OQ zHsT}7!Z?WaDn$RUlBMeHPKPKzxciWkSiT?gV z_LnjLKy2-?q#^(ukwXFrdByOh`*rMSu7e1sdV=2v0Q>wB8`y%_60!lP#PFiTVB6Jc zQh0|HYLO5KB>n8@B9Xr20B6)*Gh+8dIUqiJudWtFe-JxO4G4sOr6vel%1tc@1O7=o zQNk0p69ukI$&xM0W_ZEO;;2g7KI}h@lGt~g&kUJXK;u`AJuZg3dAY9X`6Qqx~U91>F$31+;bJ*;Lj@GPg=OqUJ49i@nYC4o_8^*z=De3#l?z& zFe6Q!w(LK$XEs*#g=BQQ)rk z!6%ryn^hGP6JLE7SNsAIDb@+Ebf`je@3+3 zbGo}~@&MuR%!RrPWVY>!KHz5w+zlG^>zY|TA#7qhHMwCy+>%R29C*e2gNpK*f;d7p zT2#edwRbckF^dF`3l9WbyS*S1Q_Vs)A)^kTxs@jMPEai{Ts|CDQb?2iI_9EPWxlf;Vu}JGLXhW*C)w z$`(MhP%fD@8`Jddz!PBkRe3?)jG!y>gQ3E^@JFs!XOWc4-q5bPp-JuQwZ}seI96I- zj^*c!0l>u0 z;LakA!S!wN9W63Mk503P=&8v`C6{aT@sndIN|S`nE;w)}LMTh8yd=W>@Ebx(;el?fi8WUK z7O@%S7yTyg*zRt0p12a$o0#uL-*TvE*sTjPA5{ySr7^ z94{49FRKOjr96;`n2!6i{@Q#^pio?SSj`Ps#_FD$B1hBt60Ha`lI&{(cg<{X=wLW*qY-!Me^8mbx`M;i{qSO%8<_I_ zlk=6@z$Tv$H}t(^A@JhoRSnp5;S~~Ypg)(IanJDf*Z83;ClJ`xW7y{Qv71%kDB)a2 z9a4v+`Mrpb3xG3PSEr2)(s#b+z$;(3vx3TX6I|oq!9|p4std$|=R7g>hgvfgFF3ju zFG$38gfF!DJ>Q4V2=9O!fS6NzK9-JGLQ&8s195gB`HtlU!JT#>{el#kLZrYZOF1?a zTK6d?PF~)pPTw*UzlwMRF~ObyBv^n0AOhmT%Xq$_boDVg-gwbAdx4(*SmuUY&KsF2xsIHxa$&$kL@q$Xp4$G$4pCU% zIV-nKlCjYjXQr(E4elg0fiU(_*K1&!!@U5VNR1M8?F_Sl;JL&P{8ZMl6*9#9!X=%k zoR>K0OnK<*;hMv?_suoD-jLc0cu+zI%cPE>F&f5Cz8=7H{_MaDeZDSf2Dv6ZGiCGO z;s}W66#u>H=W3g=OSYYUlGvDOWt7e?yOX1^_!&EjxKM_xj_)t-b?gX#g0lH4I%azE z;7^K)zI+uXa=5c4oT2>l8J`6l6WTFILg?jiOA?c?_SNw_R~AeU&Ox7_#@tOqBk8aj zX^Q#2ioI!CW~?Pm8*<<#j{S#F?PJhC?1o%j#o>rQJm6nBQU2RG@A+BAt#6jgb^2e) z+Ecw>?A1I4m(ePv8Y!6+S;4tH&VTLo3dbFwvIJn;eCQJ2OqwV=)0XfFB4kw+3FN+_ zF3!A@1H*!aUiV!%3O8C75FhK9D=XqRR%~C4)D(+HkL=xhpt5LkVq)U9hnw*GHDkS3 z@78<@#ksbTB?lZCa8oQ)q5oEpkB`ETw1ndr6}S~xRS=I{k!w(jWhQG?q@y*{I|?N{ zpod&|p{^el8Ak}2A#f;h)2^>`=#ebfTV00JaSjavX8NlKL5BhzB5ex70o+0utoj@Ll)$7K>TBGTsL3@ILM~8*a5ZuN}3Ir%Z=vPlURurAvI!pZQ z0iO?A{k%!y8S2YBAHk>nEZUK!nyU>y_?Ek!6-Dj5Lhd^`1ES#zs&UR(>5Ji=PcX-J z+^F!5b$<(_mBLN{q{D zl>UBVBLoaUjl1sjX;H~vZs=Y=b?_0s`4rBg^M2|m3Ji&U)?(cLd&H%h^Ur08Yex1bsM&r`6A1>^-o~Iwq{Ft_1DwT=rC$0;?G2NIS<56i@ zD-wU_vVNT5d835SxF6zC>PB$DfBH*2>MLW&U%l3!*F2!06w9XZi7FzK`-q2+hIxDZ z==FID?jtVi3L_(-diFLV56MpQ`~Pk-UpGP%XCLDwEULGFBbM{+)b*0Xpc?d*h3u#sA4jIn#ADj)tZ;gj=7yK>E2xA+<&3htQi)0C4Mq)IE@KysJVL^CJnTA$QxssC}h z=HW+L3J(gbGmhYFsMEaep<6O!+Hd!CV*CzJ7u6Y99e5x{@T(~BX~M-F(4)r;vR^WS zJ}^pN+-TTEx+Cq8H+~y-%o)bPlCv$(ClT^QMf#2lsi#;#AO7`|NYMe}Vb5E;X1sX` zyMQ^0cj{!MAnYC`*nYr3{ijaVKJT(UPY8y8dLWk&Q7^1i@W2iz2~ zZ+ZOnQ~2~<#86Vk0R<`|yovBl1SgR+ssz^`ST14snR+1(mcIudGC(%#Ga z?VR{kfX6nJd4VnAO*F_0`m+%@s0s#@| zN`-mthLe5G0awfQeque~X_4*Ft6Dtp;v%?$-wj_vQxK*3;lsd2bBWjZ_N?PR^NtDb z3kd+OkmJ2K3TzzLz?fcml2aAeK}g9a4hQ&buG8+UyTz@Q{Pt4+wlrFHEx1|Mi>Drod$OBTlrf^<_7{H{ah`Ze`>`34_fe}N&l~u|97DU?IP~6 zCesF^<5|`loVsc1&hcjcg1}_?kd!{WH?-@%!sHW5cX8mA#q*itKpvforL`~tQ=3#3 zoIEERCd|cnU+gec!wB)n*K3Y1*gOA2V1qH~g)1eiuL@Y4ZXssvJQire16$qwXwZv~ z>ljzcML?vUWY4Sm3m#NBH*&*+3a6jS34mxvvGVQ7=dhMJ6C;x3GpFvYDpz*Swv%NO z>Dv8d7~V2}>+rIbpL0jsgYfMaa6IA+&7{=v3g+Fqg8ewc)I8KUTXW9m{9q0{7I?|75pYPwv z3l{0EG&{>GT6Vo5sS;YcZj##f*MeIfHmWzP7sUi)e9%fRdhD}#!2Z94qGbX zJAjEvUS#cI%Y5A?<-CJ|Ntvi6(8xoaFaeu8uK1Ske_&R1eU@hl)%0wqH1`(Qn3lPd?Tz8YFAS zlC{Gza+1fSVVV(xII1uIW=dLEO5|!8rnj36Z>Yweex&RQB4godX=oQC<#KJsWZ*c7kNII^6TsCWF&vSKr)%xssRgdWxeRkzv3^hhH3 zHC6NLoA{)0p4}MGgo;B;4=@65FgAqB?Na)Ab_4rP{);PX-^lJ`&xZjIo@B zH{t6UY)-B)J>sJdI=$gxhXk;c&QjHKB^BkvIo^zI_Dy^0r z$>F!i9GX)Xhr|ZBFCNQDBOx8p;rRhu@}T~7{lZJnKw>R3?pGDQxij_qYzIm6-|r_Xfgf zlduxKnoDzp8@G3x3zR5LYTQDI*(1D|IqLe}ltWH?dJs=RAA7qhC+6pa#sT!K8zs9> zK&yPu%L%N~>@-$^cy_s0!lA4LYKI^Uus__Oq6J^Kb(s|nfzNVaLo#nJSB>=$ir{;y z0TdONHDO1Q1*@x7xQ(C9_Wwm(zC~OL4BClQW$5c#iau5vtJpg&F9VkMTCmsk22dvjP&t?lPGv2ET-!ChU zCKgCv`$AIW4erjO-Ew%HX={7}4T^pcJ7S|9$;zrs**N=bk8Q3_X+UV*wz2N)))jT1 z6SsPs)3O^GBn6V^Cv-Zhf|K$+MOz@Uohqi;`eLqbVjL8~8WTQYm}zRio~;{pPd%e< zSudysy4`QQO;DY&oH!{JaJwemV!rXVSwA+&X|v8woP1~JP?aD$Sqsn(+zQ6l+t zoRf{C@1@t7yOVlv)dBRW7~>up$W&W+bBz16O)nNM_e{C@knIr3S|`<*F7ZN|Wx8P&ep=2MyJj z%?Un)q~)3@#!kNaLc&ghBcZs<2(Sasd*uPobU`@l=cvtENG&A zAdb2TIfClcqf_KtgxD{1idn9u5#m^YtgDx}^4acyvnbJE^>;;z0PM!`f?6}w0=$+r z

    ~Yy!aTcK|%uI$qAiEBRcn9dt1w4T$2w>Y%$xf9EW8_d$`KaP5PGsAOi(S&Gq- z*e@iht$*k2H(HRMf$v*oop4{jVPShZR+44!jP=mC0?F>8kG+l!QH*19&awMIUcmpP z8iY!0^*c9EcVTHaVQe?s&7Lc%j&YOI)$aO&g<|8vVXV&oMvH#T4gm($8`}-FoRgy7 zRH(l`G_3Z_&P`*0e~;{tR4YK3cOLP0=UVMK0+oT0oLb?aifZ%3Ny#37vN0Rg^>aOuqG+Fhgi~jQxg|pW^U<&(6CQC^x|1*akT< zC`p?y6`V$MHAbnn6WJkwi}HKHD*wp@jBRhM$_yyYd^>ROf`DRqrPe-|iP~mAN7g}Z z70RUDNJF~liSkgsa<=VBDwZat;&YKL$zXKjp75k6-+V!Kik@tyt#+nn>0|Op(+i`~ z^7m9g*ctrGjT(CNux8KY)c(?3jU4@!L+$*rcJI;(xk3({U?1G+5hcct;}=GjUOwvI z)f?q7c~1w;_&aAkr^5l)yyqOja^RC@fPn84-6D=Bs12ARfr574PY`hP&p*K+G~(1L zJGOZ5y^G{)uEcQdu;@f!yW3w5NAeB9l(iH%xZagMIVV<6y*PmAaW>9ISht)m~vo>z$v2uaP9B6-4|`%y`AluaOl zpkId@->GG7YJmjN=LGOpSLdRdIvi}^I^>d!F zE&$|YyWkO}hw^ybV3DXYXm|cyx2EZIPXHt(aDr){b$-Z~b&j9$em}=P_Gn>XKZ$)lqmpe?9u?z5 zP_a;j_#Z01(g`qneem(_Q zSY5%P8vsX2NHS$PiZ8gYRquT5^Uy1cYJ1bH6nKu50~Hq|d$-b|-d`L7eNrHRa|?Z+bk?o zVYmEgEKBse8vgG0k(uSJ*Jwt<_7`P_F;PcWoAAof>yBqHh;u}Hnj&7XsyIlva}?69 zd+V$-W|kI3nBAy~bmG_V9UP1*V8{mFLFD@w$KmCy*X`1Ddp6Qu9j7aCb2D2F=9cg0 zS~VWd@aui)V{mau=vvm|Ve))dBVF8VSoBT@ZV+^m*n8@>9SZBCU}bLl(8aUi8IFA( zsu5+TDR~2bQ<1m0d3OEm>*!$e5A%mKmIA{G%2E-kXwW(hXIVEWq$D_4j)7h@{HRJQ zwID`pS9pPLcWgS`_qsY~#em!G_KEh~s{jN4;ei=aV;M*Ld~AEm`E$1;fR($$|SV^xs!?Jfhg(>8yN~nKpBm(ms(i z-Ev>ClsSfN!;OWGl@>l~_{w`BS@0o7r5R2tGou0`B)zx*XyW=*4mjz$YJDNGc;LJm z`mKa=iSG+8F-0!dx63ZGI@s= zu7`4{+?|xrxpMsN+rSg0JLzeftTupQWCdNnMq}KY?$;Y{f2g4J^~YG! zu2C@yv(?ha<2xNlt3Iezm&ijM{hmcd|4(bL1PU=@E%rF`;Sy_biAADxZoZXEdc%WV zWky}x`aKbXfc4Aab$Z8LcO}rxXYb`tO;sGrBn)yv_j=ygnv@vTkB$mSozl3{B#@@VVNAXUJGw-T@4t!D_2$;Z*p`Q?LeBA;b-{XV4&YtAg(lU%) z%1KLM3#hsGg+%r1Ztt*ES9g|;#~oTN9Zno~7NDhrWT+ny2GpbcyB}KAeDzo(E1Zp(9+^2zGTaY724Mv<-e}UKT2XRC zjwFI{;wLlJ7^Db_tSSYh$TyHPzQBh35r>@5lbMLTDH2QW2WOR2`F(IP5(vY?#v$Jh zOLVu^fKb$-aYO5bJ#CGo>p}tscX|ueV^}N{#Af`oKEqisMmH2tyrpd~;BFS;0~|Nb zmwaHRy>zxsGZ5g@H2$+cFlP)xCxl(8u}>MF@Ql@oXLMtBjS=TFw{R1<$R04l9y$2G z(E{@U=3-*_lWqJjs(0v|Ma$vw(AoHU(Y^c{1Ri@6ju(CaKI2$lOk}j(hI@~9d?BfS zB>$B{;`f^RCeGr|57gYw&=u=6oRXyiseYuu02IMc^QweU*IWw5+llX9o31c65KFfl zL)H@1(O2T`&R=rzI&)d-h8TFLZWdW#yYW-5)FsN}lFaUE~|$eYI{n%HqbnF}GscI0?o?-lA=g|G8o6^o!+kD*!0|0s{= zLY>RQQp{h-o~63k&zJv&q@<)}PKd8eK|Zxy9K42T2-`%$t!f#072o#qeX3}ux|VLe zAJD#2fZGESyJ7|sPn;qeggX^i$swL!1_-Wyw=wcGTIGpw6tk^~!@$BeCzO-_CZ$4~ z-wKeynD-J5J%cUQMVFQCt}Cku+}OH7CjBVfasyBV$94Q+M;yh>aC4>ar8gaUHidSB zNY#s>RgLsUnS@j)l{X|9WQyMj-)jj?FYR8o<aLKmYan&@0A&*vS=vd)38#(-uhwGBq`@0|_Po4b(Sr zk*_e9ABOSIVjclb0^X|1M^tX{1Ofbg1TOif<0Db)RQ^sxgL}f5{c1$!qM^=X2ZCftczO;qDL(_~Am z%p*XAdezSH?ttChnlc#b{lgwSc-0_&k7m+9UXr&;{EWcMLT&D^S();4@u8NP*dRyV z&$2$P+nnWxpN=*<-i0UIHu#CiTc)h!^1fOs_YR=W;wX>`Gal4$QN%WR&dYg=tAqf5^W-z2M~9~k>`4aY^P7!ic}dRz%N`L;Lo_T zrQ=8hRQf7-uc=fFx>4HYYxwqy46=q~Lz?qp=hK!%>X>_YUB}g)zN(&o!GbX(df(L< zHD*SYCIr^-S_1r@c_unxfiedqYJAM%QCy*vFRU*~7v<4^fR<^A_AwG<|B?+a`0S<8|cRg)noSh+sxt zbEbCG<|Ehoa*e7RF}e#6m!xvN%U0!n`+)x8nV)q+;`~s!VYX>sg3Swn+5>>3&(E3cb#E8E z=_X178}$O)gPcBCD&c#)n$m4kkW6(Ut_oWH@=VzMeW%f3rP9PgXU|pszI3j72}!JP=rP#rC3&a+iIst`P0m+)a(`J!}&n>>)l!o_mcvi7L%V!2l*N|CCMS#p zNOqw}$<)XmP?NpkW^E6%J)b{8V`$JRQUfH7m@di842WvS4-XaTPd3uF)}-0Cav#xV zd&G9)_Ztttur(o-LECZG*V!w?vSU7`inP(J|C`*W6wIF z7YRdTM3RTb7WuwpsN@VmrF(lX&B{^NXXm@|c}EXO4^@65B+i_+I8ZzL1fTlu$iW^! z3$d86>*%kPfW8^bxABCXd3&0`lWa0tM=D~{dWxaG>axFMH+-i6DUAis5a_g$=Z<0& zp9Mh1W>TOV7fGV-e{l1r0Mw$w>hRk2IN&h;42UgaQkdjkBx> zfT>%sN0n7v1mVL-I7W+&qgbrZ*s@qa+8ujKM$h@Ai7Iow{ zm~1n1f9&4?zAgjKuw1PYu750a?ZbujPq%$4-aGW3WH`K}z_Ejb_7TZEO%w<7FcxZ7BoSs0gg@jy!b5R7eF8AQ&Uojjre46@w9=yJZ&@eW*4YK5B?6B;3qYuZ+IZLmH+H$ zem+OoY>3CFkcGVZ1)UUPcO5Gp6tsaE)i|{xum*TD`!9Ad9_W@6ws?BrmebUPkfuHF zwd_zgM)#ZWoPZW z<*Oe*Ifxfnwk03wmvl3=x6JPLIPSi+pJkt<85{0WX%K14*EoI5m5RNCdu z!_wNHZ(5AqdUcRR?WZ$X^{Lvp-87mPK;f|A^-fQoc{&3oRnweEr)pY$n>Ki&x1B|a-K|AFSO^FsO zJfP98+YyZek}_USb@8an(D${nrg(8{=L(6C$9z}l`=-c4_7jjwsNp~%5aoD@z6gTl z`249m5Bi{kQDVEx>&A(*$Rk#4H04$$_7E|~HqPgt(&4#m&g=bSwW7_&$9p6Jf3nq> zuajW7;?*t%AoEvpemt|(Q5)mjh)wx(iqslFl0uO`}3AO&MgrXMV}S# zV#73HyJnR`<|FP&sc2LW+)EatBPr`USJ3l*y5-U0WuIZHdA=YCaHQ~KjFj@GTA1gI z?xAsou<9Fv@KdK>6>jR(oJQdlP^XLw;-nU)?Jk;&D(A^fj)3x!n`lXcGb6Y&{1z$qpcWl4J?F87f|)|CmxEEk{1C-fR3BI?+dAyT)`4_@IjrL%Ysw{SJw z7=N{)OZ^=L{4Bp}ut-4w6b zm#^u43V%Hjq%1A%eRWfp$cPo3oj&FnJZw-{JIGmCHeF~LFA(y8R-BY{slC<=YdHgu z_g$J}Hgag&(~S8%?$?^E+sXP)bAgN^jSaID2OQ7TWYq^P&1?yNs(TywiE=CF>)dr%+;lYhO(GRUhV-(T8AQ8;*cwz|x(u(Og8!xl2( zVr-N{?Dk`>j$Y_@qgp-G{R&%W>)>3*?JM- zPh-fnz1iwYHYHKjy0@1-!=t(R`o$bSL|BXyKkVjSaqv|VieB7ky?>HuF}|;DRKGTD zQ}lVUrC*WFZ%x}2^x3FB?suE&xXngAsymG;>2PtpznAd%K{) z0egEEN_8heWY^KlGla+4yGc%C<;bDH&2aqiA9tml&~g5{y#=Or6t%u*ar3YQ??G|9 zy_0ISbc5JfWAITjH?^@MNwwK76*^DvMcMjz&-H?1^i~WM%)0!I?2$RwwB^Gj#jWSM zL554^TivXsjn~%?lg!&5Vc?`0l((4^f4hlxL(&a(m0JcEDEquL;hjVapD>lAzT}+bH1y_bhw`-g#Y1GbZp1XN~ zJSLAc8dlYwx4bNv(&CamdJe|m5@pt2de;-ts88`^eMrhuMKS3JN0M^K>80jZK5SCC z?~(PEyaMtc5pz`4ZaWnZ??azoGPZyLmLvw^`i11A(Ks@rh3e`-EbsLRKWvoUE?X#?u|@Mpy6w|{RdLBN}#5);Bndh)KYEyhQLQ4&HZWzG<2>O z+B|ip=YYq`zQjm^N6WEp{_-YqnXfmjjSts zguI&L(8k3610q)%yy0PiMym<6q~QD^i-EO6lhF@79DFO`r+e#Xq=zrfAw$?0(GLYy z+({kYHB^^F4C_Oercvy+A2*?vR1{AW!88+1$+6>?Gq;b|ch+od?>fEpI$DTkeSc|L zs;Cpr-*u4tyG`?!r;7_hsd#K81~Eg_?oCf9A???qR<&I>M~80)#g($!;8rQFnaVx_ znei@4~$LSm2bqDOskWFkkb=^S$w{oCY83+Qtm zV-Fv^*m9A$2;14JhdxKwhcxyBN`J4RN+ID@$@3A`8z!|CY)`Kj!lefA;L$F{h=&8h z`0+PP|I~G?4wmMEjk0w%fD4aSR@@W3^Lz%Qh=TamZ=tea^VQY19ja z_V+$IQuAO6YocgxS|8?8LFz*;y=DV}TnEx%hy@4u>bl`xxG!rac3Lj#_Q0E}FtQ}e z6Ly{X6-OBMpN0Fjmp))JX^5g)W~zTIfq<0(RoE}nnka|A2Nu&!xV7HW9flSq+Zb=@1~pe zh2j@n5fy zpRxYaD?83`a2gQ#i@NuAhLE_fZ8zch()wKYWaN7eKa1|IJTd5fyjG$p+l7}3#d~JO zl+!O<4sxkMqjiJ#KeUIwiMdP|S!)vgZ1{zQd-LEDsxn&+KN-p(fsv5 z{?R3?O0x$DoFF^IFDH|h@B3-qh`U<>tu$Hs2(9R#jL{v3s7a~f19A82VCcvf*6G-n zD^qP&3;s#7YQ>*U4}vP7Z+N;et74Z+y;94gnJ#aTD!W_eATqq`o8I+GvNA?u3TQL# znejxOtwv%FYzH8WZK1Pgu1*Q9^j*Cg*B&!Dj3Wwq$ z)^fdzg$WMh%{a-ipx(}urVCEyF1_-@`{uiOj%TnjT}^&$m4lm69Vc6y0|R*wRe=-4 zK(12DRqxumkPIdG13yg$&F(9c&vZWG3NqdDRy0he6zi-FxO%7?yh%;Kt7D(`9%FKo zbkq{wS5(-y_sUza`BRg7vSnr)uHeFlhaIc*zBTqawhIm>o@NqxE_|)z3yE^Iv?k4a z=VWPIawdv)N4~M1B#PQ9O@H8ATQ;15J5N0L^gEM#o?Ix_2=DghO{xeEWu}Ne_?yX# z>_9in;T3O0gH9^I;FYVA@BL{SSArXcdl2&>rHk9XcY5t>6rD2+9To1`BW%F}^c$2c z{vgKB726DP$<*aSa3=$@;lELFVxX(B7c@s+sIUg?(3_a{7dRZ0#l8zoAE`AsES9r3Y;v!E!=a`uw&SN$Sq1m; zQhCMpyq{j%r)4)FUpSQVROhQ3DSmdVj=6CunjwJU70O5Fqo_p0;85n3)NP4L#j{V} zJqln*ZZGw^S?;3bxhE%gS}Sd$Y6mf(V+KYxTZ~4dH3_EMC1(Bx1B=jLo<2z_XSmzzMq&Ksecn%n_||Kuv7f7K zmRA2U6JItvpeKdUj{#viFh7;Qi@QKJ3BXG0{+-WGRg;$dkBrlgX6#>_bw5Tyc;rfK z|8Df`A3W#(|Lqc8w+g$&yiwlwwZNUEk>mQ~kbNuDe((iC7cnk#d^l7Bz>p^VXTNXh zJOcDT9squ@wX=?Z0yo{C1w`;Rbz{h~KQkaHF}r;{LFF+kXOa>gwDgg*ct0GbB}*ua zHsq~IP)%Q}j=%8q2*&_*MHXjmN!YCYLRAo##YCZy|5dgWw^mbZW;+x8qmogFQmUmp zIq9u7k;jXY8~9AxQ}TdJiTUfO_(a~J*RZ2;n$Ppq8sjxa$XBsDv>|f{7AxaZ{T5XN ze6Iy^Vrg^41Uh|4YT;}Fb+@zzd~N5ClYX{g${&?NF^=!3;Ydx+bFV;z(ZM9!!Y8!X zlCj6vaTf_B$e1`cFcY?!#Oq~nuDgow5qH8FKYyLkm&z|3QyLpKaDZ+>&t5EdBH;sbAI41*n#Dz83zD zI^AEpd)fcoOox60*;nv0&9uHgkgMAidx;`<>P<(m-SkI5(*KqAV29@by(z|xj!BQa%+kfv6xpo7)i z>R!to81l={UmjyEM`Rgs@*Hq`-QPW&ol{;FQIG_B;U>^_je32Dbp>`!wS3TZi7y}Q zdpgBciWoBCn!SU^!&FoPb_e$w0R;&HsA5@Nf1=gPmbC@QHKBj-vQ*o~2FNvun&Wzi zyyAvM?)bIZP?p6O_@D&B6^LKl^}yD z;AUvTk`Jy3hrQ4Rxog zQ6Fm7Jv`ZN`%}q)C$3*x1mK*KL-ip-;yaJi1yw3D+ROj~^Qe6HJB??GPo6m*qe7x% zxKWsP?X8wtOv?=EszG?8=C=wToj@$U6^@Frnd7%+)RuiRa>q@uETj6X7 zMq41hTkJxJHor9vgsikT&*FC2rZtSu&qtj`oU}>Sss_I`I8_KQ^Qp)Bz-*?Qk(8{C zs!VZfdj0E(L8dK5)PYM9h_0cMI%;1CgmbX1JgYhBLI+XHxn(Qz`g~PnCW@`163ESM z%G9Z6ikR>!EO(64b>@kjmKh)#m#z=)wEEEMpe+`(AY^`4L7yIa%6a&_vRK20?I-L#yzGGU zQCi=2s=6B`$CJ}{X}2}iy!I}gjMjPYRK0Lbx?@Gf)L1(7^ZP7@6Yr0F7CQ{2mh+}q z(~Yr(+GdVD?QMHizc;dFfEL~{4$1(mqi|_Z;RzPoE+A7i>U{lao+vY8_{?2mS) z5;iy4K9}Um<^N`p`wLI-SHflMf2jr*NY(A*1_cL(+xr2~d`tZ%V$nzmAeRGJ2MmYz zwbJoV0PUayAi?~caS*^_h=uOx4-AwR8+)N+iLz8G0OVeUK!5)JDgwQL!1Ta53^QB6 z`y`D3_26xQ9I@1kFQ|UOu@}Bd1Q8fYp8$w|@LTw>EYYoL39-f2U%$G-N1)W{FCEe; z>iuPk{e_$O+W6PHgbu?54T23Yi=X|ILHYjA4L6EWY3d#D$xBJIwzpG91;15DfRQHNuf1la1hrIz)A*IDU!0qVssY;tiRJY2us%xO z6d9JQa;Jn?0rCrQoNJ5>Z63ct!^5+oht5%lrTIg-2a`D;o(mJEVq(`)8=($J%gXsB z*!mZZ@4uS;ALRePyT}3K{8u3VQuEc;o08-O;|4c4x4SI3+t1w6OA32MLcuxw&#K-- z7*LL3_6K@tN}|D~kLMzB6dpc|*KSrkI8}!mcf`POe!T z%i$!8xrHM4ZJv!ff_*dH`ckOh(^fa~;%176N8vN>tf!|Gc^YUj1Q^`J}vr{nsG zR1*_c>fO$^x!H4ieU`!JW+~q3xKl9h*K?z$$Cz){)k(0f$3?U@-7HS;J}%n?dRnkX zEx7HcHCtaI5(@Kmy*AFn{Nz!nrD8I}lSkmQMk6eipAT}Ig$Q7c!2-z$s7h6Jg4ih8 zoduYa81i`k4opS6VoQhsS=lh0H>VMd#x%^;2&(jAr1a#V|SGX64+ z;pn#c{>Z@aE!(B;M{p`m)El>2`_p*io0rb82h(+WZ;4HKJNGyzD|vtTdi+Imbmp(> z)&FbG{@0&a;2-_RTT-S-y}6 z2(ru%!a*xMg;?l$yj6MVS-H1*aF^{*ap>*i?yNu}Z$Z`cqdpUnDEF8%wzLU*CJ;Rn zFn{~kED_wQVJ5dQ^F(et)*e9QNK-|w|t%k0i>vOAfX=boqB&ur2rHe@+UgQ&By%_!wM>AOsW zI%qAVTOFaXq;gCmh)RRPxiSXXkB^%SELYqUWgQ{6)G8*-9q4R_z9AhZ;EiAPvmd3^ z7dRoD;c02wxHqnq0XCnIe7C7z0j-KS{ zx<(7>@$L6}9CBXz!OT!mh3h?U{D)aT!Cm9aFMM{!yo)y@njBk)$0q z3?DQBs?Ft{eO(p7B3s-PT9>|XQM_Q9vDo%NWMTw;;i9;kk(QtddU0b%8{jw>`8{*b zFWEY_!J{svB^SCl!@RkqQ~92Xya;=n-+Et$w=R5SP6lW%rHno;h!*I?@Qxm>gCJfy zuN*l$+9ZZPgNEGNgAaokZ}10$z&?ym*IT%BVazuO5%x z>&y4@o_l-s;P`i8Y@1?xaD}Awg6e&1luPnm^kh*<9>AV{=UTg~yzeBo!6a3S-Y1?oyxIUh-jLA6V3=3Ut$P zm$zu|N9VmyxxBItje?u~#Bzc6;mx*?^NKjxnYR!D3x`J6J^3syzSp>)9#m4`5SrS% zsaRnT5y8Znhg?&C&vrkU`U9p951q_5BxxmDuRFi%*64dC(&E3S7u>S~?zS2ll zp-(bNvMxo`b)S241Cw(o;_2M&n?yaGrI}z_wP7Gqrc3Ww81ziL));hGeBHhkspa08 zsVx;`37Qq2A-La?uOkz7WnW(d!aa8tjJ}M8@WOHQyGV#61)Yxh3o1$>GDJtp+ev~1 zQ!Bix?jzjs@|k4)#T(jtThaF*HRT6r;uJP^dJuIEBJ>7AmX1}b|3uX7JS)?eIa5+K z=*nxd9;OP1Gqd{4LtN+0!*L(#0HkI;R0^4#cn?2Cgpeq0*0S_ zgNO6fKC-QbT`#VS3a6X$YDqcj4=H`r)cN~yq;ERnKdPq@RcP0BDtko%d3EtTYxwR z=p3`ZcNW(CO?-cm$@VV0q%;|FR#*#heGCgr+&XVh$b=ye}#qKJsK9s6}rd`l! z)mJeWT&`!o*s!^e!h@H~Xpq76MqAUW9P#lPi0)A7_W5i$_r&ny$F~BzuoLv3 z3@`+MCA4#TrRSqOV|NgrQ66{kF7~snTw|=(4Pj?KG3c5CM?6m~S+p8h)QR*S!EZV{*NOa*P`vu_Iq* z(wC-YZX3m>3+9}s3hICq&ra5Cvht@=55WvjXG9v`&bxc}?|i-~TW??5U8lWz_D2(I$c=roV-Qz?%8MDs3v@xHL*49OWC^Dyt! zpoPmp-+?Nq7{YM|CiRF{&!cUYm$uB)wKWG}{g(I&vElDAdC&Dd0zAUh(OuI8?p=Hx z6~sAlI_?dprjV?`k@pDd5%~_CS}|yE9?O}xwzod@?-<+Dsu6g*LQ$UCM5$=QI`Vmr zvg}F8}F91~XM<@R;IE3+={G8fBKw$SDdz|lkiU0Pyj*gv8lJRBqds36>D!4h+_4Pi4 z?=z@u{o_~_5veZ|MOm0p4Eqck*tA%LZB%7*0`^yzmBeP`JmvNFojr(PI5;tF zYWoZS)YE;r`1@QoE^zIS-@WU;Fr3jT%_e7Vfg9lF54IpO4YBQEq1t7tsZG=-+PfBF z8bw?MO2zgI)9r0akr&ZOAtmWC^V({JhH7ZOUIz>!`B=JGc-tqdlOox-{aV7<$!VLh zoaDd_di^EA$5MzsdGj>hcF`Er8KwNi#Cvz#7thVgT0bFFWQ}u`>Nx&H4vZdAGYRpG z2*;x~j5+KFX_R4C;w~F1e`E~S^m2Owe>1CUMm|mH^wV?k>e2!9KjF<2_y2Dz)c)4DkQx`O=0^Ve;kg4reWd;2nkl_fyx=XR^VI}b7q z?=2T-qzFO)YWEha$qlhj{vqJS&QfM5rf&vznygEDIC!?pv)1G&r6J#eyOCVz=_@za z3mrF6wvD%;4 z#Fm4^?rUd3M?g9q{2BfXjQju*(TyF(A3$3BUV!$1I5O$$SM>`MfV8(Ztj+<`jgrHq zK&IeBGvv}P!GPHnl?8f3gXu%3bWTaO?(Q!2?m@xEyV9)h8XHbK)SGZA`;&EDK&zs| zZZN+U4g-CoV>I^+vg?%C8OC>X6un>?iMj2aW);)aKKvkZ(*7XTF4r5*r>Azi)~Cce zyL+C(20n81-7l2ifx5f`-sK^My4W>Y)wy5&HI+?H?Gpz{q}_Q)WkbceY83s%N6~0> z!8yht>OSjNW9%zPyDJDpkn=i~FE3_ctfcJ31mtM11O0{;Zrkc(9J?KM_v!y1s}HJ! z%$#6V`c%rNJ}mp412s+K;##p}ZEzqI=2p|;0e)!}^H3b~DXlp8!chwf>>QPZ{YSr< z1-&9Sx;R&7j(1OX@SnW}aM)Au3r4$byCS|$)|sOuH}qVP(cQI+kDJ$v$SYe*E4?{EoTwzwVZ#l}X0<^3m|_ z=Nc|(@-p~Y$^vX{3M!;JShdvVc`In3@mA1(2t7yO?Z4<~!3n^R3vkHrN) zkGc4kj^@7S%O`o>Uc=zDq*E`3i>YuY#kVJfq%UJX+zm)Ka$zmt%gMwaM?YHP*^gfE zV?2QWt-au$?0ad>iMS9)CA|yPcj-IS4_~`$xO0Wk=P5fgXjA?eKujI)y~G&XO>v`t zr*5|mT@-#k`QzwEODr+|=mr0mdcnd~$E(YeBEY{NsV2U72z;kw6q=V*WS`Y%Y|tRc z$EsR$;}Yt`AOwHMdDfK@F^*(1?>ap{e8GjQeg4o-B5MkS4l$`!86cKtlx)ejtkLk& z<*);KZ#ivk8l<8W136&TebU_}`AD+69`k#;jLUV{U^ScCmFrhXY8i&f<6X~8Lgx%! z6KcY8i&tdxpb^Kt?D+I1@=wgs(2m@1QXnojQM6_{aVxza<(YO5#1(92_8HZLpC=8l z1$ukOD|P^R86t^Ytv1g4RB5nIw!(CDZU}ir5eCDWkE*QAY|h#&dy<1sj6Aya=&(e` z%`Iy3`$3F^A((sBPx;?sX9J`n8#;~Z3xWuWlYP`)DV;UjsQ3M zdHR_(w{8^4u9gVl?c&ZY+O4yoaz-LZ8igmKkKyeeE_j%Yo^UEVuSMS~)6*0n)EQE> z6`$pcr}%8eXGx!cXl=AN2lHH=B+JfB*@#~)Yiz+B(=NG3&didt>6TFjG@U4Fh1QBW@iIY01wNl#s>Gu= z4pQd2#`0!5e28hEeqW;_-&;A>))PM||8)Ny)s^_=dSAZiaorB3;XOAbC8onQG&|Od zwpC->u1{72TO3v2?`sS+@;4Dw=RH&{s5v#s?(~FoAg|8L)_!D@4rnVmvP5u`)0_^! zJtYT9Ig_Nk>tj~HUOMsp8=W5WYkr>A1sF88)2YSiB9n6fjxm~vP`n3p-+m~@nd$Z` z8Q7>l`FN5dk}uP6E&LRJz=kW=^KkD^syY>AhwoDFJKSRPMk1@iU0-!ywQc<2SSPQu z3AxR?R>%V3?UiS0({Zc!z&)+tUUMb6%@-WW&-P>OD%2nA>)lo&dx^g?oS%-V%_EGt zM6Iq?eVUDTdd#^XF45fJrjy*2eeciv>HI7Gw0{0}tv=WaH0W!E+_wJh`XFL_U2|J0 zrw_Pdf3NcCD<#}^@tZKJFP={qu4(?^hWI9h#TRdEKna)q-7Elq)c^Z?U;jVx`6d7% zT=*0+LJ06PY+i=GefAlI8(RmD>oJAu{o#iF!ElXxD7kuYa|(=_Y$rjgT|N zW+)ICo}v{CkUfG0Nl1R*gfxr)F|BE#4nX$v+b;i16?U9b5WW3uD_JdQ(i$>b?plY) z?_TcTcc@*8%nX@=Mp&n=7gM~~emR7o)c);l^egeuw}!;OLg)WCUtgmanGK!)Vmkbp zxN@7NGDVG2LiyR2mQa8CsXqe|nG(m z9Lg`A?~jk5O`gjptDa7-(`d-LR(|!!9u5V0IcrxN1e>z8JtHBL@if~WP;er5qA%R` zK)G;I0JZwHG4uA+F9B7p*xf#}F*b3_j!IqjkmiKew^^QmQd@`wq^<~gEG8aixf+$* za`g41)fPI>YmM_&OJM&TjfO5vMHchE*&7PAsW;RVD7Q*bK8{xRD17g;voLyBDverB ztZ9_y$_mqCy{zL%CSu7{{`of6rwSbfqa5BsH0O`RM^h~y%PZ$1+T*H9d^rcj34}dtlGyz2v6{H{;%_II1Bi!xv!~gVi%^@RwqAr3XtVtRF)TO)tsd| zdnpT5PvZ7JbX(oo9p57p6)dAGLL->3|4J%wX3=FaYNK%-xsq8omz`4}O`024jK{gW z;ZPA;fp%5i&daatTG7ouoftN;iZjYM7kTe^Iy4=~Ln>)!=a@Fcdm!_@qx3LcGBEeV z7c5gf^bn%*S@tP1LOUO09lcIgos#vlqf{Wwf!OWp!%GT538vHz^zR@JwITDQ z=Rt23MvS40*=M(r-lN+VZhtOWdzh3SsQh{I#=1Y}Xm1rD#Xv*LJ) zea$1dBREEF^7voz(Vg?2uFifMDaq2wq4#9uzGN?Adg7AaVPPD{1OBAN^D_@f0rsIg zGnlWyM=}~ic*f{D#0|W$iy(}pXZtqoj6nn=${kG_%kt((+3g5NJ#WivGM6Zc2 zS^Dg{XGGA*0?Ran``Qzgu>q4tWpN~^9)64(LF7kVsxb+KYJ5|lVHnDo`0OJRe81!@UPmw=C zc**}I!Dl>X(-L5w{WrnN;|626BUO}j-ksUfymYKKVew3`5lFHlXR>qZ-XwQDop+}) zE;syK!|Y`{p;D54Px>O(p39Vn9(E;UOrR&TYo_>R06$HOG~!~rib}Dz1>X@T+lQLs z_acd_K$f;kdDUFCiB8;!@q2S_THHQQD6Ty@W!bgbrhop4fgJnU7d1&%Oo{->N=3QY zlT(NBN!Pi6GmP|a)ax1VZtG#ncVEBHuOEi`rjeOKMqvkfN!ChXtHZv?vi*7!inEaT zl#&G&QfXs#JUB|d?C97=Bz~v2NZkF^d9|B*kfYt%<+91LV`JwwdtSB*i{GRit90vd zrin99k6)i7w>;`|1dma@V&AvMtk=2VaUshP=du`Wn*(!1wSlBTTWRV>Sba7>WTvUQ zI*m_8=QXbFn3d8&lcn(HtFo^;3-;!wU8yQlV6X986Iz&(SV1RL(vtxKpNF<})}^nH zbmnLfuNP1Bp6layMqFlh>&}Ez)j&TTu2ruLVO|n!3Y7GrUo;uQq-NhC&1iLsAZb+{ zlMSNzrWS)eeCA0Dn^N88SR)OMb`NRMhA3OpsKmFDi#lc4s^u9YW`DagvregzA5OP^ zL{VHr7ECJOMLq@ZO|B63J5E>HynkOisziNya%{|dp<}WDPV{xohF$H(#;Pryu|4jg zOx@zT_ND4>j6wp!GCeD@Y&=q-RH*dG76AcqTAkov2FJ8->)1tU%KD;A-Kh1^f} zvuGk2IH;fi;ro!6sH%=Ge$faQ%AI>hp6iHk8iiZhacy14ex$FZZ|?N%3i(~nd4g#| z)CE#=!V1z}2K<0(e*=B}OQ4#74=EveMk>W`m)k9oHihx|qk$fC4;G(DKWN?A*ItZ% zq;HE(w|JEj6Ljjtm&%aR^Yc_P^mdmg%MC0ME~yQL0mh;>?G07%b%bZc7$;}@nU!p} zu9~*I%dO!6a*aIiV1TDMkFC>%J7-x(c8Mj2X?sM07vIsTcrw*Z7iz$8XZz$L9Quoh zARKbvx)HOfRdTdH$ksNszx$&_8G~l-Ef8BQps~cg6-#3|zLP~(RVofhApJv|^*1`k z_b$Qzb4cOK6aLU<{qYw6O_8--`WEK>&}OZmDTM!R+AK{S=Ck_eG5zlWT+|{H$fVd2 z6FfS~rps#mDAAXX#XQvO0V&2buW|ovWuxoNnL=-v3{*O2MKiTaFgeK@r!nu|mpJQ*-?*CcRz7vZUq^V1RGa+MPeqHjs-bs%ZnLOSlH6)aF$avqJ8%o#Z;b@p8@M-~q1Q=y1E z858Mkk|EVBV`i!jaTGm4Frhz@&@oyv!2k>Is&4* zuN}bM5a6Ex7*jbwshF)q&IUjVCvBAe*RbuMA)e;n99j95FsXQTV{%5bRRacA156AD zKZ7cfan52$!Z_8YBWzqdd|t4H2MZ-@B6B*_|0N zTjPv>Zj19Er+146!D_qwga6@z4fjy%CiJOU-lmZ&jLo!&c!1XV464 z<~pD-``#h(MM<_z|Ge$J^o4}+tK1}=fMp`HvGS~Le|_2~Lc-u*~^HScbh z%nX=*lG$wh*+nr09(&?d*#<>Uukex6oufFH!gLmQ@j#iN(2XLn6NQH-#7c%iWORO% zNxeq(uv>)1@|Ujr08-X{pToxaKFrnO@jLS)SC#c^oT*;>@`BG!7xLP)lYQIo7@4iE&D@Y!h$o zdk=6n0=Cy~v}4dgiB29Z&FcjKzS#K+opvi&;-%6{d8M}9TG#KtxC=xb_A(q6(Ujj8 zaFz+UqCg6D_1jtQYZUS?c2W9a=le#;{II@fV?T`LkUm4xDZE!y6EsLAijo6Czq6v!#t@S1U=TqN6QFmwLUb1X~QLfCCSgA`yn&+*Q>ft zIkkCW?q+NzvgeZdyS>SZmZJ#Cg{;nxTJP?JnK*=EBvy8T8?xalb%*15F@vigjTj|^ zLJ1{GD~)Mf6jAHi^(3i+{QmPS=Wit&qyg?4OeM|$18#OE8gRd~7(fCmE`S_RYXZgW z#N(K1V0|scv=E}%L&0*=5BDSAWPYd=u<*sI6?JhNR+KCzHxj9bDYTzK2|5B;BkA`A z0c(5od2#_dGg&BXQV+bJEIZ0}+E(^TFPl5n#jv%>o1tnvRx7w2AA}b4V02C#o~?Qz z*Tqt3n71k|on_BfxD8LHR;c4sqSO0uG)^~#41^<)=e%lroM!@7`ByULroNS;Ut?l{ zhDshdW<&kn$K~mK6Nb&@0C;ru^nBt9^a4!M<0dI;v&ezM@iFII%Eg|NXnJNk`t$BD zpwX*8m4`P{&QjW=U&lcVKQ$l`+^Cf-Y5G+~K<7UpBREoqK4dj*xmRG{NNOy*0&3Kq zemZ8H zq$`%~2l9`$9#74*c0uBUrp4Ahqit^n=5#)xWA3Kxa+@eo^W!{QmDg#~eoQZC&NgZ7 ze2dH#*HZvzLTk6oWbM#lm>w>4S~#owUbo=lgGh^Ki@NSEP*jdXxnOpGH9Ybvr^Rhs z&{%>jCB7=ot#qKkNwTYVGk-KE(;_MMA(2=(?+KXN8Rq%v=}3uJ34G{i%VVFO zdM;8yrI7waro$0gy;f}t4|2J{GOENVvSNj;cBjR!3nQ(vEtbk}xUIK*?7nyHp}xgb z`HK&?6`)F?CoigPjA;kgQE(J3=&C{ta)JXet$XT_`5%A|g5EGa2dJ*CUdadUlHd3E z4FGf9)Ya8H-CJm66&Pq&l9;dW=|2buA_t0P*F=8iKb`SqNy|BHGmmBHuV!qbyV&%= z7jf4r$(XI}Mf5R0c}!xY*#6+iG!~_?1Lub^yR%DQnR#(3ay?|%a%vZ8O48%OWHWU5 zYU?r{P`pSda5Xve^{=h*M+^S~uWY6Xia04q>`}Jd&E&nw7IZV&*rQcFt1G-Njm2mg z0;-PXwaqOyj#KhH=Ut5KSg1Bb?9>tV^8%6GnK+Y>)ue{dVyyzwm9c2JMVa{ckYe*Ym5L=Aa35F#+({AM##>Ag0! z$SJeTmW4`5_}l4_Ph)v`91q1ts+NU2cc(VAvh@{P+GWrC5pNfqhZ5eTym(FegmrhJ zJ-t%VMw#tOqoPPKb{s~r$=KPBBv%%df(K$cfvA$kpJEou1qc&w*Wq&>il&8Udcaoq zBOgQOPL3;98sKv_YN|Nzpi_gp>+Y%CntQOCMs1N#X^+=*AFtZ?_ijYr4A7nQIp%vQ z>?EVG6no~*Ca&O@6}~4;;u&LD4k{&GYnpP%qUZ9G3Rpdo91K^tFjeLbmE%cx`%1=Z zFYe^>I^wTG(yx5)w_Wl7j01j-+^AsC4Lrn3}0z9#Psb@wis@Ep6d7OGo;n|I;9dFZQsnIrD+x8$q zBaxQLJ@4HS_8b+j1xl4o@9btWrcf{{xiPEjqtfmcI!<9tJ^T18HaAnEOho5a>h7(! zRCx)yQZfc=y*S)jgLh42~F5;u$=d>+RAoF?<# zNTvT?iDh02)94@{=`(2j10HU7Rhi-H?#_w3Lzi~3yB$RC8=WA1#73J9#ymfZCLZh( zh7!h)ujHJu3*wZFG@4GY-S-(}f7*oSGl)|issC3m&W;0PC;e^AE@XVt8>%MD?+8$P zXNDy7e)>p(z-*NQiuHyPV!^`X+{Y53hfG ztluIJ7iCXHQH`hYN3vNeTLr&^-q~Yb7anmRPZ=TmH$fkuZSbhT*GLx2hK0+|Bd<`u zcydeW(R4AATbO>>+Ouc|NPv-}(*Qdl0^8MhvMMyWJk*gXNkUj+1v&t8TnOwIzzX`a z3VPW*9cpSHR4NH*XJ=t|L(QX0hz-^egs3`N=4!FGc4L-yyoU9bbo+y4)rdO%8(2{+ zE4mSNXiy1zwI~lWLSa81gT=iEEH0Ju@P4ZSX4^xN1Ro3_i&@gpAlGEGz*szGwR9=L2VCnIMiGX30#StzV6e4hT~ zI^c%%QRX+Ds6@P@7~zW6UrB48r1pmjhUI`F3yLn zD@|j{CVD*1PIp=Ku3n%@*i+#kc~G}YX~2kmkG95>3sVP5WRMN)oRPjU{e0`47f5WZm9$_GMYO=)L2CactY)}=bBMMpe z20}lT20lD>6Xm2{^uo4o9sGi~JDtRXJr*(Q{_ORf0(f>n;o{-5t)(Xo+Qe@m=-Uoj zcaRwf;g<=r@AU5_(y!Vk9;G>AKERkg#g+^4o1zw-jsUi&Us_P>G)z0MZ8{_u!~k|;d+3O6_@|qqokd-qh%pfIY|CB z;uTWG=zEh!v9rnR)u~1}A%)YI7&w5;^fvuE_QNZ!<1olHin&}b3qH}nSfwj6Q=xF8 zKFy1#@YoaDvVeIR&JuFw)cQK4GUR6@kXT&o+umys`$+u+_r*n}$$c4nl#jRnnX{F) z1i=RM!G4k#kYZbIHs*#+At4st6TxoF_w;#u@!WHr_rS!~Ick79U{vXyh6ukxTR3>m zj_qJ#P+eYlcsECWz*<>d6>GVQ<0ws0n=^f$<%7b$1{>@xP5a_Vbq68wLFH1Q zTg0yJcKfi8Je=d7VC%hhNFF(n!(lFJk~fdH|2@{eYZlBEtxntL>>_Ewx?E=~tsQ9A+|5+6)H3^V=7i?b-5YChNp}WaqIt25H0dVA)JJT?7=ooq$$tj~@&P_wQ zgC1>tUkW|lv?}lhnDA6#?Gzb!%7;tL_)oBURIHPyLFlXwFkC!hRt0x^D1Vf(idW4S z&3Ta-mH#ZLXI^vp=KA^r@j($1CK-Nj!U(E--^%4R3qRGrhZUGpIrsLg09V9g@+Bf@82(BS!k7oi>l{ zNFP$T+%&RU%jRZ^7?pm|SP4g;tso6x4N?ba2a=yrW)Htrq(Do{Ylv8vAX}6Z;4y5n z@yg&Nm_)%X(F_F*ik2eU272{E=Bw`{A+Z}7Mo=s&(1x8Y`V=}!=23Rdb9cr*_36(b zcCv}ZaDTIzN6DC~EhDxkr8i2AG>K(X+%usfFy6{-eK(b}UaUKt1Rnhmgr(MQ(3J8_ zQ*7B4Qep;(;^O92F7TDn3Ok_P4?Ec%xm+lmfLXZ+(d9+72yO&5sO5sz&6#FAsYv;W z@EWb$2s%^-!(uhhydJXORv6(=g^@s?-`c){>jGiGnoX6y`ueVl(9}xj0gmSqXB0E< zU7ttb>At(J(OE6Tldm+?7iDQ;!mv@IArO*z$Q$Sq-N85%Ct1arhZfS_(7;1+GXJb7ldGcgod+!boFd=06OTL$;;S(S{09 zpq6Yc-HQ#@)%VPX7!Uar#k6T1Wyd>YTjLCOUyci_q6zv;2|v#gu0!=m|Kru`7xkv| zxw>**-5M4T=X7{oWvI&D@GE2GoIN*seE+3BB&q%ud>OL(4<7p*1Bx_n*`{ zS?21qyUXvzugecGJ?FLK=?uZ=xT8FF28;nClwKZxWrrO{YGtU4yg4;n(~1dMAbxTP zG+J)1Ng|BKHiKsmeA1OiJw4@V{b1f;s|y7X;xw?00d~B|S8`@I4|`tAUCW^=v8CT! z6legt9p}mNP)apz#6!Kci;WY-oa4n%VpGQUs%aZH0n4i|xG8nz&zwbH#G@J!(ChKi zY7F{kPy#@%j!Ulrb>3_G6HuswKwJ57!jM{rIRLY?AE&-0U3X?UO%0vf`If%5KVVsq zn(TsEVZpv8Fuj~!tYkF0q;gShDU3c z1J>P%KSQzmKSMERskmQ+41gAX3B~;pnfsTz27=(@dxdvN@hrnn5GfWH;$@Re*agfJ zny{3e#-ar6-gd!*@*-y-A4RxYIWY|q+O2Y-jpRMWU{<-GteSakHa_v}k*}V61NEn9 z<>F;?kguJ!^j>a=KlK^mT^I;2xZfZY^k!4un#?Q??q!Y1`nVa}a*=S*#kRS(wos@T zoR%%+ApJ`}}%F;GHKA3EOmVO5d=mg2$%gt>+YF7*bgoCu=_nJwiE-h`x=l^n)%u zW2`KZBT~UT*4N_)q$WA-2|F8%mBQsQrkf*dwzoBiibSd^^!V};g8ou@_li>1Da;vi zKC1NbKu7_6$X7-*4W4i4eHoKD!27)1Z@w<>Q-vRiZe?;^EW{

    iQ@BV@4&nWf_1Z ziRc#|&=-1e$15rVBE&E`Vv_CHXON%OdS8tvBc>djP@iJi{AMjV+VA~2q6vi~bHGXV zAm%(q{liB%d%53&(m-=2YfglDwq;%q>=Linb#Gj1E>$j5LWX5zOatn4(CkGeQ}%W5 z9`BxjB3JX>0DVgTv8jGfo__Z(MIRZKRFXFH*>KtZ=d!gqbp7}j_rR@-4Qf7Qu*rzO zVciv?`duPjv9$XM4!IVP&28TsQuK(dj$yFC40ViC;YHd= zNut?`ti&p|{S}1=4%6%k6X;{ncP_d}i$dOmY0S+vCY!_23gsP4XHGwF;)bn&JKSR4 zkc>v8AFVLt3{W5S8VIN<;Wzd4gU*I@Y|`HJ5W&A*f(6-5DKm=AYBM!!@GL{`Z>qI* z**$c!__#m#q&wRc99YR|THwYy)z#_gAPu{%PP(oL2K3a#xbi( zC6Afe&11&3XBZLZ*W;V2od>@YLIS5_A5mEfi!jKtU)hO+AIEbRphr|0d-OMR zoa^gq?;{@|AgSnaqd6C*kH4;Of5dNm1tR}Y@Axmf-sIoRMq+G2KsAKJ?an{Gf*BVY z!bv{}y~=vRZ;+?$`F;BCVzdx|VU^3pU&yCeEz%X_7Jk?CU&NBe^ zCJnN+abrZ*uDGlR51VTE1{@{&FCXXHxiT+MO$Lt$d50GOXcA1jHbdPAEL?TXvGxWkv-z?rT1qk zN#(A{-k(>qEm*$ohksnXE?Sy7otbu(s#SEdwHU}mMN}ML>;4!6t`Ve~>cXK@auOuK zGTkT$ma;Gaj+%riSRnV7gA)xhDq~6?4tp#adu)VkR5^LV;tV<{%p`Hm`}N0sY<4sr z)DPi%x=t>pBJ9$tP#ZydJ1gy1x6p25x93Y+)Kf#Z+(#ae|C_hyv;yWrPfjB^+x5Vt zAjjnX@KtxOvlqZ`NLZJp864F=S8a_KY{=(Zf~&8pmO}QI^lBS$>W)=RBf?hHWA*~S zePYJe_SXkTw$H}n<==K$eOr_+wQJhH*M@(sQP`e*96Uuy4-!eonhG$F76u%5Kebt^ zO8BD9T+UHzs5&5m-1X^jslDt*&W*gFN|)v18=3P6LVQFsse5!!$Z#xo_toQ7&hHLi zFZw`v_!;DkXstZgUTH)Sd?YH!G$V|QdEPhS$-w;Zkvo6z8{|ssvG1)bYrPL!gbpBk zq|`Q9I9yPmsxc%0c3wH5)`g`OAUlvvz_)(}-I#_hn>sH?AoyU)+i&PmO|WZpASKov zv@CQ4&pu{85s>;QiJgTWeOI<*-g<)mv8QxYJttSVYCd2wGSw})q$Q)uHQa=7e=yhT z2s`UxK=sGn>dhL=n9;O3e%sxtLpO;f5s|OE+uTa(6NVqmd z=-q*%y+n}9agxpor2o)tn};Ocx#HCW8OhYAJ6XcG=01ZEVrnzS@2P50R0e%}57oxF zo)?PdrW+z+OeqC_^Lj@D{cy!YeWQl#5&uD!8*;pb29L7>B>B!Y*_J!dUkIlB^A{+N zfDajwRO;@PW@ifR?Yr&IPHh5pRa;)>;_MvrWFUwRJuFwW&gjiQ5L9UK;7#N?;?vI{ zwTnCEjQ`%9t9%9TbRwS&7!<>A%ZG_`uqZV_L(#dXb8eNt_Qeg<)(W2rEuMO-0E8|e z9@#iDjVFm~&vUYbng%s0s0-7NS+g}5AM>t(Fqd_X?-&#+Jo4x>Nbl%~BBo?@Pj0!{ zsD%vAhO@Gu%7$+k_8g=9E-BqbjRn;N7dCQ=sgtxS^ESwj6>Kz=kg9M^_ z#k458Nl8G@92_)i=IdPPk3PJ~|Y=utJN}ja-~pK7-B~YnEs^#|Z*? zf_BXAb}#aR?6vHQylzZNrtO@$KV(XG>F$OQd%oLJaQ_PW9$vAUR;vB2zz}0XX~kW( z*#}L*;M+WrcEscKYhOZ+^Ahmvkd2+^c0yWR_RyTLoI!|Q%8a`+`(^FkJmzu zkxzwJ4_n2UG}|YZ?Y1FTlyN@r2e3Ao{+7qzz13wnD#Wa)N^Kub<8UDgddmfh8%kG8 znB)XJ(FaI;*iSYKn3~e3_1USdJ#nq;ML3Nq*T$-@B2Q}gs)745J||ho+Hz_2xFaQd z{pmWV{lW^`b8Gt*7obH+)!1|yfrQ3X%l4<8g4O$QuD(aB?Wfc(km5Ths*cDwANO&R zSe}zok4YvSHBviUCvirWdJ1}|x4aum6`X|6@#Bn3y{w^GwM!s<;)vhw#spcaQFk3L z60}AtD#*DLGh3+zmaVT1%umq9^}U=|)6=Pj*s=I`cX|<+`B0L1zlJCfpKpAyYtHB<26MHf zv03)nr`H>)13dWF;uLG(CCd4-drNCmQ{o&$!rX=OEs1KSiX$j{m>4{^wy2Vku=_)} z2URTfZc|tpcf6KgE;zJl?w_bsBy$s-D*5sLDxYNDU#xz3NK(?0nMDyYX6hbstTKco zKRWH9HF6*-&o#!!d+#v^hxRkV!HA|NBEKpEjDK9;PRgt~DrmYSO0(y{m9g<8Lo@b` z(9n6!n1z|D97@26tN}+DMn*gZl8`ZwTv2+L#@TVRlS6rxDK^J?-Q0J%u|w40by3mP z9kw~h(!_K~O}_Jc(T$NC3G}0)3&DbQ7HFHKH=n%vWO6AR*i29F7xQX=@5W)097WNHic%x? z8MH2BO;rP4l$wIBG86%UTaR@i2LLCc?hAml3#y_7>Td{FzC-74BY_MYYfyZ+$?3Vx zclWwJ?k~?118n#+8!j28zKP~ZJuU7?M~;Hma)PIV?nBop1Gt=ov`^Dw!h=KojW#w1 zT3UE+&{L|4+}5f_&Fdw}hI7f&o@SK+K}+U-B|Hgs^2@NgrTY*&QZ(Tzl3Ci)4Hj+p zGSTDH$h^{&!AAr$L1vgfmU7HP16BW_*EnjzU@C1$4DKE#b$A&jPgaxI`Cedan?Hf< zP^3&zw1|vQ9AN)-Lh^3}fL8#ELMb%jFF4wL)-miOET_ug&*Qnt=9)3UiGst=u>IRjZ@i_vf zAzar$ZsalbWo2h@EF5>&Bk%4Z=-iF)SIMXPFIiJVoPIH$NH@rWB>Lq$Z zk!sot0g&N9@O<6D&M6N}#a0gw%XYqD;is2}tp?L$c5ML6e~4ifH2aL|Pfa$nr{B0| z-WS&745*r82d7Z4Lgl8BG-S49gHy^0eTD}hmS?&@+=f(%@5F<2+SXw;pFw-3wObBa z-0R*&AEQ#R6di(o|Aq`=T82d7tEx-2^6FwZ3aWQbgw1(On9MBQg@SgQkP?SmeVsFv z*;EUS&H#u$Sn1q&_*63nd<8tNOF2P0Hxg&nu7I(LQmJY%3ERJBx-RV0h@o23h6X_P zlg#yBhraGJYhNHd8}o+fK?381ma8dROV9B*&%*?oy81a$0ct{t+6kPScfaRD*0m3C zXDAKaXY|%;OvFP{f9g|b*$eZ~i?kk-GEyj?@{0r^ch$=^9<~~9rQ%-@!3ldRbMeqe zQT3G!d7ZB^&!ww8G=9vDA9{e3^+#uU(2trC>>l1JxWoSrr#`~`vZ-8r*e&FizzldN zDcZwegzdD!zI>^t#qv{mg0v*g#GZhu%$GR<byuBNC`h_GKuHI%xTIp#JCgMw5p$NGIL2gS>H z!M$*8Vgux;pK{(&@t>Bi)N-F_)aI$W2AWrzHr_o#zi*J#Sa)_>?9#DeW6Niz@<(uW zE;tZJGl#%5$Dt8%?_~qCpx0^Wl*U%k;UyX{QSB{s2TW-SMO_Yl*>}n&SsozGZ z^OFTfu5F2l z!Yl2io4)K}+(Y?-u>kZEh6z#aV#K8w==RN1*!#aq|g-e0}@PNn^H* zh;z-WdtL#w!b;`GM+^pxI;88$ZUzE2w4j=h6j#WbF8aW7W#)%u0r$*OKX}v~Arv;W z`1*3|@gCMSZe>yEA?v<@>XKb6oav@YC*DtHVFr`%?& zLydG(Gu9UF;g;jL+_YebsGG8m&Y}X44WNac8SV+v#7B`jflsxtQV!|NI1lU_jh3jASW#2 zX^X7G`BZ zQ&czq_ARr>{GxS0CxI-pBafj?Hsh+gNsl-Ckdu7w;MqA!RUK@;?=whJU?3CN(q0DC z5nTKe@Mxcff=8N?51=kA6iNDhRaZh$ce;*0E|;hG@eo90T~2sMy;0msXo734n+9&& z&XqA5J>elR;y!mvi|&TnKm#&Zt_F?aHSZH$6s>Pa9kp>yj!4?><^u!4AkMh^93XUP z&Y7+L|Nc}q-$XLvEa&{}UC=Th8FzaG+1sa+VvQ}$ECodcrtcG7Ozu;q-k>@!Fr~Ja z%-H7iSR%Qb+i0t&(kc0#o601^v_Bwr1G(wJUNLl`=8UCdD(SfY$KH3qHMMMeM?pbB zBfS$81O*WVL8(!YCSXK*4GM^Wfb>p41QdY?2q*{<={3@OF9GSjNbem&4UmLy>pAb< zbIv>G-goc)zW2WO-f@1v*|YcT9XGRQ)~uQJU;jmVe6krB0d$BrOG6!>(D4$S8)|pD zuS`YhzjlmkQ`X92zEJOsu+!`pSo5F&p%Iy#DC%wJu%cR>yOfjtR>$9L@CQIoEQ2_sfn7t^LZF2oSz`d;a-$ox7Iv z22Z0}>z0e|?!%?f51Aj3yvO##7uzQn{dcq1CtyJ-ALcd+R+9QSg>;12)k(H^dSdH( z&a4_ve@}nf=l+%vVQZYu)w>-xQ2AoO`F;)n=G3Adj(Fmek`B6s9*gUDgfrdet>es7geP;0`Ad#!+wdwSRE4;VIFu@>5n2 zB$rCrpj*5NUqUc%|KJmLjQU;%NGT$Inmqp?*JnWDpO@&>U9)Yf? zAAwddMJe!m*kwMxtcOH#Jri?l?q|oA+`~M@!{OqK(N?=<88VMdX+{k7E9vZ;B^7zT zEGY`l>^eD%#cn(GH+7FF50domaS=<YyhALJD)>?Sb+F2wwIfhJa?j%Qi%-A&9)Gj!0bf=lO#X^7|7m~l)2?60(0}kH z|6ok~_xZt}sbkZS#B5kRQ5^$tlJWq8h!^0-_(@Cp@uhzwVsm$@sGp9p7SUK7L{xl! zd+#;NoCm^Do*#F*r5~@D;9@tTlCh+@8+eD8%jN@?(8pRd!6%@H|Pa8dA86q2k~?iye?x6Y-eDGRP=hhZny|MaFnlzYkogLkxCAEtq(9l6(!@JZWw-A zLb^+aU$16(a1KgcLV^{xQNeXhRNU!f-*x9U_P+Xw!|S3Q*_35jL0MsCVaQzf6yGZ@ zCdJ3kzt#4U)S-0 zAKwxdR#DSnGuF=ObZB;DyZ6Mu`-*GWm1l=`wqdk1LD31Bmh@t0KU_^nQ|=s=MGDFW zqpa@>O24oTS9c74jJeZuvDfi(G>bycoI+0CYICE)gZqM(z;3u--30UijF?G00^w!t zP#eV_WJjPo>-cx5BM`u>PGkUkAAuGmk3eDJM<6WSu-=G_vlU%i`I{>=94<35Z-H%a z_QCA#u_>0ar`c9BIz}HzFc(<;9}1H1HUMm-=SIKD+S^=cA#Gw8JvSp5`c}S>S2r># zxoMHsiYq8JkV5EsHOP^x$HXB}Buq|S_QZ$x6CklL^IS1m7DZ0p3olw*0eS&N;d)dM zI|->T`m7|s8T9a?EzdNWcMZpK9a2fBgV?OEh^v{nrXaR4-Q9101j^OYNLZ#9+x@CV;jqU^gR8>FXRk_(DU_Mc_jvkBO)hwob%&v?qrZihi!>IP> z;bo_xVBA9`hyERKZb7y2xlI$#YGbJ5eX)=N)RX`d4pAGXmt2(U8IeuG7!c06M#6NM zZrkgaRxUY}#n7O+rT?_3$|8{A6sPO`_qW=mjCgIpE*Y{|jq(9z{`KL{ezgi?YRPAX zknc~&)Q$0Wd1%-OH@0eUpP9l@P!J^(LVHNf$5#)bk+?ir7EoBx+qV|(|6)`* zD5Z1SPpUp}{u2&6c`A7jyYyTDza2Ju4^{Ndzp7h@*e9oyzD<- z@vOh?84z=5%dF9o%|;DNXl+h{E1FqRKByDaE0JSyW)-=<7aK4M7x8$K)4v0SjI>5; zY)3kEHc$#(EPMB;$hOWH;yUQ{cYna3qgwKku8WpxW!QzNn+*Pf+D0p~jF1>%XDDbp z-h9$P?m!_>f5ecn`H^o9t&!KWz7af0w_l2%Bg^82%l5V|#uxq1)~ovL=V@hqPXNfb z7XK*Ue|a(_wcBs>SfKV$!04k3A(Bm8Uc&!O%@)dMjjIql=fkC}QI*f37BczqIP{zX z`Xe4}d$9<4~;w7FSU^ z5b9xw3(o}FH{fnJ^(B+IJ~PWgme@N_^e;((%X;V0)&(NJxZ}OyxJcm zlB2&Q_Hy1n=W(m2&iiflnE`)o^WlLv1qo*|wZuZ=MMqY&^B|f}B*{vIhj7c2gXCsavx zEE=FfDp~3#5M<^>3^arUjgpdYLh(|%S8JV8*E{SFG^&1SKGwql!-kVEK=1`*ZdYjE zuPVQrjC^V~H2X@T5 zK6v|Fri7gQzzpj5x1MTcr|5)E@?iZxBwoL8dA2q2xktf?81}Uoc>pNvX%!rIqUhX?gM}0G0)eO*Y#>x&o$;WFu%O3>YaWPMABVZ@6VVu5khXP zJryi{;Zn5*3Fz1&{ILwB=7v1!^-Np2cq&>WULSAJ_D_W5E-O`eyC0+^q{fS}hM1DZ=hQztzsyyRE{1Lxs9UDbSodq?^uXP z^HT0e^kJ?^aj2(4Z5jc-g=Qth7w}MgHV53S%ea+ZGxP@WqWXYE)9>G&Z8>4>%bqc9 zRuy**YyM?F9n9IrL$QAbvvk59PU670180%MV*}o(1hhSHWjDVCZ?c9y;ETqwe8QyT zhSukUBy^uiS@Db^BYY!7_kN(0?H+ZD8`>W;Bj&)CS8_gqzHw2pro6Y_ygzE}d8 zq}uOLEL=gqrCjphQK{c&YcUf?_K8iY2zj0EiT-W9Ho@6D{!8?)ix)$C-F=%5v>K_D z?2|1nUwQVpwBVg!Xdl~s`59S{N3=y^PdGAz)BNGk52 zJ#g}qspZfKCDA}|!4mJ)WDh$T%Fl%3p_nwOg3$qIgHc*lV5M5gsEb=x&8=|X&5axr zdHq$IwW;K5(2Ox@5qd0}0y9p@@8JlLWK|sMDA};wojrfnM1NM!?)nS8fpx7D)9e29 zm14cm(1wJ}q@v)@c5ed&ui7PuGS=`f@1=M6c(D%QsP&rpg(+gfozio!#7pB7CxXEC znjRDza~;)TV~Xaf`Xey~8lk4A8D@D%johR2Cg1@gUZjzmN-ENGGo$I5Z!SHkx_pb1 zWMshHAjv7B5wDC59(ds)z#eaEMY~6%&tK}AxT>5XGDQY2>*36@t)h`IcAP*_U{ZDT zWF_kdD6Hem#npJ*ihTywwwspqZR$H1M_qVou}k!tT`*hW+HWb*_j`fZ3>=P!6@p>| zt!|YiS-2t%ogJ1B>)A8n7j6p$ZL8m@J~#$!M;^=-O^s@p^;(-%mc3nh4QdzaQY9k+ zHuo?Y%hBU+95qm?C2o6+vVuR+jSb^36!&}<7ksmNxagIHOex>{EOsSJVe1Fe{%=Eor9aUt;_p1K&+`&GF-a^puJIsWHye_#!r$JlM#@Wpom8vtDW&H= z#!ej6?P=jil_9*iRtq~fHl$?gutp@yr91s&!|^jY7~&EDyAEH6UvY_P6q|puPC8sL zeJ|afmRtk_Im{s3hgEpwOxZ9l#|f0vSPTU7rnNrc_{NG@L+^-6?Tp}rCRS&6f=V&3 zro+0sE|~du;&Z>==AvKASnWM@lmReB0mcofgSk%W2a!5Zn@nW?p)dGf>=0j*#$N0e~Xh>QzK@= z!>Zu?LU=zno|S`c2>Fr)qVLV7*79sJ;w}0v0i`Q5$)*B3$nm;I@W}7jq+5>op0-j} zk8h%w%)37B^QEN0RT||x7U(M-2%ikqruoH$P!}C`_!f(s_6f%a+EMuwUp-7ygOK&J^i%HLN^0vH|j%g$6mnP?^#=$ z6jGFEBfTRsJkQn#m1^shB^%L!6Ok?8_t_+y> z!j=Rcg`A%J!?I%KZkW&=id)j@$LC3c)@{BPkNX_324FTj+%37ROrLJbU6f7~r@J3O zh_smYB3rP7Kw2bMGeZj^5}Fw!PQP8z5QFUMWCY_N@l76xD|>~xa{Zb}uE*-UGCArC zh@mIwgyrvks)3hM*Z8N(3L}Rdz?7-R4v*?CGjb5=*c!^UoVvf=_nC~Kv<|vu%1H{T zO(-r3TpQLi@01XX5AF(}Of>SvY1IqKU5HbtJ4xOka~3CQImMJf1><_;OZqrIz=OR2 zOWE}*CG1+wi|Y^SD#5ykoHcvY1}=Qk#UI`%aid7Y*%RLna91{Mc-BW5p6<-%e%#%h zQr(V8;}&j4=So0qFAluO=X?D=Ki7OiC}&AA*v`_TFvFspXR4~x13^*1Y7x<5R7?9Ji+zTMQbDXWGEt_TsG7NwhwW80`Km}YzM%{+2l!mmh0 zJd9cbRSx)m#Z?bPx;WP!3AQH~_ezW1~_asZJ1;#>aN>Rc2d{)r= zWranXDO(?5#boCdNH|zMr-zFXuZd@R@mBGA<_C_W1yvEyk5iu2qNi^&fu`5l`|9wp z4eOL?tJB|LJ=s90zBK$i&Dyc1hoB}hh|6v^-z28i)3VO+7E-m}xX|75DO-FblQYTX zTAvrk4wI1g`x-oM;b2)VmKdrfu~w%JD=U(G!MdvxrneqkyA5^7SsX4#2S85kpwGBW zNy_Vl46SB;a`M+U9idD)eUhAPEmBfkt8f5FfE1joV(mVOvs)FBXefJChg!D-6UB4^ z09^F#@v{cWnD<4tjP`^z0D6Q`(u&60E3izq&%=LF6Qo&vc6b}9PpMwmC8nTs^(3#}(^#&HQ6#j@ zk3y3kGjK$kd}->=p?IqzsBL1d?bpN|v+If|Iq32F@eyr?W{LC5@_*)kvjr4?G+DQ2 z9DL0y|KH~*v#3KLKL|L3x`A;2c38E+yoF@q#Az0@9I6VCiF}_0olI@{M)7p78y!?2l7f;vlSh(<&Zs$u&b#59@=#Q3PHcH5c}x# zEu}0XPUn>MeVq=#&@h0Gnvc`_Fcas>u9Nt)F{}^9^oEwsH69PYkgIU}2=tWIY{b`qJsi7UzbmEhT-blJ z6HR89D+*aBLAEmQB1t?Hx;*TXDWv;{1GDFU$#Ky&Ve^_i^qrn!!Nc z9!P8At9g|wmiAKf$xMAtu}i99XS9BdT#Kq7GDw5?L$?1kP5+ty_iX|CQ!?Q2sw@i9 z_<-i|e!mwF>SorLwU!9*^pmHQAVAH7YxlJAu>=dB7Y{K&)t~eD|GXB^`D0mCm_sQ=>a+UO(jO&$C0yALw|$qagl!mGS@5 zl>&=VrVDkHtbG{{CT}RO*=uHXgj4;^&gsx0UNL zUa~7E2*GU(oVxfDi)Kg*YwvDzP!wlHPTI)yx(5Z$mY<)tGOJ-uiFvZpKZ~_DJ%65S#SVxP2v%JaB2$P(oL@Y)^r_ZfTi8>8QptZbQEC{rIQjF0#n}@wMZ-TgkFhP#FVt%>NU$Y zA`6b)h8g$z@moRj$ic8RRSer(h$d!2&|NDAe{(}(Oc+buz+uwEpL1~}Aw--*DhpX{ zvWvcnvzc%$x172dc)K}S@3B&eJgd`fPd$it^D12H+qXJPE4qquOWNxk3e$IfU~hWp zc07TI?uA`?-x_mds7XU^FrNNo1d_b|N4HPH^X2h~r;wemh`ESAKADde2yujfUG4!U z@a`6XS#)xyRI~2FiN?Ndo`ElmOA=eM*!G0U^;7VLVV$Skl^-Rd?hTsUE*`FYd9ceS zDIfQ=Qnc4Ya*~h0qQp-+&=U~0s7LvVfkmqmWmuPzI=W#~vue}e^g7i*xzzM!f`i>X zznQmArph6b%}lG&|628uBY0>|qwq!D_n)hRE8qoi-V&AxDRc_x^F|J#UZKaL@x&XZFb?V zF}}9f8M+`I4MytAiyV-6He|0>HWy1(;K%ctU#a_}0BGzIihDGuAXUIzS5IQWPCScwp49Q=rMe>5hLqqId%2D2+f%o zLbe*A^COxF&G!aV=8==-^R*oMSV8w zV=R}fs7Xlq4l(CPE3uREt>WwiK6Gcfcp}cCUT2a1x^7)xA!Qy))3^namR%*iu@*j= zL1mVx-CzmU929K#)InbHN-iZ()Rn^gGiBpKjp;Ha^^96Xcb-V(97JzHhiQniu{^{o zFwxtx71*qU?b8GNGI;30F|-gN9y+7bjac3Qu-GSy$A1YYw5|FT8_l%W@3YYW#_jww z^AVGhBCR5ndu2@>4^qeb{9GAUNnB@LU@CcMd?nX5g?f2!?mRM-J-j{UYDm-btj?&z zy*y~=bTC0%i)G_vr^>W@OC;#k6+N=951k19zDE49d>WUr%~|gY6!bOQPaGgEj==j^ zk&fLgFEJv2(eTBSDVA(=)G%ghJ&2usqkL1Ru1c*6dH!>e5f!78*#h_rX~@oEE>LIe9vbj)al_Sq?L}S@sC{1 z`|Q>ETv1Rq`|0XwcFNr_YZ4;J6*C1Zc(#DbXQfsSwTu>*4)B#si~(@)-t4xx@KrrA zo>el^a4y}skk0st4s-4a=mgnEFRnwaFXpOkakU9IHm<`x~? zedfEw8V-ahI$d%o-t=Oto{CzcG2|r4AVbF%o&BzJ=!yAP7r0!5St-fB2%zS8=U3J* zP;{KTtFXmTwk7;t@oPE%kMSa4y?8%!F8iUCL-isZI>7M3hI#GQ*9%6Va!9Q zbJjTQOFsOCI1jM}u8zM_dJ{#tEvh|}$ZKv<;Nw?fDEwd>jg`GdR#B-qGei(0>Vqj1-`hw>zftH5AH|5f;RF)q^-Q7B2 zvd1-0k4=nnHfOw;^r5y_cbLYA)oM(aJUi9w?Pc@B0n{;cP)~ZBA4-; zb(r$mz^W)oGCRH%$T^o3nGMYd+UVHsS|2Bw<7c`ReY&(Z=Rd8s#lx5-=ioY|nJ`77cBoLGt) z*i>ve;I229RV!MUJZ7OszrgzB`0Rir0Cj|ah`F8c3eJS50vy~ z-x2VWg1ETXG_l;zA9s>tUPHvGZA;R+gCrNnsSq=<0GZ6r+!5$&ES7<&*k1*hVQlbe zzpAO!1>#hPl!6H_t&Tw3j|W-|e~s|lxBL|y3jB%IP{gh&&S75&$7=W z*X@i6%V|dOCYln?lPdN^k&Tr&zKw{v*L1ad70t-K?4%cdq1xDSKj9ACx4K*xbgfo2 zm)0rkJ#Oe&Y2;~oS!0YBZ9nX#6g|$lmRtPQz^_u$`H zf2r(DRcqr&2Sm>(dwWWaSi23MU)Pa3htr!JCx5@j`EqOtaJ&$3=Acd?_$^d*jFq;* zh<9$Hc7V^iO=IvRodP{t@UQ*7Cb$VDDt(U{Old2Ac~!BL!`)G)>!y{RzlDNVGAy!Gy5cx^iJ_BFEZO4Hu; z9RUWHXv=0!^Bs!)O6{qKcCgdwlAvnHy@Qy^b-${~a~qz?G2A^4^=%GX@u8(i4-kXo z?m+K2*n=NnG79iry)h&blgw@Txq>pd*L?z1vR+u3jB}r~!QGXBm?t;qk6srtpj$Ap zP8bKB=TWMY{@~i2lb%J5isrJcl96?0mpt*mgwlb-!Tqe=QzsuSoR+=KUsd;mJ z4*tY2-SZXQ&eh;4HqLsHH};83=M3cJV39{4!9&3vwUyiGGzXh=i|ps~^!ISd)0^xnPdS9E%kErlotCRcmi1u)rhpmVTSpMMd zOfup5CuuHj%kdrV(cBBV)|JXAD}`&uSk*hBjkdprSP%)`l!Hgm5-!oa~AnUxE0Xn>#;ak z&0eX`^Q$__A{nDeMovWioZXWpNC++tdI~4C_u%S@mdpNq?)jN#$6F$$st20sHSL!e zc6T+K45y}K1BKa!LO}R7k5E%Hsd$8q=`+8zt6bU%s-y2Gz^#99vu9eeHYRCN#LWY` zv}&Y4vye^;uq>%5=OC53pKaq1eZ$pndAigu5jA#`KNzz|B@QhDifl%K4+rdXsw)1w z6R*ZxX;m!+gbD|E-PSWVtRO8#gOWaSnu{B2?4zx0!G{w5Bce`BhWcZhFr6|7emyRJUh6{#drMy=~)vRNyPYLV+bI`|#wLT#A{@Vr}T|}l!lx!!5kVR>1R=W57Aug5}z~eP%7u2trGiAVV z+q*4&$*C~?n7GMXYa77h6*EYpql`qD5sA>zu=#0lAR%z-s zHfuyg*G@At$eYc6f`vb5IzM80$`*;oaQwmhfeEfA$#&x%LN%+>o7Y(4*=#%;^^H`0QiyU{K zW)___KvGT*QlcwiNe+PHMLE-R8&reVmv=r?pL0hiMuL_5QW5LIK)Ug7Edr>9 zzhQ{~`BZIj``|At-~UGi-k6c5+-r>0Tn_0r_7|F}jX|N^X%($+IFAJ#m%j%qP+Z-A z=$Q_)`5M0Z(A`V@M-ln`s_Jf?OqLs}4oTIVfs-0CsDqgigSp-C3A50>cIY|F z9xryBzlv6^)7KSdOW3xn(7-I@G7v_`cAt4gf)eF=|f> zTX1*WAwK!CL!fh9X=@Cwu6?vfTNd=>A)kN%|xL=yqt zISc+D8NM3AVPSPs@87zS@|qrd+;yw|8_zlBNB^3a&A;aHsMPgnY8wE-)dgN=Ucg6E^NLM&e#?SDW{S(zPtURU0#0ZhLT{)_A1E;cm$TOE{GdcaxDF4il+f4(9pfBpHP zH3yGqcnSN<9lWe3V^J932~QgumXf-Qj@Mk%ynWA)%Oq`yZ%}q5=?=$nd1*1V%I{s| z{tqE1@Siecq|HYp$nph+t99_n1!^&Ir^IOn(`E~*-1#wFeSZvHvj3Df`CmOF{#B^| zBkBW18pSaT{N9OPKksRD((xtfYTJSC+>XF&3WpHb0k9F$pUeg$Bfy9Nmq$OEGkn+k z6eka!lWUdBZ1o64$j*OU8K(VE`B;UFanFrO=kp+JM}eDHXqIC7LZKM)-GxJqQrPUg z)9BZ;LXEa@`A481st)11s+0XAFBxZYX@{LMr-BoL4EDocIl0Ce3TE1Wgsc$@G!Hex zz8>SQ-nS}lmqgU&dfb^(yun9WdUy-v@L95~aGK-eJXv=MKi{-+bR63B5y7AHP#s%W zwW{;2#JgR@KB(`OhZ0vF1~ODVR%2h54D0@qS;?j7im~}IF>#o&crN$+ z5Ujf6KW3YbKXrrulon9mxYx}|-*_i&A|g?aKgd_DhEE|#kLl#6AHwSw;^QCb(El@4 zXN?-XD%Nxt8ILi0ni&RPlZ$m3Okg4zncr-)g;3+w+!GgahKBv+D@Xhti6rPz^}}#h2u?i-es@)rZ3*)I4b`FF$A0P$ z74E;CQuRN7RhT0CeEmXN_Ii1M*$>NQeGM z)bT$Bje43rr^2UcQlIXKt0v~OtVVCe9wxO0U+@j0Cc9Un#XI}M!uI<{_y6%#*8#T7 z=56TL_eY?mnFGkIGGfQh6TAs<(q;YvL-5zF*U3T(T)=|g11 zkV843tOJc>0t2&HXkft^UAf13_dGr!{IA!7o4^?1ZJSyf@|sCBnV!K7nL`=XU~8VY zA=04{Fr#CvZsBk_JoiQrJM)HPLC;-izA$6|lq>nnWhV7q5EUlv?>r0y{wf#)9B;Sg zF{sluDN9aX=ks656(u&<(HgmaGP&93Z%HeaE12wmQkO%4eKQ8$Wu_8nhn+83Fkp zoD&L%OY7r}a$)|e%Q^3>3NNCcqzZ2-V~^@g$;u_j%}`_L3JbmeT2qO-Zj! zGFKjJ&jjv69c zQFmtbWLk>W<)Hu_uKm*5^!TGEDDzl_$&K6U(1&vJ&(GMRPD@;72*jJw zI@_*)$%Ey$CqBn<@Iul!Ig3vgclfc>zG?6h3KTEi8`Mb|HhXx>;~X8hH#BsF1g_x? z0{$(W@YMW%B>6b*85?1_dpEZY$IQ6-j};~I>@t3nceOdYd*X&S1y*nqq4LBxAD25WZ61)IJCY-C#R(1V)P>qR^#Rl*6!4%aecRd zHXVcWT13YsOj+6KEf>1SESHd-P7DLgpHPky9%<=&lVsXYs5fz9(hF4lb`&%v7A=8h7{+y8R?&sG^_pnDhb7N3)`V z&{<|kpdoOshLHu5tlWu`+dq%(0cxMCH<#mNe}t zXJ4J-5{MUVboX>+!vKGjZYnahjy<1EO5079Gzq-@_<8;sM2pI!?LY+A(Z(if#{G>{5@5l4Q`6*07TA_sY6RB9cq?-j8`GLiCvlpVh7S@X=e?Ix^jc>t2+ z=8d~N;X@WhKt0!E+*0XTJJ`W28k%BBCPs+NIpLaJJdt~_SJu&&Z*M($s66#FcwI!!@~VXn=wMeLa#*-Pxt_y{XOC*g+2*r&N%qw2xF_Be}16}`K0dZSY3 zOP?l@wD}<_LcLp-t2swZLX0QZL#*+1XnB!6PZ1{yXKU~YL^;`Bfa-Ejg*^o9VedSV z>2^K}$=Z|J*DiBCyyW00N||Uv^?SF?0@3NA+)0y42D+sD z+%cE8K&vzpG`MT9I^ln=Y8rL6Tw8)|>d;f}fy&1~qterY9)+Bt+Z+%N;|iDgIy60) z%%yT%^&O4bh4)uq1flp}&3KZNjWezrif$}7_|}XG6!n^t4mBlHd`jSHc`OQ%KDO5= zKF}Xoq`B80YM|R1uJ<*5I!xs27fEvAousV3ik(C)%{;FD%~Y3};M`2G^chccOGg_| zbGp9FX5sR5c2Uk}86=&)YU+K$&jAt_33HoCD22W}Yu(|)O_9LRyf4oe_`Hukv;oYlhl2sZQZd(vz2(853xXgY>}$dY z1-7cu?=oh2_wQAv<8B^-xbhSZ03YmxxW9c`R=T!a_Cx8b#pXTRfV|RX1>!^?3G{t_ z(@%ybpy$5af({iy4)`-D8r$-!z0Mmw2ZBLBxAn9zyA1G0y;j+~rzBo$8oZo#>OKp- zha=W5uZRT~jMeaj^0s{WXgz!fvj~R_8h8e%7M2ZiZC=!Iq6z+{aEri~)sx>r?V*c( zxpl)Q@!5^7%Db9f^L`{-$K2vzY1u{hdn6RGmW?#6-6uo8^tA6&>B+~@f?H24xk@FM zj*2T|c^c4+Fd+qIxjLBmjI0&A%LC{&hP0W3=v_&^3HZy*tUepR{&*27voJO0`5`q% z$V0D!6*sNws#7|8>Ejex($73PxRQlCa+9w~B@!$Lx6wXc)VW0(l?=Ks2lwL?l`T=G z%0`}w2LKT+@%X}kQwO(?y>M_RgiB2{j9cm@>b<9(R|IMb>Rl>4n%DeEzs=ZzteLjm zBKIIg6eHQO1{`{$n@b%(zEalZJs944c_qh>8$aupBGFPF$-Oai;ufrSL|r zfl`4Zh5f9-=Od6i>n-*m(SsQ$bSe-8q|3u{@?~k1#S;De*D_h+?ycvNjP^TCs|LYN z!h>Dk=N)^#! zY!3X2UGBHov+u|<&ksM(Y#O~spcxuh09^n92$_Yo)cy+9>NEHSqzg{1^&Pq8*#JHO z6x&hA*UG5?!d=7~a`rD!uAhiDe^McSsC9oG?kXNYRR79|j($(P zqO;^SUQbZH^6YAM|LEgauIKXK6NYmZB((=x5%gDfByFa=QX@qev@ET2?n=DURrXrd z-e%9VoP)lhcZ(~+Le-U6C^8C)v_G@o<>!VvWx9big{uu0qYf<7;e#W?c@8>LCOlho z|FKH|m=xf^oj437Bzy{pZPx5f@Z7u*R|5vQt#TYPuS+rEwr+2DHW9lzW!h&lEL1D^ zsbEF{-jYslJ%gQ5lz7)qE>bgyrwixj?KBE5jeERG`65#dproW4DNx}Ed|#?)I~`VGK0QN=p={Hdo9{MlT|%y z#>E96oaK30UqItm?#yVU7igv@C#4NNJ@6Pf2nNEXeF-WLV?9RX={&2V-diBf4}nDk zJb5J{!~IlIVKUy(`h#Q5>CurXrU{E%@THsAzv56**LSEAMG)Ycc=1gXTQchmLJ6 z#xuEzvoaS5*3)J7`YozDFl0}qvd4sKTt{EGWFfD<2{s|?d<3HKkeR5Uco3rEuJR7P zPUyo2&owZlH2V}4wQaE;oL(o=;{s~j=;K+VcVjM9jUQ(0v$O>Yz`{vvY+~ks=q%%S zek}OKHovr}@T!O^qH0fT^JWaKA&UFt*!ay>`vtzm_dNbfW1_3GijP8N5?|FsyxZmo z`CR$og^P98bljMFBonQeLJ*SVoJ1TO1`ucfm9{nBHrq3)PUg``&F&FY zamC;fDF3+-?rh&?3KDPcJRNMmdX<@lT(B^5hS0EvAtd;qs-4hsxQi2~sPAH*q@9Al zdqX~AXLrq%vxkXf2^RlP*V&X(*MMnhlv)hUsd_^F4AHzr3enq5DRu+HPOxP0f#-MlD zZ7pli-tkHgR9*CJ=1KQp7FGXqf+k^oeYX!n1NS!(XDuVYFs_d_=;n$ZwzyPGd~C-TTZT%aE@^UJJuohuCg4F`?5usHR6L8b!P`qrKYfkDu8U1Z4)^`a1ohB3I1zt&oA0V?qCq z$?K8;-B!HXq2(-@J z9z_7GljY{`zMB4Giu%3v-CqD;>bt0A*kOTW%0Ult6=qHZtdV8PD1tq~99VB+;1o>U44xlOYCrw$ z%%o?F1HoRuF%3&nH*6B8Q+}xYp+@gfIXG?cU@lic0+uvXSO@*MUqf|f5bvg?o|zs0 z?ggOVk7(V`WRtmkLZOMXIP19#=uVTwi_7NbPd^9luTQa~q)^jJT{prM@eDE7Y<}?c~5T~!`+J& zSz7^_6gNQoCl!_CMbd>BbT(llsQK(`)_vnV8{ELPbEWXJEjIS%T)bgxf%3?wp?Yy( z57woL}T-g zPA?()8x(iwc8TD2cE-N)3f7>?f2H^v|4PE%wfQ3uyN%5}zMOe;b6ukQ3=zD7hTN*YU`wTWrzBh$zVfse| z;&^R`T`wN~$xQH79Lqr%P0N&Ix^6oE$J=WJ1h?v84U1iAx$wdVtGkA1YaoTv(_g=h z|F9ywJ5EYRR=^9gw*q@hHg{$hb=tI%P)z_SISd4IVUnDsFvMx5T}R}!Ud)PEXH^Ek zmk9RY*!2S_1RW^to4udiXPY#)kDfy;?jkmfV_)Q9nxipzAUXC!>>qmKJcW$d0CFQ?sonr3!GvQQ&-@DW!4nA4$7NP;oIqa3-!lF5$3OZn2L|>B z_+9N?>tP%vgVIxuBx#b~#NK@K@7xPr)GoYBCqMcNWmvHI$(^X?#U*s3e%0H;?xm@M zN*_UA`2c0;EYpyVzEt~gO}nvDzS6L6_EW-aeG;O6U}GS<6%S%DObczjwV(<}hckNrJ(FvQBkwk^Z&~ie$dM*#Kvg!$WkPCDz{6`PqkZYpF6!SuIB7`kt&+su z2%T&TN%23a4&xI(qqP$(119r&JVrvibXkNB-x*9p8+K#DN>^@0epUAwU65Xb9 zAmpg`#C1O!6Y$ad?@Y99uXiF=8?e-eSimgbYQ(P3reQ{d5#(tEjbk+wG25o{6;yo~ zLu^5edz0VOyfz|thyY~ClltT494LpEW-rw$t@-tW%jSL-$NfDo!+VNB^;u?3$9ut{ zRf3D&7dy?moUeE?1YCZ+(5|#F_~=geyGa%lQ{(6nQZ<*A_tygUm4?9kUK_eV^5VQE_rdbjG{SK?3=q`2X3C&ANFu`K|Da|=DraA4tdh0k5ncz zY#NQ(O?Xs^K=tN()_jhZdfeQCFX$EQC{#NPFx)TyRri}XpaAOGwbho9WLi67@#$C4 z=O66}Z!HlmIW+Nhh!EAgq4NcR3$(vlt#U`!aBmlBux%pR;1$J|1+!__iSuqd=Hs;M zvQAEmJ5%*S0lNEQ1Bd!nUWEw9y|;-kgQTGNS~P71Y{2#{@-%1lTSe-_;2VWcECh?9 zrI<=A_<$rB={bX^Rsu5(KS;z3s&dm0Nj$+Md0pSnaL8WSgPeGHAKzF6iFirikbEug z;_~98?(%vLE4Xop~z5wB<&#Sbsxpj729uOsGWEkg^PqIU|IGIliQs{pTYp;$n)7YEGA4eMWYMtuk zbmZ}p81Usg^I8xDz zw+E_Cw#^9UsfY{PY``jB)*=gOk@Y)}OwP*PG;XU2WwBGKuy=wT*LA!P=yB<;n~cn^`owcQU;4s*2none?gY6cmEJx~ZfFsy-j-FRvwq~WbI zcfybd;w^1U)0k^JenPM=7f4vHjhug{>iX*4Sze`?Vo2l?qOuFmSlY(ww%Xu*q{YfG zG`;jn!iXG10y7MQr~a*$GEZDYm3T?9c=ImSrorrU$WR<~tBZ}Iujx$0H%T9xx%3tE ze)(CL`#YoPdK%>}LT!GfN`~AtG1Ls*M89W?loEMpfEm4}Jg-|JG6rNXSL?+TkS^yb zh8ErL7L`!3o4n|6CM{oX{%R%JxI~YRyvl8KGF6D z81}^xsZ2fPlS|{63#w;GizHvns|O+vFm(o8qvPH|VdvF=$=OeB38C<3=MCUdCb{1% zAw6(-JmwMgDiiW&|AybB#VFw4@WJm$O#;rx!rSD2S2DPP&zbhQ1o$v*kv#g%?8HX2 z2>~k~s6a+%NW9tJ>If}OJZMnTLQ^mB_AVs3)}a}B!Q-2WE!nf9N}@CNm+wxBY>Rem zQ}8{b`!|j|Ap!>+g>hK)@$%<2)1hIwsdDAnMUzSw(jX9$GG1M9%>Qt6`Xce=EoN@j z$gPsI*f{7qB=$dVXrnUrK)RZb7;u~vS=8gc!l6(Ct+AsnV#%y;U>Omo--`aE-@JvmJ)WL3D)@dxYs zhUqQC1t}cL^IP6WKk(5^PNM}@d3Os`=0Iica)G|o8jI}Bmlk%Jl6$9P^HQxhi;Fsp z2S1!As`ef{iRStbRNl;b z^y>iH$BMg|IjZMX@%KD^FY}V&&k+~B49MB)z^Id;}v~>EUEa!@UW=2IjvRZ zy+@|3St*k&3or69f@Qfvo|DK}%<=qogx)~k#`8cuJ6)zQSH4*vzidL_cv5i?Kb)_3 zV*M;z%b*b?=KR9vg_p#LDIUUkZ$ICCxi3}tf=>oBc1K8lTuCbosn$*wV*^eGGnhKdkmTvJn#~PL^3ar+kgYDYW=Z zX7lO&;z`e8@}MUk1jhwe_+E00CtA1SoT~^dx2_=0C&H@~G}Hp417S0_BufcmP1=JC zx#OtPTgwmF(+XG|r#~>xXwB_o*i|mg1=46qB#-LaF`Klsq3m-{y)?s$%1KK^%E<{X zz&@ktkaGI%zg;YvyG1q(ApM=`g9DdpOE&KD#tf3H zlDz$Ob#A;#(P05Gg4j2N-@NkI{U#@N9)wHL)jcYl`7N{GqrK0 z@CBd3jZ_NN(RbM;*n{mw<)(a@h#rtxzvbz#pd&PnzQqBHrrb2c^s09Uo*!r^;oy5H zPfxA{JJxOjDKvtCMeUOFvc#lb=ee7s2L9Ll?;0}$97!LlX<+Htju$c2dMn}JJJcHk zHM7zp`#DeO4YWKbg9q34q*Bl7Mc%u3owrY$9c{+jH{mZSfK|95x!x3>Jz^=-n3r`& zC}O6+K4l3lPhv1C^ops(}ZSIqAoV^DP6 zbL}O`q=pCT&{@?2BuRBnI`&EX5gYr^ehI%GSCBorS*={(dimFP^8Y{Xvxp3mgrgDv z2;f^t{Fl%A*K7P&753jj_SyrOT*OM3AmHN$d;#XbXMg!$-^6#Z-W?fIj$h6ElCs`F%3NnOn=`7)+_^0{z!-NIt&fhYCd`k!2x4-d7x zy&!wygVG&eec8kC*mYQ4L$O58+0Ta_vOT*U+r|*GcKPalV6wWm$ zuzi@@ueF>U%Mus2_9aG@#ZH(-M8a3OGgmhu;g9Z%zYE9fi%&v14atUW*2^!nVlj@4 z9+-lWP%5CoaS0oQVYBgKeZ9;rDrwcdn~aAc1~H1z=W|!0zL0T^aU)#sYX;A4_-)+) zhAxPm{I^cBr)jiRz3S+dH6W9b_PY4$5|iCaT%5Cs(G5K5Rw1j>_==sN&HH59Bf54M zkbdwe(!@Hx)5N5u%UI3bjQWTc%NsuZIUvK%!79p;#V3{9ah<-V*<+q6^m@pO%fBe2 zAe5ZO%3|SI_`XTmaoH$=J*vvv+K|l_Knq=&wEVxYd)jx{Vlp*uRmq;oAxQhAfD~+!)16gS{|N5(GmQ<@zuz=jrsX62(7%(~&b2ZeB zBxkXlh^ZTZiw(B{ECn9wJpkrD2oSMo!n7vY;w2A+rLaIr8`TtM{b;fgO=*{dR{hO2 z5Nc3_A?`5kIw5C`MS(&0#PStd6%cIG?vK7=V&VDAr16J8{ztpI-(mf1m+A%VqTVv5 z2hsaRS1s!gw(5Vd%kF~T)tuC~#Q@H%?^Uf4^fX1s73=OD%R4)QOxFX1N&ff+{$?Ed zVN(_Wff-{Bqrs$)q+jajQA!7G8NRw}3B-M4U1icJ+W4 za#4GCTr+gn8dD*nRDe?Y;dT6G_WXA*{eM!IXTRrfyhcz;;ep$FispKM`XU&ZO8V!? zGUFN^y)VMT+pl2HPQ0x^F&n#aAcN`d+rrT=UE#MH@3{3IDb|9Bzm{9l*)McvDPp3QFchYeDOvAoas43CGRtIaMmKPcUOn zt7PpedSHFWLDOja3To`C9=}co^dOPj(ul7h4!}p|e`O31gv3k@eFafXpo9!BrmrA5 zG3pBdst--29bJ6{EEV^D1;qe1DA5U1mqdW>f~waZU}&O|zyIkD0GM>G!EEdSmaf1D zO)f+H?!VH%hzl@1)FF9E^4t}bwFhITQe&1SiaOV5=n^$G zT%)cmIACF$<|}jIiJM@dac32$o5D}sW8DSI{2$97#YJcqv<#{;INj$XXj(6#a`TEp z&ft>alH{!&{Tp!3uJq5bsWZ#n#IvbnZ(yCBg5K*zB;uN@2g-a1Uy?*^a-q@>GJ-9j z^&7}t<~fns$Z&5Mt*09t;56@OVYyxIEUSKo1_j2JIi$R)#jbxA5Ppu>E#Fk8eO?EW z!fuX+P2wTD7aHB;H;-ii5No6mnHNxV9u!Db z;D3VQizsZmmFabo1~n%lEYql*2AHM7lpR?U5i5`745ISIo8Bxrh)u)x-DJ_&f=ZVz za%zGQf>95;bIucptMb%1s&$J(8t8NLyjkJs@7sGzv*QMK{@*)HOI(O6(vYDSiPm71Qns!2W4fywvmW2#N zW7p2kBS>V-2E8d_=PKsIdmz_5ejJ#6S>3*ZmiK=Jo%|95NKOR;qlaV@6&M7fXp6Mk zPR!hg#UE1}enrJ_{JSsDUK=^wh0|4)+Iq2{{#6+SBZ>S{5xM#3-32%G>y^3!gCjNq z2SeuEsXZ8(HN?Q4hR@^YWJo$OcJ6PV$cUuOuIo}4KheOgPpDcQpT-#1Zyf1+hK1sw z;qI8)?PzF-%w;doi1i-NBS$7llSG^t86lxSR8|&y#Qj-L^X^?Q?+R~8k_Gw}Qt$gM z@Jc88^w5MB6&)Vkfd=`DOpApb#1S6bi_-~kRMzAr2dP_2rD$m?X=v0kxeXrhn~+3x48E-FBzT0?Y$Ww(9aLeuRPc{Og@65xgXL*%qVK{Z_8L zEZQDy+iC>O_0rF?h7JtSQnPORxH=1rK?a`{Aq>el<8DM@;jZ${+C3`^sx`1;aU1W# zO(y@1txhkYG^;g`K+*dU>E~MQRv74Iv{Z5wi{9t zEm)VJgyq|#j=GfUg>gH>MEZ=)k-^ zh_uJxw1=4Rf9nXQHVA?Y;WEn@_CM`Palcmm*&lel|E*(aO{6xyd*j<(`dwgop4o&L zH6|BBs~FwZ7ypg6Y4$Yk_X*4Y3XJ|1aE`q9{V@Q`RcFLD!w3cs*c9y=KZrm7zate| zI@ktryIxaLLOhnhxt}G=KCdRC&p2V$PS$<=%ASeI218480g3dw@;z7XJVYf`5N97R zF^5L7S*1LA(h`4QY2UK{$J}!6L9|-k2&Gf&Tww$1>~%Ws*Z}$3*>u~!k--JMV_Ut^ z!Qavv+_m2~lp}Ev3=?_Kv^je7ZE;n>)9;B5jyzJDzVpQ1eO|kp1Oo_Mp2WQ4>0}F! zHISiDiradBvHv9D9u7vvv)rUgRJw!C9c{00UmC0CO()l>U3Jm@I(=a^#I<^<1@u z2|H4L>k7aKRFxz`Qe@)|V|yA#7cHI-)6$|*i&&66dvX0LI8B&cT~%D3 z7afD%D7XUtBvV)FP$~URYsw4K>8er!1DlZ-oItsnqSJSE3cM;2VAq{6x0sp-gjVM9 zPmn5Hp)8V-7dXR|Paf$D<^bFi2(AgZm{GF>q26F!{8_`p6R@Bt3}uq|ug>1CuUS{M zn`{Grhu1ESUcDsp?2sgn)Sf zt=-3Mh53>4lm zh>N2PRtW2IxNY~NP?WCC#oS$hBiT9zpd@xYR#p2ty?b1|2D9jn^#YDLBg&Z-%<~#t z994C~)~JzEkF<8=v@k0=^Mp4lq9wG?JEICUU47W?g&xuSEq)-e>6XEAhyathS^ld{ zXx3`Nwp~N=>7EK?j^t*Bc%0sqyTNq*$ColI0~b7JDqY7jYHPtUxo)pP=Hp{sL*`g)Ziwu_O7d!oC5hqepZE3g7Y>6S&A$Rwqez0f#FQHh#qW+Ua)Os!% z6Rg~d7AD%d`T6&`V;>0WoQ25=o_=45IAl2>BD|208yjVEG46VwXOd|pIhHYWA{X4C zZQPh<=r@iC1c=xjT_DJT0z~?w&&%vRCd@=u7rNeOr^lZ&&jD-~UqRHornS%Xp3k zt>`{?uGihR3lrDi6Sn5I!HMv{=N70{(&@xqzGHCA{kF!=@h9TRnh-xh!W)nD?jjkR zt@BL+Zg`hYd-2hYnF<$Zu*b##DXC|=UH#Gwqq>{E_0hTdZens8K3ajuZS=ypptQV< z*^1}oM+T8XwGH@eaDL(zZuflG#jSdkPO_zQR%*NU3vHTpaJyOYX zsOHc^Fkfe9Ct%u5QZnj3U*BnzZnJJTn(tJf5s2u&^g!jn<+13?&1!45>f>?go)bp+ zBFl3d+XCx{m2DEG1@`g~RCy-T9i+Vvm6!Caa2?^%%h`$TqpZo%x8u{uC(C(kP6FE?GcXL{|pjeq6ls0cJ+6a%kwXxj4&1X>J+C60lw&6FjHXwp7)b#{HR zx_VfFEux~g(z@p#2|j+eh{%@0xC2D~wpHoQoc`SzicUOo0mBu&2;f{dO)yzhYak|8 z=f7UYU*AghR&srlR24`5fYj$qwdzto7-HZ%(5uxzRUn6&jiIG2`yH~cWh`y>&(j7e zV(Z_)VYl}HILuw}U*K@Yj>a4UyG96IT&y&tsh5|UqMpAv6{$T3qQ$O#$$Eoaq!i${ z);~JB+i%~KjrIgxIaqUms6IHDdy}G`oyCO;HWEmt)l)^fse1`KOG+^0t_XI$<#DETagyC zmEsdfsos3Ci<2K*?7|fjlEYEBwp?Y)YMc1PWL@s^GfSF|w9}PRqjdv{MdecOc;D>i zn?7_u;F%xMu!WdF<%cT03)PC=y#w)Fk7)>XG*Y%v+)#;?j%T9BN#<=#f@F``*N!2C$dIp~ z{Q}Y)aDD>iHU6}Ewygh^NIgyCEz{EZ#EA-6Y*a{o?452lKU2tu4~-^jZx{B}vX6H* z3P@ahn5wj3uN$zBdPY~YR_AcT80hk8|C>wf@@KDu=%cOPr1uH?8YF_41n}8ZS@Pw~ zMSc4P_=)1^PwH2X%kznxYc7&`Ly2k2$RuF`u}qS@)+@Zq4N_~jtSlAw3GB5f*=*KD z-gMs}L2!iiv6<9dlln|@z=-;}bNlWvJjyAC^etpBXu^|I=Z{aS+*Ns{sM2xuO=isv z8IZ`oaYU$l;r}7s|Mcno`VIcB@;8uf9mh8Ig2S4!p*&hy_gyX>V7h62`E|&^e!&FA zh%?>q%X#+FXI<e_rL!) zSp3h`?=ZZw`&Rt?cWhqQI#)OIHja}-pDPhEzF|w zPT^kp8~^4*(o%$rk+Nunj7C}^V&o{fx;JB|4uIneEdT0C{-ewOpLMcOBrQ)fg{IT| z6{IiN4#Y;80Xpw7bC_5FkT?I+8;e(rmJ08dIDf)tg;lb{JUrEzC2ZeqPd^Q(Tl|*8 z3jBMHL&oq;rh@G=gwbGU)|0pUi=Mr?fH~}}N7eBo|E(4vev)d&6jUL|_~PtKYeSp6 zocx0EVfGO)rSssDE%uFX8BmVbPKfQVef{YSSKN!^0V*G-CwcfIwZiCEV2wb;CZ_4U zTWFoVRelR&`s=0>(Gu=%&HE<1%|JVm4yK{s3SfE$Q7y>9t{K)YWvBfz)$JT?yar2e zdmU=HWA#KWO3e3R zxlVMfyiyZ6{+bFU>W6u0PpE1G>Qq?u_m3-D+MCxe*oT&gu4?1SR@F>Y-AU+Ca9G%hAlAWm%^I=RAJ-c6!$Z5{Yl*4skivXH~=-pv+gxGL9T1DT#_r^GDwd9L^2 zlf7;c#|UwLn^%P7dRCw2T#~IzVgVAnjV3o$tWUH>GCeMUzUx3yD4!}ek*YoaZ_#;DeIMG`nj`e8?X?EZPCIs_pM{fza(hcziz(lB=Q{!ANAlH^WEe&Pk-`}>;vA9cw_ z^54gp^wT!IZ7A!=f8A@%HAMD``#6HlcwX9ll=+T|884nS3KGYNF2F78m+x89IomJWn#6!LZ5~aYs0t=) zPS#E=GcCF1`(^iK-pY4>F0&tA8Ceayc}ED?X1~S(aNnv0lm5FK@6FdGoDQQsq28V$ z8#3R@zt&p%UCUI}A#xs+nfy_2O^Y|2f=<>q^H=(!75P@ylTonnA#$IWKG>gXp6z}n zqG=c2Ci1Q>_5PXWJ_yY3$Uv#sW4K6Q9Zf>F;;FKkH}-yP-?-NMr)EoFNNw;kQd_^f zha?FgB__n;#<%m3W3~tPD-V+R*kd(?_8~4n^Q3mBD@8t4Ns)_q`RhKX)SlV#PTP~8 zHGP6<#*EZ7>Q$WX?%FhZtUk@{R>7rHP`mC&db+Y{eAHI&lEKxu4IB^IWPFPVjx3lf zI$~!%vEtY#d`J$VH-O+Gw)u}hF^9-I*F*0}ZRUy2!hBO0=t;Jz#2<8`bXFDMaz)x` z!sH#=pwfKt1-hMF6ynQ$XIeT)Itl*?robOD-S2DT%YNVx;&P6ch(-r9Tw1gjY%A$hDU>9n+?#J4^Le1-- zUoFSaJfVOUH=xNHXiXq&bv}7tmu$Ah5u{q`GKWp|#lUtCv6s{})B=W{48BHCdOmG* zCV`?0wJf*TPJ{b(pqXZ4OiY}edpiEqVfxEK_P5mz-m(AK{IeV4zw+|^lV}9s-U23r z-*5*0N@(ei3GDvDJMm3e34IC}ZV{7c5cx%IS#tCv&ex$%moM#3BzXTQ`zTB&LP&`2I%RWkkqF4AG zPsdk_$MA1`XZ5MiEw}0Y=cXduZ{C(pAD8tmmnrPs~QNi zL1%&0gpqacK`x>Av!ydqE8#0(@&@jm?Bxk&u_JSO1BHG8Ar_xR-NVaMJ^g4f5db*X z%S6dE#`&ZUEhIdCbp_=l+FZIp-yQRaDeDc_mvbLHvp@8@-#n5B zC6h?mEceX1mhq(`DgDerhY~{Sd^=iXGW@Y4Z6AgTy>VkINbvWkT(F3@c=U;ZK1(peW#ZiBPO1f}1h znsk#sbJY6XY+r@+s)%YYAAFOsWgEK!CLYZ}gq9_jz9OHuHsqZg__((PozkO2Th6bn zrJanOu4aV`pjanA85Azxotfw)8jc=Oap5mIP$YAoPZTpC`QJZb1C53vl>rQ41~4Tm z%)o(EA*pzV)E)Jk3P2EWnsT7ye3OnR*38t77}|86jH!#UvR6YC6bgt7)3^NO<_b@= zP%hn+{Hxw42wnA>6Or6~gBLw>ZTpOeq9vq+n3#4a{i&!1IG39hRcq3d`(C7TZaMRd zXeFgazA=DlZ(kkm7Fe&ziU^UlGqdSfDJ;I@_)z6TUm6c|D}sZF%UxXbpp5()R#J77 z{B9f%BoWB=EQ6Uwa)OdU1G&xZRz(QS9QMR>bfXloOQr1f~{^*#l$!i{5YXKmqRkdSEm3 zn0&5Vz^GFGQ&qdyD~Exl$n$qmfE*tPoOK6z$;*Lg&V>)M-9QQb6i0b5E|T@Z>IEm1 za0o<+`>WnYi1#axW+t_XEN_0gvp0?D{b2>f^keF08(Lc#{fltT28k@T$H$&PT2)!T zg5r*>OTOQM&mDXqi8$1frgX?q&Qo0A0?k0P6<@9ol<%hT|3X=zZSaIt@M)jPVZ)y8 zpsA$16PIelONYcaK0M6B@r|v?T=A zlWU?9p*k>eB#fRrsUCVQio{s?V$3e&RX0`Ci8CE)+ZB8!ZH@5m1OJ>Vq~0#q6UhF| zu9!tOp1Yt1AIvzcr8+%s_C&co8Wu2WxM}B8B^;_vC~d#@6kU8>;8o10x@Nw}6ai1x zs=|dHpmb{~x*?k*IR;zfXdLgK%0_(owKZ{`2Yhe9dDk&xr~h746&9DVI8OoGOcRX3Vu4i0>{~LnVPCqgI@E@LnQqRb zYwqUy`;A*rU+=Si280C5{1zYyWxKu^#FU4c0}F83x$S{3p&kJ~tLDdDig8-IDX)FY zkFODCr|&FXC?2Hmt!y5{hVu2wo=!NMAGyqWk-e`uJ`f=SzLQkd2PvE<0c8X5v@$i@ zu@4Top=Bi*LbhDP@~@|2MNeG`K<~dTz637(Z#Ku*!B|PSpae&o;k}{gJU!Y=tkLqr;w=~SC>3M3Xlg--Q~(klpH3WU4(6y^L|a`lw5(_K`c1aSVLY5Xy8w%CnkRkj7g;ts6mTmmv zX19REP-~x#X;5X9@@+($0RHbaRRT$;b(sQR1{(HG+;VoMn+Oij>vo|4^w@R}tS1>s zcmoE@A1usm$X{5YZ#=@1o4HKFXb-+5!M6z2<2n$CFE7d{*rI2MDdaS#k=Eb>K)ID) zKd$CG{-tzAYSp6hyi?oVmCIpGX_yzB%W>}{RM>;pvX0Mk#=ld7Gh z%%`!1Q7>Q6zp6SAvveQ|NNjvzM{X|K*h3A=o%CyOqJ3_{b40#W9dUaj z#_ZP1QT{~P%q?KR#q7~@zHDeJUE6I9cYK{4yW+SVSKZdbeM@$S2Cui;9}!?T+qivs zX+KVetTB;Uacc>XJCwzf}M;6*j5KKH!F^ zcjbz$7kXi(ZmBwROJxjw1uMtuIC7C_lHo^{cE~c8cwY3h=y9^e(+H-n(hU&)2i?5< zd0b_}*P24shmBj<<))MRfDmns|Kun-W;~bA62jT#^iqM_$SM4}#|64|Xu}k~AI{au z=rf)qt;Qf;Sgg_?pL!lDPQ9-2uR8SRTKDFDhw{EH9R7ECyWSudTx4`0&bvcW9h+9h zqTb2X{<>A&IRziQ78f&ZCzs6aFKm!9A3RuInp_vX7jcT@(&QZ*nMxj2#1{s3Ic=Lq zD~5d#Fdqn`1NkI7wxyfT!!LA@KHu6{-2ZcvP@xgS9!B>zc&t)0@@=0Tg^MnnF~|w$WR95aBF-Z(3LdOJV*@So+|mD{ULP6n0v?9#X16G_ zTxx^CPz$W0Dz7`wPWkd5)!1`1{QXmICAzi@HH!YVXd$O;)e~WjN3Qzw+e|YuGQndP zUBV(Q=#~5rHKha8o_)<~#d>e7{{qqcJ3cIZ!AUW0L-M_$+JpThA&xDF`;Va`c6JX) zHB@EtbBnPT7i{hFXK%$i9_5@kj|typdbxlxoTi#ga@!p=dUkhE>gD8As4O4AvhsAr zu~t-+_t;I9mPXB%KF>E;GuQ-S)VBR@blZ`J^^6Al)5fW)voxL!9y)a24_bdO>Lp#{b>UexcHC32=y^O0Khav=Y ze;Bs2sXsXggz^?st14ldwGc*=i^^FGQ2`aQjr*q*RxkrJq~V4PX<_yIJx^t^+CD>|$RaBk3#zlN6FXQQ*_K>VBt9I)+TiZ)lG==NmU=7#8 z#m3JKHwQyT4ML>4Y(JQt2W?NjMQUO+TPlh*$hr=W6CA}oCDX96 z4s33F?VJ^kWuq8+qZ}*SrJr4)OHQW6F3Mm6oiv2}<_8r0Q+>kQjZQ*aS@2l~ZmvId zK7(V^3=A(FAKsgPf?AVTS6@GH`sw(_?#a52W}>`J5azsyT0!=AO6?!tf^1jJLf4`m zFsb%r^yUK4e70t;4xr)lyBXz=oqm9{|Eg*9jr@Q=-TtY9whS=KoO-T?$E;yns#LM+ z-S7@E3M+mTvDR4W9ospu=j<4h-!yJ5TL{okKwc+n+>+&e#h;~Tw2zMAw%=Por}3Ss zJ28f)$gBzclIAYQse33aaSBUn$M73xG(fjO0C0>{2g0`t-NpQ?r|dc~i!?AG`x$;8 zP*Zw~!7I|7>*la)kgn>*1u-CLdsktve*O=EmtV)y-&TwOtx@1}GAu^XvS@`r3m^TZ z1eAqa5I?zI;0I`>n>*#S9kTq0n~UdiY;6ygtH)j9n=*IhaRS`$ zz6%~+MPW-XYU&R*@I>ai$yPD>;xO>VeD@wJpz(-Ru( zxse0L)Cl;b;MV%?DBuGy75OrHwOT{VX&t<3K+UC|!c=0_ws7FNjyW#gyyr)8!gUqp z*b3E;d@h`VAzQpmDv?(^YzyY5+!;hZ6+gVL+I%P44X4;;qp#65QJ{REEy7?+FlHlH zrX$=EKDg-wUF8bLeJotr#*t+2SWr-|jw zwdlxH9=h%O?I9UBFIVEhbem0zMQ&AG-g%3g=1_~XfFU}V9u<7zp}XsY`XSPmBuU>FNOnF}eX#lUVDa+{P>C6@Zy6)dkLH+Ol0Kt# z$0C^q+{EhN%@-}tTx)JE#ePdefxRt5HwSY>>bmjQZYDDmmOO0B-DAYpMejGU!ZR4qi}>*J9IRFD(61| z^WJIX+WnI2HTXKIN{5#pIj*=#PxVOHW^VA<-3pQ1Niy6n*0|!8DWgM+d*Jon+Gx-}d`tu);tyl*BAPRCi4_1C zJ<7b;TUO|I*OL3GU@!;y=?)tWrsy?2-gd~8j5ICm$>BaCHWae!?_w`T&f&44Tys_l#2AjC6>MNm(ZIPq-tONXl_Xr(25L zwMMz!c~PI7?3k^S`ML^4DkbP0c9S#L>Jm%!+Jvu6+VSVQKL{VU)o$Q&Nq2oM_W<#} z2V$TdFWf(^>}5OUoR?9DIbNYK9;&i*&!AA`cvE-8*b^e|Rmt*_e6x+d_BbNU^aP*b!`Lu0Yh`;CH++Y&%O>Askw_K++az{~e7ExoXWTipChD%T;3JWLk@%N zm07fQL%^{csnM})lgxxZ!T?sJPuGC$J=~P5a0oKU2heNB*MBs zb@9Iv+u;{nP=(jew*|r(0&6Io!Nd2u^X#{@#jZsJRWF5Mvjld)8E_u*VJQ9FJwfLe zH%se>uT@IO0Pj@3gm+rZ(iP#Q?0no4I3H@wEv9K8X&pWnr_EZ@wnyNSG1>!&N&Z_+ zZ@8F(3o*>Y>W--sr)D<5}qWOH&7vW2*t#0MBO32E>la82A+w zlnZd?j7F{i#@;$+>>`4yXa|taMu?-kOfLX@IRyaT&H!w^%E@X9Seix;MEx~r{oxl< zX~(uA0M451D47+|bYWAbo?GPwBJbU+30zRx$;jXTJd{ve0mx*_11^CYOAI-rld#pO z$u&ZbS1Ty#?H@~CJ3giPzCl{#5`(#@2iJe6mEuyBgv+q}bIYNK1JD5d$L9S5Kr{x3 zPoMrLkue=fR)s%K*KYqrJ(>hWtOco|GMc;I08tVDJL1xh)WjUBLDf^3vag`GPFRYB z3`MOf8kd&&?UE}LCYtNAL(5C4%Hwk^`Ks~d@58(r%gYW0 zydjT12|V{Kztr4nRQ_^B(*Z9VHuG2ATfD?4c^zxx+eG6Znz1-YR%Dl57T=vFZ5@Y` zrs2nl5v60FX5-aM#RD!SjOY&YJfp2qcEX?@YgiVyW@CcI`ls}vXZ1W9cET$W*D&sA zbQ8GJ;~J&_Mkrzy3(Otxdbs$o1>j@4S|M`()8p>5p%w0V^r5cjzbLU zdF2+agXP;Q^?{0m1m5Mn>tjg z8q6XUR&^y|GK2b^D+P-msGm^J281~J!W`z%i&NEHWPWXeUfw3&p&%}zc?oY_Es(v- z-R-hn@hFbByPGOMA z5f6W}_D$F+ngdJ*fQs3CnPTqK$7Ze33gVElJ4)WAxxCtd*(Z9g z)#E`F%HqWFb%7_X%HKzSl(G(BD~5(TLSCd9_Nyq#eiXRCw!(Py{$j#|14ozm4z?B*CzWszkEqn2{a*9P&QPd*slam09|LJ01GF zQ8AHOviI5X`atNxQ7t6+nkH5d(E#W}!o=ZTiNIJ$b0%ywY_B;|mACQ0(ufH&6+1V& z39KlURgv0MV3ds3PsI#kc6m>sH3_aXRnzdVAlt8?4X4;)eP@%Nhsg+nA}->hSiZ_9 z)+L6@+*;1QVPJ7?PQ<>1Wj_UYHooV)98%EHN(OefPc1*#_oZnCydxO4OSfzcsOhtz zCc~MRq9y7*>BLa>N-om&n10#&b71RjSM5&cYQ{xh?vjjmRX)XyC!;S!goVjOIv_DJQ$uBl2)PN6a37ZFErjJxA&a3W>L3V*nZtGQOrmU9}T3R zGB*l!9u#p7)#+L;Je;~m*Nhpv^>!cP5xaUrH8)iucc3!;vAER@mGhsOk3EeTyWE5T zfh%tk#hSi?4lTOitnRQF>KtadaJ4a=zvQ4pWDWhQPK7$Lxzcu=F0qRc`3@u}y@wF|=Vc@Ev(jP1ROSF?+yoN@Zw2M}-agieKNZh8I2@RVPCb zFa{)dQ;F2G85CdmOTQug&u+aH{J1@eUtVMlAfR9;iLd0j9PdqLzJ$?uK8Xi0Efn27~F){+4ZxqV&B%svz;m)}grQ`SKBhx)h<9Fm1 zkM%A>($fq_KBPiy9v)Zsj0)hSn9b_|_adT-zsGiD^m?(MdUz8{RE$9CT(b|EWv7Q1 zGl>f#8MzjB<&JeuI`|2ge>_7GAM>V%la!I<#R-_+@bbo@+r^Th+aEb4)Zk%m&_`{R z4yL^ShrRCrYbt5m4x*wWU_+1=6$AwVX@azf3Wz8XklsY3cj=)-K|s2IfPfODg<=u7F_uc*8@Bj8nu3U3w&PmRh%slhVQ|=p6mOH|(+++Aw zc#+2}V)&A+WK`1ZZ#uB z^v-cK%A<&8(%2OniCF}2PQ65uuI4%_Z2#%7r|)ofBw4tK!7^sNFaVEw2Wlk8uGt9< zWVB$?OgJz4ymH1Rp@7q?oB}{qeHz^T#78Mte*0ff@(Vy(ID(ThB9GZ*>_Jys6ap~J zim#?q%ZDk3_pDGZ>2Tx@(c7C*37R2|-qS0D;l=O(*+rR&?$&4^tD3mcF{{Ry{1Q-% zA&(e4l;R8_;FZ_PJ7G~_hAxd<7;(8r_6{CIL?3C^8JR0}Bo>dKS}n5F4&Zy*gr4Kx zLAc${7Z6aiGDCJW4B0(Z>ml5w!;?|)igexWdY7mu8kNbbs);a09;IGV@qJS^a-4IV z%wZgnfOa{D+OL?UZbai=Z65e8RCJ~ZMgeS%kyAwjzI@e`sY(DYu0_wN?Wurb9tO8w zRFomkEPsT|qSlzQ?nR>d`E`0Pow=s^=rz7&AdPciM~^-D()o>0(@P^1c7p!Y{@%d$ z=NW7?is!+<+m1qMX*fHW*SD-6U@xCx1QQ;d`qq)Xq-z6^LxipdTnbGxJplD!+V@pC z2W#C$z2{qMsqb@<&N!$tDO-*cd3MS02*bzh>6fN>Jl0s-5sbCihdzmNbnEvuG$ z<8HzlH+h!Tbv8$|gz?U((V_*)D0fH#&gb_uDIqJyK@3TET_|QJuiFgwA7SG4)jjJ9#VCgF%~|k z3A`X~nkq5%0w4 zY?Xu+k|-+)ZZ0gy_LkBDncayFeo*VoHbjel4z29wTN#ZqZLWPLcMVHyMY;1CIop)h zo&oh~7xLDO45lSBv$MlNN)@zE6PX4r)f95oZf#jaHFs@XhQCq+cA4qG>N_d@XUFn{ zHv?$AIAOMYDd-RBc-D-zUZ-P{jUsdtvg3QFP_27S&2+e4c@~I9J+vXoN{&bfH%y(f z6SP^rq^9E4Ms3gioVu^FR;qy$xCL5(-hoezX|jq}hwa&()Tl)ULkv#wOHMPZ}0 z%ZO~eZfVMYprAxy{pw8GX4mR`cbUQhs=809Qq|2Ns|2T$KgUVwA}7QKw<#@N%?NR_ z!K^7@6r=l1%tfEhZurz{J@IcG=rcFlOp&ZYPzy_L8E3Q_J4|$lU z3@oujP+tbdE#nO5n9+Hz`$_a~?CN4)7ECbI3(R`AVvuzd2e*tfRExQ^)D^eX{%=sdHnwMHRw&c`zCGRYxT)|*+9X*-PvX-#PGP0W%dHV~ch_$v!*vsmII)FY4uu>rULZ=;**w~@G`d4{37+fkmXAVaDgm$0tnB}{ zh=P{peH!*+O0yei!;g;c>AP4Jggm}+5cfbGTxX2wZ4cpVc%RRN*+ekp9Hf+iQQ1%ySTE%4$N=Sp=Dr~N5}gFv zJ1?4wKdW!VI>g_AHPu|agS{ZIQwPz`x2)?-tcln%o=}D$vE~wO6Am+g$}(Or?RpNgyjaHYcUi$^YD}YpQIc;JgiKlM+9ZNVmD?nk!s=w8g=wno zDNjE8LxHdTowq_Hq-5aQXZV8B8GsAzGrFH^0M*YIey4QWI)bQ=m_+;XxRed|x%%V^ z5oijGq6P=%!bSoiwN;j7A#uERH0}GjHX2MQY*)<1@z56|PP!wHa(Io|cD$TEdqG6; z;IuO|8o!BG9UnI?_Tu0;WvCbEBUISHTxMKYSllrmS6CP-?UOWMRs6hZ#<+ew!m%eT zLf-)y^0KM^lvlh=LdX3pC)S#mk0 z=L%AL@nrbDMyLdF)*8eUh(Ntx0v35*Wt5MJHZ3ob+I=m!7Y2p{uy(LoM;jQB!SH+C z^kwB=NyU?cmdQbLl`Y`9beu<4QtLMA(Na=Ue|}HDf8RfmQ3yQhZGC}>F5mqVbglkY zfB4J)xLkkVQu@nQ@ryb0Uwh_{x?F)#rfckStW{WYkB?Hj>0AZ1VxWr+cqVh*bI_Pg z4fDopSm26kS){ows4B;2De(hH*Ru&itfD&LVGTW4b+U80$1!s^Wt`S?$&It3+E|)l zPSIWVf@816H)9PT#bgzXz;;(L{p8Z1l3TiZj#l@1w~fr+9gu|;qu)I<$;5>O%ia7S zg7kHhZ9xHW^+i&-cX$enZX_`;RoK&6OAATD{iE?&Sn%NM^Scc=Ik~!r2Lm=i>~=7{ zVB}<%E9%Be*EXUzuXOh9T@jdeMi;m9K8Hx;94#_^a`Z8|?Pcnl(4>0#d5!+?xG5Z8 zbZ)yzbk2RNm(*3R&N6}sSfLW@n2x$}|peFOZ`%pVLKr>u4*KZiSZ?c~?ABaTGF@CCjZ_?F) zktoaeu`jnJx}BvfYsQ7rp6y1t>niGsLII!_XRBWuQocui>=oousw3E4b6>mpU}6D(whn~4%y=RQG((ATH zDw|&kR(>#Y&|R=wLP#%V`J-dnE}>T1gj zz}PA~4(Q4jaQ@g;z^M{2Z~%@HfJCC=?cIg~9^$1e*7zd~yroT#{g&V=@Ajm?kJg$ojS%DzwkuH-@?Bj45MS&>rmbVDGZiX0^ z%GI{{C)51Wh(f*!Vt`gj0g`41JlY(hS?r(bQ{D(NE^aM>#9?8m znQj@xt~km0J*dz%z3KYiV2ysip-qn#PtE4p1 z!&v6JMbctZs=Ju0F99Q|(bHMo3naTR4wQU=-*@M`ela`Kn3<@(N0kR=<>^zA#|O(O zP8JK!ptJu#p1;!qkaRzN{D#%{Ym(e=UbCAWd}LoO*pvaoU{ZsA);y0M)$EO1H_M;; zj2CHV`Ho$kRVJLkzSe+`Io0dVh z{`+)Qo`Y~v$;P0))Ow7Gl+qV56duByiF~Vm3CYr6peSRdvFPG)$gyI zvgY(CJB*omZK)eqhhlThR_6+NKwmfGE;_jHXWP(hsp&7bL?kO|5A6*JfE2+LAVqkr zJseJ);w+ZPX=2JpE16rG=P}+d=IMQxJZ)unbZJ&jhbcqXYBz19!)}H%j|KBPXa;S- zuA2MH?k%Wks2sZI(rjV5E;`8epu=UaJ@@+ST2q_5QVkn?mGz?=_tQya0ovZz6P%Q} zoq;SYGbj>p@Z64=msqO79;H6+fqsg)7Rv{K5p-8#YS}LA`OdZL`D<<)*}b>nBM*$& zI3Ku>sZw?Y>)~LbQLDjkC=ZB@=ris3eS5|vp-I02l3UJRPiH;YSvRr9fW`n+* zQark9vBI`*SFf|wG_){%UaFP1bYJ^Sk%D{aGm&dm5A48lu;4kPO|6vWEge{0$O(+0 z<xp-@>A`n8m;=Oltkz8!kYmw$Nv7s`CMl3sLq_K`N%v51{xKK!TtYVhy?& zz-=$uc?*Pn1ne9v=k@Bw&pO{&FtM%ow96($Le?CBSR?<%dp1= zd-9m6=TqzBsE&cLSfe4%vfcLQXT3ax&|Fiy>LdxGH1X|ad$AmqonyI$rMefuM$bkT zNOQn-KUQ7bBgCd5+R1K`_98FeSNo*<4%SW3@Q>6Ylcr%G^-b3FSfuK7w@n?wnJUuQ z!sCKYuhPA!*yFB{eJP1kT}64%Es+D_&n?cl> z-Lf4i`&UTPzI9{?`4ag!o#iX&W1AYlGWZ$zaq;~fiL!6^@0$bddm(x899sd1)tw$x z5g#A_r3n8-jLKpxwkuxyej9`-$=cnRneuHJJd{DV>?Wy zC6ix#agY2-d;?-Ga|}+b0z-N7njh?W#OEy7KMOi>-DimzUQ``|C$m_C?{K2GI$_}d znHtPj-G|?cv1xLT5%h~D%^H2s@ytfR;acs5-~vu?L_tM@;? zC)y4O8IHF`bqEZ!()KKknsj6vxn#E)IpkC~nQ}V;7_+r*(uP(ru~!>60LfDTbv*(}y%=&&}=Kgq%8FbHI!GlrVhZsaQwJ1+vVoew;s`Zyph@+p?yXOxRuE z2vD|=72VO+xbzloOX?edcjB{HL+rrQTGvz+xdT1&%e@dAZw=ifz8*;D#(< zIyS%$`uFGD*7I0h>UIo*EQ4~sqb9e{5OzK?Ms+hxIx9chGf7#8G#D^b6sDu4TXXsj zp=OFS{I;ZGHMKfIe%iU&PF2${VKTH_w{6CBW@uWGx@r`Mke@SJ(M;*s+9wg{+MHyO zY5v)UtC6~ouN`i(t_EGaAV+b@m`w{a9z5(PVqy~s&FMModNWEVfqDl~<73!i6;%KX zk{5Br5UrEi?VRxb?xBZE^yexLkl%898&UNVP}b7~3H_@m@x?jzF_jp2?seOuXKt=o z;Rjursbxp7Y%=Bfz;0k`#wi+X&A9Y!z2&$~DjTP}=)U%h*?Cjzt+}iau|1cQwzVO8 zkQru?D zqG|Ey#`TnEpjh|YBp};#B^9js5a$7-Y$I4g@TyNk-aLREo^G+jpYlE(QFr1OsN~-| z`Z2`vKhpvKLa_9&e;S>YnU&YJyx~YHfKM^D?>Zf9X_~wn1bC|bY|kG(->r!-*VYGz zn3~hn9x`Lky;yPV0?R^rT~%F=bo=bg*^$Mxv=QZ)8?||f)Wj@I1im||3ftC%REmT4 zY}Ng25qoV)A+yjOA-?Nv%x__vUB{-B8BSu9JWG^#520c3?xH_>xxx)Jtc_yw#ilNt(_2Y%A%gEjeGo#pJl%1dSx*sCoB>VCOHkvFu zmXY>$l|>{EyT@{*DPBfCj?o&px{)^lcJLRBdNNOr<-drDRL}F$UX{OhM0#TiY}-3B z&s8tqmTzpEZ?Gj)VqVuxA+z`C*>@*2M@IE2;y@4nhX5K@>+K-jg;hb3HuF>PG{qId2^(lX*r5FGb{=$y- zf55n&aR&Qhn9NbKBW-pjBci`?n7+CZbbipn#jNZ(S64~-uwrq#p`d%oQM)vAePJQb zP>^ZGAimF85Qd^1o|Tr(D)K(fvH#}P@O2Q$@ue26YXL(?3(u~>{3C6I8W)M~`7s`n z0<+zNZ3Q99;?H!&N1$)E&*?cZT;w?T+>0q7q!5AuH--c4B~*j-V*d;nN^~J51n?$s8x?Z{fIK*OzWHCq1VMbNhbv79z}^- z+=GNdXkMhgqnExG_1?17Lmtvk=RGVego$!w>oK0aEWh{cp|d{p$rC&20>aCy3Yv+B zOuFns*Ya_XrL=7Vb@J2)-2#`um{c;J%9m;_l(o(MC_lGd5AEnyAVZq5nqgbfP+ts? zZyZv7f_eOCy#Ea5aocz=2hgKzi;a&ePKMw@ea)5jl4c%>K+UC)(7}6IjueUnEzKyA z1)-6hFv#;5`+EvuH^*3tH5DmtmSx~5GGvJBG)1K;cx2k>HRtCV1V+VYMAX)uVGc~^ z`i%Hv1cKCj!XxiTXA3bvyGnL+cWrY8Q5J?zChI zqvGKQ>4tk{7+{p{voD|CH6BlAHO);?bn)&(7=`>aoM_r51Z#{*Xs-%=ooLirYm?eo z;!1p~fG~~APjMmk4W413z+9oBJ2|~BXDU{IVeAfrTL%vDdY~XfI=#yKbYi;M?d-gu z@o@!j>L=O7&vsE#HaDHOZBtjjmUWqC&Q9n4E^ZYaSLRTqy)^r?4_8n&+nd)HDS7eH z`kcOenU!ntis$A%@{zY2Fc*OdCy|loJTtC!c<1IttvHmRz zMWOw|b<=QLFhP|Quy5|0PC=%9*4n25kAMC~>!YwyjaIcm zs@gmqu-`QP&1n!97xz1N@$Gy3rIocW1BV3YhqP9pD<2tm6jG zwr%#tG(|D~RB@unI~e>y-4z#>HeD1#TrHmek?1@oxKC`Zx*bn`Iw9*0F47QvZsU^w zbFXC*RCk`SX2v&%{y%IzKR!Ud>#zPBzxL^mvGx3kB%~Z1$dSau4Ztgn@bQp8Jb2>r z2CznK3{&7HNS0s_eK>Y=fn?LlZM_tnU5yh!1|fY0SMvD1ufA(^^;rk{3N*BpUqT}< z`P1)7vj!4F!EfQLDCmmiCduM&$IhbLPVXOmz#lqaUzz}?z(c9yz<_6Yl#idQ4i=yjCN& zYrf5**p;?@zztt%SxJBr3JE!Y4Ic&RD)AgS`s51EHrZ#bGXHUa>=Ngad1FcJaDTYh z4Br*4GP06~uz+xQq>Dn0{cy`6HO!zc=rdn4-BnzjF8~Mt? zMqwWI>}JA=@wCcyTn{FZ86(Ot#bC!Yql532FX@JV0G*<55OKG_kv~YX4^#BH(KZ|5 z=p`aLO+Hhf$&lM@7@;wqNngpcSe}(}1_O6p(a=&CDnV1H#&0fTyI&1%b^^HE>o&_RPwkF(O^+Ho~nr=OGikPq{<9>BU1U+!E>OqiY?^=cx zF=&6V|9C0geh^QDs_HkUAnRvzh#!#xzNwG=iO4#mG*6Mnx;eD61rm@8=uJo!zqNp_ zY}$EnnjU{YMD^OWYu~t;Z#JcMe*h)J)4t5n|6?sL6>+FOS$e3ard6GN9oiRMiGD?r zRcGOB%vocY)DW%7>|bf_?J^TZp=serr_ZngRZz=sXHh%4V>ILSrscf%dO=zff8^B= zj-cy0kEaI-4$V#&@fsyZphga;8LGrDMJ!gGlEPe0ZS1?SpBB;r;IQ`S4s{y)qBX`%VhaS@KL!+508jNZ!1Y4&St@REgkSusQK8t&6#q$;NOlS}}dw zzW4hwSK+g~`;R&JpRk*6ZRg>urYIPFv-`gB&wZA6zg_%@*qpObz7o6H{gGTz?B=cC zzq8*_Ek80So>_pWLD$?rLOBC@_i4b6@EiB=|9O+nFKEqN018LLGNkcWg$+o(SNZOa z{YsA{EyF3{I?+)!d zbqFEI+byN;Jbr8v_9qu}Rw8!WyH(i3unG0nLhwy&L6z38j- zcAZTL_6;4>nY>|Tr*%O1f~ggKQUChf+~IRcy6VsF=3jT-n;KpMjTh&x;Slc9Bi+b) z%rhXumYg1yw>=umtQMN&t4A~x%q-NK3l0=CKHj&yTI;kiqKx#c6O8D+T^MO`!ZPGI zeT54c(@=7~1|-W}BM!P!&+2F)s1&!YVxnSHxA?kIDu#rd51`_0rfx%k zMKB$nwykz1s!*=Z-RzN(kg#wzVitEYyJ`E(*Wa@%hL!dhXmC_NS1>g6=LG0?Yk`X8 z9qiV{XUsYElud_^>6esvyEs%8r4)U6-P-5Q)o{^Z(rckT*dXsWCzX7 z>3Z*}Q|ZAkI;Ye)>5RNCKP1$xwmZL_Xc#gaOyc?hG}MmP;&Bqkrol&!F}2UwbsM}W z@WD=04wf%<3*b=x*!;RR&EtBxd40Q|QS=hdi1gqg&+ppXRSSB0nU}TbGcc+@a^w9dZmdWD(&a>;6%_hiZ^LStW|w>GgLTlAkv4TWtE>M!7#{vF* zErZpya(icEAjVbZliJl}UgDDT@HfGdFSAR3vvhn>* zubCR_vx39~;$w35R@Wjm0#qEY@Fx~fyo+j*yi}b9I1ap_@hYM*`LjDB-Koi@9S?~} zrWq@yY5bwY*c$Gvvl%!L>t8*3f7L3!GCQ@OdD8f=x0)K^_axs> zpT3vEI$7m~3XuiLF~$r_g*L()>1;##4vKrp$~7-{RFHE^Y7WP!J!P=k(M)@7_qE-- z?&B09vg827>&W2)wAHYu2G^%e?>5~Y%B`Q<&{lUpHn?8VBlWbhQacAjk*3g5 zA*k_=Yu&BEBvGJ+a_N-QkS0_MY7o>S>aNY+CA^k@`2^WxHG_thQfHRf*TUVWeDejC zx_5Gjy<#zFXohvVH83Mg7Dt*4p5&3=vs9X%RR$tTqdJ`qzd*w(I#x*SB4nv=L}}j= zc(a!{$YEuMjrbPE%rAAiTDJVb*puToA{&$HEMzXUh?b^sFI{Y(pBL|Jx;~%7(N{z4 zk5?@9h}4O%9(|{J+4R_S)^YVs%dXs1Yc%_LFmqiOt^G#oRVs+OO-kNs-fG}XzK1|q z>yiCke%tmhgKZV1vj@6@-0Z&l0fa`NKi5+vWjm~YRwAinZ!|A|hE5p=7>eYv9iJ%H zw%`iWt&|tuxW^3C>R4Jc42|wVgPTt5T(Rn5crZ)o%t)&DkG`n12LlWfbp$cnqy@&$(eu)yp#?BIxRp8^g_) zYt|g+)L!Rb-bk^AusUua;A2|n>{0ba<$m+{9@Jv$$er8SzWBfm#5{i?{+vJt^#YYQ zCtk{?Y^bEz8d8)mzlba^TuX^Mgc11w@=8#7##i=?qU8czp3w0*XB9dj5yqp07vJBp&2i!T4A|HMG_CR;CW8tZHE z_K}yF55@P{&ea#P6lNf;MMz~Z;~_^Q<9p5?ZCxe~sxRi6gQhuhL?);j9zCP4yT|*; zj9~CI)Jn-%A`KYyVHx&rP|SD~Dr|99(~D+t5e!U(G<2RQIMcXz%GUppTj*mPkpdt6 zwI1m_p58JNOyYF?+kHOOnoQXXqM`Yr<&185%F1K0=9htxL6}c<)XAI$=BN3#18hLO z)N6@;&z`sKylIMLs!dRe#%j+?4)SVz8CyYz|2l`is`)GJR!^L6SW^cuGf=$v0HPs} zKMk>js4kpw5w>?fWldui=6*+X27%Wws6G*~XY4kS&HjsP32p_uMb@(>5zQDnCeikI4zU1{yqx|tCe(fnT0naV zR?TMM$7S<(tACU-?FyOYMTL2}#omUq%4c8s1$hqOS5GFZPKWa6^PlfR$x8EO?+QOK z`Xcc}NnSyO@{4eWtN!%2Hrth0`=H;mX#7KE_SH=IUw8Q9RAxWBuzXWRQzHeyXg_`Y zi#GzJ{c?B<=Pdg5 zt^dad=9{ohV}NDFSWs&vgRqb~1@9`~s0+WI@b&P}bY8fp2e|(dguG&G3wm;?-EF$> zkqayfZvdz*ia<+O-ES?HIiqwgBna4eiNP3ef$i&)Tw&C57q#6U8^3V@4~TgBFAMFGhWQE&9IL&bu^=J?3tKxxE1n$&~s1wvs!X zdaUY{*Xpw}c=E6k9@CP=9p05CGyX@`^Co<=<^y!pA8L}w^W?1El`NQ5Mm@6yg8$uN ziU?hXNTk}ksyD4_b&Qu!yuQ7Ef5fsHslf8AXn!NKt^b}H1NG6t{rgc0re=A0S!yrt z1STq+y=TGNtej-)g-j2yRhyQua}!w(?aa0qS!*Ukc@b^&hekNTc$hYkJD zjxI$L!jdyd8~BgvUYBVNsg>zja=`y~

    !ZNJ4<|MJoD{ z;&`_*{d2`Dr>~vw0{L1usb!UsX>lP6wZm7)A=VId%Vn;yAMid-8o`$1V%KaUfbMPyIiH_ zrKxi6$k7WG^q|!Y35!ms&ygK1uWuT+s8asY^MApmbul zv#8e03sQ;o+tIR@Y5f|+OA?tefezrtB8DQ9-Wi9sFtye_(0drCwXxjMm|zL)LBj@%$2OFPIhNl zDK{_hd@A+$ZP+29?IvNy*nTn2o-tbwX7xQAuSB5H844NDtw6Fr*X;h%ST1!(=cSco z{iKWlB#@lw1s{OCDT;((7lBX}0G(WF3!PjZdzo;hl$213fluZpB^m3LERC?>y^kVR z2nZar4lUe)45V>thVGwt!q*-3IUxDR05SkI;OovzzdX!0o~<+F8FsZXeMbEi z!bM=A1LhbtkaiDoz-+~lldPmj@nWBk*WvjXoy6rek#g1Ag)3`aIBAj4i*HWpZZwv~ zlt3?a=8}O`T$gU>@eAcW1R;12ukD$m0Nhs*3#Er|mACQPb1aYRSQZ;x+`B{svG!m8 z01`$KBQ@3E4M>V4iJDpF?4NJBBQ#zXk{c=ofY%wQ?$zYe_wv7X=z^Scky5K-TLWJl z_v^hLlHz*XwL3SgGZfsruQJ;C*3Cq}JRF2c9=^3)kg>?naO#Zd{G0Atd8zYOc+f}lw zy9ro);`Uj$oF9~zL0CmA1_r<(;M?Z&0gVCwT(H$~|Mb#7L*x7BL&@$P0oOi#r0_*b zvk6%6DClJy>gtp4HcIU>J)1gI(JZ+=_mUyob4+&gpUL-+#Q8@q|9`$1Wf0vbiPt0s zQ2+u0#1Nurd_G9gVo)!+S+DKd8@m0SDyiL4D%B4n0=8G@TkvhE6Z_Bd{EtrZkLLCl zD`F|h=aV^+;CKz$Tv=ypET-z zWg(($!meG3)WpQC=4CmAT}7W|d(2%ixU$NwKH<-6XwyR4VrmKwzvut*QX%nKatf_G z#%wi;6p53Imk*hTD+^M{QD6_NOS+5Fpu1hNb(8v_rpBXJ>FQ`51A8s&85z?oqo}ZU z>B>f{u#l#%)&46FnjG`9=5Zue^4#-6yw?btIZuKx1&d)?znAXlNzl#_e! zkc$!Tl$++MHNCska#H+|Q_~z^oeGvnve^~#FpOVba{ocH7A9ZHTd*LQeD2T9ug=!6D2DV#DQ+UiMLCwQ9t;#rFCGSn+*?$u;zH`i{mrv|NdQ+Z(EgVR?7) zX?RPT14np*78>?Mk;XYEjNj_~A>Lywy*LUvm=dYJu2o|HsoXeD-bFgr40(dH@q0Wy zW)XGiy<_4`VFxU6`tha+w0ulU5-)_ktTUv26q&kb-sZv5={lW!$jn3vJO@r8kB&Nw zq0IAn2_)I*)_wpf(93Zmlh*Jl1%RFD&2Q$D$M-8-iAY?@PJmqZ>|}_3dy$bOP+Iz5 zObP!o6t>6kmy~(GBo_i;jqzWN@b5m{3d}P6H9|gJq--76$HYz98w*)h?dZtO{+cHb{arkHKKei;%iqqEC&!(V zqzELa?>zWeoRPICpS{EH9;bi)u>WIU^_<&K@NS!RLxKYk zGzbeHuiu>3j|8tJF6j_f7);>(vCRP+9ouaI=OOd5TkXQ{K7dLk|2gTOF8F&!fjn*) zfjUAcNC-bDvv)k=uDAe8gkj*3!6?J+ktnq_CZYcf&VS}7?Eg|10BkH%30LG@9X_8H zThl;pTUrPIBe(xqy8fG1@1#u&!;f!6Lxb;8F8`f#zJE9UhlVr-SC`yEMhs3p}GV=)RIUqr{>rY9!RbuTQw`PhqBwAarjhTz~Jf){buf- zJ3=?9*e#w7Qmk3J!ifA=+U%`{qaugkB$+5xd0}GRxT}SZ?h_zKj&o9j`|Z-48S7S6 z8C(atO~#e$-W`-smF)q`gyWPbhs)`V%GeN86r(C(f;j?7z^(%2< zUI5;%q!x3l3{#=yVu1GM$n5%X3!OIB9VnvRM1Te+TU9;By*XGOq=--zw6?j*_Agl*WQtD@^3*C$HS zm$>LA=P^BAfy@OgMJyW|KQ)_;EzA$R>!CpIk38{U()g|E+==3R|KYtyuim}+YTEwz zT6)YGIr|{xr-A~FnUmtua`KbkKSjPsiu#Xp)-wz^Z5oA78;?wV0F4Z5t+gzrC$tcR zqk(u0V|;R(b1hD(gK*#jD3J3Kz=P=o#<3e2slLw;#sa_(C*6^oa3sMeDBGq5y9mWi zLITs}hbi#)foP8mz#8^ewIr-+V3B{ad<9_FBlxP;W&@EX?;vO(G(>R78oEwlIIyxp zMR>?I)s1F*|KpnPj#J^PZE(@ zCN5k}z)qn*X>P(1THfsoauIXVVbOb*-`&= z&|al`nFPtV{!jAqZ}zL5sv&3KKekgLIa~e*cBKD=?|!!h;D-eC-*@sE+PVC;z%sP+ zb|I-#5c&7n3)Ja%eS9kdp`Z$e@UGmgg8c6${rpY+oZ=S!@twSt=WLY5iR=1U(&Y~S z8#_j;sQg;NRt~zQ%k<`%|JyoC+)i!}xjn+JLTx*!ckDU7xF`C6gxD+IoE-VPfhYaq z0y_^9>FEi8$Vb~xg$kT>(6#aBmD^fF$>XA`BIdGUg)(o+h5{$RA{IV?80_;ebz}^0 zP(HCkDOSYvNfQ$FTj2q8Bf>U=<0VwX`n6;`=2lL&nv8UCvR8^ZpWbYoXoZg@T&Q!= z(%W59U&p}P&Rn3pjJ7T+ctlCXNl0}jS#S|{HogyF{Grp{wD2w-Ai3uVBAEnb&=wSw zc4jnXH?VhhH0_pAdAbaucuS<|d^Vp7r8a8F9Ce8#i6s*}q!~V><$hS|2%u_Q7C&}8 z{;7c82awY$j@%_=hCqxxD7+w^j4f2%BSpsW3`st)@;0Cd@}3Si5)WhXaG}1oaEef} zUp8o8H?ap~K59U$rL9z=zn@n55UG98>6_XIsfZ*qGpuuR@-uV2yV~{)=6l)JA29-a z2_Uw%+pcT|hxVMj8YAX@1&ET}7nG2+J<(zd^1Y|~r5#38PJ~<&JooB0%-i4oWMO{L z-Vv3Pf!B(*YfJ*;T6yoCzH4#$%%r$|?nG7dP3()AR19y|=5Sv_>j6ZOvog$Xa6uDd zhj}e0ddgAgI+-vYZM}IAsxw{PUaraZ5K%>?uV`?5xC39MH<>auXWW%Tc4(lwTUgL0 z<<&xcaFIj<(;_tgty0n?jIYcst`^xN96;wF6lW3ym7iUvd_UE7&@fcW_%ILanobZD z9&gy?r~3VhNz7jxp4x60))RnZDuovr5u1ua=Mak-Pnj`b9~y@}nAI4uJ7SBpUHP*i zL0y!$FYg4o^>~Mf?IW7r<$QR^$05y$CAOzmqP3aw$(fVqDi!w-?SzfT$ET?diLyEg>}FL`yyzV90>AKx-5^jk(=(-3zILUL5Y~UVhxt7<;?Gi#D2Kt6X*LE< zSF$y)FHSA`cEfE1Xu}u^=X-T93ka{(?o?G=vmMWC?c)HK8)4dlpF_lI-PeVV#8f6_d*N(q2c^s|HJ-|jml60whO zg{}C2PF1aywCz$yqwcRn&wqn<_M1AyI=tD5lWS}H%ZKO>C8hs<5BycBIQGbzfCE?$ zdfN%9h|x;j`>jl%#895MS<{YgJ&f`86Ez}mEg!Xlwy}b9DucYn6pc)m-v)QAk>p8U z8^p^eO&cak>n*O^Zp!M6z!35sA3!T9Nm$w8-5tCtyy5S{Q!U4W`+45FkOaJ-Y7 zMF3`#VCkp9?4iOh9qV8e6${HJb4%!xXd{niKMq>`0J6pb$+Z-i^w=5(*0vJ<-5XO& zT*t05jtyXDL|Q1bh6m^kG|6(8_=KX(j#*KrYVp2wCefa=U|lU9Hsz^)YhDt`9r)zI z1zWrjz%a};96&p*$!v8Pk^RmsB=2(Nnhsuac{Ssiu;l{3>O!jDPQO)=bLZvWFc0FW zAT@BP(IVuK{cG8U!_>X&M{kdrzQs7dTZ15T^$lF;JMiLmqlT+v6^u@4RT3h~A3!p> z0Yl~_#+v8KH_iteXxs`oZ?}Hu5iA=n7Ua0^MGO`$i<)zaq$UNqIH)~@CJ~++_c~Dy zYVcR^8XPK;EUABF2U7jtAY zhHU4u54#oAkquk&O4(y@Fo}MTNB}k>%~{7hu{*c4(aiU;^B&RYj#b6;MW)YeLoJw& zF8Hz@uK;htVNq`ydt`F_yWSk}*i%P&;5G%Jyj0rUoGg`e|G`wt#0mwx2-1Xx-1wh?R&M8N$ZWWUL zHTv%F>tuz>x4*o9HOp+vI0ovw7yMj;W=E;eI>x}&F` zoZeb9mV4Bs9cl08=enP8-%WYYVwZu+<~UCA`BoCN))wZ?za&9-0$czojiRTqVH#Pb zgvLkCp;gM&XIq1dw0jTtkoZ!dH8mDEYg9W!CRWw8CiCQ?bwj!Bt_!(3-d=dHY3#pX zo06#3>+A=yGDAO}c6e-eY<3xmXI?nF=*3Iw9(2X;`s1raCrE5qGUp%%r{tX27ml=f zzMW8Ey4umO^Zua&c5;s7BMS^q=66rO6rB~k*py5v@$OA)FL+8bNi$O8XOJT)&E_{% zosB+IE&%l<`KPC4%9>}_Z|n^1X@c$B{LP<0hEJV3^|K;RaTeYQ>H5mOvK8(r*J)!+ zf3$YqhSc3-*9c1r_@WTP2w;Q@RTT;D*Lss#RdRQQyXVMmnd94_{c`D1Lv#hv-y^^x})l z(d4KMZ7!5x0ChkFpTVU{%CVaTqPmE8BJ>hwCVYP&t zJFClchZa?|%OPVqO@r(yD-wu~NzEvoiJ9$02OWW=y9nV9s|kY%<4j%zyr<P{Fr&*j522l+bXluOiFTOt5zID-fs{T!Unk%R zVV0tBei{5U<7Ai3CRD3vX@wT~B%t8=K}esbYnjUei;qqDQO!-Ha+w1L8g^h^C*b`p z3(->OJ>$leEzm9wVf035Fv*x$70X*|%GjZdT}EZh7MSC%O>}%sZezI91V+L=HmyoH znaw=S)t5cus~Q4yA~O~4Yx@MVaF)~JT9`Gr705vWd-;Z(H#Eayi-4aeV7=Lq#Z#C* z4r_GIG-k={QMGy__r%m@>kLE{$5}Z*o&(-hMbk(ji1ig2tvE)J2<~I3UT6k5GVv@4 z_ONrN!%G}jtJSXp*G!6dqBVBeY_X_)#tHEewB-{g#7BJvfSzEjUEudHDUn5|Lea9PtgRNAbK$;g{jr&iHNoRwGfMdQ}^`25`So`XEP zj{Eek=}bdmZ&OzEenz0?+Y!=4b3fNdeg{P3yH|-{k#@HeIt;s>8+Pe9kF0!BM}mTa ze&!~(rvFD?s4w)9Eu+s%C#mQjY`|rN3}ThrVr2pFWdQtV84d4Bvo`zTk7aO~(M!I6#n zc81vK3mMdHPNZo@5pj8Xy*+VMjU3wB#LiLxx1|!yeUI zqQJPtw;Zd}mWoEr-C$v>mX{)F-iT=L&wp7>fG z{5QC66lyn8mQ#EHWZ`XPCiG{4m~d_rKcGeUYKru^ssO3n$YTpk@BC ziIaaU&e_idq$Km3AA=$1dE%aGo zQNb0FunRg^a-(sC^KK-vXFxS?lI7wgR2{4Z%hz_?9k0D>HrveOF1cqJMMf#q)RMk0 z$L=6q{YejbMWb3k-YH6C4f(NX73L!3au4U`+3u(zer93WVcGW5#++;lHddR{?Uxyz zwv>7FINeCPpg(KKYOrqN>my;Z4jyM`k5x>dy0ZB)s3#c?)*3`5qWNyZZ$c0 zl#ghrY4#m%SarPo0d)3+z)pA$EPrt|)sOK?hfU85bEIlX3;v2lqKMQa8v^qI)7H}w%brp%zLTk5C_u!oYQ@-9blvq-a;g$y##{ks;kzmORicRv>KyW zx#sd*ZDFLlc=?Jy-_=fqBiafQAO_dcI|6N|y98S0c!?Bl-3AGQ*a{VHU3~NcXe0*h zvk?S{6H=jv?2$Jxr7_JebDG!JWhDv?_n`f&6Vb~3Cl<~lhEfzFR-ToFFUE+!zCiEn zDchB36j7QUxX018Hc|*k)V-7GM6z%k>sg~jV>5G5ZEx852QpUv$xthQM{7Q>LHHwh zPyg|#szvJAhbfU4kr(O}SPJV!ifCeo5R`C3qnF*i5`hkG=RnSau8vV#n0|a)uz01r zx4bTRuVHQ7J3m8+`crML{;S(DxNs;SNo_J;kf>lk1%Q3#)Krm7{2}a$NW%# zEEztDu78{~|2mldm(~0SoHU~Z<`19-UVz&Y#=o2n9X7`YLl3}FvG8kOv}A;o9EIXp zTo@(@cWei6e8ywuy8sTCy#t-q+{yrYc_CSkE_6dzZ9g8dL&5l*b=7~gvwNymhu0w_ug?$ zW!v9yC>lf|fFK|xA}A^#0@6!Fq=|@t5Tr##q(neKBtRfY?^QrSDbj01dJCOUq&EfW zNG}OBKnQP~ndjcQckZ1#cjoteKF|9;?`QMJ$zErNle5p+Ywh)2>$|L6pJ|UT%R01U zcVAA1NzO!R?W#!4Mz$b3rnQPQ-F}UX!yFXHeNsZoyaDB;9Z5+R(xKrA@ z?aPInvAINaew+;kAyR-NqpCy9PMe{{sra#=+7C!&ytDtje(})SSLVrjhdG1Rt&y+T zDR1bORsiNIj<_@wKQ?;)9otpo4tDMYBPrrFYf>PdwRs%;-mu@O>WQxRv5vQ9y!~(s zupgcKN!-MANq89RillaW;-|p!22k5IE<;h5{p?w{&F~Zt4x)Y`zTwbs>3Y$Swj`V4 z-bJch6)lLKT)2n*mT)5~Xh=Z{_Hj%l*0ufO3=M>@&dIWEekn6@y-S{{hTQ&@rSpe_ zfLU~P2Ud!0BxbY+t}>1HjY+ogCIU#AAGy@0bF5w8$A)HnvzGB~Fd8w+*yD4o0}t#_ zWy|SlYUzIJEglV3y;rW`rtxBeFAPDopIGO_AGCLJ8W?(2&TiVpi50~10d%F05;fQ& zj~bEJ8s-9^BQWO>eKRd2{y6RDc*AoW`RDi#jm?G+QwI+1duac|;Oy#SM*zOv#-ts( zvLit6V@w8)l^8uikNP4pK@O%1+E1v1ZD=8-$?OE9sKYY?9}0phul!g%(F_D%d^dSz zwlY1vksd3mqp4W;0@x?gTRSf2N;OoiG|h^Id^GM%M`*Rj8nmg411WmIYFHI=*--of z$Pf<-fN_%Q9VKF>AXgrkUEmww1m1Ax<>EM;!6wVYTh^S`SqM3+sd4uPoi4-XHnhjE zlfiXhMN>&fGy>fWwc)Jv%grX&S(1zjTZ2%W0`_U~Rqx%JJ+4$)ejgAwxeeW`e(h{e zIFAGN=sEj0nQ}y$M+xa_yo3mdwo&kZ!Rw8K84Hq8rnaeKBqCh z@E*{T`XoggKg*_n2uT_q-`Ny9LM0KCxj|JRw+GC&o7@-X9T@K779)HwfJ-uwOSz8d zC$-X-Z_aY3*Lp8hhwH+m5ZyDe6?xy(ZIZ>T3{mG~X1XI>V@aS78}gbi8{rIy*r}i+ zfYnlwu%PN&SrA&+6iE&hx={YOcEmNWql0noZsYR6aMC3_Fwm9_y_1+Ly3ynk{c(R= z+;tR&5BIT6y@eSp{>mET_joDIE%mwTfZnnVszrgZGL-2+zyFD;K6`LZ1Hx z!rY*rhzf-7-1&}YVy1n9M&@oZ349?LeA|~IonDigFZmCHi-*bWS3Z1}7Qzu=S|V;z zmPIVQcu9=%VUbEb@4;u3ulvEydYB~k2*6leOYtT9oqMMCo72bQB~F0H&4>c)6JE>m zGDp+;wjJJ#?f8{NgH68V3sFsL1tVo;uk`zrIUxtRUN#qP#>X5rXlrBqihAPLB@Tnba_Ao66$BGsdpRzKuxwGYKRR z0@c^j_ELSTa>Az{O?;GdY~}vzC-9)Aj{s*7QOo8-h1n);m+QQw*)A*e764}jnuN*o z(9LA>ta3@K&2cUk+Ysc zNVu!(axpG z>YSK(bpQ~vqCf0Ux`JqIED})4?Q{k}#A}w>Bf{_Ag_0SUux^DXl@jq8~m{s_qFk?OJ;NE3*la$Rf1UB;%eG}*^i z*PB}Yq}%CMaNw$`5k6@eNaQ`szoYP8V$A5?P07pkUfjMlfwQ2d9dr_siEQFwxX316 z><<%feuDakiMQ_WLN@Wze=_lQ>-oqgp4-$oYVPvSCf)$LL}2yy-***1JiLD-Y3P25 zjUiU4uRvV>_LR*}YqF%>qaO?JKzw?x^^gpAjD7YJ^rW4YZB<%il^aM$3qYSXC}gBx z*t3-zs-;tI^wVk`I{L*m3ITAsh_S(kW9d-FiAL`9s(mk3A~NJ$*5n@?0sI%rvDxSZ zq#3>uHq0M8p%l6GUY752IJaB4K5Al+2Zi0>Ye0aO>M%r%w@9RgASkf7=q0K7WV9v0314l!`+R}KZ;)IW;p4X>Qo?6e zM-TBy(#Fakb5m_Zht5E&{8jNX&Bq3O_#_KMvw67z_C&t@FzE$>5jeS7ehBhgS~|(0 zUa*#-W;3P47bV@0^D0U`%eEl7usD8g>51PsGdU9F-IXkMzW9H6D*7GK4nM3vP>^1P zYvfX>SJ!s9&z`Y6zXrPFxF!Sb@{lAf=UPK`z7igVB|S{bs++Qo=2XQ@wkygtf7p$6XBh=^|5 zDCN)_OoP>U^Ub=u4k!5G`2)W{lgQ0gt93iB-nze?shUMdXxJ4vYhqn#+!)F3!oyFZ zYEhPvS8W<+tuW|Y*6W+&4CrV(0l{&LUhZ8|xQMH1Z;3N3h`TncVydQ2UWW0Jre$QO z&rE)ORq!3WBX2VgZG2Fcjz1}$q6IR-hDC03|5Z7G#{5(oIh~7Zd4l3p%4;v0R^A%7 zNuJlD5sK{8>ptf7{oixd`F-0(r_c8;-_6mQLcWv|Sx!Z^PK2D*oE~7jEfU&|g1+ zp%#w{mQ#27v}`a?F#CE^ku!uj$#R%#gJqhPB#gHRyjp4kKO6Hc>KzSlq*wIn*-4L^ z)#Rk&W|AQO!ca%PnNC%d?kj4CYdY?!#-LU`=N_VF=H+U#UR}M9YXyY9BL80D+5?#ZS|DZHFwFMr+OvyZETLoJT!_XlD^alj@M zF>JhB@yQ*Vn*h4z)Y9AG>z7Fvc2_4#J^q5!?aE5-Cvt%^tOqX<9)6=LK?OIh?1*B# zEI*KR{dt*_Ht~+^4lvAx>aU;hr*tU#-%s!#SET=XR!7J$O0yOl;-$HzlS{!QaIUPz zOq6l4t^Ej4rt$L+vr@=uc|C>q7>oJ z@oO)i9*nAWQHFP6+zHFmhZdT6r`UwFrQuTT=BIoShTr7e-oM4{^oe<xT#ycOhR@f2v7&l<^HGz?TB07DpxfecxdI>N zPfg+*{O+fDlNvF;ucEJe-it=4^?V8O@(hIe8v(22g<`VaXuOz0DQD--D{whdk^0Om zqaleIpA=+^G)t+61d6*nioW-XTM`o)^SU+J>!bq>8ZEHgzQ6G+=fdAXnV%v|goK3t zce~#HMB(ONUGGl|?=Qt;ehFj!Ihp0xm5hH1Y%SqZ)&AAa=bwKTv>PMW^RypnWhhQFcKG6wj9on};&Kxr1!2 zW9OHzl^f0^UN0WHegvQ^$;h?bS&BMS#>7|!cTnU~m6qEdPDjd=4Ccwn4aL9Dt;^=I zr1r5LaXA;3`fhu>psXQceAMbGN2}qr{5NGz^-Ch7WO~N;PTN(+=wQsb1qJ#N=bCb+ zF|*lXAHT@(T66CC?EynrS>+FqQIzm9MV(G^>hPf z>{2GrG{kfvJ&T5(7=A(@ddyjH-t+H|FidGM2yZc4?G-Q%cggxnUeubQeE##*gC ztsix1EiB>jSIY6;peX5s?%f3M?i=m`^Ao3ukMPidv?!^oVQ-&c1BB=~z^jmPh##=T zp7&l2UDc}N{6MSb^Cwa2d{J)0%;K6i6sFwls|MQd!qaeNfzO1t5x_v6_<5}^&bm<( z_wKA6Hig4nSfl8IHoSCoTGs9D*4RX~k&8s+8lsImnZf-4sx<{W^L2EoNBF04{PaBx z1(^AR#xD;KcF?)S+Uf7lk7%+f?wnwdQvpzZlqc1i!dF0`#?;0S7}yqxF`U&?1&3{M;FNDWY^KMxE{2LBN35BXXR?*D8v3nbz*{h>`5uK2+l2lr7m zWoBQob}5`53WKj^Kp^tOpU8g=D#jjkyo5|}Vf@pd!YdyRzQFoW%nNrj9sw+05?!Gj zlPF*3$2)Xd58kgDo_Sza=8HjkM^;q110lC(k*v6u1yjXr>&==%-&nQDU&)$r^WGVf zB4ZP`d)~CZ2ou|U@}h0kwEjmn4%+bN)EuWDAAS^W{&T?ePosVz7yWgFO8Whr*MIgK zuN+Qor^BihihqR5eoTN3P%+M-VQaLHYRlX9{J+EGJMiHxR$^JT-V_1gg*FmPq3xxup8*G%mvmQ=_oO!6)gsZ;q^_rH5<*;_Gxy2f_wErp!Brn-iqUJFrU*hv^f za2Q|LsMz3lD+x__TzWtC-J@4rH*#e1n@Wdr@Df8;k3R>oiFXqkb*uV{12R7)v`1#r z7+Km%6t01i(Q-WsJcNwhCRda6mTb(4wdpYB134v!B2Sf@^C@{9Hg`8Pva~bW$)9`s z$&<8I%d+e&Q}dc>d@W49mkXK3e$10M-7Wux_~L(cpIEpWG%gfppTgYF^WjTye)jCS z{RDRm=OSP1Mw;lJ&L@T_o3Y{LL?U%0p<)FPdLsGBF(?xMBzNmd^ z+S`2+cU5aMGoL}bWUxD)gKN6?qtu0UZblV{Mn|qMF0Pttqjpl~U)k#!&Q!m?yr~=`r<(8-Qz# z!~F__i;48r<<&ik<*M}l4_|_pndw1WM1kb|5puBBpM669|7ej*IGhTA>#S*_i&9&X2+B=aM! zH%{!FE+u0Fxv(n)VUlVs2=(Re=n+6A-#s4&hmH*V!{cdSDu$;eKpW1+e!3xS$GY}9 z#4j@7K5*2YeW&vgqPt083PxjX*aoPnhE?i_o>k$w2exS<*W>k_fiR$bkv!ROKFS@u z$D&%R6`Su3_cF$$XTw+qWz;m6gVgJqt`yXBRza62Rok?K=pl@h7kSUaupHTxzUFlD zz_Y^abCj$T|F^^vd=n##;BOpuLD(@1_U%{)_mjxcY=zlvbbd7*Zc`O^H{q;NJ?BUu zY+}6f`&gAPY3Trj<&WPVt(yQ{M^P^prdKm|X2l#HE*F@Lmc!Q2ABhew|6%ZQZb3n1 zIV2$I)K>Rdt7y$rj7H09Y4tBsZ8u~D-z67#K`-IJFY zO^k|0VGlYh?q1U#*y7zfkI^r#!t^)=6y$$hMd!_Z%VfK>V_~o$Tp_52 zR0DJnIN8j7tyd15nNVYjf845Id~#Fc@|NEE_JV9AOqh6s5S@cq!|{2JEIu!NSftBripbAt-5V0!)$Bs)<0N04k4M1g9P$ITyllbwTG20tLP1@f+H z10ALy7TriX8?IUyXTFog{^0c{C+|A=@z>F+TgDvd(ozoHFjkQ$9i1ntMpJkQI z08A!bsjp4jWo>P}@p3aP(-3+ho&8KL8QbRhtBXPGcD&V3be9OsU?Ki^+*GHu;Pr${`8ESD6g$BB@&*U-``BAO z*K6sm+8(8SRfgN9exNrX$M#~s4G+m&e3edcysJTXv0cE(iHpGjI~cC7Fjrt=I66M6 zZsSa?TYqi@fBRL8e+tkWdNto>-6pNH%IorEgbgD7MtftAcYSW0e(7#$pOHyDGfqvS znw$dlXhCsuxC6z8q_UeFb3OT9oOaQ9DqgCMzs;#-wmb7&$U)fP#zYGkFiMa#^_thb zS!qIe8YZf~VPan)w%E$6FjImo!~54skm!b!EBfyh#Cfo%hD0IbjBW4iJJ58OubSAc z;HT9+`m+eu7D9|#C8OTGG(5(jg8MUH_J@rQ3AD-{F`lBJg;+LB@mP~nJbfc}xv58c7 zD5lllSR~!cxv?LMPEe3XU`#Zc;8RsDG@ttGtUTq^#ZGN5v8aJ{1~)CRXx5HwL?}|y zj^~Uag6s#5ez7Mgt|3*B|AftQ)|hl|8~DxPija|N zf617F2AxiqK<+igZB;f3p>5Ufo}PeT(;WWL`ijVd##_zpVI zz)mWz2kk+oVXydb!hs5%9CDRT?Qd-^*j72VgLmS>>%1peR+FfaR>FaDVi)7wFGn2# z?u;aS+2rG2JH4bro0Pl;A61|s^ud@APc^UZ>s}zeEs-poQ`7p!KM=wKQT#Ssie$v6 zVfb*L<4v|QG!DhA?aV$$B$aDrvt9AZ$2-P8=BSRKHE ze7EA7by!i(sHLmWTsGoMS+Q?A(&-$%_qQ$XxqmkRJ|ho@4pcvywnDE_X}Y;xJHg}_ z^6tu|Elvs;`?4V>eFk(|6ZQNoeDtfQTJ*aoQ`)M@leC0x!@+G~Hbgx9z_Z_U{4?dP zcQgF7LGnNVv>!~bz-on|>z}Hu_7ljrAGluh@e~iAd+VV{zq9UE9rzAXieQpKkks;9 z+F&av!QSiZs=MYBxy!qS)g0662e^yiW~N>yOpYmVMc;{2@8=mM6>O?z?#?n_B|?+P2rX9IZAnkDoJEBG>9M+Eg`4T!1oQ!1#W9Jz6Ie#R6%i`-P>*8KA+Tpx$<#{=PBh0)%aYZ zeIgf%F$sGd3#q8HO66QSp)$kptglUML+ zz$;IbW=&vK&-?{_8q1>yReNKtW)zG16ok^mcvMYiXVEvmh(6~ty@4x3N`OLn0snMu zP#P}j)zt!pcYu%G2Cy0vkh5<6+G@2(7v}s6-!gP30r_v&Nhvs#tEH zOOHVX0^e&-Av~6wP5D0c=F>2JYxCw|r%5({a|qxc#~9(T{%h5G(;7l&dtM2Bej~~l z5p?`Pcn_uf^6w3+!IgOz!+?v~R%s*WC3-HDKRi_g*0&{7VR(OJ*}4!{CDaHof3siYy#IpB6OBd+O|G)m?^_#MNd$xzpRi@462uNB)b=N@9JABkwu8P# z8W2n#6Xjz?O@?l*s8H+gJ)GM)3|ITW{;_rR8X;dk&E1y%!iy!=pEnqfMo@R=Xf zAdYfTRgeaZ4Vm1Q2R(C9Z4UPxIy)Ecl)rc;+b++DCuZnEU8QyhB@jO&C9kD43RWOM zo1msF_zSUxmYtO+C|&?5Z$Vr@0~UKfP&|QY0W>Wks>7i8=@_+VCDp6*;A;ORG2#K) z_r!u{8TLi0o97vd*?QeDp{R=ljVo=lliYJxja+6bOM|A*fS9wm*qn7l>D+VeY)JK5UgQ@NVS|ilLU^eme5rB8yAF}cbw)ro@*ZvT;36n;m@WyfRMDDX* zH-+-_%*(Zjy4PB}d)2T9Ef|L%p%4|q;siNyY9AwmoQ~(Igp5a#NgpD^cSDii$*g?M z4yJG%!ukYFX`x>1lq&vCBQHdm7rcHp1!p!jSQfONIV6s#9usYA;Nwr*n3004WSxtg z;4M|YM-ag+jW#>?FQ2V8wSD_!is^Kpi~T$B&V2^8^~lllSx7d5lg)J1;&!O1u;iUj z&jU{^%9VG44zAGfIk&Dx!tN+i>-X@HYcVUc(MGnU=&2@CC8IOW{V!U)kYj2y_i|Eu zD0-m%42mqpC#cD#oK+~(?6dT=7XS+avM}6S%(T16)}d*aY=8k*T6nzJ;dk2{_ht(? ziLTzD~?WvyJ;4*WIpX-|a-YlLHFqHK!mfu!SPX+a2dUz81+8ir0tF zRopjWU_@G3IS+jxbH)dHi(@KkiuGunzmxm2V?=RtMWX?8-bUS*tDf3z%o+O7y z)*bsRQkTpIG!=g+@!sR=Z`V7npEj|P67FIV8|9bVr|Oxm?w^9bif$oY5;3(sYaV~1 zp!6Nq z5m(TYSLiI1`sI`|)gR@2ZFYJ#6BF@5A(?FSINpQHaKD}AlF^{kCmTH$oO#|U+rTV^ znRxF9JzL!ji+u*xrS>L9Qs19&fwF!WL&L2e3b@yaC-F8zQ6_2Lltxw@xlLnYYu6Na zk7JbZyFO_+Sg>tz)G8kv)2P~*>BYq)doNJA_y#z<`U1Zf(a0%{Z1B~^j;Ji*CGQ-B zFu2#FT?s7HR!+6YFz+2N9)w;|q>XYw#b;kI$Mr^QX@CPiq>@OT1n}n!3VE8KsT91fWs_JNGSe3x#-h{!Omh|VcR!`qt}-5 z>c0D@(6V`xy>oVr+~7()G*GY@ev`UP^kJ*Y%}eZ0AvaF!qGO37QwL}kL{x`L@i`60 zi>G{^oPQN-wgpIX{k>tor^(#i$b?Xq7*M}Xzk2a4n`DjWb?i?S^2SK-fe!_iCr%<{ zm2n>NvGJN8cx@<+`~V#y+fUcG7Gx=m25XE4|0fh2w>I8v%E_-HbqwyRoMW_nrq$dj z@cGr(4t1}Hh%S(B&kpwYRN4FlEg@*R0mJucNQk{m@!VCl0DdN9G&zFx#&bTU-H1aKRFd_9{y1VS|3kU2ck>mX3fDl0H_Uppn`^Kb%J7lA zMO$dBjEsQ)R#Dm~u@Lq6eTXNV9Bp_sMl;ToewN9-CjDsPrr){!>GJL%(v|2259-Q_ z(unlc{*y*ex%A#}e%#_wVsN)Nw)j2M>CaB@?>rUzyA9*?y-09IdPcNm!03(GDNoVQ z?hmRCW$5dm!V;zHLGZmEn=mz|=BHCyVOSnPR8iTPc-i9GW)rvG``{wEA1 z_spi>S~ffR)%Y3 zq~3sEHeS-?t-1i`5x|0b+|UP-6HhppE=UvC3angdS2vhHklNW8;5ocMjGbU{;>kg3 z4nNhojfH&0mc^!kmNIH;r|dkpPIz!xL1hYjGsjGgbMN$Z+ZHrG2BdWyXOf&;9P-69urUG_|;Dm z5A&K8Wue(S%potcrTD3&xHMhp3-KO1`j%S>)MfYV=Zul-d-T9%Q|(-&L3L!j{M9z0 z0Zx}_V)u_;W4+zbOb7k0vB%)?=sCNN_1(>eyc7iDtT2<$dV>3&PbDiXwweN_im@~Z@{!C?wbO2^p zVT_+@Usm1(jBs$y^j}Y4^*Bs@&NdciZ@gABlMlKv##siotORc~oD!p2a|L0OtY?sV zc-2O3<_YFqueEK&flvY0D>9b31#6lgsW`N2iI?!NxKO^irb_(iJ@?SPTajEY0)|Ga z50!-W8bQ7Yg>&#gq`B9JH<}TsAd(m%u1R+CQ}n^bw(^bDH+vzFk!bYypiOtX=`)2n zYe8d}#%GAp6ML<@wzaVWE#kq$n1Lq_O*v7y(fcIvdBNr{MN9_oqO>knLrez1+JhG& z3NQKOJlWYMx(?Fb?)=GxL4N-{xv#|7T_uV*@>rVCb!PFeU4zJkXGs%5`EIB>5X+F({v7YN6+E5zzd$R;OpU(YG_QF3 zSW92tBeA4op_b|Tm}67w?J~bxfdhNGt@d+L^BiucEI3Ilot9*PU~3iLq;$uNorz!f zyB1H&4p-^Uj6C^8ZvBYYEJ(=-mP$2O0X_+DncKq7o20*Fsrli^W_jAZF4>p&l}zUJ zGg(5^k4!xs6I3?Q`X{o4A6aL=dNcn^Q0ads6C<{40%Dlq8c*0q5eRXIo5bbpAN46N zL6+l>09T5W>^)+(AwG~tcV+T& zO1uBEvVG^DQ=a|}9QRhRu>Q1$U@)h(XxBUdq+=DO!6|Y*suFuPq)4QW>RZ3b(Dkb; zEH~N&pC6O^!SbF-jtHF9t?d0VPmfFykXr-dQ+Xy|^M-jSS3T}U_6F@r%_P>j>R*`f z*@7QFvmVwD7O%Te1$)i+;&Dxv)O?RVa{q#F*9YMYPq~yEjqd$nv(DlJh5(+2QtSos zJ&(^&Wx#Fw0}__W8JYM0%ZdH z7o=2JKO{fwFO!@}#i*)Z7@)JR(0cvRXY?{2m9Mqyt026cO~Pe1lS&}tEUDyLlz;4U z{s9F1|ICoTF+ct|h`CFygYoO>{rUJa{tWuid#Y1ae?#sFP&isWu76my6EY(uMa&gz zGOXPJ`HOQIwQiEIwwo?SJL@B2A(Jy3dEJcGM}RL1oC8jFyxj*}Rh{4MMr$p*#Jt1X ztFa9eT&jUctw*V-2I(EUlD6-A6E+h?UXI~{7Mb}j;l3D|a3(@xBRQGM$8lu>9^J8t z8LhRTp652`)-v1#pF}!wU%<=zg&qND=D%Ww`Qzr@%RIVHbjcMaCYJONW~Rq|C)?ti z1eVTz2uZLspa7GjlI_U;!rT-*wz=kHeYAK0bU<90U83hBB}8+*Ya*HY0ID<-9_-5M zeG$%p&aw^?wMltM?U69?zV^n69rU$|!w=Or`=1W0_MZ=iyo8CW5F3Rz{=4q{G0;v> zS?r5oliss5-N)V3C1*&0FEe<^?Xe!RR?Ky=P%9Z@Ob)?W6i0hNCh5W;r?>w7m>qer zVZYO%guK%2>ae9Dttvi?lr7#Y1#JAEk<>z$4w~~dUAl&Y{9UATkXgry$_Rrp; z$^}1){_h2*iut5o{pX*1E#vvhE{Rg_>g+u{@Bu_Aq=BtB=9v*0~iB^DF9!1HgKe(`S1f$bKbl-pRf6_ zCyHusofOk0yn1@tPF5)0>Z0(PPXxFdwN+q`vP?Sd^3_H_T?F-l&y(bK1W0!>1g(P7 zP40YLj=w(yh>#HtO6TzcJ;?L?Wpc_*PZuSU#*8k zU{<@@#v|>bQB9+-j{r%xw^wDgKMm$R#`Ld!s3>`Dej%{zGI@_0W1X*;GfUz}{VFfl z`B!#{+=H83+Ue({TxdONL!RJ9YWOK@ch#&vtYoKf z5o>s0ur-s9aN1p^lX#DEG;^F{iaXO+EQ;O*hdqAoJ)V6Ov)glrX@Za{I&k%Qk? zUTC0BxoA4fUe7oJJP*BbA%WYV3n2HzBK>*dX~KkLu$-3J2P1-6J3NjjUGl)knnLi) zM$2=G8D27P7a?;>6V_tN9Dcj+Vp)(@3E!u~ly*O5{TWY}Z}&+o{X|_{26{%ARyEz~ zv{5tvNYn$5p6^QMbM5Qo)~=vv7fF{1x=?(aFK=IQVE%OUs=8pUr9(=jUil=qGYiDm z1>0EblXw9)(ZnUIJ7|;N8S^nRB=Sz4B(u3GJxG@v{4g^$(V)ddu$!iTpS@H%G}rz` ztwk+EpCd>V4FqPBLm=#N>r?!JNJ%{K?!dMY+|m3QpBbO709`XX)Z2St|0UYvNBhY} zAXH&(P9ksMPk0|b7_cDjz9UtjgR5Wmlr@1E-arQ5tDw4Fx|ies)oJMpC)db3O|4Yh z?If_4^zx#X*Fo)+?!st|1-8G-bzgT9vrf3bFR}grzqOfIHL?z``K?*K3`v}u#1BBRw3Wlb;?)$+Io43RbzX8Fv4O{p|Ejkd zDNEp?kKr>c3%cbj8SEF-^e8o8zhYs2GPe`UJQ#m%DIR%RYyd*WuD4esqoyyF!xH3$2e$OB%Im0?#02giG6l75YL7U z5`QS;UTSxEYS^0)V%B{2BbUOcB*_m>&NTUT$OakW`lr0;ntu%WSjZ)3LX)$gqdY{G z`5zGCvZr>H%uBl`XmJVf!*E^U)4^)_PPrGzp%}NaLRQM3F($nZYr>PMYkp_s6*_Re2S?9U z<*t}iL&I;!u3WgahjR@{wEi#q;V;YJFEKoLp~V5DZmww|U$@Kkq=aY~10i;6N#XJ! z+91lJI$o=@4IO~gaCHJRFAe9Zi;ZjY&&>`G!cJ^uZ6*1|3tApu4)7S{HH#JH`gTY` zg=5)G8gi>Gb5|Ei9Jv>DG> zcMk)Eg1iZg86j^0XO95I^zY&nD9dU_fw~`yUR{Hy*@WB`z5_Bda;bmPK=F&w_|9m!!wb0KlyN~x-pk-xJ#^q z2^&K0Mlk*1!Qx+>?NJ^*hHam4dIfPDtL`^v?O^MwY~N7$87>$8)nj=H!p963?J>gx zS5>x2TlS&k^kQz2;eS77xX$L7IE-7I*t-_2>G`>0ajtNrf_M^~6SRr;9HF(w$ieqg z$Ic{BymjpFG%Il=oPp@E%)=;(nFo=G;Z4;_Aqgtc`OJ8%^*m0{BS&C~cHav_E;@6W zT`5~1kj-{(H_e2`zKgR}SybO=qmczOl@$p+J`0+Z*XkAysdDX;qlFC@N?2UCNr*Dd8CD zvc9Rli^XdBhR~R+eCFSpF6ms$Or{&=f>TX_8|6_A+*hjx#B(k6g$s-CwQ=T57COnx zgfZ`|8-Qs@?8_tuywi9}zR}G>_s|c1YTu#9g0mL~o@bW1))7>3-7uVgaKSd6^$1Jw ziVd@<>XmXq6Ro?czVcPWB~WrB&wa@K%YrxVNq497ve0TUFw;9Osx{w?YC1;sZXep9 z`{wfonZY-_hW;T~nn9+7XZ z#6AX4@g)v~)ZZ^+0I-w!$e+@tzwrdL@s}V|@o;SC421D8zFkE|IheVODy_SxE!@L< zwErSTn@}<{hffM1b(-^Xoo@~@devvK@B~|{xVjh(yF@g^Z;~TLQBOZbhDAPZ7OGnm z+Y&XKNZ#3MD_HBU<0U&DsGSZv7CeW9SE)K9KVOc}hb*}h<|(VHAb@Znk#Trk_yd(e zZ81nf^;(9a!4V*Pcjg`K+6s|U4vbTURbv9^9+P_HzH&CaJ!VGAoCtd^fUW*V%)8p{ z*8n;EpT+-*(d7@RUsIcDJFi4;yad`Qr^794blkXfSEM!1=a5~UDE8-tCR$!Z0id^> zh~0;J>2gNdsyn)m96oFD@+Y73U>P6?H+)2hHJ;fQJe~0BbX9S)1gl`vhNvqgaO!sl z_COU)jxlS)E)(rBUYpZ4BR3Tft}`m}aDAb}ZhQky{r3XXw+FJL9bj+q%U>8d%VsaS zO|kNMAcz9}5DPaKGu+d3SxVkmqE9#S{A_qP*w@u!W!+BDgY|>7wD*u)f z`rn=3f0(eAVpPlUwdhi!+GGrCh2B**(y`&qe8^YK5=#}HEE{cy$1#bnJ!ZblrrUFTIjm$Z=|3!z*Z;#J`4GuV zus{=(nulHeN^EGGcO-(?d1H*vT+PhXZb%$k{)=nmPR@^Z=|g0Y?}Y$bp!8PS;}rGB zl&`wnFSBLo7weW>tu8pHIi#Ui4CCfNQ9C^H=tD=t14!Ly?Gyk< zw$p14-`Wh5D)Jprzkj31G*Z8Rr`w38xQkUY3GP?9&ckm74W_&3OsklDzUj+L>k1gN zANr`kNE90;@=Pz+C>fUeK0e@3J{8$saFSKGKWj?McKa1Bd@8Ya3dCx%bat>cHPIp=|VP^Y%ZOE;o&{oYW1iUFpjSBcLd*QJ_gw$3DjG(UqJ!?pty8_F>86{+q84ePszS%F&LeRu~v?? zqj9;gy_1;QjkV8TNl!6jeb=|hB*a`Y!rL!n@pZMz_iFq8cxQoLd&O^Eod37*gy&Tt zRa2F+lpgNK)Q)_A9!QIs`{u^^f(Vy@F)T7nG(X<=0b9p32;Lq|a8AK$wd5#dn{l-p zi4T}MmJZ%u_vi+n=jB*|^Wg z&D}fQZ!;Hfkjm%x+RH^+9xx+auz9mLrRVya;$;`}SgAIi^mB=KwG{iM3*t0ChTr+5 zVeo#8m5)_!v(vKeyfTM6Z_fFjfrr68^DvtD2We_Eim}cQDZ_O%A2_Q;CaT_7W*5W) zXlKN`11m4aRmw`p_|~nSXrLmm4O8)(;irkua9w`fT=JvPDo&d+sQ|DG2uPx&bCBt7 zvf2T}K_wbg=p|Xk#6&pg`#6s`yI`ZARg!tyd{&jKLNIP>Ip{7iN znU2=LKJDC#PG0RH^qKxUpAy%mD)}xMggY+CcbYvgFj1LC8MVH%&Vw0M#q$Q4z`I)L5{tq&AIL^(om}cVZ3WU{g+upZ0IKv-CyB@MHagWi@(AL)&CDq z87<#Am|wo%tqTKd9Ra{hM*s}!y^{nA{~dVf2>Y%dy(Zj;$;9~+16^4Uy(h`}UvOQW zp-z|i7Og#IA;|I}WXm`vp#X)ALJcbtLmiSBP_tCPLw8}4*WfJX3^{SEmJ9@<36QPF zLqbVJ53<#6!n!wn@&l^X?Jil6RlCIlyF2{AwBxr+>A&iMc9BGfoR&MSm#_vEc3UpD z0~lCBTp46%9Zt+2uLd^nV=A2UjK5kB(~-h?v}uur;WvTEFh#k^;kWR(k&xX@qlw$7 z7qc$#h64sjHd>qTXqqYyVYlKaA}QnXB@oig-qpBA37J&bUPRHA%;X~6R-&0~1w|MY zvOK1UufRC4>vHvlY>rjoR>!wCAAR=GWNwG^5Zcw{qWqt7nEwr-`yYkhehVyJSw)js zVSimZHnsYoW9wHSBH2A&LWV&9)Sr$bsY2oBaDPwe-SR)4_~lgaqu zZ?EfL_xy|)G81ZtG7lP(Soa6WM1T6BgxX7Z~8xO)Zfa*{y5N+$-KYt8@H`M zJi(vLz&PIo+nyr7JMiECII}8nzpB?sN}S__TyEA05e&tM8m|<@kZ^E&@amSyT{@Kp ztt(5EckDc0M$vSEhA;|!B^ouXy58C!quVPzqd6wI(!9jHw+nWsx*L|)!CDt{vyC9velM|j(r5p4EaPDmz6Zxx6DpYY}4o`Hz)YhU6Pu@z0^~`XyzjxrALi0n7Uo2pHt>~z>!T=F1OpZ zXljAyos6>FISn^uvwBkM!i@Ds%uoIWrzQ~aJZ+Ft4XBuWN!0$e^uRxx)3jc<%OqV(`<9TgVT{psoAX$RTNpa zx5QNKPdVOP!mFk94$NNTJr|UlyA&ILG157ELjC)wVUu}e)#OX=v@NQEK@-^h;@<1Q zHFx*5u8s`x3WiQleca|x=FZ4j+E332Ofy+>?sIuLRLK6smcZqoEf3fh$FGOVS!5$d zO``8%96n|X*gWI7Oz8^pcq`vs3LxyZB#I4G+Z42A!K4lD$CQ@Ry?!MRti6*sKMFv) z&1kVNnMw>l84!M#cjfk|(ed^hiQW?#T8^up@~m}9loto{J`7ZA+RMKd&9YpX0^C-8 zJnLPy7_#|g_yghe=uj?Nt2-eDOd+D z-n4VCJteishvG6yjm{1BH9OPUj=cOkd8paiZ-eb1Kb z%f8RdI$3pW_c!eKp&x4N)+vjRi)0!Lm~mTHMmrBjhxb)yPJ`>=wI?5FqM>?l4WbP=V>B8?aTr_nca#~e2~;N&NE??gLnzu zOFh2<(89eF2v3#;5ov~@2jpll_tNaCudun0;8qGq!}9_K&lL!c*L3kmQ)Y&CgNr2t zF#UOpdDvW&BTO0>v`>P}#toJ)9v_ZliS?bnjn^R2(Va& zqAcv_H**kCPqvE6_;D7HeL(k60r>}T&ELoKwJloMYE5>bwkVSF-3EWOpA{lY8&L`W znwu7v-;8&X{N&B@PWAl;V?Fl6Hsp@e`3gvYhp2bGDN8x#YR1mJ$3+2~n43~kTc(+d zVQEl)JgDU!LZG3HwRvE?{gl2vw{xp1kUMzbP-GxzkG5}US$`mMVqtP ztG4Znn485Vm4hXhY;1bxt14fgzv^J}WzxZ29UYM`WLsi$o5SdZ%i3BxP4K(8mr|Tb zI`CCHdP_V3Mb7q)WIrV&)OWtl%#otQgP$LdE~%DI#ZHk)cNRx(J-Jp~rWQ;Q`WYxh zc$d_I8N$tlgZ+t;nO2Mu4Si$h1&>Q!<1CwYK%MN&|P&>7vX?zeSz zPh4a5()0(yFY9_Qd;j->`^BJ>3mDd-gR7yLjn@9_q9IjBfa?E;z3+}{YTLI4Q9)Xy zNl#D^q=_J))QCzG0R`z`P*8+O?~o9R^bP_l0!r_ZUZhEvB1)CsdrOc&2qAu(bI!Z( z-1F`|w|(CqZ;WrO49CveYdJPMd$01Fzd2_|B2iQ4tGrk`{$bxnt#le)KBTToVw>~> zY=V{2xPfU1pY?{8u8bk1bA5hX>TW#j@w9Ipu7?lTBb4T}4>+Vygrj6YXG#jts)a5* z8~RDMzITi=wu1S9rErD;u;LwU+`S5Wh^HZ`A9JfX?SVAAHl+8A*nvO;kS_hfwviML z(C&O27g7OY)~Cv!WCRfdWiu9+2ltf`GDTBBcoR;D+;iSb&U@Ndyd*#vX?Ziby_eXS zJ8cEEu1$PS*m{gA`r9r0YtgL$3fAcFB6o&)axFmH?=c`eOUA?b7KjdY5>i|8Aa~Xp z&jJ`4>CD#+K3(^GI>l3Ay__e>eC?cxyu54P^qENEeB!NsA5Of$tq-x9Q@N7(bHb9( z&z>N!>BB@s=WWQw&Kr-k+jFe#lxV71V^U*{+L<62-ozt#dj&dTN@{5F@tc@|S%nK_ z5&X~@RZ+r7Bpk+G2QTPqlRBT%?4@kQb{EwYWr8aV*A4|=EluhTZyk%jW~wRk(nmYi z=v*43ywwx2WY*9Me!J>7&XXK!KB5QZ0=4vN-o_$P*nDc_E%I?zu2k| z77e=+akKdSiOn(8YC666R&_^?7Y=d~fr!%xDU>&1e#91NcJtJD`A@Qe+guitj?r4U zHGt}Sz?Z~e=uvs8S)97|1x*!@5}6%xy`y#>oU%Td4p^+JKX#3~cCT~Ii4FV$JXb#^ zXz_+GQNW1Tl{PBpyx)q_mhj(bmZqIE(lW(UE)C`z5*gn%nd}Bsi+pP!{S9F3srMhS z{CQ8Oy{5Jdqlu?FNeP(!5K+3|P$>=R!{L3WR@BU8)m?N^1N(GaE>Zd`f5^hcH#d-P zpfRL;__}?NJJtqDSAHg4=FHO=$kXTrAnBekKAS=`j&89%@hs}5Q6}YR#sQFBUt7Dj zUH~ZZbu~Vt*{#H*=!#WeyL*M5_G}J%i~`blchF-ejzk+EE%4YSv#E5yREPJk(t1E& z>I(LJ8#U~MF=Gp!N$$DttlnOFD)58i2l^z2cGDh9(^4ww`!Wn<;?~Jsc*~UA6uk0rH0abEcn;#ZO z`yHf#0_X`b;Fkn>*tZh4a-0(Paxocd(;Gq8De?pyW?cWX(}mkC2%ll}avX&I<{R60 z*Nw82_03>xes<58xTaymoAt0IRy zBjx6G$VP2cYm}V?WzC+{(oZsW1e`SpaZx(O{t{_m@Z0-HrKRhA z^rQ((kn;w7sgd^CHAMmJ#h_>#`oq^Z%gFbc3a-t(19;wWOnZRy9E#EK+1|VDnwP>? zAda$SKGbK3!hh1~yFc4z(Y!wk4YL{pvm2Q?_2FYGi^{4fss|$Xd2ZkTPVOtb8FD^q zZ0h>?dnLF17*x$qljRBBiL0}iPih5ibW_ZlN!#ysXZEh=EnSMnAWa$%q1)8h=qT7( zXqgBo&}Fo7;Bx%6;+$9M&`&r3e*j>JI^lLj8N>}z&j&@8fv12DLG9hC+SJD(KglSE zfH|s+gef+dLHR-}rIhAu?{IxLf)a$T%vlFxk*o*vU&9uCDDf1B77xJugYSC-N%hz~Kxh0HfuI7I&B$2!UqvYX zNl6%BluE!-wnkHX!0y{Z4Tj{y+ionKx95Eeew!al7!jTWg@Tze4e4V(=zLGsFu$Ig zQ>xb$Wb}A(#RjbqMtQ+mq;mNY?7@y03&pFzx+n)Pr+n4*ht_j_W7MEBb@(h?@NN%v z_;>}GKy3~%j`&%uz8TcXI#1G87|%r1Q)Phd#Tc*n1Hj zSeSM7ijbJyAX)0#+hx+J==W$|%yN)aANP9ish3XLlBM=FwMiE(CY;R1e<6bd?tGP9A+9bP|_o^ZwYiX?B@Wqmf>=Sp%T z_T_ED%<%A*y;N4rW@6-%c)C*CDX))Ai56Sxz!I#OC^dViO@nvqRw?})G%CHVU>4df zzRwqr9~trCz#QcS66Ky`7+JPFPj*i&Ze4tJ7^hBz8&?zH;u*97i^zHI0pkGtn zS2W{C3W3)0)>kb*Z>pby%w$EMcZ@HMA@vP0# z-<3xqH6NfG9#L(;S45fSJ6=f9NFlW}A}=qHH^`i~Hh^xFQpDmYR$)rd(!lcPbBzkt zoJ_6VdFZg8Y3|hgBzqFW6`c#YL!h~h$IjB-?1kyZ&1=+<*+;1v>-8Oq_%0xC5cE(C z2ye_Uugv2!6&mf3k4FQ_jA{BJwMwg8uMs(1sG4t2=$jB65Z^QJ7iWrxNRG3T- zL)W;)SG}%6yPot{qs_?xq!ah2UClIIr3SzKA%gbM9-Gu&;$hXSYdyRZy{Vwd!8QoC zh`?-bw%^!SY_FT17mIw1>3fkqP_zgc^LisGo-5zMK07@g;kSj1{0Afc0lI~Qt}m3R z{wQNCpke7=VH2`-trveu0E2!*6n{5?Pisx&P{@_rdP3bpIiXcJ?eCAG{*z9XJVA1B zkD0)mZHyo$!2L>(B$M-?VVcI6bZ z(29EWSlQG6a@7UH~Q$?Uw^ty?fgFy+Hk%!fM{=-FN9j2YPEdW*| zI@Tq5Hfvp4)-Uksp=h)AqIeUskn<#g%b>GX6Vs1N=DyKfhD@9l*m*UhI85h{q!(T= z1I>4fJI~D*djNZpYQ&Q3boF>*Y9V+!_{R~-aRYRZuK%#PNzFNe~V>+vWv7O;x zsWm2n@o970^jbx>1%1wB^5YN1-$*FP$iVPtSkSZEp`^>0g|*?ay8SB@y%qE98N37W z3BXc5_Rsq5qJXGI2*D~^#N;!qbnRZTRoTPw9$6%xOrSR*G(b5~FowPaF;&i3A?8bW8?>5y! zb4Npj|Mq*-(D>I)SpTwO`zH^qG)TbGVM;1Rj4%QO{fAu|*I`HVce8c>Hc;@pi~X+# zf2AaB&?UNUAH{EQ1t<_V|A4N+RygD1R%|0G5;RIll-FJfsnm5l4yn6%B zosbn#GxDS4neiU!8*?!zg*A^M7`vT0gOwQ1@dU&;2=|CG&KBPrYu}c*@`Nh$Z5Y9A z%pi4`-7+-YUHNHbZ60roPr`0sd8AaKPMs}N?dfOZ`Ejz4EU#9r{+m&q_g^asc?GQM z43+~RQJE9~k;`7N8?>MGoj-r3J9Z<3kE9n_j4xBd44U8~b*2VmV>zWQA8iDPpva8~ zsWsWpR%=Onm#%l}ICZRK#2*+?79q?+uPLXGvUBF7IX4lRoq!m5!lEMI(YtpM@?g$^ zyG373rw|1=DthfX)&6QEY%UXCt8f8G=3F*)fS%$4LgrbXQ|LJb6SH`?45Uc++mIhG zVChl9o$^Zabf`AQq#>Nl7L$yjbEOo4XCB)Q_aAaS(ltho?8n`y>5K-FlJB>1s0O>* zx@p$BzAU@!VA;;#Q|OV=LIRBt?_bg6y_-7g9F)vy0V_y_(k?{`-x!k0lm2e>S!nt6 z-A9x|(JU*qV$Ihr1TR;3JyE!OjwtrEWFh(;#CT7Pmee==;nkMBdM;-WSF*|7d?Zb( z8i5>F3@j$`Mzr2fhA&6tL`FX_qr!?*d`{~@sw1AQ5`Wjrsb_^4;SkP8lz)K7xBh0 zYLDT)>Fx_(W_#NTEc_#!{Ya~wM1}PQXsFM*q~=tq`l_AIvTA2Xo9{CjTr;RzCn(74 z05k^+%);bE+S?LKMYgymj4Q8S>bMTsdK=v`RYScX9P`W5zBla)K9{h)Mbvg=H{`u# zYom7f#j!s4E5I&4p_s7QNG2~TJUxj|os;;W5;Qg#yZ?6H8}x3TbP_2%?nCBbY|!`- ztI+zyJd&;=k9S+9eGj74L8KxWG#;0~tginlPw)SF<^FY8vcMg+Hn6S_N{J zQ3cvX$Bxzi`v3In2=Eu};shTIVFWylII?-Y2A^LA2&Hqd{k|W?*?lDWcR$IB;l%uY zWE;U?kOUC*W5obxg%1b_LDa^^coZ#<{|un8fjLL098!2(nQI?@N1Lz$jV;!l0}*}A zfv8*7PqMGZbxFCOhk*eE_na#^G2=FN9ae)`dr( z{f!aozyHW0WUkR_V*4CnP1r*f+x1CxU}DI7{7_SNV&dUMoBdgmARGB{A}vc>&$(E3 zyNhZuD5kd$zG-k_GD~FZ?A|B5T(~0dFZ3)^{Wy^1F?mZ^u#;!^LZ+$_gBhE|hfd!2 z%mi0J1>Q8ZeuhrCRd&}nWxVU7#Tk+Nv$r$BXB4~~cRP4ly4O=r4M-i?iQd^e&6?<$r>Xb`7z)0I<}8|>OUpL0mM(xlg0s}|;w?-q z32C}paIY4vvi?o|vGy@J4^>S1yyEiU;hTZV@~W~I%C^+E14^Tp*Y)#;dCEOsMD zx<@vXXhIHQ=pziLjRSuE{J%VZ|N4O$FmLGMhsI$zXymWQgYIdbJ_+2*Q?M*m&;6uT z0N~dD)1Tu{o@XI7=!n2@X26jX(&m@LzoN$G08elcWNVP+l+qs-y?_7fUxC}Yfbf!W z+BWsKB93qW?j`=o)&H+Km1$o)eMjZ6X!ng}3-{Qr$)1eboF% z-x2OPhTVBuPG<%vrgCiYYt`W7V zIo6L(%dh9fvHciuzCwYM+FOdwGG6gg$WF5K6D@jd7~@Soc$k_=cys8i+F#_N03OgN zy^%OvBBG|?yN2x3L24pvGFJ6#!O_-PqdXdL!$dxCldIx#o?>?K(AY;Mb~c4eyu6fI zCoRo)(UFQ5p56Db?-*-%ePXjpy{_{C?I~6ACUBE9Ajvi`#~;WVL_`*>##|nEN$v@} z(e%K9i+qE^0`sRG3Bog#bt-H*4Qwh}H=M}J~horNhQ&J8CU;^B`=Wjvpo zZG2Bt{&XMDdx>#K^1hSw)EtyBv^PdgXsy@cy4xHG9baH={0E96d*ztDWnCu99_63 zWWPo8IVvL7*8w$iHyDE!#mmihB2=-|LznLW-2h@mNQt-ZWFv`0Zp?xr zFFw#F=@NMCGsn*DM=iEImw@QyYb`lnc()Hd-U-4$yjh{~5@c%`>3QMGY-J2HYWi*t zcasz@3uz5A21byG{FTl%c0+T2398H|1}duex>`;$#3=I$)k??)>9g?wQ2M-mhz}Tu zd~84HpV6uO%o9hx%IVt#GPSawg>fQoVRk%V9bVZm57b5W@ppRbq7%oU0e_Hn#HBavn}bI6BV)&AD0Q8O(T6q)$4He9Id^k_&D8QSf?~}Mrs?FzHxa{u;BaSJ#Co-Io{^#p9Ndc3!D%P z$22|#$m$qqh2U1E`>TG(VJ-Se7COD7DX;XC>|x}Q@IQoJ|3G9tG;TNsWBU{(J=_ny zXEz7GW!t$7>;b!+$@{?&&CE1_tJ4<=<|a+yy@3#_Hr{g_t` zMpZR{Cp9^qE^9*J(MLmUj=N*(gj{qA3G5L}Vu3hN(wTG7*x^tIPh2fq8ubY(_S>5fz-dV=q?~~Ub-qF4a$f;f4ngrw>_%l*H zii#Fet?$4P$wP*6kxi|Dy+`Bu-<<@7tFAS(tWIild)lk>hb((W2 zxAYy_wlA}P16?$@u1sVm#~ZYPFAhJ&UJG-jGiqV2tG2o=pI|!6in#|+7R>OxE%VJJ z+Wy@La*->UU!IpEFfg=;X|v9e7Ur*u2P|MXqHtU&^OCLoOB^`%qSS@);k(;8k|JG4rG)p!0v7!zwRD&_ zG6o5$%NUAtM^bPd54JeVu zRYpy>G+KAfJFN+1gBQho(d1@oB@CVt%hcYLbLVP);k3EZ>Og6(?c7m;IET05j|!bb z+MG!07a(wdjCyoa#%=fUb&3xHHS=Q)G>EJ5s<*L<733PLOh@#S9ar9See@FNBLB`b zf!)9XW%q9_1WdV4{rb^QI)dw2qlPPv4|D}zcKu4Xg2Nfl9i>X(>@Cy*U(GNZR;t5SbO1;Bh zZE4`BG<2!wA7eaCn?<4alWbdNf#kC3{D}m?a+fLPuS%CKn5!=a#-b)2JBf61rWjN( zQT6#(n_A7n12#s_N0zXCQ$XEFYeXIbgc}&fB{_=Y;fg9JQw@z+k4Ctnn?}0R7!l-9 zU))fjrSkE!HcAeRy9n3E)m5q*}}oB=yOZ}su*v$7eeatVbH z9_&{{4OXCu2@f(e)K^K!)o0IyJcFy)$_IRF2dksCI1i@TxGROw(t};i&Cp>fr zI;5NI8?U3!U;QC4qsB`*^__ZO=(rq2&!b;teIuH>c3MCm4P9yTo#m&X%~?CWji|~( zbYMrCbyi51Wf#QLKCHcZ+~g2X9;Az-aBnc_Z?M3x&kDMrSh=0p`o6o~6*s@G?%N_r z@cTF|x~hTkp0flqrE0Po#wOjVL1KF&j#6)Z5@;CkOS^e>qMr!HzovY#9Irgg_oTlV z1~7i0Rxud$?eZC`uMzu_jg$@iO0zNx-&{l4T?&$>xxV*}F32-_Z(e8LqLc1r7rlq>Q8kE(8f_w+0^|Ho*5PKb+Y8jFVbQ zw9Q?ku}?RaEG^tWpI)Kc()InGH08}{ zZO(gI@PfXM!W9+a)&^k&q_k?_viz;tWJf#O!OyOiX%6oeYC*HSc@JN4S+FTy#G1?; zB{aNtoP*GghdbM4YZUMu22x)9iaNu6XSZpd?GsikY?^YTXtz81EdJ?)NwTYinUTQ6 zC7H_sc(pZyY)ZCvPy(K^ZC{ZFt67=BDPHlI_hX1l+y&41L09nnfYhQ7ITqRHPt>)| zZSS!)4B49F<_k&nz;UZq@Ai7ad=W6`nMUSu8}Twu{R?u{!Ri+TQWaG1Zz)`bS$15| zWYplKj2x8sAafEN)bKg#Hjq;x4dTpwV(vtxK!=Ry3YAnBc@DmIud8X{tQUu?Y|1Y? z(k_qfj#?`}mjGv%+asm^qD3qp`qOk*GHOUxVT%a%d@Sk;Cg}i{#0qhX^{&Ahb zSX3qYEak&StLWk;r1q%>U$@T$)mhdS6#iCuF3)&KrUbdtQx`?W?!c{?7@RKODX>Xhk+zQorD$+#wNi5qhbrkJJRe4-k* z+Hc8Ipf;w@)2T(#*lNjsgv{kLMc9FJ%NuY3mbZP5^7TUM+AW2}ZrTIuwAYQM}a*|BjI-bhMw1*H0# zwiEpCcdD8GJ&-MjRVAq>HUbOnj)SmeA7Cr;SptYquYdnZCjLjL8c{Nnb^tl{xqqZ# zf5cJo2c&zfVy_5U@K=!m76+H#KE^Oyksc6dG9EfU`X7PsIuO9SrF%`km4KxA0Q^98C&jTS`)4;d!W z;sk37BV7I zrxtuY(>Ohr?_i{3#Kbl0-!6kj(DT9;|6j6wy1|gH`R?wcDEB zmoAKbGocg2DTc|VEqN5{cK9d^$kSwUCa3e)zhtm|RuuG-kfzMt_e0*`bL~_`zDF4> z>0X0-O?|CHen{qgX}VaBIkX6oT(oYS6E1b&O0(>pJf1_H8>S^Ebb;VTK^XayZb)8C z_-rHb{FsT2ah%xR&>Y$N$Oabo9h5gy^_6}Usz$tkw+E6o-4e$VGsBN6JbYzwhw?}_ ziZu_>U5ZNWekfG~CqSI!&Z^AHyYQ3D_8|{_y-y#+%$JZ#gCyIGUrhkY%U`!>27>dA z;MLSq{dB$Gm>zafRhH|w+(BxmM=c+u3ctioN4xZ$SUtV85{iCu(!^N!QI=xPH&th1 zAIqOjy9d`yhL7zEcGg(G>|d+WV!6-!*6o4v?gk|e9q(EXe}H}3c=E9Rujtj&$?y$Fd(i087p!cwi-IhB*3$Z+v_M*@gq4-{v3gPT;M;PU6B&?K&fsF z1G5ehAI+Z6v}Q7HtfL*dNoM%yC3muDwG1>@k`+tP^;5AMyc=>&%kM8c(`Xk93>`Ket{6{_jylI zCY?xu<*Fr~h4WKMeoA~ZH)X!yM-&3dC}x^FA)~*(fdsom(;12;#y+Aez#Z zkA0e$Zeg}!XA4f1_KTdactP(b*0Vg64B%m~o6mf>`{kv~D~*+3NPqDA(suBcQ08i} z1=lKH*Q$%2%V~zwS!mP@?+V|p95UAxiD|AjN#KetM?rL`*1zITdP3T?Ukr1!Cpj0b z=!e?oH)R{04|J#!lHq+uQp{u+dA~-r0}V?%Qz#XAdD-M^5#zX?-`&z%)U$REoK(IM zk!rl?TZ0TgmV+zCr|IC8ZyHh$t*RWpZ>&#hm#|Z=!xTNd&FV43AFT^kw=2Ef>7u^W z4<0ha_*DG;F4n8EFFC%%TIG$!nSTuAzl$ReazGxS%Xd@m&{?UK4Q{GmF>8+J_wsGI zu1Fji^U}&XU6yII=9c;D@~nEi!i`67AwD*XrUk#f9{}Xx=(Be8-TE^5iBiAqmdj^G zDbKr3GB;W+EiL5T6zTz^R+abO+27lwl7)hhQEg7DTo%wlHyiDUKg0ANeri{>vhtt|F`A?Nd1uk9Rkn^!cdI;O5>}l~xvE zebFJTQO6_QdbTn&EA>H`)Y{gk8$?aVvBuUTO09{+qKm|qa^5p(ZqNa#<%j3-)3as} zgudA20*C8u)#G3!uzk2f=j4TMjbva{%F5&;oYZCbMpEkH%}iNi7v5NNUVN4KQ~<|cBW*44vh1olZ|d=RgLH)K zNQG~yJmhf|bfd z%X(~x-(Ca&TO*mwNYR*O_L2P78)Byj8}S-^hZ^`K>K z%Ej8S8&`2UPM`tasRlSUx_J}z>2Ue&E$5took?XLc0!&E4Rteoh9$O#hbvm zHkC+`a1PosF7m&sURR{XL-N*kZh50SD~%mns4`;YOQRo4Fniu@2Ff+Bx|pf;9nr+M4$YSqKq496BLcxk$buDb8XB|9 z%`}{Bj5LO4`5fOh-4p&N>x6oZ3MBt)eE451Xzf2npKh4O<4Pj@B#TseZYSZRJ!tS{ zhj<=ac6UQE^V4Hh!UGsl@A-I!sx7nKl`da~?Jy_*eDbx^!jlL&E5)?g6rrv~X;YIi zW#;f02jG0{r-cVEE3!=OTkC0bu#~}~o01>x6Ifq5}Q}b}z9o5`pk7KY$b~oU0JlUR9N_BZIPUY~n zs!f5v7KPP2z~fkAOD@+ey&3pEI{-Calx(DiyN%Vq+!?ivlKD1SH+Y@gPoU_Z@Hj?{ z%w-O~!*XvH=ea8MVALL{UuC?5)1fq1q6Fi9RD}-Q3vOji97`A+VQM*lZ>NM0eecEw z)u)bn&xaqX?ytqSxJ$-;=8R$QyZ`;r(tM;CAu@b%uue$SivD36G0Tab9VFaW#mnu> zvermjVeJZ{rLhi3Dn$vJ1_Wsp{CZ~0<0fva93^yPylC9qV$$1ra{$9KVPJhM6ZN~z zvEDDq0lz22A6sYtuEFmc{}adm-^lo{_cH&Tjq<;z{+}>1X6Z%T0+-HRwC^Yv?n{2LN*4+^4}ZfI$5> zniUu9IV41-%uz*87(IG~JO6_i=n5-)QRuRL_O{PlHw`Ec1l)xDqqi3=ayJUPk@zp9E5gUx2xRe}d;O`o>-}F$Bnsnt-nj?=v7z zqYJzG=09&hm};m(7p)vWYc*nAM5TUtnjFun$mMCZ%<<6-#Ey5`7P^Kg;Zdy70X^#y zePVUWcHVQpUr>7Q*|dD>@?pUiiZ)d^4%^qt&D&J#p6oG&+zr#Le{-!*pa$^iPHPbe zJ1}V_2@Vmhilj(6;)(ilj{?a@8RMIQbiO$6r3QU0G|UynzOISN>v@t8_5INex7(SR zT!2@5fKI5>o=btXdkw(WoY|jPRI=UUjun&_I_BWQ$9z~2+~-b%&U&Ph*|md*+d3G$ z3>Qx^0#U8|2@t4g(U#2+yvery7TPEAPhsIfWK9k zQm~3p%hxD61h0tp$v)-)`Ut(?_gox!6~ojsse-4u*$O~6uS?-nn>M9|Awl}?RMm-l z)>bium_^DJ|At&VcXpcvrt8ZrE8|qJ$PPq@>)p{=gCPh-`S(H}cB6?4b0(u%skhc{ zy@aGw?|L1VOX+nZ^V!KP+bwbhIgq-NRKX0z#TQn)sQ!Pso@qAnV4&gR3X|aBKAfDO z{^}>$o(+JITwB({C%wCyvprczxyldl8b%8~DY8wc$jv?UlSpfH`vA#&9sQH+DY^u{ zVSIS5tYQ+RjRi+5CgnBpSG;-@d^4wv;(N65mk}2QXseez;b9Kho8d=6+|;Q(pvMYu zIkT_30K~rXW7X^J3Aj-Zn~RY56@?HS`VGPYW6C!^};ECEtc`mDGf z+wQRnlf-w-phJiXj(lULj5Y)}r|1()mf(nhIOGU#1h&7y8XNry#(?*lQ!lUP8`|Ai z1fS~ZRA8s%J1kaZpU-kUxBq6(Pfp3+InTOG{2(K8>YTs?tpS6*C;Ayv`MG`B#N?}x zH`ga;A0wOE{&r)1Qp!vtx5wCyG+aSt2CO)ed-cUV?`@w(rT9$~g1bM_bspY1T8QKH z^*DU^?hAv`c0J+fw04F4>J$xjBofX0v~19he16j_;JPwp!~Xg%yW-HAJ0NVmI~@!? zQ>WxE67F7LY8>*UX59DvsKI0U7Cz^}LkG&dX`rT@l@OYZ~Zw#zlJ_*x}4J z@D#u|-W>8beEu!8(_nM-e)b7=I89nnb>O}d?t=PNVjE)U@K$s8e39aFM09p~z}oFN ztAntEg1z9tqz+@m_XCKgGUZ?>U*8WFjT!!Ami<->N1?4lmbdX8D_jZM3!4ubPFR<~ z5GvOgi?>URKFj;~eSSdF8v5IfVfPIN^>8eJLSt8PAp0$0+Ow)BbtDSjtNfA{_vtuW z?*2=O51&ptCE>sWEhImAbe&+kkL!U>QrAYbNO8aRH=)<7#<(JX7>>t!TM zSM(z6tVg(Zv^rM0AV)dva{taVR>iPI)g5$U11l^=V>Z!Gjw_*Z2em!Uc69IK&;Q7$w7RQki%^=R?~RK#H^WhKA>xNTM z?$1HpU@yrRF5pS+4@(V?8V9AKS>a1_tILgp#S=pLkv$!y`B4F1sSkpFlHD7YH$x|f z=cN85)A{I-pMUKtxGP^4bVGQF^XQf#)~&(ra;o>yoz3R_+=(7Wya^@|M6C)gDNNTc`p_jXrE$+2WPr1qq|74- z%-S~_$_sLNwU>q}R<>M9^AuIuP=F16bOGlK2?IqiUX#0yQ4>gWle)Yy$xI%nDPf&a z<*%OY5UY|knVjw`p`NWN>4s64{K9x?@MD?Fz0>MaJAjorm*#vlQ+L1n**9T?I?b1N9fe5#^n_ISA}y5@$w~*sppm?iV8#^R-l8)W4?9UB`Zm* zss|7U`J8GPy)7+)A|I>InSJha78n5a?Bq4xr|4tOT%JC>$yB}ALHU|xt zzlOwYn^cx#PbWA!UThc)6aGH=YQcd_Myi{rinR*bZs1;b8&2ivFTTuIH5RMv%~{43 zMMlYAg9;&uU?%rl>g~n`S~>LES`!a-E}<>lEMl9;7Djp-K&is^oX@VYGG^Xu%N?(a zQ~RXHtd<$4O-4S|V2eRuO+3bxs;d(&1c|ClF2t!&=cX(3#d(m?<9^r&EQgJ^kI}WY z<}r)gNN@ASUC~o!6y%F0N)Wi0h(@(1O0AeNgH74R2^dz9vi6d4%a!1!@z9eR|6 z1xl{-5Z=0fLHv2=XuK#|GXtSqTE)mwN?{h$MfgLLZk;Sd+m z1?%(MVPM|m)>P==vO7PGwej$zb8|YQgkp{;9`KK3mRG$NDv!$hvUT@de??L4a^P(~ zOQe_%k~=@Pp@WM_ylv0Z;(wV5Si)Pibp!*B~$Z!Qed2~_L}^&{~oDPt#O;p(K|d=S5~fFIAv45af8aPbB4c*vZ! z3yixZyF6{h>)no}jt3*zoogddF(P%%pY~j{A-rkG{vEI({GSZd)u50@=JM&2CQ^l* zVp2J<$#IIEj?~EW+>}+i8#3ru_Bc9=wy}fiTF-5qa20iahO_uae#X1q6aVh`zLFN$ zc*Y!)>A23(#YY&YO-C+NP=3In^f$kHrTyC@JnqhM`E>#R|L+H7-tX_nZ`&Gl7{V$i zJ7M0|uAT1;GvJzNBP(Plr@9!1&uRDavVJH%yz%%(>@B2Fdq#Tpe7TR|-|YZ6-J}ed z5=95}LiySGqXh zlrT#7zslFo=ZMyKBLlUL2owM*&U>#4OH7kTgKt-{vjg()Ig4**aN7}6XTRz7)3gs3 zvu3)%Yn(|3&GRdo&Kzm2q7+)RB@>*VRWaic(TD3m^I2C|ILFYaa8Apq2xJJ@f@B4V z5`KJ$-=CA)`L=p)c+6Ba!{STQk4IHM$+(Nfbn)*C%or=rwpgYl|Jt~^`$z|ngh=Xb ztV^9eWaoN|q_l6Yo7Nj~HFKKp8*=4L{w&9yDZ;uU3u>;R*}QY8lhjlH@y%~dZE7;{ zFyj#_X%0lG3Tm-{E)Rg~z{0m~V4$J$T3s$h{Bwq(Ku%nXf6v5m)Dv5c<*DF`m+iY*q*cBkc=uR)J?J&U}ii+&kyiv{LXL!{C`)|F+ew#<%Q zOEOO^Cpy1(&C5Fnt;rd1VnJp@yWFy4wo(~ti_Tne%oAOX3GE)sbmJA~9yvM<1EP=O zzNQzH7&z4kd0SK!IX2SQnIK4FS8UwNOhpNv=3NV$j$QKu)lIl!RUjok%pTSj#I3Sp zG<+cc;fa&Od_qT#qu;ur58JREr^(LN7FfyQqtoWwD+{Rm06cB*!NC2YJNDL`sn3}* z4Ph4bisTm)VH1Ud1K#vU7=`E@#ee%G^r}s5dsZ<_VJpvDYO=-E)8zUd#XE3I*g>-1 zu#~9N!M3Z$Xz>*w|Xk$7$3)YM|Dg%|2t=3dLF86`e1PkQMM>lh;t$FoXoRK?gs!U z?(I*9)SHE{7`4Hwg6Ty=?`wy30V1}_kLkLDqumi+H=?;F$~StN!j z4QcV?1%cy8ncG$aHAdT{DNchErH?#JbB|4Y{TSIaDV#0gOI{ptv?J9Rt zkz$42_K`8tW^$TPP8hnAr}uA926~4r>vtMGkk$s87Y-G0qc@_cI0OVPP7Twr^YuM_z!Fr;UGmG`}N;Cnc<$8(}aTYjLL74ze_2sDBUnnG51*&9bsQYTZNgjTjb$7HYy~9lJ#pTZ1IB#;l zjZ0kQ{)J4NEBP5@z~21v^?tVD>#_HlAL*%(fqnIMl_O7F2)uWNjO|2 zk5ut{GV*`&171r1y~Or!$N%lo`-|pw{*ZCOKY>&J#p?+rQ_QNn72{MX`1|8&@G?&up?z7_{e zFhP%VM=sOgX9jkk?u(_+5Y)HUU%j}7j(*7EZkdyQ)v#}s?_@jiG# z!O-_lH$a^?h(7jR|4MBs)GAWhmiQ?5y9~vqzIT#90WUq2-vY0%x`E9tYK)NLq~t;7 z_c<-#EFX0&^q{Cak5Z*rs<1&B<_n+-qb<|a!iej{*U_^ub%TDr-Gt*O&!DT33&-4u zf9=f36)xvd^ci=33biZm!?J_!P*4^l@td{=U-&X5?1a?1mUaY!1R@HsefKp0R&A2_ z`OdPcu!%I?NC0BJ)iL`p`cQWC6;U96iXmEdzngOKf*=s%?e&6gtUtBDq!xIn$gfX} zK< z()qhsF2Ppc(Fw?2kP&F^T6B|vFXS@k^QP5{;9G(t!7& z7k$nTUO#*i_HtiSt%pBZl5EfVE78xhl$zU{E3#=lQIvDA){oE=t8-K*OxLd#n^y_E z;J(&a^==I%q4==6dKlpOynbqpqtn^BOMmTZ$qE@a*)A8Eg7D&cc%((!n}fusY4?W2 z_?qUO<-oq=UqMPu6#Wf<)^VjT2u4+exD;zM*45!$#8AV!tqR|0C|aBR=#`eC$d0&B zfk{^`fD3bfDOXv5)pMgu2~`Ddn`=H1_$QdKk>=2IMTLd#vfnskeRka%y4R+P#;fvh zvd85QbHrc13eBwi_9<^%H!c9gn(~hiUf<3B3KtYNE(g{eD-kX4QLhsT`0t5nt_;1g7j_)~7@j37F{{LF<|E_a zGxyAO-`9m5ro%==?6&pGU51xgzq>W1!ggYmc?(8x_V=Q}+U z=mxkZhF7Bdprm4Fw!ANn+zP8yylW|PKtPxZP@f|vG%@;J&Wq zN{En0%5?)sbjs&icYv^AED%7L8dIaogC$s_h#2B4n5?H*kzwuePXd z2SPw(xIs2f<@3kCSfVJljTAqWZ##LofMx+l{$Qo;N9~0%yAWg&GFaPB-`dt ze=mjaDA~i`2D7d|v2VkZ3yRyk>=j;c0S_8&7KcP|#G&(ObPNom$Ck1Dj|OAoldTAvG$Ian>RIY+Ldy@^ zn*ng{zk59!ul;lk*>vtSJsH2P`BJ~4CE4;2PQ5Xget>xCnNZ;kxRZojw1_fP5tZXj zr&pGOX_EJU(P{9eVmB&5{!q+CYy@p$tc}&3YxbrM+qI$VH?l!5#RM4KR3Z)E3V&Iy zH3H$m=VG5i$rTU9LskUJ)^<9Y_*2<^m0a88$FtYLv7XxaB8We`7n8#CcmwByh1s}X z>IU|z`P7ZUJ+dVm3AG`D0g69A-3ewTasSbqLxk;~k3{2Xx(iSy0>1JcYo^Yg5 z>DbjZ9?YF9!uoPB;b2^Cz!^!u)(N*{MvsLJ#F?85SCQ^I_hCbkM^XDpQfB!2HczJ>WK)F~3oD=yTAn^&%|L!lmtHi_y z^VyhIR$=z??d&dfc8dKH6e6p_e)2yl`8eZikQlVFG3RC;>#M|U^(ZO09z>Y-+u65FH3f^eaSejs0I z#{PVs{vUg-zvP2stdi^9%Se^v>R?G9mE9?GLG&I6b*sd+h9w7Cr3^Q&{G*%Cq?{*P z()ATH`7p|TLXm(Bb0%3*GmbTOA)$QZMCuCKl|IUn@ojMf`<+I4W)sJ^tgbYJ?z(9R zxM5&(Ez(z&C2HA`nIYz5oT9-SM@xVl03fC!p_C91MC0s<|V&mFEq|bIYxl-~* zwFJbs)UBtD;r**w=WXSiZsz{%JuXvB5e@p)OY@<93Yf|Rj>|H|x1yG+?9R2#w+P@UkAkK}55P{nJr2D@>xw-#^gEb-+*pi`tvIF!F#zaEa_^-|B+^};zb04XH1eqm7bz-)f@~KZLCY^kXL|i7rovv-eBRL!i z(wMb7@*0^pGa*xFP8`dliinU7<~k~ZRNwiBmc7^7_I*Lf2k^9l@Jhfo`h*PSzd+zY z%WPF@UWQKXXh8~i1M!W0f{po3Uyd@^NRGF}t{=|*vucY_($jKsnB{w$#DTIEK*o%| z)&z6YWPXdv@5|PPv~3Em5B^W;45CVTH}3v0!?sZ&b@c3*bi1@?1<`A^buw>-$4*Le zxOzTksZ6dv&~1UeqQ+}V^p)tUIG4kc?=#q(V7?$-D@8S_{@62j4%HGwxW=?R#+zO_ zj_Tp2Eb|FJ%QDSEW}8_E{SRl>FJrcex%hHp0|Vv7+Ckg5#UkQ!Dyv;>seo3Xin6W-6YJOsUn#;Dq`_m!&om4t2k&Sz(4q9(DuE~_3SUtx6Kd`h#* z(~5mYoWqmeZjxptr1r|2_+@El*%v?WO~S^9mCCwT&Rc=E1e=Dwj9ZMUG88_ z_*(RG)h$z&Yxg*ZwJP zIh;mTM+gvG${bJqX;UhoKem9k6>xgnnp1B+sD(`F)mL7vQT;SJtmX7|gXbnY(|z~w zQ%hqGk zNICv!dOi|ReN4m_csQFNhA$Ef$F0?fFWnF5PAlJ;8@=+hUWoFnBoT9L_4CFxx4x(E zhb_EwDGaa=*#HW7$PK1N4~SYz(N4LfbkbqfLs0_{v1R36G=U-Tl>~7Xayx1DU(rF` zl^n#lL2YnTi`Z^A6P3S2Qs#Dxmk7qZW4)GsMeb>=TXjdF7o*}BlCFUOUrBi>u5N}Y zSJ|P>?Os%Sx!f;4fG+^g!|o9nK6(iHSE|3xFt!u6hA2jrrL@>18MolTfctR}R3JDB z%lH8a{!&s>^7lKS|F;j&bbjN)ebf(d4I=l${>GFm`q@nQ$4&ix#`H^{JV%KC=)=gD zx#y*{xLm>+SRPdIMAIUv+wQ`Plt+CxFJAy{8AFlS2#pxFCbe=Oq`SE=WZ-0V^3mMX zJ1&LrBs&msH_sIM;go}foMffvE4W@7Yk?|c#ke$cGM|_TN2E9+;xu+2gK;RWqDq4e zxv>qobu8b@<(tsqDrrmq?mR7&%6UnGqE)wEHZVA62^KS_vBoI48_R;rJGSi%PKpaB z+UwhKvTLDO#fE>4ZbWPUhDjR4{VOo?%OK!kc{jrAc%8mJG~#+a|1OLA z>?8exn)GK5Zj}WYaPxFiw|;;AU9uRwHpRyMCN;JF@<@YFQ@8LFQ2D6}7Nxn`msXE# z*ehxtOPZ+#A?cTPQF6oHGI*W(kCxcURZXfeW^Y5&V*@e($P@d#3ZW@c)$Fv2nUY-A za1mUbAjY<>BI$6QHJxU(^jF>K{sskZ8Q^hqUbh`B3&&QXSp9XoBa!uq5d@bCS*1Cb zV&~Z6a0*db^02LgWa!;_6i)S66DEAP?GdqQLbFDFxD$%0;= z<5sS$&~#Yjd3qh^+aQ+};Lk z-EQ}SyU^*&(BeImbD5fxrf;jF;Ok0-~;lFaJ*$;eR8_V;hjBEQybZ5haYf?kE*%F zPtz1rS~~Hu<9R9#sYW!Q_+Ss!Uvi#idNu_~%HK?n-TdX`lMvzi;QRN<)*k7{2U&|& zP-;n+)LV2abPx_7CSSlBvhscW^eN!9Pm^GriTQ+s&uwoRqBgg`rv_Pw^`^j;7pX#> zg=ymRp(nxfJzwwlmA=Nk=8R>({(9O{)6pRuyhF%+m%j>#T=9xDGji4il~|UH$C;{- zN3IPi-)R2^l3kN9>PtoM20vd5FjYBo1)US=6h-tHQd3obrB&qdNJZP4r77$3VsQ!V zBm#NsdE8XHs=XhzY{OK2_c6(>RLj{Eg@D3?!|Cv(~}A{*@Kg?v3Lt`$FMN|U#z!gvU*4j>P|JZ;Ov}C7eEiQzjw9IToauDj3r*?troI0(QR7sxt7?=4? zq(9l2I$s}N)}l4mUuXWI+LLP^M-anmmn)9s(kMKWs+&)}03r%*N3_-$%m`HR2ZovU zQ=}BH3YB+^ciq&394$x^;6G_q8;i<-ujv0~DFA=}Dz2+zP2BO~=}wul%lK7XH(Q`? zkSNB922@hBwRwI$V*h@E{NMl3{SgeTs>50S&xmbv_XCH&lN$GBb zg5+~@a{l8@-sYSv(P|@&r{?I#GF#7x?9Vuh(Z=gw)tN7-Ur-aIZv8?6?REVi+Q$*h zq#Uxf|FG~>t?!3y%UzA%172ioGal&yKKw7$qDA8*!WAgP$v;L#%CBBy(C&-!F?-?* zzQwzg?MYEkTj7>DYKf-dpb_Tls-phoxpV|`D6>Tkf}{5A@U(taVR2!yX@HKxoA{@6 zEL8Jt>|_jpdI^zr(BMJx7=RkGS3@Oa7@6PtY=dUr31KYY|#kE6Jf7F z744)c_vSHl>)td2cDoT&26|S)iaWO>DXo<$-ukHQeu17aS`4;yGRe4Y^Sr%ZDUv)I z(L<6jk)PB1V_Wv;%>PCF{x9P9_pi+VCy1XgDl~VV=dfqiwV79);hE65;r-nFu~zy; zE=fz!d>8D2$NW3!y<-bZ)f`=BXvrm;0&eZ$4HF6{8fH-+heg3GS!{302k&CM5te+Q zRi9EEO_Q_cQsiF|9L{)Ca_8b8D}GshK=#-bH;v|>M=`I|lJzcBRYbAwDX{gUp`xhW zb%47poum`7)+S~5V)ur?rm0d*lyXUFPdD$eG(b<54ceZP!hT7d@uE_#dPBWss>#pq zv~%|x=>BKvl+~M1b|uz#b84P!yoRe%{tYtDZY&?w%eiV5!)0$bC*bb@C&kVbzKGRr zY10&2HP0|+cR*$i6O`|iwR({hJG9`^Avck5B+|slY|M!Hl9YB!-az@5$ceCxp+weo zKtO1{hw_;N0^TI$5_a~K&6P7+f1-QIsoVq8xN3e(XY*rY0X1 zZ8oR07RvG9b=2wc^sB?85>w+sm1P=3N%EhM@5Yf#gw*46XCKKJ%oyYvm`;0GH?EE< z={S?|;&}AHj=UsuD1TF|-3!}%n;5T+Vv1ZdmPdoksKM;Vvh6@Hmu&td-lADtza@p> zsehOG+HzCcwY|##MaXt}U};qyB|e~2?>pD~E0x>+vX`El$u(a9G?8^Md*!aPDd$Jw z^hhk$@~VAi8dYfKh_C!1dc>O^YaBa&j#XAk^%GS(Se(rpVQ`cu4e72|v zgWGjQrq&X=irZP|4i6oh*}kSn zji-_fCdY2mb?sL!7V~YBeX6Z}TXd$vlEY;ggyYWe^mmfotjOz>d9f*o%H+Exps&JG z36fP=0nXMank*WRE~vHIn1n~mg7p|EH1 zb{%V#>O-2ErB{R}?5!2mLw5IvxPAJeB+DWP7w<15d&ngOg;ZemUN#f_2l!^!V6)%_gU%7{C3^hH%>hgRw%!4o>-j6pB zFIEi;fLy{{ny4jrOrg$5IrUW1z5l!r6<*4(^Z-j=Du!E#aPo2!(3|IcjRCPHfmmPD zVTUuaR$1AGKh#!7ZQ7wYJDE+3SwSQNsU!m@Yo!KDS#CG$52Df0vfa3a3X{+{lX{T* zbCCOE-GONeBFhM#S5>vDj>pJxRzxQKC^*aq+I+4=cYm zn!Blxb&wGsWtL}edKJOcJq7WuCNuf`0-J4r!{f(w1(nK1ks)Q zc$c@g8UX&6-Xo`P{kV2@C+!<38Ss(xBA5BSFhUA?u$;2roA$SM|E$j2OG2L`m9jEV zQwpb3uU>0-NtsRR9s=x6eweX8GM}W#fBWPM9uDVxKOV69p8F>xKe~UfAp290_V4v$ z{~b#ETpPe;0jCQeVz2RqDBFA)Z8-IH;aBkPw9Ue!aPQQOo{!K7~gud7aIgC3ySK)hOCYCcmfijx?v<}%j zQfE3GA5DuBsZ#@wDrE=*hazPj_|}#Bki|1gz7OLVXoZzS8T45Fs0Xzshp3ZA zc(OX4+JiEya@eH{wKbxfXHKZQK2&sloRh{GTz|6mDZUSTdb-6uPwIZGP`qm4({7&Q z(XT6?+_M-!`yH#-Vb?vM;a}R#)#$Kr-+ir`F>>8J)_Z+>cS80drH{t~?h@*Ct*EDb zIo3FrDkkF|XaD-8;=6S&Ztk|MIj3&|3iP2mOX~--j{tO(py5P+#UBuOd9wfZ_-_I) z|9PQqul6pT*D06)!L>JiK*oD4QftraK3%Kx38Y z&l}gYeoxt}3Hjl#GS#xIbT!8H8-=%(?a9h3WPKKfWVN)5`kt?pp1Zp$4cAjNR-ppz z?Q<70CuHVWl}QOCiNDJ>QnG=c>Fl^t&pNfRM-l^L_f){9Cre@vP9WJ9SkeY)X zy;G}}t_B?WX76)EBTszcotC3O$f;8zpd0Z~m$q=iTv2*YqJ^L?nbV}@1PYei|7m$Y z{ClEkP8RN!VJqt{m_Cj)jHCAcI_)xHv3ad+ise5pgDT<^0l|m!R=t+)#zlLtM)%zu zyb`o0OI2APftJs%Jvx+Vo+iV;)Oo4ekBcZV?y2g0wccN_k)yZWPIgmWzo)O33lD8( zEMYW`&+~e}=QU*rGmmw((QJ#mDRt5vZD3^MT-xP%6VpcEoT3;MO()sltFO%6TEQyfnp4Ma^k{913SMYj&q%Sx&~(aPURUdLA)x`H0eg&)Xmy8$J=fdX zJ$QH*bdkQL76Iu!a%Tu=B3`R@3b1C zYOaqD9+4P3V_|bFD8J_ndHe!&rB$Ck-)3Yk;Xw#Xe2{iec?|zj%S*UjiV1%y=AY46 zR_@B6Y;rr!U;VV=ZkwIf`Z>?hS#_!jJgRwEUpC9S=kg9S80QfFD5BQ_TfYSpM`$&b z%kg5x;v%e=MA~KANRACn;!JiK2=>zG?qpibMo$Pq%`9y!plcg^z5W|W_tMwb$ET6Z zRJgsQ(rTT!B7>X0l27EBpGon&@BxGqEXNI6Ea7w|XV?R1sas#Z&$?46EJkCtfPl|8%bcY*8C@>!b z_jLs;-P#FATXr~|)ykTPIhVldZSA<=esyW>#Z;|&acLcvs+^@nded&pyw&KV(a5%5 zN^`VVw`Yn49685gEB(xMVtT4Ow92%qXrTxi%yE=(AopE&x>;(%rFW~Mt|pPerNh;v z<05KtN--i#*4UM+0F!j1$U56IH^Zv_tSo>i;RQCJ@ z^Wi5Z2I6w)%P4g~2*vT*jIS`&-_E$`+W(}~TLJka`7!$+$&U|A8lc;9fUJCD-1MOs z{A&d1H&FW#;JZa`fLtCz#mUeB8Vlc5>95)RO2R&bDur+S*=+esI5~`)V1}s%B+WO5 zKDR0)e`sC3xbZ1vN^tNxH)|;G!Z%Q8?Zx<}DcQ;jz4qe4k;z-fX7tZWX6sC&@-)?KKeX$ICzVQ?w2u`<805p^ZH^%2!YC$Ht5 zaqg&96&8E&6O7>8sr*p2StFgIqut350_VA#l|7BJn=)23?fR|t z%3n*V3#v7ZP`8T>` z#{(9aUA4SmZ~;48e~Z4f3$#sylG)u~(`mD@r1k{juEExM)j4=jdr6T__+$jOtBH*D z-NUy>g{ZW(<-ckrj!!doVEX+H9a^*NGVp zlj??3CYwz*Tkx`n2W5U@;7EScmf^XAt(xQiQ2rGUS4=W54Nw=}oD+$SYP+K~K^d)n zZ@#}+?i9k<2G(lwC|YEXpI>#8Js|c4d0l|2$7AyLH(sp4)O81jc5$Zoz~)LN|L3^6 z;R0f()%KZKLb+!V=?j0--P0dEZ_gRAH&(h&ujwMqO5I5B5)Eqgd~Y`Tx|2MTyMh&n znl+NO!{yd}9IN)_MDkDb$zOgVFMA@70`kh3Y|w5a&ql0AcyUoXfa8d-$*BlL`Ahvm zcldsc}HkR9n}c!Q{mY#Y%;B2#vm5T5J!%HO+FlY=pnla_CVBN4guvqkx3)J7m&^#kZSNX3 zU@{13a|~X!MO>{6X#@kSX5OjRbN>uol@uV z0Ep4u8ILaBMn9jXUU{&pZ`5ySa95JYO>0umg}oO&QpsBN0UvQUP_utCdTvakLF;q! zYEuzwKnYy21l}db?|HWr(;DHBwt}YMDt8Q!VYgWSti(66JhBXBP4aA-LpSHbD4*>! z$|c!ZT|xi5AMkd@paQmJ9?hxBvUcBJncj~!VY}Kk<+M(= z2pE1}YUwbOORr>9EYe1^C#8wo_e>Qo9ewfgA$%coKR`FuGF4+Og86nm#H2HkQ!1fB zX%M%bLdYAy(0w*CDxYb&H!Pn0acYb+gp;_MRS$_ol~`M+4wM|hnI4YX*<5G=;(eSS zJ_Zg<$Hc`SSdMv>hUHk7mjyo!MpotskuC7F=;i*v7yegsKI=-%!!8)&4HUu;r-lS5 z?y+4N@u?tP3a{(y#97%emrmMy38nJsCuQ-k?Fa(^aH& z(4q0m-BX%vwuoKS-M;57eI;QMPA**@( zr@}(T-zz#WZct9D!E%S5hFs0EwcW^jzhhg#<_q2WJgc;5Rr3{>oOB|2ZGxIi;7khe-r-wgn7|a0qzT^NGMUhfbq z&cG`f50fXV2|F=4azvy2bJlF!HC>h;%Db-0M5iHZexS(buP# zI3|!=Wv$Sy7$ff_%zMQqEBBDBEtbmfb(ILb#r=e{vyT8)GT>7Z52=Pm&3K=z6gruu z4LVUzQtHB!6GC@Wn*?;ihu0I73IdV%oU*WzyWB4t={=ooaI*=|C|^Z9U?#?g(Grm6bW_F( z8wa|{5?vulgxSsIrpl;DD@2CMtcry%r0Gl~*sRT=BQm}vQTg#iDdZG@ADtBq{>Io^-I*r$ECK}s|) zAl$$Nl+Nb9%Eq03aphC!wHGj_(`3F5ZMP^Go2Ym;5XK=r(&fWOm9l*WXj zd0E_Ldn59t0k*VHq1`roH)ks8dOj$4N{Fi4$wYq6FbxY4PHtwVhMnuC8Smi`&VI!H zG&Hk_j8wPD>CWCx2W5_q@<`gXb@>L`zd5_{*5F0poINcp*CJU8gUuYJ!TfFN#* z{_f)O|6@+;Onv9fUjxK{bqO(-n1brxy?gfuK=50JHxWBGjcjD`5=e58xp@9+{ByyQ zShB?hr?3hccU{?e{~7?Ty1QpU5uBQQo^z7IhEx8aVlC8^NEbhM#o;*6ey_iSIm+iC zbY_Ot?a*Qyb+T|U^W!j}BGsz$?u~h8wCj1Nj(rqG(I8jxP(F_3`&F~wuS%9zMpG;o zeAHK70PnD-Gw;CEZ;QH~R}#I)dV^L)SVdddF zH*^3u`&=@ z19$?e;KWSqZ`tsjEy4a@qqwuSMkE5snJ_jMhq);Q#eszaufA$R(S;Bj@RPg*tnMfS9;iLjZtfcg# zdddBU|9(M1c`J-cMq%dMy{WO|_wY00o{V8-@(}~xHxyZGz$Qj^p|#A2SM`i^2xH@zK*zHT>60?z^&K+7WYY z;b~>`YjeEOJ|=uY-2nVZH+eXuN904SNauxPJA^U}+b$AN`mkh6>!nN=VfFzZ(>hkn^vtdlj%N4FQ;k}w825*0o-!G=1pEQZ z@><83HuQ1r)4UfJ+-+TEl?GqH6aWxao$Mvq-iNHdiM9I~^2VB@>JMu3Jj!PzJD~rA zQn^H9AOXPRD}owcz&SU&w1+aN|L~UaTt|@ho2rkjFCy#_vW{TbMSLR0a7|YWp3Fd< zvFlgU5_3LR#MM-mgmnhvzQ9^5h?SVB7%upLmJw!GT{-LVitCDw`DVNOY1xJuT)V8N zC@RR4C1+dg9NRIXr<)=wrHOr4Y&OI5_RNNERF>t%wN~$EhM`0T$UD?I-Z==FRdv{H zKO7c|4`0)3+w8j$J}wuCPn=HOScBap2;=3!eqYs09w9bML%la>UT+jH zBZF%WsisPQ+SEArdooP~0KTaPljN`tk8EFH|$kHtIzZdS}ec>+7u=#BGKMj=XX{;yKa}NvSD#6T5&$$bnf(s{%Rb}$n?#au`m7{VQrM>JO}3Md=pw< zIPovOq^wMiQ+XT}Hqao`j8$};Ri3N-+f>^F z#rB?AL!B^Sn@59qlyFW^r@C0%q>}P0iR))^ML^lB#15E-8oL0rwDfC2E=#Y)Ri;{v zk0SVo3DXfW+H;a}Jvne!t$Kt|Hg%ep_DwQuwpbl2BDdMzE9K$vW~LA3i6*<^VU7=Y zUK8#ugVhb1Ig-oHpHx3F)0nOphSLT?S}S2Bo-Alj4QIO64AL?4m`LMCG1k%GJ6b)^ zDRzi)Y(Ji9X0vMURaSx6RjvWix4zq5iKdb6Y{_m!?4`rqg82GrGG~AQPQf8tUi?k^ z!o@h#agLXLv^zcfL2c*^FKEV!i@v}cyALZEKKi)j3zFzUVmgky;sz>nw??2-VSs;k zQtp&*|Kv#}#y!Y)1x{|UU1EI3=(9?*+QiKILVbf&<$2?#!Nk@-*SN)F5RN;l^1$n+4?P5qYfer=cK%xW4#ON3n{H>Ig3 z+?lDrAjTVpStT&L31+j`+re+_?9=!ulftFLn_XE0Nj*_>5hoE54e{1uOxH-SPFL0V z(Fa$|1h9aM8un1J1dSPWYP|49K$_WQf2MucLf<|Kne$EW_9W$ow(CM<&dxzk8x;;( zr=L&r-rPH{&$Z-x>A74R*;wAF=R<6Z|0iDvwGk~dSdt?jn9e1+ak=6!IvIy2wwD8& zbrr}+zMSPnPTxO!Y}Fm#qRy;m5Of7g*C$`U<9l~{f4~>1-&sB6sWz`B&sI?}CPi|pVME6 zHu1BKVXb;#4?SVrfI-jvQiir)lj92`QM}!dxggO!(yqjMq%=RFTj(i<=j1P)km`BG zezPwUV|j3H$3>XBt+o%pPqz*^=Y3Yy#+9mguDw^(REE*}w&!H1pTky(w`_|?>GuRM zjL;k@e*sQ>5SsSr(nFHw5nXC?=H;@1$Fh7e~yDD_6cpc9YquNo2xchc(m1!Jxl(gz1^l?H0;a_IK# z(|faF%=2WHw{~AGwCkRF|5SS8$)ML+x?;f=B#WAr&3Lo!l{2jx)G*>9MHMdpjW;iT z6|QAF#a3}fQ8);|>-T#B>&m(l3v1KTPjtc3wcon_%N<={s`uSIhKt<6v;`3?vp zl7@CaLbq&9ztpR1ZnKKuZiu~kk1%QW79BJ=lKZlH_z1FJE^P6bJKGJ+aQHT%t54?o z9F)Ibg|hot-`+yZsH6N`53gyHALz1J>mcDabKMcXS$Dw~&N)B{uW|d?6<* z@2>Es|7zGT{8^dTFro!=z@`5UbnF3HP_hf8$;jXmw}8R0kge(W;xAQus;YS?6duK28M zP!guA&imqe(_#2rp{LO-Kj1Awn_&Dt{iJJ?@G%}%3|^HEX~4Srl}s}L?o{p}k!PnV zJNIY3yP#Q{ykDm;60T#p{kWqF_@-7H9Ch|aRk@~hHUro2G%x{t-E2g#%oUk12lIU$ zisAE#E+to+`6v7vQfXDhmx`Ysxe`%7?1n9TG{0Y~w2;S)_wPIB4P7<*ZNo&H)5M4LjH zfd`BC#uE*H73E*9?lLvh@6qY%VFQD!ALyJ@*Qu`7xqL?A$=QuQ-lF@*bmGn4TgDyQCfUaA#jSk&ZF%F^ zR_Xppv!Txwy1Zm9MCt)gi+3F#tdwtlSvFU%qu6_LtmL34Cx{78oR_6i6VbeN+VwWz zS^N95M*2Mmp0%T8LiBl&N`{!N#^cvWjS1aOq5$4#4t7?ZUCn$yj$Fl{)08jKOOHwm zJKvjdfNYtjs8*f5wqThzwcVh?>t^jAW0!m4v$u>p4NMRZ@Z$x0a>|5>B~IyGP-ZiewJVHfPXSJ15sm_qBs1191&DEX1X@lc;+t=;Y|H3f?=vJ#9=@V~dcUy%;Q`?Z6x}uJXaMqH|*6oo3UqpG-OW#TM*7-nFUH z)xShpG)Vv=Fm*)+S-L0-tYDJd3oHGL$o_z8&pmc?oAO+W}~M zQ-V%;NzYDGtxVDPUG9JW$+HR($g$mjeYMLY1|ZtI1R@{G*B?S%Jx&Gqxsrk7r;)qR z0Sb?McDXjE-YQ|?S}1J&C~n+ zAf*0iH9mX()sYkF6kFvPgq*ToBJuDhc+Ef}1+Y1hwvQ8=b>+ci9TYUkY2_0@w0)oq z^_)6`QN;TA*^F?-&MCFnAg2xi_mn3w8xILLW+E;iKCdIqN7VQn#f`VE^KK`r00JtM zDOQ=YJ*2=%gRaSuc%!9B)W`i8v!~44s>zunrboI1Dd1XGOCret1KSg)tS@9^wx4Ip zk9ef79=j)x96HVJH+4hn-Ay>|2{<#rx3QlqcLK7jS{@wPOu6u%KQehvW(UbIMXGs!!CJwvBHLIR=Xf7 zYaG^{(<8dK%@@KR$`(y!@ANj}b43!(tbbW-mH|vHyN9n=nL~q-)bQn7<|X#+JTK`6 z>?0!u`~7H{sKUo|w?ZSn)KFEeu4H{TJBqhTC%M)51f6;H7!>cyU^~iX@Z|1+LU;gzVN^@HI==go=|mcD!C3>9HHxmc|M8!`uvzvw{Mf9 zhbVQOuof}|eHI-4wO^DLrXsM&4;+PLK@RDh%IoMkZqPI8qtbe~kl4P6B}2eEX@=3j z7QE`#+mQj2C%x-Da6l{^zG>b_*AeKl<8ToIy+aTda5Vo~r@tgvjhy3Mk0?7%0%OKg zVQAEv;ZRH0zLO|gL`5`zXu+`yNn>a17`cO#{6)4g?|j?o@#oiWc|8?7FxfwFm|_ z6`3}O?*ejuXlMmV;oP|dv5cPTc8F#vFJGwkE*%;nu=nLnA4{#y;o`F(mACO!Nd2wn zsL`XQI4Y`a54UV7+=DyUQ|is?u&XQU01hf1K}>XVKs04Rs#`Z0YGjO0DvV^7E>atn1KY3W;I>W_c(x zh|05!no=?!^DnH3DodBM+Tvb$JA@u8S*TJ~tS!4JEI#zAo2lc_Irp5`v*Ntdi-Ka| zC+(Pm54FcCbbftP0hL>USgw@0?%V1i;!lgq<3fb*mUq>?quT)@)+_jAw2)7jty?VY z_#c|aLWPNby0NQeHa2+^<80A)0-up^lSLge?)3z=;yjrwP92x@s-1Y&*yXQc`1L;6 z`aG0;4|*c81rwGoF}x!$%9%#NL&xb9D=Ay(fYz+(^H(k`U@Y`HKTBfN~$tN6V$Vpx)GqB3QjBnl;zT zqG&!?314*4Xx3uYgY1VZA4ZMUn&bOs+;#=2RSU-M+<%kRZZxVyeb4PNa_R>As*=_A z*!T3kGf?SrXTJZAY9eg#>GdgCs%8G53%e3kMSQT(;v&}U(4jWB3B32bT+?%hBAlq0Vq3HJ^wpb z_FrrLd&mDeM1F0O0jriP`8}BZJF|7tuP|ko9q=N&o<ib&rjH{9 zi82r59mC?co8-Q-%Q{{UV5xz>z=zGL!EeTOJYSg)VDh)Fi(}Zo#;_I@Dzvd?*b{=Y zxqZ*W0nVnxoa1eiTBc-Nr=bUJL7By7)jM?qkJcmiwDz^4ps$dUaHu zs#(T}_XakKM2{Cv6xNTJ3#l??s3vSz9uaAWHZzA=nX2A!(kQwFT8A|y%Sv{8oN{k* z8PrfvlA)e7=(H0i3wd~T)g${7TUzp^O`8Q@GcawA#^65b;}Gkp^dcF@bM33zfmvey zK;&gp!hK3cL&3{!TimR03-n?;*-A+Bfak^8W5Lts#JM9)_G2Qh7q9J@lI*rv=p&G- z9~;8^80u=czj#;g5_sRO7~nF09{~SwV*6uj`ez9AH*V{UhdICe>lQzn{)>#R4H95S za6uod&;OQXS(<`nD7o#&uV_qpeLd8+%Gb{N$A|vcu0(@z9k^`3`NA+o|JVGV*{pv9 zL`zS}Klsb{FDHo0CSo#Mh^5deT72Db=27E!&$MTM?SB4i(EcA({~FU~dH)aH-0UH# ze=?2?(apd(Be#HadqsZF z*jeZSa|!h54B&XX+=430-N-qz`pAtz1=`xm^~t@==#+C>RIy+Z_f9we?_DmL_2osx zU1d{FGY$%&1=s7m6;iOf&_b$03-6=8^#V^m5O5}cPA@f>EzF(m>I3Kr&4;m^zYT3V z+C7ZXou{7yZluX-Do}!Ftgda$R0g#;P&z5Pr-xjE)DLQnH#k#=%w1Xx#i`H=L0{yR zVgds+?QY0Or{~qUzPj4v?E&ZayfXVs;um$Q6<$H3xz9q=$zz?cGYB)TotUP|yPasn z$54r-veNl5wos+-685Jwe4ylLK(GEf^RuiFAv#46f!A2F|7x?t`}bGtwJ(uiGPSY? z|1`j19G)=jc`UeDbuoC~KyU5~4RKaF;&{&><(_T_69^nv&C<+%Ku@4I>*zst*(%}qqcx7nX9T+CQ|%sOyo2#*vS_LUTN4Jy zoxQzB#ofc|ts(pM#%ppj>I?f!_fc{kzS zl4qPo5urUVn7}<-mF+nm0bbEkdAk+;SseO?E(+>LkZ=}EbeKKnu@p(#ex%s8!&YL$ zm(RzxowxC%JmM&_^}P43zj7rrd)58#rYN2psR4`Zv{;U!@`ujf$MnDX4!uMt4l8`k`P*!vQAD8KLjQKF?eP1dhCS>1D5tZyh z6l33)vSv@#2*ofV`@ZjtF*E*8^!c=W>ig-_=ezyB|6aVFdG7N(^US^Ho_o%@=bn4s z4$w-)=Fz0Pxgn3U9-WBWvo@U`Kj-fihiryXm~aZ|pVX9QSnSdodq7Woo-FkP4`NxrSUbeMK*{r~Pm{cxgu{9*kUEln?O-g8~l z$4hQ{zkH!JPPtQhbn$TZthhk*1RotwuDsxI^E}Li0r}dyp=7SzBe~A7?Cq(pFi5pT zyg7o8!1HLI$>ltg`vn<(KrLke zS$Rw;*X;A{R*&O5V%5Qc)LM(MY!vIl?2YLe<@KC%nUKRAc_T=pWaw~DN7wtL)ob^4 z+|H>oAjll7n)C&`PPaq{i}X@IF-4r@@GbWg7cu5}Y!+>z0I;-olK|uqwRG>xD8`(y z#{4&@lG&QKp+y(^w)jw?Hch|6csEmOOTG~Jv}o{BY8W;$Gz=7ho#1qM^@97| zt0m^V*WE4(bB%>n_WR!h6V?+~Sb?m&)t2@fAcm6t*DR@r8~bZ<#a%+fi_@7-lLL^u zTuoF1a1S7lc?@J-kdth2@WAdsqxd?4uXqgNG{s`3wjw^(Or0~)!OcX1dE_RLIPF$4 zr0E$q;lyda6HA5Qw}}sV#)t^E%{@5PdFrNfV52-HA4_uxW}bB^6RL!n9o+r;f&SBX zJO<p28#l@ses*k4LYy-${cBiUitzH^5kfHfNS zN;1B^2HCIctfC5+;23^eBzCkKGI#Vv=G_Z(G~RhnGpLSK*W`}a?$p8LZ3U*X|KxriN@o5!9Pv`jx{ z2%El`KKkB*jiB0A*$)9ZsBljU$>!hW%dpKG!nzM3>kC-ll<>rQHb(kfB#}ar_ujq{ z(bgh>XV>OW46_S<;2JCMeOhOf2`WKxVeC|-{e^ayp;qo7ON(5|Y8Gy5zqofx8QM(J z^&6nq+9IJ+2e+FM6Gb8G^QR&0$W{2YR=mju$SybIL&*eiIcFj=_z=s@%ZV^TAtA33 zGw?Rcg(kJ;&Rva*aiquqFT!cG*r1$R$(&mfJr&&*K5}L^<>EE6SM$V2T}kE-1e|lO zktigD^wFPM)S6UN7o0B%s^F8MJ`i+Ms%D3STHvYn&g#h5lqErDfvZGpeI6|(JvFk2 z%H1{E!UqF&cF?htltlq55CF_$u_9vHM^&b$ky(}VdL^ASgaqvM?sL86Uu-bxGgWvbX|yczhlFS6uU+M~(tXxK|Wv4|k5yNG(~`ffd~H2K89+ zNHcSGN1Rv+{vmH&e$kFMu8dZsC~$@~uUm5&hlzVbvdJ!H$15j%5JcI9kIIdEsZUiH zp-$cL7k?Tm4Y}2!^IAV=);r>I_5}SIXq1K=EBM8Yth00W6%rJcVU)e5N|9DwID}>zoldoczfWOa_L3#&% z1pApQKuH&of;0W(3IM`iQ-0H2e@P>6J*-{40a8P1eU5VVcP5e?`2OYJ9RY>;Z5EZ_ zr4&&tie$nC*;6p8&nFM8PBn<%a&X6hs)$CM+n00rJ6}#&y}lLX{6r;HRsp8OIi^qk zUf#Z6_wdMobdY0uOc2yOy_$%PATUtIIX`+o8okUU$=RDDMLtV^LNQrPN?7b3JDWjF z7X3WbPaH~8n5+SHT)BQFd{EU}fb=>$Dck-h1~Hkyy5+$P<~Z9M!E1`~KDQ3vvW(j6 zw3L!n0!x*ji>e=yII|#DXUlKF^|GmAh=FPCvb7JN|I4ECU6bls{_cl@wC_g^Fob#z zo9r?s912Fq5n+_{Csuv?(i{znBH87dj}L3^yvCqeDB%ovb~iwKFu}UWYSDB2a4nxe zS!c2$iPn(II@@-#2WsUPsPC~S%UuXCRFJZ67VwRmz&UP#s}&Fw1h~n%5PUhtQHiV(JOeA-6M6#nt=ol_)1w+*k!0Ur(Ug zMeOW%Qc5o_6FRIJ(c>4ITNx$6}mT#Kz=buUd{82EAI9 zC1%_KvSH6O&GhWs1C}cBTiI_ZfO70&%XV#%-n;FV=zg@o-pBoq_we1c57K+Pd@sm)O=h${y+H7V^n$p_-bf z_5*g*XG86i=ZixIf@W`z_rP1Znr@yV?FqSv;xDndP}Do5z9s3tIU2Wo6kkPfe>MU6 z^xNO8(EsMec#ERm3)1TuOPeQ2K=Ae-Im%jpAF%fN1oMDUas*iWlmD~w*G`F`5_TY4 zLFipzEp|5oPn)-(4oszotbnMJsY3vIK-|Hy&P~U~pHMgxTnnL^D%p{&QITwd7TVWc z)0F+9AwcDpbgRE&&vOJLPA+@yV2lAtOp?y~v-S+44cob;l!zEENkE14CgTA$#CwrMC5Uscud!BROa z35-e}$43*;i4E}nQc-7n?F8`bFdc!W#s<)hKVSCsHDJAw@s0 zn{UQnqD`Gu@=lb*9>?ZN|DBD4FxoE7Y<|siFP%HYc2*1-xB1sg7EZyN+!!6CE$AI; zIvWEc>W}X4dG$`3f>kozO>w!|K+k$^@Fl-PYmH$04WD+!lTj;|UY>NMTQ*qm&vd3= zC;zxt%GC>`00MSWZ7Zt;9RsEZeME9{az8dQejvW)XUFiLbm;eA`?C&=Kl1L+Us0`I zPg_cRu&O?;PBW9$5*ix%FBcF^z(U(O=Te?%t!2JVxNdNt?K;yJjC$I;II zBP_NR^@ypq5g@~aO)W~2@zn`a&GeaAVAFGetiS*IOd(boVjyN zh0X<2Sk+cen`=I)$f`c|^Tu;YRqC|-kL48K%W?yrF+X>R)@1JNEdoz*MUmh^&i8VX zD`59+5UrkEj6oL6gEudqsqz)zB^v~SIYh^95cYOu?pev;#HLg3z{^7Fi@L>D>~eJk zQvkq(RIL~L!E;BsaA|g}{o=bloKs~8Y2;TB%E)2eJzv;d5;TX4y z8CA54v2fkEI!8AQh)xf}89Xy^jPE&o(1fyIm`;2jlyC>$Ajz%CTii19R*nXGr_X60 zbWxzjVc>oE)Tn~2k)iNP1^9KV8&$`IooMN3=LznZTp)Z)^RSUpedTsGr-O;O6S=7L zJneGHnh{RT=mF^c5V>t9`CRYE&l%F#t>&zSF0%1KS37nRd()_ra|HF%i0HZWvDh{)_nh?z4({ z`L4w;Wsi|Vll78fQfaX5VF~$N(`P!nS7vsx-Qs1Aww2feq;)+p)x>Qcd;eKvdLNZ! zq$v})sz|zQF)_@6o1UBwB&}mCJVD~b9C9#tfQwz%F<8EMf3EQ2@7EtTFsU^tnH+4f zJmk+%ro@X(Udb>;r9D(Ue;M<3)&Q8DawAU#ysxEslr8jXa$Dcs8B{v zL;9cl@thPlCf^pIO^Sa57t=LCpDT7YHVoN+(@2 zR}luzDcj5S?^yiqsJBpNm(?iIX%kbv@m{`j$onaahx^V$Q?mA=Q)md(CWnDPgHP`VEZMJG#kbh=`BrmspRFt1eTJolP;#)|0cE$Tr}O z^_c@rVw}{)=1D8*5nkfE_mo9l4t zl;2M{+i8z?1@6U=VeN|QSH4Wu^nFG6X{4mtl}{ii)us_`koJ$eF#pa{ajZATbQX|@ z{c|YY&-Pqy!s%uJ_WRF{sL$YYH%~wAwRG*pz9mdc&f>2FK9}fZ4zf=T{KrK2Vx94$ z4X@@4fav~g1^>dx{;&Os-{EsVoT!Q>sf_)BhybpE7Ib9;bXS0hwRu6Z!+dV7Sm?%k z-Y15}i|NgjCg3gtBg)1fQnzkYTsbn;opZCsG7#C6BYr*}VS%w$Y!L@c_vz4CipM#2 zjg@pY(g@K7UG^1cLPPrvTMEnt@!stBP)OLyp5pwcH;i8kH*vnQL3Yfp^JqRpLHds^ zx;0ob67=5*&U98hL!KNI&N|Y9FfN}ey;iFL?1YYMT<5B?UPD~&Du$EPxK#QKl;(f< z`x8rxv$^b;i%{4Av8c871Z5}8VC1qaol$^fPdqbk!JFkQNleUKkN&-VCm_Cx7X154ssP(n8&HWq;Z7++L=(3y@nyB8o+{xF!gj4)tp;!Un83d zR)vj3EFt1-_z?>=NZsBY&c=62!0{M??9-{sT0gM;_PfUSsK~(PUC5U|GQ#HiD}sbzcN`$uqurUjK@LL=8)+yQlOu%}utI zR_G~izHI4=kg_}KXDzIEyx%2}`?hhnPkP`}Ba0YnE;*&QpJ+}U$%91$yWHEq1Vj3K z$Hhk$D1_b9s!52!T-O^9-kG>RwfMlEg#c%;i#pF>x3=P27g3&59p{wpw`qEltjS3D zmvMrt3JSE`9EYP>2M>mL^9$1v&(G>*^y~7?O3yWhMmo)l&mC90exK8~%ExeT zm3k7!K)$F2SiMW?5w{R0Q^_?9sTqJOh*9c#`I`v%h3rV5@@2d1t`H>p#4Y5R*0PiL zvAFFbwTFGkM;Skex~Q!+h$KLgXd${&HWw!TxD>$zRs5`z{*qGqZ%VsyBZy5#52~Wr z_Nb2xUKa@Dwo!yC)q<4xIgVeu9Bt1|eTm6fuCVCf8&fr__kxxOtkXnl*>72^9%@@^ zco1kt5@&K^RQNu-nt>k-G!pHHZPGla*nN6|`Cj%mSigGew8kcH&KGC-IK_#qbB7yK zVJ|cu!c}N3h#?6ISx$EmQDhBVQPJPYTIgS;e(B9?uA$s3BR9nCNt8&OY#PtcMTy7&He;${qeef?e(i^-#&++0KM7pDR*2ukd%wiZP05$C#|7AcWr zOAtvkKqeDYv=kP@?&{IysWy6Cn#5UOsD&u(1Sc3)0xJaj_-`0q!6}J|;D9Cf_OtY7 zp4HOdIY*?bav3B_q-gfsx)YOG<6<*>W%Y6sy6{(?#%Na41eXnV)&y_ zc{zHH^TCAkyJ1)$_5|1ma%~bhKZIOo3JVzeS@*#`2h)Dtk z;BtImya56~MWD|UY+sHc7nobiCntFDJJnnB+SRlF`l$L9{P!#P?`s?NM}q%8>Da#{ zzW?;$9}MmJS;Orcmd>BP>W9(~|EuWnJHh^yQ83l>uzQE*nmi=qSoRJMdGWd7?nV;~ z*SBkw9iJzbqNx{4Ojxd2J(Z`R7BV%{;t`!Ct9(Cf#TI!=1?R<};ZEZ|BSd>x!-oPtFH2@h6@^32E zMtaaY<{d_>7Ha$4Y)Q@DzXYOOL&L4-3}AxsS`!7FmVWfAYG>STZG(so+R^xkse z&c-z+c8lLXkRW@#j{M|{`2eVC6Z#a~)mb*|QlTT&ak8Md0koGrYNVD@i+t~BMFw}i zew{o-rJh^?q=DDpQv!+ak+LV#c_qG=iCMFV@=f1mHSX}aMX8p|{^I-GY*93Oec4KP zj=y-3z7E-KlCNCLcOrxB2AyVa4EUnDzOJs>ALnN(E1ND@i6m?*VH&oDi@E7^{oLwH zo)Go>TFCt9NK6w%IF^N6Yn~Nq*^FLL3DXCXYz0jMvE^IQ3n5CWDu1lkk6uxmxwn9h zS~ef^=W@$4pTuk7O}9c8R8Y%e@?cmffuPUPdBVaq;aL!Ef=w zBXxJX;TBRop~rMMo*OxwmxPtwDBBZWR%Q<@9Hh!1C!*u?mg6v1082X zyhzKMJ6dc%z(h1Nt4VM8{Q9f&ohL!8{xt>SLMgCR6JLo6<-_&L9K1C|guFI&m^L7$ z97k(tLrQpzxg~8%R7u|)01_!2(xIqM4k-~Z;g&QkCZmWx)#n_k*~-iQODtW)bXybt5m=zpdf zaT2BOK`j;G%GmWq)~7YspCf7ZlcC6-+CpN&(RA=D_vtHJC143 zGgYlW78{|c8RG5U@FuV>{#b$s^^UL@)<78*s$HPKH(2Eqlg)a67!SwQXDKp%i*m`U zE$D@4B|1f5um}t$48Mq*OaV-5|6`EJhz$@&F4EF1WEpY?G9>q=dvd}^%#}P{hvyRLa;C!(>cm!Zp#vOe2 z$))>T_m@lemrM6Y#pPcxbAG_3`=dJGPffJ19{BID*nT(Nwod*+hODoe^G_^(iUQd5 z9CC4SeO1f9QPdNef2?SXTADt&Kl|9lDgKHRHz6!Zi&>1A#^js{C%Z?xIu0DQqw5P5 z1_vmwq5WL0p){8z#4Zv~dG8k^pOa&xs5_3EEW}tRa)A!IXdjN=ay9S*8+-z7UL=d5ck3 z)m61s9Y)eEq2OFXDxh6dXU%IFpRzo~)aMu|~F zzx0)zEunuZBMTRa*eCmnvyuY8)Bk00#0!DIoeo{`;k2c1m@qYgH8 z9KKn9^X5$`lc__ZpF>qZU66D)u#%6UR6^wffv!0M$bI8_U>T%J@xjUChxmNDfGjm0 z6P!Zo=%vP8hg~m>oz4#0f2{F|?HEOdN*QWusZF~0(K*I|^5Y`4Z&W4tYs#40Em~?S z75D2rKcf69(E4`pD+N)qv_wp;R2#54rv@i?vo8d891Vm!gltbZYm#LWhUT;|vo2F> zqA?&Jj2bAIwA$J^Sc1b{o?FFXO%baT5CZpe{&{1m4G>ZuO28*=fM|4jaYs8XaPvUO zY#Gf4$UCzaR{B7xH6tsA{P6SpMyCe@Xbrdf;m{@qj?6JhU3xERp_Wwjw~KC7vP$CG z@wwx+aO$edcS5!&OPppEZ;N;a_`RvC9niHw4wtY!?Ghs97vDPG?lgFJVsp47j8F@s5V*>b=L(&;6+LsKVsC9t<)L(pF3L`Ga*G(lnlDN7d6( z36rN9T!oRxkwRuwn91iG(f5~4rbctTsQtEcJOpl#h+t7pr1wVJdE(t=Sba`7S18F& zkS=E~6nl>)$9gxT&97z8tt8o+cd>i5XtLhe?zK}!SaKj4Zco)QM(>N-lYiaJC`j;y z@a1?9j~R~qIL?Yh-A1~qz?V}=bQPdLJ$knz4uD7bHLx@A2#_gn0AB511)~P9c_W5O z^l|cz8z9^fEi{gR7-HK1k*!WTdRFHu^T_TK#!17wSsubH4m7l!BZp8%EIB-pqmmKj z^8)+IDk%eXn?rg(D{&JHyf0?xE~FUsu69XaK!5+B1I~z*%94%p>1aMLp0io}a(dBX z&?R~S)-}Y1F~V-%1>5Q=`t4X*UDApXd{b_z$7#fpk*UKz!lVMTFC`FJIEk8Ug=Yct zwupIr{A$@wRK|2nkjW!yHDOeaAe-_F@P$zqTe!rihrmv*4>zFszzs&3q+609Ap0P-Y3$#>_wKkpRQ-+Z#HLiyvmT)EY|e7b_Gh!0wjy;@-Z9;boqkkx-SW zG2L|8L&V4YEysvv#L)76K(Z)`UE@^mc9-Wl28S1{IrD}n`T*fK_RE?6FWnfJX{zP9k-fmv?lBWZ;0b64%WSliIzC+si-cq1bG(r~XD1?eN9X8{V|W^U2dT zk%H9)S|%%@(~}1{?k-U?<%c9`3QlV8)?jEqrV1N79?+rH^`z2_+_;T(`XsQ1OtIRT#PbSwSU+A278#h3m*+=g$d+QHu$SLYIORC} zOrbv5!F07+>%c)lz6!=?@6)TAs<^j3ouYu8Om*^2>(NfP3?UY_c(hJmH81UNnK2&N zr7bQqc`_h;*LKj!DT<7nSe}=@_LtB$>*JYABi@}OB2U=-G(0a~;)`@h-FJPJQs+FY zxQ06UO_;$_rp2W>!6cKEPMud0F*4U=X*u&{$amE?=v8am_WlD}e8)cgu6W_0{fdsf!0Ic(mL?dy>OcCiWV3bg*9YMj34W2l;eUw)w%n&{4=2>o z4yhDwXY}@slfEivyPDj2>Ka>tzSGBI{DJ{t9ycxyY)vgeh{BFSX2DJVzmC5s@QVWf z6BJ0OTc+lQCZ||QoR@wZ$9tq`9c4z(PoMD#!+**8rC=&$213jCtL zKZycLJ~xR{q=iAKI7X0($*1+Ezwd9K1A7P4x!79)+a6QB*}$uH7QhZH(t-FIeWv#@ zkcrs)r1%Af4bZhLB1{TzSgrjr7&bW;aC^A`Y2Q22x^ijnFf+9tVq(p`k6_zYS}b)> zs=u3$vPDcLY~eKLSGPYTGU2?7$=MfNv9}75_T2aG1SI3;2I$~bDu+Yw{Fm)1pW>m* znc#ufXJEu)l!VLyL2xo5&tpza?Ic_QS(LGxB4sbd0`;F?m}mq3P{0yqmUkIfZNER2 z?$~skz^j6e^|#hJc0+38fS<*g3Et?UI&TgkcL{oSM< zd?4$ACB~pC%t`Eeqm|i;+mg;ycOi9=8KkFHt7Ze_xlDuKowWhF4J^yuOSi!2D{cuE(_L*TvxuBivlfFqmD~9726-X zVO++qR#t;3$Es#ML(URH;8Vuy8=wTR0i+jyY@Lp<0UC$CYhK*|U6B0nl;R3Mego9v z|KZt(u09(e#8TY9=o^4%WYXSk{~XTAGve%ttea1#!(|o7o;4FA>u9i`hJFZOudZDiNpeq~=S* z+DrYn+UhjAMUvUSKodRQ44g9hR3k$1sWIJ`q9slvQnjB!f0Hk)Aeq42>SA=#(d5Kg7+6$PuztaAyW zX*P%bOmK}2Q~`1DY#+nmH|nttXI2KQm}zp_xLuM*kZ!~GWfb!|r1@mWIMd%4g{i(Z zo4s}{NUr!0(ThsT_v>n_Tg`dD)!$nB-|2jHig|`A>|Kw()}d#9oyt~C;AUyzP8!-u z3atSG3npm&rGkdUL%Wv8UN?KJcx&G9`kY+Ow6E5RZ1P}A(@s~SliNOWe2{jDwf(6$ z&HR3id3NuNQ)$J{wEd4nu6YZQ3&vdWdA5|!L+Y@uHcxYZ+NL4-M4Z><;fQ1JPQEb5=B0ZGfnlgSsf< z50}(oD%A+MvxE+GKE`sSOJRU#UKZKjVnbHe9OXZo>E-1# zoTWBpH!J+B}PY8g`>9Blw9uNg)NzL|CW9aEV%ur@GIxHKI|;WztF> z>PfdF^LrYj5*)H$hWc{crplxh^?PAwpnwDN^yCakxQ( z21I4Zz$|t*Vkj4I?mJlEPQa)UZ=^YocKb?eBH?1MLW9_> z>{eOmSJP;<24VT(Lk+T2g~BtZ1;*Rkr@7MkPCY5&WR^Iuxz!N0P1>t$_Wd`6oVqVg zexA87)*)xgPW0hZsTG@>_ds-PqXl`6G*$ll;95N1lCO-C8_2=NP_kQlWkm?8FCB`N zP^YHhQ!A_Hfom7uDM(Bj_aDtjg##I$-A zLu+EI{X-N<3Ruq}$0GHeMR+wWGHf1ddLcn=9` zX4>4)%c08I&?n?d_yI=BR(JU0`Pt4>8=xJgLTUwkXZeUb=Y!Ju4|}*v+)wx4AD<>zMBiX4VI9yUYFZg~TtQAg48Q$%@@r?Vavk_^|0 z7R=)9W?^2Dn~{!YNe!G)wbUxF=x^irzo8zeJI=gWL+hoVwlR_Sh9`nq~p2Bj^@0Z z5V{J~{+1-Te4{dd@)vsVl||M3-+h@rzQRfHdhJq!H&hcvA^aZkE2mncq;qSz$PpVwWo! zSqZp7U~{Q}OWS~L*Fd9@D^C&_vzB$JUERDenJ3{jV0SPJOmBd8$1IkCO{xS1b5k8Q zK#4wx3}O**1fytK|`Ue{&p*hcGZiU(S?%x3}Hcy)L9wIQB6vWl6>|F`lwU5d?F!plX zsu>Cor+BHR&R%7g5FMgS5q9jRq%t76K8}{Ij~uA~S2&QCz=$bQKXgjA7E)7J{ui^9A!r;J-?%vcu`gJ8M*+*VSwFOfh>5XU|yXw|BkvWAWpdytR+ zXwJtwqvCS?+ND?Fj$GGnyX0~7n6QrfY@bzd*xg^2*6(WW+%;Lu?k9Kc-U;&8R+=zd zMwi6sIibo%F}ndD***q*T%>7s@#XK zhu<0^AvRu4&a|nphM(GV^q`6%+um^6OcJoWsHlJML|7Bz-OlpY^!+gy-uPtvN|Mtk z{?-FrMW&@BQwPy{Ll-d5usKHXDkVY7X^RPS#f5mErLRfwk_8zcoo1$O@^W*%I*uGU zeBM`XugrEvwCvs|EbhXgXH*XyW3#@+tGq@3l(G*kQ2E{%R8x!V!-LgI01Z)M(jZ~X9&r0uq9} zE5&V>SJT>ym>(y_aYq`!jmsHu_f&-jg_}T4d`{T5F0=iYo=WRV*0;C139ao*wWzUt zVmpBl&0`KXG50hx>o4f`?a{enZ;)t-&VX$(PvTZTT-y5h583Shj(NfVzrS(&x)dp5 z{B$mhNBL5;);_6T?1#iusVTW^!R1S-iEn}~0aLTo$7f{4{sYss|9`vXKiP5)jo5{N zOzViyVY;Pz51qL)SY}#M;C`I!06Wv-#g9^< z^`oq4{v`%}3Cdpz;g`z%FEkBoZ!q3+HGL-n!nQrNB3k|+*M@$RYtY~2n#eD?_Dgwx zFou7balg#Ct!dG3oRD^UM%6+OaUpl_u-fwI(r-mu(QiVl{M>X=y}9>*!STV#5lBto z$qi7sDI~!KKQGM}C0S;GGucnEz7mK1#xu@|zARy9TZi=g%@`=E&;R41Zd#t*bEJ3E z{uiwtZ6iJu&5)LVTrBK$_qLm~c=redKn)@Xb!IEhi`f=TT?8S9VDp*weX)^6T`NaH zkOg)OI$a(3Q#?;SND#uPW@3V?S3C0}+oM8Pnf2NtpyYxzsaD%4+h9(>>L>$_1MMO^ zus*HTGzpV)_UAEeWc6Y&P!%ECIgwNfEUEeusNrR7^R6oy#yE8*50Fa@qu2xB2q3%Jf#53H4N%P_5{P+V8bGY!TM)BLNSygMo*Db<5&y4W^7R9y zIZ)-q>!AntyR>v^Lw7$Mmg4|mO5UsIU!SmPqu4zGSevFmv@?)2!1%sdoR3 zh^QP_HvwB;b91&w>>Y~**86>CRx=N;S0pYf78cR;6StJyc1a&(dt$qqb$Tu_qKtm7 zF)^T(!Km&i&A7V&JShl3 z{9w%7PuM41K6VTkzZ5_;D>`{B02()Dr)BYI(KVF%!RxL9I}(1MC+Z1fZ))SO=R4Uy zYQaZ*cHJOp&5qu-G;suR^yK6GLE%}SwhhqckLzuYCDp8N51q6J^I7g@B}R_$o7g+~ zUOVeAp8?xlLX_|Vd%8;)EC$w#weOaPqAKVv?mRp5syVsZnsDe%GZ(I>L9t z{$$CCdXm#dEP=C)YA9lQzsI%)hXM@>J^Qce7?KcEK}5Z#`-^j;I#xX+1bqU1Zb@@C zq5DPwqCZeXHMcf^*SQ?AIJP&42MQ=y>t#Ynz5n)c-I*+kRtt=JyjF=|Xh0YHBPBKs zR6gHn+L2PKP8l<^D+ThySI?i;reh(u)-~imPfl4?Tp#O6JSa}C(!1I7VVh!0={w>~ z=kEQIT``z6Rb6SU>lu+dXHJ|RqX7kX!^F|-0}$e|vSX-r!U`NSOnGm9ceKtnn63Dt zhF1CArAE^wU7c4pLBzZ6b)0_DoGh7V@iL0K#f6z0NQ;?J5M5MNaIdLk@&b^+*ThMIS3MRZ=Ja~*#Zj&>#Ae*f!*d%pQEnmHig2VFHpQ+eL zU#}RGAydIXU8(0nVH_lMOndjJqteqYrd=Y>v~xbPC+Rp$LN|5Ol=B@|CQFC?HhJbg zyCQe~$wp(T7zeBN>mvnkaxn?M9&GnbXpLB7Na;wDr2uHHPL(HqJ3Y`Oziz@R{pm3ltcTVXE2Fj~$n3Y-;g7mnr4xO@L`$tTCHLT&bb%2vI$1nm#=!>`BxqA8Wa7Gj{F!R*Q*dqe|u zkQ8|#NLEc?$L-OUxJ`yo*&3Jr|2F%~|3?|{kFwxb-+!;~cc2Uh_pB*!$Fb8|)ZezH z6Rvbqm4GP&IEW`Ly>O}9ZD~JTAu94=yz;NGxqtQPALZx2gMH)uR0Cx}eNL#r`t0K@ zj1*cyB5LQ^w%?vq#DB23QX!jT4f-8(9lWW#ehsSc4XXcE%A{%xQE~S_aYj9>W7Dk^ zUQICwkSX@EoRtqUx_9fv;`rB}7dHjH@>X-2e~I5sa{Rm968{_#nW8q#Yw~Il5U-Dlo7O zgqR0DI<_as@jNaOgi}&YBfd^^^Y{1C{@;1SqYco+5EeXq5wUFLO0kd#!4^v1 zT~j-6sP_HrSwH7T{{FY9pOym&a6cU$+X6TUJQxH=Be03qKMV&6xz>%SZ6JW_W0Fnj z|6{bx2m!D*KONE=vM_6ijBC0;)$nk>NrI&QqyjM6{kH{gQD-722C)>wTH}OFNHjt9 zV-c3rI`(@S%D;Uw5Am^+r@4P)miOLh{%)k2nh2f_UPa*TIHh+ar=*58>K(VMrpD-! zQPzG;t>IgT(56LNKj+JZ%SHysx1ps%6*Tvq`!Wuzi0r=c44mq6cUfzxmssz}tb6W# zg(0r&Dz}sca2veUh0-CcjI8Cz*?{~8N^DXcLNx>1n}J=l@F{ozzMFnx^{Q;9%L@rr z6%TAS`mu{qi3U#Mig7WOy!8mtL~1;^EwrR-kZYi}e{#3PyC697B!#Lf3n4vEsA5vk z<0V??;`8#Clqv!G(Te&6QTG=606-XDmm0g%~u8VV7+cfy+>O>~B zsSx2-)nm}W-`n5Df!dcqL&kCh09v}|)L+1=;&6s7C*eE41ky=_5ef;puQotvNP9R0 zJBmfwGC_a)&F_zyZ*$pa`0r{r2#c;9pYY#PxXV!lfeR_B96vvRzCfPL0058DU>Sc0 z-|u$>_z<@_Ybe9@;WA@@ZyxT0R|e%*zLdfn=YLVDK+%~H9hBCzM| z&q{*7-G9{C<+g4ipAO-hN_qJUt!GN_74z?-TV5+(2O)(^(}lFvE`jSm7E_k6uKzq1 z*121yzXx)!M9}T^<5@F?M$gm3HIhbP#by-QkmO;E3GRG<&Wd5L^Yxw^9HiX5i^s5j zZqe$8=4mQn13Y_>IY-yKq!+I!h*7GaN@No0)3+bB>0kS{$U3Tn^ZFk*Ak6bFY{UL~F76Zj_jRZg~?zlA?3f88OezuC<}*cI}_Fp3b$_i?bfgBG>9<@M<^HwG0T9T$SvC z3Vi!ffh(=NC)Fh7)7kKC6Pl$GvQwlk>b~&K(hX1*&%v`yPspkLgWrOc>4~6q0X1EZoP!Zt*EFM_SMd14-(GCUeAxX!I)42 zY+q#XSL(gbMi7|6a)<1_AKPj2)GBn|v)jj9Le7mX7=tbzD^d|X`oJWyqF%d(#*X*- zG8ZNYHmE*<*Z-ZT{>QRt|IDCN14MsYQu{}3t6jVSQbTG1T0G%rnf^n{Ta(|=DKbP` zGem#aw{YIFd2EZ4($CcMgP@}RT-_GyFT<8o0SK3$eH-vXUBJXr#nHiQ1{U#!{R)-nH0Q`(Pn$}g3#YM>@{;1ARFZ?MqTFuB3= zUO(Z};kWtZA9XJLwZdkQ+1qdP4luo*pfSrb1&d-gW zo!?Wb%O`7MSIfm!xZQEth?R7*V)Y+=Z6p@MWq$N^(fcf#Ri*cwZqEJ-nWjAM?E^O& zGV13Mwp=d@MxO(=-?yIYtt_Kz5$D~{jU-xpa%J@4OyJ!_XNoJgb<6L%9Eo?hdQ?|( z`>1eb^YLz0ii<1EmD`FDdogk{b5$3MTu7TN??x#XNi&B}NqFrrR~t6}jCp??wD!BS z{c`sBKMuqCr#$v0%u>C;>vjLx_(}Yr>P7$H#ez}&qsQ3X|UDWg5aA&hgGk&W`JUdCX*V0_pe=8DC~&S4vgA@Ta8t?gMH0E=}-*Q*@4?y63FI+kc;~|ElM1WOW0o|M$Ze{@UME zt5;0&^{+YaZ&T-cFU+t3{0`tZ2o5xC*%D8>@O#-+68SHu(nq)DZ+Mg+(bF#`D*tGo z$9@3-Zo1{t1Oihhk&~Z;LqZi%Ha|N;HFMS*m(o6gL&gJ!k1_`J2_5o-&+&WI{ekNR z_Jj<{Jo8z+maA!ZFE$t3_IF%^zrl!X&Z#V?SDV{Yq7us_kp#&jKyp+-4NQDM_!SM?wK$QsQ@{y>j6K!dTrN0GNPth_UK)Z3qVMK`7!`%%nND0SZ`&1a2rI#?F*Q zW@eX${$&p4=+43>VcRxmZfSPq6Ua$mo~iN!6#X9ae5PbJPq*~TC%JX5 z>RQh79(!mDo6ItoTFtBX=I0Ba%QR3Z(E7By#bl0Q&)sKENPX8K=37@Fw2SV_#CFPv zLgKk@?OIC<4ta8KW)arQ^%IW7loixgyZVa?{04edBIpi?TS-@hpcZzrx^oQeue7yb zsxC=6#dpkM$k&52WoRFiSS93$?6W1p|ss*-Iy?imbtrdG{-{xe9ZWQ zqkT~m5|AO?5###^=i1Fi@8wEJ!njv8Tc?rhIl70zbrCrx$(p8=YoY3)tH<$UMtdPA zO&b$qjFO=vntIyrlU8FM3gar$1S32{W5D4?juuwP9xsK#MUwQkh@7u0BxUOiH=ucJ zZ@s4k(HnZ&V^Ls7+jNGHo>}*6L12rFo8~r(*C-nG{Cr-=0{fF)wfHr|oe+MNL-Vk^ znMMoI=-fiX@ocfWcZAbzJ6)9fC&OKm1*W+*MQ`{m2ton`&VUbKoJRCH_BhLhUV6-0 z;_E-O$JCv6+fJ6H!+BEVM8x}?D7B)!K<+ywb|xewd?tK2>Gf$a*LFqGm7I@E+jq-BHJWN%=AxAe>S8*G6-t?@vI_0j*AxC_c z3@^VR9F9-nxUeN^I7++mQAlvOv;B^2gp&!t#SvNd2;-#M5xwq;8_1prfYpztb@z6R z&##3Q+|*`YO$=bcy-E#@Vtuo`OT3uN_)?+U<17DGF#h*qo61ty|*YuM4BMI zB%;zpjG}ZQ3L;IwLJ2h>(wl&Qpnyo166w+c(gLC&HT2$VLJc9r?{Q|%9B0nVnN$Av z`~QEfckM;k*(ED^%6{&B-`92BRhqy>tk=`z!IvhSV3og!mF#&SuQk7M^qmPJ>Qb-Z z#!6YT(k#&-aFK_6;is79?+(}hm9YIEude^9JKa!psxCN%2lsGeTeM;Ko|S`m%bwOQ zFFT&U63$AxjGOllO2{>5uNDxsb(H_4`C*|hg!K~vH6@gTc0U$>sN_ z@;ABBZw?^~pldzC-#~!;uk)+}|%$|LQ0HHnCom6WXWj>b5L?>l+ApO^9`ilW?VH-au+^u z2Df5G@Kodr=aATLK$TbATxZg0k9!MF{00KlZ#Bd%2ETzYE8y)eWb(r*VNy`(I*|z2 z$ro9-R$by&O8;$R%wQGS2krlz`{lohyQs71{}9LcIi~Sb2;;_>_bl<&PjL+sz##s& zE{`7u{}9Lcsrnn2i}yIOi@d6K{no#FB5(W#IPkMg48$=C{@;UN{mBjT!x8u&H%Wi* zZTTB`4hUr!|H}vVFK#W?DTq8_c1Bw+dD5nYKPJjs=^_38F^>b&4OROlFDHC^Ym9?( zL)U$EAwHt>1bByGn^-a9fej{%PbWkR4!H%q{TzBlb!)L6x^ilH+o^RMWsGZX!ul|G z6*>yq3MaK37j#|vY^kSBvhVkjdL%pkY|H*t2$%L;(Nk^SsuGUg7$nzrD(!7uw@Fp5 zxhahp_xw9CnvVG`vVy5CW%dSTHh+F1MDO|lxAfm%{^tMrM?l}D>%B6+xh0Lw`SEng zlipkoH*dabe=6mh9v@wOHge`0XuA{CZx~#2DH{RTcy+6HZet?+&Y9T^$4}{%(1R!S zvT;+A42xszU0HpyiZveuIH(nExr=kwV8AkrJK+^K)yZs*sBV(yDqH{5?NxM{?(&VO zs&vwZw(9Z>iVcyp**tdYLm$e=Aa*wN_K+jP^QQ2vO36O_9K#XesdAC`}c+ zK@rVjxt0ScjK#n_hZwcs0w0wXx4iX*l}uE=t`o>CJ&tS)!} zq9n7{O(14oVbEZsuF=4B$EGua6IvOmZ$POH6(o9|Sj2AQGMDoEUWb7I%GbwPVz)rd z1jB*89a--PV{-vKTk@m>n}gxagnNuQR(D&DEqz`9qPCoJC?Ca02)l+W50lHwZ7)7X zpspzm_xRyFk<_yhrs}WsduInJy^ffhXsEJkK1LGfeeLJq9A4M)RAIs~(9+t-*N@pc zMq4S7<&6nYbJYN^_G$W1zLWTS8=5-_MLm%h2Zt*`Q9A>V=a(_>QHfr6@t2zT#8R}# z-8)K;T1}PRPBM~*>24n&c35NI62MJkr=Gzw7qB-QJg(g0m+yM%i=;4ClJq0#PH|i& znn$>(2xnwo6!7K@rozeo*#wJrM+Mc7OFg0@dEe{2ud&!&wZ}?0| zr~M0LA9lva^krK^DsdqQM3$*a2vpIZJg&E~2}AdM0>{ruKg=dqovMdMcnJIY$eEko zZq6dSgO!?8QYQ=?%)r;D*Cp$2teb~SfFly(u~N3^v$3meg%>k-pziGZg#GsQUQg^> z1l6?FY}scMr_hXj^}Oe~-ce)fWHMx9f17W6y>(H{UhqL-IEAQ4>&e}twR^lm5%(hE zx_qsy6e;;8uyq0%MfuUiRp)5)vrqbuaQ&zTVJ?e@PHk1G&kWHA3Bt-+Tt~+4$iEov zqS9@wR8?|WoQ5-#C3P~)b>9#kU*5lM?eJxe!d-Wi!FfbEwkO*>H;d~jJerpI6%hO>q{QaDqMn#AfL^O?otEBv5XIZ1`*5d@paYb%8OiR2$%ajxSC`WzU zMriB!?xz^!m4Rx4<+P5d-zxVXS8w_`M|v9~JJetBernlEVN&VC<^4$;#DVW^_gt&Lac zLVIdI?vht|8kDxn0omRf_p5QbI~~Ek8sFGf6&z4mE*{Iwm#VKau@4;o9-pK5+Mq}o zc)2P4=_P))xq|1e?CH7?hG)+`idCU$l0@ zg|*l4Z_A=Pwz-av{`dm?ZqbVq=6hE#{-33`q&@i>$5Z;|;cO&?ig22DV9Rw`&skAE z`g54CZ7ZJiKAwijUZ(g7TuQ(WH|K@E^%waFl}7L-;i47Qy;Zp6HY$OL1>nkSYP*`< z=ozrHx9CsR`1trlnXchR!5*!mX08OcC%*3#1ydUS)i$&nez(Q@l73|Z46yQzZI`aR z%G|r3I>MKOemUP88Mj#%g+9N;Rq(kA37GrsFuhx&lI=3&iEZ^Q3?#!Dl}z%+r(W-K zwCVv2|9BIRn5;z~Tn%9Ig*+}Pxy!j<*vT>Q}8=N_!8eL)tYi@G$o-{bkBj^<{47Ak*vk1qh`a(5t< zc=IAwOhq&O<2&1u;|^JzRB1Oyja>Ol?KOVRRsV}oGzhP%yYly!U$6xIR^KBv{Us6r z1d&|!W0>Zap&{eoknR(ariU%vid&$2y?@z&ZK^Po9y9y$u-~ z_JdCcW|zzlICaPO+RP{SmBHhLu!CXbypU(m$_f%WCAsVH4fHy0t?YY&8T38a(mgw` z*L#{_XgF(+2S_8cq+L%@Df^%FYzjv}M3>PbmGRuhvpuCX&*O3E{zuCKbl1F#jVBdWw95G3*KDD2RF@pDG* zh0hnD0e?2(mI>w=Npmu$cqvK0FDa1we#>>f0hiX!=^OTZ%y@9%mG*bGh6Z*V4zD;b zc;3YdKqJ)i5wIp7PEm>6Of%!0yX6n84y^{=4kybFBj~63a??iDtx%of}aEc;}XbMnjfX6w2K0;F4Ybg4e58hP@0tI|76K*K$r^U; zrVLre$8F#2QsvQGc4ns$A!AeA)i#CVv)Xs#C@}myfqK%%ATLqrt81sK%R>RrX*}n3 zmB*)AtprZ`FNXffaKMWb^Q(D}en{BMc@@QNGAKGLE`}9dSZhk{vGSV4Z{CpSlPfDW z{A6NWXxKFx0?qog*El`*)=|a5{vPT@X~}I=dNmVLH*OZV;C}i0?Ij0XeWvCNfSG1S z1(<2Wz(%vV0CkM{8|ZkUeJK8z684cZK!Am zS&($S9Cy#6p;@4+|DIWc98{3nFj2}$H z%SE`Dtnw&TnGlP=IQ%g>jD{t0**Mzm*Z}Fd$UFl4Vv z?s<(le0bm+=n=agfw~t;qv9w|0u)a)*W@e}=w8*WCl4NoUMGp+KU8df15JWI42DlA zIRcIrH|wo}OSqDjsqs$Wcl%7=KkvI(P2L+#?JjyyChpeYk=?)MPqADZo5%rNi{g%R9wdlmy*-c@A*Y~M_N8xs-ln+c4I}| zn-SMI^%(Jqt*4At%jM-wx3-4cC&@y*!D~>)5&E|f4zFu4&Wl5?Z*%ENs2%qdbe@5m z(u;U8Q_6l@nvL`!ZPRB=ul4Gm>c6WyE`0opuEMS2tFkEOr3WWNcWoLJYvKo$|T$JZ$TTh6lx~kyU?EhqVg#?z?WRK`qo$PEicbO~MHy*U2@dhI|h z*Gn8P+%!gCX{0x&6Q(fyAYT4*9LR+x<@$m0_R&mSMN=v>0y2A7Cs9Id+M(EJl~6)Aa3E&^cy_AThwT~wxu(A21Wi_%#;r6GTQI34fbgO9>g62gf=-d(R7? zrJ+o!%l~QLtj?>%b%}eGm5FmH29km?Qui%9VqhkFdUJE0?THeO_uaGO!rBDGjbEl@ z#P*|aRaT~K%mH&!Y-cStv<2Ai3+D=M=e#=`3S8D^1SvfAv`*gyu0K=JTWPi2lwEN{ zNEP%AWEI7+eUgYRBykV|9%U}!5cYbn(aEmE;$g4%m{NR^#h7r9=ic^MA6l=AAG)^@ zDzdrP;Mb}h;+s3XLSPr5gO)9-T9C3W7jIs;=HHCczj--+_I38|q%Onu%YOEPN+Y*B zw|`_arROXu{cxs#UB3U7O8(%%9PtM>lb#temt^;MHq&<>* zFMRud;oJY{-20!0Z^Idvz#B{e$fvNA^urm3&e8jK; zyVA2~zOKW=>dDa*gPM;$Q?fT$|MN~iK_`|7p5WGnE5+|WQo2wYP)672$vhSiNIUzf zk&>~O(TGU{uhrEW9{DU!l$JsBy1IAJ1bmM{MfDr#&H{AH2=$%>Xy)-#1=X$aQjx=0 zcffwgnG3kx1OGR`5x1zKUJwNci6VgYl9#x#{a@sY~{bf!aK% z3(&-!b$u7nTBuf!qb$udi(L7_z35L{6nm+T+kY|~E<_k_#zLg=v{lc-W=$pA>_Lk> z?$Zinf!@@GBVGy9NcP)=_9p2iCds%5bwc?R8IR_}rwLJd$TzGT@CcIGlW9qY_8cv= zelaQjJzX>=<$TnXsy5lzu*yq-fIxF}V~u(NoNq|&&^=K)hiR37Zy>}rG{G{}nV^Zo zdr4&$7UcqKHM3`Fs{zk&i#rV&zl4;)Ko)UPlT!ps9WzV4F!JeL+voX;72zA~2h+V| zvq*2bTA-ls69%V3WK%gIaV$YACU-U({2Q-akQl$w@C{TCEAaY)FKK47he&&$6`>y} z{Wu#y75Ku}44n>q1>aPYy;sxLp@RKh_lURjz(uzH?bP%qL_pQvn!w3C1SzwgSZ{1c zGL32%Ea5_AhBXISXd%Y4%bOlKt<#kd-_R1A+vIFrh+{_oHsW%UL;6bSQLxy?_FnC+ zdyhs^FQ^+6lyMv5O%;0f9yR>Ba$P&>6!h`#9;C5%(h6&^H~i=*{afmnufIzN9r8Wm z&G#-RG&oIP14IF$CaUV+U}e1cE*x|e#L_kqI(PhJieNk^OJ2(orxD*9|K6LzPeoq} zK1IYB-P1#H=UCnGcuIfcYRa*~J2A(nwC_e=sc}q;^IJNms_s>bx2!KBC^s>--^s9b z`NrNR!aw)4auSHO@c z@mqJ44Kuu`@qnCX*rUniN*Y+U@6K$b_OsWPIcZhIskyQkjs zF-EZA8i3F}q~gs%*SA~-l+vF~4Fhm^Sv+pnzs$@)n)1DAQE>EgLFifJbko1zVc5!M zP{CE6=VZ$`{=`kGDYJ9T?E!6SF6y~hfupR0!C1EddTz}nL?^XoZGaPc6MoXzWW;W$ zpf*F(`^(5OQv%d|^u4rC7WyNuB2Z@ixXts$B(E!J7o^*xlC0N0d&3qKcnk+1Y`B)> zNpU9L^RSRxXO0>_+Pr!&7?pcKMG?AB)iB1(!-Hqa%Sscgajo|B;KEIRJU-zl;s7P~~(gaP2NJ#*HwO^ma zr*QY2rZbjH_0P{Qcn2V`7|A0;I_aq_gALJU^-Bp>8Y;aOEK=Kdv^cjQ4K>4)alGQ`3Z;q2+L}q^=^>=jrqi>bttxPn zxB?YF%{*JIgJYKB$pR8@0o(m(w_RP#HRYQf-?;>-IXyM)48e zO|7IQZA?FTc5|bd>*+&P)?3IJ`PLzbaf;v>}MvgE=m%irS>3=#g zwa}-Mxc}U{YYSCLH447+Qx!l=p}>UAsSue1uAau7V%8W^q6Bq{SEh<&*Q;+JHG%IU z#+XzV?d*mA6mZ$|{DhgdhqpFoMJ9d1$BD;zmoa1&!dqRaMk($fKj2>7X`QFpsUk3% zt@{AiL2KRo(ggUJ&NPhWQdXeN>UH-DJ=Cpm#@C)P7r?i7P^WP8&xG*Vp{IH-$++gI z4CflY(>T_l+IEt@(9`fafvSOt(9_JYn3kk`i_f7quTOx|ns4Sg6;?HGnO9W%{nxDl z=L5NZWqYGQHW_fPYTFv@G`gs}^wkM^-5^+xgJpSH@LfwaV(duD%!d7+PATjgsy07` zM@=5&yTYalB#wk$ekl1?E#M*M@CDV!7a*0LmZ=N`ERNi-EQ~iuINZ#yz}|JT;e(~$ zNxsUH;M?;>oxxuA1f)H0EFn+F&mx+KX5snW+fwz<>2E)$FMKjE|B@g)H7EmTEsRhJ zT2V?IU`b(eniN>x_1-|oefDAomIldCtVYVE9p0-e)Uf07xajSD^d9`m9OO8mT$jDs zJ{@*ypDxSwi14#l1TEshxECtZTO6)q*xmcX4&>j(hKa@yl7aB#eJ^?J>2;w>UwY!g zMdV6fo7c5oWC?_OIo2&^q@L=)`4n`=ZU!xE2OUg3vE5eP=6HvKT*Z*O4YwI=JrjFm-1EeOT@itJ}vMNdozbD#+ys<{s!vlu2J6c#|o-7?oF z5mxVeqVFMIMGF)u15UX{=H+l_*;W!S&Y>c-Mpw2ajjR1`Hh(K#o?p|#RfHECD2(M; zu#YAvPYgS;B9iPQF3QF?UQ>^ra=aYbw4$esqJ4>N$n*6|rnw@E^m|n`ssha?4o7B7%Mfqw-b5wIrOL@so7(<-ps>Hv!NpCYKK|rU{E~F zW~Pk-XNCN1_)jJ^djRFv&8SxpUf>3~mk?GsLKo(Imv8Ev0HDciKLZWnirUF;GIO19 zHcdaa%jgFtx5H17w0e!Q!&px?ILSGOB)WhM@VIC@exlSlMn)RO`N6WH za7V0;uy})DX!SSqm38n}`_BAGtH!LAX-4%K(g(Y5Y zBr@$qk_Bd8a@B-yF1C!h_^60g2c~w_S8!1K zYPIbAHxQ@F4dEa!maitQdYddBMl`jJ_&pK#oVvj- zzmKmI zKGNE%&Qk(@Ly7J1;rc331DoPjk(nfL%Fhv~4OQedW64Dr3%!eBPl} zRRktW<-Z?*oJgiTB(9lgMgnP(^r}#@75|Is4U<)p|Z=8MtpC9CL@av@*8eWjop1 z`Uij6@955ddkaa0{iA>6|KXOBOaMIk4YbbHk#JxSsQcS1!M9OleAZ2o7e5#WUKsrJ z^_b-;@SstuM0dZ8{%U-CEWjF~|Ae+A;B&NH@boMBumoFsuCqJsRseJd6Eq8#A|ZMO zs|Z0m2Ey&7Wf82NR>c6mYPxX)b?$rl>4!K!R*}vqDl%sD7o~d>8JNryMVl-3z~J(o zPmMVOY1x_rjc0YZS))0m-!C0ouwPw0yRyWk8n?(H&xZe`x&MiN8&y%7SCV71W0-Mg z#1ta}UOxlvM~`(EcBG{bnn(LTa^lHA)&SlElL~{S(O=j6@0D9WdXr(cK`d( zKRK8IpK|0saq9fjt{*66Klzt${hd+vvws;7tGM;ULH^CR`|I}qS*4D5R1GsRKK+W{ zKv~EG5BHwq&}AfkXu}u+y0UTp8>m6c|B*1*0!lJ74TYX&2~!+Md$JrFF40xd6T0<9 z0H$;;%rcu(rN`EZhwuJ~ZTTx=t4(TLb!g0dEMBM-&F zdiOg!Ih4DjfX4MpNB8Qun(>ebxyme|QYMYan2__QA3i*W0h>(8z@H6uBo{93_P~u~ zT(MH0KXSI6GUA~{m05pGhp{$2mWiG;lKQ9`)m>SuTt5_%m2Lk-s5w{bzBY%boE9aY z!VU^vP_>@(Z{J40gXaFM_w~Qb=>KI#|E%ftd#vtXF{1?!#XLMh=_`E=^yc|d?RwT( zb8*6S`a(~e_1ljJd5;rMob!G!vg4>j=JCYFAu6ULqtanQDPdGQ1)uK8eB7ze9;}ok zJX$x`pBj%;f<&mqdx(LDDny?5Pz@hWy+2boiK%rjSjW(FnMs`+88VL25`O`p3q13_ zIQb|bx)(zN=ej?8s67A}IhRJw?LG00EeThz%FD%DcGFlviF`{jjnfI?4m{k6VkpB8 zNh2b_k}lU959X<{w3!%bv+}5I>Ys#>70WZ;6K1EmHIL5ei1w|WuAoNZzmzRQs0d~0 z1oXZ4Dd)58B6jaY?+Vtf$#X)QC>E2pQz=L$T_m`)5sb5^Ok@AO)_x3pmpeSw;?UL? zk4`_bxD8n{QA{{|aVXt;K+wBQazCO4Rs&klRfVfq>eX3BvrxK7{(X>4sqL6(mDnb@aY2)fP^nk6n zUA8l(Vb<7}+X!D4q++1i2o6a~2p8&$EMZHvce12zpSzgvd-$3To5eZMPJUD%lv!4i zLnn{-zBr_Rtc5k`y9l8d=Iv>;c268!ioNp#7(*ltt4cZ$J6!%-Z4C-h~Sc z5#%LWCe=3Zl_tC)=ELe5AGT5M#>f$ceY3BpxDR?c1U+LQag93oYz&ibt&4&MkgPbq zX!YP$YX1jY9~r`wc12+}tq$M-@9tNvdlyT@o{(%w<uYQmP zlz4FBKkEV{8f|;oE6RslUSJbqGuXc7x(hy^IKx+VWOWtDwIn+`vv{QRthu(J0yR~E zny05jwz00eyONp%bwZ3b-C@6FbI~bS)c$FNihNc^aQ5M)O$DcizWz}cVUzz!&uxHd z!=>^>rn={5;1TkSYf&^{1BpNj9z7x1;6Hb->t5qv-;W+@(Il&6kjt7o@#&cJI<>M2 zci?N9_MBkCMl7*EG8sSJ>{?j&Ahcmeg)}^Mrpc4_Bz^0@+m0~oBe z`Ihjd`E8!jlIN2hZCRMrWzM~SQ8%yJ|#Wf*myC zkLIZ-RkD^bJaid5C?-6%MUnww+2RoyVP&1A?eyTffG$r!$3kDE) zq6hZ0QQM~AjuvBz2o0+~_3~NJ*5TjT#Xr^lMT)Tnp~2RH#EjCVjAAKT#L~qGuv*>aW>Dij@t^c~ zCBH#fn&PeY{I3+p&$jz)+-x}QS)D?)sagUTw&COGCmH+P>CVrrd^}$B0vD39Ht$F3 ze1L5mq6(C)V}rkx$rEwBU9m2t!f#z&Ie|PsEW0J?3t?JBGf6G6uOtvZa56FOf1uw7 zZ9`Z2yg_s50320=nS6tW>cxW?z@0$Be-Y|-2nhV~0UW%}H$2#{Xb?dsi=c(cffvJ< zChlozu1!E!D83W-+_xx__S&1^8|Urnw)f=8f%fx~jL6n6Kx!}S%s7z~^|}TKd_$fqzn0#GJ?wYLpB z>v+5#IF&I@dU7JW3bZ^MvV#(ez1dN{!~(BQNjUNZ&1xyguAD3m&XC@ z9rmA0v-V=gX<@f}3dYr|ul2lsV8EjTy$%U$1bd^iO3*X}L3`q2|N7g}Y}*bwQ97a2 z9I*Oi6ngxo@%RxElk9=>vRjv9Pw6~2YY3XOC7N7KO9FyO=dpxaBGa9K7(O0$)6!6 zLY{mBr5W}iPlyThpm}U=Xeh+=Sqt~JZKfVjqw@&1clnZW(-%Xfn&R^mAz853fKj2} zhcz@aW4U2&i68so2muSuubY}{OdMPi0TXr?|E*R{oZEFz`j8~Mz+v96F=McY*Plbz zGfg(2{#E`1URQf=$qlSMi{J2k`poYe$onidn#9}7*En@QDXkpiELagc!Xik&zi5Dd zhkBQ{^zLUgkZ2Sk+v;>0uJd-FWX=10%p!MQYL_m+cwt$|=!I}DKX2ZRXMK4f;PQkh zQV5+&evuT^sQQ=#z0ptt&TuS5s>^Qd2BN0ANjEd>m|tIV@TBeLv7R-gBtJ!)(rrb8%S zs@TzE%0G8E%=VOO$V6(rD=JxZ{>t8ue1xB<2_m+(_H)okLyhSvm1w^BoubQ-XY7D0 zIPYI?{BV%6BA`oU)ca_^tuX$u_hE_kgOuv1!L<%S#Rl}qiETZs`!>2nh)F$zG@Y>jD=?lY_sAEl6%YL-<#DB-+!teFSli-2+l!8 zJXp&ts(re4bXbN-tf(Sgr1e1EyTVC&WLRB^CnK2G=h=Pqa7Ch{!`oy!y~}iU7tg~T zhCf%xbzKV*;irP9asCD(U2eFB>i+x7F984FYWV)h!DF2n2bY0M2udx@aC#R62WmH( zC6@RCb((OHbCCM6U+yfyGq1iGSreR*+MDSvk6G1RA=4EV88(iZ9~C{AQ5Pg)$6tYjqz1pec)%9q5QC#Y3u;qG6ldNR^0q#5GG(>Wd zT|TY%scX=*YajqjSo9#C-MmrUGd=F`#n-SS50;(K!-%(*8f#`hd5Zxy& z(v3`b>h?`z4#TC$CSXbZ2v;G0b=A|Hia1LG1lf{W8|rSk3In`j>b?0L|Kb=Zi>=}O z!L5D`R$_V)lz2`bHMo4^sW{BEC)qb;>P%L+$1^c*U~301FgZvm*!QP1JZHZbmK$(6l1J~|YW$bl46*!vSG$<#Ugh(0^d!n$lKtFxlu5X} zk77k>KwMJC7d<_tp!@d$c$9A(G{S2bzkDNb9V55%ytu@8@ZA;7>nooJpg5*%d|}j% zTWOrb_I^Xg#Z}rXWBF-qU|%cJa{58?s*tI-4=$IX`Vvz`-kHam6P!q;1;DlKsckS0 zuQ_{J;%igE(kGs1!cllfE&6-;#kzXBv!u+;9aedb|LN(t&Nnw=N$+Teb5z%;kgF@s z*2Ajy9cv_wje(Hh#F6VDvi?qTat)VxqLW>K<mh^+YUFqy+WE zf=4;&)JXsQt?f?|)#mE^7wlSw8@XKL!}U>)S0kzLf|hCDKz>T84K-mqzI_n@?qXG( zBhP#!k%xXt3v=lk=&%bkz@2^dP#(7vt?iJBltFE!v;w#(Ix>h%xrC&i_Bp)J?m5j} zaP2Z}m3Lh$%$8@Bio8d^hvmkxYnYC6jM_auY1OkzzUZknZv)+JMRt4`_pOp1BeX2v zjHZxCb=qJa(o|Lh&{&tqE?eH-V7O-2cQ?4TDFUfc0y0@-V>s0Fsa&0Wv812|nr`eX z?i_Xuv^Zd!#V8wJtG=LHNP0P-Vx83Y2|q3!}+IS!+d2WgIB z%SqzdxaJ2NQF-UU`zKLAPGlR?x5T+HTauKiO8U}gDsrnR5GNU8TR>O79YWF?beVj-Mc(hYb817+J}cTbXIFaphSt-9nbfX zW^Ts499FBV-9kHKO{oX$@C(?lvRgn-4y}b^0RdkC^~N_9-E~hx^H5yiG1X>)w*dBy z0)W1Gh7w|Ll(U&6kG@f4xQd?#!rw&0rlg4X#l35*0HVY?3R0~N?nVptIt0XLyV=lP zW>#_E9?~Mm?XdfAQ}uaqr^B^|Gm|<_N7uq_P7vqN4LF}SM3ld?{UWz>iE&f6eBSDz zy4&ADjJ;reoMVKyfMdM9LXyU|_Z#`;q@jX$L%(`Je-(uL|ExgVUdi-Mv`}`0c-gt^ zR&+Uq+rG_1&6%5IaodjnEw!G5#endNwt~B#&&bbB%my!m_21mKU8-6 zz5=)dJyKMr!%bta)uDGRUI_9D1e}@Kh<8QOTMC zsZa>4*cX}!!j-?EQc*4F+LL8~7> zybbHvA?;*zOS$>e^UqlF-?c420+{VPru@?%g6tZ zD}NKz_^s^RUuC00U@(&0Uo2^T*n4J0gqnP;meW2mrcfdyk3$AlbpM-PcWYk~jrVl2 zS-~45e+P(bZYKO0)f*gp}h^bwZ!*mWu?HWLkpla3>C!yHXcD= zUoocGH#9`GAvSTS&{3=Pf(J;s=wtnk?3P?KF8gDZYE_F20wqXsLVSMRxEAMggK!9b z$relvJW7W1Ej2?oE}ZKg^VxniPBjbmW&QI>`hY&Re?!u2dO=yJZ35z8WXIozY80{v zj^1T8Y=R$C5h*lL8aB#Gbc-78w2|}m?pcf813&s_(>Be^GVJ)+@kd%-xxGY*3xZV~ z2zeq~0+fbdJo=+^5b!2;E{8FTn$qW9_=>6g?62XBaM@)OjkHN5!)@CN_t1@Qwau3C z(BjmK=hVF~0kQe0sc)d8!(+G4$$yoqs8VQ|zkY5!_~gNpMfi1+G~SX>_py98f%e1} zt;1TRRAn!%{M0e%ZK7c>l(xo*EQxcdoo%G>rr`EW4|jB-I6-(ykA=jwk-x$>L~K(5 zxEbJ*8mfd2(U8@}&y(u_1kfu(;e9n^Yi1S_`wc|yvBN1VFB4V^WtJ5M8OK?SEyABj z^lYGVXSTMR5xmLUBv&k#%j=k9>!D&r8j1O%^^y7V#JZn{Guxw4LPqVEp2BHso&bTc!9;h=MGK&yZszAg*rx%@ZQlLB3)A2+UzdK4?|{QADe;DVazG{jl{ZTZLV|xJfV=pnFQJs3_7DtIg6>)~hHAzN6S0x~7WB zyyJD6U~fAOE?r70soQZWO}Wy@?I7Let0kOs{n%n#=Z(mR5N0pgQhd~qi>~qbzS0m( z=x#(gfCv&~?ma{4JTsqzQ2-xDa}6Odt4dk<>j%jW!ZGh#hOZXiVLHCVa#-o{lU~cz zhZO|3iDjc_HwaIzSy6DtGoB(1pRR2fpB(ouuwc}j{G#}R_P){Opv?zKyEMokAG)$& zb#Rc(+;yqMyG-CO#rDZ~!;h&amgS_&;~rF*zhRfE5ey#Kp-q-rJLgj?`rq`haPayryqt=@6$98y9r?pM90E3wJJZeJ`d5YJCN{WB+(T~nq{3SNt(r~s(_JDfnaSA@}jJNQO#r9%*%sB}T6Z_-THoJyg ztTnN~^Cm{ox?Spm_VSW_RZr=%t}raHq2b8We#UZz-q&Y3JP-c8W;-B#*sXuG6Mk+n zXgFvl{_yg9h3!`^zobn3QOWu&ceR$}%6v&xxQ>&G151vF^!tzC=p4t@lXWF29ZOQ; zHTY7!v;|;Oy=G>x!l)b)0T5Z7yVeg zL0N-FL$>81_LdGO%4#fWSk5qNex?4SfqASJ`G(CYz*aH(l|H~sY^&Qk4`)M!ku@9) z$#tgzK=~Ih<0;8K&N4WW1c1{o$!@3qhFf|``37E$TTkM8A|rz ztq%6~at*SGX~6Ucp4gQWUa<~N?uGV@rkEynbwWwfJO2D~o2cqU>%jST$H>^hI-jG|Uto><94oRV?=mABFt$(92hso^;-ITA!aCAtI+=OiHr|mFNt#e|!qq>?>@^SESVVn?D zX(K8sDaI5b(cOsHEL{6YGxGMZHt9I5qb7ZNE+c-7ru6-o%5wGli@RrhV~~e|jU+uz zB@4_)@a~-^pFT&iC4B~(_Aj>;Ew6a&1DyY#3}O4XI^3H4ff`4Q0mr_Fzpk^krOnLs z)_Q>O_LTm*ZDEL*15YR?2N1b?uC{c-s~Jx-X^=VT*|uKV?(Vo{Ak;T~Bx%HDXu6PU zx5@(mnZg;+taj$?H7Wa7E8^GHEzHc%85dy83Y8|1p4o+e`2l_7he_78xV~pf1_gH5 z9R}a`tq~y>@U_jxLjydPSPoXV`Z~^aFWI|vad{?X2hUE5NefsQCG6MW>RqWgwp)&v z;Urr;$4?kt%Cze*K;At@LmNC0FGOBfImheQqWZ|stQNC+WU|>WqCDGClY!ow9;Ho$C%y4!@1g2uTEpIKg%7M1Jm zKUq*J;h{}+92IQ^?(BmnQ>QEF6DiK=>2a2FYS^E4?+Pm5rb(f%xYeAln!n$PW z_hwvtZi@2?P}PQxsVXd-2lT#3f&@!w;LGKz?z2mJr?kWgkc%l9sq1{NojJFs2Yi^k zq*5ENx{TVgx`;4ju#v#0V0y6KsB22JMEo)*SVlU6v~lWlRUGe;H(*Kw)1AB1G4(%W`V zU$2FYSEby2hL5rsg(Pkt{Q&bfrvL&a{zl}HUjB~6JJan3Ji6y*=pWWFulse%Hh6IX zkq$vF%+6dIn{zuApUL|v+n|%40TZcSbnb=B6IfqBTjOLuv_ke+NtThqMqd!~RYi&s zNy`0+Cttje7b08ha*^2lI^rQznr!DD`?e%;JK-DXg6!7mN`Q(<2H>IQ#ehfpC|U#+ zYCo0qM+~4uva+#kMbjw=-Ef}53>D8kCID8X22S?s#1FLk^Q<3_+v2t@}&;NLl{oVTwrz9oHq+v+0AVtY7}KMQ5JPnoMhgOdm)19xkGAp z1(%FvGcR(rywGC8D2@2S#tg1!gLVBkSqFSNJzm2y?7427)Ztlvdrw2^yYRg1XF3WdJdR1#5W*!}IxbYL{U6RXAI|CtXjCP}$9nxY*S!=Y5Y7PcR z+(q>0=?Z*Q`m*@}F42AA*{&=1Eg!K9B>QO(!Wdc}Rb0a>^6DcOW&Y#NY}457jehhe zoO6~Fr43V2J0#f=hHW?57ya0sSi|_{3Pz0RQVE5N+dGyoJN~-W{(Ge4r`lhKOE$5q zR5^QNLfxg4-9vp@oi!2RJ~yH|&>jbGw!z9xRR*t>OifA$ccY7GOz$ zD?LFv_6DyY8*);68c?OpWaeg%&LD9~htja}Qu%7i?iQ-VfKlH95)`qaxcJ4rBV?-9 zx-mYXd`NxRgnRUT*v82PN=n7E^*Qq;nSvX8B@ol8DRaTt7tG`96stHW4f1g?P|qk0Vw+3 z$xw~hI<=7rkXb< zcKWMmPZB;?Wkt9-9a|RB?TX5ixIkKl8sn@(RG^#*x4H^fCwZ+zs-(89TEWQ<1m&rO zU=?ANM`exUi|L07BzRua?{I9?wGWk(c=0+-e9S2dLzC-UUB3MZbl0f%Y2D$otEK=W zCv%Gacqfm;!(F0Hy}eG5FvUTj3Tk5qmF1;6bpqN%l;J8&luUFwGsDNp;bOoW42TtO z$!>K9)u?3?QZ@YbdxSQ{XLF(sEepkAbLffs*I=^whivUQ1I+CJVZkJ+6lWK%gJ)M>BS9& zz&W{1hb#eQ9@-}>Y9C4ahLY3cM~4Z+jZxXHQ`|3yzm&fWUwJ6iSwuy(xeAvyTSN;I zJg3gwPvXp%EEsoY_IrWUE9mm0qVxnFFbN(`ArL-7C}&onJnXMew#X}48 zSlW72kMOd2S-Q_x*Aq5*g|_S>kB@S$lvgQkH=YySY9nF`Y{pA@{Y}m;C#iqB?HA}N zUKr{9@H6#+v`-mTFx2Ll$(JeIT7uGuLVe1v4debZJvVSJI6`fTe&{e;38F?hv!jCU zoN(Hb;30_zcS&m7tTNq*L@6TaRIM%1`drhu4_{b)^BfeoI2o0nt_~I`cAYfs|*^8p)c`U zo;!DmC?&fQpX@D>m}@d#&+x@TT9@Nd+(-sv^vFFxxyog$>VBp@60n9#+hp#x7(RZk zq4_8pE@F%AUQCKBARVIZ?-A?@;xzlD#>v~F?yL*M^edW_(?!g53{F)AK(1Q%6bmn! zF(Vrs@N^5G4E6eg9n)a3oLeg)M8nJDxL016s-)w3%PhEaZqBrLEA#uj*slv9%a-_l z0n~>QH3csl7y$90Td~BOYvk{$L=-Y;zA7u8Xhy)}u%`!GgjEyZ)20fv|A)QzfNCmR z+s6Yqf}%z`NC^sp3W9=&v_w?8h)R_f3q?S>^n}nsq$408Aku53_uf(I5Tp~3UJ_~u zA^wlf+v|kRuGb3)wQo#*p{z zU^~it%R4?*!dOeb4{zj5jDevU3q6QPCBV>Ti6?QP0S@DLZe;ei96htKQJ8ZwTPg{- zpG5B?AeiEA8fS%O$+e8r8fI8uIv1A*ngN=e-5*i0Sy1ruh^db>50=wOJuLeQ{zgD` zb#8X^g^>9<*hh>w7XC8v0{(2joUuJ$y!mRt>dLS`G}d;LVXJ;8-@3VuMOqW9k{;MO zr+Rg8ly3BM!3m_u%pCus=c@kX3m^t0r#VKIDe7aKWlkwiSb4fWK&?mN6L~Pf~1Lv%^k{Hg3@5Z_3gZ6@(dpg=`u>!GGeTds{CnwB^S!6YTTwm-jC>7YruheK)A6G0=_hi}lNLxFujE=_Y1le3+Jg{7870JWY) zsYt6r`jJi`K}YeAIub?eYoYxJ+l(vGGb_72o;xq)pS{|pCd5o`qEn=4XI91APT4D2 zLA#MOkf+5a9cnhH7eHpGQXWc`}$WKS9?M5mc5MBl8tY+BpD>NP`mYO>8`E)eBZBN!A)PllB_GHmo22))? ziGf%<*vYDpPfeXo0-`Sg^ZY9{=wyKfWg>mxxlC)Jha=VW9`TaKDBicBIYmhYLJ)D=iaN{^*K?kKK=};H- zqCt)0_Gs^SZv}ut{4ELUH;Rz|cXFca4JB|$bTC3(C{~IlLw!z9Eojf~g#Uso-GY16 zC+GQwomw&6Sf$a*nFO_1OQ`6Vc1cL`fL3ewUaB4l&BvUDI?bq8y;ZN>{RT*XS6FF4u#MB7b#SYzy45?z?;H_9E86m5OPo ze@99ia>a$C>cpoI&}yQ~;(uDdDh6yE0p|qOY#3@ z;V&_5!8x7hHISxll7pL<9`0HNDC{z>sF57x5Dqg5_qLNbmbE`Nc#l_}hK#8f!0>}i zcua_c!Vtnf4=#Eb?6}~Avb_TYxV33$_o8T?YxI&i%~szZLCaP}`Qxqj>j+c2MB(WZ zfpM^=Jeg7ou?2Cv_vDL{PG3PBv~W4n>0WgOf6%a@{<7rWuzf_fd z?p-;A9U<6HvdkMb*B0;BExx-aB6#jd7^R|w%;m`8ovnQ8)=65x1Y@^w9Etk0HI&B) zz5Vhir4cCNgxYPR9hn*dPkdS9Cs^yqcxjqFQY=Rf9C@bEBNoK#9of$&6KbtIh=Y4< zbyMARVve_Wxm0xUH=w3)& zX9KSMomyqDN9MWqH6+ZD$%(Q#@ z3dN;rp^Tor?7EKNf7;NKbS10>&m;S2VnKM0hFmg*I?j6;q1dD2R7tz%1B}lWS z`arFXRQ?`;he?e!GxC5J(br)$=TY9sl^~llQPo*TwvG-1@zu_~)u?F$H}hc&$6y`~ znl$SRH;|O2M@Ryx`4N@M^Cmcmua(33ZT5ttU2Zx4lL8;(cg6EhC@ku)OiL{!p@-Pq~uF&5j{njbA)n&VJhD;ROM7M>~ z0}dwo(S=KOL};St7pm$m(e8W}$Zjt>!Cl(<)g&Q$Qq~uswAp7|Xs5&7^2VM0u+lA$rQ_`s4r_5FHK4XG z-zWWqYp)qvtG;Q=^|*jbwSou8rB|D(BeJ5CEf#c%%-;qYFf~IG!O`6h;0z4!D$=<+YtD7ataDW~eISoed`B{i^Y=ozGZN;SA7^3JXo zrn)4BZ{V!wirNYZ$67KNmOa?2xj*!Uri)&-0yUxDnFP?&bMiEg@YPrqExM-Vb<(}z z^#(XfsxzXX&DwpE3NMOPUB^xPwpH|A@my0n48&r)s9it?WCNs+!O}9*Ii~UI15*n3 z!YQwr!H2o$@rz4xni!JV^!jl<>5;??O39!Ax+Z0E12rsE?f!-Qx*0XFv-#(_f$eK_ z14h?FPHFGZNRV7z!{MR;qaQJ*S@>kPdvqVIg^o@O<;H1W7s2sDwB_G{E>i0&C-h9&sP>YFk|J;jT8kDf5nw)-*77CCmT zA?vqtyAKBu=9^|P_e+6$CFeonaW;Ine_MVUzzd$DRU~~%bS4QLYM?v{1cv7!qu|Ec zpEZ77OlqpCsTcKbeF&B(JNONa({}JULI!rIDzf7eGfYz!V@?H=mXGIEvP8(Qz_M1T z?KQ<@?sO~k3yHDs4YBJz7v>EfMyU^LyXTrf-1>%wt}Z__nGNhDar+4O}TPs!jLhXw%xjWRjn{KhXZ%4&Xw5IzT&a4 zmvqftGJq#wUr2H$u>{@-M2sL*u`i$3g(*BT75-Q_&QNKY*o&hN&BXX%C?eApB$yR{w$!D@0OWwpAQ zRJtX7#vVN6!!$GZeF~x1bCly>qD5U;Ttk_@-1dlvpVU*idQHjlGhi#X+L* z5TzwT)>3eI`fQoeefPIz8~N1td#kl^7~K%1V>>L=P|Z(Oa}w93JroW-?@W3YIOTAW zy#;mLA#*mY`;m?P7yZ%NC$Fg557{W(&f01J7oE4){gQx*qipS6ue9u!mQ1CMhUY2f zcP7Ul_3G@jQD;!I{janb*#@=-ynmpjG-Uciu-5Xi4;!*4Y>dMW1|c7bAk~M2rk1OT zVBDA190xz+J#PPN0D8F;I)?=Dy+=I4#;Z{i>}E78n?y)qH{Y-s!5kDep#T|-(4wv* z8qeN3p|03x2v;^Pe-jiCS>*=01R_%W2bDStl`@H*DI<%HbbF3N?R3=kOKMsCyh-Zt zzfdFpqxUMOW1fc6e>u@U^I>ljB`cjA2Rj=kRl{2{#A z$V=|HT{fm|YCreW1nZWo1vTl(jN*b&!0mD5LegzWwM?s=<c-0H}?y=HC6Uljtx~dgPcLyvjA46KMWLFT4HsMgj zT|yYb%=UzDGH-W=V9MOlo8wBoHZ_i$Kqj!&Pl!GIO{^?Ftyz-UCldOmF!c3#umitb z2&_yu)q%*h2^`rAaiPUyo_nSlfrT8y+a+YiFt(osCM%BaVcn7F&fs%0c_GXh#y(r?w|wRx8=($>q1vMcunUp<;LAr@NQS#U;2C z6P7zjPB_=~mI>a9p?8=k0iBsy)@LhDQ)aS`vA+pZyR$t@mLkYFVb|&Pm+x5=G#hJZ zltqk%d1@T9I^LzopW#}ETc4K6@KJ#;CCcsOmG9Y|JIif2Y6r!y*|y1!0qcG*3|+ z>~6sa5~=O3B?TnW36hRyyvx4Wm1T3Jtdt)FUaxycPQ^)uZ+4|%g_%h=26+mjv2(-+ z@LjFD!3EwcDItg5pNwXq6CEIQ&ShBUEY4SDEaH6tm|a=uV;KZ7=CBdnrVrF}rY)T;U1m{OMcQ1qQ9sQyzEft5Sg zyL;kRi|an`>sFM}o9mXOMZWKjImH&Z&k!cM#aCr1yyHHUZ`m9doo8mWBKoD(?{RJO z?6HF**+fh|{N(WUezTa;%CLKp%*XCS-bzrDiA-=^0xg!E=9Hz#4(9$*k;e^zH@B#{ zzk()j*14?c?lBA5U(gnw?&fq(sW0>EV@uO{WLLPjYpzU{ zDBs`7L3}bP_JLsEW_S*Fak|*gOp8@Nw-PxL;V~axyx|Xhz5B_I%z?)QO4B-9o{rP> zV-XNaa!h?IF>5KE+?_7730HC!Xmxc8F208}ew`lVQ(pQc+P5xKCKUCU2J#o{IL|(h z>iY$k(=Q9HJ}n$vEgh%f8ajME!Nha}@o9?k>WobrFUP+2#hG=0qSPA97sZvbbCUl- zEGbFU85CSTcDaKZaN9cX12m+gO&w_pnFl^chD=cWA16ROR^rF(WV=gTN`rBfDo9s0 zG0Qu&c|y`fZS;jor<1T*K@EU7bx!_NhbB#4Qo?kvA;5`Yxs+XN@9mepY+C%{~8q zIeczJy#C0=?FFO3l50Z6OGw3Kgx}R)04R#5b6}- zmPQV#T8-1niUhIQegz4R4sbPZK|fP_5n^x~-7Q3Ej8@MX3&#cBBd;EQ2;DQ8c)P=& zyweW5v^e5B6rMFY`MI;#Ku?i3*#9vYWql9+XU`iyJyor{>%SuQRDPh!(|GjFDz9Cg zXFCuXnn$Jm(hzsxmq#-aV}QtMEU&^2*v`6iMP?W-$3>-w z8=X?hKRZfK@91~!14Py{0!dx+*DH~FQ+1#PGHrjKl+Jw%Y+YTA!`|3#+phMoyM#1m zu$C5gB6O-ohNr}ruU24x9|KS5MxY#!{xgxE{*tA~ z?NdAGf>og}Z7`|=VtAbG$Y-b@cIm&u7F#7Lor!!f|H&Xxi^k>RKkvml7`1CR|d=-Y7f6?<{I@CzJ0n;+y3QVuCI4GwhY!mFlQoE_6T6#|MF!d|bi-eJWx zEp}(-S1zl+FDMgdaT@BmarkybXLbsnuW~u>PGjrXn8Bo;EDf88%7yIE=D6kj5-D1C zds`=@xy$io|A zvc`on6(>7W=bkKjBuS#_=Oe zv(|fzPT`lUq~d9#ORIdR6F}qaK_au1B2qST&fDV&pL{>)88qU$JgkCS+3YCTILpse zyRLQ3HGavgQ$IBgbtWmAUS(EaP7&;E@IXlw}fUwKJ?i*??}Wds__i}6)E^GQ^(fLAueQ6V8^F+$b(e>Ab2 z5)NQa1lK4eHAS? z0f|D`eA@4K0)k@!cfc<%{9pWXO#f9||8YPVe^grsk~8lVv9Ck&OvEQ(x*x5p-HTtn zdi9$w|MsC?$yboZH=0fhau&J73Ui=-VE&(IBr)FmRchwX#qU{}|Byh}G|$t_{QEQi zCkwyM%=})?82<{&gRJ!f9;u8U;dm^N%)mBEW4;V{!6uj!We!}56VMUg8 zTlX=axoAPoEKT*#$)CQ#uPS;`6?(ti-rC{rKjZ=edO;;k~o2-3RZ1Psd|u@h{0rhJeH68EgyT&`5gx6%?VJ`xP__K7eo{ z_HgrLWg$<1|LO$*wMYPUFW;gtSnckl6R6pD3y^I>)b=XU4Q@E3@B-k%BcSDCR0huo z(~>$rG_}s8oL^BOcsJyR(mPwL;tgL4#bn~@egj3S04_=Q+q$);>7{6pf$_} z!Wse9!kYrZVD^xpi~oy+mU)7J!isC+&sS^=a!H*UUTq9 z+%b}OXp`G{_GTCm>7%YODE42c+&__o0;WGS(&a=##@NKz)!~a+Gb3xcyGpRI>|IRQ z;t2B7YLlhc1YflLmgb?zy`%rMDf*>@fxIPLyLuoWyq=%#l9cEhVk1-WCr{_Pb3TRO zf(b0Q3!ZD}7}1wk&8AA|c(qo%~RL!0ub$aHm-i_t>yLZ@KRDLQW;0#lY~BuqM7 zTR?Dli)s{~G7xF$H*QjxAEUg4Xxj^b-3A8_E)~md3Oyz>zQk*KbWYG9KD^! z8{B&HsMk*C=>5XDuAM`PBgW@>twdNgSW2}ywacpB}VngULXetD)i-WTuXa+9k^H$)ha~z(vo#`{Bz2J5jurtEkYb+WN z1~{I(0GvACxREzl#PL$;jbPRaU`Q;<61UONqqvOYAfU@lz&+oQhxFYOD78;y`myD#xKC`XVi)JsFq!F>-ZX2pR zPCHfivcx53)iEnwkHaeZi{FY<R(6WFuZcN!&X{= zWA{Eq?ftGC!nyH!NY-49Xfu?q56VS4jd@aV^K3IN*M3~_@Sch!dMd>Ujgtph@-`edYKzj+(e@SqUWOF`F&XnyB6cL zr{NMh^CsnQs0M^6!RacHOs=Ru=%%mGFnOc_Yt0gien&sNxWMl`Y;4fcc%Cakt#-^Q zpJ!^_X9_R=@*}4A$g}5L4Asv>@@J}=Fa0)O^AaKBM6D>NIP?Atcw?y#kdbqoSuLZCwlC%;L? zcy9w}ERC6KQJ7J==j|$a>eo>1HWJM#;#W`uu@}$cbEW1%yNLevbb}PCj}U;7JS!RA}nIeO;=|TeJS5y;KDBr}hI2P|K3>VjmlSX!5TXKWM=1> zdc$Kqx63N~P!&WE9=ETcv;1E{Sb-WKV5Mma zMg*f~Q@?^pa!z%)as&{!A-hg`mGl)9kR69^siPWO*zLKQZxyZQLdUXFbSxs3V)sIN z4&J(cS5ju{eZeN)ED*9YE1RT;lj#aY9+I3}G%gFLbN_IuU>hTtK66sJLB> z6KXBl=P=F@ue`?Ac7uW=utNL77Z-3S^r+slxX6+_N3?)c#St@0BkXywT`IDFH3(w9 z0pUV0mJL}M50E4TwVdqe`$jsN?{j@o+|L+gg$~X_r3vS)bH_ep5$tqw*JjVAl|%-l z%5;YBs+C?s=Cq^9?9LzVAS0a}iE3`nq-lVR&ZIgJNWUu!DxUu=?r)vCTNc^{A zq!1{&+|389V|i<<#+Z7=6u1t9f3KFrGSal@Y6&v0NdmnT1Kxa8#Y z@S&P$NB911fO@p(xs=+<0hMZ@jOFU%m*l;>ury?R@(9Xw;gn_gvb6;xe7Do{KwxG3 zME^eQdjGRfJvW_qz`UseUesPXfdAb#%Zu92+4{#W_XC=+hsrZCK(&21un<`$L*dJJ z2gCsSt>1*!%Gp9#E;6rAhrDM!-YaOAB@@`5v1jBi){M|E)~oZAtbZtetDrM=N8n7- z7a(Vd4sX|MMP^;5@EE6WyAU~?8;FVq)`fKb!3MB9q}ywc943Ltii?+Z@C8FJbyu?grs_ZkE^*jvXkWL#vT_!0(vR zstNzVUH&wgZA#wXd_?OYpkPwCOFBr)R>YF|#Xmb^GaeRlx!QApuDv%4Hu8++)0 z>(O1f*91dZFM@};fcN^+sklAg_Ah6;+f#;TY>A<=hOyr^IY#Xegd;AvrZq5;zbyFv z+Tf5tG>1!g!AL4GtQnlV!!(n`SWoHJi9_HQe=ehEj#<#u%T(X=^XA*E zX-3DMW?|i&2ZdG*9#=eSi)H7`R?9keod|hk=zv4PBX1GBjlr+wO5eJFxUh4!cAB_0 z+MNt7nTJzv?_E&~xO#WbN6(ykr4apCZw->aT1{kF{=<&ja>#pdjsNlAXVh+kUMtoU z=3Fja0Lj(9%H#wIDnjxQ_A@W#3h@(FRvw4+7L`4FD4RWrn19+7NsH4miJ1=e;tE$0 z0cX6{BVu~$eljt0XB|Gh$XLWpbn&gr`zMX!$URqAYDN0`+^$4K4Ps zj}{U>+$raoja1WsXohzHQ?suNdX>uR!^}m=sn7^jnY&0W1z@JW!K62J@s$%48s~EI za!EmiVh5R7FejdMo`)-cA07l8>vpa9D~Q>G`EI68-g^2AMn_FM>IDHT zFd=_#$siQz6#Cw1u|{4|OexF>gUP~K2#H-6VJ&ejuP!hPxGlbuBIek7gPmvp9DvhexX( zopYe3SOvWnFQ<*%^Srk>d5mP5Rjz}8xt!#Wu7LA`QAtby6>@j0YrL<2({4DWi$&DN z_1!)EKX1CiMMb!1_Ex_oYq_rliDVmRq!B%)I{an>pfhmgI_^g8L8jGx%5vG;I`H&qnP{DNr95Qh^ zUa8NLB=h8a2vSyMOymt6%{3rEgi-<`$5Z1%-Db`DDRuEGnXBMc8}x138rvNj9}XZQ z&yyqcUHC+;J^Ib^{C6Sx{Ql|CAQPPbOUqd^#s2)ykE(7skKCa;(0FqIh(MX)+FC`O zZ?=?fTuC*f>T>G-mE}?$tDeNGkse<`n*6Za zA=}$ENNc!W@83uK=fZ!P1b_YB|B*>hdKg$u)Fqf%!PmiEc?Y%KWOpDYxz3wpA^oO+ zXQ)UIfU(ub(3|IvWqf1cj)(|EyP!-nZt&Gqd5xSIz4?h-t~*`L{XF{2t*TT9*?vLW zd;0pLBMNi+-5lrNScNwR5sd~FtCf<~L~foa$xspuVxkiYD`KbzQFWx#<~Tmgk-n7( zIw6t0n6ntsUeJ~~B2{oSyC{n{vEHP3Nw?}Z|H^-T$n-NpK8_}45C^|A8)gG)Qop*- ze?1oePT2s!-_;3&qwsB5@XzG|rz98msDFUwn%N~tvjj1DctOum?#S|sf<3IB=`6ygf^CzDvc1T-rvr% zg1O%;x{!Mvo$Y?g{74o;q9^?(Ie*Y{*p-!h6M%3rgRtXbhX!gn7SvAz=)HOAip((- zQ0lQ*O7e^IGKZgdem)F9^Goy`x%^;2X+i846#;$IQ1{a#&c_z9*iMxqXZV-k##gjK zi3%`hS8cYL$pFVhDoN+^!ibd#mc1u7X_Pbk;oTElQLWCqSk4TOu0$ch)GBdbvd-A~ z>*XD@_JDhu--~>9(fwLYVqaq`nT`A9r|^thpMyL=r(bkK6N3MfTD!>~V1B*dcmY2A z=p`sedDLy(1(c1^M_^mLfKx!2^op(SZ$1E8!0J70O~ge4i#}zdR&5kI?diL~Y4^*h z4uK)msy{h2q#Pau-%#F8+J6N2tY`9BW>`oOHKycY)B<67zS|$Raql^pNK)S0obD#Q zGN2;Y(bpmf_P}*nfN*_uGa7BNJVM+lZ~(Iq?3JUiwV3A%e0NUqmmAD1Rdg@vRQkUp zNu(*`;TDz88TgMgj0xel_2;*84Q{rOIr`F^(Iw-OMxwC%8teZT%9=5}?ClyK%+cVZQ zGvJbOhFmOhx_ZgcQ6~yws-=%sBdo8!>v&zf zZ*sbZ7xfA?Qw2D8XWXgG4)3;ZnhVChR4aYV-lwpqK$fc8`28M4<=O~zYUa;3COQ%I zRLX^=MN+e)JLYUmbe-lm!Gs%3o87C_)@KMA$`ukDvxOU&rF;OlTDVc`a`1L_7S6b+ z%@5U&Hq<@P98Nl*(d_;_vBWzdwk-c>UWHNQ!tRB%23S0LUK?iWmKk{$lgH+tAb7Vu zXDmDB5ZS6OLH{6O?VajP!(tPz=LI*=6uh7OGtlK zq1q6FEJG8nO#T7I{ad*dTOt*Z46!YzMwZ>324(TKAT!O2nW2NLL%+LO0%0P8~Z zb&YTV5b{{Q!r~|A1VF1(m{TotT!qWOg3HtxX5nE(uSk}}O98B6hLTD5Dx+njY%wR69UZ90XmtW?d3q9pqDlDe(}N>PY7&xlld8dx{TOJ7fRVF(BUH zD>c(iq(IG%K}ZG=Tn54g;1v@l#RGHD%M>!>dMIq+CqTO028DOv09a+DZ7r<@H=nva zenDG>%%}1=tTeqOL8f=cj!Zn5>)C0cXK~!urv@F1Y#Oj9@#0%bs*64)uLkl8t?rbc z0I~7==U*t##^zK2pDQ!d^c8gJmygPyCo}Gbf=PhnlNFdORFy)!JS5%J@e8}Ra95+!moDvz+uYJp+&w(v z#4tb)rXH#dz#Wcqd*{rq-0#4Oh%Y}Q!0YC1DfMFM2(|aJu4G-nmL>HE^3cHQvyUFH z7!(=bbJ|F4Go|DZLgjl9b*q+lhCa3*k-g%nLV=;GyZ5^tPWWO!ftw5U+fvLgkC&8A zia&l&TXk*LGpW*5Lz3m?6&QVoJy&pMo8!3Xk{kiu>0cT-33Fz9+Jx0kFHl! zI7js?Hys5)RYf6+Z2K8$&xSrd>y=~rNV+kEX(AsQM3=3;s(<9q3HTeeAvf#^r{>&G zTUbm3Hm^Bmbf@#-rKXVDC#0OvWC_x7d)Ud65*%Reidn4g8((65)CRvy)@5)98+dmg9hmt)gu^+rUk z_#w3xH-7XQH9kMC(tHt^!Zz1~C0{v0j-wx$j$WJ%Z(!Y)@=hW-=vME~+)3l~Z?YJE zu=Bx%*G69E&eZ%@5T_OzO6bp0c!V3-VMZ2CC~?q*s+R-MSes_fd^e@phIyiN&*~F{ z<_RFfZ}?_S9ez-3bKdjHo|qcfQ^$gQtTm7kxN>@8lCTuFw^<*Dh|37QBBg_|6%Vfh z@0?t>CON1gU%(%04@cp-lC96CXE<02A=*uxC!ue{EU+>+CR9}KERE>zg?+@=B4xQT z&91)H(Qyfb#TA>UV`mUVFIjXx6k;IfgxhV}xX}>x>~T=|!R*~!n3&jhThnr8KADT) zuBaoD7j!QIRvpOXKbKxxPCz;^O*Tz}J7^DU76ghY?1tZXPa41|8JvCo>fSdH-!ug5 zcd9$qyXJ`;b%lr!3{bt|!LHyNa7_<3FFEBteY?vi*G3>SH6siXuR&QYpe84_gBiJI z+ky02NMo%v?v|Q(s5CU(OK)HP@XUL9O0_8pu}zfM8JB98>8&98$&pLqoE~BHD9{mf zJc*9s(@Zxw^2oMKfw%d{cLG#zeZ>gJo5=$>#C|Ev@Bk0;%D=D zOdfX1+xk(lJ{qZR!j?53cdFlYH8%^>sb;aQxM<5RdicI*&?VNU6N7UQrdn=`T53Q| z^0rsYR8???MZo9RBH?cyd9<=R=C1pq7)nsggy?0}A>CoBXT~0KT-~ucMh?6<;0f&_ zXyc`{@zyV_ipP!fJg&Ct9J;r%7v-mLUyT~(`7b)}9R0SPdlwe=HsU%}gzD+jvb-MD zym7yTm5Sm0Uu-iDk~DM7FBd$`w>}#!f~wSsI=BpHbxyjc3UARZO<`vaoZEQtgnvKn z1-zf>cRQ$(&i2pt*Rm}vURZSrpNA>feE{5IQRs9s{o;n% zGNvDOQ_QoWI(%+U^<)A-q(r@$FTUf`H)6mqKd6Cte|u-$^8iN!7@y#IeYN_7J2Eir znVaY9YfB==)hx%Z0TnbPix&h)R$B(?mZI@BmZ3tutko)i2$2F3Yzw2>zP1IpL|+`s zpd=2dILMUQ0PCXbJa}}5#o`FjG4R}X1>b+{&@T}RNUjWQur8V5b-uMpEO=jVHna!R zQp-~ts*ab>Lmm03Enaln{~+2mc3*19J#+?s!h#sNNYu(XKHev9Y!r0$suzVst7P~@(H80y!5%)4q}ErWW3?6` zD!}`wp!npGuFC@<+ckQFHFAuaoTeK7w|a#gq`dcYbab`YmObBq?fdcBl3iIRUc3W* ziPXDV?~8LqF;v&M<}+qA91`wxGTf>eSOc%+Ju=fV%|C1-)2-H8D|)MP$iZ0dV_8g* zhm4_u^^z*WK9YhhE6YjwyZpz8FAe)+**6pP4&VHarIg|jY8Y$qham^nUO zSLeoMrsDHQ!8_linvf|O59HDpqoYp-$ypw~;e8MV0)K%&T^zb+R%x8(!$YTcBkb*0 zkTDebtYy0^NM?t8@jd#8Hxj`sZH`+U1vV*i2JSCC@{;E~crjc2XGhLU#8 z03;+Il_!GQ?%qyUBUg}1I2G>w)iGo;>0TG_%l&*XN7RgmRZl8MECcE-_YF{4By$xs zfO&pXa{v1f{prGm@kwGa0L0d9n{DSfp_clWH7}%T{P-LHHva$m;^(#3!FhiJuuIy? zCSkhiu5kn+ia>}t*d#4y6#=rt=U~fmfYnr-WDBsX!F*t|Dm`^85Ng0`kBcs~=!S}* z+LM7Xg)ahz{%r2JJy|-ETnV1Fctrr#-`uRQsjGhnja z0TUPMy2=e0$Tvrv4v=y{#OhI^V`b;gch$!~^_y}W>z0z1e^%Sc8v%suPc9GQ-Ipa-KudTb%aP09 zi^cnO+bIVlKPd0K&Af2*_rBe4&;Jn2oy0;M03JrI;HN{ufAtIgYrnw%{VQMo3L5O# zf_1+B3R;>aLcaW>y^|Z*p8H4l#U5rR!{bs9Q|WS-p0hYu$KjHs z=eReOr~vh5EqtVzJLPSKTe0#ITVrqCPv^|TLlPNc)bK~011Cf*h3l0979!8JLE~S6 zo5i#VviMVzjTrick!s&7A2KF6#&6L-p@yx5QTK$}nb$Rf1BS@VK^TB%egcm*Gm9E3cwYtBNe{wu#?6^tz#YpO<2bXDp5=Ie}%*q<3>k ziDNrF8*%kmu8b_F#lo^%fYn>2)wz(TM(h!a!y@mu4>_Py^43mQdh(aWNhF6^De*k) zY#N{&$}x{CO?s!Jgv=Umv9M(Qpd|1RNu9OB5to;3KH~o3(b=60C#JmOCl`71Jh!+q zhV9HtvvSOcXMJKu62`PjdxMH2N~wEXlOA=Tqo8L9E!Ae&Sm6{cm2=u1CBc;Nx|8GuWsbawON~nyFcxx< zf54=6@2Gdt<_Gbfz`t6T@&n=3A017TzZvne@#Jb=U=0`XNBH`p?l(vsh*tC^w0s5e zq91$(l|qP6$v?o?(MeDMmgtb{fi2?&eg|H!`HrdYMb23Jr}iOih!M&ALg`+b53kXm zJG#8RFp0bHSL-GSm+|x;luA*@m&FCFkA!uY*`9Aa4|8GNnGaI~jLWjxV~AUYeU?d0 zuAe$b8;wMC^_6V`)h6U+DrOm4m3H#hy&-gh#qp-Ni6XmFTty~V_ zBak_hOi=?OVV&}_)ZCa_0f9{8)31WOPRODWTH1FzZ=MGvioNd{7>w$SD%m^PGF8(B zRTq|P-dj_nd{w}usP=3#R&w#iNzOZ-XB!O8N8<=Ic;&008lk&Vu2O@#{S zqkDSTq?Z?~;WPYI1s#Q@0eUxPpL_&G=y4Y6%nbiWwcBuyIL1;gmYTuz8~*oVZ#~=% zk@i5Xr=vP+w5RxdFZ%ngJD7zf518Czm6-|UhU_mUZJ;#?N0L<@O}mZj8l7`sdnFHc zo@oaX+D%D0L*F-SunB{8zWK@b4Iy*4VBU0aMvF`FNc+3Ke#e|dPLo&z2`LYJMwjD! z1TQ_Q2nSC!YY%<}fgSW@)arEwM)eg=dv%@T18sx^FnMxTKw`wUQBC7o-Rd~zz#R-- z`@^EZBOcNz?|yoyV5RWo6B3Tw)hrqy{q(M;q}h&D5bO02d~U&0hi)`{&)z^#RL=Hf z1lxU`4sMZ44{dB*xTXRZAH@j-_=I&vv?@`AdsBIPx9=X(Ryo$Ie~Z^oBU(i9SP&}* z2bV(mnLk==>e249EdFEnpbU=R08&#oev95`{~Aj9<*i>Uh-V=Mji3+QRe@DO9HHpf zlI+;-A0*lTm`v-pS}U@E2>bVUmmy^T=Hz?-8~stWT4tsWyX=~3OWObvRV=el^ZcTO z-WQW-C%A2i1{wWNTXrK3^^^N&UdFfH&dZBrvRn&h)~mu+q1P&^jXFm@U)CZo7hMSLcR=#M6)}BReqNkwcR@HwGH3l?z8mTV ze=cEtCAvfZ_NYRs#(A!407m+&m0JD{FvtV5^Wy$uZm-Jx9!QTWr9C@Su-~pUWeN)U z+?|;R_Hu_7_T9HWVZM9b`dFb$X{7S7+>_m~$oeh{&Z4Ayx{yO8q;YEM1jpdo{RuXs zO-sJ0_knHer};hKP)eCX-_?*#Ugw_W+FqaXqM+v9MWYU#q>-SmdEy+|q6_oAGFLsA z-^WdH{-i{N`a;e?Qjb&1U#mi-eTx~JaPDsIH;+tK=i~AEY5qeHa*!({LM@B0_C6l< zVqMx4YgVGvlNCwVK)Ly)6}l9v-oZZ*2|w>#*Swo3ioY_Fx}eb!Fy-m8F#~Z>$eN8@ zQbMPYnF%u0r>9x5mDekSKX0xnJm*DZ0l8C?2i+cUu@f4Ao0QRF zr&269J%jU8*J|*Udp_(M1sx~Ultc)(mnLZ!qC;YH%{VGrB{08Pg(+O$r3V*JLv1*HwnUr>GKGs>9bWu0UgNn zf>=8F2QxhL_txvJ2`8j5Z%D?tSGByji1E+OMz#Gq9|KYZ@!^}9yHnyMYR=^@cM*az zoZeZ4xnX2|RRROEW| zk;l-W8U;-9iYn4z8V$(v3clCNyMX7Fl8rdbtwOhDyacTQKmIPJQ9X%OXyJr4Ng{~u zG4`CTC1+mUV>@=Sh;-Z4$Pu3Ij20(^;}z6!T}jZSw6QkZJjFCd`J1$Wg~PxV%Netn zDDa8Qi@4WM63yt&SaiBP28b%l(S1t^Z6(9# z^kn6*5<1~IC;e`7d*5$soNNq?mB&) z3QE!*CK@Ij4p05OI8+~S@sXmsjLln$BzJ)or0^YY#lB}-%MWiczfV1%Sbi7OUB_gV zH(2@2!pQ!CzAE`w3NAm^`~k65#!Q`m>Y(&_%N)IAmn$7gVc@-4!Z8#j!-9xKr@Iuv zRaLz)dZeV1CGz&G*l#{RHIFvjX{a|}^&j6_pnclI#-Yx_a&m@}I^} z9&*2htqui(;UXJq1ythSO@7`zKdZlbX!X7wgcGMQdq?08yVm9u)|3ob@>CU81Y##- zUq$l+OX&b~_6pk4fn9NJCI4}GS(x$J7fk}-#{x@L0;2}1-Mf zR2f}Xz1pWzwfs6SZ|3`&1;(J{hBQkbQF21sGXcV4!h-os3Rp8?>%1$YNHul|3QF$u=kyEOh~6_oahh?S2lGe*nam1FwGFU#P2q!15!Qf7r4WcJI~{c3f4{+m%I7usH6)Y0rfXdpkXJ_e0MtwB2NlOmS0tnVKlZ)@ ztch%GI0}k@fFNBV2nZrg5Kw6mlqNz%no?CzN-EVLEdCv2MGjnE!nfILY_CkE-IBS_>+4jYO1si+yCd4r;J5SIk zV!lofa=YX8O_vciypIGk2Nx|1+hWjCC{i$?u0n!whWeGF2e^A@$K`$RGg&i%oZSci z%4kVQPQKgnpvaS(u~CFS30%kNF^at(i5qPfxbOMfvi>A-J%CM%z@G7PkL6`YTp0dY zOB^}1srtG$q6ozD5S-L?X*F(Z_Zwk^@Vekx$y zIicq6gY!4xe$af#xv@FeM~LqrMYtr&u^>(fJh!dj+c5m#4N$ZSVc~36+td9HPFHl2 z$76KUN;U@a0rP?`v~1)qPEdRtI~0(a&ie>LF<*2({nf0+v(-)gA+rY-mr3nY?Kx(n zYA+0r8#$gphntR6n-XX~txarX+j4LZX0q(mY=vsAUuY&^ksl$eDl{YIG!*Vn5EH+7 zuCM=i5METuppX4z=6l-JOGK5A{l7ao7FLiv_}M!n&xDmUdssI0`2RCbB(J`vJxRqRlOd0(;KS;VK9+P3RfUrW8Qq~{Vn=_x?H+I~1v)CF zi>4a6fXv=NovhN=xZx>Fh`aFY)>y~s5Ok34W%X97RjFG*6k9LcZS_&d+Nq4Y9v^Q= z_NBbN&x9Cd(wh*Q#j76VX~)vUu_Y!;S#t66S5ObAzA(q%0g>Z@ITmj)@}R5{!^I~A z#jbEZzik(GBxfeA&zl|XO}h!TA75?uXQb=QhKUIibKksI7|G-pMO)!%O?37#8J%GL zG~&4E*;L~$pq8!1npAtFRaCz_{!=@EvaGN`$Cmq>vhc$13>kW;=;z^)y3bswwTQ{%eFErusu>Sk8qqmy zQEy#79ec8j_90m5y+|lkxue$7%aT(|dM{)fhk9~*PpH!IfGS^M{LTB5kP#0_jAtt& z)}oO5G6)#k5}7mu5#kOZ*w3;36--^{cz4>G1GDJX&2ujHXQouPj>uwRA0zQJ3YI<= z8>D_9pX{wK!fW-COzd$30)=j(m1{I0z5<;E?e{4gDCyFlxw5ji1VDi*P;ZwKeY4=S zMyXZ_{TxqEoz>*qFAI%kjM^q~G8lo<8RE{gtIaCpDWAG_FXs+^AVN}13`0Lf2-1JK zPkSHJ;Sd+jSFHPj9~`jlu7>+qKQPK=WNhKNK00H?*WX`d5p-g!Au;;S`Sa7w&QXFW z-OxCoZ~wlC+obNJaxmLRM>JT(a%vGooI0Ih55+*{s|tQL}iAi zcQPCl;Gz_JY8H3@mmAaL&Igx5n|&P>%o3{7xXUTDuRtbVUR-uge6<15Scc%)UYV>B zXUlEBqeeaam?s{*{GQ1UqTJ$uNVfyK7M-*l10U6#&g3M1a5?;Xz^1_wQAF~TSaVlN zi6`y+u>T>Y>!&)HnSBpjI|D)@qdi4zS==a9d;|}9$L>=(4C0)fy6r!BXxM{_*-w)B zRGBIsh^Q82;}wH~dLUQr4k??17y5TV_%0LBb|!;9!GO_4GO1AnvF_CJk%UpmKt7Ie zUjriHVsj1*Ts_G6q*|Q1v~~Q1LKVEw5=(&>3c2cvFzK$dkV&$&(L6meZ*`2Wd@{{~ zqYm;688{wrZD}D#wX%0c=&XD5jdA5bIG^r`ddBFH0h3g(><$wHf~d^8L?+ywl9(lM zl@n);hNEn|lxb>;t6;1UG2`6xtwxMLE^&r;A6BNV=x$<_pMY9#LDEr;v$rxA>Jdey zNsBYie|T$lMpvQ6vhEY`QIpl;(~}ol7u1{-N3JT@AH8eZvQ)`}Zf3ztRQ5kRUP>*_ z_F>vy^}TCse;OvT;#p!aTSH&;h^GuHN}511@wh>~Gnb>n+qTuzNIaSRn`-sVcb;Tm^>N(~cdVo=1env5{Jd!xAidQWq?PAyy8$aE<9}mhr@+T zct#~UbKGcw)CsS}%yrMB&sM#$m9JLQDBu(|=erq8uvk-hSUhjs!S#p7vx>uHbx>pvgdTt8tZCmhyqm+ufQ^^5>x;C zIUrkKu)S)1g3lmLgdN4H!21T)L@8o&Vw{tuPlk?~uAzazQpT2v6)y5ht$zQIGoq(4 zNurbactAnSC>*b<)!;rGDgaDg51Q84^ni;j3j!sWY!uqQ(zD;CFUF7o&uRbOUhY z^Q5}`<;Mk^>ZZ@)RUlK`-#Y~ImDL9f!`<~e))vvS88Ltp-D_5fJag76>-B4vYn+Qp zSh6LPh$tY0n2@SNcS;T4`y46jGylN`Qs;Q58Hg*6Bt*HpbcDI!$u?10(7}B=TeWo7#!GOuB3qO>7h7i026yEG5t_)6yPDJ}tveB^s zMt-t_vf#LF2^Jil4jxeC)Iz000HB!_k1AQ=cVD`0+@MfFB(cKFU{$F=OWOUS98vC9 zTDFL)9AT+~ockyD^}zR&-Ynf0qRB|z!XpYD)ns5E&^$-sG6!)b;2LtNPY)nAq+w)7 zar+0|Pk-_FqBXe8Jwe!#U3|0 zEJtZfMJ}1d;4-b4sQl@_|7>vi#_($F09{Mm?$rls8X{(|BDO8JznEfWlsdkiyI;Wc zGrWGkbMx(1(`u>^+^!__lPNZ?U^m{RBV2a|PXEakyK5Ny3v--ngG(3BzQ4Gw;bi>T z7<(mI^@kUV>Q?3K&-HlB=QoE6u)$o*$uJn* z?E|Uxj@&yS7Uw5`t#%1MRh^~@L2tX`3V2sCXfE%70@nc#PF*E9;ISH+@uoQJ=PCQ% z&grjWgg)D2|B7iEfM_8MmxxNuDFr6(Q}-+5tN+R(Z(AymSnI1T^!rQVH`b3zAUp$_ zE=PbF$8>z^iZ5;(0*(O)8(bE=5DG{@8ju0N0_*m@U(bPpr$aY9zD}-16{{f_`=c-T zr@rPt^x`iT*KdP`QkmayGXDWoQ;Z|D!?F{af$AvJ=0?Kv!RMxAR#}o*0*w=r<3GSO zOfc55fFKr<@qxwp5nNK(?ZUy|y#+Rjpuv)Ntv(;mYmw-f`?G>1~a)Rc|Uvx#Y$H1^8L28(ctPe z9q6l!!;r_K0`Gi!bDqj=KBZ%--pVPQk ziT&d>eRuYucwufx)!?Z-b$L@|m8VOrrfycv~PC+^7en}(`WLV}r)hy$F^a(C?C1YnU^7%{o0&BPW0?f|%^Wo~= zJ4C(0)Vh=$lBep>Ks>>BxVE4mc0*{a?;VRT{LR^@$t3a2VO}?iYAfo*(Q?KPkr1dF zN#6R(p)v5B?_~ZAS-uOXjCOzVJJ3N;8P&oq(3yiEBoBHb-dMQQV|D7`fcVV1N^yU^ zDY2}I$?afDM$X2P3q~6L$Pp)DhI7z@;!s{2eoe_Xs$;bJ9t1wii~bsFfDf{+qL)JZ z0`ji>z`L-PEDz}#x)Tzkd5dl(4BZ0Am|qXlWF|g6nH;?295XA3ESD zl3}ECA#6;kHT&3klBYhbdD*tzCqsN+~N-^>Bm1g8<_ZRV&=^RBdAOarBzd(}Byp~{SJKM9Fh(xM)wN9hlAX=7!PJtFOzO>*=&FwxP^-56GE{Dknj3W#Qo^{Ec zn4GSb%_(6=i9YtWGF9>#IH~`FZex;)xfhM7T4p=ZnJo=|7#eJ1F!WO832YR8wCrh>z}JK?mrOL70Zr%kCVSV1f6qIcz+oFWgeGP-zgmq)CZIj4sXN(ds|1UMbM<2()1PROwYU3qin;vuGG5+{-2I=1X3X%91V%D^V7 zM;xpc9BR^s_Te*1AQK(w@ViP5wWKdF2h+v8_F(mwI$c)|Vsft&%m)%V?vj71Vfb+Y zF`FAGkC5qJ@n}0!2DgkY2lb#!;TF;=~94({8$A^c}jJ2073Yqi{0Cd6+RK z-rrd+{m9#~?WEdwWbG`2K+Pa%1=&%wy$wuLy_3swS;5c)0iKr@zvcX#ajmg71&Dvq z&8&u}^dybd-;8?#UOMhGG1loQ6U*B(TH0x%Vm_YMCKZ4tm9jw1l(4jh&zbAaKaIdCIF34Rt`!0=gTi=oFU1uQ~A>fj*;e59wG)cRjoy{)P z4Urb$x*3ssdjvvl8@2c@w=J7EpLM*M|F!a3&=TaV&d?H2l%v!$gSj(1pSh@`{i6@- z$5UiTh+Q#;bimI6URmnig`>}VqSiI;v!V=*I2H2jm3Yzi$BiiwYr*;5ni^!9XyZ|C zP0e7=CIxZB7{xm-n3ateL$Bt0x>MAFwi`w_#3-Pxe#1+G{@!yt`#VP1=C>EyOq#=e z=LzV_v8lBsqJ{+-nWSz4P5jHNRqdOId#-UG5WIA~q-WhX)dL)DTdlP3FyI?S+?|+y zoVX(1geUh_T<2`oaRY+o4E7Oq53EF@+NBD1rctv3_1g2*k2U4x|wSjlSg5FR=-sDqIxPT7KzmTVE2A$EQR zYQ)U^kp_>|msA$)=ftZk-`%#VBxSo8fFqJg)oM&Z8^z=n1crw-;ckqJC&3?WF^Y$d zl|axOjOms2mMnV=F2lzZB!{)6U9-c|qmteGwm8#HrD_ zRYy++TnT%>-`QwUrRtUauwU)c!JLO=9wpo;{05e`__r>I2!~F-Q;c~m=GcAdk$59! zPaGxqy;qY>hS@(xtzErBka4IV4uVZV_B)ETi<0OMN^B`c^N%{@YEeK6V$te-rOxhP z3G~sCh3CUCwq>$jE5h)j0|moDK!K);l7X#NS`1kkg6v^4-pzA?&h1H8^P=Xv@dFl; za8&DyL$7LYYkOFK5u;SO@0|<3)WPCMH;^8us!GQidLHz>=hW*EOCGjJoJXX=4hRH@ zxTCOfC|a^e9nk%}2b_&vD0V<7!DV*r2^~(r@y7u0o+~4Sqa(JCKcreeKgBs`-g3RI zt)0zN#9N0h_9k=Cm4fqiw``gGN1qGu^-C@_(brS@sJ7Nz!YjwOp{$SgAEog$?2?VU zp5f0=%Xo+-4~cLzUy@OJQxLXMF}+^McCw^SlcI7iZW}c{G}{H_m#r;lkZzdK93oEa zoqHCxb;3lR>`llIgBbNTFJ9>{(8bp!R9$t)W>a_Sv?gK1P z%c_!NeoA6a=9;nR+t?l$Mg?;}et$Dec;xB&D$_bklHf||6K5hAhHDub%VL~!Jd}Lw zy~LC*pm)zF0S0F^Ctq1X3B6vSEZ#2&%yh`VowI6GzK+dj^=Mu7T zKI6n)6piOVtel_%_v2mhkaf$S12tX3h7zl&3yVldUg~d+mZE=7L$Vfwrd|&WL%hrOjJjYR5{&H6<8ZkHU;(n3h!5Z#j_9>WZR~!w7Ey zqqr9`mr{DhLzkD>KF!%ye)B6J`dxhqT179=rVtz5X<~6@)AlISDhF0(yC0aeW^qn5 z`zQ&$5nF4^OwNUqjzxrl_LMjl+=As4r?(nVR&5|uF*W|eR+(Mk(Y0wU$y{%&&|Hd@ zHb?Uy-n-o`I7$VuD7kl)Q>GQ2ml*Z&x9ydSkQC?$sqMk^l)SA(3PqWfL_3|6D1j$i z#lZgCP-J}>FsZm)BtL3Ivtgf;GPdwi?gIFIF%fQO zMlEDB4j~;8zkAEB#!USM*0h~>%?w|&Z@TN;xe#J>f34Y3*>dai?nU5 zb{3JFnI+x;Y6$a=SuzwUupH zv*2MDGz&R!)Z&q3xo|MrW9hbFYH~K5R6uRx4aJHEr15zAz|$QNF<8;7uQUKFi9Qq2 z+0k3-MbGK*fzU1;JmIgl&;a)cNW3&ZRJ~ZlI|?V&HY))5xeLsqS2J^3oFZ)@u1K1a zrP9aP3sxnwS30=Hy;1x%eG=1}E8)~ zxSn;JZn*S-Q50dDc+gGk%*mTMTeJq*a~ac5n=ox!8! zxN-(}(bBcAKN$KYy4e<91$GP38dONNRn^;`=H-cccl5CRv-&ZH^_O~?Q-FJ@1e!yz zX}mYrLk%(*ygWTuex^3rH;Qk_s78d*<)7Ui)R>44sifgrgryi+l0B`X8fBlVq@xkVHt;AR8yS zlcp-u#I@(_4UmySH(;ZdO3TUN;8M*xB=_eXs! zdDNaYE5@SeR`C;7c6Wg!FF-AIC5?KmqJk17Zr{Eiw*H!@ZcL&K+_Ax)zl(dn($iCY zo3-$#B!&P@o%##LsqeBw{n`@wC7Geo(}ufWSxQv0P1zc?+A;(Nqz^=NjR?tlZ3ak^ zF|9Kv8}}-N<;QCo75EYhrdOB*k*zR3Vw9MZy55=fg4^;+9+0Gh8m9T^12g!e*dbB( z9-mD_4T1m&6ea1e7mvg*NO&H6{f7EOZ!rb}i1*lZTZsWGv3wq0X~Pdql;BBD(0>|6 zHNZ?JBhfs19`g|S9BZ`Xpu05iE@ZkzKE>$y$&(&7vhJ-dmS}(RNY3{I^yf~^s6HJ| zre!XgZ;iF^kH4u%6y)~JKn@l%ym-Vm#wtLro&7ms`Lm3k@R`YgSxsl~l8v{hl5lO@ zbjZ6$!|&8hl!XTb2r&}pMO@YT}zGzoi27Qb4HQa{D0W~FX;b>*#ZP0p$` zE9-)xK(YluVl072S_#2X69n6qx)W+43%qS5iA!GC$M!Va?!!P$6PWV#t|q(58t5h^ zH)M7jvZ@vOA_HC<4DXh}`dJ{3z{l|jww-u!Zk^*L)IeUUQYj#d85**Br;8hbbq4IL z+BBQp#4+$X2Y^5#lS)@l=qh&K)M@GZ9CH_rP{ ze*U-i(d5syh*X1aQU(3#1@`rx`BQxpUck5Dm!EqBK&EpXxZ&;n(y<93@@(Sg=&d9m z^Ud$7^}mb!{DrCb%Cr2FqxnB~FaO&i_#f_9^oguUolGx!&v=8`nt_;!Ehe~Y(147K zT!hpk@Tig;%m417B?WOqr z3pnoY#-ZQ){5`7ly<~2WDt)!wzsuY8*TT*>Xk@P(>en=8xBpE!RO9@mrcBn&6-z+x zPV{0+h~Ie&7djcRbWGC5KsX~l3~>D<076f%*V1|ldQ(V(ULlO#k2&iqa^|(0u(V|r zDhRV1_;*oy+$;!u1%j4R&YbSF9OPTdL){Nxa4ixl(V9II(m3>z^ROPv)?l{Adi#9f zp^dr9`|r=*)M09sE=-J1&RZ60U?q8Lb5WWvXjUsMbjf||?2R|2xc(LAMq!1wb1!U6 zZ<$9Y5Droc`9u->k6Ty+HM=tn{BV)c;b&RpnEbdJRC0^Sv1Kt6lNw zmN@rq3nyb)NH=@er|#$4t>5JSk+`PvyD#@^070K@8^epf@jC?ssdV}ueZB8RcmK)H z*ZWep_1C$709oqhcLVnO*2=G^XJU;X?#P4x>aKySf|hM)F~PBQ%UD*2a9 zLyr0avhA0jw>*HThs*vp+3BTg9Rh#wq5ro-Y6bArfGJ4muS6Uk70LD~si?{?foz|X ziUQS`RDNqYejoVN7Jw{?iCyUf0OJHr*9798)DRkfg^B(-m~EE=qzkvF3%@ffa?XA> zWV;R9B>`>Mum9-V?paUvtSA3StoHO&--}xI^i*H1o;^JkfQD7S$|L=S68sfj`WrnJ z4B+_{-yQ?%9o{=P2+`Q30$ER=KK)VT|C53z7lup5Wq&S87_XA@!_T8s`ikTK-2J5j z;U@_I@YhjI`fA1eDUR)HhW}GP5umW?;DvU8-gX6Sd{+HrACS2A-SGH2vX~P6i4p)z zf7ZWGfAGC%=TE`yPhHHx_tNdWz_a%f$LX&cF!__ntlPpTpJ7uVZ!3WkQMD6F+fm@n zkC4;i&1BdWa46Wo3uhP55b$MG<^zyOF-mVab`B^q)6BQ2^!e_jEud!4J7*QAy?ggy zwYN6@|JVyEk$nE0>{s=&<=ScIuNvO5=BgtUL;Yh%?lX=^{(@21_fW_#!reoed*o$e zkDPvDKK>i`LJIUsNL$=$f&kxHYJL1D^gnjuzA#0I&n#5P9?P`HBJQ!%d*Z`Cq5W|+ zXF$U$&uT!&i9%@0@Lc8P<^NEd{@udxA1JqfRgy_Sn?~&Q!CnJuduThYBXO+n)tpkyj^r?A}cX3prZX%r&60H8A zcQ{51Jb0Lb?s}?{`g@&tx_n6dSxhiOMbODivBji%Fwug0n1|)CO3n?pi)HxhkWd*> zl%`CHT5o=hc|>75;YMa{y65A6DM=~D47Qmc_J&f6R%k$%^VrT)L%7x zIJ8#7RZ!#tgVMc5zOrLb-G(HI(RAvMqvx56NmzZ!X&TIf6+z?b3Tm_W{3DXtoj{LH>B%11T%^0uwsz; zQNs7RisV~^jTh5uCb$)+)1RtH%2@%qF_U>pJ8*(P`q9(hP22wAyFM3@{MHQoS4tlTTBiqZ>pUcz)U4moZcKc9h(0mUK5Ms+uuS27ZsaiXt)^rSFsN}E$PM!f@f1PHm~ zmD~Znb_8R%jg2)vAVtvt@R&Ukx8aGnC&6#6n$gQp%oHRjLwS@8>v9VS!ixv$uxS*9 zR}3wmn<`xcTwZa$8r8eiDtjQaKq6t`k%!PtGNYljH5%L_>G+&JTv)61DGu*q1_* z-&!7a%Xfaqz5f8`&;R|aY^I;PpAwmVRa!DzEv4f}xuCDInSSbiV{7>0X6p7T>AThH1odxYwL4FY?t{;54y z|93F{shB-h|5MHQZ(|GgSp6TB+5hJl=Ko%5u*d4}vHHKGjEV8tWA*n~{r_Inw)f`0 z4FQ#VhaR&c+50tztD!Rb7RhP0c| zoh#!AOW79bcXC=G3r6&ZK0M|Oc4}h(1ZbnrP?y`Ag8%&$_yA1l2u(&y)+)Y`wH!%drKF%63#d~$bq_K)SK2) zf1i6$A^C`M9#t*N42*1~G{9<+5*?j2uV$#9OTEa};my%cG#0cb=(RLdTd?8dc&*nu zRe)dfiA{*{Wy*yE=5?5ewbD<>pgVp06VfO)+d~up()|AqPl}DHgU-}ZZun_|Dw&iA z1s~uYcD?$U9Gv~UB%1fA#{WFgG%m)Z=R{hG8si65EyS(V;rk$+Q%w`Kq4ch-<|4_W z%lnv9hf?~Cx|M5Q$sJdmfr`4wA|sls6dYe}hV6hhrqtgfma?!)J0J*qWg#MA1t+!8H{Sn$E{R0zCK%n9x0L9y^PTO4pQitf?WG^Bq> zF5^9x?MF$?4m!0z?K5Ud`@AQSpN}#f6-F4&Rcq*5(=?k?8l8G3K#HfoU&M`Xg|Sm- zMLxIqk@Qx_!GWiuxa`O@w0)!2TTRWdFoB!+E>&g6U1T0O!CtoGNYM@o9qDG#MIF7G zM#1{(Vf=B)_;`;9j;jI%w+txjnSw2p+(9?=0xI5ci!&Ng+XQOGSI>&_bNSG9!wcB^RU5ta8HVh4y@pH~Zh` z&3;4DDGC^c1Y|D~+r}C7s# z$W3c+e3BhtC7;Q%&Cs5h_Pt`-f30BKmPVesp9bIIAO04}ooM8Nc7=}0k>0d$&O%bi zS~P~NC444GFFxZgvpu2y@6>51;a_y430g3^Ouqk+j!b_1k;{ip*fD;LOFsP+9!e=+YW%Q@2iN!RCpcz z7Or?4aO_oZgzJL4YuDCE!+{%K@M4A$m_x|d4@)=kKft^3fh(k(+yM{ZI<`h!9sr!v z1DdH1|4lYm$3;{kPNsDSq!Y9Q5<*7e1c3L#KxW$@A3Ik{YY>}YnQeO+Y;VDkD|q=( z7i6{oKE?L?2gUby+kfC{+gE!0YK0}0T`+H7_M*^Y56Qe0>I0}t);U?y9nx6 zgA?LJ04iAD0j*84uW0j1P5ji?!qQlZD!!N?Q?%Srq&g~8UZmS ztMKkPcvI>m+z+xW9)MX5*v$SGTW91B%V6CE1278+4B_t|AT@W}ziD>%xY#`i>_OlU zAaL40KGrCrK{_JTqqw(5PD0?eTSzxuig1`;0*r&+SdDrEMt2gw)sqOSbuVc~L+E*0 zoKf-(&4D!ir$?n}ImFB(yr4^6kK_8c6QONs^9H@@?>w2(-8=N1PBTC%HP}Kd*CQcU z-ex0=bopuBa>$f|R+AnAwG0g-6q4_?KK##x`L#w<-rD)R95zVA0^rx9UR6(a0K6tSpA!j{Y?!o&nz*G$$4SV5CbdmmJi zB!>3c&AnD6Z0~2Bq8;m_5BD$}RJd!*NZ+ysLuAd+D@1l|Np6Nn(!CZw9Dz`1%^G05 za8%)SZkF63o)f;O^cH=-|75Xx%G$pP0()Mndl1-zz#atlAg~94JqY|)KtLh*vX4-( zjLPK$&z}v0goBOV$OcKb$-dF%(L zG+su>^i0Ba23c$>b>Em!%A1d~SKov|7OHNNeUyivuFgR>rKIH-v~$G=Y-Lhk+6*3Q z$TTfEYn;k+KdX^L4>uCaWArd!qqO$)VX!tXY+q{u22wWU0Ae>oN`CQQE?vD^Mu ze*Kq+rwzb0vzONW#AB^1P4vdEuCS~tEx<9`spoXN<{iaip-BU;`)D_hiq>sEbwJ=s zjhnjH3U$d0+h@+12-S#RZsv#FWt;@`G`;x&UQuT|95s5qOWnF4Zx5~85mk!h8eGuZ zZq=%-Y^IwL=Qh2pTMh$%c;q1JaXYf_?aNHuREFNjr0*J-IwyvAI6GjjLM%%1_51k` z?{DmY9;#bvH`xe$R@o@)2QmA_1$B~tH7810!NM_2zf9UU%No`s*z8LkmP>Xp;O_eC zBD>|BD)t^LmgPUYn!k62rfHh__NFwxNat?=-o21qAM%_Vo7!5$JI2jheT^^cp3g_V z=iG5y4Pr7$8(@FV9~p_>UAVu@-A@bn|MmH)`w19bIp2E!K_=Ydwc5O~!jY1Lqmd-vQC0qrk+57TS>kfQWiBO95*(b8$`> z(U_MKwGSn@=#wS?q;Kk#zwE-*ix=Y#A5iX(vJ+G;6K5+%sXaD#aH1ryXQ=l+MCt01 z;te|{?50#`WN;pvq;UjwE=V7U% z{M=*bdqt=rl^BHagroY{0B=QY-GgrRDt*lw^DJvFxYwF^X9F5pTcGO^5IB;7^sdYG z9W$H*riyIFDb*!>Oz3s{JqDp_X58%JJ#0C+A&=1cER00xcDu=S-i4BNvv=g!-@2?o zm(=lQ``rc6Ip<5R!i~$&{9)vb*lhgLWOXD&IbUA;`p_Ijenn&H!^>MyM7Y?& zKe(xt6KG#1G@+hZ>X;l$3iJMV?;d~{tjk&R{tdL zpYT!y3_;7yeV>tpv2p&k?aG9yH}v(4%!H0nhU2ZQ>^xfm2i|OtvF6a66XKQ0;844S ze3V;T*T`_|TuB#AfVf)Eqb<@nXVoXBs28d?Ev*u6%7ZuVaCxnqEDgQW=XkGEO>4j? z?0W5X&yy3_db5ceIYV^Ws^RA}?mo@j0a-KG!TB{e)njdSYczCyUg;S&QN7dS*Oc3M zY9FAq06G3cBbT&E9)7_Af4lPbzk+`6z2qJQ{-qGG^QvAXmxCFZMQdJA%hwee_AlI5 zfgF|C0hKt-z7yxQ^^w<bqHAB5A zk0qn*K`J^BzKF25sno^$z!pN9o2<#YaSkj%czQxlv6jF$Du1aR%&KUkSmz|4GY|o6@$xo&kX$T zN;(~?L%!n5813NVUSzu9Y1^g3-s0=?j~6A+*hlReJWmrh_Gt@uE+E>}K~dCsCW)|M=`yO(K|$1Z?c)htZL8kX8-=DK zDx2Z#uWPTB3_#&mP-gUK+*sA}4oGh*vw=%HCo;vcF{DQ?N%wwYX}oQ&pCjCS)DE7x zdSil`r%$m{{BHdmUk7il@=)6w@ni7%i)|%u;8Tfd0iHw4*94Gh2n@$8%SbNvDGBE+ zJI?2mi^sppoLJvoB$r@&|6RZFxqXBL`tpr+PLyz+sO%7=ZOGN7f#-Q0_xDqf)`f=$ zVou?T#bE3@D7NP#g=fu^`teyAf_QmPtSW8W+jqO8Q>%r;pDZ$dlpWxj_q=bRM52XA14FE)?pkc}cKXLNXr9G#}rM&bMd|+*?fyut~Cix8F4jw5iWr9P$jhc$9j?N9AJt`=Y~=ce}4Dr zUc9MYopeKU@S^2mR9X@=nvQDqKxn^)hez=^!I@_IhDR9kpx?Mi465AvHzHE1W;CKk zSl46ziS`xN0v5jB8fWX(<_($rZF_adD4cfMnI?zZ>QwNQZ!L^&v#%X8z&N=!t+fMs zjMa-r>-1!I#K^~-Wk@raG`k82Lk@`Uc-wQ{g2m9P?l;Ea(Z07I8B&6IxW+xeLE?!A zi;h*%4a;ipMSQGn&ti+&*Y~I5zh@KAF;@Hg84qk&?`j?l<`s8$$SOW1X=Oo8@w_ zOGfyJfw%6BrP&W!`3^7kA2pw8MHFt{3Mf;TUwT``n`Ub@m!VbMFCL=Z{N2S_z zY&WjaaWQjHkX=1hhh5PX#mW}Ini*&CPCk-imYDXS14qGz=H`PNY6iPbcn|yOT@wMF zfrL72N4~jvqp!D$?>KpyF~O~a1j|VH+Z=h$V-7bwS=ie(l)Ybp zdG1s_MOD*k@5OD6qL49#Bnl&%+tRXOY-R~<1T&rE2zt|tA+m);{FgJ&Itc|r)G|^> zoIVsRamT!+He{523|XXrNOGp2b*=9g5gVpeM-T)vL$|5|T6|_oXa-&&_xE!0-E$rH z4#A;VR+$Uw=U|ziSi=^g{f7Ds19%;y<0a*9*E@dwbn)ACS+B)JIGOJ2NdiY z@1(y2YK7`ZE%o8991L9p{I8|NoXB)9b+@ekOB6b`t3#xMNDABB>%|>xFiq;h5dC1G zO-8XvL!}-)+V|&c_8}QxjMQY0LaAre3m!GW?sQw21WOOG)E3PXi5%9WtEDXy9BX$x z-&G_xI&fv<+VgZ1jRl2Z*}iexjmT)3+rE0|$7m1cV(-2(8e~ATaW7$~e zSUnM7iIXxzH(qQn5?QLemeu}>JmC({WO(4_lSal#tj`cC%r(*0X2dhvDDfi8)hg{~ z-V-Y{VPegjRDMg!+xK!;-FHC7YUj$KYY{_jWZTI%h7LfwU~pN;dc6I>Zu`7rs8*V* zo+K2Z7GCk+xO|ut_~^0k#(ki?_MZCdTiXAEz9wFck`7UGwTkhNOt>B zMh&n<4F4V#_%4SPd zk>-qwdwacbj&;@ZBVOQK<|`Tcd8j>}GR?}uvHdvnA&jKVY^ zuB%&|#1GvDc-4uDo5Qdn9SBQJFlAOFH@FPr6zWkRaX&oOLuazlS#AcJpB~_&aW^br z*h##hVt^@EzOw>pIZ?{G#@^rA><(W(tpo2~flm>ti<1B@zsYtxAl)Xw2lk}aH=O-c z=x&>Y(`NL7i8cB-^_mNgd8MR;VAs1Nv3Cj$9l2p9=>g(X_Zd@CpeubkHYlI@=%wuR zH#wqP(RubM$&hAKsU_piqm|to4iAh9EC(VS$EmVg!+9ZKY?6w>%Yx^^?>c+gH zCsQw~@WJGW+_#700y>ClQQApGOJV8zu2rYAo+jIH3x-_dtizFOKNG#RbYJ8?ccghw z;3d3Gyv^<)EOX%*+w$Rl>wZn)u}mgUf@Ojgz$049`WDK)Ja0ZP$Ex;@#9^{=vPqrk z-L@*}OPTcVsgY5n8LEvWya88mu*xUh;Bi)xt6B?YO?tRCJDGWxuBp}9z zvq}7Hk}zY$Ky^JBJq`HDu0VZfNWBtr%`Ieb!tjcs_Az1i=;`!+Eg%xiAF-4QCLk0i zFJugF-T}po{m~Kf(r){*6<)AoaxnBJh?%}Aqc`wWvuI>g$uCOZKRAe<-Hq=17hx36 zAavvo2w(%0Fx5MtSn7Q6*R|r)Etnjf!?CIL_3h1Nzwec%EpsBo> zKRB9g*=@i-_<0rm4V|LdF?Os^4txz;ioxrSbOiYIAhl*(DG&g8(S8N#i&#GW0f_Ge zYz9+g@=InoDfwm$&TM-hhx4}_2XA@lCKWGacC&O9A9?vx<3M+eOT;AJX+Mg_2a0no zBm5LE)1S8H=7YFEQOIA74xq0_J05vt1$#`mO|Y6i^r(TR{E&=VULc|ce&yT2jE{v8 z3&uIGqF4Lk#SZh3jsIRBR)(Vs7H67v#+d=ui6w}qet@^IZs`kPTSOI+jXY-=B@JH$ zbe&U)$Y|J<28MbU(%-Q$|6woxi+AeZx*+x*z6XIl2>b&CkS~jFB|_2e$>JB}OGQ>r zl%_jQj2#e$S24(;8nicuo|A0DCV6Q&+Hp)XQ2*bhqnW|hvY%GpV1bPa~Cao1KC~% z?SMX{DvwYe1Rp4j3em0`oA%J%4$BrNzj%8|Gk;pJ-(UQhDsT<#AFe6vU4#|yk@imz z*lesJ0{qgvg+s=k7Os@?AH#IN*Eyq{h?VF-9FHH0+zcG*DzQMhMM6eNjGk<4Nzgd>3-&D=#mp2uVpPa09lMD*a6)IY*?-POnI;5 z&4m=ehpv#}8Z{t??yZO(V}>_#*6L!dplj*iM`!J#NP-}fp<_s#a3ZEFpn|Tb`CuJl zr2*Bw17c9#hLvPs3TI-|uX1NGNLxH$$pJXvlWa+|%EYDwN-tj?nva9m%cTf+RP;%7 z7_jdbF#<1NhgCXLm)%3nzwi&N?)--98h2EVK-N+lg_ zRKl$S>yU$XcKYzG@qN3`4|g-;$@-V*Tt6!% z_kQ;vum^#kAwV^Ppb^N)LTTt85Z9hNk!xSz80V}B7hY<95}~PKn-0jQJnKjLinYbB zL%2&LZ4IiMxYI?|!pouI4u?z!GY}l$u%Y+GunPM(FlUw4 zURa&Z*kTkbHTjvlZ=R6(zwZy)Jb)xa7pKZNjLLE`-)g)|4Q7bUXIUoJ0izt${5Prs zZ(J@9Yv2+W5wVaNr!Iz;7ib#dj=GZB1mdSb(E?CN z{JpgEXPG=hX4D27vMn=91JnT>cV>szLpq!@;ZxP$4wMkV)4Fhh@cAp_zu8?Y*lnNR znX^)y$H>%ZG^>Qjv9RaT{k4aive+D))t_5H_T7)x^t-UUx9v0NdYRsgW%-<`Tmgr1 zb``OwvgM9A5O+R!-+CaNAx_B?{0y6^lRYAKQ?Qh{M<>oj@usL{xGK%dm`b3Z2a9Dxpj$2_fC34B+b$4 z$>?+Prr-*C)2BXas!tq!>^<+?a9?Eyd;IP#YV-HI=6~K+e@jRGkJTVLR;Uo1lqLj& z)7{=T{ReuG_}{R?)M6Fd`jnRx+L^P6*!HLFkB*t~YGxV4J@#LO(ODy^W z=kIRALePS#%<@S_6z56Ucuo+MoHyGJU(0|Fccne%iH?&U7I>ETh!H(fx~|(*Y_Z$& zc^}hf+3UJ3QocT_9q_iMq_AWICxU4Ev*+`g-Gwy;7h+TS10U1oUg`w zIMTI!Kw2@}eELYXx`44Nn68wG28YQwJN!PZ$suXxT^zGCcgs3!VACe3bfeSZz;4@} zT6IrHt+w9wY9mL=O`F%A12fahL7S%7**~{M){ulV_5Y8(_YP~S+4sexsGy(-igbd4 zqN1P_QCdW$i&2zbA_5{M6lnnhK|nf0KtO6#dX4lRIuQ|2T96)kC!q!i;V#cUzx&&J zpZ&h?e)qoTJoi4241Z+Scg?KiGqYyC^R0OlD-(%+ov~}nhNM=A3%=% zW|O>u;k^ImQ^NmV>3)6qg}^Ta{uY55stGZ$TI)kif*9UD;A`1ibR{jIe;tCc`d29A z8YvyJP-Bv&x*Pn9Kw?ex*t|*%K%{3p>C~#9M>N=%wB#j*MxT5$)t`o&(%Eb4&<5|A>Yaoc> zpC@!780%aI^0W9#@)XbM3v6c>&3HD>@V{{zOjeci+)gF2d#{ujY06pa2j44JUemJZ z*bV4V;9o0~jdb5#QymjMFltqq>fTp!I_L#@I=eGzi#gFpVaC=?aARw_Ci`cpfCg^G z-jF|9U0z%sGh&X|Y(4eXBo?%K3&_1LH`R{zu@ku}a=t9iSg!Ei6o+}8Y&Z~b67A+_ zI+oBDq85B3ewL5Hm;OUJ_7~3dFFLdBg}-uw`0dL7 zY_zrCRgC?$(k$|?oE3iS^Z)0puuae-i`1|ONiw7WV;LqgsijzH4?1xhWRZqk$fd*@ zhcw0eJzCHYR*HRj`Qz|S5IsLgybI^thg8QZj%(bxxRIwQpkBfD$Tkr~_Xfl{2UFDf zuC=b^NV`UAGQRw6q&?2G{O+{D7v*8p-9>kBXUV@pL5w8iP@;$(S?8-ur&v0SN9^yv zG^M;nPeZu=wRg-;lhT|uG$5fZjlA*lQ~kS&H)v-L5IEoZPZKO<50A+#={!N}_kE1G z%0lhcTf-68-l)hfbqXfqsQ=!3X59O;{5N_v{Ds?gBeX!b*#Lw6g>BS2{qKtrWB?X|3w+S7=GIi_8^<;2C|FTFw%NrGtiZ+G`Jv$o9T@FF$3E zN^)G;2OSk{%7eq&MA)YeKgm5a?+$2t7le4phP!~lraD>JKxeh>^|peR@Zrj2z~f@4 z6_3=B-v^N*scL<_)Iy@yLoKy>+YBs(R_HLwwrmXkwp10Tp5sUZYsOjSx@xc?ahCMg5~aZMzJDq^$M2741K)SHrR1A{62~` zf{LFomP((e2~r%hRqd`;+;faAOFYH%j&@#P8{JZEr_oDQCCxmE95HwqI3sFz^TMs` zR5j%_a2R|Z#!(`ZpcIUU`gdq^h_j2aET@3zHroF@LCCwB-ZOhXVnM%0^ZZ9he2%>9 zko?P|^hp(yQH0TW=mEruU9Db$zLLyT^?N8uZRAQha*~x<#<5ihTPu-#ki@&0ldYU* z{YWJykY<&;J!-%GS&+|VCK3wsvL46*O6K1(BL73uj$aS`g}^Taej<>PJi`4h^l>9k zL2}MHe|nN6&n9W8=~*(zROp7@>1&WznKNbn(*mbS_$wCKpFg~!9)D8$T_WKUa?nWR z%Tei-;NjD>r&{XpQ>ulr?Im4{@1yc5dEcSahyT%SJGDBq|JT4C?t!puQ-SNeF5cq|_F9d!e z@C$)o2>e3e7XrT!`1cTa)U%N%s_3VYZKWOaC^^hgtcAH-C_W`?LEkupA>m0+-jx(N zu4(g7a5_{{`Eg%y%^8*(Sy}peO74jy|0ux>9winzA3I+WFNs-LK-hfEjxMqe+9(x60*wd?g>l~v7% zHGQpWzWNSx8+?fHkl`rn-53|F6xj(Amn=*(yS&0KXfC&IXE+`t3F`hwJX>U88S(U00n^oLFw@cRxF zh{&1~JpikwWu$6KqwIZ6l}TKX9tY1!1sfk`D}oQgHgCMVEaukxXga*04X2UHXZ~;o zfg0<2St)I@p+OtZH?>z2kvEv~Q_W5)A7U9P8B6BQLF8YZ3V(6_Ho2Aihz?*!A>hNX zqWL8H{68nUH(Uuqx)QMr>UL+Uvd^cM9n+UsO;+M}NIaLwj5YQ=?ua{29`&z2d$n4B zIWs15=+cYsFK!&KTI_@EXyAs%7k8d(^z?Ju*}eLIJK~KAEna6zlU0PsB4MY$ zUsn}~q@6c=YOip(kU=izgdHbEf543&(^M((_}wZTVqB0dJ+Y|PuU+|>;wtXEaVw(7!H z1R@6MgpM5*3b!%yun3zBfli1txF?fP9@h7Sa~ zp(-D3JPOR*s*3QDL15-~f2kJ;mYI!9LW4luf*3Wd-GnIP@DSb(KCZ!MIrTK6nRoqu z2i_ZWJQA7)?;D2qK?9NMsT3UzF8>mzzCM2i@Vm2aAk##Pr-DxNh+ND`N~|g=KVI^< z)m&a4lMm$DomCM2W=EaMTn|}K{w!G}ifANZ#nszwpwD^8>*?#s1K|!y-Vxnd<7j3? zf)d#{(QaLRvZ_?)deP;=Xp{aNkn*D**ObPQ3*W1CGPw6xw?&qszuJ7sP1AL`T*uPm z%sWfk3M#f^n`_wz-NUI@nLBceI&qC3Ly|k&@oKu>h14f!97o&ey&(g# z$^G+Q9+VLBJTd=5S2fQ9&qcM?EVjdmTdVbB%$sPTQfZ7(7Zoy&<(+43Gq?229*Wu> z4C44izn8@`2F}9%%f$S?(M=C>@pt-&;&Kjj#ral2)aYg91*5#$#jOd;kIVv=_SeBL z)gx5^H{mDfzA6LMkCm40dwfb=W6$I#V+8@vXk->R@0s-|eYG`_!Z!{V95#60rfxQF zh^kX=r%bQ~VUc`fY`~aDP;r#At?$*VQ9%y-paWp3iBRneH6)J~9Qf7pg)WWWN~Yq{ z2j}tBL&(wa>sr-pWT_^3hKf*q!;+3f=9Mc#&rAhyqsw3iif>mALU`OR5Xs`mQCwl2 zbQ3(H`=F^s*|T;?eu7M&rcKgm8a+ulH+|jmB|+LAQvE3@C^UQ*Rqlx&XI9(6HyB^( zmbG}_m}B|!6gO|-y-_cA-bVpgNFYCAs(Z0g3Dzp{ zdWTG}+~x&sWOMal;qPZ-<4dO3;FhP<`9sYE>E82|+|}=0D&}Qf)2<$Y=bf`OV+kz) zInni1LvK^sb10qT;bH0ecPhO?*KWR0;!^ci67X=Dq9Xubwr6 zD7hs{2pkuz6JV*SdU>FZs){}JOk4cg3;9~KQe996yGF$-~^AaS~ z{4C#p>sK2Klcgq{a6CQvRLJ`uGY`ENRNlV5$aXSTsOVxR!bL zhFcH6%!R6QPL);=HH501oDsSyIbM6pOG=&CuC~&+b3ECZ;Y4fx@)1q3+mLfW%&VEK z3Ar$Lombd=XUM@>S3;2lLFbG^>y@zHccD?n(PP#NNzl4V-i^g}$=>F~m+At}&jkd5 zc;{R@Gml9k0iGV>8qN+DJdvM=^#WTZzv(C#9Y!intZZLQKEDt8l-5ZLwW5UJM^_)o zs_%nL)G>P;y<~QD?c_&9EUh6HvU5FWVe}xXRhC59^T|W4YZ3@JARbYq8xgyESRaV~ zlZM42j{-5J)*4}($4Y>BrRqk9o!GwpGe;_IuZr9s6c1nylpK|b7(AQWqD%^A_@I7?pvEJhJ}JJUrL#3f)R^a!pl!A-?(Eqj8tgh0%i z!c(;;e$0b8<%JXSRHS||Zf{*aI>=UuiQz{qH0-Pz^x+IhOUWO|QR5YrJ-(iAYB4Y0 zClwfEZ9k(AuNK9gud)8a4hrw7r07mO%zS@2I}}830@FJu_$b#Q^T|UtEhP}$Cv0v6 z>&3pCJ(n*Y%T56u=zpBmGygYhGd4ihavvlx8i-mHas&c!>En3F8C0~_SzsuVI%#26 z6vr0KsvISN*5C@+k<3bFCBPbuuXJs^y&9ta+Lf_4Dh1uF3Jw!*&|jcfH^&mbT@vr|; zU1Hu@`lscX@B}Kv82EC2QR7Nk_Tl;?KWMG=>HU(HfMzt!DM)&-d_Cf2<2!qa>!=7b&1Dhch<8sHgRBAQ) z2o4;B;X2;~%5Mq`9qS+z8$eiQbt)BiY)h*GTZUfZLgnh~`Np(eYCis;pzqXliFP}e z3@P21h+a2YKEbec5NAYE4z$CuB2_E9HZ&C@ViyVX2U>=xk(rzH_8Z#rC95kwvUfd6 zQR5nYvDuMVLTjJbK0I+_W-?m&lT1K%!3H)K$uiEp;)h|iEv|VIVP?K7x#R6n1`*7b zdo?7dh0gOd3okrZdClD9P2D8R0!&XJH!wexQ`hX;twZjFK9z-Y!YN0zIhjr<@D&4p z|IF+1>z-c-{6gUWP6TuUyuQgx$3hDO8r+d-7pl_16 z`I0$H{s4J~*j{`iZ{qlc!$H2Ud(J7mhT{)DlzVwwzJk671EQ>vrU$sS$^KCXo9Y|p zS@;`DCth9TtKbJ4`p!ccNw5}H1PrgeS@>BAlPxy*AmjZr2W}dZ14c=*fyz$yOJ*nc z*5nqlWXy+_c4y6UBr5HLe0eOshuPO2rkV)7raIeMU-7ftNx51)?|wvxrFIO@xo!$G zBoHJw+W$Fu-fwY(|9PG53sM7MlFY|NcgRuOI+w^&G}YL^+JzSAlwn5G==KF;fVIPN zLZXp)5{jmVd$kWTf&tOpYyPP2iH4aH`qzK!CD3WXoB`6%WFvfOIC`3Q2|1&=cKdQN zKkzW%5$~@eEy;E?wTwW>!We3n5%!1*?7@-N#Liv%Mt~f=gC^EeqhKdc{qo?wLpnVu zAWG$AJjIb#PXai-bCtpK!kK?U)`N51`zUMH4KqNfb-{*jpBdk>oS#GndU-G7ch%=$ zGPLh}VwTvv>hqSO%kLQ-Jc>77%HM-4LR=-$K;fBH%F|R3~vcUu&dy^IqfLCu8@P(mn-SLQ+mwN@abH| z#>iVNPNAOHV}MtQ@H_3?J%5(J8-F&^Oc-R+gUr0=w~Si1)@e+Z0D^g~G(k2`0f{@m z=fO@Ox@pR_C-*`94}e^*N+pKCArSQ`_1p3}jnbWDv?bylkL~q~4j7}lGAe^sCl|$a z_n5|salt{mtl7=jpjRyutO1-GLyV}p*T36TryG0(sQ|df(Kl+`tXeKFXn%_vyk52s z;<-eb#=WD6k26zLgw;}rP`usCIkYG-BkWAF^pb^HJkb;xR<{Apq1fs4Qjs2Js?cq3r-T&4LOS3cF&^PYZq@#K-wFL9VygcO08hB`O#`v0b#O{*m4|{RV_W>f8mEugx%0_EIgm~!s>ZuS%Xmdp#NJk_P{P?tK-<-!5xAIiM{12 z7NNRsP$6YJCu4fYy_$X*HF{HcopHfPst(3cT0<22ZaX>bk-8Libe;qTW)N}=`%N^@ zz5QqTyQ%l9`U`d^U02>*Mc1|bLqb2iH%AI27`p!XS;*$UtFFX?)NcG5*3Y2xr zvr=qKEqhSFvJaB&S%OlX6_Lsl!|&FU&z>OD4YPyX{YUB^KbO zYE|8Kr%OtPt}?yn;my6~Fzc2bpPmHIwbXHkkH?f&z5ei)&bP$>gdDTv=NF^&)Z-s3 zRnG+Rer-dK7*%OREfgnJ>>Qhvu=AxI`EDc_axZ+^9KRwmoZh-I@L*`~@JlYK`h5`H zi~LB%kIIf>6I-#i-DW#WLbhH$RoTlqmAM#J1o}QHJxD$;2Rdb-SVtEVfmVDp41@?Z z96M+&)RZjHEqm!BG{>rYTl>2`Xe!n8`x93{4^FrVif<(g1+I45mS`QSAY5IZ!sRaYz^$-^_P5S*5sQP`P{Uwfgg>Tsi#*?}2>fXndX{ z3&pgBc22=vBI)HGhn?PJuria}UB24af1YrKYabLwJ>?#;SEk!F4U2nPK9a4R6-E)5 zzx0$qwHr(5K`&Ld#EMbd4!3M*%H6lC2R~9jQagb43V$%G7td zBB!Q;iM5r=q>82fo1ka9#d!$bQjQAQ+KRVm7=FImuf$#K)<^JhRr)kuZaR(H#vS&)ihcN{QMp0tTSdQ5s6QQvq%NkM>&Jwt(#`L>|s z6B(Z4=#%qO(w?|DK_B6Sj98~+Gm|?xJZEn4dqQmpAxI$#+9QJ!@EAu{4s_;Dk{`Vv zsle9W-Bt+|yY@jVoRQ~^d`78tGwu{sxu%=a=aqBd7 zXH%=CK%3mV;PIIrh7=a0~rm{Tz0gixe)R)W!GgB)%ho4e*2F>4&C;~%=4Rtfi#fI->OHOa4=UFmXdEQV<-0aT-Bd6}b@T*KwixO|J!=a&CDZqv}^E#$s4U`x+YqBbK^*v z>?N{mGmgD76yU7eGJhPD8W{O(cF0{A9Oqep&y=hnLPKy@Ni{tdyGlk%pILByn|JvI zzUxxkmcr!}usJ|%0~zocgiE(xcmFm!V^Y{wib><8EqZ~CIhZ!Zw8=&O3TY|5D5GFi zgk6SvMXAyM@$w1fg)Uqk2_LwK)FTdRSU^oD4Mkj}M#2J^GKP52gf#2E8fyYCnST62 z+}QC;78Q>jJmnQjKHgxA7{U-AEo?t8UkQY;NOXcM)#bhDn2PEBw5$q)=00e=zZGwCWsdE!pf!^S)BgMyPK$ws3w&gvnENgHL$j40N% zmeJU0yQcW<3>YPA0>(DHZSkbMEL^F{CEo42s4RTj>p7ql`2DsY_CX9f;fdT6#671n z*tJ3R+J$b(yR?&7-kVbR#+^A^oJnacijZyLQO_8_zuUA|N6Sdd&7x@^6snD5 zj3`dJd~?M)_aL!zdFj=pE&e=u3$Y>eUS5w3nP9{EOu~iK!exf7LFJCSRZrcx3tCP0 zM&wjynPZSpO0)G?1-EKfO8Az3od^$Yxt~vI@uluQ$Q7;WPPeu<6C&#{VX)~pFJ1aU zJajLn+hxc@84ONC?t|RMJ9!X&dmp63^D^&GK+KDW%lN+I@pCZ92%-qjCt3UAK}wF* zshgcY;8JjWu>*PMF|%K_bBgGoe@OlSNQyJXUr~5jWscJQr!EuJ$40|wLZqdy4pyT5c`?qlSWYS3^Gz&JR2px7PDln0>OP z%^SFm&8UW8=SGCS!#CiU9VBxb`PVOdysEP~sK7y=E>0NnVnv!&koi7<1FDrwrB>-S4T>Lre0D^w zoaacLAd9!VshsCO(apfZ&oT++YA4h0J~lRplhxP@+l+g~%1P^-vb(vky3`_<^Y4)Z zy9^#{Xdd|7n2-RH&KPUgj(eKDaI)hzTttSnLV zI6gWoENrm6#i8#H8uxo$gN;~X7@b4f7%P@UQdVzh9D2>`C`RYc6Y8TpVcbae`3nzX z{5L$v8=h;EW~>mdO>ijtfAApB{)Pwn>P-v~;E$jXf{~Xg5t){ieFd46D5D;%O`cQM zd0i2ak=v_o5r>a)M3m2PZpjrHUn1pQko5SM>Ko;4RbNOD+h^9w;OQp;z2X_8qe?&QM{LEPaE7{@`$CSVnF z2Ub|;qqdU5b4Y(1yd`%8)7?*u-DKJLaap~I8dQt4Ul~{QI_~Zb)8eqt{%89S&ry;! z9Qdw~M`|Z{?-+!s?ZD0^Tpv)HynAx-;5rq0p;FWj$ZeTM?u$yDi*Fv#ZxgXS>nh3~ zSu0M>dvo;RZ2@{gM#& z`6|Y5Y1jN;&3UQvJYx@$ix4rzMFlQ z|I62LOO}8lKH(q@DLhR$%vQdAoL7_ch_=Nkl~B2NWJ5Je9E5CW?XYQga{kR{v7(#t z_e>V?!C8(U5RHw;Y%RJ=lCGazgG39eG4D2_`?3vZjjxd!65`gEEbiZv?VM6&^`(&} zHnL--*+XTorB8dx=ykI&i*IY*0}c$;H}|YFNdYajY>1ch617!PI^Ao#pKS-7yn&r# zntmZ-$w=8xUXqg282cz~Zzvvz!HnE>8BC??HG^D(7^1D_WzUka&Bi>HVWP{Ez3Wuk zDtGBHKd`NAzuKAf(COv6fwcfK%*W?rgyO87IU;YY`1bFdL#5)7*v+m!d?V^~!5e3W9f>Ao3enLW4a7E|^pNWhjNhyFnCBg0~>LGFNZD7$?G zqHl@pjDHBXgX~^w3!QRV1`-?bSd3IBOe7{>3tv+N6vajx&3Ac5P@5*PoL`oPr)W1j zYuu#pw`5Itr$Yd)scIqE{}vFkYq3#8JbJLIjp~4L-|p0ct8S?K_qPA&Vf3O7FR!_p zQpy|?P4kd5*`=vFX^mFXi}QzTy==GKstTwE6&=_6aE`qOnx2}(5=R&3gQK-l9@WGB zw5vli91BMBNsy+3^uaJO*cnehr9IIN8?Kt%}^SG&HjS(?;-&mc1&zo6Q}CgbS>- zcdSTx-5Rb++_Roq;YM^fYbVQ+50{h$IR`!sc~q`49=@aXzO3L?JotR;;5Lwl&*0FNu5{lNNSm!7A0$ z1R`dc^+}k(QN9xxSNRAc__Chq`SU%7^oq9QlC%Agrk8RDfS~JS?uq*D<(V#7fhqMX zW~r4S-m`f_N;TZ{lyK$ua@P0I6Sk0j-@+V_r@gA1H$jFKkB|4Z9|cH5vpXviEfDA<`GVQQ<@hDLa#V zO9$))BCATTSME)4k_+w_Wexixmc;<^dQiK&kS(cTGZ3F?H?bon)T3iPhDA$n205^m z1savWWzOmif?tHX`_mvPFFh51ziHQwc8+P@oXbv3!pqn*u19gV9)AFT^R1_Uqa-}% zDXdk{w_fF`u2G>LBI7s8ll2Wft1#yKS%7UF7oFX|;BJIVOCL&WPHM0Ve=@7Q&QDU9 zWC^a&xjcn*AVPU4$xx2jAh+=(qdbF$-uH`OpC4wttMWB32(`F{4VS$%fjQMW!OJ2l z`#7g0$Li$K80+n0r`Oo+ZA!0)&PbB+uVo#_-DFKao}USJb}511IUv@KI(sMi+4Aw2 zmg|YrRnR~Tue0#(Tyf{o`|vA|g1LLaHJDNzh=b?#HP_E`Mj1`e@XF}D^#KdN^cyi3 zn~%?+?EG3B^-+f|cJ`Q76}cq2914qUw9F}M2ZXZ{N$8ul>Ba>E z&9)k$CLM3;h*N2IE5@^l%Qj>Jdj?@V>*=dk6Y%AxwVPqJ*I3IBaJprsXn3_A(c{DB z@#mZ1i^ROCm*ibvZZogA^jVxV+2ZwbK)+-{KQhI?EV>Q9%mk0vd5%k_z{uyA1G!|= zbt6Z$iU&kY?zp^hm$oRVpU8x~fl*haLQshOql(A64pWo!S~-jqZHAe3*Gnv4%w6Z1z#1 zRW|Y+?oM9BhV1mY8J*e#fiusy@O)pGCxyrTq>`n{^KM@iJFs4KEFJAD;c{=mpLLoU z>|~uMde+{BBpFkW2qYzp@_1Z?yup?(jRp4&2qR7kUgy830Bq$4wsi(wNQ%~QwrU1e zjyLD{flVJo%~`5KoGU2}9yxTBNrmO4lNKGwOY6LUE1_{ltyk2B348O+z>ur~Nub3gBGHWIJdP~v#?W$M%)Lu4m>IX*Z=FkK2SKG(Xn{I@XFgqG6WC^al zvkz+Bm5SZW35b1;9GY;r*+D-kJh%W9K)JMynQ#q8-c6+{#Sk*5u z%FYyA3m#ck=@#TkymYX}V{G|@M>bNl3oFT3vAk@QJ}TMduWX|>W{wu}KJ30#KYVBF z2?dsBY{l+4JXEEDvkqbk?~kr)UOhMI{2jneWFAp%AG?+S-h*LoqB|Pk-LE2zLeV zmRKMe*Un!a++f%zv<`yfy*_D5S2#Eg6)<^2~* z_zsH%KW5t!{E$9N6G}Z;SZg7AaxbbWKHOJ$TxRy(Hy_kgs^@LKG*t-c*p4RdEjA61 zcavZP%1ts?oiHcv?Smvj?Sw#U#paJmg0*|A!u2Ri@X5uJF66CK)UNB*iF6&`qoH+? zKa+`J5AUTS?-mkNNt4hum6la|W*H?d$U(qFa`apdg0Zpo2dZc**xBvzsrk~P!erVL zt1q>b&9(J^gIJ9rZc*Rb0V?p*PX;S(f@ z6r~*+6)gSw4ZUMkD~6i*BAiHG_LEf|GqO-Sic^KheE_fbdYJ+GfVVogCWaXhQFWCa zZ%-j32gUC|=CY}+z=&ML#(1$(f~uv+VD-d;Gh5KjTli;@ClAQimzGhF;Pfc!;}=My zO`akzn+%2_{WHA5Dz^{q9vK)Vacx@=MFSHWQ7r2fZ7g;Gr)8Sxa_KDS)FQVvs?K^b ze)j^d^-mZN{8U!_`u~N%F9iPYLBN0c?(xLc@GS0Y)WdgO&-!<`DL)B&=XLNy)tg2O z*_3RhuaE;UI-R;+lB6f`!{GVYfb~I@x}%44A7%3Tyr&ibFwf^qaX} z^Y>5N4#=(3M*<9#I~bonlB5SoRJmY1QF8acMC zTC%8l)u+;CFUm?ZnfLFatCos);(xz!K7P!uQTUR?=W2sIgDb0Fn)($kPnkY+m_F%V zz(4VgX^Ugg>j+h>FzS9tb7gN~=apOyKh}J0NqRmL`W)61a-dF!@IUNgEBj~pLZ%Op zz@D}go2#t(XlPJAAuxS+Z%Xb7`jMV7KWRF8JnVvzluogFh%1j7@-wPB1JL6M3perc zbX7k}ZA+gA4i~l)q3Af~t+#;gPZ8-b0b?{m2s9J)?-hzO=&IV?ocJ2Lnzym&Sr0Jw z)cbrGRQWCL^;DFzR{W20^(`5#PRXSqqoi3kj=TRdF8Ob=?Pb1%^P01ZF^pDv^vMWAu#*g_jOm$2^*T&{ze|N6gCT+%-DxB)PhR@1)m7xHf4^Cnp>< zsLx9ES1~ob{N?q_+p}UE4)aG>U?Nl`$vGeZsc4!t_vw5!SGiKudU`p?`z810z~AT7wVIJ~T2M zOj#&n2`EphyLv_mS+Y*|0snZ(TRxVeM;gG_yPsy)xiP!5)MT-ERAYLhLFV;QJ z&QbJ-*=j>X^fQN7{&bi-p4M$%M}aI2?D&|d^oT5!`ACkzP}`=S?59+7-NdIR-ZS4Y z`m3Wpj}TFczAr0Si2z;4BV6+4T1FD zIXx8v@rq;A7UU06rMoxCj^lDxKSbbpQ>$?J6sNNNf#)XQy+4DTIy{Bv&Ogj%yM62k zi1)CkU^d&G%mcUU=-y*fqwi#Dfi7}@oY*=jgY`Rrw)&Ps`p6xBcqlwWcH( zL&L`_M!69XC^;iQL}Kvs!}fx(;wi5eW_Tv%bccu`9hnI``Z<~eX{sf`?HFh2_0mLa zJJUPjtMv{snP5uU0~|)R7j8GUZF^NnHA*f{mu2TqUETezE9TG3(C#^#%X#;N-*eo$ zHq(cIJK~1ezqYS_S$hgK8HWg=Rh!YYzECy($|(CQ3dp28nKKLC=mj<&1HvEG`!_b_ zJkiD|aurSWM8yVRdHbDAz))?0F7M`h0w%TVNN2zTn7elJ%>u>%wFl-!#-&*nEpXMu z#95=|mz{iM*N47>I?E(ipGT*6=2~s)o9D~!R&+6}bvs_8lOH0q#%m|Y7v%h~j45AR zo>39#)c9J*wCf17KtSu_nSIyG^CT8H?$_Urnfu21T&_(D*7zPi zs&B_USK3$UnRVdDV~eRi3If<+Uh99I*iMsI&w~=xhi&~XUW+Jru6;~~Dc@nx zmFJJU0JMaQWVfrGjcy+z3QH^f3Y6qdXUjuYGVD5PP@9PAm>FXAx6eNejPB^B@C9pu z!CT#BGsd;Mvc~F;q>&e9HhK9Ut~^33UPhyL=LXlXdjCLqexb0Ni|E)Q;T zDSYcOsz~5cqafmID1=G0bdm7yP&;dxs3%8c$Tlvl;&_vT+gmS1A9}wk25Sp4e_aDI zw-7Nt+<336;SEZNMSht4vf}*7lQ(?ln_g`vJHX_r;-tHXmF9wel}=ti#+l*IHFpjk z`R1wn1|r@eyvQr8+P$tJeHC)QIJmFttY7f?IzHM=PqK!mZl#)3R{F`90YHr`*fy!k^+r7dyt`?z6Lo=#uJm${j$bAPYgdTic#PlE;c=S3R5{Rb4ixv8;>a#EQNHS zSXh3zjKJJ2)4ekFM%fk4(Qt2Oxib6<^pF!h#{#~6l*fy6;DuVU(6^;N##?4A!-GoK zB5v*GrxZrj^B!oCCSi&?L(+-}8Kjb?)Pa#44V%=x*0<)~fDMlVgmhp*byt>BX&~p0 zVl-6K$eS54Yx}4XOkOyEOojSG+Sbb*zmumo3$~50t zAAh6B<7A@xxyiv4rtEyLxdAu1mnw5GEh-PiAp?PGbdjE#%5}7sDmdCyD56n$?MwE| za#BVVK`=b}pXtar>pzMNd8@vU9mg8m^sO#p{)R}hS!Q+nscZM8@)-{@KV{BCtl&rK zb&V-%uv2#rDrfdrxgT4o+JR@YXTr-g>HVgZyF3Q9DY8$)$ROo95+D zQ9~CYI`kxL-ok?W&Peb@K-QWLndojrZFEg+D;qQJ-bdjx0B_)hH2i9KHT&i};739M zu_!?uJ;i%>S8N~jwR<0Ai`muxuos7#w%iAmLHF_=(!SQN0lqnd8MHp^d*Rt*I|qTT z-^xQ!tq)^qHD_r`xQCQIAQAE%*v@*uHrMvui7jgMQPe^gc+z@M9^eI91-|ctMlkyz zWjPNEV5Qp@bcgH$Pnw;<+EBp2iicL-2f3s6cs6F8f0jRxng18hAWuu;(q&%9FI%Y%N#<=TViXae?B>!sOA z)sL#CPe0H9#Y=p1{iWb{!Gcd_&P=(|C*8Sr-EXnJh}7)|GK*>RGRPg5PI`b1qq=2v zPSggMJ!|y?EL&`BS{Ab&-nqorL>(nvri|j_6KOJ(9G5HaR76DjTE5zTi9U2LViDR7 zI6nS<+Z~1tHLBcm;82mkd**)ZX`1qR8dU#iX3nw`4x#w(uGa z!gvYK!Pw{C0A}eWo?<=E7&Xq0q2=rg#!js?Be8$yVvf_Hcmi{QyAic{>L(``0u!bJ z8N?#Ph_$;%2Z1qf#+EKDRqopUltBvJcW!7b9wez#jn%es|0cucf9hP*hi{z$E- z5-5&^Gc0sm1EU%|PaR(C$T(1*;W)`!-ruRFxw`k5tgSsI9A34s87|?8!Mo7L%D6tH zc-p+*(-D2eTYRtIutN0z%+>BZ>F!^W@m~o1Lg4>R1TIA>UGP^)NXdFk2{!v4^da)X z?EDkjxj2buFU*1}rK2H%*jH&mV{yc2HI-1Uw;PA-6_LlUKo4~?WozDhmYb0&;3GU{ z`3!LZVXhe|z-BI|z{3J_LRgWVnHeqFvtO2-dH4k~roy~|t(28SR0g~*4(YvR5OUER zOcJEuAq?|zRU6%H7*L!~%xiuthNiI6?OAJ<2y6b8vJLB7Qq`ShJrK6blaP@0Txf4v zXopZgFg({&vZS;ZuF>98bc(iiYR`IX$##8Se>24ke_?uFF9=}rf@mdMCwxu#qKQjV z&_I)`@Mo{Rg5RUmb^{bXq18y62^me-VoD3{)G9uNqJ?^jMkcxZHwbEq5Wet><< z1a}n+-zf&x-0i{5*ur2rXd|IsIY~mip?yB{vobBzt^?&ze-FIcLjAV!Up=MjC^T46$yQ_dcBK$LESXq!YbL;6C zu*5U!?1P?%RB&}Sx!j}8-{Ox}uA&FnfZO`DyAnp9`;r9;g|;5G9?F*MzX{nnNN^^X z0SA9TWDT77cOLP&!njeuNxyazNLQK0^7mBaF3A}19GUjZKX4%3*7KeiAl=yB8mqPz zZEinmc#!V?&`zM4zy{meNLBLSmt@0Wkuyec#V&ge&%VgDJpi`WR_tKuh79(*^vw`P*s^fcwnkdsFD2F=h9k|F}0 z_uHdnb&4n>ON&VQamLI9n~1sY!fT6zCzxk~H&NWfHE3_Dg7YbOq@1*i5^sV@J(UdO zL!4{3qq-4ybsm0i&AiPEy;IeKx=+9-GZYyBCIASp-X4jURwwBnf6FIhx+TdoK34!E z4SX`V#Q8W+yx)PIb>V7@^>)ujm_1=g;y=07Ft6`haCRT3L9J(pwutZOdM-gKM4KP##px|~C&ghqVq538ZpSvlI0h)(&CIz*x^lC-;*DGauP=YqnQrCt z2GUvT5V4_fwOGxFZ?vgZyKd)-z`Wq^_XD;+{iD<0ip2Yf(C zXHgC4zrHzz#$}+f5Bl&Dm`exQsh9oBcJEl~clc(`*%1fR4B9NOwn{O!YzQYOZ`?K5 z`yi2Lq0r-0Mq291n<|c(On5!v9^DCb|By%f7O!3OeqP#u;xebbI-veiqk&wbHj`0< zsPz{;ff;Y-Bk^#EnnbPITQ^g$BLE%!nHO8$WAz?Pm?&RkQDR7A2Bk>3n*Io5zZo@= zYd0G=kFCs^WCoNsIwgNm-XIo!zd9;U-;zZ_E182hxm@fVXKvDN>)?>gVULM?plB!e@IVd09K;EA$t<6fmvpcBK$A*z5}YMty?z=(lH{v1_eYxno3bhM5Kv` zih$B0q9Pz5B0UfR0qFuF3QAOZjr5+-t4J@>A@rJ1LrCJ=ob%uNj^~_T|69f#?~bR7 zfyrKb?}WMcUURK)e)F5M6oYLu6v@3BxZC@8j7D5A_*q)A6KvYF|BsNM6YLL=VB2>( z4L^eb|J?tdfCPbYVZ>fV;(^TqL!yqTN+x3@(FZ^YIEzgpLX3IJeABv`+cRpWyx$wO zV-76$VJG_na^7d0$#YuxR0>IB-(vUjhgtmgj5rA#B?M0BF*I59ZoWQR!hbvBl$J`y z`$)oMX#@*g4VUVFS9*c?nZ@+rC(Sp)5QD2)BuCT6=jbB@{hB;3XRrHoIkY#0K1YEw z(uBPgas;-wLU1pcn(Ztzh9f(lX$2$X+UHG`SC=^_j&ny1HX4))CDKK*QS6XiC7xr0 zQZ-jkixh@uKGxJ=IeLOL1Wk70iCC6+(z2N1X3rH*xLaB(31v5c&6+kO?&_GGDw|K> z4LC;OmbBN2s5da$>6b~PboF1(DYFWg2*L#D#7ANA1_l)8DT*{c1%(YWR@O9iR(a^1TZm!EGJnrHpgDet`;K~Hp;@XYa_X?Is6$f;)FrG5)OZ-Kr|KJPW#q^HQcx?{Un`_*=3 z2Q(ppg_W9+inw_}(XXtolpfg*N}CHy{(pqkM5f zzRq-(qU6{|*+dysG+Mx{*%HrN8-4N7l@Ck+2`X=e9it(;)$3IVvjeas+yMYo@>b`m zWw`j1TAks&%YHN|ST=wy2t*gmetzkI*AAO4(}}|%7B(@T0R}G>q^WEDJ!V{SonUB0 z-t3yikKe*%_o{bC<-Z3|3~j`Qet#Q+1_(Z6%|SQ20Bmz}9afFm5kCheKZynIO=YhT z*q#1?f`4;`l&-_eIJq~R+nXW|EoY%X8Ro4Qu?{{3O&CnNxc9YYiYyjU@T?rpoT5%9 zYn!Zv>)~^RwjBIi!)1Y6uQVkOV69yTu#38WmRw$I7& z<0IIxD~J{AEX;OKBrt!F-5Bwbhv@>`vT;m7BgwY63VrH zUrILwKR@xHn*{5AtLWHB#75keFp8fKX3G z&V2)|>H(9$gvx_^?Z>KmnG@|ih^FmH$S(abFb(WOeIfzVzCQ>U!Yl}2iuP;(W{Dke zEgxT@YjF@#bUQO*K&&6QJQDCRJhpahV2nkiGE8o0A(Amh@HRbd3wH4Z*EbLbCQot$ z2#@l0+76b01WeL}X)Uh(s%s_0DH`Z%e;eSdl$6O~_`@ax-FE2oL#5YgKri4qDy91( zb~jfbG)k&u44~CA3TU;Q-qUJ%2uzg#trpZHg3Kg%8F&=pT((CXE#gmj6^xR0@$B)n5VLK+I-nn&uZ;8uL+SdG`kfs41I)1K)X+!v@g>}YucXr81LhAL6GU| zDsM&zMo;1UaI0IGi15^-tPaT+?zKC}-#86@ewaZ;u!kC;-lK&O&2o5AvR?`iE70{ifaj%X z7Y9L?_~j|SwsTU?$JTT!fC=pFdCUeYOytifO%&yOt-xjk7&Da!+^;n*z%*UPb`Qfr z5B;`OBw(@BN5R2F;_<3ei4+MQ`At-~iu46R0t)pplu8Ub*_nti{+peWybq1=V*Jlh zrxGk4U{-^;phJbk&Me9q{KMkvf9I<8{~Zq6 zuW$0p0{_Dn5XVA;iL4JGhYRDqvW_NLy3z}QvXJruRj*(KX1Em|cEOHn(lFnl@R|N+ z`w8LO?9nsWfy1qU`ZFq&B0i`49)79MZtGL9d)TmW=>9zTu;>0;h;i8s&Z@CPDaE+S zzTTt}=MM1(CRM;3i{|)psZX;u_?HMV9XEfX4!vojB?5}kkFACb* zO_|0$6Z{r$$W|JUUFcXXG|7K1al{&#P{LictxVgOX6sRi_Wv+uQ*3p}_(C^S`O#^g z6%TMWJUxkIi=XyyqPlJ}eSebiHI=XS99^w9H!9`~GR#})Qz^(s2c9*o>I8bEt-O!R zp;mS+B^pTRe8nlqtnCmJ|6KC+L3+{mLd=Bw==@xHO}!%d8X1>6Fr|xh=Lx(;Q_-Qb zKn|(PvAOxJ27-p8*4)4|>iRsw`3^K0E|fkfhs-p;rBG|~ z1<$gQrMZDBdlKKY$;{KRb&Q$4zT)u*{@UY0JN+Z)bf-K5!Yn;mX@Vz5&t46mc*#Oq zTzPkFO<7GNw=&32-O+(BP4iI;9mV-^jzP=uk7##tiln9O81rC&z+J~-t=bNmP%s%p zF<5V3mT}@WC)oE$uM34wY6$p*-bT#PuAveT)*-J4w`*NK1is;OJuJP!WVsh+hsGF_ z-z<;Z#)~xTPnVlCr1tn6ff5gq7W$Xk?H6f-BrhQ)21jL8lIZCHM;SP4h`I0SdQ(aJ z@r@n(K79J7pq3ux8T8!hZ(O4zzjKW)3FWMR$FBTSFA78eRG>vXF90#L2(oAt;KE}` zG0TjUQRqg(B^=lnwq{fywd)43Hr>S+i9`w-vxiH416k|saBe_}M8NHxM}f)7&?#64 z5V2d(Bk!+(ZoLE~@({r60+kNkU}zz~`3AzS*C98*jO{evg5^U=-fq#9(xGplv*O}g zRzP&G{V<|m5iu*`$yrBt`5WjUNt4IdWLNGnX!V&W(I^*w{#iS2wazh31e0$ic#v=b zk^J|2Hlg>Ga9|EqD9Q*P?|Dz1P*p;^A-g8^)cydfPU_%iEe6@+`$RuU?jtk9L&kZ1 zZ1Ie>`G@z1T>@z@F+N48!R-5o3b&Tou4!q3q8`y+x26Xjz5-g%JtDYYyNX{sqsSu# znfBgOe9cVk>7GmGDo*H!vc0+aw zQV>(>K>uJHTFZ|Q1;C<2OJMcU|H8Y=aJoVy5txE9xi$c>-2Si#N~^i*uC~c5+^YyD zlFS%aJBdLKx+~$XR|7lnfTD=I6s0eN zHi|8r`+E0w758L=YCCBy{RsJ8g%CBqr7XPY7MC=QTkZ=dKxZqnUwp6q7`XaV?-+$1 z(R`!>vyA-)x+IK3>^&#KfxkZ|$D=C0fq(}kivPC<<>RFdhP?)i1>kbxC%RBL|U>lg3Ph`K6kwa8+%3b1l*Hts?UBY}D_m2RR{V>{x;db_|#Fc*u;SzIh5t^k4eql5`O$6`$x zoJSx+29RR9uy!SN#+MH(KKEG_v^D5C9`WC?2Q3cfBisI*C#hq;`hsR)X?cldo)R%Z z+wu!=C+1W@s=cZERRnFK)lv`83kb}tOoTVBFSv_DC_pG>IK%-0t0}=JL-*iYHeol< z`0@Znq4xBtS4!gu;^M%@*jLo0FvO(wBxCbXSD(mp@b03w?SE`DstZj=VAVOkoUFVQ z)VVTi)!wVYMltB0hf%}nlV7@YC2U=s+jh#IT}Wg=h%IiQd{wBsS`@AIJdZx{Ed9E^ zdCeahj?bmZvr=*EG+Fu{HTkeU5P6{|Df zi^K;_!gd*ep=7QB^}J#)R?k|8*nn}GL!*y|0zMu40R3D@OBwQO-kLnFDE}^( zd#-uVO%K}hfDA7}Yyok zX;t5t?{1*qd?E(DF8+oPY5?1Et?X$yz4UwNl= z8)I@#Pl6el!U6RD6}VOF;u5 zNU(SWArlw^%j=+<3y9Y_K#dks)aoGs&q}A2)WgPSWH3^Pb@AO?{c8)|FJHvu-b|YMN-c{ z-ZHx=HOu=AXNIjC_8&YIl%)%g(StpkO)IUxU|pvKzk$AHhLYoF8L@WP53Z(i0##k^0w14m#Jwy3g|lHWiGS>h6hMAz@&iJE zs1)1zIO6^PAQ8!s{3dBXwyx9amCk*LPb|r%c&Sa0Q{Y&LQl5!4i3x)>z}&Y6mEh0Z znvVJ!IDQZCtHgt7Kh*mck2G9`w;oa=iZHzc513Icz)8+2R_iXE|vFS=aYK7z9rDF z?R8K~yxfPq-vu#OJB5{R^6yN2_4I6 z9hVP8D4*x92*q|hO#GPMEac6 zNqJJV!(qh0IR`Rz|DVCGDa`j7!fUYaGl>6P85x+WoF&vBkDqKnw{~drP_7A5V({$^ zCoYb0$ZnbYYW1%L(Qcr^y=5*PBjlp;HV$iGUTOgWdtTh*k!&>U1DQ`#jlxL3OH0sq z|LQhZ+2MYtpU9@O{f>D5`u)oSzbx?oo(0&apaM#aqR-FJ6_Qo>w~2Qm#g6YJ`K1$M z&MIt3ESsz0u~m6)e&<7A-4kPoloN+PM#O2IL#FFTM_d@~{mH?+xWz_S^Zj_9F^w?U zmsOgs_6L>f+OJVM7N9Jn74j4P;VTsfCS}oKJhmsEhOZ3sxd$aAl0Wo#3st%~)S~!D z+!*U@y?D;_>F?toDN$HwRo2{9OCxD|5V5uB<3Mf8ly%J&SPApU&eu1IHbDR2`s2nB5$uQn}51X+E{hg+D=SSa9U{%5^Z;);8 z6p7zSOmMTi9pxEx{kY}zc3={A<6u&B#|@`;=B&edj$-OeHn*lCeKUM|qC6PF-6slt zwO2&6K7{EgMM)c6Jr|{?3OfV0B4pDB1(Jlyn36Y2hGpBD#!VIGGAUI`v!x9RAY`1% zX_BE|T`h%WgyuTY)ShQ%>X9Vh69XU)BH%QPMkfHf?#d{l>8sjwN8~nZ>=y937#-z9!#*VbY#heeN17&duTR zLH<$koksHQ_Oyp@J)}{QXj#G?JuqCYqV#4{elLBwe>n$qk;Y5yF1FL(qp=DF8C;<7 z2i9`tXV|zfTnEjP;X;wcBbrxwqnonZzSf`&QYqQu*=r~-FWZ!xZJu6^{FPZ^ z=Gu23ibXgXtfI1?v~r^ya)gQt{dIs!YyQ_(Y$`W5bKY3WE^pSkY<)_17m56oq1*m1_cipi#xMOKGG`{iRUlA1N?o_STI4i!rD2bf!pp7odkQ?^H>GZ z;i$IopF!jl#K&3>0Ht74Lkn6 z4@W8@c{2h)z|0nHa7FR3?cAy_ng>wZIGBy@<<)df({d2jSorXi4!RnnA6^$nR2)YI zq~OMCGaU*wI!9~{^ER`TrQO~S-krXI%{`Vx7}|p~07Rk~K|UV-TZG){-7}v~{!E=@^ z^TY~WHT%yu;AVrKC}QZ{a&|AhEYrPrmZiBPZ&MR;&5zJun;_D$LK2xQUlzMQFZ*&z zQ}jY>FQ1nN7z^1V`SHpo#}aJsXrz60(biL;7GD4QcFERNr-V0EtEN)*5nMwA&1!ih znlWumqi@SGU?)Vn+HvXqtnz7}QS?KC(ZoDl6VIz%bmJJWyZ=aa!-Ym}=Js4gBgz4o z99$f?ffgc!B@KzOGFQ~BjAM^jh6cgqQ3`>g{0AC7egN~YT^3G@kMTf zn$yx1Ad}L^s2j;vaauH(0VDjrJLE{1D(`oK;QAoYg{ryDrVwFoIaD!nzyZ!X7WvDql3T!kt) z6J}m()-~Q!(3-YlCu-Jw6w*Ot>F{fk-3o}z9I!1j<$3kSnZGS*u~b-%2)S_XkUI^! zqf6G4*;U8ydbea^X~8>J;pYgoIn4`T!QR1gBik?DQUoG|mSAkFWAd)7m&mmo!#f+K z$1KG!ecF$_s7k|tJHUMr%G^ZMZG;Sug@!gb=Uck`l7Z>w%vm}}!28vwma zNZ6T?qW~FH$F@S}$-RrwhfoqxEn4j(w7vdbYOt&QJ+f=GfN+EO;P1i>O3pui3vd~! zfn3-**cQMoNYoYQMm&$e}D}ZQ+D}W6<6fBTlHL^F>ni7E_caE^w zPLT(I<$jeS08Ldnhtu=HtQi&{w?zS9OX|l^tCuUxtiS)sHFbFUuBvb={>&Sv+^ml> zi1Jqu;vt(I{ViYZ*h%YCvzE6m-T_p#PeL~Yd)HEzsiURpy6$~x$a`K-S-FXrQ_bwe zSn+0R;tUh5d5@QelbTP>&I~sB=ygw95O_8mzBVj$lGxJ*HCiOGm{XTacZ%`^^*45I zdec<$ZaJ0}AP(5bMdpQ+tbUG`^tQ`-&PG--g!rKD?X@&12fHVWCs0yW;iH4>Qo?z1 z?B`c>RXsgzQ*Y_Idn&nXb^Pu-X&>7#4h@-|Yq4$piY+es-OXNAjD~RoUhx4wH4No^ zQ;kvext&4Tj!p;i^4lUs`+6YMDq5e|kRVstYr!NzbEMF4aa!tv*Qv(?%jN8NWF3+t zg2!!e+u)gW0ark;3F>7f{YG=EWzmvRv3J`tlG-L{K3#@{)x)9e$?-!fbiJ(I*DZG% zkQ3%3yYfYFmJHF9q{j6yXiep-y#{DXlqIW(5uQSJR#Mm1W%0%Jy(jQSb)avcc4uhZ z2|!aqGF>kiEl5l8Oeb~fdMV>tZp2R@1I^`_4uo1qE+o=!(f~4n_r!E@?X@Ugn*9xD znl`Wb5&d9#@KZ6z2v!sQVSf88dG30oRg+b7a>~jU7AK_uKFdYC6xm-Av0-WSb1c-H z!1^6m=_gp|gg2CMN7uIc>OxUxEK>VLQ`KYmD-cwm?g){}RH_jOMrmieiSZi_o?4$j z#m#k4FRF?bJMav8-qxQ0DC-5uq7JBK3~88q9a9t9*SvNUMDjcoILGWZTMbCT){mn& z?a`0R%!qW7HxaF;-zL3Y^?TvqBIxk0I>~Rep6ZXQocm3(;yvwb_EX`MKC{yHm6D82#<8Do8!l z0pPo17Y(}`{Wj+NZY8KkkzY({uuWS+m+e7F-Ne2MPGA&`$Trav0C%U}y6?`Rv!xcv zr5^)?>k3Qud&xx@<6sdKl|nluH|Ujj_ufq1lKOh^qQw=%)0Dn(`i((l+gD^{g{)jE z)}?P$jw8Gdf`4MY-NMMAcX7 z@O8IV-^N?s&JJr~o!n3dy&qF;07JaY-KyF|r7ixZA+ZO=jx+oQ#iB3(f{3L6^ZaH> zpe&gOa^^?S?9ag08I&Jl&F~3?I4?>G_SgerQMnI($6`?mgy|H1&53)YVE?K7SK=|C zC$)B#1aX=FM8{zQIE@@Q8S_?n+`L-06pG`=ZmOD#;2_s_!S&(_+EtalwvQ3xij51t z6*}W8iCd6h!$;9Rp45Fn)TzofqW6H8HO$zk@8vahH>qVAAYPULV8c1Fkd||R!k;BY zSqT7!%_N~Ooxdk6wxgK{HT^Xz3Whx*EH_~n?UEzIIgVQ)uFcW!O zgMNuCp?9+@uPop?L*xt9@nGWoEi<(f2eg_5aq3=AvT{DW^i8^Z$n9wQ068-@eBA?d_Sio?#C8(FX}da! zZA9&{ve||ie&#-y^2K7X7L5zl{<5R8Sf`lw;4dFAd(ph6AU*= zU$pl>FkIgWHc+kcTVdM=y9NiMy-}Kp-$0d6O1K9xWE???QihP{fvB!if6rd>|Nk_# z(gx7x;c1BQOfe0ucBQI5c5eB$Y9mHAJ=6M=Esyfbo5!aQ41=j(FBbaH3Xu9zvQw(F z9&DH0Yx>OjNa?U;P9HU&=Q@n@L2TB~o|NKz!z>-{8BR*U2@Te{xG6^hNEFZU~!6XXvZ@)N7eY8lC zInj}1t6x_f4c8>(LkEWQ7C2k&9u5f8`OsyD*FG3V@a!_Qd|^IUGurZXzsXQt?nOTW zP)M5O@8y5bisqe#!@Y+-63de}KdO?%5<%V<&^3Aaepfyf=M|lQwS_+kpteAg1oQ|H zCHo#FMtp}7L%(BG{tP4Dk@}Mi<(|l7{}3?k048V5gx0G(sIbD;jcA})_k4ofrtYl6 zd@#YG!T4z}+%5-}lyKK+>@vPM!$A>o*{Ih0R1Zxi*6uM`cwH!gXcbne?>!J>`ZzM!!j+odsv`LIMc zP0em$uBg72<4DLT9hG-!wnu-q2M|2__4CUDzbx>-)B@r)-a;hWU9ZoBm}eKS=^l}i zd|P)^X2nvO6FQeGpBh8w;K;;At+vFR^kbdbW3^`J?kHl)5q1c zP0K#9Ehiv^b4lWHljT2(*QOV3XM~t#$waOk6t7)*sH8c*taS!wb54CS>abn{hf4WP zOQB&t!wsN-j+X;nkdpSJ8%+1L5?x4NwX^3`fc5?;%VD>u@ieZ_ks8Z8dC?{vK+(9( zilf4Kk?N~5Z;plyt=~JAE9=1K7F(|`eC|~yB8|f$Z~s)z%FtCuav>T28G+2N(t zIoN6_6sW_sOdMA+R0k-BKn#VpY+Ik_`qfXXV zZdQsmS|G!692zJL-EimkDsK?4N3QI8zT|!Y>+uM$a}@}rcJh|T8OCF?_ieP28WvoK zhTpedpd|LV2$gIo2*u+uz6E3a55Os~8F_v5=roNn=cYhnE`Q^PYKWLy>cna=oF0C^ ztT4VQs8&5~@NQ%E_zK^Lc1yqcMc99_-KWRu{3~Su|#<%_4x-jpacd?vZ##LJB@7Op9@6>lITLCH;?6R zBG}z(8;h?Qn~#nzJZ62pEEwVIb@2g6bc{R83s!F~jbH9Dj4duMd;4rgQA=nXd5s4| zzujO9F~S>#DtS7yCoeCrq#ijN-bF_c?a_F;-wPkNsTTmFk~CanwynoyIo7GwrbKa- zyPU#4Ra{;jzq~6^MDIm`$=50tN$ejV6E`v{X_E5kmF?h$HWf z0x4a{HK{qo=B6mc#~iYI3DJc405DE^ki-K&#)xCS%X3EiqdwTq8LuOQVT^Vp&-<}1 zQJQwyCdUSn9oJeaT~y94z7_bY0*HpOp*e;KTWyld!r?>4MY_3{u+uRfOK_)t1?4<1 z0Mk1Gmng(4grS zttkye9ChU^`?_hLwHr^G`TWn=>Elcixk!RYX zt<`9HI)UwA?Hc;! zc~soRNB5*}HzvD%iO(Sv zSDg!uG&UWZ=TyF19K+x@XDrVJFs~W_RsMSPzMi|mT{GW6TBVC36=^ph7dlI-iIL`~ zQx<_ji3byf4P)hr>g~5ArZ2oFa)dR2dxGbz2ou7)inimz>auqin_tJkwx{fAXdljY z7}7*fw6l}W_YRtvc(!Rw8j?4sK3_uZuE|qT6*S- z?Ug()ZzSm0cu`Ls@a#Xd%SPSCrp7z|vppXplu zrT@pQ+U;*3fPb#_8#?Yh_JLyE#p8l*DAkC6gg*iB_L? zpkj=Tx zx;~hFz*);9M!*_aG5D#8-*DVANgQv~!09c8BNrv2Om**V%~`%W#qKI3tzVLMphUU( zUpU9MRM;3G&D@@ip+tmNwtfd)KmH!N{xS8JngAd&BDTQD{TM+$ytz5DhgSom`V5kj z!h;Ea^4j6dNJ!Rz-?aE4>N$6r=z-Z6dfZJ4Uo_+3FoF%`Y?nnvw~J){9q`Mn^Q<4H z8uTm^RF$j*v1bLW@ra2`!mM_{y6!+(+jEucxu7e7(cH@6?$r3VexXzFZfnm;2axTI z7SFm?PvU`FW^%7!7qX;V8y{(c`rG7U(Z_H!=(|3sGhvsc4Pv^j?`??HGF7-zKVtsz zp^uRT@?nPixI-?vG$=I`+ck~_HqM*1cz2A--lV=Sabk#TooA#N;tf=(bUm@F=GJ?g z<#j>oL(9*$F2h~~xOa>yZ5=XXTc&Q++37As@hd!DYiHpRNZ4v5!xtO`#mm5$+4tq-tH?mgtw!MI_-dnR1noX|)MIv1?F{~=A_2W=_YtD}0 z%8}YHc-UnPPN(C?**%XBk`lC`=Osy(33{AQNg_!wwa448V8wbb87{NW@826NCEBjJ z3zI?R_|p?g=2W;>kzUNLBg0Co>>G6!uBUu`jPk-z%~R1ER4L?m*^(%%aYxc4;g=#k z;)@Y6-#~HRh27q5al_h<*$=KO9KLjTfqk>FVj5=c0A&u=cHgeu4~nlmjSkxaoKq(`6nQ?m|7!emHr-2FtW z$>s_@ro%cZqeV<#jFolzv&E)*(9U~*|EvQ0Rw^mSI~KH=>u_BBid zX6mC`ETtwEN|ec*MtlePw^05>e@4OSfdJBaEo_US5Qq}#zD59W71@I~FtJWBGyuS#AksH6$h-sn0lU+mli@9 zhALOyPLaO6$#n(|zm4@rv zN(8)}bs94}0`ePS8!sg~E~qP3W9TdNu;Q<$YIbP(Z1li7@$^b4)xMF)Ug~r{9&jn{K)& zHv^iO(jfLtJ%5r+3PDrVPpj+W32M{)Vkz;2oW@eWJEitFptb=XUm`%;XnN`e;vF2Iv^$Tt^O@*AdS+@ZkNu(!R5K5N zHBx)a;;+0@?)Ou2w3Dr2aZDPEILo#vgXTu?u>dITxhLD^O!)eOemeDrXm6z{{hkKG zJ<=mhEX<)^Opif_l{T#B)TcSsDV|;L6W86Y-+ZlP{~;z2h|Kp7;V(tkMAcPef73H` zr$OqaelKG1V<}2xjrsl_rF$Q2V?B&k9nRD;GTN^T?Zg9-+yXhKgQV?xcj&W<18Hup z7y2bPP@|*P0UR77Gn(u2c0k4Lhg|$StHEmsdN;tk#q;*FzcaB*_)?q!(|3Ts*vy-|Dqe2Kk!XoD+d-dqKr`mD2HQR2>4=TSxG zf)>7unzwTfj=is!zl7foQ#uxwddrrxD2QdiF6HXvQN;s~T*x$HjPLa8#|{0SAXaRv!zY&Bh5OWRbS>U&?>t7L{}GzjRjjVGHg$8TTVe+l)_A0if^|5VxLhll3C zRdG6Qhu5{cQ{&qz5~}SbgOM?JC9yWUp!Zg#&0CqsL-50+)D>M%=4aL&L_e8?d`z9b z#aJ?kt~$=W^4Ke5whlsF>?3vN-8uJ)q2?uy$+`3$!wV~Ns80+uo^O#h#M9peBs%}3 z^?(ljp7#EqROJjDhyF2HWEWh8_@nIb7UU@q2Km3b!|!u^%NTZyu-k!{JQYENwZ=1( zg-=2G;Y#&8rr>51fITBd@&@!DH0!|2$2&s23|ZtH8((9@eRjkVRhiSUh*1Gb6Tyd^ z%){c4QFH8z!aC>lBdCZ2f!&mx04PHwV#TvtNvs|&0W<7QO86JdbI{#hpH;UM7y+IV`sQ*{H}thVN1&hZq@63^sh(Rf!B8d0hp|GA;u*jR#Rlhcdt&hW@W&QmsRZYHIp= zy#)QQdi!SgmKFaao4|;zfQA{@Y!%8I@I9^+H(Vx%w0$ud&@03*ARB{OqX7 zWXq?O7A(yU#KKSXEI9Aw1>N8@G>q+ZH+t1Etby=-P#e+I^Dk`aGc`Ymt6+8iL~zgy zH=XskSqGls$eYBu`j5xA1=e~fJ)TwUY7j(77shh>RY*~fK2+iD#KxW-eI-M+%H#?3VH{b)&fd07I*x2~5kvEik>Q@`-9r?aj+t(0}-D*)&>P8ja zONCtU_(dJhG)$?IMgQ8-%u(wt<4_gd&E(1+*l>dM;tq?!Nu{$N=C8m21&c*_rIq4B zt#-<}12;b5W&)GXdMRpjXAQ5HjrIyb33Ke%Yir{KUQTZ;^Ipk!`m*SG10XA5-y6QO z?t8aquit)*%5w`afz1_#zB5uQx?IkruzzKXl?g$!)-c+=Z+qQy>Rb$oAj2|^NI|X6-|w<3srqTZGY2wU2Q}g|BuCWr3d*ky zPO`u7e&4IOETr4ZY5yU0&@64)k)a8C)#lw+WXeKF@zw5S$sU&y|GSVhS@XtP!$6hb)o@Q@}YEPWpzf$!vk0x&Il>21?k32)!M;C68yE#y~M)Cn+6ZO&_| z&@!G2hpr|=;&NAErzsr?Eax1akK-i@5OaesSlWGRz9a%=KQw2uJp0q&EO-SxxVF{A z`Yy9;GBWRy;u6)il|cL>l?>Y+6*|IOx4?<%?1DU+@~-x;BK%wXcJm{2OCSca3lM7f z6(u#?THoL;Dzka3rKs>-5cz9k$}l)1ZX*z^IP#xq9NNIvMW5{{z*0jN_SV5gJbuy-25@<>U-N^S$;;XUOYK9 z`Q|7#bf~0pSF)t1?6TqU7Aa~|^IL{}k%-5mB4G%@ z1G<(e1J*Bg&UwWYCc%b_gDhc9`wTOBjekHgLD7>F;a84yZ>%z@inc3yTriep%qZ*#cR590Z&0`cbaRPJ0~3go?IIG@oCLT$Z=*;X&FGI_Qm+;I8vL4(E)?7}HU zKtYwcuoV*kW1a4Des4GahEng5^(f70O?!iS7CLgrb_NqLI6YP?6|^>gu0sxY`5Wj? zrJ=%&vpd4X{Z7c0T-kM4t=;3*iP*ZGC+{Bcx*bF0nrHHf@sXmu_ML6tz8ObEqfw~L zA4#5mj~4#10L?!WL(SYPOM`y;19$Qw8WB`BS*p?gC{< zr#r`CRfNUF?~nWFes#cB^;2*rEiO+=LInfA_ps#fV(BWKh;_ z&xXgR-n4;odyBOzW;WU>q3vn`Hn6}}>r+nXXak!^G}4&Z*Vo6$t7Ru~=Vtb}die2< z+edw#(tg^HE-WncZRq0Fx%o=mjm0wf3>V$|+xwP4sBAmC+qne+fR;}1DD}HEl`5sA)Uajh8NOFZE{o;mjx;1OT=fq;rwLR z^0iT6zJER((tu%rD`K-RFp||#5-T6|PPX1(NKs$neO%=D<(xCoG7yidK^`P5UiJM3 zx@OzznHJr8>T6kgq$kaA_FJd$ciyiT&t&dPwl*xC`|xIs(!9`6Irnbp=?>?tc2+m3T8fO$-F_e$vM@W> zl5RaI!hXqWMY>(JFJDP_90MlQOGKM@Q~HYPLxsLXDVOIWOKO#AjrEw^L~GFpca64a zkXz8ghwB(G;rOCihcU}gd;5ff1TLIjAe?^-wZsfvLfCwr^(Jb|+kF{BH*yV+C|fJZ zj03h%T!szsAOu+{9o&y&rHdQ`?Zw%Wr1H7_+^1#7Wid>Ul#affnOH*Wr1H7_+^1#7Wid> zUl#aff&YIkAP#PDWi=*n*2#0MRh+I*F|By4QGbi;V%;H4LBB7y|CQb;69|Xf_Kk8K zT__CCKhiq;P;NWAY1t>*pE|ng7+O6SZx!LJQ&7+iWDl~845M9Y9o&_|2e=ikYAfxx z{qfO->v%s(YDCM*UtffhZhr%%W7o+!sj+)=nr;|7WGO!ZwkR*n-5 z%#jp{vYzg?8`T!R^Lfegy0&PP_Nw{(czI9`iGE@+B85TgMX2HtS+mM-sVCK&-#BY1PAPJ@0BS*@EZ2?NM$h)yqfe6b@^Ar>rxACJFB?p&#oWOx z-ro>p${=n*W&eefbjoqa4csbWHGPLu!o+mtV!+ zXL4+|Rjjk;g`R$wboUX6_ES6eQFKb^jIe0V0WV$d&sut>48*w8uU{mTuq`;Bt6;@? z`*}{ZAF{?AdUEW6l{Sast1Dgm*3JrqzW>n9w{P^nzC)#JHCn6yAM3v?8-H0UuKa$; zS(!^JYmg7~3v|kh{czsNOg(Nl^X^*(H9MI_5Avhg5?7B91rpx-jsEyhkK#;^KMcTo z6*HW(jnq3ftj}a$S*xEab#^Iy_wl6MhKN?%Ua5_2n=;A3MD1i7*H=;^t(k>c%Pbbf zAH+0l8xarqZ4Ek~DD&uw>sREuOPZNwTRjM2uB5+y+FT-K5yI;Hn#W7(8s2W>_z;iI zt(<#T2WY9&g%pG$Jn(k%Hwp1sRo(L*5g`sAGzPki+nmG#suV=DxvTj+`$MeD8tX>x z(;#(v;3i%Sat%>^wr_68?W-2k`a*{t&9TDLlJy`lBc}g0*pwneA)89xMo;8Jyv5w^ zsdTz}PV(NYZXjRaya#9`W~ehyjs+)h>lK)d5(4_99Wht^zarMeBGufACsPCTmpNV0 zM+!sv9D0tpz(~PKM(Oa=gvr6JM4G_K2NMBnF7yuWhX$jH?>R5kZ3y{Zkya$e)YmN0lJ!(SqWkPb+ z*8w*_gMz|{rmsw#QAZ^$Lf;-&;EO`=>{tTXupw~m6!`VNhf7MT8H2`+Qx5|en^`!e z8?LbN9n^+~!E^D5dbDu2$_ZOJ7XiUuI|<7*Ikf{*&qH2YiZUFe6-G9oKNg8(TL?#8 z+OJJC>M^V<%o2{$KCcbEL<}ByRroAQ`#8Pm{PmtfiGTKG|GJ&sA8Q7v852Zr^;*2p zR4z;kV|+n(*pj|_oK)v{(_FSs7>L~XI=?gIrgj=K*6Jt)`5cpeD**ni`NJb&K)LXm z6++-QkQxYJcZnk?N6~<4um1=hObOTr6ng`TM3B_s<$#Q6`6PtQ1O(|p+225fVCaM^ z97rJf@Dwr5jsZNNCP{MjIbuT^Oxh2)m&xOQIR^w+jy?jYY*s;W3_#tV=ZO?f*E*oq z2`y!x2~f<54e{r%k&N>ve@P#&WW8D$-Bwnb8(@umVD_bnUV)1$dJz3z=q*@vuq#;P zUUfKj)9$^RaNgO88%$BQSGKl>uH+_ct=$V4q&}r1l)!$z`Pkp@I%ui3@ zS-IE#aO;}NH}LMZNlmx_eC3gLYiDl1yB%7V&YznOay?cM_Li-MTVN`>D4aIiabCk) zvDaS9=~4&Cn|^*e5h&!ViTyw9y?0a-?bbdV1w~LmP(W&sA}CFICo0lG6s0#6klw4b zAV_Zl0xBgcy#}PW(3?o_9YXI3B?JQT8+^_=zxSNq`#jGn@A}razV)v8Cz*Th$z<-C zU9NrYz5i@_6TVjuUsBMEq{y=x9YwNN?6wX!ca_{yU2qiZAzCuv+dP18NKD~x(v=tZ z__F9jxeX1ZY6MJsM6X56`D*^jbfcBC?H_H07uW%$wfcE%5OPNMW-5=!(n74rosK3E zW`A))ri0)GmCypI%Sih0*QP-prIU$Kieq`Km&W`rEnf8+0Y~!QDn;>y*zqjI(jo`# zjKo=A=0~u;yu|wM{*Dn1iWRV$iWkil#Rkz7exF|tIe4E(H8u%24JIR(IK zGHD;2wDMfe@B$UZv}lW}vjmZS5PK>A8j|8++z@?jv_ z#=8zJ5xY={V`;4Xv3CDXljr~<+Lr9(PVk9wyY`$+8s6*n}>^LN{x#ISncn##NLKTLlvZN zxFr zpX`wq8dbO<1MmX6mK_rxB97*Jy()vxe2KL?o)LyTLl(})DQiBaF*m#k@P+DB7i0Hj4 znY_&t+dXxX=66y0cr;V{Yy(o%X}p2v;)2Mi67v^GQmv5@L9&kLwJ{XVB-a9o2x8S2 zjJZw>(e|N2y<1ys<`;lE1(sr6+ONr)&Gi{~VF2R$(El zB~rb4aMHv1VWpSuN^oygb;SHI@l8#26zqMhg7jU_(U21tY)lT;)61UBB9Yu$3UzcS z`XpK63)`I>{I%U!#g$BQJv2B9Mkx#-SGS$-rkvk0PX)^?uL}l0V++)TH2G>MG3+;P z7%63V5VYgD%hg_WJ*usVl6_y5x^%U^Qs6F|SJ7b=(YN4FPNDZ9yM!_bE(F5FH;@$^jA{ym)@Q`1d_&S zEGEhW=eW3}-FxWXz1A~Lu)hoMaf@t-iTt8YROcokK=f%!X_r^EZcm z0TY6lCJqBFS6VuPTC{anwM{ujeSp934X;%JbY%7zv`IGiG#pRK$FcbnWE0o5i|>z2 za*nKAVB|Nx4FldbJk66Lz`Y9A#L=9v8L5xs$2k(0PSfZ`R_GnuBwix&;dxx^-+x<5 zt|e$V0%%eH5v`zGQiQ&kXKhUzY6u1E^~hl0XXVQ$lR*8-W%LC#yo;@+NU zk-9XG-GND!kpr$9^pF1H2MQ<>H@y?|6UV^qP|_`jzUNV=-9HA@q^e!W*}n0=a^v?0 z96|L0FZVaw95pDK;BC8CXKvzWpld?7U~vScl2ojZ^<*u%qx7s_EyUSbC{CR>g`kr= zLN_JiIp8J6ZRj7=>+k<9HKJ3ALY#py^W$w64%UFuL3Xx>iw3&vPJd2W=(rZ!+PftIWxEkkps`QUjOvZy}dw#I>xD9^EpP}Xy^$6uvq!n zZOrVmkpucw8nu`a$us>#%tCuEl(ta{_X!R0^Sw1%24kF=T>mta=5v1Sn?$>_%P!{& zHd$tVRxu8kv$0(LrCH@;o?nW{{!9^RVO5Yjl$(FGfX%BuC_kN%=uZj`ZjGfHyG5TfN_w z??g6tT3>NsC&;Ulk)A@FR>R>n2v2pO>7!|^`L{Ly7e7$V&z1sz-y#}lyOpAM+}uMW zV?J)j#Dm=}PDwYXg?xmQoqj3XGIOo~bD!M4O)3%&!!&%kp@UNY&g368Fl|AQPJ`zx8+W(IaI9M+O zw$iiz^=HQ7|EFzD!}>P02Zt(Hlbq?b!$j&tPE_Eh8CiP3!*^&{ba4F7h7F82_kiba z91X^l=lMVvPm{WEnt+`wW9L|zY)-IC)r#+xz!Vq2D1L&httv+G>f^QbWq_qDxV%Ci z+U5Y%|NXNwOrHFqArD;tANm1*GW|a^eAN>K)VYwF%9<6rBgf*nI}Vxu!G=onMG1uPBCsw=^@?+IUuz)=xVM;v|H(Uwqp znpQByegT1O$#|w3SAK;y!C|alg#0j`B4(EDnB=#wVm|L^SOzZuT|`{94@!2ie{ zD1^43)gu9v@AEwP>Gk1W><-ZHAr!hvIzD0OK zy#?%u6Y~>Y{u_SU^Awb0eAByAXr00925OD z!5{B&QSwE=$d?nlj44{^#kv~rMF03q6-v{l9=xZr1P?)yCY#O0D=a@I*$}ETR~^|x z3}&oTR}=;KV|MfWe8|X&CaSynbO(iN>`T`?0}D2p=jv*6=fJW7jhMm`l@XV2yU8sH zqc7H8m&Ew&?^F`?&7pj94~+7Lp2(S4r}6+0Ur+;nY=nnykchLca)BRV z3+8OK=I&b~CGX!9JMYlv?-TAvYO*#=_<#hWty zHy7X`TZC`th?^e}V|YQr16C4xrm9hCcNDwz@-(fgPOaNzXi%F4WO;?-`l_|1x6}s6 zb9wdm3!!@G-oO({F4^3Ta;-r=9^yEcfc5Z%Q!dy@t@AvT?0esO^;UdoSJwm6Y3Adv zOZCd%zhSH9xQ@Ily_KvAHYB82_gv3^%SZ5fkl>AZ!IXM=o;}f*PNwhW=kbN7p07{r z3T{croheCcf`~rmDk`t8s4G`VQbMK@U)0b^7AQI(bg=#x_FCyBWE2uCkcR^a>V%cn zmTp!w?VIH-Oxmo=j{6347yrN_@jhH(~fG5RKz0CW`MkO7@`dk{4GY8MY%O4@O_Q4!3hg5tZA79ZmP{9K^|#uZgPVIhiOPle3RR8>^Glz14t z%({L8KD=;-%zN3IVFOw`)dNd2hsu&#%F47RXuqix69zsO=Ll%nmx)hAl2fe7P!A+& zjM!6-4C`CG>f~*qq`J45N>0#stYsV`rI3!*SGHBrtyR(2wEdFAR&!NRlOWbZid=Th zSkz+&Sy+aqLwiflcd2}EIhuUg5Fj`W#uWEM#~Iw&Fh@1*P%2k=2vDVXhfL3)Ijd)q znvgbi7070Y3deUWRB=>v&q!kP3cTfOjmbTn29_CR+{TKSe;g{D=DQeU6c{_DYgbw% zNOyvSJNJDa%JXhD(Q1iIUH`_lAl-50+~EOS98Ctqu_B#(z)vW`YaD_!BP%X&hhcl2 z2tYok);->`zhU(!m`3{uutMF<-7(Rn-hyCSy z*3+Efk4PTM$(B^6`u^>PUAuXU&NesL{EKa}ONUhd-q2nV71#5Qz?g%y25tl z{nD6Nt0Q8L=ipV7YsOOEYIp>`rhY2`&W@|EKfSv{boC!gGi%O{*W(|mspFe$0WFi3S6>1>3Hby& zeLMLRB&VPa1t9Sw3SkJ2xZXDJs(! z?-~vW-7`C{I|FqI!`bXezTNG3?&&W%+76+r6}O+~3#l0KbUG4&e_Niu{u7jUMd03k z^TqaZt_4`w3_}Gfu|wUrVseAJO`=C2(`S; zstP&Cdh?Zc(svt+fv|gfQ*{JTd0xm?d4b7iI6_eAP22K4^>sBLlX*jVTjM4=kqpOZ zne{f>^o9jzW{!hfh+nh1QJlwPB<9p-9sW#GAE)w^rQaZlGhx1+y)2+GSH8+%=~ ziywA~v2PQMY%!+=r>N&_RLg|Dq$|ubd9l0#nD-HSsn4q@bE54JE6i^k<|Jwq`-oX_dD)Dx zOEo&NKV_QTvFqXAdCHsd^4MWW3p1Xt{Mvs}Ia9iRW;)qqrb-ePjyPXdg_BBUD>v^E zyzZn}e>jk1Jo2v(RQqrk43upcmsv^#mI3OqmXc_~hfD%&Vki?=XsLGqpD0avFoC)1 zU_?x?B@@g@UR(%M8WjRsb!_Q9`eJ*gHwoWhV6sucV?&=3aX3;kaRafm6(h5$Z~X@hf9W{oo#f{*IiV zAfNcjY|lIu+ce)FoXr|w7?`nCcAD?5OPZUy5*q7eGn zaiDOo7Z6q~2OqOY9N90JpTuvua&do)a`AFwfDKs~N9A$>7BmHJj zmlJ;Ys8#l2{MB6vhqkI-CXWPTBCG(;C}^D5Xs8vJ_3}%Aa>#2&F%yH)KwnW0m6jJb ztEwc_HXL5oGT(%3b{;~d(~q@<=Zzz0DA6|*?d%@Kc~0GcU%I4@6Y!bswUmkP_RwB% ze_Jb0NuLy#K2vd#tLgkT{12G>-h_IFr^H#qCR(6L(;|gY)LE0JAPs>_;)L31d0g3M zH{VD2lij~wTKWsL_)ByNhy?qH%9rEhbF%fuWs`|{*>xIa{NhG(tn?5`Y5G2C&xUwx zzVr|#QszI0-Ba3lR>otj)?a|=&$Xg1f4p*DB~VJ#c3Wp zO$g@r7Xt?yT%ohu&C9kih>$Uk-GWH^c3&zqVIEl`T-V^yPmmi}&?a(Uz7Y~{V=*I% zf`_o{xYT)mN4n#Rj*?96zlso_ytY$H<5kC-0GKF9i_89I=I!FsN#I1`Q16mqj4~QJwzwHfK z4%7p3RbNrm@bNblR1geu6U(I8XZ*@a<(!PU+gY!C{hYmygX-IAvP|i%g=^a+u0ZKeWQMTp5@CoZ` zZ?5Zfsb~q7`G;Np`jZag$2rm)69{ULk0;tFoLYUV+M(m^@+$F8-egl;Oj-S$=9ckg zDOEfd)+cke_ZF`5{iH$iV&WqKpN@%H)Ex{wF!dIc>O^MHekIOlO4+vXk&{Xm&|$z9 zD5vSBIj(K?xA-v7)p>KjOQEK|#(!W!%Kp=9LW?RfT9bywH`rmX4V<(<|Mt%ITxoeU z{c`GkI^IVYbx`8WzQRVw_+HgguNqt>4^LX#QPw;8@VGY#Qe=wYNbN!4EwG+IB$rlk zJ-^8h>I!1sA1kyIj|2mbG<^h(`VZ1L2g#*0 zmphM0_fmFPg|V1CA4bHrM3=V@GN!AKD4=Z^z0ZMU3(iTp1{auSd!|7D@xd1{7sOh z6-HG{aDM$(u%k5a&Cu zQvVG`sZT2y@%CNTDTc;=!yw?q5JhQt`W_oQ)|qU|76{oXs)6d&A#odOD)Z4HcAIuD zs>@My1rNveIS-M!-psxLfpUx zZMQAcCs_(5eFbcg;o$evmyorWF>Ytjj3WTej6?UuHX7>9?T% z;t%+gj}tRY#yv`!J>#d`5@eVM3JXnpI-b`>P8SI{d|pHm=X>!{d)RB#L=CjJ&}k0; z_z2LgifhU*0&(xubHdSP$X?QQZN~{6Y=ClgRU8l%$B4Q$bT$P51lw}1m*uyKNr>4% z;%ozy*C`c2PD<%)oNVtvi*W`~S!k6;x`&xu^_04aL>Hd($dG^8ZGKtBsE$nZ7YbF? z_GK&KB_nCj^9IW<1+_X!z*_kTEh#?~o+!OCV4(6V#mWSCk%m=$#U3`L-u!qI(08|2 zpf$ukv7-I-gm_J7IrL7Tl&pYk#>U7~AZ+JGiDUcqEaWbSFU*p71epe_jOJ&h;5XSZ zioc#7Z3RO{7Z(7f*yg*lXH@n45meZKYG_=71O3SFt3Y` zHd~zo7DSu(_<%(rzV21$+baT*{!r-P{R-=AwhI(TWQlf%k1w~clu!*>;92{<@6*e~ zNSQ`{?72s{zxC&*Sb>#{RHUy~e8O2( zXTGGP|uP6oh6y)1~Z!2>mjcDX2kH5F{03p*+w__s1k^8NJ}mIN4+?naHPXQBcfUh=6|jQK>KU>6&EHD(3Tw>l z1x{DJyLSN$OUGBU*VEe0iz6*J7}~g@IvHVDAId`&4PHC<8Jzq^&fM}Ri0b5WPS?^THnv{}jekdX z?x^GX?;P!RX@i9;?V>#Gl`Q74O^T6++VWQ-1ZW@Kry66;4=IeGyC`EAXs(m!_lp~6qu`y^7syCSW%A_nP1piB0IM)w(1k< zDxp=9X`N7SHBffhdQ1?2i-SSO3@$QlaLx6)zt|Y8cQv_NE)cM#4n;IRE4h08O01WL z;028z_Z|xMeq7 z5=M1qLfa1S63>)lIq}JvKm=qF_BV-`nbJc^i8qMc*8)5Pm-qo~rDq3cuF7ZK12y@9 zHX7S-_MtAy5)%LbUIF1X)is9qr|B-ho(YG*~z`a zt5+y$3VcZC;Ws=U0EmuU)(KlRw~^d?{v%uHRj#)LgmxRovL4oLOjiN)CI)zahKnI^%!3-~t4GZZQ``Xk0Q5Lz6g^2y16sL4@YCAuK&Ayd06>oQ{sdKMq6eX! zo)C=SPtew|k6Au8SRS>1S*AE=Vw~079>xi@mfw!bLc#OPU{_aXnBJI=2utd-*=+4C zkr#K(K5*2!hqnmMknXcj(7eXbSSc(zdJPUd5X z-e$ozb4^7Qa>8Oc=zbMjWB?cWV+BHOGkeDi)3xr@g9<_dq@8Rwv^oG-!BWHJ6~eo< zP+9&-{L4E#CD!NPn};YGso0e?w4`^!rNlF*I|0fd>79{fDf=L=j{Z?rfD)rX2yQFh z`D5uB?Sx9H>71M8vmB{<)uR!m>9-vnOy;V4a6-Rk^IqYkQ zU&eyJirm0!$^g7yYR_ke4_4?I27S7$#94V52e=vg&;M{?loiT1`_A2j%+t(xN z5BmW4O(PMY>ifN@!by6>P9YrMhshh`R(WSfa#YaJhPzXMuvYr7!rJgre1WAW5OH)V z0PsVQgVD@mAnpdhgriS0to4kltT8EEkIU=)7-%ZqixKrLe8C6EVxxEb+`GuambFmu^v;tP=Ps9c!wAk?H}iYa^tP7HWIJlpKcirXM~a2V#hFPTC3J zdDTfYW?}uimz~R4-+$1J{!Dg`W6e<0RdX1SSrOmEbVD==*y8*yunK%lcnL7$+2+nE z{>aYw5C|wAF_1P#_K7-5K4FR1Tjiw=0|mjy5C{rn9XI65fn`;3N|a$Q<|e!J=0^({ z3li>Jhg>_M$f#0*QH~`L5#C#VNqz#N^Y22=`t2+dlZWy=OWn&m3zXft%opxUQ2&li zhOJD)s|S7-P|M~<@LilUM=7c>DdD;_|f^a1pVFHtm<=L~)N;A@et z&FF=;Z}9X+7|gJhy*hYf^y27ijDhP;YyG*k-6Lm@*x{s+3$KHh!{jVh@iM5?x;wI& z8yG>=6=LEz(+HnmM-j#LaecsR=^q80kn2xW6LjW6mp;iw3DJL?n)?l1<92ws+s)EW2S9KR*F9rB zpRy;2vAlj2V-k6B*Giq#LYPQjcDyn`WH|Lt2j0VC?IA|4b+Y&aBIWjP zX!D>0uF5TL@B0~s2AwJI8olUio}13!@0`1)gE8Vp&1ASUW<-Yw<>h@8{C0!S#NFmf zGN(9@CF1Z?v$^&rPM>hjbfi&?RyaNj3u`_u z8yyF_KC0GMGFQagx-&$-8JbrT%P)Ym;K9R%h_1|yYO|%r3$=OHm5bhFStLrWW|nvk z6u!U}V<>7k$j5t$XG!0%opsJtOykiV9_Q8>Ce+Bql3x-3w?JG!X8o#ni!T**6>^8% z!O$0XJ6sppY+7i_?kCOfojnh zHtfguc9OVjm-+Y4HFRc|!b1_4M>2J6yyae*nFK0@27WjO&6y7AX}8Q?*m%k@=Fd1SmzghtNttPng!Qt#5k}$Gx&IPzeeSKqlFzGYvh@6qR1N7fk0~qyVO*a z4hf&~4lLc(qYv*`I5RzBFCoA2)oRX9^KNYklR{NWt5m6jkh@~jP67hy{$d4+ufmX* zR{S3(+`cZM7(uHGLX0SQESlk zlwQx0MtOLX?-TPC|B)qjPIA>P4k~@M(S2LXbVDxfB7}vXz-9gS?>|cmmL_Z3iW>Kq zWyZJ^7&RSz1$FS)X=wQE_Y64d38(1+&zHw+(=lNIbq-ud{|C(T+Fb$i+$$ApI&|%k zCw!lk`>j451lD#Qei0;KKK|V08~?i#V!TbUP$7gKHi~(?&4~D!uNf#`5h36W`D6@` zQ?A-9@Db)h1pKuAJDyJdz(I?cjnf+1D&U#jmWsxg)PE=9Y0tD2hEc8}n2Pkb^q-cO zRzNFvA;$n1#mP{?^f7(JTjeX(v(diH_R++^G=8DuCul?Re&Gw}1JNem(kpyH79_92)()LTj}38grV zoZ+P{?SSXkz=5L5JBuxcFF~!=%SD*%ya8q?n?5>X!I8F2VVO(&>8Ohj&3F9pu#Jt> z)DhIGQn6xz_7`IFL#yyC^2`^1`rkyXKjcx1Vmwp68m=8W7*5K#so68f&=V0|AtPrF zD>i|e=S;BAz}zoPm#mnM>=IKHIXE=T?Oyt$Nm_SW|Nn`-N#YcMgxf&Cd>m7Q>_3ZN zs4oS$5PJ5fZwCP`gp$!ejK7DKB;`ZN%S7Es!gD%wKg^w5lI!N!T;2dTZ>dfDe_eN? zekBHa{lr-bCtlr-!aa3=o?V?B_%RB^^vqz?*b8ml;6?*6PijfXKWcjc#L{-sH6VH$ zJ3!oxtZ8L)53pTeVn6Qe0T4)-!iJ&GPAmM}7|>Y^uo_BMXakMR0RJ&Y@znZDf2~5A zM-X+A!Y~it6UUm4_x$RI!B4QGvS}XC^5`o(BGI{eMqd})V>n;JcF5Aug~9S@rby%s zJzMaz(mJ`e9hS$fkQqjW1pt85bN!<@38KDakcVj-zkON70*$a-r1-ixXBJHmOSJGu z!t&n?q5Q!#M`H${lUwY1{lNhFDP4T4w=)2#tK)RUe*ouW?Y zU+^C6V3q3xQUQqA$lL0W|8GW>p1Sf~UHv4KL!Favi4l<4epp?l7*789Mnsrh29oib zd_2praHLF|f?-FZ_HBw6>jV@rYD2ZMUo8gG^)idI#yU2tDA$)*xTWvC6yRD^4-_r` z44 z!$jxfoKC1!ZRisi0r z{qFtKtxgPaQKNen{%k}DN6YBWVrY;q7o2@XUhdVp(anA#OAVf zpZRI2oCdZh@FS9Wk|BjWi}bNN1`=Wb?a*o|WBRY`6aC-VCyoI7WVlPE#u}%yoxjae zSpgt7FC11E0OTeo*XnnE0fQhZwx*D~giwcSRp*+DCfQpkaGW4F*uKS2tqe3w@%fPiugu{}p<(Y*R}1XJES z0k65}r$)NyNu)GBTFQu~-_B^ll7(_c{o0ErSj`P-ZD!NMMyAXv_<8S(m4Irs&)@hI zk?`1%?;~j~C!M@(e>fA3^u5Nps1&YGD2@i}Xo}U5H)2IZbZ;X_An3IqRcQ`*~Q20gGaNY#^k-Rr@EXBR*7c! zan?a0pcpYW{YGPvl7{s`zTFO?EO_PX__BpqzEGKK*rhbx+Hjma;fJvgg{)G0gH9Aj zUKH(7iU>BW`a(kFt6jdW8oqW?zprzo%4N&wgFoV2O=O_#ytvez1bN1v4RBw#8 zymmY7bW9(n?IUTpz#12Nt5m{t>JhOsjp;IGn{%CPJ5!t-FgFf@SweDh6u9Zs8EM#Z+d{92`skO7h$^6?k$^*O;Q|~ZJ3yMqzat)5u@yWBSh;NZkyCbOjY+btVyz<9s%vQUIS$s7xx7=(g0%1V=V!|}- z5XKp-_WiO!p`1^bw^V%B`sTleI;LcmP&N>Z5%kRs88e)?d(9hO99132wBRe_!DYz? zg|WA}rT$O>kv}Jw4KQ*>?ajTN;p<0^x<)FiNUHd&@;`i&@!p(1REm?0!NGZSV+BGk zb4d+(%EaTYGn8IZTFKUYU6D>#-mx;S$sh0lrF{{9ev%O@SjnsRBeth;g+>Z47qz#n z3L|{T`qF(~AJc6JtB;o`TZ`a3NBLN*3Aiw2+VV2N78)|Or=+f*vNp#vgp;7A8;LQ~ z=i+gCd1+wT(%WDo-=NywM#QZV1T}Vl?QlSeD%T)Hm|kQ2K~x ztc@>wd%ED(*usW+AJRqU*nBaVt7Q88;tiuhF8JKD*!(2HxRvKXfeHA;H6vSv z_Wm{H#paC3T-!~ycSI&XLEf9-K<_f#1MBW=?6LH1gAXn>u4;8}V?mqHos<9+{Obv8 z8ej0q&GfaK_pJ4wDc!w$d4U&74U|gQH-77425>Om3Z<}dl3H7Z-nw|s+pHJa0@URR zM@2;-z^I_O^uTikwolj^8u%irPITh1Bg3{@!;bZo-eh=4Uw&yuoxV`mksbT{%)L_9 zLQuyFx5TFfUp6e`3G|DurHW^{CDrbf%5Ak33k8F7F+Do2!fgPEE(wHBAAB1~IItPu zTB=OYNb2c}sw7}dE?T$h4M2cByc#gALV2oFl`R#{R|l20Qk%0t=UR19?#%#V$2681 zZ<&;MBVqd`ouzcin9CeUEKi0E>odPYFnN8TK+tJ{a{7m?8b`SoSu%)-YEQH+8VEBS z;`)AqRzGYk+edj;1Ikx$cw2l+Y=+XX4{=X^kDZgve(=nv zo#EQSEG(t1=d>4CXwjv!Qq1VL zOGMxMP6p9Cj+Pr*7%Al<)u0I3;aNyg_-sZ5F7Q$Ky6(84M-`NFsl`13-ILZQ5D-05 z+q-~|$+ecbHh6QObfarc1Lwt_Ps(-Y$VT8nz?)dEA9%Cn=Xm*>^tzGo^2t}8raFd0=HiZuW=9eCH&Yncg8p=sW&em*Y3AH zxhHJPd))9HgV(94@TizmO12{q>p0o?lj(JZXWLm0Cs#92Z%_S*W*>5V48YU(;N+(n zkVRu)-8RNw7a^*0Lj_> z?|zF0-bWF&cv45tbw40|syCSb%JzPWNp-d22YBL*jw|=u?ypRI#u6ZOP`Q#L9iAjb0Q^`-fp+|5%zAhJ|33g#BwN=dWCu` zybycR;uc3d9sQXYHX3$RjdnGTsK2(H&@{fFlK7aIR^Q_Kg{k(e`!FX5iT`l;cvihQ zKy}d8h9}XsuJra5mDOAjknenefSFwUm^m?~&pYX5p>ZRz{~3sAk!!<8rj1lkt*ofr zupHBu&d>KX8${lr?T;UXY;XAQZaBUqEuN%(1o(Pf9amwDQ?8u8 zNKSR46Rw7;d;fJ*et@T+oeg#yI_d4RBDKX>Jh?2~wtCkCj%?Ah58TY4t`>>03%$*D zq=KJZ*b!f`*ovCvFBH8W& zpTf$?Db+E3GPp@{ZrI`dj+5R6Bek#V6QfPNV3E^K>GycGMUq)=^h(V3r9}o$x?Niu zEkHeZ993*9ZD#G-Gix20M@vOJC@?SdjmBA2mzSYR+PmwW)XgAqug_O>Nxfe5@)sv! z3aW{eY?`@)UCHf6l4=~{B;^$>w%%yWE4W4q2u|`k#%)B9Ej&V1gdxP&OFROe)!}>k zV!6_r;-oV(2!|K>Sp^+gF;DlDqK>{n z8|Z!1_lA?KLFQ=3kuoV+oLG|29sNimorL9WHg29m6Ogik*>m5gYwr{)Hw@YvdTER- zd_@Cf6U^~FLt`zd;(7M=?+tEjep#bZ`&2)?ub^F*gBLu6#9u)-x6~rkFEddZc;^$n zR3!0n?!Et~Cpa+l(Kgl`^#f|{d~~<=#8dX$>5*oWo}iQYxdm8=iW&(Q3LV$U|HE-I zg*OP$)P|>l1S|w@Hi%4-ZM7yL7s^@HNu^oy_i-HfCPj+6xS~HWKXfAJ#S6Q>&cvnj z_;rT*gBDc1>a~ri_?S6+KT(O9M6xU-*SHHd>oHodDWLm~CpAal@pG7gOCFvLOOu1u zy;wI_r?>8v$2Swga88s_SzwO89W`fa4wr?tz|J2)E;EnT(&QPcyPDzp3H)v?kThsU*@( z52-M=Ha%p2wyMkejLq}Bw%FFEU27)TFXf@ojF(Wj3p~(f5>B7)y-q zBYP=&k+YNr*6vTZ-D!xg#y|aH8u>V8mDpgR+w$8$a}u%`|!NAhsaQ@8x6)i}zUj!v0_y z{03Tkb0f>pz7kc3(^VPLo4&@TFb0`1Zg=%)534sfl-TfT58RpfZuE6z^&^W+BYqbz znb#(ziIZ3x)!&xl^BvJRpssk>Nr53hOhiu`xl|Za;;&8-Ldzz{FE%Jad@MPnqnWR5 z%4(Lv&qEw&NQ|dM8AjDlAUQuyH^UaesDBuk1-q{ew9gf60kL{k5 zX%Y4`4}@AovS8WkL%CsUurHN`^wyK&=dhWcjBW38Lw#m3Su8AlTT#$ zc4Sp`YzyhB`xo}sb|E26JhBZU=ykWluRlSmug|~!BBFGeVeW3{LUb*;QFFvmVhi-G zUa+6-!qC=^9R9;D;obwASZeWx7jf-i52m_c+C9Dypy_%UIcTyyXL2U|lz)+U`RzCx zx3ga}N0bao+KWtZ<0t66x3w2Cn$&RZIC;m>D^r3qrAJROnXx9?iKM7EQ*zI!9>vjC zf#5_9&%kne4r!`QzJ^XMrH3|7Rvt3vT{$+X7yf6?lIHGuAu{>UT_ax$B|p%`>Z181 zR=tnpfW9W1+h(PvI{syazes{E{ny-xSYJQw?CI(ICg#%9LwQuS6s6xfrm3Ep#_gX+ zsG!Xwq~y@nt;K7ePCslG-)AJG7QA_LVn3FAUP+3xhikE(+M~I}n7USkpi@w@6lYk;xsAaYd8jp zyW%|Nm`Z~LH~FZ~kA>?E@-0>mjy%55M8Htq3rln(Uu-Mp1CH*tO9#_p)B_+_fvRD_nPo%CB6(RpG zadW*b#3$DCYXz>&P&Mh1 zO@SZG1?&?cxPneI%A}@N=``x6mF!H_b2OhGOFPV#mS-iU5GZToa(I4(9^A==DiqRV z5{CAiKU*sQ1i7+T#mHo6s;?fz&qE^Vpl?oyvMfHi#qb=Q_?k?qaD}8@>CulcEk8$4 zq5K^MYm0<5;0Xpx)g%=Yj`0xwZT9$sZ36nBH05A11aDwRwTc3wIRK-h2Y_J#e(R=3X0>WX{YJl^1SXUX_jgi zeUYJ5#dr)7qU-`KjSgw;S#ziZ20`~IUey{L469KmKi^ssc(2e?c-wDsvKWZ&C$4;Cm4kn3b(_yVLv zVlPJ;0r^Ngp^Og}oTGAzl%J6D~g$ zhJD5$=YQfXGHL0)-Hu6ew&uo;PF+9T97(gGGj{sBRO=E7o1?U)S|hH9G~BiA=2s_z zPnVbKZyNpHgoYD&?2{aCnXAU_ZhWPkrehT(NlYB;1ib25giOeL1d+$YPHQT4YVXsOtRbOx zoe6VsOP1$u)Y6kn&((`K;*5q-l5L~D+^ABFXY!WJmrRMaLGdo7YXn8b+p}EfecniY z+V@d-Tt48^RUp5s&O0%2D?xi-lU8{3IO>aS`dXr1%x7B?Z`|1&+wHl5%a%ZMlrp6FJ)(>py%P zhpSTqis0(SfUu7*CU`t*Z(7TmQ1MW)@%XCJN&CDJ%mgQ5$@TK$m%^D&4+S2(keGmd z=D4HiraGB+jLm>n3#qJOT`Vd}Z<>OYX!SnF9yrkP6FwXX4RBl+0bAhvP}>#O!e1On zG7lrN*qG7V8flH8G+C7E2aT(p9UtMYk!~dwFddSgs-^2AKh3N#YOJ_ zKkR*XTvOZDZ4ece5(PneR6tZfL}}6@q7)IaL8M4TK)}#@NeD$ix}bmpQUnx42)&cg z10o>3*U)Q12?3J$w&!c-obTOp-@W&}_t*D}f4KMBDK+$EN4cmapU!JuO zg|NHo@_PhQp=nwdx^LDWG4I@( z7PJRMK90Q{I~sR`F}ktX^GK~eCCBMgM0%j`XDyB+XMz~pm*@E+75se`7JqCn_IWsy z9kj&F5*xj$yNoOSZNK`{*9WT@%V~#|I}MkrukFhV$4RwME1Ov5JyDhIS4F$8Jn`#z1Nz+&R7+|I%6vT*Q6!7E` zN&&*O!g9Trab()StdvoE}SpFM}yu&DWKq_aDKZRC)!II1#5G0S7Gy=2wsK}>hEHJ@4R=DCW~ zQ;EXFtI=;_G?m;j5)^Nu`#sWjB4W5SQzSFITNW=ir{kpBAgeWLDI_ZV+GE|sh`2Mk zmPS~X9VoHAt*yxBL;bGSY0`Mrate@8uiCXCa+e%CBL(mCWkJ_` zflAZfJlU4GZ&WzE?3Lt92!5-+1l~`*Kto_FXo*Ob{*}_o@z4B}so4{i0rZ7qzubU0 zD3)*vYp7&a>XMcQYW0q?NlyNY-(`0g!kSt2Pr<{U>Q!6K-=8-$8DUQwkf(y5eOC4k=?H)$i!2WWs2d-)T zCD4VwY=G)WE5o_8NehsJOeOOaxr~e+jFasgsvg@9Ll>7fPxzG7Q?F8N0gGHN)NRRC z`<0)d0&&}vBG0NFE&v^MjKI5+@O>G6J&*|a&73G+f{*$ACrn`r%f2{ z!Kdc^aZ?9~Jpj*r7-Bc(u(^xXjotANH*-e2_haKJo|72L^=j#1C^>kf%vgzT|7I37 zna({rF}96Kz{;RopA7iq|8kv}!$iP0V6GEie>0@WA;74yW9~p+0k~Dv1kjZMWq||w z;vN}H*$Jc7QFE3Dp@ebC9i|No3uTC;zo}h~X7=!zP5tnQZ#k<&!0C#R+Tf(W=KO2< zx$3I~%O<1tOC+kq)P9`5>plCtba{Xt8UZ%*KPr@bosdB6j7Z_Mm#)GCa=kUfqkXDa zzr7}Tb#rcdQzw7_Gb!Ec2ZV%(oM~?tW7y!Pu2O{l(RfgXia|OOS%zK zY5fRr{Sggh%IeVC;_OXKu5PQWk5zTUIDCrekaRQ4v@m2&Bd25)E6 zyVK8#%|0lE=zKdo(K4Wc@oDd`Z=E61OQ6G#%x@vT=&LPOTp!uxovJ=WVl<{$OsjX5 zL_^8X?mVk1jDN$>DG5mvaF92poM`Z1o<3YbY-@~2N1R2kG`?$cw~#!?m}~;Qp)l#t zKoklho@!)uo{A6QQ}4eC)bm25Lf5{T++k9x_Ic@AI~6>s(SN*Mpi!!w`D?UhT37GP zWuemni}1&4((cFc(w7QvoekCi)GXot;7pV$OV_9x|BuSnlc53vchwGDIieD~$+XG? z$gQ|K>2-k4d7%|C2Ohpkzb%nM^CtjND`wz3q}Y=B)(E%n5F7nB`5*mgDd~n1@ zB_e}Af2j>D?7DfwFVIA;MMIc0ki~tnT~34Kj%U4P;T>4;V{7~I@lwO{ukKyWY2H0D zldQ1Kc;Nk~1^Ok*RMuCFL#cvba?Sy+wp%BT9p?0yIK%%2Z<6{H26x_UUxge=*bK$WsSEM)~u-K?> zsyWuOUaC$3)j@ag=wIE7680DPbv^=aO)F3lSeADU}5_2PyS{E;RCGMS?tu33{ zlTrtss-)x_$xH&vvy!hS*k#bKOin8Zz5>XS=Ee1V2rDPv)gs^a(V2~tMEUh6!NKU~ zl;kE6l3>9VD0s!RIWE~`;0=E#x5GGT-$UsxsA2ifeYY5G=1-UQHT`^-g^qU(=QpR!eFvs=ra5{ z7-Qc1G*G+M_AJAdtffbhkVRkARU^nD6)_XzrQ;M><0%Pff|Qx7m_-A4_j%(sQ-RWa zq?1$u@!@pIY)2Y65UJ|avzyK(_n_4H@=s8ljqW{fjt-A`A-=!+9E%g|N{4_In@O#t z2VIPH|Uzwt%We%GF^I@~Jk0;|T$!>0I_Z(B?l1u)T(Jf7G z5UlI;QwI1=Ki@+q0R$4(Bq)qayiNI>vm`sk(w{Ke)68$7Ej$~9DioWJVu!b9A|Li` z^Em_|bnL7NY*#X4oElVyID!5ll5^eI3rl+u5UT{ ze026Gju-0))`?EOmc-duMNVViki|Wgrvu(om_WgEly?)vw;qWw@5gp@kMWxm;@N{= zW)AA={xCaSHNlEJPm*hF2I6UY<8ak*gZpOl#<^XKyG^juXT5v^xMgytp+n8uC;>l+%KlV<1*PCBb87`R^`E7C%a$Q}y z=>;W<>=-j~H;&M-*DyNToEezgYl<9ogE4{j4oIzu#Zn{*2*8xmqhsJ^vNg0wh9|H( zZaqmu%;77OSruq6pi?yxHi?VCP-O^;PuM*(=-+#vb8Q%59r<(X^93ST7?;4xhp)l? z>9RQDK=`VQ*4&%@tM}g-wc71AI+Y!(byLg-XDMxQ?_seROb)OE`CUk-?EgNbt5EuY zb>IETUL8;j7s6nk0`PzbZWQwEe;e%URIX8Vs!D6nN3G%|4mUyUldlE|hrjY$xvVO` zoaA22OSX=aE@$*9Hh*XWY>nbsUjbZi}_BX zupS-UG5=Z584P$ciS|8ZIG*@l<&@zYzU{?Z;=0URbt>gb`nrB}&=Z80&3_hb@Ycr| zWqW=UC`tAl+?ymBs4!6&Tyq!mmwe9F#OsE-f(0_pvyA*l!6u-|h-AOA>zrvIn?CjA zws*zTU3%N)0}mseBFhie_PI{V-dZeeG?Mt7 z&@k_+|BTtItUY`OuQW3dO^Iq8{v5JqE82fs=Cvo|5x3DH8; zn6`b`xFh>!nZt8HKd#MsE`N7S@16g6?xvYCsq>l)IVBi6^SB$m{0%|_!G?VRes#2& z7EmWYkKST{TT`6rw<1L8)d1z;$06j@ALXdK4difO4;p3(SeldrTtD-Y&EP-9e`te> z0MN^6rl{Dv&OUANIQ~V9yvif*M=Te?I3PZ+_p%)8Bz6WP;UrJ-RY9WBg4a!{;fzRd ztY9DGv4C|T3)lx@d=d5P)Wj*OiMFCfHP@bCG>codP{6E4$@Tiw{f!f?Dzxjhc^d?> zb%CsWDM_HVigCTw?$Z_Y7?aSZ%(yX7&^?Fe8viYp?@IJG>+Yw{_&l#_iyHdWI5<7h z=zd@Yj1#GR_wRMyffzL)ioc{QxPWIS49eL*7W^Sh&%7S>hyplp9~gJ#`t1&8eZ2!a zk;D&K7h^+d6!3cr%LximbP1oY({;8J{Vs}ea5h>pG3|eANV&hF0Wq`oda3YVK|4y> ztuP3ZhAAknxglVrRn(gsa`{Q^8~ne;@`1r&lQg#6jG-m{#&?${wFsS0zNQ5)ycjde z0c7rfP{c~NqI+@spRgx?l(en0A&xIq+Jp(rT%4A(7%MKk!VxffSbhf+C@tZ%-;mI# zke7HC?|G~|V#wWAJpAS44nw5!@{|s&*NX3|ttb?xc(`3)O>6!rG&SzMsYFNo&xL&~YG4A_a z2dF)zYwnuuNgM;*qR9>(n5RT^tv8S#53?eg5@P#u#^_tuanh?*AG)tv9^7s|I-ewX z5yDReRdl(umO$A|+OuvQh>z#Jk}h@dPLImrs~OW}|_*DFMfD{<<mAM*zSXSgs}g`oU0zVw)twHG zl0gf2V0FRP?B84(%eesBL+PR3#L_kUb&E<%U#SV1jg%&^;0w9}37IU|E%J6T#6iM# zHO+=OTh4ZLV!X|z6J&-(%tAv2mHMcz)4NK_8QK?m*e4A~Ms5tAdSEwFfvbsIOa|eR z1C}3s+DlW+GzMJT0-S2OB3n82z@O%r+y@R+DRYo*i}!g|s`8Ba;y}f2nqRU|a+ejc z<(xwcDMhxQ2fMb%oF+%}52Y90(gSuIeq-CUSxUF|P3nX5_JSUMR-xP+LH1T)=3afSATr(f8V0c8#)cmz0GUPd@Dl4-6&ArB&V%tvvRHXPbTZSnEReNL!p^*1rgb zabdLFyzw?Cb)%J61*s|l4$pk5QHR_OEddgt2vA@|Aj%3yqvQ6^id%tGN4Zll5LM%- zMyOvA<)KERVb}T$wlH8Wndjb7Gx+)e`KOA+%h%?UoPhUsxN}NJ&=#SAi`n}IPVlg} zE)s#RKJp9fs+~`EY@w=A_@IH(o+Y`0bnWHyD%Ml6pg0*iuq6ZlGsa|3yd{wtA3r=> zGaoEt6knd)Atm#*P+fNlhQVX6y{#CP2sW*Tsg`@=^{Bup?WQ+UEO=1H9X5l0+kqx){-r1^Xx zBm^qz(a?-NLn)dr-$GqDx6cx@Qkbt60dNT8VgRDAsM2|=)~;f+ARu*aO5wz(FKWpR zn#Wtj`t#f4sl{&!y|1(YvYg{;4*~K_zy9S8iqG znRs7GyVLC2JByfBz5C!#kJ%@T!I@r%Blcwn!(?oojVruA@t7CtJyKhYJ6JZrxM&<7 z<-`0U`Dls4S}I58pb(~C;DH2~i&h;)=3Q)^R^}h={oiZm6E>K+=E4YR7E+55cP$WpQ zXfDIHwB;-7eYrvt{P+OJ-srV?*_CdkMfpjVtB@r4XVew=8z57ys^m?ROUHPl0 z?C9Zx;d}nzXNWF3Gg2p|DXwtA>wDEULURW%H930o@=@sO0dS>37tRwvy<{&KzJ(C8sFC4t6OXK520YxxJY!EgXT|S`(*M*MSr(vS7 zEa+CFALt1H!MR!UmniwuR(kd?#|Sb@%2Eog2mT+&B&L^CJ?}}HzOC-vM{>3{#GC6a z;iW1z?n3!WmK&H?fP^z=f@!Jfg_l!W6~fYA)aRx}!KPV-fFA)Gi&UM0a+*+}dWjEv zVp&Iwlujsa2uVaG3bd?%d8j$P)N9031|(thh>CdMY;p3!ZZ6w|tXrr1bLa)~`~*|z zHk1u{s2`~XA$Nw!c-o3qsvy+L+CLPH4MlxJRqO!4RJS38!8L_lgH|-%Zepah7M1X0 zb<@&j$IWab#STUE_%bd}IpmsZwZmH)oGnAuZ!u38wyJMA?qr}TZ^P#3S4&X7SO#ox zpIGrKH|M4;>7Y3adCrw4TrNDwANPQbk1^?~gM8=h++TZS!^2UIIaXe8;7v9`TDhOX z#r>E>-UbBK&U5p#UG4r%OQAY?9vl3$F*KYR~R z;(mhoO;q!MouH_2FX^{%%j=gi}p`Rf9sn-Y`F=TvHsT3wv zG?bIHd*%G79_nP4S>$_u*K2z>u&*&0V)OP9P)>Wu!*b#$Kc^q63>)it&uo;U#$|*) zMg~`06JUZWBCRPo9(y0~fzr%z{zt&^C}$4S86Q%%z)2V7)|Q29yCVeMCL?_Bn$m?- zX=`^iRKKgR(US8@lvTvm*(cge=kjKY{1{?Y7i*%9p@-^# zuON-+zOwC_y-0$4#LD)|I@=3}hj}={%1VveV_qT8>j69vFoX9{99*oa9lCZ3d|{nvLq) z*R6+CMh54pO+k-qi#=`=9h$m2kIJa1RZG6{W@8d?ySi$CW5S+WQV^^Fzoe>)=bDM9 zSibE1K#rMbVDmht+ZOPHklOy7Do9DpTJV}t;UFC>ED0|}C3C2_4{IkKyf$+IdI_u+ z86dNjixPw1?)qhqh1}iO^l-KrhJ~2k<>wO%Si91d(&o{bk4b@AgV}5oZ*}(Gmoe`YMbc_6&WL;)t*pi!1NpA6D^N ziocr~tmLo@zP7Q5ETy4n53NER+$}@cksrOfAX7|Z9;oH}sgstqU zzn>a}gI&*5CNXw2PN@n8hCm--SZV3hTV#~b9pZ{)aOLZ+s@VCPK6NDH{&m0+R@;m zzn*CN_k>AbB_k(JtZ#Wv6R}}VDf&@cqNLfG{PDNkCg+cF*_Y$Sh%i9f}rQn%)K9xSxw&;WzBB0aL))9^Uv$x6fH7LnhXx;g*M$zs=o(oO={`dC+EtHoQWG5FrnU zJ5esHy7y`dt9xv@J6OD9zlW;a$>ulBA8Oq%fs^0w)4BJapjR(q_V3Vsf>=BmK+q7!B$VU!&qmmdI1vF{D>S>sq%Kbim zUG4Z}^g?42;|S{nXCkR;nseZ#i?{7nt;BD=+n~npI4|ztgHh_jlY)bGl>b`=&+4+N z^|~=Ne7`N`#qis>xT~5Y{FwJLtxPOKqJBx?NinK~8utNck$v#+Slob7FCm3r>7(2| z^caKg@{{e(m60iOnMFzew){LEd_JNVvUC06-T=yZUzUQ(9kO+;xqFS&@J+~-iT2}{ zF7IEedPaJrG$;TO7{^tcND*wh>$Ss_lB2{r4W(!!IWw1S(nQL` z*uR7`oQ=Um*?w~bx+oOYjtc=mW?7w~N$EFsqgMqNvufEdT%?dkKMM|G{&Mc-`Y@D! zQ$mhjZw-Kd85k8>I*{|-=s~ZXOWC`4`_IFyL>yI^E>av-yT?~Hl$U3?WYxR+z%5Hc z2<>gfi z-;~Ts60L_GAD%FrfX1~a>Zp%$j%qxzm}jEBd98tw--K{^$Tg-Mp{gNJ2qfJ|)>ekk z0p=)hKRyXUzN;!&P56#9n4Dlo3XxcIw{tglZH9__ZR?&ix~iKvpogv<^xBL{r}I*V zp#mPaC2qwE)r3?hmdAf=0bLVpJg)IcbDnbx-2ms)AYhK($|}roFOYlV&c0;;ViE#6 zAaAwuPh+Df2!a*Wb?STx*P}@CxedE%ld#jE8Smq&g71Zr^xXltdRN$RpdU_n0xiFyq=)&-12M^s9uEfw>0)Uk=^LOS8c^qVm<>{z>7ogVMSMT$^26_J{$S!5y z5Xd$oe(}aiFhKQKMPZ#T2ka`&_G5vq} zvdy?EObGlaVBc%H6bHkN{7OcjzicX6!P>2qI)7LWUBikXMS;?K@D~H1o?#1Qw6p{c zuFk^Us=}cT_dKymN-Qyj&Lx;_;Y}-}rI4-e7^$?)t+iQR8!yMauNIi<1nw*Y(==4h z3J&ocuGltFbj)aN#`1G6vVC%$4P9?E-Nwqi3b)udy0SZNLVNdM!d*xiXj5*_JFIOp7bxa4C!$X`+bVrU*3K)AC@a9aCs^qxqJsCDW_SC6J>Q{r+-o!0 zWPO#V&L38jKZw;L)hwY6_Mw}oSj{IY+jh1=nye?z^f`~(D(VtU7^nHJ(fN?D#FZ~M z7I$)-ZLVCm3SrAhCRh)nd5MtYL!HEt>FNoK2d8vvj1o;_7;kF28t?Gk?V$_|y1^V? zaLMkJb_kc1hggK*)%AIpHe|>Gv7@|!5jCqtArfn64W2o6#RjQTBT&H>?uXON?7eNK zwY^`(Jx+45Fnx^{df2sHyYX;!c>DaOS3YJ50UY3sX05cdaCHK6u#!6qN-WjaRtDhMe0Yf zgmz;>wSq~sEjer`fSWL${UNnr_LTs``V%zu0`yhNmShT*wd^N|5DV~>>)%j90GTe3 z>eY^*>DT^z$y@ZFF3|YnQ~bB_C$I)|ppVQCmD7M0^>ex>m;T08ZPDR0+thT1`U=q) zg=0&=QYc2s^CK~7_Q@#owG@^`Cm5*oG20&EX5(yCiv9u9BTfL_W?aCp6x6e`7shYJ zR)=@DlCzAg&euBRY0X6XV`DLyh(*Ky=N%LU%O=6cJVNKRKfrDjmsiB|%@03NuLW7W z4fw$@P@<7bVXRL+TM;v__apbxC5z@=^4sWq5Rb*_Es*Q#{be5z&~hQqyrR!VOgrqo zBNmk@Yy&!Mps5TJ@YbIhkoB^yd_V8sf0FyK#*tKTuAPpv<)@MCWDf~bRbO+5P|#lg zf4|5%A-J*g;9_)qIY~CD)|G4X=*Y&Mgn1coNb=DhAxXz++iSi{5_247Gw)?OUO+gM zI6kSH5E_S_8G4Pri`utdLCj5rCrflISrFu9Sh=)>OM_Y^hBd-J&9SY%2Fo|Fm17cp zu6UGblH$WBd!-G8V}|*J%d7>jB)(HDy{<%HQ2-hYQd+0SgqlsR2Hfj1kI}ZWi5biA z_-6NXZ3wg(et9``4>ncBML|r}qZc3mqKLnR5+ja<0Y&^N=oa`Dn(z@DOR;Oh@=_d9 z_Lv%>q%OET(xuP57khr<23~5giL)53lh#RBTK$L5->2AX1UJxmdtBa~JXl<&N#P!? zMSe%MwyMlw(~09z;9#oEr^UsARfRtGa` zGTO(2$93E0smrxcYh|v}(mGDk2OgMoKVNHD7oFXtyY~D1-kjkpEd@98?la8?NZbks z4ECYuRw>;*8i0~ogU`Ua4Jam*S>d=|T|99$KB8uyv@lY#UX*feIPDy6iVz zNasa5781#Rh*U~Y_hb`dL)G1m(e&zT0WE>6;o+o6`PMdyHL1C+Vfav9z%-wB04JvP z&{#R^%Z}@=!Y&o9d)OFwN_)UoB$o16fLfvZn-w%UmwB2gP)YN?OO0E%0X)!eqU|m1L_U54^Eamq z^4?97G_T=BVTNZ;SJQ8=19y=Tj}i!a?4KE_fL)wL+JA+t0(onhly0#02k#Z?j;`WU z$W99<2}oPZ=(3|tDgu{W*NZmClvaJw6Q^O#dv){)%82txic7@+wzJb^vy=faW$=TW z!-hD?|DIKFlGgv=K|q-Jg9iZ~_YZgw0LF&JH6PDqPL0$a-Zf1=i+Y^~+2g@{0LY=< zH+8fd%6wTj8kBDCpSc0ux(ZjMcavWw#0T4h_-2DVLdZ8>q8Fam2u)@ZOpu~oZKd;J z?XOZSqVu8RungqMYDDMDy=!ixB+mkll|osj+0d;h|M&<`Vv5G4kz`5Pv#2=rT55rb z->=7iW=#KB$3j@Fhv<}g6`}ncN<+J3fe_NB&dd+%&l_QT<;gd^&w(i~TYJi`$wRUrkm##V^)8@+r~Z zCwr4hGFXKrKABwR*ErO67^<_BzWpWn7$qW)D$$$S<;p6>`mv23ix570t@kI$Lxn+< zyLrW5D%?`$VIBNL$wXk~+saF6pUxB;pu2O;Uur0%tTWXL6S&7-t4oE?een>RmaQU| zJ&3>6E8Qp?Cb_5g_4TXyhqOt`!6Y-j!XwR6NdvvZvKR}@0=Y8p!{vnTS;l5UPr1rV zet*T|h$UM-SmD5y_Y>INcRJQiegwzGQOFH8Re@JB+p-ZkLx?@)yqwQ>&J|Z&CzWrl zfzy~yM>g^jal@80`yl8TAW0h5n?e_N?oF_ut6YKKTuwdk3rpF?0(u2EK%r<2d$JE* zj2@!O7?m)7$5zJa+c*a*g7%P~H)RHVI`_=o(5(8a*Ec2eGGi0@r|#COq+Fo3yG|6* z-wUKP=vCcQYFo~>c#fBUm=FH^4Sm%l`_}_5Omz=DOUdI*CUZ|5&uZ$SQb3#8DQF>?Qu#sN}I?PV99&&Wx>n* z`*luf@95%MR77f?e?5Y zy|5>DBU&yVjgDXRy@j-$(!@>4QEJS0zVO&@b5(xed;N$*NU{eMN*Sq-M%UYuyjs^E zU71*ta8-~yopnwf{)vH;tcQw)TL8TdNtmWwUJ3BDTM5E0@pOz{`E>=blvfcbqNY`@MO= zkuY#Qw&{1`?tQKSy7HNypgaUMXT|70q~JjFy|{muo|zYDDCwRo_!?b4+(I}LoOZJH zS)@nu1v3L7$CBt~HSmoKF-`m=r3cN0>I8&Pc#z;rSQzy-1wkC{XR0pmO(XV=9Qc<1 zp-r@#p%t?BtQtNIYk&v!=PS=PXM%(B2D$WJt{JGjX4Cu$a^?iM=j>Qss%(kh`X!n3 zNEx@nwwFa-^cwVktM`oedMYVT)UIaA5%2k48$n<#W zc-~uYH%b?U{RBq1TQ45{KR#!d+XvXCWxd!t2XqDu(=n_cCy%O-_(?$w`ReLk{2ZM% z_xiSUBu$FA5=sJVR?AV-*9a_(Ps78v$RL=#M;!JWotwE2*YWTy zIOwWu!*3A#L#B)jrnx>II?Sj%I9T>OE7nVMx}ht>t&g!c<#MMaYDXQ-Zbq z@Q=KUS%IiFFT=SLPL=vpU^H=j(LsJG%FPeAo;3FnOG*in?icf(7P!PDaDVNG9Bngc z;4RXSk~zidT$>OVn7Jh3?d{NYaAV3Ltn}71?aPcGliy>`Q%XqM^}O?bG7`*yq@PTl z`gnAXk*+{rd!HaP41Hr)A285IuE=sAe`$y_M7)+Q)a!X6 z?s*V&*yOB9GdFl?J9b}Mir!6PCtt2b!@gpM(xS-mui^`W824(tnD9CV#kjzog63Ia zY=YuFjWoq~J{QBGyj$SNgd%G+^SW8YH!YO38&ENFzf9HR_K{hD2*^C|rk@(e^SzDP zvszUZe7R;y`Er?x@TVngdCXJ|$Ycv0){IfKGU{P{<$pD; zju_uy&+2h;NxMdH*tIf7Qe-yH&8h9RWBBS4ll)i6QKT$!z&|ges%!PLQTEvl69Y?2 z@d_sHj`39I(7&FXr#Ky4&-xH=a+bF#8G~SJbMZT!EDHi@?Kdb7lK-XAs5;0oCB-S` zBiciC=r2!s>_x+`jZHj-I-ss?pR0r(M4l(EzZ5?sX?cjA?Q2n;e0km->M-(=)sRU=K zOjmw**ib23_M(3{Io{g!DEEl?b;5#Iz?#_Knt+7?hVKvx412CDUMKGU=O=SU8WNlJ zOX@S7CRZ{bHxyp$ATdD8C@2ww)Um&mD4u?|>U(LV(R^TUL~C-jg{I0&*V75R@M)Yc zddh^7F#bf=K>dUJdt3gpPUdXBH_9I0UZajIsmg3Y>pQtx36cj4Uz`%>-Q$uSxXD&{ zNyWbDc3E%29%RZg%$yYOCn3We$BJU+Lwsa1I0ccL&NKr0CWDDZO@$t9wQ&i7ZHKXe z5hY!WU&EpjNe^;?-pTHisVX|xctO>tL0Ov8TcE4#2fDl+fSi_nwOcG@#p#Mb^APjs zNIu+@?J{4bZGe4GtL}2bUXd!EDpdJ=JjFZ=vQvx6k>*F&D}J(FBx@D`%fqohjprWw zk$Y@YH%cCOVwiWzE+rVUGl-F)7)ugDYo9iZIwJ3zS{GZc>r zg{}e;1qAE|=hh(YZ&nexf!YI~`W2zN;F;hb|R#NH8gPh3^xSj9s66-Xb5ig^EPZH#L$>K}UaZ6gzq zAL?BnZ&2BPL*M26PH*>8(l*Uqw)tY=`2bKaUQD$&O+f+g3>i9yeqJLelHb2ws&}P2 z`b_TG?zUAHi>*18bUTjs;8EgpHWz@v<&4=}BagUc%VUQb$x0KlQTX{%@ z0SRH9l{k!&$w$rRZTxik9*6PgMj$D2p6ai#K5K7Y;yJy|t}d4c<;4F;Ai{@6=(m;e zv;Yf$2S5Nkt3Kdn(no>D8E_h#!k)!WcY}S z{mm&rhe_`)La)kc9h9_byl%0zkZ5uE4MyN2jK>_HC2x6bgI{sLb+|2hR(UmBSA~xI z0^1;wUwtZT1eMjM4-WLG^SJD*$6WE&Y&;F!Y4zHR!)9W#Unquoj)p01lP3%x4>t=%7!b2kpR&B!OTby%ezxM(sYyB@rp@=b(J@Db^CSyH4Eo{Yfr%4J ze4oYmQaG%iejb0krmqema<9;UC8Su45S9U z7gNL~Y4aa>!sT2y(6ai0=?`(wL1X?ti>u?+jD+CGEikXKRco5DmV@|9x=k*#`e&c- z3{?kdJtH+<>$P#f_B#n|{h5(Ym-*|%$CMGEMi=}9Xt{=_osayAv<2#nY5+fM1V?|X zp|2tfEQn`-=H);o@3s);8tpx>wcc+;Z+A@WwwgHaUj-1p9l$eZ`2%hXC@F(eC^|ghPE;e(gJQX9Lj~b@%Q(*;0 z+c4gs)B(98o-7qt6lg~d!kX#qB`Vh_m}g~6c`~f3d3MJ)c$~~#_l_UIL{LRuAe~7j zP4<1pFL(otN6*Y$nQ2+xI(-6e$>8VLjqPA$WXwb*9X`x-`}{|&9W6upv8^jj$ROlE zD~h>EmgymnF~@o^zUvlpY+utVe|ULMy@>r#%-*R`8@5kZ%0(x@Q6EEhtH`grOiKo~ zBAyE~i)=}r92B@?;h>9!KyGm^K@Q0n$iM?D;YqVIC6X_+w$v3hCNnjrOwx!C_1@@F zj52pSOtc@6Gg5Av75f}}eylAg%vVz!~N9hmK`6xG9zQg7HM0YN$+I!l-e@ z+MSm;=*|zwb+HjT$71v%nt6*m-Iyo0sV#Y?MH}FPpcu9e{Kc%IypAe`-7s>b-$Q%? zvH{fkDOF`gOB9+#&6$%NRyd?9XuZk8crL+rKUz46p1y&3hqGGXRPy}%{W43!3&ypZ zG0uBY-)h>X65p%vP+X(#oAJ`sAl-leL}lgDat`1m8A7T0qLqP^7!Z9qt@X^vaVy$i zj;_#Lo)T7>k)TmO=Hzi#I8LMtqQxzQCVWNwjmxX;$u3=Iu_U*&oZDaUcgvW$G{!uS z@&!{58KY}+fb_sphh1#_)C=C?FJE1j9SY1*1FxgY(Y1Pb>ao9`yZB}A1vUZrLkaL# zaS-Awq<(LYj*9M3UiZ>qR&98`!F9pfQl@UK3?;-AAZ-RW+3HC5%+L~6FXe`YA89-E zmSKhYDeCXdt}m$6UR4?1fL17JU!-v#0Q{N*&0OM#Q6)2ICyzM2y~_vD3j4>J7bT1L z5iRr?l6cP6(<5}(4IF-A_abor4t#~S415C!1n8M8fEsL){}Utx7o(zp`!XF$^J)Mp zzlu|xyIj&Kdm8|_cAax;{r5to9_$~4NWU6Xxcn-y!MT>*n7>d>dR^v(CHiZ`4@Ra+ z&!TgYM!AERa!B6yd)~b+Gu+B&SMcqLrI(QG%AQtYnpQRLKD#l7=&sdVV!R968yG&( z{JJq(Jv91bpx%97(83{98oxD*)=8^u-t&5T+#ohz*nhi3;lo`_q>?Ik4_(g0Q^{rk z*@S=ge2j(wd^FUh0T^%~S(i^{LdtRQeHq%2LTEe@0VTN3ziDoF|8DGd&UT_7i^mi! zuXz2XY%c2e0{Z35Xww4riuw%icfS@Y@i5j`u^pU3qj+EqTQq-cb2HB&TX0UL7KR@` z0#x2!4ouUNhy8>1ZTH7IUYg6w-G(i=5fh^_kCV^>XKudbP5#u?zeU7q;<44oJE@Z z<2{!C`q_?a&)>|?Z!#_%a&sLTu!LWscXKTy%l2G4X`0znUxpomqzr6f-lMIVU3B@Z zU7|9!6nf+Q=)d9A38i7;27Ng425L z#M86^hLZKa_d`Tl6EU}fO(^jnhm1e%J4z+o5<2~=7Yi=9$V7niBE`B)2e2XwrLYUw z(L2whHCxWgNCvFj_M;3mrySdQ?7AM}B@z40zKnwhXu*3VLVI$bJ=I5s?27sTxBLwc zjL41hr(b%(q|2bvc5JVkQ8r{HmvEVf-$cJDHWqJ^Gd zgTpUCkbp3o#DyjJ_0;MXz;nkc{e0h#T+AZ#`BKGJJTeT@wC>FcsDS~=+jR8vKoPaK zt}H4+SbXTMgp;vs_j@nz@y^?-2vTl0z{>h;w)hkgBW@BWUuR#>@K;%oSK{b}DOwYE z>h*bRusN2gLn9_51y&h>w+{)Q*io&UO#WCgq8p55&+l8^Hc~#^F-#r{yCr<_-i6aq zm2BXH+ngA5uC?KVwO&_6vCE31cY&Sf!cF}edP%0WcGdmfm9MqyjtcmnptKW)JA3`H znU_{I9u^ic)-*0d=r3g7;>SlDWXP$IjV-6ADOTXlC>h?kHX+G=3 z!r`D4Xy^gxRb%XDl5=h4y|eJ+BX`E)dZl-%_fG64?1l=cv+7QddVNT>D61T})p(}) zh<=LGjGO#f?6cte0S_r9V_trs1clfu0li2-7W0klgXc@0cuO4MeQ`Y5ppo zgJ&QS|Kw17EpsQ>YG-Y?bqD1h!m>o$*I=SjDJaeCvW3Y_SkJDCqSpJq53Fw4yBLC{^d97R#6WT^O@7Z^Ms!E`~;; z`6=h-#x+GrvLV7(vNhCe!h;@MR-OMOHj6uCA{j)#v>5bl>bbv!?n=&;Qhm)2-!1$E zRQ21DWs^BgfaCetb zzYQ6jb(e}e=z7RVW?Sx$ttm0tSfG0FJ7Ez@=U?nj+0*%JJH9yo%X4dM^OxrqWq%S+ zjjds#?c#v0CHRTM(3#u?=z2TAX*I#BP^18TyS?g9kdHl$ef!UHqW?HPMV0Ci>Z6M+ zaJ{*-K<^c?P(BiVs*b#i07?!)3g%w8#+n1&7Gsd%mtQ}po$#lqOh_Q%MEsp77$rW{ z@J?0w{=L|@TW2rBnMP(Y#W|}N_isn{J>lU#@b$9l+64iIP$C!L&s~+x z3TfDj%Tk}RL`XC%yIrvHiTy{;Za^CJd-AX%i)G2DYy8C?&v|Ems(O32C`-IT)L(mb zZ=eOuYIL`f68~x3!=HR4*X;e;r-Ze8p&hA(Gs#CK%a-A1s4}(+%hM)_p3}^OXGlgHyaQ03Z0zCHY zwkX-9Zx=G~JMS6n2V}Nkfv$4>)k5h@PK5T#!cc1|+T3*`z$H>|>WR)a;1;%*RK98V z^<%;vwC8IsnzP|H#&GNYEoY#&;57iSgZY&_5rMgE+%TD-S7N>=ky}Biqd@ysreNsQ zMWSp@#+S8ZO>JNcKA^YzCVA*II8CM(ogmB9gwoaY|XC_()Zu51RqgXp%$8*M*9k-Gr^aVH3yhRH(AK>5cyNgM?J zem6S2XKOoXuwu%>zcjk6&3s;ZOl7#aPu6JUW`1KjMejPu=LWVozc4_j zXZ5S?LyMYXZI;{6z(>DX(Esl*&)>#@0B#BFit$n0|0_x5yk~AI>57AXlU|r=Mpw~sC7h1*Ypnp)+m`o89@92n4`2?^t zyaylzey3mPLI48=R*pQ^!*QDePi^#lj&O9s^S?PG**RJ3!?^}ITHM%;J+&Zpng_rm z3h=@J>Oi>+3H-NY9_rHrMK?gSf#w46zw!US60Qt*6BX%N=c4IUpkea0<*dI#2`eN1 z3Vr;`ss95o{yl*4868;MH_lk&$Q-&fPLaPpd_YUwdi;#ImXlkE&M-Eny?-3}Dl`}0 zi-WF3-Ok*XTgY#k8iN^`{{(54SL|OY5IDhU6qW6R9uth!Cfj$JhBZ{?mA2BO9i7P* z&lJvHEQ34%zW+*Pv61Cpj}S^(dQ&b^s-F<8>TSh3YNLL;7%i*Odl)D${Ig?tv?c2U zO(l5tq9?7rF9ncMIp#BNxnTroNiu*DqtEBe`5ig^|Ha;WKsB|kZKJ^g7Br&LOH@#l zsvw{UL{vbEq9TMIY0^Y`4@5ygk&b|f5S1=MRGLx}=^!9d1EE*xB-B8Pce2kp-?#NY z+r7_s{(JvB?mc5M2COyLS_!Mn`Of!!ioY#vuJ#kOm00Gv>eML|ShJCmfa&WuSWiP2 z^FrWib}Q)c-|;AZwe|y9qU;y?zBtM^klIbq1z?US^khdKbreI3F+ng&Kx~wHqjVtx zy{PVv+?Zlvgli1LZ=2$dgCwvvJ@=2yI6c2Zz?eQ3ZI9I7Q~@6RO(FOnloSH`huYj< ztiSoOAe9MU-N`K#E$gE4EOfV6VB@L?;v!du#+UoR9aIRUg|&h66v#Hj2ag1~t#^Ic*~*smIb5ntMCCqQnNem9C-(+I6%h1_@sf^y@yiL z)UI`%$hC(wX%oi?+64vip>QJvD~JBABdlSJ72M5H`UsqraF5aA&o7@Do+p!?;AUtn zlr79KY>0y)6TCM@%2-x?NmHE)4$iq+rLWqCkE+8LyR@=4Xr(O#_91xwUgPzkU6`RgQXwr z{4>tPPhORl6woytwFghO3mVM&mV`eIu8SIKQ$c?M>b9FcmK*bb|F`~c=M8{zHn)<* zG|$x>$zar3c+Ysy`LZ%o<5S$-Aw^8wiY`v40!_8au_N;@)2823tgB+_Df%~eH`a_- zu_ZtBy~P$w5Z=lq^B2xyeDyxbx;8~BSkZjLYtH;*)uY0l1{u-XszfIES}S|?B#aql zJ9^xrOENQ}OZ54fq-$}{Y!5Cwyf^@gJ8XY)be}CgUpMp&&?NIbAh{;)&~*epq-C^@ zaLxdVo5zO>wb}Z#@O_2F`k?xE|CHmnNo^8UMn5&UQ$fvH3fzXSese*_wiP+U^?<1I5*q1R?$n|5J zIce+;e4L*!iNH|L41v#7N{%DdX)<8&upMsMAU$43G!Al%_@YCJ8+aXgyi!tGz61LnMjn{n&}`5M(}jws5LguV}67J+Z%nZ*?(S{YczJ(d_9R3T&oH?)Hv; z_TssHY%Pu=Phw8olqyMi5m>?ghX<&QNcN0YJ$qb66rcMNC+Z?7_~oG=)8P>M3I!2O zdA#aHns~J!``FhtU8C<|{n9Jg`O9YDLGouG^FKmQQ8=4b+WcyuZ|X+z5h;bqkgxl> z(1XYz@Ay&@XRVJ$L4354T~rum+2AB)O|MR=N@l`v;S-X3N~FzD#o_e@DRir4)o8yF zAC;AmXpd(?S*PWw+p-sB?*PaVl~`z``yJO=X@h}-l%$asrs*7ecbSgWs1KUqvdcv` z_rCOW|IDy)v-@IKlHhs~_3PtIskd!;9>Nx1&_==g+x_&X!OmaE*U=0>&v)K-hfL6;ND# zVDtn0C|`0aLt~;KXaD=^)l3~A zFH3?EEyGi|xYqOC(961B&^am97FJeNPYHZO1OyF|P1H$4R@1YWGT9dsqTuL9n5Nk zKUgtQQoXHd^p-qE|2k7I&~pQQz!0AApDM;U(CN0$ohW{{sxEfzBKDB4l{)Q;1(>@2 z!zJ&HrxzzcvNJlh0KD1dM5K_!tF7#eW|y6;6mejxnV=m-Cyg0~DzN`9vx+0Fpn<$o(k zZWeCc$$jue(@`Kt{v17}i}Hlh5S5U;smO0>+ zsMZmPG##jI>o!)!c#l}YZtU^%_2tzxbLR2;_UMV*W1ropK8Z^)j&W{X z`HP!Y`TatWX04#C8B#YThz>md!$QA+H0m3VSSZEFYSJlxSKhdSMway zvlh+1+f?NZ>Nc4WmiHxjnCkh?K#F6JyllLOz(N>9gd^7m2BGO-`}|6)iyJe=GTl-v zyw{*B6`xwN??h@8zCdjyU&TAG0%0YI=kJr-yu-is!3iu|mD1lUigev4L2Kmcb-iVp zs1ldYp6U~F7^m+LV?Nf6`1)n61*xu5dxw{iWzmM+fC(0ES6-b5&Eg_v_Cf5sK?OCo zQh=jJ9QUj^!M=rvbrubrW|qxfgYc}vSy4iykf0(>$Bf)@;?inPpT^L}{qWa*pO{NS z=S4sK)&Y+B3sOd4OcaBa13b;%qTaGm?}pP3J%5hg0g0vTl?FO{XugX>@ZCzUEDW$m z9gnqfD4c$9AU1LsvLDS}AGs$A}l|f};XloN0%)Xb+ufM)g|T zjt+(y77R{Fo1|Sj9ex_vrr>-1P z%ob4}t)D=G(pAprLR@yvJWHy>FwSW0_I1orOl;j(1nMP#6h=amZoY>sQ&&^9A@!yre&akDVBSZH$8WWCc14hMdFN zAVo~zLN5zvp>Id7@A3*^d;o9$OGS5Nft@r;;hojC2c3fAvkKX2D|tDq;i`@y@nSEc zo~2ophr}Ic6n6TzW;K%*Yo6>sa5Jpz{_yCqH$=>qy#n$f-Wf`^A zJ8`^K@*Rh0Q(k%gK@ix+&e!mK%d7$Ju9qy|G;3U!k3+zaamCkRbJ-;B-*jnV6_je^ zv!G{eNsae1cMKi%Pj?Jly(5LL6n_(l5uM8^o_TA%aTAtr7Rz9B zu;g1uI+);10^w~h=t-;?(qsEW-#%0A<~C-z8F8N&Up+9lDT&`K7)p1{6BflV)T2)D z0{+Y%+%fNNfQw7wN~b**W;7T>=U8lkTzZNJd~~Ar1o{YwaNZ+;8P!KB@*YZ2X|86u z*RPI_6<4OaB2_3n-{ycv)iSl1v)y40wpv!m@;8qvOd*A(s(ro>d8N1yOLn9z*xp+q3Vn8L8Hxd=Xyw1U%>bTn5*=AZ9A}()Hgy=Fau2|%H{PRfmkPo{ z3L9z8GHn+D2K5+vHQkcY?4b&W+9yy(?9)OR6s_-&IgPbln+q`c{oBvd!tYaBzg+vh z{>QIUTE7Hn|7>A}@oyTOpZT7C66l~f03DQXgZXkBz*7QUx@n5FDFC~% z_X9c%zNo$evc==D&4d`^Bq(DF69BaF33@|DG=u`)0wD|%B-5^g!MOt~LVt!IJBtOw zFmi+KS8I7mtI^?+0n6De{U(=AY&;!=)f28zFW1&p_}mPf&wF){uH_gxW}iV%v#=N{ z7g1hAT;JuNAy>C3BRo5J1hd8Ndf<{o#;n@APzAK$4gcoF6QpD5TyUxByVbs2ssDU8 z)4I*YU}HAAYIsh=z)4Wkz#xBe-$edOk6=g@@yYuk)%f@M)?W`dThF{#gN78Iu=*4( zZgsom#l>gqIX~GQO<;e-P(Q=};Ese#{Y~)kI(}2|@oxy~UzcQm#8kgjl1Wu3MH=te zdFXsKR9V52@D;<;nnqE}+qNz0kU7hX6e;^j?QokmlptZtmdpE2ZT+gvEi(bnznN7s zQN9y?u2*$*k}Gg?&a?#Ud41Ew)${=-c`ns?nN=BdAVJ=dvz;OmAF&s-zpS=?*kC>c z?%oAlI5yROlDPStVh>Xq$v3`L3h0Hrd@qrs;D0CoeK1v?@BTe6F(;p8{*PRXurNHk z1nTg(jSugU>HNBh#&gFV^Iz6;u>{nyV3m8LBmevqCR>NG5lTXts~u~w4^M_2WlnS_ zGJ6wG>fc}9I#8By9!LR2J~}}!RIHmndd8?(!{eB8iboj7AwS3(_UKn79?Iy52HHW} znfmA|$I^}DM^Vw&{ zRSk1`alux0-Pen2D{s;Ze)||o&lG^S>?GkWY6qB@ z>wr0=$!7c;Tpl>2MvF;;Zp^_MVKUaEj=6O3xEN4MGEYd$I-P z<4cY++cRK~0?xyeQ3)i2F8JeTY!>$n%_vWWwyyt^o&183W{B>a*HygWbCU8BnBiX6 zwE=@ZKgfCX@?ldbRrAZ^Oo~SzeJ$P-c77j>z5@}+Xj^(U#o#Z7`;8|9Z}H#K39XEl zr~)KwW3jqpy8DJ1Vm&)AaupTyigMeeMAJ_c+rA6me8ml&KPJvuB{kP(G-cxdRF`3A z--NemSwCKcUfmrDw4XFht$qX-FG>CgF2>W~;NH0pW2wwW;AtzwqA6(5Kh9JkS6Pd} z&9ny-S1|iys1t(mv)qmVnbB1uKRJ_%1uzF&*gD@bmdX-I=UQ2U&w-mHm=Xu_eq>OV z5Wrc})6iqCZTMLM__76|kR}N}$6|PJV@YEb9|WdLTBvgXq-twQAOUVpWC(huSu}SO zfOq^=8DX^S&UeTz#~vSGr{$;c37*J4f#)B!rs()LwhG@*nwnsu)njES3%u~kq*c>L z3ao?LC!rH6Ags-o&Pu2z$1brK9`c3C!J80Js5>A$eC!=EcCx9n)@d4O6u$Hj(wCBwb~3qEY` zxYOn{T~q^kjiCW_{#Rz8i!w{X zzsL9fgwjP`{lPBaCx9=Q2xe}QuGq=#=msD7sx%nfJ5g?fi>8ruaC)jcl3$LNkP5Um z;f#Jncj2nI-(zqM>ii|Zz3R_GcUz(-E0Fw@Qii6-%kL1gXmDevmMoi~FaMXph9DG{ zdf`h9P4kjY?4Adg2kKml7tN3wKVD(cAE)Bj-_OLq{Ajg=eGdQOUHlnbTMoq0zC&oS z*gfcODZtB6$@TpXsREe;VN;&(khfNN#$&@ZFxLk!%hfWF`@GeNrgIdw64XriQ3R?w zy1ob8I>I9`I1+L8^fdg~9T4}=RD;*p0V%_1LoUkNfM;j~y(|kHZV}+E##arlOu`d? zwU$>|x@#5;r~e!Rn@ke0j2y`gl{2`N$T{;CGqwlymp1v?A`KB;Pk^K?nw;CokeEsL z*$SauVhg1J7K%|0&4i$_%*;f2D98@_j@n`br8F;Yl65P2pQ`ALCPZx6-YPj@hr`!% zr#^9Aj{(AAZJ%~4^7L5W3gC6y+vLQ2&=T_*pij26s1_M?9}4c@n$O1+#4QY%3MfZ1 zvf5vcV5Cl(E!HF6iCLHZYB+B7@f+kF-x7Tw5a&Z^Qj()!N8r3OxoH#+qZ|iWbySj# zxXb&#rF;4j-i!t1L7*82|ySSTQM=;Sbs8>Ch}I$7gmNoBKog4 z)DS=SYEf`^#M&DR3khXUb)3&#zk4!OIQA32{r|LWj)$s>YkdPfND)0xj(cS^qqqBP zq|(jL8Vv&Ik}6Eq%Q}ruWbJ?gD7WEJT;Z+!r%U5nX>X#xQQw@U$@97W@<4LG=jxqX zhT71X7m>rk4EVPrP$`^VFhIOX9L8b%k!-75MTBQ;vjg(cqw~zvNWyTw>hOq z&RU7(EPT9r6I~v<`u&Iaj6Pb=UebMc@N9KA9DfkLBZwbA*FY z7v+f7(Of!#2j{(NLTa;%izPN~XDzTyrItt4T6r@MEaqS8ZYro6|^M{5#LAej@ zhnntnjW*3DS&V#1&z)`<#_VfeO&n8|^}KU(_NFBeR)j?PkX)aKw$oEPBkwJD!QAX@ zp!AIx5M|k{SPUu3g!J<~+X_aOv|Kn*QJ(_6Vz#E5aSu=ivqc;Ic~Qr;ANuId4H1GK z#OFT@Ls~Am>Q6o%<~KbN=M; zQY7Uzaw7@9m<0G__Jsgh30RofrQabZ@bsb|8bOcq`?kp69rsgHE~raIu6pEHgOP71 zGI7mQX-CuaW7BwKRn=7~K%=prIX8}Jfx}?-BepckY%u+-eeWea zI||aHdqKogaRWWsol^m~hOHm>{0>>&1xk>rHGkK`&%|sJO#g;x{k2Q%j~Lf(DfDaf z+7-V*;SCTfyAl4rjzW`=pehi^SRULsrU5#|Av`Dxu+XRQ%UW@uORPYzi#~%=+tHJW zqO&5@UAW3kHWD@%zo=h;-e91|I>`i3I1@93)6wunJIc&3mKHA#W8g9CGJYy#CIbe) zSCk}jwh_EEQAFG;%Dp$=A$!X%b7EJmD!xPN9gx>i=k?Gbrb4?3RH-45mzKrG`op}= zD!7k0zrv-RUbPXpnb5H0$zInO-q;=ceD&XK*8TA@DMv846Bro_vLVtZjVcsH<2ZlmVO6i(F5!w`26Bv z#^6Y4vyWwy;hl3wgwTx!Qc_BxyzqrxWI)WWLOYU8Cd#F5i_7vy?}v}SN#us9?7^%B z`AH+S2<3`uYe^LtnPa*xE6w(8JkWnw=Tnz=mf4DseH|z1smT{mI z_k#*Ms5O8{askW_cNc;Ap(gS?g@vI$2xfv(D4S(TV9g6fR5Zl}TQDUe8Wkq5R89L_(txCQ_SO9vCnh^8AXMs-eTN+306~J;Y4B{^(EHO3x`RE7ma)T$ zDl_cMS%bzW7?=La7Q}19=At-CxJmII(YuT3@f2Ko6y!Rf=&l`-a`g5TJ;4Qj<|*Rm z9Z(BY#p*Vc=55pHZjI*U&yf=CnEw@Okj`( zg>6-_VH$WT7iSWuh>oFZDDKOShG7&(E1^e4 z->x59)lOx~2mU;}{L=`|B%LY@DUv4lKIT%dYgVkUaO=Guz|`0dzhVD@assHBt1)oP>`*U{o%{sC(z-2}Y?;Y8uz(peNZo z{Ik5AjF6+KLh2=Ouo_58zrBOp;EP+9ya(nfDPH!B3O)SB3HwPT6KGc;5$FNA=;a%P zuQ(8>#CU_u_I5yinM}vVpsv3k97)L|K9jys(v&M7y%zgLh+&RXC#yE1Lw!o^Y?^n? zNEJ-04QQWC%v)hZdqQ;X_|edjfwM2%Vz>`V$@Ar$ z;NAw)LJ+TMve%Tko}UtuI&SH9Ru6Ezm7Zb?Uc`$&_L{igcG>b;{iMsAG|PQ{r&MaH zW#ik7jhp#SUP>Q}QQei58l$ebos)AP(Ma9d^|VvP{)8BHE|FIe>O#v0jg2qbIvlNO zYOUI)VX7{4>viZ^q1dm8+QEY;BhIigPw#BQm^-Pu#f3t*3hZgfM`HdD{*A^C*zU0< zB`%74xmYV&0-o-tOu}hP4@ZU=wKa1tj&2}+-oa~Oj(u3&p)d!2P+7oXKFX-?EzCog znnp)NQdr9WomL;tik62QO2CZ2>0^~f=*jmI{%c$5d zmjNf-H_ZAgl?|iu%qDl(J2U#oql5XSZ*{N9$7m~?#+`08s$9}OqO$*lwdbwZFWiMv z0?I{fUlj*Uq+ALWy76VcLihYMxM`?la%P>!fHe8iN!vW3_R}3UBMGn>lZOLUz2n#5 z{VhK0=SH<7=E|%`9^Ps1LLcw;!HRC_b|~}c>WqK_8e$9F>8^B~JUOZK?a##ae#h){Y4)M^L+RS~x9bC9?8y#;HWo57bvSWq2 zZWwuycJ4h!o8mr9wU26)>QOb&zm=!zq?Yvsz6;3r^*`A_S7D*O#=!>hpQS!mZFi9l zP*ioMAQ~BG!^&2_F9ouk6Tiu4c23jZJtF0i>R4_9!NYuWzpOT=`9%AIH z1}f0KYITfuY!cd5@x11U3FlRQhdBW-UvYrJs8`E9hmSocA}gDjIjL>u?@G@JaV;UlXW{8#S9{s#Gxg(= z@|et}yz)|SbS^jZ989{|;UH%2(T#PNuYS|-w3{uqMox=xI^0IXE%(M}no8tJVxLf{ z^mA+5Ghd+NSK4Ko1r7Hni{5;XXR~OME#4{7^o^T%RXT88$F14*a@T`QjZQIawf@qc z+)B;-v$YFUmd^}GZ?#_U z9PGg}E?v=PRBld_Q-6ZY{tf4G&18URySm`)>%OO8hg92@Ln_zjwYR(|EiY)F8yH!g z=C#>pmGXlh@|c4bdr+sxkbnz;_yuZJ4dPv2)(`>3#M9X*P!7M0|*D|%)cDVLmS zJD!*c^RT_jjOe_{x^+;vXy^ZqJyy{77<`zE6qLk#R2ng@cIsvr8wW&-eqMap%oIz4 zRmD!Cp+Ws^;08VI7l{ry@@Xd~YdbDXw3D%w;^GG#CY6?e`x?uee&ggNeJ1G@NO5bB zGyeAi*5ULFbQi^f-V11>#*TB+jN&TTd_S;4TVSw&VP3HHJ7fR^5o(GcH4Dc1vFOR~ zkOgf}pG*N+>HDB!c6s^lXk62f%>@()eL*;o?hb0s;1*8GEIQWV*F_M>l{qLQ@PBDt z{w2f~sr^Gu(6%etmQV-E$_>7ej9TaKkaXQ&;BU}cW0 zph3iiGL>SHZ|$#vJ9z}n2y}6BlzgGDH4lo)jAl;NBOVrw8*jK@T$UjZK6azxgTF&K zET3_`jVCZ34$z76gxw1^Y6gELBX+8 zjAN}1g$`2g@kICfigBpBSx?9X(HR(YW&{1Gz{tT!E7__j+2y47#eRJcv#+6rS#})H zu3{AF^lFdQw}-utMhzWjx4+gQemYsnmr8v&H+Sp8qUPaG*F?HrW*OSbqt@2e*m{Yd zg2v)6-g|+lX2_6tl96GBR~&6Gl_Z_Yo))~u&a_5MRazm#!%-Jdh*5DJBjR<5j3zsu zhaKC``>kfRl%s&y_dX0erSWFh>J!cEe4dn7GECQCey^n$kas~aSC&)7XdDWuzs^pToaUig~_5-YXc`p%;~SDa=1%Bo_w&xYZsm`xL^D2 zHp2hBF~!Sb)vaw#R(r(cg66vF&Z43wXWxK9?~o6@rryJmJ?)wWJ@7~FJ0-`tjuCrL z)y(hqn-Cav@ctGIx4t6LZpk>>A%uT&E6M&&9p?w}wWq$}g)>B@z%+_~`)rA7vV#@W zJ@{m4WR5@@HN~D#;K!m)qG$HFh07B^3(T;ZdBXG*)z=gVSeuQ#vBOmD_ftIXg-;Z_ zxGLwB-uT4Md*|}B=JITISik+OgM|81b=Tp{ibXY|sxLEraG9ZsL(?<%8&hmasOZ(` zlnT5j9UhGZZQwyk@y#y*TM zfQ8=~ZH=w;h!rc2t$*MD`uX~GtVm|-Bck)9VvU#M9LuQDnPp2-a$2MK*rHgmU8d4a z`_I|S<{r;|pw9Z3{F_e+GN5-TcR1j$g|2-Ezny(5&mQz2KEz`*FusMG`#0aPFeaoj zRtm1Hp8}#TE8iiH2KWA zHBO@A?km?hPKiF>7N_15+s)skl!geP?H~tXgUbwDGwt@j;du5+%p7rMr$}tR z@Y{1w{Vrp-Q`km#Blmc{|8}+GsJ^(&CH?9=r~SIZx3zD1p4^B=-b8e=uc$a9*%c5D z!`fTy_7_w*-W{>Gzr-?OZ5CeDqul3z&y&3db(3sT9Hg)_OQU^zdFi9v+in^yg7f~jJ-GT5pYYdBvN)Swrz$AFndYIdEE5Rf z={-j4=EoA797Lld6V9BuHmDV8xER?pvd8)wVF8_*?pL^}LnN*Ix6kh|lonibIMf)g9=Zh;ZQ5yK9 zMp1_>HqYG=4~hqAp24&oE7&v|(+CyG<8`(DMzF4&M!>lb_b1MtUw^L%y*_I{1&4Uy z2(>8(3OZiKU1@s}F@MNA;+oQ($cr7mJR91d1SAW|nGfbq@EfuJzJK{`Z%JgD$Jv5M+EwUi@fJmo7-jz8K|?%gcdcv*CWy1jwJ9gdwkFJ`xhX2XZ^sHz zeVYfbpMAIJ<}v{%ZmpFiPT*}{+Ai(9)h?IV&nt5K&K4Z?d|l_mIpitESAkPS1R3g; z-P%tznG?&tO!nwV-(p`QGAq4Nvs;f`y+;l&`iLdk7@{imPd86^s(wyPf?#o9Ppz1r zLlmGyNF6Ec6z_~4W3~75*Y4gu7`AWW3-p7@YyY@8*sd}e;UIqj+ad(pZ0Qr;q#(g< z=avHJIqfj%zG{`&J?g{AkY^5Y)xHwr%oD?xEB4Zcs6oWcDHFfu&hof|1Ua3W?PZ!J z>Q+v#13O|ru@n0Gje3mKUELL~8C932#UplQDXJ?l{n75pW+ND=U4p%R<_yuKzj2Em zuW$XB3yUyhzrB1_jgmm8L>EDuP*7SLzwM3eT6F!`-m4IyF87d7l;UfX+&m1{*3(mL zr@q62V01m-bBKDbU01H%Z_%#OkDiaeUR9(g;zviT2j`8@XYE_iw;d@IvK%#j@QdLO zA_wIxqkspcXiuNq)E$_F^KJ%iGsp#H5VwtDm4ExhNHD(pY&vCnugx|y@Zg-io9D#e zc3fc`19m2x#+ZIoX*3pmKoR(WjlI9+sDFla=fOsyv=~1$(v!Z=m1Yb4H7EDD{4b)tiSiM_?nbv<{5!;&*K|}H#9v`2Tp|Ioz-Kc zHeq^cdvnSC7?ZP~)6bGl15mn8qpNVj(#X}Mf9jq}^Usyhxd{!z1#2A#V z{qP`Lzb#K#O>%#I;Ah@i36d9I_IydyV{M2ooY`bV)ua_)Bs(t68yB+EU#(a1de^Tc@`hz<6 z&#nKCI`=d%5}BMCfwE5fTs(;^GE(35j(b=2KIo7Wde;WNxV?Dl{hR}A_8}a^d&P*dOOvsAS#C~>Wwml!NNkqK4EZqJ!b5KKDz8~B}?XC z<$M`(ay&$Ma{A*cGfszMHX=zmuXOZq=ab%Q&u-ITzN&aWOzP`z-8}2s!yymx!w|}o z5Ir47wm~x=F4w*KF8&cYm|ONUlVj?y)Xm+!`k3`}qCPDjT4P^Xb`fe7dM96YcdO`$ z`ddExd_y-j&hEE~(N8v&V~Tq+c2aSNVvPj_TODt@pVU9`4mG`ho08#yK(VLm*L-8? z+RFM2QS#A*2W4{JZ;jG^<1f!h zHAKd-e1vx_voA$fz~}lsM--&cHUsp~ZpHqQN6!ThM7_A@(uifudGZTnWo4hxn(M909s5ARAzcf)0$-R$8#{y z3ReZVuyPM1#O~5~Q?F#i$*O)nyiaHC{54s+>Pf$vJ24QUD9H4cpMRq;WPELWiWnKC zw{fRYCOC;Z=$KAi%mtU(%o0+n;%W?#ht#GFj%sRic;Q6-WUZc6T?wm@~s5Mi6GHx05y!6C;+3^;?G@vADN!bbdt)TcE zdShY&n6I>~{IyMB_~eOBqp0M)4vRVjzn3C~jzdy9!i6iv-EUgnXQFK*$I@N{v}BsC z5}W<&RG}TvA>lC0xT!VubTiL1?(l=R`xW+;1sVMT9_Q!FLi4R*fJ6$J@Niaw!9&xHe)-tuUAa-Ia=pRf{*S7Drxr0z zDk%4nbGz}ucy>!0bE24|-uzb=j?12RuVb`OnSE?Xey@nig<))s0S{NvW8Tiv0=}Ra z{@y3n?XVMT+Ynti0Wx#)h#$wGUfZ|*y;>hRuV6#Ulrz0BD#e`zAFGSn zC46Z0{hQO_8bABtg?+XI!mSP~4ie7d1&t|qDY?z*u(RQv&ks$yMY0-%hM4~7Z(x39 zMGjLsO@4nd{bNdHjZ*X7hWf;Y^+Z4AGg}EZiZf%FFx;t-+7#K#ZpG5w`k6hsJ!cP` zg-c6j2}6A5fd6MKIidC>rMj3Uc773ZF$o#ckF3N+Q+$WNk&5pXgda0|{P5-A8R0Y04IZ%j<{(q4HoOpm zsT|nSb~-Uw;z$T;==q4+(Qg0k4{4jqaX$c(O<8^<2aw=IX@-V4h8{2qQdTj9|2L8Y z-lA+@pewHrH5;iip&FB1j`Vr$hbHb^?c?~LwBT-0v_}d_!ja_HApvc}hF@mS9IEtW zJq4S6Td};2&;;8_)5C2eGi0uj42?w%`a`yHT^$YHT=ec(?laP7s z^XEGG9Sz%QifP7n&yp)EY`4sNS`fZ6^`+eN#6~%ol~Z1lHI)Tucl1Awy3rCpTzIZZ=pNtt$!{s>9_2_B)Nq}-i+3;-b})bZgTqx)!yy(W zt+U@StJf?Bw|3#0b$7kId5h`ZcE4w@*)L>$+6vi4mANSrbp0MPWRvOrdr@-O51Qo1 ze@}M!iL&q)HOYU^Td2DNun1s+-`xUauXKM;b?|$PG$(Wy0ND8toCT0T!;cl)!B)9p z8z+BeJN!L8_e*z!AJ`5nvoP`kCpB;#LHH-#A1Y|n+#Ai$p5IN zpbP*{j?@AuuIV+9#odBy0}`8$d9>-?AocfR7ge(gvnXZ@Um1ro?umYb{@9)U2|eR~ zWjdAr1%d|PLghvL8U5lJ$gN4P^PWa;kl`D^>k%aia?!})g^guc6X92DW+p)%p!6?= zT#;l(^*OwCAquQ5u#Im)NIp<7NFVbj#IFq$$De zJ7mu!fhR9hzRG^fyt%fRuSmqK50mc7oToNvAl&)&wCfw$w-OUVi*@g_=IdUt|M4-% zV_tT(3nSJwPvUJJX*SlDm6*OdbMdYyM$3%lBm1It@SD4gV<-dl+Yg_VmDx9@PYXVf z9r?IiyU#cJ*N3i1Mzk3y!Mq+F+VXWuW4xH(p>#*WbV#hIGJ{tosK9+>ulqFx07zDj|pas9c* z94#l8r=&Y6KXXtQj*3VMyB|4iKhGUKuyg-eRu`$LJjl7LXU-@%Bb}NeNSCAQEux0hb~!@`a^|-rL(Au@}mRXdK|BWRE0Ej_AHImFT)F(6&3Iu>3*L z&5NJ!ioAfvz4dWp#+d>!Ywd$m=>56oWRHBO)hJ`d+*u)!R{}cDx)4-uVEYT1#kF9D zh*zd2CC;AnabZ$OLBQ~wquF8IeTzw4H#;b1y~KPoa^_(<qyviVHO+`;2nTPZ(MYCTC@-H_$>x zM8_fnS6v5ax~4tnxD ze(Vks*L$55>-$n?Oj$_q+AiDyvT>Kslg7Q6>{qpmA1mvQ#J+pFicGw(Gz1=+trXa( zJ#r@{&t6f(Dnz@Z)xz6&*dkiJyUACw=@Z6D8$!5GgOUre4`>LPlys@8%xRleFU#D<(|b(*7WP&whI7B1CzcfHM1v)8TuE0-%RNH$Lq9v`?8OO2vv2TP=?cD&WmU z-gqLk@5Eu(rOW-%e(DN($VUnnGbu*OC7mlLE+}t_;e?+K@8Rr-t@*=45WzGB%DYi4 zhZnI${n%$C+jOa`hP`wx!T5?Br|LfMY!R}S8OB4E#Jpx|Qe^Yn)ZfPwZM9Asx*|KpsX-5uEHp0DQTOLfvKNO&fE(?!dVJGKd z6xRTP;t{#L=}x;X!s_U?Qxnz7+rj`YgjaA{bks!2cOeLfLX7%8?a64%`>gT8qWNLK zPHx5`P>4lzKhw*x$g_>IGjwS3l#R`s9J^Q{kW%e-XmO9`H4j4^o+hbS6lh{ zh)W7=Q?qIppoa**ILt8SQm}A5;%4~4{BwNUw`L2!&AD+os(SJBbo8ruYm0jTJ+#Vh zr@o&n#lYmo=^IV6P6zj-|fG0p2=MJ9J;3qPh=MK z9hW4s9(u5JQqF-znEQ+9|ENi%MnC5_M53uARmID7Zh-SWVOXm%Q**pYjkXxORd{k3 zV3)iIj~T6|d{ob%*+Pnr)KuHLE8BO7LfWT>jWgHa12RCNzW@=U)IaPi?tieU#0_U$ zjcz${Qp!K#AapIdEyTVu^^H@jvT_7BtrW$@Xy)+gO{RO_`~X}n(myRh$gU6#zUHOOu30R$pB(&*I)fa>V@YS z?|HGY@4l*{a^7O;=LOLb%)vXwl+2u>jIghH`Jz|T{Kl3Z!JlG7{{Vw{;-6y>sTw=Y zKNLsU@Cya2uttQ4d{$LvX=h)3vcJaJk?*U#I%_C5|6biEVFA#Le~wGM?(DoLy&!>8 zT8)+Mgtt(1!0Y2<0O0m7K@i!=#WgUFno&vq0Xx04q~o0qbLw2;Jl`RlBbq>A@!x4( zVX0hKXbD#0cho$MY>b>jUPDR7Hc>2wyO#4+Xdf7HKks0AfU1ISP%Q)?P)p>7lm-by z6lG}0VCjKJHZvB82S1QmZ~;GZQT(B40+i_tH+Fx5FJ9f0mAqBzNIzKk zm2lBy4~kCJqJM|5`bpqd+T(efje1&o_r zF~IKo&Sz-z*c0KB^%G%ej3EggZYx4F>}q;J8&JRCi;a0&x4!bvcil*;WkyN{;6C_Be)DwP)+z?pqp($TSk4)r6ariCwDOqX4OJJV6)2(J6m`T z_47EK&VDa@eMbPMWXt{H=~KWf*D{Jp=pM@r`=5VP+pq0=9T4VW8SM(J(x(Z-nBrBPlJ`Ng#=&UUd2tICS0a!l#9U0NGa zoUr-mj?fKxTm&{Xr;edW=^|*7-lXsrCmP-8@OX6H=;_OC`?WJ>AuLYX>0Y30jprdw z`LoAXc`S+A8Ah~^aV4u2D z(pw0Bg;HEJ^$g|qWig-t(<0F7`q)TMFy^((m@mgJrPua?tInjRCsQ4N`rYhOn;jiaJoLVUrm5ho@0()B?2@F^$q^XI4< z?(?*I_Ekl{NTkK4q#?4JF6+33cFRGdc}rSs-D@LOa!l`2^q^gzk2y}0g2`weLWb?h zHh6I}#%o2>EJe!56-u2miqt|hpbsqfl-4{#w8PCs)jaY`OD-Q#-1RAN0-TWv;aH0+iZ~rC6e_b5IPP6L3E|)F=kS{apWXh` z*IvK41(DyiK|IsO6?42p$mXT)`A-nHgVXN+EeZN}Jkfsvi~jS+f3Cp)6Ib93nnST%{2%9Vg!8)LW^- z_hZxy>&RB&wV6ZxE|p(^&f1Ljhv0*K%-?Lfk2efiMt7A-4kN%sf{WrfaxD4v^ai}= z%}axejjKyy8;T<+7XDXt@U4zDi$ zifai9morDAGF!C`eJNQXvW~HP_GoPvKu{e)F5(TqLMpc4Dp=k!QNBq!Khx-#v|K9*^ZPuL@Iv z^hayQN&YC0F4qh2|JLC@O7jHE&!Tx{Qz{a{=%n({1@kna|qD3%&-J4uJG;SMdd4j7(1J5esLX9pMkU( zsMt{~fGR<`k)TwsSD8xk$GaqGA(DzUJ#-rvf6{PK(C3P5WMVkW?0`8Z*2L z&XK`O0PLe>BS8p>OO*FqEGS5VdGb56@RUlTu(kp==ZeI&rZG*%T~uDViZ9{PO*vgb zFvDZMx;MNU^Ke*&s#*vBvc`}`?yRB%L|Mvvvs7maM zR{^_W9c1}o`+eP*x?B^x)TCMy!-;cUB2M@rZ&nvI{y)q2lJ&(*ZEs8*+^FpWabBW*5SztWm ze8C#uv$Nq)DVgWfv31W7UlWz$Z$1uDm?2SQ*exX{*KI{R3+_mZtyE|*^Z{EcQr zD*K!|_&vR^!+f|OH~cn1p* zUpg1PpGT{xH^v%!@*Q>XAzwneveA8t^apXqh#B2N%F;hHtvE2c-mLYmj;phUHdwT)23%S50cVLXoY+5tay`hVsPs7)*@k`4n>1JMp7=J z8N(p_&#Ho}boh@!E0oRM(co4;s^7-NQbuQ|;DLv* zhKg+96~+Q&4l5gP&=9TpO(9`<#)2cLxNA4;L3fV=Et>&hni&LdIffObF!9*1?D7v- zrHu59u-LaA)oRaugHEcv9qJ6+vHEk_Q=3%cb4!cP8+u9ad|cMIknt4zLHKpjxU0p} z@7?m#qpdA*VVUAeJ2=duxsh=*M{&76LFnd(Yhl?R3b^Sukj0YNh>W{IXj}tz>@QHzjQuqUb2%{6DA^Ptcj5YRyz{H=MlO=AURhre3az4; z;gFvikMof3F$oxocu!DlHWMPe^HIWnsoihi*vvCCV zirED~c2RFy=r@|Th~H?$fJ!COEG(aL0U8!WwE?8+(yIWyw%3P?!hx0-dw|aU;VP{| zgUl_dObYWqoYyag(8G3Sn^NvnR)D8c*DgbeUx)1nv0AZCCdXecJKQ^1EWwKa_41Pc z&~hPz=^z7$}kL1xE$<_zgb5WOuwO21}+O>g4Pyc||roKmT_O07?&wY`^?WOKlJ} zB6)-AxsH!@T9GBT5iVm^%k>wR3<*BX01bu8YRd|Nw#i!sCnacggRdcFn9 zMat|LT=Is*@1!XPiW))&*{y?{aqqwbC~r~?p|_1HM%>!Zh|Tc@0^4v-z4F$#XIx;m zj9W<0e#hDJzL(2(XzRXlExr=9mZLOLvEIABoKwcSjCU&2J#?ANU2A9frSBf=-2KnY z8w@^e!+&ypZRC||YelmFzyy1LNo0%S*n0rnonN1<@>{R#k;$~*`yv(WCubfRULwFp zJ)3RH72;f>PA%-k)HxksJl|PChBvLvPf(sUa-A}{sz}k%td(NI*oPh%WHx$Cl2PkQ z?Y@PJSNHFr5=#`P!7V?OJN9oi10`IxjX~$eRt?S`U&`@(uxR4k3Jp#5jNM8K#8G<@ z47wF#CAUru-(1TdsK$gLKyvHgMe(C82N_hRG=~b4*J7XICjrDq7$!cQ-%__|t{Fng z7PKDJ%j8GRsjwrkI%dZ*PLMtl*7gnh-=ofVypqXWePQ5WILsHClD z&Ji+mx^jEO?lr4sF)Dq9yNUqOd|Kl>8!S*~+=sQP3=?odtoqfHItucLE%5g>gNUtCL`HX3{Kx3Yc zZc+py8p7y6aJZ+2GZiQ)UntIgpghqUE&6WVlBc-~GP;#d8pL`uGE|%vf{nMgQ6P9xL2$ zG_63j-+tNTvz;oNlvyrb2d~15ZuQC!JwwnusqAyVQc;&PB)?o}r_X+TBP;1O?u(a4?-iwe z+tl|2&n7>4f^D?!$j1-dFUe`Pfp$lSBxm1+=zpydOX{E_eF|;H(2~&28S;uod0`fV zYmOPmbGYtSCBNV?J~5MFzz>@K1ZIRY;>{UgLzDKYXF~OADq-j1Os`KFcG^4_Pw+Bv zfkrg!AC7vhY4fI*VoYx_$#gno&C+c8n|g()RhP9hPIQ|w=-rGb5gd-7W2r(ws&JkW zd^O=dkr!Bo;$zRoH@-?75(IPAXV)Zhl<#Y*Bx_RH_3py1 z^l15UPU%JaaR$F!hRI_tFbqGe;doi^` zqEk4x-TTrnAera?%q;Q)MGALF=3wI0Ok%q!JeywQWwPy|+69!*NYij^nFmv3@<{4x zK{p3JT%b28tCAAWDCwwyVi{#=NnCY_z1N*|z_yuNw5KVb)b^D?0kS*_ZE zu%tZ=cf&eLb)&D@Mgi9~G+#1~av&kJ*^laP6jCqm;QM@U&aB@M% zRod)m&)Z9$CEjuf*bX)jQofu`%x{aU%yf4yd1K;e4Lkawddun+z3-h1Xf3>6_n@2ixtmA*koiCk=2JqY02Bbjex=G?PzTA_C{pztXZDHl}4@IaB3STg{g+} zyQ_-Vkemr(WZ`{g+crI>T^UxwXuGGdqU9>(hG0v~)r_Pyj>BO_ZAU*CT$6CNFf4Ww zk?H1p3AA{B_1J&$e%mxH51%$!Dn5Sw(s1v=_QSb)(sO*iX!u-R5@-#%bS&zlW z^wh_?=LH?fLNDpJOO&TGLJLT-xSo%>c7RmCvxavqvuzCzJbvDbmAJNWeA&da4Jc3~ zf?Lub+!}DC_WN83?T+-$Tm6zP_&A{N)JQcZ0L4fI2j!vp%mz`Nmy&5g>-a>E$vtwE z>u#vI5#Eo11a9?XNi%WuxkDDJeM}E+1cDIHzXc(_4$&k&EP{=6)zP(LRe2?F@d+!H zdPUI@lUdyXhPiK-bpL*TiMWyce{_E!?-kUA1@G8!h=9GfexmbE& zEucLcM(6LHI_oF8u)7cFZ%>-*3<_jJ6;_Ad_p+qH3g*=xw)pa==wJ^F4ARU7{kjBNkHv!_R}@)W58W8;^?OS& zT2e~$ehE^cA@3kTIgCvh0)OFjCLFj;DDNhqT0o^EN(F73nmPLDl0`jPg>S$~GZX6U zz+?K!uRb~)xXe=!2JOPbee+>!iY)u)=*@AC(d}pBS)w~i0vlHiLg2SaJm-*y+vWpy zlkYmc79!6LtcJ6l{1Zp9o}G(kJVaTnb!x-mu6bMAO-4%fRdlIotbTOu5k0E_j7YAl zegegzPuTR_7&H7vwqV$t)GtMt<8-tUHF#(d^8+Y+zut9zCTkCLiWuIog4y{NS+dYjn>BHj4f@^i7`MJymb@pnqXiHZ&}%QV=bcL0G1mW*a7JuQ z81d!{t8|gxHT(7ESO9q^WJW(7l5Y@SsVue;y$&GnztPB83t2qQ@JBa%{>G{*J~e7{ zOfYHv`Q=xjTYGi5l&`(KFrVpjiJz8I6@RW2kEu&E+6V8|{52-~w@?Yl zoWgIA^KibPb_3?3XPX+fMXdB6Ztr<=W1U2jo_jX;Nc%ecd4q0A3CLxbpw#D4V}}b) zN{?6ZT&_rR7UM~hW&M|d7Q9%%G?_WL@=G#4IA%)56W~(R(zrB+i2svyui;QqHu2=$ z5XYCM9juEAIaH%o<<-c7-Y*AsS}niPL_k?9jy*+dOt`Wn+Uw00siQ_~qsUSt|74xR z0{94w>o!3UIM`UdwT%m{sdWu`3ka*kv{coIW@f>UV@+k7yn(|@j7`RM!MVkDUR!E} zGRxFVf?ohZEZ}7??E>QG&Xr`ZV?Js5+;*A!=U0?{613<1Bq-v7${_+;y2(oNY1SJZ zZ@=mZx>bZNsEG!xsjX+)ti&a&C({yhE z%~gPw(NX?G5g*o7=39JXt@{3gNHdKTiKuHnqq=KS82cFkBUpLkhaB5OE1k_T0oL zy4cXB%veQnFlMeBJR<0|Ooa1C0TZz<*V0UxFqJlK_h z-=AiRcpdRvI9C`&v0z~knw%0RXWZ2DRf{=>qy!E2^b_qDCW1q@1$b>Y1~wQXVLYQZ zaiy5wD@dKF{BU(bNKvm%-jd%7_R`5k4a|%EAn->#HT>h)aL zS8h08w`P9VYR?}M$~cC)S4VOsg1+*WsV1j=-0Qs6;hD?j+r7kukY?<|k`3zNTwjQ) zu_4arHtDJ2A#@0ArXd9$lgr`NB_UJQSnSi$>?3t*l=Sof{(yODQWs_$qw~|VbLpPJ zyMz`#pMCTnUBIiO4HS%$C33Yo{!i5Sj^)Pe|AK@AuW-zRPeV9Ky{+bK75@_wz7pA; zvU)dfglnt&qTwyA%N!EBhCw0lZ;(A&s`vu%PAUzasu5}~V zLPLc9JOe5w{MOe9&0}|&eFfN)f`N+qEM7eI4E)NV3L;O`lgY8-7%f?T?9#3IPoJr0 zA?bCVyx5Q$tKL4Yz+pnakq?qKW7 zLh0m}Q{QW?GwgL1-|Qb^GC@dxzY7#7D%q4%x$?SK%I(A-+P<>j2fxuAF)}WMMolTa z8pRkdOFB)cxV1~*EvS8G=s+cQPDNB%*w`s6U+1EVIu~LucUd%$MSR5ssmZM^BmKZX z(~aIneHmG8=}@ukQ2?(VVU^yWYY+oeTDVoDd^jtnkH4=UnpVyVRC$x-^dkZCRG^v$ z{2);EudoPd07g9@UatkoL8@x^7z+u_^(`5eVCMujORZ4Q84;GIEsH&L5ZsRB4rHoH zJ>z%#wvZKLxq;UQd_SBg;ATWEMg^mwR|(G1P?mawX$;S}J+ENWPTj-LH;welH3a!p zUPUR>^@q-zHDbvp)1{id&t>{>CAm9VG0AFGE1)0JL`4O4uKt-><3|<7k8q8AeqdO3 z+tj(ibva3?RTqt?!k*+C_i$CE?E;6%bmw+V=+t?lXLvdJ$4MQs37cV9I<@~a%yGpv z^oci{86U9g5Jy!MdrUv0$blwu{o}$M{H-G6Gb4BR$Ks5@pcc}kX_Ybb7RE4wx z^_j_WV~H0X)e0j5Uyd^phmsl-d(6r|(_1Dfhx!!^Kw{?A}07TVFQQA}V6b1tn_}4g1eU^y>RP zjkz6G0{SSjR)spIdf@O~VrxChk0El!$oFu+Uh8n?u8TtaZM*&#=PsBxVK`7{Ok4K{ z%p|T6_Fre*cJ&F{k8QU5-=1)oKncKQ2O;3mI?dl`9EQbA^kCgFS69?1;`@o{EV@58 zU0pI=7qPcKz1yP41hga2dm z!eMXZ@6-_Zs2>NZk79Cleg}Z75mkOa=Y2ncx6S+x4kNYADBCgAb0`34`&|-nBLk3k z<9OrqP1G=G9|`qat=ru7YL{I#R{#T`IFyT}=HL)G$E;#1z5X5a-XquJd3KOF%ZIQx z&@L}cMT>xJPx+1JG*UjzkFbeZ*iRGkFRhDuLIw3Zao5g5^g&!6$W%T{XOOQu5Gsaf8`VDUx@!T zCJPI%i_Ygf38q2!_g{E??`HD}T4eTz`=39=2cD)gLC2^Z&mnDUaT-OunF~v|mSv>v&F(?B%*xbrWct?x{NjOl--P??tJL zBO~0bM_y>l6te5RaLa73Mnt5ZOUE^WO&9hbnmsBmk`|($NwCrv&6t^oMgvI_4mn-r z7C%T`|5ibLq4DD<*N%6IwijuucJ&~5_sKWHnzI)BsvfUeJ|Lav*xm_e3sM_=?^HV0 znoqbZzP!pV!Vr{yebTBTTo0RN5b=lG3{me7x0wsXd>lH0VvJXIR97EBq3x58pVZz7 z%Wesciw9ox(v)R11#ID#OOm=VxNf;oQe0#a@@$u3Y{{Q3KF&*^@XyTJR~FjWtK&WW zRrG+fJL_VV5$D^TYKsb)&M7#s6D0yWVIQE>;zVE!2Xb!$3d`3AA!sIryeoXY5h@BB zhZ_+u5fnW|Lxe_B)bl2v8QG5ELWVj-yog#MQ+K3SKMM7LHZr(*=490}X_~>Ih=T@96Q|Kir4R{pIQ=Pc?Z1`%ufw zl=1khWYy-%cNv#+f=IlJ;yEQim)*S1lQ*#LLIJvQoZ(GNYDdz9Bu@nl1s;XBVF6_6 zOs1(cDgUOA>E)ZE53ZWt_`#p%r%7v)7!)(QjeJwjM^J2)UCslaUIaPhY12p8>J$K* zm~&^7c!G=TxM0O5R}cU{h4{W~nNB~m`m#$X{`R8#DY+Mpd)!A~++k6+8VNtlZQ&Ze z6JdVF<7o_*k5*{jf+xPdP`BdQL!7#i!2%F*rsiPvP|4LFK{6M2Xl}=@SzI|&8bxUg z|DeYRHy}B?shEM2cjlVkB>B*s)7q7O7dP7OXWlx@qryitm_ECr^*Ds0nIA4MGNZv& z9SexlVJ_<4OKfiB@Dny`bq{lHwTC6%hupa56Gi|XY~=jYbv~Gu-cTcFf4Te+M)IBa z5au7_mrmk86s%+qZtmMN3>;`3^$n278zv3kAZr9#p|{%Y8usXBJLBgg0kkEt&I`_4rKOV%t0Bq*L=QR}VZfdah{v3Dx+mo}CJ*#Yee<-PFdU+9x3wwt>6 zUV8}5k4I&uQalM_MuXd4?x5p0F0BYqS}P5Y=s0;}t)sswv%0Oe>l&+i;?qCt9J4^P zG?&Yby=a^ldEYyfT4-BBajQIT!E_Zjst}TP$AB{P^2&bVqvzY07>{O&GodER41I%k z-+*?UF`Q*FgU{=t2?B#t<%(FG%%QNgOEShS_?D9P)+d)SFqbJJ`wie6r z1$jAXeXpSp3W|?&SXhM^zug))be5$4cu5r3Wx!4u$8TOz6T;3|^KQgOAQ+%H36!s! zTC%wBy`kgS*VD>TObm=9V}5VJt1t9k!yk|U<+S5Ao6D(8rN&D!S$g#OY!gqONJGDl z;`@k$3GnRc%;s2epG^ejq5BcoS)~{}9c=)WvqLa6=3U}kvOdrPmV>6Ov~nan z0QUHOlxch8T0lMMYyH5tZoE`r7N>{8*pQ3V$5)s-Yp!OyuE_p7wF0 zn4>t$kiP*t3Wy)0D7hUXOS&Mp9D9;tM)D`N6lxS4 zWV(o&OIL-1cBA07g!^`AK`v4Qkrp4SA9;@q!QMn!IJ1M-xkpLBb(raM_GI zfzPMwP5sV`^wQ3bgig#?z4zGpfmF(^q5(iWR>} zJwp13Cy(ZgSk@l{u`k^ZOOV*t8bUPbH(+q+mS|-h_08g`gTi~&9b-;EUEjTYB=FiV zKXDY~Npc4&*hq-Hs{qDnKjb8{1H7$l1vs>9z#nIJ=q9NGaHT;Mcrhj(I#$6K<(s#f z!t?vPY{^U2|0gjc)4dQTZald1VbiJPd2R&v?$L?wIkXAa`1eP8qqfM!#?3}knKoQ$ z?rt^`cRPU8jExW=J~BU23AfFkw4XXLvPC{$KVF!2!7@a(*;DocjddI&q+$kf)K7p^ z_|@!kT_ai!`NgO!zy2bS6^XcAlW>`VEqoz=11UlhC#<)bu@jRfsWrL22_w3yI0N#H z`!?U>!=;Ub2n~cxCB*fl@g6JC3`y za){&ZdhlFl%!N-9x^cGADyqa&+QaU;d@DQpt7nn{2!rg#SAa7~>=HQo*O>SUVc(3h z4Y#sUU`J;9h&3uSbIMdMBEaQS) zPVd$WmEzGghFk?&f*G$~$YOH6)>|8cJp>^EP9I(yF03=W9)WQ5$$^X>O0D0$EP}OEgDxPa~!DzWm<}xUi~2TGHe=LiWzsfY@ES+ zq2E!&c{gAbgiqbVgn*A)64Gb9N9yDhy+42^G&pbT&y#;by&9QVya`%)6lsz;*Q<4r zk&2)1>xNnVrq6$|tb$H;k$;e$xS<186>*`>kL$&}1S?8@Fi#Z(?Xqbka@0_F^roC! z=rZcrmWP2c^tXBgeUFA5HRJ-g9uya|feWo*#WN5yL33Jg3Ttb&j$oa=h|J#eH7Pd}dzWy;GgG`(*YrNB0XQeoy3^ zEpPxzCb3nYZE62{OP=q0zd@<7Y3IqH6(Rh$E<%{kq?_!Ttd0)yICTt^EAALYV?u z9v;T{v4+sE3W`_FgXB~p8_qu{u;?3_@?rU9FMw=1}uMgEL64vhwR5$=6h_3^0 zg{P3w1F|d+P}L z4Hws2LuPWnur2gwF=4LD82gElP70*>f2bs^Xx&98%!;OZ30PguJ9e=y>=8|z>pS8Q z@vpKmHE4!{V2NK*f{g=kwLCrzE{Jd49>Ilf9kw`HpkgZ*)?f z9o!c|(5a7p3NQmBqUWokqL<226%%cKWmf@OJgX-D$_qw)aJmk$>}xGLvi_`%)%%~m zC3E82ZwG(eBm^q*bjMx&Oj$CI&fplSH^qsI3$S#rddip=^<>ya)=(@qy74kQN2n4sU_~o!98NcKi2^$PgME>DHqi4N&pCZ< zJl^^Ht6+;B5Y~rnZU;lN9ob0NCVQh65&k5-D?~df0Y)0%Jagu;TM$XG)m9bL!F=va z?rZeVYhyf;ZOy;YG-fHz*Oq0h<3kcz2fjJ1WH~Y=Ph)|QzmIQo(y-T)*rFX~XCuFJ zS0O~l)djJ>z`VCsXm*;!H?7CI)Hnu_N;X!0>btR*c>IzRls~;@+bYw(0;d;%5+$+} z9%N7N*_2hHLG8OZMnm6iqwRaB|*-xI<;e96%bf6%uLW}{pgmMcDo zS>-Bw1Fx?7dGSB0_TeWM`z?I3{H)z31xuaI*5DRX6L^Bi?Aq zKVTp!Vx0phTG+*kc69mrmy@~v>SWRkK(+oig3X^K7$Hf;SxaVT0f}TgBaNytXB$|A zM#BSTYk)h$c+CfGPBc~;#m{ze~aoURP|2-FnKz0bAd z#Mm_?O<&;LzP%a`@OA`f*G)2;dI4g6bB7sqYLMEogDl(oy~G0k1LGPaQw`9U^su(T zYZQw|BAkID3oEk0Pf8|6>ySURUfsbxadjUpMvw*G!~|D#V-+B~Sb9*nLe*Q(PV~UY zdQMnHISKeWApgL@=6~Se#y_HXIX7YGNU_a>4$(+Ej5U`IP3SJMtImn?ZxpCTIyh(= z%BWkS@b?rb0QTp`ud|>k+9}KgXc$F6p?Yj5eMjx(=VJ&2e_G{w?}SxsJ@AC3zmIMx zD+EN!)F#T$y?;Ndi^$iN)jK)nCMx=F^&;eXP+t@=CNyB9w-ppb6&rx-dKEnLIAy*# zczf{c&bzMTV#>E-(}cD}RIJ`(;blZR;CCu~EAy0@J+Htk^#031IYLAJgb{7hnRm&4plaev}!xHE!AQ$@3Y1NWM5F%8=W_`U;ibMZAb4Z-w6?Mq*$I0**z@ z@8TGTW)bm`B1{sY(3Y5^?wJflaK8*0pLKTi;);N>1e*PK$PF25i{Q9JWejtgNv{iA(`$XkfcOU^iUrKwR{k%{y70MUE-9%_#u|7L~cgH|`O zE~mhOBU*gpOfx>gC!pA;s0ieT!i7)&H_E2}t^dcb@AbGS^4n0XM2}4O zZ2KzCWJP`0G3iblO-GFQ5!sMiK;oZzf$027#Wa8N*;sK~ZuD@*5vI#L_tHGSHAUeP z0CoW)0&a{0aoOz}DHOWeS-IQ#2Qh^_d^)-DSwzVid5h$X7kB1?UH`VcYIiC3w2r_Q zoYC-Fvt@RcN_f0#YeW%rMN#-t+~zV$X*J zk1SrEvrkjGF@a@b-NIHw1&mZ0hjyTrP82`Myx>CS_HvS=1u))@3Qx0dKWV}71ttlMP?F`FHGKo9od_}8Ykn0@KYul4`^ zJ^x?*d~d{gW}w`7@;cuYXVJ>wTw_=m<{X0yw0HiYd)l5{G3V~xkRIbM$@g~pQ^JZ} z0q;PYd&2@xsk-7C4MS(jk~ego89k~Bi{5x*OGlx)&jK>nswMVQQp0{{ND;%uXB+P) zC$Hrw492E0#vS=o(0ea&0Z2}W5q4?{VU3SSfOe&RdGf(6Bjeh*@jH;`g4a%b%2w6X zdk?us$ZQ##E1o_u01AwYjRuUjFW5OPsXHp|efFZc_$g|e2l9$6=>v>I{>y)hKjzZQ zP<9n7Y;OeD4p(Z!;9{J;&D76f>&fTlE{`OR^F&2Gi8A{4(vAiV@qxMW@YPvhekD~6Hv*BNk0a^u4!&@0?AAdUV!WH-3hYS?TF3lvL>lC5* z))@?VJLTIH*%2^{=zAt(-|G?{rwPRpcUEr@vzo-wIU;0I-Gi+$!# zbt*1g+~-VF$o^#7=3sYXb|wz%%lJ{%e`e6#(Oj>u{AY#0{WWppn+8&%p>zwX+AECb zP&cZ5fb1X{w|w&>UdNGeVkCrYVal)0KCI z9I?laTZ3Gn7}*ALJsMg+{e;CT;2IBPTE1(SV@C-<@tXeQKc~yf%l}*am;YCP@)W<{ z{ybG<-q5R8{Et7vhl%9&%G9+&E8M}QMJJ)srwOylBdeynTKBV6l}iOQ{tFkWq$m+OD8gp+gK|~6Rc7YtZp(9x z5}*<#^A8a_m{37L*W;B=Q|i;?#meRG%@SWYdNyFYLrr*nRD(^X=$u7K3O(2oP0Uc%rE3K+!QAu-k!?0=w0;Os)sZig`4*Ko{!Fa zkE9#&qlI;7pcEnCq2jeb#HR$Hdv6Ot1=L*Fv<>z*lj(Pk?hV}*_sPm!%89XZmZpH{ z2=)Y3Ei6~mOJlqn?%>wcg4q5?kvHStp>$0Y-cMCuVks8ZNf>i4} z&ptB7X|+YaJn5+K)ynf54M3K@m1!cbxbdl&kUiaAd$h7pWt!O2Sw3FdHRVm`oS7=~K9#@_aK81NIMunbbfeOQW%CeG!4Y*oJ= zQ60iSCG<+Plqz-PU6Wsgg8Ufms2mNU`Xf%K?hj3$d9PujPKSWmCR>cYvlU_Exnbuf z&F`@nPFz3xnCiYL_WhbrKnTw~=3Kq;w0VoFE5*hN527D0ToQid6LzBz+|wYs7e>!2 z-J(LCL4O|o;p%GPEI(XmG@)WY(A2}--uj~EzFPB|_~`Se)zzP?QkRB{odo6Wp4c*3 zSza;uD1_bRSW%EQF?nqK!`*(Q3dCFfSvEwbl)vO*oQqFHss6>be?LdS&}|?FQsXpZ z)XPZ)KIj*c{ZRC7vR`v-KeJV7{+f|F*OS; z4kIs%FZF5+6u;~~c0(b#KWtiU6lDHjB4e(>_SV44mgz>9oE;_mJ#7fK}my6AE1v)CGdWJ3YYc)8m z@x)dmxIINu=F6~!Y5b({8dHNuEioPq$W)OG=!jf6vlKjOU^Y*|s7U;aa*kP7CCgKFKk|ax%YWY&re@Q(=1(jLAtpoCH6K@~K_O>>%e4D>f!@|9>@0VpEp}Kn- z$>$sdWv3{Mr?bx}S#>Y&2fX^cJ8?f9)GQU2AzTxq>#?Ea+MKYz)w86Gw{z|m{#Rxi z3V|A)7FBQ)XURxg$@Ybm=eu7namTI|P&s;)y2NUfxOb3%^byk*g2t%Mn6qvu&$Mi+ zv)U3`n@uuM!2{$>tkoC_Op)!U(Auv)H(I~{)}z-)7#Bueip801MkV+p2E>fj*{>G- zKZXsV{76-VwAQIJ#ESN+_dna*j}Ezpnya!UC0&0PB4l+!8QqKFq@IGMwL%oCN4Aue zO0sHWq?hMET>et>TwdEM%y4NlM-_q27bm9efK-Bql zeJU@UsiuEBOuq573iH{rCk|jN{h1% zuXXDg1$f5u8RHndI#iyF1O0R_&ufhcjZp3qKe8KncuFpR11f8JIl><+yD*YRJ! z++u8w5&ys2s_L)l;X}iUkCOSNePpZAN7Cr!hv=VGQQOR%5eAqvh zA0SNi?gjM@;_5KF3WSTfd&)e$~s$+Zje)3`+YqcerqhE{UhDp9QnWI&&=NX6ka~6L%cj%vWSd(dQ6NG&}3{g*v1;s5Vy4aD_ zEl+fGdgI9eD2Oi}5U#I0T(L|Bn_f`=8^8X4#;42e?FMVlQe4@^ay`dJyFAuDh(&EO zWpa^`Kr2%xG(Hyg5&YU{`u}+w4lwOBiS!|zBCBV!_$Ps z?{UK<=oK-w`ZTS^(U=Ww76e}RyQmIlbNH=LVO_`HH^kIoPvB_@7ofGh zS3^xfy({qDlSM)l9<}Gc)O<(Y*VP!0_~(jm{d?`z*h#fl!i^&C-t4)t18W%(4j0de%+FdzW>NX=y_j&xh^+HExeDM(v zoK(bn-T+f7ME9}wegw04(+F%N5!%o_@O-v@g`w4Mg4oN*=ko)&8D7+d=Xqgb<`${m5pt9GWc?;>&5=g6-d zKq7X_m7v~sIFa$Ywch43@6IZ$7b)nV7FUQ3=S)GGHWs2w$gT>lzHq?Brn1SqG-(a| zk)|+l&Wt~jX&iZqT=(2aNEUe9F}sv#b8rimrapmhY;dQiR4=e_Im4+r(x-p#@F?D4 z{kd+7#CG%TGZ%3cWk&==Nshpq5s`c5w90*2;>B+fYXr;w#ZJk-#c% z4|~qxILe#JPk3BT;51K9A#4Nh3V2)muL4vl;VCozbIE^+BNUM5GFt0tH((J%Tet*D z^;WdD{ydUow3h~nO|OrUkWtTAL{#*_`*`cudWm)ttbT73-5ZiHBe7afX_E!qeJ&}W z6XuK;JxgxSX|9MR`X=Ap8fd*MD;#C9XhY`pq$I_Q73$n1)%(nF)VWe=_7!g!(r_y6 zwXm?+@2lb**6t`xQ(y_Bu>hw-Z&pSVR-L_8tk5xHbyY;b&-9l%-&Jm;Y5NIIRXxP>^3ljLla|9??jGbSIok7rR z-CR>rnKMW3L=)bdB~BkW28C;V8BOQdu5+r4N8Zff2lT~!;qfMb9f+%}s!f>sV?2*< z`qM@J@dQ=Jlf9eA!B-Pv4B<5mp4-;TbH(dhN3f&>onf{|HnKYCLQa{Tr^@YyQv=o$ z-1lHgwxM0EPmlB%%ub)wYVW|wMdRXH6*qK|C;y5e!AK)eNyAMh6XVRen$CwRrQX*sg4%DF?WU{l^d9 z^!>M!mNDJrPEe0?MZt5eQ0qs00)_Iquo!DpKkfh#{QwaW7ky>avJ^~z=354jB@lia z-UCTr_%lYfGNfWi@PQ4q1~O=m`322%&{7rV7*Q>3CB3t4dy@xYL0yTi(_h$(T+Fuc8WsjQx`dY zs{72xYpfr6kG^j7<*zXTr)Vu33<6VD`t?^<{r5EliAGbMOKCj)YoAm$pAgz62y`P3 zVomgVndqn;u>F;x>h)ak0YI5Qe$<_1Kyt8=axY}H{Y9W{T4Fp`5t#<#p@F$LuP+;ILkTksG^FG zi|{bONsug$mHUrjsN(7TPma8U@d#G(4P?CeDG^@6PQ$6Y`o<6odX%=99j0T7!S4(5fW}N1RC}c(4u!I9evO$MAk5y*=d**OV8pq*jAbKAa7Z z{n!Tj6F2s~LjPyS|IFh(`rKNY`2P0blR<3lU6pkVAD~`L9iUxsZs3B|ze_fv)J2R{ z#%eNFG}_Iq^uLl>*mAj}LqU{4W`D2!G|GpC;;cMVCXbga@}a3<-o|B3Ud!wJ6O5^>Qn5Dd&PatY7j#3VKA+Rd zltjg7tonPja~cj(J?3Y)AZ8z13g#}aMMhaq1-1^iVRF`636%Huzf0EwuI!q6PYiH> zd7v1C(woD8V;?)R=zDmbAw-cWPKbBy zmcD5q(Tq}>Wgh2Njq(m^m~hF8!z9`K$N{;=@bX{K_{Z6kiVU?dD{v-cX9Yv;i$4m6 za0$mQC6Z9&F`W%wExEC0XKPN!1E0wcH?kR%$BklsD`eGlEe0LThc! z7#V1)uoj?gw%a-r6P~gXR+^RXhFXzY)cqTir6Nx)BEr`yckqu8I1vfC~cOIOXe0Wk}p9()Uc;4fflcPyaSS6D(&*(on6G0|Um2hQM z(O5J*DSPBREh6NQod>0#tt3c>^K|-sKQa}l$&+$)RahJ7vmN1RHgds9r3}(d`gVh7 zL^`e;%a>Z6ST0J2J)OCd^>Wn?YNF5iSV1krJI~Jq!X-6EhAZ-*beKztyU|3gi%A%H z@elByBSSXRVL1&k^V`NIJFx4=vp9m7xL)3 zQusm~+m~}oPiIMyK=X<5EK9z|@(jr3efz~<`d9)TZ->Hb`kdZMEDiey4}D~4Q6o$-fU=P zrYS`;T?D#+ck--IkBW_blZ``3X+gM%zGW(dr<0*hhL1i38aHW!lLTvy<*lyPUSmqoT{4k-|0V5@j;^ zC84^>73N_gNHJY+-wyEdM1i|vwt`u?(ICmMbW>U>^SGpBRtoeC2sNrsJ;=2hYd4ZBXMU`5j2!yXPh%u&O zL)2Ks;`~~ysfr;B6Ny9Wp+5%N2*UZTxyJ1^Ry&ioi@8{dsw0rZyEe`W(=aaSBq-ppXC`XJUyW!K<@1R8r@(c^P1_2ni8-roGo=QZa(9<0i^-=f z&BLYPTi|LOw&wG^+Oynk}hir(NUuHYvi2CPfgs#3((Xd@0LMZ$ zc5Oh=E#%9hQfYk-xM$rkC+CS{P$cU-d31YOm{NSeL{$xJ{#i+(n8}H3Y%FFeL&=bN z43(sOg>*D<=>B(v*LImgl>0p6R=j2o96)*6*=jbY3aBcG)>|>7v@I*Y$r2MnjH<9q z)K>A9L2GLCCjU<~^5V|ijL$Uew_J-&KJpC5H>8G_#0Cq6n#W<+gB{*KBJ8cpMqo`4 zq@y?{}$}1cpoOnwgS-0EnJ$!0VV@3ThHCr_K;AMWVAKRKi{o0M;1!H4{ z3!twpQ_CD$5yWS+{`G>P%^Rv9R(SeMuE;%RM5V%QdWmrbXilzt?tl|FgfqVOje>;o z|t?J%`Ba z-U&onX;0Jw_~9~Y@cId`>Ko;0on96o@cAF$DNqSE_qzzsXZy4FFMhu<+V&Q~RmrK? zCQQO=t+65Udt5;`IUhx=f{E(i*4bRp<*+?{o$lYv4mcb|2l>V} zZ*6@o=*`IK_2=go>6ckE0QPmDrsgBE^aS$q;rnHZc-#*#hC-U|c?3idWhXVr>Jm){ zuLdw_3r#qVunS9y|F!*+fJ0UTNCv{Mrcn-IuXp8MGwLEZ=6JX9GERUo>|O!_iP_`p z#G7_Ncfk!YLws22ke8??F^d}Y0_3y-{`-NyNeW9^(h(Q_eH^=BVXP@0kNqX~tZUigBwsNmW`T)spq83dD)?ZbF zn*0uyjw&QQjC7v;i)L!F($GW%fvq*`AVc3l)wuTW>zM&dng!7wjseBg;XHRSeGk=a zGo#u9mx9^@a%joFu7`4td&S)X7DP5==$@R22)UzWaZT;$%uHRz;-qd6AVwwKF+-9J z6{!kq7IctqhCBV2wXd+Z@QyaoI3EfxekvgD>DEACDiR9z#jaDiX*WoQncL+1Wbhc^J40nn?G8QA|(9ai?qE zrejQN6`*?-N5u+~&vj?OxHe#4(N||H2(Sz^ByR$T>m7>}Y$;-dWFmU0<>C)dL>hw> z;>&3j+}J?*I(4M;4BadKcyO-rid9Zm@E7_cO>&n=JEx1T%1x%Bz=O`^4|Xw{iYphY zVt+CZCbp*XIKSZngkwGQEubbVZ9z_wqqPonumRWMIf{lyF}a`ZjB++8t1D!L5RJ`3 zaDnAhghXU{f!RZ1>FsEn(04M>)`F?yX^A_f##_o0-E@+gm4(mVIiG_k~6u@rEIfG+7&&dPm>zGD{iR!R>y! z-oiSBE&=+)Qv+$+pkYTOm4B4iY~GLT%7nOjEC)2bRVc&vwI~#7O1AkdhRAYCbh@$E zvnV7tt<<9pq)nwv9x>-IyB08(2uYY|XOhp9b}~lnTWTd_3RljDSMO_u{VAKXsi}tB zwM1lM>jvT^-hf94iDWmPdp2(aDkI2RJf|Ny65iOlty)aCKuM{lS8dU&zac8=%3H2L zfmlyIA)g@zbL8(_!{z6G0CrMvBr~eFIovG96?KRMg^<~0Qx71YwchL~uJhWJ!khXa z>x;j=@?kss&8=>V1!|#{N&TP&@*MobOE>YnQ3CiLWZGvtgn=SNK*yd>Mwf5 z!ExG4(5d9uRBtFIi`4tA0mwm19fcyVk6xsxcj3ecj>%yEnJ~RDPNIiCPtg!FWL3~p zBD6tBIqVbpakhKFHE9UvIczPRG1(@vER42A3!UzB@T8Jtd-}@aM5c2MsF5jCqnS!9 zqa9gV=HP>y=#gM3R)(^&={`bJ<})u7Ch(wtN909Wu1dBpIA)5)X?fpJ#ovMir*`kB zt$U9)$Ul2$P$nOQ(#nw+XSi#t!utI{F-3_upBjVl=PeeCfH*SLeqvqTfCOznivu0@ zlOElZ%rNQXfvqEDrq;Wvc;~D*haY8!^8rGiRFIz<(H}e-X^c}%9C5k2J30~jClL(S z#cfp+6`ZYKzN55;UFa`69cpT=QT_gzKocwaHdJ;cXsU3l(;RtGe)iHGs-1#asvi}Umd zsYxZAH5-V}JPnwiEaLq%2O;-au0CggwDw*@;vUwGD2OZWv9PL(ySJuIZ8Tv?4|ygY z3u-wXc6nq@bi$C!c#&I=01lt=BETL?+NdxXdfu4**(}R$GNp%y`fy;dkqR=Y(n0NS z9e0N0hMi+2F7(5ZD8^dZb1kHbi%V)R>Wrcx4DSmC3t)3*B|Rd@?8DxI>CU~8Rde5m z8_Qe_?p|iuM;yKY)J_2zb#U}Hb{kEv-2qGDt2k$oV42L8L!0TS600(PU`JrHsYC8U` z`C$Ba=mcyXy@+;QTq?OxKNmyBY|Onu?AH4%trL4s84hZ{=)W^$bnTSU@}w7fMKNA4 zo&znjOJB(F&RnPv9SjIQd(ob_^&V$Nq6cX1k`WV4|C-pmJsd~kx%{BhP~V5xozgv` zVFYUZ`L%OLK3^&sE><@EO}~EQ$qt2LFsfpZapbY-V;E5YuZJLHjs*mA^D<8;OMqtm z!MV*W8tv!#Y_)pqq&H>l2JBtsuGuq|k(U=#mkn|ZS&g721E-P@u=As+rb=(50D(2> ze$aTE=z_1$z0I@K^-XjR{wO|=g37nnU0wa>;Om;axdSrRm*_RIP2<+Y1oOdI

    2PwTL1`MB>|Y`XsJ5$r*c&^1$UPS|5s0 zfwvGYtrQlB-_WMU2!wj~r612ZATuiICn0^^RWL6$;M2ao2$RkT^t0y?MK1g7r1n?@ zpN^T+E}_CcJ$9NY`gueC<-eJ`O$YI&NXdc|Lf|CgcVs&TDG4YjJR|+<9SoxV3TwNW zY+iC_o^T2%7=9FM_vsC`mAJUP@i;N025e;3`L@@iqF9~wgsp~8xJ=OVu#LThurit` zLmR5>R9bL;zA}9Yh}Y!UN|e>e5_KiKpM&j-%1b?0L^bV6PYS7$B!_m>J>;3(l(0Nqe!nGnQXMcLfOqFC9O967|cb44^sTdNRy9X@v7~E?U zb><3xR?NyXIdBI%8lF`)1Yamb_T&J=3uF8lG+)#}8A-zX0xJ1pb2cS!%Nstmcb$`G?K`Ra_zFqq7E4JeyiVSmT4hR3>hw|xL?GA$iH z0z!wbV@dWxI)jMh^bid+mpw<1xPT`1wl!y1WM>AwJ!{@|*YC)X5FS6?{Yh!5k1Ql) z7w-XQA4FXTW_x*W2AF%Li5oxb**SN{_Bh2Q`H-M-8gCi6md*?qp+iczBzvt$3nyy& zNVy-jovG5%Jw)5%VM&W|GKbAk&#*}j)Z3$v#s!kycbe(IlnT|e#ex_5h55OCSPYpY(x%*2xGPC$Ek ze?+aXyri2<-0lN!8h<5%H|=ud6R}ZF59!N&9~v_aKX}cxn5J`S$)@iej1Yl68dL;@ zSg;%RRw?Owao5n;28i|HEiCz)9;z(mX2ez&6Ds8I7nv#ZtjQLmsYAH>>j|xeKp|wV zfieQadCuwYr1=}6w(13ty=fiU(+uA0$-k78l_YUpx|DkYADbszUCPhQ6+_*o5q8k! z7n(ds!d`$H%W92yPg{7Cl$;-|fXw}W`DjItlo99^)a6E8FcbmtjV_Y_KXpozaYheT z1Hz1E=MDx`%}!-!bo(cdpXhhY@PP`2uyF#db)JltLkhNP8=5o{1edA&zbP73Jc(pck^7-6kV7oy-e8ieq5n~fq5_iSk0UJz14fb#K z4;waa-n8tcxB-hYQ>ktd#uHhdlx|*X7{GZo)!|0DulC-LcCY^tq_T#n7gnmGggG-GwoCf=Tz{7@& zi}x{PDXt1GRrcT!3Sn{#rl74gVnb7+z)Qw75H5i?SI2jA2nM>*&BRY1=%EK}fr<$9wL|F+n?FGgsAg>h0w zcigk*xOHHA^g2DgwE6bj0l5hp?a9PQR0j2+VSTJjE8K7bUW`!LzL1>AzF14GSBmO! zEW$(XBKYV6G#BbMc+qBRYM!Mkyd#1TWApARj|U=BG&7%d41c(*zf$ERE!PF=3HX!l zm3MKFl@}tlAtr%x#;KCD>q4jFE~Te8p@vtx)6eR4F0iR#(QP{op?NEh5yD zXfe);a?=VT`IP8%b#^VIBTf{=>nCFZQBUlj$10GEEPds$eQGvYO09$zNrTyyC!Fhd zF0wD*P6cW09>Bb^r@xm{AwTVdC0xn~voI_o#6Jr023gfSr@us!^=*sYY?GGEq$|di z&J@C8av%ZoIBeE7U@t5=xh6;piE=bkI$#V>pg@vCLea9l!H@Olkfd?_9YEG(P`^J0 zg5{qQ5=1{h@KYD&&9|3)->MUJY=_KxRExIq9iG#abHhXd;1f4I)siqoL*l@5b*X(8e^nm$iY@ z6q23qBOY#@kYu7NrQnG)?co#juHW$biUqlsl{S`LBh;d7MhJa|9giCK2SV9)%C}B9?>FS%lWfw5Kv90yVFivn8+@ zz~2WVnwa8k3^|JCqU7Ppi!%!5tg`1Phz2`k{r;sZw^WVU8lkXdLs0=DgfFbMUy1}F z7qg(7(f*X#vOVfIFXc#ViO3g{#l{RnGgYNB_DTLWzHXc?=N-}kr0JAw(_4QF04DQ7L1Fub*3Y@zzH z<{J#f+J4Yp48VnHIwM{d3spXiSd~6{qKJA;<8~4%{nVV{U7m;1jdN|ucynSkJDW)14&yIHO}+{#+o_j^ zqo+Lxj6!}wvd~7(M1Tvhh>&DN#>~GFep9~FQ@)TKdCg{uVGxUMuIuqT;FZ@v_CFDF zGZ4ItB6Xy@{#=I84BASXsNy!kbBjWu#O_@`Zt=ouBZq;h_*PS*?h#NN(u;G`4nf}tKO%|v0rXp+aX63x zL0{NLm$p5fP@4SJpUw9WegC&PuTMKd4wdwz3Z zuJ;;Jr-tkOgK+}_Kb_?6D733Sc#SnUK$~+H4kyqzze?uXE9`U zSVRt#^=Z+*x$?!zyqkx~<70kVV=6tRf?!@8w&;9sTjja?-zkU%Z?t}Z8v{c4H=DJc zhV*u5^4D5O-$S$k(g`o=O%h#ePKw@*b;9Zk=cfDp^AUbqPH|}2w?2hM*yEQxhR16h z9}%F{7G`AZv{zpf1^YRyRU~sj^F(V$Hge~F^E3M;M{-d69GoEj6-_kvCAEytr@T+T z>!zviY2Ws4ADh?+u~F&L`!(5x8$o}&GL77vLIsA1u+Dx%M562-z`d&xE_lQvw03C! z)yct0fm#4g#mw?Z6@a8xE83ZhJ(Gi;Z1LRsf1`dhbbv(7i=a&(O&mgr;j_GvuV zjSn@}+n=@X@!)Wrk$@c2X4m^OxV(Isq4q{vbqaZYuj- zw{MDBC_g_JnbNclzwc_56f#S8wmnHn42&JMS`{_~1cbPvh577EW-*#GaXcJpHMNXD z^_Zg1bx~N%eoqvP!B_KQjteeeo|0l!V4xyA6!zfNZ2n~b7D!2PvgWA7c~GM!=C~Lx z+jl%~+fR~}p(oU`*X^5$2t?~kp?s(c+Jsc8E)$^2i&+7!ST^^TKbG$cX*wu7UI{#& zFuXN~DIYjCDfaRLu?tLl;o|H5hzlQi79E-*NVqC!Xm!WT` z+d|<>Nu}+BGy3M}l6%}dVkk2GCPGb`K;m33(hZk9QGLu!7w-UMhiD_YWT++^cO$w!m(B2vB%*P@|*>qVfFpAelqFeag@ado`3b0)@(k5O`Z80;>f zuYECq`QD7pFiJT{jU^GQIw==hGQgEd6JNTV)C89y3m`}t2hKzn%`_T(6tYQrR&Ok$ zXyvzo*Otx9HU*eTJpJ0H#PJxsqP~2PJFnS7BN>f3en@Vdscy1Z+*ypzx@*^zo>$Ot zmS?Tc`<$;ZxAY9UeG^I14dN11cJ%E?ZBZj++NDLz94v0}NCf|`UpU_T8Hi;~GJtn0n(MpW5Q!5nX59WFZ!MxbAtVm5?j#`;UBRNMWz*|bs z@}v)F7z;f}-pdc{k2*L`Q@j&Fi|V9puS1zLxhdSggR=l8gks)74L*Nxz1QKt)d7ty zQR9#hE_T=cfWi=$v-b#zke6S`-d%;m0i3j*A$CbV_^v&7wg{GeiZ7qnP(u!y+jYo! zVEb0-*8}6C2S+VW&Tbv6)1vrQQu@s6^>8{ITZf;2x`^BFuvpq7+NsbyNqv$+drv~U zVN(%mT+>UJdSw3ygxt^ogkPpL?mybV6a_?@%X6UeVP{thjPXOG-b*xR2n%$(Xd+%t zA3Y~qKDlxhix>UM^&u-(81|Y5j;9~7)<(k*TD|};9bfJw@i`8gSnXac50^SZVHVV) zeM>l6=Z(?I8e{5M*h)Ah8EzG@!uPc@J(e${+2?E z2|2PuMAG4(3Ku7RhdAK!2szfImZD=F{9ljd!3zZFUCh4;Tq2cA2-kk%lGoLk)#Q*I>vZb@*pJwuCl_C$~7f^vzg2rws0kK&dz z`TG_>tm@c}cQg0?slays%tqK8Uv7Kluu!9mY5Ja$>5@1Ck1sL^T+`)#PS`Ob?^2A_ z%UTDEw{EthN0R%(-;`i=h@rRrBHi`4S9f1I|Ld-MSkIs*Se_=?U(g>d%|DF9KcMHW z#`;*!GE#LNw}%FU?_E#z!qj*yH~U}UmE}Dm9OfUQ_OH&?Y$wvk@6;sCUZi0C$514B zP9#q*JHTHLBPD46@Bi#uwOn*p<7fc$X@c)O)D)QnZkmB(M6Ldn-&~Nq_`d&lob>mb z4k|QLv`a#vpKmou>035Y+gqRWZkx;ULOnurmm}rjJors3zN;VW`>7@$|4&9$o*aeb zwJ#vvqVi<{eK|D5cR8C;;$coC)ahrT;)qJhuo&hIhYAC?PaqeSfGoMMR{4)1azd?; zryNm7LNo=*GwgjNR|hf`yilJ|U3YL52Ud{CODoQB1P_`wS*!qgqL8sM6ks0Zyi6Wm z=OKQ|ogugTs5wBw^Y65mfo<7;ZvX$=bD9d2D zcR0J?c8^!i>jD|Ri0mJdAasKG32FTd9uTX~+w}BQWpo1MVWX=b8Mw;zD?s2V=k@iq zmIR-78aD8YLWqng?I>=~l`AxHuPNUq%>#qJd+m#8HARXx3nWHg?RIaY7pqp6B3tfW z_RBFZ;YBZ8xZ7OJJv1e1U<_)u- zCskuSf6`uzDkupTI2+$DFWvi!qT?n^OeYUWzbvxZbCF85o{Zs9P;!i`_HI9DO z=?5sNHfLw}3-08ff}KRjxxAOmTNdFuf|6ku&lu{ z^V8+plOCFF`_o{$H^J_DF@{q{`f#PWIDUAc?q}e27w-Tr78aqTxn~0(L?|{l`&<`X zx%rE0zlRq;+%!&Ybaonl=Ef#_Rp@Ay`TS|MmSZgACxUE5S=VK5WY*sxF?*rPm+Bbt zj60^%>SF6)%qrVendLEE`0tvk{?l7RYHg3;Irtuv%nj_zzbIW+a!J&x4y}dJi-UE_ zXvB*W(h+H+J>WcaKzvQ?cb$?E6XXsqZmtw66{{iLd*vIQEbucC{&F>1-#w6!K6tZ` zP&!5fs_c51gd6X(J@rJe?h0#I5oPs8H)j{zZ*fj}ygn+w8f+$!9$GX*QbzwK9}!7N z(8F5E9vLNcv|9}mq|#w()n z>e<&%+LMKTz~619ycyF@UI^Rz?pmztHV!*5c%gPbb)UXr3FT<5Qv3rbt7FFhg(r*Q zq8PW+Cxx^(K*Kr%x{kV$W*oLgJp0@6UB8KBrgT zcVnUOc61u+b7GUhsBA=V5q%usA$9XHEJ@hfC&Ax_D9KS>GM~aVAsv5O;2M5RaIq!X zJ!uJlo?Rp^EJh_D(1@6&$kE+Uiw+8E=g`|pIpK8LA;{U>wxQI5X>-)f($>S@<{|xc zo@6=n{)ElQTVGTHB%*9-=jN=t?d>8yk5{(f`!>7K{k6?xQFlbqdA6&tX`1yP+)v%J zyykZ+X-S8+pY!=uX_P8$DTACnigQFEBBcz2TS8*(4;?iL`&QK+$B0d+|AUEzF9wWY z6x55vsbUYfXT?kueKcM?l5+AIZ&>$46_nB8&QddtKu#qho|xJ>E(a`+XJ5b8pcG{h zw^#jzbfx2}D}$0X18if|-R06(?f17?4oK7`vUp!4qfu059Oh7|=KXlu!p46^u)3iVkN9-IR=!J3f%}bJg92H|KX!!cTCuds3)AK z-4x{g!<1%4r_{r1knCAi5B46}Nfi^aD-cPsrfX!)))scRfple&Uhe?%;16hrFGHM? z?*R30j)W9<4cse(BqJkD<{#unNnihEd&#dtPK^Fxd)+mF?5Oep6S?{!2r)7idewZn zXbt01>&N+G!P%m5gXt!NfLo%nvmFs?Wn~=KF)4kuxHY_xHK7+t8u($Agx55uyb6?< zv{@SaCjk2`TQZyL%z?E1uWDa25;HfF+J_yG6wKvuwf5tWHnqFSh20FJ?+Z?S;wG9g zpUCl$*obJDYP|Kxej)dxzFhuVuEPkze3Aop^MOE9nP6)NestDhnvDa>W>@R8ja8- zWbzB|WVUbCnd!Nw#YKmn(GPMP_n41W#W!G!0xM#xJm8MZ zMa=U!6OQ;Psgaqxd3;Kb6Z(_`6@Y11B)eu@@Aw+({uFWZyur)U+)U!c1vai zk2R@_nV)Mm9FKQ(zVfS(`cHQev~3%4I$?XaSE5w;(0)~+oDA_Avo)OlWoY*+?Iqvf zl_S6iT2*zD13olH+Kw;YAXx&KoFjemdlPE$it~&(2d~$4(fysP=bTe#BN`UUu}oVN z)=FyM1hC#|1q2OTa;iT?A&ehO!Z(kwK5_pp8C+^eud0WCr-gGH8Gjyr9S}CmBKKrB zWzY_1&NyKkx0-l;&{fdJe2I+cE!umWK~=Y71YJVssawoVE!GZB<7m`6(7!Ac5HyB@ zwT%oVwk>5YPmEIkf!||W(%AHC>;|ltwcsi{5k++j3$-Aj#(4>8KA3zfhsfOMblon;rb- zL^Ja6kE9auMHRUd(2h!SoZUyIN87zL+EeNI*x4J57#`%+?Y-b;`(q>rk_>0mez)y?@I@LI1C}=wS4@j~-8tt-k+1_G(f6l{w z*o}?t$|a$bOjeh4#;ijfMh`bU`+`$z$&k+Hoq!M^4Jt>+6Q_43e)|hz7r1;rH!D7( zmC@U5g(1o{8+^4eDm8#ca|L3K5~6(5ae8c0NO+{cRB~JFuW?u7rT&6RVO^arlCZ;3 zkYW8fj~K>+T6Zu|DWq%0HSYn^X6#UTE?oq8SIdT0X9qp{VvOZKck`u|4~bzW$;;~i z;WErg`dH*0*2gY5r5l`=xBC3dpXNBq*?fyYXL%$8Q*~18$sAjk&MDc?{wlcQaTTq# zA%LGK5){M1;I@~jv?{SCH#j<$vsXh@^O>r2SdoknoeIX8{3`X!S59Sx;3z7zgtler zd`C?g&`fyT81ZDo5D({2PPG{MEv7uw4umgIoxCdgc8=AY_OLmd$XviwKA}@SK#$JV zQ%MQ9KgjxIh?8=~njgT~R$MamdFv+$U=K`EZCU;LnK8Wli1rg?m9^^UYIA9;_`7A0m9hb42lF98T{VXY zAa$!Y3Xvi=E`Zm4r8qjiJF!|a)nuMA8UAv0Fx*5BLUJr~8NVT4x`rM#r@lpX1WU2w zz(i=vx2xfM5ACrdB02enO6~_1-fv?WY`n~c&(;_)`~peCX&EhvgFZu(v*iYwH}z*}M925dheS(icH z&|2DpHUgrrf#xY)#Nd?{@+R+$RzjUHG!h-Bi7}htYmgd|_vpCU*!w!qFo{(fsxo)I z)#s6D3PbKdY5u|q@3qlqj`$JoP*x5M1u@%rH4{GSB`Z=oZim<~qDhvfwms)VRn4{h z1jV1Cu~gQAIe2}pjT7o1+Lh$|0{-?g9nmXt#GG}B2az^oBW>X4JosQcBntjy5$Rs9 z94khDJATrk|BMY0TZ<9%mi!RKhG7IU2}WfbMr=-{6AE^byQp37ViDFP^?IC zhvM$;MS{CK#ogVDO9(E--6`%`io3hJdvN>m_MGqDbN|c8$k=0N&6SdIP39wjv$K9orXKz$}KX9O7=^*E25lcj$RkhD+ zxyA-HY^jOyl$E^vCfiQpF~Sw4i}bYV<7_vh&kpVZ>+vL6OmgPpF33sCI)jS*H^rP9 zESNJT^|e0|zEu*GiuL3VMV(OYmFHT|2z{k$Nuxy)FnqBa`vg^EVKCsZ4Y&# zD*!?Lo$DUF_I6n*k;N)IuKIt?a*rJ!2)|mi>WMv1E7HXhUy`2e?@(5w+V?~?UUHa~(Dxfnc#=LgJBym-X zTtz2No0#AyQgrPxeQj=810C>|R+2C|m2*15@@PLX)TEqN^dfl*wtMM}9<3Xg1owmO zbMz>*wN!Da3T6_V(J)E@S*j0UIwDt9Y1H^cC?cxHVSF4mxw@i`Ix8Bnl>DO&56{AT z0ISgKo0PC!9*d1mwjU?YkDnLxXanhw0lTEv-&L;YmQgJk(I+e}xG)hnbgFN&U4&pC zN2SLni2vQ0WwJf;rs@ZI7S8ssk1E1_LTjnD6L>MgdF^5XEp|op^(ZNd4u+04ZV$13 z3Z)pH3tEYFe^UqtpWZ8_^*)LIaZ-w;<1PuGk&(S-fvi71d_n`)%>r+=kP5^S6)UQL zWdAcCuyqq4ut4tqM@tcV+OxKW$+O(HG#1!t%yiES%%Vps5+UWR^9=b7NKP9~_vbDv?9=5vta2U&{VBay;f5;f5oDFN z9|IUkQ8-nv$_Y&b$(Lm|R44uIg{@u>eA%8K$~{83nXq|*s!3r=`y^9l$9mFIiWtQT z?nPo^Jivq-NEj}5-1^r!TbvUX-w_$|^0SY^S|R$9pw#E);r~Zq5_2$!#iwdF1=okk zD`wF7V}+?r&JJt0a*Ww<-~3XkfBScZ7WYr;j@+)M(;+0yRu3A^Y{)$58@!SxmnEe< z#d6+V4(>y%G^M*^lJ{2+N#a==eHdiN`vNf;8l_4VI4dn{2gf;O0;!?4h~9k7`cwM) zXwVeJqKAUvSc~hTix$-L6XE1ISa3UX`*5<5I)a(ret zs}}*|V)7Hx4aL^!6LZEwctJB=^Xn|`IA(fIi^j6I$Oy1KtaTm1;v#fMx`KtlYK?r9 zKM8JSIf!}Zgf?~cLLE6~ljKmPn0uJJcS}Dok=}x7;@b~1r^9*1pRR5y=${evFfzUcJQEgYLFB6_QY=DnQ3XjDmn zaQ@04iiPNAUa<=OA98UBsut@Apr9Z{(O1Nk1BP#Q_8%MG%^&j8kn$Rldd%4vyTF1c zr5GN?p8u4UWqn^c{^dbiSTwmNzE}n&d5t9YZ3z4+VeU@3=e>?eaf}jSCDb<*H^rb+ zeAp@Ti}DCw8nC>2_9XyH0-K>n>lYcGJACrFbC$+I5J9ANm=v1=$y6gJ%-927DzQ}% zOMwC*2Ght_+gvU-sEZ&Pqv!Qm_BDRLQ^!>D* zQXU@R&b8|)t4@jVJsT%NoJV-}abQ-_y%u5kvfMpR1AX@C<X)mS6oa)qLgS_ihb(w&PkwKd?6$NQ+ zvtF!+18b{4KWu;Op@PqH4SJ`Z7vZw($R6tW_#+~rs0hoHk3-mh^*?dt8rH?+>q5bO z=rDQq5bV34V)r@5aarRmAax^pFt4Z6Yi>$^7qi#6Hh z9^Twqj4pe~_jXM`M|GSR$dge97q{T8 zNT_FZe;o9z(Lxm4zB?|iR?;JSP)QzXsxRGB&uYn6m5F&puGhWCCvSQD^9oc^IuQgs z@m2Qh%*V6g+IW{^^J4=3;N*;GwCtEdfbHp+zLtrSpR<_g0_8LCq8iQhKG4Io-DO?h z$GpWJ#S{ngAqMh^Sg`?!kZP+AQ$@Tnbwy}Yl2<`!ZbHJz6#lrS+a=pm#962wbI{7t8)WpcZv>*e9Xt=7cG<-|}<2Rtnu3!DKP+tSq#2TxwRJV)&>PpEE) z%gsp;7xFONjxcxB4zAuw6D^qoh{t^;CBihQ_?$KPQ}LIm8vE8#$EdSqr6``yhBefMJi zBnQ$KS3SI{37^JF`pCi#gJe`!MFVrUVxomSbwvq{SGCN(lD_-$!`Ts9zzfz>qa6k9 zc|q42hzzq_F{G?1Tl|1SD`|um;dXLiU_6n9&Y9*L{YdM%$BtXQi!XWF30;W-CRL9u zh3Z|%V9!`Y1>iM)DKRexw^-~v0WfuHW+bqtqrAZ=XhNkC3#y~TtXGMb^%r_@546Z~ z(ZPF#beQFJXzeJH^Xm&g5&;I+q)y+TE-o$PRVGZ#N4bqpU3;(MLe4a!V@5~55Jv!X zTuhbZmv<;xZ4VA6g(it6j*SXy{V4N1MWWQ4Gp!%hNlp>YiFdq4d?wl9Y9@bt)+Hj^3@Wb752?s z%4}89T4oI2xMrC9rJ9ieZfbC$7so79Exwx>PoOM!(!!P|dU{&)#4H?(OePvd`Z7{m z)VfoJbL>05?S`ahFcntDO(RKp+~iAw;)H(nQ_!u322+epK2=PtEVq3>rv=OCctgkVo=ey*0{;%#H?Ag);Xf<2` zErK^qX)5KYIK;XiBXv$#DqH~=jtod$SbA4`hpBLUF6a}^)94uv@Ha)jx&<;3_D(us zn=}|)3%Q1q8$)HC39*@|ATxiz$Cz*gyl=%68$K#)k1HCn+Zl8Q%cP7dq+A?7pM%)3 zV|KtQgo*kbigmw*6f+?soHH%(2#0px$KnN!#ASMop8w1>N94hs&SS`jvNMpL3x10) zIj$rE#Jc&UQ%k#ZH4nnW-(TS9Ta%q{3!@329|w@)nun$Xx!WjK2QtGeLeI%J!L!6Q z*MggGhF^|PnEsj8?Y){&$W`&m6(9R(CeGKMG2JBerpf>DY{PYU`vy`lk*H6p_L%bP zU78hf@McoF*}b$t4-Adg*3|{`H43Hd%M8SO-C8AHGV0*Xvm#X*w9|v0hQ{A=MSG`n zaheWz5MX>_F4DPWjsiJ9x)YN}B!lSqS=AAn+giTK!#Dd=iAc}Hpy>ooJTvv*JdrVX z81R%7fLC)m>T!T~1KmaH%*)<1;GU>S$^sIC2JD){`!nV)c({nECdVb&CH&%%W_(+} z&zc&qSTmiKv>@GQ4t%l&^6PCl8#Sb|L5K!)+S1Ya){0l{UiVBxc-D`slf-rmBK96vnK+nl;0pEMNa2QDG8J znLr`FFZt8}hF79tHu7PXrnWPDt)4H@?8Pj6)y_Fd$!B3Z{bE;Cg`o~&ahq^Myhi^7 zktTe=kJ-G87rcy9@6l~(-n9;nRR@rG*W-?G6%WCa&eQiqn{$?|Rc30!#+e*F9a@fW z7LTu8o#2|+XH7)?~oMB&BgOTx6V7ds)i=oxGn}xfa8zk z20dm@_UB{<{s%fP&*Rm;d8)wF23HAdqw>9{Z;PaEvx~zirFNp z1C?8F`+-_vJ0Amjtj@dHs7RMduQL>OsJMWjen7=^YJ4Kszg57F#rZk-50YQEz*M>U zmoigzE>~1dUKfHpex~pr7hMv|v4hjCIX!0-+4=9=2PHyAyiZB!XSurheT99%YN2tM zhQO7cX87f=1-WGP*w|b5qe043Z*4Y3r-et?dOtUyllzHFcl)5G%F+yl2Q-*M|c#80wm8AOT?!LN#YCann80g^d#}tIukG@ev4a%gXz?DzxpaG+a zJ7MNfF{tXRK|}hZ9kTIhul?aZfC&ZkugKv`iyNncF=^;|`jr54&W5SKQB6#6i`*Yo zI9z?z$Z)iafN!(=dc8%s3XJ-l3h-6Do1z7y5CyW6#N83ikFAEpi#BeXfzeUh0Gr?! zdFlv0ID7$$J%sT^kkI$ZVLs}4UtC5B!T!t@cT~@dFa7?p#P?jjF~svuV!iACC>Nu$ z75d6b9H123HOR!~OM5-E`o+@>uFqr(KAt(GJ^!SP$xy+t{MOO=nB4iQp4RyoDfk&F z?_Qb@PvRo^SlC*{F7^?D?0`CY-j#_y?Hs_dML`mB2NZDJzKu}u@JU@9gEfH6dyn8tKf=CR`dv-emYQ2)1P%h zK#c>{Rvby@k@NCG28=t~0zNBCz!Ze*eG7P+QtAvsVoHcc&bu~BUx8s{#?{KCPsV~i zmZ&r3z>^YfQoki9#!uDkY6KsQB?jgxa-q5&N%)x1Q@8q`SJz}9ACDaUsL8k^F8GYX zMi(+#NncCf#S`aZl9L;C&5;clnn;_A0kiSTE(UglhR-MR) z+}_rfrh28O7VNOs=cSoEdDjywaIKOZQ6te-k*3;yO=X(@)^jNPDk%&#=9)G$oRs(} zeHzgcBj<`Xezm!lIwBfz)_%ul)@QzBwl?`Zm62&O6sw?=YlsYYEXDh{pa@1q`J%?o z%QViATwzrSPhSqNg_FZ`cUh*AUK>Lu?Gj#fL0g^?k_1N=%;@G`xmFCeM*FF%AdZbV zn8xuGkv&Hl1Gl4*i>;=*H{8C3-53Hsr7 zT`(FlVh*b`52i&Mb%RYkm!%aMU;Kf!e4R2%XQ1f`deft^mqc!kkpO1_eql=c#>i0V zm>7w&MP$xkTlFX2-zEc({VHG68)r)K1STA5lTkhr;{la#3r2$ELR-VPQr3S*3 z0gi$TLhm%jk|tVule*cWzjTvStB(*%Uun+#TO3W5rcv=qs!)!W0sZDU5uB>&pAy~B zP4Zuhv#0A9^hw^BTWT$oDnkEI%~Dvme0J51TgIE#MIFGVvo6c;;w3fH@23NfvOscp zoPw#Tt+@iatfC^_E0eonQUPEzW@&v)%=AmZS*aVmgwln|h)hv6mBPEiVN*|BDsgtL zNjJ-566Emd9vx8_@(a+B#G~|V>WPhtTSXtp&FPX;FZZqyb@Ok)+8o8)#_d@{$UGZf zvKm)8oC|8$;jF0_U*`)7nPvW(36_lO*(`ruSmv)0v zo15*dCBJ4GS=cFlu8bo5;JN+p+FvZnq?Z=2MmAm*VtcXUC272eB;Jz#L_>@pQwi%6 zevAOUHiP8r9EXZHL+LXkv+vB8&r=QTcCelgl+IxFO zO=G{?*`yq7R$+-Xs_Q@EM)U_fXaFx$eJ{tnMCxj0ChJrgFY>RRFAr*gle}EwVc(i& zQPsxBCa*-f2D5DXS1FoCqg+&e7rJrzSQedvX0R|`p`yqZLd}eK)5NxL z!`0{JJlb738l~FG?~Z9J1ZgEe^R|jFn2`exeKY^;U@C|jc=aU+;JLz!z%TjQXf|Tf zNJLAV)OgGoQ`3dz)U`lKAWy)y$iRe%FuqYJHK5Oc)@QcY|E!l7bNfBuMiV!H2V$08 zCp|7XEwf}x=0fSr;?dBN7>@W0siSL6Z40o)Tm0S>HADy8_Hx6QBlqyhK$gq+nk_y; z+XVO|+`moyr&KV+*Uk;3Z{MB4Hfp$xq)$mJDS#BM0mtV*c!;*AcKbM_5&>m;%w|J^ zy1pL72kuNg^;_9_nO$5NXm&;iQR^179$(x{i*>hxmql$wenQ+R?+|@?eHZm+iqe2$kcK)o`H= zNI;%DG_Y4n2s{~mo)@3l_MYZ6I zZg{`1p!j&CblK-+htbm;q(dEoZ=*y57Um?1~L4Ly@yE(f!*zK&jK%z zH|%_G8;EzS-0`ORan{$u=i}7-jUqeK1S+aGlw_tjy^hi0_OzhtkiNgc`xE#^&G^D= zcn&!UX0m9;{ODBc)g^j7vrBTzos?$0{(z?sQb?OwFQh@5C0FrKoRHH34Gt|0^2nSI zWoEb+PH?#}zrrP!1hLzL;qX{Q(n9ZZv>*3Er#SXaop&>0U3{3;6d@=2OV*uNm%`_Z zVF+u1X<^3Yb|!>{12I1!ZJd=YkJgEjV=88|l&Akv+1U_r?#ts;40wXuoqWtDuj^wT zB}mF&3wTFzhWje$Sz=P)^!~$--{N``y<-;@R+{*U(pY$^+cRHf#Io1nScy&uQfy)y z9XTB)9l5ry`Pl%D3k&?J65k*yIGi$J;#AEN#Ts8)R?rgTA%C3o_$q1;wbW88DdS$u z&b;crn14`Yqu+NErS9rR(bE3KRnyGOU`jWKg#%31oEHCRWNU=eqUJmbkmkK-<8V-q z*V*K6HLQ(paWz#MU5*(PB^lPTltV7sW1@t`e^vXGhpf)hadBBLR7dSvAxA)ns}8bB zfDDRvybP1R-k)6b{UVlHuq^bGdg9eim~DiNC?magra_W1#O>(GYO6*X4Sot!NUjv? zk^!Tk7}u`I%)my(9W}ukzoOJ*P%F4^V)EwmJ>t|rE78YJF@Ayz764z2>FPiPlIQV@ z%GnaIQu1qwI$fcU-~Xb;j@fY%@-$0-;~+V^jUqpL-3 zF&>kfrtaiq!;=Drn&ZG8h|hi_x*{xa4$&`~pr4+89Wzigt&!V{o;z$KjA5ui&r{dc zmG-5LFs>U7J%0C5lOEe1CS}_*D#*Pt5~_*kQyytS>GiTW+}0Gj()N#%cJ~_+>A#IA zmJ{HY4EBDq;GU7n>dJTg04eO0o=hoNj{g$5?o@aGNFmfn{Wk1`cNu`qLz5tJGbEWh zkzf_(qhMXtxeaI3zi1r^!3J>)#<$Z8qS1Sq#eF)vs@I<$p9t_T6L^!>z%upDX1=n) zbahJtHafww5~Gxqq|CD_srRe1{_#6Kh4!C7<7>M2BBOJHgl}P;40N3a0FM5{ z?12o40y+!j?5UJf%pHD64tkW5n#oPN_mcdU3Rr%we*_L2rAPiOTXwJCsR?lfka z(g9hMfnv`3r&Q{soYqp#pl(9Y?Tiq*7D0Y3AzG?d_JiE4=zE)bD-QJ;dGQOO25$2A z_FBn|Fn?)(BKbFg0!BGW&uD9YJuSf>f|pLL{4;~q^r`XJp7TYq7Yk@%VyAMkkFgO= zvFBUFaExih;|=0l8B1F@cb9heWT6di0rXq+@)=U`(-i8T6x(fh66uPwhx008xTL*y z!(8oBoWMk<0)-!Je3X6}t*@)ynqp9#p!5$M-%2_Es>g`e5;=P(@Twvp*lkx?$zL#P|r*-6iG zhZPGUjKRFwVhRDj~z4r;>+v(9~EYf(?L=?qmdhh_O^ zTUd*Tjk7!5pbLs4mvP@0OO)IMt%zEt;FWZBL;FOSdky!XVhh4Slm4Nyb@E{A`ev36 zk_uC+2V_A?-*q&F>hp<)W(9fb4eo!&h=6 zEpt1aHC$u>Gls-?^#I!Mmiqss&)z5`W=7?bl>vq>_43Dv`ACRsPYjUR6|ItP(cS^XzQ*u5aOaV z=&?}mJ+MG;gs6(UAvYXfb13#{A&-SXabI$;9rCNRdjDK%#qhxg|GqewUU)xEC|p_f zbbM3v_>|v~jcMdo`FlAmqPf|JBH9um9{@Y!U1csF{f9WJFPrRj3&$B_hwrvOPls}k z^zL0K5J=kP%n-$DK=b`#4Os};8VOqq!XM@)D>P&9ZNZ`0#9Y-sIv*p`U~azk-&xN?BzAdGc#B{4o7>;Bt{LxW5iYtgQpUHwr`+ciD&0lq?B+YEOLqPAHR zMgit1$Lb>EP1_hTTEpbZ??|PciObtOAty3X)*9bqIfO8AZ>Sl3ZPB8;zD?sJ>_jAm z`K^hDdtv##DefH4v}^nM3Z9SJszGi1@Wohf(e3aN^x;DBG?BS#bV8Z{yYAy(ER(wW z5!E}iv&dEJ@p^dzS}l$A90xwqM6=nl0>8WL+4xgna|?6j{B^dUx3_%kVUPr zanZ)JV$p6SvtEkw#2@k0Ht82O{{%n{@{*@T%oqAh!R4(H(|%JgCqS&pS<+TI24kt+SG3177TA5C~4OTGgTnPviSeCbKE8wbs` z|Csyc>Ps9}+~aTK-|_ zk}-BkcgKCii|*~uWJBFHrRcC6Mrh!L&97jE_n#mDHh5|(V(l%UwR&r|Y%=l3wUAky zI?-#j;{a#mM)rLIhpiYY8PY+ZA{3GrSWCw7Zp0nrKsN@xTGv<^{u=aWVpM`-b^sJC z4GR*VYQ-i};o^ERq|ltfO%X^`$VIDKAC{RSv<&@;gnDhZD1eJ#mvs?;-5zv5qVtwx zy4I1TdAWc-xEjRl_85=2*X41=I{H|^I=gJG$?0vJ7WQ(0hf08ykwrjoJMd?PscPgp z@7H8m5u9XWsNqONlBTmVsMS`xn=A#{V15q9$jixL)}MscfZ~(1`(dzGqe6}EqnDVj zR%jtC+UB((Hgo}>L%ZDpRJnF0s;+uOL6^Bvg$4D&FluilYG4|6D8Cu3*#uAa)NR?3Ih20a020A9I{;%tUplvUWjXp1SxkB&n`3_pa zQx-TOrp3U7g=iyLJsonrm8e@PRvnrC#S=&ZL9qEioqiQpSi3@`ppTlL(saXcqg_8> zKuh&3Mk;^08Y8j$gI5m!w~u7vSnGFtSf+PQ-0j?)98QbPvwvDf*B|^&?v*-!6lNCk zuIjY><1Y}`Enq>P%p_&-W~9vto2{xY>TQc_cA%t~_WD4UN&wJl5Rr2wZw$5Vj!3e0 zfDG2!YJ2WZ$2iTGa5{Jm=XAb(wl^nYGI`b{S&qr7R2<;%+b|r7eWdw{+^_P@&ZXas z!ro7%#u_7dKV&a_i3Q(z+#C;e>!rPA(dUdnUZ6qvJXEZO_@IM5+5^{B%ZJw%=a>)m z{1@Jjx6jHaGeRqjiaDBX$R+mJKmkK*M~_?Hj9E&aH`!eFZft>7`?;}#We7rEOwh0clH(r+d z{rUzi&iYRfPZyDx$>VAn-e`EjHsk(W*dsrFVE2;eE3=Or28Mosg$9`f*Ol)lmgedL zViECEQApFuhnE?r^8E=*HUC&6f2tvvpa~lc!HVHKj;vm3p$9og*!KL`@WuCq#+j$(_}$l<6jwQ4^+QoVMo^AoDBaC*7L)EOqcC7u!hN%4;bYN zZ#~w)S!;maZNknmPw!r|=*;=z_?^?t7C7ig)(ue_ee*V^!8(r$Xt(%>mt7J+m_jA_ zC_Gl1GY9sB*}Shq*YZ%4bpH<;_%m*RZ_Rwk!_hZrb8A@C4+B$Oj-t?gd#^9C3es{i z@Yz^$fF5=jzWvu!vx4OPZT``rU8_yeBJqW{>mvN89^KW+sv36@O(f@9 znwd}X@QItCqDG%aep_Df3nv!XCa4?VKJ|=XQjFmDsn$wthv+Y;G~Y*DtHr*pNfb!m zaXD&aR&X)2J6C91vK?aB3xC8WkP@%uUNc#3Y9PYHR$+=N5&*$SZ@Op~G zXZ&jvp9S7O0OR*VqQluXSix*>dFc_sGt4W!Os|~hg|3~zBRADDG5BzwkqpJ0Z{rt( z6FAQ)4nB!ckXi7`?J&K*WENC-~H6V2}hj)gr!dq_I-BC6xlCNd^HYf zRYwU{ZxWrpf7fcN43^m{; zm-YqO2BALfp!SxJZ0#`VkhzQI@rU2&<4Lq<)XEyj5@~+^8-=a_&D(EJ+Zm0Y!7Kr? zFp4k-z@sC(#>`iU`&1kNxZ(dAeRA@Tde;B^7P zfmLU$ijn{RBNTD6&Xb_OE( z%ZE*M@%%#CwjPZD*0TA+_}(p8`A>tOSrlWn{}mJZYVNq z;A(^qUK7i|6XVPooN4QmkB{(aXo^v@c|=2Jk?{s?6P6FbN9^A7>}kyPObw-bQpirP z0?D?es=qCk{g~>M2TxN0UXTvCcl_aKc$ra0((Y~FI^zAb97U(My7MsAwYi>mhN1tU zR>$yDD&RU0vov+cT&KxO`b{k|Az|xnR$Z0f0xMIYE`I+m#^kD=WflVe=R(jUrYcO$ z?U0b+^?*pBB}|v2b17Etr|&58OF$_MLy1}7DXZ7lA8hx-6ZF!&qGV-}zOqLEgVQme z&xZ@n>Nh?{2K7bDJK%d3g-(gqjEvzf1zXu+hMrl*#3CXN#+4T~plmN;QLdWU`mJ0R zeYO?^*+_GTU4s&_uQYsP5;ZDN2O0Vq-p$&g+(t$zqz%20bf36%$jpnu3qH$r zd6t0`QCKk*213;^SM&+)f%iGLGy_-Atq`7vgW%+XX?fuK?gFH{j$lCcRn`7Fn8dvqJk?M6LRXoQaNm=un$Njw@A+KktwK-3M%eWs!~5(?{VEQ1RpwJp9`UZ z7>7-V&~n1(DI8?v7o;Qum1eKMIK`cu)c?gs>^zcEog}zKn89`$drZvN5rz0XaUdPy zi`)WNB3>dFDJ+O6!o+AGYwAEW{xC}V9}LT`idw9XPO$R3eOLa6j-Zm(Hg5NlNaew8 zzR*V;?@UMYIG$x{-VPh`5Y8%j{d0MfeC7CIMj_9K*}_Hx*<4$$8BQA~A)IMqXca2o zAG!Z8qQYn#jApTsq8|!-qlV)|N-^fKE!WmwpOCix{8+U0BgLndSt$F6oGPW#I?BLM zT&r1U{$Fi4WMj6`h260h2(}k8eYYss4P{csji6X`4+Gx@*QsY5^*N@OM>vP>U+OM^whwptXzTG5?+ z8Co(TXe~dNF)@&ElddF|Gv>-6vYTli`B|ox;k4_P#Gzp*DNB<-IWTV{ zT_@s}Ps5zhBt`wzb*%q`+ z?7TbpHQD~kB+y`yA@pHG3(0u`=k?L6+2DWM)8y`0scTr%1%4Oit*QH8@(RPk%#_~u z_eyi%C}j_lB3>}4XTrUr4J3|G8dBY{jwmK?Z#PsFDX?p$-DQ=zy_6C@0FQK|^GG{R zT_ZL9-UiF+BxlQRb3=)LLq_|Rr5mJ^e~pupxC!~5&_yGWYF?h3Kapi6=gBkW$K{Td zwx;m$ER{$?2o^6yf~rkt*zBe&V~Ecl(@8?55*+TeDv>+wzF%KaGsnhBYy2xv=H97` z@`gnfB0GK)K+fJ>LTk%+=)S83q?oRaBuUD0(L{TthKDirk42Ubro!fN`lDLf{LJB2 zo-Oe~+NX4!@~XW}sJ`r80(v8lm49%&2_1aE@ew;@0x~;fKt3Rt-YQ0Ca(p5bGI5jT zYOb_AVQQT%xhP@a74cJEEg&>QG9{p7qqHSSbE9H;GX8Y-(~W*Z9d!V*ua5d@mo)AD z+Lr7xV2ISxu`Q4s+m^Z~W@PBB%Vp2Z4pO*HO1?t43R@Z{b(C%90O2h~Jj_Ye!_EYY znehTgZL9vqG3e=EJ{I>)32*!BU)e1;`g>Q&k6PPhW~FMK_IqRHU(mmx^_M`uB~M0HQES<9&_P$Nm^AO_q2RwQ-*W{c&T{0@o! z28Q@vf3r&8bke62Ry=DpEWq?Zvj@WXDA48Y+6!5r6C7r=i+MlMPjCIbZs&QK9!ZI? zppg0JQD@r&NvAovESUD9RmpQH|1m>;1kI8Rsh_y=QZ~QP|cgbJ?R;kf2mFVi$c3X7!th|XUN&} zBbx$O^o`(~-4Bydd;hhk(@#2w{}W@-Z7g>uU+Q!KnTXVbdw*hUW+?DRi{8;7BJ*BK z>}fGk^T2*GcPi~@!8Vj2-hS)@;0RbD>DTK;s`xh!t-(&dk<~Z1a3M+%3l8)F@>#6L zKG*AcA^10Lh2{Ro6>VYRgn(|Bh%hUdcpzy2uSZ~8U-~>MUajM5!sG^WhZgom_KQmV zK7Ob`@t8kp*tRv`+3d~O@S67jm~$?cd({wh6P?wt^LiJnmZKbOLo9O~V)eUd^yyJT zC7ufh^*MiCZmmjauAF5LnQnL6E9S0y=*|v)S8M(Jw#W&47TIapU93-v?5FbKw%;IF z+$>~T@9lRZ&)Fs9Hh4mM)LR`1|#APyI-ZCZ}?}fBgy<>14ivgQ$CtYTc!iwD|I?>l(nvNbz4l zuu6`Q`!lU}V~p~rPru@-wqIimK8gHOCFSeE*V&RQ_5$+NY@#D*&GWNR-oUqaQ2&c^ zSzOt6jmC6R5&=Vr^&QnNXpz^2Ivbk5IFn5IQ$&XkfP7D?>2$;L{NxljR^s>~ah@SC z%zxoA|B3y7t^sivG=s2b{`b9gBOg;GJYIh8W<*1({9Xfu<^_1+-)(o(-bY85yNk5+ zLQinKp2Dg~RzX&uSWmox1ATIzYxt%=6Nk=*cn{m~iV^8WU=HMMZZ8l8U=o5#mHdrw zYsoxH*xK1+hjwGjE508bMxu3cD2~wyB~E)M|Le#-r|H;(E*zk?Y2((Ay|cfy#_h57 zVf&Zf*3LbV6~;&fJ*2A9TNKiUdUQ)7a@?AJ1e)DCYUo*X2eT5jEB;=pL$g|-g~g^j zI+Hb34>dc?ySzWfY~I2R{!Kf+?=6OYzI8$9?MO+A>IR_Q?6~*Y%1i!>$APQ@JOOc` z7t{{fXCtDsnR4#tlP`a=%eId7FkP)NBsiV^GL-w@WWbpKdaZv+1#+Z=U%$zJ3QAE< z1k1xL^Re$hdB-0esHx@UQY92{u|_Tl#nLVfN^UKMH4ex`z(~0`Sx_ho1N@AuBrV0# zoXJYdh8><&ZW2b*_>aLwJP>!i?CPkyEwAIfLQ=K4I2U;`inPg9xO^t-ws`5}r%cu) zy16GG3cU&bbP>ceV$BE}lYik1nbRg}Ovhj3>o1_$Ts;E~q6V(O=D_D%Fd zk1UV2p7eJMm6hh=4ycXq>cJ)(npWqQwySPKCyEfZ1i_$-^yc?lRw+ z(0P~Stn)wB`sj|V=Y`H@IoI%g6&%(zZomArgQ}BcnD0{z;eM(76La?-ngv?26BPA^*;f#gO>()O3o1j>_;9|q?gC@cG9@(i@&;25!;ez9i7BO9M zB(TPT*g=^Uyi{>~Zm3i>|KPOb+T4g2Vd|~0^Rg5Km%jL^Fu(D;>Pqxa7k#p^4Ee?p z#jrsEG6*UKi*+RH{2UEzbuVNS=?B68+Vw<0W<-^C%V+al9~#e!HQ#=lH2?pW$UFI5 z^n$~Fqxqt}Wt|Vz_qrMLNfJ#FM2M?4AQnod>UQpHtj`#DZVu%(aeK$XKk z2WTeV7{?jN31*O(hZx~3;42)AjU@zx5}jtt68fAZI(N zCQQhMV4s|+e{0DPPrq6!1SVP>51AdG{GwbDVN6uWa@@`MYe1H4tzu1|DWjsQ-FjuM z;)Iq>bG5`sGd4RiteEHd?U~B`E3r3Eso2{ttFs0c#pKq-a6~(wQUXLXygoD8a6}vq z8Qdt$rRr7xFPh5H2Ta*7fz`_|MP+GW$}yB!Sh7$gc{Ns=b#^GRPW!3F9f{0YC*wbB za(|fwFr&GYzxhX1O`yARPUlKhS}wN@RILUZyNe(GBR&-~7dd9$H>i`1OwoAKqTY3= zFE6<*Zz(wSVN@bw5vq>)ZEmPiJQw0qzz8HOj>xKHB)d# zKH=00?e7%it-rz0;Yt12$LAv4<0Hl0CWx4dwE3UM=;>MS)f7IY5%=Zh@cgVdt4>N$ z{V=!_bY1M36)(ERXmLU&(OaYjp@sg}4ENo#Wl`kaJ`Nj6th|g??AX2`mJx4yT^BSL zR$nsP${}6Q*f}!^sQ9CiJuYFAnfr693sF_stFopt`YymUXI6J${MUhDlmdJ6%R$N^ z#x(8*Lzkr_3u!OaZrHm!&=Cwai?UMYoS+vMuBOQ$L+%`)tU ztIUsf{k+rGC*kOIL(NW;A$4vfzcq^qG5V#=F%qOhH$sKx(d|X8S){1I2#)VYqs={?Lt^WRWYbD&$+sl5+YvG9w`h+)~PTHO!~>^3BP`%8!&s_ z9Y^F?eL|!Wmwvc=hXP8}546c^**mqEyGIePeLUwX%9lI)$A{MhI`q~a*gDp~?eYeL zbEjhP@Dut+>x#^!=X;-rzCU!)J)ODdWQqfxiob5ev%^4`@NJ=3cRZ`=Q{Foo!ZoJK5DH$%a?Jzu*7VHr93I;TNUE)o=BZ%IMz4YTME#?MeNCvbnGT zs{jj?;niv$2D{OVFeVL(oU6m5LlsKj&jR<R% zILh?qpQ}(>bB)*jgm+Y9&4?rQgb&dIib% zA_(H*z}*+@;9xI)GRTN30(g^&!b88kLG#XQY5@J9A zN3LHxrlHR5R4kT;dSyQgK(5|WkKUL}&zVTY>lH;ujd**&pfwdK*(nBD;d~WRC%AiX z*8rgjL4ySM;7wz}CAb84cXyZI?(VLy$=>I^bH}(p-=7|%m(4Y6)~xzUR@IELCXKVi z5kVLR1BIk!Zu-nijo8&%#BGkAT?jPJQdTqGWCc{iFd%61!MNOLiFL{;YI&%WJ!Wp9 zQxR5b{+7o)J0stv2{Z|IKKi^v7X6<-_jHhol}8(tgFq7AWyHj=4{BnoS3tmf?{`0L zEM}w+pe)mm@8RE9)4fSt#JEd2cj)|gvXDldCLeu(#k%dI^zZaEZ6rgt*);=+g9@C` zb(^EhcdKf-js7gtnjM!)aVt@OVNbNHCv5 zlI8BD%i5)BP*o7$nV>bTYJwm6zl#p}n5Ns3fK-R%f+u}|2HAGMhx%}(j-YV*q$ly0 zR{2qon~NO>G~XY7TIQC275|N$>9|~9NR3!wl7)mdYG)iKL-}?#f#X7zZ%|@X^qgyZ zs{*>O?}WlPg0=-ww8ZAKr|FaUc%ex9q!4>n;|Ik>>M}h(=xq&-F z=q@@RZDh}@P>$#`eQQ;Vdg+p*tbawW&mktiYmb{~gr=YWX#Q`-OHLjk*(=>1>9|*E z%!9#&+sZr}B8^79HdBQS{cA>YPE3}}4ZemrJgCA7b&7Sb3HbNM7o#qDs9O%Tf86#1TrszKrbTF<_;3elJN zc4(4az!x==qvJ*N?L;pbtHMM5B^McZByV;y=1az{+NYnl0XCy!%kmd|%8yYMP4%o% zODgJltyp^~^V>G(cWd(R&57X}`9apKS;=pG2EQ{4C`VQ1*X1&e{TP1A9?PK87_zyt z1T#OXrx9&h6tEwDnfLe?A5X8}?!LlfkZTn;Vvb-m~!o;#UCEw<6k@ z%A~?$RN6O6lhEMAf_7-&hi}L!9&!Q@*W5#X99tO7++q1g6ma80M1fzE%p2XAiVp&d zm7>b_kK*O%4iQSg4KTKLMw(`c#B5;7?L#;b^}ch@s;j%5%SXWNt_`FtZIJ)&L!JE& zGl_s))C6M|?K8%<%_C|?i{0#*8fn#aX&9eE(>`w1eJ&UC zKXAl`Hax=M*!j|YC__KQOm7)2DG~FF+DUG&%xrAHx{UX3HOx1Rs z-2Pwlx^lVgw$C?#=6@EHh4eu8ko;?w&*}yKTR-?O8~y!(7~`W%|463)94xQJbH@2g z^8feK++Fv#{o8+8@`p@4f87rMx$X60n}7W}|8>kg1X6eRzixxP>ny}65b|G_yq;YK z{*QvQuV=4uHb(x{l>c7L2oI9E4=LyVC9nRqWcYQ~?hJbld;%V~%5L2iS+;8(fiIYt zm}i^)n4K$(4^e|kg@4w^v!nxCb*}5{>O`1#&aD5^YVPcEPpzxF`(vrLft{mcfc$%L z2?_t0j&rb|AI#z5A&R%XtKLXY4_tV7_(Wl7U1eX_MsGw;>+Ikz;D?RuAJ^#V*q;bY z-QsA3eJ1pDv0HE@m2q_1W$Bl=#xLJ$t(VqG51BUC){J&f>zs}VGBY!?)#LQ7t*vdH zoqLCWan~Ou!UP~;i;ZVW=4dgN+7S;6SzB(0ahvO}aF&YCy)(~{ECPA|p?I#2Q{`B{ z1(hfBJ0BCRZ*06?tzPm8pCAk_S1Bz{RokGvwl=7?w$^BM{pw&Q2Qte2NM?n}plm7o zx{+%sqMn{!XOA1^uJZu&TcjqoEWWFQ`}bqp;PtC-)jO^!fxBt>K zz1SILdHO45uALx?>ZIx8S)`Z#)z-uN)!V-BEDrG~XD7{F_^M!6BGT6de?j?QYxw^E zTJX^F+JsQpy_4GIzvO>*t*NOQvjNxD@z8Bunb_C>EG;bsT+dxOK?`JaK>k5kWU14%a>*+XLy{NnbrBFCAV*E?a(;u;ek;Q}1FK@8+H#3p9(7 z%C$q|Sq#53%`xpY$b|Reili4KQ(jP%m1?8a1ky!KDsg{m*zq&egBry`8~)Wn?rQ71 z6ZUfYo{dMeR@<|xbYxqX4my>?^Ol^xyTTRSY_F|tia>IZw?nAWPmOPOl-1qc{mwKY zA_6dz^r2vfZrhon>1?(2m&@eRw`oa-xOVQ~@1*4tAdUh?;yRk_$|&DJceC zE=(c2hH`Z%bwyI%<>lq->S~+5To_pLqcWZHlJGAqRhWAq@F?0>&J5;9sWVo6!zgW+XI&o|N- zY?xLcAm^a#4rhOGzzR6SVrY!$7(dzbW=05;%h>z5moQ(8G*q$Y@_5LC^YPSt6yb8| z)^`sZZWK=eH>K^I>#MmEIoWx8_Xp&%>rfi8S>-eofSZ#7o5i@*<#$fS>xcDPJ+{-* zBbWGnXFLx}hZTo+92WGMA)J?VP9r)$QUKocshD!P==%}c{*o~Cojk~%AG!k94FNPkFuBtziRzvDpvIRQ)V>%04-iy@Fx@tU(* zGo3^%XHBm^9(=wVm!X20knw0}fa9266vdl~!O^*t6Y!*4FDaLB*}F#4xf@UDb3}{-J-(MkLq-SeRjHTlscq)MspM+z~VLyfu3!V4gfdWXCeH z0d_v0!r1VF!u3#nkAWyetnZ_61HF|Ysh!R&Wz82*7_YRkxyMlF;X>E2a3KCn6C~7i zP3#*WRSI>D>c=yiR;GBJL|1Pztn`)^wWatBixF@@>dK()x9(B<<}fmTdU}#8~5d z{3U74Y1<>#;7?SNrx&>{@p#Fn*L%qRw7!!z;J0Gxq|QI|j*Si%T1b$etzq0HZN;i) zyck!`1a!z{C+X616H1;Ouo$?O#M3F1GmiTdcpR_T71IR57~%oO=FaZB4A9sl)+;{z zt(v~)u3$uUo|=;uAid)e&`j8r@Y*`XM-wa((6-=iCl=-d221{BZ3~L)<`9^dhPLi4 zLn7Bx7?7Lq5;E6n14}J~@}nh@AuF=|v_V&{VIy((+76^(JewhTdZV#kH?NCJBm{CurN;CltVbcJ{?JYG}e5--sDaSZpVgS?Sm5gxcaew|vm zLSB+{_XASOfE^}xNG3X+tT8UV5k?H-@6JaupOebm+n%ee&0mD6gFCg8QfE<;3EI(6 zsU$;Ib0)ab!Kz!z^#<-J`nP~MhYF2khL4YkxZx{u$s>x!5*up)FQ+L_9CvYf8l^=P zWZ;$c^ZJ?K01nMZhGc;=qVr<0&mkihDXc{`sF2Rr_*gapbjUBhFb{9U1QA+VJ9`b? zDV z(mvU}AlF7g_941hA1R#%gcCB9oLJfd4_X#gw$EHVJ)pi0>x6^^iz3(wlWvTG`|+ll ziFLVb!lzRnfKwj0kMZmXPolgsjsm+0^Yq^_?dc3MsRq=oei&r&k+bnhQaC!i%arK{ zo}aaL-QcIbhoh+z)RMQ!)o;oM(v&)s@9=3bHo63>(rVR{%meg6-f<4T#S}bilK~rb zxp$Sl-_`rnhN`t_lve90l-p}AJa|wGQGa!b1Zb+^tg}Eidg?0w@)MH!z&732aiN=2 z(63zmS~ua)J#AF9KaD`El>+$=;K?as$xUmYjTSsT4#um{$qVM(MYT3;1{Z3Tt{pEZ zzkl**pFD70#U2P->=r(Iyw~{D_<#fct?fdb9NNC2xiR|<;Bk&DWoAa^u_D;>HXa|3 z&xl*VTY;CvhlWtvcnI8Cchvze?AL*gLE`(P6e0l5(S}HP33J~;i;z&?-y@9Hb@-OK zP^+^lSnd`?oX5%zgov&KtRXEesTINK+|C}Ko$KDkiBU_7Uxyd0{mOJ2ou;J*$g%qi zdi&1w|ArcSli_T8=9Ip^OLx$N$5ReNKZxlMYgm%fy+M_zd-#N|v_%IB=92uCBogZ( z6!xuGhzv&nZ`QfZpL#^Q8OR*?$Mj^7ln_~Nd6*N@EW*SDn#txdhaCK*fMCx zq7Ij8#Cw@G1%C~GjP!k@8OxA~&Tot3x}ML^pBd54!L4*>^z17Zt2_th&o-14Yn-6{ zoqMZqzN+OBJe9p1)A7=ZY>R5VLxbK{^U+eh+A>h{4|b&FzBlsDaasE((Z@T?mVR;g z^lw`4sImAZnJ#jc?2P6B=!yzJ~7mjWqvWYb&(v zc6yH}A%b3uo{A{%O|32zst~%VwpcF8MN1~}jQJ`n5c(OqPG|XLoUh&vjCEJmx- zim9trwb>Gi(^2DO>Topi4jW4p!9Cup14a_v*El{{yW%_VSF{2c%l9yS9ZTh&M{IXi zDBikgs`_9@wq2IXqX{(6_!aTIQ25U8Pi*-S%}p$-@3b|fBqbrRT+R9JPTx4SzFiF? zSvkJ~oBOL)1_zNd?N}8wwWxfL#m( zc~1aP5L6F6dM|$m=kJxSqpr-tN-YjxynRdSrR?Xwg(1c%(nN(azOMAMPnF0(4gv`{ zAb_WPgW8})-ploh*9cI*GFBS8tQM4!@qrt5lHTuH?W<8w-*y>x*GBhU$WKy-b`FVV zyF%7VLrczY%c#b2ilPzwf0T3WjAPK@ChYLVF*(E5}+LjX5o*5n5zubtY4)@DrlQL z&XMfwQf=Mw`!C;cw3TSb^7GMR-oml|RN@;3i+!ns8!lzO0}sY8ZbAV%fM(MJ7`h&E zoYwltR$65jUm8fW`gmymwyM@jWz4_jX!pY_MwqP#xauZRSS-LJAkf*u;%r6F)ki(Hv5 zB{$)q9Ks@E-%<=c2PUUAp~S$G`6&@dYt|QtjUi;{*wbeuXS*bP zL^Uv30;1oV>(9(Va9a!HK1p47C382_=TR^D;XgN}P7^2*g>Ii<^wx;za5i;DXR5$HLjqDa8B^vcZkmCL&J3$H=X>OP`R*CG5{W zTkRy!!)p{Na}Mu~s8jm95VAa~LoDuM4P+b$J_w_+>8=SI(Pl3M6tIi#Dh-Mj$h9!j z^TdfK0^eqU6w~bfxKaf&)rWItVJZ<~7skY=)yfcDLR;G`ukG1)b6Pc^#j22Bv?Bt8 zH??|J?fS)|^OGR^`7Qa4Y5%%0My^5og8SXq4LO3q4ctQY(pEv7c|QLN}| za-?PMn>N>F2l-$1c!Uu`UCt$$@ni!J@2^>H-c9BXcdds>pRsNc|Ajj2a=RcOLe=EZ zsCp}W18U^Ah~bPVMi`5u9x!c7G)NB=90d!sk#_dSB>Rq8L3gCLztGwC<=Esf zX%bhVFiyOFpP1FiKsYAelpfKm$s^oGRezTzc@-Pj75r{J6eY8+%dR=KMd$`oguP(>j1(t{Lrv^Qa{;F ze(LLT7DB+AjX6C1W0O6)J4-_+_s4WqKBbQ?V+tth=)J*S*q|?&Jlz+c_wrek%$FIY z-~9+$NGX44;eO1DnjWM&6>NpJuN9JL^7P~^us~a}XJ9k!)Q6>35Az%~?p`c*!Ly0D z4=d_YKde;L8tJo}lgg;LBvBMEhv){fG&;?f~p%*Kl;iKJDM&0`Zei=3 zc|&s9emKp6ZC6uUZ=Yc5o@JIIqe`{PO()@o2*P(0=HBuE9X`paq{nY1XA zxuHgMt@^VQU?xvQ2EU3=b$JwZm(_bp#~0a__5D zC%$z3i17sB{I~vq@U;p+qXqEna0<~y*Ri9@{Anyh9}t=D@M~zhOzHENuS;+5=?mcLVmh1s5)OM#$H|S7@eJY22O^^ahP0Y)JJ95bN*$zJNEM(^5&U1>L30 zYCFM>_=SkpFHc1>UC~{tkR@{8KXHQ|MQ^ZIJNiN9jE)y{tUNYY^+8> zNN~yHSD7d4)x~Dkwkq=Z59=LSyZF~d0??(|xoBXo2xH5ejaZM$XwgD#-k8YT7_-Gs zLg-IHVcjvjiahsV!G~h8rWf!dl+;0U9Y!YsG6a9NMXmVb#?ndx^ z+Ge^u`b%5TsL>}oA9!N@rK$&!K@yG49VVa`HJ4^fH1TLQbio%Pp0&>4=DObqis(2t z{_m6CLAW4a;H?^`)eLAMQpMlYU2|RLTqNM8cN*AAp)C4a17&N|M>baAtyw&y4+Ww$ zp=w69PFnmTvet9fv@j5!{ucuXi?8MY+wm8@T?7nn$$h2H7QWF8#aX zf?-hk9{;q&TS~(wmt(-kCT;_l!1mwY9cSM!Lw#VtYrpBfaJUwu{tG>g1enZdyXk+xy6E@qY&sAjKvrgy73XCSi6xME_ zHOz$@njmc6r%JA+^l~2H-A< zK~?(^CgErmN^FZ^8r_kGwBs%W*N$y&i|7+vyq18W4(&0-ba_@a<|JZ6LftZbilyjt zL=C(m^4*h5PHc6C3%nsg*?DLO+ve+`H3wC#ZiBf+hVQ`_U&_@qlC?SE`AdY_{4Cwe zY}+xc_u<6Vzp0XLd%UlkDn#YK^EF;``pks3>=ml_pt(WDjT%^{u0QqiL7N6Y%j4As z`YDVE(1qyiH6x6lvJxPZz~K8ogc)%Z2<=A{wTU}-o>Ct$9VJ~0e9q(X-hhPUMf#+`e`!qo$Z%Tn>!JrR==y%N}( zxZ(I$q{|?#qE9E}X5;{Mh_};erNJ$)7(pH6$p51n-e%*h*i+l{=dUPzZ6wEog#n0h zPjUf0`Ew>5Yg~n5mtYqP%9PD{(@tAqCH(9IwhcvjZ8Ga;KLl}SCW!-oM65(KAwEZF z=GbK9_zWZM51(Nq#GQ?d)`?HIcGczU)Zf|bOJ&JMLGL|1+}J%_e>+a<0AWym{`|R3 ze^5s(14xO!eE+6Vaf*sbgakfgs=YK=apxpC?7iqU< z-FjTUYPcYxq@?7rej6uJ23Ac??U;bvyN1QEg^Y~sM`K+0t*Q2sF%{aKYyx*oLxQ~t z3?HF=tsRg>N%Df18)FcK5ZS>XNX~wLU}1xVNj$!sW|aoJtz?BOIaxcgncI5gTZDPM z*cOyjo(-&iXOFgrg%H81r>#o|Ytc3s3!R`t-7pk%s@<*f<~|&+e)w(YfH~!3YyB?o z#ye=Jk!Rd3t}OkryC- zlRt)$1vqJ21-9ibiI2NS2MK74X=4~iJcYD^smynDGAHLb67ob5X*e81pN%4XHT(xI1$j{390sEfUs` zloVp;BPHoOkfibOVSM~K20!!HTA$lnhviC6gm0AvA)uSK!BwcT>4Si%9*(-{DOysD zDA&}~R2`S6u8p~U5qd%aZUpdqzl5+HG3E6z~XH%ntTfz=bs=R-+pc|8EkLl!YX?a5m2LF zRNnf34^*fZ>uNkdznpK$l~6ZQ>*KbzbNFwJq0X{bP|WUPIeR1WDF}qU$wv>*0vHET z@EDn$D4Z(8(x?-;qrA}jV$O{CndDa23DgQbAh8-aP=AW(-17~G4>3F+50CAPs@g_@8aC;@Ji6=&Vt03s zXoso6<;TKg2&gO5G3-LIT?b;&tZ~dlFF`ec`N_DtlUy#gQ591K5)V7jq~_2D!;ty4 zjakf>ew)Ypi?Z^6mOF4#Xe^tsn5jZuNE1j!_ekY(sG4kvc&~5vOJjwadnII6PRtua zY)TThy1`M}m9jfenuyq^Z%hQX!cVz)eYe>|@OKRZvf4GI%ArJFlX6#(k3LMOc0H2c zAYBVBmo+`Wu2IcTNDI;G=J4Y)F@UX0%u^6z|IeSKO!2>+xcR(*ovK1k*^%%2=r*O zMI<@bAGj^En!>r7MBrj0B>;z-39H;;z&P)M{;|}kt?)j_#BnWv;*F>q~qFZg1DNxM@ddb57FJ%HoCQz^8qzFe^?rZ9x#7- zS65H82(F3Ufqn`HSr=RH8Z67OwO~k7Qm|wBKmxbx&GE)hQ%OB5!Rt_*Uw(Ru$XO00m)OR7`|ZGa)N8pYnk`6WoH zB7}i)PPSH4n9c%otl_)U`ISA_sltLHp0EefhX%hvMGh7DyZBrBP#3I=_cl$CWCOEH?L!NCA;T|bF zR~~jUT|0OysDy35Pn#uIB!&}HQj~vh6aM+sOlpsL@`IGd)aa6qP=19Cs@ltu4;>3D z#zF}wCntvho9Jr(MZZIYhx;Z@1*g$Dqo#(dqoac?_G=S&$$M4~j=}TPQC^?XozAW< ziIy2vhpKJw%yF(lp+f^pNT<8S>g3+*$bf*i&S5`=f2m62ybKkyu*f3U*oOJovAeC^_#x~bEJwfrOHPS@Ktzg|KQ)L_4{ zY;;-v7$3(1vX~2ATFQOl3J_J_exzjmE9tGaR94RJxA<>E93bCSQ4k>!W;a6mgUqIo zvGY~Xj$(zZr&)K|(il3-ANn&Rx(D~Pb|0T{oYe(lPTxdyO|L1Q9#!Eh>c1<M5e4M+N;N2Q$0 zmxF9Hk;CX=l)?{tH-5N~jo{Wgr}^aC>2nra_bo$JV>!1y_d%r+zwfsR3G@Fu^Et8;>=1-Izq>%v4)N9=1k9DKS5Mw+v=f4S zm8v$04J2zioyWOK0$z{R)14@Y=Sp!7`+he|dVBRbR|kZi-2U(ro3@}5{j2V9ogOEq zLS?!T=P)!m?@n(7>FLeQP6>v|?EL(|N^XnS6TP<~b%9ZCx^b@R!}Alrf=>dXrl#h3 z{-exDx<@wA>xP*e%a8bNRjCp+<3h>-9jCkWxsW5$QXvdtz9rrqFEt9B=_Ji)6lr4! zkN{W=npSl|4S4wY84|(oKp@ahr7%VHPDOF8-}3m!x)$n;vc4TZztf`R!()d`1%V|C zvREa~VXp1tiN`SisH~WvUKvg+zidGU9)OUO1d>HUN{^Et4jGGzl2d3{XKH0%ygQSM z7KJXTU&Z3**Dgzj~ zPfHrv1b$*1Mov?3C4NZk#$hq@DD{fTt$1&wrvShXiGt*=5Fv^0i~i?&l*mWlCun*h zq0~mHn2f9}m~Y>{-6cpe;@B5UKr)%iJ!KXQw#^_|T6pr~|0UUfZiWm-Pfrht`SSko zG&JdDvhv2f0)|K)nlk^&nPr1kLFI2@XJuV2$?4g7{%arpyV9>qdxs8Tg#Y>v;em5D zNDMGj)Cz?^v!YuR57E+==^xI31VGcIBMhNUE^9hv3t49Va?7GbH-#7{sHP1%P!|pT zJhUF?_3-PXH%B{n_QVX8aUhAf5dSFT*munTeX#%B@y{@u#_Eg|{~7V0XZ82OBI7NN z-WfPJaNekmOioNhy)fW}Y`s{pLkNWsAlB8@CGtMnt~g1~&`?-wrntgIfCQ2=w7DSi z=@ZdRLH)a$x!YTpyVfK|7VFAG`(cGcdon8F&nxyhs&vjw_7cLWYdwEnR`1s-eO=;c ztxVoPIsa14Had0nK<2h?>^Qo@^+y~s(r|m*T$PBu~!R zwP`KAquPR4j8;hBj%(BEp-KH*${4Kz9B||JuAB>O5W zdCqy@BnM|jax{u$)2Mz1uFlO-x)7;hnOI%^++L?LI`z6FEm`&g-v}FLXqB|1)WE_K~j832c!!iM(#QNwICfw>4jB4p!~%4Y877~xFS#-Bde-6bU*VD zPwQRS*iTjo_Oy^gQ{xFa`A}GBPvV@Om%|5o2KzK99lSvf*MXBQ;!llsxJu1lWFxb1 z0SXmHV<|cVoBl(a5mdJxEsq@W!>R?Lm^ns5E*=MP){PBoSMjU}L&Yj>WLNXC54|(TR!u@Pgmm^9`6_#J12V=O|UodLQ1>8@VeWN4R#5Jw}S6A)=scdJVW9w)yE} z*9*Q;4a~?OcW`vXARNWxd~D-Bor{pZKgAgpVNnNf^2_xnwm2Wa&o&u1!IWFWyidjIkUL*^OpO zV4X)aZR#Lfo1g71vlK!jdCCiaO3%60td9^fAjoQYgoIKWcZrek=GsrVTzD0b`W~hb4nc#c8HijKiiuE%m~WdJ zDk>@kts|Ax!V>FizSFyPJusS`BW>RlD6?_3D&j4SKaE$j<;@zicxC^QbUQjL9TmM) z&D0!fDXrMRscF@StuGfKyZa7>ET!17?Jj)EpkbzywLGgZ`=OM&0$qoF&zYCJ@{W?% zX@~9lm17R^)^5bkz6`>KI`P4jmUTJ63-WW4)?)lJ<@z|GMe&JH4MXty`8L)#YQpk` z#RKhHEby1V>uSrOjgu-K=WXVn^1W=N{BR#kFf0-baW@}lIPkyutxVFDp9q^-Zad<*c zzK@gG^=4qR-4#BSEyclf!d2YhUfVk9>6su~G+ZX7boTxsb@YqnDSTrC9=P_0HHNeS z%Jf9A<7k6nyi|gWd6*DHm-{$LluQ%VadP4b7Rf?u&eLym3!XbIFAHcBZD z5|cevxIz|8D&3p4G8BDl^@qg%=2N>LO$3&w20PYEF%c-^#f94XAd2Pm6zRuM8KZ9Q zED0P69>_~U_HkQ=;}1k8(B*C`zr1Fmp}r%2!Eev}1&W9JtCu)cllg0S(}L1eI2dO) zLPf(EGC#$};nnY<<8XcG7*#7gE0val@j_faS_!omu2!+^fjUf@f9p7~ko9TU39s^w z73TxD)a{dZ`G%41(rQ#a!Q+>3y_xtk4W#olQ_9oc#M zJY@xS%>xkI0Bd0a%2Bw+hm?AZcG!WptrlsU7>?f^|QB z#$H8DQX#n1z3tR>>;?C(DSyK*oS-54_=dz9KTvZ?Yt^ofEX7=+>vXXNskfz1892tA zyut~0WT_<*aPL`udy0l)3O!f7RcNbI4ut5^O?#jYPY0DV2IW)R>vF5rYz6&1(B?EE z6vEf}%A?_Qt>zd?h&-xwLWaSU`7(fdyOZV}rO#E2A5LKLYn+L}*cEa4_*3YSjep*U z2U@h@gD^O3hV-wEY`3O2U#7;8+J~EaPlX2mWb)JNt#&`g+II;x0Sl!9t3NhP@(f&_YR=;*9Lh% z&-s7ow9FRX;+4xeK~&$1PCgL+PnMF*D%UAb|pr?XwJyIt(}2!ueWDy{CgR3|ORyOVu*XQeC~9&kY?GTw{r zPcvuen!5oQ3PaJTW?}o+qNeUbk0q(yf==(r&Ims>Ttfjn?{}AT%%bwqVQHtE0R;HH z8&_Kwi{oO6`YgN(zBdc*SxyUkJcJsU(atQsvW40?LPj#n#_lKcX8cc#nHGvY$CAa9 zscxe8FwV!VQcY#hZeeE77n=-lo_q^_C(hWWTMU7(n9JV`Y&8g&5c!nMkKg!MU_9{1 zEJIV$*Zt%XYJ9L`Jh2;z_rV%R^RPac5w%i-cmpiF8mmR+57+wE*xH@1 zW(}%5_6?>aidHzGpB%|%BfNQMz5hjiDk@zJ01qr=l}s^7Jo|5mC=BW%b{Tl22F>fb6F`vD!P45( z9p7*MY=NJG1Si6`Vgnq$IVR_c&2w}uUln*kt9+B?*6R4Qia9As@>IS$ogZf%AD|S6 zEyH~YKCFkdF+@b5Bg>_Wb*ncAAz_2X``~J|_M~ymKeLK``4RWc4ohy%(}NJ}OH?G| z6mqH|)!~3|uQZ!KH9gtYI(@pBU4{S_Elzy>Rn)~7^x&Z}+X?1HFI%LGBwY1x%B8Al ztY0WVLj=Hyk_8uA3zDSVTG5X%7)9D_w5e|0ZNJm0T`H7aT)o!j|AJf4`@Yo2Hbrbf zWHmIntdUDcJdO9wRTS+z9MNMy0A|j6ZEZ zr!E6``P6+q^JtDg@dQ4>hi?=-IDg$NRn#FG3=#}j&||wSn3g6Mf1l&w=_}WJZTwO` zX!~FdA|Q6pv`3cKelL)>$uS~t5l+Aq1U&8$uXDK|P<%S@FHhM|U;aVdXXQLd_X|^9 zpL?#mjCi`yedFS4PlotpdBd+1OMp_2s;d#Cm3oSE(2)@(C?!9NWdUO z@hbW-p8Bf$%zV<0u>k68=@a4B#GnC6#)etlVUnNqmcj>{GMckqz>CXQEQRQ%_DQ#U-n6@&xx;3~_nPrmOR&%VE21g&K`wM|wr#TlG;nWojc zyxhT%91(?A_?WVJj=ftP?22D52)ElH;4DyvKYBpv&T9=yci#Z#O<0pK zdkr6VetP%i8zal}pA0v#i3CKxVGd~i(lH@_%D+0(x$_La!Tc}kqx>cC4j9l%O9 zg>(`EShjJTqRsq~9OttDlcnB(z3?9F!t|x4kUp1a&KOaKQ`&hrV%#ASOUz?9r;|n)HMWZ)1cjaA z_EUB`X^<<35ea-eDLTKDODS9=^qx;@{3o2xH^C`7CW)p6l|x6Rexyg|X*-6g+TcStYP)&Ye_(j`s&e0J;qRgtAMK~*N%%$GwR>fAZreB6K27wQ7? z%f+UN2s73~`D=#W*~fVLuE!3>p#W3CT*mTaiae?jIP8F1E z9+0d^G%zM^9?Gu75GL`0dKvgL6o-@Y65DeWd$(M$a`*AHz+?cWTiJvhnMAghNsPyv zQ^Zd!M_q^Ek{C|T#DSNN9i5vh;*>HSV(84V0W zE|Pcyh2X#Zb z+#BGXoB6QXjKIbL2M{wevAxvzKJ-Q)rQ4*+;Mr>L=HtD89=jDg-)z^$-F(X~n=w4| zqBrOP_qluO*sq+s3#CV3+hCv+?;rL$qq?oLe79{7m+>d_51u-^UloN{2)xoG+13Hs z?y@eUZWV2RH)5}lOa@a(+aOKqdE+1z5Jde>hP@6%t@?Gdpva$%ne;v^_w&MU)LHLq zEKO8PKLWIC+oBob$(!UKYRDX2O}6dx8+)TpKP}h0Pvi1*Yltjr z2m$ew$YZm#u(e!P-GUekOMufZC8QQb^y6ZM`I({aJvb)sW4RC9>!UU+Flk6MkU%3Mr@ zu?7!fDN@O?mT1K0mv9F!85cYQ!GWA-Mho_sX#6)4`3VoR0_A}DDl5O1N*0mEQe;gB zcK8Sz6b?+NN*-}q9NdtpkPyjGphm2@P{8k+nSMBYG&70dA!ScN_4!1aP`_nMy zc&>t6)gC_~Zq-AFi6l+J#Vsq>;6~6_h#3ku`|iVwGrI&Lbxo3n|{zhzAGJEJ>TqL zoSN4347F7KjnRNgZ=MpQ^n8%WYj*nx-PazB=0IYlJk>AB194ZTu=de2!abG_A) zF2U_kSPZjwL*ueLtk{19FA1q;caPa-+sD@NIN+KR(6*3`k3+%_POOgp&5s#lK7|ScUoE+>kO}X`%?U@5x}M?g z7Nn7XE$Bn<85R8`{ntkpsmP1PzKcxkh4JcE1#M%beIWS~2XI63Fd zbVR~g*JY>Z=*==7`+Y#M7)t90rN^>*>Yvn)^zPkCA z_)Ca|K`_!R8{-G@Jhf%az?OT_0+WzTC$X<~0qNR{&e;Zw01vGqMlAXS&go~b=1r5t z1I#Ua4gA0(fWWHP5f2&(4|p)bU}LL3Adm0@+e?*c7N>gS_#@U0e^`49s4ClbZC63MyHmQmyG2sEnG@;m2I)?bZV(Za?rx+@B&55$b3fp_zW4ps z`qtii{Nr~F<}ju>ed2oV`#R6#yvzb%P8VR7vrG)wlgdV>7s#T_Co19^PJ3;`gjTka zxwaa%sL1;f+kPR0u;vudZ7UF9Z$K{%fYGoz1*SOu?QA_Q&9LxPzkL`NV{I~M7JD_7 zNP5>z?-mh6qnATI6;I46M2zdF@cME!K-p+e(EcTXXQByoQr|J6Y!2v)!dAk`csZGD zr6)3LE%(+m98nstU2D!ZqEfk-Ic)cW+c}-u;c_>l}4|Jo!<#``&MR+!8-28s%cjSy!{D24hAt37UgBFMmytmTJ;pWj6luIGJah z#aSK1L`0AnOkTnv(yKr;HrP%$N{4j2q8%F~7_`fdc8MF7D>!U4)$+0KoGZan*^kah zcUyxHcjm=p(OHkW?L}c^em?B+b)@0f7hEo>wd}QRCFuP+$7I(x$hLWPJ+H5x& z@D|~@xWoz?_my?u2A6#)k(r+#JK||YxK&u__&s_CPdX!EeJu{R62rriiy?LJ_#&^z z(SD^v>Wm?SZ~jdyaoZ2*Nu|%1>iG*4VoRsIxbOUs_QLah9}NGr3mwWH|BGB8&+)db zqM?`Q%7Em#W9^f9cZUpfu_%?F_*%QRb`yUB``(QgT2Tnfpb}ft<%Xr;=Nq9Q5eOf@ zn&f6nl8gPf_A|T)jLETWwPum#{1>3h@q;;AGd{9Comvqs(5nMNp2)R%*B7_8(qaSU zoU^~b2*a8NMC~T_CG+^OM&D2n_4Tf-w>~bt3njL2*$rpgi&hi!tg=zY?g-`QvAfFi z3g?GnT_Bo{`5mWiXEjd@7opZI3&o$u;&tan1cNM~C{(SnW@I(*Oj6!4ZuUC| zeX3B@$s$L^Qs>COw8MDHk|G0>@uJ&?&<7m|bQ~J}#_|yhp+>xxiYnG;E(FSwgv{Nw zv?Cd`%4#y}(-ikPMFOPTMZDfW)4@^fClhu3+GxzJ$%}<5>m*1k!kEX~4Sq*6|GxL= z`<@}@1sX{yNt@qhAGK$MR})s_L9du*10$cRtS_?Azs~AI-5!7$06>aMhb*p8J^Q!U zwnm_lc1`aUF5)>MKeYf4qrPTb%xzAj&H?J^pIry^qdnyeg#4ww1Q%uYebjq8O?V@D z?ksE=s|zQOptcV$X_>^!_AJU)UOupN$ab>US8|fuGE0oK7u&B~K+Xx3!v}aUw>Kw~ zZ*f}l_&8@x6VcD|5i{wKx}DOOw=gx9!&Hnw+rBNps?Iar((zO#+V0Jy~`7<2%A? zHxiUy(=J4THBgdvdc3bNYVKH}(#WcOf0jHcV$eIiB?)*E zoh3HUZR@zyj+6@*-!WKgz$&ApkCyvbB4)7RI8vcV{)WydpA|%|A;JN>z_1@Y6e$@; z76&xsQRO+mWYzz+A5k))XLm3RIVac%g~4~(-H;?OjiMJ0H>oDTtLXC9k-_$Z)JKy% zqa55iri18Apa(kM%+J$m1l@397u;CK<*FD3CF{kml$20i8C}at3B&-&P>}mclPf5K zt+OVGh>K8MwdT28=-?JhVL~V~TD4PUQ{^aMAs!an=Sn;JI>#~Bzz&1;`ZBNfo-J+&b{n+qXFW4Ubh#h5g{}#N}&6d3C0XflcvY+NbL_}m} zX*tl#0Jax1>wuns z0tmd~*D}rtF*5pCSXiIJrrf2j$&gV@C#BNlvy^OR8S94M`0niUOyL#I*wA+ci~!<7 z-r59TgtxurfUFgd7m?!PqeP$tiTdZFZ1=3=WY!|y@b@`VKtbdFIRrJ)!@GP{Y)C;t zkeNx8de;oGyICc!Oxfyfx~MT@kMMhuZeUGQ=+`cbNpwa)bIe^_EM3)i%iKkOdCjp} zhWO~@?v~mz<8^4lmIus3Un!AX+n{%9sd*z;c({{IuocA=iS`OVydGp^Nl||YJI*k4 zN29T!H?(r^N$W}U9GARQZ{Z7x3z{~v5L@10Lt0IbUR66PWrP6W{G-e8^W=#VGq5Pt zymQ{&+%|H12=#MmKPlA8qfph=P5k;fqJjeXrEO;0zBud^Hl@n?Ci*WMNfWY-8;+lqLsH=qy7#MC<+>3(m>P$Ui!b)*i6A`TF56k^UBph3^&O zyXL(mYax*tXa+=4nIe5$^JsrtHF3a_ ztz(sSy#a2B0n#Y9u7PvA>Ma8LS9uaC*G zo50R4p@=)3rBBkALd}F%L1gPd3I_^cVG!>opH#+u*6aWK%??Y32kK?8Di4iqivIW5 z4$NRxX;A1I&SHyqKx?b8YZOiAuV2`JX|!!~By0V!Sc3B@EU4WdYI%1z;=_j*C7);p z`upL75O6k1(47CvZ1Klq1-Lf)ikq66fKHpazDB)+@paugkb9$xpp5hS_3H#WHFyvR z1lVvlw8JU@OMp_1l@?$T0W3C8r)f=R545|NMB$|T5N}r~e6F{_1RSYGiZhbu71y;O zzT?JV&<)=v6JXx(>4W`0_Aj`xUF_*dL<_R2+l-Bk#XZuahphqbg$oJI+1XjZ!E&`P z5R%%~)kX1SUYN$Hv)Jt>C%?dOJBA`#OS7vrqnb6D?46#*U0z;(a=Q)R_Gii^$KEXg z^MqhwVV3~24dx%i@yW-q;J`pTz&66g#YLl9h$`g!kWQ_@Qfdy5N%MlApZ@?~nfou_ zi0bntAy4bZd-f1A0WH}Ma>Y#S%5gEF|qO$#LH>5IGhfsTiqE1ezOsTX;C|U_Yz?+ z@{;!t_ykTJIQr&ay2U2o+L!7bVe1@P`oB%8tEx~*NJjJq+^uj;TO|OaMmFH70WLdE zz(_ji{!0Ud@D<1RUZ^_z}q4oLEuY1h$m!>H;aiT{)Ns zRvyjho?KR;gw(J=3^cDK+tJ3Fs4_cx&~FfcNnb|tayWjdnyv!8&K zl{11^CM zbZ~;uSRaMcoeU84v#k2X>4i80tFuqbg7#|@-~)g^JkPK)6(KJZFSgeM*%=eKr27WOw105_+OQ>L!O_46e|)^+VkPK=K`fk`W3>OF$Gg|? z{qJ{5O-59q?VFy|_G@RpZZ`+~{*q$J*cH-I*n%wCI@Xxu%Lj=f=%J>)HAb7)Fm8|R ziSBa_W~1J?ske;1KYW`>H}G=KPX;u{8J2NA!=4L-%r}lKWo~K&%ANxw^(Z-ZxL_f* z69QklGIt4fR4^IYcPPU9=?M$)r96av{z#`=$MWs__vQWlsMuK4618Ru(Gh!xDIZ;* zHK@fUnyyo45LgX!eb==++mBH>{5G$PM8Rn2pm%U_P}=XNlcn66wHxVMU6z{{7$sWQ z9isFw2lW^Uq?U`0&wfANs&$OHE8`7d7fOXnWL^(OlQ7{_(7CaR<8bCn%g&CJ32aEht2$b`H#h49z|zB zAb|L%w<4FcRR9N)%!a#%NB^QUJ9VQYD!cZ*7YcPudXKN-;<9HMtk{HDS?L&rAheVC zeuAh>r-PEzKkHAu1bW~mwJYdxUHa$*NlI0Kq=8DEM!Q9*0U19u5e{Hvy?C0T8%aXM z`k6o6boS&}v%YlIA@mUv@)MLUSqhtS4Gh0xsiO0fjcNobJ(|#Ds@}g^`J71nRDEjxjS^7j2NP2Bhvx z4dfT|B>p^BbVp2Goi{!5{8?L!8IdMGhtwkL>oG2^?EVaa&tJa406+fS zst80{J$nZMFQ8aGIPR5!D~foGd?_h5rs#RmI|1L5C_H`Y6+8{;q=ND~j~>XlH`40< z{${mS!W-P2Duly~NNv`e$H}gHM7i&x+OAl>3%nZ0kj`$Pbv>%(fUQk>M5$Ep@s}CP zZJUs8_t!pp#DmtVi0yjSphM4UF>LSlWiU`cJmGNwk3dQ-1n&08{j(i1PTh@zSZe`!$DTa2t`7Hi2u&bo5@-f zy%35N&@Y~3`HuP=JA&NK!|N?WJqb!n5G3K*LVKsiF%ANKbbGsd+sZ=Pkt~Bq+>RQV z_rt5jc-tR^zXK% z)ME(e5hP|znv)h-gg{32aNArip56$;VwFNGEZhEs>kq7n)NTkB<6-DHU)SziuiC^i}qGs5Dm+bJb9`$X&Q0JAG%-Vq>eQ$%} z-Gbq$t}9M@*(|>|;ah%#h!cAjo^u^quUTV71^tUn43!{u?NXKksX5GfK#>kQolkPq zZCaN>iv`;HE#3#}h``Mj%IS@QYl9}L_@&crYn~qLa5w0(Lzb6s(=`Bu7*uG>_}(Uo z>}(lp4(Z2M1QTo11yehfdrl|{MlVxx-FwQ!5yC*eJ)<8T%ProF(cbZPmyhf+0r~?7 zl49OQxEAK^E&AfqRC^3RpdY`CplZ|$7clGi)!)-~N|ckWZudJYq}uOxP7k;+q~c0WMLZUx6VrVGP7XbDh#;(r3YoY0FNoC2lOLsd|M zQWv+qL{iw>GKXt9#G+22U_>DPru<@>nu=%*a-6iud>d5k%- zLdTxsgZEMKHm8DIiR^CsP5K3!RCA7F*_=7sED+pu8ebO_p_@Ivw*Tp`y@2d$XT>_l zx71Nc##HBy!dCo_bRvw3+G(e*Z^piPj;D!R>@CzqX7sa?FNM*%q6@n9dEBpFip{*w z+y6jj`3o!-lV~mw!B)Mgi#G|AZOMcZlQAdfQDK?Fw8EyQUKgao2H2LsOSk#4G+%|zG8PK_=L~pxA)Ug9Uv>~p@-XWy7US)2}*AVQodUIpk zYjaDU+8C8N$)c#1s>4JPBz<7HQbdRmNdA@L52<0h)bq(mbM`ZCybY_@Kw@%@1%yYH zS+GLhgIH%55+0E$W9MQHnq7rd#K(-m-f<>8%?jbRp~Y1eP@ixUVQMroE%9wN;6a8^1WJ`7p|rpwlgrR zp6Z|)k3`s)!U4$-Q+xk7>3Q$FWm`8;Hqw&YLJ8!}e{1;XWv-ZRrFF{1yj8TfM`f*- zIa!696QV^{#^I}x3K`c82X7~e-zFNblL75hSA+kZGcrquE&K@WX7#k0) z(J~W1OvrjSH}@8mJ?~!T(EiDY*UKEAA$C&>)#X}*@yMI>myMco^-hmL>P1|s)rbBH zQF2Gi`3UKo@@?6})~wq<6(tv0I<4);Uq7nEUbXrq37E6pE7f3IXi;3G+OPIaH(0+; zPZ|`ZvK?RBWj}daEw+890knVFYY+lr}$DxF=S{6bV_A?|)4Q zIRc_>Nc(trmZPQ=C0XAnVOKwWyh?i`xrGKKf{Y|X^{k?+&Uh6*Hqzp_y_?nuH zzFK~tH&1{*3oGl2%~Y^Ar8Gqg#bE4JJSwYBu8D1FpMlQv)|>)T3>SBY8aew)?7)=x z3=zo}>12BME|9X{PDo#gw)>Z@MNh{DLBEy( zHU}#CId+SjaPz;NyB|%y`wuKf)NL+D{Gd1|^XX}a1BJE21z%I~e3pJuELQWTW*;+9 zj)d~5#I@fKP6U8XM9wWe)tcZrJUxdFEi<0{W)e^kM=HY}ZD_FL^?scbQ@7R9aXfs` zeXi*7`ZYcoEhC6oR zP3}uUT6*%GR#j-ripw^2 zlRR;{ol`r7T-IS=wdcX|Z5CGgIHl^_?D0Q^&n%W1Ko zbwr6&=YLK=vTTIOo|+`JGXHh`YSW~!>57bD44bI9ym5RxSG#$K<-PRoI7wZdJ%aB2 zYD!k;vio~pm&RT;ZVF0?lwfBNebx#O>f?PQ9Jlw3AyyPhuZB_11b8ro4V(SKvw)}Q z&Bs2{RsSfCpD?y9QtZNEN1e_v7jy6{!&($l={(mhL48{q(s|kiC!?>=TcMNo6;Xc> z&ybwLZ9dLNMYuk62B~ZwQ@wlSmj1aWYC(s6@BVbJ#m=EJx(95=AuZEuj{r{E2e}(S zw0+3{WHxF1D($L|Q6ALP5C7r%rR**%EquEnh;p>Xh|^33xgS#tZ0A3cRyt@fLh*&9 zWV(D4+rKU#u*-f0Q`(sFbIeYZMY}3my4{d5eMP9yU|yDyHy@?DzD)}wtp zt>6wVw)x5P<;M{!_fVb0ag3Dt6i?U%izKBWQrxju$UWrz<$R)X2Ft}RkLyBT3FrkfmqtR?YT`=i3i(IHSq^rLbCn?l^^YZ&>l{vc; zaVbOwCby{0xL|h}jWx zKnARfhC0OVR4pqN;}2rB!zunk5h*T^ANzL7v*(3{U@d7UW+x&N3kI8+{TN<7y0-XxsIRbb%dDvE;zFI^A(jPqxCZQ@w~c;yd3{&Ba!MR(n897Fuqa7w zO*bM8zj+9w_ZDd)dLlv&P6Ri{^VFKS6HBwgU5v3}UPmKJx_t}WW`>;R#P$1B44tRj z(X_R8`B1kX`Ro8L#9GAvzF{47`k0#cjU1LtfC7S?mXw1z26=)Tv>MtUW)Qu33&ahs zQmwLn$$BjZ95vSE<=AA6-Zo~_le%3cfulWzY5+b_KIDpjPvdnmk$k%~UjdcUmQ@SlRk@hrD2+d$O+-nnRW z@bH|RmZ@bkimx0{z`&-NS^Ng)k`jZm;_wWBvNAUB@lwDP81yGDYdVgTj zr*~YRZXLhPNq<1ov_$!b;t~ptb`q6MUlsJ>%M*<9yl8|a^CcEiB;dR2Ks}MGdxi_w zsQzkb{_8D)|B)GVV}rhQY{9|B{c)dgdUk%^UJ{<1j9VhaIdZ2w^Xuut~hV$_7@I-<> zajd@G;PN}~PlZ%DkJI)BA|fB|Ommw8A71kUq1w;g;D2Dd;lMO$jI7V@dVUa4ZL7yL zIvX#5CfU|Dt-_+{{dc}6EmrQIgy_Fy!Kd}z|B&Zk`(XJ^KoOFGYtH|GUY|NiEYG}Z zt6@xZSWL_ljQd2Q30F@07~RGcO6lkj00?VMv)uUjxW5w3+TX3azsU7xRYihaInym; z(|OO6PKO~kukL5e&^xOFaBtWiu3up=kwJNikl^3{Y{*>%cSi3OVFM1-s{liaZ~gy} z@sRoJ@|pM4I*}P>+Ijg+p88x*>{@J1^C0l)_e}Zv@PGzBpb-lK{dA$!ilH7^;Z@5$ z*<^TvCm-2gT7X#q73Z!{#=&;d>U}ud{1n62P!&R zOeA!HfFCi#VEo-Xk0*%K3q?^VSoC)hN72vke&FCaYrNQCfzEn%1H-AWkVVOq7g{bt z+|Ry&y_%#2M>$#ijR0ztx#Meyq`D8?|6ekdWe0+dbr69uy0`He9vk zC-GSnGSTEqqdCtLG|(&%pYWNV7c0IUKSs-1Le~^%HaMPJPHgPuX*Q z1>yJ1vF_oLu~%dsR)C1QS~@55E>U%hkUV}>zwwq(q+;JcEL)|A3^;S7|93_IFKoQ^ z$|yoI4y8QXS^C>?Sw|VWjpl^RCo$0;)u*Wc^$v*0^eVhdABv0WL}$Us`6`4{ZEbc) zBig%KSE>3pwXtKfOTUrC3w!Yov}bem54)?D9qpFXXif{^#UlE*SS=aV5lf*}N*J-s zNtqO_!dh-4Svt?53qD~{%*9%dM1A@UR&E$!6{X3vO8GFRV7i1wwLFXK;bJCa^O|eK z3SxJ05=lJEa3FBZj&C(+4P}gQmCL4QkZSK{MWVT9!Mu}ovyDEG%7u&WGC8Q4J~&T% zd{}+mo?YZ0V*EeG2drm-<1qacFTpb%Foj2l*oZg#+1#GSisdqamPT~By$d9*4s!22 z_8)^r+Vw}1Zj3xP9g>~sJDngJL8eRP1!%5tYv}r{cFGah>6BZv|1Xrxq zQ~q!&-{KyLLlP7Q#z^I%eL+>Pz$h5R3#vgb2)#KXabePn7S9y;Y2bil+LI_Roc_jl zX=_Oe*PafMl3%_(UD5h`MxQ>J$I z4nk|Lxvsd@aQl68B^P(J%QEv}vixQq*Yx_eFxXSBX}eR>2e3oN)wy<+xe!TAbrI-j zE@jJL03t^b88nl-??zq}T(7|dvXHbsc&VC1B#mt>xM*xm6gZy|l&HtGET5j6olvEj zuq{_i@eg;&Kc0qH7!i_WQ`C9xrT4I0Xl#d`Cb+3--Q;~b->m0fAPCSKJxn?#uO%M| zP`EV~VC^v4g{$UwR}G*Dh^u zWQ~waJ;%9%T)=sNm=v1HbM&5mHpOlq@lBg}og7JkBy|%Rx=gb4*K{c|D(imXT8R`| zY}#`|N`1}AZ%o*&CBZ?iOdxQ4N5t8H!dW3V+G9#o+x3@XCE*M!s$=aS6K9-N=jxz3 zM{{y?60vY*e$VWMu175=lcWC_0))Y$Uqv{;?Pw@!O7PF=UxM&pGt|4O5?h$WqWye7* z%{%XxF^N->CIgZ)$_%oKCMS9hvflz?ca!Iua4uldM1FW7ry- zpBIr7L{EA8(>K@293B)>QE5R~o;E8+@lB`>u0&EOc>c?dic2c-U+YMb+NwYK8vTeJ z({!Z{#FLd?K4?G#!sn^=!y%Sj-gBBn5k-xuV1rk;HDG0L8sEr3GJ_A+^p1*!piUbx zf1LYeUhUJSJ46IHCxzi27X!mDvYj4{r|Z3`O=|m=25{mC(xrKqZQh$B8XP7Z8|wWN z!HnlAG{Kvc%o@H}y4CBR@eDIqd9z?EeK>2)dT)hkp|B7o`5nvPj8^i~W+IfVaBp(V z5fXQhR`-S(K%=4oYua<=+Nu}hhYNi*y$N8U8}hlIh*)X0VkaR>d3N^=G>ow;jhE6J z4Vc0QbG^H6WOQfvepG$@1kSfk!Gen@8Y2rIYiS1hEA!VCA%l=f2{!b}0o&UYK%1w`(av6{%;X;gF2t=R0RLw^k6 z<)t5xSDe{>bG?zz35}~>4_n$0fLCyRt?Y5-!PAEz$-oK$;ZL@lmgDv&g2Fuk<-W zQ)Xc~j@&Dw-D!0$I|e*a`+F?%st+`}ypV#&Dds`V63uCN3z(_K&Qh6Q>AM&_5)|lR47^ z^=e6$el~5$xh>mVF=A!uVAI?aBK-z6H*yOZWFdzn`1+iAdL4c8H+>H`fQZb-ZdFTs zu#jc%-5_4{btiYx_d{s{%u*C+$gAJTe`d=t-zi^AJtW+tNfVH*&ciOM(5ZHBXKboc{ zCj=pMqJ;0NLNnLy9O8ejAlkd(;f{oW_Cj`VBB{?<)9i8Pl>~p;Qz~Tk>d`u-_dk3w z*I{U03mXx#J$^Wa5t!vAG=>}j-(*wP^%9Te=wM+?$xAT?km~9S5cIaZCA)UORWZrz zLis3_TxkwLN0|b8i|qs%LX6#ehQPeMet=vWgHrA-f+w+P5Eh54jfF z5+N2aV|nb#i&Tio3VARhWPmop{K8VV_Y50L>8lnqA`vINxF?tBryafWJB1JAECr%F zt`Kj3ElB4}@(-rYLzw7#Hn^Fvu$nwz!MtW+SwBAyKxN=#*`%PS_MoPNVkIx`*isS-$ zu`;u%=(c-~oV7UL7QbO~vu48Dv6OhktY-`hON!#>R>FWLeWv!DY@0mENrREfy7 zBWKqxKPh*w4=#5_c036u3P{9N17->iTw#`@v7)Dj1I*S*wC3Dw z4N^>=)mX1PLC>#B<-yiLZqbi>v!F?o84mftm=S51ged?w84lSC-6~Hnq?vmqh>7d7WQ*;OpWHqw_Jg6^iP z%k2|K@0@CKX&KFhfNLlAjzVE4<}lY92ol=_47BcAd-sAoNAF&p)<4~f}o zD_Lh?$eMe3UW`Y&XBrP5Xpb;B%|jdoPdlt{WVVR$@mBqV(g{?l;Ed6`eAw#~C^9y( zZ~X}&jI}C6i%s}aj5;u1j1k82B6Ar>K0>#5P9)(q_lovM{?3TL3kgxwwKw0ia$>*_ zZrlydE}iIH!=v`Q!m6>Y3l#xDA!f{C$##EaU{JiX;OEjs3@qzVlH0e)XsF9JfFHU& zmzeigcJn+o_~xMP$7rfgKKPBw1KAoy`dq$0_RUP}p-(L`MV7tcj$As{;aQf}ix-b) zZzM!jIlG%UJC&)L+cJ$(xV%%-ZQ%M`J0zHw2&y5=#}%J5ucD~`-{947+WKkn(}5VR z5WMrKqx&DKgY}sHV)Ghc>qqd{%d+vWVJ_Af3h@17-~CO_5&TJ(qotW82HQ?wyU3?T z3{ugIr@ua@9tGw)PG={l+M0^|iUOZOv)*XH^2Mq^}4nBYC z&MRR%pK}O+J&cJK-2{0a>6da99L{`LkW?kSiC9?ON*>0o*%UmpQ0&b_YK}WX?V#&q zsSiL}$tsmxBxWyL?eG?8@_qTJupiy-DQ;M>W!0Ub(!XR6xB=Hljw?j2dJn||*I0ox zvA#x%BlkN*;m@;$vlWuzj@2yItCy>H%g(sT?_1u3!uktM;?ANWFd58fM}%^xaW@{l zG^Z?INY885F_{Hx69t2Q&ED5t>`()9zgRqeid4B=iM#Nu?B*ROSWj1hgoiV=gFx06 zZS4za=MC&e>lg}VAnX7fCQJJ{=JO^*W$xP552gZgsmQ&+(JA;S$IJ}RT}$%8v4|JSi>So#`e~`w2meI4rifNuK{9=F4X$)N8JJxyMMc8v5W|$l z?t>cu|L7{A8I10F1x)a9^PJ9SrCY_*$ulexEPYj0#sOo1AD&H$)>ISSn@gY#R29k_ ztciTc8~4$vDdUHc5WO@ZvrKZ>#I0XQ)z0}>4{Kyoi8L!cth#qp0g@3dTbeT0%XEu1 z)LcX^QX}tJ>ssB(Z>r40xV%kQ{ap;|zHPm7Bqr%G(LzW_@wVZW#fR0{)Hf48dC?@F z3R*7DOV;|G(5TEiE~3G6X%Q0#(*zo~B8w)<2z!sxUMo2wAF@1Gi3vWi?dcM-9<7i! z7;MRoYGI-u?Mv4>?J<{YJ!)dr@2tp5IftC ze70+6P*>6Y-U=x;?U8 z#Q|HVK)1MS_nB81x!vltq}NBSY{|uFC85ms4(@2&c6%$_KNz&LZF@2KIV;GSjJ}^* zze=m_Jb6vP+Vn;Xvw|+LA}Yl2ygX{l8Y8@Mc)&h2jZ7TlJ+RemLhjPnVf7h9GON~# z{B%D)Ey@v;{-X-7PY&g|6&-5;L=+4K5}hvaY>`AC9aS-bu9})5U45m}VQRkf`Pl*; z+}jU&j@-*?+M?2!kjh0Fz4@V$ktY7hLXl3sOFLSCd-Trk!B#pMkDyc2r(9xpXdzan z)zC8pf`zLzO7dV^p6@#o1ZEX2DKmCTa@uENC;Ze-xhxp1_dHXvr0}lH^Ae_)SstYF!hL0C)dcxk#r9#v*}j?odK{c zM4a+_)uJ)d!Kn(-dg|Lb#z0m|&{=VA;`TQGs-hVZ9ycxTg534M^=F1Td*YXH$@mYw zJUbOwI<-{wb%bq1i(T9~G>2)^s{$zhH6P{3vp<~vX|*K7HU2j!Tlq6!!7S!}%DL&MFE%MlMKF(nSr1jIXDK_hl5-yB6Q|L5EVt{y^ zNM5-JMD4T#K*MNAZwc6r2VQ)}car!LJ+x$4B8NMm05PpbheF@-%3!hCIC#15O+f3i zXFj4AJwZtj#wEHd3AC7rDhwlj5nE0*rXTaL(PDI`9TJCFm^R~Bi@4=aMoTy{G5gI8 zj4t?rT#qOQRcf~TIfu}z*T|7ufpNFOZH33W>2+mjf^P??BQ#R4R$oSLaiHG{I9_V-n8@Ny(MqMtJ@LfNkvGye9t*ZE+ zOx0A;P;_Hi5fs)Vk8AusX@YlG``a)1ci-Wwh$D#fm=Zt3NZO_j%o!hrswfid6UU`hyd ziNj?7#NtY*B-d;OQf<8R;%R~o5u(Dol@{npoWDftrVrZToM!I&MA_a8Il*EzNHaKd z%cXTJO7p(wOs;7qg+d@R)_j%Kx;!*meXXP^(AF3xuPo-u?fwOTFt;Fp)>gkyI}2lX zj9ZW8yc<7VmO1X+#}j%RNTX3nr5Z+^qMdmLGneTdETM_aIRPi$5$~*=$3jvb6TNcO zxW+Fi+nUumrX#1xRUFK>u97)L?F!WTdmEx7W!KV<3X4At8dU7Kq^;<$3t5d27G#x?t?t z*c@BJOA+<5<$Xvxxl927V2$Z6KhCMB zQr`8&80}|+sNJj)%gfATHCpf*OksJ!ILjDl*~HioNp!T^!u2b0DPq3N-Vg;bxdMfj z+HBN}&zaT2!4ea-wQaUVk9B^X@Iat0qEd${+i}s^t*^3o^fQK%pjH$mvF)Opct@p3 zN=4APFi!N}%(w>P9eZulRju19)dRcjt~Rn*LTX~w^+QTe||H3wTLsatY{v(_A+?(0+_M@P2>Z5 zlHg@BNg1O2JWH3?#zhNFPoSnQ9s+z_4BDmd@o~$xXiE0BLRS1?=M1=Brs?;z*Cb(J zSCub8gS|8XIGu7Hp6p;-a=kI2fu`kYVtM=L9bmpALtZsw|Q`88;7u1jK!{DDP*9jNd2qJbz zG|Q64+SA@P4V4n+pyyL3!f2xx;hcg^r!bT0k#;RGgIFK}W5UvYReT*T{4r>Mv)1Tc z<2Y)4Mn@|FcgK1cMpxo~kUI=B*zrDJ-f+wpNdWP^tU zExwo15@L4!gC}604q;7rzbM9WgY*~O&{mycNRZ38jsyf$=i-ftjAQ%0Z|#R$aXlFL z!<&7RCXyLG>$ZF(XBtFVZ1D~81;aQb=)%xF)i$Ec$oBhhGb@5iY#vOyNCTY=SAs%8 zUE-xml2wF9!e_;nkl&|u?C{H8=H@h(l{t&Kzw>97{sQj!9G|?)hObstXVPHkCzdY@2#4ObaHqS18sE=T~00u^>`1fc8J5hU1wDKYC`H~VcM(Ze>rxB{r7 zG!3R0!*H{nAs7r^qyGJxLKw*OogBRkR@&Rwhc~iO5BYd28A+QefW1cb7c{>}uj)}6 zj?k7yZF7a%5h58TTezVV8|GwzjuYr=qqw||10$GrQmEYgN^Y|5@)O;Y|3JyHR#2^* zY%7Bx)8m>>M1gZn5}(FKS`mLzd2Ewo_|Di>EmhYReC4N$Cw>K(!6r;|X0wkXF$|_p1?szK_f& zLIFOVmKGowIdVwVmx0q*`{H!5jr87MC6gBWjW`o%`N;RUS(XHGUkjzX3UbNEgWqNG zQ_eYrDPnnJ5L7^oxaZ!>L5ujK$pFj;Qxl`LF^J>_OY|LznU}7&7yBm|ZB)+d{aBis zns!q_43BSkWMl%0(;rH)K@KM(bS?`B;MW2?8xl{ev?o44K1sQp#`L{qdFXqZMa+nw zYcaIgecioe(WOZHfppqUI4)6HVUM!%z0q;Xnw(1{KOPoh>W47;6VUH?coFgxXAEzm z;R-)dAbzfPeW$633*;~uaXYxEl^Had@m(OrB5eaU8}}8+-tlqtCmRIkPN>ck(0xw~(gQwbnHXPAxunb8d3nt-k43Hf~DE8hW;#AyFL1pgm!=Us_rKJTIc zjX3=qRIvF>`*3i~R;-}}f}A1vm4s9vHLq4N=JGPy2Q){57|WG1qR!xEWMbR4?POw1Y}>Xmv2EMV#JXeK#>BSu-!sqip7Z|a z`%c#CTuD~4(pPtNS5^0}y>(Bg+}QWh4Q<$l**qVTyO%~Fzp3}j)rEZ8ZjR3Z}+GaN}i|&-J3^q>tC#Q;O z7aAP;l7vb+Rj3YRs)zZ1>HI0+GJlDM={CKoc3eSo6E)-xh6`6X%Q54yVi2Vx`+5$t zhw`1bQTOtx@bXs>eb;O!7;(vtIO?G4QVpe3w|CeuPK(#@x}M2ca~GKg554~)(`PyB zInJ9(57Z>!WhP@I;0T_;%I5^i4J=Ik5hlpQj09>E{Jf4W0!|7pu$cO8I>AbrFkC2M z7p4A*b!rdoKj;i#*}eU@%wOaOfBtUY<$!tw2tbqeWbgEP4wDTfuna>BY=K>T4@YMB zoV~q+2IVh6A~(l9tft}P|NpQ9ME(!8fxmaULShrSKu{5|hPL9L;$Cv#kl5n@mn*Pd z_}O%X6^q0z@_~U!w{#w+krS!qUxgu{MPUFN2e75_RjU?=AO|G~>ivT}0xALE1QNvQ z)bztX_h_?N=K8;l>Ayq*ZzX{M4$H1wD>?@t_tgIlnEEdoehFek;A#S^xhUnvrIU%! zxaMU2QJWfuLni+hpcFQKdj#w$;{W)Ef2{C7yxYL8|FQc&llyP^{4Vsd4X`xufB8FL zN3%Pam42EpJt!s#5$5t7FcRc`n68dy{5SdxsDU7=(5Uu@P0sr?R@jlb?YVZ=y|zER z{n9OQu~xLd<`+y&2|#J^9tTIQfEZG61c)B{BZ`pS-Z(CgPDp$Z5EwX(c2CL3%9;eI zuDd98Tmt;XZ_zU|Gs}1enPaksq^G3VE{3%J%P;Wn1pEL3H~D_6t+QsdnHK9E1q!(=9CjA#~hc`>i$;o;B zpmgsgQD_%Fgoj(jW;=L?vGLU3J+$&|AS^mgG0$_|?qC3i+x_aZw_OmqsR1-lKVUPi z51*PDTW*@+`XJ>N5sL~`C;CZJ_nZ_ZkcgNXahl>h{uXi66Z_<-$Tg1g6~|2PCF-nq zX=zE)%423Kx!LtMh5ngDZVqjeTy^f>Pgifm%Ga8H?KZ0VL!H@&v5^50v6{SxE`GSfTuR+J3m32Z|^y z_fLQ?kA&*0_iI}0SQHym@6eFgyZ6Ywi?W!04?HGr;(#kRYOOr)ZN0*6C^2?+)<#dH z$K++V4hRnwRth;zMuKLRV!$O(pP(qV+FNTWCZ`apvLLun=&9!oHa;DQhn+6ykl}U6BT8Tew>A zMpiJf=1}9mTczNDTtU9RpMels++PG1??d>(e?-;z_PCviOjJPI7|b|Y1zLavI`u(dPU`=}HiJV!jb8uc1u*<)QH{V%kX&}uK_eMk4fg1TAR78Go*bLkjfg-^B z9E9S~As1Y(&Vx1VbBlB&TC-10W>`!HP)7g_U|>Mx-TV09V6ee32%N2WuD?r=FEvX{ zs_9O|_4E*u=iI%1kzfp`30;(@*Lz*ZRQq!#8QowWf8x~(!Y}*LS%@Y7P8Q>B>j8q# zJ~*vki=R2iP*~Y$x)05`u9z9-_)XPtd}vk!+^oWfTsB6jorA&dc~WtR{!(R>4N0O( z@?-ww@v_iW9?1N%3V_{?Rq#4@mzQ&`tDthXafkV_&+C%%Qp1yse{#a=bvi)^g#E5H z%mF2^h)pLs_NKBNj=Rq}iu0)g$axX3?DY3r8Fe`Ja913py_T$4n*iwI;B5h~M~6d% z^QG>Fa*uEQhdg7TS4#``w<-n&w;$Qx5Hr1(Ho?J&@G4O+Md_r9S5vkZyPjcV`{?Ft-eEagxcnjPnQBOA@R-iLaZ>O5D%a48Cz#}RsY9S zrM`fgkgyuIjj>20wpw3A6P@*jU)y%!RJ#V$oFpr5^-l>F%p5Z#teT4?`H%3F1qZ?? zcPP24MM-KMPAr2~7612_QTCb(;tgce$f(3I#*I{|;XMc=25{Kly#oYCXKRJ<@qqTP z2tZM(HxVa(P*OM`JLy)n@5$CcdC2D*$(jQ#gRipHl_au+vuJl!FIR5F& zZH_q=obD*jRXmFlG$X-si?;ULY%{28*(%RBJbXhRxn35 z6uTm3Md=3!^n55FHf)all18<2*6J;q**l@}y`zk1xb$Y5o>jdq@V+hC_Ue@4!NOVj zQGBEt9M)o~s#4_}T;$t%D>_BA%YJh>&*~E6nimW?yhFXc=tP#Ge%4(bMln_T>4sbO ziUa7r&ny!~75|d0`_N9I>V1#&8w4>#?lVxQlYqi4_zp*1cW-qh#pwt{Bw2h-N9MQ< z?yJUFpVcfsySoR(aS6K@zq%KpTN5shdPU#r$S>QYK2sofCFG{p*J=HIs}xwyFt8uT zwr3LWH~@a2^x7Ymmp^$I@Lm7^gSn@(A)r{zKL&y9g_~a%-51E{VEfP~R)A;Jcj;&y z>};`_WBb9w4yb?_L!<M^vx0=v>N)6n)JAXf6INA8_wD$0t|=q%`~!|B2n))Bf^Xav@)QDq8iyA$Ss$3NDvu}X+RXUpA?C}}Ju03yD~ zV7k@6c_;qSD8BCi88s3kaJVgt;HYzcrt3tN#~E2$FLgo(PWk{Wu-@8niy6{Hw46UR-fED%P?ew&EJcH>XO7) z@=@Z~17axO@4FZB%Zkz7T3ymFxrZFA()K|XisG*g`tQ}YIWwEF%LK z34m~onoWZq*WKQR(o2_rA~F~>n8ooOdiMcd*N`t)ue&1D8JrmLCUk?1H(B7) zT$fwnCkU3Bj9=qPC3|j#Pi!xv;BLe);61jdPN&gX+^}$qYcIr>GGWm9%(+?DAmVi< zPj;lP27v-&{r*mFqK4>31>Uw^kEmAyV2(I*__Zlrj1_^nXFvQee7>UL8MgOE&W!$u z2cKk<_WNalEb-p(h89O6Sf)&|(Va`tGvj%TG1&wp+MWv7KXW$-eID;IT^+Su!d|0r!`%{hU znx1(3_M@BGMymsYnr~_9R!>ZxZ4SvMj9wB-RUx_Z_?<4?qq*yC9FFI-cnZn=t!jei zC`w>zjzBH&9Nw^K6^=c4!binN-mTO5#i2V$`Su~1m25Y@-RU0~?t$S7T_*^OGI;tA zS%R9)4|0jSq|S!itIY9E6a2fDJgIt0J;$`#FR?=)U?BRMPWV(Z83uzX>Jq+%SqK<{ zRQp;Tlm0}#ih3rp$3wF8H>FYI@}Cqh2~}xBUhD z=Z<=hi6>qN{uw)bv3-!Mm2>jo=xp7$pFzx6tr5NVY%T3JD6=nf#l|OrYa!&WOG~SM z>XkuEF6*Bsv^XYn?`|;Wt6&>EDh{+IGesL5V!Ai8^4nDE&g2UMk+V4(>`-20I{3*% zL!#4W-lQ&qqg^Rx^KGxbxbn1490|59I~;y_;1!W)45M>({YG^{hSlOAeBZ~yFrI=N zsSCUsbT4ldmdR*BgQ+t~PidJ*&B>@t<*tC#qvTH(=!eRyejJ)tfDI_+)WOZ@7_n%< z1r0}g+S3*m7aeOQn;6QfHQVRR@VB3FzoyTt67XFOHIrOA;qTXTI7;NZu2qN=8)PK_ zPbK|l0Adb7Ztg~SvF+iEs@G|%v^)AcZbr@0H_=`S1yenqG=}sytLV!=6r%uA(R&47 z*Bm>ecRIkPN0(Yw zDwli5DCeLU3Wd%j4QDd=J7*^kL(ELNBf_L?r9z1!S{U@6>|a}%bJXu(saxOGo-F1~ z_jAtrYE@G@jU1{;9n&xQP-#*mFN`x)--pm|w&Rb~@$X4(d}VO26(NgwRHK~sTInHH1KQy4apSktiLWX-&CIXjE?jC zGxu6^+)h=@a^2^|o#`&dea_IppTU-zZrCb}2Fv)=pjtf-g8#0wm<;fD_dqY$7L3-# zC=Hcr`;!f~q^9xc>NokIiH?dn3dGH3#&SM|XaGsa9x?2i<9_E35AGW0SVWMTEe}iN zhQh=aLM4-xScCE1P|;OjxF}r^6t|f7v00S%N0fKq0P_S&9)f%$0AnaVSVl>W7?--K z$bNmn5syAY?<=RCR)2=_uZc^+5mWT|0kJ2Q^X_E2SSo4X^cR&vOr@=DT#b=sS4%oZ zNVcdk9p4Ta&I*yJ0%efc9Py||Bn%6^k=5}I(;2HT9~$*Phda`z&7O!N#)Fw!EI!XS z{}>L{nc+c@U3iIos;GG&$eb4w5vf2%33~`m<=%tuOcZ4(7R@DxIaeeesg*((D2Mp7 z^Wei1f5tR3XE46PADii%2ZZI_T;VgeWOD$wBboE^ctsEVyT@W zHF!Fw)+VQUi4tT5d&&_DcRLG1AHmbJD2J6C!ZkS93gR!sOjvx_t9ru`5P^T5xEpP{ zVq?sAZs6l+49BLMv?2Ec*g77A!wwxYS)D-8YP0tQg-Q({xrGXQeXD&ER*fe2_hd0! zUyG3JoMiuHMgfIZeb9Wv7BNcEFWiy0tzID<>{ktkcf;S(iZ5(@EVI!!eUr@I<^xJp z>9A$g7Wcl6_8ZK|&Ft!kZrJdYd z+!$3Utq)8xzz_p`JyKKX0n;cM4? zvyo3L9q<%5DJL;e0_7$b$1(XU*M;y{&emDihJj3CR=YeB=(m8SJR;uJ@PN~9RORd^ zKj+#BXlp}EmS)|U=(NgogQVeP6BE{2$8G%uJeU1+JB~D`GSO+B!}|F8SHJVnh||v+ z%GulD&J3Jz)aoRYacl znZ!b#Bc62Q!J4Aj&$jg}pjzbHSY?@zTWEHfrI-2sRL|xSs!L*Lj`*E=!Ytg@h7*^P zIp>oH*Qt)Fe4ez)n7zgI(?n#9UAX62i~TH?|Fu&I!Uw5bXqaRXvR5~+D+a64^un@Z zrB;|<;E3M54MzHa3Q@xWi?U4(lp6ab1M7PFv`Ie?V|_;dMEJ;Cr&Fw!16Rz>u=+FW z*+^P&Ek}P^K^bcZ3Do;wtJZ4ja=%|)Ae3yqyh2dr#z2Dlz$2H9VLt)e-Szfm$4Jt8 zG`NI9CM^z-@G=~}`b~@#wALG+x?y7Y^N2 zHGRVThXubUE7^Y>lHMW3o8Bljf)4FTa)I%lq^bMnPLjhXe(5H=>v??t78IpCNZjMa zG2bKrQWJ4E5>9KO*+MhDdX@^i`?f`h)O*s-Aoitw`$9(5oTa-saJUd0A$p!&c&yNzZy0UJe0k<{>ne@V7lDVfS`&P@VMMk7!__m-5@ z`FK)V#vp?E`wz0BkbpQ>D?08@&Gou;QGPQZS=ZP8ypVwJxT}uEYS}1jqf>EeTy&Jt zXEe0uX+MIoWmH$2D6|&26)6)9g*=^Pm>;#*d(K7q3raTvVdW@=Cq}JyQru`$IFXEJ z31lqa$`H4gNZ|>#|Jhr>5piH5B$xY^v*M=Yw)Tz!1*mw6il*5;)G>w< zq>mt;J+}9X9ak6^3XCbVIyXBftb9PTobS28CuB$*94HfqfA;L5vhh)X+qOrXsc4NX z083uG#x}#gef#D<@?jCTo=3tm8~DMXzH7af0_hIPyY4Kj);?LOyUYR?QCU=L=B-kO zHYPAY4O+TjhN`jOg#Rm^gn6Knsi->bRW7yxxAM!bmCNazCnC9^ zy5foyvk^&3kqNNRIN0Zb(7NTRl^9U069sD8e5Y0e(;dPJ>bEJ~X6wq-=^LMrV5DZy z2lrzJZGbY4onzfhco5Pm;mQlKUjh*~4peJTF>wc!C0CiVtLCBNNDNRRl~4LAXl~46 zm!VdT!a1sN0rjLS6UNW%bG^h)o9g%vp`ZC;9YQyEQULDgnb&_&;9f=JP^OyN(7A{&T%`;Q2;yWJC-%Fu?p7l^&A zEXJg^(r2w2XxZ>>}oIH9Nu(>@L;)Si1^2<4(!29bOOcn0Nh%Ri6_@{2Ma=&~r*FGI+=d9R1b z(8nWEm1a3tILiRO{ITlQ;viJA&(o%+gV&yl?Ix45RAuQd2EFCv4WS3+Y_8<>Lm51A z1~`WimAzL#_*%AIu_--T~^<}fUdd5=EGY+SHSh7jp@3H-H zMf1?}Pz9dI7Z3DvWt{u#tnf-BuGhzrV33t#hAL*0=hqFTDgatz z(AoS*w8d&p#2l>{Mk52*!hRc%T#(Kj=%T7D$gNnZ**DC}A*}L*y&U_j_g4U`nr*yIXx(SRhl$ zlVu)jrN{|Yfj|HdKjNL6gGoRKFfIUHo?WM2z9AeFPXg>5zDBZtE6g>Y{U+g$>UPYM zlfjSQv^Z(}F=~5We~L4>U)en&6D)97;j`YQX=v!lRV9tW{>IlY9esvoh8~ zepada>$!Y>j;~*As!i_SlefQsGj8Cd4`OohIYQ3&avpE7ZBG#^ycH?_*clx6g5r3i zPtm+f*E7z^dPB=eCEzLrbnNaGuAkb4T$OF=S>vL@YqS=qKROPnZA9!u{R*)%GqDsoAi2e7(l&iExSHz6^L(~oD=7_Z# z2&i@1!iJ?B$~t4G4ANx-3jXYaz`b7V3-hg43vVYyqU|xNB1LpV@ zLj{`rL;%&SNSeW^dqynG$+TOaqOmlVFx$y9^vVZn@3nu*e6`~eetIiOi4qOfwF;f< z4+2W13HaY*W_x)+;tx|-&u&2?xOoe-5K^*7JbWdkZ&7um;U6&Xi=|LZE*bsj&lHW4 zM`8y?4>5b@-BZ$_is8p9=e@E&6gXUbPXg@U*ACoCbY7>4ZChx~)XSR8I|q>aE+nno=+Wljs(oLR%?^f7ET%y!PI&Nbk;{cx;fDaNYXCJ~!+X!8 zTjr44uM?jNhigHi1_s8qe(2D48lxk?rJuXoA7A;$o#+Gy@pdi_&eqGp4M=8pH*3R~ z((l6KNtx5T%VX7v3kXy3X%$EItt}<)5Mjwz-+&iQWDJy8FU;Z9XEz1yVKA5D75X4@ zO-b7D|57J)<Y3}^eu^8eks`NI zfm1Gk^WkbGBQ?d8)gG50OUnmpfGGW(c*Hb^sG!5O?{wM|F-}(NWV`jdv;WqHFA3?~ ztc1}NUfFDJ^h57=0cfn94Y0CkBz@X?9;tyQ0Y8h!El`sP=LyP~bU>*u)fIP@_&Z4W zAN#tLxiZ@PUZ#9LYTa~+5uXV6Av|8H+R51A>`B~{!3AZeTncexGknR%>qj|1SaLv| z(Wk9r_{C%(2iSx-hAQ>72Lk;mmrO&)@nW_>Y}n@?*WzjyJ~^6 z;pDklAG($Pms)#igBf0)iG7%tmZS9SqI@g%`cAAsZ}#=)gu}K_K~^F&b)l%)+VP52 zdrgX;Vbk_w?op@M{Qclj^|(eBDkSkU{<9-$u_G-49YR`RDy82=hO_d&IrTPuddWA9 z?bwrdraqP|#phCvJeC+;;6XQWz#5mwQL8Z{Ma^B81BRu}N6PPuRp9T7DomXwRB5bd zLouLac9Zi7rRj@P`Le3uk_eA5P0@Hyx62wwdBHh}z{J1turP^~Wr! zR&dbtc+GK@3Kn{Z!!LI(PAY}POyg-ZNuM;h?|0y~ty}^%ct_y6H(kB&KnA1nqSd9B zZbtZawc)ki0O+%WRZkc0CLpXDR+3;?j3nCPaeS=QV{t*p1@>bV#D395C1xg30&5o}x$5$0= zBXgQ~Ji2QZCKls`rV2$rz#oh@FwJH?Z( zAGWVMO*|;?Rm~pcQ;g#hjp%{#s2r=bMkgODa(y41<%16eO0z|d*mXbS&s%^gtti(PkC`$0x{ei*g>_=>6U-MTxr)2s2)Hs%XiBPmF&PMT{A~lG22R>PR%RFpK zWr||KJ(G0TIithTbEOLT)zy=W)jD$Id2Y?5OpJy@F@&w!77|);vxU8zn|L-hHVrIK zgqgn(J3C`VZN$6_>K$0Uo^L&$u7!E-Ok%3i`?h2>J@{VE>O2%mWbIf;9@-5ZknRMP z-vc=I3sY`n(JDEqTb+bMrp@ORU~NWWTc=*j8*yJUA9ivTvYqf`rW7P%v22i=tLg|J<}4putmRkr z`L{lMk@IqVrS}&el4pJDNh6tcW^7eGM z4SuQS0hi896)2R5=dvPX0fY^D3k55>$m6)XyBCF+nA-PFO~urkeMII)#D5jQ>xapW zj{62|u({E{qo+iHKgrxJj9yz?iy0<#B9fukK0Q@Ti&Yt=-#g}Y{~+z&aWP|_=Q<;~ zIsAobKn%&ykT1ErWb%6wTzIMCCZ(T&|V8C^UvsRz*d{NhjV@2oBC^B>)iH z$KE&%B=eCfl1!abkb4@{*7@rq;ki} zLToev&UiS#IOpiUbeIz%Dm4?|Kj#Tk(d|iCIP6W?@do>#<=7rPzKI>2-Jw+aR_)Fa66AJB%6k8e=@+B z!^6a4=lS~Pwfcj2b!^uxzCo*abLMjkag2-dj1B~NMxrfJ6`U{RT5YTt2{MwKXEY4b zo3w^mi^gfiRO3@HREJ9W@I?ayDX3*qn~~B1^<;PY4mXYoxUIe@9p zcqB5r7uL3~OLq6v7$Xt>)`n%9fyNx~$Fi~CFGUf$34QS~5Xe8ms!uttw|29Q`SHbC z3i8Zpm>kcS^{PjB_s91foDb79WLaFa%+a3u3V*pMRUR8gS2^rB5ST9vqs-Wg6A@D`A{ddvg_6%jm8%tj4v~WqK2umJ$y82z?a){ zzWua#!&2y$bs5#j$5zBvG+d8mc+{EETMSoMV}(f@QCGAqKvu8|+PO$JTmNRik$?x3 zW_U@pxJ#WcuMUiKBlPLJR$hpx9hZDC5@mOp3G#KbX2{jUQs#y&Mf*1z^8KEB%kzdp z3j#{^Q6J*NCV(ftiug?KM)={FVPespP7} zb9jH6rbN4i)Qa>>_vB~A5}n3`n-AVZ)oS0YKG9Np9^GA;a&dn%O~nyz(l`9A5s4(t z(e4-;ER5-POcYABS)YChcazo;`*bWmd5zck0;`F#)d#z^xm3%ZS;T*$ad={j0AAo= zbruvpm94J1tO*?uqjIEtCx>#0k_71hfqUd8M2nDx;LcvoeGD}4;%zzWp z(^KdEl-}?|2G{sxKm_CW#UKuZp<3qtl~!6?tyGpn)7!XXMzJ#G`~c2Dis-l=Sk#?q z&VO}94`z*=Yc~2t??j%^W3MmYrbv;QF0Ud~_Ljmx`?JA=C_BKR`zV(TVJHqg%Nn-*D?8$V^U$Q{*&A7Iv}CPYWa~gWHA~y*Sz9!F<9M%dm1DOwIZWV}MfrzHjU;BBOqUEQ#k>qaI3!iNX zZ>Q7@Z(SC|4SiNR)~~u4njdY{bdZ%5r-*`9a>(NsM3SO`xeEvgy2b10_UUefC2EDSsChQed)R6fwWQ@CRiS}`3^@MM zi#bD*iHVEG*)sKHcwGKMOc z_19jPl?02GNR^nn7?+D2Bt_Gu7?UwpZn zcOs%C@XcZyObHkt0sW%|sCOrea1=>_S1#=lJ1<>$m0v)Cr=|Ubf8PQ8o%4^?iUIBM z_uMZryxH6Lr7El+t0OJL+GAl^vuqAeg)VE>oqs2lSP;5=KJRq!?X=xY(kXmK&kU5A zNw(OTLK}~_Z>OiBG@iwpW;PC+$l}>$bo9(k3%%uu(ZxF3Wc+6pb;par;as+^Smpkm zxR)L*ly!2h8q-}){kEKSzRrUHx8{$M0=8-y)r2IfvDqO<)#6zcHpN#G_-l0aw#6hX-$Ij`m&^CYYx&tm#%OFwTbBoEkfOk2fSApnO!t`|XQ( zA|=X9?&Zymf<_!&sY0=cj!t&94j@mK*hf5rKro2U-Et?)u@)2k>G$>xd}LR~AvsRn zZiM56#N+dG**mF;{0c`pua`SexhF5{nMrI>O8=6qs)PN*`AK14iE84}q;l!3E;C8Q zybUpRmU(Psyw7CF=zOyJT9Ew7+DhX2edW<>6HFV+EWwT59ZPe0Q96?w-;V}Z7Q)D+ zYV)<~Wul)uEz~J-HW1bz~&{8JWq`AkrdFnggi@g{>G+;6pT99fjV8UjrS6jwi`b}djGaustQ1{;&LwX@|QQ1%=ID< zL=VFffF^+fHXK4#WS@5khJ+c}=9|j_EO`_f!Snj#B>XTH>N2$e;Xv4HeJvh+Y!hX8 zD*LDCJ`_LpoI;fQFPd{&uLyU^^gW9@*Zhb11>b=U*qwquUjv^31h>3F3OTjAIUVXC!-o|4?uf{K zR)eM%nC1H2=1d%4;rKJ;dbgqTdyJhp4P|(Uqbw|B;3Oiayy?a$Nu&ju;y>gnkzRCCCNzpg?85H7Rf zpCJV0Dln-kC?v+?hvy^y7@4BC2aMAH#-N7myPL3cw%Y99cq6OzIg_gKRvuZf5e|-` zp`Z2Ynx-jN`}Og8KBpfja z92IC)Xw*ReUHb1^{D0mC_$m*;Xa@j?KrMkD3QsM+b@z%0)_9@&&`G4}xg{MVLRqI| z`aK;M=V)dl4e_Y=K7%#|rPVbimhs*#3RK!as{0=3j>BPG9hYgnQ!=swU7Q;!?}E8=0-YLU$08IY~2N)*pQ@radcB znF~1dzx}LnBSP^g9S%P~0Ebg5d?P$ZGqiE{MGWTD}Rtm48rS z3_%29tJR>c5h!i*;3enq4@2jmxL z&MWgvg0PR7ENuuxU~2nru8ORq1#@(u11?D6HeTRY27Xkp$qpp)bPsVfj*$Gx2V*P| z{`y?R!0-KJ8_#rIM2GDwgpcvWjlA+8EjOnVJeu6U85B7gH*j$!UKl*=JkOqhgyB zWOZ(1fWF_|7ObgNO83Gdq14YmL!<%RM1i9!L_q#XrDGU;DYvGg0pb(ER}$^Lb(0_% zk15-*!@G7%XhA|kx&VEi(;tMPfnYBVj4$GX&hFQYIpn$8pt-F)K-_uDJgJ?M^K)>_R6_@I2(KbKj(he$MAGoN7{>6weBAU_FYluO1*-YzZ!=Goj_}$uriQNe$S= z;_)~_D5m2ze4pC~c=AC(L-+Od3GpP-$5}{QKkc+Ame+uVTd<`nOYnfV^!TTr3^3>| zGgx=rbmMENVZvtguXQGhy*NWzjlVby+G9DNq{Yc848-q6mT(Mbo)6M8ls|f>9c0Pu zr)oVlKJiI&-}DyP;XnAJ(=xWJdt|iI=B^c0VVC-Zw%v?PDNTyJ|HMcf zV_zGBeHkVJ=i_e0H-q09=)+?$mg|8x0PahCY{q}q71p)|=^u9|?p=FZ0RbLjgIT^A z&2F+Y`G9Yd!P6F_24HcE7$~Wf3oYlBpnR9|+U?)pZ%NH|Bh>;}?E{b|FPSJLGjV6t z=m-2PDSe3!cKZ7x(v5qMJn$~r#`rl-K98lWCXXC3%QaW^P(BDry0n`_zQaq@w@4L- z-%C;zD|1MkF}0~HHLCDTWIicfsci-zQq9tPcFQssr8Ch@;%Zx&BIhQ@zji}Yrs5RE zX7a@U0B=A>>q`*^fH4?PUkFC1CD41b8p}a<6WY+i(gx387mK+c9+>JXS|Bt{z!vI4 z;+jdf=6n>O$H59qxE>L9?8adKI3kgg=S;G;wsv)Ojp1^!PGov1e>EFqtP(rO(%7O^ zswvUMq);_1%!=n0mteU4-47Lo&5@_xl$eN8D3K^X`NZPA$dRs!j*kB7NPl3n`Lq5&~M{$rV@j8bbG^!`jY zq-CjUE590t{ND3D*;xgT-MZ_0d=_|+w$ zi8?jGA6Mn_yRSPbg zd#8JChL#Huj3o1Hp2{!XL;W*}Cf7Zu8Ha^SC4k(D=zKbq=T3;(JBgRiFAm*=xzXOh zgNMJ79njPrVa49f?8!(#!{bIds6fLrxH;pOb70&IAW-{-@kmHMig>T}4f4lsISjr} zOFO7x65673+tZ04RoR(ILKw0Y$&TwIY`~B*{L*2W@!=kt7reHthP0=4tbAV&lCt8@u+QgOm;JFCGYguwn$Mv68z&m{lnV{R7KNakGlH$$^P+WG0ok1pENIY2JgGM+8dbUn&nw2`-n5VbGmjW8eTq(U)j8#cDh&hcc{?}sLo zLc%wYyAjzZcr>91)bb#%+gCi~X>YKCf}=lgkAs%wo}A8}zWNmIZ#qO)Kb_3BN+gvW zZSHC}ueAsDLeV)gq2x#=LiQCaG|5^(@0(FBmIre*}!Kz{sn_*uIMw_`E%{h~u)KpP%1eY-ayR zrY$WhJd4C&3hMNFDJ$9u-$j2LHo#IT2)}Dv&{L`*Pu^gbbUX%L49OHYC==EO?&k@I zr!bjB9b?B=K@2loEY%W0q0zqXC8LOYO^~u4%@!X3^?Hv>;R{;9*L_;-@xDbaM<1~1 zq|H(JHVDf_$Oku1nb7g*UBq%#s4eX$pZp-Ct(^QVaE&b3d1{dz8D-7n=4Sj!tpH4; zOZXc~>12cSJ-Z}T<@q$y&$krDIc~#o&|*-7Lr$%uVYH1<+HUn&z3IRSZ2 z`I@16xQjt{TL<;hmD+;ge{p|!ofKH!xvkmjq=p{|bQ*;S!qTR{Y3u}X#0zsg$c=>Jcv>EUJut}c%GHy8%HVEBcF0qx$yqd z1Xt+eoVaI{3gP@_HWaFOaSG5^Apv8+sDy&(nZh5%tvV7NYjIrSh0$?-yY>^$LwMI? z)od7!>M>e2DJz(Xhqu!g``NRiWxBBxUK`Qf+xyG{aSR~3Ty@M1Q40s{vyN*XyM<@| z-fK14B4!OaS4~(_Eooc~eAf|5g=|5f;b~@+0FAg6Q7m#mTTEFiBlbXY(ep6s5(hZ| zZ=+wK50Uye)JcT{eNR^q+{@}uAfjBdP~RViXn+d_12v}uc4m|vI&60)d?K>8Tu=4Ix>q01k7 zPS`MM93H=q+QoQKLUpFI5H1J2&3Q2C>`CM8Q&&ffdf3ix+?oTYJ4ox+DJ)M}&u$CN zSiBi-+!Kii#?ib{sl()G&5g^3f2uj8aCuOEU12LSik=?J;z|Z86K8OYWwAtt3a%Er z5)g~wilMpte}iduK1*B4Yxhj((Os!GtI%pwwnBKV%;0i~`gptWDVv;u(UD*y;IVW$ zTj^h@)KI$jfvL9f9#geVOT_A_f}q)p>=1uLWVVqF+lTq_297MQI!E2NB5Z|(O#XZ# z=egZW#&^qPNL=|$QS#`R{Bq&%+Sp0~dc8{!U4~qAHoykb;oV0xyg56@-$nvudh8XT z6+Oaebaol@U5;Emm7!djee7tON-7ZXx!wEnQ*`tT2JbF1iSe80LwhYB9SoCk7yVS? zL)EtSE#y0oWB82erEE|=#1TtM+*K=M=)!uEonZMlqD9<;l{<&ijP)!(-bU(kmY-79 z0+UV{aLIQ$i`VHx5>6)5olu$p*PkREqxdeW!rABHEqEHe_EKLVHJl3+ilwKKEy4=r zHqclk$(1RSpP?XmPq73J%uFsR7yOMxtL%2JdEXZa=(1&`i*APen*-hVAyuLxOvk4x zC&SC&OjQ}zy+7XM^Qsyx==q@8QI$_g~$0bysQ5@ zn6`YGlE&|3sfm~f3}^^PujrT`egN2NDoOM8NF%oT5(ayk!D=nIt39Y^-L_`5udE$} zt+U!!dz=nj_eQffOFVDnLz`Q#OPO19fu(4|d`?AzmF;B@SZUt^YfsVLI$KrIh=hz$ z@)KHfQ%<)T-EY+=q|_){=~e~7C<@_t8uX%V3Ca&+|O2Jufk$P}R9 zro7V_0CKeWBq*gn*q>f1QqS#3J$ASaImp1&zv4Q~zjs`7ZBGkO^(e5QQ;_5Y&D^i; z`YMQ1I3?80Mo%vO^ z5+e}Hr`HROg=?11pf@Q^+EghrjEG`JZws0(qWFDqhfw357fMapIhv=;O_2!=i7Uq{hy0-(W6ISFj&2MRn@FH=krucmo5KYt*Rm45gB0USbkAIkMzHj z&@_2R`3emr@c4ch@P3IfKxNjHKL({DAU2=Sgl;O_cGr=+28P#Pq~NMe)8=52bK2=P zP>*|Y+}w;Jz&o*9WSG2XBQS#!&&=Rj0b@OVYb5t-u`^%<-AWLGl) zO+TvrmBv%6(PVwXuAdCesQ>+gocyi@#`*AjlGuX6nC5)BummPLsS_MSB%i(}=579; z`+Kj&N%{TV_ZjMDXZEp{W^=6O&d3s0Q{He-Eu}6|?jzTCq80P`zNN)j0$$t8;yy9) zy^or>9=-{tirs!*zV8I5FPWNe`joe`Gbr+>IE2woGDK}b>f$&|VUFV_d^M?4>zqA1 zr){yuW1nYhl)g%(G@B1r-QJAukNj@EmXta~2jTMkeuZTNb)&pD;c+nou-e--S&j$g zzvt@_?5$}C#S6q^kSLbaufoZ{AAFwFSs(U;Ih-pkCSiH)Wv}Y?sLl$L@U5?7qgE2+ z$B6ZwjMj8J&N`|`uT4+@*sA(k?@abQq^YW8lU^^qeiMnxR+bkd6QTLo)NEUk6(;3B z0gi zf+(X{Do_#m(_g9nKYRRaE5MK>2Uz7>D55`+VbC z7lK{a{PQfpeH{UoewU(rAhPGAE2FyK!su&6RDN_e_3@A*^hQaIK4lbDEMAz5rzpNs z(`c0x!A-nZ=E^e$#SwM6W(k2jr@b zDt8+Ipx5oX4jwMzm4jZl232)8EiyMcQ0@j^wiRv^|7%IE8XDo*;tOC^EQ3CKciYhHOJQ#qI;=jb8e^is556Y zKZi!M8wn(k^tmQONtS@J-G8)`zH0?LRjE~^8&snAQ?nvwo^0w^rB4ksuF2U}mk<%F zhV)MSGEQDMR+z^R-x@t$ct`&z)nM4JC;xpzFNDVbSD2u!Y!!69h-O>ANtl>`%&c&s z+JiAM7q0CmXR`aS_LXE`v18WKg>JR3JwT1P#hIsH&v!k}4kbdfD2Ms);MIq)c2C2C z5(v%ZYaP^EnW{7b{`qw>iBJa7{ApcI&{AQU(=;gKH8(wy{d>A;-9iqWs$_k^M@M*X z_)_X86Oj=#`OGC!hP0*72FT!J56av0EqI~+Mo+_h>O=nqZpvn0Ue(^xqa4_F=(s^^ ze0x*D<;jiCBY{S{Gr(M~j_2WiC-r${lo3$IT{Q%#v?kTvpfPwur*f2d@Q{A1NX4Mf zf9ST;0386-nnbWPs}J}ML?V@_9d9~JegJs+5Jl)~(Omy9OLS(4eztvRW5qO^S6VI4h9rP{nds|JD*8`jLY@b5ZSX^6z zmSV)=!hXt~1(RIyQ#`3-0L=oM^TzLGx^Ld5@0Vv5oVRuu{eyP0BKuB>G^E|b>6$t*pbLgbpWcy8PVKg{_O8U(R zDSkhrw_ey6^Pc*hG_bw*72Rp*d@s-eBtCg48msVG`OS|%e&3#=g@L1fr7TiX-Vb{B z30az(xSe!YYOn9$kAUcMT=?z%VE??7MQS-X2s`P1s;u@=Bp@=`k{)iV{*OcUWd;ow z^Q7g0u-AK_*RgBL$~V#?p=a(7t68SMZu!g|Zv@7nMZ_;2X%9|Tf?t1l^jkV27U1o_>ujkWhDa~DAOBAA4&Ugc9 z+G4c~1Ay|{$3u>mw<1yp4Zj>SnR5$EFO6G=#g>DYB=U)_0aAIy6usy9N6okg?M?8J!KLsi=Ij9kh%QT#T#mERjg;C|~R%O|cSPu&y2E)$}Bo zbE{XQ54uP(4zY&J=B3Wjm-`oh1)iK6+uv+r>8vq>G(KEn;~?B&fXrr^K#g1gSc zwTS`QY?E{K=2I%$zJZiYPCArHPA}(uKT*lykzcl$qeV8Z4;ORovRS-z<}&Y`z8ko` z1Js)%i=3)0PkeGEc`DC!(q@xQiH=#E6dAQ-wWPA0i*b1Ey<6rbKPYtT)}v(qoPN5>ytg@YKR*BVJuF?0VYzH`NvCA_IGUzT z(WvyL%Y|!X9kj9pKH?x!QqOTXE+YO#@^y_QfzIaV)+>3`?_ek8hbJi&v7d9o_5gNQjBY zWGbFFth+pQAOQil#~t94(?rJ5^Wj5^3en`?m@9sU4%S?X?P4ij&HPN@;ywv%7@1f0 z<$(kr*{}wjuOJmonL4_IgaejlIz>d}5E- z-juc>bMrLap>YlW;qBTJLsBsSiobq7Jv=mO^#HrG`}mOGBHa%8yFcQ{FUT1cUXhKh8Dbjy5G$ak-ysP7I*z@JSiMXfHBOrD zHej3b9x(6n{6w3Xcd|1=AjTa#!1fWhCyUPqxwc2j2o*Gy=ZnGo(|R?g-%bfJi29a> zMz_s5A!$_UpPuDqTs%CyM)EU>N{jw~szT+J5dJ(t6YW+D6*z^aKj*Ckr4%)Cd#fYY zViWdlye_Yign`sK4UMFLLAwp_@Rj{@mFl?c4DPxY?0;`h!ALCWMT*{(EQ@w+H5R+% zyRG>>caY3!2*hk6jeR_wGx~fZQ7 z_yOyr1?s^oB}#ieC4L+p1z#fHJoA}UK~Nnedps@ByEIFe=so!}_Dmg?wyq=dp8$R* z8rrEZ=cf%5YtgKxMc20{3cIbbs9?+y`wTO=wSg{YO?I3$L}LxNK3z*hAx5ySc!gfy z!I9x&$a!a?GqeCTw{fjd?P4rde7)B*vW5>X@qg?GonYHyMq_=HGWT-BqPYjaL@pS# z7lK+o81C|=>L-t~W|TCZP(Qbe9}#TUreeavIn?f;cj;k|mYXglWV(lk)e~?tGpPqy z^E7Zy_Stk^I&1wWz5!#3^(S`{T+eKavhjx-k^QqDh*+DkCzvM3+fv(`)^Nm)5-Oh= zp^&=e+OZR=Uep7_*Q91%EdUfN*`}gGhc5_!wx(IwRvz>YX$y*aaLrvC;-6Bf zU*Babsn~ZoZaG#>mBUl;j3_x~z1fNR!%d>*n5x^cHyFxOD%yWBAKU&Rq{t}YHDb3G zS69~u&-`gmj(YU8Cz<3Ahp8pdj)kKYFihj5*VhFEMP}!x2U@*i)qB>lbLUyV=h&ON zC65LS(`h#~OyFN;2A}h*xmpkH%x#P)SF=Y-7xz8)NV*b%L!urLDdB<6blh|v6}FeXj%t4Xd!#s?POnC^N085Km0pL=yJg1!(L42L9?4B z7~`ChmR9F+Z3YSdIi0KsEy$u%D+LUMW0fbPzEtjvB}exKBbC1e#gR*6Hi1^|#(w2( zgpwhwt*)wk7k19*zDhXrceNin%v?tGORzl~D4$B8P9^A5LD8Pr9X3M+{vwF=k8{g|9-T??gCgYo&XZ4Cq~>E;PLBaa!o z{uEbKpA%(rH#V@6Crl}9w~e{)oKHHq5eh2Q?HcyaQegc{I{QRfZNZF+6{-0p}3fD5dhW2Y_ZAqe9}XnbGR-|TvivG zPHgCvUY5oqL&vL<>h=;KdH6rR68TG`kK*CG0$CrC|heSk?zbnh~julg2 z=lAMMgfIO=r(dxaqZOc00GsTy!@{{VG}sYV{;W$tz@ph)Z0HOPPbTmYTK^0cQ&Au6 zbO4-F+QoS1^1~FQM{pt=FlF=zP@(sdaVafO8m#bB{ba*k$5gq6$Z+Bei^|c};4-bJ zOfWXUm4fxDN=s-8=E7`4>aIgt1aWM%AW7iQk*b@DA!F)Q{VS!CYNdZ_7gBTehSF!A zE{De#*_T~sB|Ex~pG>o41v~p)2nqJdg zzQ_$=We{~JS1}?7Dp8KFdlP~`Ys=ZD2yW}>>FCa8-qoLm{%I?Z<^ElB(r?}%ePf_< zE%A#aROPXBC6`@Q#@pS|h~V0M${4cw?4GJp;1V4)!W15cK$&iu@lYWfN|H6?O!bC>FQA`$YXRBAUno~?36 zM8vJFiN<_Npx4F(gTc1z9if?-1ovla`L=6qN3AoY$s?EdU;iB%OSa4IzP^p8)L-`< zIK4Fow6mR0aXIB&K48Mad^7?S$E zk~faiPA?3DR(w-fOoQjXn`(@@>oHDBKlr&>&&YRk6Y2SqpL41HkVYGNR@utlv5k%! zaqqqG*gOsphuKyClQs|H7sq$GZerdPE=wLq579*-tK0X>ZJ_EDoe)<;*eqC-blpaC zYQp5&hb5*RkK=mYk;|K8rx4=>WU)^#((1ga%S6wTY9<(L@Z!Ths^+Zc6)ba#>G-f`oF&jT5=*W- za%;h@OSf{7?X=3MksZ!qFj?aNzHI8rlBbC2cg9fUU0z!u;6w0y zJfz84M!weMZV)H#!MYH|?LD1M{L>r^H`}mpmW88YG`?rr5XnOIFC+5u4-TGIu6 zoBwGyiXdAA!tcOebTucjo6k*GSlb|K82z|lz~c}YaCFbMx9or&LFo)bteM1}IiF`# z{_LbI+r_)CAp3c(b3~U2k!8U`@OGHe-w+lTG7*@x!Eej+6kpW@i-Gv!(BXwxYFY7e z%3dWfSCF8JRJH@@e@&uCBIg|6=fOJdiXR;hnI^ zhvs3C7tXSzWJ!@2=(Q&r``ZBQ%8E`qxJisFgR%bChnn3mV&5=|t;U#b)&=msp$VK- z>W%{zhdXDzS}f`_KMPrwu9f2{nyURkQg7-jyEZyAu^Q^_^x5(`P%uyczwLQM^t!4yivw{|KW!rnJlZ^Xto=vK{`v}hj^o4qUcGa-@W|O%XPtZ}L=% z`9E=LjNF0h?&zs z$w=rc82a*;5J`3pVRQbvy?CRD%fUH1ZqSL?a%O!$_HpK2&^4Jlv5aXyD#8ZD>EK}v zb{v%cN&V1LN$=viuvIcUh3rUu_VUK&?BB9thBZlh1U$i^Xdj9=YD_sdnrN0^xma6? z?ckS-F`pN!lB2<}%m5bZw++WhDW5Ak{YLxl{4{wLgpu-4M-M({C>&pRO~AiOdc&GB zXsW`mblo*h+Gh6b!k26=gSjxRI?(W8q+>jxPX^u2DXREG_T0@O&%M)1!SG>c^?*!^3(_2Gnns@m4rtl4q+RGl@?L(_4W z3OJX$;{F47?&~K%Y=vPAFZZ`lZOU^8li!vL2y3I`d(zlShNzi!NO}5~%n{YB!5*h- zHJ-zmu9IBDGrQ)k4Skrw+io8Aw_h30ItE`)v0z^Prlkv|gH8^Il}SFs(n2{)4`L|@ zgOuhNs!9z*pyqa+img@_%>=DNxvpwO+d`fz(8QGKmqwb>X|%Ci_)IOav?8Nw zrBEv%u00S(Xkm8*GLA4t$WD^LcPmBAnBi~df&O6W34}+N{B%A0%Hz_m`h1xwRXI+j z&{<`T>vFEksb9xUSwASp(gF;Bp0ciL#v_0=Z%`~y`R3AtmEH`i-aS? zuwl6kt?v`T`&Acu!s5Apr*_NhgoG8GQaToYsPUAtWCr5R%xwqkQG!lVR`<_iFLH zBFUBno>I8@5-Svtshv{quceYMd5${pFGO!qSW3iG6quAWqhhuCadJcsr%(_i76r58 za?(IghvqfMpE@%hy5rAiyNr1T7Ap>%(^tV0)a{R!>akot23k{Mw3aoQuZH#MwECn# zb;-HsuEBlf_nTBf{m5TX1LSkQ+4@j^QSnmJR-#anY8kql;%+^IDTf1@>74#{p5PBa zQ7x*i8MAVot|Qq~VzzA?I3CPdI$ zBk(U1YuREfw#tUWm8*)Xp7csdfdm(9vO~&5I9dZvGsZs8Uj|AHICj^mvKKUGXFzf* zM1|WCY6aABx{cM**_pysApmO|g%~6?|FZXo^%VpPzFF2Bp|v~&91Y4|9+9ywP-lz1 zl@2;MePrTtaYiV&Qr5M6R&j5t=1}^2Z$kA~?yyAZp;ohPWfp1xkX6}|j%NR@&~^}I zW{?S_r9_^C(dsJ4S}|%aWI@!k;g88JjX@e;l+i4oP4(9~)77=_?^bigGoF{W0Ew;Y zH-PcabD+W?E|q3Wxc|2W+5Mg7F592E%tq)IyKV_LiB9MP2!}yVuFM&8^U-zcD^@B8 ztW<)EEG=MTduieJr0z9BQIC}lk0VbnvDZZ54S$Lj%i&_N$o|oUsVVCOb_L9td)~B< z4aw+#+kT&E6I^wA8Y-6Ca_Uf$d3|O14>r_O{o~tP5O5mDYd0E-nr2gU0A@L4q?ZG} zWPGtO)~fq{TZR#~C+4m*O;MbRu?yKI{u;;H^T5}E#X@1q1qD(a_A~J_g$GpTcwpgU z)ul_(@Cg*sNb?^0D_5#xEO!e80fz*^m>%@U3Zi|1<@-?%yG4}Z7-fobhkHfL)k2z` z=c{cE@!MFs(^Q7PR4o=G(F4>bmC(luLSIgmvqUlEI^O@t)|gS$nMh_>D_y$sdY32W z%d9|JL`!{<^t#@{glWHVI|Xd${kX4QzUE#E8O4O;6UnQo16|&~d`D1XAixPMBW_h9 z%c)G1!Bv1;-!FSL_lu-4Mv1q7`C4l&kBD%sUMv|;p(wR|1S?Tl0oV5eu~;o&b_tV8 zB|!J;a*L=ub~Akb9nxWz#Ac%sO%upUb?%p?(|Yi;+tqMXU80S-b;~>a`-6M zY>t0}sfb-~IO!|6wQeP=IeNo5jS@{YEwLDq5`>_)7|*>wRR1 z=I5NFvj|=LVvf?bBYLG$Oomu}ETH`BQ|YaP=R@q@E`IIE;e*m(9PVAF=xivYZm84b z9kj?PfPdDZrrkTei1fAU6Ra5G!+fb;Oh@aia;KC}Bl#x~y=+!%OMZ2+>~WIpOw{IX zVNj5GKy4FGBhA!-P~+k9I>NP-2V|ioc2qF=j9{EfkL(*JyND;Hm|2e>EIPfG$}L!U z4qvh-UpAd1mfOkfR_QP8@I1|GE!=s6>&0K66p7R~2J3qUS`HM+VIV)ASCq4kua<(X zvwU(go?^%nM}|gn_-lRS@=Vm~nxJq*SR%WP%|@Mc5)4{YW*iIb<-j9DMUC`x^``n` zu@>{6C)6v=x`W!qT(`KG@U@T2byodMLE}q(V;9li-k&S99Z-?{!x}8~6hJS^4~|Z@ zoZ|Ri!Jz~A-%oKRcW*A8ZlOhiOFlj7yf+_$+~~h3-QpJoXjb)K=dMw?GJ5D|JHb15 zy!VwiIy#LXzI{EK)(&5!q$Aa2RVXUG5G|FMF@ABXGn+1k+y8>avHLE&-(B8yfNm+V z9Y-w7+xTs<&^5~-MU}R*jb1Hz9N) zJE#3d{8JK)P{U*&=s^O-6gZWXH4evWkd&9rv7k##li7JF0zFf)(H5#n?^NEkY26-% z(ig;JJS9ycRqRs1b@)qY0F#X|#hKD0W0L7{F*rkuGu0MTY$QpVdM}7^dvy_}A+0WS zY-;^-XBDo8@q2Mtk}nJBN;qpeSQoK zY9^Pv6HSPS`Nf|enN${7N=nL#ii&yZzw#Zs!5X+eN;Zn}YX{lXlBST&05$ccBVWo3J<{k!Q2!@0T7V$*oX z9x#d{|FDpdUy~K=)TWh=YVa)3hNRo)pbf4fXg0J7R~vVj&YAyNdP8+#u3Gv6Q8TOP z2(J!8p{TPSKb;Ge%OpuWbK<&YH+i%;X8f;)J=7z{uK!8~KnF51KQ3IC4vwwl>77Ul zlLIz^H6-tT{l1`_H8z#NDS)m(HD>*KP`PghE%@_7kyiPKh;+6rA&|8~{yu|VF^6$~ zFLA=RNa};6!8|qB9fm1)=vk;~<_I38m5ISts@FM}x2*c?SBfij$f0xhdv3-Ok(+21 z84#ou9C}NBOIFHi-OZ(^S~k1Je}I~V%TZ@?x%$7kQ%SFnu!`+3i|7ztUT({#eMR|M zM$c+nyqyLs_(w6?%keeY6N*lg?e+7K`OOduy&h8JrqKvnhi4@8V|q1>FV=1+aM+g9 zpxJ?x^*nYoP?RHNJ*%E~f2Q(~DXOKga5)5p?F(4-4*1pc>I+sY+~GG&iXz=On3SmN zBjpZzhcpK7f~G)J;3@~kUMaPlx#C^;92faOeVBF z2Rh|X&S9NBd=@>evC3HZ2LzJs@XnjWTd$@d{XCzSra4c@%g>``dOb?0LWSnS_bGq= z2`WR(4t$({9Kz?>3@8WhnDCXr$m7fwQ)oBYROqxSu?uF*r+-F7-1XHekWG(;(yC?2 zZ{8BWD%xC*S8F}lt@R$k!5Mt7>)9n7}@j;uw276gp}a1MzzM}54aWR-d4@#CvtS#-`6cocHMQb-D*Y)BQl@ zs?9B;*?)yU||9I8D-3|l~6{}$9ZNPCDsPr zZafF9Kf(BovsXGz?O*-!KrQn!4PH90yyBGS=Y&X{8Y*Bs}pCJCEvXya^PJbkiP zAIhdlr0?)+UnpRI=~Z>SUwmk;fmcCOKgDrllhv-Vzb31Y$*M6`;XTsSnzMbN!M{Cb zGCQ^%RF~4K%tfgXedYE7Dy$+A1XXNK94! zMZgwA3%W*I_R_m9v0O-xOOwB~-8Kxs*W})9Dq`}CTam9b%Id0&IWQiq;)jT2y489c zFRCBtLYwV2>cIE5P^euvNXFw}qnZ_N6!ZqK^wa#Vm$bukzb7LU5wfrm?z~0@=exBm zU9rLNznM!A5^-JTc^L}g}C<|;62e6|a#b8&J>N@yp z?;Ek5x!(e75f6~J9L1c<;PR&(`q_I--fRo_lb_8{G(e+7ob7;6*$eY{b;Hq2*p6xu z6KI4n8o$WpGtnkI7eI0E#P~n>QT%MV)YOdtw7mHriuHd922Zf`%*9UR|ML1!80nbQ zcbK(%-DKKQ$hFhZ%36iYo9wVcAaok&mk<^mJ$2qb$^U=hAWwzE;-jK%)lxp;DjQ!Z zk?(=uSAEWYnLTwR(5R!&wIGS$`g#d$IX{1A?1qcykwzI!8k6SJy@7tq{n~AUtajL( zOaM~h7$&6?NeB-;Jw1d~eO4(h`eG6FA+WgF?sAD8*`IEpL;>Is6~3d7gFA?C|Kw3~ zKqUO%ymX9?pIEleY7PHE4qdbR`wd#pvX+H~wNinN?I?s+?9r2)c_K5`Ze7S3uLXmE zfZnz8IPc9BJNHBGYkC{Bre}V>$y>J0=VDzl*SN8UMX>kWP!KvvfJlooc#JbrDiFwH>rj=yjM;Hr0(r9Q5fO{x3=o1<}Y9VwL>F zMiNa>=$?Y1;I-`+?*z6G11Qn#Cw2)uAQh4l`-^IX;?be@4+@~sNs;{J9`5QA*YpMZ zwgyUgui<`$$=jSN#q|b$8`6_P{8PgPfDsB4f%jU{1CIu^0#gmRlMNG#YTVYDRi~-s z8+$)#CW+Picu)}G%K3M>s6b0T9Z*;d5a8RryCSgn;^hE9a5A&}dk2%Gluvj_E z2KER@Qh(11w0Rf;gN}JS?q!G?>de+x;$BI%i!)5{WQ3P-g}N>1}8} z^P|cbjnTo+7EeVm$J?SFw0G6-k=4*5CE?X1p9Hqb&&2Uo1$(3G(P8S5eoAK*lEhS( zQbg>Vg&-=&O6f3n$$p)j4IOnyJVS_$2JY`#W&bKFO*ewXAWyK8LO)#VD@x~$zTU@| zCqNtPt#Q75+KCNd+=ZEc5>%08(yqf=Y$&=7f!)5nn)SnyOWw?^-+C|^DOhZOh z{xzcdXWIkePf&G-ZmY7}O=WY9a#8j4oBKO#k$-9y3=$hYF!Ip#b5obE7;k;E&-rXMo zSzS~OjWL=DLh8!?yR7MP0BxSzW?}b-9kfFkrC4rd+(z<%og}l(w9aqk9D4a~$u#pN zarz)cArWQZqX7LbA|sRDe#Ha_uUrDS<8Ue)=Kf zC^LFcec9pg&8v*8=OOunI@T;WA2Xd3K~)S+%FLY`aA`^!)Kvh%E4fiR1zYCBnJhyshUR@!t_|9|Dha>@%z>Azdi&@?!cC~jK- z@$B@gUH|}Uq97tiBtg`jg|=I0=0>9iO#|PX08f>c2MPPL_lz4~=j9?LwO+A3sa`TA z?p0%h&hCHAPLoIIONn582;}`7v{>Bddmr-V@-qWiuBBXOzrq&S?K4 zZl5v#E{5Cb@GI?tzVY^Cx|K9`YkfdL#Pih|?e@|5-uTm4ndR6Sdy2OgnaI<;$raZz z6?6pU1+oCYqQ6qVy!f{`y%U@Zc$U%|nn>75;F5apT$Nnf^{IFka7tEYg$*~Kzh$() zd}^LjgtZ_o-=a&KVUzqQMmZ%=aQrX9xQ@FP6iGrnP{oTi5kB~=!?tc{;euUzOtTAsy-_XB)@f^zaEI-CzSH7EO%@&FF zJy!|6A^I@dtd<0PNx;>~o%902?@_*E4-0hrVzh{`6@L*P$=GAvwp4BwoBFTZUyaLrU?tt zDtyI{7NL>`f)Zi8$?CpMg&99s907Vdf{ST^BSvv>@h1Z%D`0Y0eUWTu!0HCqKV!44 zBPKR7MP3*d9A=F2Fv5FJwsxToPp-shdg+!~Rcs=h6*=mW!YMS#ob)Q`U3i%fm){ld z;z*U#lmTwyGPC=+O8bFyhnipF_q0P>2|zUC=~{WdyU0U*rNjgK#wXor=|!?vVqU{z z0*($s>QMZ4f9uwzoGH zh=y>iX44*waS@T}*jdSk+!qg)yxiPh#pd(Q_~hZH`AUzg^GsvVvs$Dhs+j#pZr_Ir zGn)#ej0MLAO*MRMxVG;RiX7t|4-UwuIN0shJ($c#G$(aDE1Cin3v#F!qql zr|*|6nrCp^p9B4ooORY5nHj_S&D%<1r|wp~QHCXjQz-f$<(z%_kKuFXV+vcL_EV$p znd@WoVMM?A?Ej(7mXdxpE=CtVP3p`WKcL6wZwc9ZvrcUofb~t~^TQ66DNCcTVQcBl z-Oh&iiT+xd`KU9sn6T$j;J_|?xj%R_$d>BrPq&ur^l&4D*(BQ+sJOtUeNbS9a}M@q zkzHZjmwj}w;cd!pRm;}wd`g=oRUrL;YUQH%s*)qxuiKd~OmN#O_(pfb!Kpfz^yTgM z#*pw5g$#ec65|}zC81%TwYEynZS=DVN5{E?!abq?Y3IY?dcRbqR8#=c+WIMyQ4Vb ziI3}MrfeqDC@79>YJzJAwUyfBHYmdv{`)WTXOH)yv$F17iG4q3ISJ9MW>EFV&(XZ4 zfZ*)pi;UHE{F8*_CZs2aJ|Emd2$X~oSFYNV8;|BQwiFa_Y;?%G4mBPxOT^Lj@^C); zR4r?5s7b>Arkx(w)y?6vasO*k95?lD^YkEnHBC>8eW`T|LSluHC3#0cv}EfMH~F}H zZF4|S6-gU$B#CP-stOepUMhlskLE zKTHbekjvzDu)%C(p=~~R4soK?Gu9f5Lp?;h_eoILafD|0{1Zrd&=uV-f%E#kU-W&u z@t~@JD1ZNt^=1=FuZfPiZU@u96!XPjFYvbgp;cs{<2-PNc#uwt2Wp`B8%^d$E0qD_ zvI?m;dE^fzrszr?nlH}d33H24#SdC>(U{jG*;pYa|5k91XYwb0IK`W*8?rE)${bt0 zFrCCVn@St(&plP{Kt}z7ntr=-lJNbHILBEFbgaix`x9%W;d;H{s@_1e!`Q7?LbfS1 zVZlWmIqVwT-H>R(*lziM_M7#Lz1Fy88Zyd{#1fX5VleY@YhEU8#O==Ixy$2138|#0 z81=l(miqnic~G{7gMjdal@I!3?w?&?U`%!D-FhZB6PHoNH(^pO=PF=atkG4peFT(f z%X+r&SZ#VgH12K~y(Nev94IChvgUt3X?6ERgLJ?u<3ZQraqJaAcDtvgC+LDskCzzY zpywCU`G2UR$n2 zNkB|MQ7E%Gu8d?bSNEJZUh)v(Ky>8SvOd;dm~uz@sx z*yu``RA;!~Oe8=nB=f=&!r3f)7)-9d0oS}(8HAp3xiTJC?+->aG-}k5zmDqt6ky{v-pS$?X@|&zHZ&-14Z!%m9v-mpB3+RjgEHM$n^^cZ!)|;yyqoSC5=Pd z-{R`2rBCuW4M zNU{GBCv6l)7bN%2JgVf8*?uK&^Z5HF?|dy5+Sw1?4usU2E1Gx_otv+ZcOKkt^m3`P z`u`(`$YQ(`KYEkRli8)p^7c}cIsO=5SuQ%(T0lyzJ$cG!pB}$YI8*0fiMvQ!)f80Y zu_zmr;aKE+Ss{a~DGx&2Y;P9O{d|^VGE*UgL%<>*c2dN=Ft9R}$#@1oTNJglO~F^4 zvF_+IrdoCG_OE;^Lug!Mn9)olk14(MOVXd|DXmFKV}{CA`$(fe*10B4%|`ZsoFCk@ z96E(wr5P#eqvcH$2>RWEZ8sZoRT+mGOqHR_xWbNH=GooO=Hm_dWmB~K&HZe~xRCvW z2R!Y`S2@&GN4dRzwt9G*68DJW@}nzK|Co1_wmqB3v85p$oGk6u4BmTr!ax6xIO%kG z!L|==46nWaxO<0)a5|2)j{DE7{2A?XJxYRX+O)$@<$CR&s_@>1yjum?PGlSNUrjH2 zf3K=-%&704i0~^uP%J^qHmB-7Urc2IA8p$Ea2+9n4j9X8s&dj% z#&tWcacj3T-StR$tt6SdK(!ni>gPj%=Q9wnNyyXPODlTJFAY7lYN!Q7$`qb3pu{S| zY?U-;+!vkXM4YF-=aU`(`8(Bld~&PTK-AEN&B}%DcJ{%GeKt(<#AtfXWdfJ>Lw>d_S(6C>3PH8MW=&wc@J~#Rec_ScI11|RobS64UD7a18j$0~y?gb3PPTMNM2D$w6y6Ql9AsUb zW>(udFddedrpJSWluz~3Za`e2Hp8v{)?fsjZlaZR2IwG%W?(Ka5qGk#c^kGf+ZJ_N2xEwkYE-OR_ z%L6VqjU})iFAfeYm>c9L+&_nzu)rQSEgRNP$br6+CjMgRY*Q&RACj_?z7oc@8(q$$ ziWk@D$E89g``F;5+@N3u;9k07%aA9qpGwlsI;7H|LOWZuNohOa5nu35X>(-6BI@{K z@}ALx&)s|K9;Hy0*-a*<MdK=U>~^wFf?xB*#vw}$_(0x8o1(gdHk1YLqB_TOF~SZm$@dHf zd~QeWPK7H$PazVim+*jj5^65g2#w_W6b|E{@hTAIp>A?T zZf=tnIC!qCXg#V)$U~H4&OwXMde9W(p%= z&E_t$$gOsaMUs9ym^J0DmcGq%TT>~x>h4>R{CFsE{DYH-f48Uc<4NlqNKp9#|ybLhCo7~N5M zWoHUG+JsizrRc9;pto5T^i^c^19f2$trk`NGOF8)_X{`3DU`XNDC!!jz0NMFs_>SgZ6Fn>h0gA6o#B}rPT(cUs4?_~2v zt=HjPtXn;CgWIMJLLpN}w{vB#>4L??+?47B*myGZ)hydYoe{_p?*}$itHmz!FK%kN z-~yv%it?@+I4XFW*L*1KKy43zo-UZ4P3>&`6IB z)jH9vyV;AKTy)tQ8@K0Sxl||i<~i@g)pEIIokZ^ucR9?6OwTWbxfpHa8^an8TPG9C z=As-;9K}?%U^~O&xoW^v9t7sI;~lu5WUn0CVBCW5o%1)NteexsMQN=@bLAYnW7@1o z4a5XCQ8f(?Jh#HR*h+2-a+unWHI?eJQkabL@s@7Xe6F0s5W-cAd%qqyu!z%Ju_(6#8g49FY`;oA=eJ zX@n<3|3AQI??ZO?Q;Da(m|5!thMylg!ilDAVjV;7%cRr7%1}1LM^~z7f+adz|JvGI zPq|eT=uS`E==E+Rs5dj1b3LZa0>`mfRlo$JT0^D&OE^41L=35R%!9=C+5gAVSBAyW zHqAZ>2_ysw!QI{6AwY0A1kwiCq0o-|bQCsbcz$pu_y_ z7(gd{Ai({t$cCvr0uEc1m-O*r%nK@wTwq zVOP#B(ZoORZd{<+xL@co1#ckSbx);XhN8rRy#eKod(7mx(qF|!V>boRgD6$rr~dN7 z{74(1VoZB*B-$QUIAfm=Hyi$yDuQ+@RSba30B?t8o2Lw82qD#YXR+MKpR8Hzxhk`~ z4-vkcC5SiJ?7umd)!iQpzsLP0{BhyG`ckIk^G9#3jOT91k+(Al+Nh-5tj67&uL`8R zcmUKC6>qRvZ1TFHG47Ab1?Hh_mQz8xt!^($ITByv06XQWd~xJikNl|x1>o^lD@^e{ z|LgDd88`#)Bmd7D=M~FwU$dZ1zH?oOw|4CKYFIQH16rcXLP^2n@9lXoxab2{?Ftpj z7P&1ix6gYO8!os6S0BnNQk(n&e-z~bY$T=z9sM7bRq7`GDlDP^lVCPSov?t^vNwyx zxI=jq?0W;$Di|ZX=x@_^WWLX8J7$4Bw%UiH+LD5ts1fz>%s)sPd}gL6%=E#z|1MVZ zWo$sDD_URLd8O$XHnKRV(8)dZJJ_FZr*SRARKgX(>f9od3)Tyg`H@n1Y(kT^!ytW! zlr$5H}AP;MK?xuvrsFlAB`+9dJ9 z=p&r0r7{F6;m@R=*L08W*OS@DKEU^b|88&p$mDTVaYZ3eg$;-&S2d34#T-)q#vl3Z z-zBfWC7p2pD&-&JdFz4un%7TXfgg#HT+=BrBv$Zq49rc`y8L&mjmcu!YXFNxFqBB% z+62*#j^ma4%@zD5HyZ`**_v~1;XQdZG!n7-Qa?b!j>{VmGo|r>F1i`HHzccL*S(*O zUuw{_9el5W;1lbs;hxFPgXqUfO~OX_hVXG2WlD4UQNM^lop!`r5L`xB>W)P z8fbtur5I^{rP*19Gw57`bHS)DVzO9~w4VHRRLdn~ttX!_8{)O&tuad@^W9+P2=aX` z%4FOsW7|Kkz-UVjZmsRgWY1T;UXCx4uYX9I zIzaAyX4oCiu6jj7kp!)@x+A;a?Sn49e4zGUaH;yMFZMsk?OwUJ#9R>zzHObyd2a)k z&-AfiL^Y8`v^HJ}_5F&#MglSG!6uroRMs;s{T@Krad3%x4A6$h11LPfYwe&i`pE>1 zieGAWO(8v*oHAHuLa%MuvvXg?$IVBo|n6QzBmPA0Ol8x`wdb#-f4So%hCKyL@20VVa%CJ}(D0Hi5>#M6Sd2 zc%n5%Yg19B^fbQ&tOp~5&gu8?&YFMUo$HpW4~f@HJ*ZrXIC|cI6_sNR6l=fww2I;B zOXPm)KT0R0=qIjNBH8-;_fHfytBPNtbEVJIZK(?J6mv9Ux~*H2->un-!k2pT@|~4} z#ZX7rr?CvlXeK6!Ed1_-yqye}N=bf*ms{x%@V9C>>a9o%?i3~^y%FxN>}~r)O|rYI z?h$p2++5*LI2QZZ@eHn;Chl)LS)%XkxYnDxw(bNh%;_Y8X-tPOUbf(~-D4J3y+S}g z39!E;LYx+lpZTgG0YB}tJmC6vm#lJ3f5C34py0{}ZH!-ifvdh6j1*;MWeF`BLcR}y zxGS)^;)aAIzdJDU0Qje+twBH}c&zPhUo>u8C}hX?Px7us*jG8Wd17L^3)V$BE3^rF z!kdPTU#Op-)RS_awfsGW1UtrTs!-{NrK+Kv9|+9b^L5ixp=(B}6)8<3?3eBZ6A#FH zwm%H#m53rDUL#DSq$smBUjr`bfXG)E_$*{KV`^^?cnJ-^Jlz@NrL$4Q1M{eldFF~! z|5V>fzyz=R>*N0VZuWs@!F|8=K>CWSrWdcivam6mHcm}jX z-ia)<(qli0JF{=-BFukNv8**^tamNdbJ*}FL^q!yPaW*xa4%j~h2=(Jlfs&HlOjsB zx*h?BL)X0n)jFNf7=Z4;;;F(9%uE%vMSkhkb-wM3LQ5a8XUbZZaJp5WFzGaXz-qEm z{~vt$^Br4n{YBE=2#dU4)8(HN`}KYt4Km0@0(0fj6;}fHR~GKTsl!<}%=;H%I{~m$ z5k#u?QpHx!A9&Io_g;A$&RRv4kKzI723H7SwdqC%{j0T7Cs*e34}`EGlVP}@DOFb9 zg}ui~wNE*u>uoUmvn4f4-}>*t10JtanH6O`xe#2ZgeUdh2|o_?roCr^bn+7*;>5#p zgNS>75eYo=18$`ZG3CO0nc0bU)+*OWFQHeDyFu)Q_pY0Sbn#cG*LWc@ja{e83s_z} zMM?X$2IR(8=^@~s_n&+sdq%u-G2Fv_{>r9t7P5Pg9Ov8rPCPKF%PTs7|SJ>#?=qMozObh>=)n zt3DD2b%%qUjs&UZHJ&9}!B{FVA@ODc%(AK)A}k402zHl=o) z%PI`R{RGXz)b|Gh5CjcD``d(G@iWIriNK)4VuN!;()ZJDVr>; z!O1~jPsVPY?&~jvVbe;gl+S0mj{<8$1zoHQSAUKMswd^t1Bys@S=y~FzvYE|BS+LV z+1AhCs&n`cF=8k0w8m$Ix(RWPsgpsK%J{n9d5CLBj_cT$9;nwK_W`F`%slSQ}9X$^+C2iD(Oem$;y4 zpm5;Z&2#L|3&*CzGlSO0nmh{y|G76;)5QvKUFL)eI+YTA>8D*N2)V;c3?233mAO$* zjhiBXGXI+fDVzev&=GFOofSNKla5=r)?>O}0em>sOjZWAvrQto{&{|%5BdT_A%u`I zU~|yFW(}LfZ=eT~{h5PKVzt565;wOlU$%bbxuhI_y>h%j`fYY)s(kpbDTv!=_Y-bW z9ZBanq8eb`a?6<;FW0{{3xid6%TcqLnc9AXWgcU1ZZ{u4nDpL3;tib(t`svG32?ET zvqQC97l|YnjY=GsMKq2;8!vekChJ(NF&Nd#$Zujz!$K>UO}Cg|#uyG>!;=yd*xLsYg%nvWcjeq?f3oyO`Y z6T1ixH1=Y-8N_9o!-XCO?lrj(Z+q{n&`2Q?~IF`b`eGOC%4MRZT{B!m6GB(3h{zv{VB4CNkqC zc%BJyUis?I=PTq4c#D4$)jTg++JXdN<}Z4DWKX?Y$3_`mG<~EKN&{1>@25oKjpIk>hs>~1Nt|%R?UhBEq6nL)p+xK*TOB~O zN5Km}5wNF3ErMrU|GE{P!{^vePt{rBRAc@kbNe^!ke{c~n4>Fi2>DC+^~d+0bi%_; z1w_nRW9?6WhekN{skBLW_4M?qba@I2ja@YMY(!sn)qsW+r!mJM3Cm_a&n7WBFjojX zksKR7=_L0kTgIs?t}h>IcLJT6V|t8TD*HC1gq%Cr=KG}TNpM*D-qCTx-kSSvayGI~ z>~Z)dVqwW;bMZ)j(cdE6QEW6IgcMF47ZOD7|D!g)KW z%?o2FyE@O4f0vJ@YeA$HTZ8SIfOc>3(oAElSv+pioSV5IM@e3f@hYoJ4QM(G%C)tYYLoY z9sfDgDPE4=oW^p}~Vsde@&tjsd znq+>%Q(_p;XOfov*(>8e0}K)Q(9RmB7LD*yqFZbBE@fy26oM}y(v~I{f?0_K<3len zpR|Jm+_ia)nNL}OJt_vA$_KQtYlaP~%4)tW=C@#am$BSe`b$omQ1P^0?6Oqvg5P#tCYZ$p)zw|6#+AGVX*J@4El7Gm?BPyWY;(9@5b?SL{cQq;|Y}mdJHnGkrcMBD-uy`F3cCS zj|?P^6Iod)sS{1Kt$b5C70)mInLT%O@fQX{FgSF+KN@1vxj7(e8e6PqM=~{b;}mCR z3p!c>s=Xid94Wf^Bhl8govd~w(o#l51g^$pmaPUb5p~%R4r{g#a8C&yV&mwQI=()p zq;ffuh(=<(O!CO$=!-k`(yCkcC%@RMmY|S0zg{Y<9){4~{+m0YkL-5;4?f7hm9nbh z<8)hgi3Th|eg$bM!9{HL6dsK~*sr1|HARmuO3SNQUc}h7j&*?{Lq!R=(Gn@K$weH6 z(#eKbCrLo=4QeZNDp9hg%bsUhLPJ&hMdcI`HTYwGL>&INEEp7kepCgBv?SW2$u6*U zX~jO5gids0L;pD{CXwo9z=-oh%w5@V28DvZBVcgU`mPwb%h)n;19Iy4>7Dz7{r!6zpUX+pwM6}|-yB6=jaXL? z>r5^s^@kC)`hr@R@8w<@AI|yd`}?evDDD5bxUfo_j$T^k-e1#nKVV_Mr4Zg{&7~T# zAANO1Pctd85fh;Qn5`Flk5xly-n>uJ^V>-oCm66T0~RCKC2@-h#d3pq>h^-7Fp;x2 z^5eipeX?&FjE%hjKAoMgq#&O}P1J($o`*-P)brm=YdB?0vRYU%km?)2w29_WAX9Am zSz^^b`C#MeT&NC>#G{HItejz*Y8wRDgEH7kWxJwCXp#~*LgBv{H)PWt8lKFwpo(~(mmeG-lwQ_4=B~Z3ng+)3-tqA$H z2wVq#vbfAS+W-D&wEDP3l^SCaiWmiN8@q#^)y=rBT5`Ju_S~=)Y2Rg7 zh$+4m5yLb+tvg^WJpQU0;VUWzDnk|lzuWJXmNKV&2i@)5v%LihzATo*566e4&o@KA zeoVLv&Sph0W`Mb~Z0$_3_!>|Y3n1O-+E0`pEHMi`=dDm`(F!>7ReRoBwCMf~(w%y6 zV?M4&XygTf=LaH4xFZeu4NwNw3Lt7#nl`PsiPl?E`Gw#R1nhjCynt=!KMf<-Efb|& zhQZEolFQ*tcosj%>G9g~I*PVLYh1G8FUghP?bv$(tAgkr`9?h{eCpG&&{p2Wp4Cj= zW2)1SNbd7Jy2$SQco8C#J-Sv3XQ#K)4cb=P#a~8y>=&RW9I_M%+b?^Wo)Ddq;{y5g zGz64g{P=^_dJ^1Zx12Vl&@ejKo!^$>;m0#m=t#n5ua|xY6Cjw^cX1%q70|uj7Skiy ztbf$Fx_%{oGxU*pxw-mQ|N5-c(ahpy;zZqV!!`Ra zNpU@IqGUe?N0_hwZ9Q}=_HZ>ILoDMc8t*l=5%fw{ewt&kmcX@|I~-~Ob@gYcUcj4p zdq(*s$Cw>AsB4jGLZ8~@5Ww}BsP;8VB|%9hIUg@KHwA9-xCVy>IwyM_1wahC8|(Pe z_eXbLDz@B_BLunl@NK87d*G>5?_j4b&o@4CH+$3N(}WeTlsd*wohwa4#)Y3nhm$DK zJKCCkqgJ&WYo6|9*T9$qxkL6Uv^lOA*gJ&^1gJA-V@?a)qqUO*!N%tLIV@u$xzEhr zPYmIe?5J_V6Zg?O71tui z+lDV7xa~+4I-SJ5re47b8r63-7;<@C;qI>>$Fo<~ z#Qq1W#N~viy;zA81Kd{mHIndj3j_e5|J6pVLjO-Ka9E4KX`-KGOcrnRGx+Oc>uWc7ET7OXhl|Fbl@Z~qODtrA=@!Fos<(mbzoPY2a600$dZqgHK zVQbj`=y|#CyR9&O5j^Hr(8iOTW~#;P6!@it_ReH@_X{7$HAQ4ZY^u`REJ_sa$wcTU zQfR0QqyyJ-)hF7Gnr~dM#j=~V?de{XRq^n6u@=nbm`72r1s(RJQsc^(3sqP@P10a% z{}_B}KCw&2cPaf+Y-BgGaiV57!w)`c+j(O#oI}Yp+%y@GJ5=evm&l_gai!VG1GT@; z&~%KCV~0%e-w~O)X>@m)QaZL?1-!RZo}Q{kLPbJ0es}@nb-G~zoM|LHu0JQsjf+i= z`DR>x8YX+obE}+es9Rz`kldLEEn~-;j!K}iYzb$FhZ|J2UP9VMJnRz;!Q!W@_xTg3 zog}<>`VdP9`Za!sNII%iXfpX?T^lJN0-4_ZH@X~ESko8l^gr@2(8PsgrZ_e`N8>VZ zayJ*VHtQm@G|am&4C61!L`;}l2}-3kJ9-K1Bxwp>oU!S*|BOUu+H{J*q?qE zdWmkyd_ZL%Pj(p;ug4Q}XP^NTzTOVXgB9il($xm$0UG&AN<^6#MoN zK&p>#sRw>huMU>==*|WijA6kM+v}w^kVY6_=>aB7*+irLVq@> z4Ac29OhJ`ywo^6s%!yy@Y$Woz|Mg5IV<@fK#lZ{Z0RpW=!kR$5@eq+Nk1S*J&)Bm7 z*7pQXXK_WrH50jb?AmTgOI`mxx;W%`_hHEJ(9|dVjUU1Q#>CXM+PDq z91aZsC#REGr6-Xl>#xhhwKEe|vx7UKIpqTLGvJMZZ27}? zWT7~S%R=Ht{B}&Em)sur5P?9(16)Ytd^Cwrl@z0H4Vow(p(+~B3RfPdaMAD}EQ^3~ zJj~!-6vYW^?RcubRq0#|oL*SHPsHs`wDWXzSDLBq7CsG!I1S9Q8`V)C*n2yXN<6x} zB{~qxx;9YMO9j(N2pu9c4}#fYEa{XlzKmICZ)b2lg}sRD)Jbnx&UvESdR0y{1P?4P zXMZo$GUuwFlZ~*9&y=OHm80V4NjAUE;W3#&ks>DkCGL34?Gk#WP7>OXfG=9nQf2rY z)w7gwuG4WFz>4__{1S**As^dQ#U~n76Z5#^Yc0O~kI5JmZ7pvh%DCgT-hW_WlL!a) z;kPvB?dd~PGPfUA)lJ^?F>tOc`hG)wz&<`K6=wDMUX51UG+8Ih7J0zj)4;%JJn;dO z>-9`TR!@VE&zlW(Mz0lraqGx-SM<9eXADMX9@L*xztM5W*tV@X$8qdstt7xr)?<58 z^!@6fA==KQDGK$kWr9V&{R8ag&>(Mt=ssCFK!u4TI98ztWzR-n%VvvRA1OjUr7rwU zB)@erdaC&KCV{@3=Nli%Ow$CRj4Pc;seCAy$CKVKHtWxZJjV93C zP+!yIfM|{c9X2pqbPV^#P8K4bW5VT(-3sU&1Kq!PdcMaJDj=63&_5;`=s0*h6x`Q- zz%!ybozLi~xN>(e)SYQ$OM+p(%fVmEd4W0!Wj+g;|qNj`iuzx7_C&PS77Vb5$)4 zdJ(Pc0X$vSSWRa&r@yC|!0Na zmxuDYkW6md{%o%4f_F0R>Deg$*EtS4)5sDo|LR8yuIC2m?Op0OSeR!NZCCoaP?S#} zs1ZAz%QStUp$Je)=Ciw+0%Qzfjcv=(`$c}LV&Cp$RdF`cEnPTK|3fIT*j?I)>iRWT z6joTjx9n~)AOC$GQn%|m7wk)Z!P@-|9-nJ`dzsiYS0o(79Prz#mnS|JJt3pJ$T{;Z z;8(3$;4s63d!c2uk)q5?%zDJ8(&nLr_2+yrzp6ODIolb%eTikuJbn*D(s>oj=t9u0 zSb}oA)ETBn4%1vW9DaHe8P9GlnZ`3_I1h~->e$nF63%kotu4c}JB`~i9)9o%wH>e= z76Jmz*H;Roif40wvBk8gtmZigm1cbnsn$ z>W#YbiINAN6?%?p!sdGS`q0zM=@1;lv6I=&U`13ZXJ#cgEK}X^kLY{}H!L5o9jTB2 zu!K4>p)RJ2*^XZ=*u{m*HZx7BPE4qB)u(5F2(H(5-nI*pC@iAg$bfqa!c|31;tgNTlZR!wNZD?A|uMFsV{7M+Tx&}2qWF#G@JblnoDN=3?7-9+%{`AVX$e!BZ!+FtL zfEFVSnWi&F2#$S2bwjk1UY7+NOm+sR4xnL^6m|J+=w?a#obD9UZ)@HC;hDv%e1y$k z5(_VW7TREGBhq%Zmh07ND|0jhDoY}A(jyXG=fXqyak{T$6jtv)BRmF0R4w5FonVc^ z<^8a$Kq)#_tFDP67d~6GW^49W6Re>5RqLh8i}FC1zi%d(fy=;tBUDr=ZU$4Y+Nc(N zUrNqIse>%6phj~VoN>MJ?Xg+vcuGd{!)v40v^W)(yT2<_syb0s^TE|~zXURL8= zF;q@xVg^}gf5OqWOl{wZuGCnM6+j_PURN}b2AM+L-B7x>eCEuQ)r3ST77~K%)w_B~ zggLGl(}l-Zb}`u^-P<#2d6?JvYQmc-I45&OPM#RufjH?g9iEzyNqn!`#h!>6uN?bS zhxR!aeMWfc%bABv>h$re>mA$MG3Q?59uN{E){p7U#S*R;4w@u5!nMMmpS!>L-w}3N z2$5R+Sh0Id^t@#bo1)r#Nqzd#BPe`i({!b7Q?v{>Cj3lMlF zfefeM3$iJP0;w|&AIIsw_WOaoc<)XZudGMoygli7u=C@yv6h=|Pf2ZTJ$G)~+r8@6 zb+a#R4XLOA?8poS55BsYnHa*cZW0Gn%EGyu)y+Z|h}0G)cIKIbjEkE~V`v^~)P74q zC!D>JP9T`A=9r2WD{ipcd-=JZmn{A}v;TNiCi{YX16sZaGPS=}q4A7Ac;( zS0+Tjb8Q*cZWDfBo^QCRZ z+j*dL%wukJUuK8zwxD`kq!1}VgEJrdfS-}cPi`C3Y1ek|KCig;aZ#ZnSj2%pRP-TC zwWr9j|2IZHWgVGx9lz*Q^4n_Pq`T09inYH;0U{;pOr=iNIygCI*~3mVIPPeUrC4QD zET&ACk+suV8n2Ompk`QNt^)tZKE<^}l2ilx?ETZjNAuvmaZJHx%QVXq#Yi0$o0$-| z`m3)U;fD!@lFk9?77n};4M4WLAM&{A&wM3yzuX@Zw~hH%Qhs0-?c0kzjTbH6K8Pca zbD4M+1vy*<=P-UQ4D8P9zq$10X>>7Jc9t%U(ivD1DwN1rkaQFupHV@b(}*jjW<{x!ai)&+-SBgx6;`9toL8af~*$>%isB=2RzT&WAJ8VUp+4& zncY-~aFC)4`BGvh3Zi;iyBQu2qdwoUZ;C!1Ic#skAQ7}e9P56NC29WVoRkhVCiU@> zhToO0njRvm^#wWxS?fw&_;F~fJ(rK3I~E7`F?f0=kSCKGw}IE1f-9*{=m!D+L+@IT zd!cJwrf4!o5y1b+cl7;1rj3CcJq?ix)>+C>FfpGOKEPT!bof*f7{J6f5$mLvw-_nU zY(8WOWIGBu{y!6foK9BLo*YrDLv7?W0T6KBXC#W=F&%UN7@ZkV#XjckK zbfgMd(0~Y|Y=_3$8{HAjQ`&m*M%NB@Yh{&lye}!Qj=vQg)IOD^`#j2fcaFePWRlr} zf?)HpVHUsG0#W}o=vwOeod716+Z=j1t+Kv&o5k#M0$$s3_~DizY~qk`e-w70@@-MM zN2TzK7k!1337K`Y<&u8T-yQ&OaqLSQzCm@X%+uI)usnkK}S1%ut6t!b671KJ)Q z$(fHwirEXsgN;9ols}^E(!h&7TqE7_1u`*chPI%zQNS-B0vZCIN`46j<46G4@KFbq zdVns8QutN9`S^aaXx6nTOD(2X{%w|m9@SS2#xc{f7X^=5+P`+n(ee3$Ye93hPJLRh z+@8Ua+Tu$6ckG0-uqJ~UlG-e<54p8eXfRV4w!?oOKus5$*eMM%x#qGUo$>OWs?++x zlnNMLR~Ncx^ucuA3Ns78U75Iam6+oOwo3KXj#U~bV@Z`#+4l&F%)}QNE;eynRT24S(Jg7pQz{)OWlZg&8|( z>W;yF(wqUY8z0I-Kv_a<`p)ou49`IX*@WgPM&U7tApY@tcc&YL&@UTDx|mtCh=ZEnk$TE@p&a6eDwPr`s^jF% zXaw~G&U!6nlk(XP0hAm6&_$;bWqv|u3XWW>;FYBe{e%Qcd8KM2(HfH>;oVX2!E71k z>1mv6#lQUIVkj}TvdDz+*d0C6NE(W9)jqI+sJ-w+FQxc=m}8L0w>+0U7o+W&*78k+ z)5csZA*0v(GP*!iP}%SjqL|}#6*LeRjC!^PLM@OGdAz=ShRXUg?fhYq~1O(3+M|Vd8o?S0)MOYly!*-+o>^y2stl)wm$T(=0$W21zyI zj7LbBeSC;05JWq6#INYBF>>*W7hDm+LNpIuCvt>X62zInWfz+0)^J3 zO@2q2_6JHdcd0cok zaS1e95}g$={aQMS$y8hNZTH>z#sN_NasP8Pg)+#`8MX=j=71Mpp) z;EK-D@vHodqTVDWVC7yRyf;*VRbMM8eJW$xm#-PM%o)~k#XEI8&a=&!&a1@5Ews70 zwKXmXXIFh@v5g|ksNc%`T=g=l-aQ0@WVP884R)-)WcQ2XvuB_Gt9=#JoD_0WL;vfQnzb(){ zH?>$(z6DPQTdmF8qOJG)M%(mXdhdcX!3)?TO@>IYX+Z)tFJ_@!Pak*6r0@e~|!5X%*iZ zV2ICTDrvD5<5;4>+tA#YZ(Nddv5)0F1fL}(Md2_f9<=HO9a-$TyCeD$-ux-}L5j00 z)fAKCXlH1qNi)@D`EkI$qA2>*(&-!G?9q!1Zf&Bpzh{X?As0v09kb81_gD)>xfCl4 z3lT_78~V(L!pt-SkqIw1fub!Qkj7?FYtnuBcy)+0xv_))a}RS>?6BI8u*PzL9lD

    e0C4^I1Y7i^7)cA<`D^Sf1Yjv&--!<*GBXkwjtVy?eia z+?ZgwBW&iH_q&u@<_V32fi?gtNbi-@c2u7{y-Rs zywSt!3lN3BzIr&BFLUvz(ta1CMMa2GO2}2P^`h_i1Ht0wm}y!U=x&x+b4eBtm9t-xHeeBIVKA4|l$6{{4#)dijZPKfg(Q`{S&Dyp1 zEP=zh-~YRlf+7qXTV3#b07^6A9tLykn*v_TMMdSr-`afWDaT#Tin+4S9bG~gKeu^w;&D~4h3#RH$6kWs8yFSFMy8iD-upwaabeqF#w-89BCGHr ze`LZE(pB7%eBTKD^utpOqt~t)72{a0U+=nf$sOIv)mqNi%*Q#(%scKPmqTa(|6Y@m z9rBfztKp-lAPa|Uf%5C$tk`~2uZgN6{NdKf{kgU9+0ZfPoo*pDBzuv@KKIFy)pwA! zJ~mT7*nebG6T9ZNxZ}IB`-dYW^jB79z}iry^!!%az<`KRugze-QWwBu{;C7+PeP-L z3yr-)B}lgd>Z!A(9I{VQMw>y3*Oq#r9AE5EQoH=)L=MTLkd)d@My@-Xx5`4Blj0+t zAH{2QLAS@y@~<#ln#N+m9U>0D@3tR&~Op4?^8pkTr12IBKZ`p4afMB75Y6C34u1VKtb?bWeMpr+ zx9MIao+fWHQl^=+Zq-+QaThZ4_g0GSM7oZnN@Tt|x)YJq^484GX4*9)NxRO08I$|N7sEefIN<}i1 z4JFTph)yqCWQaSJZ-0f2T@6$!F*+?M0y@KOCYQ4{zudPoRT6G@I{>mA7}rywO2B8G zKDQ6y>%8AQ!VIf$rGZ91{J;}jJ>9g{d9Q;|LgJ@ zSTNV6&dJ!e(pGr0_Te$~4(q6Uv>WZ{I$5da@z&DVK3JCmS5_)vQB9dbpt`m;@}^l< zVtdWXk54Nw+K|R<@9d{=E>V&wQI>$b;uECnJEK}0i!tzc!3 zo13{QC@7kmn{(AD-%>~$8XB5fTC7syVINw;k>fX)BIi2Fbh!oEkf3`V6n>$;*UuGX z;AlX4WAT|aMW534jXxtpF?0XAQB^Qo9{L6?{G0VeSB#O_b-HF_ofLk{>1X_UEQdC% z89>tbMkM`|{>Pfs&=bz3p{f%TFE{^Na3dAmx2o(WBmgCnvh!I5En$+y+F zw6R}2;PC999}Nr*bDOJ%?`HOI+HSWd$1V`SzrkhM!g>NYag{%$#YXYuBY(4&dNu#{ zTu~@GX&P$Go66G0wD`G|_}PWt@}&Zz{PW7gicNcLq%8)Ii!Dfa9cdx~ieK3B#K{PQ zd}jV@&JczEJp*fl))zJE<=Tf)6B@Cm0)9^Sg8jdKL%ioqPjEZ2s+q&Cl=Hcvp>P5M z%$bmZlvVy$@$CF&EGHX4r!H*EJzk+pC2($0@ReYLiEcb7Qv1NFYC_R33vlnt@E7m& zlS3Sl|NC%TxkS!bvWnQ{xa3O^Iy#=uM5!K#LYFZK?k)+aW%F1wxk&}i(=A~ORCZ$J z!qaDVpHHqV;#C~Vg;K$Vh5KY^{PA*xeQ-4u*ouVY>Pl%95BxrCR#U#w9ZBrPHa(Q& zH3Bu&)suYIZEYm5ZBe+FFPzqMKOG?gZ*|-is;XN2gZ$k&ep>oPCc}g_jpw13yv|WQWpgX~B&yln^_< zjrmz0U#p zp6qYlSx|0;${1YD%6luz9Y{?$^~&@&4vHjRBzU_|Z~6IfrCEO(xaIvOMlskOe!-qr z{cNg-hm2=5$hmAwcxoU{RNJnHqOn&|2U%n1lXmTf6)z-ThMCt-)N_hJ%LK9!I6}?)nO(&Q& zfi~oGW^wrL^dq>fql-Anh%aKJ?h{J<)F<*+g8$VqG9pE-|9X0c z`u%5B#x~0oM5SL}D|zqo;_d?ZH8DQBkwgBKVP_<}CP88>k~*XxHdPx!QXkD-VhgQK zjG69Mld>!z^GQjeFFZ@Or28#p?XUP@Pu1w0pE)rjj4DL0-8IF|tK+%Kz$D*uL~!2o z@|m^0MJK^S`X?seh!>&k0?GkFX zy+dq}qOQo~mNshuPP4FFPJ6*x@70g+n1eq>K2Rz<32{Xljg2#ew8h-z7WZJ($P4!P z4g?qy3=8OBD}!lR4eocOqv$WU;Mxy6EmdgRqQ1f9(}w71>T#ly9&=opi6}=`@3pis zfW;Q7FQBk#VwNwTzXf=>V)W6*PnMua_F;kC;P_d^r_*kIVn?Ev+Z>R)`F!*u(4Zlv zI&_lwy(^jpQQ+9;;X20LK%{UnTVXK|aGIB#TZelIp!^~#w#%7-@d@vKZlT#jF~>f0Qz{Qnn$@mynh_hiXD zRN>)_=88=3ynQ_~)8+XU7EJOLCcO(}2M6qhEhXN@`G6g~knCsX-$POxc^@S(k@FY? zGDU~d{^NXY^$Zjzgkh4+&fe_X+-rO086)YOmN{i2e6uUV*5~~3z0{-G_ESu#6N{NA zVT5SRH_Vs?fjZswCP$+e&zbm*T%}UQk5buF?)BHY)PCwA+q8N$WiX~B2?owwIHw7Zet%Fan@~3(!G20Ju?vW6X6~PYcv>kdX{Q;Q z83ur#EiEIeRVW50z8ZP$bNhC51^p2;O$^zbx-S+ig4Cq$Lx}7eMNnb&? zU|3gpqwF!346OKh-S!75);;AoVQh9!;%Cr>U`&R`_d+M`5_Qr}4$f5C`K(&EGS=Y2 zm*;%xk3bTS&Gt6wF3(TPa!(L{1ERQJpT`~F%a$m~<+%*AVR|=Ys%?Y@x)(F6OBzn> znd$9%s)ITO;!K?5pOZQf?fdP^PNhrY9otmtXEznZSgv38pYC$f>@F;;+o8~@fQS6f zCHMY%Z7FbT)~Sm#-c8}18g2`P#@`&ARzX-&TtT%|cF!K`{EKT8lqU?0yXWn}DzQWY zGnIRbbzAhFI2?s8Jd#apgV3hBBafCAMF&QL8*yqzWYlBMbE9YH!(H6L&-UbAuoT;e zpj5b8+Vj&HJh3SKt~hP`3+W{AHzc1_rW@p8u)dMSh1RIgU)og>!~&3oBTwTq&F8t$ zd#T%2|J={y19}_BgYO*=sY${F1T$-?P{QhKC2}^*T`Y;uV0r)UBE55Hu@3 zDVmkv=)4}C#_dWOU0MZ26rIzr*&X>M@LDzQ|7H{ zBApaKs8jE$6hDWXj^nr_F8WItIW!8RK+ZHEE*yozOewyDk>4}>`#~KCO=dz(UyYHK zU7q8op==n6ldh9UMnD{Il4^V(9`uG)=N}roZjHzJrKtYjli+##E+(@>{;>|jM)RSy z|0fbNjr(!?a2`4Y=+|Mi-++_#d^3qQ^Ql}+U%%@@7pA^BSH+r3`O4Gk%m8Yx(a~6` zHob_`RbwHh4Zn?eW??n)|JZs9pgNjpTQ~^`Bm@cWF2Uj8P6+Pq7Tn!EK(HVOIJgFP zcMt9m+}+*X-jICv-TLeOR80*~=gjnU_w3%i_u6Y2`Q%J%Ogo|N{3%H8#)O-lzG^L9 z8R9|&BFaNLB-o~BUon~8aHg$WNsVimi{h8Xl5hqy&^~9cH-%TnU_BS@7Z1U29dz}u zOU?R~J3JvA+e~ahlRPhChZ&pi?Qf*=&n?Inu)*?nL)?AAa!V?=QPB$H;UO$N<;DU8 zk|d$M*j$c?BRUO?R;mIO#_-lRTJ=w%)7FdmnyhgS=aO}Vzs^8?SwA#_no4!&E$l>= zrn8DvZo6FfCL(h;L*V=5;ofN)sg8=%(3S;EbIt7~KRn^=A=2bS!bW#lPmKgniZNk_ zapG*L36v){Am_}u1x4w-Ta}Xe38@p;3JmZnNc_z`XN+1x25nt~K4EnknBU?Onrpsl*#K^L_z2B`oI}X3{ z){aUDMpfJG7vM?!`SU8R;xBpuk z1~6%tdAdz-Tl1^vg~xdPyDCF3u1SmaPL{dkn?F9cFIKA3?RFdZF1b6?;J1!$L7$U( z8~Gk&?GKH^glNdTf3IkIphzO%*~B=X-XE)-X-}I%uu9@dmE}ktWpr67>Hqv(;g>Z{ zL%%dW=uMhbVrKe95bde z)rycO+vP_S77o~v=)toK57SK5zu67RA<0QsoQ94e5?DX@vgF*CVV$prmxLW!k zM67~3+uq~WhkT;3$~d$a+v5 zC(HCQKbJ4fG&)?GQn_CpUD^{7R%B#qFbPC_pR}}Tu;q}tlpLmPf zPnDt{;}CxAowP2_>vbDb_G-yhcQc?l=Yk%Vj~t;4X^SGohu>`E|RVg+-Aq@#W5_K+?JA4_;V+ z7LpQSl|~#FSTasO4QJGyk{HYN*R5sv`4B<7nGK1?%K9<~1RAIba>~|EgEc|A5R2b^ z7*3K3>aLxk2D90ba9dcPdl>HrUADB6d)uiMFdJG*yJyNH;L56>X}_%xkXd-vCgY{4 zR1E0DyG4zXaM>Z;S?Z0%Ia;_sv*GB_7!76KV)h4=`uN_)ku&WtpGxv@CVp@a1i9_M zl2?m2^P2ZGb9Wow`Lg|?*n}tJL)ddspkv}hq9d6(dPbE12v%iS<_MXiH<}H~bX?60 zZm7ysL4*@w7Ks!`cQg@j%y zC))TBxf10oS3hhFq=YxHd=yq!X}04nQ0x`Bk2NGNrj}=bN|}$=H+klaoa&=VS`4T4 zb_Q2TOIJWiNfQk)5*^y~B=WI0HMbhk{ff9GGClYMU8FsuHeN};)(|CBIX06{!8+y| zTt~+XX-X?^HbUkSvZ(CiA-ik|m{9SkxL+dKE1E4}dUQN%s!=q+_jDS+#o?%4su0nj z3V2(;{`79QB{|^4YDV=JLr3=%oB)rfWbs%ex#O!qbh=fi5+4g~u4to}0lDf)OxEIK zfdGkfHJ7hqdsSnP1EPpLC?CgiYrDp%Xq~o%$1>aBhFt9W13aGqRQVy|$DQcW+gyIU zAC|&NHoNl=S)5aSVtyCShgrvVu(i_WnLma?>W0L*_2i;RSAC3Q7$28Q+`>%D4?Uhfxdx+wOo(Ri|;SvT{nvV)oO}zeN zv11R?B`8?8xC8f}pQV>{TvN)YPLb?z1EO+RDj3Emig9yzTv9mein1x8$839-H?#OP ztjW(n;`1?Ju}ZqZ)1*F54RzxfI)jue-1$U(D-4eZbklZ%)+QZv`4p3IIVzG;$hD5J z4kM^|>|H6OmiD+%`-I4BxV*ag3bS~Sr4_O-;pe2YX-`Cu`LL)swyHbb*F*pLw$X!z z@pX%ii}jsv?%nl`#f{uti<6FF)uoXco=52Nux=Kb|?V57As{RdA}C}3v+a8;uYfkn{s`A$bx!Vd;{ zW2zs2?!@nibv=?@MT+jNW@-b$)UcIGD5b$K^(BlRrs9X%T*7xAtAu?9kYp4{5% z)XY=0%i5gAmVM*t*Bnf}$%c-V3{;0k+NI`2vs<}_j(v<&v`IRpnWxUqqMw#Ymm`H% zjyD5TzQ4{dqG1pdUUcv5&8Q<1M(+wU09A0Lz3XCTrr~sNbNGHJY< zyOp08>Kzg*r;pDCwZr4_IqWxnQyw*6-?0)%NBv4mNlv(QJ>ST$x>ldi$?|;qVLOFu zaOd;y?QNH%myxciH7#NiBKu)rH>bM)5SHxlA>Bkb8ch6d@Mg~r0@Gk&)XF4zdLb1ohWIO=g1kGmUc>CP9}eSiArB~8w{Q4SF_Y%MnM3T}MtwQ4C%G6c{q6ny znERopR=)?K#S5OGMEb-N8Xo&%NRE_*>%BqGmp}wO<^f-w!0Thckrg@{F!lEK9?DJL z*f;yu2k=4G!9soIR<@p?fr!CCEN!)f7_dSi16z62zP_lDn4#Zg*I#q z#6Xhk`$0z;1f^3|L^{%@9D4m4;jdvdLDXtKYs(GqNngX7_bXDu4r|QXY(gB~zHWMQ zhIiMbq0nh2-I~(_=;BtJ(_r9BMkca8@!mfSK!J5#3Wp=u6U0A_1^JzR~`FMEID_Bu0FoVB||QIfTQo{WCL3ZqK*3fBQhq zA^RQ^alx=!FFg#&q53v?Yz<;rEr)YEm#%CJIbrX8MR;@q1jB5?RlP59Qt!jMXior? ztrt)WLkzH4O|VlLY)7W2ryCiJmuNMX)znPIA_FPNm-~Lout85yFuY*g3dI~Q)Ah`U zNV)xrH5-Z0?a10>Fuk!64t3CLPlm^xUjTE9VGAqzSXSd-6cnsnY@}A1PsX-9H@DMP!Rd;R-*u3Nz)3j&f7T&>KBW4b&}g50AA7%-r!_oaV>%S8{ zS0YBUU+jr5xmTJ@>+`~tE^M4FB{=L=MPLZI{i)0eN`JxBQKA4m*GA}cn!Ny7G4t|f zgz=fldk)9_sjwa}f%(}xITEhP3|K?*Ku(n544n`lE+U9^CT{iF?)}QAX#P|e3YnEm zue_mPoeeo5^XZb!W$$N0Ah-f(Q@yAoh(}YT(-OV^#|ri7ElLxq{Y3^zUrP_|i#S^bzu zd*DX4NAJRQ9VSjmw?GDZ7TLdZLgXx{j9#b3B<^dZ2vM(Y(MH_h^18~ji1X3H3mx5D z_DQcJ1(-QstFeal^IZ@}2y*xji^@jl;~eMXrNl@c%VHp!cy6b zQY&AcOuNYiX;?R_v~(m(48lxu^%Zc5JNW^AFv8VH%UIImKct^Jp+@b|^B3!zEZ*wJ z;;mj$BR(kc=aD=O&iELPu#I!h@QO!1Q0Y;Wya%E3y#ya#Hip|O$O67PIJf=*C8?#p zc_3ESDelS*H~gNw zT1Pk(Gks_jPy|2O8p7F|E*$|TduuZdWIJfK(V6}oEb1Sc9#p`UXGd-r>Q~>E>Du@JmXRFddmKB-9U+_Ceg>5_}~#~`Idh$ z;*eTxTttXDS;&m{a7T1>D(S``At|cMUe~yQID+w|dvfff&zt zH5(j0xVyVshFbwU6XBLzJWhuo5itIX2q-qIMV>8Y7y94lD;#QQY+PSm<RuU6EI-!PTP66fG;n+?2ID0lZ60!FX-T6a4elx z!G}n)+Rcdocb%z(ATT%|{9fX^ec3~>|I^vP-v~gE%jM-dH<6X1>5rk< zmnyuCw|bg6ASrJ>BGON!tWMo+dhLXRh9;KsQ5IX?dIf0`e^-saytc~kJuei_dI-FM z1pvzFV5TjSM5NAkUAPJt5LP0*!raa7TG~ORxuiC;2i|}eOb;2K6FOy4U(#ouf?9f4 zJTJwTFN8r*HRQ^PNJ5Q25hu33``hX=COCHqMk@V(?=wz(T~Q>P{s!PSK!YfLd>i~d zy*=DP_)yGJR{XzD5>nolSH9OTxWE(4&i!bc>==$nJQwr=X8C*f8^ixpX#O_k!9$P) zE`>UfEscMK_xpMWHDs2Rr2Y&eOE&%MszNZ|EOq-^fY|kK{oPyNG_1b_uK%vpCL_u$ zj81ubcEv$(!6<*?{haybia8z!NAKIWPrSR-8I_=aU;EohZU2_Le^>J2z3?TiTK0D3 z^?oXPjJ=6ZNFYjs1wf^i(q~-@3%DpKC<_Y3_b|0~PkuZxb5mrc z<*Zz>d5hL%)*})X%w}Ie`*p1itgNivy}hFPl@u|{;MVM`>&{1W!eu7b%L}RUYUyk( zSec?LtxdncKtypoZ$+6AO#Ar>!2jV9f0UBmA+0Y${ToV(RYQEGXoevK!c^wmDiHgv3hFGO>>}ied9bm8c ztRacrpV__0F_J;A@9yprjZ2EM4RDB9JC$<#FAtA*ho_HKVDEBbRRas786NUd3bk3b@k#Q_EkUjcs>-JPWMAPd6>D*4sL}LMhGfn8dOY;C1 zB^8vuL)0nTP6!;pc@RlY^rSF?CPirPn#Ni&q79>v;dzzMp=NTc2l~<&0WnW%{xToS zYn4>seAis1Gj)e6WWqypH2wif=DZnO* z%O8q#U(~j`*5sotBk*CnXkm*i22|E3)o{6&4CRQc>Oih}rr;0TcEX%b-rxE`*PvR0 zqBzFgWZT7)KCgQwDS12fm~KP0{D@Xkjc9DMK_5AmN-&|CGuWm9(z9&BFfCeBfo(GR?A{_Q8Dw2y!GO` zY^e=T=MkIoe=_C%@o8`Rr78+AUV6cE zG3N^N=RJwfqKUWHXz^QxQuhdWJHJRcP^%*D3w5>1f@(Z4^_q{P80zo8%kXb)6yn@k zJ6WiN;p#>QZzq7N4j9u0?vyZ_9$sw^6BwUw)NGu#{7%OAR6WW)%m)Sf#dHbxDD}I!Y`uI9L=ka?=lZ@>#K(qX^ zQ?EnLbJ|w;E#0J8Tg3s`#!qbABhop~?ekf^rX)Ng3^|4vTRKy@{VSWe?9Qp{NuS4A z!E6{?7r#alx1;8QL+38J73QDY5})<*?lSW6P;+kc7J1j)EbS)Iu?DMuoHQOngGk*(hAp-ah66s zWXqO`Djy=YpEo-dJe9@q)8eUlt4R4=L1rB;xVI7MvSoanEpWzs@e5OTEMQKBs)W(= z@oC%BHNEL(*>ZHi7Mhri-+zx@b4(sWg*@+c=i!a?v0c5vNcq{_#}q#ilxjaJaFHBB zfbZ5~cmk11Jih;lIOXEhx_7)6*zuOo6B{-D=B!dW4D zxr;myc)3}cB6B*elAcA8iQ;J>H*vF^BBB8EnQqq6U~$!TLI%g^K|1+rF=Df=4Uvc*$|5 z$`--3z62df2w==zUJQCvA@9#1Od#_{8ppa{+|Z-HoH~QWN&-23Woc#bPgn18?m?a; zWC6^SXGG0fr=~}^xLnkjofRn*RT8fdC%&#p!Ffe-4~>3Tvs@5ZnXjOWJN+?iwLO?f zR~SD3#=(@MNc*609l`rHLk;<=8P#@VEK>S8=(qJ)#f-`!y0cEkzHRTwz4-qha%(e&b{Z zoF(fgO?QHGozC<5QCyG$ImbCIM(5e?K91`5F>1z`>eZlu)*6G%b9vGPH0m{71G!gm zar7(E`~v8>v)!G`)RD8IGL^z34Y=M`yqyPbvR8^MSpBUaz0Fh$&+N0Xj1b1JVUP)sG3`CY+|evPBm zBX8*TT%I><&B$AwA5#)?xtRwFdZe`O&K$ z8B%d7CAlYfyNrkLvKyIhgXCp%!}n!q+fN^}>JEww2AnOH7!<`n)X215k74psH#qOLoTpe7#Yr%nJ&4&tc2J=olT~(vo>RBHD2i+VLA8p zhlX`W$$D?C#Pb(D$wsy5Cw=PkkUF9us4$;qc{9eQ`(;E{Br??N=t@$p+E*!aPZz_& zPCU=0DTBojFQ9z7k=bwRL1-{rL9@z_Z`$a}=uC~??mE850H{$G?#q?2%0rzp7%|1^ zKK=EZ+#7$4QqjZhTAL~c?lxRHjP7aLXw3agt;z2C+mZoZcm_eW!X?*ma;wNMeqHs; zBJ@3qC^4;6*0A%88=L6nZR8Stapv$lYUg9#o-z;pM1u)A&B%m1$B=ZF%V^`iGs%zt zxz}%fxVf$oxvmZj#isWrZuQBzhIKYNw_HQ_R1@S|rB;32<1tpW*;JR(-x%&)8$D!L z;_|xwz>^>!E0t60uhDA1ESPfot^2ZjX3y1jUTVe4wxFP)VSl_hO) z;X~AvL4PXkSTB~pC#P61^y=wvp~|APX8dr-7E`{~l8xabfu&Io86T>tgeb?mUYqKIf4=Bk^Tqk<+?u_rucxT4yU063KeUGuqMjW&cQRi*w)HrVv^XEYN` zn#wS4l*KLlJfi(!F-JCbO_pu(*BMVH9>0_8+MKiBlMn8;7}6}`Lfd5C>}wf#(TH(O zMyIrIDysFz%EW&ZaFU!o(-Y+Eu_Z5g2d^B3GA=FfIwTrX>7Sud##3ZA>vdl{npMg2 z8r;TrEx`5)H;Q!xH3gegDO?&aEcpFqK$)!+l2@C_trVc|^@E|KuXa6^VV;ZR4G4gp zXlc3GIXKDfo}Ba}L}8NDpQ8e(m|os7d3OGi&$AwsTpb7tTWy#7+%9&(Xn1EU_FkOc zp?p5MInkd#r!+8njC?%6CAYg-vQOo8YY&0xiCp$=)oMhF!J6X-4 z^sEwkCk=D!bh9k*n20A3SiabZoVj&D+$vpM99W(0f05sLc)l&#Q}T53T19Lfa68QG z+kd$Y+Zbt;-6m*y8Pg!B8T#J-7z9fZSM8e zb&LmRS2Uh8Pov|qVM*?7c=9eR2Io(P^7VEu?G!bwN||o;{%s^rt0{(P!t@SVqVb{~ zqvNV=c{<16cFGQ2RIs~}wQn6A9K@d}vfbR#@(88e*m;Z4{X-^x#TX1+A5BG>b%~ET z>|wPdcC!7FP1`KOUkvqCE|-@spGMe2JV<5_JlC$7AmI3^zABjFTZBixrZ|#{;a!`n zyw5Kg&l#+XxA({6N~@?a^qV}mDT*bf=_XS85oE@DkldSmu01nF(3f`-lR>0@s5p}N zEn%~Jdn8g3oq)Fvnbfnv^C4>}#5-d&QC^|JLf3b=*l72%mtQ`5q!#2lX$cn+o1<#s z2mjwDJ4^9`CV#UkntyZrEsip|s|klW{-RySc}gM23RQw*+EsC;-mXWlrg`enj)8JIN|*z!E@hz$#Acae08r^(BW^bjZu7*C_=AYKb4)^Bs+~P-NS>_;Vm|QNM34V_y7GGYC z80PpIzi|~hdyn(C>IU}PH__o2s;8=4#MJmfeonGWYHbgGX&{P)Fe0gO5huF%%?zW) z*l3yUp$LXeF%m0H52a;h)|r(K$OB^KX+w4nuj+vp587s zwM$v^j49^JYzCpoErV z^{JaB_2FbZ0_JR}n5YTZv-XZAju7X;9FfDdjRE?Ufv164&JwEpMHwb<)01Q_5M`19 z#b6$%3)aVN>u<*;SPrEsKi{~1luN&5m^w<9q&3&EqD|`vN0e(cRFqL>vKiF%-FxUN z8s=!7Umy9U>I}_N7B_c=J6D4_+z+)~@9^}>8_`rc&hbc9V@J&2;UbQSYM?jsn(Yr! z+^bj57h;0^inqtBN(h6;f>Yb`n9~iQ4sakIQ{2M;M$5eVo=!5D2qs`dwMIbOrL8yA zl8H@^d=tX_9?geEwAO-cE%sR2AQtOd1l2^A^gRDa#dO zs$K(yrV`oeL9=QjgxFF59bZ$XmG}r(yCKG0+lPCOH5FvaxnKQ9+C+$}=4{_!g+iT#1cdYmCi#(u6rb8SwCMluPx22DdVmc!xrNeq{?PAJ5; zAN*2<+{T3V@Up?hDe$n>FeN2aiugw^1()R#)&!PTT&N>+t~PLrpzQd;69u~FEYxYB|0923bZhQ zXbdhYM>8A^X|kv<_pxD<;eZq~^=+GiAb!hA7O7wu;ZmOgYF6A;=PE zil)Ln!w7=B59n1T7DOpO3N;(>e+`9wKYJ~4|J)_k;U*cs6mG#cHuqDqO0&*Cf!2Q2 z-3tUYH<4N6K!E4?JE&$LceGcy0Q3>>H7+U6XN^?2tZINyW4LmbyPCJg2RvJ65Lff1 z|I1$~lpro>xBT)y^x$CPKvt0mW+1W}L`%i%Wg`$4^^7p64-^rvLJTk#PkjhwoGo2H z_<1lV+!^xQSnz^hP8 z_e-SO!$362$3v-+(ft06`nsANWF7ABte0jArH2#U?c5E+;A8)6Y> zOT+UiZ+4GUBx^t#E1VP=vfQZ%a95Ex2cx~j5VAgvB~JeOb@^uSGQ&naD$e$16~v8Pae)I-o3*{Sb?T$oFQoRQO^x&y9gN zdQQl82-@5j@@r=`R{hV`q=)*SE(i*HXg0!2bjkT9RQa2D8{$6VQ}G@g3lW(YA5xJu zHiWnq$e-H@L5-=-$X?OcSE`-~^QG{Z0$g?3S+v9-5ddPJKOfK5LUOG%c)fzvxm?nC zI`c=qDKsOoI0kWUdb8E9BmEFdxO+fvGY4vpr8){&S6n}CyZ0Gd$Z_u|9#`VRmY`w_ z6`(2=&6)1$Evng`(oKU8zm0cW;^PzTdQdB9L@502PGE-BNnP4I~yvkgy(e z6&o7KZ>o>DWE5sL0gEv0GHWGI4&PIrbI80?dpo>`o~M10#+-UWZS@Xx#?{V74CzYE z-oON`)~zKN(7pE}_iZ}1m0;qRz*H=)cUxzn>S#ixG5Dc-)U@$O<#ey1(nvbRCU4pP za?U;)0Dq*Mb9MA(UrK2x631M-UJ*3)w+PhA89V%PRkFAAF_8RiIjnsrDZ6JkQIPzF zzhJU-=0=1}9MybiEH{!0>)M#!Mqyt+jjXb&NG6u}omgSSa9?I%l;C^t+#$Smv#)Gc zbzH2TJnOD(>s&8EjJRykrM#Gf36p?qg~1dap$5GY9hJHEnxH5=HDq2> zzGUo993E%1O!&2w>*cn_flg}_Ee0=yQv}QGdFp$^=DF@?%cb=}%H&75UX_Yy&8TVf zxd<*TVQd;#{N1PAr#rM`!g@ACSd$*4f6{4h`Ott|hh8XA{kc&OLoWniYZFAE-Lj8+ zESx?c*^Q9qe_BY~@4b-V-8g7SoYb;gb9W_w+}8Z8$8bboPNUz)U5q>H6eHi!U;lws zhkCS3PQVPcY}AVIHX|+j{kw50*=D!Sj$U6sHtXj1@>yL=yk6vnKU19EuUySacp!*N z)vL#h=I@2VvFI-NzIl^9h9sA%EanW)0|j@HjS`Iuthv}W_cU?5Fp&+Kw8Yk5=>rZG zhqg8D)mrU7V({jYizLiFO#PzUJfGG54r46Mv2Gjzj><+ZX*8(<;`qkqCOVlcC^c#8 zr-2a?I{xKa*l$Wpe(5Z_h4N-%eWUt2;b4Ub&J}ZZ65{ocuXat8BfG1mfOYOwddhYd z%*|6u^3YVgFh}M&1q-2jk||u#%E)fmyes*{pArAF*El)W8>ejMs$BzG5Y;2xAj24R z=Ki8DeB0K{RF=ZOW5_}m&qza8i#9foT2*bPU^*UJM^C($Ln4X@wfwdet1nj9w)$}E zPz0}_Y4bmE6qr^BJRV`QY3DKY>LiY#&kf!PBg?4Cy90;~TUM(kENvS%E#2L{^C;aE zoIvQdOy{rx<_s%xo`rBaatJ0zJZnA z5U^l?M5*K(D5!dy)i*%BPS-SBK}7W%eh(lrvLYgSm*vG&pjO~o;e~5Y7ntHV<|n~) zH`eT}6JS+W+IL#d3E?x=Y2$Nu&k3~>^aDXml7_&A_P7a~xK>opCMGmcW9*@Nj)L<_ z;)TLf#Km8IEGN^8G+P72hAK^KBSS%S0+|g7f9$#X&nB5M=^ZA@_K2XXh|#CAI}H2luU56e}&U9Z|_qfsJfNeQ-0)6^dy8!*Gr z(Z8RM?H*iHg^lkv7MUQg5i@1Z&FC*Q-XktDE$KehO|EUxy-dKAI%t>Gv&-t?i+;Af zZ`Hj0uTokg#|27j=j6*f_lbJg%n2sURT!7^QBu&ov$}hIMCU%k87W#S`(F9&xo}wGzMD;my2clC5!I^*vhLFtWq4r41sukUZresZQFn+~qT4hMH5!R3AA6 zxN6&Wf)D#>G&Js9cQ`Cbm5P=tbFCezs&_hqKqR}<4X{cL)~o)mSkOazGQk8hgRqTm zRYis!(-OvY>HR`}Mq~C(Hfufuoy;-6qgZBBS8|OMR*eUNF_2_yD`jD)Kf$(KnY$bV=K(Owlx3hXFi~iZJmDJ;8Cw zw~GlPjYcG@t}AeH!v}`t`ucN&jZ(5#tf9^{g_KE*e@!GQeor`F=C?LqX3M!~0D=`o zufxk~IhUnH{UXduN^~(Q<3lXKMJ`n!1AQDKX{8$3un5g$bV1m_p_p-6wExz?toKF^ z{`WmH6YjQc2OqU1d6-ZXGlj(-gO!~*Bg}%q()V3WSgs6mPVD_$Vl*Y_@C;pO9Xd%9 z=>d>Ahru=2Bf) zoJY`8$r;N>dI{i(9(#tjCRQ6<{Paw2b_mu_${o!9z&Qqn_XNOWw>0m z5K8uawDgfWD-%Oy-%nu@1CaUJR6W&fn8yJ%p*tThXc#fvIO3CTp_1UF#+P89L)pQk zZ2;d=22+?@lavM(V;ncZ3mP+k`)87D2DjvSsiU13sKM53ka>UN?UNYBt>p!=z}!m zDusB)B%l*~3=V23uAq+P8QZQOdsaT#Bru}z`JiO&GyH}iS}&blt*i72A`0`le~z_E zlHPxK(o|=RcWRwX_qx|DYS9;-^eLPLWuvn$hpKs2RH+RgbuCih+r+v)s;{1CXh74n z_-43Zpj)Mg@ytiG1KV=N9Z2)Ie2tW~l-IKa4c0>V^4>)5W7*^asIdR{Bv(9f{#iux zgpxPtYh<`lZM8Kjt8rLVzL6Kg!+O-@_u zZJ&Q_V8)VQdudU91$o02Xe((E>+^j+#3tD;6`+{U%rEyMzo@Lzy*=u3pvM0_>-uQ2 zd4gjJL$mcWgIx>V%5baJEre+A6*phg>ft=toXuhubjOsnp~0**6*d2#k5PZT zz;D=;Cq_j1HgQu4?))4g)w6#-=cweYOjuZWHAd#hjSM6o-2SC(SkpH$3h-(jp5ol{`zrb%6j0_FRqZY(WEvKfY z&{d}M+#zJpXO1WYKQ!Gnmb5l{x91a&k@|EKV?p(aCUNcd+xrqme0*72u;AbpA_-WB zNjm?tb&fyE!{uWTNY3mO4B6#teG8vEb#jsz;ZMbFwYv?r3 z`RJ(Q8$@SEVw-xX=Xq7Xfn0aH8e2}ceDt%UZ_Y(fbf79xLsq4Q4oK_15aub;?@e8y z{Hh`boF%JlL)iCtSJZ^d_M3m`$~*iVhwMkM6~)MP_(YeB${82+Lq|^eC`Ua|u(~x@ zc7Ab#K5d)=TFoF~VPWhfAurPy?$g!96!Qg_E#ZiIp4*T(!oW#qGpZGo>y*;dw8l5{ zxIz?igjy3MHG1;@!F+0KuAw}ZY`5p&Q|sU9S^?F#WOgUb9blZ-b-WGTlQ0DD8LD%? zm1i-_?v;2p-djX~c@|8b`03%J{{m}MO;TWC~ z1gO&o02-F&ae4uOnvuwhj`sh6eGth^nUysoj|(dniKm?xKCFy;8kan7hqtrB2#KQ- zYDvBokrbmiTzL+LnYKPz7V(C&s8pzOAsXxHa4ab;Ep^@MR~N5A@=|}J>FRJug~~XROl5+qr9EiAzuGpOm9WmV9cNE}Xl>3|GP~BOX%J4CfN| zt}|s6{0G>1AYA?vz_aKZ#&6cWWtvm3Iz)SUvv!UglSX#u*5{sK{DKkm5(Y)bcdEnn zc`S-nhHAOYY~woTqJAI=AdlF#VLNlW8T@ho@#Ii7)Y3791N0}>5k7-5VB%O+ogTxx z0b#p48-yxJr)BD8E1z1qLk;5=m$k@OpJ3;T*jz#0vKqsfEYue#Xp8>XNs9O)02S=> zQi^IfDT0JFOe_i^54+MZ*l2LQVK5lGiI3ErE8^@W@V=CQyC?!F3R-r2^h9L?WU#A| z0I(sESBjAD@#z2nTnr-M2+6SR!jjGFAxxZEFi>AyQ#|JW5nPE;X3|FUggp~Z)rDQY zW2?-Gco?1GAMqt(rs>3aJ%8D_#EoZs>o-^F;(~)^7sjUH3;C$1*PS(1!t+p70Em8Lx#&Zd3gvE%}uskbJOqCMfVx@M?_)k z`!5a9JSGWm!-;`-+u!t^DDK`wex_@FX2@UylX+{lrpKg=%g($%qR&3Sfw=+99boHz zVva<6T|}&}p?shte4PO-2YewQzo)F@G(RjZ=a03aR3Mje{;i41saW)vOgrJbmHR}T z&tUt9y5w-%Z~Gp1)k&Rd5UMKkSP2aZxcq|As#K28xq}<(<>bt_!y#_Zh|cW!vq!e! zxHE12VvG5+E}Y{liDiLhSG_VB^mFpBf66bP=~eIFa%m=4s7z}%T_RGMs=#5YnwH-95qjkrlY4>Oo>ehN za%@2^ZF!>3=q2idYm@hNHf|s(l$&Fq{m1{t0Iollb^wsUU?F1P{FGz2!|s|jy3*!n zx=>eM6aD2AAK-zB;*+L!1FKqOaCfrM(!pLt3M=@|{;{0`w$nh;6jq>fBOITY-1*_; z&pEAMn#GvMvWiDp_s(-cYhcgOc&`~ZzIg|BqGKN#2tY>@>Dl#!-OM?+mHNc9k#7ND z@3nwN$?WN_R*J>yF+k0>`E+Oa#+XsF(zVOMJPKEb zkpbgN;1Vcwu?5VKPEs@*P;MwV2*6`st}DzvsJ79OJE8;Xjqo4jEB{-w@;5X3)|cSl z(`y3K%O+DrSj8H(;gy-9|D_+O025M?E}gVocIW(B-frosFNPpUZGBIYmoF{gD_j>WQ2;Uma6tb%uLXP(cuUxp4i z02k=x{1XtK|M2z$*rKv`n3#W!aF1*CF9!eX{|``-nuwez42uY&+kdSv3ZdTmks_&B z)f|7`+^72P6#PeI^ktEGsgwfF@xaItW)p)AFh*Yi;A|{HF8UvyX(zpzdS8j*gYLpP z0s;aOP2lB_n2aNz-K|nM`!+=gK=jl8HC;UQw(w_h!(U;K7_Q-o0x|+W34HJa4&V&> zhcwU4&1GQF5Ayf--)f;+R@gL-B{cerH4h9F`RNis&h`@A%g%P9!~(k8mk8+cm*b`D zf%5{O&OE)f-UCiN>GA#1wX~#d&-Zw;>IVe9WqZRBZd=Ibg8+wcPLtmu63^0fJZF+l zNI3oR;kCRz9|wM*2M48cDPHR}L4TCDmYmm2$FKf(6k|?gbWd{`|1;eH%cAgi=Duue zfsVha4~nf6y)^lNry;rGQQ#Ju%oSu7I~V^whs<<=;-hu#RpxnB(tEz@f3x-F8?*nL zAp%r3EdT^N>hI0XkL-qjBHoGAfKIQ)4On5(1>B}KZ|u*BjHa1Zr(%aR@7r)o|2E zbVzxrs^G^3;NRHPeg$)6f8V00zcU3e-KYPB%z|Hv1@17hsbuf()-vsv1XxN+@ZToH z>tcr$1D5Mss#|kz+hsx`YI`9)PTfg*(GJT?8-VsjSp0jsH7J5fC@c5Ljj-ph|50cA zW|3l_k+EbCpp)+`n8j*ePi^^Uc(jD|6rbnfYHSWd35Wst7RcQWjr!2`K6c29RCOE-xTOG~haid3fo z<>loslRVeUpf>NZb>(Q+AFQZMS4w^R?t8x22@@Hy8F(Id!4<8Qre4$-*$+z2bM9e%`?Ge*LSr=~@*4>=rs@(Zz7t8RId-wnw!O5Hg z!M=l2JeG-y2vq&i2Is~3d5F?{h;&M4GhXKgyT0n@CxUwSRZ?TRg_Y63SMs^FJzuYP zr-L=U$;rivIRInwziUDfSW-%g#gdSa@K)v(Ilv1sBDmu6w-9emzXZZOCg$vNP-8Pbj(o0kaeZ3E-I<7Q zv!ua~i10=%__c@?=LH06cG)BiV`7{8!95t(cy2?8eARChNb=Vvo;+-?I|n}NB`}Dg zI|h(r2H?f6JtpoOlQuq|(LO;Ayv`k>76}mX@-HqgS*}@Tc_UbqEP@K9WA^8tL%344 zc{#mtk{{mx{sgg!L56O9X0LyIHSIYTNe|(Olvaadv2>85K+O`55pP7r;>jlx8DKnd zuZoHEhBKUPEj^J7d=O+@VpLhZPVi=`Hlz!!uBVI{N#iqbCF8XtiIeePh>zmh+S61f8qj>RS+^~vH{XW3?v%U{!Hc<(lP=s-0W5!K6ST4Tr$nGE zYHn_BZEvptpr72>C+8LYX-?mArFCMyvb&2V1MMll-m!Qou)}6b4{ixq*hbA7Rs;J~ z=8iXKDLDi{L_PvPL!L@4xn9fcD(9w_8scHx_lr;MKP6LK99=7%DB;Xh!oenzwX|Ds z>@@^E+zpFtNT;r42_SFjZ%HA!RWSdDu(yngt6RE8>$c=Hh^~h9%uDj{3bu1zvxSH(e~awz*$LM z`iO4xY@`swPg81Dk(d+Yqaao^ZkD30(BNy*>PO@gRJnDuKh&i*9!69cMdHnOfI({T0 zb|i2fj&bHUqwpC`9Gi{isiJZ2DGjt}=-{js2f)|g>O0|r2DDO(FBQl2MWU*z3g%19ygOaBidab@%BFZ!E><4qe@a<1lDyj*X|FMw^NxdD zhK#Bx;v{U|zYODRRI}{JF6EJ(z1slU%y5KXY045uTHubi?1X`L^@=~HV`o;%*S596 zL@k0ZtCzP#vLS>5j{E!eXeAEZT%UsRv>p7IjLWGmXpyql_%N|YKM0p;&u;OTQ6 zlt+kygaI0#bkUQU4F-jVe?&yAR(!;1J^$%aak!>2%f`X{sUACd&$$ScG1_$e8cjIu z3cuolUsBBFfl$V6ycmV0cx|gjfAs3{4$y;( z!JCUqO3Ux)duv>1;}_zw-H($6_|D>3UjnErYy9YUc1_~-%#S(K&h|*-;|@IcG@aP! z_Gx#F01MFpuAi1DqUzsp8%PMJ1Z0Dly-f&I5w2kmf>Gfnq z{r3Oal+84e>;8MuNT`h?yd%TRJ3i{^xi5&SJ!rPbmoEa4VfGxMapJE3ZJsh%eU(ru z9}?2CQEKdPBa<_Eefkv;14gYV%c;-hb1C8N{1Oe=3hY!8pWN)R!CY+S5YX7WS}N!r%jEb)PBLx>2bwRaD}>#pju!(Q0V+Q3s&0!5F=i}gZZ85XK%1X~uXs``>}GLwv^Gi4y}!9ENHTMF_7YZDG#`S(l;r9< z0@_u*#9itNu;;&IcNMO>%0|%(S+9#+U9(kA&KZ(1+{j z@j%HDl00hu5+(g_=Bu&EyB>+jbrbMtV+SC@m~;m0^+h+w3U_{)C0{ z%VJ+LN3=e|15@)U3A=v~tQ>-YGb8zUfl-u2C81Ku2q%am!UWVXU&|#b`G{|SGDIws z1gLBDuK%5@KaaHoxsNWduU84nc{|_c_adE+-YMKEyR`vt=$OGsS?1jq?Zf_2eDN28 zPS0sNAE#EN(R7apY>7$PxKszEPePLfIKE3UwOqw(K~IZON;u```y@&nv0)=(I7ZEL zEe4Zd>O6)fzSZ)HkdP~oet(hVCO)%FI^qGJ<*n8N+{xfktH6%MRJMc@I)jlr^-Gakc&FFP#7xofRRS57BmLC% z{^T(W#*Qv0n6hP&4(gLa{QOdox9Od7?O4UQKkS|ig>54;OhD~l9k5@;{55rYq>@Re zeWhj!JgYqC)i&DXrKm$8iJ|XBOPJ-0UFp&E9#GB-%8qvV$nMXj038N1*|OFih(PG+ z>pjn)#tNANXcdbkA0)3Ash4)+&(k9PWgm$x)ax02$monf({&jujY%3pEAn-!atrG) zYF%nJH&; zacc%YV_*HO0jCk2L~tTfdtpl22M9kylWs1(@2_d4F^f5HHt? z@@RfOoLS06-xJzOd*PUAkezNk&**uXZOVIsL;Rp5a##Yj43)Qs(=$eEqpivPWqKPk zeUwldoQeL zj6lFxD3l?1eHfXkwZT2XA1gAswYB!4&cfvXI070yV7JFbpt0Kiea%GYR_V~YOGb|F zLe_XJFmRVPA=12>A@LO`eJUow%pN888oqu$SFC$(eDmPb)>u3=mD)~ejnpQSO29sR z=J@}k*Xuo<1S8U)&RmvyHW!UHk7Ey1llfB_kEzJ(!J{^Zf6rtzP19{ZJORKoUf(Z6$-^qI2-5AL8Mgr{$ttN(@>}S-iU~1S98!xJhE0=jE3IFcCmT zPYD>o#C{;1?f>y`wuCQ{s?q4~(U|3mmg*nCsk>N?SwtuicTkw|hQTKK8@au7NS5kj zPpU*arrRcJL;c{zWMb=Dhc8TWnODk1IxjwabkY7&UehtpX-V;1J{{(*HfR00GR9y) zIdxR^`IDNoBx}CG!Z~cX#3wIaKKTyMZtQ{&t{f;$KSD9K~ORk2oG~^q~bszo9Q&@*^wEzCB}6-DDLTW z4vVI9HBdOA|0TEz1@4I5%O0y0JKIqxWro&{1g?}&G>y$*YB?>TD*JL|@_Ua;8L}(9 zc6wT;!n7ioOfg#gWmbv|$FclIu|U$okU~s2M_#_sR_Cuc3uGKU6`tM3&?AeC!;xxC zFt*x-T@&MlZiX{3pm|b~@wv}JHR?z(o{O~v;Q0;);nYxl1A+#FD_aZeqvY_j*8L^@ zT);dC!4XUrbgCx>Fsy~z9G}*hEt6;cQyaG9`Rx@GNTnMoI+6WXRvv` zta&fqe=mOT(rfvqo3{W3ZO4KqYnc~1*SGekiWm<|K_tv`xAGuUKF~R(B!2Pg{s0Q+ z#aO6fdiD^+^ijc#a-stA5@%3AzlKOrDXfd$ZX`u{D;09>k$c+`5#`D}1`P zizMrDnjJ}_Kq?J$TT;5?B*(e=?>}%~^99t2nfazBzb(&jGD5Zu^QYT=t>n*025Zsq z&uCluzjx$FC-C;(MS_ly>2=>1WMJ!7-{9>$zbRGv-vYLnqrax11bG_3uDNKUmWqeB z;}^W637|>fDX)C+;TD3^#gV>Dl$|Vm(8Ba}Bf4HL?tTd8pTmNS>$kFXkg!l$F+aZX z{DfICbG`9V8$U%nox60XKw6x0CbN{%-R&9bNm!4Bxnc{{Z5_2ee_gf`z&rL$t!9uk zTRFjQ=ev(`Es@6R@gD^b&kGUUz~c@FSfH3h`{gmG`w@wkT4bRE8iMTPOQx??wz!%F zPmb&MMnL1t-3NuDs^Hl)p9~J4h|KUW+cC@WFyUUaE=f-AG6f=swNV9PI*b%cvHaNi z;V0S*;}Y{pGL-QP!GmIp40a1Rs(4MK=w(POhw{lE{s#%tQf+&vpbZB-b2<6t&&`i7 z^VAKIn1ceZBe3Z+P&xr&EPdj$WUwvK8;c11Hw?_ov!>?LjROOUEd^dai6nPbU~a`( z23FR2X=v0RJl(39TrS1B?JfV5T!+ziaoKE}WxoXP{kB>CVR-IVZRnT6ex4Pq-h4}% zx)QM&{lkFxi&RQtpTh=V3|lq&cbf0VthMHAoHC;Rp&a^Uov&gkU)FZ|Qss8acfY;F z42m9&u#}sQ1|Sc*6Xv29SSLg`J3bRz{$#X8N4KyJoMH)Im;1p0d$n~|4_d*;i0#~0 z{*uJJzs{eRYCrZ7Bu5bhH1})4m-B(g zJ=T|XzRZSHy;>_t^pyx++)8rYxJ{=d7p-$-bA?pdQ)sep2k-wcGNd!NrFIyJCY1rj zqVXVpgT>8;oAsMd@rqG2nHv!iHB%^1Vm$R=E8KS*p-PrOv(Pex6N{YXKAt3Yz!$8z(&sV-9wzWVCJYT93- z#>x!zb!+lu4oe1zidf7r-~;i@mfRFq@l>ifssWh%;gT$+dA%Bh@h7LZkQ9l9WmFB?{j#P-Z zNPhO(E=Bq_JAjy(9Lgn5OL{1kAIt2SM)OEkwF&?o%Qx8@fKL|%W(#F%8XL*=I=mzB z`LhzK)g)a|YBv7X_SY^tN%+U=W`EmoD(+gyq+e~|XxB$3uRv&b1(dA;4J9wH3PO0! zzWLkyynEWnWx2a@;@hNaJOkx5v8IQm(l9Wx^t1W#20dR3Gnc1#?elnjOszFRFmlI; zA=Ucg{+Ljdd#pVodYc;Uxb|sRDT*d_^6BxFo^itc1KpIq(HRa%!di;K;lXSv~r z4}RQ&=QYp`T@3KqK&j$0yn^d%ICfZsOiHsSk&NSmqeVYt3!9a6oh>ql;oOf$zxhE; zIsc!D1H{c9?U*#a z-n$~kZ$J5J@Jh=>7QCVwm(FLDvKdUa^DSesO%i~#Ch#|#RK%_*QrdA(YSuB532M+C&Msw#?f1Y?c=-^=-Rjh^6UF(OD z|NK~(oC(}RRh0U0_GO}xMa`N*_qF!;fcuAa>2wd_k39K-V~+5>?B4ZK`0d59UrxI` zabz{*as}|xn(P6lhrG=Ue((@PB17U_Ta`-f|DzKtvJ-3jztm5o;B&u*bQH>97%F}I zK-=uNYdD=Nvew~~US~Er)9!U|PaOI71`wUbP(Cv*(wFE+QnYb4yF$=IH{|O;Nn}wl z&F0#;puAR^K0oVkQxC0Y(#O3wN!}ZLmYlP__jr&+$dhKptOId@h2IPfo7rh>0U-)z zZQYaDdIcZqlnwS_ril|%DIYwyNn7%Y>?0W15+;gWm{s{adehlkW~{W)7G{%@A)5wE zJ-pn>L-7NC6jITO5R26)-uXON#*0<|v3xGhUhT z2GgrU;P|vTT+!6ZOSJjf7=PtOKfZF+Ts)XeoM}vspjtid@1WAz;!0ow7QL0RV+ftd zN)q@iPG=>|WXJd2&WV3=DRlT%ea#iMIIZXGe&Ap2-!wf|pEY*N$(Y6y?yzKn zjfP+iq1N}Dn?}jccrgJ=I)x#$6aP3~)FsoUjLs@Z_*g^JkPZ`GcUqn*?8eW2X+7SH zTXd?}n64JRT(*jI^f2-CtCbo~@8A#yF|SKta+5&!C=kehqCq6Shp|WE#wPTm0}L-Z z9TKfNZ|}8Us!gto7W(l0(aG%6evbXG z60gTv{Yfc9tKJ+_gsz4U6Y7K<*3U3@IXo%1 z`HSLpz~u%vq)6J$O2!VjbPisV1mfP{C`qE0o2LTnv`3cSVGOa+GO;Sob_7ugaQ9c_ zXXdQ)E4ps?CBtH&3r?LRg~xC2&M~4ZKDC-{QdBoHx@uhP4E8PT*^$fpcDn}^O^iL( z=5;O;Lj-p?J2*-3`8M5#W1&R4pRUXu@377N;;De!^7+Pi1m(^WcJu7BnRdV!rB3?~ zXZ|VwocBRjX5aKLD0=Ka@!!cJJ__=+b%%D0msa&l!4J3gH6W^F!b{>Z|CMAeqdsRc7LHWi)uBVO@LAn z2Wio0){?1A|7-;{#}#VC6>84+Wi@SEzA4V`Qb6jV^P|z1!3_(*C#+O`q=hIZI`M98 zpnHecpjrS+eoZXP(!QJlS-$e+V;%NVA*l^gM=yHc$N!RyjPG&hVz#r_3xabsJnq#u zIQ24mFNCg3OkhPl09PW{o+JBvXlpW3q*vXYSMcHUE^))e`ary0QbX7x$g~>hNq~lm zrNp22K_u;I=eP2fn+-&|Z7};lTa}&ue&n|s=Hw#BtbFX}@)!H~)hcC-9a@3Vxs|a` zUH2oBqLCOQH#+n^+Ez2So^Jo6N+`Kl5Fv1;shoV&cl^ZW$_JyQ`5)?yd+-z2?E@LQ z#LM>!VV2u$H9&Bz2`@~74N3lMd;%KVaknL@0tolWR!bKI<<>XbXN9=h2n@OUiBv0X z|1v+s?1vJ)t3Ee^?2m31PM_YGYJaGMGqv38cDh@s6eN2a(s(yMnC)-!SDvpdNjf+E z40bv=L~_2!Up`wLvlhnvq*rqt+Zt*os9mrU#8f)9OhwVJ@2DVJ#%G?)kneq^`n z6f}uRMp6jj3OF&LAUw?j%C zT%dtIu|zPvyxOISjzNPf6~+4bAzkuWqsbdeHnPs#_bc*SInvqyXdyM5YsKE;5-xD0 z7_KdG4=+d{?(pykVcGd}tIRu6tV`s>eC1o25%F9+*LgJv`I9Q%aMm_Crw0>Drsjq} z4Zd5Q<-XTkl8d>*DpGQ!6vtlWvkl}CyLCEuI2;InGh34>5dL=GZ~2Jf*kB2L0>R@+ zJ5pz%TpbHN$Nl|Byp5)>D`ntX_%XY#p=vS4V_a}1NeCN<0kR!SdH z8RMQ}K9;K4pwEpThBq1F2ye@~22(wHlkK?)n8!1Nl*ToI^)7It5jLU&UEDO7jOhE- zyu&xr7o7ZY18^;jCsj}p2MXE1XSeH#7HFZt-_Tk4^TibFU)TtQVqm0N-1OI4h%?;y zCc9C4EoNPy+yZK6yp8Q7Ne!x6x&{$EDrb7h)bM5o-;f~xuZW?gbI1=^xD^F%n|I0k zccu?V#M-VML$UQnhf@}8i?`6zPQqf2K~FvbV7@S|Z0C*rl$jECn7fSak!IepigEQ8~DtWrb7($Nqp1wr90;gKNyn*Qx4ZDuDv+Qw+1jUo;45pYOCxB+V^N5 zjJ=F|!(KLkQ@?}#-0O#K<=?#F;IcqCckAIaQKPEO)()neg8bG1#Zw= z!#lVS=swR!Z9QB1r{Qe1&c$~hULxrs4Evv7`>B~GO`+N4;D}bAIp@llBDfztnf_Gq zu~4St_TDEi^Z6jYnw`^arnjtcM7^eYQYz-i55)XovmU}YgYR8mzW4+F=>zNL6MP)= zM?Pa~V(C`_^ex$8`s$bB*@Pqa4v;Ykd83UZxNHB#eWVieox}4c2+;aA(HPn1qQcS)|2_xg4Ox0Q@9Zc7Mdiq3v zYuvqS-5cfPD1yH`SNm2$?FE`ISj5NMIjsp@H-fHi^kMvxO*asOO6y+d4b@uJMluAn z3RAWnk$d(lRGqlE_5?ZD9aq7o)kYrMp5JdW^)P9DZh7L$?5?l-$?b8mFOf{AbKt77 zT=?Zv-)S|}`8X~G+XMX-98X_|z~@}fW*g_H<@skVPyFHWm^{!yHv3ix$B+fjd>Y-p zNXN?wKSy9sPN#DCV1GaC0e`j;{Sy@S4wgY;I~8x?*e}1`p^xtPl~s6xuZJM_2ie!h zU$tazV70!q0Vw72Ox2AH2X=;qKQJyn?mzdv#( zuP=>8{XV1^F@plU0;pS50`$ZZWOiP+UqZ7du+ka}X+ zhQ?l9Ia=*~c;O5Q%WT|KwSNb3hfp{bEFW9FefwbV>(k z+C4BBPAJEr5t}l0c<379FoMo=L5=O4abA#O_qXJN(vXgZ-t~nvezDOnAOt278jeHv zTPs54`d}|v#Q8}}2 z_Rqad_|n$UGrwMy$y^`d(;>03dcoAMKW!Hi7;}rvc1G$Awvv0s$PAg z;3>=P)DAXaaGlS8c3v@FO!0l`U!zp`r1O+WHLjLp+nB1PG!jhhipXJlyjBOoB) zMO9gm23o8~eoY)h5<`(jlB>ifGm+uO!_e=H+RhL*WO*eV?qjI z*QS$N>Qg3k^mX_lz>R6OvgJT-!y+(M2uky{CBdUz@=)%3@$P*0^zT!?^AYQ9C4K6UlGizEDLh4c*lw)_@}X;~sdRG-)K|&p)a= z`0};~WOqbuOCoLdWR|ge?3MJdF!J|@nUb&XN08)w%{EksgSpzAzO~}9hwEW-dM}AG zDF9Rl3V`l77c19x>pL;wKT9eSnE{2)=5fG z*zwkyhU3}&Q3)y%nl@?gu@aTfF}S;3Jab<=3K*sBnFTN z>UN1(ar^cJ-c8RvSK=D=bJ)%RT}v;^k2RNo9PTD_>)~e`LL9(3!L2`9HhN>z%dQ2fi#gygPM&-{`36XS=l*;O6)FTL}qY{Wnf{=uPh=Sg6JH(fy zvu$ldFFv4Uwkm$)SNr}PSutN}gP%l%FH-sHByWRzU@>HXwK8uT!MD8Kw>3)oDDFMX zQWeeAz9pUT@f5=55ed-aRU@+BAgjf&7*Z5y)6B5*<}W>a|#n@O=ie zVbv(S6d|EuQ9%+ak6@@+X(n~`>efDj2Gmy(z=s9X$06%^X?F7$NdOUedQv8~HsP5z zTr|eN$-q+%c_lz5#y*k3jvZ(Uc^g`jL_@XaA#DaubEa0o!?7q{pG4R&-YxZ?r~BvC zKoa($ONWX4`{G|uuE#)$2KDylAOkQlF%PStgxb#85BdLo61!wPmg<~e1$Ld+`;W@6 zm_H8=s{Ag&RM0nzaaoCps3TH;&d;mtB$~@BDr%~$yLx*+R;ZTQ$uyswp2pwSM}p6& ze^yk`zJLGz;o;#xONq`TQ|00D@#jl=TtS1&!o&o;o15En#ZFF}9g?8;h8Mzlp*tFpk=1a<-FuO!PnGYm#K3Q_Rl$2;ciT|}|?%&aKt!wx*ik?t0QrwJN zX6)H%Z#@4@yz`<_=Dd|Eltv0diUxzl;-aoTE8E*wza)jgfPsBuV`GAYG?w+60IDs? zL+%0ull5?XC8gP^N#|IWe@~)6w=Z6CVOhTd`|QX^y#zXDB0r*om1O`}6!k>+3P>EAa#{E(;- z|M$f|Lv6v3fmg-AIykdLNX`T>acHX;dm9wP4ZEqzvcdismzOkHiQpaiT+80)lt=`1n3nBL(Gk(ER+JQ+`UdU^ln2y!_|vtgMy5LZ{R?_nXPS9YO2OTib#d(u~uFY+|9tX z4nqwbTVw=nO`SwuXTj9g^IYh)8vdUnvj~~H+yq*s?-6^zR-=51{PB#!K9~t}(y_UbCUht&U zAMd^Eg$Iv6yG2oCRhS0GwvjrTIzdxkwoV_TmW+}ZlMZb{5bL~kH=Xy8?sYy^+YgBy zUKI?PE=}=k4h#(BWH(DDDGoqhe(lV_(tWDihj@>`QF{uD*L*ycn_)CZ?8&mh)9n1E zXmBHib0^2WSrG#xGq)h3Y9>GQ(BlxV9wnSFjsb-oyuyM5bNYx4hU}4o`jUxQQNw>% zCC?U5=})L>eqVj%I@F5ST?-e{)K+6D?COf|Tj(vdUcYe6LU!#P4J~-~Vm7(wZDTc% zfgZJO{^Aqga}R$U7F+4g9Qu$X2aF!qe#v2Wbg$i9MY{hyTa}0|S)dP{jL^{~jrmI%fT{pbS zqzDX@53i>5ACS;)sD!|nf70SWDl`k-6Ep2-e;Ur~BcmXu@i7D+^cqj=aY&=bNk6c} z^XWD1_+mTo;`)!q!fR$xx~AcumLCJ3zaV*yjfgg`tEDJOEDOl=hCdq}tk_|q^9OyB zW=hHdt)WWWrsyPNY@J_+i(C$s#P*YWiEj4(bf~xB7{r8FXHs(>4FuFr-cN7^x#Eux zXzAkXVk5U2vfy(jAFfLw4IZFWfJ1%U=IK9Ppo52s=6W$-2Xyy4dQY)Yp3B6K)fyTV zPD>jUX4CoGr0+FrTiy@W3L$&&a4Xw7YbHorcQ9o-hdTVcUok^bBd*i5)%;Zzbmu~u zFaa51O`*)v`U3I$sdXEjD}w)rTTUg-l2cH)->JUns+~PIM-qI%YuD}bkoIv;mH_QR z=LV)tx2yEBb6}krLUp;DfG(Ik{Q9iS9jB5lp5pgeM&?2ko)z9#A9{0_=w0-cs0aK> z+#_(4vcUwm&d%hxl6m}SxDhkgl*?s1hVLEkN1*V1`WelE|53y_~h>k!>g)K0(uDE?v+)y6m@Sy`;`pMZdr2T6CXg)`rhSK6Jg%*7dl7Em(f7 z#4YK2^lg<25QyfYob*_-On3DRlv)=I>@OEYnLno}?5O)*xsL82p_4!d=8$_jfqG#- zCl9mAPzO4p@A*PP4fl6tVBrSTnF((c6sdbA37RUq z=(2Aa`|LSqOE61r>Vr9tw^PrYkS$|XyH-r+Dkggw%d(3nz&vM`N%iUS4*{|!W(T41 z5x|8{w-v+6B|NzMRor!_589SX9RR=)Zc&hG;pLUv@1=vjTF=AVQ^xSgSdlb#balRR z1Y}n}!YTEDG{cA}Z{yfKJm#`Qqpi%i2!5BC_xRk1r{O9ruLkc1t$hsvyQvA$7JQr^ zfuC+s2cG2vIO(aGCoLd!Y7aodptM^X$=UsCT;6*FO4iwA)~R^vHc3(CPz_!`F}d*IE1!1?>U)aE?~ zH(n)s0@${ma$O~k)A-=C>mqNA?;w8P;Z;~RZ>@H;X8r|EXJv1d4jhk&`X|s%O$Y7S zhpMsM#e~_1ox_PIN_>dpqgDt`pm?Oqqv_K_2SqN!gh1UwqBy#Dun_3%5bJjvmrD|N zHyMh>BeDu#!~&`XC76=(QJD^B*+~?TRLz2*HdSh^6Lfl6aPx~*x)}G)#2Doz+T)S! zBO5@qNVN}M_*TVZWS3DCbdHQS7^k))(Agaq*>O=@-j`nYT3=3qWLc6QN`Xsv7Z`i95T?NIQZk=p}}Z`&MT?<^|U z;(R#Xrj*qZn@3-?|17-tQr3j|5JatI#$0P>=ZSzf*`w2#yOS4_!FsSzLe86x9?B4z zJiNF(Y*>md)!KSR#yU4LcmKE@P5sH_CH6hP4-E=s#Px5Zqf*pzEENc^yy}KP_l+a5 z#-@EE;Uppv2bSOR!USrjw}vAY_*c%^lL=FTv4Z32?0DwNY&&Bn=#>}0dK$jzGJzQ< zALp&s6)ELmIp+}>O(qe*(Gi0=WS$Pd_^^mSjIsNomciu}tRGMG`>AAPP%xIrhEtP$ zB6wsM(rbcbBZ@MJ-|BCs`4z^FZo+o#e!i8#^^Yn1lSd5Pte4V#u&DIX@9<3SXs7#% zm#(wTqKrp?>>aMQ41fyNg46lE76PvE{t;({xnAm3CYva%($`{-rVeD(kw*Qli1`z4 zhqyfMB*qdwCtr%yxLvn6(8bF^adW3Ptd#Ai*t}EYAQka4JBVY?>t^5%ryo2uh6%h? zXK=K82`f=Wj@Rvx;NlgdRMXdlfQISHiYi$trd0>>V*FOOUgJyN1YSbgG)y(-wQg4nT|cj zI)Q=ve(-tvbMQOUQncV>q=#=9 zn&ON4)m`@A{90T)ZNC*$y&Z+MHOk=6-p33MAVjC!p;X?v->+v$vxKU88%dR&V>5{5 z7JV>*INzdNUcv7CYtXdY2pRlqW;|7ajr`ZKS>{)x!82Z(Q^iD0UelWG6OSmHtjS_{ zR7w>;s(ro_3^VBouIJP?eI}dhpZF$UuJo_r={^j8rb_({(ek7rmZlJhYfElhq> z64P*^!~sp}4mPjfWK#T#-PI<@;QAnOQ5k?2wE%}OiO4W6If0`Pha8o9!U%o2wQ-6L zYzQQO+vOC9)l)pv+27Wzi2ZIb?|&-%MNDH(4?Mm}JCq;GR-Fq}?>;PH7# zA$NmkDC}c)#r46D=$X9&c3H~$F-P#a>0WJJGUMqyL?!{c_(7(Zs|6Tgd>z55%)ace z##WOpR+ApCuXqSq{F@K?M@wydJ#)(t7Yp=hism}5OcrMv-X}+lj>>S>H>Wkw&ZduT z>um$EEs?OPKV;c40Gy%CW~RXLJ+G{Al~vj<3d-pDwZ@@}T@1q+oX+%B-;(`Y z8Y8MDsuE=9+?$#YeXWEw(b3mjwmm9>%Q{F6Qc=#vujcbCG%195AkO?b=(7jU7B|%! zzwR1wFbr4oO)HobJ?GcVIe1T;pIS~?P6-zt3Mzm!$5Xbgg$lmLA7;rdi!geCg1!VK1UGwEpEKLAv6&u`@u$cnsDL zzDyuCciw!t9=*M#;g{s)xjECRa)cOk|G5W*!{TEW9c9-zXClRwkB{c@i|!=dc=3~s z!%-w}7l0A>CC|lRKfgKSwkB_5NI^J6qlG56{h4H7!C~j|{Iq!55)rvb##9}o$&$Vu zAye>G`Ya0}0Kr(&_!8W3+n2=KYp!?pMvMNSiqXH8^*N+a8O1XzuliueKV2(fConvm zo3O=?R~vA!ilqC*RD`%y$BS^&rL{d6-WBac-}->pw|q_R&7uZ=r;vn-s1?{=$#&Zg z;RdX|U@etCA&BEt$vxS3cC&S8d3Soc#obfior3<8N9Xa6ldhGfek?_dFdZGK zC3Q))w>L`O5!OSoi|?6TU{RA$M7K|ewQL}5{UUzdtFposo^S3Hgg-TV5RE&zU+vGq zJL_FCq~RiLKepAMf#IYjARhs97fyqb1tV>HuEB1VJoA+G^x5l{DbtakQ+Yi^N&wC7 zA0KT~P!308$Wrsr(90c_+HGJ)Os;lc`~j()CR|c(fWFm27TT7DB6}YA6$$OX+paWT z7naFo4&zT=AIg|qW$#m>flL!42!Q==k_YJ31)a#H*K@jRi$&h`Je6Ffo~$y;Hg_Jc ze_|=^`meK-M7LrbY6VbhNU(kJiIsen_Res7Pl~rvMBJZA&=1B`rsZJxxep(6`I}p* zt`U?etOdH79h9kOzuOY;*Zw)6)h)Z8{^dr`HAjabWk7)Wkfq;0u==T}O7ea}gwIEC zwkz2Bcs9k>3g1w}6~hYsH`77i?+$X+>PuIK!!p+*r&#waK2{RzmT&P}>lkxg3g~@% zGlh@#s%QM8KkGn`KH|(=Ro8uFnX$Gx=J#+?qW(N<3&8{H3s+OMG`$OSzf=S>mel~{ zpVkc|jy0WAyx@Wt>Xv;D@uJUk3@6)UjXPUIqFA+Rr#Q>sC2+m@DR6nIPj>wITDHkt zC8agn;4BbI8qzJb_W7%39pc8i^9;S6Xb#^shAtoNt1WKNK|q$V1zSM#spG+n9LZim zi5k09AAKclm{Nr|neut1_GjF>YwJ}GO;)^#?CEo_nz)XRQ%AI$DwCt^%9HTErp)SV^UP7>aQD*SzMfzXPwz$y`w zf$yfqBl%;!xQVfetP8Pc@+Ap+;1#O+y6bIB24K>kcLb`8N({w!E;Ssed9ptH ze`tnQ$~$I(=aJD6vuxw;$o%*ksIQg>2Upj}_i4T*(@1p`c(e2ncr!mx=d%hqVmbxD zBtPfqcz*X9xTKILBb58XNnBnrd+;)kh=Dk+tMUHj6GiK3fkF~EN)`0y(vDfiV!zf& zVNA8avmXC8nDb>`p~;pd)*@Cugv~A|m^NSMU@s%R^|IcP09r->IwHSjpM2{D?yToD zj{!$NrhCpVwN!JfT$yzfO8HW`rHs>?f zZ{4O=G2Q`Dlk9*t4IKM1Eq_@jHs*>f+-?N++MDP_AgLl9F*P+!g!3e!7OtjRV|WZ^ zWT%DXZ0(-;tIJkTe6dq6IBFG<+Z7Z#A1Eh3#gd^iOiX8}qRt+Ec}i}!XPrqnIFG7( z?&1$zn*Sx!E8fr3-zqegd5ez6cAL`RLbzVGLmn=KcBOXKb8-q}v3t;es4=^QIv#5< z+#i#H)xK0$1l(ZqO|{3FUig%1N0ukhQl7#a>+@nRhh(%xc7BG8{qYc)15q%L%>;F7my#JIL7FORYW7 za-KmeS`EAA(BmD6lEGefJs@(kJu~s<^m}ogHcVq}_3buBdq}bIIhr!=f!f%$nXG-* zI>0Z2XUUhF<7x4QsX~MqnJdGmL@cSUT8!sqLWOt5Pc=yyNWTx>XCGiI(QQjd87qg09NN@`UfHy>Hn6E;{Cv1r;MOi8S-EEG zonV72jd|z&Oxyw4QG|emR)_UfXH1d5WrDT}k!EBr&o{p`bfkj}u2=AbtefIURHVaX z31b*5c;$N-BkZ@aG@Tqv7^FMrOQE~gRJ8|^W6{#9vJeU6fC7eQ?%axu%#>C8Nnr9Vu1KvqQG^fm6z z%ThVQBhK=6JMw9+7y=uwpx`Pc^F(jy2hSdm8xGO=ngxALP#oj~X9#q%=%5wELuQq; zT_|bX{@(pUuyIv)tYFIy-R1BD+hdE*}XEd`=DDSyNRMN_;N1! zlPyJG$&vG#5)oezUs@-N{$kjYalPjz+qErrH<8YRU8EXBjZB;dKut zXDUSai+EdJ!Pq(E4X|R@aifd6xs2mtIX(XmWp4o$N0%+&#vs9y;2wgzyL5oyZowhA zLvV*AxCf`v;O_1g+}&Lox5lC2Rr3Ecckax*`_^NvW-XHHu29)^&Z)D%{q2VGyi0Nm z4G77EDvH`Io!#8Wfkx++hOvS-pVGxfaxJ^(f)#rO{kD%^E?!M>w&Y%{rg?k5Qs7?Q z$;1CZ*#@0{XpSVplvHe*VoCjYgPF?bdGu|1Hqufz08}sgno~}8tWhO5V1TrHt z&PkuB^Lqie9~Uki!a+y&S)ZUag&bXrz~0L|9x{H=m=@jwNv$IE@znP7A$H z$AP5VPOzxmr0LCtlGb_UVduNHc+wQwd`#hZ*TNRT$pUnpbPLnzft`@rqN9h#M#U(& zSy};`YVPBsEe##j5Ikwbm>h@mT&r=vJ}K#azCe)9yu864Lk;pn>Z@GaU{?Cl60ME; zZr^9wQs@(DtbM9UcsDXG&gP_=L;+IbdoL{)Pp}1Y{PMLyx@t))+;OOQZH(x(r)(Yx zh;@C(A!zGn>WMirXM6b3A;j@Hj>evvD%vO(B^N1I9CG9B&zj_9@&Vi>oxRz zfn^#NH_pc#vTomG`i?sj6-EBqk$Kgb*Q;Dgtuk)m+61_#8T~;L;n>*5m+1?Po;VF_ z)}|pVTk7XY_CamQhY36lZ&13Wb7aDwFpM0ISmwUUJ(~#w9hd8MixPSDas!DFX7HA5 zdsgXWvS@!jmkKIIfAqJ{k5ZO8?)3WYeLX=_nhfZc$tl4q(0zO*CMXMAK?){m1Sy@a zC#6t2`D!;_4Hul=r4@StHS~(S4f=`OkhJ*9fatM4GHix4ZqI{(-r!>HiS*fIw&2(o z$jVsDdVe*GJ@&j(m+kwkG3nn4%o6GMs6}*p`4K% zChmT?{>AM@QG|m!dj&iy4W?6UK!qI)kAidH%`LhYB#ylC2}s;3=oK$*G_m zofK!b#PY9!8z7DN9-M$D=6MIs8`syn$D|>Z`ki$Qoa{dq3`fC}`Y^G&EIo!pUp4jRUca#!q>yD+$+Sp@6`lngQSkbI|A`*6Zg{zwh z9@?yr#VsN-o-(7u+~nx*@h2)3k##V%;b&;L zKd$KM;tv~hstEn_KTb38z8=FFU#5*zw;fca-qW&MI)W@TLu{2aP8~-bx6u;X{Z7Ot zan#qH&EK&X)~v-VWa5sNAgXxH4})r^aQO2HC5y$u48?{cZ`k_qI*MRMbpNow#g@7Ow9GP7S)dYO@!Jf1M6InNOB?b25 z=BC(ZeyCk29?N@$(xplX_kQ@SkFd6tCW2=8DT>Tnc>4u5z1g$oWFGHCejq_sH^gU+ zx0SiS`QU-wl7sG%)+on@Gq*+VeV#6hfN)Nz5kJ^sk}z5Ym#KQNb?%2mu*8=#9QLxT zhn*i29wkF(J;ko)UD|LyBD-qtO!}9H4z^U{PuKTU;d89R%7#|sK@H$%+?<(6FzJgVj%M{?%OXobM=2e;r{SNot8Z>=uU`yz&dDvY9q;9&Jmx4x@B z1gHDs7tUHfyXmT`3|v`had6TvZ#!At$)|H@Riio1JfeE`6y>dMN_C4SeD z%iJa#-|M$j3yZ6(pJBzmnHO~(4b;)Twh>u^%?Np74b9?Z0SW-jL^7 zAFNl08`s}`S#PA);vWq-Si2-W(OLPf)%=*XnN>(|6#x8ie~XQVEdd&fwR+hqtA}*6 zXw*|geP071s7-T!{n;{1xMW?~YCa_0(;}Mmja_7YJvSg~OE6XXFk=KNnZ2} zSNQVFEIfkh<8>c$hf8_7ihvtopeKQ$h93OUox86NS_4y5g(KE!QJcJMD&9~nu~$C! zej+4ir2Km*muK>u+jY_NW!tUVmh*(VkUN`;G_;0tqh;crayvceV2uEF>Z&71!b0Us zRy0tj9LSABGCDfZ)1>mVnj^sm*JssR+1<|TVs|e~oA{8DmuD=uzw@h)*J8~aRqu66 zpZ}Wo$-zvpwP570$kX3#t-C@vwl25+2%@lT`EI>aZ1UY|jRHA^*N4c+5_ABLlZTm@ zo8#Sr89IPOIqq*X3&^sHokgyZ5eH57&&+TlEJMt7QnmU+;WV$IXTmzI6Q8$!B&|O5y!D?R+=p2l6WT2(dcaJgyDNj7B^aV_i~v_$VQ2 zV;M4#;d;rld985CnXtUxZD zj4M!Nu7qX-E4vjW*49iPy2G33h^_4kYT_8sO03zyVs4i4>HtBxK*v9kLg_REL`D#q z&Nrz=y>YJHZH;c^Z)N7%=_AlupAJ~6>~MPuWbPY9BrG`0Ro62#647#fpXd<-ss@kX6kF#d)!IMk#y^g7Z&Jl}0 zvu!jw8K01Y-Wf-@!sMeM#9yglnPoD?+1^N&TtL*B{s^)?UfCm!3W83^8Q6SGOlIHZ zb${Af!0Yu%K@wLtTLK-5;g?^aw(0H0qrJUEDHUl+3=vVzhBVf|^3n!yh6X%CiEC0h z{qPm9G+A|$=R3nyI4B5_y3r4i`Lh>_ig#SFw-L;F`krTrw8XjJ`i;8z9fKy@8k?hG%~c@*;|ojs!4 z%hGQlK!#d&@$SX5mBo#{YOy-_#Lw}SIOK>X6qYfs=O9;U7$NVYJYraY$RUV|cpI@v z+9@IMHeY2NBjjxq_P$Vv$O`k;-qTy(l_Z8wPn(>a*5}ceoQ8Oi;H2W-nYeX!gVRXU zgGKbdyV%bJ(MIqo%y|lrMZxu9Y{-5^IBA0E*zWhUr@HxmK2-bqmb|sSjl}Kz*~*vW zJ$9mcczyl&Xnk_TXztq|pMUt$VP%^N9`V)Lf!!Gd)p)QnCY=$W4fg@TB6vh4cYbeX zXqilmr7A>rlbKqaIktM3K{?3ho{ z@6T|Jz-jHip?1J~&dRVOYT-w%O-9dXqt(NHkDLDI!RxIbZZ=JvZ+t+)vJLXS-12IB zr@NLw(|19uo-d=cgj+mS8KyM!7ziYaZvlep&*nv-Z?s#mNIRp;tuvFToHJ{Yl2qcu zY$ykRPx62syn zxplo&!S8XyNVo#u#o`(tJNKZp^z7-1exbW!`gD0>WPI1ihv zXhAnf*J~L`;&9BMq=Y`1_>Rqdsi1Uafi^qJk>iv~mkb^bZr6sKf2)(j^H$ky+mi&D zOm`MvHdrK040u5R7F9wZs@(X!WZw-HA2}NJg0vB#I7%94#W0@i4G+x=c2S&to#TYo zH*p?hAMdlf^%cy?fY{IU@B(0+2Su@Rs^xnwj&lAGpN0y%s^|D#sT~8NQVC}U#;|jS z_C;MN5-CHhe*gXO<|EgmP}Sy(65CA6CtEK{(vDlMT9Lh)sLyYg-}(rz6di{;Lr3j- z=7xF<3^eG^TVf<-R})=;Hwcjt-gGQ~QKY-&`~A|D2F?l0UoU@CLVaR2H8trAQd_;@ zF|xp9=E3glvh#?3nIqF@F7ROmFLslZWL+*;L_!#N{rQc78&R3{#(Xq(>->->4y5D1 zASDJxdu;IkG2H%*Er+}BqMG@U&#NQA)1b=6^?nm&d#;sapYr>UzahRXtlv@b=T1YQ zo+41sy5Q?OZ-Kh1?U;1mD<&mxA89S{MXNX7=W&~15kiwzA0WzJH%qa>KB5!#4sKeq zbcX90yck3+Ut6;EOA?wX|7J*-HhVL&NX4-JVo0JUnY5)P&%6=|{mxU?vK|HGt{?8k zB?Kh7f6v?iUvb(SDe{L2rQNDj4yTj!=r@UD@hk{EMo-(!AAx#lhe^;R`pbs&#G(x9 z)Fmwl7^~sIz5X1RQm_O+mf1h!dxVo~yLE7uPbYAX47el(+ov(iIRf>HgMrGO9(f6z zV0;8&gukzve>4+76ANVlH-sYM@5>I1Xu!q%eSY7-FcxEpT?i5Odj`c7?vU>*XCsxZ zr{iiH39P&|+qai!RoAVq!%Fc_#tr*KoEE;ASixQ(2-^arsh)T_)vkE?UwoU;&6&h@ zEQd6Z+b^rC+B{sS&DURy8qbnR;y7nLUutyDUuR{@R@k2TBrqew6%`Sc0@OB;04ynK z*ZV({QS8}rBs7#l;N{DJQT@n}kdPJ;GOR6vG7b(7z{I<@yPI!=X=|jf|Ms>XFM3jy zPV(bh|8>z0`Hmm@3geObz&Z$+0sLxfYXNpV3nK(TP%C6&(Sz}1e{-zOO-%rAiw02a zp10?>n(xd1L8$>3f)XGwe?R}7);BZ&2Ox0q@c3KHWvj(p$LL2^$b9M!RHS1`R-{u5 zPGSz~+3MLu%D{m5c-eP{POmXj6}$x zaSsg}-_iX2Ns-Ba;P8JO@cWNW;r`z1`g5kgPWN9K>J3|-+kIU=5C{aT&ib>UEY&DR zg>jOz0!?d7#tcBt}X0$+Ed!VvRc*TYxX>upf98&ULyZ+6=`Dj z<`Vo?bYKCZ$_1OjWzcEuk+LzcWSKKC%4p?fV6$;`x*_Ws(b|Z#co&Bnp2az_f}Qd~ zHF<;(GFcB4HXyvWG8P;6^A=xw(bCeFZ$MeUbB}>`@MX}{ul%80SOs?X>Nzl2`+1xfCL0I@ENK63US zO!WVN*%~*uw;2HNTl~EKC9x4@M<)pV$uqF9zqcZ$X0*=i+yOM-{zZPT=TD;hoX?A2&N znKJyt{D);Xw+(ceN3S}n^x?^86DI-L9-kIz7Cr--{2rS1%62OFMq1T2 zJ4U<<4YGQJhnCpwE88VrYJ-%ywzZajPF(*TS_%@7oRBuUah-nauYz)QRi(p4e<+qV z*W-elXVdxpfIXn>vkqEI$aRQ8*574Y{@(uPOE>l(4H~S=joZdN&qwgM@=3gK1 zrl#0c4qQ&TpUENTXax*?1bGw>2|;3iF?q-^g@=cyFDPMSV|z;7o9Yl5n?FVtaXsGt z#%MpzrJ0l)s;PAJ@PZ&0$h*8?ezaxJUjBlr`aISzsH_d1V*YZX?H^>38N>pHNrE91+cwkVIg{eDJw$subvGDFLeD=uGmKKB;^m`SFfH=O4z zvQi3;EO$m!=e6Emk2$+tSi4zgt41isT58v+9i(1jd6OAU0-k2-AAXODih8T5&=)DP z)|+Z?3ow`Dp^&FGrr!3{NxCVSVFvZ1{E#O0o;nCOmJ*9z$*p9oVLusg6p>Mi%n_sL za)36;!~TQ27?x|Lg}9V)s+?H1^$-=&#c22l))i?;=&RGKHtj9(_6|R4g54+)XfmaB z`)rJvRB5+}!}Ft=d*+|yotF(~Dofv_Qn?;L_<*G{*5fSNc+&S*dxv9Uf*VdW z8FL7!3_*kDZlen!uo7AASUft{I0{XpK?gaQ3eSmqrnl6_01jQ-t{u(!h?Kq1KgK;7`koIQgzKo0xbuH5OugO)MeJZ*y7(`}}myBmQ< zgDD5w8|6Tf#!Xl9!mEr9h+)1td)dG&=n8K|Z-~rcFzco?HHG%95M=O_P^g>kNDQls z?qpbTo;@ivTHC_wZpFdeNIBh=DGi?8_)F`oIO@@X%raVIl9_9L%X408>xPJZN=_Clc4*)j62{`pADV0w!D+Fe z^+ar0iI?i^6agvP@1YFW&+W9@ zfP9d=-H5rfkCFK+#5cBoC6@buYaqCS-FQo^^c_E_#IW+~1*$2+uwcSBW|ZnH%L>Hr zs_HCvC1cxr$_^V+HZ}%cFC4&m-MO7=N5D1-Jrh&-E4plh`59$_wurg(sadS2zgUF> zUI8CuGm@dxT)zk_AhfuW$?osL_OCS98#fL^1C?;~HH~6ZIN2F0j7NE3a02@o0R%vw z8K8J?|3B+u5#D$|!bn5zXJ__#-3~?ub|!dtBk3axg_y7JNkbfP4Q)j^c|~eQ9H4lmy_F;f?2At|x&< z1p$NKK**~%FTXL&%)%DfMA3-azNT-0Yj5ZnJ3Jw~&ejMpw+O?Dly@FPu)aNTCNA6O z*QB`*!(Jw6+FF4h_lJByGt750?dQj!z&GfS%F|iTre*IQbO$iz^MH!25(Z>*q6!0L z;#=wYp%AK8DlnXm$y%FwGIU6!XSdZ0=j%&8SiJKtppUg*Gs^ZG+H5l(a2O1z0*^!_{ z-&5`~rtd#lhGeC%0_qQ^jVUqD{cAX%w#09=nd%QmCCGCGYjAU%E8(c2l9=?!L{{GwIKRp}6CB zt-1;eY9&$Bj8=x|(6q)NB{>k*NVCJ7iF~Qfd04Vsm349g=U1I(`0~x7c8mqZv;{)I&$HGY9>slBr!0MG%BwKbqZ3(PQ$T zHuHM_hL`QD4Hwr%=!g`b^TN`FNahMh%dJ!!IKu0SB&IF7_9|k!H&Cq8X0boOu2IoE z!+N#ynEai!-_2m78cuWT+Bqfio!Vfvw5p_k25d2`l=J&ps zSBxUe(8t2|7RBbniM3zUwVP_~i?0VFiXla`xpij*9U!)2+ar)9# z^)fG4A&|L7$ZIi9)O4Lg*--6E&;wsX5=uz-sZz7X`QqjJ#ybt{?=|N|BE{jP39W0d zb4QXt&lG@>59OoHQ$E?tfm0}dp~dHp*j^xwX zI0Ikprf;3Zl`MF2ZI+EkzTPWrmtA__`+8T4sxA0o+GJ$oySTgUrZ)DeZuS!0aOU;K zjG<<}wjo-C@m6geR`2sEYs#PBjc2u|d6y6w%}f^`+(LOui=^bQdTy1eaW1bsjuzK~ z=6wnL5FzF?;ZzsgnIZv_0v7O zc71~MlhwQ_+U6HV_e-U{IEY{y)RJ(d1LQc1j<~kb$=DJHZI9)J>i4<}q za6sm~so5`?irtS)w~1%gk9I`@k5WtR3?uAXX_Q2@cTn2z+O_{GZS)nFVe>vVG3@MT zJK_&osUcoF4{9z-;rE@MvN)M&;BAQHFr+$tuG`Gj{}>mxJ!9p)Zyz2v=O5dl*M5gl|o3<{RI93sUX}OxzGpv7@}_&{x1k-pZd(zW0N!dS1~5 zIC|SGlx!>pnynIt->%_Nz>cK9)L?}Y%7;hfGmx-I*adRuc7tz8EGS^%_Fp(OLJ2=i z>ZW&Hw7G~{U1gnrHFJnKf@5Ktpn(6o{Fm(K&m^Q>&Reup4b{)RarRs*4c+vR%A#W^ zA;r}+tA4+r00CX8<65u3{U%PCpOo|Qm(Cmbo^4K&mydR)?KCAja$~E`mTx95Ti;t0 zu5j5efNA4P?e6vjx|N5&4xDn+@tt7}(z5JD6ra?Sd^GV&-`TtSIWiL;PLw}t1Ban<(i{75YV5p#hBQj}zE=I75@y0YUXgx$cx zD@yH@063`{#MFN5(|SsEuu#vYz)AU!=6#sG-(*%gbu1i1E{zOoopH)lfG7+mu!fX_ zVB&Wo&VBM;?+kdif?%fUKkpV@e-=5^sw-c)7u4=#>_d zmFy2>8J1hRVl8Uxy*!vx&g$$}XHo~bj$dMl?D7{guBZcEj!=XHw`>up9c50$on-}Dcp72U_x2$omLoMyjo)lcnHGnUe{io6~;0s=gbicN(6< ziNF}Yw-26T?H;dn#oP;rAz4K-NaHHTCX7gCzFL1sdD-wttF0P;Tv+=v2hdw= z^-p-5y;<5o&}2ab3?;@4+uuv+tKrddBz@)MpMc45f6?ZO{v1ehH?Fw;&RA0o&&s8r z>pT8XnN;3-)Ny=AB7K<1n3!_lfZSj8dynm}O-72ZNJ%wzyrce!nOLKx9jba0&k{_s z_kNz97eo2G#+$mx7u$HPV!sU@s1x;!E)|adfb_JmF`8x|$z9d$7bCxR^l6W0JVj(C zF*tf=I2J$^E5qCnmegIkA$n$TR8|usGj!-Uz_o5Il#U8B{Xvb|DL(`vAXtiajfeGV zIlp*b*u%nHX^Yh#H|!^I;`mT|Bl?RU!83Wb(Qds@<`c1E*`#HX=y}d%c z2zo!)_3243-u6i9KtF7_X-Gbbcwr`ImD1_QgxliUa%%&GporW)rMzg)Jv3U(xx(d( zcFUzePn3>!!r}RYtNFG20!}yKtE~01e1}lm84-hu7GG7X6{c6_{3c;m3 zUbV|&z1ZvtJF8=NiQaK}G{I7RLc3#Y_ub-KH%IVLz?ubO>cPF~^Im<_(;45W8b{ zDWolE<3OD~v3stGiyLBcTjE&+dQY3Ns>z$s{F(fb_liI_6WMSebes! zm~6L;G*>jIWvIbO>`UFcG zwd8&kd4iqG@zZ=jAXK+07QI$m9+EG7WnG+~3Q9Gpm6r6%Rj<8ZXy2t7FSkmUljDDV zodANbO&`hWQH$9dslb&n00|bBFt#3!#`A!E>Z|K$3B9y?){tbixSIUO4&BS=XrG&f zIV@S=P2ZSTGkoy7UQfwkwx5(GnQWV_&zYhXs%&b{%3O1HBh);Gk1o*{n-|^1K#}7N{XCvVqKwb(SHo=}BMWad|Le8I zCYBIcs`PeE0xtMR`>f>3Gu+~WAD~X;aUASFst0iuHX;|7fX{|T0on&Wuzg%TBP&9) z4>>~Fp~S*MqkBlNDg4|k4ZYB4jL_ERz#ugNqj!hqaT%sy(eqS$UkJ5%6(N6G>%(eq z;cLr6w%ihf17Z2%I}t1gbHPWe5pi8Jvi)h)3}rW1O1Zq}1u4+3V!g-azP?QVg*E`h zn9T$ca99j~N4O|sR*YouISUCbt74mh>55F_4doG(YlwyWqfi@_Y+YbdE?JR|XDJ92 zR=E zz;8*za(l1!ffK? zZ@-HoHi~sgYJ);WB4t2)#pm|#f$?39^@pV)>^9Bk1N#Y^*`CM#zTHnZ2-psklLp5= zKF_QIe+m3eeRDW*0MxgOi!Ubg_!fg)=CoBlm~$NYN%!1!`5anSSAc~q=Xn@)d}KEH zwrGQ%{WKn1p(Q>EF&@NJyi;-8R9ClsSADX6P1$L#_b?%Huzq07sh_5Mrh@$Xl;hKZ z;~3+c6o*ZQmB48$i?`MLURmn1ZN$0wk>L+lHzA<#ruV;U5Qp|fX|}1~zK8+nY@y)Bqf;_r1wi&pLcb-p4-pcF{8AR>~wdaDPD<5z;Qd;`6 zpBI9;i||38dIMq?Fr9`Tf}GH0cjKk<@41}M*^XxA%XJRyKfDxx`LxR{u)xlF?P?Qy zE~lEQ%-YmuZx_PpZlUjUol8x&f~)V3ugQmP0PF5!e4V*W@0sJLCB<$o!x}Vttn5k! z*(`hsJbV^4yf^E2vd+S_MFtdu4yDNpg)`{^FaQUK@i;tuVSOp)DRm|fs_!B^em&S) zC~_!{AY!B%+puM|dPrZg7-C{HHi?zQMkDm>e)Qfw`8js;SRIl62e75b#gwXEe6oz% zskG1KmWGBG6mzanX6CUh{G!%D>zoo>?${XCk68p;v1LeE>F;HEXmXg+kJ_?;eFx@< z77Pl}-QLfNn6w*wK>grHa|2`Rf&o?zHtm}P?}r=8`GJ9jkaMYhpn_%UeyOSBMf49! z%Y>@rg)tPl=P-m&yVVvf-9N~9*>uhZ|v^2TnGsx^!7{!?FDueTNim7s5oSm<+dS<3emsd;p(2zX=Jq9vY2p9fcU$yiS2 z_l*4z-GsrIuACa$r;+spR|W6E^u$&!t&=>U(DjzbSm zkF#>IcEFy|nZC)hWfM7j_EF!aE-7CI+CQm9MIV!(U*^Z3 zOT35wtiIZi3z~f2H|K>QHNQo+diKnpzD00z<4XAcXoJ8_f8Yz-qut?ltEn_p{^w7y z^^Y60h1;17{hQ$;H!P#`;2D6yFc0fXW&Ct~sTS`u=`_Xe*KvEFJ2tFjiL}2uxGVGz6MzIA-li`$tJ)+~1!9FZK zU9=YAgV1r4jDAEi9aD1qd@QG7WSC5XE}Wa4LvR@K#SX2#!9gYC0dZ;nWC%^cKKe-U zDnQFuB-d`TST$bq#?oN`KgtX};BRlxTWPm~$-=;}O9Wo*!&S4oHx(nXv6fAF_&454 z$!|IQk=xn$mN@)dd|tAcK|5dhSfisat@3~5d?AyIOed`AVAb%(gw6dMIc4#HqxC~^ zJDIM8WX=?)=(e|CJ-=AR)e5pQZf(#MOj3+5UWwpZSEDcQjWGDM2l}cj{0W5p-s=}q zNK}|<0x#W3g12hKo_gpBUyVP?8$|b~TsHIVQ}0+2RSGcX^`mm(RiKHh_D=Y`Y5sRZ zdt#OgZt%Jj&nELyn%qT_HtB>V#9|q~Jhl&uz458OoDzKC+Cae#R%rMjUHPT3Y{YzM zAy%*$+FKmDIR^s-746-o1?P<>6%n-m;3;GEc`zwp*Ztce9)3p#hkZ~__ z4G~MH>G|L`UU->?JXZT5YdiS;JfO$r%p!9156^b3`A|Yn)SXcX%oqxw&-+bQd=E_0 zGbeV((w}ruD3;K|@^h01m5t;+?bq^oxA3C27`*4* zQyKXl31ObLtivXO!g1N?_e{MTL{!O$va1TGA%(Nc79;%PN0?+S>b9&pR|dsv@77f+ z(bw@bP^P&nQfu|>pNQ6+!?Im1-EUB7Sj77(QIa@GO~Alws$J&=wP6FYceuiNclXj! zRqHWI2H9O(w=xgY2|r2=C4lJC?k?a?AddvXtHMPdlchj;_S3bW$UrD;G<<5D*FaxTWB-=)K*5uTHma?BYto%$?~)-DEMfH0gHMc2gJ{4q%P; z%ChbeyytO6L=SlUn7KVsmp3c~OViwqXD7F(;8ot+zrVD9>4jJA*UP&}9!oY(nlHV|U!*(iV2saPMNkAT!`02A-CxC%z?6 zF*F;EOGFjaN}dT>D@3y&+vN+Gd62vdx34o-PDm5=-FGh}-eJvR2!DzV9%~_u<{;d< zpA#;+t0pAGTKtgGObuJuNBThFw>z6l1ojwVsy1N6Iuhv2W^DwoRI;)TzdTWiesG}s z;X;WUh8}W!Q|~Rqa+6}>))+3W<^IE7RyKK-IbO%g-+onwr~l$ms@Op9&jSB7_1FG#ID?+)j{ zYbf6;QtMFzW6N`*=8x0 zd{}hT3>2r+r6j8N-s#i*sL3lw!sm5dnf!#5R_i-Al>{1Bw1+%&tNuK^GIzCf~*MxMtE#5+YpzaM;(fg*A<-j5~Yf_)OeGe2@6%oE3sxn;}Orj z8?K7Oo9Dq@+6&B17lOk&JU!oHJI$6H5r#!wO+hu-ZyFe`Nv_h&m@0;3mUo0x+QDS? zo&aGxxtOpJ!?F^aelcFw0TFBGYkEWui=?lI8b55_1PTnbNhiJf$HemtJh-=G_L-C8L=I0Iougn2;dZQNZ18>W+O}kNFkXWzJVegPF^PxM8bV8t zGdJsRr_7?_!vjg%97z<{D5SJ>BKI^l#@;>INZwW zap@PKB#?xW1BuFKlYaaPvrsLEMiJNJqZxIT#5xRLm48p)%yPA$9A(peCrc|fQQQ^5 zb}SHwQcF+0VuG;Wqe22SuiX5cT#XCm97-1+`#j7@D3ohVzr&*sr>ZPs#%X~PEpVPx z0%74a?7qdVqAuDVKPKH7&tRr+cr~VyTfXl*+k6vhZ=)zYSI`T{^kpI-zt= zaxF?3jq&&|YK!)b- zerM=uwIP{J;AUze_2I)40fESoz#nH+`$ZiijBp-EHwgbIkXX|8rgfz{#wTfc@kf_T zLyq`Hb$2`)X{m%}L3xXnRs``stgW+`Er@?xS;sxGAXL)j_o%-d3djx@AX<%f@iPy` zTo_amLCL!)^FGpl(`|2$S=mOzUUFKWZOXi(sF|ZyEP4l~ySVC#eB58qYP=yBd2PW0 zp_MEr@aG@dfm=J>;h7<-dus>=KO+y0CY{EnC}1-i{~_SHJ~T!Tu;PE^RRKhg^rrVq zRK!Q~t-ZZqjg)6Oc!8`o9JP$ys}o%}7w4#6w>%}WMBX|pE!{(qR9`g{3f(b%_y|@| zKxU@F&gEoRm&nQ)_xCT2-m&{~P4aWwKfjdUbNzB5nt7siq_wrpDpxffzRCD0=3p1u zWBH-9-t&-RgkQL9I5{GtOCU03o#rWvgu`zyWo=(S&e+6+(#kEdp=nMSDLOhj0Rh2z zZAO&70@vRt;1{%$jENLXoZW{7C4G5Q9F_{V!NS@A34BEqsf|tktM**L?92Do-&dRm zVEVKQsIam>ORkW+mG6K6;i!bvnZn|44jfSb{sA4v8%`)(@XbO)qS~`E{#IPB{C6-M zeI3+G&qVjpm&$}<#vOlWu+av7flzSN z4vM3vIt~q$&q$Xp_{rfj74zH9NJ^Ip-&={J6oo?l=@W#ge+T~v!^jG|cIf_53@Sr;JBo3>cR`Y5el~7H^#4A|tn5klyiK%2Xg-l`@bF}!| zsEBn@z#S;RybqAUFJ8P@-Pp(kxI;2xTn6zwyqQ&cHGFJR9|-{7oX3N_pcC15~4wloVhc{Ws$(HGt}N{Go#XgW@CkXc@yC z@*4`Rj{awKt^Z((aUnzg{ibV0Dlun(O5L>ys*}H5R}`p>;l}_B(ig?=OO~(Firh~# z4c)9{^6-feXRA)r<4nv${XN;;&Q@6P2(3zANJk z8FE(`ppYcd1GKL=EXlqkr`hr~^@=AS25N*?qsr zM}2<2W+&QejFpl>_NR_j$Xo0p3#z;iCGoXvc;GzuRlJ$1L#XiC#r z-#l&Qa^6B^YziwMN`52Up!R#j-)KBC<1Z~Y*(V1CrCnnz=B1|hO(*B!N3J&;rOe&^ zi=!7LUtfxGlrQwf55l!lSjB+y+wb~B!gqB_2heoUKZAoxS$vNxPmt9)+>Y<$$WV-y zBp3jcMow}_ERy=BcYK`1f$$X~;y3_x0#a6Nf-`uu3!S1+q^RLd_kY}aMoBRTX)=On zTun!4vX2&`sZFTA1a6h~yHhQ0HYTN{Tl>T)kd|CFkDhWI2>3`Pe&4K_340DZvisa= zJzSTS?qcl@8zE;jYAg^>82S1^%Q|&^=X64=t3Qd8(uK#2D{663f8KM-9P1WvXm!ft(0g{TSf7Y|hR*Et(< zx?;W%$Uc@1bH!HwzT&fs#beUFi&qcv?Gc=QIxCv`Uv|2WQckUj++-;mZ(J;;3;lkF z7%?3!ep?K~e~y^%fG-t~e5l!PR8{Vny0IQoJXX7_W}NBP>PLsG;5Ufiz*k>i@4B<9 zhzp2GxMtQHGMM4uQ^{(GJ{j%%$3v6L@LM?5r%Le+oR>Ea?}n;r2wm}zP5Qp;#FXEh zN5A5m53orp-B58zav!+8e{evjFJ3>LZAw;~Z{<{SS|QcPR?S`MAP>!p;+73Kp!Li> z*K3;QFUAjmpUfJ%twIJlC#T4@(MER9B-c>D>P1^hdebBo6YznLtWjK%}2{K4YA5aPp;D? zj1r<9;Y+obLjsnTu|BC{!K`a%B)8rMzxKDnsDO2REY>2#JLO=sMMpMM$cJ0k?5XwR ze%53CCNPKmVr1ikPZ95s>JreX2xDSje%1J7NWfl|D&o}Yj1PeCj4%7C ziYq{vvK~iBr=>bt*Y-iSn<#mw<_^(bsPnr&_Fd0t^$H6^%S{5d%s-X1{0@-jYegp_ zB>^BfvqRq?V@J^8fTv?I!;qMmE@eqHYnQl2^0QhAQ_--yr*hT^Ob8qXw8rSsnT?AL zOs~c)o3<|2s+r4aMWK=Q;N@mA+fdmt#coxz@vO0xU>XMSr@ykKY8pCLcYZab4?Xq) zx1s9p2~b(=8+$0m{N~yEY$&ROwns$P3a750(L-XD#Y*bsnARSaWI*H*C`m}96Kkfy z{*{TNfFsP_NrTs|$Q1)> zk?;Bq+RW*z2FZ1bflPg?QE6eOOK?py?q>|C!_|hLXecw0N4hO_7S${xRN^39JD7V; zx34WQ7V;5KXGH$H#Cqp!#Pt}UIUd@uJ+%yI&YcuAn4D+*z>5ncXq<*&Xz>t zpApW*dcRjiyCfx&0};qQ5Gbd_;q!^xtbYrTnfXJ5%H&9H?Q(f9fvtKVik+9R{j+c- zVcH3o8(s}d2YvPCb9nkY>VGFfH+%o8EK=Fyt)OB##I`ex^uM#WP|{np3WmA)Ha|!5 z<{JO_A5PlUe-qpe6#Os0E!pMHIe3m_6nrDI$8!0dpKzK`-;4jHazmD#(IVPp0yL^0 znmjv39`YcLxwK#RuZr5MpxswMSMA@NZv&la!oO*Pfeb$1qoMpooaKplM9`7_Y>ve> zX~^VaqLyF(M9NJAlp}nkxV>k`Avir2zw%xiiGzop6m^VRBaNp*JXmCniWbabqiZLx zLj_DpD2xGTYOzx02_UW0ho&dgL#(AURjmzF=eN5B(L#@oNL;-gzz38@G-Toim&MGX9ZCl$(Ah?9!9w4~8LvZ&5x5nMwI=E|a4GzKG-QC??8h7XK zWUaN&-e;fd{{o(ez5uFfRLz=mzT^D}vQ^eT?-#j+;mloaeb;;p$gb+GyiX6Y=9bCQ z5n&!3#cfYEHoP}^__KxOo-q zX>BThzW)>$fF5S!5V6}~VHS%&HbMn&yR@LNhQllrDv}&XZSu{XA`t8^%LU`u%a2LX zffu40G>U79;yqMVu1ji|97bZPgY69J%Scz*>P=b(1dPF*xX|T_C07TJdeQN1m~;8_ zLGWlew#i#0a3cGt*EPXk3)tWjc2is~H1HwfOY*J5ll~4Ok+9SsiA|2o%H~lfwa$qj z&W!Rvb8hX3tOqfEgf3b%kXjP?yCsso2R*cQcKfCF7_a5!BY&tgTEV=Z@^xF!OIJBt zl>O!7MU%Z#vK)bc7IbTvUbGiF6c|*Y4r`I@n(~EL zvpqw6?;e?N*=mywa!xUgdo+&N#_P^7_96urJm&&Y6!i~tc@;{ttHqIEQ*;<9*|&Iy zT7L1kBSQJPDfo0z@3jbqkXd)ne{J9p6kFD#cYz3 zCK)UnZ?yfX!@77pI2dY_! z#k>Z(bk#c%I2BZg>y>Q|Ska|hrvq;Y2spym742Io%1r)&8)wW4np#FIPRpV~8abp37UDr$f~Em&IU0Fjh@YnHF2<2#k@RmwQ8oT1}-w6Dq1XKBOwpx z4|SaX;ONP^GwgtwzEztqr^+5%ng9&x&^*mkx~XeAUH_C!@ZH7(`dO0BT?n-pqJ)YZ znoAeUhbPIIRXq)m5sT*EiY=t&p6%N|v9h$at}tX!VR&xh2GECA=1baX#Uh4Oo=2Rt z#yYva5}~emQl7^w5)@U^{qDSPqKIU!;ZasIMr@)eEBesMaJU42uxd_P$2@I#(Xqq> zbjt`FBeb>s=6um~3{cINNL8@&6@i5s#uZLtIl%*OIUK(p@;&NU0M3G5>~Md=Ua zCT!Mx1M3NmFa1*ymViIpRm$v6&)+LokACg8hW?|Gcsp!yoaDKg&p zXN~1LE)3)}7@t=Z_4O;T>JfZ5*S6cN3q}BGM^45C+DU7K5!j0=G1pdSqdLqbxqCNK zv+v0l_TNr}_ad};o5qVT>d?yA;~{{3n#&=V`tbDQNjsNLmpEdFY!6px4(9;HdiEie z$UM_bgbb|uKi1llZz}0tq#+(U8M9jM6ID{oR6vbXH+|#}LsPHfk1_Z{ffXxt@3O&> zTHgy>dEb#(Oj5h67M+j#KlSVIn`mj;%z4I|@M=2NA*d6T(I_utbj9k&nULta=PiLCd+=86qBEwy(MW)){Z}Mao<#@&gCgI;fb8 z0{8=Geu__+RZoZSxI0=3#BHuk7%Wn*3KNKfOtsV3>w>%XwaZxI0ttjPilOaA=fY~_ zuhbRF(sX%p6<;3+cZVo%!S5!>FpNf}*|4cwbC(8ZhO|7L?y(A@t$;bQbR`_}PpoyyH0$3}U_}~{G9`9Z12Q}2 z7I+*nr0UXl3nNk3I4?GJ^CA>Yg2Y3cE-kgq945p-;$4&)oK79V_RuPfzW`3na%0(2 zDU_N)PJ0dz1WWG82}k(L!QiM%8w-wzjhY_~fq$82-FJM)54A5TH6m?04)CB=!m|KQ z*0N(D!4yi&AkQ@q#4&axKzI6=UlD0Sx6Ovh`-mTefKI*!0BvViHZ#?Uy)r2+xxfSyt1VX9Cu5`e59wzfI{r zAjxVs_GhG!Px1tk17(lD+@d2pW?vWhlvx`c7Ux>|OQ*V%=eC3qJG4FY4AI7HKj;vD(i&VRW2){@A_wR)c9t?Y@Aru= zw64(Wc)KheGVUmjn)L*?!qsZq4|4;lY4A_TTRy`T zfj%Q1Sce3-5|FE8N$FU2;>Dz{ygs4Av=+X7@BRt7?mE-9 zu7;AYCL}L;`r#mEk8A(=d<|K{sBPqvwTVn}xGsnas*1*}}RnK7e$P-)BF&-|%wxO&DR?~)Y z&a0q2w61X)EW|Zb>UkIL#H(*jQ=F3dCjY6xWi?c2UiyT?0cG!Lg`145Gw@P{$%ff!UHLsnvS4Rp!xyjac@j-wm2xEf!k^$ANS5Zke}aA!mAO% zq*G;3eE1GG*{Lj2pCy|q+aYNH&2Wrb|LDk4!L-H3IkMV1X*S%xN?oz7Pc%KJtoQDC z2}^;^B7T4S=H$)^=?T?GE1ZpG_#&97U@#rewQ7AmF##@Zx7<~o_sEB^()NJx;eA#D zpEYT+)4uS^Q}n2*eyZX$8By{;D zRg3BStfQG?{s_fQN)6!tN^~BlP~7;3OO<+eKJ*_bs~dV(HSqxIuC`=;`ysy0I=ji` z(nAE|`GQMe^oh-${8iUSqMt-LQmwnh1o`6yIm4j$Cv^{xCm6;`;*xLmnVReRwbzA0 zKVZpS66(OCiFGFMAXb4w@#YJ+=NY8cykd>Qwd(G7c#Tp6#+}p@g&=P{N zk+BrcH<-7rFAwpzn-BA`bgQBnTr!C^oA|Cv^!l&yFFA>H5pmc~wWjj^kn14AXK;i~ zg4n$MD17)3pBqLkkyfJv0P}H?#x+aeQSUt>Q(jl?5#+Pneh#f{9r~Vat6MC73R~sz zxX8)!^3a{#%hPdI4~x0evkzAQ&0k2`i*IaYR8WL1nHUpQPu5lKyzqVPDvky&b(o-s z3kcterc60PG~_=GwutEVPG`KHQK(kB8Z{_0*|4&QVsi~U=sqGzZqt!pSrr!MasY-J zXRY2-X|Z+|3d>cxVIFe!48=+&Xt_!(%{-NX_S!g_H`h7k;e7fBbT>5#XTsS#Jt0sA z(#BE?u!PQL(i+XU)T7+?*ZW9pmdm}Fq0aRU&OAF$ue~DXlCwt(S5jm=;9E92Z1%-7 z=9!L=9SXq;xbv2-@Nv{eziiim9dr7L#NBLpz%$XwVV}iQ zAqp=W53%JAbytjI$v)pOAHouK1Ji74v(W71Gw&bY-ja;< z|EHtYT&FV6k$}l_=6mi~)^57lA_7Q1-r=fCFW;EA7yVqj0%ug5`!mrCWiP5RUT}0?%s3OH zslT%-281eoFj`a2PG*X1pu7Dy$*tmvt=@I~5G1Z~zTV8!LvO)m9Da3Kz1=Y<&X0Go z5kwqG+f-tdEBXla_2IP0#3xq;&(8EqvWK0OG7_!yXr5#eX10Sq6_Xc-U{jvCG=+R4 zivrL;B+OB)g3GRV5`0L--oBFlT05D=nr#6CBX)i-erpZ62smf(sCB&I<*0`3BWr3N z}<^<-F_;sN$J5MEy41(7Ry{C&819U{g zjlMKdeZ4p3ew|m=zshlz5Em!?Y&kkq#so1KNcGzV*mvzOK%W2#uU9usEh5fA^(b8CXcn6FtTFg;qZ z+q=xhf?b>1l0RziHm3N%Zq)^LO>Tp@l3vzC5XdsTEdIAVSL{S*C3k3=St!SM)_0 zPy(KD2aa$*+HCZ9+X(M)6Y&M#ukD?nB8ob>4iG98R8h#SWjYQVxd*_?XfU|-Xv^x< zw@-{r9W1-Nao3zu0*rq;BweL+M);VJ`U~`>RJKfLYZRkM^j7(4B6M(?~q`eGcg zqVU4rfXbf(?3i#2Rcqd5h%Awu@akkkDzlK11#i-)EoO+Y`}Qx|!EGHj^V=4}JvMG7 zPP4!ZuwzaE57k!vYe9(~L-a+vlb^eIonBkRO7=VlmOKz}BP}-f-T_E%osDH}2E?36 zyHlXaZ_3?oPfX~HT|RzzZZM1Sc{QIar(Cb}lDP{;AeQHxG*l4SK3gJ}@>Z%ohe}{iL?h{% zh@Wbr5cblU=BK^_>mDZZPsiuvX>0b>nbFy=IOXvxmpB(hT&BKfPWOSpSI3=|K<_rd z0#WR%xh8Kl7Pk>;KvIcg*ucaKyA$317r<+qDnmK#wb^XW!Pt)lP_pl?Qe8!qSj6L}q2j1UE6E^STM%bUr8}<)x;kj!o!XaVYIXfF~!LA;- z?NQQPSXv?nnd71w;xzuV0nR`b7xG_blt1aWZL$1q4rUt0$45st&dzgdk_3Z~qCxZm zV6v{GRkk-3i3F)dk&l!6B9do-|#Sv!*G^z-&RyC2aL;c*i;R9 zqjwXl8eDvi@aPrPNiNuFTpWuQ7&@)Ft^Yu^&VsXpQOa#;vVSYTiFa2_LGv61HAG=!O`GJItP6%6CGuU$g80Q z*u{wa?`yYU7i=Who%bhy7fit6{HOdh_HxAcuX6rV)4#uo+x@*b^*^8gVTOVXV(2|F z^1P;e?p>D-G(KrGBE=3lL?e)W`#tOuwMt`~G(7Oh5m@9d%`s{I#?^kS@qWEo%j4`- zG4lM&m?tiKaqRnHpui@;!b3kz4G0gmnJQo>fnMV3z-+e1!SK`~z&e2d{$Bj|U+)G+ zMMp>Ty(a%-$lC@%|4q>S{m=d1iO-@$e{^{4?CigFc!q}l7m9a}k01?2x_>JA>`T$i zp@tIOznD)&fcf9dC*Q+ttdyEDx|f&NA0OV|PV9d}K7X6?Fj1U$cXz>84HXT|PrYQe zE~K96k84kOw#9{sl@+li=wD^^Z^AFhg@C+(TURqL-;~(z1OG1!OfYDkLLVbn^>a+XmGfrw|4FsQ^snj!xVAmZ(Qd`Z?s~pb z8musD-o2m(%l!>x{F^&C4sRr#<+t+k(kl<%|Eg|-k5$PR?9z??EBd(i@;m!gLlxU! za?mdM?+38yF3+MEQ>{77_k6$Qpq=uY(F~u3C(mzgdgta;fKuHeV0WY-SRTms4e60R zb<$aq(9P9VqCPnAFEZ8b--UaBg^;TONA%O7!a8TGF_K2Oz%ke{za^(&kK^FcDePy8ZPLRJ^#5N|$PL)*NJ|ENig(!_F#2QjF#Ij!0hXGY|DHvz zT2T38NRJMzO8w`K>D_X;nrm|b*CW{5_a|Okr$!zB!CDfmMh^%MhJAT?@$>Wh9dA!f zT?8hW^|P)3Q^UE1r}D&Cwb9Wirc)fcf<`PIy_uGj3y+R$92^|KaZc9KszGo|@1XvN zO{ovyEwy)b`Y+4;m2uB|S`t4_agU_0MxZ7xZtl@#UmXKN=T6Tjm#|W#Z&Z6g&LRd@ zRs@Y&-)faIaOzAT);150eKV}o4Da{p-U{gcrGxa{%MMND@ro}(e(6{vW{$ufW|&-i zl)wQtx2$f0Fh|zleybBb$@Vcl$8LAN$>Q_(^x#I?z*ds|(B~Syx)s5=dmzh?NZZc3 zRN^V`V$4Pl@G$#>D}DL$$)0AUl5e4M{S2@Zv#laqSY+1vcN9nJg{=o`vo>EufEeRALILX|kM*X>Dnu-WawMzb`UvIu1oQ`1z z6K+{3y&g^75Y+NcLyd$vnc=RfLFeC;lgE;ocN0y8=`CL<(=Lj}%OoDy& zAF!(AUEW4URC&IBdt%xlH?Q`+cj1eaV_;)LS|Ov}f*@7$to`4{Oa!;YLl5ZaC^M8%>DuXFAv$JdtLVJJlx~s_XNN|>mNz-D&ML1FsI01}ae92H zy5V0h5napEkFH_jH68`%_DE+qnz;V+aA3XZXozPwUy?W5Hr0Dvl#Z(*0qUfFbm|&Q zx)yq1avg(MZCTSSnv5wL{jxi}-|LLc_uLQhmo>3D!ph!SA;o``+7xVOEO8y!kZ8ef zJY=#WY>i~=cmcN;X|cpN>I6zl7&#s$RzFEiI*<2+WFyWsg`$JbZkix_ml1x`+5XaJJ;|^b3ia?aOr^f?;xSCI6V-K>06& z5Jsf?e?*L}TSl@nlw=C{xc_s|mO1eN$8Ec@ntu#kIvr3$=;6Y{j2;UJo+_>r+kBsk4)Fl=_Dc zX!NJ2uF4BlRaMN!qp6&ysY%Qkqk0cfJ!jH>@Ncp8!x($99_8*FpimcYyR)S1VjtJ= zEM9IuInfe^=W)KX0eBH2Xg+=w=I-_6;>H)ka3?+)F{kyoK@@uAXJ3zJLr#v=4#0;- z)*C7=?Y}hQ7Oe&O&P3`xv8JZ+L5Av^4Fmh!p2RaorN2C;huTPJBfX|nVZRcvbdPYp zqto@u@K$|fxyhY=IO+oXy!5(gX)jm^!wtESHrM0T_LKJzYa=ZJ`HBd!XO*lXG`}T_ zfyGN@IQ{0N5C&}h8lRM&c2k7!Mzdh<1{>-(sP|%^bT|_nz(3q=QSYfrp6fJKiQ8MV z9jasmH2DVtUT3xYudjQtXw%EA0uP1c+Vi@|Qd8tbB_rGF*VNFe)-~WK@&<%ma!iAP zwK5_y(3~uC30eL_CYr+&$W6}A-aY`#{K8XR(U#=9M{S8P?i!S|H2tR81NfUOng{}S zdq8(#$$m6td@0H`t90qahfD3)zSymz3AQvAo#WzLq&Gw=jD>mB z7|nE%63{A{TB4?{$@!`awPXPqBYs})H+u5k){()PLrr(9U^;H^?X7|@gW;UM9|ep2 z7W)(6Xf%u7eZ0yA`DldoU4HG&7mFgoAN1~SSuT++{j8g4wKx4}_Irvxm)j5#$kyMH zaG#>o51{!|oIH#bn0n6@mTf#@SvdG4x$p>k2>Zm2RC=5-p0U<|#?er>d+dTG19j(1 z8QkR+&aGw6P^Kqiz8c{J_36$GNXI9kCcf|<;O$vNE?r+8Gm7UY-6=XGXNK5nkfXbZ#%TZH(dLPH^k^?PTl);QS~fIb9c;pJPvmC5Xe(o&sf^3@_PO zRef|PYieiXfncnZrLKQ$0vw#H6=1VMw88b3_*;$}WI<0>KS3|$&HDNBFz(`Vw^jv# zYh9m4!lPs1{i{$Jze*SL9e$~0N@xWTp}T!U>1>REzM0*vLGDv}`btm(>Pz=`F9-&M zWtw8{d+}jPj6-f!{$@-!q$g<1@Kok!7dxbfo1;)pa(?3d2`P`-T7j3rZ_%`qoNk7U#cdz)`9OnB(*vX}3@Oa@=MC}Q$)$TFHckYqdAnRuSrLil<` zh-0@TKm=Q58X1H(pVBPe%GsuC=5_zQ4N-Clq8_qWn|A|vOXu3t$M1?77;8zjC71%V%q8r35J2R zapO{+!{G^u{ixoumuG1>*0bP$rbV&ov`Yo4rDg{Krx1GB!2}SvFVzS&Q}a8e#I^p zxwqR-F1W@oE8gKLPV4*EDnYZUYy;u%8is#*I>JHo@JR-DV$$PrT|?qbX;MVZok1$R zYSgWlC=*M)Je5!8`&IQPAScC{xwx;yD1O9zAK0F!X-zZlj0Fm)Z)c33ZF((Pa>-#6 zNq@(Aetv`f)TB?scFYk1D%-@7zT28T7L!le74S|aw0#_Io3F4%b;4_jD5w$_Pu~yt zipA~0{3LnP7hB4i6{i3$!7#=f^G63$I`wbn-?dR+JK}x&Y)!Uk5G)iSX!EUl)3usx zHcyPZ{4(WitZwP>II1y#(vV=?CJ3vIyCY)~*fF67ge3=K8^8>2V6_u`HdF{BX^GN z8`@wLtSiHhGU?zgc_N@RvI@ID>m2c2VjGd-{1n(#J%NC2^+$)l*+iVo5?%2_7PxJx z=4(2ed%A=vFA5g$)zl@)70Y(@{z07w_?nStQ^*WQUfq^CmBTMD0*O}v+u#m=>kyqe z$1_c-ggC-=-TD2cWxQ5aE!LU~1zJZK%SR|3g;w+__)vDNywY6A0gn%nIWJO>y{dX#@tZ$y(Yedp2cP1P*1%x#{vjtB!`%Ve>?n$N`%D%f0etgF*7Ty~{Z+OgfmYe}^{V?dAB0Bf+b>w#=2lnxV^!bRuwOe?8 z6dYu}ePh$f7-pu5V+eBoU_18a%1j3novOAsjQLcrO-RPbcRB#U&-x0%Z*1xI(|OyP zhJM#e$e8o9|NS0>u8RE!s0QJnkT&zyU|;S~tVanxC^15Ze*SGfk9W?8xFg^vtQSh< zv<)^Bs;8tx-A2mJ_oePalLUO1Mtj5;Px@rX(;ILOwb;0kNdRS)`_I@P8xiQaLbeXc z_jO*2d))DQk5XGQid8XI1u5T<+J3m(9D&M*)teXFaQE6&e_C{L!MJbBvLs{9^KUv2 zH=+eqI|k@|seweYdRm!2Q?G%6_KfRaI{_A)qDe8cT#?m2@j?&PruF=IgKfdI^W8UC zwAj|7+64$g(hm8=@-+pcMyx^qHhPPr+K~@xW*{ii81tube%l7h1`_t=QQSna0wsr6 zL!|FX)%oqP;XLRbmaS)byjGbHi|&lrV}hSq1WC!B*;Dd!o)N=LiKM*d>8b?r;%&X- z9w`fqKbxgxnB7`9Ngpx*^dwO5a&&82+K&Ag+G*ry5_9Baj!fyX1uU(xx1wSMRdyZU+q}f?9Rlw9iSuzE zSVo|8cR5d%BV3X+A=UYLfG=-z9KJ*}9{^0k2LT%O@V(O5;f!6&Q9>CvpmC34O8ji=) z8Law6&j}+$g^U)izRGD=MRrrUhaWYQCr1SK%A@X1mukFXG(oPEQ6SS5PHjmW0cY>U zZTl|o?G@&Ne}JK`uo-=^y2FRo!6%d3wuc}z4B(gtssxP!*I$z-vMId+H4?3D(Kt1M zuXI~54X=)x7YL&JBSZD~B2bSPtO{&qIx@eq3bZ&$&;;0R57ZID`F?cTm`6c}Ad^=- z?z;;m!+f|oIsYPm2xp=?HQ}`Dv18u}1leu5WkHlr5XX$EVRJ zS{=QxIyD%?iV|nrfd{>Z*_=^6ZJ9}lSS_z;ft1gSk zaEyt{P1!y-d&@XbwI9`}54oM%r8y6&UfSj^R*XUJt`TGa|8 zD8)Y;D{*1z49?;A`shmab)Ol2DxbC^paylk)lFf0APG5F>rsCqdBUaw)@Lu|etrYh zJ|TtY+xx2|R{W`Wi}pp>V}%wIg6&}yoYH4Zz=#RvJfy2$&lCRSwC$&z;N1xvgftth zuZ|pKHKRD7s;J-NeD8c21=`%Gj&IvC>`oE7Ku*5J;M7maaK(uLx>*IIdqjT{KK`%O zX!!V3`}!$S>z{-azizTi#tpz%{e(}{Y=cX_B?!I8jqCu0<8YcgizLL)MC}=C5hlo+ zu~vVA^r-$03Y$rs&V+;884TBB1@__H0t$5R-{xb|_HlZ;WOZb-3NdalWFDSLn5413 zEipF~s0JzFnhII#dF?r2wH)fC-f~0&SHyl=j$PmB>c3B#$DqP;XQ!^nsjqYRB#SrQ56EogF~O6?W9|K|sp|gWbwbgNdhXSugsfDu zcOIxiV_aJ8f8LHVK2_QI=-*{Ke}SWA}IUkA@k@FXHJ`=&ZPkpYKc$?5yygK>msHr@co zT!3ng-6u&^DZ&@X7xLPzb!wk9DW&P)b2f@#7z*Ycap=HmPWjsF&oqP@s7{&46{ZJP zrth{C_b4I*Xf?7$ODUY2D404*BsfuiK5YH!bM%aP-MCM*UqohO?dyClLn=s=deUyx zEEsnpR(_trGUZS2NlkL^i3N-Maz4JAqu?2Q)% z*pvzWt?7?C{(aY~qBe4A5IeZF!XTW69BP&>il~7SScIyx52stv9H^NRd6wGqg4xgAATZ@@n~&St;+8i7>K`0-u8qFN`DWTR&3BcFFQqZT+C&|4dx zp-GI?Ag_<3#gmZ?(Zm;r6fW~?mv*A<8LXF`j&Sq9@Cbkk6_lRImHf3f)S**5I`=J3 zEQ9~ewV?}-a_H{09YT`Z$6tpe46SNp6N+*$oT)2$`aO{B2Jk$QxkB8T73TU51h4ec z$)g?hjkQq&N?pClHrDqaqzq>l@4C2BH_q%-)*&+ft8spCqX#6ga`+X+5a`Eh2xG668Yw+$FYXwSCg{9be`T>_A%CUJ!@Y2Ll_>d z5#TZ;o#F=E)9bJmlELc$*IF*p(^$b%1Velm>{Qo=XIk`4gecCcpd*K`A<(7wDZ?8oK}gTV0d91@DS--LO3f8AltC>i}) zw6v>`8neQ>M+a-N2NB&azq4tG`^>qH4a<2_C;4pdr;RkcyB4{WnFdLk8Af>xV_?|3 zvwI~9ZGx3RctX}Q&T+zACJ9UP^T9M| z1~=^Z(&d0`%rU@LxguDg4pG9y%anK7G2w}Mrm*D;@hnB8q^hyXNsUA6i4cCnsmwM8 zwKx2Y@w$y@SF_;((o96uU<_yIcsm54 z;8Y!|ur;;M+gGLHH43x(z^uK-$DhU9`(c9Y%5nl3x1~fLaE4>?GK9DwlZyS$gaFUp<0@z!}iFIMU-kG>sZ@z{@DCj9H?O8h41rqM(~(kc)kmgR+nX38{?5kn&D zm}ukT`p9RReb}fzX#~bw4Z0M zMjIB&Sib|vnQrR%5_ehmgFXfB_6RLUJ_Om95Nfv|y&1rdVk?nk$ruu`)(BNevs(a| zXeWrIH9E>u)|Ie8kW{zUyXrzHTeiH>8KR-k&c!fOq4w7_6@I!rN08Nm4Pa71L93DQ zx7f*gRn}sBwOgS527Z{^pzdeu_S&df7>p~jqF{n1qfqZ?DH54nai`_vyc5+(V-pYH=k+@ILUI zF&Vw^AvEbMwi^y}72oMd2sakJkWaKW1mKRb$nVkx==DNTV}f?0*tv^m1nQd&@vVe$ z7HHn6%v$u!$iHWbFQLfACaM#I8j^Fl+UH=iY7FkLst*IRv!BG1@LA0;Kfp>F(0)TW z*cPa-_M|2dJ_Jo|&b%CRJfoCTYAR-A4XfdQv!mPq8ll$mg^Y)1d3~3`l_U8QhdE=u z6Z;W})ZhuF>gDDq*2k_lHPSEC^{o2{Je5Bxtt1I&sfXC23-=rwJhu9!~C()qw{wl2w3tp^2l3Dl9FxN)# zzH-hyXmeM9qs@aYq80I!PLY4f8{3>WdnG(wH(6|+r4ktmG4cELEs6GBuAgEiZk<5D zbZv!0>}RpO9)&t}xBjPycF&PCm~&$A+ar=jsbBkNAn8}hd_T`{0o4yRmbBWJ(2eZ^ zbb(s_t%-FmM4}BwF}u29L6ixIed8Td<2d$9M{E3;WT~Pg*m15xn@LA8Z zn?09|<2`Tf8t|#E(gJ(n#X7#R3u~p$ZS6r7=JkNG)ZMV3BI@-=(!`};#~d|mNV_5L zslUZchQT-2BXk8K^;RFt5o?)XZXZODLi4v5s|vC7qnr!!(ynSYc^l)9+F?=~U14i; zoo85YZjKW7dVO?P>Z(FSL$PY8VWSNT!&m{3jZyts9=S0vy0bIF(gZp8M%ivLR-0>0 zA2&giSx^Jc`gd(+YiiLr#{oy5V(VOeTYL{Qm7Bb=m;p2|`>N12j}|@5p_}{6=gw#m zC1v7K`GrXAm>PHPsU3(iY|~b%kQ?lXre_XaEHn++FiE+H(|bl))^%3<7&|kUr`eNN z{IdJcO)kaJ9du%JIpLXF=8E;qP}6eA7wSQDmVLT2ZN}@iMuhP%3m?-k+g?$aiWrs0nG?NN+xX}dCLx%IvC5jdA3 z1jmR2q}iya@Sn{%HijAsO{Tnflu!8Kkt6lznX1UupBs>^l@dfU_*k!}1l8UgyU+P6 zwVO&?t)bdGr}y?uaWg*NMkG4X!HkAKWO}Y5kLe)VlxM7`v$>nK2fwB6lQ zJJPrzS9j8WBc~=?jX#4rd5Al}ze3ZPCCBPsz`K`ipQ4~z@rpo~z7lAthwGrd4y!g= zi#1af1lZIek^_%1q~=sf5UF4BqtzAEf6qz>(Kr_Y1{s?Sx7y)WH7n!xcaUMPRq%&1 zxPGWQG>FD+1{-_rABS@|xUP#sSYGlOJ4%oik@3QVfAnsRSs_k148AXzniIOk;J+0t zy_52{YkB>W<{(hdP(r&Xry3}bYrgyFGgn;? zpxULAPH?R;_g%mL{qW&Ex$=|yTY|lpp23ODI%7@m;xFt7mI?Uhr!nH4*W%KJgPFI4 zj!|^`@A7IaBVj>E8_P)$s;rHOiz5w4j=R14b8N*3g|?nX`mt2naI~1Kag*EPI&G|G z90BW{#p!qUJ#F>twn(p~c;U6j#_J))ZyFIT1COGa7|?D{`2s|Z0`VFqd!y=Llm0I1 z7#1V8c`b(zPH6ZPxo_BvM4}cBofD}mB`Cp2ptK*-5KZsOo&3U2XrD7cxv^)>GZYLR;3aK8BXu3P8o;H~WOQfP~NcH2!F&?4~(8qV!fnIAG$$<4SM3$uSJ ztD|}*arW1nY0Ly&lYAo^%USg7xn&=b25r@90NmlevSt?IJ!FPT+1W!{n~4)H1yfyT zaopB8hcg3DeE63HBP)|dN3>a&q->AV_o}?T?`y$fGX{d83!Asf7})hiE}x0eE7bPk(JDZ<1~&-Qi9m&`y$5Po*VP6HPx431mPkzYQ|DqD@b>m zt{}RR_1S7_(UNl?*ZWn~ayJCcR-^T@DDvN@ni;hLVlv4|)XWf@(jUBT%`CRTccRK) z12L$|-xXaWwcdJ4U~wqZ`-@*vfE}h<(hv*o;c%0IkX2P!iE^XC@do+>9lrc9N@H|5Fzkn~>2SD(EqHMZLZTJqyI-FvnsdQS_m1Lb zYws5ERhZf3n~mJ}6D^e)H=SqFWG?Z0ky>VCP=|ur7|~c6UzZg>#k03od)iB>H~1_L z%y&6mZTa!?aITmu`FH9V#ut}GaSLGhs~yaTx!v0D-{AHt`a}})6Mymo2|LeXcq7rTL~Y1Xu3qOT1}xlRUtnBEl7^~Xui0`A>17aH-2k6y6Q4MD>3;c{4~)y|TBbSZJ5=>^fR$|#kugwx zViJK{*>_uaLC?QDJUo6XlP|upshBePsX!4{4N>D#)66*-*6cILT-w>Ut?Ec~3y(;(QBN>I(e6Oa~8#HVV=A*#pY5{}H<0>6*Ypa5$RHS^+IMcZHB& zqKW{VMgG90HYa*@dHF-JO{kxHxy24~l~A~eMCvWt=oS{>DuM&XH4=KRbTeHJW_W5> zWPz*o3l7ov&@-#~-JxwH2uH1MQ&ZCqWkM>gR$QJ4QZ3XST(-DS;AZ>Jo zxFd@bZTJ-m-7my5z5v>#h>dtT3L0h%f$QE<3Vd51RU0rXh=)Lmh!hZm1TA#l*YQD$ z(yL{Z82H5f^JC-DU<6~|Y_@%G4i_n572$;1l}_GJ)8|t#wklPTCW1#uY7YKF1fMyi zKC$z@bCkz#&;6rWKU-Q94kJS;9{RXwj4UV?1kBewM&r0`MSba#U;^859GZ6$KG2;#T`WXf>9t?f;A2S0u7D3ySuvucXto&?(Xg`L4r$gcMtAP zW80B^Gjn$K?AbS8--qTj|L!iix32%HDni5WGP_x}T~2nMb1mG2XlGqv{@q_U?DNPa z-28VVYNnBc!1E=Kb(Qa&%bt9~NP0)W^}9a>>W){jIlp8usBN5gzDmqn!!qM@^t6=< zLryA2mteU8%=9Ot|V$#11gja@&h37|e&hJzhabLRG57gcZsjzHrD%Y^(c^d8OS zxp=_HyE*c|blhzD+v$Zp*D@XDjX_GlnmG7>zM)JYJqM3sWG_hDi$;Mr|E3EYkpQWxAwC`BpmVQK*Uwr3*f@H0vT!Ein8Dq79E`6#IpA;DM`!Kb38L4zF#c zC!v`2#k1Bm;&9GA>%(=QLuI6hauW-kpY*qw4%LnOYqPTr<3BVB9>NL-X!V7YpBV3^ z)k%V4-yG9=Ji`yGR3Qc4jPUq=dFJd>vHfxWCyekUhSe`(#9|-S{Lyjv(pk1YMdL9l zXU^(~RH*b(Ku|bB2T}x!nV=7?yF>m2PY-9eeoPg1RQ*1JKOx6TwA*=+w;z~&oc7gT zixyDd6+kw}(ObX`*73TDR$0C$dNyT;?o3zyYJT_5xn=+3)lw!d5&A7(G)&?ar`rv@ zbOuNCD(3cJEHp^5&g{k$Mqa)P zd{WcSe2>x$yCe=j9XUuz@9}=^8#zs(4~-&=xIBrphGA^Pi7FtI%Ohs>$r&qLh?|Q; zkF4{SvzF9g(+J>!?`b%3E2=t1v3VyFxRer1-P|WEyT3^ULE%FnosY<46`OR}UfGKu z?>@P{*$FYPQg|lG7lH_d-iKSFOx3uUbNWzEoZpSy&qCgb7)9?)0K(F3Ur~o^w2_Ew z;&~J}@^r$`2F;4lT>Y>f=J;R&dK7&@WzYh|{P3X!SQ-g=g ze8t5cnA=YR{aCI0YDmC2;&3uwyxMqza6i4Xc^HMy?&KxIERUlSn=S;-$<6ebU|(?2%3duS@p^zM$jnwrW+RmeF`5FqEd-YHWWA? z>gXiss)FtF$)*-2$vSrLIyDo@Q3H9z1l4HiELCaEXIR1{I9&GEHC*y`RCW%WeK<2+ zqPbekK;%!j<}Zfn9IrQ_Og;%A)9jo~Ul(Cw zF6iZRk|SWvfN6c&Um4(DpH}{MsPMX{TEahLfTd=dubdcOr9Cv+3K9XeYB9 z5dLQJb8g&cb55o(@+*}R$eG$hLIOQ&qlw6FNHaiHdq8hu^;goXNe%n-D;xxL z2_JPeGF#X-xZ8Gqo9dn~!Ln+&&y?^QR2 zyVB9L6TpB87fxMK@yTc~zGC>`5f<3uSx;B`-DmDUneY(pjUFxA9CjD@pmX~(v zo=0&}2u^7g^1_15nfWU5r0d;EI_@AYM6;u3HTyq!uY9dE4TCRu%Aek2;nF>Nuui>% zoU13#S{aMiFTb{{em+fosZT37do)nw>>aqep^OT#)_%9@^7^9*uR(%J`eQ{uLIYRt z*!*u|lb$Ih=#BUTtlshc*4X07_Tj{yy-#S-)noT)59EY;nU~}@=y1QK2lDx5mr81g zcJRw)>oaX-P?*PP<-GRV#ZP;{poMt0oX!uuEi4UpY*;^z{tvh5XJVQF#Srxa5+1Vd zcPe)0lzd1&yTIk@DRRakB{D=j&4k|y76Nq8?)=+21g%8-M3*iYRp>1~wYrtS z6r+P;e$j{O<|Fhh0VB^y2Hxz~8U<+j1=e60Bi-G6z-#;9BM3ek!13_GI8R!(>DIFa zMgV!OCLU(Rp4N26C}0_{f7C`EeyucqD=vrxVI*4QV7k4tgyrw9dNKQjxgksu^@ZpZ z`xxKm zfBHMLeJWyShw%LUze)3NO26MB<3fNA|LK3o$N68EReS#H*AjgGC71r=u?j3iuKr6? z7omr$j2#9D`Of5^M{8%qf;Zj@R9u?#*tA>aNp}p zPJ?qg-5wYm7VB3_jaI^aVVL;}H*FbQ9w9>ESlLSDYDqLYK5;|HZxdDjOe#U4sXX}) z>QKY*cPi8ne(iskVM)4SpPxol()REIk_q^s;z(uRKz1_7fgZG4`U3~`=}^g);1_C* z66I8N*Xe%#VP6bvBV+6zPx>dtZ{CGP2SZ_qdeQ$^dRL!FS~)vVr&h*(ECF9Fzr~~G3impXf5fnkRt2euIVZBk9MrYB~iJ^j@w9>SFtN9Jr zC2;6Kyi0`sFs?RuW_^gAVf6U9+AbLOXiJT*oz)v(;Vm`s9a3+)_Fm6qb2MT?hZ$;o zs<2#xrS1>F;Amnzn6n7c%7xBqxxith>?67hB1X98>&%s>)`Am5!lsB?>@4n@Lp__xpcS5 za|GyWjdBovsD&S0VQu4Q3zj#8|?R%w+T9rUxDrM@v`UBl$9hG%!T_3vD(|IsB0MJUgQcsZzYA(VY3d*svloT7o|x<{T?N@THOIlcn4djRWJ)(F_txVCo$>ah#V2v>Q-z+rFZ88M2eCq4b)?Y9)3G3kM zGr2bC%X*AB0=go*A>UJ&oh1x>JZH7-+n6%?A?6OC+*O#R(Z4Q)@h${p!fU@WV*D+Z zDq_7B7u&v#f_ygazs*r~6C~#h@P4COYvi}t%kK;=F4`ir!Ee>dI1*-#Nf>4`9D`vM z>L;f^5)l@H?u?OPLkK{=zneu(t~CgvIcX4xMq8i-( z669=BIqugjqGkTAiVBFL68s!!Q7lFZ|Iu8-4#|q&J8BoW-aZ9a{8Ne7Mtp?UJhWej}L@2%G zQ_-Ou@Obyd-fRV@+;yy1@&S?pZO5Rvk}uluut!U<~a_}Eltq-dCv@P zTw4VUle%C*P>Q(mzxrv5)y){JX0Yw779siB8&VR3w8aNfCCW9QOE4dWFjiv4U0V%K zKhS~yaHo9S?L=~(`6Td0NBeILgbW$tpdj@N2mAgN^4{pMcl%a-?UPXLy|KbppY)^g z7U-8c1;mWF@vK7MO+sxR#|k^6=zCu+(08AtVipRnF9DseNMHc_wM3VV9e;2aeR43C zu|Rytq6_-ls>j>^#xLQ3$NjG+<^Rbx6W-pJJbR zRzjgV4yci0AL)|9Xlt!>9iwZ%k{8|vQ=*jFuW=qm_&Z%>2?y5DdPe?ncB;2SAxa!IFep3 zxRgIxM9H|LZir_;;zouF3XUt!h>3*(lW}0nnQzQ5zg1g{JQ$)kWZZ=nHF6Kp*LN3H zD9zJ26H48Q2mdA_#3I?@;M=&PlK=6cX>U*a~Dj?fUN@pb~p(u$P z1qXMENZNlEqfw9hxx~<4nLSYNaW!%>@fka2+mwokKAwH1Cu^aWw#<`+>{tJXb{e=? zC-R9RX)}E(W62x}zZgNqv(;JzyonqFO0Cny0QorV`&v+b9SsR7iO-La$^^Z~n!sRZ z2g1KATGVeVx2N}9_T4}G{_uNbbe`XLJD(~5$xBjQPMrtgN9_t;9fv8Kzyu1wd? zpvu8$qb-rVkvrEixk9)MCk*c{pRfDS_w{f`a^v^Z@}Y$Az~2HN4702bp^8*<@zicI zLM*g0^NYJoR-L~-<#8DwtHI5fG4mB>hgxr{ZqGK}JTaQ5O=Fj1O;1Zt*_?6UxT5YW zpBoz}D-_cr2Xb-rv}1Zqs7a{jYKdQEv>@nkW7~hlFum1?1gasNP?$x66rsO9xUEFJ z`#I4pW)ZgPgo_=}z_+q!xyRrNjTeG8=XusO%E~`c->ec@q9|LdV|JBXhcx$;2Sd8| zDq!X$_*%Mdd|5T%MzKWqTT=1PAl6lp+K5tLL zGdL6nbbcoqw?;M4J$1?GCZt7=PDN0?u!a5q36N-!X6vOy-C^T~tNM<@P=qf4dtjm$;oqIBP| zg_lYb3F))hvM?I^)f7wws*Q84d6yf-S)0hAFiq$YbOL6~;sXZTEash~a|!;~hlDhU zdvPwy@{fxYNP42YmmxdK^aMqqaeJ%!xI0Q-dq)vZxj~EK$veAkV7}bCh1%*D6f(5Y zY0K0~F0!jW3{b(FK?_ae$=)imnJZ_Lw>62SMSFXPa+8`VvI{ZWO2j7fAG9Yi>=i$mPip8S#>M6zG*>|8~Ia%*)^y^dKQN-*= zP_=t}-&FG%eBRQ}R2hbJoTRy3ai)}>z{x zRi6ziUfZ*&fK|48wic-Lb>{qLA(s)95>B1kvxtCIkXGFq z^tMx4Y*y33K)nzh90!vs=N;x?mJ=oCt2~yuFV7(DsI#;{ZEel~&riPS(H1{i@R$jK z{30aWkiEWtl2mcKfU9Z1^L`VW6-cX<%g+@XyB#L}yQYX{yxluC6fYpu$Hrk!|MFBCW$;KSV!dG)MAV z@9HaW5@($-nfw}uIK~6HiV*iLdD8mK=*&E%La3{Fkd-*#d!|?%n&KZf-s&2Wq%7#W zo8fc@*pDJAjNYK%6wkmzSRU%8*pz`w0nWESy%{cL=CxqwkD(nhXN{f_@P*FM(#ALa z8@{Vtbe~7t;NS~(|I72oR9aB?A;&L6InKfk>=8XaiikZ1d~<8MmGD*QKocfFA(JGO zR>l#eA3Xmx;lXjgD5CsXvp^!J7+=cL3|lXGtX}YdSCL7ot7W#|Yqib+Y0HC0Vj2 z!{G{*<2)e|<>lh{uz^XcM2tdM8A40}k4ZX9LP9w2ey!xRKnS_V%vVo<||=3lSPVQE!}UXx*M5q-bqD65XNc!9BS?P}gYA4`xp$ zC6K{3&#$ffj)~7!j;O^eux|7M4U`Pg;}Io7kZ*Is$1Z9GJ%mOgDu)-)b7Z6j}dvo}{* zw&ES!kBxK6iG~-kWt*XIb%f62hGhZmUXR|~gso7HW}$#|w;Vyg4RqvqFv#!4)oUWspK~_Wcv#%Z2z+;;YwJX%-Y8(3a&{P*I7p8IC8>QKV zoC}z59Uav$e(SePUGV`vi~Z22df(s3ocMvmL0v}^c;@V0=u3_o0g}fgMV7=Kcqrho zvDfdK^BK#+-+lYX_m2?1f9My6`sb4YA@O;FzQoUKo=97ObE5?d*vb=!7z3%Ze~Ad= zde@XAewQb8?XY{c4*o#N!SAMq-4OpKd^`!U>ss(-eH@5_TDtS5|Lz^Xi&>Vb()tFX z)8hk^d&DBTdezqx!=p3UZyx7tMJe8A)=z6Hw=8_2nwO|%Y-qfILOu+8wuZy@oYA`znKEACD=PD)&3`14)-4q65meFC-V^6K~Z%5U--7nSGR zo%i0wpH89l!;`O1KVT5Po5c`pVM2J4<&uault zGcSn@c6_goR=y!K!W(5}7*JCC!L7m8{;CHt#J%oZ8?)EY6FwTaBjFt~g=yq1PnGCu zid5l<-?_RTvFpQ^v+=ML>H42Wu&s$DaT#nT;)Cb?H98`eQWQw#T8d!a|2=R(9FpeW zy!#g~6YKpJ&p6TN)p=WU&gY^Gs7OZ%{xznGBF$2QMZ}cQEp6DWr{TAEPHKwtqQtVv zZ78#u%OSJ~IMz-p0`OQgP~udivMy2V5ijhBXzdP59t^g5RyFU0ogn4zHgu&(d_QiI zvhJs=5gLy%E{US7@2g@FVU#_Ow^F=^8dlX-J2F@J9B8R+Q#l(&lq@@|u*sXvg#+{r zJ?oxm8+RAl6nBTz=ItgF`kx@sKeu15Va8F2AD5wX>z6UfVwAni(i)S`n~d) z>t_+>atsa-Q=vvsAOYP2Q+MS>V9wL<_Wib7=?Q!4l<6==%XE3PK=;?bwTgtG|4d?KI^?_#OmVqRtJ95uMCR2y z6pE=G-iTtn`LrrDW^-7vExJSK3|#1 ze>N&?x2|OkjX%i{3RDv@&HPB&-v@LVFYX|R{!?hvJ4)<6pYVbxt>5iFTti|KJqq4! zlVzICNIK^xbHL5LXfSt3A2zv>#ru>9p%-KhEatxv=+Q1@G5wa@4mL>EHjFsxjf?AO zUzPa-jpZ!yyF)p1yIhT5L!@zBo*!GoD{mi2bo-vvl9(0{A~Zt(21I?He``|^tk#wh zq^i^&sq~g{FiYX_N0C5o0M-TmL+anz(%w-1Q>o~^|4s2m+p+6+R_?D>`IDdf|51MW zk6-~c>k zwc;NBDHNVmp%@vKEkz_#Fxw@Py-@l`_XAO!iEU1vIHrDMhvK(x7pRt8mw}UH_(O_R{t|#mBU$6swa$GMytC&bfs{1j4LK6_%^D0|ryITF z58B%$Yp`fxR00B>O>IuZ5!^E(r{S^5I|7kXGkH$jVlXF1cKy}6QlxVw1h8sigS2;> z_1I=o?LKzDZi-Up6vQOIbVgQrJ)4(tU&3VS&koGFGmtQjPu0Gt0Z${$>j;cE#SRl&dQU7A11KTrQFt6 zQ>kU<4SAz&4Wid*5ovvH5JoK)z0Evz_fhv{wR#9TdgJ^d8)WM&=s8wR1!+MMCz9fO zu`^D$diN7X)}%`~mi|3`Pn-TLW>TB+b_VvPsmk1v1L+>t+&4HTOxf~CMeJvV*rpElEQWXJ1bxfeJ zb4#z(W?kyj@a3#f>QHia6xV%07W;h1%{zCy8R1gc{f!!F@HT`+~ES9%UV!ReDKe29l-BLpMe%z?TmMw|VYJGpN4oHH8Us4F=)s|G<5hyeoLj6d%nx>w}kgf#DZg+oA`4*hyk8K*Z^=g1)P^hXf#DDXo3z z!1w`x<}8NW;BZ>8d*mO_OB7^w40B*NkGAq? z1Lr=p3FU?q^;jillikh)Fw~=mQ&UY6QmN-9h7G6vl#l#1N7_|_m4Cj#zhYM`qUg@y zB3c_Ma{0_4S)A%WtiN%Ym_H15yni0ST~t#W%(d3FV-eGijIe^v`0})WkfRj0re>a5Wg^I> zzH7oqKibY*Q%-p29uNSa1tt^1U5B-Q5^60Zu9wXJ6?{)zYeFUYLUcbd$)>v?0h$aG zUK?$R3MO{R)c)ZbJag_fc6{Z{R^0@bSv=g@` zgh_BRS*{HzVLbTM_Nb(STyE!I6>#*QLW zP_SHl`{XwA(?wzCoxYk`^>bUq8f5HPD7ML$95;6-9ei8-=z!atl4C%imG9We^bdt? z&1MrhzD?K*49VVdI=P4AcDbS3&=!j=scC$4fP7`ivGF-GoX*9qj@QSb3S|F3bEs;l{BUVMe*7Cmh6Er(od%`u>u$9$>LXJWQaav@Hxwqv;vlEKDrf93|H*G2mYe(}P249{bK& zanF*O`@`de`cx5vs;+q1O=-BH(JzW>(;#kDa`@}E6JmK4`3w^JJ@e_e**l!+8FGm= zN&eDss-U4&Yc@f$t_~GUCfm^wE3z3Rho<14IADWNYaHU%lgQG~Yzx#tGKXJ+$+6%* zrSUCUJpRha!kC2QqT_@)UASkqrdraNs;?q~F6`9V>E9hEs8-B&5f@u@-j86eB!l+Y zumucuWjsh$qDTx)ab4N#z+ z1;KrF2cp}$xt`ln;b~}JAViF<@I#loKHgWD5EHWfJ~?f4Pv*L36vQ!|i8qxT|F*~{ z7p6)rY?5irU_7yn387s;Wqs z^;6Vxi+Qrxti@zkuCS}cWJ>nZq0dKXFi?*n3vy!=uU=X0UiZZ7tJLN+3A&k_jnc@8 z8M9sE-LM-4ntF|G0}Hin+=g{5*TzzM1GJ@HjzaA4HRq5D7p)u*J9b$e+HyioJ2iB@ zt&6v~*fQTF9OB*G*+T`inx5)8Thjzwj#s?|Q=WyzNYVv6`-`QSWGm#qkJqI>6Y@$P zd@+Uo8z~!pyTar8Lwal2Zich2v4dTF!PlMNEJ^=7<8t{T5NvCjvgoR z9>WFShd4OiFNNk@r3;cc00y^VqlIm2tg6Y>pi{g9GDa(<0CGUJp3$6j@e>C30U9;y zu5nRFI;iV`SV7%Mu6jtr6{(@CGjYJVO7PnQ7wWVaLR^TtqSI7HD5@P*;I@u1gH~UBU_aX+0 zi3zQ+V{0;Fg9?3<(OBgn`4x0s);XHfhp^QYEmB*Ov}q=D9QpS%lz9>5LBK`d{g?-9 zEIRYo>1T|O7hbisq+nMPrkA#KGT*K+Skysrkf56Bcg8-gND(d^Y@YWL4#267+FFsz z2uFueF;Ft=FMDihY-vrRG4Tgu%fhZWH5}k1qc-{m;X4FQ?Ii^q-)(*QO(!+?yAsbu zR$SPFLI=yX;C8@_6TFi+Zu@4sI4~%{a8P-mEF-yEt3etsp%6htEyxz-w~8a)D===nLzkM< z6Bcu8pQUU`C;E#gqD4qzdX(^*GDU7SZCmM=$;Gt@{&@MIfk0Mn4l+t>-WRKsUom3u z;slMi^F_pYnfn1KE>=QRwV4_X}_6Mnv*aBj&#$)DqP+lg&e6N=f`#oL!z4$NC_vBG0Yb zBTNg^@{Hab^owzDCf+e1Q#SO=Y?AQyh97dvXn74oFS%{E=A|>z4B)VEU^XzKA8_O6 z07ynJv=x*Tv0RH`5^SNA$Z_GbD=i>Y%vd9h1lbzNDlDsh!T60`^!&~yE2OAqiqenr zQ}ncBS`}5~I~z-khT^vX5(XZ`7Addh`IzM|=ngBGv%I(x=+DE_pk{;_wL4NiO{#;O z_l$!=mVAOjnvByO*~}*9v}nl+kEvZ!Xzwgd1RI7VrnjOLfW}%=;GKO^#q(-=%8XD< z$DEZ`XI79YA@Cs~m2eFgG{KQ9t|(tjI%ef^)n9yuay;?G%pMxE=(afD#T!>Y$)I!V z3?gpucUU1_tKeV7&(dm^B#rmYeSQbNwTB$mXA~_CN-o+GmfM!M51=EZx65A8f$my| zyE5`b8?-Q;=o)}lQInCcBY<2)M%w-Q2A!gt?0YR~aogIw56*T@IlB&XI5qJi-mHU3 zaI_Cz(Hw-&6;ikFK9>5Hc zQmDg+#M$X9Y0FsKdq%F!?SUH%yGeXZ^^xw)3f50t_GM7`T<(*aUGINR_x0_>b!TfC zU760}NQTT4$~c89`V4L;7_k9v2jL8Us8XofB5stHbhh~;$X3~Mn_p7oVO7#m(D$^KXaRV$+r5*7sQfMPiLp3 zFB7coaSMeM_=$OZ^Z2B5ul|lv3?VhBKnTiPVQn>R1dl*u&K|}UJ&eWZy{%JPu!GsG zj)n&`S$I_2?CBo3qup4QbW-lK-7LIJu!Gkv$!5|q)MDdz+NL?(Rw_n#lvK7p7E4pz z`-?r6W#GrY({#2h`AFWRsw*12cOv*=T=?lej^z(J`E%lFsvPhu->-hGcQ9=QSdJ^S zeQj-NLZT0N`KZb6C~)hIQuR1bnCf z_%7YIzQ&%-Uxd^t zgra%lPNWB$%WAzex|_;PYF=0c#wF!(AXW-7d`!G`GLU1Ch>H$1|2CE_ywB!kdGCH~ z&3GO4$!#sn<<05Vg0T8Lpu)eUnUH%~G$R`sw5=4x^z?Q)auSb8EE>rH8xVN#q+`x~ zB`XGB=+W?YX*3`wOPyaovgUJVVL>R9hkDrRlaN?&IKXp`S!XfJa&NjB81UToA<;do z@y8aP+f}FS*r&Ud<%nc{w;cIEsy+5m++8i~9qfxu2Bol5pl+4a9-}+njc|If7K~Q9 zcH}<4Tef(h6rmD!WPTw2=YldgPX{DyBl!N87DoZ$YIBqX{B9z$DmYeV?DQ7OegxSv zhDPOFr$Z);nsX$E&O(|tP4PP1wk4YEDAMZS8?xE4r7&fa!(0bSY%*CGmIxC<&x6`! z6ar7?Y7a>664gd7v3+aZ^Q2y9m4MpXwb%Iy<#3{S&U$zW-zA;MN}U_$r4&xB-qcJ5 zzx#`;TISoN@oF?RhvWb~tI@BHg_bIo1Fypm8b`vwLPupT zt(g2vb^XKgIjd8xKUQfi#%o4+$`Ih9w!UEC#j@#K*?4WA+<$zwT-TpZoY9(Zd%>Gd zh@YrYO@JB8m;GEikXusBztL<24L>7K!^hX_MY2OP*ES=Y%tJis>kE%&G2WY;)FdCg zL-dd(vwiS+6czI@N5=+j6@N8iZ{{0d%+b7iVcf^sEQwRh12s&33bGrM9qap=KlZ?o0Lp zY?xQYB`u4l3rU{qanY@G+m0-i1ubX4X!~=QLbyYAdy>W8ehwJwy)7flp|S47tGwBY$b`Kj}QAS zA04mfYAaSwm~07uU1rI!MD*A$lqtwKs1Thn)U*wRizi-SUx-TP*Hg>=o<}zjnovK= zpJ2P9a*(hcHR??v*c>}pUi5YBcvA7hWIWT5hC;m~l^C&dbUweUZ5`cXhUkuA9bMO% zM;~OvlDi2W;~?44wLU$%_BE3_;9mENHYwIGK+Lnacg{!5p5_7 zNelAf5ta%y##A+Pl}fRcw>gxiolZniG&P=VIf|+=#L4Aqj95sVcT?=$-BmU zaFu~pDo={OAy?B`%IrgC1VI00O4bGSD7i+QlCbHX74^kAy=Hc?%e0-Qq)!ruBC;Y;M%OV?II`7cv(T+Rl zVh62>4nLkH4=#?`i#A9P&b6S=8bio8d%Vyf} zq2!^#?3o=>W&P4YH$wwDW-?I}&IIg?@3C1%fMQasYqhu)i8x0338+STp#KRbO+>uO z(O}S6Nx0R~h6F+jb3V=vEM2{*xQT^C@2$XNTyAX;FEA=JHbkK~oisgN2haB5fPr~a z1n)q&F5if@Mm7jT1ih5C5XB}yW4JrbmO)hn$x{l3u+pHMEHYmM-${inj|f^E$!TC) zU$F{kf$pt2-btX4EuvI2fxv2*o(zjdE;_QiMpz$h1RxeN&+(*52L=6dFmKf47FbjU zm#(92FK4kcju2cdP6tdD)Dy@@L(|3LOuMY$rL1oXfD}z_#f*dvbvqIUkBh;}XY7Dn z%O#%3YK0-W?QH(HY5+%|_s;urt7LD~i)jVRO*B||HW7XhYIYeDVdVB~T(b-_p3yC)tpwFEF(!#Y}Gb>6_0u34} z>X?6yB^3N6E(vnqp1eJ4|-oMHk>? zS9fwMC5unCRd1z-e=;FENPgrWjXkeb&cQLa6i-%YArR&q)P8yF5^y$*M&fPUm9=oI z_QYh9pC@a%B|kVk?W1G^x3H850uETEyo4+A4?+B0)XD*R?X@EDjchYRmLx*~m;d?vJbs%9&=yhwiJA=?>jc?DhE;vH@CCt*X2Tf|}+^8`Nal9Ukyg!8gN%`_3`# zyws+Nb3WU!cGV|0`UDpm%$Z@5%ln7>Lsl|wW3y|N`f7%-D}c2Lj&$i6hux;jkJ*3i$&fD~LV!+1lJ_P5?pV{;wiOb!OPA!ChvOBTQKA2mRC-lgBu7g$kd| zH1$O0WNIixb4P_umHg$o^AyYNq3Kqf6E=DD5`D$yEQFtckNitxoCRZjo=5CH1mM;L zEY)Cx8cQJ|Wkq1YpV&-B?lHi`Ld{%XW$;$q^w8->F7`x(Yy)z_$iy;|M{&5gV~rf? zK!Y>)BHA^8XGC6YX*fB~amHlSLN*y18!muvP;cH!w{Tdfqf$-U zyw+0{K7DmHu7Neth|sLxNa){{5OTYO_A5c%=7+{oSX#WJg2$-Exmo9jLki?6r^R(q zr<3L2o0f;O>p7vDKwnO>LY5!JbdZc4P#X(zJiBuL2xkHY39XS%+-Q;b{RFtLOhvj` z@;#QF68e$fgZ|1Ii!V zGoL|LVzz-wsQWmn^E+P33`A2k@_VDu#oa`_>4Gf{t(@`Lt-g2%4f%bM6_h4|tb%Tu z@wLpj(IFaLx{>D7=Go9~Q)v0?!gU2MLUKXZ$|Y$721l~4#i3@?mHTHuatNv9S0`nDfLbCqF(ELq+I~8U^$L8(0|L!bZqh_d;M?K}C<7B_63gwwm8a~&Q}8Oy z1@=*GYf70?Ek)0_=9<_iY3x7jQ6RgZaJEORG0}s#s%wLWoEqj3_?4rC{N4}PQRpwXTst$CGbNmL(?weZ1Tz|aNtK*J!VY4C^q4$HRITl;ne0q`XsCF}G8{G_5 zMa@Npwqod=(38(75y|@>4E`Uq6MzDeNS}5Yt!7PT&!wHLpDRXr>+2QkJbaKji?>QyPe$m!s<+hQP z4m74|k7bisEvur6YWQaJEUu7I4(gTo^_(Dgd=-J=kbvxwzhZCJ++sw{FGfz@!F4Ia z5gYkwKx8JnfX&8b&mQbUQQI_r`l68~g1+J*O@rE$%9bDBk1@X23(4vn@OHxnr8C51 zm(wECLzUS~-Gb3^Yy`zVpf|NqF8o9|B$j8Bsb-4Z|AC^(h$0GA|4OuhzsWNnvMD`VHVU%Q+%^8}Q~z-YXxsps-ZWNB$J^tenN z(MHCBRLFt^KPxCS+p{iBBRx)E+bw&VJmbe`PL+l6HnH?v^38#(34@if%hPm@?kFLs ztcW0iJAE%PH7>`ely0}WeHas~)>drFww7gB;FEKZt3E_t9di|B`v^bY+=XH(oA7WZ ztf1zru<;DY$+sD7d|aH7b(1c<$RRM1v*5zactXGak)O@{^HAPYmZa8x1)cKq759X+ z*SdtF0U{?8MOpinU`7G4MT8oAbTapWb8!Irrln4rZhcgR zMX#nW%mhd9_06P`Wi)_P(RXHNe673*=yVDW>ZLA(z>1Alta6Q_RnZ zl=3;oM-+gY%B&{x2JZnOXk{sRlDx+jfG?bZ6p{!Y{Q{yKDl=IzAOs`7`6$yE1}mq3 z!Z+b{!WK?d;)W-zNB5|ag?d;((5M)_#fUUNp&ec-0tDUi&Np(lkY`%dUJfN*s1g4#L3Z!-@ zeN>;!o_=u1#+8mWStF7d4^%RWuD)aAS{hDr?i>*N+IpGvH_OV#p2+9Gi z#LH2=f~DD2I!W~VaV+K)&1fV~`KP3YYjR@KZHKT= z?Y~azGoH;4_=rQ|3sP`_6VD>o2{uU5b>8g4%O;9&+1=XwB-sHs2q&T@R0b*q3PfZzk})nb zK5k~w9-PW@{w_Li4JL4h?5GNsyreB~qHo%6;601gQ<=}jD*4DBu}8!X^ur2JR3wyD z`o9Q!2j|M7uIsmzq+?s1q+=T=X2;fvZQC7nY}>YN+di>v>pRc$)vf!!Rk!N?1E*@Q zz1LZD&NaqwEc~ol`{NVHOv#Q>l+`&Hwl;Jnn?!S^%?<}|@i5dio1B;m6*l8=MIe_! znY_s=7I5vD2dfA_Uita332}9jQlFWM;z~UrKM#28T zlG*9)yEgP8kVLbg#$HZj{_u(UGBC~Ey_4x*6Lg|G`c^r7&GSssBoeat&S<;UeN;uj z8ZFJvYkq{D-iGoe#XyhY0lCu^S7Jv@!fwfb<4@l;Ruy~jDQqtl%##~|g{5UEdG!-1M*A)0W zj;xH^`fGJI(OIa11{}T02^Dn}7)WfvyBF46Jy>kBd-uFFJt}>D@uU=v#Yo(10k^n` zdMcV_cmD=|49g|4N1;MIi*+NHF9d|r5@hiE1}_ecY?XpqpAl>Q{NEb|?|^tb!a&!_ ze-;DA$?hZ2=Lh(HOSem|7fx8PZN|Qb;|Imlx{%iW2I(*Pkx|6ZNMpy|s5y%ZGj$q7 z$X`XSwHRd?E-Fs_QmqnqD&084LCsiJOd^(7-eKR=L7MWjd-w=eeBo0sEbs)@YY2#L zlq}}ytQV(d;p1opxbr~{`69J~1*_<~L9)%cVdN-S9)|QlJTu~PRbvBK>J&U@2pAHN zfWX9+<&<5~7zpc1QoWlCq(;KTPKwcw#&d$` zB=dm5&6W(K!h)IXPKUksp;8oc)#~rOS~E6H0am*KOW&_~O;9HuGj)FU9xtTXiW!8R z(5^>coO)Wy7dd(5$8`+(qT^oOo#sgRLxp+hUl9mqP~Ohmx5-2f^ycFYW_pJ%(Od5> z^Jzs7c;NqIEf4tsUy3wm|0J*eKs8c>oSTK0xk&?a`gNWow?V)qSEZEd5b+#T?H4+{o2OH;m;^ z`lFbEJnqqoj2PYqxYfg`>;5aXQA66br#p9sR(;oVdT5#>|9t=RBX;cxKH#?_EweqXT9R4By zhj)keCn@3&i7?ly(s7hTj9j|KA4JoC^2m-Pf3f6dHda^1D)f%v*Ah3?q0Szbgje3W z=&A^L1Z+4Bok>>-)4ISqv>^@=DSJt!&3&y|Dr3r*Fe3X<{^juASd4xBhjzA>-6qn$ z5ZKP)BPtR02O+4uW&13iz>UfU42Z9rp5_I^XG{#{%8)>*YxsSLC2~Hi>6bRap|wht zuV_+PygaKGtHs8{d1ZL4-maeluz^Bc`RoenCtS8?BHu}-rx3T5bKz7A zj1zz?vH9$bGwnSVIu)jW*83v6$n-OekNcVx4W0cp%uw3__1}XW50_aUYn)z5DJ0lM^Ts!^{X@>T_u_%>s4^E@KLITm z-kthsq!bTd%F8QA26Q2rilwB8i^8(06ez9_SUnp8rab^xs_~nt9Ck2^IVgDwL^ckrc=)0PPSF{$XQO}VH#RJ zqFfJYIo*IToW391lG&o3=0u~Sdl9+y5J-ufA6R4 zbC*KzlbKHFEj3r+Q!c8y+wo%_la?u?S0>;KoH7Oh2*-d3*2gCOS5gQGcI$x4D#&!C z4xH$|o*4xD3PR6;kF05{^ey*aorjjW&y%;XA3@dTYX-%~s1F~R@QeC9z1ou%i+y5y z14(hz+ZRS0rxl&7nCn4=ex)BQY##UYEK zwvZ3VlPY?Hr%groKbe!a+&KSUgSp*vFu_5X4%q;l_xHC>73TOiBJ4qVaxBr3lkMOC zGB`;Xq+-=)z`8xRu^B@v$l2s<9eB^Xv;4XLTcy<_WHB1KCUJ;D*rTsk5VGQv-1Eg* z@u5gEb@$L`Jt&UDNed1A){jD7jg*uue9?p*(m5sM^km$W`PJs`ZBujHG?w7b^ZUyK zFk}dM2fJd5s(#oIYONM^%ZO#NM)<;bj-fS%#IPr`*_~NQLbe%^TsFjLuEHF;-$NPw zIGU(~(hx}4?uzWRq!7j;uQx0eLnj2Jl$I+KK}QMX<~doQL_mkw{y2x4=3a}kDtgQI zZotQ{rMORs{V)O|*AWC?@@fAqHD*di!z1b}M}nt|Az%FYwi(nz?$x zd*%{qxUkNr*gHPWk+DOkIO4V5^a^-ilj)Ithgky{`Z8H!_rEBm-+wWmFrXMBXV79pP!cpZo$ zAa4E=qY6`smjCq@K~MAcz27t8;19Z+-mV;FO0N{&!2W|(4UZh&7hxgt7s>CNtk$!4 zu^i>X%h%Fn5w+v`Jm35cxTb~G4}RE?AN%}ArCp;VEfEF}%Sd?u;#O zOY#p2{Le^Y9`K>tn&?|{DFD9qR5yH7Icv@pY$2;0emd_aaz^v(&OU;7UO$5N{p}xE zaB-$AsE>$DI4r^|ez`L+4@Z`Zw$ijtm)Nsx6OuHDX#o=cO~l@>fL0EGrt;$Z7C`|J z?Tu*`x3$dmQ`p?hLGG%O4HhL!@`-3eksOX_Np9Y5d2&Op+SCZ|VXh>hW4{fg6>Hz= zqPTWyZ%mPgj>y;rlMb!%ykYafw48?A^Rw0y%I~vjqrx38-)73lV-E7rokENIW(OUO zHT;LDhqklG3#NTcy_Sj4T&zK&(Pji_G`h_ZBlWrhd$CYkk%wOWj#&weq2radv<5Jn z{%dwebvTcW7v1Q}oGf+|SS^#%Utpkx@67*R4e%lTuKQb1=|Cf}#<6|RFF3g(e2f3O z{JLINbBf+m$nV5bt^wtABJ8?g73@wrD@5RqZ;_NC5UrMJ^4hc=pM_J^=)#X-v}`8` zITu=Y#ZNmr;8)5Jmy*2|EICWxp9I9S$>-~eCGqOunvN*Pbo^{|twI`_ykkf(+rHfq zsgHX#|IhP{{T_82_a0!9`Uwpes=YLa`4nc5INm#Z#Y<$QHt%%vLv;~m&wK{YNQ!TF zIZ^8hy2XD&gI*w`kpQ@uxcWWB9`3c$FLI$x+t(5%+r6(fX3Q<4)l{wO$LyGpo!2>2 zddU1I7Fd3pu$@eyNFkyjAt5o?*`zJ)JKtRAN%YVGRbIv>^nK`ZSa1Th{PZ4>$QMoI z@;H#ZLQ%ny%#rte=4P5C63N~MnX~2x(4ppRk;dRi@f;i)15{HcY9xR67e@Ns zVy%6TPovX}c&QgrI)U@+qs-j5H_%?F#QX2*Qr<@1Gqh?|*cYJ`Fz-|&cyWc9#!eCu z_S8K2mf}RaXrO57Yc9;Z7QP-ORhy=*8R&;}s<0btr5{KociYVDsa-ze+fEydAsrA& z1_nM8)I!^vGhE*}b={lwOZL>#_0tj>G^^3wx{4>P6E6Eyj_V-Jf>mB#9z9lIcV}ce zi=}L@5dyO?d*zmgLlI3DWByHh_0d(s#*}4toL! z4!^DzSzSdbMOT+3<)1(b&4*a2v%Ma_=e>h+M34+{{QcPc_Lr0n*C zkDh*1O~X*gKRlcNDkkLyebKQ#>)t_6v)yy%wia28>l6Ngnd=tL@AEl4R_+}xHnp2f z6jGn@fBO!2N*-P&UkMk45IM2kCqen1HMMMN{bYH7HKeEil&zQYCmR>GhY8f1;B11{~M0j zd9vis7r(a5$Ie9Z@9^#P+C9`2(Ds;MUt3L(T`9;dMoZ+$b{j4C6NCv`uEC;a!|ypq zBxaL8;3p8$4YHW|4xp(pff{q1s6Ki9*7hX7+|x7pgXtXVsWS{{9rx!-S?ZMWt4Ze` z|Kt7X46WF&Ntu(#lB95u7Lxc*zt8omu_&qD*_-muN&8UEsmrC3Pd>-8#sl(;sXBi#DI<`xi_2eUq6Qj-+o&ZxbY zvULK)A?pmP-rZ8RTz7*fL&xc3U0sj97Sp-t1*ff6LPW6BY0tn%CE!BbmZ9k34oyXI znxK9^m$cNnrQaBv%^QiISpM};axbr)miQT&OO{&+sz-a}4c?Wb!(@qcPB--%RJQMv zu(XwYKa7yehz6ervaFxtoni z47A)|B*|69mIv_diy)Ibv#IT=-fRsGRi(P<&PT|MW(pj{)dIA8?iMquuinxq;Mbx1A`PuV8^WXcRHs;w%TcbKY1@ePC9*-a`aX)pZxR^A6*m8l1gM zEQ8U-7VB8^7`VdLI`AZmq5i9P7%x?6iB{q6*ha2hHoPApN?#$iPhuB12=)DXSMAPAFAjb?+-^ve!_;;ya-ant82=2@Vn0ww(-6&S!xF{Hi&4CoXcDF1Le1+ z#KJD|bLql~p+Kqe0;SOo$?u0a+`-jUC*&FoZwQzH6 zJ;O@4X>r)9AT7?n(-5+u9}*855l-srC$SyP6ws@<9!H*B8^jR#7dNwBae4os?<9y4 zywaWUJo7{z8syivBL8nyU>LPaLgA1rcnlW}l`+uDx{a^yzKXfrdGYg2Hz;=BiQF<) z%o9!Yb@qD_VOb819Hdch)F4@64`U|d6lOZ%(zgyaK7XwW>?fB)hWO9UY(d$~8Y0kW z^3Hmf1B2n5Q?jyo_&>8QpU&1u;VGltYAQj0o}&jCI2~JToHVd}WSUak0MTI23^&(} z)xwmJW~jR45N>KT!IOg-S!?x||Q=VB%r2x8qe#4{T#QvgQ zsX$S&1}Ty7G06Y}*PYa_K97}5Vp16{XPViw_WF9c_u5F`%u#|{n2spg7|G1oS%XXV zwoah#Pp5AlHPU<~k}7rPLA8#Lh!*_!Cw4T}wa!~(3Zpm{SRLLOFtk4;M-7`DK9iv( zcOcTS`kejdiFQ#&D9nLeI*9*>&aqP^*yCO~tt>lZW@|CSQU0!kD)dnd*Vm$pUb{d1 zLu5;lJDx6AiSKGqF#<;2!7yy!4KO$yQc4R| zctcyIr{hDjCSFUQ%8{r=b(D7_+&G~c^@O)P@eD4&Wqvps*sr@&1d7swSSXe{8CDw7K@CNmQQ zk6LV3sq|aXI45##({qAwA}nH_EAB}vfw|>Q=MNw=#7VK5Ud66Ez8yIOm#dfx(9KHEv`in{sw4&I z*%}L_S{+R=Pr7WO@OixA8z)Z$jPMeEGmpsNH+8bKO2hjd8+PI4D;efw#$XadUYdzp zDf%%%-2=WucG`b(_dbGoc$z z8%^Gtj^VodP_`IN?>F$En@=Y|B3#I3m>+GK`F`-rlHYF(N4faV^UZ}&u-0log@6-s?gVqkefa_ z(s*Xdh2B}MG>2xm!xWS$rnTIiF~1=%Q|d=@BvBlX;hvP(YBZnpsH9G%P`2SSovmF_ zY_9?vJE9a{5(40fAI$~3f?hm>JL$c%_wV~(O8!HvG1LFdyX(><)-gPYZ&AQ~+3fC| z&r#8?Z5S39fGr?uF~bL*m?X127)8E1hc4ax*IV%p2Hy>k@+x@HlQ-SL#HJV(0R1th z8x2g3?mm=RD%HJfQO+&esF+8X%kk4_c1ZlQy)q~}1Z9r7E|F;;pBM;ki#rY#l-Ctk z_u1l`+;@NOllGSFW33)id-Wu5F|$xK1-H@Q&b5A_l-?VTYf&z+vXq8b2{=UdaxQ|* zm9C^>l8~4tWkou-Ku<_};Q!RVwI@(!{hG1}EcdC(v+)mO^BEkMF+7or2em#H@#3G# zeFfCui+H!uwNOh`{6^M~+G6&nXi^ZsZpF_IP7}N}CR#uOzZ?Uij+jm)ch!D#Y$rx> zs!@d+^!pD3q{ik#Ujslm_N=xUgeZ-uez9 z^s#h4tE;pp!Ij@2HbUY-YP%^0l59qH|kxEuu6I_1|+p5WH+IyhsX9jFfh)fBcFr4DKwM@#J~1&yyH04@ z@Z32q$|5|_cH=eH{M5uWl4>m!Oea7!m=^Zwge7~Hb6=uEu$}AQEk4t2c>KypJYHz4 z{NsmLu|dW+L-I!d(UpWm5d75UljW{(3Dl0`B-x9*_a-l%1p5#=IciPT-iZ%YqCx9F zZMqW45|Ip36>F;X5IyG}@>h9;noh9$E2O@22bGH_7tUxhI^krhg}z{b|JIMKaWcPZ zH(l#xt`}eI_->|xrA!Rl9?hu#w};s3%RN6uqJ@y8J;vG;v8-Zh{r1lcu3BF*mc<6- z`1pd|hpJ~>y)xKY~3ckE(~z0uSSnsTDVi2!pNFa>P!dQGYVZ@-nmUEu&%@GuXfl!Krz7ktG- zARB-yS!`_{!)Ls2T3VSsRL1@9wYm~| zWmvlSZ2onV1LHU1e=g+J7=GjAAZs((*{Y-zkQJSYl(@Gc*Wct$v9n#U`{g_amDqUO z$;B4soH$qqu?yzGaEOtF9phvdDrJAlQ_4?2%|uA=mN=}(##48|rB8&Z;-% z^Cu-~4|I?hbPPY(Rppjqb8i+PzRlL#hgmA^PMz=Jk0F#}S}>sf(Ju2Tsx_0oL$CAR zAl8{nI+mgC$Zbq~J3a`lRGJl6%GD`Kh!bhVxjS^eR6|JS5(la0quM4phg(P{+!p4| z7g8}bITdb}Iu(WhF8;vl`7h(tarHz!%*QYeI&|VTjpBJJHFebzr4(OE9VzHY1oYQ-OedAQdC&3yMe4qgNA>HCbd%{1Ls@JVQlDDSzm}6}E>k@4OBH z+$e+DZ)C?bT1~7?v=%UM<_WjgSA3dWCgCLyaT3fTDC}xm$n8zByx(8xUrm8gI+vP5 z;0_^(g5=BfiUY)kp}8Ct(rPx*)3)tl>R}5Wf1J=M5qCgP8Zp&6YKRcV7S{#8vB^t9 zai*wdNXn8-{;mOp@n&QTbfv^d#e}Tdgn9ZY+?t~{OlF^Uzehl3FgT(GZRkjAN#v8m z7A#lMig3nq>FnTqdQo>qE`g;#ku?s2Tw!mC@>+_>U6{B+?48#MvY3Yox1NjnKi86s zU?eh{ASSv{8k}KJg%3a9BF57-=8Ut7IrDN@RsF%y%i{)ebheFVBG zzh3QWGap?`GB%FtESWO0${u!9Wmk5U;GF*{gl^JG=DB>}gOII)n04QZF-xDOw@Vm1 zvIMM#K(Jbx3Eb}}maz7ar<)jNvoJGfG{(fH?6srm3t3kGy=Wk7vJSyS1(sAzn3jb0 zG1Axp!u*ckqCN8iVsAd(wsFr1b%2}WnS1)rxA2@c!+EX=Vi{jnmqhk_#VJ!APr=Q% zpzp(^^Nomi;Ty?mE zaOpd{S+oS=DHFaks>p_u{y}oCAB#*0l-cd?Zibh|ygPxM)bakJ6M@e3rh+n1r%qC+ zU-Etw5q4<3HGrv@Ppt-7V87hYK`SYtb7k|$UEDT{y<3$rIL-Z;QGs-L^R)k^b-yGE z-pzRTz&CUF4Hgfj<$rR-Nnsief5+2vBCP5q**XjRy7I31gX#Z8UUl&JV-bFHC)CL* z|FRC=vhLk5x%RCBq+3k7Z?`_9Ng*DVpRFx@+pVT@dLD4qfJ;CL>5V58#Q&H2kw_5_ z;jXWgcGukLh=Aagh=Oe(CF>8>hS-Go4*sw? zJ33&UR|>I7n=(gxJGR0`a6Yhoef6tI8+XsA3_&kp*E<(}-v1)>qr_lb(pwFwT*BE} zDZn6bSHgqACqD(EWDOp#p{9+g{DBD$eOw}opFPcOKJb%i$|AT)G+pz|b^l*D_Q_nV z{~sU+B(Q62x$~IVvtGe3@;?NQuL*AE9LBU@0>^DH(Ja0R@X6hBAW_oWmSzqNjc_u+ zG~ae{1F&h`A^QZz2#_TS8JT~zD6*tbEB#@=GH?%RO{<-;@>h%fEhfj_V}8Pds$gjA z*6B>m2cwE*_BDBUJf=-WLy3`TEB|4a2XCztKZwq?=XHX-Sh{>Wnv!pH!7}(CU5rOu zL)D~iUnTAn7UQNqag$IZ4Uqfc<42hv{B*8ns~SOb!N6LWM)i3uA-L`k%Ohq};6i%4 zVT#Ob4Ot?>7?vwWp+a{Q4rl)c+10oO5|vjsAA{!LczhyORTp05wDY9Ek)uh64!S z$H2L(=0`{!w8mkDe7w;Emwxs}PmmeG?()g^W>mw-_J*}=d*fZN-K?t1?w7hMeH~Q+ z<4oL!RTai?tR>U4;?=jKbtRXPz>R|5UcA<4Fjum;UXuGk& zW%FqFSKnAQRphL@rY01;(9L>f)@@YB}Vfy5L>Rg7}q2=MFU>9yw9-DBv?e^cG#{syRg@)yq_Xl ziGNhlUk)s0h}j;0NIpS~>Lsv2!Kf4m8C&lo?;{~0UYEy_pu9eG7_8O2PeZu6b@h-p zK$qh)5&5*Fnl4X6wB%`(8k}LFCgAX@y6C?@C|=!pN4n@JRgck}Sb*n|$|L`h+4Od1 zz~#6B7>0;M=jygQLCz{wjvr0w!#Qucj6~N`k!RUP4|X&{lIw8h*}t|1%RUUadd}gO zp;IMmtdJON>`*8VV>4Q9Jk`T`2kbR+hu3`ag3|%O$3BZ)NK~im#bBx;y`EM-ytE_$ zN9W^<>>1DlrphujHzuY{ai{L>LzZr(a)Fz9cQBsA!5=x-K z<%L!e&d7LO%;`Anoj@v3?3^_-v@H7*^du=tc08(3<>W&7=OyyOr80s_kgB+NJpNT7 z^*=BZOtZlQJ=gz%GD%Q-&+2&nYq4{-`{iRye+(riCm1%p`7zUJw>$6_-Kqj;v0&a% z*?LmyfnJe!(IK|(VIyF-t^G@AC3?^8GFIr@52?SuhCkP)lyCNaHeEjNw|LM+W?-xM ziR+C6D}SPo&XV~sr7cLi@CFEI{=MJ8CwWuJWpFl9*HPi@l4<}oGYtP`A|XR9OTraq zQptY#)p#s0ixLcA4o`?S_q2BRFaP#xHS*ZPlfeMbVKuDYiF_=D+EEL3c|%!la0>dPp@TvM-XIjsFbQ!%Pmbwq_VpCFn7XFI$~P6>(wN*GX)g1Jtl$2$Jl{M+Tzw=p?oWl+Y^Js$CMgqENIY5HRT5Cz4nSiu%t9+dt?J}{pP;`~=@b;ITk$)t)bY7Tw7C9LVvHWNntLna=k&UWPWhCK^6j2cUm4`ca3*Q^5~s z4}GJBT8uR|lQ4q(nz+C!eXH;uLuIlW0JNYw$c=4QtMo&v2LH5?^xP=VwISTgBxeKB zD1q!}f!Uwt2{M&~L!oiYGzl& z!A6B0qK_&6QpRhFI>%vTi#vte*c^iFZwGtuDnKz8BXh_e6ThPJMyPR~W#2X1rQMAt za8`S%yO`f(Q+vz5INW`QB>1OLj(7IKB@RA5isdLZ3hnGZcW^v-4Bg15ZM*{e9IXnY zR#fv{OT`+lEmrMu@0j`h#>DdRimNr^L`|0rGI2mai4KIQJs13c}O`^*G7M1`ExE5 zsK^v`Ql)|M;9-KwQbAviNl9j>F(lluDLpMNHqvL1R+S+mPC=9jf*d@pR|(O`ss%DH zA660k(BUCB+5+`h@tjTUkb$n}lN+Y_D2}hzeS^iVsB1qf9%O5D_UqI8Z3=PKd=M?} z*|LGogP@n)MG`(j&gCM-sg=64^X2wb+VrEo6HeR`gl>q`2?Li-wX#t)tXPa&<1lB7NwHA9 zO=RcWj01U|SglO(tk;&DzQzgSfX9g$K!`OsK}1d$z{Amy81d+6Z~*dMZ60TE*5qKI z7JOR{@k-6=NTa=wPfydvrvB_Z$$vf!dM{G%hH?^-{9V>h29jt~pzmVOSYX)sX1XwP zR%y-x;n9%8><}BA;?zKxa#@o$ez_{pSX~8GhbEcq5LF@N;EYzqRy`?$Vy#_TL+BM% zljgm&+!N@P5>${Zp6*dyktKHUZSo%-=+ItZWIarJ-92%=<#34ZB6I9TsajvZhSlOO zsmqP?4$D44%O>9jI3&1jYfhUuSM*g6X?eE3!@QOCh&iT+#lNEL z|4p{9Rxry%W_L8;Y+7+jrqW$dp8QDMsIle=)7MGD9+&7P=pG@WUN7s(HE{5;)#vG{ zfcU=ZW;+&&2w}An%74GPy*iUx(UkH~{0y zM<@vCuB9dzmoGy%v9{*u_U_25Ji6}H;iS%!*!sibqhBS%t9QQW3+LSe%9e3M5p>j_Ut&tXL*|IL8_P5|4kaxu*Xg)Ylas?a>_H%M$YqHSq5db?Ix zVL9PfQ?5a(VcjV*okdMXO|G_2 zkYG;f_r0Gbh-Ye+HtOrlF_D=iFDpdzw&$QW8TUy^PlyotH&L2}8`i8D>%1$q3Vywr zam`l5LMyaG2fx8m9V?nq)55L%1+}{c2L;F}{I`d=WAKBBFIt$5ULrWxR9IkC*Q`@9 zYFNLAN>SBZ;|Nd|?feWL0M_q3fUZRNs-Y@AY-%put_%3s zfIWeEwfJzkZIqN+(c3KZ5)g&j^nvxbFTnQD;uX<@KKzOkZs9Es!W1Cj0QDATKxLan zZ4BXlVTfE>dq?fb`U$tCT~O%i@)w@YqBrA;M(us&u|6{Hw}IZD1IEbp>D_)z4q zL`yF3QBkkgU_dB{!x+Q`r$nFCJa*Pp%XDG5=11#MTGPMhYkBOlC}r8N9B)nL4a94E z(@-bdrRtzfIm_|kw8Wq*k=0=U8x>W z0i*$lP6jdY30Tf#6Aby37dJNL<>6&d^=gB$vJVOm_>U{1nh**+Dh3yjq@aF>!h{KL(M?g=l>+}I6e_D{jDj3joJ=%W zEp|iDrdD#vjHOgcxv2*TEgY?AP_P*d=*sia#}!yHu5V*w3?Q0hWlKgc=OUKhihzk_ z#KBe<2i*{{p5^C!mw|#_M=NS*9)S^6hT|2mxQka)7QHPbq~QPB$uQ0vol%zbAp#$5 zZZj4PyP=&1{IeD}1|xK_bX_8#ahw;|n5gpBXC?k=^F>9X7dNy1O2TzQGNTJ`z1b7F zQQY;wY;~QFaIoTe>qTZ-Grej7UP^n!r8dvryDOsy$!juxHMzJ;F z<79>S@ypx3Z!L?HaCckfsfTXo6uw~F=HM+jQF`7ie%Qn_}p$Vgr=M|F(8i=*{^6lm|)8Vw#I*Si}MOG~O;5es%}N;4!(L4Ws)XbSCJyFoJH?EW^bQ#%S_ zKbVTOJau;Zd4`vOU5mwCd9udC^5_HJ9Js-X?;6!+V|t+d*I*e%yh@qNppYWsZQdiB zw}r}V_st~}jp=N-jUah{uj|S|HL25d(alrr9M2%FQ$!+Rg|8KB>_Y5SI1De2covI% zFZw=fFN}hDS>6Jya}0QCPpFAJ^Sg7TfitUhRE9Z2)u%^dISe5;`_^ae(O;qvGAT0c zd-9t)!*RBYbV_?z&alWn>fv-U^TY9}vww;`k$(`2!Kxk1)gJUiOb?ncv^w4klBQwh zOxyN8Oaxt?yCyGShZ%LLi09c@GN!jh3}v^9$W!USZS+GAm_=`D1d2fU5mC+JGLx|? z@HtQwcsenf*JDbcIR)OFE1GI}9*1)HVt07xE(3kqIWNO%`0j?f2mjKkc$Ooq3%>FydbA^8a=>eD|MrlfE9UEkXHvXZ%BldXKr#OG1hb z1K0b6`y_pPdB0zzeULVSD1J54M#ehhXjF6XjV9U$s38Zi+bAj>-RFBY!JZ-p@+;)9 zuCkv(R^f;~IeNk``s`=NKYNixr01)uEOakCK1SfcZMv{BI0H?Vi+HmQ6VF8oun$Zu#Vn za|BhF$zF#b5Mr74$yb}KmT3a|!n`OKLa8MliX82@(rP5T*VQsr5c1!oKu*exeH2fz z$MK?{h(Yem4FL}m_3)mME&{4m64m1P;INfByl`v~q1WsCUt~p<9kr9}0Cmkw-1ZxU z9g=Uhx+6c}&OiAsn1}Q~A~m*TSSf9t(mkN6-=cIFvTbyp;9k(@RPX}$AV_29pd&vm&(t2zh-1ocfoGYnL{(h1+RyHIyp83#m5;!tnTnyLv zT&?7ly)uX^8%`e1<#|CC0!Eyy}ac*R{!H32UQCZ(R|EUIbaMrY?K;+ZOl)BVD~awIg+G2B=fkW zQJ86z?awgiThG^2hhWn_HL@~?e*DmfryY<2T7Cg!x1<>wYRI)4t+}@_q&Sg0B!uEV&)kv(}!!0IsPn4?zSnIY5tIkXl-O&vXCW#Feot=={xJtN~mz)I?aB^R`>GZjpWkt)&B%eb}}b21OX$|)E%(vs;P&|rD3XNPB$Hj;B1VCbhH-T zjcPBf9Aj@LbA!Fchf)BO7-s{{-U?B%f3Ce*Z|gCbuY_xR$1Ngk11agZziKSBP%t0xikT;7abnu*FM>X%KH(1+ z!&cVEwTq>Hjv!MI%JVWw@s2)ah`394?NDmW2b2j(tgpxpv2uM0Yabs}W;7;_1D;KJ zm|3fHZJjj3;@Hg@j9WE5wy2(5^wTsSQv+TUN}oq30bxpx8|(^_%;ZKCWmL;+RvpP< z;g_M)Q6i-m#3SJEp_ZtOY(w1;`PQs*%syCkx-66Q-(7Zd1@yF@(3D{%N@)U^*VHp)8g%L2Pt* zNByu?q(9Q6c-CUaD~TgH8-TO3(J9fU-sl*7{Q+qwV1g#W!-RLs&FM+ac0d-E(qMOaP<>tU)3AvnXsK6GD~j4?{ll`(+kqMt*HfZE~sjh->R>(c7xFdB_oM= z-$)6}(^MC(kgEEeIx(odRv(~4NX(sZ!7JdJ0|c%W-rzS%C5JG_IA6W(BGy+Uk8-}) zz)G}(-kAScg$nnLNHW%!OHoY0z;G|uBOe+_$+u~!7OM)7yRz5#5$lqCa8`Q3+X9$- zb$I7%&jPo%ElhPF$cnk#p}i}pG+CQ8AIlEQWfh3EIzDWe0acYS%?mJ~y^j^ti2okB}p^8YGy+@<2APe+H?S z)|&1FBNh9W#E9Jy0K%O3)*R7^H(=%bXz&kE*C&?!1(rgqK7`>uMkyrg?ZRtT$d|(%0P{X)ZshIzFf-owKje$3W5hB0I}%tNeP(95dj}^8SnxfJzE0-0!{S=92*h@= zoN?XJ!O{fQ)n=0qe79V6C15OUn5ihkZCVJ~294lKm!th$enOnBEIjR$Hj)s1jBvC^ zX_7z6P)?v{-#yezLt3$AN<^SdE4ZINn=B<$7Bd*BQV!HcOgx=F^-b-ukL_HcZ94o- zH(_X2C^s^h-hU~WWH(_GWv2XHA2941GC(m|b5Uc=@^{s;@A*nx5~~vaE3u^IX1W zaC2r2nxe1v(HB#qQ9>fMXb{NSp4)1BMai^4lz1vr<)i7c@OO5Q*;fC9q}>7C)7FN| zSS-chjBxtzdc+@PhU)Y`|XC~NG!BbatDN;}C6wN?|>7yr1Q`(PE7{z#d zHTeDMao_MgiA{bE~h}b|_rqsa8o5xS<#ZrP;c~|@!H&D)sSHGJW-fmEMikh}aZ668!>Ypm5|&RK1UzJSlN6$!t-(rBn^xRVx918*n(CJhvyUm__`zG&~ml292irOtdySRw2@qIi8h5PRYp7spO_16T;k2P8?V`<1CW^()jfGqd0D7Sc9 zt>_Db6g%;nTK>juso=T^0LWxCKGdK^QCrF5Yt>rW+;y8|YZPw&M9iZCGeNgKev&Z{ zL84)Uxm5V*#`4+`qv_5rc2V}jXIQzOb}-+WdWnJHp!kAtC=_Huk(HXStK~Nso3&p%_U zi4UKB$xxGTldU=kOJi`T2EONxxInBnuMd~wzU&O1%nqcM4T>F6p=Va4$Vhc_Yif-E z9m{(|)$9g}CvLhk{HQe5^6)>5lbA`#_b(sHsswvNZ+W6~gM#|rv`5PTR%B+i5_D#w=uGyF!mBrNsw`C$sS#WWC8(-b$6wzwnUNVypnJeaBp$BKNAU?;(H&-A31zv z5r%x#e?O#@;q?p^21)BT4An+7^SSN7<$AeRXWZFh1qi3K2xQ>k_prjlGbPyEMu@6A zQ-4{=uNNEs0{Hnwr)w}uaWv2i-*zVOTl96+Y3D+Edn4Yiv?dZ&Jk-uiJ$o>yO*gt|McH2UWYWI475 z%WvnTsyR#97jk?XR>DGyXed!z08^CvTIJ+w!+*pLudFdWtZ^H_$#rMS034>8?iMp8 z5X&5)2=1=TES-}z)S{PF(587P;4w1km*c8#DcdibbQ$e$Y#;z#HJLI4- z3nJUg$YW4YUp4+H0+m&J`#lrNbU)t+W=yx8H*Iz#z{KC2t0g;~7*?ba*WX)k63i}G$w`Pd(BLibk}jlwiJn=m!%QYTxfwjjrZb?;5d!vQ38H*N?TQGA zzXR+~E~S8y@kumP-|M}*xYoo@dBoOu0#Y#sD({%c?s?~}D%;D;F~#j0ml@Q2|hj+aF(d=Rqr-^9} zv7Z>gXaNpLAD;CL6rcGLvjE{GIU-5+(f+vo4f)yrxGUpCz!HiUH}g|k&X6z1cM`AX znBD)_dqxe}&2UJq+#w4P1^UJ$N@S#o zspY`tVj)P_I8bD%C)k{1eHW{_vD}lt-=AX4Qf;7ciH!E8_BLKAYh&RCzQJbA@9~O- z?5gtTAx?>Xg;`_>R;t;2sjwW}=aOqI_BoGhofdUIjKsgW*@5uc_o4mC<&D~-&xD=M zGXgSZLKiIM42b4%iN3%UxZp-^z3fV-yOx> zxJ9Hy%*HsW-bfl?)gJ%x$sc^iK}koGVzCaxk&S5ve8#=Xb;Kc6)G_WA#c7;yYV1Zc(iPa|2}+!i_z00Mtw9Pq%2i! zTgd^6Y77v@)`Cyzh=ADD09(>WB}izzY?~=t1kV*Y6yjnhDp4!<#}wI4H4__{ABt1` zSZV+vs82a>edlowNpA9q(cG>Qrs`ZHF48+| z!iFNNG23+n?n6FB<+d%WqqDdKt%f&wQAP$QaY^ zCrSh{pDNXW4ek}0Hkwm(K`ZX7qC_sGukF)@N9u4i zL44pSwMSyz!yLEvO;3nJYJ|G0CVk6uAY}w2yUP$-ijPCO$fh^%L(7N!ngVb!1z~B4 z{s0u1_U)xx=Ol4yjjPmO9co)(PSTV18N*Oc&$e__jm}?b8cKlPfGdJE2U&CX-F(Ny zuvF`m3kkx{4OM&zRLP=-!&u`UJqdj^0&hP!xD$9$G60&kysGK7ThKJ+PEV)`zK zkH?@;#G7P%>LMau$0O8kCYa>C5`)F4wbXDgcowz)L}?^$_(R%6F>h&GniqQt?-d^{ z+M#5F&-Z@=2!So_M-(2Yms8V%=Ks(F+9F%+!HtuCRFs^I$dL1Q}$B=WL|LE#6p2MR*4?5~94!pY>}PN7#>X zPPHge)=gumdo=JdlhGqt+jQ|9%yi~;XERjE2xcq?8Fcf$8)w8mbW=~dX^>xn2RUa7 zCBITT-#G;+_6Z@)>4rbw;0si^1{O$3erLGuYO^owKr)X4h!1%z&kGk>%i5>=#^(_wyiFu<)yjYHvkxv$s7vH#i{Da`wB3*o#G zofE0zfimv9lOtBYQDta|nhY{oUa*g(V$TPl&oQoSSeq7?v+osss8#UosaB_q<^>(= z&BYQ zX|ouJZBOP=>%)m`?O(LN_Cx5dL|Q}x>i8ZKIdIEW%KgOKh*3%$Yh%VW=~KIU+MPbUr?aX{2sBdxN)?o5cRRp7Bw) zB2U2v!JfA%+%vQTz1WS2KuOt^TCVgsD;Iqf(>W-q>o52=#GU4vDmgFndKVhtC-!5T zOX{_e?&BccPVGmg$cN{GNyS$#1PX89Sb5_w|n?MSR=Dy8l zMGe@4Wl~#xMvg(`1Zp9B>)`7EN>j6!Z6xSwLPJ^>{5tV1CJ<6#)8lT3teaWLFo_im zU8J{5mMP{N3C3}e8m$l2M=%h{8Vzh@IX^d?bul-8S$16T#8Xo5vwgG%pO-TGS{huM zyyozo#r!Kt?{5C=h>%p!=m2ii``P|yjkM+D5-;DTu{s!IsZ&S~Ihd3 zv(Ty7m{~tU!*=sk;+BlY2nkoc`z;99w^!)zSg>qN9|` zKU)$LmROS`Fyp^;wX$J4X$6O; zPSYLkj=Q{b7BK!T_+$(*|A7u26NheWxe_jw#!`UMpg$LtpqCHXH=h6z$HhkfVrZBZ zJTMk_fH-=cV?6>KB#S4_J896>gKHGd*xcJo&_DDCoa z0cXwYE331i1fuOe@v@dA<(8P8_0%~woWrOU ze5tK$or~lnhKetx_1o_h(_m}ZsYJ)4)~D@lFfY~=az$D$Ow|a& zk4Sk87@*u8mO5kG5<61wJeifuk_K&bwrJA1sVQCnW9!5Ab%j?`0hPb=TAHn#1hv2n zk%P$5Hbd3r2%87B6DwfK#ktqzP8p}O^5RP1mrEnO!N{>z6Q&;c?-HvipHt2<9($Ny zD!=nG)jofQzd#3)`0pymM=|`oj`?*hhvZebAqsS%?ngkcEGT6!_zZ3R7Mzb+bV|OV zJMjF0@WbABA>3*)y#^$&8Y*wW!@|&Ct+k-OD9v9KMc%}&cFx^jJu+`*wk0qZ$l6#@scwuhI<*h?LnX$cQ zg|l9R)oLx=HCp^*`5r&a?Idbbc~eQU(j?Hot9Q|dvAmdg_hh)_W~#Bfh~@c3G03gw z+vw30{0L3^fizeu;bx;TIq4acUtjr`mf6YakWxOO&G-GB%S=x=IZ{-5LrGSY*JF!G zNF@LfHcg&?GJv>!FjfPACxE7E^XGweBTy|oSzxUSEmLD?S26BLwfh0{pcV&c z;LvQlx41+jpF{;AqMiP?c{6P_BKWSKyUfTCH|YJU%hq2H4&O)QX2_N`d)MO4XoH$ZN%T1nJj z1X)8c{8SABGj`ZjRyR0~lqDv#v!N!7HCx1leKeP+>&an8>Y@@kK`vIwH4lr8<^b4Q zXeKO^@r)j;ijD`8?Vij-*%1u|N-Hi8zBchk@3__)? zwF-$cvVDe{c+VnWi)Zeq+bGHFk_p>=;j<*zIzBc;mYNEJg(BJp`~~D&o(D&GiGE)l zH#wblVFW<7z(ZkGD0h%k-2EmCWgy(T<|XR-d_di- zE)|9X_EXcF>BWUX)lK_l5TiP6^su4}W=%4=;7tbHq3G%4r?oV7g6CC^b4D9K)RTWM zp0ONaV~(~GqfAt+pUCkI<`z?$ik_sz9^E8QHjux(e1y-vyGs^@evWGDoU8TWd3~OE zGdz*|u`@2^DFQRE)^dly-vK@>g30?dNcTh@ay~;VG~~`KCyEmWgS|lXeF<3FccO)D z#|c|iuB}2old-*oX32*6sXC0T1r+<&e9MJsvqgFTF-ijkO%f$vvhZa;+Zax)uvQkp!@$_B_T;JGkhuHBY>W6(|zyA?( zgx(wh7pD49V6)TebMu&NnI9|DPCvSsgx;kueNjf#O4R*(Bt2lGG|FfxJ+34DDO|R- z6TT#kY!jG{ci4D}ByUq_K^OnBMi+w3;aJ?AU^_BUOWEid@7iWgWlRb$&c;*D;|_Nk zm8J3mW7ML+x&5v@@qYMl!qb$+Np2@XswB(*{_5_{BPi;uN8H>5VHweg&A9Wjj*iI) zcu+4hOS>PfRU%R@2u6(y5tNkACP;JVF4kF`@UmZcjVm}UVYfQE15g<|qiWF8($eZ3 z4lXzDzI)4AICTyHg;EwmJt&@yrF2!uSamA`G}UgFy!qAivsRJzHQW7w2WD_0PAsiMx zTQcPpW_;wE8Ea){QM{P5}Au%}F zt$5t>d4K2h^lHq~oXnd`BIV@6x%k;eD&Ms>#mOa+F2;>w-tF1g`SsMU!Ofg(-vVmMbkm$2CSK&8R=$;HVu=q z+8PCDrqwQaQ#6Dx`i%~V_4Gw@Tl$2{76yQnj&q8Sv0TsEP+1A$L*uHq-chA5YFT|j zaERn_Rmv+LdG&^#^$OJjXM~jkM$01=8aGLVcO`S5W@cB3?ag==$27>h4fW;HnH6M9 zB)zAmnw&>(Y`9ARGKR(WRgEB*6n%iZP|blxd@yT8p}tb+e!JO!ptr^o0y>YjD=W+w zwv$=R6+u(#lk7A&Kv7QG{+M9{JLKy$s1e_lY8b4AWZWL-(sw{tE*+V$oK7#W+zTbK z9QW@oQ?OD=lo{n|91c&oOb14GioHr%9boXSay6{ZsCjYMQVpd(hZ`{_l^Iedy$%UG zmXG5!TS*gF8$=ju>c#X_9`4=Lx}g=ivhe1LIy=OWQTBY`R> zn0&@wEoN~TBU8Skw^8nilLEX8zgehfsS!i20Nc*`ORN;sjhR~G^?k%{QiM|VE2~44 znw=&x&_nMxvTij4VP|1fPZ940^v)Lv>P=8JT&oF6U)6fhlfu*&S!_VjfJQSABI{ZH z_(n*$kPL(oS<0z8=3-oU9`zWkwA|ITnXf8hXYFLz->wfNaVC0yN)aj^?=1#B->1g6 zo^o*P_h_VB-IZRi@CQ&B?pA*;qsbv?G{DWqy#Ol;A$CNLJJ-`N+B1I21nufJ*_(#4 z{CKm^=m)ZLUB769jE7kMViVBPxvE+nu2;{$v z5++a$imh^t+B!>+{@%^+v-&K#t(oC8*}&bD^Wy(Tb%dCQIf{}#J3)nn!9ixmnP#Gg z_3OLA0o>UHl{}2WO50gV@&-$R(cI^{XT-`T|i=|NJ5_x~Mp~pLwpUmm*+6Fw*y70=*x&coQ zqnc`77X+sZF@7m7y}6_5Y2GPe=o)b-@%|=gV{g}tVNH82xmtYZ7!(H1cvi_1Ra2*p zF<(+toXE~syZ2}>q>haF`8!C>siuVyf#;SPJ)Y_+Cf3sPql%1#HeBY})ZJPgLN>t7ajbzz`4Z z6DTJ+>QPaWPOPk1AN89(IK?ZA>zF5p579BC9AiE;p>{{wGIhrRLUrf0Ky~I*?NY~2 zNIgrd+iwDzV26*o%JDwg1$I&_Z`$rKAIPmWMU<2V{TcE8M@V8+YDd-*i{Gf@ZjXiu z=j+2!U36vAA)soh)*`5z@mjaOjaK zchyUYgz{NVJf9-Ui?&1v4f)9Y_98sT!9FM5;KlPj(r0UkSd){7fiC^ zYaL}lBjGkwz|Ee?8bxR*4#QP3i!biflrFn0P_eZ_*5yXXBxqbNnZ*o%Z`ta(1k= z0V3@=#mYwzda0pJ`nD^zp0YLd;-J(!CM+*b29^*C)!{TWOPLe9@jyUDzT5VLjX`3k zq5_NVJ$K@1e2lgMBJ0D8*CQ>JVcE66M)5s*238oG+<^!q{Q2Vd*yh@t0cI8sQ0f#k zb+@j9r*z+NJb#saGPk#rN^<~6h*q8Tbg46F_sgoMoQYKV;%JMwO?Tk^IkUd#u*Xu; zNYdP}KYfH*kGmGG_5h2F#0x9T7129w5uv|N|lxbKXza6TYeWagvV?BxsNU6(n( zD4f94AfWDPOid_8R~`_AE*6nwS&!L*eA+c-5Xl}!#d5lkk&roq^;xf z>6+6cz|YROH; z!~ET&B~y6o6x#vmha4<)HbWul>H6wJm_PZ@o^wkh1yA+bV{7Tr)Cn#I2jdgX)VY&a z7!AkM=0pSO&mMNCwD(?Np`-nQ8x;}B2@dS@eI{stbWZZ4b=AJGOM^6^YxS}M^c zb#t8d&ku-I zz2aAlU`q6hO{Y3~94_-5VJM4ycD3Os$ToXK7j2Q=#i=j#=J7x8R8k;FxWTo%`vH}R zR;Q3r>ddm+Cz7J;2?h;dv5gc6@27CqYaW5{^hmpuvKZ&6oSUgBex;nSGBz8)cJ$RN zEMs!jT%?kCm)TO7#!-2Hp56?Nhs#p|SmGz>>?#j1*CzD>FU$EKSRZe)(B%sp2E*kJ z7z#hoFS4gTwu0o#tLNRItuwIwRyisC5%|BxN5O(%&QUNeL8S}$+g@d`&i#~msUr9D zZXHtbN@C;D%qjc=aD!rMPUpez7ZCC0?P%i))?2H|@|ZfLI%}-)Pmn|1Mb*Iw{E!6A z8hzTglxv6@YX?0SgR)Kg+p7rGjrig&tI!Y4-fRrB%;-Vvp!-129b7>D)&3@)x1;Pb zdI#{$X$FvcF{VUCr-x&Ofo_O~l?~(uMu^~lUpS)r5h!(4VoQ5Dm(@~EM#7K3(Uk{p zue1T7L)^f3RdPO9kO;sf_BqdyZY8+Mh*061Zus4~nsSaHCF4=s(PT7X-KLt1I?ESaXB1t~~KyMW^k^ z85I$w;foLg-7X3)XmbL7P@#cPF#~G7XQcvRV6)-bbFxZ^wbH_#camtkh7}gRqVII6 zZ8%{G+}SRIF5&_FV;@5=e*ca>pzQQZ;(R1!wM?_G2>Om5zzY{+CwBY(fT8SUw?#%90o!foQq!l>{-wb z`G!P%v6S>rY8KUe^ziQ|ce0>DO6dZ2gD)|sRZooTZ4?j4w#@Q}1)f(8*XIzRO^l!Q z77vIw&6@uTJXfBT75tYd_P;q}KYzLJQL=hqG0? z@Arb^f>2T7KviQ{hf-hieYr1ltCj?)>oZwMdJ8UkFN`X#PDP)w%j0lE4w7Vcw%;Ct znJI#&>#?$hW9kwE0vG?mS+>O@u(sOLnh=w)$VbBeLc6m%7vzdh{VT$PWVTof?H<^( zVkT~ZX&&t1cS1J4ectMtj9&5+{2QmP4RKqN{H}v0w-@5W#z0TLuGy@)?3b2Ny#Lq; zVlR)lnGT;sK5*-~;>>mbH~>z`a=KGrG0P6>&n<(E0X9^GA=`^jG3Vhhn6L6KNPD z?nOpV$*5#Nz!YDQbhP=Lx8Zo6Y>V|a4{~|J+cu6~ZH{78hX%zwnrCG!aDigbFgL%G zA{N!K-ed3|-ZE{HP4vCK z!#m|fFDRM%eX>I#`Km`_-S25Ps%Ti?Ri!_neY!RR?@{G304k_rL*#b4A$ok>z?dvU z-roQrLFOYEc40|9?z%&Rp!mh0?Rh|PCYT!<((Gw?3A@W{YEAYw9KTX>TQ@y?$1FFP ztDYhXFHUAep3!!&^4bzlzX%@3zRPkMxvDo5OD+$HhgTZ?ht+j*Oy{o(fQPPE4|}~` zl#VLcgi6+(Aezn{SywmMTdqJ*39fB)+B{PC3th_%f~7~6BUJ9H4V?RJYET$d!e#HY zUz6tvG#o8{_>a&L)y3Zc<8^V1^S=Tzlt+%gSK=8j7!u7Gw>4)1Hl5l|{2VUv@3$Rd zpnSI+VnsS~N==E=4@M$TDSQXBrmIZcAJ57^Wk|gGy1?*AlO25+4&K>B*cdFiy+HMX z^1zV!!|>BG&4GNI0R(uG5h)>JZ4pn}+RRZbExU)0_oox>W#14Z22$j(I&F3k*a?=B z44HleZDffuLShNUMwwm)n?5cP2RPmb6_CmgU)y~S%J%-`szv$TVK05olc2Q2y-;@# zyPst#N3mGDN1ej_0OJZrsH8?7dBzbM#eZZnoV3_}^BIYgqpQ|cJxn%a z(<_f|@d4L7JR@-YUahI9A8g7zlGghNwa{z;s;V9Rl{(A0%{s?V>a>Q<%Qd>3@ZVj% zMwyqUY_I?#3%$|(6jKAzwgg|!LoR+4{Y5ldC_sc5+5v5tJZPAR@A{_IFwAOv_adt~ zo#)0}*P>ZQj+L?jUVEPiHnyVW6qfZ62Qqq|te?AW68Yux6;TdV4BUw9d6ZWW9>4Vz z!dh#Sy#-CoSE1GiVdRmok7pa-?u6XzzqZ5w;Xd{UkV39i>2o zj?w@WGtnzgbZ0I3Z25sm^2Aw=nDFa0>2Qo1Gy*3w-K8q|XsA6kU_M8SGdWoCD}^*( zI~kMh;Fax~?d|P(z(xa?ND< zqLT%FB$r%QlO##J%zc#-$@&@2F9HhzS(hFLSjqw~X==`-o$eO|O$;5HIX{y;eC|Gp z0*pj3Xh;%s4(i_Em8LgQII|GwB2$WZlA5BQ(ESC`JiEY?bnHc{{m1^4(d#h1O#qQuzvCdYM?EZw2=HJbG zDwLC=qu$Ovob13dBoL{lRKt?re5%lD$}bCz%n&!%`3Yj7*Bd&^P|M&UiJ)A|L^6U* zlyf8T9zo)PnV&)YJWEJy^T&aocwm33)W4P>F;j2`zJ*D}wdS@tJ(p^pF2mRUuKzVt zTX3j2fGhx%0ru%-$W_k4u2x%xhxmLGHjDVD$g>%f2Y$tWFfgv#(NyhCKxY+~DzpBJ z&6aT=qXaBfX(l2w|$zuNoV=%DHa@^1@z|N%QvOMgM zgc>lS6H)4NJsSPsh{s@6rI4@vZSP&vdlGaNR(eVy@1vXdS~|By2S1BmJgNmCNl!UyCydzW*1s~IaW3#oCxwwowjA+>rR2U4KtZp~iFNLpGYJO+-B zL<35pDcRQEjQL3`iT_SE+Lfp^K0<;*x{Pfi@q0X-j`=Bx*K)ATWwF2_saFHgb#Wu z>`mxSH!Zo!HOWlB;%M+94KqS~nEZ7;u2L$XFpP)=i{I0rjSIet2D0DrG z(PyKM{z=q_e)dif$ZxIEs|(;;*RO*On(o4j5@|6Jh(d$P}HtGgjMTaC6p>wp{GaASGw%(IL*8=ODwHj1IHcZjStTLO}ToVP8Laco@f0!kH=WvuBcc<`h4 zpgA>`zmgIXxrVordj3>j-HABds3HO4zWB?(&2R2z>c}zDL)zVH1tJab+cKc>Vcud@ z&dF3u5grWt#;;y*m%$rF=L`%yW4KPP10v@yD?Non&GW z*Hb3!O#jQS#TK{3nAH*SPSQ(`8s-Q>U0zWHDO%`N$p_Pjg4Td-QsN!tb*CmmoLX#8tD*gy) z)*x~eXU|%lEUpGzhX_^4wr?PgjgWAOD!;o@yR)8zF~d_&84mNM-`)kLRbLkJUKp8b zBciT?THkB{t#T;CC%D)8tY~<})+n=c*&migK^;(dJg(GRQWf}fWbKi^2PhIE4gY;L zf>d&RlA)NVf4xEf=x}{O0UQ9&bcUD^TG$qn<@o9a+svro?Vh^xNJpjQAAl>K=4qBwBGv=H%}lgzGl3bU}D*p z&O>uCXhLBByazi&$YSQ*A|4G&A)1RZ1|>nlf5vb`%OFsN-h@z$Z{B_jH?hglDRG>k zjiusqTu8ZU99Wd<^eJ)Gix0EmQ=f3zaG%DpTL}9&IC=tIjFG_o!rShN#FaVMjeR^_ zwHJKi_RO%=EmIxU(D|NUq*Q z-jTLL8-LXM^_y_G2w;Fb{k{uWp(KDu{7Nz)mJYWHJNL2f4sjr>GE!%CjpT{I zNW#NlE#hQF8_5489Bu!T#TM0jQkebX!lQrSLCJ)}2<|@dKQ0pZ zUS4`e)L%Xs!T<$Le>Fvuam=&$iCP8#waa6q)F6l98*Oc0oGlN6Z~;{>U1FL(B*N8! z?R3^-YMSe-_yteah};T!+3EqceS zR{WK~L?u?L|MXfNNUzoYuU;eAwxLDxCI!iW@3~h0UC;$0Wv#%~@Z9E>DQR1h00j@> z<*?AI8}2s)5%}2>xzF=RARl?#*Y@JriPIAwCPm9mv10#MI=9E)(;&K%1bv_A?}>K{ z>XP*L)BoJAKYq89fXIJh_}^EtL300x$Nqo(k{Rv47xg;n&1Lxt5ve2oLsZQb-XGvUJ)192v1{Lad3;h;TZ`;X zxVv({-49a|eLS?Zgb4=+2MG(CPZ$5m6T{x#zUSs(qSJhhvGIp&_CK1Mn*J(%ljQhE zq>UgJmtB}mFy;3xz>mF zkR4!ii;JqR3AHJysXfEP#|}npzjuB!vu-Al@sz(_k9~WzO2oJKORpIN{>a)AJC*%P zW{E6bH$uHa^@lXUIkMagI2INbTfft(jkuqqs|1viB9*w6+Q-d69e?2V{%{Pj$Nv?& z`TxlXr205p2b>qZLGV2?OB17`u&*V-At8w3_B1dsFv-cu-ME1%>W272(;1ll zvQ%fPRadc{O#|QZ>tp;YAr_%(yyZ_c)Q;(n0?3|-kMZx(0K+gU@mz&4X#VQ=nS;|) zSO^G+ui)T>R8*4WV;Flu8f^B@^p8Sm;i9l1eUPM2mU4@0UkYH zxM8|vbqoxsB1(b=>?s#~>afuKbWhP>gKES{$Rk8Ru-CF}H!|ASgH$NLRWFX?d!aKh zMuv}IV+r3Vp0H*7`^@i7A)EJ8Q&SUUWpIuh_w+YV6AICkDDL420(m1r(E;uXMj6RPp%dgg~*%K<^M2M#UJl0#>R zF{^6Gh7x!yq8Gf2$`O#`pY~XK!)xhY@Q-0V{ds4AsSQONSuoctWojfKL^W70`^^&v zOGQHo&*w?T@zD%oosz`%=!(_(U0zOU+>3l&Yb|t-QYZJ^cVm(%jB>TOPY0NV>)jLi zATFxuzIi>a3NNc5r8Hi;49x(oe^_Nba8Ind<{ZUl%tA|QFJ^C<0)Qtky)yTPS zg?c4vjj1oii*c?Hch1k7qs>ZF)-7W0EF~f5%k)Nwof9kve7kS8ZQyz*X>}7Y@*_y5 zt2RvDcNJgLs9NxOPI{w1Pt1G6UkEie7xW;ii)tr!0e zF*)^b*^mM5YNP6v&AUcv2-d>7nezZEr^h61*)0=X!J(Etq z3`GwDEL;#W>MRZMZ~6q#}K;wz`da zG!W58i0xUeK+uHV3o1Sy77R>AAE0+xWIOfD0Sd{xUPSako-{)cZ+nPX4 zVs}|30XVnpU4Pfd|0Jp-F31h=ZSEZFPjUQ=v`6%5kEs1W?G*eAL+KH(W2M31<-S~X zwXv=xy0nZN#x=9$q@Gh+-3ao1ZJd_Uda(gjgQcRUZEI|kaA!klbF8|Zt&%w=m|)AI zPIIu$>5KqrHbArg<5R^NoPttYe+l9=L3wBn_G4%JHx1Ux-eIt~O9KfP)!?QFRi@AL z6J0!wOn%Dah&~=X?=X^?^7_^|UB7-)#D#sHXc+I?cEE4SYEq+-#r}eR(G%0#TJ7-Q z!`9}8)wVj8ow|1^q53p|8Szi@Pm`!DhpSkk8ea)^cvn|bxPr|xb=B46heo}%CtDh2 zyOmB0?C_Tt9jcEr0Lp%=uB><0k&nyfC$BHOe~#T)GLSU-)j9B2)I*im zv}$;o3&I4qP7z9!iwcY0esIU7`5KN?S_7}g1z+-^2ab$_Hh3Xqce#}V-Slt9WzU7L z5m>AOBXC@FwyO*{Za5_2@qpm)a=F1d)QVTxI*ia(w`}bNzDp`<$6FlqfI&9u1x+!S zyrxq62fxpi*4n)mdh9>6bq1)F9=-{atGCg`I-zI84x+FGJa%fK^oz#}_j6cn-V7i~ z-cjXyE62WK!ddbp&1wlmB1T9+MDBd!Nz(_+7AZiN9FqI|?0q>W0Ta;f(K=nVgDENJ zmxnwflNR|%joeJanP@w7!FUqEkKf|qHHRKb3v#`Fnr<}x3f`dr;bd0{|>V94`S)L75a*yHbtTdc$K9IGkrM8w7{JI2|?n6*U{MVxR4eH3_H;6G` z5>B`qzioY4w1DczDFL%Y3MUt1S9~E3Qio6E$p2-!`gr3B9_*e65pme|cJ}3ubvq|q0kXZNiM||z3$ZXUi7ISMIFO*WK{-f*3 zk8_d}*6$FIJbr$^d5S9G98H7QJL`mml=fve`={EQauGB4ekIvTC8Rb{DdtlwD~h#C z=J#{h<#=%2%GtkTa%@UMBaeahAiXo$@y6!7N6#NeQo+XQ{;Ij= z6x@eMBB5T~8_32Z-VA{3z6QhN8a9K8{ntn}gaFxVC=W%bn1)p%;AVFgv^1JIhb-fE;L2YX8(TK(4^e^=8=a zrw{$(?J&rF^Emxd`@_o-#nDuHa4!pX+XSyb8CGTe^#+p?+icekY#$qs(S9<-(X|!* z#aZ@8i+$JI%8{tj4yE_bS}}OGv7=q@5BFCwEU`i=%+Uk-BGw@1RTOw#2C~v z9@g^^J+lOvxqvVD$^5>IPn$Y_nVAt}6sDt$G}z$VIGUbCU>@{z3!;&)Ik2@@{HI7X zw^2YUnVydQ#lOmbCs>&iMI4mCg=@s`ylnLYxWvM{WCfj|ag6@RU8#JN+u$qm9a^0< z-c@}CRr^AVA=!F-@D*-{_YwZIW-BAD1LON>DQx zH1!&J+Vo*elohc^33BVPrRKHdtIh7{S6A;%-ej>Fp9xjn6wxZYNB*g1A00#TQ$!); z*~^ZcMWwZSoOHVTVqQ>TdacDi*yn7zm<#?W)Lo#bx#$CX;s1@1lu#b>lrUK}xwuk) zCWiA8F%t$eXlM@$9@jY7+wSv?$m=h!SEW=c5XhqPG`?q$&2A|~*DyZ5L*Iaj<_Hv} z!xf^$D?XmKPaL0V1LZCZX@^Au<{_B=^7r@CiCZ0b6>nVH|A$U$TGkJfT|$o1}r_SE|%ONtd0{0Fx74)O$V5m0+?YE znwjf8+2t`*FzQDXTF|V3 zD$&oEn1EOXIu2icu3#sgHsFs%po0staKsucNAfhySewx5WYaucot0snGUw!fxE@${9WO+Xa~U1h$@w-@}s7s&{k|6Zk@OSX(7y@6w3??ut)^9dl2y`6t_u~tLmo?+!+Nz z2iD#`wnEIc!gNtQkUu0b!m16L^_~gZP+(5Dwz%QWJ1gCzORL+tkUY48y&kYGW-%$) z`vK`okF;>>t^wo`vu1OigwA;Eem5rY26t>WOck0~1*HxBRZv{A$_d>lt{w+y+LThd ziI0M+G@`%(67cVVO^^BR?Zqi6m&j9?|N4XeyMiFx2ia1MRs{12i~h?mfkn<73Po0Z zlD59?{*Ud%h7u5AK;Y;2n|lNyI-2ryKjwokh$sb1J%wGRZ;bTbPb9=m3qpRw4X*Vz zXh3Stu;{+|EtMB~hgW+|aa)l!@C3aVbA00njo{i4qJP!@t|B3FGO;poLUnM2bmu#g zn>Qkm7T}jO1uJjC%5=Dh-}{jqrNjv66)LI?BW@;#H8VI4MLV;|`)SUC;_9-2&$s;J zD!Qv#AIzz9_4=RF^|Q)jXx?qmxQTRz4%qGUr>$QI9r*!kvJAgxxAH1=KdKjwOR1W( z5#LUsBTMj5M&Ze9S=sCeC@x<++ndn7U?g1gV(LBbMbT{ctjxm5UtL4a(`W}nZMX=A z(Ky(~Tuk`Agdf6BAlRM|j%T(+G-By#Y;S&j>03wE&qbha5c&krBiirra^3a|%@K56 zB-=9QLS9^2De)%c$o2daJc(`tb;&_1w6&VTtDpM>73%V^Rmlu8*+Cpl&u$JM;^hT( z@_`Z2e859!*X)hvf!yl+*t_n4B7A2WHlG1uuzhJ9t-Tu9EAy0q8J5=S+_kZeoF{z8 zyE30a@49Wv6sO(S&?^%V5%6b!cP)0zPeU3{EW9r$?RaB)jE@`RCoVU0fF%0YB8wbm zY{D|>k!}_fTM>kK?*}vl$(0u3&^bHdN{<$&ysnKEFfKc;wojt}kFR%(uCwjhh1=Lx z!^TNtG)5aYw(T^wZQHi(w6WdTwr%Yzz3=DU``OK%qiI8uDqE! zl)mlsbkEKMWB)Un0TXK~i7?rf6bSqBSx?{PR|n*>AtfKz64Cq!T>`!ScHs-no5p;K z#Vlme5?99iL!OM4$f*(wlBO9;Lr_=OCwbra;6rnYwakt-TY`^AkH#xmUM-gdj;N+a z=HI;x=jJCOtIStjmKDq$;27s7t>ku6jMLI4aJZk|{GzuC^o}%MtDAm8drO`3HGP(p z&H8-YD@37LR&@v?M6pV=?h(|Y2Dbyb>`7rqNM!G?HW*eB_Zz6T`o8$v+yP@9q309U zcq|Bt_$1UnNwfgMPwJ4K$Wcki%S>OK;C)cQDkoARh~Cuj`gP%=Q3oO@{as^mZ^X40Z+-%GIF#heKVDVuwCjD z^ea^?1OFL0@Am?UxT#&EL*VwNq{!V$jk|Y;Cmc12a??)W_gGT+^aa^QhxXC&AaFu% z&+6(42g2@&U^fj>ArLcma(}k+(`9KwJ$uQV!W}4LFYIv=7s4BEb5N-8+-BqtHNOgc zYUySfjrov#t8zJ1+7e#e&?B5(ovi~Zw)#^#GqlJ4sDz^MmQ1Q65@3M--hLo~^jq=) zrBIPwTtr}RR263VIi zMhT8n9(T(fGB-wuc%{w#sYtsvv3~prM;qj z*@#l@SQL*4lBzx|jTjlySzl}0*III>peQwIw* zoU%S2H>3}3598&0_QN}ik7~N^*hz0cZ;$J{&L96D+*9Bki%nsGW_{z^^G@xcTfDZu zk{yGDO@#M@R8rV}%H!dkL2W-q2#{4p@MV4TeQO4glKZSBU0wxD*eI9vLUXD=g;he$ z0|*&cx7uzRw9LI)-PD!e=O4*lu9D^_LEVi;dpk;0&Z9IVa&w8(($dbKA8g(3&%aa5 zq;KxHJpZw8E3veRwzm~uW5*kx(8Y}6G=RB7sRjMtX`$ZLKrNT39rb86n#GXZOL zXpX%npodw9#e|8v)I_#2h_V-n&I{*LsTG%CMdPC|lUZ%1Bh_><<3L-6hra}i8sRPt zNhN{eT9NMJ5gp&vVoBh=YDV9x969s(2^qWk{x}SHV=vfBJ4?a^e zdNZ`s^!NJo_7iCm?rM_bd?Y(WMoQHkZS{P^_weu-guvJO^nwklrLqNSezsFbSdCJ4 z(wfG$-C(klSlMuAv-oYP?A5n=1SLTTpPtob;?ZOCGfHq>g3(-5({Cuk09_yK^xx7f znJ!wf!or^!pFw%f;}un8>{6>gv^UU#o4y_rJCk%Nd>4VUO?0{Um^FKjgyrKJ7UI=Y zkF+_wXgc&9DU_0)R}?(s#nk!6{+iZ>d%*d<1he6lJ#3g8TR z)H^(^Pb&N5=hSDg!DPhZQKW@sn9`~)LbEYz1GYPUtq4h&(eyzzEHhL~4K2{Wj}KK1 zP4EiYmYxjtJH;7rg}0aJhHExgMZJn{w$@S5SnL`2GULRqlVv_@1*o6-+U(;Z+r+`D z1z?J+DXEWPa>ZXPuzopxY?ERI4(>^T2N72G{jnSpQ5vN&L4wQ>O))GFbzXc4RDz6r zr_gjgphEGM@$;2CiQ$bZ$nBO(m=yL$OUH=bb&UwDmvQ=O5%nKFaZ1mA0Rb=oRl&r> zG;L6fJip;-e#kUrk&jw z@9=JeIg97(GZZv5vZg!Uvj@M3X4X`^Ed&vwX9%Yw$c2nPcz=w+`mT0DSqv7zC6>pX z77?{33{_za#n$eJTKRer(j3jFt=n$xfve`MFk$HV{Gv1cdg@jiTEwB_cw4PRkm$;@ z?lT!A-8@AK`4U`FGM=ih=oU+Ewup}S5QJm%_@vxJ9SdAn3>21t+SBh+W=sgM$^FAO zyvXnnIfL&I1K)>mfh+$N{F+J}PjWo^B_RrOCbLDioJUt7)MtXb3=u={QnzpVJ>(W& zNo6-%a*! zuy)6GWPZu$O;`TB|15CH0ZpAYoNd_MXDr_+%JDs@-#k@vM>-UzQK#HS1;tOq=AXmn zk_MOwHkp=m1Uo5UpD9&w{Yfh?Na!UgHfsN%fE8DU?v9&{{=*;v8+FS9qjWfx@6@7sORva zvHFY;!N;%D#M&?M+9aRxD!#9npJv-MBQQfbw`nJJTE8kpB&3CU?VKEFgYv%jHf0Yg@QU5#!>=>^>T3 zJOQc>ABeyH6YKheQg=3F6H1JG+b*cOEtQLx>F)L^WRr)x%FBm2OOT!1%81KoopVrh+hlQ4#e^jstsXuF8_h!>)!wmx-?h5>&k74jd%F(g&X^qoV2q4jaN>n zX&B4Z)m2$V1^T}T63u=Z0jn;> zIA#q5+aK&YWof>b(Hqh{L?lnrcnbd~r`JaWj}~CZuQNbjR6Ss2GsGhH56?Cz0Z@bi z?=jN@{!lOa_3sc3!WLDFfcg`zNMkX={iJ5Z1&DD1f5MnV5`ebkMb;S5XPjwwYZas| z+!NZTvVOQQUYg3>y(A702DT#L4(E#<3KxhS`d&O@n^azS25~2M1dxEStE5N%zu#Et zyk8w)HT&o1v4n(#N;qKs312RTBeVkQP7L4(0`6@&2Jzz}?f8M^{QmsFn*jfuh~{^D z`Twlv*qH|r>gRv-s{bwpU{o$Y|D#I(-@kzx?EZ_E)&w`_!F@@}^r@W~=lfUfDS#;{ z#4m4ukTwsF_deJIjb87%e-fNv0a=SIe!9OCfbens=#QI5%KKvT!-83Vs9nnkYOL6W{(BUYe@1L6!u8$&o≺&j2Iq6 z9*oK2HC>n0U*d_#$jFq`)AbAuZx!asD+Gv;#U&&ZmcF^U{gzI#CAFx9 zhK4Tjw5?fg8oiu){CY9SUz&2hq|NM*I=IUxsFmb>2#x1H}(DAyNB|`9dM#bjp zT4!=Dxz(-eht)o{u89R0p)OaG(B5uhoa()wXt+aYLOjvZWt6Afr)lgVs7959>*ie4 zc=z(hfG?~U6s$)NG>#Iud>`&d8eUQ! zo>m_@a>=c(8&{_b84$HV5c;`EoLC|bTpfaX2~#*-G?b(ZraVyh22=j`%=Be#0&vR`(+Kt@r6MEiq*%S_pAWqXF99!v?sDlBKLr55dE zeFGMe@!JaragAuK>*H85d}3M{&_Y9o=y+GttQp0Z$Rgs8>6KXCFk`T5XexQc`n~^> z6AF<}dM)>)rbe<><08PZqgbPZwqPoqZ*)U$6dw00aosCi)VF`0_5bI@MZ(5T@#n1G zm|s|MpRq5cs#bmy=hd}pgssD_&fjsG79E->&+&-n;S&cEx{U9U4=2{e14 z4d?|Y6x+KUAEc+NFhVACoxDL~A$0F2ZJnN+8TGA-u23;5GrV>YOxD2golQ_w>r!EP zpI+x}-D$D0U@eO%&Nn+q;Bec}_F{Oj7y~)(O)h?l8=ppPEDeW;hbw3?Uf5%_w)ZG_ zbZls)bh~QsJUeWF3B`-5u#Y|4QFYVmbl$x%ytHGg+pBAP}Sb)`HOxedgsZM6i#?b?s{^ma1n>#JORMs&St`U7Yr}1bu7l6%*_ncV$ z%$}}~I3(PX?WT|Q4lz~klY*C!F>fEZJi@rv&6L0l`ocuHx9vs zq+d0nNYFy)+hdQz_!j>0s>(){6KzmH&42Yl1ab&5@IuVivTXPchc*oh9FLV3UQ3ls z)K5dz>+DIY-}46!T4RgqhU3}}R*J6g&~uA~n&Mt=n1|FqiANyih2hiq{!2fy8}*T| zzw7wM<-tkPOfD7=Zi?3`u_NJr=vu2=Px6JvdAolip$R=o8|2u=bG1a$=}ABl>=nKC zIX2f+(H8mD1$DvOZ!AY$|2axGE+%}9*G8m7Qh55wyANaOya5tZts5BjAFm+b`cjyA z=e^Ek+UhFr6+j>t-MrHMZ-&bN|gmLSDIm=g*%!Jk2VI;lmo1xrj$!tujH2w!ju z#~sXz-kmH_Wd?fY3B>_Kd_fs@MR%t8N*b>?rJ;w(da`nxC$pIodLxotjh4O_rf=Q7 zrHR&NQ+7_6i2WBTtsAu@--aKhiMF5Nu5p_nBBxYUE?t%PnLdP84#;G$shjayHIS zy7^X(7)YOeCvrTwoWpN!!>46eU6zSW#0m1gEdap|XNv;++ZXr-}pC~hQ@|C#5*yO-+B{RCt@J&1!vYqG= zX$~cPJbQ!LYAo4?NLN4QIe9g&&2;AB?9jhTKNfn>kj5R66Dy5T`p|VcUL%RGA_uVr z`@mA7Gtlm!2dL1mT+ET>SX@0gEm;9=r?0+G{si(87hfph6aL-&pTL1e3b%mZ0|(gq zqZtWWL$!SW_<>q|O@?3!PNi2I`~EOs1tc^v?u@REfs!|`%=-$7Z=&`x<~5sRMDDiY zUqU{NSjghYohoz^7$IyV=B~7wx8Z8Vu&j1-$bje-~VxnL?B$0eM z&2EvVn>xCMeV-9fgZXjG(4-ly{%P)i8L{~1S3+EO>OesaIy;fFlM9lH^TX8-3D9>| zPM%)UMd7%J4kukVPLOu@J5PB5L>YM`F0ainR7x)q2@aI5LW-N+oflZukK82@X+a3! zvPwJKhz>e)H%@GJ_uy;fZ`yIk59EsF>i%nLhHIGkA;MG><%U#Yt2q9L#IxEquqWwR z1|BUtO`iJ{_`@{PbEVyTqHI!|hyJJV)X`RF^tYaEsKOEbj-W`CHhd2-5rZJnlA9HJ zV_64mI4UTh7~*rq*&UA|aj_NKXc0>P}_QhtmU5%_C@-}0a& zcc?mK&OU8=XhohZN&~JE5mmI~*b>@No9UZj67t7;N(?&9K&hj4)nOkuArW>^xt#`<^ zLzY5JU#5*KMD!sb=oeow3xV~?Bj|txRjvgM?B_?)3jD=@o1?~!^BdNxqFDruMOJ?H zU)u^_cb;0YIBkgeOvC%0zgtN2igGqb&Q)xAFQdgD&H8}nTwER!nyIzpFCl34i63qQyxEwLsgK>&kJp07DSyz^GyZ(Jn!@w`lG?4HA@`a(eEj<)7$*0TIUIQ`Ti2Fc)wNy z=jXfej)W;9(>aJh*rIm;+STgnlqx$8DF)B3{LZvcOXGE^B=j&VHeV!cKH>6-&kJ%u}>CQ_FqF~&+8o`zB&97c`2A* z5_~$n=?n3YC6+5%v}g@623EL_A@l&VBplw?P~>v&z8XnUUY-wS!{zyi0=)@h z)xi*Ep@@&3V&^}e_5J){5-PsLp(l)~b77IZrfymLz5+i`(x7~**vYWdj>_kpg~GdZ zWwCpZaz@qLm;dAGS^vgM>fK?^{nI(@Isu&vq%BUIa5>9LbNe0fqw`lk;r!Vot8-FT zg+vyN%!J>=x}uYIqpa4dYz4Z&BwXV2VDkivDBXf0X%T&GXqMfgcBMi!uPl`{}4 z?hqUO9-7AcGSKDZxIM#mbjnjkzgVWoFT6y7J zfE8H%cLmZ}pI@a%a-V(ZSIj6%bt(<3!-aUN=xdTR(0TEXC#9W)l_Rh7+qy#EUns*7 z5>NIv$#vb}tZY87HSuDYg6PoLib$^H53%ueuXa%15xC${r8Yd zp7xwveio%d^vWtreXWt-xT6wxB+s*5q8b%&-kEPy7C-v<59Sf38gcvcOEImCXU>e3 zwu#5a&LGbY5~FSvi~lDj8abFQ08tz{3TQ8=+dBkRtt=x1_|<<0Cxczc5$5+ID~h|3 zrVw)?BH7C<2%pWL*iWL&C*HL6utbNQ-^-G?@t6`%I@2RridK6e&4)e}B>Ja?2nv=m z#`nyl6)Pn&h)?67<>)1SoGS;QgTKsH5FveqO;Q2a0QxdT^hVXWYRHK#WR~-eEQLnv zSC88jpC9m7fV+o}nzw(Ayi4IKv#js@BCxY9HLU#+LrH;RDkkey+fU6&=is&(>(6gS z(fEppS>7kz;kkMmQQl5Y{8@0y4!1^)mAT>$0;iWG^O$0uFV|h z*sU0x1+2ajBj)#GOBL9x$wjfs&7B0$is20Fo;%T-0 zzB~D15MZw=R|!xEd%mF@U2;719p<=V)swZ`VaT^uW{?LLb~i*Izezj92ZEpQo$i-TJcD3QERXzEb}STug*QVPNbo zx5M=G_LYP(_x62Gs60x(+RFQ`55a_rtb}U&efU%&mYV`CMt6U@m@F*b(&|R`^Jm14 z%S`euzcSK-k;9L3*Qy~+CIGOz@k$pUHhgNF^6V>9CPzNathhNkBgUs984W%~Q{&}Q z-}C+HXYkG}R=XYR@J?qZ)eRS(-St#xq_+6)KQMsQBj zYAU~!KU;mYZE5K2fcLKYc?sEIj^~>)+m-r7(aQ7>bn8?6P-AT?P^`xZVUcr(hNmGkTcYul1D+5rz$_tS^B!MrzVyYo9DG8>mAf@I)g z)=e0VGBZHwvM+QO%ky79nc`sB+X~z-uqRb>3Shl0k=Imtx!Cs--5iDphPn9qG=nGJ z)w--0g1(0{%1oEYK@fUMkmB@2l zTqH{W#=4fVzlXbXmXKz``tpZB(@obUXextv`+8K`GlRtnJS0=G_pEtZ%pP+!UP`0s z0BLSyllx7E^!-V!)l!Iyee3tbnHvmCVEw1Th}Jl)7^40YUn1n>PCi-azD>UO4{Kz+ zqlk==Wd}I}8U#rv>`$Hif{GK9srelU#J2|=eQ1%t%qch!QI)f!#I?bS{5B0E(+4c zOEzEy8H8N!_%QiB$h7`bF01h#OZ9-F!7r)~D>Plf-XwURO7lg+Chf%4aw}3LkilTg z6Uy!OJB0)a27b8nu++xj)btrLpACxp;pLjDhJ3rTRO~Y}i`!YS_YncHR`>0|(CwbB4Qb4>7U>pl85DZwde9Z6hL<5a?oW zFwrt9^sh%IhrHMomYIrFuqPRQ{#jrv)%k(nOxY7Vy2i$MqECZjx)19sms(a71)8v% z(pH9HFXt`GtXW%#6EPyQ$tE0N61;c6;V4r})K&h9F?!sKv}YM4^H$cKVxn21#agiu zjNvZ;#l0CiGsuh8IA_*3<3#MlY(f;bgPWXbLAk8P%ui_oHfA;-wq0rfI-42cSEdeI zXT66b)>Gv;7#Jy)u|6LF-xOaa<|U%8(uTdK*ZgO`q+Gh7z|9qpHIwQyjRxKfjXxiM zNSn{6Hym$`O0z%5<16!AHHw$CuwR2tG@{P7P`TI}KH|iTBN0_n_a9zWs~em6H=s{? z48`#LGbBiS*U@Wza4fTi#tV7OA`9E&)Z@ZhtyzljHb+UmSoasO=@on}n=W+Cx z!$cF~mM2#A5xQB*OYlmnaE_vC=XZk1%_5EP;k@d^YWu71ZAU}OHSM)oIjBJRlIbs0 zXuBU}9qWu0VJ3r^=Bplp`}_lKxR$H%3yBRV=5pYHM3QRO{5D2>6N-1wc>-_`OD#x| z#TLKD56i8_BwS(r2jhjH#^m}iHZpQtTA`*9EI^c$l2X#(eScq=%|m?V0MXa_AhamCR$WHN7!<{5m%;A zbj&P;s}FUMX|vwqa{Kwt5$Wg{_(>r~=q?OoE8DTd2)c~)K5L%Rqw)}=_ln`FRU^;E z#s7H;JX=puZfCan{wWoZJK3TIB53mG`J;#NaCb}?5Hr|K7zm&rcsF0UX6vUAr188u zeTf!fY&u4taevH;NEh;&ux+WQk+c5psLZ<@aT562eE~@{zYv1t=FUX+ z%mpg!i?{JI$9GL*fbfc%=P%lIJcfYF<%sg80q0+x&#>uhq4)M%i(dBuo}>xBBZkyn zdYRdTy;n;m^g!*bt8O9^Yo!28>1K|g{rKMCerKn!qgKI}-fBgUL>a>;G)WEPmxGQ{ zh|U`*tkW#j*f>(7*{ODar!CvVnxG%HS{EA+RO8)vHyv@pmXHq)1ht9}k3~Vr!(7Aj z^?0ntBRB&hgnN_lf{9)Lds2d$d_|>-!nNJupJXcWahaEo*hm)tKSf| z9?6N51~-v!L&KLzmK{`OL7y-?=J&ft*J_d0zLK?Jn;wi}vULs|qp?uVZjb_)$2 zOk#mv8@XA(zT#V~Mex7j^@B#^nF)3_wK;=$WLTqhMy%cgUhX&)7K+wcbBKQ+Y~M63 zrU5bn9=Fz|n1>L^_AhO>m_033RaIWW!O(pC{IwS3ET1_!e^s_v*pp&}>X@2_0;Vzn zAt9K2b|qZ{c2=;_<%ZGS@k|0jLan8BUUMzG8w z-o+aVk>%6J^ks`KTyQiY^rGyVB8`Iy0YBKjdH#bL{uOH9i|eQF!Ld5qUWeRdIv3)W zag4}Ab;0dkYbA|+HVdw22>1Nd+7lj@wveowuuUw^{E zDQ(l=JfeQ|48{pJ=ML@O%fji?VDpyAmvvCeda^5Q7ALOQI?II69Xf>+QKhlir#~Q| z#+Lp#h>wTuf!CHBp!<0H3rZplJ(^M-`z0tDwlCX0dOQB~+>F}q{%kxXxpFVdoTxYaAQcg-SKThfvw^xqU+DWk~OPIfcD`e6z`b2mvwol zTgEPPVkZ7l{YIYz&YJ&rknwFp2;|mR$j5gORa3$5{cc*Xb6ox?pKt) zS+n5YaZ$bLVkWG9n&0O)E9*S_pC`+|4j$^vuDE0E$F*3KxTr~?-LXS8TED~ElzHMN z$c}HlN!hX02QElFmUyyiaYt-0SBCHc@JnzFXx4V)!Y)Cp0U5pSR)5TK0bJW(KQ%L9 zr*ITAaqy=7Vyc63{$(9?x>PL8%>s}9AX5-4%Eoun^w+GE;vO-;D}K`vVMPmo^X-b- zkjDDUGAii{`pZ9DP*!MM^e^PP!QLQ>K2G*pZMoG0Rf_);HLh5$O}ws%(QW0fq7o*>nPGzk*`$bN?$fevIm%02!a1^5VnV44wMpT!Ufl=)bRprKK!H} z()^bKeW$oA#)PwVCgvON$VAa-yvS}=GUD{>5G~ZcmpJ40i?u!Y&qcc>0jk@}%>`y`T56A*k zXR!Yiz41fR=%E0Ww>M#j#S|6MoUXP9moHbw(hL0RUtBCsF=H_kAa?IKjNa2f75@rg z1wpj`#e;4;#dE>vj8qv?s4Qzz{8-A?yQ|)dBGCMefC{Mnfg>6J-@6a+Gw>K|ag3+n zI_3r?E^Ys)C;utN_LqMJaEJ&rsvgq@0VE6-oVsQbnOARVOXh~dqdwZb)8XpS>2bOoDW*ADUUW5nEmL!`{!~vt!zwqS~<_VE6Rcb z?h}MRVK=a;y~tn@IRideIwV|N>fb~yRt^pUzP_L!prFVY7-VrM8tfb#U4w(rd|utgNk(HIeyq{{iyf*H_z(+x616yAv8#Sl8HW5^s5~bPAy102u%OwkjL_ z9~SYb%F~xXsI*^b6u*a(cEgu9l>eZVrzRr*ol`lm|23zyW(tFp;c#kEuM#r5%-`nt zieItkY`Zs;HH~Mp;-ue4A4%iC+{q6mn(gp`%G7*=x(-FsvnmwtOF_f|_>cd-`29;1 zZkT7Aw6t{8`QeiM;^@b#LdTwKYxBRB0zZ9nQTh8o!w>-?K*||2s9)lVih?5l zwyWRQ*B2$4Ujpg48!+0xyo@U&Bhyuy7P@wOADA<=W77i+S3Wx?AnX*A4j?2s1sloh z)uAk%QdeZxo^}WgCrRA{x*Dp>CTJ<0f`@U2(DoFPP8i>wl~_WIHTFt^KZGF@&yCJn|I~Odk^{l(R%>& z1-zTVwJ8F-4z}GV6cblEas)u?=DfI?OSr{PWPWC_hg9h1TNpisjN&M8^c2i5nWXqP zq~`X1$GA3KfK-oU@>Ww4*Ji2i@;;M)Gos{h(t1d#xbI0ZFp*9x$7HIY$$BfGiUeqH zjGqOxqiC`}N|;@nU|DXx!$vha?T^P9m#;*<;Png%>#m;q=yZPXUbFTCmySoX;wPBI zgQkE!wFBS-mfOQGaET-^q~i#=S*kF0m$Hqbic=l_3YpPhW8Uqh#j;*W+F#d}nCuN~ zAcOC`47^tDO-#FNfEGFf0|VcWF#{c)k3e038T0f1F_qg04%hvUr(8kFde;tcls}~? zIURf{G^>>fadkqw;y%_-mmavs%x12Cez+ngArWx8u|I!;Cv^U(!CuJQVnb`YKh!*u z4YYN{+#y~8)Ju%E;R<{9Ky9`0PSCMM;h?j0!Q zqeC5=B~T5*SFCEL4wBONgihdFL7d6XKbrED!RcHZjYd`e<~2D~N_t=dCLw_gi}mEg zA~Rhm%UXV`r2VL{REB#;(GSdxgzLpND~{oVKZ%(6eCyV1XESpwM(6jEVW9};1$AnQADCON8A>-x`HoZJfyQYlqH zRZibSWVi9Nte;;z@%@OYIYl^6pHrBTj*AJdhVxH1zy3+FIhcnsvsYk7u_=+t@hS4u ztTR>VV+m(Ai^XzK06fm-SUTtOGewot&L<1DP|~+FK`Rlo(`8rUXTx2z0m}&08Fd9v zLXygCw>)6W&7u2u9~rcdgW_p~s5Kht2ur@IV*N%Ncl7-N?Tsec|I@P3$R#%++O9=N z;hWANwMFts68IWw<=<0<#PN$vj^DZ5Ps+?}xoJ{f0Kn<)T2`j`p{q|K=z(Lq5wCLr z&*%B}(s-yM7km#v_e$HT(;e`A5bN=-#NUBtI9u)rhC;Om!`%N@$o(&9BU-MAZt_$9 zY2${&*~3k*B{ z6>2O9dwwIfY54S4K!Fycw7qJ9vF&ucgvsp=`WbVFKlD=|L;a6Ky1+?v&rhBX_t2cH zRD{+C-ouh9*f?0qR{Ft&*ACq@@T7r>_w^mBiR=F|Cz3EhXDxl z?Vh|4a9B}g8~)_cq6`m_yyq`>Yp|q?7f;gq%4j?g!k>wlWp8ZPuaE||;;NXw^4$ko z_4M`-6Kamd48j`ly?6S2VK9ZN)fKtYjCQ?saEX68bG3y9B$#!WL{w=@9P^9RAV zwjMmK+Pq`*JiT+;AtsW4`{`nA5#e-NJ8W}C%41$65TCQpQ_*@Z`j6=BUGwjd3&`1~ z;s46Spa@m}afshrU^M7juTAn%zGpF<^(Iq7Gs+|=!JlIXKgWx9@PFlLNG~>R3;-us5 zOu0y{cJ0)`z2x@RGaXx>E`V*ip#`}^*H!0mf}KNH=?f=zv_5L$wa9D=46GLAVq)-L zn?kzJboFxGBk;i26zJJPWpy9t&q2b+u1G1U<7&FxzB=P}zt&X1xOvSzv|q3P7Q|1C zbU}@Uc=}tu74wY;w^8cB^A*pd$@2jkO_w2#5P5J2HPATdb7V-jdw9*B$Kg0J;3)FD zM4tF>d4o~(UwMP#14!i-Mu(^>rb7(^pUF?4^BduUa3j@T+`UyFCM-g`7vHAOS%8Dz zgQw?K=1bxQ30f76434HRM6Mn?Wd^Q#@J^~^*O@tU7~W7;_8k(OnF7cmv0)At7jGk~ zngc<9eV`>0Ho1R&EN98rqcF|%pIwwY;8r1sP0i+{iYM(s!e_e8<22zenlBUAFK}?` z*(XEnq+Ks}I-@DvY5n-|wVU_L&=RyQfF{8PmQ$&+e`ENg6FRm( zST%InacGv=O2q!sFLqHVCQ{GeIJR@@8@noDAofpNiEp)znCB8C?pXbv5*kqr%GL;u zY|AT%j@$^1-7i)MjtGI>?8_&;8lk^_$%(?=kR7B-fXZiQBfOot+nAFrRV|3KTpf>$ zDI(g8g0w58tu%$zyQVeYbir%I;|+QYim9wPn8*aD;mt4>|Dl%8d1H1*|F(vg23JeD!4ord zw|w_ceWH^}!DrzGL%SpSbn#9WS+FA&v{l8sw#E#8R4m^spZ4iOVmvk_XrJ*x;$4^YJ8jiXZcDjwCp+KZ;>f z;X@&n5CIY9JVsfvS<;wGsA|Yj4K6bVd1h#2>>infvxT+AFmC~1sLF!}VQU*B+b#hE zpCS4Dw`PwgbcBrGm8PZ7q6fO4Zt#>d)ter}hUc{QhdeuPM)?m}OE7nh2sK*Z#8YZ~ zHvJj*&)VJhvY(dr^v9z7v?kdPhj||MH--moBSm5vkx4^$wD&Tuo@>u3;D7Gq8t$m$ za#=@`AT*#2#4es=YT>eZV4AL&K3<0F(qshU(`mqkvxc8 zPK>8V=G9U_LGvRM>rl9e7|C1*TiPpfg!%=sBg67zXV97pcdIDLq!whaSE|yo^OEoT z(UU>L$~OK+bZyk^CN>@(VrKu^SFZ2m{M0ekTyM$F*bLb{yVl7h4=XOX>1K|_+YAbh ziX-_t+qN}u9|5;|4Yk%0^Noy!M9N|;Rp}HA43@uT-NA`SBfxCkTWUQgGkHGx>TYo4 zST;&vXsSPv{(2($;Ka51QgZ+^kDkzau#-AfHc`G{NDRg(1w2#jd9D(ZNvak8w(TI9 zWP7gSjlR}ivJ6geg3<+0YByXLjjWMB%dqc$4!psu;D&YUHFR#dSfj^U(Z^7lDafO| zr&<&n<3iMorc`d^;&E-Xp>YxIlKTaKY#WLS*=ZCj@Iycw)rp|bE{(?6^rPBgnIwr= zCRi%iY=9B0#ZBLp*`l*Qd#qX%SFk}9hwIP-A!OuAzQ^cq{o%A_>7T!W^SjpmXm(t# zAE;GyxHiruxTKd#k2eMQJQk-rE1R#sW?oKQC7#YNDo3%&oX_1}Ke!4>tor&lQxZce z5(o3IGdm6e#q0Eh-Gx*0^GUJ81HhnBstiZ5FZaePwa9Wv2!b>Hw}}UZVJ3w3Ocqmt2L2*=>!JX$zZNGlS$; zHYHcxE!`K6BTz~N?NkUx_#&%iyn?{s{#?)jQDT5S)POUzM%*I99ZN&@5no;Fg7s>= z{{^&C%h>6+0nbtVXMJ6<*%a;v*Gn`qICJ4aG{csDP%F;XKt0QL2P?(V@*PhmF#0uyJ|DNp=?z_^#hb0fkm!T<5P&gS2q(U;ain@K#sN%faU6dl^g`;(Ej~Bx5I1|hkY7P)} z6^dp31w-f7qezGkCg*WxWYFZl6bfW>grGe|EO*|tVpguY^(-G>CE@|4p^U~exE~{o z@~31DxMVqinN%K{x-?ffjLIhvwVjJa_OS2zKAjJ!|KcV=^yojn+!@J^2gsL5r_#13 z_I1+3h7J{D`1acuNcIjfpG*WjV|eehS!!KKni!Q@R-24cF2{lCMf)0l}X7O>YKA?Sf~G#yJ?(-%Uq5I5zSS+N^4b<+AP-M;h`tgsdfm%W{Aq*4q$Sz zf-Om);rCxGH9)wHXZdQ>b-)MKSUPZ+RKaW%AyO8Xkq$i6P?Uom>0r zg+%eGw^~{W*lyJ%` z;a^UM4#!Dk$L66AW>@Bp+3m#MnDRmlY8Xv*Q7?Bz^(cZ}hB)diR#No(BdoXj;1g)n zglmK(l2-UPVv z1q}e_SuF{HJMW+{GGY2Vu;qt@TtK9k@jG)5N0C%i0EFLkh{#ma#vS|k=ayG%eYW+% zUSK8d2NO*W+t=ugxI1-);^c)t1MlwYN{5v1rBo&KVrnI_|-01<8`oXBVG-9cF1p7Ky zRe3q&q4zvQ1z!pO4o(JuhcQ|_@^EpxJ6oTjPc2ewOE*_@ak?kwwVXArJt-Qk)nji`ExMkU@SR9m>EpR=ndYYSEQ30 zwu^ppRFA{=w{Oi6{F_Md?C=&A1fXy1Ct@r&B?8He1|XK`i&fW}+PZ(5fT~PN5GlQ1 zRU2Wc4_3UeZ#Wp8CP8M8ImYUZ@W1cQD$@QozyAvN@$}S<`MIK|J~Y8OXNzP?KTrH6 zUnoGoUs{V8W1=D{DBVx!O>Aj^&TppbF6TAz~|ufg_cxefT<>aVH3rqpuM z#?UJLbfNy)A6A=Nyjl(7aGOmRda`pe-dj4}ge+tvQ$ymgJ+kX3$ZR))wKbE97_g?B zVFMp6H5UytI5H9@p3L~^6q=Ao_)mG2D!F_!gcvt>g)JmR$!DgxX5q|DbZwzcYJ;M=3RdDmIzzth zx`1t-BfjWI04#z>w&gY=MLuk$bxH?^_wI)sE7lb<~%pi6-aTn``hCHc4 z;)lc_fU_Rjxcl*S(J=rJO7w&dT@bRdY2o*S_c3;ZyQX6-W#NiBfg#Q)ht^3K4#c+ch3AsenZp z6g5T!oX&)+i%-k97QLo#JMYnx>MekZ7X#O{lYeqRWFoWJYb&fsuDn?v+r1d!*)FhL zPJNM0R|StFv{gi-kU`?i$E$Q7tnl2mxeRYVy+c&j;>^g$bhASQGZ0Fc?EO(*Ckv|1 zR%L||m_hk*DAX0FfZpcVINrELZyTOgwAu0Gke(C;HS)rGB%PoK)5 zGhMB(37E((OqF?jO!-QoO%Y5W{{^+Bkxrs@?NYW(8iL>C8jH<^bCiR2Z@<_zAcihZ zvJo1U%xY%{9XOi$-d^u`)6&xi)7Wcupa})a{*7?RcCKa2dxQZR1S{H0Hr+**G=4JV zdT+2Inz>vyS`@wHkM0Oh#u4^DnM1QN_c@}?QK6FbhIBE_s4eBy3FNx79_fmyLJr@< z&@;~tiATf_duvLzEA`QRX@=%DnKO4&yqClHLNn);D=GH;OvGgpYvjdO&CM%t<1MaG zTr|q{EJVhS_+ul+D*l%{RMLe{x)qPgU=gd6Etj_^b15sqlyliM{-_5Tq#eGcVw_iM zy&-Xx(@E`!Z4;1RQqv?JTHQ7~dV5)4tZu}i2z9+YhMEg2MsQoAlkr{!PYQP`R6!nFU%ZT&@9OT%{= zE->xuC;B4-j&0aUzq*kz0@VJA0_~cP(C!j$tGhZ9_uf_UQ%$h$T@(#6WCO7B7kI0I|k1 z4~fXd+4-s3^@)_af@}M=fGKY*A%?*fQnp#*)5{i4gNET;8_weqYOfNu#JbaM5{r=y z|KaR_L~%|#mZ%@nMesJU9&kLydStm6qGX8^QC$ONT;bY#xo~iBUfkMNS62gKn#7Wq z=7xq~l$4a}7UxZnu!(=f{4d7dGAgdE+ZNqX5;VBGySpX06EwINF2Nl_a1XA97w%R# z!QI{6-5uUa_IJ)Z_uY3}yMOpmja94WT4Rhkr1w6_D(;uXVp+T^fkBIafPjn3+mw8E zImP|r_JIQnT|rx6t%9nwWZcE8n?EA6 z0?{gLGkX`Ag^>RS+^6~CXjGdPSYpP|p=jGPb3Rrwaf7wu!O=qKNu^Wv2|usqcl-SS z=iI;yq08y4KhPrZXwgw{2-)X(SRM)`Hgp~@v?UHfldz!*=ZTI43V6Tk z?~v{Rx&ZB8J0-9}2*%aXJaejgT~Go#M@Tq2zIve3>hHpwXZvR+Qh-JE^QxNv`RCfm@iV{55&bTIctTRJkT(?P;r)aGznw8+O|Q>~kC!ohzE)pcM&C_wx% z$XeJcET4Xg4c7fD&*R4wFdm>fKW_WP6i{DJ&B1|@==xA;Jt=01y1-_cs zC-&ICIo=0i5)ufA(o=JOnk_Js%(?-{B)`q1cY`{p@xX`J71@kQUIGdLulz2eS@3;W70pNm zEO|_PuXA(HUOt71WrOY?JGAPb+rOglE;k`G4Fh62s`u%Ct_|Y*Pc`@Vn{E+by?O<- zWcIvu1uXFwjE~!@MVy+vhWrY^ELO{rU3crK5n#99=QS1XVk7N)vRK?1I8(ISY=75B zQkhdF@t=kIeOl)&*7A<<$*!$(xuoEbTap~Fj+nGmWD_e}L5%^n6B(J+nIFT%~A#UQIwyy|Dd%G_CBH@KzWo|~QB6(@6bcgK}lXW-@KEiNwp?&v65G=(Fz zQA#Em-MR0Mt3VS63kU*xczB$ie&B-$Fev@;_5q-TVhFWyoE{sCaz0tcKJG%?vL^-X zR^ZTn0|k_RA8g6H(RUr1nz0}+@~0jmy`ysL4D`sE9Aj3xvAY?j^>9w>7;B4ITX^_I zr;YODU}ft#U*9`DM>(<*!=W^4pfN{BW{G?BiX#!!GnH>BDt{x4BJx4sxQ3^Ybc5;0woTY1 z-2lE+=))Q7ui-2rGI-H2zsy~rP#Y6(|8+(N5A)4#nXz&eos2zlaAj#dfw-Ox%oR&S-4Y2^a(4EJALU?X@CXyL7Vxxc@Q6-zWRW zr`~3aJ?;2l=>F>hz$YZH9jr_t^d;2=h7;3E-(2r|{m*1g)?QZG-KPB~FpIrHV zH*Zg;Ex2mGj`6N=JM%8cEkN8$%hf)&eUQ!?pQp0&o|$*&&vmmv@cb_~_WPuJ1~la& z@S1|J`$-ic6?qG(f?o@~QiW++yv%cl_y@D|N`b5txbD&Ne{nZjC!59~B#K0cq|{5C zc6ntL3*WgRm;Etv&j_F17LUolPt1$sZ-MZi+aV*)Bv_}W)Z<<#abll3^GD~&o4aiG z=x4Evy*N}ur(VJ=t_kZqp0lB2rq%!6RfK&4nI~Yy+f7GD=TD_pUtj;6r%^Kf5;g!J zL6}%sI~EpFe*E}H*lZDGXoy;LVkMH4n5buERZ{i_(9H=LuRBlzU)|iy02i!Ff!SFl zB@C+0$=K+B76gZ9vavyiX%28wVjVxNn`9i?*UZ;BjkW>WYO0l2w-%Q6MkJDCd0R6r zt-ZB1CTDU9?~BF-o0}jFx+0 z|Cg&mnJV;;ST5&8PgO}c1h-!C@$vV*GEynz1~9hld~@7C<(hZCKW-&hS*2yY^&Zw} zFYl*rN!>qo_3v6*V7A<#7x0+ZE<%Z}-~PNkcqoMYV3Uq^vdx!}rrlF{72kNQ``npa zjox@MlKLf98u^ktObz;pPcAaUyre)&dOD(HCr`0^{PZ^`)q>nyKvao)8fW}O>(eJy zZO4s?To(I5@s75M#LV9H z#L@x=T(PIWm0sD?f-BJs zbzW(8A^iEnHYvRg#uTypNr%VL(l>}z;6hD-k8_sZ5}HC>B%8bwOSP5rHrRDw$GMG; zT6A9Ca4bH(5U@nw(QIw8Lev4JI{|GTw^GGQav;9VrX)FGBOxF6mcsATm{8Kb<>IBM*1R)%l@g~U$V@8F z+l!MA=Vi(JHlD+qVQb66Sy*zB(_GJS`gwszl_vx!qQJa8-Pd}mmh8*IqkQ$K~YimW5UC9Ap&;BQD;V*skiE#eNpxb-;JZTkIXROcf0e$kxtpCc5!O%uuyP; zBgd^-OU$Xov_^VPn-})L2NSOd5TJRgnVms!n>cRK9Z!{+u55uCqVMf!?7b23u!NrF zL-%o>HwF@n4u=e6>dL{xX6?8KIcw87uxNyyzOP9mD;vMnGEUH#rkB_0e{{ny&+CW) zDDr0dlMU}~(w;nN#$6z^!Gl`1H8!{%CKv_vJh^xvN-feM!UHa@5){OAj=rAkOGeGW zcZ9eV{jLP;DA@hN<9r5kB_!~CaY@fGh)kOU-P_%_=dpP1F$Sm%<<0gu%H4EDj5kKo zDTj|O%80W`FZ7^@hurE z7dFc?YQmB^kKij!#?dByfRxm0NEO~lM)(oge%(kQB~>bQ@$VH-7$TsoK!!J5-Ung!t}~s zsq;WXT(Mxy|K^F67gKF;_hS5&G>Haw`Y1G?t4hMt>n%Br?3Vi69+!=&uvEvsscuPz z`kM8jEilw)-Jm8|9++G-Q1o99Yf<yyO1zuHBT98rj~^XbI4o1u}CJBj1v=? zMbzl&oBF4h3Dg9XE_Rk~F!R@1gXk;JR9#>u=IsQrSc!V9+M+pW$0OM6$~L4;VyULo z=5fsI(M45v+HE;bY7z4E-SS)*&pi-Kh26M~S;*{ju$+kM3tYUsVRyzH%Q1C)Z+VgP zJslEOcn`kt6n%AdG-N4oA|BGvyn9;DDyA>Bjj^HDWXkNV!iwkdvG+5?sbp`lp19tZ z!8|^|fqKZ1@eto;+3Sd?nDZvxlc>UzfJU_s?J=3FP&t+^4O{65j$jdKabB!s!9+vL z2>~(^J%e`0o7y00m`PpY**AvDdCEB;yMegX;)fvmbDgau27T(F*^>9U#y9SjQT}Aa zG?;gS>9(6fwjnn0;OAB&r;THos{UXl&%V1>^Olcf|Kg@&$b7_~rX@8w9E38dh_|o^ z$&59#kCQiKJ*6}F^}_p)M>!YTACQ|Lb-o%3R;zgj(EZp=L+$pB5#!QC-JyYLI(ZYrY{HsjOt;UQHS=TbX8%A* zDZ3p6c0I0hhSsT=U{}gCanU}zI~1QY*1rod7>bn(nPZlCLxLnT zLBryfY%23#nmM)d-b^&2AJm2Doeqvtr=%Udk&%UCvs}0wcow>ly*_{H3IGMKE zSZk%Y92aAyYDNOA{ZiyRDyd4%LD+_nzey}f`=hIi2P$r@wV`#&x$+)c5(1^1t=<*< zv$;yLP;2O>seFyr zhtjl0kc!W4thL&<@dV$CY{$)byzCw@P4-GM`Yp$9xH?ommiq1cn~7 zI$xK-m7cu$&Bu;C9_Rt4NsXp#Bl{h$Ig^gn->#SJW6s~hWG`c1`F>@#c=GQQ1Hs`7U7gS;6Tb@q|@u!(^+7&Ebb`0`N!DP7}nMb1?i}o&i zR||gx7e_Iay;KaIOYkWoICz%I+}g^0^~ilKc+EHTxxT&sN;hm!2NqOV-R5~WQiJs- z*O^$lm~C13zIW;X>8s`zk&P;6DdAGV08!Cw`ORy_pX~89b#*P2pA)zgO(Y1Lvc<)> zVpGW|Uezr%SW|rr1vU*fb|@x1Xc#0o&PmwuL(#{T^^akx8;uBaSkR9kovb>nVoC9j z&^B^Ee)R>_Hf_S6fM^cQnKs(r5S$Qx-j#Jsa385oB$N2*rGyQ{9FoQ^rvI94`~7f+ zQTOC|^TtVMZQ37hvB5i8l)h@!(SQUjMnH6G{?9QU-gJPECSgp@{mSD>Hz~nl{m6#q zL!ufbI-@gu?$mGXx`19zpF^sdUC!~uy4}~)UO%fn9q&viQzE^7H<$B z81e9#Uc;Rgi=#>xw`)p|Dw2{u3>nJ(vdggHW(yEFE8I9z?>4tEL7dI7*bKH2E;etr zH}f+Y-{+q3Mz^ykCW)16S^2EVRxIEWTdvT#RPvl8L2Osf#VOa=xc5kU%_h{($bh3BBAE>5Nb*)Y|4Vr!L`f*Itxc?Iwv z?G3%%)mu|$>b8m=w)&O(HyOHZWEaLE_P98)L&DEE9kW-L3rhAtA#GXja)piGP`2%z zG7__%U{npBojjFzgvjjNF4H?WdqxyfBeZr|d56!nmD_5bT_l_!5wD|OU3r_XZ0VL# zmJTN_%{W?}EG&9@M6!l1#0-IO-)OuH*>2Gx6zT4 zCj|F18L7&jzvuqQVlXG2xiuH?46k+~SQ~gm{{y;`DDCxbWP; z3@c-oYTJ*zD|^X4Hc)2oBhPBH6jm!Q=a9S)sdRI6>c~7pU|HU!N_mb!{iUj32)&#Pl522| z^+BD#fp~A_#6+v;nyvx2I~DmkL5<&<#eRlhBQua8EN4WB1g1%{T#<^w#JhBprE|Epk?A{^e1>Mh=6HXsMDX6YVRajSKXO8F1R0RAf`G2 zDwbW3Dzx~=z|NFArzST*EhZFnaysnY*g}7l?P*CB+@zEzr%+?A5=|~Gmds|hw|FM6 zwbE#4UYNC$b*v2l<BK(G2~h0Mb-&deL!0j?>Wf%!LiwgUAj zUEWh9;0NYhs9Cp~r{P@eBzZ{G++g~}LA*V&OLqFii`AN{UbbL)?+5*z>|c{w+H5h} z491(*3z2TrKLdt#HK8Xa!nq+sX3BirX;9~i@8fC|gG>GB&hD_B<^wkM0$_9yJi=OgC#38*RsGDQg8xAO_E_lt{Vy+sXT3Xj zca-Gac$UcBT}ikQ#N~k@cPKa1o}x9+y|V#XHlLLVI90-@rKT7*rP4D=(1L;%YGth0 zXpYt&6{kgx!=yJS)~#CE^Kkw;*UF_tSK|Y5SY~x*Ty3@3Ol|}$rCe$TaI$5pptp|q zb$DbXC(?1+X1@@gQy^;MTeMr7>S$-&!i}e6BZ%pB(YJ z!Wlt~*e_}l%Dwf7Q_>&p+>^&_KABGhttf8I>k@)8wyr;#C9}ZUIi(E$j{fLUQA;T7 z)Jh5R4VJNp5^!kbeLW{V<6KD z9Jx@ro+0&CrTQ~LE!KUD(S*i>28FyOmSYXfDNs@pn|{T=1&$4 z3s_OX3B~zcsw+khQo}(sYV1i7X2hISrcAtxdXFwSZbA%Vp{$HGADW!nC|KJaSyHi|d!*Ui6J62aP>5%lw3$lYpA!n} z=9HE1pnypBiVuTZ^r+B)CNQf}@25#~5Z?)AzcQ1K$8XBMgy69C#>F|X#JXN+97qfM z8=-AKwhq1qx=HQv!?zE}k*3S18cDjEo{?Zy3RYLU(}ik;Z;lW1|17S+q^aka#D{Y< z@4p+4*Sm+iT6hUi!V)iO1vh)tvzNhSBPJ_ZU5X_4_;qV>aZA9#Jx{`Vi zmm||b=+g6^g9p5crMopmE30;>bsvd83HBc_qU~jb}662utdiC>Blic^UN)LD|&r zyc|hqn()31t)d423oiVwWP*l(tnhd5)d7|=TNC}&kq27M9R0ojnRSnLGSoyJsz-3K z{jQ!~txI9+lK;&JOrRQvE7qHPB!f%A1Fk0_ITZ|`A`oFazv|}PWOmdxTEPJeW1eRML^XVv0ls84Juy4!H_u6Yy zu)x*zL}ymj;Y=qHt@P`tGR`#~ky$6t9PXyVJ;+<#_(|sT?7YG`LdBSpkrE2b3Trq$ zy0!?b{NCB7D*7Wb8UX=iGjAzNNvp9u65*x9VCiM}`$oT$7{<-^o(27O!2~wOV{*`D zb_O6^@$iX(>uZZs7tst2EV0xyJ#7Ao?Oq}7D^=0_GvI)lVP(mDt)k-NxH|i}yMWA7 zT91>eQcd>#aGuT{I{GB2Jpw;mU^67FPaJ4B8%QUg#^ulefl zWV+V+eiYuZofo7fA9xJus5+9tV~H_55h9HLD{K}7`znpIt~foG`@<0Hu(n4)Hyfx+o#8G2ehO7$s zJqQ7FB+On$GKG_}Pq|^nbElTU?rol<=P+F4KgxZnvF^Y*=COl)N(%PJq(W9%k%VXP zqwnNWY?@WsZ@xKZIOWAHN`H;d#C1NG&mL^3!%^&<8S3Ofg;>nwI`wLnj2qRmzFOLV zm`~-Z`r`$(Mp$cTF`VdiwOVlPMgPzZQQn3ot5B!W2Qz3i+Ft%*6)>KoQlomj&GW2{ z%}t7lDcsf~@L!(wfM1-Q-D@vo9?0_SFO-8&{c8PqLExv6c!NZ^QOMp!ZG|J86hzl2 zF62RYQ6_U^U~V2#Qc|*}^JsT|D7@Tq!L$fx1Q35qWP3mQ0fRW4BohjY_x7(BM{Lgx zb_oc}EO^x_4NwDZypu0y69y*SS;EOFZ zJJCy-)Cxnz$&?B-8frb>*>Ua8pEFAhOsIgVREPv+xA{MSU6%znD~d3b@_t9WDH#Ac z72hVXQ))|`N+Z*}sKyj_RYi5eFGdiw&-H{^zJuFKK+qMrQ26Bajmv4?|Hs>|d}W?P zpZ5w?)(WBt(73Yte*_;puuvgW<_?<6Z&|BsQbD;bBZY`Hd)4OzANvtO8^hkFvD}yO zEHs3oUz|eC&ho1yI;sNY&*Z=P69|hl8ThSn6l1pTQKnz6t#5~G$*ZP3Kcy&Di3v9# zp2(6{DHXr0bbKZJ{CD4@%53TC4=$>EsMjxC>)U3g`+iNSkQ6W}m)*{`VKd2K>ANyl z53g&V&S<5^E?*nAo^Gg&>)Q+Z+j54Jf+mIz*2`%0yR zRbehio8!sr_{9(Nb~kJ1c8@Y-Yt2e_t_a!RJ3xMd}G`&C|BO~xrk;@z2GF* z-a8MdEO!Otj}UrtTnx6LY}6KK+A#Ng$8AK`=2RKqf2=WjN2}^rM^7LFF``k90PVe; zz{W?I>D@l;?l{^pc)DHbT{f&*X{FP`B{e_rPx~JzF-qU+OT^JpCZRrTcsj8U{Is#; zOHC->P8H1ElTs2$Nm3Zt$Dpu!?R>nlGE%6L@H5aovT9J%P6#uAMXA|XM>z8jkWt8k z5nz`;wFxUtj4D-8&oG*g5^Z1aDQsgFdoe16Tmga50`5{~)MxUx7j^UU2n| zI-~(C6YN>YR$FLe?VscaGBM!>&OScylb*{xYPt?ka==bhxgZKr6Bao@^noLjbu** zG0Lp@1+@PHMj%;X>S7_7QvUrr@CVb2W8{ZK)r_+($4u6ydIT4=-IA0`QmXJX^O{!B`;e1q9_#NCzZJy_iy+5L3r`xQz%+|qcJ^?Fz6M|EK) z*x>Lf;B&*CXltElT@xAUBd?oTiot*)$+we+X-$c(`y(!TZ zZbZi%8Kbs%HTgx}b@}~k)WR(i%~GDhQ5!1!(AN$G%8`?=z9o${3HUxQ^(knB=Q;8y z9g~Mwr9Qt;jyRN5fY@PI6_;{goQww+N=|8|O^3O?!6<*)rH-&lksje0O7!aTE4Jzx zt;z`d9*F}0rfzirI9rxfIEPvye(y2JUo0Yq8mZImbQpb1g45ss_?J-!fk$S%b$=8QdJ=iPEn@;0P z^I^iR1!4W-V#ZLe-(;V$IZz32bq&AFWTsXR1UDaO696q~9uNTy^ibkrT`utf&)9Mx z>9$t8y|*x(0T!~>*Wh)z2#(5xYlwcKWo@MTAF#j=6rkhHy5ZqrL|R%}Ep2V#z;Q0B z|C%VH$l>APot~Ywb&%dpzOs!{G(p$VAr^D({9+3kzPDJ}DCPExqak(5U5hMqa&XvO zYW$$%!kA2zj!W$IzF%NwWo702h?+H>&97kVKv*Ut6?>hL=-f6Gjwft?M2G+pLimPFRj0$Gf%{Dnw6DUr}B@3RM@< z!Q!(NSkzz*5)7o<8BCF1nE#39pTcS|{Wci{R~gP{Q*NjCEuf5NWILy<9@L@1T#ZHu+tDgVIT5Ot&o!BJ!{N2tS=lK&h z-%wS<>FmQxL62BsR{<3)dFx_4iJ7$`t``6f64Qc*-y^qEwlaQD+erz`yB>^Ebw9rx z8_s>7y1M8UKs~6AJ>c`f7B>HNT;zCt5L=KPd*YA@K(mGc_|zXJCejePNA-<_kp_l+ zoUcCh2Dh$9`z`i^Wb$mXvjx(H)RiBaD9SHB5KA(LmDC?#zcdad!)CTWty~o2HyYTj zm-`x|bvH1$e)WU6+;Y!YTfjS|6bS&x^%k^pUXH_-zN61DhJ(iA4+j0Ph4YbfDvCXwqs_p)%w{8` zP4MEUvX-o0??$Kx@xCJG5uGuZ1ENM(@tkBz&^Mb{4q?8&b|^X%ONovT$@zWar)T?i z?;Q!d_AhL1AL)z{Hw$Od%}{w2I@`Y1xA%%$)295Y8DMB>DUf15+jruDD5v!#dKif~ zJs<+J^mSR2sOu+dv0B~U&_`Lbh5WaB^vibo10?YTa2fkSebtigiO40G`e!>d?-L#_ zeP+&$4|E+g5@Nli-IVAgLbO{vxI;1MSr*}{K?4{llo4R=*Kw|X=x1w3U#C^-y8?-F zz6yzXXncbpb|$!G{NlmAiggShI@;gcll=MC?v>V=eUO&#rILxlmu{U|QK$nmYuJ#5 zw=*o;ZDg#ld?i#qUV@#jHSi29`rgZ?e$OM#{X~W9IXdArcXXh;YV1gn1(&YJkD}>_ zSZ>%;ivW?a2cB>>Xm3a%Q_jv!1n?LiIUv>Z3J@+l??Zeym0j_uGL36fULEM)MD zk1p#ks-_(#WA!E%*DF3u!Uhz*9g%BYxYN)vTFhhz3{T=as^cIVtD$s$Lh6wkuLJIg z;n}_=L(V;pB6@aS6%M}pCxeFJ`v(h$ht89QvhF}0_wz%3%VPT81l|%aZ9{uqqC1I4 znXKw6Dyc5H>yV(6A#okXGP~z>VXZfZ-}|3w-+4*m$!(u)EP*dl8?SH#Ehz0UXt2nS z_Vbbd1=}#%*l4e=H*?-5b4L@elx<2OhhNm<{vB2LujL)ljbGe!$b)>k@(}jCL&^Ey z+Y(Lu^L(_~mlI$0aknWt6J1c{H3B0iLhgYv<@?8l7?LmTqkzzZT9tA5noh>u#ZC;> zSe}A2v$WY;+I8VCS&4GPSg??vPsy^#MsU)T-}JTPdp0n zd^@k>;jFJsTucq*RZsKhC%=q}54qw^YIc}vtzm`biv^(x*LtHsPX&AiGiQ|SPenXI zCxQg2V3-&cjRf$QpyYSN267&IbmM&7eGzarXLVH(eW=dsD$dxHn9~%U@Q%y?zIhYC zH{fqJ;YdNkj zg*GmeZJmq|TmC!>Kq)M76gpr$<^Kzu&aS)YyMNz$0e4$<#Ka*8$C4~^k&0>aS|X7S zyLKD9H?cc*=Z0|A!UgLH=2*}r6x5(A@f1$<@5K9?na;8CBq9CY33SvgBr9!C=s6xyTucu9GUb(p4VFL(yAoU|*Tz0@n zdW!asZTU9WVnB!#=fjiitflqD_~M?FY!`Q~msy!7k>s)36dz}@vK~n|5bF8jnPBVJ0RkxU)77l2k+2Q2>+@&$k< zUqf}Oa@%+(=A;>*T0(5`?0{C9`QXv1M2~}RFsRE;rNiZ$x!Lo5t^ZG(RIiTG@6(qq zt!tEZ6O72*%!ze3FLI^lxqe3^xMEq4(+UakJ15UwWd?+MAKPTkR5hlEId_80TDGo{ zm55Y?d!`IYYZNg(K@#AFhsjiZ;y1!+*d?8y!;;Tc|0D>xKYDOBCr0-TBM!3vqediP^PS zVtmB-fb)@RmsZcgjv0a3+(8MRK%#F}Pw)RHU!K-+TKC{*ksBvRp(Pm;tq~Q1Z2K<& z@{W_!9m9mijS@g2&J)^BbVoG}+=PJmVodysyQ!MfmZ>P9zQ3-vu$M*%_rk7NR-a{CM8Ua!jF$&sCn&xp0sTX&$=aaoXTss=K7^T6QaoxsTS zGQR5$7G`GswQ7oDomm<+@u)urY9RN>TSbM__dhW|KsM%PZvB0x@r~r*LCkz*0)Pp{ z=B5-GRJi`g;?~F2pU>zomJL9JR=!|!=iz;dX}Ix>jk1?Yk^FDmv)`cjh^NW7qPU)w3`+sY zz_tYLluLBvAI{;Xh@(LC{|AiC6B)#`elucjef+W)cO*0Wi$`UTfEX(;&V>@91iyOF-({E zu}ra43M3u;$V)&J{6kVXYX*xxAg&mQvFP+(~ew z?vME3o}OMB4tEALcxqpkT4)tkeY0s3$r6@`4Ro*Jo?e}A+%Shr zBzKRUN-VCOGhE7`v~to9uJ~H4>JhpGjE`iA0~MU~#^=D5P~5+v7+Lc_^Ir%J`d*3H zs-Di$U&uIckDw1Q7c}>^)exGROfpN{+~f7-yFj$Uw1mo`bsd<_$@;)uP6Jx&I65NU#_!ss~fOtx4Q3)&_8K$$ZW$gOCh zD+QFf+7>kNx99#vn^*j$srA%d4quX#NE~2zJc^T z8=~o(>bizL(WXCS8DuD6r~f{6;PQ2dxV-k+<>kh4FmJwqi^3xHD{rJSh@dZJZ8K7~ zaK2N`q70!@WP58aYwTkx!ND@;pI6pNpG)ch-}-Xd)MQ{|6#0JvBd6Byo}bsyg#m0I z9%4I_$8&IUQuczK(AC3JRBU0XIQ=Ck-KVU~rfD`(H1@i~aF~#{{fsrC?rIQU>0y(s zf|->Mhna*l>Y?b=sVIiX!vlBM zl^Py`O+8DbVK*liLokAa6)Z0;%ohFERh5-2i>PC={{i?S4~bJNk&&4F2zV1y8$%+j z`2J}I9amGjBb%AhNI;``@8|QqNEfUzk^WD{2l_2X^77E7CpF8NIog?Y*4q>Cp`cxg zhKfD5R0rVkL5UZnTcqJoUTZ?Wv-?HFr*VR-vBL5Qwes8C-68QdPn-95LZJ(B+LnAf z!t*kHA5W+~bhX!ZeL7O>uRndmvz0Ozo;8yi2<+M6cG~1JVOUyEYNWpIi_w#L8xA1F zDMuLawpPbjwOVd)1RFQG$k|wk_9{11EGQjEY@gtIo(U`?(c`F;&O31XvG6qaWzjHQb1mA zZFMzch1<=g^XaZgkUf4wcr@&P=l%R%TEdr?m+xr49R$O@Am)s0f*0>Hm}B?UAi0)1 zk}^ly$(sre0J}@AZpL>~JJHMo0U4IOAl!!fdeME}$%AS004KtshJ)jVAdKEYVot~VFcaki zkG0m}k*2!ZEJE*yxo&V|dfFG!pJ7wG{Ej3?uoQ?a@4mcEm}&v3R|&xjT-W@{Be^;$ z;%2SQS!=Piw6c%3~m-mfTV0OBnrM{rgy?=z{RS_O$kgG8lCO zFm*-HM&G)uW!8t4UDs!d08P=K@!wKlMy)$J(#T4rUR+b=yl;sXFp%=r7?1IimZPlU zPCU$FyUUR%pSN!qF1Ye&zT6}o%vCw#h6Zwy#q3}kzsv=y$hWYSvX5AQ?;-zZfezhl zJV)|WbD}#|>LvVhj%VNWD|~G4(>HS(vPMH`zK1%@$zs^c6*e;B&-2e5gXKZfaT62s z6ZTWSHa3)o@!=HnoQ+tI51*$ON25#5zCSNjCN$&bP6#Yma3EQArPC7ZlkCoz+Ai_N zItkaFl1YN@hn5DHeH+!!oJq%9mb-SZeP^%lC*oNQ)Z^II`#BMxmiKJp`qF;Cl|hN& z|2F@7%l}jRhn9IvV6Pd^MKrfAi>s^m$nk2$shCzki&v&b&7L-Oy%9J@Dh)N0-GA<{ zR38G^eT9D?SK>A{=W*R9y%hhD%z22cnHG&Fmr1{fpyBzLiNdch)unk!(=C)m1b#R0 z8ameapL@<=?tYb^qs|E%oU5sREHsr)u4sNT?Y3XVz^{!lPO4g$9sWj-(aVo`;Kj6b*cwF#hs46=f;!YJv zT|HT8WI9O=L0K}X^cq?IEd%b0VXb<}87ZU;2m={CM}#JHFADbcfA3NxO_@!+P6zHNM7S;LJ>e2*KH83UXdIV06+Nsm))xE8Xnm zkg1mkHo~?G3kQ$m;IBS1L_nm#+)Xsx@y!F8QQfC+lPL#G)wdYsa*z5Vz@B~RMw{{7 zT}hCRdls(+(nlHg1~E_Tdw*8Nkwj1j>Rpt*d8vHqmvA#q$teSD-tM@L=ZRCsNL2We z6&j|vLTADFqmLW~`}U`lY>0(6XVB=1IasHC7(0o0EV8_Cl>Ut91MXmGDZ zje68GL*F5Eb8XBz2&7Ob6Yn`As{gOLXW2U~tgZ*G5rfkg6HZmO3*>Z) z+$h7|JJ~FV>O5txe(e%wW513t% z%TyGD(4Tpd;?sDY#=l|avN;=ntr{1x-oYI_4%faz`BKBDITj-28}X~|ibw8Ad+;kk zOYaV;HcLHQL_fe1Yua={EHe#`A+|8pEz7j3Z^8R+I&kkxN{wPoFm3fRca_g`Oi>SG zt#1Xz^YAhOx((J_wpzo>>7EPjzus+}J8#Y$9c&K%t6RX;e{$toJBUB9D!{+DgwZO+T;2DZpK5qu6mD9 z?D{}By|tUwyT?(>_qk+5SjR&~WIYvBa4LOzF{2{aMHM}Uc2p$ZHcgtFe`0O&KrR?P zbJ$Oq?)$4fHY{A6$$i@LUgh55lkCtFuJak2SV>9gO z&SL9_6Y5FmjqR=v&VqqsJ~p3>LY}@P%I%85N*eDyNqQjTZ6Xyj_kb#q%UhK-<>C+6 zvNcU^m!n@Xo+cR>nr8APQU%^1eyI%T7obgwE&%j!wjG0bP{QsR7NENAjIOc`&u2iV zML)TMnbdg1z^PS=i)O}!g~eOkZOI@})~n?`J5^Q>vTvs#uy$u3q|tn$xAAfoJKa>W8>}NAGN{2zmWpUtCVYtlB}b z(!pauT235#$Wx2gG&t}9td{ZcfQ$4s1wv^u{5GIc-m))>6yJCsMyvIV9Q^+FKB`WH zbNg_9#QRNurbSWUKq4qR?i&AO>Gf|q^t}mxj}8?w`TZctAH2@i0_?H=ZEW~)4e*BR zCQYOP(^x+;q2=!1UG#6V&k%HTr(3T1Woq;gl)&dJ{*&48V7&tDB&JNW5wEgkg zQhlI-9;P0zLJ!$0Yyg0Me0hC(B`p(dZ9iM{BKSU58pGP;M^88|-`A8V0TVePNC6(V zgh}pp+ZC?QO_9v%Y}|q6K^(m@;%Upv4@?czLp($4-+rRgT1FM)=jXF8-<>$o_Fc4B zdMbKw=&CkJ9%hCY@4iP#J5Q-?(TnM8E?KyE`FJ+)R5=ZJF*H|i%TuD-N}Nbb)oBY7?m4xsi3w6 zIk*+1Hr?od4$huER}9^r6AK7i94_)B-xI8dt1o$-u7tem7K<>vw^#p+wiAKBvAFeS z&^-EM*#zq@_wxrr_yPZ+1YGIu@(cEyd@WxCW-pSkKlbqY7?QVQf?e@W7p-xyx`224Ck?2hP6tzwzvElW88twPKaS1z`TTU9Is6j^$d|xH(!$UagaxaTzm? zwBpcZg+|>;P@ZG|KWv?4P+aTQt#?8af(H*C+#$F_u;A|Q?oOjgaCf)h?(V_8fyUiw z++FX=KIc|_->v(LRZvaW@^{WT#xr`u@sG`z3-xSjC?6JC%-tV>okdb1lgS<>{FJV7 zu}wDl+`N{S6c}rNx2ivsp3z3}KEcY%6TYP=M{>%a7=||HX`gv3VGUw zD=aNU3gVeuvFg2p$Z|b3(88TfBH_r%TE-5*`10y2z*i>^JZzE)1^3hFP5$A!+5Q=w zq^-70^s2QLe=BQ|Cuq+(xfJJVLhJ`4(}`+x_$wGcWw;?lGcu(msEDU8QrKy`!&aX{ve@^QGtZrq7Xo!ipar?>{7Z z#|fx$NE_^Srg7fSqsR4H48>2sl}R=jOg3?up3~sBV>}&ogp_#7#7bR!5)%3Oh)q=O zw)!TPo4nw-w;&Mkt8E>Qcl0zO-F6ISl5<^Ba1^ZC-6N5c(1odG^gsKd0OtO`JsE)t zb+DMGnk}#!Qlu~DO3Fs_kYjw#wy22OM@7KsO$l|*9>ajHAMbrO0A52HZ`|JpQq%Py zE2)17EdKLoFv)9n8x58gfXaj(`0eR1QJ@#G;f%27=*AekudIwfaFmj7PGu{+#if6? z&=;oyOfNk1<(0eNNb4&%s8C|6T{iMW>E8-FS60QrdE3ra*NnXsa~uDDcnaKPVL$ofda62sLh>1V zCm)yXOZY+^BBla6WTQ;plqkExujc))Fag;ygb){^JYt08Ia zra%?nSJ`~M+88b|g@dcqf#HoE@gtz8UfZ~r6oF`R<@RLyJyX?Jkv>2`&8#th=4|JP z>v(jZPYMT8gHXDH76+6iW5SWJh*9qY9&EerA)v^zEb&@axq03blvHE^>1Yi!#BdF) zwn%!jV;Ntx#Fva+uC0k>c%fi-o1XX#eOt*nE?@n)ue-8o8JCqOJXZT~;B;SOs{8Iq zV%Lf!jI25f-FRLuB}h|+a|zsePuQ_nUQPCN)>I0w1F@Cr^Vn&E54qMZK1TUe7>G7V ziJ=;0E^*X!BrSRTegAeYC-s*Q1cj=j76ZtdQu{An6%X-ipDF(P@-0ztmFeHuLzZRqbNQUCa&d})uTzU4r8D5u4 zV()TIjGF0-gEj+yhi>WkvX%JVgxXJDbZOKUhwQ)oZRhqK&S`UFWUQ;}C!ePuHn-5# zG2){dqkJS`@zU;mzsV((FvKN2$*kzL0V3&7HV1RrK1-8F)#ihv3T#yz3Nc?DMAqCe zBQ01q;#uFPgmRc2ZN?}&oIzh&M6G=Zn7;w<09Y~h(;br^Fgv)aC}oEL2_+-m&x+>g z%)@NVbL3sJDs6B;T>Hjka?CKbedj|LDKf!ih!`+({k&R9<5B`;`s-~_ug;7@i!C;` zNoB8;PW(hUlw43Q<@ZPb=jBdvCja!H7e=mh6%wM-T_8ch862Y0&s)EV4xXOT*@(U7 z6V#AlMAQ2k{$A^M*ZQwVDfqrw$uy)%%*8GiHJs#q)Kb)%ks9E<2Woo(t~d*xo{U5o zbSo=58D|Sh7joQq7od5fmt0UOS}v4mu9q=zuMm8X(3#Rn+6mm!hQKY|`^jo*bh~cF zKhA^)kpFBB=>N=buJ~!8m*smZ0KLDgvK?>YFHJQ75p?3wWmYF7B^zL!{Yda-T=!5P z$n|`5`HZe`7P%n!mSxp^Ogx36-eBmgcqW@tQ9i#& zJfN)wzPwb<&CefL@6B9t4|N!w{^?+4+tw5n3KqxZ@Fqfk(EM5}ZmPXj@P{D=X(+D$ z=$|shKIT|vQK8sD4H4jEBRP-}1q|WCdTJ@Z;dciGIVDQhg>-vi>^L9p#%te#EgV4i zk^g;Bl9-~l6xNbS^9zi zkNba@ZrvYuafZ@Y(|@2~b2*Va=bU$(3#e8s^jEiLQ5;3WUtj@yWQxC}m%7bgd=>a|{^W~&P^9r~aW z)l%^oy2uvuV{nKO_8HrV(2HJ=oW&xv)I3grR0HpIBu*Z02?m8x$6mF&A!4}5#P6cj z6%Fe4W*(D4E~JSKsqqs@rUNj?3d24Hz1$I)Chpc9ss!K|9U54n^G#_Ha{DAr#@+s& z{J`}kFOFH1#5A&0?qzxHBph2PI7^cbN_u?ha#g078tY59tFWiv1)#eoQwzSh9LUEl zi?SG9D2&z)rTB%LS`w}_2^O)s9CJran;MVCOv&enOt@T`L*nXD(Bw;AC1>SIq>e=7 zokm9!vV87>9BR~msOCz^QzWMZy!xaSfMss-XjlQvC&v|D&xl&)yQ0`wk^qB}(~r>8 z!AdRZxPO5^ll^^tN&`4 zS5Cy9PClAuAMAVuHyugu>?GXaVbdUAZq%{L1pDGC+61cN6B>UtM0z*ftbJg((}=E> z#sL(&5{gUb8ymvNl{y16`o$A*mtkrS{bJa%G_W|{pF?p{XcH*IQeY`(ZMF@f^@}eM17^FFbbWqSaK7eg+>mg)Z9y$NUeUpWxg-@M4~8NuQ?j2({t6$ z=fP+#)f~!IT^HWr-F(?csoi}3tMzsjSF+|{JtdaSd#c?OlL`@#PTJ~L zFE{%K6s0mPPkgz{Bju7*uBy>T-YISr)5oyhc)W8WsTORCS&|}+51|HYqO-0I)K{{H&PfQca~I=9aMo>Ga>KZ}DU-GTgm|Z?KzzO|>G4dO4{LL8*L*k0`1!UttH$P# zI8t|3vCW5CG3C+G=92e@zvj>O4FBwD$M9B=8fTLuFR2;PPPw;6;OIjbL_%hgS3}}7 z)5`s~?6=`*niImsuAAc}zctsjt_F7pW|1zJKY)ht-|5%&m}?lwvSwk;09qk@wB(73 z(khbd+cc8x8#Lkj!qo<0H9YdCFs@_oqBHq!U14K#T5N=G?-M2Z7U5}4cgwdHmdX9x zS+Rngd$2U$N}+4 zCaLLk$SCvGhg4!WSv@P7w;gxwyNf4Wh`4S3BOMkNtUmC*#*IC_$tEzbqChIjD@TCL zTsiej1Eq>@NQ+;~-^m+1(|ubo`+rCLckxmE^~pmSwYT@>Mxc^9dNX&{2ko|p@SrH2 zp=4sX6lOBEc%QWG+==gU3%QRKEdwbCQN@Zck0}2C(TH?^77*fxyhmVO)HXU?Rl?_4 zAN34-r+(MDv-oOyxL6t1e3TWkRw$jVL2+pB_|qYWmMGxn8WByEA70cu?AXc8VJ-Vz zc`7FPyb|z0qn_kzuw5B=>2YIns2b?qA;IfM)IZ2}%QNQ;3>mA{H_F)<8eYB9zWm4K zSA3r8{;aQ9@KbT?afgvq#3l}++`lbS7DbbWt^P;i7N z!u`^q%fHgX4ktEX#v6RMzY=I0Pc<7-Z}&@|@J^bdioot>IyHLK-+=e1U zX{)vtrB4dwD=!*I;n|D$K7&ARtouE+dJZk#>W3^z(QzBRcF99R#@P(|m}IO47h&vB zwa~qJbTxKoYT0{(Af#L0Po_8)+`b63L2QNQIfeL|wb22k$Y&D;|H!;(_9tpYh?^aB z?Nh^O*pEfUUk9=jK?)JfO6<#cgR|??&srOze=5oPaviVHVP`O%Xdf$c{-J`w2ad1-7Ass z3GT0?(V*`iJ(LURb<^O>L%Kd-{XMqs+ia{6sEd#UDU^@)6VepmZvzdDs4=*EEy(8; zvBhAbr^QHlCkFT}P87+KE~4lSAuXXfXEX+$&&2swWTEQapcCnKsubLc%ML4_ze+O@ ziySSm8c`Oy>X7LetlS<&a|c3-Ha7N0+JmykTg(Ap89gpmo=`DeAli95B;P@V3#U|Z zp)3#$6o}m9=Ck`ld(KaixW9Ww%UUgzNFs z@m#W@2tTu8^8FwcP3&CeU}vsn%)=N%zng{hO21C>T_;Cg1z)IWZYeG|D=(+Z75-1u zE5ZTSfEWRnMx8<;YJ`E0Q*|=Q)rKT8wU73OtNM#`61I8B`Uhsub(gL zJ7r&xLI@x!;^yYQI9cK8X`j#bvds~)_PXh)KRFobp;mS$1kLgpYuNO>Q5m!8PZ%9( z!ox~dO&)uep?CP`^&?1WB*t4>GEqQX_?T8{uc|lRB+T=GD1vUyNZ}ER1-#@$7;5K6&9`iwTJm54b(d53H%2=rFZS zxI&b8Av#r^Wy9zvbaQj#6H5S}ChMI4L>%}ti5mnO!>=r7i?eJYk)onv_Ho~mSHGW0GB2lkToFH`ZbE6(=X zv3Lrtw@1<<{Wti6fPNynmX;P8dFX!W?n~Q$R7FLFljb0=YwDg7Iia{yY-Nksua4i? zn4i(kS-d;?=hS4NK8IgfRG6%UVCd*beB%L)*8H?3y{T!8)c~M%0~C9D;`|Q{L<~fr z&drBDT3#QbA3C9B+hex`$2)exAzm0$bwq?t=T9=aAgyRR&o@3}`qqSDO;lrIcbkq- zW;MdLzPZt#&drxGq|Mb+R(BhYk8hI*o3b6nRn4!7;FZt9$WR zuOpTb)yUZ5Wlpz)11QM6zVgOt-Q&Av9U~Iut;3a*?=h?_e&;Vx41B!AKZ*GdA{O=` z2T+8#eMXEyv;IkX9tSuNx^It(8F*29xIP+RrB%sAu4=@EW^*u$RqJ_0J5c@0l(zHS zcMhhD6jR@R2L?dOWYTIs99693+r6?mrxY-D=)2i zA;sj27JT(`!|Kzc@aiuTvpLFTstFgOIVHK`sKBc1d0R^h5C#Sp?tVz(lR6)DOU)MP zg&+A9&lnR7YbJL&{0Vs(`3TzPO>OB?BJC4pbi}iTclYB|Ba-Vew$cmqyg#d3iW@y& zZLw~2GExMMj>-%(o9d8Ojir>8z9`$-uiK{iX=Jdhp*sH4iw~Qn)f=aVLQZ;fTZ4Md z0!|Id&m`QFpWs@!0jW}~>q?^9ZS>ous#5YQ1MSVVsuvf%00y4qY;pL^B>fR$Y+xM& z&%8SwpNpj#;_By#w(W`S+4!+te{UgAMQE9L5Lco7^HZS@?>uw7$NQ<6UViG75m$p5 zK7n6^Et4GrBTupkgDH!dA~)1S3fVADvaKJ|I{vLXN$4!=1GgS4HtcM{j3$l{t8X&> z$oCN(sSCjLzHm3yU?_OXQrL}oXFLv93|5QZEBw){5)QSTjA;K~e(b+$u=A{S? zWIg^qi|2)FLi`0^_^{Xns+bOvo!ZXLvks{T1($;~O3tm=gc?l9`^db>lJo0F*5Yz3 z-%~9*{2KgPimCY;Gd@!IPGgP6iqYm=IPLDWG%bXns^v1csfHti=iu%(?b(P5r;|M* zj+1*Y&U^$R88dzo-`5@MHQoddeuU30PjC1wWvafS#mX!^C^zsACuT4Ne#_YzyOBvB zR1fmN`4x$Ju`ybtIZX)qP{>|8-(tq1luEX(-+3^d;fQInTs{|KFm1seM)@AL+Hv4} zznX)=YTK6HuE^}Nv1-o&B4^4kc9zC!-&>Lv6V3s>PBzn<@;}Fafvg`40pUfB33h6C(6dVmb1CpJ^qrCa|KeM@y(B7o&eE>m)vY9{Hw1?VTAS$~o6 z$9UyEX#ryNPeOk=%bP(LSNlpIkZ}LTX_(JfWxsTLkdR?UnvBHGJ-#hu*e8iP#knE4 z%op#2kbNBy32@v8+1m@;IuqYspQA5JX@tUab*BvQf0NpEy}U1UatXyO78#g4rY>vl z@3YFv5&UOy^f>ud&a4ERRwzF**FsOdr#@^WJotI>5_DvGlB2b~|4MY(qMU2I-*Tl_ z9nO%F;Jb4uT{farSu>VYj8#{;&~T2SaX3w>G(ng5$YDCxE>y5usxjNipC6Wxe?IZ5 zKFLO2Xa?T=5k>ik#jqm_=BGyRUOz%XLcj;YH$0WXzUpSHz&v z%wVX6P7p6JnbLD#f-Div=|hS*Zh6%h=<-!)EGpoDaEX)A6c*>>#f0w>xJ)*Sb?Tiy zQqIlJ>$rH7$G!X@k_US8pkj-Oz|eC#dYR_iiGZy_qR)~Y@)b(PC9$XTMR}8!`+UX- zGK-8`9k#7ucS092+qrk&{)#;X`E`J%kRK3f`XOH`$#kK{p_U+h*+?%G!n8KwtD= z;DZrf91t1n}vK@Q;N50zSc-oY3JTqBGmses!6I!vp z>7RNbs(rMIkb}1ak?Gq_wTU?`_Qs{YWQY_r$_0Xjq5vEcRJ^NZB*cz7;16yRrc<7L{c_&c4nOrx;({fayxf|q|8`(3L4`>FMT zTL0=Whw)*wcN9P2#qRCfLV{{~Noa~wG7EIdhGAs(RR1tovSshDRU$aJ#q*XS_j?30 z{tp!1`2#34C@l?-4;c8by`s8%-hJJ_1-bj2^_O@N?%Fl?0t|e_D4!)iF$U=jr;l=# z>#*qw;G7Pf5f&3=g3&SII!}>!spN^&83bRmtKSFni(XuH44ZHM=A8jw23_)$KX$@m zrIkFkMc44$ea|0g2xwUy2GTg}n%vKGD(LZQip#8S(^9I929N;}^k8iFPN;#y^_MW@ zH4>d>N#mDz1nUv`?4r~Wo|modG_QEZr1`UNN6aJfK}W8YP0lCOSp$6~r;aBOo*v$% zHGQo}4;34(789Hijtok>jFvovn1E3T^h@cAOyJe^iylK3Z%~>rR!zb1w@mGu zws!l}r7Y~Tt%p7<_k+?*YHBBA@{n<*<>L{Ba?ScbT07Qv+ML}1P@gQZ_wc}+f&5;) z_jj>U;RnKSM8SPdZtsUH6c&P&vlCiS{4}A=cS`X4hij71&Ah-4Y?#p4Y3B{FK^kH6Dz z4GKpEAA12BVv$xkQkk9{=P%S|pF`HIr4qL0lJGRV*_rZbcOIF`f6%~T4nud&XX%%R zRWsqKN!gj{7s-oclLUM=p8VJLTaP|sj}z(p%*~EAUF}HMRMzHew_DB=;16tH-WO}l z*()smc7FX1W!GqC%I7*ZI|1z8EY@jHJe}hn(yKQFMdl__31EUjZ%^({x6FZ`PSAOQ zN(2JawLAQYG8*R`qnD&nyQy%8G+Bq8VJ6iZJJH7&tL93_kI#1f%m8J**?U07z`_D& z*U0hlL1w`=w2ClJtJk&~Fv0|L4X23eSwZg~9&mlaI@x7b`g&mPn5yeH8wE-ya)og; z*=da3Sq;(V-=Ao$2#DX7e_E3Qo_VCA>Nbqc-j4;*URT~6fTyHWlsxW7RbX~d*X<0K zYng7}K|S7m)+I|DFa}nyp@>LjEi~DZG?v1jbG7StatLWh___$-@=^9Y{vTZav!#6q zZ7i7t+Fuwqb)h5=C+GUsmS0d%P&VtyztI@~f#uV>sN$_hasRqG*v=amm6NqO&1OBJCM}0nwVnV zpEdUz&h7+>J^@(rN=z5~Bg4Sk0i^W~|5WN0qvks{yj0xpr5|W7%_PP!oEx=A50PY$ zrVyHZ86JyhSx)YqO*$GiSbpR6s1ZQ3llYpgT=KU|73k_-lN!@B{Zo;a8Q6OP6Xn$P}Yif#*N_W#Sv^=~Al25Kz=HtRO{?eJjVh2B>v^#vV8tr6?H5nQW ziof~zSSD7w6nNz0=Sjy5%H!7h%zEXiTAk0>yzZsDo_Jm=Ct${SLcIi z>Vvt;N(5`%l^3!z7aCH;_^D-Vdd<8}A_W1_&!Kj8cFhjEaO_+car`j`tXVgxN+YIb zma}8adg=-Gl`OO!GoelkQm!SwaVy=f7+_n*c7gGjKVJ_5>nv zfiCi1G)1$LQ&VdID}RY{u_0ARQ&VhI=CV7u3O8=zV6md7;f8psavv$`9eheuJaTrV z_w4?GKT+7LML{Q_g7!u2ZY~_lt-@Dc z0q&KxNe$!Q*XxtT1ZAlLDf^|2>p8Q05h3u0%Ayv_-tR~~l}T)tEnB_g{+e&VIsb+% zK+X2)6t!ENLvE0G&XHm(r=nGt3XYD zkq#{|{NE0zsVy=9T_brh380^xlnSH`_96LRcV|C=AeyfL6-qLR!A8BC z6M%a+cRv4#E^}iUJBwP>D1Fs#EA$%LcuT7Hhgik6vg5uheKi5 zZ?+FOvs|VQ0$M(o27k7Q#+CbzIWxU!PJ`^8ss%W|{M8vzPhL+rI&Qdbi~{}D>g=l& z4W!&M@&gQXPvt)CS&4m-EX=h0ONyihpdA3ISVw`JIGE6 zunYCH7u}M&VgYL+cmT)mSEms1f0J+MoUtq%I^B|GN?(kQ18wkIUa)-8@f0yj1h;nS z@7gt79C7w&1s+sY&|TEBv(=7)ou#iKtI1AZ~lNdN4?5WEc0*eF9F z#%vEg?Oq%tXI7`zJA@$jMU9)4g5qyJsHzNn9G%2^iV$q%ssVU&E1oeSU<2j=IHDf} z9Qi{TfKUHa_2d47QETV?0Q^=H@|`UcNZtWLBe{T1Mo0VWG{2cekYycCb38f`i&Ep7 zb%UOFf9}*_@{?KlCqZ!osZiq^GVz4aJV+QL04=w?^Iu7Cy^6m~$})7kK{lnVh+Ci* z%;OHt@dKja+2P7^cd%GL;tcq0!GtM#CA07c#)>9K$M?3@D$UOokp-HW$w z>K$N<{D|s8QiW1aY&G_Cbjc;65Jk4iR0!L0y9$L3a*rS-Dc3smh&NUAMJ*OxDA=5> z$&9?lME3i_cEh_SuP?q`dY@Si-Fk92t-LZQC#}3yAFdfhl*79w9y)hU`bK!&?Rt+Y zTBxp^t>jXX)W-t`Y`t*iEF^wr`rWyx>GfxXKjta{+DIq~V9+_Ob~{IH0M84@P9s0@ zm0|)4huxh+6m`var}|^S>T5^RG{nl33(+5NBT?no%*hVCi&bJC&b*tLf zweJO3J{#`Mi5vz>(e0jQaV1F@b#P%9UlP+I&>Q0ZbR|ZzXyz!Ud?v))fOM>PGF_h8 zEN5s&R$pc8fP(0St>kn1KCG$-o@Xwo6?!@;VMXb7Z8Zt-1Ou@pBEY#aC}UY-ta6^v zJUX(m;HgB4lnq(%-9~P`UHdb|a;LE%snwv>3VD#t{k{57KG&Gv&W3_WPQo6ZdL{6H zxHP=^DvKxCi$aWb88Z+v>705Qm={UR62mvs$}!-4Zmuf+juSb!XvSrTlzxnVFF*;08%G~B;ny5Kg%gyETN{k*Fmhs*FmrG2m3YG?U;I81w&aypu zPW5qKN(j$fa%K5qH%J|ZVY+Rp9CS5+Rddub>PhGSsTx=zep)+RJYO0;XnV&Z#R7j@ z(be>RfYWn>35cpPuY1$xa?MJ2@8a`@@!H0sJl*J1DK8%krL3%>UFj>e4`TLZOymup z8PqLD5j;IlSwm?O3GbZjgiHQnPRLkjfXl;NztXMsoRpEeR9mv|s3`cty^$TJHd17k z6~<6YIhAA2jeisuQ?0Jlf8tpor6SlwWT+0!=S0MpGb)^b?xpTniey|3s5c!wK==27 zT1kW`?w=j_xNLX(BF{G^qb+{E{-#q*#DdMm=}U8Qbm#7bwmU+a6cp7gBx}>G_B|Hy zv~c|nrlzJ3*Vorp$bCBQsXrTfj`>X?0}5ZJ$X6-t_m}QA3~@iP!=*g(L=BhHSON`L>Yc%BIopP{Oq*o1!3=UXr3r^hHZILbv+q%c_Ld)39xEuj^ai+izi=F|^iZo<&=9f( zUbsOOIXjleM?3qSsAfJ!67GqC-JFVJeLfDodV+^7Dfd%zaf9#(b~f)w9{%Kau%-+3 z%_`lWkyBt)e|wxHU|bTJKaa=3to_RH%uPsNf#Wp{+nIYcsu3{dtG(U3ZmpNHDelGC z99(d|{k9^86x%)`y{O}dRWI;nvVhEn^E0JHsnYWdUqpbDGdjiYZ!kIU&oXR1i<9{q zQ0-QIwsV6}`rw~)mVB}Yssl&GZdWKTx~(ul1W9odB$WomO3QyUW`6Mod7pgPzbB2El?=hF{{A*{9EyEmLmZZ(q25lHW9seLF1i%tWgLO=R?> zAyl{7Q?sk^jON4ryr+&P67$^68{QXaayR_CK=w(L=YROmfkoSfGuHmif*mr8TR&l@ zC2v!mE5BJRdx7`8a+jPagl$!s2EjVkG+%M5A47t$^LCMl-|OoW)@3|Oz=dkBDGXIk zS$X+2=K0n@)PqapAsPUx_*?N5E7Keu9bNH!-$9_L0J6bI`29DV6wUai=bFzqP+~RM z$=YoMge}bB(8wk#t<h@y|%&fW&0&EbaL?axjUCR4-BCV{+X8Q-=Lc8v%+FSVx z(_MUtu0%+V)wsjl2f7a|_KeztvGLN*cOc^=CB0)Gim^G|%6EFLC?(lSC1+1t`a`g8 zgTU!6_E8+V1wd$_)FjD*1n&Desr!?!+mETVl(LS`DX^wPH41gg#1Mbn__D5%F(gKp z&ySWmty2(i%sW&Mq>i>WcmKFKy)Cn}&}DL|Sla!h9^{S74e+W9zT22c{r5hk$Dp&% zwMWZ$`?MR_5k02#V@a4n`VvzKEDxEuQG?DfCyXA$E zmaPiolG)(REWI`?z1v%_Cri6fxPn>09D;NhK5Q4({&#)K1o&OALW;evo=yPo@dNC* zG_^$H{0B8Xwt|*X77Jqn=DbH$PkLv5k0Y*xxelwrOnp?i(aX;)WWm*tfmN6#vz7$`IEqwn-+IqgSM z7SM|E+#-6LD@`AfO6|cb9fgP;zoNN)yHhASlxWj-_glf+eCj8uU%}d16xRGLHq9rT z6)6CLtw||)eCxb7Wy{R&vVS1dSOY<+Mt<>ZE$d@vWL00iSKiT~t{zwRNbLC8SE=s} zIr&r=U<62uK=1wZ`;+$b?rDAkP#6}mr+c>6Ay^oyq}_D;flRG})!4w3;@{S=z!D zpZj)!BtD>+!Tmi9p6u!Ak;iqTc2V8f!MrW}84REQM}`K?3Z37=kg+)I|t)*)JxEwyT`egUh%_HeuOlf-b-_%npx#I$b|QK}&w z+X@#|Jq~Ew#UskKC$u`z`n=TKXfAy$Tw6)Gvxl#=!ZKFqI$q9D+aF149%t7qwCeSH z;ow@{^cCa|E0fp5m+UeurLKi?vxH{k+GP&o+qp!d`_;k<2=A3}0Gddnpk>>kV1xw6KK#iy}2dAgb$&1yBl;w)QdG?1*kru6)F zr0x(<-}_7y$ol^emlB*Ea3fl|U^TuUsk)h&eQG!(eq}>`nhq3ud|_qbt}{Byq--(m z`04VYXeBIqULFH0YKpW-(~4#;w%+LQzBv9~a%3gh#1Ft6ZG()so|jMzW>gx- zl`>Mec5^q@Eu_u$)=Mi{qAAs|+zMB!B9W%A`JTi;3blYx_!VZiJZ#OF2889uDY<3o>nFAmDL&m^4<77mAAA!CGCHKW7kUiJp zofGPcCf<(9WS2neJPIY>|S0s}v(%aP%+WnvQLAEgyb(#|Z zzvA7I7-cv-o)}dZRj9xqr3a>z6;@1R#9{e!NiQc5Z_qW8QCB}le{0A#248QSA!bp) zeVPj`oU-_P!h0mzuNi<7E~{2%v)y}of(~k%{>k6xvB9?a?og|+N7BMa3s|#-V0- zut4vm_$xy|@RCnlVdOnDahsP2jy)h-xfY;;DPPY{3tf3N0RMIrOjIFx(Dra87@5^N zX(_)6VY8rhg=TU2QDHk9kOFr3hnv(Q{9-Os7zE$5zv!UzuH_*l3w2VCD2_}>y?>o^ z+Jt{ie(gk)u8*NrYVw^}*!MZduQT4+flp|NT<;}+*y6z^7s(gDl@C<)Z;nVH#x{sg z+p+kb>%}~I9t5~BF1GKGQ3iD+}&-l(_8WAeTI_}N&oFV)IvChQ@77FGxLAH@CS!R`h^0I5{!<^j8MH0BRGz2Cp1*xwl#( z|AS&Hn_Pv%q0K+83nh>mlacjC)iLVZ5f07VMQrQ6$7Xf`moJ$><4xpi<*L{3@dj%v&rOAVK#%>-3BkHdlS7yjh!?z`99e5CiVAzP;K@quS5VZ7(AQI>-E{nj5D19DZq z*XpSz=iA$LH_kc_gJ<}fK$Mu^rC^$S`VmJU!%`15l;!7$sq@yKUe&q`@54)%**eC# z$=v%d?0mBQcEU;3(0CTJn@Usb+VCcVWbx95+K`Rl7Zn2lXWqe_!abI_K4r|*`k~P1 zm?#0qX&0~XRZCUBJ7r-ya_6T{jKkqMdfi64`HsF#gvRGfDq0{*pc~f4f)>N3n zv#5Sp`2J(q#VPe`MR)%!7Oj-j^78UkZZz6~PopBTX<*mXxSSh8tJ=I~qYm0$gPi)4 z^J}6OXXT_cjzNLeToqNN3@Ad7I(IT2RVg&D#Rh%#jfy@1JNNe^$MF#t+JC!yfj$7((H5jEpKP zNs7Jcm;!aw(%(GP{IS^M?j-7~Cw(5ud!=%B$P?o)IVv5AkrH-?aKq4_I765B4XBi? zX}!h~^S%}DV5~g-c>mr{R=Cj1hmAK`H>R!DiMiy#=lkjrc;?lGSY}Z2ZiXd{zb2;w zJ!AUy%=(ci&;?V0`nwodRGAD+2U$)P3E0eSR?sICbGs#3f=1ORQikCv=FGi0;yGF$ z&WjCn+`?gVlyyq8P?2KV^xzLXU6DQ2&bkS~wUsLu3PHslWV<2@dNi3z^7vmFX?D)g zlC|cI_%hy%B$Gl%Am0{(llkq^92H6Odc(Zs1)uu~8zjW0wOZRLCyHC?OdgX$TXAF4 z>DUkrpgyqvHStGMi!H#-iC+$IBg>Zh_Y^)4|L?50?$)+nyQof`qgMjHOe&Bc{R+e_-YEWOXlo z-rqBIrez)*)xkn^f0U!s&y8>8{9|NF5{Ef7Feq(+Ff|1^Qh8Nylt8s--{XCFSjsv#!`)OeOr|0imJW&LtiH)xk*D(hm-N zy|(zY6wS#BNt0A0YZ2L=-PfiZ2HA}1r%P)dU-2)Yu1u*>;as&;d3PSBF+gtNr8#na zDB`yA?h8KWSARyC8@zBvz1V7wu;;Ay+JC}ILb}hSNV9*ftkAmx3OF~n=f6MnVO`w} z4GbEC;i<+>F4jCX{K+xiVL0n%C1f<$wl<#L@1}G0us%LJqs$C_LS`7iQ7@*(>m>Ul zUjtLd9r#%zucd1~HX-G?0N<(d__wg+@vY>ehj19l6?bg#iK|+&rjSRZm?HE!SUo#x z`#Mu80%CL;;|tKuPzIm9JBx_M3M_}J=b?msedvBeU|~~bx-S1m_HZ80;1|Ihys^?5 zR)&QvbX6Trd+!hV;WNDH3NdKtCq^tMbU_bhDDdo4ZH6veu~z~HqDe4wDGD^!k9%e! zjr{OS8rxs9b_qB(r|g+{KI9vy-L{OjoyWzkG|_Fzf^$sqv4jK6=x3Q^{c2kTk!mR6 zS{qI0W2Vx*&o#9m`FbHjtV40aS`d?|V^6vk>q`24MPegv3RQ+&`u)xIZRsSwpn7s0 zW5L=^7g8H)*8D^}M71*;JKZSdb9&$p9!EUg<+nt@*7pQPiR&^PU@K9#edr<0K#X{1 zEG8h^B-BExMcd;#@n?{%rBq9vT=I`GnL~4_mcc-a9X74{{0V&9IWq07x|y42-p9=n z`hDhhO^{^1R5`G^;<%@>LVY;ir@aT&>F&Luhz#nHiy9H>ksI^Um- z`F%)(LAV=0~`h8Mdi^VT|q6#&N-B^ZpEOGe&3LqPb9L=u7p0Ipu2=V+h6O8R_ZLdPIpx< z&f^jRbU5vHF_uAC5<6cPTn21e*)ALOT`vJ!Gd0HgbyxqOi0r&3*p<*G?-g!jD+zfV z3l!+&NLgAC*yOt)4HaKTHCJDgv|jkzeLS+7`MQi86WNM<@rUc^3JD!xPYMx6XeUG`3l%=EFU{Cv*NOsp+sd1##sp znXbHWa?ANv;c4R0h-QHPYD1Q3>B`=vj2$eyAlm@V<|{xn$8*blKNwsQbv@ z_=C2g{9oz=44i-qsoFR-w$r3-2dDh6cB#MNgVz%j_7&a7dF{3L< z$l6G9VtQJZ2!y@Kqbh3R%4Wqh%gG`;xKsAxQ-1A*1&Z9( zPAo!COlC0?V%eV_#P@R7AI$d`5k8kp^QwEtwsMU+FruyF!%HY%O{Op6oKLp(LaIIn zdI+}j2@&<_cw^u{x)G6-M;RN7X{IEk)#Xoo^u8*67z{ex%J=?yjgatN#>jqbwCJSF zNTl<9TXCZw9_@&enZARi^=R)e+Sa|~J^be|RWqf2koMwIfb>aCZ4nGCedv_utn%Wn zGxX}{C7e4ovN#EOlJ={P&XD*q7c7^yy~2{TJ?71UBOKZrj+eL_$r?B+6)>#rZh z8fAFxPc%*0_h5yAiOMpQ?)s?xIaLn-NGV3uGnU26(3bsLFQCNxqgl+Yfyb`JFaCYy8B}jB(r30d0Ut#|n&g-m7@xzwFU5s|Wq-yG#hVawJ#2FoX0<~SovCBFMVmhC z=E~`*oB66~LCA{(QplKl2we|I;o=>L-vw6J$$8aJYUK_medKs+`I3JaI`J`#J+_)C z^YiNMI#ZHfC-9i0P9sKAsr9GFu#?(!Tv~x$jKxQ#&{>BdDU#x}7SoUID{^+ahA=qR z&0IOD0oRsv1=kl29G> z=_K$}H{>1{t1z>Ddp@ozz)*0%#hgrs$bcB(G+`sSNO=}+UxO;E0pmydYOdXg$=(Vm z&}zWTxPItIfXQA^m;L?&3L}Zj5T@t;3+hd8)!5}OncT$>{7Yuv#?P_R8B)T7YUgi{ zPt#3;nZw0hvB(RP#Kayn()IVNlgt$tdcOryTr>6tD)Di2 zE*#(cFW$b<1J7wXZq}N%{gwNsnT%8ahpV>=YqM>-hTBqTDPG*&-5pACFYZv>-MzTG zdvSO7;!Yqq!QI{UzwYPV`Hp`tIg*{^nsd&XHEY(wPr||`Aq^I&ww0OG-7l><`KXnS zd;PSG%^>(hr&GdBr8^ir%hS{bhnunccj%CXuA}h-?$Ggy?{2s*7%!1ZB{p$$@m5G8 z$2L8SV5ly56It={wP#1Iyyvl4oaV<|;P^Us;0W#V)tN`7%E1^aLFtaK$fjjbo$ z{Fbtq9ZNDZCpoJralc{GJ~4d3V)`K91HC!%???BUne3?wV~G0iPq@Khb&7Q($R;v2 z!s*i9RJxXM*!w#AdJB=G!^8`Q{M4G3xY#Co{Z(_&N95;0;zK^_nd+mpDL9JDv&Eo9 z^BaaFGN%tZZj&Sv(t9f71HE2f>{GSGTy4;WA}=U2MJd6_g`d>8-+mHWijsQw>KKcp zKf%>#t$uQ^Szc!`RoJ;vSbX4OC>BlX$z-w~m_LsAYEu^y1yjtwO0~X;j6H}yFmHlS zZpnafN*7<%Z0sDt^58|&1{j}5)-7xJ@Kv$qda#@D4TBc1#j#>1h%}o>V}Y7fpt{(8 zQa7`@Ci06`y5Y+cjwyrS7HimuLI*qt%IaTR7pG?P5tHsBtFGqA3ooUQUVT;V2=tuK z(@xi&7x)^2LR=9Bv4WRVh$1o@IF7@?(>Z)iDC9ezt7`F?{Vc~(ygn@ebb#8mI~?cm zB2%Sx=YtHKT(vnEMnd$yC)ENwztpt*Oc!^`s;iEliiPbAmI&zT@BXcd zT)B?lspPbG5kjbdrT6Lp8dJN~q!v!~v5C3cZu!Yl_wM9D4)50AtXY?E!nFqB&c5<#ymipuHRk`VHIW?lY7bhXUFKf~;TjTljTd5UY*eq!rRTp+tb^22Glr9jVha+eZ(n(DNllb#CIj1d)6QEGTzbA> zNVZg1N+hop5A*J^P=2xCHDtG~vDS;LDz0bUU6gAp>@KSiPDT7X-0=DlIBiFmx}|vk^2Ekm;G9W2xK%@*%v+C`5=Ys# z1&cFOWox%wMS=%d^1J^*Gcvn3nq9bxt1* zc1(k8)7_K#G$UqjxEWsAQZeLZ{%nP}Aqwg~ii+KVG~)}}01FKS1*TSru=Hd|p$v@2 z2Vu}}xU>kaYVmiRf>AKvP)tUk&PO0aL?Xm9nadk(vFx|)Orwpkc&R}e9@58XEQ{RM ze3`fEsteUiI+(7E@$ngFJ6E5nC7~Cm+r5BNla%}R`IFyYbBuG*E3mpauHS!UOWZR|kb3qe)t=(vv9a_okWQIu=`D+CgCK&5jsjNOqniB%XWh zi7J`|yRSg>u*nD|tDvdcg>LXpb`hVWXdvSkXM%v9+}YmZy-+O9+S&R5G!mQ?XPI=_ zMFo$f`U&A|w7D9eq=G43U)gJ0K9xg>z2hUzYMVfe2kL(xxI#g0?+#Al zY*UsxD1Wo4tP_r({*54PZUO{{;;l11&!V$cJnAUe#n4ZbmAhB^H#VOyN}1A^vg*b7 z$cv5`X!i+s67&gp5N(i+#T6=q4oG|S#>48PE0!FRNGS;|Ed9;Yc?BbiIKlR4+}&^E zEj;yT;tGwEyQP91IEb$2Q!R2Fnrsb^#^P}spv@zU=PVt6ETX~N>FSNK%DH2^3YI@r zKapQo)m051`~|}EB>)F;9hm0Eo?ox=o`?)mtLs8LH*ttQ&5JC?6w*yu+pX;cs)zOQ zv+Cs3y*WgueX;=|^`PQU`KGRWrYwVWj^vsg)IuyV;&|H30V6ZXHTTiDs-o#rwW>Cs z1{1~gc@6x{ro=5cF}o~Y9veKl_?t^h_^rPbSL<#*B*U`Fo%dc+TOV{>T_T{U%8VXE$n2}^SRTnhA-V(FQ z%A?R}Cs()2Aeoi>@n`|Pt)anSYGH~DVWTqV1V)X&;GXW1XkkNgd-jm54CgsveS&R(EJP1eVUD^&J2wT*uX0XxHS z0Y`J?GZhNPF4kEnlwzM@{TDl~Vep@AjAx>cmvMT!MIw*#^?qEhC7bgqU99g6lA-$_ zR1Y#4ezd9xAT)xCr;v_Bd2@3QjSIQ20ZeqJ-Rzb?iz(^D(8FR4f$6d#5=5E?Mxb3WH6vBVZ}3{1=laV)*RI*p;;*wdrB+;iEJ+VG-+U z$WT*f$$~k4%r?5=LE9tSv){p;yOngcN0$0M7r_8oC2zMzy87Jy^|kY~ywo)U$lcLX zFd}%KGXGj(@1|6^i|vpaZ1=(Oeq}3vO7xT84`lihWt=BO$mmL8vHRl*X}u=>AmkFi z(NitA>V{=%q4?KZgOxfs{p_?a8&4Hk2p&9ba!BE^^DCd^V`a0?#>CU$bb|jR6DPmw zxhb&fuxM*0v@9X`$o^n_IQ*2PLo&xq`@niIAP;Cg&A4F2Qq{6Q;iw7ts^+^m_sAOl z*xI4)#Y)ou5pNVW)d#1xZ~>;rjxSe$`iAAbdy*~8CH+koKrcP39)IhUqRjOUGvqxw z#ihwwPFv5gepkjDa)E53!Hw(PYfbfyk1Idvu7i3{!1gI zI?7=s+>W#4ymuB4DY9LOWVzggI9o$%rt1IwoRqJ;>*0mZ$!Jb#{tjzmV?(@ZMOfEx z?k0z$V%mF?{Ly`?kCesQ7xk$$qsH!7Cf(?6t9R>-ty(wei2ki_vITmqcy2&bKIcId z1wnp>(*CKUKqlS4q7cIDIi_quakYI}M1JzNG1gb;jqM8#Jwh#-VNt|=k4k_bUCj%k zBx%hO8(S&^z#gPVr;Z)@1a(J(3Qmh@K zVWl?}iB`3r%IzF8%km9^A}pdpc$k)^Pm^W$WL`egp-6%s5+*bl%tmM8zqiWHAP8sg zI_tHyHC{A()D&h4OT%K*PT$vuzKSEDlPNi)xw?2m_Yr-_ddS7C_MCdp5Dq2LI+$!! zC*drC)9&a}D?1Z1+<(VW!pLa+JHWp{+EBRD2e*|{B<=?hvIwlOuy>m)mG~G8v^vBV zs`{+6P^R9X0ZT;>@)J4hfO0~9ck3_-RvBReHTEA}8yFWWp3YXZENL=W<#SF$8&-Ui znaa093|yNUq!llgKkQSHsUc{e4ZLg{apG%6i?V+PuY~j6wl?d*_&U$xqhAQGqf_Eibx+3$E-tQEo*j`?fx$i#?jvO^6%BGX;s+hcB;yu{!$ms6IsZCTW zaD@-%Uz#^;f4IQC!o7qGD55MIEl`R!mVHh=iD_^qR=D0f5MXF4v*(%0T2b|L0mg-D zTH~yZ!D_UY31nUD1A`FhQx(2eXG}F;rSSO*bdo9QoPL#~Uz0d1HhKx8(TFI40yeUlzPlNmP!o<8NoH9b1?p5NRu%1CqE+a zaKa}7evd?8jdF8uuc$KW`N2ZqYSNV1ri>72fZis-FJnyp;^GR`s%)=N>K%tm;I%}D z2KlQ2?i;~<>noE;OwAL*f^Cp$pLy&Q2EpGV!Hq-OX>5h+c!` z^|x6^Lx<2dIMq{o<6qD5iJ;RL*)kk98q-{B%kw*uXjmGyBb!bW4<2lO?$bI@w)onBoxI;cdX4ufjOYfnr_lqK2dSur0jRR8s5Yp+F>a67ck=K{jUsX=`16Vt39nY1?NQrs(*Vt5TYvLqsUMx9~? zXPUi8WypF!uzWL8jsBb}gHIiq;WW)`nNHOAB~-&uT2pzQJ_r+U(6fd_@Vj$(*n9h5an%-#7&GLz2O57K&i zBR?%&F2w^jdy|p_@gM2s)xFQx_^qieT1pwHni{HaR?zzK=4f84_S1m;^I|C?N7$(W z$)p=mRPY>$n0h*ZaDI|;(V@o*G%7V^Kn=!cJWOWM_!`SxSW3Edi|(jNo5RErzuN!y z@D!x~&*Iab@jPoH|G&7U=yjpl+c=?RuN|qfn5Rb4n4h-Dw(G6i)j5f1)C~l7b4nb} zrP9q&@-=jv;aM(lX5Xt0R4<*BFppdy!>D5pk;~>o{uCMyq~G~Ji7adET)*+O?;+-y zmqr$hYbO!&uEjQZ@eb1AO6^_*=>HdrKTjadF(*s)GgUggJkCcV03}qT)uGVEd}R>y zj!O8-aV<+PZXj{5L^yZf8usbZ=|0zIZiH*aJ<7a|EH!bor{R$jOJMVZmP?QvItdV> zAIn0lGP}Zt)~zkrt6k&`9@z!ICtAy_vOQrLm5HvBm^|p}^rlwI!?JX%bS$%GL+|r3 zk19m)xcj0FmCDyGM^UBxOOV#0FmzqWfp5(C#p33I1S*%Y7K~lBttjC$M$-C%E>21N z&vvlDOsA}HetT?sx1yC$+sVz*^HjC!5htP9K(w?%9^8=J!tXtLDVxz!m>@QpRW7|? z*8_>AW4Ew8?(L1Wnxjcry}&i)wB9vm5-oIC=^tc0!`iJ9tF#I}pe*h2wdAPL7Y7dY=zmyF)0)R^X<7dJ3cBG(yLnm&=Qj z3+F*Nw_VvOT#m&P4M%3{8(9yV689I3VzK@4RVEU_-u`xHpq$Z+Ef=2~HF)8#dw~D4 zV*etCJLA}s^*^p`W?)+_&!~??%6pWJJF#1TbAMkv9Bq0=W2dSscM)7COCL%w>j26D z!u6{UZX8&=wJvrF6j81qvM9Dj72 zP_lxoYOOw2Aa+=I7i>hMkgEK&rd_)lo-apN5bXMF&3*b!m17_&J=AvSoVe^sVwvbj zRXS=dC7({uQ7~0ErEB|6vq|@QfXh~trYL@(ky5R=$#mn4Q(YyyH@h-`>J4i8)ZLi| zu%6qCQZX(%SsMMj)nWS> zBCWMDcWT|Gp+5;#?9W$fIURzb0c#ae_0dw=orU2zQf`Nx(5AWdzJ|x4wAzc$NDbUQ z-hAHJ%MQ%hu;bHXDIX)Q+%FW&sg(E<>b#m)b#yys<*XQiP)72&yx`;gLxZk4b>AI# zW2=&VrPFjh-$p`8+4M6F0w$u>DT?}AG56)}uI$I*AV0Q%#plk9q(ZCW%8mxA(SI7= zwU3gMNU!~K=88+{wkaS7fEBrn00$i*p?Gc3_ZegTN(2P{HuqTSWWAa`Pppey6d27C z!#qC5veC^`aMLy%C?<>5c!s#!BupJd)tW{Gg9S=)8}h|i2pQzge{>tWXm@xKv?ukMExLVM zxVf5kv=XoTY(bpFKU20(;d$mU4!5E($l*k|_GcE55?H7s?o(T`SLG?bqdybx+`Des z&hgvZeo{C|>05nqyV=0D=oA4gNaDMhy(57DU+j$xqC6Cs;z$&hke83iT#8Si7B=wm z%1=g`UKmSx)KRT9J=6bQSZ8qZ=C|^8(8F4(v;5bFyKa9tDEGTHUSL<3060k*f@o`jyr>~Bqhz~J5)SWF{xhS$?mD^K~^?2&+kuXuF2GyfK>WT4(Dbje3FmY3B z9x$>!lGRHmSsN|QCRW?}(4t3|eC8Mzne>^P`EF|(6zzR17N)GVTz`jyxm+$BAM@PD zw#1-Irj1E5Yz~!LUPU;veMgU<#nrjX5DI5TSYhD+2xC^G!7T1Bi@~BXz14BwLfRJz z!E!%e>hZ)#!Zd1Mjj@O=3sfu}UEuIKI2?wM%3dq53P~!^&+;OZG>VSPz4?&%x$Os0 zs4>=F;rS6ao5VwGCv9@wY5W%r+!%wI=?SL^l$}@RiG>hran4J zJ!@}AWXx!-bv_R_|HT&#hq+#4?xufKPEnuj=58#T&6}%X=Tc8Bd~fR0XU*V3@hgMD3S+`F0UhJ#%TIYTVx&;>X7pEhX$>)BCTOf2l|1B;7TmX?+-r^`Wp zJ?jT7(a%<^&a(C_XLaqBl_>wgSL3L#-UT`SFxM_j-PQuiDHzk;?(}7|76Ucxi0X-_ zpterOQdBw?Y8h`dY?&UD|qs?jN?t7-0w1+kiHxdklxQ{0V_7bB~J72NOcW=ojdaiULusJ zy`FCNgX=TW(ufJaxmP7GMrU^GVtml+8m2}tc&~BhPCu0=fP|8WuZ{SRLLj)Vu8(5h z+v7kQ*zRb*oZWa8kp z`{qUZ&$(-6mwn`}AZC=mS&^z%H^L$W z!dUkDC`{|@uGu`hy2qk2K#yCtLg9GOwIiua@sQG<(?{p3HP4t7dlm|zt|dA2s>*W;ot|&l`;!`laGS{TJh+h9`We_!a({VX24pviJZ_Ih`Onp0 zOJmla#)p=1~#!;5Slw=)F-NYk@X_`0HTgGAi_s~;HZqypo-zd+N3 z$LID7TM{ka9~$n>fu>E+dvdf?kU`sBZ2EiIuSt?(%t;yRrr7^RI(7Q`ZH#8pU?a&O ztng1i;bBRHXW_wun{-dXIx#;RR+56K)$YLjtLNu)@5anzzd}`+Z;-wNvzd3~pMYcJ zK^=QmX19LUlnf8Z`TR7$m|$nE59#JuGa0;m)9+VOxXv2uBw`dAD!|iqhG!{mC45?3 zbUCHT_EmTT+8Z#xXAbgNt zg0lKVB~z~GY)aASu%8F+rv*B~np|sLsbd1ib}$@7KXi-$eww zw9}OX3=sAmD1%S9Y}@@3saTb@!hO7|~q(R9PwRg*6cOA{$jNe`EYdRrcGvRa=aJJZe#o)0r>euu|#o;M|OpvXafD9H@~_dGygA$7By6xprZCW8)? zfdpbjCQ>^iNP2rkFG1KN(4Ts2`v(Vu0g0yXjJh4?anN-kUMns3vn2|`5Sp{;7CE0X zwNatFNDWCNbwaoRFYP5;P~elJ-TRhMlWHL|V|tQ;5+aL3JU%6e-{@M-Gdkz7vBA?n zXEO#e#=E%g8Q}>Jt#~vbFPS{fjA?%Sev0mTV(V}{O2L8mATm7hVAY)MjA>)Hy@x9B zTDLK?vHy|^`1hKP2?}k8TyJNr_)zeW7<{^Y7LK%CPd`Jwzvhu;EsCs?{k261ptajy zy~#phx>`LQ50@P?1w$rDE(XYdvyIlLB6=gx#)D6N%Qfw!(JuCKZW?DE2qMbmqT|BV5rmHRNVDHi;oCJi)I^ zzQ4OTK6-pU<>?U&24W7(J37hmWx!ceO{kp^e{~o zl#Bv_l1iZfc+cl{@kgaxl{z~A`Tl&S(NgUc+!BW8OuhdphL91VR2Ih0=!tXBMLU=7 zxUK~sQLkgE?U|yeNUT8KQZ~!tG0~WIUaud-=p-c|bTU+M^JBj9teAcP83wy{#CCXz z-^J@&RWRG+;whgn7*7N6{j7jSAtjbw;M+>u=HMv|TN^%$#o9ma@12X#=r9q)lxHjw zf`8BcK{WLr#_D8uazkpuz%$Tec;Cn_G+UAw00yMp8C_|tC(d{KpBy7g_<}f*))k60 zm?`jZq^=?*FYoS@bO{BagSIfKQ{^<(R-N3s0|JA0B@B6xQC|~*;!{A_QhZiYN zCA2RL5aK}lY;$p)4Rcu3X8FTelc7a+anh9?DVdGfcK&X0@NKpO_y*!{8ymSsi@6e& zatv5hirM)=AKi|p@vXW2?ugo0H=k<*v2ya0G*7JKMAb-Mrceijh^b0%Nt&dI(S~Vf zv-LbG?>1F3$Kd|il1y6VNspfMpA*kYtmbMAywnw2hDkh_No{m{;FKS8n>|_V{H5`N z{E~%^Z01G1vxIF~;sPI~`8nB1^z-&ULN`0J)lABF&qW+)bKs5?+>O+!{Dq{qd-+m(kgq3*f33W}lt>}?<(m~zB_jOKKz3fwL(SV`opbh{okhhdC8Ad{#um1O5~ znW|Y;vKlGL$#5NYuSe;UVSeZs-ikwwpqIl0sResQ7W696)M?DrSzb2`>X-_bHVBz3QS(<-o1KCD|rPan0Jk8-^8WR-CfS+Ku7_N)i ze((IFVXIX8p+$-;f{_~&DDeI3=l4&WHyjTaySI*jFxg=JzI?0aBisH7;e|3oh!?l+ zcIYbgnXetvvk4V&F5bVkpPbokRgiM_4zs_%oY9IYr}s`6x{m15u_nYIkP5FgjMhoT z`>k|(Q{UX)qV31h%@#+M3PVgp6Lb<^bhL++V_>lTd2u>hS-KFNhjfTVLxN8D>oPPZwj3So5RO1?&NE7;x?? zW?Z;PCq@=?@^m^L+2=FTWrQ^~_6WhcGIAl0&s;uciN{8)X{5rJB;lu<|s-?d*F4PByhnI7!xPl`DmzR&b z9kTxFe}Enl`l?_)`Lq8p=?y?)1;`8QM0kM0OtYynspp=I(WrK2ZAyoGXA}1ltK@EM zwbj6(?LBt=PjYH3WGdj={rpZ==V+?FE``Q`yz%+l&cP9DWR(C^@&2Upv2ymi%N?mu z{KIG+B`CAD8+Ez$rg^%h4+p17OZJ-KxPe`$;iyYUW4`3o!dey?O6*)Ud89ga@vITa zRb$p}f2x;!WrXh!{c-SAjg0*$JO02P0>7lYy8xWLTfWC_JSUDN%MPQ2pBFS0#03V| zrAl97An?GvTl9-Bf(8%0q0l`J8lz@f6)KOC$mu`XFOn937{bVC$PRv8S|NX#Qkjf* zu$8)a44uQ>1z|pB^(Ta~ROmv@DXv=Eee$|FONqS=O^K(dAnCJM_kS4k2<8%LTf1gF z7Oc1)MLSn7L75kK8;jwMTzfdfZKA6ss&()PA=RcDA@HAlqCiUn`I{+nbME=gq?=O+XH)>=Fu zjS8(exJg@%_$;-&rUOrzE-jwQcc!pb@eO9EcO{T!w?2U`tgvYhba6YziE*pmSHU5D zX?OegFqG$|xtvhEif_NxCbbL(<)%nl$#ih*Pa2)`_-ulwr@>V65wYDpS?YAU zhb+#s%flJU)Ase4w6rvq@%6DWX)RRGILZ@tcJ|$|6abT}71U+1-|F|hSrkL#ULIRs z#<8`vU0LlTRL9qf1-ce_&|;1rImM(#bG0s6D51R8w~XqXRSj-C(gnn|K^Y5(vo3D< zEPOZ_zr)eT<0kFCAvMvNCulQ8P9l1dJdv=67w(&#!EV&YwlKs`)%+UpBZrSNvhYg{ z6;Xow!Q zV!^w#3XQsOn)AbwKM#ctTXPA*Jg~NItwWsZDso-wbg?R5hO1QfKCbUJrE88nf47Z7 z)vA+E2pkZTBJ2XaIQVt%O?2HIn%%kM$UQHk)Jc!*iy+m_xBSQ$FAz5b9h>ri;VhUv~XAM?PgvX;X4Hcn#cdX(*ZqfZ@#2g8>d|R_|iA2%7TWC zG9Ei>1Dy$H(NrRwA1$29 z=S-s%&<&_{T@~0zo-B||!V&uc`IJg&k02rP#ydQLk}t7=z<7{0I&U0$hIO|;^gKF` z6_bF~p$>m+L5IZL0Itwxs0-5Jd0y1*nckoZx!nQy$EiE z3v8#ec#sxz;6l<|a!Ed>mtwga7e2XX_-i}I=GETd@8@hyHGj`k^^x9rdPaPm=;8j5 z8pS1?{;WFASK;w!V;G+dr6=zvR9X61DTct6$vH#SZmGO*78=}lFw)~#H})BYBwV7i zLRnY7saasx6}IoJ1wtxj{`1QKoi5&kW^dc+mqp$tmXE8XLh6ZlV`(9GCpuFpW#(P> z<^w;DmeKOhH<|9I2!+;c9?4zfL)H5A{GMe`+VwocUNIZhHoBfsfoJMUQXKz$vXx5@ zefgACZj`fXaD0ZloKAGLBPBV&qEV_wYV}3R$_dTe>oM$*9)r1h=G#i)sWn>xMnW{g zdo~8QYcv{|!#LM5V@rw~*`4h0wm+fSGhbq?jg>m=HVZ-Lju~} zeCd3_9~%YKg7uX=_y=4B^`-nL=-N_Ko1l(S{_?JH&q0FAo@pG0?U@Ixg+(UG&jUs* zC|%eVq=Gk`8&Ax#bLnk^S2u6|j(;>qP3P2PS<7;c4y_NqBfj8dKK#6Doo zN@%Qdtk8p5S(tqz;9eN9(yNN9$=#vB^~##x@~%NmJIcx*34@GNTbFr39qpfFw?&4u@-P=flaE1>?$4)e zy&Q>Z%d8~(-8PistjJG8ifEo`2)1^&!bgV;p=@ky+}r}s$j}1iUmh-#p3A)ClX5it zhl$U5-3i;;009$IGpoLpmCVnu-_4|bfx6Hjc^%l5L$iFBt;_$tHv7W)HylX1)$1K* z>z;7X*OFsT#|&_iR`cRM@lo!-FYR4G+<`gGgc=b>MpL8N>J$s7gB=dr3Gy>c5YO+&uVITqAUXG3w-wkVna4(i#yVN4bzR1NhHL8QQ_~UiXwpXcY%B9(KnGW z#0}_%AMc=Nw`wWodw!`~%@G}&yykYh#ZbGOD6obEb&M~hF(i#MU3ZNHD|8+(n{%oW zaygv8Fjz5m46#%rEJZb}6DrVIPUU-x*~nOq{dG2Nao_$t=Fw!hR(Y;e{Px*#l(Qsy zV1#3Q+I+#P@9@bKC=Ed8+^bqo(F- zO{ai2;wm-9ItxMhKIeOBJ{5z(OWp{GL9b+&VPGV|8?LXRDjdW zxR5Nj|Hl(WEXU=y@#~NGPVC(wyzQ<&2A;yUv6os)Hv+dIw6CB2xh5BE*XZkMkm;5m?srVoP@2!M;&hT<3$}27Hxp8C^ zLQ=}ceV%(`lI|R>QmaFaT4Pm(cV2JDjnSPg;SY`wjRq>6z;9Wq8_EuN&-YP9pUu6?!RvLAlvS2;6Bj*&VZj-4Tx-dfd@60z!sb~nOYg#lBZ-qis ztkzOXkY!oEz^4?C)VG)?S8<~4_cO?X=^>PxUhT|K7vIu4 z|HpVKn>n0gnMX~nBlp!FgUG6V^RR#w?ii#H+yubp{w?8C;SN*Pq> z5|zvplm_jcrYv>cCpS5NK*ATi+Igfj7hIbG2raCpi~_r>UpRNGe<14s7x#a-6|x8s zLKf>-d0}q%rQ+I&Wk^yJ$5(cF(?s(99X2bE_8_sg{H1L)5(J(8P)p%?QJl8aOY$3AH_RhgJxzc_0tv(Z4BIgIK5gTKw4#O86}z0l~K9|5dt392mBC<^WCRhh!nT{(n&-1R4Ut&63y<9sx>e1 z-iKhLi2}>|QN%`n_nF_N`1ZHO|39!9`FT&_Y4yo$7L6BYepLL8ue6aJg%ZF`|1TZ- z4-?%e?4UeRS$y?IV}JXB!vkdu=8lTt?AlyJ4)2!C&SW4t^Zu{)fl}8@WigRpFN!QH ztc2}dfW&yiMT48Cs1U2Uf`CVTqcxWn$NL;~NOcvzY`bI~6DIlZAU7nMFtPiSpZ^{{ z#3Qjl26Wn?LNYby#mAiDyg*N-yB0ibVhyw|pM+#cZxm!mzMQnQ1fNm4-Sme6V0?|! z1T@g(9V&j|iutY)ayO2RbHwUu@QUS#1}G5nKmPN#DaTec@!z6~7jH&tJ{4YXT$RYC zP6JZKRhLe~6`FLx>p?LX|4Fq;WKVsY>icJ6Udhf5s2Lp?W_`B_JqI+{&$R^q!=5%` zQ2gRVY0e_)rE(8F;CWp9N64M|RnkF22Wm|mvX`oGHs=p{h@NB;F!cpwoU$eKhgUt2r2TBdqN`k@H+B6=uc84DYG`)spH zgxEN#iCKXQ@&JaUxn?r}dvzm`+X>SotxW}ErsnHh7Wc9eK21?6U0fFH(8%j70(#xv zDr=a{lVvXm5n5HCOK@No)V(<5Vf+;Xz^&p7VOE(lt*AC@`Rfqr=BGYe!O>eaAV(1!six`bC&b3U9ZftqFFD` z5EN*M?rk0m_jq#N{drC6j<8ESieu@5`73>|(Wh#|q?~jBRIRhTBkt;O?3rB&T<$FY zRqjb1xgC@aeZyOinbZ3=i7S2N71?1COFQ!Q6g(9=+**RNPqIICv1ar27BaCP ztxKbr=6P|JCD_`|(B~ot1s>Skx6u9}GAT-c!i~u;vZFm4iccC5C=eeOE+9p6_`$s( zwlvHpWu5xjb9~J^SmqFQ8h|MAy$kjWL6Ps1@x+zvtV0V*N1x)XhqUyv^$l=%D$my| zV&L^kTk1|&FkSVA^Z+k6x)F1}1`JV4%>K>IFD49pLIIkOC0hJ3cc>pLR@@MvyxC9F zF-7GWnQ|0Qgd^$vMaw7cuT~6Mq!#)kYxPZeAJF@U^8l=5`W%4W1py*ToH#I}AihzU z4Ylz`11>1144?M2JyA$aA3eS?F2~=WYYpnyk5`Ya{6j7$dwEJYZD+0HTSvJGO#S5H zg!o0?nCY_=s&pfB3c%ue)2qyX^Sh$^F8_c}--t^{z0bsXeSNudj-6b&<$UycDUEuc zGsk1*8%vDE#7xZp0@0Zd!j{l#Ee59Vk|~7VauglT)*hAu+36qju`o8h&t{9C$9F|PTVcY=!gZPEM}fPI~%15`UzOze>viqZ_bI5V)5@K?Ep=9HRZ5YeRNz89H=IE z7YW9wn1BEq^}A}#mujHPuKR_nab7RdC$(ng5RGp|rnaT@&^5>ZtT|3w{A|w|KVn*8 z9Z17H@ly>NG%GzkJfrwtnbI`V3%`Dx3(MiM%l0SYFJ=jcTC`{xs#*v3J+l-f$D zP-TkRo$k>VP4dd6&%&nB;#VL1IZPjYE)=n47Kw_bchRe-~>t}Kbu@hmMhw}w{cr4FID&?Efs|>i2kTc3z zXgtq0JNVPC#jkcT_itZ`|A$clWw=jX%#K;^Keew$5QXh?kof)-X$;!wO@Kr`Kv)TJ zKpS~MeH#7&CLI+>dV}*iJk)36qn`mq{YS`J#}{R}^05Gn$wuOjmggKayV}?RTM#Ez zI{IzZQSPPSWNUNpUV>Bf1^fH2t3B#1KQxmkEWQJlxqd`dME@%sUVKQ{>ZraVoK@qu zxWA)U(I{2S>=yi(OpIrS7a$beh~wg(w|_W$r6l3|1k3GbX+=>bN<5;#=6kg$mKYo7 zSev!Z?`Ns}u$OD{;>25LBqfu=LEg}~d3`v68C}6MQ5uDLVRzj>+#g#vA^odZ4L!a< zw!j))pl|SW`|?^oRVoJpAWcmiTmMUNYNY$0ePMv~3l(Y~}rl@i8eF z*T^*BMn%zCGh%k%FRPx;&h>~6ud=FQMm)W7!jBVIkHbxOSy$UQ(vAw)1CsxJ2 zRsvJ-V{9&66WG>tJ7o<`3Z#;a{LI~gmaM$?#PRBC+d8`^bUbbydv5$&y2t|j zfw?igTPwT8<2oL}cpCA{m)+^h%OAYFlr!4^kq7LASZePFkX3HXr-zq2ILi5){n;Y8 z79V&l{-kCvISZ%CA6?&C7d;OczQnAW-t|AFWhd_ogyN5u|xx$hyh zLKcjiD|{;Y{oIGSrUuc@7f|_k@m2Kly#kRGsajeW<-~lxWC%JBE!QXgCdrI?BfrQleoH`mhN z4y>oT648Y(b$2xS_9|Af0}lD?ejOQ)o_{<(0ACqPN2NHsj}{=+pg$H;a{{MSMsN39 zC4ex71TlK=+CF&Ucvv;!4Ucy!rh@oOpM^G1IUseKWNl2`n;*+asu?p~@4MvxvdiEF zHaC7ag%N{7w6Nw(KQ-O2bWt|4H%tn5`YBUFw3bJ;0QixLm5 zeYSrk5F8c$tJ2Y3(O5Ru8WwW5(tmcqAADCyw$#>kjeol03nwfb@XHYcK>1ijLam-v*Vrt7#SS`OSy~!Kw-g-)3H%>tKv)|rj#JFe#>f+2PF{TNm2j2_)t#_d6~l+m z!PIh3cE|1WT!ni>&#K`4&#K6k294w|!}sI6g+o$=s)gjK;srXn&(_FAhh!?|yN9nlE ziEut4eM#2MQy+@eG}++WDE>gn*0NuKC39COx^(bsU@}1*`QlDcuqM-o?u@ znZoQZqvf~M17zX!m@nAB+Ib=CgQTVjAK|TZ$bV_TVTmmY zs<5wLpR6!HuDu@t#jf%mW@rg8oM~$c_~FO+<4Fm5Z8ohk6SQb4xVPb3Y8A}Qi$^aW z(S3iSdU{lPlIW_&#=)Vf4*jn4bZ}UiqP^lA1;<;xwf7=hDxJZKp0u1iSmYuEFB|!@ zaP#`=YP)9}X=gP16YBO~XI1IrX~zo}?UjziIMJ)G`9A^$!m)jdVgNszgHrJV2@}aR z?b3$Ej{sU6-Wmi8OXpi#Ocnosc=ap*W&GdS?>F%-cyvhYVdtrz<3^bCK+3h;wMymD zF$W64>AIZp z0Xym9$o(Ehw#^W<7l>y(s=qt;vq5x7c%X|u(l#FJkI_i6W1Teb+hB4#i%#hVX*Ig$c&FQBs;3tj8wDQ zQsiz=nDn$GHHh;p$p&K>;ObY4D99k==8q0jT%O)7o02m;8|VY^ga}#*^?Ex`LUHz6 zjJBV>rT11jQU=@;v+gTqIdLi z#851utu1-n|7+~hu@whQ6uw)?xcrRXe`8mqJ@vcq+J=OsS~-=jb(9T^hX}XSv=Ksw z{Z!!*XowRWo^r4b{5BCDpQXIC$nG0sHP{3bFdqK79+qee$1G$H(^${eNzQU5NvK@lM^m7S*Zle3wfA>90n^uG zfGbwEug29SS`YH6v(w6B)8?3Sd=Y-Pk1EJaPcl_2xu6q=g&!DaPpmHcM|H4qfIW|kuJ)%nT);BWjn43(pjTYBi{_W$QA+unE7cvNf{UlG}2mO*@piu! z(a~x1tYS(7-AcXch><8dW`DgUt~km5YNUE?t2F+64+5^7*Lw_7OO9{oQ6xC+NxRwZ zSk!nrBe#YV|8`J;evkQ(hj^e`PUxW{?c!j?)6~=LbPoO!FXq-bJ~rYiaCoyjlt|ri zJ*#Yy1<9re$3-s;QhdjrYSZ6_ntoSp6=T>XH{tF#SmTe3H_renHIdD` z6zy^r@QNZCskn7UO->3U5rG}pHjwcrBL!W@6Y#Lh`Dg?*zOpX5Ms|dS@LT#`=9&Z5m7!h)6u+f511ev@EFtX?mIwEu0D(FJo)kL`d%CV&B{)~ zCk%niIa^*sMW++>X7MKq0;ZrB-3MF_Wi30?KYhCLpIZH7wK{1|d!teD5!kti#|uNF z@$~svB~zoyZb^3w(sT6Nlb;%j4h}nRH0(ID#PhgehL@zNe~>_0Li|G&R`e6mOGO?( z+Y;GiM7#nG|g9scnN5j4Ff{*O_T_l7>FrD%o(FVZCW@mkv#C<5>oeH z@Z?%QJzb9z8KK-=Q<8BErs(&Dq9B zV)azbhH|tNAJk97>Ntl)(moW|letwB|2UUgW{BKJbQ=9jOX;3xn}d;`OahU!JvWV?FB{i=VTO8`5F%R&`-oUJS4qvLTkKEx z0-|qm-d3pg;_SJ;iz4%cig?A1Q3|v-wq5-F^QoeS$yaF;;vYiV_zZgDBct+Vg8aRh zL}AM36g0!Vh2MIYvQzrk>VLI4e$6(Wnd}xupSRIjmqIbeJv8e#G`L`-=2an+&um_t zCp?-&DK@=@I*eG?>~3P55H}_y#o_OU*#L-o^J(n1Tv17%D8Vc#e4lO5%o_HlqADOl z`)Ee}iWSKh;LUp1E{*I2F3-4gY3vG;Mvt8jM2{elxm%#zT2UBw%lr&gTgxxNSFyIAEZ*$!80zXnX`Bdc)1 z57Ou{yN8CVm--p@*|=mTKV~-1>Oh_%-Z!%KI&TB>%BFLz=L1mfeeFSuZxW?IpIfTd zII10~>|_7A^BDa09)93xRL&*Kj(a%4U~Dau#4<(nlbJ0~|G{r^w`Y0mcNiq)Pj}Dj z6;Wz+Vm*q|8;c{H{Whi0@&%?VgsL*xicvM` zTg)c=|C)FPhHX{FqsVBtBNmm#mqymkPA8xGwgK?7q{q;aY6GlHcla?Z5$+EaQ8&pD z#%%|TeS9TnnnIn!{`P`p@Fzq;?aTxrPn>lU{l6o5_RCPd(bHdOF|ZBvyeihwylh4X z^fo7R^fkL%r^_2(YnEZ*Kl9U-$7bakO+X&uW`BbMZmC`S$kh@WkuLX-G%AoW`Rn92 zFT9uKiPm$aiCnf?mwV&Vkcmtn=`&(S5JMt2erk)?>!jzBhteX-s!+E3wVa!Uj9>Rt zo9n}??4eUrr^5>v^Brl`JIA5tWnwi;xl-N;>U_MZ9EM$M_Aa!F#JT-x)R0i3K_HnBmU3~cU3B>pH6%igN%8^c!^Dah zO+o+aJ_OhS2YA>0T37ghSeC^N__8ZNLFkI>=gLx}!Vw!z=Tc-jyA7^3G1NE^PO@~X z^i%7@VGljufBmc|bak``GAq_Qt8JWFgv|ukcBQgT^09|&FNv!~lB*R&xq3LL7{@rbDr zik{LzWbfQyS90Ku56`BNJjNcv2+%E$gr<2xg5q$`@cqUIDPDiaJese(3vss<+4U!nLPQSw!_Rp_h*GH(1#_~N zEWGsAWg?^bGt#2vTX`0fuvwUcejY*5^v}_`pwVE4kH**1mK)E)KvCuSdt(#Fbuy*4 zl>VV{MvVC@!U1^v<;u}`5zti}iuXmfRq0a0HFbr0u-T{PV-t(g}r9H#*s*-#Nyv79ZZc z2)YPgd0#>Nr+4X*M-{WVXWLz^N*E&uZalYs+00qgZukNHD01mVFd#SmUM$O~dSB_~ zb&u3(NosD|-|jZX{+&({;%Yq0wkhJSrZ(10H20mVwY2f*SwHJZJ08VbOu3vX8d_q@ z!s-(RJs`_m1ftZq-Nhc<8O95FhQB`C6nh|H)yqoPgPO5L@i4sAz`(PA3`V`47yQ## z^zO_r{hKYY!fnMEK3<~a&Se)in9!MIwF@VgHj`o2Eq7i-XcTSF^(~zE)sndh2bsUkU*ZNZe!~iVzYw+S;_M5iC zUgzxz)GnrIwE|fFiJ-b+jtp^7I)qN4OzMa#$T7yE z5k0$gof;?tA-tob)1t%-1BgV;do2!}S#YivQYQ_GqI|~#rHNk`yU;kD38UudXci&L zn$)xj*%(#CC7la))mmAEDC%qQ#ccCLHdnZ&2b!PaH}R*%g%SMCZ)6KXi!4H8R{i=- zhw9npCiL-bK{L`X)R(lEAxMExFzo80fBO;PW#}A;(`a zf{TeXuCr-&*abIG(-!a7y-#`Q&Ajay$JSd_zf#e=+W!V}Mz!||ArYeF2$Vx;sdK1f z0%Qw)B5@Fo@I~lOd!Q5mE0Ma&K}wnWwrf6k$mWRBoD_oTY^Iakcjks^3|r@chg32P|dzm2}j?^h>VVeNb^4A{?f7 zS3VP)teGCzmx)~2sG6PAR;Ll5uWfl&hez^qdj5?dSe`)gAwx@pwW%IG?u1fW&S3dc zARXaw3Qa*Pf-TOe>gqH1pZD+Hr;jwnVuXS1=dzDRORlU`rB`EgrW41P+WgF!DD-ZP zqiw|)sV41>u~e1A*g_Fcw^wTjb5?|N0m^8-ubgjIJYS6>-~M=iDslOi`=?e+9#c@7 zx_+;FuDV_sh<%bG&9h3n)8ZCM-p4ynZ@L9BV1Q*VEv@~Jq6RL_$A^QnQnTT>s3#np z$!wmb9^^mw*H+A@-F;!R0$ABivJK2I7LF_?Oi$PSdH)@nhM(qhg)sf~JSw!g3=f}T zjNd7pZXSS!Jmx8vr^|c4@~P!B(8HUWafaWYVEC9i-*dp@*LP3hzXV3!%*I!%Lzo0= zm_jLkx^h(SX3$Hn6HC$oo&MRlEhgqI7ike4I(qCG)T9|@jUal-;D-7)!>s-!mwJdx zYVRl&vt$lOZmy98^r8bA3bCe5qHa^^=4)qC40mzrPv?blG<3>0+c75@03vC708gMA zDLyXAK%Q-Do3o|BoL=$v0+g=FQ8;W)caEI>7>8`9TKEHc;G@M>Ru6uO@3aL3hHbaO znb?wwoFpW#6t!?X4T?3R&7UC*=ZapwQnilJIozDc<;%s^<6*0}xA6M0`eM7L1C_xBf)WfZu&5&zbg zErGEt=~Ddnv<6r1AuiKCZHD5E)dxa2m4h~(nkXJ$Cq&^LMyc`5Ku&hI{$L8r(uhDF zPB;0hA}iesr@-vh1KO5oG@zC*`CN^WMQ6QN4Hi5nBe8Vc>|nPVwQe~93Dq{ZmRk+0 zaaI{6I2Xa4xBtBLfgOmBr!i&nyH~0y2|*%zfR{M!c78w76V9Lpk-7ly=49C z$XUV8sReWbzmsXFi)gmD3@MsnFE4zs2;6B207EsON~p>lvMg^@h8C*G>DT7W^pifo zQf|RsX`Eh1T*4JUp(TJqPL3b+RN7*nGTXndkM=s@CfyUybZ!mV8aFuef0iuthl(Q( z*GY*ZE7;EE*tXlZukm5TG)@C;Y*)ie19AXy3WS#D#}>DnHnuT)JDp%7b*T zyO(Q^aOrc%7AKSpHft1{!}VD@j%W)Z5RBE|P_tBLBm$zD94Qf6TH&`wPtKkwlfMy# z)#HyoPBHMc!9q-v#}4CcJt`FH22XXoTrs@ii{O|}5k7h_xk<$QsNxaCO6KeXr9450 zE2Cp=3OLztYhAq4$X0t)aer~JzU9IHHY@OLEcMA$^@_Zb^9`txRo$%4VCF}ztv~{Q zi4)4dB@F!nK0t$u`mh)&OGNKj|4BBP5~a~qcY5M=^hada^&U%tz)8Qe7#^f_f5+R6 zAsg)lcYmeZj~zi*v%smRaQ>7pyNHE?|5CX0uJJ)eL{*o)Oh)W-g6bQeH`i{Z?(Xe; zS}HuZxFk`hwO1J+R%I92CC0aM>q$FxU3^&nJTb9noOox>teFmBs!HIJSSk`-ec=4S z%c|c=oWRT$08yK_-%O$}AXM*Fm1U&baJyQyx8KX(FKd|m&5zscGi^HDjN8>#AFR_| znY8&ew)a-{9YjX4MeY>8@#u|m&!~Xn=Q}u^%Fpir?;jlLgh}-wCjz?ldr5l`;Lu_Z ztH|W_+zk|J?)T?7@%W~hR~xNI9hEfx^}415I+A99qMVvLqbkB_g^ja&keteYIJVz2 z&I9KpXxk2xJ)E*%-{h9dXQ4ND|j}1|N z*v+z|{%Th0RhF44#*FMonGVjyCTracr6gW-*+bLJZ;VI*_}-iJ?L{Wg_4X!*4PBp+ zu)ObIf#bB^o!7mL8uc3j^mU;p?295iu;sevTF2uzkC()*Xk$Nqu3906*n2=zCo$*; zYMj~Ui#IA)5$YWG=LuB!pjo2(K0clZRktVw+pl{(Hk@prbzd?r7tV+tS!79+S4GPh zBK!bnjkX$E9X!Tgx5u+U*7_+^iZMSr9}_OW#qn!^7viZixalq3=KJs}OezekJSTi- zgCVigND;D`HBm^Ye%RWCT#}7Np-OK%SddJX%jK{o=E+0E_Y`r6taSNX6`C&m|~g}6(~>(x41T#j#$;nbyu!V`x$cPZOv_dFuXS?#Nv zLo+d9QBLM0GU#@l0y%xEm+e}7rG?yVz;*Nt{Ll5L2 zHt6B)es;f*VL8fZ3P-wHoWfd$bpL*5_)13rjkd5}LXXPZO3gZn+3HA2+l^S{{gVr} z3Avyj+tO3kn+}EIK?>%!9Z}i^9xa_aGZND%$Q+}KZ0sph8c0SW78u$FkFz7*Q`abL zoHN+49yHwcn-$V%a%@`s%^WFbKq<6?aoJ8^7N2ZCnM^p%KoM%$YBcm0v}>JR%MvWF z`1j}!BHl*R(4#ZEVBWn+A{n2x&B~0^SNkxB!_lNpbsfg;FuS85is=Ge9?AFya7#Lb=H1?)+vAQOB`T7x=y$ zREWNd6ci7>2IR=uIDyxE;O7S6U8cEl16^)gSNG-yi z8sRSCPSy*im!QC4M`jT|zd0`^&a%t>Mt&F4`)4g~hxKv=4~Bj2^js-G#yKXFRHN4# zmVGAJa<#pyJ!R+@b+tcZf`eNtXm-%%A7w^MiBEZF}%7SzbrokgDO6!h+RU>5Mk>&0Q9Up?`sgt!=c!Y>OSVt!3E4Im?3$p2D6u7LCtv^OLS^ zx$fM=B6V*z|TdA?MC`sJUm|Bsr@bMP81=NFX*;bWj z+<7WUBE?s(50pKyGh2EQ>Z+>l9Pd7so&{7;5OotTHtdu$lmZO5WWGntFCwyN>{Ke- z{$_~TX9pf`zRQm0`-&ncpp>66O_O2xQKrdaq-V#SEB6vh@Cxt1h>iV?&n5v;;P(zM z-<&$!!DRlFpQVrI zyHjD#m$Wz72;6iOp|vX;JGt4orEfXZ+B`%FP^v}iN{BOjE=3l*bEKgy7G9OJWnY5H z!F3tgA)`O|@m(zCrBXkvAb{|~zvQ_d07>Y)f_`;1NMgzl`*#DGo+ibnQ;A%B!9H3E zJ$l9Laf~&cj_;SqDA(>>zAQgU7sL-|g}yojgZb0}@Z6V=2zcg&S{q^mS3MI)-Zak7 z4uln6-B#S$L}F;Wckc7k_V^3F9}%b>ww;|^hi6pO3|&|?{Hm*;t7RT)fSnx@A3N2T zJ^x^0;L??9U;VP$oyxw$FD{VCtd`RpSo+`RQMFx63uS}Fxbw>U*O|)2fCu5eP|S#G zJAn>L$wn407miW>)gz4C&K(_vgh#9KFp4KEvr@6B84KPs_S` zdUFNhh-#$@vSBFrn#@^&k@PvFA3PCC1DFYeP!2H?`Mv%0MFIv7Lpkb5d-`QDv?|e=@4D_r zYQ$TyU-dZlnY1Wv_CNE5d-+1iJc}O~;3w@s13=k9aDM}nX1%w~EOR-Dvt2E@)ebF6 zj=U?0vg7!+PN~W{mUs6g(i0SdlDizCa6c!D{zn2Y`<)y2HEDaeZ@lnKli@*A;M(nm zTH$~4IFlc31VCl=r5TF+E;8h6GoOExl6Xxq8@Ps5T*ax^YFJK)7sn;+GhSX^mVDWq zF97*sF(;&XOhz><&>55W;?T*_22w=l_i`9%z}YxPWc~VQtWRG9M4b$n12V)p~8`N4rTI^RX|hA)liAoO=0_ zrS>Z4N?-7_x|$25y>TJj^wQVdPxy^HOx!{?3{nxFAr}`HebX#ixqZTDCx$*LxI;dE zye+xno<^6CQ?lGj#KVP+Q(sdFNB_Kx(eia(*SIFnEt7PL(=7L1vGU{#?QdELEXvs9 z<~#rCQZd3&aQL$N`?G7X1fJl^=*=99)7-S=+zY>|V4~aRp`Piv9cjz{)=ou!q*Om# zm05D)JsIB@v7WlI+lu^ECaH>1hrNi6K6N4iA572aH+cU36BU{i_zfrgdDdC1-nty@ zgLD0?7St0&H!d&`pOU_7-!ceK#0n9OgXJx!-kH$l{fp$Ndn4Y~Vrz>Blk zuRnwfi6kG9!PAMr74EXDO|)S^LNrBW*#uJFFV8c!xcq>ayk=~le1`@zkcwsggTm!d za>gb*LlhEzW{ZgEKa3IV=H_|ORT({cen@cD|9kR&-L`pN$QybqD6!FK`L=u;Bs-eK zl}25ld689n!%}It1D5BH;hyP(mFAfu%HE(WvirNQF^4aJxYY~feBu6Qd&V>@{%gN| zeiLUVfAkF>;|zy_Bu+G3ZEY@xHz2xB$`bFs{SutSG#9Qo2yMov3Y)O}7CF#YIOEq| z?~T(59V~Ji4$v6K^XK98ei?O@7_tNuOeA1$q;+Bc-6sy3P5z$!!^!mZ-oGQ0W@!4W zzQO8*EKc9+CAPsuI%Oh!j!-1*T>^-isD*YVqB|% zRh<;B78|Wr;}Z)OR$^1F*H1Z>(~oUv02M0ycFcqWxA%9i%jsfEE^Vc(>Jkm3 z8#Rag-YiPz_1qy~9!kT5^X)o$B^H-xxvsHr*jr5&NnX@EAGMF0=GRo{Iro9#)$-3HmehR4PX<9-Q4#g7T z(t?f+#aj|2DY;WQX_=Jb55oZAOcoA^kVU%o#4pNFe?}Oam=xrM81?uiqFjFc$b659 zL8J629d9p@C`~)6M0*c8fI{P{vT^ead*oJ|5^@ChN9J(zt(U4JDCOLy?R1QD`Hx4y zCJVpP2FhDIdGd_9FI;YS<}1SWyUs&gB-v%g70#Wme~Uj5qw^^D@V0N$Bbla_p$q4U zcxoNW|DiVly~&_qAJ&=v9umn&YsAkGsiu?2o5}@ja0(nv#L9ZsSlPIZuP$3wmEX<& z+OXNHBbvm;;A2<8@ykwcRVCu<`$yqO!l<);dR;&y0KkzTW3jlf1C^sr3cB+ggBD0g z5_6sQFvxtWoMAmYc58aqYHGeJFMClj`kSpg;1|LIa^9Sezn4dk?3~plPFOk~nwW(2 z7~XYDUv_Ediv%vFJ)>N@V**pTEsNN3?ft}siKaE@Eh?YxZK-^XSTUQ&Hnf0hLf=6d z)Z@#?SM*wI6(S;bWh$I{IYqU!iO5Jxn%KlfvdpchSf$sTA=1gz&askkro;nk>5v3~ zA=cRfnA}tiX4wAzxIak$LLgz`;o&VwsU0y!sbXQs@+v^+JeyW2M&JSHFRcm?B+{z@rke*w9wgk1)mYtj)4gsZ@ zl877b1Ez)al;b%MQ+S0l*3-4{2q}h0fZtvZ{o1Qbj^ll=-8NUEU>dva4%eR-jtcDA z)F}CUaYKDH4{n`WdRL@g3LWp4I+8v$kFlYh5>%h=W%q<{o5v5zq#Rq^xm&E|nV@-5}@ zmrKXlkDG+?bxE-dD|vuHW(Do~k>GrDV^FL|R%T1v?Y%G8P@IN`|9ny%$M;$QY*s|UOzEsRhYVO50pO5C z7~ZTj20^->T_#`fLU`>JtTF2D@Pm5i@RtT6hd+U3mu#0ON*!g%(Cr}I%HMcXrw3wL z#=}p?i!ES6udK(SsrpVmT}~z2Z-#D^+VV>K_oZpCVg*U+t)3YdiMsv-FEQWYWh7II z3y;koQXc-26BYHEm9blr&O>iyv;1pr=ji_++?!z7)szBd4YLleOw^L*kuu$Q=J%(x zpRM6Sf%3#6#P`Z>(H6x^LRL|Xc!NFo3BlC%aN4km)$#712*K7zAU6V$+&;~@kNU6L zWw!)uMi_54U6J_Tl~&MgSPRY}YEvzn#Bc(+LeC^tiCg|!*CeBpJL;Kp+_qmF+#lQO ze{v)nE?Lf|ggr9;zR@OGy+nlpoxCyGT(09f_s`?+tyCvI5u3^|*_V}-)$L@kam}8B zZ!a`24lblI26#|Yr*)N*Tf{LEk(d=u4YRd8@c zhIeKQ7#Z}|JFjU1I9U1d4?Fw2;jJ)ukKv^}f8D9k--nf8qRgb97wX%mpZ@+$3~ht+ zupEX_SA08!7bEL;Qop*(CfIevM;DS!IS!SnqFx$*y*{xPjv~t#nLk1#FRP$O-2fyf z!v4Dh2Zbh*VHRg+5ZPxkDyqpAA3C2jApkzYq2FK7*ECO?w{X69ZDqNAt?EJ_C!4Rn z;y(=A4HkSXp zM|tk*BB%(bv7B3r<(v^JdCR5{!yoAt)vHQ1a&nfw8qn_>HI6c3~g6q{rpHy!7LFPyaqSt)&R=(znFXeK`24l39`3hHy+;G=!Az--Ya zixKJ`JvyXXDZOm~O=)(&$v#G)eZlen>$mq90&G9+C^a$eS-NzWb%rFnmkw^3!SF~Y)S7_Fa~~$? z4EY4evr6UlHWIIc;+o858G))+BtV=1BAy!jo+M@0@EWXj2mv#;gM*>lLFZebC)ZN9 zxPZnE&;@?~Sx=!WvI%v;8T0_mI1m6b1GuIsBT(21;^%FeVRmT!2Qyt(?sGda4J^Ya z*|ydMMtY>f5rhvTgk|uXb?@yTL*#E)uJ$Pm+N63V{&(}0RoB(!9gIlY#j2Erko^Py z&kI@|`g*5#csld*SITLro=1@fAr|5F&e7a-<~uz~8oi!J;6ObVD#aW9rytIltT#Pe zwo5RiiM%dqW4MA=x>cYMqq~{>y6@r6!tCl;dxK9AY@*j7N}vjv&Yy-I&ZUxNH3X#! zdh2R2f0cW1J8WhG`z=82HeI95BbltfQpC4#N0bmUn^-$23`3|A;zQ!=;ysY6H+?ia z3LfU#EmR-5o?rF%H%r^jk@&9n_{`Q!TObMvXGRsVE&vwrI9$mjd?HgoQ)daImpOiXNwKdm%M zkJnS^QyEE;8pem~syE=TDNCBq4(OgNizhv@ejMt$i=(*45o6h(&ife~yP2o66*_(1 zA}mTi=XmI8pY??1%Sndw-=|K$otIZEzHJ$XUQFsqcB^H|eEX!l^4c4ud*A%BZU%t3 z>5|yk@YQrpOzjHS?ZDId4S|u3=}|FSrC_D}uQq3Oeyu0v^?{F{XhcvKzl~&TJs3SO zw;Qeu#Y6pAIe!n#g;(PYMfKC1-|ClaxwI&K@1YD!ZVPyVq9lowX<467q`wlXh)onf zxDW6{9xqf!-?fcvUGGWnq?#Ah;i=w&Mwn#kMbgW@HA~hA8nVESNbSB;NY%YpJJfOq|9=d^K ze)BHD4?klm7JGkDaPJp1DX^K?tb`CnnH(a2${3^Ak!NLlME~dQq;v%{1E!iCc&`mt zV_f(DUXB6sn2;ILHy&+q% zKP_3N>^tK?U9Ht<8mPU_1&AS>&|d_p=Dv=)s{|Yz8_*aue;}ew28g}{Y9S-MlBIx;!O>-eeM$rPDF<_f`#lqR6ZrtJ%>3fJ*`_%H3%7}(k`5)DOlnZQhAe^E zQpe2Nmc(j+h&6m)p`7MW)j+S@V#(dh=YFQfi_mV2L*Fn;!xko`yZo6JWmKl*Gqialf(& zL>itX#OxP3L9nZG9*x%G8r!Eml8rYYhJ+i5`y}jN**xfDd&G|r`-dqNu?C?hpl3% zA4#N@M_ZzmtN8u>`+-(J!_g=%(X&1280aBCi(mA9LNzP$-6iVoIC^vQtGm6)?}0X>zt3TP zcTKfdVyWCnS?fs$Ng??c_1VDHnztM(AKyzx3vGG|FLH)gt$q&@euoP+`$(=k+nPiP zj)|QKynEMg)sdX>kT%M+5xP@wyNxV$qx|o)ai%`V7DvlJ2%8=H1{aOx5hxB}fjFjc zcavLF`T0<@bH>+MWc~cEEH&bs<-+%q*vujd>I<3_jM(E)oD_03oPS_nU-!vWrl*hE znw+L79}1bgV$RZA*VT=h5FnKVF$S z-Iox+JZ3oB{Np}_7t$G%>&7JnbWk1&Fz#8zBaZ92i(R&=tLsM)((Gy z?EQgXUj5ZGEOrerB?d`*pv^44JO6!=3tNeeDi>+@`~|Eo4b7ztfzw2Ig+T8jK26h} zm(Ylam?#6c#1}qrQyx^Y>QFf`#$`sJOONz(;12#RaSA z@9;>j$P>-;zC{9p0_u-&G-n|z?+CFrVfo!Aj7gGf>7t61BlwuB{1dQVigA``due za5OV2bguc(zDXg+`@31$S+bzDUrPDB|X#PK-ylXrOv|_Gd>t>m3%z zL%N_0F44-%8_z~Eun21s(HV@Hqkg4+Dx>jNdhWa%K-lwrSePK3>0@D0 z7p@yVG2oez*_!($^R8hm(G~Q1(3_&W)S)ZF&INliC51oL#l+OKIz}a_*X(GFqs>7#yvipeR;0Gf&{=w*#!mt zSGs#Tn@~Hn4Z}B&on4;CLbjXfGL${BmJ?zMsbvf@v1WVU4f~mJ+iaB?-(kl*SBk|fbA0u9 zE(a9^#0Td9kLvARrxs!CzP|MSth@s+ONh-r@R@lNRbcN)%6ew{ZMaS$6K0*E+nfVX zQG(<158L2BTZ-kyWWNyGRb}5uK*~%<_E`2Ao5i%aS~bKW{!py%`yCdWl} z<=Zso2$O#R0KgB<6@nK;3hS2*ewNR1J!jy z=Pz$txkUWj%&y{WXtG_IQ%sbi2SJl|HrENWnr% z=H)@MYgIcM71FmNR%Q&qlaE#q|Kp#OPC4d);+ham`DE~%Yv~TpPU?;KX3phC8Cz8# ze$tT1Bqc!3`FHkuq_#>#H!|$)Ur^Qsza*m8j5pG+5yZvP7f!kpqbx|@pq5YmY}{ME zGZC14PQknEocb}9?5*y}mVAt;q`Nm<)a;KR(9D{=-%R6Mp1MR;*dMf)%mZv8!u&ro z>9v>xS}hZ2>pAW?$})~p$vCNWo?oW^tFbhFB{G6ptd95`FZ4}FlBoZRjGyW z23p3K&48z&!ton`(1bH26+>H=En)=OPjpSk%V}k-LbgZ7;NAYD!=~}Twi}IYYEkec zh{oL1bvw&!fSHHt{d*+{M+{|<+*ATZ)*}Uu>*idii$w;5c1#>i@RW#y@>P_I&~X)pbPyufi967JGm+a^$I)h zW0EZP7W>5XNZqdxl@Qh`rJfv1zfRBSaFe$cKKT|taEA%rQbn_hvRn?RK+j!8e?+6o z`wTrrd=q?(dkT{Uu8j_8G2TBL{0~9=wI~dTN(=!k14N~xF6yOPW?8Lv zO8rNJFCU~6znr&zQX&m|Yaz{SHg#@-LcAJXc^E76wGBHs94&RM&#*s?&2Qiv^~B0Z zJyZ86K}zQFZIPqoY{UKbDmS;Gdm1>0#c`_I;;j2FrCdd3weUckq;{i5k7tk#3xkio zOfq@~^Bx&+TPfSaGslj#FVsZ#f~4hh{FZEO-voxe(XiJKeRIoQ5B@q5>B803oI73} zi|BP=Mkl1Fz{%D^P-w_Oe1Qm8TnmPFceTjJoPvP7Bde4Zv zwrzu@eC_|n(yWUC{QZ-{yeGy%W_u6Ypccs4@Tg~zsl0CmDe$Gh<@jHy&HLBydH!mO zSo8TPW&N2SH9K4>M2qD|Gr63vP(XdoVh?d_{B3KUv&+RN=e3 z-ht_t=~9)C2g$|T-=tDJOcd92VY(ha5J`p3J-o*<_ckilJVl;?9GIq#^;k>Mo<|+k zT*HYrd+j#QV_tb*RLiySpTlK&?Qbt0MV#RW0aHR6s{cPIObN8N{}^;t|H>_j-(Gi^ zTr3PcxBC?$r@r70rlr~201}8?;KhI9r2qb8HqtT|^^Mgbde# z?R)&;-03VvS}q8S)jC(k{8wyK23@76&qvbTJRsFRC-S4^o*@e zmd2Y6NV17;R4b7v#qF%ZxzPZ;+5O8?NVEMBt8q9*rS9>4MIWtd&U@Nk4|OBvx4ocS{1376}~nTV*wefI-x2O#Djo=-ec zTk&E0^WETWe=9>jdF@eAtMHZcO(T_jS4jpTc(El)D1tBg-}LYgHT7eJ+-`n^>;zs; zc4PF9JO;z%j}9Ov3nLG6!Wl&QAJ~YMD)=6EK;<+267G87`3Kx)z6uvGnQLK$XCWXb z1~f!GS5?!_xVX53H&M7Oc`ekJfEm>+q)~=9y6}e+&OfTv|NI-vM>ea(p-_hLFblTwu{G_U2q8g2aA$&r;4)~i;O_3h-Q5#3xVr^+26qYW z?jB%p*Fgrjo%4RO?p>E(!|LhTy{l`NK2>$pi<645AZ8!SZ_b3woHxAHAGKI*9A@xg zX<=ak;Jnj5SEGufNVQmM!E0veMAXQ~LzUWoil6JR_J?^|Xd zOnAYohL;y3gd=oOqfxH`XmOs4_BdEJC(H*GXhJ@I#UC~yrcb(jaJ<|wUsVU)N?^Cv zl+EHJ-rxFkH5r9IMh1jok%0H)4v0cH?OQ@Nfck$E9iaq3_}|au7cwrRtaZbdVRcYh zvwK!p|ItE&t=``JSR;MF>neYM?P(&(7Qdmk3Jhd!!%o+yfvfp+z=`=Qxj(?U0{D=^ zCUeDt51bN@?|>s;;|a6*x90ah-}qS$U(v|B>nmi`O~xu0^RLwx9(nhAa$vJJY;t;f zI?*qh_p(qnqic3n1weGdeK7DfKdk?mZ@VtIHy<}0_z7+eh`7=5{c<26;vQ)gB)+H=%ps2z?Ds8V2XaV}4M|_(Tm&F}+RX&i& z#&zHdam$^Xd-s~TCk1ROU)s$#31!8yC*@81b82k8W@9xpFQpaA^Tq?Ghl4Jt*vI3) zcH+kwJRz3-R=NWl$H4-HmX_99;)4##uy$1Wo#!;A4ubXQdQ`E`m)=D7nHpf2?*AD z>WfI|AdLaPW;LG@)&fRg{D%Oqs}g`8d>GlFH=UH)7(UlG7LWUko#F^3b3J)pY(c&) zs9=xW>L`$;Rt!zp(DZ6t4tfY1w!=TMF=TRTjACA}3vFr9vj2P{D}{XhY2P#MjahND zeDH3IoT`IE+FJSw#W?@&n&V|)JJxSJ;n>G0vM(e4cI(U&aEefHXi0WEpc&i?J{pk|9%DC7yo>;CDnDDi_xHTlB0Hgnil9`+#+H`cSqs$iNjVPVz^tsSr&AFTfcRTiO>Buazvx6lvF`iR zKa7oD>DzdKK%mF*Te|xC#l6ixf4--srEO@gOtb-rTSm;fx35D(9+@y7bR zr4Dh|@Wco*888(&2}`J}t7B7DRlQFYfoWK?J|}7O`S@ANwN{EB3lBQ<4n!~5EsGI& z@$j4}1S@5xrs!Mme#Nlt23i82?;SCZt#}1y$yhjGGfGv3$IM_>HQF?{PhacTT6q%4 zon&zJEw*H;=Z^_wPxTI12`=WHpa1R_lUWcm3QDOXejmg0ajSum-j>nI_%b(qrc~+e z!)Ke&=8O=htbH;UaXuDV!BRF#P%p}$7_-=g!i+c{M!{|3rGhjwCCL1d*ZqNyDgFKd z6MQMmxe$y(POxH|0lmF@aMR5D=oxc?HJ;jYn-R;(=jL|%!6&?`Z;bR^jPm2k($)ww z>}bYJF}2dT184lflxyE1SdDLI!IVaP5Ti-LSlI*_XVxpv+w(_x8Yrepml!D!lRYQa zosaq0-h=nca21%tecM#%K)d&ErVzc4HMiQVCx;u9!mbW|_LD+Hv%8<8J(8@;715Vt zNDp4=1z*q$v%eGSi($e7Q=s$`y%Q>kW1?usUAMx!_|m&~;GE*Z#zxGMWvYpQS#r(D zs%m zGxCUF8B@hVG764bk&&!6UZe@P{mZBhkYdh~ucNQAQkS>zCo8=rj+Q;GI)vd^l#QMr z0-Py?Hn)=JHkINR3gN(sa-{fw-jB(p0tyQs$lSfIh_C5^n5>#a)%fUV|EzhZS}S8s zqnem#x$E|7aD%0aqQeY+SF6VAXZ@Z`^(RkH`CsRXT~W++cMngJWTDKug`!GrC#)3( zCj&c|({EL7JkyPRvQEO+k3tLkCJMykt617h#tqH#KWNZkC=7`$aU30JCEyIlGC_M@ zya{|qs4&0-O1|J^i(25Te$|GPzH?p3Bw2!yk=$-Z2Aw>HZ?J!nx^U#PoJ%xX2X^=JRkXajoCz=IXlLSVpBCN%<;uUTwq+?=xojc0~1HPhWO7bd> zq%ifc=F5cn82${xGT3_cMI>nDclcP~M0&Atk6I~lZiHXJsGadV4cy|qgj<|3gb1c&y zndEEh&i;9nQ*yVga9nNxQ_~a1t~Eol+2|G>87z#(x%5MA?Z=xM9`2Qz_8nH@G(Mkt z-Z=dnCJ$rfNYQO0%7r`**m~AaF|G$+PuMwXvJHj1kggA45)t5eU3i|#91pIVV9FZm zEG*K33rGTT`1n&zr)OA3%kMTKJ0fnRI>g-va?U5~S| z8-@j+#{qxX{EsoHcU^O(XCtEF+S|{%e9URDCVBV?!qs6y)9v9>`0#x_rEMR{ z2K~q=&%4Gy<}vB4dhZ{f2R#}?G}0*MgEYd$BCMb0&+|!RAmnevjt+2^AH88X;MTri zMy8pSrp?eKjV~9tPVkaWyz9gHMoZ-d)4?F2pNJ62n6z~B_}|y}T#P7p^!4-fOJ-S) z&|Bx1^cT~$j`?!0M7~H!PPh6nC^Nz;x7DF~swJn|owLK?PIt(gX3$qGHV;#Fo(f>e zIieAq)6J`ASCm=ujCoShSTBmd=8`_^Y3|70$`8IU#;xaj9?OFFxu&oalv{81w2DUR zSwl`Q5<90mWzm~`(IlHTe7-yW_d#z}Q(MMRP8Tvyd^3>Q9KYXOGxWJyhz0)`ZbWxj z5p~4f-5}oQw5rP{B{}CGkGI+4I!N%B1@|8!hF|#KSkU3lD$fq(x8bN zj8KDgF#UnFcVnwDj!bPA{;Cq`h!tHw!jpKWWTgJ`hvO-U#%lJ|6ZY;jc3J6{16y_Q z5?Hbq%~&d~TYI?1(-qZvQp(X2eN=MJ=nTg;6!x6N91{=$8RQ{Nx#FCKxF1&t7-t1q zWp{sWax4(YcOP{W!egTk>#H~e>wZ3M^09NIaln*PF-Mp41#92C94^qwgr@3Fu2}+sC%O5ti3f(2*#$)jZFc`#)&$14r5>9XzW0JIecX_2)|>dr6HQm z>!BNXHE$V(V!h$%yG;O_VTV#DBS%?^EwsCE(as%rQsy8UUEN>@bae1;KhSTS4Mv2Q zl)WbJreA+QDE6{}w5M19EViV$mf{LOP;e7m|CNYT!c)fAM~QJFXq@%quqemQ#+IT-Dj_6YDh4udWdIn z=g3}S+}V&%ize8<2^Q_`e;L3Py0&{moM|>Hjv*w*_U7)vP_G>%^*+mJt7s@Mgu*I0 z-JQ>HYO8ig=0%~fSr&nFiS(DAt?pMVN0XRG*=t;_IiH-iAH85hPB}8p_R~8k}j` z4xwhr&aa$*%M*VGSg-t_ze_K+(+$jflS+xQQrKSDvJnAJ$X~W(lKEhR zsA^9${H=KcX?>eJ0wq$3fFkTifzs`rW19Y|YSwE(831BaH0|HL)O^KOdJs`z+S4RgO^_#6AMM z@-rM^rGYYv9PbeC&DHTn(BS-%FIPBvt8+z5dllg9|E6ZHg{ZsGwHKKmRDv?cWPl#eueA7#AR*jZaL z_tRYMxR}X_DC0_hriYGTIQ%E0#AjU=eu4hP%HNbdJTz|(5XZvxyzqxXVM^j0&n+Lw zbP0GpSaBJ&zvfQv?aE)nVDsa0tA%nPo7HAxbxDA_`*6;ydA;;=S-DGU-^rSA^7~lv z1e8M2xa9frf0mYq)hi#%easJEwk0zcvARI&&mU}k!LEPa*0(wQ>RZro8oOS6k~A3v znt;7{lp-vER}V_W6@&MqUy+pQb-8q3J*EcJ;&D15Kk-KxXcnfQLy4#fc-Gs62(N-7 zgj#Aub%G@h-`k723Qkl-48mPNn3}Ezlh)nmDmH3OH^O(W-*Nhzw=`;=u}tNTjLy%R zjV^eG!f)vDd=I2Nzc0qNIY^}fBPL*@#PG*mw@;(%BgS%`p&a{PkG()QGht!QVV`#P zsg-CDaenOD>mFcuME!;psy7X)@Y`Yk0j;H&q1M`Hx7`Tu2mVtV>5SiD!e2O+`E7S| zV`daOIEjC3&ipjf{}7qAtfu|n%9y6cNCmI%7k@tLbm}71s%s{Nc%bvu9OGg|t(kk< zHsjpNY;4uG)6;=UYVEz|klzetGn224nDL@mS=#OhrnLi&GJRmi4uMz{LA$yd?K9u? z%VidRrLMlT%l>g{37K8uU|3cshq-x)s&s{I2xvxIgEfrUmTq8O|0C*@=mnei9}!iV zy=5;0%3m$9?AJ!crig;`JdCL1BM?5BkmQP7a9Y=>6&S}& z<(;<=Ms_?K!Sn8{+K)oK&p$a8WyndOeM?rmn?4&{x z)l8FEvh^?}6U~NGlNQZ5iYW0T8aYUXkET(P=ryVXzJIU8+|^Q7uQcdI>ShCiIiHl) zq0q%7GnKhU;kzM7jzoYG$~Z9dP@Gh|ihF|$9Zaom~J=vUDrFR5nHxRfWU zoyy&=DhAo|)O|r*EB3(KCMyEvQyot4LA_$OQ=s5O+yz0!aAc<5=pnQz*--MACbgY^ z>sh5`Pph-!pCV1X!j&PzgSKe4T-sRZF{ueXXMvuou~y6r-%}bX=0J+qbGX zaG_V~xoH*wAtN~-$r1N|WstQM*dl$de7vQOw0%zd5wTQtRn99h8lO)`zKAMsEY91kYIz%3QpmfpG5{o)@6%DXK_>cza< zaJWtOvG_8&Wk}Rfp7X8lef(I-=5-UM_WZHPws*Qe)w-cp4gtTI+ny}Z8Q(w-_WWDv z8_bNQZM3xwCNfn@{QBKDt~Qy54`u8|9)CvmOs?^(8GD>e^@}RYIlp)8j2PS{M!*-V z-t=BT$@Ef0QJ!phw@Mdiy_=%<4|NZc=2mnBJ7QYimaqpETh|1R7Q~!)L^wv>JHb!c zLnLWZ3{=4^JQCbqlDdT=qZ1c)O>lR^8ZK}E~ZlKP@>S2*}S%M(3T0srk9*VOWMpYQqM(r z+#%js?C*|##R;x@-M~JqJhi+zubty%zq5dCA5mpq-@;(+2vJu1AV>GyoakLg zXgFJ{5*Jj0FQGrWPG3k;)6(7LM%hlOI$hapA+??@<1I60R#*B+M4AF0bt}KAI=lAi zBAYi-@al0fn>}g`w@Meaj>Qz0O5Wp4-H6T3&;Chj>6JWgB3i(q@hG0+&>uUXW*s~k zK6m#v*UhD2(?l_CQ9;I$EfGTkV@n*9FUK+BbJ4QqIWMPj2KszWHnowi`GeR)jhp4x z>fK8}C`MMnrT*HN(?}MJ<8rY-kYcCzs;;)807p=m3b@Fg9K&i&&>e$Kn#>)|5{OhD zTp>FD=X?&c++A|&OOT^-m^;lBXYvmSB1wC*$C0TIgHdk_IGAgzaQnDwOZ(lBL`o?3 zXC+qbCGJA5JL$0Jrbi;@njEv)EM}q^EXG#;%0yy0f4ib7zve8|oWN{JiJkO)@#Ew; z2kXKr3j=zhm$o$qPomu~H>474UZQF>#VNbzXL4`nw5sZ8On9Oo(pfUO zI7mrTKh)XEGUc0FH{RuU0|WV%Tc9 z6$T~T+o!k`svec+#%zLe`xOcR`qG&j;6xY$;B6}hcH^ZVEj(@BvAl%yl@_CKTrygF zr#%r<)+o4x91)O7H?w;}FyojFMZ4=J%F5!=r1Q-%_3HD_{;8))f*9vZ2Ie}O#%jc~ z*Zyoo57_M<*7mRxtNLY3B$i3j(j^&OvH$Xr_CJcC1j>pyh~59Ml*_jM)l6x_JChx4IWwzbiOeY2!w z0#$u|lGJyKtcKgAuC1Q9YrS#7VF!4LYOl4oA^h`~SjcpKCzVD}q6)l7w|BkkxX(-i z+F?maXaXkn6jknHneB#Zz-A47K?_J*peX z67(zIlW}SwJyePm>L49ikG{RQXG(ITC?gV&Q5T8UTcGaXQ(WKJ#9nnbkd!aIF%>hU z-YBtH4b79+T}>L(RU$^d6OX}Di3Y8$Mg5htFbYseV{P7V$bGYu=80-hqOG1{nBu+Wl4L^P1X;jOlGrHW zqchkw8n<=o95Q3p#}O;%ZgCnbOsXzvz2G1)0X{S$sRCMGNg8u9?0bo#{K&;$l0?Pj za7SDinbA95_1ZWi-nvQ9KK8ZlMvsIm!!dW4(xsqs@g`pVNfdaEXw^NMLsIarSa-}-7=5c{+SSKh}enz#J6daQCcmD>S`sY%OwspD(%m$XUo zvnj4}{x_3k2YHf`p|OT29mFHg6<}Tq)^8)7FsN1C_v6wBc^-iyMr^Xn+n}0q@15Z& zrO}KqwX?U?*}~;Z0VEGfG1V42GzI^ROPMAdP9}>OexHP(gXXW{H^Yo0zS*sf2OQZz zv-;QNX2MOWIw`JXC$h~H05oGDh8*bR(*YeF9ksW!`vqjRf^bON$!~hi*qrj7>XT3NHG4p~d6lD&1+l4G9RunfiHX}4d3&q9+81j~$mw+1jr9U( z$vGK3Sm-q{=krc#$+#PKh2K z^DdUUBXW^^k(zw8eV_+7|Ztgxl5E!o!!pKP`(c=aP}PnLp~}O6Fbkl zwdNpihhpU{`g!W>k}oyD-1jPaSD33`e4wRscI0@C@Bwcu>Ahw-hC@6_RprF-C*0*j zoQ&GmrrHSO=dzuiGzueng@h&N5~U?-N*p&k=r4>|`t;A5ber)7-mQKN+oAGBi!bAk za8qySVW8$*HdhM6puBUphfq%-M)*O{O9|jsJnR72wNyX^`)=czu)lFd>kyli19T{~ zX@{A?)Ok1coy@}~(JrWnc|6(Q>V9-2y-daTQ^O)}b2Ch<+$V@^^39?JcEnNE$pNFL~6wI|InY}&OF*+EtgLp9F`=Oq34ZtM6 z9kDt_q2HL`GZDef=SN~Q6aYkM0}QlT!Pd`g_+|vdw9qR#Rj+A=UhX}2{+OB#qgn%r zv+tPUt+)KTj=-*mj=B%kJ8ZEE(}$x^(4S(SQutZ!Wc(a)RZ-J4oZ%QBeDFkaTlG^l z_MQ@{HCS)(+0^rzo*6sfE8$g^QT7kp!Hfc|>V?uGf0{(D%5?qF#jX&Okw`a-@2?NR zo;OyC1#ngskz&RCg(gQT7nc~X#<%CIO#QMAxN$OMR)RiXmJ;)QR0t!jmc|M*c57P~ z>oapx4wV?wm_hkCM&^7WKE`maS_66*C91cUvU$;LCB|T_s|LHrmqH;~!ejeTeov=7 z*C+wHj%?*iq%23JJ+@<%Ck-F{uAd$=_*{`VDUX~SZD>m4J}w?Ib+p4&kUuy59!lN0 z5nJkR?9oQp1WJrb1Qzf0x~h$b`C8~q)Dvckl;0~8U7-y>5sT$=CJT-<3-gu~a&&u- z3npr#X|O)n@2}6MqgLkp9_Oc>SIHYoem&mey4YZVfGZS{>TYk+i4pmr5uI!DGq;A% zG$vxI*XQfDE5Yt;gCES~@#{l)`B?DT?@Y3MCjr*PdHU45^kli`_BQ-OqWfX&j$y#p z+ttFrwiWkJN9SKJnZcLXbWdt|P^~1pdewC}@-mSK)=efRbAWYEs%xufFL4p`LGY(- z7L**lZKh&4rFD}%D`%9PJyL66@wbt(nYNrc6P4Dn2UY{>pAq=Fx;KY#M1@aJ0do!4 zfuY37k~8%;&d#VnC1al4{-)XjrzZ^wpPcKg#~|ngM~)F9-_xC4*;_S@ZBA<8!8xJk@N6qJdw&iRY({qMaS5 zjzJ;E_ciAsyeglp46eT`2BgZ+lQ4a`#0rO6DTwmRB3CCc^r6x4%W^|@RDs}8P5Btn z#Xk>Z`B(IPrjrY%J=1u<7ZKtXcU009f-9=`d_khz*2P!Lx)pk>U;9B7OqN#|?v8R_ zwRLpNm+R>@YD_3yPgcT-xp5d78N16jwPy1qFe`N1h8Al~o9wsV5OUZ+gF!w_D>T9* zO&3q-&%C?@C&uf9`3_;frF_Tje8pTf9^rZV#So}-oOdY-!i4WLlch4@(uim8c=vs_ zQPu~m;)P0@kVq?ohhWw`@7_7o{z27_7aHO8oTJkU)ovz!6?#wux9NzG*U}=*iCcJT zw8U#v{Ynj1&RZgQ(ujHbRS;{zWNsX@-UbQ${^x^(4H# z#cid@GZlQ^4XtDvO;1-4W6mTwlnSj8#h7*hEsKKl-5%)8)tx0bl`OI0Lk=mc70-_v z6NG)f=2u*NtsKQV$;#v)*}DTUxG~oW?WfISX`G}tFom3e$!$Y5GM#5A@y@$w-QZ2q zsKcbbHYijyHm%+EUr8+-0VNNF=AK4skbxqvN{8g=J-}YVdOpRtU<9i91$ z7Hqy~_xah1zpI#BE4k1pdI!vi8K2M90i!lo|I+GZB(rbxSez+2n!itP#^gq-6_pO% zOT4=(UiZUK8XcI`C-RnNxM$;0XHRs;^=6VXh`L`8_OYG~Rn5{_l3OrT=Zj2EcJI2$ zGLM=ru#$T-D;)-_VrI2s@e|RCayXdLRh6+2du-QoODH3He3+kNw3Nh&uom^|{WG{N z1*Z|ElSaa*X z#P(A+T!()2bL+|hfx~>yMWzaR<5*sU)2XJBM^_G4>##|SaB$1BdGYIA7*Wue{TEEM%6aB=te<% zQwE)1dAE_~<;cRWH&EbC{F%ruK7}_;vBm}YevI3{#EyHXEJZK^t;K};N5$w%(@z}3 z5zobUC}tXI7Ii-QXR)*ksz?2?&X`59n@W@=sAtgaX;U80>&&l0Y3@6!@H!uy^2<91 zH&uSkxf03Qpbi$BLs}M&%|70{<-3`3h$gH#$Bp@JulSc@ADjW3m4v!!!+?j3iH z3-FOY#+G=hiVghvKiK~nPm*)LIl?~WcZ$DQsHxTXehD>!-thOrU(grpl;d=u=yqW* zhhAw_N4`^0#KXjDSNfj=0f2ed3Bz8tY4EhY7}Vjog!!?hUyVs@#n3L)T&VGh5E3HY zXm)2}cbliHb@$2uYH8Ah!R%t%Yew?Mnn0AgyIrrdj9N3F$2{I|gvXJ3$cL!BHs@PY zY~Ea*>3zyU3^6YTqL*GPQszqr@1UQERmzd9$xV?O)<`*gTuJStmP&Ouj3^oo*eyuj zcea-(2L+GHAwg+T)wTLRE{#&RZ+2(kFKWwlA~ZWtOa`&FXl}H+n%}7~@%FXuE_8zT z-gCXZXzlH!Pg`u|N*}KB>rK&%cegU-yn@&QE=}T0t2OwMZ z7c`EBpEw!w5Br%c1OX?|L;$I~gZ$4}jwb(v5^n|~cgvohSGIX0xQWM|%EV;02AlP5 zU4uYZ4k2p@ZGCc?!8tET?Bn9*C~6VERvZNFz6OpZXy}Q zY^;R-bfsdcpMwk0oOjF~S)FD_Htr%L7ZB48Az5`+jGJzw;uoei0bLBZwh@aN58}h8mY0m4Xv%qA^1*gVVcDErT*dw ztvh{-mn-h2U8I%*p-_p-MN24V)~*_-?*`wAfD7jigLF*Upv>*2K!4VJ1%r0uC6X^P zVl`Yn*~^^VeX@76dH-H^K6tYF7@^Vr5YDBo_a=IPnXxz2gtEz;IN$TDHka>@hZBJX zuAKtA7)WE3x{-wDVdgUenXO7$@}ajQ3#q&8wL#bPLD>sev-;w@k4OYh6On1F zQTEP)ogehg=(t>+KdO~-gtsvhuFnP9Rrn-6J`$;G_75=Sd5`%KEbec!2Ot-U#&Ylx zzj`JPoAhIqZ13zO%f_YE-y_7~e-j4K>uy}cQABT2p znRPMXOLTIe6NH1lZnnC9rdlj>6dUxkDMw|W|3+EPD?sL%-njeDZ{}I=Q``;ooQpfD zBkHw6W9Rb#rGWTbQVb>_%5}1O=3bzjFOYr_en_orFs^k?;!S@H@is6+7wlpEn}}PC` z4#$kAEA@r`M$>Qm?)Wykes~`(7q%Q3Kcs40S#d??vSXVqGPUSuf51@75kTdBFP+?V zC-}VOn?e>T_{0dY`|8{Au+ZjB{2YELzI`9pl+l0|*RmU?Mm2{801&?Xn;~xJ`YW$D zTTExZ#jLkU@r+C)c0}@R&iaQDE!HK_13gubE(~>7mPYe}7Nt|AJvQOY z$EKuI1Jr{!(k{7)k84)M(lXmVrJqlW*`DWvI>Q)Zb0+CrPT~F+`mRHmWJH7J&CpLU zoAPYK9>TN_WRd@-56{a1=#_!=MFCxtdz6;t7t!jBx1^h|$j3CGqkXCxW%d52#_c;7H?n&Y3ASUBf-g3(~&^k~M$JLZ8x&w_&y|o`B8x*S& z7}LONYL?U~LB2>#PV?d$4M>g3ydU3m{srd3p#NCq&eyGY9{hJ1aR7upDAt9gn42p5 zFCa5Cm6H>wPJ*nr_LJ#|vUqh1?0LrVxI5fm?RVcCF9SXUDu7Diu=oYA8W0cod71_# z|NG%B&?UM5XJ-zUvZZbsG}!cVxlgM#>X{p$!@pOBQ2+}4`zhe|#>*WTSWd{@=VY?d z!OeL$02(&hABZ1&p*1`nDOgo901`8i=dLgf{P{A)q?3~cRc9pHe9u7ED9BnVSe^a{ zqZ&;x>jWHcQGi0iu6!&8m3s)o+;c{oDgOuwy)N@LfS+s3Brsj609erU0D_=R?sr1W zVqNkx;&?!689f&eElB@CypBZw3$PRcY;%AtefJmNCS8TQqV0hjQU1LrdY=L%~vRfHsex*OmG zG(ZqE7m!N>z{B>y1TSLt0U%feG`A?^#LH;uTg)>u12NCs6C+4E4_T-grn2f;5F1i|0w8w+vGlJT&NT0*=}^b zvgj`x0X*V0{a>l4x1{a#qNq6LHlu~kTUA7I+Wz|BdnM|W4QP2tsA7k%XlD7o#Igi# zjFKCWs`^>->to#$fX5N+QTx~8>%sX~o*0Ay%IQVAE@zrQj&n-eatgl>z1W-5KTJj@ zdZD_dE-d9is7b1jO*rn@InCeYLy~q_PFV|4=7E2H-irPkY*-+_12|sTiWzwMylN1> z-_=guPcR|Quu>NJQV&w)s8f4A7boE6?t=B@u^#R;lzHhwRHWZ}4_MC8!Pz1KR3Rez zK-ip38xz>%CgEQpeeB^JvTj?xoA*F3G~6IZ3@wJ_JG0e&SjYU|=iX7*ESb2!-^4s| zN2_aWa{pjtC`Cqo0wCNmN?wt0a6X+xZlvye)wwoqOvmHCkU{~Z9%+EM+uxuv$LXN% znEUGPIN~xY{d#-Si|2hybG>62`0FQNXK&Hd{;$k_@AAY=$o&uS7Or03MgJyNH47`! zf1PZOe*-Rm-_7Q-A)luHt?O&$JSWNSZZ>erBTSWn*K_dra^5|SlloM4%*Np zAl{LxXvdwJex;p)-o+Or$3Wo8Pp3L00n??lmE&BX}}^hB|&Y^Bx$|8dDl`FOI2GU ztS%xS8El|vU9r8|eM!XY6+Vrt75!Mpm$^G=DEun{GO&Z9*LPc`g+P&|{53i-cz@PmQ$_QPQlRk`t4CiG1m6%FM zuX1T#b!b`Q%^832CH5)9G6VUDP_MBl|Cy)u1y@P9l%bZtn@!`eMR^YOZbq|RRmxsg z-{J=T9!3AQL{ud_Ss^@^{O@`R$$YZE^%5LnK;TNq5`LZiNBXS*xVe7u3xm=Xe*+H5 zuV-@_+fiqm2bWLz#zIqCFt*yD?f-uzMd$Q1rtN8^*c%ESK5ZTL=*+EpyTiv|7#Frg z_3W?p+Ce9})RpA!!H8H^bH&Gpk`rDPSjx3ALFQ5B*DU=o&bv*ebK8`HJVl`~!!tSa zc<1Sh`wko|LYMe~%^x)0gd|xcwv9M^<^38vu!GK-N4YbOTK%|?l2@k8xl#(T_^DU5 zBr7X+dsfC*e-p>X%xcuq$ne6ln83=4Qz!4ejSckt zae2_ZO85~Q&aP#qn_Hk3d^1UUwRIvJQ$S@$|$8No@umRWL<15Jqli9GdwNmRMz6Y9TR&k?7 z623SKM>*Ul{HZMJWn1*-BZ&Asf8ivgm7xXyR@->-cV_sqLztXSdVm$%J+rlgSm-B? zis0P%s9KvNLd~rArN?_Mu7utWK71paUgynK1pw-07#+Rywpqw(=-&_c-yriodPtMvDsWG&L{-fsMdi8SCU4rqR28 z3wYX{%zB!5W}R*MPTSaOF@_eB7T4|52;j&a9UWOyKV%J6Ny9eE9)3l>#|RSkf>{TU z(w}&~QLLG^&^0ZR9T(_Oq)b9(l!N#8gjhD}YXvX1>?ra>8}1ao9ekT?+3L9LnDcey z5J6~uzb{KqWtmB$*O#RT`(~onwmeLkxv-&GEoW-$q8``)#Pp`GA&rH7ajr87pi@BM7e?PlFv{V=} zFr5c_OiLp5zyCs57-70Wjf&lGYa&rf7jqP2GQ^&{-P>m~b5w^tPA9qk{zzP<(CBuB zd!(9rTHUofT#=lk=3qX3k4#`@p5DQpPo3iK^W2^V$DkNGEo3JDzLN~>_+I&*w{cSZ z9UEx%Jh=xGVvHqOmu@u2PmuVN-)Z^#7%V=@APlf*0Ao^`6fkrOpyW#6sGSq-C)o6B z?V2a)jIOM<#L=?BbpuvwWHGPXc8R*C8wA3Z*}QpGx$2pN-rtcb_L4i@ZQaAkEY`#v zBa+Mxmoz@3#aPXnt~V%U5{0vnLHRZ+f1h$ehP0&gTU#>B`IX=GV^%JsYrZD ze2Q}$GgpyL={~6qI|z7qYu{pa7#yErn3&o%7mgWS0Ve|Bvde~VPRm`w>@WPP+~;cl z^5~;<87fZkX+@rtzYSf}ro>sKgGn;gbIg0>Ipzj)Rc}1_T&wrP+!Q7b#tU1=8b>9`rrUAW@4sbL$JoqAqTu&R72EN-2h zx4S+OrzsURlAc+gAW#JcXa7D~1XULy)~PPe3*H<@5clExsuP&}*Q{2R!k5gB${wG-P$#6M9a=~{G1F{uf zw&>^E_SByv1TMmvglQI7fm5|c%9H{JIed*4#;%>_1BG54#~IgFu*7!{E^m6>qDg9q zbT@koXurpi;0x7>jUrQ%DwewT7fG&ZN;Vg3qnh!$T5x>>c{vwNdoFlHcR`pK%5Rhw z0eGr_p#|8615Tf|bKeTbyL;6;=b9xQLy7F;uXR{b8@m(C>za1vqz{x+Mn*xwRgT`S zdIXEwqxb~Xh`WcD)|jbJ zW<+)Q_SKH7FF~lJD&EA@$lCUeCXZ$br7HeD!tix{NNl5I!uwDV*?Z{T35?xvecPHGVP-Y&dD)|LE(;Y z(mv!H$WMJMdu=%FH)@cjAO+nE#_<~SC%2&MQ=txl4zTw&`blt+E3fQGu5W|Q72FUU zC77tR#6grknPjti4?b-SR*ZbGGtgyhM$_n1dFIewVM<#^yeWJ>3xU@i6P%FxCVga4 zu@D0KwH7^Bxy@F6^cEG{ekNGa>rglW-xS;08XxxlGc~g>+aiBxB3oaOo5F3%@Tye! zVms_v#02O>`|i}LHswky@0Cb1lau4Az)3NtQi)GS6i_v>gMT>PXoc}o2Uh){dgkMG zkmkwdCMUD0cwLO?p?|=^AQk&n?dGK2*bM$PY&nx3uO5ya=z*FoJH!~AWmf1t7^1}S zu697kzkZt!fseQagS8^#)okgjBToFq8J$m7U>}(K4IlpCr7Co{EW0~&s0xd+IwjZp z{G%IpRHAcOA>cmUivS8Z3C&5&C(zZ?2sh(wX=_VlS7>KqcA|M4t(@J*B>JyGH%D19 zuL3wEdU6*r=wu^27ALwL5e*ue7dujhn_pwPdX`pBpTKKWQnG8I{Fu#0Y8&b$uNOz^ zTHWmU8>v5ICM?zF2?gH=oNQhhIVt;SY>gdqFi&@fXoH^o}I^BPX9&Cu;-A5yP*hZSm#2yxcYRCIhc z-4S*tt&8G!5o4Ftza>x*-<7x+uZ7HK^C7cE)wAf{wH{59_vFuiR&DY5@_XfSlO?FO zNV16qyLj22DDAZ8nO82bij`-LFT5H1aQZQ-L%n79Gh)M2|IClkV(ome6a*3X&meNr zMzEOYV&%8j9bEjXK2l=T%?;rOe`e~Ad{aXlM4T>75iic5s_eGwo&2kommPdH3tk5( z!Skc0BM`Qt1tXe5UKFig?w?AW2z#LlG6U$A?B%3v33*Xe=#>Nosdc=o2y`{D<{hQP2-0A z$QNpG>X{WkYMS{1D;9c~wylT<83W*}l95jEX$}X9B$PU)p(2{~%nP)y)%yY3; zOl6F|pfsP#A&9J~F}qMgoa2du;C3J!5CVYqbw%ws72}!vY3&w=Ok@Dl_RU7iq4D@n zLq!}{F=1{cwKyzr1d;IjBs8ANPaL3VVW<4S{S2 zT2_u~J_RZwz6yjQADEx$+2P}4s}$z2t;KTe*5i3)u4lb5-c)!ds}S+x6-~^_1PSS= zrEaULZm;C6ROzxKEf(@ro65QQAxHGuByZa!w$=>^%vu~Z>{r>7!-9M5_K^S_b zSFc|EzR%}bx+dtRV?Q}fKCMjJ3k2~)qK7iQ^rK|Rp`>>{m&Et+XdA^QXEg|>y9OoA zZ#U;|PMSM=N2gh9V{;A-O z9=leFr1DXe8tUAEFe6)SAMV_cMz4%U@rjOR9x3M;7nSYDg=o(`a0r$%&itYiWW zRt_(dwZ#+1~GrwB(#A@35J@!smwF<+*E~WpqRlVZ7A8 z+@rrZ;E8T^qRI7{gd(M?d++*<4CN2rP-@k7*E9zvEY>J(i5vtTz8ng2_Wh^fDrwiz zCC#C=#Wwpx_3i!kP974`dp8W!o~NE=qV9@)N7#bkc**%MjVrJZkUd!??zmBE9_jYxkuoqF%g+SIHxsiEHRmD>t^!*Vf*qdOUsxffb{F%F5s z9L4u-G``Bb%06U7ruEA^o;Emr+{bnmXj&W(O;@V06cGkDf8I@KnV(Ydha|@D&mE$v zQW1iF1zD&#{y;L%+jfktp10avmVf!`-e{edEr_l;~- zsX7qq=U5HfZ-;CPc=(tj;Q?4+Pa7ZI3Kn4&r`^f=?v_5+~g9 zV84PofuPVijq~Ufq6UWbWLi^m#BA+N8)+^q7hgwt<5RF7D%S-Ik!$xsR>jzN-T;)O zsv`|&&zz>pHyKjuKC(|%hEM6uMQNO06EV5i=}WN>b5ju(Y10J>z`}E6IYy&1Xl|5D zBT%M3GIM4*NvLeZjGj?eUh^)eiO+eXme@O3N~Ol|5+fqDDig_cjD3|VYC*%@`Y6y8 z7oq2Qx>~3ESC6cIC**n!CA6_y6n7ZCaqS8L4Y|?t( zi3YKL`P#@=C6MbgI&Vxo!I$YRLzr>O&tZqO=b2ez3 zy~&Aznt@Ai{ks#>(_wf;OgB%pnk)5d*Y$)tp7Gd_+(Vf+eF+k-lA6Y+$7Oait~mN_ zYf*mL0w?VKW6Z2?CDl?{sL!GN2TV}1ChCP5lQTctgV+V0W<*B79hl1uLA&R^B9w5j zRYzhWRpKWp^WUagsSU65E0gCQXo=Ju^T=^R)2ERxewmZGooszcV^Ao{N z7%5?I#SL7?Q<{}4*@n-Nd`z08eEcaD)6TZpE6{i6sakf=N%o+e#c zIPQo;hvP7gbO46!?P>8jZ*?>?YsJVacPnn862~aAbq@6H zNBimR>4UWQb9HQ?4SUQh6meEJnGH-K6}wS-`U!9S7nnaZt(H878^6T2c_PmOCzA-i zFyZSS++7*vKI$v6he_H(C|#n!4!y%`+y?7S6^+EzCzY;BygTOdzD^#m>=i3Ka=5$BG;ewa4f_#))?Znt%?wt5m5VlBM3;(Lk&(!KY_P)eOvr^4gWd#x)M*Bpz;wAncMVlKTNq0Fki3$^Tk=$U=$Ol;XZS&;bd}J^VVSB zO{;LUSjIw+Z<#7ZR%!82wN-AyWDSgGGJbebJ6-JKbQ-w-QAPpLVDLz^plX(U(T*z! zR4N?!tC5X%&P?TF2{DQLtQ(WHY7FptrU}OP_#xh$;gxY0$KtCucU;)6Y4PDg>z|2t zIRma`Vpy*w;&?PmxK@hCKy%JAb?6lj9hSBbETBuuKZaZcHotbD7lZmL-?I1tFMZw5iyBMziH`&=Jq(?)V9f z_#soSpRTLWFGqCn!k|6Ld-d0g`nULS_2^5ZPme7({;&}y9s z=bIPHab~zWeZ|e?9&MTvT1LUVUG>NJrd7o%+xZ4{81-b5cnQt$z}0s$U*1vj8GGx1 zb7*vE;Kq0qWWi?R7iI1z+kOpGT7{l95WZAq&?z}*6uplP&6Ks7mDvPd3dS^#8z~mO z`9aSyMeX%Fl1F$Y#)ASAwvkB-=^s4*W(a$LTKM)1j#=5DPO^CD;n>>Xb4RQs$6e~d zkWrbF7;8H%Wb*r=9-1lTlcWvCGD}sLNNiS_OfW?+68>_)l1&RK7;Bsi=xo%z>(hzg zh4@FW^x%W;9muCbH)ST8=9l8u2<9(qFLl+~d~~0CI^=Td%p@s}${p1o&YYkJYPiT$ zBb60-PhwRSE?(YsBmZ0)JUW0q>WddA2U%ifzJ zLQbDn^3yZjV#DkXDU63!vRcdK_S1YB4cn}++*Q|G`>}1X6h(|*uCp~|Y0gNMb=rA5 z=Uc^sDnE3euZ78M`@-Rxwq6vdMzw9CGm)$^EL0OnbzX}DBUf$iC0g!Z=LoS~&!CRe z4U<@rW~nB)>bz3uB($5mUsb=EJ=;)hprJH0o6MNnj!QJ`ja7lk1aed6QyE6S8h*>6 zrfLf%2YQ!dm&s0*ME0X;d0LqaBz7F1M(3i|MKn)pd&Sb*k@1`L&sZ{B!t9TYE>!Kq zh&Q3iJr2|EY3Gf{!8<_xd=02u0;fd}fRH0rM0xHiXpQiwWl|ttiak{4sDWUT|LW;i z5$o#s+z<;gs&RAsOHX4r*8Pq|cd<{bChX=<_xQR4UWSWGRk>ekG?*T?WoI1E&j{;+ zr26beWgrs?Jd^$MHH&(9-w!|Iak&LeaZ&G%i(G{2i>ERd%LET)*b*!#`?~I}F@H9~G&_KA__JDX|Qo)em;b9dXh!A+2Cqybf2*X!2WQes>1Pkoqj?Mqt3 z0dIp{ts?>z$fMz}wj2X8_&SnUk5g$(G21a;>3Za_3~S~5;2Dt9$XBX z{K(Xw41P#_6dRbxokF6>W*d^KF)+IyF4f=M9I@@6H)P+ZeXW<8&a`RY?Uin%S%n@m zo^a~))Jo-y;Of$fudH0sLGmlG360{zoVTgA*2bAW0(yPm7vdl3qo2?>^3G7%shil2 zno=PI6b_fT##1=w-3-oX1=!M&<`J2&yyU>`Y9Zk=9i!WIh`x#1UOw9mQGvXWL1&2{ zo#y_4p_VsBj{G4l1E+bL%HT2Y&W|&|wZ-^R_hy7oa_NRn;oWKD9WChi^jD53_a4PD zFEYJl(&^^?MG5@;UGPSXaHX9XZJ>XmH$hciiMj{Lt!O9frAE%){#ZAL5f0Y6{> zy;}T`!gQgx$lO4U(S-DNC#WUaRUu2#x~CCx&0f`=K$(u`$GVMCx>A+)X12hOje`=0 zbaJa@J7LN3gL)cC?$}NY)vjXl$$%GHzMU~q!d%$-z7k49P_wOSODf#AErU;*OC#v4 z3gqMZ*GD|pNX2dJ4$y0!Ui6gG5Z#Dk3g$B*kE*QG=khf@OHlWl%8$OQ%gfEI)=M8A z(I6I)9PEIp3Gb=|&cvr-}r(gcrr@OhmUERFAt+Tt&oHugx@M!Vq zHP;9#vApW|Jo;bomKMLMG8`Nn8+&_3jUeoXX(@+*py?%yX-&x2S;aH@2@8NGyZ9&{ zu-0>|BXg#tF8%1sIx{kt%sg~9(w+Sx3H&I8;NHQ{F_%kasSuB7Y*smXiBExlD0Ny= zQZ?J`^H>k>8+(UC1RJL-b{evvsS@5bX-Cg-30lw`edkG?=h=O~$BvnLZ+*nh%KA`d zk4(+Q&3$@x#i9}P@={ajVJ?`UF;zFB<@F>b1}QbTz6!)jh7TQCGL=@8wESK2(Kz9z z)o8FKBG3qQyaF~OkFJmlnlE{r*f|JRKf)_oVvE+RNi8zFBzlFYrelm9pctE$uL{&g zdU|Hdw_%U^C>gq4VGiwfVb!T=Yc4XR!68lJs)tlBTubTdj=x?Nif!9cT0KeGC&a^gi+ z?DE&hwJMqo>Rr+naWJG-tm2xWB5E%0-i>s0tQYbMRF|@hHmk|h+-+vw z{^Vim&s|u))TBzxzL;%XxKOMA#@7XJuTe-#-)w5E#MLM6pFOaHwIC~O&BzxPJCbqs zHuQF9>z+oUBr7fF>ZX?vW2pObn{3l_EXxrB`vaAX6i9=+8OXH*b$T}2h_L5ACrz)q z-mqUg@^s9qSl;bU{u7lJG)ENC=u4EOZAJk9@d&&9RP#3-6&WUJti}Utq_8#0WnkFT z0Kc@(wn63fx9*tuUAhvMAX z%x-(*q*7o;?R9iA|(VA`dPM~BvP6=@e zVqwUMZ1&=O%c`9iX)LuD^~q@T9Uw*P(~*6P;ujn>0z2@VP{O2QNP$Q13Z*S>-0F7e zf1mih!$P^n$qrr<2P#?DWVK>YlKxu|G$iV_+rdoX!ysDja4_z8%2Ujs_h!&|QOZJE zTM)ji*%f__Q{Ru-AT%cOkL12rc{g`>8CA<3KVlrUv`a(xD6B zd)p7rHM$UK-Wid2+5b&5O@)CDKB;Bnkb8%EOFs>#qu=lY4LL9-wO&bCfVH~?jFa+if-)+Bgk4BYfxff8tF+MTK);QsK#RZ69{^rMeZxx`t7 z?HVC)(j(x}g@pJAE`HN%5p=#AMB|=AIuYdw&@v?R!8n~0L(?vhQ{9>H77dYZNj%YN z_%tuZdk+H(%cH(TC*R##va`!tD(+Zl^Lc3PQ(MC!>j%tZj|iY=9}v7bcRru>LIG@| zfh0nWFT|pfwVuDx908x$kYJw1@h<6NbBE1{;Z>pG&CE6OmW2FSk(einFBO(IFz!AA zyqTDZFF*+koGxB}@G~gubvUJk&u3?CqRZYk)E^zXtU_dL{g!ABiq1LtzzdaZqpKl{ zc0{&4mb=ZCtf_@1on`8$xYy3~WXZ$WfW~-mnzMO3j9hiVl#+SGLM-dLZWxs|H6F)U zt7vtxOkj>zQKBs1rRkFJhq}aOb!xJmfO46Wf)EamHUhGF1~a@6Wk;&L2;AxXsH4NM z&W7;Xb>u!xoa>2FP)a5$FZ!V1Se^$XerPF-fZGe}x?Q^ncf9^>%`K1nooJ4mYGk6S zCU=)_=d4;Q<}ry2La$6RFnl`>GS{fP53l8O${GT)#EePt%6fS$ z)2HsPxN!qWE``+{qq`!oM&f2;4MOHTfdR*GC7N}E9kqNj*+W8Y_^oTFN#W0>^gJV3 zfO_WpZ&SmL+V#kU3s>E6h=}zl@#D9J+sgHKOVSK4tQHy^QsNTd8_28jiud?yJ`p!_3C`$#R7Qu_$2Bvg=I98l=(6yk|&BLse9;P=>F zl4m-RNEcuu0aX22LiZb>4xWSqSU%;YLhwpDk3k)}wn{jc{R{D!($BMm$gc@-DWUDq zDMjidSKkoeqB&v0$>n&M!tg&oApsRy+CQJwYI>imD*-N>s=v7K?m}38LwC>LKL!p0 z_>bj6P(k0{wTr4+%0(^BE!hk?uoO^jh+bgiQzv0RJ0J=BOz57t;xr$#FOlR*0J!jN zagBiPm>TIOMi0YtM4MuO6o_aG$4mkd?RRSsf?LsmnUAGF+ktLukgGT$t=0#?@&<=c zB4)T~m7bq!fcF$%tqF@GN8BY`@N6SV+fCjjdmLU)fC}vb@H`$(gyO>Np`rGa0YI43 z$tn$W`RHY|wElc!zu(>SU(58ERKI;if3cFl*KR@+-jKsTJsvf?o_7QEfU&uG&{6)$ zN%U?9~T#w&iwdiJcH*h?NpV2-U#;} z%deZn=_RSOnj2I6FC$0c>0L~K*?JA~(;eyjc~OMgEt<$g4wTF9zy;sG)ONCpMG}vK zNc(E89iKP1Er&v;2P(6+K#%iJ?dvm@3Lvf%dH;FR;n96R>h`js`04q5Pmd?k?RBul z^uxP*;QM-o$!@WYsU}IJ3lw>Or{RME^4*U~80Z^!ckIG%_*9`a8XYJQV;q?wX^M zZ%O6ub86!E1D^#IHTC7+7F>;uOi~P^HSG7I;z7hzp}#}sBlQ1gFabA>e~+!_e|0(oS1<4ifBuf=*86z6~b;&L)2hX6YvQ0`-jFKbSz6tB~nm0p;$ej zBNO8$r^l3xOrJS@;QNFe|4&D8$h+lNi|$rBIzLy{+H?NW7Pk+>Gn#YaM5fXeni=_3r@Yc_ID`vZmvHdR-S04&y<$pT;It2} zbmlG>Px0Z;4vLr^wn;*kTr^@js%3M%=ep*m7L90ryBTCm(ud*9J$`o8uEfIIFWSuE zTNbufVip@4dk1zv<|M|)1U$-rQRM({9dV=83HI3N2*EXHdmM|fqb`V|3@jIhT)k9h zFv-a@)?AFhf(CgK`zk?A}vIm5cKGJ)Ohh@YsgLz4&oU z08;JWk`NNS#z`$55cw|(=e$h4d#l5?+j!1dbEfpFQQW+)^G8+bhK1FbF!rkiSh)&8 zD>Yxt;h>3TF;W` zBwdn%2i9w47LuD3PBTd)0W3UAe5p8KYvZeXd2RI^Y5_32#0N#@Vz~+Pf4Pi}1!BsH z@RW0bj2U?Sz~jyVA8e#7vq=jI4+xHNr*~iaLXnMt{Ptgt=Gy7JhigwImWL7ZZmv+; zpprJi<9!Lt3Deh=YFp<>9z-qn_tBUCMHzY$5IP&6?U zQDAE*LmdY47QgXoh~`eovaNzxfX!A1(5w1kw?qPqBbq*uZUC|Tj~G`A#wi27sdibJ zmKIcU(XXN;Y?FN*lP9cyDw2h&*%afG!#9 z^QZUKA-R#$QSZ%SSoCY1@K12e{sr6}q4KG%-1hrs z;mnuq%#4gVLYId!Wt=5r6FXGveqxZc;D}yG4vQ?ssV)=}WllAoktY(9h@=n8M_W*mw~ykHx+=UK#Tokau7yoeISq#QTD;__31jd&&HY9&>_ zEc#3iZ(09_&;xEH$;C?>T1b0`f9w^jjZ#cxGgDI>D(~RdCRql1Mo=1>{%R!ptKBB!XLc}stSjpNQ$6L4g(XSefR{&cWAPPqWY z4(=i8LU&e?+SLma+|S*^-lG3v@tmv2RY#wLx&>SBC)G>f0ab0m2|i=(H!pnf3%s#@pxSkX;Q#I;uN%aAxo^xBq~b-+uQ9kG|&d)O|}& zR1>aI`R0r%Vri1(K#}zfdjaz+mX^D!_4q3i^*h#da7CfX`F;CMj60i`2Q*y6_G^GEY-zA9dxK(e@`bq?z8r_!$g7S43xcv%as@ zNTQ1Nub+;1N}d`)HG`c&)I>Mg$8LlHq_8rfp~piw@*H0ZHwu@iF&kD1^3B6GS{KRK z-8tBxjm~Gl8&kOP5PF@&lZ8Zw)^dqZDp|4{h%9?sm1a-^W!joUZyMzb~RAgsuDJ0WPhr{yK4mWQQ2|!(?{4 zW>|6_hdu}qe1S@u?{QMu+QCaR62>b3o*7Hw^RKRs5_B5|h){>i-~fJnyhap1(nrDB zQ`S$+eZIw-jNfPAq&oKH;V>8U;rEYk^-E-HqVPp}BZOeWfn_tW+Q9_kJ)ywk8_|z2f}Z~mL2}yg7e2}`Th*Yoi1vrzDBy;<7!`mYG(DGYPxTTbm4ZqPCyiQ)Ptx!xjZ6X{G zEza)9g@nhf>vpbn{wkPChknK!~9J!gDBa;#Lj%uso$$Yppp}#D3ahGSs*~q%Vd*0YT zB=6rs^mKJjZUjJc!Cw-ak~aeC132epP++QNJow_m8QW>4sctrqu<8GbORMIgZ#0G8qLNrHc)R5(3O_l zEfe&aFPu)h5>+T!)|v>8WQMNnYGiwO!WFngV!ZwB^b4?#H^n54M?wmvG2ZLtao8UV zS?VA=Uv6vc=N97kOv!%5G13CDkoJ>5bHhn)FFgbq_VXb^_7=*8a~fkQBu;aIPH(?P#jhWWO6tg>eXN%@+!<(_6j6A?@(G=r>pc1Iu4-mc0z7riXb0Y+u z-a!9;>)lVjw|;FGIIWS3VU=I<>yGYezb)|Ad~-~yrE7hVQP^kjb?lL;08L8z)zZk6 z&!MuNUdbchKlU>pPk3DF-)5?a7m93;Ix*S<&G1HA%cMuwoBw+l>4$N2DiGoItbSUKiHp%CEQp zi*L2;>ODmTLoV+nigsLYcZg?}#Pxn~v#pwFKE_eKt$~}yW64t19cNS$0(D)>r<0IM zmB0&1{-^Mn(JhG{%pbx7$gfLC>iHkppVW)goMCwt%>tu)G4*U{-hx2x{nzU4t5MjP zimEWee(Jv;7CLJOtKfa6-=Nn}2>ei6yzwkyY(zXTTD<4oQ7t7VQ6KEtY}Ty@s~Ql; z9MiK>(TPpHHgv*k2ir36cN5+3U#@0U2?0nPx$E|x<^;NGpZ3T6^ut%2 zXWL+J-#bL*k{!RTswP`dp~6{g7C4gqBGef+MjuNq@y+V0n-u8bA*OIaQ9Ya)^rC&i z{_)9CyoVT@CVHd2$%(g2Uh`E!O6xvKK`Tv|THhi@l~E(0a<| zq%_xf71lPXbe?PW5JZ_OBjQ_|jeHnzvDh{C0C6L5X-4cdN@l0p-Ku?4bJl`pThFf7 z0RT)7%86;C@%(vS4GFC%Th7wclSe5lULbJQm15&o>Dy-cv=UzeRZA|pjQKzwF%zPx z?_YV9fIgHt3ICzt+jbuXot`v4tRI^xlR z@MRw4UM$q@74WL=ZknR?Y8S8!aXMt0LxdHmz67XcI-T6WRT6ZtWJdK;5OqDQWa%V?{d{cj1Rx7bSy9Yb<`Fq`sgcXU8E2`o?}sI0+F}Bx}7O0)d|R zwYfwdaOKIeraaeKXorM6sd4i{=68F6(J44w2fyC;P4*D8;+BBi{IRWM9|_p%jRr~c znxXy?iEEi9cuK%&1eg}WAf)S04>9d&!iLt1sznK8dQB$B?>p8>S3 z^!XkUUzvtq?Mo;PMHR!FaQ+zQ37x>@{=VmTeq*v&Vt4rCtoBtE+Y~N1@gbMZU5_lt zf0`s}Th^$`y6r~3K`W?#J>bPZRL^&=o}j>(B#lcSjTes*$#s{7wF#eTN)mrX-(x?b zKssa5chTx5%VBxK?nWgS_jBOB-a#SOv&sr@Sf-tp$x@s-U5f?n2%4p0dT}HmHdme1 zW???mE@baifa_sup2gizjfGqa>p1D)1|riflL+1#NS(p3=J%hwyiP6!K0C3PPYGZ(HII(Y1*<<#>95FAYLN_196 zsBfN_0!>r+hyC8YNhGtt9f=jo^^C@0Pb9#9nbUr=&4LrLU~K_ZhJRP8^1l2ZJk8i1 zy*w%rwLS2D(NgV|%&#!ZB@q>S!p6FO2^dm7lP&2r#0%VyuNZC99nX?9+{Ajwuy zo|Uuxr9GHXolK4Wl%*e{x6v09#t;H^zI=D8P=38R*1lWhjtN=bfi7Sck3DJcC_z4- zB7c!8J2&|KNVae8d>WfU;WW#Y5z+TQiVwu^UJ6Q!Ca?XAL!*4?Z}*>$XUJq2k+8~_Jblm} z85VKFqUb}fnMb>Tx&uXE*ul}&oBx?7? zaAuM$NOXsr11JbSSLy}>;89&p;W3(rL>1G~H+i3=xoqk86o$Xo%Y~%@F&*eng@jC| z;n3%`(6e5neDz?xzL3d-`_w3v5h?DJI2jC&&%%V7I!{N~xU7OstIhhm zd3(yeeh9jH1wtUxAo8+p5bqFL34VW&cLs$_+*_eK%S++g7jL&#>CyPI^Z)IuBn-(Ri!1@20FN$xKt(Ohi z_g)HS*AWXTk21Yg#Ql(XH3XBxR4f&Tb}f2!eq7{;C*Jq&#rV$l6{B{;^2`GwRq5Nher-_6c0P*T-!kFvwNVkRw2!(iKGSQP zn*!kp)M6H`3jM09;e_-BA9_jnu{^{w2t8s@LlX3 zw)vLAz0>v-9|P^tZtbT5L;@>#bp?`KrB;?Q=^5yc_vsFW5?YQ}33(%zb97=F5ZJ|J zeGx%VX$l-zaxBtV9V{82u5Y?@7KiX`Wlu$3BmgY|CdHfiU^QolNn?f3$$X_5IhgOx z^{%uFQ8<4-)*Xi+V+tE4#S0qo-MG5@C$dnfyj#+0;8=K>bdtl)NC#dDhw3VJ1sO1M zYC+qWj~i)BnC6Y<1)5faie&A#*U-4UEk4N>vZP=C_zx%VDA#O9EGnLfmQ|)Xk9#Dk z6qbjWYKrSMlLsfawmaNtCY9)53U3)m z?7LI9L#(WMRbjOWo9vvjb+=i3uQeCfLtCwq1J0t#+Q@V;jai;JyPLItct1mspT;|m zw4|CVW^D4q%B)=&6)kkK5E)0xDkEvk5*&-_Vxm=1Y|eAQd!aoRt&rx76mo?ew3kI_ z8W+&ka9-X{>)5!7Z*Q z!ekU2fFB~IBhznd%2G0Q@z^JAsKbbydLRckd4I`vVygP^T4QS`pY=5fxlqhm#PA*t zBD1ryLylJ5=7N}9M8tkAW1|=%Nw0_Wz&e`dC*`bnL+GD$+eYrbT^)MjHJH;oPaxEJ zY_12;t1W5Fbyt9t?AN4FDq{1*4>=~u52NLNjN{?3yP)&Jkp-d$u^Gl!44I_eOPu4F z-lPwE;C)xU;y!Nn`3&>m^n*m{_s8;fogvsTRKtK-dCxqqaz~m7EAZ;g_Au{f%hU** zS;B-X$@*r#bvxoKp5YqY?U{yihBfITlV)V)&K4;@J z2nM;e8``<6->{!y&{YXyP|G}8N{2G>eldRZDZ@N^aQDvqadw|XLh62Nb62XR*}q-Z zA-S6b7?>#@ZW&$WK0RQI!Au7-EgY`Tk(gM{hm%<=^wM!h!s35T)qdu zDq@*27YQ;PYQ~174)2DOS)a0XrEznNHTHarU4ENdIlH~^-c5?r2NbIvPnUt`C>)w8 zWW+lxb=)ygnU?Ze;jsU#kFxHed}-puWStE?6@ggQw|ipXCw~kFkr>ypo%1rRk_J5Y z!iJ;K3yDww$;%{lg!MX10JWq#{%})}vG#+c`cl>7RhV3@kF^%EW9tZgO9Qb~y&31> z1^fDAQQ2YSy2uG+MtBTMW@$c!aFv&~f0ru6{L)Y0t*0!s7c6$t6E;`fbWK>7{oJ}th{NwiGcs{9o_*%f1_@9nmnQ9#%?Ju4Zhtv1!l)EzUiN>Sm zV3wqa2P42W=j?vt{k%`apIyD@Rc*X+p;Yr)&Fka@uyx__S$@0HxykqkBmB!Y24~AX z^Z=@kJW=^vWVEPT8@oxD8f_Rti4@Z4a^?k`W0mk?2YRnBx3+Vx%(eU>xu&i)lL-Ri zu~oEku!;qV@Y)r@zZJ%K!Z8!#P!9jH>G~}rg}tdSP;Tp6;}%gW+Oi5*`PowKz3Jav zHmIC3R}b&l1cuqVK9)ExA6`JhWw>!al3pUEknVtDzm!6+FOV0?e_F;@ZQC1h9t_;{ zKdl%PxdeVHWK^in#??NYYb1`b@R7)Y>2&QNaxxi?iA?@BEm}xk*8V24?4cG|DimZ1 zXWRW;`w3FHI%dNXVi8IKW0KbFgS*MD6cWmQOuiCFHd8ta3kF$T2DdEF7(ZKeuARX> z+m*B?dJ);H#GPiBaY&v)=D=32fa7Upe_!H@WLgmw*38^o_pZG;6(b`f3W<2uGSthL z{9edtyq+^gK>PWUcfE3F&PbV?H~ne0y}Sxg0(hU0eSyGoo_o(EirlB?0|e$iR-D8B z$Ik1|*Qte*eknJX{&9cKko#=?I*yi8UzwY8RP#CXi20Ri6Jxc( zT(DCA9Z0S6E8`RW(k<){3P(em!vpbIT%PIyVl&0v-cD{T3T6tif}hY-M^nCr&M(Ch zd58*<+-HH!+>GNa7pefJ#NtP^)xfvI&C3Her|?Cx#d2vgsb7T>7D-ESk8m1q2WNlO z+s}tnM^sp8pRy5VJh%3}9%^zetTBu0j+!Ex{bkO%Y|SDIwQXIexuC8R`trZN1R_Z> zPviqT&nn+SSX{CrKKXoP5_xj+&S=Z-1?1dl=b5U_j}YgS_6`0<<{arf2EQ;c9XF$J3=S<%H>9d+zZ5ZvK+doQ-y47|SjRmDP$$J}?O( z6n6tS<0rbEkTaf4!h9i2szE|dTJ?p$v@OJf2S3z!7zjG@a6ZK^2QntrR=9Uy)ugs| zG*kA>HrX(Bn8q zu1cVbq~H~F@=E+%VjbTVJC7KBJmSY7OD&BCcsYXL>qYGxiIT1ljizs%Rc6&tPOi{J zl!LRu$4RaR>Y)+m!m=95mHr~<@t&a4jpUklL!e^et#^jD@g7+Vz7$e4k;`g54JnPY zpz+{n@Y>MablqW;CTM2`39s2@b8=D2unflH~Af zAVZy>uAY9E*qS3L0(V4;C}$HE!nYS~)~}bY5i6`Z_)1z~J81+63Ydyy`W(6s#URhS z$F%CDm7I)lquFZyf!Q%UjEIemy|B2LdGZ3qT`orwGZ$Q3t^oLc<+6T(!AO65kyNAs zFH*W?B_bkXU41=fNf*N6zHq?tw6LkSkAlFyvRtjTVcddK*#vooJKxe?KII|E~z zk{Nw2jq#AfiBaEBvS#-DOr7XQw|lfg8m7e&EIr+?TYFp$Qe;FiEE1d+W5krDl>hES zlT!g`xIlebg{r|2lxd{tNr7E|i)67X8(40n`kt|FgX8ivE`cyR z9h0TE)0`_4bmCL-9X<;_Yz_vm-!#RJQz^4L395;!%2}PE)c|`hq#fF(`ue!hdo7~z zII0seDDCxUB@pGskZ)+S9@+{DPCGa71kcsvb{%#)G&tQxEh2fmrP&%1P0ps^j`_t} zS3!hNWcQ2QFQ%w18M+?RVdpIotcQyv5T#$z(B}Dm)LOi9zb`W|XH?Qzx^7I@KOqcC*9kPII$za(wvad6?CB4=sdiR2+k{WWLpX#(pBfnW8if|`X#dI**E@;#WNtEra47ba z<4Fe*A4mF8)F%wd9MmW5kIRl}yY`1qhFUTO(2hSYEpsrT?JnW~_o$>RERmlv>x^9V zIgm#Xde0)ie?j&^t_dA(;&8^p3k!{3QXQQX-*daWnQT~mCEX@E-lxJJOIcP*-j-)7C$Z1g#^lv!t7a5Y+J>^x6SXy?{xWWL?waGf z^Q-J(yY0-Veh1z4S7*h7!9tBQOpD%xJp}C<`v>3>gfT1Yz1|_71J{W)++*Id`7~2t z3aMXZII-9>$pAaY>1+-WXlt6Gm#vLPP#=Ia!&^XCnaRjKc4Gg9AyNAfD2DH?^q0|> zcADOe2V8IW`0{$ur_6p(YL!q`4Da$DHE`EQ2)3aDn)JHW z^LyBB+JzqOUc{aSU-C%i+uXKTu+XWkAXq1Y?<;oga9YQu;U7P6&gF`Bl)09H@#95X z=XUk-dZBtIdq5zfT~!o)Xns1bS4Y+)GHeYRka7L#Q8WOMuQhk%YOG62M#=ZL2m3-1 z!jxjHXRqDwwu9?J!w9sK!tS*j*X&jiOYf;|de4Y_&$CH7`Q%3>gSH>+lk2Z=vm2hOT1D1TnZInMz<4;_PV%Qc+iL4j zCLWHAsp{Y7k>o>l36q%Svb`_=#FzchIn3_ijMrLnOuWp zxjJ|cC9zcM*VPK_)ycKoxpl~=_8YOd^4Ef5 zuWUn85vm77`j$zmdrqp=>pgsFr~K83^Urq&gWbKpi{$S;TEv=r!tl>eRs}k$b)==G z??&tDeq!@Yo&q}0r(m!H8RlfjT?^=mhws2Qno5-c$eAEauhA~1+CMXtX-&)o2Ylr7 z7K35{V0paM48&nPu|kAfF>(QzjlH7Rp<-KOqBqrEmPiD^CvQJ30banrp&>w!)j|fd z*_-iooQPb}leCsu+%u*44P5PDCZAtjpX9%Frh)iALWz(fh$mrVs&A!xlB!()RkGkd zJmjW%e3^@KA{kMtKYVtNnI;MS^mz1RL0Bq3B-sDMq7$+bw=!MPn18~0b<-SIGR<)Q zhq^5MZ2shBv(XG8DwVQdHq zK6sBLA0ag)jj*(}C5X+H34JB0z-Zuxj3MH;7q9b*%I<6wbbnGxxFH#WuG;R$yOMa- zhe-1F?Sz#cZTdeUfLY-)A;Kb1Pvib51nnbTK^W}LN6D*dWq|X4|GMl49RAge#9La} zMYx&vc79$Adww=LYQVVa;_i-J(xv^ZZgwqk#HWJMwXQn0O**ta#lNrqcCT3%1Q4=` zAGJLuugev(f6Z|f1A@3kr+0DoDf_A88+}pOB`~L!QQi{{z&jQOEU_M}K0?nPDbKcc zcXzf`FMkeGxN$m9F@Zu`VAJli>86ig_N57fsN$2lhMX`lXN~j$4un82>>mWJYHQ9g(PYu*mLNADL6Wr{_fgCu?~~XH*%0wlRQ| z!KC7zoMw2fLh9`Q>dP@|u)C#^ky z?C)Kg?9)5!_EiKi7)Bu}KE?B6lff-qN&UQDF8#C&dVLs3w!Yam8=PXF;vrx(TB)Mf z!7U{D%pT#WzGvL%1q|OJ=zp?DQLp7-yRaKfzwv~(Fs58+PkcXUJxkp=z_iAD2SXa?6@(E9_+Cm0H~IRY28I5g z@B3hfC_`zJe=RH`eNj(BeP<%FB>aH6K*cK-0_2DQFE9WA8v*x)!H71(aR4%2j{1J0 zik`N^Q~K`%;RUA5mS-P15F4Nuf%@-E_fzYN6M_AgoyLqC~6mYI*n=Iu2IF-PCK4?x^9bPD&fx~jN7>MvGVknF!u_W$=_G$Vd7-94mndwpI1 zM){z!s%qj%p>Psl?Gs}D7iV7?7FW}>NrDDscZb0x zNYDVm-Q9h5@;vYNtz5f*w*Q=qVdR|d>gu{n?n=VL$H%{ae8k4ZHM5HDf)-V7UAOWk zr=<~vW7AGM!oGR)2Fj0n)W=6cNLT_P%BJnN*J`eE{?v>v>4yQOxHUcVXIV#o(zf5} zcV(_KR|!eV71TQvCIz-8ZK<#_#?drRuaAz4+Ae&##0z&dALx;scS{hpZF0TTG(k3V zpM-q2tNH(>!jE=F^7igb?brA6Ct=~` z`R9ATf8&q}xO_uth9)6Pdp}b_i4&d;ogRk2pl5`JGxi9Ep z?9_+zw(7Ut`H;|LL^x z8OnQ`#AQAr;O`J!s8;$ho;u`pd}?%bbdos0pCK7Xa#GQ1sUj!{*1^F6Wa}(-*M_y} zyMAyG-rU^0@fr0>Po|s#(Wzn5kyL*^4K#SUe;XiaI7DU+-XnDpNYS4?$RoyYe2wdzAC@{E&S6!^zHPMmJ8I%U}$Zg zZV}_pYV}>t`(mDw#BYx`0jvys#|-fUu$qs2B4VPePON@n+9{khdjd_%KGn;%9Gc(l zX7~A{f09Lh7cuL4`fqO7yKHx}BGm>;c1R;Efdx%wYS|Jo!1Us@TL(;R9WZuD`rx2uOFZ2EYs z@(5qK02i2L4x|f~-Ruwllsq>43m@=*p#z^XFMRj5G5ZbkCz1N zmyysC_x!xQ}H%#s|&$ZKT_Q~O7kf`#Z>NybRx+ZCc=cmsABh}p~*)wp#6MG z=h9;wcO8JNlH>_ASKMbK{P?#Rbb?^c$I0UhyN}|^L~)prR8bjh8gD*IylgNg6!#UG zwM=+tn@a{+jJ0Nc=PQrl09RoB>`(04JLnacdgL~LVwH6Cz&m){<9STNxbTxv2S=Uy z;VQ91i$(5le>&Zm)J6x=(QMFu>Nz#JR2x2?&lrnty4`}B zL_Xu6M^8m{fzP_8b-vja4im2xUIpcOn(s#*aFjB5^K}GL%32eQik?$MJi+V2(O>8M zF=&KijArr^HOK_AqkYk9T>nt;{Jj58W-83-HaZ#$%RJJ1O!OxnD}y{njGHxNk3zw~rpYQYrUoed+ zi=cGpM!*cJ3UJjx>4D>Oy)}mK+;~pHi~?VbozjH)T@vsC{w(H7F2jLEpg2#lTBl;A zGn6$lAm7=;QF-Fz69g|-Y&G=u!2$sy6c2m$!%Ebfw;kiy?9T$7ne)b`S~24YSG8es?{{&QZUN{#azg2?xz-pLzV&OC2#Ts94Ccb{K9b+5EW zm`>!ncVaVIyzKKh+EX2`riz;&PurN$FUEe5 zs&1|Lf|c;05) zstZ-v;!b*HIz+WZPa#UbnK088Ve`5J{{Hrm;lgZ-#m?)!RB7%}t%tO0BD)?E?a_7r z5Azp5FD1-g^XUNhNp(5WvOzPZoc|cWd=^>J-tb+>)l1;viiPRP{s_mNSn$A+=q5(| z8%qw?ZJ`d1X4yPTFG}jng2He~9)Bw(!_QYZSXh8>i7K`Jzp=bXl6%*GD{$rjh;WA! zRF>v5+Z|BLik{&3Q_!3sMBG1^PL0n_b&>e0zr~jq=epi(GH6sV2`TGD*Ya{xUf(Jo zcQ96^qU#(kC3>BK5nj?g`a6!YDW8x57;{Iknrj_40QX4Qrn3>H zR)(cDdxCv{KU4V>B zdw`v8FvLlWUqv2xmTcMPqDv#(vX|HEdh~Vq-FHS)1%T4fkvRP=Ycp}wE{co`Nor7W zXr%9Moxq<|@EJMzWhd&jJ~k4*i*6tRny$|L)+72c&$eg3_M(KbZI-TiqrWztMme|R_;uZwRC1>!#f6Dg?)pwS*f z8Td#xl3S6FTIM-nS|Jw!=os=1pe?``jGJNljHqK1?$>Hhr3nsg_M8p<!_z?#QMWcV+VT868BLF5=PDhiegsbvNr>a&1f?EF~at1IykB!=Zrz{$eNXb zsqLA#=sP35fTG^^J%ipYjbwIHV>_C^6C=U27Qk61LFSfT^Y%#v5*d_%Z>lx{Dw+4( zoBvwi6MGur;phmB%4FDE(~~@=Sop3-R4*cGK%T1kK9R+j zRUkGym;;aYJA z5dzbQsmetocPn5E+a5I+R|0!+-@{zXLQdhhIfnxu6`3qW1l^$HXg?O3$(HUi`zxDw z830|3#9GWqwn}P9mtR9M;dTU(b5+|)QUZ*%FyTYoRlQb2<)UgTzr`NCkNR^E%N1mi zGqfj551pnw9?5X+P`P|(P5SH1wztBu*+U0GN1T>G-PwxYI3yx@=yr7sfH!G|S>0JX zrkut@%p01-OdY};+ZHega z%0kO3ch}{=3VbxuLgb!U>v@3s_ zbASv;t+6nb?t{%j7KBzO2Df14Qr3;)op+p3CBM(^w`{TEQ3op#2W7sRb6Cm7vU_uI zy6I%;WTpuO?1`bHj!@8ZgT$`-1DM{8Rq`$|C+&;^|D$@oC1yEzZ41CHv9AoQka#-n zEps(E!>zWk^)DWYo3g?A1J-{>@~eKdHwv90T-#Pjbex6vN5qg_`-P@j>f$@rd2g`K z1Z}bD3Ikzrma5StLnZr+hHv6+!npRMuT5ubs>_^rmLdSZjCzH`9_UVGH6ZnXus8RP zDknfeqg=FX5NtPdofA`lwb2a z*F?&t%I~~At{~j@sG0e}g}V{dEM|zYr_uQ*_5$aYs$iKz@hpp783rmb)Ol+en?13OUNG2+ORbA?3gVdvSue&=l#rfpfTd)0v9l!Z!G-fkAp}-akSkzft zKxB?}z}T@H>;aqjG)TnfLo*)1XDXMMyuw^@HU+0YG}gQPXKSh+>XZFq6c`aSl&?TO zo+k8ZRL$@wpk_#tg=`KEp35(Q@Pk1OB0d`#hz|Of>EwrZYo6dlv$9M*J?F?W;#cSy*&wbS@eQLQw%79 zCV_UX+`X!4AAUr1MC!ZZn~Y~Ecww=)t=8|z%1RY3IHyp}WSg%u#P(N;>N*P#9y>@l zt$8!pAU6%;67MIN_hy@uQpI+Ji0V4h>>jq5?&X$5-pI-Z%Owp+5fOfkW#WBCSMHA! zMV`%Qz^a1Y-wPQ^vE3U1?q-6=>VP8AI(0JaGJVkOFx-?&+c46gY`Q%TXj1ipn7a2% zhv~9(3rKq~>>$%!$R#!mI=&zpx70Y0RfU>KMs^Y8K&z4_vzTd=Vmp)*IGW|CO0w+x z7EJ+vhDw|q#|VM=7GOC}(?y>OVqthW|4LQcV-~k?PSdX+zLWo!9g~98ZEBbdwoYB2 zrR{Gcbu4$i8xpg!9gqs=mmAERc(z4qtd0c)*;04jE6Q^_S43!ykM#0wzl&*S>Hgtu z>vX>=2TZh!h;c`uwh;>{Fk|#rr+KfDfoWuh%}>=mObEcDl2!Zk1-kBl#A*+tWohkT zZSuf_Ojr67$|h+RcJv(*QlcfqtLl(m@GApqRq3B2H63tNNRZ55(}eM3))oeCBqw_< zDv^C#(=o!YfSt0dv0VlO$k6O%7BTYLflLswdu#Q@?0FFxojY)p!E;Bb;xkj{sE2>6R_* zpf4VoS-(hiG};M`$g$FeCG7;bNkV*XCB=Z>PBZC@`Z)Pp+R1`O7h;@NiD4q$u#LHi zt)Rv#X@J{dtj}$HOM8K^kkZ0eQ-@P%ch_&VWSOZ&a>@j=1 z%tS>jB;boqk4QKqCgiRZ{Z6U`Zths<%{D%p^w@9SA&OGK=)cq%zwmBW(0|~fL&wL$ zqE!pIZUu~p6yJaJq*IgI=3ja1+s9_|4y#ZGo7**Y=rr)td(5^V$$-xjWQVx4f#Kot z=K+j$vo?WcQ|#+Z{b15)lKh5vwNOME@%$3M3$KN$&bJ#b~c1Z0^jlV$4=tRcZ z?IMdRx{;sUD=;7I5Va_-@olAP8fBZ7(TAqY}s()&uiJrxBl!je(w^8*Xd8E1}!0IRVH77h`Aj*9ZEt5jPm$wM5*GbcNq za7nrC!b1{By49#v5FcjjLz}#Bs-nJ>wUFB zP|wxFBL~%#Fiizh@hEc3n<1-nzr&54H|Za9*Ugw1JqX#{^-mC zUOv@xAD5gcWI$Vt&_WG(CdReCA;WzdCJ|@5KawnZgjY>w5dUDw=-4+?7MgK;GDG0# z+>^&qmmKGmwwhRagpbpIdiZ`7Dw@|cGzDwmeZ`b*Icb9O(y1$Lh(y@*aDU`5&sY0Ofi`fh_w4-G9!qM)&SnwE@-FTy;PjZ}MLhX@0 zFfEObic*BdL2~j302dF7$NhRggGf1W$X3p1R}gj2|Ecy`NjecBdh8_lop(lLtQ&n2VGl4J%_Y1LC@F27U;$)c zjq90Pl_hbS*0o`iCy7j>Wl?;uiWq>6B8Jjah_knWsG#AH^VAr@V>#ZR7A0X5o6Z~2 z3$tGJbfo;Cjf!=137;ms`D&|D8sCj>TlW#jNSJW(pO* zkf2Fo84Xqe1?S^z&;2!kcGmrCW-g}JYS)19xEsczNm{xzjVdY_+|XYqI49y8#P7J--Z}U(Foo_FcHX@R|8#-xGW4|05Q1P-oN5GztK+3Z>tW5gxhW9*dpbbr8 znL59X(J=~RMftp(jKccX%2DqY#kd-y1dtz5*qFKe{Pjfm1a|@YT%9upkXhAXtjG8; z)Z%B1V!dig)q|k?pb_efR0S@}U*Q(z*;1uG(KnT@RIazgsnGre^kGV&V+=@li;=nG zOQyRID#I%lVjfklvK{UEOrt5;&NY9}ys+yJAQl;9%6yG*{)sHgTR2}PNV69~1&AlV z6G$D=5~^_eMKvQu;s)6nokTJ95RK218GXpFvUb<}c(nsrA{~aYpH=;;B!7L??i92c z^DyZ%J}MBT0Bvs=j6|hjLfq(=w5CtG()6ai`o2d*j!~mp7lU_nH>8misl$t$zjtR? zwa}#;^Nyj(ej%Fq%kD6sOz3c~JiN}ESDgr9bMt`&DP>RQ0{b1Ju}(5ILmU8k zC&SVU+p}-|q}`~bkjU7P-S5MUB*Q*K=w>UT$hUr>Z2z{V^wFM3fLa9|wnTijKS|hG&QDS_#$=`mRsgbn zb*;bA((d+tw>^~Fa;OlvNJZaU#o8Z6+r0JTPZhd%u?9+E4Esuc-x|c*B+K6NktUA z;C#KnJ#z9e60Fm$R!Q`sZz28PxAUYx38~cDAuX*1fpIcS0_oOjR4z%?u?RQilu&mm zqU&KY5ihQRFh|b#2fI7PQ29Q7<2`XDtTl&}wo7xxzn&}T=;UDf4a3X*X&q9H!Y3L< z9@gvRILfvh#vz@{q}gA`z;veDawY%H8~mLiO_@az)mj$UX$(eY!TosAh2EkD6&$G4 z?ntecjJLzQhlgA+4D7}t!ZmII+oGKIS45Fycx+h|pz4fj$1ovxM(~=-8sArRdSQvu z2CoE-mTe(%u!Yk_yGDjQ68N~I4Mq{i==d7;Be5Fa>D3&1!9*$WNo*~zrP}nA;1bV{ z!G%M*oc>&6ayE^1vM#vOyak1nUI=ExJ`@(Qn0OHeE?ZEv19gXRKgC>)uQn}@(w zaAJL=)qlHEYh)!JMJPnRL?M$&jqBrz1!4!sgdJCMIs;*6NyNxm>qEA7zheRYXa;{n zLfH0A?XtUIC%|q-NnZZv6cz1Q;n#RSCO`NBQdRY`=MnQUUJ)a0aB9t03>k1tiJP-! zVt$w_^hyweY<)eqtfM&D@m9(IM50LQ>fkcxvp&SLB<C+vNHf2!3Nb?RKcP3YWgX z6>c*8P$ThXwk%_LX7Dg>qkykO)Xn;bUY*MhHfm`ymRczu6B;loX>_oUv4`={Z9Hn8 zvwFgc^m*d#Z#svbwyqJ%o)tDI8r=UE4N5;6e}3}<`W-5@fH!uyK&0OMqkAV(uGUx* z(e1MrNyPCuXN~C?Cf36?Ru(gD%}6G}?Hb{k>T*`-uDL?4-IBRi0orE}!<;_{vANpT zYaJwas~=6kV~UJGU)$7d$pPr05`D}n+t=zgo2w5RXft)nS5#dy1VP+?grNqj1stmec;r%Dw=gfo69YBGZC`gU}C`g_HCo5j^ts?=-?L*RrsufiKA;p12 zPXDPqWnGpwvT(&4Ia8o03S~bTiY!}SW>|$4=a=_oI>^;c6@dVpbQ;%feHId4iqk2T z@_0g;?M*8I-oqHIgkmF&SOhB$BZ}3}T0Q5^mAORBYT#v%PWdUdh6y^#fcY57B#x-> zV4L7X4`aZEsCt}ps{tW!37sm%GEZuc5g4$Iy}Y7gIxk|`KyrY*cD*yz6_8mnB4kn8 z^6)WsJ7lWW5Ox9Hu>1PgFJJ@YZI!`7EWCf4$=nWynFAkYCd&H&$w}J2119jT!t-UK zSF1g~)(Tok|MJ_2(JKzhTQU0OAA3Kh!H$O`DV+axR!D$Eeaq*ank%`s1GRv~j>XuOZDI%O`AoFhdsX%HLjWtEdrCDi6c@JN z)Fb=X`YoZ(LiBWOA_oK5ht7%dz3SXq+IU?hBOUT4}@3nv=x~j1_adxLxsu^LJnfWKlq2S>Phb zjF8>DtTW!9&ckbq{TzKXowv`i1g~zZt(`8l(SnQE@*?mE)w021k@#1AOfS6x zj-r7myt_Ri<6n7UAa12utXc?F+FIJ0K&^K2Sz@YKd}i-ZRLC1oy;*2(!K)knw$5ky zUTZb-Ly-jz$Dsm59rULzr7kn**xP^ zvD%EFeX9v_LQ!2V6JzFy1} z#P%J1F*+f~6Ov!Ou<_<2-hS4ZEAlj}!az#wwH$IgU44y(i>cX#^8o7JoYmqYQGLuK zr9#3_plBi6H8z&pPbZ;><`?YF4oW>SPc%ULiuw=FXv=IIhbo878&`EGrc}C$y#%vskwN3!&$IR!K(+B}7A-9# z6ci~{)ng)Yb&7GZax83Y-`&~SJ?$mS%F4=(y*+xdM?oHlL)i4U?(Pq8h_-ERiNJ%I z;`uMtHehw$u6k_NO;Pfd7WfI6jXV9AUWVi~{KpJl5!6+3ey6=wagAN{VZ#cBx?+|4 z;R+5%jOCUq(pM%|fo*nB-k%wiDHbuT`}1pj2eDg;;BZmoM1~krA~)epg&B`@K2#*6 zkB?`QVHjRMM|9**(%t=F7;}8Wb0syY3=h z1jtfLZy9u`_b^!4t;fd3;;8y2Iyjscd;Jmx#^fG*{0hX!Lzt9NWM#jV~aSl)*?pXgl0A=Q84)C_+ z*BrZs_2JhbNXLJD@b7h+<1Z}!pQF$iyYa)b;J7d3wewzmgqxQ)#6mq71d5<7O=)cv zjEauF*yuwn(O|0Oxv8tIeJEYxt1VDttf;8K#K#Bah!G)*-vTDcCAk{*OdU z%AR&z1>vh-3IfLD!mqe5rzR0I&Ut1@3TO6uQuK+dEu*OU(W^vkI^-LJ& z+j zdhr~SOVp}~Efe0&FEAF9Plt-P+C|p?wzQQ0=hFVi?)}I3g+^8S{#rqaAEO<|WN9{T z^Qkq!UL;@y3cQp7?0?>};@;IRxx`NPXp{i;06dkn8|xhP$j>@ZwX$dctKy6FXVyuF+p9ix+eH7he76P8rY=lyLuQ zNvObVsxVGK6`F6gDnr9vXvzqIxZ*mx@!j0tIe(q)t&Q6yJLA65kVYDc+x)Jg0(zsP)({cpZ%#G zUD`TuS6I7HEj*TilV`1%D^2mP3FU4O>LPSHeC8GLBMH1lPmAwS^;6D4#^?|IN_ld2 z9PE(0VUwCJ?F*1h3_S0+WRJ=21ks=M8kwXJ;lBebhGWFCZ){)GI|bYmQ_-Ohn_0t! z-`n-}p5Nc&AA4ee{Cg@s-n|f5SuZNjfW+I*N}nA!yKl>p#B51dLqoOZUBcf^ zP^fM5wA8}mU;^L}2I|p**OcVb7^AjLG&2t)!1WY<6MMJ$iMfB0#Zj)Nn*C2xMkr-$ zLxZ1^E}*+19{R+Xzx{zEJi)oMS`|q?1p|JGYEY?GQ$8G%qw-pBd-ufd)mLHUu<)#^ zts3&7x?I5ZkcCbEu6y(YQN=NLFAGsyl6ZRTH-omV+3=Ybw=K?9PzIC+0^$7vtFj5j zBQxH!BRTZ8bBD9$->gOAg#RQL@{jR)28umSq2580{iF=jI1ir8UG`|QbpC3p>m}8V z7hVEX>sb`GGc|=__063P=MspVgofK;l)=kmo^LrZgH{JQ9eDtKMJ=dil|-1@u}W|F zCOX5k(0Orj4g0wEjXyJiM7WUsR9`E^8jS&gkYNwc17sAZ@skrT%hokt;8pG3#UE*XuVZnBQs3=6u#A1 zwi$h&-;2qE)`PZB#n?+{$ZJVl``5SqM)pODRQJ-1l9#W41(gB+x7-gyKHQ+t%Kjb7 zT1A34r@*-#6E|e3T&){%k~E~Ap7;*i|UR7DY-t1Oyutm2w95xD3)&Yju&DEn#HNjx$3I*CYq=?mlL zKl^3Mkp?rg7-OJJ!4We{9vv55gkO38nXMmB2M<->n~;DltAEb=B#!?cd-rA^C1p=O zHyM}i!8TuNC}y8@0{~oV?*xrL_(m;Wy=_7pGJdHYb?UZLa1Q0?vFX#}*N#{=FB6+sPBx_ZbCd zEzoA@k0Vi~4qeX?{~nzM6eDs#VRK&c;Zc*Zm`cL6BJ5WNH3YOr*1*xYX^wO8Xf)w$ ztMa1q1q_sAmY(mx=2rj9&6y09xV_Whfk+`6XfjIRQ#qvPSBlN{VI6uX{+(2xcx2AU z0gu!=do&*bg!TTY04E-fvZl)&50*bSZ|}F*EA;tE$4Bra0yi6{Y(d@^n2vx1s#j%Jvzu-&g81i*y?i?<|W?b zwN#49(sues$OW}lr8ACgG0cGd@q!1L#DR@b?{4e8;fWf9S{+^6_+k{JJ1eG(DN2(b zj-1Z-N{q_j>Lsq{YGstMjz_G&TYZGQ%`e96dW-0E=rSJ6Wm>kxo*!Ql5c1AOJUw{u?8YTMQeo-HWpBD;p)@qKcUn1qA`2R}an1=h=IZ*T9l zhkf9==e(2Eo^gw)Pbg(6txIxQq!ud^O{l<*|M|lM;r1mq9>Vws?mqQ}wk^ZuFF0>$ z+P{@dSD+EU8l&lG{AMVF5fK5C_)aYMN5b$b+PUOd6@skP%3)Y|S5m^5fkIB4x6i(q z+MV2aW-k#=Zgyd{I2kl@QT+16&?Dod5uIlq{eHDk8kd|~wR02It9d2jNa2v`kw0=| zh%EG1N8qQPh!V{OS(a$pXQ9_BO$zQa^N_38nN$E{=DoCtMs-brF=vzub1+~}#aJVE z|B8><$yJ_qHuWSrS@+af23DP+GsbA@kmj6qfgoXVuWx=ayQWde;aVsQM@reCI~aRv zO)liFDj-)j)W3#;7cYb#qnB7l`?yPtKr^bJX)V`USc!zrV@+L5Cz{VabPJe6R`$Y+ z(@1{XyPxmPc{|OBIza&eX?A)J81f1kWxp^evUU&!%`r^6L)^z+PUV@LeC5qGGOhr+ z0l)Z<=)n%(?}Ds&=HWQ``0y#>!JHI@2JR|Kk~!44I?$Kdtw4>Y>l)eER6#CU=3KTd6t zva;8LR)(rK(j4JXD_nD=$9Js&<5(6ZXeF!0<_VI7KCQ_3Vv9j+L?SiD+oV6d>_ zerK{hAQ{U|HGj0V<9p1GquP}o#l&ji1HZKy4~QIOi>(ExS##awCVADhp&g=&gFdv| z+}m2PiX8J2%U#6`6sq@O2`j%B^4&id1k0uPU7JD$`|7V?Pj0;V*Hc^DN7ByQm*dZ#!&CdMvXDx0)t81t5+PKG zyT;R11y>`x_kM7zc7BV^z)vx>BE+SK&ry!Wa0d2alS2KTsx6qR3yl>}vj(qWcmbok zM7){wq|+jb4PLWD&e7ZXK72WToYS2z6Akb`HV1kxg6bm=yVd;Y3?ed8)k+awFDfFF zvUDeR720N1H&#aI7-(-Ecbr4S4Z=MdLpKb!&=)-H-yO;-m@}RE@9S5R z#BBcv-V&BK@ee@&R_*mr4|LKxWo^X@Nj>FSQ%N14u7{mgtr4=Qd7B!Z+3b6~r>7%Z z3;ce>oYQmJkBh6A_KKO(lm;Q-+d9vKe_u%tr@IEz$4rZICAAUe{%mUuT_Yf_6CSrOz^;P|Ow zrQk!kQgclmpaFJ71H3R>1^4)>i!z-p)({f2qn0=Ph9X1xp|Ka67mSLP*5RH*#ilW~IdN)brkAxrgr5gt z;t2W-+b7l=6fV(m4`c%g45~31$B}%0^oM-w+M&TcCa{;W9wMx{ z+Ro{|Dg&p(-@VV-2o_Z>psJMyUH5iw!mf73zEm-J`94XoE(e@n;Em=1z=H>P>Ku7; zu!*HYq>!?R+`Hx45;7XIj=`!8ni}pF?7^|4ptq9T#ceS~VTdhv9D4T~F_=Fha`gI|dT$Sd99YXXV>i(_R&SDOG-bl8pi=aY z;rE5rrb~U{Fd2sieXXaDg#Y|JjYP|HEHW;#e$sckD=ZyP2(x(5vv2r?-AFxvDaJ=6 zbZ^Vj>*5^FLePA0Nh*KJx`0`%f9VsCT%#6Ryyhi2{cV=?S72H0rC3zwo>=epgoRb| z6^R7HGr88UwOCK54=;3h1HHJE<1sPnL-|>KC>4jQDE1)5o~SOl9MeqvRNo0~P1%=d z@AZTmJn>L+TDm@3UJ98M?6eEZla#4{5f{Us;Em14 z@fIA1kjDgV6RY1WljI_1iD->-6WwvLcz|gZ%(FZ)r)2QlM;2mL__T%;Pfj_omegcb z80km~c?(6(!E5|~;B_4j3SAo2&--%guw!<*(PniCPK5vw1^c(Wd zLyc*IdhVmT? zBB=T3!TFE(t^4u(yA24XA(sOds3h(%8^4E49b!8;i?~0cCasAs2e8`3BH@t|tMuIl ztgL@IK$?rOjyew9mNIxOW5_geGjaWuK_SHKZG^E$V ztX#oNcvklri|4W*_`)zZi3c(1`i|*d5R5Fz=^v>%=;C*#u=YTL+t@u>2V&+gFhU7a zY(wZ`)cgb*3FyJ(;i3G9ck3oKf=rE8-^Sj_Ann+ak}kq?R|g}#EQAy4@CV&Xk8q6Z zzqCKrr=I3f`X zN^j0}cvuO#prISO^$qlub5zJ^+nqN{`-H2GQfBqFqeA-kw=mAHr+7&X7Kr|2pLO^1 zDHD2g9SX?o)VmXkoHES1)0rw045iM0muF3!sBt(KAl01j*%s74k0#>Be$QJOk;{y4 zx={qX@H7EYt#*^xX4ZSdDqAshYTal=r%Gi z?SY7|;v{>848IO+!Ec*z3Q5U&+7Oq$w<{X#g%l2JRkPX*l440!?T%j*$0I{p+r!Nb z{e>EFsvKu)s(zzKbJK#`nZ~D)Bb&!%%a?OoTHG)f=gOmfP6pR&jD;(H{DITLW}Ma? zl!)m_GdhYRNNO7!m?J_nB71<#NI8MW#i;e`Hv7R<63SS=NF!H93hhy|arq|I zZv^J1XiV~nLjNbKH=xj)-mNs7g441ynM!VyujGfp0^fZ9Nz#6sIGEzEcW$a$?)xga zhqE$se9z(_vYIB$^K+sq!aa>DZBTTll!&G8aNN|d&->yaYD&snTY?cli3~R`|9zP2 zQ%tvZ;e+Xm*s&`{sOC6+3CV={pvD=yvBwc;zw-|ck&R;SFS7jeVz1K7#LI(ykukBS zH_2!gMo)RinGfSzWH23T7*Ur=erxIO6 zTGX#Kma#d0{-lU(@E;ERk^GT$sr?_X0sI+lz{Aqu!yOx*kyLW60A+kb2o8hc)_tG? zlB&;^YIbkUb4Sd9y{cy^ePUS(aD{J8Hf6?+ECrDE%s%feCYBS=XkiL-#%#}4Q)n~PQ!%+b-Yz^T#@;@ zNN7&NBRyuiSx{5DLa15!wR`EbcWZVzbZ*CWzweG)?-FY6nGep^8V=%G8q!eb-Me?z zza?{I$D=qe-7wp6eK1 z6nwXWv(R}#=@7sbA{G9)FXD!vb=DQ!Zb_flVg0^CnH=w^h>pvQ`7=_J8m)oom*52{ z)G`dmbHg}dHC@D7XXnZIt)LwHZbrBf&sY>kT5ZTQXo?@ILN?$A0i(=%hR1N^2xOmA~awyWp8j9E} zH4wx9rg{;V28lX78CQsRGaGI#j?b$SZ%gI&f;ff~Fj~zdA?F}ro|K*_i5v9!D)CUs zWHfKmtu)C;?u`cvR^}d-dusGngT5Xb&zuoG3f8j0ADa>vcHBOE2hmC@Gr5N?D*_!Q zc$Ze}EE$)mXgoM}g0P6W4wn=SIli?83pNtnoY^|5^V%(-Si|qMZ zP~RAUx>MUv@+;RM?TkBikx!tdanOaBOEWZGtBV3<)pz}v+{;%)a(dx|me`io$&JIrZDuh?^Ga3?hQYK!avwnNf!ONN$q20xygNcw9`X-$o*sXhjgr)p^C`%7?OFDhTTOSHCqib zFanAGt866Po;2p-dtD(oF<($Z2LF~;1z&5M9~m3yXMFJ&nvGgE_W(O_$~;G5f^(#7 z4P$}p*JP+O|0;61_(UPJG%NDobUt#EnTm0*%fhAN{?X0=(?Z|(TpHHlbUKA`f_%~m zTt#7+T+_k!6M5#O@CK(DQ8If{Myfef#E^^1@)UXF`4adt3#6W%${DBoDq=yBMoD<} z3+w2(^3*AJq+4*4bmhTQjlETC>U^XUz(pXLJ$h`KL+?*5TC8bQaq0P5519ZC3^19c znDtYqztxJE+~p@fkV2DRLG@T_+3kOq4cP^wn~(lXUG66T5{j5B`jQ{|({_We6T;Tjqn-qc`)c%8|HfFX8w zvSWKnO}(K!W!5R@ec67o5_Xw1&7O76=y=9!?4ky%5a*-V_1;z~Aa@i02yeMw$HLT>kl)xcnA*1{==|#|_#r5e8GY;f z5+QIl@%V*||nk?Ccs32R#H5!U9^#lr6Mi!_=k`K+eP&|Smk z4?+H5v@C>AQ*|d`>Abgt1vEzV_4^tzGxkUO!(2^PWMVxkFEAQ{17b~8NWI;n-eaAsSbJezhWJo_BI?ERV?w6HHu~96)UVz z{OjL^E-VBVcJ7xHcVy^7myKYPA-e2p@>b2mJ^nS*x%>4{%f8{l7eDU71{S!TN`GLZ z8Sm|yM&8Gziv<@K3fYuV%DHDKLzJBkM!G|LM-9$r{8+KJ>vsgoh9MT0YVPaM#y~X` zPj^GE?dwFEqO`*10V*^j5}%R>5}z~&@kS>_u0|qWzxaH z!Ta+KSPdrqs@8K?Xus)y^BziZp&W_-<~DxP)BM1$&V=HVy$;Uw1+1dB|dy~)YRPrd$IBI;n&zU?#D=I3=$jYkZ zq@Dp+h_nuWBNFj+{$kb;`AAO&P?w|MkpKE!CzyiVunQEripAl~5IkMz(z8io$r#ev zj(C@mb)Ul}SM-e*Ky8UYm3|Ofbi!kwx_H+a*X-&1QbZtDGQOdj11G;*_pwIFtu$ly zr5hT&d=k$5C;s~!1`mX+D{QRM@K*wd?1i-TKJ~8#kO%D*Wq(CM87R}1!y^wT5fs3729wD z?y-QdLr$>#5jqLgxD*aP7EfTsQjE(nrfu-3`FMvXEkA?>$xLye(xM|qUI#%V;C(&R zE1al+&+&^8qio`rb0aM47p5SYQar>+HGF938rsTMTmV=gPRjBhx7kttYgA93iomfR z^2yzH&o%SY6us{VfH_ujSM=MP}5Zo2EKs;6r2+TZ=z$7}V3 zDJIu_^Z2Wk7So_*-d$giC(eT2!ZDP>Fr-*ts|D$*&?MiZ7ml9;g*|MDq`7^tVkK#6 zyv)89|8xxoCZ1sIERiNH*OER+@rJ0VE$KeoiB@7{kY*G1o9$RZ8XlyZ^R6eZHD^c4+dW8*+@4a ziP5S3%u32}MQYG)%ug+s#6Yn|5by>$;PL-{Tgb?HRH6r^dIn{Cz9jHl#}solpj<2! ze-t3YLcH0Z=H9%^zh7}df0Ks2-yiTe4t|R@JbNQ`IkcOz@!H?P{s?goSTt*IJHJNo zG7aeMyh#hjhdo}Of*XKSzh@lFu-Mnw{~qJ+ z7;gr+1H|r_Q>>u3ufC_S1L_6*@5OzRq8yEcjp_y$tipsfG&?CWEZNO1c4`T~U$6hPNz@l0vN zrFho`<3RLpTBSQO@8EnkAmvF1gcBIX0BrvEbNSJ5UV&u8+sM;<#`B8Ylh~8gg(&*B zebR53@LG99pkfE{5*aY~es&C)WFRDy1_rfd?ttp||GNIo7{6~}f1fV^oWA#rvUf4X zniIiKHwnXy&!*G}5h7 z($YSMb<#AU!XT)qs3&}H6DT2HJL7g?U_kuD%RE8zvGivTQs8iPrd$&ZPza&vD8@0hkS$!DGyj5XQRF6Hc5G(6mQKNE75ECT#U}5ieU#E8{4d1 zg>_9~?Wn%6i@%GX0g6~qOZxfFTCb~u2X*VN9aZV0%X-rzPFM9#P+FBRjWk#uf4VlO zzXGPs`bCNy))IF|7em$@^~UQJ%xG#;2yXNm(eyk40!C0sdmRd4h7RhXcE?Bo9~664 zpb&)6MPtuIOE;|Vji7Jn)<*j`e4c1Z(| zQUro;6i8SYJ`nl~)hu!JNvoQ~PlE+9;>gzzW4)Xrj6QonsGPcOfR=8=OrTwelm-Cx zL_eVL{ioNM#fkqOtcnUYRxow0nI2tU)@(-gzB~U&6)yptHI|l^-fy#}ND+pbn))Qs zKu#{^O+j-?^9mzy`M=2vA;Y8P+2e1yYG}DJRH%pj=5}xN%?2ei_*!o~lrGbX@6+NL z&^_nsg$^e6F3RZIStLzbnwX?L(IN*CKZ|i@J+e8#aoItEUXqs&;n~}e23^16LK66( z%o2sMq>&!Nr-!S(QiF%@`{=+m21j;3Y@LBdUmRE%am?aIH2!)CmY<*w=INQW^U)iO zdW3q?RIv^ukr84ru*XCjB1-Uj-J#vLW!lK;@~DI}U!&Gbemvc443rvx)sgLqG4um0YU^hnO-t?{1Alg%c|4DJBop z0VU%41#9$gR8Vr;zFLI%D}NdnF{nDrgEvRi2x{$@-5BUAGL0X>Emv^Yo&I=6 z4@#YEghzPGAF*X?;acE5@1JguGY-eYc4Tdx*u>Q$PffpQHdN>G2U&XG@9-+x+!_d1U~^nE z@^g(W1{oAY>2Ad-4;;9F_}t?7`?pQ_$D&m55^S|D!ns-Wt(;nEs0boxA;iC-2uL3E z2<$c|R z`2gqh`geziZqhx+e$qXPvh|-LO;h&+jjjP6G(y1`KHV!#w93anL%Fcq3EFc#&kzzX zgc!Fv9E1nr1Pv+u^g_9QiH9bZEM+bRlnn5m6CuDof@UC6De$C*2RZGo+x`5_(ca3< z1RJidWD(i}iA+j_rUu+nL&L1jJK0J7Q8%pN@(8LtLH{IY5^3v*6Fr z@K@L%(M6R+JJSi6Ha)=Y&V8j%_)JqIHfkog{Ja1^uDc3qcv?vioUhV7H`5qmcfHg} zR!FIw@iRI=MJ)8QWOCN&6(j|dJz?D~^<7?BoGeC;*~vkJmM(`39^SW>YN+K@Wk?yx zwXDsWt@&}v5)N9w@zo>l?9n920k(4_1VmaI83SZLq0zkYM_cU(-gey9Uu0(kNMke- zYCuz`+cTFCC|?Ht;@%~dp!RNO4hN~s6S9MAmcvn4smm(y`jf$)rNAe@+;z1mU3n)h zGR*M{86Usr8sKK2achqCP=Vfb#uNC}2;Qj#m!6D(-ZVh{7eUtiKI!}ld&RsCW}&u$ zL4i7!(=3RVb87Fj{Z}>Z52F!g5p+vW-?dK>eZplZ9gQbk5=t7P7vOPpSN(_gD_@ZE zRen9$&q|H=+7+&if(uBiYz;qg-6@B`a&AY+w<40B&0o&1aBKJ}^c=)tlUnPmN((jgwO)N zUxpa+^Q|4?i+-sH?cJWcitc`%Pfb-g|m&kO)kKAS5o|U+F~Zp z+IXe&w(TIX@Ahbxv*7V0Z?FTMk@ZIT4V|7$a(dtHHBFC3Yp&^CNvpdCz)ouSxpGaZS zl>H6ijJ9^o_*=3D-mricU1rCkE2m8H?iNc)mSNJsF-jFrYBuOdKNA93B$_I*tS;xZ zhJ+aFpMZ;fFc}XjUFA{eNIpa~vw`Z)A|sL9aL*9beuD5oO6t5iB4FnLa4wMNFlvQH z`n)b~!?ZZOcfsn$2>mc>m-Kf>g*a^2X$ZVfWRIgfeTN_s*Y`t5ux2yqnj&+=y<5xSSZn>))nl1}yZoZA8A3GII% zV8j5yVjbCn{4`Fyp|qsMoyrC2#c&H2oCZ&&7pC!_-O*tBr_vtR3Ft)n^z&jgJS7rZ zF;e@-y6%+S^uY?w|A`6%Me_1d4z`wQZ-9W=5IWZxTaOk%dVT>~B|N6+eU6B9L+EC_ zJwRY$rJFc`gHnr>O4x!jw0UtsZp{nmXfWlBV+0jkTkZ(;TB`C|`?~CI5ruM{lC4+k zS2d&iot>pAD9qvS-L{ z?itZYx}(fU!9yfhkJfLpA>%H}!Ckj`pIcV%U@b0Dv3G?wTKeQ#d82bqef6`5w)tdI zeLm&^w9)8@(i?Mt6Y^))=aCjX8HZ;EXJRo zhTys)2pYEx$-KS}+bem$goH_RBC)eA5a-l_9d`7)o*!y}S__=Ju7d{xywOHcLm)Au z_113i=UoojR{NmXn~eI15D{Iewg&)(NSmUieq9e#>uzg8G+)*J639!43hWu{uOGwS zCAD%I6E^!cv)gQq&S+t2Uy&iCd86NkaEt)N``I_-qXg!iuRrowuXUgJU}mZTxobJF zRX6S+{(Qu*`WF%1t|@u&%9;()9&;5Neb2ZYEag-*EwXy2*;{uM%F?uoe30j3DC}Sw zGo9mEGrGhHKIHWCpsAf1yznY0_J)JQOqx3;qK? zT9y)c@vM=p{(QkvLgi;Y6_nLfR}F@7z^dg+_VoM|P=+2m*pEpVfRz2`79EHq()TT# zxd_hCNv-vbK7%CAEnGiKIY(0nQ=vZ>B@T?lw{`bKeNt;fZo0yc==9>w5y%@f<-grb zWUh>BJ6kV75)=~kI9X6*95~S};0&Yhg0%65;Sga>d zPrXgazxJbTnga0r>oyKS5trLsa9`<6gYfPU#W2fz_e|0Loaqm9JYlFUmUaX_-r7Dd z!Y{YmL2VVQcRWsO(s0pzBF-7a`sKp?LS;sDrSbYDBeI;Mr4;th({Susp4x=*vG{bg zN8mMYa^_KzS`xPhk2~8*NG~FdoZY#r<9&-?)AS6Wp`VL}_ZWVDPSoFi(-NVHPWBq& zv0t{MEyf;;t(E&v-n=+qGl9BFyaGQ2@bE}%ZTZL7MlrYzqUoBb?_| zM83OJS&RynE;vBb`vpdM*DVj27NT+AGZ{Yog2UVS-cV~oZQak|M+0@rjVL1BiSe@| zQ``QZU^V?b8lMO7xe?w5kd;Gsh zBWi)a&Q&01CXgDOg52Q*hHdzun&@`*Oo%%HC~#2wi%n-rX)J}(*BgdFhJV&W1fO{Y zi2TmqSFI4Hj z8n(^oU`1LY(=-H^?%eW6hlN^fH(z%F+niyUs#k7Vfus3lWwmuV7{~;#BJz38Mu75f zj9ukYVmXIp6E>45mi%5iQ0i`S75%T{b;d6?+J(%$fvNpLCx}Qt+nBiO=>u$}lVb4T zBoTZ0ZZ#Uboj)7b4uvIp6y#VeL35z4&8O&@!L95?Y0Qo3@0B_aJlNCcyI6%o>l@t@ zrUejLL=QAej<-&MS#s<`xYQfiVlN?&YJlo~mm#ra0=3e5j@^ouc?OK}p|~VEiWNZP z+76H4TlZ@+)a5YOLA>F$+K}hbU^ZNS;B@*L+a@<7Pc>h={I=%Rvl~RiOy8mh6SEc!qvDAqsEZLtuflmH32Ge_TsX}AlN{^#T!;I(~ zCE=?rK17q?B9hu$GlASiv86<1J9$ZxY@Ogg;N@#KzJrw%#VSKsmxvRBY8gu0mDZvf zo@r##QFtO@#KtVufo0C#+fc$Hq?E^l2|^#Y7&L#bLd|I0cIT2U**&zeqq!Ys^}jA= z8^0*V2egH`hRm!aXV3jusx-S`uS;(W(wLJmScb38nw|J`s{X4qj^ubKiy7nOnRpO z^;RaSasz95dBt|vh=z;HM&z3amw157owDVRWM#qE`(KO}Gi;XWi`cai+hXZ{K3!(x z_Lj+V@ECfxmDa!ctX2%iBFslRT`B4N+5ztdh@bd~h=5Xz`a%b}%-GC_I&9j_6VIrYmofbg|yMb^C{MWu9pX6@7a}aW*O`)B&QF!C8XZP_pPdNm?Sc z$Zr0xDr<9vZ5XHSL%_=TauH{fEGI;F0xV;rFWINbtIC1%NOp+~T=bM0k;g?hgOO?? zp}KrpIpVZ&Yxb3#FqAZGG6v=;a+-kPUI$%MRf=qqgnXI7DIfVaoFVXw$Qc;X?4?X8 z{BjT;qC_Ld#~C(WFG3%Ln#&{X*?Jmi_w2Tcsb`;=L0&D?q3@;EwjSCz_ZRe-M!`eT zeVULox$FqMD}{F;>?)MvO3`3WuFM$4PXNC}0a!$M+Op~4fjBS}o6136BRCZ19|Amh zk%z!`eKIdMV;k(f`Ps_VBCkDUHV$`Au(a6FD!de9Oa`fxrLcE>9Q!t7RcyUqMN8FM z2|Q%9dUsB80Bl#Ro{IK{gUKSL*onil1Z>Hj*;fgbA+Zp{x@LMHp&jiGvC-`BzCnlRu1-JbuNjTUUa%NO)5+lRwrt$J%emA~ZLueKWH0YL zy!Nm?JT$T-)WXQB@XGvQA~;LK&k>mJi%v6=D;FFX0`4blB#Lc`f2>P!e1EpqHYGz$ zkhZzPeR6F8ABcCu{5OqqBi62%w-{%f&FO~rafvCF&SrUkFc?I*W5HEp^weYh#=r_u z(mbZfiL;O1ELLUJZLN91EEXj{1E|-QjvKLn=LE3> zKn-vFX`#?2*hsK_0VfCr&HAsO=8a5%`9rZiy<ToGK+pq&*$m(<&TwB+e3v$UmZJpOEQb0d zbBSuPQzi7!$?7M=qT{f9@t?1MKwmHXY4ydm&GQ+eP=_qzZgV^966lgOcsSy+9k+q- zU*b_HwbC8V(1f=Dh!OT|0)*1*IZ&dc1&x;(k({Vhgy(9E$#on zmi`CkPt|`jf8u)oqBCxjI0$!>=jo#C2GzpKblytt0*Re%jq{%LH+Dk&G6%JwTMvl6 z>qQzDpWJ=4_dAAIgyer*Rn|xqaei!*-tmHU(WWFGQ$ZoyYPVFF{K}mD%>aU;tK48N zft#^F3ikgGrjNoYRa2JAobGVpMpEsqNW?gb^B8zZ6l6z(Au7x0bEK7xA`HB_v0u-t zPJ^X;$bPfz{68{%Vg&ya(1@nB{mUXF>ExrZ2jzH2fa_td125cyB z-PpfP_&9^37?d}N+KhSTr&1GTGJefE?@0zWpoB+8<8+T&i=xflm-RZ{nbdUsHKMIl zlkUp57BKMVP5*{G*oB0WtQmarOu=cNKno3NhE;yD5?R2QodshPecT)Pr6XGv`%PJf zis9}>@DRZl@=8;zx0&E{S0Xh`S=cV|^e30CmeKJ*qEr+6sLl|o*eFiWTnQQ!qoSw! zLT2+QHu!W1zITSzfWiEZ<~S02({{`VJqi*l$1t`}oP+JFUTiNOVQY)6@gu@=WIT37 z#YzOVo;}BGIi^yska65zQQ)E54pdVEXme|}k}^+k)Cne%rQC z8o8l6^Wva+*l&be^GC6monS;?Du{6qc*Bt{3pvq0g(j|e z3CxBxj^%;~C&}RHa>xTyZoKT``>FgDD91`pqz$aLO5FI) zHjI_6dfRCl_ciiy=p{G`m3@6)#6{ClEAqQlv)%$PYjr&q{N5y>e*zohD5^7(Nx;ho z`(@6KgblA5>NdPwmA9I`MqL{nWuCAkQBajs6JC;r}+pb??JykYB4)pgQ% z74z!A?jXi&xC4D{%&} z+}E;e1Sq!Dpb0mp@TH`>!VP*r&}(2SA?1=?@k33d-`o#^-XAw3wx+Jmx$lSqfPN9Q zrTIStfLJ2r>co7eYXIx3KTh`i`#uRM1a$vGg&yoZ8@$5CA zyPMXhD}~SP$-xE_iR0K?`CEa}PMmxCtP<=NF1*{#v8K%;8!KCp-DJ8Fp)0UR8qj`; zBz5P3lOJ&$N=|FC9!7$Sb7M|A%lfS~jWst+Lv^AA)jetB*{eZnB?^98sGvBhpGGtMFcv`AYS*I$X3io_ z*!<4LdT6%n9j4of*_dgcZy5wHkER{BeSmoo-D@5 z%oki^H(OysTvMA3PD{N;@D@;Fr=^aDZ``bFUREK7FL9ErJDdF5G_@D9oH=!($;^Ud zj0+}%Mw-Fx8g07vzA5K-b$$2Kb?gL>4#)CbMDMFQtH=<+R@FfpG}VnpSR`tRKmn*& zD1|oJutSG9iI~%npZ@Q&F^SbLONnehj8TDFrTs*rvCz7q8~v5ST?!;SSjbuE=e_P| zUClb&mxVTHe~E+D*x4&i%rn&hZznut?<1nw3e}H^&+JI)_1L1N3z3a785Ots0e@P> zvYi090X#hZ-P|(kGRI~~3O{IY7io}~#Fs#znj7$PUguC`WbheuZ;EMLwU*k5`=x#;*;y;=n3(|YJW{X14lx zd)AvFpI%f%$&y0C!g8&1KKD;rzg@Iv&VQC41Ox^WQ&7xke&-QL_EIMOv~BW|Af2jX zl~MaIf<6#XP-MK)gD;;6^W>p_(xeM*DcV%kIdMib1JE68nlhc-tDZ1p`MlguZi{!h zl`grdonZXy`{9?}P7&i9LH}S`I>RNDUNT!`AR;0oTR$jEaXm);i24XZ0pNjj)WjD6 zTjg)^)kyysqrUTHL;qe6ckR~?#B{L{NP z11dF1qgLpIz@pEF12N~V%J0{ITn#C&BT}L z+0&oOv$hxiy+dZfC-J2xxS+x5lF^eyN>?WnENpKe=F6(2>VETMgWDeX)68z=m~hP?hciKVJ&nvy65G>OD?hji?J6m7g0gymG#o^r7VIx5P9FMi!k{kO z1|2oHW_6J6x>C_OQ&ggoRV$%e93i{GHhu&=T;J^WNddKqCmf(?P(>mjYYqEv%E5nu z-uw&oC>4z44>-azGqT2+SPHceHCB4ToWacGxANO7R>&Ez@ z&F~2Tr5cx-F;`kku}Bjho;$LyFZe*tY8-~qrw08{fz%K^CFx62<48m( zQMEheB$)*NTSw>Ng{nKuj4KKR#;n_7rTqNR2FXx54Z#{U%UkzVix<4w1RSy|bT&3UQ9^;Z z9>qXG-}7@@AeKrZ{LykGT%qRnGj+t&>JgRZJ;rOGrLcSVk4m;;;)K4u1w`*%k!Rq5 z>6)2Q@{v5WUVxN0ZGmgX24UJtCvUfXvpDSY%$-~{`>Lh%%clJwOaG#O{S*920$2qwZ;nnX*$(Zs*WoJplb6U<#savH zFf3KEYu9*x4(fzaE%Ad5L8Q6pB1u*@;!X5HBtCYq-pVToW7&{7*3DYPgbsCw$t%{? z>UZSsS$NUL!um<|R(I9}dL25xF#F?qMpX@sa3IV|pUTBE_vXd^1RKaV0}opBeOyu= z_)*ULN8@$=n}P%s49w(9HMs;VR*+*qLmZHL_4TqD4ug>pARmwUke5tkL-c(^v#dP_ z#>XL=PpZ2l8dq-6o0=vfJUmbM0VpOlgMO!Gz3XJXe|M57bqHxXUiK8Ymgi704u;7q zg%cUnn4xdN3K74`i1d@0UoEg8uu9j82oAc3^X5G2S9C*_9$*Kk;U|7sF+uI~D*ION zA)0fh4H==zjAWD(n3YJc(={|C>4}ynmnF!+5}`~9ZWeVsVF@#WOkI?=yDvBbP{`o( zdLWAuob=rAe7Xa8#<_pZlRv@C-4(AHAD8OS$90q}klH$pl`jnUN9M+xVOLA$7-Cv$U&3Mn=}IDYSQ;l}w9X z;#b_a_IRE3n|8(Q-jo>dJ@D=3*pyITN!I#{#B7WM)yXiZ2SC9qz29CJwnas+3R($nW~v4V3TxPK%bGU~$yx#S9{;pcRZZtC%o6U}34nj8)hs zZGgiHEXga-69^`vIb(#cNTKPi$-mibS^4g|&GaFsJfW`!Tt$s)*9Hg}?@0Y8rsRR^fU^X%+otbyx~1j}wt#wn08IO>wH;ZK6q z7-3bJsf$^~Vh7YJqZKxMBif-gWHJ3HRMh%L8DxD|QUjY|^yKa@;@-m$#{tytze||^ zlMcMIg83h{?Las__x}wr?!6n|fBbv>Gk~PFu@;KfdK43wbD8x5^*Z2#ob5@I@ZM(! z*2g&~rp^WgyKV#+lHNYVgP(zzLqU9s_m=_o@8KvC@RBa%a^;X{N6d2fNX!k?bAj*9 zg1m2CPS(!dS%CyiHVT=W<{$HfE>`1pU^_$o7k2Ik>OW!;{~g=#-vRLc^Zfv*vgC_u z>UBDY66x(Oci-gSA!J1whK9L!3Wxb-veM0M?$;7DUsvKJ@@{UZ#c3Z)rSw4*%mjb} z`<@?nlxQ#)@1=QaLhtvNwqwlBqzxf}i}9PxSWds6EK|?|DbJ!atR>+sS z+luDzk(WSNHhDW;64#lZn||Y}Y`iz%V&h*$?`HdN55?cF|4Eok4T{=?x#>C3@~~a( zhWx&(253=s;CTKC9ke+G9o`czbXj$(;1yw}0R^E?*^7R^iL_hs81P`Qm_1&Pa~NDN zf`fby61-c{UGQKq&L%1Z(S3PEcg%V6F+<$JkX9RZB<)2w--boAa?k8|(E*2m?>obo zI$muu_r{n_>pRwC5@MH>cPc9_DY`B4-AMZJ%>)A=H8{t?;((XXEJC8wOGTk~jRR>C z+1qvLEf=b^Spei=nGZWRLdj<6+JZ6ZN$9Ybrl0tQr}II*C<{HG*NKzHwb^R$;?iOA zZlLB613B3L*1Syo(oLyD*fnf7w1M#x5xpet+su)F600-u=;tetw;_|j1tx4r1v~5W zJ+Qs6RT3l!7yvju_FMg1FAWxKKD-lL)-OYCs0M=U2p*a_9npoDSE0K?N(hQ!i9xUeLC|;l8L}~Ahj(HBrgsIEEI zHwVBI*sHX@XH{h(2oD``*j%E$HdrFDg6e8?8nPS7X6%!(jGAxO{09rQrpj!CiQ>m8 ztM%HSP+V&gUb{zcBD}EpuDN`=2quxqjq4K)@hR!I=QA#!k?6(8q;CmEy3u%Ed1n%nkeu8Z z;4yjoRa!4$Kj@*#>N}gbp1JXl^+Xk6Rj@eutTcT#ynuXRVOP~*mJoc8NW9_*r*)f&;DJ^Bl z(x%vN`0bd&0O#-pTe;!@`j$H!8S4*?!erCY7a$u|H{ee{KE2(J+3&cPSF+S22G-1v)tP&yrCh8>gm>oi3T({Ll4jhvqk~#%c2C%h!-XOpidd)cf z;X=$0qbK|dUd~S!Gz<+q(L@BC(Fw%*Em?=hTL!0zYW=)z&N0swi-_qf6WD&w;_;MO(^rzx9z`?R@rznAoyStpKrgnc{;^0 z%}oO~BOmqfINT7uTPltI$hY}EZh&&Qjmf&kBv}bueE)CT182sT&zZM#5*sVX@zS?<)@qQ2B%A zKi!1mepLi>@Y8I6p^bI%S|gyD4G5oi_?l#9L9y;;4mx{k@9$FcYn~FDg2&FhTm9Jn za+dGur7qL;YZ;(Sj8HK?y|X6$WTHunpQg#ee;1THCwJZ!W=vte(iwBPhPGiLbP z|5_100Zk5IwwN1`R}35+lCRSs7be;Cidk*08#|EF;E)4g zdon_=#6PZi6xbae3bkAz1TFU==M~S1fcHD%RY`@NySTcZ!7Czw%Q3_jsV4o1b3JXs z;`X!9|1u=VfFjv03+^+(nITob|m882{mB|9{(7N_z2M;$CacQlAw%Rs7o zhwS0k*-h(8)oYjRKmL!4Sy+t|k|D6aMZo!QYq7ZONn3i@mE6k(_Uw1Y-7lUC{m}9~ zn?PEd>4FkP*zo;gM6sfxOCu)pBy$vhy5Bw82dEN+58^JlCrr&!FWEwr2U)=64aA59 z4&`v^&lBrpDZTH?-sr<(!(tb}oF?GFWB}pPxhlSxO!oLgM=_#>y;eO%sJc|L66>8%o~L|Jn@ z1!*<35K2ZVeoa^xmF!nS7BH?tnxmU1d2RFW4h_pkt;*Fq>rAV9{>hAl2W35o6sQ$3;su=FS^0#L> zS|eESxk?e%Ml+JY>bM*yXz2ec1gwHs3As0OFGo?JN%J_2L>7podViuWrFKb!9WC>= z4w6iw?&fUwdZNMqwGQG#hKt)gA<_j6k)l_-qy_=dnL_d=1}?Mu?*vRW3#gbVpW2*F z(QWL08#Tko{ja# zo@MpRD&kg8=ef%G7rAFd%G^iBt)}f$z0iN%mOa?QE)`r0HTOByI5i>YM4)OjCcso& z^UAf}aHK-HLd-RSj%yccH0xDjVet`GN{4)qjyX~9>u?K^u`%O)zFt)^{O;Yl$F{Y{1; zdL9U703OTGU_1`J%O6hyPvmgnmu|X;d2f;H!3|(LvdD1HKm9^ooMXTo`W9m0Fj1{8 z4abjli656vcb8F_?#0%QCMi4_QFx??5R@KV`PmsqzP0y-7n7)D5{{LYOn*aVa+r3! zJO~a`xxB0P4x#z4=TIamIw_j(uZ?i}Z5DmrXt4hS0`lpmaJ7(RxMy-cf;y^uwL68O zR*i0e1w4b!z&&lVaM6k!fd?V@XCv5ans(U7Ysu_CXPC0PvGWK@e_ve(rK`Y>Xd){%7%oEG6tFM{<82RxH9^#M-?BI5e1u!=1S`gT z)!!*hC|uTuW(kj1Hx}Diu4C{6%SX7EYY?ZK#}Y2PyoN2PEcYP=>fT|P?je_bE}+TJ zZn8}lbPvl9l4rNjx@|D_KE4cV;puNx10tA+CuHK?$dC4MGF8VhTX524wTx%7wGPOkIHANsdslV&-iVj(qVkx zlZtc6Cn0wUUS!02T~m@_K{Y+5!mhj|4nIvszKju0P_(Dasv662 z2jo>!oUbJ{sM9Ny+3UU+!%IlXg%gr#>y@v}{4^v#bf<3Z{XwDk*}de~V8pbON*ktR zw(x3tCLM8UK|XIbSV?`YR6zpPj8eswTamW;q`BZ3p2oW*~OuL*JDDeqslzjyXRR1v>h)2z)bZw>m27|m}D}RA;1j5_y-oy z*<9^T-wbQ;J832qNGrh2hkr%I&}WRe%(*-!E;PKucw}$t(xI8fb23tEr+-L%(NqX3 zg+I(J)C{e!&@q#Yqesvk%R`!H!;J*Qm$juzm;mfPDO)WC%sfj9Js3i=WxxuI-k>rz z3@7FZ?#f{rq*4pqc+%IU!J|ro%S%q5EfMNqrl7+gq6GragDZ3>d%6O|fucg}L&K*Q za(P2DHh8+DIlUjT&xzOm!vspy=-;H!Kk&cW5OiZmgOyvZMT#Br?6X;MygV&_8(4E= z3sPk2S$f9Zc&Pmt7%fle707n?0KmzV0RTl!I;0!X**!-dh#Rnw+oPysSJ+KIj0Lyy z(e?1Wiothak5@dv$!pa!)0Gqfp4*Lohzhb$WY1P!?ExBZJ5cs?@I8h1u$bMujW!|s zC+|!ot~3{;a*)Vh7$3^Vr&je2zcc#cE*>RcL?Wv&OO^ZwSDav|rF?)ZZ)Z4tnj*f`EC1`6=R&3`Qs{(auX4FdD_zui;Ny_^0IoIn@DT|dk(&|VK#gK|eXrWol5M(080PvIo5=xGRdMq6pM( z7$(|qFAlL4E;briF@@@j!pFU2yRaEf;>3TYPNZAp$G~p;HE+Wd(+@}GYwa-J@QpNV z&LY@5R$2FK2UE_d!nZsU1}Z}xQ}7WwLy3erK!68Zgka`dGWnAPc}>Zk!Ddn5tsK;A zq7Ys9S)n*9Ng!L~cWDw5gW-Dol<79cWF@Acxh!7WXt^$nG3|x|ATHdg&BZYN<91gN zz@kfogqi)#`~?ge@JT>j0yN*Bx2rd4-Bk~g$kB{2LJ|MV%1QD%Kw6+6!C-ja*H(Kw z$o3b_fF-R!%$`9@h*wS0ZebHURn}B0_D`pIiybwlZkhZpT>1)CF+cFF?YO#q4pUx& zMI+x3;m8tJuHk9wpJBm5CbiQ$ zQO#6iK)5tc)p+2?0?rR2S)Qn+Z>~>w@QU&thO>Dex5$K=;C8zb#TfkjHYJJ7?;b_D zC*?BFFFJ#5@IO-23gsBb>m55mc`Os?jkO(B7S4gxPKJ(s7Ji1#@SBNAHu)0d3i6gl zh736D@QkAv76ZIHmiwQ9j>kbHAaHeGs}t_*Hli~#ZOkALnb`C0CHw+dH9e1oo$JaB zOftvbRIVGN_=rx`c9LG*gbS`dv7#e1I*3B;7mlS9v=F#?j;PG~0v{&cCE!u=SiF_|vou%Aco9fw`xI;Ey7QiLetSm|a*+y^SQ zAEQZ$spp}zEOr9!_r@?hQI~Gl`~}Mbu z3tG{RLjTOyRcR=#IQ7<5VxyW1x|yEgi4~g`nBW9>tAV(kn?f@hc+2j1e9&N<6!PDIqcd#9lzXdq+we+q%kzOHC;slp_kKdcs8?HLNgdxTn@+> zQjf5a#n-(r5l=QZ!o~s+>I7Yk+^1fEnjj^9iAf?#rG4ld`getw5&*Oqe0%)2sV&8gOOWmt8b` zq6{TwP6ZHQM=?n1!Xa3NTevG&KVD>Y?x z9rEhyIb6-y5$v2>4uk2P)bUk~SnNf!?P4B&^}!vzNOCQ05Mn9Z(rc970spJ+-pU<` z|Ca>Z=UJQH`91{KLnb_6J&le5BTQn88aT|c2*Lkvnau)s_B`n`@Quw3+ahZxFg5r8 z;f+iGKbSwad~3d7^Buvv+vXj9*V#Mq<3+JQwj~B?>vl0!UR_vVS2Z`|i2`ua#{={r^^W2?_HW9)8U7E4|;V`=R=81^>IH8e87*_I=rKZQ4uU zBdR>V7i*b`+~(-dUAyr4Qc&R{sH**J@qNg;g1^5?Y~(s#9G6Tz(|sxQ^`gYXRV$*p z9A8{lbDo#SeBsI?p=-PEbeFGUt^Hk+q`PhZiT=FiITGO06<$m~T=T^m(gBZ`2TohO zX!lqk&e$`!a4-=#i}jDZQ{UlbWlig!GXR07tDnm{r-UW|cV1|) literal 0 HcmV?d00001 diff --git a/vignettes/img/API_plot_compare.png b/vignettes/img/API_plot_compare.png new file mode 100644 index 0000000000000000000000000000000000000000..c170792a678fe320ed9c0fb2e5dae685bb9dfb26 GIT binary patch literal 406411 zcmc$_RahKb)UcV5;1=8=K;zmt!Gb%Dy95jF?g{Sh?(Tu$5ZqmYyGs+SaTrdLbH49+ z=AXHli@E6Ts@>I9yH+jRYrP#JFDH(SfRFI%)hlF42@%CtuV7kUy?Q$d2lFx#49)P* z$7=^gaiLe0V}u7UJ8w+{Wd&cos)<5;(1(86hqsl`aCr3!o8q6>Ye_}GuUD_03nWDZ zm0fj@S71G5_XuErt?{`Sfh2>2u~L1YYDJV*PMkaIi625vf!;yoER{x}P?kx{Y(6MqDRdFFP0kz5x4h4a5KEtp+vP z=!WTkkNoo;31Q~3!T&ny_Za>E>sZY*%N6T#lQ%Lam_KMyzUS{%o+)@2djD>prenv@ zHRnk6GF1cTL~=e96!9@<_O#1X`FSUqP**ux$3IU{om^!%We!Z z{(CAMgDQig>k9b-@GHwGhF7RmO&b9X0Gij5(VetvjOzHIwO5r(|IHlkznQNJoE=S2 zWbtV)(u?-QJdUKRR=~SOV9J(I@Fb`pb+2MldDxO+cGI& zMR>RF@FHP5xQPoVgY2;y^vSfS4=(OG`&b*dG7D7J4>(T8?3|T>wFX1}h zaSpV|sr`jW7-&pIOlq>`Gqrj5%r6{<)(A{O%#4E=d{leZS9s zy9R4*+SI2wU;3_SNo|hJEFaf6P1SvvA$*+Wh{%-;N5QGc?VS%^leXpRs8^-ieHjtm zlf`2nk6SO^jvFXZ_18r~42>R3O*xFvB6%Hz6Yh{V)P@M3Epel=Q`ymK`B}s1|*mt1pW%5jl@7LPc{>xey<(r zYlWkKJ%vJ@{?J&0o1VUm`{d^n)Ou@>t~-t924Da)SOskAa0t!XqM%eBeI=ubDs=b8 zB!4j9xW{OE*LsVv%g*cv0ZY{}O{3|IMAYd zpB9z9Y7w{=@>@`#zL?dtOqqIB8Q5~qhnf}QjC{ADW*)FZrIxK@jZsOV9As#;BXtAT zena2fftFE$yt6PN#voc|uTxE0$aYu08fX@=9Nn6h%5!7&k-RR|8!GfJhpW8+2O)%m z68wyi>GXNStq8gC$-yw0&Fc!`KLzkX^!fJJv>>ao3p3plB#Q);&5q^rPi4S;O_46Y zli?Z~&F75L9?z>ummlxLNmeMFa;5v5dGY6HkeVQ`!7EB(Pz+#e^-!y804989xPD*= zBa!G+V)BC*U1PqiB*?q>K}9Xc$s!22RwU4CzNnNhObO0pxozE~8YZZ%Xx-{{}q;I?g0)`?7*I>zZp za@ieYZW=*~6}t&O4`LPC|0+XfN*MV?_5Q4Djq6GTG4vi|dXZBwj?yd%8@K(0xGuOq z;Fm-0ZUYT`kzBeknWcPh6@EEV0aLP?ua6Vez|5W<3-7A@z+bmR0{fq8`7Bxey++FVdaJ+Lrr0Zxl#D-wkb{tYB+z`2V4uBF)DuMuYNg(vG0|swyo%a327VeQ^&cgSuyL;w zC)WdQ*M#@amMKhlJxiC(%37DmR|?T2PZ|IMC_ZwQ?pOX*@hU344W^T-%ipLy?1%zyH*>3aKg_2S4l(1m3 z{L#Gm{;yOm{{}&ZlSgD+9(NpYTe75kc=uM2{vf-r#WbVoVQv_kq=bz3r$oXbw(+H@ zmAliivB~7R9kjal01C?BXDM3?Jb#dbnVt7jL$VX?Ty^FAT%I4UfH{^m9ymOiUX9$* zG?~D)4ll1=H=@i8{I0mY9siBHj~{SNu6tGdvkkYlq^%8F@CS&dwhkLy9^@bsD{&L} zl+64}Kxg7dvpG*4joC3r(BHrhS?i6{`LkVfooHkh7`za%p;AH79N;LPhQIS`Fj?T; z=_LGgKf5^NiWIF)ovA9}=R=I-iE5M&SI^kwL08=-uXhxhH?(;NlTc~#HU{&8CcI3f zho)a+^l=6rZDrhO&g_xQW00{bE$Y z`N}6e(I(6ne*q3pK%ZI{in8)P(c3f+tk1ewIlN$rdii@yc)o1;^tfPsdx+Z;{ zfBl*3|1l6{*}Ou@Ob@0#-3KZkb_8~oExIn7wxfeo8`$IjDkQE))*0u&8cC9HGrA(r z1yY#Fy5XD&WZ^@u1TRI=nL~#rFj`Un4Rb(9`_{jy(7d>)N)5ggm3D8Xq@Kb0d0yig z7dG&k(eU|U9E}UYjDBpMCw-3|SdaH_j6D4>3xg=cX!|j{C5!2x%ux6{x#Kb z;Qyavm8f4iUPqmZtZRy}Wm4b|{X3~P3QYiSyI-&cTJY|>zy8GoB<8#EEC8h`!hkH+ z9nv4oQ8{3QzD?_(zSNRy+k|hr*hH6_7j}52kh=ngK`5lvZzuA$0sKPSn zDebgt$OKpQxr%5xLYATLA>{1DUB4F@r!Kh(CeLCKPj}+|-Gp{{+9fN;F<(g9_{{r( z_e$Kk#UNqFV;;=MG_0TmeJdiX8FWYFWPgk%o=;DOq{aDCj6GB9fyu7)E5yQ-gE=e> zfo&H0@nw^k87&;*+~QjfSs^j7)zp_JmbY7kWLf6=8^^Ct-HFhq^3X!H2vprkiPaiL zyHGD0HmZV)!s}RJ zb4M{!)!k>#rjVjWg5E?DCsy~L$ZA-Ra)@y)t^e{Zi1W}1Nia&RH>PCaaA{t^=Y#j6 zD=y9{Md#uyM!RfFu8TZ!<3Xh12gSy->MPO<)urb>~>%{8)WPG9NRw0)Kzrk{IYTlbRw+>Zbp&a@LEE< zyXBvt{?^T7zq8O35h8wQ248Ga6JZl*-e$($zHzXDY1z}f=T8LwZq+THljR8A4ZMpz z*Se#6C{At7PrIp;5+VAj`@+dQ*67}=)i_i({C=AG#wjw;{ki<6^EFI?5Szfw17X}m zN8}&*7)_J4PEwx)Hb=6_1AO3UhS~9`Y4^5c#yJ`W)Y?kufm5rnBe*j~Qnl!cE7H=9ViDOh zT>@qT7j-9=3o6<|W26f6b5}SOF2hdDsLzu=(NZ2J4O*4RC%iJB=1y*QLe8gb7ai0k z{Z7X%e>EAjU$Q~;A=N^uq!0nX^Z)6+*C`$r>bFV_-x)e-GB*vQ{A(HOI^I55g3 zcwL<&h8QNcjEQ`>Tdvk+!8jVDKERErjA8Qfv2%LwU`K2e3(cKR=ThKV-xti;JFy6X z0F>hMzlx(@UbO<@9WAB!hHP{q1H<^!$bl9mZEZJ5352H9u3E&C53g7!Nm>tDSh+0; zemh`~=T-ws$qyW<=G)TW+O1!nj)sU>Y=H2c{ZCJ2ixImsM&uRE$;4$5${20@=~lWF z#pGaptr9h00`53Y0XQvJ&k}@jiwKQ_aTWGppjC_jU3VbUxzeoo2}6(8oQWl7;3LYc z_;k)CX?Wor<~=2oj9x38ezQ)dSiJ~G98LKkjVzA?4^M1_l#z%|BpM!F)id>C8b0q; z=A$IWgF~FqHb#LTtee_(!BB6;pbR0^U?tSmTH@la5wPDhH|rZ$qvng1We}52L(T4=G7siL$U^(* zCi)bY!mV^R)UI3~Pp1)lO>6%%C*(jl`Jf+=p*DPB!+s4Q%%izFk8^6;h`+#{%RKHi zDc=4;9vIuOJ?V+S{D!8jgB6qcpNQav%Re>9$c=U9iCQ3r#&SY^d|uoBnAs>8sBKXdYw2G&k6aOg%GEQuML{%K3FFsEm*`Nuaqz(5)*oVr8lkKBynZYsjR6*-1e>iB-f!+V{ z^>VnA9OvLG=?dVH-M4i_gxbzVE{94H)pF#vcc!KouHN1SVKsfqoIN9LTYAnw@0=r3 zbYmQ;*ABeO(T@)r8QJa$JgSO!l>IS=E9oU^%Gl| zPE#{1TaRNePUkY*TCZIKr)q`$;nwPJeW>Qy|K}h8uZP}3E|CRqp+P6^3J^(|I_JUw zUEG=uBA}%6OC5vdxc7ORvM?Ixcw?LT_Z}RXpakdsR%-#qqm(n zZE0-GGGDSHxi}ON$${){?nLCI0BEdtDdL=N#+J3x zvN(NeSpAcs4;@PhG=4-}uKtXL{>&Il75tnbo)w}Rt9@*A?EaIzy;ddJLSon|?M2g7 zo-+1iRBlfUyP3&YGm6I@wU%R4Eh5zU!#GS+^_(OK(|_|suWZ*^It+GEdK+o5!54<6 zx*ROLs+T1>m7ifoP+c3yPBA3g_=qP{4xaH{7(bvWxo+F0Ag{Fa&*iXA3Ovd{1O}N z$OGC?XX*3U_!q7`k?S$~r8V?1Gln>j023r{q(Z%FazR2iM$OHqPqDj3Op@{U-$u!# z;3cU{McmM!MoXuA!VXZKrw%5!8OHodca@tHwPQk@_LNa5TUImGQjXo#{^q~O0vqfs zl49Jc$5U>N8F!d!F*3CjYiCr*3rv}EvS;M5z|Rd;>}R4J(ut0-Vy*|Z5>Ba>y#5Lg zolnX#r1qKxKu3-jm%+baoE@nyXSISg=mKT-tt&bQ{VDr3g=oqw6=o{8|77eg1R&XT z!0H8u0lTes7z2`vRie|(1ZSJ=Kb3ypCL1jIG{8uHDQhe7F#&m93n?KFAsFe<@BAZ%@s$WPFM>uGf=_9Rc zTzjPR*9^R}?QKo=qap}zmt=c>EUIREELB@}>zE=}wc^9hkO<)DC8%sH~M^u&0`Qh?svlBqOCW16|!=%0cx?&q&iXEw(}Hs;%&QR)); z;fhbw!RTfJMHa~^f{@jmi&+jvjT>-Ota^JifNC{j9zzQsK1e)3t0yriVW6p@ak zyF!$tQwQ*D9ygr?5}5!zXA&N*v6uix@tr$qgbL?mDAZTeonu49wrV<#^rD*lN8<#< zhc$QBW0*MYcZQI!(N!iJua%FR^|@eQ3dW*!O-qHi(RcKeKS!WF8s7UK+-W;s_1lQp zdV6rG5|>o%1(I&^b`NaL?ggBA4mNab|!|L^r(JMAEb&NWoM)9F8J z27Y-B<5;yFd6KO??||A;6Rt}yRG9}l-R+vmeHH_fOfJr@ZD>7m9i%v#oS7hIZ6I;i zC)E-vA)Lw|rDqK5cZ;Ml4Z|nQcAu=&C;2S3zQ4ZHQOyqadA|r#FM2XUigbJa;iDMn z*L!aN1A}?%`U_< znL2PR%^b4tZJ@kFrZg3IV ziSaq0V{vtM=IgsQ4IZL6CvR{d#-u%pip=Y><@bW~gPhTnkb2scEM?c#0l-RsE-{exIiBsIZ-NH-B~59varY#t?bC6ZUXKQ z#dertHM!TJkBC8$hu7*VHL#xjyK}TO2M`lJ!moVuGi2H{@Q1N) zFrc>1)1ykj3dJ5oY}$ok)RiD1WKY^7Gg`+sJ&fu<))i$T3d00}GP+dip)z}|YCOiM zFOOE?zY6jJT^B#3yT?15RtohJf2(%gv3%?C*_?gsl*eC7lN%v{nsjakC=QODoybHhL%;NZZ%=}osOohCWg2YJa$XlsSBGeyl61FPMF0V+$h~NEbz3`H|i8u7rspE=sBnokI69(M>wt!>r+Wn;O$rM zeP#px?^&T7;rhtRz48r)9(BcA@Ijoh`4rn0@~AtQ{_`Cuq;5$nSd)fx2Ic8Q;Uh6y zybz*h=!({NQh*?49i*0ExClb)-cWJ}B)U*CvTajqZINc&!lv*h(l<4tN+eq**FrJn z!nkreD#9BYgx_2CJ}GyA_c3w(GyRJ6S4zYWs3c@88{ELL#dFzcrTM7(^8&`y*y*!B zDpl#&rh=H`j=T-ScQW(Uc|F`wTLK&UeynK5UtNgm4#(3*e6-6e62PhgcT`J>jo@Gi+Cyg@@1-CRH zc59*bSX*h_++qhB?Y>fIGnGr9hp_TSfd-{DmzP#i*}XLN=f{K2xIm(wifcH~ThDz% zr;E9tr%B#f@Bc^*X5R;I`TYRW+3{AsD)qXf@#KrOrM2X3o+%Hkq^ki$?kB;PU>af{Z#3wH zx=F7q#@me!mL`fFngi)k-=K*)71#sKz`d)()^jVQxZX*ouP6o{wC8Dd!}5s%{@>Ut zBGuJC%d%5uNw=T)-(|sX=e1lJ)Q327PwNQGT#omc4>t4_pLN&IEIm_%xIYj{#I(>b zG!}YHD{0QFyDT+_Hvna_z4Y7xYf~a6%F#0Vf+&n*MrE-S0_mCus#%o8-j?c|7VsuT z3Pi9WMsw_@=S?yZm~4(NkDQm1Dj@s%89odKl3UajsfO^1)Xw3fu|8=VLtJ5trKPY( zM#(o(xYk`ZuBZTyQWAIW(F%bcetNS^Pm9Fm2%lV^DdIj8pQ#3{QBghnJnJRJJ0a`_ z;7F}^=YU_TA;eQo6q7{}>qyF?3U86RNAHG&eXOEI$3#gJw}5o?gkok{gOF;t_VRXD ztE53vL3|S8y=ufTR`Xcouy1}2bITF<+fbh2ZJ6V>Z#V*J(7VhGWO=+QV^fq4yj%2m z9k}9dF6yX@0Sf>Vj+Hz6+7YE#&ot=iXtT2Y?6Y@}p%>X;Un4??6249#8D%EsMMmF0 zuKQq+&P0BMA16t|Ei#t69+&>DRCa{<^G}6mVT`f^>rr(-Z;2*~Y}~I|8M`2q(B&D& z&id_ZUY+^mk?`d{X8pCK?VOgj4n>;UWM6th?STbV3YO}DA}P*Nfivcv_W^ijF7Bx< zM+a%3(%7Oh<8#)@^IOz{3T}9P?qVJb?tzOwdyxIJ-vH+o4V%@k+2sO?QPH&od!?5|nXhl!mfL&@=8+JUM$Twd|Xtms3-Ku<8~BO_3QEyf!zHo7pGG~6(&`g}f{Z}B9mG$)$a zUxGJPVZI8L`nK7L%W2F7gK8SyrOA*x$IuD6XTgL^^@WdER_p*$kNe$i73O#-z=NEb zdP1c=bx8jyRLu8N1*P<0(t_B`lvT47095f+st6i=%-_)WTW`4JPBVixbPl_RN6|wj z_v~!Dp~6ppqOgZziS2+9-#zULCC?ipsvr7M8Pp` z$(;?-AbrN(9dx53O2Hc$ja9-mFhr)I_e5}yTt>Ypj05ILcUtz{YA*9Q;WzYDFXyWB zJTwYGMG=c_frVpY<~;olofYPR8KJtSN<;=C42Nf#5$qjO}1qH4lL*z4##T*_}E z5zZ&kXTw2wy{9^nPHOeGrk4zqb+pOuE@oZFW~4^HmArkzZ*f!c5VQwH$HM%uXgx3bX1A%2NRnrkHI&(AR)SQe4NNV zvN8QA6&w|Y@toMX+%+YiC^&*QawMud>4>$&;i$5F!P8(d+6kF0W&zV+~xWwbr|cp%dOo^G$OZvqQL( zQI+H-mZ|--aBfyqqC@At&Eef*womM;*9>8oAW7+*j|G!Hn~(@Nk(CzTjI~+chiw+m zS+cifr?>)2+*S7{(R(yVs21HMv68kIMOwmIpP#@K&Aq%`Kjt6%z8QCAt+JHH*cAS6XA!ay0LRPZKel*L;57Y@Y|K@^Y@!vRW>z!f^BUTI)`gup zX~j+Ib#?o3IJ=*Q-qm9l3wZRX6YIYwOQUE|GGbpbKkH`}G@2skU;sLa!ETT9`*+rR z;4)_N2X;W{MS^W~y~bjeI={_|lxI$1MlPnQvpZ0bMG%i2FJ@%sPMJQq-NTUOf;Wc7 zPUWS&(TCg3zedlx)D8^)79crDA2mNp-}=`PHxx#n7YtJZb`5If#^uJ^yYK6;NY4gr z953R_M{Am|_IBQOlfT&^Mfxe1*~eEwSWtRTri4JZf|l2hB5FI@D)GSyY7hN&8m)J6 zBDa4|tdA4d;0%`!3t@WKKiw7x=}RdiuddPIkuuYQV!pA7{HFy;fyunUIjg73FTCR; zP+!%z)Xo4hv^l1?h?TgKl81YZ9^~k#)2oHL35XQt--QPDv#M`zL^&yTU)T}r;ejg^_Thm6l$z;sn@5uDkqo^B=xKe9u^E=pF4DAN2#~txY zDd}AX?_%O7u==ZlR_PxUTeDV*x@^|!DsQXart{g+c3;f0HMV(CO<|s^GGO{pcgw{{d_(LV>0its@M)C* z{-uuF9+@^?A8on3o(Xg{w>G?=fcbUWhK&aC#%()L3okoLr|cQ-xmgl>Nb9-LNNQl2 z;O}?P;fm7;(~kZ^Zs?)EsV6mqa1e=pEwU;#_GyF5F?-%-}K_ zw3J(($nLwq)(C>!QoLwe$XhvM!sd>;6}*C01DNX%!ZnTt7%@&ZhTRW(?-K034{tZG z!Qj!CGq6}G-QU>IAOC#2dVBn7PaD^`%qMhi1=ip&@S<=fM)dRRqog2aUbj1$bawdf zWML)^-^H%enJU!BJAu>R8l3>Ju=7&>A~8GM0sqAOV_}GOzds3r6`S)Zym&0Gk!rCn z^lsp$T3+wUs9xSuoh_h|tt)?_P5#?(RPy2?a;?V_b8-L3c3HV1-;W2%u>qyV5AA%( zV7q}50Ic%C5>7-qptwr+M*$}@*{s-UU*<0Wu(I;Yp~}>$-EoQ=T=@ba21;M9Y0>R` zixZbQSK;Xg#mWcUh6EAymVg17CXk<212}lXJjfFq`J+w1ZeND5F3Q2NpH3K z=F_}x4eOx;oRz}s9lG!R>C#N7F}rh#@}bYAaj}=sg9dh=b>EwFWPS0g5uG%9(zPVg zeS?>pA%lStQN~Fes`~jocV|O0)popp+E1JO+dj>)Bk$`OF3vn?{sRd4ckx}pN8L4p za}Zti?GHSW)sC<1g1371(p_rr8v-H{tP3x=Gxm#s?E|H>0 z2zaVA6`n9PQ@AZH*LD(8{;cY}qID>NDG){upB3ckE{ydlQ}oZ*r6G(0a-tTTcwj36 ze_~cA7ea}vPu>_@doaO*8_A?Uqz4k#h`z^SyI6~UZto7<#kO9V6sjGDb-9PV zxtPG~F(c8xu5SM29@9D0Z8EQGM=ufyXZ00fhc5RqT{`7xXkZyX@x?gmXy{E&u-SmY z?e1?-S%a9lZdHSd(xV+OK3L~lNyr^NaRwvtbRL$;hnc1xmk*W~&@bR1hhQY4l; zYG4F!*BlYzx>b`ZKDs_B8&L}%Af^U2+FhY!hHX)4Ed7uYbA{a0OkR|}P&oB0$xHL? z(=GA815BIQX>a2%FANWQ%p9I9q0eftCuvRXbAnSMA-j$HgD=cxpqvE@0%LCuIl?oYq+rS zLo-0e)n(JfquNT>TxSp3Z@m{`EvlAs=Ni(^?z_gQ&FEc9Ti12OD4-7E30o3LYfKrp z=0jR0Xr=RflMrHM-Pn#+V7=~)wB2(vgM`AD9J-5ygSo7&;^a{E`O>dk;-3idG)o=_Q@P#GKt3)A{W+bU%xbeux z$h?c&(c1GH$o-SNFeJ}{|@J~>$<@^VB_$Kn#Skhgi zpYF>12ilTxdGUEN={6SH$xGYDcGN-?xVZ9IKgjWihzuj#n7e*59|+|RpCr07P>N?T zk6H>H&3jyro!y9Do+u7MrJtp$1~}?92f+(0VuTh@%~qGL63Q-%Ktt+(?ObXkv(s&{ z;GOU}(aa!U!8`?P2%rdk)P;|AaC808O9qj`-L;nSS#us8txsb4n?)FxS^ukp^5Grx=c8Y?=`}v8OeyEEn4kymYc4|Eb>$CT%NaDPGH#I5$e7 zaeC&7jZXG7Db%*e+54 z5>STsw!@ZO6<1aK*e<}yb}IMVy&_y+C41*|T;JGi`cCYmC27}HppOItX1(ZTWvFHq z#6h8i&icC%d_O+S7}x6CbCI*Z>Oy2KEjr;ehE#{0A_Niw7YclGZpfAA74Ws=YZsP6 zQi_M~!+9;2J+QMsnNO0K@gjdMX84$S9w2U>3vbZWH@*+;s&LaM=Yk{q%V=>R%C6cj zHC*Ck`xs*+lqm3*_O#qjS{{Vot%;F4=!KIRKd=j7kVqGU=mq!N9chp}gpxM%7ZGOD zIKQSDMQQ5EamIFj*0=Wn#SjA;X9tF_Vy*`&n1olA?1mm<~1Z=dm(xFszvB0HcM`JvMet#zc#$)lNeP! zv``1S(J-14DHOT!Nq`yNsrM5vmW45!&a^w?%e@Iu5*R z%aVYBbp@e#ZhqQ6QVBjzV3`!7*r^Z*h~(pJ6@95@OR=lGciUhxweghFe=A#7AhlW~ z#GlnZzXpSR80X`}bZ)DB(4emo{(<2!NYO<@_UGqWtP`B7l)a*%tU}^4N9j2II`)E< zD3@uq%+G*0o;c7c9_DvL*nrV}QGPiCfsx^fFKbzNsv|=$wYK^2?DCJ~-P6RL$f5zz z3W7Cju@zMH#5G^$PUj_$_E2*AM0>fTkBf%}y5l{mXMUQh>JZd`HXHY<(!qp9I;luY zQZ%F9ja!JcW|dVfqXSuHe#IUuAipc8;qv0;pDhPD*1c-QJmLn43J%hEgU3s;la+wG zssG_3kVNmUsfUsB3=i(ikWQWp#bVkH&ZTgAJEQN;>QsvrIkZ1rP{}V*CqF@s7>K)Q|~OJ9FjIFf`L@ zVRN`rfR^B(8tS}P&?lh7d|3f#ZmdSeV!^mC8xmfXZI-WE)hThq;$*=&RcU4~)F|4D z{Ryzc+=Jb}^W*e#p)@4_&6>@_ZY8iveg+PwQblo}ELEbB>yaBgkIiB5N2J8MqkMVd?{?E@_qcP{77gnFwKVV_i||JvVQk9*G7V_cp4ArzE%? zO~?PA5eyA%vaC9d(slur>+|>G2?LJJ+M4AU46+!!vp+v8=n&|vvKBogOcR&YNn_wc z$o}anscqBr{j@hBIpiY`cRq&8!)x;#kgOceeY0;2JU-~^GlHQ|!Nto2&s*enQ5R>= z+YBc1YDHy3AGu77T{)OZY~^keN*Jjb1Bf^X5#p8}ZDG9>rnL23(qb+zU=*&KvrKL6 zSIE-h?^B(rf~wVcD4DKnd6{qr`R<;I@>#kg3r>rG_XlZ;cl-(C4dhn@{Jw#Z6Cq@& zJ+guXSS%MDFKvyKzRc+&W+^TqKVB?@tn%WIJD}phhK^7+OVhYoB;;YtF2_+b5QGIf zfzY)_J~xMlz$2!JQ989nVP{vT#O0K6rZ}CIrq|t#;8_F*X%?WPEn$UluvnDKyDD2O zU9~z>?}lZM!L45CnAi7BPDu(OPyB-B2U7m!)0q5^-)mU?8;O_pysKnOaA%#iu_TH$ z#XylADt-%ujc*EfHMZawwjb5SOSHhTW1^u_hWvTN;8*#@12gjV+-x2oYF*ZmbJTgO z@+3dyaZ&!H7J6V%Qxu^o)H3~C3GX?Q&2?3q0H%D^oegLmmvq%KT_rMg!Z7+DJJ6u>=~USplQu!a*_B zIGqnbM`uZ!(nK|+2|Y`_bWRVDIkz22n`zf{!Hl+x@Hx&AuAcJMZhpIX-SJ`b>+P&H zGKZBdi2RJjY{nZK$69HLMj?WBE6D^z?$`iD$z6!G@*-2PSOvE%s$BScrh;%w{zsA( zmO2Fo3s&S`bTSYrNy|J;L%(?g@A$X&+AvuU-No|gCAnzWK;F=3&~7N9&1Z8>DQ z!5K%7XPLw4YA7t*IzU1Sa+9la;jWjk*;+*%!C&U#1p`qV1Ed%WEL=r9dlhv28g4$9 z7~&5^rm|VV)jkmHOam8MbAs_t(ifr@XBefS)5|3b-dWYzWjiJA@e9dz@Qx$3P0;`KqSC{$)p|Uwpi42b8a0 z5EL^1wnLy>$_q$O0nlFfxc0qVCV-GZqJ)jgqhV?rhb?q2-TNbzm}^M5rEu2MX<|+U zesjIst6Qw^R0V+V3g*m@DMtTDE)e{5hT%2alZFs#S)i;bUr9Dw{8)_a$n6D3es%K5 z_6;OlD*q#fUgfjV)}~-W+I7K%SHsjP;vX9O_zlJMqcjoEtVm$K_)2=4E^ zI2`y{#u6Y$$RFrKY`U?ofHq6J+n*L91>fia0TJ?%1aKKMVxFH1_HyEM{aSxeAmk

    i5B_vdOgsM!BO<$n(g|Nk~NCoZs1 zAnO{=gZA?s+9Og(;J@Iup-mVzeAMatP0hEtS#}72<`mw>j|U(4{OoF)YiA1PlDTtx z1IcU+F)_D;Gh!(w4C^Y=7r!K0BpD6W!c)brQ&7iWeuoiNfNH>!@>Vj(H=u$Q!BthX zdyEfFogEc3@TU_gqq(HoTbU1Emx*=_@1v#eri%Z-qoo*2N!zr^T1(yaw%jwOi+DO| zNq$?>MdY(Dg?}i)uu36A>cPaWH#$jAzU^{!tPQVO1_1B~3DA}qh(ErW3p;}Gf=k^L zuc<{JX04L1x;-uL>7YPZk<`aTU)H@zi}eOZs>Sfn)M~8eP?I}Om_&G0e$-TRLiyg4 z=6jPG>GJ%af#9H;QrS|i^lJg^$KdA*p5Ti~^Z90vt_CM2|GE;mq>&cWMgGsfOn=JP z9d;l`w#|J~kpK=L?*uP=8Mi>`_a3H9Znq$Oh)^x)%`jeh$Gl;~)sPjo7N`P@KiX;3 zS%l?cwt?|(F)KG2__QIvh8q|{kcjEe7k z9G3H#M(Tyc8k=Sxtx=~SJ;DA7U2Yrv+Wj7&3BGySVFnm@F*2E7Fe0gFW6N*XD6wu1p-)$M!LrRf(@=QLd z7=`MeN>{SfSj%3Ls9$b9SA*BxM9Qo-zz1P-Z9)@;xnVK%1_mwD?sbU5T37uX{krPk zXy5kg`oA=j?+Mw1PJ@i&4(8d%)&}_D7kSj@7+zsKIg8ylr2)%BE4OfyZ9VHyQ9iAP zuYKYT)cB3`(s$DQv4x1~7xq?}E#^|%7RZt`C}FJ?T>7>yXRLFj*y0n$IfFR}0Z+od zSS}BhkG)lJLS&*&lh#*8a89mr`!Kb6d+h2rf&C&9w})~7tvQ=Nzn9SzA`!#oT5cDAd1 zY*>esVqr4Gpv#@gTl2}}ElG{wb4CijwRAck^Q)HEWzAj7?0_ajB#-h9&V+o^_WeX5}R#|$}U58QXS4n zL}~ltWA+M35j+W1stHm}n$dvOqZbs{xO_3cd8>=2E`*1s*Da}hx!5s5YWu*PVwEoP zf(qkcz_8mLhVsM^CbcE4BrQlWUHqT?gmFwBAB3Z5$U50?@05FG7g#I9=4jZgXWv1C zTe~D*XrkD%*`Q#n+honMG(Z;PFaa}E3;)OOvdjj5ea%m)S{X@g1~VrG?R^%|q^rI%JmikvK{>NvOLYr%l(RK)Djq|CH1Ztp)#>q}GG>Zeia zt4ZmU<5;Df@$3912^LYP6@KOv{3aTa#BT*3SQ*0-4~EyGw2ci`$U4H$zrVXT5XNes z|CI~&KO!ixq2P&)7cIVq%p5RIFJ>eL=63lOe>~sbOUpcFIl0-tn+iBn5%s7Tcy7_b zV@Xy=AKYF58`JZ23&vRxyf zit0ranDyDfg%J0V2k-oC9d|wZgb=6x(*t4Xon}NyafMx6j?`8amfA{zpg%^L(^Qkb z*hn+5T11(k(EdVm#zjVrIcQFgeFYdp<2!{a{aF#VT%M=JJQodQD<6U*WP_XSp=<8C zE=Oo{O!kG!)!B&|w2cG12%`x%G+3&F88nx}+F$;s?{xm~zd1pd`a64B5!^sW%P5pK zpDxMz_G7CULOumWm**E&K!l3(J=#Xg^;YB@I{)jdjr8x=5>4_<+4$vk4b?8l*7_V7sp946mPfCN%HfXSaV-Cr^kkBZex~5cIHM zat2gcYOX96V{mzCy%8M@G}WXX_4?_A*{jgtEI42o8GO>?p)iQ&`C^619gx;qxM&oEv+AQ zxQW1TtuSuhb!lAh>MP)`zcX|P;#`@%L*sZ$wB+*fG)oSDXcZeiGLs^wg`f$d>u8VS z`SN_soGj3sHrcE#FsT=+X;}KJn~QbiBa_Ju?gxP*b#@V(wu6X{a%_ZRD)q%S9TCflMd`hVum=%#;Xk zb45eL=UxuQ5-+T;2+a+KD@Y~4u@mfIVH7ic??M+iqN0^!8q*qWVZCl}K2$g>TVoeY z9#eBd6mzRFjb2_}{ytA#yTy^n9OL>7denFX884V2^$u5{1t&D$4fi}v|HWW7XG+TC z>39{EojG^I4}-uNP-rs_%!L&^0peA+9;bZ(95V zLv`TH$viQ`p=;NlCq_)8_hyE!=pEiB6QLBm{(D~jM}oO>%>ZO^a%5wh@ryDwJ8?R{ z?M;Lg#x|y=p}J<#$cW#x!RjRNf{7SF7t?LD$)(p_a6~qrI&aN~%s7tR`GW!fg?c7v zTlIuveerR;d;v;ov+}OkK__5t+}SFg5700105j8PopM8S%1;c=a7fek_ zAP&q8YOhM!? zADEk<3Sd>_){9v*5t62b5&U~g9i#p5w@_Hz%^GF@7r;Xf3A%mDu5e+)-h}N0agWrt z0GDeyvXaP7r@CN{Ce4s$1J=Yu3tpZem*=G_2*}KF;(?uiSqfC@3F?(h5aeh4iTnO= zR>8;s(rCd)Ix}48K-rzuu}ri^g{UAzWBf(Jn-_*$6A$`EwNGEZL{LXg8NHjySzr`4 zQeH7hXG*|HafZM181;sUXYzsP3`(dEHr_^aQtWH~=h>{MIz z+4paYb;&$9GqZGpss=3w3~KosNT6dx+ZYIpZN{v+-H+a;DtTxSD(6w4Ta(ZyML8Y*kzX->Z)|+@Z>!WXh#xozEM*Hd$L#)0 z?Iq3gfFa?u7c~AXA(4U>H;BLAa<1049k7%%P-L}|r&UKWtn$=BbCwZ_HihTp^ZNEC zTW4>!>p&TvErc4gD~s4m>LPMY6YAV|A|Eyeg|eS=K~2EOh^i<2Dx*oI9|~8bgASA_ zZEv85aE#qi60#%;&Rq?E7Bx2Z9a9SD01B5*Lc$}F;rr`b^)8~p=B%QdPzT5J@1afaJvPGE zN#0BTj1MzlM2HSWY*i1^89_Wj4ZYDXgqMeUOy@l9;fxlYd`@j-r)cvqZ!A2bS$F?7 zW6UdfY3HL9)Z$2M0~Gz2tF&gH11xVH%rJOvjGS~t+l$37x0ZPP15WhfQlvOdGT1#i z0zrG1dRR{{2)V?pisq|dcNVY*=K0pEnabam$#Cq3A2t|KeJN+Ap2tJFA{EGA2ormQ zqc<-k05Pi+Id;)ksxGdSU~ZWAq9lCc)v#meNoA7|ERb+(*Q z8|~4Y2i}9rQ}Bm?Vytvq*g=$ALH}%_A*^1>A*!lKIGg6T%$9yk3Fnl)4W2uF9~f+o zh+dKRfdbR-)(IGSgO5&Z?M`sFZMW~c6f?&tALF(PqYYgekDwkV;F(wSrk<4L78z8#tp2B0+r*nM8w#Vq{^WHtK$FciUFPK>A)@ZFD z80lTYK3bh&d;4bwFBdWczg>+(dO_9so0NsBau<+eHL%v0?~B_){e^x!Zg^UUY3^>? zn&F@5)~t{eTg0=C%itp3%^0I}xPD%|Ve!dnT=upj9)T~*^WDCmks}}=+)8+IZR_Lg ztVcSqwO^4!S*v3y2PtiUoMoIeKWRb^4?v%{tWT80LfjA7$Up-hg2zX;KCaGS%mWyM z9T|T>y=y9W>{9Q#aKtt_*rY*hRgr|q%PYHMKZ6D5Vkn@qqa!i|JRtdi9#|esvrbN8 z)OshR128>24$I~jer2Le#+}4;FHcCnt^ijJ6(w|kA+^F(XL-O(8L9r}fsXECyTZ_d z1#u$`1tkmBvEvA6i`WZV^#4%lNE32#ak;SrRXV0g-$ov)HXR?y;WcNphaVv%&6CJt z#KgajC)die4Hyg zdRNa2unFw-kSs7(p<|kkf5m`G&g_r`n9GA>R4}8;ZHLG6p^vtoF%qmz*#tZ`o^HiU zSj(?{7a7Q1=J`Zg#nAF`eu@P_)Knm-MrY!2UJC=8BZF5haxLqYr;mrL( zZWC`i9N!buWG4XJO}_uvGf+8P34R0UV~2%M`9J}m;f7{U*p&tKdSUU4%O9A7Oq!Mo z>(Edayjb_YBtoa6P!vIS5V-0R8wq?pZ;TQA)Q+6;G{Q1oq0yX|pqn&_9Tgj(`Lw1- zX=ZnzY`9-`!_;JZ5`_}0#na3wo_qXP_|w=PIHqJ_doqs=&vq6wsr6uMFmpVQcyVddI^%%>GWe$&5?z78IoEOS?$dVp1_lS`PLRZ7pU@dO=hF& z8FYs1B@*e7LoJ)*DO8{3K<>aPr8ix}iex;DHJ>PcrNbN>drSQH&P8-k!|t>CI%M_~ zzn}4;Me8A8mEH<%2usJzs@QE!cP01ax){i~A{e3|%f7vR)4PzWWT>$I`pdxcg?ez~ zmkYezJJf_uwD9awY7rA(^LM_AuQ7iFmapo+w7HcA)i@C%*3Gdq~}fXuRNpY;Xg8RGwQS?F;aVx0LNv zv$;K*A)T47%LGTteb~J}`WeI10Vu5fb{?dz9Z5c@9bODdy=80@x$WgM$)#7;8BmwB z{p0!znYyALnc;uzvDIaY--(gcSC{M2G%k$nK3L8W1vd~46#p~{AIcEn{WVjvr=Ar4 zS{e7I_uc{352Pw7s!c41K`V`0dDl-HM|3h*>7btc4K*QoXf%y_N0xJ=3j6+3Sdk zrXPM6G|cb6-x%@{yvOiQY;r`252k+Jqtcsvt)q1aa4jwbej*pY9STU7UCIl)2Jbl& z(VXBIIb8a7<3g*;FOh@5TRTZf#r-t$NG@v>clu&wPdzNj=H2SSb0lQ=t(36G)0&B! zRO~GRNO%%uvsC@2ZYd394&~DoHFDfG-F!3}QVi=;ayy5@GI4iHJ88PUfgQ0W4a>UN3nVDCb!A3Kpvi1?@gfAZ zgzd<`Bo&*aTuHjlZ?<2AXhfn(-l|Xg{BJj6#X|blL%Y#BcG%-H&j2;cT`@ffdA7E~ zCXVTz2%(9{mvfiDA9nqEAIO0BjMeZ%xA&1AjnSS4h$)&{W?u4QDRFMkWG7AyR;Mpm z>6}PN{!vIsS;NY-RF=ADwvXOmqgO+krD#XS$iGOh9w>(7-7+(tkx}iztr8Pqs z%^?*n=Met$0Q}{7(bRfo{ykxck7i~~Gfh!iXn18I>-hO4Rt4Wfe&h!*%b}Ea4-F_D z2xNk1sz?mOqZQ1$2xUdu4+yH1st}_XD!D}UfHrD9E|jBASd22lzkaI!%xtQwdi^AIwP6oAPhtrAlx&3mxz&8;Ole+5SoZ? zyd#1wVA}xwV!Ak)X7(@D0 zL5abv%J@GZ`P?h8E4zdILSopFL4soU#>^bdLN@EQ%;Q&Zo_IZ95+F>jsNf?Xw>O+O z1Ls5{s_|Zt$*?VlsxH}Rd{~}@@TJj0kbqJ6528#QeFN#$87vw4m&B+z7pbo(3LYY& zpn#)`@Lq3EbGFv}L8$H)8%gv_p(7=pCn#n9ToOtRXwW7KEaLSI@+6U~ls+LpL38#m zd^xiB;e%MpaCequ=SeN5gPIyWfoVUY6ZFanQ|Jb6Qv}OuV^%A{x{%yD)R(O-ln7(3 z*i%G*ht`%T%?qT_e^DIme!G_U%jeQElSs_FZDRk!rsgN$D-8*iq{YuP=@dE^j^LLa zW`Xo_&=O7cC*Ujg3!&;lzfdT|I_$xzC%75O-HAh#Y{zmPCEIJp|0Bh73nL^;UeK|# zutf__g=EF+tShgv&E~VBp-%Gkrg@C-ok`k26qb=45)*GLh24bcB-BtD*q1yS^Fv>9 z`<4H0O=up$+m(Qcl(%B3vs%U9!>Ni8>?M}zWIpIV$84@R*zFnKLE9CQ&IJ+S(BYC1 z(MpLhyUIPm7!PO?7BajH4ARoMafI!n-$Sn**YwFoPpzb#Qxd%#YqqTRC=gG)ozsoM z6A3)rmS1DTM_kf{fZY`N*~BKblyi!^r~U*@&idSS>{7TF+zV9`>0~0JnGRFYKVL$V zP~l4wnkT(+?cxw3o98Jm*A&O^Jbh-xF&iV-{*Xn{bT&_@53Z@6?mU80rLpMpg(#uj z&|bFt$*-o^T(ULlLWU|0+*{{QcJ zRsVne8r;K}{dsfTMIkf`d-EUb5YIcQsOwI+>y8J*4_h2QoebFm7{rn#U z{@ZB%cUMo+FAD^@SB(bAB=`8%BASEa9+Ouv3dxJ-+^Z4Ik-;^8Z7DU;84)18A3g!I z|3SHbskEXq8U3cn$k=`hR?=IPEi^@-8A!Q2w&Vw|X1TkSic|curq}KWMN!A+PyRyJ z(piZ^otx+=^gADMXibl&5w;}0J&eVi+z(T_uckg>*f8e*p!oAb6*4C$ZGN9l?Jc@( zW8jde^;VSQa(K?6T8%EE&xONQ6 zU9xtP^ZB1Z`b~K*lV^*fQfa<1N3fot&j-#9ga}j~w!3}>i;wKto=nvnu>&>tYQnBd z zMPKj3h}1N_aOqy}iqwh1STxzYd?sRx&q3m*5ks!0Glc0K$+=bL%PmV;#oy)5aJ8iN zkJ$ehJK`aY{Xzk$!G?M%I2V)wV63LN&iAqid$d?=z(aCCspvmfXu4#QgG5-Vr`(Ku z&Un`A`^`d@P?=@2R%OWW-5#j1u-_B73d_Q)J}|kYjoB0P3I(zJXe9wVo$#MbeD`}d zieTp9KJ)*Y%(}z6%9IFiq-`%5 z_O*dt=0mv$&UVj5T7M~j@ayL}5G-2jETGl}^H^%5fflNF#I?+fRPk)%Z&1aoiYyOhFVHeU z8C@rN>&$pXxu0>Z-^G+f*QSLzHXlsKlvabiVS?RbYb}fkGSLCju=|r_#zjwa9$#|S z3meieRbZn$Q1#8pZO7|!i6dYZ$5)^-1HRMfQ#~u{PMxuWt)?90hE-PJslg(==SDH9 zGA~(l)dH-reG>-z;Xas)4o zbW=n&)TCJitlCjMe&;MV;O=(HE5*8W2MFW+@fJodnxhy?G%1n6%Ei)tNzy;#>)kJ! zBO5CptFS(SIrON^gv4Eh0}NnmQKGSTavFCZ)`)Po3iG(?v{0}Jdl>$AEYD@q$C#7% zHH5IR7r$9worp5bi;a^^cc;hrFF^-wULj`JZ9c<1gIpCh^5u0-snP0?ID${(Rqi|I zdH8(3`~3mP^<)KJ%3_p%Fssr-g=BxmcwZxNZP`>-qfn6=Cr!FB$S!e#q_FWse@U&4 z62+c5{(4#VsuRgH;2`KuTSa=Zg(P)VSe$0bAoX zm%0kJz~Ii^9y)g_?hj*G*_wB7XktOJEy5E1Yma^cmm-`M1E?y)L`QQZH%g=76Y&-f zz;pb$ZhR_DM3wl+u7kCd(jXRU$8@p?6YuYcY%<|DSdtLlvZG^1-r9IE!wpOL0&cC8 zzO&qQP@%5c+q@%{xnZGya*h_ZVEbBX#lSDij)j}nTIAKCw8#ypZ~V7kgOBr$re=2M zbb1M&4dewzY)GPl7Zau4!xX!m;6TA$3Y{ZM<={OE784_oDzm0`^CqD#007y(diCKf z_P_>(=bKbgAls}F!(aH3-VD@j6ft1c2aHmdc(8NE3T7p&pyX0~wknaZrE{{>jte8U zQ6SK$qBXlYV*;mH@lFU%KN}aTTq!(1`00S1YEQ6&m==kqKDR9FDJ?Pmo3Pd4$^L4^ zkGyJi>VttMmJ!rS)M|7lFjD9vflQ_7F5U=|nbov4Yf;4wcu1#)(VnKq&?3|c@^Z#= zsOe%D_QRS^Xp`?$H-JJ;nQyG$hP}O$xhPj_0@sXy%nLI~ip3-1e`>`|2z2jQ&Rup!X|{!anhboCo;< z{VCYnbRCphxLr|C4J!%&PbL9q)N$vvcc0Yn;}al30oes3IZ(w=flK zlazfclWmo8PJVf|$ntEa)4KFk4@*?SBPt-bFSp)mP{PU5Qmk-~FNq3c=Bebh#&A-~ zL~>#)`q>yysOJ5dx2!76uD$?`a7Cd`2yn#UENs{2uD}O`#@`C#c!K`r3L4Wew5}#X zD1Fan$?z}HSomSStr35UoC_-sqv&;u@4kk1e;6$`OV>rS5q@J7mqjseBgIDm>twwU zQi@!Ix}^Q^@=fL0@LEnhtw$7*Z^rzH;g?@|#&p&KS4+mwI)4(fQx+ntIn#+^kVDFk zBo*f(duMs`3Ck5B!>*{=c4PY51tY`Z#P-fr$r5_17w?3@rOYt}o-})tQpP>OdGrHf zedPuc%o-hHa2$AQuM{E(Ts6K88{lfV;8Xj6zzda*yq4xEbQOc~STgx@w_a#pib>lt zZBB&G?TOt$L4PHED*CYpmN zlavH1k56x^oQU-!SV7oP%m?s|mi|(yS>a|1vE=Jf@=blSft-A(Z;8jHF+8i|tfO^o z)i)c0MEt7X2lbEpsqb=HLp z8h6r?l(Sgly&)xkw#Vd|8kBC_;qEtD`4Odj1b??Upc3V)s|D`!djLS$2*T%|*aU=l z9zQU1m)CrS-2W2jf6lN(Ge# z^|KZhc-u7+*9Y3#g3Fkq%;fa7wzeVRu&9zd9Jae%xx65n&97pbx-b`o(V9=VEps~>V##!!HaF~3Zzmgnz%xm#Dt${wOy#2&n zpQWY(W;HO*ndQV|cB_+pY5M|HP|(oHa6=g>?<%ZV@v z)Js2RUD_!FPp2Yp2Y*{3m^`@#xm#`i`q&LS8hF{!_3862o)|FOk_x-o0!?*5r_jhZ zP*7Q3e)w~6kWpvGy%QZI$y0G~#&l{&Odk_;?- zhWvCz3gThO^i%OpwCMv6hV^o&IIV3qL26S;XNF(kU-k=9>W2@}t)9mscgXJl__oeb=I)x$HT4PcVkXL@47JFWLasVykfTg{Tp;2K= z38hr9f*`sYk04-XAO17f3@v3qz>1@;J)ynAp}i?~svUd7c~KW^zJ2Sfu3W_O1PA|- zL2}SJ4w^*P?tH^&D8_gj$-S!1d#!hYw`<}&bcGa6>>+RC9og+1|01QdvzVcUjYRBf zhP(0FlWD-?>5vk|mD@N;aK|mM`SN`VR{RYTw$C7cT>8l;J zx#yXTZlvxn6h()40?qRYzmDNu3Jn~k`DmNG{k4*9o8hfmYXzg;CgIv_0VQ170ba3X zw1Z%0c<*@Xy&bU6OVzEbW74a#HNFY(#(JKo3*KMGd3BcdaXIhnQZ_g{5>$PL9*FK3 z=_P4VtfunKKHA95!N#{A<-m$SH9DSAZP=FSD=ytGBkz!9+4KIo-w((3${4TEx78Pw z(VXD*)nRij-2vO}{B_6##h(z7pKj04FNetlso;1A(Pi_#>csAcizfrZAf@FFIvK?R zpA%(D4jt+4PzEpVn0}Nl{}9q{zM6dI{vpyP)Kc9>jj@*@ikBeP0&*I>(8RaHSu8h4 zUZq*onu{qZQ=|kqu4ejclV%_P)qdCw>EkehYmoHiTJ$9CJ0z~v0J&aPeDVFL`6fchqkepTF4QSi;iFf$aCshR*I&W0>YbMQ6@z>&VEchWM(g93 z0hzQ#?Ya5~kT4DdF0NY-4w#q~B;gEiiE1lpi)IPf8jCT}@{Whtm^fFEx}u8##G?I2 zyQ~fR4HjT!mQ{op*c^CbTosmqLG7}kFR_3hLX_4U z-Iu6xg~8FEDc)K{BKG%qaa-hIMMDPKm|ejp`f6>;dMS>uP$t&H(hKQ|HMdrLa5^n? zDZc>t$~Q1dXjQVhBYYX{DAr-#cUW}AvM7KCIwH0gn1Sh|iWm`R+!azO5ov?u)o#S` zL8?ADuW!9kE{Hu)NMuSMh|N1J-da9CJSi9zvS4}#7$FoZ38PFBGiXWw9f7;fHlEM+ zx}-f!z9zo8!^&?7o60pXE!S6mse2?;Z9i;A8!*o26I_IIwA}dI;lp7@Hv0Jt+fwzO z@?0zsP%NYrZ#{#dG`4MLctwCU+5XE#INq_m>%`Xh?hG9d%tvmpmD;e&|8jV9B0$vl7AV*Hl6gWF_M5kw+HZM2$YMa-I0M!V z+c29H_VR~HM=l7z@@emUHSQFEuosV={JU5y8NOK6nwk{nL6r!_EOOk7%Fm}V5NajR zdQ;U;A+N|M5g^oe!*rHxMS^oE(07OuX6T$Qw4!9QP7Kc~bgcNM?09&^n4-`YB43j8G}5J-WPD*AUu=*ddQp;LjB)#jd%&8hJy3Z{0P zmNfGl^F5{aKRh=WZ05ZLw?eH2g0l~PDf-$v zF%;ncOw_}Y?q6#T$utJ^erYj732-!u1h4br1Jm3BD&t=A{93-F3UGkn6_;SP zER-<6cG-lss{z-KGiDe*H@LoN*|wSqvjLHaYvLFryO|yBv$eh4Hb6-A*(Lq(!53{h zFQ3g|Ky+wL|5MPzab&mGtDZbmT>38++#Wd0B-2OD&Qi2=4Q41Si}(PK^VK1hdIF5V zvEQAJ_*4m{eupZvLBSqYZxxN9Y@V)D^Qp}Ms;uLOtLHOoxmp7RW)wyx#mMKg$OhHMm+wf#>N#G> z$h$(zxn9te#gkRP{l+k#P(_CpvT;Vpzt#9)_W->smPE0%xe{R#qX<;Aht z2|){$gk7?gq;In{L!_f=R9Yyt&#xs>D!GI`vfxSJ8K_HVG;l?vp)x<-uw# z2yB=A9xsZMlS=3^Y;HPL3~^nUav~nF98E5Ox>-H|)1c1mw_!r;FUBkP%g zRZo(NRZr1m9^zLkYB`Ejk6`zj6xm!{8l*fP0p%E((N;g!PDgZW;Wd?-T$gRMw}4*3 zy&LjD2&JdO05j1LqTYnimMKa$U&v^#h7q>cKb3C=s%l=T=beqq5s@5yR+Kw~`&Eg4 z7TLF22wR4&eY(XftfTAA_aOH}(E{*gcv62N2pDNVZ{n%LMESPu5yXD|daSex7y*VT zkjSi>SH4C0tIQEV&I$V;lXF@|K&<1}(Rqxim~NYm>}1U~w_AR{=K_rvqWC@f&dkxt z0#U|uBOrVDU6j}&$9r5q=Iw^^eW3{-BZ@0_xhXTVhrC7xVsg8BjT=1g*-516H{LB4 z7xalVxBGbZL#lRx)iS1PnInd(Cr`Ec(JQzwkuDE zrIC4G01aI9X)0Tros0~{2b+UJ_>p6P@gOgb)K;kCM@iT^U7HJn9xs$&v^0>Pe8H1k zv&FgE7bYoTN}^{q#A`G?Hh4YNCX2n2U?pGgM!U=aHfckg zvT}_UNSS`5MrV3qhhEY$DXQ$sGPb+p59B%`P{l~cmFDS)3N0;JVaPF-S ztgly^`H$w*Q`^AIA%TMkkqzSlg^T-G!b!WkV{FsED%<`n=H~ksK20SF+sd_1OM`Sa z0b{9=^g7JG`?Y&QzmrLFpSemj1OQ1v^D+~iYW&FShiU9=^N zGE5yqP)q=n>hTQ$|7GVU^A(%-k}G_vdBxP2>cPzL(Z2>P+T*UPi`Os}Qnlt4Pd`E1 z6!kEH3!QM!A{55y><6n)x1SX3?MVmT|CB3OtO+SzOvvo$mQAU{s}ePC%1^C3&Zr+;SZzwJbVvgxBfG z^~2R?hG)-#^9H2B)qASv{Gu^^GjEd-0CEL%WvOq3-pC**NRsuqW^B#$8 z(3;2R#>&>}o-2G~jmF`{45Q^Uu3g?4;gF>7By%m4V&Aep0$X=*khFC|pLUg8E?Xhy zzpGo;X%EWUFCugHP)<8OdryIL$ zUe)6nsOBT>Sy|?0dtbqeR~XouohD{8WqSxMlHq^2Qo_aZZH?^e%kNLST$!IsW-Z}W zSEBO&DdvOLa`tU&X}!i21@7l31BpDEWS`}D3Gzsfghn%(^556~HL~sv0@?4uwAT%% zKUXADC4^PA+$QQNItML{A;X)t2kh?lO-Olw3lntf{e~d44F?^Gq9|2Ky|6j zt{#O!fW`sUeMQ1+V; z{4W*s)+L7?4(`8QRT_RE_x8t3MoS82;r8gb)90%t;MG%>{n)OdEAL45Zj^BFf>u6@ z_O12w04ac;3#)xJ23R^$==lcwRQ*mqhn8I*hp)_Jo@!r_mDKV2R)yL-+w6Icpf3jV zz_7=#DtsyB7Iib)IgmUa&8Iv!mCuJGS2&PB$(nDdaQAR?s z~kiE7a4VQLNQPEyj$N*@lwrLwAg~xc#Dxn=0}x>PsbnMnAFL!-ubdm|Co% zQ7~1KmFG|7(UEN449G36F1czxJPhsc=8`-Isivt4GDf$LMLLSRtZzZ@dcXaidt6IP zLCDLZNZ+<1atM1nhWSYd)65Ny^7XQC$6@gp$%<7!{GY$zlY0^=!CffLr3%BRx-M@t zk&*9$7B5W9icFGVJ*S3|TaoFWTTS;> zYQJ7W!-+4`F%(BFowef0@HAGPQ@r9Vaq-sLs1P-nFkWpAvcAv}oGFqnC_zueUC6|H zBT>M?qj?T&V|{vhDxhhwkS&n6Hl%!R52@T$wfORe9QR5Rrm+GX*x+4!Jf36fB{#8` ztuwqkzpGuq?bWnr4ufN!p70k)P1k{ZHgw(%e@~%00`bz27NdKK-(O!qHa(n&;$=Ye znk`i%h2YkGv@FA&S!&pbsfv4aD;Sc=vTFXw%`Ae%41c$1e@j961F&ZF!v-ZA&1ydU zG<#{RAF%bDVeGJK&B7lHO2jW%d{9@YLcjpQu%I`60iU$XrQL#l#&!0GxgzFH$a@+dDI$g=^|T4ADgRbaLZ z&+LO4ARIo>a`&OB^NAOPU9)Biz7X6s3}~*4`g=Nrde!1xz>DZuQoirHUN)O78nFJgLPp7ksi2#r9A+48FAQ;tZ86pQp<$Mp1DNc7Z$CT~doj$n|7_i0xo=CYWha z%(cFe!C?4RvTbH^@k)d`*t(rum(p0#(vgKCHJRRB_}-i-oo^}o2W}0Wj5=&PUpE7~ z*UT4+1q)U!?^@*S^VJdG5r&0Hqvji%P+xL#-5n&Q^w%9VWkl=9vjmS^Nepxcmjx%0;9|EMidn-)IrR)9~3rnA!1Pvg-W`< zh-M4upb{2HeH!nm$Z2-M9+HdwgS68=oBU@<+0bZ#Ie0^f7LZWcX^sMHLS13mj9mC<`=dNk4ie=!r-8)YV0*=JsoSUk7Qnf+4^cj4mLXi$+!lY zh-1p&OfI}o!}mJ;^k|lJb-;+f54G=996k|F+uJ_beIQr_u*7XF>71KHazpmCVf$b3q z)jwIqtVz1ny8-RS=MiIEe3>uybZhR6^mMW5%LWToe81PB6y6@+RV?~*(HM+#<91j4 z&qvoa-hcv|Q{kFVYlYpV#MDw^Y{kb?n1vi(9J5~2|8c=M27#(-x z!*352&KvX{80s1#B_Wvs*dlIv@}8sDop>utS?p_%>nRtPV4|SvtzdFl6y?GQ8egE2 zZ8JjL^&Y3uecIMA@d4s{qn%D9B3sVbTP76)M>@(yJdl!J5R?n)KbI?MI2x#RUt!4h zL1o)k(5P0uu~;uQx?46D2pk1rnJ5lGRyl(}xiRrf0e819XG8EQL%RFJlh5KI;Zm98 z;u2m~hyy-x?EZJSbeLTxPpTgu-F^0tbWyKf-vP0h6wK$oS0^wACwMl!)EGw9 z2<(yw8WG{4Zh_7x`4=kT2OmGH(h>qPh`QIyFuj*+U@1GTLinq2fuXmq!%%MuV4Pmx z1o%CdFRTjmltHO6k%LZ^Q*BU4aD*23Evk#x5TqiUc;a~e?*Ae`c~~Y{6jat&QylXm zs8B(X-;N(>&g<7pa{U6dg$a1k>bwWrL9&b*aO9@mvO%t{6#z_-z$Q9&C`Pm3xVNSa2 z^4of9n*H)uvB{`rP%mN+)f_?A++*g9>@eJ24XK{?V!w?{Gud^2y3FV7qsr|#bgtvniAEUuNN2Y3&HgyiBo#ozuSMl~** zTCdn|6f2@n#!0}S?-aUIR2$C>8|MN;Hu}ut%kZr<$^jw(0KcH0O*@w>%W8t_TpWFY zoO0U5By$G0mog@B_lMKKc`hQU%(PhV^`I(m4K=9Sy_(3NOwdd}Cp+7K@PJyOTT;p+ z^R;vk@bY(xIs6@jLvLy0^(}9si-KSL#kgJ+w@3RVO>3CJ`-Ex~_^H(*xJ!B409>M_lCbAQ>`qr1?B6 z@Hr4eWqxe1DjM2`VXl{2wUr#g@F4Q{XW>TrV%TG3*&kj;(EDB2!s{T^xj&5FgNbCXf0JGSA6fhvP%LoT-MfcDV}<-~T@c5L;G zi5}4GzN5EKSx-dzsQiG`J599O?%g}2n-WL|kuq`gv(w z=V~;^mFTqwC5^CrbE6hsbA5=E^{r{*S&}>QG&P~jj+DucSW~+TLj<9(g{K;;OOvFT z^&$f7J}3bSXUyiy0au{h+ls%MXPlIuKtku?%Fy@NX9^n4Y2L&YqF6}tIST5a%SqeA zrVdwQvU$Y2q)Pw7@wB`aJu}S?y7JohYyGHU$k55KN1#m&M*jjhcPJlh!P^{+mDJ@i zYSo5pG$;c$h&J;lm^6l9fLCaxf($y2@;fbKQ&7Qq;p1_><;!3ffx-%o{^+z+2mz-n zILy$i8mdH=J7~77PIu~4*Y?Ki(O{cZ%%?X5^Yj&o837AA!e8F-}l%o0+t* zL@7}FD2c-xg<>MskQ!^$;Be8+2QF6!IgBAQJU!=nPFqTyTqBq$S$ZD*&GP@v^l`M; za_ltt^FoM(h5F*KM7G4pz;(!adqD>VpJxlUd=2X}41YeY)h0N3y=d$g1vj!Z}BA+bugS#3yrJyBg^tG)4u7&zEgDy-T7gA2GI@#fJsjY25gO1D%c(CKGcUV;)D<%8j&A_3OyaN@2D9R|9APRM8jrz#(BPRlwm#$C?X8d zRLspD4?LoRoWM-eohH+v2~PF{_Fp8X*f`O&2Rg&u&Wgp0wco=+vKzeKcuv2sgr%`K z0Vwd2w(eN*q^3By-X+GmVx`K;dHD_!1AkhiRqsy;oT|0Jvl{hJH9AoDRuIcCDU}Aq zLQq>KxtZt7_9HAYYyB`D=ZCb91r`E z!xK!*$bw(CHsjT~Ps0(hn2g4TN@GnnmbsdTY3#Z2N!r!#t3lWA2p795?kjY)scGo@ z`F_B|!`QI&|1yW<7N6&AU&Mx5%?Q8w6+Gj1qOn=X?@zX>7Jk4*TvPO9jPvd!`J4sQ z{^^G7+<@mGAJLtkiv~I0)}D|U+Bi%%#+cJ&X}SR`m^k*o=qJ+!_tEZQX+%u%6k79S z`8eZk<}tmVZ-?t|%Mb8{C+z>rS%aA0!~y0R%}_(`HuyuShBy`J*Vg|1-C`3dl!nc6 zwsqO3_HLxaef^mC&8c2))s`y~!~W%5hYCq@s050H0Dce1G!&b0 zh9c7}!JSODrr2;wZQ>wuF3wyBDGO7Zs_sWKpB?N1;PB4nTs3&m*@HygfkF?p{i8(# zhnhoMU?fnwT(c|8xft2Qk0$huJYU4i-QTL7^u3D}%p34ZLiLvNAhl^LHQvB*W2=tu zX{{Byw<@1vBh9khdRKsbV$DZw^zjAf_??n!=L5PS&1ch<-`%pQzPUskAkV+CWU4K; z7+wvI$FrFiYRsRsx#C*zvaPO0Kb( z+nSOk`hN6!MKo5zYL=$RZ-2x*z`8lkda5*1Gx&&7aP4oPX~=M#*2Ql6fnsX5)AdC- zdn>>E9<`sc9DF@X^neSdP4{`+yy>Q?>lL&Zv^we4L;tC|QPeS?)fV~M@5Y3gYWElH zp^h)`iu4XYW&e-hQ64%XLH&z9-H7!oEb+GGRg~Qv_cERvwcI3U zT?S0aecErxypoy^=96Hff`Jq|P{IbNJr#RiaBT0N&W+1i-x-v>0LZ+V%Dv@|GEk;z zD?q||NRG`Fh>b4^+~492+`W8H+PIGfA4cEf&Va-80M&C~C0NV5Vq&dv-sVr2)5z8@ zOC-ChByE#4PXk*}p&nc}VQ2=a7n;X?fcZB2aoOKv^wGZk_Wp-JPIS1~zBq(6!iotg z_Gg@G*)dF)tQQQd3L>Oyql5v~!ZAHB`LT`bK=fd{1A_;kWG0-&zArSyVA_&uQ-p3I=4u6tX2RQNP&|2+~~mlDs8u z0sTrxWcc>9Bw*14Q3v9#jTa#*VS3j+hdk#NinUSwSsP7)FJdotgRb9tt9T{*T3Hc$ z`rJzVXu(*6AlG`Xd3@1)HmwUMZD0449&=Bk*(z8BjxxVau>`}a#i7Cs%))zDCvo?8 z+r3@RXu#^J$#nzU5Tt~)zJ0)k-VQaV=XC4mhzA~z8J?RUm%p+Wv!E4pZ;;r-TNh+8 zVxVm4QrX>_j9D0wJ?V?35s^Y-Znw|zc|FxS=X?^D)me$@kn@|knkdH`wvyto=sAj{ zM%~7@ap-E|6iKlHun)2CwC9A>gg0N54rjoii}?~IJ~f~{v~6k6Eb-P!7^{VN@<`pR zKff!kjrwB=Vd6I${j)LkdX>aUB%)HcwHh4M z!{ZyK^}z@tNQv5*@}Y}Ci-8kFrluzO4{;cxg|jkAA!(tG;e{@mrx$lQ{J+}9e}1H; zj1(+cogy9n_91D6H>rAZpE>1Ok0BQ(w`WBR-fhZb)g~nNqFa|}5+>sVYJoJJvlK0N zjIh;_vW(bUQUo2Tt!%69h?y*BC3JZpKMt?Vpr}DVop{f1>OR{pl#i z&QrAXSJj3{wF=8FbTZnxu!L9uk&)DY@_B(~D5C^+W=9tZ8;YD!ac85Fx8(kMql2n? zeSQ%N6VlLj72hE25$i040qeixXDx{nN(_FdyFdKxDGE)TkBG6*1v4RPD$#CQK`IMo zk&Itcw8V-AW2^G0mr$W|X3-M+8QZ2s-5Tr8RTu}dmI{h^cr!i6h-$0r@rFmDz1tIw zAo5l;UKEJI-L5-F6r~ksSCU>&p5v-i@M~3$uft=n=d<|#K<$oiNpRN)UU0cps(V%9 z74ERWENYpek{yvL73>pva+9l+*@o_E|I~;ju_pP{SMkYH1~@Ncfs1Lwf)_3Sp3Jbh zmk6+kOv#y|$UHtR-W+{r{Vt*RNi7$Mf`Mu*9!Q!kq{u33>Sd~54soE4YqxOs%YU9g z+W;^(irANcT?El1AJCZl6fL#U<9{s%u)m1YBL5nM3Y$7U@%2qWw_kUti2_^VLejjqtiE_mPQteR3aXZP$Lc3nM&tVgj`a1lDS?z*_x z5f+84w9wauIa*DeTu(7BrM`&n4Hd0runY-B?Y~)4uf%*^Fb@8c;1o?b76(1%M4)8% zuK=b=ehTv~??1#uG8?ZtEn}`(&xAMYHt$+lcl3Hk2*VB(jgq6Bs{>jMn=kT#s-7BV zGTLW?-Bg6!u1!0^cx5EJ`BIC$DOzhMgLvMy)7Ph)m%;w5l(uYA@+*$B1k+J@iAU*; z?QPcKf}hv@SsuCF=wK_Db+*LwW35vD%~`%*z(&a>ZW z4siowERg?|%cZ-_csmEvm9-a10R@tbiuCCK?lr%d-;O|w*y0GbtA3a%Bl*3~jbuY9 z-UjE_#Jn?H#s|_HCd&9<;$Ls@d1cViW9SUUKL63n50$~$g#L6$`5otz#1G+klxcXz zo5^Xn`$scZ?wDG5i?5I0?p=V%OG{(3V_thH9{Ufd)Aw`UTlty4!gNtGisCK!M0|a` z)0g=t43p?6ud%&EMFGWC{IB-=hop(Dro5FN-(ku>j%b;(mIEaL^b`D zi(Hb90RwsMi)pVi+SJX40RQ_^91%QSO6@mgZOk81aR2-Z2d=-z0RS&Lr6dyvo#)#Dqy7aS&!I*-51VD=Y*F- zj;CUM0xM%vOi`Rt92G?DiWqqG}3J3@#+S*QNGY;QsgN9{!jXuL~pPf2$6*;v)bC-k09R@m%Ndw%=dg340Fdb3(a{C2Y@?i#1AE__Ivl#CSxbUV#Bc zV)jB>Aq#Tq-9`QT%RAlz@;{wGH)*>lIE^W~w&a)D)Fdq`baL=9LT$sOjXVwx z4W*eesEG*G`+yC8awAb#=PIhs&Xc&?@}-H}PjQ8M_uptCC4;owNVDc!=DUmzWG93P z1dBSH5d9SXi5rh0W`ut~W%Qp<`5z5bznH=D@7w=-FwtVxtQm=%VPDBJY<8ppRPrAo zy<+{j0}!%iB!_ch+01ls8N=qDY!e}@Mv>lv@(iC-cx)P@>uSI5gxD6VRzl%NzmEti z;1Sfq**%wL5t+H~V#QZ!;LW`p=a?*@vU=PafEyOqW3Us;G^S@z)nLlS{`#nTV+RuJ zg)0eYlXg|H(LK*el(|V7J^t|m(W4|+8Z4YBPBw=Lm8xEfWnkMG9e~#zIG5i%`KfeP zI0>?xZK2-j)HVP`pVx?aaXR@jH7?<(1E{uE?~s4gh1a4SeahV*+U4*6zlyTOmj|y5b=@UBM7htuOxClf3iP4eiLht( zmw&IURE}BMhX=Jvq|TO#i}8b9o-LN_d@ewV5-r@9b(?4y&a!OB241+6Zx|y)FlFXC zuRbWjZA9iH0cx*P55V8awVUy=;~4C^D?v+H&XQl==^*96U>Vnl!<#$x)dc(h%uaCs z^S6~+idS(v_zib1?Dbh`A}W|###@uD;p;l%zef_{DQP0%yJ%JHxI0ydFX~J8d8^Fd zGgxNKZ}91$3@#38r|kB`YZ(SAgd;6lkQ7BCziC+#km9$u?%Z5qFh9po16(gzj>PlE z^9H^?9!14uaF5-&6-WjWJ~sZ@nHNom!Wj~KUZfs%bdhJK-7Z82j*GR?&&Q{B2*yej zK^Qy=PcXVFg`wnI)p9neikgx@o?SZHxtB6oO=g@a^PAYBwNFd$LxLGqq$=0qRSZ{1TQgS)rfFi@ zv6qYzrBl}ieeZS%3#)!ISwnnV0X>_rtK_m2-8uYQOJnRlLar zEPBLmiS(F%7Mc;8h>Pv8qiqqdO>d77|2a%78UKf|d==YPp)pZLNRw(gMArM%hAKQR zwd?4^hvWQEPATi7NK(H~1b`C`Z#Dail#xr`WPBZF=!CpfV^RG&h^V&(;(hez6Zk!M zImNhWwVDeb0Q9uY>G3YvV{{!Pwy^{brj%P3surn=OHBCG!)mpu4*+I*J*K1cVe(t5 zlcWcy*yTs6e}sulXHxxQK>|ajrg+(P;+l3WoFZ$8u?A(pL8K(Bc`Uta3Z=0c;8ID{ zA3suA`(zr+7vRc|qVHM=>uCFod8n$MBGoWCZ=aeTnY9{g)g8So?J$-vwFppJB1ZvmS~N`Jif}ib3LkH6 zq9E!GmZl6)h?ER4kEL}@5mT22kQBUDVfQQRo=i(`y19Md!gW<>R6L|GN$^lbv_US) z@J@Hg9A|KQPiGiISVVMzSPsOtN3?6aK%S&iN~^3-m`fM79u7)Z>c7v9DYrQg1ijyMbQZ!u4|1{MOms6mG|rdU(q;oKPpa(eh)?TQ(!yJ#Bb8?=vF2ILUIbE-CikSsxN3 zEiBdfP?>1&G0DyC0pjYw7k_!!6W!qCD8r>#NQrv&!LDJSA8V^z_~Vq576&WE+0k9y zSxuYaE->;uEf7{?5T26HhVhLD8>@^nes~l80lLG5nRT6f`RI_|=*u1scwz}(|Mddz z#c9cGv4n;<%8R7xTbhHxpn5vXlBCpmMwp#%b98z|XAf%D1IWH#A#lL z(QXB1e)YxmB2OXF%Mof%qCE+wJY66uen{h~XlVaumvxc=bwwzIRNxaXP=EpM(d3IY zD?>uF%;QNrduKQEy;JTjKxl*gU8j01=u5aOVaUC{Q}AOCigg1-pAc$vU`XZZqF*dE z9jHw8@)m#^Q~}=C670qaWsB9OO`P;;QB1wDJ_ao6B%#ATplxZwlfWE1z%RkAufA)p z{h0t2zV&}4Bi=S8qw7b>buRNgXr0wIm@ubA_z?Ban}IpJ%N!$VH!^JceLeSrJ*lBB zxa@iK2qqWHvsm8HUj$2_xtoLJBLeK%xloe>YAo$>oKL_w>qNDH->Qib$*-;iNGtfz z?}~t*_ge}w-|IRPV>|&_uYTJzz2-mGjs0l{xL}@?51MuW);hOXEtv9XU_(Q+yn!DT z^BtKtG;?!`^j&BzQ8jAfEfOYXX;kRqv{O**`sNY+y&1i7fq<8kxu=`Ky;h}A z9u_F9if@yFy#!5L{ySnLnKo#Cj*Q+#w8N?8ON*>$kp3OHt?=ezSxeN5sPGC zi6qOG-G$vNCu3O~^#yspR_qv2?-^a-6&-4coa}q@h zty{Oe@P%rBafU*y@w;F7+~PkK%4wI9B)+tumvtQZ_c=`Rl7qbad}ZkN)BX`)Gy!dG z@^VI;^;YU|sby)^R0a+7PbB4fZU_T_l^iuT(&LkK-v{FWJmA2Dc$Oi&)+?T91e82} zuD>3d?@!dbLBSEg+2+AKmPR83+;i0ct!p>(E}#6s0Qq3Gi8leJTVu3q*TD)D5aAHL z#))dcE*jY$8@wt2zi#dE!DbD{d~e^Fs7x;?spzK6d>V}UxW!=VJj5hN%!WERrm57b z>$KBUMYqpiaA_I0cM&1P>MBp{?=d(wq}584xL-C)1y$m(kH%@{WS6>;g|kX<~}$MVi6S15uR7=dwr#_tfJ)Ff38If)RH#>J!A9H8St zfpMK@-B=MQL9z+Tg{nOJB8Pyq>}LHAo?||I(pD;?p|))nvkIW=*tL*gb4=-fG(PAn zvjgHxDE?_`UW{aW>EyhCSowjUy1}Xi^+S_Q%Enm^wH$R}&i(#Mw$&YF;r(~_eyxG2 zU1kIlH%5kgCenu}0VE5bNnbD-!=nSX=cCqk2#^cs=$`l&mBi`^dF-Y-&bGRo#6CuM z@>+d8hTc)$Z@+Kx<=iOLZCaZnyZSj2T+j8F8us+&X!!Fq5u*K2EXGAB4MNZ8*Uvn9 zu!-6txUFa~O64~$o=8&%P%U^@Q^Qqie5?-XtFis)6{?yNL z7fNZR#V=3%>7l1)lg?O4VxyDp?i&O5j6a5}pkXF-0DrYzI;NGbeJ*x;3CrQ_FCOYzI;y zZXxcQW&=u5#>-Tr$yO_{T#lNh;(mXz&?=a@=>EHNlF|UA?64BaUn|DHZnU_KxP?KA z&kh>(J5r-ZyH*(>$q1cWFC*c&T$v|#-lmrAYC}u2c(}}{!UEatxhLce{Yr`>Am7I- zb$!D}0OJNt4np02AuFsj~0}+jw~Acj}IZ~QNmor z_S7J8-Gi^Q)P}FQKkP65zcvUcSTBCIP$){+K+3>leZTf4oI}Os7 z{bBDDCjNM7aC=fjJx6tqN4VKP59os5xZ$$qoqK~4peJ3x`i)SDyC2W!kA=@FdJp~# zZt|H@Gp#iP3Eb?q*RvIsW=^5hQ4Yc#`~=_~3MY^M;^q9-GwKPj+IQHy(bVa{fv)I= zlkX!J=h6HAA0a>$d119e7{m#v_Hap$K*>Y>IoDEWUpa@(*iQJloQ5zHOwjB0EpIo! zsXckF-QK6|^kNhQB_4}}!GhN6D-;8-( zEOP!s9u-t{EF8`7J{>3BDnRcGSeqN4Jo?#ibUfm((=*K3+8d5Y)_fo&x`R9ELbxSf zATEcKl;?Kbz38z1#YIwK@YgiTe9bP|+nNg!AR)mpB4DuEMH4MHG(a)K?%zopd8Lfg zy0H_|I2Ix7L^-Y&H1%9#`TF_qtVKi@f0Vi+#oJRY&cNBN@CvQURPzSAUJyoDC>*7( zMfzrLVFeOKqZbX-N|f-A@87%|4;gHAQ6(>KwRu_}ogUWoLN;wuH?P-8mWrZeqf5!} zH>phVO_`#P|F@ds>`y02_oZ`qsd}|VXUM--5M+@ScJ(S1ZIp-pXfSC)n zaRgu@6GljoA9s^qq3!uL5gqM-L=DYTGGE)8<9uXi=IFbmFn2kVL;O{tK@qDK%@7(a`wSnHG36^-frSt@@B1Si=urxSz zn-LpRvOzWC?in(Annbdk5aWk7lKZ16pRrr>dLb?Z1US6TYg)g7ahev8rP55ZdXR7+q{Lci9#hUY}<~MB(_jx=u zSjNGt`w_mgGhKZw@_XIhf(*CMM-#_T2a?+d&%z6Xl5!l3!?SC9tPpG~5_Gxl!VGXyUd#4_xg+=n16AhP-^+I{s z2;$TS1XaFO?l>mkCx8tiWImezf#g56$U~S+v)jB7!pRmd;2HhfXabiydm53@oe78g z_=PLF?3@L0(378f?Uu!O>eDAv938~eh`FOkir5$LFaOL)lX&CQYGzoYxkhs()qs&S zfRUmx=9^A4arb;o!b&%&W@ElXfCt+^->>=g5O_4pV$QogQ*Dn8$Oq~8uizg9fKDu zeHf=j{3Vscn(U@5>24)?wnvO!j5$%iXTPHAvhp;#h=?K~I<4;_V4b17(h z@jl~6*=^DykshJl_-YtXOkeCyJgqCTnqc37_A-*jVUmP%WF^(AzEFP7 z$!2}Oo6{f2-)34}d*6E^@m4N`plvHbosJ|q_Za#LX7FBtER@OS z>8s@cSS?Z0TxkX7cxx7HuLK6XEIe+zHFc;sn9QX*5i|JiQL1m7YPBB+s4{W)(zqS8 zPf_~V`DzdAhxD4+!jBl>zPZ9JU|mS52$pILQl0;d3jMD_*&o&@V1$aWu=g0zdTBAj z;?lblesz_H$W99Zx?DAVSiEvSJC6Dwme~U^>g%(saD#IQ#Q7cTf~1De9@au7()KXX zFrRm)d6ansoQ04%Ak}?6QA&<=;ILPBjO0>lmI2BnC^Z)=4BHOc(>PT3q||k@SRq|7 z5w3hT=1>?v3>|3`Z@4U49h#qwhJ5u#(gGt{)|qSzV09&ae>Zi{w%DXV2_OX7FPD zN;B$(wn)u++H%T0`d5XV(L)>m!3%g#z1~0OF8Bs{v zJXI7D3)`?YncHh4{Qw$#EY|J$Ff&D&oWYa* za~#$0t5zE7+sEB(MU%?f%87ZC?C7^Ibpv)1FU9pA*^_8f##Twj2$oyIke-bwcst*} zh}O<_{{@1$zRzw;F)%tVlmsA1vX3)n{my=1_b;>R=*FO|!_&72q&kYsckKxK$CYLK zKF|PWXEiF|f@Aoov)qcaP|GRaDw%l)$P^d>0w3DcR5)xbN$?i}An6F)u}Xt}myL_) zw;`G`6Iq_BU$D-wMtU*A)|%4)e$&o7Ay?@QrGu8*9wX~YSvpl}nt>bDZX)92V(ta_ z9OXSGzlM%4Amj-mSL-en(Fb(odF8}!;wN^hpb|-q4z}2=)VPlStVcNby$i@t^6jE% z(^q1|Km1X6Zhk{&($%ngo~<{Cp4@3m&{&lb&|LvFY4oVZlSJ}M`Wz70(3f8o`FqyFQH5b%4zz81~V zg04AAC+=?@9hlCsZ1S&>e5PyWsU9{{U>BDoCavI`|eq3h=Lp^0~4yU z0p(#%f&Pw^I^k4*0%=|1ajP;7XCMq4|#EhtGhF*c{H~>iPe|(h^~#r&@3l zg9H3x2bB)H$t+H>xkz2);-tU51H_zx$Q8kAkWF{`(u0{`rpxQSJ@+&ZgcRr67RdqGC1xXarE`0 z;vE|=mRhm@4W9lM+YFu{^hEG_=Z~^dsvH6o(!I#+eZM*qRyoi-S@-&sL;?rCP7-Ob zEcin|{2#N2%rjUnho@|(lst(<7<`>4*I-GLVJs|dQt6MEQ*^gAvAuw{n~G{u`jlhr z*iDC(d!DZ9IOm{)%>C62U0=0o2S~B~v-H2Nz^TT`znIYEDN4#vXZ}?aemToi`0&myK|WM z{f)4R33hvV)!qb!jYRfF4E$s7{c23gJ<19=ed0l^@-Lc0tC?$m?#aURY5hZ5B;?A? zdxj+D-Mb%rvV)_Rm-EY+^GjSaKC&|mj`5hvCoIdRe!ljVT<^xnGU!wkMai^EM0;Yr z0~Raj;PxY9Kgy0)de5Ai@GL| zK{VR*%LM?8s*VH?SJm4qt1 z|NDIV7Errf^q~ipp)W9-eK_l8VXv!9U`1E|! zq!UFgM%ylp;#H1^zZtoOi3io)rK=pdcf;KY+#jxY%X$=DL=6R$`Xcw{f-yU0(7}VM ztL+CQrwO*bPTI~3k7~N@<$V2Nwn*&W-hf5`qgEfqo|PHK%{$sBZL&YRXB||cJ&+w$ zcU#a03GFqAQICGJ@#oV1+OZ^v;zIOJ7leni?;>$r75$;V#o+BKdc(bu*igQc7q@W` z(T)+RC;N(2|5bFc)xz3z1eN?vXCiCM90T?ky}%{9JivQp<{EB z$hKdn*QP(`{SzK`hp_lV8-?T7Q|5};@Y^3h2K!8ZG+8~J(V}eEx8Tq^h-A7LQu;ty z#vxp^W|vo~7)!uulq_2P{LIYi;fv-<+!hHtkDMQ1l{tN3H-!Z)bQ)bKp?mtJNPf0a z5$$4gV(9jcto-=`>v?h3Gt}=sQ|itVE9N;xKljhTc7b8Ak2K}+60ypi$x|Kfnr_1< zpYY|*w5*iC6;6Z|LHMo^q5Ynf2=(n=K;{H5C0Xu%mp8`DvRj{<%nBzHaQckpudxI% zW!kLmGm2*uV>D8PL1Aw)xRBm@>`il#jGk^N>N1ADbR-f4s9>G^S|;MO9Xa8-9?#`UA9d92!^1JDe|Zs}hJKutb? zK+XZrUw1}ptAw$2@)URaOw1az21}oKD;9=iiNe1kmmYPO_Q+w{G4+w%h7_ry(6&1{ zUkt)8IsK*Jq|lo`7TjgmXrwbuD))F2k-X5rX)Eb8BK-*LG63lkMK4%7p6Kp#`W@KdvFf zdffrG*hhex$o<7Hz8Tt4)Yp6FLjcjI7tG5CADqHj<+Y+XGHBQ3L0Y4L&ctQOP|0(q zZ`*C$ij^l@2D4$3OE;6a6#A>^wbzA9Zblncd_nH7d0<4|`G}t@`KuRERsC$li>@F|4o-Xb zS1nyZ4|n*Gvs7T{% zt77tcP|z3BdTJEketlto+0X&Nb6%Ual1+Y1=rfFpi~+&8_yw6ewb5D`xxt3WU7bH1 zfqbjHD+hE-qu->K=!xJHn&mU%PnAUl!4X#(1vMyg_1*?{s~y_H>?^+acxwbHBhXNU%7;no|mt2|GVLL#q0g zz9@&lOM5K#s7w60?0epwZh=&E(++U2N`_T2;Hs4)_uler+?`N;r<6(JMwOLz^tX1e z@rRYUr;H6UPhiV9Qf%j=^S9Wa1riy$bmyu=bXq1^b0)M5zViA>wgR5tlja-p18?0d zDP;@pjb9sh=$V#Y>8f_FoYn6mq*mB!)yC>3SprK-@+cHf)lwlR@5{d z1uWio#^O}?brW3U8pd|XC|elgBEt>-bozazyzykkt+lb%(-^3RX~VFDc*1@y*ZIpw$Ii;FBiNFXP)>%1vH;9R2!kR@e%Hi zmAO-%GG(8+iOsB~$QthxL_xm0_!mG3=BQa&c}7Z^o)B3%LKgIzDihM=`F-LngJQDt zulrGg&yO^D%P26pg$-LF^);1O+wK@;=6KCMopWs2nz6JKA%Zs5sX+X8^$qpajj74< zL_fuSM_V(0|F^s3h22=sI8?#Mx3B-8U|SG20A8QlgTZdm16kEcY!wt@sGfz!?s1E{ z1%lZxskHo}CIzH~7MTSZm?=*f(7PxhC%}k6hIe?~Nd*JwBo)i-dWg_T&xhfgeE2(k zMNon_VT?@6oKmXS!jbK>$bhr!|A+9B|Kq=emuYjZcw!2_MS|GE<3W>&^Ujg;uwZ>i zX(EJqD4B7X^&zF>Hi=;&a=M5JNpj*2Xo`c}SFv0sP|JOpjCzGg`0Z+}_*a<>sWi{< zrtz-{Ev^YNG8eZcgVAfYdtJ$x!#TDN8dzus~P^4vb1(gSe{9)?u?%o?`c-?iF&b9j@xx;zsfUQeVZadide>(p)g%~e8P_LF&-@k+thRP zRo0f8U*u}z@5^FQth+g+{W^W8IrMW#M8zC3mb_iedP z7J&ajUa%zl(~sNy(c>AD^V5gp0q<)!yp^xfwJ#vwwHL2uwC91MGXPbymp2fpBu@Jq z7iVn2CQ@_qjiq91Xs5B9e8Z2Tq&649gt>Pro?CQR5no~wnxIHfqZCQHTd}mU=(W2Pn;pt0mM5~|FNsL>>fw&O^<#{=> zLbYGY&Op?}u9{+nc{<(5keJ0v*WqxRqQIJ*+wMausWNqwV_E8YH-@)|$X9(ESYd^so5|)rw@&f~52IhC zn_P21V;J56Y!*Ti{&p+)RxFU*w1Gwj?07ivi<_F3I)xH9xDnaN_jss|h1tjU0Tuw_ zvU-aU`wJz6HcJaxpgg@pxv*URcG?JHXN^5nT_NH;+i|w!`=eU5W zw9$)LCqE_MW+Un^bs5aAQb*-n<+%Gpn4L(Vk{s^fs@*?gzqtDhc!d{(z4Gs`c!&wsfmawH)#{dd6B5!S&66C zKtQ3$(15Dm!9>)VO$cRQ9-Gr=T zDQ?+{o(wl~?qa&PeADjL?_&*c-B^$UiL%)qe~x;n(}XJzY2kB?9Tp zDHDXChoUg_zAWs0?TdUc#(i--5B>cg^TcRLAC(?&VNnX4hH-sQQUc66a$_XOQNX5vYgCVdgZvDcwngi=XA8jd)b>b zZ<^1~P1qjVoner=9qtb+2<7s0u=LN5vA3i#I`WsM$8Gbrtnx*^{h1@C2W59%W{e1A zzHv$+;E(!04et#nA;@CzZP82v@^qX>T>eNfTZNR-+lH3CI@@AqmY+oMV9x&cqzWXh z=*;NuM*EN~c0n-2X;&g-aHY&1iT!M=g$#iO>^;H$oaF9vKb;R3@q9Y@j7gH95|81u z+VGm{B_`YCUE+@?iG3CREVkNzd<$FGef1LsTp-Imc8QZ!MKSG zj{97$l0HYKLds&!BgS|$PSrtpWJFTO0dHyNWOQ2}Bq{E}sRsec;CI;*Wad!r&eUJn z^QEE7tFI!2?S&jevfN@LwRfTb1|R9!Dit_h%IcR|`cXkP8-|5|YWHhK^9T;9w4>e0 zoOY6QvU|f#f4?oEUPfqh$ga|SRG-cC#B7rri8NEeuDLOd?XTu3C>5fU@X)1A7N+zJ z{k!HX0)-NrXK@!fRZevN>RcSB%NUOhn~Uv^oc=`lq$6Wl)y^Zj=55+}+A4}G-+>=t zTmUg>>3lf01WCVC=GKx~{ooUUcFI@+ADR#loC>ib_JEz+0|nK^v$ZV1_M z+lBBVT`5(r8;T_E*b4qAQdfgp4EQ8-?~S^1JJEAa?lWNSMGrr?vfkMDC#Iect;^NePP<=J_rZVx|%RJHDcj^5>j00Oue11mV z?{^!28qs*8-ANMSyzK+NfbIxF)=X|fzjdHFHTDzx{n41I_`vVv)|I=_p1fMcN{4kP zs&^h+yj)JwvFbppmv#H+*fTrZ%vF`Zw@Yw<>g2{#4&n}40%*daJRHAD5!=O=u0i<} zSr1Y^!-`iP217l1ZWXcoK762<1#O1C=mKbE&2W6N38>lv3e{xkvi>0I1&xqr&+Kb> zv)s`3KgWL`ximCtcKb9E>?ZLlBk_mX&31=g8Qmq}@oDqC^>S~d#XIxyVh@zY(`d}H z{G24x-3GepFU{6mx4YE-o(|2FF{t{mgq(b#prXpC`N6}{Bgg*ngY%O&D@t&owS2+R zD{8dS>4ToRdIcr|-3nz@t?rR4-fuN(5>0&t&sIr8-Dv-dQ9a~dRGLA#ovMd}1nY~N zv%mtkay#I@?+-=H;Y8#r@0&CqIi7Lb*7>Jr0H9x)?jEFf6tp8W_^vY-eElkpvo zsMgpa0D|7e)y>3-iq_h!AE2Gs&O?r{XrJh6^qr z=e>VL2{Y0#aL&3R_0CXH!UfG^>T2(WaCvj9SE9K7h_Bt)Q_ z!Ei*0N{dt|UiO07W7Z75l&MryL8_Al?8zr$H(%`rvwvdUME|Zr7*2lD$L9U^WJPnD z0qcQ)DV4DI%5u99WA?*Z-k&Qe7QTEFWfOf0FGl4bZA^=|6gl?7&{S;&;y(#v&2?Tu zDZYE4X#Ag?zGyGrk%9z`ml2->*#{Lmzt0rP>Xuoaf4sW~xwbX=4O zT2l{Zx4h|W9pSDO)`0W=ZS$4>T~+u1GjC%=tuM;h^VMyAjt&payTh3R{YWZ69*cwdqj}f+4y(Dpxteg=;@1s2E(lz+xM@=g zP*P{*&d}E-RnNGI*ria#f2PdxzbysUMfi0^!T!ogW~TEfwAiKTz91zAFGuB^3UxCl zUcp^3Lsh77?R3^acV=>lBo#5GJ`0(2M0S`HXkd6=yO`(>VwW+1%!IlEyh1K*j;Y-3 z=8!QhFL-%pnImDnI(lJ&uTu_h&4Zg$7+-#epb~E>?Zo*|A5DsLluaRIjXz>FIjV{a z&tRKtaFX;y+xDGAr{zqUb<(Y1P2yPnB0lF3Weuo(b5id;_Ib)R%i98_stIyC;{5jKxNL~GG7|xE4>z$j9|f|H`+~qp#a1`;P9k<3%lqp0}}Lh znj=M(<44;z=tlNvF>P+#l0j_6)0RlUE(M))u^xg~3d? zNUU&1*#NW`8gBgh(#kWmMb0+#(kA@K&t4>Co%-Y)h%|`%>>{}94cL~q+E$(HaiO7l z;)&X=EGBEjeYmoDHX)Ytoww?WRx7-Q&4CFKe%(GkwDrdauz8iZ5aJv@SdO~Jc#YW| zT^YCj^JKok=YxbuCkVUtIY^XtEM0n^j(|JFr-?ob^Ui)Yb*m85AdbH+7V^2oT)FR>K$oIO_XgdvJ{&^2oi!zE z-5R73|GQoXB!Wmhk|hMOFUqR8j$&Qfr%I|gVM2fk(JfqTe@@w^?T*GzylrX(iiR3r zwVqn&QcRe5KRXXpH*4GPNWSQsGANPg@-~XJvn^rl535Qm?#TxqGGM<~i%EOIU|v@Q zatx5t%MP)%5lv#TqgX1nxRTG(<#eZv)m{45nc{XVOc8nGO*p%<`c?<=J*Z#F?ekJY zyl&&AR(5acKEXO!`b1`_c{4gJL)d_t%>`^jL2sn6tC-e>byrkX~UZ6!Ykx`S* z>Rzud+6zC9kmQ(J5~x%P{8spq&o*-VxuQ>{EFt|gX~^dIuSU(Q0R6SPRkmE(Hx*MV zR_~^>Q2yFZSs(qkQyE1q`E@?FFqrSsYS}1QbW*&{ zyT4ddRus+R^Nek}RwJ(uw~#9~N?O0~1|Mzj>hCTDo)Xa|=yHG@JL!y21vG_*1?omL zo~_`c9^_%LXClUnqOBuZ6>{I=MGBC&*31)iJnAKR%@zjyOp^j^iq0Y$1y7KbeO@|2 ziUzfA#jki4RZ$7lbqTZVp|fUzkKx@d%p^_cBd&!`Yz2)GwR&Yk#d+{g-qHNDh%JfO zs5aJqXS@z$+FCE#w=v!N%yFwYndMC!VUM!G@$4G=_jv*qOYE6pZ7H=4Oh*q)F+I)k_>zbTDVEhc2qExlT{cnkOz-&k$aHzR`tjc6!z6LppL*cf|^ z9jpMmi>e)p_+z2mS?I^>iTofg)(6E{C)(t9DcNOdY!iJ4OO6#mD!Igl`)cC*CsDhh zEhojs=e&R~l)^rh`s0nYLvMt^)d@uXDtSrMStku|<$@0{A@fV|+f32*4`*_1`*8f= z`yf>Z^$x_XyUp{9B?VLyuXjU`;2~AVxm~Q4L*n*kPRaDBEcJ3*)yVX*g{IdbM0hR4 zn~YFu0n6h3+}d?K_&cfKm#%)RswavaFKL)AWfC(Pj4Vflz~nm6k+;w5d0)L^Kc#u! zgkSj-&@-G1`oe^gF%Hi5oT)h=qIYh08IGS6sUrt+4o*&EhH+s<1?&J>Dd+FtO>19G5^OAd$z+n6*e!2}y-n z9j_7_jB=zLG%P zGT6`W{9{|1Pd0g;@E=G+U%( zx<=f@p3xMYO2@9d^pbqYO{W*Dk~Dc{53TV!0kgYqZ;Q=%B}gF{y?-N!i)OBPRwE1D z=vOPk1&n#ue*`bZl3%_R*W-c-hRf-rjpg@GWVE^7*jq<)q)e`BDQlfi*Qh5J!+lJX za#|vrg2eE&G=~-NQ9WEva;TrBa?Mg5;(4Qm3Wt=E&wyKFybofX`}%`8EOYtZmLXPCVi&|xSOWO0n1@QEkm`7 zPM9Soex^9_K2PIK#ye@~@*_seoA}JS- zuszo(K;X&=kgV28Z5E9)i+R26mTp;3crn2DL9o`; z--V>ZOJW85l^>4$`VO#0UEGlOY0qe$go7yru8%W0y5i7oSG<%}tI#1q{sDhR(c75}lZ8(fsAIq#jMmiijESli$aOyhY%t{ zUt*Ya1#d<*Vl^(a@g2=`E)IS!65m1XPWt)r`4idB*7&)Jd6T4a$*+(DPR03*ff()5 zyL9@HSU+XgX|g8ib^oIdZ3#(gIKLwY2b%?`M^g}HO6<=E*IkikL0m63(Iw_KdRbxN zuDG0WE9C}j-(f=^;U@Lkg*RoC#fdg?jR|U7ySuyl3hox%11q?@EF?g1cXx+{yZ-uLR& zt9n)U&0?~uSd%H;Jx2HJ9=~rOY&kPO^@5tD{M0xhP$X~Ko z?&NxBPc|C-ES||}u`x8-bgAb^n4RJ%9I$@??Fr8#%e!sJ8HFv! zV%luHEh+tW{-sHns;WS{I18<=Yq^s#2@P%Z3_}ANI=&SmU@Ee|MPK7S9Dm+fj&ozt zLo31a>$ABGm&qNEH6{%$_ZC*k7<-|>gMQPcAhg$|`wY_r=!7|Bgpy9X&M_gR92ar- zdoYSo4#E<=5p!h3@l3&D<6IJ{^zC{T{aOB<3;`YOvhn~PLVQTd`|Ioy>ZiZn)DKezX0ctSj&9GH)q!6j(Vk5B2Y3}#a#P0dU z%Sd~SCm&fBFAVrGuNdY|A{DZ`m|;vhv;Hh{nC!Rob-62B((LGr%6^!XPQc99Ve>Yh zp^X#t*ko0&0efM-=}%#ay~W6T_(OxAzH;&b2_Wyj5ct46K)e9Y#bVws{(-dE3!b~9 zlWms>(y6Z_lW@Po?tun7IRv-Q8m$#ZY6~R|FW&a)5q3CPbcQ4J6Fcf?y17HkDGRoK z*zZ{6zh$-(bR^`1XX8E8>&|mpT|QxzN@0E#%fBD29?`Wb(YDr;J^8D*H>r!ildQsI z)IRMa7ufz`FIxAmRyGh~w3nqUjoj`$*xkO4a+^A0EW9|p#j}7?tH%$^Au;3hMYHs{ z%H`mAXP9yHsHlS)I@gBaZIucR-g?7cHfwd%$AovMQqm2R$Zd+BMCr9iTz@+YxpMUv zXoZ>_sMB#ZlG^-`{Kg|CrebijF1_=Wv(ga;C8aX^F}19tTQ7=o=(u1U1H5h1CXi^e zejBn}Zr{apZm#`;%MKAVxF12Gg}tKRZp|exG;5NcKFLS=25r?mA-LZkQ6Qqbo7g)T z6$8o7_%UJUhA(D1Qg=9m?{XFOzT(OzttIR8VcwM-P7zZqp!u%VyiA3$SEj{ z9+t&KRj&jhV#5x$Rc}>f^Q_w+MuH_KX*+~5Lckzm!Ei52-no1D9X=$TNDut@a4i4j zhHqeyWoMzAj^56<82Cm@xfY87CdzRIx${=gdXJY;W3bnCqrv-^uhvnlm>kFHRpS~S zuZ|JA&!W|-dA0Q;34Vu|{_0@-tBhigWDHkne@a9;0)Y~hFmjx)085)(l5(eA32xX@ zEk2(yI8x#oBJUved0oedXF;WojMpUs4AzeJLL$uY9?}`~Xu!B`{%MwQfy?*Y>mn zKV3qY_<`|}-<}vNPgkaxktwSqhGmr-4hlB#E|o#-#~4T)>6X?eA{7kZ9BR-y z&<4SbXTM8ZGQGVd{mB*h`LHc}lTy#VH2iiFrmX@Odao5%pdxw0LlCHShTU#g)ylx1 znps{#Y?35^6Tw2~U%))D6c4FF{2ror!bh)?Bk>>Fpc^wU-@GiaZmO= ztsDY`S!&-K`^gJ&+dCjiJzi9~1S=!neGQTc>io`_Lh=eL2yiUAcrvR(l?4B+X3`w$N-U>q zZ6PZBOqh%K6ggDMt({47GTZoFKDYm_wphmTMXLCajQ3!pc2RifLB?8058;snTDoYO zg;%^(osDtB0{~9gNYx0R;=%l=-=i)1QULY4fk6IZKJL#s)%nG@1(&wXjw(mm4&}%h zNbc19$90szG|iF^xSx@a_$u$xF{I4CO57D@dHe_}FDi17fGW9@>3D=w;B003c32s4 zBkTY=Hgsn&1lBRRqamAwu3rPD7J?gNq&(%IIgBl-gG0vWlyvOpFr#K zz0q@!&gCjH{u_b1PgWWdz?2qCxha$?+W&x8lIN(JaEz|Ic@|}z_=C;DFv3gqLWzeu zKg@$oyRWP%qW}DebDw<*Q?a&xeCZt)&DC0|@5W`32dF1FC1dJ{C=&&7({irG6AE>4 z#?_7)#weaodX*{ZW&{YY1QPPD9!BI5hv`X&&7Cr%PZ?Ri?VA!)f;%v?zRIT|W?DD-_$EWSBw@^XS#8>tY!1vIh#qLaf3%xps+Z%(_@-FUBcNQ^hv{LClhH`6P3Ls;)`uc zd3CK8TEJUfJIWd^G5QZCoV377FujfdUZqrRTO)5uf8vQf8S z6*;&w6JiNP{PS}IfKrnY0kp*D0NarHfB}vK3AhVu;?1LxV6wrPnzFG?VosJWKs>zWfd4SlzVeDCI7k6ZGQ>~rFT_fI@9o{qFV;=YT-uNmaer&cnJ}pBXQRv*|k8_ zn<_;{&L}bTq4&?(A7Uu-cS$FAGfCX5r8CPEuD+FL0h$qSQL|Uvgax_Gwo=HvCNt`$ z=rN{vW3Q{qWhAn!efoE`e&m?y-{t3qOB<1O9-#2(l#D%>Z&8k_uIv%p`p@lPR}w^O zmlCg>dltLN#^wSiRTCwC*O2sc*+u3NM^1saM#5t{&yP+@r=AR$3VGLe-CxJTVjwQENJJpX~_7qKiu-nW+QLC&MTudeGb!sl(xp2_6%aHgM$MfjP zW?N+;J>a*C*|axcI-C@+7Khf-hYC5ku__;hh)iVCR`AatJI%9; z9U^hruj}|sgZf4dk9>Pa*S@}XM;I#Aifoqat9^VBE9R#?wtm0@GN({hLRdN8Hk@J! z4l+7Z+9_pX&E79{-wiqlS#U>zWaf$b(`n`w^0gpo_Qm|aGfH?)M)>DMZ|?0cMk<{w zs%uf{&9Qtm=B$y!#Z*+el;hT?2`cengRTy_?&tO7x&+EiSD-QElV|a@ z1`@A0I8-)U-LI*Scs6bMs5=V0l2nIB333h}8tL{xJV<$E>kKsB$+jZ0S=&|}yuH@HqV7J+N6NeW>fh1% zfixT2m)+#+1YJ>3((wBEZuQS{$V~YTrT-Uzq4|-@E>#EjmgC%K$q|Ki%eo7c+^*Z; zqvK2<8r}ud!uAj?g%n1X(?CN`S6^d;8u?lE?QQ>dzD@xtjdC?A8-KTS4z3hVlE@k^G?eXp6JC|j^wLQAA<@$7QwSITBpZATAR zqr7=oxo1zL^vrbBW_?X|h9%7J5L*Eu)s}9tdl^qIfg6_Dj$3aio-p=WKLwW_igv(N zql{p#HUVITQofy~B2x99yD4M$)9)>6p?x5Qe&6WHu<}im=;mI^B>odg&l{umReaA$ zFlo3w;r>${9*NmOE?IN?zw6$7RaiXy*gcFC84CT#H*iq2Bxhy?KMtiK2dWu-b6NF0 zaiKZmx^KLDDRpa~znuSLJ$6}QW}fv)5{bCxUAL6G;RQoLWzHMYRQJ@@(?|OG$c_yt z;?v%x_lA52y6Z@{K7)JFYPSn*_ zhGg3jbGF3%r*{gzQwcS#`rU;Q^-wwDgA@uVF&*LB>k@&k)}V&%@5!`Ru&zZ`dMoWR zsukM|&U9Kq{VC|K4<&PbW1WdL=1Or>8n&Bx0Wz5bGn7YcY4jff}rb@|VAL@J0uWRBo2$iezKl%! zCY=6eUwP5Cj#lrENB`z*s^!=q&~n&37GG#Qee50s&A77^u3Vufb^UwTC(Gs1d+T|_ zD78|({<;ok?>UKkujx^fT);|&Hf84&5XXC4%LTkI)Mj-ayME@9$1sB6=-w!aeOM|L zAKMb_mqw1^yJfVzHe*ySnGMUgL>{eB(w<+&H=vHIJ9sBY(@Z?o{%;_ovm^@j$^w-#1Sv=2_P!$y)m34HU1d1Prg_7o^ z(tL2|iKxQVWo|sS;wxn{zH7$otGg;%2DCiffkEwAF2e67X%EK!P0Xp_HMIiM_q(8% z$GMBf3QbkYuU}(oZJMyC{G<|Yug)SANlMS|jW9^}-oqir6UhUy7N_>5$Km0xF{i{V z>J#pz!gQ*DEc3~+5slK7ya4>z0qTT14qG4(`QSmo$IkK(Ipk+uIl`kE3e36U(kqWg zI6S(A9SmZu$XaseY22{2ow#8y6bPMWpNTcN)RTi#Ps?=mciVKEjb57cbjDxd^YpJgDxOBWx5(x7}2}6=26<%q} zE9UBP1)&5$C|Jwz%IiEciOrk#@V8lwy0zu60i!%U=PR+Zz=k!@kYDTZGy;aBwvueK zsXVEU+DiHMQP+CEYhcDskE--5N)nc*GOKjGj z*dI>tpiBwt(loiM{e3EMv;SAg)~-|f>8zp&1g)YE{8nY495~pIg9r_`WbQED-#X!r ze%s85X>|@E@G+fki!sIR1~Zi99ylXv#kepXf(va?mxGwCc=Xpw_fcMnT;B{{o42P_ z^WoE>k=?_324Xe9sCYx8q}M^+gZ`QLZdm=Wj@@-)Uu|io@%^-i4M3}Aj#Og?ZvtUl zh0b(2y1b4Fhm5ZuO+_|QyVeiZxED09h+f_?bQXv>wVP@#p2Da*-4PFI*k_-V>%mL8 zUaMM@nL@u~>VBt)4Yk!8_o|HWwRWTMv zL~K?-r6@?S?7mU#DszE84$Q^Pp)h5(;~su($~Dy8ATj1>#|3-wfCFy5#^VuAXSt8k zwC@g^f*^BGp80Ryzx3o@n|7tdIefSwhxNKDJLOX&v~i>=xySsHUQMLHmEsa;r4;c? ztbe$>L1V-}tRF7xs2hCJIn9H%x8eF6yimG_0C_pG@TNV{02FcN((aEaNuf8|ie*?f zjfY%C117MVHZ-)E!yP;mH8^S)RBaM~bxUy)I_q8z;2LRiVBHX;nu@xH?_WQ9tID6x z$WQbD)3Ssc`T+}g$$hj)fLuGA%F=OyH(-xMP1WdYtb|z^81B$`h|QxRyZc`nXP0r) zElH5hurqsqY-8q#{tt!fMk!}F?dJxXOodmlWQL5L0>0my0C) zEe{seIjRG0IsE}Oay%SNJN8N;5ayS{*SOid z7-r}^AFbclczJyY(;~Ty4w$8U{)p!n_h6YR!gqM2MmEIneX>nII-)oiemA&8>39lUryeT-FJir^ zPEM;ptsvh}WectE$e#WrmySF3$J0&{m}N=;Vt7Kw@KDRU>o(`<;CD{HNrz{pOucMZ zO}9|~m7VcMzVSI!Jfi5@yG0D0!G5AeCMSGpiuf|Vd!Myp z{8Vp~-oelCAmwT<{Jv@ov)y&|S!-}%upBt{o{ya(rLKNJW&6uG9o{HTU!Tccb{yKJ z39VULXLp%hn$wZ4>6~cSgRzE;_=V1+h-K@ExlNP|0NhrJgFaM;@5BpZ&Ml0Y8Knh% z;Bq%k?668yB)+u!eTiT8nDHTF*2svPdfkFEWU5n1v)UT{_yDFmGmlAUo{Cs`kb>Ju zjZL&yt*P>Qx`ff`fmU4aPtd%6&-53Hr}%{g@fYKt)fUUX8&1;PL0Dv9it1up{KR^H z+T`|J>%Gd6e5eGFi6BNiDsY`v#jwL1a5;m7B0;a5v^kS>QN|2%yuNuqQJU5>3*0L+ z7c*JXqRNH7t4|rXEH|Ih@|b=etJ%tlbxD48*{rH*_+Y!#`C-~_?7O$IN^yAy>(BV8 z(MCc|ulvmipAMrnj^)0MQDVuuTk_uuc?779Q2F&Lt6G!ae8#}~W@RZKU&LD4vdrB1 z4lUpOour`3CZBX?&U~n3A6}(Q`f;+B9%N&^Qo7G2Gxpu_5h*beA%*bL5yjWO&9{CU za@4ye1F=~t;e2{Jd-=_$X1L9j8H>O3)L$Xo>sRH=n6ko@MHA)387W5E45MHCG+;C$ z;%19xnT_|7yy2%={bop9{WdZ&N#QIr;J19=RE@DVQVq%}F`SvnS8oBR_^CpkVy1KeMT)<47O1p`3 zf&7`b5m8xLEWgpj!5ZC7QBA_3*PTS&7UqXUmJ)s)#G6B%yKU};(#XtNBMb_GtCI@8 zD`6E`cPsH@M+}AX;vG2&&B^tlD*uW78OhsA=m+FJLu@~mp&CaU1c`YRL7+D!0odZ| zGSq6c-t&!iesgR4v7NUBG7$>QZXTPH-5{0kedHlj;}M0~)g*E3%26A_Nt)^7ij`C# zd?X_Q3?Lc6B@#(QRn&Fo;8!5t%c?7+dA6*HxxvJl8szb2Iyi9`Z?c3sKGe95FH_a5 zD9+U(=694{ugOr{7LZBB-B{&2(Lf@Wv_!@UA%i%t_CY}g=ubrRC@aJ=`*LoI<462L zx^iFayRGYFEoQOqP|zjanp#sPZ-|~auv{8Bv#nW>XG|ba)!*f4-!x%678+I*X1e%t zV;)hQ{B@P){B@S%U~UydQCE^esLEwxM!XNpn|e95@T*yZitNuCh2X z*e&NS@LCeh;e--*p**_Y+zQ$Lg0GhPK_H<+KM`z|=zE;!N&pmxGxeRuF+lxZ zS)G;N(g8_~Mb^Kc&-HpwxEF_=nRci@vHyD~M&V71yh@|zWizxTq3d<}m!z~ec=R?? z=V+)kx`Z}&IOHC^?x#aPFHUWm{4+E36Z`1up3=yh_uiqSYTYjvjCx4yVhI~g7QCk1 zP*8=+3!gvg)qczGpBD7?ly{TK%EN{z=07H7B5b(9~gv$YK7)I2%dhPH<#yxgyA3!ttGdn zy>=udp^aRM@!NALv6o`Y@cOLQK~trvCh+BDsB5U;&C+NQWiB+#u%%gM%WFZj5PO*Z zP_!9G)8Wf1jSq|MB{9Mq$AXy0^-f2tM5+B{DFA&NRx~QkYmXgoUb38s+o~=1n8F(~ zr=O^l5=m{Ov&bRCZ>^vex~;qnzHjcAQ!RXr5;qH4C@(XK2Ll-RoTEDC<$Hw|d>pEH zMCyJUreMiP{ZsR9G;~My!=(*V2!#q%{xbD>p0D}#{oPe&nrV2yr^e;ro$8z-BSXVt zL^emgL}a_t2iq0P8?pnQ*8rNwe@0&=?K045gi1~5re#R^NAbkoamBzaA^MSxk$uC5 z(wTPuQdu20_bO0G^>CKboWauRP;O9^ObcZS2i!lP`M%}!jZiIwr6TQcJ;el85Ou+5 zc4D}en<9F5`39>=pM#R;aO=#4j^UbP_40QrXKE5D*hHnPX5Lfd`?p*5Ge$bYb4`nz z;z%Cu6_QpO-B^Lot?Gr2@yBvZDPE1C#JuiuE0zO46#2ZSs13#W&)i_w4LYi_i38G1 zuU3sQj1C~QT0t2qF9J=}o4VTnpc6#At{I#rWJcr6H8+foax&ccGk+#0ct&8L_GtH1 z9QgX(Il$SV5;mK7q5@Ti$hU=$D0rM~pI8Lj4+gO)J;<_%ne%Mg4|qNiTpn=+uLQYo z&?)1x(Rg$WKH|wqh%9mXfKbxA;zvwzDz^e%3PST0XIRsR*}iDI_AuXj9e)%$6cbJ) zCzeny4YYStxXeGn_92JTL=tfZS51@Y_UuNG=JaJtc}IO{{0pi36vb`S&guoyoEJRC zJ^Dqa(6h+-&vvf)jCB_&`1Nl(_hwZ<7N3nRG!qe4k850UiF)FQSHE>BsC_lTPtW7v zUNQA`i^kcm^^a;^LTCnAvk4bg@|m=*>Ci!0=7G-liI-Nd-tL5=U7kO-=O7l_atshc zHhca#?I+HJ+J3*GBI2BKs#X77hcW{LRGGWsr_5&4eF|1gNWIP@DN*wxfro_RG~Q$x`5?%>q1YcFp2!!bd9Ht@?|_1zWCR5I_>v$pgdmqTkkS3$BY?K zT3OsOcF&?QDi+#X@1)nA`%KU~ANsz1bq8i`5>fvL6d&8*-w6VJ)!LOjkO5AcwE$Pj$5SgWK)IdDLb)8tI zH=!(f-4g#-d7%ogFFc<0)I7Jvs)61z%3B68+Z=kgDh?I9pO}bts=!}1b9YVz1wPWG zZD3VaYHImvTjl;T0!XD6$*vJVQiU5>jKRgrV|5Ne1 z_;c=Bd>dA>2X$x3krZWXH@rarSyahFTds08o5+-Xl@aLf0jc$n?bW$Z%$u^TO^wCT zMxo1(+PLOzljO}K#-WIT&=lC9m=5&Nj{ZEoxzlt`_nQ~dllYsjxb=U1yQDh0iCa!l zJVX-s7J%Vv+hzGQOG0noH23O=?V`e2*ref%rzNuyGm)@aY&}pS9WKkN;AiE0RlnsQ z`!UPLf@l*l+q>46;ly<+V{2_MO4j<%>PUPLjSSDHgN@)WQMPYtP$q?zeb8^A-uJ+& zk+%2;jZ*S|g+_TBv7}}1?iP~h)e}n#am8`UmfMyyi1u_6>lsQlzJth<2}OF&f3de9 zk@i8{$nt_>7&kQLCdS!~2a9f#EMZzmeAOZD%~tSsW~B7;E2UQWjb^8s%RZP#2Nq4U zkB>8doXjas3^V=c-m3rroIr+|Lo`At!|?BH{7%)>IeK-5WC{~b&^b1%kZc(5CF!2H%yF}EnVZVO^^nKw+pCw_84gMw; zecA_G!8NwOUCr>PXGV%exiJ$}Ll0ycOPo895KwIb*w&weBsQgAX#&VI@dvPTzt98J z?NFrX^q9+-K94^{6xN8HMF;*NU2Sc*4=T>6%rtJF)5Ri4GA9Tt6vogyNFzOIBkV0; zq0e1#>b8Acv4%e0(Mgx? zN2v^SGjA_u%{VUe(+_ZRl?Vh{w)kic=IK4%fGUoz1ni*qBy>Bnf4Mk^|N3SVN#cwJ zMwR|_6*avc>OkHE+2R}`UJQHaW?Z{Y@yW-zL=1Gs4KIlj;NkDTsJXsggyGDb=nLl$ z4)F?H2jZzlyl&*u`0C+6L_AS`XFS=m068vu_#J^=c`03%$B7ao_xgG}wGRteLjpYE zwsa~?hT7|C_Oj1o%$Ar_gcZMZKfZ6kxtv&trlW6yl>CD6fQ2|8a9c0AeLEhhn&HpE z=&RT4j+8qXG1_X4VjUU>;;gS|t1WJsy`@=z#dAwe*dZPShh&#>i9u$F%lc6jWku-| zEfaC3pG%On?|S}u+`=wyaGCRc{E<8@k-Fws*xp)Fvz@^!F8VoHO-iR=5jFe!M!YK z1k3;K-RGg-&El$`{~!45*~JF&@jgb9mm~wKgs&*C1l?TbO*s=kAj$OeejvT#FMV{$W4dn+ovVVD71-%1{;bXtfP z4;&L#F(1i(w117#aXnR$c@X|xD_7q#RWtb3gQ(?>{tyef`zFF*WT=cE)(Rm=W;AVz zfd^Q(2Xv)e-w%qFr{_7X1#x+58mkhO0 zM3M1z^3m<>!v^a~&c{Up@EYx2vL6fH2AUGg)gqE$VNZC0kkm1&UC{D}gN(uaq6Vml zLf*6fGdNh&3J!S;sC`X)sGz6Ueq|WWgR1^u=FcaW3&c!6G%c}xV>s=v-woV;&z~%G zUb~t+7e)|!*cFKV#|*t0%_ZabyZ3PoMHncYY%q(!_a?M;fN!c zT~4E;S6s@(BoT@F-BMskG1oGWBnq{Xx9YDKmW||?`mSJM_~Ebxn%C4`7$UT_fv4j} z6!8Yt6Kdd6Ro&x?b>IRV^=9t+8T@Cv=aTH~Rz0pwzrNm!O!g^7Q8E6ALVE6W^u|H?V~H@!GM|n(lDp;q>tQPapF{P3AfO z(eGISga-%I6^fqH2m($ats1?Je92|pM&S8K)(Sqxu{a?|PsvwRf_FgFEN)v7ELgI8 zXyJikfihPiQ>AST@Q7o={ z5c&vLG@b5yGU;p@FV(}%lSj-yt1AjVVI9qzsjAoc@*gPl+!qZ&U=0=B*~<6OR=m0= zxc`tN@D`Zx(}uUukK{)aq4AjL-(SxBWzx2|7<)XJ05`H__08D3Lgj&rOlDVQ^k)O{ zX{Xx2PPA4MuOU%nYE`x~WUHsFlmLJ=+CK%0h@;-sQ!a#JD{KviOXfW)8wE1$r!vFTS00!1 zVJyBLVs-kRl}7M$ph<3u1dSW%q^1-2NGseZ_TB)dnwjZrv^TqCvt?rrsflJiQR8+k!eYQJ$eZAj`7GFl#6=fDlU^l(%N5*Nt^x7-=d(UYjGlXTCx%QABT+;tw_F2t}6l{%;mm-wUz35mH?RXQ*nFaxb(5j zJi4}cG0Av{+0Mfa`%a2i$Sz+fe^u#;<4st5w-#c5vm|_rK@@>HaW!!ryrg$pfOd=B zVfxsX(8JQJk)QdgULq_Dd-@BZ1v{FgIOC}aqPr^l|1V(WGt)i{jHe!4f(9+Y3MS|} zMcB@J?--Kf^IZkrWmO>bIldfs2Sr*n8eiMHqkd>|gEF64E!122n%cj2$@q=2YriRk z67l}_kZ>VPOQ~TGeD#guOE1mexu8r2{%^43If?5(QpOgdt+_WC_g=Y_z+5rFbYOK< zADaoFgeBYut2KL;D9oD16nWbqnaaPT4k561>elO=7@|VsCHyLx*j03a|EpC~d;;I) zrFKcn@6$5%_tr>~9*0eSKjbiu=e;d$j~$X)3x@&Gul;1_NsYXjW(6Ts<4-J#in6KyprhQ-q-BM zt0bsh1)~_)AFa-8E}+NeItyo+U{$`u!>(^M|10Fv44FqFwz^E5#XUE7%jg?#ai#T) zKL3$@4z#RMVFUMX7Td!s=d=Cw*x-P+e8Jyf_#l-tHOTI@2X>^E*XvPgL?SPY?pg-n zk>x9BnMbyDY|3%DX8Y+0tKCOyZ{$1t@m%Y6txZ323RsH$HIdchjU}9xeq4IWub=BS zlyfUlNGETTyAT+LLOhPAIk`H-2?^06k3YD>{aqDL-_f1}GRvO>G9w*;v;Z%P)m^ZL zYUZ+Y62Vf@p$pM3J~EV+ca}2&JPxdkO}zDsNShz=nTbv*ADIKzZU^B_&+(FoG&^os z^Xx89`F@)sGntbfQ;|x)krX@pn3)zvT_pU?m+)klha7!F9nqSQE0oswSI%$zYiAWE zp`)c=gAj>YjT2^bW8}8s%vK-Nsl^HtA>%(5;(pRR(aFGhlVx>AI-(ikprm*1U91jz z!QeDU$`l2j#0Y6^fd*7~@Qpb4DLOJ-hpS|X%t2rr1H)2kS-#91X2DzXyc8taJf6+1 zs(0eUX`8lLg>DV6dUy~9)|mwkgMgtnHv?Z`cL3A?X%JaOj)6-{Jl`}Q71w`Qz+wBLVb^y)bNa4?IxbVKqDP%;f205443ah=`~SNx-K+KDsCKf z7PL7CtWvyCG>{}^4#T@z+|DWlB%(qWZ^11PuX6)+*XF7>d6AC+uXwh=nIL{u59tY` z&&kdh<(~GEhIN`o9CcCHp5JWVV=oNg zr<;Oy=RO}2hVf&d{E~$bFHt)oilGvB={a$F54v||iY#?CfP?Hd&Ldp4$a3R1Z$E2# z8~RL<2{f%cRb~)f9go*J*nXtpc}e*gyc*#J9j>$wlmRoAJI?JNhjRPQ#wwH6;@`OH zn{@QzUj)*%`~QMQTL>mWxPLouW?CpA-I%?iaG^sz7~M=d?uFnS-&}FZ|3FQ!zJIq# zGUB==5}DMDGjH+|1;-q`%#&j)sb(|fZ*vP_`aeOXI8sonz zr@Gev7kw0wAYqB!aA>jAvqD2egptCah7z0bup*ZUs#QaTy|72K?m&)G5K}OKyldQc z5tew;lN})DeRMtCC=ul$usY8rh8EBF76U{O*~Ndk?ZI{TV-#DG`M`-$gfKZmoYsbv zm#=}<95tbo53x!C+0ng zNafIzZ|sq4R6K`8A8Kyvc4iI@32)D&ohF;XtF-4)<-%H+tApz%rGtOibeJepM8l+= z3&P7ZFsYu4zd@=#DG8<_G+C_%)6U9w`r@}jf34ymYkFF=Gd7qI<^}G)l+JK_9oE9T z_xgjTG`;;t%iuzZdISMCoTs_OHUj5Y+l-4fS^?OJ?3DKw2|m*Lwl{0!zZojog9P}m zPi!=sal>P~rPtOX-V*3=zz#~8*fG4crPV~bIXdjfFhDE!fAk&RS8=aopq=`)T^k>Q zYvn0dAt5#(uae6S_r~4CXUd*XrIbRuVT)G9Rtw>$8lo%Non))YA98qeet7;|Elj96 zgTdJzUvT&>2JJLlM~St@$Kiwb0gDnw)?XO=k?$+lne;z09GC2xv@$V0NMTE_4Ui$8 zZ|=W;ziLmTmZ#TIXe-1iO~mgL?YJ?t^9uj?j2toTUOmf6z0t$bIjBhRX8N69{zR$A z-=5|+s@%=2*tgcF^G8Dyj0I@XM+u*?1MJQ7aZnG$M?}v{Q!BLm_%JH4IszdH-Fu;x zfw!|zCUEPVADFhQ1z82@b%k5G{^$*LC)6MrjM|p?vi<^y-_mJ_l7*9jsrBa*N>WQ6 zm_;t_JF4~{5Q$CGrkd5IyQFcW;Agd7YARVOf*FR+{!l=4^w?VOUj>(+Cn4MxFHtGg zzI$WLs-DMJXM`V_nzp*HLwHDpIa*le=QP{Ofj6g2VeWVs^ytO&BgM%GPp;sUmWgKd zY()nf{oT?4=iRj6LN$&o&x7abUw=KFi;D;<4%K~U`8#I-P|!+qq~%GliFL)DWjxAy z>qe*(Hq-AS^^@2q8%Vs`pHiNqMn1*X5OLR@_LYwmpU9rZpO!74eqO^d7MuYykxv5g zYFm-TW<%)`TenUe3`yryDy?X5xC@=sgqX^#yj>d;f8Vu|zj0+s=Z_pmdzmg{7dO!L z_i#1Yze(}$41d3GmSlcbYcs+WsU*G(Ogp_jmA#`SMYG_RbpF?b%{qZQ zla4y4AW}=mrfs-aTD%&AQ~^1_5bF7sereY?vr?8*i#wSg6Qi{ znEo#5vz8B$a$OQ++Z1%mB(aMlK-@}bulz2UCvoW2x0!b2gTt<^3Coqm^VDN zGJcoCtBrF(Ol!C{25W$Hk3Sv!Zra}!A1s=ID4J!NwRC4igMow?yL}JLyGd-23-s1@)?AFnHzljZg#WFUm)T_xqW}?B; zpJsR%?xccM>!`w?_v4gHe9$YL07qTB*AIvrHw*Cp9bud+S-BDMGJCxKOT3xuYG<*z6MZTq>kaVXr}r*l$~|!)bam z+5Ssu`v>C^OjROEjWg|a(k@O{bHXdNs`yV&C32TB1$rX!KHw8$w3PwqW&XU`>#dUc zNW#>_)gu0jQO^Nyk!_0rxlGuZM(9Yq;PPm*Y@aQ1|8hZ4B-xh1V(oz{j|r1H%=xd= zq9G~)UG$~0d=-i*QkNqB9aRy(s%0nPpsceBy>93G^VU_@W^0vuTWb8hD4eh%v!<_K zRW_`U4%G1G#;Zmu%mkz~nvv&~WrUZF)0wu5i8gOhy5|GNN0i|H%$M_ti7J|71f$pc zH+z(kXmmKcdNU9B;^Pa570n>!B1P=qbkrqbznR1fR@y$NS~6l!Kv9BVh8wk4*p-op zO<7Wnf{MH}X>f~lS9Un$UYjsMytEwgm{Ip@kA7_#>14?~Y~fT1;N7T4wCBCp-Qi@u zMUqYn@!tu}mNKhh6cRhnp8(---YV ziFxvF|5ZJCtGkpCu!ENey0S#3Fj)T{CD(oSQaKVDsf>*Onz#S6Vo9lm{ut^McQ=Q-N$k8(aOeSGp9EjL15bF6^&-}rp52@a$9$tbs$s}SOI^26K2Iy zIkn`eM|D{ER`<7{dnZ^Ix>?!kzM_12rdI-K&*O~X9W`JOU;Mo&Qq%h{yWuF7$-*qh z(x)|QWx0AcPvXl=Btd@?xHl?=F0k%5f`dH(#@Mm4U_5%_2H^v|!qvl9Q? zUy`x@#|q8!`qqDK|0@TWiRe8&JzZHZw^%*3K1C`Q1yohBws&+K7_h*lOT($CsECM( zkI+Iqg?mYDt*ouRY}Sqviy|VaBFrTsB67Vx&U(lj5Co6@T3jTg zh(!R5|FR<4uT8hyyRM0<+juCA>)=TYcwR;bHi=)s!oor^E*)!4(Ik6D3LzO88LL); z-29|@WUo}XD430>Q0>#;>*RnGgNb4yEG%QDYMsd;%3Nl;-Yw{u5pPK z-|0#D%HetT!Jdw_R>pu;)!1^|sOzGn)WoS}@**SIaLNIx!i}S<#Ky^+)xa1?6XuRv z{{MsO`m-eZzuaX0zrTlsXM*(;h>?NX)(OC%! zR#+!L#hL6?`~dfIvK_HXGu7RV9~|n+?ylL>vs2S{uCrOLeOd<5dR#)`k&y=#4|pjl zDP3J%-_y|{{oNdeBMG={w}%MtWRm@gii(_M=c`6XM=vWF`Pn)Q2U8{+K_(Q3hljS# z&RxwOSGp|8Py-!LSictx3=C5b8?6bfCen9Lz^P*Pa%h|j1SR=M?seqDtjxiOj}Ld3 z%*lRp0J)4jjLk40C}_Uh7{y#y4v{e?Cg%AoJj)26VOJa0w#ykK)tP@8NT5$;o8kAo z9s!I?R>ptl!hJs^`YGj>G9W7qcpm-5W{>H)+=sG)*oo1sm6jR^wF<7(3+BIu~?)X0t4ygl7Td*7VLz zR4OOAaq3X{vTG#(7u>GoUXYdXTCPk=R!m6;O&t*`tfAg-a{GBXBs;-P(T<2Y9CDr0Pr1pFRyZ z?$5?T_&7OVgBU?ejle*d$Dh7o?(zanm{f-iIq zz+$%Am9JA$IZDQX%9oq_Hy8FKQ1Cg2$ECOf)O&n3Jk_3{z7g7g>!A1!3F184{paNW ze)Q4KP@2zKv6^i%$1pc1=!&o!n{iIZtHse|Sp8_j{tMWL;^V~QE8r?QF#pxhoj--D zPq4tks2$~o<}`zdrHhmW@zM2(&+dOulto=%Id+n~bU0bNBnGO6ivGV+9%MhMAhkYO z)02{ChmRl48a%CX1&35D)fn~0yh=#p0`N^)4KAp`!Q}wO5Si}gtV0nTcwqv#a|!(a zs@a_KSwQHW@q+?=67V7m5vSpu!1(@zH@x$@if0@m)a1N&`&`-Y~CHMHtEBB(BTi(MwLU<8XYaKZ*12r#vz48ewmgAC6)l(uUXc8go|Tx|C7u= z9!D&1yse|-)zw6iD+`)m+qYu1DpFqF1#UwMYinz!)IkaSk7N844n5z=5yM5v4wsq{ z!#eeeQ@J(=LL1gRBSJPT-WyNrDaj}S$8;(el zqPUw0-{iK-et1H!qUu&QTyD9{{GMfKcfmk+F+^8#TDCe$#u*Sqc6#e%8t3&H1Jfvz ziTNUu-p)Y*8w+bwNA6MSNr&FqY*Ih<)XT6LydSSJfq@O=jwf&c@=?fn(mC^)06XZP zUFVO77!3>UEUkVvX?Zl^0gr+DY?cX3b1e~&q?2cFOU zXS;p+{Cc#k8CG(s>60lHU>QOVXB5>@L~Ymoj7$W)@Qa)MQ>AYPZ_dbag_yti5bz`}KzTM*?cc1W zYXQyRJRA5l>*j%EFak$-8eOMr^;MKKI3YG#O#i4s-AmW7<3X$D7nba$NmyvmlY1JB zN6bd)vrCZQYe2)sPQ)frHk@V~F4m3aen)AO=-3KWKX5U76hw5_3FC-;Djg~@Y_he1g zZU7a)Kr{M?W?H5luv)jg!fQjM*>Z={l?e)bgsOc4`xJ;Eh;Ud22fHi@8n$`|TQ3ph zzQKIYWj`bE4LGZ|G2@pC$*|%KwQnBNwiiA?R)B@}3k_x_SHplJ(VLSs@wA8@zp>5J zPbR6r)Mr@b=a2R0N8-GdQGeS-c3cH7XXNDi9au82)D@y(;s`yVHhyx3kug`7tG_<0 zyIv`gcCDJ%*qO-T5Pfugn+4VM3uf`1<68|tWU^d*lbFm};$nk)dEmD-M3~gv^j4vY zf)wIdvDh$Kh$)3hD^zJz)tdZVjv?4v$yy0;K^2Z`9Kd_?UxkW2VLJ|>RasTDrkhXE#ERD!)o~VP4f0Y-0XFxrY_}YgCDq=}v`E z{cBRV^k=7FUUpPsl;wc5veqc=7Y(+62TOYFkh?y=ffdHvaNnDZ^)yzQJ4x0W#?G9L zM>6utAMTMCD!g!0-D};=He`s>s9SNoq$35wduB2b8TPn>gaULKl##YbKTp7UsCDP1 ze*ao>R%S@Ce^1*=S@Oq!0XB)K01a*UKTN%Ic%(n z+qRvF-LW;XZU1`CIq&s-f8^@!TuJwR@2*|7YSr3RH?#+G+P`!;cojP>*hO@?qQ={u zES7o%w2~$RLTwAK4(L$5CJBRwG|%mYz9CMX1jdP58J*2vP~n$IA80n18E$rZKIGV7 zFzAHVn~tygfs?YxVt#|wxw*NIzkGJrv=O4QT236No;O7Ixz_q(pxAN^)|M}g5Rc68 zQ?usP@WAHNi<-5}dp$npkU_Ce?a$aBbKB!+Jpbzy z{a?#pqoc&E)k6*nRYF}E|YOXTw^!E1lBJp3?-mrQ79UI#coY9($#*114aUCBoHe}q@(^roG zigGrEi7y+uV1ylb9)YZ*)W5Q_^0JYi4eN=*#>LI?H5cG4nWy5OA{C zF(Z>~%mr|}vscEyz{Bh7zXMd16mh1Q2j88aLZ-9Ud|! z<+`0uYii@N5B$4*_8m5!LdYKO3q)Gs_SucV=-q`M%Cax{T!tC!*I<;h_VnH!z2bpA z(>t|F!{2C_mxsv{jJ6Qlu)##?A%Xnfb-bY{)^23j zFQfRL6H|kOgHKYiSYSw=FpsRE>#Nh!<$9L<5TDV!PLuDp`Q3L5_E;cFVJuR!lTC9}JW_sL?Vbl@0vtNka( ztKNQ*TpKdpgC2RQ2C5Z?l%xfd*hU2H8P8|-+dZx!CUIwojr=HR|Lyq}m?RVouh?jz z*cEk88eyY8o{*mJ%~*z^2|03zkCQLZ&MnzQHvEtb*HpI89#bu+M1SK+>ES*8_{wU2 z_xOGk&Mu3?MlOYQ;^l$tbcRI?gP7}m2b;AHn6=j@Jsc`mhOvD(vnV>07%z0Ic6QE5%10>uuXc8e~#a@!$kZ}m^5Hp6yVq%RTrtD$ZadDB> zWTy;o>|G6xPWHrN`M8><9NeSo6^+S)F8SP!4~M$RBbJ@^(Y3xh3qdRtPN=8w_rEIf z0S%jTL9ZAYe)gukep-H;e;+0?zGB8#>Ac~=7WUAgr zr1sb9N!13)82-K_R&(>^kpzF<=jgG^CvEJ7;tfehHNiwpiZqj_BYE|=tN`izwznB_ zKaDSlpUSMq-E2f-hxwFc%RwZ6_mPtuIYE7NT+_?r$cm}g4O#hGi=xO(0dajoxg5S` zXl}b30;;_HyIa=0{tt5Ld}=)%JB9b=)L3E0u_+8sn>}wnZJDVYao2mR#zR7#F7EVt z({@ZmG|EUM{NC zZi_wcku!RTZ>mfaAexvVFOX4>uWnGQf0NXMulO_(p~KgO@c&5!-a&sKz#Xwj zpo)n;8=ttiI90DL;Q8a-OFX61iMG_!8RGR`SUImx9bY$0)L}6E$mxJB z(>*AEGDW_pT>3vB-rEyVQ;s^WRCS~xH<(4wdZb+g%XOocx0_mo=kh?ZeYi;_88@2V zCu&QbN^1K}j!t=Yzdor`S{MD(TEtNFnn>ns6^5ZWeMZ@tx6NH+9bSDUj%4M8v;e=vfC=O zSj63dRR4QR9JdQ49iqqGZ@v@3nDW*2w~vDJlW(c-x6pGF43vwe+RQe+40awAIpiPz zzwaPcLe+n>z}w)o2`JgcGn?lt{xZcCk-usn*31}MMuw@Ja@jkboaXrIjitNlntM56 z{3ZD{t(U&4zYhogOMnLva8Vj@`((i?(SFNlXFJc`DY#HZvNj9f-}faKoF3?YpOnN3 z>5QlK0|cBdQMT&wxp>|jwSeO@*Z`g$uNN|Pa|#AuFW}tl8V-MN?`C$r;|Z8jgfCc% z0vR@r7VAk?=p$7Vu)wzdhQbAo$8mpSG58503XdL9C_&sM)qh{cHJq+VmUDIVP5bVg z&kc7za1h%*@a{=~r%zNFT$Z%$@E)15lIwIG+^)7fHQ+;k2*i6jV11?Zk_(Dr`hrAnHQ=h)19 z%x$Nnp7HJf_bps)iKGR{ECy3sX)|ewr$kz|>nx)+k^AA{fwv10OLz=n-Eynq<&jcQ z5K#@IQn!cy^I{d1em9%S%MAGV1EqR+&*#wDj_CUd>q_ta@nO!rTw9QX%YPRc*#~Lo z&)Mwu=MzMRIZ~nLvCbaVVrci=qBE_iEA+(1=zR&JBX?t>AbHm^b3I(uAs4OyB}CS zKH!hZjfR1~+-(@-cq=9*%l-Rn7DNPm;0jZIIJgm<<{>c_&Z(hXl~0$TobnHN?iV^{+j-r=VCX31{)!K zC22okOUyPOA3T&)FdWTS=~=T;*_rStin5G#? z0&>f9t?6#3#j7MKe|gRpUs@Q3j_Wa`N&t;e(m|G`HWyEv-w#L9Q6TeMG#Pq^LJ+fz zjtEx&ktCOU^>xiuocBRV9I2_H(K531caq4wn``3+t8n0muT>@y{O@*q}8lI|zv#BapAh}puko>qL zreH;-Xb@gA4AD*dU#-2Qhlhc3ogkG+2+Qt{)o?*|UtQFpBoR2{(tCro)a$bkogi$N zSWoy$mc8G_I=-uor6SRxWk~^9nyfz1;{AP7)J(K1DMh;{$eJNl#!rp?LE}uyX8^sS zAnthhh+N%%#asm%CPhtyH1@A;5o(2s5n_o_7AP2yTjb!SMgSH^8Gr|x){7Uq(QHNp z@17=HkMBgHW-Qj-4wzo>J`>$DVJpw>(TF7tWgV@QK`$x}YU(tl-DP+?+3{#2=?qO0 zfvA*#~$L7EYx` zXFfY)bNqMLAj5Vi#S+pJ~xWI>@=7MQZeQ7vkT(pBMh*Tj%4A!rh6h znF^%%Wp?CEew1)B2Lk@in2cNc>de*ga_sk`X=}t1J&JolVS4$Pi-XpTj%)8$$AJ$j z#(axq2MEV49)G)y;kuKfNeA&1nJbv=P2PceMZV*nE0Rl+69u@*-8mb*j`Sbaiz3R4 zMt+m5J`Z`9w#i6Gy^MaV&a1uH9319&A1l3m+Z)*Jpy0iIE3ktaMGWp!_>K}BgJjm> zZd_*!+?*+DYNn{w=9rJd1#-0~5)f!q>PU|De30zNlc(CRhYFR`g8%Q6K?wE+U^guj z!|QQ@j~2x~yM2gl)ic&6CtNj>dY^o-VS8qNU!)uJoOv&W)`T8d{SrVSGZyq^`+YqZ zpEOAUe{UzWzfIUCog>liQyWwj%ECex>n=|U0A+cXFoI3a(i3q1ZHZ8<@-bAMFtU#< zzzu=%qE*0W#8;Abz1=CitHNx$Mwsy+)63H3iA#{W- zWVeCcaze$?kEhGh>*L{-AUrNM)9@+8AckV@I184Ndq4l<^>#z~P=fE^=G?!sP3T64 zC-<0l8tKY^SOH?V^+CXH+xy2oo9|!@oVHo2Wq!-?Y$eI10ToKyJLoTMwhI0alU?m9 z7^F4*BWhz?M{gxv-I#Zf6YcIz$!Y+y!`rgVM{y3osvD63wDA=w6-pS|*xV$LR;A6) zekUe$)Z)l+1@*p^&wRh}UqiHuM}rjwK1Sj4Miy}^6^{rxg!%))#kep!5U0lIE%&57>4C!p5lEqE zQa%7DNQPa$T87hw>zx?lYWWo6OSP8bFMf#Va; zko7}b5;|0cmT)R_Epzj6PhyBhV2=I`Jj#E9JvbxW`YHN>=&aEJ;5%KSH&+P0x`HRx zvLze-c~^Q3IO~h5NNIC><*#`&%HAely7zQT(N<@4JPwC+C-Ax%JQ+n(jV_h}_vI;> zFUDoJF_|m2J>%;PR!o}3!qZDH;pFW6rk#Wy(if0OZE~v}aYzr79i(}b)9TufuE{{9 zR7f_cKEy5S#9`d-I4*x430TnGF4~&7-Rg(|Q#df$FAo43 z9nibiSIk~X`4dtL+5K4jJ|00Vk$MZxSbZj6^vplwD4}Oe6e9r@k4E-AK=dvfrlgj# zOJ|R*a|y)u%W;^8M@E?kp{65dOLWRhztBN@F!&~O4H!=%CDUz}KxBO1!oc{lRBE_> z(z&Of5W-2>Lj_Kx~D*mn1OyjdL^j(afA`;(weC1@$pHio3mocj@Xzduu#FIR48LOP0nl>pJ6t)zdJs> z8UEhAi?_y~;l{2OGUeMoo?P_mk-g3k`ho}(!^hGXW`bE7X?qN~`=>s$~vkwHqdy=sr2S*_@4nXoloMOJJ1tjjJ0}N@yFG+lBsLMkqK-jCE+LTdLW` zyZJ>eZ;{vu1H*-P%(O(^S4>xYs?svZlq$SY=|;@xo>^mj!@?Va=7N zOkc1U%2|Q&#Il@Ck49?YU~U$M#A!T}+VU61Vks5q;%3X!OW2&?zdLfK9O^-6$V_Y+ zC&18OU!Qn$t}B#~MOn-A8jd`eLBJF0=Po68^d6S)$sehAP`m+HMr*oI(T^&-f0^?} zV?9WM|ML*Ho3oE8jq}Cf{tvbAh)^&(y0^=a8ly&IC#UN#X+;tZK)ctk1hGMj_yTNF z7HjQQ0nJhhzxC$d-sipw`N%_d-MOFWAo)Q}-X8%lJB-6D>*KOOl z#`dT=SAel_8c8N&Hz;a<%w?U*k^IOgNtiWYie zL~}9vY@6iUtp$Nj_`GQCWSP1lZ~Hbf#*5CmQy|YvY;-ajLpq04baPGK0E@h?n9QXh zv++miuQhSbY&KDi$S*p4Bh-PM{pChT+_(eStC%I6S8bfTza@7Ir4sPiaJf=x;s&ub zE07A^qbf}%_0w^pXyZs_G6(fCBzL|6*ET~&0mY)0({w$0hg!>Q1^$AW+sJ`T5kvVi z*V}QBn2b7q0#vG7dH0UzVAk7gJn)+`H^C#OcmtRkLWyZp|HoPo`OoCdd_l#-YqM~T zGuH>^BfNJj(=e0;&N?fdi74R^>OT{t`US!h zKP9HM?JmM&{iRw$H&fJhZ}vG>I|T~^Av552n~iyJbd*9tgzk1153 zZY8hF*3~<`v_gSZvBfuARHsBLIqqkKCR{`ggdM@%i{G|gJ1j*Cqxm8e6?on%d*#ZI zxPj-4=W}p}(~Y*0a5>I++^=$0f|@RBxq`21Y_+UDyT~;Sc)YeAQ$LxI?09yoE*GU( zk}JfnOC_Vp6OVCO5B~@@SEUXQ^vY7l#;8QmC6UTRQNdCjpOQgXz{ zdeNWm;Ih5;i-=?&&Vs~pm`76+@XEf0Yu=tP%Xgz;k_*=5x@`4u9oz&^s=MF3=C+#v zI&(Y&GYnJa((9{2>I{|;cv0=aiX|cmsy$Vmg>sbT8bW_aXk?ul0^%}d+^sjnprF4j zR>Ti$CP#Pi6fRc5EbctJc?mB)O&nTLVHd>O&{Q1gelVl(M?Xw1kRp5$9&zz|;Ci^2 zJrwE@;m_9f*?h#`o+OinrzuL zbn5t4K@m)u@rAGvaD*UyZfgrjQ7alY3;7CYH)uYboxzpB64HGUM1TXXc_627S{>d( zKBhTawsUOYni`Y+jzM}*cmt;et7PW&064-Ij>K=5 zvjIo7Lak_~a=i3ij;UKs_5HN8NDU~^`azAqaH7Tp(EC3e$2Y^PBOOD7UZ%n9RK|7Q zNmgML2xZzXZ>n?q7II~u8r$&UU^bB|7Xza{Z)MQIs(|#EjGt?nGgDtxRuTu;i{4TMK#0*_#%w)zF=9;pi|dm` zQkl_=c$r2MBhHeCVGQ5c02i&7mkZ%y%dpK(xB`NF9Z&g z1QEmqy^nLu_OM9RAHX75qwu&8Zg}3UURj|-gqR?S7a^hNE!%t)xR!3AixW?0K-@A`Of^|;Z%AzEY2HPf{@ zug*OAHLQ3&2NRQpf<1u9&+C^T7`W^PZU>PcP3>X`?=&n~E&}f~@K89o8Ar~Ml51>( z;n@0M=B2j>L2|3|Tri1BtHNk7U51BnJWU?M^oZXTZ}Jv5i->}&Ouz@4wfHeNAjw5P zDq?e%*JP{t>kFJg_`Kk}oML9vwE} z@ziFy(k3%kxntLBQ7KZ%NMsOa&7?sS`ucqQ097*@rjtNv)wKA89*-B-7N`h%virbp zw%9w!pN~&wJl>H=r`2(iSMKhB!UFmrzWUDUg~iJIz%xy>OS4$yIG&9lKLjfD8^kSmm#fTQ>a3;-=q&}kl&Nkm& z0;{cz^?62M!kxtR_W}J7YBB^f!+9iPpO->)p3#5kr=szF6tL?Jmw@Z1VFHYCAiTduEC~j9yT0>dIqV)`nE|_>K4a%0o7BWNaq?!IOBw*Z(oa zt=c=Hf75sUN{S?;;Q`#EHgoU8?*~~Mis&lIyyZ%`S`|qO#(tl(*dQUk9ulEp>mE%# zCW8@dhdG(+id-btddvlWy5h_#)`_5{T>1od?Ul39R43fGlf{7cChcjzC}WN4YGmKm zXg`>^wH~O+4E9_#C|nk)9m)5_ut2|WrbkZTLGoBaie~vDVe4L$xexoY)g4=VAq_gp zf>LYoLvO0rWMr^Ss}?u3D)9`VfiDtY*pOlz238#U70s&T-s^{AF)S-)bDg*Yb7y(? zjsW7je2n@3#FHuf@@ovBpkOm8bVxHoYh)0K0(`9%aE$(Hj&%L_>!xsy@C>!O!_A3L zf;g;r+8?5=W{l+rxZYQbDJ7GyF29ADB@n}CWA^a-AQ6-lXcYCrV*5_7q(b<6J!{GH zWj0J$8b)!}8iq8Z(Jb3p1f3cg_QN`;`hca&1#V&j)@nT!T%UlIOc>H2eF!R)5;ce+ z_@Z9=i{06*aitzbrvgI|pIf5E0%b^n2>DH0F}7I(UrTI8tA0bDfsSjw1=+o;h)rJj z;2Xvh*SX~ae@r%4#I6f|cYpG=-cLAsJ z5IC=)SyEca>8q|PD77(L|8FhE5C7iPY@S-8+Xt$Y_d;jc0KkcZ=V$%X-{+ZX-T15C zP?aNP=(w`ALhB5KjuDsJaYqAV@Ylz|&81di3YTn~6Ej+0U|*yDJsUJI6H)%v&?Wse z$TD37XM17O*s&pCZ#02YiF(-x4rxEkp2G6U!-q-NOz&MDc*ZiS5l3J=#0v1)W64+S zuEBNJ7X|kCwF=cr#P$6NdVp1#?#G@csof~SWXwbvvf#3Z{ z&Od2UDW?oB;t_1Lr=hz5@!woq@Nu7q#r65%X>L;J#Jt+L*e-Oou8~^q4c}$zs5SeL zwMes%-ZrlpWE=}gjT`?x^+U6g{6#?NGNU#!{B`1TCN3I(e>P>GL-?{V{)yM~A7KU) z^p$#Zc6b`g*M#92;BjJ5`ukZK-HKGIE9Lc_PvqF_6 z02|15xdQacU(M)JD1(AiAn?W2AgIGjg2+FwqK%B$#xw~T60c4Wm@>!zfwvK71y!${ ztA$BHC*Xf5kATJE$H9@qzdN)!7-^#%lDQH-d*pY!+|^9@3{hSGIfA;&4|XPg@LU{A zMbaS)I`&)nac9%=U0!)jO+VB^DdX{T%XHFm3HV@7R?%h4l=^1K!B)SY8e3tJob>TeDl<(&&->5p_Y&&1?jcawF&nIK7RrKr>6t2ri@l5Ot#Ul3`J*8&0h~ zy*?cnok;BnLRiC?9s<)vd(DASGZ9RZT6-lXb$4D}m5x22Xg@pSSVQ(ix@!a)nZw}@ z_w9t6SbmHt#7!8v)#O-|AJv=5!mPJwgrbGFgy0If;}Q|eCG53b`mTZU{uv38tK2-N{G%D+Oe>$K{Ezve~c4%okGyO&`p(T4Sj#w6MdZl%CZw(3Y}c z@z@2-Amfl=qo0I=g>H593uhkar%#!Lxp^erphPA!3Gd*RbO8 z?vmeAD#It&vx4rvZud9M>3o#de22T=AU#`l|K-~AE_ArK%XviqxNNZ5rhAY>>b=}- z$jEWO7D+W1%T9OY&D3iJWm#|5E7c=841C;-7h%nR=zA^LZWwEfzX+p%xqa--*eFf)HK+m z2hMa@Y%R-^C9LNab3DKml+UHZRK>Jyl$quHk%JTN@)QPX1UfQRN30vkF=m+*Bw z4sf#?#3C-gs@rk#@A$ePQt{#V5b$jO`7<$xG;_XdZPC_a`Za~#`ewWk<87}s?uUB5 z*I6U477wuM0RKo|Kx!E`3MnQF&%ps8^|bBkvDGs+DDCcnVmO*~@y=JR*EzAlq2*$~ z(du(fyvdEjLGNes+OhDn5$n33ogM&_gMR$!HU&;4nFHp4;w=t^Iom zx~0|acz)QOwRTE96pMuJzAzgt;b+&E^^Ra|i%K6+8l{qOK{n0gTovN}N{^_aE8&z| z*Q5zlznc2RQ+V2?>>0}HWHMY&tEB>o@97?&+i!v(9G-ZRBr*tF8-ChgKt0QZRnov> zQsA&B`G&qyqP-mCu8i!)nlW8w7t$lF;gzeNx+c3jWz5}VDUs{(iOO`1$ihyiDTy%! z$YgUTxRURl+Xh+i@tVOs2isoHOdyUm10GDM8#=xSY;;ZP8ka`@G^bpT^vl?%mFa!b z&*wCf>kc8+bozrhMWAnZ*h$Prn@!A{DNcnW@D}-~sCq4_g_K{p*AwP{qa3 z{63>bE7UEjs_xs`8bu>;w$T5gy%=E>E?J|}_3(mCr4HT0=FJiH*y0C9y7c9kX4i2g zqCn^zq)+lDbjW`nTlX>23AF^v=b0(B>**BX1Ha8laLat?gY7%sW1Oi9Q(dikKTSyHBVHBkfOTT5Apa zP3t-AVcYNS}LP9M?L;6 z>`eB+1^|1~>g{)0^~>So3)^bF)-d^Smw2d(zWG#Knt@M-6h;9`3Cw{EZJyMYXETlE zfIokxD>C0^x;sYFSLV|AH#CZ64g0S28VOqoe4~xw8iZ6!zbni5aoMM2DUuy2#@1U% z+8ATA>zsPVsTvNaMDyh%*=iw~j`IaB38%F&_^z(`TwpybN(ddz=Z!xd*_#!kop*=c zXRy~%ORdz_YHNV%f3E>KsUpa3ckZw@A*>6id>xIrH?-UhuUe^Puz6w;&w=&V)rtm1 zwMEJ~FIW_2S_PEQlmo~YC*%lA<#3H>(yByv8Rc-i)n6)ePR zU&mii&MnSwPwWQ_{E;Oe1c?DV3pBx88$ANO9^5vEHT^M?*uor2`gqcH^J&NRtO38l z(u+@g2uS9&7Nmv(@uJsCMA!4xFHP1ZQw?DB@+E-m*X%b|<$@O4J<`ifsPAtxxRQ2* zlJ>{9nAll}AMT9K&z{Kbxg6`O%rTQ3{qq=~ByH$?tL{2FtUNk_vN=PEaQ(*%0HV`= zQ7qMR6OK201gA{~o?Q`czVJjedQ0g_lhnn8h>E@#0n#k z_HP8kiPXl}%Xxgl9GgEPVI*Hho0SPqP6svD8`H=@r8+A^vEs6?0gzu0>ffInnP}#BmE&_z0QJqg4l;8Wk?^w6*R&3(zK)M?J znFl&^V%`h%!z*9eW;=>ylv@=+4(Z#h7c5Zu-Z-ZNDd%m=!P(L^oAE>_1qu{DbLHP( z(7|+VWjB=V6H?PdX)dnm^n5n%V6Hy>!>svq5JQy1t=04PI05OA{l~DmBxd`kYtHfu zSX65p&;N-^-#$;8q-n|B!U*c{wO+Pm!!c=$iE--V`e90oj)cpE)XtvZ*43PQ)C|dS zDerUBHe7tbPj@_<)pKDjsp?BJ4n*&>-Bvi*x;eav2gq9>m^=u`W2O!+NEZ2aqM?|k*@ue`OKd|AcpO-Snm(e9^Jj?Ap3z!y~-rK)3O z_O_8FA;EN~t|PrsrTXZv%4M0%HSq`3uS3m+UPUKtCpwpNNf}ez#&Lho6W- zKI>2BTl~i#hIFq;PG@iUdQez^D){j}7wkpkS^AG8n#sP~_&87<+p7{7w@A>b_V%09E z5w5*|=aDC1^EeWBWOm-O!pX8MnS{6vb&)+Uk|1Xu({a2+BQ0NaO@SfOfAYi3$AkfOL3Z5v?!MpYY(QCZX zfqV=bmE1D>!q{f~M5TN)wEI?W+th60vB-BSgX0qe90!T{Ti;Oy1JBo{dW{d;ZfSlq zndR3OI;0r7glYy!ve4;kY%=gUbu)BmlrtSaRhRU|_+2e?*$LdTM)p(9Db-JX6I)=> zyDW^H$Be;u`<)A-qf+bv&%p#U*j7rbrHVgzIhzS7o8DAuZ^!$N8>vkq$58GtTE;0k zJ+8>q37@fk^gwxnr@o2B^chAEa9XlT(jVAv0E@wqvu8~YKq!#y`FdHPZeF}-5|NkJ zv-&|DKA$UgaEPbJ7NAz-6xZSM6?$rI^j_U4t?+Ld<~vN2*7ZiXm@yV_6d}z`vyEVw z`gY#81&%YWt72$doDx>vrzjuJ_T;Ro2v(0#G#oAIg8)hHGcP(rIUd^T%9Y>ukCe;x z!wKIZFN+0`COb~n3}(G0_>8?LoM?nB7ey506O0X1vq@YjWIjFgu-6M#SEYP15SH@n~X z>;7Fd!(l6KvtY61rJtB;0CZ%i42O@Qsx!?F1$%bkfEiNPn;5OZ#uJo2qVjN7gBcMk zGw>{1R_pYsY$4o=3Y(1!x~}7?jDJ|`G3_QM<`|#;-1@tNa4iegK)(=`TakOWiYAm| zeX#j=d|rEdhWu|x!IGzR&^{{;emb|W1fM-4V;Ny;Y|}PcvfTO4vI*#0l@d5H(h68r zEBJZBUcv?~;}Oz~cz8&PxeghMU4T&G`%&$fc8vbVTh!u<6tPdMW7-<{T+9cLLN1%4 zp;cVG3bwOir5Pp#y|&b6eBSkK!EmL8Wq8O5jcT_2$WqZy)422rPbr0xagAi#=ZGBX zA~_)v>A=@KQchg+3C$$ipILOw)CraImRh5nia*D16JFaY)eVdHN?DVe);^3>hF247 zK_WC?(J9Ik3&#zGiw+>4e0RMlI7ST50>xAo8?)PD^>NUMT*>}5mlEq>m-%p}k#!2{ ziEAH|z>u?(opC{V%qOX;QgQ!49`kvQ2k=Od6P$V}HE5}ptJw}zj$6ISMV6?kKD*8< zMIid=94fb4%~v6(--0C~Z>Ml@g09aj2ih(9Z%=UsJUjvI?m#-tNc6v=)mRs%0+Ulv z;*>=ry{pp^uYG5y$pSu1S5iF$B*kO#|1DqTi1sDs$J?X^vZIT-@_mX9uc5>y$hG+vG%x`q%K76w$rRt_YX5OvrfNHf-DA~CQ&CMHGSl3|blLpE4mO z?-?oH$5&E$!Y&EWIvN+^S7pm@UnFatStKUp(e13v@ONe@`p5gN*58hDrw8+~y7Fr4 z0N-|J>rZ^JlT~zn_S#OZEVDEQK$n!EQ}uKZW7^A*_s_1PVYyMPsxFRA@GZZZ&@VKz zlaGI*(fM`c5X^|yU2n<(g|fI(yAi8sanz}Up8j|k2!K|GosJJ=#!6i}H8*23`&HiV zPmsIz-^$xd=*o3}8Jg$wai@8o?cc8!zo`2!4Jmhz;ay4cT) zx1YuOy7L#awkj|U)j+Zy_O{mRSZPQd9SXJmKiey;V)#s zV1(%CXfJc6c;Un0TOJNa?}}a$W4rL>15)1ssF-vlUPs5F_a=dMwBu3TRw^hKG4m(i zzPWq$YQ{I_ah1^TgU&|xkWue0$Fp%9_IjJ$zTYlY=Fs&9|LhU13RYvLvY)8K+GJHoLwr zCK{%xI$#P2Qcq8BNPRRgky`mAq7uqPHg+%e#s4`^IF%P56FSc^kARa)uOd-nY*NMW zc)1spl$7+bLJ|{2R$?B(%N|c68cvpnjVk3nN@jUZjywSIztcH1mU*|{psWnL&IOHF zW_J{u+oBjecE)C}(*(-u7G2M6d$D36a;oe(8fZ$`D?d#w>2Zx*vStGcS@AG+eM43N`#a6hU-_E=fnlg`1+y=xeIhAN)a4|5-#om z7F;)65jvNYN`c&lmI^iYAoy^Hl(1dL*nGKq47cj|z@MXdNx?-D^fJ{JL{+Ib4e^wp z$k^o6^{WciV!9`bgZt1blbV4E}$51d%UuJg<)8 zV6p+sGG7oq`cY%VJv?5d!YMz#c=Gk{2D?`(w;uhcn31yWqTg#}@b>G0?)%8lw*qrh1j81nK3=HT<#WJBV!n33Ausia2P1pw}_0-}~+^(gHALG#sX&!G3bfdaOtfVEA zMlXeeY-2g!qf%%~82H$_|4IkJ>;@d_O{0zA@sjv*oeM4S?R2^r5LD~yB}2BmkSqgO z;&dkOgXi6_mdkMu4roT3RF2=#e0St@AH?F(6nYGyT_V7N3W=w46CKU#7|$9`qq4EC z(6=?T&IoiD$GAP*u`=W|Ty-I`%C+s(nH z|1ReZ|J#6&kG<2e*^`v^#<;UitG(1U3pvph?B{q!dS8!DC=rvZM@Q>TA}<;pvLJ@V z*7XoBi`nFN)4@P6e0#%{5PhfaSmrLjIfNtui#7y;PhMOnT5N@n55*mhXTc|4WF*o{ zn~Q&5F^c(SVY|Y|GwT0K6T^cURUjI;YmYz`%SagPZ8Kw?_JlI9U-pA)-Qr({Ivty% z|0|*p1sjPSjuzWB&$?5|ysF9@JB%D(H4=)Iw8^CwOA>K}T*|#*Fvx7xWE-gXv@w-o z1h3H@ItD$5P+0Oi`8Z&LD=Can0__oSJczwM!MU0*#>r0g&KO-f;0AjV8XhMT-wxfg#!imi&x*4W}hgUewd^3i6>(PDi?iZT~ z>}pH}W1k^PvJDx;^uW5EEAr~Bwb8q3zSPx*qJ=2X&Ci@x+x}TcKFFL_xZxqy8f;t6Y}|J={`D zO3JkT4YA7or+7^M_N}i=&AP{*B%HOK=N^`?5@5#{4r8 znP$>w;5zOm^$f-WCq8u|RYNvg{1b9H&`IIB2a|Bsy0~0DIbc1iuzy-`xH-_>P$mi7 zC^k&@RR@k)vYnZ*QQp1wSjK8BNqRik71tpOly=}9Zi!l>VB2R9{wd*KaJ#c(Z)+*A z6(_Gq`dMr}(E3rP@xzSTos_c|4B?2%u3TxUM-p(oF_`Ox(QnKde@5A%YC2z|it@-C zzNfwN_PEFYQ1((Foq7Z<|L3rm;P*i?4tlLban#sw=qhVN({((!hWN-e=U-{6T^dV0 z1p5_DrYFx6cPkD7_qxuKNG9l_ek;A%$EqGJ&4dV6O-5r$Z*S{G9<8jyg-n5N1cs6o zXqlPo(Ktz`Gxp~^H1ccX7j@*_EU)_gRg-J2mRiBhRaFI=2&R%%)wUz39?7n_Iz=@q zIo!?sI$Z8NHc3g6+k$7j^+9UXax87S2sBHl!>jH|Y0d5&#?oILoP_+6`RT`>1_P<- zvKl3`_2@FyaB~oZu^K+34514w$-Uf|jfZnX=IwZrB354No~KE0N>a9Dq<1~nQZ>)X z{pQC-aVk{aR7~-rMJeiyW$kZ7I4yI&9=0Xa(;!%htgZejvZWUr!YRz8{u}LKwZQ?OylLeN#Yf})XW={N zv+J9K-IS(fS|m6~ajRe5hfg_MdHXrE4kIzPFss*{d7Iv`hLQ(^y+BT5s7y zpj53G-SKL8{@hHcuPWbJ@and@jE1EsBH~}&v8Uh>Tnm1;UM&Hpt#?8o9Cj1OM5(e7 z@5+uWH8HAQevAefUx!6efnE0&rs#+|%U!qrN^A~*KYW#qkNt=COqsNMdvmqWMdA?r zXlQOOk&Fz$ru}8^cV+sn4>pM9p)c3p< z!95o|Umxh@bNGMQp%1`tnUn_(tz># z@Y))WCb(yUv$Il>RB%s^Kn}kzi=8aN|0C_Kg5zqIc1>Hhm~6{pW@c6kEXiVKW@aXf zEM{i5n6bso%*@QpE!MQZz4tkLX3igTF?Zb&9kF_?T2=Mto0(4;4n}{ZuY3UWPrl|! zrpW8?dc6dzIu|E0}_&1^s|^vA3nR-cMlJXzgxz{ zosfgITX8WZrF`BbxZPYz;5d<_yloa8L#_<%ehz)+c^rlqLkz3& zR$peQ5vX=|W-@6#cV9d;zXBm<(HL2MhE;G5=HctO+cvH<9fy90FGQ|5;Z zD@(yRvi5u4&8GU*Nv2{oSz7GqBhIZYbgny+Nnankf3mm;^J7SA&zt`1ZNFiX^R=Fp zLd}az*LB15(N_g5sfbS~;!4I^M;VRfgWciZl$I2&$tzA$gHABUa0?WRetWJluV!jV zzn>=6Da?O0Z)W!#+K&KD6+=84Durspv(*$S@b~-_>Cm9TpG*r`!Fklx7Y|xZ?kDDekITjG2?_Sj+$JZnBUx)l8pf z9dI`Lc)-0AMw+FkyG0=i=0Q+zeHpK?AwM6dqgQ4do|tW@GhJzdUjwif{M_G7X#-;! zw!!oWQaZ7&rTk`l$eEjiJ8x)}(!c@_x7Q6F0Wh^8$-4z85!-XRZe>gCiEO_+Dc@xO za2FW|ES>j4+RGGwOfcd&eIjSwol(>=k}M|U#_;s{rE!W8*ahyP&cn}7y&yU`j3~q3 zh)(B^w8WYB`RLBfc(=_LPIWxd#oK4*RP;rmp~AqG)FFKVDQ_nlm%BQpQ)y`_zpXzn zv`*ESHF>U-Y?7qISHyi_Dtkb9dc1YGx(o6uEC5J-xXKVZza-K|?4qWw(U$=ZMq3yF zBNyk{Cdz(f)4b^tbvf`9jW>)IY3hd!M|BEGZFxoa)PQ=aJmaT>)8~9tt$7W`qhT{) z)T=$w4tbW1gt#f}1?F}=Xp!`12NSRk^wA zV)^d%;eqvWqR$|ndY9nCdbr&m^d}hUT3nfQB~o3OoQqGc#I$juf9U_ky*L>lNdMdU zO)OQ66=^W!KR&cRMM?}n*!5Y&SKD=nhE#UEAl>_RY$*n3g|R@?;9}2XlXAE&aZJjY z+r3Z`P{2>n3;-ADd;4#*%}!(6a8WY2QUgh<9T3E%xKVY`nTAzsmQE)y*oKUw)e?8m2Msh77c5f%`+$I7G%13B zQtGlLTih4vDx)ZJQYbn@$B3*dhLImBUJ@y*Bp$vxn@37zc0&>y8|2fS%aTtisj;O) zEd31(2VlZWW1l$wqn*7UkIZ#lzJ$_JNPc&{1N1OtrtaB(kRBnlU&i?+S}b~6cR@d` zuwox(l_?P`P`r6yG<6?XIN5(prO^P8(7B}TNhn9D;srkr18-u}4wN$6 zNG8zW|6|$YdwtQ)+>1#U{g-3&wDdK5ynol1yN957bUT9fI$YGPzmhwQxv9K0-sI;n z2+eKYMxG$s7$Y=6OYCz7d6Ki{52XgwJtmJZjs)ksEliO1@t`^b`w`I?QurqsBWpMj;bq%%Mqa1b1cQ3Exv-OCOLUOL+HDC2QA`&FM zu0AlgV6Wp#|K!BQv(QiZVu8F9YY)P&r59i7YyQ8yr0d}dK_xZ0Y!dI~^WC9l@G8N$l(j?!9Hw-p{iOo$iR#cXKuxmCTRDp zvi#-w$}(`v%l~$ejG4QOWHP_Thh?YN_BkNXyY)}i%S0vstj{wY0Srt6Ww@^!r8fjC_&5}_4S|x;(s7@nYuF9F7V_zQjw(NhFYcTsI|MIri z17scVsLCidq#t<_+W)~yHLn9kgoZ|Kri ziqxhEW|x%wl$1hm+}CNjH&#=t9_`d!_LZr-!%wj>Kz@YK|b|?JZ1^AuYEE33}O<}X{U$n82z$A2dQX_w;e(;#!7>@df-B}77ZLO z6ww1eI+{wGp%v7-A`*s2kDV(L->8j=YE z(sKTKmNCb~?`lpeHMIsrtMuU5VmzmQgv7RMJ(9yonq?|8pKdcWn(0RH;Qg5e9J$~A z0=KXxoq{NBc^18t488x!j3X0YFgqBDI4i@E zYBmIgm2JDe?Gxp_BcVyqK)4gnNRdZi=u^7Zn%1Gq6WdKGM!H;c;fSfKCU^T~@YRVJ>)YT` zehh*DqO!7_2?Pl(Slhh)r62vBM`2(IgVPPhto#J`9+TlfhKL;M#(U@_1^gy>8?29i zN&oK2@iutx{W7(6VCTc5QD4>Lg-?#l11q1O|D!I^@pL-k+{z-FJln%;!gqYStvMRS<3ntM%Gl`-XYx3&c!~u|4D9fk z>oZf6r}3~&Jq_?}-wk$%{pFJF!opuS=EFE;HVzv6zUF8%1s(of5Zxu%hsPxQy0In9 za5DaBW6VFP;n;wKxOZl?mP`eY?hAOO>=gm4P;|8_@Yine`Ub&&3nRk+ALx}Q;L6S! z(rtb75^T(EG^G)%;N8d-5@~fE*B;L%Sg)xojB&xbHxflFS_*&}7j|IAg~5+w?*ejZ z-CxgagwuD3=Ib~ab#+%`4}=?8LKr>0f_T_5XJL7NFj3?iNT^NF)w$8;vj+#E9oJo= zlp^*H^bAc@$Q)aF8=|W_=yrbhpuCI$^)!Ge#3nD|K}7urh3Bj$XyN+ZI?#=e@*?}w zkF5hX&(q#nUjOZi=T0+dv= z%n|K-^t_7&ufTaf(&F|)8b9?S~ z_fmpe>T4+sF5j%+u%J!zFKn&1RK2vEKLnA#C7S^AjSFK&AL>3mRX!48nV|cmW2q)T zQ8P0f?W2;RMpzroC#7p$EX`8k3qHg_x3oleHQtH*dy9I-0CVL=e(s!3Uu{iErRzWu zb!@pCve2SwFdDs+ln4jYV~bygt%V=81wTvGZv)FS>@22#{(Gz91#fSSe}|6n|2=ee zF3xQxMm<>%k40EBw`{YPb0KtVEz`~7=a;L*L!bZ6IBWE9F-fYGxdDq-aL*dKS=&F= z@E=+f{=OFAw@cOk9!_Ya2eOW$tr=p#`c)W`ITu)(gnyHXm+igpj{uF+n?hL6(lnQq zW+E)lPyzpW!#c-l%PvoQXLQ*Z3=i?<{ufDYA&Q@)rCpN6MS@g3%IUUDEuuuJblP;@ zXx57yL#MRl4V>UC?ZMZ4kB>BWqQ>C+$AJD<{jTqWfq103XL9us#QB6KXZ^KGGnpXR za=&bo^>_(B-j`BjxBerFB#p<%M^kS#18A;Q1Abe~m+<9i27A~YkSNz69I>?DXJy>? zo;Md}SxZ1mkh{6##jP4$MP+WE=MC04>H|J87AfvuAODO0H%|;fH_X%2xpdEb(!+b> zeLQLY7RGWSa)o$ViumN@LL!ao=2~mnVa6l728**=a+ZKk}rXx*;2pd#QmrZmWk6govZ73 z`L#My?H)yGtZ|U_S8FzZ*<63Gdu zr$a$UA4S4Xgk}oYK=2m@QGg>&O10@m(sK`Flceh<=26foKcU%_?$N66$!v@XBKC$9 z`2GJ2E&S)!C=R)sYIh(?n#(D2e|5Dban+!WN;Pv-c7{e0aF3sFpN`NdTFR#hTro(o z;1w<&r$)?2gpoAO?f>^XHmXtxl~=+Sfa_qzxm-iAlvcJGU^l7-G6%d$?31aaWWIQg zOjODJRfPX;?Xn{~%=-F$;t2(nTt_g19UHJq;IKccL-~*QEA5$@_enwV*m*T;ipy`SC`WXSz|6Z0DKvdHO`k0Vv8U7^D~8vJOG|NK3AeY zoqG;2m22<6#kl0tUVf|PGbp4@Qymk)ti?o0PE3TKpxJpVYU zalJPmxFywk6+;Tl6mFGYlSYP9_%_+OQ@kyZ$>sLjFq}gz zkfX6$OQi-g1YU`NfjS;wCQh#q_yfmJ48bmMWSuw6jdZ=|jW4k|Y`}4voZ|eeau|<^ zFSb5-1FBaCzalq&1y)kw&XXQbS?TH=tBTaE>I>f-6P>)P_heHeyB1cHlu8LstG1uuRM30m2Pr#Sme%EacO-t7dVcI|8D9y}qD};!q*DhT*DG4A zWO>nseUrNTytUGUaqQY;z>txYr@K4l#u8}^XOX^4L&j3s*!V_2kJH@k=YmB8T$Zi2 zQ+aYM>y^nm`#F+Un)YZh=0&&R?#HI&45wr%cF|r=ksxMNh7$R-N6Plz7L&WM>Uvb# zLu7y_K5s6Qm5E4+5yS$&fz>YyvWNBq&=d9z=8lF{5aw=r{({pQz$MqZxGOu+`0XlX zde1u+U$MiHS;2m?aF_ohKBKqX%Fz{Yrr&q1mG0n4_`0nSw^om3^$f~2nyRf%=6S&F z!7zWhoKe+F@ZT8@`_~hH!3moymFut4$;iuscm}bzhXPyUbCPFS zL|_x;bWT_B2&SR$I>5gIz8-c}qk7l8J`4iOS zGFwD-|3ZighTxq9oz+`fgh=Jq{WN-pknnYUnb0#Yj~Ry0%V8^Bwe_P|&c$-#VjaHt z&7xzpDo8A)v95*tZK`=8+;o7qJrii5#moe{IdF+WL3pCXqAYA1DHC^oNpvU1cdljs zf65>5KF8q?l(^IpJmbhHK`q=gHV)AFfk&q4psOA-5z%q6cM8|o6kT6lXuA#|U9z%z zqpNt3mIM{PEW6j*j6leNQA?#E8=E~7@#l?X#M}DEZQZ>Eh zD-R0&)RQ{pvc>~ZUSnX9_GwQ-C7mRfMQCfiY?(c)U#-VVc&+pkg2jB269}Su*gDJ# ziIiR|gT#*=GQho3f8(Y9XHllEM=6kc(g+hbEpl&mAdtqrHDX*2hrrGpm<;1+?3Sb) z&UYTdB=|8DRWz(42*tY6Z%EOT2~dxi>$oTlVW++1S8srHBajwr$tE;d;2ya0=}6tA zVkmD68$+2*ljM=}g+J(ih6AL`zsxN}8Q;kv?eL2JaUX~wtUIz?gguasDm3-~ zXF9ZUF@zg?F4)meioauzWP5~^&M>c?3kxN9iNt-7{cIny)p$e-Ez-wZHiO&_BlEfvep$)(j@N^0P zjBBD>?QD4)Zrv))9~i08*h2IRo30DCaj3h#JjH%JExu;`i86UW8su6&{v*Q7eUYt~ z&X<@nc;{2tlyz>Q;ht9{k)TNZsuur_YWhP1XA6X#+I&obfy`C)789P$$tb##08XXC z3yaVPcJ%uEyZ9T|!g!~1na_OA+v^srnC6lO6ZM3>H04gM04D$C4E9YQT!V=WV~;$P z*=vt?nB`lIFbiFC`{m_mr5l8#mP(i^n(;qU&&hJsf@Ne=eM?Jw2c7u1%gkr18sE)s zWNT&7B-i;mk9^R(iq9|_joF!xjo<*zlUF|9EgE7DTb!Y|teZwcE1jY_?uHuc+z%fH za^u6kj|0bEsQCK|Oa z3)dsJ1|AIa3FZ#=`=)HGGx{?IC@L9r_S?N~IJos!!1BZv3va!r>dR%ZPq^y~Xft(p zpQYQv^klgst8(8NCVHG$O3nBEcSA`dw1URc;Q z>8e{jwRt(;`X(s{9@Z5q9oH9BSL;|&q}zy<&mq?=kR&mNjH6V8>oKOTo;p7ZTi?T2 zw18XEtX`y<9B!e`&8!Zqk4hXPWNf!viIG;k`jy?2>N+IJyPB)cKSklt*>8127Hf9x zZ7F2(Hue~S;R<^!?#{1%BGH&=IvGY(UtZiN!6%D?4`q1eA?@w$mCfs5B^CFG%RNbh zMe6sMz-!BuNTS2_$pDat{*^5-Z)b;@*1Fq7(2n`;(`|Wh5d&J^q^&*stY09O$;TVp zW@2iVKi}g6`l~671_nc`qi!#yitIEw!c)Ki(aMuw6&&KfB<4xc6Q|f3kWGvc48Uhm z7J2#tR{)NbrHp#-2M3;(1EN%37bpvE4pw$5>M|TclJ?Y0cCFG^v)|1J0ua*NGNT@w zYu-Y0^Bjz{-2 z?I9(-B|1JA0%-8tqED`L6yG3OR@F)Fq8u)UmJNALG;ugxwmAxI8g0$o+^@atcPq0M zIMB$vYPs#4cQWWm=g3aqTfK2sx&|wqqZ{vrIO^Q}ucDIsdBHiS8Va2RCgbt4%yysW zEU8e$?e)No#ajYMBkCkp>wjjz=7#it7x+NI{;vX`0<{;|>tBHb@HRu5!MI#}GThwS zJ0>2usIPB$Jh9_iba<}ZUZI6DvZDt@|8DMnO0@av&B9CXc6x;F<+VJJzGlaSm9{&u z>0rpkjO-p)F{K-*JQxm{<$8F}Fs@J8{yAN1ED&Hm&5qSGThJ8lJM8O=yU$dtChTi% zr8^ctU& z*cTNx%YErTn50neeWU%^3(Mh}5hhiR(YT=^E2`%2^4^knV{4~&auVC_pB>!M$t|Vi zhJ77VnNy$41YF&2KO}Xe>9Bo>%5^xBFU9Q0eE3<>dSt*TAvfUgJQcov6*HX>+6&kX zJ8$C26}i|nI1>LJVoYvlgltCdqJm9pv28?kzk_bZf^yl|Np3kC62+)!$<9xID>Ga^9xUi_%K#fCXuh}ukL zg{{!e=;ZZ;sZbbrI7cR6_;P~__#02Bv6gmCC9suWN&Ssvd-3rjC9{U~E*x2~xZ~kc zNYf5x1XuCM!k3>?*B(eAw9;MwD9Qb?M=4P(6YUethcJTg?SGT{05M+ks|R=X2%FK^ zT)`gm^$Qv#fWbwcnF(r5zb6&mKjqbjj)P}1he|euOerVRMTjb%_6Nc@3VxVNj^S0h zI@9|TSl+#1>{5fiGp;@rh0nImcTnd=Gc%^6im8F@B)I$1Icog`)>f*5wbSY#oad?B zrK@U|gd84z)&-T9ItfY#7d^`hh}M-G=Do0m?32kW$qYt6${nbgCTF{0(8h>J3!&s;{MZBR zKc>LjUQs1;t~CGkUL3-2yMr9eqJ_-|jZbj9BO+UP8o}OQvIyv8%K5j1;cY|m*LMC> zaRqK${}%WAT1QW+6-kM>^tw$~2qE?JIAE z6&h`c@2!>t#&ZPF^!-s9!HVKcume4VJd&<*vKUUT!)}WL_>(k7E0?NC>ZQqRpXh0m zwxm_jW+64QywnSiXqpPJG))Eb_>c+O7@{t9uStD(%IqrM3`N+mO;50L@KACz&9XF} zeR%z>oHh6&-PA!RpCkC}KbG4MF>YwM-;c#`NtT%1Xse|G6WF%5pui|uIrk8)7 zjLmB51I5cr)nYSh96J4^x(3Q@wjU1i)I-JJ3{HE%pA-1x+AG*$B2SDtIzW@Xao^9# zJUjZ2v&xpI{TNfW8%K0rdAUVe?Teg>5UZTm0|e?S^g`LK^SkuwKEiDUHDgnNP^c(u z^FpAeM>(<4<1esIffw9?hQOx4VlAg-=(;t#cj*k*s&bXE)1nXTf+BeaXwS9MwvlHeW1)oD?bLU)pzL;8) z6^379A`wOe?sF6Di`wUv4n*?R;s%JOKN+Sk^ISiG5jg$4IZY69ViFk}$Up~u1^ZUO zz_6PIOyw>T(d>DN~Nkb zy^I4>qkAg!tn5p9?X34aq&rye(bwGR=%2#k@DmJ+=YBI~>&=axnyLcWOJojIIp0~f z=IDWkm2n=5#@Wh#Oj9I9uZ*f_Rs)jHBbsZ>3C54@RqABYR%j?_hIEQPzYs^n7lsyVlrxv~YryqBRhff{2J>pS+!vY^SWHC3fD#0sHI$5WE{K0 z8a=krG0PuyJ@{4R@q+^>L=3OaFBycqpSfK-nag4M_UOOhRTF$4@z{;?54?Z;bdC+V zC1Qe(XQ8&_#6wu}6=4I4=+v@+KFcCB|8 zUvORS>5R8G+iy>qgG0RWcD4Tqo#GT+b(MYRIjGbj8#*Vy*XeOv2gNl#z4rb&Hf?i*wPyRh zEYq9Q1FysWJg&>SFo05K;F);mVWU1=v7VXL8h(I8N99SmZ6pgmvJa!;%02gHd17{{ z@FBT^Fs_i5JkC&#k{PW)*BFHb&w5oNywO9Qe*KqN#?P2c$!WV>{a8lgBUJgQ8?T9= z#bdNJ0MgrX`m&K#wFOIn1DO&=wRs8&O*hC!&6DZG+eYTigxXZA0KqAhE!Vn9o+af# zc%Do_jSon86z*j7sqSg_?q!{qZ$i1YKr)4k#Y#EJK0lRVf|gpUpu)ts=W>}3jTF=3 zKF7PQby{t}N40ioVe0C9vy!D!3r(X%Sd!C3AmMANDj6)pC(p5^ zz-7|sK8K?QjO!`rEP5@AI&5mPvQ9Mvv8D;4i#)<#$E@lcC(PklGjU+^9>ts? zp0!#UgVU>Iy9~NCxR4x>Y~dcC2nn1q6f#wn#I39c6&jvv#veVhH+aoT$r3z7<+|QL zh0$urdOiH8GL$I>d;jNiS1sOu>G%XxT&?#qM)$>0c@`WgW@F4^iOq(k=yamSoUwr` zZ8mUzZ)eWA)Y8_|n5J~hxn=-i+STr@xPiqwYr>rt#aw}t08K=AsqKL#%ugxaq|y4H z>K)FO3Bhh>IxAqpc4t=eSYyp#?egjrDZ{Y@vG>ByaOT;g*rStO7HwO-6+FuGwZ6A0 zOx|xil1#Bv1Tb!u=>F!K8LN5qGq!HR3d<4dgNZ%lob?vC@B=Q{>H+gK2z*!mA}KMc zZBGjH&P0Tf3r8y~0rMxcP-Yoo#|Hfoddbm@2EU3E=3G18b!&%6S*&UBxgxwJkC~mc z8zzXn{BztMab(INs7u+)EL2ib*9xkxJ1M2lHb!$`Gm5m!0oc25@kK>;8jL=u<5)B! zPWfSSFGX4z431}*ELQBH0UAgS*Nb%Xv^X+J=BTD^m*)O2t5aVacrgo|-@6|~daI)v zA2|3EB3tuIW!7F3WZsgVpXy!hTLg0bW4ynJ$nIN^`zy#Qja*%nV_;` zu|Qqs$rXd#7gv3VyEH@-`Hq@hI@y@i1j|7^t;~0;Ci)cmt;2O3-Pz5y-Lx8i>#2T9 zQ5nC)xvMo`;_F33+P8!c6)(IYR`fJQ4EAU|_SlHDGenDM(Qo(O!6&&GJPEKOV2F`@ z59Mf8RWwZt1;ywXV;noQ*R}#e_GdmpkiQ1HmfI124n9z!!)b4}!fzE$LX|rEYU^%A zh9b|R*X*PgwvbmJTU=UvKK6eRCfNff5iHRmpAZ{Sb_f?<<#@nger7 zEPl5uV!3=;dgy9@LR3Nj3d?xmnB5b?|++cbgE{ zXu6(^+2KNXOO9#LzQ~5}wh<)|HKx#M?bKgk`~LO@W{Ul=eSMl1 z1e?-Tf3@tkSSPAiR&4}28Y%{7sYtSwiFz-Z->N<7y8Vg9nK0}cz(mvVVk+6r@^MWXOXk=8<8nJK#Wi{o}C~6TIW}q%8II8%7a+oNTh%WmB!PuC;Z6 z%|@q8Rydp67wNDdhLar52$L7-B>MC};~?TULP8IYTWsJ(qVBdHdM3A5@5})EB3Bti zVibts`oL{fl*KzKkh~>u+H6>jH?Ms7;qjF+kIxhLB3ph9r&TbGzsLMsTNC-69e66|OKxy#bM(nDM3$eTT2vO{-#}fyC9d+a_+Y+x+ z2hdjBJGM1l`S^{H)?rPj8WTIOt*awCnfBP&V%)^#9ccHILV_;K6Z8BOuDO5Ixot7$ zupf!tW{Bf*YrSCqf#yg6)Nw8$Y;g*6)zTGcM~ulSPuGJvS%;?-q@CT{%ZH&jySX&Y z%R3BvFdJX4$ZaX+Ia!xddr}7})PURQ=Di&^0j}5w>4_zszc}eglpHIl@s@qDh7V$T zPvmn+x;5xdu|&{*#ExLXkVINb>#=m7^w)}NyK;N~jcet%G~0n3rYXqdRau447*AZ! zth&su6E19iES^Al?h;6Ba)%lE4fU+8k3E8{9Ms6yXZuaSGBb4K(>Y;3P3B;Se`>#u_m0B)wXwv*;xz2$scl|JWq~a zjXTH3kwH7w!b@&;rp6}Al5Mv=%7>&dI#$5NKRLJlGu(|Q!-7$O)Au?!GM9SBX5ei9 zQwGJ*(v?bJqD;WVk{CIHQW_T+AkK!v2I+?=H zbU=837b!4;+UL(1Mg9J%a zN^VWM&PQ-?b$mhYXjRLsU(-*(+ep;kgGXFWe-I*%&ld69)|vk+9UIMH+5`es(l|`T zw44#7s`Ij%(iU^yOUT@Zi?c+n24}543AaoIGg%V0I20LDRiygDs?cVSQ$k%_`KS{XP6?#4g=QGblb;QkT5`Z#RZ#mtin7-#r-|Vxz zix=w<#VKm|OcTIN3DLt$VSLWklMZB}=3!gkJzjFaQJ+r=4MZ6ri9n<+C^s?QxjoEW z0j~1C>7k+og0=YP$?tIav%=T-T*YIz8brCQEO{j5h-bL21|J2zIwF;BmcXj*03DZx zkV_EHqWqkkO9IPUHNi5F;f?ZU+Vxtze?e4eGvls|6PNSnHmD1K!Kuw`-iG-cEg!Sl zn&(qbZ&Yj<51akXvD!Eow73!4f5Rf?ClzK^mbH|8+kCJ{-|*gT*z%7}`<&FzM-=Ya zdv$$s+2$SJAzYtR>%?2)m^K`EGa{6yfww{41)u>j8tdQJkE?ZN@F`Asf?R z1TWqShip{Tt~cSs&T2Ztp+y4S6O?PQ^w`Sbmn4~;?Ib>=D;lH~MLKF`(wD%B-3VU9 zHSS&I^*05C7am~Yfe7(O4e>)#-GVSsnc96=Nv*f9o;1WtFAoHML&~12bcOn05s$4sWMone>ta^2T7&BLco%`zwKZ?qN%|d&FyeQ~EQ8 z@BS4R7wVWuyGM3kAYGbv4&v3p)|$x1d+T>IQ3KMun&=NNpSm@3^bTKMW7w%_6ymt_ zO-lJl8XmpKsd}uh)Ly+)7#K3&Vmdif@evYqIrie zgrAQ;E2y&?FJ>0z6|?!AwG_xQ%jaz33lS`M;rHXSOBGKyKtpacZSL;o(Yx@x=GmYK z{7HhQlOE@GMX_pC;PF}TGFilDXDpvi!h_rpyF+}oZ9WOfntd09XuGtv>wfIQJ_?R` z{I&96`%vlB_&L9D>UJ)?G;Ji=d(>CcslUot+oA@F6KFh@S>@pfEAj;yk6TEt85P%3 z0Mhg)4dq%jX`jIP&MuLR9TKWPR~sxi!%#4#reKZ5wAnd z6Eh%v#TNMO{o{dTN!IZVDx;{1q)z(_RkdhVST`wr?9mNMp`Kq&vIN`V8elwzsFH-u zu0Y$vzx=nbU!>F;!?s>}7w&ip7&2N3 z_PGJsukcYPa77wDenrpZ;U0N6?NuB zV~zMgnme*1rhZOn)+2{beUYL_~^-~W$)SdGiIFD z&yc+R&g0b+v76!{E30Q$E7L!3I5MJ~wq8y=hWm(7$<)pz&LG>{B>re9g%}lX%|g5N zHza!#Jtb4Bq<=2;~@+0M=kA@XabmJ6Ww?minPP~d#aA-Pp_Pu^wXpqWj-~Wo2 zl?M<%Z#9hiBLShgFjdM=j;8tcvprIR!;&vmT&}zHje&&!z_u@;^9%mCw1sfOa6+*q zjZ;BJQhQUPJ2gO|&YtyG`7aE=8`S|o5OpI|;HHB!)>w)EMXr5@Svqp!^253~mrA*0 zopz}!h8}sfIrbRJd6NW@nvukuxqSur9DA^Bj21|DD%tI#haz9VK)(B`A)vtVQ|S5X zQ~NYMU4B_6Bt(}>U+)qo(DOOE(6}^>h2Ox$#6#pCSsKK5a3E=%WCBxMv*J-uXK57{ zP2NTcR}QeY8@K!J-NIt|2GJ7uOgg1&`*P?^6o|4|5;^cY`BEP=Gb+${g3$`u%{ zs;Ymu+{IXLp!sa5xvcdVa1|A7fUol+{ZVEd=q!&;bucEF;%uPib`4o9o=8?106WjK zU}rvJ`7}rWGnJz*{2%>pCz#1oYCXBx5^s~4U=bUoOe?iR5#Rg1unOM!Vb?M}rEZgiOySIUVr4@?8VxgFKJIT>p@_b+kU+i?N>u=IU?ErkG?%`r|OH(f6|&dK(Z zS2ue49pt{DAJrZbc?ofz+Y=Nrt$&y8_UQ)^*c);{R!*20&3k3y-{S*o-U5ZF|XgS6Fp7$;-ZvFZXC@{>SNmYH4 zpg;h7?l{EE_2EA5`mrRXzKUiECJGm~N_{t%H)ZNX%iALY@0rH>uOWrJ>1etPSU762 zGO;v4-lsnkb~vyZUiXR0%~bo83ZiWyJ_-5lZ1|o;B-e;S^gv3ASiJ!>b4T@uhg8=!}~Ku^-VPs8T9r%Yl|(IZblE( zN0ydi+WdBv7~a5v%~ilh&|z@a+5=}S+Tvu2FK3Os`DnnzbLc*y3%*xuCT7!Ml1zXa zzXn{vZ{2~J^fwyx#7GtLH~syWz0;;UUTx2XGFMp3F_LoI12P#Rc!Am|Yx{$8q!}XT z?@6OV83#~Y=%f7e@&=8Uk0Cdg=YqUq%B~e2*(lcDpTVUUCH|A&zZv&Y>RAMykKtN- ztw*o6-k@ceeLc+!R8&VT3~_v!h+2wM4@Ak+1RSM5)#lXB#>5|q%L*)4+&J!ymr^_@ z{)%pSRybm}6h}It4-yP#KXxxWn~VMGo*7*-jNy!m;oP4Y(d%YvCf}Y z;fXG|Fdj5pXFx*d$wYUC=k!9HK4^eHRhx|uih3EkL?f-DQ_aw3uHO#EwGyV=`W@#O z$II?BoEXAYOY*mDm;YP8KR4JZeY*SVOtUsj_|8>ZjBjMttVrIFL7VbYVYe^tkE77M zkj{Gn7yD6@MMf;turo!IKwoHsAE3o=eT$#R5-jXbOV4$nzy(% z7mvHS7dq*}_ZJbxr!xi#EVmm_ryY(PzL!2>JA0EOGq=a@^F2lvu-Z_VkSd zX}#HKLWHR#AC^HI-w-FBC&XicgtD)rXlHykeuG&aw9~*dYDV*qw;jEG(8BO>x9XjrV!0xwh2_9RPj~YhAvxR*$(%UytDE`x(1&c^i&bRPkinr z7&N2&h~FUujCy2V)+M$W%Q9!QJonf~s+3`KBeyfdj!Rc8PsdN_56CE;Kxu-9-fncJ zR+$s8Q7RJ#@6@DCE#dhtJ}#$^P27Dajz)(M#iPlL0d{@>g%(%0r;FF%wP;w!X>Uew zs*FcgtJx67&B|CKD`S?4D zPCJAmo(mmTP=q1;`}}W+=?kE36s;>}Lx0A9)gz$yxtQp{p`VAf@xuvqRq;KxBIrH* z-|GY^|*eTSu5Cb@~S+#QI#@gS#j0>X?bXqzq4Zg~rOZ+a$y3 zyvM<-F0Ev@yRfcDFPi2g%aq37BOi^wV{^o{$0EJppgvl{>la6#+BUdXJBtT?GihN| zk2j<-77YCT0q;y}BwJJ+%(&z6t{PJE6Dmeyp{KwMKEj@^@G=(5!qvNf&~gRSHOAt! zUbs9UI;3=lIq`2W&erI&Uy46Q4CnvcX-w!Kh8GxrYl{G2Nl>v^^~y|-Ct!x@#S#Ag zE#j``PEqqV$-B{mpQbsb8lNL{gt~AN&yXsxOo@nDBspV=~!q>pP3Zmh|Wlq@Z&yYD{XjJ`0ubgjITwMUpe20NST0 zbrx%$C?P^L7eb;;W_WNga<=KmxhHX&qg=d5zI5|Xl#R!vG>-ED|DjVYcMAJAvonYL zmugs*2*`YO7LoI1#;-|#Qv^wsM&K$ihIX#|ua21;&qxOoz$}V&JMIx=&YRJlZz~5# zd3ImjjLo+H+}&)~feIBDaE&CdtqLRT(B?puZNIXrx_ZHg61ZT$gW6wS)b& zs)#xIJ;AM~B#Sgg&)Y|1L8fLu$vGU57+WCdu5Y2{_tB4PyRI2Iqu^rmG+&_%cg_cP zpgSQh#qbufyg&~Wors`emn^XW&Po1K`6am+noEaWE!~sr)m2Um&0*UqdvEy|c6H`n zJ<7v8_KS@iSc`wN9cwG!=m4@loSBzoA`1GSVLJu?18k@JX36vdSmwgMf6h74XW-48 zcUGA`G@Y`QQ8pyojv^R@Y~relDT-@BI;_ch$X5$cBIaoM-;5oUfiIxfpp+TpOXZk2 z=^3wV4@qjn(J)z(EVzt~PntYAMF4dMyZTn!)A&qU#;QBMZ84(V1j|iEZ1Q*v`bZZQHgzu_v}|JDH?oPu#I} zd%o}7bI!&2(a+P^y{l?hExonsU2aYogae92%WU;0)3toCMlV*F!C7}E%OfIh&M#lA zDcy^&`*gdSsH8rz!KoNHnlz~)WzHoD2pT%HQN5u~^sI>SECwZt_L|L=Os$tR-N$r*@ktPBqRJ3SI~q0s*y)lnwuZR)=yl1yfu z&Hq;l$q3E=Od)Z|fPXffqUP9P{2)-xYSLc}Ji%eE@uyLX)tuP8WK`S>y%b>m<+np0 zm7SCEApMMGOM6QqHuigA_pvWkG(mfQ?V6@D4||;*b3*+A&T1j}7cPR7)(+8GsY~HW zzHV0o&0yWH_q#ak)xbHUwM!RjgQ(Gm9+k?u6g`nJ)-rcz8nv_0ncrq;=ltRIfA%fs ze;pJ|9s|*o_zhHN+2Qni;{88XM?tJAC(XncN^=GN*reV{?c^^Zc!xoqIb%u5gM|3j@AnMCphN2Ta$?;%SK1)^~ zuGf#}aNo)B`IZ%}4OOvY)*4vkVplu`MW;TK4os%q`LL}YC#>o867tSQM}&9Q%mEj( z)AeTpX>$6~he(J`^6aeE!}wt2y2&g%c&wcgMZQ|@2AO(qWp%Hfbhah89;N~j6nth4 zyE_8e{B3d6IhiaLE3{P;aK>f=tC1E&UOBko{Me&z@thyXivWoq)fRD~zrb=Xoq=0D z6VJ&|Tuz77Uq{?gL*;91@IF~TwO#mc9D@m*edZlH+)t(AfjP$u_B2`co)TwB|Iutj z^GxHi(HMvG---)`&a^bJIV1+E$o3!b49rv+m+xyOo~>+udGWLQvS%Cks*fwA!9^GL zo*T^G(R69A$3r%2F&|3#`2m%9H+~r_WeD-a*A=V6$jRAB#7^8Fw?5#f{=P7M1fb|c ztAe<_9~~)Lt;8G6lq|Qh-Fzt;4#kN5K3<6?*UkUnLQ%AzDUU9P(;nG{PiL@F^G4)I zq|MO`|DJ*LbaAS$qJR*+hPklRKVW_-%^a>%kOSlFUB77#+H3wclt6ZT!&7 z%v&oxNa#91%bnOcsY4#$}1?EXNiA2}NE1Qu6G1>?-OxPcXoIPQ9k2P`DE zY8ufi)A z2s;kCdb~d@vParoW5RDXTWd74P+j0%9n22Ix18@{75U^G>C~Cd=rTrJto+ToteRAE z0_IjrAeyRzSeM5d5jUN+P`XlE)m>8Ta#?b&IUl)Euw2UmD~ow}4>UErf5m z)db(|r#ne+YU#zeIT$6^J{WU&AfmHISL&Ajpkz()U=1S8pGJL{!j>Gxm_FgXLyYU5 z6l)y6dC%`~AtSXs`zh?jV0-I(aL^UlWWSaj7woq`x6a%2x|!?x4ugG({#A$Hc^YYe z;+Ts=E_Y`r@_0fv*B^tOtsFIoVT@3JJN^lB*xZE_Xj?S3kOI-E&RQl#LjagHR2cpH z!*($mRLEIavx7tWu_|9#BV68Nsw#`cH6FEAUtnnW+!2A0YrH)R2;zW>zA&~eOG2BC#u<9Ob92+ug7LVCrn6OEPumaP-I$IeE&39KY4ZPFZ5+V_!KU0Ss+F?y z>EWyB!|NsO-O;}C6H3jZKL|*gF@bR_jt-t-_D!Y1{|DZ#!4HN1W7TAGCQQQe;| z@OOb|6p~-`_JmHaBlrZ~61+bl${P+y{o`DAy_m&i{udt?GlcG2U>Uw9ryo7AqiG3O z;3RrYA$289xIE=W5+{uE{fUj{R=84BRu#c! zDh7QAi`TR)8u@FT&#fp;_;=x-lWd>huO;2o<|qAI+mQ1=7YK90=$MY<%h$Mm9mXmxB=b$PH!}joC)lPVkZ(Qa ze56*Thx0YqclImU%iWZXgQWOu5>=*?Au!t|o8Sz2yO~07S8pTZ7B2Ax8$JY8gtdxh zmNSG8(kHqzDDmCB%w@{3neI3wn;ct-m8&W(p!BJb8vLS}Sl_&q2<6W3c>kdv4+YSP zOezQxXBQLo^k*8aj<8U*y$8w>Q7)lYa}~q>Rff(s-$fM?IGG|K9ouea(A7<)7$X5%Al^mO%jFCgU@&DP!PTXH3$4+V-j(!nVzT^wq)<3_;El2aba_pyc3*=1tjuI|%B!S2RR%dP>9^}+~0UH}S+wLZ~mmqfEk?Qea zIBb@kL-bDrBLPtLZRI4ThDvaDTQGBTm!uDPtL@x`Cd*j1o}3itBb?8u+yH&QL@4-} zTBC3u|Fq_gjoxHbH8nLaeA4(>iyw}YUALr(qv9s7B-9ooAxrc>wYGg@d&X_K%y3&_rfq zCe0=!`?yC53ei6AVWPX-I{e2$vbseoqH#6ML5$kryT4q|k!l<1(i!WOh#y>UaEc_% z=gw@x>s?!b>udiuKXaT3$*<3iIav3-0(Cc1NI%>T^piabXRb^EoYm9~iNPV&_HlIJ zVj9;cL|&)wOOuX%8j3#vny}t_H6pk61yXqYc9!vbzWV!*+Um?boX_DZh)nHHrsp;O z1dnEF2g9^m?x)WvvfkYL3#DgIg}eDFCL+O+dH}8tngwDQ9v+YU*CT8XKP%{LjuC-$ zrYief2yijls}loxBkAwM4-d~wqK#PcZmwa8&hXU)+;(Xg#w0iL@eZ#K#@|K&#KtvA zWg6@fYms7#myVw!y5D?ucQSv&(fD5K9OPXcKiKjj#02V&=um0a)5W+FS_*{5X)o|c z(esTaQ@~taZue~lFz)Ew=F5=p*UIjdA>SNe*uD4%49tUvPNYc)Jr*CHKFw{*y=bR& ztmwwc$J^~c>8WWNTA(^#{oN&+<8=62-o}3zVew^#vcaI zK{hJ8!NL`$p?ATJH z^szP-8=3P4I)P9?YUV61&EF(%dW@o>nhq#OvK2HHEnNbMcZ?!-)lM{yEB9415AIVI z92?ru-MJ`Tx6zj(n@PSgW-C_qINKP!n^ypD7b)b$YzVdbjFHK;Bpy&1#WoIY0Ie4O zsi*>u{|u^Vu`b6$)dSB?p(@fMlZqgAMsN zGL80%8#p=K$=|9<5z)gIZ`DZJMs464i3_6p4VaX^Va8F8rW=Z8IgRDia(BqDhDh6s zj;R)b0l`%jLnki5bUEhG^@_s$q?f=d2qjgS9aj9ZBTB~Eu_LM{{2BQNDt`QX# z{P%FQay5XEkLFFJlt^rAxmw{xM2ALXIA@a+O$GNNvtw8q5hrZ_%zf8(yg-Aco!N=! zD@v=T4nu6v(A`$r-Pv>!*!?i!m?jox6acKj7F2~6OleZPJNRISg` zmygUYDxD#@PGSs8;=62q7}tjJFPd^cfU9txs*G0$?bI{Bury)*2EVEkZg@{Xj$y-% z#Q#J|)D27Q?G5zBT`}BGrAmgHo6<0(1yXderB@|{uYXg%tkG-$!SvP@0&tj$Cc+_EU=zBq_>G52_ zSR!e-f;7*ujIp+|o>=jstg0~%u~;;{5UHL8Yisi{)tcNf9UnL8=5jtOkIj9TB~N|x zYjO*!SG?9>_fK=B_V(dwrJgBSQ{~e}EuNBoiFH9JMS;t9D z=vHoXuE<)CE~K2PZ`NZ1#oRR02>BbL@3Jg#W$D{=+ViXQbjz@DS6$KM(+`FQ zv`p(7rjVcLYod5ar3$9k$32>=8Qj>%1Gg)XH45@eAy+q_?o|>J~B&YHy0K{_~I5(j5zV zYypmt`KS24Sv1ntB^m);Szs+K4(X@^b($|{&{hyn^>h?+*eau(QC;}Mik_=I$%Oh= z5Y8xpp(B2CVxsPWlHMn7iM6d*Z17i&)wws=#bR>0hRK_{v6?2(7<~zoeMo-%^>7^SrJhK2REPzO?tzVByNoNpCAE9mjoyw zw8zC=gOUJsdVIKq3M|i$WiysT-NfN-TmK5%lfaJ30_!Bs6NQ*_`KZP-a4c#PP)7?*!tjK%jOi_}2EEX&1 zz~X`Zf39!=u2gWnE!N*!zX?R3NFFN`C`En~3B`dhIxu0xmuPAX#$Or|cUN-R08m`6 zPgohgun|5zk$>xE>TMnNq5H3)D82j5PU`*!oJgWB@^OzBPNqMugYw?Y zUQfpLllqh%03KrR{mYytdk3p+nE@*8S~0qdVCGC5s7Ptxv1?HyOu3bfbtBA)@ZgWV z;bk+|#b0(Ry!ot~HuN;HGub89v8yO52Trc8hooPQr(CszW=acYF|0M@<6BgnrKoLY7bX4NXaj8_qlsH%^lYs~MU` zuDzob)ituByn7+(qv1!wcUv93?UJ!V)Pp;0jY*m zO8!t2_FmAnalb;pQy8`}*`u{oY8eicjd0JabP4gIM4yuk>5S-?oEeA#$)P#d2u~1Q z#Ny%@nb$7C#Q!cL*x_hha+W0O-WdBPwEn@rYj=cImipA7-u*WS!$e(6@aXdwel;d+ zh1k}k_f4R?9?=1YpVEq^dKK6R1vG~^m+2@Oe~BhkRQT4X^; zb(5uE843KpUM91-d_o1m{dc?R%b`XVoz0jqt_biKjUX9X#hB&65P7ZY2Hbcm!-2js zlC{kS*+MM1Fv~HC^T6JsgfEp2KU#Qk+o|VxjsJvZf4a)*`DC< z??ow~mT-BI4uhBT^;fU~zN@&cawj6f=mDqK!o6&aD z=~Gva0L~xV;PI8)BK?&lllXvQ=&*C{FmhWwM=vGsrJCh0?<@Y|&E>E4?k<*O9J|z* zPAJK1O@h%F#Z5Mm555!z>z%^Kt*15i1%g6s7eXSWSK&d;#h#yv@pCbd^(*YsP&L>*)6_%;RuawMOzTrn$>EHrZ zCgJsZYr@4UIP$Zuf?DNBx`xGzx0VKu$YkFFRwc*fSFF@-1WEdCS7a+zZpuWN<@T0 z;!MNwXL}8VF4+j(0W&4dF{88W@_{oUWMRBow1~NTH&OpZpxxw;Om<}hf3M(?yeq;CV zC$t^7@o){aPUa%vtw8fgq2@(G&L;<{qwfdNl;GgPDI%IP z#)?G}(nS-$+hW#3>p}(#Nh+PgtS;lDn->oT@kq}vC8U+K1~xk*gD!xc=-(A01*?1hsbf-xfjk#t3AVGa@3Ov%GWHS?*RP{UxYd9&}pS zE%HJJ*6L1%^hA^ue7b^zvsR4v|LSr+GeN^d>>g->#LQLns3vE=%15o3ZYEmf_?{fA z`5abDzB;bcpCQ;OfXI#7x6bNH)IveyDzsw zkH?U`l;)c3;L+%5&LtzN_3XX2ngCX>r9B<=hO#SJF9Cmpp7qqgFe55?7)7*t;b}T3 zQ>i$g%k;7X)AOL#*y&*wz2TPO(WirhfQ%YL*&iVac6RBH#8@~5KV za#OjDrY4N9eBaS9Ib?-uJ3M!?lbAh$s0>v)(c#bD`TpHibGYoP)cGplO22%;MiosM zL(!zh4qt-1cXxNc!{EQ=gRfcYQiZi>I~RbTrf4YkrNIo(xkaZ}suT13V3F|fL~y%@ zwRt!Wx)lRX@8kIFL8iOC?pDsz@GT&svCwMN%?!PRYJs=6a2=7(1tjI-bYY8FPK1t* zn_4YLd5u&5@aYMB+^jvDEIR%ipa&NE!woZw?`sXMK_hVN8yF0 z(ghgdHj5My0=_6#T1yZxg7bx;3ekgsfG8JRSo9!ab2ZZ8L;yF^Z^oXR3I-jls8ZQb zEj$EVcERH07a`qZXf)YO=w?p5&q1Rbha@Kg3*C_-CCo;>Iw(RX{HaVTEu_KE7u2u8 ziBu#pQD`>$3Z;_#Ds}m?;oUkT2vP2N`h|(qg138hzUFnqRh9@BGlH^-l-=9bvpq?h z$lnZ0O=S~lp$&5QpnL2uln{MpC@c!!_S0JbK>>A)K~q?L4$VqS1)WAvv$0gqBz?b7 z><7C>-9ll71~SOQ57EMlgT+kB`K~NfMxz?k;N|-7K0y%0U&*p%f0M1qpxf8~)xaC) z6O|J$vs6?o2UGo1AuJ1*gdG))3HrHKuq@JQLs1uTf$|)CxeT^at*v{yOXeN zzy@PnG$w2+r$uMM1?AU+?Su7Tgf}m+VqJ=WCb1q_n7P%5rPavdylNLq!%9IFG`w_1 zOi){|;ad{li5}xf+rwQH6JC{MfwSKdycZHTvO30i+{MMgEe&M?rx{G%EdC$S@!!aE z77nX#x!IAu-RJYxThL2|;MOpT22UqY)bEQ2_LmFZMg!XJTFgSk;H!C+b%8#Of#pB z^-{pnwtkrGo zCzqbCATkfBJ$_B7HxP<&#S1##>PF_WPE&{`HU4-*I)h6Qd%TDq^Z!7$ax|GrhBCr; zWbo?yA}W_fv9#wfo1-nC9gV|@q^SJ+G*TDHjFbE{Pn}gsa_(vqC@d8LjEL`?I;r1;wyOtr*c!cO>Rvp3}3rLZ$E$Q7K8hKw&P0U{9_7*kh^mK?-#Q!4JtY%YvX9@2xIj`Z(yD z_mPB4E`AjiH_8i{^ayNLB#|`-AJJmjHcT3_rM-v@E>vdU7m%!zI0>{RzY3>EtTrMq zR;Ghy@#P5_I2;Yz%t`WhT0|zEKv*_9W1}}rw0f>cV%JL0gahKQ1GC?c30d*1zj|y(P(wsn;fwp5LkyZ88?iuS5IC(}pOEP!6^(<4s*=erg}6 zAN;~TuKxkUrzS6QOJ+pGqmSZhQ;(k|1p@THX=Ev$Z6Dp7hhxR=G8)%h-j{iXZ?B{h zccKKYTV4M?h_tv3M_tb|bRd4|5UiJ^tcVhSIT7nbI!DA`K#f-!QnMX<*b$0wA+3W! zn~RSj1`u-QQ~nrUJB`wPczqNpMhz^X(U{xWn|OGA5GrQHDxpzKKADThcW;#G3H(X8!J;hpZA?;G%0caRCpcB z*7`ePQ27Oh+6@fl_5QR%AqDuB&nO`LEl> z@^#^}^dsYLmDQo9CZW|H5#Cc4;eWY-MofGE91@U|yw*2VbD8W@FHI2h<@4wXtvn!e zQSdQ-2neCrENNC?mZK3|Bqm0BS~rJ~LodYR(gZFm*6}2qL%(x=KE>!|ZH@Rvw|+7$ zA79NH8z9NB^s_jaXsNzAWdG*A5;~7RQu6g%gPH8=qjZkwi%kJI@p3>r9>)JyT3BNX zzPc=81r4rP!!p~{Fv2|Ih8Ns75}yJwrrsX0$ZY=_sl9HzocWye{nzDAocpQg{V06% z7oPKGBg%3mj)rDnruhFX7$#L7Wdn`2?+W~#P%tSq5j1})io9ZR$_kWEQ{&M!#OfI9h1>z-iC@fhZ~#xpOf^TnB69ijI^^25qGXs z!ya!BreNM)R*}Km3xJ(4RvfBjDC7O^VzvD3f55(;APCE}Ud3c35d6X8K}LAZB)g3q z#d7Bu`tA%ZH$KkTTf|<$%pw$=dML+TtD5Y=c;LQp@EaQsPzvs7Iv`io_R#|spG zGLB^X7tfl-;PYdj&Grh$_;Qc6Ns3lvE0+BstJ3AeQ{7B@t}OQocaA>Vll!%brKn9| zBLfBmRT8R<0qO-NBpvDGc=~DN7=EL1e-zGN!k%&c+yANHZ^G;XqeHaZOcTQ&&b6ey z7rYW-_8b|W^W z9RyKEQ#l<3ZK2^P&_aD2{HIm&{A0cIiDQ>!+f)&PQCsR|$X2getA`2XqamUAgXZ^e z!&j!Ff}%P$1mGmRjjlVvC45fr*!SUeIMKzopNK}Kp@0&<{ZPYh^<8AAqIZ8HOP*^O%{iaH;%}P7zh=W!`u=SzRrm|P4B^b_V@OB3dw+^whRV-PMZXa=$@|t%s{D5r zrEsoaAKzYjUHB|Ima7|tz;Cn-wMM@E7c(fq17QY!8g1$tE8XZHoxhK4k=<$W8`3Q! za{WI75y=n*hhfwA0Di+gdJ)T6Ti7milTt^Nq z?&H=QUWz?+Ap|b0f{RtOi0Adt8_sRO6{i7Gv#pI24xY@enM$iO_p->T-9qhcBI({q zm@ohQgqyHh7cu^_cw=~}RHXt#k@p!LCD2B27un<6A9=L`)oS9l z>}pE0S;F|5KTZRYup{sIsPo=eG+pJ*U@MOg;<+YN-#4;C%hU~68tgp7Z7-6z46vJV za~fU4w)1J*_=~{skU}?e8Vee?iFDfe!O`JDze1PkGYG#Y-6E-?dGy^6PFL>UW!XQg$7~ux*o5)!p!)Q&6fCxB{GVj={@ra zCEQ@D5OyP|<`3%pl; zwc(sX&yt8Gs6ONP$p`0;X@Kvy)Qkq8j5|~mUK(pY)?|3Hp~dBjDUem7)V}AENG2k) zjo1#qd?oKA91eLU8h+ezm((*+=bV9~4i}%y6;74m6F=X=s{{fiF0+@fTG4v=6uZJ6zEh8yh~U5&p_nr$iT#fT;4$|tjW9l+VzHzemHz9lWdazsbeFsY{u=Q1u%>~XubPd^u7H404>;|~w77hZ(L@4e&J5m;0! zvzRQZD!=d|vOzi1x33>E-T5P`#p(GH~ zE7qb~^3Ajx()JY6Pd&%cg%U-LH#~lRI=VQJky8?$$&PeiB155>fTDGj^^!=m>HN2-!e^a18>_e9Jj{tfdQbEC%-@zHKG zK;HmPl)=cS-4}IM7{%J&ig&dIekJ>Cr#7;B$J3v6SvMW_6>D7hFnay5Hz@h9MDJ$L z)#D>(6d}O|Z}7D7S-&z~*xBdIKrZ9JHW}uGb9oXmvPP9eJs8}l02-blum;LaP~)D-xqG8(~$i@%LdmmDpW#}E)oIt><7 zwBq$k4cG4cnap>+@YE_A zX$EdxhN2qP9d7!Fvpe0uZnX~u0VVBN-3y4@Q_~BhEoMp%oBN4)`YP{Eu;OumsL?pK zt4AR1&?skwh+yi%;W_*_zK zSO($UN(-#eTu7GL2Bd2d=}#me^F88KNj& z|F-Ly(cQd9qPvtm-LV2DpPE1*$rDy7qBf$wDp}3jIzHc#{;n)ZmwLYUs?8OZ##gq= zba7zSvx5H=aTkTH*lsVj|AS5lt`j+s;WCy1{9|}Pz}sjZo-4&Yy~sUXNW+xq5IlYY zSG&cV)VQd{LZudV?XPzrzI9x1wMB|g+pN1IhakLTSX9||9Tf~Z4Ot2am0|%yhn#Mt z0F89N805}1?LN@@PZ2oa5+CBV!I!DPd*0rsOcAEz+G{vQXQRgkeLlj#q={p3i zis*0@cS#6ejXfY%qGIFt>XPJ+Cfkde9t9;<{WoU5eIr7K8w1X&bEofbaGFul-Y;b( z&kE&==5OQ0@K>XN zkuiqjT!iO!BM_Rt!{Gm=mVO1Kj>lg6=pJ*ik<7~@`Hd+J210u0YmJ?oPI-}xDd)W2 zSP1qy!6wY+Uc51~5?n%YV_jAU^%!P)RbHv15(HU8ZiDkCjMN)CWRC*b6D*BVrQ+AL) zk~N8mWNnv&wf`Hp4{JNdKt@|O&OR+eKkdLATHuB-?P+~*cU=6gG7Y@uWaCQu@01UB z@)Nm4e9nOWzhROxuQeqO_6LePDfUa>UNl=OL+I$nW{F(0G8+c5j>NL+0Jr6N<@0N6 zhjzAyFqB!bsR>^D1SSxMCsNrng0UDp6$&lV>`%^m!U08?E&7=uG!G~9M$g8)daF^G ziyu}za1x96qk#bmq7sn1zy&Rj&N|wTk0Wr$(8#tc3t}AZwW1jt!mf@^>@!Bbfq}5N zx>{CT{#rX@Is8H4u(wl;^SejU${P5DnI60j7pllvsAWTYqO9p8ofLQbL5Z(`)QT7> zNaxI9L5APY2du=E{bGwK5}CbFX~3-*)#NpzR=Gtr7-~O@4w8Mvo!y&y4JS&R)iv3n zwwGV7+=25Rj#kv-F19f^hf;+eCsI$%n?zG?EZ*uir#YE(xFPU}t)k!z0%@rkghl}$EVq>! zq5X3>&(XM@n?qDL7SPP@j|xV1w)#rePJ_zms5C*c6LWKnC(VgxQK#?_-~MD~o$8H-~j3wcnj0HIo`A{4qHrdTHU z6>X0CnQy@g{VOQct;65gWIJAA#Bn{PQfw&3L8q+%o&1K2LT@~Lekq@wNJY?So|rfA ze4ulzKO2UP?C*`FFJ<5>ii{HdVdCKUGcMbd*Kl;jcx62atHXo^=ZIp{I}%swUMEQN zLf64}lVXFV{WnhFVwT&!YR~puGbEoob(HH#L=^MyI=?g4tT>!{JR06kXT&^CY8aIY zxb8mwXP)dFE<9hwQl za#UjYb=Zq)0s$n}tTEWCgx{6IoeSFdYf&>FU!Zs{#YwDxt(B=aBbhMD8C=(~Td@Ac z;x87xa-s=ZM&;O_YPZE&CyO@>soenyj>8IR8V~qGSH_bwI{(Hsm*B#f@mSx#k zQk<_}FZ0tpi0t_>4Yl#)Ja339MPuE+&PJH-i9&tb$oAcUJvGbh4DP{2PR_(mP`;7fVufUCAjHED2ynNOEz-uUi$lh9M~f)DnDQ0w^uSeBZo=@fMGooCX2 zy7IH2PH936o83jv;CG^egvSm%p^e`!-}rj%TFInO*roJSu}WyAPH5{KR7DF; zNbo5CJ`MRC=>GtgXg91_D)@$w#A?YAO62tpH;ei?woQ2e%}xjx(*5_V+TADN$7Anj z!R#GvgiF%?%Sh~1%W4_2G)f$gd!8Wq-qrJyN0Y_EH(3kIr7x}(DWWx1o(lFi@NF%* z!F;sb$I*r(eGvOkO>q`_ohTJ8S&@}VG*}HL{2ganX-gGd+;-8bmS z%#I7?fNqM8`wG~Kb&Ak|ZA^Kzq0w$GOnfhyz6M=N$B!u?8(nq?U);~Ann^p-i}YZ5 z3ItQ;ySxvoU8G1J=~2THd#3{iw%m*L=&X4+s;!1*H;Q}!xa|6ppx3lF-Zi&nzw7s@ zh!$1tE|({KnB{PmmMZ26erWLa=zp z9xsExf$HH(6IYl6mTP$%ywLCy<8XU|6z4TQ{QoAWd{w&P?4W)9YK8HNh`Gl zGr2jK9Y1Pn2K4@6Y;Ou7+x?rA#iOIXBiGmTO+6UYu{cXYsY&e#Z1Q|EJ-boM&JPA+ zP`=DlZxOqCjksQarfoSV=%{1Pp(=ZQ!j|7KkF%tAfIxAtL8*{19|-d_{+8yXfis2# z9etJiUA~|t63$Mafn@^txvEbY8&0>cNAVX!H|5=ty#inKPY=c7h5o5wS1AN^+wxLoRDO^P39MqxaO+_9cXnIiT-N|S_M0i$F?#lvGC z5^h-2K}Zivqm^w0-{+GaB~%(oyfj4k*OR9-nUYaq2upu_7i1LHf;P!(aWSd^FCN&V z?eMh%VhSBlJPth=OX~oEN~7hANqmdZ^sgnPOFyQAN5@wov>!NZVBPY2fO_LKr#-Y8 zegBA+0vdp6Wyo?)W`T^Yz~R=NHt~NdtL~QBhLvd5NMh-o~fkzAYi~k6Li978!3OQCv>Y;snQ^0-dmfLm+I4 z=}TzdQuu2h!%s?KaI;jNQK3#z;B1+8oN&EQ;`d2_ki{W_hX<#cNRr@wEJ#oj_iu4t z-xi2l^ucGZ^@8hl#_d=MQmq;hs|a~G_)xaktw%?H9kO4j_J{h1$$DHP5L1{RKY1o> z_r^jg;#e#NUhz{uX%%O4x)Q7q_K25FAgt0fi~lw=H2{}>#@R$%Mk3U;27d8%UO-G+ zy?x)wIJVeJ&MbD6qwULbOByHdku!{brcbJ5`% zW(x(+;(`zs&ieAW(z@9+e&zW3C~w}k>=0nS-Sg6--GbF}u_&?aw$47-^7)$AbMbHy zX6ya1)Vf(eSZ5ng@Y2%hhTU?pEW7PCOEB1?+kw^ahcKqVn&M<_zQG=Z4E}+ETLo^{ z+Dj|9;WY5MNN%eM5wzuSw_n+U;*t}N^}+Ca+Y@fy>v&AS#+bqmQ|#>pzvQrzZ1@Zl8 zNj%sNHjHm7u-wp@x!MGL^%f|VNl8o_i6Gr-b3G#<(A$hlOeMeCWJUHJ!6SNS>ZkaL z)^^qmzU2gR+m0h~>S;Si3O&N0{PaB~#=Y-}ZeHhEg-%$H;DW|`$^FIGs*;*!V#E|X zEtP-B7B10VM_(ag1!HM)*AA34jym|P_}o=xsAfqCB@sYm#STVA!taiBj|RFzDW$2+ z7jhO>CCo70JfOtrp1kUYQ~q7H!}F;K5{bm2s`QLjuhp}Zwh&q>%SJ9NI|J0;GP~q) ztHn#gF<&k^xQyfbM(Fq3Q;5IR$kUPBlq~@d;RwIcTnG^@@JOOO1~QnnKPpMV)nvB? zIK<0oIPW5<&E`b?M5QnY(!&mZAh#isg&90W_I>%*35#jq{_=zDJ_T`V4ifW z#h!Auhl;9FEi}k&Sr&fMoC%9v9<+z?rdLbkgi#Sxn)6zq-2!-EK6p-} zDq{8Y$u)vTOn4A&&04+U=mtEq*R_5b5CweOHmg7DGXd))tE9M^0tBJ|O(&;!qwZpE z9A!F>t_WgYuiZO1W*Lx?^iCmoVjNkPh1xC=VZP74uO)W4ufUhfZIV~$>W1eD9|7pK z7utJY<{GX~re8SRm2n1MyuU`SkF>t#UX)0`v>*~-wRC$ZZa?gb47Ol0SlG&E*A4Ct z_SGAsJU#hrv-|y=dU*5n)z;r0vO!(5w1wy4I-0?5VB462UwwJT=4Ze^UunL7;1$Y>WJXp`=rCw}=ho0+2 zxEmE+k+ZJ!*Ew~@ZSeij*-qoKW-CcqNcXxM(;BLX)A-FpM65JtJkPHsNEx5Z3?(VY9@7}$8->rJLws!xRswo({ znx3amKj)n9_j3>zRr6erb)*dRR$8@nL3S>rx5aG+3mt}G47!BqnEFeXyG4c4N#+E) zh)Y9`Hx)1U?SAF23tP_JIk8bjLNJV0-2Tuyd|90leReEPhadT0&Y*G(mj8^(*o}W_ z=3@28j6>6q3768u$C8b3vYGizFW`^CHD>!~AREDvdbL32=;(u`6Q!@B=f-%Yhhr%h zF2pd5u|h{xdd(wit3y^_bH}3TUpQ*^*XIBli@U@N{pt7y<0TEGpY^Xu_ii1kb5wh? zX{&;gpt3K9}VR&>|80Um+Lj}L6*q7T6DUh%~xB+rjo-s=_K z%#&Ld&Iw4X-Uhx`^*t@Z<+$f}jzG|oxQ3+TX2ac)^1l8=2%OHZfbCJ0Uf|I<*{XH|m-Pqp>w_+0V5h*A?_Uc~ba>lWJZ{Kxx-1tW8A8UtNzuyX z9(uXoG10v1-O9}V^~<}HZhLuxIy4U<>Pr+F7A>bUE7GXArXZ#bGVV#Rb(i-meNdj@ z!5m-Bwy(E(#a`4f0cYpfjs=5u67F&n80Pl?-1ZN5i2?^;myDE=t5Fh|UjKr+!!Cn@ z)l@a?9`MWmd>knL()dAJjr?B1=psuxg^6Cz6eJP{N@8p@=+u_nNsJ8xZTJUT3QV?G z37(sCixOnpK^wPc9Q#Fb>sv?C=7fz}Q4vBMY#C)-yf-sh&G9oVvj*)i#jH#~#mdu+w7Y{OBw=pPN+D;)T2 z(~XzPwXW^L5m{_~j(@Zt{|OAUb6A~jAY%UW>$p-E?$~O7PH8O_x_)nQVzMN@-G$*B zKInKwcP+Il+I#?HspO{%1G9c}tlS>^cu(8D;C@==aJXf5*Qnoeu+-dWb>}x%J>^3d z}TwCh^-@rGs1)zWU+CEO@}OeStLX{t8{He#s@@l!E8Snbp;2&y)OeJ}U-wTDjyjSHMgrw)zt*p%7)6ftNwh?Xjxl=9NXKTs>$^MQ;?#?jY3&$mX^nZiHO{!EIpBCg1*io@ldB+gkO)IWf?eg5 zrvFj}K5UcO@>!b7^z_;f?8s!2onQz;9t8LtppcwJVvuEpQ|n>){Ymtp%K%bn9^VJl z(lzL5lCupA7!_U=&jUir!N;%tt+xh4PU8EMp=ACi5G2oxfQ5szhsofq3;p_B;tPj3 zK2np`U>hbO;v)uiy=1C*S;%uB#1oITbbm%MgE|fq9-H`$yYaOIGl z|6%3Gwp|Ld8Ff3G>(M-G?Z7*%B0y8QsmnX-JbpCnl!?w2mFQl@KGxbflZUC13>_ci zOjun8;>SD#0l&U@;X=UI_9lE1LEjJ5vM?x0S`k3U$U?a%n|MIJDp7jp-2pMR_=hxC z#V76w<}cs{p*?`mtDHDLVOk#v@AP?K}f z-`Noc;EhYk-`N?CZD0e?w`ehtz^aR{Dt9}bPlFq z@%2Pp1Zm{TU_jw>&88MBVC^laRcV##S16c(+I-5#8<@g5?UF#T43P`7Rh5&Ew)>O& z0h~WXB?Xq|%1*IhEdue}cin@hMc&cKv22}()F z5E`zn_JPojna_PGPn75iVwq8QdmM%xz^3)^Q8uP`9cVzCMQF~jXKGAESv-7w=D00= zp@yd2e9ieFs4bC&dy>yR(4E?Kfgm!SqAjn(tOax1lK(6D6D9OE^V1YlIS+|aiu3Z1 zKhP=Yp$L5|En|79p1HO~t_aEa@sUm19}kBDR11=8Z3 z`{8>lb-S(yyRPGbY7s*c?gVxn#*{x$M|A%|nz`sdO{E&qZydk*G5Sw7H<#e;YCp>mkisgb6Jt&~yo7~w;^#3b)=NUn!{&hGzq#w~mFVh~c|-3Bh43b>F; zLz*JuJr5>*i%$G9Y&m0DU?hTCke}I40Sj%AtBeX}i zjLjr?rbraEMqV|EGMTJ>7cT9sDm+c6)<%1@js_Bh$4wgT9^z$clI5w>v(4-=OGo!m zm7vqJA0_c4?|P~}s*tBa>Lm#I3LWTqY!U&rj8r`pT7DOc;Pj_momxm|8E(k?N71z> zD1+9I1Vz~c-x*}~do5T-x!8&;sm8eE{xZp3L@hOOcZ*y?i9~)BRd4Sqzr`A_TJf3=chHw|v!w_a$RF=$IY>`m>-^z8ea9fV|PJC=a0#PlEV6kSM zxFVIvohiAm@ML3*Mk^!?6LxOzrf($1U4$tbVSSRraXZv2qw;SG>pUC<;;8q0obDW5 zk!~<{$EqCdrU$b!-`_eex7UYsJ10gJvN_$M=6I&jT2**}gseyq zTXwl?G&7?-pxR;`y`oZKBq=V{(UZtPjlQ$4+0ngW&bMCeEL>)xkhr$f!zkM78rF^i zfj;W5*3lW*riDiK0M!91wGsYREUl8OV3XqVuH9fUPN0xs9@)gKa_-$Wp~l%l8?hER z{w&0xGfbdenMXqy46WU9m>E$wD;De=r+k0Z_YeZp`3=cuz1&$ev=1qPqf;cwg(UqE zDEn`4U#y|uE%B`n_W75lc4O@?`-|-S{q81o7o6OFl;QG6M{ z?tGtQ3J3+WRwE#KJRGY&qx|+?cirl{x9F>%*}Augyf+7gHjhKUReI0KIR7q&YBdXT z-~`#!Q5zrHSgKbT7|aj6d0}ORzv60D&36yV1iK$^Il5xHf2K`L{1c91^75_IXs^KA zo8VS3IZkuh32`v_JsxXM>XoCDV~9`Z;$GW2c~AnJTX9u)&w*l>Ar*;C=Lzo2N1>w+ zC?;l)B6l8-aC)tth`KNPp=&R^Ur}oF_c-!Uq7Y2tANE=688l%fe#UfJuc%u_;dow% zDkA?NfI{ez%lQ6|Wf`cZ)Fa=M`u)ZcBY2KN4wf|j8_~Jh=kuvNjsc(+F}AB@?C^jN^2Er}_72<$VAVY>3Nuk@Wd;Bl4io>q~~LJmq+a zYgeY5mB>Ku;c6=tHm4H(qynf#^^cF+x4&$5A)dAEHDf5XV4hZ+-u1lCU@l$4t>6=F zU!piwRNogxV~YlUfO3`f_bjyR#zCA? zN&N(cG(u6PGiw z2~?{xY+$?Ns*fRYc&Jcnc31gd8kqtH|Mx~_H`f2!$jlmmhR))@ySfpuTB#%(xC9C} zAKMTJ30G8pxjWD|;zFAJ3@$sQ>Vov3`=$ckuLaR)mcssw;bpL81Ch{+R3Ud1xV&fi zz=O04zh^?A(#D<@BDRVYy!@P*1 z{Z+q&X><9dXzSr6vhDO(rS&$)O37EF(o5zFZw2q3l4*mZQ6P+dK6DCa%=lIHV&%CB z=kz$b;5O$N&Bp#Pz5AbV-v6&~o)lf@))}&4j#^s>^GV|YDLK9ahWfU@y{vmY&s*k+ zcN<>4D17tuCX%V|?Pd_7Xt1}2nfbwl0;J^Ua6cz9!E3_NUtOHI`KPlaM>u!kJC97IrTngi53jrYvRz4mO+UHgP$wb&R~Xgv(#)5o%RvI%Ilrk5N8@u8w|vG zR0|T@?A{8~PWajW7>{2jd1f}g^ox+a`SZk4psejd&(L%mn0RY&ko=zEMIg=Sn7@0Q z(1JrYt5c|NEbwQm`{Yl1rEl;?Ls3|rOg}PoO4WY}d1Ky`C?&6v!)-C>ifR`?-|4Lb zvJ(YI*Xc8xUTRHvOliIRvd=2kXAV~1*$1y^%pzO(^dwkd;bdat;_*+j+k^{sol+43q>m$j7d`FNpHBXhpGOR=Q@W@k7 z2)OFjv~++8y(A)L*Cr927^-Lh@1$usZ~u=Mw=bCHrOGN+MSp8~I}tG1N`>%?pv;!~ zGw+|7JT2busmO*rW>DoCmMHFV8MB>4%jWk#ao~Q-?Y7yf2~ci7#G%Hh@ez<;0(}ts zV)iFG*oCE4irSUv3FW5ERU(#bxW-;Q)DuIv*Rh%lX-N}NBo>j$(ecFbYHu1V_;n#X zt%`%$?4CEK)MzTs=EGlb2A~ai%Rs~m$zV@0q=+J1T*8g-TAw{}E1qW2ux0dB8t-#H zH=5BO_~>-VJ^`HK4gEzjvaCDT{Yf%*cJ+A^g87Ao^E%r6{QNr;Ic`2au}Vz}sy<3< zp%LjEL4l*=Bkp!X$BmVyq=A z6YDcJHKpch$-nU;^~?HFMDNBA!F;=Bp7ZCsQHGVT5zWsNp!Dk!uewx0GC$&wkPuRy zlj`53$%CG2iGuz4YAji~cQbSY$i$FN>Gh%*O_D!r&4Kw{b7mWZD=S2uot>fzB+Y_p zwy*wzc4WId&|c-5<7PvYM+yX)nVEN@e(w)3=HaK~^V)gs)<7ZA(Fm`)3jLDmpO)~h zOH3)^;^HjM@zkPtp0Ues+Q@GUq*m7)i|^m_Yfp)v-ex0QbgjqnB|6=y%9p!+V5mb3 zu~?8IJo)$}IizGP9B9!v3+6qMr-L~EZ^gEmCx0EU?C40eokK(ZaYJx98gmI%l;T*J zLLlG7d))~tHHQHls4sK!ag$|-on(&sbeP2JvH1)?DYRPGokuJk2zf|?8N>Z*@;Amv z#Xdtn5W>O3qkox=c6wg7^7ZsYxHSy<>M|0mx-GZi^QKZGcu&+&IOhEDnEc}zbGSfq zudb!>k`fiZzk){jC*pi8cKn?(QAzmeHJs?vV`lQeCaU zi*2qCCou;jxheRuFmGd-?hKK4!kO&FO0HFJk`YT=YyA=#V2UM^Cfe`~e)&>~XW z@bmG8$TwKyaBE+sBXpqvWl2leW1H*!@{{ZvHg{aS}|X1LI1l~zRkf%;*iYrxm{f&OGhbefJIy_3S; zs<+A`T7_v%+-%_j+2A-6)ukTgqM`ZgZ2zgTlfH=W=BlZ}unF#yF}J;8P6#?YMK9yE z9Q{v2!~zql&6lDM6&inE;XOuI#%a8gFAia^adD0~oNTILl@a2 z0|OI&9}CaED)pZtS-kk_RhdsBWW2cGogJ!aRcMSBTp@gUnqL4h;LWrTz^Wqj;ZFxk zb=;s=wTMFRr)&2fnTwzx2tRpemmm+Z=31Pke^>PXv#G(-0{Qju5F~V1;FuTqZv4QC(BPPY99a-BLYT?>gX7S zI~vL347TgfRfKRNeAAvSv^~`ZT-HAR-XutQKfh%m_iGDs3-DKudeTp2~BO{F0+)S=+-lW;Kyd8hlAcdtv-C0 zBB~Jg{JpP^I--2}^&*nu;;_255WIgxCK4azO^^?hu2?b}yX>@4B{43$gZ6f3Bm+H@$CSHWhkPQ} zSPV<{o9xRUs$-+cP9zt=uFw|`jRF65asL8NQPsF}le7H?UKm z(t3lsmd@?vY!X%(1ijqEYls^rHhL)NtHcWGD=`4F#3;%~ceK|uNf#M|wxF;(9`+y6 z!^u+f){t9xW&wB1Ku@zCVk}x8lY=KU-_2$*aQm?M|8z=RvPJ5rNO#!ba+wj%8u*67 zaq_0iPGg)V`I@(=PW zKCgQa20QOXYhOeMe%q)=yJm9`7O&EG0Ti~eA zkr<9Ycr}2dy3H{<@*Z~sR$p#~oKdCeLO*`*wFz{PB?`NC9lWN_Q9NPbl+Y_+cJI15 z38j+5&MWSH87Jc&`SEdj6PC~M9e&nJyuiW^yJZ|;JC7k06U(kVuUTtA0VYtwaWGu9 zb`bKz#+K6o<#1v5D;n`FFM9GZG(Ny-9QxBUByp^Q>_y4fti_|->BTpX3Y7@SYYBvk z_R213VrVE$!k-)U?U#fc&3#;i7|nD&&{+=$Z}tM_^xm0rM`sTuQuje=0w+CCOaMua z@?^0q-yrMc%^RlxxP(a{S;8-X%^zfqL8w)Q`Suf^uX_Bz`5Sjbb5|HJ0O#N4`#s(w zn#rA~!Vo2#!v->%TeMmaZM9eAxYX~%K*vZn`r)CUev9Ei;uQVDQ@G2r{3l=*i@IxK3F z;W4U75guuQ``5)e zvGD1&`Yl#fHZ*jaAVrJ&leJ7in4Q9YzfV}gji7fOAX#P;7p#9TnL`gb0P<4jHkkAxBxzo-aN)|@mFdcuUG^3iHWy99x?vBc- zLk++xTmfJ08?G(2S1(aNjd1~hZ}Lr7RSNe;rONatCJj`54hohyyGbRd6c?`whBhB6 zz0*60^n5)W z`o;446gH>z2Sx{j<52+r5zi^tld2;bPgqvjW71>kLhfJC$sR__ZJ4bNnvpY2PXeyC z6ieN41AEw3D@Gwp{W_0tH>@t-g-<$ZtTBG}Dbsh>^Xi?i_Xdc%;Q-B&7<=IxC*UbQ zO)k`;baD=nzl6#`&rmIWiTdRzEP3>%p115DQxbhbM*<|~G2`Zpfc(5vODS^AUu}KP z@EaAvf7T@KLbLpzGgh+sg#z?X&zyMuYc2_or`^-WM9OVj)#=U>p_5{-l0J0U&FvyE zc5ZSe%(@Jmwsc;1sDSMlr+K=`g`(MVj5{wHee6b829bylz$dhpn!^fW6~y`F?=7+{ zoi3@QS7O`Ln!ouqf)l^KS-!R8#&hRM&Kw%iEgP;yJ0WQ+w>(>mF%FRVgC~cdoC>SM zf35HWU(p+RkUst+MT?1==r|^UtCQu*HEhhbW$cmnt3eE)2}$5G%NS4>t;O@*oL!JW`n&1lZpF zwetLhO=?GaWr7iW4e=Lw#c^?9L^#k>-Re>+m5c9=M3_?M*l4cS4Cmm#0`~V_Z_n^O z^5w}EkNe&TuYupHyCVn^hqF#gF(K}s?JARvk!ueB;_)pvnTGepZqulU3hf4b=>*te zU4;MKf1e31a-|x<&yXZtJlqze@vPf&f4XJnt+zkRD5+4bI8YTPM;Oe~*F4ize+`ORX?9R7wH z#+?oQ;2bJocC(0&a|QWwkV$i}k-K8F%^yGjgV&!Ls%SekLT(vjrXzl$ob(ELY)i&UCG{wm%!ExIs( zVh5nUhflhoq|3&!s}pWoUAYb@a4SY*-BPKk}5#Hw~AvnoI37)X@U3h zqy}j9x|s%kaO55L#UkUfh;}&L-$7EyVOLgDc|G9*6-m>PZFF4!W~2@V!FXb*WPgpW zjW7-yLS~DY7bg-SWGcV&5Ky@$kI^!>-%^QE@W#Q9arb*?82QXn2f5x^*M0OwM%|qV zndGafN#7^j(7)d?qV%J2_)HGe{g&pcg$^TsBjE6wJh=KTH8=T-gcv z-c?Yej%MrvJRqd3Q%eKfC?@xj@8F0gmup~$FnOvq_G3FF;8g*aTy~Ba86FK{*XzSE%`SdQdKux6PHgAe=C2oZU5~9*f9H_MUT)EZ8m>>`DXCq25(o$0s$?Y zY_N7N4^QR(F)q2vGEZze0&TI(P4a>*N}pPBe&fZDkKKWhiyMN81IUoQjFJCkIDS9V zy-=!eM{hqclzY3W|9O!Gg%Y4MUwr!e}#JwWsOt$dg zk`iUKMt7vo&FZg>F1yZWW(YXEfLV)zlPOEz7O1#XpUwpnfS8y^!F%3!>5nHa+%!EbA{*B8}Y z1bLibCWEP#6+=6J+g!)Xb-+CM^@RI3T=C6@`gdIU#Kk9Lv{hf(S-%nB1nU_lIm;02 z;_LM%Z-|y8tq2U;0g)@nWpNdpOcs1YJZb*yjW(JoV|BPA*{kWdL!qkX#~`1Kz@8Z)rJI^xIB}JrqIZkU;57LBK5BhwVS6C4LQFSGf%tusuBEOv613f zWqru-qq3zP=ig>;!~pD>5jCvH3=Ers8(X8lSvKj)%ieW%kT5Wp&lUAy53Kd^X(5j` z8a>4Ps zw6?$f_nsvR3gy55N=qHTp4e-4y=pD%u&0wQQf;pUjwmm;TuN?1m45oh0gfSgKWG+o zwn}=luyVe=XHwBYCApz0k;s-zQ4!$A*j<<^ZHib=A8Xcg%=q3pv3qC*qhX6 zjUOtyT$QA%RgozsPS0s69c`*f0Z2PW8%^VAC*}TL{1YzI+`7wB7davZQy7eFAslcg z1fM?xjGUC4N@=%54#Vtb%GBu^VW9>A>&w#&EK*~r98UH6PPZ1U#{lA34DzpmU)i5v zQ51`+lsV&)ldBy_)5 zL{<&X=X%Q!7@HIP1C0Ut(v(jawM#MFDZ@&?t9 zzhGuXm|Nxi#^&uz#y%)lTboFT<-mr&o~hh6kh9P8=e;&9?I0jfutW%b&<855d@S{A zNxgdhIKA$^O#fuI=+uKXjc0TvXMaYqa!_I=!6x4m7~A-2J-xfsO1AFT>^GQj5vPrL` zr(k(Mxza{n{`{n`^UH)Xw4=kF(@h6fKc@cUq$QhwwH7K5f`-V{=<|5BuADkk3PSJF zb9gzKBtL}usiXai<6l09kny3m{u|-0u#x_`A4RUok6Iv7`$~A5XDQ|6V&YMw8@*&1_~~d(0ttY9?0N{M-Qrv zVZ&qQ7u;`XR%S6yxa-6<1uiJM5!$Qq!}W~mFTNepxy-# z9Dg9F&*w_?IH7g~pbSoxbYUM#>gPk|!=QxaOCZqvU>CW{6;alxW;`;dlyGI&SJwSN zO^tN11yFy-LLLS`xmK(ZWQYdzwz@E(;iH9}MZ}-2&SQ<1yhq78*i4V~CwZ=?Gor#-bw z)ytCl9RhT>Yf8t<5Dudlw82(>^^o^DZV}3`esz=H}EvzoJ zy2Mru&u3@-_oc!Az+5&FWb|;e*V?0eswv+0!rXaw^l2%^u3K_Bj=UxtiK~!uuM66* z-1KIgd5V6%Ls)Lw2>*kNrq^TWm=UGbVE>1S8JZl2rG2?Q(lSyaRYpItK%6$^lZ5Q| zsM3jgrk&?0JRZTE?#PTS-#3G?F;qli`JvSn;~C!LgNEp!_sZGhJZ-w5A8Q}tagd>$ zX4lteLzOS{+^#p$lSQV?F>hG`A*WpsP@eQPORM$u62Cn`a+}Bxg8J801Pb8d7{$@KYGGcx}2^DpJNx=e@`wd6p1`3ED&?;oz^=zS`U}nn-f^kZ!`h zRO#Xr#7n|I!u@{%iD*K=zmDA1?UFAi&^dW{Ik@7TF=4+fU_{#wzl+Pc6hSTNs#B9=uJXg0et3oztopQr1e=G_^L5|51CD&e_Fg!;(ZFIb79Inqt@kAIES2cWoi~mq5=4RFSZvq2Sh@!sH zAq9&G{X?a|rhEyB5IdScSYlET#d^H5s(E4|uD0!swhs6Wu+aA(z{0{b`4qv99@Y%4 z`tw-&ua|+1UE+G4^{7Zh$10W}6oZwOnCmoRV`DL?`MK{%Ia&=YC2<=fvzT$TnO6|j4vJ`Ry-7X+b>A-e0VJsP@b*1~EoS%c)mfIcC0pdnqZ_9gF z@6%YKg2S$0iEnIw-;I3UczQf_#OFe;Es!DuYC=CVdB}h{)>g|aP;~zZd(ARBN2;Et z7V*aOI2ur|RvLhAm^$uKJE+XGF~4l@%rqZOwQD z;}7(N;Vj+xt~-?`A1yk>6o%paW>o?-eL{w)r%~KbKTq`nelMN@WDkr9aS3vK*2YFk zsZrMKU*N-vjLODb#BVBWNJr5EIAzaJm*0 zP-@iuwhv*ag11aXl+5vuc1q*FEVB1fsj~26x4)wMk}?RP#mNCH9~H{{hV!w#z4&hVeOYv%@>@s5pFnb^6_cdzZDXR(g}?EydhzWvl01OSwyU61Hw;v zH0|@~qobqBApBXMEeZKoNAc+gT*W-ko#1kAKW z(il21@~5`<*0js~^+eW<-_eE^t>45zzL76kp%RKWmLS*=-L+|Ct3>Q^z|J=a92{ug zCIbCV?sV`rPtn#xY%#DCj&|_I59f+LAbZ8tsz6wbX3Vd&N-pEtivHkK*g&^H5?X1; zn%Cfq_96ZXdL;>!XB34l3YyQxcx>3s>gBlc3uM+aL2L$tsAq?o=dWDNTJp)an>z7_ zxY47-!Z?K$Yj)-%M3XHyABf}5C>|J~QRktb`(J2dsJsi~g zEuk~^thqTlt^=xywTxB^^YI!qDJiM;tU`{Rix!&MBcFeb1keMr&Mq#H_>O;K`t1cJ zw2$N23|dPr@}FfL2^Nk+=#bNs!ey)a?i? z=2BA|IYl0zTL+?wiW0AHLz(Fv>3UmD=XVADMYV1e~qV zP9hI-@L5s1<{_kx1s?23Z9MlfUGS{1KRg6Hd-reRIix84cuP&G!6vVo<73VGXLm=A z4?EN16Z;FlXdS6}|LB?E1p0(RxgnUSZ+Ute=6p4wXTS!6eIZYtrDVQh%gO+UH;=_l zWi&b7ai{?M{a?L3z02>Nr^P8pyaR?Suu5)K(7jw`FF`E)%8C;=|irkSr9o(i}-!l*{Da zo7tO?AN#A}M6lIxO8rqvb7+jwz0HfFFBnGk08FaOiCiRCE^TQr{~ab%Qe8 z$3t9Ms+@FtizaQC?EupY#>tg3XDEhAeVKe$#L#QwfN$KTWaP<*$Vw22EVd`V4m-5V zA-ZzPukdWi1YrfcgIISHLw9cFh3JkTX`YXV?~)v7w}*@XWpSmP)la;yeZpDd2aXf& zN$LdgQRo{_UVJY$m4=3i^`sd?9E9HWBPlDT(Y$i zmM2UT9CF8c2bTI}T}%WA!miw>bAmv^+u|AV8S6Y;$D8*rbS*f?wO8Wn;zD}3-{U=c z8nqBqs?Ve$;~Vp^T2>h(+k7z+&4>9sf4hkOoe&&YJNTeO(h=V422~R26VJgAZG0BK z(dg%gE=%*5#=ZA{4EE9fe*2a*TFZ0C#n^|_@>Ok)4#QgY+&DV9g+|A`MD<98g+=?; zWIwrorhBU>1H?q~Nv5>bR=EA{@Fz3jPtIjSDS@@3Py_C#Vcg8)>sx{ck7tScYuY8; zEI=)t=U;jmbAyddPw7#-eFExZ&LM8NRc; zc^0qoHwHRe8DgREd8krDJCTxuHplrqU|=wDAfsC}ndx7(%q3>50*kBP49p&Yx7v0$oM@`VXk^4=;JHNeC@HK;%4O`ubHSYFWq%HKL=MVW@^~?w zSRDs!`5a2sWU}67$NFOM@ZtBYLHDRV4_O?m%F$vH33v`!1WzPKEwrPvk_h3~x)r64 zeN%8HQ7vo9TQ^}cllh2X5tgm$Bi3)bcpbIT&9&mbXtdNIAWA2z*2rC*Q{+@BZ=Q}> zR_DH;GdU-=TOL(NISIcr^SPZ2eBVxt(1GmK?yC$~Hf&jtf$sC$>y3JyX7*_C|Bi=> zcr25&>7X9bMx~*bd_35eU?o~(4 zrUr#=TLaWF8{631fALo)$pi;A(kA&JcjL;(@zWG0hZ)ze*LG@Nq;mNCdp~a1XCg}T ze(+XrS*b}I2E3QQX3gQTE(^%6piToFxiDHBe>22tyj*K?f)ogN?2EFfH9a*!*!xd@ zK1EAO(ls}NeMpDCKSfQIM!!X=6e@ShJ{m;5y1|PTA8iTje^w2oYx?j_d-g~c;_Y5b zqI180lyf}GMbxf!+*=jsv+|SO+=Y4U4!^&x2^d15!u$j&akgVa%xMTweUU^s+#)Z1s{>* z0mXgI7v`Gj;sNaQ`CbN?|hcfn3R7aGRqzN$=0`G#+d!(`wSWjKxkI` z?-4buOoI=I%haB3^kFAj2PRX;c6(cBhNPkJ~q+-bIe$* zq()}`j>G8c?{ayrv(*4dh1mPIF4Aoo40Dr)lR9mtj13Gx9VOoIion!Hz>qZ#2oAy787PEZX zp}^X)O*D(phjb$y9U%(axV!-yJKDBuU-YYLVcNe?V>9AKKV;A1;1vvyeR4mZC+j|( z>oK0dCH{80!uJEG4PBxv#7`b^GPxN2`J7@)Lq z?9rMBJ5jbEmMD^If-Fa=hFqlccFZXxFc0A3sni6=PV{h=C+LgpO7mbMM|t8Jg3~5p z8vR5SZ3#ph#5NJ%#i2Q#oNNyxnzbP?@dQ^1Y+ zJv4D=o{liOS1#ItnGt}63-nO|9xmf$QpMPrIfl;eek{z2Qm2EH-QGvy7|+1)>MZ44 zD{StNN~ueF2r`{>I2fPesgtyv{$KgAj(L|H%lKQdRT`4(W=2rtJ3o=Oe`x5o#(I|^=PM1jAdj9N~F+_&}@vNHu1x# zAJ{D+vRXvb`1H*;GIYmjH?-nvA0z5>{kUCy!t)?pz(lbQyRV(~Vz2i#CXL1?e-L=< z?Lu7^{HIfr!cb0m%u-e_`Y>L~_#Jho2*I!Y%-Y=lSz|uQSC!md}pj&uuXyf z={|)K$-K?GD|PGgGV)(ShC<^1M-g>Dm=!3aCsDXZ0{hp3tB*?A!s5Qf2RVR4ZFfrf zvfT#%?R?%|7l1l<%PYBE4(HehLR{hd2aPgS;KAfht<>eTz?zqe%FBq^?p6*cws>+x zoa``VXY_(Tl&^t}l%Aik;G{*5Hs|DK6-;rx5ub-aJ=uf>zr4Vo*+0<$ze={wHTa zN6+#e^=pn)NPfuGSUD)wY@uzA(}}wjsiIN+O{N2~3!hc^vY0Y%{%NvYYopPX_6UVI z@Z)C!FEOOHOBD{39z-t5Y=PymNAW}il; z)+d%EmdZeJHgn=gNqkW)sjjz=`eza#P=3%G*l1}M7)r5=BYUmrx`F6-8l{HKJit?A zzze_8__A?JL1L_{mXEvhwKyWppkq{Om(O+$nfCltn3_tnDklBq`Q8mQsk#T0Y(de| zMM2Ns=pwNvJj69*jB-0W@_J7eIXZ_t*;NuF!eZ_=%aSjcj_$mVymisV(&Qz<%ZgjU zjd|*0AJb=6q2}i7x++tw)}l!7RvN=>wk{1@ypjG7=H4#$fzdNO>E1q&t==Pg--E~-lHOlT7bvl!PWU$5rF;xE znTp_t|#9;wOX#BW-Ps2DrpA+-%m5ik0TqM#VNk3Q*rn1%WVFU6w8PYTG z!{Z(4mw4r3=){Nar<*ijBgwXU;ed@KJvp&K>melV{v}1eDjwlHs!cdi$~lM{oT)H| zWi*8DyLZjPBipf-Lup_z%;gTIS{7}0&2@6uCe~i5UBS-^y-cC=&2pOnAQ#xfzHbUy z?br94mD>%xq0TzNIk!4%*VTt}Ol9y(elofncb0e2Dw7b~47PUb1bgERIBqw4;bqVH zy2Z|)ihh6nDX&E=Y)UUe>_wig9z8?^4Y%DxbAGwo3`)}C2; zUa!}E|NZ3=A(BR=UGMU1e?Q+_m4j+S6V{nHis)u<1g=Th&8-hW+_M}S^@q>73VS?b z@NG)J;grueV1+PPgUnGu@)=%ppX(0s%uD+%W`sEx4<@d_2zAAtFzq@fUPD z*FX$^8}`Ww?(0HBH7=QCRRMkAc9xHd@u=CPIoC(iu}XvR^FxOoaq>-)JQKH+yE7^U z`<)L-DnR?bKR$RGVIQ2d+I7Le+B@qN$C<>qgNe9$@s&r?qYiSHn^W~^5<|Yma ztI$97P9TavScoN@Rtp+PK!|R3c`qFZE2mUGB5pgdSQnIf=dttMA4qCbAZRRmXmM9) zb`hLa#bEye+O0ZmI1p=ce=;m9F7D^ul_Zt&fn+lVoia?pikhd{7Bq0j`M=fkv-DtG zS3s1Yj1SQ<3=tVDS1y-YJ23wdOw?9xn91ro5E>iuA;la)v@Vpmx!Dfsy+y$vz#Hln zrS=SK%+UI+U{AM1ofkGjaz`xEBVo+z;H#ABns0fM%!Xa+Fn+ktXyQjTR}Q={Qfh%U zLwP^!GwSBJt*J&lBs$jY^`i;6Y(@O#K0~6lcMA$GK%*50r|(@Fd&%oC+47N25oIB% za#(ksOpx(eS3YM6M<1`iJxZq$5=TNy2kij?s^8J+{Wpu0n_adAZWJMUUzR@3X|E6w=lzu})?{%g&kq`u$27MVXQXr!=`O@+AH{xU#Xtw*c(9~Gg!jvx%f3T7p#$K~l z-qyK2Yqxh%$NdmdC4T!t42xGL5P@BYhhvQW(ay$X`HRm=i^1LO(Y)gNqY-25+P)&x zOsReQ@#4Z%Ksr|sq5V$0JCVcl2e1a?kIv3~Mn8Hx-WP?U5m_%LI@7+XAAkl-pu2WQ zR|S-s!GV$z$V}b+YLy_+p?vGYgg8`>S#pJht`Dd;;!&L$ccDOj|J*D_v_uxI7B*9N zU)cUELQ#>jIx5f#($7CAtiq`j)afYt9EHaDG!YPM5dQv*I*jt)53__}WIdMZFmW>W z%TCGr{1RX)&Z`KrSsH~ccHgC>gJ*SQB0V1VgFUPdI|ZM+$Tnqo#zzEeh7)bYn+!O}iCdWS)uh^9oMz3h|J9EZ1xk*( zh6?m_Wt*h@Cx=zL?FeqET8#x3?rfh9>JYsm55gIW~6;KkEN zhT!!fjEmwTpWbOSGX#W!%k9ZfRRBrK=YVg);RvlXvYqyy?SBY@6TS*Y0vdG%%TiGS zUUcA4&!MKx-(d$Q=*Q#Lpml9B z3}^0RA>0?~Td|$UNv7-~*yseY0A&58FKpSPR-b&i>K{83V0U-(faLyF7(r^dtm!(N?$HP%&v z=~6;XsET|$s2%8!0^9v5X(YuWjNH@q67GQ1G}O4G4$b;|SeBYLlJ+CN z?>c4)Dj~9aW3ayml5R7+(scu;-IY^f%{J$fusu)9UQA9c z!L4^Oh!zYA@+)VVRk1$^!DGQAwJJjaCc|yjFS&#n=V2 z22gyg>0xcu-5Pl$&*gh7Ii$X|SK^C$Y5lTR|4WG^IJocRIP_bjOy{$Qr{R3WCiB5F!jZLeg9$?`3O}s7bwDJ!of>y{&19V<3^C&_paGk+OCz z#c>&GzWm0}@YS|n7)IH#U`LQ3vpLVk%;cZ+4q77H%KY)3i_OgDlc0ndKG0W{a)3YE zJ?#tk&CQLRoG4WSVlU*?%H$z|h6zh<9hM{M-mQqNI6Z{E{+?4;0|*aq?h}`->m_vz zZ&SrM_>Z?_wwW`{kkC*eG3tplpV6yc2~e*r`Kmtx{3lz?EMuXJuvFWwKeM#CfRh3L ziMvy0MUmb2RcFZA)z5NHPoFive<8~l{p$I1`m}-mmp3vpvi`VN&DH?Q905 z~HC*0ae47vi4Wh?T%qg(@6S=~M01~}4@k%RQli^dev8j-& zhI`94y|_M{Rk}7Bj!>f&3xvhGyRnq4udi?K=y;!%mBr4+C)6j3i-&jbq)+>JySNFI z5;QOcf&~+3Xyi-3T$Bd@NvMnGEu11?e1WHvgd&nG#Ihm!{p+2iByY5DQi)Ybb1|jl zpiw5&cC9#0=~sayv82QIP7zBt6s{fg@j{#*~#PwYLog zDG+Y`&gm#-O))P!_|q=c(Jwra@6hwB+TyjhbwtWyo8}J|E(yixotpMg=&*_|XYaZT zgHbf}vrrgll(XTBDtuyg#!mh7PJjBuj*KkC(&HU#`eBe)8;;LlQTcHdmz9+XMf?F# zViIx?8C^?yT};-m!XLafG<7}{n(MK?+7l&)mmP7{l*RxR! zVTOqavCWnys&ty~P+F2sR7zeQ$A`ZM7PLd7lulqDf-8*?@JPopJ*d#l#|mOVdcr8Y z?aoK3{%JSO84{|c4c4c>*iRii8N~|8#|qw}BA#bPIXv&4i0SNqnnS9k4K0sP#xudq?l^#Q;hQ|thgU0pz?m; zaUE2s!P;G5!JmG6ew;-dM-ciUgHBc=uR(c%y0+?#P^biLY;4@!-7O%~Wncm6)&ewA zZoos|sJ<}g#`1Mi8cI^V>`^k&$i>?~JF|ItvV=OY2pETnhlZ3+@}BmT1uLBsB01i> z6(Bk8H%0K;A|hfkdk`wzB|D7E z!f8%AG4#bsX!ylS==T#PK}q+Ifz|>xW4^|nDCHVr+pl5> zv=IkB)03&2Y2b-(xpd?2P5*Qk%#FT#?0Pv{w-!?MVExHLz-tn%f_Df1OIVzHj8zni zuJ!}k{@yztw1eS+6KurHM+hRj~+^wd`4OAAj6qg$sY>6d3~o{X+R@N0HE zs4tz2ec1T|O$KniUGnVGZxKA&24*F%?!eIU$Mnc+wKEf*}-*v}bFJZir@K?HHpq z0WQCF46#UlYf3(*<;HWF*;^oFm#?FPxJ2uaatc}K(o(hPr_l9*ZNpte&xAh4HN)Oy zdvc0l$UpA7KMK_A9jYo*wg}zutK0{z{Lx+=y3nrsO|}w(NA9obQG%0fUURqn2x%I_ zD^q-WKukRXfkenD(FVjf$#}V3O3`{M{iNV4DA7zlK`EGfTzzUYFbE37T1r+rqTT%g z3^uA%sT5u3ZRn#qtL>a-$|;P^YV+u9YHi$c5^=MhiqpUOp@0LbI#erOHdCbDRdG<< zZF}T*mW^J`XRp7J8Gap~f?MZ|N^Nv(E!P=`uj#_QHUqQ0YAKhNnNeQx<9_^JQa8!u z-Z#9?dvR&=pduITgy2V`EfAV1$iOXeg$elm>Z-kPq+!DFt%b}*w%?Cv!AD*gA2;?J?Q-ebXYUXH|m zVerc#^T}{Y@Z8h;rAK8G6+^-@j`_%0?Y0ilIV+mv35sS(5vKsfyzDKA9Bg=N}zp6rCtRGOOjyeiW}o$3}n^c_nxk#?=>>o&}OI25|= z7;B)6LGM|onun~9PBo1NyT}++NTnWL$bVLjC0J{U7X}{vG64E6lRxZyKQ8$f!*PpF zmM^m7K{B6U;y=zp(r%}2dJv3_h*EnD{Y(a1vEZ(p+Dnn&d^t?NyhccK8Yz2UTqa*; zR$7>w-N;^Q$)mr(0S-!`7PmadPZL5%0PyJq(muOPVL$IOyY(Y32&30x0=Wx;SxKEk zLq4*ih_A@CR&?Sk%~U7_K912ocq)0zP-vyR+45q*KNBfGAIiJ_rl`wf(gda!cARGE-U4B9oC(&R;sMz$IP| z5;=smKmM~{2CwwqBuXDW$v#a$i_3eY^DYr0B1D+-<}uN99z2sG!N@DqyI3j|f>P1d zOPE7a(3B*M)1c4KfCoL_k$j*y@J^|SSQPQH?Nv}Xpz6O!F(+8-YN}8N51V?Y4@^j? zpq`BQwC6`mVI${9(`Yi7ARwH6YamB#VNwz&ql?PTd8ye5C_RizN*97@77wC-{ zl**~`xdTY_$#Rwxc$Z#CMvkZY!$vP5Yam_B0ICvj$GG1;NL(#&S`sPk9ZZm|Tg+?$ zZud9W`yXDmAhW4*w01gT3HvM+i3<5(-i+SkUYh@w7l6+!D<(J<#QMBx4v#0F!LE{(hG0?bZf7G z0`olPOLyOReZzSnB-_c!LcIT00wc)chZ>+Qg-&yrx+qe#z2e)V&c7OiC0&$IMaU5cBIu$!qA@E z(Nri&6XKE}Z}lR8B^DF1kOK~u47{56l~cHr%K8lF2C@rR8l5?`AwQv1h6%ZuIH{Hk zxxMmbPDJOe$f=aW13h><)*gXK@(Uo1A(e$aOR(K;9Mk&W(c_eSvMSkTF_I4EM^e^b~4&F%|hB@{@oen`A@+tWo7gT&9mudks0x zQ>j0@5Clb7_+e6M%r3hSG*`if6)ua=W<1`X+|eoS{c-U^I-ezH6Zn4J`8=D6RqubO zGImBEzMM4`#SOVuW zeUF)q(a#v?l0oZxsuU=`qMY-lii4Lz=n?V6FKDk452IJS5kEFoZleN-^ z{shU0o8ySncW(!8zzW*ZYgKJRpu*-J(8>u!B+^OSUnocdg7J|=e-nx49OHaEsdECN zf2~L`OM+ew{(wR4pQUR2XQ@i(wgY?(>huf~TwFoeIyhPLFjT~ydnfMkqDg$*iN$6V zuH|}JYS1r2+jBoYGrcOB)22?t&)<8KBhT(4bbga9#0)-ine{tM_t2L9$n~5?$G|8p5M4#VkVN2ONA~_*_RIgjuV=@iM(AYz zu?qza5w^n-C5I`I{NJo|GI&SSS}RAw$e6vwBXw$rm{#sarwF3e2GgjZDdZ+r`^2>s z<&EvVr8uQ;c@1Os!w2spLh!r*4UVw$x0kXW&zDMbxD~7#+6q`Y4$qDks}S+Se8^k` z6}Sw@)4^9=`SQ--gtbmt8Nty6>?p$m=N^=0tFfuvu$b*JqjIqxMTi zXVYTiKgY~y~T8mmiO>x9s=+A;gF(?bzj?V0pi z6^s6FLE(S68TJsk{AZi(P*m0O1yB2;z2OXSI8;iN@T)bcw>=F4s5l5(+xg_v`Yy#b z9t!q25U|KB`mtA0@(3E25y8hte}!mL+>aQhsh!9fJcxNUU-v6V@x?GgJw3C}R zpoJn1ZsxNLZ|C<^neLHf#E9CyrD$OgHy=t!Sz{$t$=RASJ&bsSf?w|BNUqe6K^%M; zN#l?$Fg?Gz5=mpX^iQ?@0QSDlD&$_!j>{$;*`$rD0Yt1M==)3t^KqsEzmzEbyKCcc zvX7a5p&G^`!TS>?Q2vlyDJ3d&@PUavxqXrc3#3jharQFtbKWFW+;(~3mil%3Ct=>h zcc)ZWZi?rkg+FK0SWJxfJfFD8W*jG%^B=X%^LbzAJRLNio*T;p5ko|p83YzX*aRK5 zsA*#)B}Qbs+9upAVg^XJTJuH`$maXb7Yn|LhA9=HRsV9jN(fb7xcxQenFqZ}MOF(m zJtve9<@oDnvIV#wOU`olHxAUQdd@zKY2V;mGh-m_*vJ(S0Sh;MB&cq-(E1Ur)#cG# z#Jkz=&-%$N7?IzI73gRD#{TDih_29zO>{v;t8P*e7@fI5sSD6N9)TLHura`mUXdVX zQy^ccK$ex4Yc^e^_RAzjjs>5AVeQ-?tCNx2dga|{W?u;1dDiA0mkvdj$etQV05of5 zfK`|$fw#`lO}93RdwCOGrO;BKNL}9v@M_!G@t1Y#^VzxEUvln$rvWPoU+v(()rDqMp zq>B;#tMqfswh`@MD=^Yd6}s7S9gG#zEYA|50B9(-O(yDpJTzg)fk-MU$Etbbtd*{uA1U3%7m@Ir+CXO z92K9`PWg*Djo;u2c3oOPF4PvbNscbY_xJqr6>}WFtPQk9;u3p{b_QVETl5j;UumSC z0mvLaZ*;v&YB=a-PM9cJJ`aCY{~Yd&-LinI1n3`*=97w_-%3{ft5XR+Y=f5IvSPK? z?C5&UJ_S#k5RVQEMCHowRk~rPHhJ@VbZzkw?ZT5q6LZ#QCL^3Wlqn>o5T zk68oY9A9UE({AC}`bM^361|du!~+j)<=5HoA6IowE!W!j4AYD0Eq>Dv2|i;U6i@#3 z9-Vo?;^BNgMh$m>+`KkFMxk}KV!L;~uOmmI5z_D*?SJ}<1(7>JhOl4*e*@*Lv01H1 ze7v*rICVTxb;^H-}_}XOt`3$n++I$?wTGf{D%T?i~ zOsGz)|K>#QtMMt{yX^WI_IGWIrqscqAeDN;N7$@4_-u&@`=<7W5q@mlK1v?Tpb=S?Y8D=J1@hnc}5UJmJikiGUv&GUK^yWs}S2&zrA$nP= z6tcBF6PH2}40#p1qh#djuj&SeDmA7Lm$K$}_f&MJ$Vf=zkNyMn#Dgk>@#8rBhc1XiAg-I0W1{l+f$meyK@c9ReDfr zrLh!xO3CkMu>;}dK6%ovOjt(Ny-hR-cnT@4&LR1)FN*66HL#Hs62KkIgU4x!#2?Si zy-T1ul*5TvT|Lj_dF1If>9+ChOpLm(G9Pj4k$ zn9l3${o{Om%l%z}l(RCqG4Agvmp%+6B%~Id**DyU&Ioz#^-kdGhN|$noS3ufidyZ zjxwBin@2AD$1+Ys4vqFw5P^`>ZY0$J84Q#U4>8C^lXDi2Cw6dTV1Ha6v+>MVT>LSf zaJ>otB&PQ}CuKqD>ABy6S1>ozLklabC7*eL84YIqXJ)h=auq-JW#~8C4bJ_d2K>J< zV*Y@H^65`sR7kCvU%(E6m`ar?z{&J6Y8{gNAp*sl%C=cu5xf!@#TP1h!PDr{%e*<3 z4(!{NmtIxa-&?Nwu-#xkmP7|b6h|i2%VA-mYvahae4L<#N^2sp+RAixF|iRRtG|AX z=f`fTpS6|aOPMyl|EV#jG#ily=(7y&m}9nx4fiFsfp=^fUrlS>?=o26c$oBoWhHlIja0K_`T8KUT##6 z-lTTYm>gClo?>U8ct{Y!=IQ&N96(}t2o_68rAGs}WRe-9c_N$D$}oO@Y&g&d31v8) z+x&bzh)eO}aEPJCWQKO+YMGRnIQtd`pwK@fo~)bQ>_e7ZyUSyojUDsyZ?dD~-_{b_ zfgoVR-inbm#!=8P=xXczNNADx%6jMeG*6G^*uD+jvnLy(U{0qhMD+Aty7E{Vdsnwqc$8XWMB2i++r^?xph@?V$R8%*%4s10OXiH!+9uPOV&CXiDZFDK)0 zQv%}U)oV*=G@I=x>D5wTL(tXa4mK7kP_ ztgvsUJHE|B9qK<MTy?wBZjOMbNhz^YyFL z6c&MKop;-yLM$7mIEr*wM8q}%K*ZU!zJNIUGY0L#KQnCFH~mo2kf6+`krQBewjM;- z9gL$mjN0pi&h=ii>+hPrkH zHkTqY`NtHgPp3WV+D5XyB1s*(t}&uhr8q$#V6ch)NsKksw$$nhQP60A_$a$1;NLqT z9=rg=YZ@|RuYZ`3UdC_;J>FaN^L0XvazXS(xvvq{eEEAGXm0H*uq}0?-lhpwPcePn>Ph zHG`hl6h4?VOQKp9e-b~K8a|44xWEQ38b;3JULr>X%H=ebdh$p7WhYUfAP=pcw(RYh zP_CTUzXMKrs1u+oD=QOYj|AzHfC{a``I9MmMC{9;bSM~HqaD(qwmX?-WGAlJ6_ZR9fZ*-G`n{dSJ zBo1O;mVv5;I478*L}G(c}4 zhmVD2`ZgVJobdNaOk;yq6ez$i=XGQ>9vl&ENWF15Z=@t9<;XlOos>HQhQq|4;ASA}8_G&1MIPQG8Ikv%dqGviPv3p)3*R+q% z?`0t|V?@y_3{0KHo>{fFNFyfBacuLSt>=l@SWFyP;PaqE6Mo+F;vwt^QRq(!eSKQ8dEt|#hAfrh^Sg5c0MkmE-b6F# zw9=k?4#75PMmD=%60@_T10+)!{}n++MI~=F5g=>HfhMD+*SD#Q^|qFX9I#6)HF1VLy}``0Zl5e z&|LkG+Wsq{tLVu8$n3v=0r$SB|F2&E|L_BYRRi>%N|gBiynY=QTuh!)AMk^CMZa&e z{Uag&JZ(#%~5x-zf<9Oy1bSg^5gs{JB%0m#WlhGP)(V%d+ccV?b56DeM1nO)3 zXJp^%pi4Q4t`AS7%;82qwU%Oj*Wm)Qm)#XQ9Ivj>ol$e3cEUK!AL-6O%=U7n)S)0#1~?jYhOK`UmphIj$?4!R~GztVFQZ;!6}zu&I> zNK9_5R^SVAw-vZvTi z&)*i7mPmMbmVlfD@$9Me&fIChQFfHGKs@ldx!?uiotz+UN^)0!)4|h z+0M?+D&@8XOoS~!>`#?@-5jOlvbx(iIEa{-6l^Qs=!S!ZPsUNmRw)mghl5^h4H$5> zR-X};fML@8NExNa$5Z29 zcHwQ+H1PRfT?{%C#FBYhXe7uRs}CQp5A&!h?Y0Mr03DI2dMf7BQVpyk$ZVOGaECA0 z`oV!2u+CM7=~}&;vvcR=a#_CnEQS=lBi>Fh{SnTj>Dro|u(*q_W`9y0 zW~%2a3SUHOlo!92Knqn{j%3JPi3;nD)LvkUY?I!~Xz3Xbgjo6VdRGvW%b6}v?!D*g z^$Mt0z=s>!OvY^W4*gjcqy1SZ`m2Yygd|G{d&diN}6Fb^qaas&f17&q# ze;=xSZ)SkJf;u5Dsh{vR``&mC%0i7fv#o~ zI=r9J=Wgx3X$^4Bh6DjC^2UEf+}pF=ciL#;SQ6)bHnv{KN5D%x=%LzReiV)Q9ZfQFfi zh`6}nB;t`jfR-GTI<3vQ@hhYT?l_Aru9rJ`m7Dv&nfYM!`Xcctl?o8eW=c${$bb#Z zR_!nba0g%Y;qe9wpge$IrvK{y&qn`cJVE?}P3Qr90z9IKtMl4{} zA&--gZ!mRc^r~wcYia^gSp1N#oYH;+5$ypJ%ZkqvmKZ;1oy!&w?8Z;$K zhPGxT!Gm;X8^XkplPOY#Iai>=p?}#j;9TD}57*iW3O~uirJ3HmBwJ9#`KC1)^l3Gw zY>%F9cKfhWZ3hGV1O!+GH~u{&w1;l@FdElgiSVlF}NxL zOJ=J@30>BTDrC7OBu%fr3#7oPbh<#bs7Hh0djcxjyV%*%k;~41)2Q69(;mLhO=iAj zwX4C8P>1=dXOXX8-{eL8^#n?9jT3Yp*c3 zI~YUr4+Y520Q5|Bu;p|FM<1!uvY1n4?p3d1;rCu=I`HDk>8K%YVOh-0|Bk-Pf8C&x zuM?_lhFS8XQ83?!)**7;ySeLN8#~d5-xvXLi?_t}E;LtGI#^}*TJn{@-+3r&giJ2p z5>7A28{|5Bw2HWkrFY-7bWpAoaV)4hiF(b3ny{?VOsQn_-tapA#Qx)GsVrboSegd%NT3;lCf zRS@J&c08a$!d>qm#5u{~E!g1u%_+_}S*H}DzhkpKKKbftPs_;}QDuiK&WdE}1a=gE z5i~5ghs|OH;*0%7!bCQsF`PCke<8T$5fwT_jwYGN`dw*3`hnucdC9Lu&%y)m@%^Ew z!9-X{{z^#uD70=29S#AXZjSEDe+i2``DpOmAvj_ZR03`)BnmtQTOt>A)vP8F#4X>U z61bFOEJLYOsXwyqnAyi*sk~+p_XGXSA4x0Iq|ey`mM_`gn!W+^sY3O`uUr87S^Q)) z&25d&J=J&d_yDt$F0@YXIrd9#Bg~DI!PY0byxcl=|K@m6u2AXJgIPi1xi)@fs3=ZI z&&shuGh^dX-IZCQkcURL*NJ`53b3)j{RN`Xur~qv#Gnzyt`&GmLxJ# zIttm}W80_y^7;`f^CJa!2coR|J0Rm;d@AYk%$}xi7b>-0k!6i{9U5CYBeIN4QJpw)dQzQ^Hbs{ze+Hqe}%AG_A}xBY#ghMwpq zVEi>_bgsI9Z5`ptL6&p9X!cOP#m#YuraG0)d?SkgrK0(dI3RXodE2%P8z(FNCx$+a^>}fa)nH6&@(7uTEY(rO+(k0BdumI)55m*yBYR zv)oa1kc|D7MXJEXr<2XQIWi*JmP!9(C4P0B4457-N~7M+q}AuRo;U74U8vU8Y`_jT zrV@2$ra`4tN51GnIe&&`bCbafbnA@_XIHPHiNk=z5*`A&nt>B$Ro(ZaVcWtJa76EM z+|ZhlH+^9d1++vgELjtx4=+k<@6w!AGH+f3Ss`*5OZB7P(R^z1nYirFx-`2I)F^;+ zMuT~i&#pDQozfzhe$!F7>yPR>wN-Lz*n_<6?PpZ(mcPk5Bd~`>wT~W*D&X59XjT8(NF`_lJ^@ClBB_oj4vf*ArXzZBM(&OIB=PcgRNr5O7q2em6KK*Bzo~UspnY zY(SNS7iljQ6jpOWF;W9xQ1nKiU@z?rG;pR1^9T-{wzRQY<~eFagY&e2l%d!11x2zl z8LL1=c{8@-Tl#V38l(|`RypvcUuu|TGnE918gOM2($?c1jMjh9`yz`@L$*4>t&dta z2lreT*Xi2W35P7fQtUq?dE+sbLwIq|tpHzi)yTv})NijUek*7x4>-OtmwI6ES}1gl z!ztVlOv17ghd8dCJu9s4&2Zrjs}7IHHp@o2Xmva>cgT}SoUczXr)uBPzp`O!HFI^k zcgl3T-1L5{6^-Lz{LV}adR*8Blj%5A`C#+I6ly=r_kTbvn{9u!SHM&ql~y_1!Y|V} zMo$GO8D^}D1nbC|2%a^22)r95hJi2M=)4vM>s|wOt0_qR$W0;jnL|Y zs8C8dWGLD%gX}{zqgLKcM06KW!5E1x8U0Tk4)RfiE9jDgm(OAYo+)+;{7#}kD*Lt1khACU&BOo9s0rFNX7i&fRz~N|fukwK6MQwS7017S8Y^Zwso&*}z z4FFGKG8+PSO7ry(sCsj%yixDJL%z1h`2YUGzmDm@pE1(-&wsR_xOI#0h|NuM4jqPv zg+cdhnzU@A8HwdB$PoAejW=C@ZV)UzqC{7=zZ?wnw~QihlU^g=wBAVPe=gEuwD3(U zndR9UxBmPCR|6ZgvQ-2hXq$jh5Ugh0!xeF2IBpn>qgP-2=y$q+cp@w-ZaNUB-yK(N z2y4A4cv~|8at)3Iuus{{%vE7_dHMDAhNQjP1%9g(Uf{+7xoQ{8eUCJr;(!jK?9)T= z`J-Ed_bfv{M&&B*Y&ew7VDg&3{~B@ZukSo-a4^gZ$)vXPIbeN2v?QGe49BX+SGDY` z%-03_ohJpU6nE@~FHyZEVAYJZicCvd{Aet<{)Fkk9I-OiHWmhwtJcx=<2X)+a8Jw6 z@ZR?Pd&s~3)9gCR{}lzDx&1#-P%cBY<^KwNwBm*Lg*_@QI&H$W2;Nhunv+^DCw*Me zIpG!p==CF3oYvJ0Pm3pHSl^YlPrTp8b<}<2TXOH4 z9}PxA08^P0s2WT%g-oF6nBBaLNFD0kx-N771zAVP;gZ0{A~b4fq) zmfdTAbIe&!X3yf4Fr)2>f1hH}^xyDP*nieb44`jhPk@zc4$p z9aCtkKciX6xV~$!1IJ^ZFX_~LU#+^m-P~F4i{L732*r*etKGI2;REz; zU03x?Z8!_C%ikVFn{*Rp-<@cmb*yML*{)sDEnTEU%4*^3_Z2Xl9nbV78m%yFya<*o z+JcUky9zwV&lKCdfUw*Wbmzse(UDmvy$sTZ-?2bSw-NYat0Z;~$1V~jmEymo&2CCa zF#SA%ov~`96jdt12<(${yXq-`x4kpoD(5V#L48w0NJdm#-Mydjv~s}@x{(^B;Bt|J zC#y&vNA~rB`5cf^NE@1w#RvPT3}ulrpBP0td;Q_O%jBbM4jKnuFWeS1gyXc$y5C`A zeJtMDG@D!fkL&MfQ+MGwY+)oR7}}@fV{sVUqrcE*O>XQfT4r;9n@Hw>0==S|Nr)$k zNO4%mcPWy-YE?RiQ9jH)o;)B7e`R`kW(BXzOK}(j{4;kwaD|q?1QF8t0&W#F%Jbey zC>Mp>1=y$UO48?AhTl$DVlg0d=gaiTKRTURsWPtj^&o~}?pOEj#gWQFT393slogbI zMhQ>QSIHbaN-pb7hqY+B4aJ)!JIBzQN@Y!cmJbJ^CX>xITmp9X=??+#R0fGzN54m4 zr|(FFU`Bn`$82mM``LgzG`XfB_3TK!6K>|?F={5)2_FIex5%q3bq8A% z+LRd_?vmN&5S6uNEMYd)ty%>^%R}G6%*ghI;+@o-L^mSugi21d{J!5Q((BQSpk450S#2*k*mK-J zdi--S=g&ar3QJ>VTQF3>aDG0>>UTuf7RVFxTd+=WDXa7!f59pZr0=>nnKV<>IW65c z(a(gj@^nr%W}R5>S}|=I8*6!IF(pyJ>bkB{jM8h>5L4jEyqL(q%(L|E{_vzDHy7hz zQ4N}`QoL3Cp68~3_dNEODoV(Fh!>e%M^=x;k|c6FrCgabO+4bu+%KYgxxh-!8Y`5t zE%V5mni4vr&r~$-Sz7ZHb4=bJt;n>J-((ggOmr7fIWHoXPepeQe|O;K=Xg|t`P~}S zF>Vs)Z>|^tMEmq^zLZ-&o-11hQgR2{J1)D<{=h#nM*$4#r@!ug#hPsdUoc<6rGPgr zvmVIq*CtxGgWqq?MSKmZISyBo2G_-}dXe1|9g@s$MA{q*VK6!8RB(8WQARqFy2qf` zsA@b6Lmfs>La~vQMHj=M3zO$?96n&YVa!VC(1*zS;PUQ;D_8KjmEYjt=jmDDq;v`H zJa(zqMTg?11ro$rTb}fo@d?(J8PB`T{O3RdcO{{zNLv%ta+XBWp^QBS=^)izS4iqb zFcOLv-z>UIBHbZWhhrYB-lEb&@1R_72SKV_kbo}{eW3~7+4jpzL;!ckO5j#pPIFUuHv zIX=hDsn4$khnX}&v)$1%d`edd!K$_FJ1X&;OzQ-HZ8xe1tqP*t&1r+jT?i{LJg07 zcSdieOe1)vk9ccKf%YTf`#Nwqy?N1iK?eI~V?(SrA3*n;&guIRq-~9BFYsQJJaB3T ze=$_+*3jlrpRy5M_ScVQ!Y^L4Fw>}6b4{iU#B@E;>N!pj45;pW64|(5MJj^wxdL}N z;y?+X2=B_x68Ol>E8+60kQ45zqHw*#XWQcoeTRw`e`$?T!K8BfFUny(5j3hcJPTaYU)XnY~PmvQQ|Vi4u}P@_a~7y{GOqFJcxE?1N-Ka{}J%&z5zMlKYx3ol_J zwQssc&Lg7x6uufp?~400+XWlT<_ZicB-7JHS}q5;Gjn(_{i2CwHqYcpg8bRoMSm!Yif(9dy5b<;*S z5cHj!soT=EdeC+;Lf6ug-B#HOp5Fp``*s_6PME5=i|kwo=I9FMSgncBlQ=l5CCm7p znNpE_T&b4I>pIHsWn62CEyCG^d?=mZb8(_z4*N8$=BPkXOpXDeb=G{B+0GvU$=CN2xg<4iz!*R&i9anl# z%M@ZyNFgDxts7T5Vfj3Pg`1xrM6e0O)N^?k;=xBOYGI8Et~(a!-rHEtzjsu?Lz$F{ znMJx`=EdiS{U?T~itr;YwQ~={CAw~JcjcYy0WNLwIbABMOud2V@kdB+YfT?LHbqP_ z;o}fN@AAI#%#Rw-lwArI+-y7$&k+$cf$OgJL;tsstxt~!i{zhvh3$duIBC8f8r#Uk zM!ThK@;)2Au^KX9C$12}Q7hX8bt3v#=leywHPT=|=3Vth>m;rl7Q6?lqVD7~<;FuX ztN8hoTOu0XLShL zfR!tY|55KP+p_#~_50*{7mkqt%C#>!Bw`~Ofg@Ha^}Hh@M5U`$wp8r7Q;CWEnM0p6 z^7?gUGzSb5J#UFEEwVK>q<$%+Y>&oM(qvhtF(baDNeg3{MV0j=ws)G$XQ>>FdWRX$ z!xK&X=KPDcxTzsf=@sGe$)GzUor?`WQwMcYDvp4XK`)#~mZ@Gd_i?w8yqW8QQcmMI zKLsjfzx=48hNn=W>k3e^s$}xF=>5Kmz7}PgW-Ck|lxHGePkB}E^uiOHFMh=_vU!2> zUSpPcpbS+qt;zKp|?>P-ENjo=v z?^B8c2`3SDuhX!A*MgAC#npVns3#ehAdOZmJH|^#Xi5@$Fk%!FwXXRMEki~fg7l>I z_NAyq+QzLOw<8%T*Q}_QnnI zngwEI!4MVwgs3)O!h2*{ELt5gtN$t9kb7lAN%KuInOVIC zH?`X=DUv6NVk$YUb5^hZS@Pp~?<~E@N?mPpyc4$BnlI6>c~fOTm>C)~lo*jeRW~jD z;IwS8YcE97ZzV2eMOS3vKsFZJ_}%h_(Xl6ezy#gWn6&Hi^ZDI=#5Pj3>hjI*U>7?UB;6O!aqoK)foC3mSACk_=UtWL=W)UMfaLeIUR&!F% zSw`DYp-EH5YtS@K#cEBpL@N!TZ?7W?njF61tkn{VfHs?nrN$izanQ4_C2rpun3RySEO>->IVnF7hs z1%0(s#m)}K2jE=u0X(7%VG=MQH(?t|is->-LPrl<;l%Oob-@u{jwkFk_gDA}*~x1A z^GUqxF%zPc#h&k7_r?lcY(@Ovc0JRLk2eHU`Ey8Yn9F;sgkuK_{1rvcmkHV3Uc)xi zcE?{*25X2r!MVJVLrO$h$jwY1p{0~34ikfbasQ(27?rUCdyKI&>mtXO~vwlt*7rCOL z*mZc_#q=rh38#2|1p)J$6KTNXEOLcj+IL8 z)P7)mgQdQzAIzy5WtsjT`9>ntAGu*wj6omzgHe>Z_UrQ|+!W*w$i)w-UOErC1iD_) zi8CIqAw7EkGZHZ`ZCKDdgsyrYoQ`?s1lX}L-BPp3sG69*0SjgGA#H!Z6eVy|!cZ3} zc30;0frh%dh4sn*+_OsZ-3=ECBT0~TBM!Mq$(BM*G=N}HwGj0HKrubEZ z{{&ueFr;HuL+I3c>P#_rD5H=$ttW2YHhUv$*{yzn_s^I1*19OxdUxiV<9R}`o-b6X zVO2?2Aa=f&+_h&uI0G}e*Wu;)OuB^g3%{6iH|Wou>yT#uc~ArOOJspWY%xb_LI{nN zBYAknKed7z=1j5=`crMBIY1C*B{p&;2|?yIF+Nj=!Co^kF7^-p^=9r!t%`E+wafUm z3~>3|OlQm21g@`#c74iQ((%Rh3aq?%#jveq2FD*xyY6Kw3F>mV0w4D_>%LZOPUYOV zH!rxdpEE!73+(9OIG@7$%(<|qo%2MDa8@uB;$zkoQb+o=!l5Ful?V~R`e%c4Z4gX* zPG0;aI483msT5(_?jT~-J4ENlkk2Jr&O)OVJP|F7MDk{Tp6mi)5)O0P+FWbujFGxE zn!|xXH8A3@8g+E~hI>C>FFkk3p^K*V_myb(I^yMW8)6%3#$bh>Q0iMLBFQ;k2y^Fp zxTxf(z?U3K4T=m`F}aMm2q|4W0%Kj7yxs>$qdT5>{@ygziE)JsH8(Wa?P z%x}t8jA1~^7>*ZsT-%?r(7Vlrr_K$NNeo$|HkU7v#Fw>9oahbzkv`U%G34*9!c8Ll z5tKqk2d-Gn+tBpV(-g_L|7x_PuRy%;bSB?bJE=)`p68_-W^;oJ8;-sLZ42NV**xIr z4_Aa>n>T<|I++nHnjH}KL~v7zQdm4IG%#C$EljG&5@5I@#OU%Kt@q(xt-n9*K(^K= za*O~!XYt6$N2w|)d0rF`Z2IzSi6sAP9!sQDHc6$@!S33JStg&+b@0{#(|4nOMbIps zzu4qS#k>C6E-Vma?v7Lw&gy4paFuj~PM<_=DUJy(3+Y$Ky&X4BSlPbx#wT39>H>e~ zdYu1)XgYAvGi2m01(NdzTpe$zul!Mq9G)5fm-IgrH1?=QmunRGR(^CvG`W+!>A|3KoD@5v7qvt>|P0atKH#^Sb3b2yIkFBsa1Wjm|_8FRomu$gNg$93RY4c;Y2N;v$7ysQ+^(!UGipjoH=Gy z{7o2+gRTF4OcuFe@ZEs5TW@nk6Poo;$uhjz^rgPsWtRt=S9s#G7V@Sf1S>sU^*5If z3xirj4OoVczl={yc@FI-B-FyzF7e!yb>H~>tUoetn!HbrwFyT(ovWTWi8cHc2>5<1 z++qy3vOp8?!bMOrN2k5#Cb_36UUTYGZ`NQqY-GluIB?|X{8f!-_pZA-NLS8#H&Abr zxajdW+f1_8TH3~kJCt#jb#r>ZV`b#ZmWqN_+ilfHwP&5LXIXRDc zB|Hs^yWxA9>>-i{YQu!aPw}alhg#$*b1-#A9*rq^`h@j#WDsHkDq(XC+uMqm%U~pI z|IE4v!WX30*5a-t`34eSr|c{s{$%@;`ndTj-1 zuxUN5kD>~c_>ClhzBSja4)AawYgmuRhCW*q9jpa1wjo$WaqW2PP5PvRDafR7FLvN5 zO0#PAiRz6Fi}4!Tcr3B|n#Mun9Rk%9dFfe@ni0zDaTAWhOjc z5H6DKPtnr)9oUr0kn-_9_Y1470E|xtY5@2xmW0@^SEa(SVH0pfYM?AzDw32mMShCHQhP82NLp!N1HNwnf0?@$$!Inovk_oumBu9Wd6ue{l8ppGwv= z|0gG`Ob@4vqGrb(smR%JZ>0j>8}h3+1xI$CnOda30D`WvaDQ0!RSYVrH%gt#fHkQKHR1uuw)Pvcz5y+f^Oys-3YvBc1Qs2g7$t z0Q8yUr?RJFbz(m}IJ*p?Va<@^=`}FCCJ_N7|L~@*VX^Bua6sQDnXws{7pY5z&|vV% zj%s6T*c2F6rYW{PV_<`jVt8T~S?a3(e#VJ$e=QN{hUoh}_5L#nnVM%LdcllG+!G@5C(HG12pecBRPUXCHbVE@(NfW)#B@7L(c6$mySp#$Rm_sB*Lhh| z{Zp^Hx!Wt}Z$rATu6D+6ZfPmxNjhpryGM%G-Z?{Yzi0@rXZX*uA+Z4h!zW|~U09L0 zB$bJDXEhZ|u1YXX%%OSKAc?UN#JoNC4rK-O$d2?os>nFA>dN(Zh65NdpA&IQBIzWP z(6-}#Lq8EdxDV+Z5($fT8JfjA?8IZ!q3WT6ty5~6gBY1?S0bHTeM(l#2u$qtdy?pr zX=%8RIT@flFYRn@KjTd)eKjB?ZjYoynxtX=R;CdtM%xQIRC#j89Y_JVuF@8Si;<=p`(EQ$PKoNrm-s?P zwSuA7F)a|Br*eJstTleEv_S*0Zi-X_gbu3#$Ca&=GyPO1% zrXv1iLwl82qCw?7UIg&tW8bFmk&BZdE*7vm_RsGiyWulPYGo$1*@F@A!%O(`&{Z#h zh|~`i^xn=)FsCtbKn;sFY6gW(0`~K@fKe_|%Qdb{+RJy#9In{o;-=pPZ6WFINXl4D z5eXxqYKaGQ(QE_PeX^B(F@ynAge1lqlUFoqMe=#23~6u2aXhaSYaP}E7gG|+{K5#I zD)0!L2WGr}Q(DH$jU6b}3L-4=VoSbVLZx0`yB{uA2&T5s4h|L@K8s)Ez%oNX8cD%Lv-HI=!>+eiBjBl9W=qV) z5wdRj*xf+MH}~09ULI4@P)1i!e*~GBrHN)}&siUS-+AEcaCY*~CvA&duKl^L$>o z?^{Gv&9gonRwd_@+uygs9`3?aHU*2uhA@I^ z;JRnI1Lkr!{aBF?q-f1{;}_56X6?iZT733jr9 z%pM7$I2_mHBQoM!YUnuk?i3ay0&WP&;zYLpcAore%ysjNME61iTn45TqkMKPOJwtC zE-Hi^Nv`J3dfOLp`L+6?14mzc+oVz%Pb}BfCcM#hmFj1jCN0XMD)#ny1`8bUq==s# zs?T2-+BasJ$AcPgQIWL2G0B0>Otslvgc8>>I=3SVIrd1r*`TI9LF5pW~!xDiyRt29=q6OY);!(E5N7dnY{y0G; zw!c~C2gNfP`3?EoYV$inu21rW;M=~S#HVodbddPPrbEXQQid;4%;6!6zTP78T^O|~ zqvHcVq=P7D^c+a5j*z>dhjt9w4;N5|H)1z4X?A8a_<$=?fuYAaFAx zbn|78C(AI1W-Q+~y%x=nki~6KbB%t1fVhmB^gBq>vB`d?Q#68{Qtr!>9SqDKc1=kVM6$gF{sqU({fh|wbEi>waqKNZk@*($E z460WSv@@%Q?tV44#1n3Gs8KUE-@IX1NEb}Jzy(wFrp^bzqvRMNv#OSTFdqtxe)>IU zYxElwBF;q59J+yW+gH-ls4-;8JpN*=$BgevW+GEhDu)aAunb+PVi@O;X&WsU6c(dQ zLcx7~$uhD?7lDx+mh#ca=UTacK``Pd4~E%c5{c*UNK2wwtV9+FX6CYKfo*-h;y<9j9De`L3B-z5Ou7x?`a8^UNCGIQJ zW`1muk+ieRbqryNvT{sD@qd%yP2?`=R-NZ_%~?w9|DCUZE8x6!#ueq4NA4_aj9HkJE;ad73G|4_Mq8EADnEt!4J|ew$^MFTqRP_UHSS6Y7Uu zaY_=BWmGUO)0#%!3->I@APJ60w*^VBYF~70#F=%9;*}k3)ah)hH3NZ71K;OKN28#v z<^RV*9j?d2N98pPdTKGRp_a2lEy`c_s^?4x==Q5TaC@+ zDSg)JVMbG!qOLSJm!`)E!&WbXjP3Df|zwB! zkazW$FVaYxH+W)S4W&sm(A-{mi8jRdP47qQF8S*b{22t_*{Ue1yC<~@HvpUvD8edl?33FKW{{H0>KOHlsOh{W`^fgMBW(#>p6mv5iK zrc9GqLa z++LwVY_E~xKy#Woi)$|mUN-svK@rL?LcI5^Jglzo-LQ#cg<(1$w=w?kZ!#xqBH%*1}h`fFO#RQ2PDhcSFL2-NpZ1=#J!o%@d z@|!zii?gUcUev05sz0wuoL~ZklIx8W%DOy#M14PwdL(u_KA+mfh&RD$mH*+dIQGv! zyD3`24qnw$aKX3S(k}S-=ZR*Q6O~$DMW#aSr`n(2f7oS;QH6GCc7KEc(xLPS6H?{j z4^=>}^1p|dDa2Z(U_zSJ7w}q)b}4}}q{=x}?MA!AKKVaI|6jwaCW@ll0J#7S z9H2TZDhg^Yd1e=htaHgnJ(RDate5pov0@2M0B)X4>z(ux4TG7~(?3Mo?!+N098$C~ zg$xw+xy{bZ?;Vo`$$pIFRyT&Jz4Nx%SXu|@25+>4;ql`(^Ay}2&6n!o?ct$HOYQA&aEI522gVj>1(;YR@s#+D4^&(iyhnMe-a-W{GJ`ftva}GDi11 zFe*?77u=9{nRORUocATCwHPLlP{#ZX<)&xhBN81 zZ1U&fjqFO@o0~>yiaQShjH%m&J(cK&hh2AoI~fv7fob~%BfO1ap@Xj~e+^7D&~zTL zPpE!H9@HQgjO$jc+TZ`?wHqg=uZm*+*kdWr-HkoUFAt^c6EAgWL-on`z$1H;=>qI2 zm(!rQYdj-Z(+`S$+-QUi=oQNGj0VnMnJR7Sv-2Ppze->(tHfW$}Z$rc^=cO5eXNK>5{a^n(!B>oRZo-~rgUINXBrV*mR zBQ$gue7{a}2Z~RgQ__C{;3A6X=jqHNnt0(+*hU7gifd$hjGM_lNcqQpW|i zO?Dy;_1M^(bL-zOKYoy=yA-X-n_MK_5p)IyHR*B&TysNyFWGDY_Av0xKoJc%UV6I7|Vfu*@#7Sms#BH%FcCjJFGFB%^> zpi-#GsLrGbH$WKI+n94eKR7&SyY;Fej>W8ruCab%as&EuRGBJ>ckL*Sr28y`z+_te z3@Ls;uS@vowbAI0dF6fGgZM?P189dZLaC+=jbcPyBXf*FbR`=w9 zx+Fx?$seAKV2b`mjW>kMf>4T!Hr8k2yhNo-$V!7IQVeqZY4Iyy5>sbeNNswe4?ASc zv$t*ymS)44M(WNg{7%gmow~!mxe2?^%KzJYNxB?OL8U}Drtn%~^POl)2JdB_n7;r~ zn?;m*Is-hMnQuOQp>5?DhjyKxcxdmXu+eQ6+FsV1qA(t^%b0v6v(oec(TTs_y5jAu zqmXJG#TrP4ZO2_$i`jZk(zuW7mY_9|f=R-;Iy94Q0_;P5gZ3%ax=hf?5sKePA^?4% zKa0p-Tk|Y4MR_zWIs7h+CNfSDz_{Y8sQq{PMy9hd4gyhr;j`=~+vhh-hiqpr*KG|q z_o&->L*yR>d;{COrGb6st004vX&%EbAKuz9BM!Hq@a#^4pzeV`40JP6w?eYU%pRO> z&4LBJLoey&rm0?(T#mR9wRY?qXEuj&qe!%|F0qu(&j*H4G5wDd@f_@DRrT#^h!(T^ zw?=L?4lQm;{Ycv0-^bWi2nN6#3fAb~QED2Y^wpVfH`mr9_kvFY?dmGi&KcB_?IPa# zp7L}+94oQ^29YOVDhdqP2}NGI^jQh_e^vF`u>ZgXo+9irsEWlmC#B%yBLFNe@d;g^m(t~EXvQDXX|h8d_#elPN`_v8$1B-!&3 zeJyn#`!d&V&(*4{ObA|eTZcYBJ3Tl)_m4qmH%jwYRF1Lm6J zEsUrtKGNZ!GLwYG#l>+DhfIQgG`k2RCmhV>6Ex@d&VN2O`bAFKd6}`+&ipY!=c3+i0U0y=Kmx&Of7u#2&#K}|t z1v`44PO$y5%aLNLvA(xf>fhM;x$rb~6B-ip<@8;TAa1ZLb?^wZ_Iv}L4Vs+4d_FwR zl0(qlt9G>xh(*>nhU<)aR?R@GF=bs?`xV;5E}fGbg|)+@E*AGwZEBiVNCrLJ69-Xz zPEfxU?;A@d4AVHZaXOgxWxi*cLwfMP(}m)sUrTSZD!fEg9?HWHYjl4Y0P(B?Ug9kv zMPtAShOqO@=;a4gvAmDY!>~hGP7G;Y6g5ukFfRx07|tiq+f{y>01cVE6Ld2ahu=`a zAB1I|)_&CwU*$a(bnrOshI0@P)TpJPd+Zq9sN46r8@&ZXv3h+l=nAn2b1KQ$9TnGu z*nkOYyHA?&{n7K+;F&5x*N2Yx$H)?UbjWeQ2qF2b$dawESwokX2$doIz_osY>UoQt z8hMm6a1Ycv@mf26_Gv=j2qoxy%+U{Ay6E0X-0yvZ3j}N(idN=OB!(@a-0T)wDNO<+I9bp_`Z4xc$KmLxIlaB5i6?gTCdv!*#yH0R^8$ezijBVyZ_<| zIOe7RQdtICaPt2H6C@hx-~!j|fjk{+rjjd@hc{G&K$jHhUm?04V7g`2gi0ao7N!=E zP_lf^&j5-F9!*SfxA1lQ7Ay*|LL3fng0=zdg4BkajG?Y#J8Bd?{T~|}Lk6s0W0 zU=a6>GEG56M3lIGf}_v}6Vv*c-?B8>S~T<77JZPT>*_%xDL?w-Ola8sbdir^?t31u z4}K^fpcwnS24BwBBmX4h>_>$CS!noEotfj7WrJELbH?So+v8JN@?RKnLg@1?zrK^u zsDfW|6GVyKOV2rI_GhW{R*|zI3sNm*8IY=pAQ87A$`wyJv=TQvI@k7k1B0bA9ODZ88nU6+5fwYf|#LVW!;XTv`mk(@YGMb;C^YAcSjz~%9cO2U|+#h^z}04 z&SW&weBZ<&KSd`Qgq34my>$JI>%;NHQlCsti_rHYj4V79>gqtr#WlxJmkDWDYYM)~ zZQPjQd<{NSbT9mUtSnaPVZe(Dbu~EkQOB4n6n4q|kX(5b%1q5CIQe~L5`B(wJu?cG z?!@IKo}xZC_2I4}w#vl(H#u{t@0;sTBqaMIx6@q@rh`%$G4ffI-o(2OW!fl}p>jNg z-$~Dt`2+>@L5G{dET%g;?eSLsF3sfFKiGF??7b^_niV246ejJ8BSyJ!JD=L{|3HR> zrW&nQZY8-J#{-?s9+6ikE$wg~*p>NB9(A7)*Ux z6pF2oNH>s_#c$IW4;F~X%Z2zlcoAGH>hAOA(~Lx0+3JtKDCXRkF9tsgX~jsNez_WK zx#YrGA&P8@zI)HyXtQjR#lyoC*aN>o5d5(DeNwJPpY{U zor@Mdf6QdtJqHgCW1P$`{kiq&sZL-#ahU0>DS!kZo&{T$WANbI%pLlBGvUHD)EoG7e5bL_n`&*tE3>i1e+LXaJm-nT#}W2X zyx^fc4GA;x;tFNe6R8mh_TLPK#IG{pW?08`AI(ryTYV-?l&K%R>PC_+h_Z({FQ zFwhN)Fr@;#UjNoXKmsgr77^<<*)b~EP7VITm10H}JKFFEoMcR@Of?tJC9yj7;mDU@ zMh^I<<$0~6;CYw)DA$Uk=xa_l1~@!MerUO)V0dc9Cun?zACkS1Nz{Od`^bOupDANw`4;n&+@IO^O;`%q%4f>n5D|czC`E(qj zTg9w~-%`-^XxpBKaHg_+W#cmZoPYKg3JzZZn<$uIg6J!5|Gr|4HI;@(Mh2%f{x1A; zWx7z=K5g*FlLvsa2d^S4Hmu^mV5!ph@lSWI#MC#wBF^$iXim3YdnaTy;DCHw`09bf zn;VA>Vv6`SN9=e8bY>AI=D@SpW0ruZRt zMyqv5!d_&zkkH53bE)ivimlZ#+#x@Pl-$HYgv3NZ{sl)gU3FCQEGE>#_ z^@a&|t=4Md=zQyAgXks|v$DUv`!7-)Y-Ji)vaSsRCkc!JF%?VC2Fpkv`l?@|%pwT4N%=^r*#8ZUJa%2aXjEth0d&5j@sQK5ghCWS*78M4` z0pQYq1mgMg)MG+R3`Vp1QvTA}dm_9%%h*wuIUj?2NSK&VBC1PwcSm5gnddH+l6Eb|lK9})s0m1g5gh;O!_ z{2=Krg$$vmN&MrO5t5<~kZaOH0L}w$Tl)j_=5&fGE_Ps;(r&f8Q!sMZKal6;RkPs< z4D9{K`w#7a6M~NhY{Qo}bDb(H+qvG=u=0iX?S5C@W(a3XkPSNVJ5d&nTVA}SqnWDpZxU->2j8Js)!aqC*uA<=ys@7NzB>x6zPRs6ZQXQo5m*oQ+gqEqU8Xo91i2mA zRSsPiQN~a9z%wyD0*rEqRuq<^w#qNBMIceKkAK%A*A*O=PPitV9XHp@B7Uihbj|^N zpzbOE&f3ctUNVb%i8BY0iYSg1_e(Mvo?O?>xAb&=p={EJg=g7|4)-Ng-|4m}Z(g_w+58@n3a_I*9jk2Z zw`yFi>Dt2Ww6goo-+n|PUajJaw76kbr~Hi|3@^uWq4d^q;ZpW0X4YL;&BH}hau~tv zGcAlXx4pE(ay-u!4+dbh(@)y;!Fp@i9_Ni<1MaR0;!p7{fA##7oZ3n4WB>Iw z8UMU$V3Hzb>n7jb$K`Oscm~(VMA1R;#chl49M+(_5uMV($_CblQ~28u6GS4Yn1|Yb zT=*QnI*WN1hP!hSMJox2Ut+i8h@F3Z2SrE2zL4Tz5fJa|1bDk=cRZrx!+q+W*KQT& z77#ph^Z;$jIMy8sg0cofS+?F*vRR!*EZa}c!OyZg%cym41hG=f>^#584^Uiq*pCo> zc&YJj{rJC~+y^-TR^bwPIB|$O)8hUiX@jtIk+s`hGgSd^bji&30k%Q84UwJ{Ns^PnR|xrsmO1p zo86Cy?1Be%H{vbC9bSKbCK9G)#LZI0DwLkv{Lx)6`;`qC^ookox#dnhYqhrTYSTn?q!XzZG9zgb<+c&OPm}TXKZJI9& z#wavhkqij;#g&c zuF2(g*e_saf>1&ASu$&Uu0*&&rXTBm?9^Pq>!ZrG+83r>UM8UW*vsBZZ}t^BbAK-= zQ(s;E_I*r<$59Y+X!ED@jQhT2LNe8dL;`##-j>|pUr+_rf}%EfcG<$vn~3gcKg9?M z?pJ^Q7;;oC69y~}06W!w6n4TYj(e)jch7aa&J!YiN z>Gf*F3gnLv2Sg7hR>(aHMrQb=G%llw&vsN&UM5rNMjsGb9fp{C2npi z@mjppW;e9jmGB*sU^nnz=l8VFO`~AM{rih2%r7TeLnv~) zCt!*HNBL<0&{Y6A`KiLMIT4L0?dkZf^T2^W$rfF;-E})rxUz_ZsEEkhjIRg|V!{

    QP6ycW-=6+jgMVNsKP0Ro!KGHR!} zU4e%XrRi<4?|JtN|8AU`ITTv52~^=7znQ>(-1csa!x8iKp9v_y2uweEskTZIJ{8Um zKQfw^00mAs*t22PNzV<&K9riY-wB{fA5}plphn+_eQzXxd&A&1vn_{;2 zxlK{RMJea<`g5Sj2ldIPBj|rv!&?_mm{f4+{cg}OF}5|&ji(LKt-x|R>CKxSt^ig} z2)N&D+6Kosi%)mjz01`s4K6!%2QJmMnVf_V=A~w;(p1<4C&^NM(PYZoPW1)WY_w;< z@zeR)>gn#P42Q^4R;;#k;?3<)0B%J|YgX%7S%E8M0eOveQp1T>xtgOPuG>;3y9;eI zI7JLzI{fitg_#d_%8V+?jJ8p-OkZa1xUx?vvhd8|jA(SNIP&JnXX)!weN99hV@fW& zX2})3EDfdgSZ~tfB;L_COv#)m?^RLwtvywxPL)?zbNNZNi0zhgDBHku`Qz=dHI|j- ziK8mTD?KsD7Rr|(_|QC6HZ#>1@qS`m>@N#w2&t2zO0;TF9<7kvmZBKYloKynik-w& z{B%{Hy53N$9#?OmNnk0+l_#@(&yiHujdMg$Zgm(hZY7cFSCs74^fQ{^Z<2 zQ&BSY1uoT0S-{0xOX{AzJ`eQtm_(btVxAe;FfTGlYH6<~Y2oCPz%v78a$Krk=Cpql z7uQ4{;JG#L+YufEeW#qGbkRDA<+=Ii)}dCF8{V4Xwor%0goRuc#E><`=7uZ=;4c}v z<+o9rRZ6g32e5M*))rmd8ar`RqjyDW#jUWz0qm13QwrGvK17DH$m`3!bgEBAhidk=F6)E3n>Wl)B($h41v{G3HzDQMynE#g9^SHctQ{BJ z^el^knv1oN(U$aZ)V|-q{-3NGAq_)tj%#?~cxDC601PTkmtlG$VLd9b80KtS48e?w zkTI=vg^MD(^8!2#L&l6Ydkm%ep?>#sy6rXFd=`7nXdaf5VC59NPbi-d$Xv9jqI4G& z^Xhncd?Gq8*&W?a;HH~XGqI?3;0fuIzK@g#%k{CEKwym~_H9KoaU%cw(;%JY`b6Ga z4hfLr7perQvjdGrrknm#pv$wlcHf7&0 z4P73rOHm=7WHk5a`0K%4j9q1EWertpxAYT?9Xw8vlIc;H=Gm0E$NmqYD6Gw4b?E*u zU#;*H_#VJYjaH~>q>Q7No0f`BnRI0>#-Ep5k{}8_-5${()I{7=gLWv_vdR6a1~BvR z(bI+|DMRm5yEP9YeT%F`L8^$|0hO+j5CbuM0>|@_m!rKXtV(~6?C@?QdA2p}^ePci z(Rz_RIoEFyq)eyNOntr@fbR41gInkyWR#)vN=g~7u%!8l=dS&A^*rQ4)9b7NS5z-F zt6=IsQ~p+_dxt zT>JsiZz%AxESsTdt4lsdfTLf(HM0YY%d7yKUb)To$6p2`b|?gbTbH;^lwO3(TM055*S~|j9$Z&ea@c&B=V5Y6C~1Iu(v^H%WA*W^*|wZV-{!&q0!&;uJNIkYll5^S zo4w4E_|`v_wG#|jhoqxMRSya#!WDqB1%|pqoHceL8u4SD@eezZEpmw&v`3%R;11%b z!#e^dgWr}FYFedfb8CO_VcZw|>8Qn4nXi0p6f!BEIVHG6_LRg5qYo_^#OmF@j+g1- z<5FJ&$VYcA+F+^ZZI9OHSswc6JMho@A<)Sj$s9xIOw9NnKqRHpgjEIJMYY8r75p}wK)5W1oxOdc1zOk&y({8MpZ zF!S-Vy2fhM0^;~98s<7DYfF(7kL#w5P;Po8?h^);m*X?|7*U~<$;3DDhV490n;lU9 zV0K1%y;>U1%OaEb{Ym)scTXIw&;H#aedeVu`YBtp8>VRlAMw>HIP9xXoI-OJ^*!tphD@kS|th*L)G#6a^ z)zuEol}PVBbK`#nBkbY-0G4Nc%2_j=obk%b_CC4J@)< z#6%HF%(;->^ChLW-qY^~-fUxuzIPNcNTmc6DO2if*G@4ptZ$Fax^Lq{DAT(b&U_`e z%6FIXoj}#2twi!Men{fx+HEef+SMTBM{5}#HRo>BS!&=Vc3x1BtorLwxuxEY;Iai0 z%xL&_k?n+bt(=BqJ?}U65gG4ve)lq2VFa*5lC<416GAC{6lr1a+z$g*6Q!;^F~~YP z;g`ftr48ma&P6g`d)&ZJh3o!a@OunmRMnj2u2khVy>kb-4Zyfa`rzpib!3^o#IKRI z{=K37nAmo2Nqy84yqK~4KbgzfmCB75`Mdu;Gt+h8T6th*cM5$#G1JnCEv}Q;3 zLmfBw&aFdUze%R6N@Nr9QXeYEc^u7F1!_F*v7HI2;u&~kXqsGA zj`hB{6*PPAwZg^9*4(Kl7|^NQJxgdQTE#^I3JX749io>qKy|52E;ABl*s^QSN724cKk7Y5Vh^8v;>C&=2C9$;Wz#!LI<#-`&i zLyK`hVo~+n==036T)z!imgg6J1nH~lg)0>{ZKEIM0H;}KRPgwd#$019j%$%Fu(sLR z#72W&rC^fD`90HlG@hCyMdbY^eU@2HT#BlZHuxcWiNikkf!VTH?uNMt=e(#*zjr{E z88-LPLRD;4hMfEU`^psLbCUTFJSe!)N*+o0cH!+n-VDi$;4S40A`L~0X!m}6^V&H* zGkIXAPqX&5q@ShUP^7aXes~8PmRfKWHZf6f*|8G2BOV=<1eEToXO2GW$E_94qaFR8hVR-L>Do|@ldCFFVRzuIfO8bPLGCXJZa(os zhkSOD{5kr237-e~nkrPG3(W$W{n#f|6NFlRAZBSLZQmu6xwpvDWR^HtqgrkPaViZJ ztS><{`dyBsSE|^`hNiR$G;$3hRdz8dqZ9A2b^St*S@~H&ZJiIb25LU)jXb*JC@c+* zvVETB1qz(5uqM$d#CI_-c;|}H%C%qleW;1=IQv9A$rEc9_8;A>^=f?3rE)40HPIQuF(y|WREZn5C=X+k6Qn*x28sLm005adgC3S_Z)HfIlg zW=^M4=@@DM-xSg^zD&*z;Zciu+uDuqBR^TerPC!TkKU|&2Q}Y7Gq0w|$)g_x&iXJpP>c@KesNaQ+9Ojf1&x4c{ z2%}ERD86;eVY0uQ(4UKMdyx`@9FseWyq1z87E;iIrh9W7I#_thwxp!=2?}(25{q0l z_~j)-GGXZ%`lugrEX(;peeA8vu?#hjPtp>L_yGZjE2~2^?&)1j|IoQ2jdCs3iZAsm zm1LPQ64qWm4Heq*7Wnu#oTZ*mq<^`fXz}#_d-)bdR#rOBS5i|C3OJ%fe|B3CF z$D)~b=xt@gBcgP=Jg+yj9;o|y?}5e&JZihnI9|||)wC<|TgD=ZB$KabiJFY;AUQL) zFd-{o2Ixs)rm{Lz0UDsu?%tow9SFL-Wx6hwfOWp)j*OLk5;jx$kkm$L z{lz~1W_|YX_InaL1?m#-A%|6wRHASUGT|)IdD2PaH^{$%|K3H8)oO}}jaYt7->j=Q z4VMwEW!)CU7KdU>^9w^DVs!{n+U8`&8^)GeMnm;&-)Xjx|QeI&@(}vV%0;Y7cYD(EUe#_lXkFv_3$Wt zCvowXx-YEvo>@t-Zj}zdcO?XMsP(o-7a=I=4~mBh%hQR;?G-OgY;m0s{lCco`ak$# zv#E5l@1FEITRM6W*KH~1i z=iBu$=X6|+;)=YYJ^;>=KY_7&PHqRldSaFV} zH5NRgU#;@6*-fXZAF)U%NW-_vnkJZG*i*=yfnBWVMP?`03H56@3P`L;I6kmu2#c>fRJA=E=6wDELc_`+sNIZ?9k zlSKu)96tU5668-I30(dc1L_7^xKBXD9N@wkTkf;r^OTTzyb`wI)NY&5d6Np+s zu7jt`n@%cjmenHQd;>ucT+10$&DMdM9SWoCx5;yjMaz5w>=P(=JCyvQKqkZlV~rc` z%j@+(uZB~RKLS^4DN-^|np8O2{S?qb7jfnA5igERTntBffv*Ws@8~rc$=bk&dhV7T za@LJJ@7)QVy!xYuGxtEZ4(YSGO@Fkzyd4-*#BQs*&nr$fV+_&{@BKsYknO`)-^RI* z#7XA#p=O|U<9C6Blj8Oc(!apg@djS68{5~UBLBTWJ<5dDTBjXWq;&+4=Z<8IIADkL zxwl$$p)ev!f!nf+B|j|{DdZBh5P4-e?_cH37hSbl1h-nINq)M?Wqi^qg$Mo^*CB|G z-_1Ur_4IK!h2U_z7@wHJYk-&$tt>kCj%4WRvDfs($+5|Ge(Q}A z$`}<@x!EK@BI~LzBXk2jK90EgM%$2`Sw0O>gAhl;iJa003i&4UVudv^MV1Qk{le`#cgxE&D@p?J!b z6BeG6pfzh~zPg^0;|o;PxTwhL%4>XJfD=Md|mELIpz4q z#hl4NOqMOH-~wPB4h6U+;9#}lPD{@M{DPuPJS)A6;|V z3hd+6;@6dx2(I_+f!NBo1tCZHE~)b&)ey*0s3P50!uE7u9`ie66>NGWMSQgwLPaTH z@=yXoXWy2YEnD?OKRWtrYP8&!-uX(aK%5*rP_ueD5Y54gJz`lwKf{@FVeHMP@WzG6 z;hFV2N(jK#_58j$d(6u|$TfC*7ADd{7BU&P_)s!{PwajcO-`a8gA&yfawOIo@OcR} z2XHE_xRHmg=5hK4t&zo+rxcBn@v(B~p~R6(Fl(JipSlWY+?({^xT)k7yMmCZ5i&JE zd3y|;PQASQYnUBd+mjWH5)o&#ZwL+E41C_4^@iuiQ8?x(Q*M?P;f&OdB3}*cd!p>& z?eHe-il`24QD$+g-U#*c_{ei#-50p;uu<{uFh;Z$2JX!5&x;MZ{28=@>(SyOk-Hv+ zqpLvi4YKO=3DP*B`hlns_dg#O{I3{aP^{SH*%5AH#+CC;WHZ+B6F4FPx35(-(WI}0pDlLL-QLZG;vOLCFxG4MEh+%1 zZvH~KUzI<5&6c%`e7i~;9TE4#=&kVHl0U|fUwdxvXp0c*+`^^iOcj(_y3101|6_k@ z#1KF9n9WeP3+eymL?L+0_Ca`(<(RtfJe~UcNNA`D7_7I~tuqIBFL^xh7sPNJG8+%f zB0Tgm&C8EM_ztkIL?Fy)8d=!GFcQSh(8Ka2=l{~;_mCiIuBDnJA(kC555&r*<*eH$ zl&HAU7zie=dhw zO2>y^$a8)dE+gi}TJ@C!4v7mdG@5TF-b?yl*687=T_|Y8k z>U7l`hJVC`DPXT-tb~R(>X(rQz6)qyn8L5P5$%O#)8Z=<2+$7v)FaJf`s<#xYL;89 zwgzV-*+E1fRaZcFxNy>RKbnb`py*qvJW|)&!bS5b$jxMc-J{l6q*PN{r*D&CD4c+I z{_|v^*i?-O+lnvz-nnp8V?adRQG79PJ`>{PQ5c6|;FT-f;m$Vuoxm;TO&V+Ax#vPn zbx3V*P57|sa?X2>qPM-O^1GBLUM=C@0lQJlj z9O+~!q=@nLRA}es2HRZs;QWLa7v!;3b}+~HK1B@z4#>#xTzee8tYq7T$&_QD0);WN zX-+ZjnK&{?ttzdV_k_56xuZLq4Ulbhbaon55L5KOD!2TZHyMiK>u0EKE_;7wx|Zt@ ztv>}RN=jM^i7XsaBI_YWdhF_ z-o^tj`3wP4XA1oq#n^-qCR>FQNrR-2`r~XI-838ky4M}gU4|FYHYKHwMNhqnq+U!f zvZ0G*+84h5k-Yua-nGPZ#k8&CHMI6z^HY>_b|s>vZtU=`-uEVgb}7Aj!Aw3sW7$KF zCd?8`blGc~0Qh?6*L>l?=-Q(+>^Kej{1H{H*#mZYVjn9%4uusR5jjq#Y(*`);_VhA zZSc-9feDD1C1Jj!=ixQ=lDyu>+1H&+x%o$mQkhMpA+szb6II^S3S0!fN+vbHgk|6K z@TWD>uG{5lx!if1QknbI)#}V1@hG^}95Ir>wTHSEbDQk^V%URoBP!M`Jv5#s1Pi{B zWJvkquPgY9Sng=yJt=Ko?`swWe3v#ZR*4b}vxR7rphi8=C(88nvM+jkClzJ#p7Y0Y z*I+zbmq=!^qIo_0wywT^Rj~M*ilX@_?5#y>wX}lPs2IJ1uvhD@Sc)_I^|#B5%+|}` zK{TOq)w{u=E>rivizLuJ3!QS*S|X|s4vX~dMK6n&qa<1>qn6yySj9UI4=*;t<%aMw ztXmBGq)?~IyyT&uh8SJ5d|!k7;5>&%B%gtInEUH`Sa~Ij z8->$y{MJnLM85(PFsoP?cRlWyd1VeL5%`}9V$98M!3(gXs#Q% zXW!9%fq*njEFiG zEfGXG{Uq)`m}@wPM@3Q{Dw86OT?3Ys6S$eWdE{^r{u=1pe4yI=qfVtvBG!IvRf}#?3LrVsYFvx;wa6K(z$_iv2?}_OZ+17}Oqqz(hkRJ7xv3n0U&Lg1M&6?mi-&oBNp(uKu03A3AAvA)Y6 z>L%t_^zXpuJV>j+23w_f2k|M=jl}G%=*x2Hhc!_AH*N7T4M)zkWt@o8x#r}5N)rl2 zy}~FcmCT~C*#YT#lvv`45sZ?)_X)$@7lOFW6K9iwY@csN=vJEPqg*6Ua^qzRR#)Mu zbRP@S&e>juH&_A2cHeH62JON;x4REIJPD6_c9Q5Iq?;?wXm#EgPF{`REn;iXgd36~*K|jw59-aZhUT_d zNFa{Kw~<5!${Xo1WV&>9XKc~7yN+!j2y~71F?g zR#>%hkc^b^3=j6A1=7HR`c?d{8oEuG#ERSah9+Q`hhY6?{9hTdeUC_UfPv4GoAp=F zYVU2#D|Sqd_~xHU$L-`WUqycz@>*Q1ge;CSUUv`_1Um~zguei@j09~H^iAvMdwUZD z-VY8@ zxv7dIyPk)e$FsM|I}XgqA81aHtfmU}cP>{Hf#gc=S8Xruj{WA&2_Vaj(ai*TmZZ#Z zT0VMUO!aaLs5HpOa)n(H9M?+%5p!G#GRKRtopm*^IK|MbHBv%jN%y*v`I%_*3kEwv$vR|;Wg#DDEO z;PZcKBN_y63jci*#FSMK3Fb2Z|887oeBtU+ZXt|Q`X6+ZV8v?SwfVt&2Qw=Go2(ez znYieG&);>+zn=78v!xtI?kTaHL9=mw&LUsx{PG)j>|)wz9-igK@cE+JfVU(zz(!`P z%YE|2d1s1*clI0*1Pv#g`xJN<)m4JdNeCw$822VX%w}~=wbIjuWXhmFl&oNA>TCq7 z`)xZapz*E$Lh7!TX(6!N-yiy{_LYD#ElbMp;DLE7EqRc5HRiO>ob77ZR3hAdU|u0( zH7AQO$!vb|6}Cm7`rI(_-r$AwUldU}s;pn<^?1xJ*6zDp&#VoR%jiYTbO?;(Pr($L z(|Sk8gJ@s^Bcg(l#6LMak%k2tH5Gq0U_8sc7ym!drWi8&j*E*pf+igPybXLiaxT_9 zh6U^As|oLi?CzkS_}A0c(_xewSuB2&a1<2T6G}tJk&*|o9K46VP@WV?HEOA&2o6+w zn?^Q>&|=JF1AmA%rww&N_3k6i7e9o8q$BI^o!3~<6_I^H4Mb3LN6AxpipJyM`^`lR zv)VBd`?KBX*lG-yO8)mVP${3)K0mF&WL@<}|5Vc;B=Ui_RCwCz&;BOME>ZA5sIGOM zRb(5&dSL)OMB46Kb2wa9NbR}zr;_;vNW$5-&1r;8Q+1Kne%ReQGj6-62`#r(pW?7Z z9X38l?zHoZ!I>*jw_ElSx}JzDCP-1ny`)Py5~VZtx)k$#^rpvBXGOphTR2Uu=n1Rd z&+!%0qiMDXig*8*fy5RA0rX$m>D^HO@2>13(wsr`;8BpmmQ>p;z?YEmHulwt?xEb; zn$nbPef^%;p>#@fP8xQzV4YyaFUuvDJqUH5noHu4f0fk%_+5}yJ&S-KQqyF>>G_53 z!JsW<&^Yz%N?R|6E)4gz7x$J)Qq$Tr!jR!V)tvHkwnrotzHQ^?BqL& zK}B|Y^MeU}y)t`)o|6j$l%^_35bM?DKb_z#vq??0WGuMGt&`hoi1kI^>0e(Ko>lw^ zA3nkQ)7FsP_nFgi%i6z|11pBS?iccRxbfsw-@+{gf$BE=M!DIbJeYXmCJRZCvJJxj#wGLdf$LM}}bYky}32TKU^ zAHCwdtQb-M8`vzMDQTB8xr>4VazR2P1zFiJKp0c;qb?Js;?4bFFsfu|NQ&IB{WZe8 zN;fdv5^R#9>5y;DEB@&)ED{oW?YP*`J>6GO5OaD^#8<17WeZB?nrnvsZMu>;=ID;Y znAbqTZqDWsD^WvgR$;C};=!bBUBls@d1jI6MJ1G0!Pf;o^lqkxX$xkZ|o}2qGkie=YJSKCHm^n*c6#zGmZY@P5k=v zdS{}s+))j6b+>~}x~uZ!X+QRS`iuO7&aJ2GNh*IJ;DGu6u)6kboTLB4>VCH`NnHYV)LC)5RJLXMm;yXn=#`tr(Ka&_ zsqB+f{sZ}?#!mkaEn0M6Wmgp{Lye`ui~>yek1tlV&m!+`kvYfz<}+qyu?`%)*;k;R zaX&hbuBIden0QPFG&Nvo&}aPAZjTH%y+as1OVw~yV7#g!&#Er+FaHnmi5gLIF9g7V zgH1s{!VDP<3MFCs4+7~e4N!-+MY4>Qqn)!k2hwn2g;f^^ z6wglnH{;lHQ!Ebb`))5$zJdrTm@LZ>@qim_u{H~8KEHV`HT^Zap_sL-!C$E88m>)6 z%It3jrkSPzu=*w`qt%MYYVn`@_Hn%dgcBOm9=1gR-Fge{&A3Tu5gBVJ`co?i zf+(1xJ6_)JO>`-`M~+0Mj6|D%8!D}~3R(s`ht#Rhj)^)C0im8Kmc~@TL_)gogyr_A zze#9FGo^BkxwUxrxNhi@#8shk4h&cAshHh7g1*MDheMEkW&R&2{gW-6oeYbeF2GuN z5ripT`b8xxXH{J-)r7l!?$8k>!H{-@Jhe^(D`eFfN zEcU#bqA#v$C=tJdN)8)kZ@DwQ22~uV7Yx5Kx!laR6u6OE3zwg!*jOqDDxqB_%)u2* zI&3e+K7%yMD!dTR`NKkoT*kEU9H^;Dzn>;)rIs&!y}3wU8ul6+RV(-%;SY>{_`tbp zs?HMJf{fFQD8rUIqOB_~jPCMvBTuLYY>p21jHKCz!K{^m}xWUKyW zyVK3|?4VbYh{zIL=dXYHezFQFrc0-hMS(+$y`&<0^_=^S>XzbMWGx`K`{H1Hyj|L1lE>sH(CBd(OLK3Cvt=O)3;br=qIat|%bJ{ryS3 zhx*Dk8&PFXIMu%~W|%&CiC=rC66guDIG^*)mn>4J!f-leZnZqwTe#vjo7~DmudD7$ z)L6=|F+n+UXTs>t-VC3po+ixvvxUt4hv_$LI{J&uMAtq9)=P)S2LL<)nGwF9 z+D?bA-qTSZ;^@CN<9SE*R9(NyU#8P8tqr7LOA3IGh#VyZII&$liBM>(zcl(F9VS?5 zDfp*c^ZlGL(Y!OILH&8}QJOSwDrJBEwI;e?*7_EO9r<2=iCZ)#R$EA?>=+x2RocTW zUh&eyX#>)a2A9#j?AY1tlzo|02GI#e>}yXiI&ZBwm$InB{i+E(mbHL+p2|u0;uk2V z(B_{la25!m(+NFG7YLkEBC~C2VhZf;s^Dm$(-EEQV2trW#- zQrx>f(<7g^V>Hq{lijU@0)(>|<2>%2$;}_XyYW5m;hSlljF2NqoE8X&;i%<-84Zob5 z#t&RCcj!VG`+K9Kl{brO6dd{|iNjgtn=u1sv@USBEXAK?*@T}cI9P?HY!ta@PD-BH zzTX@j)y|H}nyo=%8DZRgw;JlKB5)2pJ>Q1nE1Tqp;_iWwB=0wkCLOZBt`o9+OdjSU z!rqgni~F5f9IXNMvQ*?@^PiWl8KbuP2M$t(n%4M4K(65XcAb;y)wDP7yb@cEik~Aj z(ADv?uZ)pn&#I=jE*Hz9e=;E!!5?uzk8@InC zU0+BMxN^aN$%VXpFN#VFD7ZZ-w{mpHCF0iSIQz*+3dNwY*&!`5mU+V$O+Tl^fLI8; zL3j{zC${BTWj{-cvWvU)S+}wCRzVfVQ+SI`_Erf%l7z>BY$&%4;!+nu9!>>m-ieOFQ%l2j6j% z4q8)o3o*l6ii?D zGSN{6j+hjc91cw6>~*klfA+QbDKh44!&P!rUL1Qf(Ys%YFHWs4xQsdJOW)p(FW??T zvvkZxFdD&V=--R>dM90YD^tzdz#z7!#~~P&Ir*JZuZ+BmAO#cSgujGZkFOfjwSHZ6 zKw{Mw+`D-iZ_6kPlU}yg>M=p>@YWWme`{p?i=2Jb{*~zNQ+~nN$@7uWL=a~KQRjoF zgXdj?a0#wXd`o(ZAIzTHb+B<8AYZ%G$7v>fGpa@vQ(>!BzK?d+l+>b`8CJF&Sz)fX ze~U|&HNRXnE{!-@^XOx5L;gbdZn_sP!qM?U7ZZAoq1#t~?GGAN9jNgE*Q|%v1xgij zO4trThgdy7jvjREeCA;}{%hZ``$Dlbq@5+~ud|}Cd9!%kMnD+SY8=EH$S~3tABPO= zljxEN7q?*4-q*>)5)EZkp5X{|7p%k6~@Coa|g zo~sXx8PgvhV~fo}1y1sAxgD@jo}^o|FN9u~AT_u1%aBV0Rlfa{PgyVaSiwlQzq_=n zmB&;NGgRIEn!Qj`<*X2C(D}4n{CMiK zH=|`o@eU(@u-0*H(;YEZZ6U&y!_(fo@v-YEpLo;}h z0f-caFjs*Be{?0UK6HscF763jLpFyX;Hic|L@CWtum_itinTLFpAs{ATx{j^zE=yZ&Xx>;*V`CWL7Tvn|9rP4CE;&laX9d1qG3ZNJJK zWf}d;aFQlwi&4J6O_%*_S<@(19wPDb+DGM7Jm30S#WbSEXzVg>KPr==q=FgTSzzqK z66jX(LfpwiCRJ7Dy|HKCcD9D9Z$pcL;RiQ~6~fwCVQynsX$N-D=beo|wMSED^0=O6N=6tiDt<8lzmOLFj zQ6avK-Lk8b_iA~$z~jpZ>+T2`n(NvGyU>wF3xm--$Mjc_Qu-V9v?IqXzeHFz_8fqx zuqbjZ6whGZ6;dw!?k$MpaI|TiI9l{Qr8}9q@?zkJviGClf9d0-(w(aJwXE`oR+4SM zb#kZw*Hyq=-Xx;L6?J>(PtukLq9ya1*l>66lx{ncX{RC(oP3U-+TZMyFx%d&0u?q3 z1(T&}xhxZ=azDb^bVSqU&jS0GN_K!!et6ihhd8?UET=itlDE^C`iZMNd}zRvqQ!(q z?$_G5S7~|HwG8sv8dBJ7Bk@Ryf)V+>U3iZWVgF1&?rC6q5S(Rdp{+I%Sca~uo8R=U zsbx6Omw`J+{ztzY3?CIa8`w>qflYZ#Q8F{-JbkS(C(ZU^=T2x)D^0?B234Y+k)L(% zOej=FNO__u!Rl`-9HEcSuHfWkD)qg#`cZIyd2H}(Kjt1L%4~-GE|;S7{Z~f2QMFL( z`V^(|qEF1nX|Je=HCBBw!eJ$q@5 z(+7-#5z_%3)*=!HBNl#ZlJ8g;)W%_B~atlDBO-oHNoZ1)r`{bfVE z)`5hv<#pd;*GI67d$6*w)CLDRg@;_OYV}WotMHcslo5=5-+z}MG%hq8a}hSZ6SrvJ zL^>oU%Y6D-#AunrhlPcgv_(sLNwGpV_-Qiv6J}I8;O`@DX|4VMSCTGzT!8L;n;~_B zU^pgwMtTMn75Sep;ux6QSQ5R%b5OgyFbCUL5a%*!%$Z~uJ>S@q~a?fMuMX}ha6$5WOTs?19Em1=nMcu)|Z4xc-iG& zUJ`*4&9{Gm-HB!F* zQZHoxc}PkhE$^A5M1c$}5m|4b9Fb|&N}-D?t6X5AqXRc-eD9zda+3&Zr(1OFOUTF74tqkDjj^N?>hv>|66G#?^l7MJ*Uz)y?=dWT)6}Xg_;ol6u|R zHK9HBW?vK6<@uL{hyS}lk%QH-AsO!#oJYiJ|6dX2zFnli*+$N_$$!TMv3YvHi|_Ep z+8)wF=zG|>EVq%Oop_UD;-6+hYzrkic;y5Z73$)pI-<5$!OEy6wr^(ct)k#Grz4dS zUA%mM4`dn#2BjJom~C9ja*mNSI{4G^O0R>1u<2r1A_o}5joL6k-L_4WGbpA(I234d&@^FfzA5ef`i0rFDKG;DL2Cu_!tm0dgqynSPiL&Rr4=pT@Bm$)BKMeO9 zOgdP?Tp@94s+&`u`Hh>Ypnu&+x#h`k-6tkFtou9; z^zNBZ?F@t0Jq5*JdM9WZ8e(VL1xK)FxAx{DoNi5A}F)5L_IYVE3p}oe3XyWcLqK>xO*pE#wJv za1gHfNCCb+NP9-g#Ept)_VJFkWsh?b4;jqX7}a&MZKke`k<4-$neHk*oki1O0&PV5 zce!mBI%J%j!0nes6LBWM9r`kh=#Ps*O_1ZX@e5T&Z_O~kJBP$%fGGsG;r z&}?6enq6zWJ?OcA6qvUgGMq;&l;0=ZXfY{wK7v-mIq?LEP6(S&;2^NdN5KYxL6**>_7oJZzkkU&u-x)#+@A4t zhGgAdBrfSWaHtM-eIwEpFXo2DZiPGplM4<-+WwXs*_Pwu=zUIqyQwZ~p{}Cb3Oal> zAjG*>&de3LG2GBZX&1igU>%2}HRt#4HC(+-6WP#ttLW%vw-P^#qa8=0j!vHnA;9*T z$7udhX-88KxDEh*aos^A<_*M2i+AkrU!Ne)FJlpANPqLURng+*{T+QqX*Bxv(`sid z16)Agx8Co(7Z6tB;bE5U^J?E!fPcNyIYHK1E4HCWda!EEDr-X$k;K5oZr(_w7MM)m z(g7GXy6@~XXY~-fjs{2_0FN%PS_iRgtkXj2_UeX|_K<+fL-U14euc1hwGb|cH}^&E z`Z^!2u-RpRQG{q5MDzZ_plS>2!h5FPi?4_II`7>GGrl%Jmt?s}wkBjN4Ua&fYJ@&R z={m6_(fL=00Oy*a|6b=Lvb$<8t zA-ait&_#vaTsvjpy%_!WAkY7!b?MU}2msc2%A4QtiCpK!6tc7*_=8k>v5)q8F*o#y z^I#dKIJw;`=R48{(!12Rg(s4~g13?&1u6+Y++;2`D=+)9Ruu6}jM4i0Sw7-rcIZ_f zg~4!9CcOqytAD{6+ua1_<;|7hLbGk!W{ba2z^^Hc?zFWK)k*`a(;H@2R-7YL(qNke z2Jn0!EH{}@n0O^9Z)Wgy_=(9F0#Niqd!CVkmgwFfk~ut;H0^&FWFBq^V|*@&*c$d3 z?F77`O5a|fUVD}zLt*{F#eVXfm6jpCwmp5V5jjz7O52ZzKzvqnv>kcad`p4^^%LDZ z>Ejn(c28c7Pd(w(!k>J52qJDL8S;HS4PQ-G;Ih+@Dmp^gigdnc+}(m=#-*K)rfgyk zIWe9a4@8R~v2&d*43a+MTg%g(r*(V3 z9W!c5$vJHkab$gcj!;5xyw40_S;+;c<|1TLwzbq`}VO{bMZYSVo&JBSSQ8>^A9 zj7!p^FDJuYXCHm?xSK{t>Y>N=rqtJ&i`%ihd5FYy&+w&G6|tnGd(Xc&M=vL}_s7^F zJ}YH96CL<;4D>95L-fr4-aIyxQoojYd#9$NScw`;q!#_G9RAx)=$_#kDb{#qXJfnj zjl_aEuSU40V14}0pH70g^R+G7urdaN<# zyHi)#|8dBdv|o?qV&i#|I$=i1AlmI&nj>z#dz=0ptp%(ZE1MXSk%g@RGu#ROpwr|? z@VJo}vv54`Ye(}4ltlnyszeMeI`pp- zCzy#uQM$7JsNA%V{LQX#&k&DjApUP(ui1hQPmGXz*QvjxCXZUlI*EQz0&G?us3bc} zudXbqNXDjxmyUtA(NIbXDxx_bWfGlbF<}(SCFtYxvGa1BY-t&dNZl)$uYP4jU*Xg! zbW`8uUG422WXk@DfBfK*py}owCD@(*G|Tk$&H_8%?hteMRrL zG*_1lnEsDe2CYXs4yIBSeqrT4wNbN$UF~e=CAr6dS4zd1En)Za&~5@c?8kDaxtg1S zOZeCHU5lJr@1_jcC*COHn!Jie2XjV|(yEHl&WfQX&SvFgHwVEKWt>usKd~dCSv1nU zr8&*fN!{%Sx|#huGZw`5->|Sv18v1|D=eC}Qk=#4Gf3~RzR=gYl#)ldQ(|W_Cza8e zO`1IwbTMetNe*4vi4~UIe_<(JfZ)Uy!oq1ZDKsh1=+k%^L1%0lI}66tOb18eHK{V} zo>wInrY%Y`j1$0iLRWVb6zd&%m@0`LHJv2e#YyXhrAj*gELDSOow;DOiqs~Z_ku9% zPFF7B^IstLanJVQmHJ*4+mz^EZ&%X~_}OmTDW<)<1?TcPfrn3YtNw?%aDTQ?qu0Gn zGAElpzh1}xyK1%5fM4?sZ%y8D9Oqj@RL}9p&>oSX*AG_#e9w-=A+O7Wrk=gwyep@y z0cGRo%>SZBeAAOvtBWUNbjT~e{RK|e$qY88ZBIX4`-PM}_S4fgSO`J~gHrj^GNf`UhdNZJtR9l0H8@udk-$sgCd=Zikn_ z+u_vKVR+ER?P;t#`4G#YOjrCk!`pAJ3_`Q|5+&4>o~Rii2ju3EWJ1)d_k{+>yL`pKb%XQ z&m2$2kw0|HcdPWf4@>9{XYk_to71l5@xQ=CaC;R0EzR0cMCyWr3DFBT=v3OLa3XLU z|9^iA$OMi`nS2V4Bkco5IDT%vmzaCv+O!_1#AhrFg_FJnfi0bC{(eM}(IIO6x3e>{ zc+~^`&H8`-+%(3&;eko=|N8mA79|M?(EtB`_y2JYs50sC-``k%{ul1S@SED)G|2W#KiKzhvWXnK+@mj z^Qa@t-1|(D3duFGG0PTtW8IJ7+>emeUWiCTj{?OHpqGytZQZ&1 zuX__+MP9s$Pmw-T%bk!_{-{pjO%fhyttpLN%!Vvp<{$9EuE8$+Og9bgC;$b+^|U_V@~1Ue8yrC8C&5E+w?LR5BTlg z>^vh9O6^6iRab#+6ba({lK`6 zk6hRKXU3)bh7Ua`bSKMqz8e0Z>VLrHzOQTB#Z(8!w@aySHo^+cT*BcT=f9Wd;fa`}OqH@zulju02E) zf4(yY=Jx0M4r~a$eKC;g?azUl7!r6JRqMfjnVH0&`MnqNA~qH70F1e`bv^_N2*PPG zmu(0<(7XtiK-memuW#stI%Ef3+OllEzuqXpnJDa^Y2j+Xt&?>Frb_4QE%luBvi?H( zYY57D8%O-xk;x)wN$pd!W-RL%G?_O~!1`J{rTy#MFRW&^62I^Y3!SZ=zGRgPVTg}H z-p5Pj#-!Qz5Cxq>C$NQc4Lk(>)w;aJ+~ErUe!6V*hfkcl%jJ+U?o8*C$lN;qKF=rJ znec&lW~h3{_rNQ|m6Rmjw*_2xIFx}p<3FwB2M4y656Rz7*yN6QKRusBnBI>|w_V8i`-L;`3frZ#0*smL2qR3 zKlzP3ZVLHrWIeB6V+=85_ON<8*ofD=4|!E}-vnQyLu^=ay4SiQ2?CzMn~$bRdplPi z=pv0jkAoQB#k?@;$o4T~1+33ZZ?jO8+zBJ8ACp?cjLwt)mMz@~NVKH|t5fHqrQsZh z2Q)jFfYF{4<|hxW9BM&NGpS`fKI}bCD1#m9mMZJ=Nf*dpOBJ^FTxU4*{r$=C6!eD% zl0(WdZdu_Wxe@W<_icr#*=Gy`{v1>vH2?OL*hnDMf+x#A>``3=nF)=Z`&k>nF35|3yV*@Pb zS++(__qDrB=_&)TL9uO7Gk9kJ7fAx15GNLUX^Xr{>CY2}ZE+y5^+;5}4}hiPXGVjM z42QCMyqwwHD*+wKK3ArE_0 zZR%C=A};+hxS_h7qtxs4f|@6jwqys(|Gw@l(6^ifY)eP2vCAOifROr#s$mm6C%0~@ z_lE@B8qQRqxeP>bw!O%eW_h0P6Ap*ontCRiA_M$T(rVYlHRQ)Saw(jyZ(vsN+@t(G zu)f|?0IkfKp5KN|vciZbZ#f%8q}UOvvH_4x;4&xRqW!#ctb2c<%y9d#dbAClc8EN4 zfF?Y;9?=`Rni|t{GH0mTt#|U~)m8asvU2R1W^`S(!}V>*RcZ?VR{Y{l;CoUhCu&x)(q+vU=bfgQKv)tP{c zfj7Yt)^-%c6fU!YD;$62N^g;|+}(IFmXCGo_^9hbo>u6uH?YibYoO5+YHI$Y&tv6= zn9V+Npz!O>#R*xC;!J3m9MIymiEvtJdkJA{&6;SJB?mGA7bc}N^?G=IV{P^uOi0

    Es>3*5wgaKB}1`8ixg5d}nIwv6^E@uzVD!;Jrq8 z3?f&!eHc3m-}TPEy29MZSFb=}Ak+~K$QT>FZ8#{6xmFu#ctK-3S7c$k%1PfZAE9x+Pu$vt5g!^=*t zj0i8qYApqyAtbO{XtAQP1(Vq#xIfbR3UHbLhCS9}ahI1(W$;>VWtQsN?0<8;Jvq3O z=$UZf^@=SA;oUrdw@VJlryk%;BoCJ2T{|Un*o-{A zL<)-5LF|JoAOstXr#{G{NRMS}oD?Zlp^}`^Rriekv#n=dwITh>(vqL{QFH#1oRktZ z`ZoV9Vjusa>=tfoe4@6TDW+*bjKtt*rGPA)yCm)li-?!pSUv~ERlH0YaiF$jl}oU4 zwWXMml7kzRX39P^C?wcP-^%~2ZKgiV_|KNmBPD1YIPEd z&=NZ^sQ4h#Hn>D}MyN0^sr*I|XCEr+-01|7d(wd-H~^0$mfOZfSv$0xf7<%BiEs9>-)ThHI&XkOp2PqeZyk_KFlwx^In1 z9+y|vBH^DRa(hZYSV8MhQuIP{WqT~+%B6%H3*)wxoM>0{`A+0Y*Ux6=mQpnl52O>V zRgDuNO2>OLogaLQ^^N%R)f$Nt%P0=oI9<^mc9a!gMCFl;2=PS9pHwN-*`~5-3$fkk zXy+^$Gu;c@l!fJ8qw|AK)yR|6V*^wD$WhrG%LN19>sm@&SyQ-B8%mp^(rECYlTW-Z zyPyo$%CpP6P3_};lAuwJ0R?gutpv66yo#vTxexCTtbslu9cYDGtEweHloF1Pr9b$h z6eZ*i)@J(@&S6%mbm`bQPG|eC0XXV^jW!9^5t(J;Pq<{_M;Xv2aXjphslJF_t04Z+ zeHu4D4!py|L*id$PqRe-vW&57oSP84(jU(A>fCqjR*@ByReAhP)Ot*Uw2?g6FKfov zE2Gnw9wTwET93g|kw$`Icye~*YLQC$Q9K@eM)SgbCT25$JU=gbryVQR>&}@eT?~GP zXSvw@s>911V6piv^O}X;mg>fl zovK;D_wa0tI_rIqXG}K;D-~K1*x+a>)?Wi7%>XgjV}c+rVbBOr+(@+(FWJ|wA&1$g zsn9HDTR?w@q$34xLQj+6>F~yGq(737D*c2}wU}8{DJX7`DkCo&@-TAhfHbr!WsJv$ zz^W`EVYn-HQ~WU|B@54(cRr#Zk)dKR_lW44^qMl0*CXt`upy!oeaA;0)(UJIX&=$z z={X9=PwZ@L`4h?F*qp{puJJ@W%Cp6yt#B0r$r|xm%e4S)&WV}3>_O4M^y!s^q4Xfq z=&{_ntOpUG=<+tEN`)w=<#rKZ_d6Imfm%;m9;(kKj`p@|3l=xfidF7reK8A)u@N-k zkdGWyc>SDuSBwP=O>!-lKyGy!mZ4w`|Ab+|74-@T5KB{QV_wt>X-!*>*D@f&jb{Pu z8VY1~R_jicdf1d0`_yLddx54C50TGAXGh_uet&4aj0Az=h;GVvNXOk02j90wym5~S zq>4&AUpYvBdT`zs?L^L#aTu3Ims2sBgpmqe;?64PHVe zG#7JW7t2ty`h`M|YqD8YZiRUpmdEUP zTkG7^c+;u5^wdIJvKPZ7zc6HhlI%f>PjVDQg-DH>7?vp?Ll2%89SS86UMUEqvLs6X zPcAmp<3G9BH0;)^0fo!jrd${Vf6;Jf1S(o+PwKqyURjDt+FXGho|4O6Epd6~RGPr8 zNUo?L!&BS*cZG?@YIY?2(*#_WOgC=o3crFN)45a*3Fnurm4~`vqZD-seO34M@g;dF zh_krO@qYQDG%RlW(YXS~HsGI_FlIb-0GUBioGMw<>5Uk!>E6}iu?{{-gBxxJUrOYR zkv>Kp97fr_sRLN{(w@7ib*0uJ&v#{8)kE3;)iz;X~Da?Jy^~W|9u*gtx<7VixVJ*Xh8M(1yG3 z71-s;&L%Eyv?f{6mOwMatJ*F_JjG^HI#!*jFRXa=&Cae$qIJ$CqFb&o$_=olEN-tk zxdL;>V11HO@_z4)24SSnigU=m;%#x{*>F|WyN*5 z<60tZE{@0Gk38H<@hTLbC$r_R&CvN5c_W6?_lniZdyq^DjIh0ExMxyjf`vuxDEV>- zglXdvT^JruTYZR~rsPR~l#myk2IPn)7?H|ReE!Cvm zb+X|+-4Ub*!~>R;MJYZ%(`4DTwq;MQ8SD)4`O;}-T3k*k3`XBbn1EB`&F>VHsXUUQUK#E!LQA zfb0E%)&j?UsYmQ2XaA=-LN^zwf1jnK-HpK0RY8WK9tJXlqRljh2U8b~fI@Md%bKKk(T%hj;F2c~ zR?>riUeg`1x~Sq|!y^n%(Vm;d@;|Y7V~0~hFCsL-Ak%I|Ts4{R4=c{$w9rLON>V8m zDe(vt2VDi&g@cslbo5i)D8iRzf!YZwKGP;!LB}TA$EYBgT`5^p!lD>1q`p;%Oa~u^ z@y&zdw0vy7t73LHX)s5c=sS5)WS~PjJc2e0??JyyF|=;pH>qJx!$i-|*!}51;3Jf*HMxt0Y73 zYtf?QjPL&^DF0dt1?7cd#w-vWhcQ8ehl@thtn3~`p2~M%q^XKxtWNMv5a(Cew3zIY+QttL zHWF)p8O0Z;XF9Al^iS=jnm30kIxA&BwNR;6&DiNC#0Lg0n~ZP$Q%#Jn1)~5F9OLE% z(F?EA=<+yPnNI5;GlPNqtH427#jt+zE*-g#9UkmsgY9$PJqTAqN|S&~7CNC1ZyX|m ztHl$vrF`at8(d*eS1{)B=xjp^p-0u zO_y_nw9s@|pzw<1fysS?(u|m3-E1Qp2$g5bSBZ%;(4m$t>h*9>Y`AXgK*svgq3>jt zXl6`9QUF|yLu4!^NTTizo;Op55T@80V`C^MegLTec;0@}|*S(@gdAnw&9727`-20kKYkVM@;7I$@Upn)C$R#@r8!wBF{H zOCLf@w~<$kn`f|l+DM&13nr|l4!(+loD_)!zCnh{hsocnU-!kv^N_$d7=ZTjs_tz% zi}5b=rA2UH0tOWrqn2gl%NO4e7%WwV3j+(m?8nn_v)lr|f!v z*<$V0k<@LK&kQ93Lmz>a;tOYUdqt&|#sZKpBro|mkWBVt&A;DRu2neM~d3gdHh|cH1F*hKSzIS zTVsZ_FT~Sge_)>q-J3IlRnQwVT&ML_@~X5oKv_>wQdJTcsAN6TcUHRXwDxpV|LCN^ zv;m7mS5%;+mnpTH6v?@_tGx9d-tpC&MQ38{!{5Yyl2uS2<0p*ss-g+~*>dED(* zbvla0q>KDd#gSJVEjBZKa+0&VD?`_TCbhyG;X0dKUQaRQN~2$y%(&a6ds-F>slTnw zA}-c=Hcpf%NvhW=Eh*u2eM-=-B5{A=&2EqgAX3QII4T%RB6V5wXb$C506w61dh6*st(s43O$55=k5ww zcWG()cUw|C#HNOKX_eS@#VE5k!UQG!!>LQR)u|%!>XH`?le?d+q%ukI1iz~dpTpIe z$4(t5sG0}8Mp}z8%_(Z7k7BiL{@qUu+XT>`h+D_`Sxhil?SHd(9)C$N$V#*QvmreC z1P)*NMqrJx&302}KxlJq8f@!8_R#oCo6*&TGn>Og8r|l)epWD8hRlb_QMusBI2k*8 zh7@goMx8=Z)e!)NDkr#zssR)>T6yNuX5z7QMT!barxUXkb)vR)o^s(ji`lGX&)eKBvf)xLxXG63A7$SfSUrB3lqH7#WrZZwac*t|2iUHHDg*2Gfg z;gz#99Sp5-op)-<*Y5DS_I8b0om^J@hl9 z7BEt4bKRs(DIrLwNcSq%w>&!+6;x4clQ$w33cV{8e#cd8tt6C-K8t?B5<~2J08bse zt2C=tIP#kS#bHm*u*+ix`@g;EqGaG>xf$$nW-jO%E_*FP;+ zd|$uUmv^%k`p_;kX$9Ng7_G=x<&YB%|I39#cBvWqF;Q%{TwV44`Qn6iCscS&uZ~H( zMY(!M=gx5yPKd;BV4{W0u;d$b53FZ#Rd8#t(MDP$WT?H)Rl9aDHEZL*0+tD#7$~os zVf?(1ZC^iDc|W@xg|P<&pzmr3zN2^;&Jh{{yjbaK&WO(UE`!dfBsPxKm{(oy!GleL zVH>Kp1Ke#+{J{dv%(g=-Z8w>JK4asl+90NHelGucVZOP8Sd2P5<$A2C9i>J*&{ItD zSgf%0%EB3pgGzE)cu!IcQ64I=r_ttep)bU&0VIEm-(o^X$~wUdo=A@pR{*6hfG(un z!y!2TdM>}oUCnv+Y6Sc<`8@s)-a3#ZC~(Uo;$su??cj(CX=?8r;ll;K!3Id$fCsg$ zD8*?Z21!1P$3MJT$o{N)P2m(b{8TxbbjQlzDux#zZ@Z-%!7i0_D*=vrrq-+aF?Tf% zK+VeR3rc;NEYLJUgy4jStx_6za@uWmSV$UZRef6W#f%2l4;U)kHJNLV;Sn+!7wZTpNKA?+#%#z$hHSkKQr*U;N_lz``pIbUy$i^wD^^4;C<4|MGFJJgJ%~-~i zs3E{jau=G28JZk)%%t5I^BK}W%m2k_M+3}+UN5QD>8}VQKwc=hO7aPG=}S_B{8JTn zD1hsRVNiBmVz75|a74L>Cl-pKjbf1@T>Mpcof1VtLcqFhmXHz0)j`7yio=#1{c*?0 zAHb&iH^*LiN*5YqR)O7JQ^N(cn9f1;xMyk|5*w`wh1Lk(^K<0W5+{c$({u*McpXIX zF}b2v$oB7qLDruyY9g+d#Oi8CHJI}?A@!0UFp*X}- z0-oHWN9Lx}urC8`!3IUQ=N)cJ7>T$ZbxSf`2PVRwv=-R`HzibToHn&`wKc;x73Bk?EK6h?@>1~&s z0e|qxEZe%#({i|<{bar7`dQcKwS@jMP=qw9sLbC^UazOos;D_9ACgy902uQk?Zk)HxD@5_tlPHyvU|X{OXP-xKI5>r7jlw(E#QS4|c(@L5+g^B{3D?@34$ zBg#*IT^`e>=q|CK-Nc8q&OO{Z2R-T_@PyeZ(^6ATPy)ptui)XQ#*edZ`ddpySO1f@ zj^r|V{U)eKbU(J@-zIrWyPW)N{`}af!*Tm7Ybc`C4!PKXJ?B z#*a4B8eb-goi}(yqq>TfhFD!4TOrg3eVd1uawV&-aJuYopMqVZ{+JCx0{+F7qvdv0 zu!P$lgf7p?qgKJ+%F@$A-XsebM(f#`vjD8PjTdtFMpZg7=U2 z2D@2p5_L?_l7+=at8rNpsaajnF^DP}hWU@KD5(;ee|R|>dF)px4W4li`!5Y{&tmKT znG|5gE~*wH5J36Dr!|;|VB!eEMrgFP%nHJ-CL_I2ix2l1{_{6UQas_2H|iW&(Cbbf z;<#NJxGVH`K#}KFJ%(hPYnGF*q8jn!{a!&&l_INax~TRHDEP=iOq!i4>Bt7NXcoR= zc4KYqG~S{0!0LYQB6Kqk?V!4$-csX%ck2G|NAHeQR@X7&^m$n2bYk^bch8+jsk!OA z8U_Esh_l<)rjICD`#jK>|3b^}Z|t@=bbj{SrMkH_0ImA}vm?GEgd5ZX#b$NjkA^MUJaF*G@6Cfv)-S^MGDyEeZRl$Bm$0v`jsgQFv52R` zxU&&Y1$H*>A4%mt7j@cK0v%9`tMDKMKG^w* ztUp#;l*BMk;_7}{nRX7&N30dT`~IcxsA_Eb-pk;DQEWO;zdZVV)7)CX24`**YiFb% z+T-go(2kbYS-tW+=4*~^u z$d_MJ!WUSH^fT)D`{~IAXIUwtZWw`P=dVWjNP-ccdc=*!whYY|Yyi6zD}e~f$vL27 z9%LdfYrZI&o`cw@J%{nG;x$!LTgIb^BH`$~^%Nbh*4EGMj%YE^y>*t`cNCi!Tg>Jd zxAt|(|0K!TH;}h`evQ2dywjcx8R+o)0ME5|Lh*=*O0)$nO%3lwwO^K~Ugw9QSoMvb z5uew{9h?`%@!o8FRWwPN_eQqj;Suloq8$;YipSr}E!yY=-B*PsW-LGnFX&`sZYy^} z88nKWg#edv$-;0oe9h) z3Yt(^o>*Gr@D9Db(6yWnsYs4I4hM$Z>PUAKmsnu-q6)a>b41;LJFNVqlJbohK^p8$ zNp$Ny3NMbuy=ZiIxKz0Xk#YWqD8O>YCxUF??3+ga=N)72>~iP;EheHaH``g&Ri28) zv<@D3fo%T1rML$Ukg1#>MbtS?Wue3xIbPw*Cv7^-?X1m9m$(n%5>M3C*(Y$fsQ*J z#2_~`PFcu5$#hGTS}ka)D1{>!^S-3w1np>$iRX8`c4nxHfImOFUeQa^h!AsD8xjzuOVGQS@84!erNwQ{O*}`8YLdNJ&=Qh@WRl~Xv!WIMh)># zTvi9O?|?&wKm+C$Z{(lxWMglv{Qq~<-KUyQS@m0Dol?e|$NQvX-e9NTIenQ4B8Q6) z8MV%4+>bXpAsuFNMv!TyDT85}7FWDbIooNs!-3Hh_GeUoT5)~Rx2hD-%}2&;!4TE_ z7iOQXPnyVQfzuit4s=w*Y1n{vj+y14+_8|I1+PQ=D4Wz@w)|9v!a10XG#E4Mx6=aq zudA;3f*>M6l%t<^QC#^W629o;RY+1q*SOj!7kJ`%dlfcZ9vkSd&$&dMODR8LfNi-M z^&cws1>QH|i%fPbw>YjtvHtXc4|a_bA<^>_p@m6mH3|KjORq=^F0U5jK-vkEK5$p9 zyNqCjw!=Sr)w=x`vIrN;ppWP`FQW?8qvp0o7TKrwwoeWjD{pK;F846v8EyInz8iek z%E)ym(TvoP?GF)7$OF`gIylpA$GrJ>1b7xcpR!&%etfKo{o%0ASEVZuC5zzO0}9AH zf2qj1poY4d7A9~O$Lzc*M8x*{jX!$@3YIOXkVc@wr&7V{%DybV6lEVNKf4i_?zuj727V zQVZI_v>GssfrUox!tClJh$eX4ZqqJ^5GwERP(9=E`}RiAKxkm?hvx)brDtPMm8M5g zS@<8}G7?7MYu>M- z{7&-!-s1KIkNnJv>JyK=Udi$9qBT@W?rJe@OkrY|aL)UR0hwPK{pA+F7z^ch0>2{w zX9mqgM184w|JU3@wEpQi2CR4Gcke+$Z#G;0EcL^v)6SrvL5q{icudq`F&&Xr?{#deIwww_76 z-fpT$?olad1Y)pjq6)QEAC3{fQb$sgP?_u;^dki^Rk*}zfcHk6^%&Ent}f{r@Fst@ zXD~>TsK-`%u^+PTeF;2t3oF#qDwmkO#_}wMXi$3aV>(e|LQ=b>e;Nr140g=(fI#z%k)%?v|x zY>C@Urn0Yo3%Tz$Kd)jnYsMM{r#9r2qkuGNhgOEt(;^pz+@`&w9d2K!r5+mDOI2hK zl4qhu6DW_VfslGkjAl-%z*HoRTMOYW4((#>trzqsyvAAu#d-`4pILiKBT94K=|z(d zCBKr{G-$UCWmZZxlewL#3;kM|KC3B3{sEVUN0;xDSvgitruEywad=x)#oS=s!T;S@ zY(bf2FpxKe|FpxTo!I(npF!&EM#-OJqsLwphipoYwP*A0ObnnuC7`)$Ccf)}74w=f z#g{ks0XR4$BNkRx?@Y0~P>k-BIEQE_rXKs2nVVt#)$jbx?m#+ii zp+z%pcqx&#flyw{56m~X5Qsz8#r^0Ik zI6%33h>JTtm=6CVbgxq>!^%Xk*ubi~C~NP)oY1D|mw=oxrLw}TMlvD^q2`nb8qT9RdsBMG9O z%_e0|FC1=HNNyKrzB@ej;rBX#(?1gA_`cUP^7E^c_N z$~*bpvtCoZggZm+E1b?W4=hCAru}WMRkz}{^(ml_?y9)``OqV` zILLoPMqGNh6ei9q3#E0K>Grz6(fZbOVp6aE3-7H4{%SNTp9)VHlm8{^zbsx!ftoX37J+ z@{KN9skn!e5upqx)!Ye@M;hi`sWip$m_+WNd|sN?nLbPhCnwb zHu<<8f%0XlD_NtWkR|lnT#hY{$(w{BXZn}9em|8lHHD;7mVpQ7$4({X!K|TcQ4eSu zHSD3w3=NmPgUW-Z@AX~K3mYEvRu0Dx17V@rMR`u5X2$|#HY^2o9T?TL_;@!q-1?oU z3wHmN$nSE0VVXFX@v$B5WMz)w;dFwT9#OHmY$j=LJ?EXh3?tT&f}*WNr>>n%7v%WP zkUUies6q#nhPaw=3o6YOPyZYj9gj1Fu4*w?xvkgW;H>aG9#7+Kt~vSn`4jY+hyd!N zt`Zpa*vy1!G0Os=zajoygu=JPX^?RrO1{^)&h$yRxWT)6^yxo)EVJjZk~ zpJ%SwjzIqsitmI1+Tbo_&9Yb6_UUz}nx)OVV>=^} z)Iu5HR{XG{fGz-Px5JhrGbzR=#U?*-OM#j2fm0tOhn8i7XN7dZ+lz_9|E&|SzRvzO zEy>0Fg+f#J8wA0OS>w(@pkIc3eXwTQ+`)sGk>CM7EA`n^|L@7b-K%a^42I>;tDjuB zf|(Ywck3YBQ!7sdha}>t}9s(H&PQXam`$yqxM?w+v$@0A~V{|oCqZq1IxQyVz zf3FFOYWh{UGkMRxGH|@q368nR?1=b#byauQqWUwJ;V?OOplSG^S1NpHv{D)M&XpG5 zK|CvKR2-pt5yHypd__|7Mgz?A1i45+rVt3Y7!kyPIVTI<$+HmFinRCa?? z=%1eATMH{(*3Gj;@io4`Mf&TO5Cveh)fp^%vlgkq|8C#mta~LjK&y7Je{~eOO$j$> zwIhEaB4z@kK(1Z;b6-u?b(>hd+r#p#vwNrkmsB!kBYIN9|8WgZG1gPwm*^_+DZx9O zj>+BUkHou7(IU~Ho^wIe9s%ylxQ-gvJ?EMAkb4v=@l+p3PV*JXHPcp9T_SK@wSoQ- zpD`d-Q1-pJx2X`2!08aF&!6v{Ikx3s0j3A-^{&ndhpGAqMOgi6>n12UH)&@RQykF2tdP89^X0+2YhC#yi5uf>MY zdnElos3zdD3zL6-7JvIaWj0ZT2z#|DXMTvO$&nFOGML2GQs1id=bUk<0&OVIa9Cxk%u~l)pIa-k1Nd@q%Dh zz{f4f+ouLto%zpWds*U3Eu^s$B+6-jhWkGe?pWozM6a1EuQ85E<>3ChTF!e)dz!>< zHkQ^!?3l0o_JEYhY^nZ{zFfAq$RtyNy1uY)p+05Rf_N^NEB7RCEJcmC>jD|6TmCgd z15()?^^?vWzY^yA`_O4*iZXWb`LAfqhv9KGfYZu+q!)~ibYSqvxK7RH#6?Noj9qW5 zz!=M2yJR>?>~IdC-Y+uz^YFZ7Bw@#LPP@*oRd%R+w9#0c>H_c)CaZI*d!-iJ8`rIG z{gpvsdbmY7%zXvYh7GA+2uFxsgZ7Gkmu(7UcC<%pDUWC~KEObhGmlpEI$^fI5<|RA zz-c}*|LXCKMZfaK1!jr)p(c{da-tw*yFx5>e{jM6qt2334&olhsp-UpdG&p(%73a$ zRMNPl=@BQY^8V|HTb9uI75NX4d%o$>8um;F=8E%+Icc;>aUpW=bJJ?=u20oCxdZJ@ ze`2QI=I;eh?3-pX&&sC{`NKtkOaIVL7nr*fZ^bnltRo2AXXd6g>gSUM=^2{@hpmAx zkv9HEhL;DM*mW-aFqqO_0)Hi0P{g~R*A&%d-MitW69$ydGon~=$8&s)@eA%m+(12m zqD*!rz$6pi<^s1K6OtxT-j-u@wKOiZ3civ%n-&1g;Hr zcC!5lRtEd#lT=y|^Yc<0PG{S31S8#RuR9PHY@-`2Ft*p-FoY^$B9)@C_`5Hk&$99K z*P6{R85le19(`b*{!iIzvBTB@p7|Jo;%G6nJ=1A4CXR4Qh{0X0+r{0F+Pn9J9kD&* zJ)g%OBYM{eZ}4Cp$;9FFBko!e9O6FJ=Xh*N|Orh;p;~8 zBiK}1igYagW@buO47C)k@p*@^G_tU8Qe-mgS5`p+b%{uqAPwJ+JFe%WIMF5gjaaV zzPX)cVc-uQ!Dd44FrNestUUPHawQ8ar#LC&?HPLkoiO&(BpM{q<3s5_^gNp|DF6lY zPz%2X-^t0A6sh~c0QHOP;Xo0!3RR|-BfKqZP|sJSS24HdcsAni_ru(y0XJ?MEm3a$W^YTv^tAX%ysU(Ex(po&rF(Rj;Mib=N!w>qX`_Iq)Dhp+NK(g^g?a)=BOq*V(L8}Uf zo`K6SHGp#H)t}%Zy%Ceuf2Xzu!3kc|xPmKiiP|5)(~)hHDQUQbgr%)j>uMqKY^sAK zpOmotoEtf3tYm>4!$GnajuP~#^fJ#WRvO)tR_GG!QI0D1c>H{GfxZ*|95?a8X1P1> z|9E{O`&wzK1cw(JDgski$r33C9T<yKG#*Sp*afXI=mb52mc`C^z ze}#udS$+voI5qlVR`+#+q`KBDLQ5b{ovtJmzTiC7cIEe9Yu;MiCo{SZ4FU%Zq#{XS z4mt1k*HK$(|a%XKJ*Pcmu^Y z0oeJU8#@F7G*s}#2f#2zEj@r<;g7^7G>6SEimg1*LYL!NKWKW|iGnJJc1yA{I3twyu>1 zhMTHmkc`#|$O^h=L=kazWOAX&#P&PKI~%a7s)Q;il^`*IGL~vw;QAuZp;T5xW zh8oqtk!O~1iRR%}BYo)DHY@m8GFH5p7zV=`0#6*&g=-#kyvc^X`B0;5FFF@g$QACJ zxzTXlzY{GW>b}F2K3diY&Cz4L3)exHoj8S2KKF;+njk`8a{cRPMZCznXUoLN9oyLq z3XzheN2S;6_D%(WZ`V#q{UwH~Hhc#GLHq@J&r1>=xAV`JOqtOIF>$~x(S)UK@>XUL zX(_oQ?Tjg0p;*+9R!|dNqJor!S_umD@M9~WFL+d>L;7}6s+7f=;o%6gb`)qK7Q~5) zYawJ|bw^5iwU1fNs&%Xcu3S_V71UIEIrz+GT(dIKC9Ro( z+fD6mBTh@39P?lXQJUnvleFEYobc^kL2Jue3caNp-htMx3=nF?! z%>p}UHgLrQG0FR%N5rJ5$$^~h_lZjjA&lmhu=UU_E|6>iSEn+6xr#LEb`;qR~eI=)9NdOqo zFKu0KEh5bdo#GlJkt7SpXGXqsiv&N5z90-s98PBWa2^1VIu;gUGYVK~dG7ToA4G&n zx}IXwSAxoB8KuKyu-XjGov5_p!n`@ypS~mwcv4O63}Hx+C@MyR{?K@+G0}t+J%l(Y z%oPzKlF*+4=Z08+qW}R#Pz&pIS0rK}?^xeLYf{dh*Tr%ata;>J zJDwIG^@S}cS()^4yLn&m?)_%IyrJgA5ZC3>SBBln-u=rWb;V?A^huqY4571)HLV^F zWm*-Snvdo4cD=_niPQh4f%D@wW8r4Y!z&9-NZHX z<_gz}HTImK0)g+n!Tw#PO_4CTL07)rchu8mnb0gL=VN8BKws9_T4X0rUT-j^`Sao9ZL zxk+$WHw4SW8rM@!z;8Z^f!S`yJf)X8^gX;VY){9iFt&;+jQ-H!%>q{&gZ3J4z(Lvy zoYTNuAO-)x8pQSYq%n8c{GIr~DS;xV5v=fcbuEc~cG4RX8LS@UjUOqPn6qiQp+-wD zg*A37h_eih?x^RS(*w+7J&o8Lo_L#wzTp(B;iiKeo`+hnfBjb|6#Qk~J)*`q*-0rL z08L-t;}e|}&H{qN1g0Rr@!J|V#sDQ%EyGEa&#|~Yo?$$9ec81iZ*DwFZ0tTXpK4vG zJvW1_-YuXXhq_QD=ZLGKw6u8sF5Z#Z4~vE@eh#!bUgzEM%O%d=KU!vK^L4sUqD3?t zcyG_7PNY+8+b0YD0%J3yYMn7nfJBGsUmhPn=!PM(mK~zU)agAj&-bsV^NPco34T42 zM98z)x{Lv9X>)lXA0(Syj<#|Xy*{&-{pjp_ID^UaitfCBbwmww*77sy0L!0>?q663 z&Lz_4c+|Xqy=m3I3+(GqQl!P`oV4)g*9Z_Pj;%M9sm0Fy<8Ss!w(IR zAZGRI&+JF{BP__Y5`@n$UcMm)lq^KE>h`${N$i{q$=EiF+QMdmDv?48-7QcC&2L?+ z=#Qe)of#rw8(tb^{RQ~<5D9Sv+6_hrA@Y$B5rrXeU{Pe8q|6A2gPC_ zLdyX!ceRNxwI+F==$5QA;wJl$jcoVwKBv3SIi54N7wnSbjRII0KGDX2cmuxEN*77b z`-LrvuUS0Mb8NEC0i&f8sXNO=FV`d9fh!L|;BwP^rkE%VUHu!W%TK$3U)VFva8mnp z*|HByJGCVrYD$(iSJX{;3)( zvj&@Wq-B)2fM&p2cQviRH&A2m~Xr4EEs7=u1- z#frgjPQ(pj_ekZmz;dU>=tGC;n9ehwJH4w_n*Oc)2SvW4FG1yZvoT)DBAvq0EH1`^ z&R1tq@3t`YmuJIk$ z_w{9$8`%f^&IrXq5!&P4T|%{n!J5Qy!OdLv1i|~|>MLJ!^-s?+%{&JT^>(Bse-k}+ z@puREYrFReSatydFKIa~LhnocnRt-#13G1;_SuZ5wPK&Lh=IURqkE;TuFWP*Z9ZEtHc%rra$e5lh%jdi9@w+b78XbZ1)RJagzfPEjTMNGec zYPX!m0``ObBB}Pjx1Jr%dhCs0ANEZVy*6#SOO-XBhdO9sqE>4xJ8cgUWqM4#rmwAEk|E9$&v7?!3i`aNpQSp01>+2~6_uBURd#wpr^u zj$l(x#v1fpCj%6zx5;DE<16FIc9f;A_2eq;t%RK9MRD%NG`nv;&HPrALM_(>oQVZV z!Q+N4ykfAI9m+Cdww{U5N!(B!=TfDfq{)q&n2`;PVE0cajdSF!>H=;fE=ZsI2fkSf z%OJz*JVKu`D z8v#A3yPMD3BiR4O=`Zs4KU2x)lUZbvzDPJ(?Qw3?hTRcNWhCM{T-3k2OQ31!8N|efaj4!db2rM;i~d zH9n45pL6n^I<*L9d_1TUjeA!)43Yk_v^z3wlwTAiVURkroIq*F3!E*X^=SLC--TAG z{{q)Q#YsYsWn#vFkgC%^`GYD%X2w`DNSmOokZm!<;T+eizh#3NiH7mAb~@hE&V$&qhx!$h!Rmni z&``KiJvgkDAI-%H9ccA^C+Ikjs+1%`=q{3+ND-xUY_DPFOZPo%(BG`}S89Y&TgiDcYhz zPWrqHcl?7JkBoQLuQ-_Lu@X_n&7cWiGBAWDGL_lu41OZi%&N_ve=WRe8^o*-&ZZd zS!U?!w=6EsH(9j3aLJTPTLf9&&)?ehMujW(Kd~jZ)d?bpiZVDK8b2QV?)8&pHXNN# z;jg3$D+cc6t9}C5t-njWhG?kdC}k8*#j z75WEgbI!q!cRlqJarbNGJ zx|q2gXeDFt>xxBxm?fn#D>#rp+>~u%e)D0LnC~mt(P={Nexg>~{e~6)E0d_$(ldtT zHcB4^jn`m%Tmmfbo;p~zR@8vPw7Jk&OzJiw0!01lU?a$J+7g1V^rLF{m5aQlWEL({ zMt~qC#7|aCe{{Z{rP9nHo-Y4~s(BO)A*(rAHkmq$jNvcMOdgV#U=(mT%00pIsg=R9 zA?j`eQ<^8VA*keaDmxJ*0?$8*P}5wvd1D^PL`*YHaJAR)Q_B)o_!nh;4b+YjdPLoa zP&Kjz`fsx3Vt+%$U{eJ1I zeRO#m|9uEdKED^mw#8rdqlkaX7xnnO{@_u8KZ(9N&-eTdO-aaGJL6vYJ)0B4R+F<~ z^+qxylITC}2=%l^H5Opl1UB70UD8C{?nE^*Lvb;vm?lXnG?#5_V&eN-s+s=k>1X<5 zC9Wql#X~~g8YXsz4BjHWK$qZ$V&rwwdOrwnJ2c}C8qu9n$L4< z?81pG=`|K2+$lcNnylPqGQ8ntB+*|Up9zs=sy{3yLYUi6^sV7XybB!lZU;!{)_)nQ z^%Gqe*q3wu6TdeqR2?Q|4iVe@K1p*7X+?$jvY~@rL!6>uab-_2+gOvb;l@5_!+9cC zRsbw#8aQobD8*B&z|2lUL^H0l>xVmdq%fLW^`5f^7As_d8W=Ox8~=npQdWH|0;$0M zT?4V7k_Sa8hw|^~u0&6{Lb=!wQmnEKdqNBr?z!5~O@l~Xo(%gBfi2hfpSo@F`;sW) zp?Pr+u66G5YW$x?tMls{!I~I3?!7pERHJN2S+y;<(pZ4wT1>Y-Z;#O;S?pN+ZV^Gr z!k__jwoFL4by0Qkpk?do=7dqyV1Zf1@|4HwL)}972 zJ#EG0{uF0P>1XDg!DGg8GQANJEyT1VBO>0P@v+u<;P1rYLE`P@7BBb;T4?cgHU6|7 z>jc~5PxsxuDlykNGHo!Xd)T?JAr)=1xQQ;VO1D2!G6h9uX$mOE8WMZyVF8*{PbxAu)Ii5(GcHr<2?e`l(IDeH#Xgw zNnG3vO9-q-Sh59^a&?1v>Cy>{`;y~vD|*BhWX_);(D3fAYu)j5j-jp?si$XvWm2kg zLyh`HMMI`A`=lqJ=!V67glu6ZJxK5^EilNU^B)aEqYqYJbEr9BYH`+LN#e&g6fA(*A|6 zZ^)_S6M4}FQq>1sUv2y;uU@-1nKHh~HyduRCqkXvnUGM}Kg!VH>Pe|_%I6$F4{?F} zGtec<&nvWldUi4L8P1@UQm}Umo1tLNmO4Se-7?Dn5>QkkXpTU*IMdT0_|{z!6lEdQ zE;8Cx*_TbeJJH&n7{vj@(rQmxiwYusXJ(4ryMh2egR_ECm=)e$IHCWm<&|EHFX_wM zCZXT^>dhvSfbW*3!K8&i1zICmf2)z*lCt-xReJri*UESJN13{p{Iuwn%$w_R%A4iNtWC3*xIS>`hu-VCap)1(kR5b!Hh_3!OZ+R^(gII!8N8^@;f z(C&Q+nzzgAE0O%a*n7tyxx%i0H_0TE$tYvnwr$(CZ6g`mwt8&4GoFlX+cr-pd7gUT zQ>RYV|NA*#c6D`ib@$%u##-yX)^Eki8eN{;%^h^^OH$s|H4I;9uW%@6YVO1%AP6Vz zBmD{9Yh)LFU1c6hCW5vnHu;D`#Z3Sh*?zHI__IG!R05icntn(|j{$kGL-r zT`+N=G>r4R@RO@LAgnh`C5miA9xPra#S7bkqJ)|Ull~JmR)O3)FmM@HPoxxvH=yUI zxPgxLH)bA2>&s)oNx#6*!nb;*%kz6kY__?eN^PrWYu6R;? zg8DttE&-Qc*L7^})UZpc!E`nH!b-(*U2bJTp&#?;k1*Ay8WAXz&LRL!jE!eGmcPF<I-02U<;ivoTmv8in&a-@7`CzDyWx5RGVd;2)(N1S)ev_p5jR-?%?l9!iLwU`5@CwcbpA#8>fB6AxgTS@^%=|<S`J+yBPlO|)|+NmdDC_mk8q-(ew zeriX$3xvYYRtm2sm1We?7rg!~+g%^CM;ju*63ga!g|P)9oXrdbm85>_AH)&0^L?^O?dM<&cj7L@fnPCwCC!!&F*DMu^nPD;w+HY2{Il(n?~~|+_i`i+4dY# zS~5fnZV(!%=#|n^O#)(4UOqLdOvTDKKk?TH$GYz=1@T|62zQCsK<7dB`tAjRiv0pS z?geJz5i0rqh-ftb_Q7F-Vg=xLaFY!<*rg$9nG)DK51*(AL6ZL%Kk2&G$CL~;7)_zv zjyKQKm2G*y;l4L-{o~G=Eo%V2K!(Q7{oMUpGefub^Vc=87$Co?*Jj+(R&P3Q&-*oP z&8|MrOlm!psOtR>Rg)G)b$A}*M1mZh{>QI}2;qA)W4cj4ROG=EDJbw8Du2*|dxz2j zrF=1e^!M!;ter(zXoH9QT>Dq~BP~rNn(do_mBkU-F$oqbZQtE4hx{o6Ak+6M(jc&T zJBc0#uJ{E%9_dY0=BustP)-X=S|7-o9c}o zC%F7H_vVFFWwc9YaxZSB%><)+dme$p+#&yq0O$TZ_z3m3ere|38>5Qq@ytkAzJFLG z;4Piamu9J%J{1FXpIJ~`mGz+_TsXBBkW*lm!RtY@P0WA*X8$q*WwzTVzr=a#3H+N= zS^)CTr4pSpxz)c(LTfmqDpe!C)zzay(@VX0%d;ZIis0)x=#I3dkOV51e4=eZk$uw& z=T;A<3*e0g6VKeZdIRO?xN3}ke{7H45%nL_#RL2fWxcF>-+yoz7ThUg{MHs#DH1L9 zC-?A}Q?3wxF}x2_RLdOLg`h?=bTS)0B*bKP9ueU#!u?GGrI_x8L>+1)W1Jw#i; zdwju32A%5IQv2%{b|W!;)css_an3jbOu^#lckym8#V7SNRVIWWEvs1mgW=uiaS z{}ll}LF^6JCP9GrFu?b4$_%CqMJZ-_!F&M94k9345x8(Fui$m=SvmIta|KRD?GbDVrbc}! zIMl82OY2U^@8oYlj`q*TmBsq%`7jzSp`Wad^cJGSYuxOgmbskn<^Xc6OgPWDRBz++ zW_uKYGc}*uvDdavJ1QRBiw>QanWLNZ&Wv0mhMJ~3Rh?No)BW`6vPa(58su8N>9Z_d_vDeDt&OeG_I><8}~ zM4-E>zEEe0ab%3%?KD~PMMJsn$J14nnnN#9;O0e~b8}v!P$Wym21x^drarGpTo;O= zj;U=dPJx{z7s|W(3$E9y)Q(CCA%z>~#_6)>!qYWqgAJ_Nqi-D1jX-SuqqzdmaYu?HM>qrFSbSB|H4}0xt=UrGKZxhjm;fs`^8XBzB zGc4#)i^L6DeCzL**rn^Oo_Cu^Gs)FNq9N&948yG<7Yx!w2=rur zYByK3uxMv4(eIyaS}e(qZ4eSL zF&0(iOR%pCC4)p$4pK6}O}wY$co=F{pSfPll2__e5orzY5l?_s>MkOgwN=ZuP;nx~ z3>2D?=dYCBn|?&w7W_Qwk6YY`Ky-~J@$vFEChnvkhlF?fN||@o)LNl*y4))Ua!E?& zlpQpb>`~(xEPzE_`a23M5(sKeMJ8DvS9~7YnX@1`6|Z!i!N)kOAP60aErrn#(|mtR zZ=}Hzo5d3192uHQ$)D`UuDc3SX;OkmN;H$uTN;~}JD59DQmWTX8&Btu(h*;N=iyuS z#gV0!455$ND;h7%An;Z##+}#-n#+^UTZej1i?CnPEDQA{YgwXw$C1!6395Z9EYHKv zJFy-fKp#p{Q+S*VJ^nz#J>_V=g%!v^Bd5fS;)|N3T^?Q>cjx>}9XSTTf-}g*YafNUiD+r&%&m z?@h*NNE7nym_&|OeiS%CIkFoL@cS1JAr%uK_F_Ung_2sEgb41!k5L zHE4jwTupIgZVk9CWkQ~bUj~bmWii-_SsNZlB1d`+k!`5W?d39jWDz==^HR^eE^-g& zr&Rw`1cE3VhBfwhBP3A&#Mg}J!fg}!>rtT-^|Ytdlsd_g;**09vCRzd$b9)jAu9y( zvG>*fpQiX}j?}cE?zJ-^6ZLRP&UN}K+sJhd#M*Civ`_HZurGM>ep3!L)D?Jol zDEI_-XX71LmvPk|BYsAo;R{K@dD(vGj^P>6Nny=a1UYviK?qEhLKL|vC^SA1*H@2_ zKtb4V?oKvYqbs13U=!5!92QQeDhaVAv|v7@jSY%)R!9JZq6?%{a%BD%At3z=bub|{ zI^ww>*A}E=J~kdo`-9&WpzLCc6vpZz{aZhZdIz|kLLlpLapalb4*9c@k0Ogs+7p_5-Scw4+-vt9`f!$Wiokl= ziPl3-xVAty_Y!>x_G9aEY>NQD35$(Vp^j@>D|-k5t!!Z!U_VbzlbgpQ(%5=vz+595g=$qqcT#`bnySEO zP*WyhVN=F21GVloc_nM>jIk_KP8kY^I~>+Pp26drR;toM!zH00#@l*Q&uBvrV+-V7p;Qsv1tn(T+^@05w0y&wAiugPm4<}{QoZXZ zhnfD3Zn8h=ocvL@|Lbi3=aNn3(}VOk!}dRyXQRu16vY4f;Q#r1ug9ou_21+nJa0Zk zcjw2Nt^D`*P7Egr@F}39akvEBn2P>RW>DJXIX*`3Sv9^3%8f$xkrDzsM7f0 zu>IN!hx%k`%k+H4kkMBDtMgJBT2pX7SN6Jvj$8&ymqM|7WC)xFXIH+=`TLEHB903? zjc6%68<4uSs^xp6y=3D~--PEXF4|@_z9BZ=Pa%pxE%PX^DB%t526hkV3(?t6CDalq zzP_|5zQ9kOv|QboE!bRMX}RNrU1nRA3}>+-FWx8GFWf389X~{EcdD;1`0IEG>6=42 z8P2eypFL5xpOHQ7HzzR%Pq{Xx%fE}j+W3uxjVUe~tjJb9eowOI{F%OKu|v5NnT8E+ zP_1jsW^84!wv;kf=8rhxGo!NrQj&=D=f-EW5j}y0E_sECQm^lh{%V@*Qz&c>k~7z3 zN_T{h%Jc;lV`QT@VeYi*EQw*g8{^;cj-8Ce{HirTjWAcG7=8R#8L%*r|BW{^+tfQ) zne&s~u00bd)cW82Ey!mhX(2~V6~=s`^k994P0no7>&xDj7cN;(5iguhB=(;gfn=e< zA=52m_PDX}zhV!jD+b%ox4vg?&TfMXGU%As-!Go}575o(oe!XalGv3?+xItww^g!U z0|R?0BM^jsF4`&ON~-wA8_E2x9%M~wL!g!UJ+R#}ujg0SMcGM$ILdFsj%g2PIK-vs zZk@KD3+?uFT>myq{!`niuDsc3HnuV!5^IEd{f7!$#*vnTkTKr#?%r`H(kOYHCs9my zEFjfNG)VlOn8F3!-v#h5F&g1**VI z0P~v|uf!TA&E+cc@}uA09{`p}Y{zJKLx6^+r0LTbtdSuNY3PAOXm_LrRj0&de{ks6 zDSupxcm#$kGz`6!LQ0#Dv+`lDyDB>|g;amZ%%K}&{ye<-Cq;5R0Yfh(mAHeKdJQEy zY4+Ciid3Nld}2q<=~J37#}g5f;_7o zimR@e3prb2VUEg>9QNh}(mti_!?XguHD}9bEu}<}7@*!#7s729|G`1~AOM#p%neGRjw79z*3pbM!+e7HymQmp ztioS$8EhB_6+5=>6>wEkZRk1U(-W}T&U2{B{t}-33ttQV(ymN|p($WA8XybFMP2KVPZ5p9My;ir+K>u37->R9%@07%xIq>zh_3cO*_Jd-62Ul`R>|ZFqY*~W zmD+hd6MTJ{Eq&}gUzmg<*#uF*p@EvD!k@cezAI;pAqns)Cmn-Vm&foTliuGi@pYmv z2eGnKCRI$VC4|oFUF3h4;1k1#d1{wFY#ad`gR63?+2}@I305#r7xc~0+20}*_=)38 zt#Mwi4s>xX(=k1TP`n=B#t$CaQFchWlZbS|G~86J+XH9^kl%)+?g;m{;eQLl&wbRNVBe_biqd5mjj#2CnG9-MP?#(V-QP_ z>)*a~P8$XL{Sq%Vr7iiWDH9}C+rw1T3L{QTah2*qZ2b08nM%CeS1HAqnYOmVDaQMd zT&_Izp%a(6IdKBJur%n!Ur9P+Ge!FvtyUWDo!GqV>+-e55?Lt={hnVa#F(t+MLP= z--Ku5del(bzUFf#+l*FH99fFr7U4=IclDn3qC-aQ{7rS!-_gGeqqM~x4DEy!{P43F zX)}d}J?zcSkx2ipEB0f z&5mAC+nktkDNBrfzKJW{9`Hs(Gl#sE@ggUP|IU3qH@eDY9EDn1m<%mw)w7#G!!>x% zd;4NckscTsnXk6wdsq@Vt76WG2Fk`xrv9kEUn#u56{gQDd4Wh9cn;r`4_ zCMJAfe0F+DhMZ(O~CYkw}irX}+H% zV682Y23QGa9$UW0#Aa#;wq2G{p!IvX$7+U`s`S1WC`DaVsn z>#qd$L8ob=n)IEPrcUVfSgJEY*0|v_W0*Rv$FyeIgj%{kg+AkO1kqJ|DP^|&G*E9E zJ%baOt{e=w`}XM#c1G8qhyDUCD$rbCz5+chgZZW#Qs%<=9mqUHe8TCUonItVbwD1lUW5o|u?3o%VBg#hMS)MgrpKt~0bE(HliUHKK;lMRlj&>B8{&8LR3-DAs8 zt!1&6*}=z-8@$A-yA@W{0<>Q@Q$=8__A35#tPonwW9ZF-ADADg2F;qlJ^VRX%t&kd z+so6qGqSY1pSXNkPokpUP(SAlKeRa%EBPt@^*a}Qr@v-FzD@t$SS)3xP&d2K3*!Y*Bdnp73O}6yf8wSOu9iY`a2CewsyBi-o?9X zWU1$HNix`>KC3U2-oMzW7F>|4)~=mD{PUk3r1wHqDk!@Iu0K$|9On-2ATPKwV-?bm zAi}h{h%AGz4QfJ5W~;A7*Xt=V(a@rzZ+(&>38sU~^Sd*=?vGrsKP$0c9zb+_=jpCT z5X;ocv7Gv6tyshDt=?>eg@r|9uT6dna)%V5n`^KYA2L5{oMY>puGQ?Xh9@>KX(Mmn zz<9kNhBe<0+FQc@U!lAWw7>uN?y}t%dR_{Er|ZgBWJg3`WY$k@`Om{g6%+M8*p!)Q;obyb;ud;-vm3_5uyb_l2#9&1 zhmuu*({}6fNh2(9vJ>{KF^IA)h1KgGJIvk z6Z$&Ri<)XeXKy))Na;6KSlxabEn_f&jApQ4#AL+|y-K$f^w3zy^%z8GfZo-D}2q(bPizwU)C&)`PLv~ch4X~Ip@@VjuFU-Lla@O_N6mKkk9p$kV(aZc=(JRYPLW3U zTB~8?@V-oa)Al)+#B4+~Oe<_G@_F?rKGg*OvO1LeoTe#OTM=oyckACNo`-YUnm{1m zwL-PsAWTHT2yfD>yS27O4Zj7=DQIj%@+Kvkpl`B(Zo3{w#-W4zgNVY>h)N?tzi=uU z{{F5agv^~1ljU}@K8U#^KghE8`Wr5BU4c%^zh`R}O2)33?yp#!f z1>UnlWC&fmn}hxvrUCvBu&fb7H5`Uv&-h;}-2yM<45C&J#s$^n*X$fFX92W4&v2@j z69iWKXiU=P(ap1EFzXCoHdQJ)=T;>AtWRy}spuVLZoc=-ck4Z@0-BP1QVlA(4TgV*R*hdKv?-Fw?CM+IjA>QoAAYN= zIi11rIyJP46@o13#LzHfXbZ?&C_bmJi9h2l(Kj_?Tt~O)8H)*7B~rM2Z^dmeXghnK zo(lgR=U!d|bZ zMDX9Z_HMF68Rt$fdb(-IGKNhPW;!t&!)u6#P73)!lI40=T^(F=l1EeDHU0hV-n#Y6 zakLOCDONKXcJ6JWThjOP8!}O%S!ue1im>YbvoVIFhs~UZqnF)pPHm$?wAmwRCP|6B zqwH?}*k=Ped`NTA^#@6Pd{5o&fZvKtUT0){*ZWQ5|L|^j&hsm;d5Pr%FQX=3>n92V z1KI^L3KwB{LJAbBE*xf;{KqwOHN;`lNMz6GjvOJxFKzunVIloA-mdGuN!kU} z#vi3$yw8u*XtV3;6vr~O$LjV+Mz$r-qeD}F6)H*rBVqq+Ld}pYrG?<|BUyk#B*Nc)V3`uCreI}70??G!gL(9mX z#8mXB+GKU*;V@&Zv9PGH_Vwa%Tp?$1HwQ6t`t}tk8S7Q*GO?Ovtqk}lkWChg|Uh=w99EK%)0~ujcr;eJlI$LlUhl#6<4sksB$7}HI1T7Y9kSBLukLk zyS@=#h55$uH$Zq{Hp`!_w4c zYhIo@)=BI=Q_FazwP8fgd4%R9^)y;y%h)Q7{S(;N$i7<1z)9C0P$$k5m=h~wkqS;0 zGm59N7sN1+*GuO`Q-!rD79EvZP)+3{|c^0Wj&e6w1 z149snB`ntdgX^qe!@M;6)fT~8zV|m|9?}QgKmhh)q0bG3EE7RF6eoT*S$AUyV!04Z z78j%>Cx`4SM0A!Jo(5`=B9FX=Gd!Dms6wMxKz*6Y_GCV(!bZJ_KIv&sWTa+O)J@jX z`c@OL`-16)qf!eP9dc2&zz#rHYC6Zm*dtS!`o>@w1wVcvx`8ZYsk1exX4~A-+O5nx zi{>d+%1NQ6IRk!Hsk{N)QCWIr3X(Uj%1)(GR7)W*crS&+txE6tw@w6Kd9~1&x2$O)dEUG2bZG^b8&{bUT`YEWI%it_}dbIQ$fMy?&N35lJ z+wQtmGnP6F>AUne@#kXCLjf8!Vq>G)qD``Fdj@TKCDPPr_U+H4+G zn8l2s10;UmGX5tFrYkQ~5oT`zk9Mi(Uo$;i0ZLzEz>gQOl&0Xq!oI6OhIc;-hua-Q zemD+#GrL`f(El?-c3PR?f2y$?ej>4M{*<_aA!9t8Zx!4AO@NYF{TUr#ykQ+p*n(+6ILo-|S`X$U=X2-jru z_w+Zr1I-K7-)LgY=V#qM`{+C{iaa4nkj0-cngE3s+FF0nP(ZqVN;24w-{B=IzO);b zDsRsd$fB^`R83Mu`Ij81-a+;>h>6A~J7K-Kdqp{>;gNMul(GU97oCKL0)hVBeYlyH zZ&2hQ9nhkESHXStt`J7Yfem}?cS11OcfppSL1)1SOwK~t{+(}Bz2(G!l#9k%j|)AseX#QKu5i^( zqze7j!3zwI#FfQYITD(@cF_O+<*#U==_+1HY%EwZc*&LG%*LU>m=+1Eq-| zH=6m_7VBFS_7sFvj`s(mEyy-mDYlQh_LS*h1o^gtFlV6Eihui4I6R zTOA*(rx6=eqz0-W1+L5oOOO>@pPmRBzBi>uVJ(SM_BRouO2!Jc_1AA`Tsg3up~1M< z)qY9k<3B?bAnQZ-s*BS|`60ASQ_rozOAEuyowA=OXB&3Mo0nZ=-0M@)L!M(PU&0e^ zv^y2mU$r0u#9fk+6m7~;F!>ZZm&LR>@{BR|Z%zFQ@M%vDQW>Re&}@j-QHawf|6aQK zD;;CTCEtJr5~1KFpKK<;BwN-Z--NZU_D>Q(xo}6;{nUO+eJG=mTuKpWy z@vaE*6*<6r!lZs`#`tudeEDJuNF!Sz{a9{Qtn?1{k zM4OwbYqcTIKoaz->X2xE>?8jCln}!Z8kgbSKlSc{n=8nvI`Pm*V?-WiH1GBi5TW0H z>WcAH4zSDS!zY)`;mHm)0y$Cu+#Z|>E?Vm|T8Y9Ux~8grX05JfAHA15d6XR*384TPMiP>>lnSvJ zPB_BDGQ2YAHav2s$&FR?<_HBM9dRR9914pV)W!ER)J~58jrS;`%dYL;(jO6^?sB*f z8>e`UOp}T3NURUe#UGKEWY|~VpddX<=X?oYvCDM#IzX}jxx65n5?t-I1`@KiYA&0l zP+Lvo7X0Wul{a^qzD5h_ZnpTn9|&Lun2fZpPX+d2m$XMBCB#u%9xtV$yj>~)r5HfI zkp^yIout8tkFXAa`PD)JpFD+_28v&Vg~o^J+AW|S`Cp=iC-1=1$*iksrqhSmp|K7R zpd}(9$w{G5^U)cnAp&%Fi-MQ@9Bl~8eNW;sO9K*h?K^6X;0*`diH%x5<~f;IvR&J& zVjp86?-ug2ljnj@P8evO%?x{jhm=JspHIJNtkiHV4#w@HYC4>@$3PFz8QyUwexF%1 zwt5uO(H4BQKp}{~AHc(|8wt{SF`2rAkomVjZYjAba{4_b=}qVXl&j{nC`f@LmD=a4wh7WACq6Y3;;v025@RdJDt33Lo#U z`=4kDZYr=`h`Hr@ddU4>>8{Xt2@LNj?+%q;?9Vv5^O38m_ku9cleqsbH-;y?$GmZW zoOq0?^9;d_KDqY9<=g^M7&kWKX2Sl{`vC)`$KI{OSzfy{54JqyMzTGXZQgj|zdPR> zaBJ-UsiQTtxvlYUWBm6EfA*l~dppy=)%Sm=+P}-Qk^TSw-v1|`!3p66-rX!>z#5cr z?=stK`*-2UV$^7Ok9Yj64#mTL@6ShMT%KrQ1GISs+heB(3pcR}23VWhw8!HMI2s;f&09K$kdBBc`Fu1LHci3%@g za*2RRPm{wJrQ#Kcc!q_+@X?M1#0itX^j{oCt;mQBmc zM9-spWg%kK?@DE>aMW$EeJ2(8Zn=}dE{OBW^Iy?m%enFu6c@!RxSbs&2GhIqPpXPx zP@I7P!%n}dWKu4!(!4uVU4x4i?&e1sARk44Ij3i>$C$33qwRgdZt|E?O}`yc7VPaS z^1%+tsH0^dd)Hz1antfsk06KXsOgvEeX;Y72DDQx=i_oEU#zHs16?{HXPE2d=A)zv zMsU&T^#q~FXG#un=K_KijZyxmwp*0tCr`24dUlg9l9xi)aAj@oIR?VA&?|4CmC|Di zjtM|dp?bsDr2M@=qa;5HqBpLKT7GsB9OV&9uHH?aO--}AQp(#Yy&a5|@D^$>1)Nrp zMSn_lt@uC>#*$MMiCX3JW5q~JlMqZjdMz3$PEnNBl&R^dsyVOY(zv)Wt5S*1cWKU> zo?d2tw>TY*@Rs17@J@eSWz&Te^*p}VJiGe3pVl=P2XsD+m4zkyhx27&$dp~PJ&4X2 z&$;s{x^_%VJ@ILwYFKD{p<$KO^!K%w@{DEc>W7M(N8=Tn8Z{i9oG~5SV)xH-@7#Op zMf5KokzKT+f`I%{u{+>Cv;Ohqa2+K0X~fj{pS4x3QZ7)h(bo9T*3+0N&50x)xVxAz zYu&yOu~y<3-&I0j0nM9Ik0Z@C=j0l{B&np zujaK?qhwJcmYvz43m6spW4XAz{kTX&Dif9TA#CsNN?{rP|SS4+gS(qH9`CGF~fhQ zYYk0Ts!W{JllyQ+x{Pn=TlB{?Jm@#<;q1ceNlEcqxp?v_A+4uw0AGC8zKIfB$#|_w zyg;&ifmN57&5B}j193wI0ld@}YIZiZ0$yYaX>V6ypznG|i!A^&rinC)C0|p(G&U^Wlu3oLnwA??g?J#cLZwe%@EjXE|XgevK+-_O{uaBV_E~ zS_yB~ha!T$@1jfTM7HlK{4kJ%;xUc!O#xqLOSL117ShF*QGPFZlbwc(b=KP-k2RKO zIXZu)HZM;Y5);{L{5`bxOR3mNSAq+>6mzU>in4X`Tkz@PPRZy-_FNDt_9+#t?;twBeoj~xTyNvxL_TSgE&n+P$<^epp@PD&H-Els{ijn`ZNa8-SQipiA5iGyk# z4>i0FbRt*I?OR*p(^YLGk&of2Q|TL=E&_8tUySEys+0sEHj>9BF0OHSL+}X zd15NYnKzZZ;#Av;)zO-`88E_$V=k*pWCI+S2*f;TB4cOI%OiTHTP8uGK5FvM(uecg zH^wjCY7=WgQpT-Mw4mT&^CUdMM%?(`ljjNHb%lsGln#Gg`S&r*A8*5fVsEBNNrQ$o zP=H81*X9P_Kux77H%d()vY|!XM5eK135&c)K&kb-vVbM{31_r|vfd zI{e8fdps^7^b}PX-{PW&e#isblTY(mi3qA>mAuJ?qzPlTBro4xfOBTbn(XyW_K8w~ zcU8JW!fd$^(jgm;pkWH(RZtQbv-GwU5z|FP%N!tsv78~bEoi!RvWG411tD#xdJwHD zBGd6*jQY^2S2qurtKOKLnsP}YIYKan1#9Z&sMQ$?W!Bu`X*0%4s-TvJTj}0*Ry%Fq zSj5jvutG)HD8)bj`+a_%LI=ZjnrJIpVPSOzcS(IoLcXzz(#Ul1lIyW}hldl<`VwGJ zgl3kXo_013O^iKKpLYCBY&6X5y2GiHDqJp+8jVS~l#q>;XwsB@A|^c1skw=Rf-UVtvxLH`Li2P$Oo6O3 z!EO92(@c-VQ&fz6mk93^?r$Eu{#Thl=`C*!p5w7f*JqE|cqx7x?Y6jdBtI*!chSw3 zSJ&57o}*nN!az;cqoYE+$^PUwQ#-;?7&>(JyQO3q!hx6w&Niby@TtieO2v*`&ftB8 zfh&b=QHzNM79GC%>Bi_Oxm6u0>8miJz5BwFqAUq%#tO97j!Hu0c#P37hn_25MyaWYPo5DnS2^SO=>8K@nLA_2U0CX|%NGY*VJdgv@i@QsL(ulXqo zlToDR;bnos>^cMfkhH=& zhSubVeyQWcFdeN`5Qb~Xss6dvqCMoSNcRMNkl$1_30TJvr9BKr~dbFf$F&)OT^9-~*tn#%P zdSXEU*)6JLFvJ9S(;van2HixfYqDBr`)=3sp|ceojmOkhbY4m);%dQ zJxXoW`d12_vBP7vbQb2c zU^=huYD|&maU&V?S#w_pSt>TtNykXW`+$#Qk%GsqeI_d*R-q(jsK0rvGN3DlxiDsP zRbqCLI8pE+48@3A%>9?CdaX?Q%-U3C6_$8XyN@U?;AfvP5!vw6{Ia0pEG@Dy7Pcg_ zwGe_7mzjYbtir--;!JByJ@#apmM2ZowYeag_G<-gi@L28KOHkSH*+Ee^2Av(HnXma zEQi7B%gPW+>Teg**D;#gcrYfa+_z=`!Qp4^f)6^9SLRkLr{mns3&ibr6@O+D9!6dr%&%`f9`eN9M#pl?4 zU6!qu+uLs|0o2K$R3bAZ@4a)Nako~ey1G;5J$ITqV)va@&tX8D5L(mO$urx&mZVA! z1Z27pftiT!$k>KUP|)BoD?cIW#^u{7oACh+M(Hrbg8P>%3mExft%>mwNOVXfa_IO$ zypaQ5PXA>hB6z4q5ma1H2wPdb>$_^FqY$OaV^_kAlg()WGo%GjS&7x2>jHn~s`P-p z^h?;Fvm{B}?tS+??;W4GIu*_7Vx-eqdrS*z+eJ^aHUw(M2GEK&>8|{fruMG5!J%Ii z)ZFH?#$E`p5h48ER$9OKS}y(8#)-yIp`ln z)v1l22)Y{=JKq+rsNyj(`oHL3wiCKp&to{w zMF?1XdLQ=|e10i{;m1~FKEvh?sh1b`561jzc=0q}tWiXO^wc6=V6~xu*kCy?!`#xd zvqMncffbFQOFfXrk6fUX#E4tvZSJ+^E~|qh?Sv1#3=>SJ1-lSRd1YZnwhL*fkb(p& zUr_yxz~3b2{RG;^^dT$6ucGbOfX=UF#Pk|%RDr3uqsOP!O*~IrCv$DOO?2ea^a1z> zIT-iZEVS7?2+)W}zw-2s#`R1Hpt?i2JCX6xlr(JrRf*fLuiE^9^xb%&t)8^B07l>L zu=&GrXVsVM2TPDhGHvaP-6sH;#dqx>ap{Tzmp5~(b8LX-`K2xbha<)6%8 zT%as&Xmu4gq~(5tF#jel)`LAxEk;jm5;ac(*37aJlk9hWqifiQLjk4?4eDP%rTsT7 zDt+Y*R?e9~-o`@Fe%U@QdPcZmn^!_Z{0`AsL(5#>X8#aCJ#>5 zzrFfMd-N+5GRamOuKI8xhUdGd9~Dn@Vsl9wz}0&o)9lo*lb{ZUd4;AD9`$5^)B#$t z-O?6m-_T57%~AtTrEJ}bn4+eE*(tpuK*lGdxWF(4l;a9Xnwqg@xccSvK! zcJawi(bDO@W^xn>NzP0bHE??jyJwt}p=9Z6xJulldhQq>J0`XhPOzB$TGtrjq#5VFPdFBF_8(b@Ck2`tug)CB_JI2>}XWJXMTo4 zlaYnNPZl(uO4_GLj33}G{j+qFop4u@?BQGaaM;PezvHEbwg*KTa^}delOmDHp#e&n zMBg6=;BCkjP4+n{&+wzD(LzvWhkljl;UnFf1=%KL4q%=>^fEEIIhzxbINb(memg|F zmK<(l;Tx#2yij$)!6RGBkEzUoL&i=nWSmtY%2gkg%uG+9P76UzAiZme$lj$lGzE&ReZ% zyQCAwkj=4F;BIS!TOc>7V}eAv8X@zm-g~&3(EB5pf++Fr>+FNc0*er9il4A{xJipN zqN_a%_y~l6QY=jhW1a9)yMB3eT4-IoD+2i@%`T;Bfc|@*-TZ=T%e=e1*|DtpuF9-r&9(PnZMT5YBqZdMb&#Rfx(^z2 z&c}!_{Zu2UZK18D{+a{1BCHHZB)&}r<%#xpFDzEHZjiGWZ^qdw!fYAb;@g*_77So( z&izi2a;Ph1H1coak&+cj&&wu&e{U@BiJf;yus;4S3xFo(e8`V#ft;VO`W4G0Yf0SR z>IIk1YSSC#_#`i^4iYB(avaqj)NZBu;7Nf`x%lzTc_g>B6NhrjW=9t<&u+TEn2J>B z6+Of;bX>Vmwb{##k;P`^r=$Lp%Gj`;R(rl*yBD%s3YVbWFRX}z)h}? zroLi&9~jSgnSp52cwcOR##-ei7WKVMk<*&|#87tv4~DHcRz%7HmUc z=*@uP`;|Ep=?K%^Wc_P%o6UE-9!9 z31XSaiGR(?8?mFS#^3Z3wy=1y5GKs1HmY4WqATuDaH6#P`O;GT>g-ILYZ3zPnv>}B zr`rxhHg8p81R4N7MZF_~}CZ%{RES9%YvM3^$kP$*3nx$!Fe==s7NV|~JSOoLExw+I>rBNW80Hx|r0=2Ps!lL- ztDj$6x^(HdAPdj+UgCuPosL$k10Uo&pdjr}>xUXGfcp>XcB-W(PXThuP}nzT zy~@_8TgoUrYv|zuYs-+DsC2wFA*ATtblg;FjY3p*6jX&vG*3y zaco<+<}rwwS+bZ}7Be$5Q;N}IwwRgOVzQVSEM{hAW~EqqY5UxF->CXWHL6*oI@!n( z5t$J?HmtSg{5CP`IXlEJMk^L{xEZ*hjMReenElJ+d3aJ|Ms^&;?{$ncxGSu<{g%}% z%PwWX`I!6RN#`btCK^#ux|s~#j~}$d#G4rb=C+PNTmK+Bx7s`Z$#f$Kdmx^^W-Z*Z zF@6t&$&e$gxeDPCRW6NNaH~r;KXJ(5#pah+tw;}Y*_{f>0I%1=LG~cGAMZVVDcp+~ z{k>HYwSkQJ5p7r0u1-1u;f5TumWmh!ft}Uw$%JO}Rv-PQqfEyX+UKUZc_OC9Rt(1V z>?!7~Nxk*f@BpydaptrC>7NJX3v#hf;Pda!*b2~Wo=a1-ThVRmiwK!*U31{9~UA-a}t$?kI4z(B>5OK@mLsAlw z`g{*)D`hdGtA-7GyA`TY?0Ik%9!~wfdK#9&?Fxe}7Z^JUKomAlOI}#rleU(NXaw(p zJ8GyFL^2jPLW?=2vySY6)$Y|SoBDv)x9Ps3dYbkt5MWIq{ zc>SVha#2zFt7@qADr{6?rqNumN@cCtKX_V9L^T(8xS*XtdLHwqS~!Dk|2^jBL8zub zaI1L~3$GtRa4zFB+?XXdqiry4a^+SpD`lHCM;Hu*SZ)mwcJh2h_YvyB`r-u*T$UAP zXe<}OuQs4CZZmE`=E=PN$kfP#1Auw3M^93UWGbL?pz)L178#Xc7jUHM8_PeI^H%*i zQfgHmAzZy$mQ$VYO!=o5OfOzdX6vw?d|e1x_232@4prcN z1`b7ODHp!~~D!q3F8 zD+xGvO2xn=|%;AXQ=?}YL3 zq|nZ36apfd(`?NWcHbIWc-$}ry0LOi5Oru%x%yk_3gmv0OH+ppCfS8I7*i$GMj=>% z8`Wy_jr=eMQv!wBc$YOtEfK_04+VCcw_%jC7TwNrsI_{d2~3nOdq`{|T1ZD7x}{=J z)qRbY?NJ|6g!vSF?L;T|kW^QrDGVx`^F7?l-`q>w?Zo-h&)#eTAvCm)dnIhi=Oi9c z$0K8J33{l5JsyOB8@GIk?TML`FlglK*}P^-Ho>eW&8e= z|Glls3@Aa1g5RL&Im!6SZEkZ2k|R9-*fabzG|8;D5xykWjtlrK;*{o1d?y5m@6CD$ zk{kq!qejiAnfCMM#xL}!vfQ;^=BQy^lH5xgFyhV}G1I!bH#54QHl_+mn6QKoJWL)- zbTaKZbf}2>K^mC|KEk(`Pg3cI;E3=ksn|xk=omUC_sMY@&6ETz^5zG(AAi!R))+DJW>CmaU*c;K_zA(ZNyI<hZv~@1 z++1&wI;TcxnT|B~9Se8QZ)jubT*>=|Y2NGKVja_^J-;_8(`RrGj*L*7m+A$VCb^JM zm*`4PC0@^^3;2kVwT0$3KEy{l;tuyqQ3$e8pVY`#eoh7BaC@4`=W(gMl;61(p6+)} zntmJ;ibM}?ugr$prk}n~MEe|1Z+67@%`ag5F4f2N1ilTks_;ZcbaN$b};kbYy2Y%iabfe8fHm%5XsKw;nH+Lj@?TF2IlX(!iTF%Z5bqt#9>|KQ6{!*z=#v4aT8EC^n5OQJ7HjNh+e2~C z8WNV5E=FXB9UsdSEBCseq>X=Ka?Vyl4&~QWFg;qNS(g!H=d0XIn^ZOP+2(|Y;wT4C z%iZNqL@B#ua>oG}KyOMBRiaDX^qwdq!Cd-PQG!)nu6cMT=rxhFXzN`>O}ep)Rf)w} zi7iNYyv0fjd0z1b?B%cP{;*HXZy~KM$Q@Tz^r|Dmh^{dvwARva z{s+%B%Wwxv>c9mX)Uc;Yw*viJFO7X)?9Rxv)lz$YwQ^G2(w(o*$BXAB?B2 zezF+1QN%@QLQk(K(?8ydJVt%;#&OYW`eC5M1sO|T{q0UAe=RJe4NlZxFYT*({CM3r z$M{to0TITKsH9~VKg#Qr0-ph!>6iv1RH{hgmiHR;UngkOJjIJYKYJEc^z{ZMg+S>> z=^@~F^P&({>T8hOI%;|06siOp%@h(A=Xd_(9XJ_Rh97TE!GIGjXK}@MoRN&MiJMXp zF_9pC7$4_&N}AHG8cK3HNQ|FyiQ#0Ua8zh!_zQ*K>Jd zu5Nk%HOH^X(u}XdQ{Xo3-hCGX3p>vyebdbd?MS_T6iRd|uc$u_tVv&!4Utgdl@UdK zO#Ae@1F03qSX@NlqLuFl5pVKrGOvehB9Wq{Fe)X!E+S{?evRGlp`0l-lb2c!I_C5f zii^&bdGu;>f5e5gRDqw*g~VypeYm^dQGfShMwL>MCphrP`d!Hv4T0)imRZPQy8G_p zBxq)+wQ~;B#PVBmi%hOoAsY3@eV~tHxDJk4&*a9%H&^$KC2e;bK!b_`rvp3Ue`|y( zK)gpngvJuJb~UoRRjekyaLz=%6<%UVo|^-J^-F#a3n)f)z-M-s6NxDx*dM=0II`}D z4}UfSQ_TtwT&?E8ZC!=gWyn$l+>s3K7ESZey_?N>!g?bTN=?!Oa4>9*c+bN1J?O}u5y1v7~ zL95e7Rp;8kYGG8GKkcVq4r34!DUs!($k?!6n!WQTgrw2|(>2van<77fU7FsRJF!^~ zDW|gyHW;}kUYG8%4l1Y;i*$&GS|X7lKn>Y^+9-AoG!1uV2uY?!om?--DMh7 z#7dEE+YsM2BmPrk*`nx5_~r~qep=TqrKTlccFrw-qE>?qu9C89lPG@N7>4J|Yuy&->Zy*%=>3>Uu?grQ8tR={36Xcd0AAGo>|W};*lm8WsQqINW>8lu_zm>j|If*B#HcwDks z$0eAf4JQi$5N&xIa_WP&h7vF>o}rlTci&%T;MXOvsC!*vJ7N2_JmbZTJ!@~#uy=m)AO5V~^9rN_7SNE|rX4va$?G9Jrx`vVtnVbm^3if?86J(b{~9JtuTQ3(Y`v`;I)h-mpdTnv?0A7{@`X zIHR9!m$r7)LT3yTK;@yH;=|UKw-sE3!08h0BA!JQxc68rpBis7WhEyL!#xwzGVKbw z&gKb!Q@a<6pJBm`{V|(WyNsR18k~&vEzA**-Z{*(U!TIs^URU<5E)VB0V1rq4TORd z2Aj zm(pKyJBx`CLHK3%7YnL(bq<1OP~>+vO!_*Xc2p<$mAJkNe(Dg2Zce^Mpniv}xyd9| z?;ckCzQ1PKCaVOC-R712azoYAGmY!#SfSg_q-=t1{)S`rSxH?Jz?v|L{k6ZmKcdiC zJ{Wv69pAy8QbphugZJilm?(7)2K>1eXjc;?Hn3&>&MGzYy?;EW>|Fom`gL$U`v6q@ z(9R9*ip?Vo!MN^fPa>a=HXzD?#t5K*WEe9_vim9n%~Zlu*uM9VA>!*f{##MRmJ$a=Jj%9)MPLk^7OF+V_%2SlR@J#^S6)cndFG8 zofqMFpl)^`?DJGq$7+7Nd)N1e5tfp$xX;}|Y4kqQ{n6G6Gdl&m#-t&}_j_baZHcZe z+$GSIV7^vq^hEB+))UHjaHn-^=4to z0`{1wSoQhNaO5LUAD5?}4q6tzc>|JVr&UZVb`?ZpzxAp^PdUD%$B`tX<$Vy#npw|^ zBALZEmS{^ zgu~)DJmdhnc7trzW5rKpa=`Aa6Lo=$E2>+Ps7l;%XG*eWxqEJUvU$7WRHj~fYyyu& zRjE{Mg|Ulq4x^eg;D$>IPgW}3B6~^24;)WQ=YyUCKlzyhV_epflTQ{#D)cuH0>mlp zxbz+VdyhYv?mWK3{zh;qSEnK~SL_$-yz`&b)A+}G%lF)ROTSZ^d+2vN1-nM1F=qFq z1@8xL$SMkwXPoK#b=nv)5piqQFF0z>BH)pvY$)b>)}BW`skoL_lj7fEVT=`BWS32M z`?Cs=_VRH7^9f13Zn6VD_|l)iVa1v6%(eY?r+Lwer$V0)9)e6xWgex~=ISYxWzr2w zr3+c2d&ZKYGeaF>T&A^`NJDvqevJ$l(C~Z*Uf}Tep*|K{D?*NdCTplTo%Wq$0YLsW znM&Yd0ZaA}k@tSOmiO#q;8}_Ll#U%AahV3qw6e2KCo_)Am&=%}VN?jNe%R8bYJMn&L5%PI*vIK6G4=PkB ziOn*A=@RIMI*Hnn9BlW<8F@F3r=a0NFyD7$E=+yEQUx!7c+qU-$9F-ODkSK=F~0Yi z7e4LYj%@tVP#n1*dFFHy%IzPT8Kke)gmx^q626AgKHZ5uwCIGhm6vhzQ{-H8m z15>4#7Mt%O3Hj3QURZkh5pq6qImev$HN2Sw6lCbXI5Fq7Gl`T};B6A|c6Gq<8O->S z$22<$FHo7=TF_N4qWF8B@*8yKG+s2SyIi>qPvun`u(Q^ZlfAvcLu2?jR;0G$_>YA7 zM4JC9?IAiwkiNPZh$hd*Y&zgWbaLU_A6-pqH}x;b2{`znU>2KwdD!^jko^@kt5DZ= z)Y=Mn_7k6;YInXM0qli5|GS`xF~zzAUBAZ?zpDfGOvfu)Bj4?UkaK5k?~B<|J=V45 zxxw9GC_8%WL-*X~Qfz2S%~|U0J94O<#S9XhHA_<~2!P6-^-{0K&Sk{z-JTO9az{Va zp*>|wE` zmHu8!XQU_D#K5AcO^DFL(c|H~8@k`l=q9f#E+?mPhFzW8kNR+2d(&k7r|yHHWqE86 z7BV8TF`rfWY~Rc(8{w`aH8>CkqcGLvu~ocW8YwDLZ1W(H&nRCm2etWl?D3|lFs?gC z(kWpua-`+WD3$%hO-wFb&Pz(bwFw7>{H&MwMAR&Kg^=cPj;q^;a0gQrMu)43-?Iu7 zdoBljk~6kDSp?PKQgG2c;QgZU2u~Z=FJGPUK;EO&D8pY-1|}1s53iXY>E1G9%Q4BQ zqbiHwgjB*QUKslj-uSY5QGOA^J|B$sHh`v-X}7E19}2WF+4x(HAMhAoXJ=Tlw^CMc z7>frcntn0~1oHlxA`C~+kfPUmNsp*#4DBU4tlK2_JR%XA)nlG=7&T~{?KJ*3MPDSo zadd|zj>|ztJdoueME@=mz%h4u7z zi{`{1p3}U7%SjqXbalWBWn$lL`kC3~$HC!3)H}WymUD?$M}#|SOG!U7nZy_JnPZ+{ zv-c;g+2)$Bp?+A+(QvcLWnt&Ew`5WR%N^!OrAeO8L*yIPb!tBGS3fIPFge(NM-q^Q zyQhzVTd#5%p39SUC@tTHFNZ5WhY~;3xwwwJ4AaF~h)#-Q#93aL)9)8WY3UvvNWtnX z0WMbo+=es)+bX8ZXZaq0WMQYw!UYCG#%QcPq_Lrs1CO8uas|G1DWS4`(o~>280k{t z^^aw^wh{qrHY$_6m>$3~d`Q@^ld@m}+cG^1}o=}sqbg7vE zgu?Oly&>M}j^xXNp1%OeY$eBn0T3^{@c0B&}mkmTytU%`Ml}* zX?v-SPhf54&ezoAHLiX7rv*pKBZ8WZW^x_W=S5omMx8+_j~-h6jx~me+LHZ+B}Y^9gt&P|kxlr0m|=Qw>Jj zmZ2V7%U;R`M3$)p5YCato_eWGda1~E94LWW@=sMQ)>Wi__U$Ou-pIcPxdJ?H8Ej81 zmM#cuoYZ_*A174J8LDu6H&xeWN{-jMFt%ffzMT;i3*BNKA50(q_mSpBy zTmEu6P(x zDskqeuA!XE2I&z+L9r!?ZhPLVITc|n8AW)I(g zWr-98nh6(_7wja}@PD{iNNn<%QKzGBt5AYe(4J!lE;l8huQs=S|Cx#x2aQ?44oe`N|Hah4t|HtYOl zZabGad~W z&W5u8v8t*anQR^rB-XsFP6v6tmQQkSC(!t`p70^(K~O*c5Ly zcJphcq-5SRbOhT^Fi52|hOI69)tb?bC^k)MqUg$LHt?C##v>P;!iJ&ii#B?gC=Xa_ zmY2{n{V!-j(gE z2W~v|wP*#Md$PCn4b`y%bP{yrE8?f8lIuxQw#YOqzdO`dHKyZJ$vfS%FBAn>drmY` zUo~$FOSI^emNAnQ_9Kd(TSb+2a!p7qxJHoYDdR+{`&r!8%v#Q#g|S?mMP{NZfFxm$ z#WVAx(Dc-Ak$<9iS<__H9y3Qb>osbA9Z+@aSEdeBqkS@yVmChMg=D%ooo-k`fe->I zS_{s;XwHf+AQ{bkBL(39f}irUT~T_K95*)2A!(MDNOBe_HuN87u~;%6F2_W7bAXUJ zR}9af-7C57s*}J&UBqp;T zHoYzQ*6G|p$XDvm$)#BoM(Ooh(SUQIigYh{L!yc;!An|hcPxlNCvWydr$8;n^i{V> zXU^Q7%FW8~M#MKxc&0KziX8% zM^O56g$`tYxfnfCQI)87QH`AwHF!D#Ru5v}CAH7icDY?!RD5@-JeI3+**|~m*NX?? zTz|;1po{*wGU#KG{LgpqP_an&S1gM0b{7GoPz)m%5q{{|12c}zR{tK_Ovm)`K3h~U zzE3akbM1>Aotf_hk-6Q{pF9QbZ&B?lgs_3o%E!aHI~{Z`N9oPl7bqaGZtDH{otX~j z?=PyKhc8c}gK=8-wbHy%8E@C($^n7Brm;OuzkjA$4*vJc`1Xm#)p-YD^+_zV4;~Nc zQPQoapbMfM>c!`C@*iP6=!x8$XRUP+G`{(AhIc}TK1z1afDZA(zxDz9a|rNg>who< zZm&T7*@p7>GyQw})pGNu^GgN&<$Y(HnmHe-l#2tNcA|(y-@^z?EpMj!RT`}_8O4yw zvTY|veqqj3A#1PD_S4pT>wbjmS#S*23LJhgd~*9;Pkhky+^f)WsVOlOQT}$vU%w1D zRdXUgx{mFKf&Ge8BZLxk*Uqf~n3NShGA+pO9*KcVnJq(WY8|ukBiS3kWAy2TF;cv)X#M7~u-O*#!52y9E5b@uafZ#;T^w zGP)b((rEhuW@&>a*3L+}T9s0NMlohdgQLc?uUnRrYvmuQd>HW#HV)7z)5~9>&xe>( zSX6#e?4d?m6t7j0w!mjbmJ`y$9^}wWeX;VQcU8p-$P5xnsT-6Euu2KgEpOXA+WIg7 zUVeGEE7Np4JgKVU>UoV3aX5=wU#9G9`ilNwvHC4z_)9>0YsV)(c&lL1`qHjEO|J)F zT8K=t-ih8AKUt~_o;^AU3n*0EGACb9$fkM!^x@>)lj_U>-8c#2ud{Q6^2{2RkKhWG zsXG&O+Q1S)XMZ*wUier~k~oX*byEOZp!KJCgHD4|-CH8dtem+^B{I|q)hfBXc$>HP z$FFPYTFD793ReOHw;-Qg4xa)Ksd$W5Os4-Qj>Dplz{f#FN@9W5Xg@#buMfUaJSry} zfC#geTL+Y3dOvATwJ9x-@52ImWjycHvP_R6z3~{>5iw-9EED&oc%{k3t?t|-J@h?VHr7>`&{H{ zj~u%qD0AokH1)~0keOdA5uv}pun5TMk#Dg>j^Y#QeJOu<9b+b?(@>P$!(_8k_S-H1w{n&6)y(pI8j={1K<~O8`|C)_CDRTBv}qFp6b~w; za#j`k3x2nJz#bU(^e79VvBykBH@V@6WNork zT25o6M^1?Y5yYX@>W^-!PJ|E+l#P;rIWrSPKtd1GnE&5Cz2`S^%Nj)V)9NRG^u5t@ ziK8f5X$6t~0jU|Pqco5Go=c3Rh5jgNzT zS1Pv8_r7Gbx)Z21!Ub9GB1N2VV?)ef)q&9LcpGrqfvrm%3jdC78A#>&Mk20lK3t&0 z1>qbh*x1rqpL(g_GTW@4>){}elXjLF?f zPo;5a@~e)8GwK;Sac`>W;hB(|smeb!Np4o*rG^O8zM%t?ul;LAV#`t?fYa!0mbEJS z6^7cICx=h08dAF&x|>n53E`Q*q|q_R#-238%haGxo(^#@VwsB)zYVlV`2B{sHT zq~Lm@PeE)E2|%?y&s&Ic?$hSdVLED$e9I2Ir;0|@VR$FV2aSjx{G;#2Znqv!b3(&k zq5dpq1qLPIGCPRSNjj&)1r?&Q;H+bWrnV2fqN{WhlVUA+%coYWW5P<(RBu$15!I## z@8_%er=FVl|BUaX+2*FnvkWe_{wCx6i*MH8pdO8gTlHxHb#AIqqx%*{!i%7+6D!Di z3XTDwpoTiOH=Tg?h|DZD8_dD;tHX&au3}p8zv6ZO_&~HVua|2ToCrS5=w)KIo!gcu zMe&)=By5GAcHEgbp_0iC2{4s58~9zol+UaEDO`&GIH@97yBPU!f$U_SKt-N8w zL`aUiBt&-(PP0v&PdKnE=#k(`=sA`)*%be-kkBc%)(f#Rkb+)UU|~6x!HD$-zEYG* zX_V``TLTf+8j^DclbIQFJ2(!Pcz>>3Df7k1{#VxzC!3O&*Zr#3A((yzfu!d_!kVoc z9CZ}LU=1sEa81^X3^M7(U90rKCY*KR58Q+6%N`&&vRPknqB5BaYA%R2mN6$(>j{4c|kuheP9noVdGcma_9Z4qq87>R^T z;=@jqLh4D^U;Zwxn)hz3ZK%p}tZQ=-dw>R7$LkeMFpDiWWC>qaa#g?yPk_^JnAKvD zWHT6fwnMj~7kdFAJu*0XH5rI^reDTM*T4DcZe4eeEjHOhj0chuq?$%a;+Yy<6i~A> zw8KfJf=XFG9BqBcMD{{>8!%@O$idm+bThI7-5}QaX%->JxMh&{EyNJeDb!G8(mitJ zYkoz*@P#fJscx1oW8W>a1{;Ot4r@LNueF8B*TY5?jC3jTUGUr}QczmUziyJ*m=T;y zD}WRpJvsXRo{!U67*ngb`+mx*_cmMJ*DG$Tx?yj`K>jsjPV{@)R4R%;+ctxo#OQ$f z1~XM<{>6?ufA}3btG@Ac$yuuv=%c=>=;;Owm^|~H;TWmMorx}o$v%djvJr@Cw;j<_ zc8nwj@>sWmsFe15F=y8GCknmb`s1*@?8^PqxCSR4(0F~0h_|sRX27sRpLm2{*)lpoVISJ-1>2tB_qfZzMR2m2DfgoOpg@| zB$~yH>i;^NXC^@(!9ga}uFz=!*hm1x)L$#?WQX|tAo|eo2$QcPYJ%XQMakaR-gTok zT|ENbGu8ds?}^vuEfZ*R6U%11?W-APRH?UJ&{3R^*X_q^WG_As%Zv^bK8Bh3Hz**8 ztpQ(VU4Z9YjkYdQ%Kxv-l4&kcB9vEiMHhSkdAthotLxnt)D}##p5`@{pE~b2Nw>~& z>XKps?Jfkc7MdS5#0?Z-(}TutxN;m11s@WqgVWX{XaX@-!UBi#w$*v4PS4WD-v|U_d}Pdr?Pg% znawvna(mKKJaIBS*HtBLjwU3oH}?V`ow&VgLg4|kow$GExeLuNhUineW`()fuoV=R zjT!~~3+weu+`h}qVC;Omw!(eHKp))*#+a5>^5j;A5ikZh(S}TR7A`$pZ13v6 z_l5QR0Vb4E`ewiW7JF-Md?>|r4o@j+ZQ#a-=yE$7XOXc6ee}Y*`$xr$9dC8#NQkuM z%nwQn4U0?t8Alpfte(pSzsE(8N+Dz+uqrw|`EU3#^Zb*mReu|*bH9&}TavYu;T-p) z^M+8?llLX9ezB{eowum1G+a%<#_Hpt^6n=L!oEY>HPbNe<+?;EBDrY)$_<1?B;5~r zz_tEb@*GI7YuLv7=)h+_F2)=g<_MlU*-poA-;^^SAn^GhMILIo*jY;Ojk`}6nq+*e z+(E3%{)Fg%6lU?_MKgf{L(9~i$`)rnB9Ktwp%l|jOhF4(y=8gCQ$HH`M8`A(L~2F5 zJ8e*;J(NEe{LBZ)Naz2cI2(GzI^_8ZndI%j*r^md(N^;}$Odlc=i)i4YjYjitvm|^ z+aG+ade+6Cy}t>}!30*X0RO6};wO(1xrprDGw5Hu7kw|G^Qta@%-m3LeetG^)jmJD z-j+B%Sf@pT&LOMhMDpSG{yuqW+T>t{d_3e=ZDWUXyKzfm5JO~6vE`=!U-6w_&l=*G zWS7garnHq=Xv*f^!(A2d?Xn-BSuL(6jj#JDsWQsY*njzw;44fx`dAOedy5&<8B$n6 zjUPoymoQEbuk*j7pY#Q@ts9lXSS3f8r5KtGj5MYSCQd$_#=hB?u|_u38o$Eai&4Iu z;spY|WUrtRLPE$XSv3Okh=;rsAG?EZkaTNd;_7-JX61iro@3=RchIfgx?v;LkDJds zwkel^%#JQeY=I8(7u5y=5bV9WJ@mB=U#?iMDM`+QLQ$}zG{RFm9{HnP^dIN#gt1h3 zKU!JQ6uguEZ>nco_$-+;i0gTRQmCO4u~ZLH`${d))&|8a2HX3idc>~8PS0wQ3pugQ zCBCuR-`W$g5SSUthjuslep2H~X3cECCs?svZ6kI$kvRg{>Dv_#7u zIf2Rb-WoiqD4uD`LE5jdgc#?9(}&WQL8V5{1`}33%E}E7cI#dxII6y;V z(jy+f-vmzr9{Rs;UJ^xP+F3RYK!vZ4f^c)|tsF8Uv~P*F6)6p|<{F0r7cT1+DTI0o zyN#O(ech(Q&S_2##FbRf0Iu(bPxh~&sk|g_Cgp@DM&t_g#^ynWV#ExzqjNL6&sQ@l z-`l-jxJ(XG=X9tY@1Pp2G%=Q@{iCoTWGCbUdproa>UH@M3PY2Wd^yLN7GsbCAK_v{ ztVv;y*t+aD!IM&&7g{K7Tam9Pj~qK>K5#36-ke@!W%&Wv*og>aL0zcS9(WD0(_Z5M z8&htyC&y->S4EDZf8*awG&9r1?^d^M%zw2j_pNTh>&|68w=3U{CgtG!Pq;^;lv}C? zlYoeC_&(3y+nd#ww3fqQyBWOy2$x@FO3-Xw`G06pioEsp$4kz21~x8OV$@0zDrW~M zmvilRN*M%DD}q-i0mM!uMCZI+;dO+t&h?hvBBCKat^^4Afg(jc6co@$+M#6riHUB4 z=i#B=!9`0$b<=NiZ$P#eG$3luLgnVuD`bG)S}5h1auY}nNO45sx!X4S=ao{AtCQGv z$ou(`ZzB#7AHNH@BZgE3nyuPbdInVA-JywSbhL6dzJI`saX+5HB;8evppgHR`GmmV z37peUo|%s1j1~!p--^@+LIae%Jo}ah60Qvi^R4qW6U)@{0Fc!@u?4+SG$G(q&`&SHa@v=R^JX3U*{vDD!057y60qm+9 z97Sn3B^J7;#e8ufd6(I`7?F{BHT&eHp)Tq-o!PG^ZNEubpvGIubsL||0Tsr?a%rd7 z9ABr_c~33!t=kWKv{R}yz|A5|{YXmHFGErS@JMHn74li-HU_icXXib+0>&|{5|YAWCKD5XwO9YCLV zlQQb+R)3W?qEG-_8aqLP4d&^q&_F>WVdW$ON(U9VMo$mXb>lJ2`}Rkh_hr1Zf%4w0yx{5+AC$=) z0kxlQF&OK7(jrCLt)HX*t|fs66kGHC7zJ1V2na;SHri`>wqX_u^sZN%C8l)eAB6|i zZ|P2d5IKPt?ZV@bbb15B={L8fP7x2Jo;mKC=cJcJU@y)#B>|wpX03wtU9owaFZ_e& zqwbp-9BugC&vAINhO0E*mm^;$fq7IQW5CpOn;x+aKyz(70wIXsKTx~i_iUX>F}5UP zxZ6Pcn->VAeC5e?#^=FAm1pj5BDXMnd#3AK@N-)syfvwJrA*usI6 zo!I+QKDp4z9+x)_-h4m-fAK^>=4kf4!V>>W7br1jHiZ-=SKl*zFT?nCv5>*M6FNlyL*)m|!m%1Cd$ z^c!^|MwEx%Hz(PM+)oB`4V1-}IePLVg_I_?k63R7x;vY7_-0d8NSeTmh)g8XN&7cl zD{OUH0^q-^mv?|90$&|XUQACYPg9J&sCI2U|RJ3z8f7PJZ0&N?9~{WUo9XB-Y=?d<&fr{ zD!P2Px|{ErWDI2RL%qsNN{n1AX)&{KEYyy z!n&Ki$Be6^qFVb%MRLRm_;}*iHFh6 z^s}U6Ms#~RcrI@6?}8ghGf$6Fm+W%%&i71Ha(NBp_^jg|!e;zIEZL%1b)0wW?F77! zXW-63pa~ltEKtY3NzKJS-i_`qRWxvGJN4$_xf$F|N?BlxN@N#+ zVD_z2%KyFgiPNrN(bnMr?~5UHrD_B6v3=d_Cj6V7eii$lFq~J`u>Tic=f4HYzbE}0 z^8Nqc{qMr<|CgT&fiHMW*5VUADdhrGWaLGAOUqlpUuJ&~VI#hXXWJ7up zi*;<{UmiWuKCw}P|0;;t-P>X`<8mapzFUike3c?EXBJb2OkD%lQCkDUT{arZx?=F; z)CIvjZKXNm-G~rr(hY%E8k2v4p36_<+JX{}dd*P3wBZQ$R;*tYd_2G4wv_j0ZB;I$i~z&!bxJdGb*M-A7{KmiP;@1we$zc&dZ)FhLfpI z$W`{)IS$zeKsL~%1Ov3-zZ{BwCIVTfK0v1%US3-G()o-1aA_BeIYD2T3NVsEAb4@D z{)dxxBXCM3@d+cYcab`V)XJ;S@K$ zf;UTK$oIqIY-5184SG8W%DEmN1I#1hM+C_4R|i;cF%?f26F+&*{WETUoP`a7T{4~x zyc-Nu>vMaS`6*iVjWAi}a+SCIjV@?4?LZ!5xp8gMg)C&S5HawFp-#TdO4RYVKBU8EF zk~GP&5Umwz57;j4StqgQ0}Q+_SX0tXVP)yepqO7zNfcWTPN`mAMp!dC@INFbqG($* z3T?cdDUkYv&D%wJE=p&Nwe3*hWj~>#`z+yyI}yT`?-O(-+zMeATP@6QsvWuw2$d; zy62nTjI*;B@AgqolVtvPerRfsZ+3Q*GQa7OkywW#it%&_h_KkACKEEN#F5? zVC;c;VKUFqXDkiQX2r4Ny&=MAagY_kZK8ue_Nfn6;Sbl5BL7u6<~acIXml?wMd{Ys zoMQ+L8W|7>`is9z{b!Nt@~ai8h_O;v$f!L&DdkLiQC>OzwVhjQKpHD}G3kU%jme$u zeIsCs9WDd8&7U|F&tOye&!H|7$x>17cw@Yw`t+WBxlxy&ph4F1Nnr1>eoUB+bS2%K zhk3gnm`b*%Kxtx7TmBv|*=IL%Ys*6vIP&fV#pKj+hYp(5+Iqt&p4#(80A&-f}=Rub>5$TH%; zSjZIdm1JJaB#~mtc<0%AQ@LXxz@b!QTJ#Bj(%S~Nc2Oc0-H&5L+X6*ipXjy5rAL?Q=KLbVvDVB>V+2W`9|m2koHdG5UomcO;o9~M91 z3`m9%*WUQg(m^drf%Jkm25Mk&H^KmgCF3bfNoL^$-gEh+kBJ3TbEL)nj?cH6r(Pi6Rwr$($vW+g=wr$(CZQJ&@dhh2s8s~iP{IPzm zF-OisWJcs2R|qN$6X@8*u9o_mN=Kq_mXwA8rAWM$kj)1hgBB>53cpRKu(r91AmZ{P ztrxVW$R;w_oqFPZq+|Tih)f$R{!*JsY&FE{t>1|*R9ULfs4kX{n}ZA5Cp5BjJ;`bH zF1wuNr2To4zARg&gdks%Py1@aLqU;2`?Jb5KTHp|^Y0a1cdqL{95FvB|B97}$;TJS zjX|FO)Ut3H_t=!nNhI?eDIfiZ-g@$JWBlY9TmDHCGh&jP-2szA;#KtzVpVMGPl#*T zF5}T!NA;k-(@2(vCuCZ z9**UHAyH&&B?`C#snrKMF+EKv*__VkvoA4lr9{M!wcG=7;HuLJSCTn4+a~{q(75qe zsRc>2=~D2amh`$Rl~(dLU!ia8=sk4y+bgK?eZ<1N+*(LN5r!13m`UEL4dn4@xjFiw zoyk(0XUDKuAzo9Z)`%2jCv)c)VPBB|fb3|Wul-i*#T<+Axhh-%vXE>yv)wXYTqjXq zi%&@o%>KX@EiJ&5={wXG!(T{LfGimSP*;MhGntMG`MD>MyqEN;$U>Qulc~K-*FwAf z+Pr)X1<(b?ex^pkQb{wMyeECQaRd~y`;-RfF*X*$g!ujeb50(iG7dC6s8;U{ON}CX@eJ_Whs<~=nr1t9O zZdz(zoEw~HP*NCC-$jDMNY8q*F#Od=zLlCKw=tCVa|twvvc^~SB@jTo*bipd0KXaTaYu1!<1 zvfb>1V5crb4*+Pr7*mM|G|j1c>O42Qgzqqh)e1$CbFJSJkU$Gpm{LWq3{(jopx8Ou zexNMEMgN>%L2=&!yB#KM(4*e?H68i($`@AS;C%#NYDOKKYskYMjrpO4%ZX&dbJc!z zj#x1)%udTt#O;8WVS$3nsXZFaAWu=iX>Mqu!apP%L2l^MBoEMt9>90zf~Y}#S9_rv z)2&|DSbaz!9En}JikeQG5IdZZbD|S&1W-l2ts1gIhKh{k>_tvE#8-;~@2t=6G@Z6g z`mYdYnHkq_O zY}a;M>gSM1vg2i>fsM8S=MVVhn$8@1YqB1u|C`i>FVA}gPwiXte0jubgM!p032Tcf zHO){`x60U(t}Muh(4Cyf%~+^z|H`ZW`~9NL;?~VXy`;%_)+*>@jkn%F6)AjPT1Gf1 z91HB=_Cu9igS3#S4>4Lte`iA*JPER&%2bZ&9!1}o0ApW#+AZLS^xs2oO?!%~-@hv+AynT%?k`~ECbnc}rJyh%lgXo##PB80cr(}5Y5-yk z$GZk_I~NcZn>c{_r7@$9A6EWxTpq3U!h9D^p{FE~VBG%d+9+Hi4ZJamO%c)m9jB>* zdjNFvz0C_fNNeYN`g@Yz)of<5e%h-tZQ}o+HEN&fh$Wpu9!9DDmY`oWrLzQEgueE- z47FB9cx({SyJ&ADBYXD);+YiCrSWLWzxM&Gis9Sdf(OHLEG@J`m$2@wsJ)0!;)RJl zaF61^b~Bl9GdZFIOTvQJ)U7l3_vJhy!5i z>-R>^F}eV;mR=Ah1rxeob}VcmLguuDo&74RoyPEp2Fc3v8y(5Bi%6S&aCoCFz~|7L zXB?>WzHGQw~ zMhj^M>sE$g*e@JnEHk))S}`d-;)}VH3-_2!axwCbr-REY#M*WmQ!ZCx;Uy-JP0-z^ zy)Uo7chxV{%X4udVH;k-I;()%|iRUTTX{}XDN->&u1#jm_C zF^(mNdw381ws_G!*AJS;j{Gf;qpwSW=N%(`CUS6R_xxKj0&)O>)}gL3lok-jPC_&x z>x&>z9R|0lepY*GNVVm;U+N(SC;KA@zx;-ax~Df&=Z{918JI#{xux6|bv`B;C*6%t z6ZkL|k+f5k>COyNNqygHw}pWCDVs46{TiHPrg`kb6$o{4=lWlV(Eb-g%s_k+C|JL- zmynA$3sWi$$XlSNGX8h!CBZ!Jo5r038Z(y5x1JKF*0<$jV@OD{`jOCH+au|CD{TrA zr8nJ~(T8Q$4j8O(@vxOVSFGO!Yq$ai+PH*;&pEQK2@mr^^(n-qY;P&l+~SzznuhEew$63qs}4} z#*Vsqi`PW9x=IPD@+{4j-1%PZOcp4vjZN>gA=EC36Kv3!i=IJM zEkytsI5|0$=)-fujz&!S{{U*9cER`N8&KaKNQM_%!@4!XojGwXIFtN{VcVn8fBgLe zJe0zh#@;wr=vFqnB}%8$%Fp(HDf8kY&lg!GC?zE^8hWfHva)3Rt5cJ$vuuqM7bfLvBX>3<_?IzS&h z@GT`q!skgFj4e*rTdI~Ua&9zy1JecvWZq)~t|>?@)%Nzu?u>_RoQ5lh%`xd41+e4o zDSm$skjN3g`%L!cRC4D~Ah>Ob7r_6)cSl8V(iA6I;JF3%qQze?lJj0T8xkd==%85( zYleb@lM=Qm#Ul_Knthw-g}MMqsb23}6=?9#n0KL}Kuhg2~qF z=_$q_^c4AD}wlPH6j4&B9I;Qj3~XiBAuu{7a2& zsI)*6UtOi5a+-PE-Rh=?)-4e5hK4y za&$XTSTEkA_sY6wq_wroC`vzv$xn1zaq=y2N6A zO<;(xzIYa>!!HSCL!tS{p*G!9cu$P0*tD^#``u;d=K@yL;@yXt7wh*8&d(=Rs>o&>*b1p@g`>cS z#q+kzkJ_!iKyz!^@g-hPX0wfXc@54>b$p#3zt*C1TiC`y$VoTb0^U|WLA2f3x$Q_M zg*V0W%NJ26LLtG|ny4qRnRov~7f5mOTL7Y?HQX{3=$syfIC zwzx^jHr4;`DtLU1HlCovAD%|>IB|D=qRBJ`4t~Mj*6rsm@Yo6hENMq~>_se3ATsgZ zjR|3I?Sk^w%AcpqAFyLlB6vCpgQn+df5|vS3fu(}+8mFVw?~LGy(R;k+qeFMa?86B z`Mt|QKGU5&Al#4p0B7uG6v~jmpVqmmOT^39o-idRiK71YZNF68K3S+vE-JHR$9Yxf=%V1VA z-NiDJy^kbUD|9gv15h>=2nC{gLg%kvujPi1)lDe8wzSvpO1o8E{{ysG#-%k&vk@J6 z#F&e0^<0~$(QC?5Q;o~+s^N!YH4v&5I0Z_E*aS=S^AC?p{=7APa%Fh01Wx@bKbz?< zd;V~Mf3}+2!fbl66*xDtwrz_BUwwxvY4(;=kb~-kI;n*t<2mg{3R3aSKKjHe#U=MF zDFH8vBkDJGNoBa)R?_zuF+mE=ovjA(T7(=s#aAm7RA=%qPTJ4j*Abn(k}|?uw&rZ< zGi~&r)=1y4yvMUJ6q`LSP;*5=i$W6=HjL>=6`Spk@EPT)Y2_+4X||l^s++G_iW$#< zCoff_CV~p=XSc|gqNKEYaIs6tav(P&Csg8!9?;V_n}M815UAfV3y!JshBa85sTPh5 zW;n;6z5aUVG}oK%Jc?#>?tbP|iaQNyN9@#SK-U^Q>zgQantZe2nj zUqcR#Ul1%+$sp0!=Ro^~O#nHM`MYF}G*`jsf>fQ<@&)Jqr^wWaPjCq* zdRwLTz)XdCwb=(wdYdgO&ztJ*Ywag`BOAdAnFQYBD6Y$#6O?aNdjBL$m!7*W-6Ko| zxX?UExwfZr({!7sYWqFIE+y=cPuNh6<%W3qYBjER<`?cenMRQh{b{?CYT0yAwMkWE1U-99pmJ zaurg01q57ECGYEm7m#Jj{@kpVXw`}}=MO9i);|9E?FB#CV|`WBpGSAt$&7cv+G$HY z)gc$NpT{(-eQi^CjMOnB#}sOOtnA6W(W`eXU(#=W&ifN-E_h7uCl6!sD#e)p4~}Qg zb`)8zJ%^+QhhB5(p-)k#!Lin~Bs75Z`fDgU#6-nIO)Rqc?%Q&#S%2c|r?Ca+ z4~T#=o>uXT^{3jE#EC`=<4p^rAdBgCukUwG8a6Mh5GB|hpc;|d-90f0Il-O&4d&8k zNu%p+XJ>R4w^r>0_Vf3aX4QRj(TrDl7J%T(q>27a`;TX@-?*ISFuk2e46M%RQG7~{ z#D%V{Kk@=Cdw}Xr(VdSOK9@f*7cIEMC3-Mt2JT@m+vm8QBK}whZ{e@=$|*rkEp(NW z4?lAlDM0W^+VO4rHq06jUoCvTV=T<|_2+yrz0BwziWb+lBKdkJfI!`>ryKASK*HrT zbLone5wCK+-~P~8aIm)8@CQpo#dVP6kx9jTMOv8Ser{OiWj8w}FAULtl%o~-!6%nd zxFy<{l_IN^#>XTD63g~f_)(JOK$UP;fXkV0ryRTVE;5T#nCr#M<4#^+shl&S;l-<%Yg_2Zxyq_h~n@p;nxhJ1BMvRs2NOqJKVs`i?=fFZ< zrK{#_AVnoSY6;J-lj7JRIRYP{(UR(oqx)r7xX|gMAJ0S;sVqr{lTu6{?Ey3-msveQ z(IRuG-k6B_ZqqJe{$874h%J%oX%Mr{B2eltnmn|8lTlJCxG4MdC!tn>kM0L1vXt#)4)3%-nMBIk#2S)@iM4mFLtT9DjM632J8ASpjTSW$AgK|$K zR*K8=GzliN?kNATB*}4#aauN`sPa9_;yt!zsc|dHai`pcFXkv$-wUWiYJ2DHuQ)#1 ziEhw3i$-UkqF&ItPH{LZymcF+i|DDPANp^Wvk?@fX`;pIP+EV`eu_*K?8TzI#42xv z&re9eOXQ$Q&jqX@Ag9=&{D~)e%e;eNsEFl!X_%QJiZVLqwt6NiOzNxtLj&ckan~;Fio5h4_fLZuYZI37BT6HoY0w|Zr$zm7~ zS~*cHR_Gg^?tUdR!!0i3aqVIk2dMCHRjN29@z$CTp$0*4V9pvuLp+6a^_f4?K!vo* z!*KNJK$HhGGAuIo2PklZ&)B0?nl|coABQYxAPt)%Z&%{+h7+s)>Q>{!SYGc-<(W8Z z;K*os79S<}PpCG3qm^&2OyW#Bv4PNUFh&HY1lv?Cu8<@^;FkW|hy>ii#~T;Q2UlC9 zL#M(KHi}k;dPKZ$O1#k3X(S61;o8#RFd#;ia2}0vwYC;vYO6XrX!kB;xu*Fl=~1J| zLwaLRDT_l2cYAv)o_e~JQ+j|sB5sxiG;30@3H^HK8MprY^y8yVP?;NP_Q@w8j`T%l zRX|Lru<%+ZO*}8dKFJSpI#na!t>LZmtxe zeM>q>%BAw2RENTZytMtz1ajoOF3$h}rPJska>Mr7U_d-QETOOA?Jod)(WHx%7uoS_ zwissPjvq#;x0?~c*QqA?E_ueC!k6lU&e@C9&r*Bca|QliH}VTAQI#SJwPhy#+97wsJ-=S2Wn$ z7T5Zm3am?40V9-f+r53>*ZZpw7HW(*9ce0o*qJ-;q1>jcjwqK!ozxJ|j?2^Uo{(QoZloE__ z!j{{T4=7t>>GIC(UF%D$q1EIaVg3~5K310)U;8Uh`IHB(EXiQ9TA9p*n!nywpi0Mk z=;mQ7Pp!sb&?uEX&#P)g)ph$j&gUKQlC(un?oG!`doA|$Ij8dduh7b}OOq0hxx}c% zn<0aF?tzVNog{4mftlw$Qt#*2*TUr0@HMcDx+4QC|7~@T-c_VvSR+}Q1xr6eW>-CG zBmK}hZxVnD)8)#yy(8>U1t_&)*1(r_69#WX0_{q<&CHcn}0FrAq;1_*= zgBH%`zaOL1WUEC6(kftno8`WKF{7@wic+;iFaTcWSE8i~Nx z?!XM)>XFoZ3_VpjQaEnCjq5jZUoL>`?Hc`n{s^XA&KacILfHy;Eu2acC71sww={yT z-G^8e87b(u`iahDj(|FW0rJ%_}I&%&r<$Xu0{Jx2g+w==CZM zzhrpV_U4^f5Q_P_d@ts_Qi$EPu4cFpN?{-N-{>X}<(uBy3%!avW$ooXzzv(0H z8#6qmzPQ{GmCsXPnI*{((>9~aaN$9xvh9!jb00HigRCpg)>bRwX-%_`kcec-F|)Xj z24hHcNCrbiL)cSKGtpvcij|UzGw~GrIC7mpf($6R>Sii3#gq-A7vtcR&T)WnC*M~R zbfRxV2Xa_a-%`K<7o}UGC1B8HI+}%j9E~%LmapWxunp7%3n}}AE-;as38PM_jTT0V`CB`Z zJWVmQIwzwv9QP_T~O$BrR^pEyMlBj|**c5y7>%;$q1?8lnr{ z-D61r+f)2Q&eib{tkj4wHruA~vCO)NOXS9yoZudzKu1bjHu|0m??6Fb5&iD7`Dbe_ zrR59J=<1E3d6xd;+|sObI9?r55F&Ajp;({7iCN!Cbz}HFq13^Fu&iw9Me%1QA5;An z&}P_!J&`r-j5VQpoJbDm>=wy~bD|Tli5%@|6NCS(wgg~ygntYX0kAWGg!B<>r08&V zeV~RV?TftYY+RZj+9W@%ou5RT)hR4BcvgsLh5X|9RRb+kpbw5mEBm2IV=ap+&4M}?Hr6$eCJg%3jXQS z&WwurKx&CTq}6HwIVfRff&x#8w_-#R8ZRIJ*!$fc;;{pSloz&B88ct*)?@or5tHB z9$%CnX`e6{f>>;!(JtRy*Ufu=b_AgnAwC`9ynpfnAx$ZpYRylxG9WYxrRx%#UGK}O zt}-b8N2Y<{9hNt+HedZAab);IU|Jca=7T~+%@90k$J=TyvyF4b_b=iV4qV#D@_|Yl z-v$v8Xc>E&{9n8VtYb>eb*^mO^C$m;fJ!?#inPWn?JVU2`v<+%Fwue5m^A4+7qekJ zGl_g^zU&ub`LO6-8X4AWG*Y*AFZtNGzmWhBe5Wt+>RVg`E?V4}o)_+l-n={Ltfp1P zYUt$2m@MW-aODcp6}9IGE^TYJJrm$TR}uVldywUmcENOkACl+V6CKz12BXm^e75*n zB1DbMGBqm7@*{NNHvTjUW2Y!;M_d?1(G#w#(at|Z!BUbn#R*yO5g-Yx6S|A!u3lR2 znVj&(dmP}l;C{xkTWW-uf*poD!`Q2K6INI*5kR<>f&--5zjN~Z2Lv-q+T^?_87)&F zFuNrKd|?A~SdD39^v2LW3)nu{Jjig2tKey)f6M#J(x&xgD9SY1P1Q(QRZ(y#W$pT? z4}6`i4!cYG1ypB|8g!*^@A=?N`T262&_*A@#Hpa!bU!Ho?! z7uMeR=fB7*by_0d5O$hd?IBZ3toEcCb+yZh(rfD~{@;wyRh#7V(znLSZzW zHrZ>-o#djU%Ji%cYs%{+r1h7J$m9mgLsmLP@fG7~l7lNdb4hPq5~_KF%?rsh^RTDW ze|gLq(8PvH`WG~S0K0`PRn>o(mI!wBq&bv={}HW{?@d-RD!M#x(=)>BX0Yh=R`i7D z@jWj#uwG*gFF63CezF4nG|taF)RUG`Av=L^`m(0%t@Cc`PY?O8Ss%09>&tjdmsmUz z?i6ekE-ZX84!-{_m*X-byVDZ~Ez2yscpH{QL87_wH0T=;Xnx8oBh5E9Lo(Ssq*u7( zpvQ&t@T%%m8w)LWUbDv|fjI=I8-rAPe5t#`?4mNndqbAbCMHdGKV1IWY)51EPBkx5 zs5QCV&@5VUalSJ^<_arDH5wds$IRlN%oQ3@)cQ%uFVL|o!)g`Oi0O$cbQ^0lX0Xog z85oWmS+WS&jZ-m^q*%v=QZmw|?U~Aj<+2X%H2l=1U>8&v#Jj#8{G?eo(0!VWnTkpf z#wZqpR~c`7aUPzc_yvw^B{A}19Sy&iw#))|?Yv3afzqFH!Qu5HHwTk4i%wt6ofruT42BFB^*RRNhu&G(+jeLv6>J3=?sUph_ zZq~h)pU^Yyk==EszR6qPuFAxEKV%}3UjEGVcq6$I3mm-9@36R^q*B<^oZP>&NF|4S zsl9iE+)#+HPr*oQj63f)f#7mbspab3DDQFJellZqh42|WrV1o$&C}VfF8g1FN?i4eEO<>(1Frhb=o1IV!sz= zpAWpYK8S7z&+GKtE4tz%uKMeWLzc2NH>19}3F;qBNOCCspYFLZd># zxbt@Oyw%SD_lwhCtFI|FCQgi}u)r&$lWo-#MBhO7^wz#4bEgX_t z0F<|;cpM6WpRW!1BroaTm-Qil36IR^V(Y{_Sn-NUvGP^pjB6u@Wr^OMMd<(!?+)bN zv*~W#L$mBYzpO7A{$f$%Y!J>wA3{C2NomITxXC*Zi6SeAkPnXK+_ZIBBZ`n8Je+cr zwIyujbY((if3<4u6ELJn_dM$-AV zp;3v;H2Q!Gn}qfKebFK*6hex5%+wb>pS#U^&ed_4dD{BIRTq^M|NRy+F;Dx7pSriK&r-ivy=J}nOK}S}M zQeK)Q8qv;`EuakpU%GO2_p1!%wV|S(I)$+5q9d8>dDYz8VB8rlM-{A4y=5WIcJf7; z&C+5uMgs=qPg(Fl z4-#y8>+d6ju!9!{nMtxJCs8j*m_5=6z6w9P`mQ!-u@i=`Rxzou@0%Muz9(viwPDHQ zIzZNuSo>cc$<_!83WkjI{rD8=pS;OKJ{Mm^Q}?(hd7hLz3YamP4}9@Led(;oCIb25;3qR6SrnR7?~NAH z2=M+~p`gOhlo-a3_^ERVw&No2H#me;TNbkvOc{?>R@tSB$bdh{sEfNXV$EK%fc| zrcHPH@^NMI-CJeQ)h4uM#fD1hQ0$Pa2<9!<6-_mpVr7>n1wCj2bYrUm=&tnLOt9Rh zj@UM5oz`)752ggJdf19ea&V9n zg#sGqU?Dndz>@ddp&4%O+U-Tvdc--E16HNUX4avPNVQ6WQ7vWCEx?Au)0K2)rG0Jh$+Buk}7anp&lI-=y$WmC%W?LY^9U z1qI`Y2PRhv>XF13WtJPQR?2;3SLoBS6IbPo2mHM>-urb7R^E1FpZhNgl~LB%O5gdv zp1|~cw{U6rnQvI;`(4A~=gy;kjggIG2VmUn6%wH)Mg9b7S)tv$@w9ge>G}vTCpOJ$ zG}RO-R%C2LPZPB?kjN3N>I(4JTYfW`EWV?^!2Ok(gWOvUyvbpr65U2uT)a%f;)tv{ zScUxf?k>9Apr5;~JSZ$nVGllmwk4^8mH0w`1J=)RHNJvE*w_IAiDN3k!HndDtxez5dIHfbg&YJ*0*dd~f~e{<-N{hg zrr(L#SYc04e>*NJM?PO-YTX&oq(u9NWIkP#);yD*GPd~*lL{o;S|z-GsU+q4OI=2^ zP6d4YN+?7`{&Rj;nQU2hfbMCuLbbwRx;q{L!E5@vNSu~@9_1$iGf6y&Z-M8xo)#|? zy?NXsf0K~!a8n@((4-4@9xW;~65%BL1ba`UZHQYkISeRKKf7d0l`(h9erWig@renF&t&%Yi_6ociags{=jH`3 zliyF4Ajhw`gRjZ6^VV=*TA)+R4-*qJ?|Z^yF0z%up)hYs%6LF&B~scyAv*aF z2gDM^X^C|>m4JT=S_4%)5x3=oe#{!v`vhrm=p}eV#yIs0>`d=o`A@=(K}E8agD5nJ z(>09XBU3D?9qu5Uk{a-K&*XSg-Ps&NJ$o_ z2ZEEcye&axV8!dFRc6yobKP5N9A7 zi*Axwatlemf4h-p7@?sDM;c_8xawHvukz z&%J_kYGJ5qAn9ppguB^)9=G$XFWC zW`w6%-+axRE)mwlZ$lSJUO`1JbxI{VXXjKZ)(d7!#AqY{tRzjc{I8G*q1>pW2wcud z&HfHvuJbTup^MT0UE(T&*L;Gky+ah4^#>T=!G6>h$VC1D@c_LiKEl5Co}X1?*UfLx zRZJ9yV=9PBrAb1W^AntzwhX7s4lHyX%EXdx`=Kz-%-Qw~c~1 z6((vZNA`#;kfNb98xM#%cPjC5)u z`_x}+^PpSxDetLQ(`ctx{1)4MefD~B8@Cxr8VQjA96O`JMra5|zu&vqzHwf5hHrs; z;}X}RRrxTqMBGs@euS;DdOs06l)OJG8Pi5$7}*itMLxnzmSkQ?lW zS*38S2#x#Ej)&<&5_kAE; z(h^BwM+#>say|##jxa6ttwTfN8 zbAUBnbsaX*&K8RcpsDZO9Z0jeZ-wL64f8#~%vrnMIab`H8IUxc-m$g8Jc&H_V=>s9 zMhqFeSnR&qH>1*OK{K&_#TT^pNf#>1cAd(3E_D=Z_jWnP!@@ZVjJaH)cexXWjwlqUDi1u>8BzjtOTr2CB3;_Lel%c~gKc z(69lWF(Rzj+*16r^~)Aby?|?#hBZ7TA}*{qHVX58YH?d4spWcj18B@SN{C6IPbYlh z^D;`=o+flg94mkyBB6w>{NgrOG{DVt=}5w%IGQU%CGd2o>66kS-P*^N6g6+7jW4-b z48GDzJ$xW7a<^3mTvr4B0MoJWdM876lV+#x6i8-wN(gKxFAi!~K{ZD{3U^ywoElA( z;HKLX!b|%yQX)zqdr})%N%M8DEr(i`HN-63V>^b~N5`MPUIn98N|#b42M1AOx0Y_J^!nJiE^y=qn8%fYlR*B`DA=Ah z4}!<9at)&4UH+L}tfvt-8s}d&W7py%?ZVpCsSBAPYxpeJB1z@>9yZ;L?8|RSy+53$ zGE7O^VsDIQA*tlczbX;{I7i+X?wJ0T?o?411YbgJgtsHdPj1kn_8%>5#1#$Ih{Oh~=058Sqy@g{*6S+coD3*b>AycTjL4seVf-3aB_l<-@j3jVFC- zO)aA4eWWJ^J(7JYHLYTeIkjPP{L3WvrfI`T5PZqa$iJrockFRlZ~iDrAUd?Zrs8!O z5dW>-GLxPi3i%{_lM*|4hZ7N6KnIW2G*>$9JlY<$Qp`^8jA)B&`_!HeMsQ6EzpTcQ z3#Q+}M4HBM%7!oB9Wd zH>}W6T5W~f=}Y{w0Pm=>@Xntygo5jR7b{0jn*Nco->)Gcb-EC!B&TG~Hg`^H!^Ci0YIRMOB=L`I4>9#TCtXw7dPHX1~|KMTb2g?#OyC=E&@x3gcT;fFIo?m+B@ve#aMV_^TTe zPJStaLb3Y>H5Cps>|556;MoA$_4cD{IwvJgSu<`16!7lw{*LN)LSiT}V0R;Yq&P1WYAY{ypb zK2_chBAV!heR*Xp*ZkH2g9>na`y+7>Nl5N=o!aZFC>T*K`dCiTRbieXQcE2>wy#v} zI4-(METq669N+wobiz1rBESw|GyM&!!gj`_mUb>|F-!_R)D~c*0TGej?U&}n@tz{h zr(bJ;APC^&!mn|qoJw}qbALeYl0ROthUD*3T{zMY-^%B?#j#hr$;1~ttppZJ1@Bz=2&4){xl|{rsLi zcn2@dIoFqa)0Di~8Ldi)$aLF~8Y)L^neF{ZyG|?gLmX+g&twlgT=ffM;WVMIEvUSw zKuW_#%OFJ909D^c2(tyNnrZ{7i~jqWj*38sqN1_5V^v2d z!r4?%U;QEYIHu<3#dOFaaqHfY7fN>IbvI9thk{bopZP0z?=wGXI#Z4peJ&KFuDR6; zrG0v8DnCT=VyJ?#7dS7!g3K3pwb=d9Bu!TA5zseBqBj<%CF|B(9@X^y!l9m)2yU-vGDulLB&Q$(XX?`tFo38b<|r z8?6vY>`bz|7s*f7Hij#ZE@oKMPPKLW-my@qUCR=2R!0#PzC zSnD%_)v&P+b~YyDYL5uUkCTz)l2o>zmLv8gls1Zt{;|yrgWin+ztmd@)!Dv#y)}{A zD&?SNYB=u}ib*+GB#^#{&vNzZY z%Qd)I!!=Ve1pj{d}UCIPda!g0-Qs4LyJ43=zqn$lXW`f>r_PL|WZ6 z&p>>4j_Va_%cBb$A)?6Omvs@*nXpzleXH|H1P#nxXWeEiFZVJfa62rtq(eeJY}Dr~ z=$3U9@7{^T3`fDJq|ip01kAvz!CUpiQ6^a`*=BeoDx7q9X2K|PX3*b;l_8j%!r1~u zxijc6+R(|h%bDu^ z`67^j*AruW|McEWt=BQ@4PNe9GnD zkolpO^uPlX6z_CV-rCTx%_=SWDme;^FBWk|0`z``Va|%F{iVZL^;g3+Xp*!}G!plB z-zwbx!wAfpJKwAvqC};a%jBjjjCR;@{-GxjJ^9)yDJa$wLYw;~HC8Nlro2xS>5uxq z!1&{b=gLtw1NHEiY%Y9IPZ@|~F1EJlUfO()7dlu#BVIt(sz8Xba&{-M*Imo~D7+!! z!!b1lj01KD`jbVUfSs+n5Ujg;GB~1g6b?i}oLK^uZuEzXW_Lz1)^-zZ<+YxEt^8va zp>J`yr>sNOttxi%qbn&SSpoNLqX5%y9@tuW5zUfq`|w z;Vs9iPMHJe%5+C5qGQn!a*j zRea`3P&$tl7)j@|oBg|dd$ytrkabD--bHB2`X{CCA5iD-Ic#QZ9673awydRQzv<7E z^=#N9{r+B7vm^DW>*^9{*q1|(3J|$;nk%hP&J(A-4I6EQg6R2xWyOPXi{|LxARo0& z8ijxqNWQcDi{w+g3%1KsX{A~Tn%IsR+kZy~S%@N+jvhKKWFpKhyMK?^hFlAyA&psJ zqn3Ea@K9>sk_R)*%gS$=PSSn@i6yVUkDCcWYR$v1#rtBg$20BvXg$WJOdXcSeyTHL zOXBI4P1_8F49gDxiQ^%ce=;3b7967;5;{=(32{ot44(`u`fMX2XEX%~7V=xFiVt|? zgk(X^f3CIzo{f@$`anu`H05sRFXsLMH4IHeKPv0H*FZeV5oV8hrEyF~2-5MjogyL6 zo%ibHt3U=Q35 z`FrV54uFG!{tCYey>bG<*k#5in4Jca(lh>c=S;$(&^^9BP6wvmpT+{;zs$g3Y@piS zR-`oQDL-Zn4RSp zkV3-hx_ZOynQbz-b;e`C+hOqG;Gw0m-YtfBp4!FDA&R=;%2uq0{|!WANN{J@|Q(aAUVb;m-O?;@O|h!LwceTFy@fhAD1@Z(d7 zqQ3%J{6^;_QJabdnUn|>qY;%QmRUk$qsa1KyZ`7=Btk8#f}*o!1i`FQz?uwZB}F(p zDTtaffc;6DT&#lXY6S{9)dCy`DnMU752e}VhN4n%FsRUn;?2J=vEJo{vUJHUL&vD^ zcJhJSLn;YZAmxSZFkGBOiQb0x>2oHxGUIf~E@^fWoE&p7v9qlIotf&=w_R?j`n-r5 zd|G68J-jE`egqgM5LU1RZOI@~MbnBC#t-ik?d7&p6>iDq$#s`-ap%Ox_BrpZ5L+OfDy<}NSu9O^z$D?)M$uL>^MlDzr z44-l(5rs$;+L25jC4W@5_fX!ig3w}BIc>9uA-S5G%8nLfY)Tcu1*@(dD|wZXf)Jdk zFD~D*8Aw&dNj5?YPqk(#{Ui4`+qZJ0VdI&Izd!&nlFo}FG0xtkE{ zTER#l-RM{{<_>tr!v@IGr6Ia`>pXYZn_zo*e&ndE=JNKO%Z5%V73(sSJ$(LuyuD>m zoXZwA8VK(08r2d@NgT7&qHzMmW$XlwPi{N9>L;;3KI3im#14u_?$2!X0+%H-Uz@N z(kvB$2;Mli>VaQIUBdD06ccv+Jb?Qf*nM!6bJbS;38aM+p;OPdzcy&{S8ENedWNFF zu^>WjcXPVihxy#n4ES$wfJrPaU(fOD-Az?`0SxdkdvsUZ94I?O?(u976$zV{Id|(z* zWP9@FkVr)t{r@A}RCYesn<(AFoLy2(6&B_Igis3;ttsP`Y5v;B zNfULONv+NrWIXHMfI^!Fj6@qvaK@6ypcIYDiwM>FVjT;!F`0}PTnI{cAqifunjz`T zNHT{+DSJ(7)LL$ZW)V@T*D1ruMo9K%#=z$AxQT{p*bhUbt7B18RDeQ?YIlqHY@v9T za3U#P88rtw$K?zYu$}m=aFFV7J@uF3J!F_lB7axx0K-osU4213(E8&>+JIvL^TzU< zEWC{yX`bZ>c(6=7qbSI=B(*zBG*G4`3^n9i#ZM&1=h`P4#Xgj~(0q?9HPt37dOpj2 z6tmO3KO*aGBh^ekzup$@sZ1};Rn~^ppfZp)&A<@%fkUT@8nBtw)Xw6@h~{OAb>>9H zpri=Ri$Ie!5$&Tekwugf$@_uK5i!>0CtVTGn=zEUW?fQkE<0YW_uM4uPzR9 z&H(qfj84vpX{n&Sn_pPA-O3VB_0Gf$+No0Q?O{z7WGa*>$LKQ-Gh@PEd5>BcXD2jJTz9r>zO{npnH1(8>95cm? zFF@xTAk=FwTuC^ENj5|u$x3o(mLtQ1Mr;>%->o~2cSO>51HL7 zt>u5JrY8TZmduMvrfV5w*I`GqeBhpT9e%en%O~tT^%wZH-~Y5oYAw;HXUaTG=$?JD z!8mI{!1qrM$BZoun;Z6as%emlGJ)QyV`r_5MxFA`gE=+PDem7F^n!FJ6bydB59nVn zs$_WyhI&|30`5zyViZXhnxIdNs6-XxL+8rO$!ND+p&*?-qi^xD_XH{^nHanT+lFEhUB<3ehczz6KK{0`^CFE$o_vb5TqL@ao1hOoHl(RN;Ex^|b9y1&@Pcoo2h5_x92 z`~ykAOfc6r6cnSB>*WCfM6gV-yt*}cDG9IfX@*qmv`g3>;WZs6@Mw2BjKuXpGIlWY z@zVRpa*!|5(4VOK8HJO%EgqxD@YTyCJ&+4|tRF}VjkJDFgUla297bCSGFeCVoc-OD z$dLf9DjP6}up(CG-g}U0pOhkuoQ+pJtiGNgaVp{l-j4j}E?lC1c9w}c4AENeHtImd z52v|m-fZ%tV{R_uICad5ekJ@-pc7Heyz~N@$vfIxwSulPL~E({aj8GO&5R>lU1NQ+ z&T)OVooBi8fiMk2gW3GXUB23p!I8RFVylI(##>s0nvns(UgIbZ;CGV!rl!ZPieVT)=u+E^*?eWpy zQT}Uzw8eCVI*O+J4cfc5o+!>m48998G@==_&_!*bI!(q^& zF{;$zHQ+m#^sb@&i9S1B7?NDyN~korYqUFFarqN*yIc@~-`rB`Hn_tjWMNsa{G(^D z&FW(Qx}N`eiN$(q{2Mg*Yb2neCQg|C-#dU(cK>ST_36id7w*3=1;F?0<^S6MGhfBB z@Yk;Y?~h2nXWjnQSas#y|M&I(w<)B8?u-oxxHatbrFpwKpiW_VkmxXUyr0u9nXv%~ z;&1ueHt0U2I)7ayn>3AmVqodNi@fG2nL5};+xnWay2SHk`|I2P1|0O2ceh}blam8P z-9$#hw2&XEm8#b?HA$(fV~C20?Wk^%WQC5wRr}~_>*)cOmkD}$dL&cM>uPG4$=iDY zfSqp@N{eg93%|q)CP>K1#Thw}CjFryA#ppE1UdfZ>Zo~i3K_Cf78Oe^EG?n%@$to; z7SlJSqC!GGf`9zDqt`DIJyR$V4gd4LTU(kXuClUnI@$Ug2CjJJPL)r_Q}mV4Xz z(fRkuFz|6yUs7jH6}fe#EhqvRtO2h?3%Nv3i`V&+<5#brk7S?)=YEGW$~IQ)B!lmu zxeos$mbf30%+mb{`k7svaR9>>vCh?tfRDRWO1?st|U;)Q?#zgEcjRQ7pH>Bl~Z&+|S0CC15-gG2DU<(eWl_bjenSE5%t zX(%=`-}+IKo8HB(BKUs@pRb*m$h^`3Z+Utes0pv|^2pNBQujHH>uvLlvOIU4OpVy!mmUY zlmCItD_?Iff{V-dOd(`#9nvy2D)G5WcxsGGC=jX5?fxfr`EL+~)lBrW6+wdo(5>K* zC=NH*q zfBXGwdSmgI3vB6fS1wU+hj7@E=4Y!YAZ7Yan2Ej6f2~SIiNiAU^}aWsP+A7Qu>)f@ z2$S>25dSr^1!f+90?Vgc+}HRo&QafUY3_J$;uaW98f`XWh+ORWlep3*=C>1_SDYq_vR&DC^0SKrFFlio z>|HTU?0q_-Xmdq{LGlf&vFgx2XEfNhZHMy?v3lSH(d%z}xuf>;HSTmEOs+N()5`ZjzxwLNf|mJj6O<~`Ycg*1Vne}&Rp{^z=V{HA2bMC1 ziN3z)69ln!C>Jo@O(^_zeejV^2F(6M3o(0GVTu#z#O5?DM~v1;khjl{0?)MU#@&0X zwJ(k^T$zqzPOefn*RbV1{?D^$l`!cC9%KuIcX3qeiRqQ6Zk%Z^exo2IPrUy&SP#lh zHGu}(cS)4^W-!rw=1fTXkdd3Fr-3o}9hw6FPHaGymjCv;&xK|Q(;f9x>RILIh?Y~O z`Uf6((Ak_DFDhDokf(2tzhPNG1o_(@Grtq?fKQnXAOJ8W-3}oPzO!Eb;GRIl!3o0yux%Y}JfO)z*$ZA%{1 zwd6%FfY*EpcR_{BUhWKIZuy6N?=%wQC6xC#3;$CnH?F5gR_Eif50Cjxi;{ePfwWGE z*lH*>%-961XA*5O8WVM)9Ghe{?fqL!I^+w5qIsHr8;7pY0rB5MjrUsST%zR60F2 z3TWY*OaSAnJoulG6eOzG>hEo4)a&b0&O)v9U+kHS^vgqVV>-pH(Oa~y2Z#fVcLq}~ zD{&@ICJW_;ny48t;2`UM>rp5)uO*|+-bBD6B1&+w1il-ZvV%iuOgmkIl_2AmjGFp) z$)ca7rDaWRt%#>5H|X@iC!Dig(MyEcOEt1AWoWHzGA{f}tdX=7@-rd{VdoK7e{bl<% z>D#+j{8lmXOKvZwLoRhw+Li3N*;BAcF+G$=&c9zvqW$8oU85NXszgB{HyCL`*DGD@ zyJq=EbxLI_UbNDUWGba>h?r@Z>7$z**Ti5tYZ)5@O+)hj)-{=w&pQ;HAC%tzkA3K1 z`1?WKpdbiKK+R7+x`sL3aULaUpH?47#h}&qoA|psV_{Eodps!^5c`=kp4y5A+ZSOY zf~9h-I`a66s;I%)Gb1RbvjrRwz#kKx=wf>`KFAQf zchSY?{`s|a2u=%ARx4UY!$Dqaw^W^Werbt}mUeJF29PeT#cPpLE~7>_qSb7HIyqyn zDyq|ZIjt@IL}#!=XVCH;vuao_roz>Y^>0vv)xR~;7(%Kfaby&aQU<8e3c3`W5DXpP zN4pXdGjcrK?Cl`Y-M3c>YSzEUt?piRn?BP zeN_Ob@G4Dws}sHU`P`uW6$ksWoWa=S6N$bZeIK&Gbz&aAu+dtA3`%Q2gs&ND_JbT5bz-WzVe>Q+UmGDlYzMUwtw;%v( zvrTYiqTG?#^^6BbZPtqXY(`0{wf}%B_PCc+lA>%*RMg;>cA2iZ1n*v1@ z^zI@&JkV8uH}(OWIT0J<)`shwi(O97ZYu0H`ry{h&0qhSGfFr-T|n>R5|WjWKdk06 z3$|Ff`1PLZk2r#5@Uqh1=`A>?_xZpHzpV5V zuic98RefaHGA1tz;2zc+$34tfkLpBDI3oSM_7i)#3`=yBpJJlfNJ?E*AiQ|b zWgjIx=2U9k=qF<5m&#CZ9{60*wvBxwtvI^Vw_YkrVoCAjyyVW#@H}|TNh_h7BeGVJ zk6wr%8Bn=YU3pugcjRdH>-w<7#2;Rr#+UjsPnhBaODE+a$}tdJGHwH7Y0nMcCH;V8 zZD9a+(oYWr9kgM*n1Ie=`-isT*^3$vBl751VSRO|A=_JDH1HR*#UekwUM&t;2BvBC zKj4^Oue#XFh>!9-jZFH5t8yRv)f3eo9A8h4I-htW)dO@Q5o64MHK@Glos>g?tI z%6CAg4xuI%2wq5K2$cM&FjX`@TR~Gz3IZu_p|G!2xZZA_ZdWLcj;o}M85d(G#`_2f z`GGpwW&4+1ITurr-oI0T;i{u>Nn~>9tFj=eL`Nw9uT;Y2<>h@Tb^c0eH$t0aTC8b9 zbvR=4Q^vdSPhuf#{a;VPd}k73TE`@KqyD#SQpM-#zTY{AzXqeSXbK+g?}dxaJR*iS z*VjLQ{Gt6DZ+@>!amK>o_3dr*`@4gw;_x+9SwlMm3jyy?{guEL_~nayVGZ@)plgt0 zvSFB3;0wB3L`*igEpPNA$FsZ4yxTGztCOeo^<#s6o#s8X8;uu8FH_@B?m2Y_f`M?o zP%f>%Y0aN*?a_7Gra`5lk^(NQw`Oh9F7b#dyCWyjg`~X;mSw zlJc6znP`h!`LzXjM-04j%NKbstWSQ7g)gIU_5$eWhK~x#cw;$2TxC}^Ix^Y(UI=^C zg)Y5g*#b#&G;DqS$O%LOtj}_#N#W*cL>mdC#(Uw2^X+a_NM3?sp~lhtDZ2S;P1*Y^ zg-FBIXMKkhS2fq`a_U)bcvNp%nw^fb-R4@4%pjCXKOW=dl200sCo_WQLD-ujg`2sb6x(UdC*oZ8HWcV zU4!jhf4)S_ww}27pJqS&uimaQ7YY$b!YyAe;XdUfyKMC%ic1!GP}jXRF1NT82nT_m zUtNWCb#>{>e$O)nMu)pxrZE|%%29Ku%DW$YtTr2a?5cGh;yf05LaBCx)84L(P0ea6 z(8?jQQe(lMzHEd_q&l~MpuFdplebcQA;Gpply@&g2KjC=Am0sOuGJ56HmE@b;qU%j z4pNdqX_`io0q+_i&fAK&m9A2Mvf*fr3i!n9K#kM0=rXksR1CC~sq!r&obv-?O#0-gV%%MpfsKt#%#Ng?I_`u# z>w4w+aE9(Zg0_i!&_N4q@1NGwh_rl9`fpK?&GP{iQBh2)`{dA*$eO>n4?HGtsAP?$Hr+eN3MF{ z?`>hYI#*b_bn>JE6iR5PXOe2A4fL^rHFvej4cmhN2Gj<>Ok-g&qxPbrp}qYqB}z=h z>z+oiq>QKDHHUlixkGt&AEZWXKNAcU^iaVVN;Tz{5l?QnoiqM)v#&~vI@2lO3XJ|k z_x{k6jKF>J#Wyt0m&16eRM?1OPdOJnvq1~7s%*V&@V|q78ax~xoRd&^8sM%mg|C8? z6;rWU4|sK~5Wo!@i zZ_j&9Fmx9EVa)<2 zN!Q#-q`6|b1#9!{dHX<}%o9ciG*!Qe_8VpNrtmezg@M&caE#X>F2 z5tTO0T^kSRl1xeM+RWxmG5bJAIKG=eH@_leJ2rK5xg+;btt9p1T(j)*pP+3LB_N5? zH9k6e5G|>uNCFi7sp~t+#+oFbo(yf8gaEu7pCgYyA3z0@{|C3X7eKf@xqZ+tzIc|K zn@i84*>=q{1Oo!^A1Y5u7(-K2=)75qof5 zabiNXnnYGHg;ry`tB%?a!jRu9bZ>)peupU*-2KdbAsWd$_{kr%>&HoagMYSE(bXcQ z(NoiguP_x90<*KTLpZTDizcQ(LPCN;KuC7Pg{IL=!=hpQy7|$J6v#gL>^b?ggd-ir zIQ8;mLW@|i*v1tM94lf0c2H7MhR<`+^(DlbMXK)g$KglDCKs>evH!{9iO%?EPY0(m@O7_PD!5&Yc`*N+w>~OjiXRVf8ewZ$Q;Ad(0(nXr} zRFT>4a+r3*8TqWm#b47GWE79qN5c3AeSWP*A$oBSrjbP~g#5yrBB`^7CPUduPI()q zTvovrT}TRwWnttT_9Ker%No=rj;C%mh4G82MY&2Iv2oA3hMxPDrCCfi0rx$&j? zRzE>zso%S4TKidR*JP|J_F`>+0W(ZXPzjZQ!9QW|eWMb26{Z(@;J_Flx9K4sHY?sIT-xJ(KU#M+%- zycCn^95P<-tZb~$HqVGDO%rm6;I4km*IWM7f9CQ}Z-(~wh8(s<8u*duhPZQ(q5~pI z7vlvDhAg$ZO}dUYAWxV^-EkxQwgJ9d-w;_GV7udy?oaZemNclh9u10-Fs7*SOOUt^ zdU;m{+})mYP>4)e_4(3$(QnFELM=y@BLvW19ZcGikxJvVB~%OBmfQ|Gi|s!@IiCjh z7YdQ*BTC8U){7*c{nXO)pVQ!(t0dy@I*kDB$R;O;4BW1_ctl;PONx|@)aq4?x^8C? zr-)g`sA_mpF3_jt@#~3~&oe1o6g?f}uKno`P7PgI)gGv=Udm(M+^9bk=jseebdCU^QTY1@jz_d?}g_}Djm{N0&yq> zI(iWS9VLZ}xBJ1l)0S22(yRD0oggHJETp;(o3=Jzu5jt0)y6DQ1AL!^ZjMXE4U4zC zg=R%z%T~OG6cOox@(>c{qK8Np|An9tF^(-TZBuHv2xxA%Wc(cU9%yu(((k)2qEN24 za-PQZ0apQSaAK$$wT{}9h{<7)d$=pHHCM=WNI02M07Xx&6-(qS zp`jxSXht2!IF!?F4@3Dg;%(M(!td0r_T+LxZ{rM(FYE#_CVx5&|3a5Bco2*94MA!Q zckjXo*HbhSF8B-p?RmZqM)U|pN*e{0pS<19R26W(E=VMh(D7SXSbQCwKY8#>C^SI3 zozKRo*X2ka;dmKah!`28X&6Ej0z8MGonYW4!Z|1r1vQc?e5)-X;?-1cR=O|1V3X{I`?_7B$kYI-0fo^xVzHrn8 zW~AQ%)H_{^Xu304zP;>j3Ggs|xE9%e+_8Ipn)X!0qx=a-`nUu#uAeS1R{CEnq1V%> zdvK`G?mXh9&IHYBpSx3<*X7V&@RX{K0ggh~fOW{?3)YD=P<^IKganM(-sa zC@3r%Df-n>{`hh|k16;YQtx_zP!Xa3+k{Jta+w(;pm2XPghq$ z%}Qz7QM5D-J?9>wRYF$oS?@b}&1uwF`W)y78--p-M3id}EsWnO@GYv^aJLKeLLc7a zh0xfp8MznqC@yoQD0HrgwPHd&OI{RJeyc-0E z3B>W2HZAm15L>?!LTc7^HM+|K+dac z&lVT7@X^)ya;64TZeikKe(Y$O8+t~I!DPu&RiJYBsJbttxF}3jb#~Z{;n~3fd3*R? z;Zo!hsKRY1Z6j;2S;i!hZ}*{akMT70*?sp*fuZpHNo6{}H%}G58I+_CGW6}5@bfE% z%G^rrnV~9Xfz}e)#oE1in<4PZh z;C67V4`m^nCR%C=Y5W<_rAh*(C4T0Y=9XU`mRY5_xo!n!*wdXK(2A0SRdCjuYoV}4 zyy_EBWtawZCVPYI(lfPTyJxgqZM$l*(0hj=kz&x@TA;~fZp)@bi=`AH z5i01edULZ7{~T6v3(YNWV7{vazJ?F<^j(gyc(t*)R&%@MbXF6f% z_g$wxJ@_Kt0-}EH>&_>FhU5zZatT^b1E#{yNAD`$cv zR~p1nb#d1mI^ZaDiF)4bJ2h^rZeju(ldjFELp#uzPASlJy^P;zIwu5OYpwY?xh}rN ztgrG$yLISpWp8YgeeQO1JtSRLrF`a#!RkPeK=#>fN!)dJnZ)Tio1H_vY1W>}ODkmh z`3VZbt2e@K)r= zor=KE>5 z?k#Y!k)<~N_78==_m4hjwps6L`Iv@$;@&5f;V5E@Z14R$`)6)B{mvIOM7ZB#IR2s9 zM=R!O)(Wu;UT9RD2vR)G3HD2`u?59STdr_J6AKJG(C;Ti@Y4`32 zPdI5?*Xttt@mcBq7v63yLI>TR)GFGHa+iYy_YO_8rP*EI$U{LuSdzbZ zaNDyk`1F)`3V;HY;_W`l5QZ@fY@&jjX%WHkSYnZ0iiKn9k5G1(@2qt zxR&A#;c3_lm|tfEXy<(yI4!B_48NIz&iDEbPOaL6F9`}WRd*u3*@K*YkAIam3}+gd1vb z7lMjP6i6qB-|bMg<$D9ygHj%7m&5Jh`iT;sO<*Rn%qMNedG0rV2C*H&aEOwTlp(HzzfjY!$XapHQJwf7^Ck9?t0>}JKJQv;({LqL9QdV6QVuOUV z0ZWtpk~QaJk&;Z57*g?$z`aIm9F{HO_OENSt)G2ZP9nm%j|smS>qYGXHS982Py<$E z+IL+r-rOcg4oB$tJL?exPTTO+m^3jbY79ro@fK+@O0NEYAp-78z^<%4IPB_~SdI z%w~a+{Q^o%5V(R+vfCww#5?F?(e$d8j$sQvccxosSIj1!w#o4;{Z0)g^6W)}4&Yr3 z@XRLz7wPOzTy_FS8S8zb+eriGT)qZ0#u-9Frc%%vJJgZjoGeCjPoc?x$4f1qE zFLn`=O-z)HS|P3)Y}Yc*RRz5ver53ibL0fr?H7f$+MClqvFNyGfJA%Wr|t)tW6RpP<~2QzEZ@G;6QU1##$wWMt50!n6`#Q1k$uRvS4a@Fnnt?&x=!2Cb8s0tuomZe=fpQg$_JY3Pn3?6 z+K_ZK>>|B+l4Px!XJs`h`*kOfJ5bSWO24l3A?snu0}{5VOl}?ZoM*XAmNv}#bY(i& z&|p>9Xzu)jsgzv76TJf+1l;j&cj0O73EAkqGmVvFCVnmb>W-BBM>Olhq5-y%s?@ z~w9 zr0Rv}0SUgm&jO_^1>r6URV74TFy*seT?*+EMqS}cqNvHVglP!!4-b_ppL@@6G!CJ5 z{T9#!C=JAGiBrvNLOcN^WkY8By|7lvQg)a>c=J{&{y6;-OhC+N?@RIK*Wn@{OVH>! z2EHiY3oym8dcb11!33r4b&M6G=D_KmY3%DYVcE>cHnacmW?jYEJ~N9i^D8p8Ycu_V zrWO{=&O>?;z(A}s`2h2;!ni$EaSK0{=##c!y5v?FDmHRD5E9JCVu^h?;t%^ z6n0k?$4$}Tjk%zFQ*JTua|k|4xD>u{0tY0gwIcPowKy~zMwRjmJf zB@Q3v#!`>ZN0bFe`4X;~RtE9;f({HOVy>_}GWqbn4w^{D(XIiVHZ?6mR32JmRP?ta z#hTs|xKa-OP_aZpV8GqRuq{o#Dv3`PR*7v6wt}8|P)fZn4B(*y8kI{o3TZ4G>i3$F z>^2PvGEchf=2iHl#x?58!&s+j^8H*pcZ8v%4=9Il2wYtgNbKzpi)a zazJ3ZvK(|yNSDcSZtIAY zKEe})51`odGND?-`WV{V zFkWH7rp{mt7q>@BkfPUsHS=WRIv4%h+5xU@li_0I4lv#^CXDdb$W^u=y;P!dS+2p| z{25*I?G?Z1wmO=BSC$%scAn=q`gF8ta0t+2EFdi^4AM1->72Jkwx%R-kmBdhxZuU$xNB&SV4Fc?QJTQ%Eds=i?;eL^~x}!!SZ6>47QufvS!qNpskY; zC(_ChhQ!99-}%s=`y?@RRKE`$M2FDGxhShI{z+(ts*crt$x1oBc1xTjym&vb7;@>< zBn`#Huh&dfb6J1PG6glMq`R3++svYklwk$pg!NpFtMIfK2OYjh7T5waO?{@3fO`HR zXAy2vIYEF6`!gF5|GWLEt~p#MveSLx^Uqi$*0@R+D^(V@*!%F*OoGsp<3~0QfrZ5j z(djv+-x%Alno?SuiiLbC@GVJ)C7E(J625`RbS##*_A&nYo|tM@mSw?0XD?vh83^4u z=Wcdj#gz=l6L0Z$6pN<_sgietGQ8@<+0%CoN<$FSYB7R&T^$Mye&f4?=9E^Kn5gx$ zxNma=d>_98?Nj6U(cBPwKueq;OVP+%=x_(CYXZ)msIn=`F%5^F9%;{<)vT}?u6s;G z+XqEIjA#6)!{q5jpW? zV*c$D1Xcfx#6)kHO0yGgEHC}+LX>lfdONNq5Xp&Ar7Rcih`Z|IYAv^hE~JQ%H{Wa^ zRPO1}*+r}{hbU+j8O6%eZ~C`Ut9w`tChRkiQj7fyX76M};cS641 zxPiHjr2?I#Tb%aG!=;v12tYGIPE%;LoKL;&6k42ZswmP0TcwvXp-%vA5b97BB@WUV z150;__Qb?jf@y({;F!DW^}4kBLh#hllb^7F24`Q>`qih}H9E^@ z7>jHuD-{KzkANy7-PuH+5t|NY<2wzO>BK%I#VD4kjPs_ojM6*_q~t1HB#KPg{Egg) zdGCD)MZ&cRq3~JZVK;cx<`#Q+MoF4n&ZsBViZ1}R25!|#BEuU32)%l z9`jNwCR`j8sCZLEtFyg5Jhlf^r6lx6G?{|tSh>hL;xGIg5jqyfJ)%4cdkVqC@*wAq zCQMo!Z)N3@KPy zohKJdp8vJ?p2$tPIgm|vM1al_R8)V>qn76saa(ffE5ymP66m*~urd2-wZ;#MmRr+F za&r zsZWj(J_A%gFx@frZf4DWHC1w0LANt}V)|6>AE%MQX$%N&w%AIwwn|z-UeY`j$!#vx zsLHHC3qEHhDN0ka$q_ofW=D8^0J9l$9zaVYd1kSrza79A5`pOmX4BfNik=V>2vYM< zQ0}y$*tUKp^#8$!E985H*vUc<7_Uo*qb=UWxpq^U9zn1Ep6?SCNK(6!OyvPZ?iCwB zE5&e4D1fxpPoXc_ilJanb}DcUgPZ`5Hq1b8ikEYicO?|fQ=$nmUP-S86}@Vu_}zIDO(T@ECCBbrr1SZo~q5lo>MzolrrjFmbAwO(wb zW%4rXmd;fpm}v(rnIng$y~7LDjAuzGLvD@9@b}i%?K9LMF{(h3lU*J#G%2YGZE%we zU^_td^uxw_tHwXX9!uD~@iBd_6FVQ9LtA@pC)CQmU%wocz}eBnguF@(8~W-s-)Vyq z-N}=%@MZrcS#Lhar6lk(R4YnI193+%%WUpe!yaI#okjpF;b`7E~Mjl@{9O zhA@ldm6e{%K$)HF$K0b+Uzo{mO^q}u+|?+TRKP> za8ZaYA!)ZuX0Qv)j-Cf#)7kwPQ!5rC9~@X@=*5@&ce@fu{wT-PYJU1oXseUI7?^W@ zRCY7p>OcfF>me#%qJi51)c|@glp0^jIG>^sl&wgK*8;-DyZIPTPk&G6ys&M?_!Y`| zPWdXZ#ZXNJieW?~L_CH+(9L7k>;)IBf!9N{w$J_}ANI9P26WFUUF}6Jk>w6u zZvCd9!%DPm|Ihp9jR6+xb8!AL7BKh-PSLf8sR@27$nZBuV#B`OHdl`ey|>l$wk>i+ z;^&WRu8*h#U+%g+RuxC03(6Qe z=V`LD2VWNS=~{bhT$>;}Z=T`eEEl1{VNpY;k-|I4s-XK(RrUrM@eb;NDjEEC)#I(! zI-%+v?Zzh?SSoflA>`>yj^hQ=RhUr9p}C~u9GkuYOorh7EwR_AOg%>xeFWQq6;1N`Ak^tTj7ONS#>F=%RO9SemrR_SC z_2=46s9N%e`AOw!XdQVK79_`1U zc>N4`@spc^Oh_}Qd0 z!AebdTIZ2SO+Z~jZBsMKBq zHAU_R&g-;|*^lcV|>Ekd!c8#@{WPD#7e=vNpzi$_U5&iejaGZPh@^b}V*1J?u?pu;E5gghxFZLv5O^DN}Kc=wG6`hs=ZoYt68{1E)sy`DKeV)&c# zz!%Ecg%$J;ZpM3TUm#+$nLl1(F?5#&Nb z%g@iQni8=@9acp3OEgeSOKwz5E4Np%ob#WZy#_>M4|TDDm)KH(RrH!mSBSye^w_TW zm9VocfHqGH6CPH)0tKjo+Rsw{$n=#EG5dKI!!jHk6E469169|E-VyWZDGfaYN&M4g zH_1gc&fxM5%aN;hkCKnLqbp7rvzh*ZxsjksW?wwI;_C3d zjPi6%n%y~lYa_ytRKk9RH)gARvWvqW+zP@KoZ75xyQdQo^KFM~zhaN?cp9JeLnyC_ z5g5|1$2xRgjGVZ5;jpQaF}XY>$B1S&njE34+DF_w&K^$2T_+gCI|YM?2m2fO)v0;S zg$!+oOf8=DS>h1FFb5HJL*)ETA`vb^21dU-(V_a_>Y1kQH>g#J-GNEZGi^XFdt?T> zwRKu;kzlLfQJdJ=qphPmzb&|gwWF?;peBExOwCNm5U3zZuMUZL`F*IvvY(+WuBmk8g5#c zvx^3c0#nOrXhB3zXQoFZvfVZLl{Q^2@$n6m76P6gHSc&46<0w3dJXN<=cp-hQRDSK zkM(lNCX{?Yw##lp(%KBJX^zp1`+>xyRNYrG4@%1wDH0`|bsh(s1gs?byr$=yueAOd z%jwsq>o1OM7%tBh898P-o2zlrX8i)EdBzv}V!LO&Jtk##E0IX(raK+v3U>sGs?s<- z+9(K3AKWwSI(9)`{di&izZiSR=*YjOQF~(Bo+K07HYc`i+nm^%*pp;p+w9o3ZJVe6 z_xPi`_gWULV)$q*c42^aX+FhBUbREAt2nxzuC=S|M+_6xqCKI>u0?igfxF=c!Z!Jt| zqyIK^^dJ`1)~L`u!J*+TV%0%yp#33zUrN{XEF)Fm=IVKFcY$_}I|qVb#qn#b$MczE z8l6dG;_RCGyC9-4zrOIbE&fU)T)R=~hPUJOJ{zyMarlovHPkUVTW(^tCZyllA_rs1 z?7znl>k}^+55x6x++3|4VdcIBQ~2~5(I+aes`mXl5%}Xc4wqAS@{ZW|@tfB&&r__y zLXqUvGVIMZ~-I>DrSQI%O;5 zFl5H;-Q}K+0Bd8F75f(m+XcK(8nPSGTZ&9y8Vp>`g;)GenU-pm__O#saAE~tS!9o^ zARcpe0r5 z60{lxGV-plK@#B3i-V;G05z1~We#4tT&jWA7)@|P&_H`4prfnb^l3AQ)AItyNSF?y zLh7l%S$B)06U3Nqq&T9{X4;_V+k69ys1|g4Gmo1AXmpt<+>J z+WJXSI~Dw*PcoVc%#Gb0=eC<9J^~Ka0P`kOQU;5C_%M=ZBN`)M)&Iyx|Zn42@_d zvvEQfZWZTax@j)N);ak|4Ngy~46LiQwQ}7-!WPj3Y4l{@r`AD{^^WbeKl2|@Pp&V# zt7T5ae0sVFOZ9;%b8Sqq$lyuuR67)!V{bGJPw#iHyxQ5|v<_bbRv=HXD^{Or{EipF zF|wWd26YgUS5Y4!r1IR_^PW$xx*1DN1A=>NR$;1GFt^`Q1`_Cm`ppCJG1eI^Z_pd) zk()`hHxxA(M=(q;_5>nv-6nUN1pI@_a9kg9pW9y@Tm@Lm^pPG;TMZ615&95gME1O9 zFZ!j8T|N#-NY2j+G$;1G#!yjw!Eq7Bo9sev2jDEElYR{jh{2ZZCj(0ZDVAg{k0k;4 zPH0LDg9fXA1i_^|(Nqb2m^`V9Tq>i14!Y=>{6-^IvJk_88KZrMw3AZ{NjZ&0{K%gl za`hzP|Owh`d1Hic#<8-$11qxiOr(7uAbOh1p!gPaL zxr~cSJgr89fmbti9!D_K+w3q=#SP*e3N!#?x{&X`zdp|``^D3xlK*6|=$?HTH>OdR^jgxl@VbCBrw&-OSa$5P5IkA-`>F62>8I zT^^j9W3l!NI|FQcU%=XRPxtYLk&bd=i9J4xa9QZ@-5@Zm`x7E|in(#7&`0fZ{pOA! z1o_I$X*t0{oXa9pto0Gn@b6pndputOR`34rE?*$E>-_IF-;r_T?7|b29e=DP`?u}J zO;9dao&p`ix8R7{=X|~G#|6A=1P~k8B%u(c*7#Lc<$rYqZ_0nYgR50>#+tWLdQ@e? zxkpW6Z`7Lf2`a+3VMt+&+uY{su&6iCeoS&UX^s}Z`pV0^RzbtUGM6=#{bzr0Wq5cR zjZRF+|A&#so+QAAqoS{AY-H=`7T~VLG}CSpB>UVv?cdrgi6tofC8d|nzPPv;x)l%P z^qQT^u))yK&@?nOus11kwZsRRq6dzh-Tp;2_?3yq6B>3cIUGE~Sxh+h)JC&Jl0*0X zWjtrH^Vk@=bKs+`hf*_EV*kGk%LnacEo=9q~1jWJeWKn`x$>U<;~01B~vbOhz^ z@86olEHV&@fpA0%v2lFC->>wBY;%{Uwf6-LkDMs8zUL(mL-lLjbY`AMat9_X zv>6vHd_U*qhZx{+6>GhU`^$M*yn-dYeWz~zqPCcX0ZLbTL#x`#1VJ+kHMY4)sHmt2 zjew90GzZK(j8cQRS>ae0=v!S&2c)1!LBn5Sxly#4 z=dUtMD-S2w{&h5Wf7w?sDA1uOo(8PS6Q0k)xFtQL`dfe;iXV_cp(k%w`rc$a?sop` zv={6c7E@HESnk&=A4R27kI7Ql+trWu{Oi#ps=$GwP*Zw|{hz1cUzy){{RkmDfsJj4 zwLjgfqe=vccw-vGKi?lqUoRHIUiNO_Ae=BK5v*HjxiSm{o+F5q+uvUdbJv6ZN2f9l zlS~Fb{AZlLU_w2kQ*lF31hC17RUtyh({@V_`meVO{#wUfzV00AtRtlwF1EtiH zZrpwGN`Zr$lt_|WdK_Nqcz38BPWWsgl##X6QpnjyZBui-2Ylg-=?fYFKksT5;D6S9 z%>TqKW5e=&h74vSFrZM{*dUT8O@mTS)+Tz^ZtR+Jlg)>E4f&m=gTgG!d^bG2uE@Qc zPuALKd@_-<){ygWDU;2A^g7*pr|vD^8H>Dt{0AXImmeD~`ojC7U_A?AfgIf3jwx8B z^H1|-{*;*|rZaG+!_a*XNXgZD0KfTU8li5H3_#gTxo2Jnf#}JWGm~?zurt=S-A-7+ zbfb08MV{UGqSmHFZv(Mdt@@{z-~O~elWQN>JdptYfq*H!CQ2+`W5|>U!u8$quKfJOUt%9#8nk2f){f!S=`*C;(2rDvT5X^L$T0$!GM89^~C-tty z^P3z62`+qlnz74t?A?bME9`Z7q<0kVXyKTvQ^ZeDxIvVc|?V1l)dV9)F6 zgtRm{xGvX$zfp@IK`7okzn&&;{cmr}D7TDtZ0}?uMU9~cSBYU%lK_#dk!Vc+nBury zdQNF(M7WZf(<#{dqrqmckps|-A z_A@V{yqdsPoI>%8R1weSPFCQwM`0ysM)I>9@wDWtaVvnTYjzPEE8^SMx+i9*6Zo}s zYXx?JP@(CJ`J&w@Vlzp9JMGb6@kT(7SOz(?+c;g~MuqNB7C?MFN7aF(C1Oo(pFj_IBAqc*7PjH$&CEqaxJ7AySzbD6OMMN3w|vSjX9`jRuDl89Z8 zJ91`$Hc`?oqOMsq3^H%I)`~-K1V~G3ilL6slO-Xk7w8wfmZ(<~>X_w(ke?$DvQ?S4 zWP4byKVa!Z*GPPru^qhqn{`%vJwd)FfiBHr4i2XTlma3Dk#rX1iVFA$dSbjI%P)rM zvjFcW6(U>D$8#_*((D1oHBL*}N-M+q=>tmT2Raqz1z!m6znfY~(tI#R5l zM-K+A?RHcMpSMw0>iyX(?&a561k4cu(_sygFyO=S9f~H4?~|2&1;Z7Dh1);kA#!us zhX)!3rMIQNi6AibUNl$#ihM1Iy0(PHdf@FyJ^Wx4O@sU64@wB`GHf zK8Sise!!LR{W%v=C?Hxwx0Hul9lp1h?rn>_^xluB=A{L9qPYhN#@A?s=sE~99@%HuHi0QQr}=aBd*#^17m;R32fPo_@B`6b z1;6RrmvtJ_VG&{pw*?h>V=Rua0;;DAm)a&}V1R(EpfrWDMI$-oychLgBL`rln|;Tv ztV$9Fu*0T((_%q!UqSKEuLfw9PzPpT!K!B+Tjb;U)%pP2JZPz8_5^8@(_8E|2Tm?6jj(a8B^4SzGLH9ff%Pl;5X z_7ZM5ZwJO@fKmWrT(f&nA1NkxzHppS3g1sv!c7o zD;aOAi4qSe zkuZq-Cm9Azj2N+kB7s7oS|(Fo1Sp_Rh%#9!I1F#9kZ<Q>CCbabW|;=dKWI*rd{9I_T+$78_cese=|^=Gs3oR zMkQt;DsT&Vp{$+3@^=s45RN)iw#pxTWN>)BMdzfo4cy%#jKX7PBs8t+T7L1sIJLJ3 zS{Fgrcr@a8T^**`gIf)*BJ(z|e=KsSOy(#W3P6r7_jUu&d|_v`GJ~luc!ATtfkJev z?k$b>F$aiR7MXqmY7{y#|d9+8hy*-x-;f&L^U@}mw3r$Ex?Q|S4sWr#&u#`V( z1{Vzs_SutUZTti{dGHdO^_Vj0+mb=ULvQ!M?*)0nV3Pb9kF#Fd*9! z5dZP$a}q4q+#R$uGDBJPJIXY}xj?bDmwSHAm#DjW_%#LC2-#Us&_TWjOmBDi#p`J53%OPvv`L@Gt;1ovRr~d( zCYN;^;XuvS`?xs}{OoZu&#l4_T*vl`NzQiKCoxiP0g@5)y&HttM6+MV84(FZ<@hx(1BXZRIKr1R=TdX--C^dGu_quSV4)_o3@qWcn9)Z>@!# zg^@AXoYXOI1=}s}Gag_Sz9+QU(Rkt?$>N9lPYRp-f`V3)S=6t7SEaL7pAIt2tvf1) zlOi|4l|>OI>kGy8yNAJuMi!<&DKNaBxN(H8um!)IX~y}+^jv`>c#`6X04_`PfUOL- z3x2EoD9R5N%Jn?HGTyDY326=keGlc9#&A5ZX~BbV*hwxFw;k-sfp$#wuXjqhO>imB z)POQUvZN`rSZRvMoeT2UZ&~fzbW^FNqL;9yih}-dON0lamgeT1cqyPBt^O#OR~@0# zNpeA_IR4&BAMrY%S}#5f5$*8oDPDMk%Ln~U?jqjg{!y6 zlO4k9r(avtrX9tc6`t^NZFlRlY&OkGX^;BHxf`y)n;fAa+XKYB@h^#SI`c^uU zubs8HTcTB*Cf@%M=bT6rGUD!G2a7!45Wv;5Jl4XQSD}-^1_VD}Yk=@4(0?`#$N`1{ z9}xX#ZrYMEE>!AY_9#CB-`zilL zBlGHX)E$58eYiM-TWE8g#bG;MYYtO*+{;}{IMph1w(O2M;SkMJ=H{;KyDA7C-2OeoA=XP%s6?W$}dSLd@-ur=N$={X`F}l;;H|s)1 zlT{CwN)v?cpu6ktlc9L`Sr~jgbrh7Vla<1DE;Lta`LF>S2K>(^Xw;&RzFL0+s)h{> zT(}NIgPKQkR)?H8RBa+7)3dbw#QAy}^(lgBEO)^E3P5q_7L#2DKT1Hq)$r|QYlgZV zl8^;Af9L)i>!%}om%F3r-yts{ZmgF6n^g;A6Yp`QJOh ztUcls!(Un8ipam*0HBFsxSVU9W{alwmq~HBP*QAPKHxdQ{Obt`#T1^ek1(faiv_Yk zwlI)VVG=?FGb=FPOkYOJ^;@^gcv}R0MAF{`xp<#bG46Ew?7#o$dvuK$d=fupt$cxo zpMUFp@+ireerx5brY@T(DxE3STln~Vuh50l6$K~BWEC>G+5KskIs>d`y4x_bmb#{Q zzMGfg&vf}BSZpo-DYQ2Jk!;OW$%@JII4;=Pvw*$c0eR}45t!HtX)ux3JzXB}Lah>0 zw`D&VYw3F9wD7&bW*sGQ3Im|dH#S7(r}DpC(u$&f6z$IR8E=T|FqKBhRmnx5>Y~!H zULJ(@B@ESiO~~HFYyBy8W}M8vmf@60`)PZBW*Ir5?;k+E%ak?A1AX>LCt7|!E2XT0 z+YaV!HZQV$+H0X#z|Sqq6`=#RxIL}kX}~%DSA#<&&JAcsP=>71r6Er^mioykm)!w5 z=0!I%4UGzX?BDtg3^UgatHb$={kG$=Mf0D(ku^e+d7kGju_F_AiW)&O)I?LLdX-;{7-C_LYqtv#J zlR&=*Cos|zy29po%u|Is;$DEhx$r9{*&xX2#S-G`muF7%rLeJK&d}QB;-a9Z_ra37 zd~!suaUogdR`aD)!?Y(80mvgMPt1(@sJ>eJteI6~#wvWg5L8Qoi0c8ZmK4G$8=B6V zGTVIOAN7>Lk0gOZFJS8^7n4xHD;T5i1=adfYebO$XSkj#K|&)G?GKUy6hb>m7b+29WZhbl{IjK0 zb>tZe<1JV;3e~}xT)&}-xS172Z?Jm21EE+{Uxz9bzF$XxDvt*I~`x`!v|8RkUaJ`5V8=_9HQCr)r*6-%x4l*#?uh`G0|_i*~ozQ|pqUQKpcHX|P>y&uk$R;|YOJ z^|UhDOiKe^3ST4#Rrh~k+9*^&DVVRH&Go=C8TM8IJ1jFmOcaNT8TAlYfqgl}XfPf9 z-sb7-34!9PCB^ypiD4avDYR_OH?B?BBNitxJwP0^%k0YJlFm!iUBMd;7e<~Z&b^AY zs%|x((+r|~=3ECHM4F-W6k~ZB%&zRV{d#wF-Q|M+)p9kogQo5vuua9w9wW5ZVR`u^ z1vE&Spfj?m1BQI@Cdnt=EUS&zsxpyPU|YXiD{{N^%);ed-=n9}969<-8M&~(K^b%V z$5evc%#HrhK()v)@btMO4|=e2Lf^2 z))G=uMSgky`3x7K)1}D&S!z4vxFtnKDHJRSNKZP3h5ps#;b@_wvyTBB0#14N$4#9> z#a%(zQX9EYnx~H+AlI6a=MZ#xyjBS#Rpd*p2{lo{xl6| zh3@djzyfwl%3I8i;OLeR*?H*<1gVca9L|zF&$#Ne?T1iQ&n0XtuH_lD!j>oq=}@am zbgF?d*_*ke`*@;5G4#i#mi#xI8$YDK)ZKGYkF`zkH;jKCN{?{K;Y*D9qm(tE#s7hX ze&bq*IgE-hRKPBaE9guf%@l5nH{d8;+5=b`yBtJok+%xV&>t5Q+)=8LBk?bxUWEfY z+vwYUfl4IkN(dibrlfVwle{r<7&Rn@w3J#tWQg4zP}Yhhwr_%O+szE;x7VT@Z?X?N zU12%S%KBruhN*D-_Aj*~(TV+v=Shoxemmk+9eA6IvBR z)R2NpsJJtL&3cl=zue6uvp$M9_=awEw>=_AVWO7Pimfb02_j3uc-U**m#0_*n>Xb_ z{NUYFF<;AfzVbMjS1i-;Jcq)=9m}`Y&q0J0rxCB$DWZYl6E8GRvHXOSO4aI~tR;6i z)DMqg=lIyFMy9S_$F1Rf`dc24n&A^oE2VPq?r_T>rG69bs489n-;R?bd8CgAGMt2) zM7j8bLbs;&{ih)eqJY%;0wY8MlB2_pq>KFm^usBK$l9iW!N`upPxvXSS>Azk)kLPh zQE<2mIzm_ar!@1zF!>!r*tiw#Q#6rqXRrKu>>u!^D zHJ`Crgd+NWg$=x26;b6?BDKZR)raMkM?HU*FF{wf`NeRpb;KKCoaGwb)rgk}SP}g` zBQ1pEjAKiL>a7$LnYUks+z6fMKcr#k*Z&o5tmO>vmctu>02mWO&~Es6p_I$z|M)z3 zCVXF>*6{=Xr{&0najg-qjKb)R*56Om_4r!}r!W!aTGtM2L#s@l8(H~u^%)}O9x;oYFz>ypvmocgMx72R-sa4t-=oy-Bhq^v1 zi7nYxL3j0*@6AZ$SKwR}Nlh{R*C1d1=$F%lnlyp00@}l|)Um1Gi2rY56OHA6BQ`mO zUROW-kGXbu@rUq3j8q1)8;@7j)qgAXI z>15t+u>Q5{O4@kJe^Z;JLSL-D-_|)cMb2#FkkQ{^pV-}n?^k=VYp#oSUV@(dk(TV& z4OuL(E}cVXBsEZEw(k&BZ{+)d@96H=n;JAupZ|ygW z@RXqCYD3)9fd$BH{-9d1S`vDxF<$oPyviOPeCP#YeU3MJ;yH(ME15KK z+p8^bO{Z%MzKo)Ir^ZMu4eA@L3o!Jj81nvC7<}S9`mEtk zyiWDEp&{ilafCh2{H(~HL7LF=iSzxu@&@PAyUhJ%kCojsu@-kt;>W%&2(`6AI^AIC zE~Dd#{zNKci2L$wXlYWo+pLoDQqo}b?dfO8&MX6gV)X*__?8Q%AGfmxrGBsT6?62} zDz<*~8x(_*m)n1vpbuPe~NBC695J)1`aa2sPy|E6AD`xav8}H z+wbAH7p+53?l^WTauE+Pr8;icqfGbO^KY>BuH^&&P~)a9O$^H49UAH>jiI{#J={ww zaz?i-%e?o$R02*HgzPas!-uz0#0|;PWjsI1zJ{L)THP2lSoy@ezTuDUhE)H}0d&B> zG6uGCflH6Y)rZGr`&pr%OcP?{4gfDmT01bjL2>&kllgX!+VqGtLg=~ZEYW#=x^J1G2e8+2GZjBNjsT?k;-E3__<5R3+D~?RgUGTeQAW@ z`+;i*C#F#5vYSX`l|9;XJuSh}HT!zBda+!D26GFK=vY z1S}KyKfIh@+MR#1$=%Qmr)>KEog6ceGH;*0z5c7UJ;(;7ownupqif3davcA1aUb4#HKMBtT=}UhxZ(W!dG{B7j(T+;;0*;a&f(X62+gOi3zudX z%-sX6nJoXW9+M3D*GY^oyrWPoOj*XKK9=Y8*3dIO{+9Nj3p_{uWp-D-w~n3Q803*T zgtV4@_Pz@qg9$nTkFBmq8V(}B)g}8qJt5Q;9U7xRBcwQM6389VX*JZuKNAp)nL)MsmLj;+8 zt>G@}I%2a#7+dr9kuRQl^?JW?cl+{UJLhgkvq9hc*iRg{zeL-3*96g~q~qMqIH?Tf z$)t&jOG$~ch}nabF4mb1>ntM)`Smo9K~OqJ+xjGre{# zehxU|P4q$d+=F3?l<2S_zftq~eUSyMR6@}c649RMUWsW}Fm%g897^E_JY3%K`!XK{ zwed{VQ_+R&K~apAK~$xwhJI@1X*Du$`}zdA-{jt$+Ok%RasFvh!c50crpXI_m&Xq7 z@`Q)ixUD_B#46EJ7&aUgRkJS) zZnOG5UzRPK0BIMa({NK zk>9ZABx9QmR>zR)@JRTS-8P?{Jl#mpKr(oj>5kH;@#ki_^;jXiT{HM)+HBFIp~ei^ z=?pfT_8b)Kf$Cy|U~5TL8=a27_uO}`QF)74qX5h^p!W6Bd-c`B>X zc-@h2BIjmYJeq<+u20@3LOfB;$U+GWP}e}3B5xamU&qkm@~AiJ8|Evw*?|W-n9npg zdGYHnxm}Rvo_0?LOm8KPyy~oRKcrrtRI%AH>l^hhELNBn=Bj>p$K&oVd0v_FcO>nU zhOdQYS-9q*-HAPg^e4nHV3cBsj58nHp&YYg%i^(#0zxlp?sKqb)XnoXMd~W`GV-R{ z!ouq)W6@~ff-vzJ?nL9uuTT?2(Q_Z5?wsgh{j~`_(Fh}SQ`LG{9q;>ogoYO`O_M!cF=wL_LleD=b6fDk zqppHXD%mC)LXT=3QRb}mT|86ceIH!zHNtSk0#yyMGWbV*BP)KYyx18&vrnrFX7~7_ zhXAiXT}X|JuZx8Omg`wr3OAc{q1T2BZozb^?X26>kFb=v*unCs$>(Be40O5;Y!OVN zKo07Hp?z7-w|6v9`zc{xno2keg@5Ac_K1`+z)rV}c)!naJ*F+Lz})|jXB>NtqIUr- zxbSyk5EyE(Kg{8KV&_7{!MtdmkT_H{1^nU}obusA##_y1F}2S*3_iZ9W6n{*8RaI77s=O=^{8eOdWKKC%h87h0_ z3GN8jU`ZlB@0yZx+4rA6Joc*(qBd%?Nzfm34K|C^t2G)9fbTp$995XyhUc~e?r6Zq zRx77<8c~9rDT+PW` zti$%>M}DV&P_Tx;l&X;k1scVnD*13SLa@3L zRAZ+P?%>T$1E>98CGPe;QtGBrz_lEmG+sB=KecoDf)Q>F4=clm03U(ZlKK=kJ*wpWX|eY6GQG$TAIdA=9w+a6bp>6OQ;?PqfHf&78FY__ua$ zuKbu4f-EypgCvs5EchbiKB@6ObLVbI^@7bC9(a+^w<%sNMd zQjSWQAph;;Xvss2nyE6h*SZPdy74VZRo#z_VP^*eTwDRXP>M$U%e9P$CeN71VhBBX zja>r85Z~@fCnz(bbvE5$eXRy!$*=B7w4S{rFGW@AbrB=+P$#fqz^8&hODAe}67>b2 zKL8baOjSg+{_2{m5yknF13xG%27rI$?15ung`R8~otD44&9;2mh6u)rht0s(f!tp+ zHK$bAnjSb}poL?bi50+j$?jIw`eGf!K>kk1Zqpi?``%%(SQI+T{Y$N6+8QQyqdhJW zjyq4Z4(U72?(W{o*IhhdQ2Y+}y3)XMgkR8DV0%IWzzhHEiD$Sx&XvYujw^nD5>6jm zz~qd$qDEiO~2HX_~`Zoy3OGO%Gp}{k8GyD1A8_V_N*6u_Z&HUB|EltQ@hc|uR7ev-2FnR zjzDba$Ry$XmDjl?q$@JvB)VjRW;eQldq)71Nx#SVh6`jD6*n~6jBT`VansK|zC?Vj zb2FB-%-bGO-@z#Jrya)&e0ncm8OQ7X?fw_zt#K6W&R&rRZ?P*!Q-A>W@iI{mBzK?X zJ}ABiZr%d1IPg$Iml7wYT*c6}_UZjBghE~`qtLSIS~J`;qc_tVt;&FBd6_05VEG# z;1eWUC}sZ5kc&ccK&;)Q(DG0gR|Ixwe6(`b;&=FsecVZOPaLe4<2ws?=?)5%%}~Wf zSG>l8uz#@?6;HcHLGeuopTQ zVaf*T9Id3FZ=Sa+^@|DUMEcze(OJ=k2(?p6f{$nkkot6MxRpmlLwQsWD_iuTk|$&7 z)9TkqlUXfFz?}R6*~_bM|I>H4&QzJR&8b9wG+%)-sY2Rp)qJ+bULnn}6&N=#@ieJ) z)*ulmD4(P&wU!&F(|{_edcDk_*!w=u!wW9Z;*HdkRxhQ0 zzX;ZJ9PSs5b@W$oSM=I;a?>f0N7+(Y`EdnENHsUIlXAn+62s{sVQLlE`J3Luh2N{W zdMx>{NE;&tK$iKfd3?y!N*1Ik72bN~l?b{Yb6Ffpet zL$7b86+bKHutV%@6BoV7Th-?A$yuyJAL2S4?Eo6{9R2}lXT^E?0AN346-FrCDpVYj ziJP%FD#F!ArsHAftARGJ&r@~(BgNt|t2vyTz2>(eqg+R$2QwY{tgfH`iZQeAl!5fR zRwAg@G3*Watnfi=C2A!bB@~z*`@J=t>b1rGhA(g$8aw*Uu zUF}9DnP$iATX19&oIC1+OhR1IJYFc7ZJOJw9eNf@-5BC+ei9!c#STVZ$tsZki3TK9 z271kM$MX?%**pbHHC&w7Dv+dZS%9X^$a%v+lFFGrVpP56+*+$3X7Un_Wtbv~!8}{% zM-Goez%bZRZC+>Pdx_-&4yUIZ3~p#^Ev$hp>uKvZLeEgcs|CK}TpO!O8;g}{mh*fg z#V&6ml^K9GhUX9%e+t4(QN-dR2XgJT78_Pr(72-ctr9$SpQRT0!Hz=Y2mT%8r=>0@ z9pCUSiab5+6#C&|1!@W8)Hr;RiMtQ}?r+su$=9ErWQ=Sa=3mv2Q}AYyQpl+`WT-xz z{2;M+8#kopBI7zNu%`R6M&WJss3VOcu#zM<58C)1poBjJf>53x5jG({1VOjJ$vZqm zhiJ~~NO-q638ncaru}ZHImsS*=ol3RP)HMZhF&l<9`j)jb*=$nPgmDBAIA6@8c=Fi z@?gh-rfxt|rjx*glcVu_( zpowW}9zVkj8_CS9$Z3s&pPqiD)@kGPdF{OH{%-G-5Fg1TzWdE)+|smqUveZg5@2R* z;0YqkK+x~mdL{*rLIjy_`)I&I zCdnD2w>8RY0rNI3#WTvJo+94W7~Kd`y{ns(lb;ot(;x%>9zCX)-&m^{zkP`@hQI8` zsiRnx#?B%Hl?-{;E|Bt!Vkom%6%g(A#UP_!ae{7?V~Sn|CeOV1i_8cL!k3=-1HACqiwON_B6HcW=AGmGzFG+9)_-W1@DdI&1t zUDDCd1Iv0{5T1TX^blr^(!VxPb^P(j4=e2QE)UMf7gES4MN>#%;xAJ0)1mVNcguJn zJnH$E1Vu`oyyvC*A$D|qMV*uQ1-K_D2>4;+OtE~c32FT}Puuq&pY%n^DswQ`2v~BP z;!Tr5(=)Ma$sm&Ymp$i|eg={E{VlO-6}L}_SCXDY2y39NJ*gccJy9~(B-hW|W68Xb zO14dS?aEb9wZgb<+YBDtG}Iskov4!N$-_(bb3Y(I?L=lQ_dzjg(sM z7qgQkO9_6HLOx+WhR)48LsJRB40VFtEN&6mgLOI@Ntp&`>j(PrVQ$kOHH7av?3?vy5MgH*zW-Eo&q*07z>@SCmBw{ z2;nY;iMo-y74*k*6z~=kF4NY!Fd(ON;|O>bjW4&^kK111U{e~*-dyto%rt&XsTbJi z7Pg=&f|EH#`Qx}0sd^jQKzVnpabOaJ5eRd$)C12g0q~sy3C2!eJZ5L-{-<*o%_^OB z6yU?e3(K(0TlA3m1=ekV;RVhMq3T~)(l9o_?ya`*u3>YUeIC`aI;k0$Q) zE@*Z-X@*wss*iMfr{P8VF2n}9tZET3na$%|h?bEwIoV{&o@6us)6(BsWu%fHG67fI z?ZW7NhrIz!oX`XA?i6ji$(+_Nz0$`Ue)S3bX~TZ+eQ~EGQ{GW9zJRukc0Gvf!nW6k zKh$=p>jxfR;o5(mTwF?ZxthT>2-j0s5FZ5wcpz7qMCgbOse*PjrZ{Rd*Luu|5}8eBbjoJd4qddH?6z;qb+ zGyD|&^*e~7K;qng*^?_d{^6eFBiLA5{(HxWAg2{)osz`s<2N0<)V|}N7r(PyLqlI8 zjqlWVALVg=Ty1P? zS(&IGjXf_rO+@A0A5Mt*=!UOls?DhXlZGv}!AoPJUM-3nU4GY|_tBsDoK}Eh_Ti3y zmr2clo*4@~5=xsym__w^FgXOmZPpBDE^#b0)0{CfvBaY+=`}Vs2ubv@Y&c&KWZuCl zGFlMjWpE9i|I9vLKH*R0Cf}NaHP}09{nRhhrT-R|3`_m+oYTwPvKZ{Q-#jwL^&9RJe)a zi^IoS(e#ln1EDRqdt6zeff6sz8kP5HG7HW9t>=K#klt{%O8Wr zT!#cm0po4oM!A7ifyyKXGdQ#ybbBz#sx$ad`zT?E%3foHjz0_;SmLkxc6dn-;yASk7>#&Oc{O!jwbiN0&FGmIIB9tT2Os!Px_c-D$UD_ z1Wz^H)ktJ7{t%3WrF!7e1x@D><0gnfB<-x_Y1Ug+h~q`2c2$4>{Dju~yoncUGd3)S zEYa`gSJyJglK@>yVW_Rw2i}Xbg12u<_AqFC^IW0!JUpzK_xJ&4ki8-07klHV6%AWJ zf(bkTrUxDAE(ekYw`8##Y^?Z}i%Q!iuXhf#MaP02ES4p^?1Gqm+RZG~CZazgQ?Gps zkAh-4Q)~L`2uXD~s`d@O(nPp5--XiGP;v)QqNWb^Gu0T*I)8qmanD)S(QwQ}0B`1@;`4d~ovTjFKWk#z~Ncy z(@Y>szSmeT%60rUlb9oG-ab1kSL^^D2N1+TX-f>qX@Q6q*fNTxkzg|E3eUWXanlLA z8)!s6#xe?BPKD@8jx3cb5Qs(a!oE4%L90KAPueN2Uj}>r`k1OnRfxW$R*AG3&5j_| z*fAnV(A$c2GyjC4O`d7JtO!QD_=BLwP7|L)|AqrI(HM^Na?VawK9`}XC74!;$_UwEaEMH=TCt5^UxX=*kDS|Dlc}qw3e+DlfvWvKRypU+JLqn&{aN_RY zio#~l4f}KUH}TnEf<#);AWa=Vf5#~`b#w?FXE#|3HHVZ&g)AnO zDZzTI)D1k4_#j3(6zrWnP-u&fdDlzqY7fn1_`z7MgT?mXkyRM|i%*|rxUc&|OF^69 zWQr&}(61XaOmp+Pl_Xdu`&_CUMv_>V%6# zw4zHlod1CTo-^cg!QHR;K4U!_cC?R zCxWnDGJr@<>}9KE2ev0YUZfS4NPO3>4?Zu83@hyqn5}=|;AO;hWOVEBSBj9T7(et5 ze$v)1{M$c{{H{dCegcbjs)YU72uweRaI3Tm^)U-2we~K?dhmh*Lr`R#T;$XUh^+vXZGOHQZ*NAPBIG8cLPqFQ?E0zWyPb>aN?7-;>@U#CM+7f>Lk zzOTP%RKtPcsduYzpu{rpxY!&7xT1tuc#|2#xsI9ACkdhk%@wmM|gxeJTW6;(H)C_S~OEL@LWP;&oh=1g+#Dm}8(I zlN{ms)a{@(sk7UFtG=(Rc5%WnCqz%o^x^o-XabGm*p?{DXolP$XjjBotkA;| zuP^nV+;7qEz-Ii8$Af?+QeU|HZo&opp8MjY@46UD%M6%+Yx%y1ca49w~{8l~r7@d!MQ*VWJs(T{bI@ zVXlM8yqgHORu`(&;M{v~=QS~46`vQG7t0MCCru{edb`Kvw;vICeH0t_kA`$L=qq|yz*>NiKxG6m35jt6eJu#oCGmn7W8-AW!04>O6Ka5F z^lw3bXYU5cgHB+X=7X7}ZG^TN_`d6Q4FtE(WWnGv8*H6w`ew+Zkvueo-TARp-n`I3 zEVy&k0lwekn$L@HF8GPb`_Wz+pTFK3F;BW5*sE+1h8w@!#H>2|agGliy^(|J(d2j6 z3toE)wu%^63Pmf`Zl>l4c!_Mq@a!d4ke;k8=X~k(byoU!tiD7?=6fqyr!}u0zcHIp z?JPElm(8e?e$;{Koy!kbTe6~8{XssoZ7QZ`7d}MUU}|Y11?8)D!@~vcz5SsQEV$>? z;3K9liG3p;2(*n-91vZ%U%ufTBFyZZuYKh&_4;}`sG)30#)&<(iyNXI#oTXj8gG9v z9b7fyXgqQiNY!(wqdz_|gfeSP7`?^txW) z%~N&=^9zlSc1Lv6pS2i}SKdgKkz33^O+6Orf!Z?H_p9AbL|0*l5~Wibbt8cAy%kHrEBGAA<;lfOT6wBTh?XjqymK&c`xa>&W^*CDC#WwQI1T6L}zfPRr$G8i;{jdo?M#%&FYy z*bS7*kR@dC7T}R?;u;XzZ4x+L-;%1z4d7=G)et0jupw=9=kyWBXmk~HV@_YI77%*! zu^!aSL#S}t_X#2-FBr2zbI%jSET;_sHX4-fq&yCAP-B*e7>!j4?Z9#YT=Tp{kUj>1 z9vUNk)^T@j@4swDIfG1&k7Gc=RxJ+rE1tx*h_2F? z3wWEmnde<3y&kqw zfKRC}t|dVJa0@{raB&jZ zp5#EXUPWBN`5o%g+{P?=l>@8VrT+2sbk0)X8CgIpS@@XwOSHB<^Hd=!;7DKv&CPkt$e%rXLWX5OjJK2 z$VahJj5Uj&Es~{%TBqkcQ4sC%LajTgR{5I*+g(rN${7@TD|z5I5GP-Xb%+0Sgh1Uz zMv>M`p7>QrxiB=T{+-(1dV7>QqV^c|Oc$j@?e_Lh#VN!~rS4pO6fGE`p3_Vn;!mUuXez7jp&mC8fNly@HL z)56(5VSxrbIm*oSBK!J9+i0(=>*xANfUe8|XRn{WtFAX_#|ZnchjSB6ff`00kBb13 z2EE&40|HUb--C~)_=e=^9x+O+pPq8z!=~SG$^Pace|Kg`!5>x z=zkV$i;4HCbc$v(|~L zB)gL9j0bc2Rs@I!h!(S*Vw#t+o5Q)wTE%9U$3(0*4n!+0ud>^*>Qm!ENyMS7T5#i< z%=Ot}tH*>;-BGQpttSMa3=z|wQ5C4- z%3^_2FD~I|Ogr>HKNgeRcZ7r4Lpe?J5{m1@48O8sAsnAbgY_J*5AFS_hKekcpR?fW zE*Z*AOrv`K&RL=P)_Bi@zrlyzR0Zl}J;cT3ehNQwYvc6dZRD!$i2Ws};OdH!*dgBz z+^8>d@cdyN#}+nC;}C0YD`Lz>lQ6n|SC0%e^4t3pdaHS;fl0Osl}E4C##@3t zWnLtBgZT6Gd&iE;h6}SYa(xLF$G(@3?0i{7Lc$#f{|ERVfuGPldDNp-cZIewXVgg( ziZmxh;hqo3NT7iv&7)x~OV)XfdJbjLoSP1iy1pMY=TdH@ zxZ6Y&`iS~;v`<9epzvbDTheJCs5$W6Y;sYLxj+ruy^Qh*M+R1yS`(=Q3STFa(w!D59^I2^@W5)WjjYOQsF$=T4;kA!DjhNfzVu-UY`)3!xfeA1m6nJTmuJ zjM&|S7^=v#1%Od;T@h5NkeUbiwgrGnBJF^@|Fb(ZqIvLLpHSQmRUukfvlpy08C^UE z_Ay+A8>?xQft1h>yK6#D(p|&g!ZwYB>`FqWowUObC5rLS)9ryBS9wB%45yOYkxS~axpCT|5P9#S! z1Io=E2lDJcb$qoBJt}8}R!KUtK86>rtO=;>eCA-hC_rv+RKF8_f-^xmDdtz&~UJcd;{47qcYq z>`qo#?sI~x>{%EJIDj2rL=G?5nJ~Fd8+m>q_li-5<_WPzd;EzRB7mDH?8{3(HEx<)WwweXn~ z5mAUH48TP+bEznK5pjyqKo+;4WFJPtB)XtQXC%&_xD*jc>3)t|&!ThcrW7m}o(Dw}Lc8Wl0&gYUfIQ3r;+vS5be36w$ZZRVC`2X+>{M@OjY!hqpFJN|iAOMx(w8-k#y= z2)%F}$o7%ZUcs~Q{D&c_sHz?)rk99XnU-K&uCV(4+WbbwKm&cEQExr|gy<;|3nw)E zQA@%#iua2Q1SLEwYH;Es2c>Nc2CSu1TDmkFw*F*fmDhxYQi1Z2DEf387J~d_ zd!%}R*4H0K!?&T(yi3|ya)punk0X+82$(}5^4C3q{NI+rhoLA(YB8b_Irqg%1DLrM zhJOC@Nu?5?#m$-ByD&bW;o-a9>?3IQeCg^NiL2dpQ2+pmwz+(=O3Forv76Jinf^I(GIn@CP)egtH1t;-zF2TL(lYFN`7M_`gVq zt3e|66rZ8{<5Z(OAuiGCep}>~;{eF&~c~;_lSXyy_Tb%``S>2T&73m3&%hni(iSMX0rz z=kxOsLD6r6UAsp1aW3?xI zh(`fj4O3C(o;893kU@6{)cO?y;K!l*h zVks4oAw$~ z0NcZMz|N2V4tpH?1*Cnk*-{=&W&~N0z2=!#OLkZ5n$P5h;HV6nC}uft8i)Pw zZUcKihmkNs3;#8ObLEsW>v6=9{qzys+wo;|xcW%#kfe3GQ5=r=78%Y(ZxbN3e@n&( z3V_+<0IqyY!AL~?f6vr<7t#Nr(CGBz1o?`e?%>qR!1OTxu5hv}q+K6bxWAUwM?z@- zo5}~LFKwg3Y~axUk3pzN7#OIgG$sHUXYak628{+=3+0dpy}C!{a0p91+WBkdZIk+V z=Npt4P53nyXa7qwQo&y>4my-uDj!%QL*q0kcfMX)pf3Cv=?y=d30Y0iwkS$~ZrzMb zS_p7H_*0gfch}kT6OACr3H!ERG5?=MJKq%E{D|q0IsEk93*J@iOBihTgbfuAkxyLgC*%uol+{B63lN=7WyNP?2rpJ* zrHh2Lk^$c+@&A_-Hrf6E(5~qF0K5vfH<@ssm+W9^^t{IXhER_=8{j6uqA#mgMvl6! z;8z~C18&kplkNCJOCaeS*fB6MfzzdDfY_fHBwvDwa%J2QMnQCZ|VxKS>^-T|=Q6c+4YEe?RKvJZwgX8~= z6e3}5qN%DFw9uA6NV{$;Xt^F&JF(hrZ=}g+|5oNm9u}ONPky5AZcv{O=>*9*WF_^lZ;wbD~w5(Xqdoel%(ge4wVLgq#R z&wsl54rXS6qlvl)8C^Jyp@}4-Nh0fNDn4eTI{N>zY>ZSZ*DV)aK=|(92mVxg&-O6k zz+x2i_eeTAD}niV5JYfHwHtM7{D^j}7_43!BBc&0Yw4F-xi0Iu zL6?`U4Qw0+XF}0ns@0)#JsV7&&Y81W#m9%I4MO3aHqvqMe(9~sld@@a3=dwpv_Pi& z{0LG~AWLJPH2;2cNR`@rJz2_ajFpYOLt$EH9 z>8Gl{{RG#`=Lhf8>64L_70mpBlatdX;l3m>a_{gkBxwS)lG2X`-FnbA=R=mr^BTCd zdb6OmHf~ZfGLnQMry&)x-az)zXCDC|N_Gd1&3)iwXJGCYmD%T*`doElAiQsr}It zfu8#|)C&LG?e-8AbSzXbr3h0rJ&#={Y+3?_(d=ZXEIOe>Rv^Of3q!OUP>#YUV?R0; zR7`}p6f(e-j)tx7A25i+Z5*&#HW#S?dp4<_3N7_C5T}dQS!Wmq=n4bf zXfp<&@9Sk6+7Q)cSLfRi@@|mv{Rj8Xy_s{E#&-7w2!Gx*!$AJqiww%kBMPB_f7~_9 znqmmcA5sXm zkLFQrEC>H<@7x#)f%U5BOdBgcJZTq)(OIgatKRB21xh>NerljV#!eK0$?=|5PVp*N z(RbO_p78eiZ$ZryOq*r`>qRX35;=OWqQFhVgoBGaz<2)do;b9xZ(rSt&SEK&Y1K!L zdRYUVOFpohz@3G(SoYAY^%oe&PZJMGQQpEL&yH@2v-cHHPCoO3J%jY2__K;v;fIfH zN#l(L_mvpc96i9uYk`mfQlsEsbZ_s2Ws>XsTVdcGh3y&6F2?zQZQqZ=TdXXUifpzT z^>=4CP6Z|y-RyWCOjp0e61~!D6^^L|&+pAASUN^^nb zD~89%Bex}`CGx!>Bu2^xGd?L8$4wAk2>KB)_M;N-YZZ?4A>&_~jE$WjqFn{JskoEW zJi$&{zJpG@@lbJhh+SzOHG(L~Zva|d66vY^PNH`w^b42H+)gz3tdN8G-he{E19mjT zJTmu3Q*G7TP+sb$>|rQvJ>dgUt43O548+JCoE#i3E7>xPgAu^G0Flqn&y#qX#=zC> zj{KR?KxFt29jc@xahQG3rfD-jfT%(Hi_%VRJv-Y&{byMGEsC>4;@h2v$oWgV2kR^A8D*L}rhfMGY2vg42N+to(NG8D(i)Vz`yHP zadQdUrnCR)R7$a1qy~Y*vK~joF^=)LRyE6FLoxaEkvsG|na!^Hu3&~-Wu?M=G_{aS zz|@ONBv`S$(bzS{Z=tr9N#(hA#_Nh~bZ08JcD2<& z_FY!3S%nIPQf@x^a-E%*lr+(F%**2hIVb{+-Hg{`I+jRK_55;KF8FpI_}^{3PheFo z2ZJ19tJNv9o`B~dzO+)MM1v7!IC?JGZiNBL2E1Y%5u4a#V^VBjZK*^Kars6$<#L0Q zkW6yeMdwGObqbgXy#E(ZtZBw1=U+NBmivx5E0MK zLSvzXd(DsG>p4m|Xzx%Qhg8&b35SI|)(%b$EYOFO8_F#dAVb!7MK)BD;?eLruGJEv{=UVNT^ty*5tcpldr|t)_uT3Cz@GcF2_Qr(&THiBrWuE zS7k&OpYQ92^akGd^UdKqkGpCLMLCZ5-_bq+6XR7s%XBS^VSB?L2A4uFh$9H`K|U2IURJBlbGrJa<1Hu?woD`zKFFx(I3B1V77opnjnI`D3q%fVaqQElEUA`}kYq|c| zi)+P#i)#;WK;!WtwX{ZYn;WL>_Lx7dWngQS&_oo0K_|U)UdhwCQW69G_Gl$R$8MjE z_W4;+Kj_q85m#b65Xy~$oJYF>D1>HU$gD@eUEMpBS;A63o+iCmFQ(Bcm6z}It<+|8 zTD@G&r_rfQMF0g;lho|+h#P6P%S0-`Ww*WA4XUu6$-P~z7guSvR>MP}(*7-Q>*&6m zT&=qn+6AI!MnJF+FbXQM9g5_DhEYnPKum42VK*bdw_U?Zvd%)lMh;`QVIzn;9AB%K z&aAlD>2uO-Q&wqqwL--yq~&$B#7|{hNv7ADS07;J@bSb?Wmrn4SD#Gv1t}XxEgdTm z&#V`ZS|_2DSVCbj3Iso2fn(3s3xQp;;_4WVi2`P@(ku4L53I5K`BbS(T6O!l<4)K3 ze?|;VW@OfT-K`39V-N*!iIgbBEjhX$PFI&V%4eWPm8+WC!<@^LVRL~r-pH`P%Gar7G~+nQPao>L{3vc3aLw>+}Stx?DnFdGL~1jTa|k0;M1 z>otGJ9SAK4c22d;IkTQlUCd+@S#7P>zze7dqvHN>X4$5qg0lx+t2vkIYcFQ>*V4w` z;g!i6Eb1jx)EA$rw*lu-fG52BCHdNkM!&`?^o&)6>F&s-s+>`%?8~=P_{Sp6@31V0 z8U1|^g`Fo>Bw7u?h{A6fP5vS%_jUTg(-%F(e0QybRJcf#$47`i;?PD0CEsDSTxQ0~ zg!ud#kyO^{13d3=zF((ft$Ctwu~rkLhEwfN-o;YyDuPiYMSM@{){J~z%2qPJwm(Rp z!${-R3!7PoJeBnp|A7cJ*1G?oGNA3Y8rhj<2qG3AO)*P%A4L~cSCBAaDWg<&ad%44 zn*(zKo%di;$Kt5zBPX8XPd3?Tm*~@@L+>~oIP_{h05u+fJ&r{R! z|NgNE7qLo`AOT}aseu^?A8Xbm%#3O!MtUk$q!fx2S?@b{Fp6^1?E|7xM@-)JGoWjA zQ+SIwLGM6dLK=qyx~Td`R?-^_U9lx8@K|RINn&gfH#_>`n)pi+&~f?5pRU;k`f{g| z71InXl{<^!64)1NM06eu5hULEBr%qsCUKofpH9{|0s}iQ|sD*O_a7b*7jmO3- zN|?!MxZ2pVX_37pKF;0|wFC^I@ND$*D*Z$dvTBUB*?j zRoWM`=(EgmMMbk~Yw8a)bNND<6{FXCVYj1dhC=%-dexqJZGP}#6NDcV(JNK>=%?>P z>GB>8S^nYh;bnz}MNQfv#1AT!cVm9JkbFm8CGiiicYOR4i^T)oBVaf~W>!ZtzBLy4>1 z%h*iC?urhEaH=Bo)qcr|&5-wwp(Zf&&1Sc(2agAjk~*#c^1r_FzcsC<(Ik1A;S>r# zmjxv(sGcm19V>?dZ5L`TqROSOSrbn-OAS)vi<8JNM#DHqWz67QWmwlBFd)l>+3}dv zRo3k2<@#q&rHL#}-U6&1(Dx)kBvT&kASYY7*aL7httF7{G+dI=tHT#C=#2`2c&K`W z%ZaW4eaVwdz0eSz4(be$|H9ZG0%Z*{g38UZng!FfLnYr-(tFl}P#)k&N}CXz0ipEF z_9-&?0g|mfO!}jFRpsT@ByWugO7&u4YH3Rx&kA|L5>xqMHI zn64~!uC0Ca3|{t5<1*HJrpxZ9F_^Yadci5IfsbcBQVk(vU49b;FpmD~I!tnmt6fvf z1MnsF?asqVgw94q^?C&_rTcg2L*p((1zr`B&^I9sZY%2XRKlr2}LE>@R5nwb88_;+S9FdCRp z%4IuGE}Yw4r^gH6V<(BYD6q7cFS2!X9?x&e=F9N8>w3C=0eY z`YgXwGv)me3Jv@ZU6`*8HX^$yZBS4=Rl-J?32(EYvtB@~9S{HX>RRX*XBi24?%bT((xl z@%=Z^$TVF*ctYgu<*wg_(^mkhTvk3CL1C%lJUkFkPAB4n_ESYitxyYUH5rM{;{H$O zA22-_E3v{nrEmdv^Y7na3);h@JC03*e?X!*0UTW3Pd6A`PI;i8HE&udNCTUly~k`W zTeV!Ec`eJ^=8Q5@@Yq8(G%O(qRoFX?$nA9ttj-kPgj@vu6D=G&3${#Ky3IuM{|GR^ zY%=6T^uG97ARE&L%`_)q^La8sBI&@-V9Nlr_YG%MGRFh{MIvbWBp=shL-MoML4m!Uj8;Kwpxi-|KyB*0WTMLCM{Xk16mKSo~W}0@3 z+(+EKYkwTIIY4$+o^2N1eVX~s%;;`~*1)-d_eOo zg1y5HDAq^uw(I|dJT_O4w9a5$U0MS%38LCdSm9GeClYGe6eU^54!jq2sRspc&C+v* zMskoIyer1@S4iFZnaFU-#*FAXAj#4d@_h-QN)k-;-ddwwz&#`RUbJqZvt#=>;{0N; z`7Jy!G>+EaZm8Bs$OiNEw)s>*_SC#((Zuu(3BsvZd?QLp&fDHX8JIG8GP;FL-a3ty`l5^??cpJPlCZ3-?ZBsJ8W`w zFQs;Mo4+`-U`-3Fma@;j_>OHMjO+6Oci)xrH!K@9fLm%z_&^2uzPigJY=37M<#Xwu zPrR7*_O*)CVp3Aj*pzma-y(yq_ro`gbiLnU`;_1(FCz<-_wBJy7EvkMMhr+pt@odi zR(9Jzi0wW7C6Z?$#c4T2w^6|6it1AJ%T0*nZMI(SkBX_{5Y=msx zfOao<73wtf(uR`LzW3nPWK>p;J8unOUr36s z8G-LN4^bzJ{cV^L5fw#v$~Fpgavo>0;sr3c zpE%UFTwY!tUIWpGZb$FG1Bx6e4DQ*Vb|qQ#l`)GsdV8hm2DOB#KILKM=a_|K4FJoY zLcUM9^|)o><2vI-sqbA@p(ts-fVQ?m6B!KG*(U5V$+am_*2+~Bh~lTTMVBK zRB8iKC}Y9reKku^XZG}1{u&cSiiX7oE(cqjonSK$GNXhZ{P8uaox(4hV4#h1Tn1^4 zttc~wmkweuJo*K*N<sqY;>g#fXABLc2-kzB`*OQ71PbM!S`xcYEW3gGjaf z{4(Am9&twzPxc7*ZV*CBq5&qmy&uVJWyv-dZz_`VT@)lAo^zUk* zBLOKno)&(7WyfCbMte8`!FijUg#LdpO7yMS83ESp20B7UcO>C!ud8tDHpK3lu6T}1 zZp1%2kiAxGdScoKl5Nh9QqL!GEBVH&9N8gYHHCRqiDxBAXPPasrmYP!k{`f4S0fGP zrhO*-*Kexnt|-S}^hjnJvGTxS-`Ik1c)=1ZSDZwU7R#|PmMRyj8iqXh^t6|!faq%A zjUDxKMa)k|0JVWeEA`};7nDX}<)wu#pWE*ZnST}s7?;ZnN7H5OFcKpns=`~vHoM;- zQMheC=@>?$7`_-NCK#NfNE2&w(%I!BCL)|Z4-BP;G*)r+u6k`LnKv|ZXCq=lP7!%B zF?|9?TmY!%*?dtH2m?DD6&Ti>XAuyDUQD*vY8NE23|FLPs-eLA{nUSXU+VaH#ILKh4f8^J zWjJ+_11;4wSM+@F1#1)yaRy8aOQKS!Na4peplcX7!xj_x6N>VI)zAO^A-BlCX8|n& zsaf6tVJ5uOvf+S_aI-6Tp>%rxF{n~=yPA5>*TZPN{#^QW4qw{-byn$19!{2;fgwADj41JiH|Ijpq`u{0=o?3hynA-{ zzvVa!wOqno{PHxKkIcC4^#db%YNXdei9l7y05dG;v5*c>S>ynyaPs=z=pniY=#CU* zQ8qrBfijrFqopw*B&DLVr-OmBu($~dYNLlhg@Ouyeb{eKtXpkGd5=f7mkB5`77u^5 zZkBwU%IbT2RWp+aC{m^ffBm})JV~Mw znS}zd?Wm>7J|qp_Gnoptq!|vC5#uFVXi~C6)|ydnDsplme?cTyn4PK4NIDyZ;8DwA1l)+;>cgx7tq$%a8j@Nf)?{Z=NhbIw<~ zH_4x=#O7vbjicIt`U{{gA?%=B7HI%Kl3SJejQMZD3KfvSsmw7fP4&2o`b>72+;&kM zr~4x*!zkFQXkB##=C==+3$L?q0bnu;= z>a-ifH>5-cADLk`R#Xk&3JAQ3k{;5MQ2@Rg{f|Z%tJ~&7k8W;a7yS9%`rqQ%C+X7| z4x1B^0Z*C1UB}5JPdIJcVqHH;N&_%gr+FG+a0Wv=gSXEW2Vv}#stUkh%@#%o#F^dG zi5P_LuXt|@A0TzN{^-$Q za0JbCco*Jwj!-|$;AFqG1de~_vpd0DqX@V@bGPidVy~EN4@EOcR@RmRt!oywse&ns z^&%W$A{~;58d_s!XL|J^d3QPG`=n3%xeoOa-|H>s0l!Wqah+4j+-1%ZDzyovyU~q& z&#BiB)lfh^`4;}fOrMy6kT&gC8qAOYq#{Ml)t{?_FX@0j1qCSzwRsK18CiZrwA!x2 z)jX{f6mNPYeR9NhaAP2>`C)A@<6LdDla}j*?*Cn-#P*&B1w(8%u@ZfRbGsPeS(-{* zW(%EM*>GIDj5REWoVBw)HPBu=_ps)*5Jknrm+8UO+|oQQ#c^k^dzwRQR^pJ$DV-hz+=cg z;B+1;9fKbJ&&X4_Rl@RU4cBJ&di)aH{@n5!!AAS~N9N>s@bBSON)xB)z$M|WG?5yP zv!Z`imC)4EG%fbk`4koWh1^U87T3ca7IstD9 zjrSp}hbl%xp(MLmt^Q$b1u35^G^I{U#khXQFoD_-P{mU9;Glk`)6>di+nv2(ST>sPBRq zE_IGhbMY8Iy__V~0IOX(qRR(;VE@{*c6MG1LjqnA-ttaC4P+U zKnle=$qf6lULn^JRJtxQT79ilfg6M(G0FEa8cmUuM7X0W4v8urJdQoFX$;mi9^>`Z z8TALU1?|k5mdf%>T#{5E7FH<dho_EmQ#_CuVx=>9`p=%>(zd1bnH|thRc9oA7^xs)+G3+T8`&TbZ zcQ%`T*(><~U5M5f?8nRWF#EGzZy3}eTN-t4^=ekc01Zx)dKDeEDt#D?ibaWgLX*1p zXBV-Oi%KaJz&3#=puIpm#@zCKLW<a-MCBL;)pUqNk{m+L`~;XU_6gE*&34jEhV zPPFz`uJWzH*x{*57Q?D3c6cF0Yx&{NsMvZ!CbmKchlrE%khFpPg#7*Z8DvyxPm;f^ zX)AabT|k)1(Bk-K=J~t!VURB(p{Wu|xYQ&?tt4J0Y3McqV=xP5 z*<6)VB5P!Ci}=1dyWtr4z{1w=l*J~bbM+R6n|qG_x(pX4i)ps#lLZt#d`Xid{CXh& z%H**MC!NJFevY@DI=KhtGmF#tErY8ab#zdLC4(*KAD=$tjx%BIF+)9FVfAf>sj5BY zm$pgEezJ?kQs3ty^4o5#1~qmRuH`b<7!Ht{$|2E!n`#)yzgwfo;s*2$s(`+M+?PDT zX(?HH!w%@)xx!FlZiwo-Xh5ucnf_yQLV|r(q&OC@{4vMERH_^t&_`ev=AF%d*L-f; zh}wAbCjD8iY?@{Teno#4>>lMa=c(~c9$|dqBgF~T>!n_L5h-9S1#TV|qqUkmIF2wt zjGKDkU>c!32n=W|8S2+^1ub}mlE-D46W4{byZL|zf#oA&EDKD{uD8>Wtmy_0rr@mF zoPi-0ZL`Zu5_+A~4e3BG74VC;M4XU=?6GJON&^9@iR4}KMB@506uB|rR4PT88$6gn zvO1jyUe@2?aTxo}EFBbrm|iV%Ls~>nU0{G-hvTw7Hy1ZSS+*}QKK1*U9R-O;V6mwB z_&CeDX#|=0F1&=QT#)dQ*(^lNc>#_H{Q>+FP|G1i72H(Fhe z58jd!QmH{o6iMu(g6!zLvdV>DK~K?u##kuJM7{F6cXboD`HyXi4?T!x|FzfWQHv#N z!TzMArK3TLC)~DURl{onJ9%Aaq$F=Gh{sO~d0m*dXu!f<)dCbxR=lyU)WO_^+VN}N zB)kHjp0>);Eh%h&j9So~!zaQ``}M%SsBc2t!q`0S+EDP;aKHj8+rsKmUqn)m!}*E7md9UH+<1mR)z-%hI^Ceq+q1zX__>LS@+N-%{6_+bpaCY1D$W(^y3E z%0>q(6G5cj;t=Lmn`xDUU@_`fdY-8_Mslkc<9@k9l6PX6-OhuzBn35J9@BIS_JvRp z`hyeJ@Zi=ay%H0H%C8ZczTIvh?dbewwFyhph~Tx(-Yp4YegSu_7(r=O2fXtw6dQmZ zJ=_q2)G_a-$Ph=!X-^4E-}rC(!)e3?DTjMOj1Y@f{3J~V#DDWU(v0$(u_-Q3fD$Wo z^-(YbmtdtNR;y4`k=i1AEx4B()dQ90R?!!)w?vR?S;2S^5_`{0ZHj7mL!OOg5bbtv zfk)?r4eg$YTNkt^>Ma7Mrlx839ONy6+(iMataW5Zo*D!54K*ju{?xSc?Gf{|33{Ob z(WIspglJ*Xj(Izk;%IeVdAPBb4EttVZD3eh9P_J#vzA7i(GPN>;&N{GLO|Z@SaSRJ zfw8jMH%ag89JfIOp{1+eHH_nD1|EjIm7Mp?)mR?PUz)1gUmJC7Q@!5x2Qb%yP#vd8=`P5u$=H~!!8SWu72KZmf z`CzRRhgsp1`VWd)tAi7ywHk?T&r41CJpbkDNUxL8WN~M$>G?a7r3m@>AZa`lN@JP3 zYB@&S%?TyQEhl zH*<@YevPm3&M^zF{Jp)UIoQ_(YIn>IAQjpGZ85{K~lnqKp=42MCC~qXMk1 zfAC^eK4Mmo3;!EpJ=g`f!Tsq>P;ewmT7w5rrs_{KEbEi48B2vi;COdQt&7+tL9(L$ z7vP(yQ`Cu0bpP8jGoLlAh@+RIH{UyTvTjP#SveW_7Qt+dc2)$vIgcQh$|u^?=HcjL z>gO}tSA$ErRw25zPMV`kwV$nb@p5V`T9Qts7^uNZFb7QVUetF&?0Cf#+4K)$%h5yK zc3sUc-`EHpMxL&5-B6`Th$cu2CbTpEW}$)m+JV?*Wq*j3=g-tG3T%vTJ6FxWX#KI`U!(SjO_)6+G z2pVzv!ycg@_ahT?B_dwQjK7tggccykaaBW~Jz1zngUZ`*-u&4;OPE+Gy!TPCs7w^t zaRp6G<3Bp1A8ZT?_7+WAuaDt~{0%nUae^{aiJaUYJ-Gx`V!q8lrz;5D{KN^w&iJJ^ zIrL2E2v^GZ;uv*K302wH11(gC&cyf!2TnoYS5FU8Zo}cxqf(jG2gcQeq{-)@qk5v< z3tpJxD_D?EPO0%aqa;=zEFxG*FQDq%b`9Z>+58Q8qKy}x>hscY%B=SjuT;j&DrcUu z@&+&4P+$knwg67-0h+u5UZk0aAE{*5m?jJPoX~uAOcQBTSb){kieD^a;HDb@TFg5aH1Wv?H&H4K`SyG`#2w$`VVthijcc7k@<(L>p%1} zkwPrk@yYik7rdEV-9Wp&HFPmc(pDG+XcG7N`pmcjCgOYw6ovbE6KN=Xgo#Sd>|bq2 zxhqhTz=X^clW{rTfZO-P%x%hpIGG}Yf(0QbNC@(X!)Z+ms1QfRS+M&Q5M_$0*qOR1 zu&T6O;SgbsXsflK7PT+g*`Ad7m;M@cz$>YF4AeU3*4*rf&m0hsa9ztUU)vZC2eGX< zkXnvaIeKc;TEFrO;Lns71ij9ixw-EQRvC%i8}#z<^oRdnl)VK|9zpl+84@J8ySqCC zcXxMp_u%gC?he7-0|a*o!QJ)62`)SN?pL?|Tf1AgmMW^KV&0zVp6+?4&v~BT3HpfS zvdk1%u{TvsSm97tSMO~}&=M>wE7Ok0wjn+jC;GCs8i)J8NfUio&s7Wn3T3Xh1)p_M z*xVi^;*ZSQ^&|}jhB^}~=?oO@y>9idBb~qz(zm53wSBZuBQ!A*r4&M70~Af4m|&P% zD||ZdCT~R_`IajD^e4g3Gp0Ph1PKik8H-uBd%7^_41J_PFqroArbK-Rnf726szljy zT8oE+M_eh(A7740xVv)O#mQTW0PZ)!?7j?_gJ3oz{~D&Y>)$w&?7_Ri1sMzpuS`9l zt}lT_OX0N_uK^8m`Q6H!)$9;|Uy*`=K4z;+@UpI)K^dbBqXz*;cC%rs4E_=yV>A=Y zu2}*H@~-(c%7l1ah3s5?E`CvPH~tt57jgEkWHFXON)mq(Na`b16J zP!MBF0T|#=6DpM>JX}KNHWT;&0|;9v=8|955-8mJxIuPePhskGOvAX?6-1S8p2ANUz>ph~QU?j@HtoPCg z+ILxLX;Z!zS+ICnI7&jS3iT1XVnr6M7NvLdKT?znHTEVVK$x6sH{a;bJiJFz4c{UC zY1)mK^+}_MN<&*L%9mx;RmtD~YkuR*VNnocL>}lHamiBYLr5yM`|xMb-ed8x#TNP@ zNqmws$?%+I3(JJ!GSK^jl~j6YY~l&xn>6__+p4+-3JD=ogItuWA2mpbr>TZ|O`$oQ zsY{jfd=z8QlFlPvX_HUNzbD*(8+0L4AONOUMQuwtEn6({fdbiK1}V$~e@sYR?W3bL zk!|~%6w_Cylc2_dX`yw%3|JTQR;u}t#};PIwB=~)p(6VeEgUlXa=XCfQ`rJ;KyV?( zs0tMaU9#uhl}qc;9BR{V#j3_EJh&h|ui}dwC@PKvnrS&YKtzH=7k;AOB!dv_FcMaL zGAI*aQ;+42fUs!u#v+Q>AApnWG|-8-{xeOOshj{34=z+JPk1!fXQ23e4mG3Z_m!1a zlT0jK!muKaGb*h_{74#Exh{r7UaD|vjTs|j ztA#i+Xw7JZnkAxwdt(oLg0Gp`2)>*%8u+IKaNhUjCwaq6Fy7opLlGGZkB(+BKjW%l zt}v1yhF`Jnwx+x?&Xu3J!<(IH?mh zY=f00&cI}F88aK5)f@br2G4BiHRn1t(^uNXsW6qd{(95??YAvmIQ*_J`8W>2OOb_C zX;GV!hWvJd(aN_*y#imMyi1tn)IiLf7>*$ySPCBW70@n!?c`-~=N@o>H_llPra}2+ zAbU8vf1{c8q~T5`cmcVWF`EYI&30Yj@ltU>Xw1lkRIXA9{aQt^?56nCg6X|;waxoj z8LY>ycvvQ~aX%}OJK4?_#=V-Lox0<}tG|NX{moA}wqlLByrZW7Ng_@+KmLODqWHMr z+|iBh^91jZQa{BnN4FoH-F%$+`sdjwkXlW&j5>bRk zUr99-C8hMU9gSROeE*}YE#b0Qk?J&J=VcUE0GoJxp*mIe-J0JP<{+Hi08(n-J;Y*t zummk}*l!@b;OkVTkB`oLrIa!>+4jT{k)%gjeX}8VNl-Bzky3y}Ya$$u7zw2~#*}q9W)+<)je0 zFp?(M=ORcXY`E~PE!IV7HuGdYPccNk=SD6vnh9WVQlHl_cr~@P>pw7yRtHtCX6FuX zcAfO2i_d1r7`8tRyWvL3A?_+xk67ca@hEXfU<#GSCI>nMe|~BT9KliRBhFHu+cxwu z@u;6pC*;y1Rc_<2mf2XB&utJ)r7`RCKZ4!5n*w~7?^H=H-;pJ?``|*=4&@ki15Q$D zO~t81@p(uJrINS)S$N-JmLJX&SDKt6x8QZA?FS;lLeV>mW)V_f>;?n5{vx?Jk$>}y zTuFDNdIcO}z0UKWZoga-Yz#HUGgoI3!fllkYVjFF)pI;JF>d2hiXxGMYB&h^ZwAV# z$i)B>O>19BiE5A5x6td#p)XH4L|G&hu!ePL=0l~ssD*c|6X7GaA5LA4CgYRF9|0QMgN{QV|OcMWM`B zrUr<|4q9$#1EMXl;}uo{dHHKB7BYll@u406kLaNisfG-0c8rgA+;C{rT_$^7yy2M0 zkak+(9SjUKki#ymf-rlUs zbwLG~MHNYani2qrbLShY=nU=zz`XnWLeG^z(lR43r=8LTqpXDMSrX^udFAisLSVGfl?ZlNxdXZ*2KUT^mY-%k5ZT;!)B-pmO7Ui_B`!omL)}6^lbHIq=<=yCRG6I#{^hE_Rnn?k1N}=VcqcyDnm^} z705OYLGii^UB=r5V8^OM7(V#tin$;=`#L2fq-<#+?Q>2O%clQG1U9yB0^)~h*LON< zX6h0Q{VpJ}TJFIw^s*vpb|@R%+In|C0a`^YXfioNM<&9VJZPtbC};#crh(_b7|X3w zpGV@eCrI1!c)|GnR7>zCv(tr6=1}Hqa|6_C29Gy$Ig8NbX?Lqh5NLK2PB-;pTJ44` z=g7cZPbC#Q8qv(g6MoP_KHaj8rpknYR?O<_4GofpiwrA}(T9S&x}ewBCmoLyuzh?X zZswza;Ir5(c)agQc#s(Sd~F$l9jVYDu6z6IAM7{xp3wPbJjht1l!)T~JU|sSJki<6YY*yMSYGih^jW)3R=CQx3Y%sPbp~$CHZlEnN(YEvQMKN}C=E5{-8_rY z87Ck*#H~H&igj0}owxpt<>r+m6LsZMsNa3VWER`YTAN;wM3VzO9I98oeECgig+fk= zjq5zy0V;g1H6q$O{`Q5jYLOVezk~jRSkO3b9DlW#>;<9TY6YF%xryG%6&@q!iO4`y zI}kj7ny&vY^sL@_L{HS(&V#=Z{YS(pJ55o2i&B=N73DqgVqA7OtwD{F!!SQ6QR0>1qU!#rF#dxY5gDz;WvO|v+ z3-D9SacG-t-JAKu%2Fgqg2;pSFyW`$#QBP1_9W@y3mKvjmQO;0pC%tJAU@VOB&Ab@ zUjx7r8XgFNWrR1#=!=YG^Ev!f4ee~|M{*4oP1;O$8M*r7Q`mO>2=6@mRGhqy!S2C5 z1E}kT~Q$;XCJh@jc;Ea7v=@yw}O^X>a5zUp%F~?ZTy7h zx1Hb8Y;qKW2H)KU;=uPMFw52JztzO~b<^&=SYhUTRZ_R7sz~~`WUkJC7pb{wO8PiW z{;iEFW}W*3Kk`OaU%i4+)6VA0eNw``2<(T;{B1~~P7(AX$Ys(jQ@HdbwMEq}9C#sN z)9Lz`4@DW5rVtjUHopnO8LKoL8;)R$WS6e4iPahGk=Ai{{-v(^TWYM<&Dg1)va{eK zV2=p&A12`dX0v;50-wPB5(b$d@9!T6pO5K*+oR9AJ+?u7-jfaXxe)i~tRtzkWghpF z;6g&5J8mOOpsLmB!T#CDJeaO#1e9fSu)+b`)$h`1tXN#i0%>$;=@cSrNObusfyjC$ z0$shSg9<>J5Ak>>6(Ex?dq9m_F%T_mG*!A3e+A<4W*yY;Z#U-JKQp9~b~9yd3(z~E z!0LSeCY*>XhuLXpAIx_6tN=B)q%*rw2sgfv8)XwoJq2FMY-lZz!Uo-!N!`t4K4qla zJ5YhWE(b2weJYyYCCHZW-dQjJH6fH2esuZrBfH%h1#? zqfQg(ubYJZ%ldou@5k)xJ)SVxE8G;hkDvd*h%i@Z^nK@qNfHT|`%+e9AcY!|lNqFM zvbcS9u-5MDB#?%166vo1HBkMEG>NSa2IFfGwFHoP3T3(GbG_tx!bR6rvF;E%(e_FA z?@aG-x^co88eDa`1I$Fcn_NSFRi0u^;unqb%(R^aXhnM!hg^M;f31VhdLRg{V5Kmz z&Bw50-9h8eP6^oy@-OJdg;p}Z0_05{Ur1@nOarlalzpBZ;B_VW`Bh*Cy=warfHX;5%#q_-k5|1O~glvX({L^Uy zF{ExoqGV~}2_-!Cvqh1OPIjeIAM6wwHR+lZ(H>A(uL>2KiI{dP9SRP65>K1y=fI-+ z{76(;?Ftl1Ga@pS4BZ|$)+CsqH#++{a6ou6W^A4F2`CIE)L5`TW|D48yazSb;Epb*(CiSXU?)G;pRaFACt)k~F1>I#Tygq~X zwW3vAhP~+C>ZZw~Vi9EyPLc~|f1v^4d{i&Y(iaEK^Ux&qnBV+=qVCvRzq<=&I=eEn zk6DT&ZlZ2$M#Z;zj}&~sVdhxawcaxPVK$uf1BaO~-Y(gEEd6gTzM-)Ay{6mORfLj9 zmC}0+iy4rz72{ig+YKj|HVQj{5;sRL?_f{~cn5=MwB<#82>(>Fh1k@Xe04n=JZF=S zF>*3(+@`m>sc!yNAHYsD+JE^UtGd$qW;K`=XkHUzNS-#cL6I@inA>?!mf)`_g?N&1 zQ31|3S;39YXJ1OKl61NpNsQTPxY1_~gPyDFCswU$C87`d>+4E{t{g6O8>7Ss`bGxz zi*>lQo^>G%=N{7r=f+Ph%ydlEuqRrkxuWfft;u7mYtb|5W2B3Cc;8jJ;9Hm)8yKU2 zut~)7ABa$>eDUVAwdfI!z*IZ1l!^_ExR30phMH(=Sx6XQi@mp*^2@>1yIJP}W@_=N zU(JqOeQd(@c-ETTr|IF>ML6#4b9xQq@JKW*vu7no^q)_f9$4qJzijQ)u+ z!;$yRf%O~V&lo7Md}L}2BJZBLA1mX?CL<3bv8Ez+b3s@R3R5E?9Z*+nbk}+$A$F;L znm?`hxiM8H1c;wvXsgN$rx_4^;*M6MEh2^C!wq*%D=gKB?9{RUxsOBXGIACzIv)4L zs&jZTYx4}Qsumtslq#pN=(Jcc{`#|Lfio_-3RW%jjBc86#0M*pAg_QmP@!l>;1p$o4**Yi6UW*^6O(W4MhnJ zx2kv%1MdHQy`*3KOOw-i5Fck6Oe;+y>lLV2q}}n6aw3qvQXkXOrePb|$QghE#}(0} zo)F$@gp9vR>iHe8&W;P%46Ja$v{+m9>X*xBHeOnscZRgIz%A8^IqOK39B@eHO^L;7 zS0y;yTIk~0kDSYe5!N1OxU+ez_3TU%U33t2hF%}6{o1%DAYiP7c`t{zRI=s=JwWXk zBCSnX(R`BiDE1z}0y%6rMyI}4vmh?%*XGVRt(0oEEo$^!A_O=;f|9kdEXd~_Ji)8p?bJ1-OE z9?#FTyK=UQ?ZWV?=4X#Ol3h)-d{||%dqMeoh3-To897wiT&djOK?7D5*??OV@a(2` z0NP;MFOuKg#JoKM+)q$EprI2|sKA`M-1f}|q_7G99rAiIT{}r3*Gqhe28nSQd4{jB zw@~Ybb7@L(hctZ8^?5BayWz*R+4pH4oJM*BC;P8$arwtI;;E+r-e0<#xx4fkYyzaK zqV~3rz8t?-Ia6=e+J@Xj!x}n_BHxA80w^?M20cZ$d6ksQ`A=dgpLb2S@^@crJnndo z!tHAQVvUs^#}Mc0osc5*%@FqUFnyMtF8ZNc%wp5z6y98z{BH+iMYfl#hsS-o6(&f@ zbH}l~7Ut|m{Rr=N=73ZDFY|k2s-LZhh@WH7SEP#i-BJaX+(kzi;}*S+P`A(XVJSg9 zGj!r2T5)DH|2N=e{!gb(o97friWY1BybF>}*X|CL-mq7EADW%66+Oa`YLLj$G3c%2 zZgbu@RQ!Py{28LeR;fCQ+yJTbq9UX9+Kjik|_s&TEU`2&0PwStWvX8L;hO&X*9>_}?224oGrX0Qfd-Ah3 zet!m2JAQ&FjMO4=_(&gkZQrpZART$p^3xB$Xe9oCbq_U*EwIGPbx7#n2U##rK`eAu zFYy02JC3-S6E<=ly>*CJGzs%*7~-NjPauIO6tQWoz5 z^!*qN@BU+9MR5z!#m!@AdnL+ylNBCij1MF{AC{Nrz*P2*`qxZw z#;Ks9L1Nu0O_tR->m5hCUNv# zwC}Rb$#9QlGM^O+HqD`*IQ}czSr1zI%ru7=073)oBQpy5j~;)efALGI6~|G91(uLY zA|x$djKpuDLJP*&?yle5u_czTthN9CJQA0=_wI`d4h5_EMLujimE3YmKje4u9+R^v z?`jKb(@TjLSLeGr2xMB{IJc?)IZ(Fl2R{(S1R^}xfnWW2ybG;c;;`DjLm}k%gk<*= z8j?9Uy8fZNt6alEo%UDLddvi%Qbob}yjC;@dui1UFK;}A3VB}-&bpFZ^*=Bk2?d1P zO`xuy0~?w|ekQAgad$pmZcQwGVeR%n4hr}*6k4E2HI@KhW5Fn-F>#i$-pX@GaP@0q z+tCO1XFTa`XW_(d`RE@DW{M@&FO!u8=3@K=7a5UL=>*$-t{k%1%>?nOVO)>uD~3by zftLp&oG(mY59x=EzsD+qaCSn-M=rKc25cOk+Az&^TSZ5pgLeufDuqraf;l}j!aBRX zib}l9FLKUjdz1M{7~8k6pu8@Dx5Fr6DPL8dQ?NL^_lR*;`Q4|bI*;2?d<_QO!Im|J zt8aI(dG8$fQ#Yk{au6`&i?U?Zgj2bEc9Wn8qeBD82r zVxwb*vDE|An@L0(iKorcfkMoh$kiL1rQqtORZA)mfdWVqkpovd*FZ?DArFm9{5N7F zzfLlRu_szSi)nUsi(ZTM=eF>F_XTbIQuOsZHe{SYsgZZkZaB*OV+< z)BV8V2mRob=8!#%7~$(1#8)^~IR|N6`$!YH*{z9; zt_(+S4iCWLVq_uzG+7wA-BE?`^CR*4Bm8kWGIYBtAZY=dp1-6156%X@#QYdXm~o?Z zbql!B2c+9hHqq$7Y@~HR^!J*I6bUA87dR|U=)xBXfOyyq@@}E||1dY47-+`3s*!tm zZ8PO%unEpwh#mYktJEyi`XHdfxI}2{eqaC348;mk{ev}}hZ8{3O<*`nPgq@<-jb@9 zHLNJWLK;gv=F?^p4k4+^9LXRZ!f6oUQf#O5hUO3ao5%g)>&}5$k?}lA#DK}K0FV8t zsxDS)dMh|7RV_mzLPGw8`H;`4RIISD*f5xBMV3mCVo{QbtQNyO&F{l(VUY>!YwH_w z%Qk|l?sNBWtIfz~3l~62Dzpg5ret&gxvpNstYN0}V?fXX7w=C~@Kk8M{PIfly!`W5 z5%)rU56B4o{1V26>Cx>6A|52a@Z|*K_PVMswcFm#%hAkslUEHloaaa5n?&g2BV2Ne z*$44+3k&x`HV+4L44@TXEZh5d?6V^?qS8`PQR%Ql!o{7)Q~zoIxAB3p3goPVXUpf) zapOZAbjneLdli+RD7t6EOMwp<{o~ zwi}j`%lFrl8qUdF9RvO;{^L<9=Btv1nc$BSz5>iBF>L2jvrIDDHt!X``(R&j$yD?9 z@#VA9sg+UECE2OPSNui_kgpKv@8Ea+{nfEi-$F>Iyqo3s+L%H!yNT34J`~4Niw#3q z{|_np2EN!+SAiAW-|#Z#S6^Vzp8@z2?X#l-8WvX6Q=R>8K8e-~1b{YrPQ;$B?Q#!o zcb^GSb6$W$#@G!YPUKVfDj6@CW;jpidS7Kn<@KdWIU6?3UVb`Xi&m;k@hkkknxi-9 zM|x(5e1t(wMlVewTnGmNOM|CVvb50qNBJ$0+EPUaYjm6?0$9knDP9tY0UaYU0YO3<{e&Gg6Q3&#AT2&> zO^Ud>3u*pt_3vYmsH6POWdANKHRB0Xm@UFRx{yu_w&Kv#K3%CU;k{)(RECwb8HtGeA~u zhGnY-cEx;h8)(e?357+yS8dp51i>_$JsP+Q&|jNT=gQhdlO9*v#;M#1J96av3w+bX zMc|Cla@mG0hG0OKKudM?rujDG(|~N;LX%#X>Z5w{A)asy_TRNO7=5Y6U_5M1B0@0m zgn___{(E*H&p^DEFMGM3c&T#8gFQ99 zEi3y93$xpbHhRA4dHd-;CpEF5)p5C80XRikb@f3SJ?s< zu_zkC74r+S&+Tu51y2Jo(8zaPQ_TH1xXlltZE>^0?I_1uz=RT@A`>L5O&zD?Zm z1hmW@GP_b7^^bSh=x%SovoqL$cX2dgN1hnl9X_?*BsfP^6kbW`HfZE#gKrVW4bNL@68$v8K;R0NiNOwLsKd0rzf`Ooo+C0cdP}Pd12GEORKK(aXZ*kUD5#3i-lF7|6tg zpCV&k1F2f8vURdVGG0m3ljMIOCv=c8pecM$slKP1In~tC8v83ccT^F~VOG5Wxuzl! z)@H%6y<84+%u!7Zx`uCaw+q*(C3tMp;Y!dXy9O9{JsT<*ADm0{4$d>{*rKQ;LoNA?_G1GaNBkA^zzoOpz3U87}CW?#ZVPaQk zIn?RnAhVY+UM+j6B(Zn<>b%$SW<|Ua%xR>`yw)4x{DqP17Vx)TTSZjC`opX~2Pfeou9dtT%QMM;@Hx?<}ukM$l0ZF>zvu%u8D~)xHAx!f5S}+dsce`uy8p z9{GyQd@{@@B6C(I+3@tuYdA<|)zmzhzX8S>KT~njrBK*G>Y^-K{mh+#y=9kKU!+g~ zrcSqia{ZT9fuIE)&z8Z!hL(cDYN{Lvp(W~&u@g%vjjqO>1TCX8GxOf_CsnMqd0n?j zxM4^2Qa956AFz6Q`u_u~hgw4Ygmw!N{<72;AVQ3!tyOqp?GKt{#&(6o6ONdLQJ2#o z-3CeSt8qj8uDPb#>c_rJ`SMN6Y>dtw{d;C7vd+8Jr?qPQX1kQx(b`Giy5IN#m(l8P zzQ$;w**F9$fknjg`_19^yx*FYXe(woPKeRmEdwN5!^`N7pMz5f-^Ifkj(3MkcuLV( z+C}k7O%oW3K@v$ReG3c1{LFHmH^gJLLXG?>jCBT!P&_<5A)%p8I^v&fBr`lb1Ro!n zvB3jFIH|N-l%3d6fEpnOqYNS@Uay?smz!fVLiiLG@`LeMeRiez2cxysqUw#_sZu$n zCUD&0#KlFHrkDo`VE~68F&6af`_DZkxjXlT1UR6L6Idp}T9mCm1z=yIs2(7}&qholf58K|Ay}QBF z<1=Tv(umS*Pv1Y9=!C^glJ}Mqz+yIcbWDOuTc^+7Hyn#`)3Pzzt5KVg0BwgRT}JHN z^2JvhVQ6#oP}BF8kEGb2h~}9#@4_i)p~dQ$dlWs;3Lnup$jSCM9LVzq--?bVV%zfjQGIf7b`Ce@{t<8Uhno=;n^XS$2|yJCvUswMT_%+WgzvW zo9RN6>iCN7Us96P2kn>x3bjgnd-T`pj|~@o245p07|zJhJ?~oT`v0}HM2q4t!CCoB`A;}c%1YApb#wDyR)=P0RS?ghx@TsU@E?-P z7@py+lR6e8O}Nh;5(31MU5t^5`1!4d%R9KV+@q^Ih6=u0p)Rjg)vlOPMVJ6wz=ctP z-LLf8s!;@dcloYTfYWWj0C{D|XP}TD0c(2&&YKWlbjxS_OSJM&-9K;(79ocFQ%9OA z1_6p6FCM{3KUDY;IjTbX;{X3~xSZyd0zF^nWx2d>A>}vkY0EGu$ zbxi?#z8MLL$JH(B_}_P*C#)2DTJp}`O@NhWpFm#FgsMKb!~+&aVE4BAbT7 zD{M#f_i61p1aYX{CkdGpntaT|N3f+hPv)#P_^oNUAY)fVWcygg_-_|+?GKJ{dE5&_ z`%Q$`B8K6w5S@K1-aOhrm&2Gvj<)L`5WmWrBEiBGtaw;}^w*K^6)=j-;$uDTsPS0V zUPtxXsk5{;hF2)_kr!mOC3tAf5(?y#s30trzT>ZT~hZJhl7HuAN?OH0UNxCe2YN zYj83fN^A4ydRkC(PVeKUs;Yf6bg7$PU#3tc?7mG>RMQzyY3abfKMbRkY0FO_2;n}! zY+o#Y=xlZ zGfa;Bh+HFj-(uB$HvqdD)7GD+S9~=vPzAMN@#IPrSRYy#|A7W*C4|5){`*KgQ@0zu zPwUp048HEM| z383vrK(&375<;dO{rd8kHov<}Dv!4Dt81-p6#EFB4I5j-I~0@On>; zZ&|S*k;v^K^bci#mF7qJ?;cg?>GXKCeKRgokXY~iaMr2(>f>wlrfmWJF~&bV2Qc4gCZab!5Lxs2kuTV%CEiFcA^%#r#NH2d4AhBDI>Tfi3X*`mSPSN+p5I zOY0|AbIa2=@B6_*Qz^9-oi=dW?ySa_hmk@}X0;Vu4)6?)8DY{PP~aCQDs5G@`&D+5 zDy_>x5hp5LO||=RbTACM*_5}-UQYFN_0;a~QUPMoY-aHUu_k{V)K*|I!8IF!6lR0; zotpEe=n;<}FT(wOW#iEdY{U18vRa=T(;T0oES95b=my)&GSJB%CubhP%s=I!|7e)^ zlbM>!D^9q0n;D~C zRA`HE-}8_^0|{rHkt=>ubmFhocoy~Jao0p%`eK%FMA#irwbteN8p^%T)PAd15x(1Y z0Fq9t<@jbha+Oih#Tw-xfcb1}vmY8?`lfDvsZZSMu;hl&faAx-!GQ`|uTTe@$mMBp zZpyqvWtkQPF==R^{^N$8onTM+N(YT1dzy{9C%Y(y`v`C$nvFV;^vdPht;sI8DyEX# ziLJ_F?@p4Rw|KV|`BV01rGk8aXk8voQE+-Fw&=^qVAtv|;ORKIeKV?Ss-(*t1#F^a zpfGp}PG?cIZ{BX$4EpmadcB(|=jjwT-xPfEkg}g%J>|6KW~BTz!m7pmE^^91rwe5u zzA74-3n^!ZN|6g0XMdFGe9Qtx;-``C0IC{z!U;d2N^a1h2n;m_?m4lvGMMA_MAQDM zY81!lLsJv4>zg!Ryjpt|p!-=-5u-?D6^e-s-GoZ{D_I&nl%2t&x_<%@KJ;XzDF=<5 z9*MQs`S#PNk2@(*AyuA0QOl}{9UM8T7$>+sS5Yj0L zMSi}_UiUF0kJnCEyqp9zI+O*%5Eb%qwJ{~mX3*ZXt23dmi*uz-({zH;t4}AVQKPgP z&1sK*Z=BR}CFIhU04A;f*a{v71WHK8jF0#_P$wl}egV}DEgB;Sp-NwByRZGffo~^L zjMGhGYX=|Dy0QUzsnuI<~=jnbq69jkDK* zIyI#3!AhFmy95kV)j?OuHVtcA?XHFS0#6?Ax&=xoD6;#=DC6YZ+CS9PNu=^^Ra1~Q zH+kW;Dpb3wJ9V8KfxT9`S;pOX)@c0GiF$uFTf7#7!%c?z}Oe z5|0`gIjgax`wxu_Onf;tEG+zT)Ck>U~p^@9=pk^F-L(^r>kq zEIdgj_tn&k;}i`JN_uveZY=S6tJJEitGnOAKuO})5)e3VH0Yt4R(SGEN~(6wEkVN7 z%cj#37bMhbgai9erXqz*87Lg({Td82g;=<{dBnLq0?CN6Ak^~L%!$)dpff9({ROcw zen61-)EE0QCpllv0q)=H{%Fi7Lvl6;vCk_OZ_7#=_?*z5L~Ib9x7!c`{^K9gE=iquKF=e$#<4W3&8a~GN z<7xqM9uN=tfVj3YO*a~i05(Qsaz}(NFkhk{2LHyDUt4SNXgYVH{=?_l=9AXvwqr+g zYZ)O%f|Bg|mRv;I*?LKI@zr4PFW^Jc#Z5Ide6$xorK+Qk^vyuczG)mN|I}OgdVq=f zYcqlL7@m)`tGRk*D36)H+97OC#f0gl0`riQ3ex=_^Us)0w68{mASOmD^jFnhv$(yK z0i9U)IIW_o0aM(ax<4y6VqxKymR|IlVvwj8(uO>?F^p-7ZL4ior;2&Lh_+d2wU^A| zZw&>L(X6jHWaE{$U1m}^0~uITY+;Z*Q1=D@(0d-9V=CJ+vh+wgU0`IXw5a3;#G^$r z-L0)zR&elcJ=R#tY0GSpR&cHr=^0t4hZHB#B?^_v$c=*+=rB`SxPl88Q4 zth;}7p8Y7E_r-9ndg+N|4M9pwaA_L3od(I15GV4W_!;Ck@XSn4Px7;NdFDOM-11fg z(sxBf9J?kMPB84n;|jsjH^B< z@w;^ZPbQzssmUt*ax`F;URxE2>kpmgk*aHGiF}O?kVIY-^d>0>O?s zM?|hDzHk%p=o+95?}u1{rd5hpLwYt^)L<@;U;XL&_D-5KyD15Yv>1-56PqCK{m6hv z)M#3{0uo$svu==Dr-pPK&nV_+8`S_24A<&|y&LU)5gIx`s?x5j+lP*w-ZEi1G5q&MNL2KWA~|ZEvE0Qi zDA*$={Cc5Lw$14!Pf$I*q^*-U%D7S;UYH?sM1*&1<;6xk?iK=~!tu5Y2cSFEn?Ti@ z$F7HWekqe}a2IL^$m(wAb9gym;L0>F?h*A^qV zU1h1%>24ufcawSA(5JE`ioD%P0U}NczxQjOQqlZTOxaef$Qd2a^?|n?v-63cZpR1K zJ4d|X0ixYi-?GZpF%yQtVv0>EWJ;Yf#;J)5lku!d|y^kiA-f&xK5cK>XSf!=Xb~j@E5A*7_>+Qe! zYxKglBz!{hSnCFg4@N8x5)G9CA|mE;zf>+%z`Z>^VKqI{q$ow?G3)p3M#^lTYeKYC zmOSGli()4ouCjB|X?_|=qi@Y7o+_0lE^>Fsz+tOLyc7NRKVXROGq!~P*C2=@m_UXZtti2Vvxas5k4sAk!S!yM$_3SUmS zIf>j&ezf!-T`J5T{t4y8*Ca5R#{ad%@Ui2+swYF?(bM4HAO4@?W{I5YriXKKfE_)8eR@8USwo5B%zPp+pH<(w@T8eMVmPH zDvUsHjKEo_P0mhV)_X4<#rHM4WuCIKw@XpTROIp9#u!yM>FT2{=1JLod$=#3^+Cf- zT=Pq{Lhe^YY<~Bfru)p=q&7=oSF#&th|YR%Pxf%E!5JG^<`hyVJp!bOBU4c;u{%{M zS$dxuaYaZ-yzt4eK%a%3j>DfVx$oH;RXqq@;UwxWWC^~%R#U`yFB@OMGd=*OWzPgRgb2#+ZyVZ1W@ptg`sBX6$PQmVl6Ao{M34mGQ zgOY+ZdwQ&?bq>G+0~3%^?O@Xho|MVshC2tANi3eLXs)wBG@6m=ZyT~@4rPsv7BZ*62kdJ-BPBo1 zI_BSvFOH654w^o-pPoMyR(rhrF>#WgM|kMqG+SjEe8y_*_k~ON^yk|fpwVf_>X`1O zgY@R^0l|Zy_baC=#mS=;TWg@V+}~4jn&VXcJ_g(h<-+UxR(KZMsoXUTkaT1Tc-OwT z88WgnuOd0$I2g^#ZAP+>{4$~1)wR;zIC@PA$pfRlO5LtX7dE4}O)71^(a3gC@Zw&F3#?b8~DfW)jw9s|&`61&%J!BQ4uww!V(YB- zv5_n`Cp7=1T;Dzd1jvdpab94PRvpXnC=LgqFmM#Z2hqId%V%8}A<57&`wfx=T8%lt zdPA~Yy447g6^&`)icIAX8Lg@nVY?(R6=~23+*~09!EyR(S&CFV+GxL+7*(mK^C&39 zpc3D<8412|A$l%J^uM|Y_G2@sG7L-l9Yu*SozBq=VBPu*cQ87?s^oAl;0FDR5q51mFm#ldp^0ou+Xd(`(|3yje*fVu|NIp zsrKc1@tJpdIa9K7#uxQd@Y#PwNX|Ct4#6u)x)r6dSkpEF4y^!H@~%=^vHzYquv(xA zuCb9Rum7|U_md(Qo96L|DlCGIfl7BdsMRjnfD4#qZ@|cKV}VG3Wou`oxm5FMmGC@} z&%$3^t~)6Qnt3_Z$3e7S=Gk`jPkCW7Me3a{KX)35m|?Bbz~UbXFQ5Tm;238(H{i=* z2t%Tt76q!8F1l0YqS!ROA%nA-e4LZ-S0M!H)l&#xgoi%?L+u+@#~)7*l)cUCV-|KS zJ@a_6s$&LNQYTw4!k7p9pfMHhV#gQ^w)gjU#@B|lFW;PvXqapDRQCEG&qv>`@aFqJ zN3TSUBC+nbDmibTN#|Zz&faNJjCMTIQRYJ!7?(}NYuCtop(*dI=x2Dp|2-l+k8J>L zP>GjLSj`B;d&Nk%31|>6J?Yiwb%eaUYp?x$6SGo=Hg!ivN~PHqDy(chC=OC-{Bd;e z$$sYrwZ<bMC2W^bickZfk4hnKFfK zZ*S@iZfv}Kf!kE9$|2c!{bxgQchPPCuK;N-qB9{&zgyn=xE_9wn6-&y{>VKbxjSA;%_}m|{Fuk#?DXg#7z&VmwaAU267gnU zHtUFJU?1NbxhmvzH0G@o-w?Cx4(FPZG5)n<{y1U5waP_%azgffB>tHDPfQQ2-(c5o zxprAj)+Pb*{F+dwKVC(qs=#@M93OKR!5^mhw_1Wd6LiLdwx*5eZLy0KCkCH?jJHk|{8rbMJX6Y;((OF8(i zptVfi#w*R3l#Or@ZjrfzVJ+Qi*ll{bqapAz92kP?;(hEN4=aLdD5md2Of^2TPoy* z9B%UIB#kCP9NrulB~fse--?AD{r5T4!9l-_?)9z^gT)I2d%rFk!cPmgs2Gx!tN0pB z$mD-vIR9O4e~6@s(M{n4o03L$F#Rveic9KWg7;Hx{Ef61p|kyv=j8i>vp|fQLrR0; zL%+Q7eiqVuA9a}6vMs?$oeVXaFY6Qj0d-|>al|byOvhrPDdYNZZrJWSe^BJEB%UCy z4A#(R`nk+=aP{z0hq<=PC%muCCe2k(er-0=f^Qtg3Bk7g5P+h{$=HP2t7RJ;tk6?p z8)i6P??CNxzf?a2dEJ8|c|C8aTo}u5?uTO=Xm^e*9Ei;jIEZg{P*2c}VCT`OYeYm3 zwC_X7omVFa%x+v_#qGSCHLF`k9@C<;;$c98vdLnl0^S=v21-R~0zT9{c&!c%E!>UW z)pREQ3k6=(|SM811)A3wI5B*B;wUOYcz3V~Tr9uvvfY~elOu?sA;8g-b*;(0< zra^S^BsZr*sJ>?$a+W;Ty#ca}lZk$Zk#nG02l9*<0-T_#Pq+`lOX3pf!NJ{lCaeIJ@jUX)idnVX(x z--Sfb3G^#(7Aae8Cx90)FCjcTq<7Oz`&gY1uw;C-j}3{eYHwfc&AOpW`%hfyY zNt(SIV7q>^=@R;o0c#R#RZkc2^@Do5FOHY$7NsVLrGY{j7x-#V(59!Zaa*akv-7nN~-WpVgy4R&V<3xSw#+xTnGFAH~Q(CqtmnlX|?W=-< zNiw+WnF**bal+K)Ssocw(jUOCJ0^MlFM z`10n88KP1d0y|34?vKE zmM)OqG5HlOQ(&v#y=a+|`&3P&_PJQTv7&2OoLyu{Ib$e^y;L3WoC5d0#eFQz$L~7d z>_U!}c^|!5FRC`zGy#7FMM!8hFK{h~K%~{L)t5A_h{M?jQixYu?Wvp5oPGQ(w^w_)We7v*j@(iru?y1|4sd(^S z>SdoO&Ud*(Y-)8~r#D5%RV?{&v&7ce7-f!I7Fec%G*L}95=S|x!AE{dkOe!e@9nYK z=R_9Q-d?p9V%B-Wx}uj-XD$~n)-*u1Yt1GRFc~*QJc?A83X^F@F$Pqsbc!(v0H)yq)IW}knsYU#OlCij z@!W8}1NH?nC8Yma<>rRE-o$zk_f75CSl8MZrrS1#1a~m^W>3c#zCX=h`_1^~C+5~U z0shA8<(=c9qFGqlOXvGj0!XA#wSfBGuk})klJgLW-uEp~9^v^9y^W{(>*X;c_9j51N>w}6bD)Kmy;3$#}CQ&N8(n{VLa zelVG4%v7l!`OP9AtXHNyp{Nrh;K!d`DMg7UQER%`v_mkoH|2QJQDKIK>-mBeE|Gj2@`{~|Fy#cX_SR?})&ad$+5@zlLQ`-}A9_hEa;1KedsQ&5UnQEh!n42yz zgF%e_+moB?H^V0lR*{IzTNMPc593WpSIG$?jBDTF|QWMTa@TwGOUFf@!ECx zU5#*G^ccc(wUY5w3EC1}dal@^q z@+cyc%4oC}aLMxS9Uh)}HW0HODZ9GN3!l$zb4Kx3C^pmhMc(?G|En`$&Z)Ct0`0{+ zBr%hX3VT#w*bYKCS)f@=!@FCPwRDE&Tv(q69~0$Fz}ym;{Z8|O_Et~Hjy_-Y)?G4< z(?@L{wnGCqyk}fU)G*=U`Cg`3`|Y4V!rb@*&U41?{z%UnjgD5y$$a0!!U7T!vVv=j zn$=M00Wb;_3CY(Ld#eY5kox!6N`x(dv5iK^ zmslhDB3U-m=~1qI8fM3vc{zQXgCI3$xbLQ^JG=h}kC+ z={&orPhd?0w1r-@E^LGflw0rPw;7gXiN}Rv@vb-=1{~Q1A)53li_s_xvkJLf6-5aF zkVJ_LSp=P~d;ZA${7_5pOeT(VAS?V~_$QbqQ24)UurzA(M6rZJ7mzR6q`?orYEA1- z`f)v9Kf;G#2sqx+%X@iMv|Pu(DU$b~+DCH}ie$mic1SX$J8M5Gkcc;aZot?LZXFU? zw~C}~K--bT*L@d?wPo2{iXw)To7Ao1Ru6v*&MfmI}>R)H#5 zul!5HX+M=gtc!dEzJTk-2UyQnxPIf`+RD}7Z!TIX*H#)eQOakbyAH3LcL__S&DGTx zl0;d|8&i<@wIe->uoVG)vQiaL7kkHf$u5^Cnp|Z2Uvl5@?#YRG^ z{E2`h!yf4)(ZuCy=5uL+fDhia(L_e`@jD9UhlF1|L4fLi_c8S+E&(1-Pq!2JHsf+z zm@5&Ldeyn*m)sxnq|-p?){XDk;k?Gn>iNQki%wf(uRxCbQHNFuzHg=!3E+)~nlCQw ztZ(JCBn6Ulv1ac(ZjQ4LOS;`_s)edI;VYf+_`m)lR=yX&aihOM%AdfeNm8d zDPKyEk#ZS+`N7n6HrMt?2)OP?o6}qNv)N|2objpx_I^YETL_$V6$>Se4vv-G%Bj;4gU8DL=%hz3-m2=xJbouRPZdRn+<$KKs@+<96et@)V0_Fm0+TX#HluXPSws zT;^I6znj+fe#X^}Jq{xjL-*Ja41=IR*(5RjJR}!6a$?wUY6K@LBWGbuZPrR=S)u;v zX*A(%q|VMxF_Rqv1czi9@LtIhJN$w#%u_21{o2yV(IR*`N_e;`c)T3dk+({CCF*!T z*h|4N6-5v26S;sw(uxun+AB8obV$#S;xHtwr{1x!Rb_3i82)HfTj3+wx8m@2DqNgq z8k3){b%jmfLnQz-A$VNiF4IFUl+j z^HqFb<>cw!*{DoE%&5^j>}jV+QGWUI<->;$PiV@jhY0r2#hd|k}+Ja4vY6c zlX6^Jzr^k3G)1f5ek*>^lg%;YI#PI6BztC3M%r-%!)U=LQcnT(8;b8!8->L}LW=qb zz#5^QWmmo0N>5v5qIS)W0?%7PrCFvl%7{_ll6e~%<}kiy0SI|v&ZQK|cE}R@pdyx3 z<{M=0Oda8x5zN9{_R|fi^KL?Who@bPq};-D4EY4tTDIKPV85dr1?<#F(UogRp=bin)q1If*?@HM-F zOW<<83RdR}S5>e=KRV?N0teM?IM(a}!E zSipWy72V>VezT7ThYn-EQToa>;$m~eBeWBCo}Bky@5xT$H6~Ff@)3Nmp2aBtfWMj| zig)-L-m5z$oiD>L6^3-aMZaA2q|05LsAAxM#idr=Z4YCcE#yR;?5ofUH#R}r9iS3U z=N}o1#u@u)NJ>IppYv_~QC+F9Wrl z#&x3!Nj(+;OI9jJxf%Tv&d~ElbYc`_NLZ4y@-hSiq{MNIZqyTEq7!t^%M|Ta8i~@AVx+ zBo{}CP)L`2D|;x78c~Z9otpOWTqzFVV)!-kgQ9selat;1X214h6x}R*c)fd&WA`nlo`h~@kT3$0jP8{<-3?grbO8@18ut*qqLndf z_=AoCr1`ojip!WLQa`;t`r!>|KQAUKeM|0;tt*L+X5OC&(~+RuSC55&!kGNL4Ff~b zX#op36`FMMA$l^|PZ5y#F7L?tl!T^^MP^)W$6L1E;ac2axW(5COo}MF*G8+Nr!(&x zJflL}9ewXnvn1g_ZvXSKgz zzury^4hBnc2TAWlhXZM2+-3$~3WLJ{lEw<}g+>NFrmlUd5e_Jor-$-Ttc)xpxb6NV z;`wr6QBC9!wb>>)DtY7vFUFfI=rQ8qaaM04lOw;s2P~0e8PMrq6GWTc&v2!Z*Bk=OGdZzNMaUi;ph%-1uM!^j z5>9bzf%h!PWed~SnWvmn*1K?pmZ~j!Tib}!COwgl;i%PCfgQg|2xIG4Vu^7+OQ*77 zdV58E`{>Co0i*{pY&#rl(?@yO{S_z;S38k>+Gl!~eTolxG9!iRY}J!tI!6e_iZG~j z7Ezl*6l4%-TQiD)e|&ss3Zrd2npSJiR>w9xcQYF8hgX&}CwE=dAp>uTFu<;D1 zGXW>3*_Y&VQu3jKty3L8XwpT;Q)e61`-`M}7WB6{!EpFJ7kH30iPRwz2Hj~B3p|`s# zg|V2z+JKT5wiupDmP!-CaNiLiv;VA$R0j_ZtZ+mq;4IquBFL41XFe9^Ojam~LhD$J zfo>=zrH>_s*DeMqS+Yihcus>~*pD*FW*pc)obU-t*wkec;afB~+tyVVJGEpz-P-g7 z#Wi79K-XAu4ZirJ!&t3*gDaJN&-u;kmnB3)F4y;TwDgtKLGO-;4d>-y_(uT3bcO2i zd-^0?CyN!%i~HZ)qQEE({nhqM-sK6FZ#PS%!F&K7}Cn zq^7svix4$7Gr)}+kPqAQDgBn-zy<>KYlhs9t@z&UAAP@4OcLSK_|nb}&+KA{Ok|UO zp^r!Vs0`gH1(75ubm!heHBwpbJ5PPO?M3Ipzg`*?#fu#HoW7)q03@InRRasRAUkch z+#z4Det($#r9B(6)!k;3`~LQHxD&&5OUS|?mMNbzO-(SE-Ceta%HqQD{6GQDVrhKN zTa834QKlk;h5al}{mr@`>bxba|F!P9_9Tr_?8Kn1ftSw|a z{*GOt6!`0<$}|*H0}5qGlv|>jyrg`2mx-5yUsH=-Q1Y&+y$V{PSGcjc3}LSB^-x!S zm3`_X&NZ-pUZ@>+aa~MP}31DA1tjj8{4+qZZu8fgoK50 zEwk-m)~{XYJC1G^4TW|RGUuprwpA93lik_q2Ri)nC>7EjU|*rEE26sfL#a2|5a7u_ z@ooQ&_5c6&3(t*4j6Vx=+~i!ZKB9%T>j+d4MI*vAnF2B;FJWkx8EJsWR8<$p~)}|yR3{3TOFCz*D28NnDY3;X^oeWObC{4QY zcF&7T(K4Sw`{c+-#Qjupk8$eOL3`{*_@wy*ri)r6whSsQ;BBSXnx%@Si>Ffsx9qHt z6!@`8`jLmez;s=~{_AT0?V$n>d*#BQr5-L*{UR_P(z?>>3vcO|64<72J>*6Sv+RZ6 zJnGwc3i5=R4VADzB5{T9j$YgMO<*i~3`80|1Z=uUL2l>BWTqs@_;((Kt!TX)o7HwO zqkv@#muoE9d4ZCYGk+}9R2dwzNzMo&05=8yuYwf26C1BVxV)n)0aL#huaSrHd%|c5 zjX9MSO(TTcbl#v=mBDO|-e7ceco?SD_?Kpt&&ZLuY*D<9cdo)w3(d z3^G-+>^j)@Bbt|OXD@VlKn1|SoL_?c2DSVKp9SDe3*6l^S8E2_5L+uRwkkKe5yA%2 zo>io&OckkA>%%2v00&U(^*O(HBq{uE7r)i~;n`6Hm#0iYljKd)L;Xqc0D^@YP*O0N zfnAlV7S_0ENi>BF^{OXc@%36H&Q%{Pj|iiW%T$#Ra(}N8&{N zC&$ugj4 z*VqVEfXS2Ngv+jvV8C;vToGrwN>OYKDZT<(%-|OCoN{%8Aj*Yy+#J z&QJbI&nUFJKRLm{-%Rg{gco-MKx8!^1tE_eW}EOT%K-pgzynx_Av33GOe0HhA$qv> z8Aw}Bi~R5g2?HjhM3rRrIj!6ix)7I)UYl3Yn-4pDKCbNzgB6QlXeRv@>}f^Ys;Pap zmg8B@Y6wWNOy9LIz-S4X$Np7pUW8ZcJ}iEsIP!h##}C|r$Xm8j=uBgwG6KWAwGfHo z>4j00M(?qQdu7;P5CHI;+Osvr;eZ## zQFOFpC{(VAG^D=4Fb8O=SnF1q&axcEnn`bUr}%14CI!VU0{`OTVw&%$sX-3|34?y^ zp;k*VL|o9%#(cDA!)P>(jA<$Zk5pQBkyO=5rC{1FS{2S%idApk9rqwbh-ph}=4u6B zQjBsb;>k(i-ZIuxm!j9)L(u!pthpk$N-bsE3R9C=#RIDW}9}s zIf^jM7Pvt++tD7`q<>Ze76u0l*_#j&Wx;mK){u8W!21^J2qc=!_?~woAWgKoR)K1i z^Z(9^s)ISOp4k7P-pDBBxGk8ZFkNIAOHK$;^MM)r@e>c7)=Fy0AHUha>9IRMC|+^ z4Tb3p^CGF^?bZHJEHGq~`2Q?;!9s}>dl`5O_j4gu?pID&P;kKv2`q=7!oc+fW6}R) z=ikOajM$`b#+;s<>Fu~+Ea`uKc>9qkOCsbAj`^!)*&!lkbcKIpr`EFQ;CbCUTk{fg z1`v)wS?~WkiP_;e8Qb$|{YSM?ZG)|d&*g5da?Jpr%M`izn{~1IBPV}u2ILBfh`qva z;1Kx%ZLyL(Y!ZjBFxR9IF)pnJs0$<#l>c-_P|$d<3yel0uc4V*zSwIxq4p1UO#<=X zXAF#;ZYQjT3U5Qb{TaXo{<;hBXlFHCD=Hb57!h>r8!%1C56RC4aei^Iv*rk|2|EL4DM6) z?(Jc5{=JE@1iXp)a#8=qHh3y~ZtwnY)e<$M^e=h~spJP>%&%whMhNnk-B>!$JdPDBb|y|Lu2* zC>R63Y?vB!hhb?KdBu?^aS{BHNYBZvP9mxD;3)79ueHf7;OZ z8r2MKJ}PL8x-J0x1%muQav?^*+x}n_Khoi^HdenF+;LA5L;t9+So8GaIP&Vw%#PL+ z!V+VoozK(#uV4TVZg5Jo6xAoy)Mc}b53yLc9Df}lK4t>C z*qeupynRn)1jin_+V=13vj{3RclLj9EcuN*LA@*8?GQ%L-Ou_9 z9HTTu!^W~jB4UloCF7}82#lPaoEoB|&yAU}8=9KBzB3cCvMP)I!nN5MNg@n)m1X7N z=C}1G(gIr*D^&d~tu1Wur;L zIRihE$qz9sWxonCX7(~>MLjc0BPuaGH?l33^zD(Hc7ws{!e{*XK$dy-oVlNzD`yxsn_i?6S*evx;3%a~237JRTF`o+r-hSpYwuCj6o5(pFL zJqJZPad~p8qs>~_pUz=z_f?15WlQT0+KV)nP_9bE&mZXgl~DyCMTq-8dFSZEh@{fC zw7)TT{h1U_d-k8l!egOUKfS(u1oT^P{7onA@Hgs@4`7N*fyLQ;EEly&fvc{ley=A% zn01hQHD*DShDtSfyqGC4d1XOj%CG|q@u!YsNBx{{Kf86M1NLQ`f?NV2irL=8t% zgYGYPscaoW&}sPhCv)T2-n3Fl(gHY`e<9g2(H>P7Q zA*tkXa2A8A!$)p6%>D>`rJW!9O%qn(AZVqhK|PgiQugt<65 zW2Z*=XgL87Y#`y8A0-R3V<+6$YY!7Mx2RaDJWDQL^7~Q)Ltg}b zd5)|q7Msl{z)|$>4Z+BkFO(Id%=HUEz|T^tHY||M4K8INe^WlWwEz3)g8Bx?Ta}JO z<9jYanXA@R)V7&SY`Dvhl=?4JgRHo>XiVXAmkLd+w zD(j0RI3!YGRH>6jjoCDGX;%KN%!(YC!f2IKxq(2eL!1MXDH?M@JlL+{Sno|rW`*Fx z=3KPU++z>SH4dtrs_)xl{?jH>K3&!X$QlXM;-zQT_8W{~ErA_#Ty-{>BNZ$-BC2A9 zGARF}_W%5+m4UG%QA5;#KV!`P4%{@VnwN0P#xR4bbkM!DT(uTjQ&aQ%R6$gmO_K_s113c=J~szMhzVNLVI{%OE3YsE$o(z|9RZ;{V#A z_lf*SN&@v|>En#p#T)YQ`6CO4u9LOgB(+oZV=03E(PVXS{WN)e#qRH{V z+ao(+Lq0>nndQ9>M&;3>S7ODrS2S-Bnu9e~+eg;-K)GYoW5$h{n?lUVR+Ofj$Z)v? z56sppRAkq{m9OW2?zBl`md-BtU|}bOu+FsqcJ@A*I{7%X`x3Dtc!4u6Lzvsfd~tb~4m@DPWlO4C&L3yPW9Fx2m2 z!?5;%BK^f3R6^6N; z_+gTMC%V73u;!A+F?|0T>$lHIFdq%ehDbfNis5p4)hqK5==-Ipa&;=$0|lIg7`2K^ zNjI8s>NB1;)J^}ezGSkrf!zYxNeVu6Ph2f__-8Mz(D;3reHWyZ?0+>!B6cN31W z=#O>&^Wid$dE}CvWOX>n;_DhOh$R&k4bB=z8`edMuil25mBTp(a=MAJHfM$D@o^Si z2u_TVWMm_369ad`YOWk}wvHTmg#9;-dJ{VQShT^}5h7cr-F}z!y}EEqz+PBvhjUVB z3-fZ5ujzUkxk?|(*orK6E==*7?LBhh^S?q?jt2}4GZhF3$a|$P4O}7i@4=O}tk9is z5i>q3U3tHKl$)KZV7Bdv1Dc<`i9PH`h$BXDPvNg7)(Mq zJDRsVlnwbtASdG5Kw-ajyz4`D)TS_rD&xf@uCcd}%QWI63`pxU42U7me}rtJ7(m-_ zzQMFgf+|bU_cwjF^q&X$Zl`LHrioRGcO#%Ld?cXn4~D&0^8`%>TuHWgR}f;9T|?=NsHCE-mjF$_Ho?QFJWdd_rD_1Y9wYRz?%0IRqI3UHq(k zNIr*#Eolmh*bM!x+yxd0b;MAz%609j3J|C@!pd0FBDW*NWfL z>XTLr9@64p{H65lit_)_ckx=wh7twr4AppBWiCe!3x8F_eNR|%^y6NX@`vxz5=Lr$ zHmBq>8LdjAy8#r>b#bEL!?^A@4`%iKFYBqR>rQO2dwL{70s< zlmIjQC6!%`;Y&6B;~?D3 zP9xh0{%@?m0y@b52nbTEEG3~#+V7MRRLJzhHprPBK`;KswUNU+tZ<5Ph*@`^%wH<+ z{A}2m#^XRl$HY-U+{?PZD2JqiK@(!M6TC@B(8b;a@%DUi9I*)e2XJsACIwG8aL_8l zU%}(!(!K!!RE0@CDJeL>5{hjcArz0NuG`=LogWBnW0Ga!u2l^?0`fbfrz1V{^H}ik z@Q~2Z-t%UPz)wFVAw)z(7M(AOwnviWoZrG%#(zRB@^3)A@Afy8|HeY@e~VRQ%#Qm0 z1SbEeHb$C%{_xik^544u*qFZ#{C}MA3ElStC$Dw`5RP;rdyz$eA{ol=y!jx2eM0=_ zvXJW-uRVcnp!D{hiP1z%|5}8-a7m2^ovTSX$WUUuKascKRnb4;&{ZA`n-2-o=d~GI zntGy9y3U+=vZ&ha+dKD{Q_ST;#FMh5P%Mt;PN%;Nu>mTqgG@3^b1OcK=U&(hoM{$+ z;Rd-vA+72)Rv1bDsxP$7ho@(s-)pvgn&m9o5Tw_qA#@mNaYW!z?z!6!Yrj=Q;(7?op0mJB;O4#GX<7q(I3h82 zQ+i42w4mpCv8+g8(Q2s9N}A?1r3SEvy3!wRC->52(*##VrM-hR9M)tj{5XH4N(R`F z7cwc07%piZVv~E2wL7=XdPKICOvkg-OLL?`kG*W7$a^^`f>c8N+*ApE((N0+J@I{s zA~CLJ3USt@_jmQ&Rlghc@@aNXPCX>?iXSAS|IaD{ z>a0(~>D<1jV!chJ%DR0)r<9p}Im453D6r=7L{17K+qGnKOONI?95YzW5ihv z7x%sy)DleUd$W`+q=~_WNh17||6a`vutd6d2%oZpFg0(HN$pbMp?`sDNBdMVVpyvR>=B1B7(F?zU+w#{>Xtpy%8nfdjxN4q5}YSn zn03oht*{6n^2O68i#<=0_%iqApYwN0GmWKQG>2lITyKkvYgM-a0uj>STvf=Va0hni zlLrc3Q%iu>XKLQpw+wR_t^&AD=MwiB@|Q~e4L9|$YITb^=*Xep7>PQtFg^@@kH|`M zHDYn^w)e%AwW=cLG5ss%a6Bp(xkF@B`(O!QW6}eJ2qx>KkDkLF(@W74X{=k&S6$%n z$Q9c_hPK8GwN9L^kM&TiTk!Nk%Rsf_PpzT)>IUVk$8+HxYJ!mVs)UL7A4-sRc9jhI za$@nQ5X_m$CmSm5BvbqRYn3#QhQ{5Xi)XdG#ecexKk_GWb0ps!hIS?FXm5zM-|yeDZO2@^WmAt%1w=w+s z_bhRNlU&VrRctmh0}ZB=<7EFRy>b>)F=Qa6}rIIK@(eh@$nu~^pY^m(qPH|$a`;jluw6_6iLtbkU% zdPG9;|ICY*t7z%&hI%Oy)^#=gXgyB{TVw_%z2Az5$#8mIBn@~gY9`W7i~*sm(Ad1FyD`#iH|JyNJNvbrA}^Y}E{M8c0@Z#5(_`qZ;P&g2tr zdrCx+tH0hsTYwe$0veO!7$3(o6gB20%8mu+kLr3*M4gE)HYww&=RNVz*Gi@#R>GHS z^t*3E5#?*k_Mj(Yo~tj(_jnH9aDpmrzW|lYh%s4c$(8Rl>>dqa+l<%2TyK=EE)yQe zx%qvdT>Urp%d_b%7gd%JeiJIq_w79#e+qr6NUSnjDnY>5>_%?2D%$+4o;E??GC%Mv zAl=jntB>yt9nek}wwLA9gMLN31mYQ=8l1wxErhq{d(Ph-I;BbXD|}4fqZEkTB42?Q!UlesG-$y=vU10HrJMsRy^vB z2LWfSY7T52+23Uf5JLNBhp+e8?!~9VpyxC!IB00!o~&J-)%FnD(Q-2ei^&x4e3e1m)Cj@afvGIiL7+jhb-UfB;p zo=%LK@OqEpd2;0?9)dMj+e8;^3hX@A+B7*?g8b6%r>LQpk!p$cB22Oay>jd39V)7BQe)Yz@#QH<79M-DNYk*)mM z2yIkIzNer&fWAuo$uSI!+5)aT4PxAF`x~|KW=Rey(;UkId7hsg|1!lWru_qATUfY* z(8jpZwzQ)PP05NPNDQT$-|sPqX6>G|F|o|^)Rsgm>o5L*SOmOT%rw2mFrZLKpH|y^ zBvbKd8fmE0#U4c@3z-e73x<}b8ZHNTSeIW@41KP6)Ly(+CP#nfV<^2{ItMt-76Ddn zkp1C|&e2>YCZ`j9lihw6fTSdGxqjXm{TY((@c{KLnOR1bqBInX3H)%jyuZcyQo7B} znIsOlG5NhRQzkQFuechO)#mkdo7GO<2RpIa*kw?*mM<4dbDs|6-F!bd-q#h31? z2$;3?JWGa+atMZ|g6a;QEprL>3j7c<*#7ZyGTr-`^mEP6#G_^_W?DUN@a^tja1vnQ z=#6K&sgurF{9$o?z?whnI)O1szH+1Cq<@WQ_wdq^*YXIU(BmLp%}h#c`|`ohNC8XCW$_Tl5>Ep1POjt_&~6t&r-B^Ea=P(HQo zqgOj#Ps8ENMnq&i*?PxIZz8=Ld0Scou9~L@!hEPvh4UqgL1u&C+F2VhM9 zNn0rV_F|17gEjUcu!9iO8Mb&vE5N84L1tA()Ya?#c5w?F#BbxH)mM4ZH@rNHwNPCq zbGrYoK@O+p`$QLas}@q@w270V6UON*6_}FydsK>ofb{w=-dQ2x{}rfBi~jMZhA@>m zGN+7cJ9MLPU`;Ya`M*r|b*EH3r$K9e49GHF$F!8+<-aU<$*v-O*F1B|UlC0`J-)8o z{BdEJrVQ02Laabp8V2cV;In088`^6sOZV}!*PaHYu#p=)+SzvU@3XcR#N$+2o##AT z`dv2&8cLCkhd8P_T7j*>FKQah~I&*Dyys5+72|Zl7DC@w;!rVis3`nF4p!}m&kW#%L<`RL4V+?+BHa}zO}wDx^lVk zCO=AI=OKF#1K#||YUT2*sxHHAyA`D{=fs4NTwfgEq^A*0?FT~~!45K8rY^99z4Nw{ zjr?a}b*9sDd>w5Mfcg!0%jNQqR-I-VbWd6-7zxFJPe*PqnT#xZ$WcZJcfHObQ!hMz z(7eXUNSq{i)5Cygr~ssjWYZV0*lgMP%-ur+UV_5M36}aH5K6F};wZy*7k!MOWBIL> z(D>bR4YHI9`9C{G%ylBfy?1GxG_R!7Z*vB9%(360Q@v`m?w%S*ZvOz?%)x8k7JkT$ zu8d#8J61&klxGSplt+1TTlg@X-Q0ka*P@U$v;!Y8hvVPbrlYKjAcqK1TeEsnc`LFB zJLY`?xxfLV*M=Qq$D?T^?BF_pWysC%)h&T_k9UAT`c7@zho9~;f9rh zUzd_9X)-0wlAb341yJk5Xj_~+vKRm5J%~vH?ogtswUfmX_}BEU+@JX-R9WW58y!h- z%BCR>Sk~XCg_nkAagPsr*dElFzrlZLD4=$F8c+X|6U#!487iH2S-YIUYv44ZZ>l-{ z!M#~Wm}Q~`Yoc*BAExzYdI2f{rjJG}I4rqV+b3p4tyHf4kh^Y;%sH+?I{&8{)P9hX z@$W!QA&rkpp9C#v@;Jlts^H)sC)dkZZf3Rc$dT)uLhF>NyQ|-(Id1 ziMi5GZ|gdiF&5|QhtrN(7V)fw03Ujfb@H!jrc53hSFlgkeWz8H^Z@YOxhDip;=^8>>Z3+zLb!5+^T zfBYrQXVf);CT>lbM*3Ot6)y35*iGWm9<;1@njV!pumu~YWh}k_avf>-`m*6kzJo&R z{g!AKP0qp-SfrG>SH!J?Ai1#v`cmTJ$5ZB$u=^EfY4UXNnRmoX*fqk3GYt8p1qf1^h0vXCJ)Bbq|mf~{HQf!&7Ob3=;3AA;qdcpY)2#f8$X0@ zM&b@MpN6(zu>?<-xk4-_vvsJu3Sk!cCoA@{PqkW{Vc@EeiA2OGkn%~^mwmuqn?{*dW3&b#Pb!** zRujUPC?MQSOalu=Rxig>P;Cu)YVc|&rQ<&;QTKuJO!e>0rA?j|7nAH0xI_;|wFAL> zT)T;B$kI@}vs4SMZIdbY+n8!GU`0;i-IG*9H&=`EX01if&bRDp<)@h_Q|*c)_ZxP@y!luKZfl?B5A`48~88S7yqf%ke9IkFI*>a{20_ z9LBZVXZJl)GM_KBU`t=&n>@JSH$@Qo0%})!eVOJb?j9{CCWRt~x;=XH4ZJotR|KYa zK+n5UkjYS}a;{OhGzXDBad+J=(h@R#hV+S6n=y+|{HYW8KmUgcE_-t^;WPq?RWrli9*+~j`ZqmRm5^Refi3N6Uv zPFSxa&uGt0Kgqar7dx&p3u12cM7Nh|cY3AXqvf6)H*T|0L?;3dO%Ia&M_82>6i)kPmeD>>hI$$1n_gth;&Zq}P?hNja?RUA>;W?fvOABj*qI@e_^zi!=xz6FO7pM>zm8IUt3j^T zw6}1hH>In4E+-ojI_hqzTwU)^T0CzMG?Gwud{+z}&wpTto+;dRyDEZqEbvsn%dCkT zEFMyoF43!mmahG(C0@C2;=r8Fijy8E*>H(tp7i;|$Z^3-JRfp# zMtEr>GveBv#WqJc-4usiEE+xuFIiS@nX!qpdX>LEm8M-T;By z6TOPQsqXc1w;I@I+J04Fc&7Bs<5>*Wu2pi%dBXZDS~3>Yk0yZR*>}0+HIQxBq__d&{V}pRH>!3GVLh?gW=0 z4FQ4%*8o9+yEg=vMgjqv1Zmve-7UDgJHg%IZT|P(dG5?Sv)0t=wfYPEy1MJssj9tq z?Q>gUruymr_tV)V_()Z7WJnP@noIv0%|B2LLZ*5K(*y>Kl5OAVz_svQbwa4=Vz9F| z)F*`4oh4s#{JF@%e9%GNK_w3Q4WOty>nkT#&~Ecx%sfgzCsY$9DN=^c-;l_e_AvA# z#X)Acd|5C)Jzwvx&S9{3^tgSyI5T1X6 z8nt@tfcJY3taEWvIFUI@`glcIfR<8G=o98ItOv|r#{Td^YzO4w;Qx7E;@CgkfzqZ? z#HE7z-`5xrapmJ!xe=A6z8|s+#>0A`ctoUc_8^<#~#0HE#cyC z`m3ld+M+^B!jVI3=rrQ)`#Rkj_q8SeEoqXM)hXirP{X=g?se?8gbKxjUkDRf7eEY# zSL5kPBejv+E2_mt4fvrax;7W_iLCYRE~1*HqNv_(|9z0a$w>ToOQ9D4@P@P(`NA-U zhG8>7R{@iiS4kM|BnedLM0xwH2)#E>GqS()^yM28i{zu-#!evSwkY&3UR!}|Y6-EI z&k8X)c=w9~_5g0vQ(4p@~aQB^TD>UFxo)a1|$hY^F)H=-!V_395cVw?F0McGG zfd*ZYZQV2TN3jhXr4I_$ z|Bwk z56aL+%-m3jtv#8X{vm010IVbO(k1>OlM_ z`>%uS1}#PoJQJu@ck{TOTIeoJDBbC9K$2nc;*c=E-p!)7%VW86Xz|QT?|AHWjB9ki zw7O!gWY{rYx%m@H6tU)Oi!qR7r6j@W4)u; zv1be%%gx5Rp+G_``kt#o7w_yBfD<}GDP(5`40=H~{5~%hh|rX~c9DVN*jI$rh@SfW z4(b&<6?v1

    %9&+>IFVpRT{YtHyE8U8z}p{qqZFWCPyq<%wg&petaPHxZM7fV?a-co3`1Ghvy^a!r3V74-V33mnUSnpDo5=LA1W|ps4Lpk!qMsl z`IDX#Zf}5wDjNiz)2QR#sCRw#O3PO7RXhZ3^0DQMb8V*xmv+mT?^)s{&(soB>NF@K z4V_4zHO+p_Y6rE62Yh~VmT6xVCsZw}fj?}|eg>XxcRI@t6k$e4Wszh!jc(V2yZ@hj zXxNRW{vaMJ#kiJkDTY|8tGXO&=M0Bc`pgeDL=TveSK-3IEtHb~u8@3|#8b~|_jvx6 zIk7nC2L1(YQx?S8V(TW-?16s6<^`?I#Q%Js3CpguA0czKxSq#@$C<8xWXY>*nd2%j zMHH3b+}Lh5dSm&y2)nTD1#ad*ymLvzR8@z!d_A#-kujd?{K*!8`*kI z?31Mqc~ozznwR6-?*FD$+rqlUjn_CZ#>(BTx8yeP$S;n7+CqL}JEM?Lxu4)od69AU zi-w#e0ngIvB_G!No5r}m0lh7{Z~c5iuwG!9q2?=4TqIilWBhJB>C78_K}P~~z+n1! zkc=F!iR??JrDHRHGzED$w^R4O6vT=fEtpA5en-Kz&TscF=RiG>ig zESl~K88uH^qeTzfMw4EH4Ji^qgnBI^G6?AHBcRV`(S~x$RD(Sg`G&r{?+^~VdkRk4 zYjrn8Q-mFH*2!~JYQlgzEO`!Rv=N)4v#WYI*A!goAR+O_+RS zw{Gxq%c&0uS@Pl4SickmmDrLIYDi$PnadtlsYe`ctr#Rv2<-926}no^Pk z0BvIO=kd87yb~qSAjPbO45wBbhq3+j__}vux8``Iz1o`Qp5+ugVnB-R3$xHbLyW*8 z0xS3AAcGqd_!9EXy`|By!=vW@zv-bXYZ0CAh1dHO`LPOEsci{AlQgwoEf)w>f5TnS z7zwpO7urib&+J54{h~1yB9)ll;thxtGY;79MdfuI4w*1I{<-3Z);0xRS+yZeM7953 zmvZGWq>A05b=$#g`!e@PWogiYxKu@$K6$YAgN=f@nlK_~S1Mt;Hq^UkT)?<;tv8b1 zVOW#c=$ME3E*8%a=DC8+0-V%by|y#e>);3^_>5uOneUbm%aI&dZOgD#a{9Ja#}#kX zY#UUJQQ@{?wKTX$dURl>itXS3(ke55$eu6ytmfhl;=@|xEdQvMRbNuUvh-{%7}(rFtJG;)}^3rQuLA|7LolSDH;EXa3zM1*%$C+*X8TGgGyAUrJPV;kEpDTX`yT|vWYu?o#_>A8{k-qET4Yy+X_Vk7ef~wO$D04oC3>LPj(*#*N)ROabwGi zl=>P+>_)e=FrITUp_wi%h1?7UE;il|K4Ec^Sj87c(-S{w@&V*i!7#y?g0cFi>7sE21jQ zt$z4mD_Cu-gS&C*RUCzP6ww_%eXxEsj!H2z9FRX|$+{3{c{-xUNv0F(T1RvQU3W6I zK9X1c=f(u6a=;9t7+svTZsn9wpZOL%YvB#Jw6eX+z;E!ft7M=R;uzlO z-4c>SsOcZKN%Tlez+V@>0md5S;Ar$2s7-9(w-$i=OJ+dszAa|Le5#QT@E~g4)cniM zySd#Dx8~z4b-H^bp9oq9NILm_SVg9<&7?5=*yQC-iny;ks~+EzV;bR3hWh|(Bi0VY zK?_0&4t7nSJkNf$_fQ~OxN44Dt((%lUU_1CYUxmnp~l+s#^DFTKwP6R5sF?Mi}n28 zz2!>2lNIX-e0YoK{hUiT$aZLOcYEo)5m@#$bN0`IwFqcvV(2u5@kdH7@kbA zaVXAG;WAHr*kpG?O(Uu;_2_W10~0j2BYAc@qj(El62i0v03T?z-wSTURXgPJmxNRT*}H*eVZ4?YUB;%yZ0r3zoC3 zV^zmQ)8zT;6_nM~h%w}J`bnS73L+b8QW6BiGthm7Jc#mYqX1q1P-`Jgvgr8$flf&r zqmQ4Q3=2tBn+&`~2Ib$2Fl$IllzbSYq2t*6+VM1~b%r>vT3&8Z=rW&GHU-ZHqS4d} ziIvqf-W(ROTq!k7F(8!rqgKy(o=@X&G*B~V!0?*9a#mO10;9T;+Xsiy8ZPR)=w=r!dE6KtGgnIgMCUCcWDM5RgsH^E z^&+>?EvqaHqR@%|4!v~)#j&6sAS6osIaWAhq}eKY^$|8CN=SBo~>S@h{L`t zBhV>acQ7|3;?)ub4kSqL0x;AV5G}8Jj+p|vJeB1$TXEYsZOGNp>4Z5t1HY1%Yxh0l zaXuXP#&`V0a`g%-p$OxqYckzuxmEjZU))hn4~U(d#__z6Z`&s~8#7-jwP@Ra&Emfz zh(`pSJLPP9HlfU3D;M)ppDeSM)tW{j@1?vhuA;vh^t2E z$IV|0RebK%?kHhR%X0$2_-^B8bqgqs5xl&f&bN8*N}*khQJ!g`6VIqh-K&nQ=qrZy za~tb;rRK`rGV6b+y>Ft|@nBVj6Ze=Jabl?BevtQ=;Sli!9=w}9$lV$&)sfOL=90@l zq=xo~Sr!9_>5pf@0Q}7y#m518(L z%;+ie=`LoL-5DArjx0vb)kPQQRqcuGOtFK>(W14QQwGYbdb zvg-SAjl9!29icdTT6aG^O0UaESaJSl#qaXV4ddj~Jc>P}==P?MyPmTY2A=g=BLKG4 zlCN33a^!)Shn=q03M;S&fdzahQCq07?(~HU-{>pXSq;7;CQ0pW#?da?2I?aaJ>eWb{y%{fwZl z95dZqCGB-+Rg4M>dWp5xdiG9o&^k=X{6*q!J_a~+MZhqLO#+iXK|jlL4cX9jo-=EU zvbjNe$+!zOI$+vYU&ZA8FhdF7oceD6#(4 zW-_Z5kr}$9kZOvFK+N#4e;CG`Sbk_hfQAUOLG+G-XO+lDN{o@mI|OubBlPN}_5h?o z?^!hDFB{5MoaY3WLLa;Y*cB zG+nDteC@+2Hab}wRf(2vUygG=hHut8Fq9sjN1nFP150W8vX2l%QSfC~z_q)9d73EiO36Ah2A>B|DsL~Q zMj{znCmcn5WfoTJW8`t~<|rz+f8lkwk8DoOAB3II^g@&|9QVf@mwsH+T|$wqCi2q> zc15E!iZfCRxqw|SRE|{{T)avzuZ)jkvxEsJ-Ma=$Y92O2%4^; zO)+KT8rZdkSgHEQrITN5eo7zja0uO>yB~zy4s69gi*@Q(EvgnueHgJW5g<#@@3a8{>Kx=N>CzDCYKUK65RHq)ipZ;i1I7Z~MF+JscT zp?kQCyr&4X+5aM<{W9#nHu#c*A;<#TEZ;>&z1Th_@rfgEeeT-Wj4B#Um}KMM$$Suw z8uxDHKPMPKhN zCx1~$)AdbkB-5N>99Vmn%exHc;q-(Y#*n9L;@3B)_OD-OXcK>dU>Lnr^lv6Agmd(}~2M~s5@0I{Pty@X4%tfild=}1L|K^hZI zSSu{u7Bv@$f$}VuUL`8RI|OK<_So*WS%V=FJtdW4B4`T{?jo0xd6VI4Mr8Qw?)>5Q z#CX^vx+M<%8AD|U!94{&B{1N={OF$L`#5GEL)n2iAE4v$;#ONC(&%*J* zaLg4JF`SwU!XSAsgE9@2zDKm4Q$=?On$1JXSdOjqOtWpb7GxH?;c~*u)hZ+I`lcm3 zwEMHCf4aD|bD%`E_LtFBiM3+VV^ISj50tmO^2*QpLVh8V(061c{)l z`4V4FIJ)B-vN1%!_@9ID9o;ASGgYZ9GNy&XSkZ+t)C9wt(R?wRDD;B1SA51xzZW^E z6a;@B@yXO)tvOG|9{LPAk>RS=WY3u03o^z3maI#ldY-k~v+vQ$U2A$WukW+alM0#qdxD6uD5x#(gE#B%^Ub&UQD6{TWY!GHhNf1f z0@`6?75GFYtCb$1>$rF_642?gfcn$`UCse10KY}X(m*~U##fxpaH$!vl)S2h>)?vX zT=TR4S6R|t6W>yzxKd+8CJ-V-T_?eSIw7x}=s<{u}`_UGOn31UGTOKaH*1=7ezD z_`;x~QbD4C^oUuPt=^u+{g?eGd{-CZ*t*df!Yj4#y8yz^It zlJsR6cs(D&N-FqS*&_>Br;nPuExZ#-k~lz+LWRMd6Am|NHtTDA9IO6sFx_ojD-^Ab zRs9(=5gSr3AdNi!)%(xYgGE?l_&8G6i$+{V&vNQuG4JO+ukv{FL5!OIY3HA!RO6oC z@cHRyv4j*2#~H2>;wqgY^NS~u%SNx6nH*7c?qVHONu)PdpAOATf*n`Cs7j+Sl`VkG z+_Maku=@I@uyr&ry>iH@P*zVXTuS$(bD$@?zjNn~!dF1Sj7cs061^>g`wgicKh=4! zCks_QAu-3gW{3UXVV7G=A zl*tA8fgD#~Xf+KY#2w5r%=e``{9hK>v6Dw4u@f%YGq)*Jg8@GU&K199a9oDZ5gAlM zkFlDrn0H>b_*7W3-8XnC(j!8vVOLrK!9CbevqB8)gv!RSkjc`IkdNpo&VtXT^X6S;6!Y-CjYl=lRI}_%cbJdyg%~u~>k{h7GkT)fmOCV9GA@I!tjxCQJ@C&45*meV?&%`U#*P=l;IKCw``~ zK7ljeC3EZh@J1SwzQ`$xPsIlc%TfM1_f|YTJNfq?FH9Z1B=}W3xsvmF_ETD@u^OeT z6R%6=n+0fyE(Z6o2xboFB*C!l)mz&l3tgp(^O$i=E z#5Nr(EOJLAABf@MrBul;wtjg)Jws@s?(QfXM3lNN+yJ@GN{98Zl0Whr^197}OpFc* zuq3PjHzE_B3&#HSx9ay(YR~$5lgjZk!eRH5c8lj78yDiLt83Ik&up_PbVxe|s*n8D zNu0PR417y9sj3^tiKEhjeTSLb0SMQwB7MGx)6^Eru_m)XCjKb?o`UE?iMKf&Yu4!_iE^^ts2F0e32~*QY zWmGnE%$^6^AFcN1gYG?vqXS5NhipCX1a&Xpfllv?fW{8{jG0O?`HyEdyfTMzTG)UQdeMMKi6shecq04&w1-yMsk(rRJ zn_rcHb<~>7yfX}e+N?HK<)_Iq(|CV;NFQPIvejfq7WvKb+ah)#gmQb5_i~In;9`iml&JOvH|GLj^Ze(`>a)SmSx%oRud&B(cnpSStL2${yvsz6&him3XIqK#iHaVh|p16c&yvS|^i z&)6NwUg6D+*d}uw`MN=Mw+*#{4#hn4zQ%?oLj1bwPK=cI_H_ic+cOq;Xu&;sO`U+- z88Paz)?z|m0d>MC88c+uq9!k7U=Br(=TA|GOqQFLFm^v(auCnKZiM)Ai&;~-H35~I zpYF#!g#|qpxTk5udSa_Eq;XFgq!miB#Pc!oLu3NIhb_GO%C4UEvHT8+X{PncteSoxud#rc^H$L>umvr4=CvsZ8xg0h-qZRtjT8>5^V2`+}g#08IS7v0# z47CzE_MEPp#-l_^l;f9x=VQjDtAy@7=UnNntZID0xf~XTRzEojF-uS3^}-@rnVzK| z9?Ua;2#yp`acT{ezLvAhaG|U+-)~KWD!VX1V|!0L5g!`hA})!1tB=xs){Pia{qjsx z{5nj4F-ww0#@PaFbiE{p5pzuN_*3E3YCV5-g8$H#+N81IAJr$F^;$==>^c(KXe^WTFu44BF z>f`@x@Nl#+o|#SAKMjhC3hD6v$-zlGdBz8F{iAP~vP9V5J8hPI|&;VDu7Z^Dn!!Zpz*hQ5TaBDAus zj3gTrO6>!#eek3QIlvLl9Ru&U2WcEVMs_pJassGBv#QYx*kkMTKXa|s!PL%N^T{E* zAz{_~rC4fC0rsYt*T-CHtF@Op*c*KQ*6mu1=j4KI7ljbCV%sEn&i-7AZp@@{NOP4a z#gjRHVp4{Wc-s6Op2_aS@eVz6|1i`Mw&`p5pTT(O%$h~bz5?G1X)4n|r=^lQG56=k zvC4P{cV5KZ<^<_JBdxI5_pV6rO+owBggO!o>W$ncx8oL9DbVUBJJu7vd%@QYPf)WM zYI%Em{qln|BMKz&3|!BWyoVDMJXv7oxltg(6a_qLlUg$U@3K6&`GDk6III~e(Rg+WpKDiF~5?GLKnVuZZ0J@*U zX1lX>z1Am;&8RQrpgooTd5e*a$uS($O|}a=dL_N(X;T69bhcU%6}~QTwE47g9x#$w zU!|L`F0`(j9bzf^CFS-&z1^8WIkOw*Fz$SpUyp@fc(ULGASgw3_Dy{?jpHdb&ae)y z2{m&)l5jaUDLP`^3^j9a4TuEWG}P&SFq@g1th8mvEk_!?oW=IK{ogT1$K_W(#?qT9 z!#dzQ!tS$&m&>8>64mZr795to-nB0VA-naUe#xP#x*5%^4GhfZ8(9Ip$`r?o&dsC9 ztggBia$YDIZx$IhiJ@n9#Ko^Jj3E&KwEAina<>rq!2*pRFA^moGtWvS3i;yiBu!AC z3)#NcF8}U)+9x7y!ZqE~s(~kFvdDQ)8!>IqmiUYlv}6zVx6TGasHr0z7&Wl~Xy9^} z6{Y?rI7Q>?6BQig+S1O__D$`EUJ|-RcS*CBYPN*x_fiItqAujSqkU;3M`R!`^jbx^ zgE5hZPcskN%X!SqH58%4v!5JT770cD9&vcQaMj@xG$e|q-_YYwZx61Hf8x}O&vR0m z=M%*bOs^F;`2f%DeoQ-HWn^R|0%XR*m^b4`YQ(*1Fhym^{$h3f~kraSg0xa;F#<< zycJRz<-O4-ZjmnAajW$^Nn{%T#Gh^#ig{fF2v={&>hEmY=ag#3_CmV`bT_^vTrGMquGhQ8j~^?~m156LvjAu03J%ZLo;F6j z)`S@%5EI}Qs}P*j*hFcb%*y5j%;&@rw2)8rFFGO$wQNVV?VQva@qBcT6{tB?CLLbE zhTJfBIKQ%eh6P}QYu_VnA5D`#BZ%tHE^jqijiR^5Cyj2sKcQ@$8bpcn!GBZ`>gZZV zqCUkUmoc!8o{RJaTx9m%Aed zQYC`0Yh#&0viHl{xN-sLx24Z8waannTCKHYsvI^5Gb7p&u62W1z`n{c`Tex*0ZPaf z_Q;Bp?4OAo)djxouB?(tPT;Z*Y+oaxJp;nLIa^b(e3sj0`)|)AZZE?7Y9^%3Ct1u+ zWU3=zhWz&0^A;?6YWP_J#Zzb?LHt_U0?zipR^Ziy&XN;HfsNMhbJ5P3Z<7_rHs!#E z>m?k4^7bTg2{9ZK|5eOg zT@XrM{JWU@1j{$M>}%Fg?z`f8muvhb1(_qGZ(H8gc$2whUGw>5xE%tXr?k|E&J(pK z#;g8CV=V?m+eWoVtY#`R3TvIQT^^aVZ>i?^s;SRs$UrSc=En0S@`N=HZ)S#)1ID}V z(-q}tj>WMtHMi#&-y%HdQ;#TKz#RTQ7Yt!nsJ<)^r14 zA>AE6#~~{BVGj;#h3NKL?2ua@`F@29Q)`q7DeLi2wDJ?doiQ2fI?ru!td@~45 zoZA-}+8%up<(H{0=hFc`H zSl$FKvVSbNRG{l7)Q5Jo;ce?(DN(1EQpbiK(kdf(q4@0qmsy9c`jZLmf@iBL_%&V` zVY~w6Y4G)RYEcmYXw~*wTfvm^3RR_+zgQ6Uo^Mg=O5mFfN@>++Io8$GO;JMK$4aO5 z>T6E*BA0;_=KGMB^;Is1Lq5xcn|9frw32bJ7w%@5%8biJfDN0|kk-s5*s;yzX<7go zlE|W6dq^oAb!`d#j26kNQnpwYOO)r^gIYE~>H&<4l}&e{9Ll=h6^#p{m0wKj^&6k( zXd-Jd>!^;Zy0x`&AaoLFUEaD0j%Yj6Sdhx)=s^riwZZCHzI)%^F!Eq56QS% zo1b$!WxRe8g*Wi_0c~3p_mi~*;_Ii*qb$>x^gO@R8jn~Uoi39ryO2*H-5FgIT_&8K zwcm%`S|fTrR>QxLiHD)JU3Y-}h{ns^wVIFqzjb**Y^UjNP9Z;qaCht2`g%=Uk#-CC zgk4$}&lbzY2)XSMqEkhKpICB@|ESU+YnGU=mep&QnwXc_B~`nLKQHnjKx!V)y+wpg zKjuBk_2; zB1IFUWLnku3}~9Db^Vz~`a5-1_ZsNE>%$}! zj#&P9lqyP&mmk(mdQ>^{ z)^kMDvh`u3mB>Sn;6jZTEOH=MGOsG^%Rox=-SxdK%4#bH)x8#q?r1{Ov;KF_Hf;L( zdLVI%`Q5HrH#|FH_i0z(=En5LX?+Gm!uEz0zp>6t>-cF0hr3Ot^^J5 zb$Xhrd`w&V&Tqq#rpq!IUrYJw20E~*OSz<#f1Yz!CVJU#Y2fOm;t5Z-ZpBrM*u_QH zWwLilz>a!QBzPIJ;&2j}!TD^r;Jw86V1rL1&d6{sa1h*4lVo|{6O$<`*TQ(YZ)f(2 z8|2~hHF0mYJp0ro4guEiWpN`BtcQF z%hJyu>j^KZi$v0)77Czo*Q##vDwY|cc&;YqNZdRlZga4AlcR||Se`oOr=fsXJoa$N z6I-)sq}=s66gDy;sX7ql;`gUYWcBs#;Sl{BMr{{eD-nL7WyRL2<15kMygp^lO>xscL3JMJ&3bNq)E@;OOY_qnolbwi|^)x}) zur0E9SojtzW@oWs{0>=}w;i!Vian+8G`o6MwM=~au!k5Pk_=AhJSdIgD9#6wNO!wa z4v=hVYN2M~bnj10$h_s`V-)-6gEuC7bEMfV_M6JUBQ=#L5u^C2K({pUJ}2*-J)=KT z0+ueB_sZbS5r{VQA2;0PiK>eJ3?YpAIzxZ%h;Bi1uw2SrM&{Uja#9QDeql5o!S?j? zvTD7hQ+Qgk;o}kgYnC723^)N<&pu`Umh_6ijIr}XSxpyUVS7bV_m${g5WHfyiG6KV zkS>bsy9&am&x-lEQPP&gLNDs1*5lhy2U^E=8^jZ<*}~W7pWE-?*kb2H{VL$~JHngL z8Fh2t=x2)MJ0jc@*!pj_#B84Sb2kUFWFhH=)RK#0anB>@J$N@K4)b><)&$FrVt%@w zk9a08+hoX&q;&fT2izoVW=?~mX|G1`qsp6+Gq z%^wAYi)k)`8*aPu-Y#gG{YRMzUDIex%Ma-ES1H0Nn2&o$t2mhb(}F}g+J0Klq(4ae zXkK3-!h9RN>~I$qt*Ejm!e!PYN|48wo;Pedo%ykP1{6gwV}d%W$JE~TX;(kXPHiZY zL3jH9G}Vw^J5-!6SHfWl2-TKLxy(!0$Y{UqO?J;g{ma+D_<_vq7JTZn(}&c@liS(RcPsVp~NhBZ*(^da`%w_fF94S_5-#r+z^Zwx16{>$kw{4xZt zDbmAdmptIp2mF|K{oACn_4J2ScH)Ts)8k}tPG*YIANnFN+ZIo?8nS-mRmI`!?RDvS zSh`C2egh&Ift5Xg`_z|IcB0jtY<}!thZ#G9#tg{OR$u#1k2;#Q9TW@CfQT1g7u)=%b%cqqKlhWM8@+%nC z+^_De!1#WkJcjWBSNSJ77o&T`GP^Pp2#=hYTLI-$-LHw0SMwpP9D;)u@v(*=usR0F zn%RHEZ|P@5wO^L>+cl-6)!U# z6;bg`h1HM)tI!=HzFxpv4TR@t!7k!XI-Kp=jK3cq#ViPk>7DXQZnTVtP5}aU{m%va z({g_+6wvlthiA9EU#-6`cg8aQhWR=Ez5JFE{hq9AiM=7g>|YZgZa1o#_3&9qD!!o( zt_T8h`=wmgd%vimlGm&$7pqOavC$D&f6FQ3jCFvsB;bpg2b4?*VvMc#d&c!i(=|q_ z51|QV?^-RC)Kuoc{j-bgS)%zeDBuFs3Y2KVt_sF{wkYco?|eQ6b0e(JG;9j^t{^C5 zhcVFklEfm``@;7{8?~pd&9P{hy_)X%IMkR0<2{2hHs`J=_kUqM&nj)+&g&s^FXAU? zI#cW_->nr)2Yk1db=a$HI}fN{RQ7San{rHPIHr(QXsqu)0AKI-bEVuMNlww5;2^fR zzhzJ|3icCWi9)T9hUzUgJ5#^V5mIxlbTtHqI{XoLo1{4SNh08Tifb3lh%})Y_;1<9 zPZje%O39P;&hW{4;!!1{r!u(*7uddRQ^HhtF4`oma1n$!mqQb|mEA--?_?Q2ePL%* z*=V`NNbfvMA`g;XAi85qx^RiOayYKTV8F?}$ykqllIQyZ79%a&tvpOi? z`iNTEr{(#IMp0)DDU(+nL>Vt}gg~`}b@xNKS%rcToseUEtN{hdr0(%`GwJBWwum!D z)Xp)NL=Q#=geR)sB&eA^0eQ7KHq>q)iD0yiqZ1|h6J%^ZUT~s)#Rrj^C7g>zJj_yb z<_xz1rgOXlmYI;y2)v^zB&opt&RJ^dy$L?*A`9oUZzmC*(`&4i!ry{dstWhoE+aS> zG|5eYwRec?EgL+l!Z8y0)m|C1g~6uJAttxEO`SI0PXHu)sjz=B)PliEB{=BtB`Ow7 zl*GU)i6u=<;>OIDesfF8+(BVB$({*59l#2oQTV9!Hnvx)k{3jNA?BvLTS__j|IHUm zYWwu`X4FWtx5(^~Rw1^?u;|PC()x;%*{!ytux=dZ+Dm6ijz|`{V(O5(Nai?UdXhX+ zx``*=bUZhtxFkq7#S}%P2$fW)$nS|1hP@pu1NgD;2ZsMLVEI^96g<*FS^bwa^Fx+> zH~d{7;1CZ&Fb<-IoJ2V;4Q~u|>voP;RcYhVvTd|T`e+KraOP)=Oe)-MBpLCNw#qF< ziB|zg7*g}6j!jkH=P4~Pl&I{BNGH4#!h|)t4r!254mP?cNf-sRYhpFc zA0#~!#so1RQsf3IKyh26PbswalTKPT_qnl*TdZWVp{$(}dDzUM&6yn-O~Fp}In$4j zmWS`wf305LJkwAGW=N{4lr!dQ<2rsRXgV%*H35*;J5H+_$<~zAlopnh*e;j2PO%-^ zl7$6QF;WWrpvpv*fDNYfryYIyN|{W#aCPJJu=A9(wUgouakdi}6>X3cusyQ^%&5(P zvAK}oa@EUDkQ?K2PXq?3R`;*u^!)o~-rbPGsR4JZ)-_^)`^?4`m+0ZKn#_1a?o!)CH$nL_3Ck&sl$N9lmfRX6A;DDjdQ?Qhs1O@dYc)6)a=NJ@;IH>cvFhG-^!YBpGqbMkXVa%XF)d`?fQsYuyXbQ`HU%(xRhfT@R1RUI$4OtZ2GpK$2 zt~Ub>=d%7kP*nFC-^We=iYQ+dmzkMCB5c}W_a5dUeR2}<4SRl5WG`m+Kquuj^)`~X zDF6@TwuZIH1*|AMBxF=^Tcs<2VJSQG1?N2qLCBu4H~qqT5sK_Lm_XsIqR0p`zt;yM z0CO4W$XlmIys$Vo1#1<%DX)lU) zSI`RKf>eaH!ZMdR_^r%g6X=qF;|Ep)%oF#_m)m~Vv7o7PDlg?jSLWwh9x$EKJ0^2RSyM7?b^qUQpqy%7`daeq(z`$4 z3n`}bw?EP}(P!c|v4d2N3bNK&7v$Ta@qT?6x# zR>YEwe&ajrg8`N z=1@P+uyyyj(R1=zzZ=y6X|q07Sg(>Lo~HHUpU66-HNvl67NeLV8n3wE&ak?Nerq>> z#LAWg86R85xsa}at5*;5>uWF&x{AmBv@H;!I-LtPZx5h2h3Mai43)4ii{4nRdmJ6x zw%(3)ml_{>F^6-DyEDO-zh(YBxJSf(+r9A|qY**~^Z06}NZIX)lM+B^dM>&`Pg{4lN-KgM0$UVcB$fgCu--O)kVy zbt2Of*=&qjrQew1&=4}>SRig@DI)72Yiaf3Tm`P#z_*+ zx?!N8+`Z%;`o;UsZdtGD`nuy@0B_J0C6N!c@V!h`=MkSRDuXa3J2Ub?kmVBiS66{2 z%5cW7uESi^2ZV~&g>y15&-ttdY#5<`!K!}Q!>xQa^%nPOEx4x{x|YSP11 zBqo`zUH7SoL;`GdKw|LIWA!@gLW<+si;U6*L+eWqI6gm|i3fK+bt2XsTMi3lj@}E@ z8Zi%NDmGMjMRBQU&ja%cAAJv0-BRBr3E%WGP;9MTRthHZcA_oo@dp4QS7D}H<1X%+ zye4t54i0wj!fW63VxqV78h_P7AUq&v`k6r!;#DpE_Y7E134?3=;BcBq29Iuy;wVp> zspgE;T8#I}@VE?i2U>EvVuQ+rrK#&*IYVDidhfOixWzo@bGpq&5W{yR8P3s#xtA=( zg6S@d%ng!pDE-XX#A)Ymj(>x5sJwc1aP)c|s$rt;6?$q)u=SKMpBY^&1h=zhlDj z#mxT5gdpf@ZKe$_PMQ3>kvU~^jHnb?*{i)dGA#dR;XBX%VVdPO7Kt2nKkbS)+msBU zIeu{gllQvtoSa|2ErcqpQDFIpQP(-#vhU|Fmg1VtP=%;i_PbGGcmi5Ef_@~^SU7S8 z8S5MXC9f=)K};;DA!uAyvasaRkKwk1y;*?(k!W_Jh*|>zO3IhyZDdtCvhUy`lqGQ5 z2bVOs-!3G9fW=u8b!gQs<^(|5-wcud3++f+RscS-asNGi*G%SJ`?hx!w27uIbSrW)If1op zWP+O<0jyL65dAWz`M6s#nMNID;&$(AjxgT7G}yk;i{U;{r`rEcpl`5LaVgDv&iXrj zF$pl&>V|9RR%b`bJSV{R>5LWb+dLq^0G{e_S#)e?p6RgdNAwyH0c(3NI%6T)Ts9Gw zg8hu6q77@kRaA7G$%`oO1r_aLeP}TvBtHYXLbA$fHr`S{FNK(G z3b#`~GbWfHF1`WrWX#uV8+^7xeZjYy~aU6UL;kIu-3AwhuoKg=5J8Y*Rj<6-~laFI*XB2$4 z%|Bj})<=`&wOi8mE_#B^^VNy!;^%QCNmO?uW6z(g=Cb-~(AD$i*RhVw6`>f|9tJ&X z{A02Ap$1~Llw8vyvq)<>@}z}bPnVa$x}dY5uQ-0>j~WUokN?BhI|o+nLzr#5mE3oryWIZQHhO0Z6Mf8BlZjgFV5 zT|HayI{W(~>VdzlSNY~iE3XDyZ0|_r-ObJ19JZgAnjQ%b(ZC`l=~n#qNjESQM1J=O%*FC?7z`(slbXz|;6jvbZzY7 z$+w`YLW^2f7NKO05pBT0H&gCaq|wGlt-hwgcl6N)z3)iNdlCdYjrK1ISytU#g0MK^ z`;!G9_mohkTa?-znBrJ)>|fX#&H6Y%ca-r(q}h6faQQxdz_z_I zL?3qFw8pkxIMh=U0BrtDE*q}izyUwz9BB#t6vIIx|N36mbSlW-RZDo(=TEzm!f z5xz#0s)bPYbq~DYbQ_%$-k#bfZ}H*(tWk+M*hMKbmq%gqi0q*!2if%X;N`=u{o*s9 znY?8HQg8I=q$rhVg%!Oe^{^u;jxcVW3H9LqQ-Ad*m*|O$w0sSJuuGiLhpQHFlM4gy zd+ixwLt5YwE(!;S^%uSsHzc10x-QQua#8OlY=aWbBHjHd!O-QyAp4GV;a?x-Wgkum zXpb5_j=>P?tbd}83j)>gZPQ_*yV@pe9<779_p`==B{KtXkPgEV6!r#wfT`iCc(KHjOsT>h9h~6C+{8qmr)KFpV=(uCpn#L@ z`8C0|owvcNeXR>Sp`d5znhaf6%N-#^owQwOG?kk3uOe#fi0)M1z`Y4KY>W~Kmm$f z_Dtj3@2+Df?>PLAnwrRI2zzB3vqP9_L7q^I+W!jHSAHz6nEgGHH#6TokRpi9i-d4U z412Mowp!3P*Z%BmP@1TKij9tC*V9(>F`JRo*E!&tB7p6|bmd`5aDr8f`lzctY}b&I zG`k4Z+w+0*%(+4`cD$5QK!RlDNR({5p2dBN!J&$cPy*G`V%`?dU95ewHC2-G!h91v zb+QjwCM|4C!ARaR-(&XlL~<{Ebi2?cDRZBXFIrdlj3!DFn+p6h@+Gz91#M4Epnf5v zM3QU9!Z}w$lzUB`b8TT}Cn;fns?J@Or1%3rjh&l76_ zRVp9-9ZF=o$O}sxo6Lz&j2amUQ*v;%ob|hwPiE{e99vV${BHp%wJAGvOEg#FYO7g* zsi)XczdGI;KL?-6PL`4VZMn&Xx3t*0 z;^eUdoWtA?+8l)_!|Jr{+zi0awY)z{%?i1x1)r_j9XL_Vqn>%vh&aLADc64>@yKcVu zoXV$MG`(I7ah?a2qx0DB4Zt;v{YR2~VN^6p%K2k+{FHE$_k8UGUunqL4g)sryC5Hz zp%Nauq5pfo+(${s0ecTho44Sxs|?1;yEFAeL+*$Twt?K6A8KnL|4PwnM;Mg>J6UtH z;pn}anQuNddesZtmT)zzW?kt7dh>rA9p|(?=q(&kGb5E-W>(zQkkp-Gp5G7B7Ae={&DJj9_xbL zwis(28{ZuAc)db*Yn}26YqUhcGfjrS7Bl7rgEw2R)3`4S@kpz6<&_}Lp2&hvTNEku zz>4}BfZvOr$PdRnbKp{iQIb?N+mT5LXbX}Bsw`Pjub{bO;qe*Yr6~si<%8oJL5-nH zyKASx66F$+LIR};OHw7@mq;{#{%O9MolTa&L56yf4A*cU@8744mOm2_=G3{R@S7^I zs4?+s&T0bZ7VlAc(2S!sK1>DFBkwNs93Pc`L2C@rpfMqi%4kHa_a?uHy@I`|aG(te zGOg&6F@>;6f5h64|J}u}kh6n8T}ccELX}`8Bx5{o>Pn zw|ko`Lq{2ctutIN8@x1H!Y774W^}0+Xc8OVVGj8VFVU5Z30a?@90L0p=G(I!KmRGK zmYyx|IfHLil|~@5rD}4XH4Py;xR$L-f6z4DUVl-`sWgAzK;e8vcL_AAz_*ur5xM?A zk`#WQMu&58sigLDJd9?Yl3Zh3g8cA?)tvW$P@S*S*UkOPr)!5cRDqClimWs>YmZUS zTkfU3_YN~PRfX=O48iaMTEOPqTWKA=q3ILobdaE>tY11f1upo=#D_=TY!7_>*RP@{610m; zJej;_7!|-y*d7rULFLZRhy9G(Ei%UfRZ4VEVCri7>v&(ava0wivlMwFZQCUiJEE#* z6n`Pyz;q|h8Ayd>LIf@`Rt?S+VgP%enj7D!iae=9WJeTqn5XDxBS~G1bJnj$YUx7r z8*@bt2fGz=z|8=atUtXXe8nG9t-9qJEVgei2|N$k59!@{B8Y&1nwDGvXGis=#oxgx zr0J`P+ufz1wi-m`o-u*!-!1GGOaD>YkamTIz<;ZP;90nm>vg-ezYaXw2@RB|EvY zZhI)J*O_VljSE|6bbXQ`uF>$iS&y-01pC|IuFj4>p_{&{KIf`#RWv}G4GxJDr<~&?wyr0>zlzyh<$HoeG^m?Ny00dNa}*ofx^1J4Xor)-bTZhO#~y@2v++YdWB z*dc@cZNYU`hzMk0!CJ`b=IGJHhMlF>8$N@7B@lmAgrmmBGANEefJ(JUt%Ge;BMMrD z>Kq)DkW47wh9gJg)u!L1vRGDPcocLM4ob-C>I;^#pGw+kS)Xr8NuSDW#|J^TFiSkQt{@eW9%14!nRe0;XV zY331^uCgzc8d`En*Zy5u`zS8Xy6Jq8ol>7zpS3~^UiN<>Ir5vFqS0*7`VI6(%SW!M z1)lb;%QM63-ZS^tSBc43iaDh<;W=`f?sWUjG?yX;79AV~-Mgyp3^4a~pbFrVo}Vp) z`Nqj6KRNrVhgc8n|9Vv&0%Dv)d~g?A@o9t}V;Tm$At*9D8O;oF1VTX6H0f30C?xoE zzjuY2#7SeO0YV1ysxZ~ts}CZc;x)n=k+H(X&p`1S-kdq-q@ay^gNQjezFqCf8e_I` zrXW!^yluL2=TE+uT+*;%_+($jn4hCj5p$=EZ3)?tKbaJaDi&e{f`{w~U|LgJo$HcGE{;DxRXaWXKVZkk`R3Ma){C2;Ba7MHn|I>P&E17t%a6T(8QqP*kw z*i7^+)kV*T?n`EI__CTe7Jb0LtDa#tQpi>Dp=UWwV!aLX>LHzMN&5N*-Q%9ZPxmcK(E;NQ+?D{1Zs6F=M|{Zp|&FV#7&EkV1<@Un-6si}PoD=0k;v5TOF+ik51P;>%{^1&3>; zYFo2FR8XM@CnsYfPVUGiY}iO#-otIohG`{J_T{h(@3P5Qdr27T^IeG1rpqmdNEUeY z(Drh7SQ<)kQ>wZ0`W2BdF=A#5m}xKFC7TOkXuM$D>#E5pEgOVsNc_xsk6X5(^Gma& zUot$>R13EtGUcZ;ES=`)BerX<^@axNr)xb7EjUIh#I>f`?ud$OA*`jRcz=gjRdA~$ zI2Fu6m02yxI+Pj;**F#`t)v=Szrscg)*nD$`<8q9F-6kRUWmb|Xm~EQV`44ju4k?d zik?dA6@yT$NS&*Y&bmAM+why9wD$otHKZg6Vq=o~)@pV2H0?!dlJ*89Qp7vpON90n zL6DM_3zy+`jwWF+|FiLuSToL%ZmwF7OI7=6jVd8wNI|f}rDJ|R1(7#7`x~3w#?j1U zC6&bVg#-yB252p(dF4|j~oUoVYLP< zh_;cLb|s(IaDF;|XGHwGhW_)KNY}9Bz;E;Xyom}vz`h}uW?u5aE+0POOrmS8NOmiXEzkx{weTW-axp@WyXhd1L~*7=BTiktwDdN~$2$FQ80 zohLSMps2>Jga%KEDJ5d8Pe7VB4l{UAY%}{l6&>-1d!`dEahZ)ZRp{%H$cvQis?*yZ zlNn1>^;NM?2P1;U^h=zJQZ3!1h#~NQc0gp3U^_e&yY`hI!|1cZ$^pTrGk9WH!z9bI zD-om5*7*a=Yny+qaZeFkyYBcuU;trQHQS zM`hHA<`SIP`^qw)AUsbDU!zf=3HKyhA-DZJGt@Adu8r8_zl^0ZRrzLBnojY*QDHKn zJDlbb9lQv#Lr0d8fd}K?h zjXFo=itF;@dy$;Wl>?T2z0+lB&jjj4kG)Z1Dm9r?U1*xR9o3w9_r^!0B8|*b9634D zU$JOU^`+4I!HxBe1=#B8SXzv$Ri3>vR8)Lg>zYDTE+|>bgE%FmOMy@;@YD-owakhO z1yv(nZCp7dtKcK|$2j9=b91GLrWJTYAA76baZ zoL}?PK`8kb7Sc*ja8E3rk10yTeeO!CsO_ze0CBNMQDd{UIuuMqMyk=-Da7A((Mx!f z?x^mP?9YWRIKk$FuQv**9Qk%Rc^mChzJ<4E&*aW!NLb7Uuvx56>P>!?qgEYv;e|5|je?T;nLx&j zhRnQB@6gY~CT2%0i(8^7_2lEw&IyeYHTvkd+D2LE^v6d_x{$+$xw4#cg3LMXV6sfN zOdkyDwu-Ez|mr#Qhpgcc4rlJM8vc92Ynm>}L6p_U5}4Nc^_zR*kG7A3`rT?OpG; zZBAj0d4-3mVlB5}t}1df5XS0Vd;6`gLw*{t=*_Y$AY4FmC9Axkp#3a?WlK&3fYY0n zu+BzlHUVw>shqIvi#|T>DOw)@jv-aFP%urt1a_yXu+WEoh?w?epNB(wX9F1sRmv`* zV+&L_nH;)uv9fZ>C$&0lkKxac89V0E@I}!$HGKHfJiQHLba2JtkbF1qR&dU+;>XL#Gna`h z(%hg;MMmfJyD8>Oi)qO63?yRKfYMNK(l3EgVLTD+5VrV4HmXWr->39^?A=i~8W_XQ z`0{U_kZt>DHMgnqmyP7)Rr?9C%xQC)@w5)_9aa6906Flozxxd-ou5TKd5YtHhWUl! zkZ1hvZAHK3;LM2cdzQLboV!cv%)#}x=Si%-o<7>g&m96r=ED0n=1Rm+)h_1Kl|I`4 z4*lJCA$6D`&{9htj$!i3b*!7u)pRlL8~E>@2GyL8rFUN$(DlY9?qT}r_UxT| zxo{+AhdbjKa6G;1n5z0olF*T`ok*pz##!8pZ)&q8)#S>-koh`UhEYpcM&~1IaH4Q@ zaHc5R$~i_0D;C6#t>nN>Dko7H&+nm6OOww5SdbEtxny&Y!`yGT?V0lV=lFk)PVN%1 z7N5l4+=lLn$_cT}gg!(puBtXHCLoL7q@~H<-8&wM8wk0XoQwaWru zeahYmy}b#;aA_Tyechm0+5dDqENP*hh}CcS-o{npYyinJ#PeFwqbZx>qiFaSDt_>P zs>0_JigG)jyWuKo7ptSlxL2w%rx^JjC^6P2zS3W^vX+vfbI;Rgs$J9zdc#fdZ3if~ z`}GMN_=>582WF|nmMdZ>hwUDrl|a-gSH>|tmzZ;l^M70`+I?*a0G*uF$Rg)7w%On{ zP2Wj>EX}mo#nrG?wWkxZ)@AT(WiG61yfg+3uEci<);%R??rUsoK6JGryu@G9 zRm4@f=g2<~$dz;yyi-*lcS78OPTLKCoY)ja<=O^-Mr-h9ulH%GpaM^?Y-d;p!lJSL zEH6xH&&HpfF>55;9=?mvZw+&@ryPf3PnVVE*OsD?qPGao9^Q2N%UK_l6L`uwf@zSs z!@Gy{em)u5H!ivQ7NABkK!?-G$3X{aE=zS+DbXEBe%SEm=Te}8Z~Cy_>G1EhfKiFv z>+fqctF9C9mSkQRWA{d`wL72VIzrPdQZ{q^!3*100! z<1g#J6w^4w106FYLAS6r4Ifj8T56;Kx}y1EsJ8T`1iY3ShS3wJo91GPA0ZSj>bAvQ$#sN|5_m5*g=KR@cM31wOQce zr%W7xD@4QTs8Q4;ST_yODVsmU=ZdLn!nXF!X~Q2u`Wcs+=~TH{2Jx?Rih78LFVRZ) zV(Ro&qM9hY-Ikm*_nx{AAZS4kH_ec!^w}~=#SBk*_QsOB*i!~k<4#?uL3jMB)`_-KzH}pAkSt7FNO>%9OlRh1-S-g0>m%q+kUl)VcjF9k! z68*3b#yN_jfb8a*cp`t2al}M2ZJcR9NOm|K ztCilLnxY9_?kh(xY#kI`4crGCgx;^Zb{a!PG)xl7EB|X>iJ-T@0=!_vqnc@RmRa6! zN2F8y+wF+Lp2IorL_H45QInIBkOpF@5_?q4s!A8VbbMQ#o5X4=C~M`{Qp7|RXzd-J zHQ)3(9j~t)AEiC8TmpSoyrRP4QYekd$N6pLy{e>qrAH?EB(qNjO!Y$0jsv8*m`c#X z(n=p%h@KK$s-$L}d^iupZ+D-op>J!}tI8|j)uqji}v^UYFg*8RzQ)G$=|n{tJ@ z%4No~A)==;SVH)3FDH0L4VB5tD&D~6LO%<$W9^DXSGy$9sNT*s_2WB4P1md_;_Cg& z^bW|($lm4y7{uhBrU&vzf&-Ssv6MhWo3*KCAn$Wow9%Qoc{@HIH5a(VHwX@PpqXB- z>ESQk9nqZ90LD@Nr|%6H5c)fpWU2T)sLJ-eF$pkRs%Loj7f_(WisGQc_ z)|l4)b6w1?wpuuV%_g~q7Bq#37*d5YG(u9u=8>tE3HXC(YHbw4@WluWuOIDJz|IL18h*8{(teH__Jze58vyr4zlz;=@P`7^KGnHOAnv)(cO!1wgP#j zzsy;;(eD`OUYVZXSXk_q@`s;3gvh!sF=h9Sxbh?fmjIqgS^KXq(fL2}Bm5d%zl?gq z3p`LY%lzGY?dVEy$y)J;8#8Y02SZ`-da#H_Yx$Ql84ZHe8)${PT<3VaV-#zEGgR0p zSY?(J2yY)X9Zosob!Q}P4`#|K@aQlxH0WchQ^n$+WSm*%XLa7^4k66QSS5EZ_b#*A z45_INpe@`{VqT@wM6bSvasa*n&dO`7n6nXo>MjF&{ z{_bVHI3NxD!P^Ejx~e*YoSYg#Q2N$dg}-4F(E*@y3Nt18rc`KE;|7juiBy&e?5<;f z4qIEzaHQOVaAYfpZtlYSSH7rZq-GmrH%DTz`}3afthYJ%8c55**+M%WtUvAs;H2xa zLBxqRW_wzy+I*5!N&}6xTe^PQg{#`qYSK{PDqFK<2HAWJf<}p@oA11kf+IospK6JKaC&fML4?i%eP+PoEhlEIR8La)drM>sJh{dSY*~~y1I8S*gl|YGA zyDaDQ#N7{2s8Ux{U%kW?hI?m{S8~bsgSd^3fV_{jwKsbIxCtM^*Sq`56(MP->`TbC zzi->!DUOcB4S^FWgoV|9eW_5k(n9n!(bc`epQW)(`2`f&xjn|Tb1a7WYzkL-Rn8h* z-WHyGII?(uM{Y-T)>};l1<|U#wcUcxb(*x~6}tRjul>mE@GiYHC$K=oH) ztL`2wohnFZ1GB+rL10Ku%M&c6`I5XUf$Sb~HHUv+rMf2tI;VqmgdP&KWTJ*>158~| z&LIQgt_4hxM-r9v;BwK+Pj^^#tsojn_a+hSghC2VjKH!{wH#$Mn)V_EyxlS(5+pW> za&deNw%#IKL^p&h@_JhAXgIVhj%H(uWfz@aUpTp!)pHK_!L5adwySG~Ma?25T z|B4@dZAgn4HV=0lKKgV()rCF^&RR%LK3A3;*B5#<^hSDKze64vmLoQBKz&7DQFEWx zZ(P0nlFLPtDtauhUGo6=qtb|6MM$evhFWI3t4@28jkRbHc8lzfNm+&|-ig2L%LA42 zP)OyC6SxH@cNY&k1SjWl8jfNJni)Y;Kt|fQ(5J7ci2UcN?>B*~uvl1jc8}iyE1G$} zuh`@GDUtA>@D!DB=YF++^>rPRvN&HYav`%t*V0h>*nsm{tkl+I&Q}sw7sDBM=hDDR z*M}czKMN~A1iAblaE0S@xr0l{eaqUwV>Ww8-~0AsPtnc+q_|7z>SA#ahld%=Se326 zWJW&yuYdwn_i%r06>eZ3(ud()wbmz^hEmcTSnbG!d-pB;Jj=qp$z3Gtrzb5E>IJd& zM#7)gCdkj)gaz5+K0$-G|*HPpPRDY-luNttGWt~w-j2b>6s#9wW&VzElo#rAOMPA@xa z1n=becrsV9YD5jlftj;agd6IH;K$!U+w%yA7RuiYDzxI#_stosLdBPGFI}m~&gKRB zK~grIBVlmY56fGz?&rG{G?Fp=DePvh3#(L+K#C_2*2eKNp zccXNI4@|?(SMCsStNFda#Bs%5a4^EXy;DYrELPihKSGq;+3F?7d0RpjjEE>u&D zYH}#3QTzzOYRv!3yg7pPmq16;mv!H!XkAt6s=1A8M{Pud5gVTkAgnk4l7gC>nk{Bi zcC{fY4<^Q9w<&9z^YK^eDC^%!OKH}mme5xjx&|xawS(j`&Fagp)!C;d=0FDcU^t;0G9-3F~Z2)N(otNmVq#jUxL!9 zniJiX4OU>HxV?z?1;eW$BG3qP28q;Dhig_1LuC_0d)V!C#U787word$UC`R_b0EOf zK?W$!q8IG3DU=0#Z%ot@ho>2>3!cv}({rK8UU^;<3+TdSs?{dU5Ui-?CX$x9|Dowp zL}dF;l=a6cY6GNZu-shM@D0F_-FQA*nQNs&wSG~R$&lA_hG5^Z=w$T8TWMs=On(L| zh2Ib^RyiT{S0?&qlD8${15p%f|DtPAOgTeMX?sppeA?QY+(8neRBF}=mBRjNx3ibj zR}|xR1brTsK2@#p6sFt6`HG}>x={&ZPq)!|Ff3rDS%*;5wz^3n*Ntqbkx=efd&2eP zdfRua@zk`~!<6Vrfz1AD^IIPs+5TvlH#A)0x^v_(FDrnqD-mK`=>p$~o^2-are|;)_2^ZqEK zOn?c`BPNqGkF4DoFgV=yzP#g(rmf+<+)Jq@ck&0{vFD(|N@}3(oP4m%Av(eNwsTx$ zBN=*k)!%f9u?oWr*f4E0dS9|C+T|QHaD=NGF_S)z58!1M-C7AyLp*gw;rAHp#&buH zz@A4r^Kkap7*+ME+vP!W{3=qyKQFER3pp6yV48wl6#(WDeHvncuBQK7z`&!lPw?KW zmfS*(N-G-itF#~+dX=*lNy?Y&vkH%6Q#kPV&Mu`{#yxlccby3Db{~!o6E>c9o`7j$ zir|sMp~LtZ2xd`lK!94nmg}vU+t@OQdy@U7Q~fkHIi$3{1<@~>ZCDq47(qecTTISL zVcaB>335NYUih1uAcB((vuX2059SVEGGB9*O^X`w*)t_sope{hRZo@E2WlW_M$dlA zd9rIihIc`<=uS2Nx~hA>4x@>oWACT-ouY={ss3=cN;~jd63g_bs;Sn(5HZMI;COXl z`tn}5urnh7v-$HZ3=@wH6{GZJKye4&=1s*jdG;&!;O(cs6( zRNpYvD&UmDgQ6ce0|!=x4wp6nO^urD7o>K{i0 zG?z8O2e9yqt;1>Rm;-+971@uAy$~B8UbuJsSChC8|4M&_IA)km%j=InYm7xcS0WV5 zx7VkDR7~e`tM2Y~LD%CJ(y5L}*Z0T_*(PM)WOonj2kf>bS*o2@ zisi=1)*=Np=lbo+C&=c)#c`etD1CSwTJ!no1NslwyYa~g-W{Q7F$_04t8dn%6X zpPVbzb*<pA8}=Vbyf z=PBqOQ`n$0?300O$2WtEly*O#c{MTju%>pN`m)8n8GLd9Rz#$C?SLg+=E@^01e;*( z{&hW<&D2&pZT?E{yXO(!2ZdDjxRu1;tpRg!`Kykyd5VWYp0={F{#GaCKP#;~8$ z_!fFUEvq&ar;fEdm%*#-;(Ninjol=65D+0Ik3zVn+f3OsTjN8v+4s-(UN0UVWwX3_ zPk!=Htn{}=W$p$rMM1rp1fvM*xbyqk|nX$X;Zg*g9XO%A4cuA!v8NG z@e?T=5K1tAuQjz2v(P6b1r}i~)nm!>>&g<2ol|5@&s{t#fhc{2$|ozs`HH#nkkg0m zG*MdR{d6-DWlW0}BThw_T}j0W_mN@K_Ijm?=?>3GY%s>?#Pi`A3ZQ%iDPP79O^|=M zi-tKKY!SUlCsF>Wk!r?|R8g#+c-UR)j~Z3aP_bT_Jfs&>R3iTQEQ$MLN!Ou*Dto*X z*~x^0a?JO8m@*(*I>rY3falPndq~ zpSO!V<;PkB9p1}$*J1W`QHMABqB$l$6wPbS_+q2aH z@(t#sX%)&hh_VhT8;fsK&Cliyuq?YU^J7VRU^V)YIoXp?BO_u~*RRy!iH=N=A1!O# ziq!%lnxOBZ+pkCNUoXW=NXrCy*>7Rab=f=A`5I z(7EH7Z3xZsTX@?z=-em6(8Br}+3Nq*Mr|h7{_VfXtaN9st-X$JN^$g_%f6;T)NA*i z?Uk~!!IHry1_#fz>$Bm{?rFrB#~GZ zuFTY4)^MR;t$`rALoE{_kZ`5{Ux4?zlrEcyQ$v;Fjjfz_DMey&bv0N!*h_95hM#2T zHN8Hb$zfcspgDH`*77^K~DLAvKblu(E+@2=k{U0yAQS9xqu!*Tw{@6mw z_0FF$-d=0+nH+=9S`3EDea)D6X$LaErzeLdM+a3O%_UB+^|t_)Qcs~0I#%PIdNS5y zHb2#@^&jUK7@rgNP*>qw8BNx#9;-}|qq?!K!kDmhD==CN-Ams&s<3Qq z@+sG_6l9d{Ta){mCE!!*&kD|4yGrNvu2)0W9icro3U%MSLice}i*6qrL$%Gr_P^_V zG?D$onomOV+m!)nwH-9S6OT zRrDeztkK>+@qFN~gYXj;)*L>>pIX{;t>r@YNByHqI3&L2=NEM&@9YR#fBRPP@eY7C z2QFNRFMpABhIU|hS_(6pB*)nC2f1X;>iifnHd^>06)~h4_Natx@I*!z{L(PA9^{v3 z6jR59S4gIMjcw0SPW1Tq1OTmpHAXE(xvi;1AM~I16d(^(+RVWn+q!QxZpXtv7`=5B9&$LC z4OQH4{q<1203c7I`^)62s~#GdDQ=axJSY%r9GU4@lLJ5Qo-01@Rvc65Nu;eapzqlQ ziub~n@uS+Ax^@TI?ejZqY#*flV_6RG0CcoTKlhD?)*RJEw2u>E?<1I8T_>fCm0bLI zvMw@{(|w4}X%T%vu0QqHUZYw+8goz@DqEFglwC2xX6g!!-sLUdL;U}V!8LXOIr-i_ zzG^;tMMpL`!|*=yaEByd&oDUjv9LV(R>2uVl2=qP^dIx|b1!8}NTGAgTl-g`ulGeb z-%J7JHaVkSd;wXO{~(rB(Y}#{18t-ZO5IzYS6thfF#21Q&>1V7oe>p=cBF&$8xLQ+ zkpE0JyP~s{<#;Cl8v?Y=6|COi(`GycXIF!1!*5ks<&R!#ur$~lh}8egc=`xhMG1V- z?Y(O}Kv3uSt#aUEw~74dONpAv8zG!iLWXmkjQ*k;|3R)iamm1hSdt1?WHjFK?DzNG zeDT{C`~H)t^RF58_xJ7RRdmq*p7zE4h|jjXNp>OR6a5=shTQ%TjohdueL$m7vfF!X z$ewb!K`}C|1w0u?*PYS)Tpd>2w&UkSMqNW)GCI4jaG+4$XSGeGqE5jbhz91je3ZPr z*rgR)J!-Kf$<&;QdrL=DQMK)zC zwQ76gYGfR-bKw+`MER73R`-;3T|1}S?sw_CHnp`2UqHw2j&NLGk!|JErvHJ9E28OL z{(loh>jws2))qWDDeuza_hZ9I{fw?F%W;j-#8+|;-IPjzZe*Tj`}IsWaQk>KgyDh% zYNkNO(>;x85%mJ2h&^U&`n4A%#g6O5N_{p;|^6?b^tP$a{}v668?Rwrnwnsqd2dECO* z!jjH<^@iws#rcEY+;i#1>P^?{Y8W6ZH|NS;h?lgGVgoly7yC|(f~LT*G|4KQfcohS(jA6!m0;U* zT{h))zIGmeXy@IgmYe$WLiLamA}(5B=Wobf^b!Vk%5Q{M6WNLdgj|#Ou1YEO_nkJ7|{yqd4u(F_DNUPIo}S(n(grjf$_x!;8vuq2b=he^^qH z7vVeDsxBYMu#pcY5o>P)0YAv_PleLvZ8vM`6QW<>&ulMoox znX;UzGf}bz3Z1vt(l#ep>JK zxri{XQ+38o=TFrXM^jf#vvcF|u;25IX;6WFe(_dZ^aNRjsfi3s&>Pz#f6DU9){u~3 zz>GC3=>IgvmbmjSryU@b7%khs_IMH-MQh^yl;pSy)@?qcSRTB)Okx% zd&FFP4b)31)zx|ZB&e7%ezU<`^q1L%lBA^Xe4)q5QbRxV1?MceCm)6ACF8T)jd-eXi}1gWdg!+NOHHan`7BK8Z@iIs(^U5Qj@c=b5^cl8jvR8o?IEpB-p zB~IR0xZjE&b_~b-vRU54J#b%mYTf*7P}8t;nU+k*4{^yQMQi}yoSV?d(Kc56c@j;A z8F20z^eiU#B(fKCar^w4R+Zre;~Y-p09MCZon!FAyjaOC>)5gkqy&V_s!I}qfW$64 z6@c-{Ev++E^A}}Ru{z@|`q8jjTL?RTn+Dt^wKu8|{FMWHkEc~359L>mMc<%yGol!3%HP}7C_);eRsO93M=nnK!j^z&k(hDN@{<@y;BO39pdShA`qzla$z-3X<+ zBJ1$CrzUzBUk5^y)Ru~nqV)&XbQe+Ia5yJ&s}_X99RcWu4W^%nF$XI$NMVL>0+bj+ z+|{@0cx?5TE#g-mFAkpwgw3}KZ~KFTXnm6NKvYC{gjXGMaiOWIbn-gf{2~T%50k3Ed&J6n+N$ZhJc?i6 z-RG`J&6sbISwi{4z140iycCJ1U%r%U-S$u7bxzR_?1UV`S3d76)ps!EiQ#sN*HEih znL*&~4Jf1pjx=B!NoliX@;Co-zW_MP9V%~Ps8O@uqY_cLw=4v3T1+CYYbDxPlHfa#u6y zQI(0|22&2-=IIV2Et;o?jjUGSh})N-vx+z#|5yRYA=a<_r4N2fD7kFg(WEF^!2aAd))10PwF zL9Bd&2i@~M%QFyiqe~5vy^th~SO6pHsKlynQ8(Q3UKbf=p4nn7MROf#HK z-Lqr=-nq~3@3f-wrPOscma}Yw^j9w$uh?C1+cw{MA6iAyT+#WgApXQULE(d9L|N#+nc)0hjNZr4_eRWItkQ38$F@e+pqsErel@o-?k!XwOWgl8Kpv? z|B*6#0v0XHCQr&Q*j33aoGaHl*_KF{m#9kWQz-SpSgxXbN-Y=q5bU-YknXtX%OrCX z`v38D&e3(X``T_}+qP||v28nz(Z*?P+qP}njqS!(V}Gmde&6%%{q1wc$iE$F)?Ck= z&wQ@meP2I&1YGo31>~Zlt|IplfA4Q@DDMt3{@wxaY%usaPkns^)$VXhSbssVd!^ep zk~Ii_z}OFe0P9R;Ua|mEUtOSVo{^&Q6_>|lt$?a@LJI3YW}cO&#M{!9Mk{5pf^p9| zmnhU!`aDPd&0bjp5Mf&DK+(l-5WPPVBd|OVc?{!mltUwBa2CCgEKEmoUdVLeT(*+9oyHRfnayAU5B{ySRj^N*K@1- zra(ma#Am!OYqpVX_e%EnP>+{Nd^VaDv=bDN5i$lQMGl2^hd_$=;WJY*H>=pRp;oqt z5OBZP&@o=|2i1$VfD=|GUzC>Uu`nITqTs$W3QQU-&OF(iDXb*L>kIPs|R2wS<9**%UPWl1L39tP*&(Z;xa!>1dbQ|mkH z>(O$;;3%if2l~o!{|17;n?6{}8OP9D!L7+&E0%R@Z{?*D;0Z1LfjVtvz%#4N`^`wZ z;$^7|E@z#&HJ8^eAd!R#A?&|NO3l5L}DO~~#k2E1`I`u2dsbTc% z3=|~$#*GjuT+L2{rM@SS7_I`1wzntgF(y`hcLWke^S~}LL@;x4%AbG;nYe@uxW$}s#i;3p;O&eiW9tXN42!TX zC@=*Ji?I%1Ak38zibqO9s8KN>A6VDU(SB$Kd3w0c%-6;U&ER=O!3C3y*I#hqzWg%x zjBs~HRy}z*l&<176W*5Zf;Za&guf>kHhrxc~c* zO(Mp9>Xi!EtNkn${auxaK5$b`hEEu{9nT}(9e%Tq=4()HT*$fWpIZbKS>QKDVqAQ1&cfxZG6 zIfjn`)KW`x_8|7;MnLiU8YZhrPqQ+@r(#7QyNd7+Slp}vysZJG2oh92Fx0EnYw$muyzmnzl;M!i?BW-u$_kbjj{7Jf3ZVWrA>#WXBQie%k&mk*+(){ zK;;~q9}VjezgHiK=Ya#MKITT@B~i08KH*Cbtsd|uv{r~I5cz%a>;G*LqmPLQ4pZWA zJ4w59*F&FlVuUlE80jxNvpi|2lCdWIFYsA<9gP%nO8><`SVV8I5me~Pb3C*>6GC6R zgG-tcjc?-s0q-k(&S$SanEOYLv;ETidy>p5NhLw>Dv>8<=Rikks?Ws6-#9?4(Z{P6|nSC-sKye{dI|F7WaArBX9C%+U$i2-JpX+WKoVh$7GZ&9KRFgxyqm5 zaLx3)Lsk&;pa+A8gVDN^Z7gG}Y)bI{l_jIajU-OzY1H-Vevi=|B2U3$J5X>=al|Fo zJ+v&?!_Li<9HW^JemU>w?!H0!3w73FGQr*~ONLcTFt!ZX-tp+MrROm??YPB&6YvHN z@}|E0Biw8b4p?Bm)!;bKMY|DqMjkPbkaYv9xze}Pq8KVI084s;KLdMwyQpUELG|Os zGOG+m#!wS;R1z$YVxI^Y`k{NM@xs=Jdp&6?L^|nXx^$!hAn9eNOI?!Mqa1L6Z2RF5 z+2!NgXYHzYNFHtKy4JB@TW4GPf1dxoHYguGeD%S8x;q=Qd7YZ{z}df${M2{Vwfzv- zQ>-!aeQwH}><(8m+)1ucUodLI?wRbv?GSv>*OV|KAmzFSzdh#IQZl3$Fk3X!{d8@G$ZGwm;AR%zc3>U8w4&!T3ciI{Sh7kFQEB6d>R*pg4b1?aI zTfn8bNeoq-wUn7FfKHsQ5f;q&?yT{kxyLo!p>LjTpiSp*`{vMC^({=JJiA7w4w5z* zl{_G!LWs_Sj5YU?3eQA;1vg=maA&U9&`o^HLr#>P(;|`6= zVlHuYQm;7R_+;&98eZj8T-G*uuh!~aX~e0&Om%_c=(ue&+j4^0YDM_WE821MNGJ)< z(-AYwaDsA^!SvVj=dwn1kk~}J21Oc}KeJe6EaBoiVE6|l(K4P#)h+FtYaJnDZ0}#& z9WE)>%dLintn+^g5`eZ}{(|$y(FU8@=rwMRXkX`gxpB?k?(B}r)8^EhZQD2XZN{#h zT-j@{z$Q*`naz9Yr)UGuInrL z8>aC<0eAT3gLjP76zs&;C(P9TH}5xEoUNH_W|uK=qt#=d;>0i5TgQHNKvZACPr_cy zC|)@jM4Aj<^ZM1gsyP8$Y)SNL^!zywdfrv1-0wz(@DX>z+45s}`n#@dKuk#$x( zLopsF$~K6ANydLgCbegy{1T0m<9r?!ornI%5Zp^?lovhf3{lliO#R37W0aekms4Su zL*#J#o{tZj9<2C7sDPt0*a-I^{q2abwg$V?G-hkZ04`ud~Qo9+|W8c)hMLJ zLhqO(B?D9@S}~Q=AypGV_sRZ*-74}T+~?(F{B2KJe2EvaveKxUSNEP+r=@18=?EmY zLMundqjPE?LGTgbc@e*VHj(esIew%lAsvti?N-6i>T|YweF)Z-@ zPGe|`Tn*6u{U-pP@a(kgpj(~j_PpnuAZT!A^DVeI-yfLJ)nZ>d>ERy8dP^N`9n955 z?kRr%^QvuHt2Nn2%>o0bI!d_%hG{j{L z;#8Qa)iKap>$Ne#H-V>%=c}l3NLq)e1TzDJLMG*>Xg>OjnpW4c2w{%9$*gefCa-i4 zzH~j_qDyK}Dc0s!SC{$%3V}2vaTJx&sw*@K!mD7X` zTBtr!cUt_YqU+lJ1%1v9IWn<2!{GUjz1_%K$ytnDzOP82IjVDyVKmpG^cNKC8)zY; zt^oK?BX3VG+-hg;kf4d~bzw@34vFE$iuMV7t2j*ePK|f{Sx#~J! zHt8xatG|lAet#r5_jiv)vY_wGyKm}CH6M@X%ZfUdSNkd>SvN{lp=o(MyAz72)&sdp zjZfdLC_16hb5gk!L)CH8*KuJ>)A~jS!C1f3Z0$CppvO8^A*=RX^A{OD%zWB4!!JQ- zc^7oB%CH4W(Qu@NhXzq#lNYiD>{MI3XakI3TV2(}IPR~( zTE`zuv%2RBBQYA!uBhwta6&;I%Aa7U=|>yxHys`m@+H^&VraE;7wzb!G1`C*YC{{y zo*~G%ISqFw$W0oVpZk?r9B~4zQDHpqVn*z~;DltzQFR_9xQ=5d9l_FziMgCj&aHXO zzrHoOT)(Q^JdEAk`R3)J*BekdS)uX&AvAw2tjL|wOD9?${v z>sx*kAtw2|Q>Ml?D*9i|GhxfvoY~3}&owR^Y-=vL*h03=FQcRXAHTAV_^Y;Nqqge& z0l=@)Y@J<)^rjCaalrq3_?! zHU9>u`tAazkt#+tieP%dHeFw0KD%#c{m$5~>KT@E!RIrXVmZYkl@QwYQ6P9k-_eA8 z$3`6DoaD2mZbf1mn%~q9J02I+(Gdd^G9;TI0-C#$jj|S$t+DAA1NU(4dTfEHYhXqD zf40P^B&J1zBQ7F-J0WC(W>@*IEip^-;~bHWtA^9xp6HWTD+sMNPr@hJUOzZbW0tSF zwfU-*U}lG^@Xl3PPY_kY9qE9841B^>bZisyvn8sW6QzzxvBM@bsBzJJG54dYE>**C z7@sFa8D>{|3_YCEUkj&J7HjzugVwi#3h1|ic9h+JJ%MP?2*&|dg2)8h(R6Togsx8g z-4qixXDL4bb$h%h8l$6NN_ZtpAxNyGt{m_3Z51C-v_m?&cr)p^z<-3gitJ4w)gEw? zb04iaI3TbWr2?8sx+WrShhaEM^(n@u`BERGZZXMeX^*;gvucJPl}0ZU1CIZlTbve& z1vPU3tdE|g@<)fbj-EOKkRK6(o^gPo4xaymw0+Jgqob?i$`zt)(*#-UHh~Se3Op1)-3%|Vbbw_KK=&KrVxvDn;j9A z&^i=6;|!ncOv9IxVZQQA9~n+&NsNuK=m{L3h{ALO@8$7s3m1rA#Yk;|0x=5|#LaN=Z;KVsmmB z=TFWg)~)(?U*=)0TLvg*U(9#v`R4KilR*X>=WO}~R~%_mc3Tg|a=$sG?>jXRD+vk3 zVo6CD>wi*Ao2c(TD5<3VUuaw6jAzkC;k@~S4|%-90hZ1!blyX`Z}TXl zoz#q(51NA2F#1}3gOYw>-7 zhTk+~vMnc{+@F^qL5NW{9DeGAbIfp$$D`PFur>g%1-JyPS&5*rwZ5cy_{k|>r?RIjX+)11Z9fr>-J8#xA0`>8 z1G<&SaPm^DEo&L60A_?n{6N!P4j0^jP9EW}6c!gO7N2PeffsCQa=gQ>+NRofqQqyR zG1E$#gaths&9pR(yQt^*-A3ujhMc+P(HD!3Is@E95GANruwv$`U*mJW2@f4Ok^ZVL z`PFFwW=znKGXecA7?xX9)a!|_GC#IK-HCSo5%-mL~uE64u&Yk8Sioy#Ce;Lik> z{AdY^3dIM1raTNIBPnI{zdPEXn~Rr7D{e}`yj^`tj;DtM#B{@U9^zU*|7pVgYlrEs z)gGYcgjieo?&Df#YLNKEX2itP)--hEZJOL=0hP{@giV3y{6s@k+8M<*@wkYu>|=fH z^pNd|y6!=?4!&8@24x=9d1#}6Fj{K8(#v^5B>OnZau54=Ge2pSiAzYW-D{NV3R}%; z_(iAG8r7WnLKrxcNgBs0RWIwUi9Rzs?4Z>vwwrJM#2d!MDtL-b)Z(A<# z*j=kRuNDLUm57nWHnuB5Y?udJ@#7DSH&Z-R;zzh$tuo|9@M6{DhlsTKT{h2Ab7pQG zChc4a-GHlmTvHk|Vb0{i>E|z_maEqTN6n$vJka+>hdgKhT=D~`ABJVy!|Bgn8NI$6 zYR3S#AR06iPX+EizcJp8DAaz>m)Crb^^1rPUgo& z+OVji`Tr(h7*HedazfFIeE&F&Up_cq#DrGlAdHIvSw~G>Z8k)ly?}Ar(*B`hKxNw5 zgM^6vZZRQ^9=OO9uD?D`g<(q^hDmog`il`Q-?tm)K=^k=#79Q`o!#Ncw!;Q$tjVvL z#BNpK`3Go5Tj%*RRo){U0V%*mTgC~H97u6K=(Q+o>d%CDuRJ(?UhP5qde7SvllVR2 zYmn4Lcmxk^veAdSn(;seo%hoopJA9ZI%>dq4Ze9oqFvDKInQTi^d9tedcU{TU44G} zYFq$f7;=Vr3OPJ$ot+2ackz0@gc&#TM2-f|8)5G`Vt6|7UeP{7A!tWfO5G@0>mdQ# zcY*)e-~`ZV_*Lzz{2^vp3&evx*#gf|&?`LCvi%(nd}O5e!y(VN4ssEt_LmjK=BQ;* zKg4G{_E%6{V_`$FE|_vmKBSZLgs+gQe7vvMrF&8y>!uXT5B zeWmIdVPG?A4f6Edm$m-#0*vTD4ymy`0s-9`1~ZQ43en|?ZVc!O5lID?9EItH$Lp(k zGbg8cw5K_Sa*SdIq6VL}{<`JRir8oB#pCA83Z8_wpO`cnP*?~@%HCJRKQ16WHt^71B8x7CUc@0KZsH8>$mj)5> z>2C#k>tJ}?k$ldwimRP#!8==GBieB|QNRo_Fj4Uu!J;MmKTSXzC)M34(DemgYO_FR zY$OO0GzfLY@am^w2NiQHxNCf_Igw{d^>{+wcc>3kw(?0tUN98U_!$3x2q$8S{sBFg zJRzjztCGOEmW!ibC`xXsYN=0`&8@CHK@LhRFJ&fM8BBM2+K(v8HO}E?y~iJjDY|T7 zrl-ClnmW3nEBc@~y^7`rS<`LjZcA3|EFaNcdhUjoSau3bwhme)r{oVxruIheuuOU75aB`z=N7mY|YdEeM1JFa}aNTEIp7O8` z+L|}a24lFe7?9|t+=JqcYPGeYj-@ZTCjaRNnbO;i0*GXl^~;g4Wn1J;NVg}>IP$4U zs*hSw$OWr*76s7CFL55MR>HOJbRRrD;pb4Pvk{ha?|;+78tV%kYwS@K-9PvcV}Aog zVyMHO5`YhZn(lCglO4TaPOL!wfm`9)+z$7qA=yfec_gWV^9=Ije$02E!4xD`Q@!PB zy6qIMR<gbSVYvk!1?M>QKqcely}aT+?KCiI_G*Cm3eKX;|NAiS z?-!Cat^B3s?@c}*H;!6x&?|KZRGhA%nfK-nhLh?F2BXn}U^9Pi@Sgc8I3Ec^5%0^_ zuu6-)eX0+QliQ<_rUJA}D`@>f`c^>1z@#YU>U(+a!6T)$Hv$(N7HS9z7<58%NN)UaUdWexA46PDgPk3*iem*m;y?V0PWlcPEAIx< z3sECOlKi5R1daTvKMbtOD`$Sj&+;cwZ6ZVp@lG+_a@^@en^y*|I$xrlg24%Cm3-Kr z=(rjI=j7k+cfBUggiH@i`SN&0-8dlw*}sLjqMYimKo z!(FRpdo_A-dV?_ak{?Co10wXNsV(`FH#DrC(HtC%vrL)w885H4M!RT5vg`@r(g&F`GRo* zA$6{tvQB4wW*UHoP42&j^El>FNFi&)Kz(#|;`4R0(tj5?(%RvXBJJaL>js`ClKB=3Z2nbQc zX6sUCMnNkW&*WZiZxnr{tuJq!Ieo?J<5ADE9m6Q%xsaA13~DT#OV9iOu9TcG@nkM! zYlMdXnWb1xfAws56_YZ74c6YkTLXmt4jW2_JtBA{`Of(paI-=gz-GYoR~-J&xg4Mz zdbM<^z-b|ALGt*{`n*tSXWpDn*i<0-_SPCse<^&40}2lIh>~#t_!q z2m}?{6dPBhI~*;No&=xdPTDt0(OFfC9t=E{A^C+>#GRm`A+#iBvg+fHJ~A_ucZ*CCkg11$+r{*L_3V` z_T+=XsXy5*L=zCOe07=z2Xh^$6`wZH<|}qJ^#thVgLY4kOj)&EBl;T7p17MJL4wV^ zSQCWeN^g9%tP)FQOn@Z-hz5!5)J&SJ1p;FwIn8J2{!ijN#~x_j=s~*^mV-sKAe1&K z`c~s#29L)srh(FLUr;@pM)A^6MKp3CU??fn9xsXL#6q@qx68fCYhOF7Ex1f=Jc8YH zcp1MwUT~n{_%`4}+n@B3F7T_G9V=s(anmm*dhp6$#4AKS3K9 z?Zm~5vv~a*xZ!sMn4MwF4TpVG!-cS&2q*TiAGA4xWy;VD8c{a*}5v3vQR7|B&=))yF^m?5x@#}Y zZtBXl)c_?bgYgUI4<2jsG#dxdUDsL+t2&Qxq`Zz zxk}TJ3_aTI>3G2I1t+(gFwc{{*s!Tw;l7B&Bu&RnQ+|dw4SzxduLA44IE=bXZ2jIV?}6J&JsMhyYU6*SJg z&Ug{d_#}-VA&I6%w^OOaP~*z85Q!C$5Jcbi{=)YCIyr(^uB03ql{zxFdfF1llM@pV z3qH9z$_BlxyX%L6$9^@M&&Cpl^fDZ`qW`|+fF{5$WaoN8zho~H*;5}_&ZlqKP>j(nPux*qhsW`IV#DQ!?#Zc5bx_!OuVrHpI=WBX_1P_ z$_}Wu-Qe%E!j6UfVPaxcIrx432ktN5I{5g0g_137pO*gP6^4I@R{KYY)OH5QvFJX{&pdw{@2f7y4ByLp1yKI&U(@gmGC+7R4Xwmw8^Tx_EEH_kIRc-JV0y{k;LR*Lw*!qwqQA+hKSPEcYPyg^wKFU?xw*5YI;!Clas+18XyC%P^lAOVsk=#neiiV(Q6Lv9Vuh#B)7kj)GD#{iLk?aHZT}%JIt89*N;;+xg}Mn z^x!n3jT|HO6+T!ka;G71Trh(z6RGg$9hyehl{Z#flx@@GgAVX__X{>vS0|AoflZ?F zM-mt>If$IClZr~r!gbI>YaY78-~wv$GBxg^?J?lU2yDu1CKUl zCo@p^?-vmLeqMcVr1%!2=v=Zs_a&@$%v?dB=eX02&mdN=GiYIO`2A~uW^zpJf-$cH zBbYOjP%FQ?OS`H*(Y#d5wZzxZ$<+Sspf}ndhcn1ou49ZYs}?ZjiN32_5~&q8rQM8` zsy3&3B7pR~d6U86=a`UFQQ)oV@+l72ogu!z9?XBH`VZg6Q47NdqcU_Z-OHFE zG^R^`9DnRktTDEYi$YpX}J?X_jT{LxkBY$3PkQv7 zQz{a@7LL>9*5LKlx+{W7sUWHmnmI!5Nl4H-@@u`eX*<)d*=6S+&o?C#sWY)RKc|IrR_c+=kIOTp4Bk+e2tW_hq#5XEC1s z33*0!%e=jI@@z2>`DWJE_k7i4qgq5YH7D;oDVUb7Bp{6xsAScc6`~h2S_&@UCZuN8B_p9}K#i8P12XmP3VfLSkwj~{OdW|;aRv7xl%WgpfgogPkjQLw8LF8UD9 zU8MyRQd}JTyOovxL|h;HX;xMc+U?|S;J`I-CidIVup&ZIu5W;~jI!(PE`r7ge6)o; zu+w|wE<){))k_TMarM=G6iz}YO@1LyQ1^EzG#<`h$)t^FuRiH({2a**AH;~0oXj14 zt5CHgyuFS1Q{uR-T@EDftQTyH+_iru2z=yL{OgDxKlUtO<)cR}x51A{kXYHf+ z4lg@A%^ChAY_xIs4F{Xz%(rL#`Onlb{I3Ta<$sx3ROmSUo05oeI_~PcUXeqyxQ7R0 zMr7@9T9Cb-DX~Rp;3m!^!RE&eOpN@nOcU+CXoW)m>(ljaa;T9CdGO%2t0|?{9(9xjZ?gV{k{lEsL%8y5g~FyYi1P zJ0ExNd%a~>B0U@0c3rjG8R6&QLNQS1GX`NJ@e0QOmKPIm2Ti`eFmxN>$Ka&&$H#$l z--w{D-@Rf90Sjx=gbi`S8#sTC^uoD_t8`a{q6sq6|0r^eIJG4u?MQc1Hd4x>t-}c6 z=LOLhw!JB1xB-1lrrJ|DxwtJ$N`^lA;IU+1L#3@VZfA0W-#i}I_dfKNwI6s2A-U3p zaoxDy&CmP#{w}%Ag?Zwc5kdDp4mi;Ma{kGudQXVKP>6}|r3Zal0_81D{4Yh-!2A`Vk|%mmlgG|1nlt>c$QNvgc%R??BFA8x!rEJI36#xe2SKZp z0aWt5LRQuIf;%QFZ2_ahvYlbk(cIz_3p@k6M6_fmJzMajX3zqOF3^iY7laMra>+jOT1E8$)w zzps(TD?qUU86^-?IvU;tRpR_=Ps@c%r9y@$>i@%3no25b)XA`u^pLgS_%C0i0 zPEW%A`jMzIi6*aj=DDo5hPvt6oqXPPyq+7lMJa_=op9V`wK>R*BOmW`_6dK*Jgl!SnGv+zC#CBI~eim%Q zyl7-IWTnkv_jK`2Lil^(zat1GcdUZQq_LSa{pX|r{Xx*^60Lft7En|Oevamw(G_`3 zwjTA(3mvG_MM|xProG_Y^^M>&ciGiWN)n_ND5bsaBHcrpL+|&h=RPhgZZ>q1AaR&` zzxRwe!7%%9Iz1>#aX4yD^h9D-E*JqHfm6qV$&z>t8h%Jvk$g7JervCF?bCwV>lvh* ziM@F7mNW3K)c|yS6&EyYn64=ov)aC16Jzo^S4)U<6q2CS7PntH-uP)W!^ee+lbmKX zr!VSm=eMJrB3On?-x|$i6=K%pbyQqk%`~n&g<1$#%l;DDNXfxTWfUEdi4c&yaVn3p z2!lWE*i7$MuU&(CiP)$+Ww?F0*uL2fEVyUBrg9DIS?W>BAHorv6!RM=2Q7UDw~G7v}t zNLSKbN6r!lI9V>^zYZ_8GQ*zgOBluk3rFnBcZZ2Ne6vxjWo9K2`X>%OEKz*slDyBm z0B6a!5d0V-TyAv|$>QN)8QaMnGhu-hC#2wBq`++niHQ*^VMReeyh_J%@j$%LI|C3? zD4=4qr!sfY&ZE>d27?%PudIFz;OAAdjsDB`u%D?K2`|%-6b(q8QbeuKCo+1Qdak6> z6d1-D?J!kSaIV=KA9CYRhhMJL)^Pu>Z{ zU82z3OR)irVNEfh%S)|Or_i9hWu$rhPndCz2R?H>ir)=Maz(!asdL{BX#MuA{F^Re zV$_l7EPRfQ5q?xbg(LPqk)hxHvWFh^2g<&{JO0; z>=dhoN`1_0g44i|6m8CmtXhfMBD*HhsxzlobP9j`*-9n@+=)PH9K%ZZtK`}6&m9FD zerC6!)>NAGMwbR6OG;`XBC?$B-!lh~Dkv)DUAnAJ15p)=r`RUFjH%0wWbWF+qJ!mU ze*k=fY6sJmGnVpDdOjEsQ;BXG4nX?=9=s+kJlDG(wz3#|c$d|XGsM)Iice6Gc~3d+ zQcc*zIa^{ab5=vdpl@=cE$|kwAsFiN=53=5mtEXDS?8weoEWPR6>-Dy{u=dbhur+$ z^yOP&Y{zh@C_XKhy#kqSk&0#>r z3jG971J-gfG=={k<-$&*!pGjr+ zSPm}{_WF^W!tjsG`~?e%ibzuGnE#BM&rI|M%%@J*8;#`4xYu9HCkf<@G;pn=CvIW{ z(;U4@v{AMaaMJMKm)gn3NU$%sD}Ggt`b0tsNj=motCs41^O2G&9=o)RiWi=if8*(E zU+$y8)mk(!QfENBrbe7H0TJXFB*>pMw-pJ)-o$J|{KGRrsSzD1un(k4)!C<=h7p5D z##ibueNeko1qT}gMDYs1;Mj`grs|lFJc`{2zQqf& zMP=WI!-yAaosL4L%Z)GZ=D)5HqokA=n+Q+)l+Y;;ltaHFm1H2H7HK#zA;jK_NgWBk zKr40z7kK31iW`rTA%&E0K+!psj1|vcyZ@9^h~B<3PkqVc+A5XEKua$Y@HYyy*^T%VM5N~1NB^u#;3 z3kGU-=g4)i*~8#&_C}tqS_f8;S_4GeKMSj@dWmhNl4yu>gJHzwFOpg3%KN(Yj+3Pj ziKRLa#r)LeDcp510o|_1Ai#nsoek2{%O+7xdU-QQomq=7t!}lgkr@U2`B%^B=_K>R zw_ZV%Tv8+3ZV8EwWdepl@6&tfFkCD%sS!%QbtkK~XjzATEIBpF`5B&sCw7fD>`{PO9iH0N`h!~@Ed1T4ZHjqZ6g5EqAxED0EUiqAfBv{p+ zHn+@16{!xd=1t}*0+VsxoHdZ6azpPHsfQ|uYi?UTh>OaYam8osfN(wXT@&##(nVz= zN)*pi0mLG57a`KcLxUvaH3>Nv9#ma0 zCsAfc0WNMi-vnx&MdSR2;}c@kN3S$miw+87ep?yNPh$V@t2h2%E|S#fYx1n=?MRc$mglUyh(0nfW!MUi`B*v`A#drQTko15-1H~D?EUwu6Cp)g>f%E-!vWtT2 zqt#dEdbuRRUt><6ud_y0cB6Yc?Fnl%^j6Ac;3({sqR7BH zvIf(Uog8>l8m>nU*HP2EX37bCFI$m?6>eXvp!QLYQk(xJjbVdT<$*1rCEhS{HFJNG zjl($}gPm7Nhz&Z9XnI?#UK^;y;eT3_5S-V37YoX(69;_D95vWW37xXvbtb0yik{71(qr3uiinoAR-Tw2uX*eP#6B9GV%TO1$$U@HAMvwZ)^Rgg-4;OF@5!hr~ zLw(H=(SSJZUia#dg{LS#cYh{sF_)=oL8eEO1NoP`!8$YnFmb6Veri4%fPS+bkG>q7 zHr4(Cb7b$!I&B7=i)PG{38F~xfy(hn4M5D|Xw7=Y zUoaRjH(2t)EKhpv5{oj4=&>1DQ_w%vCfUa;J$;m`MQWQOLK}{?rx6*n!7`>JO0u=F zSV_HjG;n0P#2a6zZ!rX@ND8kTAk#%f0C$$uoB*mx9;Q%>khIyw)1F%Nwl9Y- zyR9Up{1wAR!q-G{Q?^=@wU8Ho+eOTHs)fIX;)dWlsx_l#RjU#da{iKx#K7KaT#>JP zlv+FN=ZS~PPEaY!5vGy|2#c3Ln;5y`!XYE6n-7^w@_42-Bn=xiCCG(3x<{(iYC{(VzqR>(MhYKyeWHoS~FhdCCNrh>tudm-a}cneBpS#b1sxLpI0M(%VRIm5O zSX1Jp# zGISoOhElYm03WOOEKY$$kA(#*S%hbj!p^)Zw52U>0W387Ed9O+dc>7-Ow?AD_W4vP z1bLrRDB}E&w?PVvLYBbY%+uPOMzRLIkhcbkwAtWNJ8^LSTk?iC`t2Kd zq*d5VW6iP69M;!Vh^kxa(fQ$F-CCvrT*>1d;n8UN5tcxxoSw^^jyL8H1|mOYom9qh zW?pGCU}-Z>nM{4yP>k>b&1QQ^>v!fnj<`AoN9d0D00XoXpK$`tDpNYj;)VkUmd7gPyZ)I7vdo{q$dOO5+!+qDy2sAVpnVuiv z*k8s5)>YkFDfy;NKQ?e<2VOjHakcNiF;Wd;9W^duO2B!Iw156>N?)N9QTmwx)9}aH$HALI-W^ zDzx)`6-nEr4cw{JSucg6lSV)*a9@91Kxz+9qO%>K{H#hMbavywp?X$;E!r5fYj{DL zP;toD;9tn6HU3z6WOy4tLkJQe{qGx`$~_T z3oVBi7CE#@WZos7o%KTd%I%?y#(C62lSyPX(D4b0 zzQ#C3;r@;;$(4P0a89aIl6dm<57sB-ha1FrEj~&$2J>Q;%vKkGNyX~Pxs~%pZfXz zuzt`W=TBOYU(}q42Rg^2EnUb_6f7}=X)3j&pkeYCIuzH|pa0+~P}tB;{1U!}@M!X- zE=jm>3T^xQqanv*7sxCIl|L9rQ-fd+CUi;*R~-&jQ`bou zm)RjyI$hjp%UnC@)+&F#H(u3eG87rTPb%M3yC*Q<6sX#5Nu!jAM3ms`9GAG4dL*@U zpI^+#>btB5$k*Ko_}CGY*vosxaNsbF!sq??7e?sTQOmVzP@Pl3dN)g8NJ&WpwMr`3 zeLLnjY77w-Z|lxAn*@b7Bb(byXlHEjdyjX&JqX{36<@Y3j*dze)9Ciad$VPmKbblju=hD-O36Hy%vA-(PZhIR140hbGN42fu35$7W{Hue@Kmf0xPjCV|7 zdv0(w(#irmFX(e=Lt0W&SU6?Iz|j04Rwx#+^+x281XYeoy!rQwpacYcX=n-Ft=qYD zoE3jnOHai>7K(X@)oe5_i6so`;;WT-kNHNC<~>t=NfWWuJ0sfiihymEL-vSA;X-Ay z@Uly7Z0xYAsdNJ!)ZP0gS!xvb?XFw#E<<7hY2>GndUzlqkDUEjz^*x?#ZPE&Rq&bpakaW}8d?kC0P8+ZOGv1*{=!Qn_w3 zitz>q3#~~K4|Ie#?h2Cma*@-a*$gG$lcr5(JZlhL%L6*gGj8lleI3VTE1iT(Dls^r zpK_I|K-N6n2^HD(O(x*9yvrpuubrZdZOYI=AbBt%rM!#Fq$hewx#%4)b#+L8h zkjwXb9h;A`%vCz&edp0fc@js=Xn_Upx zPn_fl8a=ycH4)metP^axTp0ib+iP||Bg2C@iPtJpiTbSc_P!vRE~U5+N3eDA8NA6m0Yw605He zqAg2^Akm4odRcWt^bo!7C&~Lh-#Op;=8yT~&Yih)XYQTfoqJ}w**J3jCN(8sGi|qB zY!tZo6y(tl2#mX-byNauE%SC*Hz+F-S)f)#Fd=o;=;xn%ryb$6TXDHUD6?J=`ji zipPdG*g%@O_nguL*Dz=Nluhmx^{j8zKDBDSfS-r|tdYs6z$cDzR6x&RENi&v+>?B?`SknnWTLFaM@RA|0gcYdI^eO8 zQ+~_H?lc(Sb~v&(rCND{awm@Io{9_~Xeyl6IMeEjUZH2VFLDh$B*&6*DLy;%Ytwj< z=SrZ*>rxo8IVaZsx(sd9?a2DB@#f5wGcWKcXZIHk-Ae1Ek(fwZZqnwErP&SLXL)od}mg*`Qr;_=u&ezZSZaK-MgI0A3ArB}z*nIv7SapGU@)5E`~M1n(( zKb@xkvVBhh1K686+~43|$7j;M4yCv}vX|mhdM_u_hJn#xqxHOa;L`Mn_c{dNe{vKB z=YEYpFLMSB!(Ly)7TAFwa7Rc&YT2w&NzbdLSH10yY_?yTWY1j0kgWFiY_cuP`yz() zK_8GFsg5lOaL{KLp&wOb(<3rH+=|?AiE7O>Re}@&$;jEQ|7B{lBcWyu!8IvITvtht zA((Kz&eT$G;s)}e132$UhqTiD^(h>1**=ZA@NSv9fRBoLHb}OyVQ{Nd)qiXQ0J>=% z9u3Vcb`PXIt4~F2e1sda?wjrINki23x*cOSOya)3Igont^`ZU4jpp=na-Ls5wZX;C zQSH@x@0+<}ITT;?y|e4RSqBb0rtlSu(P;glxTRtim2@rFu;S+nDYP|I6?!A@VOhs! zaFIFtEQ<%nljmXh!Y180QFKS1aey>p28bj@-Ab%>rfKA6jBFC*3NL$Xr)C_l%N3?f zD&)R(VvtxNOJz|6r(-!X;4F(*die`;{V90KWhOrO-VXvAlAN#tp}+*ARur$HJA9!5 zp42nIkC#xlsw&_VuV3;KN%77vz-{3RGUY1B>) zkMQDk%F=ho!(=om;p32-030T|g75%P=|>Ec|5jxUeyS&()VGfN%e<&`S6sSE!sm+vaQ1YyZ)Pt&2)HY38Bxu`Ayw$^9`-Vi zHDD?!!L!29%ISH=g)KQ6^t3HUqKuALwPL6n;?Gcb5|R*~T_?TBG!_UKo+`CpBC2M) zpW3Z(-COsG%>2rPZ$b5c1l3^*-l_wgIX0Sw9+6kd>;bZh& zEUcIZ8cR91Jl+oRnlu*0NGA{Q$t+D1J_ZhfTc;Hx9+H3=0!h5oNWec z-Di()^x$y+#tK+Vh4UBD?-pJX0))gHFx2phiZa0$c(?nHuOd5b=wj!+Kz78&(lZ$<+aB@yPeRAU zIabj+jF8id|4VI}2+LpAoZa|W7C45A;$0eQAR~oYm%@D#au~T#)J}!CFey1zDgW{C zyYnjBhFG*ZCEsn;1YFU)lcnJ$D+|Z>-9|D*-}d zm}EEhkH|pOx1JQkcJR$gqwvA+R)l}D4@PNo3r72m4qBno!BP98Bs!c&WJk3M34@w? z`dM6#Ut&x?i9tFgb4x#wi+^@FwJ`94ycO_vhR3?PYOO45Hr|H~;!7hLah-7r{Sdbx z!vGT3;{_$BADdbt)eHemM{?<$D{3PBQYlZ~$e6-E0&Wa;$^~_fsA_|n?QSbl=dcx} z^;%~aEig57s!qo)*_1vF6A;Zh9dUKUOA!9a(SR`zZkZ_+5oY!j#?o-q|K^ruUUE+wW;?43pqlDl{+xnz;uPc>*2ME3Eh3+L9BcML}LhQQ;Zl2w9L2d66tyJ{b~hO}BgCC~qp_gLSnWr$py9`w*sf8{akuH9qP5OCtgO@v z_6eVYi648(txhWot453q2>58Xd%Eu(a{*jov!iielGO0XSS)AwiD`eGvC09fWxDZ% z#S%5cN%8U`t>DlzIzL-w|2X{1bLh6SKAYh3XtL9gRIlGsChmOWt$!#9-b($e|OQ- zBP*A~JL{{FE7Q=eW|pNG27>dGVm!X{4_oCXd&N?1mKO5pm9ErnMj~8=is9lV@&;WD zpNyv3YwXe9H{@o^WIQ+T>clvz`({2$&K)lF6dB(oZ5Zpz?ugXEKfOtNGy zV(0Jz@gIZi--kUlV2<-!W?faemhWLGBdw;Nj=g5(iNSM^c0WjQj+(=?SCPYa&aMR; zF#%`@@1N{pq&il!3FBeMx|w=c_TEArU=odPM)>p~H5#WIi4EL5##UX2~LW zx8lqbVlZHBrH6)Eb>U&kyOZrfGejAVNVYE<3gp^$L+LLU=ci42MPLB2W(#kx{k( zgH2&w1W90PBU%xA$Yom}c&^p%Ep#@aZ`5~N|J&N2Hss!gZ{Ep6zeNNBF~3h9 z{H^u!)h9beA`oYxlO5mueNMHR)w+W=RF) z99Z?{-8)(B)}<^~h=QjGTcYzP6xiobxnl1ZEINW|wpF+-&d7Q>z!41CAYMNAIpgEs zxA}ERG_d}GBTkpmg^lzq%_v)*_HN$CZ-$J$Vqa2?B>b7>5--vj7nUTCee`gCF9Ar` zD9$k(rrgZmRelrZmhFGL2~4Zpc!KRG=C$-1Be#L~ZXSMgG!HOM8stLHjqK1x04L*b zf;l0!V2+Dq+C}VH?h*Vee}IYiu?cH)goN62|A6I6uMZf-#mwM&%a4yW!JoJ2|}aZx5~@`$+zrJ9DTl~`l1n&Dfv zDUoWwrAW0q%_ZMApyUWu4+Sxn74gmeWP3J12gFjdMqpVG+vWX=FALZ0{|JgvI?34D zXGx~ZIOk&KWHH#)sym^2C{Y{9GuwK7?k$+s{t9uqUvgNMiSJa2o{s%;b}9*L>i%T} zaZg^s3;cJG60*jad4_^@O9^RT?)LCNN^l^OuxIuemtdd`$@Q)cTwx3us{2|WZoIgt zktO`8zSetHZW;d>*Szu;5B)Rc{Z`z(&XUtQW+lqnwl8URKukG1DxaW-J8`uckN%c* z)nP0Fg<(M6#J_Bw;FvFOy6gr(8VL18{LzBw98?+oXRrRZQmQ_5w*9N)zr^*THo^M; zEb)Jv#*L#5eE;S6OT`p2XRjmv%kiHM2I7#3w*S*P%kuvfY|rv{8~+_4P=|y_E9vvR UhN&h`_R>Ys*3efkgFbliKkgxXn*aa+ literal 0 HcmV?d00001 From b347703d8cced4ce4cbd7b613295d74445d66795 Mon Sep 17 00:00:00 2001 From: cthunes Date: Thu, 23 May 2024 19:35:56 -0400 Subject: [PATCH 13/32] 235 fixes to support standalone-compare API plotting --- R/tcplPlotUtils.R | 3 +++ R/tcplQueryAPI.R | 2 +- 2 files changed, 4 insertions(+), 1 deletion(-) diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index e772a0ef..188c851a 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -6,6 +6,9 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ # set order to given order dat <- dat[order(match(get(fld[1]), val[[1]]))] + if (getOption("TCPL_DRVR") == "API" && tolower(fld) == "aeid") { + dat <- dat %>% arrange(m4id) + } dat$order <- 1:nrow(dat) mcLoadDat <- function(m4id = NULL,flags) { diff --git a/R/tcplQueryAPI.R b/R/tcplQueryAPI.R index 0c5127a3..c6999cca 100644 --- a/R/tcplQueryAPI.R +++ b/R/tcplQueryAPI.R @@ -37,7 +37,7 @@ tcplQueryAPI <- function(resource = "data", fld = NULL, val = NULL, return_flds dat$dsstox_substance_id <- dat$dtxsid # unlist logc to conc - dat <- dat |> rowwise() |> mutate(conc = list(10^unlist(logc))) %>% as.data.table() + dat <- dat |> rowwise() |> mutate(conc = list(10^unlist(logc))) |> tidyr::unnest(cols = c("resp", "logc")) %>% as.data.table() } else if (resource == "assay") { From 6b41516ff5549966b9119cd6e5c16f3f686a9e32 Mon Sep 17 00:00:00 2001 From: cthunes Date: Fri, 24 May 2024 12:39:51 -0400 Subject: [PATCH 14/32] 235 Fix unnest to include flags, exclude m4id, add is.null(flag) check --- R/tcplPlotUtils.R | 2 +- R/tcplQueryAPI.R | 3 ++- 2 files changed, 3 insertions(+), 2 deletions(-) diff --git a/R/tcplPlotUtils.R b/R/tcplPlotUtils.R index 188c851a..4156ca20 100644 --- a/R/tcplPlotUtils.R +++ b/R/tcplPlotUtils.R @@ -54,7 +54,7 @@ tcplPlotLoadData <- function(lvl,fld, val, type,flags, compare = FALSE){ if (is.null(dat$flag)) { flag <- NA } - dat <- dat %>% rowwise() %>% mutate(flag = ifelse(is.na(flag[1]) || flag[1] == "NULL", "None", paste(flag, collapse = ';\n'))) %>% ungroup() %>% as.data.table() + dat <- dat %>% rowwise() %>% mutate(flag = ifelse(is.na(flag[1]) || flag[1] == "NULL" || is.null(flag[1]), "None", paste(flag, collapse = ';\n'))) %>% ungroup() %>% as.data.table() dat$conc_unit <- dat$tested_conc_unit } diff --git a/R/tcplQueryAPI.R b/R/tcplQueryAPI.R index c6999cca..d9629b51 100644 --- a/R/tcplQueryAPI.R +++ b/R/tcplQueryAPI.R @@ -37,7 +37,8 @@ tcplQueryAPI <- function(resource = "data", fld = NULL, val = NULL, return_flds dat$dsstox_substance_id <- dat$dtxsid # unlist logc to conc - dat <- dat |> rowwise() |> mutate(conc = list(10^unlist(logc))) |> tidyr::unnest(cols = c("resp", "logc")) %>% as.data.table() + dat <- dat %>% rowwise() %>% mutate(conc = list(10^unlist(logc))) %>% as.data.table() + if(tolower(fld) != "m4id") dat <- dat %>% tidyr::unnest(cols = c("resp", "logc", "flag", "mc6MthdId")) %>% as.data.table() } else if (resource == "assay") { From 04a2c33836b72508fd14a8608730fe2eab3fd487 Mon Sep 17 00:00:00 2001 From: cthunes Date: Fri, 24 May 2024 13:42:10 -0400 Subject: [PATCH 15/32] 231 added standalone plot image --- vignettes/Data_retrieval_via_API.Rmd | 12 ++++++------ vignettes/img/API_plot_704.png | Bin 401951 -> 417208 bytes vignettes/img/API_plot_standalone.png | Bin 0 -> 336962 bytes 3 files changed, 6 insertions(+), 6 deletions(-) create mode 100644 vignettes/img/API_plot_standalone.png diff --git a/vignettes/Data_retrieval_via_API.Rmd b/vignettes/Data_retrieval_via_API.Rmd index 771f8012..5f9296bb 100644 --- a/vignettes/Data_retrieval_via_API.Rmd +++ b/vignettes/Data_retrieval_via_API.Rmd @@ -440,13 +440,13 @@ tcplPlot(val = m4id[1:4], fileprefix = "API_plot_compare") ``` -

    ![API-sourced plot with parameters: output = "pdf", verbose = TRUE, multi = TRUE, flags = TRUE, and yuniform = TRUE for m4ids 1833668, 1834094, 1836233, and 1836494, compared with m4ids 1839401, 1842443, 1847540, and 1850045](img/API_plot_compare.png)
    +
    ![API-sourced plots with parameters: output = "pdf", verbose = TRUE, multi = TRUE, flags = TRUE, and yuniform = TRUE for m4ids 1833668, 1834094, 1836233, and 1836494, compared with m4ids 1839401, 1842443, 1847540, and 1850045](img/API_plot_compare.png)
    Supply `fld = "aeid"` to plot every curve available in the API for the given endpoint(s). ```{r plot_aeid, eval = FALSE} # plot all curves across endpoint(s) -tcplPlot(fld = 'aeid', +tcplPlot(fld = "aeid", val = 704, output = "pdf", verbose = TRUE, @@ -455,7 +455,7 @@ tcplPlot(fld = 'aeid', fileprefix = "API_plot_704") ``` -
    ![Plots with parameters: output = "pdf", verbose = TRUE, multi = TRUE, and yrange = c(-100,100) for aeid 704](img/API_plot_704.png)
    +
    ![API-sourced plots with parameters: output = "pdf", verbose = TRUE, multi = TRUE, and yrange = c(-100,100) for aeid 704](img/API_plot_704.png)
    ## Standalone Format Plot with API @@ -470,17 +470,17 @@ tcplConf(user="", pass="", db="", drvr="", host="") # add tcplPlot(dat = api_data, - fld = 'aeid', + fld = "aeid", val = 704, compare.val = 704, output = "pdf", verbose = TRUE, multi = TRUE, flags = TRUE, - fileprefix = "API_plot_704") + fileprefix = "API_plot_standalone") ``` -
    ![Plots with parameters: dat = api_data from tcplPlotLoadData(), output = "pdf", verbose = TRUE, multi = TRUE, and flags = TRUE for comparison of aeid 704 to current database version](img/API_plot_standalone.png)
    +
    ![API-sourced plots with parameters: dat = api_data from tcplPlotLoadData(), output = "pdf", verbose = TRUE, multi = TRUE, and flags = TRUE for comparison of aeid 704 to current database version](img/API_plot_standalone.png)
    ```{r, include=FALSE} end_vignette() diff --git a/vignettes/img/API_plot_704.png b/vignettes/img/API_plot_704.png index 7185726e759959e2a15f9a385f21e053eec77369..1c65367f9488195ffd8017b9e8eb6c9de52246ca 100644 GIT binary patch literal 417208 zcmbTdWmH^Q(*~O05Fog_ySuwfXe7A1yGs&+yF=sd(zv_3yF+ky=VoRy^WJsW_v`-X z?z8tgtIpn4b!tCV^>oM=1xW-r9Jmi3J|IX-i2*)*fC~Qb0ip;7>h}!gi4@!KpN~!e zNs$i~<9LU^2M}h$^1>fJfTBLV7(o6W!`e$}IDPnlLH^h0qcni*;=_mcd}%RZ6?ff} zHE3t5%f zkV?oFZufppZlCb%iGq@o4&I+VQYoEA)=y4O&R$ZMG_Yay!DYpN-P`s^W+a5{=xq&<4!4r=askJdX1!nuD=X26QhONjwjc{_D4Uq!j zS(G8%Avi0YM$(_%-8{gO{IkzRNm0!9k9wS^A>^D+IhWBUi*8SRk#-qB5g!Q+Z$FP+ z{Hm559EP^vROu@;^#E zA&~D>@I#N?=@e_aM(A&PB0l7O` zBTM++LyGX;_fG7nZOb(_xgGUxT^73}GoL^^pRXdH@;XaYzM)oaKNy+kvB#QU?mhs* z4`&cE{njBj;M2oiKO5RREk&8H*nXH7kef0>y@v@(3K!oXNS^{JfA!{c=BU?;iWQI} zL@x_tY`N)PD1X%_&p)KT{v~OfFgR2*;2xWen8Vpv=S3j#_CU_#a`N-Hy?ahh7h;k> zo!XQgtYF~xpZCyCZ+8`RnXfd{w`)18p4e#CHuCTzwa;CQ~E$~#kA^)1nXEH_(r>+FQjU=1H-lk zUUs~OgUBu}?Iq!1+eY)yb5*J%FHV|<+WPrztYkw5# zw1zU+vE;{Q^*zY3g%&E4J2=xPd}7Vqu2Q6ObNu0TS9b7JJ9>tgU@Jw=N;b8@ z4P&;%iSvN!`map6I$onZ4ygMT0iwUQz%#X72Nzs95^wJk?)b?O#uW~J#!TR5Z8VHs zhInHCSXdF{#j7r51%B-#;!o++!1LbOb>oD>^tFVp3Ijhj;jCG5 z!LMFOffruTOw?SQ1QoA{V;xK1_F3$lwY(vq``NzL$c2bxGWKrmNP=j_#)naiYbaa#zEPJg5_$h; z#e|E}`41ZrXF=bzEnh=_@VBPEesj%Fm<(L&m-i8jJfohM)A@O-q`I7Rj zmywjhaH|5>oqi+|OnfbCK2NYC?QFI-p+Ki0h?_%E8!85yfxe71(4Fjo4>K0N=3*0dYL<$96#paGjXVWz(`etV!N z?Ku*)$4;Qj7mVP?(EVK!;tSsPjhK@bQq~}6t^cqSky6pg6&)Sf3Yf&nMJa(#VpQO zD#zYI9I*)zc_Kra+M%(*#wO<&-e+wZ*w{S z7+`4WsKvWD3^P@!N9rPtq}ve*W-PO~s3~jluPdDQ{(JI*!l%TyUW&ser37&-9L^75 zS7%B#caA^x;`iN5;a+^v#Q?uc>&ck&)9;=noGMqvk9Uab?2&x3MQ3q+QBUZkT$eFF z&*(2Mq;A%#<#f0jWsOt7LT~kf6A@>$H{NjQl_?HcPwQJwaRPY{kW+WTuknwYWCqT&Q#wth-={`p6( ziycUANPn(bs0c9kf4`lj4$~9g?#AKZ(;TrbBiSdLHFUq}ZvV0ZQ(>^5C{CQ84(m%0 z956gY@VSqLx_pwSYMp9TC0~>{@7gucy5ItFO8KwI`gV;f7w9NC?!sAzXh!mAXU=@i z{hZQHbpVM7e;!`H#nh=WL;S-13=!K#esGICs%;N(DZ>ac%RoV1 zP(X$DQ{PXk7atg$iJ>bAkT$nB`!(@kbB|jT$|*b(Tkt&o2cNtPto|2oiMXwETyrE7 zLd};?y1h}ae}`@| zlYHUeK*~^hW^PoY_FgWa^nKZ)t%aqE;3177Wl&TO$3ZdHUZP_kzQy^8;Q?dT&nEtA zXQsba0lrx0Nz(pO2HT%Tfo9GLC#Y5*JI^V)6+wXND;#kWRaN2y8E>(Oz47*d-);^- z{I$%`Yvbj2lYRw0?C_5C2hHe3@&^A=0(PEQF=3*<<|i|4b#8<>%(H>xoN{L8Ti>$B z60UF`5``i`TkyTRiXiW;6=oMHKlt=o6tnUp{oeYx#Y-a(b&Cr9jg05OIs+|4pN01b zZ2pp-$2-$eAQM69ljsX{tqJX~!E?1%YL65M)pF3(k*C_G6sdsZ~sfWvfA5SxA z^&!t&1I=Ep!ztvCU;(lhh=1YXI~kM}uRBT0SE2&#DH#ii=Bf_RYdF-fNIR7QCAlfJ zRpYaoWKY2ul6ni68{)qLc>eRhXF;W0Lm}?Xbqe^`ZOPF!2e_n4-QKCOnM>6f!m3Mg z4iyBOFo2AO%fF~zBk(^9zEe87yQcl%ZhOt<;v-16ObCo}b5Jp#1nUk`Smd1bivbGv|EdOcu-$dvxCMJgHHC6a`x?)xJa)5eS3BfYB>sVBF zvU#BPp&flVTgo;6CMD)<>LZ^(F4^@^6eZ@w7kCT7Y8DP>i}_#OtF1 zBfsXWCbmA%9-8H<^YMXDpT`4;#~C&Efh)0FM1;+_5^omDvn$il6&FI=1W}{|E5>|H1t*hFdnc{X3o`V`yM>imf1Bpy zJ!&Txen1kc(qVs)0I&H5i+SGm;_@90{VIP>qMk@#x~+GN^x5I$$f#9`tEW`OM1>}U zRlGGpC~QCJ-e>}p>Rvqhz55sVrrsp+SWI^1IbK(WXwn5&KaQ=y+e590Kwg5;=?E@Y z?K4wFhf2>_3tfrYVCG(Pa}uY6@jJ7&&kGcs8Do5jHf*0Vw1r(^TZGQ1`fbN>1n;9d z@mufT8K$yBW2*;&>)J#>i49Kf&-C~g(3EypA~&zYL>)>y%vBr;_FpcwF7i8C0inaS9t*Appsq?IZdm9_cG zM^;{2PNwNuU5tyaG&0zK4!!&;B2(br++M``$TK8OQBN61EoG8VkuPVu*gjhDfgRiL zC(74_FhO~6+2UTe=b0ia93$W!7y>=*wA^)~bxcg18Tt{&K3mF(Wll1E`jE20*}WKn zwZFMRd~HsaPkW{W`vr+r${`OVwf%{3X!N}F#nUW29QB!0Xs?S&o;{sR*AC+Jb$kGt zLo!7@oq~eQPCI3p-LYyCl&!2%0kc+7O<}h&f1J3ftT5nryq_sbTpr~q2(m(D1I|Tct~-(}m0~u&DNi%DuZ7XC6=li9hZSMUB!rfgA{J1y&q0(nvt6gu#)^yi z@Ug^s&RQ$75>g~s_ntf%L$a&lx{b);k2el_MD)3;s5~wl1K|FCd!OHT9;hs&1qG&8 zb!9iyTuBowMspo=W%Md@v@WM*P-M4rgL_bmO&lmeg3`xFJD8Qt;1;RUEvuWi)IelF z8XmgzWsKaGl(_%ER9Adg{2oX7YduTTp;2J(X~|&u^g=C-N#G%S`g1O7f-}azfU(X3 z%c;fDlnQr252_Zxfzo8U*)V3wQ)%t{3YAIX28G0Ies^GVUS7A}d4V}Ke-jK)XCpKV zF-!V>gPi8^d{Tg0gw<;{?~YY|JYmpdb`dVG%l&;u3F25Y< zyVMxOfJ*{L&##Ls11aXOy)_m7)*9DJT-wAQ1@xqmI#UmjNRzXKvSNtHw?t%#HLH~3 z-#^L4Megr!*_*TBVS3jp0V=aCt3DQw^zR2c`#(5?5hZ*M7}rcn?r^dCIyK!CXa2=p z^$M*kNp4G~ZXh#%R|gNLnPoUr#Sxljy$UrTFpxrv$1PJP$S7a6?%qPl=`&z3y=XOw z)#ADM+S&V>?C2mhVi!))vWAZiBwXrKpCNKxDu(nm`9~l_u213Zu|k0Y`R#GD@<<;= zgx)E*=B$YIR|v`Vt{(Hp_8RBQ7h+A`3h+nnVd*n8p$;7>IBT}A5-}Yz3W$BUfI_rK zgwxgZ0t(}YIa{0s_P+h;>0%Hg_pq?zf&|-f0hOfeJi8>W!oHiWR0*!325&wBI@-tR zqqqt-Hyyy!(=Dz=6lmL6i0<@ELnvOJ1McBA4Q9XhZD7r705NButu#a6phP&1kZf+Q z?1(6oUm(i&Y$mGU6gCO)_Yt=EPB5587N4zt-<5;0 zOI&Yoj4#)dc%EB>IWd!6w^QVwNjlUg0R7@B?CmAdRv@3VIVjyJh4)Nbnu;k5`ITyIFsDPUEx*~ z28VbSeJsJY40E)67l$&Dw;9 zhJDk$`Wx-rDx-=71ljyYRBB>{S#2zdUt&P{d?jh&nD2?U6Gf5=Brr6SP7U!Cj;%TD z+#{+gCMRQTkxN>=Y1zyl4KwG&i$O=Ni*zN0~U#>W3@@M;g&Y#NqUb-=R0()>Q_C~3(wk|#=r z{0GmOsA(!A*RTz)9T}aBW?U#qY;BflaG_E9L{pC!@f%WjK9^itTj@Ecdn4nt_O5@# zXL3Kc+J#N|k)i`fYyq^Q*KKu&`~h~iG&)8~A7s_@<;Hvpr7J%Tx!f;VaAw!OR1kyJ z>q!XP1*ygqUu3(&vSNF*Zz0;_DLX!>i8~9`+}@xELwjy9*Yg#{qQ6_)&)09s@kLT*Wjy# zsyl71yZtLLzMyN474uSa54Hn9kaI(a9%e+!V=#HPaB=p=>uYtAxQDl%SZ>wSC>aDY zw${5jSVc~6_6^FeY1r|Mzsb&OYXkFHaqWEY$;mJ$)Sua`H($HsrE4xpm}j~)#0_k~ z959$wXibbo;oIPWKhb0P9{dBe-*e=_JUnStS~;r$1ZWe!}%1aoBYVVo*+S7Xw_ zW5&r1I-yA_xpCJj5^Tp1?}Eq#Li_8y7`INeQCx7*n3v3iGjKE2ZUaSX?<@7fW0# z-q&U-SMAQ&F zuEE1UXY=y7Sw|tJdu6}>MCW>2Y}|nTT?nKxOwLGl5#c1dOoRp;YrhTri$ zBd>pKQg_4JJ86dWK|XG9GB>33X5KF=lGoJMyg*;BJ@q$v+N5(O><@jYSj$2PWEVdJ zJulpu&lqux_ls{|6%=DFma+Dq`fMrH1^6=k}~dxoY*qoK4{>k2uqer4y5= zPI{Su0*OKFKEn4D0j2LMXgPbqf= zC)}l2IaMH3x^&8vJC9%yJVt(WHV|Qp~0wjzPA0Qq=7HmGdrSp99jg zS1J<#VgfiTF{2g4ua_6d>1$1i7!&D|vK)lD&qJ)%YA<~oMV=ho)SsNQX_Ipq0&e_X2gsq>$D+QMJj(iv(IQc`Q0-m9FKH(# zce~qrV)GSa=37QKM{Y>sqXkcDa98H5{>#scG1>;A40*9Y{UEB{VY zL2mt*N-}%fq^IRWD$2WG57**cljXkOJxTe|7?G1&y~hOBJI(h>dRCh2NWQYURLuI? zJbjcO&8JqG5LXCY&8}r8PM%)R8Dbar&bukd7-E%s9Z`=NUCxw{QIzTdk(|hdFYGu%L95GN8$XaU$k^;6yL3 zZi?}8HS(r#E0&LwH`|U^>gjahfhXkI(v$N8xla=8?)f{sZu|sLi2c2Mlp2U+Csa)R|PA?wE`(8 zy*tF;q8NUQB2kQ_r!x2&!I+*9qjM&*Yhm;RP^P_tKM*}WmqM@{6UR~0^$t?y2U_gS zvGfmYtEw3EnoyI6?45A{SKqBHalb_4p}{#atfbDT%Go3qB(t)K2);LvaJpzRLaKqh zirt8(VCqNY1Ndy@bQ5X7tGfas@TrLF%Ya`ww#s4-M~YEvKuS(eBNO4Hl}*{-r~7^d8UqvZP1u!R%E3DBB&l|%;P!uJ?#QdcwE zZE=Ml@zL_^8D!fQC^JLpj&>m|;}=5F6#9xBqTX&sIxDFgRS*FstHpbR{_z)g%41_7 z74~xKsvSjupCCvu^yOx*!r0D4Mi_4b`N@rdn#!&4w*T;8UBt9{Cr&HXf*8+$RNG=nTQ+g=H2S6{-E@$~w#;k^v zz^_V2p@@VIj?|unq2&CQy^*wnTF9pu>IU~E>~P>9rQNc3Jtu(vI$ETxRHaF&laco@ zTcBv_=hWS~Ok9MVbb!}+!a6UyqM78^Y->mMU!R{M?)aDrEcLXr$oYqZd2Gc6HqH{S zFk}ay6OlVAiS8!?r|(+&wR>0B<$OxHaMwpxT=PNO$?1j+5r`zO9@)by(GsVPcB9I> z;!ia;#DK%=$FcUjd!xVJgp=I(gc>~`vG~C~V@jX~bFeoyX@1)$+6P~L7@MnMVKRTG zbln5hE`=vLNb!%gTJ{jnd$-~v!;c229^gTouOXMOEhI$%;YQ4|?`N!0+f8gHI-nnnViwAq5@f16xj*4yF?*@D@h_n7_N)$5~xmMSgGTITsQy z9dZT;T2`;;6lNwy2m$cH^Of-;FCl`LBf%l+jmJ>BBh|S=N}NUPc1zT!{AGtraH4%l zUTpXw!U%W>L(OJp4&%uN?i{ZO$DcEM`dGcHjHQ&_+ZH4Aw4e>DhiSKFBW%S-Zr+dp6Lu|ksDjbm#PAq4D z8hiT4&WGRy@0E#kbGiwgzlS)U`RsSf_;=Yt_RJ_U>c(0rPeHP_82CvkY2N6lN*Ig9 zfn1?u6!AUU)_nU|U;7k)I~QWv%WAS_?hCS=N7mt>aI{Fq?zZCQgr0={cDGLBrDos> zWN5d1IdY6P$_k0gBuHL$H?;ZZt#XjTWORtS#}j$=b5NERs-6^gAc-Qo%B33d+X2ao z1D{7b$>-4lnI30%hhX{ZDk}#&dBs{BPb51&py6&76jRc#T{f;Jdsu~jULvAAZZUSG zUHeb)!fSXxp-bO8n+r`5i&kN8CFy$xJHfVt5BzRK_p#%qreuR~!~6yUF-er12o)22 zi{>|Z!_P3kY4DF%pJOgQDqhj}U#wqd!#~+vR0WHn~5*2dghvNDsUMekq2i)q$ho4*mBvCcehnPaSS|-D7>PNb38zFZp(}si@=;?^rXp&-!4e~YqXuf?f?*YYj>w11$S%wk#W@XI)-%IAqMEzC{q z^h~dlk=UJSB-VvKuj%J&P)}Bz*4EP5)WJqa#}EsaY{gMlfm9lgx7t&H9}p#AI8hXF zrZfa5(y^(8D3{Y6Kc8?kN$C4aUuc)a)1gg#z;IUDVe7&6{hCt~4udv`d8(i6?=t?K z-~DC3q|oYPh&iAfQi9M;^qG3ae#;l@Om8vrP^Z=2*IQP_h7ZxqDB{@kXVZfe#+fQ&Iq8{R~@Mn=WM%AO*pzjUWYIV&g zpFZlLgBf;xtNCtmZRaYArmDyhxE>UYs6mQKm6ooXbJBPMxRiGT(3um9!Rg1(xv`*k zNZ`U}hs#Z>zDTJ=MMMfomOp=}!I zt3l;>PUJ0MEU4>M+n?tkzgf`oy=kqZYdFY`a5#5d32hGOHjp(mQguCTlcu$dpMRpe zGn=Q!bYJk;*^Sb?e}737D>j<&3AW`(y%tI{&{a6skorz1hLHHwk_eZ?!TH@`il;uP zE!|w-N<4RFG`KpMb80dasxe)s`=OT1apC3S&e>mb>ga&Qg`NVUndohpPfq(yN|Q9? z>`)-wTpJvJUoU9JEVs&{he*XWR$$hNE)<7ebShtonQQ_C_9(iXEy3XcA9}`Cmz6By<$>Q->{|G7}xag-1wc5(8U`qBqCQ* z-^|?=LP0$$Wz8x(IoOCVY)))}8kf1W9Gb-S^FVaM);SX4;f3=C3|qw%@^vNeR*h0> zmBAO2zEk@15!Zlh9brOSm%>8yptfg*=caC+UB0+IprQhQ zeUm#2K2f0NfpSp<*@+p=9&iyZqzm*E$>TCnX+$U1FRZ-v9-l|u!evsxD-Z?+lu&B5jjF97VhSBJE1VD<*q0F-%*tK%7wb^KQsc?(B&t8G zZP87lR>HL*=xxq>$?1H~j=l4PU+6w*`$d9K2Uued_Faf&2am~~#@^@5PUOD}=V;{Zb(I*kQK zwJNnRLwk!L_Nl=8z!Z&I7(Fbq@=W1CL_Fa_S!Nt%ypDrK6=9`jmgSvX%9`D3qoF@A z`n_)ekIK`|=HVcBc=FiUf(% zH+Wz6Mgq8;p5YL!b^YgX?>AS|aTf)uan@I1{S^|RAKTC0jRclfA zPBnuFS@81s2Ld6FFN4#*2idINywE5h;^qf zOcABvpWusGXSankmD6OeFT{aP+eu%J{2~b@6?$UJ2kftB?H^Lh+kZDihj@KiMu%}M zl`0rc=ZTiB@hCBDxGsr4W~2Y0A&zzi zD}HJwcqF@4mczIkmB=YR-PtAio_11K%duRz9Z;5ykAKQ>8?E*}cIWcx{IaihWE(eP zS3%caS#tYVNS%6xAK!YJyVyW*r{o!g*}fZJD{v&4)u+Zhhd0MGte@$mD}(9s*%cpjY;xc*%OdxptObeJ!hWvLX=Jh+JFX?-TDT6Y=oc{{1yKm1+rFDv zN{%=Z*P}#9VEx%6!YbT?@YW%DK3Q;2u@3Y_Jl>al-H3+p&1&N{xi20)g;{Vn+c00Sz*2r3qx=c{wobun#i)5FEz*AcG=ih?{A2lX`UaDdvzx)jK0+u<0FMX+}5>J$I9&X zh^XzE?O**x39b5L4r50DBift>CI>D;%}P&OU#5Hacbvb#WA!9&eY7A)Ok-^=rbyt4 zWW0;C_gn)yKn}tBJC`dJ7zCq8!|q35;v=G&`fhy6$uzGlylc2D?k>Y z1Dh^7(!=mZ)?a`4^Du~z5=v4chD)##6RI-oTaFZxriyzI=9ZXl_p~lCR<$79Jb8!6 zhMH~vFo~OJyEUWz>yutG=Q&wy#FD2ER-D$xWLu+X=cbMLMI&cY92MwMXC4 z@2hjq8at{g^b&T@JEh5jwA!uR9bS3ffSjKxJs2SB%OEA!Tt*K$af0M>voN8VTAj3m>$mX&JC7@JI%+>=QkwG_jWQa8!+6u!+5+b_I8=d+T;ZFYO`_{z0xdG&nhk+!89Dd+N$VX^UlRWvu}~1fRwC1Mne*PcZC%9 z6;!=M#82O9<9MoN3Wx-2m?+LsX@OJy7mpX_T}5rh6YY?${3b!8Wmx(&%Lb9GqO_YU za@{a{iC^21X$5n{cW`fbEohuKzp_Ix>zJ(uogi~e=p_#-CWJetf?{3F+qjtU(pOwX z_bd0e!9pAzOTtX+YDC>!K1#fLtdV_=;o`HvxRV(Ak|!cAx>~A2o$dD<`RpM^{!M$k zQwUC(oD9e|k%r`MiZ4^_>gt-Fjt9EmhwHJQBta6CZ=Vgi0ziwh9d zkYL*RmCRMaLe678j_gxiQIZB&x!|~NCfs}yd9lDzml6N+_#cO1Zi1D_Ej#uW^-h^i zKJ`o6Hu5O&&u#$|h>^qOxIgbC=VoKGW*W#1ZnP ziEduzYBmApKhU!AQblb&EPJZvMpyb~oqPTKa{J;+hWebq=}xc~jYzM=R(>2Ew@agU zSo*x`Xx(p30MZzWA=HfZhmI(5S zXmSR=odG4|vtu0-%VfLs#jL!O8Ns<)iWb7lsO=J+yfO+|ON?N`c$CsZLZ30?nwN|R&)dRyr;xR|JF9rLT^HfQ~NP2fE5H$GLzYQ~vNM5zH0CnuIU zv;ibX%B$kFQ90kfX-_6{WA20pC$_vY&3IAdCsV!UI%&PY8XRL(hiGA$HP z#vC40nW^YaiHJEB8#j3q$4OZyBtC<;OrHUI@U!!-kTrjW!PP4{N!`L!#P_V z$!UUmJ6OD}&qI~qGP(d(-hpBG~`&r9z3?X$hNG`!p@l$Re)RjW)TxCLjaQql&Ae6~Q7*A-ZKKYLj z7XL$QAheX>P_tc(DRhkPi_Y@f3Z_bfv94piQVif!Dudh-a8Rjrs8Ibtor^Cfa$};o z-awsj?MPykfMCM7sYu+@Fdad!2ha_$fQ}JR*APk{@rX``VKTWBzS;i-I{w2jy!-f@ zoRoVxRXS5s?DVLerx0!=#$D_ft(OYx%=AmYHoR97*{K+012{4CWv(wrZ4;1mYKf<8 zFlLUzM}Ih>)Qm%u!*1h|ui;H9)V7Q}k1nPP(!&MXGx0q#PYdL>k>UV8@_HD;Q^c(( zcR~4^AN%KB1t+g8E-EEe@jHd_e4|)XR0W4O{CuBnC=*@%py<3y@1Xh+i?K_B$*c|% zaORp{L?&^wkqnC(%_d-P9TM-AogaTJHZ1L`eUrG_d4GBlc`Eo$=)qGWU0h9?1ZGm~ zP-#(n|3(i4j076je`LE%bm*wg@t0zJJ9B+H4Qp0msjSKNEy3q6790EWL(@| z0g`j~4>F6~?v1cNz~fWO(dI^TW*Mc|4@6|NBk0Sn`FznojNkr-{)KAH#pvST#2~Ga z0I^)u)*H}H2gg-VS7EZw$LF6*X-lNN|6u~<*O!Vc)N0d_zw`IMsvvY3+I)eiUkOPi ze*O57Khm|ZruIZfF1t-S(#yva)k>W-KDL$+(0 zYX3O0))5cW7h5t)TTH!-p3jFihi?GzxAb?9|AS)++Kq_$=h=U^0{r-nkD)GQdRfh1LJj)RAfrwZ+OqFv(b2!FD3Kt@JUbQil!#}O&2c6!1hW~sBqmUs37 zAO$P!%vfo-0Aycu-37B1@P&+6My~J(%XLf_f`D@GnaYy|+#h^MtPl)KD)^O%;o*vQ zF}-y+_SOEvCR{CHZRT)ocI$8|LEVQ0tO8vt$AX%Y8b8>_9gO!rT~s{{-|^WeRME$Y zWXXUT{TYeU^{l69HQy7L-@9?iU?07oYIqtuBVBq1uHCPDecYQfmTMztdk2K7cs<)BzT9=H`;6~p$ zKf+vfSsYY9cTMaPfyAO(Ihsy5El|j{V9dh3OGCTJ-JJc+4lyR*>Npd z*7mINBQa`2WM$9r^M`W{jU$VEc9>@-j6r+yBi)Bf24(6_aEy4~Q;n)7jfKh=&4rR6 z$6HvjMm4d8g8V#{ku&H-sYa;waUFbooQF;NujZ&ct*yXJd8>dCO6>Ajh*4+4sem3*WY+dZG1mLP+7VTv5GCK zq_@lx(hOqyq~Z8J>E&bqj&bG#F%iDH5gXE*QYUNAG$$_Y*D<%zfWH|#0Bu71(8XHb zgNqr6nyO~77P-@S#{@Rz2)#?Q8&-m#MN}jsVBD@|Jl#Pr7!LZ3G9Y=l`9Ot!dOfn( zv5#fju0kTYbp><52oq$CEysnyC?8qg4h+6)sB4dW=-TK|59KjDI<;}sIgu4>4VA5b zjo+2g+O@Bb^BvB+U!=f{;KI|YLm41-?Cvl@3O7)~$i!?`Zw+@3xalGJi!>d>M>p*5 zBeiD~66PG`VE(9?7KsE|dLfh$EtH3k!9Q?0M{9pljOdtDeX!h`cJrM(B_vEn)X5og zKF#wIaUqQBXZqq#)nnJqhq|EP;KUx{ufz{(Ho+Les?m>CgWboDEQ$T%d++1XX;6v^ zk`&6(!!q(RDRLVz5-h1;v&JvTzyA_p8R5A3nY*&329~H!=o_OVmSxTUeJQkRDw0CaSDT zTU1wYDb(w#xNUNH7A2^$B0D(qxX`8htFY|2n!uqKtM)$?ylec@%xGq0E~hm$&z$V9 z5SPlQkric3riKr@)Zz`Xm+B}sOo<_9H z1XPo?@#PH(`_bBb9_=fvSN3e70?t^?fycW;QbRBG-RN^DFginuXR-lpDfl?V*Xxi# z>r-#AQ&H6x9ssaa=@$1Wnw5=fRFdbVBdxw$aZ0^~)SHPdmVawPKcSE*-%e6*IQ|JZ zGbxjnX<~k{zzpv&PRAA zo_NESZ;$O4-|WM)G=~HvV9N#4iQD8?c%YLhC*)=y>Tw}BKuVb5A?DHD0M@F@4e z%&IE=Hib=tQYmd@J_7e5CD$}>Pb5bt$HsJoqPpc$}>C8HD{rU>4L)ja+f zdpeZ*B*&N-m$TpWiY?m`SM&bmT}`-DHQ8EpxrP)^C3lyk`H9y1rN2VJ@07JxOXZD? z285hcw;#Y^jWY*G-B8%hxyU)=ML8-Vza`F(qGAZ;7uxW`-7y)|Df-6(emrv^&Wx}U z0C@gvtuX^b=<+iA^+MRgacxlzBR6)1UVn#ydWgGlA`&B-xyTOd+Gg!Za~hShL(F3b zD_L+G2#OXQwlm)! zHvn^KPl9ZFg$%fHw%V{CqlYQuP0O_uj~6KEj?HhYn{KS`Eq94+HCbr&o(_fLZ?p~} zg=nr|)5VWb>T7K2%QbnDC=lTCOEN5b0>U89WglRo8kxq;I(9+Z6$*F(F}VIhtD3_h^kT`&loKg2;jK6 z6P{yDZ3V^mqwET#@qMUMwS_Zm65|ff%+DEf_6XoWjK2;>QdSOUA9rd!0FqZ@6qEsG zxSAP_)rkajmc;e6I6doKY}StgJYJW4_?o_` z9cjyo#i$7Z)Q(Cms(ZMtDWzWz-H^xy7v`syRb?&C@`TYe=i+9cB;u`XaNg%pchOG? z77|26MU@%TapEd-SCLLQfi5$R&36LymS@6n4kyDt+;R1pJc zVneC-h6@cU-7*_YL&HJ`>^5*?@^Hr}D#McEq1vZ|FT_$XKjT%1j9JR%HO?qT0y`AR z=OcQBq}U3k5&5PMiDE;p#b<%cd-O#pncL5sykrg3-+8II(eD0u5vWUM&L2S5YQ5DqP{A4673V z&T=c5lnyF6rk|XY?mUI=#H<9zf@`XHUIO>z#l}6`? zl7@@j>#Y3zlE$D7Q0{2OGPTLwynB=5#}k2=maBf(irh{|CT*$W@%&O6K46X7!%nQx z9=BI;=k|MZ91TMvPq^uJw({sL%t2}?v!lF>N9h9QBFv75CRo^1NjEv3D5@32)kw_1yF0{+12Wvv zPhMbqtJxSTDqO{JX*RCx@~6=qWqwJik2VN_V|trMs=j=B3Qj-S$J|$YzFgtpixN)iQWSF=g;*Le!y+uWX`dC>Fy9u%yGC$H73%J#-S%4+S?2D zq-q;^(O)@c0khX;^W$m^en* zl2}rM(qc<4F)m9#D@)bK+Wq>-GTf8VNu=4|fDFXu;mJqWiZI#I^(8CzE!Pw3I|E+Y z=;RD%=?YDHphTQZy%3L6-}RO3dNi@Ft;u%*eFdLzdKQb1K6oWZyvi!nC(nJ9K;8m6(`9TEkpnL#Xxm$m8Q*(OSRlhb zDJz_tHS|OFPzRu6w!@W&m1UQ|b!>A%IGOzbfNMNGoBqy1i6~Mr&Fu?;1Lk~KvOr54 zRe|Vm37r~4HATCO4GR(GdchdGos`-Q8cjv-29$Xn1-DTpEh0>P!qrxP^N4$wY1q>z zC8M)P(mol0`+5m2GJ=Z<#LmBA6@!GyYDTVuoFjef3KBO@$*zq+0#6`?w|jgn>yAGO z8Be$NEWVqgkx1z7XIo_RebbbIW+N)E zCd-IF%G2Qsap$8byvg>O2#**%U2R@p?l(BL?09zVZ<*cA6`)&Lj*bg-_>oBhvomPk zUTCTGTA|ekBt=dBA|E+q(<4}&TFTZOc>Ji6hNG*Tp=z>O0<|lw5YZb^YLK!tx&vOI z^a8G~em9~7+WorN8Z(`~AEEZhisj}w7gp_l|7Y9wiU8l+1xq6y#x@c`?bg}|+slJ` zr&GW`JR^r~JA90EtBgBJ5H&DLh)nm?H zyC6W#;ZxJsnjP(AW_sg+kCS|8u&d**Os`=qR+D)AaPY(3koGZ3B2CgC9 zj!cUw5Rn6sr~9i0(a3fVB>vW;9U(>PocFSaW^IY&L*Kk~9Mw$Xj;nRB4`9-$ zu3E*PGnY~P{YV#ZX+poOtJpr&!9PsH?CA z2RD@tIkmhIAAaC|1Xdk$x703&rYT#Ktn*jt`J!C*2*c5(HyDC>^{qeNynNoXC8_gO zRFLg`y2GcAY6VD=+gLKx4zpZiA>-?G;U6@|maX@su+=_1cMzE>4}O+S|MA(WB?aX0 z^i}d%c@-X}Lqiw>L=NZZ{+V9b9?qS_xm8X_v=WCK{ceD_NZDB^h3J{MP0`Quh;S>l zeOpF@%stjRj-&fvr+)w@eYuvF$Kx5*L_Hf2%z$uClzE*#*N7w{GGg?GM?EzdbxJz> zy$D9!*8h8PR}5Ok0v&>P2G`=*CYHuK($gp`Px9F2egU1xdn)WPJv@>o34|s@hEEp0 z#o@fc5jj1-vKx&N{u>(8WR*5C*XT0aC7G_aoqxl!v%z0PfIZX!|8S(mQxS zW*F!YH+{HNPTPaWgST2M!&xP!wDejzY7w{0g@+X}kyT=BSUdf|*97|{rx`N0MLi=3 znr?6V!s_?NN`;qRSMb*T-;iQrVqRsR z4pw$krLVhCF2|1KChAO=)w5;pA^874*2tXijlSY5g}{EBWCASGhY68eAKnF984Qew zI!k(WqUbOOMPlVJz!3qX%noo;k5McLjWHTY-jsFokC-Tk!xqGXU7TH5Ja~V|KM2T- za$)*0r!sogJW|&8o{0!ktuM|uP>HG+%QenE0uHQ9q^xWDW0m-9R?PLu7&+Pq^ugzM z3H=jYCwWVVmSGZn)(GK&-YltIvLqB?vt3h=6;dP?Lpygl$ckJk~o0Qa5yF zsljoMU5c~>8UxWMvs)am!~i352cqv1=#94s^JHb_QBc0FHTR7Xugd8 zW2U5?cm6uTH*ts0NL(rDcN-F;fSMu{tk=Wc&uq_n5(Y;Sl|{TF^0NZ@8MloIvRd(8 zr}F$8R9*)fszTo>TRCXah&KHMT2YtBRaL!aaW0X@hVqDvJsW=YjO7gnAGnk!RC7U! zVU;T0qhB6aN#bCP{mq)q+ZTtVdqL5QW1`N*89m!{cG5)k&^B!G-)!kQcdDjG5rV9_ zE6unCyJSe?Q0lMCyO#`q#4l{BFol_0Y(T3MaZMboUc_a=#yO(mhR2>lYBAGui@xO2&LoQ1Uywf5AC5q0QR+R_8=G5?r~|-7BAfPq_3-4#r#?{D&%!o&!@wufT8iC!plVK+VJprJ4?%CIb~WiAeP|_!I%q1c ze9&E66;&tm$<5$shwkG&=(vqjXeb9TWNoZKyej?k<#LxP!x1NQufmQFTr>gDMyl z2I8g)hM%~Gp_jOEd33oZR8MbH!Ly&ag`3{Kq$k>{?q13w51$zEWOsfnb++Akdl~gF z5k^5x0}NkQ-INw4jPX|VCgODxZ2WG)iPfMoj(8qAj>e~u86g(lE8>!QKuHU|l6J^f zlc&P++b@g$VHQEugGQ*&oGgos5G5CDmX9Xd7(chq#1XBvzqPN!5A+(r`tbTtED-ht zEoK~@#&ie%P+8n6kPrE$CK&SEnc4xy8-mvnEol##&_Eler}}fY39r}TF6`KjudKbV zxQ4LS>GesYCf%S$VD^3n&x#>$a5;^KDoRyo2>(sUEzvt)tFvRYpfkoz=Dq}5k068~ zYT*y^6-k*1KNk+T3C{Zh`x02u`D0)F>cB@#$*YaDG#lmluxHD{ZV84jmU48RFM;=V z+;N8b%)CC%QIM`1#9hzDyQfj*_0f|JUfk_9NFZ~9>&G3r>o`f7B6C;Bl9}(xo<(Ly|fE-Ko^y zscED+!Pe&XSi#mnNqP{5Y&7xN_-13#@ypAn-g&oF@FzQLLcUlmdK^yAk{av_$C)qO zL))NNCTcmsZ?@DuXWbubE5G(N=?@hof*S+x#=p@Cpde*QSI;(t_cJAyX-Ud)Su>hk z67d>BP*Aq@*9O#B%^Y-Vw)+sSC4P0-63M<6(Ako-m?+NRjQ$ek6~B6cvsOl~xUi!Z zpRjVWn8L+hNCC{5hfK{Mv=T7dB%iWk2qve9Urc$f!U=HmWj2eh3q&e!5TGuH^J(!t&Vi(18 z|5)1a_LJX(i1hD~Z}xLHd4s{!_;VP)bqJfV{<4a#UOh(1&X%juNuAFD?UJf}0Olvz zP~0e++bHkF#5~xvnVpB+=5&ZJu}Fz7bgl~a9O{0tKH?NB{uR$$ttjM#g$K(H7+bTa z`n!oj&_fWLVe@rIeq7o}4X^O-Oi0jQ>DM^RgWt6hzSatXfHKEqip;caGYXiD(Nv+; zcxb`YJFw1eqW(GsiKf-^`xS8_-BeueKE9vL;uqFw?!wEZ^)>>?N9Y5V^zWLnE8`t{ zrFU!pPyVs6Nh>1zUz6*fmNsFSEKhSb?Xt{!c)(oyd(Eiy=5P;e1QZW{%+1gM=V zEp-+WK}(|hC7&C(RQG#S4{K7Fy~MXh6t*$ifw^j0=ug8BbnNk7j+d}#H=+DMk;<^D zw48nobz3z**rEs=m-3pi$^i`5rn3t4qfL*}n{2?^e&ceqGm< z!twGF4cA$6QOLwui`x-K_*I^f8kFv};X)Aa&-sNO1_rQID0vC(9zT&Tx~L99LW*KZ z%%z{BW2eq#=xMQtB~oraxV@67#CL1F^L>0yFm*|!h>lm;tr6Dq|10YIBsmecsWdZd z_|#Na=#*?b$r}@bLP*07XTR6u^GU*fCCrC`9dtfSY!Z>i!Tw%~)ed6n(B8t4#xszy@D6_Zj*z#Yc{Vwg0`u^xNwjsRfsS4o->$`FcP$JxmEY%&c@R@QOFx(h$U zh-g7!bh#{%b)?0Y4)dBv<~W8~)PdWb_^l_WS;to{p)dyigawphi~TRaGJqVQJ0(G7 zV$ZzBLu-hO1aW(1)(dde-n4lNG1?~(tA{;$21+|2vy~1-;LU?`sGCRS?VWp|qmxm8 zQ=!{_;K8(#?R|OuHQB8xGZQ;i+CxvP@?OG8Px6J|X}$Fx_>ChSdYQ0 z9=5j>D9ycR*~3+C+vH&>P0yQXVI$O-$j}pL_8778^l49tipt8n=Gwxa(`^99PtQhPshR*f z+ayXf1xnadvS!)0*zBZ;!auC%c~(iib7*2X0*r}Kg52@ak=`8;U-|L@5`>e15qzu+ zKH(-VY0hQSvrf{;pF1ieCFQc^drPg&30jd!Qy~2!A;gXZO5BMTBx4?K6FOm?);~fJ-_FHNIO$^w>%K;Qj>`v$0@~SFXnd={%(eB`77Fx5hEn7*aHI|XuW~?c> zL^GcocEQJ}_s^p{a(MeQ>XL8!jH=o3_BofYBbwzl6ZQqr4dNRUFdQqLZ7)sqc8t{KR*GxNa{WDZr7vz*?};6`Sr zfG$_hFV;Qw(;T#urF|9yWD9=kzAaM8@og*LjM@+}h_uo`F7B~pilxg`%UNhNYNBbH zpJi-J6MgBMzB0U9E|k;kp;wmvm}{>aNI#QIMF2)NLksh^Ksh?c!vPRC4mcY-xj9+P zTk+y)*wUE%YRIt6;;hflXTn6^R>4BYbgML`qxARXR%1z4*`sL&`Flq8YySXgp)rqY%)QyG$ zEV&k}Lw*%S)f!6qv9&e5G4;EWRQa{w6+Yif_$QfNBv#HwJg{8N8x5qQQ6m({a;KT@ zl{(IR((o0rMZ9U8npm$a=%{5kzPkksDOeYrdK5A{oZ#?*ABfBD7vby_Kg5P^nnu4; zIze}gl{zMeB&<~-W`bv-{J)CzdJ7vD<>=0^!g)4dQf$R|^F@mDT8%e*e8CM^oe=%7 z5VRhEUa3p^a&<|Wj(6gUJ&vJmQYlI^!Q4TPXqSnd>svqL(b1pDC;#R#deg@rs3E6w z2V1&bq}Cp9A2JZ4z8%Ai0Hn|_;H?9%jxCm2%sW-{n%nBVkYdMZ^Q{_R%vZ8;ETFxf zv6B!!39Tlgdh}-pzP`dJ?>e7jL!aLy?>6M?+Zt_nI(}Eg_~BT;>y5fc!zu^p7WpSq zF`RWv0Dv?;LQYER(4}ODgnhi(D&SiroUKkh&M-e{`>q0m3*|IiyZS?tV1O<3rS_XIayJBFG z=kxQE`XFWV%62E{y6$$8)Y2z#_W4ASjjB%x^%*OXCsH$147_KyUY^|TmkT*&gM`+< z@m-dODsRrEHXaa=#1!|b(#>ICw)9@z5Guf1e2_#a>$%#L3+}|Ol{#PnvW6i&vch=g# zx*g7)nQTYuR~s)fq%`4n#}mIM%gQe@R5b)EO19w!;xc7O%L4se6}z>}bNRlMX1LuJ z2GW4TljCZkYLJbsyo6F|ahf=uo0IQJSQ&>_470NhG=bnSKUqCRSLhKGIpeaV^Jt9A zJ0E>Pyasy(jyAkDYwmhIt*HpdQ;)5D$1|HSZ{S+O7XLP;YL+-F zCZ_Gh)E;VtY&655!@@;#icxKUAnx2w3vI*f>wDIaY1EK@ z&x)-ovitlWuB&8mTI|XU&aVf%0fMpP`kXNx9r zF;x2aF#*Lt@#(o7YBCa;ipPjQ?146RTDD(wQ_EeR(MzOBvZH`PzJ`~)d%aVjN~%wa zJXN?Au^9KAt<8meoFOg2w{ZxJYrHtcCyegh_7wwdv$ldM@J6Mjmk1orsJVtN8BgN5euH;;yg+PimE@ z&lry+bMmlPz{^Quj-_#abGp0BtJs|J7atQka9>mZZqSfr+o+9DOt%ua*nRRfD23xb zI@sp0l@TAe)mP=-#nSfQSs#XD9fnkM2}nomkX|=^-B*dP^fNdCoriwkbP&YM)ah06 z^?h7gU~0jmw@fO%v3BEiPQqLL=pcCIaIerjwt4ggh?s{(pK3x#V`hvgOky5ay{)Q8a#1~!OrLX9#$?6k5-V#w z$3XX-k&y0lD@+`ushM5vhVE5M!_lbGa$Az9sk1c9;2+KSoiqm_F<^Z3OJ?wY=QG_0 zL-@ONULu9%TtqOv2}`GkWRAX7;*T0saYbS+G7c$Dj^KUbZyeyMlzAM||I1tW-u535 zR9gDwO%c5+FtQzEc4H}qfKwSgQw899$oUTDv*d)rcdApWBmo~z>CF~6>QeCsgNZt7 zUHr~Y+IrJ_8`H{lLVC2^6=ua>{H?H6raXK6G7oklsq_9Yc6fvwqb%_xj z7w^6**G9uCxW;R>lX@^D)uYuf*0;I1&7brV)JD4Zcj=v6hywnZ_SEn|>7g}6O9#XI zSUhTRX6^#xFh8k1wm+1?$?jtN(&NxcKYxvcPzOQnD;Kl-$Wa#ebSszoIlxkL8s_SO zRr6-#eOIYP9?PFkcW1n$ck7>f_N2{ik+;g$m+D@r;|n=5Gvpg`guchNhhdm@PSneFew+MRx7ATy?Ys7IvR!qBOtFZ!`5q zeO`Pdl*wfT;h#(P7@@z8q%UNtU=ej`#sW~FBH9hquM5Qt0xQy0H_Vym=#voN|DT4$Uu&W$C2vFt?0g$W>7 zsdg;7Ty@T4_FdEJc&9r1avYJzIp?ri(gA^LG$gGeQFxsm#J9yQFi+(Af}j7C#)C&k zi`DgjAI7;R3ff&!VDpNxE6kpYog<(8Hd6*96f4+6BeE7$hFm zgHM!De^z6RSR3a8Bb&J&^K&E;H9UoNhL-Q}N#l%USM4=@7K?NTAKxr0yGGA+zYI)j zz%O~X{;GvOw@T?S4-|5el;_eKbfeL!z!k+@4kYz9dtQ7IozWPTv7$+p-?b^bsA!WO z>l@Ug^xU9k@1Q4P5pyiN2a$n}5*BBL1{(BeW}VtUeL01if;L=Ut>q!x?oiq1nBm98 zXMsyMqO*b#};od-#>C=Lf{=eW?a+BXEtNp@Xu??+}B^dEQye$>SeIZ<4`4Dxvy zh%I9-QdVDpb>0K+d;sKm`@6Gq!l$>^F;*(H1Hk+l5>qH(DzV#}N_hALhKoU3D&ebK z=EDHZi$m2i=9j78YMS24A>(~=@fb!46;SX4owekD4F}o z-|t?isV{wh5IH5_lG7vyH0lP)z9Km0O7Qo z(GTQy8LD*OK02jo82)xba%Q*9d4T+x+#7)(t}7#05X*{-2>%CYHeC|~A_4$Z=zO1b zYWaTU6rM2KcsewdtKqxHeKi{UV>tf|p=b4Fy7Q06Xf5~}x;BPje=OO>SC2U{L(#Ry zR{Rfd8x^tkWqSH8ZhP*}Rrb-+3%+C3@`sp4OX*PA#)@F~>PTT6{|~GZ)mVMO$&emu z_(Hc;>pI_d7+Q|dt(7Y?F6=C{m=#zOvxKFTo1j+Zpc9MfqRh-czsp&HP8Gqe22v)0 zdQuNRXbal?K3hQNIV(xJlGk%VQBHD6d+g(>P2o;g<*2#~6~}pIL_CQ)IIN^fv0RT9 zU1fM@a8hae^D6{?9I6%%KKrgt|AH`MMhHjP{6Qv-t}hXN;)>e<*rXkmHDO`ma@9@> zVa}XzVOsYL%m?gb<8+J;<*bCjD11RyJ1z(fN=}a^kbe3hN*#NjF^>WBe+c2bI@)hP z&HMV`R{;tZp;>)F&E8MPYlU3%z{n(ru5 zXEw5ppJM4qKE(CRefto%q3L>l>ZX<3`Xy5p{rzZ5^TYEzO%-po_-}J4{0&HBJaP7A zK7D4XTTm#U^+p9xCw>UgX$7#arY+SQllIrpk2D0;k1m(-e^Alog4o@|R7#)DR-}Ks zq%=29w#2p=!x*f=48+?FqTT6cA% zvafE-m!i&qWAdhsPh{3FflqXFHYE}tMu2Z4*I%9NUo_V(Vv7Erg_mo|;sX09cS|c6 z;$drKkv_m!Xm=HCDEG|+z7v`66St}`|8UW;?^oKYhYcH+kzM#8T9&U6|nU8|4Cn z#7b*`CAI_1`Nr!L$2loOLnTJ^=l0$3HEui?h7uf%t?jP%C9mrb(_Kx%>Y;$Q=C;E; zJ3OlRT7ZpeYgGS6^NEw`)aUGlJ@K6d_5^fHGZH}>hX-`k0Db(vo}F?a2`Xmw&}92W z{Z3-B##j3OY1^TOb{j_;FeafHUV%&RrRKxE)fyki2Q|ALCzlg(E4^U|f5WlBjgg{; z$ieJYU6f!%y&aFy)7A(z#1J#$`r6Crq63a9@?!xYL{@I}8JWb%%8D@lQ6O~q*Z+g;CX$}Q02!VMLOrP7J$8p2f~y2MvKXm?39@6f zRtH$tXX`Ef>7h=Zh*9nUkz7ucYMUas4zh8e9g6bU=NnI${VJbycK^W^q21!*LkyOW z&xKV=SCu`MDFtX^VPPZke_G&zWgebMvywBjzX>3n6r{6!<2|4kx-!lQYvah;~qk&(Qp2k^pBs+%nE+_r0*Gt=ksW9T548q>g=(=mU9V z%NJpCy#5^|m%6L1XYLPD0V95Y1xRtV97tz^ei8d?@;@UaJ<*NeoG5_km^3gqepV^f zoU`q~^}Kc_=%?=H_F3L%kdk=R_D8o@I_V~1P4O(qyxJ%Guf7WDVQwOw|NL;}t+`Z; z^W@ND(;_N_=8n>6VJ9)n(2QL6W~ZQ97d5<=-sxA#vST?z?7qp z+nl=;I3t1vcv#11$2!#c_Ze34ic+DV2U@p)M{o-0A_>u+fr&v}aSLzJJ(WZkK z^#Yb5gHWPaI{7Cg&Rc#oVMot=(IWcQz|kl93z35lna6cVs|z3S>uba^Wujp7<wO&V`2^v& zyJ|AK>YC*rtVe4tP)hyjul*@y>xuZFZ4~iGuF%IvsQHpX(yYZJj;8+#VnBPt6)*+V zMzynu;8r{hNAD2!kYoZXnRCULU;i`Mr4L*uC=g1>$5h_-z7g0a343~IvG}wEAQ~P; z-Zb{Dh-$%%YrU5^td&45WQb+#v5SOi!67zIO6IGdpW1{dU;q+*4Rus-)i&JQQ;>ho zoY1F06ypxkjIp@z<_|iNnlc^)E>AJyS9OQ)LOtxG>~ngD*AOsG=Y^tdwmVnc&w_~{ zZOK*kG-}%$rf^XWEq6?*KG%(T$fxqs)poRW zH)SxBiqGm7vU^)T zhMuk<$C8o#_v%R{sup%`$*R$6VZNTNPJ*>!cTdRKcf$@r>CXiL*r7Q2lDj2Fe>M~O ztf72a(h)Ps0SWb)}CThlWFvHe<o=2nZ~>P1 zaqOOf7v0q_`c+3lXVN;(bsF&%o(4Rb!(JKf&@F^50x|fRD|FK{&+y{gUokgy^;PD@hI&dFAL9jf@yb5E+*Tq=Inb7Gdr z;waV+NaqSk)D22o+6D6tH>#QZ-ZU{UHRLHCiw27ryWf~1V|!BlhDfAbq!l_GAc$jY zuLCc<;n5_P07>~*{Em-i%*QTVLyw93x~nC|hY$G;+e=X=evs)V=1U$z8IAoA>@(P> z4%@wLIY=|Ea?-D-ZQSHIe5AcY>EB@lOxzB}hvzjv2Af5tpspCje`@zs=dH}@1(KaLSkm%5J6L$buMPzpZ-Lg|4M1Nv@AKo2AIIeX*3vjIP09F_s)KpM zhr3S+#DKaM?CxmKA%jN>%~gICptmwK^BptXz{lK|M^ zzOR8JS!2yaHTV6^)J=1f%bUD5dja0#foh_xUc7+8t>Q|YYb-!f6#l}E63_Rs>`G-7 zYIb(Vk7jq3K2@+=5TE3IC@x*voX7m;n8o+%fnv7Z6)q?)DsT&2)6WB?UsGF4Oq#>r zD#owzCxgF6v1k)bK3i@Blc85&7MwH2UVLKJ-$_9ZZDN?-d77!|CWB5wARJ6_A~y%= zOSzNdAziOFN&^%Ds)G55doHRt+n*MX2dG?(63iCO3Zc4lDEelI;+)1Av-;K<7v4OAsq*rE3gE#Lt--#$~JUuQ}bONNWhj zvsD}HnS9v~0=YW7;(?M;7?a;P5vFVzbfr2t5Miq-t-K8F)8tjmzhsRyy~>1*7VLXtGwAQt?qK+FIdWy&%U5Pb>qSS8@B>xJO&jn@)W;+7q4ga z`mk~Z=3+}#^wPZ8qTi13!Hfl%3_#`*77ig6jau+IvGkoc&~Hp_A$h8rIHhJi_i08@ zT0t2j;-5w9<16Tw^zLF)5-Cz`EO<9{XjJLr-0=A#C!ufI@A)JLZhaEib8NUF!ZXpK zWMZ?+yu;J5{7>zp07LtSAZHQcWZ>E){Z;n7Q4TY%j}0*y*=ItWLt>Isy-aNxwx(Tq z^qT`TYNZ)n*o5|-+dCo2-SAjMIukC&xf9}VSjfi-21b@#>iABe$=mthkb4*zGFOxg zeoQbB;>x!!<^BZ(hKgm%Jc7RMk_4j9xtSUJJEKF4&l({eqIyM;#5Hg|ygQM9W=zIN(7KO>Ie-A4T5Ou2-!zvp$OUD-oNrv+X`T7hs z3x9;&=$3tREG-UioUpRAgrPAQ49d1uEmB=pa#tX#Sb4$A?0S{2aN&cjd^pyf4*HwC z&Er5M=HD}F2n#h2;s`x{gDU}oVHBbof8kGD7YgQ`*}ui~l<6d1@vO#6ms3d0d{bq; z(OB^sVOwj+heG{VeDp_nvMG^m2|?P~v>fuutF4&60zRbclP~4{*w37Q9uDcDtyC%f zx%PIwvaT!|tGrwPzjPNkuTA?UTpzxGc`%bQ3>bVJHT3>7lFo`sK}^Fr*d!Ub`| zIbtKn5e2e_yV-UiNB@E@WB!by2Y|nRPc7l$C#rsIe^et0!XJWgH6vb17GqOQy9A2v zK!X4%Fg575b*2jKZ5nG*f+%D$F*A;cS-iU%7#PMMZbkg@xMU{6LY0HA0HXs^n|`VZ zdhQBWo_u0P8&wW6N%xXY(`6decUWcc9mVS0qQeM@+tD*Q7Rxes z(S7bV(3LlQ!$sHBsS00V5!1EAnb5rm{n>=*hO&FqusxihK+$)kY19V1iKIL#`x|R({K8WwCr1_y&&wCdng!2Gsuz0)LL8Irz zF#K5$q)c)2i98t2Nrujz?<0(8PbV1G1~9^J&J03rNf1X)!4nf3#v`q z;mzK`6tqA( z<##g`?&SU8?A$Y`mCC>dYB4NG9d+h#KHwb{XH2;DcMGkJ5E_Jfrl8nk8$h>VV4w81 z*?sSsQ6D{a)h3A+pkp!pXIsx{DwKW=K1C!$VNI^Y3j%8j^4$rFh}w7wsR7^__8cf? zZ){@WV=|{U|5sWVQM_c;`EF3jL^t!<%jV(UEm15X$s*KvPlfKDFznj@zTf|c#=mJK zP&sAMS4xIR-OVooa%ltJYd>DrCr$+U-o@AZQ~oFAcq8SEyC$zI)FLx_U3qW%lhVQ} zhSsC>ihtnQqg!^@9U{)E9CtQCYDnveU}M?}?{nSV5?WVJ7xq9{^+4ACgrm7|Bb{Hs zUqRt0-sgqwrKH8SE>Et|YVV-^iD^S&R=*7De_eo|J)Sv75VR!14i*)*S6E|=Ag!&5 zyoH8Z4lgR5k9~uH72c)RJM7%9p6H>0Fr)RXeNA`s_gr+wbSF;#CJ^7%Y*Y!+&ZKJI zk(jiqR*Jh^y823RNeaGcbZLR$bLrE*n{--*h`Zz&`;PdVGwvY2!u494IBJmwscqdo zxIE)GjXoP7aNKS?9!dzR;<@19W?;a#zM-uiH2v~-{?GYZlGxkCXEe>>)C7&A(WiBf zYQiR{kxu${5WdaZ`!P8wt$lwv)Ic&}upw@wiN5oWAZogLFtbg-;=EDrT?7PO4pxzL1Kxnj6oPtd4%F;i=j>!CnW!t3P*EfDI3ET zz&;VT9Wi}T7$8d#rfc?zSArA$qWY&Zph1+{*PNSxM82wTd{rL~nFhw9aoI11SK{u^ zZ1G5Vy?apHTWMK5V|4=)stb+|=Bcn}f;e3Hu~7-Ea#$K?oZ(x2rRR(Idy87-GTm}6 zXKg8>QtE0JHc_kqG#mA8XzXwx)WhQZQ;cso8t?sXb}df)#VF&eZt zb!9Xn@joP>ZRURY_n+NP) z@ewfk#%u2e^r()Di^JERHIa%-vxS%bH&*~sur9W=nObPM>=Yx5%~cgRWa_XB&WuxeEU`zWJd=-kkh0>k zhe6e>vxU)^5)^JiC!kVP%IZw;#Cp)I+nQDSy4t!Z-PsEICPVM1RtnL2pG_@YK7Tly zk!Fdl@LuMsA9%8DWeMu?-v`XfL?1T3!<{i9Se@pc^(njBU9z@xJ$zg@w;w6L9;w&* zt5HyjH(UCsp?SGvs!8(il4KISQ}~rb0KB!eU1Rxl>b&M`6Id{Dzx8+Mnybkje+4V{ z*XBTG;Z$&xBq`RvbMdbzF_g-Hu?o(f3>{Zzkh5-wl7SGBr^)2hGuaxcmI~mFl#&_` z>2B`a0^vqci(7H_@-AjvyowsWRN7RuA*mg<-LX=3l^IJzEk`IrrVb?r62Aabg7))L zl5R0cimthPur5@yrz%2TXzOM%>zf2JUI}xdn$?mY@9(y9s7kgxepEl+s;1Cc%uber zI%j3?_cPH@w%Djxq3cPit7>=f7ZP$uY*POd)?|KcXGR6$D}h1NNs8;vRyBUxWpN?h zH9i_u7#ix~Ra!r4l@*wqow9NhBb-;Y{zL7g`d?2Cd?MdJmkIx%o~0xia^$!vd}u}8 z{6WXu5vN#(Qk_$$ME_aSi7(K^%&Fr`g^9;2a!sBy?L4WADZuLkE5Bh;&+&qP1zKSg zAS-abgcGt3C>Crwvdv_K0O&nLU+Y;xa}p6{L5)l&iv8*AmpP@JM$3t2OI{2j(sOg$ z$2UR`>gO@PYhOVgN0w|&DFV{M*SpO9&CaHbn%E2!TB!$AvA{ED%RIip!er4=SB3hm z5yEsF_4lu#oMG*HF+J{I8FO-!8th@vr8v0T@Y@Be;T=LSzt$Kefxns7AvS9;^Uq@a z_O2badF#>S>G(c*miyniJMviP51+1D?c*|+x1IcUw2RmkJt;5=5px=)Oqz z`aA>erh06WxnD+I{39zi;4O)CN1CbrD=gaAv7t^4Vw7-zB$CuX6MRytB#HXo>b$Bi zb3i-UdIkMcq8CmgD5QGW!(d9nGbJE>qmxQi*(aUHjexFiibumsH-~A`UUXulS zxBR?J@Fh0a{Skc;1fxjeM&Wpyi+p8U<0#kS|6dcQpFqqi;Xpz$$yqVPVIb2KH6GJr zp{mbFPm9e?eaYwj@tM)lVt4(nn;T-r0>V%u-xEmXzYFirn?IaEs%MLBus)_u7)dfK z_qX2XX|fcN3ph!?#ZPqe7)@S;UbOKeP0_$^SH2fzD)Vqrtrmp0Xk7f2zv=aBgzRu` zT_>{Eo3ZcYSd^(+!)XGhd#N$~>V$?b5El27M%uSeGUJLzQ5*gYeetPz#NF$2P_5IB zXW-ftTD!_;A?dGe2gyOkL|cC8>e8nFF}K2T^ttI9lCX*zTBhzb{!RL;P>HFc^wJgM zKhxuULe=GRhgbrVPeE0SJaX5(npC1RyU~BlF7eY@*iwCT?ShNme&#&HL1P4XcVTs? z&t|3|wxDG05||T>g7)~0ITZa9{KvOIE7lUAe<5Ee`ouC&GAGtjg&hmXP(3nl6vSk@ zEuHO`K>+!_K0CN5tgSG+G5n&xY3ycehnTlOfO%eVN4Rif8&Uwf`K$0q64Clk`bD2N zwP>VQ5NEuwksX2!HGKqzZ577$oMqP!lSc%Xf3r)lpX;1_ZVHAZ_MwXQ|0^s(a`e-G z26y2ItHgt@57nIO$5^Z`7ACgtkXp9li9bDjyg0x8Gmz?PNxt44RG3u|X#5FoerUX!Dd{z|&}l8Aml6>jkBe?@Yq!b4}Mmk)YWCDapI zes#IcSOo_rbxLeCSeEIZ=RDLKsr3$AI2x9pAE_v~8rr;i1HBm+)vNoQ001_dOh&f> zT^H1(PDr#}h4_P;vP9#1S0`egXvFo?8{m5=uWW!1>!S+nBg z98&I(HSi=kCjIvU3~FbX$>_LaePt5p_P|b&{Rtz9XTOz762!kAh8km&zw>h9_+*RD zVTT<&E)NbnuSYbyyQ_l{#zUizp<=@b;sj}5mJ|HNH&y=EW*6Ip4i!2mRiEVOGwQn- zXuE;nV5eiw0=wA?<}vTswnA20MGAsK3#oSv)#np7%!nnJ8V65G=TB zaF^f&ch>-c;BLX)g1Zyk-QD?`JkNR0z4trg{=PqU_ZYjockf!OcGX;Su38ni)Yy50 zf4=pRi2;siv!PRII^VXVcCtRihDv-a3uCkOz0GM*Pq|a;(@vLMCcih{eM5PF2Mi)n z#UTt+L0z`-|3CeL)9`;P7tS8ew`Pt@yW-s2D+{%n2<>j@ZEcGdE$x+yzP=r^(!6H9 zGyHcZTJ!@}un8CZ_CT$C;tF&;;q8_VOuw_uw!G~zHI;{<{Zp= z1D0R5cCc&FT=7ylEdN+i=4d4hSUMybH+SE3IaC|rPTU`SA^RsS*h4N>MQ0DBLVI5% z?s@UZexBL`;nEzH$oD+W-?)V`(h5a$qR_ZWvJ@u~5I?nsUoqrr@zxyTMhxvA+Gqsn z;%`_r$8H}j3|h(d^u|Kc#kfosMo}Su&;OV#0bUs)z*LXUpss$Dshwe0EQH$-ft#Jt$`m2^wQAuA=6pNr!NHJA+ zgpSgaB=i4PwGuAG5|DI8ZR z*C9Pcl3hrFR!E5igPr6ZD`qmGr+)&r0YBmSxfE?P*<7ak*iNl`%Z-k!Q(Rfe=+Bv< z`;32QSS(;yck{-O2!%=_;rkx2a`Y*;7R&r!c)DGGZ!B7__UBWvas$ZKQ?TLFA@`0oCoDX)D)V;(oxp9eGBUrcmtwZN zfTS<5*4|I6Anb0jJz3euc~i(UHDB&U2o_sF#B>(AQ_BFoHJ%1Hh%QO<6VwcLV~4S@ zRC&bCgGggpBnQN&iHB%cBUqNN_Y&bMtIwp1uN-c7)CjmZ3!*Fd2L4oE|G!4?aR5Hc z;5*IWQ*{XprcP3`Fm~VksNek0{#e@RH>1(rj+CltwpwB1G&@LIW>jon*6Iczk}xF@>PX$_4sf2-@f&U=;&K+Y$QI zc8ygOlcA`S5*6I^*ixn)R zM{VP+BN>Y;MMB+w0<5<@Zowz!t-L{jWrx8uSly+DVH+a#%B8^LDc(b_f1c)0$wI#< z=_f7|O5@9&EtbrtCma@9Yz%rmq>i(OX>$O`s@w{{CyY6u%|E%7>4gp>AW`(`pP81W zKjE=!o9v%BO?m5o*o1wesPFH;{O9HW{Y}_ETz!(4J9BukGlYIfm4e#rw9ES9r>jel zCFE!Kz%|kobTwmD@BVaCvbj#b?X))v+nhPj^tXq!BLmmT#%$+(?Y*389g27e;|r7L z_qvmR!uG=dE+6tPJNL-6n~Va@&?k(9KWIivlWYcAS)1bM=otUjw-|bQw%WP^Qy*7U zRFs42cfI#XTwGkbgg$R&b#-%d)1U9_nZq(0x~`sHJeR%xA=O=nBjH#Ra(zXKfnuce z;Ljk@FLVWO&Tn$NPX@i0@n+nD#sK)3So#6r&1^m#teQ%A|L#41qp-2HH8L?Fd%ZdT zVs9Tyz~l5{E@^*s{bcZyX@aY?(?PIQP~YlKw&Y#^iMPz)4gSsAmDB6)WV-XO7X=jv z0PR94zomG^akmneS%lj;>3Y*5AQmV%GpMvA{3Z+=u>CO!c3h_|H#S|A(ri z|06N-FKYPDZ+(CTO2Yn{_&+ZvWMpI_Pxn&ie`?LAJKsDS8X6`65eEkrG`s5~YimUF z^YiX+FFY>1Ka!r#cel2#`~(_sDN;vJ?OhS>^%+AVa~V!B3-T4;e%!dKpO0m5g}lFW zJy*^B0UCsupI`Us@LkMrjroqH$?KjmOVEe*H3@2!E%VI_xv~@M6Qu`ZlBFi(BXFO4 zw9|I6MTZ?w_N{f!$FiRy-*x+MsHiR%)-v3|aZlj=B3gXki=5@2A*kM$A~UuU7;2fK zzPP^Tn~q%XA0CG5Hal(Zjb(&|g~h3`N!_2YzpXhFKIMLrqzo0!38@!z19G9kigsSq z`LR)TFnl$T&-Q)NLXifJv?1CY5#3X!4~b`ekS8mSuuN!;_J~!qw@RF;i|J=H3X!bM zM9EttW^l#jCmTt00B>1$vZDH=EQ$Z_Po`SW;@FNvd~W*va<7$x&bg|uR@7;B9j;+* z9x!}vgx$?Lv6rlpQ26G^7&O;3N3$1V;~2Ng!q}k;Rk(S5r?*w7o0{GnO6;M*gbwrvRkZ>5nQ@Ik& z6uFj3u}O)k*YWiF5Q|WK6gVWP!r13EE@$tGPce&pAJV~)ILxM@M zPMiRWvSm~E4S0yjIWB**c-CUoaiabqFtpvgd}=^R2ya-zPmp|qBjRZUIN@|LP-$0; zZ_>Uwsvu}W1EpELj*B{Q2eZB9Bga#HNjd|ldg)PEwRXY~f^aTck&(4WLnGTnj1mhh zRGU=jKP}!XxH&o^+A=+q9s~tL82CE!x?3zQ;`^dcRJVwXEf-k052*rwTKMtvb7ave zoZl8O(SgT3Jks6}_~O{i6-L@4gkq6Z8-B4*;@TQU3H6HPHF^0CQb<$P#by^1yq}U6 z4Xe=w)5(ncV{fIa%3dvtgSUz&@(1lSc2Hr#BC7 z*k_I-U_G#3*t=xAN`lh}!&2#DkJ7G5vC_UGkJRSZ%D-AZVFUV+7?=ZWYv19dlVZ`7 z1y$6rY-L4ZNPFCM;iOK8rh;X-i$9Vl%bNAmCkYHu;Sw!`81jsTeB~Wb=Yu zD^dmlNTSM5m1o!BpsrBEF2f$(5X%O}dP=H>#7YLQ(c6;$XcY)@HyYwKP$CMIFJ?DA zcUo$C54~$xPz0fT+~8GwscG1aQ{RzgnIm7|H}S_XvB!hP;=r(vPsPPt=#YCGwy7Mp zezVvRs46HAvMaUocNAu+Gi0Ny1EPJX7F&!N2Vyr5a`ZIWawsB>s;vtiJmzrkr{zh! zVHU9%(CH2MA3Oocuj;Ixg9DnSOMa zu%$X44jSK3o4`EkAo+YF(vx=MDeTxl0^(lKjk{((^^mQI`Rq5C=h!hx9M0c9TZ(GRtY|3 z)Qc}yzOn$z;xze2Y@H?XUEGWsoo|3Z->I}g$nvU-_O6jlH4|_-I@@57n#|znP|yb? zAbE}=(zIm@bt6|26$oW*1$$dT>0vNwK@1i8DTJGYz_N9Ku_I2EgOf>FCh9Q9HbsZK;~b{OSzBnXG(@Zz`sG4rnZrv8U)xInDjpupIdZIn?=m|AQ6sdy z?~kwSV6j|LJqNo|4%fTb4^Y7*r2G(|>+9P?1wYbwyeSo^^8Iyb@1Di@_wh!0wvv^n z_$vy_NN80VX^^=S6csPYgDRwPMY9BZsocm@sxfH!aBIJ+BCZp-de)23csNB!Ek+Kw zXV@r!FrawiW7|Q}N`hk91o&_BUfgAtY%RiYb( zpUF=Oesf-^+Z|_JGf@R8p*} z7@_#zp0=&M?~)i)4B}5Oi4px(|K=a=aCD_+sOjv=`%y`>ZJQc)W~KmtdFuJk)#S* zSD`EghOy24MwoX3hTp_~S z!gw!3)Q@sukmo{Mr3wq@y2>0FPS*Df?yniJs{}(DOfPX%=)#Q_GD&gB1#f4o7kk%og)y54F3YejKB;G~g>;mUU~0o*;l1CX+cD8WC0v-_6zt-}(E{IA6m zFG^uZw1w#r#p;3{jUyF3qUeF$x&j3dV}Dk4ain%Na$J=&42jrFd%)%agNM13Zpa&R zz-$Rsh-eS$<&VRp$0#i59%gy5@P02Of4&YirtLCt(3dz_E9p9GI}Je*)GdFV)f{Q5 zhoIHPE;muNBx=+FaXPs^_5Kez$=i&JTrq+!0%8yKP*OgU%nlXIWsb#rm7_E8da zeh-WgC-{hEj%L$+i~|WjfdGl-X#RB!+FJvH`~b5e^bS$3i~GkvgEj5+$e*A%f(y1Q zj4Vhuk)|C%jgL95>_UEq8`O+Kl|E%Y=an|$Y5PZL6=^lhaITwe+3x{%+kkML2IJmg ziL|LkyhRoz??{#6nKtkiH#>w{#iDB4U4kh5S;$k$%(uCNWY*}pl>l>X3K1*zp*_0;@m zqDhou?EJaUn_ed>l^=aoCg3W5kGyO-!hv=l23p7DaZ0JiK(EH>0foNhDEo^P!7kab zRO#e666vKz(+d}J=sI~uT`Vf(1in{|)3~bq_YM^N7=bRuKDT#@;cKWnRshK7BKd(H z#DNRqUBVAAB+4px5afUSIrCdWvkj59TC^l5l^}u<>WXa#YSftTjC^A7)}J%jgQ*Vu zx9^vL2EyiVt!Hat@(CUf{HHcY1ri7BD97kWF84$yLM~wYOhnz8SdhDj>X-NMi%sVe zOP|%4H%nxbff*v?uXhj{i~_;fI>ulrzaqt?iWWE&>Pw1&Uw0ZgiSbcCPGv|_F zV;yT?bEt@F9K%mN!NtVRu$1w3$vy^S3!qWc6U*(snoPWjaXY?|#*A8mK7wj&oi|lG z0`&9e>hiqBAEhCe?yE%czCrV;8&3!*K1flV$|UwIoAG?H_W*JH4rQS`hPJk^ZaDwM z2P1m`dFR%B^+)GISQiQrPb0A4o~Jymp6DyunebmoTH*dQsc6AJERG^!zTz9+)(Be5 zwcdY!;0`lJIMuX_BA?cY)tYiIu3Y(J9DOGjBnb-~y6#W~8FI&73~v3a{YJKWFCiF4 zrHU5IM8j`z^YONLz#bE|F0LB9SqGBwdds!|c2kf9fwH#F6Gtwfd-n*r&q9_`SKLdW z2lH{r_s@uH8bNgH&+VCoNC%q9)b?j4*{+LATc^+^)gl`3vaQA&8Ut4tPPojC9s_{{b zO6LP*2)=iGnZ~w*{^;T`LzeP%0-H)N`JK0LaJibOVtusVvDf^hSuy0VPzUxtb0T8HieoL zPy$ne%)bUnQ`i;O^@Yxi8G94pPa{1>k&)`I@z$Rc{(nTU-~mSEAQyKnEp`$_j@xj#}OxT#rn z30@)@QNvT=)#YJem)Z@T|~i5AtY0Kgjd0mmPgiCVq~< zUv2{SWh^@EPkobXekNnR%pR|o@O5450wdITcRZi4x=x_)QEAt!`-{0QnROX;yMj$q zofq#kAp4G^k^9=67dDvKB=U^NrlfsC^l<}L)J>$TI$2z&WcOYbdM5?_jCR`%B@CyS zLIwRAgOb}Sqm|11jrG4ucW&+kXe}Ok0`99$`d&Pwnk@;Ulq)R3HLrpliVdJ8b`|M+ zW&*7p4(7>LRyyHAo0^$|3XXERtNM9|aQ+#KcEFQjrzxLfGWgK0tkbkkq4=$DA-3GFS zp*oFrj&g9lA&7zT@u-bS?Lne_LNqdr+*;`|F)=T<5#qVOkqsEW7#e;{!+B)+rX4-7 z-OY5zEEqx`n)inlW72-CVoITI!YZbtqvNH1FKKa6Gc6;-SuSYD7Fan#OjsDCF$w9? z8Cc(yAhf+;6k1kbw55$mPrlieV5(rqg5?-$W@kH3IJLfsyDY1X|7=smh0qzzmlZVP zZaw1jc3Jg(fAk+h=3V3BHb(|_cK;4Xbb5XPY{W+c2h$al@-4hI6ujOQrGPMpcw?9N z9P|+T)ew?h7gS$cPR~!RVZwccMut{l55*2)?w*rk^u`qYIE}gi@Nzmm%x5GiZiIn} zzN|12cLTkjxBm#q?%$e~J8bq)YgQBU3kaa1q4gwxiTMw$@+HcHNg=St_u4_#I6dNo zVCEjnwf}()G!FI$^Un+_ANbU6vyb1m3> zIQHBer1_00?hqT^+0d3(@}^;C`P1fbBFB#3zmYB5n1d}9;DR&nTm2-Jr=X}7$>@8o z{u%6Ac>GJ)ABYoBq5gk7Ysjw1%&e|Z?R#`ce*hm8$sjcz7s)W ztfK4h1riq7a|FXuL8gFVDV~hjgt=4ui>M#W?yp}EQlbCiZB{0_1{18!-Z)sH!}g!t z$^`k|djOYdJB2L4o5feI6wBG);V4wQY$HQwAU=JB#IiN@Ywcd4pNkYITB{M28fr4p zu^asR^{2IqY*T|mn3kpGtlJy(G%b^@mxC)5i4t{fC?i^WojIgN%aA(bsQU%8wtp=pT<#)GlM2xJugCc?y6S}vE_r&p<35Q^804Cq=aFb3lw|~4Z*U)@1@;WjLpzKrf;0J z8YWH|3Cs#AmfqW2795Tgg=MI|S3pP2&d-hpC#!obVT*YPqQU_!`v+bpo4&z!M!U)u zd&!*RYmT?Lw7%5i!99@j3_>}=?OJSs8Rj|)#Km7Q(hLC&zfx8Kj$K6(QYaJ&1uUYB zPfMf-55Rmzg0yHXSgNjsr;XVtWo}z8OukSF1`;um17SNru={oOYtV04BlTkTVLq%NqtcW-1ZAPMjonZXY59m;?*f%-h3U1a zAbLWQROAvqQATqa)W>bY6`?0GNeigwUkcPe9H!?~(|oS?b=sabVl@TulPXn-f}>|+ z1s{)La>bKk>+pBU#y&!$kKq0>Y=;W?F7+rakQ6(ci1|pp;DQpKZPPVLv3AgA3EM(> z;})@QGO>8*uIdas|B4#UAeP$IdQC}xs2!IPsuOkZ)o=Wim#+Eij4A2U{9LNG!dXyA zNXV5~t8=faMSp+)RlmK1gF~f-{I70KF7K{tP#}k`LPSkUM%Juy+ILo4zJfCEv@AFh zf_x{Hp85N&m4sYqa0nzxM;Sy#@eE0rCzdyi8esVWi$xx#ov%I%dcKZBJJz77R;dKh z4FR8R@=joDc!#Bqa=i1i_&NJ@`yu+|a>F*D1-<&6DCCvk-Vr811Tg4~kO@T`ljupi zVkfd5T#>c7o!>zYFzG;_*Mk6mc@Q92W1t40ib_9;_8MQ@>~h)s@xdOM*9)%l<8BQ3 zz!fsP=}4p<61MD>VElrfAhBS-g)_PAPI)4^3U4RNLs-0^XVq6gp@|@cqqyDImjY|; z<&~?n5Sj0ZKcFBkQD)bVaK_-Fc8L@ zj-8Mf?9&5Rjj5*J%^4RSzP?W0bCZzrsZgaMW>cJ}`?Js~eEr^*XYQAh zCh)&_6L<~850pi&S6_M8Y zs8~gF68a3kABmf={)X`G!xln~f=d>!nf)q_JyugekZz*GW)WjMmg9_460^5R`3MO- z%L_a!z&_C6d3DSa#wz|uJ)ry#9iF&;rJPOTMVvCoY-EZK+!G{#P7QIFEWrTC;SuhV z-2&efJ9wd|n7qL;sP%~ycBkQl=minrFr+++oM?mp;|kZmt_TTvR|6!|VTiV;_cf#a zz4bvKASJb9w6+;~*;NJGL;kht@A(g`jXV8d(H3Ka%rr#+jA2jr064G<_(WG^DCq1Z z26)btji9ju+p>RS0OI>kEJY&h!2wPdaFAn$MM_~PnSBFsyVQkT04(0IW{#!sLZwN9 zbmN$~lkM$oa6dmkyKw5>wKe@Wp4->wuaEn*%7}bEV0?&O6WKzRPcibSY`Vyo#$D|olc zf~1d-yJT}fT#O8~k*S1WE>bQzH3&^8Zy0+Z@BqH6N`Z#$K%d+*Mw5>bl=9swy_SR? zF+BtAiR6l62?ab9^hc#o<4L2wyP-)+dKRnIQ$yWVelJ+Z{E#PvZOcdVT0SGsWqZz6 z2ptj227tvm6$eVQ0S{;3@mCQdO_pue5yu7d|JEwunu@FHcO;|jCw@&0_|J_1TR_&3 zNKH-;B>}JFK%o_Sg*v2I99@cMwO$r_q$r>jA6pzq4GSkcoP$I<_7ivj-{+J;fbDzE zOVp&_O9^AWxw-jSRz_!ED@~48nM55~!PkIfxjsTbNJ#kjm3N2;sDA-z$8-_kk(hlo z6;~5#WNi}B$F}TD@%>}S!k(2>`>(E~zC$MX_0xw-KRO4BsC3rFt5n!aST1t*fj8~P z3D197`G3B#!@G$}N+9%1VC;Bg8E#V^Jyjt_QD?0c^OrM{mYo$555uZqI}4&!4>cq$ zA4>kO>yB^qqQpS)8CG${(~*dKH3>Wg@Qg5S3?A+`Ib92Aq)RI*Lce;=b{V`LIs8>q zWWssFV5Uf0!02#}lS1RnhyRyLT|O{lBn1<#XMJ2Mv-1i|$fswr&_k=vPCbS0(s)O^n;~3HO8O3W}?P*<)#1e$;nyVgE|^e0Xp$SVe&r{-T|6cyuI6jX_FD z33YjS2^1Px+1W>@Y|H40Vxhso!5;-tu(1b{t*U~2)akKCs_M1uR?Pn_q$e&e2uu5R z`R)yyvf9x&8~bE!w;XdcwZB9WXK}zSV{&a`m1Cc_l*##qN z=lUf6u6R%pZC^B^5@q2g4VLa8?X)cdbf{Vk)!BQV*TIzp&{! zhR7rY?QgD!!zoESN0e`r z?b9M}pBh!;IxufEKWhL6-9z=m7$kW{R|2B9rT zt0>l_T-B4>5ZJV#w?pf2-8rDQmk$rhE!Z&r44jV1`a1sUHZ|!WkPhjGPgHTht}=Oa zSA~k6wWHt`OEl=IJ)&u1SC{aa`ke_r{z>8BAs{%}$i@c2$HxZ(8rpml89&{`*7ir< zvbvVHARr|r1qE2GJ1S~Nwq8RNoQErDWTjz3TT6?CnmSBp826+TU-Sz6j*V+ZXlGFL z!f=%tLCXnu-ME<*=cjw?_r-=?gIUh~2v(FQceeg$?SNV$qc|tC6B7*EOD0a6^q4}( z8KFhKt8V_f!#cb(PBDkOLo4?AZS{O|_}>MW6_fUzu!YTf14+M*B!~qB1Rjy)Y%(N% z0PM_2kgM$$QRtgrqAmNK5hC(dM{O6c>}_8wsv(3{F zOdiPqL_*@AkC|--(R3A7G)HIZdq-_`F6<+s3&!0Z2^-E9c~z~~zK?{8Rh$)H+|8zwd<{e;zJ`n^U&GHyWPQ;(p*wYHkdeEQRwN*9_bh zE2FEiof&uo8SyPj{NMaP?|pOY#hg;r3Dx-x27yos+crIQ`z(Hm>)h~BSsd{=N!*O; zwkQY4++9V|TjzaY4J=MVRUISt6vJ+L8A2bv#~1EK0&0SZ>v}?V!83tbyal*ix5>Afy=8*Y#KlQ^t&Q{NsFU zvjSansuKc?X}r5jrfBm$V_nBoaDcht-6iwMDiEpme(UOWz}@|pIpu~feA1eZ+2P`S zBVNA)rZtelglj7~Oh+M>9_Bvf)qm4VP^7GXW5jps_o9E=IbH}{;6m@?nb-<%4cMz3 z#MV}(f11nEyGAdME$ai1qIi|#^Clx*tWXL;z;U}*Q?(h!FxxF}^S;u_Q|4kl*|P_j z3G{fVwI(Ej{&`d@vi;`oh&O6fcT{I6g`Pule7TC#1aMQ4`|6X}&Bbe(dh7z(ALI!n z2WzY^EZ)e|UcBG4*(mSuLSN5Vlip2Wk($?f+u?PXOWTlRKAnZm?S~fQg(=*s z<>l~5^t|*Y_HNwakaY{)pMCQ>W<3IBwO}A?)KqIq&sm7uq*i{c8wZ?8!%!H|7~Uc_ z7V%L=!2SXqZJIOOhDsOzY#Ha#k@*}2E3T)(EYsc;Y2gIngSme>Q_F_vcmH~4WEt~RC&;qZgT)p?XU}fLri11X zDR5GovU-pt$XZ9B>?o?SYURV$pZml3=TpQt=nR&8S7drW45T^E8d}$$c&Lr;Jravm z6CR>q_~|V5n8!#izPH{>`%7vT3oc#G7|BpxOywF8A$tB_=wfmqTf@KJ9b{^ZU`U#U z`LEA;itKThH6h| ztDA{zV@vTM(3@JJrzW(4=U<7u6y7&@WmHF`)??m~sXD-t-&TWHKey!AN!-=H2D&Z} z{A686-oMZ6k0m%GQE7csfoX05*>3Rc{=G!*dZt`b=_~~VcBFsjYfPCnz2C`-XgFL4 z{*`?R@~OlQ!m%CEMzp?>a*RZ}M%u;~fA|RYu#zWpT}yWM>o>6_13e2!;$DOH_o*wH z{So}JznE;<3C*UlW9z}^uO=n>uJ{YOE*X_NV_1D!352w*vt09rUDIm|P((9fKbXQC zDyxEi;^Yi|IHhPZbx4aD-RC@O#}w17;R@lXm!JR1QL=!oH+-?Ve-zbvLNAo?waI-K zoxC4$GS9k(d?p8WV=|8kFC*geE&=|ls?wK6Ik&{E?HIx089Um{JS(HEEJ!6w^fFZ{ zghQ#5gU`^Xg}h{?^WrC3lTem|KSrS&&)b7FHBs9`IfBiu5Cc2(hME0`FvqVD#eis} zIAmf!=gVB~3L1&{a&fAN>Ih8f4$EzAMqx>I>>>$apAJ&@PgJtWTI1=G$slT#auk=e z7nB{q&x1N87Wm)T_TeOfl7`|F5z=>q5)nCZNVThhFQ{>OzzzPC{lZQCv6;QL>>lRQ zf|`N0n)1jM)!R?-PP(gt`wNfA^-!x;FSSU;!y}Rnhm$FoD>YI3g3-J^U(@MiB3YKI zyr3qkG+64rhtXvvx3{V62i+;F8x(wvN$xIga1)V8n$A?q2@eO^1!u4T`0$aE=+)2j zKABlFU=7-HTajJX_Y-k2azBj=RO>?{FeAmNAA=UEX3m4+A)&~~i6(29kV2E@1{wn^ zIFK)Mh}^F~4cpN-`K1VJ=8~!i=}D;4GY0L(gf;fQS--?EpjnQ{SsHr6n8x9XL|9I|%AJ)SNXREmT)Y5+nrmni~OD zl|j_o5C8{&l-&i63gDcx?qxBX5z;Xed8LSZ?Dps_REI6VQ7-9(G%$M=bJ%Ad-gIm-o(;TP-0_Mv1XSBKghjfYhU zVy(iyTTA}b^=ubI$eE$GSr&j_rAxCmFi|{02Kceez}1W7h?ZC(L&E>ct25rbpNXZD zi#9i+ME;tvAq-JSP|?qR^cs*R*+h@?28y5~ZMO6CL1yWh5rsiUXY5RNj%qk;~ zC`^&^amK3au+s zR1_Q&k#~v8B}N2$ek#_{hPj+ES-hwB5Rl^M4r04H1m8lTGtOqjizs3fJ}R0C>@YSV z;ic49P71kclsikpbWNc27dTpAK+Jidi8=M6^oubdCEA$8MILNKXax?&L2>I3Z)Ctu zsoM*Ge|~ZK`3(Z`4HWeXi9$?F4;ZiK-l`6NJoRH{jr57Yd6kDnpFlq%IU{y!JXQLF zo?ycw4<2?wC`SPcrIS0VfR1bX;0IIKj#gLq6jTc=a^~k>#c%lr$i`PL=D#^J0_Vh< z$-ep0{bMX(DE1K@vXki70~Sn#h=hBdHb zXDfbf#;i{7s^R9C+(%TEkQJ5iH0@_yA;42%IsE#bXk+d1G;L*@=>)#!8%=C;>J>ha zQ<4^Rd#}On>5+ISGw@NZR7#_JZNKcr&(j;Zx^l)s6}?J9U=x)E8U?dfM?vYW{Wy0V zL8I;YhDdR|Y9PC>&A~<=;PTxKGiOD>m+6%Lr;a(4?z&IUGu3|0+l282FDEiE=IK@2 z1#k}lxuofdMFAsD#=ge>0JT6RmBX&r)|PR?$FRSFYRZ$VQjaMd0%VNtN6Oo2Z(vOg zsxyN`IdycrU@lJBVnY$C7r<-~<)8troeyC^M3Id>+mB$NaKWFa5ep632DcSt!F9=a zGvdu*5STX1Z$e$lgk`Cb9af^%@Wh&4{0;e8AK%f`j43IiIrP)^bFOV!!vWVdzss|2 z@6~w9#^om?BTB=pah!-EbduYdaFo17O=ebwN3v=A206x*N8U$)4j(2P{$FVAvV9wC zg_j4*4VX)J8R6G0uhq65=9*Uz%=Lr2p@yglu@^r>dshUs$SN6hv7R5AyA5t6niuZAb=@LD}%cl5Ja290$dDw)XsCz)%swj&k_*t)!%6%Xk$kgTElo zXW2gnQr<|*9P}PrTfs0=6!I2C3&i&+zf|Di1;NltJ+{O|r;=WPvY6Kt`m9x`HyJ(D z;bM`3-}@PEe{Vr-^sCUI%ZYM%ahykss1pCGV!kgg;6>Gj9^=<1JP6-TJ*V2yx$rCb zQl##f=QDS=T?iyX{t!9j^{u()$71YjLSI(GMQpm^)kKus(+7S+jLB12HY2ghptuvY zhMV&xa3Jw1QV{i1mS|-7q>w}_B{t1VZm}|M=fTZ(vLzjf_$lf>D`C_OG+cabC;?#| z$yQq<5J~*uWi63z6!d65dltWP+zuxBsoN|FogVF~p@d_}<|;__4v~)+>syH#A-#Lb z!^7~bE12zs6p+CAc+_)A^JFoVwWFIntk26KYU!qmUE5()G=4DK#($5!G!BzYn-Ze5 z6~0jQd5%cG<1R>C6AzQlj5$IPD=d}qx#l_yAMBItPq#9pgT+FkVQqN-$>pX?O$ehu zc*R3^2RLe?ebb`S{03yVGwr{v3pW|*^-#kVi&or*=2R=u&4y4OrXiod68Y==gq5AO z3q~Sb{;98J4TBo7%ta(dP9KT)4^+yhOdckVzy!*eaW7)^f32E+QYdq@Pxk$u=!U^I zvWJkXm(Hv+m>vvO`BJ``J*WoNpq`%ix<9L2Cc9obs{6bM8#JG!^pA|>)O+DN?d{0%Tk(rft%If_LxeDlq@ZFJhz;*TS+F zdc733@MI-cAkxdhFXuFfdZv(K7>>;0c>|Tasw0rwfewvV!FDo7Ua|->I%Ih-97o8F zB*sT(i57cv?(TilI1JRv^&CpdZ8D=8VX2ND-srb20sj@x&>$DAAOZh3op@dcs~J#O z#iElBLI8G`gr#nDMP|!!t(P0b z4~F1sdjck$~yy&+LlprG_QB@ng5aBIzIO6_8>Y7L?2!b?q_6LGtdr1 z+9b|U?mbkbbDu14*_Oe9MV}qm-vP!Jv*q*}Y3Q@%LcXAN8O?mIYiphGY}!lTCK^Q( zY4~dVCX8R(TqE_N!A+B*&PQ96UdDB~yUtO9Km1W3jkb`FgTUuIB;DW=#!$rIq zxx+JZa*Sf^bj&W@`EhV?2Jiiwnz$=fy(ms7TWo(Vp>OhL9I0bid2@ zGn9O@k7V5g028+*bUW^d_^stGz_PXmGix;6C_vm^)s0?%{$k!Lv`yjHiMeA4HT+(N z@yTme#NVCi1doT{St#7d$^hf#Uc=$(<`4rLyN$~(EQA6P134k#hOg32D2VD;>A|z2 zHFtgn_HTDDD}hWQ?VPC%A?0=L_A{h^sJo6c9PedT=644$Dn|YO`g?v&ohy`!8<@Q) zy%0K3w}VD20jOk-fVL;{iRv~VIRvdeILjHL;?LhaUir~6=6oVeimEo|#Q->e(!{pj z;Ziw2^*6a9qi9$XG?X6=uSmVwR5O^wAX6!9Z0%aRPt=A`Fo7t>j&?7aX`mP`AeYS} zi)y)<$kZCPzCh`GwIMA1>{k-DzBTJ9cn}EKZ{tW(zH+d?EQP;2-k( zQJM{?S;aJ*)mE)P8lJ~XT`kNO=uzys(h8m@k4dFgb@pZ!U~lXL{L|+m91FApfh0Q9 zugd6jM<|)(*t9uXGYGY-w1_{S)U@McfvLOJudwEs_8UtD&@deAp>~-}`n*-$58*nO z@;l$&tlvY8Fc-;;RfoX97L)7yi`d4S98b}Rg7A8DxsW=Te$;$<5x4Q73=n&-e^{@E z8~lAJxBCm2rlaR)nXvUdcglSu9#ZP_E^-|7!6xpgx(aIf!#%=q-7_UrtKwY90v zAT9F4P!Fl8VY#`zMI|7}bQQ9(h^w!6{o4^Ay*0J9Maj`fSXmS3=Ja6^cUDkjKE@w z`%Ov)p<^RV%Wi?CpxiSr5hyb32+`NrV%7ULMY~5-n1q;Ye!rJ47nE}O(TI*8qTXM1 z6zTO17l>H$GvJTX)Xcwhq;! za63@U*FwcEUA)t{-TK;o;4`xunFN37c6&tp%QM=q%aJ^BzftqxU=x^kpFUxbFaJKA z1BjLI%81=u3Mn~VKyr^e_1@B$eP2vVLJ+aDW;TBCYdXP1>`U3~E_SDjG79)Ji{(ah zR)u#5t$D}y!xVW~Y8WVP;sW_*DV=+*eYrDkhZmN@Xj^})WVDHqG8@74j!8&>;B#+I z7==2+2{17P@k19KY~i%($0b)2l(opE%|P8rnlLF{)!@)hj714}6EQag)=2AG@%jNJ|E@Fwt}+q<{cl|<9urg=>kd+psNG*NiqVE{ zR&*?3&x+%sPA>(Lm06N^{|2@>NGlwNa-KNU zEfaiiDpl-7KNVC<1Ex~h7n$M*7poa*=y+asH7ZAuhl?9n{+BI7Lk&<4>!iVifdZu5 z6N&$(=`F4W@o_L)?OB?AtvE&m_p!ypc2E}Ef#%jJqEe8=_Y5~z$`Rx!JNRH9cI;uPn zBJHUC3zhznkAA61Td-qQxb^Kco0CKoC~pHVA*}!u@c#Mu15+hbFzWlj$4f^Ysh#9h z74;^62(RRP|E|0E_y$meRfjD9WN2#^^(J8DMDcyW??Dg&&j*DS_s5qE;K$04z-IsF zigENnX*CcLpVM%y&4b(P&L*A8&i+q6!aTzv6uOB(CAl*xa4j903<@ePykPb~GOf6z zr15ftEe@+GOrc_S%tDocv-QXS_WT#C_HpSQzAF88QDBCba+|v&HxG}|pI>G`sbfVu zL5q=*u~@sFHigL`hC!#n@OK!h#dJQbsHkX@7daZt?7PdTcXuOmVm`t8;{$`V)ts`hb-9U4)v999UcK;$IeVhOiTWmW&`s$B z^ByJ_7Ni^;m`z!6HA>sdD=M5_mT4m=_QeX{;np^(jJl7J$o$b8CHZQe>FIcRwS6nb zfLRd#$9Tz60{b6Cfe zy1q-UpUo*1|HN(FyJyXa^}IU?Z~b~+$mH7(za*&xP`ve{TZFCA3BSFGCGbDF!OW zrFkGgg#{qw+qJ%)twTCo-PkDQ4+eR0d#v#x*MG_p4K}p4hPSu3hk$@^C=l1;hh`(y4JzlzUy=lzErd^|%eiRyTW`qciGy1cJ6(=NLx}_&n}GBN6!p z#Mov|Rx8L>fQOFHJtk~!u%a+@`-?HHA4~J;`_v;AHzXMA5qWvTbdO1E)#6%>*rOo zGtt|kHHw@!;KB()(VV!}WV~gTf})}UhJy2%RAGLf%O5(jcDH*OnoU=%jY%u`$ObD; z&k)MxX>>9>+klwHb01Vf^nqk@IQUrq{RLuii9RQa@Z8+3o#URK&)GsWoa&?o*cb$T z$>a&LrdO`Mps2bsPA4q@L8BEFr**%eo@1{gfG9Sj?%=G^(#&dFdU|(_i=+2DE?f=y z?Y@VDMcoUJiFnB|CBF)}0rvNPVDYg?J#4g;#T?yyY1GHq7)zsA(^3PW$Hxd55;$O5 z!K>)0*DWJ3??DgkNRiM5LK%%+RDlP0upPhvQyIvBSr}wH(!Sj>j0MWFrAAUznDm+` zSy@?@SvKjWqvPWWZ-JP6JR9pF2oF{4%+*MxrB+!4 zX2tB}H39-0rXOK>8!EraVkW#VzHcT9-4Qj#YGa-#Ri80?iPXv2o~Ie1a}Bda7lpR?(Q^B z0|A1&1$T$w8rEwl5{9=YhtEK$g4BsBnDE~2H{)F8bb;mvGBEzjQV;%1_TJ4-AT{if*t!o z3jX538{7L8?>VCcJzwcQ!$ZT0x6h3SyO3g)s`wn5-R=^hvSE4T$_>>k1?2B=x!>X< z8&dFdVOJPQVR~VPM#QegnnKvyLt8Uwc+-E1l3G7aE3ms_PqeGrl)`dxzesE?Q=%%i z-nfMC@UM|1au=)w#bv$=e1J@@7m=c z0;TseB;`-&Yz~%MZ5wL*J?9Kmpm?d3qR^8w#~t3tiCyM;R7d83nmBP3=F&X z7=n-uK#!8|zPm7D7GQ4;nr~GGHBn-a;J_(<2fN5X!9(|f%t9h@MX-tBl(+a19Af0> zaq;LA$XpDK@{#zPH?~;~KnVtUMr@-K0Y3U?4oU^#1yEP~;13Luay27A#UUz`XAzQI z*(Fa&XT3lK&Ce&y7}-&M%M`o;MCLQR*2qvz;DSSE?N zoW;g`B?9=ay_1vJtE+ub3XTTbOvb$Q2z_X@5CxI1qFjNGmzVw`M+Z1(*knu}<1QGX z`LOWeiR;D(ZM=XkgrzOr%a40)bNyg?*`wbjPF&4*d<(}-iB1yb&?bTT<8{Pe-!p>V zY$9eU&}o4+snV5Xl?6NyydxF74bBQ?SjFxwY%xQyv+_t2t$I-gTvH^H8ERw{&#^ zOa9h&caLhcT-@^g{sj8eRRZA<@v-2o{^OK6{%9lW-Xv{%d|~7woO&Dxdj_?=&rbe_ z>!yMF`${&oWPs!I$6?`L6j>n3&|si(5>6Htva_AQw!`qPJVVVia6Q-0nD`C^_GY2n zLm2>RsZRjg8zAgS@W1RAB%-rnKzwm#D-hEozUH7p1cv{bncYrU`ra;EX0ge0-|wwl zKs{!+ir#+jVQNpn<{mWW64X^`NC72*b`;&9K!BD)+Q4Tzfy z8hN7C9z_-t3(YEG1-63!dLO_xMwPzu7w2r_6{~-9b7(98j&vcI^4&#;jP)yd@in$R zJtBN>x`?44T+DtNu@?GFLu0c`6@VlRKSq5}ZyMu>3geE{@eoOWdUGSPqlK^E7AOR^ zaW8JNqvef%s|c~5=%`j?7o0s*ksUFYDzdB38`X_@D5x2R9-~7`mJ@J>p$PC2|HS(n zJgm?Qi+;}ujGaF>%~uY{SNlJ`e)Ju9*77kPG%TKROnn)I?z?p_dN7Yh&8zuRH@h4l z=BOGPk#7Odx)KQRp9`0ueyZ3#6|UOXNzp3e_7VC*7NRmE*O-Uq_IOwQaPJEEXViH; z3#b+9%nT<#A2vbhJ|A$ajV=bI?XVd!J*C>j0GZK-6+jIaz73`Yc$I(UEH9}Iqpv5l zp$+IV7(P^VSwn}}bD9}Hnb6vteS56344>_hvUJIHBz^<+d}~MqxGMBJVJ+sW5Of;s z+kvpD>Kjid@3r9iT`Guc^}&~ZjN#fz;B4QSAeG(cCF_Cv`zZi8cQEeP-@x0e)fiUze0?YhwHh!Wk-+IViZ3aLAOsGMNNIOWMmpa{fMa5Hlu)ccgLe0 za@A-HgM^U3JXK}la)yGI(wk`d}tFn-0QBx93nhbgF2X>Bsh2}U5YHm|};_5WnI zLs<;yCN||d-ioXoTB1*CKsD>q#MSlyke>bVOsph zUEyvx6PF)OEz|rk*5n*&na!Qdk6@0RcAyigd`z{XHPuZJf_rt7NkmU=Q zyVR=5-%1HGwB`wKG5nq3z8oH(%E7PvX+uge2Rq-BbC`n}TYSz15A+f>^v#ru&Yjgm zg|`}1boJ@R6~$Z#^osvV@ghJyjXN#OxGDjDPkf~+F83h*o+P9)7GoK^$zmmFimxLd zZ)!ipeLeCI2okrsmLf_4F)%WcV}_s;BwbBf7h;CxjE-SgOKV7D-R6H=Y`D4D#j1_d z?u(&1U1^8PIQ#O(EToit7|fw4|2mE3GPBR|vZl z4O-Os1elen{tB?&15~C`b=wVd*%@a-32`9d)`HN|&({l@S7;{R&xDIJMSV=+wX{fX z?gPmMG$0H*=7wHBonBG{t?`(&TG$y>MnH~sLluG z1p71>HDs21dq_)MIJk>gepa7IH&F!I7PU?z1LDQjM~U_H(<7W2F@8uye2r>$4kzn#GMe0( zLw++|X)WJE(OL7TL=2us#tkLWxP4>@1A@nwg9^ZEcHQpQc)u+_hkL>P?yOGbv@vV{ zf?cMA7&aW4xSbvjFt^>ea)L@yu8-L`b<%RLG_IBz0D^kLPas|R_e1lc~n=oqmhLA|n5l$!xE;Oyc zc8_SX-f%Is3%`4Sw=`b|6-b{f$Mo%JWkL84-i_ilGMnGxK-;$d4owwKv+D1y-p|FezG4!I(}KFnH(eFHjfG3rX-;N9EJo@^OY1P0$_8 z?a+Pmk-psG?)9WG8HE7xh+}cP4HKQybCVG6g(|71e_$^2)R<7xU4-7V`6wUOUOJz+ zcDx|7!>;Y%kuHo$C<%eQT&hpd7Z2pLYGi3@#}9Pfk;ttncq=`R0x8#5Y{J30fJg*- zUHrXJojh%1nYB-JJ$dc{@!k9|xdXr3B?&-@uFqL8{}n|(sxQ!~Y_MNuGL*caG<cnKA}P^I*y|cg#?!U}iffGiT-?R88@Efs@cmgtS*^>SuIlGi z(71))=fF0idz(ErUJE)@c^#|v#7C_(mc7VDZ>mn7EaQQro9kAX9mV&X*xanpy1afV zXBU*BNst5O_RgkNyUg%*YEOQ979y&5P^G4e=v1v<-`f1XERw4;TM_m|q=p5sJ$*=_ zju>k?|8P-gUSjsE2afzTv){=ZPlQAyvZOhqq6z_Jr-`vvS+=Sj0m3kvOVNluhp}u) z1bDx5%^+B`EeD#_ANvm4t?tBOjXbY+Njq!51<*Z5h>Ro*jk#>3o5j^pWKD$U;E(0N zXkLHN*{k$*&sNA|pKmD}qfDHa93d#H9QJhqwl+}p> zOLcBjVpxYSK?r#sI1W&Bl#+Rn5<+{=sHA7ueUl=ybNQC>>gKt!)CL1nDC+fQuy?9# zTT_+fhKZh0lS7;%<1~G4zMp0mvF#}PYA&A>M*&nAtM1j`2i}k*DZxh|6)^Q<-$@7MM_H(kM0wCm%x3q4G0{!oS z{Y>gJ*2^YDP6;K9Pe4S?@#9ALhyx9_r>B+B_u#B-)^3J_LIfAP7@wqflu561=+pNP z5L#O1-=LNGg#G+phk-sAb)Zx5D}#w>9-*$9khkavZI%23#c0#yw)~XWwK8qidqSnp zTPwC>-%v?FJ+7v=d$U?nAbA8XV!8hCsP$rAZ?)vIU46IEOc6U6KLp3*@{tmY3^x$| zh-3MeI>otwIh79z;w;TkG#x@x1M|ZtJa_o|c|IsZe41Of&;2Capd(X%^r2w*u%5Kp z-i)j=KXUqeo1Elrg)YqaR75-JdaVFN9P7)yPfZ^8xB!gY;RlDN(CX>&&2sqW04Ep# zp15r?8oywPKTTAwjzzjzWLg3`G)#`~l70%~z56Sw@ruYcVHA*N+O zV!{qdW*SDhpF|;#$!G|>DK57`@THMnV8V`dhoHwEpskUIhTZ?B{G>-%fgqT0627X? zob~`m*_{JP$Y~y+TB4cZ5PMcW%-&icy0#QJJL7)Oo4Fpq>|_!CO@vzSX--Fdsgf2C z-v!-hG;?!zpF-cFQif8v%0OL5;0Ib~mw#;N>qnBLqUno`?#FO|6W;O&-#+9B=cvnT+E?*V>rOP^(fSl7X9%?>9)p*Yh6dJ6?Qth097jn z*bH9^6-nZ^v_NwEhj9^u;(wL1qSr+desqdGQirAaR&-@|;yM(ft5$UPX8_pIObDB? zc;x*t0j7M@xdf|}8m>R5mFE+p45BbLou&i}3Y5KK?!Ec!S98 z8g0#gF0F4bZ=@=UR(8c~EXT-g9_X1QGjGaWO-$!85eVDz0=N9(RsvAijRRSozge`E zzMIW-Euk>g^dEJaOQ61G)z^G3n|y{9)~OP%pbX9|k! z*p0mb&K8qKutsc;-kc97o!Iu5O6M-SP6%T_OnSuY_7mtGT6fsBlp?f1JdfEW83V$R z=_!XLoaRUrr%Zarv6w%__c>5}V)<-6+X9F8O}F!Q;+-?zmz$Jm{rafDR|-q>z<#|O z-6OvG(TKu5GN~(`HczoR#!P*XSidDBf4P}jDuKSMq)(HD#oz_NwpiQ`j8eGb^)>U| zmqn9F+74eqFEkXEz|92OIs(Xt@GY(EA3aq_qF3Ai80{We;MYsOqeN}S`$Hy`IQi7JAmf4do#U=FJzi2pE3}nmImWRj z4f==reiR#37;tdh_efHR>f3kv;3clyvEjuTC5{5B9jjuu+k| zt)|Au-_aZ1-~h8Wa5D_f9!qB;91Gk42QI7lFt;dt-v9vDg`Y*M_8;C8{GAmVVR^Ps zfh&!vp1vsJs`ALp>tIJl1*_*`yz@5>hy*v-Km~r19JiRH4{B9q=w4>Gz@~AI7k$GZ zg@(#Vt+&})-9CgI6|4(UVp7^!T#BPV^yI^U8@cZ~aUbaI4e^c6EkvYg<@A*3RaQVbttu)`s1~iTT=E+F%_`N>LwG=v2$hOG z^W)*_(^?dh^Z68#4+|f7CO$fyzKs^ibD9n)5+UL;z{|_a`}_M_=MYkdb$~dTPRT#K zip|_qEQn)gO;lS$zvv@5ZV7rVXBH@&GtgP_L%${xY#`74IbVU?{qc@ntxDcgT=`zZ zbtbk7@1?}_CRq$9PrGoFNzO)hD_ZKk$q$KvHLn|A)>?3bTCi&BE>>Pw$PgkZRbjUf z_*qruFF`46Wb_kD*(|5&JLri2%>SO3?BU$hqmo7*Xq{{dc6LvZ4)|3fA z8~876bn!2M92W=uf)B$*n*i4qaP84TL_fTtfl~MuPXS4b)@Ke$+xV{x27r%m&Ng45 z1s_v+-IeVLh`68m{;_0^*5;oQRpBri<()l{#7+%V&x|dF0de+>`^NS*sP&mYe1;1l z@(3T;DgblR7iY|W1EGLC^k=0=)JqWYCz5apPe~ynd~fE>?{>A)Hz9uFgLmZ5(>Xhv z)F?j1<+#P2JLuH&*!x) zk6t1dpNPotXrUe*K8DODGb_t)wKE8iH>c4nrk;1>)!naP)r$Vqw3i`vB(4MDM}z4V znK`5yJDKu``5&Q)oECgQR``DjNsBweOle@KZGC)v7D^6Gfue1CI(HFT>ohb6#LoWy zKptjPpAn!V{aI5p{Guauyn~UJmJSxpWZ;i3$}Ru@6~G@JA7AvyK%Mr?JVZ2RwMv-M z65+D9=6;;l6i!n2KSE4wSf^Bfb0>L`E|9SPeFr|92{K@I)m8FIN5!7_DajdG7?SK+ zYYa*(uwjAlFplVaEYPwPfa+c~H>!MO+RBWW$qLM6wAa6yg+G`Z1epqTD#?kQYAy^i1H#{#uy-qi|E6)zr1NF;N&5Ua_5| z*IGH_YPb)|7gJMH6F|W_bW7@#)1bme{M$2Fo(hh&e z^r#2zYkX)deRg1{1xOY{84#ipSNdM|nPT~0XCS&b)@C`70FeGgQ%n9bAlTRcVl2II zSP03WM!=GQ)>&M?SyB7TSEkZ>Lzm^}41=JrJ8XIMQe64V3E9A}N;ZtNJZ}VzQz5>9 zkAKjQYQ<0gv84ze(ZLd~@|IZhvp!{$SQGh=^>c6(9!_!{C&Vb!DBkXR+zP-M$S-`@*p3Z ztvs&NCxXzjC35HMb`U+eMuEt{8LgS2Z}O)wYpOX$G0MPRajylhwSYQoasEGI?ft*g z*gs2?b+bRD_spE%jsDib1c%-rggvam;O562um?)X19rJ(UeMo`uQ#NsQc5Es7*n`1 zg*CLm`D3RNz_+8q|H;N-rP?$1ewfSE*1v%h{bgmE5TAn~6Mk7o6%#*KLkl8U*UXfk zF4PWj#Dc%U7s!Xil`$XrQ!x<5`me`y_VgqUZy!+i)FUoHh2Q5Q=+RkjnNE}qkXtep znx!yKocX?myzJ@F=!1sVwdc)%Q#l|*o){a8)|IBjyshS#`29OTfmT#T26=6L9dQ0I zHZudi2$3yB7AJq<20omPf|$@CN5DV{1@lUyLj7JIKbh!Syn7cE&@#pi zjJU@<9Z)we3c2iOZ4iJYHT^bZxHBcg;8vKKRb>q-u`|t7Oq_NlA;$1L8rWdn$%4be z)}^WwIX1Io8;@3N=1sAgz9QTUZ)tyd^EW#z%wkB~hRoV!`OCs>LD+aC$FGxlku%6r zH~ICNTGYaX3S-2~)1wZ^@6G#gS!X$VLmX&X%c~tem38~3{)IWkn_dYd@8bdMuMW6r z5w3eKM3@0Qp| zBz(CnKORebEHD8^^J2fJg`wXfHuvI=;y);-9=e2I%l|$@1k%y|oFQ)jMwo5R9DRn* zpr_fF#{XTx&S`I7#Bc_=RlV!~`-lVI_KHrGbGTvG_1_fHP0zacwfS2Yd;xu|qdUr} zYPt41{7M_nt*W>10$9QiPWD3e2%OPlQ!98Rz6#gB7nJ5QmySB)GAgZ49B9w;5rvE1 z?rz>_7I7mDDM1 zihk_X?99!>qCZ|hfWgLWGD!G3L%d+D zPSFq{O$R^1fPfvA0xc8N316qGvdd%4RLQR&#_}>Nq`K0G>PW3($*=ru6rjVPS+B+Chy1{>%I~cd(5_DsJT0BFC zY+b5Bhxv-uolFuoRsgn5#Z4X(XZ7b(57HM&SUIazFAaAQ?4H-(s$smTb!^yWRy@E7 zFP+4?cOSoNdH*5kP}e%2^IE4!CDq8XWiZq|TLzWlPY_oxhJVCB5EfA;x?nqu*vL=R z{Gkm9@gOGnQ#17D>A$wui}yA zaZ+u@9vsn}c)Wfp(tY)oz!ila7PaS@uTK0$X=%U|K7Wj=aVuE95k(Jp<#{t^^|O^3 zvbv%!28YlMRKoap-J&iHN>QlhoKlj1dLkMVr=upiWY)|U|fNM_@GQRy>d z%zrVk?4hGgM&W_lI)-gw7KSarZJxrgou%B^6Rq0ufM_=n-m)8c%_{#+P z`I1Vz_Ou;%CGLbL+qt!YeQ(4KHgEP@9XIzQ8Lr{tbcR+Vx3eBU`u)2S5x0~JPl>pd z%e7pyp9>@(pLhcI%{4n%S4%N!S#l)tEW&mI{6MuonhDf~qhR^kY6`L{RvGt1r5((_yC@bUon{DZ-|X`; ziyD@JQ35@WHZ2J^l?ag4GDV87iTpaTRFj`1^FqPx)IQm3g^g$M*%BRg&`@7WYa_e`S*m@76qJQkX?UEry(d zDme6I3qTvT1MbmOY~BtsQsoWZAB0UWsn_+#&pz=HFJC4$g}(%WG+O7;Z^hAb;96T^oa8Ysx70_{bSJED&M@)oBD-_tOCS>B$XyY6(?8 zc}20V(h(mPG#{W=0qN{&k7E)}5TF>lW!RZC4KHP?ki>BE%0zwvrIj$2xz^l=*lI^| zDZOVm&xUr!fiLh8u&08Qdal53bUf%7tRZ+y?K~nJOLpskP^KWj%YU-nQUyg#jRmsG+WwIzz ztv%q86I9Nik2$zzI&WRNR`I@hyXL?|JzmJv2ihS`w z7UUOX8(_UzXbGwX`ixwW2IltB6J6dp3K6uBX{R3dOUHR>3rl=EJ2!uA@QUJxp=I)J zmNzo8{Ww1yhT`xpz#_EiJya2&&z|PaJ}gwJ>McenVg8|p@&fBJiMo65Uv-1|zCw%1 zeh-Q;)g@>CvK8Xc*`V*Gzq5vzf(rV;W1qIFA(nT>}(?5Y zuJ*D!#0LL#7hp~M^}$!Zj32#^-aj<{aQv9qpg@aeHjZf`#$)6!tl3oZ^zs0@Dt{Ky z&(x}I6^YY&^TLsVV1mG5AFWN!>0=(i84#mgbHEUvmhY(Y)2-hfHag*E$1zMG?$|u; z9;-@#nfQRUKCr0FWiv&P^877us#9&PtNFgp(V4^q)xtlSB%yKU)|$5N zU2Z7}f_QiRPdk;F*gR(@mJiji4*KC{?q2Q~y=cU3r_%DL6Lr))mwUbma=Q-bk|&<8EZZ;U9M!E>6B<;))dk&{pleX2g zQ#A#C(>CmY(pMPQ+eHO@lMxEq$%BJX55jn}8<>`dai^M`{au@)ndqPE{G%4Swjbqh z9g>o%thd`u{R7OO$3DBrYJZ1zB6D54Eg~Cq`f)XK@T0ge{$Q*?_9GD4$4vJ#0Oqh*;?cv)U@(d0o z#B*Uv-x550H`N=@(3?zcz@?Z#2z^^U>oAa^qyhEIbHRVWPvIj0{T|M{rH5AqpEXoU zql8Wr{Kju-*Vq>XrC&2BV#LeT|Ag)VEI#VcW8}+DdHf*l4-VkVmYsz&bxGp~{MUvK z&j+t~g0V_RPS`f5OEn#0JZ@PT|1L~qQun2x;PcqhEP-n~*TSq$E(hG)AMOy)oKQZ_ zelV3Gse*T!4b1ao57*_zsE+Wp{<11V{7mO}F^?gW?1?B~62W4=&ZQz}3-qoYbs+Xs zAXXk}_3f=RJ-K;+;DzOSbGL+uobH99zwkIC)_NU62X^H{L@_OG54P1DM%otxAAF{mq_BbK@4Uq`Bj`;J8oof|mV(j!`74Rj(j z^?+=2Odb0W;Fs+g;?P@DZMurYTeUwZ2i5BrkogmX7$5wVsQ=*s9eYF@?%s}SSK{)| zj5xnlyJa8ghc>TW=$JkxKidpfpi!C{|BaKWAtH`XP&sj){lE=E7q*4l&2w|sa^)Fr zzVl@w<6FJ8M}v)nZQ(8Jni5YIh?aHi7Zr$cS?`J~;3EBv&NdzX!NeeK@E$r>hCebt zkgdW*l>0X?c>HVSd6<4%CbyaSHO~CAS%?4@p26%|0sd$MoNA-ikJF28d`&Snad`R^ zQ1+9+2_75M?_6}moQF_sTv4Gb=0bJBhYM*_S5(yn-a5A~R?g4*4(p-$^BGK)&0;IZ zq_PSHU)=`lPf}+KiP`rkdC!eC|3GkDB_$KTTf+nrmmwcWldU+7Qq<#;WY z+!m6JO2qRag_>Sl3qlQqpP>7S&8D>=wq~hkgTpvi<}0W6hx+-`*1pP>HLHLcq-jI- zBy2{tGy=`xS>KS$y4|%4k}>n&Jjf=mVyF8SxkhArnI2uyWAk_^YG#RxN%z33#Qn44 zq2*E5zt*5^T<>U!cUD!~6PXolJ1r%m5(7##?GeW{=KRGovzmx;)(`HtJ^$65(C7CY$HS6~6_M-|m#% z(|)lmi`=+FTg5#Jy)xN+xu|GzX{g&XCg4g}S{2V=xM+4d4ynYeZJ zfv;Pk#mo5H3~R$?*ekI@0~XuoTJQDy{JNOq>UsKZ-6j9j@ycfsPa@|KqGd2@UT)x3 z%yr%K3>s?-sqax~yDtnpIeg+T-32Rt0HvhFHa>Khk(Rudg$p$t;` z@-5JNIp+d3q{Dd}sU^LMvd}FQi*}H6U=WjGlGwfJK^ikr;+mFWd!Z0*L6VPV(whY4 zh}|0rf5PjwTr8RVFP~712Uw239B>e)PD4|Zb5?kUt?{wSkQBKy@*ry~{OKx&pGEjtA zBDve?*bmg)BOQ>yM-_{^UeB(IF&$>3V{!b+q|oO5``4@F{-1*M48(bZb&G{s(ExJ>c`&Vob$mgg?ZBFox#q&21)iT>0PuxAXV5E8NREl&k zb>=?#7fANdNJNH*2h=A)7MFy#t+S+Kh#FgnN692S1QqK;?XR}Fq^_!u2h#VY&RpXV zCfK%+3QKqb`#jF?*whIn2qG=>9p+_W7Da;L=lK2n7*KY)lVQh!bg)%3L=kNK;LQUk zAY45^LI8Wvk(S^Ucf9`OXCP*IRaZMRS<4Pv>VlfmQe=G<4JY8j=X*XUM0@p(;>qGS z5zzu0K0_}18bas+D2#o$Z0?>2X>RnA;HS9Fl zPQw{&2DC$n#`l`Wd=tLqvh0Hr5cGiL+BgFqF*Kkzp+enS2hI|&^n({1;~vQ?w7|f- z!RK4rxf&)-N`6I}b5be$<47J?)(7_oZ+dBLn@6s955Ym720V9EByP9fF1O%ukZOc{ z&M~mInsC0boJX|0AL?>h^qi?_VqQO42b59SmL1|9Ko9r|ZVSjv#c{U?xigjez5-@kB z&9x8yWT{1HRur`L&MaJnOj3h$=C8`65-iJKiJHk@|8)GaMdIJtXGKvM5a8M%i#$20 zdZ&NWkVWC-CH9@S=E(_D@U=hl6PDx1QtLE2Hg(br&a$pHl&u9?SA7&4iCfMdkuOn@IC?0;7T8 z`pizvPR$DJ8)7)Ufm;fEHR)Gh z^TM>h+;e`t^6a27#!k3dF@?aYy0lRI#SwdmsY9<$c#6Sf0J0qb7PolI;3pE%ac^<1 z8cU=a3rX8qNA%j+dI)aCG|qCTO=6i;RuUvm;!eMGmt7;17a(bjhbKodw+?l!Gp+5= zW$$yEnG@c@k{2T9a*!=mg>$_lu_|A%SYNA?;k7Om#1^g$|w z0?stP>p+z}I}6;KIaq}893~w>7*gy9{==!sSxv@{a7>V)s-+M_E!fL~ zO{U2$eSN-OE2c(#Hyn=I2sB4HM||+2O_DlQ7TNuSzgeMM?AxDG#aD36d@-xFGDLbg z^3|pYh5gsAB6`sg1~SED*058x)Mp*I2S_R z=Ocy_Ncz!t5X;q?fj907udyOscd#5n@y&;sPLZgD$6hqW)mWbqTG(p2%`h6>*nD#1 zsN`WC^S6S)8}7}`)ax_zBBh!$^B59mbi`ZdivuEq^`CB|L0b_-OVIZm*S&FGDFCYs z$S7#jLC#`1qqLuZS&>SZ@!qWq=|65O({wD7~B%JMc#|jP;+uHr8}bv z8P6Xy@EnMmod#p&jg`jry^d!o`vC4V?O`wU56uaPa&GC_hc9Iix{+?Wiu<76@aAnr z5J8S);4xfKmi}eoPGvV1ooQxlfP4G29s#stC}eO_Ar@m_Vtt_>?eIFRoUW%osHNrP z(cx5_>sl*(avo;D)T$lIhTy%KHcGjHul`$fV_#e>rP#B!{~O&Q!LVEEj` z?hGD9>q7MKeilP(pBYoOUP(1@_1~ePKRwQsC-R(2zs3~0`wSt8&IyzILW$+7>|8e zLx9x_>h3VqjbUH;rvVDLNek(ui)Auig!sTyN7uwsxmi87X{3zsqS1sZE%_Zr!XrCI zUNhsU?Jfavk_z6gfM^vFhdeQ;0tvJ#eb(P|^{gWrEW~Jkyp>O@ylE361qkZCzX=b9 z1daHmW|5EzJ_myFS!${4e?(1g50WPtT4V!Z3NEc`*DGP6r3Z9&)=|F#n)D{eb*IxVn&4#`H7C;!;;pV$P~1dW4EiDqj*xW9Qe$bUlnumhqU#e>ebGqx zQn}F64p`W1i2Tzr#(4a&cdauwAE86QtLL{L-07QHvtbFoxt~PWqQY_CdWW%N>UqWz z+>^pIag?0BZc%M2rto>)NVkU8-`VwK`8`l-z2Ot|z_ha9G3<|f+L>vg5gSVNPUyJj z@}#>3LH_}wHG)9Gk9dYQ_rk#qtr<;P7AzM!e0YqENv$;&5iZhqKO`2AiiuiZp~aw5trNVyyMnIzI)!FvI^1z1n4Gy= zzJ8-WOI(TjnDIz+#rZWHfsHpqA)E;JYA0aUjcM)367S&q6biqZfM2#Vnaph?vXd#y z>AllQ+?n2{I&J{#&OkKa0#hSrygF%2veZYk;y&X<sCuDXtqc}@W9-GzpzoYD8Wb1b;8BM7d+y*4rAJSy(KooE z5n|D8s3X$O>13rHhxqdoUPHK3V5^3R%=ekkp3C1UL^m_A#&Yy1zYQG+w5q0dmE6}_ zpS23@RPMYp2)*cu%fJD<(Pe+~a=jEYFi3e7)uip`xtMD(Uq4^x)k~1l>mbxxUDig= zh9B1ZJ8GGe%^{QVmKCr1ZRX15Z!)oN=^w9^^;tDS6|D^9o7}Nr8{e|)r7L6v%KhEm zs4aaiixQ7{iqX#(b}^%uY4D|1+lS+y!(zRR^Iek<{&J{gwZG+g)ywVOdZoTBvbr^L zqSKYQjS%z^BS}z1*_z(68^Ts~^%|jpyLxR((8on2@}u9+%-?qTA9!AU2HL_nl?ZX# zp?zO$fe}9zZ?D+4AhzfC_v)_*DmUi^+TJV%vZcUgX)cfy6HO2u@?3P@$b#C+u7G${ zC!~fhFsJ+GjzXQbGE`=i$u;{PXa__foPoHZLSVx-@kKOrBkZPP@dL> zK3Z~y?iO)xL)or+N~>SEj9X6Ow=KOdYz8mRy*j>@6z~3AXoVW-F>>9V5mNpM{Gc5(Ubi|GTQJ+25z`#M^2GxJHnD48;@}dmzfNy z*^vIs=hs-W*mX3+@s(pCoWAYN4Mmf17c;F2LJ91H-_zy64~m8mDyS(6$CGb^R)#%~ z(b&t8fMrq`6^q+Et;+A!Py)aVgUfCUxi-7ppc@ek-WUX+%oYPvDV&3sCPv#%HofR-JdnD8qtEq$mI&KW7JgJ^Plz)lywDSxX-@Oxlh*f8%$2vSE- zp8U!x9voC7V!lQe^kDTyt>lZ9&g7DZ{3jduyAy1Az6W$uy&yz(^B?}O^eL9~yZaLt zBDO#?6EV*L@w{oBwktX~=5O=NRdKwwkURaj{X@! zQ)uvGxgJ*+x7*CDlOjdAyQ$)U_Y(Om-Eoy-rF`ixaYAgO6(7?P!FEAa_@cE>3PT02 zk?S4$eIzZ$9Z3BNOV8a=$x zsAht_E<}S{gy7??gmOFT${K2lziHf&9VDuPYA{4K5S#G#l4HF|PYqe^MbtYxLdZ|a z)~Pn^MZJ~Oj%{$iWi2i)uA>6hdOFZI1+a7nEdFC^6#?=dD~Wfo_R{|A{?7n`C>Rif z(@EczbVpEJmp@*9t0@KNvK80F=A-UvzQS#j7@?&U0~fRD~F#4GshuM@tOZ zOH~?y=wap5Toxo8a|*Va^OUxdWd?!@PCPf`S=tKE!8~8?rTV;tIKu)Dx4a!l*{&;v3jEW#u)rM?BEwldi&G!&~ z1S5Df5QGfaA;glAyQZQ~Rc{>WFB+f!1|dKe<3K_S5mx!Y<)6^=#St~YUyOny(vw(u z>Y9uk{QjB&HQlv8p0<3OaBsOXP>d(2YG^Hq#M=2jeb@1CVv_9;r}e^wB|e)os+=1Q z!EfqEpY*3w=IRQcXt{s&tqI;#6~T=hNrN1vSABIAXZ3&t=2YT{M>zMLkCbC%sDm4e6ZM z2Eog{oaJhthxwKJQy_M?^wdA9odj5#OZlBVoXBaPRfta{#Qzwm{czax$-7tFWr2zGW%5!?G7ZxP?q1bJ(QP7PuLI>3~2IFNE6OBDOw+e%=n1ghNofeI{ z#@j0z5)#Nj)cmmBb**2Cea96J)Un+nZ=&DuP)Gjh&H>1~o1Cw>P8LLoBgsB5W4vV# z)HyXMpIqMef(NoE%4ApomXj;ZYv!{ahqNkk%bfb>?+a93**=dHZl16_B zq24k*C$=0j#$!hmT$mMGUic!>CB16m+5-f-BN^^->;IR4e9)`{TX)&n@H(-2^!M}u zU%(%laGcj?u|KSseW%+UK)r13we8n>KfNl2Z6Im@4|BlX7L%qRQ)%m(etC)3>pyEc znpr{dbd=a6@FI(jIuNl``9~v~exThBp(v!p3*Ye{yhqAbJ))CI_)jSF&ZaNC#4Lzx z9u5cu=vQ;stRW~L05h1s>CLw}e!qlFsbIOoMcOerZjP@kj!2VZ6M2HO2R&I_O4&Sb z{0)XOOV7UC*eb~#S4vOSt?f!%fs^(Or|&$qzuWrwRN!*JS>? zJtyFCL|{pm->-;p#aD_v&QaBkUjS`+fO+`hXY|L^46xMrFI$cBs~`)v53EO}?V^o?3FpezEcJphZ3|MmViHX-6-{}SW^ zUJ&SgOdTB^`51+7l$DhMyCYyoPiEpOol_)QK^Ykt^=rH;^Y{b=?Sl-ac_#hx{~4PT z-tX?5Lr&&z&+zK;HL+!0w_7x6O*erb+2%xEuM7Rx~g1bX-9oz{H!QI{6-DPlhcMTrg-QC^&AD;L7cHiCFrD|%1sbcP- zPv3pI`&@lpg>)Rj^JBw$SEKN1>zoO|Gu~T7P|vVuPUE5l860%~sk71ocm73pgLJp# zsiP2Sb4jXwe6zoO<0knJS{wAKcF+WF+}{r`PdE48@xa5>yZ??NMjj_65D@8G^kt?1 ze{#ni&op2k&)V?sK?gP?$8D|w_^J=eKbJM+{*&CSUW{mmu2_2$RVvW&|3;N!ea$2q z#=`T-ywC{=MeNSeLvnS!5sd4=p7}B5jBfoMfKL0hK0{?%O3? zApakKISQW~Upke~dHtC5|Aw`TFO0#^?=4t+^fH>Bt2KAs#L^!aSF-b5ZVa4o*d2qQ zn13?$O=dTPY-kL76A_bykf?E2o-i6K&d2_P>BRYOkm>Z@(;ho$HO}HFj(&p=#)0pS zJgN2mB$dyTKvK%Jhb!ru70zlC`CL0o!j!>Hs{{9`sVNY?yC^S@q$^1*jv%u#(!tS@ z2o)L$1;zi-<&3X8|9^-{Ye>dmLA(45zh?UV#87(mL|DHb2m?Cu-^8SP`ug_$2Pte* zGc)ntm9<%lR1F$>Z(HY1cui}WJN`PjQqarYN>|Ep5(y8?tDRmT>L@QiopeTvGpU?g z1D0vbfWROUs-L3o*zwxJ#8{6Iqt0LL+0`sK1bc{)GPZfe>52DG7Ww)5!Pu8XL;*s~ntxqvmInei9# z{f_c{wKY7Lo_iCI%qOsd)$74wxIMbQ`mU%-mXFQ|%mBSNepO3)Y+4O;8I@ z-TeOOEJ;9~V0-Hw4RD&M>^>0D-4Fbj#c{#xH1%9PY3hb}$T&126#BF7Rm`~q&lE=J z@xpiYwuNjZ9{3RZ<+Fr+%q&l?J5g=FEL_h0@ntBh5=!*72^$5wK#{!5li-M%iODZD z73+UE#5I~LV$E?Dz*(N zG|*{HM3;-%!Q!m%^tf{~5v;OuYB3{|-O# zjsX+hA)qQq3PUSjGa^i*!2qe8U{Pz%Mlkd#*z}Iq0lm&2hH4%-bh4o50!ONC za0(|?%8nR31D|42*Nw;3X6qiO;L66V#^MPYe_&ZiBMB&$LZ=TBM(+>MJtLqL2So=8 zlGkGT6HJ;2^x?kLQJdFy;fr0>7-8SFy0^WJwl)8Jf+{;UwuOFkN8oDY zFGi_1!-m+xBu`OYG)?@vAKp?oz^qdPO);cM-@=W^Y&Fz!*O7M0IvFU z-wU>S$IB(*Y3uK1VT!{TvVXMB;OjD$v>GB@ax5#uYdeY28fWO1h;p=NjWzpDG=BKi zVkv!Nrh3#oc*;V~@XKT5Xhcjr1n)p5XMFYO5{&IvN)#R{J-cBfyJ-Z~g&NXd?NxqQ z7_xc^`rA{#m@eKh7wvvpr6TmyXoSnDG^i0wm!lj7J033Dfv>Bi`i7GOh^~$dF4y@G zX^S@ep0f3uyNc;lDtBKV;r=<< zOf=c>f?G#>2Xog-$}JJ;$&M9U1+Kxr-3#ZQL;+P-mJ_IDvj(n_wl6)z%^j9@!yzO! zYpj1GRVvDbS-XGFzLR1{#XIo3iBI2Ej41+%IR7w%B;ug4)UFidUQzVSG5B7zrKrwU|w6cMSzG5}NCGSx+}JC_GOCTQh7wCY^l$-L z8`eQN;=DU&gA|w0zkK2?$rOH{!dRqKBU{OnUL9PwbYbsObwtyUy|rU_vtIaeV&utt zjv9?x#EuJN=F&f6=|bEpg2z0$5e-=tq&pl7-|mqUkB-Xch}-}0 z{>giKJTEHl3)`u!)69gn4vGO~r+n`TZQ!VTQG~%CayZ z_3jKC=Cd9N5JT~Hy@gO{3n+UnZ}e=M>@xmCYI%n^q;5$#xx)TIUH9t0RJdL2_)fv8I|K0qDX{V@iY z1IcRrLh!~Q$j+099rtl^pb_oz*$<}--f-scQQHI2eFKHJgJ`&mo)FG{ku7oQNbj%U zyb`zaEmpLcL=b$LTHUF60Nedzm`6+%p|(oA$$D-KABT}YL-GVnSzOJx98&TFVP5{! z&Ygm#2arW}U7WY1*R<=NvHVr#C=$UPy&WUQHn)pdn%+mf+%Femm$nnc7S0%XCRLo6 zI`lQ?N^S&dG`wu^`*#5SnZPm*mIg|TY4Z-8hJkCYs>=aa?%_h*uNXI2nS6$uSQ_0D ziSj{Mv!U`Qd(Ah;aOs1|(yZHb`*q}A!!8Vs66GibpPNb`4By+?6gJ=D+VD*AdIl|HnHtzK*lF(%igS*c{zGL^JIm2}CaP<= z9wAqE@0{s8-e0%?j{FO@C${(9Bp^{fESPuGaI%hHTe@*EXixWeonp6g^Cc`j>ubGx z%mCZdQOEY%p(T=d=6Gs@cMJyaecOOp>}W$FNkf-<$z_AfE(QYT=-}-6M?*|?sxyEb zNT5YXPK;tZ)g8@=BI&r(W94i0c0b8!FIVLcbIJ_r6pP1s#jiO+;7SZz!^oJ4fG0hW zB*w<3Wf0gQ@s;=e_*a@RI_O?{qU;dAH9co%atJ5q&mU^g)5}UET%%sNxY!`w$M`v6 z10kN9P8KznvC+x+>FCq`s{43+k@Y3(sARY1ICqDWdPCQ}&Ecz%Ag+Y`bY0F#wk(X*Vg3)yx=VrS-c!UoPnUnPMRZXUprDQKtwim}#EKhR#S0M>A zX^uaZD}Yt^#}uyMB6+?y6&dNHp?u~jiui;A^`%{kjrHB-iyTMo)i$qS9fcshEOJ$i zw!cn^yRgm**&*ttDb3;ACu|1O_7Gh~0tW?dM#c!k!aN`@PVe zsi6b&jN7XT&9v8V`)E-IEcWEU8}jKo@$X4|tOeVXp$_9{_m_MZ2eK|i;FI|DgSDE{ z>P}~alSFTaztu9sXpL<46%TuR6E>n4tox-`6=sbdFU?Yh?;*XTO+@*;5t7s+v*kN? zV;xpITxzGnc65leD%=vn|MX={zWjh~&#az0=FkxbRJeUP+RJ_C`Sw*nGlm&RR*@9d zi4P$fIvf4*>wLw-V8qJ2@w_I9_Dj9#FTY>XVIRzn$=|;E5|%#lYK{5iXt*S`qoX`* zY}brwor9>DpU^Uf?ry%tKacJOIq0t!L%tayWE&uVA0NvYCUPeYi+;i4+oRBlQ#ROr z?L=joZZ8bT>NUJq12Vf@z@2Nh^kf8o)U-RwtXk9QUY<%)S^n4>yCJ8aO~t^cZ_3vk zOL914Pat~x`CF}%nARwr2v!ZzUszCug3s1v`v-hWvVLE=)oy4X2l!r5uT;7N@lyf_jDcod&^(4@ey^@i=G;+x|uokni*s1HFgJnep1}kr=_N zU_(c|R0KmS~Q& zg6faIh&<=hEhUP;~CENoU?bVdL~1IDJ75AV=8ovDPZI;OPc0nLK(NFtBa?+oKJ(`1IG&7S^7|poKH78PhtCV7b{B{)WDJgtc3zOo;O6s z&vm+OMn*YwnsTidz*WuhSPn;aXv;Wm6tlkKeV-<@{Efl6y+QJxy*V>)Ud{^z-cK$QbEY_A73bqCRRt6uVy&zc)-zj4yHL(s<~c%4i&SRA%P9&Pp{6h4U5NP z*&n8WtrM&dn0`-`KKc`HoTZ#ujWF!snA&_q@u9^%@{ZP9GYSfVWt|RMzwx4A!KS2z z9RvLk+{qZ80x%K*W4VeH%-%i1SH3(bWcEE}OnF9*#69#mb6pE0LQB)TlMh?nz8T!G z)3KGR7d(aHEBh!-rfP4iJhLyV3k;0DdJ#-Pm{<~k7;=1kFYI{q1bA7OLZp=ZGOk!@ zz{k$^(px#EmAKKtiR#_iupj?dW;-`FoRW8K zbKhJGdhSpR%U;WCwX2{+XxA%#q)AI$vlc>G&;3xI!NW6=YGM`6cxQlS^=JI}TzCwZ zER@-U+Hhe_qS&!RqB73z>g@W2>Ouol$1m<5$~Rc2?b*-k&UDr0PFzfUIzkr%8ES9B zb4WS4l5rAXs@&dm=FXPJZsagw2V)}dwUJo0W;pSssoSP)v1q}aLo45V-k>#{`1;A! z41YFIXCqbnhD<($u)AD6Z`v&1Z*-gIDZpy8CL3XqY(9VF$O>-WrTO=+OnVQSM@YaK z&8-><@1B9e*X!;Mv-{mf{t(NT+>#p^My~4@Pn09m0oDcb_MbCYK4?OkDliRqFNlX4B z0p>(~olL$pOQKpuZ9w^xUh#Fec>#i(&`L3b@<@Te!X1&bh4KOZ+7Bh{>Xaw@g%a3`h{7&RRbJGjU(tzZ#Wec zE_If$GZRnp`m0jQhT)sk0b3g<80UX|T8}Pk)C8KM;ur0n$>!N*>r6eqKc74F%nEqpfOUvh()+XhG^*7Wem29UE6+{ea-Cdo6{BncRDx5K)nKdS$Y0{9bz{qI zrG`MP1yT3@8?Kh8x_?-v#gGKtj*6KUhEI$0)WaE*8z;C?iUWU*$kBBu<%{RomGflS z-pg@XmXs+pgnXfMuCiTF44sJta^H`LFNL8|YS5rbv~jJz=k}eflU8zJ%C)#{aXe3oy_qH=wjo4Y_ zo%`1H%E&NTq;-Sra3L49YsW8zXv^KDPzkzMo8(?MfqBRtXB-`N zl#{+}9#lQoCZ0q-%FT{!N7{!&m6SXt#3M2oxZ0AhR7B`CNl~1qc#L|$X;WXrERjhU!fykl?#O+yv6=rWO zgdJ3*kk~J%5FzX1IMuj@3tJ*eywH}2Khv#%u;k!miTiItM?qz61V6=pDCZ$ViX-Rk z9E1Yfl5{1#&Z*jtt1^*7Nv)OWN#@FS0S_ydl{`+}&jUQ|(@FUjR{CKoGy)1)gR8A) zA!q&OizjG>>UR#dr-w(eWLi`W|40~-p(Viu)nFBdI$qkxn~^{18Q**}<`a^bugpUV z>Y5@obd;n@>!t^`)zWVNkkAdPsU*le?*;_6*}t8ldFhGnxh-Gw0CwH`z}nYsY+RU^ z$6EX($LDF*+hRLOiLoo56tli<-t80i0vq(l(J<^9wMW+@Jwq>7puYLJ^p-}dsI~4h zMdO=)6|z46_-#A&YA~HDMeND*vz|s|WT1cc1ewapYMtBtDN*BLeJJT4vtL6(bI_c7 zqyh$ycO!~>O^5n1V$t;_!lm-Qn;U)q^a@io=+8&oRq_9X0@{hSYycj_$VFf z6*PJsWb3b;c6*F^K1^`$0i|s}`~ailRm{>XfIVFlDts$VEDt>z;dphEAna~%XYuH$ zB89xI3fju<%IH;9;F4syMGO% zGPh9>F2p%&{c~U4qF*jNrbg2JEsjV0@b~A+;s6J<3-p=W%UZ^9NfZD^AqGkfU*e$3 z)vns;8I|?i_%3W#CXwl>NVeO*N}y9VM>LSwufpClgve2`-R#=ytcVaP@{zd$qKo;6 z@>!8^f$roK!p?K?YhPw}Ly2Y$431JRC51%#dgq{g37}Of)c_dLM7vPoy`5aoGDmGP z0*zO5fmHO^sXLK954&y|EM5?6vBDKi#;NpOO!!GZ%jD9tE?A)Ad)>--fCNcXjk7ii z@y%z{d7rFP1W#k95ZwBTH9K;V)T$=m=VP_~S-J$*@o}`pst>?#5BE8sH zN&-}=kEi|WyO~8I4{w)B-gB|wX~hGLwRh!W7iQTOWwTdMXK~dtV8#+&!Si>%8@lX% z>9V~pL7o~vDCKGE;2n1*hB*8sTFH${p6+^&U2e#a2ewixHB5^QQ30Lf>b`?SqQk); z%&`O2ODiY-2N&A$T%Pu&k(w{=bOgrS^L5f)b$J}X%gM$;38)15^Cf^>A?p55^Wybm1^qMUwIY9-Q9c@J);(;Y(_Wav(j{BIwzJ!aJAl;fh~=3{ z!Hq4wmAVk=3-P}$gURRh8gfU5*oWbvb82*zx$x?QfJVUi)0*VLBThcYmM2jl+QRWz zp16kHd11of1IQnhe*uUZQyYVe7Tzt<7yrVERO5ACsx*E)7!O9x@gk7bvo~B^GcQ3KhbK#D-GD93((fSkTeTLSmHBYN+RX&!0&($_dZhmRjpZ20N~SCw`AgCgU@$}sYlx)=l1j) z)Iz_*8kw3XR06j9M}kSB3^k!Ze!B{ZIEtSsRD-(PxwwydecctSm7<&-fr>q-5}eP7 zSJ+zv%@d&vHKFvPe}`%1tp3Vdh}MRQ8(`pe2=qfG#a{m zkHF@QU7KKKcHus!*WbNvb1}B;-$lAB=CUKEt#z^W?x#rFfMI*tcmQw1xY%;^`MbR{ zAXEz-S&}TTLJGqad%J+MuDLpf56mVaYih$;^cq2V!)++mV7M>q2vAWuEG+G} zDPt{HLn*Jo6m6I-y-3ML_D`zP-Rm2;zVXkKELHEVfqwT;)?h5hE^%}emp4TmStvKq z+o4G-67K7IXdZjE)yL#~AiVerkm0sms=tSo5hXR5Wr#A~JwE8kb+fwFs;V&tt^F5# z9qqHFG36%V-MV6-N;!I!Qr^*o1Rd*j8`}qbKYR(R)wSvjjm+oWV$!jI@bpZ$ZEF?8|c1}jamtiShJmZ(o zj)xo;Ofy9h+2Mv-5T_qLwnJY=4;5Lm?!fP9k0n>8$R9JyxxpZ2e_2y+z1Sd)4JYJF0Ta1ZxHf|l zju?H?N<3<`rXufA*zK;DEi1EBCl1-xs%z(nRDwfqY0;G+pW8jgH3H!&?e@vEOavMr zJ))Zhue>nq7nV13;!zbhaA>e+<1=~u8#-Y)E{d0U4L-mx4|wG-y%sd*mtC^sXHhqB z!ZA@_JCrIe{BExALE(-_&+{qpxymc78D|O`?HuyHsJ_rxSGAJ z=Py*nUy4wYUZz`2xp<|{#`44Y%upOzyR&;onQ{VYpw+L%|zr3yGt+ zy~CQ`OhWT>`fTwf(b2Y@@PjMegeqeFSj!>bKpc#&=uRwjETH78+G%C0WuNe=(2|mvu=JqWJwMyHUg$hB2 zUea{f@a};ajzYB)wS?4tpK3P3f68WgibU~-^i*{*mYA1al{1%lOv6ckw6*OJ-E`tr zdZy-*AgM4pa9*;JsY#lbyQ)IZ;sKq-YBf{fM)sP=T%XKZTe^w+i!Ob^1AXVx%FSLd z_4`iOU2UV`)qV-f$WGwh^Ob}3QUE#+S?!sv9@Tx5-pQ_63iyo|PnVZUQKlr2NFVcG z=jQ0S8!$X?F2R3%+n!5A!R7PfHsG?2Z#vd1Uw#3pnLUJ3v(s$|+&EP=+X;@imn??@ ztyzIE-~7IXp3{%vwLqf>&U)*#zXt(^2?5|-@FH6co?*QAW=~~9`Pw^ybzDOBUGo^O`g&ZsTji=I zLmF%2x`D~hP)2mhU7Wer{BqVHD7cv&%eJH`7^~8DS*$m|+nO|y-d%c*PFJuO>$dp1 zE3tVzb=l+%V#(-oON=^KGv;d-wK^{kXLUAHf#}c`m-J@hw~9ulmNYfoHPmQMEuq*;Kl1?6vyHlr}FaIA+hC zzSGWnv+1x-d)X^mMUuiwplF8D7te}@kK5X5rz@jEwh{m2JGTL6Yw>t=o|NV@#!%|} zL9-Ks(kGZv$YZt8OVgthxJ& zSxfc+vjT|Fny^s$L}G?ZG5^oZ42sIa<`Cl!!89ZF);UP%*6fue2d|D&v2gcbBI{aV zmGI3f*T4Dk?Cq%Tg*RQeWV(!^{QwS#Gej4@%~?l>9W2|W1B_9F2QEhIKDW`X1wtAGX?m=s;LwT+xRGv}KJjbycq=Qd7G17p&5 z{&`3T84eUb)2aK(Yz=i}nFb@TLm1;oB@210Bo360($K8hy)R$a!A{ea7PxNwP{)8l zlcjtvZ!X=v04I-!X>yTyLDaFVq>#0No6V7(7jCzM5S?j?L zw?;rTSTucf%f}&Jl$W@8auKA+SUk$Iq_EaRP}bojz=EU&W~DN6*dB)i zZZzm7=!{=&?BLd4$YWJz?Ok8EBX%`A-64ez&t``~VgABKuh1iH)sdxkTcVU#${God zx*@54SMfS{e3#50O2&!R6hWlM%qNyzN}H`v%wY0H9zesoCbvF6=&Za?i_~F*}b_MCa(7XCFm9Ep-WDpKYb(~;9sk@-v zsny1AI1Oa_JJ+CAodnCNR=8fJ3WvL-OxCs|ka}JlwL%-ubid~1em|wqB2Vq0J++WB zjLD@J+D&OlNL^8JdcQ>GB9hHypq-(2B)n%Wybey-L}gg2^W94Sp%47LcjTby|4uNpBwgl^9$p zKerU{l`{IlKEnTw%~R8Qg!qFs@IS{y&7|_gJVvq>e~SfJ#dXnHkRqz0{SYR2;~Q+K zw5eOS^qSN0@rLD_jJ#aKAA4sobX@PRfj_~uf8T;y$jmigXt7Prz##Rac(tgQ?0!2A zARwq~2*mIsK8r<80zf63j>xwVQ1>99sppIHh6=?iai*XEA!0!C52fN?LBa^uHi|s< z>xq&FR=?$@{Gj()OENEDFeZ5AqBCzi-6A#kuH_m;e~ld?7SL<2zb~02KDu!0pFPqZ zHfi_e%($m&E@zItz3AQv#`|j>?R3{Q>@4MOq=^K})H&Okp0Ym_WhE9K+V^Qs#N$w1 z%@`eNghj6QO!>o@9=8NRX`Ei(Dt|*F>=svOz-mC&*`K^3sD+fjK0EwUxo09ZW8pj4 z;bLcQCWI~BBJx~0!s+o$2%}EE^9m`MMpG?NI&`y20w`8EM7)j^?+FYFI-+}iidD4EH6SHF}zDO>wdX4AMBC}eCw0`Uvd zTToW?sPaEW;j8{(T&@8Wzf1`fRaL)Y_AMy8^|N+Z}cl zlTxneyWBANGv&~nC+orIIZ-$}|B?0JTU9VaNb?Y@^i&ll+JkwvVwrgpaEJ44}Q^v#*7Q;YLsgYT(CopuRi z4vhW9QvE1i*MAxY?Bce@kC6c7TQrr`r5C&By|9{F95_E*TWy`r$h1*02lmlAN)&UL z#s(~O9TzORid5XS8uhN`Mq!t0V|Ase}I~5_s5KzOwxRHL3|N zCJp!xs}5d{zp#yCQ7F^#Tl`i{fG$vcebTEm7mPG&U`(2!pg2RY-~7dk%|3y4sZQmw zv3z-}qAsB_T67HM9YOJ{2DNY_OYdb09!M^ePxXr_#zsQ$=vrhiy;Y)<+og{@E4kb( zJ=|ic)>M6c-ooRex2;GvGSNViq_VxwgmEu^@QaC z1?)g;4{nctP6VY*(0_RPLC@hliCQrb;HOw?f*zSg9Ku>S$|Ih&^X_HJG35;P) zd7omRkj0;KSJm;(8852n1|4i&Y$g!1yD}N&*$6OqZnO>EY~Z-uJa*DrnaSq^f?i$4 z_MW~N*O|>$XsFDX?e*WRlb(BCzwv`tV3n!c_2w zrXker>8Z^6l<%4Ujib=j^Z^e6;ln}c3%A>ADoK&WT*>}7+i-=W;4u{U&NrJqU$ZXA zcZmPBNm&3%xs~v8LZ+q;SK9pE=#Wx2+gg#;{xr_QWrhv-zpaE|OqEhm+n2Y~c1sDv z@Z2wyU=E7%d2UGSc)Wde?Q?rQdblW(&rU<*Yn&OFolnRQ7w?0|UKwiFgu8I4 zXPAl=rdn~CS^ckV{U+1GbTl}abMCiCX~E<$%TxMCP*!}+{jpCOhxM;`B5t?&g|Unc zFSq%VH~kLBbzvXpt6Qt3owu4-yG<0#rBgud{!_KJ2HHCK)y=6qY73mDSbRmN8+CS( zzYh`m`SRYmBJJX0dCUzJD72^he5J~_I=dRHB)74Ix^Z;UO#3os!VmC?2H{Sf9WTDY z;pF>)Oe5$F%+iAI?MHhBDIjL$6Mx+cAae|GI+t6BCct*12 zvZ=^wpgSnp0_}&xzlIb9UXU(l0Rt{CNEQNk!`#BDetJ>u4(e{-?ZFQ^Ss5Rkzopl{ zhqPHS*(q7@kIbJPP7eFE7hatupxb)AJ`(YTdB*(^_p7Jo=H@n#d?huV&IipzY;A7( zC}4dU+LS7lY&&cOVH^pkEcW36n#d1bjEQ20p~5G`2FnB5+S;D2J;?q)%Zb33I%;i( zA_akgPK$12uQsfU44HCSeDg43!av{vtP!$Ea|8;`m|*YZ`{T!<=;~4->9rt$0%m23DCNv z3@eu0Itfe&i0Ax23lK}!$SC#;rizr#W0>@O<4lOtzfB26MbB|+d%>L67W~V+&`B#< z*=E?LU z>`K(3UOn>(GJ!L(>Ody(JfEbSts6)F@qb^ zx+hSk-tEgZ(^kkA^DQbO2aS$iqhDd?3}q*cNX3 z$Ia;m%~^&=i7(2^F7dBuDn$QYL6_=3PrL>SB}^7H)u}i@jaYfv?xwolYLohm)sxKX zHp}D7-AJ@=LO&0l9|PDyGblZilZaqoU=0)7Cpa;YT8O;)o$=3dxbCqe^0~st=5Fo6 zhj}I}SO)Wj+>Dm*k!-#m`cmOJ2XX&PwvxWob3?l51w7ug?9!%Fye3 zewa>bG)w-{Q7DQvS8A$0t}8@+rhou7Jhnk5L;(4RC?c;}AL!W(^gC;=5P=8-|L)kr z%ivOjCx-h&*6u!+%4-CZT)P#_a)Y%fmj58`T5Z_e3xWQ!D?R%H3$f$ZpExjIP4fD;pF9%5qSepux$hW3BwlrM40yF71Gcl=BwHw@bp&u01b58?fkw~K2Swu{!We0j&A zSk?lINIX#Z!UXL!o~UR6(V$E5f-XfM5~&J}NNMZk7z?)ITYkosScw1Urzj`K@x&UeBkNXnF5$QgIcF{Ox~z0rZtQK?eBr1-r-XzNV&)x#&Ec z8I~dOWS+?OTXq;iIEf|%?)t{9Ja;`NG%D%X(E&XJO;kh~lRl)cAlrXIW!(n&h#lrF z@`G0RW~Mtb{)49gbg(UOJsn&S?e*qRpwfwCK%bg{MJ{@|w?f~*qm^cG+=aB)OAd&L z$BgTtIrQy%ne@CbUM}`!rO@Iovw#bm1TX>&qL$!28@JE5gt|SBQkhCC|9_3J2!%+= zSDkMp1EHf7!y<`w++YR>ma#03-+(>qcA=+(r;&=cPdaVu3c-e=*eXKg-xB&3q6b0b zqX!SVA2_CHee~i(Je^1t!Zdg~TnLF0pgrDhCoxFY^w72fL~)6Ha)S{0-^g@DYC z26}MzOas`GGnwl86^`#p#9t`KR6Ea^K+4H_?+Ky?;hW{L?$Nvq`dezpYP&_|ZMC(^ z{%dVn$4eBJz(hjXaUYx|-_HOSGRk;zdfL6Z_rd5`Z&>~^{<)$Y3jo1`9~A$+$e@PA z7RL@bk*xnz`A^-E?``I%X*0=gIbj4)LR9o_VLR~wq+XzWY14YEC=d85hR9Z_iKmrx zjZ$%yKwA^EK$6s04mz%Hd~A!>ekf8X+2tSS9D?{v<@yvs+vICUyX&L&+d{jX(cMOS z%d|qF@GmAq7G-)sfS>D3JfG~(IC2=*8DjVOgkv>|9Pr?8SJAseD9rkrZ;y=C5{N?I z<^fi?Selu`c``esRd7-N(=x8xtd8#7D`UROt#1H(c}^;N?h8Lw7CiXOoL~1RRGiil zX0ez8wH>eZux0r8RXAY33gp{dHV;uBU^P=`j-dMzzKZ2p7}N5O6jK5?+?IbeLJRhe zxZw-k@9XwWD)gPJIyjdb-~B%AT;YD-4f;rt?nU;;Qhfc^YpkVWN%V;%a0#CT__>7T zDbDhQs64C}f9%s(RlaL<)N)$7tqzL2%5{`SMrUPkxHIN^U0umvPM^2AK}=^MCxiaB znY@_ydhg)mW!3x4M^KvpH^TtyZz6NYbItSt7ySia-?;pphRXBh+ny)>GH2-mR0av? zl2<@JYP3CPc-RWbHbVsOXgl~YzanZ41rBG7`w-?1ene8u_N?oEeR}QTXi!N2$){lT zB!wjcYMIsT9(F!Kis2WL9l=?nHeWrzah>vTX!w6#gjmu?-vkK0(?0^QH9r8YE7jy=e& z2zgN?;E3sQc|8V(01d+zI2v3^`ktAQ=^1iq!q@0sS8oHcIdGU>EmSL=r_ypFD*hyU ztnixc%xtmO;1WLqG{Y6N#XLPd9j*2PY`~Tm7ctqJ9<%Huf8KY#obDIw;M%2*5+};j zx=OzaMsz?iNLiP*-IYZ(Q?%>!~`xWZUh6??$fXla|LGqG|@PVqCi( zzB!4@dNZz!q->7+Vr${tDT)wauB>5$Qq&qjy>M1G_IgBLlQ}T@V2LMe`;a&r^Md}? z;IVF3LV#-Hn#fC5l7RzynFyd)z0AqhwNp$+sA|W0aYHw=B6V(X(+5u4JXBaD1|Mrs>MR{D- z`3f*z_cw96*SYYMBWc6fV7${Hc_XWxk)fsiK+#(Fgr)Q@JK|6B972!T5RzN@S!HO)m-j(`IEIr^8hZ{wxMFHouJblPNeQwdDx{kU!N96E;KcD)ZoJD~?(;>|s~5bbW;A$N(X z#ZA0X*QH|sd1 zKBp;*qcsrKQv3dav(6hw!x?|K{mi-D&|M6bV`Xjg@!ay1!v*4`sYZuI>&PXm7YJ{^ z!FY?*EOEfT`m-VHth968@s>%p3-CH%_W1IH_=WoXh5j0pUSQDjdIVjvc-L2iS0piZ zV1bgY0csUZCd}P#Elovhz%V%B`$!KLX*T)%1~Z%?rZHY^-k2 zzMokvwT9;y zHBWlRjQ2uO@TvBExu;RBCY+9Pl_IE{k{(W=d@5=E`%Uy1=HsGD&NKK+-u=$)NQS5* zw619^L41DN)K`V~hYrAbotr?J*h8|gi)dC_y0mym0BIS>xa3zNT#Aw96%SJeIhThT}^Sm|YAVda_-&$HF!W%d)Cz9l$_ zWD#2lm(440;VB5&f6`vS(yqq_oV*8*^;~n{or?!{ZeY6Z5%Sco8hczx;6n2Hi}g=5 zBpKi*r8s6i%=`-DfznG*#VgpY58UT`vCr9+I?p(iov*HSZni3Fa3vT=1%~x5byE$V z!kA;D{eFz3qVe?d8K)$j!Nx|z9FGJ|IoM{`z4oP$Z?>?V$_rrO%)acQ8#Ej1r}ptZfCQG2*oQ@r;e*Nk`&VQK7zH z6@BbTAk=2wIvO;@xQ8GES0b`fK^D>Jl^N^m|FSNlT7@gsl^X22k9&A7xlJ>R+YDRA zI46cNZ%d98%NzRlJ*@COybViunuzRH-h%j6eiSKa=JS8iyEleg>Yu zU%H@p5>>5~nh>Q=&~i-Qh`T`NSm??()keA}6yU+{ZV7x(ul->YX45e_X`82|UFq?(Xiz9g4eqaEIU$B-q(~zwey$H$RfScV^Grv+lL7G5)bC z93kpMh)z73tx;eq-raY9iJ;@AJVPdQja?A2P7wwsi04L_rcvwv*P0r0lah_y;gETZMh~^)f%@ z>8ZD-)tX}!zVVWr%pE{77`Rr_a6N6|Y87nfZbvORjR3*4k*4fMU#}IEOazP-H5-A$ zocS%Lxq?5wjGag~ewq;Ts1(LNhzmKcx|{T!`VT0;?*euxrMN*)?T< zDUFYQ5cBWZO7o-U2hgBvwwZicSwJt&<>a9X@w!%jU>8CNMyUP|7rYbYb0hGWsg`do z>-3RCfRdmIk5B6J?h&^MpXQmmXyPe2Sal&aYdT1p$Oe(js>w$&zonsqw%jG5UM% zoZO%GBeiEfRAaid`QyinkycAjO0kD>ObW_u0jpwO4d-?%P~CqZVFaWDws_ZBZvVa0Zd4?+LQ z(opYw0-atl2Mk{IedZ5{%Bk&dVmmA6GF-@XqO!Fqb@u!8O`uDadaM|=)wJuWTj3mA z-_shV+X{-DS+a8V%Lk2eE$njUd?h*0$mpEce^@i$Qp(f~XBy zBhwo?&i7)T@v%~vQrSxK3^x`s=L?|vK(N#H$_MI#F^}DjTo^-vn^hyY;w<+E>KT}saD7Pe1@=_RD$n%PTmsP((&vTpLb&2`7UJjWd!5J>7`?+U@~6FS7j? zolnD33m*b^3$pe8cnutnT!yL#!rx7*@XGlJ?I@Y_8;>Aac{y~nHqZE+sd&&+74bL5 zk_Ae5W?p;SGS!slcp9FlPFNVWbOmys?NVbr57+?T_M-%z3E_bs7nJ&*4#|nqmq91! zOMNipp|d5sQsh%|#_}=r&eDYtUoZ6sHjY%A^(sD0zs$9#sHJ)ZXe@n7Xg_}Vg$1k0 z(~tr1j5jW+OVap*fg8xc%KCHI;TsX1tyS!U*Q4HvWh(%B%9Jej(R{w6f0{KmG^FmR zO-`w4P_bQEX znzIyh(sjGnX%Q*^bcW~Fzict|rB6zc1Hz%(b&T*l*$IK~X$`!3hr7iKUhJy4)f@VS zTY=OJd_BMS*2HSGx9+?7C{dER#0%jyzo%qH)Z=5miAalWx-?9GPAQBNOa-gBmO;x` z9D0*rFx9_a9`#u5?2tPVGjj=2&Xpr05q?OH{q{AEOW`ZbN$)7{@7)olZNQ{d7a#=0 z!lg5eSxDYuaG$#x673-Twy{l*&E&Jb;8_&vrr!$~m%;B%7XqC>t%){}wRK;Sp~j{q z<){SX=C`u>6BMEU5O5`i6+8ynX=(|WemrADH*!;bJASs(}!P+=U#i+ z7(-e{9R`El55r=9+EFRz`)(~%q~{vZ^WDw5VKv?JFqYu6n$H_yK~$ySE!QLh+{Dr9 zG5Pf#yyO#By%&+ug5(*_&(%N#3O!$Ojyy)?gKH$@OIo#xADL*9nyUznDoHdXHIoBD z04KKCEudjvdhGLo!{uju=+V;}OLI)&Ju9t7yZMiUL+Ilg%g?wDaV;u#)F*yfF>;PK zzEUs?1)FOx-WY>yGQ%(7Z@>c^%+)@Fl#;2kv?PlU&yXk6Ur=WF6*NQcP=E-sA`>2{8L zq>BL3`r1n}=WGqx6Win^$y1t(JYtb*ks{=_6Ix3>VqEEyDMR;K$X6a+tRv}#jp&Ar z6z(IRPXzbjc(;wu4Fc{!dO&T%_ERQm+p0I)ywddpKh5;Q?rBfdqQHGQY2RVgi*x?d z;qwR@E1vyajrqE)u~O;s_2sUdt6yhlk&GKKd(a=mnEmG2XNdv=cxlT(eP+t<|SZ-Le^u^Fci6ige{J|hbpXi+@UZc zXa27?S7xWWS>II}Gs|DJQ#w{<Roah71 zxclkl3O8FHW1?y(nY)lymg!l8?XjS1(u9oM)E_gGh`X3CgHoGqp(;KtgVkxjkZhU+ zw|4rt>Cmr0`67!8&F}AoEXEKRNj=kM?D~t>yU0=Sh;$7epmFWWMjVaZZ=`jK-!EN* zJsz=G(6~tSXVbTdQ89SY(xh<$Qgjua!q1?s~Nc%-91QrYr553xiPFGzg7tWcB;n*l)i5sBB#9y zWX$DLclx2bA<#StpB6d+oYDcLPT15)tNpAmSU%Q4Y1dcwZNejXU`KLDjoC8#30oH~ z4X>PjAPlZ1s|OGKWoFuH6}pt-!>t#TvYN_?B8B)E_uS|L4b3P+megw_$BL*ojly6l z+ldSNSRqu5oT$gC+^AfV9Oq}-^yd0(wp}YXv#pwpbRPFuTW7eDb`G|xJF)T0^Oe9; z0YTH}!|XB!5|`s0NhGy0`LY z{&vZ8ad+uB_Y4{DV86X1_V$*EhfBCd>ao8r3kJ>-OY16jKnl)9t6&d#R+qq@KPN|7 zOJ?Y17$arSsrwNU(u%|Jr>@R)wZ*lD8fbi&Z8-tf0+oPI2Aw_%bEWEY;P?1~3DL3B zScwdunstcTJVqsPu$0JLecZrL*_wY^v4qY~g3%I2_NnCdt~Q?YVTi zEk_1w;LSB}G*&^g$1yrRVOBs=**`2S%rlKay|h@hpg<;0vK>H}pJF?0fK8~rS?T4C zWGKhQb>lpO+N2J&!`?^b%_rX^aaHS4{d~p zXV(=P0vCAKo(UsnU;`D)-(#N}f7hPHo6=1M{Hopil5Gr)&SUdF`_l1~8gsUN(4W`r zj@cvOObe9vY9uWEubbm;b{_>Io7iYX^o*Z?|3P@85W$h6Da>z8ZQL|qKkY5L^_qW$ zoA#mm7ESGNN#whQlRB=mo)lwMM;?AHR~xEc0*Q{5G*C=x*ves@69p2HWcAIwdxE;Z zQDG{&ZhdM@!doB8Q>==EX>*Dq{Th`bGx6Vr4!ajatHfThA-}g9t4)3obe}Pl1x%hQ z#vgeg5SH)36X)|Eo=nuvy$uwG6>4)J(|E^c#5TAA+vcgegnt9O;~aQ|lN;rj>4ly# z3oO>QC0@!!eP*6(?J`Y|L*vH0mk9Z=NyzbV+;18tL>oWqNDc=6#%n->s#^c%9O66P zm`9b19kKTN5F!3A;=jg9y!|QOm z%DdZZ6^@C|ANXjy-hYG-?sk7+;MN@(u&L1gppgVv&;>auD)ejl@DRw2Cs_z7M+|q@3H; zM6t`p>E&r%`Z?L~UYf_B4oA8Uhn>(fxb(dvmcG^XmhqZ)`szB-)p8!azP)+~fke)h z*@z#!KG`@U9FyO!x*Ig(KUJ^_h+g!W6M5#%mWyh-!(mSu{-#pOp+sEVBYpp&1*W)M zG4(hF=a#iqvA4JgmUrY+dpRK=AHO}-B+RdpSpQa*{3GSwU4*#?ocq|4rnu|r6o6FT z(GfWRx*HbNyMmtkmrl60S{DNnq2E_hr1<*K5y21tvn`~~X01&d?C_BF9R`C9C9#r) z;WEcIet4|d8I1Ao3C1dWfyW7fJsWJ7aSu0?Z74#!?AJR=?9G2{caE?g@O?+VwG|r1 z#h89KwqWn8T<$;<9*00elEj;*U5x0<7(YH<{CX}$xF84Gm^%T79i?zsPM>W=_tsl4 z%yy|;YQ%hg!2+F2C2hM=Fc?I7$7b8BG}NU8Pbk(V;+f{KjEdFA2-=cPayW$3D-VMbSX3Z@}`UY zQwLYMuBRUvJn(=k*D@Qplq~29l1-#{FphFbI=Mw49%6?jqRyTmrQ50+iQ#zffhx4KOPEjF1hyuBl)c%-MGYV0sk$i$e=AgJ*%YV6_g+b951BtDq(nV5b95hrNq6 zP&`QY#oxt>tX%4`?o4;lZAp$qRG1@N`mFyAsVei^Hb>6rrJQ-!ftf$>4WaoSI$z6e z$rH>yC*lTvnOh);9o}W$M*18S4Jo|Vw$4fO`vA76{<+6gST|Tv-ACY<9i>L-{1C!M zd{H{y8z?wP0+&!cp%Vg5l(g7eaiRtH424&I%%;gzZ|!^KV|Q9S7hz=F94_)5UA-ex zXJz9QyCtjO(Q;%vs`P2ILJj`#MxX-5AvUy`XWs3_ z0;9STiO#%32+j?2Xv-6lTw~?=QpB2w$R5+~%_zwt9CR}Aha&fl=uU}x87>zW7nErA zEi$I*(R@WZzdPo~xF(_ccgFr(ePPa5dkS{z9b*wh+&}Nm$pM)*e!)tLq4el*FEFi^ zztg8_*otqcDvW3N{0PY#F*Eb!1UTNX~#C~ zsj;mE&(q7HPs8=~4<+Du2YTh~R~}b8CPT+&M4X{ifT&S*V_`LZ z*>9xf@mAZnc+_*0g%Fp4(GFG0csvTkiu~vQcsZ%d6SLO1%&Cv{uPObpQca5tJB=$G zdxN>|(_d!M$XnCIuARkFq*|fDREzO~HGk60*C2dD?g1lpp~vC4BemN}tAY2mu$PN^ zdXqBc+J;S)3;RT*EkxG3NjSIIIQBB7KuycZ*6j*CFPxNo3EkI6M|#Z&>OJTy*rogz z&pTB}emy08d0=G%Tpqoo25TLodM=6Vc$q_q=Z>e-&WV-HqxH+FvyQ)pQmLsW8M0=( zRGh~gUv__0K^+^!w7pY-)C7k zZOKmSKy{Txs%Xzm8}{?u_1}M<&dzG5qXr?($y=(Y%GCVyu*%XePpf>BfJ(UO0shK4 z%#r=D_|1mjx(9Dvfa72xDbn>)>ftyiVET{N-DBAX2t#&eVlCtQE!Au56`mF&_ zk*ThY9l+x8pK~*lmZ2dXE8;i422U8YZ?;6$Y$WS`S(UC>rOiYYO%8KGxbL|#rH9>^ z!X=%1`tzy?I=8o(VOqAL{ZAE$eV%JXh8n+TfDpFp3PKDG4Tvt_cRI_a*bu=AKihxh zzcBf31y2Uoo~RIuw4CjvBRi@3(z!K(UR77AyXmQGIR6y`lB=7qO`*s0>+}hJ%;1qc z2i|Fa3X+=*&57UE%aE8&_ZPZ*$9$|${HNV{&xC8XXzhzXU$GFMXvg2QCU7jfL}4iS zX^Lr_8~;KyD-y_s)BrUV4pT;I4^8SG>0lp4oWq?`oFYcjLpjlO82v-$X1SZM%a>ub z6d`B6t*@2HY2m?}4kmt{Gk-!7aGZz9^b8j>SlB171l2KU?3M>NrgIj!XWv%~g`WSf zDJKjF6GFc&1B9l}ht^WqW+G#I1U`L~n#EL6>Kjwo#q(m6Ho~2K`FZ(>cGS3@uhW-4 zTcxhtVD*JvE=O^J8WDlYhDFfKJgh+Lrc^Q5l3AagZ$($LdV>wH{>pg-4qa5%m|l``O!$TcV4rTkxe$d^@D*PLC!SV zk?L0#t>3)1sY4#ta!%L$QlW>pJc5&YWu%v$;1J86qMG|H#`ImH7f%{(I_)As@qVnX zue#S0MqyR(!P_NN!Ue*KtKTE{_SXD0gTlgRN4|<|MURddfvc@wt{&Y%bIF4Z5&kGl zw7IISeOkYp|9>gO*th6A{T}h+EC=^nR$Qa$G4`CIWHhv-c9+5R2uh?AM<3fyheD3L zkht6v_dJ`1P%om?_j=9Gp^GwXMUq+Zh(}Wvdm1clkG*A#%gJj62*12OUUI zxX=1iZoC=xFb9)jb3ZlxdL7OjL@nEG-%8EiFvjYHp;#AoQ#zkRK@Ewg)eUos*JNHe zR->0@x7R=-8;Lcw1qJD>mLga#L2*Q5xY;{v=r1N+F>r}v&$q{Jt!Ixxhqund4Rqp_ z!ya?it{;hzJOp0~^Psf)1zGd1lCp>`sDbmY)SzG=lo%G=De5233_xtvan23Cr}{X4 zPh=VE{(T`S%El7A87O?FY4KJY%JYieE4;iCwLg7oKZxN1Tg^4jQG1})Mk`uO<0Mm0 zbxpvMth$mkv1}YJ*>mOF;lI)?QS?D`R?_MTQfH5oIt@>+8yVBv&fkL6ic}PA_oe16 zMxqs|gW|nkY{<5VH>_V$&SVo7<S_^oSXE=c# zyM%+Ztjdbn2IdWM2dnNIX)Bw-IW3iCdFiA$7lodaOj9 z8B6=CrL(MG$g4J+hQV;&pe;GU@?AC7Lg9CGF=NM zV7ecP;if|z%<3eJ$2hWURn{UKO^GJq(d&sD#A7-A-`D z4@z9*_~xpM9-j#wqPK!32pz?P>S6@A3G%4|t66+9r^Am2Z$gPQ6%96!>5JEj%>(?! zr@n=lTue}rTL(6TYda>7EMT%1xxNnXSlvG_1+RRhWq1b-KNgRT?&)tpRgNdo{13p4cR1$ma69~V|c56 z+J{_Kw$bLX{CUvj;`G>S`h%}!u(Np|9kkfpk^JY%34=_roLM2Vxq*QQ$XkXNpS55$ za{*3y`S#R%g4s^V=!I+hhX&ZjV+kAiaRm)mAG-=gJRELXs?X62w>(>K&;NzJZc zyb1M6d*yh{th-}q5uBt@la+`n)+f~G=fe+2x&+y|W(`+Kjf}TF{O%CKvhY!XUCgKhmcSkuGZXNI)1~skr^2dv46WxW{BRH0PO;V1=6VfbwR+3t2 z)V9n0n|T1+!AyW^2dSNd_$*PDRZInX!WR096bNY!<1n2!yYeqSs7 zi_ktR`q>=LF(e%~jDR%}jjWR>Z!S-uo$F-JUCBsF|Hx$R*wk+Pj9TiIPZM zUS0J~?W41FkXtmOeV{>|LxC^f8kVZoli9EF4{H1p5x+jndlfK#KfpGs^h*y;CnU5r z74;pPqED9;@{CR`g5!u|Xv@>;%P2+G5={kmWa7uLxM}IpYi#b_xs*BgaE?@s+M4DK zQvm1tJB|-?Sk2N&SZnd($+)U@_>RkR*vv)~-m4By#O(CCd2&I=8Z>FtGX7+3kLcto zC`uH$g|UUBsY<&Z-$RzZe*~?3H`x#KsT9NEO0*?czBKZ(XGoxvJW_W!dCM1K|0kcBc;w0 z2ls+}*c- zg=ZP-OdY|zqWeKO^zT^tOMlJtoS17G*oQdJ?M4&XPAA+-i^^x47VOf-X1-inaaHaJ-eciG3T~Q z?yi_lq{a^KIs@BxxMxdS-9shI>2i&S$+dX%flQvj+l6uHWG)pYvRaYz@>eycH2sF4 zD5_A514t!0;#I*wZmBsg$YF0HOX>OXelBak_je`E7f7Au$HVD@xJDp1=(pJON1hT2 zn94Rs3Auz&00hvb!wgG#I|iLzUXYb`7V)lJjLJfsu9w>d#o#+u>a3{K&D@X433Rl} z-D06ns}F6e2XR#{mUR}Kn(Zc;d|Eqm1G|@QZta*Z80X-w8`~rY1+{2C*wqi4(*{puwThV$jeR@ZYaf973iu9t}PJC$|!5_Mw z5<~}5b|rMsU~fL*q?f4 zb1UrL4d+W#-OdpOO<9Tv74Ax*bUhE7A zGt$(AI7wLBL93qmL*>G+Hv%1PiyaYim7#Q6MM5585hjPRG+`*?Rff)X4{oFgj#GNg z?N*cv0(5?nVK&cfH@0B_k<^5%G>ITVOUA*! zV%`XgKd6}ujTWL4&XU=Bw8GRdLjnU4hvJaqMVLTeD9vP(k!23Cv7y>H%25ay81(qA zH^6_#tQIPn?f-e}tHT{X1w~p*BSjs_Td&2Uq$xSUF4^Xz>}134 zZ_mf(Q)BcwMe*}~zs0vq!E7v3wVZbnIEpmb+#9PsPM-mNjL0O&eny7 zu+PqAG1t*?`A6nfvKAwCKlQWZ7P`uKeV%AEqpD0?YH>$v=5wSwhg?QJH5#j4xG~O@ zlWtU+_@$hwo8Ll3f-$>v7PQl2ki)D`I^O}ON8f0Q9dw2OiRRBVO+L$!Ydtp(3a|w- z@wY$@P%)r!ctIWEiWdU|b~sZ{(et30#EiYa7)bJ}Nn{*sVZ63c9R0aMbej=m(=XI`;HNryYOU7>R{)vKfH^2ZdtNW$vacHPccV)c*SGreQ@wz z7IoO=M~$&Cqa|m)WwHZM>4-~%K6oscwn&>hhcclih!0B+$Rm7vygSIod^KiM9dOzl z%vP}^7Fo&Dv#)75q)Jo7$GOr3_Mc_<%dfN7->=KjSw@A5M0dz8A{E}A3%U^1sRHhY zf}<(`-O8V7Kwe~;N~09s(ZNz_N4|h@qMESzRH{-UKbXS13eo&ttIjR^2~B(bFI5S) zc_HMeKOKHX5UjX(4)YqMst5g{S0Bzd9Zkk&WMp*3*0-FG+?hK#IEWGOuu5dorm!dR zlI|)?<+T0^ERdep2RSSU0E`k~3X*C=$~S>$uD9}lDu-0pUE`x0q_ry9_!BSjEK^DU z#mLfg&qb>}tAGS;%h8fve0eTUqr&_;)iK_Fk2$&C0u6kLsHYUaHV&kSQYO~*-sud_ z`m?SRD?M0r`2Ym)=`VQP((X9&XuQh568`S!B}MT)0M{i zCCy#s?JpGnvpAt-zfb@Tdq4c|{oU;4D?b$kTg7)3hBYucI%EM9Y40-QIgS8E!pN@j z#Lp-urAi^qmoXiIG1V2Sj(cLIldB+C3{m%ZFNYwktCy2jNg(Gonq#?FMVvAnh*VEBX$E2IFt_VpIdLv| z(On6c_MK*{x59GP-S0WtlMQMtQ#$cHA*i1UqEZj8aa?C&0!aYJOZ@b{5Ap{^U8j6~ z!Bp!*{9n`;qT;hX7)~HCHkXJQF%rGWsu*{^9eh)AUo8qGd!yX~gM))@LOZDxQgJ9L zDT#@R>&DYV?4|qexBqqD=>Klyx+f<^IuBa$Al6Du$4@uyZaaI~k#$DFs*&63pFZo7 zi&whD7po_4aiYakiy+DSA!<=!FIV2;x-vAJl<^PGze;so%YJUPH^Fliq5Lwlm(|}h z6MP|VUE+f`6?e~5ZgMm3f2-H|B$;8MPZ&s$T*TT@YVoi$oXOW)PIh<;eH>9Gsf)ck z-+bHZezpftiSlLRB09i)v0AXq7*SN{sGdVWBN<5wXGe!kgns_Ig3Ein&h`WNv7hf- zB_$7WiHJO?; zNt@y%U)0GvpX0zzC5oEP+%;bi6aWyB76E|+#>WcyK~WwN{g@aMHjw5jt3+nEl(79; zhy_APC7K8N%5u14xo`{#@K4L{V2)C#i%|O?i`^Lyo>q^m<6TYJPa|SZ9)+FV6Q770 z`H~M3D5SQ&S?Su4ALilEgNi4TDl4a%%kCmvMrE5?TgzVhk@K}JK)=PLq}=CO?4GTHRa(Hc&h zd>k@yT4K<`=TzbPYMTh5c>KxSD+bs$o4<9bJyI{1*el>R{}=1jd4)1d75_@bn;J+j z0v9NRN(SVEMi%tHX&)w7Kr(T-T8=Tnn9rxzxjg36JlRryY!qcBOLCmNedDt#?eu^Mi00<7FBi3EsX1e=Sr}400Kod%|1ISF{xK=R*YY zySnLsBl&*_41{k7l%hXlpvFSpk0`8F(L%W~Diok(YL$f>47M0C1z-NY_U{w zz*2a`7Kdi0$T|1-;w;=aiEmR2D5)A0rA;j!j`wgzQo&~?-M^aD2KFTF1HEpH+J8wpvs=6TYllfv~{u>{ft=V z?Jd4%{sJ2jr|uU17n!s{`3#1b?u;ffNTBkDF5j-P+28x#-354$vH3IOLmE^0v~WJU z*y-y$!Tpl|rV+6-(J$Mu0Vj<(ME$>b!QVb@_7jDohq3YHlTqOHdIZai$S?UdR^aAe z#HiY0j4M3HM{*uvLzmN84&M#eFV(Vssu$k)|qsx+*8)sw^`A&Vh~TT^E^;VW&miVKd>JFRQW((OM)m#&P==lZVGh$tYVp>4Ef`}&Cd>)WSuQd3 zp`c{Vn2sous>k>mcm8&q#Hy49IDOzM1jqT;dwQJiV5*-Vr(IlLa8NHYiVKw;9AUli zXRm3%>)z!}U|JRgq@~SP=ZP2`qvK;pMjVX>I4e&Y`^Sbz3OYzTaQnVY&Kccb_veo$ zi}@rX$*jmylFSsy(CBjXHsYXa+C!?Hw$(k|7?ct&dCkg@Nc0mX=ciON&f6$mMk|-y z{Nn&n>k;`UMq+15`U0>;EXQ}gV(FasoX?L-?L2er$QZ1Rn_GDv@llx|P0{m~n*TD1 zV2f==e{4bx+MbW(P9bIYAt2Y#{{{5`P@8(6|%{gg%*%^#j zwl7wu;ZOORj5Ho!t%?wQ zgiUQse{_6=_QI3UrlN90l~hClk)3BiQMgcksGJ;xk3^ee>G^-A6d+9E567xcP3!WVH?rH6ShLsK3(q1&s2r ze%r&vX37d8wMRxjalimCLI=n@#6oRd@F&hR_LOm9c( z=O}*ccOQ_djyp_VU`cH_e}PpbxpV7{?yc5H;wvY!nQ+utKf33(wuhiO|AwyvPMDso zLfvs#IHjpkzpPtpr_H(a%^PW?*qj-XCa{a%aJB(X!qMwMi>9BPpAB1uK{}BMSGu5f z5X;gBA-gs3$Z*6$lP3U!Mfq%N^|8hrlYk>kv8|os@aTB0|0IM*)B$JFFj;B8)I-KT z5xrI(v3P0bHxcHuCLcGc?Xgrv?p{6{C$&N(h=ZU$Y2P5V9*D`Bq}D{3cX_ZYsN$HN z2YtFOjt#CWJ(>AGP`bws`-6ud%D7a}v;e0$eXUBv_8VOH34iUGiU1)4E|gD13*85o z>Q{vWOeq8@sI&P+a~M9p)NR%L9KQ;wYh#C* zIGamv%pMr+->k2J_}0u_?a@$8zfv}9BV8^Wgw81-pDg$`O4%H1hUM;Ae&JLQj|3^; z*WWe|_W)Hppf*fOy%0`k=fBRob-aKu0%KLpLRw6U*7Wz*Rv>%rT4f=f8ZQmmMk!L3OM3;_w+f7A(JFYv4(hVuUY+`)k4a&J^L zGJQAMyC)7S4HC^AY{mO?L^YCpz&AGE6!G_fT{HHt&!XFhhh>!*IOzpt6YN${m4;(X z0)*id=6anFKHfn2dO(zr98TmYl1({IH*k-MQ7>exKGg%rk&3aVp_XfZ@JFIB%#JgE z#apZSNd#RuACEpnMULut1O01G-l?~7tnNC5vn=m72?W=KI#yb&2adSOi>{Jb5)&H6 zWR)w`xRyS&a?~*OMz5(ay_aP!>I`fU5+s1NP@L^SwSr< zN_NG)N@)f5^juD8QdlhcCHsUlHq|{dn%ENmA<)Xqna|34r-%>u4pK-AHRd5VCFZdy z)FO^=9S>EMU|4eO;vTlL?4KX{GyTX2zoKNatobV`_-5@1B0<=wKmHJFvgl?bTxdiNIBmL_djib7jc&dcrN(5vE(crG3t)-yx8^5co_RH#G#MOJX@T zGd{#BheCoAs>J87|LGTZQ2+{)5_G>)0xqg(Nk>#pCdOv&%d(rwG3## zD_4PWIA39rx=$kV@z2~B2o_LFs|86`H};_amuvc>$fX! zb;VFI@HP~jk)tTnw+E@AbAQR|{rd zPtQpj8V0W(wG`Vv*Qtb3+S^B{w)v`R!VG=$O+@)lE5zt8 zRv^joVAzGj67o2aWpo1`ndI8u_-roJZ+Ey6tt8Q%FU8H<+^ZtaWppYr$^XpRRo+0s zQL!p5oWUTJns@&4N!mi5O84_DZv%7H)CK&TEDNKw#lWF}@M0jxVr`)hIhSU~@Khb; zAmH_Pq91U}^>-OuOC12)IXcU#%NExv7*1BWr2%b)?rft(_KfgcK z!&gp*crk1}xqdXjLyE3CRp(o&GnZAl?@zks4O8EZ-u1BA+xz}>M!f9GJ59}4VZ-ON zwTNC?pxU1IpgNxMQwm~LPZ$5yb3#hxTh9AjCW?bY#5=FtGm6N6?53s{VwA2q%i9lEw&j^109{OWvTV~%WBYtH7}kJFE3m$uOt zCGvi?eBDia_uAHUJ5m>zS~yC=r)K6hgNIA76eET`REpDGwyDV5zPb*-D)V6W2~$(z zW_@1vOsM9xVC$H-f!XBb7xr@ysYLDGT6}f#GL)SKyc1nH#h36Cte|k=!JLnT`|tZ>NS6pzuGMV^!E~2Ch^*-y{+P?h;Vj!pWUh|l(6QP`enKa37ioCZ9Zj44 z&u5k4kE!S2R(e<=7pN*txcQe2%6G_tC)9NsBW#1iUYTyzRi*ounM=txrorXgB_f=F z@Kc#I{mhv_ef>bOr#l?SwZcz7CXW{MiBV>JT}l2Qtx=}jr+jC`U&{N^W2m&h zc`%VVt#H?Ntp8T1%?pmh4Rd?OS84Ym``xK65y50Rq|!jXYLPj>?yHU3%YH#g&a0Li z*oi2)>^aqK_iL)bpze>Z9#G(S@64r!2m z=6v2H|HsG_BYP5L{sNf~!*xRoZ-C_nuIBnHTf9dccv|w=lV1;0S!WJc!J<9in*Hx9 zy01ZGM_kc#t2b0Qt9YB&7)j;sJ$uNTMUM>@+6lpbaZ!$PRluII*mlGvrMLvD`;J6| zUPY+^-vsAhW5wgMlP~D`;kxob{gU^ zoezO!y92q-X1^C0a2Q|b2uDQ6SjA+f%iB{S<; zhuiZ))%6q8u~@%*Rl*?+jEl`=Fl>)MuaH<>xFK~R9oRXQkXdir6O-emNq7XLS7E3Q z#~X_unzU(Y$E`2@5{R1Qm6JP`6yCm6cAj%v_i(vq)nUHeN|CN3k|SrecZBorn$z4<5+86@FI_eU zIOeVd`9L;GB;_wevct?6(u`5jM~{xEX0o=~*VTCCyHW{T_n+}augYVATo8(Uj`X}ZeyH1E<(hhj^rUXPEDqjcMc+9xL` zf48w2tupL1HjBSs51Mrck@X`3wj^ze+^BS44~N@LCg7j`HYG-o z@}<1NX700~{q%91T2(rK04o_bmEqNcl6z!&n_O9cpQ-hunR#u&qMpa_H2;iD26chW zTx1=V_hUzHnMp{8;$XZdTWGRqK8a;k9kfHc!n!cBhN@H6{u>UP|39D_0Q~`!;y1Q{ zTE_`o4I!Xvbr)#k*mF&FNLm-3v=5I|J#(t!;1|k9Ok}vC7po>+BAF;C`GL+CqMb`ZZ+NAcCdjq_J&3_Iy z4&8&thO+P~!8A5bb0@p2Pv{?Lb2tA&n5r}TlULu;X*WtIcaa~OTAP`DE7PbrSgNJP zV>O6hkiev$q@F{KMeuNlB_z7sxyKW-9y(;%H78psvjWT+fVw?z*WT4)%MEmOWj+v1 z=Be_wG_o@4ZsCER=;Xp4PS9gquiTHnQCpFlQR7G{#m+84J zJ4$XlC!|SiPqwK~LW?qVuCd2GjwIf+LnsS}?lZ}E()k6$;www*^Q}!7KTpA+LT309o!(^l z*{$8><1NyfK!<%;nkRlJDZ%AFdBQ$&`dFz-qn*A&SpwdKS5njM(8KM4Fz4`@o<4U< z;DY?0V@`sycD$dDa4K-^qT|k>zDFK_Nl=xj3*knwgm*T$0&~mb49yQ+TAe!`Z-C6! z)Ya1y48(7`RDM;zT!sN#Sf}GrAT}g|%04zGMac}~j-!f&^@X06qCQKq8sTE^|EAs#y#^8tTqbgREdJLs8RH zB_(V2eJ0)?N3`0vH`*_Cf;_lTPsAbC9aYDFY$S6y8uaFK)fsQ45IoRkN0AXYt92Fg zg^%+Lo)oeE^oG6is{DWWddKESyRdC^Cbpe)GO=w>Y}>YN+Y>vP*tTukb|$v7`+lDH zt=eDq{sG<9)pf0Po#(+dBgIxQ520;87~KD_3|GcNfKfSXmDK!wLz-U;mQ02*d;*_9 z%sKCy^VC2h_~mKc16T{e=Kko1th448l~vqsEY*+m*eoik@e+ z`<+%2_R^_Ljp0+})q08sr0vb=9C~xig?JogheuT=(W%!tS>OGaD%r#JM08M#%E|JG zHg9d1)e{*SUA)@%fAA#=l_0?o_>8V^kxy>b`7ddEXJeI$DgLB+OsTV!H%lUwj99X9d*;=vjEjWs9J9V1dBU$p6MKkUoA1 z4iMpK9#3Q4Or_-ZmRAQgG z>2&-kwLmCTq=|D-$Pvz#fM`;RCAw3&k}8-O&KhZqC|u4l5s!Pjhok3~h^R{D^vk*v z@U^G{mxxtr220z`o9yroq0nsL@PHa(?<8n)v08WjE54l?$S<0?;f>CAl?HN~!Fx>_4W-HL zeh0)gJKiNSaZ?Xiom#+EhO9h}te9oG@)EoJIn5)fOXyy|<1cNpq*}@Q zdW~|LV-hi{RD}{5R!UB9z*f+huN{{Rm1_Ru{>-AaT1ep+KkGn3G`Dm3m`QhiwU~=! zN~7_hh0%HycYi`C(i~uGrT)*N+3i54GSFP zBU`Thm>lm6o(Q}sv_OCgG^t099Y4n;+MhrP4opS$7mXX4-v_L)$V82V><4*hA43jl5h_ocJ)8`(wV^p z5b>b@&P|N{uZgyEE@ak`PE^2aj#Z0$t({zbw`G-x*Rp;fvxfJJdC#a>KR=OMD3X8j z=8yM4%nh!QyMJ83#?Zpf<(W`Ea{0+-`AjbJx=|<*Q3rXcC0F4TYA`9CWUJO#Dc00l z$6)8IRrNDZvBknO0-d0+HmIR-;LX*p+eT&~9?A|(4GO~o#ao*Om+0qJLlnqo;o6jhza zWP7{EeAy1dQg@I`l%|2DB~1-9KhcQmVtDloz7<8!{o%4#!XbUAhvO?zh4(~%`Kx-` ziTC&p%yET_lLx#+sRmZ=n%6O5Wc0W){V|^3U?_)o;NDYozX)PiktQBhaE0o9$c4^#wx8m~yt$#RO!}Vp4!Evc$#JaOBU51|O9$abV2m z_pkApiz}^w@z19_3El``4DUBa!>g>~xC(VZYa48y+>Hm>3I5OG8&K80g>&f$&T2ofYWr449$`#DRdk7g9yA5k&m?=7$BO&A791 zu9IpxiEp=IFTowbEl+yporxzQmfC8_z)LX4?2cLE?c@V&vQX1Pm6y z+03Nphl#-F!lU8?UWbweUa;~gp3eldeA>QfNndg7x6{-Q3gmgba{JF_DqU52f1guK zM^jjt%(MeAaD*88-(o|#-Y%%wfa#QyLQD7kT)l$tmD%`JgMI8t$gt&@Eb1wNd^*(f z4UYJ0r3M$VL92%zRT{G?0T;$78EKgRlg3KuU)ycu*hOMZJ+G!a{|mgdP?Jw;65kw7 zb6buHFn0&=`?SwX+`{pGOd_eWDruIWJj|eHAX2)tGG@$@jud8HdJ4a}Z9vU*+bMR> zlU}S!*K4*c)oj9vBiI<1`bi?06n-?3`k(3*h)RRR{YjK1URUgf$7{&F=GR&4E-&CB z71!5Y_W@E-L_ngk`mt?JLOS}-d-Zx4GiGj)XVGTfa(X0H|QEp!ys^Lkoa$N00MeMz-B6BvHwf26k!XO$1pXU zY}G9})1MDbRl%k)SpWKjL@=A**WqC)9lQaMt0(mi&E($P!g5X!@&q4!gf-F8pq2Y6 z2tE!608iEY{2J^D@saz;pxeh$F;`ybtubYe{`*5zC))3`{q!TT^|OVl%H`eJT=^I9 z%X{EFxCg0f(9WD{vSx z8XaPG%Bk$tl|6psDBq!}+u14f<@;abW-(kbBR*avCEHcw@uwI$kUS^X0t+0?mwNNO zZ~J;;U3se1-;3PR_IXUfl?r)5{tsvc+I;6zxytf**N_-T^*AXYo+PJ+~{_XA;(x>8vELdj{ZPEHBrS!DkKRV1;Oo zSNMFL?p3_^fxmCAf#Ab`S-)g^83JhjC@YA~n|^orrGZp*Se#b>x#Ad^Mw)*7i&t*=H%_7xIlCu^6~RI8rM)@ z`l8IFA~aqp_U3I0(Z%0DzJ>}2upXE_NoV;agu1|lmg*JAbFNg|>XOK%s5hI7P6$7D zCr7fbudkO|y}uAI-AN>p!9QQ`sPU)VI6fbLapG1JbPfbLHNT9WEi#=<{2n?sDV?oE zqhvO>#RtPDbi2+2cp>u3pP1ArvzgnvcC_$gF}{YkBiUU~3;YA8O!hrDEH*99n6v7u zYi>3LDsRtw<{4L-ZL~yVaEi7|4C-t*;Jd%=O(ykW*H9P)ZTlw&yg!foE1}`Vvp9TZ zpJF4B9p~%Frv997=g|zogaFc_DgNgyx)UFQIgIVF2+Hp5MK^TRq-4f%onql65?MSL zTg5#7EY@qI1Vx2o)l(FcKUMe zouj5$RRrno8>f*$Uxt>F*Gv-}h8nrjWF!%0U#w7d`R*N_qaMfT0J;VXp^n~g(@JCi zC~*PPBW@9mtJPBbi`M~mM>TGn9iKlsuJKRPO^fx*5)LKM<3DQ-S30~lef3A&5P7AU zF$CtvkY!$M}3b-T8y)Xq) z{K$)IBrHPm{n*T@Ojr6dPvc1GW~4*_E+!ezZhr9-M*}0@C6T|RF$!9bnd|oHF3&4K zfr7VF<5r)H^Ufqr=@M7>s|ZIp(`~ER;8#|aPTi_EH)-+eh}V<+f5NbSa6i&Fg?>@j~c^#&DyQX)pq`9;Y5 zc#a|3krh7rF7nwh)W{dvE*l#j8xeUtS1s}_43y$PL4*e$L~i+Ut2dYev}TNrpGtz9 zUmECQTLy~~@iIXuT+aXYrS$?Gb756lE#p$_5#h{jz8mnsJ-&Ak*#($Mm8i5yaCZDg z?qyc4Iy&Z$F92Jh+xD6@m`f%lInGWg5mH< zYPso_2kFP0V-y-y{1srJtO`kN=xEnfbe`^B^SQzA(e65(%gX{{v=1(gMqsT*VRY9@@Gy7yIBD!exS{_@_34-dZ4oAzM@JtO+3 ziRH%RrnI@?CdUk-?bJODZ8ns{y3k!$IV?o1N+sEw8Q6};fx(%NG#Smh(}~L2s~#R? z=u6Wb3D=n$ik27X{oY5?*)R51#hqwe3MjwFbF*+4(rh~tm<}%(Ax;qZqLv!Wz_4ueQlP55Pa5sbju(C=&f0g6yv+@y`F(&3=;c%S9Mc+`AN_upItzXr4|veK zAt3NeHDV;PszRpG+00A`aEV+24^6!uou=1}lRu|vF!5R7C&;^{|BZ$RoEoEmw81=$ z8>NU7!u_A_ppLMXb_@&m@W>i$Tx%`&goB2-Ki$%@82A8;OJI8c%La%rs#)&t*gZW> z_EI$5+5Qs`#!lSY?*C$B|NX;kzYk5PDvPT$zDUrsU3E>1hv(uj`fK8d@~Ag$*0>CR zFvoWG4t+aUSqa9r3u$n)aFYsQGhpD1=bm6KwBmLoAnaY#^#%VyMfT`1fBP?6GhcvQ zOn5|C;NE;C-;ZoraS~kYb|F*<_D!MYx9XkdgW+@zH%D4wAB|!SSvb8oLTg!BStpur z;he0{Fu`G})M(=FrPuZA(?Ih7wxn39P8WS;k}8cp;1)%i7#wwC0GCqfW-xtV?&5ip z!~i;8By_c24;}w}pki3tR%%`6jA&&X|8IIVh@?l!IY$k%l8YEM6lgXJx^td1AF5R3qZd_NZ#0O9xU zY|r4)zZwVUyWK@UITK(t9MYf=8iB{%KBVt(TiIGWYgJGqTVuJgthUMFi;E3c_FMIS ztSvYM-PXhzv)C#_893*bZJl8+Lvzn_oZ!oywF*B(Wm}Y8AHw9OXEgIj3v-8)0owC2 zbLlmVb=Q$hQ(k7;=8_ip`_)$!#;dgQiVQ&M4t+w|Zuk-G4K0e&GZOJ*M4aF<4qV9)2AD_Yw{-bIIhCLTV~ zJbo)(D#~ll?=nh0hq~aSzfWN+-TRQY>|eC;QlFDHPtBU%S~h)MtD4_(_l+Mo=~I~4 zoYj+u@6qMxrcMc`pCk2xrs=`S8ukN@TheuaHq6indFRVsn8Q^D;d`A7HC6h^5;6`i zluy#lpFp{w;S003K<4wG>V435_7sHrPKVW++>JQ8a@pl?XHH%oG5^6IcTz5!ecJ=i z|MUMs8HVX;=kiCg5&}Ne$pYI2kG^x$XR~j^wiC;jp;YmC3Z7a@S|IM zh6n`(&g>IKcp)0L=+H!v;-90AXD}$gO5>D;gZ}4&Z9Ilni5f;gP7^pBEBWW8(cuZm zMASaYuCS!XEzGmOOliDcOhEL1)Rr_j>bc> z1nLb&WPp|&W-D)AU>hg0aihY?*M@_`W4_Blexo^_b8{S8G>7AOif;CVQiY}NT6y2X zgjlvOkv&&y+Al8AQ3+z$oz8EGTfuaD*Dr~=e37MhDclqdP5BlJ8_5;=adra!=F2Xj zOw*zNIyX8)AijS`=alb|<{JfPJ*2DJw1>tU5Vbeb5^I5;avRoI>Uor#fqWgcj>a24GKMz|tGPTlNGfYDcmho-Y_U+`Ee}u}ttrNP*l$T^@v>^*C3D=u| zp+c27#jkwyB1-G*k8XEE^~ZR%?Go0P9!&cs?@SUCvI|F-dwo6cl$m;B{gfrbWSPu4 z68mL#D@Qe9wi{=H^bWGvLhK$+)6t_b>1F0jFP90fDnXjig@2S@P^{!trT5GTPJkX!ne|dJh|{Zj$MF@|N?&3psrLZrCFk8A9$&b7HEAXmEir)QuE`Eaj z63A8*MVXQQw-cH|alV&Uov*HTRXc?PZNq4T;lPj?;a2xc^oeC%)fEPq>9wetCCckq z+m7MBvy!p2QM_z@ega+{pGXY4;o}a~M*NlV3z2$7VEx?02@4`ni1r6W=&LVpc9tzu z45nNr!zU2P0RVfn3gZLjE35u3+ZhAd&h+1~#jNqEfka2)z%t2GJE8NLuY#urYn@TP zWK#zhD?PSlp!O@^m%+j3BVCy4wDCo49~^))M1-5}p6pNDKj*DT1D|&${Wk+&xvY5k zuigHA!iP(4xC$#-3Wt;SrQdHc+mTf(i1>Kw!%4^kSZuaz6>+@7gz8m}J1cVTXT?J8 zAm9?X&?W4}H$EOo1&Eyz8-EFOd?CX~9!BRZnW$50^n*ntW5%8#`SH+CGcpos?dLFb znC}jygR1u-^?D%Q_xF1L^)ZD`_rz+&%1)*i(sC3Yo}`~eZ#~5rf{HEtS|Zpog4ab< zXLIIT*>aq81hG@l+!yh_5VO>kfpy3OX^}feWJuF5m)eQPepC|R^Xfm2tayX$C6Sw#NL4$eW%}BSB2Jr=i zTe@giY!#4EbIr1NKLy#|?%u|vHl61c{_3xbLx%0c3KEdgOzU~%$=ZA_5FSodv&lqN zSY>?4G=zX0?C*{r-+Ill&z4LD4=+}z_}2;10BQZC&X8a2={+AbuvK)W&L-kI@$_!( z?#Mt@Fwj~^QVk4;9M3gN<8#H`iG(+H4pR2(M#jesE~fsdSFBRvZg;VgMxrdrji5PG znQre7xaR*tJ5;;zbi%Y`$sLt=MuAi3jGa9c4&J8MK<(qo!x?BCYV?oET5#!Xcy)=sqwy7Iwz} z#y~Ec)jK{Oi2&f5?ecPy&E<>9v(RwiYK3ghJ*)zyP@}>dGw^4x{ zw}K8Nkt{5cjljqh51`2;&jseS(&#uvAo#SD-N!(RjYHCcM|4-b{qEly3hF2!sB`Jp zy|U{L-d=dd%Wz1mc(+v|vJinWqbx=k74Kt>z+tU$y1DuJcyP0OP_cXYp6mU!50qls zJ3E#XoI6SG6LExwz5&giePMF4^`sOFBg;m&&X)pztu>Sq$d-Dr!S2K)FEO(&9Jf6X zXKL$v|AXJuDPHWoY2Yi^igzBCE_j_nV8z%Q^o4OPH6M&8P^X~W7xvLdU%qG{Rb$NN za}dkTB!B~jF%dDw#Zix(MwxQI^3mVdo2y|31Oi}PyYHg~lRIUY-S+W(ce3=QN@_VR zru_tE@1CpAT@rhD=pk(y>`BQAhmSeC7ee+)p3mfrG(wc#Gr`ULN;uJxq){|v?p5~D z?9~USS*PUJgIs`tx_g=T-ipT57qR?!FZUdT=Ms z`-gRlC5PHDp%Vg>kuY;GVE$;{e>C%o9bKm|A9pk1W1Q>JWoCld9IWu31(}f6+Q$j9RmEhcrJPE0HHXu^}N9YL04R+)Y;aE{+PY} zPTHSE;Bm8Ft^GNXN}mdszTDi#X{ka@)r4$5e`;E*wE(F?jlL(D6!%HQ&!zc>`E)Vs z;)T%R|ajm-oZf-EGAtqu&oE^PfO9pNXOgQJ$62Z&T;oU zmQ3(|zr|fE;70zNAhs~@h@WstB9;@d8*KC~|VVnH00PlnyH6%51 z*?I%YV6y@pQ}1}|dLhMO+v88bAkrawAwMYi@%9zP+0T=fmQe)F^wA&E=jt2vKDKp2 za>c6qCNV8<-C!Nu>?6i>(#Il=XBaUo^R7Rna?B&4&NP$noz(K$`9)Xu&7U|wR|TKw z@WkYD0`a|?jC+ExJ)%SIhE|~;TCK!oUnGqD0SYqb6--<_!#|Zw!bolHf8ZsiKS#5E z68y(c>*|;|1xioby7p8W4QEO_LZM#u!6|LBP4ETW4Y1N{>PXO7-`EFGV2y6fj#%c} zyg%D7xJ#p5o6DoSVR*+&sXOVoT z0x&l+VyL%>Ava`UuVi;=4jj!pZTcm-u5vXylQFETv`#Rt3%EDj?@V)r&#%EQI8|>e3RNdb(6uh)ff>gJy!FSAD`F2le z=XB$MH8FC7pj6toDuUqU0?j<_OGUqG941D_pLz>$)Ge)hZ`mse^@oB&1-stI&^%rI z4x|!9O~gp-oLFjB{QHvr^n26p4-EjKJu-_w?{?~_SLsQs72)B|7f2BoD#m3hbaoKU zQw%gTHVwR9JglcOu}BFfjIAf9P&1`Or(K53UsmQYV=i<&ylHNFf$&D`5{xk--d0?bIL<;S(*y)~>lBu-oblNOWM=(%?h1T%s~Kc0n3n5*Kj@28Vow zisJ=4MO8US<@8=nht8n$@`pxFtb##lU~d4Euf;-u`MFZx-IkftRN^hp)cch253*APeo%Mjz#>h1V(6*$ z#2$`J+C~p||5`>`#2gh$#~;8oO@%lv<^j6#Q(BXpv-#reo<1Qoe{ps1z`60e>h_ChAPuhm0qtHATvOT_ zvO9w+C$w7#v&JPs0$D8)b!DxNO& z9$DyR3>y|xPuTi?O`VhGxq5Om4X=&pi&M68Cy=*f^M+6n9D;PbPgo~yaZPp(cvLvM zZ0i+&|IaHX)uTQ`Bw6S@y+qfJPByn?;HCZ6e#a_kF55ESc&z=@q6xVq_iOT=_u~%b z37;uIdWeaGf_h(H>hn1?=Hs-^gVZV z-zd`pL&cDz!~xQV_`^RXq)27T(0&;z!^7ph)q7V^RqgDc05)EQ1{rks?w3IDX3X0| zk9Fz*bpgWoggt6SqcDs#Gn0Vn%W`{C33ncq{Um3KWO@T%?EvwyXF_k9Y5Q z7Mgk?%3{^BK2rIY*i!JevFHQ$nJZu zk?%iUlyN#>7I4q@H_E`(U1`xww^9sE_$k@z7E6PkE+-XLS6M0wObP^dMR*1dFegvI z<#4CS?E2eTI~*=<9N`*DVhlFZg8Q{tjo+b?TI)u_XKDY*Ljt5-jE!M81P>;qJ^>l$M zNzPFC@&qK;`$F}X+?;@b#MoZF2K-9bY5{s|Ta-+}N`BcHtZ)gjk35YT819vaK<%Eu zj*QHbEx1JXs)3BH5qtMn2KB}2@VjK({P)Iej>b}SI78juxvOa7wa&;pg)1+hbqQD! z5bdPMHCxvfa0xcN{r#Yai3tc}4Z8RR6&2{3ywCBu3+Vp-h%r}C4O7G*)ct@3se9O~ z`c@?(dyZ{#P029Qko5}PEB$1!jYSd^hiS`>3%<5DzjD;ZZ0Ymf5TKx)`31%)k)xfb zi^x3fzFT$zz|&(!8sg6x9!CbPJ#}5*lSLQI=}BGqM@9{PXzbw_%`;)j8ATQG5I(XH z=JEbrdw1#s=KV0dHl{YVMyxaC2Rm%B7aL zySerH7*VDx*w9+}6{p)%y7N<-6Ui+acekqt8Gx$?F%h_WbO@BaO`g zbO-z!I7<yMIoE%U3ZsU3&kaxS_|!ce$e!Npgb&WLZzXzuJWON?O0k>R ztvZ@Wlf>{`+}M;YRcfMzxgm(O#4fcakZ4Xmt(0lt6^9&N)kw`FKXKzYrDhL+Y`|(u zB%G^6N`9%RrG71IRyRUFha(B1iDQN55=s{-BKcEuH|tNNBqe4?A?6bfU(Xun)_6O? zrLUr!TFXc`p|vAi|4^cAVoC-HQJ|1f`Hdbr9J&i^TgIDIHGPz?wqS?DT0}T5qdS(T zodfO4MEgOM(|e$?J|lCaXut=_n)ZDsKbg<2i9@>cTP5jy9sQ9-_~q)1kTRmxHjMUJ zP=D4J`l$*Kdwgulz{o7tKuB$`Z$qCJ+Ga2@+<5&tFS0v*R`Ei{CRo9j0{za(89?wf ztsB!}iJ@LwNiR97KpfZVgrn9IVX#<^NVD*<&m)Ky9HtdoP?OBO{ja6B6ZG9cN3NTC zP(%Q+&ct0$owFy*H_C&fb_YkIM-ZHg%UVY%cr`68IRDTvA9)}rV_n-vxdt!871v+j zax(r7O+_REzboE8k}M0-1LLRw4;cp|=3dRG5CL7SRsQD~`i`|&{o?9-4hEZnY@uJ4 z{I9{`_@^5$H2-#hRquRxf$@vIkk8rLpC3Rw;V@A90(_ZVK!LWm<4DJzEcJcWZG?kX3;1>-R2WjV_@#dE=MBisIVMMhS3jx2%Tq+vKEB_HK7bE+nT02liaq}8gcsi~re zBxsqIYbgT57{L6b>5@npJVjWnm;U?(>dOP^C6c!9SC9SE9qe&iBfRjNrzVBYy!iZX zyk;4SXhLWXhRir{a9V|^wwYuT|2IXB5|uZsCiBcEgxkE+KMZJTYfDP0Y4_JqLO58C ze^1D)sm8B`Pqds$)W&u;8H4WRzmCX+)V_VoAf7=Q80BY{zn~qS8Nk>n_#l;&@g|NTN3iLSOiP@&Y%ZP+Ug#{|};dN-w)KJM4g5vWK-1o7BMM?mk zDs9RNqm6$H1H@&*eiao#oiO(+8j4`#w-Bp^ z9{Un0plw#S5kZBTZ%ed2~MoWU4!yQjDd3& z;oazvci}C7ot{rP?S`CA&dMJp;_)NDXl`MTH#mQ0b*Ba{GQ~P*X~yv$$6muJ^SlYi>`jNFihMXzDQ%*!02K!FrKZ{vD0%W= z#Gp2X%!+u!>VSbkjS=7@9Gmqp2&Cai2TF>D*=}B5d{Z~0C|H{V3N#9sW*3ch%gR_R z4oSY;CeZ`Cho;DP5by!)K6bdAfA5KZS41gQIW0s~y5`7WG?KQdkY4%eC``eKT z9+xXdwH-RYjlsn`G{gCuN@oM`->aQ>J^f zw@s%Cs@(=5;MZAZ_#Ft(^mwsqC?5$?gISQ_g(@A2aE0@!|5g*EcQ-l7@VWNXJ*%Wg{RY8>7dDlF6GHQ5NJDRgPT+l}}lmDbPCCvR!3u-Ne5 zNoiB8k#8RfC)Y<0?Ito$PW3#TqE99bSt7|4R!t)C%!}9Tklgfdy9XN`9JR(InixuA z+W4m=nArBP?<;HiPnB)z%}dx*a2U$rc;2bCy#(MJTUEK^ z_af`a`iI3t61%|If!LO==&6dzQ2&}Mp~7C#YO9h*6w!jB?VOxd;sElUD0!ah=;#xg znq4;$jx}}tK6R(o{E@Vk*AqC^MTCbB9pTm#ZlkFtLX&|zv;IxA4Cj0rE(0c=hl!vo zC8;1w;P|`B@P;3CvGtV)z=tNM1%@jjBDo!;7aE)%uEQpT5&Soa2Erx=^^6eatAli(&d8fQe_YD8}#5U zmrur-i2CD7wqHmN3k0*d{ya(aQ?DX0H*XAV^DP;h#i)`^^08WmmTg?r4UipuB8c$k z^uH$}eZaWLi@k{{(?y1!4Bw`?T~Whn(heh!P?qKzs`FzDdl??QcyK%~{iwnq2slW3 z6Teownb7*%#7Thsob7O@Qx8Sr4r^B86|P(X7KLz>4uTJZu`qP)c5S~ghD|9qC+>d5 z8y&{zon(_*32EUg{7M0yyRyUJF)g9pnbVA1Dy#r1p=%(fC>{gQ`77h(R5rl%J<-|K zrO@T+0*B9owNNZ0R3I9|;Q3%aI5Kk3mp-CCX95V^`4mnkJFay||5`Eq)qKC&%v-&w zEos%f-5=2~)7qA_8qcumM8(8p6LsmI?O!YtTOwxQoM0I}udU|lom1dd3SJT9n*1UiE%wwqm!aOrYNk~3J5?|yKst>HR$ z{|xj))RVn)YUJP%zt?L_<&P&_YW{JJD8@28@c%c1$M`EXj19w=FK!9et)I6WB%`?$ zzF_90*0c|!6@rpIy{zIsU9zO^(3iXHc1d~eudGB8O-gfKSeIn6Z52wXqQKh?E^@pB z)O+?Fn5^^Vv=tub9%UO0d6U-jcJJO_Zo#7Hg!JX_l~8jBz8K8x^t)it;8Y8=uNXo9p+mgfBJq@gtb;QxUh z)L!MlKlyD&SLsqST)!wst1s!@c`uow8_1^#8rvG+qLEMY1vG8gIs#|Oyj=u>=Rv}g z5#V-%GHDeEpwH=wl*MsPYrV93vv&%n5W>pgrXQ|VO;%X^jq3dfLZR3M7`Ag8pl{=2 z6Nb9&4)n5UFD#_rpW||-twCf}aX};SLS{sctF5;3IAyMZe%v>5P*pF8PgQJ)n8Q7iN_b#r&m0hXLiwzroP z^H!>ckxb5(UL%Fny&1U+XHg{RC-)7PNRT4WcBe05UL^8(dZu7}9sSpoRVQY7Z)p~% z^nI`T+!!=JJ`hisL9WV&1?>a1&f>x_8Y#{os~nNJ3cPN7mkW;@S=N8PH!nTK`F*2L zTwMI+VVY5!^WJ%)HdHH-Ezfa>uZocAUq$zPbD9Io7Do`kifAa`Sb`p^BH6kxRnUhe zZL5V8i0O*Ox(X4SdUX)LA##z<{G*_`$6xZ5ur^&@s{Uff{|;HcGW=%-8wK&0cv&4_ zge=xFRP<5OiIjx6$M0LT#dZq`3yY#Hk|MO@dL;xF(?DShMQivf049+dTtzZ}x^(%q z-GPFP4Z)~{+u-~|2?(QI*q_c{MNBX;E(Zj3V;COHv-wwR%>%Slp91sp5Y&LkU+f*S zLX!5h*sDKHn_$;5h4i%|m|-pei`SSDLAwnx?j3WlcQH@w%KfLq*mfE_VcEU&+p9R+ z-3PD73a#2`dScNfzlWo=?=+9Jj^a2e#j7G5z8xSg`6m$Xw*4j9Kwn)-zG~2fSEE_k zH!NVn{2Az9z0K|EJEX45)P;v>qDuPi~l zT7~_~f*~?i)^ahuZZrh?r=YdwTq3nZKLX=35Vw&2tP#n806Y~}^Mex477AFHTNQn< zg?IJ&IZN|Ir;jtfA9*__^bjBinVY7U-e3ubh!EeoB^mP(vA`%y_FN?M*C9JdYrqNm zh7j>^fFSq9Pu|Ce$4z}~iD}8fh8Dj~8sD7g5i^6L(U_8?OGn~Lr6?2zg2S4=u2P}m zUJbuq2E}I}uqopZwIP?s>hkpGgZzqQ{i#Q4c5Q9{ZSaFm*Ka8Jb^dg{;w@7_`Gp1xl$2Sltw38ZUsnlK#p`P++Z*QMn zToksqXAsWknN4O#9UdNrf`QpTc7%LyR|wv8zZ`44%KxREyMW)t?ju@6n8?`dq=Tl0 z*mp0*T|2!E8&cf9d%V7^e_ou9(zO%Vyu_XtIYDi0LpmWZ8*hK51{aj;I-CMOAm3yS zSiHdxLkY^wzfXb3Qf;C+XQ_r7@K&swy6*4qN5W2TUJy=!>h5)!F}>jNfR+33BN8kH zPh?`9t$%ixCfGs|St8!;uEd47dI)kL@X}tNMFvNWYd9sJmZ=*IUg%>Wa08=*rQX~8 zlaaQkiOLLk+fV&;ZFTn*&9Ze+wpxQVs`?UopC9W1gBws92}x_(2InJ;$Q_}YrCEk6 zNUiRhd>YCt<(5A^JCoQ}TYFv{q^DxW0PRVXVsKhh;Q2~+-w|*@t6so#TA>xlJ#>SM zx#^o5YN&l1RQk|J(r_9W*U@is#1>s<{aEOroHl}9f2bcBfl+O>w;(J3TI*%N1B_pE zaHBJP-g&4y#h@`oc!i5pz3JEJGsJE;i7Y77pVbx!DL4%Sl+%2%PpYU*EOP7LW4FTc z^76tX6P~-d=Qx;)xyW>B!_rr#2gZ5I=rE62K$=SQWSHT^U@T+mE&@pZ-Prbv#p=D|% zHZS_ux28+3bfK#c0qSzNq>;sXPS7UXHC1UB3i2|T?-?3n-qu5gghV2I(rlDJWPnM( zU9Ijv7nc;feb)@Y+z6b7(i4VX?A%eSSpu#z3I2;+x@RuuX!pWW%P0iWUI~6{?~(Pd zqobqZcN(b3$N^JlWwBs~ANREkLcQ%~xkBDCt`0~9UYF@nV6f7OwTT9X3 zF3|OF<~nL+bmnFtUhm_9bi+8NY*eMezYnwkzw=p5iaBc%jH;Xf1k!}=XBmD1QdA!Z zqjI^yB}Zn5%TDx!p$IU?58k$vDgXLA1&}o-$M$!*9K6Kr$wUbZnK+`mxt)dIXx}Ja zWc0m>q7}6cX`Cq4M-gEs%Z%!`Wv~~(TTp`xnxcYW@xsS-bz2%p732$KD{5N=wsQR3 zhm_Qw?q+|}BaR)!UgR*_-g2MJ0f2|UAX-EDYOgcuL=5M$h$$4{kczSx*Z zA#E1!x(SAFrinqO`-?6Q!vaIpFO%Xl@#<)w$)twwdUzr0^v*?=ms!?DfuF=WXbj6C zd=1&2!;{AS(vwE6y15>ecKMJ&f}ZknOZv&Ecb1?EmSv!`B{hUl&=I1KR3fdU33%K` z;NQ;ySp4-C8PxVEcC8?KJ-NUwi7|tXW+Is^t$DZcP*-6dhbFbEBN`Y2DjE8@npUnb z|2m1v!KjoM*uGj|!sjtQjgBAzYXy@V^CWujS#KVDX1jg?Rf^ z4T3JX|E_KZa(o;ic^>b?_Piztg8mT<*()XavD8nrf{LZ3JuHm(3E-3Kyd@Nd(^-Hi zRcJtaV19>Cm(_s&jp7jCe))*@GjH-lr>wkGqfWklMOU&ez}Nj4;ICKbjg?#(nvo29 zVAm$%{sbbwP4f2nQ;tV(&#RFOMx{Jxz36el#y$M&Du{fW0EuWh#3BTzRDiu2RX^N zcW^VE1Q_)V6Ehk-EJ%R!Ha|hCW`WM6j!Zi*aO$A4xKq#-gBKnbdZqB9AVBu`aCxPG zH0C52BRn3Fa`)&F3m3;UMYqZqmEaADP5P6;<451|FNOG3{O5nObmG<|F{0%!NxEY; z>o9A93korsvp=m$!7rygsH&;shIyaDi;~#?UFovpJ5nVk_3-Y+V+p$Laf>ON`UK8lN{&G$l(L(AN0UgsEcgC3~-n8(?92m zHP$m7x4f|Y33_~)`|_Ar7M0kzwwxaaHrxVE=euDhVg8js{l0LD%k@pz9H4ah(SE;6 zTfKQB!c6wV#abzXTIOc-p7)8{<1bD_&VgtloS5B*pW)hDMM8zKHKy~iBE>UY8HuWWN6+)S&rgM!V$iaZmzX$r?N+ahFng);56Pg`12LYv1BqV&ZBT+ z^L|;3WJX7Mp=y@Cd=<>w{%7tCcDkT4BQ3`w=qsiTzpF^Z40f6zIzYKY5wLfmkO$4b zp8Vbgap3l+3FE1OpSEuse3cS7g2Jp19_KCkv5r^1uK`)5GiBUR2*R)4x=fPFTHf@F zjx?k6H9~LoJA43@>`09GPvw^k3idN5Z+4cx7A;&xw+PT`p7%(s?EO+BPUH#I7$IUE zx5;vw0GaN&NiT|A55%gNJ)Z%G(^)HF*i{1wRt2{?;@0Vk%EfVf3BjM@zMRPZU#6TW z{$GZRze&QhC&jEG!o$OZic>5z+PU7f_3cSmmX?4&qWLVfOO8}e1^s9|qsZcy;lG!Q z88r&EG$7hDe$7o(urJ?Y3e?azK2p!&g2c7Mz|;xBgRa@aN5tQusGX z8;Pc-=FRc>4bY*e!ixib;|~F0kr5;F9?yi(zlX2p{nBP*-4@zC zXqDuRDM_UD2K7ORi2%uDpewY9vSyw0Dq%Jt+9wv!Puph4-(NfQMMss6Y5G-6^BkKP zixZv{b{GFaL7>3*rY6sqKmde~fp8e_;_sx*>j`z9&7bFqh(_DF_%K8t&gpRu(`0F9 z9DtYvlK^1RU2k7sK&F)a@gz1D)+m4F%6hVy{oEz|y)HVmON*Me1&G2=TBr}8wG_|}0+BOf?j7#_b5cXD4aYaqLF7EE`5Zo%(WEu zRHVQ|%cFI!Z7env9h=-zAJYy8ODRzD59!;F4sL(`Y@es8?x^|t;&XC}GS)k0d6OeG zgNlJ5S*I_Ek;?SV&fu8Sgo%pE9N0nFC`U`OSj<>UZkGXQ4`3FYDWcTT`Svv$%cv@R z{=tc7>hUzrpux11K~m8BRg0FN$l-7+{B9;t+F51@_mOo<&kXzZvvYfcrCbG^~lSeMb#C9pFu(>Z^z>g@&JlZVuKx@)Jf zW;Qh3|2QEP;o55O8gx;VQcYme6mrkjdE8fQ^%h9%de zjA3X=_*HG9h2m7Wwcu+MVyqke+b#~07`PZBMHsLu5k!%@i7}7X<85n~Zi;Qjn#Yv2 zu!?u4GP))u{_(iDx$G%=TKVR+igHz@bn?E+akW{WGR}q$JQZ7#QBp@1hjpE=6!*=@ z8haB+vEo?pxNha{j42yQlYs+&8PhTz^>II^O4oxwvGec+Ep}WXBp|4$rCSnztE#H1 zbJ>$0^DXty&a{sjy>kmu9TVCUb{JI>4fP-oFx}t1v;JM=67Ab`KP$ZI^MD8a%q{kN zpFwb}`ws>Jd9P!cZaYErCwAXlPTCn6FT-uGbmL#Cx%A{?;b1k+l!Q0$l!RTGe@@X7 zod<&!-wk>q0`x)X4Fj)5iNr-A(y?^kblZk&a@{-(Zp;P9E5CC(1#vjA_SYD8HZ)0~ zlXWNfDW9`56okS4X%1)1hu8f6v9_Wj`rbIi^m72Qw*V2Sxq*foi#Vk(kF*lZ zR+0&{D0!t$F6xUowLjq4>uHG3Og95pSi9jL@$+ajIWJ_5MSWeBnTm?2lubzL%1qjN zndWR!*%8{mPfR7dJjK$e&|)c77#=Jkl`9Od^Jr=KHNVk|^m)DiE`EyT6rS^Ws|q0s z@^Df?^wjf463pLBM;qP$-EExd8tV}j&K&&s8AvmRXJzsK619|IWBLh!<3ngZ;XYh4 zjeqH0D%BxjAZLLWc;}|X6DlsGjLs19CbDxi>xXFTk}t@C{;5!TqS)H|4%NLGeY6IR zmc4gY%~xdB5G)vQb{vRxjl6Yu0DZ{%NKI3!3Xx0>TX0$k?2P}qGhSEpow@0gWHz^$ z5?h@}GfqWS_UoQXC^}IB=Mp&)KeV(L{or!_#^i{_p#zY&hi%jhE(cHIZvC!E03uwr zH!4b#ni$_6Fc;OaFnNTGl&-e^*6m!-AJJW>1*8MX&GSHS_K9Md4A*D?|3oyi3m1=U z%Hlmw3WGfq*>lL`pJg?ofdO-xL8;2m6@~6oA62dVMe4B&GRnWMTY#|z%_J_2ZVM}G zp-De=gG@W(GTeF}=^>=UZf3`*7%IEGZ;=c;-G@t6@-w`tvhBAyTy|wa%ge9jUni)& zM8;3($r<2*NJ>>iJ{&w}obb;PS)v0jXe<+sYK|=@iv#DKLhZoY7|*v=ZiPr~LAZhq zX;Nm-8c65+cEVFir}vC4Ne% z{5P^*v@}fDWG?9Jjo!$o)h8)9w)51E5Vm)43dFy{B-UI#zX}-)=L}ya`(d)5;GXN9 ze1sU606RdKHF!(1Q*A%Ya?FN&S|1Yy%v=fLS>9M!nY`(Ut|{AthS<)xUcEJB5L zEgDy2iZwFh%ioEj8?-wiv-Qfz65_sxFHe(R-mZAqChw~fmbuB+Jusf7*M%GAL=+9h z5Kk#B_R=LGpEW#AF?ujf<>5?u;yR^adHEsPO=YX`OS)}F{XzbOo6r^ivvlm>%I6KN zea(;PpRpo5O}+h?K$e;0a_g`Bn9tPnaLy-?_9nRkOi+82bQA#VRoXB{iW6*uTwe`zYZA##t? z(c<3=t{D2veW&rK+EyK9YClPWfB&u@I->N=Ga8+i2lEK&878C09Myu(8 z(upUJLSkDopUq%tdpKku%QK8H9ch~psmoi-vv5t{fC1;!lP2oBRFE>ep13`KIF z5I-CSs?2X9DG3OayT){b!jZvF4qE~I`evB!FWO4u1i!uF5axPCHrEme4sjS_lBLJa zyRs08%=LL6?Yp+S1V(s&$2f-n!5rIhZMKpf0ikKT^=Bt8(wEo6gxlKF%_(1Xmpnhab6(YwZ7I5EF+7WVT&MXE+7})LF`{U{DfKHO2qkq1BTG2QyG40oWc0P z79<_AU+58vnih3-X>Y78_JH>s?mm2j?T_(AByi*1^Y&mEZbrQ)Ta8zMM3=wK!UZQ@ zOqzaS3E{KS78{YdAiAlj&-F3z32>kD#?2h@a>X14)szo2)cl`s6zCaJ%vYFSVRkAf%Y1LL{dPu7=@UxuMnS%1(58ce4I49C+_?c>ASGF zSXfaZe_(_M^iK!P%s?-l0`^E?TqaryxKNo#;6lj(>r73BUQs-r09LzG6&WX!+NCBW zij;hCGo!b?6AdH6b#dR=0*m=Ro>oThJ=5l`R`jc0#4%Ze*rrZjT40fKXgLoLVTDR zZRvnp#(AfRUb`HrLaREul`4u|W$;zErfu~Ihg@N}*q zCO-bCu)@FB`>`Px&J+pr@OmrkUxp)%NJ3=@#5`>^YR!r)D*Biiw%Ms%9GJ}kQvP-rnWN&X@ z7eOT;ki|6C`Nhqxu)I8KbJHYJlB$OLf>Ec=q=rmi_sUa?%awI+OJmB7dpNMKtJaZlatR(?cu6yt8G*+P%>?U4y&ZTE*f{v*~! zs$oyodbKd$mWmpUBb2Gce|&Xydenhh>sSy6^CvMa$0arU(ujiu(Sq zQHeEz<-lds(Na3H{M%gX6xK(?;t?}b3bc|M*7QZ+;1#V8iKs1yk}o{R{K;fXBYkO% zq18@3ggV`@(O><=Tjvl^sz}4%<%yL%(O&WmH3iT@SmMJ{>=pb=DecNYM!qnCEg-P` zBK%qzGp-6?Te?KTwnhxRv?8ILz4Qc8gmfTWR~^i>q%_Z?s=f+CL|y(Y6l7HDjf=fw zuN|@u?E&>o(S99vOX%iBTzn?!sCuarqIW_lZRCZ*A{SU!Ye zL!o*~sULE*cSLlW7a`E|&~yS9{t?tskm`9mv@>3bkbkZE3>BvTssYqQw53|*4#f+f z8=m_rV(?}Ja#gmrbX<_nCiVo2JVKHj{q@Mw;%8EC(dD63h%M)y2O=+&`l1;FM8HTS zOBGS98uJkB+;xYYzJhR~;H#t0*gbz>$X&cFe6_?CzRSWR&?@g|$yZEUGK@@M^Sx52 ziiswjf14@{(JNGJ@OB5Sg#q&jkjW|lDDD}#&EtPZi?3J_LKBQ( z%+H~SglxV605^t7`qBP5ky3)AOp}n#?Zi{+rzy6Bf7fDg4Uma{!Xgz^tU=t8o zd-U@?o7ut8_`|*sw%^EUSim-`>95!Ast*~?FT#q<_$C{v&z_zKFu%|kqb{uQO)i_h zKIGl^<|~H%b?f%u9*6-Unre|CqQdJ++khFhbH#K{GXQfB$hE&7Cl`XPHFhAwK7pc) z1B+OBb?8;Uw9dwk1wq(-vp0!&E7ucQ5_YLj>cf4#?Ir)I4-<>huC)6E)Epnb3TbG2 zsYrq9K^Q1t4^oJXZnvSKkgx93AwB4kt_oJAl4=Dttw&gbxl&98R+XbFm?)Eb2tl+b z@Pduw3zNI-vrjmhc;!$a!_rmqj?fQCPQwp0H;o~d#pO!yE)lP%ays6e5cL(}-=B1`kzHPpif)E` zK(TpgyiRQVIPk2F(xu{Z#(ke0*QlL8Sgs$))cv6{-4qxefd5D^Okhm_`L>3q2* z`L3;W%0oAFf_gS*QIB82`epDe6L(La7hAVISa#nJ%L|U033V_tdScVf28na!Wio8D z!%hE25C_H2pFJ2=rlc)c_R<$tuh}3De^{pPabH@8fR=2~X*G8dYwc`s?!FG*-F-gd z^40x|Jv%)5_{=~YF|sO?^F5-GndZs&I=@AP%I;}X->b>q$QdSW3^kFDJvoyygAwSX zz%08GG>%sDQM4~7zv7sZSVb3j$YGxQ?_QTfN6)l?GGy2`f>6R~AXLSzs@7*}?JTZC zBq~6|{0-}NjX!8(jH%T4(p(O0)8T8w3bwq4LOvhdpbzB*PMY;#S>ZMcPj^e(JTI{+dnhep z85r&Mo3&U$C5RVBzi3u!cVRFyHgQ!^0JY%{%|fTwx2qST)D}buabcx~=YANrG-~56 z!I}Tf*&d%xa`54k%OO$`zfjXgwEjyC$a|P@;?L*s?PJDdD-9H4)A2b4(5xEvOgw3r z6+PgRN@*Ra8cO05a+H`lQ+LK~Wuyj`csU&^1lfnpv>v3pdLtaPQmTID0Gi$pkvB1LOd1}XB2VpG8w86bQfB`*^+ z$Mnwl7LP*Z+v!8jw)0r_%aK{{)rQ0jS8NAzO)cmiT6@Mtn

    JIM>Q4mV5(#G5JEo z-#LZ3XvEF}!~bpk*;tjX(D$ZQx4{At1qFo$QV{dmQtEntYOdYY>Oay?7wafm$y}!2 zwwBK5!@uF&c%EB+t9 z0nND%kG17_wJp3rSEdxLx$hY#(BpmU`adby&P;Z3o;!e;-U#Ao;8{t~ zkHEes-yE5n$`EaOf9z(2*qUg8dl&hxj(i>lRY0i^OVG-o#|!qIJM-wS1L~a9CYooM z>qN;28|2qRAAUD$Y!b(Bda^gj2Ojn#^{$GB)sm2MN&LKc;Zvo9SJTirEjBR&oC|j@ z@es9V_-4tENRjx&LwLTB74=@M?y6td`p--FVVLSX^9$;#`{iKdtn(IdM zJXvPN&%VbMOb9)X?O?@|3xw{Z3twrrl6Bmjp~X}n#)*KLE3Lt&UoQ_t5HPHZT;h-r zZrfv!N71(~qbe_-7>ym>=Mow-_;wJ2iKj-sBks#SjSD3q1ocy5aLwQ_88S}catbvL z(3eq3m(?a%7&U*9(WwRnR>t) ziAitR!3{|K=n{qW?alrWRm~}_&rE-nIRNahmt#AYL6$K4l;fKm^p~tU829OP=j(CAQyme)H6q@jK2jq^rPy-gtYeD9J2{f&GblQ} z7tAAXl+GNL?T2-VwmXLMBe{noED{gW(dvSfN9xgXZSmV^Jq*A0xa)I7(ia-4Zs(&r zK?EMgBI(r7U$Daqg~O3?Jd)Q(@om?e+;%H?X(b$i#k;3zupPO)gG`&yH8V9ibRm-6 zUNJLNxHvyHE9Ck=`!KJ*p*WYonGTUo5ptyIqjYe{4k5$mTh? zG=bdncJ4%A7GL)KncZOwHB>GQX;3LUDPso=3Cohc1D?1?xV#>P-}tQavzxvrH$S4# zm6b}z)=&Yz`pI3|IaSO+(2sPiA_3#IE%2vDfJCLK$_;bwB`sa=u_Q>4Rjif~&PC(R zHT-Z?j(NkA9CIX>-LVH2r5!A}YMNE>pox&nzjkR9VEutQKksdK!Gv<$82IWb!TotDlxc#tE195S6^?XD#N^%t`KHwncsYN^5l+0q(os+>VvL?!IWd@^QCxgZ*GRV=T-y@^HL0@2S zBFcYr7aZ3{ZW^n6y+25G3nzztkHm%rMaSDz7A~C&&;H&?Nczqp>bO~;e}DTO9j08; z^40jUR{;$tNiS5{Mjg@6JxTpfrZWio;QQ&iwG-6ltXnmvYtyU$gyyV_Pjz+6h$ka- zh`3Bjt~Z9ggvH~~7b*hV;uz}quWopqIWLrq90*$ zi@3HrnnKBndn(e`B@1@U8)-JFNkkMdp3WV3l{Mr(Swo#?wfLbA<9S{Oix2%+#%oLG zoyF)KCWYX=6*8kJ5{sQ#SXqtj(B{*3Hg7a}p@(H!lg;i@z_Lm!+#QO5{D_*wk5PJ{ z9Qw5YSu4LSPUaLvg8;d6uq8^ayOeB3z$|;gfW=K>}-moe{*W zXSoSAw1b-+HZ*W69i{EbjI@*@BzaNoR_1dnpP)y+{iasK9nRtw_wpAK%0=&E8fHU{ zcuwLGiOx7l*aEB#Q6`voT;`vX0Dqio4V+T`%)KAZ z_KW)><~CcVP-uPU+Yan^$xve}kNz>^P^=JMv!#>~*+?Z{99woY!Bc6j3ICy}v*`zB zPO%vGxB{k|ph~7CU4=d&_djT7boR4iTv&Pcg($kS8oQ!w{D7=r6-9( zvAiA({-s>hkm8;WEp%xtOXM5zR=8PEjN0(YL}DzDBN8sTKf=J6-JfibQADb1wTO(zii)l)Uc zCrKXqHy>BBCjIHY8hd@G!&93o(lyLmMs2Z0x^51iKXM>F0;;D>Vcxt4N?ie?K8>4U zOoYX=xU+Y>CW@UaWjays)6~zln%ZcQLRUx9auM%mldP5v27gLV5O&ttPf+FvcjFZc z{*u^3(wzHtZ+9wcgN!_AE!4OXi7h&xkR%=;qiF0&xP7Nk@9(*cG78#XB0@c3{WRI$ zjS2lc*`J4ezvcf2%6;ZE4ijG7q^xv+nP%@8`8GVm;}&d$(*mtLXbsjeY6^WYt~_w z%-*8iRx)$j$m}`rj-cZT5eZcXJzb{9^W+)9iVsz0O#3%`m7%DeA7#l`P35J+)Vwtu znmg2-cW$GHuZ{(aiDSb0PsMEuPaZT5?@7W{xG|-UtzY~TeAj|?a5?<6d9KuXYado}{^93u-Co&gdWZzJ+#y6N@9#M%LhH6KO~Po8 z7pr4BqSRl3LaH;xcgNn4+JGAL_`zaLL)Cn*p0Oe9ME8r)*~Xu5QE=(1pbn23v=QOS@W@U#XRNs4RSZj_b5ym7A6+{6m;?6&a@Xd;KsGU4(bQ zk!*CB&5S@FMRG}_Usdg9O21%fcB`(cY%JADL!nUR&;G2rQF+2zcLo%$_2#iW~N&$uYN7YsJnQkBqv}K-ZSKC+d?hg6dbBHHy0;)c=&o{ZDstJ} z`y&>=`Y3~?5lqeYwljo?7L(mIQ4jXff)oA36FGjk4EG}IkSm|N} zvLw3~5Ci-<`zr&xcsdsS0y#tM$aRsSkXouCksin;3bzIOCAigLg?73Z zuyj=?Hp-xKuu7{&OLG)Ss395gS8SF~$_UEq#48owFWR03!u znHk=*f89ylyB3qPSSQcgf34g4F51)O6$Gr$!zy|?m>#GP`T;YT(`k=I833=Y z1f5eUEWt_3_-zeN6QxyLyBY3ZF^^+F#B*o)o#DdCJnCA9n}qhnuQE$8?z?KiJ~QcU zVe=t`KZmHb?^J+F>W3V3#oWMPr>#E!)%%;FudP9dJJZorSHlMk>lIouR{QtvC%<5G znTd)>@=TTjSk!u3g^fzC*OC=abPMiB`N&s*;ts<od_sxn-rF_s@#f!!EPv}BV4O)~a86eE9lw9^8BTIHi0 z>?@T`LjtG8)Pq=&*(Gb^)hRFV<0KC%7~R^2Eq zU)~r^orICiO&O(BF+5kJ#B=E{)Mt3H;naH&M9>Ilt(WvZU4KC)=;6T02P4*M>0&#^ zmPJP=qojJ`fF5#P#4ld8o{s3tacs&Ns}PRe5-v+zV4W420U;CL@oank8YlM2MXVgD zkJ(YRQwI8S6!K`5s%VHR$&oi=E7Wr3bVp%z5wGkTfwX{7qdzOi-@o}#L1I}L7 zB3~7=xy^piRj$_uw~LrJKNd=nRpKe;QS;7hu*2lviUxg{sW3`rCk8NdD|Bib7v#B# z6tB!2#`jF>#IlUhP+@soK=+4r+CbKe+I_ATncu4vgE6y|R9vprn|#vJ|6(AFSEuO< zs(X%iWQ30o1pcSN@h#G_;?)f)l1Ho=8a@L#=?B7ueBW@@YN!eg%?Q0mB>G~;p?7TP zW5O;UG5ki&XYMh|(!?GcK8Ekg4+(8Fs&E}ju8%&(BsiZZ^GQmv%yn9dv~>pL@Bz(T zl&rG|cvGp|Sq+ESXbGRg1)87Ct;Di&V-r2dF_=Gw=|*i&b}`B?lm&|m?Pol6f1*;A zFWO{#Afkk;O(f)cH`CBAb92N#!c!TdXDZ-(4*~J#Mo#jB#;XU_*?z?4T7*fY#*}JN z+s!jl`C*EL>li*?`S+SBH6v|UlRU>?&BPro<;=Q9I1eZX=;!?$tztOzKOxQpJU&E> z;Ho7)-WGZ|_EU!^M7y2TD{No)K++qx(RZAB=I_6%;E=`3a$MgxU-x_EAOTf>pmvEn zE+bh!6zTiOyd{!4h9D|Bf=x$Ju4z)Mp(*i*WLd!Y0>g%Wx1Pli)gu~y-~)*rGfqv( zTVABt$y@df3u5Wy!1-Q{9%;cG90*si)C6n$IdtdhthmjI34(EvdA3J#dhJG3_}KOo z^vP^!Siy!6H;Tf-NQ2S0r6(`O?J(zu!!pICXl(u3$kyy{DC_o18dkfr7%<`8WOPVt zr6ANW?Cg)Cc9Q!$%&nhW&emF`cuyB7vOXx{>su0a2o;}bLGOW-*y+KC>BRCN*#`%5 zxYnZt%h8Lisf3}ci_lqm>)?k`w2ak4YP{7{10i`}x$UY~%v$;|+1P&IdMqt=SO4Nz z8U^?=it?{H2tfxb1I-#9UznICWEjXx;HyS%=<3`29{AVQpq@Gre4VYQOuHV{Td}uy zj&SSlBY{yEB8OTz@QV$(bJab(+hk{bMdojcxI9S^%rloWM7U+_ygTgNW3thT7Y`!M)aLgD|2 zqvCpQ6hiZ^%$o9;)pfmzEVBF>-(+P|%bMqozlWf?KX@+$+abB!Hom^{pfGI9qfOB^ z?vo##+4+E1#%eFDUaUwsdIzdWw?E^t#e&GtChlou51urFM{mr#0hh!1N{1eT5yrP$ zCKv=w6FVbJDIAAR<@>)?Vf0h2_!AKolo zW2DU$>&_vt`?>5$K-i6EGh64-+Bs{cVdv0%{rV+P($#h1+xw+!0pKm%lc=qA3Ib3>=T93#KFc?nn^I@XagFe1Eu_q6BanJ&uqK{iL(lEG=a6aKl!j9I6q z2MXvE)%gfg$81rx!R}4$5g6Yi3&0U(s=$HsW!6$#=Qr-w!cL6)z|@@nYCY4_D>io9 zMu-XcM(xMOdK+e~na_}e7pxfz9fVJcIWb|^bj1NNcm#f@&|ipk%wHD-9GNHC~TfpimzaFJlKOam!(lo-xJ>*oNou6=$@Ly z_xCBStCq7PF;yMQr==cvj=7TU!T?~%z~(D6ge}X6i7j;qw`hUhP%`4sEykZ+NTDOt zTwq8gPN#_BXb#`#H|6UMepiK(J+eFLzsp&%ml{~k)KAXP*`M^d$U7#v&EfW|1>ne= zIoa9DqEp-$aIKrqquf{I2I(XHbB4#@ac8@=-~TW&{uq{*$BOYv-22ryPz)^U@20rc zi7AZgyVc|MZV;Yi4zirUy;9>BQ90pZkn zOzJGcD1y051py^GZ5J6qA98;e|J+=5@~w$W`$_6-RstLQrtwKr%`8xO+KxPI#kmF~ z)K1PUh(6SGme5xz4D~zbSK&_nxiwIl*4I$;1}XE`9wo@vpMyBeF$7vKLi-y@uM9eA zzYFH|$s-qwx_JS2gtcqnu-RV}uZ3^u1e%MZKtfOlEhC=PD9f7bnIdPOC*@{6Wizwz zU>_UASp^4!e#&kyX4P~eMBqwdEY>>Aed@6sT5~Fw>-ZOC!$<}I8yx`Z;CVS#ulF!l zA$aI8xmSKC6v-`<9|jze{v$v(S}CiHV;E5zeMTmqQCvv4k=PxL)sw0!9FkYY>2*@* zTdWdM+2=WuuuP;(+j42^r_!*Gq&!(Xl9Vl77Q|m<4;Y_FO7)N=+;fN03N zABVc1d2jXN9$YqRkXHf7)>UfT5RDb7!0%h1c+Q4wv(TOOYMDqAvZ%oqr;{pV1A}jh z_fS}PDmbsCqO=nIxDo=z_6o9V0Tm@2cBNduZfZky?nyH^%D7fMh+>!HXA0L`1V~h> zLZ!_5QvS0#A^rj>Iq@d^Ul^mug5x{`Y;tyC(~~hAm$+q8HA|dsPE2nU=PD@zfI80q zLRPZ6on6+yS5_h`DJj9g!%NUSxe7byY1Wza8wj^FY+re@b8?C+Dxy$Pfm%De;)Jbq z)zrq|sHcm;zu$khvx_Y#xbcbGgZT@sMAdeiZ;)-u7qsp=+gdgunVPnf0o=*Vps3m4 zvjXr}R)sA{&5MRFo#xstVR*0Ja_;sVV)f1_W+du%s0<=UA4DE&70A9td&HBq~#HcY4zPG}icEcIIxnTT#+)&~@gWCq8p{jV|p%jXE5m zz5m@1<&PQc1it_Zw8q55w2TW-!+F7&*68CCnmAmg4(Z!n&y`6D~4A$D_R7FBop z2lta%FWvZEYS_r9JCZz=bxNHoDI zE2tn|x#dnxoG++aEFFFQ7P!7O`eXhKHe`R%H=ID65Wk&lQYRGY7bqQzbp@=zFSnYP zg2&XM9FxQm^6NdiTmTmHNDQs2JnjNv7Dg^zTSR^7y)6u!4Na{Jp$B(8QLJhzOOe*S z5`9?Myt&#B&G(&nM+~13I`NR$-JLmt;e+etkRN5mZgma+pQ=+$aaUkIF$q51!f=85 zUOl)Fc_e-EFdVTu4F4@MHo|Kb0Pl6^Hu&Ev?VRq8t=?3>6$ zuqXKJ!q$G>>InE@=q((>b@I`2`2MQ%CG|%bvmrMN!NkCh9L2n7!`jpzA{0VBj@Sr} z05Tyo@1laCF$Wf8zTD2E-In~UcqeeUI-L0m?=;>B*KtqJpq-FQk1lxH!z6u{C#)JY zfS&aAvY6Olx^43^%UNgh1v;!V_QQsOH3?N{9X)x{%Yo*CjNF|kL7purRWTAHY-x`A z^1VCDUvfA7AGr QG|;MbKML{`k^Mv0=~sw>s9suwTDV_7y3OUMhAIej;g)j3Y&D zF9C3tL|=+0uDsQ*_>-mOBO+FQ`~KYzOq&(UP$Ax_J9zTarMTYi3&T^XC!4yJ@ZJ`e zd%mX$2WAUa)j_Gw@hA?7{{n7HH??>gc zS=smVs6%&!{^h~n1pcwM`84X#YKnbazVsp_od%-Y2hXK#K93~RdA;F2>-m>!7f4$7 zj7&?Q6Ciai>wxVi6fQ@~Vq$6<1wm}R|vX?eh7uQ^>&xJ z`Xc&a7(s}SIBoKx*?I{rO*q`NWl){qc0HIWJ+0VlW!i&ggHud&bP3_ob>Q$u1tCne zmV@Z`ox`a6sH;q&y%RK@m;lCW~t|O4hqL2F^%HM+)nE&$-Wf~i}oTM!>$s~T^ zZ`^PXN@3~0eKpb!yytwwM?h()Yaz1#H((N5Pg-*v%tu+N_R$;>WpPC|Z=w>wZ}$p0 zS{h~4PL$tJxu@%2tYgnk|3320aWy0otfpMx`%MQu_|@e3&2C`Fz0yLYMcf%CPsUvg za?zW0^xmONH)^5ZKnn?-2hZxckLeQ&ZFBQ4|%DqIc+3=D_Gz zorLP;W4kZY=YQP=NoHQ5Pv$m#He=?G;TbUl6F-b*HLFAB^(NZqb3RB+{ts=2^#9>_ zdv<266{@^b#vtddQGY+{&!$4Drl~@F%ymqA0F$%pYO0WiMdP>C+UbIJbodP%;~CM6}UQd1$5l9G<~o<7_7m$mNlL_H@+ z9pt?vUx)&%Z-Rxy|Bb_80T&qY|ANMkM3H8_JImGCo`?6?9dXhoCTHwIS1^o=Y(c)O z9OvjrVhx25-$-x*Qz8JCm>wXVrF3)%G{yJ6m6pEqGPc}MU!Gy6B6r`Ye`e?A<~H^X z-{-M|m|t2t*at(5%g6)o4j|5dTT=c9H3qu5{uk*?cJD|h`QYq|$jp=`RUIF4xv`)N za(;&pOwL;8U_{6RcOIm|+)Dr7)$y|UKdT5Vnn@HH>MzLNG{d>NbQI~8T{S14-w9c% zW%%Vn3(7c`&ivuH6oV$^A3260{=+!te{f|-3JGX660#M?VHSUFyYB7Sy+1q>&bOfu z-^@S=>hVSc;qh6X?x*xZT{4k<7HPra&5v z!M`Z{)h6hTliI*v%P-(o2D@Gg(N)aq0z9Fi9HLhQ<$grn z0JQNjL8dGq>y#3?kRNLu(;gE;IN~3x0OW|U38@qy7aVm^w|(M4N4R6Dw3uBU;b%sU zKy;p(6m7xIdnCN16{B4cf38Y>k_-dfV5=*Oi|T7GKZuI7}2cV>+jDsh;jaOG!$pP05FP_s4Ct2AbH`TwhO&Dy~#(F7v zd3lYy62{~SzAy}qDXHpg<3)kB`!5n7tDH5hi?|CI3h%d-DMy7mJF7K?En~*X;h=#BooA>(c zoX7q4eAp%pHbvpWwl4$tVw!;q^gO3-S9J9Jr)}2^MigZHP~LnWJ-C1DvZA75+O)9l zo!s3Fv{#Gzv>(hu266NOi75InkGo_0KBmT&-O2{}m1*GVuL8H_f|O zhYj|BWy8>x)eEKdW%Ph-H8eoHfqcJ}l+eD1-`)nlp?3cRUH_Sh-4Bnl{@~r>T`EzZ zt@Ei)&xcbMAdyp4mq|7+jYnBDD1If#DGz>DS5(ZyxN0h3mBCAj^oq$IW$RrA~$8U8`j_Kb?dCJaC~p= zRPv~4VnP9|i+XaSwzkVQ>|g1hEKnnz2OI+WSNb1$k>25Qy(Gwzhkj+v4!k|=-7(KF0;YQqe2$G^jLa?r33fTGV_iM_cNiY$r8ThZ+Lq?ILM{U zA&n|P&K~hWdU1Bm8#fKD7SXRpQ5**;fmEH{<`vcV?dN+VY}(&bLupDos(gqOVHIGvfK>DZt;o|=3R}^?HmUou&IUg8*H!iO; z<=Pi=A!ik;w-v6K28v&m+wF-eeoEaQV@@140xx0lnDCoRY6 zp&^KOs^AydUQ97^sYzxd`T!O>^ajFWhrapZ{8m|}5%(B#C&M9#k&1k5RV+m;a27(v z(=$L!HHQdAK||uTW6y-%QNfaII2^qtJ-JH6_aQKjm~VT3Dx001z3*_Yn8WkZL{3V} z$nJvlP8A_cxBEu)pia10LsOHs8);X-&jnHcD)k6eAfg-PH8g77hbF<1$C&y3ea|RK z5;unCtT8Hf^P8!|Ycq)~^!jIj&iP6N z0$|$JwI4J#5_VMZR*y5cw4-k%#^P}XgE@54;enLm1t-~PuXUlz#!(&FEX*)0o3nQa z%jsH}wap3CC}l}|Wr*a1ySI>lQhVT`twf#4ImN=_pQz{f79GDAo-dt_qkAldCRB3x z8_wRrwBK`(C61KU*rx!oW2wlt9uR_wReSemOJO~o{ z&2S*{=of(Kjk1OsP>e?)YDFcWxzLyX3}5g5iueH5H`^`p>Jkk(#LhJ!GKQZ(`<_y!KN(kTI& z$779`P!+gMm`Jq3b+b#|5TkhrJ6K{Jyydxu)T*P(YHk(d`Pxf!CVTaK@0bZad$LqJ z_g#rt&RV{zsv-T0+r>I58X8)%msg$W#5j8TbR#OOU0Cwja4I?DS6Cz*F;7o^zI2Z+ zq}SN;+B*d@V|#96mvdOe1O=kV@uQl+dTGHiS1;V$#_>Ua{{2sEa(BXUXVv8hzyzGa z;LhariV@p1gD78m2w*%6E~M-OCfcjM>0Gf(oqz`(SLHjctIW&#LavqCdx_VQ8Yd!6 z4a)A_U1YKO;hxo?{%-BQK~D(xT)nuvWUUOC0WtK`#>^m1s|{*p%^!ABJcPuNFqgVZ zh`GEy;&c7a&iVx!B_ceqPkA=n||CIa>L%9Y9X_31rst(b%e*LPql+@_Pqaw+9VQg zO2ZxGhcUE{%JO85sFDr))Is!6d6d-!wZ9;6Z(E#!-a+Ae(7j@dLl(Z^ONsPB6<8G* zGbQPQ1~iC_r6$0r)HfLN**(wWR639kVQ@L10zD0O8cdUIrlD%1j%IQpfJ7*}##Z%M zh0S1d8Xj||ohO9Tmo9AO=sj^FL7syarGbHyDB;7f6i%?rxt^z15&0;~8sis58scLf z7Qq2`DiF4KrZg{%4kL0hTmDnJi&22!d8Ssf@>^ikGcpT@lQE1p|LO>xT%RJv$(#DZ zUr#E3PmlPLVDcpwT()dOPp6z6A0;7BnC9j8a)8rk2il0L{!uS1VUY=pT%f^C*%i(N z<%@cOY5pFudTYg*1u{~zQ=zt**=uH~$IlmfX5#yQ2s`KSJl^fyH*IV-wr#7iZ8u3{ zvvC^Rc4OOVY&(r@+d9*J_uglp^SjP<{(IkR=AF#sdFH`d_xjxAiFH>inOobjh`aeg!jull&le$FNv+``35RB_aKM#w!B=nM&Y$aYa6<6G^DC7 z2X$JdR0rUkmf?>9-K1+X3?JD!Dm`>>xy%fMzAtOTI)YJ2qk`=+9~jC$PH))47arbv zG$~`v9=A8D6RvZ=4OHBtK8i(i4Dbl7fHUuQ7n4hcGJni#Jwjh^Fs2UXs9?{~@|pQA z+8Ua`a^3hEyFqV$(YiypG%1B5W><*4#stGAP%`D_<_=Mw4kkBvo5Wd;-f62Jd>JEt z_t#`}eBu}tk{3@{)?ko7XNtI6NZ8=3m8E{VXBAK&o`+eey^x47p0^WeuYXX{Y!FC6 zwF2QuW;Op&Q$pn7{T@lJM6-DRuXS3c5tz;R=E@8Q>KPLfv0_;o)$pAb>@O?lWHbHI zgk7EZD0^pMqFtbLwKkH_5?w+?Pm*UhIu4r7RNISBj=ECX8;PAzcsy2>lXuFC1*#u6o&-;!pJvE=E(0+3bP5dm3d+^F3-L=zd3w&O z-}OztgsQFb2U(4^dcU{NN`72^-g|kxUcn(eq%PL?4_z`gEzrxP1_?d5`*P|_o;_gm zXRi=1c>_aE&MveX*i&_{!YOlQyb@dowpXgDrNMX&{1*W3rZO!*T(%8TCzMzH`_h#02jouE}ZA(e8l=egh z;YJ}KjCbvJ1N_VdOy07F&c0Wqv-Aa@{C6kek@n+DhIsBzDpK7BzHq-6ZbTk;5_T3E zIlTHmRr8?CmT5&o3A*}xu(_ihI77drn3@Nl!8*3zh3c)gV=!fcTBg?>h*>O`7tfUL z^3RNxXN-Fe%~2kj)fy4fM=>l4?%B9MipwL}+LZ!@e4tRthlUoHj6G1U2#@su`RJib zHrl8Mr)Gnno}tP(<`sU2(5V&!?HG|T(@A*Er_kw2FyTC0dvZ=LcPaWa1S{f52x97C z%L&dTJ>7QiNy%fT9Bu?JBjtX9XYEhvn{lOXTld@Rv)$2bamNlGxOb4|66y3e1dWTI zV=pTLsPoBxYF^*Wf$H9FfI=kM_OT?@Lhxn`Es3|gNl-K%p`zLAhkOr?3N@)VZ?A6t z)zus~BnwrJ`6EMXi+4b=5cl@zn8^d#JS~>UgR33X9zKG=t63>Sf%cPD<}FX6-MCWx z$sSWznx}gEGuW2YO~6=P|DX#kpc97*NPd(OkxG!hzIO?b`C3LKn!HY3A)NVISY%j= zF|EdY!Zp4MEwtHw*W~Gjvd3t1z^sbbck9_B&vQj5oBo=Gg=9ipZbcE=AnIwcQC9Km^N5uQsY=SIU==Ky}2eU1I6k z$nc_IHs!?8q1(PWOEJZC|EzkttbaF#Xf08|bhSb7dnwBgLWvRzQaqiHAo|%B{lQuY zKP<#H#3H!;({j(~cbKOJJg~ybo0Lm-#MY&Np&6jTI&dvz`TQpw&tfl{ulv%P<4W{oXF=wvk-a zvPk|;Lp3!XFXvCoPf0@Y&&KNIEq?1O_7eUN_VY1NLUB`t38a>1!SYslw8jnN*jdy$ zStixL$8lpsPZh0XGofZE5rUAXt;qCLPU*!a_aNX(d&}l z)%B0oJDH^W>%QhXcKy|0_>M?AM6anTPfcfK!bV$y%RsN&?iuXm2j!B}u!l=?+29hN z!o{DySfHW$Lk_?FODA=3cN16|P$$wfVk@1_hl>*ABv`xWSGDPd*V0W3WVe|5bWeNM z;_5}h0Ed#VAY^ix;ll~k+jpnSE66155+isu@(P;*acWpcJW4>p&J{Zl+e8hxQs8pw zoAU0$QAd6Ae>H5;?|oris2T@1bcgL~Py;vRS_OQ+9OmPC+xn&W@60vv|LqXxbYPau z(Tg0BcGneJDvisnKLi`n-qdM4g(=LM8j_Gp^=*M6agHZZV_b<#<0=&3i&oV8x#uA* zO(grMrc~rX!vbP-L0{kL*;^5QZ$kCa7woGr>KMcKKbwxwStm3PuOK-_4}ds|HFQ32 zG~2+OdK8AZaU2wnUi7ZDQ2lx|S301aI1@QA1~6%|g&_VK|E!VrrsW3Nt>=+jimG%S z_rN#B88j_JuGC=$$($eQk3}pmFnfc#)!Br}z82~)=g%bTbfIgRSamTE6*hdR%xn|1 zoMW`*@kT%Vha;yybysYDY{IBl*6fst_|zp; z_oso0X9-=4%h=7>-r!KSgk^E_)NqV=t^1oMN2DN3A}I@cH!o^Y=Z9 zEk{-v8>Taqdpcjv!jEPQHPSgN?E2$w^J{C%%vGcS5>K%1ilkY@VwpC?vU0T?i*6PX2jjyyFjH z*<_KOFcZB}6LSh?Csfild0{q%pT92F%O^W&g(ke_tt2bv!Y?&4OKIrOltm^+K>MIy z!ba(lgpXtiA%mP{FZr1AXZ>#%L*@;2&Ki z@1cy(g^4SZf@sPPErgESiS`|#NpCR-Oo(j5vYaN#+{a=ra^g4ZzCkb4f7)80P~U@iO&wuTBmQh5IV4bG$&z%!khrPu1hjb^8NFx9>Rnu}YwbXj}5C6rpb?vLM*oI!HkXplzdlcWKh=Y6lZy*fgd1GnO^h zoz!?+qDdXmp@fKx_VS231cZm?1$!D!^acLr$=0klZ?fA4ce^`*VrFJmE>lO6N~Gz^ zxYTE00DK$oD0s2(h48V2=8bpF6C^Z&Dx<8XS1d$P z~iCQUd6ItPmC|&PmFrR}+jD=I<(VfCm-*3X<9Tx6c)u$7^ zJBrlJP23E1!?)B}f(oSKIlw$%mMZxo7WA5<=f8kKX}CHdOdPnXQ;huyBj;z(0#hq} zS^BzAM;{N)f=z_mN#&?gjW^z4Z3ZTN=|@^xxV;V@)Y^lH#37shk@S)L7H1J&IHY!W zH(MiDl-=C$fS{oF=0i_&%iJjd5Arwu?}`R!?HJ;trqS$H;kC{JI)A<*pJ;L8jE#+b zH874e7E;~lT+(HLbLdHoKu7-kn>wgq75u9__qB2*r%L?66t)aBL&v$qlar~>y6z~T zM>78mQ&mH;vjY> zc(0pVbrQ<;WT_D<8z?139meF-j>C>oa~I1eGTPd0evCi_qMO&fgoWcD-F{P-en7$iC~7LIQE4zY>Fe z^)_$W(TdP5!U9ZMFP5H>6WO19PyK%BzpaWBkReZf#H(|PjdCdah-*blz=e$T{$$kr zn90R5n@nuJ0OS7Bu`z;fHe>Q&c|1rv5$qn)mZozN0oCnc_W_=^F-Y!c+`4SRw6}nh zUpP2C*jHTyyG2t%PZb8#tRsClr9mVOYjn7;y(jIyIi)Ul!+8u%fI;|Lb{IEKv+;?+ z^4A+;1sz27fIh$Ms)s*>?DZs&iS`P8pipeZsEwzBPC+w{1k|PL?S+{A!WXaHA5&V3 zbO*z!B@q9ol~e}LZ;rg+KcU)D4-I3zw9oM@h=-Up>=?2l1Bl?Gt~8Ob`_STEd6kt2 z#KeH@3n?J&kTBr_GAkN?3KjU{qw-J)HXfz?Ls;b-J%jxFtN2|QtgS){0z1$5Gqp9q zXT!f1_4sj+^>IWGL0;bOiSWRpZ0+xwnabx-gnpJumb`cDbkBy&y1y4n$swIGzGXf$ zsUh08*R{XetD$JLu>Iqz^*wfTO{n-lb)d>>{&I2-4C0>S>w9sU%S|WLHJ0%9wH(re zNT>r0m3YB`>LrsY0W$H+2n>(=9gUgW8y=zE=*SuSHIb}t=7aV)dn=GtdmKTXPYZH665EblyHFJVA(+w5Em`g)vA_4G7pM8%E7l!uae$e|4n z)iZ+PFja2N8DBAtwf%j;(1Viy7&r86Leq#>_wA$LU&N{YWB+EA# z@#cjo5|<++NT7v6rID4((J~BtuU~o;w#QSAzV~WOq10K>ezHOl)9CSItM?-^Qfw^A zCcVdnZl~Dduu2m$*?5~n|LmKpEi}as<68L5hb26UG;_yb#DoTkVlNUou8ZTY7@0)i<({fEb4Dfc4XO zELB3O4TYozodp56U)sAEo4bLjNg6%Bq zPOa;0sEQP2(e&5b3Da#pq7ajP2YZve+oTu%`jz3UHe`VPrMr91hgLz; z^?J-3;d5Kdd|W*8Jsj0!2)2o2|3zlYjTp3CB()m+&l4y9k+qhSg~BwM z3uFCkmCEcns1IFcam+98I}n6?Sz0h+l`aRYhmo=(t{W-Jf*PJ620U^b!QY36)$`^F z(>;(8=C&fHR(N*N8#yIzwkccrp}H#NA)KIX10)e&O%e7cG6Gl&`SXf^x~GMpRW+e( zjY8}erb?;L9j#!R%+DlS?aZ?6QVn$*wCNdVgo@?JG+gm=6k&J0{g>CaXQd#Tw0s{2 zC~sp7^6GfL5dIC`57b~eac5g0q4}>Y1PQed_1MDd;&6ggayTiQP5Dxfi~z*3Zzl`Y zv7$tG?PZoiNXw?mCCZfAO|~H5;GA<=@p=1B3-c_CLZ6B3U|(_zx3$W6|IOut7Ja0^ z^@z8Y4|2`u+qgW8b4l9@An9(DDzuAQR0C%{X1?Y@r6~woKVREyh-1zyTnPU!-=Y($ zGSuWO8}?7jr>FW^<~6m}U?_M9qGJUHX|M1Lj`Urx;V<@7`>!zx+GI~Yg=<*^J8EBW zUDcSLknTpa!Za*o3tQPWM`2EuJ<+mLohHjII4k5;7kL{(3yF+vquvqQxkK_x={BXV z;3mQ~X~UOzkRq5mrdcMS|B)Ns1vZ{!2S>`@_9sCc9vw-#eFTSqC~TYhil_XqgrmOD z670J__FX1WJT=|Jq&){_BdD62*N==*QvWv%y_UyGMYT`oI$HALJdTBpO-w-%oHl}c zax98uzg?en*b=s8SSq42s-gjwRT?MHq+vv~_xqc&nK$IziQeX{yb8x{Ww^dB@8(uD z3~t=_5+u(qpS60%BL$Q6yH&r23MB>aR{B7lX2@e`ZD?eke%~dT4fS`Hms5+cHqX%N z+NS(32=~5ul0;9TxVWQ?>tESFrbFy3IrIe=o<^(vZ(g%@?IwhBLZIYYNd z^F?HVVH@_&PE{4IzxxCQ@dM(QtW*F)3*%)PIW@i4$#LGp*IKSgj8rW#& zPBD-NKcDsZ-CE^`YthTFjE5IThNz9`@6}&dG080^DPLF;KSl6{PZ)`Ac6MDBb?$Ia zO)w`fcrlIlDfa<=A~=;|jxyJ^0Pxgd^= zIE_q65>lw!g$&1E0Z)MG-|FEdUpVE6Vh5~54rYNK1GI~g)XWIDHKgHNMp_6 zsoeBjyqw5d@|}bX)(~&lx>0Ikl351Sd63Ag^oW?wnb3p!MQv4BDdl-z%JjR2C)B4W z#hyG;gf-LLk(H&q?vtE_c_RGIwc?_tbb1f*+8XV>OZK1xSAiJyRXH!2gz*d+f!9i2 zzr{`{!09U1xQ)IWuP=kW%Ss<$BMu!DQ^XE_Q)yld{sKT6i+li`(+5fffX_Q*xf)Pu zIhFU@9K+_eubHvfS{CCT(!qkg&p0>1#cc#DU)M@_;B)O|>y|o=78epPR$}1NeGo@` zKUVF%mvCK==u@y#*_#4IA^4YQ+Z`mLmoeP8A4AoHbQkx3|ITfae$`M zTJHO1t@?Z)=sA3(=zjJ6oM8+Y8u;(iog8&W)WVi^Qknkpg52wq*G}irAl+mzuNZf+NUtgUT4o>d1f+|3u_vpz(c+a^>3`Gd$(z?-P~xCV54fe{gM6&TOr`j3$&y%+5^~oU z7n^Y75uZqe9bA)mtr*LTZ^W1sfZI2j%4}QM?WoOX6Crtcn&fzwMe#s*QlO!K9T640 zr>US^CzW%{p;cCG4mDHvDYd|v0r zz_ms0hYD;6)e5Y%a*-I*~cw=38Tss zf=#Aq;MUTR9zySjfFWBqt2zppOHA-&SztCcLYK98zCU!*#V1+m!+`gbHl)Jxeq|iE zNy{^RoJKRK?b%WR`|v+zCw9C$+7|jT$57$4blVch*PrOyS}*y8L3L_Fi!^dcZl=qt zjAc}@g6*}n8Gu^Pj~!WdlT79QOZAd~7U`AXe>j>Xu-&ztfKXuDZ}1G(G<|8ka|`_; zj~6bfA~F^lzyz6ZrU1Z7|KAN|#ERbs{3q|I6oH;>Dey7P9{fWBPw; z3(e!mf#^+PZ%8|_>P<-62=xO4g$iy&YU7s~u0wzP#1_WUV^*Qs!0B#;Fo;!T*2z3q zL+C$H=RZm~X+U8IEJ~$kzx+{P%DJL5L$oUhHT}`>{W;?ikj4M|xHuhUnSO8U2bG`s zIsFMA`ZXgIWNkp|RH*;Lj^AXS4w`#V)^wj4>L^s^fuDbqGdmU3zKcFjT;VazN$!_U zF1p?QQ|B1H@~6_tC|eDcu(|h(5(-^?`KGo7mDMb3U? zbHD#wFRr)%B#F1cmb6AeVKeuqCi}r9_FvGd_}Nbn;b8kosnCDPaR0e^!X11eIN^UD z^gjpQG0X{oCjy?&UJ1Ai9+E4`8T*p=KWDx07I|f{0-4XO(Bv-Ow|y{haQi6x%!UTG z1tBC{+_8imo&RzoBSKP3{fxs%#CRXF7M&cO!(;j&wj($_7k{ zfO-VTn`xm15owU6K}c`wGTz5?bsLjd_5?!T~@guX9QS3S>yy4_y7q&c4C z{D02$cn35D9wgX+=oXOA0ZLUsnu-Jn*>P3)lshK=Tr4-(L-;=z>w^r1>bppSmk)p* zpKVBN{i))_w<-33YZ`_Hq&HHvm~3+XLO3CZI8Tyf0mb49PE0^xAUJ>lCUyGk^QAKZ zS)=-oBbeivQN-Wsii{oDe^A6@2#g&Jhr3=EU49naTELP(949F2QtW58B5I)dXKl0b zpTPL~AJX0b)?5F%Kb;H6AyS`es4juvJhr7t40@07g-BEV55ThhZ(k)`yk?~mzN-9i z#R?vb6m)I}5BXVp=TCQI4zeel)tLe^ZoNIj)Cs6lCguOWIVE+SD0dQkw4$!) zb-b36+kaS(|CXG-U+3iHG>LJ_0UO|}$}a@bFKJ1|rKJEbmY9nR%b+@$dhAzSeZ9l& zLV;LPWr&Y)1SyIXpdsydLj$>%kD?Smvf4p;0 zBSE%vaMhlr*5=vqb?0}KFVz;PVA!udFDxl3VLIgoAhy0j#3WfghcZ*u2BsFp4*Xrn zgeR-SEA6fj)|vE|jM8YL1!R+(4swN3{tH!K{YAy!xuKL;4El~H73CJisP2|gR$ARY zSx>wmwPkgH5*%=ZW8qy6)v{{tyd)PceLU$2P z&9T4yIB1ISt-aEoADY#~f^B|gOV)ij>Js=SJzOLA2 zEXpFRPXtdh2_XqZ+}!K@0spoIrd333KGVXx8H;3Rtyu#!K}rD5ube#mWvvo!C%Uuq z%bCKsAvN|%_TZ^x6wQCo#v42j*)ghJzF5%zHC>%!GFdln}-UwLp97Iaa z*bwLPj#4vXWz(~fjQYEM4Vn{PXn7!#PL}VT{tpSZ;85?4?g=XBEP>(GInW!9RP@(I zU*Kn`+8o3t8@#Zo2DJ-Dw(Q_X3koYv{5$T#p8{8JSpSW^#V7SJoIPPiz*dVAz{Pxa zuKF`XXmH&N`!w;C?`F32OVknDc+3ED|F_*D(Bb9>VXrye)>Ka5vn z#3mQbq6O=!*$&ok!K5Vz#UH2wixhK7?mrQE@G_zaC25POCnzk~-{Ik{ar&_O4HI0% z!Uc|VL}Z14e7X5#QvTe1v;h-Lg%EfeQ`+SHPUI|G7H%`nJY_Pf`#^3Hr2wsfcvguO zZuh(<_@s--c+7<6x0l%+B$!cc`;NwQ;Szi-X2n=#Nnu@v8LHsie)wWZ#CZpGou+Gz z8Nj%VCm?S~!j|3?^4ut^KeM2T=yuZSP0ZfSUESlYyYSC6ytAHY=E+4qs1THBp|R-S zykv01X47kXeK>5Xx0~?fnM`e2XzlmC0J|63uk=*eGR|rfbkwVf!vfJ5#~T4<1Z?5^ zZaWEnIj%DD`UG9)h8g)KuLgfu)i0Q-@4cUSl&yR)@6c_}y#zB^qa1ts8BwawJ*Q=X zSJEi=U!#8xDp;y)w=p;OLVhY+IAHUaWP33J*Vj-kL^1;X3a|g%d@gUp017j~UX+xUcZ%s7$zjrxlF zfkmq2l;CvSfxL#pL^n%RWo?`W0xt{dDUM%y)OSQBB>%#>JR!f(^Jv&r@DqqgiE&F)!w`JF8UD4yO~wVj!ci zskRznZDsKsuu7Mj$0DWF%)!bqvHqr5&hntW-dj*g*g;c0Aoq8=^jNj>1baby-Q2`bC1i+v``$E>$vHq=TeR9CRd z)agzY;5R(-igjAX$6jLx83c{_Gi3{>D_veb!S6*KibdhIVe%RBqOUz&dhBDgIH&ct ze{Uh0eulmFKJV_Vmj(6k>di)r!<;UKXakQl3E8&NHe4|ij~MV1DobTcUt9e(W6^19 zT+TV_c`yHqk(BjqK6%xF%B1yb+Nw+Wr~rmi%rmQfPYDYkyzJUMTqV|yU7FO5wSM^tO9mfv%-B&*x&z#;CZDuSJgnDgXJNVT43h|OocbujB zFEc;)Ru3IkU|6zEN7joiv0FT3B^G~23|89i4QAH1G&JSAwZ^J;%<3=T*+{}^_Vj8h zq<`wVr>x}9?-+-c7@+1$n-0lfu z#!hA~;OG5ypSNC=QpWqJd>xmQ-8#_HrE{=ifrL(^F*mclWBGRQ0#PgH2C6szD^nKI zZGI9f@FpT;Dd3YK_~wRoY}Ync9GjyAUZ|I00_u@FD;-2X!(dlRtlz*CM+rn;t}|z6 zvH(0s63%E-zu9dTBGj@Cj@F(1^p}E|N%*{3qUa$G2)MuDYYhQfjuWb7;64#&!#Fi;xsk0R4;eR`! z+rBPJMZ!@FKP1$7;_+|RF9pX3R=ihw42CjFHKRrQH7Erl9nD`pMxw|iknK=uhAX!; z(3gdMCM^t!CI5bAT4B~5l*TQP97}2v33)FQ!^nFlD&WG?RB92TCGhsPpo|gRvyQ&N z+JJSKTe4PuT(j}Stc!;&njQRUFmB#FTye<|pUc}n_dVG(87)uU2eoKD-C(^h`T}?K znGHgYSIkKF2R^igx5idv*5AdiIE4=n|1-Zc$C#LsWUan`O_hP(q#_EEe7sHnF6^Uy@&iUrV8)hw=feV*k+y+R~>NIb{u#W zaZkk0Z`z%SZS)LdpA}z@b>zrF+bm4sgq}pDBCa!IVApm;Q}nM7Qzn$>@nV4P@o?L= z(ZpzF} z_mnNJ<~#i;Xnoo077;Xzib}5rZsGB;KP=E-v(R}bH1A^Z$_%H;lH(Q=&0`_H?oWUs zEJ%WUIyCR~t3F=$JFX*bD%-9*&kH?Dk@I{#(1FCQ`Lfc*? z;~rbL?)3FQ@VGq&qr{c!U%x@l?BNg;(=O#ZuMO?E?qAfDjtnZyRZrE6jjV^DUE{jS zi5{`g6k5y%kwKoOkG4AKF3jN$6&+=Jr-dS%^O+Kr`8uXBi9oWFVKRZ9tL&e@s5*>6 zrp+!LB9mIv(WPc#B`z&u&J&DvSmQg=+KuFi)2niX7np6btgAOYZ`T>{MV=EHW(3BE z*#}7o^$QEdWH`qSC~|L0y*-t4m4nL|JjLtRl`e)i%d#osFa}sZ){7C6o;^Sj3c4KB zh;_JIIMO~rK`UNrxZ>)~q3DDG9SEt7U>?P?JvmPQ+2(rV$qA3AZE)E6@q&{*?hGaJ zm?@N;yx-ZlX#SbA@=4V}mRCO!!vlBrg~cr;tBpD~XI{2-9BJq5}i!ob3K~|!+@(Y{m$|K*|yN~*wKze#N*YcPbJ_2oiSnAbNjTmo{0XAZDKq&aNE zx8JDLkj|)v9azp>h&LBVaub1EG-2k9%0hg{z4z1wGl??sqHFp5T6DQvtf#jIPBZoA zy+UMUkd(Qt9>G*rZH!M6;nN(|_>$CmVNm$#S%>wU9{>Jg|94?gZN1T2mM3KzAqhlE z9<|K9k<>xS;j{UGVnbWxi=llO6Rl~omd|pC4vy0dtNB{}+Q}>aerq}9dKqC#+(F^m z)7&H>>>)PgoD>^8W*6Q&Rd~iS+-etHb$s$|TWAt?5Q9M!ze@jjz7{Nk_^my$kmyNQ z$FTaI^9Z^=IfozU+PCYvMVe)|zvhe-(4z4 zixKI-g0X+1E%JoX}dFs3gTf!vo(98*Z(I=j)>+E=L%C(^-nBexg!4 zkE336VUM0wX_+cE4ey|}7a)`ZNqw135V&PFXX@fvV!OJ9*zbH54DztY#NyU&1%Mf4t}UP(RF$CDU+vZ zH1iR6$jh4%*SzjqjFLEobmle?!vt0s?IEs|N56+q?}SXkvWhh6cta=Vn;l2=l+bne z3L25jsDI}RK1>?iGT)XO4J_P$PO5x9#Oh(B76>B?U~uLisvvH`tyH16TX8~KpG`2; zWEYx#nOy#Xwe+(+M)7i1pTH0vOu=CbhifnL(UjPeRMoT6?WnVpF$l7RGlmn_!9vl2 zMOn@cgCkH#fHj4qkht3G!MKCrYS1&2r*-%(0C(`s0DD`D)!?Bz8kg%+0+o#FRd-Jd zrquV*e65HrREnZUt%FA2@@?vv=~q;kq@eVqA)s{$CEm*aX~|K}yvo8_i{XGhfFV`nC@iZ`7do=mc-+ zW;ic+%y45aAA6nQTcNru+_15}g|>sL{7N@*9&vMAe+ZvdA+PdWhV+ui{iQ&k#aaFO z!N&KbXsrMQ$vXq-_ixoyZ_<-0VTYus*HiRU(A;{Y0jpPFCi# z);&e9#&sHuet`|56pDxSUv<0Xf7yCDOC33_57y4Aq*Qrg6C2=s>FM9O&UPJrTZT(( znOSTp!cKtsMx;~lQTd1`=rl|-W@;O@w(uPOEbXNKUpoNiTxCpg{LRVFh9@Uh3PrrO zPAb_~wgXC5;hurvF*tMj(n~kasYkQu2vLLI6KDJhq1i3E#xOT2N2USZft|K&}LvfN|S)1v2t1v*T}OMK)$B z6={ke9Sbq?%y{WfSx-KeXLXZtn_ERL#y7?`2voG-?$@}w>70DTueDpG8;cNC*VHt9 zt0d4m{jChscx_TqAoJL#J+@4Z&N>fwn8uJJxBqudEa=^zn8y%AfUnmIu#6D>qY8Mh z4l^kdGsApb&qSryoHBy$WdQ__x?4k$w7>|0_8MP;vy7M>Qwhp1G7g(@9G(!E24ypK z+9d~sNB&jO^Cg+&qUP(zC0djB#J6}RQ+x5AXIKcimLFDVSgK(sjhJzKO5mdk*O#Z< zG9Hjpk7ri4gDi4c67xARSL7`ftv_aNb59oPVyuGb?9T6W$>MK!@l99@G-{5y$e7*> zEsu55$WY|2IQ6&_&({UL+rTHI85OQ}_HcQ8X()6Wb(^3#!0uSFh1F|Z-1J+{*jR&0%9peO)7bH&6sWqNPZieRb-uPVA9wvf1C#m8%*T;%{V?2 zPnJLW=&=;@3ICHz-Ez$F@Xf5XDz4DBP&Y$f;9H;@H!NCZ)X8RR5cIw$FNHx|sB*C& z-Ccd+m302z-0)MLjL`@^O2;J&I+XT$sV=_$ge!vb`1656@80@A+;ID6sjOo84o!*I zy5g!=qnrk2vAgsEq21ATJdvu$Y4!x(`b0jVe6POYCo>77XBd>qAUVEG$|<}Hltka~ zdUM4U)R#=YS?&36#o=atqM)vx)7p%AHr>It_0G$r%%1tgzyfRRp(YWOkH0^A z8Kh+`gl2=ygsufKz6N%VTDVQI;p$M-%Vr@1PEJwLY*hA+-dsS}VKo9AvdJ?rj7}hr zMk%AnD?_C^XNOhc>SP?Zdm`7f#VN={66NYM?Pm|2Q~NN_W3}qtRv1c$gaXmFr&%hk z5AG-z9G9 zKU8>4%vsROW0?@!oS7z4&aABExw@9MPE?6=Kj!ag{(}*tOrrFaY^IEEH zr4F1h_hH;=PSA-9lZceQQLblGRob2WQ0~@|Sm@VX!Ty004{Qb|3t^W!H=I#Cmew+dj`&7e z@w(1-zZ4o7n3Mw5)eM8rgi*nFtlo-wHs!2_G+MtA#645@wqn=sr{MG|WT-SMp+J*L zylE=af9>9%!Ct&#QEsmE=Vk9d!o zZ@NU1Rl!*OVC(8e4u0wuA#-bXvc{Cm1P=f6&Co#btcE{MV{;(iO3MXx&#Zj!bj>RL z>O&f`kzi_UAFu@f^Pn8r9-VsYeMq>;3F zd*V^56g8hBazM$SVfAErj(o7@N-Dz~Ju%AsqRw%NM&7J}`%>lw++J{AbUm zv>oj2MHU*bj$tCIA1^o$r2mLq8OijLhG40zhT`TEqj!yX{MiizApNs+Q z>f()AS=4!lI$EMuBU7q1R%nVbOuL$^xNhXs& zTe>{sdLE!I^^ycH%gIAkzZ%CwDdm#5F+l)bN&<)kd&nZ>i6*e!V6&!zbf^?uoiDor zF}JBWZ{pIsZH8@+7d}H0G^@4kg>wSe?75DXGIoRGDS(6c^gT+HsgLw#M0&C8h7jUh+kv+o(rPpcWE zvL)}-u)_PQI&Wf4`X(9q@!!%1?^5C>rJ=Amb3dfp_fuxezzl!m?VKEXmSL^=@6}f3 zjxL5~XE<>aU`?}wkd#6Z%?*rLYE`H2jtJ?fTJAU&86vf1Wqdn5sfNYo@|6f{u)DN6 z(BL49jnw{)xuE4?d$AifN|~m>bn2y;7C-lQ&+kkl#bA1D{rN>VlZ8I2%6Lfc#PzGt zw(Bycj_NZ=24%te6Q_=8Kj&eUJw7$WZ_>(lR_E9HU=eC(`@YH#v;)>#ozupfze{9! z+Rynn3fRaD6U&6#A-he+Gh4%x_DTsR#L`!`gL4f@l4>UeTP%t`@z{A?CpO~qp%hub zY>qr5SQkYw$C6qoOVOE94o*6Pq#3gimR{qLIhM$cJ!K@DF56`;H`Lh(Zzhb69ZA4i zY(C1&UUU%eiGi&qFM5uxMk9RsU%NR<(T=%m)7U+bNN-w`V=$X5R{WlR;OjD6()|;^5w2pOs3|_aYPZOZ%VMt zk|ATjKos4MrLdpta)DoVPK?VhBAQCG(A5pk|FgBqAEf+PA$QFN_PcF&%hreAT;qj4 zcSGo-$(H46Rqkf!p%Cf%0$GW(#q)t6QuMhLYaxAFCQ8riXn4Sm@IBm@#ZiykwcW&c z()CS<32m&uV`PY0QK`mC?`W4z^wtd@g+;DAN(4*3Fd4H__I&eU03UgwtndwYSJujfmg5{YeXo;lW9o|LH2mR44m*VjEG zQqNFw(*>U6=8q2#pzmq%q>cM!85y`hp+bvAh|u$Q;@&ENlKI^W9IIazS}l2H^+L(q!Se9lf)vy??V_8yA->M*(AXaITtxGS4Q~FIwEu)N1EdH z`k}3sd=z4ZZ{SHWXOWC4f^#B9;4w#6fFRSuf^WJbkgd$7`^oDnX5F2Zrj{aznM@UvyA!sZ*|jqVKciQ2hmI}jz4|fSZ5V%0f>-emq4>x@wxU1@dL%v| zuZK0!3%=T(XeRTadl}DGM7+eDTij-QHD3*c~bCvHvQuEhGkqLT+BE80VS zkw}n63?O@?D310(8D zteW_d!g-4bpLC^KvU+bUED67AI3)}=wc{32M0$hSdi9oMJBoDZYPY_#1~NaiVCS|x z%>&Z2o96HI?V{g5fhO5`EHrw+9e7)4eR**CsRB=T=x2i=$3aYJ&8gO<5K{&YvLFd* zY}B6>>!qh+8&}k}wHVv@$@qcQI52}pd=6pYBbQdHdqx&Yqr#c zY2_AfGWPhL@c3g1-^K~F^Wn_3lZH2#+01hHzWyu;L4cEPF?B_o}v zsAyNxptY1a`swRz=t)DKi-h$(Dw;}_L+DUsXFWA!=S%_Lq#!50V#K1n9@V%F{RoP>0sE;2nLOUhtfjZk8iIt*-=G2(9<39Tfo=dyje$GFm%JfX5l8Qf2@@b>>dSfkM11>due$b|8KAX^`vi*a7aJ=gnVyl~PPK>~YJh2As;(aqsD- z&%E0+S)7KH$8n*c#BDqupPyG+NG#RSGfCXGw?EwA!7#%xspmnhg^kS4g630wNZ5Pb z8PU~|NZ>Kqj=CFTBp~?mop#e~Jzl9$w!mZpz59!zKbGuA`4iwZ$~ZUn6~Bs^O}*TZ zx*N>oY7@9u!9@*5TFRAe=b1tdWJ561W3Hd@*}3o{o>+V!eiRS(CuS`HMu@)1o!o`T zb7@3RX8cGw^MTkObY)l>k#OG9yG}j%(pKpLjgC?T2=h0Fy}MZ{Ek9Af+AGQtDLJ7^ zy<(T4Xyc9~)bZWgjV@+ny7bOz`GDrSo#>C`an2HOzJ^*zR)uS)Esl+=>cLedH3ZK-`1vWov`?R{y6SF9vzGB z$vt8%t>uk*sZ%5ziHx1x|M37JVIJ|8pOxU68hrV5`fHAz{ug6!9oE*@?D4jxEv0A+ z#jQ}>ihEKVin~Mc;_lW0#Vxo~+}*vn26qeY?m@y$+uwW6d(M0AeeOSbLfDd>J$u%y zna_Mzev7S=waeZ6K&9PrJ)@-PMfEV(^9#JkBZMqi*MtcP^GI3U+EdF+MNJ8}uv4}rY_Q;4zV>%Z5oRAFA?z#M8BzfT5@PqdzT<{M(WTQG2K1%e* zQ#e!`9-vUI6onrFT^If;C7fm;2P+Hr5P(VVPR0x&LXm(OnGLk*Jv1OwqdS)3~> z0tJ5kPH^j&(b^#A$Hx9+1poH(NWmiTL71#Rod?tL(CepS&+A6)zNkuyoN;1`8VT+{ zMU&sA(={v`H%DfO?nzyqS-xpisVO!3C$bU@e0-Zo`j+gCGz6`x2)^c z)S+bb#7uvU4g(_Gl%jTXkny`mPwL%O0&dRVxa^<3|E9G5BrD-BH^cuF%m3LK{@*TV zQOdyo{`1efR@R<%b_ZSWYYz_(2VDw2Ma78~@7T{qCv6gmiHUfWl$1BOw{NkqvdyI% z=@}R>9T)Z_n_8WNv1okK5#X!9H%@2o5889UmCbG-+4S51lbUOGX47L|3xi77BV*5e!0Fl^jZ8{Qdo(&MTRa{#Y23I#w*L4u@0^Ou6ZSG91wlOVJ$Zp3 zBuDNZ0@=DaRn)R`3ny?glrj&hIO6d9+AG8B@8#tMxmZ+mU)=gNTy$eJDCCAru5He> zT-M;Faqhynv=+2=s+Kpym$pOfjZ5pn&wsOVh-vF?dQ_zWdR9eU_k%=M#=_*$kz^dF z&&ScPDQ|5eq$q{QHjY3Ru#!$jgqOAS@r`M(tUKd7(8muXyJBbZ_wWegUr(pb{mdEY zc0#f=6`EWXZ*{g(L)F8vTfs@K)-@FAaS^NMXlubLj_W1MRpAMo@f=qq4Pk$S`Q!C9 zRXp4EA>j;3OZyBN0^US|$T*X*{&rRZtGJq%tW3G*qoc<-4ymM6>Z4I#0&b-xD#3nV zmk5Am91B6B4PTs;k&&^n>}^`@?5I_67o*#So~0$xeV4txy-{L3~{H&@qPjp$OQ7j|~9;`CDUkrIwu|Le~J)ICwVhdv_h=fJcenA7`dnt>M@vox}luq}c z$;Mg?S{;%!(MJ$n!wGD^g-!Yq*?UN5pqw_tD}COVZt!;8eb`p#ZhyX<)IIDyeF`Ks zO3&LSrrIEnNC+Jry%QodRZ2)O7RabsjA!FO@^JnmLTA30HBm=M)qZNzoQu7JNg}{B z1W%KSj=4wgF&c$&Aq{*??%r1YbDE4wgg<)^#5fG&SxO18C6u1(SrxR*97$W zlLpxKh$^I|nNcvPcyDAQS2#ateiw4X}Iu^vQ^H7_rY+@U`_0&_p$LT?~V%mZcz z!J_Hcb|$DP|oO8~n8kXv0`whzFLK z_iMpdLM<0};t%^(zD&B!*Ymy7Gmx9&=1lY7pe)L1P^Z0U)z&!gv$vi&q%UaBlrxNq zRH}nF6tcd24rP1Hp;7yg-E_;}V1B~n!CtUi2#}gA6_7UAP;?)EV!Vws!&%pj;p&Fv32i~pSa<< zUTm30*Wq*{#iqS*1#l(re2BRASzaGY#VrD&sMD95IQM+yYQx3CB|`2>U+B{7m1c94 z!@J^b*Bw-Hzd(B#;rI26pbq@MnO`+j=O~b0BI9P&GAYc7QU5r}DI? zO|5@T8;ow-eiS%vBNkCt?4|SFTdN--O&=aHo_$S4mfADE5k_v%$l`WQcVLd9H&;sD z-ezqVV!=g{AYAvx-3E4jP4V3$` z73!oW6_Apal2Z50KzCVRIYJ$1PlO&O$>MTo=FiR`3F?@Ka0VE81{>_z`h%O&{4Y@J ze{^;Td6bv-1p=uiYCYbZ;S>pO&lTaRx8rYnhN!zU!N_t4HeVOHapo>Hn|pACo3%fs zkZE$Vn^;H+?o?%|5qjrEdruxaFRj11W0rl@(tUNv8E6{Z_XyKY%MYcQw0q0iY27rZ zxU0rjx%q~Vi`{?=jj5y}#4z#Y=7S^s>_gH|LQC~pOOCdg+r*9^gQFhR2qC;1UFREo z*!N9(ei)~#RrBA_g*xO`vsxqCZgY+r;e$JwTdBkTEQ9?7R;!N>cj)?E*)J^kU>Ffhjt0M!RnQ0r;_i|JwJsBgvfL)zE6E>; zpGPa*Kn%xz&81uqO9$Ys!!g%v!b^8p+(^NMT)l#_-4As{X@MS=oPNvVt%s29##-_G zRBrFn_unahd>yagz$C24sC*L>ab0G9L6G7FYd-a zgQmLfX2?R$>9La6+F4*t0?^5~1$cu3zEfhEjf2kgI8kzvXUNOe5U9|!Mr;1&+8=|T zY?~kGaKwUqZ&~G{gSISrz~^#Bfv#U!#(t*p?_vV#^0m3Ry`S*ISGL;aMwb@Z?S$rd z?y`IE%fJ{H?;&KAD0p2zQb%k)K8M=RJ~jXGhA{ay?>Ads zA5c2?*0{i=W~$**#Qpy0z%geRPqLT;4S~6W#S8}cI^Secd@TKfwV_G2N)4xDBAj?p zflz8;DZCH#HT!QUBNl%Jq~EeMx3<7A$=o7>z9;s6tAGP}5dnYV($N551jlu*Tf^-| zN_}WafUK>>jF~a2l|;=gId}E~CiThYi>o8d~nG%Tz z%d%FlgffqTIAZpKIlbq|9E58_bI}Jn{2>{K=5jSz2Bnr9{PM!z)9FO$T^#q#dqy9_fJflKEHWO_4~+ z;--QTO#xdK$%d3-S0_LLf!k^)+!wBAJ1}57L%P-CM#Z=f$v{lUYu#ln;J{Id=A7pN z<#BO{VxBEOEzWDGr_S}!sg$W;c*hS3yv4IvU<+}pY0r&mGRT3SROh1v4bt8%EePk$Gwyg!-Jo zW9Z*S3ixvy1$_5-KqBG$Ic$d=DqBm!-Pzw_p2(WbK2`WQ-01$k+bC(REebj%53BQF zTd#e{8U&gxAL9*1axZYhD0w#}v&WRqzc)9Rz)SoH)ELZaCkG|?m4OOMj!qz%99;N#7ufx>u-^lz{5-G`5XvksD6_>%}c3c zQ7m+z!fiy5-okVw+``~9o!=MuCg7PBQ|9rGHeVg%NF>9yZKJ&}ugta@r0D}C`ZTNl zp1`7`XN_13;haqxAwsPU6vl7Gy|i}YL%FfS5P)5}m1H%CkiH(0*!oDMuJO=6*CeCW z= z#bdLFuY#Ven+!|sDpO1e1f+w2I9?>AJ)rt^aM7MIX<367(E6AUMSEe&Y8Wbaken?` z(u}C{E5NxiuHHx?p8z=?Ekmz;k{Rphb!9C+_+)PvYGTQW?}Xny)KGp>IqDIZ%$^iDTx6&kw8QRsu=hOTayiKgK0&m)HDA<@vI7U0@GCbjdZS z$+^^a{YYAderyAC1|f8xIU0GM+=brj=gb8lrrKeBb|~n;D-WLWrplr^*z_#4LrGnV z&cuEXRHW-WWaBN}`1yE+ti^BdUsM-fRj*9!!N~aY@uDrrYfRt!h@0N1jnyz;KAuIM zD1pQpr66RT(KjE$#p1MRAF}dG>7TNPEcah8k+$X1EAxu^BGvf^K+HFzXmn>BM?&X6lo@ z+#^-J3Mc7$jHyX1hdrT^JRtrimR}V(k@S#yc+>!;zqho2s_N5-KDYURT4*yfc`+|=a_(YkDo!|tiwivQH2~y6- zxivg=TT*+-s(=sa_$e^v1Y0QQ5UoG0nn=G>P8kRWqq9B_(2x2tbbGpr86i#%T;* z^$2PiA*anOL%r$;rDkrfB;xb3wd4#m@|P;)NrrD^f13)mZ$3owpr0iF@DbWSc zjq(JIcZ=R|>T&pdd?Ao+?ksXzDku3ye8?l)`Xy4vtqFla56Q2#j*q#Hfve(K3BtUT z6@7eTutmQNF&3OZF_D{m%f@^OdOq0e=jY98J!A%H&4{+z)sHQX`8jA(eexG#7DCQ! zGGaWumO@Wp?b}$Yk*yARuQhILO*K3Vs}I0_6q?+wGk8YJ^A7v-NoFtJ0+w-ywo&$L zm#ID~zu>86Ana5y!H3DtvDc%vaPoJrZNuo(=VFG&R7xqa%pn2uc+VQDvXKvaOV&@i z;mvu?{$q!3m2>2%G+}I==J+f(pL23I(9U`$3g6hz$mSTtlJv#5J!f~PHw5>cskx^Z zLCp|`Lol(j@5m~ipL{Vg!GEmq)4T#FR6;+fTI+0X#O+ptZzJC=5saOVxQ{V%=arQ$| ztj0sH91}Z_@&poIx~@7L4!-R)#=7_9K^Rm!Kl08>beQxFMWtdXF{%w@&uz%nDFZQE z3|CT%=CJI_xh$;}DjH6e0%e_1bES`^`D$(wVS^^)Y`0(DSg$oRhI9DlyR_;(kB)dD z?>MP6zs2^&6sam5ulepZXW0YzD$%m<)(mHYr^a}(pbS~Pmzwwt^d3)mA`z9G(w;t_ zHY>NbJ2HTz0Jmo&xz186)RCTISl1WB=VGfi0WUGKXI5e6nJELEA}Ls^I5gys$NWG? z%elzs`?0dRQ>IL)Bdol-7ELvhM(%5fs}30N2OSiq&TWT3R+rM+oJmKky`e9-#s~C-B zZah{Y2w=$ti?^N~CRAEsOS8Jzd9CtYi8ZL^h!*n2n9nBFvY)+i(uD&T>{dNxH0*6# z{>D=9mHzlGUgk*`vAQWBS9W97VkMgLEqw0}vtM<$r6A|w%#oj9l;W`vJ^z7OV4gMi zw%|g;M()*V*qM4R@-T5NrGJTP=4dniMtOp`TUB@?Hhg|U_L3F{P;dU)aFZ2{Nwcrx zhaQt8;qjUzMmnEhIO%KSs0gPPd<;U&Q2WuJ1`I61Z}CDEa;dcavev>XDyjrBu6}_T z7Hx6NR2dl##6w^UE}%v-@|hB&NI*MT>y9=~FTj_Yq{MhObRt281e}cxlByLE(-W)Z z!;?sUk8ZReV|3}4H2V@@v@p;DPiNDR;Kc~U@M-Xe;^j#f0Nma(=%diP1v*Jp*LfRk z1?_HAe%qO7z#v=Bt|{E7_`A%Ale^>9d*c<|)6Kr5NTaHJKWyxj*hQVzeNVFon!` z$R$V8m}5&b8H^j1qozbmd218+G^Yy0ZNC*MIZRpXksNBbU58yYnkYTi0pn{R~SKfP9K`2})L`11B56g67ahI8EayT@sS&6i+&YbFw( zQ2L7L$&<%3@8QyRX;a>Hl=SmzeV7xX8~$7RwGf@(xzfPkIw~}qe#PzpAq47FY1J}w zM(*U|jUS)E`!x*xvE01MCX3^q5pi#GoMI0@Vj1SE#FDTrOg=&lz?WV9VlRy_rZi;; z>;3Zf5CUGtP%gx`Cfbi1ZXzq~%@kWEh78RWv8=1yh+(7w3^EPmwwPD8dsyM=`QMH* zkdBhOFS_&DJ@M)V>Edn29=e5@ZeTMI*6w84UCb#h?|uCtTocW%m+l3gSH3`UE2diW zCN&OP=ud~>PdaHlx%e{={@i-PJGJE%3H!iP^#yK7|Zv;DrM=2F3C!6J*>zO=D+a9)Ag7|p= z-=QDT{hb$aPb_YL^*)d05ok3M*~ax=FTdxonCndJ)r}iH+a4ZY9co*X9Cngaztxnv zFJ&~Gjnec30x0^n-^;X9*&~Tu#u3y(GFiZq?ShRziepFSrpw+v)B(tipcxjkfRLVB z#1Iz)ac#mT6#Zes&_vM(|!gAXvku45}WE;*W?52tW)qf2l zr;~zZYf$>_fo<$Z|@V`5@*)`^-@-))R8B z_mqUUaj)I2DEV)6bh`832qiY`8zl%XjF_T&6P^Cb6c)nYKvLKF)oiF;XvEU-aD&g` zmpF9ZX*z*cikKi@uiw3b9o;-t5H<3=%zj}O$~P&i0)S8Hs$7z>v)xLX8+*F+qN>;^ zSZLYw+;Di){ZPSs&WLl4Dww|}?!^mye&wdkKc1;;mTZbG4RVxi5#!tI8(`b{97g3G*z{a^_-nABaHStBb(RU4c-Xh z=#rDVOZK1_NFHVwn5Kc#2_*e1Zrl>89?bWS#Vk_W!tx&Dj%js{Q-5?`eo}at4{U7T z#y;DeZzc|1yo+Ot?XBw1V9G&3#Xjx+*2v|AC#<+IgF7^Sa@n|5X((qjPKz}gcig-7 zZV-2YTGQsS`h|V8#%^y7QF1*IBeE8xJeuHpk0FER`+5rIGmrqDu%2vKyCnIQc7>n7 zy!{J03mS+uGhJL*j(p7E2p$LJt+ghCx7D+c#AO+Gw@usYm|l-#eg%a7z}26&tvST+?qMN2>i9&=|1av!7-xCW$QI!M=1+w7m7~b;k9OQ ztV&ort`6B0(*ac|m}ta^6Pe|3d#5-tZTE$sC><>NL={N)Ck#HL>P1N5t4t>6OowOE z*oTSLMhA4N3 zfA$2=BC>)7pC*eP0BxeO#H?0~Qt>BblORoIY(kIC!LrlXQmJFXi}OabSf>5aw@BgP zV%$!9%%Zg%xDAV6dSmp4_;)}1Zz(3sagfBxA9`R1I~`OT>}+peqmJ-XpkFbr|5DWS zvV{2S3RGAad{n3rb{s}qh74^|F9e)1f)JZswp__X!*z1%m_#I^~j!+ zvuyT^_k+lBhHdVHd5vknukLrcGAPJ#8*Z_`yYhTAks+}2*J&hYn<9`YSsF%lWKMD{ z{LHcB&rvz-GuNqoz-t>vH>{E^U9z#hWKc}V>SLt(jC#=?ptx^>#Qlu+<@{+?`73w- z4{zYr#s4TYc1Z(R$c)(xXSio{B47Y{pKKdp-E74qVNxT(pS#wJ2! zI8x)gr;orYZg}ZwsAMfu;dF;O*_||2U{>p0m1ukGF$-Ae{XXGse^5w8!^X|_Yc9xF zl3o4RDmH9RPqt?tvQrNu>_!qcWU3Fbs z+s+iIqqB-WD&^LS)z|-Ci}F92yhDGd6N*Nv1mOQkX5Na-mXt zS<(EA(xH1CfRD3ohHtv9A9#Xs_wrq+p-*3QNop|biTDL@r260kd}T4hd&gg~NJ^HC zKB~~Ws>c{jt{AAdeR3vU}wyHy!{HF%)B18}5#pfe&pfa!Vh&2xW$AI)KZ zxgP&fU-b4Z11_`sGw}Hj#_E>(-H(1S)~nN-s-qTRJ?XStay7mpa*<2ETyQv!I4U+j@a49jUB-4Hga2CGLAE6gvm}Q(c=B}>9-*1_j}jrJ=wz)P`eY2jrF`$ zSIhurp~Q6;oNFfNbe|9XW)q9;7KWK|7^UqCEq$%ctzs2e&(?$@4UXA6^qK{VIFy|c zpY^gEJDX&XkyD{V`oIt@whv<}+Z_*RV<#`_*B4(B%30{(zMeKt`MUDsqX z=b$rG6BULp(BbGsm)oaI%CE<_Zohv9yL~J-r(j8TwY60cny2^n(>{Mkn4)>NpY4B( z;C?rqvCYVN<_PgyPw+Xgye9V@x$ldNWw@!=rwO0Y!TgdMn;DyQ=KcuGho^R(t{3Nn z)(|3u)zTPICMu;G%VUREhnJuXC}1)FsqR~oNb3DNn`ew+S$5}B)ZPn2y9JvtFsR*w zxZH7(G}o#rXs}J4^u^qOv+-hR`{V$&8@o?-WCUAgKk1tnHl|ueNo6W$3tJOXs8ien zr>tM3Q08l2hB;2c*~I?m^3=Z(o2S%XaJ&on_8SV-Q*jTbHA|lz;DII_y3zVZAZxX} zG8XVe!H`<~G~F(erx7Xe2@bJNTR$s0*xfdq>|Tvjd-f+*Fq~Ad(rOxU*JT}lM=x-i zQqU>QBf>QORGb9H$k*tYY(nzDTmhCDBS8i&|7s!kgg`cX4&&<))uZ1(qTeTUmiOW{ zJXuUz+~~vW^36Ei^+eJMN)8X z>BEz5R8=54&$4C^XseCC8}S7qDfwVt^PNLNjDWI)UP}EoOJLCRpEu-Be*-{{{zTWuMP{=yLAq25yKjiPt>|pQiGrTE4aTCHwICpTdA2M#Vbe3C)eJWBx%# z1nDyW?PG4 zD*?;=*XDmV`k=lwT{}CM+aU-5W0T4Br^ozruzwEmf1^O60{D$(ZSMbIBk)x`=cQNo z_lwLW8jDLxD$2`${q~?5C2$nz;P4QR0*Q7{jrfLNtLSG#-DFSOsj*&*pC&k`qk~xT zdE$DYf;^P+^V`L75fQR~LKpYp`MJ5(y}iPwIIe1MPC*a!>N2E%2rwGOTojmUff8j% zBSis}#fvtUR=qiZl3hhb&MKqxq*hJ@e_xh`l%@vofLF4j*3em>M!Z#x| zYP&Di^Wrl}AFI9hYinz7pwQLL%^djm{LAAp=e~>*D2eJsjDc~pFBuJn9 zqo4e#YW#=w?AG;NKDkTuqbY#Tua^{e-H-*lfb>we}QWS@~Hm?mBGPYk-rv<4nK|9 zv&hvCPlAqrT(PSLyL5ge$7PGxv$IQ-->LrVVBye z4%78Z7i&s)<*Wksyhe%vXq?eXASE~S@yhsN;EDq`6F zpbw(udV-&hh1YLr5Dq$;#x3wTvAOP|tAuP8b?!i#=YnM&a zP)q-6T$Zl+iiz;mI>7bh5$9~xB}?nvIfz-LOI{x8vT}qsw|>^GY80B&kTHS?Bqo~k zTYqQGf;I4Y;8mN#kL@Z+!WoOQq6o-(JQ;uDgdcI$D7-PEfoYxUt^ZX+v>M!SN@iM1 zQ%+rQ?;U3rr!JOj1)iV0w?Wtn9-2*>9^buk^P;Ee40se_%A3@f|Uen^Z4r} z;Rug`GBx@YMCo-;Yj{NPd*}{b=brwfGbfkr2G_PVfA>^h+R$$C$LS^Gk8NUva~pl{ zj#01%l31cra;%9JSJzj=^HgsZGaA0?R4Mnw?O^ijCr9WH)9FF^c{(V2>0C^xg{KpE z#Avr5I1^X5we2w z`~?nLbbbiS&2H{W*)=vvs9?rQRRwv(l1b!}$1{#xWnXK_LU`;qk5iJ(*uZaccyM6j z=s2YT@xlHz-;@Mb8zXgZH)+R>?|GkRazSJSQ@4!zyMY6Sfm!Q4@bxi# zfokK^^kd#OMO&Q%qF973!8@XApb|P_8GE5p7l^SVq%?F1`b}0>r}SMxpQbmLB+gZK zwe%2r$KzM)V0PW!raqk`#mV)u?c}efP}FPi`s=~lYyHA?gbp-Y_FG1cfxrR03m!Jz z-{9(f?snSz4(Pyg$89*_2oGfUgbJAD@wMa{wOKSmzzem@mqb*+z z{!llKwkly6I485==q1CkdojU$*cid_%IPLf((I|hIcO+(EbOhRgQW&s(Z~M^LG94J zQ5^Rl$BS$gk#MUo+c(3WyWe7|ETFS^S}O8+J-t6wKdqEq@9R0Jq{Q-MKPNt3Pja2& z<=>7H3?wRvE%Hlu6*l^z736p7Hz(c>)e|-Qbm4n9`8(+m4)FTW)RC6f39oh@@m6eG zX&BZCOo!pW)~=Z$?g8mI~TG2x}*GYJHi+kGN;cNg%dWU*x}AwXMms+|+6plidZMqbS}nY}KY8xqUS=xk51$ zc)XO!M}Fv;losQ1K6*0f{%)L)Bw)08!7R-SX~qBI-QOxt>4zUY05ybtw8M?1d*xA=z3NCXL;yoEBhElt~HI^ZD?HK z;N!b`{-TspeltjAK+4{_hziO+xGQz!gi|GBLrhf6={e}yiU;T5*U_`+darUO$jOP2 z?e^?Xv+BhaQ8P@=MThai1NrLf&VOCeQ*B7(gz)Pdmp~atS?^A(iaD?Zt$wKbBHSyLDa?}}~>b)!luB)eMPBS=&-k!Mw8!O)0_h@Hl z(Foj%m%Y=O7B-p+Ii6@=DFQx$7SpQcFNKr~yB1`mu;U2WdX0DRBsPew9DLrxIYrw*D!_vY0Q|UIZZ)LE)u{nde`%eND;nBOA z?VA#ltXI-!G(zbS~!fizL>N8RjJeWV0gXw z>KhX-=1iLeX8Gj=VQ68MtyOD~iT5AhL z+8T6DfYXPXIrNPhJa|;hHBX-hCg`WI{|X<>-T!nrR1AtOr;KrS-VX-gn8136$yHr% znV%>&5n`21#~8=jXNAZm;Y{0L3Ktw#SltlHKw;u_>Ymh?R_|CNqO0&~Va%=z;Gaz+ z^;|{kS()AdmTdphqM}2S)5|?iURq)bGjGP0PckCzXkKzU znc%i>kP+aOf5!7@yG$nyhF*8Oxr=~A49MV9!J(xkZFop|dp(!%2H?-mBlpLsH=_`f?8DrOSl4O6m7Y^EnCC!^YuF7wReM>$mR#xbX-)NJpV zhyq4Sug$F7Xv-@lLu$su(9>WE+h%>$sNUl_fs_q5+9qzPjZ!Vf0;wW-v$Fu+o+SPA zrSMXvqsHhFU<7=5q4xVPtL=@(t~>T6gq8yUqr0a#7WT%%tM@*2>AvNUj?@Gks96?L z+Z)j4bYhD6N}6(t#xjh)+ zn)f|%MUweOB~9;HjtIUgms91@(r;~LzU6Cli%=yN&8Aa}v+HKJ$sJz4jW=9A0(#L za{U@T%K?jCGkh)a0&-)vz2s1~nCQz*Wn-v`G!4^;-_&~+8AT91py)WwYF6UXldJOB zbNyxSn(nKb%g62D(4NEN?=LTi3eCfk{xb&vg7;ri!R_y*F>V<_@y=KxbGYm&dqvMO z;02741X|2S<=zrh{7{A1U6T$HgF4TO<+}->6MQ@K1DJ&n#py)eKL#YhQxHO*n!IA589k?l!VPbuk4%p$`e@|mK$)V8*17DmrB#V} zSTO$f(o(@9l$4u_P){?c=3c|u)ek8%UpTFIac;DblwVf)%PCkS#>FAly^QbUXVu8c z&0vF17azGuOuJK51?73Gn%s?eNQV0T$QP(9u2lCJIW2s|(;+xbhnJS>N_6nfq@i9K zPqAwE><`l-ys~)=JY-D_1=_7xk)WkGET;a$RN)TTZ!1VLOG zSLZiNZl!BhNjy^AF7fdrBxg69n2aSyqHsZVlzpzms^z3`>~6e|-WWM0THI`=SPKxd zX^_`RmI}qx_jhWPbLHD)k)wdnIRjL|70{ z`K~8K@Z4Fy+e2(Q8pMOz=BXaMlYq6`{W@TbjUk27zk~nVoeVmgruN+lokFz~zlQU! zM8q&SU+I8qFP#4q8~P*NrMVLdQIFH{S!mLXuTO5{)yL3siISygjiBU^5K24$94Dt9 z<#Uxxr@NmG#^So5NnsVL50fJBRvhi91Y!CgpP4QHw- zV@(vg);T#CQ`7-)4Gf7Uy4G2LI1C{9#o%#@JCroQum_sz`;pZY{>JTA?XdaZB@y+P0UDx))I(NhR zFn$JTPB>Hh<(VSrgJVyJog>vU?XWxNI}E0kKgeqgcZ+C_h|| zAz_ao9&-*)(P?9HTG&sn{7M)MFnRquLllU6W4kv3Y&b~$FzZRBBh6-;sTqonbVgjT4@@p?A{}4Nm0)m zy^>}TR`h@QZ!&60q_N~AyF)Q=1eMgxv{H}GG;;ds_Cnbb8e`XS%4}dOW}@tU;oFH& z2P@Xt5YUmI)i2LGLCmBpw4=UINr0in$F$X&x2}FurCdv%C39y_^Vt_X_NLdhn(fkj zi^RrAo2X2-oO8jGA;N9wt^Y&ft@UJV3)!IZUc* zw(6Yh^HrtaO;#1m*Re9}3*^61#T#6-f|5xsc1b}XILU{XsOoIt6!+Fxzc1v5NglA# z@y=xOwY}EJu)$haPzIyo985S&ebmHCx1s3nCF|?!w2>1#8rLSrS6S$d(FJo-TMyX% zLHuAz`8t{0@)yb7vPul`#NFHbT8;1K0`_2h%hSoC+B0Wd-ApK&O_3^%m_d}Z$I-=$ zF7dx6m3O8KzV?04P#W^m+W_71xw^zYAoE5(baV97nRT5Qj4?1}{i+=Q0@G@aM0Iy! zE;6_DVvI>AYvY&*ZI{VascXNUe!X>QGkuBP9eJ0#`IunYLNMldXrOS<5?X_-3EB}V zF3%oc0jf9KAhULTd?YGCTjOwk9zMaGJzNH-GB>ADLTlWN58N0vEwHsFQTtDK0}?2_``Qu zhyB&b_?SXH21{1bu_^9RlHjdbjlYyd_N`nbS!%szRs5r7cHZkaG z%hqI6Qs%6t#+r6rFs?7%@s*VWc^p~SM9_Dh!n+PYl}0L<1B_I9nD zbWeM0HCWB&_8Wgheb{qp+1Dp8E~(k3R#+vOYdE}zOY4aW6qRo?zm|r6;eMb@`&E7Q z!MHZe(4=dpE2dXrJ4=7!%Ar{CTlrXL0wGxQ&0BuPz4^630auZJ-_3^vmyVeEXyb8? z9ve&~UoS|VHIuKM9iK!Bg!cDMJWbaN|B;ycq1v)L7d`#vf~GQrib-{P=5pqh&Dw}M zuWJ?(2c>|l4Q^EeFNhdrBgESe0Wj&}3dJxql=wU-my`0SSbJG29UVjkO(`Q9ytdBp zF34u)e!iT-?eZ4KqF}sSgUy_lPToKHd_1lQ&wMJoz96^M>sD^Yn2VKHvlvU@#x(#v z@phT>5W_ml`H)hI51Qz47+2*j=^ZtMAvTD@t4W6?;N@~B>II*xU%t6Yx&E}-96>B% zAs$Ps+}HiT#oLZ}*%V;HGqE@}jb1TC$sCo3qZCI=%Y%NEt@rE2J#6sFs~B7a`0r@7 zAsK;^RbEZ@160d#4RfBWEb}?J8c+K*^;>yvfBgSVc`o&Y!Y!(B{jxA5Od_4em(sKl zdUKUZN%14cr8A-;#tVT}^7-qQu_5qubA;h&^PIY9@xx zMWGCeK^j{wMlw$&;7!!x!sd_M-Co;eOkK1!Bu{BMCk5mWmf&uMY?m1<2}{X+?y9qS z9~M}}2avh5QF{c+@ZVSRB?0TUu1&T?NbH=Qeq|_Hc`$)>t%e)XjfwSWIAx2 z=(%W|?r<+C6O~4ygVB;kWc3=$~1;W&}DJlq=;5i_uWL1^<;RZ z4kS(tSGefyEu#0f7o2%k2DIKf>!o#}9ohNayz#*`_+rvhBXM#sub2cFA(1Iq zZ)qAYyO!fvL|3<--QKgf9c~Hr9)=`vG`_#=mCBGt1C|c&kEGD8%4ih)BL{cvg+Qxw znA8zW_dUCGHpRak+4$~%%gi}R6m==KHT8tW(@MRL%T%J(Ho$#7{%%+@>60#_wa#GJ zM^+=9|JG&8G!OA3BbrliJGw1>iYQ5k`PS zz~5Zoy!hSTi*lm`)9ghU*B3b*`Rtrw>VQDcnKEO;O9yH!CnfyG;7jw|QTpJTbvPUV zscg9z$VB?|k2-_Ch(KYg5l z4DGdjBY@4B@*5FOS+YYcHKR`zH9_nvl*liKHuQJMPs0>e?A=J&3#&6A`C}+IB`mSt zkYR#_!qBvP%@ZVLWu|FX(_LwgPzC)gzQGIN{8;H9xjRDJiH9L!jGGg{h?3~+Cf%o8 z>S-$ux-s83(v=tvCQmJs!@o?yCbalk0&*S*#@yO1ee7zD1s`=CTG$=0F7YNA6~2*$ zVcP&*5Jl_vsfA?!{7uZtd&J;g95x#Rr^6|X<0!u!mvR`e`Y{FNE z;>z}}9sP=OUpkBVyv`yfom%eh{MVW=7EcFhIb()i>cvfZy6Exm><-PAE)14GsP~JX z&Ov9)!zIp4#vT7MJCp18N#3K`ISKOz=cJXYY&2A}h^s>*uR~cMyglY*AdIFLLxv#9 z*1+ru^=vh2|E_GU9X->tZbf>ei6!C;u0T%L0zI<$CU8U_aEzc0%Iqq9)(7$#yeN zl%;H_XW{l3(GVEcv+D3P^zx<|w||&0^QmxKMCHZpfhe_^(i7y_=2#yWD?7W8E!zM? zOYaC*^auA9ulFj;RN~VjQhbG3y&}=z9Llq65HYBLq{xBGbn-rI4Ngi~39D7L=a#Ye zq{?0a!g>8+i^__}{Sz?wNT~oDs2R#u;Ps-W#*|oaWh%H|pv5{;mNoef#*wSg!>oRZ zdG2u!>@tmqL|+Hcd5Cj2rqo91e)iIg-J1ucDHaTBGNaD~1Mg~bG>7URmU^gC1?W{Sx^mRFj2M?N*S#>!@zEmKi$YYpP((9jWFZ| z#g!HFcHbGupMaw$QEN|xe$sbX?(mhmEKq4djJ{%vuG*Dg9{wpj|7Gse)n(IbmqAt% z>^Lhu!@_SjTI$`a)tC7y*DU^Qi)}ywO)N)=EZ3XW*v>B32be`oRo7peZ?%!KHRP4w z+S%BQdBmOoz!jevr>jd?ul3FBp80tUXlUrg#l) zy_#xnw2`2|)5EY`4!C^|wh&9{iZI-NFUtSM(fO*ukwJ=C0z*s=4s{I;hnbH7SI0tu z$KL7bxZd6?iceiM|Bd^Wx<0?Sh{eEAv6>`U@DQg_sJnH&97MsAW)f^*MvqMXTN*@X z9zc$}yj0g6wr%-V#VA|*^y8*jG-LReu@?^AW!?69ILD0T$s*PJ{ZMc+O#;-@>l3j5 z3a$$^{0U%Y*?yB}uI*p=DI@^mX`Xm1w|N%v%pq(SP~aTa1splg5agVWY)a8d{}y`O z_D)YT-&~FlQ0%6Ii2|!Uz`~9|dyqz05-WQ5wz8HOdUH{hL~Z1z2QX6M03S@)qy3 z2_VsS5O=;E^P2Obdqqr?h$p5DBufER(SHFHg>16$UL-zpiH~1-xgB~w6LSFITEy7Xng7aiUZ#1zAI84?Zv;5+|E>f=kw1o`FO%bNl~^9&QBk9_F!wmH zuYtseArv3Lu5spg;;Q*i&rHpih@ecm0#7O4mvK#x`el_ttLPDZ$Pl|D00(r`P zzX8cwGTiQ?zu+^oWlYMbQMGTB86P;xefbW0KiWZx14@%9@uGqu95O1|F9hPeKGj9+ zBGHnx)0@%0Tps0=bg2JC-gH(ANtVKFTt`7ejGV})#>!6hN7Fd0gMa$VP16rz!;h*X zFewL@hV#(T*AH#)i+uI}MOzewrP&h|MN{(J zmt!ev+8ml5$9WBd>iQt?5Dg>`f$Tc}i^c1+_6e`M5itGG0fZdC$!q}Fj0jO6L*&&s z=mCs(V}wzk*3BNs#?oKHm2Cb+VRF_6DWYp(!E(JRPEYfdh%)2pj# z4aB?Olf0AtA6HBY_Zg|Qp?}q#_^)>`|0pa?mzWTMy(hcB`zQ-n8pGDy@M;OoWJ2+E zwF3C<$!H$KbT?1LkghMF3IG^lK)3vJk@zoqxqsNa?9LN19}z9jbKt(|yB|Djd9KJ< zoqw&LfcoY~i-V*W(`()mNSM3t4b(4xcoP2`3IEl?>l{FD``5>pcmKK7|J058djjBh z|5^X`2jXREDK6#*t}r+SYLYJAk=ap_+Ue9RIGP$FrFj~iH6g!%b_TUuJ?Pnl|%jT^iuQxvtJ{NAXk zsXaVAoSdBjdK-=ZyJGGi4JA(Q?&7RZg36=+-Td5ilWB$tQ(!1Bex}a-939sqOfwk$+dLl68@;^j+&8UDFiP*w_Gpj`2-PI-xdM5q6kCCd*i&XN|T!uKJM7RHq>!}+M z9Z;=D6jHl$7#@-pCmLpuX4^yl+J^BC0?HCwzI zMpGxegUio>(&QS+{(^C07YR)9-pJ!Udmn5c!6K4CW(z0hy$o;nR0*>FNzB^lyuFE1juu64-NOJwQk7~e%>#ltJx#1GVXMggZ$cUb$guHmNuK~+Lkd9GY`QrH;IB4K zWr=kYG;+pkob$OL$&bM)ZHNNg@Uxt`G||;dUFQShr9o7Jn6SEco#78?3I&*YD5C)^ zO1VrKQ|oTCPP4zI)Ak%A9{i5{UHcsqJ3O|;sLNiD)DssiCp`x_Fol^~M~tkv=ut{1 zYi(O}7pawD0Lln+Au|k((Srax3+o_XFj)_#-pYo-6Y$yVPbGic2oc<+nt;L7!51P}4G zS8A})mrxQq_Vn`rP-F`ZzK9Sr40VFcDew}R3xQm$JvZoaxxLNT@8j_(&J;p!IMiw= zrNh1KVu0cnZevDWOfiDrubwN zP>$1EB0qkjNnBRia6qkNi?sco19hTVQi1B68X~ZSIWX_L;pQFNgT(=D!&W41vpgSJueeEA8d#qoURB~S|D2UU7DJ?ri33PlfoBjY3o9Zm#p6% z1?VH5QT-z~iwB(2zyu+=@ z8Ms1}Ahme+nk7NC0zrHwUT-hbp>pKMeccbGpB75dGTRknUMrsOP$3;UWsqQ&`K9=O z+4?c*K`?lXK)(r9Ncy52gCBXwv{L~}BW|eRSuq|yIFPc3=OO35ca<%__dE;Z?ifCr z%S`)nw?%ilI+_2@esNuj9MNfUqB5Q^FpBm+xXR}y!a&a1iv?*IwtI$X8q196=6wvz z)(H3PMvmlqhix04bE}_AEMfi3T1Oz%?e58pAq*Of63(uNqyqcHclzE5&MCU`KH=sz z(tbe=947MtfR4yC(tt%Cq%xk3GI4}zaC202L4ENnFWCZ4O$FB@ z9sXzUtq3D`iq?F*X2;CN=5hPbGnH<81TPE*Q!3B(QWw=Ywx_#`gC|AECwL?6XK$Ef z)^y3dbTdy`#u&h_{6OV`cnL>0j2aqte7@^fTCA9 zm$440?C5o>J`*SMU{!9sYCi0?o!b#=ga4YJf|MhcqcTT4Ug$v$*DO&VUrlJpM+QJM z5&OfJ#Yop(&thi5_>o0%`?qG>w{>aw5lF(>&ij)GAv14|M8o;@gBxu}gyp+C$3&0B zD94%zJklWIt9H*BPc~waf#F(ToDgd0Ey@DqqP!nNXl|ncA3fseeyC1Dcao(qZakYgBP{~4P)c!!2_t@o0!a~qVQAGj@ zFVY*XZM!(;2}FoSDLuX6=WG`6|62GHi#3MoI<^hB_ZV#|c{v(ev=xk@U1r1mi2xo< zl5{eg@Yi!H)_8fY{kiL=g8OQxH*`I7NBQT<$zrTT&L~)1&&=bKyB!UG;mDmgAn$mB_htIzi_kj&?Pjy+^;My1Z>;v24~s@~>lk|=;YQekyegq1$7>?U z|Jnk}vqb9G7Fgob%rmRw9czQqkgmx75Bc5lU^SUTEQ=^)x0aBDrTQ4yymkj5SJtb8 z&H>-l&REE#$Yf-_b)|6yL;CqR!yP=6jyG;UkJC((xyeKF&2<1y;@L+Gq737jJ^i%f^wqj)u8<3l5NlAln>1Pwt^ zMo!1Os_TjoUaw3%4~NFVdS)4a((h&#EH@o3ZP$&byb(NGcX`GNaI!L3I6_=>%{xXw z(_CzL#>#Pd9lUwD`Bc|&uv{OuL}H2XB=~ z|H2fzpeAAfZ*FW|<_ch~w|Vbi=AeIID{08S*X!T4aoc1m>1ytF=@2Dy8$-oqDqGR< z9>tusGqHkXuE`aJe_`gksW1eNaeOe`S=;TcIQPw4ljf^m8-+%kUK_=AEJ1={g$)qA zN#v|{;Rgt&I)ZnVv*_S!w>!e35CD zjzAe9?)4`gx)HR!c)g1js~{H7$Y@|+&c{AC9{4@2bZqzA_Ni-15NFR?*4>>U9S1wbtVi z#i@jyzCcqb1zvLX+D6zKbnyzEqMxN$(2!6`>WE7;zW_!u!!@C4n_KVH4h%ydWQa@r z?8ZvD1Y$tXm$_buj}M``4B#46wMDR6NP@vpPh_mWdjFp}Oyf&9eqRHwowH$moKWTR zB$!m~kGfi4HyJDCQT|GjUh7T%Lg7eJK5lwp{Uh%=plS(Y++YZzzXIBcQp#uK9- z7E8RRah^`$^z>0!l2bNa`}eTWx#1bs@T+T0 z!b#6&xSrVk@@Bl-nqcUoh1d@Laap%9gub3PkxDV@730SDOIW>3PoIrhn}aK|jtCQt-V!TnAQKP->;dwz6ZZKs$B(;*=cRco`HR05 z;+Pjs$p&Z4$0;`kl|NYm&+lXKXTe7vGN>FS@g7dpg~fs(KNiYe~%_d20Ki$RlXDW z$uCh!d$PFbf=cHH*_V(py~o#AH2WgfLFuHSBGFee(`2Qni+>Pb@ImN&)pT zC8Ke5+v)_I&8!(tnq#4kN%CzR(H5E;-dXE@5u(rCNbs>32Fxoi7% ziX%O1c>LQgbiEwAM{gwAClm2;m*tez<`Sn8{h5W{fzKhbVFk%@-uJs6DGy0$&Q8`e zs2)E_7fRu@q%sh__hA1ELF=xl6ze)>QKKe>5I`kauEgK%W|8rO9hd42^C>EF=3)(@f?Ef?`$(--BZ99mqf* z#u75ielT}MjXykY|C5dN+@i(HnvCvzzYD5#w#^ilEtPzF<2N3r@oU0`(yRe@q1*<) zya)GW!b964`+^(8?nfIVAb-rj*B%#0zBOIcYUw8I^{sS)iV{@{CpY)Z-oM!m#pH?V zcHx_kLeZmt1TbQsyaC{(p`{<$U{h_m2QH{`<3oNjcnI_luUTe8PKXBzT60y13!09s z0ZVdDF76CCTZ7{p-Un%wWXOGZ>$Bg?UP}RHklf&77Q9({_oJ%k-8S-&vC*BMY@Ou$ z##GQY*#2z( zHHVNwsi(Kgb=}ywga-pt+2%L5=mYDM#WBcwEgb4i=z^0Jug-GrMW)5N3k^EB!F`U?|Hi4E3M z3XXE_5kK3l6-?35au8SCQfI{+Dp^|d*Va_DdE#>1Pk5!#CK=(UMx)j@NWA`@2N-~o zC+3(TeU9N-cc8n^K3_BCjSKXtc-Cvm725EAlLu>C<@O_Z8R-f#%7F=^Cv(H6D!;I3 zjxSBlug_5K{Di>bDs%kpKr=P7Qc zYhRTb?w91p&$0a`9fm0X;F>XkKRqrk`Cx5Xkz`GAQGp^}nPYHBnrPY8ML{ZWG<^JM&LitIc5`oRNPr4MJvJAM zTg0cF$gR_)J=dPN;B8DH+FRuh3c`{(7E)k8PSDDeWefU{c$b}3nRJit3haNLf!&^& z+1h~oexj@3n1L!NwH`0k#caC1H|olUUU`^C=oQzSG2a#r~ zcQBp@+KlkjJD8X=4VL5K1o~v3T2y$REflq zC^l&7>hz#otXzGYL>4Z$JjC;qDr%rZaDHqGAw2$8TC|wLE`xKFomEPxmKK^l6cJEv zkyq}@Cut6rUT*PAQzM`^r(Z7Izi2_0P^&geHMC-^cCIA5GXzt~5}d^aTdlpl;wZa- z&6}x$T^2um>)K#Y_|{QQnWc~nopYqZdf8J_n(*gON~Y%@Ox}#Fk^aB7L((0GyJQzg z=yC|8>-;M%)qDcsTj+*7B@0|eS!!)5lDIy~{mM}9n64~}1eNl%CzyvNBb*Ty8y92J ze(D$giNowOkvoOXRRBJx@A#4sT))q-?HFQsPbkiDpsP&H?u!sNJ-xp|J107mU<9WTFoYR#(AL>dyVDfw z3vA~yn$G))1`HWDTN5}~gnr2mw#B#nul%jK%+$sAGMaINzW9$vQ6l*?ZaD< zS-fDL%u44^Nz5#rbWP{Mao+~Rj5cWN=<3{Q%54RVl9)}!;za}K%$g&D94u&Mvk4^k zNQJsbvGhL2iB+D4@WJe=zu1GozzXW~dk9ee>D3v2Z|}!_Bq6k%QX)T@51z~1NowuT zKmmbbs&`ZbYQ^F`tV;YCF|^LU87sc?Qm(#@d||WY+}wp zzL{vSL|IiCAHrq;=$Hj(SKl-wEcP2-OT_k%W}xf4eFKZrUKfD-KVnkZ*-m42mBm^g^)*7_LO?dVp@jQNMf!)&Qr5Taib8Q$zb+w| zJ|&j#v3L9bH-?ta|72+S9(=x5keHK<2B)8ekhab)7e%zOZR_`EOoGAMd{mi<_}so3 zOY@U#T8FNOIpT&nN`-*udzqB2gcB9=ps@76>8nn@ zh!OsjZ!(&<%W{%2`pKJhrsLEl_a6XSnmZf_|IXR+?I>cLY@C}-Ot;<6`}IR9i4`$!{x|kX zQn51hz|CROYIeHi6LP_)-q(HQH9QJi&(J6MeP;??KJ>(ot zoF8=LfQR!=JUgA9gxo)7av2i1(7FL$vN(li^d6nZqo=c%9<^nfgG&n^r%e&XQee9uv zsN0DB2E#M?U2+AIa@jTp8bas`yC5EoH1@=$r0Qg`6KkabHU~|eZfX{hg6UMQ>aP2& ziEhAl9fSHc3;v39mqU|YhlrfvGe+6F8TGw~q~r+tMoNdh=?q;@%%$s{&V;4VKG{k< z6XYcK`wP0YkJbP;ZKhboYk0-NS^$G>?LzoV!h#DgDhs>=_hW(`&vONtCPhPo4 z7ob4=fql9Nq1>ckie}wupfTHgB&?sxv20mttSIOmrK9TmSyUZ*K5Emh-JfG)_`K>m zY049L8cjl*Er)G-J=e#hNW9CC1HmK2!jqj*S}3*A&+M$h)?=YSZOZZxR007};9Op9YXjZ2`CmQYh;R+y>fG&rjcusI$x( zPJeQ^hf{3BmD)O+vD4TQkh(DlT|KDGVE)zuRoaV+)o6BitU}`0i8<}_Gr18xa;LjkXB6x>FCX*1$z8yPa?<6{qO;G^SOe zdwvBK^pEFB53M#QAZ73$*JodI4^+Z&scbsO4H#jojAkJ+(A-4UiF&akg>LPX_-bn= zS$h1?DY4fTjbB0Aw~nxjAF-()TOo;A>q3a?X=)32V6igy(;;GO4m+cy2*2G7Fk;ub7?1@{AcG@ic?KJtS^Yw$x z?#W%+KpVMSdXt-DMsw~|@qUTP`>fdF5;FAhg^VxDn5<#^Ny5$Pku)g`IM2%&5SnFt? z;D((=(87@EVJT^WL{Pn9H0mLqeHs${A_G0394`elIgY5f*=F91C_Ir|2JirC;$@O3 zawZWxs<+FCk?q;}R8=_VG8e!Z=3j1mP0s%7nSDb~rjos$WOf!?9k{;Zdp z;F@8Fa+MK-k66z5WvG-XIZLsWt0cIQY$;AyuwRt)ZK+I1H@H@msjV2 zcL)t%JqaGqHmGf&A!j5eku(nm3Ei01j*DRdiPz-G_Oe-Kgh*CWVORH3>yY^Urbc5DCi_ z#9?Yz`db(fqw zQ~}i!Atukzt8v38)lbYrpyybH(4+Zp-9rs@jvX4ZG5bT~mm38S$FDvG&>`@-M=lXq z_yQ%f{36lOhZ?laek9ZWCP>2=L`6>zIIhuVl7WL+miMgDOdog!3hoXM&ewatCgyki z&g@%#q}6DF&}6pN{k)|){d7xWhE=kWUIN*nc&KlgMY9dTlxKduR{79|lMazL+j2-+ z(^0Y;8-cWIOl!c#Uzodgx;18RIUZ=3DqOyo%Z3bL+-)#Ag2s)3Pf&E+;;lI+*&v}> z0dAhOkcRt)rqow)z!J(q6$`7Cfy?OKI`&80-=;*VM zKMeZQgkG}pH%r&NXvFsR_77NC_a;wTxEhI5w>PIP<|>HWY7`Z_6L|qGEiD%lUi?nW zv~ehnUe7rA`1RDW+0GzXY;oO_K3Oz7TMAdhXL?lYj2{0?)gG!|#tS^hi;-)S&WZRa zY7KUerXPiJ4i<{0@7+8w<4brDz!25+spUTs+vYOZ@$j#??L!swz`mU`nIxmIiyFLOc8c*Fw!c~Wy`t3EGJHJA&axIM5b~TIHg1t-LK!?-u za*ie@#$Je;Qt^ffUK_I5VK++x^RxH&lCAYf-Df;dGKDsGOXXb6bl!^sJG@!~bVFHl{aT7$gJ z8OX+-qFhsJ`CW6AEe$Kc5JMX*D1 z{<3hH!@bPnRfw;}m2Cb*IXXESO~fm>uO9=zzE8Hj{<63Bs@EOsRaxcw!ag2U_wzdi z;cE>Sx~rXc_5)A9d;)34crUobO<#4wjGIFs^ayJ)g@a@vdV~uCHVDsc+&jmij_~Ml zdxZNsPG!!r1>7%wZIKhlZNUyxB?l?wHLaoQE;{9mwRE~nuG*<+lQvO zeS89ZTDK8=ZkTGQT_m_nj;jgl?LqfNq@4}D>FaJZz0fkNi0*C9tE0J)p$Z7yZ}GVF z%sZi5&%E0o^bUAhPZ9J&>42Y6#=0wD3+T`c>m1hVBsko0h4ysq`e}I2RIBywa3k?^ zC4ZOMZ$@LtheI-|S#8w|vwW?7I`6NBzC>rAPm;uF8rH1$E+c%MvKq^o(qH=Jm@A*c zj(H{aClFf(XF;ecYPy3~u&YFm;dEDz>om(-jIm#LkiT!$8qm882l8`q0% z_QgE=nrYEB9i4c<@cv?udtdk0iBBqgvBss(r*X^~%O>HiD1%5U*Vi%kZE)N(#qA(M zyx&L5A$6-%zMv`A()5#3k-Lr(Q~1eXNS)xP0?o3v+N@%n)b9nNyJA}X=gI4vGo3z| zoYE0t#W5?kCTpNgxlz!=srkSD1vAnE$H9z_z3rd1&~KBEd#TJd#9)p?|Ka{TygkbD zm@aEW-PcJi$Yu5TWGyezNf{qpI_Vgym|gx;zo6^DIPsF!&9gy z{CFL~E*<<4a;jU0b^2si`w`8@lQo}xH8>nkxFxUW&$Zo9x82YQ(FXf1VGu}tqhVW!$c>8qgUFi^$IqKm7sa_gEv_6TnQ9>xXmFlkn~J|g!=)Kcl^LJ>jUWb`2i zq-q-wte9N%ZSt=!PEQ2v)j!{u9Fk5}Pm=^iPEnZSj-hHM2I#nqXiFT|zPgxD4Gq?O zRZHE-YXxE?qN1Z0JU^EtTI$E}WsIg* zY7M=ue7hqRQ&MKra6Sz2XjL@%eE;Q_Ohli)Gh&_S3UADcB^15#^wjf_S(gFxrLvmZ zb6!~HQ35+Fs|XL>mB+@5w;_gy_}q8iWdFg&{ldk)D6w3ssm`bDx@PaWXdh3^d?9Zi zuYO01pT{jfu;UHc<-ll{aQ(h+mFlD9VE-CmOTYs;7+AXj92YJzJm7oIhwMKj4#>Yk zaxuYimALZ0Z|^fs6Ag|dIM$i^x>mc&j&8^PR?i01cVeRz*f+!=IrWg7bRBnelO1ty2%^i7^KK-jj5kg_}jU=Z`+P zMKjNCPP=V)!lZBeoc1^ZZB;{kvdZJ0oU|x@hdmVXW2>UUJ)yn3`+ISoM;7~SSUr=j z8f(2xv&;q^RKN3K_Y|)_y%ewCt*TXHwWfM*-s&OYSw3)bTrY>{Va|jUiiv-zL*gW; zS;&(!NyCqdyNk1*(=eBt+;&<8n8BsBd*^I?*G&G_+W!6K+JksnOdzN^kp*kOZd=gt z7Mk-c9EUCY@#Ouo6=ej2G&AY1x=5A=EE*h_jfs!*@atz*+K~+KzH1Uqh>*G_YG0>}iJ6NWK`ga@B54d`{o+IhL|M-<`JIe$w5o?_A zWmIdIq?yf{B+-X8pN&Gtb;WwIe3fa%npgdpD6R9*Rv&`i-(YF^rPhpR$PSgS=5^7( zIMD89)ITQxE+J|^c^B_n1db(_Cm-w@+NbLa0X2|kf)gQ_D%?RRJ@XxS#BvdY=MVhV z+0C>Q^L=m6b4xt_0q-4i<*$F-ad$KPzmB$B=nf(Ctun*;{DMw1U=B}wImMdZwd{vC zN`_V1`sqIHtbSieiVbQYDvutA%?-8y*@nq1=0!u3>hp2F(+5FS_0IF_{Yc*B*VSjT zcPk!6H|Prm0qJE!zoU}C#?21THI=&AvimhmM-$8bv&Aq+U?tMK39 z(9MAeGkd+a;L?fpC&azPq~9;%2#dU(zk|=82lx_(x~(DpM#6u5t&GuuE%1*Ie}8QP zYO|G)3*?@j-G264Y15ks*jfoSsr08_ zy6yy?&5TQqduIyqEh}%9t~@DD-}MOpK1m1xBF+1o;ID}Wo4t{&)~l}?8yh3I+#Jbb ziDxQ|Mn*FQp(jhUa1lwQVq{gsR_O;`E>IR)%PjY$)#FuuH;CXG`u}UQ{r4N}?Fr8I zVu&NHM^!Z(h=VOIE-tOC1kPoEA93*XZ7lEu4f@3SP-NjFzi_>x<%T@HK*T_ph>Q4^bf(4syQa z88FC;>_ER<4W-5E4QXs*q%;r~LSMRFXkw7jhq44l?pX#4B$V_Jfj06fnfX45hCEQ` zV)WCfSV%%{Te95%t=*J~^S$3!H|&i(7dyBC!{T-mD;{5>7#UG+6cgWn8_p6EGM&sZ zz-FPO^Xs>f=WEVGayR7ZZ7xQifJinNx!q_jCUsLnC+9MPLu=1gr8RGr+TP3oFtvCxp*hFZRGNd^}dH;3}y169F7_) zMF8%ByY=A@t;MhZ8Y&~CPIY}bg5bDOZwO{goqB0z6AWPb(bwp{enaZ{H$v^!`UIkn zwH{aTL@a|-3w4CQH9}=wgLU_ilqRVuK7&RX!tgchI>3(>4WgvpC%-Wmql7V4gt{BR&=+Y0HJc`_p`_NcwH_ltt@iXC)B0A=!WDO^|DF1cn0Pi!K%XPwNPc z9XUixeyfC5jb*(-oO7XRDuc4lN0heHm|P@R!dZFC<9w>B`LHwUAKcG%`Wx>#-w zQTIU8S!Gq+`P@9Rl=db>?3#v3wvq?z!rl0(zdEY`-Xa4hwWgS=A*T7_DC zF_wj&x`T_hPv(vN*~MR*T4CL~fmf%w6+NGx_k2qv$_`KirGMdP_3z{28k^3--CFAX z8VAOa6&hn>dQ5oZ)}@#-fvWp@cgb}%593X^yp@jLoTtiWLzE$u&@=wpxY zGd|GO|3)zJub~3tE$H_Gn0N1_aa)8EBvCepcHhRv3^#Lfqljk1b|vS5PT2?Fshn;3 zP8cyrg^aRDpWZm2nU`-04v%>K^>7I8l24bbdXWNuZg=qQe~uI{m+-Hb|7~#c+cbYa z#Xm1EVf-H-{(SxaJkt5Sq-98nTyVOzC4*IGjXI(UKnw9{`lo+_`dt9sBRyNYht2gC zv@rv!P$cEF?0S55TeQb{8Cy2@goT z-n>`V7x2clZI!xSVkj)#vBbYPk|kR{{&Ue+mw=m60EX*-mMaF^C zua;HHhF#m*7b_!JY_HH0x$7hacx7CJ&QE9Y1JK(*QfN=NMHs+_Pnl|UFbQ@{{G6Ul zkFYQ6=!m4-~Er^vqlr^2PffZ<=bHi6n~zs2L&tl`b{s=A1`*b0>q`bAIs?& z0sap6+H*h|1MC{O9xLvy{TUkT?M~IupYd=kN*8=SQiVJkqh2(V@rLU?nszpW!d_iz z^po+l=RKMUZi5gqX0dFsg8S*7eD}fBvi+#p9zn1jB&&QTbfbj^B*aOgpFS5~cBdVp z>X5%3Z(jDZ=<)gBmXsBdg(!4g+R>d6ZOy4HrvGw@2Nb}PT8}W~Uq_;a=JcU#^86I( z(?!ZR=skM0=53;BkU7Xy&<;wQr15A_Piu zpxayJ;GAcH2IEZ5)LiN|Ua`WcUV(~=3(j@%K*0QT9bi;(mp}0xydF*~bYnzM)5Z*} zSa)L6^Tb$Hx@8c=zrC@#f#!t_Qo8;;RG(#ivP5{0%=9X4z1#t_M!3af0pZf911|Kl z4>#tCd|}(tuT+_eX*_4}9UPX@H%q3>tqC48r8cz?7)-|D#d?mbk+mE1PBo==N7fg{ z6i32Es`=YTK~K>vYpUOoE`70E1K)X+t`(ppH4Kc^8B)P~RQlmkkJ4l|-3byu#)zAc z+n7pJKwD^_!k8%v@uzCgoqc$2<1l=u>i|m1=h(wr=9&*s0psl2_<|a?aNSXPSo47e zLeDLL3;L%7CI67yp>=ld#2t?eGGqohf2aFNk^0*!W#M{tL@f0jd)qOvuQ>!AE>6`Qeo zJw0cSMca_J`0P6RQ{oat6-8y|I)^`n(Pfju38~U+oQ;|_$9$%7GB9h$Tf9jc4a62) z$cT4&2;b7x+X^-sXmd;iE7M$HnoGZ3?dnjXFJnxpQhhxdfeL4nq0|ym{`_u#5M1UU zfV1~IqxpGDUbwcw^QRk=bGu&T*R_|7?-iRhcT}1wRbkZpLZ04?v(4kJxAEMV>AT6B z(4s5ZCzG-g7?rvA8o%!S$&jU8h8rPVGY*pOa%c4u2W7np$4g0-h0igy@2b?eMzGX_ zo*T$gX8n%eFOM1eIEEfbq9nC;Q%q*8TE=9ELH|J-o~G?&dTP|P?a@~_75u29+vBPC zOBPN)CYO5hGFR(ube?qwi=lunt7e|{uS6T9T*B5I6KMJJzg|60t zn9qS&GI^fh`A1egxzJdz|287}OC$ar2Wi3TQZgB9j(wXa|5i>ubfG97l#VE5M1b;*S*jIMm5oFY!*V#qo|%pPV0tGfv?}^;X@X=?|1k^MX}+VyIl^c&lgIfkG3?IREDDc zjUGGN5!A#{#ULtvvG8QEvi$AM}FA6yKO zVn5WVq%|R0T!+j@S+hSU*N&W}Oq%Q$N-qfSp;lHqe2Sv*`i_7KyN{$K)`F}MQU0J` zPgo@H;YJWEM_w>{0)3a>F$|NHDQ0v3L;8Eg7`lj)Vr3>46q~_eW$FbRnoDYToJU zaw^L_Y91IqV?8sDD3!@PV$Ts{9SuxbBs77%_8hGcwp0CZ%sJMoOotNK1@e(oL~N*N zPpY6s_9U_3eJX|{e`otY!TVke7*_t%L0(m@q6<*Q`r=El7>gQ0nwdp+B(Ddvf+QD? zyw9AvHZzb{@rXOhKd_HHAS)=8l-dn(zZL7NA5#d2z0Yhhn~bv6w~~h^M#5-3b19Y{ z<6QDPG~y=E3jww`4DC+DumzB}=*>grk6aD(_qZp#8!;5lawYyg+W2k6t||r%_qCKI)t3=AQ}MU@W_0L>2EP67AgVz7%0klT*_NlsMV^&|0xUuP9 z;COoz5qk>tdMtVsdtbsE$nX*8i24p1$gl@|1%Yr^ck`g_*yy)=@imu)5zQ^M3A@$y zL^}BP08Nu})@Sc^V(lX7$oIQz^FO(g6bHelQWu=_$5#8Ix_gbS;P0hzg^@7aVGvZk zoO#?4AK~O(3^#ibHcHy3yWi30<3G;5-Kl27%yg3WrYx3R8~Z`Kj5{Al>=oKk+MGJJ zSj5;5V)Yg|EipyJe8ziweasU86z+=&OZFyJV~6ksfll$*!MZg1yb~I9p)vX21-l{Q z(zUu@3bAk^3=iKyXm#?I!Pg~x@FM$go^4_$U*`U>O9z#dr+HGZ9a3Mk*D+QaVe;cb zV!runfa_p2=aQ@SelM!S0P7qMshFh*75P713!`lnx&2y1~vY-dcj z$b`b-p||K9kaBsFyw|~wLL?zrK+#@ES#sTXB*!C<-no9~net%p7ns+mjl( z(xs(iCr1>JsmfP%Zg4Hw(DC{7EHqh<72~K*-7mi9Bt}~I#@A?#>t#*;;~Hr|8(BBj z?ntPA=0f+fzzjL(BeED{ewaER9-P$z>hVs_Dq+a!eXsWp!!cI7MLE8iEBd#l;|-Go z8J+quJDSRMKU+n8rmRWwas$5*^$=7LZV$#O@;83O`K%3^LYo<4O!}bLKFn?wFlh8| z`9rx|t_}hnm+ro&j%6Xs#@s;}UZQ(99rtT@HVeOZ{y*%!LzHD(&^20>wr$(CZQHh; zm9}l?N!zZ>O53(=SNhNU-TVEm*LY*R?(3e$8hf9$SHzk#V$OI*dZx$kpHiKl?Ji4c zQZQO2&|Z3o2ld|f-GCYRc%#opWg@KP#I#7naeHbpIz$ZIF;G?nC%lQ7{q}EIn}+`h z8S{XwGgBnWs=>Dvba{Mb_!jH8JCl!kwj$XR2M{dhg&DQt6=u6U$OcvJQ1k=;XjA7`Y}G%v3QX03i{<`cPtbUW2{Vr zpSD%gokzA$fVg0m(Y`{0@Kq?3*I_XyA^oA2MXNXd0B|dBde~>J7rIv>L+)D)hN}@w zDAp008xZkq{{o-qVdxfH=Nj5BD~%i~0R_pEvUF3^3C0V@;~mED{HYG_Y;)yDx+9Xk zG0xeji&<-pr(S8gCtD~A5Mv*Z7e^pquVTraH9#v{DMMqj`Wmd@3^M}BFHd&KZY zlNo3km$O)@K(i^{9uj{$!qfvB-$|67;HHfEFPVN{u5s{B|2rqO5>B7XgT-n@C;hzD`Ot1FwBqEpn3@)g(?2$tJc`j^_2yVpwe??xr!D9c2LYAd zM$JyxQUrUfcKvI+13|-wX&}MAH)8_x-CYts?AI)oV%B3Y)&=@^{~4}K&75UwWNc@- z+(&@}R4lQWT3t?O8hoSsi9ybw641^E3`@-}Je~K}2M_~wS$)J)%PY49IUcf5+=PN} zu^BjgfSnzaRVPD2bG*d5vZzw5_=Z03|Kf%V>Y;xC&A&+bg8G}Yr%^4BeCl5UU^5iS zdGTy9;sSHA2nW4hop5;I#rn{MPWj>e`6^isOj1EY_3Sk2kFdp9U%-4`lJDCQG_HT> z0%8TL?W_Na5nr5^EsqlxNL7<|G+7p58FzrTCW9G@k2t?2kj9?aXoN?uJR4Gl9NCi7 z`PwSKp}7Hj`^1UW50&djyOwdl|BWiH?nw}qVICR(n>Q4$Dm0q@D=dWB%wQZ=*)UKd z7yd)d{?ABB#;wDmg3IL$a1SjPtY?xahmQ@1P71!`;e=@LX)0<1;A1ABEcKT3v(*92 z%%;6SUlb;?>!f2Bq$S1{>e&07(ej2MTGtCN5-X_wY~_n#>m7zgQn8K^3+1O>9!Dg) zqY*c11^gRw^<|C0d?G5xO$Wg%Ep|j^UKHWrk6OhjED3VFxT+X!fLL_vQ6^Hr_^@36 zb_W#JqHM9a4#WR21gU}lz}oQtLV&CZN#f_EMg^3gGybx@=e{e$cZ&yMGED|H+|h5- zWFJwsfvcMn2j55jU+Q(GHG(_*o8coWvX4y=rrMjmTU|k? zAoZohvaibh4Qs&**3))3-~11M|NXjOwEv-Z+C4a;Aq}Ka#jnR)|Kn9_pwK2F(1RoslEc8zjdd&%VTC}v;aK*g_^q}w) z0*|#=#r~RhGaC2gR{&FQvQtEpBkMfl+k47=~Wjh4Q4~R(}C4i99 zSXt>Om3K^br}fw9#FA#n&E=16bk`%Em;()=Rug~8Zkf9_f*v0Ci`zMX)fZVY5so-p zROA6jz3S3r{@CDk#Xdr6_36rSrT;^gr-CTz0oC@eH;8XI z16PS7B$RcLdsBjMB=yCWZx#1d9FQ!J0;|=aSkv`y$Ik`P4ZjaWr(qom)pn#vv!;08 ztRI)w*_&O!>cE55N#=s6@b2#j`e;_b4wi3dI==v@QHq)mR+km>YTN5^sN%W(?Mm7# z^n`dDajkXUmylg!TEM*6s7v(7j_&wsxQ~J*6}c8#G@l>uHRacaUy;NfS2~cqS!wY| z%1RhDbSF`e(^&?+2WBJ5K%3W&v9_70vBPiZ22-K)9`Ax+Z$!4Y&j(9$*U=XJw|qCi zL`ZzAhPKxb*!vx{@1&o+PDt#(hz*jeK`PYgW7`&!(0-zS4dMG;4(2?cDwGMrzt0r| zWgFv~PtM2ub^Rk}^65$$sv2``5-a)kO2c;D1|`g@0E&0TPw;8AgVbW*9?q`y6LYLZ z$a?v~r~>QxsrFC8@l+Yf((P*@QYl{epG}`ihXr!v3NN<7R!!LSm1&gH-Xwsv!;T$B z6%@Nb7#1gCn(w`)p?kgGrsH393!u0P%|uQh@gV=sQiu0K_ATl;Vn0rHl?iL~Yp#C% z&nRMY`#JThjSk2${&PK@9X!>#y3H zaJA{WLrjGp3teLQ+#~s07;85MQB>W#nq^Kpm9(EXAZx0%^Q%r{{>-w1JFrhcgf9Mmhmx3)hw5~Ms;}%dO%hD8xfE!Z|L>Hfo}?l zm1!dcdznpTvsgeoiS>+P-lGbOr83Z}sLy2vE5DD1pL*%3UzWbf64 ziIb96r6_*%;XFkD&4HhmXVLCVL~g! ztF}!_tn)SEbrcRuWi=$Z;pBQGnNG#>51SVbB`wJ;NOoa)j8j7KZNrl1sLv55RB~zr z(l1j+Pn2fzmr_$xl2&?=YO|aI|F#Si;hEE2l`$zDK6QL995T|#my^yqw(_DL>}~Pq z91qZ(lHKAe39@NXpF(vS$RcOwH6=yxkWUYhYI(DqsIxde33~pSHL({{%t@otT2%4DgADmLj?SsASD5EX5jH^t+EQTgb54dI`q zB}xFDRI%gQ=&JjU`3Yvm>A@T8`SMJU+*10@#12oj0vjrAD$WOus@GfG%j=XZ8mKQR za^a#P5eR!`0wG zmYTwjm?_wkk1uNDA{!qvj)vqG2EM{MRU`cVu_02Yd8i_#VQECv^|Dio#|(pZloLq5 zLeRWXNWI$&x|e-SoV=+Ptk7~IHW93VP8Jr#lE<06G)Jl^Yu{udRfBu#nW_rX?yVzi zTR|7~@0RK$c9^UvmUgLH+aD&;c15JTHuE$LU5pHTl}^T@i1=Y8%JQ=m@rY|>^PO5a z%l6guZy_44#YuFrm9_BkA>~{xw|;w^ZM##K)n9Q{PH1%CQKK<105&oZJZ)i8)FQvH z&t+F#-bM>%W87M^8tQ4u1@$HDLRClLO1?fm#rf~Ru?e2qz5k-H=dj`Dj3SX;JL!7o zWx9(wAGfPNEiu%L?lSBul3!q@UuOYawC4L_ZHAVjvsW5>q_mY^7k_?DcPWIQzZ5Kw zojjiK={fIasQ)Ci#-7O725mQ;t~V6$tMW#39_c(9#d^4EM}e=VGF}+FEu(`aSlq}7 zs`;I^U!nl_p_V<+@6R9-9725YVVteU3!!?EYjiy0hS9)2a}zSHh$hxr%*}7RJ%zho z=Xj_SeX0g}x}80w&wG}Cc!3@7wkY6(%*@NZH{F;(v1m>Bl+zOl4UPt|$Aq1lzKnjF zuOSlBLRmv!S*e8e-Ts2(f6xmQR=3-m>ux{EzJ_&!w~q1E*7M6;1w3xY{G@#~4ssV` z!R>)0uaz1<@{PC@*4itTt=-E5efY!}ddLi^Ea>n?9|F-pw+zScbQNyp$g8o?+R)Px z@}GwpT4E&Y%CBDBR|BkMtDbs?p8f$ynveZ{vxpy8mmSx82!6Y!M0?-fpm=8NA+80B%Ez z1vu*$z?$^2S`?#)4kRY@D^jYS%*i(wCQt_s1SfD=aK72UhHta|17%MQmLo0!QyR>Q{*mNajqr50?DJ81z1cDN?ilWfg;urIbY z;u#>AtE`%GwE#2;3$TO+AlY_nC;3r#dwnV^O5zM#)=WokuZ$7s{_=DsvC}j9SjI^8 zdneF#Zm6OW{&=}y?76<_FEP;+AkGDSk+_)8=rwP`MP~#FRVxF2UeeC zAh?I(Kq_mesr1<373S~(p6rtfk_=VSOfTvq3em}=!3BX0e$U)b7nw2Wq#{farpgAD z_NK^Sm`h9N=u>^9N##uS@yz59-+ZC5bmnlQeN2%;|KbG!_PMSj9 z5!{wRe&CC7sQhABmqt;mxi0#IpXF4^Zmy#efeje2JqBJZH|8O_08G1Bk}@cTxEw{| z_5Ra$dr?VB4uucVxR^7idO9tQI2;hv6fB=Xg)gzKd`HvdqKYSQ-qZ$Wmr8I>Dkp{O zAf=rA+hSN-<|NluN0-HkNtTK3_ypC}F%>ORh0v!g<0+sNi`*%I){+#}gD{~FH!ANN zQO&h8n4%SQzU*c8V1rr!*;TH<;h?eMw#Di3dAvXHLTi3xRSvTf7ojI}_`+7>=%g0e z(kj)lB}5Qbm=yP}Y|qmYL-Xk%b$$a{+=q#7xPjkRK52UB{9DN;^r zpv>)rHekIO(P=56xtSWfd$pQOC$iQ>*QZ*GPFYE$So1w=_LQ?!XZmLyeIDkiO86k~1t zFG|_#We%SpX=53fApKC(Kn!G-PTRXEEoYM44d+TqGca&O-NM6&)w_3Tl-=4ND4W9Y zCc;?dJu;Sz`xWl18VYv3SQ0Dp~KSK(k zDTC9w#ym67@(;a!ed0fq_P!D!iYQ|=0{hQMwGZ=V3vJEb{8yE>iU1$%117J5 zRvve6mx>g)1omfxVcUKj>@jV8{>Q(Vz-wv#x9i?0oX*5qN*iyjwTACwB*3&=7kH7~ z(!Uga2S}RaE`+c9>5ZJ089C5&5PUvgfn{~~eC6NF*h8Omfwu368OmLU+Fo#9e@t(4 z_tl&DuuvJi3n4SoH>ip)20B^j@eBkZP%;wUU059Gp-Fv=oIfiWv0UEcuK1E64Q6!` z+gHIt@^d2Rths-SbZd)~gDns}Y?({ouOezTUk(1^XE}~eKR`@`s~^`H9yvT*Zh`80 ze?&r#!|fVY`9N~A;pXtX84pfEfNb6L<@LYiTc=%NF!-WQy<#n4-|nHP$zg=!@wh;L|X%L1-)L#ne>F}3r^c|k&^&N=YYmwD)M2X|a z@ZpWDz3^3BC%u$ecu=#w`xD}6fQFl#jwOfYw5LTMXFPbe_@YI!5ICgu>pp?x>cK-Beu@kVXo{8hVk-Kj=FmBL=YVJRUndoUVax zf=3TmG@Y4;6iA@&#wO6^Hk5 z$%_Tl${Wiq=V};^{HQuTj)3cD+pYf_;toz8aef|LE*@BHF9!K1AR=d`d)@^niH+c7 zM1|2F%;>Q?jpMfoh?nbiOaXJtPRA7~vDXnUa}polP`#=$!$WD!$y_r#n7mG?u-KvS zy$N)v`$;sveB@*95$IFwrT-JI?;uyB7;M=7-a!q9GYtml+j|IqW(UTU=_BpMmLI;= zI+n#YS=#Iy%E1Wjkz%z=LR-5zILx9l2NBWWm$GKB)H5Jf3A8vJ56`U3qMzI`?qQeNZW93iU-0PKC=7ho74PN`IR|*_*^T^@aeT<9PTqY!b zTY?(f+}K{;&O+_H-M_~7r0F$aNbb?fHFyximC#uX=g)bAhrTFZTOw5)uNZUXw2_^8 zlumHcP2GALo!j_#NHH^2a@oK-RO}y;lW3_1_0ZOvWnb{kcX#Z{e#P z+!t>KkJN}Qc*NEM;#SKFVzJfD_{)dY#=1#7D;>7VgKk-#SAH2LXwo8XmJjz`>p)%BXlWs}fBB++x|+UB=idinsd$+LXj$~y%gj%ZbD z{DDbf<}qUwQAYVDXVv`&{U}GWp$F%uOXc3`FM5Y&C>B4kIL^Z>W)-`S+o(!ZAov); zFVW}8zujovde-&Z`msncnFVs4Y817v{{59pLdbpT{46z4hi7C$5sFnlw0k%EFhp{jXYXJJ4+XqgtPOT zncP8UVaOvwWDX}feZps@$jQ&=;eCqKwhTN%wLMJ_N`|w07@joXVr0Oll<5wlz{7V_ zN~3W?%I2Pp4c^*EU=12+A+7$+mqVouad1&jx-??V>iMM^RHbrgF*k@B`g}riiYp>T zrBljx*o-osSxnr{p_!obESDC|YOxXV1K?CqGOYckfCzQxRiR>q;`j1~kxjohhlYT1iKZ zpmWb>WL#X>@Cyb|QS6iy^y4;rOp? zch=$yFYDq=Sj>dmZsJBHecP1^iCH$)b&?TLA7^_q=%})#HX(dm(!^smubNSgDRW5zVTvG8k3 z^ut?m!5v-k&8fIt0Bn=7rKC!9OaXHl?ZG_zmBcrp^(!Ci6h!IZRM0y{{>eXOL4=*D z`vD_Tn|HJ5wqy3TWl}<)*HUj@|FK#^(*{I$fxfap9r`?8RArOwXt?k-*5sOv+l#CW zv(QX`rA0@2xm2ADx;KNTWuO9maqGbxmRcz#O9WjVV@x!0OR$JW#`Wx&RQfi%-o=HG z{I)A)6eYQSh=a@Uoez;Y)-iGc*s#^2-JGxibz1vld;CJC#Yme1`J&7NpWbpv;v1ny zIIjp)nIE5+)oUpXmb(w+u{_ua;x?e3XB75NC7ed&8*#48B{)&wj$FoNp;YwSL)=ZyqmG8rR+UAYOPD#^9$ zUTe&=F*?aoQpbrI*$?Lk6v8>4q1HM1n+vp+D_fl|MVIw@Yu`S&i5r6*D-CBbl=}SJ zp{E0$;0X)4CYEd8_988Wf_9`=-e3)g_d2b)7u9MB?nH4}Yu>TGYVo3jxj9~VJFT6+@V~K$rb1GRuZyD%X9FW^5P1Nm z2&LlHKR>f*O8TM?D{<;xpd9B&Ku!=Ko#%7f?YV}9V8COt1)?p~qn?Kqve49H|Hl-# zhjWJ;Ntl2mg3flJxfu!A%iFSLbRb*lfhSyr_BNNRj_SDwX}I67wBW?>q3^3Xvpf>N zt_!<6%RgJ8VwPv$DTavUoTNqgB`mL!qnMnUMF zE(95`DkHu}-dm-bC|Xi&`jERik(38X&@c;uRq(ig^UmQ)%M$47o(aCt4*cNt=U1oe_8k&qKKB5L0wMU!lMyDB7O&CHTFj66>|y zY-qRXfOB6U6g<~c`9A6UoCTFJDY55K2g~jZbHD6L9eIt4|1?HVpwo|0JfQ~$&y@EL~X!Ag^*#_jh+e~K%GQ&I<9tx+`SnhCNY zqpw*8*KiMoJZPX61`82}B_~38nAPJ>9HK zM%bMP>DzX#{ZD1n0x`d4_#um5Pyd`F^EC!}4<1CRG+;d3(x|zIs;Pd0G{xQiJQ%y23M*D4r}UrhQ1h|p&AO9f~}{Wm=8tM{Z-lX3GLUF zx@MM^BtxgS-qtqTMod5W?LTls_}bi*q9K1+8t^*Cl??YhDeKgmv1ZTaJ5d&@M`J1A z76`kT`K;o%fwUf)@hvlNBIm@CFYXTwloM?IDuH_$=up{6)kjjFIbABcD?(bQY2}=I zEFVf!>);MQ)^s~FtjHIatm7F%aVx?tXo z919M!9y>ZMIy6;hW2*_qIoMrq|8+K@XQ@p_&$wR_$sd_Un}OO57H+z)1d|I%>~h`5Sktd*v- zz^@+G?{uB+f$ZOXxp!nE;pUpuj}csK5Gekt;Eim`ia`aI7V@?SJ-UQhD3&s*E9b^> z_D&V`+I%W^Do`!$a6n{Voc-jfrRpc=YWAyvf3^utA zeyId6&_esrNB+`5Y|8o#1T1akXg|n<@u`C$N2485xhrSEb!i`6ma=(6ArzHu!SEy> zZJ~!-({g<~cQYWwJQ82?i9v&_gsl1Kw}lqM8wzlS1YMA~-y13wugE}(piZ+R5XyxO ziAv|2W6J8l;AJPw9XMy3+!N@9S4# z$o7+`#+yP^wl13CW36g}W)Bpo4%O4}*dc$xk6fev3s;Za2`?ERTST)fFJRG#t-rrz zk1*nz3ghF9Fp~xCEMvZlf}mA2hkN$IgIqGpr9=e7anN;L_Hx-@)ofB~XQ8;MxOEUZ8Z5rJd@LBTy{fhdPTs_!t>qC;rqqSL%aj~96J0=*2X?V$hblMxO~A8@{$O#f z-n%?Hvt6cqfZ<)z0FN#9><&ofjr(xc_N!r}lWq^Zj)S?q+1DO}GO$Fa=p<$M>^}{v z>WEhhDD$6q0a~k%<}Dsp?0;7H#q&K~)mOUxD3`WwC8s!T^1Hjxu<6A6rY3=_2U|46 z9UQ~NKOXYY*Xw^BW7i*G&GPh~<$)V|d*I4wt$;_^1x_Ho(0}5wV>&P44FU`>v+qy> zqoinU!3hUu{`Aec07FX)15=a!;y2ZBum~^DD*3ZH6W?1P;!cyh4BFllSNBPOidZN~ z+0TT%fXj!@J6^JEpGT!m?NV_LBuFeA(S3i@scrW0=)X}6=G8>?Gvo*p?}XY~TIJRz z;ysZ6bF~5gXNT*lh0jj&3y6@7b-wPn&0Z>54{TC#WgMe)Sbj-Cet%0Hc&IyCtLO&` zyZwOnshG0<&>CzSqUAAI+!7~@YvB%%d)%vpJbj(di(FU4waY(2tcXSldn-c`WsDI|Rh{jl6U`~Q|T18+Z=%)netiZIH@^A*U>)pAH+)Xn4i zJIu8lQ-c5K8Z-WqugX#!3Vxtiw`5|=^#bWpZ*}~24-|d53}y$4i}3kCf%aGv!$llR zIJN(kBm&!CLxs>>iO7DOui4C&?luaVbA&%Yi?9E8gDY5+*J<}C&sMSdltzbrzx`gs zQJ72h(2?VD0-gQ}XHb9Bx!3yxqHXyN^eZWMx7M=_#3%IXCu?>jDDOnuDhiR^aRqjG zQ*96*uQUc1f3zi@kz`)MiZCprs~|ixw@II)pO5>(c^%Ai)pup6g!F`9(?SM^(}~qS z)TyGC2moa5F+8AIzGoJQ!iG88eN0+mP3Bh@6nt7Z(67nCs0$maR`ljh*NrApw(ljuxHZO z2@!=a&<6lPB`TA+6+jxo12I)>>RliY^hkpKXjae_4uNqM$i1 z9f;@fTwfnVA~?vsjlxY?E4&hqMeh0KcVE`gJ^qCrG7qOUIt8D zKkucHZT1C7rk&vx}9;4o%SL=aD#o>2IDBj|+{(MOv4buNoS9BSvAGQ~Ac z6ar0R ze;##Nj&g)O_BmKhnr$p{6w19Fh2yb*_jc#X#%rSa15>l_t(KNZ1%*k!8l2z>^?%PD zA@<~bzExHoYEz!xdE0}F{anOt?^-qv_U3&@T0|fNJLTda-4?}6?JX2iW{Fshj}UG9 z2_yP9`}3G2#ZXi)nJ#PVWFx+}cNUJR7jjVQh}Ft(&;^`PcVc}c9O9!nb8HdWHgXiv z!vXr~1v_<)XEl_zRM=3z6L-TkgbH+xLA0C6;d^9z0%uaAukLOh{RsqjGg#KO)s99f zZzeWuyra!Y1X+eD1V!-+eqLa<0J;(N`8XIkZM?gOorghwpr{aMieX{8=E3b zaWRnN4GM}HcIg7FlX?Sivrcn?gWsy@jW4MA-7%iOeTM~2k!AAML60`9p+KjKsD~~+f8V?bl4i=}S#QC*Ut(uxZ=kStRt*V++|PB zb_GJ&!(aUo-1K3c1h%>F0Pze-wMbyjU?&{h-`z`;dnL@=$wrh5L<{)bW1Q~_t?fZW z@xUEP-KCupj{9_v>Ny75p;zpu<-P1v}YbQVR>0Ftdin zMqn{42-oHf*)=W`d#{esU^Bu)3DN!T@82^x(Shsq=O@4P@0z55p(ys>UJ6;c;o*O+ z+3+t1m>bMDan@;`K+p-&Tr=0HJX-318Noz_vyI zAIH&h2u%Su=+j?Cc>5&F!1mij@g{YyZenwCmnPZ$T)p78&rjqE^WYaBl<*gWAK|Yi zk1Id;8R_|QHDXj-Vca_wTaOEtufYp!m~fptNgDV02m_g&&?lhMXhIYK!$245m$5Jj z&vjN)X18fZzL;1V!5MZ2h*lN`#laTaZkTA#>w}<x4>)7l)#5!#48Q!@OzrUVcIP_Iv!pN_RAPk9i~e8ut^ci(r)!s z%)JUTf_tB2G#KDtTe0L;ePO@(3F8zwTc^(gV113&zivU)YCBB5TJ!=B8PRUN`iI28 zY;VAS{e3T{c_Y*8du#>8&{?{hhryfo2^ghu&oexI&FTh>F;xJla#KL?-?7*8$^`MB z_DXrg)(!Gd@vsM+Q~CA=&Q#+oJpaQU$qVhJe}8+s1CiH8AO@>Cwxy~_MMwf3*JJcM zzap&9vQHR};U8W+@ywdXfbLeqfBLBJM=0XQEnV9;jqidCOCdXsn{3C?LbYVXGSV^$ zq4^@K+lfe>Neb|oB=S@}c;*^iblg=00zDNOQ z>NjVJ(2-@2k?R_^Pr_xa@^y8oq$U-67@ngRetq~xKF?Sd40i~8C})wX;_gNgp!eKi z4+osHRhpt2f4_ihg9MG-?E7QKrBv(|VOEp8Ta-YA`uDcV3*veqNHJ|}T-~c^49bxj zd4$D1Le91o&GrBRUu#F9^ylAwij4Mu$udJoRg5UdW@e=~z?8qUxy5^ZOM7vfqS~uC zs#4q4Q0apYF;@Kr$qS!KBAcE#WJq_MF!864j}Q)%Ai{Y3gD_M?8y|cU+iSR=9%M%k zh_Jb?uo2m%sBM@UHgzclO2O{!hEDPzmB$edbJ9QF0K#OSlRE~;;?aSKI7FYCA-f*r zsw4HA91ma;`lY02!&OPo>ZXqX7O0ft~F51l=zxB_qyk!i|w=H($fh;6V#*J+|O< z)YJgg#*0zACQ2fd?@ChN@Qy_eUp5w+O7_QG@^=} z_};=b8y=OYLnA|4jWHDpzPrQ+^oe4$b?no;JcyCGHbR$LI2dmS@pnzSmK;q3!uh`I z!6*)PwMC=MJhct7`t0FrZJPez@R_(YazI7&g5qNu z2DwB}1e*V*wc9Q#XTAomJ4<9eEbQ#aZ$_O)i14l!xbdVG#Q(DIe4=+PC9Kl^Rix+& z`j3@mtDq9hq=b;nQjP6r@+uDs;a)xI8}ld`gy1R*ZgW1aL!=w8WrGJDkLURq{9ZzI z9Th>3uWL9Pxt&|t0>gxkklmB?iT=v&DAcH@2*VU!t7c26{+f#Xg-!NC2a)tP;_5|< z{16zZkgJjkSgBMBh>%yp8r`UmUzzZ2PM3rWk%1J7b7Jp%&NQ~UplnagjL(i2GjdVz zf`kN)zuDYc;#X1pwa3-IEpwJiO=VG-D-@8ROjpm+75!D?Y9D$@LR85Z7XUCcSlAFp_mP`3tp!qo+e0}6dMCyDXL znanH*9K#29e-ENwciXF|pwb$;ik60Y4fkd@j=Nd-^VVnDHCLff=bkX+s52AJO)>7JRBR04PJsw8N}6Yl$VW*cK7R$r}w*L4KP2P3|h z?TUZyi;$z46TM95Lwgn$kcw2X2bv`!77ormSmY}t-Wv(s_5_z18Kq*GgWd@1w8QE9 zJqNo}Q|;7#U@O+04rl`Z=*Kl;o6`f!Ry=OS_rK(&7AY&4Oi_j)zia)Sesz1B!>lNv zQvGYZm`*79L;z$ev)Xmo>CJC6xE8S z%T3mc#Igxqy=J#SD*8q-D6=rH=*R~B0l zpn-l48oHLYUiakpGv3rPq+FYAXfqTxtA4L^P9ef}_sH}uo=Ls!zthT{=+{aq3)z0D;{hSOpQpVB*T9 zKOP1JuUAx6JUB3>w?h^s-i_TmfqS61h?rhze)MnbN5px7)5fEj_u(oBf!aAl2uy6f zZLr#PrqWf@uk{uLcnE~Tw$VDRpxEXuNoof9KAwnQe2T(~RYX)nK69CEu$Z$Z8=-CI zn+h!}a3`BSKh(A&&08Wef@Q8OwAb<0!l)UH)>bhDUpnWLW_}CXyWrO$ zwMw*p!If<{z-2c**PESfGpxaa? zYd_-b`klmYe0|Ti*LRSc?nQ^=>HCh1ti?7wz|TeOz5*(9&I@`B*b=AD^_JS40D}?@ zR|H!z84rbVg0;itjz-VB$`jeyT?1WtA#!B*pX4?x8A+)1q*iH){jeQ$i8rdsI#U(FufFH6xy5)zGFYwIhc{ z#9mC6pgQkhaqs2ee*Kj&FATO4aOhi))WK*P@ZF5L$HPV)+oP~O&pbr}w|*|jR-SRB z|Haj$;_M#nC%Zcan|`CnW9pSehSd&PY8*SCU!Q~d;kCx!S}-`*wO(EIFtRs{tkD8K zttH36r%x=IkGFzZnG}NTtWFeiArlIPZlUOB>|&J3Bv}o276>6Y_oiCQ4t52_5oElS zDuG&e<3Tlj6ALCd?7b#r?K)o@;M+_AfzUPLdb@G437a%+Eny=_2TDDJ*n|R(w`Znz z>_)e9N;L{c3kuvDB>W7hgYuO5}Y`6xx)IP*B}h6bf>Li>m31U1J+mNDe= zE;KB&ha7G{>%MdWNeVaRrpzp^YN-Rwk=V{?i7N*d2|<{*cY4hcD#gKRfRtMBa;G}U z8RGVT5kg*x5b6WZ;>KZ~pvig@tNJl7)ncoTZ0u+>00}S3ft83{Yf3jt@i6K09T10J zvNN0zhG3x$*+Y*XG^R)_^9aJRm={gTj~;Z^Zz*%Z26-&xatif+b1pSupNHSp3Fkv~ zC~_o}qEIU7%wkPqr(bhHvFS>SS5g_vC@o%~WJK0rfoC+I?>6TfnU^{_TW6+uFscZI z7ga+9qZg60;IsSCH zQ^Xg0n*$h&njJRAdCIy!1H&cc-pEo99?U}K@S2BW)e@cDk|N7MZJ?MAKP(~AdcX_L z>tqYGPT5-7O@ovzofasi>EI_KuukJ=nCGPyl8X_&R9f6!^`i)VxDVDo^-6c51X|UW z8T@-hmb;pQBBbW>VobKt7`n5tvPPl0iTn`;C&(|)o?OEYnnu(B7+knzc<1~{cUfwf z>221vxeAUt-VQk4F~nG?=F`EJ=|_!n!r*FVhdPO^rh;zZfL74Y4q5tEA%2am*K;W= zM?wu!xA!61J6=Y%Dv}GIL2xod{x*M)y3xtG89sP*m|H}JCEt&O<3w=u1oO@G0DG+v z+Nhz?%qA?OH&Qzvve@(^wTr?uP@Dv&y&pqtdp1|8Ttx&1gCB^4l`7ou&l=I1_yGPwwgEdr*WbDZD-_S*Uoxb17W;@=g(9wieO>UKlTFJCy5pBoq%bTBJ z>eYk5jq(o=*?6ju?G49*^PcdT33l;%ZklEf~2*Fe<1)~;g+iTqZmB(Sgh4Wb;ejcr&?}U zY(Uhied5oSo&O6#s^OUbs*}pSLnCIz$&e*1Gh%h_QcJjU#OBVvrGJT#5k=Ghsqk|} z#b(VoN#bH(B!_S?lxBjA_}sIJ-^6sdaq*2T711$&pJ~fh=*5df63F6f>~jS+u~Gm) znm8j;MKfOo)|?(`GxNPYentDFM64H)jJwb! zx4Ph-u{g2n-Z1|z#jl|QTpcncNSP(ek3FdLIkV;5#x)P))6I0Xh>qydy*;=eoI)vg zf~HYQXpu_yO+ zNK-Jqc|UpBDYNBZCd8pU>CTLs_Wq>EN=AniUq&AToW3>Nj#2_mH}foQ`GF=aw3a^M z$z*dp+5*kC13vB+a(-`;5nO_mW#ym}npRE8`O;QWXbMV)r|^&b)_PN=T2%3(AEd8& zu0Uz5B;OrKTs8di)UQiLftXbTOqUYv)J=f;PCUizi^yMMVV@_GkJ3j3;?$&+Do@GH z8nkC@A3u0mx!_(OGbxUDOTm=|L$Vtlc@T^@Gnb>vYT9foI-*XRXVHoBa0~gpmP!*j zaUKsfP4iMB7th4z;dxM<`BQI(o9xHp4%9f9iyIZr(r8yLe$e)ySTw;VJQ&EjJ53r1 zLuEwUWPQnA7v6o#r7Sc4w&tDSR$JH*<}#~VmbmwsbA#HIJWT;XMPo(! z$*bC;@y2Fwz8cd_FD1bZOyFp#sFS8OD$@0D&#@swU`SK zZ~7|5A!)Uc7zctKf1#}@oyKnc-jH*K1kK@zB7}}sV;Wx@5 zomgFNQAmJu&xb&&Ca-0b{zdleOl8o1xhA7|gVL(PQbR7wn~neIJF^*w{(#e()9-X@ z#ebT-Y#R{Q@xklghpNC}4ht7fDitZ4D#~lR)Jjg_VGmjDco8JVv9#iMHWHTd^aXva z(TZU9+P^y;v#6S|r91Hkt67k}qm?W0ApE-GO5RVzLYPa5p^GCg8dHnD#{$m(AFA## zIe#5*`D(xWJ!hORKav_XlKQcpwPt2L zweD*c|1JyOy)c z$f25zEf)H^Pu%V{F(%tZS4>9u1W|pi5Tl)>U|q7(1I?CHdTG0lR!a0HfN|JdO#HC> zOwe4#gNJ6*>bFbxXIlhoX=ePnSppoUqIbXA0LeR>I?i$U-pNN)uR?<{P@SG`6yOSO z!R~^QPWdOCwm-!2TZIJ+jft^rDI^B!`iIp5Gw5+G#v)p)tf(`_U{$2^YkjGfYCWHV zqPhLHOiG1FlR^FZz1upjn7TUrp}qt!!bYiZ{7E#CJP+lJMJe^DNKxOqBl1Vryq<2S_>WUb$PV4> z7(hXzEsUw%m&n+<5p7(w@gw1`MHC}R&orNWMcoYE2KP8HYlHN^n)ZrX^gmVrZTbQ`MWIwXa3-cLh?yiZ{kaAnq)GpL z_2BlY;=!i3q&M;y{MAJe=e-%=l5e?#zM^f1Zu4==>`>gN%k?RHA>X#A!E)abV;l_| zi}N3I6qMx$F^2ZuAl+0Z!qA(sLl|9Kiwy%Zut;PGbAJBs&ZV&YdjoQ>}**l@FgiqOi~3 zDfxdl!ZBab|07`+|DXe-cQ?p%Wn-~a!Jp#cPXr9j1=UfM*1fI>n>i|rykmnKsNhZPtYaCv-TwrcqWsvANb zV+zW&r|~Xr0OE@ldf7umI?KQ4D=P)fb%`^XvU%Y}_^+h{`{3Gx=ga=L>@ql}mbl zx97tRzy3xDlPEiff>vMW{zE=Q-4DFkCgE`J$3S9Rl`rscMvbkN$AsyOd_Rln?-f9C zQ=UvH9x9?&z$NVM|Dzb$>Wh-EeVQ1E$J=vhDhkk8Z3rKk1d81L7@Bbg@8q zR(+2}q_$35G*Ci3!14^8@{IH{`GIxHX3M|Q-*9NGF)t#N+b67c#{7REfZ(`%T90Oz zWFLbF8(aQu2@~hk= z;C6{ty+v0@e<;Fiy^D0W2TKI5mxjB(?~K&O}btvpAOrg~?@(A`c zkoD;0Z)Di@V6SJZ!O@Pi+cgtnegGcR0ZmLr^m?9qa@G?JePcogYP;Tv*^faaCTH@}2 zY6-s~nx-POybsh_A0Q7@>3ca=WKR8{NL&tG6L>po#=?k_(|&ia3<{3s)xHTksj>*XIN z{fhq>>(O`i*L~y0CmO*5?L6Bt&+Nd%&ec`8uk9;_OD(UznucXwDQ0a3NslKYQ~HAfo^)@_$(Y!v_#>uc%ojL6msHH78+`9Gda& zp0gz>eO6{Go7W(9>}&f%LZWggwcz^B3!T_g_{yy&o=QxXq-=lsjY?Lwl{^V;UZ%SL zI$p!1n7UhSW)Wdd4H@+(1;ilGO2)9BJb~}r%fcvFRDob9d%_e z$vbweYg(nllAu=lMUQy*Sg{AmkaXW*8i_v1}L{^RTL$Q_aVd?A(!@0(imwW`MG$>&ADA3ht|% zHgu(}*@z+Z-FA(TA>Gt5l_zs-?HPG`!hc|e-D#|UT?NX*e_VxyCy}{kK=J)65yxV& z`{Qo;m#ykN(4W4HMUici2jdCRg;w_ArtGjgLXHw)yE+SCdig4CV_w^RQ=I81yVpu$F8YttH;EYFDR(RZn4`Iri z=7s@2g%2yV66^xU=g;M&!~n)ofYC=(f)g+Adw0X{^p+Cn^8dW29ZX>a2d^$D={PGL zn=cNk)j+JasObEtl9?xv!eA|TxB8gh!zUlQc^*{Pr9FyxVxdPY%65^^ zL!JgxS`Ph3*{~8iONcjKqF(SERC#$jDIwYpZXP^iRXPj*7;(IhPr*n>YaB*(^595r zK&}lQxW@{%8%@jr*zU7pD`}=KgK;iqivvU1qX%zwC5=G~sQBmP?r%Vd1CbBAaHlMA zxB#0#Q+ayHPN$4kw6K=ki-AxQpg;2UG+CH_h^U5zXvZ%S|6M~kDjZGOYy^vn4$8Tn z^UvU3svM6GIvgcZYd@)ExU5LLnz<7d(2bgAZeitXs@nvpplPuq=V@bK8!vj~^!T%~G}%z)eX0ai zcyb%4#ss4zzuA**f|iDitY`KqyOhk^QlXTLL8--iLGs`gEXtd%Ef93$Uv|3kY@|x z3I+6H^>}sE((Rw265CRgUlbKVT!gvlf``jxo;8lz+y-E?%tAG}XUD1LmO|(AJXmgy zD-6}0$7~CJ?>+2(^&LS6$XeqPc=A?Mu}`U*79b3Dlhzjh(-ShnlM?!|)N@#Mp7Igw z7m4a6x+uh)LHXsv({>R_XY_J+;GyRsTC18Q|D7gQ_h-j+&Ysg__0D1AIWq?P>3U*$ zmlQ15cuXnI%OJ~sV-2fuJk0*z7Zf^9r(hf1HF3vI)KaH_tOgGo^1aR3r>epwjs4x8 zwmCUz_}S#lRM34_^vXQh0ykATP0#axus!N)qT6(_G%&10QP^{f&RT8fR`D9k9HBgs zze75_?xheBIE|CH2aaT2#1`Qw(IjTebj{E%XQE$n%c(Ko<_*46%R|_6TZ7WmG{ARz z=I>V*VypWp%2mn+iet(Jx2^#*2%T z=>3$zGGzm@QD$e-`B1{sT^T`lp2J!AJ)T(5!Jkf+J2+OdBh(EV+$KWtg^ZV>O?42& zsI!Wp(4U=Y1a}_b>bqv2I3bi`42xJ4yfgQls9|1kGBsiCcUR8mujY6TgO&Bq;N#(x zt%Ou5j_Qah-QXQ5qhgF)#S`f}GFMa)2MTFaK}xyJ3`CcXYFXs|dB2*iUo0Hy_KS9d zSC^0X4>kI(2y{j)&#fYf-7vf+DJmqkCZ9QUlsgH$d^|+xJf*RCl>WNZL<@vy8Ru=R+}MAvX)Ft0el*xm7XnwnKiXitU;jEr(#7M zFRB3H07!ad@ye&%ER7l2Zf{v-LZ4_(H}OfXyFgC|4_3H}3T_{%u}venU2Y;Qqlus^ z8a}DDk0J~29EtKJK~$e`)px!qFrP8)h-!3#WWp9l5`Thf~i zqoWP#RMb^TN+mJtGJ0yh9WA56__v07>zKYS^ZaUF#SDXv-k6L3WZX7WF5m7pv$T05N2q+}x_fekhD6{Cvg=C_6qm|J+o zf`hbo>~TsBfs`snTXLYNj8~#Ss7x20$S!M#_5=-)F!!33N2A28)z`)PcrG^30wSl% zdBI{f^Ztjq+0k4;y|>QL)~%{kF*ffa`YWZWV+G#`icw%^h7s?b5h~6nI^!p4SzQG= ziIz-`>F6B|B!g^wa4uvi?jnS$eE-CL#hbkIc#XA`%rO5#y z_~M2!_alPx;TU{su)bPdemVaIFtE=q%MV8lE&dYf zHXWSE4d3B0jUE#+nZA-R%v>ApvK3d#MS4d$$loTYws9xqjmUkIBW(?(^kZvwBp1~9 z7m-i_TV>a@U^0`^On*T>665((GYiWO$W;a}8=gA;nR|WPtDsPfSp{M}00@0T6%_cU zD&@0x){LhWEZA15YMv0n>>Zw6`>v$%*x9n^UETc$xj=qhBBmwDhw)PVg?RHh>GEH>xj>}+AfnCOD zYH-MuEr~o4vq+VMg}BI=xsk&G?O`0gY=Opg*7C_!DW4I(EP0pWiG0mmi*F=MdHomE z=vey))WEZoTxJ_IFTxV^`hzEeW)?Auq9)wq`KqWOjWudjIUBVOm1_-z>SPPtz#YV_ z5I|VNS~M_Jov@+xgTJGbptdv}E5n&dH^dVu$GsJEMjTcCl|Sd4kaigt-Wxa)F{VmS zH{_31)_vj^nKM->x-=#PVnj9pvR;t!?EwA#=6YqZF7oJGR8*39H8CYgdn`*}$08#H zb2zBkm^detTJo-T;|gQpt1NdH1A1&!kiL5iZ2#JP-`SU^&VTL1(wxaqlU$ws9;B0} zQ0xTEB3VpxkhHKgnva{#P)*WcziuDOy)$<(Y2Xe^Qudf=b~CiAm*t+(B0v~-d@L-S z-qhktCi~J*V0w!|6(34@Xz;PHHJ zG@7Fj{{L=>RnQ%b8SwB_*J`Z}3ex7gl)0V|q06*xfF;sW8IK`SNK*LGYPpbV6V4)} ziUUS~&apJrtTr_2#b1A^6pM|`9w-dHi_ZA4NcG-la+U|@neyx%tiDqaM)%o+-NL$7 z7!CAH+;5-lQKBn~>kGNE`AQR`cd=+;zK3v`4W`qQVIwgUd>1aFctPM1y81O><+}>+(C5&=- z`Mssf_qN&=(dY;3yQ|}H;^|HNY>Q&y{Yl=Hd8Xk-aX&er$q|f99{RLvl$F~bT&JoaMg?4i=1%6RE%$V#A1@kAqJo_)F z9ji?@Pc#VX$oIU;Ppd!R0&AvPaVfJk6!n#JbIJ@>A}D4dxq_D!GmV`}^E%E>y5WQ` z)2yVmGTv=J+#^}~!gZ)eAd&^L#dy{JcC>*_X0sk2t$yui<3(Ra_3i0u@A)5SVqi1b zm4l_7nTJa*#72$fYO7CPX1>n}U>#-Sy`E=Xsc0AF-G>Z>K4O~~xbE4UEw*HM<1)a4 z=Z#ua5611k`GhG5V#7pbvz$6^CQ0M%dZh)w_Sy61SSn8xFs>+3i? zFY0pA50hs09S+V$lr>k}z|GobNiMb!6DqLU+Vg?kaN(I!PYkEi4LttXtZ2GaUFi!S zp$-VXsKjD8I>)rr?|x0tK{!}7HIosAE6 zQM2ED4x*|0hccFY5__?AJ&VMgM{g*oV)+T{LLyP@&hZV$T$mziba8I%L1;q_4Id8q zMHJxuRTxD+?Od-Pb^09~dB(n1GKBBU)ttCxoup|ktynzdO~-0en-}P|CE#o~9J9@nEk!%h z&-nmJoux>I=PCs)u6dL4t~>!J_*}?2J0kew_4S5!JfDFoUKe@^v48BOk- zqBn%XjOxuu-dUfm$oOvdZMJ%DrXcBDR~{MMe7sD2st+H!tC{?9yibxieO%mGdk=E6E9nlUnncGy-{FViUOm3!inf+P8miSsJ3iM`>y1l1O9jnB)^5aoO!X zX$KrU#otD+%NVunUnAhTF-&`V_F;*;MRIZMMYlczEs9Vi;!7bfqU}4r&y0~Tkur1c z5hmEgEKkbU7n=Z}gF|$!Pb4^#I)-7liuB*D;!!gMiylfq;=zNuauG<7$eQ6P1b4O? zyr7ZlpBm%@8_f{>HT#R~SqE48z)B|CLRudp-dbAI)0<1B1#x86NIGgb`(!-s@_D|( zf#qZux}W(f+7vN3w?Ggab=O0Brc7>_(E=hKoK@pQ9Ah|z1V^cGZ5O00kmXO!OcJi1 zo(Kh~*Eq7_i?7!{lW|=kk7r?t2x{?C2HMq6SGe=_DwC&e^yX$Kr7-f%QVq8R5!IRH+Lo#G(N)zb&H+oje}ETh4{ARHi1+~L1q%W2DsXSS9J0b}H@pfQU~b}C zRf>s_I33NjknF2V!5=oT(Q4dLvOqX0r*Y~=rAn3A@gZ+W1wuMY%1gDBl7&_!g9fDi zUkArRSXKj;Je!@=4Xp(#vv7Vj2Km+AV{w6(z$z&%hpCKoT-w10NfXg$O}YZhT!!r$0l_KEfQlBgfCzK+XYzSNb;t+E8=K6 zilJ-roCL&ASYj=U_6IK6T3TIOPS2SX^+$?@Enh`A8non0r+C%lX)F-9S8_H)I_%fs zi6@P%$d!J%_N>0KLVWk*e!Q>}f!DlpmM)^GiOvLI3ZdX|Wtk4Tl=#_INE1yZ}_To zE8(e{WDzRWF%zSc&Z2^-qqb1#FM!LfSZo7A@xzFVnL;&$CI?xDVlp_ zlj(PiE52xAh3)RBv#Vx#RLWTBlU@OPo1=T?kTs_2^Y3rmm40HSP1^C+?~!s*N~r~N+;p9d=Va#DqKVNHBru7bq)wSW4!8w4%n>o zw$VaOF!>9!pRP<-m`lK=OdJJ2BBE#AXGm#R?cwEQb?VA&|Hj7X)IWugWK8jdP<;4Y zyPqIz;KW+a|2?=Q<4AEuh3E4Q{j$w|-Q9zYcLT=9O>UsO!1x~L zoyKH{%k;a%JMW*NTO7 zX$I{4CF#2Ngz9ZYsC#UclHYiP@%FhD^1HL%bnXj8VOOx5AmZ`ZqtGpU*|{95q4YCd z;WN*fJ*SF4By(Zl4CyL_-#zL4V!!TX@9hk^AB^BKpu6;aa(q+WftEoG&nv?9YmeKW zCtf8S+!yl6$PCVcp=f@tg0o#5J1Z`f;hd-b=_9f?Z(DuuTw=FIZ^E@`uADFp)^ICZ zL&>rFdM-wYcXVBF>X<(}rnW%MWfSn8zKdvH1!W-iXC@!Qa6gKstJH;~7fV~K0q@UH z&3whq7DnyM)*x{@PqWLK;hU##^uV=4p9xExJa6%imBx2*_qztfeMKIX;{w))wE?iv_7(}%HW}*TT02_d&?jX3zWnhElY7C zHO8F|LV$H&G1ff`qA zEWRLDJD8Y_V^6$P6&2Ti_V*rjWVQqAQRaVbSm_eN+OOVuN2s z9&qrP<|n4Z80^GFWmKMm2gSeeZf4Z>Ms%OKa zLy{+b6)fwuuwf;sB`DuVTm-``NLTyYIs0>U7R*chTYI@ocr;HJ@#15@@rkD)Fz1q- z-#bWXgK4V%Oo5L(f1aa{QJkm8m3w~4n2MdJCB1?jwjzaF+6vd%j{UH@9SyI^yz2j~ zM#$;C9v*jOmY+UBdx*^p(80B<-;d*pNCQlQHp@LYnya%y&y(k*-<=53v#cE3XXSje zV}U&(Wk?P;R;=aAGX^YHX?IvJH1}6a5fw+R>`@Do%h@j89zRW(#6}b-FD^4AySy6m zAf(@lS(Fmk0*~iEhHe2q5RS)NHlz?vFACuHEu`mYn_RvrQ#ok-rc*QN%%vxH=0L}X zm?iU*7)r5@$4C}EOG8Sv5lxGl zOn|ai(Z}#eBuQDC+eCF{Z8W~zYi-gqdSnR^IikKxnPefeTAn%N(%_QP4l| zd3Wqr6yCs*u8U=u9^v(n<&rAESWN(v>T7b#24ITuR#X?WW;)j?I%RHL4pPE{uQ4u1 zv*te1ej`D##OXEbWJtTA$2@*X|Pkwhvv2WG-cX^#N@mH zs?83CB4FXn;#oXK7_~^rOb|uqf_FM@;$pDrys@&E=eWaz?&!>`^`b}!qqhLrSF^ck z(`T&syd?xmC?4@c9iS3>C=P0s-5_RP5LtP%G?Hn9qxRcbJtQ(;{ME^6Y0D#QoD>$q z7DajkCD;Q;7{@5?cGVq{#hNE$u@_B1?Q)EUvlt5~G0^1Urd5$Otjo{EPTl*&~$Vg#-v{49sm?CtjFzwnft6J)I+`&Q8^Vj$&%lr~mwXh{;Aj)Hfftm%)}m}k9T^bXyWg=A1mC~N1W2Kbe(J7TEVx6JC~_6V>wMfZA5m-u7769 zjz4UKu_nfW%IvevF3G5xQf}y6-xj9?eNEx>cDyDupqUYF8Dp2msJD*7B5I)SVhG& z-vCDlL4NvtmsNG@vWeZMzaW>0h@+{<8A|6oZFVaR2ge8^K1XAiJi(^+STuSgVy6eWZEb43r)MntE$T zhl4))S_S0kB3{f+j>VZ4+W@}NukFUie-}kUk?TZE*TTr`kHQie?Wr{ey;U0FvLH&) zN*C6Wnv9d?SAsCyobi#KaD@%NEVfB^J~H=4IWouW?r`3!lQVUGbsDOZE1jOhD-Q^N zg)gwz;#jCsdmqn9MAPb6IuP#>dcLgh&&9Ika?{_EM-LF4 zSX;P|k?K39SQ(b{U6Uiq)D_;8D}tnwsS6zr#>x~;i<(4`SC_;}Row|an=vvGASA~IV(mL1J7KO0XI-KbAYJ;*;WiH0!`EtOrhu^D@l3I%Y8|1m zjN-#C`SyQR5it^8JkV#FP)y@scKQcmJk0Uzhe_r8OrIM+kZw)UY(&-yf9B>;8rZDH zhtah>>A~UCp9JQ6{(vi`7l`$u^70AE{*y83nr~kf_%O*V9t-AR^<$bmod|}*FBvB{ z9W$L=d}vIEaYSSbhp#tJmP%>bC*@eY8ICQ=0w;S#!P;TpVhi>_+17sM3=!6}0wT7> zbEiNapHA~I2GB90{i0wU2v@i!=4+#@g?t7}~jX&AxzDj*qwMHAvU>y2#ZSn-wP>^y}KiUwosqZofNYZiAa4CAa-Y=+;=Zr9Y*Rfu3W*6HJ29{}d5Ou_6 z1Uidf^{FXAPQ_)KP7;R|K@+x9Day)?1Za*2%_NB?!m|p=hh=!m6JdUW& zwYG3LyLUK*5NcslT0ZwOR#BNw`6`?xh^S6cFb8Nu*#1fljVM z@gh&prd#00hx!;slcV1~6-O%)%e8m;`R8nGpj_)(#`p)i1EkuOZ)rQSc;;F3RKht9 zr_`OMe_-jOk)bn*b38FB0lwal|9z(2XzIETEjA#Wh5}f0#AS)>ZvU;tlPbPb0i!9> zb#i*M3rBNR^7`Od(`pgdE?;bVr6W4TTtqxcy4EkUQmL%h#=(rhA$#D)83EB~^+(`K z>hqG27KPzN<(+Q0pb>lkYi@M!E1I;DO#DJ@g!^JQX%xDLWZK)iF0u&Iu#1`2Dq^nO zd7mU;LZN3RnwPz(Y;Nn@Pji?yr?9V+v)86_sPRv`GY=?+=fgn$FgkHQVci}YpE+E+ z;_Y@0IHtp%6e0{q`%gQ7_E4xc6Gt*__;)qpa9E~$DKg$tDt`TWzl>AoilJI1XM=2u z1*@QN3X;KKWM+|K8@wHIn1OJ-(EOe%Dxk$OymmyLNdJ^Iax+9qUyJIM?IWSj#WMPV zb(>}K0xp@aZt%KouKxDESe+cU-3j8hS8T||pLu}G!aL(vPz!n1{1m%w_En^wssouolkam`XEQxIX`TLJ2~gkZ5TEdT@sf@f zC#iuS8*P{#BlOUy3(qvvD#kQr+(%2hE88v;L_tLgfrcD)7GLp^#(dC;G`+leUizj; zKDiuhy?nGba%$J6mz-}MGx<4zU>D1Z4f91`xe zG;X9FMD)J5Q>8+EI>EWVsf6+SsIGyIkLNL2fKIMrc={0EBKmDNy2wV?pHR9o%ZVbk z%~kpj4B&c01rc*~Yg+ei>@-UgA+m_JsS$sELJL$%=) z)EB&3rpPNb-oh}sE9@ns$b~>@uf!J1&=An;5AJDHRm3N0wCIjMh0dbsHfpf?;8xM^ z@*RwgOTFO1L~u{d8NFLyvPc7oHy$QNAdtwSA(2In{hk3a_n58f z9YgvJE!;b!d5MRhKIrvg+O=+0HY**C-z4a|lT^lLXT-wkJ^R8pen{LMipYbua!`Cb zarEf6tkFtcfiqF_bKpUwEHa_c25n$a(w8hI@hPRxM4OlAa`b*bHM+WY(eT!Am{p<% zJl??iL2VAkucJoAGKY~~em}lPXp;rlOxicFINx#c)8N3VW9xV&KmxQwV^}LkZ_>|u z*1#lcl^#r_HvE^bRK#K+3a;HU&EQ)LOUr6l$aXgUSymNdOD~3R^tD{3YHa_bB7j!{yrDwC0;?p=s=gNLupz?1}5m zMrX(n+9&e?l#Pa4q;z2m#5HmT$udTsl3~v_FvLFVz`f3!ZZ;=1NbQZ5sxesEv--hP zKbm{Guhx88KJbYTTG z4fSNt_0E-b8gKfBSR$K>Lvf2*cjP;4G4Fii(sckywFn&zc4nLG5?N#K$|Hk0+hMfU z$Al)rT}pgMU>6bwL$itH;#Z7JooE8c%E-29_t99vqC4I(v81D2l*HOPFJq=$Q`>nlP^^mnfS*S=CQ~h=pEh;#U0_){chl$6g5| zTUOFi>4)dwEQy0w{A`#5!OK(TYl*#nq(i%tCyJ7$R)5k{qD!7Iq;XL(_Z{U1RH@|M z(gaG4Kj5NxH@`W$TODTHwcAR+$ZRN-TUlge77=L7W|V0PKpaFia@-ToiZxb5;G>Wm z%#qq-FQXmMwa=?_#dW%hFH42|;Anvh1#9zuG@)q8f(sTc%$=nYti;1QhhFKICHmUJg3_|Yxb$)M{|Nzm|DC|C;+-!bfF=&;9m)@oPM z%lRVO+4NzjwE|S5WKneZdcme`wuK3q#qQaxcjErGB@*j7BCw3WeBb{0d0b?Z)-6NK}WMHjO~b!`OzJ;pTjw7SN>!Zl+Ejx_#v<*h7UE2A3?VF z(AteeO3mLT=OJ%r>?1E3)%Ko*U>kcr6f6Ml^>`Ols0|h_!i%-2`@=RExi*E>uYLgW z62&%xzc!MAqt1ZeD;;eEyIC;uX+1Ynv&lSM>OpZ}V?D^1!FT|lQLNbB*T@On=w8YC z)6Ms@oK3@^$yy6e?CWs-k;o6!X%~Yl>u(F!R*?ZG_PQ)JLH53}V*mYZiqG&Sep9>c z=KE{~N;w5`|l7Yy^(zrX8^=~MK)AbuH zHJ0vPpDdO?TB*_Ev?_ilj;8`SpF@A;ztkaLM79_DZ2JN!fjhO|Bn#fNk(S}p9Zj7o zOoHN=x$CzXuywgzc1r%B({&CI=uvYjuCS#?!_A-dG3`Sfx)AtH+U~N+WSl{cN_6Qg z{Ia{;fLe?avNJjIc@p(B7_P~bUuh9ZU5Qz5zny)V3XY?2b)J}c^Ka{KBKgRg!)HsN zv?wZ}4?_x!!kC2KH(Rv3P=S zXDp@s+KTOEU8y=Ku8OR4P~5|nFE!)$0;aygPT0(~dlIzh91zY4s&o$1!~1bKI;veW z7awAE|w_9)7a3}vV{Fo&Wwu|L*(G3@fonw~C z_ciqakhg)i*{K>}@Ec&oP5NDXrTu_bhz@(_=w~o;Q_M)2qrHXkh&P=uyK;FPj^ZGS zcF&tezdCEZ@>5*{Z$$gD__i+r8RtiH3d>)i$qH~nrJmobN({&s>@><303w@g@@V1Z zo0M&SnDMOHb`*^5(5$|xcb~9_HGds;v^wimvc4z9(fBpCzH_*Fg=wbm?1wJH|C|sl z($ssIS94zeOT;cR2j2e5x+F~lvH)}Rnd*L_vPKT`@4%^_VCqCk~)(FHJIyVcA`Ih zY=Uyma{3DToN)OXk#({MFQMnc>2tSd{A~Lt5YejhaX6EarEESW_QONp7XnVdxmfdr zFd%!nO>OyCYqjW07nr|h_*2@Bfa|QQ?b*G>e=x~f^x(|4IUXW|K&%BTRf6_`xu6O8 zmMED0jh>#=yS(4oo?G%GI`Sn|oD*4Ref{$&IpO57FZ3g1$-lMTdU>%s&GBJb$SM#z z>wqg566d@C&*3G~b>H!n3w7o?9@u2Qm7W*7fIjs3XnV3KJ@m{ttQc9_-pAn70z`~D zWmeeV;oZabrptUAtX1H#E$}BUKtK%({6b_r0a93yBX! z#IN_o0!pd?Z!DEhsBGymBu7g!6Gt@Q9miw_>zxRU7M0M?+M$f$(O@EI9^F=Sac}$` z-8v{MCHqqeRWWVuU%|8W(mH9u*~44!%XLS;b;_Wd#8M#+cfq!e!V-i(hLSo|^$A>z z?yjS^V@fA#2u7e?MN&IVesK32#oL$@L&cHXx%Me@1|>09U_ zRlofF9S}WizkCE?vdAPFHLZZ#mAFw#8g$%vj!tm0`K+xATQex*7dG7X$~b$Z;5~4f z;;wJAjC96KH!>IPFAasts{f=?=43*7b{uq<)e}dOUAk` zq9nfc`j_GF+8fK0FqSCg2PLahPKfKSAQqSeCxDXXRCaekWy0swF47a_dE$h zS~>XlI|*OhWg$T!lqE5Ur|HLmzigZSrkK7z?a0{mfbBV=|iMIc$M!lQK@?>+K*6|94| zi#|}}CmY)e{kzj)kk-L~$aLg#tWKuFdsHI$BgYCaq-LI;c%qFqBajo%9ayI{90 z{a8UHq7~=0&uG`6Yu0I3*=yinvC{6ws6*SFQ<1~%BWNgvh@;aIeCe_WN|XrU&MKv8 zUe-N4#Y|N(CT{+$j_8AgL;JvGb4}?7tDX3G3)zA(=$0ptQh^ziHPitI%#GOrn|8Le zr(XDSNw;1QWVZ-Eyl9>ca2wXzH|HW4evlQI{Ein;ig3Z-i#uqkBKp;wl-_phN9}jW zTIj1stD$lMLb-zs!}N!w+7^TPbi|sQRS2EaVUuCx1kiA$mhG^sw$kH10{G`fZE2yC!D6@flBL4J93c-A?pr-Tl%>EW-T>kc7rD; zeK;4Nku+Y!)VTJr#>ch{P;3~cMX=LC?8(atFl5sUxyOZXW|Wz;o#-aGFxV*ZL1OMZ z#aOk4;Z2=MbojvIbk>avTC9r6P@aJf1EqQfd59wyyum-PztoWmO&$c0PPDAfkNm?! zx6P^;Y4~)9PE{!K7tPt!9HVeG!A+3Vfa0<7E4ljv)dQu8D6>b?XJIU~!5<{+!jDZR zQcSyRM8Vdb^k!yQF_AcJ?~bwg5}h^LanwE4aP2e@4A`-!?QK`HAD;$qmvX0$8Wv}e z4&O$|kn6%2gG!xRsQ~44YtH6B#;+q+7@Y|&>xs>lo7r|%2N4%v9|VmXF*kCS;kr}x zMCbaQ@IvhQaVQ_pigszn#`$F{A zM!My)G;cj*=3UK3x5_MgJ#UI#v>C$bYb3`CB=b6zj@-2`-zOqWId zyJt-F*v%NvA?LrdL#mbDg>=?N0_A}eJ{DHtagCjIh8H#)%BTV2()(nA}| zV~bv-A*ul3fkplqqy3MfUZrO!3W|rm++`92^$LEm7P+Ia%3aEdbA|77tvIvOM#S)z zx>R0WUD%aBeHKpLQr238F)nd2eeA!r`d<2@nTOVNfNR^~b^X|@JlgFMe+BjeJAsmT zcE!a1kG8jrimPebg+p+6cXxO9;O_1ag1fuBy9EgD4#5X^2p)W}1eXAVpSg2CuY7BL z>-;-EV9ka-wRd$@U0v4QeQIfhS9S3C6aavR;uY<)&7bcB_; zaHNsC+3Qf;n0CP{c?0M&M-s)UEKo8wMxFz%D_HDr#P4(wn*xsI>o#>QP?e@em5KF= z%6ON8B(QvK;O#WllI5t>t+gu&PC=)dJWlIh+D|Th>~Bm_wYS)D({75kTJh{SZ__~< zF}9*GDf(y|i$jSMN^b0KIS`E8Z@!^#O8a!{QFTVyVTyohL%~Kp1C=JkiuPuFl9#|t z&M{-Za1j{`dQp2TBO*&h^P@?D>7SFzMtmdfvsb3GZT3jWAuEHOWh{ z8J`b|%>-REvZ~G+=M!ANjFACRyUgqh69&KG}Co zS?pCtq@HYLj(`l(wG|eWO;2u%dSdIQx(b#?4FelCR2vPN6v1X=KTzOdTGkPJv^hzm zEq2#s)@DvZXYvclt|*u^&gR2>_Hy>n!y@U%dqcWj7q>MDe7jFcl?7@0pU5XKyNe)j zlYpJQE41U*qpz&I1sZ(%*kG2pRJ()jtuMB&nF6FE;goLQcTU|N zg%D-)F|t&CP3v>6b5zF@jz`m;z#Pf-0%`|cGfDU~*%{s9FU0E&8plmmH9AfG$4b^= z!quEI7lN}%l2-b)$ay{|VIa57mBpnoA=VRigN0G?0HYSVS%UkVfuon++`6}CRGw-L zE95< z^o?Da6nYpoVa-)mJ+SMQcJIOG$s*RQG*a7bl=Ii<6tlH(?LL@@XnT#8dGGAw-Mf1T zY9|NHEu}192!y}#__Cequg2uK6zzOXrZvFb7<=wuCqD`bQiOBtuK!X{Bq&3`X7`X; zJ9pJ&zxfMdx}{mz>zvIr;=7|97YhkFmBNJfHM-2s>@oY?`iUoWXa7`z!$=W zN?%?x797K^t!jomU%deAH=cUcR6hC$_UKfmnhiXu+crE*@}u8hR_e)2csZ;R+q#>{ z`xC6gx>u}}tvB07zoOk5K7?+>(a#_Hmf9jw6x=J32`=r#Y^)e=t!;%RWb;JL6!Jvg zIRXK-@%FkY5;%$kLA5vu{er|RdSThHi@MVF7t~%PgX;Ac4d%>Do&6SuVKZv5h9}>V zanrtYE7Q&>NngL?A5TT?a*tb2ipM%^k*ySS{vgVpT~wn2nj^QO&X77^w5#gJ%cjOj%v=`024hCX^{l`EefPB$&zk zjg$XT&K%-+UNq(EOFLVFFj=fSZ)m&yuZg70vAmW6G}C554aPHXZx&dmn(K*zN1b=A z^<&m1DpteTf-AE?ubA0~l6gUUxjX=1CnXo#d|BXavV7KHRJ-9RZzfMD+eg#Ovg_Ms z(@?=&Y+KHRa*RczEfM%Bou!N|DK}%~`58oiHS_Tw&FtZi&;n~_%x2780%E5+`p#9w ziHWZG#U^<9pBiC-}O^FPx zuep@2f0&z`F6{Qi!#bI4R~?Z45sV>~O9#3BdcLSvgp-le(u>W>p3Di^A~anr#k^uR zjNy6X0U(fhf)#s-;c*1AD#MK8Fa<5#)Go|nt_Q8Ya%u9Fu8pM30>18B(QG|xmn)-z zTae&sCADn^?e@a)4Vo5u3}56X?S0QQ-ebJe19jG`_n5QuxV^*^`h~p6IVMjh3GVZz zP`o3e73@mvLZfR+^9iQ&LE_H|)y;ZI8b3iM>vz-zx^fEjp{#){G1H+Lzg~E|>-H!E zdi%mX7;GmjB_iTYU@y##OE{kew*et`265Q!SmjRQa{3rjLd4)IK)1ce&g67vx2*p& zk>Nm2hazwLm20r}26xEXAogL|TBqHF(Y7>%fv$`lz1M<L+|XEto4n5ING ze0wKg@S}>V<$z`Uq<>E9fJwe_HfZOldW&AcE|d=3k)f@QLc_|P7!ZW(ZntWLOMQ6ymb?C3o3n3??O7#b~Dzw{Rr6t(Dt-^F*D~~2^WJy`@ zI4CsLDCcFabN>uq0utAhf7W<*g9)PVoNHIP9MaeHw7%D-nHF;#n7#p@$jKe*qqZfuSNSSJi=)4$X6*{caa!Q*Auo^0P&H$5H0)%!Nmi?-M5Dik{F(Tv=^&U<;S zeeous{Xn$eAWYw0k0P`u?foLH#!==$O(tm6AJ6z40FP?$t8?j$k zD>-LMcC&AsaV(Ly30a~n6X?{au2GJnYb<|U9d2mu%*c(PihBU zDQ&4d3MAM$SEL?FH#jGkE%jv}p82MwsCZGlo z_wn6fFurqcik4s9n0L$k9_mLf+2k3x_6AQe3l4`LFr^F!M&2C93t+!#*BSwW6(mDt zZ@bu+*-g#SE7nYD@pZCz&9!WVSDYOaWscpNP|Pu<2p%H%@K?+b!Ig!oXeB;+s%URD zR@CMl;VE{)QYrA6D5?Cs#53(e@{+@4N)%GR$Li||X7xMuIESDf8appL)QpdQHj?J~ z4KNM{B&37OQUfDTSEyQU>{^>H*b3cH=t1Y-xmF4Ud7WMIrr11BHpH`HK{QAF8}l6) zExc)NcaUxuf&)g-t@3EsHK`J3bn-I+5a;#i-;JFl*M^w)b8I|pGDZJNH(LwBYo&2j z(KGoYOX??#x1i0KkmNt5NPwDWuWQhiVSniJ<&c@>apD)P*ufLnhA@^Q(aB48$4%czl@ypp7JZV8&2ylK zjkvl@glW-fr|Y{gAmMD+xDFxq^;cNvf$Zd0oz9>KcH@A=U?v?AEO&ZHFPW)>Ih&nQ zxZx?khbs`W*Y?pY)?-|TWW2sZPZ z+rXc0T=wmZS?+MORPKexd^Dq9SS^^TYCq_CVpPyU7!Mc1ql7GxVYY!-j5-iy=Nz0s zb&6lh0h<9Y2t|~Z;~5QPhLfE`Y7fDP{hjRtK`4tZ4?u6r!zumy7-D!iLU}ZF2{>}9 zJh;KPZR+{JZp0%|p+vJpz0O$DX3}1T)-lhlM{jR`yylx~GzrA(L?J(vgQ- zGP{e=h9|q1K7G90n7h{N7K8e+DXq3ZO^Tah$^O(+IJw%{_yF@F(c9>Agmi{@8SL=D zL&j*l(yVeOEBjOog-#A0KA1g0fuZ6>9w=K6Zf=R1wzst%&Mdwnk6*XGpG@$>INFW@ z3gjVb*F{Zl2L$d+>36Blo4LD_*&LO^tB43O=&|oTB($sUQkjO>5^xg>zxzff(*ycT4j7!gd^ z-FRzFW?$_g(cPSR@?*eYt>snVMH5gfMv)@%#T1Hj>V*zy44sjGE5_1SA&C9a>3ncj zC-KT&2cnBR@JzL*&l5$b&|l)4OJI7XHmnu`Z3i>|8^&!lv^o~+cVqjN3$BMAS`xX9iQ&_>JF(s|mpBJO`ggpmcew>dDW z`qRQ63byye@TXl(5u{tBU5-XOQDM8<3NhMHm~o7WpJ{&6rHeN6qRp~^VKZH}7R8;y z(-6v?WgxgJBF~XCpChHC?9t?DA+_YDnkU#;io)Tfp4IV38V zAPw{6BCU51T)&)`FRl`6W!HzCr3X`0iX| zKKL*j39r9QnW(=Y{nZDm(^8vIt`zXDOAsc?7lScmO-$&^&jD)z?247*6?7n`@)r(L zFUr1dOAHw5C)4G=*R}qlqIN=%?LtQU@V7Owj0 z6G)!-A0(6={Zeo3i%qY90HHu{Xusq4cwopFd#NNZlYcE5uCmmrL#4#PqwUpM6T(ED zF_BRw^}npZmV)T=MrAgiVFRU~iw$-y76}&HjRv-&cwMp$SSwJwuk*&l>~9lR?c@Fq zk)^14Ni^Ir?Ew`{t$D)DwCb0c@Ajw|J8>!##;mpjipYj~wmM;0g~`u=L=;c6$nwYR zgb2-J+5@EOx4|ARZacL=%P5#E^HFe{MT2mb@JjXXxX^&_tcf6O@zF{n=4EU z7}y|pw|=G;s#Ip#pv`5Wy*Y=4@2kxecj>pG`VBP9!h8ad&sNBR=m=DoL#PY=Z>bZ- z0ZZ+{y6(RQ@GVyaoHxkv?!Twv-S0jiOpBRMpD_C>)%^oTXcEorU&OzqAVC|nic5#F z@^u|Ug^v7i(sXL_daxSq?2ybWnQ)N6enE{N+|3|WvjQl(H_DAEG0!9&-D;bEhUW*c zGytj@o91d=f^IL!?Khf{Wk{i7t%RrxnVldXz7I7Cwi1jw6@+D$0}W#6UPQ>n=%ouw zM$CvWDHU!rLu(4KIL8w& z^-wQrwwbsp5knwpsY$X#*a6LZK{^s&-ac{RJ*0l9`a>$hi}nGi-g7|-xF8vrz?H|# zV2b(y52L8Hw|}9AcVqJ5i?VUzUVZNBQqK&6&?{E(RN7`L5((kk8UA+lx5n`-6(+Ss zU&3Ztsl%!$7X!!Lw*~yqU-AHEbyLlMwLcsUVnk-0O(Ydte2V?{YOaTb4*gwH%E#@;%!vusT}U3)`igN63}FadrJD zW0~{cv)k?QU7HpwDGhq&sN#Mcbuq7x*x(wEzvDptSe9FFAHBFDk{ZqB=IMOiGLDqV~ z#YCtr{~*SCB9i&mh1l09!#MZdoLnZ$fzE5}>dt_zPQ%vU=FZ*VUtB{g`Se%7eQLn- ziLz|27uqFOE&P5GosyS%tL&9&L;s?Gja$Y&PDoFkugxxQG7^HX>%r2H7hy7Mt@oHf zwTf6M*49@@IY#Fld1!n~?K77fK1`SO=B>6XB4f539))BmI(_=M>hP@>lfgAFO*;c! z`mb56StZ{R17?G8;q|0`8^ys^X+alWKGbRt;^6j+uHi$zNga^Wn(SHPm++h^81Z8* zt-g`M;sW+pSH822_Yit!CX1c%RtMR?)(5u$0~VK{NbF$UUBAUjNdn(31y-t%^lt7B z8p4T5;y*l48I(e)Ay_7!&$l;|ixjPerIDX-9L8;}xk<({oD1)MBY#u#Z5aN_4m+4T zH@fp0>q0IEqdx4s>~Nl#?Zzn@XzcqjX**!JTZXo&r-+h-7o=<770SOFxsF5~txmxh?|EJgxVnWu z6CRWilNZ`)gXOi-+FR&z{t?>+WY2uL5zS}&3|i&>43L%CAASM z$6Ii7j(*mM1{ZNj^2a@0k|L#&w)Cg&ue#uyWezU3%z^oU5)h^>diX8wg*XIerw&7& zNLY{Ssn@eHS+)o${Uq+1fqc%12GpD*tJrxV9e#gU`B7i}AX8obNQ2a6c; zP19(*mAyqXEffqXgL$bStSj{IjS=vSUS7AZJ2kd?jE zN1dy~^&!qbk#=+EU;fuIsiXTO^(&cwYI940OXYllHn{g&+)~U*?auR!hg8Z}@OoU%8?DE`yrbM!_9lV*TMdN&zla(#g zlz@gmaQ$1;r@Z!c1%Dm)AXVO!rDumEVG9Torse$}RYZ6<{M`oUGutcMZ0#9>4du0x znzf_kzbs_YdP%${oo6&R@)*fHCG- zpSsz)hVy;wQ81^{&z6Bt)0);pUsf4skeKxwwff|*d(qnK+t99(Z!GP`v&uuurKER+HG|Xk+2ld}` zd49y-xm?=F%0hvFEyhfbXHOqchvVu4_CKl2{`wD>FM)rDE!AV8RBVS@dXVQ_b!MFO zcupu>&Pb)TeIkFR{Lgk|N`c^4N!YuCg?j!I9i~tTtMBHITc5G+b>kD#s)tWa3_|i2 zPXSe5F>|N=s4{;8@H{>#N!WF>@#JThhk)v;a%`zm(NuKf|_`rH#klf2}nSna;J1V ziFikO4->gS=X+fxYi-bh$Jd=pBRZ~!wGexttU%&DPsEtuY88F zO25#0n&0u?JeYuaFalE2p9#K&Nisf{HhUGVT8%#ZS!EmF|6Km1f+7h|@h`!DCl+v^Nfh}v zGXJmZf2i?;!T5h)gQ}9VZ)C|T;`mPb z-m5#AK;mZC&itHb^3wUhdDL|)(W~cRlcc4uplC~8e*gC8l)5xNE}OsTL_1ukD}`qb8~ZJsqq;NAEhcegJSrpGQXkr zl@YwpD{E)0gWoMXFVE)p>j14baLii|yPp)~F;Q*)AgTQ>@{e@!L;fG@lPsQ$f5Cph z+l!um#-pN=(%@xmbTnL(R8US{-q6|_o=Km7hK; zbOM4{(-G-#hD(Z~5L%?NcA)xGn5ebS-rgRd|B0!FxW(u8NLoxRnD4>jYKKt5HI&zB zdthhBBwr!&g!6(#6!ucJesZ`ViLtd7T$#8QPPsY9ChEK=LAYp((NJow{3_za`0BX7 z=0h4T`SBL$G2c3k`s7Ie>ioRs19GmgkMVKw=3=JAIemL1A|f)ivqK~$C53{4i7l%t zee%a0oAU|VX@!^lmOO!Emd}Wa@V&EC3c_uCxML|DFg!xwM@AKLdCXu-E)9~s-e>7?m9hX=KNlT8t?u zAU-=kzka$qb+0L^{74F1vSo$3t)XZW?>cHz;~JT(lZc+f&KGb)Ml}wUaQ+5G({;XQ zSd5ap#0r@wHP#`9oiN{E7A@D);JwMi$(A;yiWwCo5kp>FY$v@|&tl@!wqUrIGET=aU9VY7T=vJSe!;w%6l5j|rL zw!73?>Xrw|Pfe|@SipqZ@1&L-_^!vZugs%U)u2~292}U4(1zcZ!oQnH=|m{jkx3!1 zn^Y$?LH-YXvp!Lw;s_fE%xavrWZ{gk^?SVnXc9B!*aJFkcQhzKAWZ+pn6oi4T(Nh- zD4hkf((>{CIQVwWMjxe1pHVQ-PXEBu8sBAvj53h8xNj@-!Qr&*eAdBq^>lZ*8$n=sQ z_$oj{Vi4bs1N18yFYPbh8|I8Y_*miZfD0TSK9TVG(09~eL}TzLv&5Jq*itI zRo%a*iI`ElUwTG*f1a(BaeZO+N~XJb?M@C_uh_A(-7j1>fAd(u*q0{S{Ng171+qPO zr*$GVcc^JkO!3)-Hk}J|3N1l_^QY;saZvqaJq^24@Nd|oueK~r!MAr;PM?Jzk@}3Z zs8>F>n3B>ga{&WKlwN-G!)=IC1sNq9U`f7iTU;Bgx{enppIf-&T$+Y$W7b16Y>jI%t{DjAK9`x(LI%W45TSaI0n55=f zaj{ptidiV@VzhJeMC=o`JEk3t@2gtwjb&2qYlYcQ6)UrpNC!FilIaX=3@Q8w z45=qD^8E9IMVfLZ(+#DDbn&tb0omTO|0N%$Qsf#BhZZ^f%3vsl4|BrE@1|`85P+#x zP=is9Wi#yG6LQX|z3(t1jhA&Df>!^!fFkJ?5Gt^RHg~E+kX$0|dQxn@hF9CU)i^Nc6RYg=raV0$XiJhP!^~b0bIU*#N&Mz z3LT+P(gg)<_K;G~UY9t(uRwk~WQQ5iaUwGL!x+iZ4c*(@TkV}lDMLB}jdjLYPsBG1 z-3|2jXBSyx_aqD4!6rNyH?ubS5P@(I5pxAaAvv6%Ym5e5nXl8=F$UV{u*QEA~EBvUGWd@IHaW$Ni&y ze*_5i#Dt{OV(&mG@Eb_eotN zoej?xY&5mnzNj|Z84<94s+cb5_pl@RF+GE}~1RDcRVQP)Jup#rh1`Gkc zV}QLj7oN9XLeb72qzexyz-$!&8Wr%KoX9tak4X)d9JFFF(n&)%{!se$Dcj>+34P}xB)Qv{^>k85U$Hqwo_*7}7Syv8-cLB~I&kx-Y{gI&1~vj{rY zC%!;~))W{zu}WgfZ-4eCD+rx=m{YM+q# z>-Kpkd!ano_l$Cck?5xndp#peFM484l=2>Af3CWnX4M`7xuK@e$O2^2eyF(dH00T~ z2QEO3oH4jv!@Af>OYq7d(dK9gsx;^_B=viUF(r5D``45Bk13!22AvC}mU8!TVncCr0Pwcom^OOyQ64oo#02@DlTsTsDz=3_Kt+jG$M}&uvq=qXUQ=@m@+IUhWy^Cr>(?>B^y4#%OqAfUW4lGWz)BeVx)o5XUWlA2<4 zK3?eM_P{=r!~31sybqDcgWfCFR|lgPp%Uy#gzIn&C*`xTJ8zd(z%hd(LJk$nEd3@L zGb7a&%?$-fcC#xbO1?mXWKEFx`dX8kg)!hcL%=x|hXw9-?AZBWKs>+aB7qeiSVbrF z5LkDiE^ZwK9ARD_jO1c9G_oHty+JM%UF|@Y`x_+u&`9NjTkv+frJD7Fj)6yp7TFe# z*{5aMt->Re_H`JoG#YP(H0titJA7?W>T`bqc-4Fg3r^zzJG^NzzvFZ_N&zS=E^3?L*Er-so`;)d{G zu}5FlxAnaQSy|Jg9|%J>(?ce1G{sIzfqEWp4;HvU82V+e*r-$Xvkji}7!sq6V(HcO zPP}0r`Q$&Om~pJ&Z@!X;=2!Gytb zSd-%M?TcDMwh!)Fl97jVZvX{`Ei!p)o{ zft)Kw%;Unoybc+S%Tq?~sJ?fKNLo2WLw&(=8r4@yv-eQ7&sM2m;7-s2kJ=Zzp)dz5 zU+Y(fTj1QAJcf(shlW3O|V29lNV36POZZh`zkLqF5cyFSI!>`bvim(l|6<&q^Yaw zsfvr4-oJ3a4X>XqLgMvXUNHH~j4czT&5ootZ6IHBs)}A&n&&JXm8z221 zPeN{sS^7k=ltY;=V*WRS`Ga(5l@}FrSPbxIm)l%WMmC3j((?^Dz-}Yf!xxgTgD3%h zALgqW1itwN@vxZ(8PqMo5Sy1jFIU|T8i}N}xqDP>rD`3^2~NsBA}*X&2OphYjQLzt zQsG{mfLN$n@yTbk8o22+_+(d0|8%6ojZ!{W1>&G_V#2R6c@W=LJQiAGp*y%cm9X6L zVO0WOaONsR9MuPoyVe+@H+~?nI6g&2?9cp;z`J{f@W=}C#o?vKwZW7KY!n+o?@7!J zrCT;=0(%JKsI*PPMeplm2ql}Z-c2moNUDk zK3AxMa&EYi%P`Cf^-9FLzL%quK56VdHU?azUB?FMV)*^))yGsg*D%*i=aCq*iQ`VQ zGAwG|0sbT~e+oj<0&`1MVu}SPGk|^(+T^?2%tAh%m|hVqQ1NQb_O`?K>E(jZ>62?; zqiR~mRyOW}0nc!WBAQVwH|EF-!+OMrddv2)xjsvzTrVr)L_T#W35PJQ*ZZ8qQlH%3 zSB<4iv5;yN$+HYfEH_d>Zig`Ty6n(Ko6HeA6Mcrm-yKlVh9Xo_4=Cu$-v=otaw#$EHDfw znj`0dja9GMdNEfuN@=gt;|gxLksjGa1L|WblBpF#)Mhi)&%_r@Mqc}YSbC#fM|vqG zkgE%EyYQ}H-eNuQ}s37 zYY6p#BBg$px}61u|2bnFV>?EA5Q zP?35>Kjv*1+uOKA!(si=YA*!com4bdhA7kIX|A)xYVwhqp&f8Fv85^x*O-3Q8-#nQ zHOiJi+?#+QTPD)N1V`ny%nS7QWjl24{T) z^k$lvuy#>x#uzTNYjPa2J`-|>GN9!RpC^}|HXt(oPU6K4Ez8d$BLC?RB$3d)#8$P8 zdGxs8yE(@{&QdL<6FM#r@#rA!i8u9~OBywS%6h{7G3y>+p)Gr@O=L2QE+n=t(!#Yv z9ncs21NY&wFG{_{#3k)5z##pt^Sdv}iqTDoiSA2$4#p+Q?BF+S9rS&5OpnRq!EVSP zb082AE_w!~Uoe_KO?&rCJmQxX`Xr%Cl-;?QI2Uryzk)^!7}3H=uwaa-mX(UEFbsn4 zZG}q9EE?NzhUv=SJZZg*OX+7F&gCaom94E%u+$S`<8YB$Y+p`M(M6^f5%GZ%Rl;^3 z-vuv%{9fb`fqQ=uKm`TC5ye4gQ}pD3b_XIajD^VR`N|o4s$fj{B7jnO@Db50lKcgH z8Y3DE#8Jhf_bzF7O1gJ|y{O}-50Uj3bo7CNBe#s5XL;_D3_B!aK?=AQuJ8Asf4Y#= zUj^X1_EWyxGJ0?Ih9cTr4)PlBGPkrvDcPgKp_{>F9f^zBU6WZ4!ac3*L?eiYm~^R3 zaz?f(k?dhl1cru&HahP~aDATtVASn7@_TWqI_e+c?ofuffNgbr+&Q7n-25;ajH)!w z_CIl!m;VWLigr`Lflk!OKVEPk8f}Eg79SH)LwymN1&yP?>jxLJMLVL6AdO#>!pkmc z97IJXK6@7#hJu=OWU8da?o{AM9O-Jv$)2cLA8$e6VrC7Y3%WuhzHfEa!v&FyU{SL6&Hz7 z4?<8M2|Z)*eaq@@13ct>o3v6Vo^)7T1{B6c*2r5`tsI2O>8|d_ zS&3P?7l!I`=9|-hZ>yy+mBAeu$z{TH$$JkM3+b-1o{cgp2`Iabm|0* zrrDT3#JI}v;i{Y~lRurkK0j3Iwa^?*=TK5b-k+^gQpJ=j7cj7h{{z+e%H{lMp$>bY zs;Ca7fSQUq;2pu&f!lKpcGokkY5glwmcZz7au?MbtiEk;VqCI8zMK#Av?DUP(EETv zH!%EiWFILLaIUZEN)Yo@UH$$8ab>1aybK^@mu10Mo`n#&8V_vIy5H+?W_N zm%`eQ{Lp>J==cL%?xveBk7~w7yz0<`DtF9K6Id18 z>^_CHibuT=Mu;?8kEKKF_`r}g8{zeEL37(m|F_}*UTZVJ)=mgcsz60mevOYk2qn|d ztkrhF+PmfR_>77o0v|!Ivuf59fLRlIbu(db<*`Dy zGX;9+Z`sk;VJyLhmtYMj_w~c6$zmGBaMAB^CMi$4h=4#!3K46Nl@R5E~yiJ@U7%aCzbaOvdB1WM-T)JWAS_=Aj>)`d=gGibN>| z^k1JJ-O|;ohQZlim)j$y;`o2SfIkNc#w7%;4<<^iEM9_2$Ahg-7glR21not+cKC#_ zsEfK&_Sdp_t-crDu?jJuFiZt)5?W%N85~8QFwfQ}#wCUGSv`IJbJma50Zx>}D`-iU z9en(jk3mW;c^HHcRS#8_1bKUc*LG-Hk{y$WQY*#kQM7Kj<_-_5d~G36#^K0O6QBD+ zrbl#`XOzuzZ9>%V3Qha=Osvrnv$dI%CDWVhLw4AnFEXMuK_o63O8+HMH}R2j12ChW zN;OsU=Q;etf%MzUHHXa)|M4Q&t9MX}U@>S<<3loU(3^K%(zo#n#MRuBVg^3XWoHJP8B9wXKG_nUw=yHXdWU1$@Q5RcD3X~jqmG11&8RB zsN}CO54^Qza)K47aAi*Ap`?bX>`aL)k~=eK$@E%vap6iD#E}GP(PFvRr_b}Acq>BD z;l-*8ntO5m{h)8DZyJ5Q(KGL_QSZaHucLKqUMq+Y5=#0X-8wGtj(&sA#fz!FW$rw! z% zGPk}f1Pp&T__&=yZfH)r8uOx@4-zmqqO?H)Z?a2m8mpO(4bX-G-}OY@-8eB5*DE`08vOyPNW}e6G65im;pHO6`;mF=lco|Rc~6PU z?hBU4X;zY|*Pl?|ku2U&O?qR{+TalvUdSczXd6&#?Z7rkGQwS;RJ$b>60rOKSn;E1tUGmE6s zDdQFR)slV(2t4Wp$wq737er)%a;2+N;*F@d$;X>n4)@|>!{ZRgd@f7RQ)&DVzl=!6 z5y&+1_~$n!iHLu;DG(nI?mfq73U4kQ)z1rKmM3d#tO9`DMbpGocX!^mxem8u!1$VCl zr@j%$7#6Dv6_9XH-Jzb1T^;cjG%MYJae`1O-D|?$l$Ynr&oU4TdcvL*!oI#GRhS3w zkXz0czSAAMah*40gN;FN>B=9kIBjOsNcF|5Ft{x4X~;;?`!h~Mkwaj;7=C(((hQ~! z#yC<}zri@Nhd?4AHGz?>vLvHWGZ))?5Ske^B5LwmWBno#cUsK#H_wEH?*c{k2U4Pd z6iJncij`@3&(Wg1RSWHR?aC8#SVj%V@x#%^M&`sx=4bQKpYLpSWfp*o!UXx^xt=ai znWz0KDMc4_eqI6qz;Cqo!d#S&szf_8=A;w{5ZeBfmMd6%UFn0jqpBehM@3uXK1ht2 z_QH%OVmnNm%n_?-j-p{JhbQYW{5Mzri*cWU zZ~16oguDJ2l_;d?rA62Fso;panBP7XQ14==dCZxX|4T;3`B#+yL{@I+M5QL_blx-K zmoZOb)>H$&()G%S?8Rk0zDQ_aEMB>_4o{ya$-{oqG?=sSnYCq5TeELVL{V-?(VI11 zrwazbC`xeIpOFjru%hv9(_y1CEoidF5n$;P!13QSJu!hYFZ)30sg+1`=gOiZ|4Nk~{tL{%+ z895t+Y?>nXxKS%#vg(qWUQ)Qz5+1%0+_HQM=fck_M zo*w<_4W2~gK{9+31KMy)RmjtMnX1#`cF1Bg=qQSgk`T*_6&|*wHHz=?=1{U&B4W7f zj0J1V25Hc2vHjPUerTPA7kN+*i0}{#RYo_T4ULIJhSH02ul$x#7CdLnB~Br@lTf&QHbM6n@Ik5D)u? zdwbED!C#A&j7v>1zJY73=pPuC;E3Ctgg><773o#}99ycn2TzfQM6AGA-6KU<-9ktTX5UEH7h2BVg_JRXkqb&WXNXMGe4_ zOR7MoYAt9mpeOhNbAp9CYb5jG=O*h%kQr9-UQ^M7QN(K!atn?Vp2 z3Va}(jx=3f6F3?4(72*30)E4h!jIBNvqJhJp6*f!jZU6(EYnUlSzQUO_S5nlM@rOq z_KP@{jE4W8yI-1r3>~72^Ju;r+s{|s4E4Pu58V6rn>p;5PM>rUL`w3SNo;<++ISE} zS}R2DuOp86a_v}dzuAdyw^ECKyyOYqkBX6z(dFW~-nch51`~W5P?-W?Eh*sne&m~6 znyGoJ`FpZ&jEZ}iOyzXP_q7hEB30Bn?K%Pm%}TPqv}+J3)C5)->9H--_?f)LVXYCO z*Y{5TYW>lJUj1A2d~d*)u^0cBKahrT8!pd0ZU&TA%dcoA`hBP`4}6}}rV`C@q(4LH z;!1F&au^jl$bLYsH$$gzd0{WnBW|v>qp!YN1po5l>u@9`(bJT9jXiq#SXpBHfw18g zGDUiStIK2UVf^Frsm_a|>wh&AH6wI|5Mg9sOoGDT*&U6``p_qtKXge^$3tL6x!eLi z%6$|E&;G>*Z6J-a8BGUT5qQ83S4?8!=xT#WL>}!6q;qcO@@vF&;Izr4iZvW90$UuUg)`d-|^ z_b2Ye%C+2o@fW46Seq-#D0jo{MZ+vbn+@@MxEKkC$GloK34%YSQ<|#a`lq35T`$vC zd|2bj2rw!7Hrk|vfHzTsZefg2SUOtbW{c<%T>59IEF)<5(xTxjTPnH0C{dY^jG6uM zkH&cl>`%{Z$*;q zrhh!?GE(4tyNTxtg)t`|FQJRr^m~1|^;DO0yp5h=FR5KE?|nWKNuOm&c@ z9@!=2bg$6LqFh_@aI;-C1T}qm(^SmugR9Y*m0DdpKvS^}BY=Dd^w%6&oP7JO+v-bg z?YYdt|6k2%dJ)rAbO@8%`w=SXx*se1`ht`C(GhUzKS1VS#^R*!y&{tO8%W$`7;KY% ziirC<;FT)*9oU_!@IrA!as%h?YuCr-x^*Sv08of5>_Zpg6X$U3VwAySuvu_uv-X zg9Qoh?j*Q-fS|$MT?Z#Xf&>jVxWk~qhtp*5^WXE=rK*dHR8LR$>QA5VUGv_G|Ba%M z2OI`xfi`}6$ZkDfs&9-|6h;$1}!61d4CE8chLHye5h4_|=#(2O<&jAPc6$sM_G_LSW87LZNi(4kXmmjc#nbFEl8vA#B)wRV5l; z7~%WbeZXrcixeu$3N|v3MbciwI{Xnhoi&90#Ob{L_FP*7VDR?egjuNi>#kJ4Z^quk zPL`+L2ZKNYa&I&gjVvw{XnG!8UM^t&fKXZ-IZmR8j5vhRoR&OfKVa7EcEn!JB?XT& zr9DdN00a1kEnwY+TI7EFMhT4A%K_&7Q&d!xvqLdgr2B}t{)9>T{-P2Y2?>cQD=KyZ z^J{3W$);uz(Q%CJ;YW!u#ODR?J0@()KQbP`AJc{00bb8}e=46=_2`m+P&H2sjlVUv zd@@kmFhq5mahrc1Nw~1b%x0oZ zs+K=9=_ZO}LE_H)w=_HzN60iZ?Rxj-7R_9d-j8}xL(zCjo-5Ho&^v^a zezt%Bd<*`^Zer-tSRO`s)>!OFg2bS>^E*%>!FXlb#QsQ_i$ln zQpB`jsHBf1=68%0_BxGpLt5<#Ab~@{$K6ZzdaNRV>U$BP9SN9!sLeDxNJzrNkrsjG z$8L*VHhdhP%9la_{K*T7g%tFh6!a+sGr8O5!Kf5gT?D{#(dhs)1suR{cez)XqY4d6 z%B2)Pd*6ySh?+Q!+VV$VNgV&#nyxSHyj@PP5HUKM@)z|4%s?9;0^}^!?y%hA?BzuO z{z-VBNx3;S zm1Xv=q4|fq4&3J{tm!y*7XW_W{Quu$d6m9Aw{q87lAf;}`T6;3R=|Hby>%FIk`nr( z5rN@;YbP{HT3#+?&R9D!8C8?#s`9e?Z%GI0IbO6lxK zqtn}G9swM+RlF1SI*ORrBt3X0!Tm|#UlhW8lQ>E#W9b|e69E)|gFAzViv`32 zQK-;_SMyIN{=kQ%*rA2HyAE*^jBmiTm~DAF$PWemhxh{-uL?egaqQjYUZMZp1*2gb zr;x{CD7V#wg|}|o)4A( zvE&enTCcqapZM$ad2!`t1I|0<|2SI{A5C~Vni+XrH7T|l?3$hZb&zC z2;Dh%aU(_5d252iTl5A;N&db6?HSdO%PbHqv-G@R)2@6KGB}d*d<7a@jJRVKdGG!O zvqCLM0pR%MO3(;JzgeNZBb-LmX2!(_&d}w5r{Q0$uUH-P_iKf|K(EPhq+;iYFtU)| zwgUvrGrD)I{|+05TEGKw7jPPUeEiMIP~iSDr!p~4B+cr9PK3k|%FMq3+XEmy(~r#0 z>-fL)vbXIU%1O^X;t9yf*?|lT9v;3Q1i;2Ge6p&@=#Hzjw6sN(4l2N9nS8>_s3T;%ccs+jo4TX8(LKNU!C`POjqPCtfj-kjxq zPR#xU2>WO;yRbWGefFvgTK15}^$gF6+C4Sri3x_}%m@S?zB%ni{4}`qiqG=Rd3RBP zKV<#tT(iv|0{5DB-nouT%2ny8p{nKfviu#rQmI4fa)(_3a$wYvmFm{Yj)C_hJz;}L z%Xh0kIqdJXKesgok<`fHhBxLQ@j$B8y4qcc872&ePpo<(-?WB>d_0^eKR;iN2ZtZ{ z9J{cD_6k4LpZLNe3olEQ4sfLLEz^z>c&Si~l#kz>QNMj{hd@FL>ipH?#2d95Nb6Qq zf=*^os?GdGzd$96l!m6z9hz%dbKF1?8y6Sm4Q$qj(DQK&^bBR0pc`UHghwZ3ocM^Q zZz{ghb%S5YZ#a~ssXCRftlt&zfM2OojSW_=kO+bAFJg;MkoO!gp}1u-ves^$XB{vj z$vLcEN>VKD@2+!S^;9U5B72|ivG7rUhd`v$AA4kS_0vM9bH?ItnpSn&*BB>*!#R)F z3_ou!er{{?yCt*3NQn>}OnK~3PtJ2X@4jC&I6$D8oK54%LEz~GulPL4-*0j-_$^ui|AWv+(0 z1i33(=IOy~zMkKZk@Ag;@r;yRHX&H8q zsZrV-R?tkUYS*O)K6KZ{_MqvM7;aM|YrLr={(9qDxVtowoScv#!@xl#HmSTgCzPk;v#;3PhX@FmYn|6+P=D;l=|@_mYWn?jhIbqUPmH)jEdkDqA58dlfAtosJ|%XHB!5~ z0J#R4K@g-9D}3Z=cQgUASv0raqpNXpIJ~Zv;X26j>iK;O8WO&hFCK}gYVFTEHP zmgPQKJ-zgg9)J_0&Y3sD!Sipuk<5YmVH!4}$*Piu?$T9b?gk*+SxyY6$zjiCyS#n~ z?{EdAyR{J8ct}<|e)jEfyh+U}%P*+$j)nV4Y&PZrqqWbAwAHCAvG$E*@nVFhss}3! zIVFDMyVGfTUvpsX@6d%4Mur+SV8R$tY;Xk%^G z^YazOcVBymRDTG6I0^e=P2l&o*aut^i!J>%23tCn@_xF(EcpBQI7+ka9QI!FW+z`~ z(6iW!!}-+f{EqZDp-vk8X6M%!5JG;ex@5T;l8c738le{QaE{f^3dr!QhUizqtp0}~ z1ZlaEUi#X0wc*>FwmfwvqP3of;K(y;0sJwRwDR%0AaFN^^w|O;E>kMPo71-KXL?N+ zh|Bn0AZqyYo|*vu_n%K_QX8T@*&rpnGeKBLK*+`iyH_!W!-j&o-=A4;RMpf3*1Axn zq5ivd6Xs9{quU#5>Vl1@Ulcx7?_9R$@kRW7Fch`>Nn##vwgBHO*`Q+Z64%fNU`xNB zt>ztTTa+#Jt&D%eBaw>kVQn;TRQeGH-Q0Thbn&d56QGJh^M5M#F5ZX$LmX%%6kiKg zD^T=i`uJ8y>J<`T)t3??W{2m&4~}JLHqVqi`|U(d%BxcjE3l7-rJT4JEn5jpN-he& zF)vl^WgrDYaGprO@XMF~R$}ZRQbEG>(HY$?CTW~izt%1*d$IVx(WD7Om1%^qAqw@L_h^&v3!Qt;2(twr#M>^3 z;`g&MG#a_^@8^deV}z#|98IhKRE4SUp_u>p+IUL=s$(B7k@TgFbbs%qoNAo0{7tAt zyyg>llA;fBp$$&kY5tp39G1YBPI2_L?3m1Y53^$Nni|p=su|Bd21R(fo9S^|L^HhB zk^ZM9d(^YXT z4)K1mNfgcTMGgOC;+^)+=Qx}IMUnv<6GDJ}IGP!3x3^Q*|yny@V z_Av}rz3hT~O?u)}^JfNoRN<&%oAfU@(&-!~!?8r%p(N{;mX`ZV%`C%lBsbO2+%FbG zut^CC7!_LO)IjXp=4@)%?ur)l?Dr~941O!!QTqdJ3N<~DtM}uwbp<}3qVU7@)3*|# ze#E|hQ0Iz_(&z<4Sk}6bJ~e+~`k{>aEm8+@hie5y)rWPvPC}cSl|_iWqX?%f7p0C2 z66T@R2*62D{l$1K&ZihdIBYcFjK6`1)nUZLx!r=N>!siBO836ik&V5W?8RlK?7}9c zdDz9hVQrbNUaP2#eTP~6uiqQG#7^7EtIUeK=e62UXclY> z_&|wV;ug+$f>iKg`EU&EE`b7V?+;%Ou02zUtEE6<6ylw`v=1nP;_x2JHPZ4U%5C)p zaI8bFMhD51ihD+KhzcBvfAFS%5X1`SVLPt&3lX|Qsg2T}xZDlA;;4<+S9MvoJ)I)yhp=__iqU!1yW3DJFvPs`$xAcA z`g*JF%$W(R33X$Ib&l^fXQt7en&+9{*aK6uybc2_x;4rTXYsZ+yr@BD<7R) z*zJ-yvMiVkPq_$VVP{^I?3d*5Pwy?Td0*2XguIVX6_HKoBXPMrB{3DF zXNETsgWsrLKsbKyg=O@fZ7{X($i@CzKYP_%Mvq?bl@rYLqz`V5>hE~n@pv=;I51bk zA#QB7FicA3MBh~l3TNk~hCN|7Q7Hj=-#n9Wec&d#{nvVe&Rz0;=+KDs$0NKh&?D*% zI(Vqqh~N37muy80`VYp0SYM@ZE#}XF7LHo6frSwaiM(JeENrT#+bA6_PAS1yx2!@n zBm`U*2x2<3jCw;j_l3(PGl`O3`(mL+OhegHhe$*xSga*vrQQQd^kaOspB+{cCrp>&$ziF9nS8F1#miQDb z98c^&SrJ@)UB(mLbB7keF^xWR|xy#up=M*i=43A zlrnIc2hp4lV|bA*#B{acwFR$|+4@)yA;^Jo*oh(>NjQ8XNH|C)$+7vLQ!76=kkjyI z7lAGaqNQ?n9JD*AZ+kSw<>u5VCq*hWQQE!Cz%CgGFI28|0+RnV=_4nD*~Ixylb;C} z^RHTg8klh%=P_E_097vr^!~O>LWmSYXk`9UObkeo%MYHYSJeHM{i@ z^-$^7g9}$m?r7=Du!e4f+|@ANX4?}gY(z^yTm%viwV%bA_Dvn+DAQ(YWs zRU-F=L~wjdB#^N2LaAp>6I4w13^v?|L%^6NicdtqIG3c7OZs&x-{5}m%Q=~4{b~I( zXYF`{c(~(HO_C1^YsX2*0>emw1u%HfpEvN3gPd$QUl$+uK@YdUbz%5>^Pcm^NeiBL zrdC90&JmSS$dF0$!8ywML>$j&#EBlQ{_oAGibDypfr#N{Wh-T(u51%Vze7gRE{}}M z7d*2zGI!H zKn_FBH&saC#Y*BLyjn(om)We!s<02LUZ{7NBm-WS5moWcdj}6{hWffXYgjlr+5_!R zPVG47bhu-aeFCiy@G4GSk)kN^>!4?ck>po)&bAX`(qy0zxD$eJrCYVP?dzPVo)igO z&86mh8OpuQrQR)D$n(mJ;j2pM(ID+cMtmf@h!sYy4$30Fv_yjMF%8PA>a_-FJO>5@ zYzX|459&Wn4SNt-?b-@vAmoyp7K2MBq1)dFR|htx>V+2BJyNT;oli(_eXkwoEO4P&W;WPB?~OSU#wa4_K4aOrw>gw3Lz=vk~a!%mL8Bz z1ympqqdB5xEzwQedTV;e+eH1L$tq;K>A0?=F9Ua?Uud(%6B|_&?tFrmbS+n(T(Vv) z#J6?(c-Q9PZg(6{zv8bvIaaozP6SNyV`FRHjSKaczjv91=;7gIwiWsp{$gC1Liteh z8r;MvU*FwlAaR=#Y?;64%)ftx`;5xTxDGoqxU6Cu@i>oNN68`Ln<9vDvrno76mzF3 zBur>}+n$k^4El;Q;`9^|M^Rl{`}Ep9sYMj^4~+9Q?)w%v!YiYG_pXV##HpbhEc>rO zV*5)m^4fgp9{ry%2fi#WE;HCb*;|`s#7<$P1MYi&9yAvJdtod@{P^ zDC&E~I`?b1dfJJhN-@M+ z?C|g3i;TvNKu^SJ_`_wIg&BI-d*!VZv8WdNGu0J(ucgCfHdZxFvVVJ!iS3aOTs&Dl z&N=Z~dKkuXd6X2^UNT-W@}QQ|J4($)`3VTwQRu|2gq{Q)k4$S@Is4q8`L{j8W7n*q z6(i5XUGx?!a%ou~#tRu$^!1dmxN0+pD~j5h_a>8Di?-z7rt_u{D{?|MakVH`k%u}K zhF1#BIX$1=UYSghiCTF`wlbZVYF5G`&#{FixpjU!=?$0MEOL!$kaU$c{fOT9+UH#J z+1I&x9d?jVbY*DH!@Ii)fp-e$k zH{&bu=GI680O*w@3aqxd(4?^&MFWMs533y>o2uB78Zr?b9vVah%lleRa|{P+5%V8c zXBu)+ArtF)2jk38U^s)!%xSwS_9L1oFv=sVn;#wJT@8?t7>3d(Z?oI3 zzZ~L-!Ev5~InFLs^L;dh6gLWAR=XED+xUmM;E7v1UxN%nlE~svOkm=U5_N-~d$XtW zu;4Z}HZGL@3~S?YF%;GGFwC^b$CR*~U>8~nIDkl%qZ$;tH8R4uT(=skl^WiXc)QFo zXr{7yl_|e_RW608Du(&oihf3;KgB7+p6pJ1z|=3c^ftqZ-u`|d+@Y86=#2ePCH4)I zybq3xsKp71YDwNEmg?)fv_r1QRK+h-wolvbrDh6}GrMF%$3qN5?V-1h>+#vX!Pm=< zk#sJPk8`W9cYm7GKazmuK(%VlL9KoxZPKc&VlG#wQk)lint2I#^KYR}FlT371niET z!FvdfrboBcgnBN?iH`?6Jfxtx%sFRZ-_#NgC`&$T_C^)#ls`=vJ zNZ29p%|4=HpC3db`^5hbh~i$^IzMFh%ZHg#D!y)GT3W9Xa>B6bBLuVFf;@mS{>K#V z0%o}!AqZV-?Uo=qLmP!}ezJ)S?1GI!nZ@@TL|;SiFtca1nj3`!0Z zhTZs!2jD4fO3Sc>-mLW`EQsg~YGJNj`V{-D)JLeUp+pfW-xkdbF!TU{UM(078N^Rd zfAEtZtlHP_=U-Vf_`0WTAuouKovX*s0V?|ZNv$4svHk{q-myI%K~)S9()~=xnu9N==M&ypdSYD4g|*3TFE5w6MURn z`+MG=Hsa)O*jv)@%0Al;?L@XWlN~uRJl-W%X4UKN->?&_D^$KB3jSM79r~K}bk-9O zND72xs?3&9F?us($BH=RcIU!F)!wLpTr9X0UGpABLs%1P;X@6X@3+gxztuhdJV zgZ^xEr1N*xKt}p=!_F;iFnCUzU@>MmbDjPS!et7PRdgI1NJh5Y!m15~qlHE%MWP$+aKRB&D-}xcSrDgsV=qEun^C>%BF@(%YpJLB$&Uf&t-7{Z>ov! zd~fEE5q8s`sJZq4AN%_~hE(KKteGx8uF?s5Fhgy&fxauCIuUH>h!nHFZ zzvjj`yH2ZrHx87ZWf6z%M){<`ZVm_;k~RzJNGxM1hq*Y3Sa}TZ8x7PS9*9&0b;8Ct zP4vbBejPf@Qza%!ZvK4w`F_=|z^w6&bB&g?b$+Ac&SZwL_GKIIWuQ|CuTn>}TQAU| z9t3LNo=ywt%Y0eScSK<*+xWX%cHn*^@7gXuiF#UmY_$ydGPsbRc;I)7sZAO<4BdH;dCHGqdm>|6YqA1~dj zPOmcBuF`UXP)jr=WQca{F>TslxmHi&nekDHOLa^%UOoPMR9+`NMeka#g^K=LgVE;9 zt%U1m=z}Vdl2bvF#F+&JSQk9{0UDOBBwua)QG zW6aP*T8AW-hIaN4e?n+7r|7S#OC`|pfqWuhG!DP9)l>oG>)hP>x!ca@3TlUt=H4PT z73P!C&42LE?(Z*yE2M|3cu_^2EZA6pQ?=Ypz5=&~V&?qJ;>Q4xqL8Gd`&ZQETFmbX z(CE_Zit&+UcrGjIW5~kBk4!g2-wX1- zp3mPQ79om1#}UnMu5uRea6C~5wzszGpeJUm?YuZCH*tgCibbbw{7HBYv=PVyj=o8< z5oGMCc(d`m*>oDDRjxUYMcv`trU%Ahpig@B%TPbm?Kc}vinIy~d8%XQ5St~wH;zFU zkn?fcVU9^qdYhjh`LkE3$2PQvzTa=OTKvY?^=R_>-Q#rvN3qAYIL&kJum|o!p2@-> zPxW(ERCQgT{tfIA=~kn z?m6`xW&nD z*rXs}m&3Ul*!HlO@&lvO1*KJJB5FS@kYbA!@-nFf3Bck4V2}RQ2nf)Ml24-@$M7?t zdApN<(G!)|rqg>9BCf?L8TjzH(iQu#kd~#{_Z-4;<0y#?#yHb`C3|<$E(nwbB;4QM zKq7rVpGalqKQ(b9xe=(#>$n^U2xah9w-riv?0H5YEsoxPkUeJa@6rXAp2Mr;B=+&%&CII?*S zkHZpfj9{uH+TxfMfyG$zAx5|{X>_D>kfM-`(N?V^1qnsS&QA9pBIis*5a z8!B@iAR9O031;_Q=EM((dkA?(b(>XF1Oimjd0+dw-Ce%piFu#B6@{0|u5G*NML_m( zN%hn0sZ$F4xQrqx>bJ!jt{b1F+mJHNGujK?T?BE(Fo37HIsiifw>_jJ z)!q5a28>+*(>^F!#!aH=FobPpV-p3mhBv<_(dac=qS?+y+TAri?@Pr#1%Rf^80(+o ztYed4j%@6w`#L=!Y-zRKK$n}x%GM6(M9P~hB@N!52eTiyg=-h`Z7fu1axOZs;$Q21 zeu)qH=S>})?d{*-PHkUZe2yWw1{Ngn`e(9pf z*6e+KIEQ1B6suJrjRZ6+0X6~01i*m}!iV^T<_xYCgl1pNvr(FM_do~xP!c#FFAbz< z=%of|x}e6!B)kht-p z-LAn?XG+Os`l|zFLFMC?g{*4IXQ%dBhO~OjPAZVD$7hEX< zyT|V^6yxpTFx05L=*^A`@2EWeOXg`Xaiy4vxP1)EH4vwT-jFbhFITGUGf8HPR)Wm8 z{|XKI0yUGTVd{QsR9=PRbzVo-TH{&hbMJlBwQ9HjvDxOe2j8=9Xqr`E2-H2X1}Bo> zReZrlar>toC6muJOk`Vx&mjN{GAaR=>#!8*mJjc2w}gGT`i1-<4Kq1OEbu;B*9o+~ z!?M~rCgOH3sFLd!Ub+@&ra-D}^m)j4Z!03G1TqxsIL=wL0&Chu*^|{aL&Cl}-pRo^ z;RLr(@{!a2BL!;*7a2?UuIXb-{yty3DEwos=n4w~99Y>{=ltA!Z1wnTOCl-O$}!i~ ztE5zZ_I6{qcj7aq#B zJm5Qt2n-^&E-usw&yU>ggNPtEt_HWz3Xlu!6zmt#r2)Z|+>j*Yoyc0ZuCp`ebM0Mj zOt~BlMr?k)8S(J&@Wk<*$jHd4#jsC38whq!NiV&~8BaiEs-Fv!ta_vVqbSb*?mlbd zh%wC;s4Hl(8ps2M6r~Rtm`&+!UT^23o ziK-0V_>rR{oso@>lm^w}m<5&hCDlmH8DZ85v3ZFK1e zqZ>WHkIk*I#LOK^+l`2s<33*TfgMp14I31~poO;9d0fu>VyHd%-EG$u&tPvU5|$Cdgw!-v4zfAWe2aH8bRgDBC(Muutk zGo~MQbCT*f8>;k}m)`vNkf8Xk=7(=`Xh+_v??%<9=m^M9e@CQ@#Ba{)N@WmB)13W= zv(FSG1ws5^X5OdN*}JltQk1~|ZEyyTkTdLZd2*~J?D^OgswNQ2JKx$Y24>QNl#9MY z%)+dMy*9tsYkD)+%aTWlJ38dVnpow10vYK(Hn%Yt4#6mv24o@E1LREn>}eD7(0>zN;De_GPaqW+K`v#PgRa<$<$Vkz-xO0%4u^=pzo z->~w%TZ=MsL*JacCOEq}-x>*)Eze{xTWA&%8EKN76c_3@w>F=3(8Yo?Ix$Tv6BaTz zH>XCs74Nmge3`$MZ++>l z6CE2?Z*+T!Ph<;4S4x!By@?$j@q4KMFv$4mCX5}wioXeg7ALMr2@n14wtL)MxQmeU zI4tlC&yNQ3)3&R9KjUhF2!3{3@He$IhYJG-kQ)6V3FqjDw!YcWJJ%IX`9+nTmpW9)GOu?r-+q)aVdlk_iLrM%(=Nm?b*|ghakOQwW!!)55&O+&!|J6 z4*bq}98CpUv!a92ucW@hq5uGf<84-n|7K2Y;~BrIrt-2!LQgc3c9!WuB{rek9}#+2 z5)Nx~t2R`jSX?`0_~x^{5E#M_6ynm_DBx)_nFrGF%fWF0(cv#Be%Q!9b>v$S$^&Tz zfw!LS-!FTsp9ooR-TtZAR=5{#9&!>6Bq;&ck060RpUOO}*Ih~*iiyG_p^Kv}tENC4 zQw*Lz?0-5~e7Itn?No|3oH*gU2Gi}Q-+uaa&^C`ok$Sn{o-C-L84>?~#lT#wNcAJa z!or+$m0BS-^qX5_ntOQzW4~Ts+u|+Qh=+#Dn1YiK{?<>le+9D6a^wZqI}F)$b)3ej zCV*+8A4EmIenzbUc4R1fYpms{LEN0#A;mlcB^~oh9~pUR@UL|H5yTPmzI1m-D1D)i z?Z6s6d!Pao0v#5fP&v&u$-8_ABF$9hGq{VJ^(uz*LZS&cYR<_~g2-~k0)%|859!kU z|3$7S$k#y(2UNwr77Z?H@WU@&(W4jayhqWq-f9po0-F+k%b3P~R5RXSn!s2@}cP z;N}M&Tu|+D+tx`0qmQw`7d8z3b*^Mn74D=b_P`B*L zAczc9XBpq(I=t@G_@Y)XfB$H#h*^wH2LRVd1+f5K5t{<^V@+NU)SEw(;ku1Qz&GcF zHT-xBpp8ro+sgM8tN}REf~sjMmDie!^lwc2`>&_l$9M(qx4o5e6%hY3|Ko zQS}{42e*#_FfJcX;JQHPuT|N_pXYaC%nyR=SdJnU*~SXqKP5}*`+ko`Dj0~s0P;j~ z05bLW;sBGB%7gdqg7^Jy7oD#5rx%-SQkL0MCqBJy>2Ckewrp0=|Y>JdLyu9)R4L(y~$h*OT95h@^jVK}^UC#LoT4 z=#Ldb&6{K%wMoPmh$PtY*HJvSv<+}Cng9*E-7#dO0>mAZ+adel;x4|bZI7W}P2-11 z)DC|JmTx}SwKj&v8t~C6hGBcDiuT_*=(;?ei9%~S)r^bY0h?DCU}?Wkm+J}k32V4Y z1E5myky*S6gOd}`lC=9?fmEQECl(N#kdS~$(9zzG1W>Qhe@SqFcL%QD5D>g1F~XKE zhrG?fOwOm)GDg%QjR=N|qN8Q71s9+)r?EvM4Uh!#3pQEKXjg$fb1KWG&{9a`w|!o(?YNd!?5#33E9Ta>v+R|)LW4;rV9_G_?Jr8ieVGB{`s+Ukm z(DQ#Ps(~UeN@DVS>c8m3t5}so&!d6+1t^mwct9V0wkPu_Ub0LeRZ%Z_M>JcezO~#Y zYBQ98#baq5@Q!4GG!38LtlaZrmv5l|>xp{4y@aXQqa7?dyYOcd7Uljl7X!>cOB6a` z)m$H@C-u(vRbPtm6JKJG$CE>Cb(n(rey*HpmMWSdaavDN=4bT}0%*0&sznJ*m}FR= zx#x$=i7YdPvEX2uvo(IqX|CCs*MD)(7pYq5$Q=vw#7hqm2YFDwuJm+5q1j{olA zVPIf@M&Zr=??$UK?aDNPbWgf$2lX!bF$@GB&||he!Qd;3*Y&2q&{3JW$+JpMWv5DO z%jW8l;cG}f?eLcrs-)X;zL~3ezRy-zsHLCdkxJM`Vd3GM`_qMLjLGynw|y;Mrz=bVTUudQ!#S4b`F22v9k^}LxDzq( z%}SI`xox!MFAsJ0FVX8u%_>5?e6uQHVS#F)K`ip+h54tgd~uVvij6o7Dv`BKmjHqr z9=jTKnQjtEx5Q-7L75%%+xZzEV7dYx>+HV^#g_A;sh7I8UxwyD)@2@KbhlBNQPlSLKud_6v8qxt`j+H2S;0yVWeiQ$zTCqF;Iy)yJ-Cx$b!yr=R1 zqLCj;d@i;RBB)3KyuJJ^o84gIjW_GAd@#`OCT>D%TQEdPmt_@Av zBjHP&b{r2n)u0piuwE`ka{x8vpQQWzPoz@pT`1BmUA{)6=7PQ3@Mc9zhgDfP@R3lA zZ_8=FRJO;TX#tD@jDA;WH+Q!G-0B?8gf4J-H!%Z^8>N`y(XAU8RbU$T=7FbUgY#PqLMWP12&mUj|1aB)Ph4<{7#{t2Z7w@f9vf^8+dwp z)&a=p(L!yb^piCBtojWy9y9GkQmicC=j|k}06GA|UKmrx2!~%QlwhzBzdk$dVP-=r zh+6MB0nhW;j&9-lRj=atiVYa$Dkn@;#6v~pagu{x;~dda+i z2sYrpp3b;1DNwLZ&Tni<$;dX2jw+`~N6%FiIH)v*yAc;Yfuv3h=G4-j8X**wGu0`3l5?nBV(HY1a!y#Ms(8wzdy?`w8zA|SI5Br z^%vE{zZ-r5^B`D&8dbj+&Kv(nM^-%-{2TIa0woV!P#SmI#JO~#P|g3is>9jx6#Mb( z&7l|+Hsa(h3e0HJEw7ESI9&jSB_bYEU!6l`{&>MAf=(tx+e1wh<;0XJ9u(-pP6Y!4 zqgAD+o=wx?3n7W+kk~j2ywfk`Vv>Eg5~pK?AL9nt0K_O@)dFTbr0WI^JNGTC@gVU> zMZuRY<6k4S+-#@Yz+VTXoq1*^_dOIKYEA)Ch?w=lFIs?5x(u%w>7dFqz!=(0!I9=~ zg@A^RWf;Qn8J9M19srUih4$6m$)uO)LWhT4edvBPgg4(Reaw1VzBLyoT2Q~x-sUhj z75Jd(zhr;+U;@GR-X6omM^(Uo)I00={m5KY{BIYT-+cgeoqX~-hGJv~SWQ5bc3ON~ z|3OyR-C9$HRUz8Rs7R}P-Q!yDr6O;zT+=&9s~cU-T%lb_-$T75;Vl2ISU>J$(n1+IY7x_oI+Vs@mg`}Eng*4a2eH+06?@mn(6G+?+zfE`QW>go zwnIA<`87cfoOCxQY3z4P<+Ts{ns*@+IAr*(0o+^{HdIxvuUlFbh#})Bz0B z438vG47C^KiufcSNDTh5=JJ3MgFDbSw9bLOQwl4N(`o45Bq{Gt zAIL$=gWZX-HuO7YGP!F+)h#`{cbIH}w}&7|gHfA!d`neCc_*_ZkcMxg7NlzH&%uWC z5);VlV3zwvd8uDwR<$vv?IS=x=cN|$z)#;ucVm3|&C5Y0mw zL>1kFMi?NGj;N>>=(psKe=9n!Y< zG_VWRHh-f85xPj2)l(yJpCzetS+Csl!#=D^vU7(6FQM7ldSCwxde^0{@wZPobgZng zTrRs*P4wr_WPUlW;^oFe2+{%&t+)yovyM-oid{BJb1DIXt5 zjDV?JT^(zQD{U7vv82L8@Hd9z*!yUJ;+@Br2K$*^0;M%@nqa^NQPpJziqUv6tq?V_ z8+=t?A+2Wa;)5g1e% zPASNv(^=YEd}&;yUoav~#q@1}KQKp4a*(Jn{j6UQK6I323xfEy!fg~Pn;`~2_Z%|=>dR+aU-75X*gL;Rh|)M@o5Fwd zc`g*<7z@(>33}$G#jcz;>FdX{!umN!vh^H)JHt|QDxAMT;qAXoj>@V$Z6#xJl`)Mq zY&ndSwsrI^^9(}?&`@CSYtT2{{5W5ai&fs6w%XdhNaHcmQxf%j{IwmOi1(c5i`DMn zNZ=zbE^hw$6GXY5r~9Tm3bR0!5&ak3keoCLu)QHUu-zFMFpS^$LR-c zMet)ol07>D`2xSwU#c;ypA(#BMBgyhCcMxN^N>mv5fwB`i2BX z^PWME30+`lyN`ZX67XyIMw9bCVX=3}fbRT=15Klu;x>aHh$JN?_N6^rEBJUk&4JK+o~er-vB2%yV%5R4*s&Lj+|g zO3B@VSS`%ANR7UwK}?Cf5KKI*I70SbHEE`G3ZfACFl3*v$jl#C2A^|l6Dgy!SlcJ5 zcV7RwEggG%dI?KROwB=XmIngCaezb!zzP*kJEokxS~r5^V<+ZL>~-Jqa6$@JJY%-S zLRu5VS=nMuj}l1|SlLXAwE9JvnI)8%p$32CQRNlw_A7S2ekCes2OCBEas0tosYh1X ze^XyAP%5m536x=823N-HUn(F#eW_-av=A6`%3d2H1(WI4n+@@Jj?Pu;ay;Jc%hOIrc}xT z*rXmnlWhsufFv}LH44I=ql$U1T0u-m_?A8WQrRVOvIX~j>j5HY@(@Kb5v;o+eo2V% zEcO|1fdAXfWaadb8&jYwVKB4?w9)#0hO_#o{}0F=MoV5m{Hm_Wht;C$#m;@k_$raO zl%t8Qt z>|RzxsalD{mn&dn&xzC4(~0aHQAig<4Mq1$v$Wmqg6d{MWE1*(WYMqEJLSheoeL@= z9gndiy2n9lYwdRzQcut|A)ocl;{qR5EFaIyoyq6ZYc~YtuMr`YmJf5)x{TSY&VHA1 zRv2q`JKOjLBKx~h_)u~&5hR^I^XzBWuo9S1I$yYs zdfRlKuzr;^_wRJ+$ib9@-J>ZCa^744Tf=cdq(jcvgD~*vSyc+?#Xl^EvX!<1vq+OO zGBd|+`jbnV8=IO^TSLzXX=jS{LnOJ2o4bm&?0F2#M_QG@PfBrrpZ z-VMr0T0~+=_W?%|jV$I+{1iuXb>kba0bW+zSNm%|QJ1BOqVoacdol~l>9L15W|=~8^yM0fhGcIEvxv`s%#j3y zSj;k~zN|(+=goBP^gQ!# z(03Bg6PJ6F?aycAOq#_-Km|F|!aysE+_fJ>?Mf4=C17kg)V~E$vn?%^1q~DC=#4H7 z@OvMi?&>SeH0e4K@6B!OO!HRVLP$OHM5kNFl!tTz_SJ=1K3n~uH16u|N+)}mbRLJ| zOo$0(l#EK$+y0#0%T6vrT79K*@O{coI}LX`|E5xX^^6O=dY|?%^%Er`0AR zG#HMC(Dt}5%FYa<@sagy7(JP_0UL_!MI-hMB6abM=${&J|2c{3-TLw8JZd8Pa_+=Z zdvl?tN)??usXNf(WEUF$T%Nu}MS~Hcp70{ELyt*YyA_SF%HqXU3W^xAxrP<{Tbb)X z8%;XRGILx%GcVXAf>u5iD+qTG?ryQQrs`-7(NWulO!`&vGIvoHlT|wDUXDiA74QA@ z;yx_P0{O1&2bmK08RIL*Y=WG0IsL{>@rmC7!50&_eRilJF!(#sD4)@YXl;DP)cj? zGx(hzSbIh`E*2QUtv4Tu=hR$QpwV|+?FfrgUTm?D#80P*Gz%e=NaY+Hbiq7NN}QE; zgjIhxB5^o>xIBKmTA#<=dVIHi91?Fs?220{+t{MaNF;=*_`yX@l2{@&b+a&X@DP!@ z*1$fyC*2Bq=xJBZH>-JSHr&DDKdr2K@MnO~=pLsMe^_m$$aP~nAI)CC`KuhnNR6n7 z+Wa#z&%soht-cwHEw<*5C*CB=Xj0%H%g2#MGI~cJ`S_$wDte6=5MVQ#7|guWXzuh7 zeT3lXb~7v0(*+GT*mHw9g2;#8 z*?f8>vl!}DwZD6IkBj$s%5^_w|AzL+eFW4I1fAD=CwsM#-xh6s1zG6EYFK=Lrpgwz za?Oa~6KNDmy$_MkMDLq=i=mm4n0N9t0(qC|CfQgsJ&4sTZ$mB+mU9IG(g~v!!<5~x zy3AiP+Z%uuZH<1a0JHQzw2v&*>6985fl>sSY(9}7PoZdh9hb>JG<_UN*2Rp9g=1^k zA|E3B&eFcL(0P@{7ka5Bu8$#dyEK1ZB+t@+`79S--ddtq6*Kb6|fU>MOV zQS;6Jq3Ru@D~pz>(c7J*W4mM9cG9tJb!^)mb!@w1+qTuoiEZ1?+kNl%jrZOdIX|<{ zK5MUCwQ9~;v*7vt$^0AOY8&SE%U^hrk%$?UARP|PW~?S`^*kW??^YlcS z;`I1yNkiAHHUGL0YU>4k2%^x*0G&j;YhnfS$^1&-%9QQ`CaZt_Y1>8yL&H zn!MpOKfTDPsC2qY)M z{^=Hwt_nM@?eE>`t;y$3lj62HFftH(5wW6Jq4wo@W+ZN-o|XD@yFWw#Rb`e*6R@%Y zO4~(i3i8?{!uW^D)^Uas4f1l&PZ6K2$`KUkydWXcP;jD(5wcK2Mg*m1f^OYZ;ZKM5 z8blnZTt+&HVr-`)wKD`C)9^Wv$WrK$dgD8&F&2+F4Ti6lReA@%#b_7(+9@T>j^4{If|@7JH`_!(Th1c znvK_Gra^M%rApru$c(5b`-*atsFTBH0?Wi{xJWhIoT)%XvLt3xndu330Qss>Z_9H) zRUb=~rI{En+$#wp3X(&Rl+&#ler~7G?`q2}&;J-qi6Ril1|VniuXrz_jL(5zW9k6DIi+x~=^o>%`OXkKdnq@o&gHl2vHfUC-2t6{2i z-g=uU2hYw@@#g1@8g+D(7_I}i`7Lks(2(0en=ZAErn>EDhi7D(-KRKZ;qA)wm!t{^CGd5BoUo}hGvm{A2GI%3u}4?4;Ow1Qmh@aT3dWMm8}C0UJp706?CP=6Ywn9Cjcx++%89wRsn{|&Iw=+Y=-45*;;q!56XczqFppK-?k=7zO%56=0m;lNukL5YGz?3EMxBay%l0&2`3eIR$e`h z-l&){SKg-Xy9M&rN9d%oT0Bx&p#&0i0MaFM8d<7)OY(pI^LZyJBBVl6Uk|&2sJH8L z@nv)Fi(@S}1a?C%kJZ^B^IJFn+>w$Zi=o8H7wi?#AwnkSqslEuLm9ebjj=ub)(v{0>2 zV9JdgHV3i;yjpIO387~42~F+|Ch-48TB?5kTkhjAu^&AQbNUjQzLD@-wH#FE=LB;M zk^JiY8jvv8^x!wPalU9DmxtZC=A6!v^JTJ3x%A}|tK%oTO`RmXCwlZDd;Mc!;@rdj z!ziqG+=n)uk<`8ZM1w7SiCQJ}yQzGh#fv`ljv#gB^x0ttdC4r1_$s!{<;<^i7am4m zIk#{Lc(r|TIsBIJkb~zie+()q7lYX#WVj=N?9u!cg?dAXGFEf(TO}$moVqV^-cEoX zXvZz5Up%M$v8VxOyyS6RLTj-?W}e(9mAe32G$Jw2aB$*?lcF)`H%3w6@0$BP&8h6A z!8tK(Xgwn|s&W?VhySFjmj4LUJE!_ACsy{GbM|Dfkh)KPxA-V0z73D?{Q3cdb&d$W5r<20;SJkf7mws*zEG@k8Fw)`yc0$#O(ZE}L&WOjp?= zk;(Y|<+Md|ehQ?cH2)&ElEj+3Bx=X_3bO#DTXNZS zwC&I=r^Bf?>*lOY*Q7}>_T6GzoRm|oG}n49r9Fn#hS?DZik`$+UaCg>B!4s}%?|k-&)_+}&U54Exb-*S)4E40y1# zY?(O_H_3$ca9*m9`}#5xO4mDKhD;4GEpBffb}#x7c@Zdt61fYRJRG(1F=0njOP+4- zL%bO-B&`C#D`C;oqoWZt>rIoI!G%Kc@ggJP{n-AXao_mR!9_;-eIuTInEn!Tb1#&X z;Iwr_)M#9)G;Y-jJ~K4ST*%u;@*hky3YC+gJTC<^;&-&v?~tE}1#J9#&#it+J3BiV zPt&FR^=?1e07FM4_wv~=c!sa};Dx*DT^~ilnm_U#Tl-&xWJ^IUJo%>8hOaZ@OFs69 zaExqd=D};oMBpuLC=D>-eIuM|3xkre4ax~a2kKF9vf`Z#aDErC5dZEG%qTMO-ApT& z#u23wc)Xwjs&!&wGAq3f_g+8chkC~z(|GKY8An$dPgxtW^%IXhGtu>&h5Ak}b(vyv zQvUWuH{+>--{v7K2_nXC_O~+?+b6puo^((@?%sTGNh>M#-e{1BT}A|SQ`7g>xRciFl*cHz*fxa~Oa&hh?QOb=JOKmh)el{A6pDE3;GOwjr$1qIP(DQGNfs zJ|(FB3Y6G|udW0hUia89k9s%Wi)>0OsUR~C@uD1T(a{&tIWuKC+fBb}Y&tY8e_jg> z-hAlElX2J+GDa`N&En}RKAnyiCHgRJPft(h%MCo;_1JF9**iBeF)>z)SrK|M9Pi3^liWmR+N5q$*yr^Cm` zZ%D^~E^7Xd%Vs1Y6pIb634qlEO=r6_d-G_ebCKp585kjFzS5r%jgT+&>UcxqH$6#r_|>xFq!V1gKA zVJ&l9GYW>qSYX0oj)iC7$;r^Bh0ESZT!YQ3S^`=;irDPt-7&~%Zv;6q>N6_0Hy}3l zc*&S7KaTh4?bzl5ymF~*d+2<1`YWmkj8omdOunt1Rvf<#v&*gCv#B4_Ow~ zfF@ZZ(~6Ao68y>%Wp>Dyu58DjC56xWA`O+yu~Up!4)YmiOOV=Slb_FWBI_lS z0F^j>mVShQVT()=P|O)G?6911yUPQ65lCr?(eRoq-yxcod~zIlj0uBQ&sTY2;er^a zlM`4yi4nqMLt_lH<^GztU=<}q-&yRXMc+C8HLuX2mgma$S6h@HnpFyh+{Gwo~R4lzZ3ATFa^T9b<87z7Yje!6xPPA z{P_}{so5FiL{RW^ECI9qklA6ycnI!zJd`eG$0vGs1eWl~vv_QuO@70x?DF~Q`9zC7 z+b#ZZ>0x;BlLJ!}K0+xssFYkp$%k*SjID`Ns{grj!`}V=TeKc;f1FQ<$Br%5C110l z4lP+|ydEDa3Jc;sm~6&##wC6$sX;2QN1Zo=H^wsa6_eBVY(M8X={yG6^i7I%K+Zw8 z`P!^PnH3D^=SptqSi1tG{6Y$y)O=!-!h%&$G3wUhwk707(J0r}z1$z_fxvaOipY-Ex+bOvO;C9|*AgiWtGIR{T2||7 zY~ZQYtA6zRp1L1ZVlGK5>`ye?bz7-qD3xlPg=duLll5eU;CL#j`$Sjhocqaey{e*$ zU>{gWzK#|7%VT~}j?S|Pg+c(xNb+ScFz#Sut|B|755jsc{)mN%iOA(-?nX@m*qzCj z@7jRT8a7`EH^#wEMPe#oQ4TH8?U#4iM)-yrpK{v!>$?Tpxm&lJc-m6kH`Q|0T(OMO zOc=PJkyQh5JU0K>&_H6+oqQ3Il#a?a#d#%V8jm(7$|xH30>>!!iB57Cg!#S(5wn$) zuum;2K&(nQz$wq5AC1=*vJtr0vE~Jqk!g|Y=?Fg0qxzS(>vhW~I@_~C(~h!Mi5l$H zWT0{1DSf6yjvqLe(gLTV*i_02OGev4+&1;eu;8k;^NaVuOI!XEu@-~_j}s>EQNuQL zxCOzvY0+U#(6I`u%T|q(pPLTf-Kd5OlG96)U^ey^rYLn;jNVA9*s}!HJ0vy1nxFf2 zwe1bIS;db}E@ksfBBpyVX`#Xoqq*K(i=Q>SmxD0`QWFtPMlU;6drAC8zbGE7H-%1k zFp<|~=u&I#DP0`Dbwzi#!wPgHoxGcfyg06>vbB@61{`oaHfgoCZIV>>OfVLl6P}lF!+Mq~54zc*UZNQJn2>7npiTK_bEiqEQYssi013E-)}6 zUvIa5aR}}Mj}i`V=!kaox1^ru!`(ljp-+@diUnm;N5Mwsi428B_~qVf&)fUezCEdt zsxK^NQbs608s}i1Kq7;mNC3nCthdI($~rfJeZId>mO`pCt3^Hy=A&m)7 zq*5L_t&O6!=)`hza_Z>pbZ~P!%%3LidOj!3=!J=FxE-68;w<2%xxRyYO}M>#fi-Q= z3y;a*D8#|ce|=*=!hU-(c|N-eRJX&U(xnAW--j3~%PcNmo)DT$G>|mB>I3!FC}qkJ zE-Wl;W@hGIpgIDX3Ffh!Gw+@qznb+oYdFys?n&jWEtsTpkHMR#xZNIH%< zn4JApw{PFApzVd{a4L($ZX?xZS9+KR;P`;|Y=11t292Nrj5G9g9K_yx=hPSTUgJY)+!2Zc7*++rvR=!>rSiQaAfjfs!}I zZ`FzeUs?#E0)W4(OUBKwOQM@fxYh|A4N^t*4|^?htCa~YEoAvw>=f=sY9Rv_pX`&;|DI|~SYP-??7U$}&et3z`|gg8 z&G0YUqIWN>G&C}pwy%)tFc5T7ijBrmB9HWw_J$-G1VJDWEhLs1`6Rzwz1-a4ulL$p-sR*}@fIHdBl+(F(Bo;cDH?3{u)nF`Qkm?&YlYW96H^%|*BMJreiyG5 z@>~b%_*&a_?r-ql2bOA$Y8x91fq@n`Eb#~wW{5yvB()v1NtNrXKuZs%|y2`vXJU17<{vY! zi&#;;9U=SQef{`RYt-wo0Jr=*E{ur8^&wxV+|&7F4jL~@KYz-_#f6ET-SlFu)lu>+ zR*V8Dq~vceBXPOn0a9@!hLp}JCCg}ksGJvNG>CK;gsD!if(O(_ z|85S+#cqR(scKQ|L6+xNRWANJ$HUL-s@2TSyG%eFR_}Rl3Dn|(fM)Gzt(66nL66ky z;q1nbPDDH=+T`C+*~9TIy;o3TEzwtsR+)@K+0&_&)U#ljFuAgQVmrb0UkL_$O|Aum zME@6X`2ROUMNVAZ+{8l$hiIwFmA7<^fc7pMXTh}sjn7-xq7EHw|fu7__l*dGyr@CIBvhFN)>A#p782AIT zK|0U{3NE7v-)K-yxHxj-r%Htex+1u1Kl3P_K2QxeHyd*QKM_AHhE+8KE#vw5d6aDX zbki0cVfZqyuw3>rDN8beg)ZSR`;TMmnX|R(4_~!4Y3kwLfdO!N`Dp?CkRYk=lP0F7 z$$yMGMq;A_LqZ@wK0X{JcK}~I;r0z}s>JEv5Fl;QQ_j#Q35jqKZB|PW9)8=fcRW7D zu#Ep3cuNDqz!fK?;h^)>?QpSYe89p(>?E>zu|e{Y#3n;2|DkoP-WPcfWPfe zb+z=yTH3$&3%Euf5eh)DgDdU7C6Ug)Wyrplm~P})WoG>>^& zd{^Pel1F47DoXcfTQGTr?w%uPJYTpqQn4+XcEh251^ES6S63g9i(~`SSxoWZkMoQS zJAY#41U%%Fc=?IT%gZ~V?);WO63ry^w7+1gU!fJwt^7Igz`sYIRZ|otZ3&$R^dtb@ z(0^R#*KSC{0ws{h;Fuh6MZ8H#*=8R#U*w?TC>pm5n>yy$V}135mrQ;FZTx=H=S+o4 zR4FiVWV(>>T^I+Kp=zX;uyt?Mk>p&7bG+_v zVI;-)^@h9Xt)w5a+Vtz25f>ctnsKULP7SVI^hxN_P0B-8g_eZzpO_w{Q z4_VufW;PpB$W2+`J#F`SKz8D(_`62Xk?R#8jX=g$CD5_t^~CRmus%F4?JNT($;}`^ac%9}X8RB4^zQ#fls<+pPe3Lp`_+OS=k`1xe9)j7 zozpDvuI73WV!&*D*_A*5FMV?Dx!nixaK1X+?uINNADSu&12zO#HU-GU85#d3Ne34U z^ln4qz1o^A_ImxFH`PJ(Uq%i68^vR{+|Zv~o9}viA4SsWrII^bvvPDSY8z^3s9d4o zIRszX`|AQ7h$tL>mLyG8=HjDy*#9RaffMn2``#zH_^|)#j(6-Vi)&Z1RkLjw0|Kl4 zBNWg41TcPMG)F*yPOIUMezz|gomL_sbrLTXFGixYI#AIllp_M-@Z{K}`t$Zd|1}G= z(F5GSo&S^)`mYQ`ZnJwt_BkYQ*Y}W$OMkZD%dLHrm{lc|*P47gfR+S;Jqr=Ve}h}B z2B)8^ffgv(z14FkhXybB1g&pLB8MrkoTbIhWb%Eh%kNVz@EiOSutw7^_yx!OuIDR* z4Hlq1GwAK>JCxJQX06+cvGbW2SAbKw-HnYq z+TzK{*=@=?8Eqm%%}JmI@cA=G5mr*7VZ+VMI zlOdHG63LL{AJVsreG?M59JyRRz1bkloLrS~t`h(;0M=zEu)90ncizmIrSr7RE#ecoe1QxHtd%zblnDjO&P*rkws=Z+KlN%vo+7g zR+KvbY86k)%&RJ!e-vW1*!zmLhdT=U1zDA@kfz!;b9*mXoA+}k%HKpQ&l9U3wc#_U zg~$gnkGe#*T!os=W@V`;-y}Ls4n49FHoww@FhwjUaV>4t27Q`=S7>u3GVJwRjmaaP znr(+v(?n^_OFzV6g=YP4o}|pV-+(a;2RgM%thAxH4nat2LG|M)Pd2S4^CZ7aMfdzH z+Ip{1#{hLxbRb%WqzfA`UwKfTW^iT186S^LwM z^$D&TnIhX5UaqlZuoMTzG1-O0lTD~;3fy(aU*ia3Xk+P0AD4zX&h&ATvAy^6$9k+fIj(-O=BpUVqHlHfIKnKXpx@MWKt%60H^gEfTlxJ$ zWSAqMNC*jtN!T$ci zXrtBA$TlhbN|=Fc>Oq~WGMdLG$F~R6lg?`TvQ3Zz1%BQ=@>l6{3&_U;(VX1eV~;!8 zb4#%Z!OmZJa#`5f7g&+9va(P`h4}!~{=a+wC6|eVW0Cgf>BR+o%1|Yhlf2{OHe|zP zXMu6AGu+BwVPDdUKi}${cchO1NC4t_*047$cS=h`ISeqyv6HMcggHCK0 z$Nx5Z7|{%#$;D!tLOuWOnG$Hf$L2sawDmUBnLi2TQYk~U?eC2^fALX5H+BYph}#F- zpNo@4>(?CbnZaGAjNdLM6AK|N;C#Bn0RfX@On#>7;Uancoe}4b-|n)9{EMqjOkI$` zX4TJ!cT7l1jmhBus9(Ft3OmAcPhUoN5&K~3oE<>e4)k~>NW99egv?ZWjk$?qt+o=- z*m^66%rIxEBpz|+uqmG=Y{wwy!ZwXV{`FeZh(i zTjXj#h(L%yPbl2_9;?l5kp2Tn-;iTB4ndu_2h}l{Y zTB7v10+H>TEDm>xERAgS!NCD}3OWC7C6rGr8w)Mhcl2$fE;8V}c6Aq>{y0(JdpL zmPJ4nKAh^#-`%1gi2Cgg>mALkA|mg2HA5wvqge>+G4$2g2&ZGMR5b1)JMm~0d^AM^ zd4*fl43ML}ct$>T&l2ccq(@CHx<%=i&w6)d`;WLyX%PJ&kTlS&hf1DVj$c;))0cIM zYN_OxjaS-^yYlzAfjVVVIYFi#T>0cE zw!=MbzvFMYL`n}g#`l@D?d2TwGyNKBk0BgTG%)Xn4c)`@mf8ax!cVNg=q#zc;E<`F_krn5#Z z-vKGW?SzPXF*{aGKLbBvbvy=WVA1!>SKfs8cC}BEM(L6yv8*?;32~Q1fDVXVYIU^G z@=NBuN^agwxyizl?}qr9Sx*kk3WE2rT1=Np+lLa`@9FKG#I9LJP`zN6S#^!4QID?6 zbF<~Y#FeVAI(2^zX%W2lpm^7gF}_@#o5O35LtV6Pb$AgdY8(p~Pt$BT?MN(6rxf)U znmTEKe)rweKIf(StMoZdEB|HkbZEdULh&O;bFP&}+V(~H4~W+_r?aoM6ZS|=BJBL; z!a4o(*Jels_5JIG{Arw*M@AdH5l8k``Z>JZCr6Z;rVb}dIbK!@e-aosx}12(jOPgb zMnTzRDm+Dt)Q-(*Lrn?lEso9*olbtH zhks3-bsw2EcI1#yifFuS*hYzzrBMN(Yha(}vc-O%OBANa=-}xkP6|PCv=NY_g&beM z?2ls>$)pk6y|)*^!!bCY#xp@1uO7~3A<3m1nox&9HvcmoGKgS?%ERn2 z(eBI8UIjLLvc+N>iV)F4PU-54y6NAd;ct2(e<20$EjZp+W%mlK@VObdM@*hr zqKB~-ZJ}PfzKzF<@W_RIp{A&sFc*%2XYeH}`QgyXnS6kU=^)(xRagyg`z8tW#!-pB z%vZ(SZDq&a@vJ<65^VHGX;|o8o5k@`TWJw*d1rW5(;(!_zQzrr<3^E+07<;Lrb zK_zzGDSWAAj6r`G&00%M#&RXg)&3UN3f!7-&0m_K|DQbi30KJZ;>IbtqBZEj%d1aBl?Qh_Od*9p(a1mqE>7z0Vyy2x&jK4we-DeP zGmm$~vI)tB`>#d1D^>GJD$Eo)?7H2yInWXpH2L^ib|<$gHJ$B-{a~=F*{-> zes9838UDB(Bq|@hmMU}{%3pLtRbQTHdb3L`)8QWJ&*di?TLxHWshJX*O|&^YEm)6P zb{lBEqeQkOM;Vw+F%~H(=-wP&M~)?CJp?JST-ukIanE^$hbYr1Iuzj@b6@P8y;;7k zsA6KP)e@DjrPt59Lc}epZljQd?ksczt8=aDRm7$pRF#d85DnMQ-JWEsJ7S6M^r!N} zI<67uJ~W+3MYcsWDn;n_er8q^M<)Bddv$e9ai;H^FUiM+O@P1zl;WY4$RhFO9Qw*_ z?gRNFdAooZhm*Tixy+n=wxAY`1gHs9gLnccSygv%h4wyUOOvRXLG*ZdZrLWjY_~c2 ztZVcL`G)`y5r(-{o>7z1;Wnqm+EY892%BposNtqZp*`A#zGNFPYo9&0-0ZZ%k#C$Kbmp zej6Ne3UGImKZLtxqD*W?5-Rz&PnB)^q&6I)^RGy`I4i|6<%%Owo_kj|I3{XlUlFNqJ zlILgPJKI*=lh)V6dkTg|mMEzcQU zr@P_TMi%#s%NhO;XDKD0U4SJ6ptlSN%#j);8-vLp@YXX&E1+s+49~S$PfTYbZ6>UJAEw@mC}Gau zoCdP`p0ZXyqu$3p*?Z)`2cTL__ba}vj*zH744vP#I{rcQY`2BrrpY2kKy^M zAFcjPwKR@xAY19OtS)h?DCz`6(|YkOwp0s~`|eD#-n+X`$-*3U6j@*Q@f5n3X`^PeRH@-!ldthu z4n7_p1RKp^xRRp;v&C!y6a&5_W~r_&>h#FNQapoO`X+fuke{$MSqLe`6u-etS;U*Y zG**5Ygph(${o&q8Dct#b!bTuP&0Y@}uJ8amzmD!wRJ3lfBkR*hqKMf2GqF1UYi`1& zpL6*gpvaZfYa@eqqO|Aqh-I8KOd=5& zKrj;pe(cc7T(OS5AJJ36`|2C{Je*%N->2E@lG`d~xfs~-0}B`F47qm3afNn$^i1Q& zUn)YF;hxidNZ-`-xNb}MAHVfrW|Qe;*=^8s^g7{aVMat6>G1&T4s0UfYG-4K{PK@j zIq!Fj+s%lQMn?!C3CFj$Bx~$$$duEEL@SL%smd_`&&88H#Wa0hV^^uZYd`A-PZg;rF50$1`o8J#{p z;3}vey1hL6b|(;~a*t}}jQU(=?mJ_WsIqnf$&-`M*|XiFO9y%>l@hVnmaigY!_+32 z;Nou??EW*V3OeOH^sPRS_~jn6kOXHJ&)ZMi)%~XyFOa!0m}BDT=$6B4i`k>1uh^VK zen>%f#hG zHFod3VvUs|!E&nsF4@Y%LW>V|X44*L>!_Cn>eS+9Uo!^NpjK&{hL{U6zR=5i+|i3v z3*jO}8;-D>Nx|z2R)>D&ZVut~+?TIggBaPq35^hUtu;BdmD_kOi1s9=>VYJvzk$>8 z^S62(Qk-WFK=Xgutn)gKkvs6-L*&CLap1o(neF`?6viL(xyr*U77_jxgJ`-BS^Lq) z_7GJrB|ULawyl$x)v$xN%{3Q(%^f5~FQz{W(lrfnaU80eu?`uC}))zY!3+R7@o#pD2z5GLs zKMdRmeE(>7e{yzRva6*jgFMuvpW_Ck)61^grI&IB*0^Rz9#NWRlo45MU%q(1iy+ZK zg@t|Q4?3SWCW{v}rg@$r+vyAJKCfb~X)GpXMnht67{H_yiaFKw!RaujqKL`i=J2NL z=BQ9^+L(=ubb7Ow_N0=5Q6gE_82tiieza$YZHwby-A&415rRBa~9^13fj28Hi2sDwC(Z=$+4 zf%+yy!a3g@T%A??(qmN+5I9T0Xp?T$TS+aw&(vzSdN6CMWCQEAA4!$D&J4!hXj-)A z4Can3-`bpU+Aq)TD482f##*#Ax^-nUEa|X#J-#W2G#842JeJZ_f9}my?LC!G1@SLc zY6)&tSqd)c7Vh=8CduG$BykVYFrP(+2k;#*6}35R^=p}eUr?Lj;sHAu7dI11;nU^g zMV1~lD5!UFHO2!^?T_OlxmVOz)>HjJiiaGJ_l2<4$IbES@brVp467pJZ!=_&duGY%=+tcVg_FHW{UG1ou8yAH+%1*} zMlZ(Jqa%PQdy~h@f5>yXl|rLlNyWz8Uq<#N5sUVZ!7InW-GW`1vsF-|hZB4DccP(S z>9E2JSH~T~Ru%G`z!6qBLQnWF#YsugE!=VQJ-qp(QU}Ec(9Y)rb8ideveE%JEKt3d zer9)jUS;Lap7bhG={@BdN!ZLOec$YDRK(y6QmLbkj(0$?K!aJmvU`Cc?(_waM1ys3 zbvu%A@L8L4nUVR7YviXLs~h~7Dq_)Gpb;oL%+Pe$Yd=_ic?LWnH7p{#@lAK0=4tV` zfA{Otm9Tjrum6CXQ2;ULuC$=T(bLIerqJ?C9?}=obH{qtoAHV7?T;neH8VT!33*e; z80o2du!?{E<5;&l1L;z;Ro>V3!RngX8ht)*RDq+L16P%z@wXHmR3&|AWn(>-NSqN( z(ClWrBNwXNg0t9sj+oih!*K%4CkPRSJ7!G4$zGVtVGKy$uJYNP?q`eOJSh?Gni96K zM(+s2^}0O2#Ex&Yv`SBD8rWS{RGZEon%IYQ-?9_~(Ad%p4)Z%@70PFOb0|F1jUG@N zKdRUq91j7v@7k*!w^Q=v)~uDA%T`9*S?T>1V)&m18%kwr9B$v{<jMu}ib&L4tGQ+ld`HWB`i=`Mlcx?e~a-4mK?K>@O_L&3OB}m|HHpC-f>nrQ7R`!v|s9 zO=qXE9m5p6K0#~xGiJ2B8zAulVg)_Q^=^ed;7tT4XsNyS$IyW}$rHe^W;Vd#t{JmB zTYtYdEx6%AKMKwR^|MVFCKw~9`=e)m5|-m}Am!%_Xue2nKXY$1>6?=iNvjG{5cu>b z_M$bO0@a;E8?S!-#X$8ct81r1ZZUs~Kn;9)fJ_Xp4+dkNwIlyI)>x|1rXct9}-xllDngb6(Wy??t_^o~S zG~yb34ODm>KEt%Z$uE+Mr(e!)y(xUYyBh2|fk~BpPKwga25&yya}K9h#$2(K$}C1d ze?|4~9T@V8K-e4}H`mO^yS*$b+Ft`(^L_~^=0L3bBm6C!)4*ERN7TBB<;&#N|FfkoNag>iiSVip&;-n!d&58`oL1N^Wo0t zN^^EYI`JxA5;lVtTUpHGJa-G2TMbOm*pr4B8mQ>RVtOW98Ww#`IRzkw*W00=?pVtV$WCc ze!gM*fS^Dfuytz(pGeY zgL3kDw)o;n@MxMep4+4TU^FzkC&x&^krM~-26_8i zPMR;rzdcy5jjK7A4QJ=doGU6UmWjabrVsc0x==+36*iX2WOVhI;z{{NEPJ~%irAq{ zo+avdyI)6M*or)Qhq~E-H!D$PdoES)tY-C($`uiMMu#**pZ$>}jxl90l^NUo+)hw7 z-T0-&7jc0`j)EfV8#{UB913VkCZWou7NJ?7iP01KqCjv_12L+=3vbSW`IiSo6J#`KC8nVW+#k~0= zlA}hg!HI7N=2S{QP4l8YLFjim&KT=j32F1(nR0=-sm9fU39fi0SuAs@_~((VR*KnZ zC+^z|_dJdUcjnkQBrf`DFYc(W2>-F`=qQ|sMHU;HRgB!`BvUg7h7HTSf5OZzT1u)$ zY@sV#O=%}f$PiX$31VPE=_tDXj^wemh7paN*J(gS58&Mk_e0wujo|(@@ z8Pox>+V!zD9CKw`)uF2_@7tALjYng4xlO`-1m5xUeTj@0u9_k#29w`lD7M_*?U7V) zJa%uC-|1#cRVNVv_aY6m9*v4MBBxj)Ev}^dxJvfhb6EFo|9F;9$-Fzt;aVNY zbr87;krLm)QDWV5Z?@Kn(@<{zn`&SsADUETM>E#eXMh)?E|i2?0Jn>96umMe^8Bef zp!QO~SmjTK_3J+*<9VISyDo5QF|ivDCt1Z-;CG6*bUJ_#W&sU%M@x-T9*0 z9glg^mu}^{#?_c%qwVJSHe`g4n=WBd{m5D3Tss=8=UWszN2}Ek3aAE^0nrc)2CYP^ z;mFDqAr;3Z`+lz>FG zlxwNdohNd z(bfclPq`@q2Eq&w3v56mT{psAfAZe!Q`3yp z?bjI~O=!@D-uj75qcjJ|ikDIWe-so%i>cdCb1SQIu&n{EtmXNP>gR(!pl5e>cD8SX z@orBLkfYQ}aNuw;AERt}MwGktn|kn`Bh>re>P-p2euuf}e}@1|by-iK&047MGQ#Mv zoyh%s<1z3wfpF(N=rZ*^`I$)2;_?V4wT`Kk9v6|slt&;?iD&cX82xryE;q)yv~gy4;m z3JrnpVL+;f9g`@c?y(tt4`#Rhi%_YG)P45i5Aj1pAH;Y4x<+jLU8~UAI5f2q`wqX3__~8lR!v)SXR0%%IV567Wyih!mm{y(Z9+*0@@|lgi6NR<>BEH#xfp2S>HTP4u=ScrwnxAhi)BWlnN5DXX`A<#oAO>TdevPRt=AEFh=<=`%+{69>+bx<5l+lQNk00|y6xCGbW z4grF@1cC>5cMtCF?(WXw?h+PvcVFDk@VwtSb^e&Dq*9gIo$2lFx%+orHv?yz1I?|V z295pRZpgL9#VoP9g^Pat-me5?0{R>;nl<2y?(-~>JZjMO@ zVfjC!S$5LmNX036R$7x*46(KNTa6hTzKk{hdW&dj;g5hp(o|#5NmYPKcD3Du#>$@s zm>KT1z`Dj+1AhrHu=(rAhr)a44d_1ElzW!DD^(^5tpf3%Aju33O}-@WXNp>8{dZly zGm@M)D}Ohoabh*q1xglkRSC&6mPP@NMXX%zkG#!SGj^*#rc+@GTWMEAnlASc7WKwe z_=T>2&*U_K+)bSVxBdtt3O-ky0+zLO=jXr)iF#uP!fgBPfaeh=ebZ4)qoJm)SoV*w zUaD%@j-ODbi^d!7wiri*uoL<&c3wS><{sCB+W8?Gm=Q$;P!p*D&7R~zI9kN!!M_w3 zNAmPf5}$u>D4;kKi~V&;Z1CR*{?hdlXs1v*0204blN1XKaKQinh>*hDS?Q)wgn)=MUvTaQDp@RtSIx>vK z6=-Skma|h*OaS^I9%Sc31G#cap-f~{U{&jwY`ui(m*J;=qi>oh#im@T6_4_|wia0q z6U)W-i1o0Uo0#iISoKfwwapJ@_3e3?9qe|wYGG-&D`a8RWbkEK?XJBnw0u8LsYQ+7 z62QZbZ@QjaN~ys(YvKL89xmVKcSV3&Qp!`tPx=++)(dOyjq657S8xZ&l+ zSB`^hG?N{w(PAI91BC-N?SiVawKqKc+qp*MFRjNl-O#&tNXv!zdnmee4&<(n_$`G+ zuelr(+Eq5ou0cB(`jwlxIG&xt1($w17~O+%t;z+$bn0Rny*!#Z!rVO7V6i0EC?myx zfOq$Ssl!OtIe)sF#7zeLi^RTL`!Zdt?FJeK1OfPFHc*$tSVSm6iC;L1w8i9!I zd`?5Y1H;@D(c0kqif=eOEIHnas9Llj53X1o-8Q&ApO%P7el;+(M{diUZj_kgpn?+h*JP0Gvbo7wrZ@g%Q?K9-dY?!fN?LmVv#{QV!_`*xms@(5~ zxKq}ol;S54e+Nc*VCCk&J~IujrnL8n>ecJsn4Da)20!Fo4AZT3y^AKZf6R5U)Y}H8OzKFu4_rV=^(qKl0E*i+ciaaP-IqYvW5%1vUM@38(uCjD?$UB zhw6m~6s(nHDtQ#&aFDyMg~A8Y?1gGGq4vx5Beu)>T7|Xz?>GE!{n9a)OUi!tVJAJfs-}s78|Z zm3l?IP+ZkawqrW<+-~t-PuhBt;jO4nwS)1v{EL29ppK=m0;L>A*DK@uI>YIr zv{1)anurFHFFVaWHdjjP!f1h3pUoaH0H)vv1?~x3y6)LDQXHepK(Vx>YV*cN2E@=w zN3e`cnT0gD1$%`QVP_0%`}~s?4w@-+xTSnl&CSOG7IEJ*-+Y85Pyfu^TL;LL*NQt% zD&J1$A;xjjuE33<-h!(w?us3m&jCw4^Q32=jA8wt|HSnUf{A7#j>F=2_h%sl8YJE4 z(*q^u#EA_!$&}HR!Fe1*o+XyJ1lCf;mK~ymHF1&njnoCkk~~B2X(DQE6+AxA%_)_} z&W5ZdgYlKP0(`{InHM}*WW4ns9E~HDf)PF!4-i&sxOb`cwtvtfDBBz73(~9UXl`k9 zG_@G$X>ooYam^I3=5Z?`dywhX9vm-E$7%==itL1z_K5O%JcOhgii)=!;(50WV?5fy z_N>UlB5CZ#H%|Xm{Yz? z7%C>y#ZhuDgYB3gi}b3%MNS~p1Y6xQ*A!+M4xcY&DV@N-0F=99lv zUf$#x*j2~}MHR4W{Mq+|;@}9#$OUrs#K0@-f<8U&z-;I70(n3~nfUc09d_Ll(ohM4 z(Pf1ElSS=sZbdic<22z=4L%KRKEGK9Gr7Vs>sfx5yv?lZ;|#6vEEJm7-$W(o%F@4^ zEXc#BIIXR9MGt3+L(S$c5Xcrg*)%XMNiq0Jz*0%~}-4Pq0zIh=mH@TmZduJ!|?jZ$WITc$aYKzM% zpP8HCFf5Pd+(4gqG{kw+9VxU~;);|t_B3_>U?ceb!=qIDk-NYcT1>M5_5IAPp44%3 zimbmH803P@bm*}){=#bBg#Kgfv)z8&3lADsnLy>4vdAyE6wDueb5OYl)yx<|bI3VL zRY#PmY!<14enM4*-I zne}a-in~4SpinCDd1{%I8rVn4<^yu*?vybcKUhp5kcgLP$Ko?ln#s&S!&lJIv9zqf z?%LVKyaY_*bld~+sg>C5c`(qB{?%$$M#jmoCW*4otS0?1%*@PVoNFt*+l$4)!S;B0 zUx}$Z9^nNNx;ROP;>G17GVv{J(%KWuY#E?9;aBpvK!w!GT zv!{s4Sl&h}-oCE6cSk&ZlsGzg=)W@DJ)KiqD$_rIZy;CMAgRV>FV=AJI3kbabIUeL z4&3akc`EQAeC7}~y_B@@D#kxAj9~W~yTz3?x4PVH`4Bn^O&PNUxjmW-_~JIu`521d z;H14##zZcCN`gMFkDBj_hTbSDk|T~{a(BO3`cH_#*y@hgz~ePKZHOzao|h+S#gXbg zZ{zm{Q#pS{h|3wJ>shVg-QxSWPYtq;fJMWQ{uuE0n&R+X2$*(Cq6(1+xmJSdxWapy zNYgvfrrhEWe@M;wrq?3ZcwTv-m#RjI!v>DzPogC{IIcyv9P`^o_A#qRk$}84a9o1R z$0goNl|A1H`&@0&Xrh1d^YR8xXjj(AgZzFlrV>5e0%(pkKL;xaUR^4%rrCn1s1O>g!Fzh^~(Icbfrg=fTvuo272;PBCvHhuNu5&zF*d2tl+Ymid0g3jzpbb;E@ zYFi5cL!D|lcbDyk&Vo~|xnm;V__lE{l=Md#5l=o5R zl>iS_1R$yVZ#XG%{dqe6J>y2J0(4Z~eM)0rd;TsKn|Wx_GSyti+Pu1#JnQ&{FMW== z+EDIMcBmy?2-}(#UQgw^K(6XetRxmp$8o?-z+(C&i%I*tb2OP*Xxi+cBYrUqXmB!F zXSM0OC2Az1k{VH(%Pn2_5?P>0V|)0d=t$T+Q8($}6+r?gjU$bpes++#s34oc6MX&U zCm7o1fJ9kWM(QWKJl0xXuOEwKuu@{)M@d~Wd|0YeNvV#7M znf}K~kqDqW09PYGeYwWy`wZURP{S}h{@4lLGSUC$W;vi z8GEpVIDb;3S(($uUJ#iL_gd%r9PTOQJCQr^|8N2qw=S0e=}e)~jW#y-4vN|Y-*$gRoo8TfMlT0=rEbh0N{LjZ!mBU zS;cK0Hy66hM%)(d9GD~YXq!*{=mlswrBYa^mf^(|@Dpx+>HFT?-Q2XHVT1c*ePmHy zW|QG%lUN>6+FF!yTzYhE57weL?WhXS{qla22Ia_*25lw)zcJYuDU{;&Oe4cJf1Zh{ z^y+7`81c2>me(=EaZlM2*<_)|G%k+x44Ky%Z7P0e1pLs{b!$t;*hC)kvmoIsx|_ZD z4&XN10+(a2lFxoiCGFVVi$~ybl2}3G@O!%F(T8}xzTnf)&;XP#@NN^J`pQZ_YTOni>1HWcY=9k5c1D)i z?So-NsZ0rFAff+;2h)EL$NKidrt$J{O#|4Q5bZ9cxnRYnCdSgaRp^6x!5w5C0s9(C zoSyv=_ahVEi&TD@Dvf_j>`&hZ7)K)V2qAaLuz{}AAqqg=AXXm&qS7F0+r8bgiu9e{ z4X)hz^pUs$n6IXR2fhp#BlpE)K9dwTre2=VjcU686+LzRYV5LAp6ETS2{V#c zAFmCnG3An!ZSB(5#?|K6gRtO_o@3sNeF=uA0lxMB1|YS7{hc5F(QAu1(h+*AmK%&B zF8r=0p0BsfsFqZ4_{Zog{CTJC_dAjX#0FKuKDji&?Zwn&-`p$AvudS^ zAtQ+}sICV-pAY#9=-ozh3P}`1mg8=qyD~D?F92v3P%{eO6^xmlO?;Ux`6U@k8+&ML z4i`d~=f%urhT`$CIb3&NxW8C|4h{L~QL?v>Y6gIfUM(=usV(g7ht31t#}oLDda=I& z;ISLHX>T*r8!SJG7XMNH!(rqD#UYGkw4;<}TSorWz;{E)huI4CA8T3LK=_!|z;)c< z7q^V zjZZUf93vE9C}OWY8$EO>19`Ccvxl3?QZSnG?{B;2h-eaC2o=y5V;4B!q}6Uu1G@28 zpDuHmT+Lo=WYNv=tM3GNk7cYV_t#YCKN+KhjJv_D+GKnMy2`4%x-l zu#?A_`UD02D{yLa+6o%{L*V8eMAX|rI9%#}qZw?~i3K8sSe9`IUJjg1pJ>LXk$Htn ziSH{EGKs)Vc{PzeYte$CgJ&+)&({tezYg-M{SQhbk)*J51mE#&|Jzk;O@Ohd$){?X zvwf;Xj4#;{mDLdmhJ)^MgjKin>_OJ%)0pq{7Nw%p1nm>f8HI;rMel4xyPhu1&kw3I zPKaK=B^@psXUx6oUPmXfVP|x*G0P1bwy#y#36{96@B3-Swqn8#M#atW*{6iXdBd6Y z2Y&#fOfPOkZNc@c6{visV`DdeS8cfNwQ~p(-hDiOWc_aCe{}U{S&|f8`kP>?T@q0# zMl5bYS;pH*qc3Yujxl3@phXs4c8s1E`gqw@SM7MQA&cL4?yT)~O)ggE)qIV2`f1|m z6N24AQ-fraiNJ!Hq$`868DTGjGUYBD&Z4AAf_RCgI4YdZ5+is>N_4oo7A>MBW*i+yH<}C>F|IyrcOCRO`byxdeE?L{IetBY2jpml5CZ7n?l6#_< z6h{HM-Tm{L*1Ec?OJ)bjm&sO>1G_eg4@4W<#G2MI^v(clt;rJaS(_Ic5uCje^N&2;J}fK@b>@LCSW{`~AGmJ|kYC%Jt@27gmIAg3{jro^o-B?Z$%61I zFpY$886XK0LxcDp^2V?m z5nnwgg(&9kv2^;3N+P5uPh7UL83$p}u1b*w~N+=l%B9{vlPfc@bUv$9321ic+phE@9yKyi&- z+sF?yr0axOu}}K8Qcqd+5-jt&tFo11i-=S|YN08ld)#fKg{o-gi3T#E(?`kBBmM_) zpNa`Y14AU-eo~36Qesc(fL$^O$7D_X@n2sbfKb2q#1X~#;QvR0Jy@ZlO@4_ZYOdj6 zy?KPlS!gK2VU3C5ly-;)3^+6*qGFzZqyB2Vspa%3N5vf%{cs_OlrEp;&o!L$7Q7G&~X`1&j`i*B)0sed= z{+Z-pF?X5(16W&PJzMhUshCieZ;61)Q<+*HUf8Lsx072%^r%?odm64jS6j;Fx|#Q8 zK%p?@$I8I%np%hMNx~6_$F2TK!_oiI;eueI>mpwFyDGznI$*j!f4DZgkDkALxESc< zR#Rh1nU1?|v0`=`QkCB07N>^S!<4e1)h3N-Id>XOV*E1xOz)r(Qu%Wau;C(nZHtuV zHV26DAl1kW_kzbPd>+pmVftV~sAiRE_p|>d;5%LbW%m0x{39AlF}-Bp_}Md@04RKB zT(n$VT+NKuXHd8KKZ$j3?4vg%DnBOlB{P*E?HXRR{4vouS}Xs64Njga_b>s{ApiZ0 zFJfK6%B9NT^qS38#*-vti$Y`)aev;Foy@u!p}sUN{h3=A0%%OzRI+_3(EH2Hq#i8^ z$c*^`{-DW;FTytYz#Gzr%u#k>q3A#aKC9Q3&@KXIo+NN+DW%Kehr*3n2@1-s4Kz%E z|8E^d<@?`<*Jy;nj+OqQt@AC>&+4`{_buY4TMsW+{i|D&YZQnXW}_jkZ{pZK{4}Zl z=f^hSqA{3mZ+$=-6^Rc_(M&MS>f@#!v^Pj1KUa0 z!&erA&k>l;F86`lA^+JVJ_?9E<>mbY=DQwE3K3D!KmcL~Rz0JY^Any%58+8QXk(_j z2n`%DwKFE-C=oevGsJSOwiG}xVs`*0o2}3+U7)b(x;e$gYk!Gq1X8Q>d5i{Kb^Uqu zFV9k6-#!ZwDZ<-tKR7JT_<+-%f@V(JP+;QvBPIH8qgwL%X5tJK11X~j>L32Kp}&LF z|M$G9AXi~c=@ew)|9PmAY>e+s#x2@>ekn_;$(Ru6QnQ;(gX2IH3w2xM5(ZBcA$bl# zrgIfQ%S#KOh3Kis36JwtG_jsjjs1zs{|zC)n}G^!C&lzvTb=rQdJ^|kj^&@u^XeRI z3&JW1Px1C_PTV-evta5WCYUhvS{%L_5G&VGKFj~U!6)(P;NZ^yw+YyeTrPLx&xF^a zE#~IgbdVqVhpZ=Jqk}JHiT=V1w&?6wz+lK=Z;enH0nL*6~-F6kN$4i8OV9v&afUdZ*qc#Gh=Pg+`9DFm*c z)3dX6S_zg0V^DcuU|>?X){l;85(CKSs#2+c3?(lFRt?96L@&AO8Rs$Z<2d;on*UQG zc`I_a?(9+iVnL&dp_qyj&zp$X!0#L=ysM~HKpvM@j4=KX|G@g{?)|f*7VH)-3wA>R zN*Q$`BF>5=WFis_DjJ^7>&1LtVtY~A>{hM6;1I5K4JE!6v$xu7#cOd(oM2{F&TI0H z^p!eQJDrn(;#sLacuA1t*}8O2@;08!WMYiyd)Z~H_>cJJ9)otIAIcJbUZL`76Ifr2 zx>(M)^<%@ADPrdUe059+p_P^0LAQbBvfD7Mip40cqV89JO_~#K6GB%vw}Brkm+L+0 zp=oW-zK;xe=d2CAT*69N?YA4HE5EMIGX-?I2?@~+LT<(ig3V{1gr<+-{d(HDZN@ZX76h?+8=!?`C#%I z*oYO%bRHLXmX?)4=j;0fmM(=9 zr3N)suL-?-@Bpm7@r1~&#qI0wK#kCYoHCt52rt&b3+78)%mqIr$YT`$hA`+(XU1tY zH9vLsFxx+!SDoK6+vI(;{p|uh5EZQ1VtjD6*b{;ADG4Gk8PbNA$ z-*S}ViRQ_scXCp`9qTr)Kfs}g=uD~4@;MCgO*dVqdGvrIdRY-As^^j-h?vYTo zV{|mb)g!VJ4Xj&l2FCGtG1zK0lj`1DmkUayd}A?D`|}sgkr?~T+OUmyx*kGsh3)3m zV1WIqcXio^ZDeHeke`{=XW|*u`vbH`gl zjr4_9FG%pN9xk}Z3K7@|5PQhx&(mf*kyt-(^d)FE7Rggls4^GENP6{Qg8TT{+1WuX z7t!r!U=UL_Vc=V^$V_DJnW`V~3v3b9Cz2d~WwIXSTlKiBNM_Y_?f|rM-CxlD&w=Mr znE#tnUXHV>-QaWoGHp-UlDdfnec}Kk6(?!BWZv4$;B$j32;vb#NhKP>+kP{*7^5?4ws0*(;L>V*lPUibUgMB*O;mI&Fixe20-~2B@I>X334Njz;l-$46>#~G{)Foe3 z==DB+)74#zq){|pGlOnKH`s49#-flR&|kST)W2@(0=N4vJkY1D{-HLim^d5$TVCl2 zjUk_B+dlqO0X6?XoueXmao=g(Ji##%nRb#?|NPM?(!$X8Qi>xzMdEfc@D6jDNX0{E z?VMhU<1RvpHLzND&15_i@d+-uBm&2Ax!i+Djw5x2uUsr-e( znsu`j$6$*RD|Uk}Vc|q3qPwM`3O((pOO!PNDM5`-~;7c#sb0&Uz>Sy3GgWHU<|~tD#Jlv+%#S z>#WVAN%=a$>hytXV0>dj}4isN;bdP6TZOQRkHlCGAM2 zlIKqi{L0anUR$ayucQ=C3|VF}us7irqHAN7JC5%9Mb_&wHWBsEs(lbKJG^!viO7L$;rS3FJoV&Amq~6~z3#9=O9qRue zUOR(d(f^8)B`9^=#_F|vH+(n+*l=(qSA0X>M9~tYPWc}OBigaj zdVUz*DB&S^iTre9mFX3xPN?y(LOBRrK4Lt)={wC$TUSHI#O$QtD<++N!@$HQ18je* z|BDLrxM!U2`=g#Lzv@BCK%?onPi%oE_;8|@IKD{*?&G_vsm=wOam2WDjIH7(kX

    12EX^C*?Y;am-b>vMOyG%~8o{q{b)@a|1|453!S_axe*`}&} zE{)J|?5**%QWb$}ChjzSIzfOnB-58--Jh>+o&9_vOFeph=#7avvbF=-OJ5^+QS>yoJqDelxXn0=Pxan&lk;9TdqP3gCW(0NhW= zCUTg8blpqn09r?S%K!2wZWO*Bxly$KIX8-SsgG{Y%|1I<>AhRJWo;&(NPb>G9?muO zdxP6XvNS4{1M73Nh9l?Q%?RX6D)khV;%a(>Pqt)v=C$fxD%d;$AY}`b*}P=bvzYd( z@%&t6oqUz^vlyJw3UAXpMpYNZL=L!sa6bY9#E_jULQ`WSc($nRj** z7e9HELp1QBjb$im>=-K6HYgIhOJ{b}fM(o2^8t{w3_RI$Vi+&oU>^b^iu1FliKkcpHE*{G)=? zk4Z=7eoQ*j0sXyLk-xof{D4RA8^4U}XKX>Dpl$vq7K~O?o0QU)Y32cP*XBQw>P-gu zk$R5d9;KhV5J~@D5#*|IR0Ex|)4s<4*F+fco;`+bA;LCr-`B;L6XuDbg!lt5VEm;p zZ+AJ96b{r#wH831oPugW&SF}`|4G7-Z>B1GG*K1jig`-BBrbh%b+*#`ng2Q03wPvs z{p1%iYaM}jx*8ML$+{EacRHj!1x=?o6p~c5B2^|&d-1Is!krhj#J29=^a&9NgH7I6qp1(U)|$;Ig}GW$@wpyN z4m)OFs89$e9uIzir!{5B1Kea0`Q(9uDgC|vr*^gSev=ak~kn z`F^iMRouPLpTxu@uWob6y{nX^Q-_?k3AXplHT-n^RY|;i(dk-G$+d}lqDz0+5Xezv z8R&vIz94L{cuO_$ve$HD-psAlw`iH+pqu`{xrOXd`OQfr*_O473WApH?DPa zNBH$?6r0FgBGZ%!Z=)BLu9xPSv{%t;Z=UuSg1ouHyvXZ8NiO0aF*koT2SPh>7?LXB zRYqQ`OVs;N#|E2yhahZ*?v?&1Ng?%2Y+QH@+M%^SU|{p2Spg8voVss;ta|5w7%@l8 zPx3A=p!~3V(d{@GBz*T_@hvQGs93OWW{y<)+7&&gKpwAl#)6Eai=c*D4^<^uCs3~b@izlu~N^nA~9WpV^aUUb)kDFrJk zKlum+s!Uod$f$@}?^s#g<`u^td{}pN6>moP>RH-nOCp2TEWH8vA@}}9wX}~)mlq=3 zmwzSVw!PmLDm@h%_q2O>{F-G= z*wozl>z9J?+FlVFc2b0Y`6C7Ag0b*csjWi`1{c!qo$9=>l6ca4wZZ;_?w=OiTZU2A zJa{)!+E5s=bC&5*QOpN^z*)>8Oe9YqBGGs>DU{m;n6a%~6zQ_yeWgb_blnV3p_Wf% z$2||V!yIju{&d$Op+n;el6cq;jXhcj<(*NtY^d_9=(l5O7kHg-9CJ2x)J<+CN*_gs z%P5{4yKZbVOf`$Hcdl zo)I<8rVkFW>DEsf&Bbv#^(sqc6M^sw`TVMp{HpI(D*z}i*i^6z3kg)rv|y`=7jlT? z>`u#WJxof1z`f`&e=IC8y&uhiDXJm*M!>>1E^*y!K-^ z&5?Ge-Q$NYFR8wHszDaetKs$6=8VQ|csRT8V9J&B0cNi&=TR-^TESSJ3qg|#PF_3- zC=Se-@lD;*_jJP6g6rnzy*8Z3P-&I}dc5zfbEi)^3apFU7?F#fi(cEg!GPqI9a&QJ z`QwIzfc`6pnUX!qFMBcg-ffi&-SXC-;I&b$vSgDq-T%>KQ}DcsdBN(Ndm=U2Bj0we zB3U7VF|xXv^~hZj72+ky`H-P;qu^Qnso;~BuVNI*|#Rf(4kO`$!%* zpPYy806d&zfSh%Q)z{`OfCA*svV*W*kREoS(%X0TmI?uAr#LZU9nVneCHt*>o7(h( zp&EF#$E(iMY@8c?&4oga_O2I0u9}UpV$+h*5nd6o(-1n+nc-?h8pOC<1wKKctcJIANeI(o4b3$dsV?JvUp!$Zh zc?31|NiFJC_$Lb4a-6w^#;~Ds6dm|GWrSytr}0usCYN?ki(0Iv9a4Tpm?0lRAtY!jK{oCr}uCW&Fhj%M28r$Ycl}FUv zJ~MwWaJ|4NF?89Vd7n%JL$2*}#IfxC(zq1vidvE?1FF)_PN?9p%?df#_=x5fed};j zuE%n7gP`k0Q^H(j1*(D;`Tp>M1HIBmy}ofWyiX>cMZ=NhAXD=VO^FG8tJ1Ev8)Sas zJxI-iVrmC5X)D`ozmufsAlK`n#{?SF{0u|**82!d(gY2|{7ZIe>xNyK>h~3Tjm=@M zN){xaeezEjGn4S|bdljAsQ{cp(kVbJ%@Anje*LQbzrq;U9e-f+m8`}_3bKtP;eJg` z{`z*t@7VjkyXarl^{?5-wT5B&;I)BY@{*Ud1KJQg^cqZkQWs*}K3&C?l!?n0tQ#PSU%&t~;olO6|8rmBZ!h<^HT2)} zPE^-zTWR7P@y5|69-mAWgLTC-})>ip!cF&FOCpV3h zLalR`$_>91x@V80_7k(IBD@cI)7-zt-iY$4Lm}?fCGX6YtBb~)9ZIX7?$JO1Qq3mP;*^D5` zUHD1{MDj^33|+g>ci3Gu-0mYeN6cC*T5_jFP0T^f95a8_~d2# zNfV|=C(NW=&Ih=l<3tnoF!yXPp_@14Ue!J6fA~s-yWVe!T9ptr0^k4vPHU6+U~V5t zUrc7p6>}AT@_I@BC8Z|>JsOuMtJ{xkw!z_lJ05UHc>2b&&5uLUl{|Oj7XhYx-QRhlKfP(c{d!3mjNu(h3pjA{ zdHl;E!kttCtNt-4V1WL}-!pFh_Wk;~246Rnx!;IjAPjsZ^U#_G<_5(2iQatX-ru>z zx6Y*6I+{6cK^UfdikJfslJ5Wvy9%1x+Q0jb{-e|AeV4%jO zXIuTw{{#AfuShYv)hvp>x8hP0N56Uag)lTHf2xDdbNP&RW;LdWTY8Fs*6*_Yu%eMnAkBS1MJ(IH$D43oRy=ZeEBH_r@yNeZqpqbr@a?vB)-PY)J_b!3Q5Jkin(YmOv<-T9 zo|L@-;@Rmt`Kqo`>;Yy&+;pR{=WbAYZOPLwLTl=buEg+rMcBHatfr%v83jhCD_ zl4dpWie9y|kp$|0w3#O+ATne;4?P!^>U&>@U+5$rrk>dS{$oj}fpZepP%(VZ->@{- zu;kkX+>T?M4}O;*7JZe`-1RUhORW7tghv8jstVVG=Sp|w2?0N!ARbHkj3{a2ypsr{ zS-jixX0PybYyO^pLPtQOFKcP#zB+JWS(e?)?@&VI~c zK0MrcjlEhMv8XK$;AU5lG)smrn68!;byF4$@)Gn~ZnwNDKBNC8+8guF5Bn38TI|Ud zy~HCB=L$O6N{*j^7peDZ)2!|5{Uwo358fDc7_g3X!X~*VhzfxE4(y!NAW)T)4yglf z)Su-bY$fzKz^xqzkc_C*;X}YvPIx*}0FblNF9wD?3u~Oi@*W&D0(N#lAp10bH%SOT z(ufkkuDU0s$)p>)1Q79isG=;P6vwstrbM2{Vx~%^!yx9%; z+E)mFl0@rcv#+HQY8L~Y4b*Htv(2|c!|luU%~k=chhRgOA;Sq!BbUT^?n@CI@!1;p zJ-KjfxnVKQgp%ZQp-r|T6l`ZsJC=(ubP@08&QF=|K ze-(7V#^@-MT33Z!@>o&uVrW1FeI*+)48ezLJxh}71&k!UL3AC``#Ge{h-SS%Z0y4T zQNZ-NXexL}tkMF8kzvXMC&XU*AARFp+05XYST;<}>^bW=(mMV@O@ibHB(&>(1&8H7 zjzGw0qU~9{g)dJK4)yu=NIjG#mF7r6aY}48wkyrWu!WPR+uw@9SzV#ft+~M(wmki! z=b{E}3|!alr)3k5QDXBT42zw)9@6@S7F3UlBLx*58dS9Kr)j42Q9}Lkx>&cuhaHSv zmK?@mQ%|Eau^gaAluThwyvBe4^8U4iah+J2RKCN$@BT#PNcfO`w8DNK1mEFgK*C{tAKFRVoSCh;dDWpO1rZrWFYV1@WS)k$ET2bQK7uFhI8l?S!s%lH7k4T9>m z9W-%w!BMQ{Zo7=)Q^{gj#mvcYZNmxMxZ_T?Yj>eV{=^qET;&xFNGe?BQ*rR&$M1&r zpS)L#v3ClXdr32^#KczHddkbb0U6BTE>Vbw7*<&CX7AHC2VFkKBwV<5<@jNOSp_Mdyr9b?XLR>Q^QYbUZ00c$4{y z@O+ctmHcZS@tUCw<<_Cv4?f&QOcTmC2nj2w6CO1C{CC(d3_NUE9ey~-=zNwJkIE;a zGOC51CR30)`h$X984JDLUX?1cwj3u3<-&xrk*2>C=AS$^Ha~f6aQ_954Mc+Y2)Dko zljm|u%6PF%Xn)8w=JqwPj_LK?_W6*#x)}*Lti04L#ky}^y%08Dw3YCnfsnI7iPDhK z>-tK@RO5Y6o6AOVCtk`nl(Ze6)=y0{s23@_;W_;W_gBz4ndt{;;gYFo6UED>V;KUP zLBcm+p-U5;OE!Pdo7+p@%8$3*T4x2>BVVZ72F4cQ81kn+tJL@rWcr7$mml)I15*hl zP7SR#xlY5lY7QF4q@=%Jo`X+E9!PsfePW&@@p&u)9=aK}ynubft+Qop&_d!pP^P_; zG=(v!MTiYpc*>ZSM#5}NpT;#I*|w^rAb?%OoUv3LmDvw9#Hq`Q;sZheF2e*OiX zi)}|z;cX`?YaFMc#_Lk9mA?R-&A$Ph5luWbqEqEhzu?fpIOm$hq1kW9U4dVayD+K* zLea(4r`+ElxMzXrnIjZ_WLwBw&X8-I%I_4EdvCl0;J4QR?D9W3EywG7mrP~>tgS8^ zhRLfVkpC#bXQ23yAvSCByGnhiS&)kl|1XDeadF?Q1pJgOzO?;NiwE`=IpXNglW*>v zV>ns)G0~^=wr+Z$Lc>uqyCk}1^AMPR#zifBkN%#xeWiF`hgYp4?0%8*J^pRg{ zoWvDL#!a&-r>2Q7+`h408d!}6(d%YvEU#F@JPXGpAFOYl0jq9+UqFtpL)nfGBz+T)!Nk z9>c>+QE&<>38B_&iUl$#QPj}dX0;0iZ!_M?wik-EWC?>`A-nx*J3Wm(cgz;XyK_SE-y0tK`FX#K2NSHxl`4eV7EK`)AU1Fzvdxo{`l zLKI>x{k~i8%ypF+4_4Zbc5M69qO-8mD7taH6kWE#ZOrhU717w{$TJ?}l!skdf_$68 z_CU=-&vsGN&z5wx#CKwta^8v*=O&nY=V2L(i|~8dPUS z7JS=6zz)(?DHkOqu+=k0c#nKfeIFgB@$lcaex~ym{=JNSl`+ zOvHywJYWWNcGv^l6~|=f`Grbi`xY6dqiW)X_ymiMjlfplnDK{wj`A?J zEd5DNA-kr5-F9TGYu#xZ)YYLOqs8>9%GW#c_KebZ3+r#0js<0}$3QME`*L8Qw)uJG z{c5hxqAO3wueiN6^LtTSO`|ozQ|sJVM=qd{=Pt)v9lOSO^lID(dacihX!IgH8)=M1 z)~jjSu=ND5&3Qj34^J;XqP=4|TSzclvcbskW6um2qMfI`D@~{T%&ea@=*Yg_yX^al zkg#Ou3k-b^D#y>pBZZ7-6aX!Dumxzb>`FZE^L-Wi{y5NXFEH{m<^k4#>E?W(5r=hnNU51Y6J@2i1NQ#Jw~1Iio2;V-*<(&kT{H&&tkMNuKH{7q5$V}W4n zhL2^b-`)+$CS|=dH-FJonI8a6W!XmJfb!H~T?Dc|e|t9^`skY@XK^*u#}+rK4}zG= zu}#xSU;JVAX*Lo9a^ZZmxgDQvv_78Jz$@KPcdz}|CiwuaELS7n z2tb+XA`Jh=1b#0^NA>r9hQH01-vhoXQMll?zMt#FUBR&pb*S?LzurM6lVm*5t5q*e z8H!`B7}5%S*4jO9Qz8hUINvmwL|Pq(x_{oZ>{p|gM68pcWM9t zyK8JRcO-37ITpDs*EC+)6F{P3=ffF}nY7fY_ZMDn2s#7C@_rHVc`iMq;RlrwuXRwD zvMVlWjy`nl5s98uC%6Y-5zATg%Bet}P1XRwEczy)ur8nkTXRaZIaJ-EGi0QD_A`R;~J*wMFusQ!VZFkE4!kxu0rswewcfD4e zt<_o2xu1FsXueLm(X2I^OtaPgH-j?l{YxqrVlF$VI&*+GdPadzebtFUU)E2i9)=S) z-Xm62&Mr%Tc(}=|d!lpGNpi1_%8dT=XZ)j1^**ltJf)W*4Z}A?`mPGctm|#loG==* z>a`x)I7qsu$rqWiF?&dI)@w*G78|fHs#jD;8r_uZlyQEt&m&=b-!X}3NzW}M6f5K8 zlPb-4^{Q(FVaOuh4~2%=x*nw0wa1!|%$i-}n31l{?awu=mioQ%@w@f^XXGfRpECt0 zEpx0;g5K&P$_eA+;s$0>6#SL5o0zv00mC&-t?Y6GB{2Hhf<$ihBUP8$Szj<2^zbIv z9%E%6L@%Rwstbn_SQKxvs#4?%%G=eMPFFz=<7YkI_Z%*JH2&oQKn7G5s-nY_B^A(-RQeHMjHw)a^RKm)o!ZN$>SA}+b<{*oDeU`n(g{Mfs z^<=i-JH=PAmSkZxhJofzlXT-X@Fvh{87-gbe4f5}y=Y~g>JZ7(tpQGPWD)18P834q ze}2P%LYw}b=^J47{$*?W+ur;?zvj>TIePFbbdxlvSCed9UFobF&<|;{upS$dPbb_qOaxJx2;>7xphG8HEYXj5(9$Q(Ygu6Yw|&Xh>qL z`)LUY`8AtC@Dzfm2ly9Gv5)|28X(*9^1oHJ@RjU23)&D;~0?hM=i7YsV=R~v2$Gh=WMk6EA zqIn{1#!u56PLNLwl@sZ(_RXd&xQL|OannV6`zI^i?>o;sortQxNC`8X01OOuv>x`Y zQf^33@ATT*;$o?$%Yki|l*m%p4s1sGfdUM$jk<8s<>G!B5f>Uk$@Nk)>el)8FxGX# z?0sL}aydO*T}zyobZ?=|0q*2j~XD8 zWEC$Od~Rqh(VT^%I(`dW0trbk34p2rc$sI^M9`untir zp2NkWN~cObrqi~-GFs_1uOHH{zQ&&N1_Wi_{^Q1`Z@(45_!Z#W3&I_wz%YDY$rAqP zn{N5aR)@QzMt5C9)vKaNON}eOe$4q z_Z7f*-=RkOHQ)8+&A@8jb0V@dbpbs7uTyFTGL%_Ns;4Pm%L{(BOAbRvyQ}I16CVXL zPopkdeOv}pm#QzxjELL?6y$>iNMX~H4n zwnBINfNV53WY$Y7RGx!B--o3`%hMpJ*t}0mwDUgsjkkqKofHTBbG4iYTltUBcj3~j zc4r>Icl1GvkSCZC@tq$-V*h6guG@IfLiq0EXUfXNU&3SYuuIS1W?B8DE`AdO`$zVc z#j}xQ3Z)J*;67Qkc$Rg~6n_d>dDoxxMW}hYcgo zWJqE}h!JJjjEs}WwPlEqHG{63VQK#0K~!yNa8tYO7f)Y1DZVG{qG7nUwwZkIiwEzt z$tVLID6fmtkT9klV5?X%@+o8TkEd<|nba{w@Zk&B$vpJPTqy2-C0li=!}i`J1=B3?6{OvL3OqBQP< z4TtJ^3P1L%d$0EX#vBb zB~sh?aP!n`*``dL1l!p%8m3l{S#!rBlxd$}-b$&BQSLsMw+&rT^vH(|;;75LPcoKF zGf`1!!yV22TUlf@Cnl-=9s^Ic_N8y{B{GV}3W^kFzpg+5r_S_u1`hBvx}Vwhp%Zb)f|mj6)DPhPQ?@ zKgo@J84<6GpZE0WyY}r? zU&}hqg^^sBw}G?(btdJ@e06(a^T01!|H!xs$hXJ>jnV6K6b% zNTltJaT^6@ie|^`^V+av72aB?^Nfk_ZgcYGy1H6uc|xzEACC30vJPlIT4mh?8GsV{ z>><(gaZxv!LF9_`mp2o(qRL){><~6Tpx6Mwsh0nbz4w4>DqH`Cqo~*rMNt7EA|Of; z0Rg2XD$+!x_Y##RARxUa5l}irKtNDIq}NDCI?_>kiS*tAfrJu5NaA;N=FT1GotZm# z=KI$7f7ko2orOE+**l)H&)!ej&+oS*w2$P;&e!{KPM+So_Z2S9icyE_)AW0~_jI|g z)kjD*<`d(LvZ)5{MlH3g@lNofc1~=Ahqo)p732cw55JxXfUP9;a*Sl=nze6ZVhKrO zy@2cj+C&5Mi}q^G!((3QBSXNQ5H0KoN**Orrq6~>f7;608ZX*k)w^PgoMaiCztz36 zgK&5*?=ZX5@3lI#$7FE};Jgl9UVry+3tn@zh3o1Xb*Yj6TN!D_od7jc&iyp%Tvkkp z!5~xGv7e@>E#VzG5Rizn|EEdH6Z5QioTOAKYMMiRwLETplcq!6dEDSq+o^hc6Me|0 z1|Q{a(X78CF<9OAjFP)UoD5v@Nl1uZGC7GsPM*iNhZhp<3*niEwhgy%^~W%DGBUsp zApQqG8z{cS4u+deUQ!tiG3!m;Edj|FPoH~RRp_UdpU{C7=BXqUIdU$v$?wk)dNk1| zU|Coms$?&1dnV9RB*K?}s$HY8sNIBE_sYqj10S==*I>DU4iQs6*(>HXywA4XM(U$s zU-q%Yo@#-90mD1}tB+Vp#d1~;*lXm-BX5&SC&PBIFovRQ<2*6rt@E_F{7~eA*rt6w z+g4vS+e4>nWx<-LPO7NsX+Xua!H)Y&tY&(Pcg=gp7$SKS$req(U3!Z#G`4jq`ZgAS zjE(#s7c~KrE|oF|-#~RL3m(mlxdqNsW4Oq=4e@W{dN*x8o$s)ncMnGnK7gkFUb8+J zefRN6yRbrfx7Q6j+nrxQSPDN@$ZsJCUn)Q7SJCkRPMHV1EC}Y!Q*|4+NQTLe>PF{< zAv6G+kX&_n$?7=U}*UuF-lfk+Sy-rJ) z(~)EDL)VUOm~-vXI#u%6`lRUKs62ORf_V5X85YGl=DoPrtj|J;Zt6jT^I^#mjPe?n zffUv(y^^@>u`i-_Hu_^sW2t(fv}l4w=7S*%wAa1%54o1^%AU~=M1lQf@u?wJ@l`lK z@wwtRlY&_7z|KXO4n?>It~^;1AT?7kye$oIPlyYnsQapONu~&LY`yIfw^sAgHIJ{L zv`403G6UQY-$dOM@*g_08u`h7X8kMZ&X*?W2J4bdZe9rxj(S-wzGSIIpu{|Es87H3 z{zB*8&d<$D>$`yMRex8O_lXGay5%aFP{ZfFR#x;hqD8wNA``?9Y(&PG??4vLNwKTK zq9Gne1~(OF_$CuM8lt~~s%;9WiO$E^!_(1iiPCw3oZODgk2_HhZhr-hi{V^=;{5IA zn;h7=iM=}%9+n!w$rZH1;#4Q#>PND*|BUfPbd^VyBqv+lZ&94`@;AaOv%jUW8Lo>> zBo&2^&g3uno~NKBSzh;V`Bj#!##zh6?Z$oJlE4P>B58%oF-ZlXnEyISteH7VqaCfUqx=Mn?8{a43tO zi4o4flju|mKwoL&hqa>gNN(@OZYwLzcnExU)N5)Kfp?71#QJr$je*Pj*@yanu^E43 zX8ri}r_6}&9{Ox?q(^o1_soc&JoJ6BFf5WaRVyp{m%I62SNj%b#X8-G8;_D?KbCqHy}FZCAvg_P>(Sg&*o4#$=mu_PY_KzV&DXiG zJ&>i`^<-Sy*jMf1mOv)F2~ly7j^oXAHKnwQ5jG-?t>Z%!XIF$SrE(|aa^=&^;_`KmW`^miX6ia#p8)p#MAr$ed=o&pwzT~idXT(Y%W)i4H^x-l`#5be z;Fa?z0jSYmECpw~UDkK$ z)zR8ls7#qBKc#l0rP`-h#h%(y2~1LH?n|ikitD6GvZ zlKu226mCye0nn_CFRFK{@1;x z|075?JrshgPhwA%zZpwSGj6lw#a(F2v>x|%hqhsaGTBh8;bGh2I8j$^ zaN(3>@j7CKdHX1bnbVelOku zFsG9Ltq~T}zEh?TD|xb`DDh++8(C+mTM?UQ4alwXUo3K9l3{d$QL% zBpX|f3Z}@4Q9Bk_(LB4Vajt-%<71nxSGqC>dvjn;0_?$922G@|vKgqd z!TjZTg*J5XD@Z>W)4-Y#!N1q$i;iM}XOS7O30xS8XHDOME(sfu{4{%b?&W$NY(1%} z6Z+a`)t{F}rv(tz`}Ic1Jyz!8ZWeH#Q3fu8Rh??v-d=Dr025_q1( z&mhh(sXs(A7F)d`@HCtsIQE)pjiJ)(i88WQ#k*=UjI((4gjKvj=6$Effu!ZQPvE*6 z&}aX>01miS06P=#xV)k9xNkLio(d}#)6rq6(o|+JMM_uvguv|%EG(gDH{LM zv4>wlM~XGMcJYiL&4QG6K2y%XPdQNdLrCZxxnv-Wb0>69tOGTYhj&#J@33LqjL#FA zs?I-&!Y^ryTxK$ECMv#2tn937?sfw*R!q8_F$3N=(ibxhNa!9oMfX-<7xYOh;AmzC zNU@Guk*#;D^naAAT{r|%oe;5^#nG$4EgM)7@lT>$9!ETu++BN|bU1!Tr@9|q{P6dc zssG7HS^V(;QgO|s7=E$`F-nAv3sl=j&%s9sVfC1S4`_CGW!iDr5q4hOxG8n*)7-X+ zk>hLD5`okxo6pF}H%Kht18PHl1=#}e z;(s@U{!>Yw#1yz*h;)7VQ693GHcE_Rm8r2Qo9pg2VM(M9ETS6Hn4r+*D1mC-FRrU~i;0(~*U$#|)!NQw#$#6GQVKT$Ie1>* z8~q+P?$-;s-#lwP9$pD#j2}P;9El>X=F_&#*S*oAEAydt9M#36q@|BAd_3v#BGhgN zycz?OXj_M@xHnBME&XY~IVirPW>X9~3;hZz!2s$`z2sL=U;kIoi?1Nsu!$*vpuYs{ zSJS0w0+chh;9oTcQsMr&$f4#ajRpCU-qhTQiYBfWwRGclB%({{u5}RG|E|p3ovtns z|Hh`*3TeM{D*6$I!!l~l@^E&j9e8Xhp+96PcDqx(b}*zj;*ph`TJ_!X4zq0{a#=K-;J+*Z~!NnQDXGbx@N_euQ1ajtjMo}@?t zGGXo%Y{Tvk*U+bV*Q461Z0c+1pzo#S(y`_cxO8R9PNn-KIcTPGY67j-bK(cochL56uAAWKaIEl^xbp(nX?c{-dof(8J>=Vn%_)tZGTnJu+iEKGuW&-xB$b4 zk}R6#cT|TEZO^1}uO!Ta7Nf$ei%OKIkzlZujYUFE2aXrV}Ab z%5JDW8Ff2Ku8(zKVAf2@^<&t2-u~Ga5p`7lebCSGu0~ z%(;~>`E6SaFST1QaUTVqg{>B-=yhqoYm-*t=Th^U!k?z3&Av}7AG#9UK$4io>1q?q z$6n=GI~j|Ou;o(bCyhmJXDo=M27LuN>y~4H0_@LV80|YL?ld~m!sWYvNQu3i&nFVe zsWv)#!_-n{^t12PvtcO_!vN(T@7nJ-g)w7Gn>G7a?FU_7WzM`rr_J$#bG>!5#@SVM zt7^=L?9wA2RKI%p8c|Fz$@X@UF(Fc8t;!RWg2{Fd9LSgfD8mM(2f@A&6S*5rbl|^u z`fQ8x1mH2&-bB^I#WoTHJb6-{WK&|7DXkVLHsQV z7SL^r7gj4dA>kd;RLBEuxT#YacxMT@xMYIHvzdhNd_2CeJl)wl$D=zSA>{+O(@SXy z#edrETM8s#I>u652Oi|(`4%ez-eh!S9hY9d$^Ht@Nl!UgSuMU) z=3efsa6dl1#4Wi8-fRS7b{45%RRtq*lgI?DdwL$o>gm@kj-`;J0RpEx+INufO1p zp1Fj+O|N01aT?a+JpbZ{pynl*9z~)TrUV2g3=|L63^wGX-1FlU0@!8Yx_@In0N#0w zrb^^3f8I#>gMq0p6KXZhA~=I)B7EOnwBUVzVvt+$fd}`!j9~qs<-OkOS>x5&IVM<< zP$d_sj{2^`<5ZieFdbm>c(A4Z;(>DJm@CJ#mx)WT6V|1xSxcwNLz9_|@2?!^^Y09i1h2Te4Ox$YT&eB(nt$%RMf&^WAQkMGIs>tm?t-FTZ1GIW(I8BIqBBc{6O?l6HO}2isNkfQ;{-hGZk<8SV zn^nsPxILimO?R(v)kl4^W;b}?2VggWFi~ioR^d^A9+{Y8aWM7e6HqH}G1p~nfd zU=rXT2=%N9ae>R99A#*nDUf#vO)@RrXoO4Qvzk<(lQBUjl8+Fsj6V(Us7XFZcAL}= zjYrlCGF_BspR%es!2Sj)&%CkvF`ETYWc&@dHA1BtdJ#-glC)6%{Jf?LfG_FiT?`o2 zO$RFdTCVd~kS@3j$@la3^xnmde?`B3bk6;*$L?<()N!s^f>Eb`lZtYs&0OT?bNl5a z|ER+EL-I*_5ikOgqiL$N542yyfB^|83V-Vafg7Ox3R*dS`&S@f%4h)U=vN?Mw*dgK zKRUhtd_3C?iS1p|S@{a;PapU>8wCiJY5e{T;I9Yp8D84Nj}HnaitF5Z_uSo$c7BT; z*qmij4I_P;R-dvz4lMZktraT0%JL~3+_A}}Wz%#Es-6T?AmkitQz22=tvxmF!hUHf zfbIneEC!f7o;A?K`q&33gH@9aszfpUQ|P3KWGQeb^PLSvxyP*>)_6y^pj7KEr2k{< z1Cv()7e!{;`j?^u{3i!bPnbd~6Vvz?R|77Oqn|~3?Zl-5B7Uyp1;VvWa1ZDm-2#$^ zR7A2ssi-3D{%7lXDc!euZROaJ@53*6Zs5=-x6%*(*ODCk!{rX|C$k1m4FQLI=T5|* z0(P;{}w7+XJQPqAE#dw(+WMYV|L2-1M8bI~;6L=3NPSf7aGYk&Hrebu4C zdUHWMLH*M%hjY?7eHLz@jebg$yxjKw+8!M*AXt?%x6{0&-@b(!h>VQ<{ju{G#-eKt zHgQP@hwO(Aq>`fZtmJyw5OTh%7uPk1vL4eb?82bq@bG-Q)YZr~PYY8Hw~{ z(^A<`&tspxrAc8P6E>KzWSiVelRgRKSNS~cRpp!Q0#0vmy(D=MSl4SYXf}C_fpI;Z zO!Z@}jj@EV@X;f}3ko%h$P?adS;Il57{T0O@D(@9R&z+A1U;Tx_iu@`WxS?VpI$Mv zd|1rfXD7UN!*YEEvbuGh;it}wvV*Fic0teVux{5kCS0f?AZo<35jP7NB5tM60+b>Oa~>;7V(S4R z((1@5D#BKW^2~zmT#)Lg6Q=I~3h$9fn|a2Q?(cvc7cylicl+RHaXF^Mm#-y4tsY z`u@5cqk7`a<~^wERqG}=ykYISyO(0DLEnAh@$rmfP4#oZ9LbPp;RiT;yymJ@Uh>5} z*zFUkYP~6bFH1l0;5W6aZ_qc>;_L-LDMQCp^O10s_tDgZ4q0l1S>su{l-#ZsL=}B$ znu>QZLATjB1eTKF7rL+J}Ef)@Fm zMZoAAxWy=A``Xpr+v~`W`WbRBr+Ea91&rB+@lLjIY;Q0RP>$e*5+x`+@lW-`MKtP8 z!{-)y5NCW=6L0)kw^gxkWdeD|n}KMEBHi8~36?aZeNu>h}n z%pXnCo-V;7YKUH~j6}JmJ+F^9sB|ep-Y}Nt?Si4Ve&>wKS{_NYz z8>Cwb_NcYENRfp28hyAN?c`U`wdt~U_rD>5gC~W;AmD*V(aVZ_+EQ!4*Xq=l*t zFP6-N*gTq9?;q|*&Ct_*fXaB^B>8zvzfn1zRN8CXdU9Z}bw0Z^8{Be)-VxzRdPdl{ z-Ygj}ENh=O94VMv7}cq3uLFI4=Ew|Lp>~x{`C%@wnTH9*cOqZm%u}eR>Z5S_60c(> z5qPQEo*{nsZ1tzfZO;VMn>iWBqK3JAa0v~%Dc(o$S4x7%`1W^`l8a~dh502e^_a*r^IW4!ybG$S9=uKCbSk-v1b4r? zfvq0qEXsj><|zT!TDCNl$j28=lnAA@y*8fSCTDx!iJ0iiYfOo;SaEhZ%JfAdo|1J# z+(jF=#sJm;jl$ixxXg&lj|tGb=0kj*mia4; zrdSciKkGM-D1}9#9B;uId5Yk{gMuLUOT+$k$2Y^Z8;M_4yB~yuTV{=O8ttwT%Ru;Gf@i75rntrsSY{q}&M{$7qUVgKnfLKSS)QepLZPofM%u0O5C+QYf`LlFvNzvaQ~HXTbgu z>IH&Zx6?$L0C;S|U9=ON*96|Sl$7YST=$Ih%AbzkUTRK|t|4?}6?P=ZyL+6gA(zTO;5yVkGc(c4nscW!9VkQ1O3S!oWp>8U>8zR$+vRHNtX^CB%eA05&_@3sG7=x0A`P`Y71GLwk?hMB}2 zgFEyUbXMjRtr`ZTeKP-si{#HaVbCf3iwDU!e^J0I{~WIDN8GNw9|>iQ(rX#F!S={y z7G7Ft@NYo8;G8f;-5%hQJTQ$guyw*d)NNalu?|yLb0&ByOMa<^aB;v^*xwgALFhiMs(axt)FZUEy0({^DfHbAWL9#3K4Ba4px_3~Ia zv_)(!SUh#I-9hibqfIuJLf^~X<%z0m3~b#YBjKXfdD;{=CPcppg(_ATaEl#X=%v%BP@?xKrx7)s)$8$`KHD&`HIu;o$+SB76GT{Vje zx+L6n6oQ?9?ILZ-&M!2Hd}2xPFONMXe7QUKj9A0dd$$$N31d}}H&)~wX{Sj0kf&`j z9h{Ccuy)rQDa!9japdAi+1lWkvHa7nhz!s!pIY=c%$>*l*e9UVXMVQz_~&5ZHEZgs zRF6i=P_;P;h`jQg09+lfVeQ$!7FE#`5x}_P2O@dzLy!w)OI=9I)orF?#vLGmC?x!U z5f9h^<>3$JU5V}ry64}23V+~l$@zpPZ6kAK)%vb{H(7q3f`Gd2Z+W~-|Xg z+cWJfJFS}&$4KFu^Uzb347?#%_OD(cZDC{B;;+!fB||+RmAj$G#wzEhwtP|u7C!8A zi5ygodMEiOPFE~fc`;8Erlc^PCM*Pw)Cnp==57NnK_DgKs+1XQN}l62Vh`O=wI{wa za8rnWiGX$GeMB(l4yqeI2e1=e-k8Rp<>+6>_}L#7-#gphfnxm=RdXW{3*v9KlWCW0QDNn)BUIQAk!JQe5P@ zKKM#Lu!4Ih6U0o7Ncn&f)SqIk!@r&X!nb8R6}3}83l7R=oo__#e^`=x4x0~a4^26# z&@O-+17D!1cu!6vLD<#By@q7Vn3R3C7pb_osld#GTKC}3y zXXn#18ch3&K?lN`SWgFxYA&d1K>RY$9wdng4{zZlrA(~w=}p1wyG5E)Z)F;Co>UG%BOy))X!a(R z#8{Rq9vtBp!SOYd6t8V7c>YuQI*gI>m~bg~N`+q~p;<}KZuOk6ykg2>=8=nBBFA2{ z{!{tZ(6=&6JL|6GZ9XX#CU!fw=a^V_sa%9p=+03^iqp^sWFQ9o1%Xj+hlUQtXC^*l=HYjg|q&ttDX6KP|ZMQ?Fn1u`uM5$OoLc) zQOiB|lU*Q*GpyTkY#R8vvYb67o?)Sbb*CSWs-|!6t5%oqtGt%Sze_M7*;M?oJgbD} zBJBn`iNZ@j*ORMK9Beeggw#OvV+WpfW|dy$Xb*L6{U_4Ag!L(?U(Q=m)Y86fU8|)-nSVjXIwDE$Ba?6|c#^vKR`_w0e-v z;3RpIG0B3CjA>=HePu0~ni~9C?DOJ&$g`J>OE6o$r`NMCXI-X$i!O=2c~<+h_G!8< z-Qn9wNBKheLU%1(w6glXN_z;$kTl>j2XkjEJBnQwxIuV8ukZrWxnGb1CYcF| z&v<*gvc}}SmvrrXuQSpE+DZv9lK-sZ>_hWDU~7p$=G>sQj;J%&;c%&At8xRIUDRqOa0tJX`dwI$fbq?$_HyxcOK&rW-@AN{tHpHOqX z-!?hK$bPwE8Pt&Z(1@IU7)O>+)r8$}*PTZAWDP5vEE^wm`?4!YqYE&9S%x?40MZR# zJi3WWr(F^*=ulIz`ksy{HOUE^BU-vJDx>03NRh?EEB9Fv&c|yVp1M{Ks3aetssG(! z4{!rAG=J&j@rTuHOsP4wDO=&(1byWt#vJ zav~eeO7fR7S1{bK=+#;~d3@(BfW1);AeV@37O8(@-&SP0+Q-ND4Tg3v-1dZe-9cHV zJ>g;pgOhh%pV$R6lsobG=JN)CZ1m>4jBmKKnu{CcZyxCHpZ_o8apqVAcek^}V1~60 zUMY0@(YCiI?hGwDHj@-3*Zs;ODbuj-yy$G-ZtJp)qc;*&X~^F z=DhCCMJ+*TuSuIhaoL<7zDOzIv5Bt?H* zA$!u8Rn_{PsppSfO7hxUz~QfZsA6%6q$7YlT6s}mOk+uSUx!Ewwq~pQG}Y!LG|=Qk zjQvHImwuKkW-hRug-}Fs2!MroP+8(d`R5yjp#_p?>V`bjV8M3fUWE^DNjwmgijEXN zoV#(ZoXzXyr3ocmTKGdFbF(l%e)#@8|FOA4WlUaH$?>OH^ttY}jo;)mhygGwe|eDn zKd>4VrUDVQub@>{bCI~e8jEC>NhkNxa6gb7{fpAb>^rvJokXe=)mk$A*TJk`PT;Rp z{s(35>0TtzH7H!i&-k*4j~QEBc01TSAiHd*2k;Cs^(e!K!$drY@Em zbY$D4>&u&c`0!kTbth`P3jmwdY3s1PNn}%Y9>3CYOyL7M=@ErLwQh3QmUU`?EravU z@pF~}9v19%yfXYtRIa+AyRnnXGP{-a@@#R_bt1e1^D)Q=O1$CGtDXoSQ}cI*i?#=q zPbmB9Bi1>Ty_lQ~@Hg0tD<9wVITv*ETzK%?dk07TPva)S_p5QMXWUZn0$tu~)yygf zu)aULwM*+rt=0>&%fIb}pUj4*Pec^iKcsLUNjZ3cE>}_2P<^4?IGjW4ggN`2qluU9e`$*0UE(7;|Q13q5Ay@z(piKgK8qu4DG0 zAXs(7J%Cco9s&T;BhyXjZ;}j|^NP8LUS~U4o=7YUM1H#QrH152c9|<0-^VQ(qU1iM zcMOQB`H`A;V3Q`bSs6aZZf1po_5o}Gx3hwowE)g~0R7Y$ze|e`FvdWxIRoE68Ww*AX#p?OH{z|o`-4DS|5ubnKhYO`XDd=4gU^z+ zzEc<(WNTahl~?HZ+Wd;L=zG;_3%R7Q^FxI4hMLx2K6}*=sx`9mA_1AJy7deqw3$i6 z1C&L%|K7y$!#QM~f-Vi?Y1%jEsa^=CT{UNyhk*Bxnk@jI^30z&>qs5wot&{MA(V z{lEV$%TbLjEeQ#p*XS$$Hemm^{AhxyMv1bNOcX6oHHoGL#B6nWy8y_emYm?0-(LRD z6Tewkqr;x(s;tTnoM(qAFuEK)}u$K!dQ6040`>u0G0AddILoiR%E|LzJ!mq@d zuveYDGzc|+eKG{P{C@idVE*Z%Na+)TVH-Wh?yehp6=u|!#|8qxrt11Rb&|xS(cbww zD4XFmy&T)T=B=di>rld4ajl8>aYAunba2zqGSZVRg$|%r;s4#1f~eY6meKde>n+Ws z;#TO83v5}2V4pG3ihI2N9W8F6Bm00sA)!?QrK_}btyN`s^L)j!i~#@`u|uojE$iUm z`dHy{tR~VL*5sy8CEm!gd8k8i6Z%{X%W;?_luUA*lcL_X$0?IK7Piv9Btw!sS~=3! z_EpK&CGOoo9x-Z0W~xv#ku0Me8^b3o`-HA>_0g_l(!Lj9(NG{T21;Kg-}P~@d}OC& z7-z@r0)e?0XL)WwMw}9^sRpt_1HErdHupFm3Xw8(ygl;Cfh%)uCkv;ENg__aCbW59 z@21F3F&=?Ly*1JwW{cFBGYn!^jUCkmBB+d|XXa5{@2QEK>qvWQQpTchr~7&+lcL#R zf~)TnORP=HGSrglJwE&u^w3)JUg4PZ^qxo-amzPv-?EV7*Q6K+fndG_5rD>F4Sy-H zg}PeD?XMCy|M0>-L|U~^VNvP(0^g1Sp5U=P$C_C;wCO;)UE;1W#FJ|JLk;H`%FKe&I+MTr)u!Z}`9y3c0|0=gh8fps6NOHLH1~Jt!Gkmn9XSikAySi=oh4X^U zdnu=-8paLeQ4+E~C}nBuq}%x~&q`v(6ijD{IwQ&HH*h|~iN+*kGAW>*c1DF4R#x~y zyg{(2WK9YzR8TU@F3I@l$jCP8*Fi;(Kl!Fc;(BLA<18gydX+gW*jSW*BU;qSUn@`xoMofwmOoG_30<2U`I(b5%7* z(%H>Dp25gK$Sy1q!+74$Ywv9S?1M7UKW)#O|ZSr$fF}l@KhCQtmnK_R@#CYq{4j& z-pnxwfCb0a8G{=nm|#|#Nb|7|BiPJx7RJ0W@kEE_5}VIL)%2vE?)<&QsSBIFvkJ6; zlFE-e6UZ<@wxfmyCMdm2TF3>j-)j~E_Mu&=c%))$Wg%nvLG#;G^sX7`cxm{!p@BY1 ze+5t=7T7ZKN#JSal7@kS7}Ei-XefCfcB5uLtn)=(pEM3;O$+$)GjtylRuOArfn+{9+SN_RpvXtg+GxD37Fb7qU_c2ZjG zSy3j@o$5+Vrzg5L@%XsSsZs~n;_hoJ+|jZsm#$lITW-NU(2wzBuf$Q4Vf=T>9uCPbpp>i76#>aU6*{n`p+Af41Oy=YnR%6xe4pa6~&<$9!c(frPpsi z7v1hRzCE~lrJ_QwEg=3>n6mSpOgiYB-)o5JgyB1B{J>PqpIlhP_jd}z7V-5pEf;Hs*568F2Fq#BRAsmEGZU*UgPe1woI+v}odP{UstP^b8 z#7f>~KdpSq@MZb5^Zm{FuHflPEBv@DAGg2N zrp&pKWJBwNWy&qrN5ks^(^Er6j@Wpp@bBaSXr=gD}i!0hSfL#GXQ1+9CHT zEAiGeS-YC?7_11CFu=Q!GmP{dyBe=jVD)?$y)|1NilVp#QTa>o(oe>9&z|voLO)Pp&p-j`%_&ioG6k~I z&kuB-mFRDw=Xkqo6K&DEu_MFR#Ls`o9f!MboZrYgap5aSW@)g93hBI^9}IA+NO|e$ zK5~#RI|%LcB-%n%3wv@N6ud7D9~)pEKBJzu8?`=`(;r{>^I!mU>4wB-lB=QKy439S z(Z%i?MCTCOhVa~o*Z8BMPD>_G0`KJAifJ(OSCIAMmZ!5C{LQ&x2d->0OX)paXUG^7 zMTw-D2k>(shsxn&Z%%+M6-!1Gv4bp~yY@Fjiu=4T;q8(q5*dxH$S(#8J_!!KQ7II? zpb=cTqTZo}QO8%*m7{#UWn9v+ng*W)N-bQ(KYvcT&A0wR;hLtg!pGHpSjYkV=0IYm zij6?QXk6d0sK~Pm*&VZIW>wsnM|2&2FqxPOYFrS}|Nax_0%+?(n?FYwEsT-PpQzTX z{z<>JN~*p35qn4pJ94NuWFNyPkG@U5LfuAXBA``A~UQ~TMjpb(pJ%8e}CfFEpxY5d8L4F zicT}SVk?%KqNdm#sa23c&jOl8-R{f1-S_<()&b0HZ=P;xWB##^&3F5TS5=wJ%^-QN z&31el^K3dPw)ogv1ZT9@A$BQE`zmRr=;!2ehp3hPkPm1mq4cBi@y4F2WdUcLO7#Ze zypAk(u}QV;EP1XnR-ME$eMrH+AT@f;((mx362~L~)$!jQewR<;oK`N~?Pa6Pxg^t; zNTqX;GsVj`#oFy54#dd*tV#qoPXvTr8aaT=6$r@L;zMpQ^kWkak|a{xAI!?4Z#Bar z$LS9!wZ8MT-aam=WPw)?f~sz=N6M)7foyt~fU@un2!PjJ9)K!OI2~}OH?1VttU~FN zktiSTU_D9eHKo4T0eQTV3puTNST@b7*HBKxIAu1ECEE4beG1=Q#QmYNnxL^`HH373 z&fY7Fx$ojG^*CYX#mVVPktk_khQKw)`)b7wVTflbD;`dnc;{rnT1X)N_mX8u84WwQIgt zpUjAcJk<@yChn@#wBmYoU>QBt`Kd%zuw{#(76_|_xvym6*&4+ouf0!bqX|$d%+^Lw zk4G4H7BGL@$6^?O8gJ;ajk@DMimVarGeb`2s4nW4d6N<&}!u1apgb^Gk+M`W(kEg6^k(?9}F+%)dK7;Vic8_VZx*cm#M8ie#Dt_)D%P8|?+pS9ysirVlRa z2{8fX)v<2Z2QnjG5w-$Wr8OrisH`9LxXM1P5sQ{@G8FKid46D_ zI=Y>-Q@@pP5pPTjyDxBT#Aw^gz?E~~Aal6lo(Ki0EyaYirodH(*o_q#%mj1|w&&XCxrWcV9~Op@K;sbW>BBbqJw%A605 z`Q4*C&0b|Q&JUDdlx%(!A+bJ;u_)`r^2x%`)Zc5UYxow? ziBT14onp|rFhzf!O`s5Po5PQ8 zs2eQO@}O^N+IflCX)@#N&tJ93aL6CpMZY}3KdqEOgG@wX>q~^c=s`wrE-H;lHiA{g zH5}=?F!TieCJmBnlhh&l;SA%8Qq6kFixt?r*U79C002xI?8ukq`}cNS4yE$CFP(r( zz?E9SvPQg55gaC@JgzL*XjN58xT2#(t8gc`Wr&Wr!H#{-tE4zPN$r_B9KCSz1zISbZ;j-qmv-YWBGos^P=Sue?!u z^T>Pr{6jM+mhI|@%w^AMU;aPsS~c~pgbKVXaQk?9$K5d3srC40#xTvY5bTn1G#Icxqzt;kns)Pd+rTk!F5s==`%> zZ~1}w@(<;lr{eO=SPmovXH&1zZ4*nO`>w28%jIP|mY$wW)i&c@0CBD74a`q8CD| z$YaOIBpT0Fvn+{Y>hBAy$U{^76?%F19^>15x|`)SL>Rm_iyL%Z^NngJC!^_-!$VWd zShtpJ0`qVWKKRtv^U*7?vnaNR2`X!J|4Z5XzbTOy{(4GeM4URysBcziH0>$cP| zNt@6_2ri9N!aIkdABq51k#yb8mrc_slFv{jxN&IR-OnUuQjZ!B9j%29vVR3})X=hU zv=gL<3Wt`q)G4bkagLHg^7l6vx5=1v?|t}t{zEY4vBsTNCx++uw{(-s$kgs-wt)&E ze+b9gB;0Wl;`Z5fkey!MzBzq<$t2Na)CBeY>9?i@4;|o5kPE-iS6K0SFJ0#OxGUYm zAJQ5Llk8I-CM=0O>!dHv`tf0C0#dQ2UeD<-23FduwOOGC7`&4>J zs0>n_OtC@Z=d#adr`yGyR%RLM3M0N|%H9eXh(_SaJ?Js8K@BkwIbVd_ z>dFNRL#u1vs89=2{rob4?74Bk9%p^4$o<@r(X+$85>ad@;+m^0{V?jT6A`_A&EO+jm;QtH;-{P%b0+C<5$m*)T_@4Nvk` zBy^0IglfUam`)q&KQ4V<$w1xQj-@CpnFO84?>wk-Ji7_YVtiMYt}A$TD(2dh(gPRw zQCa?rEoXsE7iK>bh59lAWO5tWzj8|=88=%uGtUA*)Z&UoLp17f7%kKyCdL zhArNEL+xMJ{>x4HqsmXw)*o_1i)`eJ9{&Dw&Q`WtyRFAux0%&5Tp1a&_c7eMsAQEp z)yD{IU^&RW3G0X>D#_@sr@KPrkM7(o$~5)~Ash|;A+ zM4AYZE+8NxQbG~wH537*3J54llU@QMgkGcb_l9ci+DK{oj+x zXL4umoiKCeo^#JV_nhx3cH*dEwiSNBy`XXg4SbJa<7B_DWKZiL%< ztjWslrzoiWTOa8g2sZgaT<{quQsl8tMK$`!zxcsmZS_q8Lj={dmaR0yzF$^!&<)QTmrJkfs`(ar;X*|-4! z3RKQLhEBbL)K2xmf$eu#AMy`etwo;gxcSAMzIFhiur7(-Hx>@YWvdf zKOV5e{qAFaix~T^Hh-JLAo-X&+nTZMkea@sG>ys`=0v|@=4%8Xvz`NU0nG*0?Ougc zeQUugFXh}7pGY!BKaeEd1)|~JZ9B3wr*1yX>b6>VrY*K*u=TZUO#(Gp*_A7VQt!gn z1^C*n<2uXZ^xE2PdWjj6RTN#hq&6C^b1XDYRr%^AntaI)D{bd$t zX86(`^80{ocfEgz-%o0I=H@%0U49Z8a|AaLH%08`(6r*Q=#}_8CmpMzQ&*kOLE}#s zTCVxh%UNy6Up#!}o~+VF@li+%sm7I#HKf8&BwVgJBs-AjGVLAKIlM04cbMySeZoZ7 z9fo^1Uv%g=-x_cbf{g)=r!Qr6T9#%m9(jB2#x#2|^8@I~xW$yQ!Mf+UI?l|XoAfzy zCZ`}}s(wJQ-wedn5_-t2yqTZ$&TgkOH7}p+$Di);#ailOnR3=lV=ufI@B|$_a6!ID zTnv3|1TmZ^HmIgxuF$F!WT(?Clbq3e6GSgTl1KgUopb3zSAVFrPK7<^iT6^ipxxJ= zcBfS`?`MXxAlKV}r@5isxt6ev;v|AcLFq3d310c<1LlH;$5Q} zAY4Ih<>{g% zNWkj<0_*}L08aSUd;JZG^F=mcqdA<4y*`ls;9sAfd~6eRlwT4T8bflr6K!f$lz(y| z4UnmYx%TYpQs~MGLP~0;Ypi36|Lawxy+DV|nD-O>&k}S*1J8+|5 zCJ3TFu9@@WiDMzTg;{!c7U|D(ICA*ByJOB%Z)Zk}8o(cIfIYE;X+^KUCpN7j@K4{B zM#yYE=i`!7ZXM(v6RM@0nYKs(r^C)lbEP6GoBIm=Gc(=l+L+*G2Z+TplDp_?k?9eB+uVZcJA5fbJK*oV-hA+w&YhT$68KOzv@IA z#^CVv%=FOao?Q!>-~-{M4D+k0ylY8`eZ`vlLW$Xs$zx{CPM@k$lq!O=NV~=0)JCTQ zUeH$(HkxAE1?DqX)$Gj;48|CwZr;n0*f%1Bua7!1u{K8TG+(!Z9tO2WAa?(3%&ngx3qQ zA*v$v0PmxTP0;I+Cj2SPg%T_yr7w)pe*^2;){)jLZxiu@>FZL7tzNPTb=RLmN?_&nXS(YqzOw_%; zZ+_S70X=BU$kqbtYTC!y#EL2+kY&J@c z%?cWlAxn>YUp)fgLz)j|gQwvmMQ%-S>(kb^PcrA*n>MsJW@a`jcL~FH&$u1E)o6c| zc-J}+hN!ELN%EFqq*~fl&l9Y#ot)Goi6sawl~R_Rc9j|5;w`p$Tf`c=IypK1l@VZJka@HsGS)7OrCJNxlaJ0U<}AHW-bMJaF3-`W~~V~F|+ zmB`-|0rKRR-KS)$|Dupb0($OOpXl$@fsuh5NlU-%zE}u{vrXXzHKu;UN$M-l{THjq zzg*7vd36I8*F63$a`LNfKA;c1$=&B-naHoMn|0H!pxct{${rq`5saeFV{_LA4ypo~ zp+%8gmyfgE+5Vv8#gzHNaU7n~w`Cw(bGSXv;g7QJOpL3M{N3kHsKRhHuvS9&9x zlZW2)T)fvmnvJ0bLFv?`lI=8FjSahKc0p*Ci+QMox&2lAfe?yC#RiF7#XAm5F7e05`ipYr zyGw#{>!NcDBM}6(2iKEy>3f+jLT!Xvh!^Mj`@5O8ws#JUH?+~cHAnD?=bj?^PZh1` z&qF){j@wy2d<3AAdC)^vtBi3W`GiB!6&f@>koud5r7L=7pBp$}JK1bn3Ulp!uiJRVhwRemfn;C>g{ z+9O)J3~9?ocwRcde|TC9llQp8Aqvw5E>^x(jJ)bFnZYa=%>%7c{KFGUNn0C$Jv&Ov zvX;f*#t*ZOO7RNb-LEqzRjt}^~q(seb7FIW<<4of|Oy*cE$hS0w9yND9ZOT23f0BH&62W5&3Sk{E1 zaWxqBAQUU|t4bLl*Wjcvh5|5n?*>v9l8Sxa7BXKL3k>?^(0Raz98Esir3LuN=qcJb z(JJRUF?6;YeI)T(t$?>?RN`Bjl9zY$r`U~i1EkEhMmJSjN(Xa97`U*Rt)EiWsc!m zJ?hur+&eV?^6SSN`0wdX z)0S7eW`PLF=&UBQZqJQ`%+lQyT0XEhs|-%dsUhY_mEqg1vz$}`iyt}(~^ADqH{H4FUIaYQuARc3nMUb~rO{eUSIWI3*Q{iA_vJyC%phA1_@Lrrgn z*iy0i>OC*`>W^#ME7G&)wo^^ZXn6(7z$89$7iFI#h$x9e57p>mQT8dW3nif zcqx@7mg71cWJX3ZDOO`mnX0nJN1JM|Z7tBcR2y4%?VtycGS;d*DEmjLFt4_1eSoB4QESJTx|6Iwh78swYSM|0jZT_OIQiBU2=BZ= z8>JmNHiiG@@l&Qp@1|OJK|xJ)L)FFc@%@^!jC|e~4#v|Sbd|Vk;wE-Qh<51Zg;46o zjE6I3n$F2N`_h+S`zOL^+^jM>K1gzeX^o8vmNL9LR1&Y-ceL4Tf2^mp@QK>9EA4WF?{Dnvwm-gm(R?8lV6aNo>}Oj>M2Xm7+LKr zz`m}aYCUZmhZBeHLpcHVn<6X9vuB-|qOCP6pL1Z4_o4&y>8eII50Fl zQvnI}W0Z*c?Qn4VWlnT7psJx+H^$c6wYA`RuuMbTUAgA2j3HDn5f?rYd>vC-+?JP5 z8j*?5wa)=;LO0stcK)68&X?-8g2q%Q$SL&EimNe82Y+@yFQWM}6GPcWYZV)=Y5dZm zu!h=IkFz`~Tlln>Y{Xd9E@37PQ#Mvpr)WVdt>X-LDpam2 zg93?|a1*DSH%j0_%~HjFVN)Z2!}{Asgfx49_Y#>nT^nhiCaxDToyx~ShYXQT0v!{f z5jqJ`(hWT1)`t{x5lOz|&_H+`CL8av{_~+=IP5p>{`=NF7*Y6ey+q}LnCXK8c~4ci#vceB z$6iTn$Joav++PWP!@M#pq}v@?OrV3_ouo0b5)$*WOZ{DXch24@BXKdhQQe}KO0O2Gg3C>AwTBVRm(S$5F4^i<@aQVN*IY|s0@4zMQ5IxfEc7*`tRx{? zH-M6tTh)8m3D^#3kX~yGX4_vsXLx~-r1GYHr9&C%lm|Ne=$g&yyTa2?kQeTehWB;d zK1AgcvEhSzOxI36EO>r?dCtjB*fBn!RrL}9wfr$sUM;fdYauLc8OmF_^ zc+7$5d^fV_?wzfP55n8DXz$UPw*It>y8t*=XhlxHvxmi$amRBIkN_lnSUqiP1HcRY zfzUM3q#=!CeE@>Qij1(y#~BH3BPuP0%kP#|7GNjr&b8V}4t4jccj0T!8Sxh+oSi8( z(2wJxO;VQ_hPj?dePX9-o7An*DMC^ijH2(&HuRPs+tUgs#2;190U)cT08cy!5Tg9Y zCv-PKt`sSV203ZKcW)E476KgqDx4qyWccU@c;LQ36D$D1X_W1R90$(GhPP0JX``%ibto3J* z`47@ruPR)jw>41`Yzyzz&soX9Pbt)+;#O6Bf9yV^K{z!4(E{>euNA!9rr5QMS|`NL zG#Qz(o2Q^i2MN*j`yMKZP@_sko`h)0bQS@@m(T@8o zkrGGWpFg?#(v&2%P2=heNt)9PKjNdx`|9h9@ z4hW2LZ@PE$kBJSf6RYx~GDP?2;upgQAqhD6pRatk?CV{4xi#*-ue|Dhi6JVUz$-xL zF?H6II$^S%A-WF9$6@oj<0|ZMXIUa4cK^pBm3bi2z}UxJuQRIkSP7YxTiuzP&;c